

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
26 September 2002 (26.09.2002)

PCT

(10) International Publication Number
WO 02/074979 A2

- (51) International Patent Classification⁷: **C12Q**
- (21) International Application Number: PCT/US02/08456
- (22) International Filing Date: 20 March 2002 (20.03.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/276,947 20 March 2001 (20.03.2001) US
- (71) Applicant: **ORTHO-CLINICAL DIAGNOSTICS, INC.** [US/US]; 1001 US Highway 202, Raritan, NJ 08869 (US).
- (72) Inventors: **WAN, Jackson**; 10929 Corte Luz Del Sol, San Diego, CA 92130 (US). **WANG, Yixin**; 12511 El Camino Real, Unit E, San Diego, CA 92130 (US).
- (74) Agents: **PELTO, Don et al.**; McKenna & Cuneo LLP, 1900 K Street NW, Washington, DC 20006 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GI, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: EXPRESSION PROFILES AND METHODS OF USE

(57) Abstract: The present invention relates to gene expression profiles, algorithms to generate gene expression profiles, microarrays comprising nucleic acid sequences representing gene expression profiles, methods of using gene expression profiles and microarrays, and business methods directed to the use of gene expression profiles, microarrays, and algorithms. The present invention further relates to protein expression profiles, algorithms to generate protein expression profiles, microarrays comprising protein-capture agents that bind proteins comprising protein expression profiles, methods of using protein expression profiles and microarrays, and business methods directed to the use of protein expression profiles, microarrays, and algorithms.

WO 02/074979 A2

EXPRESSION PROFILES AND METHODS OF USE

CROSS REFERENCE TO RELATED APPLICATIONS

5 The present application is related to and claims, under 35 U.S.C. § 119(e), the benefit of U.S. Provisional Patent Application Serial No. 60/276,947, filed 20 March 2001, which is incorporated herein by reference.

FIELD OF THE INVENTION

10 The present invention relates to gene expression profiles, algorithms to generate gene expression profiles, microarrays comprising nucleic acid sequences representing gene expression profiles, methods of using gene expression profiles and microarrays, and business methods directed to the use of gene expression profiles, microarrays, and algorithms.

15 The present invention further relates to protein expression profiles, algorithms to generate protein expression profiles, microarrays comprising protein-capture agents that bind proteins comprising protein expression profiles, methods of using protein expression profiles and microarrays, and business methods directed to the use of protein expression profiles, microarrays, and algorithms.

BACKGROUND OF THE INVENTION

20 The identification and analysis of a particular gene or protein generally has been accomplished by experiments directed specifically towards that gene or protein. With the recent advances, however, in the sequencing of the human genome, the challenge is to decipher the expression, function, and regulation of thousands of genes, which cannot be realistically accomplished by analyzing one gene or protein at a time. To address this
25 situation, DNA microarray technology has proven to be a valuable tool. By taking advantage of the sequence information obtained from DNA microarrays, the expression and functional relationship of thousands of genes may be resolved.

The expression profiles of thousands of genes have been examined *en masse* via cDNA and oligonucleotide microarrays. *See, e.g.,* Lockhart et al., NUCLEIC ACIDS SYMP. SER. 11-12 (1998); Shalon et al., 46 PATHOL. BIOL. 107-109 (1998); Schena et al., 16 TRENDS BIOTECHNOL. 301-306 (1998). Several studies have analyzed gene expression profiles in yeast, mammalian cell lines, and disease tissues. *See, e.g.,* Welford et al., 26 NUCLEIC ACIDS RES. 3059-3065 (1998); Cho et al., 2 MOL. CELL 65-73 (1997); Heller et al., 94 PROC. NATL.

ACAD. SCI. USA 2150-2155 (1997); Schena et al., 93 PROC. NATL. ACAD. SCI. USA 10614-10619 (1996).

Microarray technology provides the means to decipher the function of a particular gene based on its expression profile and alterations in its expression levels. In addition, this technology may be used to define the components of cellular pathways as well as the regulation of these cellular components. High-density oligonucleotide microarrays may be used to simultaneously monitor thousands of genes or possibly entire genomes (e.g., *Saccharomyces cerevisiae*).

Microarrays may also be used for genetic and physical mapping of genomes, DNA sequencing, genetic diagnosis, and genotyping of organisms. Microarrays may be used to determine a medical diagnosis. For example, the identity of a pathogenic microorganism may be established unambiguously by hybridizing a patient sample to a microarray containing the genes from many types of known pathogenic DNA. A similar technique may also be used for genotyping an organism. For genetic diagnostics, a microarray may contain multiple forms of a mutated gene or multiple genes associated with a particular disease. The microarray may then be probed with DNA or RNA, isolated from a patient sample (e.g., blood sample), which may hybridize to one of the mutated or disease genes.

Microarrays containing molecular expression markers or predictor genes may be used to confirm tissue or cell identifications. In addition, disease progression may be monitored by analyzing the expression patterns of the predictor genes in disease tissues. An alteration in gene expression may be used to define the specific disease state and stage of the disease. Monitoring the efficacy of certain drug regimens may also be accomplished by analyzing the expression patterns of the predictor genes. For example, decreases or increases in gene expression may be indicative of the efficacy of a particular drug.

Generally, oligonucleotide probes are used to detect complementary nucleic acid sequences in a particular tissue or cell type. The oligonucleotide probes may be covalently attached to a support, and arrays of oligonucleotide probes immobilized on solid supports are used to detect specific nucleic acid sequences. To assess gene expression in a given tissue or cell sample, DNA or RNA is isolated from the tissue or cell, labeled with a fluorescent dye, and then hybridized to the DNA microarray. The microarray may contain hundreds to thousands of DNA sequences selected from cDNA libraries, genomic DNA, or expressed sequence tags (ESTs). These DNA sequences may be spotted or synthesized onto the support and then crosslinked to the support by ultraviolet radiation. Following hybridization, the

fluorescence intensities of the microarray are analyzed, and these measurements are then used to determine the presence or relative quantity of a particular gene within the sample. This hybridization pattern is used to generate a gene expression profile of the target tissue or cell type.

Thus, differences in gene expression profiles may be used to identify the pathology of many diseases involving alterations of gene expression. The types of genes and their expression levels may distinguish normal tissue and diseased tissue. For example, cancer cells evolve from normal cells into highly invasive, metastatic malignancies, which frequently are induced by activation of oncogenes, or inactivation of tumor suppressor genes.

Differentially expressed sequences can serve as markers or predictors of the transformed state and are, therefore, of potential value in the diagnosis and classification of tumors. The assessment of expression profiles may provide meaningful information with respect to tumor type and stage, treatment methods, and prognosis.

SUMMARY OF THE INVENTION

The present invention relates to gene expression profiles, algorithms to generate gene expression profiles, microarrays comprising nucleic acid sequences representing gene expression profiles, methods of using gene expression profiles and microarrays, and business methods directed to the use of gene expression profiles, microarrays, and algorithms.

In a specific embodiment of the present invention, the gene expression profile may be an endothelial cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof selected from the group consisting of SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; SEQ ID NO: 8; SEQ ID NO: 9; SEQ ID NO: 10; SEQ ID NO: 11; SEQ ID NO: 12; SEQ ID NO: 13; SEQ ID NO: 14; SEQ ID NO: 15; SEQ ID NO: 16; SEQ ID NO: 17; SEQ ID NO: 18; SEQ ID NO: 19; SEQ ID NO: 20; SEQ ID NO: 21; SEQ ID NO: 22; SEQ ID NO: 23; SEQ ID NO: 48; SEQ ID NO: 63; SEQ ID NO: 70; SEQ ID NO: 82; SEQ ID NO: 94; and SEQ ID NO: 144. With regard to this gene expression profile, the present invention provides a microarray comprising one or more protein-capture agents that specifically bind to all or a portion of one or more of the proteins encoded by the genes comprising the gene expression profile.

In another embodiment of the present invention, the gene expression profile may be a muscle cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof selected from the group consisting of SEQ ID NO: 24; SEQ ID NO: 25; SEQ ID NO: 26; SEQ ID NO: 27; SEQ ID NO: 28; SEQ ID NO: 29; SEQ ID NO: 30; SEQ ID NO: 31; SEQ ID NO: 32; SEQ ID NO: 33; SEQ ID NO: 34; SEQ ID NO: 35; SEQ ID NO: 36; SEQ ID NO: 37; SEQ ID NO: 39; SEQ ID NO: 40; SEQ ID NO: 41; SEQ ID NO: 42; SEQ ID NO: 54; SEQ ID NO: 55; and SEQ ID NO: 69. With regard to this gene expression profile, the present invention provides a microarray comprising one or more protein-capture agents that specifically bind to all or a portion of one or more of the proteins encoded by the genes comprising the gene expression profile.

In an alternative embodiment of the present invention, the gene expression profile may be a primary cell gene expression profile comprising one or more nucleic acid sequences or complementary sequences thereof, or portions of said nucleic acid sequences or complementary sequences thereof, selected from the group consisting of SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; SEQ ID NO: 8; SEQ ID NO: 9; SEQ ID NO: 10; SEQ ID NO: 11; SEQ ID NO: 12; SEQ ID NO: 13; SEQ ID NO: 14; SEQ ID NO: 15; SEQ ID NO: 16; SEQ ID NO: 17; SEQ ID NO: 18; SEQ ID NO: 19; SEQ ID NO: 20; SEQ ID NO: 21; SEQ ID NO: 22; SEQ ID NO: 23; SEQ ID NO: 24; SEQ ID NO: 25; SEQ ID NO: 26; SEQ ID NO: 27; SEQ ID NO: 28; SEQ ID NO: 29; SEQ ID NO: 30; SEQ ID NO: 31; SEQ ID NO: 32; SEQ ID NO: 33; SEQ ID NO: 34; SEQ ID NO: 35; SEQ ID NO: 36; SEQ ID NO: 37; SEQ ID NO: 39; SEQ ID NO: 40; SEQ ID NO: 41; SEQ ID NO: 42; SEQ ID NO: 43; SEQ ID NO: 44; SEQ ID NO: 45; SEQ ID NO: 46; SEQ ID NO: 47; SEQ ID NO: 48; SEQ ID NO: 49; SEQ ID NO: 50; SEQ ID NO: 51; SEQ ID NO: 52; SEQ ID NO: 53; SEQ ID NO: 54; SEQ ID NO: 55; SEQ ID NO: 56; SEQ ID NO: 57; SEQ ID NO: 58; SEQ ID NO: 59; SEQ ID NO: 60; SEQ ID NO: 61; SEQ ID NO: 62; SEQ ID NO: 63; SEQ ID NO: 64; SEQ ID NO: 65; SEQ ID NO: 66; SEQ ID NO: 67; SEQ ID NO: 68; SEQ ID NO: 69; SEQ ID NO: 70; SEQ ID NO: 71; SEQ ID NO: 72; SEQ ID NO: 73; SEQ ID NO: 74; SEQ ID NO: 75; SEQ ID NO: 76; SEQ ID NO: 77; SEQ ID NO: 78; SEQ ID NO: 79; SEQ ID NO: 80; SEQ ID NO: 81; SEQ ID NO: 82; SEQ ID NO: 83; SEQ ID NO: 84; SEQ ID NO: 85; SEQ ID NO: 86; SEQ ID NO: 87; SEQ ID NO: 88; SEQ ID NO: 89; SEQ ID NO: 90; SEQ ID NO: 91; SEQ ID NO: 92; SEQ ID NO: 93; SEQ ID NO: 94; SEQ ID NO: 95; SEQ ID NO: 96; SEQ ID NO: 97; SEQ ID

NO: 98; SEQ ID NO: 99; SEQ ID NO: 100; SEQ ID NO: 101; SEQ ID NO: 102; SEQ ID
NO: 103; SEQ ID NO: 104; SEQ ID NO: 105; SEQ ID NO: 106; SEQ ID NO: 107; SEQ ID
NO: 108; SEQ ID NO: 109; SEQ ID NO: 110; SEQ ID NO: 111; SEQ ID NO: 112; SEQ ID
NO: 113; SEQ ID NO: 114; SEQ ID NO: 115; SEQ ID NO: 116; SEQ ID NO: 118; SEQ ID
5 NO: 119; SEQ ID NO: 120; SEQ ID NO: 121; SEQ ID NO: 122; SEQ ID NO: 123; SEQ ID
NO: 124; SEQ ID NO: 125; SEQ ID NO: 126; SEQ ID NO: 127; SEQ ID NO: 128; SEQ ID
NO: 129; SEQ ID NO: 130; SEQ ID NO: 131; SEQ ID NO: 132; SEQ ID NO: 133; SEQ ID
NO: 134; SEQ ID NO: 135; SEQ ID NO: 136; SEQ ID NO: 137; SEQ ID NO: 138; SEQ ID
NO: 139; SEQ ID NO: 140; SEQ ID NO: 141; SEQ ID NO: 142; SEQ ID NO: 143; SEQ ID
10 NO: 144; SEQ ID NO: 145; SEQ ID NO: 146; SEQ ID NO: 147; SEQ ID NO: 148; SEQ ID
NO: 149; SEQ ID NO: 150; SEQ ID NO: 151; SEQ ID NO: 152; SEQ ID NO: 153; SEQ ID
NO: 154; SEQ ID NO: 155; SEQ ID NO: 156; SEQ ID NO: 157; SEQ ID NO: 158; SEQ ID
NO: 159; SEQ ID NO: 160; SEQ ID NO: 161; SEQ ID NO: 162; SEQ ID NO: 163; SEQ ID
NO: 164; SEQ ID NO: 165; SEQ ID NO: 166; SEQ ID NO: 167; SEQ ID NO: 168; SEQ ID
15 NO: 169; SEQ ID NO: 170; SEQ ID NO: 171; SEQ ID NO: 172; SEQ ID NO: 173; SEQ ID
NO: 174; SEQ ID NO: 175; SEQ ID NO: 176; SEQ ID NO: 177; SEQ ID NO: 178; SEQ ID
NO: 179; SEQ ID NO: 180; SEQ ID NO: 181; SEQ ID NO: 182; SEQ ID NO: 183; SEQ ID
NO: 184; SEQ ID NO: 185; and SEQ ID NO: 186.

With regard to this gene expression profile, the present invention provides a
20 microarray comprising one or more protein-capture agents that specifically bind to all or a
portion of one or more of the proteins encoded by the genes comprising the gene expression
profile.

In a further aspect of the present invention, the gene expression profile may be
an epithelial cell gene expression profile comprising one or more nucleic acid sequences or
25 complementary sequences thereof, or portions of said nucleic acid sequences or
complementary sequences thereof, selected from the group consisting of SEQ ID NO: 47;
SEQ ID NO: 60; SEQ ID NO: 67; SEQ ID NO: 73; SEQ ID NO: 75; SEQ ID NO: 76; SEQ
ID NO: 77; SEQ ID NO: 78; SEQ ID NO: 80; SEQ ID NO: 96; SEQ ID NO: 98; SEQ ID
NO: 99; SEQ ID NO: 111; SEQ ID NO: 112; SEQ ID NO: 123; SEQ ID NO: 127; SEQ ID
30 NO: 131; SEQ ID NO: 150; SEQ ID NO: 153; SEQ ID NO: 154; SEQ ID NO: 155; SEQ ID
NO: 156; SEQ ID NO: 157; SEQ ID NO: 158; SEQ ID NO: 159; SEQ ID NO: 160; SEQ ID
NO: 161; SEQ ID NO: 162; SEQ ID NO: 163; SEQ ID NO: 164; SEQ ID NO: 165; SEQ ID
NO: 166; SEQ ID NO: 167; SEQ ID NO: 168; SEQ ID NO: 169; SEQ ID NO: 170; SEQ ID

NO: 171; SEQ ID NO: 172; SEQ ID NO: 173; SEQ ID NO: 174; SEQ ID NO: 175; SEQ ID NO: 176; SEQ ID NO: 177; SEQ ID NO: 178; SEQ ID NO: 179; SEQ ID NO: 180; SEQ ID NO: 181; SEQ ID NO: 182; SEQ ID NO: 183; SEQ ID NO: 184; SEQ ID NO: 185; and SEQ ID NO: 186. With regard to this gene expression profile, the present invention provides a
5 microarray comprising one or more protein-capture agents that specifically bind to all or a portion of one or more of the proteins encoded by the genes comprising the gene expression profile.

In yet another embodiment, a keratinocyte epithelial cell gene expression profile may comprise one or more nucleic acid sequences or complementary sequences thereof, or
10 portions of said nucleic acid sequences or complementary sequences thereof, selected from the group consisting of SEQ ID NO: 187; SEQ ID NO: 188; SEQ ID NO: 189; SEQ ID NO: 190; SEQ ID NO: 191; SEQ ID NO: 192; SEQ ID NO: 193; SEQ ID NO: 194; SEQ ID NO: 195; SEQ ID NO: 196; SEQ ID NO: 197; SEQ ID NO: 198; SEQ ID NO: 199; SEQ ID NO: 200; SEQ ID NO: 201; SEQ ID NO: 202; SEQ ID NO: 203; SEQ ID NO: 204; SEQ ID NO:
15 205; SEQ ID NO: 206; SEQ ID NO: 207; SEQ ID NO: 208; SEQ ID NO: 209; SEQ ID NO: 210; and SEQ ID NO: 211. With regard to this gene expression profile, the present invention provides a microarray comprising one or more protein-capture agents that specifically bind to all or a portion of one or more of the proteins encoded by the genes comprising the gene expression profile.

20 The present invention also provides a mammary epithelial cell gene expression profile comprising one or more nucleic acid sequences or complementary sequences thereof, or portions of said nucleic acid sequences or complementary sequences thereof, selected from the group consisting of SEQ ID NO: 78; SEQ ID NO: 212; SEQ ID NO: 213; SEQ ID NO: 216; SEQ ID NO: 225; SEQ ID NO: 226; SEQ ID NO: 227; SEQ ID NO: 239; SEQ ID NO:
25 271; SEQ ID NO: 285; and SEQ ID NO: 289. With regard to this gene expression profile, the present invention provides a microarray comprising one or more protein-capture agents that specifically bind to all or a portion of one or more of the proteins encoded by the genes comprising the gene expression profile.

In an alternative embodiment, a bronchial epithelial cell gene expression profile may
30 comprise one or more nucleic acid sequences or complementary sequences thereof, or portions of said nucleic acid sequences or complementary sequences thereof, selected from the group consisting of SEQ ID NO: 27; SEQ ID NO: 131; SEQ ID NO: 150; SEQ ID NO: 169; SEQ ID NO: 214; SEQ ID NO: 215; SEQ ID NO: 223; SEQ ID NO: 224; SEQ ID NO:

241; SEQ ID NO: 243; SEQ ID NO: 244; SEQ ID NO: 255; SEQ ID NO: 256; SEQ ID NO: 261; and SEQ ID NO: 314. With regard to this gene expression profile, the present invention provides a microarray comprising one or more protein-capture agents that specifically bind to all or a portion of one or more of the proteins encoded by the genes comprising the gene expression profile.

The present invention also provides a prostate epithelial cell gene expression profile, which may comprise one or more nucleic acid sequences or complementary sequences thereof, or portions of said nucleic acid sequences or complementary sequences thereof, selected from the group consisting of SEQ ID NO: 64; SEQ ID NO: 217; SEQ ID NO: 218; SEQ ID NO: 259; SEQ ID NO: 293; SEQ ID NO: 302; and SEQ ID NO: 320. With regard to this gene expression profile, the present invention provides a microarray comprising one or more protein-capture agents that specifically bind to all or a portion of one or more of the proteins encoded by the genes comprising the gene expression profile.

In yet another embodiment, a renal cortical epithelial cell gene expression profile may comprise one or more nucleic acid sequences or complementary sequences thereof, or portions of said nucleic acid sequences or complementary sequences thereof, selected from the group consisting of SEQ ID NO: 49; SEQ ID NO: 57; SEQ ID NO: 104; SEQ ID NO: 123; SEQ ID NO: 160; SEQ ID NO: 165; SEQ ID NO: 166; SEQ ID NO: 219; SEQ ID NO: 267; SEQ ID NO: 270; SEQ ID NO: 279; SEQ ID NO: 280; SEQ ID NO: 283; SEQ ID NO: 291; SEQ ID NO: 305; SEQ ID NO: 307; SEQ ID NO: 310; SEQ ID NO: 313; SEQ ID NO: 325; SEQ ID NO: 326; and SEQ ID NO: 327. With regard to this gene expression profile, the present invention provides a microarray comprising one or more protein-capture agents that specifically bind to all or a portion of one or more of the proteins encoded by the genes comprising the gene expression profile.

The present invention further provides a renal proximal tubule epithelial cell gene expression profile comprising one or more nucleic acid sequences or complementary sequences thereof, or portions of said nucleic acid sequences or complementary sequences thereof, selected from the group consisting of SEQ ID NO: 106; SEQ ID NO: 138; SEQ ID NO: 158; SEQ ID NO: 228; SEQ ID NO: 236; SEQ ID NO: 242; SEQ ID NO: 250; SEQ ID NO: 258; SEQ ID NO: 260; SEQ ID NO: 262; SEQ ID NO: 266; SEQ ID NO: 272; SEQ ID NO: 273; SEQ ID NO: 274; SEQ ID NO: 275; SEQ ID NO: 276; SEQ ID NO: 278; SEQ ID NO: 284; SEQ ID NO: 288; SEQ ID NO: 295; SEQ ID NO: 296; SEQ ID NO: 297; SEQ ID NO: 299; SEQ ID NO: 300; SEQ ID NO: 301; SEQ ID NO: 306; SEQ ID NO: 308; SEQ ID

NO: 309; SEQ ID NO: 311; SEQ ID NO: 316; SEQ ID NO: 318; SEQ ID NO: 321; SEQ ID NO: 322; SEQ ID NO: 328; and SEQ ID NO: 329. With regard to this gene expression profile, the present invention provides a microarray comprising one or more protein-capture agents that specifically bind to all or a portion of one or more of the proteins encoded by the genes comprising the gene expression profile.

In a specific embodiment, a small airway epithelial cell gene expression profile may comprise one or more nucleic acid sequences or complementary sequences thereof, or portions of said nucleic acid sequences or complementary sequences thereof, selected from the group consisting of SEQ ID NO: 173; SEQ ID NO: 174; SEQ ID NO: 183; SEQ ID NO: 220; SEQ ID NO: 221; SEQ ID NO: 222; SEQ ID NO: 229; SEQ ID NO: 230; SEQ ID NO: 231; SEQ ID NO: 232; SEQ ID NO: 233; SEQ ID NO: 234; SEQ ID NO: 235; SEQ ID NO: 237; SEQ ID NO: 238; SEQ ID NO: 240; SEQ ID NO: 245; SEQ ID NO: 246; SEQ ID NO: 247; SEQ ID NO: 248; SEQ ID NO: 249; SEQ ID NO: 251; SEQ ID NO: 252; SEQ ID NO: 254; SEQ ID NO: 257; SEQ ID NO: 263; SEQ ID NO: 264; SEQ ID NO: 265; SEQ ID NO: 268; SEQ ID NO: 269; SEQ ID NO: 270; SEQ ID NO: 277; SEQ ID NO: 281; SEQ ID NO: 282; SEQ ID NO: 286; SEQ ID NO: 287; SEQ ID NO: 290; SEQ ID NO: 294; SEQ ID NO: 298; SEQ ID NO: 303; SEQ ID NO: 312; SEQ ID NO: 315; SEQ ID NO: 317; and SEQ ID NO: 319. With regard to this gene expression profile, the present invention provides a microarray comprising one or more protein-capture agents that specifically bind to all or a portion of one or more of the proteins encoded by the genes comprising the gene expression profile.

The present invention also provides a renal epithelial cell gene expression profile comprising one or more nucleic acid sequences or complementary sequences thereof, or portions of said nucleic acid sequences or complementary sequences thereof, selected from the group consisting of SEQ ID NO: 37; SEQ ID NO: 253; SEQ ID NO: 304; SEQ ID NO: 323; and SEQ ID NO: 324. With regard to this gene expression profile, the present invention provides a microarray comprising one or more protein-capture agents that specifically bind to all or a portion of one or more of the proteins encoded by the genes comprising the gene expression profile.

In yet another embodiment of the present invention, the gene expression profiles may comprise one or more genes, wherein said gene expression profile is generated from a cell type selected from the group comprising coronary artery endothelium, umbilical artery endothelium, umbilical vein endothelium, aortic endothelium, dermal microvascular

endothelium, pulmonary artery endothelium, myometrium microvascular endothelium, keratinocyte epithelium, bronchial epithelium, mammary epithelium, prostate epithelium, renal cortical epithelium, renal proximal tubule epithelium, small airway epithelium, renal epithelium, umbilical artery smooth muscle, neonatal dermal fibroblast, pulmonary artery
 5 smooth muscle, dermal fibroblast, neural progenitor cells, skeletal muscle, astrocytes, aortic smooth muscle, mesangial cells, coronary artery smooth muscle, bronchial smooth muscle, uterine smooth muscle, lung fibroblast, osteoblasts, and prostate stromal cells.

In another embodiment of the present invention, the microarray may be a microarray comprising an endothelial cell gene expression profile comprising one or more nucleic acid
 10 sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof, or portions of said nucleic acid sequence or complementary sequence thereof, selected from the group consisting of SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; SEQ ID NO: 8; SEQ ID NO: 9; SEQ ID NO: 10; SEQ ID NO: 11; SEQ ID NO: 12; SEQ ID NO: 13; SEQ ID NO: 14; SEQ
 15 ID NO: 15; SEQ ID NO: 16; SEQ ID NO: 17; SEQ ID NO: 18; SEQ ID NO: 19; SEQ ID NO: 20; SEQ ID NO: 21; SEQ ID NO: 22; SEQ ID NO: 23; SEQ ID NO: 48; SEQ ID NO: 63; SEQ ID NO: 70; SEQ ID NO: 82; SEQ ID NO: 94; and SEQ ID NO: 144.

The microarrays of the present invention may also comprise a microarray comprising a muscle cell gene expression profile comprising one or more nucleic acid sequences
 20 substantially homologous to a nucleic acid sequence or complementary sequence thereof, or portions of said nucleic acid sequence or complementary sequence thereof, selected from the group consisting of SEQ ID NO: 24; SEQ ID NO: 25; SEQ ID NO: 26; SEQ ID NO: 27; SEQ ID NO: 28; SEQ ID NO: 29; SEQ ID NO: 30; SEQ ID NO: 31; SEQ ID NO: 32; SEQ ID NO: 33; SEQ ID NO: 34; SEQ ID NO: 35; SEQ ID NO: 36; SEQ ID NO: 37; SEQ ID
 25 NO: 39; SEQ ID NO: 40; SEQ ID NO: 41; SEQ ID NO: 42; SEQ ID NO: 54; SEQ ID NO: 55; and SEQ ID NO: 69.

Also within the scope of the present invention are microarrays comprising a primary cell gene expression profile comprising one or more nucleic acid sequences substantially
 30 homologous to a nucleic acid sequence or complementary sequence thereof, or portions of said nucleic acid sequence or complementary sequence thereof, selected from the group consisting of SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; SEQ ID NO: 8; SEQ ID NO: 9; SEQ ID NO: 10; SEQ ID NO: 11; SEQ ID NO: 12; SEQ ID NO: 13; SEQ ID NO: 14; SEQ ID NO: 15; SEQ ID NO:

16; SEQ ID NO: 17; SEQ ID NO: 18; SEQ ID NO: 19; SEQ ID NO: 20; SEQ ID NO: 21;
SEQ ID NO: 22; SEQ ID NO: 23; SEQ ID NO: 24; SEQ ID NO: 25; SEQ ID NO: 26; SEQ
ID NO: 27; SEQ ID NO: 28; SEQ ID NO: 29; SEQ ID NO: 30; SEQ ID NO: 31; SEQ ID
NO: 32; SEQ ID NO: 33; SEQ ID NO: 34; SEQ ID NO: 35; SEQ ID NO: 36; SEQ ID NO:
5 37; SEQ ID NO: 39; SEQ ID NO: 40; SEQ ID NO: 41; SEQ ID NO: 42; SEQ ID NO: 43;
SEQ ID NO: 44; SEQ ID NO: 45; SEQ ID NO: 46; SEQ ID NO: 47; SEQ ID NO: 48; SEQ
ID NO: 49; SEQ ID NO: 50; SEQ ID NO: 51; SEQ ID NO: 52; SEQ ID NO: 53; SEQ ID
NO: 54; SEQ ID NO: 55; SEQ ID NO: 56; SEQ ID NO: 57; SEQ ID NO: 58; SEQ ID NO:
59; SEQ ID NO: 60; SEQ ID NO: 61; SEQ ID NO: 62; SEQ ID NO: 63; SEQ ID NO: 64;
10 SEQ ID NO: 65; SEQ ID NO: 66; SEQ ID NO: 67; SEQ ID NO: 68; SEQ ID NO: 69; SEQ
ID NO: 70; SEQ ID NO: 71; SEQ ID NO: 72; SEQ ID NO: 73; SEQ ID NO: 74; SEQ ID
NO: 75; SEQ ID NO: 76; SEQ ID NO: 77; SEQ ID NO: 78; SEQ ID NO: 79; SEQ ID NO:
80; SEQ ID NO: 81; SEQ ID NO: 82; SEQ ID NO: 83; SEQ ID NO: 84; SEQ ID NO: 85;
SEQ ID NO: 86; SEQ ID NO: 87; SEQ ID NO: 88; SEQ ID NO: 89; SEQ ID NO: 90; SEQ
15 ID NO: 91; SEQ ID NO: 92; SEQ ID NO: 93; SEQ ID NO: 94; SEQ ID NO: 95; SEQ ID
NO: 96; SEQ ID NO: 97; SEQ ID NO: 98; SEQ ID NO: 99; SEQ ID NO: 100; SEQ ID NO:
101; SEQ ID NO: 102; SEQ ID NO: 103; SEQ ID NO: 104; SEQ ID NO: 105; SEQ ID NO:
106; SEQ ID NO: 107; SEQ ID NO: 108; SEQ ID NO: 109; SEQ ID NO: 110; SEQ ID NO:
111; SEQ ID NO: 112; SEQ ID NO: 113; SEQ ID NO: 114; SEQ ID NO: 115; SEQ ID NO:
20 116; SEQ ID NO: 118; SEQ ID NO: 119; SEQ ID NO: 120; SEQ ID NO: 121; SEQ ID NO:
122; SEQ ID NO: 123; SEQ ID NO: 124; SEQ ID NO: 125; SEQ ID NO: 126; SEQ ID NO:
127; SEQ ID NO: 128; SEQ ID NO: 129; SEQ ID NO: 130; SEQ ID NO: 131; SEQ ID NO:
132; SEQ ID NO: 133; SEQ ID NO: 134; SEQ ID NO: 135; SEQ ID NO: 136; SEQ ID NO:
137; SEQ ID NO: 138; SEQ ID NO: 139; SEQ ID NO: 140; SEQ ID NO: 141; SEQ ID NO:
25 142; SEQ ID NO: 143; SEQ ID NO: 144; SEQ ID NO: 145; SEQ ID NO: 146; SEQ ID NO:
147; SEQ ID NO: 148; SEQ ID NO: 149; SEQ ID NO: 150; SEQ ID NO: 151; SEQ ID NO:
152; SEQ ID NO: 153; SEQ ID NO: 154; SEQ ID NO: 155; SEQ ID NO: 156; SEQ ID NO:
157; SEQ ID NO: 158; SEQ ID NO: 159; SEQ ID NO: 160; SEQ ID NO: 161; SEQ ID NO:
162; SEQ ID NO: 163; SEQ ID NO: 164; SEQ ID NO: 165; SEQ ID NO: 166; SEQ ID NO:
30 167; SEQ ID NO: 168; SEQ ID NO: 169; SEQ ID NO: 170; SEQ ID NO: 171; SEQ ID NO:
172; SEQ ID NO: 173; SEQ ID NO: 174; SEQ ID NO: 175; SEQ ID NO: 176; SEQ ID NO:
177; SEQ ID NO: 178; SEQ ID NO: 179; SEQ ID NO: 180; SEQ ID NO: 181; SEQ ID NO:
182; SEQ ID NO: 183; SEQ ID NO: 184; SEQ ID NO: 185; and SEQ ID NO: 186.

In a further embodiment, the microarray may be a microarray comprising an epithelial cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof, or portions of said nucleic acid sequence or complementary sequence thereof, selected from the group

5 consisting of SEQ ID NO: 47; SEQ ID NO: 60; SEQ ID NO: 67; SEQ ID NO: 73; SEQ ID NO: 75; SEQ ID NO: 76; SEQ ID NO: 77; SEQ ID NO: 78; SEQ ID NO: 80; SEQ ID NO: 96; SEQ ID NO: 98; SEQ ID NO: 99; SEQ ID NO: 111; SEQ ID NO: 112; SEQ ID NO: 123; SEQ ID NO: 127; SEQ ID NO: 131; SEQ ID NO: 150; SEQ ID NO: 153; SEQ ID NO: 154; SEQ ID NO: 155; SEQ ID NO: 156; SEQ ID NO: 157; SEQ ID NO: 158; SEQ ID NO: 159;
10 SEQ ID NO: 160; SEQ ID NO: 161; SEQ ID NO: 162; SEQ ID NO: 163; SEQ ID NO: 164; SEQ ID NO: 165; SEQ ID NO: 166; SEQ ID NO: 167; SEQ ID NO: 168; SEQ ID NO: 169; SEQ ID NO: 170; SEQ ID NO: 171; SEQ ID NO: 172; SEQ ID NO: 173; SEQ ID NO: 174; SEQ ID NO: 175; SEQ ID NO: 176; SEQ ID NO: 177; SEQ ID NO: 178; SEQ ID NO: 179; SEQ ID NO: 180; SEQ ID NO: 181; SEQ ID NO: 182; SEQ ID NO: 183; SEQ ID NO: 184;
15 SEQ ID NO: 185; and SEQ ID NO: 186.

In yet another embodiment, a microarray may comprise a keratinocyte epithelial cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof, or portions of said nucleic acid sequence or complementary sequence thereof, selected from the group

20 consisting of SEQ ID NO: 187; SEQ ID NO: 188; SEQ ID NO: 189; SEQ ID NO: 190; SEQ ID NO: 191; SEQ ID NO: 192; SEQ ID NO: 193; SEQ ID NO: 194; SEQ ID NO: 195; SEQ ID NO: 196; SEQ ID NO: 197; SEQ ID NO: 198; SEQ ID NO: 199; SEQ ID NO: 200; SEQ ID NO: 201; SEQ ID NO: 202; SEQ ID NO: 203; SEQ ID NO: 204; SEQ ID NO: 205; SEQ ID NO: 206; SEQ ID NO: 207; SEQ ID NO: 208; SEQ ID NO: 209; SEQ ID NO: 210; and
25 SEQ ID NO: 211.

The present invention also provides a microarray comprising a mammary epithelial cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof, or portions of said nucleic acid sequence or complementary sequence thereof, selected from the group

30 consisting of SEQ ID NO: 78; SEQ ID NO: 212; SEQ ID NO: 213; SEQ ID NO: 216; SEQ ID NO: 225; SEQ ID NO: 226; SEQ ID NO: 227; SEQ ID NO: 239; SEQ ID NO: 271; SEQ ID NO: 285; and SEQ ID NO: 289.

In an alternative embodiment, a microarray may comprise a bronchial epithelial cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof, or portions of said nucleic acid sequence or complementary sequence thereof, selected from the group

5 consisting of SEQ ID NO: 27; SEQ ID NO: 131; SEQ ID NO: 150; SEQ ID NO: 169; SEQ ID NO: 214; SEQ ID NO: 215; SEQ ID NO: 223; SEQ ID NO: 224; SEQ ID NO: 241; SEQ ID NO: 243; SEQ ID NO: 244; SEQ ID NO: 255; SEQ ID NO: 256; SEQ ID NO: 261; and SEQ ID NO: 314.

The present invention also provides a microarray comprising a prostate epithelial cell
10 gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof, or portions of said nucleic acid sequence or complementary sequence thereof, selected from the group consisting of SEQ ID NO: 64; SEQ ID NO: 217; SEQ ID NO: 218; SEQ ID NO: 259; SEQ ID NO: 293; SEQ ID NO: 302; and SEQ ID NO: 320.

15 In yet another embodiment, a microarray comprises a renal cortical epithelial cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof, or portions of said nucleic acid sequence or complementary sequence thereof, selected from the group consisting of SEQ ID NO: 49; SEQ ID NO: 57; SEQ ID NO: 104; SEQ ID NO: 123; SEQ ID
20 NO: 160; SEQ ID NO: 165; SEQ ID NO: 166; SEQ ID NO: 219; SEQ ID NO: 267; SEQ ID NO: 270; SEQ ID NO: 279; SEQ ID NO: 280; SEQ ID NO: 283; SEQ ID NO: 291; SEQ ID NO: 305; SEQ ID NO: 307; SEQ ID NO: 310; SEQ ID NO: 313; SEQ ID NO: 325; SEQ ID NO: 326; and SEQ ID NO: 327.

The present invention further provides a microarray comprising a renal proximal
25 tubule epithelial cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof, or portions of said nucleic acid sequence or complementary sequence thereof, selected from the group consisting of SEQ ID NO: 106; SEQ ID NO: 138; SEQ ID NO: 158; SEQ ID NO: 228; SEQ ID NO: 236; SEQ ID NO: 242; SEQ ID NO: 250; SEQ ID NO: 258; SEQ ID NO: 260;
30 SEQ ID NO: 262; SEQ ID NO: 266; SEQ ID NO: 272; SEQ ID NO: 273; SEQ ID NO: 274; SEQ ID NO: 275; SEQ ID NO: 276; SEQ ID NO: 278; SEQ ID NO: 284; SEQ ID NO: 288; SEQ ID NO: 295; SEQ ID NO: 296; SEQ ID NO: 297; SEQ ID NO: 299; SEQ ID NO: 300; SEQ ID NO: 301; SEQ ID NO: 306; SEQ ID NO: 308; SEQ ID NO: 309; SEQ ID NO: 311;

SEQ ID NO: 316; SEQ ID NO: 318; SEQ ID NO: 321; SEQ ID NO: 322; SEQ ID NO: 328; and SEQ ID NO: 329.

In a specific embodiment, a microarray may comprise a small airway epithelial cell gene expression profile comprising one or more nucleic acid sequences substantially
5 homologous to a nucleic acid sequence or complementary sequence thereof, or portions of said nucleic acid sequence or complementary sequence thereof, selected from the group consisting of SEQ ID NO: 173; SEQ ID NO: 174; SEQ ID NO: 183; SEQ ID NO: 220; SEQ ID NO: 221; SEQ ID NO: 222; SEQ ID NO: 229; SEQ ID NO: 230; SEQ ID NO: 231; SEQ ID NO: 232; SEQ ID NO: 233; SEQ ID NO: 234; SEQ ID NO: 235; SEQ ID NO: 237; SEQ
10 ID NO: 238; SEQ ID NO: 240; SEQ ID NO: 245; SEQ ID NO: 246; SEQ ID NO: 247; SEQ ID NO: 248; SEQ ID NO: 249; SEQ ID NO: 251; SEQ ID NO: 252; SEQ ID NO: 254; SEQ ID NO: 257; SEQ ID NO: 263; SEQ ID NO: 264; SEQ ID NO: 265; SEQ ID NO: 268; SEQ ID NO: 269; SEQ ID NO: 270; SEQ ID NO: 277; SEQ ID NO: 281; SEQ ID NO: 282; SEQ ID NO: 286; SEQ ID NO: 287; SEQ ID NO: 290; SEQ ID NO: 294; SEQ ID NO: 298; SEQ
15 ID NO: 303; SEQ ID NO: 312; SEQ ID NO: 315; SEQ ID NO: 317; and SEQ ID NO: 319.

The present invention also provides a microarray comprising a renal epithelial cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof, or portions of said nucleic acid sequence or complementary sequence thereof, selected from the group
20 consisting of SEQ ID NO: 37; SEQ ID NO: 253; SEQ ID NO: 304; SEQ ID NO: 323; and SEQ ID NO: 324.

In yet another embodiment, a microarray may comprise one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof, or portions of said nucleic acid sequence or complementary sequence thereof,
25 selected from the group consisting of SEQ ID NO: 27; SEQ ID NO: 37; SEQ ID NO: 49; SEQ ID NO: 57; SEQ ID NO: 64; SEQ ID NO: 70; SEQ ID NO: 78; SEQ ID NO: 104; SEQ ID NO: 106; SEQ ID NO: 123; SEQ ID NO: 131; SEQ ID NO: 138; SEQ ID NO: 150; SEQ ID NO: 158; SEQ ID NO: 160; SEQ ID NO: 165; SEQ ID NO: 166; SEQ ID NO: 169; SEQ ID NO: 173; SEQ ID NO: 174; SEQ ID NO: 183; SEQ ID NO: 187; SEQ ID NO: 188; SEQ
30 ID NO: 189; SEQ ID NO: 190; SEQ ID NO: 191; SEQ ID NO: 192; SEQ ID NO: 193; SEQ ID NO: 194; SEQ ID NO: 195; SEQ ID NO: 196; SEQ ID NO: 197; SEQ ID NO: 198; SEQ ID NO: 199; SEQ ID NO: 200; SEQ ID NO: 201; SEQ ID NO: 202; SEQ ID NO: 203; SEQ ID NO: 204; SEQ ID NO: 205; SEQ ID NO: 206; SEQ ID NO: 207; SEQ ID NO: 208; SEQ

ID NO: 209; SEQ ID NO: 210; SEQ ID NO: 211; SEQ ID NO: 212; SEQ ID NO: 213; SEQ ID NO: 214; SEQ ID NO: 215; SEQ ID NO: 216; SEQ ID NO: 217; SEQ ID NO: 218; SEQ ID NO: 219; SEQ ID NO: 220; SEQ ID NO: 221; SEQ ID NO: 222; SEQ ID NO: 223; SEQ ID NO: 224; SEQ ID NO: 225; SEQ ID NO: 226; SEQ ID NO: 227; SEQ ID NO: 228; SEQ ID NO: 229; SEQ ID NO: 230; SEQ ID NO: 231; SEQ ID NO: 232; SEQ ID NO: 233; SEQ ID NO: 234; SEQ ID NO: 235; SEQ ID NO: 236; SEQ ID NO: 237; SEQ ID NO: 238; SEQ ID NO: 239; SEQ ID NO: 240; SEQ ID NO: 241; SEQ ID NO: 242; SEQ ID NO: 243; SEQ ID NO: 244; SEQ ID NO: 245; SEQ ID NO: 246; SEQ ID NO: 247; SEQ ID NO: 248; SEQ ID NO: 249; SEQ ID NO: 250; SEQ ID NO: 251; SEQ ID NO: 252; SEQ ID NO: 253; SEQ ID NO: 254; SEQ ID NO: 255; SEQ ID NO: 256; SEQ ID NO: 257; SEQ ID NO: 258; SEQ ID NO: 259; SEQ ID NO: 260; SEQ ID NO: 261; SEQ ID NO: 262; SEQ ID NO: 263; SEQ ID NO: 264; SEQ ID NO: 265; SEQ ID NO: 266; SEQ ID NO: 267; SEQ ID NO: 268; SEQ ID NO: 269; SEQ ID NO: 270; SEQ ID NO: 271; SEQ ID NO: 272; SEQ ID NO: 273; SEQ ID NO: 274; SEQ ID NO: 275; SEQ ID NO: 276; SEQ ID NO: 277; SEQ ID NO: 278; SEQ ID NO: 279; SEQ ID NO: 280; SEQ ID NO: 281; SEQ ID NO: 282; SEQ ID NO: 283; SEQ ID NO: 284; SEQ ID NO: 285; SEQ ID NO: 286; SEQ ID NO: 287; SEQ ID NO: 288; SEQ ID NO: 289; SEQ ID NO: 290; SEQ ID NO: 291; SEQ ID NO: 293; SEQ ID NO: 294; SEQ ID NO: 295; SEQ ID NO: 296; SEQ ID NO: 297; SEQ ID NO: 298; SEQ ID NO: 299; SEQ ID NO: 300; SEQ ID NO: 301; SEQ ID NO: 302; SEQ ID NO: 303; SEQ ID NO: 304; SEQ ID NO: 305; SEQ ID NO: 306; SEQ ID NO: 307; SEQ ID NO: 308; SEQ ID NO: 309; SEQ ID NO: 310; SEQ ID NO: 311; SEQ ID NO: 312; SEQ ID NO: 313; SEQ ID NO: 314; SEQ ID NO: 315; SEQ ID NO: 316; SEQ ID NO: 317; SEQ ID NO: 318; SEQ ID NO: 320; SEQ ID NO: 321; SEQ ID NO: 322; SEQ ID NO: 323; SEQ ID NO: 324; SEQ ID NO: 325; SEQ ID NO: 326; SEQ ID NO: 327; SEQ ID NO: 328; and SEQ ID NO: 329.

In another embodiment, the present invention provides a microarray comprising a gene expression profile comprising one or more genes or oligonucleotide probes obtained therefrom, wherein said gene expression profile is generated from a cell type selected from the group comprising coronary artery endothelium, umbilical artery endothelium, umbilical vein endothelium, aortic endothelium, dermal microvascular endothelium, pulmonary artery endothelium, myometrium microvascular endothelium, keratinocyte epithelium, bronchial epithelium, mammary epithelium, prostate epithelium, renal cortical epithelium, renal proximal tubule epithelium, small airway epithelium, renal epithelium, umbilical artery smooth muscle, neonatal dermal fibroblast, pulmonary artery smooth muscle, dermal

fibroblast, neural progenitor cells, skeletal muscle, astrocytes, aortic smooth muscle, mesangial cells, coronary artery smooth muscle, bronchial smooth muscle, uterine smooth muscle, lung fibroblast, osteoblasts, and prostate stromal cells.

This invention also relates to methods of doing business comprising the steps of
5 determining the level of RNA expression for an RNA sample, wherein the RNA sample is amplified, fluorescently labeled, and hybridized to a microarray containing a plurality of nucleic acid sequences, and wherein the microarray is scanned for fluorescence; normalizing the expression levels using an algorithm, and scoring the RNA sample against a gene expression profile database. In one embodiment, the RNA sample is obtained from a patient
10 and the patient sample includes, but is not limited to, blood, amniotic fluid, plasma, semen, bone marrow, and tissue biopsy.

In another aspect of this method, the algorithm is either the MaxCor algorithm or the Mean Log Ratio algorithm. The invention described herein further provides algorithms useful for generating gene expression profiles. Specifically, the present invention provides
15 for either the MaxCor algorithm or the Mean Log Ratio algorithm to generate a gene expression profile.

The present invention also relates to a method of constructing a gene expression profile comprising the steps of hybridizing prepared RNA samples to a microarray containing a plurality of known nucleic acid sequences representing genes of a particular organism;
20 obtaining an expression level for each gene on a microarray; and normalizing the expression level for each gene on a microarray to control standards.

In a further aspect, the method of constructing a gene expression profile comprises the steps applying an algorithm to each of the normalized gene expression levels; performing a correlation analysis for all normalized gene expression microarrays within a group of
25 samples; establishing a gene expression profile using a signature extraction algorithm; and validating the gene expression profile.

In one embodiment, the algorithm of the profile construction method is the MaxCor algorithm. Specifically, the MaxCor algorithm is used to generate a numeric value that is assigned to each gene based upon the expression level contained on the microarray. In one
30 embodiment, the numeric value is between the range of (-1,+1). In particular, a negative numeric value represents a gene with relatively lower expression; a zero numeric value represents no relative gene expression difference; and a positive numeric value represents a gene with relatively higher expression.

In one embodiment, the numeric value is between the range of $(-2,+2)$. In particular, a negative numeric value represents a gene with relatively lower expression; a zero numeric value represents no relative gene expression difference; and a positive numeric value represents a gene with relatively higher expression.

5 In another embodiment, the algorithm of the profile construction method is the Mean Log Ratio algorithm. Specifically, the Mean Log Ratio algorithm is used to generate a numeric value that is assigned to each gene based upon the expression level contained on the microarray. In one embodiment, the numeric value is between the range of $(-1,+1)$. In particular, a negative numeric value represents a gene with relatively lower expression; a zero
10 numeric value represents no relative gene expression difference; and a positive numeric value represents a gene with relatively higher expression.

In one embodiment, the numeric value is between the range of $(-2,+2)$. In particular, a negative numeric value represents a gene with relatively lower expression; a zero numeric value represents no relative gene expression difference; and a positive numeric value
15 represents a gene with relatively higher expression.

The present invention further provides a method, in a computer system, for constructing and analyzing a gene expression profile comprising the steps of inputting gene expression data for each of a plurality of genes; normalizing expression data by transforming said data into log ratio values; filtering weak differential values; applying an algorithm to
20 each of said normalized gene expression values; performing a classification analysis for all normalized gene expression values; establishing a gene expression profile; and validating the gene expression profile. The algorithm may be the MaxCor algorithm or the Mean Log Ratio algorithm.

This invention is also related to computer programs for constructing and analyzing a
25 gene expression signature. These computer programs may comprise computer code that receives as input gene expression data for a plurality of genes; computer code that normalizes expression data by transforming the data into log ratio values; computer code that applies an algorithm to each of the normalized gene expression values; computer code that performs a correlation analysis for the normalized gene expression values; computer code that
30 establishes and validates the gene expression profile; and computer readable medium that stores computer code. The computer program may utilize the MaxCor algorithm or the Mean Log Ratio algorithm for gene expression profile analysis.

The present invention also provides methods for identifying the phenotype of an unknown cell. This method comprises applying an algorithm to extract a gene expression profile from gene expression data generated from the cell; and matching the gene expression profile to a gene expression profile generated from a cell of known phenotype. In one embodiment, the algorithm is the MaxCor algorithm. In an alternative embodiment, the algorithm is the Mean Log Ratio algorithm.

In a particular embodiment, the application of an algorithm to extract a gene expression profile comprises setting a cutoff value for expression relative to normalized values, wherein said cutoff value is at least about two-fold induction above the normalized values. Moreover, the matching step may be performed using a database comprising one or more gene expression profiles generated from cells of known phenotype.

The present invention further provides methods for distinguishing cell types comprising using an algorithm to generate a gene expression profile from a biological sample; and matching said generated gene expression profile to a gene expression profile of a specific cell type. In one embodiment, the algorithm is the MaxCor algorithm. In an alternative embodiment, the algorithm is the Mean Log Ratio algorithm.

In a further embodiment, the specific cell type is selected from the group consisting of coronary artery endothelium, umbilical artery endothelium, umbilical vein endothelium, aortic endothelium, dermal microvascular endothelium, pulmonary artery endothelium, myometrium microvascular endothelium, keratinocyte epithelium, bronchial epithelium, mammary epithelium, prostate epithelium, renal cortical epithelium, renal proximal tubule epithelium, small airway epithelium, renal epithelium, umbilical artery smooth muscle, neonatal dermal fibroblast, pulmonary artery smooth muscle, dermal fibroblast, neural progenitor cells, skeletal muscle, astrocytes, aortic smooth muscle, mesangial cells, coronary artery smooth muscle, bronchial smooth muscle, uterine smooth muscle, lung fibroblast, osteoblasts, and prostate stromal cells.

In a specific embodiment, the present invention provides a method for determining the phenotype of a cell comprising the steps of applying an algorithm to extract a protein expression profile from protein expression data generated from the cell and matching the protein expression profile to a protein expression profile generated from a cell of known phenotype.

In one embodiment, the algorithm is the MaxCor algorithm. In an alternative embodiment, the algorithm is the Mean Log Ratio algorithm. In yet another embodiment, the

applying step comprises setting a cutoff value for expression relative to normalized values, wherein said cutoff value is at least about two-fold induction above the normalized values. In yet another embodiment, the matching step is performed using a database comprising one or more protein expression profiles generated from cells of known phenotype.

5 The present invention provides a method for distinguishing cell types comprising the step of matching a protein expression profile generated from a biological sample using an algorithm to a known protein expression profile of a specific cell type. In one embodiment, the algorithm is the MaxCor algorithm. In an alternative embodiment, the algorithm is the Mean Log Ratio algorithm.

10 In a further embodiment, the specific cell type is selected from the group consisting of coronary artery endothelium, umbilical artery endothelium, umbilical vein endothelium, aortic endothelium, dermal microvascular endothelium, pulmonary artery endothelium, myometrium microvascular endothelium, keratinocyte epithelium, bronchial epithelium, mammary epithelium, prostate epithelium, renal cortical epithelium, renal proximal tubule
15 epithelium, small airway epithelium, renal epithelium, umbilical artery smooth muscle, neonatal dermal fibroblast, pulmonary artery smooth muscle, dermal fibroblast, neural progenitor cells, skeletal muscle, astrocytes, aortic smooth muscle, mesangial cells, coronary artery smooth muscle, bronchial smooth muscle, uterine smooth muscle, lung fibroblast, osteoblasts, and prostate stromal cells.

20

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. Laser capture microdissection (LCM) of 10 μ m Nissl-stained sections of adult rat large and small dorsal root ganglion (DRG) neurons. The arrows indicate DRG neurons to be captured (top panel). The middle and bottom panels show successful capture
25 and film transfer respectively.

Figure 2a-2b. Microarray of cDNA expression patterns of small (S) and large (L) neurons. Figure 2a is an example of the cDNA microarray data obtained. Boxed in white is an identical region of the microarray for L1 and S1 samples that is enlarged (shown directly below). In Figure 2b, scatter plots are shown that demonstrate the correlation between
30 independent amplifications of S1 vs. S2, S1 vs. S3, L1 vs. L2, and L (L1 and L2) vs. S (S1, S2, and S3).

Figure 3. Preferentially expressed mRNAs identified in small DRG neurons. The ratio value describes the mean fluorescence intensity ratio of the small DRG neurons as compared to the large DRG neurons.

Figure 4. Preferentially expressed mRNAs identified in large DRG neurons. The ratio value describes the mean fluorescence intensity ratio of the large DRG neurons as compared to the small DRG neurons.

Figure 5. Representative fields of *in situ* hybridization of rat DRG with selected cDNAs. The sections were Nissl-counterstained. The left panel shows results with radiolabeled probes encoding neurofilament-high (NF-H), neurofilament-low (NF-L) and β -1 subunit of the voltage-gated sodium channel (SCN β -1). Arrows in the left panel denote identifiable small neurons. The right panel shows representative fields from radiolabeled probes encoding calcitonin gene-related product (CGRP), voltage-gated sodium channel (NaV), and phospholipase C delta-4 (PLC). Arrows in the right panel denote identifiable large neurons. The large arrowhead denotes a large neuron which is also labeled.

Figures 6. *In situ* hybridization of selected cDNAs identified in small DRG neurons and large DRG neurons. Based on quantitative measurements comparing the overall intensity of signal in small and large neurons and the percentage of cells labeled within the total population of either small or large neurons, the preferential expression of these mRNAs was demonstrated.

Figure 7. Profile extraction analysis of several primary cell types. Clustering analysis of the gene expression profiles of the primary cell samples confirmed that these cell types could be classified into three groups: endothelial, epithelial, and muscle cell.

Figure 8. Cluster analysis of the 30 gene expression vectors using the hclust algorithm in the S-plus statistical package (MathSoft, Inc., Cambridge, MA). The hclust algorithm groups together primary cells with similar gene expression patterns. The three sample groups (endothelial, epithelial, and muscle cells) were easily separated.

Figure 9a-9t. The gene expression profile of human primary cells. The profile represents 459 genes identified from 30 primary cell types. The sequence source (Seq. Source) is the gene database (GB: GenBank; INCYTE: Incyte Genomes) from which the sequence was selected. The endothelial, epithelial, and muscle profile values are the numeric representation of the specific profile. The p-value is based on the Kruskal-Wallis rank test in which smaller p-values represent clones with higher discriminate power for classifying samples. The source description identifies the particular gene.

Figure 10a-10c. The gene expression profile of endothelial cells. The sequence source (Seq. Source) is the gene database (GB: GenBank; INCYTE: Incyte Genomes) from which the sequence was selected. The endothelial, epithelial, and muscle profile values are the numeric representation of the specific profile. The p-value is based on the Kruskal-Wallis rank test in which smaller p-values represent clones with higher discriminate power for classifying samples. The source description identifies the particular gene.

Figure 11a-11c. The gene expression profile of epithelial cells. The sequence source (Seq. Source) is the gene database (GB: GenBank; INCYTE: Incyte Genomes) from which the sequence was selected. The endothelial, epithelial, and muscle profile values are the numeric representation of the specific profile. The p-value is based on the Kruskal-Wallis rank test in which smaller p-values represent clones with higher discriminate power for classifying samples. The source description identifies the particular gene.

Figure 12a-12b. The gene expression profile of muscle cells. The sequence source (Seq. Source) is the gene database (GB: GenBank; INCYTE: Incyte Genomes) from which the sequence was selected. The endothelial, epithelial, and muscle profile values are the numeric representation of the specific profile. The p-value is based on the Kruskal-Wallis rank test in which smaller p-values represent clones with higher discriminate power for classifying samples. The source description identifies the particular gene.

Figure 13. The profile vectors (endothelial, epithelial, and muscle) generated by using the Mean Log Ratio and MaxCor algorithms are plotted graphically. The numbers are plotted according to the color bar. Numbers in the middle are plotted with colors in between as indicated.

Figure 14. Self-validation analysis using the Mean Log Ratio algorithm. Each of the 30 samples was scored against the three expression profiles generated by using all 30 samples. The scores are plotted on the bar chart (white – endothelial, black – epithelial, hatched – muscle). The order of the primary cells is listed in Figure 7.

Figure 15. Omit-one analysis using the Mean Log Ratio algorithm. Each of the 30 samples was scored against the three expression profiles generated by using all but the sample omitted. The scores are plotted on the bar chart (white – endothelial, black – epithelial, hatched – muscle). The order of the primary cells is listed on Figure 7.

Figure 16. Self-validation analysis using the MaxCor algorithm. Each of the 30 samples were scored against the three expression profiles generated by using all 30 samples.

The scores are plotted on the bar chart (white – endothelial, black – epithelial, hatched – muscle). The order of the primary cells is listed on Figure 7.

Figure 17. Omit-one analysis using the MaxCor algorithm. Each of the 30 samples was scored against the three expression profiles generated by using all but the sample omitted. The scores are plotted on the bar chart (white – endothelial, black – epithelial, hatched – muscle). The order of the primary cells is listed on Figure 7.

Figure 18a-18f. Gene expression profiles of epithelial cell lines derived from keratinocyte epithelium, mammary epithelium, bronchial epithelium, prostate epithelium, renal cortical epithelium, renal proximal tubule epithelium, small airway epithelium, and renal epithelium. The data is sorted from highest relative expression to lowest relative expression for keratinocyte epithelial cells.

DETAILED DESCRIPTION OF THE INVENTION

It is to be understood that this invention is not limited to the particular methodology, protocols, cell lines, animal species or genera, constructs, or reagents described and as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to “a protein” is a reference to one or more proteins and includes equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs. Although any methods, devices, and materials similar or equivalent to those described herein can be used in the practice or testing of the invention, the preferred methods, devices and materials are now described.

All publications and patents mentioned herein are hereby incorporated by reference for the purpose of describing and disclosing, for example, the constructs and methodologies that are described in the publications which might be used in connection with the presently described invention. The publications discussed above and throughout the text are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is

to be construed as an admission that the inventors are not entitled to antedate such disclosure by virtue of prior invention.

DEFINITIONS

5 For convenience, the meaning of certain terms and phrases employed in the specification, examples, and appended claims are provided below. The definitions are not meant to be limiting in nature and serve to provide a clearer understanding of certain aspects of the present invention.

The term “genome” is intended to include the entire DNA complement of an
10 organism, including the nuclear DNA component, chromosomal or extrachromosomal DNA, as well as the cytoplasmic domain (*e.g.*, mitochondrial DNA).

The term “gene” refers to a nucleic acid sequence that comprises control and coding sequences necessary for producing a polypeptide or precursor. The polypeptide may be encoded by a full length coding sequence or by any portion of the coding sequence. The gene
15 may be derived in whole or in part from any source known to the art, including a plant, a fungus, an animal, a bacterial genome or episome, eukaryotic, nuclear or plasmid DNA, cDNA, viral DNA, or chemically synthesized DNA. A gene may contain one or more modifications in either the coding or the untranslated regions that could affect the biological activity or the chemical structure of the expression product, the rate of expression, or the
20 manner of expression control. Such modifications include, but are not limited to, mutations, insertions, deletions, and substitutions of one or more nucleotides. The gene may constitute an uninterrupted coding sequence or it may include one or more introns, bound by the appropriate splice junctions.

The term “gene expression” refers to the process by which a nucleic acid sequence
25 undergoes successful transcription and translation such that detectable levels of the nucleotide sequence are expressed.

The terms “gene expression profile” or “gene expression signature” refer to a group of genes representing a particular cell or tissue type (*e.g.*, neuron, coronary artery endothelium, or disease tissue).

30 The term “nucleic acid” as used herein, refers to a molecule comprised of one or more nucleotides, *i.e.*, ribonucleotides, deoxyribonucleotides, or both. The term includes monomers and polymers of ribonucleotides and deoxyribonucleotides, with the ribonucleotides and/or deoxyribonucleotides being bound together, in the case of the

polymers, via 5' to 3' linkages. The ribonucleotide and deoxyribonucleotide polymers may be single or double-stranded. However, linkages may include any of the linkages known in the art including, for example, nucleic acids comprising 5' to 3' linkages. The nucleotides may be naturally occurring or may be synthetically produced analogs that are capable of
5 forming base-pair relationships with naturally occurring base pairs. Examples of non-naturally occurring bases that are capable of forming base-pairing relationships include, but are not limited to, aza and deaza pyrimidine analogs, aza and deaza purine analogs, and other heterocyclic base analogs, wherein one or more of the carbon and nitrogen atoms of the pyrimidine rings have been substituted by heteroatoms, *e.g.*, oxygen, sulfur, selenium,
10 phosphorus, and the like. Furthermore, the term "nucleic acid sequences" contemplates the complementary sequence and specifically includes any nucleic acid sequence that is substantially homologous to the both the nucleic acid sequence and its complement.

The term "homology", as used herein, refers to a degree of complementarity. There may be partial homology or complete homology (*i.e.*, identity). A partially complementary
15 sequence is one that at least partially inhibits an identical sequence from hybridizing to a target nucleic acid; it is referred to using the functional term "substantially homologous." The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization assay (Southern or northern blot, solution hybridization and the like) under conditions of low stringency. A substantially homologous
20 sequence or probe will compete for and inhibit the binding (*i.e.*, the hybridization) of a completely homologous sequence or probe to the target sequence under conditions of low stringency. This is not to say that conditions of low stringency are such that non-specific binding is permitted; low stringency conditions require that the binding of two sequences to
one another be a specific (*i.e.*, selective) interaction. The absence of non-specific binding
25 may be tested by the use of a second target sequence which lacks even a partial degree of complementarity (*e.g.*, less than about 30% identity); in the absence of non-specific binding, the probe will not hybridize to the second non-complementary target sequence.

The term "oligonucleotide" as used herein refers to a nucleic acid molecule comprising, for example, from about 10 to about 1000 nucleotides. Oligonucleotides for use
30 in the present invention are preferably from about 15 to about 150 nucleotides, more preferably from about 150 to about 1000 in length. The oligonucleotide may be a naturally occurring oligonucleotide or a synthetic oligonucleotide. Oligonucleotides may be prepared by the phosphoramidite method (Beaucage and Carruthers, 22 TETRAHEDRON LETT. 1859-62

(1981)), or by the triester method (Matteucci et al., 103 J. AM. CHEM. SOC. 3185 (1981)), or by other chemical methods known in the art.

The terms "modified oligonucleotide" and "modified polynucleotide" as used herein refer to oligonucleotides or polynucleotides with one or more chemical modifications at the
5 molecular level of the natural molecular structures of all or any of the bases, sugar moieties, internucleoside phosphate linkages, as well as to molecules having added substitutions or a combination of modifications at these sites. The internucleoside phosphate linkages may be phosphodiester, phosphotriester, phosphoramidate, siloxane, carbonate, carboxymethylester, acetamidate, carbamate, thioether, bridged phosphoramidate, bridged methylene

10 phosphonate, phosphorothioate, methylphosphonate, phosphorodithioate, bridged phosphorothioate or sulfone internucleotide linkages, or 3'-3', 5'-3', or 5'-5' linkages, and combinations of such similar linkages. The phosphodiester linkage may be replaced with a substitute linkage, such as phosphorothioate, methylamino, methylphosphonate, phosphoramidate, and guanidine, and the ribose subunit of the nucleic acids may also be
15 substituted (*e.g.*, hexose phosphodiester; peptide nucleic acids). The modifications may be internal (single or repeated) or at the end(s) of the oligonucleotide molecule, and may include additions to the molecule of the internucleoside phosphate linkages, such as deoxyribose and phosphate modifications which cleave or crosslink to the opposite chains or to associated enzymes or other proteins. The terms "modified oligonucleotides" and "modified
20 polynucleotides" also include oligonucleotides or polynucleotides comprising modifications to the sugar moieties (*e.g.*, 3'-substituted ribonucleotides or deoxyribonucleotide monomers), any of which are bound together via 5' to 3' linkages.

"Biomolecular sequence," as used herein, is a term that refers to all or a portion of a gene or nucleic acid sequence. A biomolecular sequence may also refer to all or a portion of
25 an amino acid sequence.

The terms "array" and "microarray" refer to the type of genes or proteins represented on an array by oligonucleotides or protein-capture agents, and where the type of genes or proteins represented on the array is dependent on the intended purpose of the array (*e.g.*, to monitor expression of human genes or proteins). The oligonucleotides or protein-capture
30 agents on a given array may correspond to the same type, category, or group of genes or proteins. Genes or proteins may be considered to be of the same type if they share some common characteristics such as species of origin (*e.g.*, human, mouse, rat); disease state (*e.g.*, cancer); functions (*e.g.*, protein kinases, tumor suppressors); same biological process (*e.g.*,

apoptosis, signal transduction, cell cycle regulation, proliferation, differentiation). For example, one array type may be a “cancer array” in which each of the array oligonucleotides or protein-capture agents correspond to a gene or protein associated with a cancer. An “epithelial array” may be an array of oligonucleotides or protein-capture agents
5 corresponding to unique epithelial genes or proteins. Similarly, a “cell cycle array” may be an array type in which the oligonucleotides or protein-capture agents correspond to unique genes or proteins associated with the cell cycle.

The term “cell type” refers to a cell from a given source (*e.g.*, a tissue, organ) or a cell in a given state of differentiation, or a cell associated with a given pathology or genetic
10 makeup.

The term “activation” as used herein refers to any alteration of a signaling pathway or biological response including, for example, increases above basal levels, restoration to basal levels from an inhibited state, and stimulation of the pathway above basal levels.

The term “differential expression” refers to both quantitative as well as qualitative
15 differences in the temporal and tissue expression patterns of a gene or a protein. For example, a differentially expressed gene may have its expression activated or completely inactivated in normal versus disease conditions. Such a qualitatively regulated gene may exhibit an expression pattern within a given tissue or cell type that is detectable in either control or disease conditions, but is not detectable in both. Differentially expressed genes
20 may represent “high information density genes,” “profile genes,” or “target genes.”

Similarly, a differentially expressed protein may have its expression activated or completely inactivated in normal versus disease conditions. Such a qualitatively regulated protein may exhibit an expression pattern within a given tissue or cell type that is detectable in either control or disease conditions, but is not detectable in both. Moreover, differentially
25 expressed genes may represent “high information density proteins,” “profile proteins,” or “target proteins.”

The term “detectable” refers to an RNA expression pattern which is detectable via the standard techniques of polymerase chain reaction (PCR), reverse transcriptase-(RT) PCR, differential display, and Northern analyses, which are well known to those of skill in the art.

30 Similarly, protein expression patterns may be “detected” via standard techniques such as Western blots.

The term “high information density” refers to a gene or protein whose expression pattern may be used as a predictor or diagnostic, may be used in methods for identifying

therapeutic compounds, drug or toxicity screening, or identifying cellular signal pathways or co-regulated genes. Identification of high information density genes or proteins is accomplished by assessing the information content of one or more genes or proteins comprising one or more gene or protein expression profiles. Genes or proteins providing the highest amount of information content comprise high information density genes or proteins. High information density genes may also be referred to as “predictor genes.” Similarly, high information density proteins may be referred to as “predictor proteins.”

The term “information content” refers to the value assigned to a particular gene or protein based on quantitative and qualitative expression under selected conditions.

Information content may be derived by measuring one or more parameters of gene or protein expression including, but not limited to, the cell type in which the gene or protein is expressed, the magnitude of response over time, and response to chemical or physical stimuli. Algorithms may be used in assessing the information content provided by particular genes or proteins.

A “target gene” refers to a nucleic acid, often derived from a biological sample, to which an oligonucleotide probe is designed to specifically hybridize. It is either the presence or absence of the target nucleic acid that is to be detected, or the amount of the target nucleic acid that is to be quantified. The target nucleic acid has a sequence that is complementary to the nucleic acid sequence of the corresponding probe directed to the target. The target nucleic acid may also refer to the specific subsequence of a larger nucleic acid to which the probe is directed or to the overall sequence (*e.g.*, gene or mRNA) whose expression level it is desired to detect.

A “target protein” refers to an amino acid or protein, often derived from a biological sample, to which a protein-capture agent specifically hybridizes or binds. It is either the presence or absence of the target protein that is to be detected, or the amount of the target protein that is to be quantified. The target protein has a structure that is recognized by the corresponding protein-capture agent directed to the target. The target protein or amino acid may also refer to the specific substructure of a larger protein to which the protein-capture agent is directed or to the overall structure (*e.g.*, gene or mRNA) whose expression level it is desired to detect.

The term “complementary” refers to the topological compatibility or matching together of the interacting surfaces of a probe molecule and its target. The target and its probe can be described as complementary, and furthermore, the contact surface

characteristics are complementary to each other. Hybridization or base pairing between nucleotides or nucleic acids, such as, for example, between the two strands of a double-stranded DNA molecule or between an oligonucleotide probe and a target are complementary.

5 The term “hybridization” refers to the binding, duplexing, or hybridizing of a nucleic acid molecule to a particular nucleic acid sequence under stringent conditions. Hybridization may also refer to the binding of a protein-capture agent to a target protein under certain conditions, such as normal physiological conditions.

 The term “stringent conditions” refers to conditions under which a probe may
10 hybridize to its target nucleic acid sequence, but to no other sequences. Stringent conditions are sequence-dependent (*e.g.*, longer sequences hybridize specifically at higher temperatures). Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength, pH, and nucleic acid concentration) at
15 which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. Typically, stringent conditions will be those in which the salt concentration is at least about 0.01 to about 1.0 M sodium ion concentration (or other salts) at about pH 7.0 to about pH 8.3 and the temperature is at least about 30°C for short probes (*e.g.*, 10 to 50 nucleotides). Stringent conditions may also be achieved with the addition of
20 destabilizing agents such as formamide.

 The term “label” refers to agents that are capable of providing a detectable signal, either directly or through interaction with one or more additional members of a signal
producing system. Labels that are directly detectable and may find use in the present
invention include: fluorescent labels, where the wavelength of light absorbed by the
25 fluorophore may generally range from about 300 to about 900 nm, usually from about 400 to about 800 nm, and where the absorbance maximum may typically occur at a wavelength ranging from about 500 to about 800 nm. Specific fluorophores for use in singly labeled primers include: fluorescein, rhodamine, BODIPY, cyanine dyes and the like. Radioactive isotopes, such as ^{35}S , ^{32}P , ^3H , and the like may also be utilized as labels. Examples of labels
30 that provide a detectable signal through interaction with one or more additional members of a signal producing system include capture moieties that specifically bind to complementary binding pair members, where the complementary binding pair members comprise a directly detectable label moiety, such as a fluorescent moiety as described above. The label should be

such that it does not provide a variable signal, but instead provides a constant and reproducible signal over a given period of time. Capture moieties of interest include ligands (e.g., biotin) where the other member of the signal producing system could be fluorescently labeled streptavidin, and the like. The target molecules may be end-labeled, *i.e.*, the label moiety is present at a region at least proximal to, and preferably at, the 5' terminus of the target.

The term "oligonucleotide probe" refers to a surface-immobilized oligonucleotide that may be recognized by a particular target. Depending on context, the term "oligonucleotide probes" refers both to individual oligonucleotide molecules and to the collection of oligonucleotide molecules immobilized at a discrete location. Generally, the probe is capable of binding to a target nucleic acid of complementary sequence through one or more types of chemical bonds, usually through complementary base pairing via hydrogen bond formation. As used herein, an oligonucleotide probe may include natural (e.g., A, G, C, or T) or modified bases (e.g., 7-deazaguanosine, inosine). In addition, the bases in an oligonucleotide probe may be joined by a linkage other than a phosphodiester bond, so long as it does not interfere with hybridization. Thus, oligonucleotide probes may be peptide nucleic acids in which the constituent bases are joined by peptide bonds rather than phosphodiester linkages.

The term "protecting group" as used herein, refers to any of the groups which are designed to block one reactive site in a molecule while a chemical reaction is carried out at another reactive site. The proper selection of protecting groups for a particular synthesis may be governed by the overall methods employed in the synthesis. For example, in photolithography synthesis, discussed below, the protecting groups are photolabile protecting groups such as NVOC and MeNPOC. In other methods, protecting groups may be removed by chemical methods and include groups such as FMOC, DMT, and others known to those of skill in the art.

The term "support" or "substrate" refers to material having a rigid or semi-rigid surface. Such materials may take the form of plates or slides, small beads, pellets, disks or other convenient forms, although other forms may be used. In some embodiments, at least one surface of the substrate will be substantially flat. In other embodiments, a roughly spherical shape may be preferred. In the microarrays of the present invention, the oligonucleotide probes or protein-capture agents (defined below) may be stably associated with the surface of a rigid support, *i.e.*, the probes maintain their position relative to the rigid support under hybridization and washing conditions. As such, the oligonucleotide probes or

protein-capture agents may be non-covalently or covalently associated with the support surface. Examples of non-covalent association include non-specific adsorption, specific binding through a specific binding pair member covalently attached to the support surface, and entrapment in a support material (*e.g.*, a hydrated or dried separation medium) which presents the oligonucleotide probe or protein-capture agent in a manner sufficient for hybridization to occur. Examples of covalent binding include covalent bonds formed between the oligonucleotide probe or protein-capture agent and a functional group present on the surface of the rigid support (*e.g.*, -OH) where the functional group may be naturally occurring or present as a member of an introduced linking group.

As mentioned above, the microarray may be present on a rigid substrate. By rigid, the support is solid and preferably does not readily bend. As such, the rigid substrates of the microarrays are sufficient to provide physical support and structure to the oligonucleotide probes or protein-capture agents present thereon under the assay conditions in which the microarray is utilized, particularly under high-throughput handling conditions.

The term "spatially directed oligonucleotide synthesis" refers to any method of directing the synthesis of an oligonucleotide to a specific location on a substrate.

The term "background" refers to hybridization signals resulting from non-specific binding, or other interactions; between the labeled target nucleic acids and components of the oligonucleotide microarray (*e.g.*, the oligonucleotide probes, control probes, the array substrate) or between target proteins and the protein-capture agents of a protein microarray. Background signals may also be produced by intrinsic fluorescence of the microarray components themselves. A single background signal may be calculated for the entire array, or a different background signal may be calculated for each target nucleic acid or target

protein. The background may be calculated as the average hybridization signal intensity, or where a different background signal is calculated for each target gene or target protein.

Alternatively, background may be calculated as the average hybridization signal intensity produced by hybridization to probes that are not complementary to any sequence found in the sample (*e.g.*, probes directed to nucleic acids of the opposite sense or to genes not found in the sample such as bacterial genes where the sample is mammalian nucleic acids). The background can also be calculated as the average signal intensity produced by regions of the array which lack any probes or protein-capture agents at all.

The term "cluster" refers to a group of nucleic acid sequences or amino acid sequences related to one another by sequence homology. In one example, clusters are formed

based upon a specified degree of homology and/or overlap (*e.g.*, stringency). "Clustering" may be performed with the nucleic acid or amino acid sequence data. For instance, a sequence thought to be associated with a particular molecular or biological function in one tissue might be compared against another library or database of sequences. This type of search is useful to look for homologous, and presumably functionally related, sequences in other tissues or samples, and may be used to streamline the methods of the present invention in that clustering may be used within one or more of the databases to cluster biomolecular sequences prior to performing methods of the invention. The sequences showing sufficient homology with the representative sequence are considered part of a "cluster." Such "sufficient" homology may vary within the needs of one skilled in the art.

The term "linker" refers to a moiety, molecule, or group of molecules attached to a solid support, and spacing an oligonucleotide or other nucleic acid fragment from the solid support.

The term "bead" refers to solid supports for use with the present invention.

Such beads may have a wide variety of forms, including microparticles, beads, and membranes, slides, plates, micromachined chips, and the like. Likewise, solid supports of the invention may comprise a wide variety of compositions, including glass, plastic, silicon, alkanethiolate-derivatized gold, cellulose, low crosslinked and high crosslinked polystyrene, silica gel, polyamide, and the like. Other materials and shapes may be used, including pellets, disks, capillaries, hollow fibers, needles, solid fibers, cellulose beads, pore-glass beads, silica gels, polystyrene beads optionally crosslinked with divinylbenzene, grafted copoly beads, poly-acrylamide beads, latex beads, dimethylacrylamide beads optionally crosslinked with N,N-bis-acryloyl ethylene diamine, and glass particles coated with a hydrophobic polymer.

The term "biological sample" refers to a sample obtained from an organism (*e.g.*, patient) or from components (*e.g.*, cells) of an organism. The sample may be of any biological tissue or fluid. The sample may be a "clinical sample" which is a sample derived from a patient. Such samples include, but are not limited to, sputum, blood, blood cells (*e.g.*, white cells), amniotic fluid, plasma, semen, bone marrow, and tissue or fine needle biopsy samples, urine, peritoneal fluid, and pleural fluid, or cells therefrom. Biological samples may also include sections of tissues such as frozen sections taken for histological purposes. A biological sample may also be referred to as a "patient sample."

“Proteomics” is the study of or the characterization of either the proteome or some fraction of the proteome. The “proteome” is the total collection of the intracellular proteins of a cell or population of cells and the proteins secreted by the cell or population of cells. This characterization includes measurements of the presence, and usually quantity, of the proteins that have been expressed by a cell. The function, structural characteristics (such as post-translational modification), and location within the cell of the proteins may also be studied. “Functional proteomics” refers to the study of the functional characteristics, activity level, and structural characteristics of the protein expression products of a cell or population of cells.

A “protein” means a polymer of amino acid residues linked together by peptide bonds. The term, as used herein, refers to proteins, polypeptides, and peptides of any size, structure, or function. Typically, however, a protein will be at least six amino acids long. If the protein is a short peptide, it will be at least about 10 amino acid residues long. A protein may be naturally occurring, recombinant, or synthetic, or any combination of these. A protein may also comprise a fragment of a naturally occurring protein or peptide. A protein may be a single molecule or may be a multi-molecular complex. The term protein may also apply to amino acid polymers in which one or more amino acid residues is an artificial chemical analogue of a corresponding naturally occurring amino acid.

A “fragment of a protein,” as used herein, refers to a protein that is a portion of another protein. For example, fragments of proteins may comprise polypeptides obtained by digesting full-length protein isolated from cultured cells. In one embodiment, a protein fragment comprises at least about six amino acids. In another embodiment, the fragment comprises at least about ten amino acids. In yet another embodiment, the protein fragment comprises at least about 16 amino acids.

As used herein, an “expression product” is a biomolecule, such as a protein, which is produced when a gene in an organism is expressed. An expression product may comprise post-translational modifications.

The term “protein expression” refers to the process by which a nucleic acid sequence undergoes successful transcription and translation such that detectable levels of the amino acid sequence or protein are expressed.

The terms “protein expression profile” or “protein expression signature” refer to a group of proteins representing a particular cell or tissue type (e.g., neuron, coronary artery endothelium, or disease tissue).

The term "protein-capture agent," as used herein, refers to a molecule or a multi-molecular complex that can bind a protein to itself. In one embodiment, protein-capture agents bind their binding partners in a substantially specific manner. In one embodiment, protein-capture agents may exhibit a dissociation constant (K_D) of less than about 10^{-6} . The protein-capture agent may comprise a biomolecule such as a protein or a polynucleotide. The biomolecule may further comprise a naturally occurring, recombinant, or synthetic biomolecule. Examples of protein-capture agents include antibodies, antigens, receptors, or other proteins, or portions or fragments thereof. Furthermore, protein-capture agents are understood not to be limited to agents that only interact with their binding partners through noncovalent interactions. Rather, protein-capture agents may also become covalently attached to the proteins with which they bind. For example, the protein-capture agent may be photocrosslinked to its binding partner following binding.

A "region of protein-capture agents" is a term that refers to a discrete area of immobilized protein-capture agents on the surface of a substrate. The regions may be of any geometric shape or may be irregularly shaped.

As used herein, the term "binding partner" refers to a protein that may bind to a particular protein-capture agent. In one embodiment, the binding partner binds a protein-capture agent in a substantially specific manner. In some cases, the protein-capture agent may be a cellular or extracellular protein and the binding partner may be the entity normally bound *in vivo*. In other embodiments, however, the binding partner may be the protein or peptide on which the protein-capture agent was selected (through *in vitro* or *in vivo* selection) or raised (as in the case of antibodies). A binding partner may be shared by more than one protein-capture agent. For example, a binding partner that is bound by a variety of polyclonal antibodies may bear a number of different epitopes. One protein-capture agent may also bind to a multitude of binding partners, for example, if the binding partners share the same epitope.

A "population of cells in an organism" means a collection of more than one cell in a single organism or more than one cell originally derived from a single organism. The cells in the collection are preferably all of the same type. They may all be from the same tissue in an organism, for example. Most preferably, gene expression in all of the cells in the population is identical or nearly identical.

"Conditions suitable for protein binding" means those conditions (in terms of salt concentration, pH, detergent, protein concentration, temperature, etc.) that allow for binding

to occur between an immobilized protein-capture agent and its binding partner in solution. Preferably, the conditions are not so lenient that a significant amount of nonspecific protein binding occurs.

A “small molecule” comprises a compound or molecular complex, either synthetic,
5 naturally derived, or partially synthetic, composed of carbon, hydrogen, oxygen, and nitrogen, which may also contain other elements, and which may have a molecular weight of less than about 5,000, and in a specific embodiment between about 100 and about 1,500.

The term “antibody” means an immunoglobulin, whether natural or partially or wholly synthetically produced. All derivatives thereof that maintain specific binding ability
10 are also included in the term. The term also covers any protein having a binding domain that is homologous or largely homologous to an immunoglobulin binding domain. An antibody may be monoclonal or polyclonal. The antibody may be a member of any immunoglobulin class, including any of the human classes: IgG, IgM, IgA, IgD, and IgE.

The term “antibody fragment” refers to any derivative of an antibody that is less than
15 full-length. In one aspect, the antibody fragment retains at least a significant portion of the full-length antibody's specific binding ability, specifically, as a binding partner. Examples of antibody fragments include, but are not limited to, Fab, Fab', F(ab')₂, scFv, Fv, dsFv diabody, and Fd fragments. The antibody fragment may be produced by any means. For example, the antibody fragment may be enzymatically or chemically produced by fragmentation of an
20 intact antibody or it may be recombinantly produced from a gene encoding the partial antibody sequence. Alternatively, the antibody fragment may be wholly or partially synthetically produced. The antibody fragment may comprise a single chain antibody fragment. In another embodiment, the fragment may comprise multiple chains that are linked together, for example, by disulfide linkages. The fragment may also comprise a
25 multimolecular complex. A functional antibody fragment may typically comprise at least about 50 amino acids and more typically will comprise at least about 200 amino acids.

As used herein, single-chain Fvs (scFvs) refer to recombinant antibody fragments, consisting of the variable light chain (V_L) and variable heavy chain (V_H) covalently connected to one another by a polypeptide linker. Either V_L or V_H may be the NH₂-terminal
30 domain. The polypeptide linker may be of variable length and composition so long as the two variable domains are bridged without serious steric interference. Typically, the linkers are comprised primarily of stretches of glycine and serine residues with some glutamic acid or lysine residues interspersed for solubility.

“Diabodies” refer to dimeric scFvs. The components of diabodies generally have shorter peptide linkers than most scFvs and they show a preference for associating as dimers.

An “Fv” fragment consists of one V_H and one V_L domain held together by noncovalent interactions. The term “dsFv” is used herein to refer to an Fv with an engineered
5 intermolecular disulfide bond to stabilize the V_H - V_L pair.

The term “F(ab')₂” fragment refers to an antibody fragment essentially equivalent to that obtained from immunoglobulins by digestion with an enzyme pepsin at pH 4.0-4.5. The fragment may be recombinantly produced.

A “Fab” fragment is an antibody fragment essentially equivalent to that obtained by
10 reduction of the disulfide bridge or bridges joining the two heavy chain pieces in the F(ab')₂ fragment. The Fab' fragment may be recombinantly produced.

A “Fab” fragment is an antibody fragment essentially equivalent to that obtained by digestion of immunoglobulins with the enzyme papain. The Fab fragment may be recombinantly produced. The heavy chain segment of the Fab fragment is the Fd piece.

15 The term “coating” means a layer that is either naturally or synthetically formed on or applied to the surface of the substrate. For example, the exposure of a substrate, such as silicon, to air results in oxidation of the exposed surface. In the case of a substrate made of silicon, a silicon oxide coating is formed on the surface upon exposure to air. In other instances, the coating is not derived from the substrate and may be placed upon the surface
20 via mechanical, physical, electrical, or chemical means. An example of this type of coating would be a metal coating that is applied to a silicon or polymeric substrate or a silicon nitride coating that is applied to a silicon substrate. Although a coating may be of any thickness, typically the coating has a thickness smaller than that of the substrate.

An “interlayer” or “adhesion layer” refers to an additional coating or layer that is
25 positioned between the first coating and the substrate. Multiple interlayers may be used together. The primary purpose of a typical interlayer is to facilitate adhesion between the first coating and the substrate. One such example is the use of a titanium or chromium interlayer to help adhere a gold coating to a silicon or glass surface. However, other possible functions of an interlayer are also contemplated. For example, some interlayers may perform
30 a role in the detection system of the microarray, such as a semiconductor or metal layer between a nonconductive substrate and a nonconductive coating.

An “organic thinfilm” is a thin layer of organic molecules that has been applied to a substrate or to a coating on a substrate if present. An organic thinfilm may be less than about

20 nm thick. Alternatively, an organic thinfilm may be less than about 10 nm thick. An organic thinfilm may be disordered or ordered. For example, an organic thinfilm can be amorphous (such as a chemisorbed or spin-coated polymer) or highly organized (such as a Langmuir-Blodgett film or self-assembled monolayer). An organic thinfilm may be heterogeneous or homogeneous. In one embodiment, the organic thinfilm is a monolayer. In another embodiment, the organic thinfilm comprises a lipid bilayer. In other embodiments, the organic thinfilm may comprise a combination of more than one form of organic thinfilm. For example, an organic thinfilm may comprise a lipid bilayer on top of a self-assembled monolayer. A hydrogel may also compose an organic thinfilm. The organic thinfilm may have functionalities exposed on its surface that serve to enhance the surface conditions of a substrate or the coating on a substrate in any of a number of ways. For example, exposed functionalities of the organic thinfilm may be useful in the binding or covalent immobilization of the protein-capture agents to the regions of the protein microarray. Alternatively, the organic thinfilm may bear functional groups, such as polyethylene glycol (PEG), which reduce the non-specific binding of molecules to the surface. Other exposed functionalities serve to tether the thinfilm to the surface of the substrate or the coating. Particular functionalities of the organic thinfilm may also be designed to enable certain detection techniques to be used with the surface. Alternatively, the organic thinfilm may serve the purpose of preventing inactivation of a protein-capture agent or the protein binding partner to be bound by a protein-capture agent from occurring upon contact with the surface of a substrate or a coating on the surface of a substrate.

A "monolayer" is a single-molecule thick organic thinfilm. A monolayer may be disordered or ordered. A monolayer may be a polymeric compound, such as a polynonionic polymer, a polyionic polymer, or a block-copolymer. For example, the monolayer may comprise a poly amino acid such as polylysine. In another embodiment, the monolayer may be a self-assembled monolayer. One face of the self-assembled monolayer may comprise chemical functionalities on the termini of the organic molecules that are chemisorbed or physisorbed onto the surface of the substrate or, if present, the coating on the substrate. Examples of suitable functionalities of monolayers include the positively charged amino groups of poly-L-lysine for use on negatively charged surfaces and thiols for use on gold surfaces. Generally, the other face of the self-assembled monolayer is exposed and may bear any number of chemical functionalities or end groups.

A “self-assembled monolayer” is a monolayer that is created by the spontaneous assembly of molecules. The self-assembled monolayer may be ordered, disordered, or exhibit short- to long-range order.

An “affinity tag” is a functional moiety capable of directly or indirectly immobilizing a protein-capture agent onto a substrate surface or an exposed functionality of an organic thinfilm covering the substrate surface. In one embodiment, the affinity tag enables the site-specific immobilization and thus enhances orientation of the protein-capture agent onto the organic thinfilm. In some cases, the affinity tag may be a simple chemical functional group. Other possibilities include amino acids, poly amino acids tags, or full-length proteins. Still other possibilities include carbohydrates and nucleic acids. For example, the affinity tag may be a polynucleotide that hybridizes to another polynucleotide serving as a functional group on the organic thinfilm or another polynucleotide serving as an adaptor. The affinity tag may also be a synthetic chemical moiety. If the organic thinfilm of each of the regions of protein-capture agents comprises a lipid bilayer or monolayer, then a membrane anchor is a suitable affinity tag. The affinity tag may be covalently or noncovalently attached to the protein-capture agent. For example, if the affinity tag is covalently attached to the protein-capture agent it may be attached via chemical conjugation or as a fusion protein. The affinity tag may also be attached to the protein-capture agent via a cleavable linkage. Alternatively, the affinity tag may not be directly in contact with the protein-capture agent. Rather, the affinity tag may be separated from the protein-capture agent by an adaptor. The affinity tag may immobilize the protein-capture agent to the organic thinfilm either through noncovalent interactions or through a covalent linkage.

An “adaptor,” for purposes of this invention, is any entity that links an affinity tag to the protein-capture agent. The adaptor may be, but is not limited to, a discrete molecule that is noncovalently attached to both the affinity tag and the protein-capture agent. The adaptor may be covalently attached to the affinity tag or the protein-capture agent or both, via chemical conjugation or as a fusion protein. Full-length proteins, polypeptides, or peptides may be used as adaptors. Other possible adaptors include carbohydrates or nucleic acids.

The term “fusion protein” refers to a protein composed of two or more polypeptides that, although typically not joined in their native state, are joined by their respective amino and carboxyl termini through a peptide linkage to form a single continuous polypeptide. It is understood that the two or more polypeptide components can either be directly joined or indirectly joined through a peptide linker/spacer.

The term "normal physiological conditions" means conditions that are typical inside a living organism or a cell. Although some organs or organisms provide extreme conditions, the intra-organismal and intra-cellular environment normally varies around pH 7 (i.e., from pH 6.5 to pH 7.5), contains water as the predominant solvent, and exists at a temperature above 0°C and below 50°C. The concentration of various salts depends on the organ, organism, cell, or cellular compartment used as a reference.

I. Nucleic Acid Microarrays

Microarray technology provides the opportunity to analyze a large number of nucleic acid sequences. This technology may also be utilized for comparative gene expression analysis, drug discovery, and characterization of molecular interactions. With respect to expression analysis, the expression pattern of a particular gene may be used to characterize the function of that gene. In addition, microarrays may be utilized to analyze both the static expression of a gene (e.g., expression in a specific tissue) as well as, dynamic expression of a particular gene (e.g., expression of one gene relative to the expression of other genes) (Duggan et al., 21 NATURE GENET. 10-14 (1999)).

An advantage of the microarray technology is the use of an impermeable, rigid support as compared to the porous membranes used in the traditional blotting methods (e.g., Northern and Southern analyses). Hybridization buffers do not penetrate the support resulting in greater access to the oligonucleotide probes, enhanced rates of hybridization, and improved reproducibility. In addition, the microarray technology provides better image acquisition and image processing (Southern et al., 21 NATURE GENET. 5-9 (1999)).

For microarray analysis, nucleic acids (e.g., RNA) may be isolated from a biological sample.

Nucleic acid samples include, but are not limited to, mRNA transcripts of the gene or genes, cDNA reverse transcribed from the mRNA, cRNA transcribed from the cDNA, DNA amplified from the genes, RNA transcribed from amplified DNA, and the like.

A. Methods For Producing Nucleic Acid Microarrays

The microarrays may be produced through spatially directed oligonucleotide synthesis. Methods for spatially directed oligonucleotide synthesis include, without limitation, light-directed oligonucleotide synthesis, microlithography, application by ink jet, microchannel deposition to specific locations and sequestration with physical barriers. In general, these methods involve generating active sites, usually by removing protective groups, and coupling to the active site a nucleotide that, itself, optionally has a protected active site if further nucleotide coupling is desired.

A microarray may be configured, for example, by *in situ* synthesis or by direct deposition ("spotting" or "printing") of synthesized oligonucleotide probes onto the support. The oligonucleotide probes are used to detect complementary nucleic acid sequences in a target sample of interest. *In situ* synthesis has several advantages over direct placement such as higher yields, consistency, efficiency, cost, and potential use of combinatorial strategies (Southern et al. (1999)). However, for longer nucleic acid sequences such as PCR products, deposition may be the preferred method. Generation of microarrays by *in situ* synthesis may be accomplished by a number of methods including photochemical deprotection, ink-jet delivery, and flooding channels (Lipshutz et al., 21 NATURE GENET. 20-24 (1999); Blanchard et al., 11 BIOSENSORS AND BIOELECTRONICS, 687-90 (1996); Maskos et al., 21 NUCLEIC ACIDS RES. 4663-69 (1993)).

The present invention relates to the construction of microarrays by the *in situ* synthesis method using solid-phase DNA synthesis and photolithography (Lipshutz et al. (1999)). Linkers with photolabile protecting groups may be covalently or non-covalently attached to a support (*e.g.*, glass). Light is then directed through a photolithographic screen to specific areas on the support resulting in localized photodeprotection and yielding reactive hydroxyl groups in the illuminated regions. A 3'-O-phosphoramidite-activated deoxynucleoside (protected at the 5'-hydroxyl with a photolabile group) is then incubated with the support and coupling occurs at deprotected sites that were exposed to light. Following the optional capping of unreacted active sites and oxidation, the substrate is rinsed and the surface is illuminated through a second screen, to expose additional hydroxyl groups for coupling to the linker. A second 5'-protected, 3'-O-phosphoramidite-activated deoxynucleoside is presented to the support. The selective photodeprotection and coupling cycles are repeated until the desired products are obtained. Photolabile groups may then be removed and the sequence may be capped. Side chain protective groups may also be removed. Because photolithography is used, the process may be miniaturized to generate high-density microarrays of oligonucleotide probes. Thus, thousands to hundreds of thousands of arbitrary oligonucleotide probes may be generated on a single microarray support using this technology.

To produce a microarray by the spotting method, oligonucleotide probes are prepared, generally by PCR, for printing onto the microarray support. As described for the *in situ* technique, the probes may be selected from a number of sources including nucleic acid databases such as GenBank, Unigen, HomoloGene, RefSeq, dbEST, and dbSNP (Wheeler et

al., 29 NUCLEIC ACIDS RES. 11-16 (2001)). In addition, oligonucleotide probes may be randomly selected from cDNA libraries reflecting, for example, a tissue type (*e.g.*, cardiac or neuronal tissue), or a genomic library representing a species of interest (*e.g.*, *Drosophila melanogaster*). If PCR is used to generate the probes, for example, approximately 100-500
5 pg of the purified PCR product (about 0.6-2.4 kb) may be spotted onto the support (Duggan et al., 1999). The spotting (or printing) may be performed by a robotic arrayer (*see, e.g.*, U.S. Patent Nos. 6,150,147; 5,968,740; 5,856,101; 5,474,796; and 5,445,934;).

A number of different microarray configurations and methods for their production are known to those of skill in the art and are disclosed in U.S. Patent Nos.: 6,156,501; 6,077,674;
10 6,022,963; 5,919,523; 5,885,837; 5,874,219; 5,856,101; 5,837,832; 5,770,722; 5,770,456; 5,744,305; 5,700,637; 5,624,711; 5,593,839; 5,571,639; 5,556,752; 5,561,071; 5,554,501; 5,545,531; 5,529,756; 5,527,681; 5,472,672; 5,445,934; 5,436,327; 5,429,807; 5,424,186; 5,412,087; 5,405,783; 5,384,261; 5,242,974; and the disclosures of which are herein incorporated by reference. Patents describing methods of using arrays in various applications
15 include: U.S. Patent Nos. 5,874,219; 5,848,659; 5,661,028; 5,580,732; 5,547,839; 5,525,464; 5,510,270; 5,503,980; 5,492,806; 5,470,710; 5,432,049; 5,324,633; 5,288,644; 5,143,854; and the disclosures of which are incorporated herein by reference.

B. Microarray Supports

A microarray support may comprise a flexible or rigid substrate. A flexible substrate
20 is capable of being bent, folded, or similarly manipulated without breakage. Examples of solid materials that are flexible solid supports with respect to the present invention include membranes, such as nylon and flexible plastic films. The rigid supports of microarrays are sufficient to provide physical support and structure to the associated oligonucleotides under the appropriate assay conditions.

The support may be biological, nonbiological, organic, inorganic, or a combination of
25 any of these, existing as particles, strands, precipitates, gels, sheets, tubing, spheres, containers, capillaries, pads, slices, films, plates, or slides. In addition, the support may have any convenient shape, such as a disc, square, sphere, or circle. In one embodiment, the support is flat but may take on a variety of alternative surface configurations. For example,
30 the support may contain raised or depressed regions on which the synthesis takes place. The support and its surface may form a rigid support on which the reactions described herein may be carried out. The support and its surface may also be chosen to provide appropriate light-absorbing characteristics. For example, the support may be a polymerized Langmuir

Blodgett film, functionalized glass, Si, Ge, GaAs, GaP, SiO₂, SiN₄, modified silicon, or any one of a wide variety of gels or polymers such as (poly)tetrafluoroethylene, (poly)vinylidenedifluoride, polystyrene, polycarbonate, or combinations thereof. The surface of the support may also contain reactive groups, such as carboxyl, amino, hydroxyl, and thiol groups. The surface may be transparent and contain SiOH functional groups, such as found on silica surfaces.

The support may be composed of a number of materials including glass. There are several advantages for utilizing glass supports in constructing a microarray. For example, microarrays prepared using a glass support, generally utilize microscope slides due to the low inherent fluorescence, thus, minimizing background noise. Moreover, hundreds to thousands of oligonucleotide probes may be attached to slide. The glass slides may be coated with polylysine, amino silanes, or amino-reactive silanes that enhance the hydrophobicity of the slide and improve the adherence of the oligonucleotides (Duggan et al. (1999)). Ultraviolet irradiation is used to crosslink the oligonucleotide probes to the glass support. Following irradiation, the support may be treated with succinic anhydride to reduce the positive charge of the amines. For double-stranded oligonucleotides, the support may be subjected to heat (e.g., 95°C) or alkali treatment to generate single-stranded probes. An additional advantage to using glass is its nonporous nature, thus, requiring a minimal volume of hybridization buffer resulting in enhanced binding of target samples to probes.

In another embodiment, the support may be flat glass or single-crystal silicon with surface relief features of less than about 10 angstroms. The surface of the support may be etched using well-known techniques to provide desired surface features. For example, trenches, v-grooves, or mesa structures allow the synthesis regions to be more closely placed within the focus point of impinging light.

The present invention also relates to nucleic acid microarray supports comprising beads. These beads may have a wide variety of shapes and may be composed of numerous materials. Generally, the beads used as supports may have a homogenous size between about 1 and about 100 microns, and may include microparticles made of controlled pore glass (CPG), highly crosslinked polystyrene, acrylic copolymers, cellulose, nylon, dextran, latex, and polyacrolein. *See e.g.*, U.S. Patent. Nos. 6,060,240; 4,678,814; and 4,413,070.

Several factors may be considered when selecting a bead for a support including material, porosity, size, shape, and linking moiety. Other important factors to be considered in selecting the appropriate support include uniformity, efficiency as a synthesis support,

surface area, and optical properties (*e.g.*, autofluorescence). Typically, a population of uniform oligonucleotide or nucleic acid fragment may be employed. However, beads with spatially discrete regions each containing a uniform population of the same oligonucleotide or nucleic acid fragment (and no other), may also be employed. In one embodiment, such regions are spatially discrete so that signals generated by fluorescent emissions at adjacent regions can be resolved by the detection system being employed.

In general, the support beads may be composed of glass (silica), plastic (synthetic organic polymer), or carbohydrate (sugar polymer). A variety of materials and shapes may be used, including beads, pellets, disks, capillaries, cellulose beads, pore-glass beads, silica gels, polystyrene beads optionally crosslinked with divinylbenzene, grafted co-poly beads, polyacrylamide beads, latex beads, dimethylacrylamide beads optionally cross-linked with N,N-1-bis-acryloyl ethylene diamine, and glass particles coated with a hydrophobic polymer (*e.g.*, a material having a rigid or semirigid surface). The beads may also be chemically derivatized so that they support the initial attachment and extension of nucleotides on their surface.

Oligonucleotide probes may be synthesized directly on the bead, or the probes may be separately synthesized and attached to the bead. *See e.g.*, Albretsen et al., 189 ANAL. BIOCHEM. 40-50 (1990); Lund et al., 16 NUCLEIC ACIDS RES. 10861-80 (1988); Ghosh et al., 15 NUCLEIC ACIDS RES. 5353-72 (1987); Wolf et al., 15 NUCLEIC ACIDS RES. 2911-26 (1987). The attachment to the bead may be permanent, or a cleavable linker between the bead and the probe may also be used. The link should not interfere with the probe-target binding during screening. Linking moieties for attaching and synthesizing tags on microparticle surfaces are disclosed in U.S. No. Patent 4,569,774; Beattie et al., 39 CLIN. CHEM. 719-22 (1993); Maskos and Southern, 20 NUCLEIC ACIDS RES. 1679-84 (1992); Damba et al., 18 NUCLEIC ACIDS RES. 3813-21 (1990); and Pon et al., 6 BIOTECHNIQUES 768-75 (1988). Various links may include polyethyleneoxy, saccharide, polyol, esters, amides, saturated or unsaturated alkyl, aryl, and combinations thereof.

If the oligonucleotide probes are chemically synthesized on the bead, the bead-oligo linkage may be stable during the deprotection step of photolithography. During standard phosphoramidite chemical synthesis of oligonucleotides, a succinyl ester linkage may be used to bridge the 3' nucleotide to the resin. This linkage may be readily hydrolyzed by NH_3 prior to and during deprotection of the bases. The finished oligonucleotides may be released from the resin in the process of deprotection. The probes may be linked to the beads by a siloxane

linkage to Si atoms on the surface of glass beads; a phosphodiester linkage to the phosphate of the 3'-terminal nucleotide via nucleophilic attack by a hydroxyl (typically an alcohol) on the bead surface; or a phosphoramidate linkage between the 3'-terminal nucleotide and a primary amine conjugated to the bead surface.

5 Numerous functional groups and reactants may be used to detach the oligonucleotide probes. For example, functional groups present on the bead may include hydroxy, carboxy, iminohalide, amino, thio, active halogen (Cl or Br) or pseudohalogen (*e.g.*, CF₃, CN), carbonyl, silyl, tosyl, mesylates, brosylates, and triflates. In some instances, the bead may have protected functional groups that may be partially or wholly deprotected.

10 1. Microarray Support Surface

The support of the microarrays may comprise at least one surface on which a pattern of oligonucleotide probes is present, where the surface may be smooth or substantially planar, or have irregularities, such as depressions or elevations. The surface on which the probes are located may be modified with one or more different layers of compounds that serve to
15 modulate the properties of the surface. Such modification layers may generally range in thickness from a monomolecular thickness of about 1 nm, preferably from a monomolecular thickness of about 0.1 nm, and most preferred from a monomolecular thickness of about 0.001 nm. Modification layers include, for example, inorganic and organic layers such as metals, metal oxides, polymers, small organic molecules and the like. Polymeric layers
20 include peptides, proteins, polynucleic acids or mimetics thereof (*e.g.*, peptide nucleic acids), polysaccharides, phospholipids, polyurethanes, polyesters, polycarbonates, polyureas, polyamides, polyethyleneamines, polyarylene sulfides, polysiloxanes, polyimides, and polyacetates. The polymers may be hetero- or homopolymers, and may or may not have separate functional moieties attached.

25 The oligonucleotide probes of a microarray may be arranged on the surface of the support based on size. With respect to the arrangement according to size, the probes may be arranged in a continuous or discontinuous size format. In a continuous size format, each successive position in the microarray, for example, a successive position in a lane of probes, comprises oligonucleotide probes of the same molecular weight. In a discontinuous size
30 format, each position in the pattern (*e.g.*, band in a lane) represents a fraction of target molecules derived from the original source, where the probes in each fraction will have a molecular weight within a determined range.

The probe pattern may take on a variety of configurations as long as each position in the microarray represents a unique size (*e.g.*, molecular weight or range of molecular weights), depending on whether the array has a continuous or discontinuous format. The microarrays may comprise a single lane or a plurality of lanes on the surface of the support.

5 Where a plurality of lanes are present, the number of lanes will usually be at least about 2 but less than about 200 lanes, preferably more than about 5 but less than about 100 lanes, and most preferred more than about 8 but less than about 80 lanes.

Each microarray may contain oligonucleotide probes isolated from the same source (*e.g.*, the same tissue), or contain probes from different sources (*e.g.*, different tissues,
10 different species, disease and normal tissue). As such, probes isolated from the same source may be represented by one or more lanes; whereas probes from different sources may be represented by individual patterns on the microarray where probes from the same source are similarly located. Therefore, the surface of the support may represent a plurality of patterns of oligonucleotide probes derived from different sources (*e.g.*, tissues), where the probes in
15 each lane are arranged according to size, either continuously or discontinuously.

Surfaces of the support are usually, though not always, composed of the same material as the support. Alternatively, the surface may be composed of any of a wide variety of materials, for example, polymers, plastics, resins, polysaccharides, silica or silica-based materials, carbon, metals, inorganic glasses, membranes, or any of the above-listed substrate
20 materials. The surface may contain reactive groups, such as carboxyl, amino, or hydroxyl groups. The surface may be optically transparent and may have surface SiOH functionalities, such as are found on silica surfaces.

2. Attachment of Oligonucleotide Probes

The surface of the support may possess a layer of linker molecules (or spacers). The
25 linker molecules may be of sufficient length to permit oligonucleotide probes on the support to hybridize to nucleic acid molecules and to interact freely with molecules exposed to the support. The linker molecules may be about 6-50 molecules long to provide sufficient exposure. The linker molecules may also be, for example, aryl acetylene, ethylene glycol oligomers containing about 2-10 monomer units, diamines, diacids, amino acids, or
30 combinations thereof.

The linker molecules may be attached to the support via carbon-carbon bonds using, for example, (poly)trifluorochloroethylene surfaces, or preferably, by siloxane bonds (using, for example, glass or silicon oxide surfaces). Siloxane bonds may be formed via reactions of

linker molecules containing trichlorosilyl or trialkoxysilyl groups. The linker molecules may also have a site for attachment of a longer chain portion. For example, groups that are suitable for attachment to a longer chain portion may include amines, hydroxyl, thiol, and carboxyl groups. The surface attaching portions may include aminoalkylsilanes, hydroxyalkylsilanes, bis(2-hydroxyethyl)-aminopropyltriethoxysilane, 2-hydroxyethylaminopropyltriethoxysilane, aminopropyltriethoxysilane, and hydroxypropyltriethoxysilane. The linker molecules may be attached in an ordered array (*e.g.*, as parts of the head groups in a polymerized Langmuir Blodgett film). Alternatively, the linker molecules may be adsorbed to the surface of the support.

The linker may be a length that is at least the length spanned by, for example, two to four nucleotide monomers. The linking group may be an alkylene group (from about 6 to about 24 carbons in length), a polyethyleneglycol group (from about 2 to about 24 monomers in a linear configuration), a polyalcohol group, a polyamine group (*e.g.*, spermine, spermidine, or polymeric derivatives thereof), a polyester group (*e.g.*, poly(ethylacrylate) from 3 to 15 ethyl acrylate monomers in a linear configuration), a polyphosphodiester group, or a polynucleotide (from about 2 to about 12 nucleic acids). For *in situ* synthesis, the linking group may be provided with functional groups that can be suitably protected or activated. The linking group may be covalently attached to the oligonucleotide probes by an ether, ester, carbamate, phosphate ester, or amine linkage. In one embodiment, linkages are phosphate ester linkages, which can be formed in the same manner as the oligonucleotide linkages. For example, hexaethyleneglycol may be protected on one terminus with a photolabile protecting group (*e.g.*, NVOC or McNPOC) and activated on the other terminus with 2-cyanoethyl-N,N-diisopropylamino-chlorophosphite to form a phosphoramidite. This linking group may then be used for construction of oligonucleotide probes in the same manner as the photolabile-protected, phosphoramidite-activated nucleotides.

Furthermore, the linker molecules and oligonucleotide probes may contain a functional group with a bound protective group. In one embodiment, the protective group is on the distal or terminal end of the linker molecule opposite the support. The protective group may be either a negative protective group (*e.g.*, the protective group renders the linker molecules less reactive with a monomer upon exposure) or a positive protective group (*e.g.*, the protective group renders the linker molecules more reactive with a monomer upon exposure). In the case of negative protective groups, an additional reactivation step may be required, for example, through heating. The protective group on the linker molecules may be

selected from a wide variety of positive light-reactive groups preferably including nitro aromatic compounds, such as o-nitrobenzyl derivatives or benzylsulfonyl. Other protective groups include 6-nitroveratryloxycarbonyl (NVOC), 2-nitrobenzyloxycarbonyl (NBOC) or α,α -dimethyl-dimethoxybenzyloxycarbonyl (DDZ). Photoremovable protective groups are described in, for example, Patchornik, 92 J. AM. CHEM. SOC. 6333 (1970) and Amit et al., 39 J. ORG. CHEM. 192 (1974).

C. Oligonucleotide Probes

A microarray may contain any number of different oligonucleotide probes. The microarray may have from about 2 to about 100 probes, about 100 to about 10,000 probes, or between about 10,000 and about 1,000,000 probes. In addition, the microarray may have a density of more than 100 oligonucleotide probes at known locations per cm^2 , more than 1,000 probes per cm^2 , or more than 10,000 per cm^2 .

To detect gene expression, oligonucleotide probes may be designed and synthesized based on known sequence information. For example, 20- to 30-mer oligonucleotides that may be derived from known cDNA or EST sequences may be selected to monitor expression (Lipshutz et al. (1999)). The oligonucleotide probes may be selected from a number of sources including nucleic acid databases such as GenBank, Unigen, HomoloGene, RefSeq, dbEST, and dbSNP (Wheeler et al., 29 NUCL. ACIDS RES. 11-16 (2001)). Generally, the probe is complementary to the reference sequence, preferably unique to the tissue or cell type (e.g., skeletal muscle, neuronal tissue) of interest, and preferably hybridizes with high affinity and specificity (Lockhart et al., 14 NATURE BIOTECHNOL. 1675-80 (1996)). In addition, the oligonucleotide probe may represent non-overlapping sequences of the reference sequence that improves probe redundancy resulting in a reduction in false positive rate and an increased accuracy in target quantitation (Lipshutz et al. (1999)).

In one embodiment of the present invention, the oligonucleotide probes are relatively unique, for example, at least about 60-80% of the probes may comprise unique oligonucleotides. In another embodiment, modified oligonucleotides from about 80-300 nucleotides in length, or from about 100-200 nucleotides in length, may be used on the microarrays. These are especially useful in place of cDNAs for determining the presence of mRNA in a sample, as the modified oligonucleotides have the advantage of rapid synthesis and purification and analysis before attachment to the substrate surface. In particular, oligonucleotides with 2'-modified sugar groups demonstrate increased binding affinity with

RNA, and these oligonucleotides are particularly advantageous in identifying mRNA in a sample exposed to a microarray.

Generally, the oligonucleotide probes are generated by standard synthesis chemistries such as phosphoramidite chemistry (U.S. Patent Nos. 4,980,460; 4,973,679; 4,725,677; 5 4,458,066; and 4,415,732; Beaucage and Iyer, 48 TETRAHEDRON 2223-2311 (1992)).

Alternative chemistries that create non-natural backbone groups, such as phosphorothionate and phosphoroamidate may also be employed.

Using the "flow channel" method, oligonucleotide probes are synthesized at selected regions on the support by forming flow channels on the surface of the support through
10 which appropriate reagents flow or in which appropriate reagents are placed. For example, if a monomer is to be bound to the support in a selected region, all or part of the surface of the selected region may be activated for binding by flowing appropriate reagents through all or some of the channels, or by washing the entire support with appropriate reagents. After placing a channel block on the surface of the support, a reagent containing the
15 monomer may flow through or may be placed in all or some of the channels. The channels provide fluid contact to the first selected region, thereby binding the monomer on the support directly or indirectly (via a spacer) in the first selected region.

If a second monomer is coupled to a second selected region, some of which may be included among the first selected region, the second selected region may be in fluid contact
20 with second flow channels through translation, rotation, or replacement of the channel block on the surface of the support; through opening or closing a selected valve; or through deposition. The second region may then be activated. Thereafter, the second monomer may then flow through or may be placed in the second flow channels, binding the second monomer to the second selected region. Thus, the resulting oligonucleotides bound to the
25 support are, for example, A, B, and AB. The process is repeated to form a microarray of oligonucleotide probes of desired length at known locations on the support.

Microarrays may have a plurality of modified oligonucleotides or polynucleotides stably associated with the surface of a support, *e.g.*, covalently attached to the surface with or without a linker molecule. Each oligonucleotide on the array comprises a modified
30 oligonucleotide composition of known identity and usually of known sequence. By stable association, the associated modified oligonucleotides maintain their position relative to the support under hybridization and washing conditions.

The oligonucleotides may be non-covalently or covalently associated with the support surface. Examples of non-covalent association include non-specific adsorption, binding based on electrostatic interactions (*e.g.*, ion pair interactions), hydrophobic interactions, hydrogen bonding interactions, and specific binding through a specific binding pair member covalently attached to the support surface. Examples of covalent binding include covalent bonds formed between the oligonucleotides and a functional group present on the surface of the rigid support (*e.g.*, -OH), where the functional group may be naturally occurring or present as a member of an introduced linking group.

II. Protein Microarrays

Although attempts to evaluate gene activity and to decipher biological processes have traditionally focused on genomics, proteomics offers a promising look at the biological functions of a cell. Proteomics involves the qualitative and quantitative measurement of gene activity by detecting and quantitating expression at the protein level, rather than at the messenger RNA level. Proteomics also involves the study of non-genome encoded events including the post-translational modification of proteins, interactions between proteins, and the location of proteins within the cell.

The study of gene expression at the protein level is important because many of the most important cellular processes are regulated by the protein status of the cell, not by the status of gene expression. In addition, the protein content of a cell is highly relevant to drug discovery efforts because many drugs are designed to be active against protein targets.

Current technologies for the analysis of proteomes are based on a variety of protein separation techniques followed by identification of the separated proteins. The most popular method is based on 2D-gel electrophoresis followed by "in-gel" proteolytic digestion and mass spectroscopy. This 2D-gel technique requires large sample sizes, is time consuming, and is currently limited in its ability to reproducibly resolve a significant fraction of the proteins expressed by a human cell. Techniques involving some large-format 2D-gels can produce gels that separate a larger number of proteins than traditional 2D-gel techniques, but reproducibility is still poor and over 95% of the spots cannot be sequenced due to limitations with respect to sensitivity of the available sequencing techniques. The electrophoretic techniques are also plagued by a bias towards proteins of high abundance.

Standard assays for the presence of an analyte in a solution, such as those commonly used for diagnostics, for example, involve the use of an antibody which has been raised against the targeted antigen. Multianalyte assays known in the art involve the use of multiple

antibodies and are directed towards assaying for multiple analytes. However, these multianalyte assays have not been directed towards assaying the total or partial protein content of a cell or cell population. Furthermore, sample sizes required to adapt such standard antibody assay approaches to the analysis of even a fraction of the estimated 100,000 or more different proteins of a human cell and their various modified states are prohibitively large. Automation and/or miniaturization of antibody assays are required if large numbers of proteins are to be assayed simultaneously. Materials, surface coatings, and detection methods used for macroscopic immunoassays and affinity purification are not readily transferable to the formation or fabrication of miniaturized protein arrays.

Miniaturized DNA chip technologies have been developed and are currently being exploited for the screening of gene expression at the mRNA level. *See, e.g.*, U.S. Pat. Nos. 5,744,305; 5,412,087; and 5,445,934. These chips may be used to determine which genes are expressed by different types of cells and in response to different conditions. However, DNA biochip technology is not transferable to protein-binding assays such as antibody assays because the chemistries and materials used for DNA biochips are not readily transferable to use with proteins. Nucleic acids such as DNA withstand temperatures up to 100°C, can be dried and re-hydrated without loss of activity, and can be bound physically or chemically directly to organic adhesion layers supported by materials such as glass while maintaining their activity. In contrast, proteins such as antibodies are preferably kept hydrated and at ambient temperatures are sensitive to the physical and chemical properties of the support materials. Therefore, maintaining protein activity at the liquid-solid interface requires entirely different immobilization strategies than those used for nucleic acids. The proper orientation of the antibody or other protein-capture agent at the interface is desirable to ensure accessibility of their active sites with interacting molecules. With miniaturization of the chip and decreased feature sizes, the ratio of accessible to non-accessible and the ratio of active to inactive antibodies or proteins become increasingly relevant and important.

Thus, there is a need for the ability to assay in parallel a multitude of proteins expressed by a cell or a population of cells in an organism, including up to the total set of proteins expressed by the cell or cells.

A. Microarray Supports

The substrate of the microarray may be either organic or inorganic, biological or non-biological, or any combination of these materials. In addition, the substrate may be transparent or translucent. In one embodiment, the portion of the surface of the substrate

on which the regions of protein-capture agents reside is flat and firm. In another embodiment, the portion of the surface of the substrate on which the regions of protein-capture agents reside is semi-firm. Of course, the protein microarrays of the present invention need not necessarily be flat nor entirely two-dimensional. Indeed, significant topological features may be present on the surface of the substrate surrounding the regions, between the regions or beneath the regions. For example, walls or other barriers may separate the regions of the microarray.

Numerous materials are suitable for use as a substrate in the microarray embodiment of the invention. The substrate of the invention microarray may comprise a material selected from the group consisting of silicon, silica, quartz, glass, controlled pore glass, carbon, alumina, titania, tantalum oxide, germanium, silicon nitride, zeolites, and gallium arsenide. Many metals such as gold, platinum, aluminum, copper, titanium, and their alloys may be useful as substrates of the microarray. Alternatively, many ceramics and polymers may also be used as substrates. Polymers that may be used as substrates include, but are not limited to polystyrene; poly(tetra)fluoroethylene (PTFE); polyvinylidenedifluoride; polycarbonate; polymethylmethacrylate; polyvinylethylene; polyethyleneimine; poly(etherether)ketone; polyoxymethylene (POM); polyvinylphenol; polylactides; polymethacrylimide (PMI); polyalkenesulfone (PAS); polypropylene, polyethylene; polyhydroxyethylmethacrylate (HEMA); polydimethylsiloxane; polyacrylamide; polyimide; and block-copolymers. The substrate on which the regions of protein-capture agents reside may also be a combination of any of the aforementioned substrate materials.

1. Microarray Support Surface

The support surfaces comprises the surface on which each of the protein-capture agents is immobilized. The support surfaces may comprise the substrate surface, an altered substrate surface, a coating applied to or formed on the substrate surface, or an organic thinfilm applied to or formed on the substrate surface or coating surface. Support surfaces comprise materials suitable for immobilization of the protein-capture agents to the microarrays. Suitable support surfaces include membranes, such as nitrocellulose membranes, polyvinylidenedifluoride (PVDF) membranes, and the like. In another embodiment, the support surfaces may comprise a hydrogel such as dextran. Alternatively, the support surfaces may comprise an organic thinfilm including lipids, charged peptides (e.g., polylysine or poly-arginine), or a neutral amino acid (e.g., polyglycine).

The support surfaces may also comprise a compound that has the ability to interact with both the substrate and the protein-capture agent. For example, functionalities enabling interaction with the substrate may include hydrocarbons having functional groups (e.g. --O--, --CONH--, CONHCO--, --NH--, --CO--, --S--, --SO--), which may interact with functional groups on the substrate. Functionalities enabling interaction with the protein-capture agent comprise antibodies, antigens, receptor ligands, compounds comprising binding sites for affinity tags, and the like.

In another embodiment, the support surfaces may include a coating. The coating may be formed on, or applied to, the support surfaces. The substrate may be modified with a coating by using thinfilm technology based, for example, on physical vapor deposition (PVD), plasma-enhanced chemical vapor deposition (PECVD), or thermal processing.

Alternatively, plasma exposure may be used to directly activate or alter the substrate and create a coating. For example, plasma etch procedures can be used to oxidize a polymeric surface (for example, polystyrene or polyethylene to expose polar functionalities such as hydroxyls, carboxylic acids, aldehydes and the like) which then acts as a coating.

Furthermore, the coating may comprise a component to reduce non-specific binding. For example, a polypropylene substrate may be coated with a compound, such as bovine serum albumin, to reduce non-specific binding. Next, a support surfaces comprising dextran functionally linked to a receptor which recognizes M13 epitopes is added to distinct locations on the coating such that phage expressing recombinant proteins will be bound.

In an alternative embodiment, the coating may comprise an antibody. More particularly, antibodies that recognize epitope tags engineered into the recombinant proteins may be employed. Alternatively, recombinant proteins may comprise a poly-histidine affinity tag. In this case, an anti-histidine antibody chemically linked to the substrate provides a support surfaces for immobilization of the protein-capture agents.

In yet another embodiment, the coating may comprise a metal film. The metal film may range from about 50 nm to about 500 nm in thickness. Alternatively, the metal film may range from about 1 nm to about 1 μ m in thickness.

Examples of metal films that may be used as substrate coatings include aluminum, chromium, titanium, tantalum, nickel, stainless steel, zinc, lead, iron, copper, magnesium, manganese, cadmium, tungsten, cobalt, and alloys or oxides thereof. In one embodiment, the metal film is a noble metal film. Noble metals that may be used for a coating include, but are not limited to, gold, platinum, silver, and copper. In another embodiment, the coating

comprises gold or a gold alloy. Electron-beam evaporation may be used to provide a thin coating of gold on the surface of the substrate. Additionally, commercial metal-like substances may be employed such as TALON metal affinity resin and the like.

In alternative embodiments, the coating may comprise a composition selected from the group consisting of silicon, silicon oxide, titania, tantalum oxide, silicon nitride, silicon hydride, indium tin oxide, magnesium oxide, alumina, glass, hydroxylated surfaces, and polymers.

It is contemplated that the coatings of the microarrays may require the addition of at least one adhesion layer or interlayer between the coating and the substrate. The adhesion layer may be at least about 6 angstroms thick but may be much thicker. For example, a layer of titanium or chromium may be desirable between a silicon wafer and a gold coating. In an alternative embodiment, an epoxy glue such as Epo-tek 377® or Epo-tek 301-2®, (Epoxy Technology Inc., Billerica, Mass.) may be used to aid adherence of the coating to the substrate. Determinations as to what material should be used for the adhesion layer would be obvious to one skilled in the art once materials are chosen for both the substrate and coating. In other embodiments, additional adhesion mediators or interlayers may be necessary to improve the optical properties of the microarray, for example, waveguides for detection purposes.

In one embodiment of the invention, the surface of the coating is atomically flat. The mean roughness of the surface of the coating may be less than about 5 angstroms for areas of at least about $25 \mu\text{m}^2$. In a specific embodiment, the mean roughness of the surface of the coating is less than about 3 angstroms for areas of at least about $25 \mu\text{m}^2$. In one embodiment, the coating may be a template-stripped surface. See, e.g., Hegner et al., 291 SURFACE SCIENCE 39-46 (1993); Wagner et al., 11 LANGMUIR 3867-3875 (1995).

Several different types of coating may be combined on the surface. The coating may cover the whole surface of the substrate or only parts of it. In one embodiment, the coating covers the substrate surface only at the site of the regions of protein-capture agents. Techniques useful for the formation of coated regions on the surface of the substrate are well known to those of ordinary skill in the art. For example, the regions of coatings on the substrate may be fabricated by photolithography, micromolding (WO 96/29629), wet chemical or dry etching, or any combination of these.

a. Organic Thinfilms

In a particular embodiment, the support surfaces comprises an organic thinfilm layer. The organic thinfilm on which each of the regions of protein-capture agents resides forms a layer either on the substrate itself or on a coating covering the substrate. In one embodiment,
5 the organic thinfilm on which the protein-capture agents of the regions are immobilized is less than about 20 nm thick. In another embodiment, the organic thinfilm of each of the regions is less than about 10 nm thick.

A variety of different organic thinfilms are suitable for use in the present invention. For example, a hydrogel composed of a material such as dextran may serve as a suitable
10 organic thinfilm on the regions of the microarray. In another embodiment, the organic thinfilm is a lipid bilayer.

In yet another embodiment, the organic thinfilm of each of the regions of the microarray is a monolayer. A monolayer of polyarginine or polylysine adsorbed on a negatively charged substrate or coating may comprise the organic thinfilm. Another option is
15 a disordered monolayer of tethered polymer chains. In a particular embodiment, the organic thinfilm is a self-assembled monolayer. Specifically, the self-assembled monolayer may comprise molecules of the formula $X-R-Y$, wherein R is a spacer, X is a functional group that binds R to the surface, and Y is a functional group for binding protein-capture agents onto the monolayer. In an alternative embodiment, the self-assembled monolayer is comprised of
20 molecules of the formula $(X)_a R(Y)_b$ where a and b are, independently, integers greater than or equal to 1 and X, R, and Y are as previously defined.

In another embodiment, the organic thinfilm comprises a combination of organic thinfilms such as a combination of a lipid bilayer immobilized on top of a self-assembled
monolayer of molecules of the formula $X-R-Y$. As another example, a monolayer of
25 polylysine may be combined with a self-assembled monolayer of molecules of the formula $X-R-Y$. See U.S. Pat. No. 5,629,213.

In all cases, the coating, or the substrate itself if no coating is present, must be compatible with the chemical or physical adsorption of the organic thinfilm on its surface. For example, if the microarray comprises a coating between the substrate and a monolayer of
30 molecules of the formula $X-R-Y$, then it is understood that the coating must be composed of a material for which a suitable functional group X is available. If no such coating is present, then it is understood that the substrate must be composed of a material for which a suitable functional group X is available.

In one embodiment of the invention, the area of the substrate surface, or coating surface, which separates the regions of protein-capture agents are free of organic thinfilm. In an alternative embodiment, the organic thinfilm may extend beyond the area of the substrate surface, or coating surface if present, covered by the regions of protein-capture agents. For example, the entire surface of the microarray may be covered by an organic thinfilm on which the plurality of spatially distinct regions of protein-capture agents reside. An organic thinfilm that covers the entire surface of the microarray may be homogenous or may comprise regions of differing exposed functionalities useful in the immobilization of regions of different protein-capture agents.

In yet another embodiment, the areas of the substrate surface or coating surface between the regions of protein-capture agents are covered by an organic thinfilm, but an organic thinfilm of a different type than that of the regions of protein-capture agents. For example, the surfaces between the regions of protein-capture agents may be coated with an organic thinfilm characterized by low non-specific binding properties for proteins and other analytes.

A variety of techniques may be used to generate regions of organic thinfilm on the surface of the substrate or on the surface of a coating on the substrate. These techniques are well known to those skilled in the art and will vary depending upon the nature of the organic thinfilm, the substrate, and the coating, if present. The techniques will also vary depending on the structure of the underlying substrate and the pattern of any coating present on the substrate. For example, regions of a coating that are highly reactive with an organic thinfilm may have already been produced on the substrate surface. Areas of organic thinfilm may be created by microfluidics printing, microstamping (U.S. Pat. Nos. 5,731,152 and 5,512,131), or microcontact printing (WO 96/29629). Subsequent immobilization of protein-capture agents to the reactive monolayer regions result in two-dimensional arrays of the agents. Inkjet printer heads provide another option for patterning monolayer X-R-Y molecules, or components thereof, or other organic thinfilm components to nanometer or micrometer scale sites on the surface of the substrate or coating. See, e.g., Lemmo et al., 69 ANAL CHEM. 543-551 (1997); U.S. Pat. Nos. 5,843,767 and 5,837,860. In some cases, commercially available arrayers based on capillary dispensing may also be of use in directing components of organic thinfilms to spatially distinct regions of the microarray (OmniGrid® from Genemachines, Inc, San Carlos, CA, and High-Throughput Microarrayer from Intelligent Bio-Instruments, Cambridge, MA). Other methods for the formation of organic thinfilms include *in situ*

growth from the surface, deposition by physisorption, spin-coating, chemisorption, self-assembly, or plasma-initiated polymerization from gas phase.

Diffusion boundaries between the regions of protein-capture agents immobilized on organic thinfilms such as self-assembled monolayers may be integrated as topographic patterns (physical barriers) or surface functionalities with orthogonal wetting behavior (chemical barriers). For example, walls of substrate material may be used to separate some of the regions of protein-capture agents from some of the others or all of the regions from each other. Alternatively, non-bioreactive organic thinfilms, such as monolayers, with different wettability may be used to separate regions of protein-capture agents from one another.

B. Protein-Capture Agents

A protein microarray contemplated by the present invention may contain any number of different proteins, amino acid sequences, nucleic acid sequences, or small molecules. In one embodiment, the microarrays may comprise all or a portion of a gene, including functional derivatives, variants, analogs and portions thereof. The present invention also contemplates microarrays comprising one or more antibodies or functional equivalents thereof that bind proteins, ligands, and/or binding partners.

For example, the proteins expressed by the protein protein-capture agents immobilized on the microarray may be members of the same family. Such families include, but are not limited to, families of growth factor receptors, hormone receptors, neurotransmitter receptors, catecholamine receptors, amino acid derivative receptors, cytokine receptors, extracellular matrix receptors, antibodies, lectins, cytokines, serpins, proteinases, kinases, phosphatases, ras-like GTPases, hydrolases, steroid hormone receptors, transcription factors, DNA binding proteins, zinc finger proteins, leucine-zipper proteins, homeodomain proteins, intracellular signal transduction modulators and effectors, apoptosis-related factors, DNA synthesis factors, DNA repair factors, DNA recombination factors, cell-surface antigens, Hepatitis C virus (HCV) proteases, HIC proteases, viral integrases, and proteins from pathogenic bacteria.

A protein-capture agent on the microarray may be any molecule or complex of molecules that has the ability to bind a protein and immobilize it to the site of the protein-capture agent on the microarray. In one aspect, the protein-capture agent binds its binding partner in a substantially specific manner. For example, the protein-capture agent may be a protein whose natural function in a cell is to specifically bind another protein, such as an

antibody or a receptor. Alternatively, the protein-capture agent may be a partially or wholly synthetic or recombinant protein that specifically binds a protein.

Moreover, the protein-capture agent may be a protein which has been selected *in vitro* from a mutagenized, randomized, or completely random and synthetic library by its binding affinity to a specific protein or peptide target. The selection method used may be a display method such as ribosome display or phage display. Alternatively, the protein-capture agent obtained via *in vitro* selection may be a DNA or RNA aptamer that specifically binds a protein target. See, e.g., Potyrailo et al., 70 ANAL. CHEM. 3419-25 (1998); Cohen, et al., 94 PROC. NATL. ACAD. SCI. USA 14272-7 (1998); Fukuda, et al., 37 NUCLEIC ACIDS SYMP. SER., 237-8 (1997). Alternatively, the *in vitro* selected protein-capture agent may be a polypeptide. Roberts and Szostak, 94 PROC. NATL. ACAD. SCI. USA 12297-302 (1997). In yet another embodiment, the protein-capture agent may be a small molecule that has been selected from a combinatorial chemistry library or is isolated from an organism.

In a particular embodiment, however, the protein-capture agents are proteins.

The protein-capture agents may be antibodies or antibody fragments. Although antibody moieties are exemplified herein, it is understood that the present arrays and methods may be advantageously employed with other protein-capture agents.

The antibodies or antibody fragments of the microarray may be single-chain Fvs, Fab fragments, Fab' fragments, F(ab')₂ fragments, Fv fragments, dsFvs diabodies, Fd fragments, full-length, antigen-specific polyclonal antibodies, or full-length monoclonal antibodies. In a specific embodiment, the protein-capture agents of the microarray are monoclonal antibodies, Fab fragments or single-chain Fvs.

The antibodies or antibody fragments may be monoclonal antibodies, even commercially available antibodies, against known, well-characterized proteins.

Alternatively, the antibody fragments may be derived by selection from a library using the phage display method. If the antibody fragments are derived individually by selection based on binding affinity to known proteins, then the binding partners of the antibody fragments are known. In an alternative embodiment of the invention, the antibody fragments are derived by a phage display method comprising selection based on binding affinity to the (typically, immobilized) proteins of a cellular extract or a biological sample. In this embodiment, some or many of the antibody fragments of the microarray would bind proteins of unknown identity and/or function.

1. Attachment of Protein-Capture Agents

It is necessary, however, to immobilize proteins-capture agents on a solid support in a way that preserves their folded conformations. Methods of arraying functionally active proteins using microfabricated polyacrylamide gel pads to preserve samples and microelectrophoresis to accelerate diffusion have been described. Arenkov et al., 278 ANAL. BIOCHEM. 123-31 (2000).

The method of attachment will vary with the substrate and protein-capture agent selected. For example, in the case of a phage display library, the method of attachment may involve either the direct attachment of the phage as for example, by anti-M13 antibodies, or by attachment via the recombinant protein as for example via antibodies to an epitope-tag incorporated in the recombinant sequence, or by binding of a histidine-tag (his-tag) incorporated in the recombinant sequence to a metal coating on the support surfaces.

In one embodiment, the protein-immobilizing regions of the microarray comprise an affinity tag that enhances immobilization of the protein-capture agent onto the organic thinfilm. The use of an affinity tag on the protein-capture agent of the microarray provides several advantages. An affinity tag can confer enhanced binding or reaction of the protein-capture agent with the functionalities on the organic thinfilm, such as Y if the organic thinfilm is a an X-R-Y monolayer as previously described. This enhancement effect may be either kinetic or thermodynamic. The affinity tag/organic thinfilm combination used in the regions of protein-capture agents residing on the microarray allows for immobilization of the protein-capture agents in a manner that does not require harsh reaction conditions which are adverse to protein stability or function. In most embodiments, the protein-capture agents are immobilized to the organic thinfilm in aqueous, biological buffers.

An affinity tag also offers immobilization on the organic thinfilm that is specific to a designated site or location on the protein-capture agent (site-specific immobilization). For this to occur, attachment of the affinity tag to the protein-capture agent must be site-specific. Site-specific immobilization helps ensure that the protein-binding site of the agent, such as the antigen-binding site of the antibody moiety, remains accessible to ligands in solution. Another advantage of immobilization through affinity tags is that it allows for a common immobilization strategy to be used with multiple, different protein-capture agents.

The affinity tag may be attached directly, either covalently or noncovalently, to the protein-capture agent. In an alternative embodiment, however, the affinity tag is either

covalently or noncovalently attached to an adaptor that is either covalently or noncovalently attached to the protein-capture agent.

In one embodiment, the affinity tag comprises at least one amino acid. The affinity tag may be a polypeptide comprising at least two amino acids which are reactive with the functionalities of the organic thinfilm. Alternatively, the affinity tag may be a single amino acid that is reactive with the organic thinfilm. Examples of possible amino acids that could be reactive with an organic thinfilm include cysteine, lysine, histidine, arginine, tyrosine, aspartic acid, glutamic acid, tryptophan, serine, threonine, and glutamine. A polypeptide or amino acid affinity tag may be expressed as a fusion protein with the protein-capture agent when the protein-capture agent is a protein, such as an antibody or antibody fragment. Amino acid affinity tags provide either a single amino acid or a series of amino acids that may interact with the functionality of the organic thinfilm, such as the Y-functional group of the self-assembled monolayer molecules. Amino acid affinity tags may be readily introduced into recombinant proteins to facilitate oriented immobilization by covalent binding to the Y-functional group of a monolayer or to a functional group on an alternative organic thinfilm.

The affinity tag may comprise a poly-amino acid tag. A poly-amino acid tag is a polypeptide that comprises from about 2 to about 100 residues of a single amino acid, optionally interrupted by residues of other amino acids. For example, the affinity tag may comprise a poly-cysteine, poly-lysine, poly-arginine, or poly-histidine. Amino acid tags may comprise about two to about twenty residues of a single amino acid, such as, for example, histidines, lysines, arginines, cysteines, glutamines, tyrosines, or any combination of these. For example, an amino acid tag of one to twenty amino acids includes at least one to ten cysteines for thioether linkage; or one to ten lysines for amide linkage; or one to ten arginines for coupling to vicinal dicarbonyl groups. One of ordinary skill in the art can readily pair suitable affinity tags with a given functionality on an organic thinfilm.

The position of the amino acid tag may be at an amino-, or carboxy-terminus of the protein-capture agent which is a protein, or anywhere in-between, as long as the protein-binding region of the protein-capture agent, such as the antigen-binding region of an immobilized antibody moiety, remains in a position accessible for protein binding. Affinity tags introduced for protein purification may be located at the C-terminus of the recombinant protein to ensure that only full-length proteins are isolated during protein purification. For example, if intact antibodies are used on the microarrays, then the attachment point of the affinity tag on the antibody may be located at a C-terminus of the effector (Fc) region of the

antibody. If scFvs are used on the arrays, then the attachment point of the affinity tag may also be located at the C-terminus of the molecules.

Affinity tags may also contain one or more unnatural amino acids. Unnatural amino acids may be introduced using suppressor tRNAs that recognize stop codons (i.e., amber)

5 See, e.g., Cload et al., 3 CHEM. BIOL. 1033-1038 (1996); Ellman et al., 202 METHODS ENZYM. 301-336 (1991); and Noren et al., 244 SCIENCE 182-188 (1989). The tRNAs are chemically amino-acylated to contain chemically altered ("unnatural") amino acids for use with specific coupling chemistries (i.e., ketone modifications, photoreactive groups).

In an alternative embodiment, the affinity tag comprises an intact protein, such as, but
10 not limited to, glutathione S-transferase, an antibody, avidin, or streptavidin.

In embodiments where the protein-capture agent is a protein and the affinity tag is a protein, such as a poly-amino acid tag or a single amino acid tag, the affinity tag may be attached to the protein-capture agent by generating a fusion protein. Alternatively, protein synthesis or protein ligation techniques known to those skilled in the art may be used. For
15 example, intein-mediated protein ligation may be used to attach the affinity tag to the protein-capture agent. See, e.g., Mathys, et al., 231 GENE 1-13 (1999); Evans, et al., 7 PROTEIN SCIENCE 2256-2264 (1998).

Other protein conjugation and immobilization techniques known in the art may be adapted for the purpose of attaching affinity tags to the protein-capture agent. For example,
20 the affinity tag may be an organic bioconjugate that is chemically coupled to the protein-capture agent of interest. Biotin or antigens may be chemically cross-linked to the protein. Alternatively, a chemical crosslinker may be used that attaches a simple functional moiety such as a thiol or an amine to the surface of a protein serving as a protein-capture agent on the microarray.

25 In one embodiment of the present invention, the organic thinfilm of each of the regions comprises, at least in part, a lipid monolayer or bilayer, and the affinity tag comprises a membrane anchor.

In an alternative embodiment, no affinity tag is used to immobilize the protein-capture agents onto the organic thinfilm. An amino acid or other moiety (such as a carbohydrate
30 moiety) inherent to the protein-capture agent itself may instead be used to tether the protein-capture agent to the reactive group of the organic thinfilm. In one embodiment, the immobilization is site-specific with respect to the location of the site of immobilization on the protein-capture agent. For example, the sulfhydryl group on the C-terminal region of the

heavy chain portion of a Fab' fragment generated by pepsin digestion of an antibody, followed by selective reduction of the disulfide bond between monovalent Fab' fragments, may be used as the affinity tag. Alternatively, a carbohydrate moiety on the Fc portion of an intact antibody may be oxidized under mild conditions to an aldehyde group suitable for immobilizing the antibody on a monolayer via reaction with a hydrazide-activated Y group on the monolayer. *See e.g.*, U.S. Patent No. 6,329,209; Dammer et al., 70 BIOPHYS J. 2437-2441 (1996).

Because the protein-capture agents of at least some of the different regions on the microarray are different from each other, different solutions, each containing a different protein-capture agent, must be delivered to the individual regions. Solutions of protein-capture agents may be transferred to the appropriate regions via arrayers, which are well-known in the art and even commercially available. For example, microcapillary-based dispensing systems may be used. These dispensing systems may be automated and computer-aided. A description of and building instructions for an example of a microarrayer comprising an automated capillary system can be found on the internet at <http://cmgm.stanford.edu/pbrown/microarray.html> and <http://cmgm.stanford.edu/pbrown/mguide/index.html>. The use of other microprinting techniques for transferring solutions containing the protein-capture agents to the agent-reactive regions is also possible. Ink-jet printer heads may also be used for precise delivery of the protein-capture agents to the agent-reactive regions. Representative, non-limiting disclosures of techniques useful for depositing the protein-capture agents on the appropriate regions of the substrate may be found, for example, in U.S. Patent. Nos. 5,843,767 (ink-jet printing technique, Hamilton 2200 robotic pipetting delivery system); 5,837,860 (ink-jet printing technique, Hamilton 2200 robotic pipetting delivery system); 5,807,522 (capillary dispensing device); and 5,731,152 (stamping apparatus). Other methods of arraying functionally active proteins include attaching proteins to the surfaces of chemically derivatized microscope slides. *See* MacBeath & Schreiber, 289 SCIENCE 1760-63 (2000).

a. Adaptors

Another embodiment of the protein microarrays of the present invention comprises an adaptor that links the affinity tag to the protein-capture agent on the regions of the microarray. The additional spacing of the protein-capture agent from the surface of the substrate (or coating) that is afforded by the use of an adaptor is particularly advantageous if the protein-capture agent is a protein, because proteins are prone to surface inactivation. The

adaptor may afford some additional advantages as well. For example, the adaptor may help facilitate the attachment of the protein-capture agent to the affinity tag. In another embodiment, the adaptor may help facilitate the use of a particular detection technique with the microarray. One of ordinary skill in the art will be able to choose an adaptor which is appropriate for a given affinity tag. For example, if the affinity tag is streptavidin, then the adaptor could be biotin that is chemically conjugated to the protein-capture agent which is to be immobilized.

In one embodiment, the adaptor comprises a protein. In another embodiment, the affinity tag, adaptor, and protein-capture agent together compose a fusion protein. Such a fusion protein may be readily expressed using standard recombinant DNA technology. Protein adaptors are especially useful to increase the solubility of the protein-capture agent of interest and to increase the distance between the surface of the substrate or coating and the protein-capture agent. A protein adaptor can also be very useful in facilitating the preparative steps of protein purification by affinity binding prior to immobilization on the microarray. Examples of possible adaptor proteins include glutathione-S-transferase (GST), maltose-binding protein, chitin-binding protein, thioredoxin, and green-fluorescent protein (GFP). GFP may also be used for quantification of surface binding. In an embodiment in which the protein-capture agent is an antibody moiety comprising the Fc region, the adaptor may be a polypeptide, such as protein G, protein A, or recombinant protein A/G (a gene fusion product secreted from a non-pathogenic form of *Bacillus* which contains four Fc binding domains from protein A and two from protein G).

2. Preparation of the Protein-capture Agents of the Microarray

The protein-capture agents used on the microarray may be produced by any of the variety of means known to those of ordinary skill in the art. The protein-capture agents may comprise proteins, specifically, antibodies or fragments thereof, ligands, receptor proteins, and small molecules.

In preparation for immobilization to the arrays of the present invention, the antibody moiety, or any other protein-capture agent that is a protein or polypeptide, may be expressed from recombinant DNA either *in vivo* or *in vitro*. The cDNA encoding the antibody or antibody fragment or other protein-capture agent may be cloned into an expression vector (many examples of which are commercially available) and introduced into cells of the appropriate organism for expression. A broad range of host cells and protein-capture agents may be used to produce the antibodies and antibody fragments, or other proteins, which serve

as the protein-capture agents on the microarray. Expression *in vivo* may be accomplished in bacteria (*e.g.*, *Escherichia coli*), plants (*e.g.*, *Nicotiana tabacum*), lower eukaryotes (*e.g.*, *Saccharomyces cerevisiae*, *Saccharomyces pombe*, *Pichia pastoris*), or higher eukaryotes (*e.g.*, baculovirus-infected insect cells, insect cells, mammalian cells). For *in vitro* expression, PCR-amplified DNA sequences may be directly used in coupled *in vitro* transcription/translation systems (*e.g.*, *E. coli* S30 lysates from T7 RNA polymerase expressing, preferably protease-deficient strains; wheat germ lysates; reticulocyte lysates). The choice of organism for optimal expression depends on the extent of post-translational modifications (*i.e.*, glycosylation, lipid-modifications) desired. The choice of protein-capture agent also depends on other issues, such as whether an intact antibody is to be produced or just a fragment of an antibody (and which fragment), because disulfide bond formation will be affected by the choice of a host cell. One of ordinary skill in the art will be able to readily choose which host cell type is most suitable for the protein-capture agent and application desired.

DNA sequences encoding affinity tags and adaptors may be engineered into the expression vectors such that the protein-capture agent genes of interest can be cloned in frame either 5' or 3' of the DNA sequence encoding the affinity tag and adaptor protein. In most aspects, the expressed protein-capture agents may purified by affinity chromatography using commercially available resins.

Production of a plurality of protein-capture agents may involve parallel processing from cloning to protein expression and protein purification. cDNAs encoding the protein-capture agent of interest may be amplified by PCR using cDNA libraries or expressed sequence tag (EST) clones as templates. For *in vivo* expression of the proteins, cDNAs may be cloned into commercial expression vectors and introduced into an appropriate organism for expression. For *in vitro* expression PCR-amplified DNA sequences may be directly used in coupled transcription/translation systems.

E. coli-based protein expression is generally the method of choice for soluble proteins that do not require extensive post-translational modifications for activity. Extracellular or intracellular domains of membrane proteins may be fused to protein adaptors for expression and purification.

The entire approach may be performed using 96-well assay plates. PCR reactions may be carried out under standard conditions. Oligonucleotide primers may contain unique restriction sites for facile cloning into the expression vectors. Alternatively, the TA cloning

system may be used. The expression vectors may further contain the sequences for affinity tags and the protein adaptors. PCR products may be ligated into the expression vectors (under inducible promoters) and introduced into the appropriate competent *E. coli* strain by calcium-dependent transformation (strains include: XL-1 blue, BL21, SG13009 (lon-)).

5 Transformed *E. coli* cells are plated and individual colonies transferred into 96-microarray blocks. Cultures are grown to mid-log phase, induced for expression, and cells collected by centrifugation. Cells are resuspended containing lysozyme and the membranes broken by rapid freeze/thaw cycles, or by sonication. Cell debris is removed by centrifugation and the supernatants transferred to 96-tube arrays. The appropriate affinity matrix is added, the
10 protein-capture agent of interest is bound and nonspecifically bound proteins are removed by repeated washing and other steps using centrifugation devices. Alternatively, magnetic affinity beads and filtration devices may be used. The proteins are eluted and transferred to a new 96-well microarray. Protein concentrations are determined and an aliquot of each protein-capture agent is spotted onto a nitrocellulose filter and verified by Western analysis
15 using an antibody directed against the affinity tag on the protein-capture agent. The purity of each sample is assessed by SDS-PAGE and Silver staining or mass spectrometry. The protein-capture agents are then snap-frozen and stored at -80°C .

S. cerevisiae allows for the production of glycosylated protein-capture agents such as antibodies or antibody fragments. For production in *S. cerevisiae*, the approach described
20 above for *E. coli* may be used with slight modifications for transformation and cell lysis. Transformation of *S. cerevisiae* may be accomplished by lithium-acetate and cell lysis by lyticase digestion of the cell walls followed by freeze-thaw, sonication or glass-bead
extraction. Variations of post-translational modifications may be obtained by using different yeast strains (*i.e.*, *S. pombe*, *P. pastoris*).

25 One aspect of the baculovirus system is the array of post-translational modifications that can be obtained, although antibodies and other proteins produced in baculovirus contain carbohydrate structures very different from those produced by mammalian cells. The baculovirus-infected insect cell system requires cloning of viruses, obtaining high titer stocks and infection of liquid insect cell suspensions (cells such as SF9, SF21).

30 Mammalian cell-based expression requires transfection and cloning of cell lines. Either lymphoid or non-lymphoid cell may be used in the preparation of antibodies and antibody fragments. Soluble proteins such as antibodies are collected from the medium while intracellular or membrane bound proteins require cell lysis (either detergent solubilization or

freeze-thaw). The protein-capture agents may then be purified by a procedure analogous to that described for *E. coli*.

For *in vitro* translation, the system of choice is *E. coli* lysates obtained from protease-deficient and T7 RNA polymerase overexpressing strains. *E. coli* lysates provide efficient
5 protein expression (30-50µg/ml lysate). The entire process may be carried out in 96-well arrays. Antibody genes or other protein-capture agent genes of interest may be amplified by PCR using oligonucleotides that contain the gene-specific sequences containing a T7 RNA polymerase promoter and binding site and a sequence encoding the affinity tag.

Alternatively, an adaptor protein may be fused to the gene of interest by PCR. Amplified
10 DNAs may be directly transcribed and translated in the *E. coli* lysates without prior cloning for fast analysis. The antibody fragments or other proteins may then be isolated by binding to an affinity matrix and processed as described above.

Alternative *in vitro* translation systems that may be used include wheat germ extracts and reticulocyte extracts. *In vitro* synthesis of membrane proteins or post-translationally
15 modified proteins will require reticulocyte lysates in combination with microsomes.

In one embodiment of the invention, the protein-capture agents on the microarray comprise monoclonal antibodies. The production of monoclonal antibodies against specific protein targets is routine using standard hybridoma technology. In fact, numerous monoclonal antibodies are available commercially.

20 As an alternative to obtaining antibodies or antibody fragments by cell fusion or from continuous cell lines, the antibody moieties may be expressed in bacteriophage.

Such antibody phage display technologies are well known to those skilled in the art.

The bacteriophage protein-capture agents allow for the random recombination of heavy- and
light-chain sequences, thereby creating a library of antibody sequences that may be selected
25 against the desired antigen. The protein-capture agent may be based on bacteriophage lambda or on filamentous phage. The bacteriophage protein-capture agent may be used to express Fab fragments, Fv's with an engineered intermolecular disulfide bond to stabilize the V_H-V_L pair (dsFv's), scFvs, or diabody fragments.

The antibody genes of the phage display libraries may be derived from pre-
30 immunized donors. For example, the phage display library could be a display library prepared from the spleens of mice previously immunized with a mixture of proteins, such as a lysate of human T-cells. Immunization may be used to bias the library to contain a greater number of recombinant antibodies reactive towards a specific set of proteins, such as proteins

found in human T-cells. Alternatively, the library antibodies may be derived from native or synthetic libraries. The native libraries may be constructed from spleens of mice that have not been contacted by external antigen. In a synthetic library, portions of the antibody sequence, typically those regions corresponding to the complementarity determining regions (CDR) loops, have been mutagenized or randomized.

III. Target Samples

Biological samples may be isolated from several sources including, but not limited to, a patient or a cell line. Patient samples may include blood, urine, amniotic fluid, plasma, semen, bone marrow, and tissues. Once isolated, total RNA or protein may be extracted using methods well known in the art. For example, target samples may be generated from total RNA by dT-primed reverse transcription producing cDNA (*see e.g.*, SAMBROOK ET AL., MOLECULAR CLONING: A LABORATORY MANUAL, Cold Spring Harbor Press, New York (1989); AUSUBEL ET AL., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, Inc. (1995)). The cDNA may then be transcribed to cRNA by *in vitro* transcription resulting in a linear amplification of the RNA. The target samples may be labeled with, for example, a fluorescent dye (*e.g.*, Cy3-dUTP) or biotin. The labeled targets may be hybridized to the microarray. Laser excitation of the target samples produces fluorescence emissions, which are captured by a detector. This information may then be used to generate a quantitative two-dimensional fluorescence image of the hybridized targets.

Gene expression profiles of a particular tissue or cell type may be generated from RNA (*i.e.*, total RNA or mRNA). Reverse transcription with an oligo-dT primer may be used to isolate and generate mRNA from cellular RNA. To maximize the amount of sample or signal, labeled total RNA may also be used. The RNA may be fluorescently labeled or labeled with a radioactive isotope. For radioactive detection, a low energy emitter, such as ³³P-dCTP, is preferred due to close proximity of the oligonucleotide probes on the support. The fluorophores, Cy3-dUTP or Cy5-dUTP, may used for fluorescent labeling. These fluorophores demonstrate efficient incorporation with reverse transcriptase and better yields. Furthermore, these fluorophores possess distinguishable excitation and emission spectra. Thus, two samples, each labeled with a different fluorophore, may be simultaneously hybridized to a microarray.

The nucleic acid sample may be amplified prior to hybridization. Amplification methods include, but are not limited to PCR (INNIS ET AL., PCR PROTOCOLS. A GUIDE TO METHODS AND APPLICATION, Academic Press, Inc. San Diego, (1990)), ligase chain reaction

(LCR) (Barringer et al., 89 GENE 117 (1990); Wu and Wallace, 4 GENOMES 560 (1989); and Landegren et al., 241 SCIENCE 1077 (1988)), transcription amplification (Kwoh, et al., 86 PROC. NATL. ACAD. SCI. USA 1173 (1989)), and self-sustained sequence replication (Guatelli, et al., 87 PROC. NATL. ACAD. SCI. USA 1874 (1990)).

- 5 The target nucleic acids may be labeled at one or more nucleotides during or after amplification. Labels suitable for use with microarray technology include labels detectable by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical, or chemical means. In one embodiment, the detectable label is a luminescent label, such as fluorescent labels, chemiluminescent labels, bioluminescent labels, and colorimetric labels.
- 10 In a specific embodiment, the label is a fluorescent label such as fluorescein, rhodamine, lissamine, phycoerythrin, polymethine dye derivative, phosphor, or Cy2, Cy3, Cy3.5, Cy5, Cy5.5, Cy7. Commercially available fluorescent labels include fluorescein phosphoramidites such as Fluoreprime (Pharmacia, Piscataway, NJ), Fluoredite (Millipore, Bedford, MA), and FAM (ABI, Foster City, CA). Other labels include biotin for staining with labeled
- 15 streptavidin conjugate, magnetic beads (*e.g.*, Dynabeads), fluorescent dyes (*e.g.*, texas red, rhodamine, green fluorescent protein), radiolabels (*e.g.*, ^3H , ^{125}I , ^{35}S , ^{14}C , or ^{32}P), enzymes (*e.g.*, horseradish peroxidase, alkaline phosphatase), and colorimetric labels such as colloidal gold or colored glass or plastic (*e.g.*, polystyrene, polypropylene, latex) beads (*see e.g.*, U.S. Patent Nos. 4,366,241; 4,277,437; 4,275,149; 3,996,345; 3,939,350; 3,850,752; and
- 20 3,817,837).

- The labeled RNA targets are then hybridized to the microarray. A number of buffers may be used for hybridization assays. By way of example, but not limitation, the buffers can be any of the following: 5 M betaine, 1 M NaCl, pH 7.5; 4.5 M betaine, 0.5 M LiCl, pH 8.0; 3 M TMACl, 50 mM Tris-HCl, 1 mM EDTA, 0.1% N-lauroyl-sarkosine (NLS); 2.4 M
- 25 TEACl, 50 mM Tris-HCl, pH 8.0, 0.1% NLS; 1 M LiCl, 10 mM Tris-HCl, pH 8.0, 10% formamide; 2 M GuSCN, 30 mM NaCitrate, pH 7.5; 1 M LiCl, 10 mM Tris-HCl, pH 8.0, 1 mM CTAB; 0.3 mM spermine, 10 mM Tris-HCl, pH 7.5; 2 M NH_4OAc with 2 volumes absolute ethanol. Addition volumes of ionic detergents (such as N-lauroyl-sarkosine) may be added to the buffer. Hybridization may be performed at about 20-65°C (*see e.g.*, U.S. Patent
- 30 No. 6,045,996). Additional examples of hybridization conditions are disclosed in SAMBROOK ET AL., (1989); Berger and Kimmel, GUIDE TO MOLECULAR CLONING TECHNIQUES, METHODS IN ENZYMOLOGY, (1987), Volume 152, Academic Press, Inc., San Diego, Calif.; Young and Davis, 80 PROC. NATL. ACAD. SCI. U.S.A 1194 (1983).

The hybridization buffer may be a formamide-based buffer or an aqueous buffer containing dextran sulfate or polyethylene glycol (*see e.g.*, Cheung et al., 21 NATURE GENET. 15-19 (1999); SAMBROOK ET AL. (1989)). In addition, the hybridization buffer may contain blocking agents such as sheared salmon sperm DNA or Denhardt's reagent to minimize nonspecific binding or background noise. Approximately 50-200 μg labeled total RNA or 2-5 μg labeled mRNA per hybridization is required for a sufficient fluorescent signal and detection. Typically, the amount of oligonucleotide probes attached to the support is in excess of the labeled target RNA.

Following hybridization, the nucleic acids may be analyzed by detecting one or more labels attached to the target nucleic acids. The labels may be incorporated by any of a number of methods well-known in the art. In one embodiment, the label may be simultaneously incorporated during the amplification step in the preparation of the target nucleic acids. For example, a labeled amplification product may be generated by PCR using labeled primers or labeled nucleotides. Transcription amplification using a labeled nucleotide (*e.g.*, fluorescein-labeled UTP or CTP) incorporates a label into the transcribed nucleic acids. Alternatively, a label may be added directly to the original nucleic acid sample or to the amplification product following amplification. Methods for labeling nucleic acids are well-known in the art and include, for example, nick translation or end-labeling.

The hybridized array is then subjected to laser excitation, which produces an emission with a unique spectra. The spectra are scanned, for example, with a scanning confocal laser microscope generating monochrome images of the microarray. These images are digitally processed and normalized based on a threshold value (*e.g.*, background) using mathematical algorithms. For example, a threshold value of 0 may be assigned when no change in the level of fluorescence is observed; an increase in fluorescence may be assigned a value of +1 and a decrease in fluorescence may be assigned a value of -1. Normalization may be based on a designated subgroup of genes where variations in this subgroup are utilized to generate statistics applicable for evaluating the complete gene microarray. Chen et al., 2 J. BIOMED. OPTICS 364-67 (1997).

Use of one of the protein microarrays of the present invention may involve placing the two-dimensional microarray in a flowchamber with approximately 1-10 μl of fluid volume per 25 mm^2 overall surface area. The cover over the microarray in the flowchamber is preferably transparent or translucent. In one embodiment, the cover may comprise Pyrex or quartz glass. In other embodiments, the cover may be part of a detection system that

monitors interaction between the protein-capture agents immobilized on the microarray and protein in a solution such as a cellular extract from a biological sample. The flowchambers should remain filled with appropriate aqueous solutions to preserve protein activity.

Salt, temperature, and other conditions are preferably kept similar to those of normal

5 physiological conditions. Proteins in a fluid solution may be flushed into the flow chamber as desired and their interaction with the immobilized protein-capture agents determined.

Sufficient time must be given to allow for binding between the protein-capture agent and its binding partner to occur. The amount of time required for this will vary depending upon the nature and tightness of the affinity of the protein-capture agent for its binding partner.

10 No specialized microfluidic pumps, valves, or mixing techniques are required for fluid delivery to the microarray.

Alternatively, protein-containing fluid may be delivered to each of the regions of protein-capture agents individually. For example, in one embodiment, the regions of the substrate surface where the protein-capture agents reside may be microfabricated in such a
15 way as to allow integration of the microarray with a number of fluid delivery channels oriented perpendicular to the microarray surface, each one of the delivery channels terminating at the site of an individual protein-capture agent-coated region.

The sample, which is delivered to the microarray, will typically be a fluid. In a one embodiment, the sample is a cellular extract or a biological sample. The sample to be
20 assayed may comprise a complex mixture of proteins, including a multitude of proteins which are not binding partners of the protein-capture agents of the microarray. If the proteins to be analyzed in the sample are membrane proteins, then those proteins will typically need to be solubilized prior to administration of the sample to the microarray. If the proteins to be assayed in the sample are proteins secreted by a population of cells in an organism, the
25 sample may be a biological sample. If the proteins to be assayed in the sample are intracellular, a sample may be a cellular extract. In another embodiment, the microarray may comprise protein-capture agents that bind fragments of the expression products of a cell or population of cells in an organism. In such a case, the proteins in the sample to be assayed may have been prepared by performing a digest of the protein in a cellular extract or a
30 biological sample. In an alternative application, the proteins from only specific fractions of a cell are collected for analysis in the sample.

In general, delivery of solutions containing proteins to be bound by the protein-capture agents of the microarray may be preceded, followed, or accompanied by delivery of a

blocking solution. A blocking solution contains protein or another moiety that will adhere to sites of non-specific binding on the microarray. For example, solutions of bovine serum albumin or milk may be used as blocking solutions.

The binding partners of the plurality of protein-capture agents on the microarray are proteins that are all expression products, or fragments thereof, of a cell or population of cells of a single organism. The expression products may be proteins, including peptides, of any size or function. They may be intracellular proteins or extracellular proteins. The expression products may be from a one-celled or multicellular organism. The organism may be a plant or an animal. In a specific embodiment of the invention, the binding partners are human expression products, or fragments thereof.

In another embodiment of the present invention, the binding partners of the protein-capture agents of the microarray may be a randomly chosen subset of all the proteins, including peptides, which are expressed by a cell or population of cells in a given organism or a subset of all the fragments of those proteins. Thus, the binding partners of the protein-capture agents of the microarray may represent a wide distribution of different proteins from a single organism.

The binding partners of some or all of the protein-capture agents on the microarray need not necessarily be known. Indeed, the binding partner of a protein-capture agent of the microarray may be a protein or peptide of unknown function. For example, the different protein-capture agents of the microarray may together bind a wide range of cellular proteins from a single cell type, many of which are of unknown identity and/or function.

In another embodiment of the present invention, the binding partners of the protein-capture agents on the microarray are related proteins. The different proteins bound by the protein-capture agents may be members of the same protein family. The different binding partners of the protein-capture agents of the microarray may be either functionally related or simply suspected of being functionally related. The different proteins bound by the protein-capture agents of the microarray may also be proteins that share a similarity in structure or sequence or are simply suspected of sharing a similarity in structure or sequence.

For example, the binding partners of the protein-capture agents on the microarray may be growth factor receptors, hormone receptors, neurotransmitter receptors, catecholamine receptors, amino acid derivative receptors, cytokine receptors, extracellular matrix receptors, antibodies, lectins, cytokines, serpins, proteases, kinases, phosphatases, ras-like GTPases, hydrolases, steroid hormone receptors, transcription factors, heat-shock transcription factors,

DNA-binding proteins, zinc-finger proteins, leucine-zipper proteins, homeodomain proteins, intracellular signal transduction modulators and effectors, apoptosis-related factors, DNA synthesis factors, DNA repair factors, DNA recombination factors, cell-surface antigens, hepatitis C virus (HCV) proteases or HIV proteases and may correspond to all or part of the proteins encoded by the genes of the gene expression profiles of the present invention.

IV. Control Oligonucleotides And Protein-Capture Agents

Control oligonucleotides corresponding to genomic DNA, housekeeping genes, or negative and positive control genes may also be present on the microarray. Similarly, protein-capture agents that bind housekeeping proteins, or negative and positive control proteins, such as beta actin protein, may also be present on the microarray. These controls are used to calibrate background or basal levels of expression, and to provide other useful information.

Normalization controls may be oligonucleotide probes that are perfectly complementary to labeled reference oligonucleotides that are added to the nucleic acid sample. Normalization controls may be protein-capture agents that bind specifically and consistently to a labeled reference protein that is added to the protein sample. For example, a protein-capture agent/normalization control pair may comprise avidin/streptavidin or a well-known antibody/antigen combination with a known binding coefficient. The signals obtained from the normalization controls after hybridization provide a control for variations in hybridization conditions, label intensity, efficiency, and other factors that may cause the hybridization signal to vary between microarrays. To normalize fluorescence intensity measurements, for example, signals from all probes of the microarray may be divided by the signal from the control probes.

Expression level controls are probes or protein-capture agents that hybridize/bind specifically with constitutively expressed genes in the biological sample and are designed to control the overall metabolic activity of a cell. Analysis of the variations in the levels of the expression control as compared to the expression level of the target nucleic acid or target protein indicates whether variations in the expression level of a gene or protein is due specifically to changes in the transcription rate of that gene or to general variations in the health of the cell. Thus, if the expression levels of both the expression control and the target gene decrease or increase, these alterations may be attributed to changes in the metabolic activity of the cell as a whole, not to differential expression of the target gene or protein in question. If only the expression of the target gene or protein varies, however, then the

variation in the expression may be attributed to differences in regulation of that gene or protein and not to overall variations in the metabolic activity of the cell. Constitutively expressed genes such as housekeeping genes (*e.g.*, β -actin gene, transferrin receptor gene, GAPDH gene) may serve as expression level controls.

5 Mismatch controls may also be used for expression level controls or for normalization controls. These probes and protein-capture agents provide a control for non-specific binding or cross-hybridization to a nucleic acid in the sample other than the target to which the probe is directed. Mismatch controls are oligonucleotide probes identical to the corresponding test or control probes except for the presence of one or more mismatched bases. One or more
10 mismatches (*e.g.*, substituting guanine, cytidine, or thymine for adenine) are selected such that under appropriate hybridization conditions (*e.g.*, stringent conditions), the test or control probe would be expected to hybridize with its target sequence, but the mismatch probe would not hybridize or would hybridize to a significantly lesser extent. Similarly, an antibody may be used as a mismatch control protein-capture agent. For example, an antibody may be used
15 that has a base pair mismatch in the binding domain that affects binding as compared to the normal antibody.

V. Detection Methods And Analysis Of Hybridization Results

Methods for signal detection of labeled target nucleic acids hybridized to microarray probes are well-known in the art. For example, a radioactive labeled probe may be detected
20 by radiation emission using photographic film or a gamma counter. For fluorescently labeled target nucleic acids, the localization of the label on the probe microarray may be accomplished with fluorescent microscopy. The hybridized microarray is excited with a light source at the excitation wavelength of the particular fluorescent label and the resulting fluorescence is detected. The excitation light source may be a laser appropriate for the
25 excitation of the fluorescent label.

Confocal microscopy may be automated with a computer-controlled stage to automatically scan the entire microarray. Similarly, a microscope may be equipped with a phototransducer (*e.g.*, a photomultiplier) attached to an automated data acquisition system to automatically record the fluorescence signal produced by hybridization to oligonucleotide
30 probes. *See e.g.*, U.S. Patent. No. 5,143,854.

The present invention also relates to methods for evaluating the hybridization results. These methods may vary with the nature of the specific oligonucleotide probes or protein-capture agent used as well as the controls provided. For example, quantification of the

fluorescence intensity for each probe may be accomplished by measuring the probe signal strength at each location (representing a different probe) on the microarray (*e.g.*, detection of the amount of fluorescence intensity produced by a fixed excitation illumination at each location on the array). The fluorescent intensity for each protein-capture agent and binding pair may be accomplished using similar methods. The absolute intensities of the target nucleic acids or proteins hybridized to the microarray may then be compared with the intensities produced by the controls, providing a measure of the relative expression of the nucleic acids or proteins that hybridize to each of the probes or protein-capture agents.

Normalization of the signal derived from the target nucleic acids to the normalization controls may provide a control for variations in hybridization conditions. Typically, normalization may be accomplished by dividing the measured signal from the other probes or protein-capture agents in the array by the average signal produced by the normalization controls. Normalization may also include correction for variations due to sample preparation and amplification. Such normalization may be accomplished by dividing the measured signal by the average signal from the sample preparation/amplification control probes or protein-capture agents. The resulting values may be multiplied by a constant value to scale the results. Other methods for analyzing microarray data are well-known in the art including coupled two-way clustering analysis, clustering algorithms (hierarchical clustering, self-organizing maps), and support vector machines. *See e.g.*, Brown et al., 97 PROC. NATL. ACAD. SCI. USA 262-67 (2000); Getz et al., 97 PROC. NATL. ACAD. SCI. USA 12079-84 (2000); Holter et al., 97 PROC. NATL. ACAD. SCI. USA 8409-14 (2000); Tamayo et al., 96 PROC. NATL. ACAD. SCI. USA 2907-12 (1999); Eisen et al., 95 PROC. NATL. ACAD. SCI. USA 14863-68 (1998); and Ermolaeva et al., 20 NATURE GENET. 19-23 (1998).

Indeed, the methodologies useful in analyzing gene expression profiles and gene expression data are equally applicable in the context of the study of protein expression. In general, for a variety of applications including proteomics and diagnostics, the methods of the present invention involve the delivery of the sample containing the proteins to be analyzed to the microarrays. After the proteins of the sample have been allowed to interact with and become immobilized on the regions comprising protein-capture agents with the appropriate biological specificity, the presence and/or amount of protein bound at each region is then determined. The detection methods, analysis tools, and algorithms described for the nucleic acid microarrays are equally applicable in the context of protein microarrays.

In addition to the methods described above, a wide range of detection methods are available to analyze the results of protein microarray experiments. Detection may be quantitative and/or qualitative. The protein microarray may be interfaced with optical detection methods such as absorption in the visible or infrared range, chemoluminescence, and fluorescence (including lifetime, polarization, fluorescence correlation spectroscopy (FCS), and fluorescence-resonance energy transfer (FRET)). Other modes of detection such as those based on optical waveguides (WO 96/26432 and U.S. Pat. No. 5,677,196), surface plasmon resonance, surface charge sensors, and surface force sensors are compatible with many embodiments of the present invention. Alternatively, technologies such as those based on Brewster Angle microscopy (BAM) (Schaaf et al., 3 LANGMUIR 1131-1135 (1987)) and ellipsometry (U.S. Pat. Nos. 5,141,311 and 5,116,121; Kim, 22 MACROMOLECULES 2682-2685 (1984)) may be utilized. Quartz crystal microbalances and desorption processes provide still other alternative detection means suitable for at least some embodiments of the invention microarray. *See, e.g.*, U.S. Pat. No. 5,719,060. An example of an optical biosensor system compatible both with some arrays of the present invention and a variety of non-label detection principles including surface plasmon resonance, total internal reflection fluorescence (TIRF), Brewster Angle microscopy, optical waveguide lightmode spectroscopy (OWLS), surface charge measurements, and ellipsometry are discussed in U.S. Pat. No. 5,313,264.

Other different types of detection systems suitable to assay the protein expression arrays of the present invention include, but are not limited to, fluorescence, measurement of electronic effects upon exposure to a compound or analyte, luminescence, ultraviolet visible light, and laser induced fluorescence (LIF) detection methods, collision induced dissociation (CID), mass spectroscopy (MS), CCD cameras, electron and three dimensional microscopy.

Other techniques are known to those of skill in the art. For example, analyses of combinatorial arrays and biochip formats have been conducted using LIF techniques that are relatively sensitive. *See, e.g.*, Ideue et al., 337 CHEM. PHYSICS LETTERS 79-84 (2000).

One detection system of particular interest is time-of-flight mass spectrometry (TOF-MS). Using parallel sampling techniques, time-of-flight mass spectrometry may be used for the detailed characterization of hundreds of molecules in a sample mixture at each discrete location within the microarray. Time-of-flight mass spectrometry based systems enable extremely rapid analysis (microseconds to milliseconds instead of seconds for scanning MS devices) high levels of selectivity compared to other techniques with good sensitivity (better

than one part per million, as opposed to one part per ten thousand for scanning MS), As a mass spectroscopic technique, time-of-flight mass spectrometry provides molecular weight and structural information for identification of unknown samples.

Additional levels of sensitivity are added by coupling time-of-flight mass spectrometry to another separation system. Thus, in an embodiment, the present invention comprises using ion mobility in combination with time-of-flight mass spectrometry for the analysis of microarrays. The combination of ion mobility and time-of-flight mass spectrometry is referred to as multi-dimensional spectroscopy (MDS). Ions are electro-sprayed into the front of the MDS device. Electrospray is a method for ionizing relatively large molecules and having them form a gas phase. The solution containing the sample is sprayed at high voltage, forming charged droplets. These droplets evaporate, leaving the sample's ionized molecules in the gas phase. These ions continue into the ion mobility chamber where the ions travel under the influence of a uniform electric field through a buffer gas. The principle underlying ion mobility separation techniques is that compact ions undergo fewer collisions than ions having extended shapes and thus, have increased mobility. As the separated components (comprising ions/molecules of different mobility) exit the drift tube, they are pulsed into a time-of-flight mass spectrometer.

Although non-label detection methods are generally preferred, some of the types of detection methods commonly used for traditional immunoassays that require the use of labels may be applied to the arrays of the present invention. These techniques include noncompetitive immunoassays, competitive immunoassays, and dual label, radiometric immunoassays. These techniques are primarily suitable for use with the arrays of protein-capture agents when the number of different protein-capture agents with different specificity is small (less than about 100). In the competitive method, binding-site occupancy is determined indirectly. In this method, the protein-capture agents of the microarray are exposed to a labeled developing agent, which is typically a labeled version of the analyte or an analyte analog. The developing agent competes for the binding sites on the protein-capture agent with the analyte. The fractional occupancy of the protein-capture agents on different regions can be determined by the binding of the developing agent to the protein-capture agents of the individual regions.

In the noncompetitive method, binding site occupancy is determined directly. In this method, the regions of the microarray are exposed to a labeled developing agent capable of binding to either the bound analyte or the occupied binding sites on the protein-capture agent.

For example, the developing agent may be a labeled antibody directed against occupied sites (*i.e.*, a “sandwich assay”). Alternatively, a dual label, radiometric, approach may be taken where the protein-capture agent is labeled with one label and the second, developing agent is labeled with a second label. *See* Ekins, et al., 194 CLINICA CHIMICA ACTA. 91-114, (1990).

- 5 Many different labeling methods may be used in the aforementioned techniques, including radioisotopic, enzymatic, chemiluminescent, and fluorescent methods.

VI. Types Of Microarrays

The microarrays of the present invention may be derived from or representative of a specific organism, or cell type, including human microarrays, cancer microarrays, apoptosis
10 microarrays, oncogene and tumor suppressor microarrays, cell-cell interaction microarrays, cytokine and cytokine receptor microarrays, blood microarrays, cell cycle microarrays, neuroarrays, mouse microarrays, and rat microarrays, or combinations thereof.

In further embodiments, the microarrays may represent diseases including cardiovascular diseases, neurological diseases, immunological diseases, various cancers,
15 infectious diseases, endocrine disorders, and genetic diseases.

Alternatively, the microarrays of the present invention may represent a particular tissue type, such as heart, liver, prostate, lung, nerve, muscle, or connective tissue; preferably coronary artery endothelium, umbilical artery endothelium, umbilical vein endothelium, aortic endothelium, dermal microvascular endothelium, pulmonary artery endothelium,
20 myometrium microvascular endothelium, keratinocyte epithelium, bronchial epithelium, mammary epithelium, prostate epithelium, renal cortical epithelium, renal proximal tubule epithelium, small airway epithelium, renal epithelium, umbilical artery smooth muscle, neonatal dermal fibroblast, pulmonary artery smooth muscle, dermal fibroblast, neural progenitor cells, skeletal muscle, astrocytes, aortic smooth muscle, mesangial cells, coronary
25 artery smooth muscle, bronchial smooth muscle, uterine smooth muscle, lung fibroblast, osteoblasts, prostate stromal cells, or combinations thereof.

The present invention contemplates microarrays comprising a gene expression profile comprising one or more nucleic acid sequences including complementary and homologous sequences, wherein said gene expression profile is generated from a cell type selected from
30 the group comprising coronary artery endothelium, umbilical artery endothelium, umbilical vein endothelium, aortic endothelium, dermal microvascular endothelium, pulmonary artery endothelium, myometrium microvascular endothelium, keratinocyte epithelium, bronchial epithelium, mammary epithelium, prostate epithelium, renal cortical epithelium, renal

proximal tubule epithelium, small airway epithelium, renal epithelium, umbilical artery smooth muscle, neonatal dermal fibroblast, pulmonary artery smooth muscle, dermal fibroblast, neural progenitor cells, skeletal muscle, astrocytes, aortic smooth muscle, mesangial cells, coronary artery smooth muscle, bronchial smooth muscle, uterine smooth muscle, lung fibroblast, osteoblasts, and prostate stromal cells.

The present invention contemplates microarrays comprising one or more protein-capture agents, wherein said protein expression profile is generated from a cell type selected from the group comprising coronary artery endothelium, umbilical artery endothelium, umbilical vein endothelium, aortic endothelium, dermal microvascular endothelium, pulmonary artery endothelium, myometrium microvascular endothelium, keratinocyte epithelium, bronchial epithelium, mammary epithelium, prostate epithelium, renal cortical epithelium, renal proximal tubule epithelium, small airway epithelium, renal epithelium, umbilical artery smooth muscle, neonatal dermal fibroblast, pulmonary artery smooth muscle, dermal fibroblast, neural progenitor cells, skeletal muscle, astrocytes, aortic smooth muscle, mesangial cells, coronary artery smooth muscle, bronchial smooth muscle, uterine smooth muscle, lung fibroblast, osteoblasts, and prostate stromal cells.

In a specific embodiment, the present invention provides a microarray comprising an endothelial cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof, or portions of said nucleic acid sequence or complementary sequence thereof, selected from the group consisting of SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; SEQ ID NO: 8; SEQ ID NO: 9; SEQ ID NO: 10; SEQ ID NO: 11; SEQ ID NO: 12; SEQ ID NO: 13; SEQ ID NO: 14; SEQ ID NO: 15; SEQ ID NO: 16; SEQ ID NO: 17; SEQ ID NO: 18; SEQ ID NO: 19; SEQ ID NO: 20; SEQ ID NO: 21; SEQ ID NO: 22; SEQ ID NO: 23; SEQ ID NO: 48; SEQ ID NO: 63; SEQ ID NO: 70; SEQ ID NO: 82; SEQ ID NO: 94; and SEQ ID NO: 144.

In another embodiment, a microarray of the present invention may comprise a muscle cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof, or portions of said nucleic acid sequence or complementary sequence thereof, selected from the group consisting of SEQ ID NO: 24; SEQ ID NO: 25; SEQ ID NO: 26; SEQ ID NO: 27; SEQ ID NO: 28; SEQ ID NO: 29; SEQ ID NO: 30; SEQ ID NO: 31; SEQ ID NO: 32; SEQ ID NO: 33; SEQ ID NO: 34; SEQ ID NO: 35; SEQ ID NO: 36; SEQ ID NO: 37; SEQ ID NO: 39; SEQ ID

NO: 40; SEQ ID NO: 41; SEQ ID NO: 42; SEQ ID NO: 54; SEQ ID NO: 55; and SEQ ID NO: 69.

In an alternative embodiment, a microarray comprises a primary cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof, or portions of said nucleic acid sequence or complementary sequence thereof, selected from the group consisting of SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; SEQ ID NO: 8; SEQ ID NO: 9; SEQ ID NO: 10; SEQ ID NO: 11; SEQ ID NO: 12; SEQ ID NO: 13; SEQ ID NO: 14; SEQ ID NO: 15; SEQ ID NO: 16; SEQ ID NO: 17; SEQ ID NO: 18; SEQ ID NO: 19; SEQ ID NO: 20; SEQ ID NO: 21; SEQ ID NO: 22; SEQ ID NO: 23; SEQ ID NO: 24; SEQ ID NO: 25; SEQ ID NO: 26; SEQ ID NO: 27; SEQ ID NO: 28; SEQ ID NO: 29; SEQ ID NO: 30; SEQ ID NO: 31; SEQ ID NO: 32; SEQ ID NO: 33; SEQ ID NO: 34; SEQ ID NO: 35; SEQ ID NO: 36; SEQ ID NO: 37; SEQ ID NO: 39; SEQ ID NO: 40; SEQ ID NO: 41; SEQ ID NO: 42; SEQ ID NO: 43; SEQ ID NO: 44; SEQ ID NO: 45; SEQ ID NO: 46; SEQ ID NO: 47; SEQ ID NO: 48; SEQ ID NO: 49; SEQ ID NO: 50; SEQ ID NO: 51; SEQ ID NO: 52; SEQ ID NO: 53; SEQ ID NO: 54; SEQ ID NO: 55; SEQ ID NO: 56; SEQ ID NO: 57; SEQ ID NO: 58; SEQ ID NO: 59; SEQ ID NO: 60; SEQ ID NO: 61; SEQ ID NO: 62; SEQ ID NO: 63; SEQ ID NO: 64; SEQ ID NO: 65; SEQ ID NO: 66; SEQ ID NO: 67; SEQ ID NO: 68; SEQ ID NO: 69; SEQ ID NO: 70; SEQ ID NO: 71; SEQ ID NO: 72; SEQ ID NO: 73; SEQ ID NO: 74; SEQ ID NO: 75; SEQ ID NO: 76; SEQ ID NO: 77; SEQ ID NO: 78; SEQ ID NO: 79; SEQ ID NO: 80; SEQ ID NO: 81; SEQ ID NO: 82; SEQ ID NO: 83; SEQ ID NO: 84; SEQ ID NO: 85; SEQ ID NO: 86; SEQ ID NO: 87; SEQ ID NO: 88; SEQ ID NO: 89; SEQ ID NO: 90; SEQ ID NO: 91; SEQ ID NO: 92; SEQ ID NO: 93; SEQ ID NO: 94; SEQ ID NO: 95; SEQ ID NO: 96; SEQ ID NO: 97; SEQ ID NO: 98; SEQ ID NO: 99; SEQ ID NO: 100; SEQ ID NO: 101; SEQ ID NO: 102; SEQ ID NO: 103; SEQ ID NO: 104; SEQ ID NO: 105; SEQ ID NO: 106; SEQ ID NO: 107; SEQ ID NO: 108; SEQ ID NO: 109; SEQ ID NO: 110; SEQ ID NO: 111; SEQ ID NO: 112; SEQ ID NO: 113; SEQ ID NO: 114; SEQ ID NO: 115; SEQ ID NO: 116; SEQ ID NO: 118; SEQ ID NO: 119; SEQ ID NO: 120; SEQ ID NO: 121; SEQ ID NO: 122; SEQ ID NO: 123; SEQ ID NO: 124; SEQ ID NO: 125; SEQ ID NO: 126; SEQ ID NO: 127; SEQ ID NO: 128; SEQ ID NO: 129; SEQ ID NO: 130; SEQ ID NO: 131; SEQ ID NO: 132; SEQ ID NO: 133; SEQ ID NO: 134; SEQ ID NO: 135; SEQ ID NO: 136; SEQ ID NO: 137; SEQ ID NO: 138; SEQ ID NO: 139; SEQ ID NO: 140; SEQ ID NO: 141; SEQ ID NO: 142; SEQ ID NO: 143; SEQ ID

NO: 144; SEQ ID NO: 145; SEQ ID NO: 146; SEQ ID NO: 147; SEQ ID NO: 148; SEQ ID
 NO: 149; SEQ ID NO: 150; SEQ ID NO: 151; SEQ ID NO: 152; SEQ ID NO: 153; SEQ ID
 NO: 154; SEQ ID NO: 155; SEQ ID NO: 156; SEQ ID NO: 157; SEQ ID NO: 158; SEQ ID
 NO: 159; SEQ ID NO: 160; SEQ ID NO: 161; SEQ ID NO: 162; SEQ ID NO: 163; SEQ ID
 5 NO: 164; SEQ ID NO: 165; SEQ ID NO: 166; SEQ ID NO: 167; SEQ ID NO: 168; SEQ ID
 NO: 169; SEQ ID NO: 170; SEQ ID NO: 171; SEQ ID NO: 172; SEQ ID NO: 173; SEQ ID
 NO: 174; SEQ ID NO: 175; SEQ ID NO: 176; SEQ ID NO: 177; SEQ ID NO: 178; SEQ ID
 NO: 179; SEQ ID NO: 180; SEQ ID NO: 181; SEQ ID NO: 182; SEQ ID NO: 183; SEQ ID
 NO: 184; SEQ ID NO: 185; and SEQ ID NO: 186.

10 The present invention also provides a microarray comprising an epithelial cell gene
 expression profile comprising one or more nucleic acid sequences substantially homologous to
 a nucleic acid sequence or complementary sequence thereof, or portions of said nucleic acid
 sequence or complementary sequence thereof, selected from the group consisting of SEQ ID
 NO: 47; SEQ ID NO: 60; SEQ ID NO: 67; SEQ ID NO: 73; SEQ ID NO: 75; SEQ ID NO:
 15 76; SEQ ID NO: 77; SEQ ID NO: 78; SEQ ID NO: 80; SEQ ID NO: 96; SEQ ID NO: 98;
 SEQ ID NO: 99; SEQ ID NO: 111; SEQ ID NO: 112; SEQ ID NO: 123; SEQ ID NO: 127;
 SEQ ID NO: 131; SEQ ID NO: 150; SEQ ID NO: 153; SEQ ID NO: 154; SEQ ID NO: 155;
 SEQ ID NO: 156; SEQ ID NO: 157; SEQ ID NO: 158; SEQ ID NO: 159; SEQ ID NO: 160;
 SEQ ID NO: 161; SEQ ID NO: 162; SEQ ID NO: 163; SEQ ID NO: 164; SEQ ID NO: 165;
 20 SEQ ID NO: 166; SEQ ID NO: 167; SEQ ID NO: 168; SEQ ID NO: 169; SEQ ID NO: 170;
 SEQ ID NO: 171; SEQ ID NO: 172; SEQ ID NO: 173; SEQ ID NO: 174; SEQ ID NO: 175;
 SEQ ID NO: 176; SEQ ID NO: 177; SEQ ID NO: 178; SEQ ID NO: 179; SEQ ID NO: 180;
 SEQ ID NO: 181; SEQ ID NO: 182; SEQ ID NO: 183; SEQ ID NO: 184; SEQ ID NO: 185;
 and SEQ ID NO: 186.

25 In yet another embodiment, a microarray may comprise a keratinocyte epithelial cell
 gene expression profile comprising one or more nucleic acid sequences substantially
 homologous to a nucleic acid sequence or complementary sequence thereof, or portions of said
 nucleic acid sequence or complementary sequence thereof, selected from the group consisting
 of SEQ ID NO: 187; SEQ ID NO: 188; SEQ ID NO: 189; SEQ ID NO: 190; SEQ ID NO:
 30 191; SEQ ID NO: 192; SEQ ID NO: 193; SEQ ID NO: 194; SEQ ID NO: 195; SEQ ID NO:
 196; SEQ ID NO: 197; SEQ ID NO: 198; SEQ ID NO: 199; SEQ ID NO: 200; SEQ ID NO:
 201; SEQ ID NO: 202; SEQ ID NO: 203; SEQ ID NO: 204; SEQ ID NO: 205; SEQ ID NO:

206; SEQ ID NO: 207; SEQ ID NO: 208; SEQ ID NO: 209; SEQ ID NO: 210; and SEQ ID NO: 211.

The present invention also provides a microarray comprising a mammary epithelial cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof, or portions of said nucleic acid sequence or complementary sequence thereof, selected from the group consisting of SEQ ID NO: 78; SEQ ID NO: 212; SEQ ID NO: 213; SEQ ID NO: 216; SEQ ID NO: 225; SEQ ID NO: 226; SEQ ID NO: 227; SEQ ID NO: 239; SEQ ID NO: 271; SEQ ID NO: 285; and SEQ ID NO: 289.

In an alternative embodiment, a microarray may comprise a bronchial epithelial cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof, or portions of said nucleic acid sequence or complementary sequence thereof, selected from the group consisting of SEQ ID NO: 27; SEQ ID NO: 131; SEQ ID NO: 150; SEQ ID NO: 169; SEQ ID NO: 214; SEQ ID NO: 215; SEQ ID NO: 223; SEQ ID NO: 224; SEQ ID NO: 241; SEQ ID NO: 243; SEQ ID NO: 244; SEQ ID NO: 255; SEQ ID NO: 256; SEQ ID NO: 261; and SEQ ID NO: 314.

The present invention also provides a microarray comprising a prostate epithelial cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof, or portions of said nucleic acid sequence or complementary sequence thereof, selected from the group consisting of SEQ ID NO: 64; SEQ ID NO: 217; SEQ ID NO: 218; SEQ ID NO: 259; SEQ ID NO: 293; SEQ ID NO: 302; and SEQ ID NO: 320.

In yet another embodiment, a microarray comprises a renal cortical epithelial cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof, or portions of said nucleic acid sequence or complementary sequence thereof, selected from the group consisting of SEQ ID NO: 49; SEQ ID NO: 57; SEQ ID NO: 104; SEQ ID NO: 123; SEQ ID NO: 160; SEQ ID NO: 165; SEQ ID NO: 166; SEQ ID NO: 219; SEQ ID NO: 267; SEQ ID NO: 270; SEQ ID NO: 279; SEQ ID NO: 280; SEQ ID NO: 283; SEQ ID NO: 291; SEQ ID NO: 305; SEQ ID NO: 307; SEQ ID NO: 310; SEQ ID NO: 313; SEQ ID NO: 325; SEQ ID NO: 326; and SEQ ID NO: 327.

The present invention further provides a microarray comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof, or portions of said nucleic acid sequence or complementary sequence thereof, selected from the group consisting of SEQ ID NO: 106; SEQ ID NO: 138; SEQ ID NO: 158; SEQ ID NO: 228; SEQ ID NO: 236; SEQ ID NO: 242; SEQ ID NO: 250; SEQ ID NO: 258; SEQ ID NO: 260; SEQ ID NO: 262; SEQ ID NO: 266; SEQ ID NO: 272; SEQ ID NO: 273; SEQ ID NO: 274; SEQ ID NO: 275; SEQ ID NO: 276; SEQ ID NO: 278; SEQ ID NO: 284; SEQ ID NO: 288; SEQ ID NO: 295; SEQ ID NO: 296; SEQ ID NO: 297; SEQ ID NO: 299; SEQ ID NO: 300; SEQ ID NO: 301; SEQ ID NO: 306; SEQ ID NO: 308; SEQ ID NO: 309; SEQ ID NO: 311; SEQ ID NO: 316; SEQ ID NO: 318; SEQ ID NO: 321; SEQ ID NO: 322; SEQ ID NO: 328; and SEQ ID NO: 329.

In a specific embodiment, a microarray may comprise a small airway epithelial cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof, or portions of said nucleic acid sequence or complementary sequence thereof, selected from the group consisting of SEQ ID NO: 173; SEQ ID NO: 174; SEQ ID NO: 183; SEQ ID NO: 220; SEQ ID NO: 221; SEQ ID NO: 222; SEQ ID NO: 229; SEQ ID NO: 230; SEQ ID NO: 231; SEQ ID NO: 232; SEQ ID NO: 233; SEQ ID NO: 234; SEQ ID NO: 235; SEQ ID NO: 237; SEQ ID NO: 238; SEQ ID NO: 240; SEQ ID NO: 245; SEQ ID NO: 246; SEQ ID NO: 247; SEQ ID NO: 248; SEQ ID NO: 249; SEQ ID NO: 251; SEQ ID NO: 252; SEQ ID NO: 254; SEQ ID NO: 257; SEQ ID NO: 263; SEQ ID NO: 264; SEQ ID NO: 265; SEQ ID NO: 268; SEQ ID NO: 269; SEQ ID NO: 270; SEQ ID NO: 277; SEQ ID NO: 281; SEQ ID NO: 282; SEQ ID NO: 286; SEQ ID NO: 287; SEQ ID NO: 290; SEQ ID NO: 294; SEQ ID NO: 298; SEQ ID NO: 303; SEQ ID NO: 312; SEQ ID NO: 315; SEQ ID NO: 317; and SEQ ID NO: 319.

The present invention also provides a microarray comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof, or portions of said nucleic acid sequence or complementary sequence thereof, selected from the group consisting of SEQ ID NO: 37; SEQ ID NO: 253; SEQ ID NO: 304; SEQ ID NO: 323; and SEQ ID NO: 324.

In yet another embodiment, a microarray may comprise one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof, or portions of said nucleic acid sequence or complementary sequence thereof, selected from the group consisting of SEQ ID NO: 27; SEQ ID NO: 37; SEQ ID NO: 49;

SEQ ID NO: 57; SEQ ID NO: 64; SEQ ID NO: 70; SEQ ID NO: 78; SEQ ID NO: 104; SEQ
ID NO: 106; SEQ ID NO: 123; SEQ ID NO: 131; SEQ ID NO: 138; SEQ ID NO: 150; SEQ
ID NO: 158; SEQ ID NO: 160; SEQ ID NO: 165; SEQ ID NO: 166; SEQ ID NO: 169; SEQ
ID NO: 173; SEQ ID NO: 174; SEQ ID NO: 183; SEQ ID NO: 187; SEQ ID NO: 188; SEQ
5 ID NO: 189; SEQ ID NO: 190; SEQ ID NO: 191; SEQ ID NO: 192; SEQ ID NO: 193; SEQ
ID NO: 194; SEQ ID NO: 195; SEQ ID NO: 196; SEQ ID NO: 197; SEQ ID NO: 198; SEQ
ID NO: 199; SEQ ID NO: 200; SEQ ID NO: 201; SEQ ID NO: 202; SEQ ID NO: 203; SEQ
ID NO: 204; SEQ ID NO: 205; SEQ ID NO: 206; SEQ ID NO: 207; SEQ ID NO: 208; SEQ
ID NO: 209; SEQ ID NO: 210; SEQ ID NO: 211; SEQ ID NO: 212; SEQ ID NO: 213; SEQ
10 ID NO: 214; SEQ ID NO: 215; SEQ ID NO: 216; SEQ ID NO: 217; SEQ ID NO: 218; SEQ
ID NO: 219; SEQ ID NO: 220; SEQ ID NO: 221; SEQ ID NO: 222; SEQ ID NO: 223; SEQ
ID NO: 224; SEQ ID NO: 225; SEQ ID NO: 226; SEQ ID NO: 227; SEQ ID NO: 228; SEQ
ID NO: 229; SEQ ID NO: 230; SEQ ID NO: 231; SEQ ID NO: 232; SEQ ID NO: 233; SEQ
ID NO: 234; SEQ ID NO: 235; SEQ ID NO: 236; SEQ ID NO: 237; SEQ ID NO: 238; SEQ
15 ID NO: 239; SEQ ID NO: 240; SEQ ID NO: 241; SEQ ID NO: 242; SEQ ID NO: 243; SEQ
ID NO: 244; SEQ ID NO: 245; SEQ ID NO: 246; SEQ ID NO: 247; SEQ ID NO: 248; SEQ
ID NO: 249; SEQ ID NO: 250; SEQ ID NO: 251; SEQ ID NO: 252; SEQ ID NO: 253; SEQ
ID NO: 254; SEQ ID NO: 255; SEQ ID NO: 256; SEQ ID NO: 257; SEQ ID NO: 258; SEQ
ID NO: 259; SEQ ID NO: 260; SEQ ID NO: 261; SEQ ID NO: 262; SEQ ID NO: 263; SEQ
20 ID NO: 264; SEQ ID NO: 265; SEQ ID NO: 266; SEQ ID NO: 267; SEQ ID NO: 268; SEQ
ID NO: 269; SEQ ID NO: 270; SEQ ID NO: 271; SEQ ID NO: 272; SEQ ID NO: 273; SEQ
ID NO: 274; SEQ ID NO: 275; SEQ ID NO: 276; SEQ ID NO: 277; SEQ ID NO: 278; SEQ
ID NO: 279; SEQ ID NO: 280; SEQ ID NO: 281; ~~SEQ ID NO: 282~~; SEQ ID NO: 283; SEQ
ID NO: 284; SEQ ID NO: 285; SEQ ID NO: 286; SEQ ID NO: 287; SEQ ID NO: 288; SEQ
25 ID NO: 289; SEQ ID NO: 290; SEQ ID NO: 291; SEQ ID NO: 293; SEQ ID NO: 294; SEQ
ID NO: 295; SEQ ID NO: 296; SEQ ID NO: 297; SEQ ID NO: 298; SEQ ID NO: 299; SEQ
ID NO: 300; SEQ ID NO: 301; SEQ ID NO: 302; SEQ ID NO: 303; SEQ ID NO: 304; SEQ
ID NO: 305; SEQ ID NO: 306; SEQ ID NO: 307; SEQ ID NO: 308; SEQ ID NO: 309; SEQ
ID NO: 310; SEQ ID NO: 311; SEQ ID NO: 312; SEQ ID NO: 313; SEQ ID NO: 314; SEQ
30 ID NO: 315; SEQ ID NO: 316; SEQ ID NO: 317; SEQ ID NO: 318; SEQ ID NO: 320; SEQ
ID NO: 321; SEQ ID NO: 322; SEQ ID NO: 323; SEQ ID NO: 324; SEQ ID NO: 325; SEQ
ID NO: 326; SEQ ID NO: 327; SEQ ID NO: 328; and SEQ ID NO: 329.

5

10

20

25

ID NO: 78; SEQ ID NO: 79; SEQ ID NO: 80; SEQ ID NO: 81; SEQ ID NO: 82; SEQ ID
 NO: 83; SEQ ID NO: 84; SEQ ID NO: 85; SEQ ID NO: 86; SEQ ID NO: 87; SEQ ID NO:
 88; SEQ ID NO: 89; SEQ ID NO: 90; SEQ ID NO: 91; SEQ ID NO: 92; SEQ ID NO: 93;
 SEQ ID NO: 94; SEQ ID NO: 95; SEQ ID NO: 96; SEQ ID NO: 97; SEQ ID NO: 98; SEQ
 5 ID NO: 99; SEQ ID NO: 100; SEQ ID NO: 101; SEQ ID NO: 102; SEQ ID NO: 103; SEQ
 ID NO: 104; SEQ ID NO: 105; SEQ ID NO: 106; SEQ ID NO: 107; SEQ ID NO: 108; SEQ
 ID NO: 109; SEQ ID NO: 110; SEQ ID NO: 111; SEQ ID NO: 112; SEQ ID NO: 113; SEQ
 ID NO: 114; SEQ ID NO: 115; SEQ ID NO: 116; SEQ ID NO: 118; SEQ ID NO: 119; SEQ
 ID NO: 120; SEQ ID NO: 121; SEQ ID NO: 122; SEQ ID NO: 123; SEQ ID NO: 124; SEQ
 10 ID NO: 125; SEQ ID NO: 126; SEQ ID NO: 127; SEQ ID NO: 128; SEQ ID NO: 129; SEQ
 ID NO: 130; SEQ ID NO: 131; SEQ ID NO: 132; SEQ ID NO: 133; SEQ ID NO: 134; SEQ
 ID NO: 135; SEQ ID NO: 136; SEQ ID NO: 137; SEQ ID NO: 138; SEQ ID NO: 139; SEQ
 ID NO: 140; SEQ ID NO: 141; SEQ ID NO: 142; SEQ ID NO: 143; SEQ ID NO: 144; SEQ
 ID NO: 145; SEQ ID NO: 146; SEQ ID NO: 147; SEQ ID NO: 148; SEQ ID NO: 149; SEQ
 15 ID NO: 150; SEQ ID NO: 151; SEQ ID NO: 152; SEQ ID NO: 153; SEQ ID NO: 154; SEQ
 ID NO: 155; SEQ ID NO: 156; SEQ ID NO: 157; SEQ ID NO: 158; SEQ ID NO: 159; SEQ
 ID NO: 160; SEQ ID NO: 161; SEQ ID NO: 162; SEQ ID NO: 163; SEQ ID NO: 164; SEQ
 ID NO: 165; SEQ ID NO: 166; SEQ ID NO: 167; SEQ ID NO: 168; SEQ ID NO: 169; SEQ
 ID NO: 170; SEQ ID NO: 171; SEQ ID NO: 172; SEQ ID NO: 173; SEQ ID NO: 174; SEQ
 20 ID NO: 175; SEQ ID NO: 176; SEQ ID NO: 177; SEQ ID NO: 178; SEQ ID NO: 179; SEQ
 ID NO: 180; SEQ ID NO: 181; SEQ ID NO: 182; SEQ ID NO: 183; SEQ ID NO: 184; SEQ
 ID NO: 185; and SEQ ID NO: 186.

The present invention also provides a microarray comprising one or more protein-
 capture agents that bind one or more amino acid sequences encoded by all or a portion of one
 25 or more nucleic acid sequences selected from the group consisting of SEQ ID NO: 47; SEQ
 ID NO: 60; SEQ ID NO: 67; SEQ ID NO: 73; SEQ ID NO: 75; SEQ ID NO: 76; SEQ ID NO:
 77; SEQ ID NO: 78; SEQ ID NO: 80; SEQ ID NO: 96; SEQ ID NO: 98; SEQ ID NO: 99;
 SEQ ID NO: 111; SEQ ID NO: 112; SEQ ID NO: 123; SEQ ID NO: 127; SEQ ID NO: 131;
 SEQ ID NO: 150; SEQ ID NO: 153; SEQ ID NO: 154; SEQ ID NO: 155; SEQ ID NO: 156;
 30 SEQ ID NO: 157; SEQ ID NO: 158; SEQ ID NO: 159; SEQ ID NO: 160; SEQ ID NO: 161;
 SEQ ID NO: 162; SEQ ID NO: 163; SEQ ID NO: 164; SEQ ID NO: 165; SEQ ID NO: 166;
 SEQ ID NO: 167; SEQ ID NO: 168; SEQ ID NO: 169; SEQ ID NO: 170; SEQ ID NO: 171;
 SEQ ID NO: 172; SEQ ID NO: 173; SEQ ID NO: 174; SEQ ID NO: 175; SEQ ID NO: 176;

SEQ ID NO: 177; SEQ ID NO: 178; SEQ ID NO: 179; SEQ ID NO: 180; SEQ ID NO: 181; SEQ ID NO: 182; SEQ ID NO: 183; SEQ ID NO: 184; SEQ ID NO: 185; and SEQ ID NO: 186.

In yet another embodiment, a microarray may comprise one or more protein-capture agents that bind one or more amino acid sequences encoded by all or a portion of one or more nucleic acid sequences selected from the group consisting of SEQ ID NO: 187; SEQ ID NO: 188; SEQ ID NO: 189; SEQ ID NO: 190; SEQ ID NO: 191; SEQ ID NO: 192; SEQ ID NO: 193; SEQ ID NO: 194; SEQ ID NO: 195; SEQ ID NO: 196; SEQ ID NO: 197; SEQ ID NO: 198; SEQ ID NO: 199; SEQ ID NO: 200; SEQ ID NO: 201; SEQ ID NO: 202; SEQ ID NO: 203; SEQ ID NO: 204; SEQ ID NO: 205; SEQ ID NO: 206; SEQ ID NO: 207; SEQ ID NO: 208; SEQ ID NO: 209; SEQ ID NO: 210; and SEQ ID NO: 211.

The present invention also provides a microarray comprising one or more protein-capture agents that bind one or more amino acid sequences encoded by all or a portion of one or more nucleic acid sequences selected from the group consisting of SEQ ID NO: 78; SEQ ID NO: 212; SEQ ID NO: 213; SEQ ID NO: 216; SEQ ID NO: 225; SEQ ID NO: 226; SEQ ID NO: 227; SEQ ID NO: 239; SEQ ID NO: 271; SEQ ID NO: 285; and SEQ ID NO: 289.

In an alternative embodiment, a microarray may comprise one or more protein-capture agents that bind one or more amino acid sequences encoded by all or a portion of one or more nucleic acid sequences selected from the group consisting of SEQ ID NO: 27; SEQ ID NO: 131; SEQ ID NO: 150; SEQ ID NO: 169; SEQ ID NO: 214; SEQ ID NO: 215; SEQ ID NO: 223; SEQ ID NO: 224; SEQ ID NO: 241; SEQ ID NO: 243; SEQ ID NO: 244; SEQ ID NO: 255; SEQ ID NO: 256; SEQ ID NO: 261; and SEQ ID NO: 314.

The present invention also provides a microarray comprising one or more protein-capture agents that bind one or more amino acid sequences encoded by all or a portion of one or more nucleic acid sequences selected from the group consisting of SEQ ID NO: 64; SEQ ID NO: 217; SEQ ID NO: 218; SEQ ID NO: 259; SEQ ID NO: 293; SEQ ID NO: 302; and SEQ ID NO: 320.

In yet another embodiment, a microarray comprises one or more protein-capture agents that bind one or more amino acid sequences encoded by all or a portion of one or more nucleic acid sequences selected from the group consisting of SEQ ID NO: 49; SEQ ID NO: 57; SEQ ID NO: 104; SEQ ID NO: 123; SEQ ID NO: 160; SEQ ID NO: 165; SEQ ID NO: 166; SEQ ID NO: 219; SEQ ID NO: 267; SEQ ID NO: 270; SEQ ID NO: 279; SEQ ID NO:

280; SEQ ID NO: 283; SEQ ID NO: 291; SEQ ID NO: 305; SEQ ID NO: 307; SEQ ID NO: 310; SEQ ID NO: 313; SEQ ID NO: 325; SEQ ID NO: 326; and SEQ ID NO: 327.

The present invention further provides a microarray comprising one or more protein-capture agents that bind one or more amino acid sequences encoded by all or a portion of one or more nucleic acid sequences selected from the group consisting of SEQ ID NO: 106; SEQ ID NO: 138; SEQ ID NO: 158; SEQ ID NO: 228; SEQ ID NO: 236; SEQ ID NO: 242; SEQ ID NO: 250; SEQ ID NO: 258; SEQ ID NO: 260; SEQ ID NO: 262; SEQ ID NO: 266; SEQ ID NO: 272; SEQ ID NO: 273; SEQ ID NO: 274; SEQ ID NO: 275; SEQ ID NO: 276; SEQ ID NO: 278; SEQ ID NO: 284; SEQ ID NO: 288; SEQ ID NO: 295; SEQ ID NO: 296; SEQ ID NO: 297; SEQ ID NO: 299; SEQ ID NO: 300; SEQ ID NO: 301; SEQ ID NO: 306; SEQ ID NO: 308; SEQ ID NO: 309; SEQ ID NO: 311; SEQ ID NO: 316; SEQ ID NO: 318; SEQ ID NO: 321; SEQ ID NO: 322; SEQ ID NO: 328; and SEQ ID NO: 329.

In a specific embodiment, a microarray may comprise one or more protein-capture agents that bind one or more amino acid sequences encoded by all or a portion of one or more nucleic acid sequences selected from the group consisting of SEQ ID NO: 173; SEQ ID NO: 174; SEQ ID NO: 183; SEQ ID NO: 220; SEQ ID NO: 221; SEQ ID NO: 222; SEQ ID NO: 229; SEQ ID NO: 230; SEQ ID NO: 231; SEQ ID NO: 232; SEQ ID NO: 233; SEQ ID NO: 234; SEQ ID NO: 235; SEQ ID NO: 237; SEQ ID NO: 238; SEQ ID NO: 240; SEQ ID NO: 245; SEQ ID NO: 246; SEQ ID NO: 247; SEQ ID NO: 248; SEQ ID NO: 249; SEQ ID NO: 251; SEQ ID NO: 252; SEQ ID NO: 254; SEQ ID NO: 257; SEQ ID NO: 263; SEQ ID NO: 264; SEQ ID NO: 265; SEQ ID NO: 268; SEQ ID NO: 269; SEQ ID NO: 270; SEQ ID NO: 277; SEQ ID NO: 281; SEQ ID NO: 282; SEQ ID NO: 286; SEQ ID NO: 287; SEQ ID NO: 290; SEQ ID NO: 294; SEQ ID NO: 298; SEQ ID NO: 303; SEQ ID NO: 312; SEQ ID NO: 315; SEQ ID NO: 317; and SEQ ID NO: 319.

The present invention also provides a microarray comprising one or more protein-capture agents that bind one or more amino acid sequences encoded by all or a portion of one or more nucleic acid sequences selected from the group consisting of SEQ ID NO: 37; SEQ ID NO: 253; SEQ ID NO: 304; SEQ ID NO: 323; and SEQ ID NO: 324.

In yet another embodiment, a microarray may comprise one or more protein-capture agents that substantially bind one or more amino acid sequences encoded by all or a portion of one or more nucleic acid sequences selected from the group consisting of SEQ ID NO: 27; SEQ ID NO: 37; SEQ ID NO: 49; SEQ ID NO: 57; SEQ ID NO: 64; SEQ ID NO: 70; SEQ ID NO: 78; SEQ ID NO: 104; SEQ ID NO: 106; SEQ ID NO: 123; SEQ ID NO: 131; SEQ

ID NO: 138; SEQ ID NO: 150; SEQ ID NO: 158; SEQ ID NO: 160; SEQ ID NO: 165; SEQ
ID NO: 166; SEQ ID NO: 169; SEQ ID NO: 173; SEQ ID NO: 174; SEQ ID NO: 183; SEQ
ID NO: 187; SEQ ID NO: 188; SEQ ID NO: 189; SEQ ID NO: 190; SEQ ID NO: 191; SEQ
ID NO: 192; SEQ ID NO: 193; SEQ ID NO: 194; SEQ ID NO: 195; SEQ ID NO: 196; SEQ
5 ID NO: 197; SEQ ID NO: 198; SEQ ID NO: 199; SEQ ID NO: 200; SEQ ID NO: 201; SEQ
ID NO: 202; SEQ ID NO: 203; SEQ ID NO: 204; SEQ ID NO: 205; SEQ ID NO: 206; SEQ
ID NO: 207; SEQ ID NO: 208; SEQ ID NO: 209; SEQ ID NO: 210; SEQ ID NO: 211; SEQ
ID NO: 212; SEQ ID NO: 213; SEQ ID NO: 214; SEQ ID NO: 215; SEQ ID NO: 216; SEQ
ID NO: 217; SEQ ID NO: 218; SEQ ID NO: 219; SEQ ID NO: 220; SEQ ID NO: 221; SEQ
10 ID NO: 222; SEQ ID NO: 223; SEQ ID NO: 224; SEQ ID NO: 225; SEQ ID NO: 226; SEQ
ID NO: 227; SEQ ID NO: 228; SEQ ID NO: 229; SEQ ID NO: 230; SEQ ID NO: 231; SEQ
ID NO: 232; SEQ ID NO: 233; SEQ ID NO: 234; SEQ ID NO: 235; SEQ ID NO: 236; SEQ
ID NO: 237; SEQ ID NO: 238; SEQ ID NO: 239; SEQ ID NO: 240; SEQ ID NO: 241; SEQ
ID NO: 242; SEQ ID NO: 243; SEQ ID NO: 244; SEQ ID NO: 245; SEQ ID NO: 246; SEQ
15 ID NO: 247; SEQ ID NO: 248; SEQ ID NO: 249; SEQ ID NO: 250; SEQ ID NO: 251; SEQ
ID NO: 252; SEQ ID NO: 253; SEQ ID NO: 254; SEQ ID NO: 255; SEQ ID NO: 256; SEQ
ID NO: 257; SEQ ID NO: 258; SEQ ID NO: 259; SEQ ID NO: 260; SEQ ID NO: 261; SEQ
ID NO: 262; SEQ ID NO: 263; SEQ ID NO: 264; SEQ ID NO: 265; SEQ ID NO: 266; SEQ
ID NO: 267; SEQ ID NO: 268; SEQ ID NO: 269; SEQ ID NO: 270; SEQ ID NO: 271; SEQ
20 ID NO: 272; SEQ ID NO: 273; SEQ ID NO: 274; SEQ ID NO: 275; SEQ ID NO: 276; SEQ
ID NO: 277; SEQ ID NO: 278; SEQ ID NO: 279; SEQ ID NO: 280; SEQ ID NO: 281; SEQ
ID NO: 282; SEQ ID NO: 283; SEQ ID NO: 284; SEQ ID NO: 285; SEQ ID NO: 286; SEQ
ID NO: 287; SEQ ID NO: 288; SEQ ID NO: 289; SEQ ID NO: 290; SEQ ID NO: 291; SEQ
ID NO: 293; SEQ ID NO: 294; SEQ ID NO: 295; SEQ ID NO: 296; SEQ ID NO: 297; SEQ
25 ID NO: 298; SEQ ID NO: 299; SEQ ID NO: 300; SEQ ID NO: 301; SEQ ID NO: 302; SEQ
ID NO: 303; SEQ ID NO: 304; SEQ ID NO: 305; SEQ ID NO: 306; SEQ ID NO: 307; SEQ
ID NO: 308; SEQ ID NO: 309; SEQ ID NO: 310; SEQ ID NO: 311; SEQ ID NO: 312; SEQ
ID NO: 313; SEQ ID NO: 314; SEQ ID NO: 315; SEQ ID NO: 316; SEQ ID NO: 317; SEQ
ID NO: 318; SEQ ID NO: 320; SEQ ID NO: 321; SEQ ID NO: 322; SEQ ID NO: 323; SEQ
30 ID NO: 324; SEQ ID NO: 325; SEQ ID NO: 326; SEQ ID NO: 327; SEQ ID NO: 328; and
SEQ ID NO: 329

VII. Expression Profiles and Microarray Methods Of Use

In one aspect, the present invention provides methods for the reproducible measurement and assessment of the expression of specific mRNAs or proteins in a specific set of cells. One method combines and utilizes the techniques of laser capture microdissection, T7-based RNA amplification, production of cDNA from amplified RNA, and DNA microarrays containing immobilized DNA molecules for a wide variety of specific genes to produce a profile of gene expression analysis for very small numbers of specific cells. The desired cells are individually identified and attached to a substrate by the laser capture technique, and the captured cells are then separated from the remaining cells. RNA is then extracted from the captured cells and amplified about one million-fold using the T7-based amplification technique, and cDNA may be prepared from the amplified RNA. A wide variety of specific DNA molecules are prepared that hybridize with specific nucleic acids of the microarray, and the DNA molecules are immobilized on a suitable substrate. The cDNA made from the captured cells is applied to the microarray under conditions that allow hybridization of the cDNA to the immobilized DNA on the array. The expression profile of the captured cells is obtained from the analysis of the hybridization results using the amplified RNA or cDNA made from the amplified RNA of the captured cells, and the specific immobilized DNA molecules on the microarray. The hybridization results demonstrate, for example, which genes of those represented on the microarray as probes are hybridized to cDNA from the captured cells, and/or the amount of specific gene expression. The hybridization results represent the gene expression profile of the captured cells. The gene expression profile of the captured cells can be used to compare the gene expression profile of a different set of captured cells. The similarities and differences provide useful information for determining the differences in gene expression between different cell types, and differences between the same cell type under different conditions.

The techniques used for gene expression analysis are likewise applicable in the context of protein expression profiles. Total protein may be isolated from a cell sample and hybridized to a microarray comprising a plurality of protein-capture agents, which may include antibodies, receptor proteins, small molecules, and the like. Using any of several assays known in the art, hybridization may be detected and analyzed as described above. In the case of fluorescent detection, algorithms may be used to extract a protein expression profile representative of the particular cell type.

The present invention further relates to gene expression profiles and protein expression profiles that define a particular cell or tissue, or a particular cell or tissue state, *e.g.* a normal or diseased state. Such “cell type specific gene expression profiles” comprise genes that are only expressed in a particular cell, *i.e.*, are differentially expressed between cells.

5 Similarly, cell type specific protein expression profiles comprise proteins that are only expressed in a particular cell, *i.e.*, are differentially expressed between cells. A cell type specific expression profile may define a particular cell type including its origin within the body and cellular state. For example, a cell type gene or protein expression profile may define an epithelial cell and more particularly, an epithelial cell located in a specific tissue, an
10 epithelial cell at a specific stage of the cell cycle, an epithelial cell in a specific state of differentiation, an epithelial cell in an activated state, and/or an epithelial cell in a particular diseased state. Thus, the methodologies, microarrays, and algorithms of the present invention may be used to determine the phenotype of an unknown cell sample.

Moreover, all of the cell type specific gene and/or protein expression profiles may be
15 compiled together in a database to be used for a variety of applications. For example, the profiles and the database may be used in methods for approximating cell type and cell number of a mixed population of cells. Armed with a database of cell type specific gene and/or protein expression profiles, a gene or protein expression profile constructed from a mixed population of cells may be compared against the profile database. Using the
20 algorithms of the present invention, a user may identify the number and type of cells comprising the mixed population.

In addition, the profiles and database may be used in creating cell type specific gene or protein microarrays. A microarray may be produced that comprises genes or protein-
capture agents that represent all cell types or a specific set of cell types, for example, normal
25 colon cells and cancerous colon cells at different stages of disease progression.

The gene expression profiles, protein expression profiles, microarrays, and algorithms of the present invention may also be used to differentiate cell types (*e.g.*, neuron *v.* muscle cell). For example, mRNA isolated from two different cells may be hybridized to a microarray. The mRNA derived from each of the two cell types may be labeled with
30 different fluorophores so that they may be distinguished. *See e.g.*, Hacia et al., 26 NUCLEIC ACID RES. 3865-66, (1998); Schena et al., 270 SCIENCE 467-70 (1995). For example, mRNA from skeletal muscle cells may be synthesized using a fluorescein-12-UTP, and mRNA from neuronal cells, may be synthesized using biotin-16-UTP. The two mRNAs are then mixed

and hybridized to the microarray. The mRNA from skeletal muscle cells will, for example, fluoresce green when the fluorophore is stimulated and the mRNA from neuronal cells will, for example, fluoresce red. The relative signal intensity from each mRNA is determined, and an expression profile for each mRNA is generated and used to identify the cell type. An
5 advantage of using mRNA labeled with two different fluorophores is that a direct and internally controlled comparison of the mRNA levels corresponding to each arrayed gene in the two cell types can be made, and variations due to minor differences in experimental conditions (*e.g.*, hybridization conditions) will not affect subsequent analyses.

In one aspect, the present invention provides gene and protein expression profile
10 useful for identifying specific cell types. For example, the present invention contemplates gene and protein expression profiles generated from numerous cell types including, but not limited to, coronary artery endothelium, umbilical artery endothelium, umbilical vein endothelium, aortic endothelium, dermal microvascular endothelium, pulmonary artery endothelium, myometrium microvascular endothelium, keratinocyte epithelium, bronchial
15 epithelium, mammary epithelium, prostate epithelium, renal cortical epithelium, renal proximal tubule epithelium, small airway epithelium, renal epithelium, umbilical artery smooth muscle, neonatal dermal fibroblast, pulmonary artery smooth muscle, dermal fibroblast, neural progenitor cells, skeletal muscle, astrocytes, aortic smooth muscle, mesangial cells, coronary artery smooth muscle, bronchial smooth muscle, uterine smooth
20 muscle, lung fibroblast, osteoblasts, and prostate stromal cells.

Furthermore, the expression profiles and microarrays of the present invention may be used to distinguish normal tissue from diseased tissue, and in particular normal tissue from
tumorigenic tissue. In addition, the present invention may also be used for patient diagnosis. Specifically, a patient sample may be hybridized to a microarray representing normal and
25 diseased tissues. The resulting expression pattern of the patient sample may then be compared to the expression profile of a normal tissue sample to determine the disease progression status. For example, alterations in the level of expression of the prostate-specific antigen (PSA) may be indicative of prostate cancer and variations of the carcino-embryonic antigen (CEA) may be indicative of colon cancer.

30 The present invention also relates to methods of using the expression profiles and microarrays. For example, the gene expression profiles and protein expression profiles and microarrays may be used for drug and toxicity screening. Drugs often have side effects that are, in part, due to the lack of target specificity. *In vitro* assays provide limited information

on the specificity of a compound. In contrast, a microarray may reveal the spectrum of genes or proteins affected by a particular drug compound. In considering two different compounds both of which demonstrate specificity for a target protein (e.g., a receptor), if one compound affects the expression of ten genes or proteins and a second compound affects the expression of fifty genes or proteins, the first compound is more likely to have fewer side effects.

Because the identity of the genes or proteins is known or determinable, information on other affected genes is informative as to the nature of the side effects. A panel of genes or proteins may be used to test derivatives of a lead compound to determine which of the derivatives have greater specificity than the first compound.

Thus, microarray technology may be used to identify drug compounds that regulate gene and/or protein expression or possess similar mechanisms of action. This technology may also be used to create microarrays that model various diseases and in turn, novel drug compounds may be analyzed as potential therapeutics. In addition, microarrays may be generated that comprise the genes or proteins of one or more of a particular pathogen (e.g., bacteria, viruses, fungi). These microarrays may then be utilized to identify promising antibiotics, antiviral, or antifungal agents.

In another embodiment of the invention, a microarray corresponding to a population of genes or proteins isolated from a particular tissue or cell type is used to detect changes in gene transcription or protein expression which result from exposing the selected tissue or cells to a candidate drug. In this embodiment, tissue or cells derived from an organism, or an established cell line, may be exposed to the candidate drug *in vivo* or *ex vivo*. Thereafter, the gene transcripts, primarily mRNA, of the tissue or cells are isolated by methods well-known in the art. See, e.g., SAMBROOK ET AL. (1989). The isolated transcripts or cDNAs complementary to the mRNA are then contacted with a microarray, each microarray probe being specific for a different transcript, under conditions where the transcripts hybridize with a corresponding probe to form hybridization pairs. Similarly, protein may be isolated by methods well-known in the art. The isolated protein sample is then hybridized to a microarray comprising a plurality of protein-capture agents. The microarrays may provide, in aggregate, an ensemble of genes or proteins of the tissue or cell type sufficient to model the transcriptional and/or translational responsiveness of a drug candidate. A hybridization signal may then be detected at each hybridization pair to obtain an expression profile. This profile of the drug-stimulated cells may then be compared with an expression profile of control cells to obtain a specific drug response profile.

Similarly, for toxicity screening, a cell line or animal (*e.g.*, rat) may be treated with a particular toxin (*e.g.*, carcinogen, immunotoxin, cytotoxin, teratogen, pesticide) to determine its effects on gene expression. As described above, RNA or protein may be isolated from the treated cell line or a tissue (*e.g.*, liver) from the treated animal, and hybridized to a microarray containing oligonucleotide probes or protein-capture agents. The resulting expression profiles may be compared to profiles generated from an untreated animal or cell line. An analysis of the expression pattern of the treated samples may reflect the effects of the particular toxin on gene expression, and possibly predict physiological effects.

This data may be used to identify genetic response profiles. Individual gene or protein responses may be sorted to determine the specificity of each gene or protein to a particular stimulus. An expression profile may be established which weighs the signal patterns proportionally to the specificity of the response. Response profiles for an unknown stimulus (*e.g.*, new chemicals, unknown compounds) may be analyzed by comparing the new stimulus response profiles with response profiles to known chemical stimuli. If there is a gene or protein match, then the response profile identifies a stimulus with the same target as one of the known compounds upon which the response profile database is based. For drug screening, if the response profile is a subset of cells in the support stimulated by a known compound, the new compound may be a candidate for a molecule with greater specificity than the reference compound.

Gene and/or protein expression profiles and microarrays may also be used to identify activating or non-activating compounds. Compounds that increase transcription rates or stimulate the activity of a protein are considered activating, and compounds that decrease rates or inhibit the activity of a protein are non-activating. The biological effects of a compound may be reflected in the biological state of a cell. This state is characterized by the cellular constituents. One aspect of the biological state of a cell is its transcriptional state. The transcriptional state of a cell includes the identities and amounts of the constituent RNA species, especially mRNAs, in the cell under a given set of conditions. Thus, the gene expression profiles, microarrays, and algorithms of the present invention may be used to analyze and characterize the transcriptional state of a given cell or tissue following exposure to an activating or non-activating compound.

The gene expression profiles, microarrays, and algorithms of the present invention may also be used to identify the components of cell signaling pathways. A cell signaling pathway is generally understood to be a collection of the cellular constituents (*e.g.*, DNA,

RNA, receptors, second messenger proteins, enzymes). The cellular constituents of a particular signaling pathway may be identified, for example, by variations in the transcription or translation rates. Each cellular constituent is typically influenced by at least one other cellular constituent. Thus, a cell may be exposed to a compound that interacts with a specific cellular constituent. For example, the cell may be exposed to varying concentrations of a specific receptor agonist. An analysis of variations in gene and/or protein expression as compared to an unexposed cell may reveal components of that particular receptor-signaling pathway. Thus, the cellular constituents that vary in a correlated pattern as the concentrations of the drug are increased may be identified as a component of the pathway originating at that drug.

The present invention may also be used to identify co-regulated genes. Similar variations in the transcriptional rate of a particular group of genes may reflect that these genes are similarly regulated. Thus, analysis of the transcriptional state of these genes may be accomplished by hybridization to microarrays. The level of hybridization to the microarray reflects the prevalence of the mRNA transcripts in the cell and may be used to determine if particular genes are co-regulated.

In another embodiment, the gene expression profiles and microarrays of the present invention may also be used to identify a class of diseases. For example, gene expression profiles or protein expression profiles may be used to distinguish tumor types (*e.g.*, lymphomas). By monitoring gene or protein expression, it may be possible to distinguish, for example, Hodgkin lymphoma from non-Hodgkin lymphoma. By identifying the lymphoma type, the appropriate clinical course may be implemented.

In addition, new tumor-associated genes or proteins may be identified by systemically comparing the expression of genes in tumor specimens with their expression in control tissue. For example, genes with elevated levels in tumor cells relative to normal cells, are candidates for genes encoding growth-promoting products (*e.g.*, oncogenes). In contrast, genes with reduced expression levels in tumors, are candidates for genes encoding growth-inhibiting products (*e.g.*, tumor suppressor genes or genes encoding apoptosis-inducing products). Thus, the expression profiles may point to the physiological function or malfunction of the gene product in the organism and shed light on possible treatments.

In a specific embodiment, the present invention provides endothelial cell gene expression profiles comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof selected from the group

consisting of SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5;
 SEQ ID NO: 6; SEQ ID NO: 7; SEQ ID NO: 8; SEQ ID NO: 9; SEQ ID NO: 10; SEQ ID
 NO: 11; SEQ ID NO: 12; SEQ ID NO: 13; SEQ ID NO: 14; SEQ ID NO: 15; SEQ ID NO:
 16; SEQ ID NO: 17; SEQ ID NO: 18; SEQ ID NO: 19; SEQ ID NO: 20; SEQ ID NO: 21;
 5 SEQ ID NO: 22; SEQ ID NO: 23; SEQ ID NO: 48; SEQ ID NO: 63; SEQ ID NO: 70; SEQ
 ID NO: 82; SEQ ID NO: 94; and SEQ ID NO: 144.

In another embodiment, a muscle cell gene expression profile may comprise one or
 more nucleic acid sequences substantially homologous to a nucleic acid sequence or
 complementary sequence thereof selected from the group consisting of SEQ ID NO: 24; SEQ
 10 ID NO: 25; SEQ ID NO: 26; SEQ ID NO: 27; SEQ ID NO: 28; SEQ ID NO: 29; SEQ ID
 NO: 30; SEQ ID NO: 31; SEQ ID NO: 32; SEQ ID NO: 33; SEQ ID NO: 34; SEQ ID NO:
 35; SEQ ID NO: 36; SEQ ID NO: 37; SEQ ID NO: 39; SEQ ID NO: 40; SEQ ID NO: 41;
 SEQ ID NO: 42; SEQ ID NO: 54; SEQ ID NO: 55; and SEQ ID NO: 69.

In an alternative embodiment, a primary cell gene expression profile comprises one or
 15 more nucleic acid sequences substantially homologous to a nucleic acid sequence or
 complementary sequence thereof selected from the group consisting of SEQ ID NO: 1; SEQ
 ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7;
 SEQ ID NO: 8; SEQ ID NO: 9; SEQ ID NO: 10; SEQ ID NO: 11; SEQ ID NO: 12; SEQ ID
 NO: 13; SEQ ID NO: 14; SEQ ID NO: 15; SEQ ID NO: 16; SEQ ID NO: 17; SEQ ID NO:
 20 18; SEQ ID NO: 19; SEQ ID NO: 20; SEQ ID NO: 21; SEQ ID NO: 22; SEQ ID NO: 23;
 SEQ ID NO: 24; SEQ ID NO: 25; SEQ ID NO: 26; SEQ ID NO: 27; SEQ ID NO: 28; SEQ
 ID NO: 29; SEQ ID NO: 30; SEQ ID NO: 31; SEQ ID NO: 32; SEQ ID NO: 33; SEQ ID
 NO: 34; SEQ ID NO: 35; SEQ ID NO: 36; SEQ ID NO: 37; SEQ ID NO: 39; SEQ ID NO:
 40; SEQ ID NO: 41; SEQ ID NO: 42; SEQ ID NO: 43; SEQ ID NO: 44; SEQ ID NO: 45;
 25 SEQ ID NO: 46; SEQ ID NO: 47; SEQ ID NO: 48; SEQ ID NO: 49; SEQ ID NO: 50; SEQ
 ID NO: 51; SEQ ID NO: 52; SEQ ID NO: 53; SEQ ID NO: 54; SEQ ID NO: 55; SEQ ID
 NO: 56; SEQ ID NO: 57; SEQ ID NO: 58; SEQ ID NO: 59; SEQ ID NO: 60; SEQ ID NO:
 61; SEQ ID NO: 62; SEQ ID NO: 63; SEQ ID NO: 64; SEQ ID NO: 65; SEQ ID NO: 66;
 SEQ ID NO: 67; SEQ ID NO: 68; SEQ ID NO: 69; SEQ ID NO: 70; SEQ ID NO: 71; SEQ
 30 ID NO: 72; SEQ ID NO: 73; SEQ ID NO: 74; SEQ ID NO: 75; SEQ ID NO: 76; SEQ ID
 NO: 77; SEQ ID NO: 78; SEQ ID NO: 79; SEQ ID NO: 80; SEQ ID NO: 81; SEQ ID NO:
 82; SEQ ID NO: 83; SEQ ID NO: 84; SEQ ID NO: 85; SEQ ID NO: 86; SEQ ID NO: 87;
 SEQ ID NO: 88; SEQ ID NO: 89; SEQ ID NO: 90; SEQ ID NO: 91; SEQ ID NO: 92; SEQ

ID NO: 93; SEQ ID NO: 94; SEQ ID NO: 95; SEQ ID NO: 96; SEQ ID NO: 97; SEQ ID NO: 98; SEQ ID NO: 99; SEQ ID NO: 100; SEQ ID NO: 101; SEQ ID NO: 102; SEQ ID NO: 103; SEQ ID NO: 104; SEQ ID NO: 105; SEQ ID NO: 106; SEQ ID NO: 107; SEQ ID NO: 108; SEQ ID NO: 109; SEQ ID NO: 110; SEQ ID NO: 111; SEQ ID NO: 112; SEQ ID NO: 113; SEQ ID NO: 114; SEQ ID NO: 115; SEQ ID NO: 116; SEQ ID NO: 118; SEQ ID NO: 119; SEQ ID NO: 120; SEQ ID NO: 121; SEQ ID NO: 122; SEQ ID NO: 123; SEQ ID NO: 124; SEQ ID NO: 125; SEQ ID NO: 126; SEQ ID NO: 127; SEQ ID NO: 128; SEQ ID NO: 129; SEQ ID NO: 130; SEQ ID NO: 131; SEQ ID NO: 132; SEQ ID NO: 133; SEQ ID NO: 134; SEQ ID NO: 135; SEQ ID NO: 136; SEQ ID NO: 137; SEQ ID NO: 138; SEQ ID NO: 139; SEQ ID NO: 140; SEQ ID NO: 141; SEQ ID NO: 142; SEQ ID NO: 143; SEQ ID NO: 144; SEQ ID NO: 145; SEQ ID NO: 146; SEQ ID NO: 147; SEQ ID NO: 148; SEQ ID NO: 149; SEQ ID NO: 150; SEQ ID NO: 151; SEQ ID NO: 152; SEQ ID NO: 153; SEQ ID NO: 154; SEQ ID NO: 155; SEQ ID NO: 156; SEQ ID NO: 157; SEQ ID NO: 158; SEQ ID NO: 159; SEQ ID NO: 160; SEQ ID NO: 161; SEQ ID NO: 162; SEQ ID NO: 163; SEQ ID NO: 164; SEQ ID NO: 165; SEQ ID NO: 166; SEQ ID NO: 167; SEQ ID NO: 168; SEQ ID NO: 169; SEQ ID NO: 170; SEQ ID NO: 171; SEQ ID NO: 172; SEQ ID NO: 173; SEQ ID NO: 174; SEQ ID NO: 175; SEQ ID NO: 176; SEQ ID NO: 177; SEQ ID NO: 178; SEQ ID NO: 179; SEQ ID NO: 180; SEQ ID NO: 181; SEQ ID NO: 182; SEQ ID NO: 183; SEQ ID NO: 184; SEQ ID NO: 185; and SEQ ID NO: 186.

20 The present invention also provides an epithelial cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof selected from the group consisting of: SEQ ID NO: 47; SEQ ID NO: 60; SEQ ID NO: 67; SEQ ID NO: 73; SEQ ID NO: 75; SEQ ID NO: 76; SEQ ID NO: 77; SEQ ID NO: 78; SEQ ID NO: 80; SEQ ID NO: 96; SEQ ID NO: 98; SEQ ID NO: 99; SEQ ID NO: 111; SEQ ID NO: 112; SEQ ID NO: 123; SEQ ID NO: 127; SEQ ID NO: 131; SEQ ID NO: 150; SEQ ID NO: 153; SEQ ID NO: 154; SEQ ID NO: 155; SEQ ID NO: 156; SEQ ID NO: 157; SEQ ID NO: 158; SEQ ID NO: 159; SEQ ID NO: 160; SEQ ID NO: 161; SEQ ID NO: 162; SEQ ID NO: 163; SEQ ID NO: 164; SEQ ID NO: 165; SEQ ID NO: 166; SEQ ID NO: 167; SEQ ID NO: 168; SEQ ID NO: 169; SEQ ID NO: 170; SEQ ID NO: 171; SEQ ID NO: 172; SEQ ID NO: 173; SEQ ID NO: 174; SEQ ID NO: 175; SEQ ID NO: 176; SEQ ID NO: 177; SEQ ID NO: 178; SEQ ID NO: 179; SEQ ID NO: 180; SEQ ID NO: 181; SEQ ID NO: 182; SEQ ID NO: 183; SEQ ID NO: 184; SEQ ID NO: 185; and SEQ ID NO: 186.

In yet another embodiment, a keratinocyte epithelial cell gene expression profile may comprise one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof selected from the group consisting of SEQ ID NO: 187; SEQ ID NO: 188; SEQ ID NO: 189; SEQ ID NO: 190; SEQ ID NO: 191; SEQ ID NO: 192; SEQ ID NO: 193; SEQ ID NO: 194; SEQ ID NO: 195; SEQ ID NO: 196; SEQ ID NO: 197; SEQ ID NO: 198; SEQ ID NO: 199; SEQ ID NO: 200; SEQ ID NO: 201; SEQ ID NO: 202; SEQ ID NO: 203; SEQ ID NO: 204; SEQ ID NO: 205; SEQ ID NO: 206; SEQ ID NO: 207; SEQ ID NO: 208; SEQ ID NO: 209; SEQ ID NO: 210; and SEQ ID NO: 211.

The present invention also provides a mammary epithelial cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof selected from the group consisting of SEQ ID NO: 78; SEQ ID NO: 212; SEQ ID NO: 213; SEQ ID NO: 216; SEQ ID NO: 225; SEQ ID NO: 226; SEQ ID NO: 227; SEQ ID NO: 239; SEQ ID NO: 271; SEQ ID NO: 285; and SEQ ID NO: 289.

In an alternative embodiment, a bronchial epithelial cell gene expression profile may comprise one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof selected from the group consisting of SEQ ID NO: 27; SEQ ID NO: 131; SEQ ID NO: 150; SEQ ID NO: 169; SEQ ID NO: 214; SEQ ID NO: 215; SEQ ID NO: 223; SEQ ID NO: 224; SEQ ID NO: 241; SEQ ID NO: 243; SEQ ID NO: 244; SEQ ID NO: 255; SEQ ID NO: 256; SEQ ID NO: 261; and SEQ ID NO: 314.

The present invention also provides a prostate epithelial cell gene expression profile, which may comprise one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof selected from the group consisting of SEQ ID NO: 64; SEQ ID NO: 217; SEQ ID NO: 218; SEQ ID NO: 259; SEQ ID NO: 293; SEQ ID NO: 302; and SEQ ID NO: 320.

In yet another embodiment, a renal cortical epithelial cell gene expression profile may comprise one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof selected from the group consisting of SEQ ID NO: 49; SEQ ID NO: 57; SEQ ID NO: 104; SEQ ID NO: 123; SEQ ID NO: 160; SEQ ID NO: 165; SEQ ID NO: 166; SEQ ID NO: 219; SEQ ID NO: 267; SEQ ID NO: 270; SEQ ID NO: 279; SEQ ID NO: 280; SEQ ID NO: 283; SEQ ID NO: 291; SEQ ID NO: 305; SEQ ID NO: 307; SEQ ID NO: 310; SEQ ID NO: 313; SEQ ID NO: 325; SEQ ID NO: 326; and SEQ ID NO: 327.

The present invention further provides renal proximal tubule epithelial cell gene expression profiles comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof selected from the group consisting of SEQ ID NO: 106; SEQ ID NO: 138; SEQ ID NO: 158; SEQ ID NO: 228; SEQ ID NO: 236; SEQ ID NO: 242; SEQ ID NO: 250; SEQ ID NO: 258; SEQ ID NO: 260; SEQ ID NO: 262; SEQ ID NO: 266; SEQ ID NO: 272; SEQ ID NO: 273; SEQ ID NO: 274; SEQ ID NO: 275; SEQ ID NO: 276; SEQ ID NO: 278; SEQ ID NO: 284; SEQ ID NO: 288; SEQ ID NO: 295; SEQ ID NO: 296; SEQ ID NO: 297; SEQ ID NO: 299; SEQ ID NO: 300; SEQ ID NO: 301; SEQ ID NO: 306; SEQ ID NO: 308; SEQ ID NO: 309; SEQ ID NO: 311; SEQ ID NO: 316; SEQ ID NO: 318; SEQ ID NO: 321; SEQ ID NO: 322; SEQ ID NO: 328; and SEQ ID NO: 329.

In a specific embodiment, a small airway epithelial cell gene expression profile may comprise one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof selected from the group consisting of SEQ ID NO: 173; SEQ ID NO: 174; SEQ ID NO: 183; SEQ ID NO: 220; SEQ ID NO: 221; SEQ ID NO: 222; SEQ ID NO: 229; SEQ ID NO: 230; SEQ ID NO: 231; SEQ ID NO: 232; SEQ ID NO: 233; SEQ ID NO: 234; SEQ ID NO: 235; SEQ ID NO: 237; SEQ ID NO: 238; SEQ ID NO: 240; SEQ ID NO: 245; SEQ ID NO: 246; SEQ ID NO: 247; SEQ ID NO: 248; SEQ ID NO: 249; SEQ ID NO: 251; SEQ ID NO: 252; SEQ ID NO: 254; SEQ ID NO: 257; SEQ ID NO: 263; SEQ ID NO: 264; SEQ ID NO: 265; SEQ ID NO: 268; SEQ ID NO: 269; SEQ ID NO: 270; SEQ ID NO: 277; SEQ ID NO: 281; SEQ ID NO: 282; SEQ ID NO: 286; SEQ ID NO: 287; SEQ ID NO: 290; SEQ ID NO: 294; SEQ ID NO: 298; SEQ ID NO: 303; SEQ ID NO: 312; SEQ ID NO: 315; SEQ ID NO: 317; and SEQ ID NO: 319.

The present invention also provides a renal epithelial cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof selected from the group consisting of SEQ ID NO: 37; SEQ ID NO: 253; SEQ ID NO: 304; SEQ ID NO: 323; and SEQ ID NO: 324.

In a specific embodiment, the present invention provides an endothelial cell protein expression profile comprising one or more amino acid sequences encoded by all or a portion of one or more nucleic acid sequences selected from the group consisting of SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; SEQ ID NO: 8; SEQ ID NO: 9; SEQ ID NO: 10; SEQ ID NO: 11; SEQ ID NO: 12; SEQ ID NO: 13; SEQ ID NO: 14; SEQ ID NO: 15; SEQ ID NO: 16; SEQ ID NO: 17; SEQ ID

NO: 18; SEQ ID NO: 19; SEQ ID NO: 20; SEQ ID NO: 21; SEQ ID NO: 22; SEQ ID NO: 23; SEQ ID NO: 48; SEQ ID NO: 63; SEQ ID NO: 70; SEQ ID NO: 82; SEQ ID NO: 94; and SEQ ID NO: 144.

The present invention also provides a muscle cell protein expression profile
 5 comprising one or more amino acid sequences encoded by all or a portion of one or more nucleic acid sequences selected from the group consisting of SEQ ID NO: 24; SEQ ID NO: 25; SEQ ID NO: 26; SEQ ID NO: 27; SEQ ID NO: 28; SEQ ID NO: 29; SEQ ID NO: 30; SEQ ID NO: 31; SEQ ID NO: 32; SEQ ID NO: 33; SEQ ID NO: 34; SEQ ID NO: 35; SEQ ID NO: 36; SEQ ID NO: 37; SEQ ID NO: 39; SEQ ID NO: 40; SEQ ID NO: 41; SEQ ID
 10 NO: 42; SEQ ID NO: 54; SEQ ID NO: 55; and SEQ ID NO: 69.

In another embodiment, a primary cell protein expression profile may comprise one or more amino acid sequences encoded by all or a portion of one or more nucleic acid sequences selected from the group consisting of SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; SEQ ID NO: 8; SEQ ID NO: 9;
 15 SEQ ID NO: 10; SEQ ID NO: 11; SEQ ID NO: 12; SEQ ID NO: 13; SEQ ID NO: 14; SEQ ID NO: 15; SEQ ID NO: 16; SEQ ID NO: 17; SEQ ID NO: 18; SEQ ID NO: 19; SEQ ID NO: 20; SEQ ID NO: 21; SEQ ID NO: 22; SEQ ID NO: 23; SEQ ID NO: 24; SEQ ID NO: 25; SEQ ID NO: 26; SEQ ID NO: 27; SEQ ID NO: 28; SEQ ID NO: 29; SEQ ID NO: 30; SEQ ID NO: 31; SEQ ID NO: 32; SEQ ID NO: 33; SEQ ID NO: 34; SEQ ID NO: 35; SEQ
 20 ID NO: 36; SEQ ID NO: 37; SEQ ID NO: 39; SEQ ID NO: 40; SEQ ID NO: 41; SEQ ID NO: 42; SEQ ID NO: 43; SEQ ID NO: 44; SEQ ID NO: 45; SEQ ID NO: 46; SEQ ID NO: 47; SEQ ID NO: 48; SEQ ID NO: 49; SEQ ID NO: 50; SEQ ID NO: 51; SEQ ID NO: 52; SEQ ID NO: 53; SEQ ID NO: 54; SEQ ID NO: 55; SEQ ID NO: 56; SEQ ID NO: 57; SEQ ID NO: 58; SEQ ID NO: 59; SEQ ID NO: 60; SEQ ID NO: 61; SEQ ID NO: 62; SEQ ID
 25 NO: 63; SEQ ID NO: 64; SEQ ID NO: 65; SEQ ID NO: 66; SEQ ID NO: 67; SEQ ID NO: 68; SEQ ID NO: 69; SEQ ID NO: 70; SEQ ID NO: 71; SEQ ID NO: 72; SEQ ID NO: 73; SEQ ID NO: 74; SEQ ID NO: 75; SEQ ID NO: 76; SEQ ID NO: 77; SEQ ID NO: 78; SEQ ID NO: 79; SEQ ID NO: 80; SEQ ID NO: 81; SEQ ID NO: 82; SEQ ID NO: 83; SEQ ID NO: 84; SEQ ID NO: 85; SEQ ID NO: 86; SEQ ID NO: 87; SEQ ID NO: 88; SEQ ID NO:
 30 89; SEQ ID NO: 90; SEQ ID NO: 91; SEQ ID NO: 92; SEQ ID NO: 93; SEQ ID NO: 94; SEQ ID NO: 95; SEQ ID NO: 96; SEQ ID NO: 97; SEQ ID NO: 98; SEQ ID NO: 99; SEQ ID NO: 100; SEQ ID NO: 101; SEQ ID NO: 102; SEQ ID NO: 103; SEQ ID NO: 104; SEQ ID NO: 105; SEQ ID NO: 106; SEQ ID NO: 107; SEQ ID NO: 108; SEQ ID NO: 109; SEQ

ID NO: 110; SEQ ID NO: 111; SEQ ID NO: 112; SEQ ID NO: 113; SEQ ID NO: 114; SEQ ID NO: 115; SEQ ID NO: 116; SEQ ID NO: 118; SEQ ID NO: 119; SEQ ID NO: 120; SEQ ID NO: 121; SEQ ID NO: 122; SEQ ID NO: 123; SEQ ID NO: 124; SEQ ID NO: 125; SEQ ID NO: 126; SEQ ID NO: 127; SEQ ID NO: 128; SEQ ID NO: 129; SEQ ID NO: 130; SEQ ID NO: 131; SEQ ID NO: 132; SEQ ID NO: 133; SEQ ID NO: 134; SEQ ID NO: 135; SEQ ID NO: 136; SEQ ID NO: 137; SEQ ID NO: 138; SEQ ID NO: 139; SEQ ID NO: 140; SEQ ID NO: 141; SEQ ID NO: 142; SEQ ID NO: 143; SEQ ID NO: 144; SEQ ID NO: 145; SEQ ID NO: 146; SEQ ID NO: 147; SEQ ID NO: 148; SEQ ID NO: 149; SEQ ID NO: 150; SEQ ID NO: 151; SEQ ID NO: 152; SEQ ID NO: 153; SEQ ID NO: 154; SEQ ID NO: 155; SEQ ID NO: 156; SEQ ID NO: 157; SEQ ID NO: 158; SEQ ID NO: 159; SEQ ID NO: 160; SEQ ID NO: 161; SEQ ID NO: 162; SEQ ID NO: 163; SEQ ID NO: 164; SEQ ID NO: 165; SEQ ID NO: 166; SEQ ID NO: 167; SEQ ID NO: 168; SEQ ID NO: 169; SEQ ID NO: 170; SEQ ID NO: 171; SEQ ID NO: 172; SEQ ID NO: 173; SEQ ID NO: 174; SEQ ID NO: 175; SEQ ID NO: 176; SEQ ID NO: 177; SEQ ID NO: 178; SEQ ID NO: 179; SEQ ID NO: 180; SEQ ID NO: 181; SEQ ID NO: 182; SEQ ID NO: 183; SEQ ID NO: 184; SEQ ID NO: 185; and SEQ ID NO: 186.

In yet another embodiment, an epithelial cell protein expression profile may comprise one or more amino acid sequences encoded by all or a portion of one or more nucleic acid sequences selected from the group consisting of SEQ ID NO: 47; SEQ ID NO: 60; SEQ ID NO: 67; SEQ ID NO: 73; SEQ ID NO: 75; SEQ ID NO: 76; SEQ ID NO: 77; SEQ ID NO: 78; SEQ ID NO: 80; SEQ ID NO: 96; SEQ ID NO: 98; SEQ ID NO: 99; SEQ ID NO: 111; SEQ ID NO: 112; SEQ ID NO: 123; SEQ ID NO: 127; SEQ ID NO: 131; SEQ ID NO: 150; SEQ ID NO: 153; SEQ ID NO: 154; SEQ ID NO: 155; SEQ ID NO: 156; SEQ ID NO: 157; SEQ ID NO: 158; SEQ ID NO: 159; SEQ ID NO: 160; SEQ ID NO: 161; SEQ ID NO: 162; SEQ ID NO: 163; SEQ ID NO: 164; SEQ ID NO: 165; SEQ ID NO: 166; SEQ ID NO: 167; SEQ ID NO: 168; SEQ ID NO: 169; SEQ ID NO: 170; SEQ ID NO: 171; SEQ ID NO: 172; SEQ ID NO: 173; SEQ ID NO: 174; SEQ ID NO: 175; SEQ ID NO: 176; SEQ ID NO: 177; SEQ ID NO: 178; SEQ ID NO: 179; SEQ ID NO: 180; SEQ ID NO: 181; SEQ ID NO: 182; SEQ ID NO: 183; SEQ ID NO: 184; SEQ ID NO: 185; and SEQ ID NO: 186.

The present invention further provides a keratinocyte epithelial cell protein expression profile comprising one or more amino acid sequences encoded by all or a portion of one or more nucleic acid sequences selected from the group consisting of SEQ ID NO: 187; SEQ ID NO: 188; SEQ ID NO: 189; SEQ ID NO: 190; SEQ ID NO: 191; SEQ ID NO: 192; SEQ ID

NO: 193; SEQ ID NO: 194; SEQ ID NO: 195; SEQ ID NO: 196; SEQ ID NO: 197; SEQ ID NO: 198; SEQ ID NO: 199; SEQ ID NO: 200; SEQ ID NO: 201; SEQ ID NO: 202; SEQ ID NO: 203; SEQ ID NO: 204; SEQ ID NO: 205; SEQ ID NO: 206; SEQ ID NO: 207; SEQ ID NO: 208; SEQ ID NO: 209; SEQ ID NO: 210; and SEQ ID NO: 211.

5 In another embodiment, a mammary epithelial cell protein expression profile may comprise one or more amino acid sequences encoded by all or a portion of one or more nucleic acid sequences selected from the group consisting of SEQ ID NO: 78; SEQ ID NO: 212; SEQ ID NO: 213; SEQ ID NO: 216; SEQ ID NO: 225; SEQ ID NO: 226; SEQ ID NO: 227; SEQ ID NO: 239; SEQ ID NO: 271; SEQ ID NO: 285; and SEQ ID NO: 289.

10 Still further, the present invention provides a bronchial epithelial cell protein expression profile comprising one or more amino acid sequences encoded by all or a portion of one or more nucleic acid sequences selected from the group consisting of SEQ ID NO: 27; SEQ ID NO: 131; SEQ ID NO: 150; SEQ ID NO: 169; SEQ ID NO: 214; SEQ ID NO: 215; SEQ ID NO: 223; SEQ ID NO: 224; SEQ ID NO: 241; SEQ ID NO: 243; SEQ ID NO: 244;
15 SEQ ID NO: 255; SEQ ID NO: 256; SEQ ID NO: 261; and SEQ ID NO: 314.

In yet another embodiment, a prostate epithelial cell protein expression profile comprises one or more amino acid sequences encoded by all or a portion of one or more nucleic acid sequences selected from the group consisting of SEQ ID NO: 64; SEQ ID NO: 217; SEQ ID NO: 218; SEQ ID NO: 259; SEQ ID NO: 293; SEQ ID NO: 302; and SEQ ID
20 NO: 320.

The present invention also provides a renal cortical epithelial cell protein expression profile comprising one or more amino acid sequences encoded by all or a portion of one or more nucleic acid sequences selected from the group consisting of SEQ ID NO: 49; SEQ ID NO: 57; SEQ ID NO: 104; SEQ ID NO: 123; SEQ ID NO: 160; SEQ ID NO: 165; SEQ ID
25 NO: 166; SEQ ID NO: 219; SEQ ID NO: 267; SEQ ID NO: 270; SEQ ID NO: 279; SEQ ID NO: 280; SEQ ID NO: 283; SEQ ID NO: 291; SEQ ID NO: 305; SEQ ID NO: 307; SEQ ID NO: 310; SEQ ID NO: 313; SEQ ID NO: 325; SEQ ID NO: 326; and SEQ ID NO: 327.

In an alternative embodiment, a renal proximal tubule epithelial cell protein expression profile may comprise one or more amino acid sequences encoded by all or a
30 portion of one or more nucleic acid sequences selected from the group consisting of SEQ ID NO: 106; SEQ ID NO: 138; SEQ ID NO: 158; SEQ ID NO: 228; SEQ ID NO: 236; SEQ ID NO: 242; SEQ ID NO: 250; SEQ ID NO: 258; SEQ ID NO: 260; SEQ ID NO: 262; SEQ ID NO: 266; SEQ ID NO: 272; SEQ ID NO: 273; SEQ ID NO: 274; SEQ ID NO: 275; SEQ ID

NO: 276; SEQ ID NO: 278; SEQ ID NO: 284; SEQ ID NO: 288; SEQ ID NO: 295; SEQ ID NO: 296; SEQ ID NO: 297; SEQ ID NO: 299; SEQ ID NO: 300; SEQ ID NO: 301; SEQ ID NO: 306; SEQ ID NO: 308; SEQ ID NO: 309; SEQ ID NO: 311; SEQ ID NO: 316; SEQ ID NO: 318; SEQ ID NO: 321; SEQ ID NO: 322; SEQ ID NO: 328; and SEQ ID NO: 329.

5 The present invention also provides a small airway epithelial cell protein expression profile comprising one or more amino acid sequences encoded by all or a portion of one or more nucleic acid sequences selected from the group consisting of SEQ ID NO: 173; SEQ ID NO: 174; SEQ ID NO: 183; SEQ ID NO: 220; SEQ ID NO: 221; SEQ ID NO: 222; SEQ ID NO: 229; SEQ ID NO: 230; SEQ ID NO: 231; SEQ ID NO: 232; SEQ ID NO: 233; SEQ ID NO: 234; SEQ ID NO: 235; SEQ ID NO: 237; SEQ ID NO: 238; SEQ ID NO: 240; SEQ ID NO: 245; SEQ ID NO: 246; SEQ ID NO: 247; SEQ ID NO: 248; SEQ ID NO: 249; SEQ ID NO: 251; SEQ ID NO: 252; SEQ ID NO: 254; SEQ ID NO: 257; SEQ ID NO: 263; SEQ ID NO: 264; SEQ ID NO: 265; SEQ ID NO: 268; SEQ ID NO: 269; SEQ ID NO: 270; SEQ ID NO: 277; SEQ ID NO: 281; SEQ ID NO: 282; SEQ ID NO: 286; SEQ ID NO: 287; SEQ ID NO: 290; SEQ ID NO: 294; SEQ ID NO: 298; SEQ ID NO: 303; SEQ ID NO: 312; SEQ ID NO: 315; SEQ ID NO: 317; and SEQ ID NO: 319.

 In a further embodiment, a renal epithelial cell protein expression profile comprises one or more amino acid sequences encoded by all or a portion of one or more nucleic acid sequences selected from the group consisting of SEQ ID NO: 37; SEQ ID NO: 253; SEQ ID NO: 304; SEQ ID NO: 323; and SEQ ID NO: 324.

 In addition, the protein expression profiles may be used to create a database and to create specific protein microarrays. Furthermore, the protein microarrays, protein expression profiles, and protein expression profile databases may be useful for epitope mapping, the study of protein-protein interaction, binding of drug candidates to a plurality of proteins, drug-drug interaction (*e.g.*, competition binding studies of two drug candidates), binding of a plurality of drug candidates to a single or several proteins, diagnostics, or antigen mapping.

VIII. High Information Density Genes And Proteins

 Although it is possible to analyze the expression of all genes expressed in a cell, a significant number of genes are expressed so infrequently and thus are of limited value in generating gene expression profiles. On the other hand, a number of genes are sufficiently expressed in a cell or differentially expressed between cells to make them useful in analyzing gene expression data. Accordingly, the present invention further provides methods for identifying the subset of genes or proteins that provides the most utility in analyzing gene and

protein expression. This subset is termed “high information density genes” and “high information density proteins” and may be used to build microarrays useful for analyzing gene and protein expression and generating gene expression profiles and protein expression profiles.

5 Indeed, the construction of microarrays comprising nucleic acid sequences or protein-capture agents that represent high information density genes or proteins provides a means for efficiently analyzing gene or protein expression. For example, such microarrays may be universally useful for diagnosing one or many diseases. The high information density gene or protein microarrays of the present invention may comprise the least number of genes or
10 protein-capture agents that are the most useful to researchers and healthcare providers. The microarray may include the least number of genes or protein-capture agents that produce the most specific results with the highest accuracy, specificity, and sensitivity.

 More particularly, high information density genes or proteins may be identified by assessing the information content of one or more genes comprising one or more gene
15 expression profiles or one or more proteins comprising one or more protein expression profiles. Genes or proteins providing the highest amount of information content comprise high information density genes or proteins. A high information density gene or protein provides more “information” about a particular tissue type and/or tissue state, as opposed to a gene or protein that is expressed infrequently and, therefore, is of limited value in
20 expression analyses.

 Information content may be based upon, but not limited to, the magnitude of response of a gene or protein relative to a reference state or a separate reference gene or protein. For
25 example, the reference state may be baseline expression at a certain time point, such as prior to treatment, or may refer to a physiological state, such as being healthy or status prior to treatment. Another basis for assessing information content is the frequency of detected expression across categories of tissue, diseases, or patients compared to a reference category such as unstimulated or uninfected patients. Information content may also refer to changes in expression levels relative to categories of cells, tissues, organs, or patients.

 Methods for identifying high information density genes or proteins that may be used
30 to generate the high information density expression profiles, via the use of microarrays comprising nucleic acids or protein-capture agents representing such genes or proteins, involve algorithms that generate the high information density expression profiles. Using algorithms, genes or proteins may be ranked against each other to determine the relative

information content of each gene or protein analyzed. For example, the basis for ranking genes for information content may be an algorithm adding together the number of times the gene or protein is expressed among all categories and time-points, then dividing that number by the sample set size. Furthermore, information content may be subcategorized using an algorithm that ranks the average change in expression level in all instances in which the gene or protein was expressed by the average number of times expressed.

High information density genes or proteins may be selected using an algorithm that ranks expression levels across all tissues, stimuli, and times with weighing in favor of expression that may be greatly increased or decreased among the sets. For example, high information density genes or proteins may be selected using an algorithm that correlates about 90% gene or protein expression in all cell lines or tissues with greater than about a 50% increase or decrease in expression occurring through time or after treatment with all stimuli.

High information density genes or proteins may also be selected using an algorithm that correlates a unique expression profile observed in a single cell line or tissue to a specific disease state for diagnosis or correlates to a treatment modality that may predict a positive or negative outcome. An algorithm that correlates a change in the expression profile in a single cell line or tissue to a specific disease state for diagnosis or a treatment modality that may predict a positive or negative outcome may be used as well. Further, an algorithm that correlates a change in a combination of expression profiles in a single cell line or tissue to a specific disease state for diagnosis, or a treatment modality that may predict a positive or negative outcome, may be used to select high information density genes or proteins.

High information density genes or proteins may be selected from categories that are based on patient characteristics including, for example, gender, age, disease-state, and treatment regime. Another basis for selecting high information density genes or proteins is the time of gene expression. This may include, for example, different times in a disease course, different times after stimuli exposure, different times in organismal development, or different times in the cell cycle. Another selection basis may be an increase or decrease in gene or protein expression in response to a stimulus. For example, the stimulus may include environmental alteration, viral or bacterial infection, drug exposure, protein activation, protein deactivation, chemical exposure, and cell isolation procedure.

Of the various stimuli, environmental alterations may include alterations such as changes in temperature, gas pressure, gas concentration, osmolarity, humidity, and pH. Viral stimuli may include, for example, infection with different viruses such as papilloma viruses,

lentiviruses, retroviruses, hepadnaviruses, alphaviruses, flaviviruses, rhabdoviruses, herpesviruses, adenoviruses, picornaviruses, reoviruses, coronaviruses, pox viruses, paramyxoviruses, togaviruses, and arenaviruses. Bacterial stimuli may include, but may not be limited to, lipopolysaccharide, formylmethionine, bacterial heat shock proteins and

5 lipoteichoic acid.

Drug exposure stimuli may include, for example, metabolic regulators, calcium ionophores, G protein regulators, translation regulators, and transcription regulators. Protein stimuli may include proteins such as cytokines, matrix proteins, cell surface ligands, acute phase proteins, clotting factors, vasoactive proteins, and mismatched Major

10 Histocompatibility antigens among others. Examples of chemical stimuli include organic compounds, inorganic compounds, metals, and other chemical elements. Examples of cell isolation-procedures stimuli include density gradient purification, chemical digestion, mechanical disaggregation, and centrifugation.

Once identified, the high information density genes may be used to create high

15 information density gene microarrays. Similarly, high information density proteins may be used to create high information density protein microarrays. The high information density microarrays may represent a particular tissue type, such as heart, liver, prostate, lung, nerve, muscle, or connective tissue; coronary artery endothelium, umbilical artery endothelium, umbilical vein endothelium, aortic endothelium, dermal microvascular endothelium,

20 pulmonary artery endothelium, myometrium microvascular endothelium, keratinocyte epithelium, bronchial epithelium, mammary epithelium, prostate epithelium, renal cortical epithelium, renal proximal tubule epithelium, small airway epithelium, renal epithelium, umbilical artery smooth muscle, neonatal dermal fibroblast, pulmonary artery smooth muscle, dermal fibroblast, neural progenitor cells, skeletal muscle, astrocytes, aortic smooth muscle,

25 mesangial cells, coronary artery smooth muscle, bronchial smooth muscle, uterine smooth muscle, lung fibroblast, osteoblasts, and prostate stromal cells.

The high information density microarrays may be used in the applications described in the present application. For example, the high information density microarrays may be used to diagnose a patient and predict treatment effectiveness. The microarray may comprise

30 the fewest genes or protein-capture agents necessary to produce the most accurate, reproducible, and specific results that correlate to a positive outcome. Once a treatment course begins, the microarray may be used to generate a gene expression profile or a protein expression profile that correlates to a particular outcome. The clinician may then use this

information to adjust or change therapy accordingly. The microarray itself may contain genes or protein-capture agents that provide the highest amount of information on at least one type but possibly all therapies, for at least one but possibly all diseases.

Used in diagnostic applications, the high-information density microarray may be compared to standard diagnostic pathologies. Specificity, sensitivity, accuracy, predictive value, and standard error of the microarray may be assessed, as well as confidence intervals and prevalence of a disease in a population using standard techniques. Such diagnostic microarrays may be validated based on at least one of the following parameters or combinations thereof described below, wherein "a" represents the number of true positives, "b" represents the number of false positives, "c" represents the number of false negatives, and "d" represents the number of true negatives.

For example, sensitivity may be defined as $a/a+c \times 100$ and indicates the percentage of individuals with the disease that have positive test results. Specificity may be defined as $d/b+d$ and indicates the percentage of individuals who do not have the particular disease and have negative test results. Accuracy (efficiency) may be defined as $a+d/a+b+c+d \times 100$ and may be the percentage of true positive and true negative test results that are correctly identified by the test. Prevalence may be defined as $a+c/a+b+c+d \times 100$ and may be the frequency of disease in the population at a given time based on the incidence of disease per year per 100,000 people.

Positive predictive value may be defined as $a/a+b \times 100$ and may be the percentage of true positive test results based on the prevalence of disease in the population. Negative predictive value may be defined as $d/c+d \times 100$ and may be the percentage of true negative test results based on the prevalence of disease in the population.

The standard error (SE) of the diagnostic microarrays may be calculated using the following formula: $SE = ((p) \times ((1-p)/n))^{1/2}$, where p = sensitivity of the test and n = sample size. The 95% confidence interval may be calculated by the formula: $p - (1.96 \times SE)$ to $p + (1.96 \times SE)$, where p = sensitivity of the test and "1.96" may be derived from statistical tables. The high information density microarray may have a gene or combination of genes or a protein-capture agent or a combination of protein-capture agents that yield the highest sensitivity, specificity and accuracy over the widest range of standards, and also offers the best positive and negative predictive value for the most applications.

In another embodiment, a high information-density microarray may comprise the genes or protein-capture agents that best diagnose leukemia in the most patients with the

highest accuracy. Such diagnostic genes may be 100% sensitive, 100% specific and 100% accurate. A microarray may also include a combination of genes or protein-capture agents that together, rather than individually, yield high sensitivity, specificity, and accuracy, thus diagnosing leukemia with 100% sensitivity, specificity and accuracy. For example, any two
5 separate genes or protein-capture agents may only offer 50% or less sensitivity, specificity, or accuracy for diagnosis leukemia individually, but if combined on the same microarray the specificity may reach 100% because these genes or proteins are only found together when the patient has leukemia. Hence, the gene or combination of genes or protein or combination of proteins that yield the highest information content on leukemia diagnosis may be included on
10 the microarray.

For predicting treatment efficiency, the microarray may contain the genes or protein-capture agents that best predict treatment outcome for leukemia in patients. An expression profile specific for either positive or negative treatment outcome may be 100% sensitive, 100% specific and 100% accurate. A microarray may also include a combination of genes or
15 protein-capture agents that together, rather than individually, predict outcomes of treatments with 100% sensitivity, specificity, and accuracy. For example, any two separate genes or protein-capture agents may only offer 50% or less sensitivity, specificity, or accuracy for outcomes of various treatment modalities for leukemia individually, but when they are combined the microarray may indicate the outcome of a specific patient treatment with
20 sufficient, preferably 100%, accuracy. Thus, the combinations that yield the highest information content on leukemia treatment modality may be included on the microarray.

The high information-density microarrays may be used for indicating when, for example, erythropoietin (EPO) treatment would be appropriate for a patient or for monitoring
drug effectiveness during such treatment. The expression profiles used on the microarray
25 may be one gene or protein-capture agent that may be 100% specific, 100% sensitive, and 100% accurate for indicating when EPO may be provided as a treatment or determining EPO treatment effectiveness or a combination of genes or protein-capture agents that provides the same accuracy. Accordingly, the microarray can provide valuable information on when EPO is appropriate as a course of treatment and when EPO is effective in that treatment. In like
30 manner, a microarray may be used for indicating when cytokine treatment, such as Interleukin 5, Granulocyte Stimulating Factor, Interleukin 2, and Interleukin 12, would be appropriate for a patient during or after chemotherapy or radiation therapy, or for monitoring drug effectiveness during such treatment.

Cancer treatment is an important field in which these types of microarrays may efficiently be used to indicate when a patient has cancer, the type of cancer the patient has, as well as the best treatment modality and prognosis of the patient. The microarray may also be used to monitor drug effectiveness during cancer treatment by measuring whether cancer is present and to what extent. As an example, and without limitation, the microarray may be used for indicating when a patient has Human Immunodeficiency Virus (HIV), the best treatment modality for that patient, and the prognosis of the patient. By measuring whether HIV is present and to what extent, a microarray containing expression profiles from either the host or pathogen may be used as well to monitor drug effectiveness during HIV treatment.

The nucleic acid and protein microarrays of the present invention may be useful as a diagnostic tool in assessing the effects of treatment with a compound on relative gene and protein expression. In one embodiment of the present invention, the methods described herein may be used to assess the pharmacological effects of one or more of the following growth factors, proteins, cytokines or peptides. The genes and protein-capture agents of the present invention may be specific to such growth factors, proteins, cytokines, and peptides or relate to their expression levels.

Briefly, growth factors are hormones or cytokine proteins that bind to receptors on the cell surface, with the primary result of activating cellular proliferation and/or differentiation. Many growth factors are quite versatile, stimulating cellular division in numerous different cell types, while others are specific to a particular cell-type. The following Table 1 presents several factors, but is not intended to be comprehensive or complete, yet introduces some of the more commonly known factors and their principal activities.

Table 1: Growth Factors

Factor	Principal Source	Primary Activity	Comments
Platelet Derived Growth Factor (PDGF)	Platelets, endothelial cells, placenta.	Promotes proliferation of connective tissue, glial and smooth muscle cells. PDGF receptor has intrinsic tyrosine kinase activity.	Dimer required for receptor binding. Two different protein chains, A and B, form 3 distinct dimer forms.
Epidermal Growth Factor (EGF)	Submaxillary gland, Brunners gland.	promotes proliferation of mesenchymal, glial and epithelial cells	EGF receptor has tyrosine kinase activity, activated in response to EGF binding.
Fibroblast Growth Factor	Wide range of cells; protein is associated with	Promotes proliferation of many cells including skeletal	Four distinct receptors, all with

(FGF)	the ECM; nineteen family members. Receptors widely distributed in bone, implicated in several bone-related diseases.	and nervous system; inhibits some stem cells; induces mesodermal differentiation. Non-proliferative effects include regulation of pituitary and ovarian cell function.	tyrosine kinase activity. FGF implicated in mouse mammary tumors and Kaposi's sarcoma.
NGF		Promotes neurite outgrowth and neural cell survival	Several related proteins first identified as proto-oncogenes; trkA (<i>trackA</i>), trkB, trkC
Erythropoietin (Epo)	Kidney	Promotes proliferation and differentiation of erythrocytes	Also considered a 'blood protein,' and a colony stimulating factor.
Transforming Growth Factor α (TGF- α)	Common in transformed cells, found in macrophages and keratinocytes	Potent keratinocyte growth factor.	Related to EGF.
Transforming Growth Factor γ (TGF- β)	Tumor cells, activated TH ₁ cells (T-helper) and natural killer (NK) cells	Anti-inflammatory (suppresses cytokine production and class II MHC expression), proliferative effects on many mesenchymal and epithelial cell types, may inhibit macrophage and lymphocyte proliferation.	Large family of proteins including activin, inhibin and bone morpho-genetic protein. Several classes and subclasses of cell-surface receptors
Insulin-Like Growth Factor-I (IGF-I)	Primarily liver, produced in response to GH and then induces subsequent cellular activities, particularly on bone growth	Promotes proliferation of many cell types, autocrine and paracrine activities in addition to the initially observed endocrine activities on bone.	Related to IGF-II and proinsulin, also called Somatomedin C. IGF-I receptor, like the insulin receptor, has intrinsic tyrosine kinase activity. IGF-I can bind to the insulin receptor.
Insulin-Like Growth Factor-II (IGF-II)	Expressed almost exclusively in embryonic and neonatal tissues.	Promotes proliferation of many cell types primarily of fetal origin. Related to IGF-I and proinsulin.	IGF-II receptor is identical to the mannose-6-phosphate receptor that is responsible for the integration of lysosomal enzymes

Additional growth factors that may be utilized within the methodologies of the present invention include insulin and proinsulin (U.S. Patent No. 4,431,740); Activin (Vale et al., 321 NATURE 776 (1986); Ling et al., 321 NATURE 779 (1986)); Inhibin (U.S. Patent Nos. 4,740,587; 4,737,578); and Bone Morphogenic Proteins (BMPs) (U.S. Patent No. 5,846,931; WOZNEY, CELLULAR & MOLECULAR BIOLOGY OF BONE 131-167 (1993)).

Additional growth factors that may be utilized within the methodologies of the present invention include Activin (Vale et al., 321 NATURE 776 (1986); Ling et al., 321 NATURE 779 (1986)), Inhibin (U.S. Patent Nos. 4,737,578; 4,740,587), and Bone Morphogenic Proteins (BMPs) (U.S. Patent No. 5,846,931; WOZNEY, CELLULAR & MOLECULAR BIOLOGY OF BONE 131-67 (1993)).

In another embodiment, the methodologies of the present invention may be used to assess the pharmacological effects a cytokine or cytokine receptor on a patient or cell line. Secreted primarily from leukocytes, cytokines stimulate both the humoral and cellular immune responses, as well as the activation of phagocytic cells. Cytokines that are secreted from lymphocytes are termed lymphokines, whereas those secreted by monocytes or macrophages are termed monokines. A large family of cytokines are produced by various cells of the body. Many of the lymphokines are also known as interleukins (ILs), because they are not only secreted by leukocytes, but are also able to affect the cellular responses of leukocytes. More specifically, interleukins are growth factors targeted to cells of hematopoietic origin. The list of identified interleukins grows continuously. *See, e.g.*, U.S. Patent No. 6,174,995; U.S. Patent No. 6,143,289; Sallusto et al., 18 ANNU. REV. IMMUNOL. 593 (2000); Kunkel et al., 59 J. LEUKOCYTE BIOL. 81 (1996).

Additional growth factor/cytokines encompassed in the methodologies of the present invention include pituitary hormones such as CEA, FSH, FSH α , FSH β , Human Chorionic Gonadotrophin (HCG), HCG α , HCG β , uFSH (urofollitropin), GH, LH, LH α , LH β , PRL, TSH, TSH α , TSH β , and CA, parathyroid hormones, follicle stimulating hormones, estrogens, progesterones, testosterone, or structural or functional analog thereof. All of these proteins and peptides are known in the art. Many may be obtained commercially from, e.g., Research Diagnostics, Inc. (Flanders, N.J.).

The cytokine family also includes tumor necrosis factors, colony stimulating factors, and interferons. *See, e.g.*, Cosman, 7 BLOOD CELL (1996); Gruss et al., 85 BLOOD 3378 (1995); Beutler et al., 7 ANNU. REV. IMMUNOL. 625 (1989); Aggarwal et al., 260 J. BIOL. CHEM. 2345 (1985); Pennica et al., 312 NATURE 724 (1984); R & D Systems, CYTOKINE MINI-REVIEWS, at <http://www.rndsystems.com>.

Several cytokines are introduced, briefly, in Table 2 below.

Table 2: Cytokines

Cytokine	Principal Source	Primary Activity
Interleukins	Primarily macrophages but also neutrophils, endothelial cells, smooth	Costimulation of APCs and T cells; stimulates IL-2 receptor production and

IL-1- α and - β	muscle cells, glial cells, astrocytes, B- and T-cells, fibroblasts, and keratinocytes.	expression of interferon- γ ; may induce proliferation in non-lymphoid cells.
IL-2	CD4 ⁺ T-helper cells, activated TH ₁ cells, NK cells.	Major interleukin responsible for clonal T-cell proliferation. IL-2 also exerts effects on B-cells, macrophages, and natural killer (NK) cells. IL-2 receptor is not expressed on the surface of resting T-cells, but expressed constitutively on NK cells, that will secrete TNF- α , IFN- γ and GM-CSF in response to IL-2, which in turn activate macrophages.
IL-3	Primarily T-cells	Also known as multi-CSF, as it stimulates stem cells to produce all forms of hematopoietic cells.
IL-4	TH ₂ and mast cells	B cell proliferation, eosinophil and mast cell growth and function, IgE and class II MHC expression on B cells, inhibition of monokine production
IL-5	TH ₂ and mast cells	eosinophil growth and function
IL-6	Macrophages, fibroblasts, endothelial cells and activated T-helper cells. Does not induce cytokine expression.	IL-6 acts in synergy with IL-1 and TNF- α in many immune responses, including T-cell activation; primary inducer of the acute-phase response in liver; enhances the differentiation of B-cells and their consequent production of immunoglobulin; enhances Glucocorticoid synthesis.
IL-7	thymic and marrow stromal cells	T and B lymphopoiesis
IL-8	Monocytes, neutrophils, macrophages, and NK cells.	Chemoattractant (chemokine) for neutrophils, basophils and T-cells; activates neutrophils to degranulate.
IL-9	T cells	hematopoietic and thymopoietic effects
IL-10	activated TH ₂ cells, CD8 ⁺ T and B cells, macrophages	inhibits cytokine production, promotes B cell proliferation and antibody production, suppresses cellular immunity, mast cell growth
IL-11	stromal cells	synergistic hematopoietic and thrombopoietic effects
IL-12	B cells, macrophages	proliferation of NK cells, INF- γ production, promotes cell-mediated immune functions
IL-13	TH ₂ cells	IL-4-like activities
IL-18	macrophages/Kupffer cells, keratinocytes, glucocorticoid-secreting adrenal cortex cells, and osteoblasts	Interferon-gamma-inducing factor with potent pro-inflammatory activity
IL-21	Activated T cells	IL21 has a role in proliferation and maturation of natural killer (NK) cell populations from bone marrow, in the proliferation of mature B-cell populations co-stimulated with anti-CD40, and in the proliferation of T cells co-stimulated with

		anti-CD3.
IL-23	Activated dendritic cells	A complex of p19 and the p40 subunit of IL-12. IL-23 binds to IL-12R beta 1 but not IL-12R beta 2; activates Stat4 in PHA blast T cells; induces strong proliferation of mouse memory T cells; stimulates IFN-gamma production and proliferation in PHA blast T cells, as well as in CD45RO (memory) T cells.
Tumor Necrosis Factor TNF- α	Primarily activated macrophages.	Once called cachectin; induces the expression of other autocrine growth factors, increases cellular responsiveness to growth factors; induces signaling pathways that lead to proliferation; induces expression of a number of nuclear proto-oncogenes as well as of several interleukins.
(TNF- β)	T-lymphocytes, particularly cytotoxic T-lymphocytes (CTL cells); induced by IL-2 and antigen-T-Cell receptor interactions.	Also called lymphotoxin; kills a number of different cell types, induces terminal differentiation in others; inhibits lipoprotein lipase present on the surface of vascular endothelial cells.
Interferons INF- α and - β	macrophages, neutrophils and some somatic cells	Known as type I interferons; antiviral effect; induction of class I MHC on all somatic cells; activation of NK cells and macrophages.
Interferon INF- γ	Primarily CD8+ T-cells, activated TH ₁ and NK cells	Type II interferon; induces of class I MHC on all somatic cells, induces class II MHC on APCs and somatic cells, activates macrophages, neutrophils, NK cells, promotes cell-mediated immunity, enhances ability of cells to present antigens to T-cells; antiviral effects.
Monocyte Chemoattractant Protein-1 (MCP1)	Peripheral blood monocytes/macrophages	Attracts monocytes to sites of vascular endothelial cell injury, implicated in atherosclerosis.
Colony Stimulating Factors (CSFs)		Stimulate the proliferation of specific pluripotent stem cells of the bone marrow in adults.
Granulocyte-CSF (G-CSF)		Specific for proliferative effects on cells of the granulocyte lineage; proliferative effects on both classes of lymphoid cells.
Macrophage-CSF (M-CSF)		Specific for cells of the macrophage lineage.
Granulocyte-MacrophageCSF (GM-CSF)		Proliferative effects on cells of both the macrophage and granulocyte lineages.

Other cytokines of interest that may be characterized by the invention described herein include adhesion molecules (R & D Systems, ADHESION MOLECULES I (1996), available at <http://www.rndsystems.com>); angiogenin (U.S. Patent No. 4,721,672; Moener et al., 226 EUR. J. BIOCHEM. 483 (1994)); annexin V (Cookson et al., 20 GENOMICS 463 (1994); Grundmann et al., 85 PROC. NATL. ACAD. SCI. USA 3708 (1988); U.S. Patent No. 5,767,247); caspases (U.S. Patent No. 6,214,858; Thornberry et al., 281 SCIENCE 1312 (1998)); chemokines (U.S. Patent Nos. 6,174,995; 6,143,289; Sallusto et al., 18 ANNU. REV. IMMUNOL. 593 (2000) Kunkel et al., 59 J. LEUKOCYTE BIOL. 81 (1996)); endothelin (U.S. Patent Nos. 6,242,485; 5,294,569; 5,231,166); eotaxin (U.S. Patent No. 6,271,347; Ponath et al., 97(3) J. CLIN. INVEST. 604-612 (1996)); Flt-3 (U.S. Patent No. 6,190,655); heregulins (U.S. Patent Nos. 6,284,535; 6,143,740; 6,136,558; 5,859,206; 5,840,525); Leptin (Leroy et al., 271(5) J. BIOL. CHEM. 2365 (1996); Maffei et al., 92 PNAS 6957 (1995); Zhang et al. (1994) NATURE 372: 425-432); Macrophage Stimulating Protein (MSP) (U.S. Patent Nos. 6,248,560; 6,030,949; 5,315,000); Neurotrophic Factors (U.S. Patent Nos. 6,005,081; 5,288,622); Pleiotrophin/Midkine (PTN/MK) (Pedraza et al., 117 J. BIOCHEM. 845 (1995); Tamura et al., 3 ENDOCRINE 21 (1995); U.S. Patent No. 5,210,026; Kadomatsu et al., 151 BIOCHEM. BIOPHYS. RES. COMMUN. 1312 (1988)); STAT proteins (U.S. Patent Nos. 6,030,808; 6,030,780; Darnell et al., 277 SCIENCE 1630-1635 (1997)); Tumor Necrosis Factor Family (Cosman, 7 BLOOD CELL (1996); Gruss et al., 85 BLOOD 3378 (1995); Beutler et al., 7 ANNU. REV. IMMUNOL. 625 (1989); Aggarwal et al., 260 J. BIOL. CHEM. 2345 (1985); Pennica et al., 312 NATURE 724 (1984)).

Also of interest regarding cytokines are proteins or chemical moieties that interact with cytokines, such as Matrix Metalloproteinases (MMPs) (U.S. Patent No. 6,307,089; NAGASE, MATRIX METALLOPROTEINASES IN ZINC METALLOPROTEASES IN HEALTH AND DISEASE (1996)), and Nitric Oxide Synthases (NOS) (Fukuto, 34 ADV. PHARM 1 (1995); U.S. Patent No. 5,268,465).

A further embodiment of the present invention applies the methodologies described herein to the characterization of the pharmacological effects of blood proteins. The term "blood protein" is a generic term for a vast group of proteins generally circulating in blood plasma, and important for regulating coagulation and clot dissolution. See, e.g., Haematologic Technologies, Inc., HTI CATALOG, available at www.haemtech.com. Table 3 introduces, in a non-limiting fashion, some of the blood proteins contemplated by the present invention.

Table 3: Blood Proteins

Protein	Principle Activity	Reference
Factor V	In coagulation, this glycoprotein pro-cofactor, is converted to active cofactor, factor Va, via the serine protease α -thrombin, and less efficiently by its serine protease cofactor Xa. The prothrombinase complex rapidly converts zymogen prothrombin to the active serine protease, α -thrombin. Down regulation of prothrombinase complex occurs via inactivation of Va by activated protein C.	Mann et al., 57 ANN. REV. BIOCHEM. 915 (1988); <i>see also</i> Nesheim et al., 254 J. BIOL. CHEM. 508 (1979); Tracy et al., 60 BLOOD 59 (1982); Nesheim et al., 80 METHODS ENZYMOLOGY 249 (1981); Jenny et al., 84 PROC. NATL. ACAD. SCI. USA 4846 (1987).
Factor VII	Single chain glycoprotein zymogen in its native form. Proteolytic activation yields enzyme factor VIIa, which binds to integral membrane protein tissue factor, forming an enzyme complex that proteolytically converts factor X to Xa. Also known as extrinsic factor Xase complex. Conversion of VII to VIIa catalyzed by a number of proteases including thrombin, factors IXa, Xa, XIa, and XIIa. Rapid activation also occurs when VII combines with tissue factor in the presence of Ca, likely initiated by a small amount of pre-existing VIIa. Not readily inhibited by antithrombin III/heparin alone, but is inhibited when tissue factor added.	<i>See generally</i> , Broze et al., 80 METHODS ENZYMOLOGY 228 (1981); Bajaj et al., 256 J. BIOL. CHEM. 253 (1981); Williams et al., 264 J. BIOL. CHEM. 7536 (1989); Kisiel et al., 22 THROMBOSIS RES. 375 (1981); Seligsohn et al., 64 J. CLIN. INVEST. 1056 (1979); Lawson et al., 268 J. BIOL. CHEM. 767 (1993).
Factor IX	Zymogen factor IX, a single chain vitamin K-dependent glycoprotein, made in liver. Binds to negatively charged phospholipid surfaces. Activated by factor XIa or the factor VIIa/tissue factor/phospholipid complex. Cleavage at one site yields the intermediate IXa, subsequently converted to fully active form IXa β by cleavage at another site. Factor IXa β is the catalytic component of the "intrinsic factor Xase complex" (factor VIIIa/IXa/Ca ²⁺ /phospholipid) that proteolytically activates factor X to factor Xa.	Thompson, 67 BLOOD, 565 (1986); Hedner et al., HEMOSTASIS AND THROMBOSIS 39-47 (R.W. Colman, J. Hirsh, V.J. Marder, E.W. Salzman ed., 2 nd ed. J.P. Lippincott Co., Philadelphia) 1987; Fujikawa et al., 45 METHODS IN ENZYMOLOGY 74 (1974).
Factor X	Vitamin K-dependent protein zymogen, made in liver, circulates in plasma as a two chain molecule linked by a disulfide bond. Factor Xa (activated X) serves as the enzyme component of prothrombinase complex, responsible for rapid conversion of prothrombin to thrombin.	<i>See</i> Davie et al., 48 ADV. ENZYMOLOGY 277 (1979); Jackson, 49 ANN. REV. BIOCHEM. 765 (1980); <i>see also</i> Fujikawa et al., 11 BIOCHEM. 4882 (1972); Discipio et al., 16 BIOCHEM. 698 (1977); Discipio et al., 18 BIOCHEM. 899 (1979); Jackson et al., 7 BIOCHEM. 4506 (1968); McMullen et

		al., 22 BIOCHEM. 2875 (1983).
Factor XI	Liver-made glycoprotein homodimer circulates, in a non-covalent complex with high molecular weight kininogen, as a zymogen, requiring proteolytic activation to acquire serine protease activity. Conversion of factor XI to factor XIa is catalyzed by factor XIIa. XIa unique among the serine proteases, since it contains two active sites per molecule. Works in the intrinsic coagulation pathway by catalyzing conversion of factor IX to factor IXa. Complex form, factor XIa/HMWK, activates factor XII to factor XIIa and prekallikrein to kallikrein. Major inhibitor of XIa is α_1 -antitrypsin and to lesser extent, antithrombin-III. Lack of factor XI procoagulant activity causes bleeding disorder: plasma thromboplastin antecedent deficiency.	Thompson et al., 60 J. CLIN. INVEST. 1376 (1977); Kurachi et al., 16 BIOCHEM. 5831 (1977); Bouma et al., 252 J. BIOL. CHEM. 6432 (1977); Wuepper, 31 FED. PROC. 624 (1972); Saito et al., 50 BLOOD 377 (1977); Fujikawa et al., 25 BIOCHEM. 2417 (1986); Kurachi et al., 19 BIOCHEM. 1330 (1980); Scott et al., 69 J. CLIN. INVEST. 844 (1982).
Factor XII (Hageman Factor)	Glycoprotein zymogen. Reciprocal activation of XII to active serine protease factor XIIa by kallikrein is central to start of intrinsic coagulation pathway. Surface bound α -XIIa activates factor XI to XIa. Secondary cleavage of α -XIIa by kallikrein yields β -XIIa, and catalyzes solution phase activation of kallikrein, factor VII and the classical complement cascade.	Schmaier et al., 18-38, and Davie, 242-267 HEMOSTASIS & THROMBOSIS (Colman et al., eds., J.B. Lippincott Co., Philadelphia, 1987).
Factor XIII	Zymogenic form of glutamyl-peptide γ -glutamyl transferase factor XIIIa (fibrinolygase, plasma transglutaminase, fibrin stabilizing factor). Made in the liver, found extracellularly in plasma and intracellularly in platelets, megakaryocytes, monocytes, placenta, uterus, liver and prostrate tissues. Circulates as a tetramer of 2 pairs of nonidentical subunits (A_2B_2). Full expression of activity is achieved only after the Ca^{2+} - and fibrin(ogen)-dependent dissociation of B subunit dimer from A_2' dimer. Last of the zymogens to become activated in the coagulation cascade, the only enzyme in this system that is not a serine protease. XIIIa stabilizes the fibrin clot by crosslinking the α and γ -chains of fibrin. Serves in cell proliferation in wound healing, tissue remodeling, atherosclerosis, and tumor growth.	See McDonough, 340-357 HEMOSTASIS & THROMBOSIS (Colman et al., eds., J.B. Lippincott Co., Philadelphia, 1987); Folk et al., 113 METHODS ENZYMOL. 364 (1985); Greenberg et al., 69 BLOOD 867 (1987). Other proteins known to be substrates for Factor XIIIa, that may be hemostatically important, include fibronectin (Iwanaga et al., 312 ANN. NY ACAD. SCI. 56 (1978)), a_2 -antiplasmin (Sakata et al., 65 J. CLIN. INVEST. 290 (1980)), collagen (Mosher et al., 64 J. CLIN. INVEST. 781 (1979)), factor V (Francis et al., 261 J. BIOL. CHEM. 9787 (1986)), von Willebrand Factor (Mosher et al., 64 J. CLIN. INVEST. 781 (1979)) and thrombospondin (Bale et al., 260 J. BIOL. CHEM. 7502 (1985); Bohn, 20 MOL. CELL BIOCHEM. 67 (1978)).

Fibrinogen	<p>Plasma fibrinogen, a large glycoprotein, disulfide linked dimer made of 3 pairs of non-identical chains (Aa, Bb and g), made in liver. Aa has N-terminal peptide (fibrinopeptide A (FPA), factor XIIIa crosslinking sites, and 2 phosphorylation sites. Bb has fibrinopeptide B (FPB), 1 of 3 N-linked carbohydrate moieties, and an N-terminal pyroglutamic acid. The g chain contains the other N-linked glycos. site, and factor XIIIa cross-linking sites. Two elongated subunits ((AaBbg)₂) align in an antiparallel way forming a trinodular arrangement of the 6 chains. Nodes formed by disulfide rings between the 3 parallel chains. Central node (n-disulfide knot, E domain) formed by N-termini of all 6 chains held together by 11 disulfide bonds, contains the 2 IIa-sensitive sites. Release of FPA by cleavage generates Fbn I, exposing a polymerization site on Aa chain. These sites bind to regions on the D domain of Fbn to form proto-fibrils. Subsequent IIa cleavage of FPB from the Bb chain exposes additional polymerization sites, promoting lateral growth of Fbn network. Each of the 2 domains between the central node and the C-terminal nodes (domains D and E) has parallel α-helical regions of the Aa, Bb and g chains having protease-(plasmin-) sensitive sites. Another major plasmin sensitive site is in hydrophilic preturbance of α-chain from C-terminal node. Controlled plasmin degradation converts Fbg into fragments D and E.</p>	<p>FURLAN, <i>Fibrinogen</i>, IN HUMAN PROTEIN DATA, (Haeberli, ed., VCH Publishers, N.Y., 1995); Doolittle, in HAEMOSTASIS & THROMBOSIS, 491-513 (3rd ed., Bloom et al., eds., Churchill Livingstone, 1994); HANTGAN, et al., in HAEMOSTASIS & THROMBOSIS 269-89 (2d ed., Forbes et al., eds., Churchill Livingstone, 1991).</p>
Fibronectin	<p>High molecular weight, adhesive, glycoprotein found in plasma and extracellular matrix in slightly different forms. Two peptide chains interconnected by 2 disulfide bonds, has 3 different types of repeating homologous sequence units. Mediates cell attachment by interacting with cell surface receptors and extracellular matrix components. Contains an Arg-Gly-Asp-Ser (RGDS) cell attachment-promoting sequence, recognized by specific cell receptors, such as those on platelets. Fibrin-fibronectin complexes stabilized by factor XIIIa-catalyzed covalent cross-linking of fibronectin to</p>	<p>Skorstengaard et al., 161 Eur. J. BIOCHEM. 441 (1986); Kornblihtt et al., 4 EMBO J. 1755 (1985); Odermatt et al., 82 PNAS 6571 (1985); Hynes, R.O., ANN. REV. CELL BIOL., 1, 67 (1985); Mosher 35 ANN. REV. MED. 561 (1984); Rouslahti et al., 44 Cell 517 (1986); Hynes 48 CELL 549 (1987); Mosher 250 BIOL. CHEM. 6614 (1975).</p>

	the fibrin a chain.	
β_2 -Glycoprotein I	Also called β_2 I and Apolipoprotein H. Highly glycosylated single chain protein made in liver. Five repeating mutually homologous domains consisting of approximately 60 amino acids disulfide bonded to form Short Consensus Repeats (SCR) or Sushi domains. Associated with lipoproteins, binds anionic surfaces like anionic vesicles, platelets, DNA, mitochondria, and heparin. Binding can inhibit contact activation pathway in blood coagulation. Binding to activated platelets inhibits platelet associated prothrombinase and adenylate cyclase activities. Complexes between β_2 I and cardiolipin have been implicated in the anti-phospholipid related immune disorders LAC and SLE.	<i>See, e.g.,</i> Lozier et al., 81 PNAS 2640-44 (1984); Kato & Enjyo 30 BIOCHEM. 11687-94 (1997); Wurm, 16 INT'L J. BIOCHEM. 511-15 (1984); Bendixen et al., 31 BIOCHEM. 3611-17 (1992); Steinkasserer et al., 277 BIOCHEM. J. 387-91 (1991); Nimpf et al., 884 BIOCHEM. BIOPHYS. ACTA 142-49 (1986); Kroll et al. 434 BIOCHEM. BIOPHYS. Acta 490-501 (1986); Polz et al., 11 INT'L J. BIOCHEM. 265-73 (1976); McNeil et al., 87 PNAS 4120-24 (1990); Galli et al., I LANCET 1544-47 (1990); Matsuura et al., II LANCET 177-78 (1990); Pengo et al., 73 THROMBOSIS & HAEMOSTASIS 29-34 (1995).
Osteonectin	Acidic, noncollagenous glycoprotein (Mr=29,000) originally isolated from fetal and adult bovine bone matrix. May regulate bone metabolism by binding hydroxyapatite to collagen. Identical to human placental SPARC. An alpha granule component of human platelets secreted during activation. A small portion of secreted osteonectin expressed on the platelet cell surface in an activation-dependent manner	Villarreal et al., 28 BIOCHEM. 6483 (1989); Tracy et al., 29 INT'L J. BIOCHEM. 653 (1988); Romberg et al., 25 BIOCHEM. 1176 (1986); Sage & Bornstein 266 J. BIOL. CHEM. 14831 (1991); Kelm & Mann 4 J. BONE MIN. RES. 5245 (1989); Kelm et al., 80 BLOOD 3112 (1992).
Plasminogen	Single chain glycoprotein zymogen with 24 disulfide bridges, no free sulfhydryls, and 5 regions of internal sequence homology, "kringles", each five triple-looped, three disulfide bridged, and homologous to kringle domains in t-PA, u-PA and prothrombin. Interaction of plasminogen with fibrin and α_2 -antiplasmin is mediated by lysine binding sites. Conversion of plasminogen to plasmin occurs by variety of mechanisms, including urinary type and tissue type plasminogen activators, streptokinase, staphylokinase, kallikrein, factors IXa and XIIa, but all result in hydrolysis at Arg560-Val561, yielding two chains that remain covalently associated by a disulfide bond.	<i>See</i> Robbins, 45 METHODS IN ENZYMOLOGY 257 (1976); COLLEN, 243-258 BLOOD COAG. (Zwaal et al., eds., New York, Elsevier, 1986); <i>see also</i> Castellino et al., 80 METHODS IN ENZYMOLOGY 365 (1981); Wohl et al., 27 THROMB. RES. 523 (1982); Barlow et al., 23 BIOCHEM. 2384 (1984); SOTTRUP-JENSEN ET AL., 3 PROGRESS IN CHEM. FIBRINOLYSIS & THROMBOLYSIS 197-228 (Davidson et al., eds., Raven Press, New York 1975).
tissue Plasminogen Activator	t-PA, a serine endopeptidase synthesized by endothelial cells, is the major physiologic activator of plasminogen in clots, catalyzing conversion of	<i>See</i> Plasminogen.

	plasminogen to plasmin by hydrolising a specific arginine-alanine bond. Requires fibrin for this activity, unlike the kidney-produced version, urokinase-PA.	
Plasmin	<i>See Plasminogen.</i> Plasmin, a serine protease, cleaves fibrin, and activates and/or degrades compounds of coagulation, kinin generation, and complement systems. Inhibited by a number of plasma protease inhibitors <i>in vitro</i> . Regulation of plasmin <i>in vivo</i> occurs mainly through interaction with α_2 -antiplasmin, and to a lesser extent, α_2 -macroglobulin.	<i>See Plasminogen.</i>
Platelet Factor-4	Low molecular weight, heparin-binding protein secreted from agonist-activated platelets as a homotetramer in complex with a high molecular weight, proteoglycan, carrier protein. Lysine-rich, COOH-terminal region interacts with cell surface expressed heparin-like glycosaminoglycans on endothelial cells, PF-4 neutralizes anticoagulant activity of heparin exerts procoagulant effect, and stimulates release of histamine from basophils. Chemotactic activity toward neutrophils and monocytes. Binding sites on the platelet surface have been identified and may be important for platelet aggregation.	Rucinski et al., 53 BLOOD 47 (1979); Kaplan et al., 53 BLOOD 604 (1979); George 76 BLOOD 859 (1990); Busch et al., 19 THROMB. RES. 129 (1980); Rao et al., 61 BLOOD 1208 (1983); Brindley, et al., 72 J. CLIN. INVEST. 1218 (1983); Deuel et al., 74 PNAS 2256 (1981); Osterman et al., 107 BIOCHEM. BIOPHYS. RES. COMMUN. 130 (1982); Capitanio et al., 839 BIOCHEM. BIOPHYS. ACTA 161 (1985).
Protein C	Vitamin K-dependent zymogen, protein C, made in liver as a single chain polypeptide then converted to a disulfide linked heterodimer. Cleaving the heavy chain of human protein C converts the zymogen into the serine protease, activated protein C. Cleavage catalyzed by a complex of α -thrombin and thrombomodulin. Unlike other vitamin K dependent coagulation factors, activated protein C is an anticoagulant that catalyzes the proteolytic inactivation of factors Va and VIIIa, and contributes to the fibrinolytic response by complex formation with plasminogen activator inhibitors.	<i>See Esmon</i> , 10 PROGRESS IN THROMB. & HEMOSTAS. 25 (1984); Stenflo, 10 SEMIN. IN THROMB. & HEMOSTAS. 109 (1984); Griffen et al., 60 BLOOD 261 (1982); Kiesel et al., 80 METHODS ENZYMOL. 320 (1981); Discipio et al., 18 BIOCHEM. 899 (1979).
Protein S	Single chain vitamin K-dependent protein functions in coagulation and complement cascades. Does not possess the catalytic triad. Complexes to C4b binding protein (C4BP) and to negatively charged phospholipids, concentrating C4BP at cell surfaces	Walker, 10 SEMIN. THROMB. HEMOSTAS. 131 (1984); Dahlback et al., 10 SEMIN. THROMB. HEMOSTAS., 139 (1984); Walker 261 J. BIOL. CHEM. 10941 (1986).

	following injury. Unbound S serves as anticoagulant cofactor protein with activated Protein C. A single cleavage by thrombin abolishes protein S cofactor activity by removing gla domain.	
Protein Z	Vitamin K-dependent, single-chain protein made in the liver. Direct requirement for the binding of thrombin to endothelial phospholipids. Domain structure similar to that of other vitamin K-dependant zymogens like factors VII, IX, X, and protein C. N-terminal region contains carboxylglutamic acid domain enabling phospholipid membrane binding. C-terminal region lacks "typical" serine protease activation site. Cofactor for inhibition of coagulation factor Xa by serpin called protein Z-dependant protease inhibitor. Patients diagnosed with protein Z deficiency have abnormal bleeding diathesis during and after surgical events.	Sejima et al., 171 BIOCHEM. BIOPHYSICS RES. COMM. 661 (1990); Hogg et al., 266 J. BIOL. CHEM. 10953 (1991); Hogg et al., 17 BIOCHEM. BIOPHYSICS RES. COMM. 801 (1991); Han et al., 38 BIOCHEM. 11073 (1999); Kemkes-Matthes et al., 79 THROMB. RES. 49 (1995).
Prothrombin	Vitamin K-dependent, single-chain protein made in the liver. Binds to negatively charged phospholipid membranes. Contains two "kringle" structures. Mature protein circulates in plasma as a zymogen and, during coagulation, is proteolytically activated to the potent serine protease α -thrombin.	Mann et al., 45 METHODS IN ENZYMOLOGY 156 (1976); Magnusson et al., PROTEASES IN BIOLOGICAL CONTROL 123-149 (Reich et al., eds. Cold Spring Harbor Labs., New York 1975); Discipio et al., 18 BIOCHEM. 899 (1979).
α -Thrombin	See Prothrombin. During coagulation, thrombin cleaves fibrinogen to form fibrin, the terminal proteolytic step in coagulation, forming the fibrin clot. Thrombin also responsible for feedback activation of procofactors V and VIII. Activates factor XIII and platelets; functions as vasoconstrictor protein. Procoagulant activity arrested by heparin cofactor II or the antithrombin III/heparin complex, or complex formation with thrombomodulin. Formation of thrombin/thrombomodulin complex results in inability of thrombin to cleave fibrinogen and activate factors V and VIII, but increases the efficiency of thrombin for activation of the anticoagulant, protein C.	45 METHODS ENZYMOL. 156 (1976).
β -Thromboglobulin	Low molecular weight, heparin-binding, platelet-derived tetramer protein, consisting of four identical peptide chains. Lower affinity for heparin than PF-4. Chemotactic activity for human	See, e.g., George 76 BLOOD 859 (1990); Holt & Niewiarowski 632 BIOCHIM. BIOPHYS. ACTA 284 (1980); Niewiarowski et al., 55 BLOOD 453 (1980); Varma et al., 701 BIOCHIM.

	fibroblasts, other functions unknown.	BIOPHYS. ACTA 7 (1982); Senior et al., 96 J. CELL. BIOL. 382 (1983).
Thrombopoietin	Human TPO (Thrombopoietin, Mpl-ligand, MGDF) stimulates the proliferation and maturation of megakaryocytes and promotes increased circulating levels of platelets <i>in vivo</i> . Binds to c-Mpl receptor.	Horikawa et al., 90(10) BLOOD 4031-38 (1997); de Sauvage et al., 369 NATURE 533-58 (1995).
Thrombospondin	High-molecular weight, heparin-binding glycoprotein constituent of platelets, consisting of three, identical, disulfide-linked polypeptide chains. Binds to surface of resting and activated platelets, may effect platelet adherence and aggregation. An integral component of basement membrane in different tissues. Interacts with a variety of extracellular macromolecules including heparin, collagen, fibrinogen and fibronectin, plasminogen, plasminogen activator, and osteonectin. May modulate cell-matrix interactions.	Dawes et al., 29 THROMB. RES. 569 (1983); Switalska et al., 106 J. LAB. CLIN. MED. 690 (1985); Lawler et al., 260 J. BIOL. CHEM. 3762 (1985); Wolff et al., 261 J. BIOL. CHEM. 6840 (1986); Asch et al., 79 J. CLIN. CHEM. 1054 (1987); Jaffe et al., 295 NATURE 246 (1982); Wright et al., 33 J. HISTOCHEM. CYTOCHEM. 295 (1985); Dixit et al., 259 J. BIOL. CHEM. 10100 (1984); Mumby et al., 98 J. CELL. BIOL. 646 (1984); Lahav et al., 145 EUR. J. BIOCHEM. 151 (1984); Silverstein et al., 260 J. BIOL. CHEM. 10346 (1985); Clezardin et al. 175 EUR. J. BIOCHEM. 275 (1988); Sage & Bornstein (1991).
Von Willebrand Factor	Multimeric plasma glycoprotein made of identical subunits held together by disulfide bonds. During normal hemostasis, larger multimers of vWF cause platelet plug formation by forming a bridge between platelet glycoprotein IB and exposed collagen in the subendothelium. Also binds and transports factor VIII (antihemophilic factor) in plasma.	Hoyer 58 BLOOD 1 (1981); Ruggeri & Zimmerman 65 J. CLIN. INVEST. 1318 (1980); Hoyer & Shainoff 55 BLOOD 1056 (1980); Meyer et al., 95 J. LAB. CLIN. INVEST. 590 (1980); Santoro 21 THROMB. RES. 689 (1981); Santoro, & Cowan 2 COLLAGEN RELAT. RES. 31 (1982); Morton et al., 32 THROMB. RES. 545 (1983); Tuddenham et al., 52 BRIT. J. HAEMATOL. 259 (1982).

Additional blood proteins contemplated herein include the following human serum proteins, which may also be placed in another category of protein (such as hormone or antigen): Actin, Actinin, Amyloid Serum P, Apolipoprotein E, B2-Microglobulin, C-
5 Reactive Protein (CRP), Cholesterylester transfer protein (CETP), Complement C3B, Ceruplasmin, Creatine Kinase, Cystatin, Cytokeratin 8, Cytokeratin 14, Cytokeratin 18, Cytokeratin 19, Cytokeratin 20, Desmin, Desmocollin 3, FAS (CD95), Fatty Acid Binding Protein, Ferritin, Filamin, Glial Filament Acidic Protein, Glycogen Phosphorylase Isoenzyme BB (GPBB), Haptoglobulin, Human Myoglobin, Myelin Basic Protein, Neurofilament,
10 Placental Lactogen, Human SHBG, Human Thyroid Peroxidase, Receptor Associated Protein, Human Cardiac Troponin C, Human Cardiac Troponin I, Human Cardiac Troponin T, Human Skeletal Troponin I, Human Skeletal Troponin T, Vimentin, Vinculin, Transferrin

Receptor, Prealbumin, Albumin, Alpha-1-Acid Glycoprotein, Alpha-1-Antichymotrypsin, Alpha-1-Antitrypsin, Alpha-Fetoprotein, Alpha-1-Microglobulin, Beta-2-microglobulin, C-Reactive Protein, Haptoglobin, Myoglobin, Prealbumin, PSA, Prostatic Acid

Phosphatase, Retinol Binding Protein, Thyroglobulin, Thyroid Microsomal Antigen,

- 5 Thyroxine Binding Globulin, Transferrin, Troponin I, Troponin T, Prostatic Acid Phosphatase, Retinol Binding Globulin (RBP). All of these proteins, and sources thereof, are known in the art. Many of these proteins are available commercially from, for example, Research Diagnostics, Inc. (Flanders, NJ).

- Another embodiment applies the methodologies of the present invention to the
- 10 analysis of the effects of a neurotransmitter or the receptor of a neurotransmitter on a patient or cell sample. Neurotransmitters are chemicals, some of them proteinaceous, made by neurons and used by them to transmit signals to the other neurons or non-neuronal cells (e.g., skeletal muscle, myocardium, pineal glandular cells) that they innervate. Neurotransmitters produce their effects by being released into synapses when their neuron of origin fires (i.e.,
- 15 becomes depolarized) and then attaching to receptors in the membrane of the post-synaptic cells. This causes changes in the fluxes of particular ions across that membrane, making cells more likely to become depolarized, if the neurotransmitter happens to be excitatory, or less likely if it is inhibitory. Neurotransmitters can also produce their effects by modulating the production of other signal-transducing molecules ("second messengers") in the post-synaptic
- 20 cells. *See generally* COOPER, BLOOM & ROTH, *THE BIOCHEM. BASIS OF NEUROPHARMACOLOGY* (7th Ed. Oxford Univ. Press, NYC, 1996); <http://web.indstate.edu/thcme/mwking/nerves>. Neurotransmitters contemplated in the present invention include, but are not limited to, Acetylcholine, Serotonin, γ -aminobutyrate (GABA), Glutamate, Aspartate, Glycine, Histamine, Epinephrine, Norepinephrine, Dopamine,
- 25 Adenosine, ATP, Nitric oxide, and any of the peptide neurotransmitters such as those derived from pre-opiomelanocortin (POMC), as well as antagonists and agonists of any of the foregoing.

Table 4 presents a non-limiting list and description of some pharmacologically active peptides which may be incorporated into the methods contemplated by the present invention.

30 Table 4: Pharmacologically active peptides

Binding partner/ Protein of interest (form of peptide)	Pharmacological activity	Reference
EPO receptor	EPO mimetic	Wrighton et al., 273 SCIENCE 458-63

(intrapeptide disulfide-bonded)		(1996); U.S. Pat. No. 5,773,569, issued June 30, 1998.
EPO receptor (C-terminally cross-linked dimer)	EPO mimetic	Livnah et al., 273 SCIENCE 464-71 (1996); Wrighton et al., 15 NATURE BIOTECHNOLOGY 1261-5 (1997); Int'l Patent Application WO 96/40772, published Dec. 19, 1996.
EPO receptor (linear)	EPO mimetic	Naranda et al., 96 PNAS 7569-74 (1999).
c-Mpl (linear)	TPO-mimetic	Cwirla et al., 276 SCIENCE 1696-9 (1997); U.S. Pat. No. 5,869,451, issued Feb. 9, 1999; U.S. Pat. No. 5,932,946, issued Aug. 3, 1999.
c-Mpl (C-terminally cross-linked dimer)	TPO-mimetic	Cwirla et al., 276 SCIENCE 1696-9 (1997).
(disulfide-linked dimer)	stimulation of hematopoiesis ("G-CSF-mimetic")	Paukovits et al., 364 HOPPE-SEYLER'S Z. PHYSIOL. CHEM. 30311 (1984); Laerumgal., 16 EXP. HEMAT. 274-80 (1988).
(alkylene-linked dimer)	G-CSF-mimetic	Batnagar et al., 39 J. MED. CHEM. 38149 (1996); Cuthbertson et al., 40 J. MED. CHEM. 2876-82 (1997); King et al., 19 EXP. HEMATOL. 481 (1991); King et al., 86(Suppl. 1) BLOOD 309 (1995).
IL-1 receptor (linear)	inflammatory and autoimmune diseases ("IL-1 antagonist" or "IL-1 ra-mimetic")	U.S. Pat. No. 5,608,035; U.S. Pat. No. 5,786,331; U.S. Pat. No. 5,880,096; Yanofsky et al., 93 PNAS 7381-6 (1996); Akeson et al., 271 J. BIOL. CHEM. 30517-23 (1996); Wickzorek et al., 49 POL. J. PHARMACOL. 107-17 (1997); Yanofsky, 93 PNAS 7381-7386 (1996).
Facteur thyrique (linear)	stimulation of lymphocytes (FTS-mimetic)	Inagaki-Ohara et al., 171 CELLULAR IMMUNOL. 30-40 (1996); Yoshida, 6 J. IMMUNOPHARMACOL 141-6 (1984).
CTLA4 MAb (intrapeptide di-sulfide bonded)	CTLA4-mimetic	Fukumoto et al., 16 NATURE BIOTECH. 267-70 (1998).
TNF- α receptor (exo-cyclic)	TNF- α antagonist	Takasaki et al., 15 NATURE BIOTECH. 1266-70 (1997); WO 98/53842, published December 3, 1998.
TNF- α receptor (linear)	TNF- α antagonist	Chirinos-Rojas, J. IMM., 5621-26.
C3b (intrapeptide di-sulfide bonded)	inhibition of complement activation; autoimmune diseases (C3b antagonist)	Sahu et al., 157 IMMUNOL. 884-91 (1996); Morikis et al., 7 PROTEIN SCI. 619-27 (1998).
vinculin (linear)	cell adhesion processes, cell growth, differentiation wound healing, tumor metastasis ("vinculin binding")	Adey et al., 324 BIOCHEM. J. 523-8 (1997).
C4 binding protein (C413P) (linear)	anti-thrombotic	Linse et al. 272 BIOL. CHEM. 14658-65 (1997).

urokinase receptor (linear)	processes associated with urokinase interaction with its receptor (e.g. angiogenesis, tumor cell invasion and metastasis; (URK antagonist)	Goodson et al., 91 PNAS 7129-33 (1994); International patent application WO 97/35969, published October 2, 1997.
Mdm2, Hdm2 (linear)	Inhibition of inactivation of p53 mediated by Mdm2 or hdm2; anti-tumor ("Mdm/hdm antagonist")	Picksley et al., 9 ONCOGENE 2523-9 (1994); Bottger et al. 269 J. MOL. BIOL. 744-56 (1997); Bottger et al., 13 ONCOGENE 13: 2141-7 (1996).
p21 ^{WAF1} (linear)	anti-tumor by mimicking the activity of p21 ^{WAF1}	Ball et al., 7 CURR. BIOL. 71-80 (1997).
farnesyl transferase (linear)	anti-cancer by preventing activation of ras oncogene	Gibbs et al., 77 CELL 175-178 (1994).
Ras effector domain (linear)	anti-cancer by inhibiting biological function of the ras oncogene	Moodie et al., 10 TRENDS GENET. 44-48 (1994); Rodriguez et al., 370 NATURE 527-532 (1994).
SH2/SH3 domains (linear)	anti-cancer by inhibiting tumor growth with activated tyrosine kinases	Pawson et al, 3 CURR. BIOL. 434-432 (1993); Yu et al., 76 CELL 933-945 (1994).
p16 ^{INK4} (linear)	anti-cancer by mimicking activity of p16; e.g., inhibiting cyclin D-Cdk complex ("p16-mimetic")	Fahraeus et al., 6 CURR. BIOL. 84-91 (1996).
Src, Lyn (linear)	inhibition of Mast cell activation, IgE-related conditions, type I hypersensitivity ("Mast cell antagonist").	Stauffer et al., 36 BIOCHEM. 9388-94 (1997).
Mast cell protease (linear)	treatment of inflammatory disorders mediated by release of tryptase-6 ("Mast cell protease inhibitors")	International patent application WO 98/33812, published August 6, 1998.
SH3 domains (linear)	treatment of SH3-mediated disease states ("SH3 antagonist")	Rickles et al., 13 EMBO J. 5598-5604 (1994); Sparks et al., 269 J. BIOL. CHEM. 238536 (1994); Sparks et al., 93 PNAS 1540-44 (1996).
HBV core antigen (HBcAg) (linear)	treatment of HBV viral antigen (HBcAg) infections ("anti-HBV")	Dyson & Muray, PNAS 2194-98 (1995).
selectins (linear)	neutrophil adhesion inflammatory diseases ("selectin antagonist")	Martens et al., 270 J. BIOL. CHEM. 21129-36 (1995); European Pat. App. EP 0 714 912, published June 5, 1996.
calmodulin (linear, cyclized)	calmodulin antagonist	Pierce et al., 1 MOLEC. DIVERSITY 25965 (1995); Dedman et al., 267 J. BIOL. CHEM. 23025-30 (1993); Adey & Kay, 169 GENE 133-34 (1996).
integrins (linear, cyclized)	tumor-homing; treatment for conditions related to integrin-mediated cellular	International patent applications WO 95/14714, published June 1, 1995; WO 97/08203, published March 6, 1997; WO

	events, including platelet aggregation, thrombosis, wound healing, osteoporosis, tissue repair, angiogenesis (e.g., for treatment of cancer) and tumor invasion ("integrin-binding")	98/10795, published March 19, 1998; WO 99/24462, published May 20, 1999; Kraft et al., 274 J. BIOL. CHEM. 1979-85 (1999).
fibronectin and extracellular matrix components of T-cells and macrophages (cyclic, linear)	treatment of inflammatory and autoimmune conditions	International patent application WO 98/09985, published March 12, 1998.
somatostatin and cortistatin (linear)	treatment or prevention of hormone-producing tumors, acromegaly, gigantism, dementia, gastric ulcer, tumor growth, inhibition of hormone secretion, modulation of sleep or neural activity	European patent application EP 0 911 393, published Apr. 28, 1999.
bacterial lipopoly-saccharide (linear)	antibiotic; septic shock; disorders modulatable by CAP37	U.S. Pat. No. 5,877,151, issued March 2, 1999.
parclaxin, mellitin (linear or cyclic)	antipathogenic	International patent application WO 97/31019, published 28 August 1997.
VIP (linear, cyclic)	impotence, neuro-degenerative disorders	International patent application WO 97/40070, published October 30, 1997.
CTLs (linear)	cancer	European patent application EP 0 770 624, published May 2, 1997.
THF-gamma2 (linear)		Burnstein, 27 BIOCHEM. 4066-71 (1988).
Amylin (linear)		Cooper, 84 PNAS 8628-32 (1987).
Adreno-medullin (linear)		Kitamura, 192 BBRC 553-60 (1993).
VEGF (cyclic, linear)	anti-angiogenic; cancer, rheumatoid arthritis, diabetic retinopathy, psoriasis ("VEGF antagonist")	Fairbrother, 37 BIOCHEM. 17754-64 (1998).
MMP (cyclic)	inflammation and autoimmune disorders; tumor growth ("MMP inhibitor")	Koivunen, 17 NATURE BIOTECH. 768-74 (1999).
HGH fragment (linear)		U.S. Pat. No. 5,869,452, issued Feb. 9, 1999.
Echistatin	inhibition of platelet aggregation	Gan, 263 J. BIOL. 19827-32 (1988).
SLE autoantibody (linear)	SLE	International patent application WO 96/30057, published Oct. 3, 1996.
GD1 alpha	suppression of tumor metastasis	Ishikawa et al., 1 FEBS LETT. 20-4 (1998).
anti-phospholipid β -2 glycoprotein-1 (β 2GPI)	endothelial cell activation, anti-phospholipid syndrome (APS), thromboembolic	Blank Mal., 96 PNAS 5164-8 (1999).

antibodies	phenomena, thrombocytopenia, and recurrent fetal loss	
T-Cell Receptor β chain (linear)	diabetes	International patent application WO 96/101214, published Apr. 18, 1996.

IX. Database Creation, Database Access, And Business Methods

The business methods of the present application relate to the commercial and other uses of the methodologies of the present invention. In one aspect, the business methods include the marketing, sale, or licensing of the present methodologies in the context of providing consumers, *i.e.*, patients, medical practitioners, medical service providers, and pharmaceutical distributors and manufacturers, with the gene expression profiles, high information density gene expression profiles, and/or protein expression profiles provided by the present invention.

Furthermore, the present invention also relates to business methods in which gene expression profiles, high information density gene expression profiles, and/or protein expression profiles are used for analyzing test samples (*e.g.*, patient samples). In a specific embodiment, this method may be accomplished using the gene expression profile microarrays of the present invention. For example, a user (*e.g.*, a health practitioner such as a physician) may obtain a sample (*e.g.*, blood, tissue biopsy) from a patient. The sample may be prepared in-house, for example, using hospital facilities or the sample may be sent to a commercial laboratory facility. Briefly, RNA is extracted from the patient sample using methods that are well-known in the art. *See e.g.*, SAMBROOK ET AL. (1989). The RNA is, for example, then amplified by PCR, labeled with a fluorophore, and hybridized to a support representing a particular gene expression profile. The support is scanned for fluorescence and the results of the scan may be sent to a central gene expression profile database for analysis. In another embodiment, the sample itself is sent to a central laboratory facility for scanning analysis. The scanning results may be sent to the central laboratory facility for analysis via a computer terminal and through the Internet or other means. The connection between the user and the computer system is preferably secure.

In practice, the user may input, for example, information relating to the fluorescence scanning results of the support as well as additional information concerning the patient such as the patient's disease state, clinical chemistry (*e.g.*, red blood cell count, electrolytes), and other factors relating to the patient's disease state. The central computer system may then,

through the use of resident computer programs, provide an analysis of the patient's sample and generate a gene expression profile reflecting the patient's genetic profile.

Those skilled in the art will appreciate that the methods and apparatus of the present invention apply to any computer system, regardless of whether the computer system is a
5 complicated multi-user computing apparatus or a single user device such as a personal computer or workstation. A computer system suitably comprises a processor, main memory, a memory controller, an auxiliary storage interface, and a terminal interface, all of which are interconnected. Note that various modifications, additions, substitutions, or deletions may be made to the computer system within the scope of the present invention such as the addition of
10 cache memory or other peripheral devices.

The processor performs computation and control functions of the computer system, and comprises a suitable central processing unit (CPU). The processor may comprise a single integrated circuit, such as a microprocessor, or may comprise any suitable number of integrated circuit devices and/or circuit boards working in cooperation to accomplish the
15 functions of a processor. The processor suitably executes the algorithms (*e.g.*, MaxCor, Mean Log Ratio) of the present invention within its main memory.

The main memory of the computer systems of the present invention suitably contains one or more computer programs relating to the algorithms used to generate the gene expression profiles and an operating system. The term "computer program" is used in its
20 broadest sense, and includes any and all forms of computer programs, including source code, intermediate code, machine code, and any other representation of a computer program. The term "memory," as used herein, refers to any storage location in the virtual memory space of the system. It should be understood that portions of the computer program and operating system may be loaded into an instruction cache for the main processor to execute, while other
25 files may well be stored on magnetic or optical disk storage devices. In addition, it is to be understood that the main memory may comprise disparate memory locations.

The computer systems of the present invention may also comprise a memory controller, through use of a separate processor, which is responsible for moving requested information from the main memory and/or through the auxiliary storage interface to the main
30 processor. While for the purposes of explanation, the memory controller is described as a separate entity, those skilled in the art understand that, in practice, portions of the function provided by the memory controller may actually reside in the circuitry associated with the main processor, main memory, and/or the auxiliary storage interface.

In a preferred embodiment, the auxiliary storage interface allows the computer system to store and retrieve information from auxiliary storage devices, such as magnetic disks (*e.g.*, hard disks or floppy diskettes) or optical storage devices (*e.g.*, CD-ROM). One suitable storage device is a direct access storage device (DASD). A DASD may be a floppy disk drive, which may read programs and data from a floppy disk. It is important to note that while the present invention has been (and will continue to be) described in the context of a fully functional computer system, those skilled in the art will appreciate that the mechanisms of the present invention are capable of being distributed as a program product in a variety of forms, and that the present invention applies equally regardless of the particular type of signal bearing media to actually carry out the distribution. Examples of signal bearing media include: recordable type media such as floppy disks and CD ROMS, and transmission type media such as digital and analog communication links, including wireless communication links.

Furthermore, the computer systems of the present invention may comprise a terminal interface that allows system administrators and computer programmers to communicate with the computer system, normally through programmable workstations. It should be understood that the present invention applies equally to computer systems having multiple processors and multiple system buses. Similarly, although the system bus of the preferred embodiment is a typical hardwired, multidrop bus, any connection means that supports bidirectional communication in a computer-related environment could be used.

The gene expression profile database, high information density gene expression profile database, and/or protein expression profiles may be an internal database designed to include annotation information about the expression profiles generated by the methods of the present invention and through other sources and methods. Such information may include, for example, the databases in which a given nucleic acid or protein amino acid sequence was found, patient information associated with the expression profile, including age, cancer or tumor type or progression, descriptive information about related cDNA associated with the sequence, tissue or cell source, sequence data obtained from external sources, treatment information, diagnostic and prognostic information, information regarding gene expression and/or protein expression in response to various stimuli, expression profiles for a given gene, high information density gene, and/or protein and the related disease state or course of disease, for example whether the expression profile relates to or signifies a cancerous or pre-cancerous state, and preparation methods. The expression profiles may be based on protein

and/or nucleic acid microarray data obtained from publicly available or proprietary sources. The database may be divided into two sections: one for storing the sequences and related expression profiles and the other for storing the associated information. This database may be maintained as a private database with a firewall within the central computer facility.

- 5 However, this invention is not so limited and the expression profile databases may be made available to the public.

The database may be a network system connecting the network server with clients. The network may be any one of a number of conventional network systems, including a local area network (LAN) or a wide area network (WAN), as is known in the art (*e.g.*, Ethernet).

- 10 The server may include software to access database information for processing user requests, and to provide an interface for serving information to client machines. The server may support the World Wide Web and maintain a website and Web browser for client use. Client/server environments, database servers, and networks are well documented in the technical, trade, and patent literature.

- 15 Through a Web browser, clients may construct search requests for retrieving data from a microarray database, a gene expression database, and/or protein expression database. For example, the user may "point and click" to user interface elements such as buttons, pull down menus, and scroll bars. The client requests may be transmitted to a Web application which formats them to produce a query that may be used to gather information from the
- 20 system database, based, for example, on microarray or expression data obtained by the client, and/or other phenotypic or genotypic information. For example, the client may submit expression data based on microarray expression profiles obtained from a patient and use the system of the present invention to obtain a diagnosis based on a comparison by the system of the client expression data with the expression data contained in the database. By way of
- 25 example, the system compares the expression profiles submitted by the client with expression profiles contained in the database and then provides the client with diagnostic information based on the best match of the client expression profiles with the database profiles. In addition, the website may provide hypertext links to public databases such as GenBank and associated databases maintained by the National Center for Biotechnology Information
- 30 (NCBI), part of the National Library of Medicine as well as any links providing relevant information for gene expression analysis, protein expression analysis, genetic disorders, scientific literature, and the like. Information including, but not limited to, identifiers, identifier types, biomolecular sequences, common cluster identifiers (GenBank, Unigene,

Incyte template identifiers, and so forth) and species names associated with each gene, is contemplated.

The present invention also provides a system for accessing bioinformation, including gene expression profiles, high information density gene expression profiles, protein
5 expression profiles, and annotative information, which is useful in the context of the methods of the present invention. The present invention contemplates, in one embodiment, the use of a Graphical User Interface ("GUI") for the access of gene expression profile information stored in a database. In a preferred embodiment, the GUI may be composed of two frames. A first frame may contain a selectable list of databases accessible by the user. When a
10 database is selected in the first frame, a second frame may display information resulting from the pair-wise comparison of the expression profile database with the client-supplied expression profile as described above, along with any other phenotypic or genotypic information.

The second frame of the GUI may contain a listing of biomolecular sequence
15 expression information and profiles contained in the selected database. Furthermore, the second frame may allow the user to select a subset, including all of the biomolecular sequences, and to perform an operation on the list of biomolecular sequences. In a preferred embodiment, the user may select the subset of biomolecular sequences by selecting a selection box associated with each biomolecular sequence. In a preferred embodiment, the
20 operations that may be performed include, but are not limited to, downloading all listed biomolecular sequences to a database spreadsheet with classification information, saving the selected subset of biomolecular sequences to a user file, downloading all listed biomolecular sequences to a database spreadsheet without classification information, and displaying classification information on a selected subset of biomolecular sequences.

25 If the user chooses to display classification information on a selected subset of biomolecular sequences, a second GUI may be presented to the user. In one embodiment, the second GUI may contain a listing of one or more external databases used to create the high information density gene expression profile databases as described above. Furthermore, for each external database, the GUI may display a list of one or more fields associated with each
30 external database. In another embodiment, the GUI may allow the user to select or deselect each of the one or more fields displayed in the second GUI. In yet another embodiment, the GUI may allow the user to select or deselect each of the one or more external databases.

In another embodiment, the business methods of the present invention include establishing a distribution system for distributing diagnostic of the present invention for sale, and may optionally include establishing a sales group for marketing the diagnostics. Yet another aspect of the present invention provides a method of conducting a target discovery business comprising identifying, by one or more of the above drug discovery methods, a test compound, as described above, which modulates the level of expression of a gene, a high information density gene, the activity of the gene product, or the activity of the high information density gene product; and optionally conducting therapeutic profiling of compounds identified, or further analogs thereof, for efficacy and toxicity in animals; and optionally licensing or selling, the rights for further drug development of said identified compounds.

Another embodiment of the present invention comprises a variety of business methods including methods for screening drug and toxicity effects on tissue or cell samples. A further aspect of the present invention comprises business methods for providing gene expression profiles, high information density gene expression profiles, and/or protein expression profiles for normal and diseased tissues. Also within the scope of this invention are business methods providing diagnostics and predictors for patient samples.

A further aspect of the present invention comprises business methods for the manufacturing and use of gene microarrays, high information density gene microarrays, and protein microarrays. The business methods further relate to providing information generated by using gene microarrays, gene expression profiles, high information density genes, high information density gene microarrays, high information density gene expression profiles, protein microarrays and protein expression microarrays.

The present invention also provides a business method for determining whether a patient has a disease or disorder associated with the overexpression and/or upregulation of a gene, or a pre-disposition to such a disease or disorder. This method comprises the steps of receiving information related to a gene or protein (e.g., sequence information and/or information related thereto), receiving phenotypic and/or genotypic information associated with the patient, and acquiring information from the databases of the present invention related to the gene or protein and/or related to such a gene- or protein-associated disease or disorder, such as cancer and specifically colon cancer. Based on one or more of the phenotypic and/or genotypic information, the gene or protein information, and the acquired information, this method may further comprise the step of determining whether the subject has a disease or

disorder associated with a gene or protein, and specifically a gene or protein of the present invention, or a pre-disposition to such a gene-or protein-associated disease or disorder. The method may also comprise the step of recommending a particular treatment for the disease, disorder or pre-disease condition. Similarly, the present invention contemplates business methods as described above using, for example, high information density genes or proteins.

In one embodiment, the present invention contemplates a business method for determining whether a patient has a cellular proliferation, growth, differentiation, and/or migration disorder or a pre-disposition to a cellular proliferation, growth, differentiation, and/or migration disorder and specifically a cancerous or pre-cancerous state. This method comprises the steps of receiving information related to, *e.g.*, sequence information of a gene or protein of the present invention and/or information related thereto, receiving phenotypic information associated with the patient, acquiring information from the network related to, *e.g.*, sequence information of a gene or protein and/or information related thereto, and/or related to a cellular proliferation, growth, differentiation, and/or migration disorder and specifically a cancerous or pre-cancerous state. Based on one or more of the phenotypic and/or genotypic information, the sequence information and/or information related thereto, and the acquired information this method may further comprise the step of determining whether the patient has a cellular proliferation, growth, differentiation, and/or migration disorder or a pre-disposition to a cellular proliferation, growth, differentiation, and/or migration disorder and specifically a cancerous or pre-cancerous state. The method may also comprise the step of recommending a particular treatment for the disease, disorder or pre-disease condition. Similarly, the present invention contemplates business methods as described above using, for example, high information density genes or proteins.

Without further elaboration, it is believed that one skilled in the art, using the preceding description, can utilize the present invention to the fullest extent. The following examples are illustrative only, and not limiting of the remainder of the disclosure in any way whatsoever.

EXAMPLES

Example 1: Cell-Specific Gene Expression Analysis

By integrating laser capture microdissection, RNA amplification, and cDNA microarray technology, diverse cell types obtained *in situ* may be successfully screened and subsequently identified by differential gene expression. To demonstrate this integration of

technologies, the differential gene expressions of large and small-sized neurons in the dorsal root ganglia (DRG) were examined. In general, large DRG are myelinated, fast-conducting neurons that transmit mechanosensory information, and small DRG neurons are unmyelinated, slow-conducting, and transmit nociceptive information.

5 As shown in Figure 1, large (diameter $>40\mu\text{m}$) and small (diameter $<25\mu\text{m}$) neurons were cleanly and individually captured via LCM from $10\mu\text{m}$ sections of Nissl-stained rat DRGs. For this study, two sets of 1000 large neurons and 3 sets of 1000 small neurons were captured for cDNA microarray analysis.

RNA was extracted from each set of neurons and linearly amplified an estimated 10^6 -
10 fold via T7 RNA polymerase. Once amplified, three fluorescently labeled probes were synthesized from an individually amplified RNA (aRNA) and hybridized in triplicate to a microarray (or "chip") containing 477 cDNAs and 30 cDNAs encoding plant genes (for determination of non-specific nucleic acid hybridization). Expression in each neuronal set (designated as S1, S2, and S3 for small DRG neurons and L1 and L2 for large DRG neurons)
15 was monitored in triplicate, requiring a total of 15 microarrays. The quality of the microarray data is demonstrated in Figure 2a, which shows pseudocolor arrays, one resulting from hybridization to probes derived from neuronal set S1 and the other from neuronal set L2. The enlarged section of the chip displays some differences in fluorescence intensity (*i.e.*, expression levels) for particular cDNAs and demonstrates that regions containing different
20 cDNAs are relatively uniform in size and that the background between these regions is relatively low.

To determine whether a signal corresponding to a particular cDNA is reproducible between different chips, for each neuronal set, the coefficient of variation (CV) was calculated. From these values, the overall average CV for all 477 cDNAs per neuronal set
25 was calculated to be: S1 = 15.81%, S2 = 16.93%, S3 = 17.75%, L1 = 20.17 %, and L2 = 19.55%.

Independent amplifications ($\sim 10^6$ -fold) of different sets of the same neuronal subtype yielded quite similar expression patterns. For example, the correlation of signal intensities between S1 vs. S2 was $R^2 = 0.9688$, and between S1 vs. S3 was $R^2 = 0.9399$ (Figure 2b).
30 Similar results were obtained between the two sets of large neurons: $R^2 = 0.929$ for L1 vs. L2 (Figure 2b). Conversely, a comparison between all three small neuronal sets (S1, S2, and S3) versus the two large sets (L1 and L2) yielded a much lower correlation ($R^2 = 0.6789$),

demonstrating as expected that a subgroup of genes are differentially expressed in each of the two neuronal subtypes (Figure 2b).

To identify the mRNAs that are differentially expressed in large and small DRG neurons, the 477 cDNAs were examined and those with 1.5-fold or greater differences (at $P < 0.05$) were sequenced. Twenty-seven mRNAs appeared to be preferentially expressed in small DRG neurons and 14 mRNAs were preferentially expressed in large DRG (Figure 3 and Figure 4). To confirm the observed differential gene expression, *in situ* hybridization was performed with a subgroup of these cDNAs.

For the small neurons, five mRNAs were examined that encoded the following: fatty acid binding protein, sodium voltage-gated channel (NaN), phospholipase C delta-4, CGRP, and annexin V. For the large DRG neurons, three mRNAs were examined: neurofilament NF-L, neurofilament NF-H, and the beta-1 subunit of voltage-gated sodium channels. Based on quantitative measurements comparing the overall intensity of signal in small and large neurons and the percentage of cells labeled within the total population of either small or large neurons, the preferential expression of these mRNAs was demonstrated in large and small DRG neurons (Figure 5 and Figure 6).

Although this study identified preferentially expressed mRNAs within large and small DRG neurons, there is a great deal more heterogeneity within DRG neurons beyond simply small and large. For example, small DRG neurons are unmyelinated, slow-conducting, and transmit nociceptive information; whereas large DRG are myelinated, fast-conducting neurons that transmit mechanosensory information. These structural and functional differences would presumably be reflected in a heterogeneous gene expression. To address this more complicated genetic heterogeneity, immunocytochemistry may be coupled with LCM followed by RNA amplification and cDNA chip analysis as a means to further differentiate cell types within large and small DRG. In addition, chips containing a larger number of cDNAs (*i.e.*, >10,000) can be constructed to more accurately identify the differential gene expression between large and small neurons.

The results shown herein demonstrate that expression profiles generated via these methods may not only be useful for screening cDNAs, but also, more importantly, to produce databases that contain cell type specific gene expression profile. Cell type specificity within a database will give an investigator much greater leverage in understanding the contributions of individual cell types to a particular normal or disease state and thus allow for a much finer hypotheses to be subsequently generated. Furthermore, genes, which are coordinately

expressed within a given cell type, can be identified as the database grows to contain numerous gene expression profiles from a variety of cell types (or neuronal subtypes). Coordinate gene expression may also suggest functional coupling between the encoded proteins and therefore aid in determining the function for the vast majority of cDNAs currently cloned.

Laser Capture Microdissection (LCM). Two adult female Sprague Dawley rats were used in this study. Animals were anesthetized with Metofane (Methoxyflurane, Cat# 556850, Mallinckrodt Veterinary Inc. Mundelein, IL) and sacrificed by decapitation. Using RNase-free conditions, cervical dorsal root ganglia (DRGs) were quickly dissected, placed in cryomolds, covered with frozen-tissue embedding medium OCT (Tissue-Tek, GBI, Inc., Clearwater, MN), and frozen in dry ice-cold 2-methylbutane ($\sim -60^{\circ}\text{C}$). The DRGs were then sectioned at 7-10 μm in a cryostat, mounted on plain (non-coated) clean microscope slides, and immediately frozen on a block of dry ice. The sections were stored at -70°C until further use.

A quick Nissl (cresyl violet acetate) staining was employed in order to identify the DRG neurons. Slides containing DRG sections were loaded onto a slide holder, immediately fixed in 100% ethanol for 1 minute followed by rehydration via subsequent immersions (5 seconds each) in 95%, 70%, and 50% ethanol diluted in RNase-free deionized water. Next, the slides were stained with 0.5% Nissl/0.1 M sodium acetate buffer for 1 minute, dehydrated in graded ethanol (5 seconds each), and cleared in xylene (1 minute). Once air-dried, the slides were ready for LCM.

The PixCell II LCMTM System from Acturus Engineering Inc. (Mountain View, CA) was used for laser-capture. Following manufacture's protocols, 2 sets of large and 3 sets small DRG neurons (1000 cells per set) were laser-captured. The criteria for large and small DRG neurons are as follows: a DRG neuron was classified as small if it had a diameter $<25 \mu\text{m}$ plus an identifiable nucleus whereas a DRG neuron with a diameter $>40 \mu\text{m}$ plus an identifiable nucleus was classified as large.

RNA extraction of LCM samples. Total RNA was extracted from the LCM samples with Micro RNA Isolation Kit (Stratagene, San Diego, CA) with some modifications. Briefly, after incubating the LCM samples in 200 μl denaturing buffer and 1.6 μl β -Mercaptoethanol at room temperature for 5 minutes, the LCM samples were extracted with 20 μl of 2 M sodium acetate, 220 μl phenol, and 40 μl chloroform:isoamyl alcohol. The

aqueous layer was collected, mixed with 1 µl of 10 mg/ml carrier glycogen, and then precipitated with 200 µl of isopropanol. Following a 70% ethanol wash and air-dry, the pellets were resuspended in 16 µl of RNase-free water, 2 µl 10x DNase I reaction buffer, 1 µl RNasin, and 1 µl of DNase I, then incubated at 37°C for 30 minutes to remove any genomic DNA contamination. The phenol-chloroform extraction was repeated. The pellet was resuspend in 11 µl of RNase-free water and used for RT-PCR and RNA amplification.

Reverse transcription (RT) of RNA. First stand synthesis was completed by adding 10 µl of RNA isolated from the LCM samples and 1 µl of 0.5 mg/ml T7-oligo dT primer (5'TCTAGTCGACGGCCAGTGAATTGTAATACGACTCACTATAGGGCGT₂₁-3'). The primer/RNA mix was incubated for 10 minutes at 70°C, followed by a 5-minute incubation at 42°C. Next, 4 µl 5x first strand reaction buffer, 2 µl 0.1 M DTT, 1 µl 10 mM dNTPs, 1 µl RNasin, and 1 µl Superscript II (Invitrogen, Carlsbad, CA) were added to the mix and incubated at 42°C for one hour. Following this incubation, 30 µl second strand synthesis buffer, 3 µl 10 mM dNTPs, 4 µl DNA Polymerase I, 1 µl *E. coli* RNase H, 1 µl *E. coli* DNA ligase, and 92 µl RNase-free water were added and samples were incubated at 16°C for 2 hours. T4 DNA Polymerase (2 µl) was then added to each sample and samples were incubated for 10 minutes at 16°C. The cDNA was then extracted by the phenol-chloroform method and washed 3x with 500 µl water in a Microcon-100 column (Millipore Corp., Bedford, MA). After collection from the column, the cDNA was dried to a final volume of 8 µl for *in vitro* transcription.

RNA amplification. The *Ampliscribe* T7 Transcription Kit (Epicentre Technologies) was used to amplify RNA. In a microfuge tube, 8 µl double-stranded cDNA; 2 µl of 10x *Ampliscribe* T7 buffer; 1.5 µl of each 100 mM ATP, CTP, GTP, and UTP; 2 µl 0.1 M DTT; and 2 µl T7 RNA Polymerase was added and then incubated at 42°C for 3 hours. The amplified RNA (aRNA) was washed 3x in a Microcon-100 column, collected, and dried to a final volume of 10 µl.

Amplified RNA (10 µl) from the first round amplification was mixed with 1 µl random hexamers (1 mg/ml, Pharmacia Corp., Piscataway, NJ), incubated for 10 minutes at 70°C, chilled on ice, and then equilibrated at room temperature for 10 minutes. For the initial reaction, 4 µl 5x first stand buffer, 2 µl 0.1 M DTT, 1 µl 10mM dNTPs, 1 µl RNasin, and 1 µl Superscript RT II were added to the aRNA mix, and then incubated at room temperature

for 5 minutes followed by a 1-hour incubation at 37°C. Following the 1-hour incubation, 1 µl RNase H was added and the sample was incubated at 37°C for 20 minutes. For second strand cDNA synthesis, 1 µl T7-oligo dT primer (0.5 mg/ml) was added to the aRNA reaction mix and the sample was incubated at 70°C for 5 minutes, then for 10 minutes at 42°C.

- 5 Following this incubation, 30 µl second strand synthesis buffer, 3 µl 10 mM dNTPs, 4 µl DNA Polymerase I, 1 µl *E. coli* RNase H, 1 µl *E. coli* DNA ligase, and 90 µl of RNase-free water were added to the sample mix and the sample was then incubated at 37°C for 2 hours. T4 DNA Polymerase (2 µl) was then added and the sample was incubated for 10 minutes at 16°C. The double-stranded cDNA was extracted with 150 µl phenol/chloroform to remove
10 extraneous protein and purified with Microcon-100 column to remove the unincorporated nucleotides and salts. The cDNA can be used for T7 *in vitro* transcription and aRNA amplification.

- In situ Hybridization.*** Briefly, cDNAs were subcloned into pBluescript II SK (Stratagene). The cDNA vectors were then linearized and radiolabeled by ³⁵S-UTP
15 incorporation via *in vitro* transcription with T7 or T3 RNA polymerase. The probes were then purified with Quick Spin™ Columns (Boehringer Mannheim, Indianapolis, IN). The radiolabeled probes (10⁷ cpm/probe) were hybridized to rat DRG sections (10 µm, 4% paraformaldehyde-fixed) which were mounted on Superfrost Plus slides (VWR). Following an overnight hybridization at 58°C, the slides were exposed to film. Subsequently, the slides
20 were coated with Kodak liquid emulsion NTB2 and exposed in light-proof boxes for 1-2 weeks at 4°C. The slides were developed in Kodak Developer D-19, fixed in Kodak Fixer, and Nissl stained for expression analysis.

- Under light field microscopy, mRNA expression levels of specific cDNAs were semi-quantitatively analyzed. This was accomplished as follows: no expression (-, grains were <5-
25 fold of the background); weak expression (±, grains were 5- to 10-fold of the background); low expression (+, grains were 10- to 20-fold of the background); moderated expression (++ , grains were 20- to 30-fold of the background); and strong expression (+++ , grains were >30-fold of the background) (Figure 6). The percentage of small or large neurons expressing a specific mRNA was obtained by counting the number of labeled (above background) and
30 unlabeled cells from four sections (at least 200 cells were counted).

Microarray design. The 477 cDNA clones, obtained from two separate differential display experiments, were printed on silylated slides. The print spots were about 125 µm in

diameter and were spaced 300 μm apart from center to center. Plant genes were also printed on the slides to serve as a control for non-specific hybridization.

Microarray probe synthesis. Cy3-labeled cDNA probes were synthesized from aRNA isolated from LCM DRGs with Superscript Choice System for cDNA Synthesis (Invitrogen Corp., Carlsbad, CA). In brief, 5 μg aRNA and 3 μg random hexamers were mixed in a total volume of 26 μl (containing RNase-free water), heated to 70°C for 10 minutes, and then chilled on ice. For the labeling reaction, 10 μl first strand buffer, 5 μl 0.1 M DTT, 1.5 μl Rnasin, 1 μl 25 mM d(GAT)TP, 2 μl 1mM dCTP, 2 μl Cy3-dCTP, and 2.5 μl Superscript RT II were added to the aRNA mix and incubated at room temperature for 10 minutes, and then for 2 hours at 37°C. To degrade the aRNA template, 6 μl 3N NaOH was added and the sample was incubated at 65°C for 30 minutes. Following this incubation, 20 μl 1M Tris-HCl (pH 7.4), 12 μl 1N HCl, and 12 μl water were added. The probes were purified with Microcon 30 Columns (Millipore Corp., Bedford, MA) and Qiagen Nucleotide Removal Columns (Qiagen Corp., Valencia, CA). The probes were vacuum-dried and resuspended in 20 μl of hybridization buffer (5x SSC, 0.2% SDS) containing mouse Cot1 DNA.

Microarray hybridization. Printed glass slides were treated with sodium borohydride solution (0.066 M NaBH₄, 0.06 M NaCl) to ensure amino-linkage of cDNAs to the slides. Then, the slides were boiled in water for 2 minutes to denature the cDNA. Cy3-labeled probes were heated to 99°C for 5 minutes, cooled to room temperature for 5 minutes, and then applied to the slides. The slides were covered with glass cover slips, sealed with DPX (Fluka) and hybridized at 60°C for 4-6 hours. At the end of hybridization, the slides were cooled to room temperature. The slides were first washed in 1x SSC and 0.2% SDS at 55°C for 5 minutes, and then washed in 0.1x SSC and 0.2% SDS for 5 minutes at 55°C. After a quick rinse in 0.1x SSC and 0.2% SDS, the slides were air dried and ready for scanning.

Microarray quantitation. The cDNA microarrays were scanned for Cy3 fluorescence using the ScanArray 3000 (General Scanning, Inc., Watertown, MA). ImaGene Software (Biodiscovery, Inc., Marina Del Ray, CA) was then subsequently used for quantitation. Briefly, the intensity of each spot (*i.e.*, cDNA) was corrected by subtracting the immediate surrounding background. Next, the corrected intensities were normalized for each cDNA with the following formula:

$$\frac{\text{intensity (background corrected)}}{75^{\text{th}}\text{-percentile value of the intensity of the entire chip}} \times 1000$$

To determine “non-specific” nucleic acid hybridization, 75th-percentile values were calculated from the individual averages of each plant cDNA (for a total of 30 different cDNAs). The overall 75-percentile value for S1, S2, and S3 was 48.68, and for L1 and L2 was 40.94.

Statistical analyses. To assess the correlation of intensity value for each cDNA between individual sets of neurons (*i.e.*, S1 vs. S2) or between two neuronal subtypes (*i.e.*, small DRG vs. large DRG), scatter plots were used and the linear relationships were measured. The coefficient of determination (R^2) was calculated and indicated the variability of intensity values in one group vs. the other.

To statistically determine whether the intensity values measured from microarray quantitation were true signals, each intensity was compared, via a one-sample *t*-test, to the 75th-percentile value of the 30 plant cDNAs that were present on each chip (representing non-specific nucleic acid hybridization). Values not significantly different from the 75-percentile value are presented in Figure 3 and Figure 4 and so noted. To determine which cDNAs are statistically significant in their differential gene expression between large and small neurons, the intensity for each cDNA from neuronal sets for large neurons (L1 and L2) and small neurons (S1, S2, and S3) were grouped together and intensity values were averaged for each corresponding cDNA. A two-sample *t*-test for one-tailed hypotheses was used to detect a gene expression difference between small neurons and large neurons.

Example 2: Algorithms To Produce Gene Or Protein Expression Profiles

Each cell or tumor type in any given state or age has a unique gene expression pattern that distinguishes it from other tissues or cells. Using profile extraction algorithms, the gene expression profiles from many different cell types may be extracted to create a profile database. Thus, in the broadest sense, unknown samples can then be identified by comparing its profile against such a database.

To create such a database, tissue or cell samples may be divided into classifying groups (*i.e.*, tumor vs. normal; endothelial vs. muscle, etc.). This can be done either manually or if the groups are unknown, by using a clustering algorithm such as k-means. The gene expression data is transformed into a log-ratio value, and the genes with weak

differential values are filtered from the data. The gene expression profiles are then extracted using the MaxCor or Mean Log Ratio algorithms of the present invention.

For an unknown sample, it may be necessary to transform the gene expression data of the sample prior to scoring against the expression profiles. The type of data transformation may depend on the profile extraction algorithm used (*i.e.*, MaxCor or Mean Log Ratio). The sample expression data is then scored against the profile database. A high score indicates that the unknown sample contains or is related to the sample from which the profile was derived. However, the most accurate scoring function will depend on the profile extraction algorithm used to extract the gene expression data.

Preparation of data for profile extraction. First, a reference gene expression vector is constructed where A, B, ... Z denote the groups of samples (*e.g.*, tumor tissue or smooth muscle cell) that will be differentiated and *a, b, ... z* denote the number of samples within each group, respectively. As an example, the notation A_{21} represents the expression intensity from the 2nd gene in sample 1 of group A. If each sample was hybridized to a DNA chip with size n genes, then the following matrices represent expression data from all of the groups A, B, ... Z, respectively.

$$\begin{bmatrix} A_{11} & A_{12} & \cdots & A_{1a} \\ A_{21} & A_{22} & \cdots & A_{2a} \\ \vdots & \cdots & \ddots & \vdots \\ A_{n1} & A_{n2} & \cdots & A_{na} \end{bmatrix} \begin{bmatrix} B_{11} & B_{12} & \cdots & B_{1b} \\ B_{21} & B_{22} & \cdots & B_{2b} \\ \vdots & \cdots & \ddots & \vdots \\ B_{n1} & B_{n2} & \cdots & B_{nb} \end{bmatrix} \cdots \begin{bmatrix} Z_{11} & Z_{12} & \cdots & Z_{1z} \\ Z_{21} & Z_{22} & \cdots & Z_{2z} \\ \vdots & \cdots & \ddots & \vdots \\ Z_{n1} & Z_{n2} & \cdots & Z_{nz} \end{bmatrix}$$

The geometric mean expression value is calculated for each gene in each matrix.

Thus, $A_{1(\text{geomean})}$ is the geometric mean of set $(A_{11} \ A_{12} \ \dots \ A_{1a})$ where A_1 denotes gene 1 in group A.

$$\begin{bmatrix} A_{1(\text{geomean})} \\ A_{2(\text{geomean})} \\ \vdots \\ A_{n(\text{geomean})} \end{bmatrix} \begin{bmatrix} B_{1(\text{geomean})} \\ B_{2(\text{geomean})} \\ \vdots \\ B_{n(\text{geomean})} \end{bmatrix} \cdots \begin{bmatrix} Z_{1(\text{geomean})} \\ Z_{2(\text{geomean})} \\ \vdots \\ Z_{n(\text{geomean})} \end{bmatrix}$$

The reference gene expression vector is simply the geometric mean of those vectors:

$$\begin{bmatrix} \bar{X}_1 \\ \bar{X}_2 \\ \vdots \\ \bar{X}_n \end{bmatrix} \text{ where } \bar{X}_1 \text{ is the geometric mean of } \{A_{1(\text{geomean})} \ B_{1(\text{geomean})} \ \cdots \ Z_{1(\text{geomean})}\}$$

- 5 The original data set is then transformed by taking the log of the ratio relative to the reference gene expression value for each gene creating the matrices $\{A' \ B' \ \dots \ Z'\}$ where $A'_{11} = \ln(A_{11} / \bar{X}_1)$ and $Z'_{nz} = \ln(Z_{nz} / \bar{X}_n)$. The values now represent the fold increase or decrease over the average for each gene.

$$10 \quad \begin{bmatrix} A'_{11} & A'_{12} & \cdots & A'_{1a} \\ A'_{21} & A'_{22} & \cdots & A'_{2a} \\ \vdots & \cdots & \ddots & \vdots \\ A'_{n1} & A'_{n2} & \cdots & A'_{na} \end{bmatrix} \begin{bmatrix} B'_{11} & B'_{12} & \cdots & B'_{1b} \\ B'_{21} & B'_{22} & \cdots & B'_{2b} \\ \vdots & \cdots & \ddots & \vdots \\ B'_{n1} & B'_{n2} & \cdots & B'_{nb} \end{bmatrix} \cdots \begin{bmatrix} Z'_{11} & Z'_{12} & \cdots & Z'_{1z} \\ Z'_{21} & Z'_{22} & \cdots & Z'_{2z} \\ \vdots & \cdots & \ddots & \vdots \\ Z'_{n1} & Z'_{n2} & \cdots & Z'_{nz} \end{bmatrix}$$

- The genes with a weak differentiation power are removed from the matrix. The Kruskal-Wallis rank test was used to rank the genes with the highest differentiation power for separating the groups, A, B, ... Z. A low p-value from the rank test indicates a high differentiation power. A p-value of 0.0025 was used as the cut-off value.

Finally, for each resulting matrix $\{A'' \ B'' \ \dots \ Z''\}$, apply a profile extraction algorithm to create a profile representing each group.

- Profile extraction using the MaxCor algorithm.** The MaxCor algorithm is applied to each group $\{A'' \ B'' \ \dots \ Z''\}$ separately. For each pair of columns in the matrix, the genes coordinately expressed in high, average, or low levels over the mean (defined below) are given a value (1, 0, or -1, respectively), producing a weight vector representing the pair. Thus, for matrix A'' , $\left(\frac{a(a-1)}{2}\right)$, pairwise calculations are performed to produce a weight vector representing the matrix pair. A final average weight vector which will be the profile for group A, is computed by averaging each weight vector calculated for matrix A'' . The

profile contains the same number of genes as A'' and its values should be within [-1 to 1]. These values, -1 and 1, represent the genes consistently expressed in low or high levels, respectively, relative to the mean of all groups. The MaxCor algorithm is applied to each group individually to produce a profile for each group.

5 **Value assignment for coordinately expressed genes.** For a pair of columns (c1 and c2), the values are normalized to create $c1'$ and $c2'$. Thus, $c1_i$ becomes $\left(\frac{c1_i - \bar{c1}}{S_{c1}}\right)$ where $\bar{c1}$ is the mean of column c1 and S_{c1} is the standard deviation. For each gene pair in $c1'$ and $c2'$, the normalized values are stored as vector $p12$ and then the $p12$ values are sorted from lowest to highest. A cutoff value is established, such as 0.5, and all genes with a greater normalized
10 value than the cutoff value are collected in $p12$. The Pearson correlation coefficient is calculated for this set of genes using the values in column c1 and c2. The cutoff value is then continually increased until the correlation coefficient is greater than a set value, such as 0.8. When this is complete, the set of genes meeting this criteria is assigned a value of 1 if both gene values in $c1'$ and $c2'$ are positive and -1 if both gene values are negative. For all other
15 genes in $c1'$ and $c2'$, a zero value is assigned. The resulting vector is a weight vector which represents the pair.

Sample scoring using the MaxCor algorithm. Before scoring a new sample, the genes in the sample S with weak differentiation values are removed so that the rows remaining are the same as those in the profile vectors, thus creating sample vector S'' . The
20 score is the sum of the normalized values for each gene in S'' and its weight in the profile vector. For example, the score between sample vector S'' and profile vector A^s is $\sum_{i=1-n} S''_i A^s_i$. The normalized score is (score - mean of randomized score)/(standard deviation of randomized score), where the randomized score is the score between S'' and the profile vector which has its gene positions randomized. Typically, 100 randomized scores are generated to
25 calculate the mean and the standard deviation.

Profile extraction using the Mean Log Ratio approach. This algorithm is also applied to each group or matrix $\{A'' B'' \dots Z''\}$ individually. For each matrix, the profile vector is the row mean of the matrix. Thus, the profile vectors for groups $\{A'' B'' \dots Z''\}$ are:

30

$$\begin{bmatrix} \overline{A_1''} \\ \overline{A_2''} \\ \vdots \\ \overline{A_n''} \end{bmatrix} \begin{bmatrix} \overline{B_1''} \\ \overline{B_2''} \\ \vdots \\ \overline{B_n''} \end{bmatrix} \dots \begin{bmatrix} \overline{Z_1''} \\ \overline{Z_2''} \\ \vdots \\ \overline{Z_n''} \end{bmatrix} \text{ where } \overline{A_1''} \text{ is the mean of } \{A_{11}'', A_{12}'', \dots, A_{1a}''\}.$$

Sample scoring using the Mean Log Ratio expression profiles. Prior to scoring a new sample, the gene expression vector of the sample is transformed by taking the log ratio relative to the reference gene expression vector for each gene. For example, the transformation of the sample S is:

$$S = \begin{bmatrix} S_1 \\ S_2 \\ \vdots \\ S_n \end{bmatrix} \text{ which leads to } S' = \begin{bmatrix} S'_1 \\ S'_2 \\ \vdots \\ S'_n \end{bmatrix}, \text{ where } S'_1 = \ln(S_1 / \overline{X_1}).$$

The genes with weak differentiation values are removed so the rows remaining are the same as those in the profile vectors, thus creating sample vector S'' . The score against each profile is then calculated by taking the Euclidean distance between S'' and the profile vector. The normalized score is (score – mean of randomized score)/(standard deviation of randomized score), where the randomized score is the Euclidean distance between S'' and the profile vector which has randomized gene positions. Typically, 100 randomized scores are generated to calculate the mean and the standard deviation.

Example 3: Gene Expression Profiles For Human Primary Cells

Gene expression profiles were collected from a set of human primary cells via DNA microarray technology. These gene expression profiles can then be used to classify unknown cell or tissue samples.

Thirty human primary cell samples were purchased from Clonetics Corporation (San Diego, CA). These primary cells were classified into the following categories: endothelial, epithelial, and muscle and also categorized based on the origin of tissue (Figure 7). Total RNA was extracted, amplified, and labeled with Cy5-dCTP as described in Example 1. The resultant labeled cDNAs were hybridized to microarray chips, which contain 7286 DNA

molecules representing 3643 unique genes each spotted twice. Each labeled cDNA probe was separated into two aliquots and each aliquot was hybridized to an identical microarray chip. Following a wash, the cDNA chips were scanned and the intensity of the spots was recorded and converted into a numerical value. To normalize the data, the spot intensities of each chip were divided by the intensity value of the 75th percentile of the chip, then these values were multiplied by 100. For each primary cell, a final gene intensity vector is produced by averaging four intensity values for each gene (2 spots per chip times 2 chips). The controls, low quality samples, and missing data values were removed, and 3940 genes were used for the final analysis.

Clustering analysis of the gene expression vectors of the primary cell samples confirmed that these samples could be classified into three groups: endothelial, epithelial, and muscle cell (Figure 8). A reference vector was generated, and the intensities were converted into a log ratio. A gene was filtered from the matrix if the p-value from the Kruskal-Wallis rank test was greater than 0.0025.

The resultant transformed matrix, composed of 459 genes from the 30 primary cell types, was then used for profile extraction using the Mean Log Ratio algorithm as described (Figure 9). Four expression profiles were generated, primary, endothelial, epithelial, and muscle (Figures 9, 10, 11, and 12). The primary profile represents 186 genes that may be used to classify primary cells. The endothelial profile represents 55 genes that may be used to classify endothelial cells. The epithelial profile represents 52 genes that may be used to classify epithelial cells. Finally, the muscle profile represents 40 genes that may be used to classify muscle cells. The sequence source (Seq. Source) is the gene database (GB: GenBank; and INCYTE: Incyte Genomes) that the sequence was selected from and the Seq ID is the accession number of the particular gene sequence. The endothelial, epithelial, and muscle profile values are the numeric representation of the specific profile. The p-value is based on the Kruskal-Wallis rank test in which smaller p-values represents clones with higher discriminate power for classifying samples. The source description identifies the particular gene.

These expression profiles are also shown graphically by assigning colors to the numeric values obtained (Figure 13). The expression profiles were then used to classify the 30 primary cells by taking each transformed primary cell gene expression vector and scoring it against the three expression profiles separately using the Mean Log Ratio scoring algorithm. The results demonstrated that the endothelial, epithelial, and muscle cell types

scored high against their own expression profiles but low against the other two expression profiles (Figure 14).

In additional experiments, a different primary cell sample was removed from the profile generation step and then scored against the resultant profile. The results from this analysis were similar to that in Figure 5 indicating that the expression profiles can be used to score against independent samples (Figure 15).

The analysis was repeated using the MaxCor algorithm as described. The self-validation results are shown in Figure 16 and the omit one analysis result in Figure 17. The results are essentially the same as that from the Mean Log Ratio analysis.

Figure 9 shows a gene expression profile for primary cells. Specifically, a primary cell gene expression profile may comprise one or more of the following nucleic acid sequences: SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; SEQ ID NO: 8; SEQ ID NO: 9; SEQ ID NO: 10; SEQ ID NO: 11; SEQ ID NO: 12; SEQ ID NO: 13; SEQ ID NO: 14; SEQ ID NO: 15; SEQ ID NO: 16; SEQ ID NO: 17; SEQ ID NO: 18; SEQ ID NO: 19; SEQ ID NO: 20; SEQ ID NO: 21; SEQ ID NO: 22; SEQ ID NO: 23; SEQ ID NO: 24; SEQ ID NO: 25; SEQ ID NO: 26; SEQ ID NO: 27; SEQ ID NO: 28; SEQ ID NO: 29; SEQ ID NO: 30; SEQ ID NO: 31; SEQ ID NO: 32; SEQ ID NO: 33; SEQ ID NO: 34; SEQ ID NO: 35; SEQ ID NO: 36; SEQ ID NO: 37; SEQ ID NO: 38; SEQ ID NO: 39; SEQ ID NO: 40; SEQ ID NO: 41; SEQ ID NO: 42; SEQ ID NO: 43; SEQ ID NO: 44; SEQ ID NO: 45; SEQ ID NO: 46; SEQ ID NO: 47; SEQ ID NO: 48; SEQ ID NO: 49; SEQ ID NO: 50; SEQ ID NO: 51; SEQ ID NO: 52; SEQ ID NO: 53; SEQ ID NO: 54; SEQ ID NO: 55; SEQ ID NO: 56; SEQ ID NO: 57; SEQ ID NO: 58; SEQ ID NO: 59; SEQ ID NO: 60; SEQ ID NO: 61; SEQ ID NO: 62; SEQ ID NO: 63; SEQ ID NO: 64; SEQ ID NO: 65; SEQ ID NO: 66; SEQ ID NO: 67; SEQ ID NO: 68; SEQ ID NO: 69; SEQ ID NO: 70; SEQ ID NO: 71; SEQ ID NO: 72; SEQ ID NO: 73; SEQ ID NO: 74; SEQ ID NO: 75; SEQ ID NO: 76; SEQ ID NO: 77; SEQ ID NO: 78; SEQ ID NO: 79; SEQ ID NO: 80; SEQ ID NO: 81; SEQ ID NO: 82; SEQ ID NO: 83; SEQ ID NO: 84; SEQ ID NO: 85; SEQ ID NO: 86; SEQ ID NO: 87; SEQ ID NO: 88; SEQ ID NO: 89; SEQ ID NO: 90; SEQ ID NO: 91; SEQ ID NO: 92; SEQ ID NO: 93; SEQ ID NO: 94; SEQ ID NO: 95; SEQ ID NO: 96; SEQ ID NO: 97; SEQ ID NO: 98; SEQ ID NO: 99; SEQ ID NO: 100; SEQ ID NO: 101; SEQ ID NO: 102; SEQ ID NO: 103; SEQ ID NO: 104; SEQ ID NO: 105; SEQ ID NO: 106; SEQ ID NO: 107; SEQ ID NO: 108; SEQ ID NO: 109; SEQ ID NO: 110; SEQ ID NO: 111; SEQ ID NO: 112; SEQ ID NO: 113; SEQ ID NO: 114; SEQ ID NO:

115; SEQ ID NO: 116; SEQ ID NO: 117; SEQ ID NO: 118; SEQ ID NO: 119; SEQ ID NO: 120; SEQ ID NO: 121; SEQ ID NO: 122; SEQ ID NO: 123; SEQ ID NO: 124; SEQ ID NO: 125; SEQ ID NO: 126; SEQ ID NO: 127; SEQ ID NO: 128; SEQ ID NO: 129; SEQ ID NO: 130; SEQ ID NO: 131; SEQ ID NO: 132; SEQ ID NO: 133; SEQ ID NO: 134; SEQ ID NO: 135; SEQ ID NO: 136; SEQ ID NO: 137; SEQ ID NO: 138; SEQ ID NO: 139; SEQ ID NO: 140; SEQ ID NO: 141; SEQ ID NO: 142; SEQ ID NO: 143; SEQ ID NO: 144; SEQ ID NO: 145; SEQ ID NO: 146; SEQ ID NO: 147; SEQ ID NO: 148; SEQ ID NO: 149; SEQ ID NO: 150; SEQ ID NO: 151; SEQ ID NO: 152; SEQ ID NO: 153; SEQ ID NO: 154; SEQ ID NO: 155; SEQ ID NO: 156; SEQ ID NO: 157; SEQ ID NO: 158; SEQ ID NO: 159; SEQ ID NO: 160; SEQ ID NO: 161; SEQ ID NO: 162; SEQ ID NO: 163; SEQ ID NO: 164; SEQ ID NO: 165; SEQ ID NO: 166; SEQ ID NO: 167; SEQ ID NO: 168; SEQ ID NO: 169; SEQ ID NO: 170; SEQ ID NO: 171; SEQ ID NO: 172; SEQ ID NO: 173; SEQ ID NO: 174; SEQ ID NO: 175; SEQ ID NO: 176; SEQ ID NO: 177; SEQ ID NO: 178; SEQ ID NO: 179; SEQ ID NO: 180; SEQ ID NO: 181; SEQ ID NO: 182; SEQ ID NO: 183; SEQ ID NO: 184; SEQ ID NO: 185; and SEQ ID NO: 186. Accordingly, these sequences may be used to identify a primary cell gene expression profile, which then may be used to classify unknown cell or tissue samples.

A primary cell gene expression profile may additionally comprise one or more of the following nucleic acid sequences: SEQ ID NO: 188; SEQ ID NO: 193; SEQ ID NO: 216; SEQ ID NO: 224; SEQ ID NO: 230; SEQ ID NO: 248; SEQ ID NO: 249; SEQ ID NO: 250; SEQ ID NO: 253; SEQ ID NO: 271; SEQ ID NO: 281; SEQ ID NO: 324; SEQ ID NO: 337; SEQ ID NO: 346; SEQ ID NO: 388; SEQ ID NO: 403; SEQ ID NO: 410; SEQ ID NO: 415; SEQ ID NO: 421; SEQ ID NO: 422; SEQ ID NO: 425; SEQ ID NO: 427; SEQ ID NO: 428; SEQ ID NO: 432; SEQ ID NO: 433; SEQ ID NO: 437; SEQ ID NO: 440; SEQ ID NO: 443; SEQ ID NO: 444; SEQ ID NO: 447; SEQ ID NO: 449; SEQ ID NO: 451; SEQ ID NO: 452; SEQ ID NO: 455; SEQ ID NO: 457; SEQ ID NO: 460; SEQ ID NO: 462; SEQ ID NO: 465; SEQ ID NO: 466; SEQ ID NO: 476; SEQ ID NO: 477; SEQ ID NO: 482; SEQ ID NO: 484; SEQ ID NO: 490; SEQ ID NO: 492; SEQ ID NO: 493; SEQ ID NO: 495; SEQ ID NO: 498; SEQ ID NO: 499; SEQ ID NO: 502; SEQ ID NO: 504; SEQ ID NO: 505; SEQ ID NO: 514; SEQ ID NO: 515; SEQ ID NO: 518; SEQ ID NO: 524; SEQ ID NO: 528; SEQ ID NO: 530; SEQ ID NO: 531; SEQ ID NO: 532; SEQ ID NO: 536; SEQ ID NO: 539; SEQ ID NO: 541; SEQ ID NO: 545; SEQ ID NO: 551; SEQ ID NO: 563; SEQ ID NO: 565; SEQ ID NO: 567; SEQ ID NO: 573; SEQ ID NO: 577; SEQ ID NO: 580; SEQ ID NO: 582; SEQ ID NO: 585;

SEQ ID NO: 588; SEQ ID NO: 590; SEQ ID NO: 592; SEQ ID NO: 594; SEQ ID NO: 595;
 SEQ ID NO: 598; SEQ ID NO: 599; SEQ ID NO: 601; SEQ ID NO: 605; SEQ ID NO: 607;
 SEQ ID NO: 608; SEQ ID NO: 613; SEQ ID NO: 623; SEQ ID NO: 625; SEQ ID NO: 626;
 SEQ ID NO: 631; SEQ ID NO: 650; SEQ ID NO: 652; SEQ ID NO: 654; SEQ ID NO: 657;
 5 SEQ ID NO: 661; SEQ ID NO: 665; SEQ ID NO: 671; SEQ ID NO: 672; SEQ ID NO: 673;
 SEQ ID NO: 674; SEQ ID NO: 675; SEQ ID NO: 676; SEQ ID NO: 677; SEQ ID NO: 678;
 SEQ ID NO: 680; SEQ ID NO: 681; SEQ ID NO: 684; SEQ ID NO: 685; SEQ ID NO: 686;
 SEQ ID NO: 687; SEQ ID NO: 688; SEQ ID NO: 689; SEQ ID NO: 690; SEQ ID NO: 691;
 SEQ ID NO: 692; SEQ ID NO: 694; SEQ ID NO: 695; SEQ ID NO: 696; SEQ ID NO: 697;
 10 SEQ ID NO: 698; SEQ ID NO: 699; SEQ ID NO: 700; SEQ ID NO: 701; SEQ ID NO: 702;
 SEQ ID NO: 704; SEQ ID NO: 705; SEQ ID NO: 706; SEQ ID NO: 707; SEQ ID NO: 708;
 SEQ ID NO: 709; SEQ ID NO: 710; SEQ ID NO: 711; SEQ ID NO: 712; SEQ ID NO: 713;
 SEQ ID NO: 714; SEQ ID NO: 715; SEQ ID NO: 716; SEQ ID NO: 717; SEQ ID NO: 718;
 SEQ ID NO: 719; SEQ ID NO: 720; SEQ ID NO: 721; SEQ ID NO: 722; SEQ ID NO: 723;
 15 SEQ ID NO: 724; SEQ ID NO: 725; SEQ ID NO: 726; SEQ ID NO: 727; SEQ ID NO: 728;
 SEQ ID NO: 729; SEQ ID NO: 730; SEQ ID NO: 731; SEQ ID NO: 732; SEQ ID NO: 733;
 SEQ ID NO: 734; SEQ ID NO: 735; SEQ ID NO: 736; SEQ ID NO: 737; SEQ ID NO: 738;
 SEQ ID NO: 739; SEQ ID NO: 740; SEQ ID NO: 741; SEQ ID NO: 742; SEQ ID NO: 743;
 SEQ ID NO: 744; SEQ ID NO: 745; SEQ ID NO: 746; SEQ ID NO: 747; SEQ ID NO: 748;
 20 SEQ ID NO: 749; SEQ ID NO: 750; SEQ ID NO: 751; SEQ ID NO: 752; SEQ ID NO: 753;
 SEQ ID NO: 754; SEQ ID NO: 755; SEQ ID NO: 756; SEQ ID NO: 758; SEQ ID NO: 759;
 SEQ ID NO: 760; SEQ ID NO: 761; SEQ ID NO: 762; SEQ ID NO: 763; SEQ ID NO: 764;
 SEQ ID NO: 765; SEQ ID NO: 766; SEQ ID NO: 767; SEQ ID NO: 768; SEQ ID NO: 769;
 SEQ ID NO: 770; SEQ ID NO: 771; SEQ ID NO: 772; SEQ ID NO: 773; SEQ ID NO: 774;
 25 SEQ ID NO: 775; SEQ ID NO: 776; SEQ ID NO: 777; SEQ ID NO: 778; SEQ ID NO: 779;
 SEQ ID NO: 780; SEQ ID NO: 781; SEQ ID NO: 782; SEQ ID NO: 783; SEQ ID NO: 784;
 SEQ ID NO: 785; SEQ ID NO: 786; SEQ ID NO: 787; SEQ ID NO: 788; SEQ ID NO: 789;
 SEQ ID NO: 790; SEQ ID NO: 791; SEQ ID NO: 792; SEQ ID NO: 793; SEQ ID NO: 794;
 SEQ ID NO: 795; SEQ ID NO: 796; SEQ ID NO: 797; SEQ ID NO: 798; SEQ ID NO: 799;
 30 SEQ ID NO: 800; SEQ ID NO: 801; SEQ ID NO: 802; and SEQ ID NO: 803.

As the example shows, primary cell gene expression profile may also comprise, for instance, the nucleic acid sequences having the following accession numbers: INCYTE 2997284H1; INCYTE 1726828F6; INCYTE 1690295F6; INCYTE 530695T6; INCYTE

2313677H1; INCYTE 2510757F6; INCYTE 1696122T6; GB M20566; INCYTE
 1742456R6; INCYTE 3584702H1; INCYTE 2222054H1; INCYTE 928019R6; INCYTE
 1716001T6; INCYTE 2211526T6; INCYTE 2604309F6; INCYTE 3269857F6; INCYTE
 1751294F6; INCYTE 3118530H1; INCYTE 1519824H1; INCYTE 1429303H1; INCYTE
 5 449937H1; INCYTE 150224T6; INCYTE 1652456H1; INCYTE 2116716T6; INCYTE
 637471CA2; INCYTE 3105066H1; INCYTE 1946704H1; INCYTE 5547273H1; INCYTE
 2194901H1; INCYTE 3097063H1; INCYTE 399998H1; INCYTE 3320154H1; GB X87344;
 INCYTE 2169635T6; and INCYTE 767295H1.

Figure 10 displays the genes that comprise an endothelial gene expression profile.

10 Specifically, an endothelial gene expression profile may comprise one or more nucleic acid
 sequences including, but not limited to, SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ
 ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; SEQ ID NO: 8; SEQ ID NO: 9;
 SEQ ID NO: 10; SEQ ID NO: 11; SEQ ID NO: 12; SEQ ID NO: 13; SEQ ID NO: 14; SEQ
 ID NO: 15; SEQ ID NO: 16; SEQ ID NO: 17; SEQ ID NO: 18; SEQ ID NO: 19; SEQ ID
 15 NO: 20; SEQ ID NO: 21; SEQ ID NO: 22; SEQ ID NO: 23; SEQ ID NO: 48; SEQ ID NO:
 63; SEQ ID NO: 70; SEQ ID NO: 82; SEQ ID NO: 94; and SEQ ID NO: 144. Accordingly,
 these sequences may be used to identify an endothelial gene expression profile, which then
 may be used to classify unknown cell or tissue samples.

An endothelial gene expression profile may additionally comprise one or more
 20 nucleic acid sequences including, but not limited to, SEQ ID NO: 427; SEQ ID NO: 460;
 SEQ ID NO: 484; SEQ ID NO: 565; SEQ ID NO: 580; SEQ ID NO: 590; SEQ ID NO: 670;
 SEQ ID NO: 672; SEQ ID NO: 673; SEQ ID NO: 674; SEQ ID NO: 675; SEQ ID NO: 676;
 SEQ ID NO: 677; SEQ ID NO: 678; SEQ ID NO: 680; SEQ ID NO: 723; SEQ ID NO: 741;
 and SEQ ID NO: 754.

25 As the example shows, an endothelial gene expression profile may also comprise, for
 example, the nucleic acid sequences having the following accession numbers: INCYTE
 530695T6 and INCYTE 1716001T6.

The gene expression profile depicted in Figure 11 may be used to identify epithelial
 cells. Specifically, an epithelial gene expression profile may comprise one or more nucleic
 30 acid sequences including, but not limited to, SEQ ID NO: 47; SEQ ID NO: 60; SEQ ID NO:
 67; SEQ ID NO: 73; SEQ ID NO: 75; SEQ ID NO: 76; SEQ ID NO: 77; SEQ ID NO: 78;
 SEQ ID NO: 80; SEQ ID NO: 96; SEQ ID NO: 98; SEQ ID NO: 99; SEQ ID NO: 111; SEQ
 ID NO: 112; SEQ ID NO: 117; SEQ ID NO: 123; SEQ ID NO: 127; SEQ ID NO: 131; SEQ

ID NO: 150; SEQ ID NO: 153; SEQ ID NO: 154; SEQ ID NO: 155; SEQ ID NO: 156; SEQ ID NO: 157; SEQ ID NO: 158; SEQ ID NO: 159; SEQ ID NO: 160; SEQ ID NO: 161; SEQ ID NO: 162; SEQ ID NO: 163; SEQ ID NO: 164; SEQ ID NO: 165; SEQ ID NO: 166; SEQ ID NO: 167; SEQ ID NO: 168; SEQ ID NO: 169; SEQ ID NO: 170; SEQ ID NO: 171; SEQ ID NO: 172; SEQ ID NO: 173; SEQ ID NO: 174; SEQ ID NO: 175; SEQ ID NO: 176; SEQ ID NO: 177; SEQ ID NO: 178; SEQ ID NO: 179; SEQ ID NO: 180; SEQ ID NO: 181; SEQ ID NO: 182; SEQ ID NO: 183; SEQ ID NO: 184; SEQ ID NO: 185; SEQ ID NO: 186.

Figure 12 shows the gene expression profile generated from muscle cells. In one embodiment, a muscle cell gene expression profile may comprise one or more nucleic acid sequences including, but not limited to, SEQ ID NO: 24; SEQ ID NO: 25; SEQ ID NO: 26; SEQ ID NO: 27; SEQ ID NO: 28; SEQ ID NO: 29; SEQ ID NO: 30; SEQ ID NO: 31; SEQ ID NO: 32; SEQ ID NO: 33; SEQ ID NO: 34; SEQ ID NO: 35; SEQ ID NO: 36; SEQ ID NO: 37; SEQ ID NO: 38; SEQ ID NO: 39; SEQ ID NO: 40; SEQ ID NO: 41; SEQ ID NO: 42; SEQ ID NO: 54; SEQ ID NO: 55; and SEQ ID NO: 69. Accordingly, these sequences may be used to identify a muscle gene expression profile, which then may be used to classify unknown cell or tissue samples.

A muscle gene expression profile may additionally comprise one or more nucleic acid sequences including, but not limited to, SEQ ID NO: 188; SEQ ID NO: 193; SEQ ID NO: 216; SEQ ID NO: 250; SEQ ID NO: 499; SEQ ID NO: 504; SEQ ID NO: 563; SEQ ID NO: 652; SEQ ID NO: 681; SEQ ID NO: 682; SEQ ID NO: 683; SEQ ID NO: 684; SEQ ID NO: 685; SEQ ID NO: 686; SEQ ID NO: 687; SEQ ID NO: 688; SEQ ID NO: 689; SEQ ID NO: 690; and SEQ ID NO: 691.

Example 4: Gene Expression Profiles for Epithelial Cell Subtypes

Gene expression profiles that define a particular type of epithelial cell were generated using the methodologies, microarrays and algorithms of the present invention. Epithelial cell lines were used to generate the cell type specific gene expression profiles. The epithelial cell lines used in this example were derived from various tissues including keratinocyte epithelium, mammary epithelium, bronchial epithelium, prostate epithelium, renal cortical epithelium, renal proximal tubule epithelium, small airway epithelium, and renal epithelium.

Complementary DNA made from each of the eight cell lines was used to probe the microarray. Briefly, and as described in the previous examples, total RNA was extracted, amplified, and labeled. The resultant labeled cDNAs were hybridized to microarray chips. Following one or more washing steps, the microarrays were scanned and the intensity of the spots was recorded and converted into a numerical value and normalized. Next, the algorithms of the present invention were applied to extract a gene expression profile that defined the subtype of epithelial cell.

The microarrays used in this example comprised the following nucleic acid sequences: SEQ ID NO: 187; SEQ ID NO: 188; SEQ ID NO: 189; SEQ ID NO: 190; SEQ ID NO: 191; SEQ ID NO: 192; SEQ ID NO: 193; SEQ ID NO: 194; SEQ ID NO: 195; SEQ ID NO: 196; SEQ ID NO: 197; SEQ ID NO: 198; SEQ ID NO: 199; SEQ ID NO: 200; SEQ ID NO: 201; SEQ ID NO: 202; SEQ ID NO: 203; SEQ ID NO: 204; SEQ ID NO: 205; SEQ ID NO: 206; SEQ ID NO: 207; SEQ ID NO: 208; SEQ ID NO: 209; SEQ ID NO: 210; SEQ ID NO: 211; SEQ ID NO: 150; SEQ ID NO: 27; SEQ ID NO: 169; SEQ ID NO: 212; SEQ ID NO: 213; SEQ ID NO: 131; SEQ ID NO: 214; SEQ ID NO: 215; SEQ ID NO: 216; SEQ ID NO: 217; SEQ ID NO: 218; SEQ ID NO: 138; SEQ ID NO: 219; SEQ ID NO: 220; SEQ ID NO: 221; SEQ ID NO: 222; SEQ ID NO: 223; SEQ ID NO: 224; SEQ ID NO: 225; SEQ ID NO: 226; SEQ ID NO: 227; SEQ ID NO: 228; SEQ ID NO: 229; SEQ ID NO: 230; SEQ ID NO: 231; SEQ ID NO: 232; SEQ ID NO: 78; SEQ ID NO: 233; SEQ ID NO: 234; SEQ ID NO: 235; SEQ ID NO: 236; SEQ ID NO: 237; SEQ ID NO: 238; SEQ ID NO: 239; SEQ ID NO: 240; SEQ ID NO: 241; SEQ ID NO: 242; SEQ ID NO: 243; SEQ ID NO: 64; SEQ ID NO: 244; SEQ ID NO: 245; SEQ ID NO: 246; SEQ ID NO: 247; SEQ ID NO: 248; SEQ ID NO: 249; SEQ ID NO: 250; SEQ ID NO: 251; SEQ ID NO: 252; SEQ ID NO: 253; SEQ ID NO: 254; SEQ ID NO: 37; SEQ ID NO: 106; SEQ ID NO: 255; SEQ ID NO: 123; SEQ ID NO: 256; SEQ ID NO: 257; SEQ ID NO: 258; SEQ ID NO: 259; SEQ ID NO: 260; SEQ ID NO: 261; SEQ ID NO: 262; SEQ ID NO: 263; SEQ ID NO: 264; SEQ ID NO: 265; SEQ ID NO: 266; SEQ ID NO: 267; SEQ ID NO: 268; SEQ ID NO: 269; SEQ ID NO: 57; SEQ ID NO: 70; SEQ ID NO: 270; SEQ ID NO: 271; SEQ ID NO: 272; SEQ ID NO: 273; SEQ ID NO: 274; SEQ ID NO: 275; SEQ ID NO: 276; SEQ ID NO: 277; SEQ ID NO: 278; SEQ ID NO: 279; SEQ ID NO: 104; SEQ ID NO: 280; SEQ ID NO: 281; SEQ ID NO: 282; SEQ ID NO: 283; SEQ ID NO: 284; SEQ ID NO: 285; SEQ ID NO: 286; SEQ ID NO: 287; SEQ ID NO: 288; SEQ ID NO: 160; SEQ ID NO: 289; SEQ ID NO: 290; SEQ ID NO: 291; SEQ ID NO: 293; SEQ ID NO: 294; SEQ ID NO: 295; SEQ ID NO: 296; SEQ ID NO: 297; SEQ ID

NO: 49; SEQ ID NO: 298; SEQ ID NO: 299; SEQ ID NO: 300; SEQ ID NO: 301; SEQ ID
 NO: 302; SEQ ID NO: 303; SEQ ID NO: 304; SEQ ID NO: 305; SEQ ID NO: 306; SEQ ID
 NO: 307; SEQ ID NO: 308; SEQ ID NO: 183; SEQ ID NO: 309; SEQ ID NO: 310; SEQ ID
 NO: 311; SEQ ID NO: 312; SEQ ID NO: 313; SEQ ID NO: 314; SEQ ID NO: 315; SEQ ID
 5 NO: 316; SEQ ID NO: 310; SEQ ID NO: 317; SEQ ID NO: 174; SEQ ID NO: 318; SEQ ID
 NO: 320; SEQ ID NO: 173; SEQ ID NO: 321; SEQ ID NO: 322; SEQ ID NO: 323; SEQ ID
 NO: 324; SEQ ID NO: 325; SEQ ID NO: 326; SEQ ID NO: 158; SEQ ID NO: 327; SEQ ID
 NO: 328; SEQ ID NO: 165; SEQ ID NO: 166; SEQ ID NO: 329

Figure 18 shows the results from all eight of the hybridizations. The cutoff value was
 10 set for expression values over 2.0, *i.e.*, two-fold induction over baseline. This particular
 portrayal of the data shows the relative expression values sorted for keratinocyte epithelial
 cells. Several genes, specifically, nucleic acid sequences SEQ ID NO: 187; SEQ ID NO:
 188; SEQ ID NO: 189; SEQ ID NO: 190; SEQ ID NO: 191; SEQ ID NO: 192; SEQ ID NO:
 193; SEQ ID NO: 194; SEQ ID NO: 195; SEQ ID NO: 196; SEQ ID NO: 197; SEQ ID NO:
 15 198; SEQ ID NO: 199; SEQ ID NO: 200; SEQ ID NO: 201; SEQ ID NO: 202; SEQ ID NO:
 203; SEQ ID NO: 204; SEQ ID NO: 205; SEQ ID NO: 206; SEQ ID NO: 207; SEQ ID NO:
 208; SEQ ID NO: 209; SEQ ID NO: 210; and SEQ ID NO: 211, show a relative expression
 value over 2.0, which is the cut-off in the context of the algorithm. These genes represent
 signature genes, *i.e.*, a gene expression profile of keratinocyte epithelial cells, which may be
 20 used to identify and classify unknown samples.

With regard to the other columns, it is possible to sort the data and identify genes
 representing gene expression profiles of a particular cell type. For example, and referring to
 Figure 18, sorting the data based on relative expression values and using the value of 2.0 as a
 cutoff in the context of the algorithm, the following genes represent a mammary epithelial
 25 cells gene expression profile: SEQ ID NO: 212; SEQ ID NO: 213; SEQ ID NO: 216; SEQ ID
 NO: 225; SEQ ID NO: 226; SEQ ID NO: 227; SEQ ID NO: 78; SEQ ID NO: 239; SEQ ID
 NO: 271; SEQ ID NO: 285; and SEQ ID NO: 289.

Similarly, and referring to Figure 18, sorting the data based on relative expression
 values and using the value of 2.0 as a cutoff in the context of the algorithm, the following
 30 genes represent a bronchial epithelial cells gene expression profile: SEQ ID NO: 150; SEQ ID
 NO: 27; SEQ ID NO: 169; SEQ ID NO: 131; SEQ ID NO: 214; SEQ ID NO: 215; SEQ ID
 NO: 223; SEQ ID NO: 224; SEQ ID NO: 241; SEQ ID NO: 243; SEQ ID NO: 244; SEQ ID
 NO: 255; SEQ ID NO: 256; SEQ ID NO: 261; and SEQ ID NO: 314.

Referring to Figure 18, sorting the data based on relative expression values and using the value of 2.0 as a cutoff in the context of the algorithm, the following genes represent a prostate epithelial cells gene expression profile: SEQ ID NO: 217; SEQ ID NO: 218; SEQ ID NO: 64; SEQ ID NO: 259; SEQ ID NO: 293; SEQ ID NO: 302; and SEQ ID NO: 320.

5 Likewise, referring to Figure 18, sorting the data based on relative expression values and using the value of 2.0 as a cutoff in the context of the algorithm, the following genes represent a renal cortical epithelial cells gene expression profile: SEQ ID NO: 219; SEQ ID NO: 123; SEQ ID NO: 267; SEQ ID NO: 57; SEQ ID NO: 270; SEQ ID NO: 279; SEQ ID NO: 104; SEQ ID NO: 28; SEQ ID NO: 283; SEQ ID NO: 160; SEQ ID NO: 291; SEQ ID
10 NO: 300; SEQ ID NO: 305; SEQ ID NO: 307; SEQ ID NO: 310; SEQ ID NO: 313; SEQ ID NO: 310; SEQ ID NO: 325; SEQ ID NO: 326; SEQ ID NO: 327; SEQ ID NO: 165; and SEQ ID NO: 166.

Referring to Figure 18, sorting the data based on relative expression values and using the value of 2.0 as a cutoff in the context of the algorithm, the following genes represent a
15 renal proximal tubule epithelial cells gene expression profile: SEQ ID NO: 106; SEQ ID NO: 138; SEQ ID NO: 158; SEQ ID NO: 228; SEQ ID NO: 236; SEQ ID NO: 242; SEQ ID NO: 250; SEQ ID NO: 258; SEQ ID NO: 260; SEQ ID NO: 262; SEQ ID NO: 266; SEQ ID NO: 272; SEQ ID NO: 273; SEQ ID NO: 274; SEQ ID NO: 275; SEQ ID NO: 276; SEQ ID NO: 278; SEQ ID NO: 284; SEQ ID NO: 288; SEQ ID NO: 295; SEQ ID NO: 296; SEQ ID NO:
20 297; SEQ ID NO: 299; SEQ ID NO: 300; SEQ ID NO: 301; SEQ ID NO: 306; SEQ ID NO: 308; SEQ ID NO: 309; SEQ ID NO: 311; SEQ ID NO: 316; SEQ ID NO: 318; SEQ ID NO: 321; SEQ ID NO: 322; SEQ ID NO: 328; and SEQ ID NO: 329.

Moreover, and referring to Figure 18, sorting the data based on relative expression values and using the value of 2.0 as a cutoff in the context of the algorithm, the following
25 genes represent a small airway epithelial cells gene expression profile: SEQ ID NO: 173; SEQ ID NO: 174; SEQ ID NO: 183; SEQ ID NO: 220; SEQ ID NO: 221; SEQ ID NO: 222; SEQ ID NO: 229; SEQ ID NO: 230; SEQ ID NO: 231; SEQ ID NO: 232; SEQ ID NO: 233; SEQ ID NO: 234; SEQ ID NO: 235; SEQ ID NO: 237; SEQ ID NO: 238; SEQ ID NO: 240; SEQ ID NO: 245; SEQ ID NO: 246; SEQ ID NO: 247; SEQ ID NO: 248; SEQ ID NO: 249;
30 SEQ ID NO: 251; SEQ ID NO: 252; SEQ ID NO: 254; SEQ ID NO: 257; SEQ ID NO: 263; SEQ ID NO: 264; SEQ ID NO: 265; SEQ ID NO: 268; SEQ ID NO: 269; SEQ ID NO: 270; SEQ ID NO: 277; SEQ ID NO: 281; SEQ ID NO: 282; SEQ ID NO: 286; SEQ ID NO: 287;

SEQ ID NO: 290; SEQ ID NO: 294; SEQ ID NO: 298; SEQ ID NO: 303; SEQ ID NO: 312; SEQ ID NO: 315; SEQ ID NO: 317; and SEQ ID NO: 319.

Still further, and referring to Figure 18, sorting the data based on relative expression values and using the value of 2.0 as a cutoff in the context of the algorithm, the following
5 genes represent a renal epithelial cells gene expression profile: SEQ ID NO: 37; SEQ ID NO: 253; SEQ ID NO: 304; SEQ ID NO: 323; and SEQ ID NO: 324.

Example 5: Rat Toxicology Reference Database

To assess the toxicity of known compounds on gene and/or protein expression, a rat
10 expression database is constructed. The database consists of gene expression profiles and protein expression profiles, as well as serum chemistry, hematology measurements, histopathology, and general clinical observations, from 100 different compounds at two doses and at two timepoints per dose. The compounds contain at least 10 different mechanisms of liver and kidney toxicity.

15 Sprague-Dawley rats are treated with compound via intraperitoneal administration. Dose groups include a low dose and a high dose for a 24-hour exposure and a low dose and a high dose for a 72-hour exposure. Three animals are treated per dose group as well as two control animal per timepoint. Following treatment, tissue are collected for gene expression and/or protein expression analysis including liver, kidney, white blood cells, lung, heart,
20 intestine, testes, and spleen. Other toxicological evaluations include serum chemistry, hematology, organ weights, animal weights, and clinical observations.

Dose selection is based on literature reports with low dose defined as the lowest historical dose that elicited an endpoint and high dose is defined as the dose reported to result in a significant number of animals exhibiting characteristic toxicity.

25 The toxic effects of these compounds on gene expression and protein expression are analyzed using a toxicity microarray. For each compound, 15 rats are treated with the compound and tissue samples from each rat are collected and analyzed. The expression patterns in liver, kidney, heart, brain, intestine, testes, spleen, and white blood cells are analyzed following treatment with a toxic compounds. To generate the target nucleic acids,
30 RNA or protein is isolated from each tissue sample and prepared for microarray hybridization as described above. Genes and/or proteins demonstrating alterations in expression level are selected for inclusion on the rat toxicity microarray. In addition, approximately 600 genes and/or protein-capture agents derived therefrom identified as toxicologically relevant based

on review of the scientific literature are also be included on the microarray. In total, about 4,000 cDNAs or protein-capture agents reflecting the genes and/or proteins susceptible to the toxicity of these compounds.

Data reflecting the gene expression profiles of each tissue and toxin is placed in the database including an annotation describing dosage and clinical observations. The database provides information describing mechanisms of action as well as previously reported alterations of gene expression observed following administration of these compounds. The database is also used in the drug discovery process by providing information which permits the elimination of potentially toxic compounds.

Example 6: Expression Profiles As A Diagnostic For Disease

The microarray technology may also be used to identify a particular disease (*e.g.*, cancer), and provide a patient diagnosis. Initially, reference genes and/or proteins are generated for both normal and cancer cell types. Isolated cell types are derived by a number of methods known in the art (*e.g.*, FACS sorting, magnoferic solutions, magnetic beads in combination with cell-specific antibodies). Cells from tissues are isolated by tissue staining with a cell-specific antibody, followed by laser capture microscopy or electrostatic methods. RNA is isolated from the cells and then probes are created for the generation of microarrays using the methods described above. Similarly, protein may be isolated from the cells and used to probe a microarray comprising protein-capture agents using the methods described above.

Data from the microarrays for each cell type is then placed in a database along with an annotation describing cell type and location. Using cluster analysis and algorithms, gene and/or protein expression profiles for each cell type are determined.

For a diagnosis of Hodgkin lymphoma or non-Hodgkin lymphoma, biological samples are collected from patients and RNA or protein is isolated from the samples, as described above. The cDNA or protein is then hybridized to microarrays containing genes or protein-capture agents representing normal, Hodgkin lymphoma, and non-Hodgkin lymphoma samples. Based on the gene expression profiles and/or protein expression profiles, patients are diagnosed with either Hodgkin lymphoma or non-Hodgkin lymphoma.

The expression data from these patient samples is then added to the database. In addition, clinical information regarding the patient and treatment course as well as clinical

outcome are also included in the database; thus, providing expression profiles for disease, disease stage, and outcome.

Microarray technology is also used to identify a course of treatment and as a drug discovery method. Normal and tumorigenic cells are treated with a known cancer drug (*e.g.*, tamoxifen) or a novel pharmacological agent. As described above, RNA or protein is isolated and then hybridized to a microarray containing normal and cancer cell genes or protein-capture agents. A comparison of the expression levels following treatment provides an expression profile of the particular drug indicating which genes or proteins are activated or deactivated by the drug. This information is also added to the database. The database thus contains information describing the gene expression profiles and/or protein expression profiles of normal and cancer cells, gene expression profiles and/or protein expression profiles of patient samples, gene expression profiles and/or protein expression profiles of patients undergoing treatment, and gene expression profiles and/or protein expression profiles of *in vitro* cell studies. This information is used to diagnose and classify a disease, select and monitor a treatment course, and identify a prognostic indicator.

Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

We claim:

1. An endothelial cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof selected from the group selected from the group consisting of SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; SEQ ID NO: 8; SEQ ID NO: 9; SEQ ID NO: 10; SEQ ID NO: 11; SEQ ID NO: 12; SEQ ID NO: 13; SEQ ID NO: 14; SEQ ID NO: 15; SEQ ID NO: 16; SEQ ID NO: 17; SEQ ID NO: 18; SEQ ID NO: 19; SEQ ID NO: 20; SEQ ID NO: 21; SEQ ID NO: 22; SEQ ID NO: 23; SEQ ID NO: 48; SEQ ID NO: 63; SEQ ID NO: 70; SEQ ID NO: 82; SEQ ID NO: 94; and SEQ ID NO: 144.
2. A muscle cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof selected from the group selected from the group consisting of SEQ ID NO: 24; SEQ ID NO: 25; SEQ ID NO: 26; SEQ ID NO: 27; SEQ ID NO: 28; SEQ ID NO: 29; SEQ ID NO: 30; SEQ ID NO: 31; SEQ ID NO: 32; SEQ ID NO: 33; SEQ ID NO: 34; SEQ ID NO: 35; SEQ ID NO: 36; SEQ ID NO: 37; SEQ ID NO: 39; SEQ ID NO: 40; SEQ ID NO: 41; SEQ ID NO: 42; SEQ ID NO: 54; SEQ ID NO: 55; and SEQ ID NO: 69.
3. A primary cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof selected from the group selected from the group consisting of SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; SEQ ID NO: 8; SEQ ID NO: 9; SEQ ID NO: 10; SEQ ID NO: 11; SEQ ID NO: 12; SEQ ID NO: 13; SEQ ID NO: 14; SEQ ID NO: 15; SEQ ID NO: 16; SEQ ID NO: 17; SEQ ID NO: 18; SEQ ID NO: 19; SEQ ID NO: 20; SEQ ID NO: 21; SEQ ID NO: 22; SEQ ID NO: 23; SEQ ID NO: 24; SEQ ID NO: 25; SEQ ID NO: 26; SEQ ID NO: 27; SEQ ID NO: 28; SEQ ID NO: 29; SEQ ID NO: 30; SEQ ID NO: 31; SEQ ID NO: 32; SEQ ID NO: 33; SEQ ID NO: 34; SEQ ID NO: 35; SEQ ID NO: 36; SEQ ID NO: 37; SEQ ID NO: 39; SEQ ID NO: 40; SEQ ID NO: 41; SEQ ID NO: 42; SEQ ID NO: 43; SEQ ID NO: 44; SEQ ID NO: 45; SEQ ID NO: 46; SEQ ID NO: 47; SEQ ID NO: 48; SEQ ID NO: 49; SEQ ID NO: 50; SEQ ID NO: 51; SEQ ID NO: 52; SEQ ID NO: 53; SEQ ID NO: 54; SEQ ID NO: 55; SEQ ID NO: 56; SEQ ID NO: 57; SEQ ID NO: 58; SEQ ID NO: 59; SEQ ID NO: 60; SEQ ID NO: 61; SEQ ID NO: 62; SEQ ID NO: 63; SEQ ID

NO: 64; SEQ ID NO: 65; SEQ ID NO: 66; SEQ ID NO: 67; SEQ ID NO: 68; SEQ ID NO: 69; SEQ ID NO: 70; SEQ ID NO: 71; SEQ ID NO: 72; SEQ ID NO: 73; SEQ ID NO: 74; SEQ ID NO: 75; SEQ ID NO: 76; SEQ ID NO: 77; SEQ ID NO: 78; SEQ ID NO: 79; SEQ ID NO: 80; SEQ ID NO: 81; SEQ ID NO: 82; SEQ ID NO: 83; SEQ ID NO: 84; SEQ ID NO: 85; SEQ ID NO: 86; SEQ ID NO: 87; SEQ ID NO: 88; SEQ ID NO: 89; SEQ ID NO: 90; SEQ ID NO: 91; SEQ ID NO: 92; SEQ ID NO: 93; SEQ ID NO: 94; SEQ ID NO: 95; SEQ ID NO: 96; SEQ ID NO: 97; SEQ ID NO: 98; SEQ ID NO: 99; SEQ ID NO: 100; SEQ ID NO: 101; SEQ ID NO: 102; SEQ ID NO: 103; SEQ ID NO: 104; SEQ ID NO: 105; SEQ ID NO: 106; SEQ ID NO: 107; SEQ ID NO: 108; SEQ ID NO: 109; SEQ ID NO: 110; SEQ ID NO: 111; SEQ ID NO: 112; SEQ ID NO: 113; SEQ ID NO: 114; SEQ ID NO: 115; SEQ ID NO: 116; SEQ ID NO: 118; SEQ ID NO: 119; SEQ ID NO: 120; SEQ ID NO: 121; SEQ ID NO: 122; SEQ ID NO: 123; SEQ ID NO: 124; SEQ ID NO: 125; SEQ ID NO: 126; SEQ ID NO: 127; SEQ ID NO: 128; SEQ ID NO: 129; SEQ ID NO: 130; SEQ ID NO: 131; SEQ ID NO: 132; SEQ ID NO: 133; SEQ ID NO: 134; SEQ ID NO: 135; SEQ ID NO: 136; SEQ ID NO: 137; SEQ ID NO: 138; SEQ ID NO: 139; SEQ ID NO: 140; SEQ ID NO: 141; SEQ ID NO: 142; SEQ ID NO: 143; SEQ ID NO: 144; SEQ ID NO: 145; SEQ ID NO: 146; SEQ ID NO: 147; SEQ ID NO: 148; SEQ ID NO: 149; SEQ ID NO: 150; SEQ ID NO: 151; SEQ ID NO: 152; SEQ ID NO: 153; SEQ ID NO: 154; SEQ ID NO: 155; SEQ ID NO: 156; SEQ ID NO: 157; SEQ ID NO: 158; SEQ ID NO: 159; SEQ ID NO: 160; SEQ ID NO: 161; SEQ ID NO: 162; SEQ ID NO: 163; SEQ ID NO: 164; SEQ ID NO: 165; SEQ ID NO: 166; SEQ ID NO: 167; SEQ ID NO: 168; SEQ ID NO: 169; SEQ ID NO: 170; SEQ ID NO: 171; SEQ ID NO: 172; SEQ ID NO: 173; SEQ ID NO: 174; SEQ ID NO: 175; SEQ ID NO: 176; SEQ ID NO: 177; SEQ ID NO: 178; SEQ ID NO: 179; SEQ ID NO: 180; SEQ ID NO: 181; SEQ ID NO: 182; SEQ ID NO: 183; SEQ ID NO: 184; SEQ ID NO: 185; and SEQ ID NO: 186.

4. An epithelial cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof selected from the group selected from the group consisting of SEQ ID NO: 47; SEQ ID NO: 60; SEQ ID NO: 67; SEQ ID NO: 73; SEQ ID NO: 75; SEQ ID NO: 76; SEQ ID NO: 77; SEQ ID NO: 78; SEQ ID NO: 80; SEQ ID NO: 96; SEQ ID NO: 98; SEQ ID NO: 99; SEQ ID NO: 111; SEQ ID NO: 112; SEQ ID NO: 123; SEQ ID NO: 127; SEQ ID NO: 131; SEQ ID NO: 150; SEQ ID NO: 153; SEQ ID NO: 154; SEQ ID NO: 155;

SEQ ID NO: 156; SEQ ID NO: 157; SEQ ID NO: 158; SEQ ID NO: 159; SEQ ID NO: 160; SEQ ID NO: 161; SEQ ID NO: 162; SEQ ID NO: 163; SEQ ID NO: 164; SEQ ID NO: 165; SEQ ID NO: 166; SEQ ID NO: 167; SEQ ID NO: 168; SEQ ID NO: 169; SEQ ID NO: 170; SEQ ID NO: 171; SEQ ID NO: 172; SEQ ID NO: 173; SEQ ID NO: 174; SEQ ID NO: 175; SEQ ID NO: 176; SEQ ID NO: 177; SEQ ID NO: 178; SEQ ID NO: 179; SEQ ID NO: 180; SEQ ID NO: 181; SEQ ID NO: 182; SEQ ID NO: 183; SEQ ID NO: 184; SEQ ID NO: 185; and SEQ ID NO: 186.

5. A keratinocyte epithelial cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof selected from the group selected from the group consisting of SEQ ID NO: 187; SEQ ID NO: 188; SEQ ID NO: 189; SEQ ID NO: 190; SEQ ID NO: 191; SEQ ID NO: 192; SEQ ID NO: 193; SEQ ID NO: 194; SEQ ID NO: 195; SEQ ID NO: 196; SEQ ID NO: 197; SEQ ID NO: 198; SEQ ID NO: 199; SEQ ID NO: 200; SEQ ID NO: 201; SEQ ID NO: 202; SEQ ID NO: 203; SEQ ID NO: 204; SEQ ID NO: 205; SEQ ID NO: 206; SEQ ID NO: 207; SEQ ID NO: 208; SEQ ID NO: 209; SEQ ID NO: 210; and SEQ ID NO: 211.
6. A mammary epithelial cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof selected from the group selected from the group consisting of SEQ ID NO: 78; SEQ ID NO: 212; SEQ ID NO: 213; SEQ ID NO: 216; SEQ ID NO: 225; SEQ ID NO: 226; SEQ ID NO: 227; SEQ ID NO: 239; SEQ ID NO: 271; SEQ ID NO: 285; and SEQ ID NO: 289.
7. A bronchial epithelial cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof selected from the group selected from the group consisting of SEQ ID NO: 27; SEQ ID NO: 131; SEQ ID NO: 150; SEQ ID NO: 169; SEQ ID NO: 214; SEQ ID NO: 215; SEQ ID NO: 223; SEQ ID NO: 224; SEQ ID NO: 241; SEQ ID NO: 243; SEQ ID NO: 244; SEQ ID NO: 255; SEQ ID NO: 256; SEQ ID NO: 261; and SEQ ID NO: 314.

8. A prostate epithelial cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof selected from the group selected from the group consisting of SEQ ID NO: 64; SEQ ID NO: 217; SEQ ID NO: 218; SEQ ID NO: 259; SEQ ID NO: 293; SEQ ID NO: 302; and SEQ ID NO: 320.
9. A renal cortical epithelial cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof selected from the group selected from the group consisting of SEQ ID NO: 49; SEQ ID NO: 57; SEQ ID NO: 104; SEQ ID NO: 123; SEQ ID NO: 160; SEQ ID NO: 165; SEQ ID NO: 166; SEQ ID NO: 219; SEQ ID NO: 267; SEQ ID NO: 270; SEQ ID NO: 279; SEQ ID NO: 280; SEQ ID NO: 283; SEQ ID NO: 291; SEQ ID NO: 305; SEQ ID NO: 307; SEQ ID NO: 310; SEQ ID NO: 313; SEQ ID NO: 325; SEQ ID NO: 326; and SEQ ID NO: 327.
10. A renal proximal tubule epithelial cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof selected from the group selected from the group consisting of SEQ ID NO: 106; SEQ ID NO: 138; SEQ ID NO: 158; SEQ ID NO: 228; SEQ ID NO: 236; SEQ ID NO: 242; SEQ ID NO: 250; SEQ ID NO: 258; SEQ ID NO: 260; SEQ ID NO: 262; SEQ ID NO: 266; SEQ ID NO: 272; SEQ ID NO: 273; SEQ ID NO: 274; SEQ ID NO: 275; SEQ ID NO: 276; SEQ ID NO: 278; SEQ ID NO: 284; SEQ ID NO: 288; SEQ ID NO: 295; SEQ ID NO: 296; SEQ ID NO: 297; SEQ ID NO: 299; SEQ ID NO: 300; SEQ ID NO: 301; SEQ ID NO: 306; SEQ ID NO: 308; SEQ ID NO: 309; SEQ ID NO: 311; SEQ ID NO: 316; SEQ ID NO: 318; SEQ ID NO: 321; SEQ ID NO: 322; SEQ ID NO: 328; and SEQ ID NO: 329.
11. A small airway epithelial cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof selected from the group selected from the group consisting of SEQ ID NO: 173; SEQ ID NO: 174; SEQ ID NO: 183; SEQ ID NO: 220; SEQ ID NO: 221; SEQ ID NO: 222; SEQ ID NO: 229; SEQ ID NO: 230; SEQ ID NO: 231; SEQ ID NO: 232; SEQ ID NO: 233; SEQ ID NO: 234; SEQ ID NO: 235; SEQ ID NO: 237; SEQ ID NO: 238; SEQ ID NO: 240; SEQ ID NO: 245; SEQ ID NO: 246; SEQ ID NO: 247; SEQ ID

NO: 248; SEQ ID NO: 249; SEQ ID NO: 251; SEQ ID NO: 252; SEQ ID NO: 254; SEQ ID NO: 257; SEQ ID NO: 263; SEQ ID NO: 264; SEQ ID NO: 265; SEQ ID NO: 268; SEQ ID NO: 269; SEQ ID NO: 270; SEQ ID NO: 277; SEQ ID NO: 281; SEQ ID NO: 282; SEQ ID NO: 286; SEQ ID NO: 287; SEQ ID NO: 290; SEQ ID NO: 294; SEQ ID NO: 298; SEQ ID NO: 303; SEQ ID NO: 312; SEQ ID NO: 315; SEQ ID NO: 317; and SEQ ID NO: 319.

12. A renal epithelial cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof selected from the group selected from the group consisting of SEQ ID NO: 37; SEQ ID NO: 253; SEQ ID NO: 304; SEQ ID NO: 323; and SEQ ID NO: 324.
13. A gene expression profile comprising one or more genes, wherein said gene expression profile is generated from a cell type selected from the group consisting of coronary artery endothelium, umbilical artery endothelium, umbilical vein endothelium, aortic endothelium, dermal microvascular endothelium, pulmonary artery endothelium, myometrium microvascular endothelium, keratinocyte epithelium, bronchial epithelium, mammary epithelium, prostate epithelium, renal cortical epithelium, renal proximal tubule epithelium, small airway epithelium, renal epithelium, umbilical artery smooth muscle, neonatal dermal fibroblast, pulmonary artery smooth muscle, dermal fibroblast, neural progenitor cells, skeletal muscle, astrocytes, aortic smooth muscle, mesangial cells, coronary artery smooth muscle, bronchial smooth muscle, uterine smooth muscle, lung fibroblast, osteoblasts, and prostate stromal cells.
14. A microarray comprising an endothelial cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof, or portions of said nucleic acid sequence or complementary sequence thereof, selected from the group consisting of SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; SEQ ID NO: 8; SEQ ID NO: 9; SEQ ID NO: 10; SEQ ID NO: 11; SEQ ID NO: 12; SEQ ID NO: 13; SEQ ID NO: 14; SEQ ID NO: 15; SEQ ID NO: 16; SEQ ID NO: 17; SEQ ID NO: 18; SEQ ID NO: 19; SEQ ID NO: 20; SEQ ID NO: 21; SEQ ID NO: 22; SEQ ID NO: 23; SEQ ID NO: 48; SEQ ID NO: 63; SEQ ID NO: 70; SEQ ID NO: 82; SEQ ID NO: 94; and SEQ ID NO: 144.

15. A microarray comprising muscle cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof, or portions of said nucleic acid sequence or complementary sequence thereof, selected from the group consisting of SEQ ID NO: 24; SEQ ID NO: 25; SEQ ID NO: 26; SEQ ID NO: 27; SEQ ID NO: 28; SEQ ID NO: 29; SEQ ID NO: 30; SEQ ID NO: 31; SEQ ID NO: 32; SEQ ID NO: 33; SEQ ID NO: 34; SEQ ID NO: 35; SEQ ID NO: 36; SEQ ID NO: 37; SEQ ID NO: 39; SEQ ID NO: 40; SEQ ID NO: 41; SEQ ID NO: 42; SEQ ID NO: 54; SEQ ID NO: 55; and SEQ ID NO: 69.

16. A microarray comprising a primary cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof, or portions of said nucleic acid sequence or complementary sequence thereof, selected from the group consisting of SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; SEQ ID NO: 8; SEQ ID NO: 9; SEQ ID NO: 10; SEQ ID NO: 11; SEQ ID NO: 12; SEQ ID NO: 13; SEQ ID NO: 14; SEQ ID NO: 15; SEQ ID NO: 16; SEQ ID NO: 17; SEQ ID NO: 18; SEQ ID NO: 19; SEQ ID NO: 20; SEQ ID NO: 21; SEQ ID NO: 22; SEQ ID NO: 23; SEQ ID NO: 24; SEQ ID NO: 25; SEQ ID NO: 26; SEQ ID NO: 27; SEQ ID NO: 28; SEQ ID NO: 29; SEQ ID NO: 30; SEQ ID NO: 31; SEQ ID NO: 32; SEQ ID NO: 33; SEQ ID NO: 34; SEQ ID NO: 35; SEQ ID NO: 36; SEQ ID NO: 37; SEQ ID NO: 39; SEQ ID NO: 40; SEQ ID NO: 41; SEQ ID NO: 42; SEQ ID NO: 43; SEQ ID NO: 44; SEQ ID NO: 45; SEQ ID NO: 46; SEQ ID NO: 47; SEQ ID NO: 48; SEQ ID NO: 49; SEQ ID NO: 50; SEQ ID NO: 51; SEQ ID NO: 52; SEQ ID NO: 53; SEQ ID NO: 54; SEQ ID NO: 55; SEQ ID NO: 56; SEQ ID NO: 57; SEQ ID NO: 58; SEQ ID NO: 59; SEQ ID NO: 60; SEQ ID NO: 61; SEQ ID NO: 62; SEQ ID NO: 63; SEQ ID NO: 64; SEQ ID NO: 65; SEQ ID NO: 66; SEQ ID NO: 67; SEQ ID NO: 68; SEQ ID NO: 69; SEQ ID NO: 70; SEQ ID NO: 71; SEQ ID NO: 72; SEQ ID NO: 73; SEQ ID NO: 74; SEQ ID NO: 75; SEQ ID NO: 76; SEQ ID NO: 77; SEQ ID NO: 78; SEQ ID NO: 79; SEQ ID NO: 80; SEQ ID NO: 81; SEQ ID NO: 82; SEQ ID NO: 83; SEQ ID NO: 84; SEQ ID NO: 85; SEQ ID NO: 86; SEQ ID NO: 87; SEQ ID NO: 88; SEQ ID NO: 89; SEQ ID NO: 90; SEQ ID NO: 91; SEQ ID NO: 92; SEQ ID NO: 93; SEQ ID NO: 94; SEQ ID NO: 95; SEQ ID NO: 96; SEQ ID NO: 97; SEQ ID NO: 98;

SEQ ID NO: 99; SEQ ID NO: 100; SEQ ID NO: 101; SEQ ID NO: 102; SEQ ID NO: 103; SEQ ID NO: 104; SEQ ID NO: 105; SEQ ID NO: 106; SEQ ID NO: 107; SEQ ID NO: 108; SEQ ID NO: 109; SEQ ID NO: 110; SEQ ID NO: 111; SEQ ID NO: 112; SEQ ID NO: 113; SEQ ID NO: 114; SEQ ID NO: 115; SEQ ID NO: 116; SEQ ID NO: 118; SEQ ID NO: 119; SEQ ID NO: 120; SEQ ID NO: 121; SEQ ID NO: 122; SEQ ID NO: 123; SEQ ID NO: 124; SEQ ID NO: 125; SEQ ID NO: 126; SEQ ID NO: 127; SEQ ID NO: 128; SEQ ID NO: 129; SEQ ID NO: 130; SEQ ID NO: 131; SEQ ID NO: 132; SEQ ID NO: 133; SEQ ID NO: 134; SEQ ID NO: 135; SEQ ID NO: 136; SEQ ID NO: 137; SEQ ID NO: 138; SEQ ID NO: 139; SEQ ID NO: 140; SEQ ID NO: 141; SEQ ID NO: 142; SEQ ID NO: 143; SEQ ID NO: 144; SEQ ID NO: 145; SEQ ID NO: 146; SEQ ID NO: 147; SEQ ID NO: 148; SEQ ID NO: 149; SEQ ID NO: 150; SEQ ID NO: 151; SEQ ID NO: 152; SEQ ID NO: 153; SEQ ID NO: 154; SEQ ID NO: 155; SEQ ID NO: 156; SEQ ID NO: 157; SEQ ID NO: 158; SEQ ID NO: 159; SEQ ID NO: 160; SEQ ID NO: 161; SEQ ID NO: 162; SEQ ID NO: 163; SEQ ID NO: 164; SEQ ID NO: 165; SEQ ID NO: 166; SEQ ID NO: 167; SEQ ID NO: 168; SEQ ID NO: 169; SEQ ID NO: 170; SEQ ID NO: 171; SEQ ID NO: 172; SEQ ID NO: 173; SEQ ID NO: 174; SEQ ID NO: 175; SEQ ID NO: 176; SEQ ID NO: 177; SEQ ID NO: 178; SEQ ID NO: 179; SEQ ID NO: 180; SEQ ID NO: 181; SEQ ID NO: 182; SEQ ID NO: 183; SEQ ID NO: 184; SEQ ID NO: 185; and SEQ ID NO: 186.

17. A microarray comprising an epithelial cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof, or portions of said nucleic acid sequence or complementary sequence thereof, selected from the group consisting of SEQ ID NO: 47; SEQ ID NO: 60; SEQ ID NO: 67; SEQ ID NO: 73; SEQ ID NO: 75; SEQ ID NO: 76; SEQ ID NO: 77; SEQ ID NO: 78; SEQ ID NO: 80; SEQ ID NO: 96; SEQ ID NO: 98; SEQ ID NO: 99; SEQ ID NO: 111; SEQ ID NO: 112; SEQ ID NO: 123; SEQ ID NO: 127; SEQ ID NO: 131; SEQ ID NO: 150; SEQ ID NO: 153; SEQ ID NO: 154; SEQ ID NO: 155; SEQ ID NO: 156; SEQ ID NO: 157; SEQ ID NO: 158; SEQ ID NO: 159; SEQ ID NO: 160; SEQ ID NO: 161; SEQ ID NO: 162; SEQ ID NO: 163; SEQ ID NO: 164; SEQ ID NO: 165; SEQ ID NO: 166; SEQ ID NO: 167; SEQ ID NO: 168; SEQ ID NO: 169; SEQ ID NO: 170; SEQ ID NO: 171; SEQ ID NO: 172; SEQ ID NO: 173; SEQ ID NO: 174; SEQ ID NO: 175; SEQ ID NO: 176; SEQ ID NO: 177; SEQ ID NO: 178; SEQ

ID NO: 179; SEQ ID NO: 180; SEQ ID NO: 181; SEQ ID NO: 182; SEQ ID NO: 183;
SEQ ID NO: 184; SEQ ID NO: 185; and SEQ ID NO: 186.

18. A microarray comprising a keratinocyte epithelial cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof, or portions of said nucleic acid sequence or complementary sequence thereof, selected from the group consisting of SEQ ID NO: 187; SEQ ID NO: 188; SEQ ID NO: 189; SEQ ID NO: 190; SEQ ID NO: 191; SEQ ID NO: 192; SEQ ID NO: 193; SEQ ID NO: 194; SEQ ID NO: 195; SEQ ID NO: 196; SEQ ID NO: 197; SEQ ID NO: 198; SEQ ID NO: 199; SEQ ID NO: 200; SEQ ID NO: 201; SEQ ID NO: 202; SEQ ID NO: 203; SEQ ID NO: 204; SEQ ID NO: 205; SEQ ID NO: 206; SEQ ID NO: 207; SEQ ID NO: 208; SEQ ID NO: 209; SEQ ID NO: 210; and SEQ ID NO: 211.
19. A microarray comprising a mammary epithelial cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof, or portions of said nucleic acid sequence or complementary sequence thereof, selected from the group consisting of SEQ ID NO: 78; SEQ ID NO: 212; SEQ ID NO: 213; SEQ ID NO: 216; SEQ ID NO: 225; SEQ ID NO: 226; SEQ ID NO: 227; SEQ ID NO: 239; SEQ ID NO: 271; SEQ ID NO: 285; and SEQ ID NO: 289.
20. A microarray comprising a bronchial epithelial cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof, or portions of said nucleic acid sequence or complementary sequence thereof, selected from the group consisting of SEQ ID NO: 27; SEQ ID NO: 131; SEQ ID NO: 150; SEQ ID NO: 169; SEQ ID NO: 214; SEQ ID NO: 215; SEQ ID NO: 223; SEQ ID NO: 224; SEQ ID NO: 241; SEQ ID NO: 243; SEQ ID NO: 244; SEQ ID NO: 255; SEQ ID NO: 256; SEQ ID NO: 261; and SEQ ID NO: 314.
21. A microarray comprising a prostate epithelial cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof, or portions of said nucleic acid sequence or complementary sequence thereof, selected from the group consisting of SEQ ID NO: 64;

SEQ ID NO: 217; SEQ ID NO: 218; SEQ ID NO: 259; SEQ ID NO: 293; SEQ ID NO: 302; and SEQ ID NO: 320.

22. A microarray comprising a renal cortical epithelial cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof, or portions of said nucleic acid sequence or complementary sequence thereof, selected from the group consisting of SEQ ID NO: 49; SEQ ID NO: 57; SEQ ID NO: 104; SEQ ID NO: 123; SEQ ID NO: 160; SEQ ID NO: 165; SEQ ID NO: 166; SEQ ID NO: 219; SEQ ID NO: 267; SEQ ID NO: 270; SEQ ID NO: 279; SEQ ID NO: 280; SEQ ID NO: 283; SEQ ID NO: 291; SEQ ID NO: 305; SEQ ID NO: 307; SEQ ID NO: 310; SEQ ID NO: 313; SEQ ID NO: 325; SEQ ID NO: 326; and SEQ ID NO: 327.
23. A microarray comprising renal proximal tubule epithelial cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof, or portions of said nucleic acid sequence or complementary sequence thereof, selected from the group consisting of SEQ ID NO: 106; SEQ ID NO: 138; SEQ ID NO: 158; SEQ ID NO: 228; SEQ ID NO: 236; SEQ ID NO: 242; SEQ ID NO: 250; SEQ ID NO: 258; SEQ ID NO: 260; SEQ ID NO: 262; SEQ ID NO: 266; SEQ ID NO: 272; SEQ ID NO: 273; SEQ ID NO: 274; SEQ ID NO: 275; SEQ ID NO: 276; SEQ ID NO: 278; SEQ ID NO: 284; SEQ ID NO: 288; SEQ ID NO: 295; SEQ ID NO: 296; SEQ ID NO: 297; SEQ ID NO: 299; SEQ ID NO: 300; SEQ ID NO: 301; SEQ ID NO: 306; SEQ ID NO: 308; SEQ ID NO: 309; SEQ ID NO: 311; SEQ ID NO: 316; SEQ ID NO: 318; SEQ ID NO: 321; SEQ ID NO: 322; SEQ ID NO: 328; and SEQ ID NO: 329.
24. A microarray comprising a small airway epithelial cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof, or portions of said nucleic acid sequence or complementary sequence thereof, selected from the group consisting of SEQ ID NO: 173; SEQ ID NO: 174; SEQ ID NO: 183; SEQ ID NO: 220; SEQ ID NO: 221; SEQ ID NO: 222; SEQ ID NO: 229; SEQ ID NO: 230; SEQ ID NO: 231; SEQ ID NO: 232; SEQ ID NO: 233; SEQ ID NO: 234; SEQ ID NO: 235; SEQ ID NO: 237; SEQ ID NO: 238; SEQ ID NO: 240; SEQ ID NO: 245; SEQ ID NO: 246; SEQ ID NO: 247; SEQ

ID NO: 248; SEQ ID NO: 249; SEQ ID NO: 251; SEQ ID NO: 252; SEQ ID NO: 254; SEQ ID NO: 257; SEQ ID NO: 263; SEQ ID NO: 264; SEQ ID NO: 265; SEQ ID NO: 268; SEQ ID NO: 269; SEQ ID NO: 270; SEQ ID NO: 277; SEQ ID NO: 281; SEQ ID NO: 282; SEQ ID NO: 286; SEQ ID NO: 287; SEQ ID NO: 290; SEQ ID NO: 294; SEQ ID NO: 298; SEQ ID NO: 303; SEQ ID NO: 312; SEQ ID NO: 315; SEQ ID NO: 317; and SEQ ID NO: 319.

25. A microarray comprising a renal epithelial cell gene expression profile comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof, or portions of said nucleic acid sequence or complementary sequence thereof, selected from the group consisting of SEQ ID NO: 37; SEQ ID NO: 253; SEQ ID NO: 304; SEQ ID NO: 323; and SEQ ID NO: 324.
26. A microarray comprising one or more nucleic acid sequences substantially homologous to a nucleic acid sequence or complementary sequence thereof, or portions of said nucleic acid sequence or complementary sequence thereof, selected from the group consisting of SEQ ID NO: 27; SEQ ID NO: 37; SEQ ID NO: 49; SEQ ID NO: 57; SEQ ID NO: 64; SEQ ID NO: 70; SEQ ID NO: 78; SEQ ID NO: 104; SEQ ID NO: 106; SEQ ID NO: 123; SEQ ID NO: 131; SEQ ID NO: 138; SEQ ID NO: 150; SEQ ID NO: 158; SEQ ID NO: 160; SEQ ID NO: 165; SEQ ID NO: 166; SEQ ID NO: 169; SEQ ID NO: 173; SEQ ID NO: 174; SEQ ID NO: 183; SEQ ID NO: 187; SEQ ID NO: 188; SEQ ID NO: 189; SEQ ID NO: 190; SEQ ID NO: 191; SEQ ID NO: 192; SEQ ID NO: 193; SEQ ID NO: 194; SEQ ID NO: 195; SEQ ID NO: 196; SEQ ID NO: 197; SEQ ID NO: 198; SEQ ID NO: 199; SEQ ID NO: 200; SEQ ID NO: 201; SEQ ID NO: 202; SEQ ID NO: 203; SEQ ID NO: 204; SEQ ID NO: 205; SEQ ID NO: 206; SEQ ID NO: 207; SEQ ID NO: 208; SEQ ID NO: 209; SEQ ID NO: 210; SEQ ID NO: 211; SEQ ID NO: 212; SEQ ID NO: 213; SEQ ID NO: 214; SEQ ID NO: 215; SEQ ID NO: 216; SEQ ID NO: 217; SEQ ID NO: 218; SEQ ID NO: 219; SEQ ID NO: 220; SEQ ID NO: 221; SEQ ID NO: 222; SEQ ID NO: 223; SEQ ID NO: 224; SEQ ID NO: 225; SEQ ID NO: 226; SEQ ID NO: 227; SEQ ID NO: 228; SEQ ID NO: 229; SEQ ID NO: 230; SEQ ID NO: 231; SEQ ID NO: 232; SEQ ID NO: 233; SEQ ID NO: 234; SEQ ID NO: 235; SEQ ID NO: 236; SEQ ID NO: 237; SEQ ID NO: 238; SEQ ID NO: 239; SEQ ID NO: 240; SEQ ID NO: 241; SEQ ID NO: 242; SEQ ID NO: 243; SEQ ID NO: 244; SEQ ID NO: 245; SEQ ID NO: 246; SEQ ID NO: 247; SEQ ID NO: 248; SEQ ID NO: 249; SEQ ID NO: 250; SEQ ID NO: 251;

SEQ ID NO: 252; SEQ ID NO: 253; SEQ ID NO: 254; SEQ ID NO: 255; SEQ ID NO: 256; SEQ ID NO: 257; SEQ ID NO: 258; SEQ ID NO: 259; SEQ ID NO: 260; SEQ ID NO: 261; SEQ ID NO: 262; SEQ ID NO: 263; SEQ ID NO: 264; SEQ ID NO: 265; SEQ ID NO: 266; SEQ ID NO: 267; SEQ ID NO: 268; SEQ ID NO: 269; SEQ ID NO: 270; SEQ ID NO: 271; SEQ ID NO: 272; SEQ ID NO: 273; SEQ ID NO: 274; SEQ ID NO: 275; SEQ ID NO: 276; SEQ ID NO: 277; SEQ ID NO: 278; SEQ ID NO: 279; SEQ ID NO: 280; SEQ ID NO: 281; SEQ ID NO: 282; SEQ ID NO: 283; SEQ ID NO: 284; SEQ ID NO: 285; SEQ ID NO: 286; SEQ ID NO: 287; SEQ ID NO: 288; SEQ ID NO: 289; SEQ ID NO: 290; SEQ ID NO: 291; SEQ ID NO: 293; SEQ ID NO: 294; SEQ ID NO: 295; SEQ ID NO: 296; SEQ ID NO: 297; SEQ ID NO: 298; SEQ ID NO: 299; SEQ ID NO: 300; SEQ ID NO: 301; SEQ ID NO: 302; SEQ ID NO: 303; SEQ ID NO: 304; SEQ ID NO: 305; SEQ ID NO: 306; SEQ ID NO: 307; SEQ ID NO: 308; SEQ ID NO: 309; SEQ ID NO: 310; SEQ ID NO: 311; SEQ ID NO: 312; SEQ ID NO: 313; SEQ ID NO: 314; SEQ ID NO: 315; SEQ ID NO: 316; SEQ ID NO: 317; SEQ ID NO: 318; SEQ ID NO: 320; SEQ ID NO: 321; SEQ ID NO: 322; SEQ ID NO: 323; SEQ ID NO: 324; SEQ ID NO: 325; SEQ ID NO: 326; SEQ ID NO: 327; SEQ ID NO: 328; and SEQ ID NO: 329.

27. A microarray comprising a gene expression profile comprising one or more genes or oligonucleotide probes obtained therefrom, wherein said gene expression profile is generated from a cell type selected from the group comprising coronary artery endothelium, umbilical artery endothelium, umbilical vein endothelium, aortic endothelium, dermal microvascular endothelium, pulmonary artery endothelium, myometrium microvascular endothelium, keratinocyte epithelium, bronchial epithelium, mammary epithelium, prostate epithelium, renal cortical epithelium, renal proximal tubule epithelium, small airway epithelium, renal epithelium, umbilical artery smooth muscle, neonatal dermal fibroblast, pulmonary artery smooth muscle, dermal fibroblast, neural progenitor cells, skeletal muscle, astrocytes, aortic smooth muscle, mesangial cells, coronary artery smooth muscle, bronchial smooth muscle, uterine smooth muscle, lung fibroblast, osteoblasts, and prostate stromal cells.
28. A method of determining the level of RNA expression for a sample comprising the steps of:

determining the level of RNA expression for an RNA sample, wherein said RNA sample is amplified, fluorescently labeled, and hybridized to a microarray containing a plurality of nucleic acid sequences, and wherein said microarray is scanned for fluorescence;

normalizing said expression level using an algorithm; and

scoring said RNA sample against a gene expression profile database.

29. The method of claim 28, wherein said RNA sample is obtained from a patient.

30. The method of claim 29, wherein said RNA sample is selected from the group consisting of blood, urine, amniotic fluid, plasma, semen, bone marrow, and tissue biopsy.

31. The method of claim 28, wherein said algorithm is the MaxCor algorithm.

32. The method of claim 28, wherein said algorithm is the Mean Log Ratio algorithm.

33. A method for constructing a gene expression profile comprising the steps of:

hybridizing prepared RNA samples to at least one microarray containing a plurality of nucleic acid sequences representing human genes;

obtaining an expression level for each of said plurality of nucleic acid sequences representing human genes on each of said at least one microarrays; and

normalizing said expression level for each of said plurality of nucleic acid sequences representing human genes on each of said at least one microarrays to control standards.

34. The method of claim 33 further comprising the steps of:

applying an algorithm to each of said normalized gene expression levels;

performing a correlation analysis for all of said normalized gene expression microarrays within a group of samples;

establishing a gene expression profile; and

validating the gene expression profile.

35. The method of claim 34, wherein said algorithm is the MaxCor algorithm.

36. The method of claim 35, wherein applying said MaxCor algorithm to each of said normalized gene expression levels assigns a numeric value to each gene represented on said at least one microarray based upon expression level.
37. The method of claim 36, wherein said numeric value is a number between the range of (-1,+1).
38. The method of claim 37, wherein a negative value of said numeric value represents a gene with relatively lower expression.
39. The method of claim 37, wherein a zero value of said numeric value represents no relative gene expression difference.
40. The method of claim 37, wherein a positive value of said numeric value represents a gene with relatively higher expression.
41. The method of claim 36, wherein said numeric value is a number between the range of (-2,+2).
42. The method of claim 41, wherein a negative value of said numeric value represents a gene with relatively lower expression.
43. The method of claim 41, wherein a zero value of said numeric value represents no relative gene expression difference.
44. The method of claim 41, wherein a positive value of said numeric value represents a gene with relatively higher expression.
45. The method of claim 34, wherein said algorithm is the Mean Log Ratio algorithm.
46. The method of claim 45, wherein applying said Mean Log Ratio algorithm to each of said gene expression microarrays assigns a numeric value to each gene contained on said microarray based upon expression level.

47. The method of claim 46, wherein said numeric value is between the range of $(-1,+1)$.
48. The method of claim 47, wherein a negative value of said numeric value represents a gene with relatively lower expression.
49. The method of claim 47, wherein a zero value of said numeric value represents no relative gene expression difference.
50. The method of claim 47, wherein a positive value of said numeric value represents a gene with relatively higher expression.
51. The method of claim 46, wherein said numeric value is a number between the range of $(-2,+2)$.
52. The method of claim 51, wherein a negative value of said numeric value represents a gene with relatively lower expression.
53. The method of claim 51, wherein a zero value of said numeric value represents no relative gene expression difference.
54. The method of claim 51, wherein a positive value of said numeric value represents a gene with relatively higher expression.
55. A method, in a computer system, for constructing and analyzing a gene expression profile comprising the steps of:
- inputting gene expression data for each of a plurality of genes;
 - normalizing expression data by transforming said data into log ratio values;
 - filtering weak differential values;
 - applying an algorithm to each of said normalized gene expression values;
 - performing a classification analysis for all of said normalized gene expression values;
 - establishing a gene expression profile; and
 - validating the gene expression profile.
56. The method of claim 55, wherein said algorithm is the MaxCor algorithm.

57. The method of claim 55, wherein said algorithm is the Mean Log Ratio algorithm.
58. A computer program for constructing and analyzing a gene expression profile comprising:
- computer code that receives as input gene expression data for a plurality of genes;
 - computer code that normalizes expression data by transforming said data into log ratio values;
 - computer code that applies an algorithm to each of said normalized gene expression values;
 - computer code that performs a correlation analysis for all of said normalized gene expression values;
 - computer code that establishes and validates the gene expression profile; and
 - computer readable medium that stores computer code.
59. The computer program of claim 58, wherein said algorithm is the MaxCor algorithm.
60. The computer program of claim 58, wherein said algorithm is the Mean Log Ratio algorithm.
61. A method for determining the phenotype of a cell comprising the steps of
- applying an algorithm to extract a gene expression profile from gene expression data generated from said cell; and
 - matching said gene expression profile to a gene expression profile generated from a cell of known phenotype.
62. The method of claim 61, wherein said algorithm is the MaxCor algorithm.
63. The method of claim 61, wherein said algorithm is the Mean Log Ratio algorithm.
64. The method of claim 61, wherein said applying step comprises setting a cutoff value for expression relative to normalized values, wherein said cutoff value is at least about two-fold induction above the normalized values.

65. The method of claim 61, wherein said matching step is performed using a database comprising one or more gene expression profiles generated from cells of known phenotype.
66. A method for distinguishing cell types comprising the step of matching a gene expression profile generated from a biological sample using an algorithm to a known gene expression profile of a specific cell type.
67. The method of claim 66, wherein said algorithm is the MaxCor algorithm.
68. The method of claim 66, wherein said algorithm is the Mean Log Ratio algorithm.
69. The method of claim 66, wherein said specific cell type is selected from the group consisting of coronary artery endothelium, umbilical artery endothelium, umbilical vein endothelium, aortic endothelium, dermal microvascular endothelium, pulmonary artery endothelium, myometrium microvascular endothelium, keratinocyte epithelium, bronchial epithelium, mammary epithelium, prostate epithelium, renal cortical epithelium, renal proximal tubule epithelium, small airway epithelium, renal epithelium, umbilical artery smooth muscle, neonatal dermal fibroblast, pulmonary artery smooth muscle, dermal fibroblast, neural progenitor cells, skeletal muscle, astrocytes, aortic smooth muscle, mesangial cells, coronary artery smooth muscle, bronchial smooth muscle, uterine smooth muscle, lung fibroblast, osteoblasts, and prostate stromal cells.
70. A microarray comprising one or more protein-capture agents that specifically bind to all or a portion of one or more of the proteins encoded by the genes comprising the gene expression profile of claim 1.
71. A microarray comprising one or more protein-capture agents that specifically bind to all or a portion of one or more of the proteins encoded by the genes comprising the gene expression profile of claim 2.
72. A microarray comprising one or more protein-capture agents that specifically bind to all or a portion of one or more of the proteins encoded by the genes comprising the gene expression profile of claim 3.

73. A microarray comprising one or more protein-capture agents that specifically bind to all or a portion of one or more of the proteins encoded by the genes comprising the gene expression profile of claim 4
74. A microarray comprising one or more protein-capture agents that specifically bind to all or a portion of one or more of the proteins encoded by the genes comprising the gene expression profile of claim 5.
75. A microarray comprising one or more protein-capture agents that specifically bind to all or a portion of one or more of the proteins encoded by the genes comprising the gene expression profile of claim 6.
76. A microarray comprising one or more protein-capture agents that specifically bind to all or a portion of one or more of the proteins encoded by the genes comprising the gene expression profile of claim 7.
77. A microarray comprising one or more protein-capture agents that specifically bind to all or a portion of one or more of the proteins encoded by the genes comprising the gene expression profile of claim 8.
78. A microarray comprising one or more protein-capture agents that specifically bind to all or a portion of one or more of the proteins encoded by the genes comprising the gene expression profile of claim 9.
79. A microarray comprising one or more protein-capture agents that specifically bind to all or a portion of one or more of the proteins encoded by the genes comprising the gene expression profile of claim 10.
80. A microarray comprising one or more protein-capture agents that specifically bind to all or a portion of one or more of the proteins encoded by the genes comprising the gene expression profile of claim 11.

81. A microarray comprising one or more protein-capture agents that specifically bind to all or a portion of one or more of the proteins encoded by the genes comprising the gene expression profile of claim 12.
82. A method for determining the phenotype of a cell comprising the steps of
 applying an algorithm to extract a protein expression profile from protein expression data generated from said cell; and
 matching said protein expression profile to a protein expression profile generated from a cell of known phenotype.
83. The method of claim 82, wherein said algorithm is the MaxCor algorithm.
84. The method of claim 82, wherein said algorithm is the Mean Log Ratio algorithm.
85. The method of claim 82, wherein said applying step comprises setting a cutoff value for expression relative to normalized values, wherein said cutoff value is at least about two-fold induction above the normalized values.
86. The method of claim 82, wherein said matching step is performed using a database comprising one or more protein expression profiles generated from cells of known phenotype.
87. A method for distinguishing cell types comprising the step of matching a protein expression profile generated from a biological sample using an algorithm to a known protein expression profile of a specific cell type.
88. The method of claim 87, wherein said algorithm is the MaxCor algorithm.
89. The method of claim 87, wherein said algorithm is the Mean Log Ratio algorithm.
90. The method of claim 87, wherein said specific cell type is selected from the group consisting of coronary artery endothelium, umbilical artery endothelium, umbilical vein endothelium, aortic endothelium, dermal microvascular endothelium, pulmonary artery endothelium, myometrium microvascular endothelium, keratinocyte epithelium, bronchial

epithelium, mammary epithelium, prostate epithelium, renal cortical epithelium, renal proximal tubule epithelium, small airway epithelium, renal epithelium, umbilical artery smooth muscle, neonatal dermal fibroblast, pulmonary artery smooth muscle, dermal fibroblast, neural progenitor cells, skeletal muscle, astrocytes, aortic smooth muscle, mesangial cells, coronary artery smooth muscle, bronchial smooth muscle, uterine smooth muscle, lung fibroblast, osteoblasts, and prostate stromal cells.




Figure 1





Figure 2

PRI ID	GB	Description	Mean±S.E.M. (Small)	Mean±S.E.M. (Large)	Ratio	p
192294	AF059030	<i>Rattus norvegicus</i> voltage-gated Na channel alpha subunit (NaN)	161.34±20.07	51.3±12.99*	3.15	0.0005
192195	D86642	Rat mRNA for FK506-binding protein	496.33±40.11	158.8±35.13	3.13	0.0005
192207	U16655	<i>Rattus norvegicus</i> phospholipase C delta-4	146.33±10.03	53.06±4.23	2.76	0.0005
192163	X90651	<i>Rattus norvegicus</i> P2X3 receptor	390.28±10.4	164.81±26.22	2.37	0.0005
191858	S69874	C-FABP: cutaneous fatty acid-binding protein (rat)	448.26±30.01	196.97±18.68	2.28	0.0005
192139	D45249	Rat proteasome activator rPA28 subunit alpha	104.46±5.24	47.74±6.97*	2.19	0.0005
192178	L12447	<i>Mus musculus</i> insulin-like growth factor binding protein 5	288.97±8.47	141.67±5.61	2.04	0.0005
192306	X77953	<i>Rattus norvegicus</i> ribosomal protein S15a.	415.77±54.08	204.19±25.03	2.04	0.005
192129	M38188	Human unknown protein from clone pHGR74	114.72±10.98	57.47±11.64*	2.00	0.0025
192339		Novel	83.94±6.26	42.42±7.75*	1.98	0.001
191857	L00111	Rat CGRP	900.1±45.83	459.99±35.39	1.96	0.0005
192203	AF059486	<i>Mus musculus</i> putative actin-binding protein DOC6	861.16±32.58	448.32±68.77	1.92	0.0005
192351	U25844	<i>Mus musculus</i> serine proteinase inhibitor (SPI3)	271.95±30.44	142.81±6.93	1.90	0.0025
191837	M29472	<i>Rattus norvegicus</i> mevalonate kinase	94.44±9.63	51.83±5.95*	1.82	0.0025
191628		Novel	635.92±73.01	363.86±11.53	1.75	0.005
192175		Novel	181.28±13.23	105.36±10.39	1.72	0.0005
192284		Novel	188.28±13	110.53±7.27	1.70	0.0005
192330	Y10386	MMC1INH <i>Mus musculus</i> C1 inhibitor	134.88±11.01	79.3±5.51	1.70	0.0005
192199	D42137	Rat annexin V gene	439.57±13.62	265.21±14.97	1.66	0.0005
192011	M98194	Rat extracellular signal-regulated kinase 1	319.35±32.79	194.88±6.83	1.64	0.005
192206	U59673	<i>Rattus norvegicus</i> 5HT3 receptor	139.96±4.07	85.48±6.17	1.64	0.0005
192167	U23146	<i>Rattus norvegicus</i> mitogenic regulation SscCKS	456.44±13.34	300.71±23.25	1.52	0.0005
191848	M93056	Human monocyte/neutrophil elastase inhibitor	125.16±14.75	82.56±15.38	1.52	0.05
192309		Novel	463.17±45.37	308.05±25.45	1.50	0.01

Figure 3

PRI ID	GB	Description	Mean±S.E.M. (Small)	Mean±S.E.M. (Large)	Ratio	p
192393	M25638	Rat smallest neurofilament protein (NF-L)	63.3±6.12	551.56±34.94	8.71	0.0005
191624	M14656	Rat osteopontin	53.4±4.11*	218.52±22.81	4.09	0.0005
192157	J04517	Rat high molecular weight neurofilament (NF-H)	475.86±18.59	1319.77±50.3	2.77	0.0005
192282	Z12152	<i>Rattus norvegicus</i> neurofilament protein middle	75.93±3.75	206.55±9.92	2.72	0.0005
192378	D87445	Human KIAA0256	30.26±2.66*	77.42±17.52	2.56	0.025
192283		Novel	50.9±3.45*	128.56±6.86	2.53	0.0005
192125	V00681	<i>Rattus norvegicus</i> mitochondrial genes for 16S rRNA, tRNA	186.5±14.61	445.82±23.95	2.39	0.0005
191851	X51396	Mouse MAP1B microtubule-associated protein	90.84±5.91	215.55±21.35	2.37	0.0025
192424	M91808	<i>Rattus norvegicus</i> sodium channel beta-1	83.99±7.93	194.88±20.61	2.32	0.0025
191862	S67755	hsp 27:heat shock protein 27 (Sprague-Dawley rats)	144.74±10.14	265.94±19.44	1.84	0.0005
192016	L10426	<i>Mus musculus</i> ets-related protein 81 (ER81)	43.85±1.89*	80.04±7.16	1.83	0.0025
192228		Novel	28.9±1.11*	52±3.41	1.80	0.0005
192411	M21551	Human neuromedin B	57.62±5.56*	97.18±6.61	1.69	0.0005
192422		Novel	110.06±11.78	168.52±12.14	1.53	0.0025

Figure 4




Figure 5

Clone ID	GB	Description	Small DRG		Large DRG	
			Intensity	% Labeled	Intensity	% Labeled
192393	M25638	Rat smallest neurofilament protein (NF-L)	±	100%	+++	100%
192157	J04517	Rat high molecular weight neurofilament (NF-H)	± / -	21.40%	+++	98.60%
192424	M91808	<i>Rattus norvegicus</i> sodium channel beta-1	± / -	10%	++	96.30%
192273	M13501	Rat liver fatty acid binding protein	+ / ++	62.20%	+ / -	1%
192294	AF059030	<i>Rattus norvegicus</i> voltage-gated Na channel (NaN)	++ / +	96.70%	+ / -	4.20%
192199	D42137	Rat annexin V gene	+ / ++	95.00%	+ / ++	74.00%
192207	U16655	<i>Rattus norvegicus</i> phospholipase C delta-4	++	42.20%	-	0%
191857	L00111	Rat CGRP	+++ / ++	83.70%	++ / -	9.40%

Figure 6

Vector	Primary Cell	Classification
1	Coronary artery endothelial	Endothelial
2	Umbilical artery endothelial	Endothelial
3	Umbilical vein endothelial	Endothelial
4	Aortic endothelial	Endothelial
5	Dermal microvascular endothelial	Endothelial
6	Pulmonary artery endothelial	Endothelial
7	Myometrium microvascular	Endothelial
8	Keratinocyte epidermal	Epithelial
9	Bronchial epithelial	Epithelial
10	Mammary epithelial	Epithelial
11	Prostate epithelial	Epithelial
12	Renal cortical epithelial	Epithelial
13	Renal proximal tubule epithelial	Epithelial
14	Small airway epithelial	Epithelial
15	Renal epithelial	Epithelial
16	Umbilical artery smooth muscle	Muscle
17	Neonatal dermal fibroblast	Muscle
18	Pulmonary artery smooth muscle	Muscle
19	Dermal fibroblast	Muscle
20	Neural progenitor cell	Muscle
21	Skeletal muscle	Muscle
22	Astrocyte	Muscle
23	Aortic smooth muscle	Muscle
24	Mesangial cell	Muscle
25	Coronary artery smooth muscle	Muscle
26	Bronchial smooth muscle	Muscle
27	Uterine smooth muscle	Muscle
28	Lung fibroblast	Muscle
29	Osteoblast	Muscle
30	Prostate stromal cell	Muscle

Figure 7




Figure 8

Primary Cell Gene Expression Profile

Seq. Source	Accession	Muscle Signature			p-value	Source Description
		Endothelial Signature	Epithelial Signature	Muscle Signature		
GB	J03278	-0.41	-0.40	0.81	0.000011	Human platelet-derived growth factor (PDGF) receptor mRNA, complete cds
GB	U52165	0.68	-0.48	-0.20	0.000013	EST: AA150416 z105b02.s1 Soares_pregnant_uterus_NbHPU H
GB	W49672	-0.15	-0.19	0.34	0.000016	EST: Wingless-type MMTV integration site 5A, human homolog
INCYTE	3486371H1	0.19	0.48	-0.67	0.000016	EPIGN0T01 L24893 g529405 PO; myelin protein zero gb103prip 14 -1
GB	U16811	0.03	0.23	-0.26	0.000017	Human Bak mRNA, complete cds.
GB	K01918	0.57	-0.16	-0.42	0.000022	Human c-sis proto-oncogene for platelet-derived growth factor, exon 1 and flanks.
INCYTE	1227785H1	-0.32	1.07	-0.75	0.000023	AB000714 AB000714 Homo sapiens HRVP1 mRNA for RVP1, complete cds. Blastn P. 0.029
GB	AA293050	0.09	0.34	-0.42	0.000025	JNK ACTIVATING KINASE 1
GB	R09836	0.31	0.01	-0.32	0.000025	EST: Weakly similar to K04G11.4 [C.elegans]
GB	R06417	0.01	0.66	-0.68	0.000025	Junction plakoglobin
GB	AA243828	-0.17	-0.51	0.68	0.000027	H.sapiens mRNA for receptor protein tyrosine kinase
GB	M11749	-0.54	-0.50	1.04	0.000028	Human Thy-1 glycoprotein gene, complete cds.
INCYTE	1321982H1	0.50	-0.07	-0.43	0.000028	BLADNOT04 AF009225 g2327068 Human IkB kinase alpha subunit (IKK alpha gb104prip 90 -52
INCYTE	285478CA2	0.85	-0.40	-0.45	0.000028	EOSIHET02 g1296608 Human mRNA for chemokine CC-2 and CC-1. gb96prip 32 -74
INCYTE	547531H1	-0.03	0.36	-0.33	0.000028	U36445 Bos taurus calcium-activated chloride channel mRNA, complete cds
GB	AA521243	0.49	-0.36	-0.13	0.000029	PUTATIVE 60S RIBOSOMAL PROTEIN
GB	U46005	0.52	0.16	-0.68	0.000029	Human MDC15 mRNA, complete cds.
GB	Z74616	-0.71	-0.74	1.45	0.000030	H.sapiens mRNA for prepro-alpha2(I) collagen.
GB	H96850	0.38	0.26	-0.64	0.000031	Human mRNA for KIAA0115 gene, complete cds
INCYTE	2997284H1	0.38	0.50	-0.88	0.000033	OVARTUT07 D30785 g1648847 Mouse mRNA for neuropsin, complete cds. gb104rod 41 -24
GB	AA488073	0.02	0.41	-0.43	0.000035	Mucin 1, transmembrane

Figure 9a

Primary Cell Gene Expression Profile

Seq Source	Accession	p-value			Source Description
		Endothelial Signature	Epithelial Signature	Muscle Signature	
GB	AA055193	0.12	0.32	-0.44	EST: Weakly similar to No definition line found [C.elegans]
GB	X63368	-0.25	-0.08	0.32	H.sapiens HSJ1 mRNA
GB	AA435938	-0.19	-0.16	0.35	EST: zu01a08.s1 Soares_testis_NHT Homo sapiens cDNA clone 730550 3' similar to TR:G817957 G817957 GLYCINE
INCYTE	1726828F6	-0.07	-0.20	0.27	EST: PROSNOT14
GB	X00663	-0.29	0.37	-0.08	Human mRNA fragment for epidermal growth factor (EGF) receptor
GB	U09278	-0.30	-0.30	0.61	Human fibroblast activation protein mRNA, complete cds.
GB	H40103	-0.20	-0.15	0.34	EST: yn85c06.s1 Soares adult brain N2b5HB55Y Homo sapiens cDNA clone 175210 3', mRNA sequence
GB	L41147	-0.04	-0.07	0.12	Homo sapiens 5-HT6 serotonin receptor mRNA, complete cds
GB	M32977	-0.52	0.51	0.01	Human heparin-binding vascular endothelial growth factor (VEGF) mRNA, complete cds
INCYTE	3014785H1	-0.21	-0.21	0.42	MUSCNOT07 M33210 g532591 Human colony stimulating factor 1 recept gb106pri 100 -71
INCYTE	4872203H1	-0.35	1.04	-0.69	EST
INCYTE	3985758H1	0.42	0.09	-0.52	EST
INCYTE	853668H1	-0.33	-0.12	0.45	NGANNOT01 U78192 g1688304 Human Edg-2 receptor mRNA, complete cds. gb104pri 67 -35
GB	U96113	0.12	0.10	-0.22	Homo sapiens Nedd-4-like ubiquitin-protein ligase WWP1 mRNA, partial cds.
GB	AA292676	0.17	0.31	-0.48	Human metargidin precursor mRNA, complete cds
GB	H58873	-0.78	1.02	-0.24	Human (HepG2) glucose transporter gene mRNA, complete cds
GB	X60957	1.46	-0.81	-0.65	Human tie mRNA for putative receptor tyrosine kinase.
GB	AF023476	-0.19	-0.14	0.34	Homo sapiens meltrin-L precursor (ADAM12) mRNA, complete cds.
GB	V00509	-0.22	-0.19	0.41	Human gene for preproenkephalin
GB	AA452627	-0.20	-0.07	0.26	Endothelin receptor type A

Figure 9b

Primary Cell Gene Expression Profile

Seq Source	Accession	Signature			p-value	Source Description
		Endothelial Signature	Epithelial Signature	Muscle Signature		
GB	N95657	0.07	0.29	-0.35	0.000054	EST: Highly similar to HYPOTHETICAL 63.5 KD PROTEIN ZK353.1 IN CHROMOSOME III [Caenorhabditis elegans]
GB	U79666	0.20	0.06	-0.26	0.000060	EST
GB	M58664	-0.60	0.94	-0.34	0.000061	Homo sapiens CD24 signal transducer mRNA, complete cds.
GB	W87741	0.57	-0.17	-0.39	0.000063	EST: Novel
GB	M75165	-0.26	-0.80	1.06	0.000065	AA477400 zu42a03.s1 Soares ovary tumor NbHOT Homo
GB	AA487812	0.52	-0.94	0.43	0.000065	Vimentin
GB	M24899	-0.02	-0.13	0.15	0.000066	Human triiodothyronine (ear7) mRNA, complete cds.
INCYTE	3415853H1	-0.25	-0.28	0.53	0.000067	L40459 MUSLTBP Mus musculus latent transforming growth factor-beta binding protein (LTBP-3) mRNA, complete cds.
INCYTE	1690295F6	-0.11	-0.07	0.17	0.000074	PROSTUT10 M81784 g205039 Rat K+ channel mRNA, sequence. gb102rod 19 15
GB	D13515	-0.06	-0.18	0.24	0.000077	HUMMARR Human mRNA for key subunit of the N-methyl-D-aspartate receptor, complete cds.
GB	Y00757	-0.15	-0.17	0.32	0.000083	Human mRNA for polypeptide 7B2.
GB	L76380	0.48	-0.27	-0.20	0.000083	Homo sapiens (clone HSNME29) CGRP type 1 receptor mRNA, complete cds
INCYTE	290375H1	-0.35	-0.02	0.37	0.000087	TMLR3DT01 X83864 g1770395 Human EDG-3 gene. gb104pri 10 11
GB	M32304	0.15	-0.64	0.49	0.000088	Human metalloproteinase inhibitor mRNA, complete cds.
GB	M30704	-0.77	1.27	-0.50	0.000093	Human amphiregulin (AR) mRNA, complete cds, clones lambda-AR1 and lambda-AR2.
GB	X51416	-0.03	0.22	-0.19	0.000101	Human mRNA for steroid hormone receptor hERR1.
INCYTE	530695T6	1.05	-0.51	-0.54	0.000103	EST: BRAINOT03
GB	M32315	0.42	-0.28	-0.14	0.000107	Human tumor necrosis factor receptor mRNA, complete cds
INCYTE	4504614H1	0.39	-0.07	-0.31	0.000108	BRAVXT02 AF001434 g2529706 Human Hpast (HPAST) mRNA, complete cds. gb106pri 37 -7
GB	U80811	-0.34	-0.04	0.38	0.000115	Human lysophosphatidic acid receptor homolog mRNA, complete cds

Figure 9c

12/47

Primary Cell Gene Expression Profile

Seq Source	Accession	Signature			p-value	Source Description
		Endothelial	Epithelial	Muscle		
GB	R93149	-0.19	0.04	0.14	0.000117	EST
GB	AA055101	0.35	-0.03	-0.32	0.000126	Homo sapiens NADH:ubiquinone oxidoreductase 18 kDa IP subunit mRNA, nuclear gene encoding mitochondrial protein, H.sapiens mRNA for transforming growth factor alpha
GB	X70340	-0.27	0.61	-0.34	0.000126	Human mRNA for ICAM-2, cell adhesion ligand for LFA-1.
GB	X15606	1.90	-0.91	-0.99	0.000126	UTRSNOT05 X92521 g1731985 Human mRNA for MMP-19 protein. gb104prt 100 -48
INCYTE	1570946T6	-0.15	-0.15	0.30	0.000133	Homo sapiens (clone pAT 464) potential lymphokine/cytokine mRNA, complete cds
GB	M25315	-0.92	1.58	-0.66	0.000134	PROSNOT18 AF013598 g2352948 Rat proton gated cation channel DRASIC m gb103rod 30 -11
INCYTE	1858095F6	-0.55	0.90	-0.35	0.000138	Homo sapiens CaM kinase II isoform mRNA, complete cds
GB	AA443177	-0.88	-0.83	1.71	0.000139	Human interleukin 11 mRNA, complete cds
GB	M57765	-0.09	-0.08	0.16	0.000140	Homo sapiens G protein-coupled receptor (GPR4) gene, complete cds.
GB	L36148	0.35	-0.17	-0.18	0.000141	Human class III alcohol dehydrogenase (ADH5) chi subunit mRNA, complete cds.
GB	M30471	-0.28	-0.08	0.36	0.000142	EST
GB	H25229	0.28	-0.21	-0.07	0.000142	Homo sapiens mRNA for ST2 protein
GB	D12763	0.95	-0.30	-0.66	0.000142	Homo sapiens mRNA for GABA-BR1a (hGB1a) receptor.
GB	Y11044	-0.08	-0.11	0.19	0.000145	Human collagenase type IV mRNA, 3' end.
GB	J03210	0.40	-1.24	0.84	0.000145	Human LTF mRNA for lactoferrin (lactotransferrin).
GB	X52941	-0.13	-0.11	0.24	0.000149	H.sapiens RON mRNA for tyrosine kinase.
GB	X70040	-0.20	0.42	-0.22	0.000149	Solute carrier family 9 (sodium/hydrogen exchanger), isoform 1 (antiporter, Na+/H+, amiloride sensitive)
GB	AA459197	-0.39	0.81	-0.43	0.000151	Human mRNA for KIAA0313 gene, complete cds
GB	AA488969	0.00	-0.57	0.57	0.000153	Human monocyte antigen CD14 (CD14) mRNA, complete cds.
GB	M86511	0.02	-0.49	0.46	0.000154	H.sapiens mRNA for E-cadherin
GB	H97778	-0.72	1.41	-0.69	0.000156	Fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor)
GB	AA058828	0.48	-0.28	-0.20	0.000157	

Figure 9d

Primary Cell Gene Expression Profile

Seq Source	Accession	Signature			p-value	Source Description
		Endothelial Signature	Epithelial Signature	Muscle Signature		
INCYTE	938765H1	0.53	-0.33	-0.20	0.000161	CERVNOT01 J03004 g183181 Human guanine nucleotide-binding regulat gb103pri 50 -59
GB	N46975	-0.23	0.00	0.23	0.000161	EST
GB	X76180	-0.48	0.94	-0.46	0.000161	H.sapiens mRNA for lung amiloride sensitive Na+ channel protein
GB	AA004759	0.11	0.05	-0.15	0.000162	Homo sapiens dolichol monophosphate mannose synthase (DPM1) mRNA, partial cds
GB	X62421	-0.19	0.33	-0.15	0.000167	H.sapiens mRNA for DnaJ protein homologue
GB	U76833	-0.37	-0.33	0.69	0.000168	Human integral membrane serine protease Seprase mRNA, complete cds.
GB	U40992	0.63	-0.55	-0.07	0.000173	Human heat shock protein hsp40 homolog mRNA, complete cds
GB	H96738	-0.26	-0.50	0.76	0.000173	Cadherin 11 (OB-cadherin)
INCYTE	3437994H1	-0.20	-0.24	0.44	0.000173	PENCNOT05 Z66513 g1041336 F54D5.8 gb103eukp 34 -1
GB	M80436	-0.27	0.55	-0.28	0.000176	Human platelet activating factor receptor
GB	S82666	-0.50	0.95	-0.45	0.000176	EST: AA459401 zx89g01.s1 Soares ovary tumor NbHOT Homo
GB	AA453712	-0.51	-0.47	0.98	0.000181	Lumican
GB	AA234897	0.13	-0.19	0.06	0.000182	MADS box transcription enhancer factor 2, polypeptide C (myocyte enhancer factor 2C)
GB	R83000	-0.24	0.49	-0.26	0.000186	Basic transcription factor 3
GB	M14764	-0.35	0.77	-0.42	0.000186	Human nerve growth factor receptor mRNA, complete cds
GB	AA456585	-0.27	0.55	-0.28	0.000186	RecQ protein-like (DNA helicase Q1-like)
GB	M36089	-0.14	-0.46	0.61	0.000186	Human DNA-repair protein (XRCC1) mRNA, complete cds.
INCYTE	2313677H1	0.22	0.12	-0.34	0.000191	Human synapsin IIa (SYN2) mRNA, complete
GB	X03363	-0.21	0.23	-0.01	0.000193	Human c-erb-B-2 mRNA.
GB	U27109	1.50	-0.74	-0.76	0.000193	Human prepromultimerin mRNA, complete cds
GB	AA393950	-0.43	0.84	-0.41	0.000194	EST: z178a10.r1 Soares testis NHT Homo sapiens cDNA clone 728442 5' similar to gb:L29007_cds1 AMILORIDE-SENSITIVE SODIUM CHANNEL ALPHA-SUBUNIT (HUMAN)
GB	L03203	0.48	-0.94	0.45	0.000199	Human peripheral myelin protein 22 (GAS3) mRNA, complete cds.

Figure 9e

Primary Cell Gene Expression Profile

Seq Source	Accession	Signature			p-value	Source Description
		Endothelial Signature	Epithelial Signature	Muscle Signature		
INCYTE	2701503T6	-0.39	0.80	-0.41	0.000200	QVARTUT10 U20428 g1890631 Human SNC19 mRNA sequence. gb104pri 18 -30
	GB	-0.07	-0.52	0.59	0.000202	Human monocytic leukaemia zinc finger protein (MOZ) mRNA, complete cds
	GB	-0.22	-0.34	0.56	0.000207	Human mRNA for LDL-receptor related protein
	INCYTE	-0.35	0.59	-0.25	0.000212	ENDCNOT01 M14300 g183097 Human growth factor-inducible 2A9 gene, gb103pri 100 -88
GB	M88279	-0.05	0.40	-0.34	0.000213	Human immunophilin (FKBP52) mRNA, complete cds
	GB	1.82	-0.96	-0.86	0.000215	Human mRNA for ICAM-2, cell adhesion ligand for LFA-1.
	GB	-0.17	0.37	-0.21	0.000223	EST: zv78h08.r1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 759807 5' similar to TR:G1136412
	GB	-0.29	0.34	-0.05	0.000224	EST: G1136412 KIAA0176 PROTEIN.
INCYTE	AF083552	-0.16	0.46	-0.30	0.000226	Homo sapiens canalicular multispecific organic anion transporter 2 (CMOAT2) mRNA, complete cds.
	2798465H1	-0.17	0.32	-0.16	0.000228	NPOLNOT01 X04366 g29663 Human mRNA for calcium activated neutral gb103pri 98 -69
	GB	-0.71	0.54	0.17	0.000231	Human CIBP mRNA, complete cds
	GB	-0.08	-0.16	0.25	0.000232	CD44 antigen (cell adhesion molecule)
GB	R94659	0.53	-0.62	0.09	0.000232	EST
	J05036	-0.33	-0.01	0.34	0.000235	H94487 yv19e06.s1 Soares fetal liver spleen 1NFLS
	U97669	-0.97	1.66	-0.70	0.000235	Homo sapiens Notch3 (NOTCH3) mRNA, complete cds.
	J05392	-0.17	-0.18	0.35	0.000237	EST: AA074511 zm17e08.s1 Stratagene pancreas (#937208)
GB	U37791	-0.15	0.31	-0.17	0.000240	Homo sapiens clone rasi-1 matrix metalloproteinase RASI-1 mRNA, complete cds.
	M14058	0.23	-0.02	-0.21	0.000240	Human complement C1r mRNA, complete cds.
	W58658	1.09	-0.66	-0.44	0.000241	H.sapiens mRNA for CLPP
	M60315					Human transforming growth factor-beta (tgf-beta) mRNA, complete cds.

Figure 9f

15/47

Primary Cell Gene Expression Profile

Seq Source	Accession	Signature			p-value	Source Description
		Endothelial Signature	Epithelial Signature	Muscle Signature		
GB	X51417	0.03	0.00	-0.03	0.000241	Human mRNA for steroid hormone receptor hERR2.
GB	L76191	-0.08	0.21	-0.14	0.000243	Homo sapiens interleukin-1 receptor-associated kinase (IRAK) mRNA, complete cds
GB	T98559	0.57	-0.50	-0.07	0.000246	Ribosomal protein L17
GB	R43734	0.77	-1.23	0.47	0.000248	Laminin, alpha 4
GB	T51895	0.42	-0.06	-0.35	0.000248	Hepatoma transmembrane kinase
GB	X04481	-0.07	-0.05	0.12	0.000253	Human mRNA for complement component C2
GB	AA486628	0.13	0.25	-0.38	0.000253	Early growth response protein 1
GB	AA495846	0.58	-0.59	0.01	0.000256	TRANSFORMING PROTEIN RHOB
GB	AA460679	0.07	-0.36	0.29	0.000257	Human mRNA for CMP-sialic acid transporter, complete cds
GB	H27933	-0.21	0.32	-0.11	0.000260	EST: y158e09.s1 Soares breast 3NbHBst Homo sapiens cDNA clone 162472 3' similar to gb:M64572 PROTEIN-TYROSINE PHOSPHATASE PTP-H1 (HUMAN);, mRNA
GB	M57285	-0.14	-0.14	0.28	0.000264	Human coagulation factor X (F10) mRNA, complete cds
GB	U78180	-0.14	-0.04	0.18	0.000264	Human sodium channel 2 (hBNC2) mRNA, alternatively spliced, complete cds
GB	AA455067	0.75	-0.29	-0.46	0.000265	Synuclein, alpha (non A4 component of amyloid precursor)
GB	J03258	-0.31	0.29	0.02	0.000268	Human vitamin D receptor mRNA, complete cds
GB	S56805	1.26	-0.61	-0.65	0.000268	Endothelin-1
GB	AA069517	-0.40	0.02	0.39	0.000269	Protein convertase subtilisin/kexin type 2
GB	AA393856	0.21	0.04	-0.25	0.000269	Human putative transmembrane GTPase mRNA, partial cds
GB	AA146802	0.65	-0.32	-0.33	0.000277	H.sapiens mRNA for phosphate cyclase
GB	AA490721	-0.39	0.09	0.29	0.000277	Human splicing factor SRp30c mRNA, complete cds
GB	M19645	-0.17	-0.07	0.25	0.000280	Human 78 kDa glucose-regulated protein (GRP78) gene, complete cds.
GB	M97370	0.27	-0.16	-0.11	0.000281	Human adenosine receptor (A2) gene, complete cds.
GB	W01240	0.35	-0.34	-0.01	0.000281	Membrane protein, palmitoylated 1 (55kD)
GB	X00588	-0.24	0.29	-0.05	0.000281	Human mRNA for precursor of epidermal growth factor receptor
GB	X83864	-0.40	0.47	-0.07	0.000285	H.sapiens EDG-3 gene

Figure 9g

Primary Cell Gene Expression Profile

Seq Source	Accession	Signature			p-value	Source Description
		Endothelial	Epithelial	Muscle		
GB	N66942	0.50	-0.29	-0.21	0.000289	H.sapiens mRNA for putative progesterone binding protein
GB	M31210	1.07	-0.59	-0.48	0.000289	Human endothelial differentiation protein (edg-1) gene mRNA, complete cds
INCYTE	3090747H1	-0.39	-0.05	0.44	0.000296	BRSTNOT19 X62841 g57648 Rat mRNA for potassium channel protein (gb102rod 27 -7
INCYTE	2027449H1	-0.92	1.79	-0.86	0.000296	KERANOT02 g179896 Human CaN19 mRNA sequence. gb97pri 68 -76
GB	U83410	-0.16	-0.19	0.34	0.000301	Human CUL-2 (cul-2) mRNA, complete cds.
GB	X15606	1.78	-0.88	-0.90	0.000301	Human mRNA for ICAM-2, cell adhesion ligand for LFA-1.
GB	AA489275	-0.19	0.24	-0.05	0.000303	Human sodium/potassium-transporting ATPase beta-3 subunit mRNA, complete cds
GB	X61598	0.14	-0.64	0.49	0.000308	H.sapiens mRNA for colligin (a collagen-binding protein)
GB	N69574	0.04	-0.25	0.21	0.000308	EST
GB	T62627	1.36	-0.67	-0.69	0.000313	Human nuclear phosphoprotein mRNA, complete cds
INCYTE	2301338H1	-0.14	0.39	-0.25	0.000316	BRSTNOT05 X04366 g29663 Human mRNA for calcium activated neutral gb103pri 98 -7
GB	U76549	-0.92	1.50	-0.58	0.000322	Human cytokeratin 8 mRNA, complete cds.
GB	X02530	-0.39	0.37	0.01	0.000322	Human mRNA for gamma-interferon inducible early response gene (with homology to platelet proteins).
GB	AA411440	-0.28	0.62	-0.34	0.000328	Villin 2 (ezrin)
GB	AA487370	0.43	-0.07	-0.36	0.000332	Human myosin regulatory light chain mRNA, complete cds
GB	R96668	1.07	-0.54	-0.53	0.000336	H.sapiens mRNA for chemokine HCC-1
GB	X81120	0.87	-0.48	-0.38	0.000336	H.sapiens mRNA for central cannabinoid receptor
GB	X04882	-0.09	0.32	-0.24	0.000345	Human mRNA for dihydropteridine reductase (hDHPR).
GB	H94944	0.58	-0.23	-0.35	0.000346	EST: RAS-RELATED PROTEIN RAL-A
GB	AA490238	0.11	-0.35	0.23	0.000348	H.sapiens mitogen inducible gene mig-2, complete CDS
GB	L04510	-0.04	-0.05	0.09	0.000348	Human nucleotide binding protein mRNA, complete cds.
INCYTE	2510757F6	-0.09	0.24	-0.14	0.000349	EST: CONUTUT01 X95241 g1487972 (2)id gb103eukp 9 -6
GB	AA465593	-0.25	-0.12	0.37	0.000356	PROTEASOME COMPONENT C8
GB	AA284495	0.82	-0.44	-0.38	0.000356	Human mRNA for KIAA0081 gene, partial cds
GB	H57727	0.47	-0.21	-0.26	0.000356	EST: Highly similar to PTB-ASSOCIATED SPLICING FACTOR [Homo sapiens]

Figure 9h

17/47

Primary Cell Gene Expression Profile

Seq Source	Accession	Signature			p-value	Source Description
		Endothelial Signature	Epithelial Signature	Muscle Signature		
GB	L36148	0.43	-0.22	-0.21	0.000356	Homo sapiens G protein-coupled receptor (GPR4) gene, complete cds.
GB	AA393452	-0.14	0.31	-0.17	0.000360	EST: z171c01.r1 Soares testis NHT Homo sapiens cDNA clone 727776 5' similar to WP:D2045.8 CE00608 TNF-ALPHA INDUCED PROTEIN B12 ;
GB	M16768	0.25	0.00	-0.25	0.000364	Human T-cell receptor gamma chain VJCI-CII region mRNA, complete cds.
GB	AA448667	0.09	0.27	-0.36	0.000365	Human heterochromatin protein p25 mRNA, complete cds
GB	R65759	-0.13	-0.30	0.43	0.000368	EST
GB	M69215	-0.79	0.48	0.31	0.000375	Human hyaluronate receptor (CD44) gene, exon 1.
GB	U13666	-0.11	-0.16	0.27	0.000380	Human G protein-coupled receptor (GPR1) gene, complete cds.
GB	U38545	0.23	-0.12	-0.10	0.000382	Human ARF-activated phosphatidylcholine-specific phospholipase D1a (hPLD1) mRNA, complete cds
GB	H57180	0.15	-0.03	-0.11	0.000385	Phospholipase C, gamma 2 (phosphatidylinositol-specific)
GB	M58552	0.11	-0.62	0.51	0.000385	Human collagenase type IV (CLG4) gene, exon 1
GB	X92106	0.35	-0.10	-0.24	0.000391	H.sapiens mRNA for bleomycin hydrolase.
GB	X56134	0.46	-0.86	0.41	0.000395	Human mRNA for vimentin.
GB	N45139	-0.10	-0.01	0.11	0.000396	EST
GB	R76770	-0.08	0.19	-0.11	0.000398	EST
INCYTE	4727571H1	-0.26	0.61	-0.35	0.000399	X99897 H.sapiens mRNA for P/Q-type calcium channel alpha1 subunit
GB	X54936	0.91	-0.41	-0.49	0.000400	EST: AA130714 zo13h02.s1 Stratagene colon (#937204) Hom
GB	R22412	1.92	-1.03	-0.88	0.000401	Platelet/endothelial cell adhesion molecule (CD31 antigen)
GB	M31210	0.82	-0.43	-0.39	0.000405	Human endothelial differentiation protein (edg-1) gene mRNA, complete cds
GB	AF004327	0.86	-0.44	-0.42	0.000406	EST: AA125872 z123d01.s1 Soares_pregnant_uterus_NbHPU H
GB	X04385	1.70	-0.86	-0.84	0.000412	Human mRNA for pre-pro-von Willebrand factor.
GB	AA490462	-0.15	-0.04	0.19	0.000416	Human mRNA for AEBP1 gene, complete cds
GB	AA448194	-0.11	-0.41	0.52	0.000420	Human duplicate spinal muscular atrophy mRNA, clone 5G7, partial cds

Figure 9i

Primary Cell Gene Expression Profile

Seq Source	Accession	Muscle Signature			p-value	Source Description
		Endothelial Signature	Epithelial Signature	Muscle Signature		
GB	M16405	0.25	-0.36	0.11	0.000421	Human m4 muscarinic acetylcholine receptor gene.
GB	W74565	0.19	-0.23	0.04	0.000422	EST: Weakly similar to contains similarity to C2H2-type zinc fingers [C.elegans]
GB	M80436	-0.21	0.37	-0.16	0.000427	Human platelet activating factor receptor
GB	X00351	-0.35	-0.09	0.43	0.000429	Human mRNA for beta-actin.
GB	AB000712	-0.23	0.44	-0.20	0.000441	EST: AA430665 zw26a07.s1 Soares ovary tumor NbHOT Homo
GB	AA284668	-0.78	0.97	-0.19	0.000446	Urokinase-type plasminogen activator
GB	R63295	-0.26	0.11	0.15	0.000447	EST
GB	S57551	0.23	-0.11	-0.12	0.000450	guanylate cyclase-coupled enterotoxin receptor [human, T84 colonic cell line, mRNA, 3787 nt].
GB	U66198	0.13	0.08	-0.22	0.000452	Human fibroblast growth factor homologous factor 2 (FHF-2) mRNA, complete cds.
GB	U07225	-0.09	0.24	-0.15	0.000453	Human P2U nucleotide receptor mRNA, complete cds
GB	L29401	-0.56	0.55	0.01	0.000459	Human low density lipoprotein receptor mRNA.
GB	R33755	-0.21	0.48	-0.27	0.000461	Glutathione-S-transferase pi-1
GB	AA428170	0.35	-0.42	0.08	0.000463	Dihydropyrimidine dehydrogenase
GB	M59911	-0.61	0.88	-0.27	0.000464	EST: AA424695 zv33a02.s1 Soares ovary tumor NbHOT Homo
INCYTE	g1967662	-0.54	0.05	0.49	0.000468	U73643 U73643 Human Chromosome 11 Cosmid cSRL34e5, complete sequence. Blastn P. 3.2E-21
GB	M95167	0.03	0.01	-0.04	0.000471	Homo sapiens dopamine transporter (SLC6A3) mRNA, complete cds.
GB	AA489699	1.22	-0.55	-0.67	0.000471	Human COP9 homolog (HCOP9) mRNA, complete cds
GB	M86400	-0.10	0.43	-0.32	0.000485	Human phospholipase A2 mRNA, complete cds.
GB	D83812	-0.09	-0.04	0.13	0.000492	T80924 yd25g11.r1 Soares fetal liver spleen 1NFLS
GB	M37435	-0.04	-0.21	0.25	0.000496	Human macrophage-specific colony-stimulating factor (CSF-1) mRNA, complete cds
INCYTE	1696122T6	-0.01	-0.15	0.15	0.000500	EST: COLNNOT23
GB	M17783	-1.14	0.53	0.61	0.000500	EST: N59721 yv56c02.r1 Soares fetal liver spleen 1NFLS
GB	AA457119	0.43	0.10	-0.53	0.000506	EST: AA457119 Homo sapiens cDNA clone IMAGE:810454 3', mRNA sequence

Figure 9j

Primary Cell Gene Expression Profile

Seq Source	Accession	Signature			p-value	Source Description
		Endothelial Signature	Epithelial Signature	Muscle Signature		
GB	M20566	-0.11	0.24	-0.13	0.000506	Human interleukin 6 receptor mRNA, complete cds
GB	U83115	-0.16	0.52	-0.37	0.000506	Human non-lens beta gamma-crystallin like protein (AIM1) mRNA, partial cds.
GB	AA454743	-0.24	0.49	-0.25	0.000510	Human protease M mRNA, complete cds
GB	AA181500	1.19	-1.34	0.15	0.000510	Protein kinase, cAMP-dependent, regulatory, type II, beta
INCYTE	1742456R6	-0.24	0.17	0.07	0.000511	HIPONON01 M94055 g456678 Human voltage-gated sodium channel mRNA, gb103pri 100 -81
GB	AA456271	-0.04	0.19	-0.16	0.000514	Human Hlark mRNA, complete cds
INCYTE	3584702H1	-0.17	0.27	-0.10	0.000515	Mouse homer-1a mRNA, complete cds.
GB	H79888	0.37	-0.28	-0.09	0.000518	EST: Weakly similar to contactin associated protein [H.sapiens]
GB	X00187	-0.11	-0.11	0.22	0.000533	Human preproenkephalin A gene, 5' flanking region.
GB	AA486221	-0.16	-0.11	0.26	0.000542	Human inducible poly(A)-binding protein mRNA, complete cds
GB	H59758	-0.14	0.32	-0.18	0.000543	EST: Novel
GB	D10995	-0.04	0.00	0.04	0.000545	EST: AA909121 clone IMAGE:1542757 3' similar to 5-HYDROXYTRYPTAMINE 1B RECEPTOR
INCYTE	1452259F6	-0.26	0.53	-0.27	0.000569	EST: PENITUT01 D13626 g285995 KIAA0001 gb103pri 17 1
GB	AJ001015	-0.09	-0.12	0.21	0.000575	Homo sapiens mRNA encoding RAMP2.
INCYTE	2222054H1	-0.20	0.32	-0.12	0.000584	LUNGNOT18 U42975 g1150862 Rat Shal-related potassium channel Kv4.3 gb102rod 57 -44
GB	Z67743	-0.63	-0.07	0.70	0.000596	H.sapiens mRNA for CLC-7 chloride channel protein.
GB	L31409	-0.30	-0.03	0.33	0.000596	Homo sapiens creatine transporter mRNA, complete cds
GB	AA504617	0.44	-1.11	0.67	0.000597	Homo sapiens autoantigen p542 mRNA, 3' end of cds
GB	AA608557	-0.08	-0.13	0.21	0.000602	Damage-specific DNA binding protein 1 (127 kD)
INCYTE	928019R6	-0.05	-0.01	0.05	0.000608	BRAINOT04 X62840 g57652 Rat mRNA for potassium channel protein (gb102rod 16 -5
GB	M24748	-0.07	-0.09	0.16	0.000613	Human thyroid hormone receptor alpha 1 (TR-alpha-1) gene, complete cds.
GB	AA598978	-0.10	-0.14	0.24	0.000623	Filamin 1 (actin-binding protein-280)
GB	N59542	-0.64	0.08	0.56	0.000627	EST: Weakly similar to coded for by C. elegans cDNA CEESW58F [C.elegans]
GB	H68845	0.11	0.13	-0.24	0.000628	H.sapiens thiol-specific antioxidant protein mRNA

Figure 9k

20/47

Primary Cell Gene Expression Profile

Seq. Source	Accession	Muscle Signature			p-value	Source Description
		Endothelial Signature	Epithelial Signature	Muscle Signature		
GB	W68044	-0.17	0.25	-0.08	0.000633	EST: zd39f04.r1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 343039 5'
GB	AA487681	0.25	-0.31	0.06	0.000633	Human mRNA for ornithine decarboxylase antizyme, ORF 1 and ORF 2
GB	H94163	0.20	-0.26	0.07	0.000636	ESTs
GB	K03226	-0.74	0.84	-0.10	0.000638	Human preprothrombin mRNA, complete cds.
GB	M18692	-0.18	0.16	0.02	0.000643	Human elastase III B mRNA, complete cds, clone pCL1E3
GB	R92609	0.12	0.09	-0.21	0.000652	EST: Novel
GB	T96731	-0.24	-0.14	0.39	0.000652	EST: Highly similar to HLA CLASS II HISTOCOMPATIBILITY ANTIGEN, DX BETA CHAIN PRECURSOR [Homo sapiens]
INCYTE	1650566F6	-0.26	0.50	-0.25	0.000654	EST: GPCR_48_TL45 PROSTUT09 g285995 KIAA0001 gb99prip 30 -9
GB	R98877	-0.04	-0.08	0.12	0.000658	ESTs
GB	H94469	0.44	-0.25	-0.19	0.000661	EST: Weakly similar to T01G9.4 [C.elegans]
INCYTE	1716001T6	0.40	-0.18	-0.22	0.000661	EST: UCMCNOT02
GB	AA419164	0.43	-0.48	0.05	0.000663	RETINOIC ACID RECEPTOR BETA-2
GB	AA457644	-0.02	-0.17	0.20	0.000664	EST: Human clone 23707 mRNA, partial cds
GB	X63924	-0.06	-0.03	0.08	0.000665	H. sapiens CD18 exon 14.
GB	R01272	-0.14	-0.06	0.20	0.000671	ESTs
GB	M74782	0.35	-0.22	-0.12	0.000671	Human interleukin 3 receptor (hIL-3Ra) mRNA, complete cds
INCYTE	2211526T6	-0.02	-0.10	0.13	0.000673	SINTFET03 AF026260 g2605715 Human vitamin D receptor (VDR) mRNA, com gb104p1 17 -10
GB	AA452556	-0.05	-0.17	0.22	0.000686	H.sapiens mRNA for TRAMP protein
GB	W47576	0.40	-0.37	-0.03	0.000688	ESTs
GB	X07549	-0.42	0.80	-0.38	0.000697	Human mRNA for cathepsin H (E.C.3.4.22.16.).
GB	U48730	0.09	-0.03	-0.06	0.000699	Human transcription factor Stat5b (stat5b) mRNA, complete cds.
GB	T95693	-0.32	0.35	-0.03	0.000702	ESTs
GB	L01639	0.72	-0.40	-0.32	0.000704	Human (clone HSY3RR) neuropeptide Y receptor (NPYR) mRNA, complete cds
INCYTE	3248833H1	-0.20	-0.16	0.36	0.000711	Human mRNA encoding RAMP1.

Figure 9I

Primary Cell Gene Expression Profile

Seq Source	Accession	Signature			p-value	Source Description
		Endothelial Signature	Epithelial Signature	Muscle Signature		
GB	R88734	0.58	-0.27	-0.31	0.000717	EST
GB	AA504554	-0.07	-0.22	0.29	0.000723	Human cytoskeleton associated protein (CG22) mRNA, complete cds
GB	U12512	-0.20	-0.09	0.28	0.000726	Human bradykinin receptor B1 subtype mRNA, complete cds
GB	M11723	-0.09	0.18	-0.09	0.000734	Human blood coagulation factor XII (Hageman factor) mRNA
INCYTE	2604309F6	-0.10	0.20	-0.10	0.000734	LUNGTUT07 D30785 g1648847 Mouse mRNA for neuropsin, complete cds. gb104rod 30 -13
GB	S60489	0.39	0.39	-0.78	0.000739	CD9=CD9 antigen mRNA.
GB	M59916	0.30	-0.47	0.17	0.000744	Human acid sphingomyelinase (ASM) mRNA, complete cds.
GB	M11233	-0.52	-0.53	1.06	0.000745	Human cathepsin D mRNA, complete cds.
GB	L01639	0.60	-0.43	-0.17	0.000750	Human (clone HSY3RR) neuropeptide Y receptor (NPYR) mRNA, complete cds
GB	H25761	0.44	-0.16	-0.28	0.000762	EST
GB	AA025156	-0.18	0.18	0.00	0.000775	Growth Factor/ Receptor
GB	W74362	0.16	0.21	-0.37	0.000786	EST
GB	X61800	-0.52	0.44	0.08	0.000793	M.musculus mRNA for C/EBP delta
GB	N71365	-0.10	-0.18	0.28	0.000812	EST
GB	AA454662	0.07	0.18	-0.25	0.000812	Human mRNA for KIAA0020 gene, complete cds
GB	AA450180	0.01	0.26	-0.26	0.000813	ZNF75
GB	N76338	0.26	-0.11	-0.14	0.000819	EST: Highly similar to UNR PROTEIN [Cavia porcellus]
GB	U88880	0.40	-0.23	-0.16	0.000837	Homo sapiens Toll-like receptor 4 (TLR4) mRNA, complete cds.
INCYTE	3269857F6	0.22	-0.24	0.02	0.000843	X60007 NSGRP2MR N.sylvestris mRNA for glycine rich protein 2 (GRP2). Blastn P. 0.086
GB	M60626	-0.03	-0.05	0.08	0.000848	Human N-formylpeptide receptor (fMLP-R98) mRNA, complete cds
INCYTE	1751294F6	-0.17	0.26	-0.09	0.000848	EST: LIVRTUT01 AC002306 g2213635 R33799_1 gb103prip 46 -12
GB	M29871	0.57	-0.13	-0.45	0.000851	Human ras-related C3 botulinum toxin substrate (rac) mRNA, complete cds
GB	M58603	-0.14	-0.14	0.28	0.000860	Human nuclear factor kappa-B DNA binding subunit (NF-kappa-B) mRNA, complete cds.
GB	X12881	-0.11	1.11	-0.99	0.000863	Human mRNA for cytokeratin 18.

Figure 9m

Primary Cell Gene Expression Profile

Seq Source	Accession	Endothelial Signature	Epithelial Signature	Muscle Signature	p-value	Source Description
INCYTE	3118530H1	-0.03	0.27	-0.24	0.000863	EST: LUNGUT13 U95727 g2281450 Rat DnaJ homolog 2 mRNA, complete cds. gb103rod 33 -39
GB	M94054	-0.09	-0.35	0.44	0.000863	Human lysyl oxidase (LOX) mRNA, complete cds.
INCYTE	1519824H1	-0.10	0.33	-0.24	0.000864	EST
GB	X70070	-0.04	-0.02	0.07	0.000877	H.sapiens mRNA for neurotensin receptor
GB	X58454	-0.13	0.21	-0.08	0.000878	Human HD5DR gene for D5 dopamine receptor.
GB	M37435	-0.02	-0.20	0.22	0.000891	Human macrophage-specific colony-stimulating factor (CSF-1) mRNA, complete cds
GB	AA486275	0.15	0.07	-0.21	0.000892	LEUKOCYTE ELASTASE INHIBITOR
GB	M80800	0.37	-0.33	-0.05	0.000894	Pig gp145-tyrC (trkC) mRNA, complete cds
INCYTE	1429303H1	-0.04	-0.10	0.15	0.000904	EST: SINTBST01
GB	U41163	-0.22	0.37	-0.14	0.000904	Human creatine transporter (SLC6A10) gene, partial cds.
INCYTE	449937H1	0.07	-0.18	0.11	0.000922	M57428 RATS6KIN3 Rat S6 kinase mRNA, complete cds. Blastn P. 0.00000002
GB	D13538	-0.06	-0.15	0.21	0.000923	Human alpha2CII-adrenergic receptor gene, complete cds.
GB	L12350	-0.41	-0.25	0.66	0.000941	Human thrombospondin 2 (THBS2) mRNA, complete cds.
GB	M11730	-0.28	0.18	0.10	0.000948	Human tyrosine kinase-type receptor (HER2) mRNA, complete cds.
GB	M54930	-0.06	-0.03	0.09	0.000951	Human vasoactive intestinal peptide and peptide histidine isoleucine mRNA, 3' end
GB	N76944	0.08	0.06	-0.13	0.000955	EST
GB	X02544	-0.06	-0.01	0.07	0.000961	EST: A700876 zj36c12.s1 Soares_fetal_liver_spleen_1NFLS
GB	AA451716	0.02	0.11	-0.14	0.000969	Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105)
INCYTE	279279H1	-0.45	0.70	-0.25	0.000986	Human cutaneous myofibroblast protein
GB	Y09479	-0.32	0.04	0.28	0.000987	H.sapiens mRNA for G protein-coupled receptor Edg-2
GB	H84982	-0.10	-0.06	0.15	0.000991	Human checkpoint suppressor 1 mRNA, complete cds
GB	AA443688	-0.18	-0.23	0.41	0.001004	GTP cyclohydrolase 1 (dopa-responsive dystonia) (alternative products)
GB	L33404	-0.15	0.33	-0.18	0.001008	Human stratum corneum chymotryptic enzyme mRNA, complete cds

Figure 9n

Primary Cell Gene Expression Profile

Seq Source	Accession	Signature			p-value	Source Description
		Endothelial Signature	Epithelial Signature	Muscle Signature		
GB	H19264	0.02	0.08	-0.10	0.001014	EST: yn50c10.r1 Soares adult brain N2b5HB55Y Homo sapiens cDNA clone 171858 5' similar to SP:B41359 B41359 POTASSIUM CHANNEL PROTEIN SHAB11 - FRUIT FLY ; mRNA sequence.
GB	M85079	0.45	-0.18	-0.27	0.001032	Human TGF-beta type II receptor mRNA, complete cds
GB	AA598527	0.03	0.17	-0.21	0.001035	EST: Human BAC clone RG083M05 from 7q21-7q22
GB	AA286908	0.20	-0.41	0.21	0.001036	Myxovirus (Influenza) resistance 2, homolog of murine
INCYTE	1594625F6	-0.05	-0.15	0.20	0.001061	BRAINOT14 S67803 g544589 excitatory amino acid receptor 1=glutama gb104pri 94 -48
GB	R78516	-0.28	0.28	0.00	0.001070	EST: Weakly similar to C35C5.3 [C.elegans]
GB	AA280924	-0.13	-0.16	0.29	0.001095	Carbonyl reductase
GB	M37763	-0.10	-0.15	0.25	0.001119	Human neurotrophin-3 (NT-3) gene, complete cds.
GB	AA279601	0.26	-0.27	0.00	0.001122	Human Hou mRNA, complete cds
GB	AC004126	-0.31	0.83	-0.52	0.001123	GPCR 101
GB	AB000714	-0.02	-0.25	0.26	0.001123	EST: AA434144 zw28b06.s1 Soares ovary tumor NbHOT Homo
GB	U66199	-0.05	0.13	-0.09	0.001156	Human fibroblast growth factor homologous factor 3 (FHF-3) mRNA, complete cds.
GB	AA133129	0.53	-0.59	0.06	0.001163	Transcription elongation factor B (SIII), polypeptide 3 (110kD, elongin A)
GB	N22980	0.36	-0.24	-0.12	0.001165	EST: Novel
GB	AA085318	-0.24	-0.18	0.42	0.001165	Human stanniocalcin precursor (STC) mRNA, complete cds
GB	T61575	-0.53	0.21	0.33	0.001171	EST: AA630328 ac08g12.s1 Stratagene HeLa cell s3 937216
INCYTE	150224T6	0.00	-0.06	0.06	0.001173	FIBRANT01 Z80147 g1657296 Human CACNL1A4 gene, exon 37. gb103pri 99 -35
GB	R23586	0.06	-0.16	0.10	0.001177	EST
INCYTE	3384890H1	0.27	-0.13	-0.14	0.001178	EST: L77606 HUM17QYCAH Homo sapiens (clone SEL277a) 17q YAC (303G8) RNA. Blastn P. 0.00000018
GB	L08044	0.19	-0.07	-0.12	0.001189	EST: N74131 za75h01.s1 Soares_fetal_lung_NbHL19W Homo s
GB	M63099	-0.27	0.52	-0.25	0.001189	Human interleukin 1 receptor antagonist (IL1RN) gene, complete cds.
GB	H52141	0.36	-0.11	-0.26	0.001195	Inositol polyphosphate-1-phosphatase

Figure 9o

Primary Cell Gene Expression Profile

Seq. Source	Accession	Muscle Signature			p-value	Source Description
		Endothelial Signature	Epithelial Signature	Muscle Signature		
INCYTE	1652456H1	-0.02	0.04	-0.02	0.001214	PROSTUT08 U75329 g2507612 Human serine protease mRNA, complete cds gb104pri 92 -59
GB	M60828	-0.14	-0.17	0.31	0.001233	Human keratinocyte growth factor mRNA, complete cds.
GB	U39613	0.26	-0.13	-0.13	0.001242	Human cysteine protease ICE-LAP3 mRNA, complete cds.
GB	U59832	-0.31	0.06	0.25	0.001249	Human transcription factor, forkhead related activator 4 (FREAC-4) mRNA, complete cds.
GB	U62801	-0.24	0.47	-0.23	0.001255	EST: AA454743 zx77e01.s1 Soares ovary tumor NbHOT Homo
GB	H91337	-0.07	-0.09	0.17	0.001257	EST
GB	X54936	0.98	-0.47	-0.52	0.001264	EST: AA130714 zo13h02.s1 Stratagene colon (#937204) Hom
INCYTE	078114H1	-0.24	-0.08	0.32	0.001282	SYNORAB01 Y09479 g1679601 Human mRNA for G-protein-coupled recepto gb104pri 90 -70
GB	H38799	0.01	0.23	-0.23	0.001282	EST: Weakly similar to F59C6.4 [C.elegans]
GB	M38425	-0.18	0.25	-0.07	0.001285	Human EGF receptor (EGFR) gene, 5' end
GB	AA448755	0.07	-0.30	0.23	0.001303	M-PHASE INDUCER PHOSPHATASE 2
GB	T90375	-0.48	-0.01	0.49	0.001303	EST
INCYTE	2601724H1	-0.15	-0.23	0.38	0.001335	Human integrin beta-5 subunit mRNA, comp
INCYTE	g819904	-0.04	0.10	-0.06	0.001351	Z81585 CET05E12 Caenorhabditis elegans cosmid T05E12, complete sequence. Blastn P. 0.86
GB	M29870	0.04	0.17	-0.20	0.001387	Human ras-related C3 botulinum toxin substrate (rac) mRNA, complete cds
GB	D29990	0.11	-0.04	-0.07	0.001401	amino acid transporter E16
GB	R27082	0.01	-0.21	0.20	0.001403	EST
GB	R33030	-0.08	-0.04	0.11	0.001403	PROBABLE PROTEIN DISULFIDE ISOMERASE ER-60 PRECURSOR
INCYTE	1381683H1	0.05	-0.01	-0.04	0.001404	X14385 ALCRPEF Astasia longa chloroplast rps7 and tufA genes for ribosomal protein S7 and elongation factor Tu respectively. Blastn P. 0.00047
GB	R31521	-0.27	-0.04	0.30	0.001410	EST
GB	R91550	-0.14	-0.26	0.41	0.001424	Human arginine-rich protein (ARP) gene, complete cds
GB	M97016	-0.10	-0.01	0.11	0.001424	Homo sapiens osteogenic protein-2 (OP-2) mRNA, complete cds.

Figure 9p

25/47

Primary Cell Gene Expression Profile

Seq Source	Accession	Endothelial Signature	Epithelial Signature	Muscle Signature	p-value	Source Description
GB	AA454652	-0.06	0.29	-0.23	0.001451	Human proteinase-activated receptor-2 mRNA, complete cds
GB	D55696	0.25	0.06	-0.31	0.001461	Human mRNA for cysteine protease, complete cds.
GB	M29366	-0.13	0.21	-0.08	0.001470	Human epidermal growth factor receptor (ERBB3) mRNA, complete cds.
GB	H98534	-0.23	0.27	-0.04	0.001471	Human small GTP binding protein Rab9 mRNA, complete cds
GB	M27492	-0.28	-0.37	0.65	0.001484	Human interleukin 1 receptor mRNA, complete cds
GB	AA424315	0.00	0.24	-0.24	0.001494	Human mRNA for proteasome subunit p42, complete cds
GB	D49728	0.11	0.09	-0.20	0.001501	Human NAK1 mRNA for DNA binding protein, complete cds.
GB	AA460727	-0.16	0.14	0.02	0.001512	Human mRNA for clathrin coat assembly protein-like, complete cds
GB	M93415	-0.04	-0.03	0.07	0.001584	Human activin type II receptor mRNA, complete cds.
INCYTE	157873H1	-0.05	-0.05	0.09	0.001593	THP1PLB02 D63785 g961439 Human mRNA for LD78 alpha beta, partial gb106prt 21 10
INCYTE	2116716T6	-0.01	-0.12	0.13	0.001594	BRSTTUT02 U67865 g1527201 CO6; putative potassium channel regulato gb102vrtp 10 8
GB	AA448929	0.04	-0.26	0.22	0.001594	Human clone pSK1 interferon gamma receptor accessory factor-1 (AF-1) mRNA, complete cds
INCYTE	637471CA2	-0.08	-0.12	0.20	0.001595	EST
GB	AA486626	0.37	-0.24	-0.12	0.001614	Poly(A)-binding protein-like 1
GB	L15189	-0.13	0.36	-0.23	0.001617	Homo sapiens mitochondrial HSP75 mRNA, complete cds
INCYTE	4161733H1	-0.02	0.07	-0.04	0.001635	Human apolipoprotein AI regulatory prote
GB	W60890	0.33	-0.43	0.10	0.001636	EST; Novel
GB	AA287196	-0.07	-0.25	0.32	0.001637	Human globin gene
GB	X95383	-0.42	-0.12	0.54	0.001652	O. cuniculus mRNA for alpha-B-crystallin
GB	U16953	0.02	-0.11	0.10	0.001669	Human potassium channel beta3 subunit mRNA, complete cds.
GB	M21571	-0.01	0.03	-0.03	0.001672	Human platelet-derived growth factor (PDGFA) A chain mRNA.
GB	W02116	-0.02	-0.13	0.14	0.001674	Human (H326) mRNA, complete cds
GB	M32977	-0.17	0.21	-0.04	0.001677	Human heparin-binding vascular endothelial growth factor (VEGF) mRNA, complete cds

Figure 9q

Primary Cell Gene Expression Profile

Seq Source	Accession	Signature			p-value	Source Description
		Endothelial Signature	Epithelial Signature	Muscle Signature		
GB	T97257	-0.05	-0.01	0.06	0.001713	EST
GB	W96114	0.23	-0.22	-0.01	0.001715	Human hnRNP H mRNA, complete cds
INCYTE	3105066H1	-0.18	0.24	-0.06	0.001715	EST: COLNUCT03 L05628 g1835659 MRP, multidrug resistance-associated pro gb103prip 31 -16
GB	AA486836	-0.11	0.21	-0.11	0.001718	EST: Weakly similar to product of alternative splicing [D.melanogaster]
GB	L24470	-0.10	-0.10	0.20	0.001723	Homo sapiens prostanoid FP receptor mRNA, complete cds
GB	AA443497	-0.14	-0.23	0.37	0.001731	Human clone 23732 mRNA, partial cds
GB	AA487526	0.60	-0.18	-0.42	0.001736	Receptor protein-tyrosine kinase EDDR1
GB	D12614	0.21	-0.10	-0.10	0.001752	Human mRNA for lymphotoxin (TNF-beta), complete cds.
INCYTE	1946704H1	-0.08	-0.06	0.14	0.001760	EST: PITUNOT01
GB	T61078	0.20	-0.11	-0.09	0.001763	Carbamoyl-phosphate synthetase 1, mitochondrial
GB	S40706	-0.29	0.06	0.23	0.001783	EST: AA015892 ze40c09.s1 Soares retina N2b4HR Homo sapi
GB	H25907	0.14	-0.06	-0.08	0.001799	EST
GB	H72027	0.14	-0.24	0.10	0.001799	GELSOLIN PRECURSOR, PLASMA
GB	Y00106	-0.15	0.39	-0.24	0.001813	Human gene for beta-adrenergic receptor (beta-2 subtype).
INCYTE	5547273H1	-0.01	0.05	-0.03	0.001813	EST:
GB	N90246	0.28	-0.07	-0.21	0.001813	EST: Novel
GB	H59203	0.07	0.21	-0.27	0.001814	Human Cdc6-related protein (HsCDC6) mRNA, complete cds
GB	L29384	0.08	-0.15	0.07	0.001816	Homo sapiens (clone pcDNA-alpha1E-1) voltage-dependent calcium channel alpha-1E-1 subunit mRNA, complete cds
GB	H84113	0.17	-0.19	0.02	0.001823	Retinal outer segment membrane protein 1
GB	AA477082	0.07	0.17	-0.24	0.001841	Homo sapiens brain and reproductive organ-expressed protein (BRE) gene, complete cds
GB	Z73903	-0.05	-0.12	0.16	0.001841	H.sapiens mRNA for TRPC1A
GB	H57941	-0.42	0.46	-0.04	0.001844	Human mRNA for KIAA0386 gene, complete cds
GB	M81882	-0.06	-0.01	0.07	0.001866	Human glutamate decarboxylase (GAD65) mRNA, complete cds
GB	AA401448	-0.26	0.14	0.12	0.001887	Human mRNA for KIAA0146 gene, partial cds

Figure 9r

Primary Cell Gene Expression Profile

Seq Source	Accession	Signature			p-value	Source Description
		Endothelial Signature	Epithelial Signature	Muscle Signature		
INCYTE	3358822T6	-0.28	-0.11	0.39	0.001973	Y12337 HSMMPKIN H.sapiens mRNA for myotonic dystrophy protein kinase like protein. Blastn P. 0.42
GB	N39161	0.44	0.26	-0.69	0.001974	CD36 antigen (collagen type I receptor, thrombospondin receptor)
GB	AA398883	-0.10	0.17	-0.08	0.001979	EST: Similar to gb:S66896 SQUAMOUS CELL CARCINOMA ANTIGEN (HUMAN);:
GB	R64190	0.35	-0.13	-0.22	0.001985	Homo sapiens DNA-binding protein (CROC-1A) mRNA, complete cds
GB	T84762	-0.15	0.22	-0.06	0.001993	EST
GB	AA056148	-0.01	0.24	-0.23	0.001993	Human protein tyrosine kinase t-Ror1 (Ror1) mRNA, complete cds
GB	U43431	-0.03	-0.07	0.10	0.002024	EST: N21546 yx60a04.s1 Soares melanocyte 2NbHM Homo sap
GB	X14787	0.45	-0.30	-0.14	0.002039	EST: AA464630 zx85a05.r1 Soares ovary tumor NbHOT Homo
GB	M26685	-0.09	-0.06	0.16	0.002042	Human genomic DNA, 21q region, clone: PQ
GB	AJ001014	-0.22	-0.20	0.42	0.002051	Homo sapiens mRNA encoding RAMP1.
GB	S69200	-0.04	0.00	0.05	0.002066	EP3 prostanoind receptor isoform EP 3-II {alternatively spliced} [human, mRNA, 1082 nt]
GB	N90137	0.31	-0.43	0.11	0.002066	EST: Novel
GB	M21121	0.00	-0.05	0.06	0.002067	Human T cell-specific protein (RANTES) mRNA, complete cds.
GB	AA418689	0.59	-0.35	-0.24	0.002074	DNA-DIRECTED RNA POLYMERASE II 14.4 KD POLYPEPTIDE
GB	T87069	-0.18	0.04	0.14	0.002076	EST
GB	X15357	0.28	-0.11	-0.16	0.002093	Human mRNA for natriuretic peptide receptor (ANP-A receptor).
INCYTE	2194901H1	0.08	-0.06	-0.02	0.002103	THYRTUT03 M69013 g183690 Human guanine nucleotide-binding regulat gb104pri 50 -34
GB	N63635	0.20	0.13	-0.33	0.002116	EST: Novel
GB	D43950	0.08	0.25	-0.33	0.002158	Human mRNA for KIAA0098 gene, partial cds
GB	R25895	0.25	-0.40	0.15	0.002164	EST
GB	AA424743	0.19	-0.22	0.03	0.002173	H.sapiens ERF-1 mRNA 3' end
INCYTE	3097063H1	0.09	-0.02	-0.07	0.002174	U73193 HSU73193 Human inward rectifier potassium channel Kir1.2 (Kir1.2) mRNA, partial cds. Blastn P. 0.0000000000033

Figure 9s

28/47

Primary Cell Gene Expression Profile

Seq Source	Accession	Signature			p-value	Source Description
		Endothelial Signature	Epithelial Signature	Muscle Signature		
GB	L41351	-0.15	0.30	-0.15	0.002222	Homo sapiens prostatic mRNA, complete cds
INCYTE	903559H1	-0.24	0.39	-0.15	0.002238	EST: COLNNO7
GB	M86849	-0.54	1.06	-0.52	0.002246	Human connexin 26 (GJB2) mRNA.
GB	M34539	0.40	-0.30	-0.10	0.002253	Human FK506-binding protein (FKBP) mRNA, complete cds
INCYTE	399998H1	-0.03	0.25	-0.22	0.002267	EST: PITUNOT02 g38479 Unknown. Possibly-related to neuroendocr gb97prip 10 -2
INCYTE	3320154H1	-0.03	-0.29	0.32	0.002287	Human imidazole receptor antisera-sele EST
GB	H75632	0.02	0.13	-0.16	0.002305	calcium-activated chloride channel
INCYTE	4875766H1	-0.02	0.04	-0.02	0.002306	Human dsRNA adenosine deaminase DRADA2b (DRADA2b) mRNA, complete cds
GB	AA489331	0.08	-0.21	0.13	0.002308	MPHGNOT02 M29696 g186365 Human interleukin-7 receptor (IL-7) mRNA gb108pri 16 -3
INCYTE	205581R6	-0.07	-0.05	0.12	0.002308	EST: Weakly similar to No definition line found [C.elegans]
GB	T67104	0.19	-0.22	0.03	0.002325	EST: Weakly similar to similar to enoyl-CoA hydratases/isomerases [C.elegans]
GB	R65792	-0.42	0.41	0.01	0.002350	EST: Highly similar to 6.8 KD MITOCHONDRIAL PROTEOLIPID [Bos taurus]
GB	T90621	0.04	-0.12	0.08	0.002372	Human stress responsive serine/threonine protein kinase Krs-2 mRNA, complete cds
GB	T94961	-0.02	-0.13	0.16	0.002394	EST: X87344.2 H.sapiens DMB mRNA.
GB	X87344	-0.06	-0.19	0.25	0.002405	Human inositol 1,3,4-trisphosphate 5/6-kinase mRNA, complete cds
GB	AA464067	-0.15	0.23	-0.08	0.002407	Glutaredoxin (thioltransferase)
GB	AA291163	0.25	-0.37	0.12	0.002407	ENDCNOT03 M77235 g184039 HH1: sodium channel alpha subunit gb103prip 99 -32
INCYTE	2169635T6	0.04	-0.09	0.05	0.002411	Human hap mRNA encoding a DNA-binding hormone receptor.
GB	Y00291	0.05	-0.12	0.07	0.002412	EST: DEFENDER AGAINST CELL DEATH 1
GB	AA455281	0.52	-0.28	-0.24	0.002413	Apelin (ligand for APJ)
INCYTE	3386845H1	0.18	-0.10	-0.08	0.002413	EST
GB	N53024	-0.08	-0.05	0.14	0.002432	Human mRNA for KIAA0275 gene, complete cds
GB	AA398230	-0.10	-0.11	0.21	0.002459	LUNGNOT04 g205039 Rat K+ channel mRNA, sequence. gb97rod 13 16
INCYTE	767295H1	0.12	0.10	-0.22	0.002475	Human mRNA for KIAA0164 gene, complete cds
GB	H21107	-0.06	-0.07	0.13	0.002475	EST: Weakly similar to ALU SUBFAMILY J [H.sapiens]
GB	R70598	0.21	-0.06	-0.15	0.002476	EST: SINTFET03 Y08724 g1806030 BMP1-5 gb104prip 15 6
INCYTE	2210910T6	-0.34	-0.35	0.70	0.002492	

Figure 9t

Endothelial Gene Expression Profile

Seq. Source	Accession	Endothelial Signature	Epithelial Signature	Muscle Signature	p-value	Source Description
GB	X15606	1.90	-0.91	-0.99	0.000126	Human mRNA for ICAM-2, cell adhesion ligand for LFA-1.
GB	R22412	1.92	-1.03	-0.88	0.000401	Platelet/endothelial cell adhesion molecule (CD31 antigen)
GB	X15606	1.82	-0.96	-0.86	0.000215	Human mRNA for ICAM-2, cell adhesion ligand for LFA-1.
GB	X15606	1.78	-0.88	-0.90	0.000301	Human mRNA for ICAM-2, cell adhesion ligand for LFA-1.
GB	X04385	1.70	-0.86	-0.84	0.000412	Human mRNA for pre-pro-von Willebrand factor.
GB	U27109	1.50	-0.74	-0.76	0.000193	Human prepromulimerin mRNA, complete cds
GB	X60957	1.46	-0.81	-0.65	0.000052	Human tie mRNA for putative receptor tyrosine kinase.
GB	T62627	1.36	-0.67	-0.69	0.000313	Human nuclear phosphoprotein mRNA, complete cds
GB	S56805	1.26	-0.61	-0.65	0.000268	Endothelin-1
GB	AA489699	1.22	-0.55	-0.67	0.000471	Human COP9 homolog (HCOP9) mRNA, complete cds
GB	R96668	1.07	-0.54	-0.53	0.000336	H.sapiens mRNA for chemokine HCC-1
INCYTE	530695T6	1.05	-0.51	-0.54	0.000103	EST: BRAINOT03
GB	M31210	1.07	-0.59	-0.48	0.000289	Human endothelial differentiation protein (edg-1) gene mRNA, complete cds
GB	M60315	1.09	-0.66	-0.44	0.000241	Human transforming growth factor-beta (tgf-beta) mRNA, complete cds.
GB	X54936	0.98	-0.47	-0.52	0.001264	EST: AA130714 zo13h02.s1 Stratagene colon (#937204) Hom
GB	X54936	0.91	-0.41	-0.49	0.000400	EST: AA130714 zo13h02.s1 Stratagene colon (#937204) Hom
GB	AF004327	0.86	-0.44	-0.42	0.000406	EST: AA125872 z123d01.s1 Soares_pregnant_uterus_NbHPU H
INCYTE	285478CA2	0.85	-0.40	-0.45	0.000028	EOSIHE02 g1296608 Human mRNA for chemokine CC-2 and CC-1. gb96pri 32 -74
GB	D12763	0.95	-0.30	-0.66	0.000142	Homo sapiens mRNA for ST2 protein
GB	X81120	0.87	-0.48	-0.38	0.000336	H.sapiens mRNA for central cannabinoid receptor
GB	M31210	0.82	-0.43	-0.39	0.000405	Human endothelial differentiation protein (edg-1) gene mRNA, complete cds
GB	AA284495	0.82	-0.44	-0.38	0.000356	Human mRNA for KIAA0081 gene, partial cds
GB	AA181500	1.19	-1.34	0.15	0.000510	Protein kinase, cAMP-dependent, regulatory, type II, beta
GB	AA455067	0.75	-0.29	-0.46	0.000265	Synuclein, alpha (non A4 component of amyloid precursor)

Figure 10a

Endothelial Gene Expression Profile

Seq Source	Accession	Endothelial Signature	Epithelial Signature	Muscle Signature	p-value	Source Description
GB	L01639	0.72	-0.40	-0.32	0.000704	Human (clone HSY3RR) neuropeptide Y receptor (NPYR) mRNA, complete cds
GB	AA146802	0.65	-0.32	-0.33	0.000277	H.sapiens mRNA for phosphatase cyclase
GB	U52165	0.68	-0.48	-0.20	0.000013	EST: AA150416 z105b02.s1 Soares_pregnant_uterus_NbHPU H
GB	R88734	0.58	-0.27	-0.31	0.000717	EST
GB	AA418689	0.59	-0.35	-0.24	0.002074	DNA-DIRECTED RNA POLYMERASE II 14.4 KD POLYPEPTIDE
GB	H94944	0.58	-0.23	-0.35	0.000346	RAS-RELATED PROTEIN RAL-A
GB	L01639	0.60	-0.43	-0.17	0.000750	Human (clone HSY3RR) neuropeptide Y receptor (NPYR) mRNA, complete cds
GB	AA487526	0.60	-0.18	-0.42	0.001736	Receptor protein-tyrosine kinase EDDR1
GB	AA455281	0.52	-0.28	-0.24	0.002413	EST: DEFENDER AGAINST CELL DEATH 1
GB	W87741	0.57	-0.17	-0.39	0.000063	EST: Novel
GB	K01918	0.57	-0.16	-0.42	0.000022	Human c-sis proto-oncogene for platelet-derived growth factor, exon 1 and flanks.
INCYTE	938765H1	0.53	-0.33	-0.20	0.000161	CERVNOT01 J03004 g183181 Human guanine nucleotide-binding regulat gb103pri 50 -59
GB	N66942	0.50	-0.29	-0.21	0.000289	H.sapiens mRNA for putative progesterone binding protein
GB	U40992	0.63	-0.55	-0.07	0.000173	Human heat shock protein hsp40 homolog mRNA, complete cds
GB	M29871	0.57	-0.13	-0.45	0.000851	Human ras-related C3 botulinum toxin substrate (rac) mRNA, complete cds
GB	AA058828	0.48	-0.28	-0.20	0.000157	Fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor)
GB	L76380	0.48	-0.27	-0.20	0.000083	Homo sapiens (clone HSNME29) CGRP type 1 receptor mRNA, complete cds
GB	H57727	0.47	-0.21	-0.26	0.000356	EST: Highly similar to PTB-ASSOCIATED SPLICING FACTOR [Homo sapiens]
GB	T98559	0.57	-0.50	-0.07	0.000246	Ribosomal protein L17
GB	L36148	0.43	-0.22	-0.21	0.000356	Homo sapiens G protein-coupled receptor (GPR4) gene, complete cds.

Figure 10b

Endothelial Gene Expression Profile

Seq Source	Accession	Endothelial Signature	Epithelial Signature	Muscle Signature	p-value	Source Description
GB	M85079	0.45	-0.18	-0.27	0.001032	Human TGF-beta type II receptor mRNA, complete cds
GB	H94469	0.44	-0.25	-0.19	0.000661	EST: Weakly similar to T01G9.4 [C.elegans]
GB	AA521243	0.49	-0.36	-0.13	0.000029	PUTATIVE 60S RIBOSOMAL PROTEIN
GB	X14787	0.45	-0.30	-0.14	0.002039	EST: AA464630 zx85a05.r1 Soares ovary tumor NbHOT Homo
INCYTE	1321982H1	0.50	-0.07	-0.43	0.000028	BLADNOT04-AF009225 g2327068 Human Ikb kinase alpha subunit (IKK alpha gb104prl 90 -52
INCYTE	1716001T6	0.40	-0.18	-0.22	0.000661	EST: UCMCNOT02
GB	AA495846	0.58	-0.59	0.01	0.000256	TRANSFORMING PROTEIN RHOB
GB	U88880	0.40	-0.23	-0.16	0.000837	Homo sapiens Toll-like receptor 4 (TLR4) mRNA, complete cds.
GB	M32315	0.42	-0.28	-0.14	0.000107	Human tumor necrosis factor receptor mRNA, complete cds
GB	L36148	0.35	-0.17	-0.18	0.000141	Homo sapiens G protein-coupled receptor (GPR4) gene, complete cds.
GB	M34539	0.40	-0.30	-0.10	0.002253	Human FK506-binding protein (FKBP) mRNA, complete cds

Figure 10c

Epithelial Gene Expression Profile

Seq Source	Accession	Signature			p-value	Source Description
		Endothelial	Epithelial	Muscle		
INCYTE	2027449H1	-0.92	1.79	-0.86	0.000296	KERANOT02.g179896 Human Can19 mRNA sequence, gb97pri 68 -76
GB	J05392	-0.97	1.66	-0.70	0.000235	EST: AA074511 zm17e08.s1 Stratagene pancreas (#937208)
GB	M25315	-0.92	1.58	-0.66	0.000134	Homo sapiens (clone PAT 464) potential lymphokine/cytokine mRNA, complete cds
GB	H97778	-0.72	1.41	-0.69	0.000156	H.sapiens mRNA for E-cadherin
GB	U76549	-0.92	1.50	-0.58	0.000322	Human cyokeratin 8 mRNA, complete cds.
GB	M30704	-0.77	1.27	-0.50	0.000093	Human amphiregulin (AR) mRNA, complete cds, clones lambda-AR1 and lambda-AR2.
GB	M86849	-0.54	1.06	-0.52	0.002246	Human connexin 26 (GJB2) mRNA.
GB	S82666	-0.50	0.95	-0.45	0.000176	EST: AA459401 zx89g01.s1 Soares ovary tumor NbHOT Homo
GB	X76180	-0.48	0.94	-0.46	0.000161	H.sapiens mRNA for lung amiloride sensitive Na+ channel protein
INCYTE	1227785H1	-0.32	1.07	-0.75	0.000023	AB000714 AB000714 Homo sapiens hRVP1 mRNA for RVP1, complete cds. Blastn P. 0.029
INCYTE	4872203H1	-0.35	1.04	-0.69	0.000043	EST
GB	M58664	-0.60	0.94	-0.34	0.000061	Homo sapiens CD24 signal transducer mRNA, complete cds.
GB	H58873	-0.78	1.02	-0.24	0.000048	Human (HepG2) glucose transporter gene mRNA, complete cds
INCYTE	1858095F6	-0.55	0.90	-0.35	0.000138	PROSN0T18 AF013598 g2352948 Rat proton gated cation channel DRASIC m gb103rod 30 -11
GB	AA393950	-0.43	0.84	-0.41	0.000194	EST: zt78a10.r1 Soares testis NHT Homo sapiens cDNA clone T28442 5' similar to gb:L29007_cds1 AMILORIDE-SENSITIVE SODIUM CHANNEL ALPHA-SUBUNIT
GB	X12881	-0.11	1.11	-0.99	0.000863	Human mRNA for cyokeratin 18.
GB	AA459197	-0.39	0.81	-0.43	0.000151	Solute carrier family 9 (sodium/hydrogen exchanger), isoform 1 (antiporter, Na+/H+, amiloride sensitive)
INCYTE	2701503T6	-0.39	0.80	-0.41	0.000200	OVARTUT10 U20428 g1890631 Human SNC19 mRNA sequence. gb104pri 18 -36

Figure11a

Epithelial Gene Expression Profile

Seq Source	Accession	Epithelial Gene Expression Profile			p-value	Source Description
		Endothelial Signatu	Epithelial Signature	Muscle Signature		
GB	X07549	-0.42	0.80	-0.38	0.000697	Human mRNA for cathepsin H (E.C.3.4.22.16.).
GB	AA284668	-0.78	0.97	-0.19	0.000446	Urokinase-type plasminogen activator
GB	M59911	-0.61	0.88	-0.27	0.000464	EST: AA424695 zv33a02.s1 Soares ovary tumor NbHOT Homo
GB	AC004126	-0.31	0.83	-0.52	0.001123	GPCR 101
GB	M14764	-0.35	0.77	-0.42	0.000186	Human nerve growth factor receptor mRNA, complete cds
INCYTE	279279H1	-0.45	0.70	-0.25	0.000986	Human acute phase serum myofibrillar protein
GB	K03226	-0.74	0.84	-0.10	0.000638	Human preprorenin mRNA, complete cds.
GB	AA411440	-0.28	0.62	-0.34	0.000328	Villin 2 (ezrin)
GB	X70340	-0.27	0.61	-0.34	0.000126	H.sapiens mRNA for transforming growth factor alpha
INCYTE	4727571H1	-0.26	0.61	-0.35	0.000399	X99897 H.sapiens mRNA for P/Q-type calcium channel alpha1 subunit
INCYTE	2135769H1	-0.35	0.59	-0.25	0.000212	ENDCNOT01 M14300 g183097 Human growth factor-inducible 2A9 gene, gb103pri 100 -88
GB	M80436	-0.27	0.55	-0.28	0.000176	Human platelet activating factor receptor
GB	AA456585	-0.27	0.55	-0.28	0.000186	RecQ protein-like (DNA helicase Q1-like)
INCYTE	1452259F6	-0.26	0.53	-0.27	0.000569	EST: PENITUT01 D13626 g285995 KIAA00001 gb103pri 17 1
GB	M63099	-0.27	0.52	-0.25	0.001189	Human interleukin 1 receptor antagonist (IL1RN) gene, complete cds.
INCYTE	1650566F6	-0.26	0.50	-0.25	0.000654	EST: GPCR_48_TL45 PROSTUT09 g285995 KIAA00001 gb99pri 30 -9
GB	AA454743	-0.24	0.49	-0.25	0.000510	Human protease M mRNA, complete cds
GB	R83000	-0.24	0.49	-0.26	0.000186	Basic transcription factor 3
GB	U62801	-0.24	0.47	-0.23	0.001255	EST: AA454743 zx77e01.s1 Soares ovary tumor NbHOT Homo
GB	R33755	-0.21	0.48	-0.27	0.000461	Glutathione-S-transferase pi-1
GB	U83115	-0.16	0.52	-0.37	0.000506	Human non-lens beta gamma-crystallin like protein (AIM1) mRNA, partial cds.
GB	R06417	0.01	0.66	-0.68	0.000025	Junction plakoglobin
GB	AB000712	-0.23	0.44	-0.20	0.000441	EST: AA430665 zw26a07.s1 Soares ovary tumor NbHOT Homo

Figure11b

Epithelial Gene Expression Profile

Seq Source	Accession	Signature			p-value	Source Description
		Endothelial Signature	Epithelial Signature	Muscle Signature		
INCYTE	2798465H1	-0.16	0.46	-0.30	0.000226	NPOLNOT01 X04366 g29663 Human mRNA for calcium activated neutral gb103pri 98 -69
GB	X70040	-0.20	0.42	-0.22	0.000149	H.sapiens RON mRNA for tyrosine kinase.
GB	X83864	-0.40	0.47	-0.07	0.000285	H.sapiens EDG-3 gene
GB	L29401	-0.56	0.55	0.01	0.000459	Human low density lipoprotein receptor mRNA.
GB	Y00106	-0.15	0.39	-0.24	0.001813	Human gene for beta-adrenergic receptor (beta-2 subtype). EST: zv78h08.r1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 759807 5' similar to TR:G1136412
GB	AA429219	-0.17	0.37	-0.21	0.000223	G1136412 KIAA0176 PROTEIN ;
INCYTE	903559H1	-0.24	0.39	-0.15	0.002238	EST: COLNNOT07
GB	M86400	-0.10	0.43	-0.32	0.000485	Human phospholipase A2 mRNA, complete cds.
GB	M80436	-0.21	0.37	-0.16	0.000427	Human platelet activating factor recepto
INCYTE	2301338H1	-0.14	0.39	-0.25	0.000316	BRSTNOT05 X04366 g29663 Human mRNA for calcium activated neutral gb103pri 98 -7
GB	U41163	-0.22	0.37	-0.14	0.000904	Human creatine transporter (SLC6A10) gene, partial cds.

Figure 11c

Muscle Gene Expression Profile

Seq_Source	Accession	Endothelial Signature	Epithelial Signature	Muscle Signature	p-value	Source Description
GB	AA443177	-0.88	-0.83	1.71	0.000139	Homo sapiens Cam kinase II isoform mRNA, complete cds
GB	Z74616	-0.71	-0.74	1.45	0.000030	H.sapiens mRNA for prepro-alpha2(I) collagen.
GB	M11233	-0.52	-0.53	1.06	0.000745	Human cathepsin D mRNA, complete cds.
GB	M11749	-0.54	-0.50	1.04	0.000028	Human Thy-1 glycoprotein gene, complete cds.
GB	AA453712	-0.51	-0.47	0.98	0.000181	Lumican
GB	M75165	-0.26	-0.80	1.06	0.000065	EST: AA477400 zu42a03.s1 Soares ovary tumor NbHOT Homo
GB	J03278	-0.41	-0.40	0.81	0.000011	Human platelet-derived growth factor (PDGF) receptor mRNA, complete cds
INCYTE	221091076	-0.34	-0.35	0.70	0.002492	EST: SINTFET03 Y08724 g1806030 BMP1-5 gb104prip 15 6
GB	H96738	-0.26	-0.50	0.76	0.000173	Cadherin 11 (OB-cadherin)
GB	U76833	-0.37	-0.33	0.69	0.000168	Human integral membrane serine protease Seprase mRNA, complete cds.
GB	M27492	-0.28	-0.37	0.65	0.001484	Human interleukin 1 receptor mRNA, complete cds
GB	L12350	-0.41	-0.25	0.66	0.000941	Human thrombospondin 2 (THBS2) mRNA, complete cds.
GB	U09278	-0.30	-0.30	0.61	0.000039	Human fibroblast activation protein mRNA, complete cds.
GB	AA243828	-0.17	-0.51	0.68	0.000027	H.sapiens mRNA for receptor protein tyrosine kinase
GB	AA464566	-0.22	-0.34	0.56	0.000207	Human mRNA for LDL-receptor related protein
INCYTE	3415853H1	-0.25	-0.28	0.53	0.000067	L40459 MUSLTBP Mus musculus latent transforming growth factor-beta binding protein (LTBP-3) mRNA, complete cds.
GB	Z67743	-0.63	-0.07	0.70	0.000596	Blastn P. 1E-57
GB	M36089	-0.14	-0.46	0.61	0.000186	H.sapiens mRNA for CLC-7 chloride channel protein.
GB	X95383	-0.42	-0.12	0.54	0.001652	Human DNA-repair protein (XRCC1) mRNA, complete cds.
GB	AA599173	-0.07	-0.52	0.59	0.000202	O.cuniculus mRNA for alpha-B-crystallin
INCYTE	3437994H1	-0.20	-0.24	0.44	0.000173	Human monocytic leukaemia zinc finger protein (MOZ) mRNA, complete cds
GB	AA448194	-0.11	-0.41	0.52	0.000420	EST: PENCNOT05 Z66513 g1041336 F54D5.8 gb103eukp 34 -1
INCYTE	3014785H1	-0.21	-0.21	0.42	0.000043	Human duplicate spinal muscular atrophy mRNA, clone 5G7, partial cds MUSCNOT07 M33210 g532591 Human colony stimulating factor 1 recept gb106prt 100 -71

Figure 12a

Muscle Gene Expression Profile

Seq Source	Accession	Muscle Gene Expression Profile			p-value	Source Description
		Endothelial Signature	Epithelial Signature	Muscle Signature		
GB	AJ001014	-0.22	-0.20	0.42	0.002051	Homo sapiens mRNA encoding RAMP1.
GB	AA085318	-0.24	-0.18	0.42	0.001165	Human stanniocalcin precursor (STC) mRNA, complete cds
GB	V00509	-0.22	-0.19	0.41	0.000053	Human gene for preproenkephalin
GB	AA443688	-0.18	-0.23	0.41	0.001004	GTP cyclohydrolase 1 (dopa-responsive dystonia) {alternative products}
INCYTE	853668H1	-0.33	-0.12	0.45	0.000045	NG2NOT01 U78192 g1688304 Human Edg-2 receptor mRNA, complete cds. gb104pri 67 -35
GB	AA488969	0.00	-0.57	0.57	0.000153	Human mRNA for KIAA0313 gene, complete cds
GB	R65759	-0.13	-0.30	0.43	0.000368	EST
GB	R91550	-0.14	-0.26	0.41	0.001424	Human arginine-rich protein (ARP) gene, complete cds
INCYTE	2601724H1	-0.15	-0.23	0.38	0.001335	Human integrin beta-5 subunit mRNA, comp
GB	T96731	-0.24	-0.14	0.39	0.000652	
GB	M94054	-0.09	-0.35	0.44	0.000863	EST: Highly similar to HLA CLASS II HISTOCOMPATIBILITY ANTIGEN, DX BETA CHAIN PRECURSOR [Homo sapiens]
GB	X00351	-0.35	-0.09	0.43	0.000429	Human lysyl oxidase (LOX) mRNA, complete cds.
INCYTE	3248833H1	-0.20	-0.16	0.36	0.000711	Human mRNA for beta-actin.
GB	U37791	-0.17	-0.18	0.35	0.000237	HumanmRNAencodingRAMP1.
GB	AA435938	-0.19	-0.16	0.35	0.000038	Homo sapiens clone rasi-1 matrix metalloproteinase RASI-1 mRNA, complete cds.
GB	AA443497	-0.14	-0.23	0.37	0.001731	EST: zu01a08.s1 Soares_testis_NHT Homo sapiens cDNA clone 730550 3' similar to TR:G817957 G817957 GLYCINE RECEPTOR SUBUNIT ALPHA 4 ; mRNA sequence.
GB	U83410	-0.16	-0.19	0.34	0.000301	EST: Human clone 23732 mRNA, partial cds Human CUL-2 (cul-2) mRNA, complete cds.

Figure 12b




Figure 13




Figure 14




Figure 15




Figure 16




Figure 17

Seq Id No:	Accession	keratinocyte	Mammary	Bronchial	Prostate	Renal cortical	Renal prox tubule	Small airway	Renal
187	T70429	4.547079	0.313402	0.86323	0.483849	0.230928	0.175945	1.176632	0.208935
188	Z67743	3.876564	0.42035	0.507089	1.040867	0.447039	0.960801	0.346956	0.400334
189	M33882	3.595819	0.278746	0.390244	0.557491	1.045296	0.752613	0.641115	0.738676
190	M13755	3.214564	0.301691	0.49935	0.530559	1.102731	1.144343	0.551365	0.655397
191	M10901	3.024	1.264	0.576	0.752	0.416	0.608	0.96	0.4
192	M23317	2.728242	1.83659	0.611012	0.998224	0.316163	0.476021	0.703375	0.330373
193	L12350	2.695082	0.531148	0.734426	1.147541	0.616393	1.101639	0.622951	0.55082
194	2499967T6	2.585789	1.629116	1.109185	0.987868	0.298094	0.519931	0.506066	0.363951
195	093603H1	2.524456	1.984222	1.032502	0.916377	0.30041	0.403913	0.426633	0.411486
196	X57527	2.505837	0.544747	0.88716	0.513619	0.747082	1.291829	0.59144	0.918288
197	g1949404	2.387974	1.643522	1.088046	0.916249	0.355047	0.475304	0.692913	0.440945
198	H79778	2.33954	0.884995	0.709748	0.814896	0.779847	0.788609	0.884995	0.797371
199	X72781	2.326241	1.34279	1.229314	1.040189	0.406619	0.312057	1.106383	0.236407
200	5171695H1	2.295567	1.093596	1.103448	0.995074	0.384236	0.35468	1.497537	0.275862
201	K00650	2.252427	0.634304	1.177994	0.440129	1.061489	0.504854	0.673139	1.255663
202	U26644	2.216777	1.259189	1.28935	0.980207	0.233742	0.211122	1.651272	0.158341
203	T98394	2.20885	0.948673	1.146903	0.495575	0.552212	0.849558	1.231858	0.566372
204	L26336	2.186139	0.69703	0.570297	0.570297	1.346535	0.950495	0.665347	1.013861
205	Z29330	2.166376	1.891798	0.823735	0.881908	0.477022	0.611984	0.511926	0.635253
206	4694921H1	2.1473	1.538101	1.060556	1.008183	0.484452	0.549918	0.733224	0.458265
207	N39161	2.125352	1.020169	0.791152	0.813706	0.839731	0.397311	1.136413	0.876166
208	U41070	2.094808	0.884876	1.571106	0.848758	0.613995	0.577878	0.939052	0.469526
209	D89078	2.072072	0.828829	1.495495	0.828829	0.630631	0.576577	1.027027	0.540541
210	M27602	2.025641	1.589744	1.064103	0.974359	0.5	0.410256	1.064103	0.371795
211	M24594	2.020761	0.525952	0.719723	0.747405	1.051903	0.99654	1.107266	0.83045
150	M86849	1.716609	0.280263	2.554895	1.784173	0.090084	0.205192	1.283703	0.08508
27	M75165	1.456765	1.717192	2.213632	0.602238	0.618515	0.272635	0.29705	0.821974
169	2027449H1	1.41744	1.707792	2.074212	1.654917	0.24026	0.342301	0.461039	0.102041
212	1442951T6	1.414274	2.287121	0.922067	0.712059	0.574241	0.843314	0.446267	0.800656
213	AA486305	1.302932	2.442066	0.666356	0.342485	1.0349	0.748255	0.323872	1.139134
131	M63099	1.269036	0.436548	2.263959	1.269036	0.365482	0.274112	1.796954	0.324873

Figure 18a

Seq Id No:	Accession	keratinocyte	Mammary	Bronchial	Prostate	Renal cortical	Renal prox tubule	Small airway	Renal
214	M59373	1.198984	0.948349	2.011854	1.144793	0.724809	0.636749	0.514818	0.819644
215	AA047666	1.186226	0.93324	2.063247	1.163739	0.382291	0.376669	1.54603	0.348559
216	AA488969	1.181664	2.037351	0.692699	0.611205	0.63837	1.113752	0.814941	0.910017
217	I09069	1.17889	1.425634	1.88074	2.582591	0.169979	0.180946	0.422207	0.159013
218	M63904	1.168646	1.083135	1.539192	2.014252	0.294537	0.256532	1.35867	0.285036
138	H98334	1.167653	0.489152	0.757396	0.804734	0.710059	2.130178	0.757396	1.183432
219	H78484	1.15122	0.643902	0.663415	0.741463	2.321951	0.839024	0.760976	0.878049
220	3386358H1	1.142857	0.474725	1.072527	0.879121	0.703297	0.615385	2.514286	0.597802
221	R07560	1.125926	0.82963	1.204938	0.88889	0.523457	0.602469	2.449383	0.375309
222	4730434H1	1.116751	0.426396	1.461929	1.116751	0.649746	0.609137	2.192893	0.426396
223	R53652	1.107692	0.615385	2.092308	0.8	0.861538	0.769231	1.261538	0.492308
224	AA398883	1.076453	0.562691	2.006116	0.66055	0.733945	1.46789	0.978593	0.513761
225	AA598776	1.069692	2.424635	0.735818	0.557536	1.128039	0.936791	0.269044	0.878444
226	AA423867	1.053556	2.156277	0.660228	0.965759	0.60755	0.428446	1.675154	0.453029
227	Y14734	1.045149	2.789625	1.260327	0.630163	0.422671	0.49952	0.845341	0.507205
228	R93782	1.044335	0.550246	0.7422	0.689655	1.425287	2.055829	0.407225	0.985222
229	2723646H1	1.027933	0.513966	1.564246	1.162011	0.648045	0.625698	2.011173	0.446927
230	U46005	0.992908	0.778116	0.911854	1.14691	0.636272	0.656535	2.289767	0.587639
231	AA479252	0.967033	0.791209	0.879121	0.683761	1.074481	0.791209	2.06105	0.752137
232	T70122	0.954274	0.779324	0.689198	1.134526	0.795229	0.827038	2.078197	0.742213
78	S82666	0.951351	2.205405	0.73033	1.566366	0.73033	0.163363	1.475075	0.177778
233	3447387H2	0.942966	0.51711	1.247148	0.912548	0.882129	0.821293	2.159696	0.51711
234	2863932H1	0.9	0.575	0.8	0.825	1.05	0.9	2.075	0.875
235	5208013H1	0.845528	1.105691	1.322493	0.737127	0.758808	0.650407	2.081301	0.498645
236	873192H1	0.843956	0.386813	0.861538	0.914286	0.984615	2.338462	0.632967	1.037363
237	R83270	0.838021	0.538021	0.938894	0.419011	1.101843	0.876819	2.071775	0.915616
238	L12060	0.834356	1.006135	1.079755	0.809816	0.883436	0.736196	2.159509	0.490798
239	1909132F6	0.832215	2.52349	0.832215	0.832215	0.751678	0.751678	0.993289	0.483221
240	AA292583	0.829876	0.829876	0.630705	1.145228	0.962656	0.746888	2.024896	0.829876
241	2581223T6	0.814159	0.679646	2.024779	0.920354	0.665487	0.665487	1.465487	0.764602
242	T94781	0.808602	0.378495	0.808602	0.963441	1.015054	2.511828	0.636559	0.877419

Figure 18b

Seq Id No:	Accession	keratinocyte	Margmary	Bronchial	Prostate	Renal cortical	Renal prox tubule	Small airway	Renal
243	N67917	0.7979	1.126859	3.107612	0.657918	0.88189	0.279965	0.713911	0.433946
64	290375H1	0.787879	0.989899	1.414141	2.020202	0.707071	0.727273	0.848485	0.505051
244	M69226	0.768293	0.768293	2.012195	1.341463	0.378049	0.560976	1.756098	0.414634
245	AA011215	0.743276	0.586797	1.017115	0.899756	0.821516	0.723716	2.288509	0.919315
246	1693028H1	0.733624	0.89083	0.681223	1.344978	0.908297	0.69869	2.061135	0.681223
247	2519384H1	0.730097	0.792233	0.807767	1.335922	0.823301	0.714563	2.066019	0.730097
248	R31521	0.723404	0.957447	0.829787	0.659574	0.808511	0.680851	2.617021	0.723404
249	H96850	0.719393	0.754063	0.7974	1.109426	0.667389	0.702059	2.626219	0.624052
250	X95383	0.703297	0.43956	0.492308	0.58022	1.178022	2.602198	0.931868	1.072527
251	AA453663	0.696517	0.577114	1.273632	0.716418	1.014925	0.79602	2.149254	0.776119
252	AA504204	0.695652	0.811594	0.672464	0.742029	1.02029	1.02029	2.226087	0.811594
253	N59542	0.678571	0.455357	0.5	0.5	1.508929	1.339286	0.383929	2.633929
254	AA599176	0.665169	0.683146	1.132584	0.808989	1.006742	0.898876	2.103371	0.701124
37	AA443688	0.657825	0.636605	0.721485	0.615385	0.827586	0.976127	1.018568	2.546419
106	X56134	0.652316	1.839008	0.506197	0.706588	1.042661	2.045662	0.049054	1.158513
255	T58002	0.639309	0.506839	2.37293	1.071274	1.174946	0.575954	0.956084	0.702664
123	X12881	0.631706	0.470163	0.62608	1.055254	2.340366	1.353426	0.269238	1.253767
256	M76672	0.627178	1.240418	2.341463	1.686411	0.45993	0.432056	0.752613	0.45993
257	H73961	0.621601	0.696193	1.498057	0.640249	0.901321	0.640249	2.455322	0.547009
258	L76631	0.595238	0.47619	0.642857	0.642857	1.238095	2.404762	0.928571	1.071429
259	L78207	0.590497	0.879217	1.468263	2.012332	0.899528	0.821182	0.645629	0.683351
260	2211267F6	0.584927	0.512936	0.710911	0.485939	1.088864	2.654668	0.368954	1.592801
261	M54933	0.58427	1.423221	2.367041	1.707865	0.419476	0.419476	0.808989	0.269663
262	AA402960	0.582996	0.615385	0.809717	0.777328	1.036437	2.072874	1.263158	0.842105
263	D14695	0.580609	0.913019	0.647091	0.576177	1.010526	0.686981	2.699169	0.886427
264	X87159	0.578723	0.612766	0.885106	0.817021	1.32766	0.953191	2.144681	0.680851
265	U59167	0.568421	0.463158	0.715789	0.757895	1.052632	1.221053	2.189474	1.031579
266	1649377H1	0.561988	0.561983	0.859504	0.826446	0.92562	2.512397	1.190083	0.561983
267	L22206	0.550607	0.582996	0.744939	0.809717	2.234818	0.939271	1.263158	0.874494
268	X06989	0.543909	0.736544	0.566572	0.532578	0.589235	1.133144	3.184136	0.713881
269	3107995H1	0.540084	0.540084	0.742616	0.877637	1.113924	1.181435	2.396624	0.607595

Figure 18c

Seq Id No:	Accession	keratinocyte	Mammary	Bronchial	Prostate	Renal cortical	Renal prox tubule	Small airway	Renal
57	AA292676	0.537764	0.410876	1.003021	0.622356	2.030211	0.827795	1.268882	1.299094
70	D12763	0.536489	0.315582	1.293886	0.946746	0.883629	0.457594	3.092702	0.473373
270	M17017	0.533333	0.853333	0.853333	0.8	2.053333	0.933333	1.36	0.613333
271	L33404	0.526946	2.299401	1.021956	1.229541	0.750499	0.510978	1.229541	0.431138
272	2726949H1	0.518519	0.555556	0.888889	0.851852	0.962963	2.37037	1.296296	0.555556
273	2726952H1	0.517241	0.517241	0.862069	0.793103	0.896552	2.655172	1.206897	0.551724
274	H51066	0.512535	0.401114	0.64624	0.824513	1.470752	2.339833	1.069638	0.735376
275	AA446565	0.508124	0.732644	0.78382	0.768095	1.353028	2.002954	0.59675	1.252585
276	T99650	0.505747	0.45977	0.574713	0.62069	0.873563	3.241379	0.91954	0.804598
277	463614H1	0.504505	0.576577	0.864865	0.864865	1.081081	1.369369	2.018018	0.720721
278	Y00318	0.492813	0.361396	0.50924	0.459959	1.084189	3.022587	0.788501	1.281314
279	M64349	0.489664	1.349007	0.518849	0.573976	2.010539	1.044183	0.713417	1.300365
104	H57180	0.489209	0.517986	0.834532	0.805755	2.215827	0.892086	1.093525	1.151079
280	U04357	0.48855	0.519084	0.732824	0.793893	2.59542	0.854962	1.251908	0.763359
281	4161733H1	0.48731	0.609137	0.893401	0.974619	1.05838	1.015228	2.395939	0.568528
282	M60278	0.482353	1.152941	1.411765	0.811765	0.764706	0.564706	2.176471	0.635294
283	X61498	0.48	1.048889	0.746667	0.746667	2.133333	0.871111	0.924444	1.048889
284	M37724	0.48	0.512	0.768	0.8	1.184	2.432	1.184	0.64
285	1322305T6	0.479616	2.532374	1.323741	1.016787	0.690647	0.613909	0.863309	0.479616
286	1284795H1	0.470588	0.5	1.264706	1.264706	0.852941	0.823529	2.264706	0.558824
287	349590H1	0.467153	0.525547	0.788321	0.759124	0.992701	1.284672	2.452555	0.729927
288	M28638	0.466302	0.276867	0.422587	0.408015	1.384335	3.497268	0.582878	0.961749
160	4727571H1	0.465696	0.393624	0.532225	0.371448	2.361746	1.61885	0.310464	1.945946
289	W85914	0.46438	2.237467	1.182058	1.034301	0.527704	0.633245	1.245383	0.675462
290	3526532H1	0.45977	0.521073	1.164751	0.888889	0.950192	1.042146	2.421456	0.551724
291	M54894	0.457831	0.409639	0.578313	0.60241	2.506024	1.180723	0.963855	1.301205
292	3382940	0.455696	0.455696	0.886076	0.734177	0.835443	0.911392	3.265823	0.455696
293	X07820	0.454545	0.575758	1	2.545455	0.909091	0.818182	1.212121	0.484848
294	R00275	0.45283	0.467925	0.558491	0.528302	0.845283	0.860377	3.54717	0.739623
295	AA029889	0.442211	0.348409	0.80402	0.482412	0.763819	2.921273	0.696817	1.541039
296	L08096	0.438819	0.57384	0.742616	0.776371	1.012658	2.632911	1.248945	0.57384

Figure 18d

Seq Id No:	Accession	keratinocyte	Mammary	Bronchial	Prostate	Renal cortical	Renal prox tubule	Small airway	Renal
297	R32756	0.436526	0.311804	0.74833	0.890869	1.728285	2.03118	0.685969	1.167038
49	AA488073	0.433812	0.325359	0.937799	0.433812	2.347687	0.905901	1.097289	1.518341
298	556963H1	0.424581	0.446927	0.826816	0.715084	0.759777	0.804469	3.463687	0.558659
299	M37722	0.421907	0.340771	0.503043	0.454361	1.022312	2.953347	0.600406	1.703854
300	AA448094	0.415584	0.292208	0.448052	0.415584	1.376623	2.844156	0.376623	1.831169
301	AA489400	0.414169	1.416894	0.588556	0.566757	0.959128	2.179837	0.871935	1.002725
032	g1751443	0.407407	0.358025	0.691358	2.271605	1.037037	0.506173	1.703704	1.024691
0303	2731293H1	0.401544	0.30888	0.957529	0.432432	1.281853	0.571429	2.795367	1.250965
304	AA521431	0.392707	0.291725	0.695652	0.392707	1.492286	1.952314	0.437588	2.345021
035	AA233079	0.383562	0.438356	0.657534	0.684932	2.164384	0.876712	1.041096	1.753425
036	M26383	0.383333	0.316667	0.55	0.466667	1.383333	2.883333	0.65	1.366667
307	3530687H1	0.382166	0.407643	0.789809	1.070064	2.012739	1.197452	1.070064	1.070064
308	N41062	0.371134	0.412371	0.639175	0.721649	1.546392	2.082474	1.092784	1.134021
183	903559H1	0.37037	0.311111	1.214815	0.444444	1.422222	0.607407	2.207407	1.422222
309	AA419108	0.369231	0.298901	0.43956	0.457143	1.441758	2.813187	0.773626	1.406593
310	J03561	0.366197	1.028169	0.859155	0.464789	2.464789	0.957746	0.802817	1.056338
311	M34064	0.362369	0.390244	0.641115	0.66899	1.254355	2.759582	0.97561	0.947735
312	1334463H1	0.35468	0.35468	1.615764	1.852217	0.610837	0.571429	2.246305	0.394089
313	AA486085	0.348515	0.744554	0.50165	0.971617	2.006601	0.987459	0.744554	1.69505
314	M64749	0.337778	0.388889	2.88	1.6	0.551111	0.515556	0.888889	0.337778
315	M60278	0.330794	0.618063	1.479869	0.739935	0.696409	0.417845	3.299238	0.417845
316	K02765	0.328767	0.591781	0.810959	0.635616	0.920548	2.761644	1.227397	0.723288
310	J03561	0.326531	0.755102	0.908163	0.469388	2.969388	1.030612	0.632653	0.908163
317	AA460571	0.31746	0.31746	1.174603	0.444444	1.015873	1.015873	2.555556	1.15873
174	4872203H1	0.306011	0.091075	0.830601	1.315118	1.260474	0.52459	2.185792	1.486339
157	268	0.302267	0.246851	0.397985	0.347607	3.511335	0.675063	0.710327	1.808564
318	1226731H1	0.289738	1.448692	0.450704	0.515091	1.046278	2.478873	0.595573	1.17505
319	264	0.286765	0.147059	0.474265	1.084559	0.738971	0.433824	3.488971	1.345588
320	X54925	0.285714	0.396313	0.451613	2.073733	1.253456	1.437788	1.658986	0.442396
3173	1227785H1	0.285389	0.11537	0.570778	1.16888	1.190133	0.522201	2.556357	1.590892
321	H16637	0.279365	0.304762	0.444444	0.380952	1.320635	3.619048	0.55873	1.092063

Figure 18e

Seq Id No:	Accession	keratinocyte	Mammary	Bronchial	Prostate	Renal cortical	Renal prox tubule	Small airway	Renal
322	2496910H1	0.272545	0.320641	0.46493	0.432866	1.667335	3.142285	0.609218	1.09018
323	3558269H1	0.264591	0.29572	0.544747	0.404669	1.929961	1.089494	1.120623	2.350195
324	T90375	0.248939	0.724187	0.565771	0.384724	1.471004	1.459689	0.701556	2.44413
325	U81233	0.234483	0.275862	0.427586	0.524138	3.462069	1.089655	0.827586	1.158621
326	M84683	0.208605	0.177314	0.490222	0.292047	3.588005	1.011734	0.792699	1.439374
158	279279H1	0.206406	1.864769	0.768683	0.704626	0.690391	2.298932	1.024911	0.441281
327	1484836T6	0.196248	1.466089	0.380952	0.34632	3.578644	0.496392	0.507937	1.027417
328	T52894	0.182077	0.216216	0.295875	0.534851	1.672831	3.834993	0.614509	0.648649
165	AA454743	0.158612	1.258984	0.39653	0.297398	3.925651	0.465923	0.406444	1.090458
166	U62801	0.154176	1.027837	0.394004	0.316916	4.471092	0.4197	0.359743	0.856531
329	M23699	0.126582	1.324895	0.7173	0.700422	0.953586	2.708861	0.987342	0.481013

Figure 18f

SEQUENCE LISTING

SEQ ID NO: 1

>gi|32623|emb|X15606.1|HSICAM2 Human mRNA for ICAM-2, cell adhesion ligand for LFA-1

5 CTAAAGATCTCCCTCCAGGCAGCCCTTGGCTGGTCCCTGCGAGCCCGTGGAGACT
GCCAGAGATGTCTCTTTTCGGTTACAGGACCCTGACTGTGGCCCTCTTCACCCTG
ATCTGCTGTCCAGGATCGGATGAGAAGGTATTCGAGGTACACGTGAGGCCAAAG
AAGCTGGCGGTTGAGCCCAAAGGGTCCCTCGAGGTCAACTGCAGCACCACCTGT
10 AACCAGCCTGAAGTGGGTGGTCTGGAGACCTCTCTAAATAAGATTCTGCTGGACG
AACAGGCTCAGTGGAAACATTACTTGGTCTCAAACATCTCCCATGACACGGTCCT
CCAATGCCACTTCACCTGCTCCGGGAAGCAGGAGTCAATGAATTCCAACGTCAGC
GTGTACCAGCCTCCAAGGCAGGTCATCCTGACACTGCAACCCACTTTGGTGGCTG
TGGGCAAGTCCTTCACCATTGAGTGCAGGGTGCCCAACCGTGGAGCCCCCTGGACA
15 GCCTCACCTCTTCTGTTCGGTGGCAATGAGACTCTGCACTATGAGACCTTCGG
GAAGGCAGCCCCTGCTCCGCAGGAGGCCACAGCCACATTCAACAGCACGGCTGA
CAGAGAGGATGGCCACCACAACCTTCTCCTGCCTGGCTGTGCTGGACTTGATGTCT
CGCGGTGGCAACATCTTTCACAAACACTCAGCCCCGAAGATGTTGGAGATCTATG
AGCCTGTGTCGGACAGCCAGATGGTCATCATAGTCACGGTGGTGTGCGGTGTTGCT
20 GTCCCTGTTTCGTGACATCTGTCCTGCTCTGCTTCATCTTCGGCCAGCACTTGCGCC
AGCAGCGGATGGGCACCTACGGGGTGGAGCGGGCTTGGAGGAGGCTGCCCCAGG
CCTTCCGGCCATAGCAACCATGAGTGGCATGGCCACCACCACGGTGGTCACTGG
AACTCAGTGTGACTCCTCAGGGTTGAGGTCCAGCCCTGGCTGAAGGACTGTGACA
GGCAGCAGAGACTTGGGACATTGCCTTTTCTAGCCCCGAATACAAACACCTGGACT
25 T

SEQ ID NO: 2

>gi|777193|gb|R22412.1|R22412 yh23b03.s1 Soares placenta Nb2HP Homo sapiens cDNA clone IMAGE:130541 3' similar to contains Alu repetitive element;

30 TTTTGTCAAAGAGCAAAGGTCAAATTTATTTAATACAACATCCACGAGGGTCCCT
GCAGCTNTGTCACTGAGGCAAACAGGAAAAGTGATTTTGGCTAGGCGTGGTTCTC
ATCTGTGAAATCCACAGCGCAATGACAGCAGCCTNTNTCCCACCCACTCAAGAC
ACTNTCAGGANITGNTTAAGACCTCAGGAGACCANTTNTTTAGCAAGCAATTTTG
TTTTTTGTTTTTTTTGAGATGGGNTTCTCACTCTGTCACTCAGGCTGGGAGTGCAG
35 TGGCGCGATCTCCCGCTCACTANAACNCCGTTTCCNGGGGGGTCAAGGGGNTA
ATTTACCTCAGGCCCTTG

SEQ ID NO: 3

>gi|37946|emb|X04385.1|HSVWFR1 Human mRNA for pre-pro-von Willebrand factor

40 GCAGCTGAGAGCATGGCCTAGGGTGGGCGGCACCATTGTCCAGCAGCTGAGTTT
CCCAGGGACCTTGGAGATAGCCGCAGCCCTCATTTGCAGGGGAAGATGATTCCT
GCCAGATTTGCCGGGGTGCTGCTTGTCTTGCCCTCATTTTGCCAGGGACCCTTTG
TGCAGAAGGAACTCGCGGCAGGTCATCCACGGCCCGATGCAGCCTTTTCGGAAG
TGACTTCGTCAACACCTTTGATGGGAGCATGTACAGCTTTGCGGGATACTGCAGT
45 TACCTCCTGGCAGGGGGCTGCCAGAAACGCTCCTTCTCGATTATTGGGGACTTCC
AGAATGGCAAGAGAGTGAGCCTCTCCGTGTATCTTGGGGAATTTTTTGACATCCA
TTTGTGTTGTCAATGGTACCGTGACACAGGGGGACCAAAGAGTCTCCATGCCCTAT
GCCTCCAAAGGGCTGTATCTAGAAACTGAGGCTGGGTACTACAAGCTGTCCGGT

GAGGCCTATGGCTTTGTGGCCAGGATCGATGGCAGCGGCAACTTTCAAGTCCTGC
TGTCAGACAGATACTTCAACAAGACCTGCGGGCTGTGTGGCAACTTTAACATCTT
TGCTGAAGATGACTTTATGACCCAAGAAGGGACCTTGACCTCGGACCCCTTATGAC
TTTGCCAACCTCATGGGCTCTGAGCAGTGGAGAACAGTGGTGTGAACGGGCATCTC
5 CTCCCAGCAGCTCATGCAACATCTCCTCTGGGGAAATGCAGAAGGGCCTGTGGG
AGCAGTGCCAGCTTCTGAAGAGCACCTCGGTGTTTGCCCGCTGCCACCCTCTGGT
GGACCCCGAGCCTTTTGTGGCCCTGTGTGAGAAGACTTTGTGTGAGTGTGCTGGG
GGGCTGGAGTGCGCCTGCCCTGCCCTCCTGGAGTACGCCCGGACCTGTGCCCAGG
AGGGAATGGTGTGTACGGCTGGACCGACCACAGCGCGTGCAGCCCAGTGTGCC
10 CTGCTGGTATGGAGTATAGGCAGTGTGTGTCCCCTTGCGCCAGGACCTGCCAGAG
CCTGCACATCAATGAAATGTGTGTCAGGAGCGATGCGTGGATGGCTGCAGCTGCCCT
GAGGGACAGCTCCTGGATGAAGGCCTCTGCGTGGAGAGCACCGAGTGTCCCTGC
GTGCATTCCGGAAGCGCTACCCTCCCGGCACCTCCCTCTCTCGAGACTGCAACA
CCTGCATTTGCCGAAACAGCCAGTGGATCTGCAGCAATGAAGAATGTCCAGGGG
15 AGTGCCTTGTACAGGTCAATCACACTTCAAGAGCTTTGACAACAGATACTTCAC
CTTCAGTGGGATCTGCCAGTACCTGCTGGCCCGGGATTGCCAGGACCACTCCTTC
TCCATTGTCAATTGAGACTGTCCAGTGTGCTGATGACCGCGACGCTGTGTGCACCC
GCTCCGTCACCGTCCGGCTGCCTGGCCTGCACAACAGCCTTGTGAACTGAAGCA
TGGGGCAGGAGTTGCCATGGATGGCCAGGACGTCCAGCTCCCCCTCCTGAAAGG
20 TGACCTCCGCATCCAGCATAACAGTGACGGCCTCCGTGCGCCTCAGCTACGGGGAG
GACCTGCAGATGGACTGGGATGGCCGCGGGAGGCTGCTGGTGAAGCTGTCCCCC
GTCTATGCCGGGAAGACCTGCGGCCTGTGTGGGAATTACAATGGCAACCAGGGC
GACGACTTCCTTACCCCCCTCTGGGCTGGCGGAGCCCCGGGTGGAGGACTTCGGGA
ACGCCTGGAAGCTGCACGGGGACTGCCAGGACCTGCAGAAGCAGCACAGCGATC
25 CCTGCGCCCTCAACCCGCGCATGACCAGGTTCTCCGAGGAGGCGTGCGCGGTCT
GACGTCCCCCACATTCGAGGCCTGCCATCGTGCCGTACGCCCGCTGCCCTACCTG
CGGAACTGCCGCTACGACGTGTGCTCCTGCTCGGACGGCCGCGAGTGCCTGTGCG
GCGCCCTGGCCAGCTATGCCGCGGCCTGCGCGGGGAGAGGCGTGCGCGTTCGCGT
GGCGCGAGCCAGGCCGCTGTGAGCTGAACTGCCCCGAAAGGCCAGGTGTACCTGC
30 AGTGCGGGACCCCCCTGCAACCTGACCTGCCGCTCTCTCTTACCCGGATGAGGA
ATGCAATGAGGCCTGCCTGGAGGGCTGCTTCTGCCCCCAGGGCTCTACATGGAT
GAGAGGGGGGACTGCGTGCCCAAGGCCAGTGCCCCCTGTTACTATGACGGTGAG
ATCTTCCAGCCAGAAGACATCTTCTCAGACCATCACACCATGTGCTACTGTGAGG
ATGCTTCACTGCACTGTACCATGAGTGGAGTCCCCGGAAGCTTGCTGCCTGACGC
35 TGTCTCAGCAGTCCCCTGTCTCATCGCAGCAAAAGGAGCCTATCCTGTGCGCCC
CCCATGGTCAAGCTGGTGTGTCCCCTGACAACCTGCGGGCTGAAGGGCTCGAGT
GTACCAAAACGTGCCAGAACTATGACCTGGAGTGCATGAGCATGGGCTGTGTCT
CTGGCTGCCTCTGCCCCCGGGCATGGTCCGGCATGAGAACAGATGTGTGGCCCT
GGAAAGGTGTCCCTGCTTCCATCAGGGCAAGGAGTATGCCCTGGAGAAACAGT
40 GAAGATTGGCTGCAACACTTGTGTCTGTGCGGACCGGAAGTGGAAGTGCACAGA
CCATGTGTGTGATGCCACGTGCTCCACGATCGGCATGGCCCACTACCTCACCTTC
GACGGGCTCAAATACCTGTTCCCCGGGGAGTGCCAGTACGTTCTGGTGCAGGATT
ACTGCGGCAGTAACCCTGGGACCTTTTCGGATCCTAGTGGGGAATAAGGGATGCA
GCCACCCCTCAGTGAAATGCAAGAAACGGGTACCATCCTGGTGGAGGGAGGAG
45 AGATTGAGCTGTTTGACGGGGAGGTGAATGTGAAGAGGCCCATGAAGGATGAGA
CTCACTTTGAGGTGGTGGAGTCTGGCCGGTACATCATTCTGCTGCTGGGCAAAGC
CCTCTCCGTGGTCTGGGACCGCCACCTGAGCATCTCCGTGGTCTGAAGCAGACA
TACCAGGAGAAAGTGTGTGGCCTGTGTGGGAATTTTGATGGCATCCAGAACAAT
GACCTCACAGCAGCAACCTCCAAGTGGAGGAAGACCCTGTGGACTTTGGGAAC

TCCTGGAAAGTGAGCTCGCAGTGTGCTGACACCAGAAAAGTGCCTCTGGACTCAT
CCCCTGCCACCTGCCATAACAACATCATGAAGCAGACGATGGTGGATTCTCTCTG
TAGAATCCTTACCAGTGACGTCTTCCAGGACTGCAACAAGCTGGTGGACCCCGAG
CCATATCTGGATGTCTGCATTTACGACACCTGCTCCTGTGAGTCCATTGGGGACT
5 GCGCCTGCTTCTGCGACACCATTTGCTGCCTATGCCCACGTGTGTGCCCAGCATGG
CAAGGTGGTGACCTGGAGGACGGCCACATTGTGCCCCCAGAGCTGCGAGGAGAG
GAATCTCCGGGAGAACGGGTATGAGTGTGAGTGGCGCTATAACAGCTGTGCACC
TGCCTGTCAAGTCACGTGTCAGCACCTGAGCCACTGGCCTGCCCTGTGCAGTGT
GTGGAGGGCTGCCATGCCCACTGCCCTCCAGGGAAAATCCTGGATGAGCTTTTGC
10 AGACCTGCGTTGACCCTGAAGACTGTCCAGTGTGTGAGGTGGCTGGCCGGCGTTT
TGCCTCAGGAAAGAAAGTCACCTTGAATCCCAGTGACCCTGAGCACTGCCAGATT
TGCCACTGTGATGTTGTCAACCTCACCTGTGAAGCCTGCCAGGAGCCGGGAGGCC
TGGTGGTGCCTCCACAGATGCCCCGGTGAGCCCCACCACTCTGTATGTGGAGGA
CATCTCGGAACCGCCGTTGCACGATTTCTACTGCAGCAGGCTACTGGACCTGGTC
15 TTCCTGCTGGATGGCTCCTCCAGGCTGTCCGAGGCTGAGTTTGAAGTGCTGAAGG
CCTTTGTGGTGGACATGATGGAGCGGCTGCGCATCTCCCAGAAGTGGGTCCGCGT
GGCCGTGGTGGAGTACCACGACGGCTCCCACGCCTACATCGGGCTCAAGGACCG
GAAGCGACCGTCAGAGCTGCGGCGCATTGCCAGCCAGGTGAAGTATGCGGGCAG
CCAGGTGGCCTCCACCAGCGAGGTCTTGAATACACACTGTTCCAAATCTTCAGC
20 AAGATCGACCGCCCTGAAGCCTCCCGCATCGCCCTGCTCCTGATGGCCAGCCAGG
AGCCCCAACGGATGTCCCGGAACCTTGTCCGCTACGTCCAGGGCCTGAAGAAGA
AGAAGGTCATTGTGATCCCGGTGGGCATTGGGGCCCCATGCCAACCTCAAGCAGA
TCCGCCTCATCGAGAAGCAGGCCCCCTGAGAACAAGGCCTTCGTGCTGAGCAGTG
TGGATGAGCTGGAGCAGCAAAGGGACGAGATCGTTAGCTACCTCTGTGACCTTG
25 CCCCTGAAGCCCCCTCCTCCTACTCTGCCCCCCCACATGGCACAAGTCACTGTGGG
CCCGGGGCTCTTGGGGGTTTCGACCCTGGGGGCCCAAGAGGAACTCCATGGTTCTG
GATGTGGCGTTTCGTCTGGAAGGATCGGACAAAATTGGTGAAGCCGACTTCAAC
AGGAGCAAGGAGTTTCATGGAGGAGGTGATTCAGCGGATGGATGTGGGCCAGGAC
AGCATCCACGTACCGGTGCTGCAGTACTCCTACATGGTGACCGTGAGTACCCCT
30 TCAGCGAGGCACAGTCCAAAGGGGACATCCTGCAGCGGGTGCGAGAGATCCGCT
ACCAGGGCGGCAACAGGACCAACACTGGGCTGGCCCTGCGGTACCTCTCTGACC
ACAGCTTCTTGGTCAGCCAGGGTGACCGGGAGCAGGCGCCCAACCTGGTCTACA
TGGTCACCGGAAATCCTGCCTCTGATGAGATCAAGAGGCTGCCTGGAGACATCC
ACCTGGTCCCCATTGGAGTGGGCCCTAATGCCAACGTGCAGGAGCTGGAGAGGA
35 TTGGCTGGCCCAATGCCCTATCCTCATCCAGGACTTTGAGACGCTCCCCCGAGA
GGCTCCTGACCTGGTGTGTCAGAGGTGCTGCTCCGGAGAGGGGCTGCAGATCCC
CACCTCTCCCCTGCACCTGACTGCAGCCAGCCCTGGACGTGATCCTTCTCCTG
GATGGCTCCTCCAGTTTCCCAGCTTCTTATTTTGATGAAATGAAGAGTTTCGCCAA
GGCTTTTCATTTCAAAGCCAATATAGGGCCTCGTCTCACTCAGGTGTCAGTGCTG
40 CAGTATGGAAGCATCACCAACATTGACGTGCCATGGAACGTGGTCCCGGAGAAA
GCCCATTTGCTGAGCCTTGTGGACGTATGCAGCGGGAGGGAGGCCCCAGCCAA
ATCGGGGATGCCTTGGGCTTTGCTGTGCGATACTTGACTTCAGAAATGCATGGTG
CCAGGCCGGGAGCCTCAAAGGCGGTGGTCATCCTGGTCACGGACGTCTCTGTGG
ATTCAGTGGATGCAGCAGCTGATGCCGCCAGGTCCAACAGAGTGACAGTGTTCC
45 CTATTGGAATTGGAGATCGCTACGATGCAGCCCAGCTACGGATCTTGGCAGGCCC
AGCAGGCGACTCCAACGTGGTGAAGCTCCAGCGAATCGAAGACCTCCCTACCAT
GGTCACCTTGGGCAATTCTTCTCCACAACTGTGCTCTGGATTTGTTAGGATTT
GCATGGATGAGGATGGGAATGAGAAGAGGGCCCGGGGACGTCTGGACCTTGCCAG
ACCAGTGCCACACCGTGACTTGCCAGCCAGATGGCCAGACCTTGCTGAAGACTC

ATCGGGTCAACTGTGACCGGGGGCTGAGGCCTTCGTGCCCTAACAGCCAGTCCCC
TGTTAAAGTGGAAGAGACCTGTGGCTGCCGCTGGACCTGCCCCTGCGTGTGCACA
GGCAGCTCCACTCGGCACATCGTGACCTTTGATGGGCAGAATTTCAAGCTGACTG
GCAGCTGTTCTTATGTCTATTTCAAAACAAGGAGCAGGACCTGGAGGTGATTCT
5 CCATAATGGTGCCTGCAGCCCTGGAGCAAGGCAGGGCTGCATGAAATCCATCGA
GGTGAAGCACAGTGCCCTCTCCGTCGAGCTGCACAGTGACATGGAGGTGACGGT
GAATGGGAGACTGGTCTCTGTTCCCTTACGTGGGTGGGAACATGGAAGTCAACGTT
TATGGTGCCATCATGCATGAGGTCAGATTCAATCACCTTGGTCACATCTTCACAT
TCACTCCACAAAACAATGAGTTCCAACTGCAGCTCAGCCCCAAGACTTTTGCTTC
10 AAAGACGTATGGTCTGTGTGGGATCTGTGATGAGAACGGAGCCAATGACTTCAT
GCTGAGGGATGGCACAGTCACCACAGACTGGAAAACACTTGTTCAGGAATGGAC
TGTGCAGCGGCCAGGGCAGACGTGCCAGCCCATCCTGGAGGAGCAGTGTCTTGT
CCCCGACAGCTCCCACTGCCAGGTCTCTCTTACCACTGTTTGCTGAATGCCAC
AAGGTCCTGGCTCCAGCCACATTCTATGCCATCTGCCAGCAGGACAGTTGCCACC
15 AGGAGCAAGTGTGTGAGGTGATCGCCTCTTATGCCACCTCTGTTCGACCAACGG
GGTCTGCGTTGACTGGAGGACACCTGATTTCTGTGCTATGTCATGCCACCATCT
CTGGTCTACAACCACTGTGAGCATGGCTGTCCCCGGCACTGTGATGGCAACGTGA
GCTCCTGTGGGGACCATCCCTCCGAAGGCTGTTTCTGCCCTCCAGATAAAGTCAT
GTTGGAAGGCAGCTGTGTCCCTGAAGAGGCCTGCACTCAGTGCATTGGTGAGGA
20 TGGAGTCCAGCACCAGTTCCTGGAAGCCTGGGTCCCGGACCACCAGCCCTGTCAG
ATCTGCACATGCCTCAGCGGGCGGAAGGTCAACTGCACAACGCAGCCCTGCCCC
ACGGCCAAAGCTCCACAGTGTGGCCTGTGTGAAGTAGCCCGCCTCCGCCAGAAT
GCAGACCAGTGCTGCCCCGAGTATGAGTGTGTGTGTGACCCAGTGAGCTGTGACC
TGCCCCCAGTGCCCTCACTGTGAACGTGGCCTCCAGCCACACTGACCAACCCTGG
25 CGAGTGCAGACCCAACTTCACCTGCGCCTGCAGGAAGGAGGAGTGCAAAAGAGT
GTCCCCACCCTCCTGCCCCCGCACCGTTTGCCACCCCTTCGGAAGACCCAGTGC
TGTGATGAGTATGAGTGTGCCTGCAACTGTGTCAACTCCACAGTGAGCTGTCCCC
TTGGGTACTTGCCCTCAACCGCCACCAATGACTGTGGCTGTACCACAACCACCTG
CCTTCCCGACAAGGTGTGTGTCCACCGAAGCACCATCTACCCTGTGGGCCAGTTC
30 TGGGAGGAGGGCTGCGATGTGTGCACCTGCACCGACATGGAGGATGCCGTGATG
GGCCTCCGCGTGGCCCAGTGCTCCCGAAGCCCTGTGAGGACAGCTGTCCGGTCG
GGCTTCACTTACGTTCTGCATGAAGGCGAGTGCTGTGGAAGGTGCCTGCCATCTG
CCTGTGAGGTGGTGACTGGCTCACCGCGGGGGGACTCCCACTTCTGGAAGA
GTGTCCGGCTCCCACTGGGCCTCCCCGGAGAACCCCTCCCTCATCAATGAGTGTGT
35 CCGAGTGAAGGAGGAGGTCTTTATACAACAAAGGAACGTCTCCTGCCCCCAGCT
GGAGGTCCCTGTCTGCCCCCTCGGGCTTTCAGCTGAGCTGTAAGACCTCAGCGTGC
TGCCCAAGCTGTGCTGTGAGCGCATGGAGGCCTGCATGCTCAATGGCACTGTCA
TTGGGCCCCGGAAGACTGTGATGATCGATGTGTGCACGACCTGCCGCTGCATGGT
GCAGGTGGGGGTCATCTCTGGATTCAAGCTGGAGTGCAGGAAGACCACCTGCAA
40 CCCCTGCCCCCTGGGTTACAAGGAAGAAAATAACACAGGTGAATGTTGTGGGAG
ATGTTTGCCTACGGCTTGACCATTCAGCTAAGAGGAGGACAGATCATGACACTG
AAGCGTGATGAGACGCTCCAGGATGGCTGTGATACTCACTTCTGCAAGGTCAATG
AGAGAGGAGAGTACTTCTGGGAGAAGAGGGTCACAGGCTGCCACCCCTTTGATG
AACACAAGTGTCTGGCTGAGGGAGGTAAAATTATGAAAATTCCAGGCACCTGCT
45 GTGACACATGTGAGGAGCCTGAGTGCAACGACATCACTGCCAGGCTGCAGTATG
TCAAGGTGGGAAGCTGTAAGTCTGAAGTAGAGGTGGATATCCACTACTGCCAGG
GCAAATGTGCCAGCAAAGCCATGTACTCCATTGACATCAACGATGTGCAGGACC
AGTGCTCCTGCTGCTCTCCGACACGGACGGAGCCCATGCAGGTGGCCCTGCACTG
CACCAATGGCTCTGTTGTGTACCATGAGGTTCTCAATGCCATGGAGTGCAATGC

TCCCCAGGAAGTGCAGCAAGTGAGGCTGCTGCAGCTGCATGGGTGCCTGCTGCT
GCC

SEQ ID NO: 4

5 >gi|396814|emb|X60957.1|HSTIEMR Human tie mRNA for putative receptor tyrosine kinase
CGCTCGTCCTGGCTGGCCTGGGTCGGCCTCTGGAGTATGGTCTGGCGGGTGTCCCC
CTTTCTTGCTCCCCATCCTCTTCTTGGCTTCTCATGTGGGCGCGGCGGTGGACCTG
ACGCTGCTGGCCAACCTGCGGCTCACGGACCCCCAGCGCTTCTTCTGACTTGCG
TGCTGGGGAGGCCGGGGCGGGGAGGGGCTCGGACGCCTGGGGCCCCGCCCTGC
10 TGCTGGAGAAGGACGACCGTATCGTGCGCACCCCGCCCGGGCCACCCCTGCGCC
TGGCGCGCAACGGTTCGCACCAGGTCACGCTTCGCGGCTTCTCCAAGCCCTCGGA
CCTCGTGGGCGTCTTCTCCTGCGTGGGCGGTGCTGGGGCGCGGCGCACGCGCGTC
ATCTACGTGCACAACAGCCCTGGAGCCACCTGCTTCCAGACAAGGTCACACAC
ACTGTGAACAAAGGTGACACCGCTGTACTTTCTGCACGTGTGCACAAGGAGAAG
15 CAGACAGACGTGATCTGGAAGAGCAACGGATCCTACTTCTACACCCTGGACTGG
CATGAAGCCCAGGATGGGCGGTTTCTGCTGCAGCTCCCAAATGTGCAGCCACCAT
CGAGCGGCATCTACAGTGCCACTTACCTGGAAGCCAGCCCCCTGGGCAGCGCCTT
CTTTCGGCTCATCGTGCGGGGTTGTGGGGCTGGGCGCTGGGGGCCAGGCTGTACC
AAGGAGTGCCCAGGTTGCCTACATGGAGGTGTCTGCCACGACCATGACGGCGAA
20 TGTGTATGCCCCCTGGCTTCACTGGCACCCGCTGTGAACAGGCCTGCAGAGAGG
GCCGTTTTGGGCAGAGCTGCCAGGAGCAGTGCCCAGGCATATCAGGCTGCCGGG
GCCTACCTTCTGCCTCCCAGACCCCTATGGCTGCTCTTGTGGATCTGGCTGGAG
AGGAAGCCAGTGCCAAGAAGCTTGTGCCCTGGTCATTTTGGGGCTGATTGCCGA
CTCCAGTGCCAGTGTGAGAATGGTGGCACTTGTGACCGGTTCAGTGGTTGTGTCT
25 GCCCCTCTGGGTGGCATGGAGTGCAGTGTGAGAAGTCAGACCGGATCCCCCAGA
TCCTCAACATGGCCTCAGAACTGGAGTTCAACTTAGAGACGATGCCCCGGATCAA
CTGTGCAGCTGCAGGGAACCCCTTCCCCGTGCGGGGCAGCATAGAGCTACGCAA
GCCAGACGGCACTGTGCTCCTGTCCACCAAGGCCATTGTGGAGCCAGAGAAGAC
CACAGCTGAGTTCGAGGTGCCCCGCTTGGTTCTTGCGGACAGTGGGTTCTGGGAG
30 TGCCGTGTGTCCACATCTGGCGGCCAAGACAGCCGGCGCTTCAAGGTCAATGTGA
AAGTGCCCCCGTGGCCCTGGCTGCACCTCGGCTCCTGACCAAGCAGAGCCGCCA
GCTTGTGGTCTCCCCGCTGGTCTCGTTCTCTGGGGATGGACCCATCTCCACTGTCC
GCCTGCACTACCGGCCCCAGGACAGTACCATGGACTGGTTCGACCATTGTGGTGG
ACCCAGTGAGAACGTGACGTTAATGAACCTGAGGCCAAAGACAGGATACAGTG
35 TTCGTGTGCAGCTGAGCCGGCCAGGGGAAGGAGGAGAGGGGGCCTGGGGGCCTC
CCACCCTCATGACCACAGACTGTCCTGAGCCTTTGTTGCAGCCGTGGTTGGAGGG
CTGGCATGTGGAAGGCACTGACCGGCTGCGAGTGAGCTGGTCCTTGCCCTTGGTG
CCCGGGCCACTGGTGGGCGACGGTTTCCTGCTGCGCCTGTGGGACGGGACACGG
GGGAGGAGCGGCGGGGAGAACGTCTCATCCCCCAGGCCCGCACTGCCCTCCTG
40 ACGGGACTCACGCCTGGCACCCACTACCAGCTGGATGTGCAGCTCTACCACTGCA
CCCTCCTGGGCCCCGGCCTCGCCCCCTGCACACGTGCTTCTGCCCCCAGTGGGCC
TCCAGCCCCCGACACCTCCACGCCAGGCCCTCTCAGACTCCGAGATCCAGCTG
ACATGGAAGCACCCGGAGGCTCTGCCTGGGCCAATATCCAAGTACGTTGTGGAG
GTGCAGGTGGCTGGGGGTGCAGGAGACCCACTGTGGATAGACGTGGACAGGCCT
45 GAGGAGACAAGCACCATCATCCGTGGCCTCAACGCCAGCACGCGCTACCTCTTCC
GCATGCGGGCCAGCATTACGGGGCTCGGGGACTGGAGCAACACAGTAGAAGAGT
CCACCCTGGGCAACGGGCTGCAGGCTGAGGGCCCAGTCCAAGAGAGCCGGGCAG
CTGAAGAGGGCCTGGATCAGCAGCTGATCCTGGCGGTGGTGGGCTCCGTGTCTGC
CACCTGCCTACCATCCTGGCCGCCCTTTTAACCCTGGTGTGCATCCGCAGAAGC

TGCCTGCATCGGAGACGCACCTTCACCTACCAGTCAGGCTCGGGCGAGGAGACC
ATCCTGCAGTTCAGCTCAGGGACCTTGACACTTACCCGGCGGCCAAAACCTGCAGC
CCGAGCCCCCTGAGCTACCCAGTGCTAGAGTGGGAGGACATCACCTTTGAGGACC
TCATCGGGGAGGGGAACCTTCGGCCAGGTCATCCGGGCCATGATCAAGAAGGACG
5 GGCTGAAGATGAACGCAGCCATCAAAATGCTGAAAGAGTATGCCTCTGAAAATG
ACCATCGTGACTTTGCGGGAGAACTGGAAGTTCTGTGCAAATTGGGGCATCACCC
CAACATCATCAACCTCCTGGGGGCGCTGTAAGAACCAGAGGTTACTTGTATATCGCT
ATTGAATATGCCCCCTACGGGAACCTGCTAGATTTTCTGCGGAAAAGCCGGGTCC
TAGAGACTGACCCAGCTTTTGCTCGAGAGCATGGGACAGCCTCTACCCTTAGCTC
10 CCGGCAGCTGCTGCGTTTCGCCAGTGATGCGGCCAATGGCATGCAGTACCTGAGT
GAGAAGCAGTTCATCCACAGGGACCTGGCTGCCCGGAATGTGCTGGTCGGAGAG
AACCTAGCCTCCAAGATTGCAGACTTCGGCCTTTCTCGGGGAGAGGAGGTTTATG
TGAAGAAGACGATGGGGCGTCTCCCTGTGCGCTGGATGGCCATTGAGTCCCTGA
ACTACAGTGTCTATACCACCAAGAGTGATGTCTGGTCCTTTGGAGTCCTTCTTTGG
15 GAGATAGTGAGCCTTGAGGTACACCCTACTGTGGCATGACCTGTGCCGAGCTCT
ATGAAAAGCTGCCCCAGGGCTACCGCATGGAGCAGCCTCGAAACTGTGACGATG
AAGTGTACGAGCTGATGCGTCAGTGCTGGCGGGACCGTCCCTATGAGCGACCCC
CCTTTGCCAGATTGCGCTACAGCTAGGCCGCATGCTGGAAGCCAGGAAGGCCT
ATGTGAACATGTCGCTGTTTGAGAACTTCACTTACGCGGGCATTGATGCCACAGC
20 TGAGGAGGCCTGAGCTGCCATCCAGCCAGAACGTGGCTCTGCTGGCCGGAGCAA
ACTCTGCTGTCTAACCTGTGACCAGTCTGACCCTTACAGCCTCTGACTTAAGCTGC
CTCAAGGAATTTTTTAACTTAAGGGAGAAAAAAGGGATCTGGGGATGGGGTG
GGCTTAGGGGAACGGGTTCCCATGCTTTGTAGGTGTCTCATAGCTATCCTGGGC
ATCCTTCTTTCTAGTTTCACTGCCCCACAGGTGTGTTTCCCATCCCCTGCTCCCC
25 CAACACAAACCCCCACTCCAGCTCCTTCGCTTAAGCCAGCACTCACACCACTAAC
ATGCCCTGTTCACTACTCCCACTCCCGGCGCTGTCATTGAGAAAAAATAAATGT
TCTAATAAGCTCCAAAAAAA

SEQ ID NO: 5

30 >gi|298590|gb|S56805.1|S56805 preproendothelin 1 {alternatively transcribed} [human,
placenta, mRNA, 1251 nt]
GGAGCTGTTTACCCCCACTCTAATAGGGGTTCAATATAAAAAGCCGGCAGAGAG
CTGTCCAAGTCAGACGCGCCTCTGCATCTGCGCCAGGCGAACGGGTCTGCGCCT
CCTGCAGTCCCAGCTCTCCACCACCGCCGCTGCGCCTGCAGACGCTCCGCTCGC
35 TGCCTTCTCTCCTGGCAGGCGCTGCCTTTTCTCCCCGTAAAGGGCACTTGGGCTG
AAGGATCGCTTTGAGATCTGAGGAACCCGCAGCGCTTTGAGGGACCTGAAGCTG
TTTTTCTTCGTTTTCTTTGGGTTTCACTTTGAACGGGAGGTTTTTGATCCCTTTTTT
TCAGAATGGATTATTTGCTCATGATTTTCTCTCTGCTGTTTGTGGCTTGCCAAGGA
GCTCCAGAAACAGCAGTCTTAGGCGCTGAGCTCAGCGCGGTGGGTGAGAACGGC
40 GGGGAGAAACCCACTCCCAGTCCACCCTGGCGGCTCCGCCGGTCCAAGCGCTGC
TCCTGCTCGTCCCTGATGGATAAAGAGTGTGTCTACTTCTGCCACCTGGACATCA
TTTGGGTCAACACTCCCGAGCACGTTGTTCCGTATGGACTTGGAAGCCCTAGGTC
CAAGAGAGCCTTGAGAAATTTACTTCCCACAAAGGCAACAGACCGTGAGAAATAG
ATGCCAATGTGCTAGCCAAAAAGACAAGAAGTGCTGGAATTTTTGCCAAGCAGG
45 AAAAGAACTCAGGGCTGAAGACATTATGGAGAAAGACTGGAATAATCATAAGA
AAGGAAAAGACTGTTCCAAGCTTGGGAAAAAGTGATTTATCAGCAGTTAGTGA
GAGGAAGAAAAATCAGAAGAAGTTCAGAGGAACACCTAAGACAAACCAGGTGCG
GAGACCATGAGAAACAGCGTCAAATCATCTTTTCATGATCCCAAGCTGAAAGGC
AAGCCCTCCAGAGAGCGTTATGTGACCCACAACCGAGCACATTGGTGACAGACT

TCGGGGCCTGTCTGAAGCCATAGCCTCCACGGAGAGCCCTGTGGCCGACTCTGCA
CTCTCCACCCTGGCTGGGATCAGAGCAGGAGCATCCTCTGCTGGTTCCTGACTGG
CAAAGGACCAGCGTCTCGTTCAAAACATTCCAAGAAAGGTTAAGGAGTTCCCC
CAACCATCTTCACTGGCTTCCATCAGTGGTAACTGCTTTGGTCTCTTCTTTCATCT
5 GGGGATGACAATGGACCTCTCAGCAGAAACACACAGTCACATTCTGAATTC

SEQ ID NO: 6

>gi|181948|gb|M31210.1|HUMEDG Human endothelial differentiation protein (edg-1) gene
mRNA, complete cds

10 TCTAAAGGTCGGGGGACAGCAGCAAGATGCGAAGCGAGCCGTACAGATCCCCGGGC
TCTCCGAACGCAACTTCGCCCTGCTTGAGCGAGGCTGCGGTTTCCGAGGGCCCTCT
CCAGCCAAGGAAAAGCTACACAAAAAGCCTGGATCACTCATCGAACCACCCCTG
AAGCCAGTGAAGGCTCTCTCGCCTCGCCCTCTAGCGTTCGTCTGGAGTAGCGCCA
CCCCGGCTTCTTGGGGACACAGGGTTGGCACCATGGGGGCCACCAGCGTCCCGCT
15 GGTCAAGGCCCCACCGCAGCTCGGTCTCTGACTACGTCAACTATGATATCATCGTC
CGGCATTACAACCTACACGGGAAAGCTGAATATCAGCGCGGACAAGGAGAACAGC
ATTAAACTGACCTCGGTGGTGTTCATTCTCATCTGCTGCTTTATCATCCTGGAGAA
CATCTTTGTCTTGCTGACCATTGGAACCAAGAAATTCCACCGACCCATGTAC
TATTTTATTGGCAATCTGGCCCTCTCAGACCTGTTGGCAGGAGTAGCCTACACAG
20 CTAACCTGCTCTTGTCTGGGGCCACCACCTACAAGCTCACTCCCGCCAGTGGTT
TCTGCGGGAAGGGAGTATGTTTGTGGCCCTGTCAGCCTCCGTGTTCACTCTCCTC
GCCATCGCCATTGAGCGCTATATCACAATGCTGAAAATGAAACTCCACAACGGG
AGCAATAACTTCCGCCTCTTCTCTGCTAATCAGCGCCTGCTGGGTCTCTCCCTCAT
CCTGGGTGGCCTGCCTATCATGGGCTGGAAGTGCATCAGTGCCTGTCCAGCTGC
25 TCCACCGTGCTGCCGCTCTACCACAAGCACTATATCCTCTTCTGCACCACGGTCTT
CACTCTGCTTCTGCTCTCCATCGTCATTCTGTACTGCAGAATCTACTCCTTGGTCA
GGAATCGGAGCCGCGCCTGACGTTCCGCAAGAACATTTCCAAGGCCAGCCGCA
GCTCTGAGAATGTGGCGCTGCTCAAGACCGTAATTATCGTCCTGAGCGTCTTCAT
CGCCTGCTGGGCACCGCTCTTCATCCTGCTCCTGCTGGATGTGGGCTGCAAGGTG
30 AAGACCTGTGACATCCTCTTCAGAGCGGAGTACTTCCTGGTGTAGCTGTGCTCA
ACTCCGGCACCAACCCCATCATTTACACTCTGACCAACAAGGAGATGCGTCGGGC
CTTCATCCGGATCATGTCTGCTGCAAGTGCCCGAGCGGAGACTCTGCTGGCAAA
TTCAAGCGACCCATCATCGCCGGCATGGAATTCAGCCGCAGCAAATCGGACAAT
TCCTCCCACCCCCAGAAAGACGAAAGGGGACAACCCAGAGACCATTATGTCTTCT
35 GGAAACGTCAACTCTTCTTCTCTAGAACTGGAAGCTGTCCACCCACCGGAAGCGCT
CTTTACTTGGTCGCTGGCCACCCAGTGTTTGGAAAAAATCTCTGGGCTTCGAC
TGCTGCCAGGGAGGAGCTGCTGCAAGCCAGAGGGAGGAAGGGGGAGAATACGA
ACAGCCTGGTGGTGTGCGGTGTTGGTGGGTAGAGTTAGTTCCTGTGAACAATGCA
CTGGGAAGGGTGGAGATCAGGTCCCGGCCTGGAATATATATTCTACCCCCCTGGA
40 GCTTTGATTTTGCAGTGAAGCAAGGTCTAGCATTGTCAAGCTCCTAAAGGGTTC
ATTTGGCCCCCTCCTCAAAGACTAATGTCCCATGTGAAAGCGTCTCTTTGTCTGG
AGCTTTGAGGAGATGTTTTCCTTCACTTTAGTTTCAAACCCAAGTGAGTGTGTGC
ACTTCTGCTTCTTTAGGGATGCCCTGTACATCCACACCCCCACCTCCCTTCCCTT
CATACCCCTCCTCAACGTTCTTTTACTTTATACTTTAACTACCTGAGAGTTATCAG
45 AGCTGGGGTGTGGAATGATCGATCATCTATAGCAAATAGGCTATGTTGAGTACG
TAGGCTGTGGGAAGATGAAGATGGTTTGGAGGTGTAAACAATGTCCTTCGCTG
AGGCCAAAGTTTCCATGTAAGCGGGATCCGTTTTTGGGAATTTGGTTGAAGTCAC
TTTGATTTCTTTAAAAACATCTTTTCAATGAAATGTGTTACCATTTTCATATCCAT
TGAAGCCGAAATCTGCATAAGGAAGCCCACTTTATCTAAATGATATTAGCCAGG

ATCCTTGGTGTCTAGGAGAAACAGACAAGCAAAACAAAGTGAAAACCGAATGG
ATTAACTTTTGCAAACCAAGGGAGATTTCTTAGCAAATGAGTCTAACAAATATGA
CATCCGTCTTTCCCACTTTTGTGATGTTTATTTTCTAGAAATCTTGTGTGATTCATTTT
AAGCAACAACATGTTGTATTTTGTGTTAAAAGTACTTTTCTTGATTTTGAAT
5 GTATTTGTTTCAGGAAGAAGTCATTTTATGGATTTTCTAACCCGTGTTAACTTTT
CTAGAATCCACCCTCTTGTGCCCTTAAGCATTACTTTAACTGGTAGGGAACGCCA
GAACTTTTAAGTCCAGCTATTCATTAGATAGTAATTGAAGATATGTATAAATATT
ACAAAGAATAAAAAATATATTACTGTCTCTTTAGTATGGTTTTTCAGTGCAATTAAA
CCGAGAGATGTCTTGTTTTTTTAAAAAGAATAGTATTTAATAGGTTTCTGACTTTT
10 GTGGATCATTTTGCACATAGCTTTATCAACTTTTAAACATTAATAAACTGATTTT
TTAAAG

SEQ ID NO: 7

>gi|339561|gb|M60315.1|HUMTGFB Human transforming growth factor-beta BMP protein
(tgf-beta) mRNA, complete cds
15 CGACCATGAGAGATAAGGACTGAGGGCCAGGAAGGGGAAGCGAGCCCGCCGAG
AGGTGGCGGGGACTGCTCACGCCAAGGGCCACAGCGGCCGCGCTCCGGCCTCGC
TCCGCCGCTCCACGCCTCGCGGGATCCGCGGGGGCAGCCCGGCCGGGCGGGGAT
GCCGGGGCTGGGGCGGAGGGCGCAGTGGCTGTGCTGGTGGTGGGGGCTGCTGTG
20 CAGCTGCTGCGGGCCCCCGCCGCTGCGGCCGCCCTTGCCCCGCTGCCGCGGCCGCC
GCCGCCGGGGGGCAGCTGCTGGGGGACGGCGGGAGCCCCGGCCGCACGGAGCA
GCCGCCGCCGTCGCCGCAGTCCTCCTCGGGCTTCTGTACCGGCGGCTCAAGACG
CAGGAGAAGCGGGAGATGCAGAAGGAGATCTTGTCTGGTGTGTTGGGCTCCCGCAC
CGGCCCCGGCCCCCTGCACGGCCTCCAACAGCCGCAGCCCCCGGCGCTCCGGCAG
25 CAGGAGGAGCAGCAGCAGCAGCAGCTGCCTCGCGGAGAGCCCCCTCCCGGG
CGACTGAAGTCCGCGCCCCCTCTTCATGCTGGATCTGTACAACGCCCTGTCCGCCG
ACAACGACGAGGACGGGGCGTCGGAGGGGGGAGAGGCAGCAGTCCTGGCCCCAC
GAAGCAGCCAGCTCGTCCCAGCGTCGGCAGCCGCCCGGGCGCCGCGCACCCG
CTCAACCGCAAGAGCCTTCTGGCCCCCGGATCTGGCAGCGGCGGCGGTCCCCAC
30 TGACCAGCGCGCAGGACAGCGCCTTCTCAACGACGCGGACATGGTCATGAGCT
TTGTGAACCTGGTGGAGTACGACAAGGAGTTCTCCCTCGTCAGCGACACCACAA
AGAGTTCAAGTTCAACTTATCCCAGATTCTTGAGGGTGAGGTGGTGACGGCTGCA
GAATTCGCGCATCTACAAGGACTGTGTTATGGGGAGTTTAAAAACCAAATTTTC
TTATCAGCATTATCAAGICTTACAGGAGCATCAGCACAGAGACTCTGACCTGTT
35 TTTGTTGGACACCCGTGTAGTATGGGCCTCAGAAGAAGGCTGGCTGGAATTTGAC
ATCACGGCCACTAGCAATCTGTGGGTGTGACTCCACAGCATAACATGGGGCTTC
AGCTGAGCGTGGTGACAAGGGATGGAGTCCACGTCCACCCCCGAGCCGCAGGCC
TGGTGGGCAGAGACGGCCCTTACGATAAGCAGCCCTTCATGGTGGCTTTCTTCAA
AGTGAGTGAGGTCCACGTGCGCACCACCAGGTCAGCCTCCAGCCGGCGCCGACA
40 ACAGAGTCGTAATCGCTCTACCCAGTCCCAGGACGTGGCGCGGGTCTCCAGTGCT
TCAGATTACAACAGCAGTGAATTGAAAACAGCCTGCAGGAAGCATGAGCTGTAT
GTGAGTTTCCAAGACCTGGGATGGCAGGACTGGATCATTGCACCCAAGGGCTAT
GCTGCCAATTACTGTGATGGAGAATGCTCCTTCCCACTCAACGCACACATGAATG
CAACCAACCACGCGATTGTGCAGACCTTGGTTACCTTATGAACCCCGAGTATGT
45 CCCCAAACCGTGCTGTGCGCAACTAAGCTAAATGCCATCTCGGTTCTTTACTTT
GATGACAACTCCAATGTCATTCTGAAAAAATACAGGAATATGGTTGTAAGAGCTT
GTGGATGCCACTAACTCGAAACCAGATGCTGGGGACACACATTCTGCCTTGGATT
CCTAGATTACATCTGCCTTAAAAAAACACGGAAGCACAGTTGGAGGTGGGACGA
TGAGACTTTGAACTATCTCATGCCAGTGCCCTTATTACCCAGGAAGATTTAAAG

GACCTCATTAATAATTTGCTCACTTGGTAAATGACGTGAGTAGTTGTTGGTCTGT
AGCAAGCTGAGTTTGGATGTCTGTAGCATAAGGTCTGGTAACTGCAGAAACATA
ACCGTGAAGCTCTTCCTACCCTCCTCCCCAAAAACCCACCAAAATTAGTTTTAG
CTGTAGATCAAGCTATTTGGGGTGTTTGTAGTAAATAGGGAAAATAATCTCAAA
5 GGAGTTAAATGTATTCTTGGCTAAAGGATCAGCTGGTTCAGTACTGTCTATCAAA
GGTAGATTTTACAGAGAACAGAAATCGGGGAAGTGGGGGGAACGCCTCTGTTCA
GTTCAATCCCAGAAGTCCACAGGACGCACAGCCCAGGCCACAGCCAGGGCTCCA
CGGGGCGCCCTTGCTCAGTCATTGCTGTTGTATGTTTCGTGCTGGAGTTTGTGTTG
TGTGAAAATACACTTATTTTCAGCCAAAACATAACCATTTCTACACCTCAATCCTCC
10 ATTTGCTGTACTCTTTGCTAGTACCAAAAAGTAGACTGATTACACTGAGGTGAGGC
TACAAGGGGTGTGTAACCGTGTAACACGTGAAGGCAGTGCTCACCTCTTCTTTAC
CAGAACGGTCTTTGACCAGCACATTAACCTTCTGGACTGCCGGCTCTAGTACCTT
TTCAGTAAAGTGGTCTCTGCCTTTTTACTATACAGCATAACCACGCCACAGGGTT
AGAACCAACGAAGAAAATAAAATGAGGGTGCCAGCTTATAAGAATGGTGTAG
15 GGGGATGAGCATGCTGTTTATGAACGGAAATCATGATTTCCCTGTAGAAAGTGA
GGCTCAGATTAAATTTTAGAATATTTTCTAAATGTCTTTTTTACAATCATGTGACT
GGGAAGGCAATTTTCACTAAACTGATTAAATAATACATTTATAATCTACAACCTG
TTTGCACCTACAGCTTTTTTTGTAAATATAAACTATAATTTATTGTCTATTTTATAT
CTGTTTTGCTGTGGCGTTGGGGGGGGGGGCCGGGCTTTTGGGGGGGGGGGTTTGT
20 TGGGGGGTGTCTGTTGTTGTTGGGCGGGCGG

SEQ ID NO: 8

>285478CA2

GCCAGCCCTGCCTGCCACCAGGAGGATGAAGGTCTCCGTGGCTGCCCTCTCCTG
25 CCTCATGCTTGTTACTGCCCTTGATCCCAGGCCCGGGTCACAAAAGATGCAGAG
ACAGAGTTCATGATGTCAAAGCTTCCATTGGAAAATCCAGTACTTCTGGACATGC
TCTGGAGGAGAAAGATTGGTCCTCAGATGACCCTTTCTCATGCTGCAGGATTCCA
TGCTACTAGTGCTGACTGCTGCATCTCCTACACCCACGAAGCATCCCGTGTTCA
CTCCTGGAGAGTTACTTTGAAACGAACAGCGAGTGCTCCAAGCCGGGTGTCATCT
30 TCCTCACCAAGAAGGGGCGACGTTTCTGTGCCAACCCAGTGATAAGCAAGTTCA
GGTTTGCATGAGAATGCTGAAGCTGGACACACGGATCAAGACCAGGAAGAATTG
AACTTGTCAAGGTGAAGGGACACAAGTTGCCAGCCACCAACTTTCTTGCCTCAAC
TACCTTCCTGAATTATTTTTTAAGAAGCATTTATTCTTGTGTTCTGGATTTAGAG
CAATTCATCTAATAAACAGTTTC

35

SEQ ID NO: 9

>gi|1764967|gb|AA181500.1|AA181500 zp16h08.r1 Stratagene fetal retina 937202 Homo
sapiens cDNA clone IMAGE:609663 5' similar to gb:A12297 CAMP-DEPENDENT
PROTEIN KINASE TYPE II-BETA REGULATORY CHAIN (HUMAN);

CTAGTATGNGTTTTACTTATTCAGACTGATAATCATATTAGTGACTATCCCCATGT
40 AAGAGGGCACTTGGCAATTAAACATGCTACACAGCATGGCATCACTTTTTTTTAT
AACTCATTAACACAGTAAAATTTAATCATTTTTGTTTTAAAGTTTTCTAGCTTG
ATAAGTTATGTGCTGGCCTTGCCANTTGGTGAAATGGTATAAAATATCATATGC
AGTTTTTAAAACTTTTTATATTTTGAATAAAGTACATTTTGACTTTGTTGGCATA
45 ATGTCAGTAACATACATATTCAGTGGTTTTATGGACAGGCAATTTAGTCATTAT
GATAATAAGGAAAACAGTGTTTTAGATGAGAGATCNTTAATGNNTTTTTCCCCCA
TCCAGCCATATANCCCGCCTTTTTTTAATTTGCCAATCCCCGGTATTCCCATGGCC
TTTAAAAAATTGGNCNTGGACCATTTAAAGGGCCCCAAGTTTTGGTTTTTT

SEQ ID NO: 10

>gi|2177843|gb|AA455067.1|AA455067 aa04c11.s1 Soares_NhHMPu_S1 Homo sapiens
cDNA clone IMAGE:812276 3' similar to gb:L08850 SYNUCLEIN (HUMAN);

5 GCAATGAGATAACGTTTTATTTTAATTCTCACCATTTATATACAAACACAAGTGA
ATAAAACACATCGCAAAATGGTAAAATTTTCATATTTAGTATTTATAGGTGCATAG
TTTCATGCTCACATATTTTTGAGTATTATATATATTAACAAATTTTACAATACGTC
ATTATTCTTAGACAGTATCATTAAAAGACACCTAAAAATCTTATAATATATGATA
GCAAATCACTAACAACCTTCTGAACAACAGCAACAAAAAATAGTGAGGATTTAG
AAATAAGTGGTAGTCACTTAGGTGTTTTTAATTTGTTTTAACATCGTAGATTGAA
10 GCCACAAAATCCACAGCACACAAAGACCCTGCTACCATGTATTCACTTCAGTGAA
AGGGAAGCACCGAAATGCTGAGTGGGGGCAGGTACAGATACATCAATCACTGCT
GATGGAAGACTTCGAGATACAC

SEQ ID NO: 11

15 >gi|338201|gb|K01918.1|HUMSISA1 Human c-sis proto-oncogene for platelet-derived
growth factor, exon 1 and flanks
GAATTCATGCCGGGCCAGCCGAGCGCGCAGCGGGCACGCCGCGCGCGCGGAGC
AGCCGTGCCCGCCGCCCGGGCCCGCCGAGGGCGCACACGCTCCCCCCCCCT
ACCCGGCCCCGGGCGGGAGTTTGCACCTCTCCCTGCCCGGGTGCTCGAGCTGCCGT
20 TGCAAAGCCAACCTTTGGAAAAAGTTTTTTGGGGGAGACTTGGGCCTTGAGGTGCC
CAGCTCCGCGCTTTCCGATTTTGGGGGCCTTTCCAGAAAATGTTGCAAAAAGCT
AAGCCGGCGGGCAGAGGAAAACGCCTGTAGCCGGCGAGTGAAGACGAACCATC
GACTGCCGTGTTCTTTCTCTTGGAGGTTGGAGTCCCCTGGGCGCCCCCACAC
GGCTAGACGCCTCGGCTGGTTCGCGACGCAGCCCCCGGCCGTGGATGCTGCACT
25 CGGGCTCGGGATCCGCCCAGGTAGCCGGCCTCGGACCCAGGTCCTGCGCCCAGG
TCCTCCCCCTGCCCCCAGCGACGGAGCCGGGGCCGGGGGCGGCGGCGCCGGGGG
CATGCGGGTGAGCCGCGGCTGCAGAGGCCTGAGCGCCTGATCGCCGCGGACCCG
AGCCGAGCCCACCCCCCTCCCCAGCCCCCACCCTGGCCGCGGGGGCGGCGCGC
TCGATCTACGCGTTCGGGGCCCCGCGGGGCCGGGCCCGGAGTCGGCATGAATCG
30 CTGCTGGGCGCTCTTCTGTCTCTGCTGCTACCTGCGTCTGGTCAGCGCCGAGG
TGAGTGCCACGGCGGCTGGGGCTGGTTCTTCATTACCTTCGCCCCCCCCCTTC
TGACCGCCCCCTCCTCTCCCTGCAGTGAACCTTGGACCCTTGCAACCGCGAGCCT
GACGCCGGGCGCTGGGTGACCTCTTCGGGCTGGGAGCGAGGTCCGGGGGTGACA
GGCTCTAAGGGAAGGCAACAGCGGTGGCTTCTTTCCAACCGGCGGGCGAATCT
35 GGCTCCCTAAGCCGTTCCGTGTGCGGGGAGGGTGTGTGTGGCCCTGTCCCCCACC
CTTTGGGAACCCGAGAACAAGCCCCTCCCGGCCGGGGGAGAGGGGGTGGGGTGG
TGCCAGGGTGAGAAAGGCAGCGCTCCTCCCGAGCCCACTTCGGCGCCAGCCT
CGGCTTAGGCTCTGTCCTGCCATCGGCTTGCCAGGAGGTGCAAGCTT

SEQ ID NO: 12

>938765H1

GCTGCACCGTGAGCGCCGAGGACAAGGCGGCGGCCGAGCGCTCTAAGATGATCG
ACAAGAACCTGCGGGAGGACGGAGAGAAGGCGGCGGGGAGGTGAAGTTGCTG
CTGTTGGGTGCTGGGGAGTCAGGGAAGAGCACCATCGTCAAGCAGGTGTAGGTC
45 ATTCCCGGGGGTTGCTTATTCCGGGGGGGATTCCCGCAGTACGCGCGGTTGTCTA
CAGCAACAACATCCAGTCCATCATGGCCATTGTCAAAGCCATGGGCAACCTGCA
GATCGACTTTGCCGACCCCT

SEQ ID NO: 13

>gi|1219067|gb|N66942.1|N66942 za48c12.s1 Soares fetal liver spleen 1NFLS Homo sapiens
cDNA clone IMAGE:295798 3'

AAGACAGAGTGGACTGTTACAAATGATTTTGCAAAATACAAAAATAGATATACT
TCCACTGAATGCTTTAATCATTTTTCCGGGCACTCTCATCTTTGGTTCTTCCTCAT
5 CTGAGTACACAGTGGGCTCCTCCCCCTCCTTCAGCAGTTTGCCCACGTGATGATA
CTTGAAAGTGAAGTGAAGTCACTCCAGTCACTCAGAGTCTCCTGCTGGGCAGCAGTG
AGGTCAAGAAAGTCACTCGTACTCATCCTTCAGTGCTTCCTTATCCAGGCAAAATG
TGGCAAGGCCCTGGATGCATCTCTCCAGCAAAGACCCCATACGGCCCCCTCTTTC
AAAAACAAAACCAAAGATCAATTCTTTATTAGACAGTCAATTTCTCTGTGATTTA
10 TACACAGAAAATGGGCTTCCCTANT

SEQ ID NO: 14

>gi|190825|gb|M29871.1|HUMRACB Human ras-related C3 botulinum toxin substrate (rac)
mRNA, complete cds

15 ATGCAGGCCATCAAGTGTGTGGTGGTGGGAGATGGGGCCGTGGGCAAGACCTGC
CTTCTCATCAGCTACACCACCAACGCCTTTCCCGGAGAGTACATCCCCACCGTGT
TTGACAACTATTAGCCAATGTGATGGTGGACAGCAAGCCAGTGAACCTGGGGC
TGTGGGACACTGCTGGGCAGGAGGACTACGACCGTCTCCGGCCGCTCTCCTATCC
ACAGACGGACGTCTTCCTCATCTGCTTCTCCCTCGTCAGCCCAGCCTCTTATGAGA
20 ACGTCCGCGCCAAGTGGTTCCAGAAAGTGCGGCACCACTGCCCCAGCACACCCA
TCATCCTGGTGGGCACCAAGCTGGACCTGCGGGACGACAAGGACACCATCGAGA
AACTGAAGGAGAAGAAGCTGGCTCCCATCACCTACCCGCAGGGCCTGGCACTGG
CCAAGGAGATTGACTCGGTGAAATACCTGGAGTGCTCAGCCCTCACCCAGAGAG
GCCTGAAAACCGTGTTCGACGAGGCCATCCGGGCCGTGCTGTGCCCTCAGCCCAC
25 GCGGCAGCAGAAGCGCGCCTGCAGCCTCCTCTAG

SEQ ID NO: 15

>gi|1551654|gb|AA058828.1|AA058828 zf66f10.s1 Soares retina N2b4HR Homo sapiens
cDNA clone IMAGE:381931 3' similar to contains element MER36 repetitive element ;

30 GTGTTTTTGGAAGTTTATTATATGAAGATGGTATACAAAATACATTCATCATGAC
TAGAAATATAGGACCAAACCATGTCTGTCTTATATCTGTAGCATATATTCTTGGTT
TGTATAAAAAGTAACTTTAAAATTCCAGTTTCCTTAAATAGTTATGCACAAAACAC
ACATACACCCACACACACACACACACACACACATACAGTTACACCACT
GTCGGCCAAAGATGCACTCCTCTTTAATCAATTTAAATGAGGCTAGCGAGTATC
35 TGTTTGATGTTTGCATTCTTGTGGGCTAGGAAACAAGGCACGGGTCCCTAAAATT
AACATCTCGGTGTCACTTCTTGGACTGACAAGACACAGACTTGCACATGGTTTCA
GCCCCATTCCACCCAGACTGTTCCACGTACATTATCTCAGAACTCTGAAAGGAA
GTGCTCGTTCTTTGTTAGTGCCAACCATTTTTGTGATAAATGGCAAATGATTGGGA
TATTATCAGTTAATTCATGTTTCAATTTCAAGTGCTATTTTAATGGACAAGCACTTG
40 TAACTAGCCCATTTATTACAAGTCTCCATTTTTTTCCACATTAANCTCCNGAGGGAC
CATCTTTGGCCGATGGAGG

SEQ ID NO: 16

>gi|1010559|gb|H57727.1|H57727 yr21b09.s1 Soares fetal liver spleen 1NFLS Homo sapiens
cDNA clone IMAGE:205913 3'

45 GTTGGGGGAGGACGGGTTGCCGACTCGCCTACCTAGCGGTCTCTTGATTGTCGAC
ATTTTGTTGGCATAGGTTTATGTAGAGACGTATACATATATATAGACACACTGTC
TATAAATCTAGGCCTGTATCCGGTGTCCGAGGCGAACTCAGTAAGATGATGTTAA
GAGGAAACCTGAAGCAAGTGCGCATTGAGAAAAACCCGGCCCGCCTTCGCGCCC

TGGAGTCCGCGGTGGGCGAGACGAGCCGGCGCCCGNCNAGCCATTGGCGCTCGC
TCTTGCCGGGGAGCCANCNCGCCCGCGCCCGGCCTCCAGAGGACCACCCGGACG
AGGAGATGGGGTTCACTATCGACATCAAGAGTTTNCCTCAAGCCGGGCG

5 SEQ ID NO: 17

>gi|598152|gb|L36148.1|HUMGPR4A Homo sapiens G protein-coupled receptor (GPR4)
gene, complete cds

ATAATTCCATCCCTCCTCCAACCTTTTCCCTCTCAAGCTCTGCCCTTCCCAGCCCAG
CCCAGCCTACCCAACCTCATCTTCCCTGTAGACCACATCCCACCATGTTCCCCT
10 GAGCCTCCAAGGAAGGGGCTCAGGGGCCCCATGGCCTCCCGCTCCCTGTGGCCC
CACAGCCCCCGTGGGCCAGGGGAAGCGCCCCAGAAGCCGAAGTGCCCAACCATGG
GCAACCACACGTGGGAGGGCTGCCACGTGGACTCGCGCGTGGACCACCTCTTTCC
GCCATCCCTCTACATCTTTGTTCATCGGCGTGGGGCTGCCACCAACTGCCTGGCT
CTGTGGGCGGCCTACCGCCAGGTGCAACAGCGCAACGAGCTGGGCGTCTACCTG
15 ATGAACCTCAGCATCGCCGACCTGCTGTACATCTGCACGCTGCCGCTGTGGGTGG
ACTACTTCCTGCACCACGACAACCTGGATCCACGGCCCCGGGTCCTGCAAGCTCTT
TGGGTTTCATCTTCTACACCAATATCTACATCAGCATCGCCTTCCTGTGCTGCATCT
CGGTGGACCGCTACCTGGCTGTGGCCCAACCACTCCGCTTCGCCCGCCTGCGCCG
CGTCAAGACCGCCGTGGCCGTGAGCTCCGTGGTCTGGGCCACGGAGCTGGGCGC
20 CAACTCGGCGCCCCTGTTCCATGACGAGCTCTTCCGAGACCGCTACAACCACACC
TTCTGCTTTGAGAAGTTCCCCATGGAAGGCTGGGTGGCCTGGATGAACCTCTATC
GGGTGTTTCGTGGGCTTCTCTTCCCGTGGGCGCTCATGCTGCTGTCGTACCGGGG
CATCCTGCGGGCCGTGCGGGGCAGCGTGTCCACCGAGCGCCAGGAGAAGGCCAA
GATCAAGCGGCTGGCCCTCAGCCTCATCGCCATCGTGCTGGTCTGCTTTGCGCCC
25 TATCACGTGCTCTTGCTGTCCCGCAGCGCCATCTACCTGGGCGCCCTGGGACT
GCGGCTTCGAGGAGCGCGTCTTTTCTGCATACCACAGCTCACTGGCTTTCACCAG
CCTCAACTGTGTGGCGGACCCCATCCTCTACTGCCTGGTCAACGAGGGCGCCCGC
AGCGATGTGGCCAAGGCCCTGCACAACCTGCTCCGCTTCTGGCCAGCGACAAGC
CCCAGGAGATGGCCAATGCCTCGCTCACCTGGAGACCCCACTCACCTCCAAGA
30 GGAACAGCACAGCCAAAGCCATGACTGGCAGCTGGGCGGCCACTCCGCCTCCA
GGGGGACCAGGTGCAGCTGAAGATGCTGCCGCCAGCACAATGAACCCCGAGTGG
CACAGAATCCCCAGTTTTTCCCCTCTCATCCACAGTCCCTTCTCTCCTGG

SEQ ID NO: 18

>gi|339569|gb|M85079.1|HUMTGFBIIIR Human TGF-beta type II receptor mRNA, complete
cds

GTTGGCGAGGAGTTTCTGTTTCCCCCGCAGCGCTGAGTTGAAGTTGAGTGAGTC
ACTCGCGCGCACGGAGCGACGACACCCCCGCGCGTGCACCCGCTCGGGACAGGA
GCCGGACTCCTGTGCAGCTTCCCTCGGCCGCCGGGGGCTCCCCGCGCCTCGCCG
40 GCCTCCAGGCCCTCCTGGCTGGCGAGCGGGCGCCACATCTGGCCCGCACATCTG
CGCTGCCGGCCCCGGCGCGGGGTCCGGAGAGGGCGCGGCGCGGAGCGCAGCCAG
GGGTCCGGGAAGGCGCCGTCCGTGCGCTGGGGGCTCGGTCTATGACGAGCAGCG
GGGTCTGCCATGGGTCCGGGGGCTGCTCAGGGGCCTGTGGCCGCTGCACATCGTCC
TGTGGACGCGTATCGCCAGCACGATCCCACCGCACGTTTCAAGTTCGGTTAATAA
45 CGACATGATAGTCACTGACAACAACGGTGCAGTCAAGTTTCCACAACCTGTGTAA
ATTTTGTGATGTGAGATTTTCCACCTGTGACAACCAGAAATCCTGCATGAGCAAC
TGCAGCATCACCTCCATCTGTGAGAAGCCACAGGAAGTCTGTGTGGCTGTATGGA
GAAAGAATGACGAGAACATAACACTAGAGACAGTTTGCCATGACCCCAAGCTCC
CCTACCATGACTTTATTCTGGAAGATGCTGCTTCTCCAAAGTGCATTATGAAGGA

AAAAAAAAAGCCTGGTGAGACTTTCTTCATGTGTTCCCTGTAGCTCTGATGAGTGC
AATGACAACATCATCTTCTCAGAAGAATATAACACCAGCAATCCTGACTTGTTGC
TAGTCATATTTCAAGTGACAGGCATCAGCCTCCTGCCACCACTGGGAGTTGCCAT
ATCTGTCATCATCATCTTCTACTGCTACCGCGTTAACCAGCAGCAGAAGCTGAGT
5 TCAACCTGGGAAACCGGCAAGACGCGGAAGCTCATGGAGTTCAGCGAGCACTGT
GCCATCATCCTGGAAGATGACCGCTCTGACATCAGCTCCACGTGTGCCAACACA
TCAACCACAACACAGAGCTGCTGCCCATTGAGCTGGACACCCTGGTGGGGAAAG
GTCGCTTTGCTGAGGTCTATAAGGCCAAGCTGAAGCAGAACACTTCAGAGCAGTT
TGAGACAGTGGCAGTCAAGATCTTCCCTATGAGGAGTATGCCTCTTGGAAGACA
10 GAGAAGGACATCTTCTCAGACATCAATCTGAAGCATGAGAACATACTCCAGTTCC
TGACGGCTGAGGAGCGGAAGACGGAGTTGGGGAAACAATACTGGCTGATCACCG
CCTTCCACGCCAAGGGCAACCTACAGGAGTACCTGACGCGGCATGTCATCAGCT
GGGAGGACCTGCGCAAGCTGGGCAGCTCCCTCGCCCGGGGGATTGCTCACCTCC
ACAGTGATCACACTCCATGTGGGAGGCCCAAGATGCCCATCGTGCACAGGGACC
15 TCAAGAGCTCCAATATCCTCGTGAAGAACGACCTAACCTGCTGCCTGTGTGACTT
TGGGCTTTCCCTGCGTCTGGACCCTACTCTGTCTGTGGATGACCTGGCTAACAGT
GGGCAGGTGGGAACTGCAAGATACATGGCTCCAGAAGTCCTAGAATCCAGGATG
AATTTGGAGAATGCTGAGTCCTTCAAGCAGACCGATGTCTACTCCATGGCTCTGG
TGCTCTGGGAAATGACATCTCGCTGTAATGCAGTGGGAGAAGTAAAAGATTATG
20 AGCCTCCATTTGGTTCCAAGGTGCGGGAGCACCCCTGTGTGAAAGCATGAAGG
ACAACGTGTTGAGAGATCGAGGGCGACCAGAAATTCCCAGCTTCTGGCTCAACC
ACCAGGGCATCCAGATGGTGTGTGAGACGTTGACTGAGTGCTGGGACCACGACC
CAGAGGCCCGTCTCACAGCCCAGTGTGTGGCAGAACGCTTCAGTGAGCTGGAGC
ATCTGGACAGGCTCTCGGGGAGGAGCTGCTCGGAGGAGAAGATTCTGAAGACG
25 GCTCCCTAAACACTACCAAATAGCTCTTATGGGGCAGGCTGGGCATGTCCAAAG
AGGCTGCCCCCTCTACCAAAA

SEQ ID NO: 19

>gi|37464|emb|X14787.1|HSTS Human mRNA for thrombospondin

30 GGACGCACAGGCATTCCCCGCGCCCTCCAGCCCTCGCCGCCCTCGCCACCGCTC
CCGGCCGCGCGCTCCGGTACACACAGGATCCCTGCTGGGCACCAACAGCTCCA
CCATGGGGCTGGCCTGGGGACTAGGCGTCCTGTTCCCTGATGCATGTGTGTGGCAC
CAACCGCATTCAGAGTCTGGCGGAGACAACAGCGTGTGTTGACATCTTTGAACTC
ACCGGGGCGCGCCGCAAGGGGTCTGGGCGCCGACTGGTGAAGGGCCCCGACCC
35 TCCAGCCCAGCTTTCCGCATCGAGGATGCCAACCTGATCCCCCTGTGCCTGATG
ACAAGTTCCAAGACCTGGTGGATGCTGTGCGGGCAGAAAAGGGTTTCTCTCTTCT
GGCATCCCTGAGGCAGATGAAGAAGACCCGGGGCACGCTGCTGGCCCTGGAGCG
GAAAGACCACTCTGGCCAGGTCTTCAGCGTGGTGTCCAATGGCAAGGCGGGCAC
CCTGGACCTCAGCCTGACCGTCCAAGGAAAGCAGCACGTGGTGTCTGTGGAAGA
40 AGCTCTCCTGGCAACCGGCCAGTGGAAGAGCATCACCTGTTTGTGCAGGAAGA
CAGGGCCCAGCTGTACATCGACTGTGAAAAGATGGAGAATGCTGAGTTGGACGT
CCCCATCCAAAGCGTCTTCACCAGAGACCTGGCCAGCATCGCCAGACTCCGCATC
GCAAAGGGGGGCGTCAATGACAATTTCCAGGGGGTGCTGCAGAATGTGAGGTTT
GTCTTTGGAACCACACCAGAAGACATCCTCAGGAACAAAGGCTGCTCCAGCTCT
45 ACCAGTGTCTCCTCACCTTGACAACAACGTGGTGAATGGTTCCAGCCCTGCCA
TCCGCACTAACTACATTGGCCACAAGACAAAGGACTTGCAAGCCATCTGCGGCA
TCTCCTGTGATGAGCTGTCCAGCATGGTCCTGGAACCTCAGGGGCCTGCGCACCAT
TGTGACCACGCTGCAGGACAGCATCCGCAAAGTGACTGAAGAGAACAAAGAGTT
GGCCAATGAGCTGAGGCGGCCTCCCCTATGCTATCACAAACGGAGTTCAGTACAG

AAATAACGAGGAATGGACTGTTGATAGCTGCACTGAGTGTCACTGTCAGAACTC
AGTTACCATCTGCAAAAAGGTGTCCTGCCCATCATGCCCTGCTCCAATGCCACA
GTTCTGATGGAGAATGCTGTCCTCGCTGTTGGCCCAGCGACTCTGCGGACGATG
GCTGGTCTCCATGGTCCGAGTGGACCTCCTGTTCTACGAGCTGTGGCAATGGAAT
5 TCAGCAGCGCGGCCGCTCCTGCGATAGCCTCAACAACCGATGTGAGGGCTCCTCG
GTCCAGACACGGACCTGCCACATTCAGGAGTGTGACAAAAGATTTAAACAGGAT
GGTGGCTGGAGCCACTGGTCCCCGTGGTCATCTTGTTCTGTGACATGTGGTGATG
GTGTGATCACAAGGATCCGGCTCTGCAACTCTCCAGCCCCCAGATGAATGGGA
AACCCTGTGAAGGCGAAGCGCGGGAGACCAAAGCCTGCAAGAAAGACGCCTGC
10 CCCATCAATGGAGGCTGGGGTCCCTGGTGACCATGGGACATCTGTTCTGTACCT
GTGGAGGAGGGGTACAGAAACGTAGTCGTCTCTGCAACAACCCCGCACCCAGT
TTGGAGGCAAGGACTGCGTTGGTGATGTAACAGAAAACCAGATCTGCAACAAGC
AGGACTGTCCAATTGATGGATGCCTGTCCAATCCCTGCTTTGCCGGCGTGAAGTG
TACTAGCTACCCTGATGGCAGCTGGAAATGTGGTGCTTGTCCCCCTGGTTACAGT
15 GGAAATGGCATCCAGTGCACAGATGTTGATGAGTGCAAAGAAGTGCCTGATGCC
TGCTTCAACCACAATGGAGAGCACCGGTGTGAGAACACGGACCCCGGCTACAAC
TGCCTGCCCTGCCCCCACGCTTCACCGGCTCACAGCCCTTCGGCCAGGGTGTG
AACATGCCACGGCCAACAACAGGTGTGCAAGCCCCGTAACCCCTGCACGGATG
GGACCCACGACTGCAACAAGAACGCCAAGTGCAACTACCTGGGCCACTATAGCG
20 ACCCATGTACCGCTGCGAGTGCAAGCCTGGCTACGCTGGCAATGGCATCATCTG
CGGGGAGGACACAGACCTGGATGGCTGGCCAATGAGAACCTGGTGTGCGTGGC
CAATGCGACTTACCACTGCAAAAAGGATAATTGCCCCAACCTTCCCAACTCAGGG
CAGGAAGACTATGACAAGGATGGAATTGGTGATGCCTGTGATGATGACGATGAC
AATGATAAAATTCCAGATGACAGGGACAACGTCCATTCCATTACAACCCAGCTC
25 AGTATGACTATGACAGAGATGATGTGGGAGACCGCTGTGACAACGTCCCTACA
ACCACAACCCAGATCAGGCAGACACAGACAACAATGGGGAAGGAGACGCCTGT
GCTGCAGACATTGATGGAGACGGTATCCTCAATGAACGGGACAACGTGCCAGTAC
GTCTACAATGTGGACCAGAGAGACACTGATATGGATGGGGTTGGAGATCAGTGT
GACAATTGCCCTTGGAACACAATCCGGATCAGCTGGACTCTGACTCAGACCGCA
30 TTGGAGATACCTGTGACAACAATCAGGATATTGATGAAGATGGCCACCAGAACA
ATCTGGACAACGTGCCCTATGTGCCCAATGCCAACCAGGCTGACCATGACAAAG
ATGGCAAGGGAGATGCCTGTGACCACGATGATGACAACGATGGCATTCCCTGATG
ACAAGGACAACGTGCACTCGTGCCCAATCCCGACCAGAAGGACTCTGACGGCG
ATGGTCCAGGTGATGCTTGCAAAAGATGATTTTGACCATGACAGTGTGCCAGACAT
35 CGATGACATCTGTCCTGAGAATGTTGACATCAGTGAGACCGATTTCGCGCGATT
CAGATGATTCTCTGGACCCCAAAGGGACATCCCAAAATGACCCTAACTGGGTTG
TACGCCATCAGGGTAAAGAACTCGTCCAGACTGTCAACTGTGATCCTGGACTCGC
TGTAGGTTATGATGAGTTTAATGCTGTGGACTTCAGTGGCACCTTCTTCATCAAC
ACCGAAAGGGACGATGACTATGCTGGATTTGTCTTTGGCTACCAGTCCAGCAGCC
40 GCTTTTATGTTGTGATGTGGAAGCAAGTCACCCAGTCCTACTGGGACACCAACCC
CACGAGGGCTCAGGGATACTCGGGCCTTTCTGTGAAAGTTGTAAACTCCACCACA
GGGCCTGGCGAGCACCTGCGGAACGCCCTGTGGCACACAGGAAACACCCCTGGC
CAGGTGCGCACCCCTGTGGCATGACCTCGTCACATAGGCTGGAAAGATTTACCG
CCTACAGATGGCGTCTCAGCCACAGGCCAAAGACGGGTTTCATTAGAGTGGTGA
45 TGTATGAAGGGAAGAAAATCATGGCTGACTCAGGACCCATCTATGATAAAACCT
ATGCTGGTGGTAGACTAGGGTTGTTTGTCTTCTCTCAAGAAATGGTGTCTTCTCT
GACCTGAAATACGAATGTAGAGATCCCTAATCATCAAATTGTTGATTGAAAGACT
GATCATAAACCAATGCTGGTATTGCACCTTCTGGAACATATGGGCTTGAGAAAACC
CCCAGGATCACTTCTCCTTGGCTTCCTTCTTTCTGTGCTTGCATCAGTGTGGACT

CCTAGAACGTGCGACCTGCCTCAAGAAAATGCAGTTTTTCAAAAACAGACTCATC
 AGCATTTCAGCCTCCAATGAATAAGACATCTTCCAAGCATATAAAACAATTGCTTTG
 GTTTCCTTTTGA AAAAAGCATCTACTTGCTTCAGTTGGGAAGGTGCCCATTCCTACTC
 5 TGCTTTTGTACAGAGCAGGGTGCTATTGTGAGGCCATCTCTGAGCAGTGGACTC
 AAAAGCATTTTCAGGCATGTCAGAGAAGGGAGGACTCACTAGAATTAGCAAACA
 AAACCACCCTGACATCCTCCTTCAGGAACACGGGGAGCAGAGGCCAAAGCACTA
 AGGGGAGGGCGCATACCCGAGACGATTGTATGAAGAAAATATGGAGGAACTGTT
 ACATGTTTCGGTACTAAGTCATTTTCAGGGGATTGAAAGACTATTGCTGGATTTC
 10 TGATGCTGACTGGCGTTAGCTGATTAACCCATGTAAATAGGCACCTTAAATAGAAG
 CAGGAAAGGGAGACAAAGACTGGCTTCTGGACTTCCTCCCTGATCCCCACCCTTA
 CTCATCACCTTGCAGTGGCCAGAATTAGGGAATCAGAATCAAACCAGTGTAAGG
 CAGTGCTGGCTGCCATTGCCTGGTCACATTGAAATTGGTGGCTTCATTCTAGATG
 TAGCTTGTGCAGATGTAGCAGGAAAATAGGAAAACCTACCATCTCAGTGAGCAC
 CAGCTGCCTCCCAAAGGAGGGGCAGCCGTGCTTATATTTTTTATGGTTACAATGGC
 15 ACAAATTATTATCAACCTAACTAAAACATTCTTTTTCTCTTTTTTCCGTAATTAC
 TAGGTAGTTTTCTAATTCTCTCTTTTGGAAAGTATGATTTTTTTAAAGTCTTTACGAT
 GTAAAATATTTATTTTTTACTTATTCTGGAAGATCTGGCTGAAGGATTATTCATGG
 AACAGGAAGAAGCGTAAAGACTATCCATGTCATCTTTGTTGAGAGTCTTCGTGAC
 TGTAAGATTGTAAATACAGATTATTTATTAACCTCTGTTCTGCCTGGAAATTTAGGC
 20 TTCATACGGAAAGTGTTTGAGAGCAAGTAGTTGACATTTATCAGCAAATCTCTTG
 CAAGAACAGCACAAAGGAAAATCAGTCTAATAAGCTGCTCTGCCCCCTTGTGCTCA
 GAGTGGATGTTATGGGATTCTTTTTTCTCTGTTTTATCTTTTCAAGTGGAATTAG
 TTGGTTATCCATTTGCAAATGTTTTAAATTGCAAAGAAAGCCATGAGGTCTTCAA
 TACTGTTTTACCCCATCCCTTGTGCATATTTCCAGGGAGAAGGAAAGCATATACA
 25 CTTTTTCTTTTCATTTTCCAAAAGAGAAAAAAATGACAAAAGGTGAAACTTACA
 TACAAATATTACCTCATTTGTTGTGTGACTGAGTAAAGAATTTTTGGATCAAGCG
 GAAAGAGTTTAAGTGTCTAACAACTTAAAGCTACTGTAGTACCTAAAAAGTCA
 GTGTTGTACATAGCATAAAAACTCTGCAGAGAAGTATTTCCAATAAGGAAATAG
 CATTGAAATGTTAAATACAATTTCTGAAAGTTATGTTTTTTTTCTATCATCTGGTA
 30 TACCATTGCTTTATTTTTATAAATTATTTTCTCATTGCCATTGGAATAGAATATTC
 AGATTGTGTAGATATGCTATTTAAATAATTTATCAGGAAATACTGCCTGTAGAGT
 TAGTATTTCTATTTTTATATAATGTTTGCACACTGAATTGAAGAATTGTTGGTTTT
 TTCTTTTTTTGTTTTTTTTTTTTTTTTTTTTTTTTTTTGGCTTTTGACCTCCCATTTTA
 CTATTTGCCAATACCTTTTTCTAGGAATGTGCTTTTTTTTGTACACATTTTATCCA
 35 TTTTACATTCTAAAGCAGTGTAAGTTGTATATTACTGTTTCTTATGTACAAGGAAC
 AACAATAAATCATATGGAAATTTATATT

SEQ ID NO: 20

>gi|2229167|gb|AA495846.1|AA495846 zw05a06.r1 Soares_NhHMPu_S1 Homo sapiens

40 cDNA clone IMAGE:768370 5'

TGAACATATTCATTGTTTGTGTTATTAATAAATTACCATTTCAGTTTGAATGAGACCT
 ATATGTCTGGATACTTTAATAGAGCTTTAATTATTACGAAAAAAGATTTACAGAGA
 TAAAACACTAGAAGTTACCTATTCTCCACCTAAATCTCTGAAAAATGGAGAAACC
 CTCTGACTAGTCCATGTCAAATTTTACTAAAAGTCTTTTTGTTTAGATTTATTTTCC
 45 TGCAGCATCTTCTGCAAAATGTACTATATAGTCAGCTTGCTTTGAGGCTAGTAAA
 AAGATATTTTTCTAAACAGATTGGAGTTGGCATATAAACAAATACGTTTTCTCAC
 TAATGACAGTCCATG

SEQ ID NO: 21

>gi|2459627|gb|U88880.1|HSU88880 Homo sapiens Toll-like receptor 4 (TLR4) mRNA,
complete cds

5 ACAGGGCCACTGCTGCTCACAGAAGCAGTGAGGATGATGCCAGGATGATGTCTG
CCTCGCGCCTGGCTGGGACTCTGATCCCAGCCATGGCCTTCCTCTCCTGCGTGAG
ACCAGAAAGCTGGGAGCCCTGCGTGGAGACTTGGCCCTAAACCACACAGAAGAG
CTGGCATGAAACCCAGAGCTTTCAGACTCCGGAGCCTCAGCCCTTCACCCCGATT
CCATTGCTTCTTGCTAAATGCTGCCGTTTATCACGGAGGTGGTTCCTAATATTAC
10 TTATCAATGCATGGAGCTGAATTTCTACAAAATCCCCGACAACCTCCCCTTCTCA
ACCAAGAACCTGGACCTGAGCTTTAATCCCCTGAGGCATTTAGGCAGCTATAGCT
TCTTCAGTTTCCCAGAACTGCAGGTGCTGGATTTATCCAGGTGTGAAATCCAGAC
AATTGAAGATGGGGCATATCAGAGCCTAAGCCACCTCTCTACCTTAATATTGACA
GGAAACCCCATCCAGAGTTTAGCCCTGGGAGCCTTTTCTGGACTATCAAGTTTAC
AGAAGCTGGTGGCTGTGGAGACAAATCTAGCATCTCTAGAGAACTTCCCCATTGG
15 ACATCTCAAACTTTGAAAGAACTTAATGTGGCTCACAATCTTATCCAATCTTTC
AAATTACCTGAGTATTTTTCTAATCTGACCAATCTAGAGCACTTGGACCTTTCAG
CAACAAGATTCAAAGTATTTATTGCACAGACTTGCGGGTTCTACATCAAATGCCC
CTACTCAATCTCTCTTTAGACCTGTCCCTGAACCCTATGAACTTTATCCAACCAGG
TGCATTTAAAGAAATTAGGCTTCATAAGCTGACTTTAAGAAATAATTTTGATAGT
20 TTAAATGTAATGAAAACCTTGTAATCAAGGTCTGGCTGGTTTAGAAGTCCATCGTT
TGGTTCTGGGAGAATTTAGAAATGAAGGAACTTGGAAAAGTTTGACAAATCTG
CTCTAGAGGGCCTGTGCAATTTGACCATTGAAGAATTCCGATTAGCATACTTAGA
CTACTACCTCGATGATATTATTGACTTATTTAATTGTTTGACAAATGTTTCTTCAT
TTTCCCTGGTGAGTGTGACTATTGAAAGGGTAAAAGACTTTTCTTATAATTTTCGG
25 ATGGCAACATTTAGAATTAGTTAACTGTAAATTTGGACAGTTTCCCACATTGAAA
CTCAAATCTCTCAAAGGCTTACTTTCACCTTCCAACAAAGGTGGGAATGCTTTTT
CAGAAGTTGATCTACCAAGCCTTGAGTTTCTAGATCTCAGTAGAAATGGCTTGAG
TTTCAAAGGTTGCTGTTCTCAAAGTGATTTTGGGACAACCAGCCTAAAGTATTTA
GATCTGAGCTTCAATGGTGTTATTACCATGAGTTCAAACCTTCTTGGGCTTAGAAC
30 AACTAGAACATCTGGATTTCCAGCATTCCAATTTGAAACAAATGAGTGAGTTTTC
AGTATTCCCTATCACTCAGAAACCTCATTTACCTTGACATTTCTCATACTCACACCA
GAGTTGCTTTCAATGGCATCTTCAATGGCTTGTCCAGTCTCGAAGTCTTGAAAT
GGCTGGCAATTCTTTCCAGGAAAACCTTCCTTCCAGATATCTTCACAGAGCTGAGA
AACTTGACCTTCCTGGACCTCTCTCAGTGTCAACTGGAGCAGTTGTCTCCAACAG
35 CATTAACTCACTCTCCAGTCTTCAGGTACTAAATATGAGCCACAACAACCTTCTTT
TCATTGGATACGTTTCCTTATAAGTGTCTGAACTCCCTCCAGGTTCTTGATTACAG
TCTCAATCACATAATGACTTCCAAAAAACAGGAACTACAGCATTTTCCAAGTAGT
CTAGCTTTCTTAAATCTTACTCAGAATGACTTTGCTTGTACTTGTGAACACCAGAG
TTTCTGCAATGGATCAAGGACCAGAGGCAGCTCTTGGTGGAAGTTGAACGAAT
40 GGAATGTGCAACACCTTCAGATAAGCAGGGCATGCCTGTGCTGAGTTTGAATATC
ACCTGTCAGATGAATAAGACCATCATTTGGTGTGTGCGGTCCTCAGTGTGCTTGTAG
TATCTGTTGTAGCAGTTCTGGTCTATAAGTTCTATTTTCACCTGATGCTTCTTGCT
GGCTGCATAAAGTATGGTAGAGGTGAAAACATCTATGATGCCTTTGTTATCTACT
CAAGCCAGGATGAGGACTGGGTAAGGAATGAGCTAGTAAAGAATTTAGAAGAA
45 GGGGTGCCTCCATTTAGCTCTGCCTTCACTACAGAGACTTTATTCCCGGTGTGGC
CATTGCTGCCAACATCATCCATGAAGGTTTCCATAAAAGCCGAAAGGTGATTGTT
GTGGTGTCCCAGCACTTCATCCAGAGCCGCTGGTGTATCTTTGAATATGAGATTG
CTCAGACCTGGCAGTTTCTGAGCAGTCGTGCTGGTATCATCTTCATTGTCCTGCAG
AAGGTGGAGAAGACCTGCTCAGGCAGCAGGTGGAGCTGTACCGCCTTCTCAGC

AGGAACACTTACCTGGAGTGGGAGGACAGTGTCTGGGGCGGCACATCTTCTGG
AGACGACTCAGAAAAGCCCTGCTGGATGGTAAATCATGGAATCCAGAAGGAACA
GTGGGTACAGGATGCAATTGGCAGGAAGCAACATCTATCTGAAGAGGAAAAATA
AAAACCTCCTGAGGCATTTCTTGCCCAGCTGGGTCCAACACTTGTTTCAGTTAATA
5 AGTATTAAATGCTGCCACATGTCAGGCCTTATGCTAAGGGTGAGTAATTCATGG
TGCAGTAGATATGCAGGGCTGCTAATCTCAAGGAGCTTCCAGTGCAGAGGGAAT
AAATGCTAGACTAAAATACAGAGTCTTCCAGGTGGGCATTTCAACCAACTCAGTC
AAGGAACCCATGACAAAGAAAGTCATTTCAACTCTTACCTCATCAAGTTGAATAA
AGACAGAGAAAACAGAAAGAGACATTGTTCTTTTCTGAGTCTTTTGAATGGAA
10 ATTGTATTATGTTATAGCCATCATAAAACCATTTTGGTAGTTTTGACTGAACTGGG
TGTTCACTTTTTCTTTTTTGATTGAATACAATTTAAATTCTACTTGATGACTGCAG
TCGTCAAGGGGCTCCTGATGCAAGATGCCCTTCCATTTTAAGTCTGTCTCCTTAC
AGAGGTTAAAGTCTAATGGCTAATTCCTAAGGAAACCTGATTAAACACATGCTCAC
AACCATCCTGGTCATTCTCGAACATGTTCTATTTTTTAACTAATCACCCCTGATAT
15 ATTTTTATTTTTATATATCCAGTTTTTCAATTTTTTACGTCTTGCCTATAAGCTAATA
TCATAAATAAGGTTGTTTAAGACGTGCTTCAAATATCCATATTAACCACTATTTTT
CAAGGAAGTATGAAAAGTACACTCTGTCACTTTGTCACTCGATGTCATTCCAAA
GTTATTGCCTACTAAGTAATGACTGTCATGAAAGCAGCATTGAAATAATTTGTTT
AAAGGGGGGCACTCTTTTAAACGGGAAGAAAATTTCCGCTTCCTGGTCTTATCATG
20 GACAATTTGGGCTATAGGCATGAAGGAAGTGGGATTACCTCAGGAAGTCACCTT
TTCTTGATTCCAGAAACATATGGGCTGATAAACCCGGGGTGACCTCATGAAATGA
GTTGCAGCAGATGTTTATTTTTTTCAGAACAAAGTGATGTTTGATGGACCTATGAA
TCTATTTAGGGAGACACAGATGGCTGGGATCCCTCCCCTGTACCCTTCTCACTGA
CAGGAGAACTA

25

SEQ ID NO: 22

>gi|189185|gb|M32315.1|HUMNFR Human tumor necrosis factor receptor mRNA, complete cds

GCGAGCGCAGCGGAGCCTGGAGAGAAGGCGCTGGGCTGCGAGGGCGCGAGGGGC
30 GCGAGGGCAGGGGGCAACCGGACCCCGCCCGCACCCATGGCGCCCGTCGCCGTC
TGGGCCGCGCTGGCCGTCGGAAGTCTGGGCTGCGGCGCACGCCTTGCCCG
CCCAGGTGGCATTACACCCTACGCCCCGGAGCCCGGGAGCACATGCCGGCTCA
GAGAATACTATGACCAGACAGCTCAGATGTGCTGCAGCAAATGCTCGCCGGGCC
AACATGCAAAAGTCTTCTGTACCAAGACCTCGGACACCGTGTGTGACTCCTGTGA
35 GGACAGCACATACACCAGCTCTGGAAGTGGGTTCGCGAGTGCTTGAGCTGTGGC
TCCCGCTGTAGCTCTGACCAGGTGGAAGTCAAGCCTGCACTCGGGAACAGAAC
CGCATCTGCACCTGCAGGCCCGGCTGGTACTGCGCGCTGAGCAAGCAGGAGGGG
TGCCGGCTGTGCGCGCCGCTGCGCAAGTGCCGCCCGGGCTTCGGCGTGGCCAGA
CCAGGAAGTGAACATCAGACGTGGTGTGCAAGCCCTGTGCCCCGGGGACGTTC
40 TCCAACACGACTTCATCCACGGATATTTGCAGGCCCCACCAGATCTGTAACGTGG
TGGCCATCCCTGGGAATGCAAGCATGGATGCAGTCTGCACGTCCACGTCCCCAC
CCGGAGTATGGCCCCAGGGGCAGTACACTTACCCAGCCAGTGTCCACACGATC
CCAACACACGCAGCCAACCTCCAGAACCAGCACTGCTCCAAGCACCTCCTTCCTG
CTCCCAATGGGCCCCAGCCCCCAGCTGAAGGGAGCACTGGCGACTTCGCTCTTC
45 CAGTTGGACTGATTGTGGGTGTGACAGCCTTGGGTCTACTAATAATAGGAGTGGT
GAACTGTGTCATCATGACCCAGGTGAAAAAGAAGCCCTTGTGCCTGCAGAGAGA
AGCCAAGGTGCCTCACTTGCCCTGCCGATAAGGCCCGGGGTACACAGGGCCCCGA
GCAGCAGCACCTGCTGATCACAGCGCCGAGCTCCAGCAGCAGCTCCCTGGAGAG
CTCGGCCAGTGCCTTGGACAGAAGGGCGCCCACTCGGAACCAGCCACAGGCACC

AGGCGTGGAGGCCAGTGGGGCCGGGGAGGCCCGGGCCAGCACCGGGAGCTCAG
ATTCTTCCCCTGGTGGCCATGGGACCCAGGTCAATGTCACCTGCATCGTGAACGT
CTGTAGCAGCTCTGACCACAGCTCACAGTGCTCCTCCCAAGCCAGCTCCACAATG
GGAGACACAGATTCCAGCCCCTCGGAGTCCCCGAAGGACGAGCAGGTCCCCTTC
5 TCCAAGGAGGAATGTGCCTTTCGGTCACAGCTGGAGACGCCAGAGACCCTGCTG
GGGAGCACCGAAGAGAAGCCCCTGCCCCTTGGAGTGCCTGATGCTGGGATGAAG
CCCAGTTAACCAGGCCGGTGTGGGCTGTGTCTAGCCAAGGTGGGCTGAGCCCT
GGCAGGATGACCCTGCGAAGGGGCCCTGGTCCTTCCAGGCCCCCACCCTAGGA
CTCTGAGGCTCTTTCTGGGCCAAGTTCCTCTAGTGCCCTCCACAGCCGCAGCCTCC
10 CTCTGACCTGCAGGCCAAGAGCAGAGGCAGCGAGTTGGGGAAAGCCTCTGCTGC
CATGGTGTGTCCCTCTCGGAAGGCTGGCTGGGCATGGACGTTCCGGGGCATGCTGG
GGCAAGTCCCTGACTCTCTGTGACCTGCCCCGCCAGCTGCACCTGCCAGCCTGG
CTTCTGGAGCCCTTGGGTTTTTTGTTTGTGTTGTTTGTGTTGTTTGTGTTTCTCCCCC
TGGGCTCTGCCAGCTCTGGCTTCCAGAAAACCCAGCATCCTTTTCTGCAGAGG
15 GGCTTTCTGGAGAGGAGGGATGCTGCCTGAGTCACCCATGAAGACAGGACAGTG
CTTCAGCCTGAGGCTGAGACTGCGGGATGGTCCTGGGGCTCTGTGTAGGGAGGA
GGTGGCAGCCCTGTAGGGAACGGGGTCCCTCAAGTTAGCTCAGGAGGCTTGGA
AGCATCACCTCAGGCCAGGTGCAGTGGCTCACGCCTATGATCCCAGCACTTTGGG
AGGCTGAGGCGGGTGGATCACCTGAGGTTAGGAGTTCGAGACCAGCCTGGCCAA
20 CATGGTAAAACCCCATCTCTACTAAAAATACAGAAATTAGCCGGGCGTGGTGGC
GGGCACCTATAGTCCCAGCTACTCAGAAGCCTGAGGCTGGGAAATCGTTTGAAC
CCGGGAAGCGGAGGTTGCAGGGAGCCGAGATCACGCCACTGCACTCCAGCCTGG
GCGACAGAGCGAGAGTCTGTCTCAAAAGAAAAAAAAAAAAAGCACCGCCTCCAA
ATGCTAACTTGTCTTTTGTACCATGGTGTGAAAGTCAGATGCCAGAGGGCCCA
25 GGCAGGCCACCATATTCAGTGCTGTGGCCTGGGCAAGATAACGCACTTCTAACTA
GAAATCTGCCAATTTTTTAAAAAAGTAAGTACCCTCAGGCCAACAAAGCCAACG
ACAAAGCCAACTCTGCCAGCCACATCCAACCCCCCACCTGCCATTTGCACCCTC
CGCCTTCACTCCGGTGTGCCTGCAGCCCCGCGCCTCCTTCTTGCTGTCTTAGGCC
ACACCATCTCCTTTCAGGGAATTTCAAGAACTAGAGATGACTGAGTCCTCGTAGC
30 CATCTCTCTACTCCTACCTCAGCCTAGACCCTCCTCCTCCCCCAGAGGGGTGGGTT
CCTCTTCCCCACTCCCCACCTTCAATTCTGCGGCCCAAACGGGCTGCCCTGCCAC
TTTGGTACATGGCCAGTGTGATCCCAAGTGCCAGTCTTGTGTCTGCGTCTGTGTTG
CGTGTCTGTGGGTGTGTGTAGCCAAGGTGCGTAAGTTGAATGGCCTGCCTTGAAGC
CACTGAAGCTGGGATTCTTCCCCATTAGAGTCAGCCTTCCCCCTCCCAGGGCCAG
35 GGCCCTGCAGAGGGGAAACCAAGTGTAGCCTTGCCCGGATTCTGGGAGGAAGCAG
GTTGAGGGGCTCCTGGAAAGGCTCAGTCTCAGGAGCATGGGGATAAAGGAGAAG
GCATGAAATTGTCTAGCAGAGCAGGGGCAGGGTGATAAATTGTTGATAAATTCC
ACTGGACTTGAGCTTGGCAGCTGAACTATTGGAGGGTGGGAGAGCCCAGCCATT
ACCATGGAGACAAGAAGGGTTTTCCACCCTGGAATCAAGATGTCAGACTGGCTG
40 GCTGCAGTGACGTGCACCTGTACTCAGGAGGCTGAGGGGAGGATCACTGGAGCC
CAGGAGTTTGAGGCTGCAGCGAGCTATGATCGCGCCACTACACTCCAGCCTGAG
CAACAGAGTGAGACCCTGTCTCTTAAAGAAAAAAAAAAGTCAGACTGCTGGGACT
GGCCAGGTTTCTGCCACATTGGACCCACATGAGGACATGATGGAGCGCACCTG
CCCCCTGGTGGACAGTCTTGGGAGAACCTCAGGCTTCTTGGCATCACAGGGCAG
45 AGCCGGGAAGCGATGAATTTGGAGACTCTGTGGGGCCTTGGTTCCCTTGTGTGTG
TGTGTTGATCCCAAGACAATGAAAGTTTGCACCTGTATGCTGGACGGCATTCCTGC
TTATCAATAAACCTGTTTGTGTTTAAAAAAA

SEQ ID NO: 23

>gi|182627|gb|M34539.1|HUMFKBP Human FK506-binding protein (FKBP) mRNA,
complete cds

```

5  GAATTCGGGCCCGCCGCCAGGTCGCTGTTGGTCCACGCCGCCCGTCGCGCCGCCCG
   CCCGCTCAGCGTCCGCCGCCGCATGGGAGTGCAGGTGGAAACCATCTCCCCAG
   GAGACGGGCGCACCTTCCCCAAGCGCGGCCAGACCTGCGTGGTGCACCTACACCG
   GGATGCTTGAAGATGGAAAGAAATTTGATTCTCTCCGGGACAGAAACAAGCCCT
   TTAAGTTTATGCTAGGCAAGCAGGAGGTGATCCGAGGCTGGGAAGAAGGGGTTG
10  CCCAGATGAGTGTGGGTCAGAGAGCCAACTGACTATATCTCCAGATTATGCCTA
   TGGTGCCACTGGGCACCCAGGCATCATCCACCATGCCACTCTCGTCTTCGAT
   GTGGAGCTTCTAAAACTGGAATGACAGGAATGGCCTCCTCCCTTAGCTCCCTGTT
   CTTGGATCTGCCATGGAGGGATCTGGTGCCTCCAGACATGTGCACATGAGTCCAT
   ATGGAGCTTTTCTGATGTTCCACTCCACTTTGTATAGACATCTGCCCTGACTGAA
   TGTGTTCTGTCACTCAGCTTTGCTTCCGACACCTCTGTTTCCTCTTCCCCCTTTCTCC
15  TCGTATGTGTGTTTACCTAAACTATATGCCATAAACCTCAAGTTATTCATTTTATT
   TTGTTTTTCATTTTGGGGTGAAGATTCAGTTTCAGTCTTTTGGATATAGGTTTCCAA
   TTAAGTACATGGTCAAGTATTAACAGCACAAAGTGGTAGGTTAACATTAGAATAG
   GAATTGGTGTGGGGGGGGGGTTTGCAAGAATATTTTATTTTAATTTTTTGGATG
   AAATTTTTATCTATTATATATTAACATTCTTGCTGCTGCGCTGCAAAGCCATAGC
20  AGATTTGAGGCGCTGTTGAGGACTGAATTACTCTCCAAGTTGAGAGATGTCTTTG
   GGTAAATTAAGCCCTACCTAAAACTGAGGTGGGGATGGGGAGAGCCTTTGC
   CTCCACCATTTCCACCCACCCTCCCCTTAAACCCTCTGCCTTTGAAAGTAGATCAT
   GTTCACTGCAATGCTGGACACTACAGGTATCTGTCCCTGGGCCAGCAGGGACCTC
   TGAAGCCTTCTTTGTGGCCTTTTTTTTTTTTTCATCCTGTGGTTTTTCTAATGGACTT
25  TCAGGAATTTTGTAAATCTCATAACTTTCCAAGCTCCACCACTTCCTAAATCTTAAG
   AACTTTAATTGACAGTTTCAATTGAAGGTGCTGTTTGTAGACTTAACACCCAGTG
   AAAGCCCAGCCATCATGACAAATCCTTGAATGTTCTCTTAAGAAAATGATGCTGG
   TCATCGCAGCTTCAGCATCTCCTGTTTTTGTATGCTTGGCTCCCTCTGCTGATCTC
   AGTTTCCTGGCTTTTCTCCCTCAGCCCCTTCTACCCCCTTGCTGTCCTGTGTAGT
30  GATTTGGTGAGAAATCGTTGCTGCACCCTTCCCCCAGCACCATTTATGAGTCTCA
   AGTTTTATTATTGCAATAAAAGTGCTTTATGCCCGAATTC

```

SEQ ID NO: 24

>gi|1418929|emb|Z74616.1|HSPPA2H100.H.sapiens mRNA for prepro-alpha2(I) collagen

```

35  AGCACCACGGCAGCAGGAGGTTTCGGNCTAAGTTGGAGGTACTGGNCCACGACT
   GCATGCCCGCGCCCGCCAGGTGATACCTCCGCCGGTGACCCAGGGGCTCTGCGA
   CACAAGGAGTCTGCATGTCTAAGTGCTAGACATGCTCAGCTTTGTGGATACGCGG
   ACTTTGTTGCTGCTTGCAGTAACCTTATGCCTAGCAACATGCCAATCTTTACAAG
   AGGAAACTGTAAGAAAGGGCCCAGCCGGAGATAGAGGACCACGTGGAGAAAGG
40  GGTCCACCAGGCCCCCAGGCAGAGATGGTGAAGATGGTCCCACAGGCCCTCCT
   GGTCCACCTGGTCCTCCTGGCCCCCCTGGTCTCGGTGGGAACTTTGCTGCTCAGT
   ATGATGGAAAAGGAGTTGGACTTGGCCCTGGACCAATGGGCTTAATGGGACCTA
   GAGGCCACCTGGTGCAGCTGGAGCCCCAGGCCCTCAAGGTTTCCAAGGACCTG
   CTGGTGAGCCTGGTGAACCTGGTCAAACCTGGTCTGCAGGTGCTCGTGGTCCAGC
45  TGGCCCTCCTGGCAAGGCTGGTGAAGATGGTCACCCTGGAAAACCCGGACGACC
   TGGTGAGAGAGGAGTTGTTGGACCACAGGGTGCTCGTGGTTTCCCTGGAACCTCCT
   GGACTTCCTGGCTTCAAAGGCATTAGGGGACACAATGGTCTGGATGGATTGAAG
   GGACAGCCCGGTGCTCCTGGTGTGAAGGGTGAACCTGGTGGCCCTGGTGAAGAT
   GGAACCTCAGGTCAAACAGGAGCCCGTGGGCTTCTGGTGAAGAGGACGTGTT

```

GGTGCCCCTGGCCCAGCTGGTGCCCGTGGCAGTGATGGAAGTGTGGGTCCCGTG
GGTCCTGCTGGTCCCATTGGGTCTGCTGGCCCTCCAGGCTTCCCAGGTGCCCTG
GCCCCAAGGGTGAAATTGGAGCTGTTGGTAACGCTGGTCCTGCTGGTCCCGCCGG
TCCCCGTGGTGAAGTGGGTCTTCCAGGCCTCTCCGGCCCCGTTGGACCTCCTGGT
5 AATCCTGGAGCAAACGGCCTTACTGGTGCCAAGGGTGCTGCTGGCCTTCCCGGCG
TTGCTGGGGCTCCCGGCCTCCCTGGACCCCGCGGTATTCTGGCCCTGTTGGTGCT
GCCGGTGCTACTGGTGCCAGAGGACTTGTGGTGAGCCTGGTCCAGCTGGCTCCA
AAGGAGAGAGCGGTAACAAGGGTGAGCCCGGCTCTGCTGGGCCCCAAGGTCCTC
CTGGTCCCAGTGGTGAAGAAGGAAAGAGAGGCCCTAATGGGGAAGCTGGATCTG
10 CCGGCCCTCCAGGACCTCCTGGGCTGAGAGGTAGTCCTGGTTCTCGTGGTCTTCC
TGGAGCTGATGGCAGAGCTGGCGTCATGGGCCCTCCTGGTAGTCGTGGTGCAAGT
GGCCCTGCTGGAGTCCGAGGACCTAATGGAGATGCTGGTCGCCCTGGGGAGCCT
GGTCTCATGGGACCCAGAGGTCTTCTGGTTCCCCTGGAAATATCGGCCCCGCTG
GAAAAGAAGGTCCTGTCGGCCTCCCTGGCATCGACGGCAGGCCTGGCCCAATTG
15 GCCCAGCTGGAGCAAGAGGAGAGCCTGGCAACATTGGATTCCCTGGACCCAAAG
GCCCCACTGGTGATCCTGGCAAAAACGGTGATAAAGGTCATGCTGGTCTTGCTGG
TGCTCGGGGTGCTCCAGGTCTGATGGAACAATGGTGCTCAGGGACCTCCTGGA
CCACAGGGTGTTCAAGGTGGAAGAAGGTGAACAGGGTCCCGCTGGTCCTCCAGGC
TTCCAGGGTCTGCCTGGCCCCCTCAGGTCCCGCTGGTGAAGTTGGCAAACCAGGAG
20 AAAGGGGTCTCCATGGTGAGTTTGGTCTCCCTGGTCCTGCTGGTCCAAGAGGGGA
ACGCGGTCCCCCAGGTGAGAGTGGTGCTGCCGGTCTACTGGTCCTATTGGAAGC
CGAGGTCTTCTGGACCCCCAGGGCCTGATGGAAACAAGGGTGAACCTGGTGTG
GTTGGTGCTGTGGGCACCTGCTGGTCCATCTGGTCCTAGTGGACTCCCAGGAGAGA
GGGGTGCTGCTGGCATACTGGAGGCAAGGGAGAAAAGGGTGAACCTGGTCTCA
25 GAGGTGAAATTGGTAACCCTGGCAGAGATGGTGCTCGTGGTGCTCATGGTGCTGT
AGGTGCCCTGGTCCTGCTGGAGCCACAGGTGACCGGGGCGAAGCTGGGGCTGC
TGGTCCTGCTGGTCCTGCTGGTCCTCGGGGAAGCCCTGGTGAACGTGGCGAGGTC
GGTCCTGCTGGCCCCAACGGATTTGCTGGTCCGGCTGGTGCTGCTGGTCAACCGG
GTGCTAAAGGAGAAAGAGGAGCCAAAGGGCCTAAGGGTGAACCGGTGTTGTT
30 GGTCCCACAGGCCCCCGTTGGAGCTGCTGGCCCAGCTGGTCCAAATGGTCCCCCG
GTCCTGCTGGAAGTCGTGGTGATGGAGGCCCCCTGGTATGACTGGTTTCCCTGG
TGCTGCTGGACGGACTGGTCCCCCAGGACCCTCTGGTATTTCTGGCCCTCCTGGT
CCCCCTGGTCCTGCTGGGAAAGAAGGGCTTCGTGGTCCTCGTGGTGACCAAGGTC
CAGTTGGCCGAACCTGGAGAAGTAGGTGCAGTTGGTCCCCCTGGCTTCGCTGGTGA
35 GAAGGGTCCCTCTGGAGAGGCTGGTACTGCTGGACCTCCTGGCACTCCAGGTCTT
CAGGGTCTTCTTGGTGCTCCTGGTATTCTGGGTCTCCCTGGCTCGAGAGGTGAAC
GTGGTCTACCTGGTGTTGCTGGTGCTGTGGGTGAACCTGGTCCTCTTGGCATTGCC
GGCCCTCCTGGGGCCCGTGGTCCTCCTGGTGCTGTGGGTAGTCCTGGAGTCAACG
GTGCTCCTGGTGAAGCTGGTCGTGATGGCAACCCTGGGAACGATGGTCCCCCAG
40 GTCGCGATGGTCAACCCGGACACAAGGGAGAGCGCGGTTACCCTGGCAATATTG
GTCCCGTTGGTGCTGCAGGTGCACCTGGTCCTCATGGCCCCGTGGGTCTGCTGG
CAAACATGGAAACCGTGGTGAACCTGGTCCTTCTGGTCCTGTTGGTCCTGCTGGT
GCTGTTGGCCCAAGAGGTCTAGTGGCCACAAGGCATTCTGGGCGATAAGGGA
GAGCCCGGTGAAAAGGGGCCCAGAGGTCTTCTGGCTTAAAGGGACACAATGGA
45 TTGCAAGGTCTGCCTGGTATCGCTGGTCACCATGGTGATCAAGGTGCTCCTGGCT
CCGTGGGTCTGCTGGTCCTAGGGGCCCTGCTGGTCCTTCTGGCCCTGCTGGAAA
AGATGGTTCGCACTGGACATCCTGGTACGGTTGGACCTGCTGGCATTCTGAGGCCCT
CAGGGTCACCAAGGCCCTGCTGGCCCCCCTGGTCCCCCTGGCCCTCCTGGACCTC
CAGGTGTAAGCGGTGGTGGTTATGACTTTGGTTACGATGGAGACTTCTACAGGGC

TGACCAGCCTCGCTCAGCACCTTCTCTCAGACCCAAGGACTATGAAGTTGATGCT
 ACTCTGAAGTCTCTCAACAACCAGATTGAGACCCTTCTTACTCCTGAAGGCTCTA
 GAAAGAACCCAGCTCGCACATGCCGTGACTTGAGACTCAGCCACCCAGAGTGGA
 GCAGTGGTTACTACTGGATTGACCCTAACCAAGGATGCACTATGGATGCTATCAA
 5 AGTATACTGTGATTTCTCTACTGGCGAAACCTGTATCCGGGGCCCAACCTGAAAAC
 ATCCCAGCCAAGAAGTGGTATAGGAGCTCCAAGGACAAGAAACACGTCTGGCTA
 GGAGAACTATCAATGCTGGCAGCCAGTTTGAATATAATGTAGAAGGAGTGACT
 TCCAAGGAAATGGCTACCCAACCTTGCCTTCATGCGCCTGCTGGCCAACTATGCCT
 CTCAGAACATCACCTACCACTGCAAGAACAGCATTGCATACATGGATGAGGAGA
 10 CTGGCAACCTGAAAAAGGCTGTCATTCTACAGGGCTCTAATGATGTTGAACTTGT
 TGCTGAGGGCAACAGCAGGTTCACTTACACTGTTCTTGTAGATGGCTGCTCTAAA
 AAGACAAATGAATGGGGAAAGACAATCATTGAATACAAAACAAATAAGCCATC
 ACGCTGCCCTTCCCTTGATATTGCACCTTTGGACATCGGTGGTGCTGACCATGAA
 TTCTTTGTGGACATTGGCCCAGTCTGTTTCAAATAAAATGAACTCAATCTAAATTA
 15 AAAAAAGAAAGAAATTTGAAAAAAGTCTTCTTTGCCATTTCTTCTTCTTTT
 AACTGAAAGCTGAATCCTTCCATTTCTTCTGCACATCTACTTGCTTAAATTGTGGG
 CAAAAGAGAAAAAGAAGGATTGATCAGAGCATTGTGCAATACAGTTTCATTAAC
 TCCTTCCCCCGCTCCCCCAAAATTTGAATTTTTTTTTTCAACACTCTTACACCTGTT
 ATGGAAAATGTCAACCTTTGTAAGAAAACCAAAATAAAAAATTGAAAAATAAAAA
 20 CCATAAACATTTGCACCACTTGTGGCTTTTGAATATCTTCCACAGAGGGAAGTTT
 AAAACCCAACTTCCAAAGGTTTAACTACCTCAAAACACTTTCCCATGAGTGTG
 ATCCACATTGTTAGGTGCTGACCTAGACAGAGATGAACTGAGGTCCTTGTTTTGT
 TTTGTTTATAATAACAAAGGTGCTAATTAATAGTATTTTCAGATACTTGAAGAATGT
 TGATGGTGCTAGAAGAATTTGAGAAGAAATACTCCTGTATTGAGTTGTATCGTGT
 25 GGTGTATTTTTTAAAAAATTTGATTTAGCATTTCATATTTTCCATCTTATTCCCAATT
 AAAAGTATGCAGATTATTTGCCCAAAGTTGTCCTCTTCTTCAGATTTCAGCATTGT
 TCTTTGCCAGTCTCATTTTCATCTTCTTCCATGGTTCCACAGAAGCTTTGTTTCTTG
 GGCAAGCAGAAAAATTAATTTGTACCTATTTTGTATATGTGAGATGTTTAAATAA
 ATTGTGAAAAAAATGAAATAAAGCATGTTTGGTTTTCCAAAAGAACATAT

30

SEQ ID NO: 25

>gi|181179|gb|M11233.1|HUMCTHD Human cathepsin D mRNA, complete cds

GGCTATAAGCGCACGGCCTCGGCGACCCTCTCCGACCCGGCCGCGCCGCCATGC
 AGCCCTCCAGCCTTCTGCGGCTGGGCTGCTGGCTGCAACCCGCCTCCGCG
 35 CTCGTCAGGATCCCGCTGCACAAGTTCACGTCCATCCGCCGGACCATGTGCGAGG
 TTGGGGGGCTCTGTGGAGGACCTGATTGCCAAAGGCCCGTCTCAAAGTACTCCCA
 GGCGGTGCCAGCCGTGACCGAGGGGCCATTCCCGAGGTGCTCAAGAACTACAT
 GGACGCCCAGTACTACGGGGAGATTGGCATCGGGACGCCCCCCCAGTGCTTCAC
 AGTCGTCTTCGACACGGGCTCCTCCAACCTGTGGGTCCCCTCCATCCACTGCAAA
 40 CTGCTGGACATCGCTTGCTGGATCCACCACAAGTACAACAGCGACAAGTCCAGC
 ACCTACGTGAAGAATGGTACCTCGTTTGACATCCACTATGGCTCGGGCAGCCTCT
 CCGGGTACCTGAGCCAGGACACTGTGTGGTGGCCTGCCAGTCAGCGTCGTCAGC
 CTCTGCCCTGGGCGGTGTCAAAGTGGAGAGGCAGGTCTTTGGGGAGGCCACCAA
 GCAGCCAGGCATCACCTTCATCGCAGCCAAGTTCGATGGCATCCTGGGCATGGCC
 45 TACCCCCGCATCTCCGTCAACAACGTGCTGCCCGTCTTCGACAACCTGATGCAGC
 AGAAGCTGGTGGACCAGAACATCTTCTCTTCTACCTGAGCAGGGACCCAGATGC
 GCAGCCTGGGGGTGAGCTGATGCTGGGTGGCACAGACTCCAAGTATTACAAGGG
 TTCTCTGTCTACCTGAATGTACCCGCAAGGCCTACTGGCAGGTCCACCTGGAC
 CAGGTGGAGGTGGCCAGCGGGCTGACCCTGTGCAAGGAGGGCTGTGAGGCCATT

GTGGACACAGGCACTTCCCTCATGGTGGGCCCCGGTGGATGAGGTGCGCGAGCTG
CAGAAAGGCCATCGGGGCCGTGCCGCTGATTACAGGGCGAGTACATGATCCCCTGT
GAGAAGGTGTCCACCTGCCCCGCGATCACACTGAAGCTGGGAGGCAAAGGCTAC
AAGCTGTCCCCAGAGGACTACACGCTCAAGGTGTGCGAGGCCGGGAAGACCCTC
5 TGCCTGAGCGGGCTTCATGGGCATGGACATCCCGCCACCCAGCGGGGCACTCTGGA
TCCTGGGCGACGTCTTCATCGGCCGCTACTACACTGTGTTTGACCGTGACAACAA
CAGGGTGGGCTTCGCCGAGGCTGCCCCGCTCTAGTTCCCAAGGCGTCCGCGCGCC
AGCACAGAAACAGAGGAGAGTCCAGAGCAGGAGGCCCTGGCCCAGCGGCC
CTCCCACACACACCCACACACTCGCCCCGCCACTGTCTGGGCGCCCTGGAAGCC
10 GGCGGCCCAAGCCCGACTTGCTGTTTTGTTCTGTGGTTTTCCCCTCCCTGGGTTCA
GAAATGCTGCCTGCCTGTCTGTCTCTCCATCTGTTTGGTGGGGGTAGAGCTGATC
CAGAGCACAGATCTGTTTCGTGCATTGGAAGACCCACCCAAAGCTTGGCAGCCG
AGCTCGTGTATCCTGGGGCTCCCTTCATCTCCAGGGAGTCCCTCCCCGGCCCTA
CCAGCGCCCGCTGGGCTGAGCCCCTACCCACACCAAGGCCGTCTCCCCGGGCCCT
15 CCCTTGAAACCTGCCCTGCCTGAGGGGCCCTCTGCCAGCTTGGGCCAGCTGG
GCTCTGCCACCCTACCTGTTCAAGTGTCCCGGGCCCGTTGAGGATGAGGCCGCTAG
AGGCCTGAGGATGAGCTGGAAGGAGTGAGAGGGGACAAAACCCACCTTGTGGA
GCCTGCAGGGTGGTGTGGGACTGAGCCAGTCCCAGGGGCATGTATTGGCCTGG
AGGTGGGGTTGGGATTGGGGGCTGGTGCCAGCCTTCCTCTGCAGCTGACCTCTGT
20 TGTCTCCCCTTGGGCGGCTGAGAGCCCCAGCTGACATGGAAATACAGTTGTTGG
CCTCCGGCCTCCCCTC

SEQ ID NO: 26

>gi|2167381|gb|AA453712.1|AA453712 aa20f04.r1 Soares_NhHMPu_S1 Homo sapiens
cDNA clone IMAGE:813823 5'
25 GCCATTATCTACTCCAAGATCAAGCATTTGCGTTGTGGATGGCAATCGCATCTC
AGAAACCAGTCTTCCACCGGATATGTATGAATGTCTACGTGTTGCTAACGAAGTC
ACTCTTAATTAATATCTGTATCCTGGAACAATATTTTATGGTTATGTTTTCTGTG
TGTCAGTTTTCATAGTATCCATATTTTATTACTGTTTATTACTTCCATGAATTTTAA
30 AATCTGAGGGAAATGTTTTGTAAACATTTATTTTTTTTAAAGAAAAGATGAAAGG
CAGGCCTATTTATCACAAGAACACACATATACACGAATAGACATCAAATCTC
AATGCTTTATTTGTAAATTTAGTGTTTTTTTATTTCTACTGTCAAATGATGTGCAA
AACCTTTTACTGGTTGCATGGAAATCAGCCAAGTTTTATAATCCTTAAATCTTAAT
GTTCTCAAAGCTTGGATTTAATACATATGGATGTACTCTCTTGCACCAAATTAT
35 CTTGATACATTCAAATTTGTCTGGTTAAAAAATAGGTGGTAGATATTGAGGCCAA
GA

SEQ ID NO: 27

>gi|339730|gb|M75165.1|HUMTM1E H.sapiens epithelial tropomyosin (TM1) mRNA,
complete cds
40 CGCCTGCCACCGGTGCACCCAGTCCGCTCACCCAGCCCAGTCCGTCCGGTCTCTCA
CCGCCTGCCGGCCGGGCCACCCCCACCGCAGCCATGGACGCCATCAAGAAGAA
GATGCAGATGCTGAAGCTGGACAAGGAGAACGCCATCGACCGCGCCGAGCAGGC
CGAAGCCGACAAGAAGCAAGCTGAGGACCGCTGCAAGCAGCTGGAGGAGGAGC
45 AGCAGGCCCTCCAGAAGAAGCTGAAGGGGACAGAGGATGAGGTGGAAAAGTAT
TCTGAATCCGTGAAGGAGGCCAGGAGAACTGGAGCAGGCCGAGAAGAAGGC
CACTGATGCTGAGGCAGATGTGGCCTCCCTGAACCGCCGCATTCAGCTGGTTGAG
GAGGAGCTGGACCGGGCCAGGAGCGCCTGGCTACAGCCCTGCAGAAGCTGGAG
GAGGCCGAGAAGGCGGCTGATGAGAGCGAGAGAGGAATGAAGGTCATCGAAAA

CCGGGCCATGAAGGATGAGGAGAAGATGGAAGTGCAGGAGATGCAGCTGAAGG
AGGCCAAGCACATCGCTGAGGATTCAGACCGCAAATATGAAGAGGTGGCCAGGA
AGCTGGTGATCCTGGAAGGAGAGCTGGAGCGCTCGGAGGAGAGGGCTGAGGTG
GCCGAGAGCCGAGCCAGACAGCTGGAGGAGGAACTTCGAACCATGGACCAGGC
5 CCTCAAGTCCCTGATGGCCTCAGAGGAGGAGTATTCCACCAAAGAAGATAAATA
TGAAGAGGAGATCAAACCTGTTGGAGGAGAAGCTGAAGGAGGCTGAGACCCGAG
CAGAGTTTGGCGAGAGGTCTGTGGCAAAGTTGGAGAAAACCATCGATGACCTAG
AAGAGACCTTGGCCAGTGCCAAGGAGGAGAACGTCGAGATTCACCAGACCTTGG
ACCAGACCCTGCTGGAACCTCAACAACCTGTGAGGGGCCAGCCCCACCCCCAGCCA
10 GGCTATGGTTGCCACCCCAACCCAATAAACTGATGTTACTAGCC

SEQ ID NO: 28

>gi|189731|gb|J03278.1|HUMPDGFRA Human platelet-derived growth factor (PDGF)
receptor mRNA, complete cds

15 GGCCCCCTCAGCCCTGCTGCCCAGCACGAGCCTGTGCTCGCCCTGCCCAACGCAGA
CAGCCAGACCCAGGGCGGCCCTCTGGCGGCTCTGCTCCTCCCGAAGGATGCTTG
GGGAGTGAGGCGAAGCTGGGCGCTCCTCTCCCCTACAGCAGCCCCCTTCCTCCAT
CCCTCTGTTCTCCTGAGCCTTCAGGAGCCTGCACCAGTCCTGCCTGTCCTTCTACT
CAGCTGTTACCCACTCTGGGACCAGCAGTCTTTCTGATAACTGGGAGAGGGCAGT
20 AAGGAGGACTTCCTGGAGGGGGTGACTGTCCAGAGCCTGGAACCTGTGCCACAC
CAGAAGCCATCAGCAGCAAGGACACCATGCGGCTTCCGGGTGCGATGCCAGCTC
TGGCCCTCAAAGGCGAGCTGCTGTTGCTGTCTCTCCTGTTACTTCTGGAACCACA
GATCTCTCAGGGCCTGGTCGTCACACCCCCGGGGCCAGAGCTTGTCTCAATGTC
TCCAGCACCTTCGTTCTGACCTGCTCGGGTTCAGCTCCGGTGGTGTGGGAACGGA
25 TGTCCAGGAGCCCCCACAGGAAATGGCCAAGGCCAGGATGGCACCTTCTCCA
GCGTGCTCACACTGACCAACCTCACTGGGCTAGACACGGGAGAATACTTTGCAC
CCACAATGACTCCCGTGGACTGGAGACCGATGAGCGGAAACGGCTCTACATCTTT
GTGCCAGATCCCACCGTGGGCTTCTCCTAATGATGCCGAGGAACTATTCATCT
TTCTCACGGAAATAACTGAGATCACCATTCATGCCGAGTAACAGACCCACAGCT
30 GGTGGTGACACTGCACGAGAAGAAAGGGGACGTTGCACTGCCTGTCCCCTATGA
TCACCAACGTGGCTTTTCTGGTATCTTTGAGGACAGAAGCTACATCTGAAAACC
ACCATTGGGGACAGGGAGGTGGATTCTGATGCCTACTATGTCTACAGACTCCAGG
TGTCATCCATCAACGTCTCTGTGAACGCAGTGCAGACTGTGGTCCGCCAGGGTGA
GAACATCACCCCTCATGTGCATTGTGATCGGGAATGAGGTGGTCAACTTCGAGTGG
35 ACATACCCCCGCAAAGAAAGTGGGCGGCTGGTGGAGCCGGTGACTGACTTCCTC
TTGGATATGCCTTACCACATCCGCTCCATCCTGCACATCCCCAGTGCCGAGTTAG
AAGACTCGGGGACCTACACCTGCAATGTGACGGAGAGTGTGAATGACCATCAGG
ATGAAAAGGCCATCAACATCACCGTGGTTGAGAGCGGCTACGTGCGGCTCCTGG
GAGAGGTGGGCACACTACAATTTGCTGAGCTGCATCGGAGCCGGACACTGCAGG
40 TAGTGTTGAGAGCCTACCCACCGCCCACTGTCTGTGGTTCAAAGACAACCGCAC
CCTGGGCGACTCCAGCGCTGGCGAAATCGCCCTGTCCACGCGCAACGTGTGCGGA
GACCCGGTATGTGTCAGAGCTGACACTGGTTCGCGTGAAGGTGGCAGAGGCTGG
CCACTACACCATGCGGGCCTTCCATGAGGATGCTGAGGTCCAGCTCTCCTTCCAG
CTACAGATCAATGTCCCTGTCCGAGTGCTGGAGCTAAGTGAGAGCCACCCTGACA
45 GTGGGGAACAGACAGTCCGCTGTCGTGGCCGGGGCATGCCCCAGCCGAACATCA
TCTGGTCTGCCTGCAGAGACCTCAAAGGTGTCCACGTGAGCTGCCGCCACGCT
GCTGGGGAACAGTTCGGAAGAGGAGAGCCAGCTGGAGACTAACGTGACGTAAGT
GGAGGAGGAGCAGGAGTTTGAGGTGGTGAACACTGCGTCTGCAGCACGTGGA
TCGGCCACTGTCGGTGCCTGTCACGCTGCGCAACGCTGTGGGCCAGGACACGCA

GGAGGTCATCGTGGTGCCACACTCCTTGCCCTTTAAGGTGGTGGTGATCTCAGCC
ATCCTGGCCCTGGTGGTGCTCACCATCATCTCCCTTATCATCCTCATCATGCTTTG
GCAGAAGAAGCCACGTTACGAGATCCGATGGAAGGTGATTGAGTCTGTGAGCTC
TGACGGCCATGAGTACATCTACGTGGACCCCATGCAGCTGCCCTATGACTCCACG
5 TGGGAGCTGCCGCGGGACCAGCTTGTGCTGGGACGCACCCTCGGCTCTGGGGCCT
TTGGGCAGGTGGTGGAGGCCACGGCTCATGGCCTGAGCCATTCTCAGGCCACGA
TGAAAGTGGCCGTCAAGATGCTTAAATCCACAGCCCGCAGCAGTGAGAAGCAAG
CCCTTATGTCGGAGCTGAAGATCATGAGTCACCTTGGGCCCCACCTGAACGTGGT
CAACCTGTTGGGGGCCTGCACCAAAGGAGGACCCATCTATATCATCACTGAGTAC
10 TGCCGCTACGGAGACCTGGTGGACTACCTGCACCGCAACAAACACACCTTCCTGC
AGCACCCTCCGACAAGCGCCGCCCGCCAGCGCGGAGCTCTACAGCAATGCTC
TGCCCGTTGGGCTCCCCCTGCCAGCCATGTGTCTTGACCGGGGAGAGCGACGG
TGGCTACATGGACATGAGCAAGGACGAGTCGGTGGACTATGTGCCCATGCTGGA
CATGAAAGGAGACGTCAAATATGCAGACATCGAGTCCTCCAACTACATGGCCCC
15 TTACGATAACTACGTTCCCTCTGCCCTGAGAGGACCTGCCGAGCAACTTTGATC
AACGAGTCTCCAGTGCTAAGCTACATGGACCTCGTGGGCTTCAGCTACCAGGTGG
CCAATGGCATGGAGTTTCTGGCCTCCAAGAACTGCGTCCACAGAGACCTGGCGG
CTAGGAACGTGCTCATCTGTGAAGGCAAGCTGGTCAAGATCTGTGACTTTGGCCT
GGCTCGAGACATCATGCGGGACTCGAATTACATCTCCAAAGGCAGCACCTTTTTG
20 CCTTTAAAGTGGATGGCTCCGGAGAGCATCTTCAACAGCCTCTACACCACCCTGA
GCGACGTGTGGTCCTTCGGGATCCTGCTCTGGGAGATCTTCACCTTGGGTGGCAC
CCCTTACCCAGAGCTGCCCATGAACGAGCAGTTCTACAATGCCATCAAACGGGGT
TACCGCATGGCCCAGCCTGCCCATGCCTCCGACGAGATCTATGAGATCATGCAGA
AGTGCTGGGAAGAGAAGTTTGAGATTGGCCCCCCTTCTCCAGCTGGTGTGCT
25 TCTCGAGAGACTGTTGGGCGAAGGTTACAAAAGAAAGTACCAGCAGGTGGATGA
GGAGTTTCTGAGGAGTGACCACCCAGCCATCCTTCGGTCCCAGGCCCCGCTTGCT
GGGTTCATGGCCTCCGATCTCCCTGGACACCAGCTCCGTCCTCTATACTGCCGT
GCAGCCCAATGAGGGTGACAACGACTATATCATCCCCCTGCCTGACCCCAAACCC
GAGGTTGCTGACGAGGGCCCACTGGAGGGTTCCCCCAGCCTAGCCAGCTCCACC
30 CTGAATGAAGTCAACACCTCCTCAACCATCTCCTGTGACAGCCCCCTGGAGCCCC
AGGACGAACCAGAGCCAGAGCCCCAGCTTGAGCTCCAGGTGGAGCCGGAGCCAG
AGCTGGAACAGTTGCCGATTTCGGGGTGCCCTGCGCCTCGGGCGGAAGCAGAGG
ATAGCTTCCTGTAGGGGGCTGGCCCCCTACCCTGCCCTGCCTGAAGCTCCCCCCT
GCCAGCACCCAGCATCTCTGGCCTGGCCTGACCGGGCTTCTGTGAGCCAGGCT
35 GCCCTTATCAGCTGTCCCCTTCTGGAAGCTTTCTGCTCCTGACGTGTTGTGCCCCA
AACCCTGGGGCTGGCTTAGGAGGCAAGAAAAGTGCAGGGGGCCGTGACCAGCCCT
CTGCCTCCAGGGAGGCCAACTGACTCTGAGCCAGGGTTCCCCCAGGGAAGTCAAG
TTTTCCCATATGTAAGATGGGAAAGTTAGGCTTGATGACCCAGAATCTAGGATTC
TCTCCCTGGCTGACAGGTGGGGAGACCGAATCCCTCCCTGGGAAGATTCTTGGAG
40 TTAGTGAAGTGGTAAATTAACCTTTTTTCTGTTGAGCCAGCTACCCCTCAAGGAATC
ATAGCTCTCTCCTCGCACTTTTTATCCACCCAGGAGCTAGGGAAGAGACCCTAGC
CTCCCTGGCTGCTGGCTGAGCTAGGGCCTAGCCTTGAGCAGTGTTGCCTCATCCA
GAAGAAAGCCAGTCTCCTCCCTATGATGCCAGTCCCTGCGTTCCCTGGCCCCGAGC
TGGTCTGGGGCCATTAGGCAGCCTAATTAATGCTGGAGGCTGAGCCAAGTACAG
45 GACACCCCCAGCCTGCAGCCCTTGCCAGGGCACTTGAGGACACACGCAGCCATA
GCAAGTGCCTGTGTCCCTGTCTTCAGGCCCATCAGTCCTGGGGCTTTTTCTTTAT
CACCCCTCAGTCTTAATCCATCCACCAGAGTCTAGAAGGCCAGACGGGCCCCGCAT
CTGTGATGAGAATGTAAATGTGCCAGTGTGGAGTGGCCACGTGTGTGTGCCAGTA
TATGGCCCTGGCTCTGCATTGGACCTGCTATGAGGCTTTGGAGGAATCCCTCACC

CTCTCTGGGCCTCAGTTTCCCCTTCAAAAAATGAATAAGTCGGACTTATTAACCTCT
GAGTGCCTTGCCAGCACTAACATTCTAGAGTATTCCAGGTGGTTGCACATTTGTC
CAGATGAAGCAAGGCCATATAACCCTAAACTTCCATCCTGGGGGTCAGCTGGGCTC
CTGGGAGATTCCAGATCACACATCACACTCTGGGGACTCAGGAACCATGCCCCTT
5 CCCCAGGCCCCCAGCAAGTCTCAAGAACACAGCTGCACAGGCCTTGACTTAGAG
TGACAGCCGGTGTCTTGAAAGCCCCAAGCAGCTGCCCCAGGGACATGGGAAGA
CCACGGGACCTCTTTCACTACCCACGATGACCTCCGGGGGTATCCTGGGCAAAAG
GGACAAAGAGGGGCAAATGAGATCACCTCCTGCAGCCCACCACTCCAGCACCTGT
GCCGAGGTCTGCGTCGAAGACAGAATGGACAGTGAGGACAGTTATGTCTTGTA
10 AAGACAAGAAGCTTCAGATGGTACCCCAAGAAGGATGTGAGAGGTGGCCGCTTG
GAGTTTGCCCCTCACCCACCAGCTGCCCCATCCCTGAGGCAGCGCTCCATGGGGG
TATGGTTTTGTCACTGCCCAGACCTAGCAGTGACATCTCATTGTCCCCAGCCCAG
TGGGCATTGGAGGTGCCAGGGGAGTCAGGGTTGTAGCCAAGACGCCCCCGCACG
GGGAGGGTTGGGAAGGGGGTGCAGGAAGCTCAACCCCTCTGGGCACCAACCCTG
15 CATTGCAGGTTGGCACCTTACTTCCCTGGGATCCCCAGAGTTGGTCCAAGGAGGG
AGAGTGGGTTCTCAATACGGTACCAAAGATATAATCACCTAGGTTTACAAATATT
TTTAGGACTCACGTAACTCACATTTATACAGCAGAAATGCTATTTTGTATGCTGT
TAAGTTTTTCTATCTGTGTACTTTTTTTTAAGGGAAAGATTTT

20 SEQ ID NO: 29

>2210910T6

ACAAGAGATGGGGAAGGAAAAGGACCAGACTGTACTGTGGCCATGTACACAAA
GGCATGCACCACATCCCAGCTCTGCTGCCCTGGGCTGTCCCACAGGCAGCTCTCT
AGAAGTTGAGAGCCTCAAAAGGGGCCTCATGAAGCCCAGATCTTCCCTGGTCAA
25 GCTGATGGCATTTCGTATAACTGAAAGTTGGGGAAGACCACCAGGTCAAGTGGAGT
GGAGAGGTTTTGTATATGGTCTTCTTTGAAGAACTTACTTCTTGCAAGCCCTGG
CATCTTCCAATTGGCTGTCTAGTAGTGACGTGGCATCAGCCTACCAGCAATGG
NGGTCTACTCACCTTCACTGNGTTTTGTCCCTGAAGTCAGAAAGCCCTGGCACAG
CCAAGTTCACAGGCCAAATCACACTTCAGGCCACACTGCTTCACGCAATGACAC
30 ACGTACAGACGGATATACAGAAACACTTCTCNAGGAGTGCATGAGCATGGTTCA
TTTCATATTTTCNTTCNATCCAGTCTTTAAAANGCAGCACCTTGGTGAAAGCAGTG
GAG

SEQ ID NO: 30

35 >gi|1888315|gb|U09278.1|HSU09278 Human fibroblast activation protein mRNA, complete
cds

AAGAACGCCCCCAAATCTGTTTCTAATTTTACAGAAATCTTTTGAAACTTGGCA
CGGTATTCAAAAGTCCGTGGAAAGAAAAAACCTTGTCTGGCTTCAGCTTCCAA
CTACAAAGACAGACTTGGTCTTTTTCAACGGTTTTTCACAGATCCAGTGACCCACG
40 CTCTGAAGACAGAATTAGCTAACTTTCAAAAACATCTGGAAAAATGAAGACTTG
GGTAAAAATCGTATTTGGAGTTGCCACCTCTGCTGTGCTTGCCTTATTGGTGATGT
GCATTGTCTTACGCCCTTCAAGAGTTCATAACTCTGAAGAAAATACAATGAGAGC
ACTCACACTGAAGGATATTTTAAATGGAACATTTTCTTATAAAACATTTTTTCCAA
ACTGGATTTTCAAGACAAGAATATCTTCATCAATCTGCAGATAACAATATAGTACT
45 TTATAATATTGAAACAGGACAATCATATACCATTTTGAGTAATAGAACCATGAAA
AGTGTGAATGCTTCAAATTACGGCTTATCACCTGATCGGCAATTTGTATATCTAG
AAAGTGATTATTCAAAGCTTTGGAGATACTCTTACACAGCAACATATTACATCTA
TGACCTTAGCAATGGAGAATTTGTAAGAGGAAATGAGCTTCCTCGTCCAATTTCAG
TATTTATGCTGGTCGCCTGTTGGGAGTAAATTAGCATATGTCTATCAAAACAATA

TCTATTTGAAACAAAGACCAGGAGATCCACCTTTTCAAATAACATTTAATGGAAG
 AGAAAATAAAATATTTAATGGAATCCCAGACTGGGTTTATGAAGAGGAAATGCT
 TCCTACAAAATATGCTCTCTGGTGGTCTCCTAATGGAAAATTTTGGCATATGCG
 GAATTTAATGATAAGGATATAACCAGTTATTGCCTATTCCTATTATGGCGATGAAC
 5 AATATCCTAGAACAAATAAAATATTCCATACCCAAAGGCTGGAGCTAAGAATCCCG
 TTGTTCCGATATTTATTATCGATACCACTTACCCTGCGTATGTAGGTCCCCAGGAA
 GTGCCTGTTCCAGCAATGATAGCCTCAAGTGATTATTATTTTCAAGTTGGCTCACGT
 GGGTACTGATGAACGAGTATGTTTGCAGTGGCTAAAAAGAGTCCAGAATGTTTC
 GGTCCTGTCTATATGTGACTTCAGGGAAGACTGGCAGACATGGGATTGTCCAAAG
 10 ACCCAGGAGCATATAGAAGAAAGCAGAACTGGATGGGCTGGTGGATTCTTTGTT
 TCAAGACCAGTTTTCAGCTATGATGCCATTTTCGTACTACAAAATATTTAGTGACA
 AGGATGGCTACAAACATATTCAGTATATCAAAGACACTGTGGAAAATGCTATTCA
 AATTACAAGTGGCAAGTGGGAGGCCATAAATATATTCAGAGTAACACAGGATTC
 ACTGTTTTATTCTAGCAATGAATTTGAAGAATACCCTGGAAGAAGAAACATCTAC
 15 AGAATTAGCATTGGAAGCTATCCTCCAAGCAAGAAGTGTGTTACTTGCCATCTAA
 GGAAAGAAAGGTGCCAATATTACACAGCAAGTTTCAGCGACTACGCCAAGTACT
 ATGCACTTGTCTGCTACGGCCAGGCATCCCCATTTCCACCCTTCATGATGGACG
 CACTGATCAAGAAATTAATAATCCTGGAAGAAAACAAGGAATTGGAAAATGCTTT
 GAAAAATATCCAGCTGCCTAAAGAGGAAATTAAGAACTTGAAGTAGATGAAAT
 20 TACTTTATGGTACAAGATGATTCTTCTCCTCAATTTGACAGATCAAAGAAGTAT
 CCCTTGCTAATTCAAGTGTATGGTGGTCCCTGCAGTCAGAGTGTAAGGTCTGTAT
 TTGCTGTTAATTGGATATCTTATCTTGCAAGTAAGGAAGGGATGGTCATTGCCTT
 GGTGGATGGTCGAGGAACAGCTTTCCAAGGTGACAACTCCTCTATGCAGTGTAT
 CGAAAGCTGGGTGTTTATGAAGTTGAAGACCAGATTACAGCTGTCAGAAAATTC
 25 ATAGAAATGGGTTTCATTGATGAAAAAAGAATAGCCATATGGGGCTGGTCCTAT
 GGAGGATACGTTTCATCACTGGCCCTTGCACTCTGGAAGTGGTCTTTTCAAATGTG
 GTATAGCAGTGGCTCCAGTCTCCAGCTGGGAATATTACGCGTCTGTCTACACAGA
 GAGATTCATGGGTCTCCCAACAAAGGATGATAATCTTGAGCACTATAAGAATTCA
 ACTGTGATGGCAAGAGCAGAATATTTTCAAGAAATGTAGACTATCTTCTCATCCACG
 30 GAACAGCAGATGATAATGTGCACTTTCAAAACTCAGCACAGATTGCTAAAGCTCT
 GGTTAATGCACAAGTGGATTTCCAGGCAATGTGGTACTCTGACCAGAACCACGG
 CTTATCCGGCCTGTCCACGAACCACTTATACACCCACATGACCCACTTCCTAAAG
 CAGTGTCTCTCTTTGTCAGACTAAAAACGATGCAGATGCAAGCCTGTATCAGAAT
 CTGAAAACCTTATATAAAACCCCTCAGACAGTTTGCTTATTTTATTTTATGTGT
 35 AAAATGCTAGTATAAAACAAACAAATTAATGTTGTTCTAAAGGCTGTTAAAAAAA
 AGATGAGGACTCAGAAGTTCAAGCTAAATATTGTTTACATTTTCTGGTACTCTGT
 GAAAGAAGAGAAAAGGGAGTCATGCATTTTGCTTTGGACACAGTGTTTTATCACC
 TGTTTATTTGAAGAAAAATAATAAAGTCAGAAGTTCAAAAAAAAAAAAAAAAAAA
 AAAAAAGCGGCCGCTCG

40

SEQ ID NO: 31

>gi|1874639|gb|AA243828.1|AA243828 zr67a10.r1 Soares_NhMPu_S1 Homo sapiens
 cDNA clone IMAGE:668442 5' similar to TR:G433338 G433338 PROTEIN-TYROSINE
 KINASE PRECURSOR ;

45

AATTTTGTTCACCGAGATCTGGCCACACGAAACTGTTTAGTGGGTAAGAAGTACA
 CAATCAAGATAGCTGACTTTGGAATGAGCAGGAACCTGTACAGTGGTGACTATT
 ACCGGATCCAGGGCCGGGAGTGTCTCCCTATCCGCTGGATGTCTTGGGAGAGTAT
 CTTGCTGGGCAAGTTCACTACAGCAAGTGATGTGTGGGCCTTTGGGGTACTTTG
 TGGGAGACTTTCACCTTTTGTCAAGAACAGCCCTATCCAGCTGTCAGATGAAC

AGGTTATTGAGAATACTGGAGAGTTCTTCCGAGACCAAGGGAGGCAGACTTACC
 TCCCTCAACCAGCCATTTGTCCTGACTCTGTGTATAAGCTGATGCTCAGCTGCTGG
 AGAAGAGATACGAAGAACCGTCCCTCATTTCCAAGAAATCCACCTTCTGCTCCTTC
 AACAAGGCGACGAGTGATGCTGTCAGTGCCTGGCCATGTTCTACGGCTCAGGTC
 5 CTCCCTACAAGACCTACCACTCACCCATGCCTATGCCACTCCATCTGGACATTTA
 ATGAAACTGAGAGACAGAGGCTTGTTTGCTTG

SEQ ID NO: 32

>gi|2189450|gb|AA464566.1|AA464566 zx85d12.s1 Soares ovary tumor NbHOT Homo
 10 sapiens cDNA clone IMAGE:810551 3' similar to TR:G49942 G49942 AM2 RECEPTOR. ;
 TTTTTTTTTTTTTTTTTTTTTTCTCGCTCACATATAAAATGTAATTCCTTCATTTTTTAC
 ATTTATACATCCGGCGGGGCCAGGGAAGGGCTGGCTGGGGAGGGGGCTCACTGAA
 GGACTTCACCGGCAGGTGCAGGAGGCTTTCTGGGGGCAGTCCGACGGGGCAGGG
 CTCATGCCAAGGGGTCCCCTATCTCGTCCTCAGGGCCCCGGCACGGAGTTTCTCG
 15 CTTCTCGTCCGTGCTGGCCAGGGAGTGGGTACTGCATGGCCCCCATGTAGAGTG
 TGGCATAACGCGGTGTTGGTGAAGTTGGTGGGCTTGTGAGGGTCCAGGGCAAAGT
 CAGCGTCCAGTAGGCCTCCACATCATCAGGCTCTCCGCCTTCGTACATCTTGTA
 GGTGGGGTTTCCAATCTCCACGTTTCATGGCCCCGTTGGTCATCCGTTGGTGCTGG
 AACCCTTGAGCCCCTTGACTCGCCGCTTATACCAGAATACCACTCCGGCCACCA
 20 GAACCCAGCAGCAGAGCAACAGCAGAGGGATTAAGAATGGAGGCCATATGTCCC
 GGTTGCTGCTGGCTTAAAACTGCTTCTCAAAACGGGA

SEQ ID NO: 33

>3415853H1
 25 CGACTCCTGCCCCGGCCCTACCCCGAGCTGATCTCCCGTCCCTCGCCCCCGACCAT
 GCGCTGGTTCTTGCCGGAAGTGCCTCCTTCCCGCAGCGCCGTAGAGATCGCTCCC
 ACTCAGGTACAGAGACTGATGAGTGCCGACTGAACCAGAACATCTGTGGCCAC
 GGAGAGTGCGTGCCGGGGCCCCCTGACTACTCCTGCCACTGCAACCCCGGCTACC
 GGTCACATCCCCAGCACCGCTACTGCGTGGATGTGAAC

SEQ ID NO: 34

>gi|2432798|gb|AA599173.1|AA599173 ae46c05.s1 Stratagene lung carcinoma 937218
 Homo sapiens cDNA clone IMAGE:949928 3'
 TTTTACCTATCCCTGGAGCAAGTAATAGGAAGAGAATGGGCAAAGTGGTTGCA
 35 CGAGAGAAAAGAGAATGGAGTTGGGAGCAACACATGAACTTGCGTTATAACATT
 CTGCTGTCCAGATCTGCCCTACTGTGCTGGTGGTCGGTCTGTCCCTCTTCTCATTA
 GCCACTCACAGGAGAGGTGCTTGTGCACTCTGATTCACAGGGGATGAACTCAGG
 ATCTCAAAAAGACATACAAAACTAGAGGTATGTATCACTTAAATAGCTACGAAA
 CTCACACCGTGATCTCCCTTCTGACACACATCTGCGCCATCTCTTCCAACATAAA
 40 ATAAACTGTTTCAATGGTTTGTGTCAGTTATTTTCAAATCACTAAAATGTACAGTCA
 TCCACCAACAATTTAAGAAAGAACCTAAGAGGCAAATCACTGGGGAC

SEQ ID NO: 35

>gi|3171909|emb|AJ001014.1|HSRAMP1 Homo sapiens mRNA encoding RAMP1
 45 CGAGCGGACTCGACTCGGCACCGCTGTGCACCATGGCCCCGGGCCCTGTGCCGCCT
 CCCGCGGCGCGGCCTCTGGCTGCTCCTGGCCCATCACCTCTTCATGACCACTGCC
 TGCCAGGAGGCTAACTACGGTGCCCTCCTCCGGGAGCTCTGCCTACCCAGTTCC
 AGGTAGACATGGAGGCCGTGCGGGAGACGCTGTGGTGTGACTGGGGCAGGACCA
 TCAGGAGCTACAGGGAGCTGGCCGACTGCACCTGGCACATGGCGGAGAAGCTGG

GCTGCTTCTGGCCCAATGCAGAGGTGGACAGGTTCTTCTTGGCAGTGCATGGCCG
CTACTTCAGGAGCTGCCCCATCTCAGGCAGGGCCGTGCGGGACCCGCCCGGCAG
CATCCTCTACCCCTTCATCGTGGTCCCCATCACGGTGACCCTGCTGGTGACGGCA
CTGGTGGTCTGGCAGAGCAAGCGCACTGAGGGCATTGTGTAGGCGGGGCCAGG
5 CTGCCCCGCGGGTGCACCCAGGCTGCAGGGTGAGGCCAGGCAGGCCTGGGTAGGG
GCAGCTTCTGGAGCCTTGGGACAGAGCAGGCCACAATGCCCCCTTCTTCCAGC
CAAGAAGAGCTCACAGGAGTCCAGAGTAGCCGAGGCTCTGGTATTAACCTGGAA
GCCCCCTGGCTGGAGGCCACCGCCACCCTAGGAAGGGGGCAGGGACGTGACCT
TGACTTACCTCTGGAAAGGGTCCCAGCCTAGACTGCTTACCCCATAGCCACATTT
10 GTGGATGAGTGGTTTGTGATTAAAAGGGATGTTCTTG

SEQ ID NO: 36

>gi|1627385|gb|AA085318.1|AA085318 zn12f12.r1 Stratagene hNT neuron (#937233)

Homo sapiens cDNA clone IMAGE:547247 5'

15 ACATTCTGCAATGGCAGCATTCCCACCAACAAAATCCATGTGACCATTCTGCCTC
TCCTCAGGAGAAAGTACCCTCTTTTACCAACTTCCTCTGCCATGTTTTTCCCCTGC
TCCCCTGAGACCACCCCCAAACACAAAACATTCATGTAACCTCTCCAGCCATTGTA
ATTTGAAGATGTGGATCCCTTTAGAACGGTTGCCCCAGTAGAGTTAGCTGATAAG
GGAACTTTATTTAAATGNATGTCTTAAAT

20

SEQ ID NO: 37

>gi|2156363|gb|AA443688.1|AA443688 zw86d05.s1 Soares_total_fetus_Nb2HF8_9w Homo
sapiens cDNA clone IMAGE:783849 3'

25 TTTTCAAAGTTACAATAGTTTAATAATTTAAATAGGACCAACTTCAGGAACATAC
ATACTCATACATAAAAATTAAACAATTTAATTTTGAACAGTGTATTGAAATACATC
AAATTCTTAAAAATCCCCCAAATGGACTCAAGATCATGGATATGAAAAGGTAAT
TTTGAAGTACTAAAGACTAGAGTAAAACAGACAAAGTCATTACTTTGCATTTACT
AATAAGACAACAGCCTGTGGATACATTAGACCTTTATAAGAACACTTCTAGGAA
ATGTTAGAACAAACGAGTCATTAAAAAGGAATATAAATGAGTTCATAAAGATAAA
30 TGTATAGCTGACAATTTCTTTGGTCCTCGAAGTCACACTTGTTTTTACTTTAAAT
GCCAAACATGAGTTGAGTGCT

SEQ ID NO: 38

>29 BLOOD 441249.1 AF086432 g3483777 Human full length insert cDNA clone

35 ZD79H11.0

GGCAGGAGAATTTGAAAGGGTGCCCCAAAGGACAATCTCTAAAGGGGTAAGGG
AGATACCTACCTTGTCTGGTAGGGGAGATGTTTCGTTTTTCATGCTTTACCAGAAA
ATCCACTTCCCTGCCGACCTTAGTTTCAAAGCTTATTCTTAATTAGAGACAAGAA
ACCTGTTTCAACTTGAAGACACCGTATGAGGTGAATGGACAGCCAGCCACCACA
40 ATGAAAGAAATCAAACCAGGAATAACCTATGCTGAACCCACGCCTCAATCGTCC
CCAAGTGTTTCCTGACACGCATCTTTGCTTACAGTGCATCACAACTGAAGAATGG
GGTTCAACTTGACGCTTGCAAAATTACCAAATAACGAGCTGCACGGCCAAGAGA
GTCACAATTCAGGCAACAGGAGCGACGGGCCAGGAAAGAACACCACCCTTCACA
ATGAATTTGACACAATTGTCTTGCCAGTGCTTTATCTCATTATATTTGTGGCAAGC
45 ATCTTGCTGAATGGTTTAGCAGTGTGGATCTTCTTCCACATTAGGAATAAAACCA
GCTTCATATTCTATCTCAAAAACATAGTGGTTGCAGACCTCATAATGACGCTGAC
ATTTCCATTTCGAATAGTCCATGATGCAGGATTTGGACCTTGGTACTTCAAGTTTA
TTCTCTGCAGATACACTTCAGTTTTGTTTTATGCAAACATGTATACTTCCATCGTG
TTCCTTGGGCTGATAAGCATTGATCGCTATCTGAAGGTGGTCAAGCCATTTGGGG

ACTCTCGGATGTACAGCATAACCTTCACGAAGGTTTTATCTGTTTGTGTTTGGGTG
 ATCATGGCTGTTTTGTCTTTGCCAAACATCATCCTGACAAATGGTCAGCCAAACAG
 AGGACAATATCCATGACTGCTCAAAACTTAAAAGTCCTTTGGGGGTCAAATGGC
 ATACGGCAGTCACCTATGTGAACAGCTGCTTGTGTTGTGGCCGTGCTGGTGATTCT
 5 GATCGGATGTTACATAGCCATATCCAGGTACATCCACAAATCCAGCAGGCAATTC
 ATAAGTCAGTCAAGCCGAAAGCGAAAACATAACCAGAGCATCAGGGTTGTTGTG
 GCTGTGTTTTTTACCTGCTTTCTACCATATCACTTGTGCAGAATTCCTTTTACTTTT
 AGTCACTTAGACAGGCTTTTAGATGAATCTGCACAAAAAATCCTATATTACTGCA
 AAGAAATTACACTTTTCTTGTCTGCGTGTAATGTTTGCCTGGATCCAATAATTTAC
 10 TTTTTCATGTGTAGGTCATTTTCAAGAAGGCTGTTCAAAAAATCAAATATCAGAA
 CCAGGAGTGAAAGCATCAGATCACTGCAAAGTGTGAGAAGATCGGAAGTTCGCA
 TATATTATGATTACACTGATGTGTAGGCCTTTTATTGTTTGTGGAATCGATATGT
 ACAAAGTGTAAAAAAATGTTTCTTTCATTAAAAAATAAAAAAAAAAAAAAAG

15 SEQ ID NO: 39

>2601724H1

CTCGCAGGTCTCAACATATGCACTAGTGGAAGTGCCACCTCATGTGAAGAATGTC
 TGCTAATCCACCCAAAATGTGCCTGGTGCTCCAAAGAGGACTTCGGAAGCCAC
 GGTCCATCACCTCTCGGTGTGATCTGAGGGCAAACCTTGTCAAAAATGGCTGTGG
 20 AGGTGAGATAGAGAGCCAGCCAGCAGCTTCCATGTCCTGAGGAGCCTGCCCT
 CAGCAGCAAGGGTTCGGGCTCTGCAGGCTGGGACGTCATTCAGATGACACCACA
 GGAGATTGCCGTGA

SEQ ID NO: 40

25 >3248833H1

GGCGAGCGGACTCGACTCGGCACCGCTGTGCACCATGGCCCGGGCCCTGTGCCG
 CCTCCCGCGGCGGGCCTCTGGCTGCTCCTGGCCCATCACCTCTTCATGACCACTG
 CCTGCCAGGAGGCTAACTACGGTGCCCTCCTCCGGGAGCTCTGCCTCACCCAGTT
 CCAGGTAGACATGGAGGCCGTGCGGGGAGACGCTGTGGTGTGACTGGGGCAGGAC
 30 CATCAGGAGCTACAGGGAGCTGGCCGACTGCACCTGGCACATGGCGGAGAAGCT
 GGGCTGCTTCTGGCCCAATGCAGAGGTGGACAGGTTCTTCCTGGCA

SEQ ID NO: 41

>gi|2253586|gb|U37791.1|HSU37791 Homo sapiens clone rasi-1 matrix metalloproteinase

35 RASI-1 mRNA, complete cds

CCTAGCACTGCTCCCCAAGGCTCCCAGAAATCTCAGGTCAGAGGCACGGACAG
 CCTCTGGAGCTCTCGTCTGGTGGGACCATGAACTGCCAGCAGCTGTGGCTGGGCT
 TCCTACTCCCATGACAGTCTCAGGCCGGGTCTGGGGCTTGCAAGAGGTGGCGCC
 CGTGGACTACCTGTCACAATATGGGTACCTACAGAAGCCTCTAGAAGGATCTAAT
 40 AACTTCAAGCCAGAAGATATCACCGAGGCTCTGAGAGCTTTTCAGGAAGCATCT
 GAACTTCCAGTCTCAGGTCAGCTGGATGATGCCACAAGGGCCCGCATGAGGCAG
 CCTCGTTGTGGCCTAGAGGATCCCTTCAACCAGAAGACCCTTAAATACCTGTTGC
 TGGGCCGCTGGAGAAAGAAGCACCTGACTTTCCGCATCTTGAACCTGCCCTCCAC
 CCTTCCACCCACACAGCCCGGGCAGCCCTGCGTCAAGCCTTCCAGGACTGGAGC
 45 AATGTGGCTCCCTTGACCTTCCAAGAGGTGCAGGCTGGTGC GGCTGACATCCGCC
 TCTCCTTCCATGGCCGCCAAAGCTCGTACTGTTCCAATACTTTTGATGGGCCTGGG
 AGAGTCCTGGCCCATGCCGACATCCCAGAGCTGGGCAGTGTGCACTTCGACGAA
 GACGAGTTCTGGACTGAGGGGACCTACCGTGGGGTGAACCTGCGCATCATTGCA
 GCCCATGAAGTGGGCCATGCTCTGGGGCTTGGGCACTCCCGATATTCCCAGGCCC

TCATGGCCCCAGTCTACGAGGGCTACCGGCCCCACTTTAAGCTGCACCCAGATGA
TGTGGCAGGGATCCAGGCTCTCTATGGCAAGAAGAGTCCAGTGATAAGGGATGA
GGAAGAAGAAGAGACAGAGCTGCCCACTGTGCCCCAGTGCCACAGAACCCAG
TCCCATGCCAGACCCTTGCAGTAGTGAAGTGGATGCCATGATGCTGGGGCCCCGT
5 GGAAGACCTATGCTTTC AAGGGGGACTATGTGTGGACTGTATCAGATT CAGGA
CCGGGCCCCCTTGTTCAGAGTGTCTGCCCTTTGGGAGGGGGCTCCCCGAAACCTGG
ATGCTGCTGTCTACTCGCCTCGAACACAATGGATTCACTTCTTTAAGGGAGACAA
GGTGTGGCGCTACATTAATTTCAAGATGTCTCCTGGCTTCCCCAAGAAGCTGAAT
AGGGTAGAACCTAACCTGGATGCAGCTCTCTATTGGCCTCTCAACCAAAAGGTGT
10 TCCTCTTTAAGGGCTCCGGGTACTGGCAGTGGGACGAGCTAGCCCGAAGTACTGACTT
CAGCAGCTACCCCAAACCAATCAAGGGTTTGTTTACGGGAGTGCCAAACCAGCC
CTCGGCTGCTATGAGTTGGCAAGATGGCCGAGTCTACTTCTTCAAGGGCAAAGTC
TACTGGCGCCTCAACCAGCAGCTTCGAGTAGAGAAAGGCTATCCCAGAAATATTT
CCCACAACCTGGATGCACTGTCTGTCCTCCCGGACTATAGACACTACCCCATCAGGTGG
15 GAATACCACTCCCTCAGGTACGGGCATAACCTTGGATACCACTCTCTCAGCCACA
GAAACCACGTTTGAATACTGACTGCTCACCACAGACACAATCTTGGACATTAAC
CCCTGAGGCTCCACCACCCACCCTTTTCACTTCCCCCCCCAGAAGCCTAAGGCCTAA
TAGCTGAATGAAATACCTGTCTGCTCAGTAGAACCTTGCAGGTGCTGTAGCAGGC
GCAAGACCGTAGATCTCAGGCCTCTAACACTTCCAACCTCCAGCCACCCTTTCTCT
20 GTGCATTTTCACTCCTGAGAAGTGCTCCCCTAACTCAGATCCCCTAACTTAGATTT
GGCCCCCAACTCCATTTCTGTCTGTCTTAGACAGCCCTTCCAACCTGTGTCATCTC
TTCTCTGGAGGTCAATGGTGGAGGGAGATGCCTGGGTCTGTCTTCTTCTACATAA
AATGCAAGAAAACAGCATGGCCAGTAACTGAGCAAGGGCCTTGGGAATCCTTGA
GAATCACATTTATGTGCTTATGATTACGGGCAAGCTAATTAACCTTGTGTAATCT
25 CAGATTCCCCATTTGCAACATTAGGTTAAGACCAGTACTGCAGGATTGTTGCACT
AAATGAAATACTGTATGTGAAGTGCCTGGCACAGTGTCTGGTACATTTGTGTTTA
ATAAAAGCTAACTCCATGTTTACATAAGAGAGGACTGAACAGCTCTTCTCTAGCTG
TCTGGCTGTATAACTCTTACAGTAGTCTGTATAATAAGGGCATCTCTATTAGATCT
TTAGGGGACAGAGGATTTGTCAAGATGGTTAGCTCTTTGTTTTGGGGTGCAGAGA
30 AAGAAAAGAGCAGCAACAGCAGAGGCTGGACTCCCTGGTTCAGTATTTAATGCC
ATTTTATTACATGCTCCCATGTTCTCCCTCCCTCCCATTTGTAGCCTTGCTGCCCA
GGGGAGGGATATGTCTTCTTTATGCATCTGGGAAACCAGGAACAGACCCTGCG
CAGGAGAGTCAGAGGGGGAAGAGTTAGAATGGGTGAGTGGCTGGAACAAAGTT
CTGGTFAAGGAGGAAATTAAGTGCCACCCACGGTGAGAAGCAGAGAAGGCACTTG
35 CATCCTATGCAGCCCTGAAGACCAGGCTCCTTTGGGCAAAAGGCAAGACTCTGG
CAGGTGGGTCAATGCTCTCTCCTTGGAGCAAGAAGCCAGCTTTTGGGGAAGGCA
GGTCCTGAGGCAGGCACTGCCCTGTGGTCTTCCCCAGGTTGAGGAGAGAAAGTGG
AAGCCCCATGGAAGACAGTGTCTCCAGCTGAGGTAGGAGGCGGAGGTGGGGGTG
GGGGTAGTTTAAGCCTATGGGGCCAGGGGGAAGGCCAAACAGAAACCCAACCT
40 ACCCCCTAATGAAGGGCCTGGAGGTTGGGGTATCTTGGAGCTCCTCAGAGCCCTT
CTTCCCATCAAAAAGGTATCAAAATGCCTTGAAGCTCCCTGATCCTACAAAACAA
AAAAATGCTTATTTTTACCACTGTGAGGCAAGCTGAGGTGAACATTTAAAGGCT
ATTTCAAGACGAGGTGCGGTGGCTATAATCCTAGCACTTTGGGAGGCTGAAGCA
GGAGGATCACTTGAGCCCAGGAGTTCAAGACCAGCTTGGGCAACATAGGGAGAC
45 CCTGTCTCTGCAAAAAAATAAAAAACGAATACATAAAAAATTAAAAA

SEQ ID NO: 42

>gi|1923242|gb|U83410.1|HSU83410 Human CUL-2 (cul-2) mRNA, complete cds

1
GCGAGCTGACAGCCGCCGCCGCCGCCGCCCTCCGCCACCTTCCTCGCCGGGGCTT
CGTCTTTTACTCCTTCGGGGTGCCTCCCCCTCCCCCTTGCCCCCTGCCCTTGCCCTG
CTTCTGCAGAAGATTTCAACACTACACTTGCACAATGTCTTTGAAACCAAGAGTA
GTAGATTTTGTATGAAACATGGAACAAACTTTTGACGACAATAAAAAGCCGTGGTC
5 ATGTTGGAATACGTCGAAAGAGCAACATGGAATGACCGTTTCTCAGATATCTATG
CTTTATGTGTGGCCTATCCTGAACCCCTTGGAGAAAGACTTTATACAGAACTAA
GATTTTTTTGGAAAATCATGTTTCGGCATTTCGATAAGAGAGTTTTGGAGTCAGAA
GAACAAGTACTTGTTATGTATCATAGGTACTGGGAAGAATACAGCAAGGGTGCA
GACTATATGGACTGCTTATATAGGTATCTCAGCACCCAGTTTATTA AAAAGAATA
10 AATTAACAGAAGCGGACCTTCAGTATGGCTATGGTGGTGTAGATATGAATGAAC
CACTTATGGAAATAGGAGAGCTAGCATTGGATATGTGGAGGAAATTGATGGTTG
AACCCTTCAGGCCATCCTTATCCGAATGCTGCTCCGAGAAATCAAAAATGATCG
TGGTGGAGAAGACCCAAACCAGAAAGTAATCCATGGGGTTATTAACCTCTTTGTT
CATGTTGAACAGTATAAGAAAAAATTCCCCTTAAAGTTTTATCAGGAAATTTTTG
15 AGTCTCCCTTTTCTGACTGAAACAGGAGAGTATTACAAACAAGAAGCTTCAAATTT
ATTACAAGAATCAAACCTGCTCACAGTATATGGAAAAGGTTTTAGGTAGATTAAA
AGATGAAGAAATTCGATGTCGAAAATACCTACATCCAAGTTCATATACTAAGGT
GATTCATGAATGTCAACAACGAATGGTAGCAGACCACTTACAGTTTTTACATGCA
GAATGTCATAATATAATTCGACAAGAGAAAAAAATGACATGGCAAATATGTAC
20 GTCTTACTCCGTGCTGTGTCCACTGGTTTACCTCATATGATTGAGGAGCTGCAAA
ACCACATCCATGATGAGGGCCTTCGAGCAACCAGCAACCTTACTCAGGAAAAACA
TGCCAACACTATTTGTGGAGTCAGTTTTTGAAAGTGCATGGTAAATTTGTTGAGCT
TATCAACACTGTTTTGAATGGTGATCAGCATTTTATGAGTGCGTTGGATAAGGCC
CTTACGTCAGTTGTAAATTACAGAGAACCTAAGTCTGTTTGCAAAGCACCTGAAC
25 TGCTTGCTAAGTACTGTGACAACTTACTGAAGAAGTCAGCGAAAGGGATGACAG
AGAATGAAGTGGAAGACAGGCTTACGAGCTTCATCACAGTGTTCAAATACATTG
ATGACAAGGACGTCTTTCAAAGTTCTACGCAAGAATGCTGGCAAAACGTTTAAT
TCATGGGTTATCCATGTCTATGGACTCTGAAGAAGCCATGATCAACAAATTAAG
CAAGCCTGTGGTTATGAGTTTACCAGCAAGCTACATCGGATGTATACAGATATGA
30 GTGTCAGCGCTGATCTCAACAATAAGTTCAACAATTTTATCAAAAACCAAGACAC
AGTAATAGATTTGGGAATTAGTTTTCAAATATATGTTCTACAGGCTGGTGCGTGG
CCTCTTACTCAGGCTCCTTCATCTACGTTTGCAATTTCCCAGGAATTAGAAAAAA
GTGTACAGATGTTTGAATTATTTATAGCCAACATTTGAGTGAAGGAACTTAC
ATGGTTACATTATCTGTGTACAGGTGAAGTTAAATGAAGTATTTGGGCAAACCA
35 TATGTAGCCATGGTTACAACATAACCAATGGCAGTTCTTCTTGCCCTTTAACAACA
GTGAAACTGTCAGTTATAAAGAGCTTCAGGACAGCACTCAGATGAATGAAAAGG
AACTGACAAAAACAATCAAATCATTACTTGATGTGAAAATGATTAACCATGATTC
AGAAAAGGAAGATATTGATGCAGAATCTTCGTTTTTCATTAAATATGAACTTTAGC
AGTAAAAGAACAAAATTTAAAATTACTACATCAATGCAGAAAGACACACCACAA
40 GAAATGGAGCAGACTAGAAGTGCAGTTGATGAGGACCGGAAAATGTATCTCCAA
GCTGCTATAGTTCGTATCATGAAAGCACGAAAAGTGCTTCGGCACAATGCCCTTA
TTCAAGAGGTGATTAGCCAGTCAAGAGCTAGGTTTAATCCCAGTATCAGCATGAT
TAAGAAGTGTATTGAAGTTCTGATAGACAAACAATACATAGAACGCAGCCAGGC
GTCGGCAGATGAATACAGCTACGTCGCGTGATGTCGCTCTCCTCCAGCGTGGTGT
45 GAGAAGATCATTGCCATCACCATTTGGTGTGTTCTGTGGGAAAAAGCAGGACTG
TGCCTCCATAATTTGGTCATTTGGCAGCCCCTGTTTTCTGCTGTTTACAACATCAC
CAGTGCCACGTCATGAGCGTCAAAGAAAAATGCCTAGAGATATTTCAAGCTCATG
ACATTATGACATTTCTTAAACCTTTATTA AAAAGAAATGAGTGAAGTATTGCTGAAA
AGTGGA AAATCGGTTGGGTACCATGCTTTTTCTCCCTTCACGTTTGCAGTTGATG

TGTCCTTTTTTTTTTTTTTTAATGTATCTTAAAGGACATAAAATTTAAAAACTTAAA
TATTGTAATATGACAGATAACCTAATAATTGTATCTACATTAAAATGACAAACAT
GATACTGCTGCTTGTCAAATAAAAAAAAAAAAAAAAAA

5 SEQ ID NO: 43

>gi|1337927|gb|W49672.1|W49672.zc41f07.s1 Soares_senescent_fibroblasts_NbHSF Homo sapiens cDNA clone IMAGE:324901 3'

TTTTTTTTTTTTTATATTTATATTTATATTTATATATATGTATATATATATATATGTN
ATGTACAAAAGACTTTGAGATATCAGGCACCATTAACCACATTTCCCCCCTTAT
10 AAATGCAACTGTTCAAGTACACTGGGAACAGTTTTAAGGTACACCTGCAGTACA
NTAGGAGAAGCATGAGTGGATAATCTAAACACAGGATCATAACAGTGATACGCT
GCAACACCTCTGTGAATTCCATTANCCAAGTTCTGTCATTAAAACATNGGAAAAC
TACTGGCTCCTCAAATAAAAAGGTTTTAGGNAACCAAAAATCCCCTAAGTAGTG
AACTGTTTTCCAAGCAGAGCTCCCTAATGGTTTTCAATTTCTGCGCCTACAACC
15 AAANGGGGACCCAGTTGGAAGCTGCCGTTTGGGAAACGTGGGCCAGGCATCAG
ATCANCAACACGGGGGGGAATCCNGAGAGGGGCNCATTNTTGAAGAAGGNG

SEQ ID NO: 44

>3486371H1

20 TTTCTCCAGCTTTGCCCTGTGGGTGATGCTCTAACAGTGACCTGGAATTTTCGTC
CTCTAGACGGGGGACCTGAGCAGTTTGTATTCTACTACCACATAGATCCCTTCCA
ACCCATGAGTGGGCGGTTTAAGGACCGGGTGTCTTGGGATGGGAATCCTGAGCG
GTACGATGCCTCCATCCTTCTCTGGAACTGCAGTTCGACGACAATGGGACATAC
ACCTGCCAGGTGAAGAACCCACCTGATGTT

25

SEQ ID NO: 45

>gi|595923|gb|U16811.1|HSU16811 Human Bak mRNA, complete cds

GAGGATCTACAGGGGACAAGTAAAGGCTACATCCAGATGCCGGGAATGCACTGA
CGCCCATTCCTGGAAACTGGGCTCCCACTCAGCCCCTGGGAGCAGCAGCCGCCA
30 GCCCTCGGACCTCCATCTCCACCCTGCTGAGCCACCCGGGTTGGGCCAGGATCC
CGGCAGGCTGATCCCGTCTCCACTGAGACCTGAAAAATGGCTTCGGGGCAAGG
CCCAGGTCCTCCAGGCAGGAGTGCGGAGAGCCTGCCCTGCCCTCTGCTTCTGAG
GAGCAGGTAGCCCAGGACACAGAGGAGGTTTTCCGCAGCTACGTTTTTTACCGCC
ATCAGCAGGAACAGGAGGCTGAAGGGGTGGCTGCCCTGCCGACCCAGAGATGG
35 TCACCTTACCTCTGCAACCTAGCAGCACCATGGGGCAGGTGGGACGGCAGCTCG
CCATCATCGGGGACGACATCAACCGACGCTATGACTCAGAGTTCCAGACCATGTT
GCAGCACCTGCAGCCCACGGCAGAGAATGCCTATGAGTACTTCACCAAGATTGC
CACCAGCCTGTTTGAGAGTGGCATCAATTGGGGCCGTGTGGTGGCTCTTCTGGGC
TTCGGCTACCGTCTGGCCCTACACGTCTACCAGCATGGCCTGACTGGCTTCCTAG
40 GCCAGGTGACCCGCTTCGTGGTCGACTTCATGCTGCATCACTGCATTGCCCGGTG
GATTGCACAGAGGGGTGGCTGGGTGGCAGCCCTGAACTTGGGCAATGGTCCCAT
CCTGAACGTGCTGGTGGTTCTGGGTGTGGTTCTGTTGGGCCAGTTTGTGGTACGA
AGATTCTTCAAATCATGACTCCCAAGGGTGCCCTTTGGGTCCCGGTTTCAGACCCC
TGCCCTGGACTTAAGCGAAGTCTTTGCCTTCTCTGTTCCCTTGCAAGGTCCCCCTC
45 AAGAGTACAGAAGCTTTAGCAAGTGTGCACTCCAGCTTCGGAGGCCCTGCGTGG
GGGCCAGTCAGGCTGCAGAGGCACCTCAACATTGCATGGTGCTAGTGCCCTCTCT
CTGGGCCCAGGGCTGTGGCCGTCTCTCCCTCAGCTCTCTGGGACCTCCTTAGCC
CTGTCTGCTAGGCGCTGGGGAGACTGATAACTTGGGGAGGCAAGAGACTGGGAG
CCACTTCTCCCCAGAAAGTGTTTAACGGTTTTAGCTTTTATAATACCCTTGTGAG

AGCCCATTTCCACCATTTCTACCTGAGGCCAGGACGTCTGGGGTGTGGGGATTGGT
GGGTCTATGTTCCCCAGGATTCTAGCTATTCTGGAAGATCAGCACCTAAGAGATG
GGACTAGGACCTGAGCCTGGTCCTGGCCGTCCCTAAGCATGTGTCCCAGGAGCA
GGACCTACTAGGAGAGGGGGGCCAAGGTCCTGCTCAACTCTACCCCTGCTCCCAT
5 TCCTCCCTCCGGCCATACTGCCTTTGCAGTTGGACTCTCAGGGATTCTGGGGCTTGG
GGTGTGGGGTGGGGTGGAGTCGCAGACCAGAGCTGTCTGAACTCACGTGTCAGA
AGCCTCCAAGCCTGCCTCCCAAGGTCCTCTCAGTTCTCTCCCTTCTCTCTCTTA
TAGACACTTGCTCCCAACCCATTCACTACAGGTGAAGGCTCTCACCCATCCCTGG
GGGCCCTGGGTGAGTGGCCTGCTAAGGCTCCTCCTTGCCCAGACTACAGGGCTTA
10 GGACTTGGTTTGTATATCAGGGAAAAGGAGTAGGGAGTTCATCTGGAGGGTTCT
AAGTGGGAGAAGGACTATCAACACCACTAGGAATCCCAGAGGTGGATCCTCCCT
CATGGCTCTGGCACAGTGTAAATCCAGGGGTGTAGATGGGGGAACTGTGAATACT
TGAAGTCTGTTCCCCCACCTCCATGCTCCTCACCTGTCTAGGTCTCCTCAGGGTG
GGGGGTGACAGTGCCTTCTCTATTGGCACAGCCTAGGGTCTTGGGGGTGAGGGG
15 GGAGAAGTTCTTGATTCAGCCAAATGCAGGGAGGGGAGGCAGATGGAGCCCAT
GGCCACCCCTATCCTCTGAGTGTTTGAAATAAACTGTGCAATCCCCTCAAAAA
AAAAACGGAGATCC

SEQ ID NO: 46

20 >gi|1940946|gb|AA293050.1|AA293050 zt54d02.r1 Soares ovary tumor NbHOT Homo
sapiens cDNA clone IMAGE:726147 5'
GGTGCTGTTTAAAGTCACATCCCTGTAAATTGCAGAATTCAAAAGTGATTATCTC
TTTGATCTACTTGCCTCATTTCCCTATCTTCTCCCCACGGTATCCTAACTTTAG
ACTTCCCACTGTTCTGAAAGGAGACATTGCTCTATGTCTGCCTTCGACCACAGCA
25 AGCCATCATCCTCCATTGCTCCCGGGGACTCAAGAGGAATCTGTTTCTCTGCTGT
CAACTTCCCATCTGGCTCAGCATAGGGTCACTTTGCCATTATGCAAATGGAGATA
AAAGCAATTCTGACTGTCCAGGAGCTAATCTGACCGTTCTATTGTGTGGATGACC
ACATAAGAAGGCAATTTTAGTGTATTAATCATAGATTATTATAAACTATAAACTT
AAGGGCAAGGAGTTTATTACAATGTATCTTTATTAAACAAAAGGGTGTATAGTG
30 TTCACAAACTGTGAAAATAGTGT

SEQ ID NO: 47

>gi|757037|gb|R06417.1|R06417 yf09a05.s1 Soares fetal liver spleen 1NFLS Homo sapiens
cDNA clone IMAGE:126320 3' similar to gb:M23410 PLAKOGLOBIN (HUMAN);
35 TTTTCAACGCATCTGTGTTATTTTATTTCTTTGCTTTGGTCTATACAAAAAAC
CAATAACCAAAAACATAAAGCGATAATAATAAAACACTCTGCTTGGACCTCCCC
CAGCCCCCACACCATGTGCGGGAAATGGGGGGTCTGAAACAGGAAGGGGAA
GAGAAAGCCCCCTCACACACACAGAGGGGTGAGCCAAGAGCACTTNTCGGGGT
CAGCTAGGGGCAGCTGTGTGGGGTGGGGACAGGGGTTTGAGGGAAGCTNTCCCC
40 AGAGCTCCCTGGGGNAGTTGAGGGGGTGGGGCAAAGCCAACCTAAGGCACCCTG
GGGAGAGAGAA

SEQ ID NO: 48

>1321982H1
45 CCGGCCTTGAACAACCTGTGGAACCTGAGGCCGCTTGCCCTCCCGCCCCATGGAG
CGGCCCCCGGGGCTGCGGCCGGGCGCGGGCGGGCCCTGGGAGATGCGGGAGCG
GCTGGGCACCGGCGGCTTCGGGAACGTCTGTCTGTACCAGCATCGGGAACCTTGAT
CTCAAAATAGCAATTAAGTCTTGTCGCCTAGAGCTAAGTACCAAAAACAGAGAA
CGATGGT

SEQ ID NO: 49

>gi|2215504|gb|AA488073.1|AA488073 ab13d08.s1 Stratagene lung (#937210) Homo sapiens cDNA clone IMAGE:840687 3' similar to gb:J05582 MUCIN 1 PRECURSOR

5 (HUMAN);G TTCAGGATCCCCGCTATCTCAGGGCTCTCTGGGCCAGTCCTCCTGGG
AGCCCCACCACAACACTTCCAGGCATGAGCTCTCAGGCGCCACATGAGCTTCC
ACACACTGAGAAAGTGTCCGAGAAATTGGTGGGGCCTCTGAAGGACGTGTGAGCA
GCCACCTGAACTCCCAGCTCACCAGCCCAAACAGGGTGCAGGGGCTCTGGCCTG
AAGAACCTGAGTGGAGTGGAATGGCACTGGCTGGCCACTCAGCTCAGCGGGCGA
10 CGTGCCCCTACAAGTTGGCAGAAAGTGGCTGCCACTGCTGGGTTTGTGTAAGAGAG
GCTGCTGCACCATTACCTGCAGAAACCTTCTCATAGGGGCTACGATCGGTACTGC
TAGGGGGCACATAGCGGCCATGGGTGTGGTAGGTGGGGTACTCGCTCATAGGAT
GGTAAGTATCCCGGGCTGGAAAGATGTCCAGCTGCCCCGTAATTCTTTCCGCGGCA
CTTACAGACAGGCAAGGCAATGAGATAGACAATGGCCAGCGCACCAAGGACAAA
15 GACCAGCACCAACAGCGCATGGCCCCAGCCTGGACC

SEQ ID NO: 50

>gi|32468|emb|X63368.1|HSHSJ1MR H.sapiens HSJ1 mRNA

20 CCCGCCTGACGACTGACCAGTTGCCATGGCATCCTACTACGAGATCCTAGACGTG
CCGCGAAGTGCGTCCGCTGATGACATCAAGAAGGCGTATCGGCGCAAGGCTCTC
CAGTGGCACCCAGACAAAAACCCAGATAATAAAGAGTTTGCTGAGAAGAAATTT
AAGGAGGTGGCCGAGGCATATGAAGTGCTGTCTGACAAGCACAAAGCGGGAGATT
TACGACCGCTATGGCCGGGAAGGGCTGACAGGGACAGGAAGTGGCCCATCTCGG
GCAGAAGCTGGCAGTGGTGGGCCTGGCTTCACCTTCACCTTCGCGAGCCCCGAGG
25 AGGTCTTCCGGGAATTCTTTGGGAGTGGAGACCCTTTTGCAGAGCTCTTTGATGA
CCTGGGCCCCCTTCTCAGAGCTTCAGAACCGGGGTTCCCGACACTCAGGCCCTTC
TTTACCTTCTCTTCTCCTTCCCTGGGCACTCCGATTTCTCCTCCTCATCTTTCTCC
TTCAGTCCTGGGGCTGGTGCTTTTCGCTCTGTTTCTACATCTACCACCTTTGTCCA
AGGACGCCGCATCACACACGCAGAATCATGGAGAACGGGCAGGAGCGGGTGG
30 AAGTGGAGGAGGATGGGCAGCTGAAGTCAGTCACAATCAATGGTGTCCCAGATG
ACCTGGCACGTGGCTTGGAGCTGAGCCGTCGCGAGCAGCAGCCGTCAGTCACTTC
CAGGTCTGGGGGCACTCAGGTCCAGCAGACCCCTGCCTCATGCCCTTGGACAGC
GACCTCTCTGAGGATGAGGACCTGCAGCTGGCCATGGCCTACAGCCTGTCAGAG
ATGGAGGCAGCTGGGAAGAAACCCGCAGGTGGGCGGGAGGCACAGCACCGACG
35 GCAGGGGCGCCCAAGGCCCAGCACCAAGATCCAGGCTTGGGGGGGACCCAGGA
GGGTGCGAGGGGTGAAGCAACCAACGCAGTCCATCCCCAGAGGAGAAGGCCTC
TCGCTGCCTCATCCTCTGAACACCGGGCCCAACCTGATCTGATCCAGATCTTGAC
TGGGGGGTCTGACTCACTGTGGGAAGAGAAGAGGGGAGTATCCTGAGTTGTAGG
AACTGCTTTCCAACCTCCAAGCTCCCTCCACAAGTTTCCCTCCCCAGGCCCCAC
40 ACCCCAGTGTGGACTTGGGATTTGCTGTGCTCAGCCCAGGGCTGATAGGTCCCTG
GTGAAGCCCAGGGTGGGGGGTGTGAGGGCAGTGGAGGGGCCCAGGAGCCAGG
TTGCATTTATTGGATGGGGAGCTCCAAGGGGCATTAGTGGTTTGGGCTGGGCTTT
TGTGCCCTGGTACTCTGCCACCTGTGTTGCTGATGGTGTCAAGGAAGGAGGACTT
GGCCTAGGGTTGTCTGAGCCGGAGCCGGCAGCTCCACTGGAGAGCAGTGCAGGC
45 AGAGTGGAGCCTCCTGCTCTCCTGGACCAGCTGCAGACCCCCAACCTGGTTTCT
GTGCCATGTTGCGCTCTGACCGTCTCTGTTGCTTCTTCTGGTGTGCTTCTCCTC
CCTCCCATTCTCTCTGCAACTCCTGCGGGCGCATCGCTTGCTTTCAGTGCCTGCTG
GCTAGGACTCCCTTCTTCTCCTTCCCCGAGAAGGCCTCAATGTGGCGAGGAAG
ATGCTGGGGCCGGTAGGGCTGTGAGATCTTCTGGGGAGGCTAGCCGGGTGGGGC

GGGAGCCTCTCAGCTGTCCAGATTCAGAACTGGAGCCCACTCCTCCTCCCTCTCG
TTGCCTCAGCCCTGCCCTCACCTCAGACTAGGCAGAGGTGAGGCTGGCTCACCC
TGAAGAGGTGGGATAGGAGGGGACTGCACCCATACTGCTTCCCTACCACAAATC
AGGGCTCAGGGAGAGGCCATGCGGCAGCCAGGTCTGCATGCTGAGCCCCATCC
5 TCCACAGCTTGCCGCTGACGCTCTCTCCTGTACCCCCGCCCTGCTCTCTCCCCAG
ATGTGTTCTGAGCTGGATGCCGGGTTCCAGAATCGCTGCACAGTTCCAACAGGAC
AGCGCCTTCCCCCATGCGCTGGGAGGGGACCCTCCATTTCTCCCCCTCACCCATG
CTGAGTGTAGAGCCGGGGCCTGGGTGGCGGGTGGGGGCCGGGTGGGAGGTGGCA
GTAGTCTTAGCCTGTGCACTCTCTTCCTTGGGTGTTTGGTGCTGGCTCCTGGGGAC
10 TACAAATCCCAGAGTGCAGGTGTGCCCGGCCTCATTTCTGATAGATCCCGCTTGGG
GGAGGTGGTGTATGGTTACGGAGCTGTGCATCTTGGGACATGTAGTAGCCAGGT
CTTGTCACCTCGCTGTGAGATGGGGAGATTTTGTCTTTTGATTTATCCCTGTAGGGC
TGGCAGGGTTGTAGATGAAGGGGGAATGATCTGAGCCTTGGTTCCCCTGACACGT
CTTGCTAGCCCCAGGGTTAGAGTGGGCAGGGCAGAGCCGCGCAGCACCTGGGAG
15 CGGTACCTTTCCCTTGGGCAGCCTGGGGTCCCAGGAACAAGCCAGGGCGAGTGG
CATGTCTGCCTGAGCAGGGTGTGGCCCCAGAAAGCTGAGGAGTGTGGGCTGGCA
GAGAGCTTCGAGGGCAAGGCCACCCGCGGGGGCGTGTGTGTGGTGGGGCTTGGC
ATGTGATGGCAGCTCCAGCTCCAGGCATGCCGCTGCTTGTATGGCTTTCTTTGGC
CTCTGACCCTGCTGCCATTCTTTCCAACATCACAGATGAACTGCCTCTCCTCCTC
20 CCTGCCTGGGGAGCCAGTGGCCAGGGAGGGAGTGGTGGAGCCAGTCGCTGTAA
CACTGAGCCTCAGAGACGAACCAAAACCAGCTGGGCTGAGCTCAGATCCAGGGG
GAAGAAATGCTGGAAGTCAATAAAACTGAGTTTGAGAAAAAAAAAAAAAAAAA

SEQ ID NO: 51

25 >gi|31112|emb|X00663.1|HSEGF01 Human mRNA fragment for epidermal growth factor
(EGF) receptor
ATCCTGCATGGCGCCGTGCGGTTCAAGCAACAACCCTGCCCTGTGCAACGTGGAGA
GCATCCAGTGGCGGGACATAGTCAGCAGTGACTTTCTCAGCAACATGTCGATGG
ACTTCCAGAACCACCTGGGCAGCTGCCAAAAGTGTGATCCAAGCTGTCCCAATG
30 GGAGCTGCTGGGGTGCAGGAGAGGAGAACTGCCAGAAACTGACCAAAATCATCT
GTGCCAGCAGTGTCTCCGGGCGCTGCCGTGGCAAGTCCCCCAGTGACTGCTGCCA
CAACCAGTGTGCTGCAGGCTGCACAGGCCCCCGGGAGAGCGACTGCCTGGTCTG
CCGCAAATTCCGAGACGAAGCCACGTGCAAGGACACCTGCCCCCCTCATGCT
CTACAAACCCACACGTAACAGATGGATGTGAACCCCGAGGGCAAATACAGCTT
35 TGGTGCCACCTGCGTGAAGAAGTGTCCCCGTAATTATGTGGTGACAGATCACGGC
TCGTGCGTCCGAGCCTGTGGGGCCGACAGCTATGAGATGGAGGAAGACGGCGTC
CGCAAGTGTAAAGAGTGCAGAGGGCCTTGCCGCAAAGTGTGTAAACGGAATAGGT
ATTGGTGAATTTAAAGACTCACTCTCCATAAATGCTACGAATATTAACACTTCA
AAAAGTGCACCTCCATCAGTGGCGATCTCCACATCCTGCCGGTGGCATTAGGGG
40 TGAATCCTTCACACATACTCCTCCTCTGGATCCACAGGAACTGGATATTCTGAAA
ACCGTAAAGGAAATCACAGGGTTTTTGTGCTGATTGAGGCTTGGCCTGAAAACAGG
ACGGACCTCCATGCCTTTGAGAACCTAGAAATCATACGCGGCAGGACCAAGCAA
CATGGTCAGTTTTCTCTTGCAGTCGTCAGCCTGAACATAACATCCTTGGGATTAC
GCTCCCTCAAGGAGATAAGTGTGAGATGTGATAATTTAGGAAACAAAAATT
45 TGTGCTATGCAAATACAATAAACTGGAAAAAACTGTTTGGGACCTCCGGTCAGA
AAACCAAAATTATAAGCAACAGAGGTGAAACAGCTGCAAGGCCACAGGCCAG
GTCTGCCATGCCTTGTGCTCCCCGAGGGCTGCTGGGGCCCGGAGCCAGGGACT
GCGTCTCTTGCCGGAATGTCAGCCGAGGCAGGGAATGCGTGGACAAGTGAACC
TTCTGGAGGGTGAGCCAAGGGAGTTTGTGGAGAACTCTGAGTGCATACAGTGCC

ACCCAGAGTGCCTGCCTCAGGCCATGAACATCACCTGCACAGGACGGGGACCAG
 ACAACTGTATCCAGTGTGCCCCTACATTGACGGCCCCCACTGCGTCAAGACCTG
 CCCGGCAGGAGTCATGGGAGAAAACAACACCCTGGTCTGGAAGTACGCAGACGC
 CGGCCATGTGTGCCACCTGTGCCATCCAACTGCACCTACGGATGCACTGGGCCA
 5 GGTCTTGAAGGCTGTCCAACGAATGGGCCTAAGATCCCGTCCATCGCCACTGGGA
 TGGTGGGGGCCCTCCTCTTGCTGCTGGTGGTGGCCCTGGGGATCGGCCTCTTCAT
 GCGAAGGCGCCACATCGTTCGGAAGCGCACGCTGCGGAGGCTGCTGCAGGAGAG
 GGAGCTTGTGGAGCCTCTTACACCCAGTGGAGAAGCTCCCAACCAAGCTCTCTTG
 AGGATCTTGAAGGAACTGAATTCAAAAAGATCAAAGTGCTGGGCTCCGGTGCG
 10 TTCGGCACGGTGTATAAGGGACTCTGGATCCCAGAAGGTGAGAAAGTTAAAATT
 CCCGTCGCTATCAAGGAATTAAGAGAAGCAACATCTCCGAAAGCCAACAAGGAA
 ATCCTCGATGAAGCCTACGTGATGGCCAGCGTGGACAACCCCCACGTGTGCCGCC
 TGCTGGGCATCTGCCTCACCTCCACCGTGCAACTCATCACGCAGCTCATGCCCTT
 CGGCTGCCTCCTGGACTATGTCCGGGAACACAAAGACAATATTGGCTCCAGTAC
 15 CTGCTCAACTGGTGTGTGCAGATCGCAAAGGGCATGAACTACTTGGAGGACCGT
 CGCTTGGTGCACCGCGACCTGGCAGCCAGGAACGTACTGGTGAAAACACCGCAG
 CATGTCAAGATCACAGATTTTGGGCTGGCCAACTGCTGGGTGCGGAAGAGAAA
 GAATACCATGCAGAAGGAGGCAAAGTGCCTATCAAGTGGATGGCATTGGAATCA
 ATTTTACACAGAATCTATACCCACCAGAGTGATGTCTGGAGCTACGGGGTGACCG
 20 TTTGGGAGTTGATGACCTTTGGATCCAAGCCATATGACGGAATCCCTGCCAGCGA
 GATCTCCTCCATCCTGGAGAAAGGAGAACGCCTCCCTCAGCCACCCATATGTACC
 ATCGAT

SEQ ID NO: 52

25 >gi|1162923|gb|L41147.1|HUM5HSR Homo sapiens 5-HT6 serotonin receptor mRNA,
 complete cds
 CCCGAGAGCGCCCATTCACCCCCCTCACCCACCTCCCCGCGTTCCCACTTCCCCG
 CACTCTGACCCGGCCGGACGCCCCCTCCCCTATCTTGCCGCCCCGCCCCCTCCAGGG
 GGCTCTGCTCCCACCCAGGGAGCCCATCCGACCTCTGCTTGACTTCCCGCCGCT
 30 TCCTTCAGGGGCTCGGCTCATCGGGTGGCCCTCCCCAACTTCCAACCCGTTTG
 CTCCAGGAGTTCTGCCCCATCCCCGAGGGCGCCCAAATAGCCACACTGTGTCT
 CCTGTAGTCGCCGCCCCCTGACCTAGCGCGACCCAGCGCCCCCGCCCATGTCCCC
 CCACTCACCTCCCCCGGGGGGCGTGGTGAAGTCGCGGTCTGTTCTACGGACGGTC
 CCCGTCCAGCCTGCGCTTCGCCGGGGCCCTCATCTGCTTTCCCGCCACCCTATCA
 35 TCCCTTGCCGTCCACCCTCGGTCTCATGGTCCCAGAGCCGGGCCCCAACCGCCAA
 TAGCACCCCGGCCTGGGGGGCAGGGCCGCGTCCGCCCCGGGGGGCAGCGGCTG
 GGTGGCGGCCGCGCTGTGCGTGGTCATCGCGCTGACGGCGGCGGCCAACTCGCT
 GCTGATCGCGCTCATCTGCACTCAGCCCCGCGCTGCGCAACACGTCCAACCTCTTC
 CTGGTGTGCTCTTCACGTCTGACCTGATGGTGGGGCTGGTGGTGATGCCGCCGG
 40 CCATGCTGAACGCGCTGTACGGGCGCTGGGTGCTGGCGCGCGGCCTCTGCCTGCT
 CTGGACCGCCTTCGACGTGATGTGCTGCAGCGCCTCCATCCTCAACCTCTGCCTC
 ATCAGCCTGGACCGCTACCTGCTCATCTCTCGCCGCTGCGCTACAAGCTGCGCA
 TGACGCCCTGCGTGCCCTGGCCCTAGTCCTGGGCGCCTGGAGCCTCGCCGCTCT
 CGCCTCCTTCCTGCCCTGCTGCTGGGCTGGCACGAGCTGGGCCACGCACGGCCA
 45 CCCGTCCCTGGCCAGTGCCGCCTGCTGGCCAGCCTGCCTTTTGTCTTGTGGCGTC
 GGGCCTCACCTTCTTCCTGCCCTCGGGTGCCATATGCTTCACCTACTGCAGGATCC
 TGCTAGCTGCCCCGAAGCAGGCGGTGCAGGTGGCCTCCCTCACCACCGGCATGGC
 CAGTCAGGCCTCGGAGACGCTGCAGGTGCCAGGACCCACGCCAGGGGTGGA
 GTCTGCTGACAGCAGGCGTCTAGCCACGAAGCACAGCAGGAAGGCCCTGAAGGC

CAGCCTGACGCTGGGCATCCTGCTGGGCATGTTCTTTGTGACCTGGTTGCCCTTCT
TTGTGGCCAAACATAGTCCAGGCCGTGTGCGACTGCATCTCCCCAGGCCCTCTTCGA
TGTCTTCACATGGCTGGGTTACTGTAACAGCACCATGAACCCCATCATCTACCCA
CTCTTCATGCGGGACTTCAAGCGGGCGCTGGGCAGGTTCTTGCCATGTCCACGCT
5 GTCCCCGGGAGCGCCAGGCCAGCCTGGCCTCGCCATCACTGCGCACCTCTCACAG
CGGCCCCCGGCCCGGCCTTAGCCTACAGCAGGTGCTGCCGCTGCCCTGCCGCCG
GACTCAGATTTCGGACTCAGACGCAGGCTCAGGCGGCTCCTCGGGCCTGCGGGCTC
ACGGCCCAGCTGCTGCTTCTTGCGAGGCCACCCAGGACCCCCGCTGCCACCA
GGGCCGCTGCCGCCGTCAATTTCTTCAACATCGACCCGCGGAGCCCGAGCTGCG
10 GCCGCATCCACTTGGCATCCCCACGAACTGACCCGGGCTTGGGGCTGGCCAATGG
GGAGCTGGATTGAGCAGAACCCAGACCCTGAGTCCTTGGGCCAGCTCTTGGCTA
AGACCAGGAGGCTGCAAGTCTCCTAGAAGCCCTCTGAGCTCCAGAGGGGTGCGC
AGAGCTGACCCCTGCTGCCATCTCCAGGCCCTTACCTGCAGGGATCATAGCTG
ACTCAGA

15 SEQ ID NO: 53

>gi|181970|gb|M32977.1|HUMEGFAA Human heparin-binding vascular endothelial growth factor (VEGF) mRNA, complete cds

CAGTGTGCTGGCGGCCCGCGCGAGCCGGCCCCGGCCCCGGTTCGGGCCTCCGAAA
20 CCATGAACTTTCTGCTGTCTTGGGTGCATTGGAGCCTCGCCTTGCTGCTCTACCTC
CACCATGCCAAGTGGTCCCAGGCTGCACCCATGGCAGAAGGAGGAGGGCAGAAT
CATCACGAAGTGGTGAAGTTCATGGATGTCTATCAGCGCAGCTACTGCCATCCAA
TCGAGACCCTGGTGGACATCTTCCAGGAGTACCCTGATGAGATCGAGTACATCTT
CAAGCCATCCTGTGTGCCCTGATGCGATGCGGGGGCTGCTGCAATGACGAGGG
25 CCTGGAGTGTGTGCCCACTGAGGAGTCCAACATCACCATGCAGATTATGCGGATC
AAACCTCACCAAGGCCAGCACATAGGAGAGATGAGCTTCCTACAGCACAACAAA
TGTGAATGCAGACCAAAGAAAGATAGAGCAAGACAAGAAAATCCCTGTGGGCCT
TGCTCAGAGCGGAGAAAGCATTTGTTTGTACAAGATCCGCAGACGTGTAAATGTT
CCTGCAAAAACACAGACTCGCGTTGCAAGGCGAGGCAGCTTGAGTTAAACGAAC
30 GTACTTGCAGATGTGACAAGCCGAGGCGGTGAGCCGGGCAGGAGGAAGGAGCCT
CCCTCAGGGTTTCGGGAACCAGATCTCTCACCAGGAAAGACTGATACAGAACGA
TCGATACAGAAACCACGCTGCCGCCACCACACCATCACCATCGACAGAACAGTC
CTTAATCCAGAAACCTGAAATGAAGGAAGAGGAGACTCTGCGCAGAGCACTTTG
GGTCCGGAGGGCGAGACTCCGGCGGAAGCATTCCCGGGCGGGTGACCCAGCACG
35 GTCCCTCTTGGAATTGGATTTCGCCATTTTATTTTCTTGCTGCTAAATCACCAGC
CCGGAAGATTAGAGAGTTTTATTTCTGGGATTCTGTAGACACACCGCGGCCGCC
AGCACACTG

SEQ ID NO: 54

40 >3014785H1

GCTCAACCCCTCTGGGCACCAACCCTGCATTGCAGGTTGGCACCTTACTTCCCTG
GGATCCCCAGAGTTGGTCCAAGGAGGGAGAGTGGGTTCTCAATACGGTACCAAA
GATATAATCACCTAGGTTTACAAATATTTTATAGGACTCACGTTAACTCACATTTAT
ACAGCAGAAATGCTATTTTGTATGCTGTAAAGTTTTTCTATCTGTGTACTTTTTTT
45 AAGGGAAAGATTTTAATATTAACCTGGTGCT

SEQ ID NO: 55

>853668H1

CGCAGGTGGACGTCTGATTTATGAAGCTCCCCATCCACCTATCTGAGTACCTGAC
TTCTCAGGACTGACACCTACAGCATCAGGTACACAGCTTCTCCTAGCATGACTTC
GATCTGATCAGCAAACAAGAAAATTTGTCTCCCGTAGTTCTGGGGCGTGTTCACC
ACCTACAACCACAGAGCTGTCATGGCTGCCATCTCTACTTCCATCCCTGTAATTTCC
5 ACAGCCCCAG

SEQ ID NO: 56

>gi|2072500|gb|U96113.1|HSU96113 Homo sapiens Nedd-4-like ubiquitin-protein ligase
WWP1 mRNA, partial cds

10 GACTAATCATGTACCTACAAGCACTCTAGTCCAAAACCTCATGCTGCTCGTATGTA
GTAAATGGAGACAACACACCTTCATCTCCGTCTCAGGTTGCTGCCAGACCCAAAA
ATACACCAGCTCCAAAACCACTCGCATCTGAGCCTGCCGATGACACTGTAAATGG
AGAATCATCCTCATTTGCACCAACTGATAATGCGTCTGTCACGGGTACTCCAGTA
GTGTCTGAAGAAAATGCCTTGTCTCCAAATTGCACTAGTACTACTGTTGAAGATC
15 CTCCAGTTCAAGAAATACTGACTTCCTCAGAAAACAATGAATGTATTCCTTCTAC
CAGTGCAGAATTGGAATCTGAAGCTAGAAGTATATTAGAGCCTGACACCTCTAAT
TCTAGAAGTAGTTCTGCTTTTGAAGCAGCCAAATCAAGACAGCCAGATGGGTGTA
TGGATCCTGTACGGCAGCAGTCTGGGAATGCCAACACAGAAACCTTGCCATCAG
GGTGGGAACAAAGAAAAGATCCTCATGGTAGAACCTATTATGTGGATCATAATA
20 CTCGAACCTACCACATGGGAGAGACCACAACCTTTACCTCCAGGTTGGGAAAGAA
GAGTTGATGATCGTAGAAGAGTTTATTATGTGGATCATAACACCAGAACAACAA
CGTGGCAGCGGCCTACCATGGAATCTGTCCGAAATTTTGAACAGTGGCAATCTCA
GCGGAACCAATTGCAGGGAGCTATGCAACAGTTTAACCAACGATACCTCTATTTCG
GCTTCAATGTTAGCTGCAGAAAATGACCCTTATGGACCTTTGCCACCAGGCTGGG
25 AAAAAAGAGTGGATTCAACAGACAGGGTTTACTTTGTGAATCATAACACAAAAA
CAACCCAGTGGGAAGATCCAAGAACTCAAGGCTTACAGAATGAAGAACCCCTGC
CAGAAGGCTGGGAAATTAGATATACTCGTGAAGGTGTAAGGTACTTTGTTGATCA
TAACACAAGAACAACAACATTCAAAGATCCTCGCAATGGGAAGTCATCTGTAAC
TAAAGGTGGTCCACAAATTGCTTATGAACGCGGCTTTAGGTGGAAGCTTGCTCAC
30 TTCCGTTATTTGTGCCAGTCTAATGCACTACCTAGTCATGTAAAGATCAATGTGTC
CCGGCAGACATTGTTTGAAGATTCTTCCAACAGATTATGGCATTAAAACCCTAT
GACTTGAGGAGGCGCTTATATGTAATATTTAGAGGAGAAGAAGGACTTGATTAT
GGTGGCCTAGCGAGAGAATGGTTTTTCTTGCTTTACATGAAGTTTTGAACCCAA
TGTATTGCTTATTTGAGTATGCGGGCAAGAACAACCTATTGTCTGCAGATAAATCC
35 AGCATCAACCATTAATCCAGACCATCTTTCATACTTCTGTTTCATTGGTCGTTTTA
TTGCCATGGCACTATTTTCATGGAAAGTTTATCGATACTGGTTTCTCTTTACCATT
TACAAGCGTATGTTAAGTAAAAAACTTACTATTAAGGATTTGGAATCTATTGATA
CTGAATTTTATAACTCCCTTATCTGGATAAGAGATAACAACATTGAAGAATGTGG
CTTAGAAATGTACTTTTCTGTTGACATGGAGATTTTGGGAAAAGTTACTTCACAT
40 GACCTGAAGTTGGGAGGTTCCAATATTCTGGTGAAGTGGAGAGAACAAAGATGAA
TATATTGGTTTAAATGACAGAATGGCGTTTTTCTCGAGGAGTACAAGAACAGACCA
AAGCTTTCCTTGATGGTTTTAATGAAGTTGTTTCTTCTCAGTGGCTACAGTACTTC
GATGAAAAAGAATTAGAGGTTATGTTGTGTGGCATGCAGGAGGTTGACTTGGA
GATTGGCAGAGAAATACTGTTTATCGACATTATACAAGAAACAGCAAGCAAATC
45 ATTTGGTTTTTGGCAGTTTGTGAAAGAGACAGACAATGAAGTAAGAATGCGACTA
TTGCAGTTCGTCCTGGAACCTGCCGTTTACCTCTAGGAGGATTTGCTGAGCTCA
TGGGAAGTAATGGGCCCCGGAATTC

SEQ ID NO: 57

>gi|1940670|gb|AA292676.1|AA292676 zt21c12.s1 Soares ovary tumor NbHOT Homo sapiens cDNA clone IMAGE:713782 3'

5 TTTTAAACGCTCCCAAGATGTCACGTTTATTGCAACTGAGCAGAGACAGGCTG
TGCGGACCTTCCTCAATCCCGTCCAACCCCGAGCCCCTCCCAAGCCCCCGCTGC
AACTACGCCGGCAGGTCCGCAGAGTGTTGCTTGACAGCGCGTGGCGGTGCCCGT
GAGTCTTAAGACACCTGCCAAGTCTCTGGCGCCGTTTCAGTCATAGGTAGAGGGAC
TCCATGAGGGCACTGCCCC

10 SEQ ID NO: 58

>gi|13027659|gb|AF023476.2|AF023476 Homo sapiens meltrin-L precursor (ADAM12) mRNA, complete cds, alternatively spliced

CACTAACGCTCTTCCTAGTCCCCGGGCCAACTCGGACAGTTTGCTCATTATTGCA
ACGGTCAAGGCTGGCTTGTGCCAGAACGGCGCGCGCGACGCACGCACACACA
15 CGGGGGGAAACTTTTTTAAAAATGAAAGGCTAGAAGAGCTCAGCGGCGGCGCGG
GCCGTGCGCGAGGGCTCCGGAGCTGACTCGCCGAGGCAGGAAATCCCTCCGGTC
GCGACGCCCGGCCCGCTCGGCGCCCCGCGTGGGATGGTGCAGCGCTCGCCGCCG
GGCCCGAGAGCTGCTGCACTGAAGGCCGGCGACGATGGCAGCGCGCCCGCTGCC
CGTGTCCCCCGCCCGCGCCCTCCTGCTCGCCCTGGCCGGTGCTCTGCTCGCGCCCT
20 GCGAGGCCCGAGGGGTGAGCTTATGGAACCAAGGAAGAGCTGATGAAGTTGTCA
GTGCCTCTGTTTCGGAGTGGGGACCTCTGGATCCCAGTGAAGAGCTTCGACTCCAA
GAATCATCCAGAAGTGCTGAATATTCGACTACAACGGGAAAGCAAAGAAGTATGAT
CATAAATCTGGAAAGAAATGAAGGTCTCATTGCCAGCAGTTTCACGGAAACCCA
CTATCTGCAAGACGGTACTGATGTCTCCCTCGCTCGAAATTACACGGTAATTCTG
25 GGTCACTGTTACTACCATGGACATGTACGGGGATATTCTGATTACAGCAGTCAGTC
TCAGCACGTGTTCTGGTCTCAGGGGACTTATTGTGTTTGAAAATGAAAGCTATGT
CTTAGAACCAATGAAAAGTGCAACCAACAGATACAAACTCTTCCCAGCGAAGAA
GCTGAAAAGCGTCCGGGGATCATGTGGATCACATCACACACACCAACCTCGC
TGCAAAGAATGTGTTTCCACCACCCTCTCAGACATGGGCAAGAAGGCATAAAAG
30 AGAGACCCTCAAGGCAACTAAGTATGTGGAGCTGGTGATCGTGGCAGACAACCG
AGAGTTTCAGAGGCAAGGAAAAGATCTGGAAAAAGTTAAGCAGCGATTAATAGA
GATTGCTAATCACGTTGACAAGTTTTACAGACCACTGAACATTCGGATCGTGTTG
GTAGGCGTGGAAGTGTGGAATGACATGGACAAATGCTCTGTAAGTCAGGACCCA
TTACACAGCCTCCATGAATTTCTGGACTGGAGGAAGATGAAGCTTCTACCTCGCA
35 AATCCCATGACAATGCGCAGCTTGTGAGTGGGGTTTATTTCCAAGGGACCACCAT
CGGCATGGCCCAATCATGAGCATGTGCACGGCAGACCAGTCTGGGGGAATTGT
CATGGACCATTACAGACAATCCCCTTGGTGCAGCCGTGACCCTGGCACATGAGCTG
GGCCACAATTTCTGGGATGAATCATGACACACTGGACAGGGGCTGTAGCTGTCAA
ATGGCGGTTGAGAAAGGAGGCTGCATCATGAACGCTTCCACCGGGTACCCATTTC
40 CCATGGTGTTCAGCAGTTGCAGCAGGAAGGACTTGGAGACCAGCCTGGAGAAAG
GAATGGGGGTGTGCCTGTTTAACTGCCGGAAGTCAGGGAGTCTTTCGGGGGCC
AGAAGTGTGGGAACAGATTTGTGGAAGAAGGAGAGGAGTGTGACTGTGGGGAG
CCAGAGGAATGTATGAATCGCTGCTGCAATGCCACCACCTGTACCCTGAAGCCG
GACGCTGTGTGCGCACATGGGCTGTGCTGTGAAGACTGCCAGCTGAAGCCTGCA
45 GGAACAGCGTGCAGGGACTCCAGCAACTCCTGTGACCTCCCAGAGTTCTGCACA
GGGGCCAGCCCTCACTGCCCAGCCAACGTGTACCTGCACGATGGGCACTCATGTC
AGGATGTGGACGGCTACTGCTACAATGGCATCTGCCAGACTCACGAGCAGCAGT
GTGTACACTCTGGGGACCAGGTGCTAAACCTGCCCCTGGGATCTGCTTTGAGAG
AGTCAATTCTGCAGGTGATCCTTATGGCAACTGTGGCAAAGTCTCGAAGAGTTCC

TTTGCCAAATGCGAGATGAGAGATGCTAAATGTGGAAAAATCCAGTGTCAAGGA
GGTGCCAGCCGGCCAGTCATTGGTACCAATGCCGTTTCCATAGAAACAAACATCC
CCCTGCAGCAAGGAGGCCGGATTCTGTGCCGGGGGACCCACGTGTACTTGGGCG
ATGACATGCCGGACCCAGGGCTTGTGCTTGCAGGCACAAAGTGTGCAGATGGAA
5 AAATCTGCCTGAATCGTCAATGTCAAAATATTAGTGTCTTTGGGGTTACAGAGTG
TGCAATGCAGTGCCACGGCAGAGGGGTGTGCAACAACAGGAAGAACTGCCACTG
CGAGGCCCACTGGGCACCTCCCTTCTGTGACAAAGTTTGGCTTTGGAGGAAGCACA
GACAGCGGCCCCATCCGGCAAGCAGATAACCAAGGTTTAACCATAGGAATTCTG
GTGACCATCCTGTGTCTTCTTGCTGCCGGATTTGTGGTTTATCTCAAAAGGAAGA
10 CCTTGATACGACTGCTGTTTACAAATAAGAAAGACCACCATTGAAAACTAAGGT
GTGTGCGCCCTTCCCGGCCACCCCGTGGCTTCCAACCCTGTCAGGCTCACCTCGG
CCACCTTGGAAGAGGCTGATGAGGAAGCCGCCAGATTCTACCCACCGAAGGA
CAATCCCAGGAGATTGCTGCAGTGTGAGAATGTTGACATCAGCAGACCCCTCAAC
GGCCTGAATGTCCCTCAGCCCCAGTCAACTCAGCGAGTGCTTCCTCCCTCCACC
15 GGGCCCCACGTGCACCTAGCGTCCCTGCCAGACCCCTGCCAGCCAAGCCTGCACT
TAGGCAGGCCCAGGGGACCTGTAAGCCAAACCCCCCTCAGAAGCCTCTGCCTGC
AGATCCTCTGGCCAGAACAACTCGGCTCACTCATGCCTTGGCCAGGACCCAGGA
CAATGGGAGACTGGGCTCCGCCTGGCACCCCTCAGACCTGCTCCACAATATCCAC
ACCAAGTGCCAGATCCACCCACACCGCCTATATTAAGTGAGAAGCCGACACCTT
20 TTTTCAACAGTGAAGACAGAAGTTTGCATATCTTTCAGCTCCAGTTGGAGTTTTT
TGTACCAACTTTTAGGATTTTTTTTAAATGTTTAAACATCATTACTATAAGAACTT
TGAGCTACTGCCGTCAGTGCTGTGCTGTGCTATGGTGCTCTGTCTACTTGCACAG
GTACTTGTAATTTATTAATTTATGCAGAATGTTGATTACAGTGCAGTGCGCTGTA
GTAGGCATTTTACCATCACTGAGTTTTCCATGGCAGGAAGGCTTGTTGTGCTTTT
25 AGTATTTTAGTGAACCTGAAATATCCTGCTTGATGGGATTCTGGACAGGATGTGT
TTGCTTTCTGATCAAGGCCTTATTGGAAAGCAGTCCCCCAACTACCCCAAGCTGT
GCTTATGGTACCAGATGCAGCTCAAGAGATCCCAAGTAGAATCTCAGTTGATTTT
CTGGATTCCCCATCTCAGGCCAGAGCCAAGGGGCTTCAGGTCCAGGCTGTGTTTG
GCTTTCAGGGAGGCCCTGTGCCCCTTGACAACCTGGCAGGCAGGCTCCCAGGGAC
30 ACCTGGGAGAAATCTGGCTTCTGGCCAGGAAGCTTTGGTGAGAACCTGGGTTGC
AGACAGGAATCTTAAGGTGTAGCCACACCAGGATAGAGACTGGAACACTAGACA
AGCCAGAACTTGACCCTGAGCTGACCAGCCGTGAGCATGTTTGGAAAGGGGTCTG
TAGTGTCACTCAAGGCGGTGCTTGATAGAAATGCCAAGCACTTCTTTTCTCGCT
GTCCTTTCTAGAGCACTGCCACCAGTAGGTTATTTAGCTTGGGAAAGGTGGTGTT
35 TCTGTAAGAAACCTACTGCCCAGGCACTGCAAACCGCCACCTCCCTATACTGCTT
GGAGCTGAGCAAATCACCACAACTGTAATACAATGATCCTGTATTCAGACAGA
TGAGGACTTTCCATGGGACCACAACCTATTTTCAGATGTGAACCATTAACCAGATC
TAGTCAATCAAGTCTGTTTACTGCAAGGTTCAACTTATTAACAATTAGGCAGACT
CTTTATGCTTGCAAAAACTACAACCAATGGAATGTGATGTTTCATGGGTATAGTTC
40 ATGTCTGCTATCATTATTCGTAGATATTGGACAAAGAACCTTCTCTATGGGGCAT
CCTCTTTTTCCAACCTGGCTGCAGGAATCTTTAAAAGATGCTTTTAAACAGAGTCTG
AACCTATTTCTTAAACACTTGCAACCTACCTGTTGAGCATCACAGAATGTGATAA
GGAAATCAACTTGCTTATCAACTTCCTAAATATTATGAGATGTGGCTTGGGCAGC
ATCCCCTTGAACCTTCACTCTTCAATGCCTGACTAGGGAGCCATGTTTCAAA
45 GGCTTTAAAGTGAATAATGGCATGAGAAATACAAAAATACTCAGATAAGGTAA
AATGCCATGATGCCTCTGTCTTCTGGACTGGTTTTTCACATTAGAAGACAATTGAC
AACAGTTACATAATTCCTCTGAGTGTTTTATGAGAAAGCCTTCTTTTGGGGTCA
ACAGTTTTCTATGCTTTGAAACAGAAAAATATGTACCAAGAATCTTGGTTTGCC
TTCCAGAAAACAAAACCTGCATTTCACTTTCCCGGTGTTCCCCACTGTATCTAGGC

AACATAGTATTCATGACTATGGATAAACTAAACACGTGACACAAACACACACAA
AAGGGAACCCAGCTCTAATACATTCCAACCTCGTATAGCATGCATCTGTTTATTCT
ATAGTTATTAAGTTCTTTAAAATGTAAAGCCATGCTGGAAAATAATACTGCTGAG
ATACATACAGAATTACTGTAACCTGATTACACTTGGTAATTGTACTAAAGCCAAAC
5 ATATATATACTATTAAAAAGGTTTACAGAATTTTATGGTGCATTACGTGGGCATT
GTCTTTTTAGATGCCCAAATCCTTAGATCTGGCATGTTAGCCCTTCCTCCAATTAT
AAGAGGATATGAACCAAAAAAAAAAAAAAAAAAAAAA

SEQ ID NO: 59

10 >gi|2166296|gb|AA452627.1|AA452627 zx33f03.r1 Soares_total_fetus_Nb2HF8_9w Homo
sapiens cDNA clone IMAGE:788285 5' similar to gb:S57498 ENDOTHELIN-1 RECEPTOR
PRECURSOR (HUMAN);
GGCAGTTTAATAGATGTTACTCAAAGAATTTTTTAAGAACTGTATTTTATTTTTTA
AATGGTGTTTTATTACAAGGGACCTTGAACATGTTTTGTATGTTAAATTCAAAAG
15 TAATGCTTCAATCAGATAGTTCTTTTTTACAAGTTCAATCTGTTTTTTCATGTAAAT
TTTGTATGAAAAATCAATGTCAAGTACCAAAATGTTAATGTATGTGTCATTTAAC
TCTGCCTGAGACTTTTCAAGTGCCTGTATATAGAAGTCTAAAACACACCTAAGAGA
AAAAGATCGAATTTTTTCAGATGATTGAGAAATTTTCATTCAGGTATTTGTAATAG
TGACATATATATGTATATACATATCACCTCCTATTCTCTTAATTTTTCTTAAAATG
20 TTAAGTGGCAGTAAAGCTTTTTTGATCATTCCCTTTTCCATATAGGAAACATAATT
TTGAAGTGGCCAGATGAGTTTATCATGTGAGTGAATAATACCCACAAATGG
CACCAGAACTTACGATTCTTCACTTCTTGGGGTTTTTCAGTATGAACCTAACTCCCC
ACCCC

25 SEQ ID NO: 60

>gi|180167|gb|M58664.1|HUMCDA24A Homo sapiens CD24 signal transducer mRNA,
complete cds
CGGTTCTCCAAGCACCCAGCATCCTGCTAGACGCGCCGCGCACCGACGGAGGGG
ACATGGGCAGAGCAATGGTGGCCAGGCTCGGGCTGGGGCTGCTGCTGCTGGCAC
30 TGCTCCTACCCACGCAGATTTATTCCAGTGAAACAACAACCTGGAACCTCAAGTAA
CTCCTCCCAGAGTACTTCCAACCTCTGGGTTGGCCCCAAATCCAATAATGCCACC
ACCAAGGCGGCTGGTGGTGGCCTGCAGTCAACAGCCAGTCTCTTCGTGGTCTCAC
TCTCTCTTCTGCATCTCTACTCTTAAGAGACTCAGGCCAAGAAACGTCTTCTAAAT
TTCCCCATCTTCTAAACCCAATCCAATGGGCTCTGGAGTCCAATGTGGCAAGG
35 AAAACAGGTCTTCATCGAATCTACTAATTCCACACCTTTTATTGACACAGAAAA
TGTTGAGAATCCCAAATTTGATTGATTTGAAGAACATGTGAGAGGTTTGAAGTGA
TGATGGATGCCAATATTAATCTGCTGGAGTTTCATGTACAAGATGAAGGAGAG
GCAACATCCAAAATAGTTAAGACATGATTTCCCTTGAATGTGGCTTGAGAAATATG
GACACTTAATACTACCTTGAAAATAAGAATAGAAATAAAGGATGGGATTGTGGA
40 ATGGAGATTGAGTTTTTCATTTGGTGCTTAATTCTATAAGCGTATAAACAGGTAAT
ATAAAAAGCTTCCATGATTCTATTTATATGTACATGAGAAGGAACTTCCAGGTGT
TACTGTAATTCCTCAACGTATTGTTTCGACGGCACTAATTTAATGCCGATATACTC
TAGATGAAGTTTTACATTGTTGAGCTATTGCTGTTCTCTTGGGAACCTGAACCTCACT
TTCTCCTGAGGCTTTGGATTGACATTGCATTTGACCTTTTATGTAGTAATTGAC
45 ATGTGCCAGGGCAATGATGAATGAGAATCTACCCAGATCCAAGCATCCTGAGC
AACTCTTGATTATCCATATTGAGTCAAATGGTAGGCATTTCCCTATCACCTGTTTCC
ATTCAACAAGAGCACTACATTCATTTAGCTAAACGGATTCCAAAGAGTAGAATTG
CATTGACCACGACTAATTTCAAATGCTTTTTATTATTATTTTTTAGACAGTC
TCACTTTGTCGCCCAGGCCGGAGTGCAGTGGTGCATCTCAGATCAGTGTACCAT

TTGCCTCCCGGGCTCAAGCGATTCTCCTGCCTCAGCCTCCCAAGTAGCTGGGATT
ACAGGCACCTGCCACCATGCCCCGGCTAATTTTTTGTAAATTTAGTAGAGACAGGGT
TTCACCATGTTGCCCAGGCTGGTTTCGAACTCCTGACCTCAGGTGATCCACCCGC
CTCGGCCTCCCAAAGTGCTGGGATTACAGGCTTGAGCCCCCGCGCCAGCCATCA
5 AAATGCTTTTTATTTCTGCATATGTTTGAATACTTTTTACAATTTAAAAAATGAT
CTGTTTTGAAGGCAAAATTGCAAATCTTGAAATTAAGAAGGCAAAATGTAAAGG
AGTCAAACATAAAATCAAGTATTTGGGAAGTGAAGACTGGAAGCTAATTTGCAT
AAATTCACAACTTTTATACTCTTTCTGTATATACATTTTTTTCTTTAAAAACA
ACTATGGATCAGAATAGCCACATTTAGAACACTTTTTGTTATCAGTCAATATTTTT
10 AGATAGTTAGAACCTGGTCCTAAGCCTAAAAGTGGGCTTGATTCTGCAGTAAATC
TTTTACAACCTGCCTCGACACACATAAACCTTTTTTAAAAATAGACACTCC

SEQ ID NO: 61

>gi|2215243|gb|AA487812.1|AA487812 ab11f04.r1 Stratagene lung (#937210) Homo
15 sapiens cDNA clone IMAGE:840511 5' similar to gb:Z19554 VIMENTIN (HUMAN);
CAACGAGAAGGTGGAGCTGCAGGAGCTGAATGACCGCTTCGCCAACTACATCGA
CAAGGTGCGCTTCCTGGAGCAGCAGAATAAGATCCTGCTGGCCGAGCTCGAGCA
GCTCAAGGGCCAAGGCAAGTCGCGCCTGGGGGACCTCTACGAGGAGGAGATGCG
GGACTGCGCCGGCAGTGGACCAGCTAACCAACGACAAAGCCCGCGTCGAGGTGG
20 AGCGCGACAACCTGGCCGAGGACATCATGCGCCTCCGGGAGAAATTGCAGGAGG
AGATGCTTCAGAGAGAGGAAGCCGAAAACACCCTGCAATCTTTCAGACAGGATG
TTGACAATGCG

SEQ ID NO: 62

>gi|23910|emb|Y00757.1|HS7B2 Human mRNA for polypeptide 7B2
25 CGCTCCTCGGGCTGCCCCTCGGTTGACAATGGTCTCCAGGATGGTCTCTACCATG
CTATCTGGCCTACTGTTTTGGCTGGCATCTGGATGGACTCCAGCATTTGCTTACAG
CCCCCGGACCCCTGACCGGGTCTCAGAAGCAGATATCCAGAGGCTGCTTCATGGT
GTTATGGAGCAATTGGGCATTGCCAGGCCCCGAGTGAATATCCAGCTCACCAG
30 GCCATGAATCTTGTGGGCCCCCAGAGCATTGAAGGTGGAGCTCATGAAGGACTT
CAGCATTTGGGTCTTTTGGCAACATCCCCAACATCGTGGCAGAGTTGACTGGAG
ACAACATTCTTAAGGACTTTAGTGAGGATCAGGGGTACCCAGACCCTCCAAATCC
CTGTCCTGTTGAAAAACAGATGATGGATGTCTAGAAAAACACCCTGACACTGC
AGAGTTCAGTCGAGAGTTCCAGTTGCACCAAGCATCTCTTTGATCCGGAACATGAC
35 TATCCAGGCTTGGGCAAGTGGAACAAGAACTCCTTTACGAGAAGATGAAGGGA
GGAGAGAGACGAAAGCGGAGGAGTGTCAATCCATATCTACAAGGACAGAGACT
GGATAATGTTGTTGCAAAGAAGTCTGTCCCCCATTTTTTCAGATGAGGATAAGGAT
CCAGAGTAAAGAGAAGATGCTAGACGAAAACCCACATTACCTGTTAGGCCTCAG
CATGGCTTATGTGCACGTGTAAATGGAGTCCCTGTGAATGACAGCATGTTTCTTA
40 CATAGATAATTATGGATACAAAGCAGCTGTATGTAGATAGTGTATTGTCTTCACA
CCGATGATTCTGCTTTTTGCTAAATTAGAATAAGAGCTTTTTTGTTCCTTGGGTTT
TTAAATGTGAATCTGCAATGATCATAAAAATTTAAATGTGAATGTCAACAATA
AAAAGCAAGACTATGAAAGGCTCAGATTTCTTGCAGTTTAAATGGTGTCTGAG
GTTGTAATAATTTGGCCAAGTCTGTAGAAAGCTGTCATTTGATTTTGATTATGTAG
45 TTCATCCAGCCCTTGGGCATTGTTATACACCAGTAAAGAAGGCTGTAAGCAAGAG
GAGGAGCTGACACATTTCACTTGGCTGCGTCTTAATAAACATGAATGCAAGCATT
GGC

SEQ ID NO: 63

>gi|1321593|gb|L76380.1|HUMCGRPB Homo sapiens (clone HSNME29) CGRP type 1
receptor mRNA, complete cds

5 GCACGAGGGAACAACCTCTCTCTCTSCAGCAGAGAGTGTACCTCCTGCTTTAGG
ACCATCAAGCTCTGCTAACTGAATCTCATCCTAATTGCAGGATCACATTGCAAAG
CTTTCACCTCTTTCCACCTTGCTTGTGGGTAAATCTCTTCTGCGGAATCTCAGAAA
GTAAAGTTCCATCCTGAGAATATTTACAAAAGAATTCCTTAAGAGCTGGACTGG
GTCTTGACCCCTGGAATTTAAGAAATTCCTTAAAGACAATGTCAAATATGATCCAA
10 GAGAAAATGTGATTTGAGTCTGGAGACAATTGTGCATATCGTCTAATAATAAAA
ACCCATACTAGCCTATAGAAAACAATATTTGAATAATAAAAACCCATACTAGCCT
ATAGAAAACAATATTTGAAAGATTGCTACCACTAAAAAGAAAACCTACTACAAC
TGACAAGACTGCTGCAAACTTCAATTGGTCACCACAACCTTGACAAGGTTGCTATA
AAACAAGATTGCTACAACCTTCTAGTTTATGTTATACAGCATATTTCAATTTGGGCTT
AATGATGGAGAAAAAGTGTACCCTGTATTTTCTGGTTCTCTTGCCTTTTTTTATGA
15 TTCTTGTTACAGCAGAATTAGAAGAGAGTCCTGAGGACTCAATTCAGTTGGGAGT
TACTAGAAATAAAAATCATGACAGCTCAATATGAATGTTACCAAAAGATTATGCA
AGACCCCATTCACAAGCAGAAGGCGTTTACTGCAACAGAACCTGGGATGGATG
GCTCTGCTGGAACGATGTTGCAGCAGGAACCTGAATCAATGCAGCTCTGCCCTGAT
TACTTTCAGGACTTTGATCCATCAGAAAAAGTTACAAAGATCTGTGACCAAGATG
20 GAAACTGGTTTAGACATCCAGCAAGCAACAGAACATGGACAAATTATACCCAGT
GTAATGTTAACACCCACGAGAAAGTGAAGACTGCACTAAATTTGTTTTACCTGAC
CATAATTGGACACGGATTGTCTATTGCATCACTGCTTATCTCGCTTGGCATATTCT
TTTATTTCAAGAGCCTAAGTTGCCAAAGGATTACCTTACACAAAAATCTGTTCTT
CTCATTGTGTTGTAACCTCTGTTGTAACAATCATTACCTCACTGCAGTGGCCAACA
25 ACCAGGCCTTAGTAGCCACAAATCCTGTTAGTTGCAAAGTGTCCCAGTTCATTCA
TCTTTACCTGATGGGCTGTAATTACTTTTGGATGCTCTGTGAAGGCATTTACCTAC
ACACACTCATTGTGGTGGCCGTGTTTGCAGAGAAGCAACATTTAATGTGGTATTA
TTTTCTTGGCTGGGGATTTCCTACTGATTCCCTGCTTGTATACATGCCATTGCTAGAA
GCTTATATTACAATGACAATTGCTGGATCAGTTCTGATACCCATCTCCTCTACATT
30 ATCCATGGCCCAATTTGTGCTGCTTTACTGGTGAATCTTTTTTTCTTGTTAAATATT
GTACGCGTTCTCATCACCAAGTTAAAAGTTACACACCAAGCGGAATCCAATCTGT
ACATGAAAGCTGTGAGAGCTACTCTTATCTTGGTGCCATTGCTTGGCATTGAATT
TGTGCTGATTCCATGGCGACCTGAAGGAAAGATTGCAGAGGAGGTATATGACTA
CATCATGCACATCCTTATGCACTTCCAGGGTCTTTTGGTCTCTACCATTTTCTGCT
35 TCTTTAATGGAGAGGTTCAAGCAATTCTGAGAAGAACTGGAATCAATACAAAA
TCCAATTTGGAAACAGCTTTTCCAACCTCAGAAGCTCTTCGTAGTGCCTTACAC
AGTGTCAACAATCAGTGATGGTCCAGGTTATAGTCATGACTGTCCTAGTGAACAC
TTAAATGGAAAAAGCATCCATGATATTGAAAATGTTCTCTTAAAACCAGAAAATT
TATATAATTGAAAATAGAAGGATGGTTGTCTCACTGTTTGGTGCTTCTCCTAACTC
40 AAGGACTTGGACCCATGACTCTGTAGCCAGAAGACTTCAATATTAAATGACTTGT
GGGAATGTCATAAAGAAGAGCCTTCACATGAAATTAGTAGTGTGTTGATAAGAG
TGTAACATCCAGCTCTATGTGGGAAAAAAGAAATCCTGGTTTGTAAATGTTTGTCA
GTAAATACTCCCACTATGCCTGATGTGACGCTACTAACCTGACATCACCAAGTGT
GGAATTGGAGAAAAGCACAATCAACTTTTCTGAGCTGGTGTAAAGCCAGTTCCAG
45 CACACCATTGATGAATTCAAACAAATGGCTGTAAAACTAAACATACATGTTGGG
CATGATTCTACCCTTATTCSCCCCAAGAGACCTAGCTAAGGTCTATAAACATGAA
GGGAAAATTAGCTTTTAGTTTTAAAACTCTTTATCCCATCTTGATTGGGGCAGTTG
ACTTTTTTTTTTCCCAGAGTGCCGTAGTCCTTTTTGTAACCTACCCTCTCAAATGG
ACAATACCAGAAGTGAATTATCCCTGCTGGCTTTCTTTTCTCTATGAAAAGCAAC

TGAGTACAATTGTTATGATCTACTCATTTGCTGACACATCAGTTATATCTTGTGGC
ATATCCATTGTGGAACTGGATGAACAGGATGTATAATATGCAATCTTACTTCTA
TATCATTAGGAAAACATCTTAGTTGATGCTACAAAACACCTTGTCAACCTCTTCC
TGTCTTACCAAACAGTGGGAGGGAATTCCTAGCTGTAAATATAAATTTTGCCCTT
5 CCATTTCTACTGTATAAAACAAATTAGCAATCATTTTATATAAAGAAAATCAATGA
AGGATTTCTTATTTTCTTGGAATTTTGTA AAAAAGAAATTGTGAAAAATGAGCTTG
TAAATACTCCATTATTTTATTTTATAGTCTCAAATCAAATACATACAACCTATGTA
ATTTTAAAGCAAATATATAATGCAACAATGTGTGTATGTTAATATCTGATACTG
TATCTGGGCTGATTTTAAATAAAAATAGAGTCTGGAATGCT

10

SEQ ID NO: 64

>290375H1

GGNCCACCAAGAACCAGCCGCGTCTACGGCTTCATCGGCCTCTGNCTGGCTGCTG
GGCCGCGNCTGCTGGGGATGCTGCCTTTNCTGGGCTGGAAGTGCCTGTNCGCCTT
15 TAACCGCTGCTCCAGCCTTCTGGGGGNNTANTCCATTTTTTANNTTCTCTTCTGCC
TGGNGATCTTNGCCGCGTCTCGGCCACCATNATGGGNCTCTATGGGGCCATCTT
CCGCCTGGNGCAGGCCAGCGGGCAGAAGNCCCCA

20 SEQ ID NO: 65

>gi|187522|gb|M32304.1|HUMMET Human metalloproteinase inhibitor mRNA, complete
cds

GAATTCCGGCCCCGCGTCCCCACCCCGCCGCCCCGCGCGGAATTGCGCCCCG
CGCCCTCCCTCGCGCCCCCGAGACAAAGAGGAGAGAAAGTTTGC GCGGCCGA
GCGGGGCAGGTGAGGAGGGTGAGCCGCGCGGGAGGGGCCCGCCTCGGCCCCGG
25 CTCAGCCCCCGCCGCGCCCCAGCCCGCCGCGCGAGCAGCGCCCGGACCCCC
CAGCGGCGGCCCCCGCCGCCCCAGCCCCCGGCCCGCCATGGGCGCCGCGGCC
GCACCCTGCGGCTGGCGCTCGGCCTCCTGCTGCTGGCGACGCTGCTTCGCCCCGGC
CGACGCTGCAGCTGCTCCCCGGTGCACCCGCAACAGGCGTTTTGCAATGCAGAT
GTAGTGATCAGGGCCAAAGCGGTCAGTGAGAAGGAAGTGGACTCTGGAACGAC
30 ATTTATGGCAACCCTATCAAGAGGATCCAGTATGAGATCAAGCAGATAAAGATG
TTCAAAGGGCCTGAGAAGGATATAGAGTTTATCTACACGGCCCCCTCCTCGGCAG
TGTGTGGGGTCTCGCTGGACGTTGGAGGAAAGAAGGAATATCTCATTGCAGGAA
AGGCCGAGGGGGACGGCAAGATGCACATCACCTCTGTGACTTCATCGTGCCCT
GGGACACCTTGAGCACCACCCAGAAGAAGAGCCTGAACCACAGGTACCAATGG
35 GCTGCGAGTGCAAGATCACGCGCTGCCCCATGATCCCGTGCTACATCTCCTCCCC
GGACGAGTGCCTCTGGATGGACTGGGTACAGAGAAGAACATCAACGGGGACCA
GGCCAAGTTCTTCGCCTGCATCAAGAGAAGTGACGGCTCCTGTGCGTGGTACCGC
GGCGCGGCGCCCCCAAGCAGGAGTTTCTCGACATCGAGGACCCATAAGCAGGC
CTCCAACGCCCTGTGGCCAAGTCAAAAAAGCCTCCAAGGGTTTCGACTGGTC
40 CAGCTCTGACATCCCTTCCTGGAAACAGCATGAATAAAACACTCATCCCCGAAT
TC

SEQ ID NO: 66

>gi|36608|emb|X51416.1|HSSTHOR Human mRNA for steroid hormone receptor hERR1
45 AGCTCACAGCAAGTCCAGGCTAGAGGTAGAAACGTGAGAGCCCCACGGCTGGGG
AAGATTGCCATGGGATTGGAGATGAGCTCCAAGGACAGCCCTGGCAGTCTGGAT
GGAAGAGCTTGGGAAGATGCTCAGAAACCACAAAGTGCCTGGTGCAGTGGGAGG
AAAACCAGAGTGTATGCTACAAGCAGCCGGCGGGCGCCGAGTGAGGGGAC
GCGGCGCGGTGGGGCGGCGCGGCCCGAGGAGGCGGCGGAGGAGGGGCCCGCCG

CGGCCCCCGGCTCACTCCGGCACTCCGGGCGGCTCGGCCCCCATGCCTGCCCGAC
 CGCGCTGCCGGAGCCCCAGGTGACCAGCGCCATGTCCAGCCAGGTGGTGGGCAT
 TGAGCCTCTCTACATCAAGGCAGAGCCGGCCAGCCCTGACAGTCCAAAGGGTTC
 CTCGGAGACAGAGACCGAGCCTCCTGTGGCCCTGGCCCCCTGGTCCAGCTCCCACT
 5 CGCTGCCTCCCAGGCCACAAGGAAGAGGAGGATGGGGAGGGGGCTGGGCCTGG
 CGAGCAGGGCGGTGGGAAGCTGGTGCTCAGCTCCCTGCCCAAGCGCCTCTGCCT
 GGTCTGTGGGGACGTGGCCTCCGGCTACCACTATGGTGTGGCATCCTGTGAGGCC
 TGCAAAGCCTTCTTCAAGAGGACCATCCAGGGGAGCATCGAGTACAGCTGTCCG
 GCCTCCAACGAGTGTGAGATCACCAAGCGGAGACGCAAGGCCTGCCAGGCCTGC
 10 CGCTTCACCAAGTGCCTGCGGGTGGGCATGCTCAAGGAGGGAGTGGCGCTGGAC
 CGCGTCCGGGGTGGGCGGCAGAAAGTACAAGCGGCGGCCGGAGGTGGACCCACTG
 CCCTTCCC GGCCCCCTTCCCTGCTGGGCCCCCTGGCAGTCGCTGGAGGCCCCCGGA
 AGACAGCAGCCCCAGTGAATGCACTGGTGTCTCATCTGCTGGTGGTTGAGCCTGA
 GAAGCTCTATGCCATGCCTGACCCCGCAGGCCCTGATGGGCACCTCCCAGCCGTG
 15 GCTACCCTCTGTGACCTCTTTGACCGAGAGATTGTGGTCACCATCAGCTGGGCCA
 AGAGCATCCCAGGCTTCTCATCGCTGTCGCTGTCTGACCAGATGTCAGTACTGCA
 GAGCGTGTGGATGGAGGTGCTGGTGTGGGTGTGGCCAGCGCTCACTGCCACT
 GCAGGATGAGCTGGCCTTCGCTGAGGACTTAGTCCTGGATGAAGAGGGGGCACG
 GGCAGCTGGCCTGGGGGAACTGGGGGCTGCCCTGCTGCAACTAGTGCGGCGGCT
 20 GCAGGCCCTGCGGCTGGAGCGAGAGGAGTATGTTCTACTAAAGGCCTTGGCCCTT
 GCCAATTACAGACTCTGTGCACATCGAAGATGAGCCGAGGCTGTGGAGCAGCTGC
 GAGAAGCTCCTGCACGAGGCCCTGCTGGAGTATGAAGCCGGCCGGGCTGGCCCC
 GGAGGGGGTGTGTGAGCGGCGGCGGGCGGGCAGGCTGCTGCTCACGCTACCGCTC
 CTCCGCCAGACAGCGGGCAAAGTGCTGGCCATTCTATGGGGTGAAGCTGGAG
 25 GGCAAGGTGCCCATGCACAAGCTGTTCTTGAGATGCTCGAGGCCATGATGGAC
 TGAGGCAAGGGGTGGGACTGGTGGGGGTTCTGGCAGGACCTGCCTAGCATGGGG
 TCAGCCCCAAGGGCTGGGGCGGAGCTGGGGTCTGGGCAGTGCACAGCCTGCTGG
 CAGGGCCAGGGCTAATGCCATCAGCCCCCTGGGAACAGGCCCCACGCCCTCTCCTC
 CCCCTCCTAGGGGGTGTGAGAAGCTGGGAACGTGTGTCCAGGCTCTGGGCACAG
 30 TGCTGCCCCTTGCAAGCCATAACGGTGCCCCCAGAGTGTAGGGGGCCTTGCGGA
 AGCCATAGGGGGCTGCACGGGATGCGTGGGAGGCAGAAACCTATCTCAGGGAGG
 GAAGGGGATGGAGGCCAGAGTCTCCAGTGGGTGATGCTTTTGCTGCTGCTTAAT
 ... CTTACCCCCTCTTCAAAGCAGAGTGGGACTTGAGAGCAAAGGCCCATGCCCCCT
 TCGCTCCTCCTCTCATCATTTGCATTGGGCATTAGTGTCCCCCCTTGAAGCAATAA
 35 CTCCAAGCAGACTCCAGCCCCCTGGACCCCTGGGGTGGCCAGGGCTTCCCCATCAG
 CTCCCAACGAGCCTCCTCAGGGGGTAGGAGAGCACTGCCTCTATGCCCTGCAGA
 GCAATAACACTATATTTATTTTTGGGTTTGGCCAGGGAGGCGCAGGGACATGGGG
 CAAGCCAGGGCCCAGAGCCCTTGGCTGTACAGAGACTCTATTTTAATGTATATTT
 GCTGCAAAGAGAAACCGCTTTTGGTTTTAAACCTTTAATGAGAAAAAATATATA
 40 ATACCGAGCTC

SEQ ID NO: 67

>gi|37089|emb|X70340.1|HSTGFAA H.sapiens mRNA for transforming growth factor alpha
 CTGGAGAGCCTGCTGCCCCGCCCGCCCGTAAAATGGTCCCCTCGGCTGGACAGCTC
 45 GCCCTGTTGCTCTGGGTATTGTGTTGGCTGCGTGCCAGGCCTTGGAGAACAGCA
 CGTCCCCGCTGAGTGCAGACCCGCCCGTGGCTGCAGCAGTGGTGTCCATTTTAA
 TGA CTGCCCAGATTCCCACACTCAGTTCTGCTTCCATGGAACCTGCAGGTTTTTGG
 TGCAGGAGGACAAGCCAGCATGTGTCTGCCATTCTGGGTACGTTGGTGCACGCTG
 TGAGCATGCGGACCTCCTGGCCGTGGTGGCTGCCAGCCAGAAGAAGCAGGCCAT

CACCGCCTTGGTGGTGGTCTCCATCGTGGCCCTGGCTGTCCTTATCATCACATGTG
TGCTGATACTGCTGCCAGGTCCGAAAACACTGTGAGTGGTGCCGGGCCCTCAT
CTGCCGGCACGAGAAGCCCAGCGCCCTCCTGAAGGGAAGAACCGCTTGCTGCCA
CTCAGAAACAGTGGTCTGAAGAGCCCAGAGGAGGAGTTTGGCCAGGTGGACTGT
5 GGCAGATCAATAAAGAAAGGCTTCTTCAGGACAGCACTGCCAGAGATGCCTGGG
TGTGCCACAGACCTTCCTACTTGGCCTGTAATCACCTGTGCAGCCTTTTGTGGGCC
TTCAAAACTCTGTCAAGAACTCCGTCTGCTTGGGGTTATTCAGTGTGACCTAGAG
AAGAAATCAGCGGACCACGATTTCAAGACTTGTTAAAAAAGAACTGCAAAGAGA
CGGACTCCTGTTACCTAGGTGAGGTGTGTGCAGCAGTTGGTGTCTGAGTCCACA
10 TGTGTGCAGTTGTCTTCTGCCAGCCATGGATTCCAGGCTATATATTTCTTTTAAAT
GGGCCACCTCCCCACAACAGAATTCTGCCCAACACAGGAGATTTCTATAGTTATT
GTTTTCTGTCAATTTGCCTACTGGGGAAGAAAGTGAAGGAGGGGAAACTGTTTAAAT
ATCACATGAAGACCCTAGCTTTAAGAGAAGCTGTATCCTCTAACCACGAGACTCT
CAACCAGCCCAACATCTTCCATGGACACATGACATTGAAGACCATCCCAAGCTAT
15 CGCCACCCTTGAGATGATGTCTTATTTATTAGATGGATAATGGTTTTATTTTAA
TCTCTTAAGTCAATGTAAAAAGTATAAAACCCCTTCAGACTTCTACATTAATGAT
GTATGTGTTGCTGACTGAAAAGCTATACTGATTAGAAATGTCTGGCCTCTTCAAG
ACAGCTAAGGCTTGGGAAAAGTCTTCCAGGGTGCAGGAGATGGAACCAGAGGCTG
GGTTACTGGTAGGAATAAAGGTAGGGGTTCAAGAAATGGTGCCATTGAAGCCACA
20 AAGCCGGTAAATGCCTCAATACGTTCTGGGAGAAAACCTTAGCAAATCCATCAGC
AGGGATCTGTCCCCTCTGTTGGGGAGAGAGGAAGAGTGTGTGTGTCTACACAGG
ATAAACCCAATACATATTGTACTGCTCAGTGATTAAATGGGTTCACTTCCTCGTG
AGCCCTCGGTAAAGTATGTTTAGAAATAGAACATTAGCCACGAGCCATAGGCATTT
CAGGCCAAATCCATGAAAGGGGGACCAGTCATTTATTTTCCATTTTGTGCTTGG
25 TTGGTTTGTGCTTTATTTTAAAAGGAGAAGTTTAACTTTGCTATTTATTTTCGA
GCACTAGGAAAACCTATTCCAGTAATTTTTTTTTCTCATTTCATTCCAGGATGCCG
GCTTTATTAACAAAACTCTAACAAGTCACCTCCACTATGTGGGTCTTCCCTTTCCC
CTCAAGAGAAGGAGCAATTGTTCCCCTGACATCTGGGTCCATCTGACCCATGGGG
CCTGCCTGTGAGAAACAGTGGGTCCCTTCAAATACATAGTGGATAGCTCATCCCT
30 AGGAATTTTCATTAAATTTGGAAACAGAGTAATGAAGAAATAATATATAAACT
CCTTATGTGAGGAAATGCTACTAATATCTGAAAAGTGAAAGATTTCTATGTATTA
ACTCTTAAGTGCACCTAGCTTATTACATCGTGAAAGGTACATTTAAAATATGTTA
AATTGGCTTGAAATTTTCAGAGAATTTTGTCTTCCCCTAATTCTTCTTCCCTGGTCT
GGAAGAACAATTTCTATGAATTTTCTCTTTATTTTATTTTATAATTCAGACAATT
35 CTATGACCCGTGTCTTCATTTTGGCACTCTTATTTAACAATGCCACACCTGAAGC
ACTTGGATCTGTTCAAGAGCTGACCCCTAGCAACGTAGTTGACACAGCTCCAGGT
TTTTAAATTACTAAAATAAGTTCAAGTTTACATCCCTTGGGCCAGATATGTGGGT
TGAGGCTTGACTGTAGCATCCTGCTTAGAGACCAATCAATGGACACTGGTTTTTA
GACCTCTATCAATCAGTAGTTAGCATCCAAGAGACTTTGCAGAGGCGTAGGAAT
40 GAGGCTGGACAGATGGCGGAACGAGAGGTTCCCTGCGAAGACTTGAGATTTAGT
GTCTGTGAATGTTCTAGTTCCCTAGGTCCAGCAAGTCACACCTGCCAGTGCCCTCA
TCCTTATGCCTGTAACACACATGCAGTGAGAGGCCTCACATATACGCCTCCCTAG
AAGTGCCTTCCAAGTCAGTCCTTTGGAAACCAGCAGGTCTGAAAAAGAGGCTGC
ATCAATGCAAGCCTGGTTGGACCATTGTCCATGCCTCAGGATAGAACAGCCTGGC
45 TTATTTGGGGATTTTCTTCTAGAAATCAAATGACTGATAAGCATTGGCTCCCTCT
GCCATTTAATGGCAATGGTAGTCTTTGGTTAGCTGCAAAAATACTCCATTTCAAG
TTAAAAATGCATCTTCTAATCCATCTCTGCAAGCTCCCTGTGTTTCCTTGCCCTTT
AGAAAATGAATTGTTCACTACAATTAGAGAATCATTTAACATCCTGACCTGGTAA
GCTGCCACACACCTGGCAGTGGGGAGCATCGCTGTTTCCAATGGCTCAGGAGAC

AATGAAAAGCCCCCATTTAAAAAAATAACAAACATTTTTTAAAAGGCCTCCAAT
ACTCTTATGGAGCCTGGATTTTTCCCACTGCTCTACAGGCTGTGACTTTTTTTAAG
CATCCTGACAGGAAATGTTTTCTTCTACATGGAAAGATAGACAGCAGCCAACCCT
GATCTGGAAGACAGGGCCCCGGCTGGACACACGTGGAACCAAGCCAGGGATGG
5 GCTGGCCATTGTGTCCCCGCAGGAGAGATGGGCAGAATGGCCCTAGAGTTCTTTT
CCCTGAGAAAGGAGAAAAAGATGGGATTGCCACTCACCCACCCACACTGGTAAG
GGAGGAGAATTTGTGCTTCTGGAGCTTCTCAAGGGATTGTGTTTTGCAGGTACAG
AAAACCTGCCTGTTATCTTCAAGCCAGGTTTTCGAGGGGCACATGGGTCAACAGTTG
CTTTTTCAGTCAATTTGGCCGGGATGGACTAATGAGGCTCTAACACTGCTCAGGA
10 GACCCCTGCCCTCTAGTTGGTTCTGGGCTTTGATCTCTTCCAACCTGCCCAGTCAC
AGAAGGAGGAATGACTCAAATGCCCAAACCAAGAACACATTGCAGAAAGTAAG
ACAAACATGTATATTTTTAAATGTTCTAACATAAGACCTGTTCTCTCTAGCCATTG
ATTTACCAGGCTTTCTGAAAAGATCTAGTGGTTCACACAGAGAGAGAGAGAGTAC
TGAAAAAGCAACTCCTCTTCTTAGTCTTAATAATTTACTAAAATGGTCAACTTTTC
15 ATTATCTTTATTATAATAAACCTGATGCTTTTTTTTTAGAACTCCTTACTCTGATGTC
TGTATATGTTGCACTGAAAAGGTTAATATTTAATGTTTTAATTTATTTTGTGTGGT
AAGTTAATTTTGATTCTGTAATGTGTTAATGTGATTAGCAGTTATTTTCCTTAAT
ATCTGAATTATACTTAAAGAGTAGTGAGCAATATAAGACGCAATTGTGTTTTTCA
GTAATGTGCATTGTTATTGAGTTGTACTGTACCTTATTTGGAAGGATGAAGGAAT
20 GAACCTTTTTTTCCTAAAAA

SEQ ID NO: 68

>1570946T6

GCACCTTCACATACAGTATTTTCATTTAGTGCAACAATCCTGCAGTACTGGTCTTAA
25 CCTAATGTTGCAAATGGGGAATCTGAGATTCAACAAGGTTAATTAGCTTGCCCGT
AATCATAAGCACATAAATGTGATTCTCAAGGATTCCAAGGCCCTTGCTCAGTTTA
CTGGCCATGCTGTTTTCTTGCATTTTATGTAGGAAGAACAGGACCCAGGCATCTC
CCTCCACCATTGACCTCCAGAGAAGAGATGACACAGTTGGAAGGGCTGTCTAAG
ACAGACAGGAAATGGAGTTGGGGGCCAAATCTAAGTTAGGGGATCTGAGTTAGG
30 GGAGCACTTCTCAGGAGTGAAAATGCACAGGAAAGTGGTGGCTGGAGTTGGAAG
TGTTAGAGGCCTGAGATCTACGGTCTTGCGCTGCTACAGCACCTGCAAGTTCTAC
TGAGCAGACA

SEQ ID NO: 69

35 >gi|2155852|gb|AA443177.1|AA443177 zx98g10.r1 Soares_NhHMPu_S1 Homo sapiens
cDNA clone IMAGE:811842 5' similar to SW:SR72_CANFA P33731 SIGNAL
RECOGNITION PARTICLE 72 KD PROTEIN ;
CAGATGTGGGATTACTAGCTGTAATTGCAAATAACATCATTACCATTAACAAGGA
CCAAAATGTCTTTGACTCCAAGAAGAAAGTGAAATTAACCAATGCGGAAGGAGT
40 AGAGTTTAAGCTTTCCAAGAAACAACTACAAGCTATAGAATTTAACAAGCTTTA
CTTGCTATGTACACAAACCAGGCTGAACAATGCCGCAAAATATCTGCCAGTTTAC
AGTCCCAAAGTCCCGAGCATCTCTTACCTGTGTTAATCCAAGCTGCCAGCTCTG
CCGTGAAAAGCAGCACACAAAAGCAATAGAGCTGCTTCAGGAATTTTCAGATCA
GCATCCAGAAAATGCAGCTGAAATTAAGCTGACCATGGCACAGTTGAAAATTTTC
45 TCAAGGTAATATTTCTAAAGCATGTCTAATATTGAGAAGCATAGAGGAGTTAAA
GCATAAACCAGGCATGGTATCTGCATTAGTTACCATGTATAGCCATGAAGAAGAT
ATTGATAGTGCCATTGAGGTCTTCACACAAGCTATCCAGTGGTATCAAAACCATC
AGCCAAAATCTCCTGCTCATTG

SEQ ID NO: 70

>gi|220076|dbj|D12763.1|HUMST2M Homo sapiens mRNA for ST2 protein

ATCTCAACAACGAGTTACCAATACTTGCTCTTGATTGATAAACAGAATGGGGTTT
TGGATCTTAGCAATTCTCACAATTCTCATGTATTCCACAGCAGCAAAGTTTAGTA
5 AACAATCATGGGGCCTGGAAAATGAGGCTTTAATTGTAAGATGTCCTAGACAAG
GAAAACCTAGTTACACCGTGGATTGGTATTACTCACAAACAAACAAAAGTATTCC
CACTCAGGAAAGAAATCGTGTGTTTGCCTCAGGCCAACTTCTGAAGTTTCTACCA
GCTGAAGTTGCTGATTCTGGTATTTATACCTGTATTGTCAGAAGTCCCACATTCAA
TAGGACTGGATATGCGAATGTCACCATATATAAAAAACAATCAGATTGCAATGTT
10 CCAGATTATTTGATGTATTCAACAGTATCTGGATCAGAAAAAAATTCCAAAATTT
ATTGTCCTACCATTGACCTCTACAACCTGGACAGCACCTCTTGAGTGGTTTAAGAA
TTGTCAGGCTCTTCAAGGATCAAGGTACAGGGCGCACAAAGTCATTTTTGGTCATT
GATAATGTGATGACTGAGGACGCAGGTGATTACACCTGTAAATTTATACACAATG
AAAATGGAGCCAATTATAGTGTGACGGCGACCAGGTCCTTCACGGTCAAGGATG
15 AGCAAGGCTTTTCTCTGTTTCCAGTAATCGGAGCCCTGCACAAAATGAAATAAA
GGAAGTGGAATTGGAAAAAACGCAACCTAACTTGCTCTGCTTGTTTTGGAAA
AGGCACTCAGTTCTTGCTGCGCTCTGTGGCAGCTTAATGGAACAAAAATTACA
GACTTTGGTGAACCAAGAATTCAACAAGAGGAAGGGCAAAATCAAAGTTTCAGC
AATGGGCTGGCTTGTCTAGACATGGTTTTAAGAATAGCTGACGTGAAGGAAGAG
20 GATTTATTGCTGCAGTACGACTGTCTGGCCCTGAATTTGCATGGCTTGAGAAGGC
ACACCGTAAGACTAAGTAGGAAAAATCCAAGTAAGGAGTGTTTCTGAGACTTTG
ATCACCTGAACTTTCTCTAGCAAGTGTAAAGCAGAATGGAGTGTGGTTCCAAGAGA
TCCATCAAGACAATGGGAATGGCCTGTGCCATAAAATGTGCTTCTCTTCTCGGG
ATGTTGTTTGCTGTCTGATCTTTGTAGACTGTTCTGTTTGCTGGGAGCTTCTCTG
25 CTGCTTAAATTGTTTCGTCTCTCCCCACTCCCTCCTATCGTTGGTTTGTCTAGAACA
CTCAGCTGCTTCTTTGGTCATCCTTGTTTTCTAACTTTATGAACTCCCTCTGTGTCA
CTGTATGTGAAAGGAAATGCACCAACAACCGAAAACTG

SEQ ID NO: 71

>gi|180670|gb|J03210.1|HUMCN4GEL Human collagenase type IV mRNA, 3' end
CCTCTGTCTCCTGGGCTGCCTGCTGAGCCACGCCGCCGCCGCGCCGTCGCCCATC
ATCAAGTTCCCCGGCGATGTCGCCCCCAAACGGACAAAGAGTTGGCAGTGCAA
TACCTGAACACCTTCTATGGCTGCCCAAGGAGAGCTGCAACCTGTTTGTGCTGA
AGGACACAATAAAGAAGATGCAGAAGTTCTTTGGACTGCCCCAGACAGGTGATC
35 TTGACCAGAATACCATCGAGACCATGCGGAAGCCACGCTGCGGCAACCCAGATG
TGGCCAACTACAACCTTCTTCCCTCGCAAGCCCAAGTGGGACAAGAACCAGATCA
CATAACAGGATCATCGGCTACACACCTGATCTGGACCCAGAGACAGTGGATGATG
CCTTTGCTCGTGCCTTCCAAGTCTGGAGCGATGTGACCCCACTGCGGTTTTCTCGA
ATCCATGATGGAGAGGCAGACATCATGATCAACTTTGGCCGCTGGGAGCATGGC
40 GATGGATACCCCTTTGACGGTAAGGACGGACTCCTGGCTCATGCCTTCGCCCCAG
GCACTGGTGTTGGGGGAGACTCCCATTTTGATGACGATGAGCTATGGACCTTGGG
AGAAGGCCAAGTGGTCCGTGTGAAGTATGGGAACGCCGATGGGGAGTACTGCAA
GTTCCCTTCTTGTTCATGGCAAGGAGTACAACAGCTGCACTGATACTGGCCGC
AGCGATGGCTTCTCTGGTGCTCCACCACCTACAACCTTTGAGAAGGATGGCAAGT
45 ACGGCTTCTGTCCCCATGAAGCCCTGTTACCATGGGCGGCAACGCTGAAGGACA
GCCCTGCAAGTTTCCATTCCGCTTCCAGGGCACATCCTATGACAGCTGCACCACT
GAGGGCCGCACGGATGGCTACCGCTGGTGCGGCACCACTGAGGACTACGACCGC
GACAAGAAGTATGGCTTCTGCCCTGAGACCGCCATGTCCACTGTTGGTGGGAAGT
CAGAAGGTGCCCCCTGTGTCTTCCCTTCACTTTCCTGGGCAACAAATATGAGAG

CTGCACCAGCGCCGGCCGCAGTGACGGAAAGATGTGGTGTGCGACCACAGCCAA
CTACGATGACGACCGCAAGTGGGGCTTCTGCCCTGACCAAGGGTACAGCCTGTTC
CTCGTGGCAGCCCACGAGTTTGGCCACGCCATGGGGCTGGAGCACTCCCAAGAC
CCTGGGGCCCTGATGGCACCCATTTACACCTACACCAAGAACTTCCGTCTGTCCC
5 AGGATGACATCAAGGGCATTGAGGAGCTCTATGGGGCCTCTCCTGACATTGACCT
TGGCACCGGCCCCACCCCCACACTGGGGCCTGTCACTCCTGAGATCTGCAAACAG
GACATTGTATTTGATGGCATCGCTCAGATCCGTGGTGAGATCTTCTTCTTCAAGG
ACCGGTTTCAATTTGGCGGACTGTGACGCCACGTGACAAGCCCATGGGGCCCCCTGCT
GGTGGCCACATTCTGGCCTGAGCTCCCGGAAAAGATTGATGCGGTATACGAGGC
10 CCCACAGGAGGAGAAGGCTGTGTTCTTTGCAGGGAATGAATACTGGATCTACTC
AGCCAGCACCTTGGAGCGAGGGTACCCCAAGCCACTGACCAGCCTGGGACTGCC
CCCTGATGTCCAGCGAGTGGATGCCGCCTTTAACTGGAGCAAAAACAAGAAGAC
ATACATCTTTGCTGGAGACAAATTCTGGAGATACAATGAGGTGAAGAAGAAAAT
GGATCCTGGCTTCCCCAAGCTCATCGCAGATGCCTGGAATGCCATCCCCGATAAC
15 CTGGATGCCGTCTGTGGACCTGCAGGGCGGCGGTACAGCTACTTCTTCAAGGGTG
CCTATTACCTGAAGCTGGAGAACCAAAGTCTGAAGAGCGTGAAGTTTGAAGCA
TCAAATCCGACTGGCTAGGCTGCTGAGCTGGCCCTGGCTCCCACAGGCCCTTCTCT
CTCCACTGCCTTCGATACACCGGGCCTGGAGAACTAGAGAAGGACCCGGAGGGG
CCTGGCAGCCGTGCCTTCAGCTCTACAGCTAATCAGCATTCTCACTCCTACCTGGT
20 AATTTAAGATTCAGAGAGTGGCTCCTCCCGGTGCCCAAGAATAGATGCTGACTG
TACTCCTCCCAGGCGCCCCCTTCCCCCTCCAATCCCACCAACCCTCAGAGCCACCC
CTAAAGAGATACTTTGATATTTTCAACGCAGCCCTGCTTTGGGCTGCCCTGGTGC
TGCCACACTTCAGGCTCTTCTCCTTTCACAACCTTCTGTGGCTCACAGAACCCTTG
GAGCCAATGGAGACTGTCTCAAGAGGGGCACTGGTGGCCCGACAGCCTGGCACAG
25 GGCAGTGGGACAGGGCATGGCCAGGTGGCCACTCCAGACCCCTGGCTTTTCACT
GCTGGCTGCCCTTAGAACCTTTCTTACATTAGCAGTTTGCTTTGTATGCACTTTGTT
TTTTTCTTTGGGTCTTGTTTTTTTTTTCCACTTAGAAATTGCATTTCTGACAGAAG
GACTCAGGTTGTCTGAAGTCACTGCACAGTGCATCTCAGCCACATAGTGATGGT
TCCCCTGTTCACTCTACTTAGCATGTCCCTACCGAGTCTCTTCTCCACTGGATGGA
30 GGAAAACCAAGCCGTGGCTTCCCGCTCAGCCCTCCCTGCCCTCCCTTCAACCAT
TCCCCATGGGAAATGTCAACAAGTATGAATAAAGACACCTACTGAGTGGC

SEQ ID NO: 72

>gi|34411|emb|X52941.1|HSE LFR Human LTF mRNA for lactoferrin (lactotransferrin)

35 CTGTGTCTTCTCGTCTGCTGTTCTCGGGGCCCTCGGACTGTGTCTGGCTGGCCG
TAGGAGAAGGAGTGTTCAGTGGTGCGCCGTATCCCAACCCGAGGCCACAAAATG
CTTCCAATGGCAAAGGAATATGAGAAAAGTGCCTGGCCCTCCTGTCAGCTGCAT
AAAGAGAGACTCCCCCATCCAGTGTATCCAGGCCATTGCGGAAAACAGGGCCGA
TGCTGTGACCCTTGATGGTGGTTTCATATACGAGGCAGGCCTGGCCCCCTACAAA
40 CTGCGACCTGTAGCGGCGGAAGTCTACGGGACCGAAAGACAGCCACGAACCTCAC
TATTATGCCGTGGCTGTGGTGAAGAAGGGCGGCAGCTTTCAGCTGAACGAACCTG
CAAGGTCTGAAGTCCTGCCACACAGGCCTTCGCAGGACCGCTGGATGGAATGTC
CCTATAGGGACACTTCGTCCATTCTTGAATTGGACGGGTCCACCTGAGCCCATTG
AGGCAGCTGTGGCCAGGTTCTTCTCAGCCAGCTGTGTTCCCGGTGCAGATAAAGG
45 ACAGTTCCCCAACCTGTGTGCGCTGTGTGCGGGGACAGGGGAAAACAAATGTGC
CTTCTCCTCCCAGGAACCGTACTTCACTACTCTGGTGCCTTCAAGTGTCTGAGA
GACGGGGCTGGAGACGTGGCTTTTATCAGAGAGAGCACAGTGTGTGAGGACCTG
TCAGACGAGGCTGAAAGGGACGAGTATGAGTTACTCTGCCAGACAACACTCGG
AAGCCAGTGGACAAGTTCAAAGACTGCCATCTGGCCCGGGTCCCTTCTCATGCCG

TTGTGGCACGAAGTGTGAATGGCAAGGAGGATGCCATCTGGAATCTTCTCCGCCA
GGCACAGGAAAAGTTTGGAAAGGACAAGTCACCGAAATTCCAGCTCTTTGGCTC
CCCTAGTGGGCAGAAAGATCTGCTGTTCAAGGACTCTGCCATTGGGTTTTCGAGG
GTGCCCCCGAGGATAGATTCTGGGCTGTACCTTGGCTCCGGCTACTTCACTGCCA
5 TCCAGAACTTGAGGAAAAGTGAGGAGGAAGTGGCTGCCCGGCGTGCGCGGGTCTG
TGTGGTGTGCGGTGGGCGAGCAGGAGCTGCGCAAGTGTAACCAAGTGGAGTGGCT
TGAGCGAAGGCAGCGTGACCTGCTCCTCGGCCTCCACCACAGAGGACTGCATCG
CCCTGGTGTGTAAGGAGAAGCTGATGCCATGAGTTTGGATGGAGGATATGTGT
ACACTGCAGGCAAATGTGGTTTGGTGCCTGTCTGGCAGAGAACTACAAATCCCA
10 ACAAAGCAGTGACCCTGATCCTAACTGTGTGGATAGACCTGTGGAAGGATATCTT
GCTGTGGCGGTGGTTAGGAGATCAGACACTAGCCTTACCTGGAAGTCTGTGAAA
GGCAAGAAGTCCTGCCACACCGCCGTGGACAGGACTGCAGGCTGGAATATCCCC
ATGGGCCTGCTCTTCAACCAGACGGGCTCCTGCAAATTTGATGAATATTTTCAGTC
AAAGCTGTGCCCCCTGGGTCTGACCCGAGATCTAATCTCTGTGCTCTGTGTATTGG
15 CGACGAGCAGGGTGAGAATAAGTGCGTGCCCAACAGCAACGAGAGATACTACG
GCTACACTGGGGCTTTCCGGTGCCTGGCTGAGAATGCTGGAGACGTTGCATTTGT
GAAAGATGTCACTGTCTTGCAGAACACTGATGGAAATAACAATGAGGCATGGGC
TAAGGATTTGAAGCTGGCAGACTTTGCGCTGCTGTGCCTCGATGGCAAACGGAA
GCCTGTGACTGAGGCTAGAAGCTGCCATCTTGCCATGGCCCCGAATCATGCCGTG
20 GTGTCTCGGATGGATAAGGTGGAACGCCTGAAACAGGTGTTGCTCCACCAACAG
GCTAAATTTGGGAGAAATGGATCTGACTGCCCGGACAAGTTTTGCTTATTCCAGT
CTGAAACCAAAAACCTTCTGTTCAATGACAACACTGAGTGTCTGGCCAGACTCCA
TGGCAAAACAACATATGAAAAATATTTGGGACCACAGTATGTCGCAGGCATTAC
TAATCTGAAAAAGTGCTCAACCTCCCCCTCCTGGAAGCCTGTGAATTCCTCAGG
25 AAGTAAAACCGAAGAAGATGGCCCAGCTCCCCAAGAAAGCCTCAGCCATTCACT
GCCCCAGCTCTTCTCCCCAGGTGTGTTGGGGCCTTGGCTCCCCTGCTGAAGGTG
GGGATTGCCCATCCATCTGCTTACAATTCCTGCTGTCGTCTTAGCAAGAAGTAA
AATGAGAAATTTTGTGATATTC

30 SEQ ID NO: 73

>gi|36109|emb|X70040.1|HSRON H.sapiens RON mRNA for tyrosine kinase

GGATCCTCTAGGGTCCCAGCTCGCCTCGATGGAGCTCCTCCCGCCGCTGCCTCAG
TCCTTCCTGTTGCTGCTGCTGTTGCCTGCCAAGCCCGCGGCGGGCGAGGACTGGC
AGTGCCCGCGGACCCCTACGCGGCCTCTCGCGACTTTGACGTGAAGTACGTGGT
35 GCCCAGCTTCTCCGCCGAGGCCTGGTACAGGCCATGGTGACCTACGAGGGCGA
CAGAAATGAGAGTGCTGTGTTGTAGCCATACGCAATCGCCTGCATGTGCTTGGG
CCTGACCTGAAGTCTGTCCAGAGCCTGGCCACGGGCCCTGCTGGAGACCCTGGCT
GCCAGACGTGTGCAGCCTGTGGCCCAGGACCCACGGCCCTCCCGGTGACACAG
ACACAAAGGTGCTGGTGCTGGATCCCGCGCTGCCTGCGCTGGTCAGTTGTGGCTC
40 CAGCCTGCAGGGCCGCTGCTTCCCTGCATGACCTAGAGCCCCAAGGGACAGCCGT
GCATCTGGCAGCGCCAGCCTGCCTCTTCTCAGCCCACCATAACCGGCCCGATGAC
TGCCCCGACTGTGTGGCCAGCCATTGGGCACCCGTGTAAGTGTGGTTGAGCAAG
GCCAGGCCTCCTATTTCTACGTGGCATCCTCACTGGACGCAGCCGTGGCTGGCAG
CTTCAGCCCACGCTCAGTGTCTATCAGGCGTCTCAAGGCTGACGCCTCGGGATT
45 GCACCGGGCTTTGTGGCGTTGTGAGTGCTGCCCAAGCATCTTGTCTCCTACAGTA
TTGAATACGTGCACAGCTTCCACACGGGAGCCTTCGTATACTTCTGACTGTACA
GCCGGCCAGCGTGACAGATGATCCTAGTGCCCTGCACACAGCCTGGCACGGCTT
AGCGCCACTGAGCCAGAGTTGGGTGACTATCGGGAGCTGGTCCTCGACTGCAGA
TTTGCTCCAAAACGCAGGCGCCGGGGGGCCCCAGAAGGCGGACAGCCCTACCT

GTGCTGCAGGTGGCCCACTCCGCTCCAGTGGGTGCCCAACTTGCCACTGAGCTGA
GCATCGCCGAGGGCCAGGAAGTACTATTTGGGGTCTTTGTGACTGGCAAGGATG
GTGGTCCTGGCGTGGGCCCCAACTCTGTGCTGTGTCCTTCCCCATTGACCTGCTG
GACACACTAATTGATGAGGGTGTGGAGCGCTGTTGTGAATCCCCAGTCCATCCAG
5 GCCTCCGGCGAGGCCTCGACTTCTTCCAGTCGCCCAGTTTTTGGCCCAACCCGCCT
GGCCTGGAAGCCCTCAGCCCCAACACCAGCTGCCGCCACTTCCCTCTGCTGGTCA
GTAGCAGCTTCTCACGTGTGGACCTATTCAATGGGCTGTTGGGACCAGTACAGGT
CACTGCATTGTATGTGACACGCCTTGACAACGTCACAGTGGCACACATGGGCACA
ATGGATGGGCGTATCCTGCAGGTGGAGCTGGTCAGGTCACTAACTACTTGCTGT
10 ATGTGTCCAACCTTCTCACTGGGTGACAGTGGGCAGCCCGTGCAGCGGGATGTCAG
TCGTCTTGGGGACCACCTACTCTTTGCCTCTGGGGACCAGGTTTTCCAGGTACCTA
TCCGAGGCCCTGGCTGCCGCCACTTCCCTGACCTGTGGGCGTTGCCTAAGGGCATG
GCATTTTCATGGGCTGTGGCTGGTGTGGGAACATGTGCGGCCAGCAGAAGGAGTG
TCCTGGCTCCTGGCAACAGGACCACTGCCACCTAAGCTTACTGAGTTCCACCCC
15 CACAGTGGACCTCTAAGGGGCAGTACAAGGCTGACCCTGTGTGGCTCCAACCTTCT
ACCTTCACCTTCTGGTCTGGTGCCTGAGGGAACCCATCAGGTCACTGTGGGCCA
AAGTCCCTGCCGGCCACTGCCCAAGGACAGCTCAAACTCAGACCAGTGCCCCG
GAAAGACTTTGTAGAGGAGTTTGAGTGTGAACTGGAGCCCTTGGGCACCCAGGC
AGTGGGGCCTACCAACGTCAGCCTCACCGTGAATAACATGCCACCGGGCAAGCA
20 CTTCCGGGTAGACGGCACCTCCGTGCTGAGAGGCTTCTCTTTCATGGAGCCAGTG
CTGATAGCAGTGCAACCCCTCTTTGGCCACGGGCAGGAGGCACCTGTCTCACTC
TTGAAGGCCAGAGTCTGTCTGTAGGCACCAGCCGGGCTGTGCTGGTCAATGGGA
CTGAGTGTCTGTAGCACGGGTCAGTGAGGGGCAGCTTTTATGTGCCACACCCCC
TGGGGCCACGGTGGCCAGTGTCCCCCTTAGCCTGCAGGTGGGGGGTGCCCAGGT
25 ACCTGGTTCTTGACCTTCCAGTACAGAGAAGACCCTGTCGTGCTAAGCATCAGC
CCCAACTGTGGCTACATCAACTCCCATATCACCATCTGTGGCCAGCATCTAACTT
CAGCATGGCACTTAGTGCTGTCAATCCATGACGGGCTTAGGGCAGTGGAAGCA
GGTGTGAGAGGCAGCTTCCAGAGCAGCAGCTGTGCCGCCTTCCCTGAATATGTGGT
CCGAGACCCCCAGGGATGGGTGGCAGGGAATCTGAGTGCCCCGAGGGGATGGAGC
30 TGCTGGCTTTACACTGCCTGGCTTTCGCTTCCCTACCCCCACCCCATCCACCCAGTG
CCAACCTAGTTCCACTGAAGCCTGAGGAGCATGCCATTAAGTTTGAGTATATTGG
GCTGGGCGCTGTGGCTGACTGTGTGGGTATCAACGTGACCGTGGGTGGTGAGAG
CTGCCAGCACGAGTTCCGGGGGGACATGGTTGTCTGCCCCCTGCCCCCATCCCTG
CAGCTTGGCCAGGATGGTGCCCCATTGCAGGTCTGCGTAGATGGTGAATGTCATA
35 TCCTGGGTAGAGTGGTGCGGCCAGGGCCAGATGGGGTCCCACAGAGCACGCTCC
TTGGTATCCTGCTGCCTTTGCTGCTGCTTGTGGCTGCACTGGCGACTGCACTGGTC
TTCAGCTACTGGTGGCGGAGGAAGCAGCTAGTTCTTCCCTCCCAACCTGAATGACC
TGGCATCCCTGGACCAGACTGCTGGAGCCACACCCCTGCCTATTCTGTACTCGGG
CTCTGACTACAGAAAGTGGCCTTGCACTCCCTGCCATTGATGGTCTGGATTCCACC
40 ACTTGTGTCCATGGAGCATCCTTCTCCGATAGTGAAGATGAATCCTGTGTGCCAC
TGCTGCGGAAAGAGTCCATCCAGCTAAGGGACCTGGACTCTGCGCTCTTGGCTGA
GGTCAAGGATGTGCTGATTCCCCATGAGCGGGTGGTCACCCACAGTGACCGAGT
CATTGGCAAAGGCCACTTTGGAGTTGTCTACCACGGAGAATACATAGACCAGGC
CCAGAATCGAATCCAATGTGCCATCAAGTCACTAAGTCGCATCACAGAGATGCA
45 GCAGGTGGAGGCCTTCCCTGCGAGAGGGGCTGCTCATGCGTGGCCTGAACCACCC
GAATGTGCTGGCTCTCATTGGTATCATGTTGCCACCTGAGGGCCTGCCCCATGTG
CTGCTGCCCTATATGTGCCACGGTGACCTGCTCCAGTTTCATCCGCTCACCTCAGC
GGAACCCACCGTGAAGGACCTCATCAGCTTTGGCCTGCAGGTAGCCCGCGGCA
TGGAGTACCTGGCAGAGCAGAAGTTTGTGCACAGGGACCTGGCTGCGCGGAACCT

GCATGCTGGACGAGTCATTACAGTCAAGGTGGCTGACTTTGGTTTGGCCCGCGA
CATCCTGGACAGGGAGTACTATAGTGTTC AACAGCATCGCCACGCTCGCTACCT
GTGAAGTGGATGGCGCTGGAGAGCCTGCAGACCTATAGATTTACCACCAAGTCT
GATGTGTGGTCATTTGGTGTGCTGCTGTGGGAACTGCTGACACGGGGTGCCCCAC
5 CATAACGCCACATTGACCCTTTTGACCTTACCCACTTCCTGGCCCAGGGTTCGGCG
CCTGCCCCAGCCTGAGTATTGCCCTGATTCTCTGTACCAAGTGATGCAGCAATGC
TGGGAGGCAGACCCAGCAGTGCGACCCACCTTCAGAGTACTAGTGGGGGAGGTG
GAGCAGATAGTGTCTGCACTGCTTGGGGACCATTATGTGCAGCTGCCAGCAACCT
ACATGAACTTGGGCCCCAGCACCTCGCATGAGATGAATGTGCGTCCAGAACAGC
10 CGCAGTTCTCACCCATGCCAGGGAATGTACGCCGGCCCCGGCCACTCTCAGAGCC
TCCTCGGCCCACTTGACTTAGTTCTTGGGCTGGACCTGCTTAGCTGCCTTGAGCTA
ACCCCAAGGCTGCCTCTGGGCCATGCCAGGCCAGAGCAGTGGCCCTCCACCTTGT
TCCTGCCCTTTAACTTTT CAGAGGCAATAGGTAAATGGGCCCATTAGGTCCCTCAC
TCCACAGAGTGAGCCAGTGAGGGCAGTCCTGCAACATGTATTTATGGAGTGCCTG
15 CTGTGGACCCTGTCTTCTGGGCACAGTGGACTCAGCAGTGACCACACCAACACTG
ACCCTTGAACCAATAAAGGAACAAATGACTATTAAAGCACAAAAAAAAA

SEQ ID NO: 74

>gi|180020|gb|M86511.1|HUMCD14MCA Human monocyte antigen CD14 (CD14) mRNA,
complete cds
20 GCCGCTGTGTAGGAAAGAAGCTAAAGCACTTCCAGAGCCTGTCCGGAGCTCAGA
GGTTCGGAAGACTTATCGACCATGGAGCGCGCTCCTGCTTGTGTGCTGCTGCTGC
TGCCGCTGGTGCACGTCTCTGCGACCACGCCAGAACCTTGTGAGCTGGACGATGA
AGATTTCCGCTGCGTCTGCAACTTCTCCGAACCTCAGCCCGACTGGTCCGAAGCC
25 TTCCAGTGTGTGTCTGCAGTAGAGGTGGAGATCCATGCCGGCGGTCTCAACCTAG
AGCCGTTTCTAAAGCGCGTCGATGCGGACGCCGACCCGCGGCAGTATGCTGACA
CGGTCAAGGCTCTCCGCGTGCGGCGGCTCACAGTGGGAGCCGCACAGGTTCTTG
CTCAGCTACTGGTAGGCGCCCTGCGTGTGCTAGCGTACTCCCGCCTCAAGGAACT
GACGCTCGAGGACCTAAAGATAACCGGCACCATGCCTCCGCTGCCTCTGGAAGC
30 CACAGGACTTGCACTTTCCAGCTTGCGCCTACGCAACGTGTTCGTGGGCGACAGGG
CGTTCTTGGCTCGCCGAGCTGCAGCAGTGGCTCAAGCCAGGCCTCAAGGTACTGA
GCATTGCCCAAGCACACTCGCCTGCCTTTTCTGCGAACAGGTTGCGGCCTTCCC
GGCCCTTACCAGCCTAGACCTGTCTGACAATCCTGGACTGGGCGAACGCGGACTG
ATGGCGGCTCTCTGTCCCCACAAGTTCCCGGCCATCCAGAATCTAGCGCTGCGCA
35 ACACAGGAATGGAGACGCCACAGGCGTGTGCGCCGCACTGGCGGCGGCAGGTG
TGCAGCCCCACAGCCTAGACCTCAGCCACAACCTCGCTGCGCGCCACCGTAAACCC
TAGCGCTCCGAGATGCATGTGGTCCAGCGCCCTGAACTCCCTCAATCTGTCGTTT
GCTGGGCTGGAACAGGTGCCTAAAGGACTGCCAGCCAAGCTCAGAGTGCTCGAT
CTCAGCTGCAACAGACTGAACAGGGCGCCGACGCTGACGAGCTGCCCGAGGTG
40 GATAACCTGACACTGGACGGGAATCCCTTCCTGGTCCCTGGAACCTGCCCTCCCCC
ACGAGGGCTCAATGAACTCCGGCGTGGTCCCAGCCTGTGCACGTTTCGACCCTGTC
GGTGGGGGTGTCGGGAACCCTGGTGTGCTCCAAGGGGCCCGGGGCTTTGCCTA
AGATCCAAGACAGAATAATGAATGGACTCAAACCTGCCTTGGCTTCAGGGGAGTC
CCGTCAGGACGTTGAGGACTTTTCGACCAATTCAACCCTTTGCCCCACCTTTATTA
45 AAATCTTAAACAACG

SEQ ID NO: 75

>gi|1118663|gb|H97778.1|H97778 yw02b02.s1 Soares melanocyte 2NbHM Homo sapiens cDNA clone IMAGE:251019 3' similar to gb:Z13009_ma1 EPITHELIAL-CADHERIN PRECURSOR (HUMAN);contains Alu repetitive element;

5 CGTTTAACAAAATTGTTTAATAAAATTTATAAAAAATGCATCTTTGAGAATACTTTT
CTCAGCTTGAATTGTTTTCTTTTCCACCCCCAAAGAAAATACACAATTATCAGC
ACCCACACATGTATACTCAAAACTACAGTGACATTCTCTACACAGAACTATAT
TCGATATAGCTTGAAGTGCCGAAAAATCAAGACAATTCCAAAAAGTGATTGCAG
GGTTGATTTTTTTCTCCAAAACACTTTGAGAAACACGTAAAGCTATTTCAACAAA
10 AGTCTTTTCTTTGATTGTCAAAAGTTGAAATTCACATTTAAATAAAAAGAGATCC
AAATCAAGATCCTCACTNACCCCCTACCCCTCAACTGAACCCCCTTTTAGGGCCA
CATTTTCTTCTTGCTCCTAAGAAAAAAATTTGGAATTTTGAATATTCTCGGTTTTT
T

15 SEQ ID NO: 76

>gi|452649|emb|X76180.1|HSLASNA H.sapiens mRNA for lung amiloride sensitive Na⁺ channel protein

CCGGCCAGCGGGCGGGCTCCCCAGCCAGGCCGCTGCACCTGTCAGGGGAACAAG
CTGGAGGAGCAGGACCCTAGACCTCTGCAGCCCATACCAGGTCTCATGGAGGGG
20 AACAAGCTGGAGGAGCAGGACTCTAGCCCTCCACAGTCCACTCCAGGGCTCATG
AAGGGGAACAAGCGTGAGGAGCAGGGGCTGGGCCCCGAACCTGCGGCGCCCCA
GCAGCCCACGGCGGAGGAGGAGGCCCTGATCGAGTTCCACCGCTCCTACCGAGA
GCTCTTCGAGTTCTTCTGCAACAACACCACCATCCACGGCGCCATCCGCCTGGTG
TGCTCCCAGCACAACCGCATGAAGACGGCCTTCTGGGCAGTGCTGTGGCTCTGCA
25 CCTTTGGCATGATGTACTGGCAATTCGGCCTGCTTTTCGGAGAGTACTTCAGCTA
CCCCGTCAGCCTCAACATCAACCTCAACTCGGACAAGCTCGTCTTCCCCGCAGTG
ACCATCTGCACCCTCAATCCCTACAGGTACCCGGAAATTAAAGAGGAGCTGGAG
GAGCTGGACCGCATCACAGAGCAGACGCTCTTTGACCTGTACAAATACAGCTCCT
TCACCACTCTCGTGGCCGGCTCCCGCAGCCGTCGCGACCTGCGGGGGACTCTGCC
30 GCACCCCTTGCAAGCGCCTGAGGGTCCCGCCCCCGCCTCACGGGGCCCGTCGAGCC
CGTAGCGTGGCCTCCAGCTTGCGGGACAACAACCCCCAGGTGGACTGGAAGGAC
TGGAAGATCGGCTTCCAGCTGTGCAACCAGAACAATCGGACTGCTTCTACCAG
ACATACTCATCAGGGGTGGATGCGGTGAGGGAGTGGTACCGCTTCCACTACATC
AACATCCTGTGAGGGCTGCCAGAGACTCTGCCATCCCTGGAGGGAGGACACCGCTG
35 GGCAACTTCATCTTCGCCTGCCGCTTCAACCAGGTCTCCTGCAACCAGGCGAATT
ACTCTCACTTCCACCACCCGATGTATGGAACTGCTATACTTTCAATGACAAGAA
CAACTCCAACCTCTGGATGTCTTCCATGCCTGGAATCAACAACGGTCTGTCCCTG
ATGCTGCGCGCAGAGCAGAATGACTTCATTCCCCTGCTGTCCACAGTGACTGGGG
CCCGGGTAATGGTGCACGGGCAGGATGAACCTGCCTTTATGGATGATGGTGGCTT
40 TAACTTGCGGCCTGGCGTGGAGACCTCCATCAGCATGAGGAAGGAAACCCTGGA
CAGACTTGGGGGCGATTATGGCGACTGCACCAAGAATGGCAGTGATGTTCTGTT
GAGAACCCTTACCCTTCAAAGTACACACAGCAGGTGTGTATTCACTCCTGCTTCC
AGGAGAGCATGATCAAGGAGTGTGGCTGTGCCTACATCTTCTATCCGCGGCCCCA
GAACGTGGAGTACTGTGACTACAGAAAGCACAGTTCTTGGGGTACTGCTACTA
45 TAAGCTCCAGGTTGACTTCTCCTCAGACCACCTGGGCTGTTTACCAAGTGCCGG
AAGCCATGCAGCGTGACCAGCTACCAGCTCTCTGCTGGTTACTCACGATGGCCCT
CGGTGACATCCCAGGAATGGGTCTTCCAGATGCTATCGCGACAGAACAATTACA
CCGTCAACAACAAGAGAAATGGAGTGGCCAAAGTCAACATCTTCTTCAAGGAGC
TGAACTACAAAACCAATTCTGAGTCTCCCTCTGTACAGATGGTCACCCCTCCTGTC

CAACCTGGGCAGCCAGTGGAGCCTGTGGTTCGGCTCCTCGGTGTTGTCTGTGGTG
GAGATGGCTGAGCTCGTCTTTGACCTGCTGGTCATCATGTTCTCATGCTGCTCCG
AAGGTTCCGAAGCCGATACTGGTCTCCAGGCCGAGGGGGCAGGGGTGCTCAGGA
GGTAGCCTCCACCCTGGCATCCTCCCCTCCTTCCCACTTCTGCCCCACCCCATGT
5 CTCTGTCTTGTCCCAGCCAGGCCCTGCTCCCTCTCCAGCCTTGACAGCCCCTCCC
CCTGCCTATGCCACCCTGGGCCCCCGCCCATCTCCAGGGGGCTCTGCAGGGGGCCA
GTTCTCCACCTGTCTCTGGGGGGGGCCCTGAGAGGGAAGGAGAGGTTTCTCACA
CCAAGGCAGATGCTCCTCTGGTGGGAGGGTGCTGGCCCTGGCAAGATTGAAGGA
TGTGCAGGGCTTCTCTCAGAGCCGCCAAACTGCCGTTGATGTGTGGAGGGGAA
10 GCAAGATGGGTAAGGGCTCAGGAAGTTGCTCCAAGAACAGTAGCTGATGAAGCT
GCCCAGAAGTGCCTTGGCTCCAGCCCTGTACCCCTTGGTACTGCCTCTGAACACT
CTGGTTTCCCCACCCAACTGCGGCTAAGTCTCTTTTTCCCTTGGATCAGCCAAGCG
AAACTTGGAGCTTTGACAAGGAACTTTCCTAAGAAACCGCTGATAACCAGGACA
AAACACAACCAAGGGTACACGCAGGCATGCACGGGTTTCCTGCCCAGCGACGGC
15 TTAAGCCAGCCCCGACTGGCCTGGCCACACTGCTCTCCAGTAGCACAGATGTCT
GCTCCTCCTCTTGAACCTTGGGTGGGAAACCCACCCAAAAGCCCCCTTTGTTACT
TAGGCAATTCCCCTTCCCTGACTCCCAGGGGCTAGGGCTAGAGCAGACCCGGGTA
AGTAAAGGCAGACCCAGGGCTCCTCTAGCCTCATAACCGTGCCCTCACAGAGCC
ATGCCCCGGCACCTCTGCCCTGTGTCTTTCATACCTCTACATGTCTGCTTGAGATA
20 TTTCTCAGCCTGAAAGTTTCCCCAACCATCTGCCAGAGAACTCCTATGCATCCCT
TAGAACCTGCTCAGACACCATTACTTTTGTGAACGCTTCTGCCACATCTTGTCTT
CCCCAAAATTGATCACTCCGCCTTCTCCTGGGCTCCCGTAGCACACTATAACATC
TGCTGGAGTGTTGCTGTTGCACCATACTTCTTGTACATTTGTGTCTCCCTTCCCA
ACTAGACTGTAAGTGCCTTGGCGTCAGGGACTGAATCTTGCCCGTTTATGTATGC
25 TCCATGTCTAGCCCATCATCCTGCTTGGAGCAAGTAGGCAGGAGCTCAATAAATG
TTTGTTCATGAAAAAAAAAAAAAAAAAAAA

SEQ ID NO: 77

>gi|189537|gb|M80436.1|HUMPAFR Human platelet activating factor receptor mRNA,
complete cds
30 CTGGTGGCCTTTAATACCTGGCTGTTGCTGAAAGGTCTTTAGAAACGGCGCTAAC
AGCAGGTTTGTGGAATGCCGGATCGCTCAACGGCCTGACGTGGGCAAAAACCTC
GCCTTCCGCACCCATCATTATATTGATGCTCATTGCCGCCGCCTTACTGGTACGCC
GGATGCGCTTGCTGGAAATGGGACACACGGTCACTGCAGCTGAAGCCGCTGCCC
35 CTGCTACAGGCACCACCAGGACCAGCTGATCATTCCAGCCCACAGCAATGGAGC
CACATGACTCCTCCCACATGGACTCTGAGTTCCGATACACTCTCTTCCCGATTGTT
TACAGCATCATCTTTGTGCTCGGGGTCATTGCTAATGGCTACGTGCTGTGGGTCTT
TGCCCGCCTGTACCCTTGCAAGAAATTCAATGAGATAAAGATCTTCATGGTGAAC
CTCACCATGGCGGACATGCTCTTCTTGATCACCCCTGCCACTTTGGATTGTCTACTA
40 CCAAACCAGGGCAACTGGATACTCCCCAAATTCCTGTGCAACGTGGCTGGCTGC
CTTTTCTTCATCAACACCTACTGCTCTGTGGCCTTCTGGGCGTCATCACTTATAA
CCGCTTCAGGCAGTAACTCGGCCCATCAAGACTGCTCAGGCCAACACCCGCAA
GCGTGGCATCTCTTTGTCTTGGTCATCTGGGTGGCCATTGTGGGAGCTGCATCCT
ACTTCCTCATCCTGGACTCCACCAACACAGTGCCCGACAGTGCTGGCTCAGGCAA
45 CGTCACTCGCTGCTTTGAGCATTACGAGAAGGGCAGCGTGCCAGTCCTCATCATC
CACATCTTCATCGTGTTAGCTTCTTCTGGTCTTCTCATCATCCTCTTCTGCAAC
CTGGTCATCATCCGTACCTTGCTCATGCAGCCGGTGACGAGCAGCGCAACGCTG
AAGTCAAGCGCCGGGCGCTGTGGATGGTGTGCACGGTCTTGGCGGTGTTTCATCAT
CTGCTTCGTGCCCCACCACGTGGTGCAGCTGCCCTGGACCCTTGCTGAGCTGGGC

TTCCAGGACAGCAAATTCCACCAGGCCATTAATGATGCACATCAGGTCACCCTCT
GCCTCCTTAGCACCAACTGTGTCTTAGACCCTGTTATCTACTGTTTCCTCACCAAG
AAGTTCCGCAAGCACCTCACCGAAAAGTTCTACAGCATGCGCAGTAGCCGAAA
TGCTCCCGGGCCACCACGGATACGGTCACTGAAGTGGTTGTGCCATTCAACCAGA
5 TCCCTGGCAATTCCCTCAAAAATTAGTCCCTGCTTCCAGGCCTGAAGTCTTCTCCT
CCATGAACATCATGGACTGAGCTGGGGGAAGAAGGGATATCTACTGTGGTCTGG
GCACCACCTCTGTGGGCACTGGTGGGGCATTAGATTTGGAGGCTACCTCACCTGG
GCAGGGATGATGGCAGAGCCAGGCTGTTGGAAAATCCAGAACTCAAATGAGCCC
CTTCATCCGCCTGTGGGGCATACTACAGTAACTGTGACTTGATGACTTTATCTGA
10 GTCCTTAT

SEQ ID NO: 78

>gi|1835924|gb|S82666.1|S82666 Homo sapiens serine protease-like protein mRNA,
complete cds

15 ACCAGCGGCAGACCACAGGCAGGGCAGAGGCACGTCTGGGTCCCCCTCCCTCCTT
CCTATCGGCGACTCCCAGATCCTGGCCATGAGAGCTCCGCACCTCCACCTCTCCG
CCGCCTCTGGCGCCCCGGGCTCTGGCGAAGCTGCTGCCGCTGCTGATGGCGCAACT
CTGGGGCCGCAGAGGCGGCGCTGCTCCCCCAAACGACACGCGCTTGGACCCCGA
AGCCTATGGCGCCCCGTGCGCGCGCGGCTCGCAGCCCTGGCAGGTCTCGCTCTTC
20 AACGGCCTCTCGTTCCACTGCGCGGGTGTCTGGTGGACCAGAGTTGGGTGCTGA
CGGCCGCGCACTGCGGAAACAAGCCACTGTGGGCTCGAGTAGGGGATGATCACC
TGCTGCTTCTTCAGGGCGAGCAGCTCCGCCGGACGACTCGCTCTGTTGTCCATCC
CAAGTACCACCAGGGCTCAGGCCCCATCCTGCCAAGGCGAACGGATGAGCACGA
TCTCATGTTGCTAAAGCTGGCCAGGCCCCGTAGTGCCGGGGCCCCCGCGTCCGGGCC
25 CTGCAGCTTCCCTACCGCTGTGCTCAGCCCCGAGACCAGTGCCAGGTTGCTGGCT
GGGGCACCACGGCCGCCCGGAGAGTGAAGTACAACAAGGGCCTGACCTGCTCCA
GCATCACTATCCTGAGCCCTAAAGAGTGTGAGGTCTTCTACCCTGGCGTGGTCAC
CAACAACATGATATGTGCTGGACTGGACCGGGGCCAGGACCCTTGCCAGAGTGA
CTCTGGAGGGCCCCCTGGTCTGTGACGAGACCCTCCAAGGCATCCTCTCGTGGGGT
30 GTTTACCCCTGTGGCTCTGCCCAGCATCCAGCTGTCTACACCCAGATCTGCAAAT
ACATGTCCTGGATCAATAAAGTCATAGCTCCAAGTATCCAGATGCTACGCTCCA
GCTGATCCAGATGTTATGCTCCTGCTGATCCAGATGCCCAGAGGCTCCATCGTCC
ATCCTCTTCTCCCCAGTCGGCTGAACTCTCCCCTTGTCTGCACTGTTCAAACCTC
TGCCGCCCTCCACACCTCTAAACATCTCCCCTCTCACCTCATTTCCCCACCTATCC
35 CCATTCTCTGCCTGTACTGAAGCTGAAATGCAGGAAGTGGTGGCAAAGGTTTATT
CCAGAGAAGCCAGGAAGCCGGTCATCACCCAGCCTCTGAGAGCAGTTACTGGGG
TCACCCAACCTGACTTCCTCTGCCACTCCCCGCTGTGTGACTTTGGGCAAGCCAA
GTGCCCTCTCTGAACCTCAGTTTCCCTCATCTGCAAAATGGGAACAATGACGTGCC
TACCTCTTAGACATGTTGTGAGGAGACTATGATATAACATGTGTATGTAAATCTT
40 CATGTGATTGTCATGTAAGGCTTAACACAGTGGGTGGTGAGTTCTGACTAAAGGT
TACCTGTTGTCTGTGAAAAAAAAAAAAAAAAAAAAA

SEQ ID NO: 79

>gi|1859520|gb|AA234897.1|AA234897 zs36c04.s1 Soares_NhHMPu_S1 Homo sapiens
cDNA clone IMAGE:687270 3'

45 ACTCTGCTTACATTTTATAAGTTTAAAGGTCAGCTGTCAAAGGATAACCTGTGGG
GTTAGAACATATCACATTGCAACACCCTAAATTGTTTTTAATACATTAGCAATCT
ATTGGGTCAACTGACATCCATTGTATATACTAGTTTCTTTTCATGCTATTTTTATTTT
GTTTTTGCATTTTTATCAAATGCAGGGCCCCCTTCTGATCTCACCATTTCACCAT

GCATCTTGAATTTCAGTAAGTGCATATCCTAACTTGCCCATATTCTAAATCATCTG
GTTGGTTTTTCAGCCTAGAATTTGATACGCTTTTTAGAAATATGCCCAGAATAGAA
AAGCTATGTTGGGGCACATGTCCTGCAAATATGGCCCTAGAAACAAGTGATATG
GAATTTACTTGGTGAATAAGTTATAAATTCCCACT

5

SEQ ID NO: 80

>gi|927844|gb|R83000.1|R83000 yp87a05.s1 Soares fetal liver spleen 1NFLS Homo sapiens
cDNA clone IMAGE:194384 3'

NTGAGGNTGAGAACTTTATACCACNTTGTNACACTACACCGTGATTTTAAATCT
10 TTAATCAAATTCCAAAGGTTATCAGCCATATTACATGCCATGATTAGCTTTCTATA
AGCAATTTTTTTNACTGTGTACAGATCGGTGTCAATGAAATAAAAAAATAAAACT
GTATACTAGGGCAAAGAACTTTATTAATCTTTGTTTCAAACCTTGATTCCCAGGGC
TTCTTCGGGCTTAATTAGGCTGCAAAGGAATGAATTGTGTATAAGGCAAAAACCTG
AAAAGGAGGCTGGCAGTGTCCAAGGGGGCTTGGGGGCTTAAAAATATTAGGAGG
15 ATCCCAGGATTTTATCC

SEQ ID NO: 81

>gi|31197|emb|X03363.1|HSERB2R Human c-erb-B-2 mRNA

AAGGGGAGGTAACCCTGGCCCCCTTTGGTTCGGGGCCCCCGGGCAGCCGCGCGCCCC
20 TTCCACGGGGCCCTTTACTGCGCCGCGCGCCCCGGCCCCCACCCTCGCAGCACC
CCGCGCCCCGCGCCCTCCAGCCGGGTCCAGCCGGAGCCATGGGGCCGGAGCCG
CAGTGAGCACCATGGAGCTGGCGGCCTTGTGCCGCTGGGGGCTCCTCCTCGCCCT
CTTGCCCCCGGAGCCGCGAGCACCCAAGTGTGCACCGGCACAGACATGAAGCT
GCGGCTCCCTGCCAGTCCCAGACCCACCTGGACATGCTCCGCCACCTCTACCAG
25 GGCTGCCAGGTGGTGCAGGGAAACCTGGAACCTCACCTACCTGCCCACCAATGCC
AGCCTGTCCTTCCCTGCAGGATATCCAGGAGGTGCAGGGCTACGTGCTCATCGCTC
ACAACCAAGTGAGGCAGGTCCCCTGCAGAGGCTGCGGATTGTGCGAGGGCACCC
AGCTCTTTGAGGACAACCTATGCCCTGGCCGTGCTAGACAATGGAGACCCGCTGA
ACAATACCACCCCTGTACAGGGGCCTCCCCAGGAGGCCTGCGGGAGCTGCAGC
30 TTCGAAGCCTCACAGAGATCTTGAAAGGAGGGGTCTTGATCCAGCGGAACCCCC
AGCTCTGCTACCAGGACACGATTTTGTGGAAGGACATCTTCCACAAGAACAACC
AGCTGGCTCTCACACTGATAGACACCAACCGCTCTCGGGCCTGCCACCCCTGTTC
TCCGATGTGTAAGGGCTCCCGCTGCTGGGGAGAGAGTTCTGAGGATTGTCAGAG
CCTGACGCGCACTGTCTGTGCCGGTGGCTGTGCCCGCTGCAAGGGGGCACTGCCC
35 ACTGACTGCTGCCATGAGCAGTGTGCTGCCGGCTGCACGGGCCCCAAGCACTCTG
ACTGCCTGGCCTGCCTCCACTTCAACCACAGTGGCATCTGTGAGCTGCACTGCCC
AGCCCTGGTCACCTACAACACAGACACGTTTGAGTCCATGCCCAATCCCGAGGGG
CGGTATACATTCGGCGCCAGCTGTGTGACTGCCTGTCCCTACAACCTACCTTTCTAC
GGACGTGGGATCCTGCACCCTCGTCTGCCCCCTGCACAACCAAGAGGTGACAGC
40 AGAGGATGGAACACAGCGGTGTGAGAAGTGCAGCAAGCCCTGTGCCCCGAGTGTG
CTATGGTCTGGGCATGGAGCACTTGCGAGAGGTGAGGGCAGTTACCAGTGCCAA
TATCCAGGAGTTTGTGGCTGCAAGAAGATCTTTGGGAGCCTGGCATTCTGCCG
GAGAGCTTTGATGGGGACCCAGCCTCCAACACTGCCCCGCTCCAGCCAGAGCAG
CTCCAAGTGTGAGACTCTGGAAGAGATCACAGGTACCTATACATCTCAGCAT
45 GGCCGGACAGCCTGCCTGACCTCAGCGTCTTCCAGAACCTGCAAGTAATCCGGG
GACGAATTCTGCACAATGGCGCCTACTCGCTGACCCTGCAAGGGCTGGGCATCA
GCTGGCTGGGGCTGCGCTCACTGAGGGAACTGGGCAGTGGACTGGCCCTCATCC
ACCATAACACCCACCTCTGCTTCGTGCACACGGTGCCCTGGGACCAGCTCTTTCG
GAACCCGCACCAAGCTCTGCTCCACACTGCCAACC GGCCAGAGGACGAGTGTGT

GGGCGAGGGCCTGGCCTGCCACCAGCTGTGCGCCCCGAGGGCACTGCTGGGGTCC
AGGGCCCAACCCAGTGTGTCAACTGCAGCCAGTTCCTTCGGGGCCAGGAGTGCCT
GGAGGAATGCCGAGTACTGCAGGGGCTCCCCAGGGAGTATGTGAATGCCAGGCA
CTGTTTGCCGTGCCACCCTGAGTGTGAGCCCCAGAATGGCTCAGTGACCTGTTTT
5 GGACCGGAGGGCTGACCAGTGTGTGGCCTGTGCCCCACTATAAGGACCTCCCTTCT
GCGTGGCCCCGCTGCCCCAGCGGTGTGAAACCTGACCTCTCCTACATGCCCATCTG
GAAGTTTCCAGATGAGGAGGGCGCATGCCAGCCTTGCCCCATCAACTGCACCCA
CTCCTGTGTGGACCTGGATGACAAGGGCTGCCCCGCCGAGCAGAGAGCCAGCCC
TCTGACGTCCATCATCTCTGCGGTGGTTGGCATTCTGCTGGTCGTGGTCTTGGGGG
10 TGGTCTTTGGGATCCTCATCAAGCGACGGCAGCAGAAGATCCGGAAGTACACGA
TGCGGAGACTGCTGCAGGAAACGGAGCTGGTGGAGCCGCTGACACCTAGCGGAG
CGATGCCCAACCAGGCGCAGATGCGGATCCTGAAAGAGACGGAGCTGAGGAAG
GTGAAGGTGCTTGGATCTGGCGCTTTTGGCACAGTCTACAAGGGCATCTGGATCC
CTGATGGGGAGAATGTGAAAATTCCAGTGGCCATCAAAGTGTTGAGGGAAAACA
15 CATCCCCCAAAGCCAACAAAGAAATCTTAGACGAAGCATACTGATGGCTGGTG
TGGGCTCCCCATATGTCTCCCGCCTTCTGGGCATCTGCCTGACATCCACGGTGCA
GCTGGTGACACAGCTTATGCCCTATGGCTGCCTCTTAGACCATGTCCGGGAAAAC
CGCGGACGCCTGGGCTCCCAGGACCTGCTGAACTGGTGTATGCAGATTGCCAAG
GGGATGAGCTACCTGGAGGATGTGCGGCTCGTACACAGGGACTTGGCCGCTCGG
20 AACGTGCTGGTCAAGAGTCCCAACCATGTCAAATTACAGACTTCGGGCTGGCTC
GGCTGCTGGACATTGACGAGACAGAGTACCATGCAGATGGGGGCAAGGTGCCCA
TCAAGTGGATGGCGCTGGAGTCCATTCTCCGCCGGCGGTTCAACCACAGAGTGA
TGTGTGGAGTTATGGTGTGACTGTGTGGGAGCTGATGACTTTTGGGGCCAAACCT
TACGATGGGATCCCAGCCCCGGGAGATCCCTGACCTGCTGGAAAAGGGGGAGCGG
25 CTGCCCCAGCCCCCATCTGCACCATTGATGTCTACATGATCATGGTCAAATGTT
GGATGATTGACTCTGAATGTGCGCCAAGATTCCGGGAGTTGGTGTCTGAATTCTC
CCGCATGGCCAGGGACCCCCAGCGCTTTGTGGTCATCCAGAATGAGGACTTGGG
CCCAGCCAGTCCCTTGGACAGCACCTTCTACCGCTCACTGCTGGAGGACGATGAC
ATGGGGGACCTGGTGGATGCTGAGGAGTATCTGGTACCCCAGCAGGGCTTCTTCT
30 GTCCAGACCCTGCCCCGGGCGCTGGGGGCATGGTCCACCACAGGCACCGCAGCT
CATCTACCAGGAGTGGCGGTGGGGACCTGACACTAGGGGCTGGAGCCCTCTGAAG
AGGAGGCCCCCAGGTCTCCACTGGCACCTCCGAAGGGGCTGGCTCCGATGTATT
TGATGGTGACCTGGGAATGGGGGCAGCCAAGGGGCTGCAAAGCCTCCCCACACA
TGACCCCAGCCCTCTACAGCGGTACAGTGAGGACCCACAGTACCCCTGCCCTCT
35 GAGACTGATGGCTACGTTGCCCCCTGACCTGCAGCCCCCAGCCTGAATATGTGA
ACCAGCCAGATGTTGCGCCCCAGCCCCCTTCGCCCCGAGAGGGGCCCTCTGCCTGC
TGCCCCGACCTGCTGGTGCCACTCTGGAAGGGCCCAAGACTCTCTCCCCAGGGAAG
AATGGGGTCGTCAAAGACGTTTTTGCCTTTGGGGGTGCCGTGGAGAACCCCGAGT
ACTTGACACCCCAGGGAGGAGCTGCCCCCTCAGCCCCACCCTCCTCCTGCCTTCAG
40 CCCAGCCTTCGACAACCTCTATTACTGGGACCAGGACCCACCAGAGCGGGGGGC
TCCACCCAGCACCTTCAAAGGGACACCTACGGCAGAGAACCCAGAGTACCTGGG
TCTGGACGTGCCAGTGTGAACCAGAAGGCCAAGTCCGCAGAAGCCCTGATGTGT
CCTCAGGGAGCAGGGAAGGCCTGACTTCTGCTGGCATCAAGAGGTGGGAGGGCC
CTCCGACCACTTCCAGGGGAACCTGCCATGCCAGGAACCTGTCCTAAGGAACCTT
45 CCTTCCTGCTTGAGTTCCAGATGGCTGGAAGGGGTCCAGCCTCGTTGGAAGAGG
AACAGCACTGGGGAGTCTTTGTGGATTCTGAGGCCCTGCCCAATGAGACTCTAGG
GTCCAGTGGATGCCACAGCCCAGCTTGGCCCTTTCCTTCCAGATCCTGGGTACTG
AAAGCCTTAGGGAAGCTGGCCTGAGAGGGGAAGCGGCCCTAAGGGAGTGTCTAA
GAACAAAAGCGACCCATTACAGAGACTGTCCCTGAAACCTAGTACTGCCCCCAT

GAGGAAGGAACAGCAATGGTGTCTAGTATCCAGGCTTTGTACAGAGTGCTTTTCTG
TTTAGTTTTTACTTTTTTTGTTTTGTTTTTTAAAGATGAAATAAAGACCCAGGGG
GAG

5 SEQ ID NO: 82
>gi|927595|gb|U27109.1|HSU27109 Human prepromultimerin mRNA, complete cds
CTGCTATCAAAAAGGCCATAAGGATTTTGTCCCAAATTCACATGAGCTACCTT
GCTTCAAACACTACTGAGATGAAGGGGGCAAGATTATTTGTCCTTCTTTCTAGTTTAT
GGAGTGGGGGCATTGGGCTTAACAACAGTAAGCATTCTTGGACTATACCTGAGG
10 ATGGGAACTCTCAGAAGACTATGCCTTCTGCTTCAGTTCCTCCAAATAAAATACA
AAGTTTGCAAATACTGCCAACCCTCGGGTCATGTCGGCGGAGATAGCTACAAC
CCAGAGGCAAGAAGTTCTGAAGACAGTCTTCTTAAATCAACACTGCCTCCCTCAG
AAACAAGTGCACCTGCTGAGGGTGTGAGAAATCAAACCTCTCACATCCACAGAGA
AAGCAGAAGGAGTGGTCAAGTTACAGAATCTTACCCTCCCAACCAACGCTAGCA
15 TCAAGTTCAATCCTGGAGCAGAATCAGTGGTCTTCCAATTCTACACTGAAATT
TCTTCAGAGCTTTGCCAGAAAGTCAAATGAACAAGCAACTTCTCTAAACACAGTT
GGAGGCACTGGAGGCATTGGAGGCGTTGGAGGCACTGGAGGCGTGGGAAATCG
AGCCCCACGGGAAACATACCTCAGCCGGGGTGACAGCAGTTCAGCCAAAGAAG
TGACTACCAAAAATCAAATTTGAAACAAGTAGAGGAAAGAATTGGTGTGCTTA
20 TGTACATACCAGGTTATCTCCACAGTGACATTGGACAACCAGGTCACTTATGTC
CCAGGTGGGAAAGGACCTTGTGGCTGGACCGGTGGATCCTGTCTCAGAGATCTC
AGAAGATATCCAATCCTGTCTATAGGATGCAACATAAAATTGTCACCTCATTGGA
TTGGAGGTGCTGTCTGGATACAGTGGGCCGAAATGTCAACTAAGAGCCCAGGA
ACAGCAAAGTTTGATACACACCAACCAGGCTGAAAGTCATACAGCTGTTGGCAG
25 AGGAGTAGCTGAGCAGCAGCAGCAGCAAGGCTGTGGTGACCCAGAAGTGATGCA
AAAAATGACTGATCAGGTGAACTACCAGGCAATGAAACTGACTCTTCTGCAGAA
GAAGATTGACAATATTTCTTTGACTGTGAATGATGTAAGGAACACTTACTCCTCC
CTAGAAGGAAAAGTCAGCGAAGATAAAAGCAGAGAATTTCAATCTCTTCTAAAA
GGTCTAAAATCCAAAAGCATTAAATGTACTGATAAGAGACATAGTAAGAGAACAA
30 TTTAAAATTTTCAAAATGACATGCAAGAGACTGTAGCACAGCTCTTCAAGACTG
TATCAAGTCTATCAGAGGACCTCGAAAGCACCAGGCAAATAATTCAAAAAGTTA
ATGAATCTGTGGTTTCAATAGCAGCCCAGCAAAAGTTTGTGTTTGGTGCAAGAGAA
TCGGCCCACCTTTGACTGATATAGTGGAATAAGGAATCACATTGTGAATGTAAGG
CAAGAAATGATCTTACATGTGAGAAAGCCTATTAAAGAACTAGAAGTAAAGCAG
35 ACTCATTTAGAAGGTGCTCTAGAACAGGAACACTCAAGAAGCATTCTGTATTATG
AATCCCTCAATAAAACTCTTTCTAAATTGAAGGAAGTACATGAGCAGCTTTTATC
AACTGAACAGGTATCAGACCAGAAGAATGCTCCAGCTGCTGAGTCAGTTAGCAA
TAATGTCACTGAGTACATGTCTACTTTACATGAAAATATAAAGAAGCAGAGTTTG
ATGATGCTGCAAATGTTTGAAGATTTGCACATTCAAGAAAGCAAGATTAAACAATC
40 TCACCGTCTCTTTGGAGATGGAGAAAGAGTCTCTCAGAGGTGAATGTGAAGACA
TGTTATCCAAATGCAGAAATGATTTTAAATTTCAACTTAAGGACACAGAAGAGA
ATTTACATGTGTAAATCAAACATTGGCTGAAGTTCTCTTTCCAATGGACAATAA
GATGGACAAAATGAGTGAGCAACTAAATGATTTGACTTATGATATGGAGATCCTT
CAACCCTTGCTTGAGCAGGGAGCATCACTCAGACAGACAATGACATATGAACAA
45 CCAAAGGAAGCAATAGTGATAAGGAAAAAGATAGAAAATCTGACTAGTGCTGTC
AATAGTCTAAATTTTATTATCAAAGAACTTACAAAAAGACACAACCTTACTTAGAA
ATGAAGTACAGGGTCGTGATGATGCCTTAGAAAGACGTATCAATGAATATGCCTT
AGAAATGGAAGATGGCCTCAATAAGACAATGACTATTATAAATAATGCTATTGA
TTTCATTCAAGATAACTATGCCCTAAAAGAGACTTTAAGTACTATTAAGGATAAT

AGTGAGATCCATCATAAATGTACCTCCGATATGGAAACTATTTTGACATTTATTC
 CTCAGTTCCACCGTCTGAATGATTCTATTTCAGACTTTGGTCAATGACAATCAGAG
 ATATAACTTTGTTTTGCAAGTCGCCAAGACCCTTGCAGGTATTCCCAGAGATGAG
 AAATAAATCAGTCCAACCTCCAAAAGATGTATCAAATGTTCAATGAAACCACTT
 5 CCCAAGTGAGAAAATACCAGCAAAATATGAGTCATTGGAAGAAAACTACTCT
 TAACTACCAAGATTTCCAAAAATTTTGAGACTCGGTTGCAAGACATTGAGTCTAA
 AGTTACCCAGACGCTCATACCTTATTATATTTTCAGTTAAAAAAGGCAGTGTAGTT
 ACAAATGAGAGAGATCAGGCTCTTCAACTGCAAGTATTAAATTCAGATTTAAG
 GCGTTGGAAGCAAAATCTATCCATCTTTCAATTAACCTTCTTTTCGCTTAACAAAAC
 10 TCTCCACGAAGTTTTAACAATGTGTCAATGCTTCTACAAGTGTGTGAGAAGT
 AATGCTACCATCCCTAAGTGGATAAAACATTCCCTGCCAGATATTCAACTTCTTC
 AGAAAGGTCTAACAGAATTTGTGGAACCAATAATTCAAATAAAAACTCAAGCTG
 CCCTATCTAATTCAACTTGTTGTATAGATCGATCGTTGCCTGGTAGTCTGGCAAAT
 GTTGTCAAGTCTCAGAAGCAAGTAAAATCATTGCCAAAGAAAATTAACGCACTT
 15 AAGAAACCAACGGTAAATCTTACCACAGTCCTGATAGGCCGGAAGTCAAAGAAAC
 ACGGACAACATAATATCCTGAGGAGTATTCAAGCTGTAGTCGGCATCCGTGCC
 AAAATGGGGGCACGTGCATAAATGGAAGAACTAGCTTTACCTGTGCCTGCAGAC
 ATCCTTTTACTGGTGACAACTGCACTATCAAGCTTGTGGAAGAAAATGCTTTAGC
 TCCAGATTTTCCAAAGGATCTTACAGATATGCACCCATGGTGGCATTTTTTTGCAT
 20 CTCATACGTATGGAATGACTATACCTGGTCTATCCTGTTTAATAACTTGGATGTC
 AATTATGGAGCTTCATATACCCCAAGAACTGGAAAATTTAGAATTCCGTATCTTG
 GAGTATATGTTTTCAAGTACACCATCGAGTCATTAGTGCTCATATTTCTGGATTT
 TTAGTGGTTGATGGAATAGACAAGCTTGCATTTGAGTCTGAAAATATTAACAGTG
 AAATACACTGTGATAGGGTTTTAACTGGGGATGCCTTATTAGAATTAAATTATGG
 25 GCAGGAAGTCTGGTTACGACTTGCAAAAGGAACAATTCCAGCCAAGTTCCCCCT
 GTTACTACATTTAGTGGCTATTTATTATATCGTACATAAGTTAGTATGAAAAACA
 GACTATCACCTTTATTGAGAAACAGCCAGTGTTTTCATTTATCTTTGCTTGCACAT
 CTGCTCTGTTTTGGTTTTTCTACAGGAAATGAAAATCAACTTGTTTTTTAATATG
 AGTAAACTTGTATGTCTATTTTATAAAATTATTTGAATATTGTTTAATGTCTGAAT
 30 ATGAAAGAGTTCCTTGATCCTAAAGAAATTTAGTGGCACAGAAAACAAAGTGAAT
 TTGTTAGCATAATTATTCCTATTCTTATTTCTTCATTTTAAGTCATTGCAATGGAA
 AGTAATATTATAAAACGGTAATTACAACATATTATCAGTCACAGTTTTCTTTCCA
 ATTAACACTTAACTTTTGTTATTCCCTGTATATAAATATATAACACACATTTTCT
 AGATTCACAAATTTAAATAAATTACTCAAAAAATG

35

SEQ ID NO: 83

>gi|182984|gb|L03203.1|HUMGAS3X Human peripheral myelin protein 22 (GAS3) mRNA,
complete cds

CGGCGCCAGCAGCGGAGCCAACGCACCCGAGTTTGTGTTTGAGGCCACCCTGAG
 40 GATCGGGACAGCTGTTCCCTTGGGCTGCAGAACTCCGCTGAGCAGAACTTGCCG
 CCAGAATGCTCCTCCTGTTGCTGAGTATCATCGTCCTCCACGTCGCGGTGCTGGT
 GCTGCTGTTCTCTCCACGATCGTCAGCCAATGGATCGTGGGCAATGGACACGCA
 ACTGATCTCTGGCAGAACTGTAGCACCTCTTCTCAGGAAATGTCCACCACTGTT
 TCTCATCATACCAAACGAATGGCTGCAGTCTGTCCAGGCCACCATGATCCTGTC
 45 GATCATCTTCAGCATTCTGTCTCTGTTCTTCTGCCAACCTTTCACCCTCAC
 CAAGGGGGGCGAGTTTTACATCACTGGAATCTTCCAAATTCTTGCTGGTCTGTGC
 GTGATGAGTGCTGCGGCCATCTACACGGTGAGGCACCCGGAGTGGCATCTCAAC
 TCGGATTACTCTACGGTTTCGCCTACATCCTGGCCTGGGTGGCCTCCCCCTGGC
 CTTCTCAGCGGTGTCATCTATGTGATCTTGCGGAAACGCGAATGAGGCGCCAG

ACGGTCTGTCTGAGGCTCTGAGCGTACATAGGGAAGGGAGGAAGGGAAACCAGA
AAGCAGACAAAGAAAAAAGAGCTAGCCCAAAATCCCAAACTCAAACCAAACAG
AAAGCAGTGGAGGTGGGGGTTGCTGTTGATTGAAGATGTATATAATATCTCCGGT
5 TTATAAAACCTATTTATAACACTTTTTACATATATGTACATAGTATTGTTTGCTTT
TTATGTTGACCATCAGCCTCGTGTTGAGCCTTAAAGAAGTAGCTAAGGAACCTTA
CATCCTAACAGTATAATCCAGCTCAGTATTTTTGTTTTGTTTTTTGTTTGTTT
TGTTTTACCCAGAAATAAGATAACTCCATCTCGCCCCCTCCCTTTCATCTGAAAGA
AGATACCTCCCTCCCAGTCCACCTCATTTAGAAAACCAAAGTGTGGGTAGAAACC
CCAAATGTCCAAAAGCCCTTTTCTGGTGGGTGACCCAGTGCATCCAACAGAAACA
10 GCCGCTGCCCGAACCTCTGTGTGAAGCTTTACGCGCACACGGACAAAATGCCCA
AACTGGAGCCCTTGCAAAAACACGGCTTGTGGCATTGGCATACTTGCCCTTACAG
GTGGAGTATCTTCGTACACATCTAAATGAGAAATCAGTGACAACAAGTCTTTGA
AATGGTGCTATGGATTTACCATTCCTTATTATCACTAATCATCTAAACAACCTCACT
GGAAATCCAATTAACAATTTTACAACATAAGATAGAATGGAGACCTGAATAATT
15 CTGTGTAATATAAATGGTTTATAACTGCTTTTGTACCTAGCTAGGCTGCTATTATT
ACTATAATGAGTAAATCATAAAGCCTTCATCACTCCACATTTTTCTTACGGTCG
GAGCATCAGAACAAGCGTCTAGACTCCTTGGGACCGTGAGTTCCTAGAGCTTGGC
TGGGTCTAGGCTGTTCTGTGCCTCCAAGGACTGTCTGGCAATGACTTGTATTGGC
CACCAACTGTAGATGTATATATGGTGCCCTTCTGATGCTAAGACTCCAGACCTTT
20 TGTTTTTGCTTTGCATTTTCTGATTTTATACCAACTGTGTGGACTAAGATGCATTA
AAATAAAC

SEQ ID NO: 84

>gi|2206902|gb|AA478268.1|AA478268 zu45a06.s1 Soares ovary tumor NbHOT Homo
25 sapiens cDNA clone IMAGE:740914 3'
GCGACCGCGCTGGGCCTCGTGTCGCTTGTCTCGTCCGTCCTGTGGGCGCTCTGC
CCTGTGTCCTTCGCGTTCCTCGTTAAGCAGAAGAAGTCAGTAGTTATTCTCCCATG
AACGTTCTTGTCTGTGTACAGTTTTTAGAACATTACAAAGGATCTGTTTGCTTAGC
TGTCACAAAAAAGAAAACCTGAAGGAGCATTGGAAGTCAATTTGAGGTTTTTTTT
30 TTTTTTTTTTTTTTTTTTTGTATGTTGGAACGTGCCCCAGAATGAGGCAGTTGGCAA
ACTTCTCAGGACAATGAATCCTTCCCGTTTTTTCTTTTTATGCCACACAGTGCATTG
TTTTTTCTACCTGCTTGTCTTATTTTTAG

SEQ ID NO: 85

>gi|1925839|gb|AA282906.1|AA282906 zt14h05.r1 NCI_CGAP_GCB1 Homo sapiens
35 cDNA clone IMAGE:713145 5' similar to gb:X66733 CD44 ANTIGEN, HEMATOPOIETIC
FORM PRECURSOR (HUMAN);
AAAATGGTCGCTACAGCATCTCTCGGACGGAGGCCGCTGACCTCTGCAAGGCTTT
CAATAGCACCTTGCCCACAATGGCCCAGATGGAGAAAGCTCTGAGCATCGGATT
40 TGAGACCTGCAGGTATGGGTTCATAGAAGGGCACGTGGTGATTCCCCGGATCCA
CCCCAACTCCATCTGTGCAGCAAACAACACAGGGGTGTACATCCTCACATCCAAC
ACCTCCCAGTATGACACATATTGCTTCAATGCTTCAGCTCCACCTGAAGAAGATT
GTACATCAGTCACAGACCTGCCCAATGCCTTTGATGGACCAATTACCATAACTAT
TGTTAACCGTGATGGCACCCGCTATGTCCAGAAAGGAGAATACAGAACGAATCC
45 TGAAGACATCTACCCCAGCAACCCTACTGGATGATGACGTGAGCAGCGGCTCCTC
CAGTGAAAGGAGCAGCACTTCAGGAGGTTACATCTTTTACACTTTTTCTACTGTA
CACCCATCCCAGACGAAGACAGTCCTTGGATCACGACAGCACAGCAGATCCTGC
TAC

SEQ ID NO: 86

>gi|2668591|gb|U97669.1|HSU97669 Homo sapiens Notch3 (NOTCH3) mRNA, complete cds

5 ACGCGGCGCGGAGGCTGGCCCCGGGACGCGCCCGGAGCCCAGGGAAGGAGGGAG
GAGGGGAGGGTCGCGGCCCGGCCGCCATGGGGCCGGGGGCCCGTGGCCGCCGCCG
CCGCCGTCGCCCAGTGTGCGCCGCCACCGCCACCGCCACCCGTGCGGGCGCTGCCC
CTGCTGCTGCTGCTAGCGGGGCCGGGGGCTGCAGCCCCCCTTGCTGGACGGAA
GCCCCGTGTGAAATGGAGGTCGTTGCACCCAGCTGCCCTCCCGGGAGGCTGCCTG
10 CCTGTGCCCCGCTGGCTGGGTGGGTGAGCGGTGTCAGCTGGAGGACCCCTGTCAC
TCAGGCCCCCTGTGCTGGCCGTGGTGTCTGCCAGAGTTCAGTGGTGGCTGGCACC
CCCGATTCTCATGCCGGTGCCCCCGTGGCTTCCGAGGCCCTGACTGCTCCCTGCC
AGATCCCTGCCTCAGCAGCCCTTGTGCCACGGTGCCCGCTGCTCAGTGGGGCCC
GATGGACGCTTCCTCTGCTCCTGCCACCTGGCTACCAGGGCCGCAGCTGCCGAA
GCGACGTGGATGAGTGCCGGGTGGGTGAGCCCTGCCGCCATGGTGGCACCTGCC
15 TCAACACACCTGGCTCCTTCCGCTGCCAGTGTCCAGCTGGCTACACAGGGCCACT
ATGTGAGAACCCCGCGGTGCCCTGTGCGCCCTCACCATGCCGTAACGGGGGCAC
CTGCAGGCAGAGTGGCGACCTCACTTACGACTGTGCCTGTCTTCTGGGTTTGAG
GGTCAGAATTGTGAAGTGAACGTGGACGACTGTCCAGGACACCGATGTCTCAAT
GGGGGGACATGCGTGGATGGCGTCAACACCTATAACTGCCAGTGCCCTCCTGAG
20 TGGACAGGCCAGTTCTGCACGGAGGACGTGGATGAGTGTGAGCTGCAGCCCAAC
GCCTGCCACAATGGGGGTACCTGCTTCAACACGCTGGGTGGCCACAGCTGCGTGT
GTGTCAATGGCTGGACAGGTGAGAGCTGCAGTCAGAATATCGATGACTGTGCCA
CAGCCGTGTGCTTCCATGGGGCCACCTGCCATGACCGCGTGGCTTCTTTCTACTGT
GCCTGCCCCATGGGCAAGACTGGCCTCCTGTGTACCTGGATGACGCCTGTGTCA
25 GCAACCCCTGCCACGAGGATGCTATCTGTGACACAAATCCGGTGAACGGCCGGG
CCATTTGCACCTGTCTTCCCGGCTTCACGGGTGGGGCATGTGACCAGGATGTGGA
CGAGTGCTCTATCGGCGCCAACCCCTGCGAGCACTTGGGCAGGTGCGTGAACAC
GCAGGGCTCCTTCTGTGCCAGTGCGGTGCTGGCTACACTGGACCTCGCTGTGAG
ACCGATGTCAACGAGTGTCTGTGCGGGGCCCTGCCGAAACCAGGCCACGTGCCTC
30 GACCGCATAGGCCAGTTCACCTGTATCTGTATGGCAGGCTTCACAGGAACCTATT
GCGAGGTGGACATTGACGAGTGTGAGAGTAGCCCCCTGTGTCAACGGTGGGGTCT
GCAAGGACCGAGTCAATGGCTTCAGCTGCACCTGCCCTCGGGCTTCAGCGGCTC
CACGTGTGAGCTGGACGTGGACGAATGCGCCAGCACGCCCTGCAGGAATGGCGC
CAAATGCGTGGACACGCCGATGGCTACGAGTGCCGCTGTGCCGAGGGGCTTTGA
35 GGGCACGCTGTGTGATCGCAACGTGGACGACTGCTCCCCTGACCCATGCCACCAT
GGTCGCTGCGTGGATGGCATCGCCAGCTTCTCATGTGCCTGTGCTCCTGGCTACA
CGGGCACACGCTGCGAGAGCCAGGTGGACGAATGCCGCAGCCAGCCCTGCCGCC
ATGGCGGCAAATGCCTAGACCTGGTGGACAAGTACCTCTGCCGCTGCCCTTCTGG
GACCACAGGTGTGAACTGCGAAGTGAACATTGACGACTGTGCCAGCAACCCCTG
40 CACCTTTGGAGTCTGCCGTGATGGCATCAACCGCTACGACTGTGTCTGCCAACCT
GGCTTCACAGGGCCCCCTTTGTAACGTGGAGATCAATGAGTGTGCTTCAGCCCAT
GCGGCGAGGGAGGTTCTGTGTGGATGGGGAAAATGGCTTCCGCTGCCTCTGCCC
GCCTGGCTCCTTGCCCCCACTCTGCCTCCCCCGAGCCATCCCTGTGCCCATGAGC
CCTGCAGTCACGGCATCTGCTATGATGCACCTGGCGGGTTCGCTGTGTGTGTGA
45 GCCTGGCTGGAGTGGCCCCCGCTGCAGCCAGAGCCTGGCCCGAGACGCCTGTGA
GTCCCAGCCGTGCAGGGCCGGTGGGACATGCAGCAGCGATGGAATGGGTTTCCA
CTGCACCTGCCCCGCTGGTGTCCAGGGACGTGAGTGTGAACTCCTCTCCCCCTGC
ACCCCGAACCCCTGTGAGCATGGGGGGCCGCTGCGAGTCTGCCCTGGCCAGCTGC
CTGTCTGCTCCTGCCCCCAGGGCTGGCAAGGCCACGATGCCAGCAGGATGTGG

ACGAGTGTGCTGGCCCCGCACCCTGTGGCCCTCATGGTATCTGCACCAACCTGGC
AGGGAGTTTCAGCTGCACCTGCCATGGAGGGTACACTGGCCCTTCCTGTGATCAG
GACATCAATGACTGTGACCCCAACCCATGCCTGAACGGTGGCTCGTGCCAAGAC
GGCGTGGGCTCCTTTTCCTGCTCCTGCCTCCCTGGTTTCGCCGGCCACGATGCGC
5 CCGCGATGTGGATGAGTGCCTGAGCAACCCCTGCGGCCCGGGCACCTGTACCGA
CCACGTGGCCTCCTTCACCTGCACCTGCCCCGCCGGGCTACGGAGGCTTCCACTGC
GAACAGGACCTGCCCCGACTGCAGCCCCAGCTCCTGCTTCAATGGCGGGACCTGTG
TGGACGGCGTGAACCTCGTTCAGCTGCCTGTGCCGTCCCGGCTACACAGGAGCCCA
CTGCCAACATGAGGCAGACCCCTGCCTCTCGCGGCCCTGCCTACACGGGGGCGTC
10 TGCAGCGCCGCCACCCCTGGCTTCCGCTGCACCTGCCTCGAGAGCTTCACGGGCC
CGCAGTGCCAGACGCTGGTGGATTGGTGCAGCCGCCAGCCTTGTCAAACGGGG
GTCGCTGCGTCCAGACTGGGGCCTATTGCCTTTGTCCCCCTGGATGGAGCGGACG
CCTCTGTGACATCCGAAGCTTGCCCTGCAGGGAGGCCGCGAGCCAGATCGGGGT
GCGGCTGGAGCAGCTGTGTCAGGCGGGTGGGCAGTGTGTGGATGAAGACAGCTC
15 CCACTACTGCGTGTGCCAGAGGGCCGTAAGTGGTAGCCACTGTGAGCAGGAGGT
GGACCCCTGCTTGGCCCAGCCCTGCCAGCATGGGGGGACCTGCCGTGGCTATATG
GGGGGCTACATGTGTGAGTGTCTTCCCTGGCTACAATGGTGATAACTGTGAGGACG
ACGTGGACGAGTGTGCCTCCCAGCCCTGCCAGCACGGGGGTTCATGCATTGACCT
CGTGGCCCCGCTATCTCTGCTCCTGTCCCCAGGAACGCTGGGGGTGCTCTGCGAG
20 ATTAATGAGGATGACTGCGGCCAGGCCACCGCTGGACTCAGGGCCCCGGTGC
CTACACAATGGCACCTGCGTGGACCTGGTGGGTGGTTTCCGCTGCACCTGTCCCC
CAGGATACACTGGTTTTCGCTGCGAGGCAGACATCAATGAGTGTGCTCAGGTG
CCTGCCACGCGGCACACACCCGGGACTGCCTGCAGGACCCAGGCGGAGGTTTCC
GTTGCCTTTGTGATGCTGGCTTCTCAGGTCTCGCTGTCAGACTGTCTGTCTCCC
25 TGCGAGTCCCAGCCATGCCAGCATGGAGGCCAGTGCCGTCCTAGCCCCGGGTCTG
GGGGTGGGCTGACCTTCACCTGTCACTGTGCCAGCCGTTCTGGGGTCCGCGTTG
CGAGCGGGTGGCGCGCTCCTGCCGGGAGCTGCAGTGCCCGGTGGGCGTCCCATG
CCAGCAGACGCCCCGCGGGCCGCGCTGCGCCTGCCCCCAGGGTTGTGCGGACC
CTCCTGCCGCAGCTTCCCAGGGTTCGCCGCCGGGGGCCAGCAACGCCAGCTGCGC
30 GGCCGCCCCCTGTCTCCACGGGGGCTCCTGCCGCCCGCGCGCTCGCGCCCTTC
TTCCGCTGCGCTTGCGCGCAGGGCTGGACCGGGCCGCGCTGCGAGGCGCCCGCC
GCGGCACCCGAGGTCTCGGAGGAGCCGCGGTGCCCGCGCGCCGCTGCCAGGCC
AAGCGCGGGGACCAGCGCTGCGACCGCGAGTGCAACAGCCCAGGCTGCGGCTGG
GACGGCGGCGACTGCTCGCTGAGCCTGGGGCGACCCCTGGCGGCAATGCGAGGCG
35 CTGCAGTGTGTCGCTCTTCAACAACAGCCGCTGCGACCCCGCTGCAGCTCGC
CCGCTGCCTCTACGACAACCTTCGACTGCCACGCCGGTGGCCGCGAGCGCACTTG
CAACCCGGTGTACGAGAAGTACTGCGCCGACCACTTTGCCGACGGCCGCTGCGA
CCAGGGCTGCAACACGGAGGAGTGGGCTGGGATGGGCTGGATTGTGCCAGCGA
GGTGCCGGCCCTGCTGGCCCGCGCGCTGCTGGTGCTCACAGTGTGCTGCCGCCG
40 GAGGAGCTACTGCGTTCCAGCGCCGACTTCTGCAGCGGCTCAGCGCCATCCTGC
GCACCTCGCTGCGCTTCCGCTGGACGCGCACGGCCAGGCCATGGTCTTCCCTTA
CCACCGGCCTAGTCTGGCTCCGAACCCCGGGCCCGTCCGGAGCTGGCCCCCGA
GGTGATCGGCTCGGTAGTAATGCTGGAGATTGACAACCGGCTCTGCCTGCAGTCG
CCTGAGAATGATCACTGCTTCCCCGATGCCAGAGCGCCGCTGACTACCTGGGAG
45 CGTTGTGACGCGGTGGAGCGCTGGACTTCCCGTACCCACTGCGGGACGTGCGGG
GGGAGCCGCTGGAGCCTCCAGAACCCAGCGTCCCGCTGCTGCCACTGCTAGTGG
CGGGCGCTGTCTTGCTGCTGGTCATTCTCGTCTGGGTGTCATGGTGGCCCCGGCG
CAAGCGCGAGCACAGCACCCCTCTGGTTCCCTGAGGGCTTCTCACTGCACAAGGAC
GTGGCCTCTGGTCACAAGGGCCGGCGGGAACCCGTGGGCCAGGACGCGCTGGGC

ATGAAGAACATGGCCAAGGGTGAGAGCCTGATGGGGGAGGTGGCCACAGACTG
GATGGACACAGAGTGCCAGAGGCCAAGCGGCTAAAGGTAGAGGAGCCAGGCA
TGGGGGCTGAGGAGGCTGTGGATTGCCGTCAGTGGACTCAACACCATCTGGTTGC
TGCTGACATCCGCGTGGCACCAGCCATGGCACTGACACCACCACAGGGCGACGC
5 AGATGCTGATGGCATGGATGTCAATGTGCGTGGCCCAGATGGCTTCACCCCGCTA
ATGCTGGCTTCCTTCTGTGGGGGGGCTCTGGAGCCAATGCCAACTGAAGAGGATG
AGGCAGATGACACATCAGCTAGCATCATCTCCGACCTGATCTGCCAGGGGGGCTC
AGCTTGGGGCACGGACTGACCGTACTGGCGAGACTGCTTTGCACCTGGCTGCCCG
TTATGCCCCTGCTGATGCAGCCAAGCGGCTGCTGGATGCTGGGGCAGACACCAA
10 TGCCCAGGACCACTCAGGCCGCACTCCCCTGCACACAGCTGTACAGCCGATGCC
CAGGGTGTCTTCCAGATTCTCATCCGAAACCGCTCTACAGACTTGGATGCCCGCA
TGGCAGATGGCTCAACGGCACTGATCCTGGCGGCCCGCCTGGCAGTAGAGGGCA
TGGTGGAAAGAGCTCATCGCCAGCCATGCTGATGTCAATGCTGTGGATGAGCTTGG
GAAATCAGCCTTACACTGGGCTGCGGCTGTGAACAACGTGGAAGCCACTTTGGC
15 CETGCTCAAAAATGGAGCCAATAAGGACATGCAGGATAGCAAGGAGGAGACCCC
CCTATTCTGGCCGCCCCGCGAGGGCAGCTATGAGGCTGCCAAGCTGCTGTTGGAC
CACTTTGCCAACCGTGAGATCACCGACCACCTGGACAGGCTGCCGCGGGACGTA
GCCCAGGAGAGACTGCACCAGGACATCGTGCGCTTGCTGGATCAACCCAGTGGG
CCCCGCAGCCCCCCCCGGTCCCCACGGCCTGGGGCCTCTGCTCTGTCTCCAGGGG
20 CCTTCCTCCCTGGCCTCAAAGCGGCACAGTCGGGGTCCAAGAAGAGCAGGAGGC
CCCCCGGAAGGCGGGGCTGGGGCCGCAGGGGCCCCGGGGGCGGGGCAAGAAG
CTGACGCTGGCCTGCCCGGGCCCCCTGGCTGACAGCTCGGTACGCTGTGCCCCG
TGGACTCGCTGGACTCCCCGCGGCCTTTCGGTGGGCCCCCTGCTTCCCCTGGTGG
CTTCCCCCTTGAGGGGGCCCTATGCAGCTGCCACTGCCACTGCAGTGTCTCTGGCA
25 CAGCTTGGTGGCCAGGCCGGGCAGGTCTAGGGCGCCAGCCCCCTGGAGGATGT
GTACTCAGCCTGGGCCTGCTGAACCCTGTGGCTGTGCCCCCTCGATTGGGCCCCGGC
TGCCCCCACCTGCCCCCTCCAGGCCCTCGTTCTGCTGCCACTGGCGCCGGGACC
CCAGCTGCTCAACCCAGGGACCCCCGTCTCCCCGCAGGAGCGGCCCCCGCCTTAC
CTGGCAGTCCCAGGACATGGCGAGGAGTACCCGGTGGCTGGGGCACACAGCAGC
30 CCCCCAAAGGCCCGCTTCTGCGGGTTCACAGTGAGCACCTTACCTGACCCCAT
CCCCCGAATCCCCTGAGCACTGGGCCAGCCCCTCACCTCCCTCCCTCTCAGACTG
GTCCGAATCCACGCCTAGCCCAGCCACTGCCACTGGGGCCATGGCCACCACCACT
GGGGCACTGCCTGCCAGCCACTTCCCTTGTCTGTTCCCAGCTCCCTTGCTCAGGC
CCAGACCCAGCTGGGGCCCCAGCCGGAAGTTACCCCCAAGAGGCAAGTGTGTC
35 CTGAGACGCTCGTCAGTTCTTAGATCTTGGGGGCCTAAAGAGACCCCCGTCCTGC
CTCCTTTCTTTCTCTGTCTCTTCTTCTTTTCTTTTCTTTTCTTTTCTTTTCTT
ACCAACCCTCCTGCATCCTTGCTTGAGCGTGACCGAGATAGGTCATCAGCCCA
GGGCTTCAGTCTTCTTTATTTATAATGGGTGGGGGCTACCACCCACCTCTCAGT
CTTGTGAAGAGTCTGGGACCTCCTTCTTCCCCACTTCTCTCTTCCCTCATTCTTTC
40 TCTCTCCTTCTGGCCTCTCATTTCTTACACTCTGACATGAATGAATTATTATT
TTTCTTTTCTTTTTTTTTTACATTTTGTATAGAAACAAATTCATTTAAACAACT
TATTATTATTATTTTACAAAATATATATATGGAGATGCTCCCTCCCCCTGTGAA
CCCCCAGTGCCCCCGTGGGGCTGAGTCTGTGGGGCCATTCCGGCCAAGCTGGATT
CTGTGTACCTAGTACACAGGCATGACTGGGATCCCGTGTACCGAGTACACGACCC
45 AGGTATGTACCAAGTAGGCACCCTTGGGCGCACCCACTGGGGCCAGGGGTGCGG
GGAGTGTGGGAGCCTCCTCCCCACCCACCTCCCTCACTTCACTGCATTCCAGA
TTGGACATGTTCCATAGCCTTGCTGGGGAAGGGCCCACTGCCAACTCCCTCTGCC
CCAGCCCCACCTTGGCCATCTCCCTTTGGGAACTAGGGGGCTGCTGGTGGGAAA
TGGGAGCCAGGGCAGATGTATGCATTCTTTATGTCCCTGTAAATGTGGGACTAC

AAGAAGAGGAGCTGCCTGAGTGGTACTTTCTCTTCCTGGTAATCCTCTGGCCCAG
CCTTATGGCAGAATAGAGGTATTTTAGGCTATTTTGTAAATATGGCTTCTGGTCA
AAATCCCTGTGTAGCTGAATTCCCAAGCCCTGCATTGTACAGCCCCCACTCCCC
TCACCACCTAATAAAGGAATAGTTAACTCAAAAAAAAAAAAAAAAAAAAAA

5

SEQ ID NO: 87

gi|36610|emb|X51417.1|HSSTHOR2 Human mRNA for steroid hormone receptor hERR2

CTCCTCCAACCTGGGAATGCTAAAACGGGACTGATGGACGTGTCCGAACCTCTGCAT
CCCGGACCCCCTCGGCTACCACAACCAAGTAGGTTGCTGAACCGAATGTCGTCCGA
10 AGACAGGCACCTGGGCTCTAGCTGCGGCTCCTTCATCAAGACGGAGCCATCTAGC
CCATCCTCGGGCATTGATGCCCTCAGCCACCACAGCCCCAGCGGCTCGTCGGACG
CCAGCGGTGGCTTTGGCATGGCCCTGGGCACCCACGCCAACGGTCTGGACTCTCC
GCCTATGTTTCGAGGTGCGGGGCTGGGAGGCAACCCGTGTCGCAAGAGCTACGA
GGACTGTACTAGCGGTATCATGGAGGACTCGGCCATCAAGTGCAGTACATGCTT
15 AACGCCATCCCCAAGCGCCTGTGCCTCGTGTGCGGGGACATTGCTTCTGGCTACC
ACTATGGAGTGGCCTCCTGCGAGGCTTGCAAGGCGTTCTTCAAGAGAACCATTCA
AGGAAACATCGAATACAGCTGCCCTGCCACCAACGAGTGTGAGATCACCAAACG
GAGGCGCAAGTCCTGTCAGGCCTGCCGGTTCATGAAATGCCTCAAAGTGGGGAT
GCTGAAGGAAGGCGTGCGCCTTGACCGGGTGCAGGAGGCGCCAGAAGTACAA
20 GAGACGGCTGGATTTCGGAGAACAGCCCCTACCTGAGCTTACAGATTTCCCCGCCT
GCTAAAAAGCCATTGACTAAGATTGTCTCGTATCTACTGGTGGCCGAGCCGGACA
AGCTGTACGCTATGCCTCCCGACGATGTGCCTGAAGGGGATATCAAGGCCCTGAC
CACTCTCTGTGACTTGGCAGATCGGGAGCTTGTGTTCCCTCATTAGCTGGGCCAAG
CACATCCCAGGTTTCTCCAACCTGACACTCGGGGACCAGATGAGCCTGCTGCAGA
25 GTGCCTGGATGGAGATCCTCATCCTGGGCATCGTGTACCGCTCGCTTCCCTATGA
TGACAAGCTGGCATAACGCGGAGGACTATATCATGGATGAGGAACACTCTCGCCT
GGTGGGGCTGCTGGAGCTTTACCGAGCCATCTTGCAGCTCGTACGCAGGTACAAG
AAGCTCAAGGTGGAGAAGGAAGAGTTTGTGATGCTCAAAGCCCTGGCCCTTGCC
AACTCAGATTCAATGTACATCGAGAACCTGGAGGCTGTGCAGAAGCTTCAGGAC
30 CTGCTGCATGAGGCGCTGCAGGACTATGAGCTGAGCCAGCGCCATGAGGAGCCA
CGGAGGGCGGGCAAGCTGCTGTTGACACTGCCCCTGCTGCGGCAGACGGCAGCC
AAAGCCGTCCAGCACTTCTACAGTGTGAAACTGCAGGGCAAGGTGCCCATGCAC
AACTCTTCTGGAGATGCTGGAGGCCAAGGTGTGATGGCCCCGCATGCAGACG
GATGGACACCGATCCACATGGAGACTTCCACGGCCACCAGCCTCGACTTCTCACA
35 CCTGCATCGGGGCTCTGAGCTGTCCCAGAAGAAGGGGTTTCTTGCTTCCTGGCCA
TGTGCAGACTCCTGGGGGGCAGCAGATGGGGAGATGGGGATGGGAGGGTGGGG
GCGGGGGGCTCATCTGTCACCCGAATTTTCTTTGGTATTTTTTTTTTCTTCTCCA
TGGGCAGTGCTAAGGCTTGGGCGGGGCTGACTTCCCTTAGGGCTGGAGACCAC
GGGAGGAAGCATCCCTTCTGCAAGGGATCCATTTCTGGACCACTCCATATTTAG
40 GACCTGGAGGTACCTGGATGGGCAGGGCTTAGTGCCCAGGGCCCAAGAGACTTA
GATTGGGTGCTCCTGAAGGTGTTGGTATCACAGAGGGCAGGCCCTTGGAACAGG
AGGTCTCTGTGGCCTCTCCTGGGGCTCTGTGCCTCCTCAGTCTAGCTGTCTCCCTC
CCCTTCCCCCTTTCTTGTCTAGTACATCCAGCTCTCAGTGGATGCTCCTGCTAGA
GTAGCCACATCCCCACCACTAAGAGGGCCCTCCCCTGCTTCTGCCCCCTACCTCA
45 GCCAGCTGAGGTAACCTCAGGACATGCACCTGGGAACTCGCTGGCTCAGAAAAG
AGTTGGGTCTATACCCACCCTTGCCCTGTTGTTTCTCCTAATCCTCTTGGGCATGG
CGAGTCTAGAAACCTATGGA

SEQ ID NO: 88

>gi|1220312|gb|L76191.1|HUMI1R Homo sapiens interleukin-1 receptor-associated kinase (IRAK) mRNA, complete cds

CGCGGACCCGGCCGGCCAGGCCCCGCGCCCGCCGCGGCCCTGAGAGGCCCCGGC
5 AGGTCCCGGCCCGGCGGCGGCAGCCATGGCCGGGGGGCCGGGCCCCGGGGGAGC
CCGCAGCCCCCGGCGGCCAGCACTTCTTGACGAGGTGCCGCCCTGGGTTCATGTG
CCGCTTCTACAAAGTGATGGACGCCCTGGAGCCCGCCGACTGGTGCCAGTTCGCC
GCCCTGATCGTGCGCGACCAGACCGAGCTGCGGCTGTGCGAGCGCTCCGGGCAG
CGCACGGCCAGCGTCCTGTGGCCCTGGATCAACCGCAACGCCCGTGTGGCCGAC
10 CTCGTGCACATCCTCACGCACCTGCAGCTGCTCCGTGCGCGGGACATCATCACAG
CCTGGCACCTCCCGCCCCGCTTCCGTCCCCAGGCACCACTGCCCCGAGGCCCAG
CAGCATCCCTGCACCCGCCGAGGCCGAGGCCTGGAGCCCCCGGAAGTTGCCATC
CTCAGCCTCCACCTTCTCTCCCCAGCTTTTCCAGGCTCCAGACCCATTTCAGGGC
CTGAGCTCGGCCTGGTTCCAAGCCCTGCTTCCCTGTGGCCTCCACCGCCATCTCCA
15 GCCCTTCTTCTACCAAGCCAGGCCAGAGAGCTCAGTGTCCCTCCTGCAGGGAG
CCCGCCCCCTCTCCGTTTTGCTGGCCCTCTGTGAGATTTCCCGGGGCACCCACAAC
TTCTCGGAGGAGCTCAAGATCGGGGAGGGTGGCTTTGGGTGCGTGTACCGGGCG
GTGATGAGGAACACGGTGTATGCTGTGAAGAGGCTGAAGGAGAACGCTGACCTG
GAGTGGACTGCAGTGAAGCAGAGCTTCTGACCGAGGTGGAGCAGCTGTCCAGG
20 TTTCGTCACCCAAACATTGTGGACTTTGCTGGCTACTGTGCTCAGAACGGCTTCTA
CTGCCTGGTGTACGGCTTCTGCCCCAACGGCTCCCTGGAGGACCGTCTCCACTGC
CAGACCCAGGCCTGCCCACCTCTCTCCTGGCCTCAGCGACTGGACATCCTTCTGG
GTACAGCCCGGGCAATTCAAGTTTCTACATCAGGACAGCCCCAGCCTCATCCATGG
AGACATCAAGAGTTCCAACGTCCTTCTGGATGAGAGGCTGACACCCAAGCTGGG
25 AGACTTTGGCCTGGCCCCGGTTCAGCCGCTTTGCCGGGTCCAGCCCCAGCCAGAGC
AGCATGGTGGCCCCGGACACAGACAGTGCGGGGCACCCTGGCCTACCTGCCCCGAG
GAGTACATCAAGACGGGAAGGCTGGCTGTGGACACGGACACCTTCAGCTTTGGG
GTGGTAGTGCTAGAGACCTTGGCTGGTCAGAGGGCTGTGAAGACGCACGGTGCC
AGGACCAAGTATCTGAAAGACCTGGTGGAAAGAGGAGGCTGAGGAGGCTGGAGT
30 GGCTTTGAGAAGCACCCAGAGCACACTGCAAGCAGGTCTGGCTGCAGATGCCTG
GGCTGCTCCCATCGCCATGCAGATCTACAAGAAGCACCTGGACCCAGGCCCGG
GCCCTGCCACCTGAGCTGGGCCTGGGCCTGGGCCAGCTGGCCTGCTGCTGCCTG
CACCGCCGGGGCCAAAAGGAGGCCTCCTATGACCCAGGTGTACGAGAGGCTAGAG
AAGCTGCAGGCAGTGGTGGCGGGGGTGCCCGGGCATTGAGAGGCCGCCAGCTGC
35 ATCCCCCTTCCCCGCAGGAGAACTCCTACGTGTCCAGCACTGGCAGAGCCCACA
GTGGGGCTGCTCCATGGCAGCCCCTGGCAGCGCCATCAGGAGCCAGTGCCCAGG
CAGCAGAGCAGCTGCAGAGAGGCCCAACCAGCCCGTGGAGAGTGACGAGAGC
CTAGGCGGCCTCTCTGCTGCCCTGCGCTCCTGGCACTTGAAGCTGCCCTCT
GGACCCAGCACCCCTCAGGGAGGCCGGCTGTCTCAGGGGGACACGGCAGGAGA
40 ATCGAGCTGGGGGAGTGGCCCAGGATCCCGGCCACAGCCGTGGAAGGACTGGC
CCTTGGCAGCTCTGCATCATCGTCGTGAGAGCCACCGCAGATTATCATCAACCT
GCCCCAGAGAAGATGGTCCAGAAGCTGGCCCTGTACGAGGATGGGGCCCTGGAC
AGCCTGCAGCTGCTGTCGTCCAGCTCCCTCCAGGCTTGGGCCTGGAACAGGACA
GGCAGGGGGCCGAAGAAAGTGATGAATTTTCAGAGCTGATGTGTTACCTGGGCA
45 GATCCCCCAAATCCGGAAGTCAAAGTTCTCATGGTCAGAAGTTCTCATGGTGCAC
GAGTCTCAGCACTCTGCCGGCAGTGGGGGTGGGGGCCCATGCCCCGCGGGGGAG
AGAAGGAGGTGGCCCTGCTGTTCTAGGCTCTGTGGGCATAGGCAGGCAGAGTGG
AACCCTGCCTCCATGCCAGCATCTGGGGGCAAGGAAGGCTGGCATCATCCAGTG
AGGAGGCTGGCGCATGTTGGGAGGCTGCTGGCTGCACAGACCCGTGAGGGGAGG

AGAGGGGCTGCTGTGCAGGGGTGTGGAGTAGGGAGCTGGCTCCCCTGAGAGCCA
TGCAGGGCGTCTGCAGCCCAGGCCTCTGGCAGCAGCTCTTTGCCCATCTCTTTGG
ACAGTGGCCACCCTGCACAATGGGGCCGACGAGGCCTAGGGCCCTCCTACCTGC
TTACAATTTGAAAAAGTGTGGCCGGGTGCGGTGGCTCACGCCTGTAATCCCAGCA
5 CTTTGGGAGGCCAAGGCAGGAGGATCGCTGGAGCCCAGTAGGTCAAGACCAGCC
AGGGCAACATGATGAGACCCTGTCTCTGCCAAAAAATTTTTTAACTATTAGCCT
GGCGTGGTAGCGCACGCCTGTGGTCCCAGCTGCTGGGGAGGCTGAAGTAGGAGG
ATCATTTATGCTTGGGAGGTTCGAGGCTGCAGTGAGTCATGATTGTATGACTGCAC
TCCAGCCTGGGTGACAGAGCAAGACCCTGTTTCAAAAAGAAAAACCCTGGGAAA
10 AGTGAAGTATGGCTGTAAGTCTCATGGTTCAGTCCTAGCAAGAAGCGAGAATTCT
GAGATCCTCCAGAAAGTCGAGCAGCACCCACCTCCAACCTCGGGCCAGTGTCTTC
AGGCTTTACTGGGGACCTGCGAGCTGGCCTAATGTGGTGGCCTGCAAGCCAGGC
CATCCCTGGGCGCCACAGACGAGCTCCGAGCCAGGTCAGGCTTCGGAGGCCACA
AGCTCAGCCTCAGGCCCAGGCACTGATTGTGGCAGAGGGGCCACTACCCAAGGT
15 CTAGCTAGGCCCAAGACCTAGTTACCCAGACAGTGAGAAGCCCCTGGAAGGCAG
AAAAGTTGGGAGCATGGCAGACAGGGAAGGGAAACATTTTCAGGGAAAAGACA
TGTATCACATGTCTTCAGAAGCAAGTCAGGTTTCATGTAACCGAGTGTCTCTTG
CGTGTCCAAAAGTAGCCCAGGGCTGTAGCACAGGCTTCACAGTGATTTTGTGTTC
AGCCGTGAGTCACACTACATGCCCCCGTGAAGCTGGGCATTGGTGACGTCCAGGT
20 TGTCTTGAGTAATAAAAACGTATGTTCCCTAAAAAAGGAATTC

SEQ ID NO: 89

>gi|821647|gb|R43734.1|R43734 yg20e10.s1 Soares infant brain 1NIB Homo sapiens cDNA
clone IMAGE:32609 3'

25 TTTTTTTTGTGTGCAAGTGTTTATTTGGAATCCCTTCTATTTTATTAGAAACAGA
AACAGTAATTTACCCAGTAGGAATTGCGTGTGCTCTCAATACAAGTTTGGC
ACTCCTTCAATTGTTGTCCATTGCAGACACTTTGGATTCAAGGTTAAGAATCCAA
ATGAGAAATAAGAAATATCCGGTCCCTGATGATTTCGTTTAAAGTCCTGTTCAACTC
GATGGAAAGCTTCCACCCGAAGGAAGGAGTTACTGTTCCCTCCTGGGCTGGGCTTT
30 GTGTTTCTTTCAAGTGTCTTAAAGGAAGTTTGTATTTGGGGCAGCTGTGCTCTGGTC
ATGTCAGGGCTGGCTGGGACAGGGAGTTTGGATGGCTTACGGGCGGCCGCTGGA
CCGGGGGCTGGCTTTTTACTTGAAGGCTTCACTGGGGGTGTTCCATTCAATTAC
AAAGTGGGGCGTTNTGCAGGCCNGTGGAAGGGTTTTGCNNGGGGNTT

35 SEQ ID NO: 90

>gi|34627|emb|X04481.1|HSMH3C2R Human mRNA for complement component C2

GGCTCTCTACCTCTCGCCGCCCTAGGGAGGACACCATGGGCCCAGTGATGGTTC
TTTTTGCCTGCTGTTCTGTACCCAGGTCTGGCAGACTCGGCTCCCTCCTGCCCT
CAGAACGTGAATATCTCGGGTGGCACCTTCACCCTCAGCCATGGCTGGGCTCCTG
40 GGAGCCTTCTACCTACTCCTGCCCCAGGGCCTGTACCCATCCCAGCATCACG
GCTGTGCAAGAGCAGCGGACAGTGGCAGACCCAGGAGCCACCCGGTCTCTGTC
TAAGGCGGTCTGCAAACCTGTGCGCTGTCCAGCCCCTGTCTCCTTTGAGAATGGC
ATTTATACCCACGGCTGGGGTCCATCCCGTGGGTGGCAATGTGAGCTTCGAGT
GTGAGGATGGCTTCATATTGCGGGGCTCGCCTGTGCGTCAGTGTGCCCCAACGG
45 CATGTGGGATGGAGAAACAGCTGTGTGTGATAATGGGGCTGGCCACTGCCCAA
CCCAGGCATTTCACTGGGCGCAGTGCGGACAGGCTTCCGCTTTGGTCATGGGGAC
AAGGTCCGCTATCGCTGCTCCTCGAATCTTGTGCTCACGGGGTCTTCGGAGCGGG
AGTGCCAGGGCAACGGGGTCTGGAGTGGAACGGAGCCCATCTGCCGCCAACCT
ACTCTTATGACTTCCCTGAGGACGTGGCCCCTGCCCTGGGCACTTCCTTCTCCAC

ATGCTTGGGGCCACCAATCCCACCCAGAAGACAAAGGAAAGCCTGGGGCCGTAAA
 ATCCAAATCCAGCGCTCTGGTCATCTGAACCTCTACCTGCTCCTGGACTGTTTCGC
 AGAGTGTGTTCGGAAAATGACTTTCTCATCTTCAAGGAGAGCGCCTCCCTCATGGT
 GGACAGGATCTTCAGCTTTGAGATCAATGTGAGCGTTGCCATTATCACCTTTGCC
 5 TCAGAGCCCCAAAGTCCTCATGTCTGTCTGAACGACAACCTCCCGGGATATGACTG
 AGGTGATCAGCAGCCTGGAAAATGCCAACTATAAAGATCATGAAAATGGAAGT
 GGACTAACACCTATGCGGCCTTAAACAGTGTCTATCTCATGATGAACAACCAAAT
 GCGACTCCTCGGCATGGAAACGATGGCCTGGCAGGAAATCCGACATGCCATCAT
 CCTTCTGACAGATGGAAAGTCCAATATGGGTGGCTCTCCCAAGACAGCTGTTGAC
 10 CATATCAGAGAGATCCTGAACATCAACCAGAAGAGGAATGACTATCTGGACATC
 TATGCCATCGGGGTGGGCAAGCTGGATGTGGACTGGAGAGAACTGAATGAGCTA
 GGGTCCAAGAAGGATGGTGAGAGGCATGCCTTCATTCTGCAGGACACAAAGGCT
 CTGCACCAGGTCTTTGAACATATGCTGGATGTCTCCAAGCTCACAGACACCATCT
 GCGGGGTGGGGAACATGTCAGCAAACGCCTCTGACCAGGAGAGGACACCCTGGC
 15 ATGTCACTATTAAGCCCAAGAGCCAAGAGACCTGCCGGGGGGCCCTCATCTCCG
 ACCAATGGGTCCTGACAGCAGCTCATTGCTTCCGCGATGGCAACGACCACTCCCT
 GTGGAGGGTCAATGTGGGAGACCCCAAATCCCAGTGGGGCAAAGAATTGCTTAT
 TGAGAAGGCGGTGATCTCCCCAGGGTTTGATGTCTTTGCCAAAAAGAACCAGGG
 AATCCTGGAGTTCTATGGTGATGACATAGCTCTGCTGAAGCTGGCCCAGAAAGTA
 20 AAGATGTCCACCCATGCCAGGCCCATCTGCCTTCCCTGCACGATGGAGGCCAATC
 TGGCTCTGCGGAGACCTCAAGGCAGCACCTGTAGGGACCATGAGAATGAACTGC
 TGAACAAACAGAGTGTTCCCTGCTCATTTTGTGCGCTTGAATGGGAGCAAACCTGAA
 CATTAAACCTTAAGATGGGAGTGGAGTGGACAAGCTGTGCCGAGGTTGTCTCCA
 AGAAAAAACCATGTTCCCCAACTTGACAGATGTCAGGGAGGTGGTGACAGACCA
 25 GTTCCTATGCAGTGGGACCCAGGAGGATGAGAGTCCCTGCAAGGGAGAATCTGG
 GGGAGCAGTTTTCTTGAGCGGAGATTCAGGTTTTTTTCAGGTGGGTCTGGTGAGC
 TGGGGTCTTTACAACCCCTGCCTTGGCTCTGCTGACAAAACTCCCGCAAAAGGG
 CCCCTCGTAGCAAGGTCCC GCCGCCACGAGACTTTCACATCAATCTCTTCCGCAT
 GCAGCCCTGGCTGAGGCAGCACCTGGGGGATGTCCTGAATTTTTTACCCCTCTAG
 30 CCATGGCCACTGAGCCCTCTGCTGCCCTGCCAGAATCTGCCGCCCTCCATCTTCT
 ACCTCTGAATGGCCACCCCTTAGACCCTGTGATCCATCCTCTCTCCTAGCTGAGTA
 AATCCGGGTCTCTAGGATGCCAGAGGCAGCGCACACAAGCTGGGAAATCCTCAG
 GGCTCCTACCAGCAGGACTGCCTCGCTGCCCCACCTCCCGCTCCTTGGCCTGTCC
 CCAGATTCCTTCCCTGGTTGACTTGACTCATGCTTGTTTCACTTTTACATGGAATT
 35 TCCAGTTATGAAATTAATAAAAATCAATGGTTTCCAC

SEQ ID NO: 91

>gi|2216792|gb|AA486628.1|AA486628 ab16a05.r1 Stratagene lung (#937210) Homo
 sapiens cDNA clone IMAGE:840944 5' similar to gb:M62829 EARLY GROWTH

40 RESPONSE PROTEIN 1 (HUMAN);
 GCCAAACAGTCACTTTGTTTAAGCAAACACAAGTACAAAGTAAAATAGAACCAC
 AAAATAATGAACTGCATGTTTATAACATACAAAAATCGCCGCCTACTCAGTAGGT
 AACTACAACATTCCAACCTCTGAATATATTTATAAATTTACATTTTTCAGTTAAAA
 GAATAGACTTTTGGAGAGTTCAGATTTTGTGTTTAGATTTTGTGTTTCTTACATTCTGG
 45 AGAACCGAAGCTCAGCTCAGCCCTCTTCTTATTTTGCTCCCAAAGCCTCCCCCA
 AATCATCACTCCCTGCCCCCTTAAGGCTAGAGGTGAGCATGTCCCTCACAATTG
 CACATGTCAAGCCATCAGCAAGGCGCATCACACAAAAGGCACCAAGACGTGAAA
 CTTTTTAAACCAAAGGACGAAGAAAAAACACTTTCAAAAAAAAAAAAAAA

SEQ ID NO: 92

>gi|898286|gb|H27933.1|H27933 y158e09.s1 Soares breast 3NbHBst Homo sapiens cDNA clone IMAGE:162472 3' similar to gb:M64572 PROTEIN-TYROSINE PHOSPHATASE PTP-H1 (HUMAN);

5 TNGGNCAATCAAAATGANGGGGTTCTTNGAATAANTNAACATCAGANTGTGTTT
ATNTTCAGATAGNCTGGGCCNCTCCTTNGAAATGCAATGGNGACCNTTGTGACTG
GGGGTGAATGCACACNTTNGTNCCTCCNTACAG

SEQ ID NO: 93

10 >gi|340202|gb|J03258.1|HUMVDR Human vitamin D receptor mRNA, complete cds
GGAACAGCTTGTCCACCCGCCGGCCGACCAGAAGCCTTTGGGTCTGAAGTGTCT
GTGAGACCTCACAGAAGAGCACCCCTGGGCTCCACTTACCTGCCCCCTGCTCCTT
CAGGGATGGAGGCAATGGCGGCCAGCACTTCCCTGCCTGACCCTGGAGACTTTG
ACCGGAACGTGCCCCGGATCTGTGGGGTGTGTGGAGACCGAGCCACTGGCTTTC
15 ACTTCAATGCTATGACCTGTGAAGGCTGCAAAGGCTTCTTCAGGCGAAGCATGAA
GCGGAAGGCACTATTACCTGCCCCCTCAACGGGGACTGCCGCATACCAAGGA
CAACCGACGCCACTGCCAGGCCTGCCGGCTCAAACGCTGTGTGGACATCGGCAT
GATGAAGGAGTTTATTCTGACAGATGAGGAAGTGCAGAGGAAGCGGGAGATGAT
CCTGAAGCGGAAGGAGGAGGAGGCCTTGAAGGACAGTCTGCGGCCCAAGCTGTC
20 TGAGGAGCAGCAGCGCATCATTGCCATACTGCTGGACGCCACCATAAGACCTA
CGACCCACCTACTCCGACTTCTGCCAGTTCCGGCCTCCAGTTTCGTGTGAATGAT
GGTGGAGGGAGCCATCCTTCCAGGCCCAACTCCAGACACACTCCCAGCTTCTCTG
GGACTCCTCCTCCTCCTGCTCAGATCACTGTATCACCTCTTCAGACATGATGGA
CTCGTCCAGCTTCTCCAATCTGGATCTGAGTGAAGAAGATTTCAGATGACCCTTCT
25 GTGACCCTAGAGCTGTCCCAGCTCTCCATGCTGCCCCACCTGGCTGACCTGGTCA
GTTACAGCATCCAAAAGGTCATTGGCTTTGCTAAGATGATACCAGGATTTCAGAGA
CCTCACCTCTGAGGACCAGATCGTACTGCTGAAGTCAAGTGCCATTGAGGTCATC
ATGTTGCGCTCCAATGAGTCCTTCACCATGGACGACATGTCCTGGACCTGTGGCA
ACCAAGACTACAAGTACCGCGTCAGTGACGTGACCAAAGCCGGACACAGCCTGG
30 AGCTGATTGAGCCCCCTCATCAAGTTCCAGGTGGGACTGAAGAAGCTGAACTTGC
ATGAGGAGGAGCATGTCCTGCTCATGGCCATCTGCATCGTCTCCCCAGATCGTCC
TGGGGTGCAGGACGCCGCGCTGATTGAGGCCATCCAGGACCGCCTGTCCAACAC
ACTGCAGACGTACATCCGCTGCCGCCACCCGCCCGGGCAGCCACCTGCTCTAT
GCCAAGATGATCCAGAAGCTAGCCGACCTGCGCAGCTCAATGAGGAGCACTCC
35 AAGCAGTACCGCTGCCTCTCCTTCCAGCCTGAGTGCAGCATGAAGCTAACGCCCC
TTGTGCTCGAAGTGTTTGGCAATGAGATCTCCTGACTAGGACAGCCTGTGCGGTG
CCTGGGTGGGGCTGCTCCTCCAGGGCCACGTGCCAGGCCCGGGGCTGGCGGCTA
CTCAGCAGCCCTCCTCACCCGTCTGGGGTTCAGCCCTCCTCTGCCACCTCCCCTA
TCCACCCAGCCCATTCTCTCCTGTCCAACCTAACCCCTTTCTGCGGGCTTTTC
40 CCCGGTCCCTTGAGACCTCAGCCATGAGGAGTTGCTGTTTGTGTTTGACAAAGAAAC
CCAAGTGGGGGCAGAGGGCAGAGGCTGGAGGCAGGCCTTGCCCAGAGATGCCTC
CACCGCTGCCTAAGTGGCTGCTGACTGATGTTGAGGGAACAGACAGGAGAAATG
CATCCATTCTCAGGGACAGAGACACCTGCACCTCCCCCACTGCAGGCCCGCT
TGTCAGCGCCTAGTGGGGTCTCCCTCTCCTGCCTTACTCACGATAAATAATCGG
45 CCCACAGCTCCCACCCACCCCTTCAGTGCCCAACCATCCCATTGCCCTGGT
TATATTCTACGGGCAGTAGCTGTGGTGAGGTGGGTTTTCTTCCCATCACTGGAG
CACCAGGCACGAACCCACCTGCTGAGAGACCCAAGGAGGAAAAACAGACAAAA
ACAGCCTCACAGAAGAATATGACAGCTGTCCCTGTCACCAAGCTCACAGTTCCTC
GCCCTGGGTCTAAGGGGTTGGTTGAGGTGGAAGCCCTCCTTCCACGGATCCATGT

AGCAGGACTGAATTGTCCCCAGTTTGCAGAAAAGCACCTGCCGACCTCGTCCTCC
CCCTGCCAGTGCCTTACCTCCTGCCCAGGAGAGCCAGCCCTCCCTGTCCTCCTCG
GATCACCGAGAGTAGCCGAGAGCCTGCTCCCCACCCCTCCCCAGGGGAGAGG
GTCTGGAGAAGCAGTGAGCCGCATCTTCTCCATCTGGCAGGGTGGGATGGAGGA
5 GAAGAATTTTCAGACCCCAGCGGCTGAGTCATGATCTCCCTGCCGCCTCAATGTG
GTTGCAAGGCCGCTGTTCCACCACAGGGGCTAAGAGCTAGGCTGCCGCACCCCA
GTGTGGGAAGGGAGAGCGGGGCAGTCTCGGGTGGCTAGTCAGAGAGAGTGTGTTG
GGGGTCCCGTGATGTAGGGTAAGGTGCCTTCTTATTCTCACTCCACCACCCAAAA
GTCAAAAGGTGCCTGTGAGGCAGGGGCGGAGTGATACAACTCAAGTGCATGCT
10 CTCTGCAGGTCGAGCCCAGCCCAGCTGGTGGGAAGCGTCTGTCCGTTTACTCCAA
GGTGGGTCTTTGTGAGAGTGAGCTGTAGGTGTGCGGGACCGGTACAGAAAGGCG
TTCTTCGAGGTGGATCACAGAGGCTTCTTCAGATCAATGCTTGAGTTTGGAATCG
GCCGCATTCCCTGAGTCACCAGGAATGTTAAAGTCAGTGGGAACGTGACTGCCCC
AACTCCTGGAAGCTGTGTCCTTGCACCTGCATCCGTAGTTCCTGAAAACCCAGA
15 GAGGAATCAGACTTCACACTGCAAGAGCCTTGGTGTCCACCTGGCCCCATGTCTC
TCAGAATTCTTCAGGTGGAAAAACATCTGAAAGCCACGTTCTTACTGCAGAATA
GCATATATATCGCTTAATCTTAAATTTATTAGATATGAGTTGTTTTTCAGACTCAGA
CTCCATTTGTATTATAGTCTAATATACAGGGTAGCAGGTACCACTGATTTGGAGA
TATTTATGGGGGGAGAACTTACATTGTGAACTTCTGTACATTAATTATTATTGCT
20 GTTGTATTTTTACAAGGGTCTAGGGAGAGACCCTTGTTTGATTTTAGCTGCAGAA
CTGTATTGGTCCAGCTTGCTCTTCAGTGGGAGAAAAACACTTGTAAGTTGCTAAA
CGAGTCAATCCCCTCATTACAGGAAAACCTGACAGAGGAGGGCGTGACTCACCCAA
GCCATATATAACTAGCTAGAAGTGGGCCAGGACAGGCCGGGCGCGGTGGCTCAC
GCCTGTAATCCCAGCAGTTTGGGAGGTGAGGTAGGTGGATCACCTGAGGTGCGG
25 GAGTTCGAGACCAACCTGACCAACATGGAGAAACCCTGTCTCTATTAATAAATAC
AAAAAAAAAAAAAAAAAAAAAAAAATAGCCGGGCATGGTGGCGCAAGCCTGTAATCC
CAGTACTCAGGAGGCTGAGGCAGAAAGTGAACCCAGGAGGTGGAGGTTGCA
GTGAGCTGAGATCGTGCCGTTACTCTCAAACCTGGACAACAAGAGCGAACTCC
GTCTTAGAAGTGGACCAGGACAGGACCAGATTTTGGAGTCATGGTCCGGTGTCT
30 TTTCCTACACCATGTTTGAGCTCAGACCCCCACTCTCATTCCCCAGGTGGCTGAC
CCAGTCCCTGGGGGAAGCCCTGGATTTTCAGAAAGAGCCAAGTCTGGATCTGGGA
CCCTTTCCCTTCCCTGGCTTGTAACCTCCACCAAGCCCATCAGAAGGAGAAGG
AAGGAGACTCACCTCTGCCTCAATGTGAATCAGACCCTACCCACACGATGTGC
CCTGGCTGCTGGGCTCTCCACCTCAGGCTTGGATAATGCTGTTGCCTCATCTATA
35 ACATGCATTTGTCTTTGTAATGTCACCACCTTCCCAGCTCTCCCTCTGGCCCTGCT
TCTTCGGGGAACCTCCTGAAATATCAGTTACTCAGCCCTGGGCCCCACCACCTAGG
CCACTCCTCCAAAGGAAGTCTAGGAGCTGGGAGGAAAAGAAAAGAGGGGAAAA
TGAGTTTTTATGGGGCTGAACGGGGAGAAAAGGTCATCATCGATTCTACTTTAGA
ATGAGAGTGTGAAATAGACATTTGTAAATGTAAAACCTTTTAAGGTATATCATTAT
40 AACTGAAGGAGAAGGTGCCCCAAAATGCAAGATTTTCCACAAGATTCCCAGAGA
CAGGAAAATCCTCTGGCTGGCTAACTGGAAGCATGTAGGAGAATCCAAGCGAGG
TCAACAGAGAAGGCAGGAATGTGTGGCAGATTTAGTGAAAGCTAGAGATATGGC
AGCGAAAGGATGTAAACAGTGCCTGCTGAATGATTTCCAAAGAGAAAAAAGTT
TGCCAGAAGTTTGTCAAGTCAACCAATGTAGAAAGCTTTGCTTATGGTAATAAAA
45 ATGGCTCATACTTATATAGCACTTACTTTGTTTGCAAGTACTGCTGTAAATAAATG
CTTTATGCAAACC

SEQ ID NO: 94

>gi|1716184|gb|AA146802.1|AA146802 zo41b09.r1 Stratagene endothelial cell 937223

Homo sapiens cDNA clone IMAGE:589433 5' similar to SW:YHGK_ECOLI P46849

HYPOTHETICAL 15.4 KD PROTEIN IN MALT-GLPR INTERGENIC REGION ;

5 GANGCTCAACATTTATCTGGACTGGAAATGATTTCGAGATTTGTGTGATGGGCAA
 CTGGAGGGGGCAGAAATTGGCTCAACAGAAATAACCTTTACACCAGAGAAGATC
 AAAGGTGGAATCCACACAGCAGATACCAAGACAGCAGGGAGTGTGTGCCTCTTG
 ATGCAGGTCTCAATGCCGTGTGTTCTCTTTGCTGCTTCTCCATCAGAACTTCATTT
 GAAAGGTGGAATAATGCTGAAATGGCACCACAGATCGATTATACAGTGATGGT
 10 CTTCAAGCCAATTGTTGAAAAATTTGGTTTCATATTTAATTGTGACATTAAACA
 AGGGGATATTACCCAAAAGGGGGTGGTGAAGTGATTGTTCGAATGTCACCAGTT
 AAACAATTGAACCCTATANATTTAACTGAGCGTGGCTGTGTGACTAAGATATATG
 GAAGAGCTTTCGTTGCTG

15 SEQ ID NO: 95

>gi|31113|emb|X00588.1|HSEGFPRE Human mRNA for precursor of epidermal growth factor receptor

GCCGCGCTGCGCCGGAGTCCCGAGCTAGCCCCGGCGCCGCCGCCAGACCG
 GACGACAGGCCACCTCGTCGGCGTCCGCCCGAGTCCCCGCCTCGCCGCCAACGCC
 20 ACAACCACCGCGCACGGCCCCCTGACTCCGTCCAGTATTGATCGGGAGAGCCGG
 AGCGAGCTCTTCGGGGAGCAGCGATGCGACCTCCGGGACGGCCGGGGCAGCGC
 TCCTGGCGCTGCTGGCTGCGCTCTGCCCGGCGAGTCGGGCTCTGGAGGAAAAGA
 AAGTTTGCCAAGGCACGAGTAACAAGCTCACGCAGTTGGGCACTTTTGAAGATC
 ATTTTCTCAGCCTCCAGAGGATGTTCAATAACTGTGAGGTGGTCCTTGGGAATTT
 25 GGAAATTACCTATGTGCAGAGGAATTATGATCTTTCCTTCTTAAAGACCATCCAG
 GAGGTGGCTGGTTATGTCCTCATTGCCCTCAACACAGTGGAGCGAATTCCTTTGG
 AAAACCTGCAGATCATCAGAGGAAATATGTACTACGAAAATTCCTATGCCTTAGC
 AGTCTTATCTAACTATGATGCAAATAAAACCGGACTGAAGGAGCTGCCCATGAG
 AAATTTACAGGAAATCCTGCATGGCGCCGTGCGGTTTCAGCAACAACCTGCCCTG
 30 TGCAACGTGGAGAGCATCCAGTGGCGGGACATAGTCAGCAGTGACTTTCTCAGC
 AACATGTCGATGGACTTCCAGAACCACCTGGGCAGCTGCCAAAAGTGTGATCCA
 AGCTGTCCCAATGGGAGCTGCTGGGGTGCAGGAGAGGAGAACTGCCAGAAACTG
 ACCAAAATCATCTGTGCCCAGCAGTGCTCCGGGCGCTGCCGTGGCAAGTCCCCCA
 GTGACTGCTGECACAACCAGTGCTGCTGAGGCTGCAAGGCCCCCGGGAGAGCG
 35 ACTGCCTGGTCTGCCGCAAATTCCGAGACGAAGCCACGTGCAAGGACACCTGCC
 CCCCACCTCATGCTCTACAACCCCAACACGTACCAGATGGATGTGAACCCCGAGGG
 CAAATACAGCTTTGGTGCCACCTGCGTGAAGAAGTGTCCCCGTAATTATGTGGTG
 ACAGATCACGGCTCGTGCGTCCGAGCCTGTGGGGCCGACAGCTATGAGATGGAG
 GAAGACGGCGTCCGCAAGTGTAAGAAGTGCGAAGGGCCTTGCCGCAAAGTGTGT
 40 AACGGAATAGGTATTGGTGAATTTAAAGACTCACTCTCCATAAATGCTACGAATA
 TTAAACACTTCAAAAACCTGCACCTCCATCAGTGGCGATCTCCACATCCTGCCGGT
 GGCATTTAGGGGTGACTCCTTCACACATACTCCTCCTCTGGATCCACAGGAACTG
 GATATTCTGAAAACCGTAAAGGAAATCACAGGGTTTTTGTGATTACAGGCTTGGC
 CTGAAAACAGGACGGACCTCCATGCCTTTGAGAACCTAGAAATCATACGCGGCA
 45 GGACCAAGCAACATGGTCAGTTTTCTCTTGCAGTCGTCAGCCTGAACATAACATC
 CTTGGGATTACGCTCCCTCAAGGAGATAAGTGATGGAGATGTGATAATTTACAGGA
 AACAAAAATTTGTGCTATGCAAATACAATAAACTGGAAAAAACTGTTTGGGACC
 TCCGGTCAGAAAACCAAAATTATAAGCAACAGAGGTGAAAACAGCTGCAAGGCC
 ACAGGCCAGGTCTGCCATGCCTTGTGCTCCCCCGAGGGCTGCTGGGGCCCCGGAGC

CCAGGGACTGCGTCTCTTGCCGGAATGTCAGCCGAGGCAGGGAATGCGTGGACA
AGTGCAAGCTTCTGGAGGGTGAGCCAAGGGAGTTTGTGGAGAACTCTGAGTGCA
TACAGTGCCACCCAGAGTGCCTGCCTCAGGCCATGAACATCACCTGCACAGGAC
GGGGACCAGACAACTGTATCCAGTGTGCCACTACATTGACGGCCCCCACTGCGT
5 CAAGACCTGCCCCGGCAGGAGTCATGGGAGAAAACAACACCCTGGTCTGGAAGTA
CGCAGACGCCGGCCATGTGTGCCACCTGTGCCATCCAACTGCACCTACGGATGC
ACTGGGCCAGGTCTTGAAGGCTGTCCAACGAATGGGCCTAAGATCCCGTCCATCG
CCACTGGGATGGTGGGGGCCCTCCTCTTGCTGCTGGTGGTGGCCCTGGGGATCGG
CCTCTTCATGCGAAGGCGCCACATCGTTCGGAAGCGCACGCTGCGGAGGCTGCTG
10 CAGGAGAGGGAGCTTGTGGAGCCTCTTACACCCAGTGGAGAAGCTCCCAACCAA
GCTCTCTTGAGGATCTTGAAGGAACTGAATTCAAAAAGATCAAAGTGCTGGGC
TCCGGTGCGTTTCGGCACGGTGTATAAGGGACTCTGGATCCCAGAAGGTGAGAAA
GTAAAAATTCCCGTCGCTATCAAGGAATTAAGAGAAGCAACATCTCCGAAAGCC
ACAAGGAAATCCTCGATGAAGCCTACGTGATGGCCAGCGTGGACAACCCCCAC
15 GTGTGCCGCTGCTGGGCATCTGCCTCACCTCCACCGTGCAACTCATCACGCAGC
TCATGCCCTTCGGCTGCCTCCTGGACTATGTCCGGGAACACAAAGACAATATTGG
CTCCCAGTACCTGCTCAACTGGTGTGTGCAGATCGCAAAGGGCATGAACTACTTG
GAGGACCGTCGCTTGGTGCACCGCGACCTGGCAGCCAGGAACGTACTGGTGAAA
ACACCGCAGCATGTCAAGATCACAGATTTTGGGCTGGCCAAACTGCTGGGTGCG
20 GAAGAGAAAAGAATACCATGCAGAAGGAGGCAAAGTGCCTATCAAGTGGATGGC
ATTGGAATCAATTTTACACAGAATCTATACCCACCAGAGTGATGTCTGGAGCTAC
GGGGTGACCGTTTGGGAGTTGATGACCTTTGGATCCAAGCCATATGACGGAATCC
CTGCCAGCGAGATCTCCTCCATCCTGGAGAAAGGAGAACGCCTCCCTCAGCCACC
CATATGTACCATCGATGTCTACATGATCATGGTCAAGTGCTGGATGATAGACGCA
25 GATAGTCGCCCCAAAGTTCCGTGAGTTGATCATCGAATTCTCCAAAATGGCCCGAG
ACCCCCAGCGCTACCTTGTCAATTCAGGGGGATGAAAGAATGCATTTGCCAAGTCC
TACAGACTCCAACTTCTACCGTGCCCTGATGGATGAAGAAGACATGGACGACGT
GGTGGATGCCGACGAGTACCTCATCCACAGCAGGGCTTCTTCAGCAGCCCCTCC
ACGTCACGGAATCCCCTCCTGAGCTCTCTGAGTGCAACCAGCAACAATTCCACCG
30 TGGCTTGCAATTGATAGAAATGGGCTGCAAAGCTGTCCCATCAAGGAAGACAGCT
TCTTGACGCGATACAGCTCAGACCCACAGGCGCCTTGACTGAGGACAGCATAG
ACGACACCTTCCTCCCACTGCCTGAATACATAAACCAGTCCGTTCCCAAAAGGCC
CGCTGGCTCTGTGCAGAATCCTGTCTATCACAATCAGCCTCTGAACCCCGCGCCC
AGCAGAGAGCCAGACTACCAAGGACCCCCACAGCACTGCAGTGGGCAACCCCGAG
35 TATCTCAACACTGTCCAGCCACCTGTGTCAACAGCACATTTCGACAGCCCTGCCC
ACTGGGCCCAGAAAGGCAGCCACCAAATTAGCCTGGACAACCCTGACTACCAGC
AGGACTTCTTTCCCAAGGAAGCCAAGCCAAATGGCATCTTTAAGGGCTCCACAGC
TGAAAATGCAGAATACCTAAGGGTCGCGCCACAAAGCAGTGAATTTATTGGAGC
ATGACCACGGAGGATAGTATGAGCCCTAAAAATCCAGACTCTTTCGATACCCAG
40 GACCAAGCCACAGCAGGTCCCTCCATCCCAACAGCCATGCCCGCATTAGCTCTTAG
ACCCACAGACTGGTTTTGCAACGTTTACACCGACTAGCCAGGAAGTACTTCCACC
TCGGGCACATTTTGGGAAGTTGCATTCCCTTTGTCTTCAAACCTGTGAAGCATTTACA
GAAACGCATCCAGCAAGAATATTGTCCCTTTGAGCAGAAATTTATCTTTCAAAGA
GGTATATTTGAAAAAAGTATATGTGAGGATTTTATTGATTGGGG
45 ATCTTGGAGTTTTTCATTGTGCTATTGATTTTACTTCAATGGGCTCTTCCAACA
AGGAAGAAGCTTGCTGGTAGCACTTGCTACCCTGAGTTCATCCAGGCCCACTGT
GAGCAAGGAGCACAAGCCACAAGTCTTCAGAGGATGCTTGATTCCAGTGGTTC
TGCTTCAAGGCTTCCACTGCAAAACACTAAAGATCCAAGAAGGCCTTCATGGCCC
CAGCAGGCCGGATCGGTACTGTATCAAGTCATGGCAGGTACAGTAGGATAAGCC

ACTCTGTCCCTTCCTGGGCAAAGAAGAAACGGAGGGGATGAATTCTTCCTTAGAC
 TTACTTTTGTAAAAATGTCCCCACGGTACTTACTCCCCACTGATGGACCAGTGGTT
 TCCAGTCATGAGCGTTAGACTGACTTGTGTTGCTTCCATTCCATTGTTTTGAAACT
 CAGTATGCCGCCCCGTGCTTGCTGTCATGAAATCAGCAAGAGAGGATGACACATC
 5 AAATAATAACTCGGATTCCAGCCCACATTGGATTTCATCAGCATTGACCAATAG
 CCCACAGCTGAGAATGTGGAATACCTAAGGATAACACCGCTTTTGTCTCGCAA
 AACGTATCTCCTAATTTGAGGCTCAGATGAAATGCATCAGGTCCTTTGGGGCATA
 GATCAGAAGACTACAAAAATGAAGCTGCTCTGAAATCTCCTTTAGCCATCACCCC
 AACCCCCCAAATTAGTTTGTGTTACTTATGGAAGATAGTTTTCTCCTTTTACTTC
 10 ACTTCAAAGCTTTTACTCAAAGAGTATATGTTCCCTCCAGGTCAGCTGCCCCC
 AAACCCCTCCTTACGCTTTGTACACAAAAAGTGTCTCTGCCTTGAGTCATCTAT
 TCAAGCACTTACAGCTCTGGCCACAACAGGGCATTTTACAGGTGCGAATGACAGT
 AGCATTATGAGTAGTGTGAATTCAGGTAGTAAATATGAACTAGGGTTTGAAATT
 GATAATGCTTTCACAACATTTGCAGATGTTTTAGAAGGAAAAAAGTTCCTTCTA
 15 AAATAATTTCTCTACAATTGGAAGATTGGAAGATTCAGCTAGTTAGGAGCCCAT
 TTTTCTAATCTGTGTGTGCCCTGTAACCTGACTGGTTAACAGCAGTCCTTTGTAA
 ACAGTGTTTTAACTCTCCTAGTCAATATCCACCCCATCCAATTTATCAAGGAAG
 AAATGGTTCAGAAAATATTTTCAGCCTACAGTTATGTTTCAGTCACACACACATAC
 AAAATGTTCTTTTGTCTTTTAAAGTAATTTTGTACTCCAGATCAGTCAGAGCCCC
 20 TACAGCATTGTTAAGAAAGTATTTGATTTTGTCTCAATGAAAATAAACTATAT
 TCATTTC

SEQ ID NO: 96

>gi|1770395|emb|X83864.1|HSEDG3 H.sapiens EDG-3 gene

25 AATGCCAAGTGATGGCAACTGCCTCCCGCCGCGTCTCCAGCCGGTGCGGGGAAC
 GAGACCCTGCGGAGATTACCAGTACGTGGGGAAGTTGGCGGGCAGGAATTCAGA
 ATCCATTGAGGCCTTCACTCACCACTTTCCCTCTCTCGCTGTGTTCCCAAATGTGC
 CACTTTTCTGTTGGCTCACATGCACCCATGCTCTATTTGATATTCAGGGCTCTGAA
 TTCAAGCCAGACTCAGTCAGTGTGATTGTCACTGCTTTCCTGTCCTTCCTTTATC
 30 ATCTGTAGACTTGGGTCCCGTTTTTGCAGGTTGATGTTCTGTCTTCGCTGGGCTCT
 GGACTCACTGCTCACGAGTGCGGTGTCTGCATGGGCACTGCCCAGACATGCACTG
 TTGGTCCCTCGATGGCTGCATGGTCAGGCCTCAGGGCTCTCTGCCAGGCCGACCT
 ACAGCCCATACAGACCTGATTTCTGGGCCTGGATCCAGGGGATGCCATCTGGGA
 AGTGCGGGATCTTCCACGATGTCACTGTAAACTCACCAGGGAGGTTTTAGAAA
 35 TTGAACCGGCATCATTAGATTCCATCCTGCTTTTGGTCCTGAGAAAATCCTGCT
 TTTCCCTGAGTAACTGGGATAATGGGTCACCAGCTCCCATGCCCTAGATGAGGAC
 TAGTTAGCATTTTCTAGTGCCTGGAGATTCCAGATGGAAGCTGTACTTGGGTCT
 GTGTATCTTTGTTACAGGATTCAATAATTCATGCACTGAATTTCCCTTCCCGGCAA
 CTCCAGACACCAAATCGCTTCCCATGGTGTCCCCCAATCACTTAGGAATTTAGCC
 40 TGTGTCTAAAGACCCTCTCTGCAGCCTGACGTGGCTAGCCATCCCAGTACTTCCA
 CGTTTTTCATGCCTTTCTCCAACAGCGTTGCCGTGGCCCCCTTAGGCGGCGATCGTT
 TTATCAATGGTCGCTCCCTCTTTTTATCTGTTGGCAGGAGCCCTTTTTCAACGCCC
 TCGCTGGAGTCTGGCCTGCACGCCTTGCTGAATGAAGCCGGAACCTCAGCCCCGC
 TTCCCTTTGAAATGAATGTTCTGGGGCGCCCTCTCGTGGATTTTGGAGCTAATCG
 45 TCTGTGAATGCCAAGTGATGGCAACTGCCCTCCCGCCGCGTCTCCAGCCGGTGCG
 GGGGAACGAGACCCTGCGGGAGCATTACCAGTACGTGGGGAAGTTGGCGGGCAG
 GCTGAAGGAGGCCTCCGAGGGCAGCACGCTCACCACCGTGCTCTTCTTGGTCATC
 TGCAGCTTCATCGTCTTGGAGAACCCTGATGGTTTTGATTGCCATCTGGAAAAACA
 ATAAATTTACAACCGCATGTACTTTTTTCAATTGGCAACCTGGCTCTCTGCGACCTG

CTGGCCGGCATCGCTTACAAGGTCAACATTCTGATGTCTGGCAAGAAGACGTTCA
 GCCTGTCTCCACGGTCTGGTTCCCTCAGGGAGGGCAGTATGTTCTGGCCCTTGG
 GGCGTCCACCTGCAGCTTACTGGCCATCGCCATCGAGCGGCACTTGACAATGATC
 AAAATGAGGCCTTACGACGCCAACAAGAGGCACCGCGTCTTCCTCCTGATCGGG
 5 ATGTGCTGGCTCATTGCCTTCACGCTGGGCGCCCTGCCATTCTGGGCTGGAAC
 GCCTGCACAATCTCCCTGACTGCTCTACCATCCTGCCCCCTCTACTCCAAGAAGTA
 CATTGCCTTCTGCATCAGCATCTTCACGGCCATCCTGGTGACCATCGTGATCCTCT
 ACGCACGCATCTACTTCCTGGTGAAGTCCAGCAGCCGTAAGGTGGCCAACCACA
 ACAACTCGGAGCGGTCCATGGCACTGCTGCGGACCGTGGTGATTGTGGTGAGCG
 10 TGTTTCATCGCCTGCTGGTCCCCACTCTTCATCCTCTTCCTCATTGATGTGGCCTGC
 AGGGTGCAGGCGTGCCCCATCCTCTTCAAGGCTCAGTGGTTCATCGTGTGGCTG
 TGCTCAACTCCGCCATGAACCCGGTCATCTACACGCTGGCCAGCAAGGAGATGC
 GGCGGGCCTTCTTCCGTCTGGTCTGCAACTGCCTGGTCAGGGGACGGGGGGCCCC
 CGCCTCACCCATCCAGCCTGCGCTCGACCCAAGCAGAAGTAAATCAAGCAGCAG
 15 CAACAATAGCAGCCACTCTCCGAAGGTCAAGGAAGACCTGCCCCACACAGACCC
 CTCATCCTGCATCATGGACAAGAACGCAGCACTTCAGAATGGGATCTTCTGCAAC
 TGATCGTCTCCATGCGCCCTGCTCTGCGGCTGTGTTCTTATTTATTGCATGCGTCG
 CTTCCACAGGGGCC

20 SEQ ID NO: 97

>gi|30129|emb|X61598.1|HSCOLLIG H.sapiens mRNA for colligin (a collagen-binding protein)

GGTCCTCTGTGGTGCACAGCCCACCCCCAGCCATGCGCTCTCTCCTTCTGGGCA
 CCTTATGCCTCCTGGCTGTGGCCCTGGCAGCCGAGGTGAAGAAACCTGTAGAGGC
 25 CGCAGCCCCTGGTACTGCGGAGAAGCTGAGTTCCAAGGCGACCACACTGGCAGA
 GCCCAGCACAGGCCTGGCCTTCAGCCTGTATCAGGCAATGGCCAAGGACCAGGC
 AGTGGAGAACATCCTGGTGTACCCCGTGGTGGTGGCCTCGTCGCTGGGTCTCGTG
 TCGCTGGGCGGCAAGGCGACACGGCGTCGCAGGCCAAGGCAGTGCTGAGCGCC
 GAGCAGCTGCGCGACGAGGAGGTGCACGCCGGCCTGGGTGAGCTGCTGCGCTCA
 30 CTCAGCAACTCGACGGCGCGCAACGTGACCTGGAAGCTGGGCAGCCGACTGTAC
 GGACCCAGCTCAGTGAGCTTCGCTGATGACTTCGTGCGCAGCAGCAAGCAGCAC
 TACAACCTGCGAGCACTCCAAGATCAACTTCCCGGACAAGCGCAGCGCGCTGCAG
 TCCATCAACGAGTGGGCGCGCAGACCACCGACGGCAAGCTGCCCCGAGGTCAAC
 AAGGACCTGGACCGCACGGACGGCGCCCTGCTAGTCAACGCCATGTTCTTCAAG
 35 CCACACTGGGATGAGAAATTCCACCACAAGATGGTGGACAACCGTGGCTTCATG
 GTGACTCGGTCTATACTGTGGGTGTTACGATGATGCACCGGACAGGCCTCTACA
 ACTACTACGACGACGAGAAGGAGAAGCTGCAGCTGGTGGAGATGCCCCCTGGCTC
 ACAAGCTCTCCAGCCTCATCATCCTCATGCCCCATCACGTGGAGCCTCTCGAGCG
 CTTGAAAAGCTGCTAACCAAAGAGCAGCTGAAGATCTGGATGGGGAAGATGCA
 40 GAAGAAGGCTGTTGCCATCTCCTTGCCCAAGGGTGTGGTGGAGGTGACCCATGA
 CCGCAGAAACACCTGGCTGGGCTGGGCCTGACTGAGGCCATTGACAAGAACAA
 GGCCGACTTATCACGCATGTCTGGCAAGAAGGATCTGTACCTGGCCAGTGTGTT
 CACGCCACCGCCTTTGAGTTGGACACAGATGGCAACCCCTTTGACCAGGACATCT
 ACGGGCGCGAGGAGCTGCGCAGCCCCAAGCTGTTCTACGCCGACCACCCCTTCAT
 45 CTTCTGGTGCAGGACACCCAAAGCGGCTCCCTGCTATTATTGGGCGCCTGGTC
 CGGCTCAAGGGTGACAAGATGCGAGACGAGTTATAGGGCCTCAGGGTGCACACA
 GGATGGCAGGAGGCATCCAAAGGCTCCTGAGACACATGGGTGCTATTGGGGTTG
 GGGGGGAGGTGAGGTACCAGCCTTGGAATACTCCATGGAATTCGAGCTCCACTTG
 GACATGGGCCCCAGATACCATGATGCTGAGCCCGGAACTCCACATCCTGTGGG

ACCTGGGCCATAGTCATTCTGCCTGCCCTGAAAGTCCCAGATCAAGCCTGCCTCA
ATCAGTATTCATATTTATAGCCAGGTACCTTCTCACCTGTGAGACCAAATTGAGC
TCGGGGGGTTCAGCCAGCCCTCTTCTGACACTAAAACACCTCAGCTGCCTCCCCAG
CTCTATCCCAACCTCTCCCAACTATAAACTAGGTGCTGCAGCCTGGGACCAGGC
5 ACCCCAGAAATGACCTGGCCGCAGTGAGGCGATTGAGAAGGAGCTCCCAGGAGG
GGCTTCTGGGAAGACCCTGGTCAAGAAGCATCGTCTGGCGTTGTGGGGATGAAC
TTTTTGTTTTGTTTTCTTCTTTTTTAGTTCTTCAAGGAATGGGGGGCCAGGGGGGC
AATGAGCCTTTGTTGCTAATCAAATCCGGGACTTGTTTGTACGTTTTTTTTTCTCA
CTGAAACCTTTTCCAGTGCCAAAAA

10

SEQ ID NO: 98

>gi|1673574|gb|U76549.1|HSU76549 Human cytokeratin 8 mRNA, complete cds

CACTCCTGCCTCCACCATGTCCATCAGGGTGACCCAGAAGTCCTACAAGGTGTCC
ACCTCTGGCCCCCGGGCCTTCAGCAGCCGCTCCTACACGAGTGGGCCCCGGTTCCC
15 GCATCAGCTCCTCGAGCTTCTCCCGAGTGGGCAGCAGCAACTTTCGCGGTGGCCT
GGGCGGCGGCTATGGTGGGGGCCAGCGGCATGGGAGGCATCACCGCAGTTACGGT
CAACCAGAGCCTGCTGAGCCCCCTTGTCTGGAGGTGGACCCCAACATCCAGGCC
GTGCGCACCCAGGAGAAGGAGCAGATCAAGACCCTCAACAACAAGTTTGCCTCC
TTCATAGACAAGGTACGGTTTCTGGAGCAGCAGAACAAGATGCTGGAGACCAAG
20 TGGAGCCTCCTGCAGCAGCAGAAGACGGCTCGAAGCAACATGGACAACATGTTC
GAGAGCTACATCAACAACCTTAGGCGGCAGCTGGAGACTCTGGGCCAGGAGAAG
CTGAAGCTGGAGGCGGAGCTTGGCAACATGCAGGGGCTGGTGGAGGACTTCAAG
AACAAGTATGAGGATGAGATCAATAAGCGTACAGAGATGGAGAACGAATTTGTC
CTCATCAAGAAGGATGTGGATGAAGCTTACATGAACAAGGTAGAGCTGGAGTCT
25 CGCCTGGAAGGGCTGACCGACGAGATCAACTTCCTCAGGCAGCTGTATGAAGAG
GAGATCCGGGAGCTGCAGTCCCAGATCTCGGACACATCTGTGGTGCTGTCCATGG
ACAACAGCCGCTCCCTGGACATGGACAGCATCATTGCTGAGGTCAAGGCACAGT
ACGAGGATATTGCCAACCGCAGCCGGGCTGAGGCTGAGAGCATGTACCAGATCA
AGTATGAGGAGCTGCAGAGCCTGGCTGGGAAGCACGGGGATGACCTGCGGCGCA
30 CAAAGACTGAGATCTCTGAGATGAACCGGAACATCAGCCGGCTCCAGGCTGAGA
TTGAGGGCCTCAAAGGCCAGAGGGCTTCCCTGGAGGCCGCCATTGCAGATGCCG
AGCAGCGTGGAGAGCTGGCCATTAAGGATGCCAACGCCAAGTTGTCCGAGCTGG
AGGCCGCCCTGCAGCGGGCCAAGCAGGACATGGCGCGGCAGCTGCGTGAGTACC
AGGAGCTGATGAACGTCAAGCTGGCCCTGGACATCGAGATCGCCACCTACAGGA
35 AGCTGCTGGAGGGCGAGGAGAGCCGGCTGGAGTCTGGGATGCAGAACATGAGTA
TTCATACGAAGACCACCAGCGGCTATGCAGGTGGTCTGAGCTCGGCCTATGGGG
GCCTCACAAGCCCCGGCCTCAGCTACAGCCTGGGCTCCAGCTTTGGCTCTGGCGC
GGGCTCCAGCTCCTTCAGCCGCACCAGCTCCTCCAGGGCCGTGGTTGTGAAGAAG
ATCGAGACACGTGATGGGAAGCTGGTGTCTGAGTCCTCTGACGTCCTGCCCAAGT
40 GAACAGCTGCGGCAGCCCCCTCCAGCCTACCCCTCCTGCGCTGCCCCAGAGCCTG
GGAAGGAGGCCGCTAT

SEQ ID NO: 99

>gi|2068972|gb|AA411440.1|AA411440 zv30d05.s1 Soares ovary tumor NbHOT Homo

sapiens cDNA clone IMAGE:755145 3' similar to gb:J05021 EZRIN (HUMAN);
45 TTTTTTTTTTTTTTTTTTTTTTGCCTTTGCAAAGCTTTTATTTTCATGTCTGCGGCAT
GGAATCCACCTGCACATGGCATCTTAGCTGTGAAGGAGAAAGCAGTGCACGAGA
AGGAATGAGTGGGCGGAACCAACGGCCTCCACAAGCTGCCTTCCAGCAGCCTGC
CAAGCGCATGGCAGAGAGAGACTGCAAACAACAACAAGCAAACAGAGTCTCTTC

ACAGCTGGAGTCTGAAAGCTCATAGTGGCATGTGTGAATCTGACAAAATTA
GTGTGCATAGTCCATTACATGCATAAAACACTAATAATAATCCTGTTTACACGTG
ACTGCAGCAGGCAGGTCCAGCTCCACCACTGGCCTCCTGCCACATCACATCAAGT
GCCATGGTTTAGAGGGTTTTTCATATGTAATTCCTTTATTCTGTAAAAGGTAACAA
5 AATATACAGAACAAAACCTTTCCCTTTTAAAACTAATGTTACAAATCTGTATTAT
CACTTGTATATAAATAGTATATAGCTGATCATTAAATAAGGTGTATAAGTACAATG
TATTCTAAAACCTGTTAAGC

SEQ ID NO: 100

10 >gi|2219420|gb|AA490238.1|AA490238 aa44a03.s1 Soares_NhHMPu_S1 Homo sapiens
cDNA clone IMAGE:823756 3' similar to TR:G505033 G505033 MITOGEN INDUCIBLE
GENE MIG-2 ;
GGGCCACAGGAGCGCTTCGCAGCCGAGGAACCGGACGCGGACACCGCGCCCCGG
AGCCTCCAGCCCCCTCGCCTGTTGCCGCGCGAGTCCCGGGCCCGGAGCGCTAGGA
15 GCGTCGGAAGGAGCCATGCTCTGGACGGGATAAGGATGCCAGATGGCTGCTACG
CGGACGGGACGTGGGAACTGAGTGTCCATGTGACGGACCTGAACCGCGATGTCA
CCCTGAGAGTGACCGGCGAGGTGCACATTGGAGGCGTGATGCTTAAGCTGGTGG
AGAAACTCGATGTAAAAAAGATTGGTCTGACCATGCTCTCTGGTGGGAAAAGA
AGAGAACTTGGCTTCTGAAGACACATTGGACCTTAGATAAGTATGGTATTCAGGC
20 AGATGCTAAGCTTCAGTTCACCCCTCAGCACAAACTGCTCCGCCTGCAGCTTCCC
AACATGAAGTATGTGAAGGTG

SEQ ID NO: 101

25 >gi|292069|gb|L04510.1|HUMGUABIND Human nucleotide binding protein mRNA,
complete cds
CTGTGGCGCTTCCCCTGCGAGGATGGCTACCCTGGTTGTAAACAAGCTCGGAGCG
GGAGTAGACAGTGGCCGGCAGGGCAGCCGGGGGACAGCTGTAGTGAAGGTGCT
AGAGTGTGGAGTTTGTGAAGATGTCTTTTCTTTGCAAGGAGACAAAGTTCCCCGT
CTTTTGCTTTGTGGCCATACCGTCTGTCTGACTGTCTCACTCGCCTACCTCTTCA
30 TGGAAGAGCAATCCGTTGCCCATTTGATCGACAAGTAACAGACCTAGGTGATTCA
GGTGTCTGGGGATTGAAAAAATTTTGCTTTATTGGAGCTTTTGGAACGACTGC
AGAATGGGCCTATTGGTCAGTATGGAGCTGCAGAAGAATCCATTGGGATATCTG
GAGAGAGCATCATTCGTTGTGATGAAGATGAAGCTCACCTTGCCCTCTGTATATTG
CACTGTGTGTGCAACTCATTTGTGCTCTGAGTGTTCTCAAGTTACTCATCTACAA
35 AGACATTAGCAAAGCACAGGCGAGTTCCTCTAGCTGATAAACCTCATGAGAAAA
CTATGTGCTCTCAGCACCAGGTGCATGCCATTGAGTTTGTGTTGCTTGGGAAGAAG
TTGTCAAACCTAGCCCACTCATGTGCTGTGTCTGCAAAGAATATGGAAAACACCAG
GGTCACAAGCATTCAGTATTGGAACCAGAAGCTAATCAGATCCGAGCATCAATTT
TAGATATGGCTCACTGCATACGGACCTTCACAGAGGAAATCTCAGATTATTCCAG
40 AAAATTAGTTGGAATTGTGCAGCACATTGAAGGAGGAGAACAAATCGTGGAAGA
TGGAATTGGAATGGCTCACACAGAACATGTACCAGGGACTGCAGAGAATGCCCG
GTCATGTATTCGAGCTTATTTTTATGATCTACATGAAACTCTGTGTCGTCAAGAAG
AAATGGCTCTAAGTGTTGTTGATGCTCATGTTTCGTGAAAAATTGATTTGGCTCAG
GCAGCAACAAGAAGATATGACTATTTTGTGTCAGAGGTTTCTGCAGCCTGCCTC
45 CACTGTGAAAAGACTTTGCAGCAGGATGATTGTAGAGTTGTCTTGGCAAAACAG
GAAATTACAAGGTTACTGGAAACATTGCAGAAACAGCAGCAGCAGTTTACAGAA
GTTGCAGATCACATTCAGTTGGATGCCAGCATCCCTGTCACTTTTACAAAGGATA
ATCGAGTTCACATTGGACCAAAAATGGAAATTCGGGTCGTTACGTTAGGATTGGA
TGGTGTCTGGAAAACTACTATCTTGTTTAAAGTTAAAACAGGATGAATTCATGCAG

CCCATTCCAACAATTGGTTTTAACGTGGAAACTGTAGAATATAAAAAATCTAAAAT
 TCACTATTTGGGATGTAGGTGGAAAACACAAATTAAGACCATTGTGGAAACATT
 ATTACCTCAATACTCAAGCTGTTGTGTTTGTGTAGATAGCAGTCATAGAGACAG
 AATTAGTGAAGCACACAGCGAACTTGCAAAGTTGTTAACGGAAAAAGAACTCCG
 5 AGATGCTCTGCTCCTGATTTTTGCTAACAAACAGGATGTTGCTGGAGCACTGTCA
 GTAGAAGAAATCACTGAACACTCAGTCTCCATAAATTATGCTGTGGCCGTAGCT
 GGTATATTCAGGGCTGTGATGCTCGAAGTGGTATGGGACTGTATGAAGGGTTGG
 ACTGGCTCTCACGGCAACTTGTAGCTGCTGGAGTATTGGATGTTGCTTGATTTTA
 AAGGCAGCAGTTGTTTGAAGTTTTGTGGTTAAAAGTAACTTTGCACATAGTATGT
 10 TTTAAGAAATTATACATCTCAAAAGATGGTAATTTAGGATGCATATATATATATA
 TATATATAAAGGAATCTTGGATTGGGAATTCAGTACTTTGCTTTAAAAAAATTTT
 GTGGCAGAATTAAATTTCTAATTGAGCAGATTAGATTGAATTAAATAGAACTTA
 TTGAATATACATTCTTTTAAAAAGTATATTTGTTATTTAAGTTTTTCAGATAATAT
 GTGACCAATATACTGGGAAAGAGGTAGTCACAGAGAAAGGGTAAGTGAAGGTTT
 15 ATTCTTTCAGTGAAAAAAGAATAGCCAATTGAGTGCCTAATGAGACCTCTGTGTG
 AAGCAAGTGAAGTATAGCTGCTTCTTTAACCTGCCTTTTCACTGAATGTTGGCA
 GCATTTAGTAGTAGAAATGACAGTTGCTTAATGAAATAGAATCCAACTACATAT
 TTGGATAATAGGATTACTTTATGTTTATGTTTCAGAGTTAACAGAACACCTTTAAT
 GCTAAGAACTATAAGGTACAGAAAATTAATACTTTATATAGTGTTTTATTAACCTT
 20 TCTCCTACAGCATTTTGTATAAAACACAATGAGGGAGTGAAATGTTACCCAATTA
 GGCTTGTGAGGTTAGTAATAAACTGAACAGTAATAAAACTGTGGAAGTAATTGG
 ATCTGAATTTATGAAAGACCCATTTCCAGGACTGAACCTAGGTCAGAGCTCTAAA
 TTGGTCCTTCTATTTTTCAACAAATTTAAAGTAATATTTCTTCTAATATAATATT
 GCATCCTTTGTGGGAATGACTATAGGTAAAATGTAGTAAGTAACGCAGAACCCAG
 25 GGTGGCTTTATTTAAAAGCTAGTGACCTAAATAGAAAGCGAACTTCAAGAGAA
 GTTGTAAGTACAGTGGCAAATGCTTATTACTTCAAACTGTTTCCCAAATA
 AGTGCATTTATTTTGACAATAAACTTAAGGCTGTTTCATGAGAAGGCCTTGAAAA
 GTTACTCTAGAGGAAAAATGTCTAAAGAAAAAAATTCAAAAAGTTTACATT
 AATTATTCAGTGTGTGAGTAAATAAAAAATGTGTGCTCTTACTGTTTTTCATTTT
 30 TAAAGAATATTATTATGGAAGCACGATTTATTTAAATAGGTACATTGAGACTTTT
 TTTTTAATGTTCTGATACATTAGGATGAAGTTAAATCTTAAATCTTATTAGTTGA
 ATTGTTGTAAGGACAGTGATGTCTGGTAACAAGATGTGACTTTTTGGTAGCACTG
 TTGTGGTTTCATTCTTTTCAAATCTATTTTTGTTTAAAAACAATACAAGTTTTAGAA
 AACAAGCATTAAAAAAAAGCCTATCAGTATTATGGGCTATATGTAAATAAAT
 35 AAATGTAATATTTTCATCCTTTATTTTTTCAGGTAAAAGGTCATGCTGTTACAGGTGT
 AGTTTGTGTGCATAAATAATACTTCCGAATTAAATTATTTAATATTTGACTGATTT
 CAATAACTGTGAAAATAAAAAGGTGTTGTATTGCTTGTGAG

SEQ ID NO: 102

40 >gi|577412|gb|U13666.1|HSU13666 Human G protein-coupled receptor (GPR1) gene,
 complete cds
 GGGCTGCAGTGAGCCAAAAGCATGCCATTGCACTCCAGCTTGGGCAACAGAGTG
 AGACCCTGTCTCAAAAAAAGAAAAATAATACTATGTCTGGTCCATAACCTGA
 AATATTTTTATCTTCACGTTCTTATCATTCACTGAACTTTTATTTTTCTTTTAAAA
 45 TTTTTCTTTCTTTTAAATTTGCTTCTACAGATTTCTTCATTCTCCATTTAGCAA
 GGTCATGGAAGATTTGGAGGAAACATTATTTGAAGAATTTGAAAACCTATTCCTAT
 GACCTAGACTATTACTCTCTGGAGTCTGATTTGGAGGAGAAAGTCCAGCTGGGAG
 TTGTTCACTGGGTCTCCCTGGTGTATATTGTTTGGCTTTTGTCTGGGAATTCCA
 GGAAATGCCATCGTCATTTGGTTACGGGGCTCAAGTGAAGAAGACAGTCACC

ACTCTGTGGTTCCTCAATCTAGCCATTGCGGATTTTCATTTTTCTTCTCTTTCTGCCC
CTGTACATCTCCTATGTGGCCATGAATTTCCACTGGCCCTTTGGCATCTGGCTGTG
CAAAGCCAATTCCTTCACTGCCCAGTTGAACATGTTTGCCAGTGTTTTTTTCCTGA
CAGTGATCAGCCTGGACCACTATATCCACTTGATCCATCCTGTCTTATCTCATCGG
5 CATCGAACCCTCAAGAACTCTCTGATTGTCATTATATTCATCTGGCTTTTGGCTTC
TCTAATTGGCGGTCTCTGCCCTGTACTTCCGGGACACTGTGGAGTTCAATAATCAT
ACTCTTTGCTATAACAATTTTTCAGAAGCATGATCCTGACCTCACTTTGATCAGGC
ACCATGTTCTGACTTGGGTGAAATTTATCATTGGCTATCTCTTCCCTTTGCTAACA
ATGAGTATTTGCTACTTGTGTCTCATCTTCAAGGTGAAGAAGCGAACAGTCCTGA
10 TCTCCAGTAGGCATTTCTGGACAATTCTGGTTGTGGTTGTGGCCTTTGTGGTTTGC
TGGACTCCTTATCACCTGTTTAGCATTGTTGGGAGCTCACCATTACCCACAATAGCT
ATTTCCACCATGTGATGCAGGCTGGAATCCCCCTCTCCACTGGTTTGGCATTCTCT
AATAGTTGCTTGAACCCCATCCTTTATGTCCTAATTAGTAAGAAGTTCCAAGCTC
GCTTCCGGTCTCAGTTGCTGAGATACTCAAGTACACACTGTGGGAAGTCAGCTG
15 TTCTGGCACAGTGAGTGAACAGCTCAGGAACCTCAGAAACCAAGAATCTGTGTCT
CCTGGAAACAGCTCAATAAGTTATTACTTTTCCACAAATCAGTATATGGCTTTTAA
TGTGGGTCTCTGACTGATGCTTTCAGATTAAAATTGTTTCCAAGATAGAGAGCC
GACTCCACTTTCATAGTTATTGTTTCTGGTCCATATATGGCATCACATTTT

20 SEQ ID NO: 103

>gi|1185462|gb|U38545.1|HSU38545 Human ARF-activated phosphatidylcholine-specific
phospholipase D1a (hPLD1) mRNA, complete cds

GGCACGAGGAGCCCTGAGAGTCCGCCGCCAACGCGCAGGTGCTAGCGGCCCCCTT
CGCCCTGCAGCCCTTTGCTTTTACTCTGTCCAAAGTTAACATGTCACTGAAAAA
25 CGAGCCACGGGTAAATACCTCTGCACTGCAGAAAATTGCTGCTGACATGAGTAA
TATCATAGAAAATCTGGACACGCGGGAACCTCACTTTGAGGGAGAGGAGGTAGA
CTACGACGTGTCTCCAGCGATCCCAAGATACAAGAAGTGTATATCCCTTTCTCT
GCTATTTATAACACTCAAGGATTTAAGGAGCCTAATATACAGACGTATCTCTCCG
GCTGTCCAATAAAAGCACAAAGTTCTGGAAGTGGAACGCTTCACATCTACAACAA
30 GGGTACCAAGTATTAATCTTTACACTATTGAATTAACACATGGGGAATTTAAATG
GCAAGTTAAGAGGAAATTCAAGCATTTTCAAGAATTTACAGAGAGCTGCTCAA
GTACAAAGCCTTTATCCGCATCCCCATTCCCACTAGAAGACACACGTTTAGGAGG
CAAAACGTCAGAGAGGAGCCTCGAGAGATGCCAGTTTGCCCCGTTTCATCTGAA
AACATGATAAGAGAAGAACAATTCCTTGGTAGAAGAAAAACACTGGTAGATTAC
35 TTGACAAAGATACTAAAAATGCCCATGTATAGAAACTATCATGCCACAACAGAG
TTTCTTGATATAAGCCAGCTGTCTTTCATCCATGATTTGGGACCAAAGGGCATAG
AAGGTATGATAATGAAAAGATCTGGAGGACACAGAATACCAGGCTTGAATTGCT
GTGGTCAGGGAAGAGCCTGCTACAGATGGTCAAAAAGATGGTTAATAGTGAAAG
ATTCCTTTTTATTGTATATGAAACCAGACAGCGGTGCCATTGCCTTCGTCTGCTG
40 GTAGACAAAGAATTCAAAATTAAGGTGGGGAAGAAGGAGACAGAAACGAAATA
TGGAATCCGAATTGATAATCTTTCAAGGACACTTATTTTAAAATGCAACAGCTAT
AGACATGCTCGGTGGTGGGGAGGGGCTATAGAAGAATTCATCCAGAAACATGGC
ACCAACTTTCTCAAAGATCATCGATTTGGGTCTATGCTGCTATCCAAGAGAATG
CTTTAGCTAAATGGTATGTTAATGCCAAAGGATATTTTGAAGATGTGGCAAATGC
45 AATGGAAGAGGCAAATGAAGAGATTTTATCACAGACTGGTGGCTGAGTCCAGA
AATCTTCCTGAAACGCCCAGTGGTTGAGGGAAATCGTTGGAGGTTGGACTGCATT
CTTAAACGAAAAGCACACAAGGAGTGAGGATCTTCATAATGCTCTACAAAGAG
GTGGAACCTCGCTCTTGGCATCAATAGTGAATACCAAGAGGACTTTGATGCGTC
TACATCCCAACATAAAGGTGATGAGACACCCGGATCATGTGTCATCCACCGTCTA

TTTGTGGGCTCACCATGAGAAGCTTGTCATCATTGACCAATCGGTGGCCTTTGTG
GGAGGGATTGACCTGGCCTATGGAAGGTGGGACGACAATGAGCACAGACTCACA
GACGTGGGCAGTGTGAAGCGGGTCACTTCAGGACCGTCTCTGGGTTCCTCCAC
CTGCCGCAATGGAGTCTATGGAATCCTTAAGACTCAAAGATAAAAATGAGCCTG
5 TTCAAAACCTACCCATCCAGAAGAGTATTGATGATGTGGATTCAAAACTGAAAG
GAATAGGAAAAGCCAAGAAAGTTCTCCAAATTTAGTCTCTACAAGCAGCTCCACA
GGCACCACCTGCACGACGCAGATAGCATCAGCAGCATTGACAGCACCTCCAGTT
ATTTTAATCACTATAGAAGTCATCACAAATTTAATCCATGGTTTAAAACCCCACTTC
AAACTCTTTCACCCGTCCAGTGAGTCTGAGCAAGGACTCACTAGACCTCATGCTG
10 ATACCGGGTCCATCCGTAGTTTACAGACAGGTGTGGGAGAGCTGCATGGGGAAA
CCAGATTCTGGCATGGAAAGGACTACTGCAATTTTCGTCTTCAAAGACTGGGTTC
ACTTGATAAACCTTTTGTGATTTCATTGACAGGTACTCCACGCCCGGATGCCCT
GGCATGACATTGCCTCTGCAGTCCACGGGAAGGCGGCTCGTGATGTGGCACGTC
ACTTCATCCAGCGCTGGAACCTTCACAAAAATTATGAAATCAAAATATCGGTCCCT
15 TTCTTATCCTTTTCTGCTTCCAAAGTCTCAAAACAACAGCCCATGAGTTGAGATATC
AAGTGCCTGGGTCTGTCCATGCTAACGTACAGTTGCTCCGCTCTGCTGCTGATTG
GTCTGCTGGTATAAAGTACCATGAAGAGTCCATCCACGCCGCTTACGTCCATGTG
ATAGAGAACAGCAGGCACTATATCTATATCGAAAACCAGTTTTTTCATAAGCTGTG
CTGATGACAAAGTTGTGTTCAACAAGATAGGCGATGCCATTGCCCAGAGGATCCT
20 GAAAGCTCACAGGGAAAACCAGAAATACCGGGTATATGTCGTGATACCACTTCT
GCCAGGGTTCGAAGGAGACATTTCAACCGGCGGAGGAAATGCTCTACAGGCAAT
CATGCACTTCAACTACAGAACCATGTGCAGAGGAGAAAATTCCATCCTTGGACA
GTTAAAAGCAGAGCTTGGTAATCAGTGGATAAATTACATATCATTCTGTGGTCTT
AGAACACATGCAGAGCTCGAAGGAAACCTAGTAACTGAGCTTATCTATGTCCAC
25 AGCAAGTTGTTAATTGCTGATGATAAACTGTTATTATTGGCTCTGCCAACATAA
ATGACCGCAGCATGCTGGGAAAGCGTGACAGTGAAATGGCTGTCATTGTGCAAG
ATACAGAGACTGTTCCCTTCAGTAATGGATGGAAAAGAGTACCAAGCTGGCCGGT
TTGCCCAGGACTTCGGCTACAGTGCTTTAGGGTTGTCCTTGGCTATCTTGATGAC
CCAAGTGAGGACATTCAGGATCCAGTGAGTGACAAATTCTTCAAGGAGGTGTGG
30 GTTTCAACAGCAGCTCGAAATGCTACAATTTATGACAAGGTTTTCCGGTGCCTTC
CCAATGATGAAGTACACAATTTAATTCAGCTGAGAGACTTTATAAACAAGCCCGT
ATTAGCTAAGGAAGATCCCATTTCGAGCTGAGGAGGAACTGAAGAAGATCCGTGG
ATTTTTGGTGCAATTCCCCTTTTATTTCTTGTCTGAAGAAAGCCTACTGCCTTCTG
TTGGGACCAAAGAGGCCATAGTGCCCATGAGGTTTGGACTTAAGAGATATTCA
35 TTGGCAGCTCAAAGACTTCCACCCTGGAGACCACACTGCACACAGTGACTTCCTG
GGGATGTCATAGCCAAAGCCAGGCCTGACGCATTCTCGTATCCAACCCAAGGAC
CTTTTGAATGACTGGGGAGGGCTGCAGTCACATTGATGTAAGGACTGTAAACAT
CAGCAAGACTTTATAATTCCTTCTGCCTAACTTGTA AAAAGGGGGCTGCATTCTT
GTTGGTAGCATGTACTCTGTTGAGTAAAACACATATTCAAATTCCGCTCGTGCCG
40 AATTC

SEQ ID NO: 104

>gi|1010012|gb|H57180.1|H57180 yr10f05.s1 Soares fetal liver spleen 1NFLS Homo sapiens
cDNA clone IMAGE:204897 3' similar to gb:X14034 1-PHOSPHATIDYLINOSITOL-4,5-
45 BISPHOSPHATE PHOSPHODIESTERASE GAMMA (HUMAN);

CTCTCAATGGGCGCACGGGCTACGTTCTGCAGCCTGAGAGCATGAGGACAGAGA
AATATGACCCGATGCCACCCGAGTCCCAGAGGAAGATCCTGATGACGCTGACAG
TCAAGGTTCTCGGTGCTCGCCATCTCCCCAACTTGGACGAAGTATTGCCTGTNC
CTTTGTAGAAGTGGAGNTCTGTGGAGCCGAGTATGACAACAACAAGTTCAAGAC

GACGGTTGTGAATGATAATGGCCTCAGNCCTATCTGGGCTCCAACACAGGAGAA
GGTGACATTTGANATTTATGACCCAAACCTGGGNATTTTTTTCGCTTNGTGTTT
ATTGAAGGAAGGTATTGTTTCAGCGNTTCCCCAATTTTTTTTGGNTCATGGCCACT
TTACCCCTTTAAAGGCAGTCAAAATCAGGGNTTCAGGGTNCCT

5

SEQ ID NO: 105

>gi|180602|gb|M58552.1|HUMCLG4Q01 Human collagenase type IV (CLG4) gene, exon 1
CAGGTCAACGGATCATCTGTTTCTGACCATTCTTCCCGTTCCTGACCCCAGGGA
GTGCAGGGTGTCTAGCCAAGCCGGCGTCCCTCCTAGTAGTACCGCTGCTCTCTA
10 ACCTCAGGACGTCAAGGGCCTAGAGCGACAGATGTTTCCCAGCAGGGGGTTCTG
AGGCTGTGCGCCCAGATCGCGAGAGAGGCAAGTGGGGTGACGAGGTTCGTGCACT
GAGGGTGGACGTAGAGGCCAGGAGTAGCAGGCGGCCGGGAAAAGAGGTGGAG
AAAGGAAAAAAGAGGAGAAAAAGTGGAGGAGGGCGAGTAGGGGGGTGGGGCAG
AGAGGGGCGGGCCCGAGTGCGCCCGCCCGCCCGAGCCCGCTCTGCCAGCTCCCT
15 CCCAGCCCAGCCGGCTACATCTGGCGGCTGCCCTCCCTTGTTTCCGCTGCATCCA
GACTTCCTCAGGCGGTGGCTGGAGGCTGCGCATCTGGGGCTTTAAACATACAAA
GGGATTGCCAGGACCTGCGGCGGCGGCGGCGGCGGCGGGGGCTGGGGCGCGGG
GGCCGGACCATGAGCCGCTGAGCCGGGCAAACCCAGGCCACCGAGCCAGCGGA
CCCTCGGAGCGCAGCCCTGCGCCGCGGACCAGGCTCCAACCAGGCGGCGAGGCG
20 GCCACACGCACCGAGCCAGCGACCCCCGGGCGACGCGCGGGGCCAGGGAGCGCT
ACGATGGAGGCGCTAATGGCCCGGGGCGCGCTCACGGGTCCCCTGAGGGCGCTC
TGTCTCCTGGGCTGCCTGCTGAGCCACGCCGCCGCGCCGTCGCCCATCATCA
AGTTCCCCGGCGATGTCGCCCCCAAAACGGACAAAGAGTTGGCAGTGGTGAGTT
GCT

25

SEQ ID NO: 106

>gi|37849|emb|X56134.1|HSVIMENT Human mRNA for vimentin
CGCGCCACCGCCCGCCAGGCCATCGCCACCTCCGCAGCCATGTCCACCAGG
TCCGTGTCTCTCGTCTCTACCGCAGGATGTTTCGGCGGGCCCGGGACCGCGAGCC
30 GGCCGAGCTCCAGCCGGAGCTACGTGACTACGTCCACCCGCACCTACAGCCTGG
GCAGCGCGCTGCGCCCCAGCACCAGCCGCAGCCTCTACGCCTCGTCCCCGGGCG
GCGTGTATGCCACGCGCTCCTCTGCCGTGCGCCTGCGGAGCAGCGTGCCCCGGGT
GCGGCTCCTGCAGGACTCGGTGGACTTCTCGCTGGCCGACGCCATCAACACCGAG
TTCAAGAACACCCGCACCAACGAGATGGTGGAGCTGCAGGAGCTGAATGACCGC
35 TTCGCCAACTACATCGACAAGGTGCGCTTCTGGAGCAGCAGAATAAGATCCTGC
TGGCCGAGCTCGAGCAGCTCAAGGGCCAAGGCAAGTCGCGCCTGGGGGACCTCT
ACGAGGAGGAGATGCGGGAGCTGCGCCGGCAGGTGGACCAGCTAACCAACGAC
AAAGCCCGCGTCGAGGTGGAGCGCGACAACCTGGCCGAGGACATCATGCGCCTC
CGGGAGAAATTGCAGGAGGAGATGCTTCAGAGAGAGGAAGCCGAAAACACCCT
40 GCAATCTTTCAGACAGGATGTTGACAATGCGTCTCTGGCACGTCTTGACCTTGAA
CGCAAAGTGGAATCTTTGCAAGAAGAGATTGCCTTTTTGAAGAACTCCACGAA
GAGGAAATCCAGGAGCTGCAGGCTCAGATTCAGGAACAGCATGTCCAAATCGAT
GTGGATGTTTCCAAGCCTGACCTCACGGCTGCCCTGCGTGACGTACGTCAGCAAT
ATGAAAGTGTGGCTGCCAAGAACCTGCAGGAGGCAGAAGAATGGTACAAATCCA
45 AGTTTGCTGACCTCTCTGAGGCTGCCAACCAGGAACAATGACGCCCTGCGCCAGGC
AAAGCAGGAGTCCACTGAGTACCGGAGACAGGTGCAGTCCCTCACCTGTGAAGT
GGATGCCCTTAAAGGAACCAATGAGTCCCTGGAACGCCAGATGCGTGAAATGGA
AGAGAACTTTGCCGTTGAAGCTGCTAACTACCAAGACACTATTGGCCGCTGCAG
GATGAGATTGAGAATATGAAGGAGGAAATGGCTCGTCACCTTCGTGAATACCAA

GACCTGCTCAATGTTAAGATGGCCCTTGACATTGAGATTGCCACCTACAGGAAGC
 TGCTGGAAGGCGAGGAGAGCAGGATTTCTCTGCCTCTTCCAAACTTTTCCCTCCCT
 GAACCTGAGGGGAAACTAATCTGGATTCACTCCCTCTGGTTGATACCCACTCAAAA
 AGGACACTTCTGATTAAGACGGTTGAACTAGAGATGGACAGGTTATCAACGAA
 5 ACTTCTCAGCATCACGATGACCTTGAATAAAAATTGCACACACTCAGTGCAGCAA
 TATATTACCAGCAAGAATAAAAAAGAAATCCATATCTTAAAGAAACAGCTTTCA
 AGTGCCTTTCTGCAGTTTTTCAGGAGCGCAAGATAGATTTGGAATAGGAATAAGC
 TCTAGTTCTTAACAACCGACACTCCTACAAGATTTAGAAAAAAGTTTACAACATA
 ATCTAGTTTACAGAAAAATCTTGTGCTAGAATACTTTTTTAAAAGGTATTTTGAAT
 10 ACCATTAAACTGCTTTTTTTTTTCCAGCAAGTATCCAACCAACTTGGTTCTGCTT
 CAATAAATCTTTGGAAAACTA

SEQ ID NO: 107

>gi|2219635|gb|AA490462.1|AA490462 aa45b02.s1 Soares_NhHMPu_S1 Homo sapiens
 15 cDNA clone IMAGE:823851 3' similar to TR:G607132 G607132 AEBP1 MRNA. ;contains
 element TAR1 TAR1 repetitive element ;
 TTTTTTTTTTCCGTGCCATGAGCTTGTTTTATTGGAGTGACCTTGGCTCCCTCCCT
 CTGCCCCCTACTCCAACACTGCAGCAACCCCATCTCTTACGAGACTGGCAGGTGGA
 GCAGGAGCCTCTACACAGCCTCTGGTCCTTAGGTCCCAGTCATGTTTGCACCCCC
 20 TCAAAGGGCTAGGACCAGCCCTTCCTTTCAGTGTCCATACCAGGGGCCTTCCATG
 TGCTGATGGGTGATGTGACTGTGGTCAGCAGGCTTGGGAAGTGCTGCTGCTGTAG
 CTTGAGTTGGGCTGGGGTCTTGGTAGGACGCTGATCTCAGAAGTCCCCAAAGTTC
 ACTGTGTAGGTCTCTACTGTTGTGAAGGGGAATGCCTGGCCAGTGCCTATCTCCT
 CCTCTTCTCCCTTCTCCTTCTTCTCCTCAAACCTCGGGTTTCAACTGGGTCTCAAAC
 25 TCAGACTCCAACCTGGGTCTCAAACACTGGCTCCAACCTTGGGCCCAAACCTTCGGG
 GTTCACCTCGGTCCCAAACCTCTGGTAACAACCTCTGTGTAAGGCTCAGTTTCCGC

SEQ ID NO: 108

>gi|1384184|gb|W74565.1|W74565 zd56e05.r1 Soares_fetal_heart_NbHH19W Homo
 30 sapiens cDNA clone IMAGE:344672 5' similar to SW:HEXP_LEIMA Q04832 DNA-
 BINDING PROTEIN HEXBP ;
 GGAGAAATGGGGCACCTGTCTAGATCTTGTCTGATAATCCCAAAGGACTCTATG
 CTGATGGTGGCGGTTGCAAACCTTGTGGCTCTGTGGAACATTTAAAGAAAGATTG
 CCCTGAAAGTCAGAAATGAGAGCGGATGCTCACAGTTGGTCGCTGGGCAAAGGG
 35 AATGAGTGCAGACTATGAAGAAATTTTGGATGTACCTAAACCGCAAAAACCCAA
 AACAAAAATACCTAAAGTTGTTAATTTTTGATAACAGCTAGCACTATCATGAGTT
 ACTACCTCATTGTTACTTTCTAAACCCAGGCCCGCTTCACAAGTTAGAGTTGAG
 CTCCCCCTTGTANGCCAGGACTATGCCTGTAAGATATCCAGTAATGATCCTGGGG
 TGTTGGCCAAAAACCAA
 40 T

SEQ ID NO: 109

>gi|236181|gb|S57551.1|S57551 guanylate cyclase-coupled enterotoxin receptor [human, T84
 45 colonic cell line, mRNA, 3787 nt]
 TGGAGTGGGCTGAGGGACTCCACTAGAGGCTGTCCATCTGGATTCCCTGCCTCCC
 TAGGAGCCCAACAGAGCAAAGCAAGTGGGCACAAGGAGTATGGTTCTAACGTGA
 TTGGGGTCATGAAGACGTTGCTGTTGGACTTGGCTTTGTGGTCACTGCTCTTCCAG
 CCCGGGTGGCTGTCTTTAGTTCCCAGGTGAGTCAGAACTGCCACAATGGCAGCT
 ATGAAATCAGCGTCCTGATGATGGGCAACTCAGCCTTTGCAGAGCCCCTGAAAA

ACTTGGAAGATGCGGTGAATGAGGGGCTGGAAATAGTGAGAGGACGTCTGCAAA
ATGCTGGCCTAAATGTGACTGTGAACGCTACTTTCATGTATTCGGATGGTCTGAT
TCATAACTCAGGCGACTGCCGGAGTAGCACCTGTGAAGGCCTCGACCTACTCAG
GAAAATTTCAAATGCACAACGGATGGGCTGTGTCCTCATAGGGCCCTCATGTACA
5 TACTCCACCTTCCAGATGTACCTTGACACAGAATTGAGCTACCCCATGATCTCAG
CTGGAAGTTTTGGATTGTCATGTGACTATAAAGAAACCTTAACCAGGCTGATGTC
TCCAGCTAGAAAGTTGATGTACTTCTTGGTTAACTTTTGGAAAACCAACGATCTG
CCCTTCAAAACTTATTCCTGGAGCACTTCGTATGTTTACAAGAATGGTACAGAAA
CTGAGGACTGTTTCTGGTACCTTAATGCTCTGGAGGCTAGCGTTTCTATTCTCC
10 CACGAACCTCGGCTTTAAGGTGGTGTAAAGACAAGATAAGGAGTTTCAGGATATCT
TAATGGACCACAACAGGAAAAGCAATGTGATTATTATGTGTGGTGGTCCAGAGT
TCCTCTACAAGCTGAAGGGTGACCGAGCAGTGGCTGAAGACATTGTCATTATTCT
AGTGGATCTTTTCAATGACCAGTACTTGGAGGACAATGTCACAGCCCCTGACTAT
ATGAAAAATGTCCTTGTCTGACGCTGTCTCCTGGGAATTCCTTCTAAATAGCTC
15 TTTCTCCAGGAATCTATACCAACAAAACGAGACTTTCGTCTTGCCTATTTGAAT
GGAATCCTCGTCTTTGGACATATGCTGAAGATATTTCTTGAAAATGGAGAAAATA
TTACCACCCCCAAATTTGCTCATGCCTTCAGGAATCTCACTTTTGAAGGGTATGA
CGGTCCAGTGACCTTGGATGACTGGGGGGATGTTGACAGTACCATGGTGTCTCTG
TATACCTCTGTGGACACCAAGAAATACAAGGTCTTTTGGACCTATGATACCCACG
20 TAAATAAGACCTATCCTGTGGATATGAGCCCCACATTCACCTGGAAGAACTCTAA
ACTTCCTAATGATATTACAGGCCGGGGCCCTCAGATCCTGATGATTGCAGTCTTC
ACCTCCTGAGCTGTGGTGTCTCCTGCTCGTCTCCTGATGCTCAGAA
AATATAGAAAAGATTATGAACTTCGTCAGAAAAAATGGTCCCACATTCTCTGA
AAATATCTTCTCTGGAGACCAATGAGACCAATCATGTTAGCCTCAAGATCGAT
25 GATGACAAAAGACGAGATACAATCCAGAGACTACGACAGTGCAAATACGTCAAA
AAGCGAGTGATTCTCAAAGATCTCAAGCACAATGATGGTAATTTCACTGAAAAA
CAGAAGATAGAATTGAACAAGTTGCTTCAGATTGACTATTACACCCTAACCAAGT
TCTACGGGACAGTGAACTGGATACCATGATCTTCGGGGTGATAGAATACTGTG
AGAGAGGATCCCTCCGGGAAGTTTTAAATGACACAATTTCTACCCTGATGGCAC
30 ATTCATGGATTGGGAGTTTAAGATCTCTGTCTTGTATGACATTGCTAAGGGAATG
TCATATCTGCACTCCAGTAAGACAGAAGTCCATGGTCTGAAATCTACCAACT
GCGTAGTGGACAGTAGAATGGTGGTGAAGATCACTGATTTTGGCTGCAATTCCAT
TTTGCCTCCAAAAAAGGACCTGTGGACAGCTCCAGAGCACCTCCGCCAAGCCAA
CATCTCTCAGAAAGGAGATCTGTAAGCTATGGGATCATCGCACAGGAGATCAT
35 TCTGCGGAAAGAAACCTTCTACACTTTGAGCTGTCTGGGACCGGAATGAGAAGAT
TTTCAGAGTGGAATAATTCCAATGGAATGAAACCCTTCCGCCCAGATTTATTCTTG
GAAACAGCAGAGGAAAAAGAGCTAGAAGTGTACCTACTTGTAaaaaaactgTTGG
GAGGAAGATCCAGAAAAGAGACCAGATTTCAAAAAAATTGAGACTACACTTGCC
AAGATATTTGGACTTTTTTCATGACCAAAAAAATGAAAGCTATATGGATACCTTGA
40 TCCGACGTCTACAGCTATATTCTCGAAACCTGGAACATCTGGTAGAGGAAAGGA
CACAGCTGTACAAGGCAGAGAGGGACAGGGCTGACAGACTTAACCTTATGTTGC
TTCCAAGGCTAGTGGTAAAGTCTCTGAAGGAGAAAGGCTTTGTGGAGCCGGAAC
TATATGAGGAAGTTACAATCTACTTCAGTGACATTGTAGGTTTCACTACTATCTG
CAAATACAGCACCCCCATGGAAGTGGTGGACATGCTTAATGACATCTATAAGAG
45 TTTTGACCACATTGTTGATCATCATGATGTCTACAAGGTGGAAACCATCGGTGAT
GCGTACATGGTGGCTAGTGGTTTGCCTAAGAGAAAATGGCAATCGGCATGCAATA
GACATTGCCAAGATGGCCTTGGAATCCTCAGCTTCATGGGGACCTTTGAGCTGG
AGCATCTTCTGGCCTCCCAATATGGATTTCGATTGGAGTTCACCTCTGGTCCCTGT
GCTGCTGGAGTTGTGGGAATCAAGATGCCTCGTTATTGTCTATTTGGAGATACGG

TCAACACAGCCTCTAGGATGGAATCCACTGGCCTCCCTTTGAGAATTCACGTGAG
 TGGCTCCACCATAGCCATCCTGAAGAGAAGTGAAGTCCAGTTCCTTTATGAAGTG
 AGAGGAGAAACATACTTAAAGGGAAGAGGAAATGAGACTACCTACTGGCTGACT
 GGGATGAAGGACCAGAAATTC AACCTGCCAACCCTCCTACTGTGGAGAATCAA
 5 CAGCGTTTGCAAGCAGAATTTTCAGACATGATTGCCAACTCTTTACAGAAAAGAC
 AGGCAGCAGGGATAAGAAGCCAAAAACCCAGACGGGTAGCCAGCTATAAAAAA
 GGCACCTCTGGAATACTTGCAGCTGAATACCACAGACAAGGAGAGCACCTATTTTT
 AAACCTAAATGAGGTATAAGGACTCACACAAATTAATAACAGCTGCACTGAGG
 CCAGGCACCTCAGGTGTCCTGAAAGCTTACTTTCCTGAGACCTCATGAGGCAGA
 10 AATGTCTTAGGCTTGGCTGCCCTGTTTGGACCATGGACTTTCTTTGCATGAATCAG
 ATGTGTTCTCAGTGAAATAACTACCTTCCACTCTGGAACCTTATTCAGCAGTTGT
 TCCAGGGAGCTTCTACCTGGAAAAGAAAAGAAATTTCAATTTATTTTTTGTGTTTAA
 TTTTATCGTTTTTGTGTTTACTGGCTTTCTTCTGTATTCATAAGATTTTTTAAATTG
 TCATAATTATATTTTAAATACCCATCTTCATTAAAGTATATTTAACTCATAATTTT
 15 TGCAGAAAATATGCTATATATTAGGCAAGAATAAAAGCTAAAGGTTCCCAAAA
 AAAAAA

SEQ ID NO: 110

>gi|1563886|gb|U66198.1|HSU66198 Human fibroblast growth factor homologous factor 2
 (FHF-2) mRNA, complete cds
 20 ATGGCGGCGGCTATCGCCAGCTCGCTCATCCGTCAGAAGAGGGCAAGCCCCGCGAG
 CGCGAGAAATCCAACGCCTGCAAGTGTGTCAGCAGCCCCAGCAAAGGCAAGACC
 AGCTGCGACAAAAACAAGTTAAATGTCTTTTCCCGGGTCAAACCTCTTCGGCTCCA
 AGAAGAGGCGCAGAAGAAGACCAGAGCCTCAGCTTAAGGGTATAGTTACCAAGC
 25 TATACAGCCGACAAGGCTACCACTTGCAGCTGCAGGCGGATGGAACCATTGATG
 GCACCAAAGATGAGGACAGCACTTACACTCTGTTTAACTCATCCCTGTGGGTCT
 GCGAGTGGTGGCTATCCAAGGAGTTCAAACCAAGCTGTACTTGGCAATGAACAG
 TGAGGGATACTTGTACACCTCGGAACTTTTACACCTGAGTGCAAATTCAAAGAA
 TCAGTGTTTGAAAATTATTATGTGACATATTCATCAATGATATACCGTCAGCAGC
 30 AGTCAGGCCGAGGGTGGTATCTGGGTCTGAACAAAGAAGGAGAGATCATGAAAG
 GCAACCATGTGAAGAAGAACAAGCCTGCAGCTCATTTTCTGCCTAAACCACTGA
 AAGTGGCCATGTACAAGGAGCCATCACTGCACGATCTCACGGAGTTCTCCCGATC
 TGGAAGCGGGACCCCAACCAAGAGCAGAAGTGTCTCTGGCGTGCTGAACGGAGG
 CAAATCCATGAGCCAGATGAATCAACCTAG

SEQ ID NO: 111

>gi|460288|gb|L29401.1|HUMLDLR01 Human low density lipoprotein receptor gene, exon 1
 GGATCCCACAAAACAAAAAATATTTTTTTGGCTGTACTTTTGTGAAGATTTTATTT
 AAATTCCTGATTGATCAGTGTCTATTAGGTGATTTGGAATAACAATGTAAAAACA
 40 ATATACAACGAAAGGAAGCTAAAAATCTATACACAATTCCTAGAAAGGAAAAGG
 CAAATATAGAAAGTGGCGGAAGTTCCCAACATTTTTAGTGTTTCTTTTGGAGGC
 AGAGAGGACAATGGCATTAGGCTATTGGAGGATCTTGAAAGGCTGTTGTTATCCT
 TCTGTGGACAACAACAGCAAAATGTTAACAGTTAAACATCGAGAAATTCAGGA
 GGATCTTTCAGAAAGATGCGTTTTCCAATTTTGAGGGGGCGTCAGCTCTTCACCGGA
 45 GACCCAAATACAACAAATCAAGTCGCCTGCCCTGGCGACACTTTCGAAGGACTG
 GAGTGGGAATCAGAGCTTCACGGGTAAAAGCCGATGTCACATCGGCCGTTTCA
 AACTCCTCCTCTTGCAGTGAGGTGAAGACATTTGAAAATCACCCCACTGCAAACT
 CCTCCCCCTGCTAGAAACCTCACATTGAAATGCTGTAAATGACGTGGGCCCCGAG
 TGCAATCGCGGAAGCCAGGGTTTCCAGCTAGGACACAGCAGGTCTGTGATCCGG

GTCGGGACACTGCCTGGCAGAGGCTGCGAGCATGGGGCCCTGGGGCTGGAAATT
GCGCTGGACCGTCGCTTGCTCCTCGCCGCGGCGGGGACTGCAGGTAAGGCTTGC
TCCA

5 SEQ ID NO: 112

>gi|789613|gb|R33755.1|R33755 yh82d06.r1 Soares placenta Nb2HP Homo sapiens cDNA
clone IMAGE:136235 5' similar to gb:X08058_ma1 GLUTATHIONE S-TRANSFERASE P
(HUMAN);

GGATCTGGTCTCCACAAATGAAGGTCTTGCCCTCCCTGGTTCTGGGACAGCAGGGT
10 CTCAAAAGGCTTCAGTTGCCCGGGCAGTGCTTCACATAGTCATCCTTGCCCGCCT
CATAGTTGGTGTAGATGAGGGAGATGTATTTGCAGCGGAGGTCCTCCACGCCGTC
ATTCACCATGTCCACCAGGGCTGCCTCCTGCTGGTCCTTCCCATAGAGCCCAAGG
GTGCGGGCCCAGGGTGACGCAGGATGGTATTGGACTGGTACAGGGTGAGGTCTC
CGTCTGGGAACCTTNGGGGAGCTGCCCGTATTAGGCANGGAGGCTTTTGAGTTGA
15 GCCCTCCTTNCGGCCGCAAGCTTATTTCCCTTTTAGTTGAGGGTTAANTTTAAGTT
TGGCAATTGGCCTTCTTTTAAAACTTCGTGATTTGGGAAAANCTGGGNTTTAA
CCAATTTA

SEQ ID NO: 113

20 >gi|181134|gb|M37435.1|HUMCSDF1 Human macrophage-specific colony-stimulating
factor (CSF-1) mRNA, complete cds

CCTGGGTCTCTCGGCGCCAGAGCCGCTCTCCGCATCCCAGGACAGCGGTGCGGC
CCTCGGCCGGGGCGCCCACTCCGCAGCAGCCAGCGAGCCAGCTGCCCCGTATGA
CCGCGCCGGGGCGCCGCGGGCGCTGCCCTCCCACGACATGGCTGGGCTCCCTGCT
25 GTTGTGTTGGTCTGTCTCCTGGCGAGCAGGAGTATCACCGAGGAGGTGTCGGAGTAC
TGTAGCCACATGATTGGGAGTGGACACCTGCAGTCTCTGCAGCGGCTGATTGACA
GTCAGATGGAGACCTCGTGCCAAATTACATTTGAGTTTGTAGACCAGGAACAGTT
GAAAGATCCAGTGTGCTACCTTAAGAAGGCATTTCTCCTGGTACAAGACATAATG
GAGGACACCATGCGCTTCAGAGATAACACCGCCAATCCCATCGCCATTGTGCAG
30 CTGCAGGAACTCTCTTTGAGGCTGAAGAGCTGCTTCACCAAGGATTATGAAGAGC
ATGACAAGGCCTGCGTCCGAACTTTCTATGAGACACCTCTCCAGTTGCTGGAGAA
GGTCAAGAATGTCTTTAATGAAACAAAGAATCTCCTTGACAAGGACTGGAATATT
TTCAGCAAGAACTGCAACAACAGCTTTGCTGAATGCTCCAGCCAAGATGTGGTG
ACCAAGCCTGATTTGCAACTGCTGTACCCCAAAAGCCATCCCTAGCAGTGACCCGG
35 CCTCTGTCTCCCCTCATCAGCCCCTCGCCCCCTCCATGGCCCCTGTGGCTGGCTTG
ACCTGGGAGGACTCTGAGGGAACCTGAGGGCAGCTCCCTCTTGCCTGGTGAGCAG
CCCCTGCACACAGTGGATCCAGGCAGTGCCAAGCAGCGGCCACCCAGGAGCACC
TGCCAGAGCTTTGAGCCGCCAGAGACCCCAAGTTGTCAAGGACAGCACCATCGGT
GGCTCACACAGCCTCGCCCCCTCTGTGCGGGGCCTTCAACCCCGGGATGGAGGATA
40 TTCTTGACTCTGCAATGGGCACTAATTGGGTCCCAGAAGAAGCCTCTGGAGAGGC
CAGTGAGATTCCCGTACCCCAAGGGACAGAGCTTTCCCCCTCCAGGCCAGGAGG
GGGCAGCATGCAGACAGAGCCCGCCAGACCCAGCAACTTCCTCTCAGCATCTTCT
CCACTCCCTGCATCAGCAAAGGGCCAACAGCCGGCAGATGTAAGTGTACAGCC
TTGCCCAGGGTGGGCCCCGTGATGCCCACTGGCCAGGACTGGAATCACACCCCCC
45 AGAAGACAGACCATCCATCTGCCCTGCTCAGAGACCCCCCGGAGCCAGGCTCTC
CCAGGATCTCATCTGCGCCCCCAGGCCCTCAGCAACCCCTCCACCCTCTCTGC
TCAGCCACAGCTTTCCAGAAGCCACTCCTCGGGCAGCGTGCTGCCCCCTTGGGGAG
CTGGAGGGGCAGGAGGAGCACCAGGGATCGGACGAGCCCCGCAGAGCCAGAAGC
AGCACCAGCAAGTGAAGGGGCAGCCAGGCCCTGCCCGTTTAACTCCGTTCTCT

TTGACTGACACAGGCCATGAGAGGGCAGTCCGAGGGATCCTCCAGCCCGCAGCTC
CAGGAGTCTGTCTTCCACCTGCTGGTGCCAGTGTCATCCTGGTCTTGCTGGCTGT
CGGAGGCCTCTTGTCTACAGGTGGAGGCGGCGGAGCCATCAAGAGCCTCAGAG
AGCGGATTCTCCCTTGGAGCAACCAGAGGGCAGCCCCCTGACTCAGGATGACAG
5 ACAGGTGGAAGTGCCAGTGTAGAGGGAATTCTAAGCTGGACGCACAGAACAGTC
TCTTCGTGGGAGGAGACATTATGGGGCGTCCACCACCACCCCTCCCTGGCCATCC
TCCTGGAATGTGGTCTGCCCTCCACCAGAGCTCCTGCCTGCCAGGACTGGACCAG
AGCAGCCAGGCTGGGGCCCCCTCTGTCTCAACCCGCAGACCCTTGAAGTGAAG
AGAGGCCAGAGGATGCTCCCCATGCTGCCACTATTTATTGTGAGCCCTGGAGGCT
10 CCCATGTGCTTGAGGAAGGCTGGTGAGCCCGGCTCAGGACCCTCTTCCCTCAGGG
GCTGCAGCCTCCTCTCACTCCCTTCCATGCCGGAACCCAGGCCAGGGACCCACCG
GCCTGTGGTTTGTGGGAAAGCAGGGTGCACGCTGAGGAGTGAAACAACCCTGCA
CCCAGAGGGCCTGCCTGGTGCCAAGGTATCCCAGCCTGGACAGGCATGGACCTG
TCTCCAGACAGAGGAGCCTGAAGTTCGTGGGGCGGGACAGCCTCGGCCTGATTT
15 CCCGTAAAGGTGTGCAGCCTGAGAGACGGGAAGAGGAGGCCTCTGCACCTGCTG
GTCTGCACTGACAGCCTGAAGGGTCTACACCCTCGGCTCACCTAAGTCCCTGTGC
TGGTTGCCAGGCCAGAGGGGAGGCCAGCCCTGCCCTCAGGACCTGCCTGACCT
GCCAGTGATGCCAAGAGGGGGATCAAGCACTGGCCTCTGCCCCCTCCTCCTTCCAG
CACCTGCCAGAGCTTCTCCAGCAGGCCAAGCAGAGGCTCCCCTCATGAAGGAAG
20 CCATTGCACTGTGAACACTGTACCTGCCTGCTGAACAGCCTCCCCCGTCCATCC
ATGAGCCAGCATCCGTCCGTCTCCACTCTCCAGCCTCTCCCCAGCCTCCTGCACT
GAGCTGGCCTCACCAGTCGACTGAGGGAGCCCCTCAGCCCTGACCTTCTCCTGAC
CTGGCCTTTGACTCCCCGGAGTGGAGTGGGGTGGGAGAACCTCCTGGGGCCGCCA
GCCAGAGCCGCTCTTTAGGCTGTGTTCTTCGCCCAGGTTTCTGCATCTTCCACTTT
25 GACATTCCCAAGAGGGGAAGGGACTAGTGGGAGAGAGCAAGGGAGGGGAGGGCA
CAGACAGAGAGCCTACAGGGCGAGCTCTGACTGAAGATGGGCCTTTGAAATATA
GGTATGCACCTGAGGTTGGGGGAGGGTCTGCACTCCCAAACCCAGCGCAGTGT
CCTTTCCTGCTGCCGACAGGAACCTGGGGCTGAGCAGGTTATCCCTGTCAGGAG
CCCTGGACTGGGCTGCATCTCAGCCCCACCTGCATGGTATCCAGCTCCCATCCAC
30 TTCTCACCTTCTTTCCTCCTGACCTTGGTCAGCAGTGATGACCTCCAACCTCTCAC
CCACCCCTCTACCATCACCTCTAACCAGGCAAGCCAGGGTGGGAGAGCAATCA
GGAGAGCCAGGCCTCAGCTTCCAATGCCTGGAGGGCCTCCACTTTGTGGCCAGCC
TGTGGTGTGCTGCTCTGAGGCCTAGGCAACGAGCGACAGGGCTGCCAGTTGCCCT
GGGTTCTTCTGCTGCTGTGTGCCTCCTCTCCTGCCGCCCTTTGTCCTCCGCTAA
35 GAGACCCTGCCCTACCTGGCCGCTGGGCCCCGTGACTTTCCTTCTGCCCAGGA
AAGTGAGGGTGGGCTGGCCCCACCTTCCCTGTCTGATGCCGACAGCTTAGGGAA
GGGCACTGAACTTGCAATATGGGGCTTAGCCTTCTAGTCACAGCCTCTATATTTGA
TGCTAGAAAACACATATTTTTAAATGGAAGAAAAATAAAAAGGCATTCCCCCTTC
ATCCCCCTACCTTAAACATATAATTTTTAAAGGTCAAAAAAGCAATCCAACCCA
40 CTGCAGAAAGCTCTTTTGGAGCACTTGGTGGCATCAGAGCAGGAGGAGCCCCAGA
GCCACCTCTGGTGTCCCCAGGCTACCTGCTCAGGAACCCCTTCTGTTCTCTGAG
AACTCAACAGAGGACATTGGCTCACGCACTGTGAGATTTTGTGTTTTATACTTGCA
ACTGGTGAATTATTTTTATAAAGTCATTTAAATATCTATTTAAAAGATAGGAAG
CTGCTTATATATTTAATAATAAAGAAGTGCACAAGCTGCCGTTGACGTAGCTCG
45 AG

SEQ ID NO: 114

>gi|2179481|gb|AA456271.1|AA456271 zx99f08.r1 Soares_NhHMPu_S1 Homo sapiens
cDNA clone IMAGE:811911 5' similar to TR:E217390 E217390 NEOSIN ;

GGCGCCGCCATTTTAGCGTTTTGTGTCAGAAGCGTCCGCGCCGAGCGGCAGGAGGC
CCTGCTGGTTTCTGTGCGGGCTCTTGTGTCAGGATGGTGAAGCTGTTTCATCGGAAAC
CTGCCCCGGGAGGCTACAGAGCAGGAGATTCGCTCACTCTTCGAGCAGTATGGG
AAGGTGCTGGAATGTGACATCATTAAAGAATTACGGCTTTGTGCACATAGAAGAC
5 AAGACGGCAGCTGAGGATGCCATACGCAACCTGCACCATTACAAGCTTCATGGG
GTGAACATCAACGTGGAAGCCAGCAAGAATAAGAGCAAAACCTCAACAAAGTTG
CATGTGGGCAACATCAGTCCCACCTGCACCAATAAGGAGCTTCGAGCCAAGTTTG
AGGAGTATGGTCCGGTCATCGAATGTGACATCGTGAAAGATTATGCCTTCGTACA
CATGGAGCGGGCAGAGGATGCAGTGGAGGCCATCAGGGGCCTTGATAACACAGA
10 GTTTC AAGGTGGGATGTGTGTGGGCTG

SEQ ID NO: 115

>gi|3171911|emb|AJ001015.1|HSRAMP2 Homo sapiens mRNA encoding RAMP2

GGATATAGGCGCCCCACACCCGGGGCCCGGCTAAGCGCCGCGCCGCTCCTCGC
15 CTCCTTGCTGCACGATGGCCTCGCTCCGGGTGGAGCGCGCCGGCGGGCCCGCTCT
CCCTAGGACCCGAGTCGGGCGGCGCGCAGCCGTCCGCCTCCTCCTTCTGCTGGGC
GCTGTCCTGAATCCCCACGAGGCCCTGGCTCAGCCTCTTCCCACCACAGGCACAC
CAGGGTCAGAAGGGGGGACGGTGAAGAACTATGAGACAGCTGTCCAATTTTGCT
GGAATCATTATAAGGATCAAATGGATCCTATCGAAAAGGATTGGTGCGACTGGG
20 CCATGATTAGCAGGCCTTATAGCACCCCTGCGAGATTGCCTGGAGCACTTTGCAGA
GTTGTTTGACCTGGGCTTCCCCAATCCCTTGGCAGAGAGGATCATCTTTGAGACT
CACCAGATCCACTTTGCCAACTGCTCCCTGGTGCAGCCACCTTCTCTGACCCCCC
AGAGGATGTACTCCTGGCCATGATCATAGCCCCATCTGCCTCATCCCCTTCCTC
ATCACTCTTGTAGTATGGAGGAGTAAAGACAGTGAGGCCCAGGCCTAGGGGGCA
25 CGAGCTTCTCAACAACCATGTTACTCCACTTCCCCACCCCCACCAGGCCTCCCTCC
TCCCCTCCTACTCCCTTTTCTCACTCTCATCCCCACCACAGATCCCTGGATTGCTG
GGAATGGAAGCCAGGGTTGGGCATGGCACAAGTTCTGTAATCTTCAAATAAAA
CTTTTTTTTTGA

30 SEQ ID NO: 116

>gi|2456985|gb|AA608557.1|AA608557 ae54a09.s1 Stratagene lung carcinoma 937218

Homo sapiens cDNA clone IMAGE:950680 3' similar to contains element MER24 MER24
repetitive element ;

TTTTTCTCTTATATTTCTACTTTATTTGGTAAAACTCAGAACTAACAATTCACA
35 TCCTCCCACCTTCTTCTTTCCGAAGAAGGCAGTTTGCAGAGACAAAAGGGCTGTG
GCGTGGGGATCATCCACCATCTCCAGGTTTTACACCCAGGCTACCCATGGCTTGG
CAGTCAGGCCTCTAGGCGATGCTCTCAGAGGCAATAGAAGAAAAGTAAAAGGAA
GGTCTCACTTCACAGACAATGAAACCCTCCTAACCCTCTTCCCCACTACCCACAA
CTCCCTACACTGCCAATCTAAATAAAAAGAGGACAATGCATGAGTGTGAGATAC
40 ACATACACACACACATACACACACACACACGCACAGCTTCCTTTTCAGCCAAA
GAACTGCAAAATCCTTCCCCGGAAGGAGGACAACCTGGCAACACCAATCAAGGCT
TGGTGGTCTAAGGTGATGGCTGGAATCATGTGAGACTGGTAAAAATCCAGGGAG
AAAATGTTTCACCTTCAGCTCATTCCCAAGTCTCTATGAAGCCCGCCCCACTTCCA
CATAGGGGAACTGTGGCTCTGGGGGCAGCTGGCTTAGGGAAAGGCCTCCCATGG
45 CCAAGAAGACGATGGTGGAGAGGAGGGGGAGGGCAGCAGG

SEQ ID NO: 117

>83 BLOOD 231120.25 Incyte Unique

TGTTTCATGCTCATTGCTGTTTATTGAAACAAAAGAATCAGAAGAAGATCAGAATG
 AAGACAATAATAAAAAGCAGAAGCAGAAGTACAAGAAGAATAAAGAAAGAAAG
 GGAAAGAATTGTAGGAAGGAAAACTTGTAGAAGTAGAGGGTGGAGAGTGCGA
 AGAGGTGGAGTATGATGGGCAGTCCGATCTTTCCATCTGGGCTTTCAGACAATG
 5 GGATATGTCATGGAAGGCTTCTTTAAACACCAGAAGAAATTCAGGATAAAGCTC
 AAAAAGAGCAGGCAATCGATAGGGGTTGAAAATCCACTCAGTAGGCCACGGAA
 GGACTTCAAGAAGGTTGATCGTTCTGTGCTGGATGTTGTAGGTGTCCTACGTGA
 AGGCAATCGACATCTGGATGGCTGTGTGTCTGCNCTTTGTGTTTCGCTGCCTTGCTG
 GANTATGCNGTTCTNACTGTTGGATTTCTTCNTCNTGATCTTCATTGGGTGCATTA
 10 GAGTTGTTGGGCTTGAGTTGTTGTTCTCCCTCACTCTTTTCTGTAAACCTCATTTCT
 TCTACAGTAAAGTGATCACTTGGTTTGCTTTCCTGCACTCTTCTTGACACTCCAGT
 CAACATTAGCCAAAGCAGGGAACAAGATATTTCTAATGTATTTTGAGGCTTGGA
 AGACAAGTCATCATGGTTAAACAACAGAGTACTATTAGGGGCTTGGGCTAGAGG
 CAGGTGAAGTTCAAATCCTGGTTCCCATACTTGTGCGTACACAGTCCCGACGCC
 15 AGGGGCGCACGCCTGCGCAAACACAGCACCTCCCGAGCCACGAGGGCCGCTCAC
 ACAGCAACCCACAGCACCGAGCCTGCCCGCGCACTAACACACTGGCCTTAA
 TGCCTTGCGCNCGTTGCACTCACGACCCTCACTTGCAAACACAGCAGAACCCCCA
 CTGCGCCTTTTTTTTC

20 SEQ ID NO: 118

>gi|2079053|gb|AA419164.1|AA419164 zv35f12.r1 Soares ovary tumor NbHOT Homo
 sapiens cDNA clone IMAGE:755663 5' similar to gb:X07282 RETINOIC ACID
 RECEPTOR BETA-2 (HUMAN);, mRNA sequence

CACTAGGTCAGTGCATCTGCTTAATCTGTGGAGACCGCCAGACCGTTGAGGAACC
 25 GACAAAAGTAGATAAGCTACAAGAACCATTGCTGGAACACTAAAAATTTATATC
 AGAAAAAGACGACCCAGCAAGCCTCACATGTTTCCAAAGATCTTAATGAAAATC
 ACAGATCTCCGTAGCATCAGTGCTAAAGGTGCAGAGCGTGTAATTACCTTGAAA
 ATGGAAATTCCTGGATCAATGCCACCTCTCATTCAAGAAATGCTGGAGAATTCTG
 AAGGACATGAACCCTTGACCCCAAGTTCAAGTGGGAACACAGCAGACACAGTCC
 30 TAGCATCTCACCAGCTCAGTGGAAAACAGTGGGGTCAGTCAGTCACCACTCGTG
 CAATAAGACATTTTCTAGCTACTTCAAACATTCCCCAGTACCTTCAGTTCAGGA
 TTAAAAATGCAAGAAAAAA

SEQ ID NO: 119

35 >gi|186330|gb|M74782.1|HUMIL3B Human interleukin 3 receptor (hIL-3Ra) mRNA,
 complete cds

GCACACGGGAAGATATCAGAAACATCCTAGGATCAGGACACCCCAGATCTTCTC
 AACTGGAACCACGAAGGCTGTTTCTTCCACACAGCACTTTGATCTCCATTTAAGC
 AGGCACCTCTGTCTGCGTTCCGGAGCTGCGTTCCCGATGGTCCTCCTTTGGCTCA
 40 CGCTGCTCCTGATCGCCCTGCCCTGTCTCCTGCAAACGAAGGAAGATCCAAACCC
 ACCAATCACGAACCTAAGGATGAAAGCAAAGGCTCAGCAGTTGACCTGGGACCT
 TAACAGAAATGTGACCGATATCGAGTGTGTTAAAGATGCCGACTATTCTATGCCG
 GCAGTGAACAATAGCTATTGCCAGTTTGGAGCAATTTCTTATGTGAAGTGACCA
 ACTACACCGTCCGAGTGGCCAACCCACCATTCTCCACGTGGATCCTCTTCCCTGA
 45 GAACAGTGGGAAGCCTTGGGCAGGTGCGGAGAATCTGACCTGCTGGATTTCATGA
 CGTGGATTTCTTGAGCTGCAGCTGGGCGGTAGGCCCGGGGGCCCCCGCGGACGT
 CCAGTACGACCTGTACTTGAACGTTGCCAACAGGCGTCAACAGTACGAGTGTCTT
 CACTACAAAACGGATGCTCAGGGAACACGTATCGGGTGTGTTTCGATGACATCT
 CTCGACTCTCCAGCGGTTCTCAAAGTTCCACATCCTGGTGCGGGGCAGGAGCGC

AGCCTTCGGTATCCCCTGCACAGATAAGTTTGTCTCTTTTCACAGATTGAGATAT
TAACTCCACCCAACATGACTGCAAAGTGTAATAAGACACATTCTTTATGCACTG
GAAAATGAGAAGTCATTTCAATCGCAAATTTTCGCTATGAGCTTCAGATACAAAA
GAGAATGCAGCCTGTAATCACAGAACAGGTCAGAGACAGAACCTCCTTCCAGCT
5 ACTCAATCCTGGAACGTACACAGTACAAATAAGAGCCCGGAAAGAGTGTATGA
ATTCTTGAGCGCCTGGAGCACCCCCAGCGCTTCGAGTGCGACCAGGAGGAGGG
CGCAAACACACGTGCCTGGCGGACGTGCTGCTGATCGCGCTGGGGACGCTGCT
GGCCCTGGTCTGTGTCTTCGTGATCTGCAGAAGGTATCTGGTGATGCAGAGACTC
TTTCCCCGCATCCCTCACATGAAAGACCCCATCGGTGACAGCTTCCAAAACGACA
10 AGCTGGTGGTCTGGGAGGCGGGCAAAGCCGGCCTGGAGGAGTGTCTGGTGACTG
AAGTACAGGTCGTGCAGAAAACCTGAGACTGGGGTTCAGGGCTTGTGGGGGTCT
GCCTCAATCTCCCTGGCCGGGCCAGGCGCCTGCACAGACTGGCTGCTGGACCTGC
GCACGCAGCCCAGGAATGGACATTCCTAACGGGTGGTGGGCATGGGAGATGCCT
GTGTAATTTTCGTCCGAAGCTGCCAGGAAGAAGAACAAGAACAGAAC

15

SEQ ID NO: 120

>gi|6981725|gb|U48730.2|HSU48730 Homo sapiens transcription factor Stat5b (stat5b)

mRNA, complete cds

CCGGGTAAACCATGGCTGTGTGGATACAAGCTCAGCAGCTCCAAGGAGAAGCCC
20 TTCATCAGATGCAGGCGTTATATGGCCAGCATTTTCCCATTTGAGGTGCGGCATTA
TTTATCCCAGTGGATTGAAAGCCAAGCATGGGACTCAGTAGATCTTGATAATCCA
CAGGAGAACATTAAGGCCACCCAGCTCCTGGAGGGCCTGGTGCAGGAGCTGCAG
AAGAAGGCAGAGCACCAAGGTGGGGGAAGATGGGTTTTTACTGAAGATCAAGCTG
GGGCACTATGCCACACAGCTCCAGAACACGTATGACCGCTGCCCCATGGAGCTG
25 GTCCGCTGCATCCGCCATATATTGTACAATGAACAGAGGTTGGTCCGAGAAGCCA
ACAATGGTAGCTCTCCAGCTGGAAGCCTTGCTGATGCCATGTCCCAGAAACACCT
CCAGATCAACCAGACGTTTGAGGAGCTGCGACTGGTCACGCAGGACACAGAGAA
TGAGTTAAAAAAGCTGCAGCAGACTCAGGAGTACTTCATCATCCAGTACCAGGA
GAGCCTGAGGATCCAAGCTCAGTTTGGCCCGCTGGCCAGCTGAGCCCCCAGGA
30 GCGTCTGAGCCGGGAGACGGCCCTCCAGCAGAAGCAGGTGTCTCTGGAGGCCTG
GTTGCAGCGTGAGGCACAGACACTGCAGCAGTACCGCGTGGAGCTGGCCGAGAA
GCACCAGAAGACCCTGCAGCTGCTGCGGAAGCAGCAGACCATCATCCTGGATGA
CGAGCTGATCCAGTGGAAGCGGCGGCAGCAGCTGGCCGGGAACGGCGGGCCCCC
CCAGGGCAGCCTGGACGTGCTACAGTCCTGGTGTGAGAAGTTGGCCGAGATCAT
35 CTGGCAGAACCAGGAGCAGATCCGCAGGGCTGAGCACCTCTGCCAGCAGCTGCC
CATCCCCGGCCCAGTGGAGGAGATGCTGGCCGAGGTCAACGCCACCATCACGGA
CATTATCTCAGCCCTGGTGACCAGCACGTTTCATCATTGAGAAGCAGCCTCCTCAG
GTCCTGAAGACCCAGACCAAGTTTGCAGCCACTGTGCGCCTGCTGGTGGGCGGG
AAGCTGAACGTGCACATGAACCCCCCCCAGGTGAAGGCCACCATCATCAGTGAG
40 CAGCAGGCCAAGTCTCTGCTCAAGAACGAGAACACCCGCAATGATTACAGTGGC
GAGATCTTGAACAACCTGCTGCGTCATGGAGTACCACCAAGCCACAGGCACCCTT
AGTGCCCACTTCAGGAATATGTCCCTGAAACGAATTAAGAGGTCAGACCGTCGT
GGGGCAGAGTCGGTGACAGAAGAAAAATTTACAATCCTGTTTGAATCCCAGTTC
AGTGTTGGTGGAATGAGCTGGTTTTTCAAGTCAAGACCCTGTCCCTGCCAGTGG
45 TGGTGATCGTTCATGGCAGCCAGGACAACAATGCGACGGCCACTGTTCTCTGGGA
CAATGCTTTTGCAGAGCCTGGCAGGGTGCCATTTGCCGTGCCTGACAAAGTGCTG
TGGCCACAGCTGTGTGAGGCGCTCAACATGAAATTCAAGGCCGAAGTGCAGAGC
AACCGGGGCCTGACCAAGGAGAACCTCGTGTTCCTGGCGCAGAACTGTTCAAC
AACAGCAGCAGCCACCTGGAGGACTACAGTGGCCTGTCTGTGTCCTGGTCCCAGT

20

>gi|1490144|gb|AA025156.1|AA025156 ze78h06.r1 Soares_fetal_heart_NbHH19W Homo sapiens cDNA clone IMAGE:365147 5' similar to gb:M11730 ERBB-2 RECEPTOR PROTEIN-TYROSINE KINASE PRECURSOR (HUMAN);, mRNA sequence

25

>gi|189177|gb|M58603.1|HUMNFKB Human nuclear factor kappa-B DNA binding subunit (NF-kappa-B) mRNA, complete cds

ATATCCACCTGCATGCCACAGCCTGGTGGGAAAACACTGTGAGGATGGGATCT
 GCACTGTAAGTGTGACCCAAGGACATGGTGGTCGGCTTCGCAAACCTGGGTAT
 ACTTCATGTGACAAAGAAAAAAGTATTTGAAACACTGGAAGCACGAATGACAGA
 GCGTGTATAAGGGGCTATAATCCTGGACTCTTGGTGCACCCTGACCTTGCCTAT
 5 TTGCAAGCAGAAAGGTGGAGGGGACCGGCAGCTGGGAGATCGGGAAAAAGAGCT
 AATCCGCCAAGCAGCTCTGCAGCAGACCAAGGAGATGGACCTCAGCGTGGTGCG
 GCTCATGTTTACAGCTTTTCTTCCGGATAGCACTGGCAGCTTCACAAGGCGCCTG
 GAACCCGTGGTATCAGACGCCATCTATGACAGTAAAGCCCCCAATGCATCCAAC
 TGAAAATTGTAAGAATGGACAGGACAGCTGGATGTGTGACTGGAGGGGAGGAA
 10 ATTTATCTTCTTTGTGACAAAGTTCAGAAAGATGACATCCAGATTCGATTTTATG
 AAGAGGAAGAAAATGGTGGAGTCTGGGAAGGATTTGGAGATTTTCCCCCACAG
 ATGTTTCATAGACAATTTGCCATTGTCTTCAAACTCCAAAGTATAAAGATATTAA
 TATTACAAAACCAGCCTCTGTGTTTGTCCAGCTTCGGAGGAAATCTGACTTGGAA
 ACTAGTGAACCAAAACCTTTCCTCTACTATCCTGAAATCAAAGATAAAGAAGAA
 15 GTGCAGAGGAAACGTCAGAAGCTCATGCCCAATTTTTTCGGATAGTTTTCGGCGGTG
 GTAGTGGTGGCGGAGCTGGAGGCGGAGGCATGTTTGGTAGTGGCGGTGGAGGAG
 GGGGCACTGGAAGTACAGGTCCAGGGTATAGCTTCCCACACTATGGATTTCTTAC
 TTATGGTGGGATTACTTTCCATCCTGGAACACTACTAAATCTAATGCTGGGATGAAG
 CATGGAACCATGGACACTGAATCTAAAAAGGACCCTGAAGGTTGTGACAAAAGT
 20 GATGACAAAAACACTGTAAACCTCTTTGGGAAAGTTATTGAAACCACAGAGCAA
 GATCAGGAGCCCAGCGAGGCCACCGTTGGGAATGGTGAGGTCACTCTAACGTAT
 GCAACAGGAACAAAAGAAGAGAGTGCTGGAGTTCAGGATAACCTCTTTCTAGAG
 AAGGCTATGCAGCTTGCAAAGAGGCATGCCAATGCCCTTTTCGACTACGCGGTGA
 CAGGAGACGTGAAGATGCTGCTGGCCGTCCAGCGCCATCTCACTGCTGTGCAGG
 25 ATGAGAATGGGGACAGTGTCTTACACTTAGCAATCATCCACCTTCATTCTCAACT
 TGTGAGGGATCTACTAGAAGTCACATCTGGTTTGATTTCTGATGACATTATCAAC
 ATGAGAAATGATCTGTACCAGACGCCCTTGCACTTGGCAGTGATCACTAAGCAG
 GAAGATGTGGTGGAGGATTTGCTGAGGGGCTGGGGCCGACCTGAGCCTTCTGGAC
 CGCTTGGGTAACTCTGTTTGCACCTAGCTGCCAAAGAAGGACATGATAAAGTTC
 30 TCAGTATCTTACTCAAGCACAAAAAGGCAGCACTACTTCTTGACCACCCCAACGG
 GGACGGTCTGAATGCCATTCTATCTAGCCATGATGAGCAATAGCCTGCCATGTTTG
 CTGCTGCTGGTGGCCGCTGGGGCTGACGTCAATGCTCAGGAGCAGAAGTCCGGG
 CGCACAGCACTGCACCTGGCTGTGGAGCACGACAACATCTCATTGGCAGGCTGC
 CTGCTCCTGGAGGGTGTATGCCCATGTGGACAGTACTACCTACGATGGAACCACAC
 35 CCCTGCATATAGCAGCTGGGAGAGGGTCCACCAGGCTGGCAGCTCTTCTCAAAG
 CAGCAGGAGCAGATCCCCTGGTGGAGAAGTTTGAGCCTCTCTATGACCTGGATGA
 CTCTTGGGAAAATGCAGGAGAGGATGAAGGAGTTGTGCCTGGAACCACGCCTCT
 AGATATGGCCACCAGCTGGCAGGTATTTGACATATTAAATGGGAAACCATATGA
 GCCAGAGTTTACATCTGATGATTTACTAGCACAAGGAGACATGAAACAGCTGGC
 40 TGAAGATGTGAAGCTGCAGCTGTATAAGTTACTAGAAATTCCTGATCCAGACAA
 AAACCTGGGCTACTCTGGCGCAGAAATTAGGTCTGGGGATACTTAATAATGCCTTC
 CGGCTGAGTCCTGCTCCTTCCAAAACACTTATGGACAACCTATGAGGTCTCTGGGG
 GTACAGTCAGAGAGCTGGTGGAGGGCCCTGAGACAAATGGGCTACACCGAAGCAA
 TTGAAGTGATCCAGGCAGCCTCCAGCCCAGTGAAGACCACCTCTCAGGCCCACTC
 45 GCTGCCTCTCTCGCCTGCCTCCACAAGGCAGCAAATAGACGAGCTCCGAGACAGT
 GACAGTGTCTGCGACACGGGCGTGGAGACATCCTTCCGCAAACCTCAGCTTTACCG
 AGTCTCTGACCAGTGGTGCCTCACTGCTAACTCTCAACAAAATGCCCCATGATTA
 TGGGCAGGAAGGACCTCTAGAAGGCCAAAATTTAGCCTGCTGACAATTTCCACA
 CCGTGTAACCAAAGCCCTAAAATTCCTACTGCGTTGTCCACAAGACAGAAGCTG

AAGTGCATCCAAAGGTGCTCAGAGAGCCGGCCCGCCTGAATCATTCTCGATTAA
 CTCGAGACCTTTTCAACTTGGCTTCCTTTCTTGGTTCATAAATGAATTTAGTTTG
 GTTCACTTACAGATAGTATCTAGCAATCACAACACTGGCTGAGCGGATGCATCTG
 GGGATGAGGTTGCTTACTAAGCTTTGCCAGCTGCTGCTGGATCACAGCTGCTTTC
 5 TGTGTGTCATTGCTGTTGTCCCTCTGC

SEQ ID NO: 123

>gi|34036|emb|X12881.1|HSKER18R Human mRNA for cytokeratin 18

TCGTCCGCAAAGCCTGAGTCCTGTCCTTTCTCTCTCCCCGGACAGCATGAGCTTCA
 10 CCACTCGCTCCACCTTCTCCACCAACTACCGGTCCCTGGGCTCTGTCCAGGCGCC
 CAGCTACGGCGCCCGGCCGGTCAGCAGCGCGGCCAGCGTCTATGCAGGCGCTGG
 GGGCTCTGGTTCCCGGATCTCCGTGTCCCGCTCCACCAGCTTCAGGGGCGGCATG
 GGGTCCGGGGGCCTGGCCACCGGGATAGCCGGGGGTCTGGCAGGAATGGGAGGC
 ATCCAGAACGAGAAGGAGACCATGCAAAGCCTGAACGACCGCCTGGCCTCTTAC
 15 CTGGACAGAGTGAGGAGCCTGGAGACCGAGAACCGGAGGCTGGAGAGCAAAAT
 CCGGGAGCACTTGGAGAAGAAGGGACCCAGGTGAGAGACTGGAGCCATTACTT
 CAAGATCATCGAGGACCTGAGGGCTCAGATCTTCGCAAATACTGTGGACAATGC
 CCGCATCGTTCTGCAGATTGACAATGCCCCGTCTTGCTGCTGATGACTTTAGAGTC
 AAGTATGAGACAGAGCTGGCCATGCGCCAGTCTGTGGAGAACGACATCCATGGG
 20 CTCCGCAAGGTCATTGATGACACCAATATCACACGACTGCAGCTGGAGACAGAG
 ATCGAGGCTCTCAAGGAGGAGCTGCTCTTCATGAAGAAGAACCACGAAGAGGAA
 GTAAAAGGCCTACAAGCCCAGATTGCCAGCTCTGGGTTGACCGTGGAGGTAGAT
 GCCCCCAAATCTCAGGACCTCGCCAAGATCATGGCAGACATCCGGGCCCAATAT
 GACGAGCTGGCTCGGAAGAACCGAGAGGAGCTAGACAAGTACTGGTCTCAGCAG
 25 ATTGAGGAGAGCACACAGTGGTCACACACAGTCTGCTGAGGTTGGAGCTGCT
 GAGACGACGCTCACAGAGCTGAGACGTACAGTCCAGTCCTTGAGATCGACCTG
 GACTCCATGAGAAATCTGAAGGCCAGCTTGAGAACAGCCTGAGGGAGGTGGAG
 GCCCGCTACGCCCTACAGATGGAGCAGCTCAACGGGATCCTGCTGCACCTTGAGT
 CAGAGCTGGCACAGACCCGGGCAGAGGGACAGCGCCAGGCCAGGAGTATGAG
 30 GCCCTGCTGAACATCAAGGTCAAGCTGGAGGCTGAGATCGCCACCTACCGCCGC
 CTGCTGGAAGATGGCGAGGACTTTAATCTTGGTGATGCCTTGACAGCAGCAACT
 CCATGCAAACCATCCAAAAGACCACCCCGCCGATAGTGGATGGCAAAGTGG
 TGTCTGAGACCAATGACACCAAGTTCTGAGGCATTAAGCCAGCAGAAGCAGGG
 TACCCTTTGGGGAGCAGGAGGCCAATAAAAGCTTCAGAGTTGATTGGATGTC.

35

SEQ ID NO: 124

>gi|183986|gb|M11730.1|HUMHER2A Human tyrosine kinase-type receptor (HER2)

mRNA, complete cds

AATTCTCGAGCTCGTCGACCGGTGACGAGCTCGAGGGTCGACGAGCTCGAGGG
 40 CGCGCGCCCGGCCCCACCCCTCGCAGCACCCCGCGCCCCGCGCCCTCCAGCCG
 GGTCCAGCCGGAGCCATGGGGCCGGAGCCGCAGTGAGCACCATGGAGCTGGCGG
 CCTTGTGCCGCTGGGGGCTCCTCCTCGCCCTCTTGCCCCCGGAGCCGCGAGCAC
 CCAAGTGTGCACCGGCACAGACATGAAGCTGCGGCTCCCTGCCAGTCCCGAGAC
 CCACCTGGACATGCTCCGCCACCTCTACCAGGGCTGCCAGGTGGTGCAGGGAAA
 45 CCTGGAACCTACCTACCTGCCACCAATGCCAGCCTGTCCTTCTGCAGGATATC
 CAGGAGGTGCAGGGCTACGTGCTCATCGCTCACAACCAAGTGAGGCAGGTCCCA
 CTGCAGAGGCTGCGGATTGTGCGAGGCACCCAGCTCTTTGAGGACAACTATGCCC
 TGGCCGTGCTAGACAATGGAGACCCGCTGAACAATAACACCCCTGTCACAGGGG
 CCTCCCCAGGAGGCCTGCGGGAGCTGCAGCTTCGAAGCCTCACAGAGATCTTGA

AAGGAGGGGTCTTGATCCAGCGGAACCCCCAGCTCTGCTACCAGGACACGATTTT
GTGGAAGGACATCTTCCACAAGAACAACCAGCTGGCTCTCACACTGATAGACAC
CAACCGCTCTCGGGCCTGCCACCCCTGTTCTCCGATGTGTAAGGGCTCCCGCTGC
TGGGGAGAGAGTTCTGAGGATTGTCAGAGCCTGACGCGCACTGTCTGTGCCGGT
5 GGCTGTGCCCCGCTGCAAGGGGGCCACTGCCCACTGACTGCTGCCATGAGCAGTGTG
CTGCCGGCTGCACGGGGCCCCAAGCACTCTGACTGCCTGGCCTGCCTCCACTTCAA
CCACAGTGGCATCTGTGAGCTGCACTGCCAGCCCTGGTCACCTACAACACAGAC
ACGTTTGAGTCCATGCCCAATCCCGAGGGCCGGTATACATTCCGGCGCCAGCTGTG
TGACTGCCTGTCCCTACAACCTACCTTTCTACGGACGTGGGATCCTGCACCCTCGTC
10 TGCCCCCTGCACAACCAAGAGGTGACAGCAGAGGATGGAACACAGCGGTGTGAG
AAGTGCAGCAAGCCCTGTGCCCCGAGTGTGCTATGGTCTGGGCATGGAGCACTTGC
GAGAGGTGAGGGCAGTTACCAGTGCCAATATCCAGGAGTTTGCTGGCTGCAAGA
AGATCTTTGGGAGCCTGGCATTCTGCCGGAGAGCTTTGATGGGGACCCAGCCTC
CAACACTGCCCCGCTCCAGCCAGAGCAGCTCCAAGTGTTTGAGACTCTGGAAGA
15 GATCACAGGTTACCTATACATCTCAGCATGGCCGGACAGCCTGCCTGACCTCAGC
GTCTTCCAGAACCTGCAAGTAATCCGGGGACGAATTCTGCACAATGGCGCCTACT
CGCTGACCCTGCAAGGGCTGGGCATCAGCTGGCTGGGGCTGCGCTCACTGAGGG
AACTGGGCAGTGGACTGGCCCTCATCCACCATAACACCCACCTCTGCTTCGTGCA
CACGGTGCCCTGGGACCAGCTCTTTCGGAACCCGCACCAAGCTCTGCTCCACACT
20 GCCAACCGGCCAGAGGACGAGTGTGTGGGCGAGGGCCTGGCCTGCCACCAGCTG
TGCGCCCGAGGGCACTGCTGGGGTCCAGGGGCCACCCAGTGTGTCAACTGCAGC
CAGTTCCTTCGGGGCCAGGAGTGCGTGAGGAATGCCGAGTACTGCAGGGGGCTC
CCCAGGGAGTATGTGAATGCCAGGCACTGTTTGCCGTGCCACCCTGAGTGTGAGC
CCCAGAATGGCTCAGTGACCTGTTTTGGACCGGAGGCTGACCAGTGTGTGGCCTG
25 TGCCCCACTATAAGGACCCTCCCTTCTGCGTGGCCCGCTGCCCCAGCGGTGTGAAA
CCTGACCTCTCCTACATGCCCATCTGGAAGTTTCCAGATGAGGAGGGCGCATGCC
AGCCTTGCCCCATCAACTGCACCCACTCCTGTGTGGACCTGGATGACAAGGGCTG
CCCCGCCGAGCAGAGAGCCAGCCCTCTGACGTCCATCGTCTCTGCGGTGGTTGGC
ATTCTGCTGGTCGTGGTCTTGGGGGTGGTCTTTGGGATCCTCATCAAGCGACGGC
30 AGCAGAAGATCCGGAAGTACACGATGCGGAGACTGCTGCAGGAAACGGAGCTG
GTGGAGCCGCTGACACCTAGCGGAGCGATGCCCAACCAGGCGCAGATGCGGATC
CTGAAAGAGACGGAGCTGAGGAAGGTGAAGGTGCTTGGATCTGGCGCTTTTGGC
ACAGTCTACAAGGGCATCTGGATCCCTGATGGGGAGAATGTGAAAATTCCAGTG
GCCATCAAAGTGTTGAGCGAAATCACATCCCCCAAGCCAACAAAGAAATCTTA
35 GACGAAGCATACGTGATGGCTGGTGTGGGCTCCCCATATGTCTCCCGCCTTCTGG
GCATCTGCCTGACATCCACGGTGCAGCTGGTGACACAGCTTATGCCCTATGGCTG
CCTCTTAGACCATGTCCGGGAAAACCGCGGACGCCTGGGCTCCCAGGACCTGCTG
AACTGGTGTATGCAGATTGCCAAGGGGATGAGCTACCTGGAGGATGTGCGGCTC
GTACACAGGGACTTGGCCGCTCGGAACGTGCTGGTCAAGAGTCCCAACCATGTC
40 AAAATTACAGACTTCGGGCTGGCTCGGCTGCTGGACATTGACGAGACAGAGTAC
CATGCAGATGGGGGCAAGGTGCCCATCAAGTGGATGGCGCTGGAGTCCATTCTC
CGCCGGCGGTTACCCACCAGAGTGATGTGTGGAGTTATGGTGTGACTGTGTGGG
AGCTGATGACTTTTGGGGCCAAACCTTACGATGGGATCCCAGCCCCGGGAGATCCC
TGACCTGCTGGA AAAAGGGGGAGCGGCTGCCCCAGCCCCCATCTGCACCATTGA
45 TGTCTACATGATCATGGTCAAATGTTGGATGATTGACTCTGAATGTGCGCCAAGA
TTCCGGGAGTTGGTGTCTGAATTCTCCCGCATGGCCAGGGACCCCCAGCGCTTTG
TGGTCATCCAGAATGAGGACTTGGGGCCAGCCAGTCCCTTGGACAGCACCTTCTA
CCGCTCACTGCTGGAGGACGATGACATGGGGGACCTGGTGGATGCTGAGGAGTA
TCTGGTACCCAGCAGGGCTTCTTCTGTCCAGACCCTGCCCCGGGCGCTGGGGGC

ATGGTCCACCACAGGCACCGCAGCTCATCTACCAGGAGTGGCGGTGGGGACCTG
 AACTAGGGGCTGGAGCCCTCTGAAGAGGAGGCCCCCAGGTCTCCACTGGCACCC
 TCCGAAGGGGCTGGCTCCGATGTATTTGATGGTGACCTGGGAATGGGGGCAGCC
 AAGGGGCTGCAAAGCCTCCCCACACATGACCCAGCCCTCTACAGCGGTACAGT
 5 GAGGACCCACAGTACCCCTGCCCTCTGAGACTGATGGCTACGTTGCCCCCCTGA
 CCTGCAGCCCCCAGCCTGAATATGTGAACCAGCCAGATGTTGCGCCCCAGCCCC
 TTCGCCCCGAGAGGGCCCTCTGCCTGCTGCCCCGACCTGCTGGTGCCACTCTGGAA
 AGGGCCAAGACTCTCTCCCCAGGGAAGAATGGGGTTCGTCAAAGACGTTTTTGCCT
 TTGGGGGTGCCGTGGAGAACCCCGAGTACTTGACACCCAGGGAGGAGCTGCCC
 10 CTCAGCCCCACCTCCTCCTGCCTTCAGCCCAGCCTTCGACAACCTCTATTACTGG
 GACCAGGACCCACCAGAGCGGGGGGCTCCACCCAGCACCTTCAAAGGGACACCT
 ACGGCAGAGAACCCAGAGTACCTGGGTCTGGACGTGCCAGTGTGAACCAGAAGG
 CCAAGTCCGCAGAAGCCCTGATGTGTCTCAGGGAGCAGGGAAGGCCTGACTTC
 TGCTGGCATCAAGAGGTGGGAGGGCCCTCCGACCACTTCCAGGGGAACCTGCCA
 15 TGCCAGGAACCTGTCCTAAGGAACCTTCCTTGCTTGAGTTCCAGATGGCTG
 GAAGGGGTCCAGCCTCGTTGGAAGAGGAACAGCACTGGGGAGTCTTTGTGGATT
 CTGAGGCCCTGCCCAATGAGACTCTAGGGTCCAGTGGATGCCACAGCCCAGCTTG
 GCCCTTTCCTTCCAGATCCTGGGTACTGAAAGCCTTAGGGAAGCTGGCCTGAGAG
 GGGAAAGCGGCCCTAAGGGAGTGTCTAAGAACAAAAGCGACCCATTACAGAGACTG
 20 TCCCTGAAACCTAGTACTGCCCCCATGAGGAAGGAACAGCAATGGTGTGAGTA
 TCCAGGCTTTGTACAGAGTGCTTTTCTGTTTAGTTTTACTTTTTTGTGTTTTT
 TTAAAGACGAAATAAAGACCCAGGGGAGAATGGGTGTTGTATGGGGAGGCAAGT
 GTGGGGGGTCTTCTCCACACCCACTTTGTCCATTTGCAAATATATTTTGGAAAA
 C

25

SEQ ID NO: 125

>gi|340247|gb|M54930.1|HUMVIP89 Human vasoactive intestinal peptide and peptide
 histidine isoleucine mRNA, 3' end

30 GATCAAGTTTCATTAAGAAAGACATTGACATGTTGCAAAATGCATTAGCTGAA
 AATGACACACCCTATTATGATGTATCCAGAAATGCCAGGCATGCTGATGGAGTTT
 TCACCAGTGACTTCAGTAAACTCTTGGGTCAACTTTCTGCCAAAAAGTACCTTGA
 GTCTCTTATGGGAAAACGTGTTAGCAGTAACATCTCAGAAGACCCTGTACCAGTC
 AAACGTCACTCAGATGCAGTCTTCACTGACAACCTATACCCGCCTTAGAAAAACAAA
 TGGCTGTAAAGAAATATTTCACTCAATTCGATGGAAAGAGGAGCAGTGAGG
 35 GAGAATCTCCCGACTTTCAGAAAGAGTTAGAAAAATGATGAAAAAACCCCCCCC
 CCCC

SEQ ID NO: 126

>gi|1679601|emb|Y09479.1|HSEDG2 H.sapiens mRNA for G protein-coupled receptor Edg-
 2

40

CTGACACCTACAGCATCAGGTACACAGCTTCTCCTAGCATGACTTCGATCTGATC
 AGCAAACAAGAAAATTTGTCTCCCGTAGTTCTGGGGCGTGTTACCCACCTACAAC
 CACAGAGCTGTCATGGCTGCCATCTCTACTTCCATCCCTGTAATTTACAGCCCCA
 GTTCACAGCCATGAATGAACCACAGTGCTTCTACAACGAGTCCATTGCCTTCTTT
 45 TATAACCGAAGTGGAAGCATCTTGCCACAGAATGGAACACAGTCAGCAAGCTG
 GTGATGGGACTTGGAATCACTGTTTGTATCTTCATCATGTTGGCCAACCTATTGGT
 CATGGTGGCAATCTATGTCAACCGCCGCTTCCATTTTCTATTTATTACCTAATGG
 CTAATCTGGCTGCTGCAGACTTCTTTGCTGGGTGGCCTACTTCTATCTCATGTTT
 AACACAGGACCCAATACTCGGAGACTGACTGTCAGCACATGGCTCCTTCGTCAG

GGCCTCATTGACACCAGCCTGACGGCATCTGTGGCCAACTTACTGGCTATTGCAA
 TCGAGAGGCACATTACGGTTTTCCGCATGCAGCTCCACACACGGATGAGCAACC
 GGCGGGTAGTGGTGGTCATTGTGGTCATCTGGACTATGGCCATCGTTATGGGTGC
 TATACCCAGTGTGGGCTGGAAGTGTATCTGTGATATTGAAAATTGTTCCAACATG
 5 GCACCCCTCTACAGTGACTCTTACTTAGTCTTCTGGGCCATTTTCAACTTGGTGAC
 CTTTGTGGTAATGGTGGTCTCTATGCTCACATCTTTGGCTATGTTGCGCCAGAGGA
 CTATGAGAATGTCTCGGCATAGTTCTGGACCCCGCGGAATCGGGATACCATGAT
 GAGTCTTCTGAAGACTGTGGTCATTGTGCTTGGGGCCTTTATCATCTGCTGGACTC
 CTGGATTGGTTTTGTTACTTCTAGACGTGTGCTGTCCACAGTGCGACGTGCTGGCC
 10 TATGAGAAATTCTTCTTCTCCTTGTGAATCAACTCTGCCATGAACCCCATCAT
 TTAATCCTACCGCGACAAAGAAATGAGCGCCACCTTTAGGCAGATCCTCTGCTGC
 CAGCGCAGTGAGAACCCACCGGCCCCACAGAAGGCTCAGACCGCTCGGCTTCC
 TCCCTCAACCACACCATCTTGGCTGGAGTTCACAGCAATGATCACTCTGTGGTTT
 AG

15 SEQ ID NO: 127

>gi|3242744|gb|AC004126.1|AC004126 Human Chromosome 11q12.2 PAC clone
 pDJ606g6, complete sequence [Homo sapiens]

ACGAGGTCAGGAGATTGAGACCATCCTGGCCAACTGGCGAAACCACGTCTCTA
 20 CTAAAAATACAAAAATTAGCTGGGCGTCGTGGCGCATGCCTGTATCCCAGCTAC
 TCAAGCCTGGCAACAGAGCGAGACTCTGTCTTAAAAAATAAAAGGGGGAAGAAG
 GAGAGGGGAGGTCTGCCCAGACAGCAAGGTTTCAGCCAGGTCTGCCAGGGCA
 AAGGAGGGCAGGATTCCACCTGCCTGTGGTCCCAGGGCAGAGCCAGGCAGCCCC
 ACCCTGAAATAGTTCTTGGGGTAAAGGCCTGAAACTTCCACACGCACTTCATTAT
 25 CCCAGCTCCATTTCTTCCCTCTTTGCCATCATTTTCTTTCTCCTTCTTTTCTCCTT
 GGAGGTCCTAGTCTCCTTTCCCAATATGGTTCGGCCCAACACAACTCCCCACAA
 GCAGATGTGGGTCAACCTTGCCCTCTGAGGTCAGGTTCTGCTAGCATTTGGGCCT
 GCTGAGCTGGACACAGAGGAAGAAAAGCTCAGGGAGGCCTGGAGTGTAGCAGC
 TCAGTGTCCCTTGCATCAGCCCCGGAGAGGGGCAAGGGGCTGCTTGAAGGTGCA
 30 GTCTTCTCCTGCCTGGAGAGGCCATATTTTTCAGCAGTAGGACATACACCCCTG
 GCAACCCTCAGGAGAGTTTACAGAAGCCGCGTTTAATGCTCTGAAATCGCAGAG
 TGAGGAAATTATTCCTGCCCACGGTGTTTTCAGTCCTTCTGCAAAGTCAAGAAG
 AAAATACCTGCTAGAGCTAGGAGGCCATCTCCTCTCCCCTCCTCATCACCCCTTTT
 ACAGAGGGGATGAGCTCTGGCTCTTCCAGATCTTTTCACTTTTGTAAAGCGTA
 35 ATAGAAATTGGGTTTTGCCACCATTTGTTTTTATGTTTCCCTTTACCTTTCACTTAT
 GGCAAATGATATTGATTTTCCACTTATAATAGTGATGTAAACTTTCTTTCAAAAC
 TGAGCTTGCATTGATAACAACAAGTGAGTCAAGTAAATATCAACACAGTTTCAA
 AACCATAAAGTGGATGACAGTACTGGGAAGGAGCAGGTTCGGGCAAGAGCTGCC
 AGGGTGGGACAGACTGAATCGAAGGAACTTGGAGGCTCCAGGACTACTTTGTTT
 40 GACCTCCCTGAGCTCTGCCCAGGTCTCTGGGTTCCACCTCTCCTGTGGGCACCAT
 TCAAAGCCAGTTCTCCTGGCTGGCTGCTGGGCCAGCTGCCAAGGCTCGGACGCCA
 AGGGCACCAATGCCTAGCTCAGCCCCTGGCCCTCATTCCTTCTGGGAAGCTGAGA
 AGGAGCTGGTCTGAAGCCCTGGGTTGGGGAAAATCTTTTGGACCCGACTTTACTC
 CTGAGCCTGTGGCTGGGCTTCATGGGGAAGAGGAAAGGGGGCCACTCTCGGACA
 45 GTCTGTTTCAGCTCAGGGGCAGAAGGCAGCTGAAATTCCAGAGCTGCTGCTCCAG
 AAATCCTGGTAGAGTTAGCAGGGCAAAGCTACATGCACAGAGCTGAAGGCACA
 CAAACTCCAGTTCCAGAGCCGAATGGCTTTCCCTGAACCAGTATGAGGCCACAG
 GCTCGGAACACATGCCTGGAGATCAAGGCAGAGAGGAGAGCACTCCCTGCCAG
 AGTCTCGCGACATGTACCCAGTCTCCAAACCAGCTCGATGCCCCCTCCTGACTG

GGTCTTCCTGGGTCTCCTCCATCACAAAATGAAAGCACTTGGCTCTCTGGCTGCA
AGGTGGACCCAGACTCCCCTGGCCCGAATTCTGTTTCCATACCAGTCTTCCCAA
TCCCAAATGTGAGAGCTCGATGGGGTCAGGATCTCTTGCATCTCCAGGCCCTG
CCCCGCTCTGGCCAGCTTGGACCCTGCACTCAACAGGGGGCCAGCAAGTATCTGGG
5 GAGCACAGTCTAGTGCCCCAAACCTTCTGGCCATCTGATTCCCTGGCCAGGTGG
CCAGGTGCCTTGACACTTGGGGGCAGCTTGAGACGTGGGGGTGGCCTTCATGCTC
GCTTATGCCCTAGACTACCCAGCTGGTTGTGCTGAGGCCATCAGCGCCTGGTTG
TCCAGAACTCTCCCTGGCTTCCCTGAGTCCTGTTTCGGGCGGTGCTCTCCTGTGAT
TGGCCTACGCCTGCTGGACCCCAAGCCTCAGCTTTGGCGTTGAAAGTACCACCAT
10 CAGTGGTCCCGCCTCTCTGGAAGGTGAACGGTTCCTTCTTAAGAGTTGGCAAGAA
ATAGGAAATGGGGGAGTTCCTGAGCTTAAGGATGGGAGAGGCACCTCCCTCCTC
ACACCCTAGGGACCCATTGGTAAGGCACAAAGCATGCTTCCACATTCTGTCACT
CCAGGAGGCTTCCAGGCACAGCCCCAGCCCCCTCGAGGGGCTCCTGTGTCTCTCC
TAGCCCCAGATGCTGGACCTCCCTGGTACCTGAGTGTAGTCTTGGCTAAAAGATC
15 CTAGAAAAGTGACCACAAGGAAACAACCAGAAAGGGGACTGAGAGGGCCGGAC
CCGGCTCCTCCAGCACCAGTGGCAGGAGATGAGGGAAGGGGGCCTACCTGAGAG
GGCTGCCGTACGAATCCAGTGATCCCGAAGAAGAGCCACATGTCTGGAGCTGT
CTCTGGCTGCTACGCGTGGCTGCCTGTGGGAAGCACCATCTTGGGGCCGGGAGGT
GGACACGGCCGTTGTGCGCCCCTGGCGCAGGTCTGCTCTACCCTTTGCTGTTCTTG
20 TTCCTGTGTCTCTCTGCTCTCTCCTCTCCGACACGCATGCGATCAAACCCAACC
TGTGAGTGTCTACGCCTGCTTGTCTGCTTGTGGTTTTGGTCTGCAGGAAGCTGG
GCTGCTGTTACAGGGGCTGGTGGGGAGAGCCCCAGCTGCCTGTGCTGGGAGCCC
ACCCATCCAGGCTGCACCCCAAGAGTCACGGAGCCAGACACACGCATGCACACG
CATCCATGCAGACACACTTCCCCGAGGGTCTTCTAAGAAGAAGGGAAGTGGAAG
25 AGCCATGCCTCATTTCTGGTGGCCAGAAGAAAAAATTGATAATGTAGTAGCTGC
TCAATCAGTACATATTGGAAGAGGGAGTGAATGACCCATTGCCTGTCCCGGTCTG
TGTAATTTGGCTCTCTTGGATTAAATCCTGAGTTTTATCTTAACCTTAGGTGCAAT
GGTGGTTGGGAAGGAGGGTGTGGTCTTGATGCACTTTTGGAGATAAGAGCCTAA
GTCTCCCCTCAGAGAAATATAAATTGGGAAGGGCCTGAGAGATGGCCATCCCAC
30 AAGTCCTTCTACAGGGAAGGGTGCCAAGGCCTTGTGGGAGCCGCCCGCTCAGAT
GGCACAGTGGGGCCAGCTATCCCATCTCCAGGTACCAGACTGGGCATGCCTCCGT
GGGAGTCAGGCATGGGAGCTGGGTCTACAAGGCTGAGCAGGATTTTGACAAACA
GCAATCATGGGAGGCCTCTGGGCCAGAAGGAATAGCAGGAGCAAAGGGCTGAA
GGAGGAGGCCAGGGCTGCCTGAGAAACCCCGAGTTGCCCCATTGCACTGCAG
35 CAGACTGACGCTATAGGAAGAAGGCAGGGGCCAAGCGTGTTTAATTCCCATGGT
ACTCCCTGTGGAGCATATGGTAGGAGGTGAATAAATGTTTATTGAATGAGAAAA
GGAATAGATAATTTGGTTGTCCAAGCAGGGCCCTGGAAGTGGTCAAATCCAGAA
GGGGTTTGGTTCCAAATCCTGGCCCTGCCTCAGTTGGTCCCATCCCAGGTCCACC
TCTCCTGGCCCTCCACTTCCTGCATCCTTGCTTGTCTTCATTTCCCCAACATGTGG
40 AATGAGGAGCGGTCTCCTCCATTGGGTTCCGTCCTAAAGGTGGGTGTATGCATT
TGATGCGGCAAGTATTAGAGCCACGGGGAACCAGGCGCCCCCAGAGTGAGACTC
CTCCCAGTCTGCCCCAGCGCCGGCACCTGCTGCCGCTGCCCTCTGGTGGAAGTC
ACTGGCAGCACAGGTTTGCATGGGTGCCTCGAGCTCCAGATGCAATTCCATTCA
TTTACACAGTCTTGGTGTGCAGAACTCTGGACAGGACTCTGTGGAAGCGAAAGA
45 GAGGAAACCATATTCTGCCCCTCAAGGAGGATGAAGTTCACACACACACAAGTG
ACCAAACCACAGGCCAAGGTAGGACACACATAATGTGAGGTCTCCTGGTCCTAA
GAGGAACCCGTTTGAAATGGGCCGGGAAGGATGGCTAGACTCCATTTCTGACAA
TATGGTAGACAGCAGATGCTGAAGAATTCTCCTAATAACAAAACACCACAAAAAT
ATTGTAAACCATCTTTTAAAATGTGTAGCTGAGGTGGTGAGAAATGAAGAAAAAT

CATCAGAGATCAAAAACGACAATAAGCCTGGGCAACATGGTGAAACCCTCTCTC
TGCAAAAGGTGCAAAAATTAGCCAGGTTTGGTGGCACACACCTGCGGTCTCAG
CTACTCAGGAGGCTGAGGTGGGAGGATCGCTTGAGCCCAGGAGGTCAAGGCTTT
AATAAGCCAAGATTGCACTGCTGTACTCCAGCCTGGGCAACAGAGTGAGACCTT
5 GTATATGTTAATATATAAAGACAACAAAAATCCAAAGAGATCACAGCCAGCAGA
GAAGTATCTGTTGATCCAGTTGACCAAGAGCTTCAGTCTTATGAACATGGACAAA
AGTTAAAGCTGAGAAACAAAATCGAAGTGAAAAACAAAATCCAAAATTTCTGCC
TTAAACAAAGAGCACTGAAATACAACATCCACAGTGGAGAACTCGGAGAGAAA
AATTCCTTAAAGCGAGCTGACACAGAGCTTGCCCAACTCAGTATGGACTCTGAGT
10 GGGAGAAAAATAAATGTCAACCCTGAATGCCCTCACCACAAGTCTACCCACTA
ATAGGCCTGGAGGTGAAACTCATGGTGACTTTGTGGCAAAAACAACCACACAAA
AAACAAACAAACAAAAAGATAAGATAAGAATTTAAAGTAAGGTAAATAATAGC
TCCTTAGGCACGTGGCAGAAACAAATGATAAAAATTGTCTCTGGAGTAACTCATC
CTATATTCATGACTCAAAGAAATCCCACAGAAAACTCCCATGGAACATGAGTTC
15 ACATGTTTGTAAAACAGAAAAATCATAAAACACAGGACACAAGGTGCTTTAGGT
GAGAGGAGCACCAAGCAATAAACTAAAAATGCAGACCTTCGAACACATCTCAGA
TGTTGGAATTGCAGTATATATAATATAAAATAAGGATGTTTCATATGCTTCAAGA
ATTAAGTTGGTAATTGAAAGTATAGATAAGGAACAAGAGACTATTTAAAGTG
ACCAGGAAGATTGAGGGAAAAAAGCAAGCAGTTATGTAAAAACATAATTTTGT
20 AAAATAGAAGCCCAGTGTACAGATTAAACAGTAGATTAAAGGCTCAGCACTTTGG
GAAGCTAAGGCAGTCTGATGGCTTGAGGCCAGGAGTTCAAGACTAGCCTGGCTA
ACACAGTGAAACCCTGTCTCTATTAATAAATAACAAAAATTAGCCAGGTGAGGTGG
CACATGCCTGTAGTCCCAGCTACTCAGGAGGCTGTAGCACAAGAATTGCTTGAAC
CCAGGAGGCAGAGATTGCAGTGAGTCGAGATTGTGCCACTGCACTCCGGCCTGG
25 GTGAGAGTGAGACTCTGTCTCAAAAATAAATAAATAAATACATACATAAAAAATA
AACAGCAGATTAATATGGCTGAAGAGACAACCTACTGGGGTGAACAATAGATTTG
AGAATTTACCCAGGATGGAGCACAGGAGGACAAAGTGGTGGAATAATGAAA
GAGGCTAAGAGACATAGACAAGGAACAAGGATTAAATATGTCTAATTAGAGTT
CTAGAAGAAAATGGAAAATTTCTAGACTTGATGAAAGACACAATCCTCAGATTC
30 TGGAAGCTCCCCCAACCAAGCATGATAAATAAAAAGAAATCTACACCAAACAT
TTTTGGTAGCAAACTGCTGATCACTAGACAGAAGATGGATGAATGATGAAGTA
GATGGGCAGCTAATATGTCAATACCAATAACTAAAGCCAGAAGGCGATGGAACA
ACATCTCAAAGTACTAATAAAAAAATAACTGTCAACCTTGACTATCTTTCAAGTA
TAGGTTTAAAGATACATTTTCAGATGAAAATTGAGAGCATTTATAGCTAACAG
35 ACTCTCACCTAAGGGAATTCTAAAGGATGTTCTTCAAAAACAAGAAAAATAATCT
CAGAAAAAAAAGTCTAAGATTCAAGTAAGAATGGTGAGCAAAGAAATATGTAA
ACACAGAAGTGGATTTAATAAGCACTGATAGCATAAAATAATTACAAAAATGTC
CACTTTGTGGAGTTAGAAAAAAATGAAATAGGCTGGACATGGTGGCTCATGCCT
GTAATCCCAGCACTTTGGGAGGCTGAGGTGGTTGGATCACTTGAGGTCATGAGTT
40 TGAGAACAGCTTGGCCAAAACGGCTAAACCCCATCTCTACTAAAAATACAAAAA
TTAGCCAGGCGTGGTGGCTCGCATCTGTAGTCCCAGCTATGCAGGAGGCTGAGGC
AGGAGAATCACTTGAACTGGGAGGTGGAGGTTGCAGCGAGCCAAGACTGCACC
ACTGCACTCCAGCCTGGGCGACAGAGCAAGACTCTGTCTCAAAAAAAAAAAGAA
AAAAAATTAATAAAGAAAAAATAATGAGATAAACTAAAGAACCATAAAAC
45 AATAACAAATTGGTGAGGAGTGATCAGAGTGGGAAAGGTCTATTATTTGGTGGG
AGGGCAAAATATTGACTAGCATTTGACCTTGTTCAATTAAACATGCATGTAAAC
TAGTTGAACAATAAAATGGAACCTTGTTGGGGAGAGAAGCCTGCTGTAAAGCCAA
AGAGGGCAGGAAACGAAAAGAAAGAAATGAAAGGGAGAATAGGACAAACAGA
AGCGTTGGTAGGTTTCAGCAGGTAGCTCAGGTGTAGGGTGGCGGGAAGGGTGCT

CTTGACAGGGCACAGGGTAAGTAGAGGCAAGACAGCATGATGTGAGTGTTGCTG
GGGCTGGATTGACATGATACACCCCAAGGACAGCCCATGTTTCACAGACTCGAAGTT
TCAAAAATGAAGCTGAAAGGTGCACCCAGCTGGGTGTCCAAATCAATGAGCTCA
TTTTTATTTAGAACTCTTGGAGCAGGACCTTGTGAACTCAATTTGCAAGGGACAC
5 CCAGTGGCTCTGCACCCTGTGGAGAACTCAGGAGTTTTTCATCCAGACTGTATCT
CTCTTCTGACCTTCACCCAACAAATTGGAATAAGCAACATTACTGAGGGAAGCCC
GACTCTCCCACCAGAAGGAAGAGAGGACCTAGAACTGAAAGGCCGCCACCCTCA
CCATGTGGCACGTGGGAAAGTTTAATGCTGACGGGTACTTAGTGAGCACTTCCTA
TTGTGCCAGACACTTTATATGGAACCTTAACCCTCAGTTCTCATTACAACCTCAACC
10 AAGTAGAATGTGTCTTAGCACAGCCTTGACAGATAATGACACTGAAGTTAGAGA
GGTAGTTTGCTCAAGATCCCACAATAAGAAGTAGTAGGGGTAGGCTCTGAACT
CAGGTCTGTTTGGATGAAGACCCTGGGCTCTTAACCACAGGGGTGGGTTGTGGTA
CAAGCATAAAGGCTTTGGCTGAAACATGGCACCACGGGCAGGAAAGGCTCTGGT
TCTACGAGACTCTAAATTTTGGACCAGCCCTGCTCCTGGGCCAAGCCAAACCCAC
15 TCCTTAGTCTCTTGAATCCCGAAATTTCTCAGTCCTGACCACAGTCTCCAAACCAG
CTACAGCCAAACCTTGTGTTTCTGAGGCCCAGAATTTTCTACCATGTTCTAAATA
TTTAGCATCTAAATGTACATACATTAGCTCTAATCACTTAGTCACTCATTCAACAC
AACTTTATCTGTGTTCTAGGTGCTGGGGACACTACACGGACCAAAACAGACAAAT
ATCCCTGTTTTTACAGAGCTTATATTTTAGTGGGAGAGAAACATAATCAACAATA
20 GACATAATAAATAGGTTATATGGAAAAAAGAAACAGAGCCGTGTAAGAGAGG
CTAGGAGTGTGAACAGGGGTTACAATTGTAAATGGGTAGTAGCTTAACCTTAGCCT
CTTCCCCCTCAAATGGAGCCTGGAACAAGGGCTTGTTTGGCAGAGGTTATTTGGG
AATGCGATCCGAGGGAACAGGTTGAGGAACAAAGAGAAGAGAAATAGGAAAAG
AAGGAAAGTCAATAAAAGGATGCCTCATTGATTTGGCCACACTACGGACAATA
25 GTACTCGATCTCAGACTTCTGAAATGGTTCCTCATAACTATCTGTCCATGTGTGGTC
TCCATTCTACCAACCATTGCACCAGCACTGATGTGGCCAATGGAGAGAAGCTGG
CTAATGTCCTCTTGATAGTCGTAGGCCTCCCTGTGGTAGAGCTTCTCTACTGGACA
TTAACATACATCGTGTCCATCCACATGCCTCTACCCAGATATCCTTGCCTCTGAT
TTTCCAGTCTTGTTCCCTTCCAGGCCCTGCCAGGAGTCCATGTATATCTATACCT
30 CCACTTGTTTCCATATACAGTCCACGAATGACCAAAGGTACTATCCCATCTCTGC
CTACTGCCAGTATTTCCCTTTACCATTGTTCTTCAGAGCCACCTCTGAGTGAGGTT
ATAGTATAGCTTCTGTCCATTTCTGGCTAGTAACAACCGATTGTGCTGCCCCATTT
GTGAACCAGGTCTGAAGTTTCCACTTCTATCAGAAAGAGCTTTCTCAAGGCCAT
AGATGTGAGTTAAAAGAGAAATATGGGGCCGGGCGTGGGGGTTCCACCTGTCA
35 TCCCAGCACTTTGGGAGGCCGAGGTGGGTGGATCATGAGGTCAGGAGTTCGAGA
TCAGCCTCGGCAAGATGGTGAAACCCCGTCTCTACTAAAAATAAAAAAAAAAAAA
AAAATTAGCCAGGTGTGGTGGCAGGCACCTGTAATCCCAGCTACTTGGGAGGCT
GAGGCAGAGAATTGCTTGAACCCGGGAGGCAGAGGTTGCAGTGAGCCGAGATCA
CACCCTGCACTCCAACCTTGGGCAACAGAACGAGACTCAGTCTCAGGAAAAAAG
40 AGAGACAGAGAGAAATATGGATGCAAAAGAGGCAGGTGCCATCTGTCCATGTAA
CTTACTTGTACCTTCTGGTTCTGTTTGGGTTTGAAGCAATTGTACAGCTGCTGCCC
CTCTCCCCAGATCTTATAGCCTGGTGTGTGATGGGGTCTTGTGGTCCCCTAGTTGT
TGGTGACCCATCTTCAGGCACAAGTCTCTATCAGGGCCCAGTAGCACCCCTAGGAT
ATGATTTTCAAGTGACAAGCATTCTCTACTGCAGGAGCCATGGCCTTGGTTTCAG
45 CACCCTAGAGGTTTGTGCTGCAAAATTCTCTTTTTTGGAGCCTTCCAGAGACTCCA
TATGGCATCCTTATCCATGTGGCATCTCTGATATGACTGAACACGATTGTCGTAG
GGCGTCACAGCAGCTTGCACCATTGCTGGACCTGCCACAGAGCCTTCTCTCGTG
CTGGGCCTCCCTCGGCACTAGCAGCCCTCAAGTCACATGATAAATGGTCCGACA
GAATTCCCCAGGATGCTTTAAATCCAGAAGTACCCACCCTGTGCTGTGCCTTGT

TCTTACTGATGGGGGATGCAAGTTACAAAGGCTTGTTCTTTACCCTAGAGATAAT
GTCCCAACATGCCCCAGACCTTGGGACCCCTTAAAATCTTTCCCAATGTGGCAGCC
ACCAAAATCTTTTTGGAGCTTATTTCTTACCTTTTAGCATACAGAGGGCAGCAGTT
CTCAAATTTTTTGGTCAGAAGACCCCTTTATATTCTTAAAAATTTATGGAGGACCC
5 CATAGAACTTTTGTTCATGTGGGTAATATCTACTGATATTTATCGTATTAAAAGTT
AAAACCTGAGAACTCCGGAAGATGGAGAGTACAATCATGGGTACCAGAGGCTGGG
AAGGGTAGTGGGGATGGGGGAGTGGGGATGGTTAATGGGTACAAAAATATATAG
AATGAATAAGATTTAGTATTTGATAGCACAAACAGGATAATTACAGTCTACAATAA
TTTATTGTACATTTAAAAACAGCTAAAAGTTTATAATTGGATAGTTTCTAACACA
10 AAGAAAGGATAAATGCTTGAGGTGATGGACACACCATTTACCCTGATGTGATTAT
TACACATTATATACTTGTATCAAAATATCTCATGTAGGCCGGGGGCAGTGGCTCA
TGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGTGGATTGCCCAAGCTCA
GGGGTTCAAGACAAGCCTGACCGACATGGTGAAACCCCATCTCTACTAAAAATA
CAAAAAAATAATTATCCAGGCGTAATAGTGCGCACCTGTAATTCCAGCTACTCG
15 GGAGGCTGAGGCAGAAGAATCACTTGAACCTGGGAGGTGGAGGTTGCAGTGAGC
CGAAATAGTGCCACTGCACTCCAGCCTGGGTGACAGTGAGACTCTGTCTCAAAA
AAAACAAAAAATAAAAAAATACTCACATACTCCATAAACGTATGTATACATA
CACACACCTACTATATACCCATAAAAAATTAATAAATAAAAAAGTTTAAACAAAA
AACTGAGACATTTAAAAATATTTATTTAATACATTTTAAAAATATAAACAGCAA
20 CATTACATGTCAATATAAGTAACACTTTCTGTGAAAAATTACTGTATATCCCAA
CCCCACAAAATTATTGGGGGCCGGGCATGGTGGCTCACTCCTGTAATCCCAACAA
TTTGGGAGGTTCGAGGGGAGCTGATCACCTGAGGTCAGGAGTTCAAGACCAGCCT
GGCCAATATGGTGAAACCCCTTCCCTACTAAAAATACAAAAATTAGCCAGGTGT
GGTGGTGGGTGCCTGTAATCCCACCTACTTGGGAGGCTGAGGCAGGAGAATGGC
25 TTGAACCCAAGCTGCAGAAGTTGCGGTGAGCCGAGATGGTGCCAGTGCACTCTA
GCCTGGGTGACAGAGCGAGGCTCCGTCTAAAAAATAAAATAAAATTATTGGGA
TATTATTGTTTTATTTTTTGCAAATGTCTTGAACATCCAGCTTTGTAGAAGCCAC
CTGGATTTTCATATCTGCTTCTTCATTTAATTTGTGGAGATATGTTATTTAGATTG
AAGTATATGGGAAAAAATCTGGTCTCACAATATGGAGTAGATAAAAGGAGGAGT
30 ATTTTAATAGGATTTTAAAAATAATTGTAGATATTCTTTTCTGATATTGAAAAGTT
GGCAAGTGATAGTTTCCAAAGGTTAGCTCCAATGTGAAATCTGAAATCATATCAA
AGACCTTTTATATATTTTTCAAGTCCATTGTTCTATCTTGTACTTTGAATGGATCTC
TTATCCGTGCATGATTTTGTAAAAATATGTCTCAGTCATTGTGGAACATACTGTTC
TACAGTCCATTTTTTAAATCCATTGTTCTATCTTGTACTTTGAATGGATCTCTTAT
35 CCAGGCATGATTTTGTAAATAACATGCCTCAGTTATTGTAGAACATACTGGTTCAC
AGATGCAGAAGTTATTCAGATCTTCCAAATGTTGACATATTTGTTACACAGTAT
CAAAAATCACATTCATTGATATCATCTCTGATCCCATCAGAGAAGTTTGAAGTATT
GGAAAGATGTCAAGATCATGACACGGGTTTTCTAACATTTGAATTTTACTTAAA
AGCTCTGATTTTCATCAATGGCAACAAATACTGTCTTTTTCTTTCAAGTGACAGGCT
40 CACTTTGTTTCAATTTTCAAACAATTGTCTGCCAAATTTTTAAGTCTGAATAACCATA
GTTTCAAGTAAAAATGGTGTTCATGGGGGAAAAACGTCTAGTTCAGCTGGCAAAT
CCAAAAATAGCACAAGTGCTTTTTTTTCCAGAGCTACCTTCATACTGTAGTATTC
AGCAGGAGTGCTTTTTTGCTTACTTCTTATTTGTACATAGAATAAAGATTGTGCTT
TAATAATATTAATAATTTTAACTGCTTCATTGAGGACATTCTTAAATAAAAGAAC
45 GCATCCTCTGAATGCATCAGGATGAAAACTCCAACAGCTACTACTGCAGCTTGA
TGCCACTGCTATTTTTTTTTTTTTTTTTTTTTTTTTTTTGGCAAGGTGTCACTCTGT
AGCCCAGTCTGGAGTGCAGTGGCGTGATCTTGGCTCACTGAAACCTCCACCTCCC
AGGTTTTAATGATTCTCCTGCCTCAGCTTTCTGAGAAGCTGGGATTACAGGCACG
TGCAACCATGCCTGGCTAATTTTTGTATATTTAGTAGAGACAGAGTTTAGCCATG

TTGGCCAGACTGATCTCAAACCTCTGGCCTCAAATGAACTGCCTGCCACAGCCTC
 CCAAAGTGTGGGATTACAGGCGTGAGCCACCGTGCCAGCCTGGCGCCAAGGC
 TTTGATTCATGTGAAGGCACAAGTGGTTTTACTCATCATTGCTTTTGCTCCAGGCA
 AATTATGTCAGTGAAAAAGGCAAATTGTATCTTTATGTTTATATGCAAATAATTT
 5 TGAACCTCGTGGACCACTGAAAGGGTTTCAGGGATCCTTAGGGGTTTCATGAACCTC
 ACTTTGAGAAGGGAGAGAAGAACCATGGTGCTCAGAGCTGAAACTTAGCATCTT
 GAATATCCGACCTAGTTCTTCTCCTAAGCATTACTTGAGACACGTAAGCTCTCTTC
 AAGGGGCAGCCAGCTCTCTGTTCCCCCTTATGTATAGGATTCCAAGGTGCCTGA
 TCAGTTTCCATTGAAGTGTGGTGTCCACTGAACCCAACACTCTATGAAGGAACTA
 10 ATCAGTCTGGGGTCTAGCAGAGTGAGGTCCCTGATACCAAATTTAACCTTTATTA
 TAACAATCAAAGCCTCCGAACCTACATTAGAGGAATTCTGGAAAATTAGGAAAAG
 AAAAAAAGTCACCTATAGTCACACTACCTTGACAACCACTGTCATGCTGTAGCCT
 AGGGTGGCCTAAAGGTTGACTCATCCTGAACTTCTTGTTGTTGAAAAAATCCCAG
 GGCTATTTTTTTGTCTTGATGCTGCTAAGCCACATCATTCTGGCCCTTTCCAGTTG
 15 GGTCTTAGGTTCCCAAGAGGGGGACCTGATATTCAGATCTATCCACTTCATTTCAT
 ATAGAGCTCCCCTGTCAGTGGTCCAGAACCCATTGCCCAATTGGACTAACCCTTC
 TAGCTTCATGTGATCTGCACATAGAATGCATCCATGTCAATGGCTCTTTCCTAAAT
 TCCCTGTTGAGGCTTAGAAAAATGATACCCCAAATAAAGTCTCCACAGTAGCCTC
 AGAAGCAACCATTTTTCTCTAACCTTCTGCCCTCAAGTCTCTCAGTCCCATGCTCC
 20 CCCAAGATTAGCCATAGAAACTGGAATCCCTCTTCTCCAAGGCAGGTAGAAACA
 GAACCTTTTCCCCCAAAGTCAGCCATAAAACCTAATTATATTACTCTACTCTAA
 GTTCCCTCCACCTTTCTGTATAAAAACTGGCCATAAAGAAATTTTCTTGGTTTCG
 GCTTTGTTTGACTCTGTGTAGGTTGTAAGACTCCCATTCCAGAGAGAGCCCCGTC
 CTACCCCCAGAAGGAAGGAATGCAGCACAGAGAGGCCAAAAAGAATCTAGAAC
 25 CTGGGATACCAAGAAGAATCTAGAACCCAGGATACCTAGAAGAATCTAGCCAGA
 CAGGCCTTGTTTGACTGTATGTAGGTCATAAGACTCCCATTCCAGCGAGAGTCCT
 GTCCTACACCCAGAAGGAAGGAATGCAGCACAGAGAGGCCAGGAAGAATCTAG
 ACAGACGGGCCTTGCTAGGTTTCCCCACTCAGTCCGTTAGCATTAGATCATACCC
 TTAGGGAGCCTGGATAGCTCAGTCGGTAGAGCATTAGATCATACGCTTTTTGTTC
 30 AATTCTGTATCTACACGGCTGTCCACACTTTGCTGAACCTAAGCATCAAAGTGGA
 CAAGTTCCTCGTCTCTTTGGGTATTCACTCTGTAGGCTCCCATGTACACACATTA
 AATACATCTGTATGCTTTTTCTCCTATTTATATGCCTCTTCTCTGAGATTTTTCAGT
 GAACTTCAGAGGGGCAAAAGGGAAGTTTCCCCTTGGTGCCCCCACACCCCATGG
 GAATCTTGATTATAGCTCTTGATGGTGAAGCAACCGGCACTGATGATGCATCCC
 35 TTCTGTATTAGTTTTCTAGGCTGCTGTAACAAATTACTACAGACACGGTGGTTTAA
 AACATCAGAAATGTCTTCTCTCACAATTCTGGAGGCTGGAAGTCTAAAATGAAGG
 TGTTGACAGGGCTGCTTTCCCTCAAGAGTCACTAGGGGAGAATCTGTTCCCTGCCC
 TCTTTTACCTCCTGGTGGCAGTGGGAGTTCCTTGGCATCCCTTGGCTTGTGGCTTC
 TCTTCTATGAGGGTCTATCCAATCTCACTCTGCCTTTCTCTTGTTCGGGCACTTGA
 40 TATTTTAATTTTTTCCCAAACCTCTTGTGTCACTTCATAGGGCATTTCTGACAGCT
 GTTAGGGTCCATCTCAATAGTCAAGAATAAGCTCCCTTCTTCAAGATCTTTAATTT
 AAGCAAATATTTACCCCTACGAGGTAATATTCACAGGTTTCAGGGATTAGGATGT
 GGACATATACTTTTCATGGGGGAGGCACCATTCAGCAGACATTTATTTGTAGCAGC
 AGTTTTTCAGCGAGGAATAATTTTGGCCCCAGGGGATGTTTGGTAATGTCTAAGAC
 45 ATTTTTTCAGTTGTCAAACTGTGGGGGATGGAGTGCAGCAAGCATCTGTGAATAG
 AGGCCAGGAACGCTGTTGAACACGCTACAGTTCACAGCACAGCTCCCCACAGCA
 AAGAAGTATCTAGTCCAGAGTGCCAGTGGTGTGATGTTGAGAAATTCTGACTTA
 CAGTAAATTAGTATTATAGTATACACTATCCGAAAAGCAACTGCTGTATCCCTG
 TCTCTAACTCTTTTTTCATTATCGCCTTTATTACGTATGACATTAAATCTATTCTATC

CCATATTTATTTGCTTGTTGTCTCTTTCCCATCCCAAGGGCAGAGATGTTTGTCTG
TTTCATTCACTGTTGTGTCCTCAGCACCTTGAATAGCACTCAGCACATTGTGAGCA
TTCTCAATATTTACTCAATTTATTAGTTAATAACGGTGCAGATATTTCTCTCTCT
CTCTCTCTCTTTCTCTCTCTCTGTCTGTCTGTCTCCAGGGTCTTGCTGTGTACCCG
5 GGCTGAAATGCAATGGCACAATCATGGCTCAATGCAGCCTTGACCACCTAGGCTC
AAGAGATCCTCCACCTCAGCCTCCTGCCTGGCTAATTTTTAAATTTTTTATAGAG
ATGGAGTTTTTATTTTATCTTATTTTTTGTAGATGGAGTCTCGTTCTGTACCCAGG
CTGGAGTGCAGTGGCACAATCTCAGCTCACTGCAACCTCCACCTCCTGGATTCAA
GCGATTCTCCTGTCTCAGCCTCCCCAGTAGCTGGGATTACAGATAACAGCCACCA
10 CACCCGGCTAATTTTTGTATTTTTAGTAGAGACAGGGTTTCACCATATTTGTGAGA
CTGGTCTCGAACTCCTGACCTCAGGTGATCCACCCTCCTCGGCCTCCCAAAGTGC
TGGGATTACAGGCGTGAGCTACCGCACCGCACCAAGGCTGAGTTGGAGTGTTGC
CAATTTGCCCAGGCCAATCTCGATCTCCTGGGCTCAAGCGATCCTCTCGCCTTCAT
CTCCCAAAGCTCTGGGGTTATAGGCATGAGCTACCACGCCTGGCAGGTACAGAC
15 ATTTCTTGAGCCCTTACTCTATGCCAGCCACCATGCTGGGTTATTATCTCTTTTG
ATACTACCAAAACCCCTCTACGTTAAGTATAATTTTTCTCCTCCATTTCTCAGAT
AAAGAACTGAAGAGGTTAAGTTATTGCTGAAGATCACACAGCTCTTAAGAGGT
CAAACCAGGGCCCTTTCTCTGGTGACCCAACTCCAGAGTATTCCCTTGAGAGGA
TGTGACTTCTAGGTACCAGGCATGGTGCCAGGCACTGAAACAGAGAGGAAGAAA
20 ACACGAGCCCTGTCTTCAAAAAGTCACTAGTCCAGTGAGAGAAACAGGCAAGTA
AGCAGGCTCGTGTGACATGAGTTGCCGCGAGGGATGATGAGGGAGAACTGTTAT
AGGCTGGATGTTTGTCCCCTCAATCTCATGCTGAAATGTAATCCCTAGTTTTGGA
GGTGGGGTCTGACAGGAGGTGATTGGATCGTTGTGGCAGATCCTTATGAATGGCT
CATCACCATCCCCATCCCTTATGGTAATAGGGAGTTCTTGCTCTGTAGTTTATGG
25 GAGATCTGGTTGTTTAAAAGACTCTGGGGTCTCCCCCTTCTCTCTTGTCTCTT
TGTCGCCATGTGACATGCTGGCTCCCCTTTGCCTTCCATCATGATTGCAAGCTTCC
TGAGGCCTCACCAGAAGCAGATGCTGGCACTATGCTTCTTATGCAGCCTGCAGAA
CCATGAGCCAATTAAACCTCTTTTCTTTTCTTCTTCTTCTTCTTTTTTTTTTT
TTTGAGACAGAGTTTTGTCTGTCTCCCAGGCTGGAGTGCAGTAGCACAACTTG
30 GCTCACTGTAACCTCCACCTCCCAGGTTCAAGCAGTTCTCCTGCCTCAGTCTCCTG
AGTAGCTGGGATTACAGGTGCCCCGCCACCACACCCGGCTAGTTTTTGTATTTTA
GTAGAGATGGGGTTTTACCATGTTGGCCAGGCTGGTTGTGAACTCCTGACCTAGT
GATCTACCCGCTTCGGCCTCCCAAAGTGCTGAGATCACAGGCATGAGCCACCAG
CCCAGCACCTCTTTCTTTCTTTATAATTACTCAGCCTCAAGTATTTCTTTACGGC
35 CATGCAAGAACAGACTAACCCAGGATCCCAGCCTTGAAAAATCAGGGGAGACTA
CTCAGAAGAGGTTACATCTGGGTCAAGTCCTGAGGGATCAGTATTCATGAGTCAT
AGAAAGTTCTAGGCTAGAGGAGCAGCATGTGCCAAGTTCCAGATGAAAGGCGGC
TGGAAGCTGACCATGGCTGAAGGCAGGGTGGGAGCAGGAGACATGGAGAGAGA
GCAGTCAGAGATGAACTTGGGAGTTGGTCCGGAAGGGGTTAATCCTGGAGGGCC
40 TGCAAAGTTGGACAAAGAAGTTGAGACTTTGTCCTAGAGAATCCAGAACCAGAG
GGTGCCCTTTCAGGGTTTCAAGCACGCTGGCTTCAGTGCTGAACGTGAACCGAAA
GGTCTACTGCAGTGGTTCAGGAAGGGAATGCTGGCTGCCCAAACAGGGGCAGT
GTTGTGGGGGTGAGAGAGAGATGGGTGGACACAAAACAGAATGACCAGGCAAC
ATCAATGGAACCTAGGGGCAGGACCCTTGGGGATATCTGCAACAGGGGGCAGGC
45 ATGACTGCAATCCATTTTCTAAAAGGTGGGTGAGAATGAACACTTAATAAAATG
ATGTAAGAAGAAAAAACTATCTTTGGCAAAATGTTGCCTCCCCCTCCAGATCCCA
GTCTGTGGATGGCCTCACTCCTCCTGGGTGCTAAGGGACAGGGAAGACAATATG
AGGGTGTATCCTCTACTGTCATCCTCCCCACTGGGGGCCATGGCCTTCCACAAGC
CAGTCCACAGTCTATGTCTCATCCTAAGCTGTGGCCCTGGGAATGTGCTGCTGAT

TCATTCTGGCCCCATCGGCTTGGAAAGGTGTCTGCTCTGTCCTACTCCTTTCAAGG
CACCGGGCTGTCTTGTAGTCATGGGGATGGGGCCAAACATCAGTTCTCAACCTT
GTCCTGCCACAAGTAAATGATATTCCACGGGCAGCCACTTGTCTCCATTGGGAAT
GGGAATGATGTGTGGACAATTACGCGGTAGGTTACCTGCAATTCCTGGTGCACCT
5 GCTACACACCAGGGCATGCTGGGACTGACCACCCTGGAGTGAGCAGGATGTTAG
GATTGGTCACTGCAGCATAAGAAGCTGCTGTGGATGAATGCCTGCATAGCAGTC
AAAAAATTCCCCAGACTGTCACTGTCCTTCCCTCTACTTTGCCTCTCCTCAATCTG
TGGCTATTATGCTTTTATCCAGGTGGCTCAATTTTTTAATTTTCACCTATTGTCAA
GCCAGGATCACCTACAGGTGTAGAGAGTGGGTTGGCCAGGTATAAGAGAAAT
10 CTAAATTGTTCTGAAGGTGTGAGGCAGGCCTTGGCTAGATCTGGGGGATAACCTT
GCCTCAACTGCAGGGGCCACCTCTTGGTCTGCTTGACAGTCTTGATGAGGCTG
TGTGTATTTGATGCTCACCTGTGAATAAAACCTGTGGGCAACACAGCAGGAT
GGTGCCAGTGCATTACTAAGAAATTGTACCTGGAGAGTGAAAGTTGGATCAAGG
TTTCATTGCTTCATTTTTTTCAACCACTAAAGTAATTGTGCTGGGTTTTAAAAGG
15 TAGAGCTGGGGGCCTAAGTGGTTAGTCAAGTCCTACTTTTGAACCTCCTAAAATC
TGACGTCTCTCACCTGCCCTGGCAGAGTGCCATCAGGAGAATCTAGGAGACTCG
AGAAGCCACTTCACCTAACATCCTCATTGTGATCTCTCTAAGAAAGCTCGCTGAT
GACGCAGCCCCTGTGCTTCTCACACTCAACAGTAGCTGTGTTAGATGCACAGGTA
AAAAGGCTCATTTTCACCAGCCTCCAACCAAGGCATCTGCAGGGACACTTCAGCA
20 TGTCACCACACCAGACAGTGTGCTGCCCTTGGCTCTCTGTGAGCATGCAGGCCC
AGAGATGCCAGATCCTCTGCAATTTACAGGAGTAGCCAAAAGTCCGGATCTTCATG
CTAATACTTCTGATTTTTTTTTTTTTTTTTTGTAGATAGAGTTTCGCTCTTGTCTCCAG
GCTGGAGTGCAATGGTGCATCTGGGCTCACTGCAACCTCCGCCTCCTGGGTTCA
AGCGATTCTCTTGCTTAGCCTCCTGAGTAGCTGGGATTACAGGCCTGTGCCACC
25 ACGCCCGGCTAATTTTGTGTTTTTCAGTAGAGATGGGGTTTTCTCCATGTTGGTCAG
GCTGGTCTCGAATTTCCCGACCTCAGGCGATCTACCCACCTCGGCCTCCGAAAGTG
CTGGGATTACAGGCGTGTTCACCGTGCCCGGCCAATACTTCTGAATTTTTAAGG
AGATACTAAAACTTCAAAAATGTTTTAAATTAAAAAACAATATGGCCGGGCA
CGGTGGCTCATGCCTATAATCCCAGCACTCTGGGAGGCCGAGGTAGGTGGATCA
30 CTTGAGGTCAGGAGTTTGAGGCCAGCCTGGCCACCATGGCGAAACCCCTTCTCTA
CTAAAAATACAAAAATTAGCTGGGCACGGTGGCGGGCACCTGTAGTCCAGCTA
CTCGGGAGGCTGAGGCACGAGAATCTCTTGAACCCAGGATTCGGAGGTTGCAGT
GAGCCGAGGTCACCCCACTGCACTCCAGCCTCCAGCCTGGGTGACACAGTGAGA
GAGCTCTCTCAAAAAAATAAAAAATAAAAAAGAGAAACAGTAACAG
35 AAGCTACAACAAAACTAAACACCATGTAATAAACTATCAGAGCCAAACCA
CATAGACCTGTGGGTACGGCCATGGCCCACCAGCTCTGGGGCTCCTCAGTTCTA
AGATTCTGCTCTCCAGCTCCCTCCCACTGGTCATCAGTGTTGTGACTCGTGCCCTG
GGTGACAGTCATGTCCGCTTTTGAACATTACTTCCCCTATCTGCAAGAGGCAAG
TCACCCCTACCTTCTCCCCAGCTAAATGTGTCCCCAGGACTTCCCCAGTGAACC
40 AGCCCAGCACCTGGCCCCCTGGTACCTTGGAGATGGAGGCTGGGCAGTAAGAAA
GACGCTGGGCTGGGTGCGGTAGCTCACACCTGTAATCCCAGCACTTTTGAAGGCC
AAGGCGGATGGAFTACCTGAGGTGAGGCATTTGAGACCAGCCTGGCTGACATGG
TGAAACCCCATCTCCACTAAAAAACAAAAATTAGCCGGGCGTGGTGGCACAC
GCCTGTAATCCCAGCTACTCAGGAGGCTGAGGCAGGAGAATTGCTTGAGCCTGG
45 GAGGCAGAGGTTGCAGTGAGCCGAGATCGTGCCACTGCACTCCCGGCTGGCCAA
CAGAGTGTGACTCTGTCTCAAAAAAAAAAAAAAAAAAAAAAAGATGCTGC
ACTCCTCTTTTCTTTGCTACTTTCCTCTCCTGGGTTTTTCTCTGCAGGCCACACTGC
TTTTAGAAGCCTTTCCCTTCATCTACCAACCGCTGAACATCACCGATGGCAGGCC
AGCACTCTCTCAGCTCTCTGGGTAAGACTCAGCTCTCTGGGCTAAGTCTGAGCTC

ATCTGCCAGCCTAGTGATCTTGCCAAGAGAGGAAGGAGCTGGATCTGATGTGAT
CTGAACTTCGTACCATACCGTCACAGCTGATGACCTAAGCTTCCTCCAAGTCGA
GGGATGGTGCAGCTCCATTGAAGTCTCCTCTTCTCCTCCAGGCTCTGCCCACCT
CACGAGAGCACATGGTCCTGACTGCAGTGAAGTGCAGGAAGACCTGGGATGGAGG
5 GCTCTGCTTTCTCACCATCCTCTTGGCCTGGCTTCTCTAACATGTAAAACTTAC
AGTGGCCCACAACCTGTAATCCCAGGACTTTGGGAGGCCGAAGCAGGTGGATCAT
GAGGTGAGGAGTTTGAGACTAGCCTGACCAACATGGTGAAATCCCATCTCTACTG
AAAATACAAAAATTAGCCAGGCGTGATGGCACGCGCTTGTAATCCCAGCTACTC
AGAAGGCTGAGGCAGGAGAATTGCTTGAAGTGCAGGAAGTGGAGGTTGCAGTGAG
10 CCGAGATTGTGCCACTGCATGGCAGCCTGGGCGACAGAGTGAGACTTCGTCTCA
AAACAAACATACAAACAAACAAACAAACAAAAATCCCTCGCTTTTTTGCTGG
TATCTATAGTGCTTTTTTTGCTGGTATCTATAGCTTTTGTGAGACTCAGTTATTTA
GCTTTAGCTTTCCTGATATTATTATTCTTACAAATTTTGCCTTGGGACACTCTTTCC
ATTCATTGATTTCAGGCAATACTTATTGAGCACCTACTATTTGCCAAGCACTGGGA
15 AGCCATTGAGAATAAAACAGTGAAGAGTTAGAAAAGGTCTCTGATCTGATGGAG
GGCCTATTCTACTGGTGCTAACTGAACAAGTAATATGTGCTCTGAAGACATTAAA
ACAAGACAATGTGATGGGGGATGCTGAGAATCCAGTAGGAACTACTTAGATGG
GAAAATCAGGGAAGGTCCCTACAAAGGAGACATATATGCTGAAACCTCAATAAA
GAGAAGCAGCCAGCCATGCAAGGATATGGAGGGAGAGCAGTTATGGCAGAGGG
20 GTCAGCAAAGACAAAGGCCCTGAGGCAGGGAGGAGCTTAGCATGGAAGGGGAA
CCTGGGAGGCCGGCTGGCTGGACTTGAGTGAACATGGGGCTGAGATGAGATCAG
AGGAGAGCAGAGGCCAGATCCCCCGGGCTCCTAGGTCAGGGTGGGGCTGGTGCT
TAGGAGTTCTGAGGCTGACTCTGATTTAGTCTGAGGTCGGTGTCCTCTCAATCC
CGACTCACTTGTGGTCTCTATGGCCCGCAGGCTTGTTGAAAGTGCCCCACTTCCT
25 TCCTCACAGCAGCCTCTGTGCAATCCGAATTGCGCTGTGAATTTCCCTGCCACTC
AGGAGCCCCGGGGCAGGGCTTCACCCCTAGTTTCAGTTACCAGGAACCAATCTTTCT
CCACCTTCCTGCCCTAGCCCCACTGGGTCTGTCTCTGCATCTGTGAAATGGCTGA
GTGTGACCAAATGATGCAGGTAGCCTTTCCACTTCTTTCTACCCGTGGCGCCTCG
GGTGGAGGCGTGAGTTTGAATTGGAAGAGGGTAAAGCAAAAGTGGAATCCTGGC
30 GAGAAATGAACTGAAAGAAAAAATTCCTCCTGGAATTTTTTGGCTCTAAGGAG
GCCAGCAGCGGGGGTTTGGGGTAGGAGGCAGAGGTAGAGAAGGAGGGAGGTTT
TTAGAAAGCTGACCGGGCAGGAGCCCTGTGACCCAGGCTTTCACTTCTCCTAAAC
ACCCAGTAGCGCCATGTGATGCAGGCAGGGGACTGCGGATAGGGCCTGTGAAAG
GGGAAGCGAGGGGAGGCCAGAGTTTCTCAAGAAGCCGAGAGAGGGGACAGAGGC
35 TGAGCCTGGGGGGAGGGCTGCAGGGGACTGAGAGGGGAGTGTAGGCAGTGGGG
GTGAGGGGGACAGGGAGGAGGTGGAGAAGACGGCAAGGGGCAGCAGGGTGACT
GGGGCAGAGGGAGCCCCACCCACGCCAGGGCAGGCCAGGAGTCATAAGGA
GAGGGGACAACAGGAAGGGGCGACAAACGGGGAGGGGAAAGGGAGGCGGAGG
GGCAGCGAAGTGAAGCAGGGAGGGTCGCAGTGTGAACAAGAGTGCGAGGAAGG
40 GTCAAGGTGGAGGGAGGAGAGGGGAGAGTTAGGGAGAAACAGCTGCAGGAGAG
GCGCGGGGAGGAAGCCTTAGGGGTGGGGGAAGGGAGAGGGGAGTTGAGAATTA
GGGAGGAGGTGGTAGAGTCCGGGTAGTGAGCGGAGGGACAGGAAGGGTAGGGC
AAGAAAGGGAGAGGGGACAGGAGGGAAGGGTGGGCCAAAGCGGTGAGAAAGG
AGGGCCAGCCAGTTGGGTGGGGGAGAGGGCCGAGGCCCGGGGGCAGGAGTGCA
45 GGGCTCTGAGGCGGGGAGAGGAGAGGAGAGAAGAGCCGCGGGGGGCCAGCCC
GGAGCCAGGATGCCCGCGCCGCGCGCCCGGGAGCAGCCCCGCGTGCCCGGGGAG
CGCCAGCCGCTGCTGCCTCGCGGTGCGCGGGGCCCTCGACGGTGGCGGCGGGCG
GCGGGCGCGGCCGTGCTGCTGGTGGAGATGCTGGAGCGCGCCGCTTCTTCGGC
GTCACCGCCAACCTCGTGCTGTACCTCAACAGCACCAACTTCAACTGGACCGGCG

AGCAGGCGACGCGCGCCGCGCTGGTATTCCTGGGCGCCTCCTACCTGCTGGCGCC
CGTGGGCGGCTGGCTGGCCGACGTGTACCTGGGCGCTACCGCGCGGTTCGCGCTC
AGCCTGCTGCTCTACCTGGCCGCTCGGGCCTGCTGCCCCGCCACCGCCTTCCCCG
ACGGCCGCAGCTCCTTCTGCGGAGAGATGCCCGCGTCGCCGCTGGGACCTGCCTG
5 CCCCTCGGCCGGCTGCCCGCGCTCCTCGCCAGCCCCTACTGCGCGCCCCGTCCTC
TACGCGGGCCTGCTGCTACTCGGCCTGGCCGCCAGCTCCGTCCGGAGCAACCTCA
CCTCCTTCGGTGCCGACCAGGTGAGTGGCAGGAGGCCTGCCCCGGCATACTCCGG
CGGGTGTGGAGGGAAGGAGGGCTGGCCCCCAGCGTGACCTGGGACAAACCAGGT
CCCCTGCCTGCACTAGTTTCTGATTTGAAAGAAGAGGGGGGCTAGCCCTTGCAA
10 AACCGATGGCAACCGCAGTGGGAATAACCATGGTTGTTTTTTGTTTGTATTATTT
TTTGAGACGGAGTTTCACTCTGTGCGCCAGGCTGCAGTGCAATGGCGCGATCTCA
GCGCACTGCAACCTCAGCCTCCCGGGTTCAAGCGATTATCCCTCCTTAGCCTCCA
GAGTAGCTGGGATTACAGGGGCCTGCCACCACGCCCAACTAATTTTTGTAAATTTT
TTTTTTTTTTAAGTAGAGGTGGGGTTTACCATTGTTGGTCTTGAACCTCTGACCTC
15 AGGTGATCCACCTGCCTAGGCCTCCCAAAGTGCTGGGATTACAGGCATGAGCCA
CCACGCCAGGCAGGTGGTCTTTTTTGAGCTACTTGCAGGCCCTATGCTAAGCAC
TTTCACTGTTTAAGTATTTAATACTCTTACCACCCAGGAAGTAGGAATTATTAT
GCCCATTTTACAGAGAAAGACACTGAGAGGTTTCATGGCATTAACTCAACTTGCCC
AAGGTGACATGGAGGGTCGAGGAGCCGAGTAAAGGCAGCTGGACTCCAGGTCCC
20 ACCATGAACCTCCTCTCTGTGTGTTATGGGGATGTGCGGGCAGGGCAGGAGCAA
GCCAGCTTCTTCTACCAGCAGTGCTAGAGGCTGTGAGGCCGACTTGCTCAGATC
CCAGCTCTGCCTTTCCTAGCTGGAGCCACATGGGCAAGAACTCATTTATATCCT
GAATGGGCTGCCTGGTCTTCTCCCTTAGCTCAACCTCTGAGCCTTCTCCGTTCCC
CCTTGAACAGAGCATGGCACGTAGAAGAAATTTAATAAGTATTTGCTAAATGAA
25 TGAGTAAATGCCCAACAACACGGCTATATTTTGATAGCTGTTCCAGTGGGATAT
TAGACAATAATTTAGACTAAAATGTAATATTATTAATAAATAACCACATATGGTGTA
AATGAGCAAAAGCAGGAGGCAGGACTGCATACAGATAGGACTGCAGCCATGTG
GAAAGACGAGGTGTCAACGAAAGGAACTGGAAAAAGATTGTCACAGTGGTAT
GATCAGGCCACTGGACTAATTGCATTTCTTCTTGTCTCAGTTTATCAAATGTTCT
30 TTGATTGCACATATTATACTCATAAAGGGGACATTTTTCAAAGGATCGTTTCAT
CCAATTGGCACCCACAATTCAGCACCTAGCAGTTTCCAGTGTCTTGACAAGGAG
TCACTTGTCCAGCTTGTTTAGGATCCTTTGATGATGACTTCATGCCCCCAGGCCAG
CCCTGGCCATCTCTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTT
TCCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTT
35 CCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTT
CTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTT
TTTCTTTCTTTCTTTCTTTCTTTGACGGAGTCTCGCTCTGTTGCCTACGCTGGAG
TGCAGAGGTGCGATCTCAGATCACTGCAACCTCCACCTCCCGGGCTCAAGCAATT
CTCCCTGCCTCAGCCTCCCAAGTAGCTGGGATTATAGGTGCCCGCTACCACGCTG
40 GCTAGTTTTTGTATTTTTTTAGGAGAGATGTGGTTTCGCCATGTTGGCCAGGCTGG
TCTTGACTCCTGACCTCAGGTGATCCACCTGCCTCAGCCTCCCAAAGTGCTGGGA
TTACAGGCGTGAGCCACTGCGACCGGCCAGCCCTGACCGTTTCTTACTTCTTGTT
GACATTCTTTCTGACCTAGAGACCCCAATATTTGTCAATGGGAATCTCTCATCTT
CCTTTAATCCTATTATTTCATTGACATCCCACTAGCACCCCAACCCAGTACCCTT
45 AACCTGTGTCATTGACCCTATTGACCTCCAGAGAGCCTCACCCATCTAGTACCCC
CTGTGGCAAACTGATCTTCTGGAGGCCAGGCCACTGAGCAGAGCCTCCCGTGG
CATCAACAGGGGCCAGAAGCTCCTGTACGTTCTCCCTTGGCTGGGCACGAACCTT
GGGTGGAGCAAAGGCAGGCCACAAGGCCTCATGAAGTCGGGACCTGATCCCTAG
GACAGTGCAGAAACACCAAAATGATTTGAGGCAGGAATGGACATCACTGGATTT

GAGCTCTTCAAAAATGGCTCCGGCTGCAGTGTAGACAGCATATGGGTAAACAAG
AGTGGGTACTTCACAACAGGCAGGAAGCGGCTGCAGAATTCAGGGGGGCAGTCA
GATGGGGATGTGGGGGTGGGTGGGACTGGCACCATCTGGCAACAGCTATACCCC
AGGAGCTGCGTGTTCACATACTTGCTGATTTTCAGAAAGGGCCATCCATCACTCT
5 CGACAAAGCATCTGCTCATTCTAAAAGAACTCATTTATATCCTGAATGGGCTGCC
TGGTCTTCCCCCTTAGAGTTACAATAGTCACATTCATTTACTTCCAATTAATAAAT
GGAAGTGGCTGCTTCTAATGGGACCTATTCAATTTTCTGCTTGAAAGTCTAGAGC
GAGAATTATCAGTGAGCTGATATGCCCCCTCCCTCCCCACTCCAGGAGGACCCCG
CAGAATCTCCAATGGAATGCGGGTTTAAAGTGCATCTGTGTGGACTATAATTTTAC
10 ATTTGAAAAAGGAAAAATAAATACTTGTCTTTTCCCCAATGCAACTACAGAAAGT
AAAGTTTGACAAAATCGCCCTAGCTAGTGGAATATAAATCTCTACTTGAAAGGC
AGTAATGGATCCTGAGATTTGCAGGGGCATGGAAAGGGTGACTGGTTTAGCAAT
GTAGAGAAGTATTTATTCTCTCCATTGAAATGGCCCCCTAGTCCTCACTGCTTTTTT
TTTAAATGCAGATGCCCAGGTCCTGCCCCAGACCTGCTGAGTCAGAATCTGGGAC
15 CTGGGCCTGGGAGATTTGGAAGCAGCTAGTGCAGCTGACTGGAGCCAACAGACC
AGAAGGGGCCTGGGGCCTGGCTGTTGCTGATTGATCCAAATCTGGGTAAAGATT
TTCAGCCCATCTGCCCTTGCTGGGAGGCCTGAAAAAAAACGTTTTTTTACCAGG
CCAGAACTCACTCTTGGGGCTGTGCCTGGGACCACCTCTGCTGTATATCAGAGGG
ACAAAAGTGGGGTGAAAGGATGGGTACAGTAGGCTTCTCTGCTTGCCTCTCCGA
20 ACTGCAGAGGAAATTCTCGCTCAGACTTCTGTTCTTTCGGTAACATGCATACAAC
ATTTTAAATAATGTGCAATAAAACTGAGATCTTATTGGCTTTTTTCTGATTATAAA
AGTAATGAATAGGCCGGGCGCGATGGCTCACGCCTGTAATCCCAGAACTTTGGG
AGGCCGAGGCGAGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACA
AGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCAGGTGTGGTGGCA
25 GGTGCCTGTAGTCCCAGCTACTCAGGAGGCTGAGGCAGGAGAATGGCATGAACC
CGGAAGGTGGAGCTTGCAGTGAGCCGAGATTGTGCCACTGCACTCCAGCCTGGG
CAACAGAGCAAGACTGTCTCAAAAAAAAAAATAATGAATAGTGTAGGTTGCTC
AGTGA AAAACAAAGGGATAAATCAACCAGAAATGAACAAGTGGCATCTGAGAC
ATCTGTTGTATGTGTTCTCTGCGACAATAAAAAAGCAGTGTGTGTGTCATGGGTAT
30 GCAAAAGCAGCTGGGCCAAATGTCCTGATCTTTAGCAAGTGA CTCCCAAGAGAA
GGATTCATTCATTCACTCAGCAAATATTTACTGAGCATCTGTTTGTGATCAGAGA
CTGGGAAAGTGTGCGGAACGCCACCACCCACTGACCCAAGAAGTGTCTCTGTAG
GAGGGAGGGGTATGGGTACAGAGAGTGCCCCGGACCCCTTTGGCCCTCACTGTC
ACCCCTTCCTGAATGGCAGGTGATGGATGTCGCCCCGAGGCCACCCGCCGCTTC
35 TTCAACTGGTTTTTACTGGAGCATCAACCTGGGTGCTGTGCTGTGCTGCTGGTGG
TGGCGTTTATTCAGCAGAACATCAGCTTCCTGCTGGGCTACAGCATCCCTGTGGG
CTGTGTGGGCCTGGCATTTTTTCATCTTCTCTTTGCCACCCCGTCTTCATCACCA
AGCCCCCGATGGGCAGCCAAGTGTCTCTATGCTTAAGCTCGCTCTCCAAAACCTG
CTGCCCCCAGCTGTGGCAACGACACTCGGCCAGGTAAGGAGGGGCTCTGGGTGC
40 AGGGAGCCTCCAAGCCTGGAGAAGCGCTGGATCGCTCCCGGGGAGGCATGGTCC
AGGTTGCAGACATTCTGGTTCAGCTACAGTGATAGCTTTTTATGATGATCTGCTCT
CCAGTGGGCCAGAGCTGCCCGCTGTGACTGAGGATGGAGGTCAAGGTAGTGGTG
GTAGTGGTGGTGGTATTATTGGTTGCCATCTACGTACAGAATGTGTGAGGATGGG
GCTGGGGGCGGTGGCTATCCCTCTAATTCCAGCACTTTGGGAGGCTGAAGCTGGT
45 GGCTTGCTTGAGCCTGGGAGTTCGAGACCAGCCTGGGCAACATGGTGAAACCTC
ATCTCTACAAAAAATAAAAAATTAAGTGGGGTGTGGTGGCCTGTGCCTGTGGTC
TCAGCTACTTGGGAGGCTGACATAGAAGGATCAATCGAGTCCAGGAGGTTGAGG
CTGGAGTGAGCCATGATGGTGCCACTGCACTCCAGCCTGGGTGACAGAACAGGA
AAAAAATAAAAAAAGAAAAATGAAAAAAAGGAAGTGTGAGGATGATCAGGGT

CTTGACAGTGAAGATGGTAGTAAGGATAAGGATGATGGTGGTGGTATCTACACT
GAAGACACAAACATTGGCAATGCGGAAGACAGTGGCATTAAAGGAGAGGATGA
TGGGGATGATGTTTCCAATGAAGGCTGTTAGGATACAATGTAAATAATTCCACAT
TACCTGTTACTAACCATCACAGCGTCTTAGGAAATCGGCCAAACTCGCTCCCTC
5 CTCATTAGCTGACATCCAAAGGAGGAAGGTTCTGAATGACCTTGCATAGGTCCCA
TGGCTTCCTTTTGGCCCTCGCCTTCTAAATTAAGTGTCTACTTATGCCAAGCAAA
TCTGTCTCCAGACCTTGCAGCCAGTTACAGCTCTTGTCAATAGGATCTAAATGAA
AAAGGTGAAGAACATGCTTTCCCCAGTCTGGCATATTGCTAGAGGTTTGTAAAGTT
GTCAGGAGCCGAGAAAGTGTGGTGGTTTTATTATCTATCGCTGCCTAACAAACCA
10 CACCAGAGCTTAGTGATTTAAATGACCTTTTTATCTCCTCTCCCAGTTCTGAGTGA
CTGGGCTCAGTCGGGGCGTTCTGCTTCTCGTGATGGCACTGGGGTTGCAGTCATT
TGGGACCTGGAAAGGGCTAGAACTTCTGAGTCTGCTCACTTACATGGCTGGCAGT
CAATGTGGGCTGTTGGCTGTGAGCTCAGATGGGACTGTGTGGACCAGAGCACCTT
GGTTCCCATTCGTGTGGTCTTACCATGTGGCTTGAACCTTCTCACAGCGTCTGATGA
15 GGGTTCCAAGAGGAGGGAGCTTTCCAAGAATGAATGTTCCGGGGAGGAAGAAAG
CAGAAAGTTATGGGTCTTCTTAAGGTCCTTAAGAGGCGTTGAAGTCCCAGACCACC
ACTTCTGCTTCATTCTAACAGGTCAAAGCTGTCACAAGGCCAGCAGGGAAACAAT
GGCAGTGAAAGTAACTCCACCTGTTGGTGGCAAAATGGCAGCACACGCTGGGA
AGGGTGGAGTTGACAGTGGCTGTCTTTGGAGATGACTACACTAATATTGTCCCTT
20 TTGGAATCTCAAAGGACAGTGCAAGGCTCTTGGACAAAAAGAGGTCAGAAAGCT
CTCAGGACAAAGGGCAAAGGGCAAAGGGTAAAGGCTGCAGCAGTGATTGATCA
ATCTTGTGCCTACTGATATTCCTCTACCCCCACCTCTCCACTCTCTATGCCTTGT
CATGGAGGGAGAGGGTTGCCATGTTGACTGTTGAGGAGGATGGACTTGAGACAG
CAAGGGGGGGGAATTTTGGTGTATCAAATCTGTGACAGCGTCTCTCTCTGAGTCA
25 GGCTTGGACTGGGACTCCCCTGGTTCCCGTGGCAAATTGATGCTACGAGCCAAAA
AATCCCTTCAGACTGTTTTCCACAGTCTCTGGTCTTACTTCCCTCAGGACTCAGAG
GGGCCACAGCTCTAGAGCGGAATGAGTCTTGGCTAGGCACTTTTGCAGCAAAAG
AGAGGATAGAATAATATTGGCAGTAGTGGTGGCAACATTGAAAAAGAGTGATGG
TGATGTGAATGGAACTCCGTGGAGAGGACGATTTTGCTGACAGCAGTCACCTTA
30 CTAAAGGTGATGATAGTAAGGATGCTGGCCTTGGCGATGGTGGTGATGATGGCG
AAGGTGGTGCTAACAGCGGGGTGGAGGAGATGAGGGTACTGATTTTCAGAGACGT
GCTGATACTGGGAGGAGGATTAATTAAGGGGTGATGGTAGAAGTGAAAACGTT
GGCTGAGGTGGTGGGGAAGATTATGGCTGCTGCGTTTGTGTTGCTTGTGTTTTT
GAGAGGGAGTCTGGCTCTGTTTCCCAAGCTGGAGTGCAGTGGCACAGTCTTGGCT
35 CACTGCAACATCCGTCTCCAGGTTCAAGCAATTCTCCTGTCTCAGCCTCCCAA
TAACTGGGACTACAGGTGCACGCCAAAACAGCCTGGCTAATTTTTGTATTTTAG
TAGGGACGGAGTTTCATCATCTTGGCCAGGCTGGTCTTGAACCTCTGACCTCAGG
TGATCCACCCGCTCAGCCTCCCAAAGTGCTGGGATTACAGGCATAAGCCACCAA
GCCCAGCCTTGACTGTTGTTTTATCTGCTGCCTCTGGGGTCTCACAGAGACCGTCA
40 ATGTGCCCGCGTGCTGGCCGACGAGAGGTCTCCCCAGCCAGGGGCTTCCCCGCA
AGAGGACATCGCCAACTTCCAGGTGCTGGTGAAGATCTTGCCCGTCATGGTGACC
CTGGTGCCCTACTGGATGGTCTACTTCCAGGTGAGCATACCTGCCCTTTTTCTCTG
GGGGCCTGGCTCCCCACTACCATCTGAATGGCCTCATTCTCATCACAGAGGCC
CAGGGCATGTGGAAAGGGGGAAAGTCTGGGAATAAAGTGAGGTGCTGCCCCGTA
45 CCAGCTAGCATGGGGCCTGGCACAAAGCCGTCTCAGCAATCCGACTCCCTCGGTG
GTACGGCAAGAGGAACTCTGGAGACAGCTTCCTCCTGCTATACCTCCTGCGGGAG
TTGAATTACTGGGATGGCTTTGTGCCAGGCTAGGTCCTTGAATAAGTCACCTCAT
CTCTCTGGGCCTGTTTCTCATGTGTACAATGGGTGGCTTAAACGAGAGGGCTTTTC
CAGCTCTGCTGCATTGAGATTGTCCGACTTGGTAGCTGAGGCCTAGAGAGGGTGT

GTCAGTTGCCCAAGGCCCCACGGCAGGCAGGTCAGGGGCAAGCTCACAAAAGTG
AGTACTTTGCAACAGTGGTTCCCCAGCCTGGCTGTGCTTCAGAATCACCGGCAGA
GCTTTTAAAAATATGCTGTTTTAAAAACAGATTCCAAGTCCAACCACAGGCTATT
GAATCAGAATTGCTGGGGAAGTTTCTAGTTTAAAGAACTTTTCAGATGATACAGA
5 TACTCAGAGTTGAGAACTATTGTCTTCCACTCACCATATTACTCCTCAGTGGGGA
GGTTAGTGATGTGTTTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGATAGGA
GGGTGGGCAGCAGCTTAATGCTAGCCCCAGGCCATAAGGTCATTGCCTTCCATA
CCCCCTTCACAGGAACATTTGTTGGAGCTCCCAGCCTGCTACTTAGGGGCACACA
GTATTTCTATGATGAGATGGCGGCATGTGGTGGGAGGGTGTCCATGGCTGATTCT
10 CAGTCATACCAATCAGATACTGACTTCCTTCCATACCAGTTGGTAAATGGCTGCT
GCCCTGAGCAGTCCACATGCTCTCCCCTGCCCCAGCCCTTCCTGTGGGAGTCTCCT
GGATCCTACTCCATTATATAGCAACTAAAGGGGCAGTGCGTGGTATTGGAGGTG
GCCCCGGGGCCCTGCTCCTGCAGCTGTGTCCAGAGCCATTCTGGCAAGTCCATGT
CTATGCAGTGCTTGTGTCAACCTGTGGACTCAGCTTGGCTTCAGTGTGATGAG
15 AACTCCCTGTGGGGGCAGCCATTATCTTTCCCATTTTCAGCAAACATTTATCCATGC
TTACCCTGTGCTGGGGCCCTGGGGACACAAATACTAGTCAGACCAGCTGTGCCTGG
GCTCTGGGATAAGGCTGCACGCACTGCCTACAGGCCTGAGAGCAGAGCACAGGA
AGCTCCCTGCCCAGCCCAGCTACCTAGGAGAAAGGAGGGTGGGAAGGTGACTAT
CTCCCTGAGACTGGGAGAGGGGACAGCTGCCAGCTGTCTGTGGTACGGCGCT
20 GAGGAATGCCACCTAGGAGTTGGGAGGGGGCATGGCCGTTTCTGTTCCAGCCTC
ACCCCTGTCTCTCTTGGCAGATGCAGTCCACCTATGTCCTGCAGGGTCTTCACCTC
CACATCCCAAACATTTTCCCAGCCAACCCGGCCAACATCTCTGTGGCCCTGAGAG
CCCAGGGCAGCAGCTACACGGTGAGAGATAAAGCATGTGTTTCGGCACCCAGTTC
AGCCAGGTAGCGGCTTCCTCTGAGAAGAGGAGGAAATGAAACTGCCTTCACACT
25 CCCCTTTCTGCTGCAAGGCAACCTCAGGATACAGGAAAAGCACCTGGAGGGT
GGGAGGACTTGTGTCACAGCGCAGGGATCCTGCCAAGATGCTCAACTGCTTGAA
GGAATTCAGGCCAGCTGCACACCCCCATGCTGCTGCTCTGAAGCAGGTCTCGCTG
CCTAATTTGCACCCTCAGATCAAGCATACTTAGGTCCCTTTTCAACTCTTCCTTGT
CCCCTCTTTCTCTGGGACCCTTAGATACCTAGATCTCTGCCTTTCCCAGAACTTTC
30 TAAACCAGTTCCTTGGCATTTCAGACTCATGAAATGAATGATCTGCAGAGCTGGC
AGATATATGAGAAATTTGCCATTGTAGTCCATTTCCTTGCCCATGGCAGACATCA
CTAGTCAATCATGACTTTTTTTTATGCTGAGCCCATAAATGTTCCATAATCAGCCAC
TACCAATTGATAAAAAGTTAGAATACAAGAGGAACCTATTTGCCATCTCTACATAA
TCCCCTGCTGCTTACACAGCTGAGGAGCATGAACTCCAGAGAGGGAAAGGAG
35 CTGGACCCAGGGTCACCCAGGGCCAGTCTAGAGTCCAGGTCTCCTGACTGCAGC
CAGGCTCCTTGCACTCTGCTAGCCTGCCTCTCCTGACTTCCTCCTGCCAGATCCC
GGAAGCCTGGCTCCTCCTGGCCAATGTTGTGGTGGTGTGATTCTGGTCCCTCTG
AAGGACCGCTTGATCGACCCTTTACTGCTGCGGTGCAAGCTGCTTCCCTCTGCTCT
GCAGAAGATGGCGCTGGGGATGTTCTTTGGTTTTTACCTCCGTCATTGTGGCAGGT
40 GTGCAGAGGGGTGTGGGGCAGGGGGCTGAACTTTGGGCTTGGGGAAGTCTGCTT
CCACCATGGGCTGATGCTGAAGTGGTAGCCTGGACCAAGTTCAGCCTCTCCCAGT
GGGCGTCAGTGTTGGCTTCCCAGAGGTGCAAGCTGAAAGAGACCCTCCTATCTAA
TCCAGCTGCCCCCTCATTTTGACAGAAGAAGAACTCAGGCCGAGAGAGGAACAA
ATATTTTCCCCCAGTGAATTATCAGCTCCTTGAAGGCAGAGATAGTTTTTCTTTTT
45 TTATTCAGTGTATGAACATGCACGTGGGCCCTCCATAAATGTGTTGAATGAATT
TTCCACTTAGTGGCAAATGAAGACTTAAAAAAAATTATCTTCCTTCTTCCATTTC
AAAAGGATCTGAAGCCATTTGTTACAAAGTGGGGGTGGTGGGGGCAGTGGGGG
GGATCAGCTAAAGAAGTCTTTCACACTGTTGCACAAACCTGAACCCCTTTTACTT
AGTAACTTTATGACCCTGAAGTTCCTTAGAGTCTCTGAGCTATGTCTTTAAATG

GGGACAGGTGTCATTTCGGACCCTGAGCAGGGCTCTGCCCTTGTGGAACCTCAGTCT
GATGGGGGGTGTGTGAGGATTACAGCAGATGAAGTCTGTAAAGCACTCAGTAG
TGTGCCTGGATCACAAGTATGTGCTGGAGAAATGAAAGCTCCATAAACGGTATT
GTGTTGAAAGTGTGAAAACCCAACTAGATTTTATTCCAGCTATATCCTTAAAGCA
5 GTTTGTCCTATTTTATCCTCACAATAATCCTGGGAATGTTATTCCTGCTTCTTGAG
TAAGGGAACCTGAGTCTAGAGAGGTTAAGTGATTTGCCCAAGGTCACACAGCTAG
CCAGGCTGGGAACCCAGGTCCCCCACTCCATGTCCAATGTTTCATTCCACTAGAG
CACAGCTATCTCCAAGCAACACAGGAGAAGGAGATAACATAGTTAAACTTGAA
AGCCAGGTTAGAAACACTACAGCAATACTTGACGTTGCAGTAGAGAAGTCATGT
10 GATATCATGGAAAGTAGGCCAGCTTTGAAACCAGACATAACCAGAGCTCAAATCC
AGCCCTGACTACTTATCAGCTGTGTGACTGTGGGCTAGTTGCTTAACTTTCTAGTT
AAGCACTTGAAAGTGCTAGTTATTTCACTTTCTTCCGCAGCAAGGATGCATGGTA
AATGCCTAGCACATAACAGGTTCTCCATTAATGAGAGTTGTTAGTGTTATTGAGT
GCAAAACTCAGCTTGGAGCTTCTAGCAGCCAAGACCAAAAGGGAGGAGTTGGTC
15 ACATCTTGGCCCCCTCCTCCACCCCCCAGTCCAGCATTCTTTTCCTTGCCTGCTGC
TCAATCTTTGGCTGCTTCATGAGTACCCCATCCCCACCATGTACAAGCTCTTCTGT
GGGCTAAGCTGCCTGGGGTGGGCTGACTATAATCCCCCTCTGCTCCTCCACCAG
GAGTCCTGGAGATGGAGCGCTTACACTACATCCACCACAACGAGACCGTGTCCC
AGCAGATTGGGGAGGTCCTGTACAACGCGGCACCACTGTCCATCTGGTGGCAGA
20 TCCCTCAGTACCTGCTCATTGGGATCAGTGAGATCTTTGCCAGCATCCCAGGTAC
CCTGGATCCCCCTCCCCCTGCTCCTGCACCAGTGATGGGCTCTGCCCGGTGGCACCT
CAAAGTCAGGTACCCCAGGGATGCAGCCCCCAGGGCCCATCTGCATGGAGGAAG
GCAGTGTTTTCTGACCAGGGCTCATTACCCCAACGGGGGTCTATAATTAGCACCT
GGTTCAAGTCAGCCCCTATGTGACAGGCACTGGGGATTTGGAGGCGAGCAAGAA
25 ACTTCCCACACCAGCTCTCCACGTATTCCCCTGGTGCCAGGTTCTCCACCCTCTGT
GTCTTTGAAGTTGCTGTTCCCTCTACCTTAGACTGAAGGTGAACTCCAATATCCCC
TTCAATTCTGAGCCTAAATACCAAGGTCCTTGGGCAGAAAGGGTCTCCTTCCC
GCCCCGTGTTTCATCTCTCTATCATAGCACACAGTACTCTGGGTCATAGTAATGGA
TTTCTATGTCCTTCGCTCCCCACCCTCCCAACCCCCCTTCCCCGGGCTGGGAGCTAG
30 AGCTGCAAGGCTGGGGCAGGCCCTTCAGTCAGCAAAAAAGCAAGGGCTTCCTCA
GCTGCGGGCCAGGGCTAGGCTGGGTGAGACATAAAGAAAAGACTGACCCTGGG
AGCTCACTCAGATGGGGAGAGAGTCAGGCAAACAGTGAGCCAGTGAGAGTGCTGT
GGAAGTCAGGGCAGAGTGCACTGGGAGCCCTTAAGCATGGAGAGGAGGCGGGC
AGGTGAGTGGGTAGGAGGAGCGGTCTTACAGGCAGAGGGAACAGCATAAGCAA
35 AGACCCAAGCCTTTGGGAAGCGTGGGGGATAGGGCTGGAGAGGCATGGGAGGT
GCAGGGAGCCGAAGTGTCGAAGGGCTTTGTGCGCTGAGCCTGCACCTTGGGATTT
CTCCTGAAGGCAACAGCGCCCCCTCCTCTCCAGGGGGTTTTGGCCGGGAAAAGGAC
CCCATCCGAGGTCCTTTAGACTGATGCTCCTGGCTGTGTGAGGAGGACAGGAGTC
AGGGGAGTTTAAGAGGCATTTGCAGAAAGTGACCAGGGCTGGGGTTGGACCCAG
40 GGCAGAGGGAATAGAGAGAAGGACATATATTTAGAATAGATTTAGAGGCTGTA
TCAAAACAATTTGACGATGACGTTGAAGGTGGGCAGAGAGGGTGGGGAGAGAG
AGGAGGTAAAGATGGTGCTGTCACTGAAATGATAGACCTGGCAGGAAGGGGAG
GAGGGGAGACAGAGCTATTGGGGCAGCGCATGGAGTACCCCGGTGCAGGGGTTC
AGCCAGGAGGCAGGTGAGCAGGGCAGAGGGGAAGGCGGCATTGATGCATGGGT
45 GCTGTCAATTGCCACTGAGTGGACAGGCATCCAGGGGAAGCCTGGAGGGTGGCTT
GGTGGGGGCAGGGTCAGGGGCAGCAAGCAGGGGCCTGGGCCTGTTCTCTGCGCC
TGCACCAGCCCCCTGAGATCGTCTCTGCTCCCCCTCTGCAGGCCTGGAGTTTGCCT
ACTCAGAGGCCCCGCGCTCCATGCAGGGCGCCATCATGGGCATCTTCTTCTGCCT
GTCGGGGGTGGGCTCACTGTTGGGCTCCAGCCTAGTGGCACTGCTGTCTTGGCC

GGGGGCTGGCTGCACTGCCCCAAGGACTTTGGTGAGTATGGGGCCTCCCCAGGA
GTGGGACATGGATGGAGGGAGGCTTGAAAGGAGGTGGCAACTGCTAAAGTGCT
TTGACTCTGGGGAGAAGCAAGTAGAGGGCTAGACTTGGGAGAATGGGGTTCTAG
CCCGGGCTTGGCCAGTCACCCACAGCGTGGCCTCCCTCCTTGGGCCTTTCTTTCCC
5 CAAGTGTTGAACTTAGTGGACCTCCAAGGCTCCTTTCTGCTTCTGGAACCTCTGCC
ATCTCTGGCTGAAGGGTTACCTTTCTCATGGTGTTTATATTTACGCCCCCTTCTG
AATAGCTGAAGAGGAATTGTAGACACCCCTGGAGATCTTCAGGAAGTCAAACAT
TAGTGGGTATCTGTCCAGTGTCTTCAGATCCCACCACTGCCACATGGCCTCAGT
TGCCAGCCCCAGGGCTAGGACACGGCAGGCACAGGGCGCAAGACAGAGGATCC
10 CTGTCCTGACCCAAATCTAACCCCTCCTTTCCCCAGGGAACATCAACAATTGCCG
GATGGACCTCTACTTCTTCTGCTGGCTGGCATTTCAGGCCGTACGGCTCTCCTAT
TTGTCTGGATCGCTGGACGCTATGAGAGGGCGTCCCAGGGCCCAGCCTCCCACAG
CCGTTTCAGCAGGGACAGGGGCTGAACAGGCCCTATTCCAGCCCCCTTGCTTCAC
TCTACCGGACAGACGGCAGCAGTCCCAGCTCTGGTTTCCTTCTCGGTTTATTCTGT
15 TAGAATGAAATGGTTCCCATAAATAAGGGGCATGAGCCCTTCCTCACGACCATG
GTCCATGACAAGGGGCAGGGCAGAGGGGGCCTGGATGGGAGTCCTTGTGGGGGA
CCAGGCAGGGGACTTGGATCAACAAGCACCAGACGAGTGGCGGGGGCAGGCGA
GAGGCTCAGTGGGACCTCCACCCTCGTTGCCCCAGCTGGTGGCTGACCAGGTGGC
TGTGGAGGGTCAGGAGCTGCCCCGGATCCTCTCCATGTAGTTGCGAAGCTCCTCA
20 GGGTCCTTCAGCCCCATGTCCTCACACACCCAGCGGATGTCTCCTCGCCTGCCA
CAAGGATGGACTGCACAGCAGGGGGCCCCTACAGGCTCCTCAGGTGACTGGGCTG
GAGGGGCTGGCGCAAATGTCACAACTCTACTCGCTTCCGCCGCCCCCAGCCTC
CTTTCGGGCCAGGGTGCTTGAGGAGCTGGTGGTGCCCCCAGGAGGGCCAGGGGC
CAGGGTAGGGGCTCCCCCTCCTCCCCACTCTCACAGGGGCAGCTCCCCCTCCCC
25 TTGGGCGGGCCAGGGGACTGCCGGTCCAGCTGGCGGCTCAGTTCCTCCTGGTCAG
TGCCACAGCCAGACCCAGTTGTGGGGCTGGGGGGAGGTGGGGTCAGTGGCACTGT
CGGGAGGTTCTTTGCGCTGATAGCGCAGGACGAAGACCACACCATTGACCAAGA
AGATGAAGATGGCCACGCAGAAGACTCCCAGCAGGGCGTACATGCCCAGCTCTA
GCTCAGTGACATGCTGAGGGGCAGGGACCATCTCCTCCTCCTCTCCTCCTCCTCC
30 TCCCTGGCTTCGGTCTCCTCCTTCTGTCCTCCTCCTCTGCCCGCTCAAACCTGCC
CCTCACACCTGTGTTGCCCCGACACTGCCTGCCACCTGCCGTTTACCACCCATG
GTGGCTTCTGTGGCTGGTGGGCTCCAAGCAGGGCTGGATGGGAGAGCAGGGGCT
GGAGTGGAGGCAGGGGGCAGCCCCAGCCAGGCGGTGCCAGAGGCCAGAGGCAC
ACGGTGGCGGCCCCGGCGGCAGGGCTCGGGCGGGTGCAGAGCCACATGCCAGGG
35 CAGCCCCCTCGGCGCCTGCCCCACTCACCAACACCCCGAGCTGGGCACCCTGCTCC
TCAGCTGGCAGGATGGCACCAGGCTCCTCGGCTGAGACGGACAGTCCCAGGTCA
CGGCGGTCTGATAGCTCAGCTGGGGCCACAGTGTGATCAGAGAAGGACAGCCAT
AGGGAGAGGGCCACCTCCTGTGGGGCACACAGACACAGGCAGAGACATGCGAG
GGCACGCACGCATGCACAGAGAAACCACTCCCACAGAGATAGGCCACATGGAGG
40 AGAGACCAGAGAGAGAAAACAGAGACACAGGCAGATAGACAAAACACAGGGAGA
GAGGGGACGCGTGTCAATCACCTGTCTGCCACTCAGCCCTAGGGTCTGAGTTATT
GGGAGGGTCTCAGTTAGAGCCATCTAACCAACCTCCCCTGCCATACTCCAGCC
ACTGCTTGATCACCTCCAGCTGCAGAGAGCTCACTACCTCACAGAGTCAGTCCTC
ACTCTGAAAACCTAAGGGGTGAGGTACCAGGGTCCCTTCCTCCCATTCCTCCTC
45 TACCATGAGCCCCCATCTGGAGATGTTGACCTCATCCCCCTGACCCCCCACTGT
CACCTGCTTTGGGGCGGGAAGGGCTGACTGTGCCCAGCACGTAGCTGTGACCTCC
CCGGGGTGGGCAGTGCCCCGGCTCAAGGTACGCAGATGCCCATCACTGGCTGC
ACCCTCAGCTCCAGCACTGAGACCTTGTCTGTCCTCACAGCCAGCGCCTGCTCCC
CCAGGATGGAGTCAGACAGTGGGGAACGCACCTGAGGGTGGAAAGGAGCTGGA

GGTGGGGGGCCTTCCATACAGACAGCCCCACCCAGAGGGAACCGGGTGCTCCC
AGCACCCTCACGGGCTGCCCTCCGGAGGTGGGGGAGGTCTTCGCCACGGACAGC
CCCCACCCAGAGGGAACCGGGTACTCCAGCAGGCTCATGGGCTACTATCCCTCT
ACTCTTTGCACCCCGGTGCATACCTGGACCCCAATCCCACACCTAGGGGGCAGTT
5 CCCTTTTCCCTCAAGACCCGGTCCCCACACTACCCACACCTCAGCCCTTCATAGCT
AGAGGGGCTTCCCCCCTTATGCGGCCACCCATTCTGAGCCTATCCCCAATCCCAC
TGCACTCAGACCTAGACCGCACAACCTCCCCACACACTCTGGGCTCCTGGCACAC
TCTTCACTCCCACCCACGAACATTTTGGGGGCCCTCCACCCTTCTCAGGGGGTCT
ACTCTCCTGGTCCCCAGCTGCTTACCTCAATGGAGGTGACACCGGGGCTCCCGGCC
10 CACCACGACACGGCCACCCTCCAGAGAGGCTACACGCGAGTCCAGCACGCGGGC
GTGTGGCGCCACGAGGTGGGACACGTCTAGCAGCCAGTCGGGGCCAAGCAGGTG
CGTGAGGCGGCGGCGCCGTCCAGCGGGTGGGCGCGAAGGGGGCGAGGAAGC
GCACACCGGCCCCGCTGGTACTGCAGGTGGCAGCCACGGGCGCGCCGCTCGGCCT
CATCCGACGCCTCTGCAGCGGGTTCGCGAGGCCTGCAGGGCGGGGAGGCCGGGA
15 CTGGCCGTCAGCGCTGAGCGGCCCCAGCCTGCCCAGGGCCCAGCTGCTGGAGAC
CCGAGCTCGTCCCCGGCGGCTCCTAATCACCAGCAGCTCCTGTTTCTCAAACGC
AGACATCCGCCCCCTCTTGGGGTCAGGGCCCTTCCACCTGCAGGCGAGCCGCCCCAG
CCCACTCCCGACTGGCGCTGTGCCTCGATCACCGCTCTTGCTCCCAAGTGGACCG
CAGGGGAGACGCTCTCTTACGGGGACCCTGGGGGCGCTCACTCTCTGAAGGGCC
20 TGGAAGCTAGATTCCAGAGGCGTGGGCCACCTCTCCCTGGGTTTTGGGGAGCCCC
CTCCGAGGGTGTTCATTTCTGAGCTCTGTGTCATCTTAGGCTCTGAGGGTACGA
CCAGCATAGACAGACCGCAGCTTCAAGGGGCTGACATTCTCGGGGGAGGAGCGT
GGAAAGGATGGACAGGCAACATTAACCAGTACTGACGTAGATTAGGAAGTGGAG
GGTGCTACGGGAGAAGTGAGGCAGGGAAGGAGGAGAGGGATGCGGAAGTCAGC
25 AATTTACAGAAAGCGATCATTGGCTGGGCGGCCAGGGTGGAGGTGGGCAGAA
GGAAGTGAAGCAACAGGGCAGTTTTTCTGACCCCGACTTGGGCCCATGGCTGTG
TCCCCTGCGCCCTCTCCGTCCAGTGTGACTCGCCAAGGCCTGCCAGCTTCCTCA
GGCCTCCACTACCCCTCAGCAGGGCCAGGTACCCTCCAGCCGCGGACCTGCTCG
AGGGTGGTGTGCGGTGAGCTCGATACGCAGCGGTAGCAGGGGGGGCCACACGGTC
30 AGCCGCAGCGAGGCGCGGAGCCGGCGCCACCAGAAGTCCACTCGCACCCCCCGG
GCGCCCCGGCTCTCCTTGCCAGCCACGAACACGGCATCACAGGCCTCAGACACCT
ATGGAAGGGCAGAGGGCAGGTGGGCGGGCTAAGCCACTAAAGACAGGTGTGAG
GCTGGGCGGGTGGGTGGCTCATGCCTGTAGTCCCAGCACTCTGAGAGGCCGAG
GTGGGTGGATCGCTTGAGTCCAGGAGTTTGAAGACCACTTGGGCAACATGGCAA
35 AACTCCCTCTCTACAAAAAATAACAATAAATCAGCCGGGTGTGGTGGCACATGCCT
GTAGTCCTAGCTACTGGGGAGGCTGAGGTGGGAGGATCCCTTGAGCCTGGGTAG
CTGAGACTGCAGTGAGCCGGACTGTACCATTGCACTCCAGCCTGGGGACAGAGT
GAGACTCTGTTTCAAAATAAATAGATTAAAAAAGGCATGGGCCAGA
AGAGAGCAGCCCTGACCTCAGGCCGTAGGACGGGCTCCCACTGAGTTCAGCTCT
40 GTGTGTCACTGGAATGCATGTTGCAGCAGGATTGTTGGTTAAGCCCCTGTTCTTT
GTTTAAGATTTTACTGTAGGGGCCATTCCCTTGAGGTTCCCTGGGGCTCAGTCAGG
GGAAGTGGCCATTGCATACCAGTCTTCCTCCTGGCAGAGCAGGGGTGTGAACCCA
AACTTTGGCTCCTTATTCATGCTGGCCTTTGACATTGCTCTTGGAGCCACCTGGC
AACCAGCTACAGCCAGGTAGGCAGAGGTGGGACAAAGCAGATCTCCACCAAGG
45 CCCTCCAGCAGGAACACACACATTTGAGCAAAGGACCACAAGTGGGGAAAGGC
ACCTTCCCCCTTCAGGTGGCTGGGATTTGCATACATGCAGACTCCATGCTTCCCT
CTTAGAACTTCAAGATAGAGGAAGTTGCTCTACCACCCTCCCTTTTATTTCATTC
ACAATCACCGGTAATAATAATAATAAATTTTACCATTGTATAATTATTACAT
CATATTATAACAGCAATAACTGCCATTGTTTCAGCCCCTGCTATCTGCTAAATACT

GTCTTAAAGTGCTTTTAAATTCTTACAACAACCCGAAGATATGTTCTCATTTTAAAG
TTTAGGTAACGAGGCTCAGAGAGGTTAAGAGACCAGCCCATGATCACAAAGCTG
GTTGACAACAAAGATGTGTTTCAAACCTAAACTTTCTGATCCCAGAGTATGTGCT
CTCGACTCTCTCAGGCCAGCGCACTTGCCAGTGCAATAATGAGCGTGAAAGTGTC
5 TAAGGTCGGGGGGGCTGTTAGGGTTACTTGACTCGGGAGAGAGGTTGGCTGGAACA
AAAGAAGTTGAAGCTGTGGTTCCCTCCCATGAGGTTTCTCGTCTCAAGAAGAAGCT
GTTCTCTTGGGGACCCACATGAGGAAGGAGGAAAGGTGTGTGTGCGTAACTGTG
CCACACAAATGCAGACTCACATGAGCTGGGCACCTGCCACTCACCTGCAGGAC
CTGTGTGTTGGCAGACTCGCAGCCGACATGCTCTGTACCTCCACCAAGGCCCCC
10 CCGCCGTCCACAGTGACAAGGCGCACGGGGACATGCTGGGGCACTCCAGTCAGT
GGTGCTGTATTACCAGCTCCTCAGCCTGGGGGTGGAGGAGGGGCTCAGCCCCA
GGCCCCCTCAGCTCATGGGGCTCCTGGGACTTGCCCTCCAGCCTTCCCAGGCAGAG
ATGGAGGTCTCCTTACCTTGGCCAGTGGGATAAGGGCTCTGATGTCCCGCTCAGA
CACCAGGATTTCCCACACCATTTTGTCTTCTCTGCTTCAGGGGCCTGGCCTGGGT
15 ACTCCAGCTGCCACGTGACGGGGCGAGTGACCGCTACGCCCCCACCAGTGCTATT
CTCCACCACAAAGTCCACCCATAGGAACCTCAGACAGTTCAAGGGGACTGCTGGC
CAAAGGAGACAGAGAAGCCAAATGCTTGCTAGCTGCCAGGCATGGCCTCAGCAC
TTCCTGCATTTCATGATTATCCCCATTTTACACAGGAGGAAACTGAGGCACAGAGG
TTACATAGCTCACTTAAGACCACACAGCAAAAAGTAGCGGGGCTGGGATCTAAA
20 CCCAAGCATCCTCGCTCTAGACCCCAAACCTCTGACCCACTCTTGGCCTCTCTAAG
ATCCATGAAGCCATTTAACCACTCCACCTGGCAAGGTGGCTCACTCCCCTGCC
TGCCCCGGGGCCGCTTCCCCCAGACTTCCGCTTTCCACAGCCACTGAGGTGGCATG
CGGGAGATTCACTTCCAGGTCCCAGGACCAGACACTTGACCCTCTGAATGATAAG
CTTCCTTTGATCAAACAAAAACCTATGTGCTGGGAACCGTCCTGGGTGCCTGATA
25 TGTAGCACTGTATTTTATTTTCAAAAATGCTAAGGGATGCATTATTATTCCTATTT
CACAAGTGAAGAACTGAGGCTTGGGTAGGGGAATGTAACTGGCTTGCCCAAG
GTTTTGCCCATCCCAAAAGCATCAGAACCAGAATTCGAACTGGGGCTACTGAGTC
CATGGCCTTGACCCAGGCTCAGGGCATGAATAAGAAGAGTTACAACCCGCAGAA
CTGCAGCTGGGCTTTTGGGGGAATGTGAACGGCCCAGAGAAAGGATCATTTGG
30 TGGAAGCAGGGGGATGGAGTAGTGGCTATGAGGGCTCTACCTGGGGCACAGGAT
TGGTTGGCATCTCTTAGAATAAGACTCACAGACACTTGCTATGCCTGGCACATGG
CTGGGGCTGGGAAGATAGTGGCCGAATGAATGAATGAAGGAATGGATTATGCCT
GCTTTGTGCTGCTTCCCTGAAAAAATCTGTCTTGGGTCTGCTCACCTGGGGATCT
AGAGGCAGCATGGGAGCTCCCAATCTGCTCAACTGCACTCTATAACCAGCCCTC
35 CCTCCTTTGCCCCCTGGGTGGAGGGAAACTGCCACCTGGAATCTGGCTCTGTGA
GCCCAGCACGGTGGCAGGTGATGAGGGTGGTGTGGTGCCTGGAGCCCTTGAAGC
GGTCCAGCTTGGCAGTCCAGAGTGTGGGCTGGGCTGGGCGGGCGGCTGTCACAT
GCAGCCCCTTCTTCACCTTGATCCTGGGGAAGAGAGTATAGGCTCAGTTTGGCAA
GGTGCATGCTGAACTGTGGGCTGGATTGAAGGGGAAAGACAAGGAGCCAAAGCC
40 ATCTGACCTCCCTGGCTCCAGTCTGAATCTCCTCTTCACCATCCTCCAACCCAGAA
GGACCCCGCCTCAGTGCAGCTCACACCTTACAGCTCTCCCCCACCCTAAAGACCAC
TTACGCCTCCCCACTGCCATAAGGTCAAAGCTTAGCCGGGCATTTGGGGGCCCT
CCAGGGTCTGGTCCAGCCTTAACTTCGGTTGTGACATCTCTCCATGCACTCTCTGC
TTCAGCTACACACAAGTTTCCACACACACGGCACCCATTCTGTGACTCCAAGCCT
45 TTGCCCAGTCTGTGCCTTCAGCCTGCTCTGCCCTTTCTTACTTTACCTGCTGATGCT
TTAAGCCTCCAACAACCTCACAGACCATTTCTTTAGAAAGCTTTTCCAGTGGTGG
GATGAATTTCCCCCTTACTGCACCCACTCACCTGAGCTCCCACCGCACTTTGAAC
CTCCCTCAGTGCTTACACACCCACATGCCTTCTAATCCAATTCATGCCCATCCAGC
TCCCTTCCCTACCACTGGGGGCCCTTTCTGCCAGATAGGGACTGGCCCTTGCTC

GTGTTTGGATCTGCAGAGTGAAGACACAGGGCTTGGCAGGCTGTAAGTGTCTAG
GAAAGATCTGCTTAATAAGAGTGAGCATAGGAGGGCGTAGGAGATGGGGAGAC
ACAGAGACGGGACATGCACAAACCCAGGCAGGGCTTGAACTAGGTCTAGGTTT
CAAAGCATGTCCACAGACCGCTCTTCGATCCTCAGGAAAGATATCATTACAAAGT
5 GAGCAAGTCCCAGTGCCTCACCTAACCAAGCCCAGGACTATCCTGCCTAGAACT
CAGGCTTCTCAGAATCTTAAAGCCTAAGAGATGCCTCTCCCATGGATTCTTGC
TGGACTCCAGAAGCAAGTCATACTCTGCAAGCCCTTGCCGGGTGAACTGGGTAG
GTGGGTGGGGGCTGCTTTGGGGAACTTATTACGGAAAAGGACACAAAGAATCA
GGGCCTTCCTATGGGGAAGAGCAAGCTCTGTCCAAAGGCTAGACTCCTACGGCG
10 AGGGTGGCAAGGAGGGACAGCATGTAGGTGAACGTGATTGGGGCAAATATCCCT
CTCTGGAGCACTGGAGCAAGAGCTCACACTTAGGTACTGCAGTCTCTAAGCCCTT
TGCGGGTTCCCTCCCTGGAGACTTGACAGCTGCCCTGAAGGTGGACCGTTAGCCC
CATTGGACAAAGGAATCTCAGGGAGGTGCCAGGGGAAGGGGCAGCTTCCTACTT
CTGACTCTAATTCCAGGGCTGTGCCCATGGTGGGCTCCTACCAGCACAGTCATGG
15 CTTTTTACCTGGAAGGAGTTTAGTTTGGTGGACACATGTTTTGCAGAGGTCAAGG
ATCCAGCAAGGACCCAGGAGGAGCAGGTACCTGTCCCTAGTCTTCCCACAGA
GGTCCCACCCTCACCCATCCCCGTGGCCTGGTGCTACCGCAGGGTCAGGAGGC
TGGCTGTGAAGTTGTGCCGAAGCAGGAGGGTAGCACTAAAGAGCTGGCCGGGCC
GCACTGGCATGTCAGGCACCCGCAGAGTCACAGCCTCGTCCAGAGGTACCTCCTG
20 GTACTGCGGGGGGTCTGCTGGGCGCAGCTCCACACCCCCCACTGGGAGGGCCTG
CTCCCCAGGGTCGTTCTCCTCGCCGGAGCCACAGCCCCCAGGGCCCTCAGCTGCA
GGCTCAAGCGTGTAGGCCAGCTCGGCCCGTGTGGTGGAGGCCTGTGAGAACCAG
TGCGAGGGAAGCTCCAGCTCCACCACGCAGGCGCCAGGGATGGCTGTGAAGAC
ACGACAGCAGTAATTGGCATGGGGGTGGGTGCAGGGCGAGGAACAGGATTCTCA
25 GCACCCATGGCAGGAAACCCAGAGCTGGAGGGGCTCATGAAAGGGAGGCCAG
CATGGGCCGGAGACACAGCCTGAGTGACACAGCAAACCAGCAACCTGGCTGGGG
CTTCAAACCAGGTCTAGGTTTCAGAGCATGTCCGCAGACCACTCTTCAGCCCTTG
GGATAGGTCTCATTACAAAGTAAGCCAATCCCAGGGCCTTACCCTAACCAAGCCC
AGGACTATCCTGCCTAGAATCCAGTCTTCTTCTCAGAATCCTAAAGCTCAAGAGA
30 CGCCTCTCCCATGGATTCTGTGCTAGACTCCAAAATAGTGGAATAGCAATTAT
AAAAGTAACACTACTAATAATGCAAACACACTGGCTGATTGATTACTCTGCCGTA
AGCTATCCTTACATTCATCTCACTTGTTCTTACTCCAACTCCAGATGGGGTAGGA
ATTCTTAACACCCCATTTCTTCAGATGAGGAACTGAATCTCAGAGAGATTAAGTT
ACTTACTCAAAAGTCACACACCAAGGACTGAACTCCCTCTGGGGCCCTAAATAACC
35 TTTTCACAGCACTGAAAGCTAGTGGGGGCAGAAATGGAGTCGGGTGGTCCACAA
CCCCCGCGCTTCCCAGGAGTGGGGGTTTCTCTCTGCCGCGGGGCCACACCTGG
CTGATGCAGCTGCAGCAGGACCAGCCTAGGTGGGGCCTGTCTACTCACCTGGAA
GCGGCAGGCTTGGTGAGCAGTGCCGGCAGGGTGTGTGGCATGGAGCCGGGCACA
GGGCAGGCTGCCAGACCCTGGTGGCCAATCCTGCCCTTTGAGGTGGAAGAGAAC
40 CCGGGCGTAGGGCTCTGCTGGAGTCACAGCCGCTTCCACTGAAACGGCCCCGCAC
GTCCCATGGGACTGGCCGTTGGTGGGGCTCAGTGACTCGAGGGGGGACCACCTG
GAGGGAGAATGAGAGGGGCTTAACAAAAGAGGAGCTTGGGAGGGGAAGATCTAG
GAAGATGGGATCCCAGCTTGGCAGAAGAGAACCTTTATGGGCCTCAGTTTCCCCC
TCTGGAATATGGGGAGCACAGCCGGGGCTGGGGAAGGCTCCCAATTTGTACCCA
45 GCAGACCTCAGGCCCTGAGTCCTGTTAGCCTGAGAGTCCCCGGTGCCCCCTCCTT
ACCTGCTGAGTGGCAAAAGGTGGGTAGGAGGCCCGGAGAAAGTGGCTGGGCCCTG
GGCCAGGGCTGTAGGAGCAGAAAAGGTCTCAGATCGGGAGCTCAGAGAGGAGTTG
GCAGGTGGGTAGTGGCCACCTGCTGCACACGGAAGTGTTACGGGGCGTCTAGG
AGCTCCAGGGCTGCCGGCAGGTAGACAGGGTCCAGGGGAGCCTGGCCACAGTCC

ACTGAAGAGGCATAAGAGGGGAGAGATGATGACAGCTCCAGAGCTGGCAGGGGC
TGACCCGGGTGCCATGCTGGGGCACAGTAGTTGTGGGCAAGGGAGGGAGAAAAG
GGCTGTAAATGTCCCTTCCCCTCTCACCACCATTTACAGATGAGGTCACTGAGG
CTTAAAGAGCCTCACACAGGTAGTATGTAGCAAAGCCAGGATTCGAATCTGAGT
5 CCAGGACTGGATGCTTCCCAGCTATTCCTTCTACTTCCACAGACCTTGGCCTTCT
TCTCGCCAACAGCCTTCTCAATGTCTCCTTTTCCCCAACTCCTGCCCTCCATCTAC
TCGCCTCTGATACCAAGGCACTTCTGGGGTGCAACCGTCGGCAGACTGGGCCAGT
GTAGTAAAATATGGTAATGAAGTGAGCTTTCTCTGCCCTGAATCCTTGGCCAGGC
TCTGCTGGGCATCCACCCCTCCTCCCCCATCATTGCCATGGCAACCTGCACCATCT
10 TTCCAAGCTTGCTCCCTTCTTCCCTGAACCGACTGGTATCGAGTGCAAGTGTGGG
ATGGGCGGGCGCGGAAGGTGCTGAAGAGGTCTGTGAAGGCACTTGCTTGCCCTG
GGGGTGGGGTGGGGACCAGGAGCCTGGGGGAAGACAGTCAAAATAGTCAATCATC
AGAAGGACAAAGGAGCACTAAGCCATATTGGTTTGCTCTAACTATGAGCACTAA
TAATAATAATTAGCATTTTGTGAATGCTATATGCAGGTGAGAATTTAAATACTGT
15 ATGTATATGAACTCTTTGAGTCTTTGTAATAATTCTGTGAACCAGGTTCTATTATG
ATGAATCCCATTTTGTGGATGTAGAAAATGAGGCCGAGAGGTTAAGGTATTTGCC
TGTGGTTCCACAGCTGGAGAGTGAAGGAGCTGGGGGTTGATCCCAGGTATTAGC
CACTAGACCATCCGGCGTCTCCACCTGCCACTTCTCTCTCCACTCTCCACTGCCAC
GGTGCACCCTGCAGGCTTCATGCCCTGGAGCGCACCTCCTCTCCTCTGCTCTGCCC
20 GGTGGCACCTCCCTCCTCATTCAGGGCCATGAGTGAATACTGCCTCCTTCTGAAG
GAAGCCCTCCTTGTTACTCACCTTCCCACCAGTCTCCTGTCTTTTGCAACCCTGG
GTGCCTCCTCTGAATTAGTAATCTTCCTATAAACAAGGGACCCTGTCTTGCTCATC
CTGGAATTCCCCCAAAGTAGGAAGCGCTCCCTAGAGAGGATTTCTTGGGAGCCTG
GAGACCTGAATTTAAATTGATGAACTTGGGTCAGGCATTAAACATTTTGAAGCCT
25 GTTTCCTCACTTGTAAGAGGGGCAGGAGCATTAGGTGGCACTGTGGACAGGACA
GGGCTGTGTAAGTGTGGAGTGCTGTCTGGAGGGAGCAGGCATTATTGCTGCTGC
ATAATGGATTGACAAGGTTTTCTCCTCTCTCTATTAGGACTCCCATGGCGTCCC
TCGGGATGGGGAGCAGGTGGCTGAAAGCAACCCACAGCTAGCTCCCTCTCAGC
CCCACAGCTGGACTGTGGGTGGGGGTGGGGGAATTGGTTTCAACCTCCTTCTG
30 CCCTCCCCACCAAGGAGCATATGACTGACAGGCTCTCCCTGCCCCCTGCCCCAAG
CGTAACAAGTGACCACTGCTCTCTGGGGGCAGCCACTGGCTTCAGGTTGCGCTCC
TACTCCATTGCCTCCATAATTACAAGATGCTCTTAGCCTGACTCCACGGACTCCC
ATCACCCAGCGCTCGGCTCTCTCGGTGGGGAGGGCAGAGAATGTTTCACTGTCCC
TCTGTCTTCTGTGGCATCCTTTGCCTTGACGCCACAGCCAGCTAGCCAGGCCA
35 AGGGAGTCCGACCCCCACCCCGAAGCACAGGGAAGTTGCTGCCCTTTCCCGCAG
TGACAGGAATCCTCTCAAAGGTTCTGGAAGGCAAGGATGCGGCCATCCCTGGAG
ACGCCAAGGTCAGGGAGCCCTGGGGGAAGGGGGAGGGAGGGCTTGCGTCTGTTG
CAGGTCCCAGGCAAAGGGGCTGCTTTCCACTCCCGAGGGGGGTGGGTGGTGGC
GGCGGAAGGAGGCTAGGAGGGTGCAGCGCTACAGACCACAGTGAGGGAGTGGG
40 GATGACGCTAGTGCGCCCCGGGACCGGGGCCGCGGGTTCGATGCCCCGGGCTGAG
GGGTCCCTCGCAGAAGGTGCGGGACGGGGAAGCCCTGCGCCGGGCTGCCCCGG
GTCAGGAAGGAGTTGCCGGGTGCTGCAAGGTGAAGGAAGCCTTAGGGGCGAGTG
GCTGGGGGCAGGTTCCCGAGGGCAAGAACTCTCCGACCTTCAGGGCGCTGCGGG
GCGACCCCGCTCAGGGTTCAGTCCGAGAACCCAAAGGTTGGTGGCTCCCGGGCA
45 TCACTCGCTCCCACTCGGCCGGGCCCGGCCGCCCTCGCCCCGGCCCTCCCTCC
CGCTGACCTCTCACGACGTCCAGGGCGAGGGCCACCAGGAGGCAGAGCCAGGGG
CCGTAGGGCCCCCGAGGGGCCGCTGTTGTGCGACCGGCCATCCGCGCGCACATC
CTTCCACAGAAGGCGGGGACGAGGCGGGCGGCTCAGGTGGCCCCAGTCCCGCA
CGGCATCTCCCGCACCCGCTCCGCGCCGTCCCCACCTGGCCCCGCTGGGTCCCGGC

112

GCCAGTAGACGACCAGGGCCCCCTGCTCCCCACAGCAGGAAGGTCTGGACCTGGC
CAGGGCTGAGCTTCAGGCCCTGGGCGAGGTAATCACCTGGAAGCCAAGAGAGTC
ACAGAGTCAGCCAACCTGGAGAAGTGGTGAGGGGAGAGCGGGGCAAGAGCTAA
AAGGGTGGGAGGTGCTAGGCACATTGCAAAGGAATAAGCCGTTCTCGCAGACTC
5 AGAGTGATATGGGTTGGAATCTCAGCTCTGTTTCTTGCTGGCTGTGAGGCCTGGA
GTAGATTACTTGCTTCTGTTGAGCTGCAGTTTCATTTACTAAACGGGAACAATTCT
ACTGCCTCCCTGTACTGTGGCTGGCAATTAAATGAGATACTACAGCTCAGCACGA
TGCTTGATAGGAAGTGAACAACTGGCACGTGGTGGCGGAAGTTCTTTTTTAGGGG
GTCTGGGTGGGACAGGGTTTTGCTCCATCGCCGAGGCTGGAGTGCAGTGACGTG
10 ATCCCGGCTCACTGCAACCTCTACCTCCTGGGCTCAAGCGATCCTCCACCTCAG
CTCCCAAGTAGCTGGGACAACAGACACACGCCACCATGCTTGGCTAATTTTTTAT
AGAGACGAGGTCTCATTATATTGCCAGGCTGGTCTCAAACCTTCTGGCCTCAAGT
GACCTCCTGCCTTGACCTCCCAAAGTGCTGGGATTACAGGCGGGAGCCACCACA
CCTGGCCATGGTAGTTCTTGGCTTGCTCTTTGGCCATGTCTCTGCAGAATCCTGGG
15 AAGGGTTAAGCAGCTTGGGGAAAAGGCTAGACCCTGACAAAGATGAACTCCAC
AAGTAGGAAAGTACAGGCAAAGCTCTGGCTGACTACCCAGCACTCGAACACTCA
CCAGCTAGTCCCAAGGCATTGAGCAGCTGTGCGGCGATCCCAGACAGAGCAAAG
AAGGCCACAGAAATGGCTGATGAGATGGCCCAACAACACTTGGGACGAAGACTGT
GGAAAGAGCACGGAGCGAGATGAGTTCATAATGAACAACGGTCTCGCCTTCAC
20 GCCTGATCACCCTGTCCAGGCAAGAACTGCAGGAATGTCTCAGACCTGTTTCTC
ACCCAGTGGTGACAGGCCTGGGTGAGAGGGTAGGGGCCTTGGGCCTGGCTGAGG
GGTCCCTTCCACATCCACCTTCTAGTCTACAGGGATGGCCAACAGGCTGTCTCTC
CTTCTGAACTGGAACTAGGGCATCTGGGACATAATTTAACTGCTTTGCTGGGA
TACTTTGGAGGGAGTAGTAGGTGTACTTGTGTGTGAATGACGGAGACAATCAAA
25 TACTTTTAGTAGTCACCCTATAAACTGGAGGCCTGCTAGCTGTCCAGGGAGTCA
TGAAGGTGCGTGGAGAACATCTGTAAAGGGATAGGATGTTCCAGTGAAAAAGGA
GTCTATCAGCTATACTATATTATGGATTTAATAAATGATTGTCTCAGCCCTTCAGT
CCAGCCTATCAAAAGTATGTGATACCATGCTTGGGATGCCACCAGGTAAAAAAA
GATAACCCTGCCTTAGGCTCCCAATAAGCTCAACCCACTTCTGCAGGTGAAGGAA
30 TGGATTGAGGACTTATGATATTTTGCCATTTGAGATTCTAGGTCAGATTTAGACCA
AAGTGAGACTCTACAGTCACCCAGTAACATGGGCTTATAAAGATGGCTCATTTCC
CAGCCTTTCTGGCAAGGAAAGGGCAGGAGCCAGGAAAGGATAGGGGTGGAGCT
AAAAGGCCCTAGGACAGCAATCAAATAACGAGGAATTCAAAGACAAGTGCTGTG
TGGCTTCTTTTTGTGGAATTTGGGGCTCTGACCAAGGATGTGGAACATAA
35 GATGAGGTGGCCATTACCAACCTTTCTTCTTTATTTTTCCTTAATGTGTGTAGTC
ACACAGGGACTACCTTCCTTACCTCTGACACCAGGTGCATGGTCTCTGGCCCAAT
CCAGGCATCCAGTGTCCCTCGCACAGATCGACCTATCTGGGTCAAGACATCAACT
GGGGCTTCTCTCTTCTGTTGGCCTGGTGGTGCAAAGTCTCGACGGGACTGGGCCA
ATGCTGAGTGGAGGAGGATAAGGGCCACTAGGACCATCAGAATGGCTTTGAACA
40 CATGCTTTCCCATGGTGAAGTATGCTGGAGGCTGCCATGACTGGGTCTGCCAG
GAGAGAAGCACAGTGAGCTGAGTGCCATGGTAGACACACTCACCTCTCAGCTC
TGATTATCCCAACATCCTTCTCCACCCCTACCCAAGCAAGCACCAAATAACCC
TGGAAGAAAGTGCTGTTAGCTGGGAGAGGAAGGACTGGGACTTCCAACCTGAAG
CTGGGCACAACCATCTGACTCACAGGTTCTCTTTTACATTCTTTACCCTTGCAT
45 ATTAATTAACCAGCAAGTATTATTCAACACTTTAGAGTTGGCGAGAAGATCTCTC
TAAGGTTTGTGCCAGTTCTAAAAATCTGAAGGCCTGTCCCTGTATCTTAGGTGCT
ATAGGCATAAAAGTATTATAAGACTCTATAAAGGCTCTGTCCCAAGGAGCTTATA
ATCTACTTAAGATACAGCTGGTATAAAAAACAACCTAAAAATAGCACACAAGTA
GGATTACTGCCATATAATGGTATAAAGAAAAGTGCTCAGTTATGTGCTCAAACAA

GAATAACTGCACATATGTCATCTTCTCTGCAGGACCATCATGTGAGGTGGCTTTT
ATCCTCCTCGCCCCTACTGGTACAGACGAGAAGAACTGTGACTCAGAAGTTAA
GCATTTTCCCATGGTCACTGGGCTACACAGAAAGGCCAGGATTTGAACCCAAGCT
TCTGCTTCCACCCATCTTCATTAGGAGTCAAGTTATACTGTGGGTCTCAACCATGG
5 CTGCTCACTGGAATCACCTGGAAGCTTCCCAAGTACTGATGTCTGTGTCCCCAGC
CCAGAGGTTCTGATATCATTGTCTGGGTGTGGCCTAGCCTTGGATCTGCAAAAGC
TCCCTAGGCAGTTCCACTGCATGAAGTTGAGAACCACTGATACAGAGTGACCTCA
CCTCCCCACCCCAATGGAGGTGCTATGGTTTGAAGAGCAAAACTCATGTTGAAA
TTAACTGTTCTTGCACCTCCTGCAGAGCCTGGGAGCTCCCAGTCCAGCCAAGGA
10 TGTGGATCTCATGGTCCTAAGTACTTCTTTGACACCCCATCCCCCTCAGTAAAAT
AGTTTGACCCCTTCTCCACCAAAAAAAAAAAAAAAAAAGAAAGAAATTTAATTGCCA
TGATGATGGTATTAAAAGGTGGGACCTTAAAGAGGTGATTAGGTTATGAGGGTTC
AGCCCTCATGAATGGATTAATGCCGTTATCTTGGGAGTGGATTAGTTATCCCAGG
AATGCAGCTCCTGATAAAAAGGATGACTTTGGCCTGATTTCTGTCTCTGTCTCAT
15 GTGCTGGGTTCTGCCTTCTGCCATAGGATGACCCTTGCCAGATGCCAGCGCCATG
CCCTTAGACTTCCCAGCCTCTGGAAGTGTGACCCTAATGAATTTCTGTTTATTATA
AACTACGCAGGCAGTGGTATTCTGTTATAGGAAGCAGAAAATGGACGAGGACAG
TGAGCAAGGGTATAATGAACAACCTTTAAAGAAATACTATTAATAAAAAGCTAA
CATTAGCTAGGTCTTGCCATGCACCACCGCGCTCATTAACTGTCACAACAGCC
20 CATCGGGTAGGTGTTGCTATTATCCCCCATTTTACTGAAGTAATTGAGGCAGGTT
AAGTATTAAGTGGGGAAATCAGCATTGGAATGTAGGTACTTCTGACATTGGACCC
CTCATACACAACAACCTCTGCTGTATTGTCTCCAACCTAAGTCTCAGAAGTGATTTA
GAAAGTCATACAGGCCAGGCACAGTGGCTCATTCTGTAAATCCCAACACTTTGGG
AGGCTGAGGTGGGAGGATTGCTTGAGCCCAGGAGTTTGGGAGCAGCCTGGGCAA
25 CATAGGAGACCCTGTCTCTACAAAATAAATAATAAATAAATAGTCAGGTGT
GGTGGTGCGTGCTGTACTCCCAGCTATTTGGGAGGCTGAGGGGGGAGGATCAC
TTGAGCCCAGGAGGTACGGCTGCAGTGAGCTATGATCATGCCACTGTATCCCAT
CCTGGGCAAGAGAGCAAGACGCTTAAAAAAAAAAGTCACACAACAGATTATTCA
TGAGTTAAAATAAACTTGGCATCTACCAATCATCTCAGTGAATTACTGGTGAAAA
30 TTACCTAACAACCTTTGTGCTTTGTGCTCTGGTCTTGTAACACAATGCCACAGACA
AGTTAAGACCCAACAAGTGCCAACTCATTGAAGCAGGTAAGGATCAGCCAAGAA
AAAGTACACAAGTTCAACTTCTACTTGCCACTGTGCTTGAGAAATGTCAGACAGC
GCCAGCAAATTCCTGTTCCTCCAGGTTTCAAGAAATGAACCTGTAGCTCCAGGA
35 GTTTTCATGATTTCACCTGATCATCAGAGGCTAAGCCATGCCCCTGAGGTAGGA
GCAGTCAGGTTTTTGAACTTTTTGCAGTTACACAGGCACTCAGGGAGTTGACAAT
AAATCCAGAGCCATGAGGGATGGAGAAGGAAGAGAATGATGTCCTAGTCTTGCT
TAGGGGGAAGGAGGAGAGTCTAGGAAAGGGTTCTAAAAATACTACATTTAGGGT
ACTTTTTTGGTCCAGAAACAGCTGCTCTAAGCCCTTCCAGAAGCCTGGAGGGTCAA
GCAAGGCTGAAAAACATGCAATTCATGTAGAAGGCCCTCAGGCTGGGAAAGCCT
40 TCTACTGTCTTTGGCACAAATCAAGAACCAGATGGTTCCTGCCTGCCAGTGGTCG
CAGATGAGGAAAGCACAGGTGAGTTCCTGAGCTATCTGGGTCTATAACCATGTTG
GGGACTTAAAAGAGCAGGGTTGCTATCTTGGGTTGGATCCTTTATCCAAGGACCT
CCACCAGGAGGGATCAAATATCGTTTCCTCAGCCCTAGGAGGTCAGGGTGCCAT
AAGCTGCTCCTCCACAGCAGCCTGCCTTGTTCTGTGCCAGCCCCAACTCTCCAG
45 TGGCTGTCTGCCCCAGTTAAGGGGAGCTAGGAGACCTTGAAATAAGCCCTCTGCA
GTGAGGCTGGCATCGTTATGCAGACTGATGTTCTGAAGTGCACCAGATACCAAAC
CTAACAGGATTGTGTAGTGTATCCTTTGGAGATAATGAGTGCAGAGATTGGCTGG
CTGGTCTGCTTTTTCAAATTGTTTTCTTTAATAGGATTCCTTCTCATTTTTTCCAG
GTGAATCTCAGGCAGTATGGACTCACTGCTATTAGGCCTCCTCACTTTGGCCTAA

TCAAATAGTTTTACTAAAGGCATGGAAACAGTCTCAGCCTCTGAGAGGAGGAAG
CATGTCTTAAAACCTTCTTCACCTTCTGCAATGCCTGGCCTCAGACAAATAATAGG
CACTCAATTAACAACCTCATAATAATACAAATGTTATACATATCTATACATATACA
TATGTTATAATAATTTTTGTGTGGTGCTTTATAATTCACAGAGTGCTTATTGTTTC
5 ATCACTTCATTTAACCTCTAACAACAATCTTTTAAGGTATTATTACCCTCTTCATCT
TACTCAGAAAAGTATGGCTTAGAGAGGTTGAGTGACTTATCCAAGATCACACAG
CAGAGCTGGGACTTGACTCCAGTACCCAGGATCTCAATCTTGCCTTTTTGCTTGTC
CCATACCCGCATGCTGCCTTGATAGTGGACATAGTCCCTGCCCTCATGGAGCTGA
AGTTCACCAACAAGCTCAAAGTGGAAGGACATCCAGACTCCTCCGAGGGGAACAC
10 ATACCAGGAGACCATCTGCCTTCTGGGCTTACAGGCCATGGTTTTGTACCAAGAG
GTATGAGAGGACAGCAAAAGGTGGGAGACAAAACCTGCCACTTCTGTTCCGGCAG
CTGCAATATGGCTCAGGTGGGTCTGGAGAGCCCAGCCTGGCTGGGGAAACAGCT
TACTTATTGTGTTAGTGAGAAGGCGCCACTGCTTATGTTTAGCTGTGGTTTGCTA
CAAGGGTAGGATGGGGCATTTCGCGCCCCCCCCCTCCCAATCAAGGCTCCTTCCTC
15 CTCTTCTCTTTCTTTTGTAGTTTCATTTTCATGCTATGAATCACCAGGTGGCAGG
AGGGGCGGCAAAAAGTGCCCTCTACCGGCTCTGACTGTCCCGCCGCTGCTCATAG
CTGCCCTAAGGAGCGGCGGTTCTCAACTTTGGCTGCCCATCGGAAGTGCCTGTG
CAGCCTGTAAACAAGGACGTCTGCCCCACCCAGGGCTACTCACTCAGACTCTTC
CAGAGAGGGACTCAGCCCTTTGTTTTGCAAAGCTCCTCAGGAATTTCCGGATGCAT
20 AGCCAGCAGCTCAGGAAAAGTCTAAGCAAAGCTTCAAAGTGCAGCAGTGTAC
AAAGGACCCCTGACTTCCGTCCCAGGCTCAAGTGTGCCACGGAAGTGAAGCTACT
ACCTTACGCCTGTTACTTAACCTGCCTGAGTTGCAGTCTCCTCAAACGTAAAAGG
GAGTGAACCCAGGTGAAGAGTTGCTGTAAGGAGTTAAGATATTTCTGCAGCAAG
CGCTTTGTAACTAAACATCTATAGAAATGTTGCAGCACACACATTACCACTGAC
25 TATATATCGTAGCATAATTTAGCAGTTTATCAACCTGCCTTCCCCAGTAGACCGA
GCGACTCCCGGTTAGACTTGACATGTTGGAATCCCCAGCGCCTAGTAGGAAAGAT
GACTAATAAATGTTTATTAAATGAATATTAGCAACCTGCCAAGAAACCGTGAGG
GTCGAACGAGAAAGCCATGGAGAGGTGAGGAGGGAGGTTATTTTAATAGTAGAT
CCAAATATACAGCAGCCACACGAGAAGCACAGCTGAGTCTAAAGGAAGGTCTTA
30 AACAAGGCGAAGCCGCCACTGCAGAGAATGAAGTCAGCGCCCTGGCAGGTTGGG
GGCAGCTCCCCTAAACCCCTGACAGCTGCTGCCAGCAACTGTTTGGGGGCAG
GGCGACGGCAAAGGGGGCAGCTTCCCTGCCGCTCCGCGCCCTAACCGGGGCGCAG
CCTCCCGGAGACAGGGTGTGAGTGGCATGTGCTATTTGCAACGGCGCGTCCCCTG
CCAAGCGCTGAGGGGTAGCGTCGCTGGCAAGGAACGTGGCGCGACCCATGAGTT
35 TGGGGCCCCCGAAGGGCTCGAGCCGAGGCTGCAGGAGGCTGGGGCCGTGGGTGCG
GGGTTCCGGGGGCTCGGGCTTGGCGCTGGCCTGGTCCCCACGCCCGGGAGCCGCTC
CACCTCTGCCGGACCTCGGAACCTCGCCGCAACCCTCTTCTCCCCGGAAACGTGC
GCCTCCCGGGTTGCCTGGAAACGACGCCCCCGGTTGCATAGCAACGGGGATCCG
GGTCCCCGGTTTGTTCGACGCTGGGCGCGCGGACCCCTCCCCACTCGGACTCT
40 CCAGGCCTCGCGGCTCCGCCTGGTGCCGCTGCAGCGGCTGCTGTCTCCCCTTCC
CGTGCGCTGCCCCACATTCCGACCTCGGCCGCTCTCACCTTTCTCAGGCCACTGC
TATCCTTCACGTGCGACTTCGCTGAAACGCGCCACCAAACCCGCGCCTCAACTCG
GGGCGCTGGTTTACCTTCTCCGCATGCGCAAGGCGGGATGAGCTCGGAGACTAG
CCGGCCTTCTCACAATCGAAGCCTGTGCCGGGAGCGCATGCGCCCCGCTTTATC
45 TATTGCGTTTCTTTTTCCCCCACAAGCATTCCACCGAGAGAGAAGATGGGATCG
GAAGTTCCAGCAGGGAACGGAAGTCTCTGGCTGGAAAGGGGAAATAAGTGACTA
TATCTGGGCTGTAGAGTGGGTAAACTGGATCTTTGAAATCGGAGTGGAAGCTAAT
CCTCCTCTTGCCACCACTCGGCATTTTGGGTGATGTAGTTCTAGAGCTACAAATGT
TCCCTGGGGCATTGTGGGCAATGTAGTTCTAACCGAGCCGCTAACGAGCACCTAG

TCTTCCCATACTTTTCGCGCTAAAAAGGCACAAAAGAGAAAGATATTAAGG
AGCAATTAAAAGCACACTGCTCTAGGAAAACGAATGCGCTCCCCCAGAGAGAAA
ATTCATACCTGAATACTGTAGACGGCTCCCAAATGTTAGCTCAGAATTTTCAGAGA
AAGAGAGGAACCAACTCTCACTCTCCTTTTCTGCCACAAAGGCAGTGCATAGGG
5 ACAGGAGGCAGATAAATGCTAGGTAGAAAAGAGCGGGTCCCTGGTGAAACCCCA
CCCTCAAGCCAAAAAGCCTGAAACCATGGCCCAAAGTGAGAACTTCTATCCATG
TTTTTCCAGTTGAATGTTGCCTTTTCCTAAGCCACCCATGGCTCTGCCCTGCCTCA
TCCTGTGCCTAGAAAAGACCCCAGACTCATCTGGCAGAGAGGAGAAGCAGCTGGA
TGAGGGGACGACCATGGCTGGATGTCAGAGAGAAGCAGCTTGTCTTCAGAGGGA
10 CAGCTTAAGGCGTAACTTCTGAGACGAATCTGGCTGGAGATAGCTGGACTTCAA
GGGAAGACTACATAACCGCCTGTCCACCCCCCTCTTTTCAGCTCACCTTCCCTCT
GAAATCCACTTTGATCAGCAATAAAATCCCAGGCATTTGTCCTTTAATTTGTTTCGT
GCAGCTTTATTTTTCTTGGACGCTGGACAAGAGCTCGGGAGCCACGAGTGCGGAT
ACAAAAGCTGTCACGCTGGCCCTCTGCCCTTGCTGGTGGAGGGCAACCGCGGGC
15 CCACGGAGCTGTAAACACTTAAGCTGTCCACGGACGACAGAGCCAAAAGAACAC
TGTAACATGCCCTCTGGGGCTTCAGGAGCCTCAGGCACTCTGCCTGGACACTGCC
CCGGGGCCTGCACGGAGTTCGCTCCTGCCGGTGTCCAAAAGCGCACGCTCTGGCT
CCTGCACCCACTCACCTGCACGCTCCCTCCTATGAGGGGTGGAACGCGGTGAATC
TTGAGTGAGTGAGTGATCCCACTGGTGCTGAAAAACGGCTGGCTTGTTCAG
20 CGCTTGTGCACTCCAGTTCCCGCCTTGTTCACTTGCGTACTCCCTCCCATGAGGAG
TTGAGAGCAGCGGGCTGAGTAAACGGGGCACCCCTGTTGTGAGTCTGTGAAAG
GTCAGGGCAATATCCTGCTTCAGCAGCACCGTGAAGGAGAATGAACAGGGCTTC
AGAATGAGGTGATCTCTTGCTGTGATCCTGAGCACACAGCTTCATTTCT
CTGAGCCTTCATTGCTTGACGTTCAAGAACTATAAAGGACCTAAAAATACCACTT
25 CACAGTAGGTGTGAAGTTTCAAGGAAGCAACAAGCATGAACATTAAAAA
AAAAAATCCAGGTTGCTGACTGAATGTTTTATCACCATCAAGAGCTGTCATA
GGAGAGCTTCCTTTTGATGTTAAACCTGTTTCTCAAACCTCAACCCTCTAAACGT
AACTCTTCCCTCCACCCCCAACCATTACAGCCTTCCAGTTCTGCCTTCTCCTAGA
GTACACACTCTGTAGGCTCCCAATCTGTCACCTCACCCAGTTGTTTCTTTCCATCA
30 GATGTTCTCAGACACATCCATCTTCATCTGAGCTCTTGTCACCTCCTGCCCTCA
GCTAAGAGTCCTTCTTCCAGGACAGGCTCTGGTAGCATCCTAAACCTCACCTTCC
AGCTTTTCTAACAGTTTCAATTTTACATTTGCTTGTGCGATCCTTTCTGATGTCTA
AGATTAACAATCTCAGGTACAGACTTTTCTGGGAAAGAAATTTAACCTTTTTTT
TTTCTATGACAAATTAATTTCTTTTCAACTCTCTTTTCCATGTGGGTAGTAGAAA
35 CAGTCTCAGACAGTTTCAGGGTCTTCCCATCCTTGATTTTCAGGTCGTAGACACCT
TTTGGAATAATGAATATAGGGCCAAAGTTGGGGGAGAAAATGTATCTAATCCTGG
CCGGGGGCAATGGCTCACACCTGTAATCCCAGCACTTTGGGAGACTGAGGCAGA
GGGATCACTTGAGGTGAAAGAGTTCAAGTCCAGCCTAGCCAAAATGATGAAACC
CTGTCTCTCTAAAAATACCAAACAAAACCTAGCCAGGTGTGGTGGTGTGTGCTGTA
40 ATCCCTACTCAGGAGGCTGAGGCAGGAGAATCACTTAAATCCAGAAGGCAGAGG
TTGCAGTGAGCCAAGATCACGCCACTGCTCTCCAGCTGGGTGACAGTGAGTGAG
ACTCCATGTAAAAAAGAAAAAAGAAAAATTCATCTAATTATCAGTGTCAGT
TAAGCTGGCAACTTCTCCCTGACTAATCTTCTGTCACTTATCCACACAGATTGCTA
CTGAAGATACCTGGGAAATTAAGCTTCTTTTGGGTCTTTGGCCAATGTGTCCCA
45 TGCTCCCCAGGCAGCAACAGCAGCTTTGGTCTGGGAGCAACAAGGCATAGAGTT
CCTTCTCAGGGACCCACCAGCACCAATGCATATATCTCTTTTCCCTTAACTCTCC
CTGTTTCTCTGAAACCAAGTGCCCTGAATTTTTTCTATTCCCTGTGGGCTGGCTTA
TGAAACGGAAAAGCCTTGACAGGACTTCCTTTTCTGCATCCTGCTATCATAGC
CATAAACTCCCCAGTAGAGGGACACCTCTGGTTTTGCTCATTGTGATACTACCAA

CACCTAGTATCGTGCCGGGCTGACACGCTATGGGTACTCAATAAAGATTGGTTCA
ACAATTAATTACTGAGTCTCCCTCCTTCTAGTCTGTCCCACTCCAACCCATCCAGT
AAGTGTCTTCCAGAGGAACTTCTGAAAGTATGGTTATCACTCCATAGCTCAAAT
GCAAACACATGCTGTTGTGCTGCCAGCCCAATCACCACCAAGTTTTACCACCTT
5 GGGTTCAAGGCCTCTCCTAAACGGATCCATTTTATTTCCAACCACACATCCAAGT
ACAGTAGTTGAGATGACTGGCCTGTCAGGCAACCTGTCTTCCAACCAACAATCAT
CATAAAGTTCCTGCTATGTGCCAGGCACAATGTGGCACTCTTACACTCTTGAGAG
CAAGAGTAACCAGAACAATTATGGTTCCTGCCATCATGAAGTTTACAGTCTAGTG
AAGAACCCAGACATCAGATACTTATAAATAGATAATTAAATGATTACAGTTCCTT
10 GAAGTGGTTTGGAGGACAATCACAGTTTGCTGTATGGACTAAATTTAAACCAGG
GACCATGAAAAGGGCTCCAGAGGAAGTGACATTTAAGGTGAGACTGAAGTTTAC
ATTGGAGGGTTTGAGACAGGAGGGGGAAGAGGGAGGGGGGAGAGGACAGTGAT
CCAGGCAGAAGTTCTGAAACCAGCCAGCGCGGGTATGTTTGAGGAACTGAAAGG
CCAATGTGGCTGGAAAGAAGATAAAGTGAGACTGTGATGGTCAGCATGGGCCAG
15 ATGGTGCAAGACTTACGGGCAAGTTTCCTCAGCCAGAACTCTCTCCCTCATTCA
TGGCCTCAGGAATGACCCCTGGTTGGGGCTCAGAGAATGATACCCCAAAGTATG
GTGCTTTAGTATTGTTTCTGAGCAAATAGGCTCACTGCCTGATGCACATAGAAGC
CAATACTATGGTACCAGCTTTTGAGAACAGAAAGGCTTTATTGCAGGGCCACCCA
GCAAGGAGACTGGAGGCATGGCTCACATCTGTCTCCTAATTTGGGGTCTGGGGCA
20 AGATTTAAGGGGTCAGAGGGTGATATGGTTTGGCTGTGTCCCCACCCAAATCTCA
TCTTGAATTCTCACATGTTGTGGGAGGGACCCAGTGGGAGATAATTGAATCATAG
GGGCAGGTCTTTCTTGCTGTTCTTGATAGTGAATAAGTCTCATGAGGTCTG
ATGGTTTGTGAGAAACAGGAGTTTCCCTGTACAAGCTCTTTGTTTTGCTGCTGCC
ATCCATGTAAGATGTGACTTGCTCCTCCTTGCTTCTGCCATGATTGTGAGGTTTC
25 CCCAGCCACGTGGAAGTGTAAAGTCCAATTAAACCTCTTTTGTAATTGTCCAGTC
TCAGGTATGTCTTTGTGTCAGCAGCGTGAAAACAGACTAATACAGATGGCAAGGAA
ACGTATTAGGAATTTTGGCTTGGCAGGGTCTGATTGGAGGGTGTCAAATTTGACT
ACACGGGTATGTTGAGGTGGATTTTACCCCTGGATCTTTCTGGTCAACAGACCCT
TTGCTCCTGAAAGAGTTCCAGCATTTAGGTTCCGATCATGTCTAGGTCTTCTTGGT
30 ACCACAGGGAGGAATCATTGGTTCTGGGTGTTGTTAGATGTCAAAGCATTTTCTA
TTGGGCATGCCCTACTGACATGACTTGAGGTTTTGGCTCTGTACCTACAAGA
GAACATGACATTCTGTTATCAAAAGAGTAGGCCAGTTTGGATTGGTCCTGAGGT
TACAGCATGCTGAGCACTTTTGAATGAAAAGAAATGGGAAGGTCTTAGAAGCTG
CCTTAGAACCAAGGACTTTCTAACCTTCTCTTCCCCCTGAGCCCCACCCTAAGTA
35 CAGGGAGAAGCTCTCTCTAGAAGTTCCTTATCTGACTGAGAAAATTTCTTTTACG
AAGAAATGCAATTGTCTCAAATCTCCCTCCACAGGAACTCATCAAATAACCAG
GAAAGATTAACCACTGGAGAAGAATAAAACTAAAAGTCACCAACTCACCCTA
CACCTAGAGAGACTTTTAATCTATTCTTCTGATGGGAGCTCTAACAGATTACCTG
AGAGACCTTATGTGCATAATAAGACAACCTTTGTTTACAATGGAGTTCTGCCCT
40 CACCTTCCCACAATTTGTTGCCACCTCCTCCAGAGCTCATAAGAACTTTGTCCCA
GGCATTGTTTGTCTTGGGGCTCATTCAATTTCCCTAAAAAATTATTTGCTAGCCCT
CCCTAAAAAATTATTTGCTAGCCCTCAAAATTGCCTACATTTCCCCCATCTCCGTCT
TTCTGGGTGCCATTTAAGTAAGCATCAGCCACCTGTTTCTTTGAGCCTCATA
TTTTGTATTACTCCTGTGCACACTCACACACTAATACACTTGTATGCCTTTTCTCC
45 TGTTATTCTGTGATTTGTGAGTTAATTTAGAGGGCAGAGGGGA
AACTTTTTTGTCTCCATACCTCATTGAGTTCTCAGCAAAAAAATCAGCTCCTCAGT
GATGCACTCTCTAAGTGCCCTGCCTCAAGTAGCCGTTCTCCAATCCCCAGCACC
TCTGTCTACCTTGCTCTGATTGTTGTATTATAGCACTTACTACTCTGGAATTTTC
TTCTTAAGTGTTGATTGTCTGTGCTCCCACCACCCACAGTAGAGTGTAAGCTCC

AAGACAGCAGAAACTGTGTCTTTCTTGTGACCTTTTCTATCTCCAGTTTTTACAA
TAGGGCTTGGCACATAGGAAGCACCCAATCAATATTTGTTGGATGAATGAAATG
CCTGGGGAATAACATGAATAGATATTTTCGTTCAAAGTGGATCACTGTCTGCTCTG
TGGAAAGTAGATTAGGAGGAGGAGGCCAGGCTGGAAGCAAGGAACAAGTGGGA
5 AGTTACTTTGTTGGTGCAAGACAGAGATGAGATGCCCTTTTGCATATTAACCTCT
CATAAGAGTTCAGTGAGTTAGTTCTACCCTTGTTCATCACTCCCTCTGTTTTACAGA
TGAGGAAACTAAGGCATAGAGAAGTTCATACTGCCAATCACCTGAGTGGTGCTA
GGATTTGAGCACACAGTCTGACTTCAGAGTCCATGCTCTTGGCCACTATGCCATA
TTGCCTTTTGTACCTGTAACTTTTATTTTTCTCTCCAAGCTTTTGCTTACGTTGTTT
10 CTTCTTCCGGAATGCCTTTCGTTCTCCTTCTCCTCTGAATACTGCCACCTGTCAA
AGTCCCTCTCACTCACATCCTGTTTCATCCTGCCCTTTTGTCTTGATACCTTACAGT
CCACACCACGTCTTTTGCATGATTCTGAGAGTATCTTATCTTACAGATATCCACA
AAGAATCATACACTATCTGAGCTGGAAGAGAAATAGAAAATACAAAATCCAAAA
TACAAAATAAAGAAATTTATAGGAGGCCATTGGTTTGGACTGAGCTCTTCTGCTA
15 GGCCTAACAGACCAAGCTAAAAAGAGTTAGTCCTGCTGAAGCTCCACGCCAATA
AGCTGAAACGAAGATCTTTACGACCTTCTGAGTGTGTATGTGTGTGTGTGTGT
GTGTGTGTGTGTGTGTGTGTGTAGGGGGGAGCTAAATTCCCAAACAGGCAAGTTT
TAGGTGGCATGATAAGTCCCCTCCACTTTAACCTTTACAAGAAAAGTAATTTTGA
AATTACCAAATGACCAATCCGCTTTTTGTTCTCTGTTCCCTGTTTTCTCAGTCCCTT
20 TCTGTCTATAAAACCAAGTTCTCCTGTTTCAGCTCATTGGAACAACCATTATATTTT
ATAGTATGAGGCACTGCCCAATTCTATAGAATCGCACCTTAAGTCCCAGCTACTC
CGGAGGCTGAGGCAGAAGGATCACTTGAGGCCAGGAGTCCAGGATGCACCTGT
GATAGCCATGATTGCTATGACCGCACCTGTGAATAGCCACTGCCTTCCAGCCTGG
GCAACATTGCCAGAGTCCGTCTCTTAAGAAAAAATCTTTGAACTAAGTTTG
25 TTGTGATTTTGTCTTTTGACAAAGAAAGAGGGCAATGTGAATTGCCCCAAATCA
CAGAGCGAAATGGTAGTAGTCAGGACCAAAACACTTTCTTAGCCGTTTTCTTAGT
TCTTGTACCCATCTGTTTCTGTATTTTCTTACCAGGCCATCCAGCAGTGTCTCTT
AAAGGGTAGCCCGAGAAACAACCTGACTTAGAAAAGCGTGGGGCACAGTCTGTCT
ACGCAGACCCGAGGAATCTGCATTTTAACAAACTCACTGGGAAATTCTCGCGCAC
30 GCCAAGGTTTCAAAGACCAGGGTCCCGTGGCACAGTGCCGCACAGTTGTCAAAA
CAAGTGCTGTCCAATTGTTTTGGTTTTAAATTCTCACTGCGTCATGGGAAATGTAG
TTTCGAGCCTCCTCTCTCCCGACGCCCCAGCCAATCCTCCGGCGCTTTACGGAAC
GAGCCGAGTCAATCCGGAAATAACCGAGTGTTCTGTCGGCGGGCCCTTTCTGCCCCG
GCTGCATTCTGGGAAAGGGCAATTTCCGTTAGGTGCTGAAGGCTGTGGCGCGCG
35 GCTGTCCCCATTCCACAGTGAAGCGCTACGCTAGCATCGCTCGGCTGGCGGCTCC
CAGCTCGCCGCGGAGCAGTCCCGGCAGCAGCGGGGGACCGGAAGTGGCTCGCGG
AGGCTCAGAAGCTAGTCCCGGAGCCCGGCGTGTGGCGCCTCGGAGCACGGTGAC
GGCGCCATGTCCCTAATCTGCTCCAGTGAGTGTTGGCTGCGGCCAAGCGCGGGTC
TCAGGAGGCCAGAGAGCGGCGCGGGAGCGTGTGCGGTCCGCTGCGGCGCCCGGG
40 CCGGGGTGGAGGCGGGAATGGGGCGCTCCGGAGGCCGAGCGGCGGCCTGTGAGC
ACCGGAGCCCCCCCCGTCGGAGCGGGGTGCATTTGCGCAGTGCCCCGCAAGTTTAC
ATAGTGCCTGAGGTTTATTGTGCGCAGACATTACTGAGGCCGGTCGCCTCATTCTA
CAGAGTGGAACAGGTCTGGACAGAGAGAGCTGGTGCAAGGGAAGCAGCCTTA
ATGTAGGAGTCAGAAAACCTCGAGGTCTTGTCAGGGTCCGCCTCCCATTGGCTTT
45 ATGAATTGGCTCAAGGCTCTGGGCCTCGGTTTCCTCATCTGCAAAATCGAGAGCA
TTGCAGTGGATGTTTTGCGAGGCCTCGCTCGGATAGTCGGAGCTTTTGCAATTTG
CAAAGGTCACATGATGAGTTAGAGGTAGAGGCAAGGCTGGCAGCCAGGTATCTG
GCTCCCAGCCTTACACTGTATGACTAATAAAAACAGCGCACATTTATAAGCCCTT
ATTGTTTTACAACGCGCTTCCAAGTCTATGATCTCATTTTATCCTCACAGAATTC

CCTAAAGGAGAAATAAAGATCCTGGTTTTGCAGATGAGGATGCAAGGCGCAGGA
AGAGCGGGGCTTATCTAAGGATGCGTAGCTAGTCAGTGGCAGAGCTGGGTGACG
TAGTTAGGTGACACGGATCTTGGACCCTGAATCCATGCTTTTTTCATACCTTCCAC
TATCTTTCCCTTTGATATTTTATCATGACGTACAGACATTTTCCTTTCCCTTTTCGT
5 TGTTCATCAGATTACTCGTTTTCCCTCCCTTTTGCTATTCACTTCCTTCTCTCTC
AGAACCTGTACATTGATCCAAAGAGGGGGAAGAAGGAAGGGAAATGATGGAAA
AGGAATCCCTCACTTTGAAGAAATTACAGCTCGCAAAGTACCTTCACATTTATTG
TTTCCTTCCAATCTTCGGGAAGCTCTCTTTACGTTCCCCAGCACCATCCTTCCTG
GCATGGTTCACTCATTTGTTAGATGTTTACCGAGTGCCCTGGGGGCATCTGCATT
10 GTACTGGAAGTGAGAGACCAGCTGTAATCCTTATCCTCAAGGGGTGCACAGTCTA
CGCAGGCAAGAGTGTAATGATACCTCTATTGCGGGTTGTTGTGAAGATGAATTA
CTGTACTGTATGCCTAGAATTGTGCTTGGCACATAGAAATGTGCCATGCAAATGT
GCCATGTAAATATTTTTAAATATTTTTATTGTAGCGATTGCCACTTTGCTCCTTGG
AATCTTCCAGGTGATAAGTGTCTGTACGCTAATCAGTTGACTGGTAGCTGGTAGA
15 CTCAATAGCTTCAGGATGGGGACTGGTCACCTAGGAAGACTAAAGGGTATTAGA
AGGTTGGGATTTTCAGTCCTACCCCCCATTTACCTGGGGAAATGAGAGGAACTGA
AGTCGTCACTAGTGACCAGTGATTTATTGAATCATGCCTTTGTAATGAAGTTTTCA
TAAAAATACAAAAGGACAGGATTCAAAGAGCTTCTGTATAGCAGAACATGTGGG
GGTTCCTGGAGGGTGGGGTGCCAGGGAAGGCATGGGAAGCTCTGTACTTCTCC
20 CATACCTCATCCTATGCACCTCTTCATCTGTATCCTTTGTAATATCCTTTACAATA
AACTGGTAAACATAAGTGTTCACACAATTGTTTGAGTCACTGTTGCAAATTAAT
TGAACCCAAAAAGGAGGTCATGGGAACCCTGATTTACAGCTGGTAGATCAGAAG
AACAGGTCAAACAACCTGGGGCTTGCATTGGCATCTGAAGGGGCGGGGAGTCT
GGTGGGACTGAGACCTCAACCTGTATGATCTGACACTATCTCCAGGTACCTGGTG
25 TCAGAATTGAATTGGAGGACACCCAGATGGTCACATCTGAGGTCACAGAAGTAT
TTTGTTTTGTCAGAGAATAGGAGAACTGAGTTTGTTATTCCTGTATTCTCAGACT
TTATAATTTCTTTGATAATCTGTCTGGAGCTATAGACTAAGATGGATGGCAGGGA
TTTGAATGGCTTCATGTGTATCTCCATGTCATGGAGTAACTGTATTCATAGAGT
ACACAATCATTGTTTCAGATATGAGGTGGTGATAATGGACTGCTATTCTCTAGGTG
30 CTTGGCACATAGTAGTTGTTAATAATTATTTGTTGACTATATGATTGTCAGATAGT
CAGGAGACTATCTCCTCAGTCAGGAGACTAAAGGAAAAGGTAGTTCCATAGCTG
GAAAGCATTCTGGGGCCAGTACAGAACTGGCTTAGGGTCAAATGTCTTGCTTTCT
GCTAGTTGAGTGTGAGGATGCCTAGTCTTGTTGGGGCTAATAGCAGATGAGGAAT
CCTCTAGGCCCAAGATTGCCTTCACTCCAAGCTCACTACCAGCCTTTCTCTACAG
35 TCTCTAACGAAGTGCCGGAGCACCCATGTGTATCCCCTGTCTCTAATCATGTTTAT
GAGCGGCGGCTCATCGAGAAGTACATTGCGGAGAATGGTACCGACCCCATCAAC
AACCAGCCTCTCTCCGAGGAGCAGCTCATCGACATCAAAGGTGCCTATTGGCTGC
CTTAGTCTAGGGCCATCTTAGCTCAGAGCCTGAGAGGATGGGAGGTGGTGCCAG
TGCACTGGAGGAAGAGATGGTGGGCTGTTTATGGCTAAAAGGAAAAGATGTGAT
40 GGCGGGGGAGGCCCTGGGTTATGTTCTTCATACCTGCTTTCCCTTTCCGGCAGTTG
CTCACCCAATCCGGCCCAAGCCTCCCTCAGCCACCAGCATCCCGGCCATTCTGAA
AGCTTTGCAGGATGAGTGGGTGAGTTCTTGCAAGAGAATCAGCATCTTCCCCACT
TGAAGAGAATGCATTGCTGGGTTAGGACTTGGGGGTAGGAAGGATGGAGCATT
TTTAGAGGGTAACTTTGTGACATCAGGGATTTGTTTTATTCTTCGTTGTATCCCC
45 AGCACTGAGAGCAGCACCTGGTACATAGTAGGTGCTCTAGAGTTATGAATTGAA
TGATTGAATACATCCTGCAGGACTGTCTGGCACAGTGCCTGACACAACGAGGGC
GATCAATAAATAGCAGCAGCAGCAGTGTTGTTATTCTCTTTTAGAGAGGGGACGG
CATGACAGCTGGGATTTGCCAGTAAGTTAGGGAAGGTGGGGATGGGAAAGAGCT
GGCTCCCCTCCTGTCTGTGTGCCAGTGGTTCGCTTGGGGTAGGAGCTCAAGAG

TGTCTGCCGGCACATTCGTGTTTGCTCGGATATTGTTTGGGTCACTGATACTGGTC
TAGGCTCTGGGATAGGAGGCAGCATCCCCTCCCCAAGGGCTGACTCCACTGGGT
ACTCCCTGCACCCCCACCTCACCTTACAATGATATTTGCTTCTCCCAGGATGCAG
TCATGCTGCACAGCTTCACTCTGCGCCAGCAGCTGCAGACAACCCGCCAAGAGCT
5 GTCACACGCTCTGTACCAGCACGATGCCGCCTGCCGTGTCATTGCCCGTCTCACC
AAGGAAGTCACTGCTGCCCCGAGAAGGTGCAGCCTCTCCCCTGCCATCCCCACCC
TGGGCTGGTTCTGCATTGTAATATCCCATTCTAACATCGTCTTTTCTCTCAGCTC
TGGCTACCCTGAAACCACAGGCTGGCCTCATTGTGCCCCAGGCTGTGCCAAGTTC
CCAACCAAGTGTTGTGGTAAGTGTCCCCCTTCCCTTACCAGCAGCCCATTTGTGT
10 ACAGTGGCCACAGAACTGTCCCTATGCAGGTGTCTTTGGTGCTCTGTGCCTCTC
ACCCTCACCTTTCTTCTCTTACAGGGTGCGGGTGAGCCAATGGATTTGGGTGAGCT
GGTGGGAATGACCCCAAGAGATTATTCAGAAGGTAAGTCCTGCTCTCACCTGGTGG
GAGTGCTGATGGGCCCTTACTTTTACCATCTGTCTGGAGTCCATCGTGACTAAA
ATCACTGTGCTTTTGGGAGTTGAGTGGTGCAGAGCATGGACCCTGGGACCAGATT
15 GCCTGGGTTTGTATTTTGATGCCACTACTTGTAAGCTTTATGACCTTGGCTTACTT
AGCCAACCCTTACGTGTCTCATTTCCCTAGCTTCTAAACTGAGAATATGATCATAT
CCACTGTATAGGCAGGCTGTGGGAATTTAAAAGATTTTCACTACTGATAAGTGCAC
CTTTTAGCTCTTATTGTTATTGAGATTCTTTGCAGATAGTAACTACTTTTATATA
TTTTCTTGTTTTTTTTCTATGAGGGCAATAGGATAGGAATTATAATCCTTATTTTG
20 CAGATGAAAGACACATCTGAGAGGCAGAGCTGGGCTTCTGATTGCAAGTCCAG
TGGGATTCTCATTTGCAGGGCTTCTTAGTGTCTTTCTGAGCAGTTCAAATTGTGAG
CATGTGTCTGAGCCCTTGGCTTAGTGGCGTGTAGACCTATGGGAGCTCTACAGTC
CTAGCTTCTATTCTTGCTCTGCTGTTTATCACCTCTGCGACCTTGGGCAATTGACT
TCACTTCTCTGAGGCTCAGTTTCTCAGCTGTAAAATAAGGTCGTCAACACCCCC
25 CTCATAAAGCTGGGATGGAAGTAAGAAGAGAGAATGCCTTTAAGCCTGTAACGT
AGAAGTTGGCAGATAGCAAGTTCTTGGTGCTGCTTTTGAAAGCACAGGTGTGACC
AGCATCTAATGTACTTTTCTCCTTGCAAGATGATTTGTCTCACATTGAGCCTGTTC
TTCCCAGCTTCAAGACAAAGCCACTGTGCTAACCACGGAGCGCAAGAAGGTGA
GTTCTCTTTCTGAAGCCTGGAGAAAGAGCTGGCCTGGTGGGAGGCGGTTGACTCC
30 TTAGGAGAGAGAGGGGCGGCTGAATCTTGGATTCAATTGCTGCTCTTCTTTGGGGGC
TTTTCATTTTCTCAGAGAGGGGAAGACTGTGCCTGAGGAGCTGGTGAAGCCAGAA
GAGCTCAGCAAATACCGGCAGGTGGCATCCCACGTGGTGAGTGTCTGGGTCTCC
ACTGTCTTGGAGACAGCCCTCCCGTTTTGTTTCTGGGGTGGGCGGGCCAGCATGG
GGAGTGCTGAGTGCAGAGCTGTCCCAGGTTCTTGGCGCTGTTCTTGGTGCTGTTT
35 CTCGCCTGGGCTGCTGAGTTGTGAGGGCTCCTCTTTCTGCCAGCTGTGGGTTTCC
TAGTGATGCAGTGAGGGAGTTACCGTACCAGGCAGATAGCCAAGAGGTATGGAT
AAGGAATAGAAGTAACTCTTGCTCCCCCTGAGAACATGGGTGACTGGAGATGGCA
GTAGGGGAGGTCTGTGGCTTTGTGGCCTGCTGTGATTGGCCGTGACAGGGTTTG
GTGTGTCTCTCTGCAAAGGGGTTGCACAGTGCCAGCATTCCTGGGATCCTGGCCC
40 TGGACCTCTGCCCCGTCCGACACCAACAAGATCCTCACTGGTGAGAGTCTGGGCCT
AGCCCGGCAGGCCAAAGTGGGGAGGGGCAGCAGGGAAGGCGCATGCTCCTTGTC
CTCTTCATGGGCATGGGAACAAAAGCATTTCCTTGAGCAAAAAGGGCCTGGGTGG
GCCTGACTCATTGTTTGGTCTTTTGGGTCTTCTCCAGGTGGGGCGGATAAAAAT
GTCGTTGTGTTTGACAAAAGTTCTGAACAAATCCTGGCTACCCTCAAAGGCCATA
45 CCAAGAAGGTCAACCAGCGTGGTGTTCACCCTTCCCAGGTAAGGGGTTCTCCTCG
CCACCCTTGGTTCTTCTTCTTGGCTGTTGTTTGTCCCTCACCCCGCTGCTGTCTC
TGTGAAGTGGGGCTGGGAAAGAGCTCTGACTCTGACTCCTGAGTGGGCACTTGG
AGGGGCTCACTTTGGAGTTGTGGAGATTGCCCTTCACTCTGCGTGAGACCTTCTA
AAGCAGTGATCTTCCAGCCAGGGAGAGAACGGAAATGTGTAGTTTGACAAGCAT

ATTCATTGAAATATTTTCATATTAGGGGAAAGAAAAAATCTTATAGTGTTCCCTAATA
TAAACTACAGAAAACAAAGCTCAACACAATCTCAACTCACACTTACGAGGAGGA
CAGATATATCTGCTTTCCCATGATCCTCCAAGATGGGTAAAAATCATGTTGACTG
TTGAAAGTGGTGTAGGTTGTAAACAGAACCTCTGGTTTACAGGGTAAAGGTAAC
5 CATGGGACCAGATTAATGATATTATGGGATTTCGAATTTTAAGCCTAAGACAGTTT
GGGTTTGGGGCTGCAGGACATGGTTGGTTTAGTGCTTCGCAGTCAAGATTTCCCT
TGGACCTTAGGGAAATGAGAAATATAAGAATAACATGGTGAATTTTTCATGACT
AAATTTGTTCAAATTGAGAGCACTGTTTTCTTGCTTATGGGGTATTAATAGTTAGG
TCTCATGAAATTGTATTGATAAAAAAAGATGGTAGTTATTTTACCTTATGGCTTT
10 TAATATCCTAACTAAACAAAAAATTGGTGAGTGACGCGAAATTCTCTCCCTGCCC
CAAATCTTTTGGAAAATTAACCTTACCCTGGAAATCCATAAAAGTGGAATGCACTG
AAATACAGCCATGCAGCCCCCTCCAGTCCCACTGCTCAGACCTGTGCCATAC
AGTACAGTAGCAGTTAGCTGCATGTGGCTATTTAAATTTCAATGAAATAGAATAA
AAAATTCAGTCCCTCAATTGTACTAGCTACATTTTTCCTTTGGTCCCTGGAAATGGG
15 AAAATTGCTCTCTGTTGCAGTTAGCCTTTTTACCCTAGATGGCGAGGACGCCTC
CACAAGCCCTGATGCTGTATGAGTTAGCACTTTAATAGCGTTTACCATTGGCTGT
CTTGGGCACCAATTGGGTGGATAGGTGGTTCCAGGGAGGGCAGAGCTGAAAGGAG
AAGCAATTGTTGGCAGTTGTGGGCATCCCCAGCCCCGTTTTATAAGATTGTTTTG
GTCTGTATCTCTTTTCTGACTCTGATATTCTGTCTTTGTTTTCTTGTAGGACCTGG
20 TGTTTTCTGCTTCCCCCGATGCCACTATCAGGATTTGGTCGGTCCCCAATGCCTCT
TGTGTACAGGTGGTTCCGGGCCCATGAGAGTGCTGTGACAGGCCTCAGCCTTCATG
CCACTGGCGACTATCTCCTGAGCTCCTCCGATGATCAGGTGCGGTCCCAGCCAGT
GCCCTGGAGAGGCCTGCTGGTCCCCAAGCTTGAACATCCTGGGTGGCAGGAACA
TCTTCCCACCCAGCTGGTTCCCCAGAACCTCAAAGGAGAATGTTTGCCAGGGTT
25 TGCCAAACCAGGGGCTCTGTCTTGCTGAAGGGCCACCAGAACCTGGGACCCACTT
TCTCACTGACTCCATTGTCTCTTTTTTTTTCCCCAGTACTGGGCTTTCTCTGACATC
CAGACAGGGCGTGTGCTCACCAAGGTGACAGATGAGACCTCCGGCTGCTGTAAG
TTGCCTCATAGGCACTCAGCTTTTTGTTTGCTGTTTATTATTTATTTTACATTTT
ATTTAGTCATTTGTTTATTTGTTCTAAAGATATATTTACCATGAGCACCTGTCTAG
30 TGCGGGCTTTGTGCTGGGTTCACTGAGGAATGTGAAGAACAAGGAACCTACCTTT
GCTGCTCTTAGTCTCTCTCCCTGGTGGGCTCTGACCACAGGTCTCTCTTCCCTCCT
CCACAGCTCTCACCTGTGCACAGTTCCACCCTGACGGACTCATCTTTGGAACAGG
AACCATGGACTCTCAGATCAAGATCTGGGACTTGAAGGTAGGACATGGTAGGCC
TCCATCTGAGGCCCAGGGCCAGAGGGAGTCTTTGTGACAATGCAGTGCTAATTA
35 GGTGCTTGTGGCACCTGGCCCTGAAGGTGGAGAGACACTGGCTGTGCGTGTGTG
ATATGATGGTGTGGTCTGGGGGGTCCCGCTGGCTGTCCTTCTGGAAGGACGTGA
GGGACATCTCAGGTAGGAGTTTGGTGAGCCCCATTTTCTTCTCTCATGATCTGTG
GGTGACGTATTTTACTACCCACCGCCACTGTAGGAACGTAATAATGTGGCCAAC
TCCCTGGCCACTCGGGCCCCATCACTAGCATCGCCTTCTCTGAGAATGGTTACTA
40 CCTGGCTACAGCGGCTGATGACTCCTCTGTCAAGCTCTGGGATCTGCGCAAGCTT
AAGAACTTTAAGACTTTGCAGCTGGATAACAACCTTTGAGGTGTGCCCTTCCCCCT
CCGCCAGCTTTCCATTGTGTCTCCTTGTGTTGTCAATTATTTATTGAATTAATCTA
ATTGCTTCTGCTTATCCGCAACTGCCCCATAGTTTCTGTTCCCCTTGTGTGACCTT
CTCTCTTTCTATTTCTGGCAGGTAAAGTCACTGATCTTTGACCAGAGTGGTACCTA
45 CCTGGCTCTTGGGGGCACGGATGTCCAGATCTACATCTGCAAACAATGGACGGA
GATTCTTCACTTTACAGGTAGAGGCTGGTCTGGGCTCCTGGGATCTCTCTAGGT
GCCCAGGCCCGGAGGGAAGCCTCACTGGGTAGGAATTTCTAGGGCTTGCATGA
ATTTACCTAAGCAGCTTTCTGTTACCACCTGAGGCAGAGCTTTATGACTAAGGAA
GCAACTGAGTCAGACTGCATGGCAGTAGATGCTAGTGCTTGTCTGCCACTTCCA

TGCCCTGTGGCATTGGGCAGGTTACTAAAGGGAGAGAAAAGTCCCTCTGAAGTTT
TGATAACTGAATCTAAAATAAATGAACATTAGACAGTGACAGGAGGAGAGCCAT
TTTAATTACGTGCATATGCACGGGAGGCCACATTATATTAGATCTGCAGAAGGG
TCAGATGATTGAAGCTTATACAGTTTATATATCACTTAATAATGGGGATATGTTC
5 TGAGAAATGTCTTGTTAGGTGATATCGTCATGTGCGACCATTGTAGAGTGAACCTT
ACATATATCTAAATGGTGTAGCCTACTACACGCCAAGACTATTGCTATAACCTTA
GTATAGTCTATTATTGCTCCTAGGCTACAAACCGGTACAGCATATTAAATGTAGT
GAATACAATTATAACACAATGGTAAGTATTTGTGTATCTAAACAAGTGTAACAT
AGAAAAGGTTTCAGTAAAAATAAGGTATAAGAGATTTTTTTTAAAATGGTACACTG
10 GTATAGTGCTTGCCATGAAAGGAGCTTGCAGGACTGGAAGTTGCTTTCAGTGAGT
GAGTTGTGAGTGAATGTGAAGGCCTAGGACATTACTGTACGCTGCTGTAGACTTT
ATAAACACAGTACACTTAGGTTTTACTAAATTCATAAAAAAATTTTTCTTCAGTA
ATAAGCCTTAGCTGACTTTTACTTTATAAACTTAAAAAATGGATTCTTTTGTAAT
AACGTTTAACTTAAAACTAAAACACATTGTACAGCTGTACAAAAATATTGTCTCT
15 CTTTACATCCTTGTTCTATAAGCTTTTTTCTAATTTTTTTATTTTTTACTTT
TTAAACTTTTTCTTGTTAAAACTAAGACACAAGCACACATTACCCTAGGCCTACA
CAGGATCAGGATCACCAACTGTATTAGTCCGTTCTCACACTGCTATGAAGAACTG
CCTGGGTAATTGATAAGGGAAAGAGGTTTAATTGACTCACAGTGAAGTCCGGGAGG
CCTCAGGAACTTACAGTCATAGCAGCAGGGAAAGCAAACATGTCTTTCTTTACA
20 TGGCAACAGGAGAGACAAATGCTGAGCAAAGGGGCTAAAGCCCCTCATAAAACC
ATCAGATCTCGTGAGAACTCACTATCATGAGAACAGCATGGGGGTAACCACCCC
CATGATTCACTTACTTCCCACTGGCTCCCTCCCACAACACGTGGGGATTATGGGC
ACTACAATTCAAGATGAGATTTGGGTGGCGGCACAAAGCCTAACCATAGCACCA
ACATCACTGTCTTCTACCTCCACATCTTTTCCACCGGAAGGTCTTCGGGGGCACC
25 AACATGCATAAACCTGTCATCTCCTATGATGATAATGCCTTCTTCTCGGATACCTC
CTGAAAGGGCCTGCTTGGTGCTGTTTTACAGTTAACTTTTTTTTATAAGTGGGAAG
AGTATATTTAATACCAAAAAAAGTATAGTATAGGCATACCTTGTCTTATTGCACT
TAGCTTTATTGTATTTTATGGATACTTTGCTTTTTATAAATTGAAGGTTTTTGGCA
ACCTTGCCCCAAGCAAGTCTGTGAGTACCATTTTTCCAACAACATGTGTTCACTTT
30 GTGTCTGTGTGTCAAATTTTGGTAATTCTTACAGTATTTCAAACCTTCTTCATGATT
TATTGTGTCCGTTAGTGATCTTTGATGTTGCTATTGTAATTGTTGGGCGGGGGGGC
ACCATGAAATGTGCCCATAAAAGTTACTGAATTTATTTGATAAATGAAATGCTGT
GTGTGTTCTGACCACTCCACCCACCAGCCGTTCCCCTCTCTCTCCCTCTCAGACT
TCCCTATTTCTTAGACACAACAATATGAAAGTAGGCCAGTTAATAACCGTATT
35 ATGGCCTCTCGGTGTCCAAGTGAAAGAAAGTGTCCTCATGTCTGTTACTTAAAATC
CAAAGCTAGAAATGATTGAGCTTAGTGAAGAAGGCATGTGAAAAGCCAAATAGG
CCAAAAGCTAGGCCTCAACACCAAATATTAGTCAAGTTATGAAAGCAAAGGAAA
ATTCTTGAAGGAAATTAAAAGTGCTACTCCAGTGAACGCACAAATGATAAGAAA
GCAGAACATCCTTATTGCTGATATGGAGAAAGTTTCAGTGGTCTGGATAGAATAT
40 CAAACCAGCCACAACATTCTTTTAAGCCAAACCATAATCCAGACCAAGATCCTAA
CTCTTGAATTCTGTGAAGGCTGAGACAGGTGAGGAAGCTACAAAAGAAAAGTTT
GAAGCTAGCAGAGGTTGGTTCATGAGGTTTAAGGAAAGAAGCCATCTCCATAAC
AGAAAAGTACAAGGTGAAGCAGCAGATGCTGTTGTAGAAGCTGCAGCAAGTTAT
CCGGAAGACCTAGCTAAGATCATTGACGGTGGGTACACTCAACAACAGATTTTC
45 AATGTAGACGGAATAGCCTTCTATTGGAAGAAAGTGACATCTGGAACCTTGACA
GCTAGAGAGAAGTCAATGCCTGGTTTTCCAAGATGCAAAGATCAGAGTGATTCCC
TTGTTAGGGACTAATGCAGCTGGTGATTTTACATTGAAGCCAAAGCTCATTTAGC
ATTCTGAAAATTGTAGGGCCCTTAAGAAGGTGGGGCTAAATCTACTCTGCCTGTG
CTCTGTAAATAGAACAACAAAGTCTGGATGACAACACATCTGTTTACAGCATGGT

T T A C T G A A T A T T T T T T A A G C C C C C C A T T A A G A G G T A C T G T T C A G A A A A A T A G A T T
 C C T T T C A A A A T A T T A C A G T G C A C C T C A T T A C C C T A A A G C T C A G A T G G A G A T G T T T
 C A T G C C T G C A A C A T C C A A T C T T C G G C T T A T G G A T C A A G G A G T A A T T T T G A C T T T C
 A A G T C T T A T T A C T T A A G A A A T A C A T T T T A T A A A G C T A T A G C T G C C C T G G A T A G T G
 5 G T T C C T T T G A T G G A T C T G G A C A A A G T A A A T T G A A A A C C T G G A A A G G A T T C A C C A T
 T C T A C A C G C C C T T A A G A A C A T T T G T G A T T C A T G G G A G G A G G T T A A A C T A T G A A C A
 T A A A G A G G A G T T T G G A A G A A A T T G A T T C C A A C C C T T C A G C C C T C A T G G A T G A C T T
 T G A G G G A T T G A G G A C T T C C A T G G A G G G A G T A A C T G C A G A T G T G G A G G A A A T G G T
 A A G A G A A T T A G A A T C C A A A G G G G A G T C T A A A G A T G G G A C T G A A T T G C T G C A A T C
 10 T C A T G T T A A A A C T T T A A T G G A T G A G G A G C T C T T A G G G A T G A C C A A G A A A G T G G
 T T T C T T G A T G G A A T C T T C T A C T G G T G A A G A T G C C G T G A A C A T T G T T G A A A T G A T A
 A T G A A G G A T T T A G A A T A T T A C A T A A A C T T A A T T G A T A A A G C A G G T G C A G A A T T T G
 A G A G G A T T G A T T C C A G T T C T G A A A G T T C T A C T G T G G G T A A A A T G C T A T C A A A C A G
 C A T C C A T C A C A G A G A A A T C T T T T G T C A A A G G A A G A A T C A A A T G A T G T G G C A A A C
 15 T T C T T T G T T G T C T T A T T T T A A G A A A T T G T C A C A G C C A C T T C A G C C T T C A G C A A A C A
 C C A C C C T T G T C A G T T A G C A G C C A T C G A C A T C A A G G C A A G A C C C T G C T G G T G G G T C
 T T G G A A A A A G A T G A C A A C T C A C T G A A G T G T C T G A T G G T T G T T A G C A T G T T T T A G C
 A A T A A A G T A T T T T T G A T T A A G G T A T G T A C A T T G T T A C T A G A C A T A A T G T T A T T A C
 A C A C T T A A T A G A C T A C A G T A T A G T G T A A A C A T A A C A T T T T T T T T G A G A T G G A G T
 20 C T T G C T C T G T C G C C T A G G C T G G A G T G C A G T G G C A C G A T C T T G G C T C A A T G C A A C C
 T C C A C C T C C C A G G T T C T A G C A C A G G T G G G C A C C A T C A C A C C C G G C T A A T T T T T G T
 A T T T T T A G T A G A G A C G G G G T T C C C C A T G T T G G C C A G G C T G G T C T T G A A T T C C T G
 A A C T C A A G C G A T C C A C C T G C C T C G G C C T C C C A A A G T G C T G G G A T T A C A G G C A T G A
 A C C A C C A T G C C T G G C C A A C A T A A C T T T T A T A T G T A G T G A G A A A C C A A A A A A A T T T
 25 G T G T G C C T T G C C T T A T T G C A A T A T T T G C T T A T T G G T A G C C T G G A G C T G A A C C A G C
 G A T G T C C C T G A G A T A T G T C T G T A C A T A A A C C A G T A A C G T A C T G T A C C T A A T T A T G
 T T A T A C T T T T T T T T T T T T G A G A T T G A G T C T T G C T C T G T C A C C C A G G C T G G A G T G C
 A A T G G C A T G G T C T T G G C T C A C T G C A A C C T C C G C C T C C T G G G T T C A A G T G A T T C T C
 C T G C C T C A G C C T C C C G A G T A G C T G G G A C T T C A G G C G T G T G C C A C C A C A T C T G G C T
 30 A A T T T T T T T T T T T T G T A C T T G T A T T T G T A G T A G A G A T G A G G T T T C A C T A T G T T G G C
 C A G G C T G A T C T C A A A C T C C T G A C C T C G T G A T C T G C C C A C C T C G G C C T C C C A A A G T
 G C T G G G A T T A C A G G C G T G A G C C A C C G C G C C T A G C T A T A T T A T A C T T T T A T A C A A C
 T G G C A G T G T A G T A G A T T T G T T T A T A C C T G T A T C C C C A C A A A C G T G A A T A A T G C A T
 T G C A T T G T G A C A T G A T G A T G G T T A T G A C A T C A C T T G G T G A T A G G A A T T T T T C A G C
 35 T C C A C T G T A A T C T T A T G G G A C C A G T G T T T G T G T G G T C C G T C G C T G A C A T G T C A T T A
 T G T G A C A C A T G A C T C T A T G G C A T C C T G A A C T G C A G A A G G G A G T A G G G G C C T A A G
 G C T T C T A G G G G G T G G T G G T G A C A C A A G T T A T G T G G G G G G A T G G G G A G G A A G T G C
 A C T A C A G A G T C T C T C A G G T A A T A A A A G T T G T C T C A G A G C A G A C C T T A G A T A A A T A
 A T G C A T G A C A G T C T G T G A C A A A G A C T G G C A T C T A G T C T T C T C T T G T G A G A C C A
 40 G T T C A T T T T C C C T G G T T G A G A T T C C C A G G A A G G G G A T T C A T G A T G T T C C T T T C A G A
 T G A C C T G C C C T T A G A G A A A G A G G G G C A A G A G A C A G G A G G G C A G G A C A T G G T C A
 G A G A G A C C T T G G T T C A A A G C C C T C A G C G T G C C A A A C C A C C A T A C T T T G G G G T A T T
 G T T T T C T G A G A T C C A A T A T T A C T T A A C C T C T C A G A A A A G T G G G A A T G G T A A C T A T
 A G A C T C A G T G G G G T T G T T G A G G T T T A G A T G A A A A T A C A T A C A G G T G C T C C T T G A T
 45 A T A C G A T G G A G C C A C A T C C T G A T A A G T G C A T C A T A A G C T G A A A A T A T T G C A A G T T
 G A A C C A T G G T A A A T C G G G G A C C G T C T G T G A A T A C A T A G G T C A G A A C G G T G T C T G
 G C A C G T A G T C A G G A T T T G C A G T T G T T C T A C T C A G C A T T G G G T C T T A G T C T G T G G T
 G G G A T A G A G C A G T G A A T A A A A C A G A C C C G A T T T G G G C A C T G A T G T A A T T T A T A G
 T C A G G T T A G T A A G G C A G A T G T A G A T T A A T T T C A C A T G T A C A C A T T T A A T T G C A A T

TATAAGTGCTAGAGAAGAAAAGCATGAGATGCTGAGAGAATGGGTAACAGGGTT
TCTAACCTAACAGTTATGTGGCCCTGGGTACGTGACTTTCCCTTTCAGATCTTGAA
CTCCTTCATCTAGAAAATGGGAATATTGGCACAGCTTTGCAGGGTGTGACAGCTG
GTGTTGTGGAGATGGCATGCTAATATGCTGGTAACAGGGTGCCTGATGCTCACTT
5 AAGATGCTACATGAATGGGAGCTACTGCTGTGTGTGTTGATGAAATTCTCGTCCT
CATTAGCAGGTTGTGAGCAGGATACAAGATATTTCTTCTTGCCCCGATTCTCCTG
AGCCCTGCTCAGTGTGTTTGTATAACAAAGGTGTCCATCCTAACAATATGGCTCA
CCGGTTTTACCCCTGTACTGTACCTGGTGTGTTTATTAGAACCGAGTTAGGTAGC
TGAAAATACAGCGTGAGCTTTTTAATGGGGAGTTGGTTGACTCCAGGTGTGATCC
10 TAAATCTAGAAGGAATTTGGCCAGATGTTTCATGAATTTCTGGAGTCCCATGAGGA
ATGTTGCCCAGCCTCATCTGCCTCTTATCTGGTCTGCTCTGTGTTAGGGGCCTGA
GTGCCCTGGGGTTGGAACACTATGAGCTAGAAAATGCTGATGGACTGTTCCACTT
ACGAGCAAGTAGTGAGCACTAGGCATAAACAAGCTGAGCTCTGAGGTTTTTCAA
CTAAACCTAGCCGAAGTGCAGTTGCCAGAAAGCTCAGGTGAGAAGGGGGGGCT
15 GGCATTGCTTTATTTCATTCATCCACCAGTGAAAAATGCCAGGCACTGAGGGAGG
CACTGGGGGTAGTGTGCAGGTCAGCCTAGGGAAAACAAACAGGAGCCTGCGGTG
TGATAAATACTAATTAGAGAAGGCCTGGTTGTTTGGGAATCTGTTATTAGGGATC
AGTGTTCAGACTAAAGGAGGAAAAGCCTTCTCACAGTTGCCTCTTATCTTTCTCC
TCAGAGCATAGCGGCCTGACCACAGGGGTGGCCTTCGGGCATCACGCCAAGTTC
20 ATCGCTTCAACAGGCATGGACAGAAGCCTCAAGTTCTACAGCCTGTAGGCCCTGG
CCCTTCTGATGGAAGCTGGGCCTCATCTCAGTAGAGGGGTAGAATTAGGGTTTGG
GGGGGGGGTGGGGGGAATCTATGGGGGGAGGGGGCTCTGTGGGGTGGGACATTC
ACATCATTTCACTCTGGTCTGAGTGGTGGCCTGAGAACCATGGTGGCATGGACCA
CCCTCATCCATGCAACTCCAGGCCCATGGGAACGGATGTGGAAGGAAGAAGTCTG
25 TCACCCTCTTAAGGCCAGGGTCGGAGCCCAGGGCCTCTCCCTTCCTGTGCTCA
ATGGACGTGGTGGTGGCTGTTCCACACCCATTTTGTGTCAGTTCCTGTGAGACAG
GAGAGGCTGAGCCAAGGGAAGTGTGAAGGGGATGGGCAGGAGGGCTTGTGCAG
GGTTTTGTAAGCAGTGATCTAGTTTCATTAAGGGAAGGGAAGGGAAGGGAAGG
ACCTCCCCGTGTCTGTCTGCACCAGGAGCACCTGGGACTGGGAAGGTCAAGGGG
30 AGGGAGCACACACTGGGACACTGGCTTCCGGGAAGCCCATCTTCCTTTCTTTCA
CAGCTCTTACCCTTTTTTTTTTTTTTTAAATTGCACAGCAGAAATAAAAAACAAATC
TGCAGATGAAATTTGCCATGTCCCTGCGGTTCTTGACCTTGTGTCTAAAGGCCTC
AAGTCACTAGTCTGCCACTTGCCTTGTAGACTTGGTTTCTACACAAGCCTGGA
AAGGAGGGGAGACCTGCAGGGAAGATTAGCTGGATCTTGCTGGTGGGGAGGTCTG
35 AGCATCTCCATCAGGGTTCTTTAGTTGTAGGCTTTCTAGCCTGTCTCAGCTGGCA
TAAGTCAAAAAGGAGATTTTTTTTATTGACTCTGGCGATTGAAAAGCTGTGGTAGG
ACTGGTTTCGGGACAAAGATCTGATAATGAATGTGCCTTATAGGGAATTCCTGTA
GGGTACGTGACTGCTTTAGATTGCAGGTCAGGAAAGGCCTCTGAAGTGGTGGT
GATGAAGCTGAAGCTGGAATGAGAGGGACCTGAGAGGGGAGGAGTGTGGCAG
40 GCAGAGAGCAGGTTCTAGGGCTGGACTGAGCGAGATATATGGAGGAACAGGAA
GGAGGTCATGGTGGCAAAGTCGGGGGAACCATGGTGTACAGTCTGGGGTGATTG
ACAGTCCCCTGACAAGGGCCATCCAGTGGAAGGTCGGGGCTGGCTGCCTCCCT
GGAGTGGGGTAAGAGGATATGAGGTGAGGAAGTGTGGGAGTCAGTGATTATAGA
CAAAAAATAGTGCTGAGAAGGGGAGCTGAGAAATGGGGTGTTACCAGGAGGGG
45 AGCTTTGGGGGCAAAGTATGGTAGGCCATATTGTGGACATAACAGGAGACCTCC
AGGCATGTTTTGCTGGGGCAGTGTTCTGTTGTCAGGGAAGCTCGGCATGCCGTAT
CTGCCTGGGAGGGTCAGGATGCCTACTAGCTAGGGAAAGCTGAAAAACCCCA
GTAAAGAAACCACTTAACCTATACAAGTTGAATATAAACCATTAACTTACACCA
GTGTTTATTATTAAAGAAAAGACCTGGGCCAGGTGCGGTGGCTCACGCCTGTAATC

TCAGCACTTCCAGAGGCCAAGGCGGGCGGATCACGAGATCAAGAGTTCGAGACC
GGCCTGGCCAAGAAGGTGAAACCCCATCTCTACTAAGAATACAAAAATTAGCTG
AGCATGGTGGCAGGTTCTGTAAATCCCAGCTACTCGGGAGGCTGAGACAGGAGA
ATTGCTTGAACCCAGGAGGTGGAGGTTGCAGTGAGCTGGGATTGTGCCACTGCA
5 CTCCAGCCTGGGGGACAGAGCAAGACTCCGTCTTGGGGAAGAAAAAAAAAAAA
GACCAATCATACAGTTCTCCCAAGGCAGGACATACTTTAAAAAAAAGTTAGGAC
AACTGCCTAGTTAAAAGGTGGGCTAACAACAGCTATGGTTTGCAGATGGTAGAA
TGGGTCACTCGAGTGGGAGAGGGTTGAGGTGGAACCTCCCGACCTCAGGTCATCC
GCCAGCCTCAGCCTCCGAAAGTCCTGAGATTATAGGCGTGAGCCACCACGCCCA
10 GCCACTCATTTAATTCTTAAAAACAACCTTTGCCCTTGGCCGGGTGTGGTGGCTCAT
GCCTGTAATCCCAGCACTTTGGGAGGCCGAGGTGGGTGGATTGCCTGAGGTCAG
GAGATGGAGACCATCCTGGCCAACATGGTGAAACCCCATCTCTACTAAAAATAC
AAAAAATTAGCTGGGTGTGATGGTGCATGCCTGTAGTCCCAGCTGCTTGGGAGGC
TGAGGCAGGAGAATCGCTTGAACCCGGGAGGCAGAGGTTGCGGTGAGCTGAGAT
15 TGTGCCACTGCACTCCAGCCTAGTGACAGAGCGAGACTCTGTCTCAGAAAAAAG
AAAACAACCTTGCTCTTTGCTGTCCAGCAACTCAGCAGATTCTTGGTCCCTGCAT
AGGACTTCATACCGCTCTTCCTTTGCAGAACGGAGCAGAAGGTGGGAGCATAGT
CCTGGCACTGGACTCTCTGGCTTTGAATCCCAGTTCTGGCACTTAGTTGCTGCA
GACCTTGGACAGATTATTTAACTTTTTCTGTTTGAATTTCTTCATCCAAAAGATG
20 GGGATAGTGTACTTACTAGAGATATAGTAAGGATTAAGTGAATGTGACAAGTGC
TTAGAATAGGAATTGCACATCATAAATGCTGCTACTATTAATACTATTACCACTCTC
CTGCTCCCTCTCCCTGGAGTCTGCCCTCCCCAGAGATAGACCAAGTCCTTCAGGA
AGCCTCTGGAGCCCATTTGCTGCCCTGCCAGGTGAGTGAGCTTTCTTGGAGCCCAT
GGTTCATGCCTTTAGCATAGCTCTGTGTTACCTTGAAGGTGTTTGCGCATTTGTCT
25 TTCCCACTTAGAATCTTAAGAGCAGAACCAGGTATCCGTTGCTATCATTATCTCT
TCAGCTCATGTACACTGCTGCCAAGTGGCAGATTGAGAGATTCAACCTTGGGGC
TCAGTCCAATGCCCAGGCAACGTCTGTCTCTTTCTTTGATAAGTAAACACAGAGG
GCTTGACAGAATGTTAGTTATATCAGCCAAAATGAATGAAGAGCTATCACCTCCT
GCCACAGCTCACCAGATGTTGGCCCAGCTGCCTTGTAGGTGAACCTTCTGGAAGT
30 AGATCTTGGTTGGGGGTTGGTGGATTCTAAAGGACTCACCTCTGTTGTCTAGCTA
GTGAGTTTTGTATTTAGGACCCAGCAGCAGTCAGTAGTCCCAGGTGTCCATAGGG
AAATTGTTCCGGTGATATTATCAGTGATTACTGCATCTTTTGTGCACTTGGGCCTTT
GGTGATCAAACCTGCTTAGCCTCCGCTATTGAAAGTGAGGAAGCATCTATATTG
TTCTTGAGCTTGGAGCACTAACCAAGGAGGTACCTGGGGGCAGTGTAGTCA
35 GCAGTCTCCCCAGTAACGTTGGTACTGTGATGGAGCTCCTCACAGTACCACAGAA
TGACCCTGCCAGACAGGTGGTGGTGTCCCCAGTCTATAGATGAGAAGACAAGCT
CAGAGAAGTGCCTTGTTTAGGCCACCCAGTAAATAACGCAGCTAGGGTTTTTAAG
CCGTGTGGCTTCAGAGACCAAGCTGATTAAGATAGGCATGGGCAGCTAATGACC
CACTGCTCAGCTTTGCAGGAGGTAGTATCATAGTTAAATGCAGGCTCTGGAGCCA
40 GCAGCCCAGGTTTGAATCCCAGCTCTGCACCTTTCTGTGATGTGCATCTTTATGTC
TCAGTTTCTTCATCTGAAAAGTCAGTTCCCTGGTGCCTACTTCGTAGGGCTCTT
AATTTTTATTTTTAGTTTTATTTATTTATTTTTTAAATAGCATTCTAATAGAATC
TAAACATTGATTGGTCTGACAGGTCTTCTGTGTGGCATTTTTTTGTGTGTTAAATT
TCTTAGTGTTTTTTTAAATTATTATACTTTAACTTCTAGGGTACATGTGCACAACA
45 TGCAGGTTTGTACATATGTATGCATGTGCCATGTTGGTGTGTAACTCGTTAACT
CGTCATTTACATTAGGTATATCTCCTCATGCTATGCCTCCACCTCCGCCACCCC
AGGACAGGCCCTGGTGTGTGATGTTCCCCACCCTGTGTCTAAGTGTTCTCATTGTT
CAATTCCTACCTGTGAGTGAGAACATGCGGTGTTTGGTTTTCTGTCCATGCGATA
GTTTGCTCAGAATGATGGTTCCAGCTTCATCCATGTCCCTATAAAGGACATGAA

CTCATTCTTTTTTATGGCTGTGTAGTATTCCATGGTGTATATGTGCCACATTTTCTT
AATCCAGTCTATCACTGATGGACATTTGGGTGGTTCCAAGTCTTTGCTATTGTGA
ATAGTGCCACAATAAACATATGTGTGCATGTGTCTTTATAGAAGCATGATTTATA
ATACTTTGGGTATATACCCAGTAATGGGATGGCTGGGTCAAATGGGATTTCTAGC
5 TCTAGATCCTTGAGGAATCGCCACACTGTCTTCCACAATGGTTGAACTAGTTTAC
AGTCCCAACCAACAGTGTAAGTGTTCCTATTTCTCCACATCCTCTCCAGCACCT
GTTGTTTCCTGACTTCTTAATGATCGCCATTCTAACCGGTGTGAGATGGTATCTCA
CTGTGGTTTTTGATTTTCATTTCTCCGATGGCCAGTGATGAGCATTTTTTTCATGTCT
GTTGGCTGCATAAATATCTTCTTTTGAGAAGTGTCTGTTTCATATCCTTTGCCCACT
10 TTCTGATGGGGTCGTTTGATTTTTTCTTATAAATTTGTTTAAGTTCTTTGTAGATT
CTGAATATTAGCCCTTTGTCAGATGGGTAGATTGTAAAAATTTTCTCCCATTTTGT
AGGTTGCCTGTTCACTCTGATGGTAGTTTCTGTTGCTGTGCTGAAGCTCTTAGTT
TATTTAGATCCCATTGTCAATTTTGGCTTTTGTGGCCATTGCTTTTGGTGTTTTAG
TCATGAAGTCCTTGCCCATGCCTAGGTCCTGAATGGTATTGCCTAGGTTTTCTTCT
15 AGGGTTTTTATGGTTTTAGGTCTAACATTTAAGTCTTTAATCCATCTTGAATTAAT
TTTTGTGTAAGGTTTAAGGAAGGGATCCAGTTTCAGCTTTCTACATATGGCTAGC
TAGTTTTTCCCAGCACCATTTATTAAATAGGGAATCCTTTCCCATTTCTTGTTTTT
ATCAGGTTTGTCAAAGATCAGATGGTTGTAGATGTGTGGTATTATTTCTGAGGGC
TCTGTTCTGTTCCATTGGTCCATATCTCTGTTTTGGTACCAGTACCATGCTGTTTTG
20 GTTACTGTAGCCTTGTAGTGTAGTTTGAAGTCAGGTAGCATGATGCCTCCAGCTT
TGTTCTTTTGGCTTAGGATTGTCTTGGCAACGTGGGCTCTTTTTTGGTTCATATG
AACTTTAAAGTAGTTTTTTCCAATTCTGTGAAGAAAGTCATTGGTAGCTTGATGG
GGATTGCATTGAATCTATAAATTACCTTGGGCAGTATGGCCATTTTCATGATATT
GATTCTTCCTATCCATGAGCATAGAATGTTCTTCCATTTGTTTGTGTCCTCTTTTAT
25 TTTGTTGAGCAGTGGTTTTGTAGTTCTTGAAGAGGTCCTTCACATCCCTTGTAAGTT
GGATTCCTAGGTATTCTATTCCCTTTGAAGCAATTCTGAATGGGAGTTCACATCATG
ATTTGGCCTGTTATTGGTATATAGGAATGCTTGTGATTTTTGCACATTGATTTTGT
ATCCTGAGACTTTGCTGAAGTTGCTTATCAGCTTAAGGAGATTTTGGGTGGAGAC
GATGGGGTTTTCTAAATATACAATCATGTCTGCAAACAGGGACAATTTGACT
30 TCCTCTTTTCCCTAATTGAATACGCTTTATTTCTTTCTCTTGCTGATTGTCTGGCC
AGAACTTCCAACACTGTGTTGAATAGGAGTGGTAAGAGAGGGCATCCCTGTCTTG
TGCCAGTTTTCAAAGGGAATGCTTCCAGTTTTTGCCCATTCGGTATGATATTGGCT
GTGGGTTTGTCAATAAATACTCTGATTATTTGAGATACATCCCATCAATACCTA
CTCTAGGGCTGGGCGCGGTGGCTTACGCTGTAATCCCAGCACTTTGGGAGGCTG
35 AGGCAGGCGGATCACAAGGTTAGGACATCGAGACCATCCTGGCTAACACAGTGA
AACCCCATCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCC
TGTAGTCCCAGCTACTCAGGAGGCTGAGGCAGGAGAATGGTGTGAACCCGGGAG
GCAGAGCTTGCAGTGAGCAGAAATCGTGCCACTGCACTCCAGCCTGGGCGACAG
AGCAAGACTCCTTCTCAAAAAAACAAAATGAAACAAAACAAAAGAAATACCTAG
40 TCTATTGAAAGTTTTTAGCATGAAGGGCTGTTGAATTTTGTGCAAGGCCTTTTCTG
CATCTATTGAGATTATCATGTGGTTTTTGTGATTGGTTCTGTTTATGTGATGGATT
ATGTTTATTGATTTGCGTATGTTGAACCAGCCTTGCATCCCAGTGATGAAGCCAA
CTTGATTGTGGTGGATAAGCTTTTTGATGTGCTGCTGGATTGAGTTTGGCAGTATT
TTATTGAGGATTTTGCATCGATGTTTATTTGGGGATATTGGTCTAAAATTCTCCT
45 TTTTTGTTGTATTTCTGCCAGGCTTTGGTATCAGGATGACGCTGGCCTCATAAAAT
GAGTTAGGGAGGAGTCCCTCTTTTTCTATTGATTGGAATAGTTTCAGAAGGAATG
GTACCAGCTCCTCTTTGTACCTCTGGTAGAATTTGGCTGTGAATCCGTCTGGTCCT
GGACTTTTTCTGGATGGTAGGCTATTGTTGCCTCAATTTAGAGCCTATTGTTGGT
CTATTCAGGGATTCAACTTCTCCTGGTTTAGTCTTGGGAGGGTGTATGTGTTGAG

GAGTTTATCCATTTCTTCTAGATTTTCTAGTTTATTTGCATGGAGGTGTTTATAGT
GTTCTCTGATGGTAGTTTGTATTTCTGTGGGATCGGTGTTGATATCCCATTATCA
TTTTTTATTGCATCTATTTGATTCTTCTATCTTTTCTTCTTTATTAGTCTTGCTAGCA
GTCTATCAATTTTGTTGATCTTTTCAAAAAATCAGCTCCTGGATTCAATTGATTTTT
5 TGAAGGGTTTTTCGTGTTTTCTATCTCCTTCAGTTCTGCTCTGATCTTAGTTATTTCT
TGCCTTCTGCTAGCTTTTGAATGTGTTTGCTCTTGCTTCTCTAGTTCTTTAATTGT
GATGTTAGGGTGTCAATTTTAGATCTTTCCTGCTTCTCTTGTGGGCATTTAGTGC
TATAAATTTCTTCTATGTACTGCTTTAAATGTGTCCCAGAGATTCTGGTATGTTG
TGTCTTTGTTCTCATTGGTTTTCAAAGAACATCTTTCTTTCTGCCTTCATTTTGTTAT
10 GTACCCAGTAGTCATTACAGGAGCAGGTTGTTTCAGTTTCCATGTAGCTGAGCGATT
TTGAGTGAGTTTCTTAATCCTGAGTTCTAGTTTGATTGCACTGTGGTCTGAGAGAC
AGTTTGTTACAATTTCTGTTCTTTTACATTTGCTGAGGAGTGCTTTACTTCCAAC
ATGTGGTCAGTTTTGGAATAAGTGCGATGTGGTGCTGAGAAGAATGTGTGTTCTG
TTGATTTGGGGTAGAGAGTTTGGTAGATGTCTATTAGGTCTGCTCGGTGCAGAGC
15 TGAGTTCAAGTCCTGGATATCCTTGTTAACTTTCTGTCTCATTGATCTGTCTAATG
TTGACAGTGGGGTGTTAAAGTCTCCCATTTATTATTGTGTGGGAGTCTAAATCTCTT
TGTAGGTCTTTAAGGGCTTGCTTTATGAATCTGGATGCTCCTGTATTGGGTGCATA
TATATTTAGGATAGTTAGCTCTTCTTGTTGAATTGATCCCTTTACCATTATGTAAT
GGCCTTCTTTGTCTCTTTTGATCTTTGTTGGTTTAAAGTCTGTTTTATCAGAACTA
20 GGATTGCAACTCCTGCTTTTTTTTTGCTTTCCATTTGCTTGGTAGATCTTCCTCCAT
CCCTTTATGTTGAGCCTATGTGTGTCTCTGCACGTGAGATGGGTTTCCTGAATACA
GCACACTGATGGGTCTTGACTCTTTATCCAGTTTGCCAGTCTGTGTCTTTAATGG
GAGCATTTAGCCCATTTACATTTAAGGTTAATATTTTATGTGTGAATTTGATCCT
GTCATTATGATCTTAGCTGGTTATTTTGCTCGTTAGTTGATGCGGTTTCTTCCTAG
25 CATCAATGGTCTTTACAATTTGACATGTTTTTGCAGTGGCTTGTACCGGTTGTTCC
TTTCCATGTTTATTGCTTCCTTCAGGAGCTCTTGTAAGGCAGGCCTGGTGGTGACA
AAATCTCTCAGCATTTGTTTGCTGTAAAGGATTTTATTTCTCCTTCACTTATGAA
GCTTAGTTTGGCTGGATATGAAATCTGGGTTGTAAATCTTTTCTTTAAGAATGT
TGAATATTGGCCCCACTCTCTTGCTTGCTGTAGAGTTTCTGCCGAGAGACCTGCT
30 CTTAGTCTGATGGGCTTCCCTTTGTGGGTAAACCGACCTTCTCTCTGGCTGCCCT
TAATATTTTCTCCTTCATTTCAACTTTGGTGAATCTGACAATTATGTGTCTTGGAG
TTGCTCTTCTTGAGGAGTATCTTTGTGGTGTCTCTGTATTTCTGAATTTGAATGT
TGGCCTGCCTTGCTAGGCTGGGGAAGTTCTCCTGGATAATATCCTGAAGAGTGTT
TTCCAACCTGGTTCCATTCTCCCTGTCAATTTTCAGGTACACCAATCAGACGTAGAT
35 TTGGTCTTTTCATATAGTCCTATATTTCTTGGAGGCTTTGTTTGTCTTTTACTC
TTTTTTCTCTAAACTTCTCTTCTTGCTTCATTTCAATTCATTTGATCTTCCATCACTG
ATACCCTTTCTTTCACTTGATCAAATCAGCTACTGAAGCTTGTGCATGCGTCATGT
AGTTCTTGTGCCATGGTTTTTAGCTCCATCAGGTCATTTAAGGACTTCTCTACACT
GTTTATTCTAGTTAGCCATTCGTCTAATCTTTTCTCAAGGTTTTAGCTTCTTTGCGA
40 TGGGCTCGAACATCCTCCTTTAGCTCGGAGAAGTTTGTATTACCGATCGTCTGA
AGCCGCCCTTCTCTCAACTCGTCAAAGTCATTCTCTATCCAGCTTTGTTCCGTTGCT
GGCGAGGAGCTGCGTTCCTTGGGAGGGGAAGAGGAGCTCTGATTTTTATAATTT
CAGCTTTTCTGCTCTGGTTTATCCCCATCTTTGTGGTTTTATCTACCTTTGGTCTTT
GATGATGGGGACGTACAGATGGAGTTTTGGTGTGGATGTCCTTTCTGTTTGTAG
45 TTTTCCTTCTAACAGTCAGGACCCTCAGCTGCAGGTCTGTTGGAGTTTGCTGGAG
GTCCACTCCAGACCCTGTTTGCTGGGTATCACAGCAGAGGCTGCAGAACAGCA
AATATTGCAGAATGGCAAATGTTGCTGCCTGATCCTTCCCTCTGGAAGCTTCGTCT
CAGAGGGGGACCCGGTCTGATGAGGTGTCAGTTGGCCCCTATTGGGAGGTGTCTC
CCAGTTAGGCTACTCGGGGGTCAGGGACCCACTTGAGGAGGCAGTCTGTCCGTTT

TCAGATCTCAAACCTCCGTGCTGGGAGACCCACTACTCTCTTCAAAGCTGTCAGAC
AGGGACGTTTAAAGTCTGCAGAAGTTTCTGTTGCCTTTTGTTCCAGGGCTCTTGAG
AATTAAGTGAAGTGTTCATGTAGAGATGAGGCACTCAGTAAATGTTGACTACCG
TGCATCTTCCGTGCTCTGCCCTGCACTGGCATTGTCCTTGAGATTTAACTGTATTGA
5 CACATGTGCGCAAGGTCATGGTGGTCCCTGACACTTGACACCTATCGAATAAAGG
CATGGTCTGACTGCCTTCTCTGCTGCATTAGTAAACCTAAGGCTCTGTTGACACA
AAGCGGCTGGAACATAATCCAGGCACGGAGACAAGAGTCAACAGAGCAATACA
GACATGATGCTAGAGTTCTGATAGAGCTGCCAGCACAGAGGACAGGATGTGCAA
CTGTTTAGGATGTGAGGTGGACCTAGGGGAGGTGGCACAGCCGCGTTTTGAAGT
10 GGAAGTTCCTTAGGTGGACATAGGACAGAGGAACAGAGTAGGGGTGTCTGGTGT
GAGCAAAGGTAAGTGGCAGCCCCACTGCCTGGGGAAGGAGTGAGAAAGCAGGTTT
GAGGGAACAGGCAGCTGGGGAGGGAGGAGCAGCACTGTGGTTGGAGACAGGCC
CAGCAGATTGTAGTAAGGCAGGCCAGGAGGTTAAAAGTTTTCTGAAATATTAC
CCAAAGTGTCTAAAAATGTACCTGTACAGTTTAAAGAATAGTAAACATCTTTGTG
15 TCCACCAGCCAGCTGAAGAAAGCATTAGGGGCCATCAGTGTGTTCTCAATGAAT
GCATCGCTCCCTGCCCTGCAGAGAAAACCACTACCCTGAAATTGGTGCTGATCA
TTCGTTTTGTTTTTCTATACAATTTTACTACTACATTGGGGTTTTGGGGACTGATTTT
TGAGCTTTATATAAATGAAGTCATTCAATCTAGTTTCTTTGATTTTACCTTCTCAG
CATCGTCTTGAGATTTACCTGTATTTACACACATGGCCCTAGTTCATTCACTACT
20 GGGAAAACAAAGGAAAATGGCCAAACAGAACTCACACCAGGTACTGTGACAGC
ATTTATTGAAGGTAGGAGCAGCAGCAGATGTGCCGGTCTGTGTGGCCCATTCAT
TCTAGGACAGTGCACGCTGGGAGAGGGATCCTGGCCATTGGGCTATGGGGCTTTT
AAGCTGCATGATTAGGAAGCACAGCTCCTCCTCCTGCTGTGATCAAGGCTCTAGG
GTCTGAGTTTTGCTGTTGCAGTTATTTGATGTGGTCAGCCAGCAGCAGGATTTACT
25 GCAGTGTGTTCTGTTGGCTGGAGAAGCATCAGCCCTTCTCTGATGTGATTAAAGGG
CTGGGGTCCAAACCTTGTAATTGATCAGTGTCTTAGGCACTTAGCAATGGCCAGA
TTCCATGGAACCTTGTAAGGGGCCAACTCCTTTCTGGGAGGCCAGCCTGCCAGG
GACAAACAGGTTAACTCTTACCTCTCATTCATCGTAGAATTTGATTGTAGGAATA
TACCGGAGTGTATTTATATGTTCTAGTGTTCATGATGGACATATGGGTTGTTCTA
30 GTTTTTTATTTTTATTTTGCTATTACAGTGTCTGTGAACATTCTGGTGCAAGGGT
TTTTCTGGGATAGTTAGGAGAGGACTTATATATTAGGGAATGACAATTTTTCAAC
ATAGGTATACCAGTTTATATTCTAATTAACATTGGTAGAATGTTCTGTCTCATA
CCCTACCAATGCTTATTTTTCTGGCTTTTTAATTTTTGCCACTCTGGTGGGTGTAT
AATATTATCTTCAAGTTTAATTTTTTACATTGATTACGTTGAAGTTGAGCAT
35 CTTTTAGCCACTTACAGACCATGTGAGTTTTTCTCTTGTGAAATGCCTGTTAGT
GTCGTTTGCCTATTTTTCTATTTGTGTTACCTTTTTCTTGATTTGTAGCAGTTTTAA
ACATATTTTTGGATAGTAATCCTTTGTCAAGAATGTATTGCAACTATCTTCTCACT
TTGTGCCCTGACTTTTCACTGTGTGTTGTTATCTTGTGACTTATTGTGAGGTGTTT
ATCTTGTGTTGCAACTTGATCTGTCATAATTCTCTGAGGCTTTGGCTGAAATCACCT
40 TTCAGACAGGACCTGCATTTGCTTCTTCTGAGCCTGGGGATCACTTTAAATTA
AATTTAGCCCTTGAGGTTTGTTCCTAGATTGAACCTGAGGGGTCTTTCTCTTCTC
TCCTTCAGTCTGAGGATTTGACTGCACACACCAGAGAAGAAGGAATTACACTTTT
CATTCTCAAGGTGATTTTTTTTTTTTTCAATACATCCTGCCCCATGATAAAAATAG
GCAGGATTCCTTGCTGCCCACTTTTGCCAGAGGCTTGTTTCTCCTTCACTCTTGCA
45 CTGAGGACTGGGACCTCTGAAGTTCAGCTTTAGAGGAGGCCCTGCATCTGGACT
TGTTGCCTTTTGTAGGCTCCGGGCTTGATCTACAGTTCCTGGACTCATCAAAGCA
GAAGGCCAAGGTCTCCAGAGTCTGTAGAACTTCCAGAAATAGAAGCTGATTTTA
CTTCCAGAGTTTTTGTCTTTTTATTTTTGGCCTATCTGCACGCCTCATTCCCCATGT
TAATTCAACACTAGTCTAAGAATATTTTAAAATATTTATAATCTGGTATTTTAGTT

GTTTACTTCAGGTTGATCCAAGTATCTAGTGTTCTACTGCTGGAACAGAAAGTGG
CACTTTTCCATGAAATGTTCTCACATAAGTGTCCAGACAGGGAGTTGAATTCAGC
TGAAC TAACAGGCGGTGAAGTATTCTGTCCCCTTTATTA AAAACAAAGCACCATG
AAGTTAATTTGCTCTCAATGTATAATGTAAGTATATGGAAGCTGGTGGGGGCCTG
5 GGGAATGGAAAGACAGGGGATTCCCTTAGGTCTTATATAGATATAGCCACAGCC
TCTGCCCCCATCCCCATCCCCACCTCCCCAAAAGGGCAGGAAGAGACAAAACCT
GACGGGCCCTGAGCAGCTCTGCTTCTGCCACAGGTCAGAGACAGTGGTTATTGT
CCCCATCGGGTCTGATGAATTGTTCTCAAGGTCCAGCAGGGGCCTGCTCACATCA
GGAGGCAGTAAGAAGGGAGGAAGAAAGCTTTAAATTGGGCAAAATTTAGACTA
10 AATTTTGTTATCTAGGAAAGCCAAAGTTTAGATTGCTTCCCCCGAGAGAAAGCTA
GCACTGCAGTGAACCTTCATTGTTTCATATAGTTTGTATATTTGTTTCAGTAAACAGA
CTCCTTTGACATGGAATTGTTGACAAAATCTATGCACAATTTATCAGTTGCCAAA
ATCATGTACCTATATACACTTGGAAAGTAGGAGATACACAATTGCATTGTTACTGG
AATATCACAATAAAGCAAATGGATACTTGGATGATTATATAGGATAGGGGAAAG
15 TCTTTGCCATACTCAAAAATACAAATATGAGAGGGGAAAAATTCATTGTTACATAA
TCCTTTCTAAGATAAAAAGAACCCGGCAGAGAAAAGCCAATGGCCAATTAGATGG
AAAATTTATAAAATGAGGATACTGGCCCCCTTGATTTGTGAAAGCTCTTTACAGAT
GAGGAGAGAAATAGTGGAGAGTAGATAAAAAGACATGAAGGGTAACCTATGCGA
TACCAATGGCTAGAAAGATGCTTGACTTCTAATCAAAAAGAGCCCCCTTCAAAAC
20 GGCCAATGCCATTTGCCTTATGATGCTCAGATAGGCAAAGATTTAGAGTGTTACT
GGCCTGTGGTGGCAAGCCTGCACAGTGGGATTGGGTGGGGAGACACTCAGACAG
TCCCGAGTCCCACAGTCATAAGAGGTGTGGTCTTGACCCAGCAGTTCTAAGACTG
TCTTTCAAGAAAATAGTATACAAAGAACTATATGCTTAAGTAATTGTGTTCAACA
CTCGTCATCCTTAACCCACTTGGTCTCTATCAACAGATCAAATATCATAGTTCAAC
25 CGCAGTTTAGAGACTACCTCTATTTGAAATGATAGGAAATGACACAAGACATCC
ACCCTTGTTGTTAAAGCAAATTCAGTTACACAGCATTATTCCAATTGGTACCTCTG
GAAGTTTGAAATCCTTACATGAGCTTGTATGATGGAGGGAGGGGAAGGAGGAGG
AGTTAATGCTGGAAGGAACCAGAACCCAGGCCCTAAGACCAAGTCAACCTGGC
TTCTCCAACCAGCCAAGCTAAGAATCCTCACCTATATCACACTGACCCTGCAGGA
30 TATATCCTGTGTCTCCCTGTACAAGCCAGGAAGTTGGGCAGGGCAAGACTGGCCC
TTGCTAGCCATAGATGGGAAGACAGGCCAGAGAAAGGAAGTCACTTAGCTTCC
ATGGCAAATGTTTGGGCCTTCTGCTTTTATGTTCTCCCTCTAGCTAGAAGAGTC
AAAAGACAGCAGTTTCCCCTAGCCCCCTCTTCGTATTGGCCTGTAACTTGTACAT
ACAAAACCAAACCAAACAACTTGACAACAAAATAAGTAAGCATTAGGCTTGGG
35 GCAAGAGGAAATGCAATTCTAGTCAGTAGTTAATAGCACCCAGTTACTGTTGGCC
GTTATGTACTATTCTAAGCATTCTTATCTGTAACTCATTTTACCCAATACTTCTAT
GGGAATAGACATTAACCTCATTTTACAGATGAGAAATCTGAGGCCAGGGGAAGT
TGAGTAACTTACTGAATATCACACAGCTAGTAAGAAGCCAGCTCTGGGGTCCAC
ATGCTTGTCAGTATTCTGAAGACAGGAAGGCTGAGTAGGCCAGAGCTGGATG
40 AGTAGGGGGTACATGCAGTATTAAGGCCACAGGCATGACTTGAGTACCTCAGCT
CCTCTTGTAACAGCTCTCTAAGCTCGTGCTCTACCTGAAGTCCGGAAGGTGTCT
GAAACCAAGTTCAGGCTTCCCTACCAGATTCTTCTCCCTGTCCCATTGAGGCCAA
ACCTTAGCATCCTGTCCCCTTCTCCACCTAGAGGATTGACATGTCTAGAAAGGGC
TTTGCTGCCAAGTCAGAGATGAAGGCCCATGCCATACATGGGCAAACCTGGGCTC
45 AGCGGCATAGCCAGCACTGGCACAGACCTGTCTGGTGGCCATGCCACCATCGC
AGCCAGTGTGAGGGCCAGCAGGCTGCCATTCTCCTGTGCCAGCCCTTCCCACAT
GGATAGTCTTGGGAGGCCAGGGGAAGGGATGGGAGGCTGTGGTCAGAAATGCA
GCCTTTAGCGGTAGGCTGGCAGGCTCAGGGGGTCTGTGAAGTGCTCCTTCAACTC
AGTCTTAGAGTAACCCTTATCCATGACAGCAGCTGCTCAGGGTGCTTTGAGGATG

CCCTTGT CAGAACTTCTGTGTCTGTGAGGAGGTGACAAGCCTTCACAAGCCATTC
ATTCTGCCAGGGGGCCAGTTCCCAGCTGTTGGTGTCTTTGACTGTCAATGTCTT
AACCTCCAGTATCTTTGTCTGTTTGCTCTGCCTGAAATGCCACCGTTCTTGTGG
AGAGGCAGAGGCTCCCGAGTTGAGCCTTGGGGGACATTGGCCTCTGTGCAGGGT
5 GTGGCATATATGAAGTATTTGTAATCAACGTCACAGTTTTTGAAGGACAGAGCTG
ACTTGGAGGAAGTTTCTCACATAAGAAATAGTTCTGTTCTAGTCGTCACAAATAA
CTTCTCCACACCTGGTTTCAGTAGGTTTGAAATGATTGTTTATTGGGCCCATTCAC
TGTCTGTTGCTTTCCCAGAGCTTCTGGGGCCAGGTCTGGCTCAGGCCCAAAAGA
CACCAAACCAAGGACCAGGGCAACAGCTGGCAGCAAAAGGACCGCCCAAAGG
10 AGAGGTCTCAGGCTGGAGTTCCCATTTGGAGTCTGT CAGAGAGACGGGATTGGCA
GGGCTGGGTGAGGCCCTCCAACCTCCCCTCCACCCAGAACTTTGTATCACAC
TGGGCAGAGCTGAAGCTGCCTTTCTGCAGATGAGGTGGACTGTGTCTGTCTTCAC
TTAGTTCCCCACTGACTGCAGTGACACCATCTCTTGCCCTCAGCTATGGCTGGAG
CATCCCTGTTTTGT CAGCACAAATCTTGGGGGCTGAGAGTGGGTAAGGCCTGAGGG
15 GCCACCCAGAAGCCCTCCTACCTGTGGGGCCAAAGTGTGGGCTCCTGCCCATAG
AATCCTCAAAGCCCACTGGCCCCGGAGAGCTCACGATGTCCTGGGGCCTGGCAG
TGTCATTACGGTGACCTGAGGATCGTCGCTGTCTGCCAGGGGAAGAATGAAAT
CTTGGGCTGGTCTCCTGCCCCCTGTGGCCCAAGAGGCCAGGCACAGGCCTGAAGATG
TATAAAGGAACAAATACCACTCGCAACCCAGACTCACTTGTAGTGCCAGTGCTAC
20 ATGCAGTGGAGCAAGTCTCCAGCCCTGAGGTGTGGCAGGCAGAGGTGCTGCAGA
ACAAGTAAACCTGGTGGAAGGAGAAGAACATCAAAGTGGCTGGCTCAGTGCCAC
CGGGCAGGAAGCACAAAGGGAAGGACATGGAATCCCCGAGCTGGGCCAAGTCT
AGGCTGCTGCTAGCCAGGCAGGGAGAAATCTGAGCTGCTTGACCAAGATGATGA
CTGCTGCCCATGCTGAGGGAGTGCAGAGCTGAATGTGTTCTTCCAGATTTGAAA
25 TCCACACCTTCTTGCTCCCCAAGGTCCAAGTCTGCAGTGGAGTGCCCTGCAGGC
GGGGACCACCGCACTTCGTAATGCCCCAGTCTTGGCGGGCCTGCTTCACCAATG
CTGCCTCTGGCTGCACAGCCCCTGGGAGGGCTGGCTCTCTCCCTTCCACCTGCCCT
ACTGAGGGAGACAGCAAATTC AAGGAGGTGGGACTTGGCCAGGCAGCAGGAT
AATAGATGTTTGCCCTCCCTTTGTGACCCCTGGAGACCAGTGACTGGGGGCAGAG
30 GGGAGGGCAGATTACCACCGCTTCCAGATACAGAAGGGCAGGGGCAGTGCCCTA
CGGGACCAGAAGCAGGAGGAGCTGACCCAACCCAGCACCCAGGAGGCCCACTC
ATGGGCAGCACACAGCAGAGATGAGAACGAAGCCACACTAACCAGTGCTTCCAA
GTGAAATCAGTCTACATCTGACATAATAACAGGCAGTGATTTAAGAATCTAGAG
ATTGGGATATGTGATGTGAAAGATACGTTGTTCAATGGGACAAGTGCATCTGTCA
35 CCTCTGAGGCCATCTGTATATTACATAGGAGACCTAAATATACCCTGAGTTTATC
TACCTTTACCTTCTGGAGAAGTTGCTGAGTTAAAGAAAATTCAAAGAATTACATG
GAACACATTATCATTTCTGGAATCAGAAGTGAGGTGAGGCCACCCTAGAACACC
ATGACCAGAGTTCAGATTTAGGGCTGATTGCAGCACAGGCAGCATTTTCCTTCT
CCTGGTGGTGGTTATGGGTTACCTTCTTGCTGACCCGAAGCCCGCTGCTTTCCATG
40 ACACCTGGTAGACGCCAAGCCCCATCCAGAACTTTGTCCATATAAGTTCACAGG
GTGCCAGAGGGATTTGGCGACCAGCTCCTCCCACTTAACAGATGGGACCAGGCA
TGCGGCAGCCGGGGCTTCTTACCAGTCTCTGAGGGCTCTCTGGGAGCCTGAGTC
CAGGAGGGCGAAGGTAGCAACAGTGAATCGCTGGTAGTGCGACTGGAAAGGTGT
GGCCCCGTCCAAGGCTACCATTTGGGTTCTGTAGCTGTCGCCCTTGAAAGGGCAT
45 CTGAGAAGAGAAGTCAGAGAGGCTGTTTACAGGAGGCAGAGCAGGTGGGGGA
GTGTGGGGGCACTCACCCGTCTGACAGGATGGGCCACTGGGGCTGCTGGAAGGG
GTTGGCACTGGGAGCGCCCCAGCACTGGTGCAGCAGCAGGACCAGGTTGGGGTC
TGTCCTCTGCAGAAGCCGGACCTCCACATGGACTGGTTCTCGGAGCAGCCTCACG
ATGGGATAGTCATCCTCCCCATAGTACGAGCTGAAGGTCTCGTCTGCAGGGAGA

GTGACTCATGAGCCAGGGCGGGCTGTGCATCAGGGAAGTGGGGGCCAGAAGAG
AGCAGGGATAGCATAGCATACCTTTGGCAATCCGCAGCTCAAGCCGCAGGGGGC
CGGGCTGGGTCATAGGAGCAGGCGATGGGGGTGGGAAAATGGATGCCTGAATGG
GCAGGAAGTCACTGGCGTTGAAGACACAGCGCACATGAAGCCTGAAGTCCACGT
5 GCAAGAGGGTGGGGGAGAAGACACAGAATCAGAGCATCCTGTTTACGTAATAAA
CTAGGCACCAACTCCGTGGGTGCAACAAATAGGGTACTGTCCAGCAGGGCAGAT
GGATGCTACTTAAGCAATACTCAGCATTTCCAAGGCAGGCTCAGGAAGCTCACCC
TGCCCATTCCTCTGCCCACCTGGTCTCCCTGGGATGGCTCAAGCCTGTTATGCCAG
GCCCTGCACCTGGTGGGAGAATACAGCAGGATAGAGATGGGGCCCTCGGGGGGCT
10 GGCACCTTGTTGGGTCTGCCCTGGCTACCCACAGCTGCCTGCTGTGCCGTTTCGAG
GCCCCTGGAGCCTGACAGTTGAGGCTGGTGAATGAGCCTAGGTGCTCTGCCTCCC
GACAGACCTGGATTTGAGTCTTCTTAGCATTTACAGGCTTTGGGACCACAAGCAA
GTCCTTCTAACCTAAGCCTCAGTGTCTCATTTGTAATAATGGCTGTGACTGCCTCCC
TTTGAGGGGCACTGAGACTGAGTGAGATCACAAGATAATGCACCTGTGTCTTCATT
15 GTCCTTGTAGTTGCAGCTGGTTTGCCACAGCCTAAAGGCCACAGTGTCTAGCATC
TTCCTCACTAGCCTAAGGGCCATGGTGGCCACTCCTCCACACTCTGGTGGGGCCA
ACACCCTCCTAGCACCCCAGAGGCCTGGTACCAAGGAGATGCTGAGTAGGTATA
GGAGGCTCACCCCTGTTCTGAAGGCCTTGTGTCTGAGGAGCTCTCTGGCCTAGTC
CTGCTGGCTACAGCTGTTTCCCCCTGACTTCTGCCTCCCTCTGAGAATCCCTAGGC
20 ACTCTGTTGACCTCTGGCTGACTCCCAGAGCTCTTACATCAGAGAGTCTAAAGGC
ATGACACAGACTTGTCTCCACCCTTGGCCATAAGAACATATGGGTTTTTTTAA
ATTAATAATAAAAAATAGAAATGGGGTCTCGCTGTGTTGCCCAGGCTAGTCTTGAA
CTTCAGCAATTCTCCACCTAGGCCTCCCAAAGCGCTGGTATCATAGGCGTGAG
25 CAGTCCCCTGCTCCCCAACCCCTCACGGCAGGGCGGGGAAGGGGAAGGAGATGCCC
AGCAACCATGCAGTGTCAAGCACAAAGATTTCTACAACCCATTGGCTCCGTCCCAC
AGGGTGAAGGTTAGGTGCTTTGCCCTGGTCACACAGGTTCAAGGCCAGGCATG
ACAGACAGATTCCCTCGGGTCACCCCCACTGGCATCCTGGGCACCTGGGTTGGTT
TTGCCTCTTGAGTCAGCAGGTCCAGGAGGCCCTAACAAATGAGGGGTTCTCCCC
30 CACCCAGTTCTCTCCACCATCCTCAGAGAGGTATCTTCAGCTTCATCTGTGG
CTTCTTAACCTGACATTAGGAGGGGGCAACAGCCGTAGCCTCAGCCTCCTCCTGGG
ACCTGGAAGGGGACACTTTCAGTTGCTTTGAGCTTGGTTCTTGAGAGACCAAGA
CAGGGCTCTCTCAGGACTCCAGCTCTCTCAGGACTGGCCCTGGGCTTCTAGCCAA
GCCCTGCAGGGCCAGGCATGGAAGGGCTCCACTTAACACTCATGTCTGCCCTGAGA
35 GAGGGACATTTCCCCTGCCCAGCAGGGGAGGCTGGGAAGAGGTGGGCCCCTTGC
CTAAGATCACATAGCCGGGTAACAGCAGAGCCTGGGTTTGAGCTGAGATGGCTC
CGAAGCCTGTACTGAGCTCGCCTGTGCCCTGACACCCTAGCACACAGCCACGCC
TGTAGGAGGAGGGCTGCCCTTACTGGAAGGTGCTGTCCCGCGTGATGGAACCCT
GTGGCCCCCTTTTGATGTGGATGCCAGACACCAGCCAGTTCTCATAGATGAGCTG
40 GTCGCCAGCCACCTGTAGGAAGAGACAGCTGGGTGAGGCTTTCTGGTGGGGGAC
CAGGCCCCAGCCTGTGGTCCCGGCTCCTACCTGCATTGTGGTTCCACAGTGGGTG
AGAGGGGAAGTAGAAGACCACGAAAGCTTCCGTGTGCTGTGTGGGGAGCAGCTG
GTGGGGGCATAGGCCAGGTGGATGTTGGCCAGTGTGATCCTGTGTGTCAAGGCC
ATTTCTTGGGACACCACGAGGACGAAGTAGCCATCTCTGAAGCACTGGACAGTA
45 GCTGGGACAAAGGCAGATGAGGGCCTTGGGGTTTGGTGTCCATCCAGCACAGAG
ACGGGATGGCTGGGTGACAGCCAGGCTTTAAGTGCCGGTCTAGGAGAATGGACG
CTTACTCTCCACTTAGGCTGGTGTGGCCCCAGCAAACCCTTTATGGACTGATTTT
CTCATCCATGTGACAAATGAGTTGAACTACACTCTAAAAGTAGGTTACCATATA
ATCTGTCATCCAAACCAGGGCGTTTCAGATCTGAAAGTCCAGATGTGTGTAAGGT

132

CCCCAGGTCCACTGAATCAGAACCTGCACCTCAACAAGGTGGCCAGGTGTTTCCC
ATGCACACTAACGTGGGAGAAGCTGCCCTGGGTGATGATTCTCCTCCTTGCCCTT
TTCTGTGGTGAGGGGGTGGGGGGCTGGACACCCCCAGGCTGGAGGGAGGCCTCT
GTTCTTGCTCCTTCAGGGGAAGGGTCCCAGCTCCCTTCTGGCAGCAGCCCGTGGC
5 CAGGGAGGCAGGGGCCAGGACTCTGCCAGCACTACCCACCACCTTGAAGCGGA
GAGTCTGGCCTGGCCTGGGGAACACCAGCAGCTGCATTCCCTTGATCCCACAGTC
GTAGCTGTGCCGAGGCCTGGGAGGCCAGGGTCGGGCTGGAGCCACCTACCCAG
CCCCAGGGTGGCGACCAGCAGTAGCAGGGCCACAGGGTAACCCCAGGTCGTGGC
TGAGCCTCCTGCCATGAGACGCCACAGACACACCCCTACTCCCTCGCCACCAGA
10 GCTGGGCCCCAGGCCTTTTATGGAGGAGGTGGCAAGTGGGTGCCTGTAAGGGCAA
AGGGGGCCCCACCTGGAGGAGCACCCACCTGGCCACCAGGGGGCTGTGGTGAAACT
CCTGTTCCAAAGGCAGCGGGAGGCAGAAAGCTGCACGTGGCCCCCTCACCCCTGGC
TTTCTGTCTCACAGCTGTGGCTTTGGAAGGGAGGAGGGAGCTTTCCAGAAAAGT
AGGTTGCAGATGGGCTGTGGGAAGGGATCCAGGGCTAGGAGGTGGCACTGCAGA
15 CCTCAGGCCCTCCACTGTCTCCCTCTCACCCAGCCTTTCTGCATTCCCTTCCTGC
CCCAACAGGCTCTCCAGGTCCTCCTTCCTGCCTTGAGGCCTCAGGACCACTGGGA
GCTGCCGGCCTGGTTAGTGCAGTCACAGCTCCTCAGGCAGGGCTTTAGGGGCATT
AGAGCAAGACCAGGAAGACACAGCCCTCAGAGCTGGCAGCGGAATGGGGACTG
CAGGTGAGTAAACAGACCAGTAGCACCTCCAAGGGCTCTCCTGAGGATTCAGCC
20 GGTCAGTATGATGATGACTATGACTAATAAAAAATAACAAGGACAATAAATGT
AATGTGGCATCTGGATGGGATCGTGGAACAGAAAAAGGCAGTAAAAGTGAAGA
AAGTGGATTTTAGTTAATAATAATGTGTCCACATTTGTTTGTTCATTAATTGTAAT
AAATGTATCATACTCAAGTAAGATCAGTTATGGGGTAACTGGGCCTGCGGTGTA
TGGGAAGTGTCTGTACTATCTTCTCAGTTCTGTAAATCTAGAACAGTTCTAAGAC
25 ATAAAAGTGGCTGGAAACAACAAGAATGGCCTGTGGTCTGCCATGATTACAGTG
CCAGGTCTTGCTTGTGTTAGATCCTTATACCGCCTGACCATCCTCTGAGGAAGGG
ACTGTCACCAGCCCCACGTCTGGCACTAATTCTGCAAGTGATTAGCCTAGGGC
CCAGCAGCGTTTGAGCTCAGCAAACATTAGGAAACTGAGCTCAGCAAACATTAG
AAAATGCAGCTATTATAATTAGCAGCTGCTGGAAGGGGAGAGCAAGAGGCTTGA
30 TAGCTAAGAGCCCCGTTCTGGTGAGGTTGCGGAGAAAAAGGAATGCTTATACGC
TCTTGGTGGGGGTGTAAATTGGTTTGACCACTGTGGGAGTGTGGTGATTCTCAA
AGAGCTGAAAACAGAACTATCATTGATGCAGAAATCGCATTACTGGGTATATAT
CCAAAGGAATATAAATTGTTCTATCATAAAGACACTGAACCTGCGTGATATGTT
CAGTGCAGCATGATTACAAATAGCCAAAGACATGGAATCAAATGCCCATCAATGG
35 TAGACTCAATAAAGAAAATCTGGTACATGCTGAGCACGGTGGCTCACGCCTGTA
ATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAG
ACCATCCTGGCTAACACGGTGAAACCCTGTCTCTACTAAAAATACAAAAATTAGC
TGGGTGTGGTGGCACGCACCTGTAGTCCCAGCTACTCAGGAGGCTGAGGCAGGA
GAATCGCTTGAACCCAGGAGACGGAGGTTGCAGCGAGCCGAGATTGTGCTGTTG
40 CACTCCAGCCTGGCCGACAGAGTGAGACTCTGTCTCAAAAAAAAAAAAAAAAAA
AGAAAAAGAAAAAAAAAAAAAAAAAGGAAAATGTGGTACACATACCCATGGAATACT
ATGCAGCCATAAAAAAGAATGAGATCACATCTCTTGAAGAACATGGATGGAGC
TGGAGGATATTATCCTTAGCAAACAAATGCAGGAACAGAAACCAATACCACATG
TTCTCACTTATAACTGAAGGCTAAATGATGACAACATATGGACACATAGAGGGG
45 AATGGCACACACTGGGGCCTATTGAAGGGTAGAGGGTAAGAGGAAGGAGAAGG
GTGGAAATAATAACTATTGGGTGCTAGGCTTAGTATCTGGGTGATGAAATAATCT
GTACAACAATCCCTCTGGACATGCATTTACCTATATAACAAACCTGCATAAGTAA
CCCTGAACCTAAAATAAAAGTTTAAACAAAAAAGTTGGTTCTAATGGTGCCCC
AACCACCTTTCTTAGCTGTGACTCAGATGCATTATCTATTCTGAGCCTCAGGTTTCC

TGTTTGTA AACTGGGGGTGATAATGCTTTCCTTGCCCACATGGTGGATAGGAAGA
CACAAAGAGACAAGTCATGGGTACCAGGTGCAGTAATGATTTAATGCTTGGCAA
TAATTCACCTTCTACTGTGATTAAAGCTCAGCTGGGAAAGCTTGGTGGGGCGGGGT
GGGAGTCCCTCTGGGGGCACAGTGGGAAGAGGCACCCAACACAGCATCGAGGAT
5 GGGCGACATGGAAGTGTTTTTGGAGGAAAGGGGTCTGAGCAGAGGTGGGAGGA
GGCGGGGAGGACAGGGATGGTGCAATGGGGATCTGGGGAGAGCAGAGCTGGAG
GAGGAGGGAGGAAGCAGGTCACACAAAGGTCCAGGACAAGGACTCCAGGCAGG
CTGAGGGTGCTGGCGAGGGAAGGACTAGGAGGGGAAGGAGAGGAGCCAGGCAG
GAGCGGGGAGTGGGGTGGATTTTCCCTGAGGGACGATGTGGAAGTTTTAACTTT
10 TAATTTTGAAATTATTTTCAAGATTTGCAGAAATTTCCATATAGCCTCCTCCAGATTCC
TCAGATGTTCACTGTTCACTTTTTACATTTGCTGTAGCTCCCGCTTTCTCTCTCTGC
ATGTGTGCAGACATACACGCACGCACACGCACGCACACGCACACACGCACACAT
TCTTCCATATCATTCAAGAGTCAGTTGCAGAAATGACAGATTCCCCTTTACCTCTA
ATTACTTCAGTATACATTTTCTAAAAAAACAAATCACCCCTACAGTCAAATGATC
15 AAAATCAGGAAACCAACAATGGTATAAACACAACGATCTAATCTGCAGACATTA
TTGTAAGAAATAAAGAGGAAAGCAACATGAAAGGGCGGTTCAACAGGCAACAG
GGACAGGTTTATGTTGAGTAAACCTGAGAGGGGCGGCTGGCCGAGTTAGGTCAG
AGCCCCACTCTCTTACAGATTAAGAGTTAAGGATTCAGGGCGGGGGAGTTTATCA
GAGGCTTGGACTGCTCCTGTGTCTCTTTGCTGTGCGTATCTGGGAGGGAGAGTTG
20 TGTGTCTGTTCCCATATATCTTTCTGCAGCTACAGGCATATCCCCAGAGTCTGCTT
TTAGCTTCCCTATCTTAGTGCCCTGAAGGAAAAGGAATGTGCTTATTAAGGCCC
ACTGTTTTACTGGGGCTCATTGTGTGAGGGTGAAGTTTGGCAGTTACCAAAGAGA
CCTTCCCTCCACCCCGCTCTGTGCCGGAGCTGTCTTATCTGTATTTTACTGTCTGC
TCTTTCTGGCTGTTGTAGTTAGAAGAGAAGTGATTTTCTTGAAATGCATGAGGCT
25 AGAAAGGGAGCTGGAGCTTAAAGTGGCAGTATTTGTCCGAGATGACGGTGCTCC
TGCTCTGACAATTACTCAACATCTGCCGACTGTCCTAACTGTGACTTTCATGGCA
AAGGAGTACAGTGGTTTTGGGAGTCTGCAGGATCCAATCCAGGCTCAGAGTCTC
GCTGGCGTGCCCTTGGCCCTCCTCTGATCTGGGACCGCCCTTCTATCTTCTTTGT
CTTTCATACCCTTGACATTTTTTTAGTACAGCCGGATGATTTTGCAGAAATGGCCCTC
30 AGTTTGGGTTTGTCTGGTGTTTTCTCCTGGTTACATTAGATTTAGTTGATGCATCT
TGGCCTTGTATTAGTCCGTTTGGCTGCTGTAACAAAATACAGACTGAGTGGCTTA
AATAACAGTCTTTTTCTCACAGCTCTGGAGCCTGGATGTGCTAGGTCAAAGTGGT
GGCAGGTCTGGTTGCTCCTGAGGCCTCTCTTTTGGCCTGCAGACAACCGTCTTCT
CACTGAGTCTCTACGTTGGTCTTTCCCTGTGCTGGTGCCTCTTGGTGTCTCTTTG
35 AATGGTCAAATTCCCTCTTCTTCTGGCTGGCACGGTGGCTCACGCCTGTAATCCTA
GCACTTTGGGAGGCGGAGGTGGGCAGATCACTTGAGGTCAGGAGTTTGAGACCA
GCCTGGCCAACATGGTGAAACCCCATCTCTACTAAAAATACAACTAATTAGTTG
GGTGTGGTGGTGCACACCTGCAATCCCAGCTCCTCAGGAGGCTGAGGTGGGAGA
ATCACTTGAACCTGGGAGGTGGAGGTTGCAGGGAGCCAAGACGGCACCCTGCA
40 CTCCAGTCTGGAAGACAGAGTGAAATTCCATCCCAAAAAACAAAAACAAATTC
CTCTTCTTCTAAGGACACCAGTCAGATTGGATTAGGGCCACCTTAAGGGGCTCAA
TCTTAAATCACATCTTTAAAAGCTCTATCTCCAAATACAGTCACATTCTGAGGGA
TGGGGGTGGAGGGTTAGGGATTTTCGCATATGAATTTTGGGGGGATACAATTGAG
CTTGTACAGAAGTGATGTTGTGTCTTCTCAGTATCTCGAGGCACACCCCGCTGG
45 CTTGTCTCTGTTATTGCTGATGTGACTTTGATCACTTGGATAAGGTGGTGTCTGCCA
GGTTTCTCCACCATAAAGTAATGATGTTTCTCTTTGTAATTCATGAGTATCTTACA
GGGAGATACTTTGAGACTATGTAATCAATCCTGCTCCTCTTCAAATGTTCACTGG
CTAGTGTGGTTGCCAAGTGGGTGGTGGTTCTCTAACTCTACCCTTCTTCTGCATT
TATTTGCTATCATAAGAGAGAACTTTTCTAACGGGGGCTTTTAGGGGCCAGAGA

GAGAATCAGCTGGAGTCTTTGAGAGGCCTGGATTTTGCCTGGTGCTCACTGTTTA
TGAGCACAAGGGCCCTGGGAAGTCACTTACCGGCTTTTTTCCTCTATCTGGAGAG
TAAGGATGAGAATGATTATGGTGGGGATGCAATTACATAAGACACGGAGAGGTG
TTTCCCCACTGGTCATGGACCCATGGGGAAAGTACGTCTCCCAAGGTGCTGGAAA
5 TGGGCAGGGAAAGAGAAGGGGGGGCTTCCTCAGGGCCAAGGGCAGAACACCTTTG
GGAAAAGGGTACCAGAGTATCCAAGAGAGAGAGAGAGCGCGCACGAGCGCCCT
GAGCCCTCGGTTACGACTCTACGTTCTTGCAAAGACTCATGGACACCAAGAATTA
TCAGCCTGGGAGGATCCCAGCTCCTCTGCTCACCCACTGGAGACCTTGGAAAAGT
CCCTTCCCTGCTCTGTGACTTGCTTTCTCATCTATAAAATGGGGTTATAATAGCA
10 CCTAAATTGTAGGGTTGCTCTGAGGATTAAATGAGATAATCCATGTGAAGCAGGC
AGAACAGGGTCTGCACATGGTCATCATTTGAACACGATAGCCATTACAACCACG
ATTATTTTATTGATAAAGAGAGAGGGTTCAGATGGAGGTGACTTGACTTGGAATC
TTGGCTTTATCCACTTGGCTTCTGGTTTTTGGGTTTTTTTTTTAGAGATGGGGTCTTG
CTATATTGCCAGGCTGGTCTCAAACCTCCTGGGCTCAAGCAATCTGCCCCGCTCT
15 GTCTCCCAAAGTGCTGGGATTACAGGCATGAGCCTCCACACCTGGCCACTTGGCC
TGTTTGTAACCTGTTTGTTCAATTTCTTTCTTTCTGTTTTTAACCTATGAATTTTTTT
TTAATGGAACCTCAGTTTTCTTTCTTTCTTTTTTTTTTTTTTTGTTTTGTTTTGAGACAG
AGTCTCACTCTATCGCCCAGGCTGGAGTGCAGTGGCGCGATCTCGGCTCACTGCA
AGCTCCGCCTCCCGGTTACACCATTTCTCCAGCCTTAGCCTCCCGAGTAGCTGGG
20 ACTGCAGGCGCTGGCCACCATGCCCGGCTAATTTTTTATATTTTATAGTAGAGACG
GGGTTTCACCGTGTTAGCCAGGATGGTCTCGATCTCCTGACCTTGCGATCCGCCC
GCCTCAGCCTCCCAAAGTGCTGGGATTACAGGCGTGAGCCACCGCACCCAGTTG
GAACCTTGAGTTTCTTAATCTATAAAATGGAACCTAAGAATACAGTCCACCTAAGTG
GGGCGCCGTGTAAGTATCAGTTGCTTGCCCTGTCTCCTCTGTGAATAGAGCCTAG
25 GGAAGGCACTGGAGGAGGATGGAGCCTCTCTAGGCTGGAAAGACAAAATCCCCT
TTCAGGGGATCCATGCATGCCAGGAAACCAGCAGGAAGCAGGCTGCCTCACTCC
GGGGCCTGCAGAGTAACCAAGAGCAGCGCCAGCTGTGTGTGTATGTATGGACC
GTGCTCACCGCAGAGATGCTCCCAGAAGGCCAGTGGGAGCGCATTTAACTGAAG
ACAGGCAGCCCTGCTTCCCCTGAGGGAACAAAGAACCTCAGAGAATCTCATCAG
30 CTGCGAAGAGCTGGGCTCTGCTGCTGGACCACATGGCTCTGAACTCCAGCTCCTC
TGCTCCCCAGCTGAGCAGGCTTGGTAGGGTTGCTTAAGCTCTCTGAGCCTCAGTT
TTCCCCTTGGTGAGTGACGATGATAGTGGTACCTAACTCAGAGGGGTGCGTGAAT
ATTTGATGAGCTCATCCATGAGCAAGTTTCAGCCTTACGCTGGCACATAGTGAGT
GCCCCATAAGTGTTAGCTATTACTGTTTTTCATTTTTTTTTTTTTTTTTTTTGGAGAT
35 GCGTCTCGCTCTGTCACCCAGGCTGGAGTGGAGTGGCAGGATCTCGGCTCACCA
TAACCTCCGCCTCCTGGGTTCAAGCGATTCTCCTGCCTCAGCCTCCTGAATAGCTG
GTATTACAGGCGTGCACCATCACACCTGGCTAATTTTTGTATTTTATAGTAGAGAT
GGGGTTTTGCCTGTTGGCCAGGCTGGTCTCGAACTCCTGACCTCAAGTGATCTGT
CCGCCTCATCCTCCCGAAGTGCTGGGATTGCAGGCATGAGCCACCGTACCCAGAA
40 GCTATTGTTGCTTTCACTGTGTTGAATGGTGGCCCTCAAAGACATGTCCACAAC
CTAACCCCTGGAACCTGTGAATGTGGCCTTATTTGGATAAGAGGACTTTGCAGAT
GTAATCAATTTAAGAATCTCAAGATGAGAGCACCCCTGGATGATCCAGATGAGCC
CTAAGTCCAGTGACCAGTACTCTGTGAGAGACACATGAAAAGAGGGGAGGGGGAA
GGCCAGGTAAAGAGGAGGTAGAGATTGCAGTGATGCAGCCCTAAGCCAAGGGA
45 CGCCTGGAGCCACCAGAAGCTGGAGGGGGCCAAAAAGTCTCCTTTTCTAGAGCTTT
CGGAGGAAGTGCTGACATCTGATTACAGACTCTGGCTTCCAGACTGTAAGAGAA
TAAGTCTCTGTTGTTTAAAGCTGCCACGTTTGTGGTAGTTTGTCTGACAGCCCGA
AGAAACAAATACACCACTGTTGTTTCTGCGACGATTGCCTGGCACATGTGTGGGC
CTGAGCCCAGGCCAGGGCTGCCTCTGCCTGCTCTGCCTTCTTGTCTTCCTTCCTAC

TATAAAGCGATCAGTCCCCAAGGTTGTACCCACTGCAGGTGAAGACAGAGCCAT
GGAGAATTGCACCAGACCATGGGTAAGAAAGGTTCCAGAATGGGGCCGGACACA
GTGGCTCAGGCCTGTAATCCCAGGACTTTGGGAGGCTGAGGCAGGCAGATCACC
TGATGTCAGGAGTTTGAGACCAGCCAGGCTAACATGGTGAAACCCCTTCTCTACT
5 AAAAATACAAAAATTAGCCGGGTGCGGTGGCGCACGCCTGCAGTCCCAGCTACT
TGGGAGGCTGAGGCAAGAGAGTCGCTTCAACCCGGGAGGCGGAGGTTGCAGTGA
GCCAAGATAGGGCCACTGCACTCCAGCCTGTGCAACAGAGCGAGACTCAGTCTC
AAAAAAAAAAAAAAAAAAAAAGTAAAGGTCTCAGAATGGGTACCACAAGGG
ACTGGGGTCCCTTTGAGGTCTGCACAGGGAAGCCAATTTTAGAGATTCATTCTGTT
10 CAGCAAATATATGTTGGGACCCCTCTCATGTGTGTCAGGCCCTCTGCTTGCCTTTGG
AGGTGAGAAGATAAAACAGGAATAAGTCTCTGTCTTCAGGTGGCTCATGAGGGT
GGTGAACAGTTGTGTGAACAAGAGTTACCAGGGAAGACAGGGGGGGCTGCAGGTC
AAGTGAAGTGGAGATGTGGGAGGGAGGGACAGCAAGTGGGTCTGTCTGAGAGA
ATCAGCAAAGGCTTCCCAGAGGAGGCAACCTCTAACCAGGGTTTTGAAGGATGA
15 ATAGGAGTTCAGTGAAGAGGCAAGGGAAGAAAAGGCATTCCAGAGCAGAGCAC
AAACAGCATAAGCCAGGGCACAGAAACAGCCTGGTGGGCACAGAAACAGCCTG
GTGTGTACAGAAAAAGCCTGGTGTGCACAGGACAGGAGGGGACAGTGGTGAGTG
CTGGCTGATGACAGGATGCCACTAGGGAGTGGCAGCAATGCCAGGGGAGGCTTG
GGTGGGACTGGATCACCGAGGGGCTTGTGTTGGCCATGCGAGGAGTCCTGTGGGTG
20 ATGGTGGCACCAGGGAAGTCAACCTGGGCCTCCCCAAGGTATCATTTGGGGCCCT
GCCATGCTGCTCCTCTACTGGGTGTGGGTAGCTCGAGGGCCTCCGAGCAAGGGGC
TGGAGGATCCCAGGGCAGGCCTCACCTGCTTCCCTGCCCTGCATCTCACTTCCTG
TTTGAAGTACTTCTTTAAAGTGGCCAGAAAGGAACATAAAAAACCCACCTAGAG
GGAGAAGAAAGCCCATGTGGGCTGGGCCTATGCTTGGGGGCTCCATCTGCCCTC
25 CTTCAATTCCTTTGCTCCCTTGGCTGTATTTGTTAAACATTGATGCTGTAAGTATCC
TCTGAGTATCTAGTGACATTGGTGGTCTCAGAAAGAGGTCCTGCAGGATGAGTCG
TGGAGGGGAAGTGGCATTCCCAGCAGCACGTGCCAAGGCATGGAGGTGGGGAA
AGAAAGGATGGGGTAGCTGTGGACATGAGGAAGGGGGTGCAGGGACTGGTGGT
TGGTGCAGTGGATCCTGAGAGGCCTTGAATGCTAGGTTGGGAATCTGGACAGCTC
30 CCATGGGCAGCAGAGATGCAGCAGAGGTCCCGTGTGCCAGGAAGCGACAGGCTC
AGATTCATCTCCTCCACGGCAGAAAGTGATGCTGAGGCAGCGAGGGACCCGACT
TCCGCTCTTACTGCCTCTGATATTAAGTTCCAAGCCTTGGAGGAGGTTGTAATTTA
GGGACTAGGGCCTGAGCCTGAGTGCAGCTGCATCTTTCTCCAGTCCTGGGGGAC
ACAAGCCATGGGATAAAGGCAGGGCACGGCTCTTCTTCAGAAAATGCCTCTGGGG
35 CCTGCTCATCTGGAACCTTGTGTTTGGTAACTTTAAGCTTAGTAGCTTTTTTTGTTTAC
TTAGTAATACATTTTCTTTAGAGAGAACACACACACTGGGTTTTCTTTAGAGAGG
AACACACTCGCACTGGGGCTGGACATGAGTCACTACAGTGATTACAGGACTGGA
AACAAGGACTGAGAAGGGGCAGATGAGTAAGGGTTTTTTAGCCAGAAAAGAAG
CACCTCAGCAGGGTGGCCAGGAGAGGTTGTGCAGGATGTTCACTGTACAAGGAT
40 ACCAGTGGAAGGGTCAAGGGTGGGCTGAGATCCAGAGGAAGGGCTGTGCCTTAT
CTCAAGCCTGATGCCCTGGTGTGAGATGTGTCTGTGGGGTGGGGTGGTGGGGA
AGGGGTGATTCTTTTTCTTAGTCCAAAGATAAATCTGGGCTCCAACCCCTGTCCTT
TGAGGGTGGGACTGTGCAGAAAGGAACACCATTAAAGTTCATATTTTACTGCTGT
GAAGTTACTTGCCCAAGATCACATAGCTGAGGAGTGGCAGTGCCAGATCCAGAC
45 ACTGGTGGTCTGGCCCCAGAGTCCCTGGGCTTAACCACAGCCTGACACTCTCTGT
GCGCAGACAAGGCACACGTGGCCTTGTCTGTGGTTCAGTGGGTTGGGTGTCCGGG
GTGGGTGGAAAAGAGGGGCACTTTCCCATGCAGAAATGGAATCATCCACCTATGTT
CTCTGGAGGGCTGCAGGCATTTGTCTTTGGAAATCAAGCCTTCCCTGACCTGGAG
GAGAGGGGACATTTTCTATTGTTAATGATTGGATACCAAGGCTCTTACTGAT

CTGCCATATTGGGCTACAGTGAGATGTATTATCCCCATCACAAGGGCATAGCATT
TTACTCATTTTTCCACTCATGATGGTAGCCTCTCAGCAAGAGCGTATTATGCATTAG
TCTCTGCGTTAAGACTAGGCCTAAATGGAAGATGCTTGTGCTGTCCATCTCATGG
GAGGTGCCTTTGCCTCGATACAGGGATATTGAGTTCTTAAATGTTTTAATGAGT
5 ATCCATTAGGTGCTGAGATGCTGAGGTTGAAGGGATGGTCCTGACCCAGGAAG
CTTGGTCAGCAAATGAGAGTAAGGAGTTAGGGAACAATGAAATGCAAACCTTCTC
TTATCCTAGGGCTTTGAGCCTGTGTGTTTTTTTGTGTTGTTGTTTTTGTGTTTTTAGTT
TAAATTTCCATTTTTTTTTTTTTGAGATGGAGTTTTTACTCTGTACCCAGGTTGGA
GTGCAGTGGTGTGATCTCGGCTCAATGCAACCTCCACCTCCTGGGTTTAAGCGAT
10 TCTCATGCCTCAGCCTCCCAAGTAGCTGGGGTTACAGGCATGTGCCACCACGCCT
GGCTGAGTTTTGTATTTTTTAGTACAGACAGGGGTTTTGCCACATTGGCCAGTCTG
GTCTTGAACCTCCTGACCTCAAGTGATCCATCCGCCTCGGCCTCCCAAAATTGAGC
CTGTTTTAAATAAAAAGCTATATGACCTTTGCCTTAGAGCCTATATTCATTTTTCCC
TCAGAGGAGAAGGAAGCTGATTTTTATAAGCACTTACTGTGTGCCACGAGCTTTG
15 TGCAATCCATCTCATTCAACCTTACCACAGCCTGTAAGGCCGATGTTACTGCTC
CCGTTACAGATGACAACCCAGGGCTCAGCAAACAGAAGTGACTGACCTCTTG
GACTGCGTTCTTGCCACTGCCCCACTACCCACTGTACTTTCCTGGCCTTAGAGC
CCTCGGGTCCCTCATGGACAGGCCCCACACTGCCTGGGAAACTCAGAACAGCT
GGAGGGGTTTCTTCTCTGAGGATTCTGGTGTGCGGAGATGGAAGCCAGGAACA
20 GTGGACAGATGGATGAGACATTCTCCTTCTCACGCACTTATCCTACACACTGGTC
ACTCTCAAAAGCACACCCCTAGTCACACTCGGGCTCACACTCTCTTGACACATC
GATTTTTTACGTGCACTTGCACTGCCCTCTGGACTTCTGCAGTCTCCTTCATGAA
GCGGGGATGGGTGGAGCAGGGGCTGCCGGCATTGATGGAAATTGATGATATTTG
AACATCTGTGTGGCAACTCACTCTCCAGCTGTCCCCGCCTCCCCAACCCACCC
25 CTAAACACACATGCACTGGGGCTGACAGCTATTTCTCTCTCAGCCTCCCTCTCCC
ACCTCTGTCTGCCCCGCTGCCTCTTGTCTAGCTGCTGTGTCAGGAGCTGACTGCCTCCA
GGGCTGGAATCCTGTGCTCCCTCTGTGCCAGGTAAGGAGGAGTGGCCAGGGG
TTGGGCAGCCTAGTGCCCTCTCTAGACCCACAGAAGAAGGCAAAGTTTTACCAG
GTGAGAGGGCTGTTACCAGCTAGGATGGCAGAAGATTGAGTTTACCAAAGACTG
30 GAGGGGACTTGGTGCTCAGAGGAGGGAAGGATTAGCTTCTCTTAGGCATTA
AGATGTCAGATACGAGGGGAAACCACTCAACTGTCTGTCAATATTACAAGCAG
TCTGGGTGGGAAGATGACACCAGCACGCTTAGAGTAACTGGCCCAAGGTACGC
AGCCAGGAAGCTGAGGAGCTGGGATTCAAACCCAGGTCTTGGACTCCACAGCT
TGCACTCTCTGTCCCTTTTTTTTTTTTTTTTCTTAAACCTGCCAAAGCCGGACCTTA
35 GCTGCTTGGCTCCTGAGAATCCTGGGAGGCTGGGGGCTGTCTCTATAGAGTTAGA
AGGACTGATCTGGTGGTGCCCAAGGGTGTGGCAGGACTGTGCTCTCTGATCATCC
CCATAGGACTTGGATCAGCAGCAGCTGGTCTGCAGGGAATGTTTCAGGGCAGAC
AGCGGGTGGTACTTGGCTATCTGCTGGGAGTGAAGTCCCAGCCCCACTGTTGCAG
CTGAGGAACGCTGGGCAAGTTGTTGTTTCTTCTGAAAAATGGGGTGTATAG
40 GTTCATTGCAAGAGTAACTGCTCTGCACATTCTAAAGCCTAGGAAGTATGACCAT
TCTCAGGAAGCACAGGCTCCTCTTCCATCTACCTGCAGGTCTCTAGCTCCAAGG
GCTCCTCCGCCAGCAGAATTCTAGTTTGATATTCCAGAACCCCACTCTACAAAGG
ACTGTGGTCTCTGGAAGGGAGTGGGTTTTCTCATCCTGGCCAACAGTGTTTTCCCT
AGAAAGATGAGTACTGAAGACCATTGCTCCCTCTCCCGCTTTTCTTCTCCTCCTCCT
45 CCATCCTCTCTTCTTGGAGTAGGGGTAGAGGAAAGAGCACAGGCTGAGCATGA
AACTTTCTCCTCCACATGTTTGTGCTGTCTGGGTGGCTCTGGGCCAGTTATTTAAC
CACTTGAGGCTCAGTTTTCTCATCTGTAAAATAGGATGGAGTACTAGCACCATT
TTCTAGAGCCAGAAAGACAGCACCTATGTGAAGGACCTACCATAGTACCTGGAG
TGTCATTGGTGCCAGGACACCCTGAGTCCCTGTCCCCTGCTACTTGCCTCCTACC

TCCTGCATGGAGCCTCATGGAATTTCTCAGCCCTCACTGGTCTTGACCAGCCTC
ACATCAGATGGTCTTTTCGGGCTTTCAATGAGGATGTAAGCATGCACGTCTTATTT
GTTGGATGAGTGCATGATGGAGTAAGTGAATGAACAGGGGTGGGTTTCTGGGG
CGGAGAGAGCTGCTGTGGCTGCTCCTGAGAAGGGAGAGATCTTTTGGCCCCACT
5 GGGCCTCCAGAGCCCCATGTGGGAGTTCCTCCTCCCCAGCTCTCCTGGCTCTTATC
TTATTTCTCTCCAACCATCAGAGGAGGGGCTGGTTCCACTGTTTATGGTCGGCA
CATCTAACCAGCCACCCTGAGTGCAGGGGAGCTGCATGGAGGATCTGTAGAGAG
GCAACATCTGGGGGCGCTGTGGATGCTGTGGGAAGGGGCAGCATCTCCATCGCC
CAGGCCAGCAGAATCCTCTTGCCCTAATTGTGGGGCCTCCTTCACCCGCCAGTGC
10 TCTGGGGATGGGAAAAAGGAGTCTGTGTGGCCTGACCTTGTTCTTTTCTCTGT
GTGATCTTAGACCATTGTCTAAATGCTTTTATGTATTAACTCACTTAATTCTCC
CTCTGTGCCAGGCCATGTTCTAAATGCTTTTATGTATTAACTCACTTAATTCTCC
CAATAACTCTATGAGCTAGGTGATGTTATGACTGACATCCAAGTTTCAGAGGCAG
AAAAAGGCTCGGGAAGGTTAAATGACTTGCCCAAGCACAGCAATGCTGGGATAT
15 TATTCACCCACACCCACCGCCCAATATATTCGTGGGTCACATTGGCATCTCCTGG
GCAGGGTCCCACTCCGGGCCTCTCTCTTGGTTCCCCGGTGGCCTCTGCACTTCCAA
CTTAGGCGCCTCCTTCCCTCCACTGCAGAGCCCCACGATGTCGGCCAACGCCACA
CTGAAGCCACTCTGCCCCATCCTGGAGCAGATGAGCCGTCTCCAGAGCCACAGC
AACACCAGCATCCGCTACATCGACCACGCGGCCGTGCTGCTGCACGGGCTGGCCT
20 CGCTGCTGGGCCTGGTGGAGAATGGAGTCATCCTCTTCGTGGTGGGCTGCCGCAT
GCGCCAGACCGTGGTCACCACCTGGGTGCTGCACCTGGCGCTGTCCGACCTGTTG
GCCTCTGCTTCCCTGCCCTTCTTCACCTACTTCTTGCCGTGGGCCACTCGTGGGA
GCTGGGCACCACCTTCTGCAAATGCACTCCTCCATCTTCTTTCTCAACATGTTTCG
CCAGCGGCTTCTGCTCAGCGCCATCAGCCTGGACCGCTGCCTGCAGGTGGTGCG
25 GCCGGTGTGGGCGCAGAACCACCGCACCGTGGCCGCGGCGCACAAAGTCTGCCT
GGTGCTTTGGGCACTAGCGGTGCTCAACACGGTGCCCTATTTTCGTGTTCCGGGAC
ACCATCTCGCGGCTGGACGGGCGCATTATGTGCTACTACAATGTGCTGCTCCTGA
ACCCGGGGCCTGACCGCGATGCCACGTGCAACTCGCGCCAGGCGGCCCTGGCCG
TCAGCAAGTTCCTGCTGGCCTTCTGCTGGCGCTGGCGATCATCGCCTCGAGCCA
30 CGCGGCCGTGAGCCTGCGGTTGCAGCACCGCGGCCGCGCGGCCAGGCCGCTT
CGTGCGCCTGGTGGCGGCCGTGCTGGCCGCCTTCGCGCTCTGCTGGGGGCCCTAC
CACGTGTTACGCTGCTGGAGGCGCGGGCGCACGCAAACCCGGGGCTGCGGCCG
CTCGTGTGGCGCGGGCTGCCCTTCGTCACCAGCCTGGCCTTCTTCAACAGCGTGG
CCAACCCGGTGGCTTACCTGCTCACTGCCCCGACATGCTGCGCAAGCTGCGGCG
35 CTCGCTGCGCACGGTGCTGGAGAGCGTGCTGGTGGACGACAGCGAGCTGGGTGG
CGCGGGAAGCAGCCGCCGCCGCCGACCTCCTCCACCGCCCGCTCGGCCTCCCCT
TTAGCTCTCTGCAGCCGCCCGGAGGAACCGCGGGGCCCCGCGCGTCTCCTCGGCT
GGCTGCTGGGCAGCTGCGCAGCGTCCCCGACAGCGGGCCCCCTGAACCGGGCGC
TGAGCAGCACCTCGAGTTAGAACC CGGCCACGTAGGGCGGCACTCACACGCGA
40 AAGTATCACCAGGGTGCCGCGGTTCAATTTCGATATCCGGACTCCTGCCGCAGTGA
TCAAAGTCCGAGGGGGCGGGACCCAGGCACCTGCATTTTAAAGCGCCCCGGGAGA
CTCTGAATCTTTTTCAGAAACAGTGAGTTAAAGCAGTGCTTCTCAAACCTTGATG
TGCCTGTGAATCACCTAGGGGTCTTGTAAAGTGCAGTCTGATCCAGGAGGCCGGG
GCCGGGTACTGAGAGTCTGCACTTAACAAGCTCCAGGCCGAGAAGCCAGTGCG
45 GCAGGTTACAGGGCAGGCCTGGAGTAACACAAAGTGAAACTCATAATAGACTT
CCCACTCTAGGGCAGTGGAGTCGGAAGGGCACACGGGGTGCGTCTCCCCGGAGT
TCAGTTTTACCAGATGATGGGGGAGGGGGGAAGGAGTTTTATGTTAAACCATCC
ATGTATTTTTGGAGAAGAGAGAGGAAAGGTTTGAGAAGCACTGTTCCAGCCTGC
CCTCTTCATTTAGCCAATGCTTACTGCGCTAGACGCTTCATCCCACAATCTTAAGG

GGCAGCTTCTATTAGCCAGTCTTTACAGCTGAGCACATTCTGGCTCAGGGAGGTT
AAGTGACTTGCCCAGTTTCAGGGCTAACGACCACAGGGTCTGCACTCTAACCTA
GGCATCACATGCTCAATGACTCTCTGGTGAGCGAGGACATTCTCTGACCTACTCG
AGGGACTTAAGATGCTACCTTGTGACCCAGCACTGCCCAAAGTGCTTCCAAGGCA
5 GAAGCAGCAGGGGATGGCGTGGTCAAGCACTCGGGAAACCTGGGGGCTAATCAAA
TCCAATGGGGGAAATGACTAAAAGTCTTCGGTCTGTTAGAAGTTGAATGGGCACA
GCAACTCTAAGACTACAGCACACGTCATTTCTTAGCTAAGCGGACCAGCCTCCCT
GTCGGCCTGGTGTCTGTGGGATCCCTCTGGGCACTGGTAATCCCAAGATCTGTG
CAGCCCCGCTCCAGGCCACATGGGGCTGGGCAGCTACCATTTCCCTTTTGC GGA
10 TGGGAGGGGTAACCTTGACCTCTGACCTATCACTTCCACTGCACCCCGTCTCATT
CCTCCACCTGCCGTGGACTTGGGGTCAGAGACTGCTGTGTTTGAGCTCTGCAGCC
CAGGGACCGAAAAGTTGGTGTCAATGAATTTTGCTTGGTGGATGAAATGTCAGTG
GAAGAAGCAGATGAGAAACTCTTGAGATCTTGGTCCTGTGTTTTTCTGCCACCA
AAGGCCAGGGTCACTGAAGGCCTGGCCCACAGCAGGTGCTGAGCAAAGGGAAC
15 AGTGAGGTGCCAGCTAGCTGCAGAGCCACCCTGTGTTGACACCTCGCCCCCTGCT
CCCTCCCATCCCTTCCCCCTTTACTCATAGCACTTCCCCCATTTGGACACGTGGTGC
ATTTTGCTTGTATTATGTTTTCTCTCCATCAGAATGAAAGCTCCTCGAGGGCAG
GGACTTTGGTCTATTGTCTGTATTTGCCGGTGCCTAGGATTGTGCCTGTATGCAAC
AGGCACTCAATAAATATTTTTGCTGTAGACTGGACAGGCATGAGTTAGATTCTCT
20 GGGGCTTCTGCAGAGACTGGTTTGGGAAAGTGGGTGCTAGGGAAAAGCTCTGCT
CCCTGCAACCTCCCCATTTTAATCTTTCAGTATTGAAAAGTGGAGAGGAACCGGA
TTCAGTTTGTGTTGGGACAGAGGCAGTGGGGTGTGGAGGTGCTCAGAGCAGCCTT
TGGGAAGGTGTGGGGGAAGCTGGATTCCCAACTGTCAGCCTCCAGGCCTGGGAT
GGACCTAGGATGCTGAGAAAGGGCATACTGCTGAGGGAGTCACCTGCCAGTC
25 ACCAGCTCACTGAGGAACCAGAAGAATGTACAGTTCTTGGTTTGAAGGCACTTG
GAGAAGGAGAGGAAGGAGGGATGGGAGCTGAATCTCTTCCCGCCCCCATCTCTG
CCAGGTCCCAGGCCCCCTCTGGGCTTCTGTCCACACAGACCTGCCTGGAAGCCT
TCAAAGGCCGAGGAGCCCCGGTCGGGGTGGGGGTCCCTGTTCTGGAGCCATGGG
TTTGGAGTGCCAGCTCCAGCAGAGGCATCTGAGCAGCGGCCTGAGGTGCTGTGTC
30 TGACATGGTTGTTGGCCATGGAAGGCCTCGGGCCGTCTGAGCTCAGATCTTGGC
TGCCGGCTGCTGGGGCGGCTGCTTCTGCAGCAGGGCCAGGGTGTCCCGCTTCTCA
ATGGAGCGCAGCTGCTTCTTCTTTGCCCGCTTGAAGTTGGCGGGGTTTCGGATCT
GGGGGTGGTATGAGGGGAGGACATTAGTGCGGCTGCAGCCTCGGTCCAAATTCC
CAGGGGAGAGGAAGGCCCGCCCCACAGGGGCTGAGATCGTAGCATGAGAGTGG
35 GGGTACATGAGGCAGGGGTCGAGGCCCTGGTTTGCACCCCCAAGTGGGGCAGAA
GGGCAGAGGGGGAAAACGAGACACTCACCCTTGGACGACCTCTGCCTTCCGCT
CATTCTCAGGCGGCGTTTCAGGTTCTCAGCCCCGGCGCTGTTTCTTCTCCTGGAAC
ATGTGGGAGAAGGGGATTTGAGTCGGGGAGCAGAGGCAGCCCTGGTCTCTCAGG
CCCCAGAAGAGTGCGAGCGGGCAGAATTCCCAGGAGGAAGGGGAAAGGCCCTC
40 TCTGCCAGGCTCCAGGTTGGTGATGTGTGGGTGGAGGGCTAGCAATCCTGTGCCA
CGGTCTAGTGCCAGGGGCTGCTGTGGTGGAAGCTCCTGATAGCATGTTGAGAG
GTGGGTATGGGACAGGCAACTGAGGACAGGGGCTGAGACACTGGGGGTGCCAC
CTGGAGATTACGCACATGCAGACAGTGACCCCTCATGCCACCCTCATCAACTGC
CAAGGGAGAAAGGGGTGCTGGCCCTTCCCCATTCCCACCCTCTCCGACAGTCTC
45 CCCCTCTTCCCTGGAGTCCTGCTGCTGCAGAATGCCAGGCTAGGGGTGAGGGCT
GGGTCCCTGAGATTTTCACAGGTGTGGGGCTGGGCAGGGGCTGCACTGCACAGA
AAAGGCTCTGGAGCTATCTGGGCTGGGTTTCAATCTGGATCCTGTTATTTCTTAA
ACAGGAGACCTTAGCTAAGTCTGTGCCTCAGCTTCTTCATCTTTAAAGTGACAGT
GACCACAGTATCTACCTCGTAAGATAGTTTTGGGAAATCAATGAGGGAATGCAC

GTGCAGGACTTGGAGCAGCCCCTAGCTCCTTGGGCACACTGAGACTCTAGATGG
AGTCTGTCTTGGGAGGGGAAGCCCAGTGCTCTCTAGCCATGCTGACTGTGTCCCT
CAGCAAGGCCAGGGTGGGGACGTCAGCTCCAAGGCTGCTGCATGGTTAGGAGTC
TCTGCTGGCTTTGGTGACTTGGGGTAGCAGGGGTGGCCCAGGCCCTTGGGGAGG
5 AAGGAGAAGTGAGCCTTGGCCTCCTGTGGTCAGGGCAGGCCCGGGCTGGGGGCT
GGGCAGGAGCACCTCCGCACTGGACGGTGAGAAGTGAGACGGCAGCTCTGTCTT
GCCAAGAGGGGAGCCAGGGCCACACAGGAAAAGAGATAAAGGCCTCAGCATATG
GTGGCGGACACACTGTTCCCTCAGATGTCAGCTGTAAGCTGAGCTGGGGTGACTIONA
GAGCAGGGGACAGATGACTGAGTGACTIONGGCCACCCCTTTTCTCAGTGGCCAGC
10 CTGGGACCACGGACTATGGATGAGTTGTCTGAATCCCGTTTCGGCACTCCTCCTAC
ACGCCTGGGTCATTAGAGGAGTGGAGGAGGAATCTCCCACTGACTGCCCTGCCCT
GGGGGGCAGGAGCTGACCAATGCCACTCCGCTTTCTCTGCATGCTGCCTGCTGAG
TGCCCTCTTCCCCCGCTTAAAAGTCCCTGGCAGATGTGGGTGAGGCTGTGACCC
TTTACAGGGGCTTCTGGCTCTGGGATGGGTGACAGGGGACAGAAAGTGGAGGAA
15 AGGTGCGGGGGCCATCCACGTTGCTGGTGTGTGGGCTGCTTCTTGGAGAATGACA
GCAGCCATACCGGGGACATGGAGTTCAAATCTGCAAGCCCTTCCCAACTGAGTA
CGTCCCAGCAAAGGGGCCCTCGACCCCATCTCACTGACTGCCCTACCACCCAGGAC
TTCTCCCGGGCTTCTCCCCAAGGCCCGCTTCTGGTCTTCCCCCTCCGTCCCTGTC
CCTGAGGCTCTTTACAGCAGCCAGGCTAAACTGTATGGTCCCCTGGGCCTCCCTG
20 CCTGTAGTCCCAGATTGCACTTCTGCTTCTGGCCAGGTGCCCTTCTCCTCCCGG
CCTTCAGATTCAAGAACGTTTTTTAAACCAAGTCGGCCTCCCCCAGGCACCCGTGG
AGGCCCTCGCCTCAGGTCTGTACCAGTAGACACTAGCTTAGTCCTCTGAGCCCCA
GCCTCAGCCTGGCTGGCCCCCTCACCTGGCGGCGCCTCTCCTTCTCCTCCTCCAGGT
GACGGGCAAAGTCCTTGGCCAGCTTCTCCTCCTGTCGTTCTTCATCTTCCGCTGC
25 CACGATGTGCGCAGGGGCTTGTCTGAAGCATCTGGGAGAATCTGAAAGGGGGA
GAGTGGGTGCATACAGGGTCTGTGGGGCAAGCGCCACCCATGCCCTGTCTCCTCT
CGGCCGGAGGCTCTGGACCTTCTTCCCCAGAGCCAGGCAGAACCCACCTCCTTGC
TGGCCTGACAGGCGGCCTTCCAGGGCTGCAGAAACTTGGGGCGGGAGGGAACCC
TGATCGTGTCTGGCTGCCATTTCTCAAGCCTTGGCTACATGCCTCTGAGGTGGGTA
30 CTCCTATCCTCTCCACTTACAGAGGAGCAGGCCAAGGCGCGGAGAGGTTAAATA
GCTGCCTAAAGATACCTTGTGGCAGTCAGGACTTGAATCCTGTCAGCGACTGCAG
AGTCCAGGCTACGCGGCCCTGCTGTAAAGTTCTGTTGCTTCCGCCAAGTGCATT
TGGCCCGGGTGTGAATGCCTCTGGAGGCGGGGCGCTCACCCCTAGGGAGGTGG
CCCATTCCATTTTCAAGACAGTGTGAGTGGTTAAAGTTCTGGGTAATGATTCAAGGA
35 TCTTCCCCGCCAAGACCGGATGCAGTGGTCATGCTTGTAATCCCAGCACTTTGGG
AGGCCAAGGTGGGCAGACCACGTGAGTCCAGGAGTTGGAGACCAGCCGGGCAA
ACATGGCAAAACCTACTAAGCCTACTAAAACCTACTAAAGTTTCTACTAAAAATA
CAAAAATTAGCTGGGTGTGATGGTGTATGCCTATAGTCCCAGCTACTTGGGAGGC
TGAGGTACAACAATTGCTTGAACCTGGGAGGTGGAGGTTGCAGTGAGCCGAGAT
40 CGCGCCACTGCACTCCAGCCTGGGTGACAGAGCAAGACTCTGTCTCAAAAAAAAA
AAAAGAAAAAAGAAAAAAGAAAAAGAATCTCTTCCCCCAGTTGGAGATGAAGT
GGGCATCAGGGCTCTCAGGGAAATCTGAAAAGAGCAACGATGATTTTAGAGTTA
CAGGAGAACTGAGCTCATCTCTGTAAAAATGCATACTACAAGGATTTATGAATG
GGATGATATGTCTAGGATGTACTTTAAAATATTTTACAGGGAAAAAAAATGCCAA
45 AGATCAGCCGGGCGCAGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCTG
AGGTGGGCGGATCACCTAAGGTCTGGGAGTTTCGAGACCAGCTTGACCAACATGGA
GAAACCCTGTCTCTACTAAAAATACAAAATTAGCTGGGTGTGGTGGCACACACCT
GTAATCCCAGCTACTTGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCAGGAGG
CGGAGGTTGCGGTGAGCCGAGATTGCTCCATTGCACTCTGGCCTGGGCAACAAG

AATGAAACTCCGTCTCAAAACAAAAAAGAAAAAAGAAAAAAGCCAAG
TATCAAAGATGAAGCTACACTAGTAAATGCTGAGCTGTGTTGATGCTGATAATG
GGGACTTGAGAGCTTTGCTCTTTCTTTGTATGCTTGAAAATTTCCATTCAAAAAA
GTAAAAACAAAATGCAAAGAAGTCTCTCGGTGGCCTCCACATGCTGAAATTAGG
5 TCTTTCTCTTTTAAAGATTCAAGGCCCATTTTGGTGTCCCTTGGCCCTGCCGACTT
CTGGCCCCAGCTCCCTGATTTCTTTCTCCCTTCCCAAGGCCTTGCCACTGAAGGC
CTGGCCTCCTAAGCACTAAGAATGGGGTGCCACATGGACTTCCCCATAACTGTA
AAGCTGGGCTTCCCAAGCTGGGGTACGAGAACCCTGAAGGGACAAGGTGTTGGG
AGCCTAGAGACACACAGAACCACAAGACACAGTGTGCATCTGTGTAGAGCAGG
10 GCTGTCAAACAGAACGTTCTGTGATGGTGGAAACATTCCACATTGACACTGTCCA
ATAAGGTAGCCACTAGTCATGGGTGGCTGCTGAGCGCTAGAAATGTGGTTGGTGT
TGATAGAGAACTGAATCTTAAATTTTATTTAATTTTAATTAATTTAAATGTACAT
AGCCACATGTGGCTGGCGGCTAAGGTACTGAGGCAGGGCAGTTCCAGACCATTG
GTTCTACCTGGGTATTGAGGAACTCAGGCCTGGGTTCCAAGTCCAACCTGGGTG
15 ACCTGGAGCAAGGTAGCCTCTCTAAGTCTCAGCATCCTGTCCAGTGGAGATGAGA
ATCATTCTTAACCCAAAGGGTGGTGGGAGATTTAATCGACACACACACGTAATA
GGTGCTCCATAAATGCTACTCCTCAGAGAAGGCAGACAGCATGCCCAAGGGCAC
TATGGAGAAAGTGGCGTTTGGCATGAGCACGAAGACAGGGCTGCAGCCAGGTCT
CCCTCACCACATACACTTTCCAGCTGCGGCTGTCTTCCCTCCCTGCAGCAGGAGC
20 TGCTTCCCACCCATCTCCAGGCTCACTTACTACCCACCGAAGCTGCTCCCTCAA
GATCCCAAACATCCATTCACTGAGGCCCTGCTGGGCCCCCTCGCCACAGACTTGCTG
CAGCTTCGGAAGCTGTTTTAGTTCTCTTGAGACAGCCTCCTTGTGGGTTTTCTG
CTTACCCCTGCCCCGCTATGTCTGTGTTCACTAGCCAGGCTGATCTCACAAGTC
AGGTCAATTCATTCTTTGCTTGACACCCTTCCATGGCTCCCAAGCTCACTCAGGA
25 AAGCCGGGAGTCCCTGTAAGGGTCACCAGGTCTGCTGTCTCTCTGACCTCATCT
CCTACTGTTCCCTTCTCCCCCTCATTCCAGCAGCGAGACCTCTGGAAAGCCTCTC
AAACGGGAGCTTGCTCCCGCTCAATACCTCTGAACATCCCTTTCTGTTGCCTG
GATACTGTTTCCCCAGATCTCTGCCCGGCTCCCTCTGCTCAGACCTGTTTATCTGC
AAGGCCATCTCTGAGCACTGTGGCAATACCCTGCCCTCCCTGTTATTCTCTGGTCC
30 CCATCCTGGTTTATTTTTCTTTGAAGTCTTTATTACTGACATATCATGTGTGACTT
GTTCTTTATCTGTTTCCACATTTAGAATGTTTGCTTCAGGAGAGCAGAGACTTTT
TGTTACAGACATGTTTACCCAAGATCTGAGCAACTGGTTGATGAATGAATGAAC
TACCTTCTGTCCTCAATTCATCCACTTGTTCACTTAGTGCCCTACCCTGCACTGG
GCTCTGGGGCATCTAGTCATGATAGGTAAGTCCCCACTCTTACACTCTCACGGAG
35 CCTCCGGTTTAAAGGAAAACAGGCAGTCAATAAGAATCACAAATAAATAAGCAT
TTGTGCAAATGGAGGTGTTACAAAAGAGAAGTACAGCACACAATGATAACATAA
AGCATGGGGACTTAACCTAGTTGGATAAGCCAGAGAGGCTTTTCAGAGGAGGT
GACATTTGAACTGAGCCCTGAAACATGAGTGGGGGACTGGCCAGGGAAAGAGCC
TTTCAAACAGTGGGAACAGCACGTGTGAAGGCGCTGAGGAAGGAGGGAGCGTCA
40 CACATGGGAGGAACATGGAGGGGACAAACAGTGTGGAAGCTCTAGTGATGGAGG
GGAGAGGAGGGTGGGCCTGCCGGCCTCATTAAAGGAGTCTGGAGTGCATGCTCTG
AGTGAGCAACAGTGAGTCAGGACGGGTCTGCAGTTGGGCAGGGAGCTGGAACCA
CACACCCTCTCTCCAGACTTCTTGGTCAAGTGATCTGTGGCCTCCTACTCTGCTCC
AGCTGCTGATCCTGTGTCTTGTGTGGGCCCCCTCCCTTCTCCCCACCTCTGCATGGG
45 CCCAGCCCCCTCTAGCTCAGCAAGCCATCTCCCCACCTGCAGCGTGAGTACCAG
GACCCCAAGCTTCAACCGCTCAACTTGCTCATCACCTCTTCCCACCTGAACCAG
CCTCCTCCAGTTCCACATGGCCATCAACGGCCCTGCCATTCTCCTGTGACCCCTG
GGACAGGGCAGAGGGGTAGTGCCATCATCCACTTCTCCAACAGTTACAGTCACTC
TAGCCTCAAAGTCTCTCCCATGGGAGACTTGACAGTAAATTACTCTGTAAGCCTCA

GTTTCTTCTGTTTCATCAGGGGTGGGGGGATAATATCCACAGCCTAGGGTTTTAA
GGATACAAGAAAAGGGCCTAGCACGAAGCCTGGCACAGAGTCAGCTTCTTCCTT
AAAAACACCCTCCTTCCTCATGGTCCCTCACAGGCATACATCCCTGACTCTCCCT
GTGGTTCCCATTAGCTCGAATTGGAAGTGAATCCCACACCTCTCCTTCATGGCAG
5 CCTACACTCTTCCTTCTTCAGATGAGCTACTTCGTTCCCTTCATTAAATAAGCATT
ATTGGGCATTTACTATGCCCTTGGCACAGAAAGACAAGAAAGATCTCGTGCCTGC
CCCTTAAGAAGGTGCGAATCCAATCAAGGTGGATCTACAGGGATTGGGTAAAG
GGGTTTTTGCACACAGGCTTCGGAATCAGATCTGTGCTCAGGTCCTGTGCCTAC
CACTCATTTAGCCTTGGTTTCCTCACACAAAAACAGGAATAATAACACCGCCTG
10 CTTACAGGGCTGACGTGCAGATTAAGCGTGATGACACATGCTGTTCCATGTTTG
AAAGGCTGTTGACTGGTAAATCCTTATTAAGGCTGTTGACTGGTAAATCCTTATA
TAATCAGTGCTCAGTAATACTTTTTATCTTAAAGGCAAATAACTGTAATAGACTA
TATTGGATGAAGACCTCACTGCTTTGATCAAGTAATGGCTGGTTTACTTGCTTCTG
CTTCTCTCACTAGAGAGGGGCAGACAACGGTAAATGTCTGTTGAACGAATACAGA
15 CCGTGAAGGTGCTACAGGAGAGGGCCCATAGGGACCCTGAGGAGGAAAGGCATCAG
AGAAATTGATCTTTGAGGGCCTGGCCCCACCCTCTCCGGGATCCCAGGGCATT
ACCACATTCTGATTGTAATTACCTGTTTGCTAACATCCCCACTAACGTGAGCTCTC
TCTAACCTGGGGCTATTCTCCAGGCTGCAGCAGGGCAAAGGCGGGGTCCCAAC
ACCATAGAGAACGCCACCCCTGTCCATGCTGTCCCCCACTTACCTTTTCTTGGA
20 GCGGTCTTCCACACTCGCCCCGATTTGGGCTTCCCCTTCGGGATTACAGGAAGC
TCCTCTTTATTCAACTTCTTGACGCTGGGGCCTGGGATGAAGAACCCTTTTCGCTT
CTTTGCCCCGAAGCCGCTGTACCGTCTCCCCAGCTGGAGGTGGCTTGCTCGGC
TCATGCTGACCCCGGGGGGAGCCAGGTGCCCTGGGTGTCAGCTCCAGTAGTGGCT
GAGAGGGCTCCGGACCGGGAGCTTGCTGACCGGGGTAAGGCTCTGGTGATCCTG
25 GGACCGGCGGTAGCTGATGCTGGGGGGCCCCCGGGGTCAGCTCCTCCTTATTCTG
GGCCAACTCCGAGGCCAGTACTCCCTGGTCTTGAGAACACTTTGGTGCTCCTCA
CTTGGCTTCGGCTGACATCGTGGGGATTACAGACTGTACTCTGGCTGTCTTTGAG
GCGACTCCAGGTGTAGGTCTTGCTGACGCTGGGGGGACGCTGCGCCTGGCTCTGG
CTGCCCTTGGGGTGAAGTCCAAGCCTGCACCCTGCTGCAGACGGGGTGATCCTGGG
30 CTTGTCTTCGGCGGCCTTTTCGGGGGACCCAGGCCAGCCCGCTGCACACTCGGAG
GAGACCCGGGCTCCCTCGTTTCTTCTGGGTTGCACTCGAACTCCACAAGGGCCCG
TCTCGTCCGCGAAACTGAGGTGAGGCTCTCGGGGGATTTCGGGCCTTAGGCCTCCC
AGCCGTCCGCTGCGCCTTAACGGTGTATCCATGGCTCAGCCGGTAAGTTTCCACA
CCCCTGCGCAAGTGCAGCCCCCGCCGAAACCGGGCCTTCTATGACGTCAGGAG
35 TCGCCGCGTCCGTGACGCACAGGAGGGGGGCTGTTGCTGAGGCGGCCATGTTGG
TGAGGGGTGGAGAGGCGGGACCGGGGTGGGGAGAGTGGGGCTCAGCATGCGC
GTGCGCAATTCGCGCGAGCGCAGTCAACATGTGATTGATGAGCCAGTCTTTTCC
TGGGATTTCGCTTTTGCCTTTCTTGCAAAGTTTCTGGGGAAAGAAGAGCGAGCAA
GTAGAAAAGGGAAAGTGGGAGGACCCATTTACAGGGAGAGAACAGAGTCGAAAA
40 AAGGTCCGAGGAGCCCATAGGCAAGGCCAGTGGATGTTTTGCAGCCAACTCCG
GTGCAAGTTGGGCAGAGTCTGCCCCTCCTTGGGCCTGTTTTCTCATTGTAATAGGG
GTCATTTTGCCTAGCTTCGTGCATCCCAAATGATCCTGTCAGAGTCTCCTCCCA
CCTACCTGAGGGACTGCTACCTGGGGGTCTGGAGGTGGAAGATCGGTCTTTTCT
GTGTTAATTGTTCACTCTTGATTCTTCCGTCTGTGCTTCCGTATATAATCCAT
45 AGCTCTCCCTCCCTTTTACGCGTTTTCAACGTTTGTGAGTGAAGTTGAGGTACCAA
TAAGATGCACCACCTTTGTCTGTGGCTCACCTGGGCCCTCGACCAGCTGCATAT
CCTCCACGTCCCTCTTCTTCTGCCCCAGTTCTAGAAACGGGTGGATCATCTCCG
ATCTTCTTTACAGCCAGACAGTGGTTTTTGTCTCGTGTGTGAACCTGCTTCGCTC
CCCTCCCTTCCCTTGCTATTCACCTGTAAATGTACTTTGCTTACTAAGCACTTTGG

GACCTCACCAGTGAGCAGGTGTTGACTTCTGGACCTCCCGAGGCCTAGAGAAGA
CTCTCGGGATGTGGGGTTGGGGAATGTGGGGCTGTGGAGACTTTCGTGTGAGACC
TAGGAGTGGGGCTTTGATTTACTTACAGCATGCTTCTTAGGAAGAACATCTTGGA
AGTGGCCCAGTTGTGTAATTCTTGGA⁵ACTGCCTGGGGTTGGCCATTAAAGGTCCC
AGGGCCCCGTCTGACATTCCAGTGGTTTCTTTTAGAAACCATTGTTTCTCCAGCTG
CGGGCTTGTGAGAGGGCCTGGGAAATTGTCCAAGAATATCAGGGATCAGAGTGT
CCTCATCTTCTCATGTTCTGAGTCAAGGAGACCCCTGCAGGGGGGCTTTGCCT
GCCTCACTGCTCCTCTCCGGCCATGCAGCTGTCCACAGCAGAAGCAGCCGGGACA
CCTCCTTGGCCAGCTCTTCCACCCCCCACTGTCAGAGGAGTGAGTCCATTTCAG
10 TTCCTTAAATGCCCTGCCCTGCCTGGAGACCCCAATGATCTGACACTCAGAACC
AAGCCCGGCAGGTGTTGCCAGAGTGCTGGAGGAGACTGTATGCCCTCTGCCCTG
CTCCAGTCCCCCTTGGCTTGCCTTGCCTCCTAAGCTCTTGTCCCCAGCTGGAGGGA
TCACTCTCCAGTGCCGATTGGATCATATCCTAGTCTAGCCTGAAATACTTCAGAG
GGTGATCTCAGGTTTTTCACCAGAGAGAGGGGAGATGTGTTTTAGAGGAGGCCTTTG
15 GGTGGCCCCCAGACATTTGGAGGCAC⁵TTTGTCAACCTCAGCATCAGATGGGCTCT
GGCCCAGAACCCCTACTCCCACATGAGCTCAATTTGTCATTGTCATTATACATG
GTGTGCAGAGGCCCAGAGGAGACTCCTGAAATTTTCAGAAGAGCCTGGTGTGGC
GATCGCTGTTGGGACCCTGTCTCCTTACACTCCTTTGCTTTCTTTTAAAAATTATT
ATTATTTTGTAGACAGGGTCTTGCTCTGTTGTCCAGGCTGGAGTGCAGTGGCACA
20 ATCACAGCTCACTGCAGCCTTGACCTCCCAGGCCCCAGGGATCCTCCCACCTGAG
TAGCTGGCACCACAGGCTCATGCCACCATGCCTGGCTATTTTTTTTTTTTGTAGA
AACGGGGTCTCCCTGTGTTGCTCAGGCTGGTCTTGAACCTCCTGGGCTCAAGTGAT
CCTCCTGCCTCGGCCTCCTGAAGTGTTGGGATTACAGGCGTGAGCCACTGTGCCT
GGCCACTCCTTTGCTTTTATTGCAGCTTTCTACATCACAGCTTTCTTGCCTTTAGGT
25 GGTAGGATACTGAGGGGCTTCTCTGTAGCCCCCAGAGGCCACCAACAGGATTGA
ACTTGCAATTGCCACAAAGGTAATCTGCTCATGGACCCTCTTTTGGCTTCATCTCT
GTCTCACTTCCCCACTTTCTTATAGATGCTTGTGAGGTCATTCTCAGAGCAGACA
AATATTGTACTTAATCCTCTTCTCAGAGTTGGCTTCTGCAGAAACCTAGCCTGAA
ACATTGGTGCCAGCAATGATTGGTCCAGGCATTGTTTCAAGTACTCTCCAAGTAC
30 AAATCCATTTCTTAATGCTTCTCCCAACAATCCTGTGAGGCAGGTGCAGTTGTTAT
TACTCCCAGTTTACAGATAAAGAAACTGAGAGGCTGGGTGCGCTGGCTCACACCT
GTAGTAATCCCAGTACTTTGGGAGGCCAAGGTGGGCGGATCACTGGAGGCCAGG
AGTTCAAGACCAGCCTGGCCAACATGATGAAACCCATCTCTACTAAAAGTACA
AAAATTAGCTGGGTGTGGTGGCAGGCGCCTCGAGTCCCAGCTACTCAGGAGGCT
35 GAGGCAGGGGAATTGCTTGAACCTGGGAGGTAGAGGTTGCAGTGAACCAAGATC
GTGCCACTGCACAGCAACCTGGGTGGCAGAGCAAGACTCTGTCTCAAAAAAAAAA
AAAAAAAAAGACTGAGGCACAGAGAGGCTGAGACACTTGTAAGGTACACACAGCA
AATAAGTGGTAGAGGCAAGATCCACACCTAGACTGTCTGATTCCAGAGCCACAA
CTCTTAACAGTAAATCTGCCTGTTATCCAGGCAAGGAATCAGGCATGGGAAGGCT
40 AAGGTGCTTGCCCCAAAATCAGACAGCGGCACATTTCAGGAGCCAGGATTGTGGTT
CCAGAGGTGGCATGCTTAGCTGCCTTGCAGCTGCCCCACATGGGCCTTGCTCAC
CTATTCGTACACTGATTCTGGTCTGTGTGCTGGGAGGAGGTGGGTACCACCTGG
CACACACCATCGTGCAGAATGTGCCGAATCAGCAATACCAGTTTATTTATGTAAC
CTGAGATCTGCTGACTGATGGAAACCAAGCGCTGGCAGATGGATGGAAGATAGG
45 ATCAGGTGTTCTCCTCTGAGTCATTGACCTCCCCCAGCTAAGGGGTGCTACAGT
TGAGAGGGTCTGACAGTCCCCAGATGTCAGAGACCTGGGTCCCCATGGCTTTCTG
TTCAACACCTAGCCTTGCCTGAAATACTTCAGAGGGTGATCTCAGGTTTTTCACCA
GAGAGAGGGAGATGTGTTTTAGAGGAGGCCTTTGGGTGGCCCCCAGACACTTGG
AGACACTTTGTCAACCTCAGCATCAGGTGGGCTCTGGCCCAGAACCCCTACTCC

CACCTGAGCTCAGTTTGTGATTGTCATTATACATGGTGTGCAGAGGCCAGAGGA
GACTCCTGAAATTTTCAGAAGAGCCTGGTGTGGTGGTGTACTTGCAGAGTGCTTG
AAACAATGCCTGGACCAATCATTGCTTGCCCCGGTGTTCAGGCTGTGTTTCTCC
AGAAGCCAACCTCTGAGAGAAGGGCAGGGAAAGGGCCCCCTGGCGGTATCAGCA
5 GCATTAAGTGAAGCACTTACCACGCGCCAGACCTCTTCTGGGTGCTCCTGTGCTCC
CCAGAGCTCCGGTTCGGGAGGGTGATTTTCAGCAGGAGCACGGTACTTGATATGT
ATTTGTTGAATGAAT

SEQ ID NO: 128

10 >gi|2570128|dbj|AB000714.1|AB000714 Homo sapiens hRVP1 mRNA for RVP1, complete
cds
AATTCGGCACGAGGGCAGGTGCAGGCGCACGCGGCGAGAGCGTATGGAGCCGA
GCCGTTAGCGCGCGCCGTCGGTGAGTCAGTCCGTCCGTCCGTCCGTCCGTCCGGG
CGCCGCAGCTCCCGCCAGGCCAGCGGCCCGGCCCTCGTCTCCCCGCACCCGG
15 AGCCACCCGGTGGAGCGGGCCTTGCCGCGGCAGCCATGTCCATGGGCCTGGAGA
TCACGGGCACCGCGCTGGCCGTGCTGGGCTGGCTGGGCACCATCGTGTGCTGCGC
GTTGCCCATGTGGCGCGTGTGCGCCTTCATCGGCAGCAACATCATCACGTGCGAG
AACATCTGGGAGGGCCTGTGGATGAACTGCGTGGTGCAGAGCACCGGCCAGATG
CAGTGCAAGGTGTACGACTCGCTGCTGGCACTGCCACAGGACCTTCAGGCGGCC
20 CGCGCCCTCATCGTGGTGGCCATCCTGCTGGCCGCCTTCGGGCTGCTAGTGGCGC
TGGTGGGCGCCAGTGACCAACTGCGTGCAGGACGACACGGCCAAGGCCAAGA
TCACCATCGTGGCAGGCGTGCTGTTCTTCTCGCCGCCCTGCTCACCTCGTGCCG
GTGTCTTGGTGGCCAAACACCATATCCGGGACTTCTACAACCCCGTGGTGGCCG
AGGCGCAGAAGCGCGAGATGGGCGCGGGCCTGTACGTGGGCTGGGCGGCCGCG
25 GCGCTGCAGCTGCTGGGGGGCGCGCTGCTCTGCTGCTCGTGTCCCCACGCGAGA
AGAAGTACACGGCCACCAAGGTCGTCTACTCCGCGCCGCGCTCCACCGGCCCGG
GAGCCAGCCTGGGCACAGGCTACGACCGCAAGGACTACGTCTAAGGGACAGACG
CAGGGAGACCCACCACCACCACCACCACCAACACCACCACCACCACCGCGAGC
TGGAGCGCGCACCAAGGCCATCCAGCGTGCAGCCTTGCCCTCGGAGGCCAGCCAC
30 CCCCAGAAGCCAGGAAGCCCCCGCGCTGGACTGGGGCAGCTTCCCCAGCAGCCA
CGGCTTTGCGGGCCGGGCAGTCGACTTCGGGGCCAGGGACCAACCTGCATGGA
CTGTGAAACCTCACCTTCTGGAGCACGGGGCCTGGGTGACCGCCAATACTTGAC
CACCCCGTCGAGCCCCATCGGGCCGCTGCCCCCATGTCGCGCTGGGCAGGGACC
GGCAGCCCTGGAAGGGGCACTTGATATTTTCAATAAAAGCCTCTCGTTTTAGC

35 SEQ ID NO: 129

>gi|1563888|gb|U66199.1|HSU66199 Human fibroblast growth factor homologous factor 3
(FHF-3) mRNA, complete cds
ATGGCGGCGCTGGCCAGTAGCCTGATCCGGCAGAAGCGGGAGGTCCGCGAGCCC
40 GGGGGCAGCCGGCCGGTGTGCGCGCAGCGGCGCGTGTGTCCCCGCGGCACCAAG
TCCCTTTGCCAGAAGCAGCTCCTCATCCTGCTGTCCAAGGTGCGACTGTGCGGGG
GGCGGCCCGCGCGGCCGACCGCGGCCCGGAGCCTCAGCTCAAAGGCATCGTCA
CCAAACTGTTCTGCCGCCAGGGTTTCTACCTCCAGGCGAATCCCGACGGAAGCAT
CCAGGGCACCCAGAGGATAACAGCTCCTTCAACCACTTCAACCTGATCCCTGTG
45 GGCTCCGTGTGGTCAACATCCAGAGCGCCAAGCTGGGTCACTACATGGCCATGA
ATGCTGAGGGACTGCTCTACAGTTCGCCGCATTTACAGCTGAGTGTGCTTTAA
GGAGTGTGTCTTTGAGAATTACTACGTCTGTACGCCTCTGCTCTCTACCGCCAGC
GTCGTTCTGGCCGGGCCTGGTACCTCGGCCTGGACAAGGAGGGGCCAGGTCATGA
AGGGAACCCGAGTTAAGAAGACCAAGGCAGCTGCCCACTTCTGCCCAAGCTCC

TGGAGGTGGCCATGTACCAGGAGCCTTCTCTCCACAGTGTCCCCGAGGCCTCCCC
TTCCAGTCCCCCTGCCCCCTGA

SEQ ID NO: 130

- 5 >gi|1689891|gb|AA133129.1|AA133129 zm25d01.s1 Stratogene pancreas (#937208) Homo sapiens cDNA clone IMAGE:526657 3' similar to TR:G992563 G992563 ELONGIN A. ;, mRNA sequence
- ACCCCAGGAAGAAGAAGAAGCTGGATTTACTGGGCGCAGAATGAATTCCAAGAT
GCAGGTGTATTCTGGTTCCAAGTGTGCCTATCTCCCTAAAATGATGACCTTGCAC
10 CAGCAATGCATCCGAGTACTTAAAAACAACATCGATTCAATCTTTGAAGTGGGA
GGAGTCCCATACTCTGTTCTTGAACCCGTTTTGGAGAGGTGTACACCTGATCAGC
TGTATCGCATAGAGGAATACCAATCATGTATTAATTGAAGAAACAGATCAATTAT
GGAAAGTTCATTGTCAACGAGACTTTAAGGAAGAAAGACCCGAAGAGTATGAGT
CGTGGCGAGAGATGTACCTGCGGCTTCAGGACGCCCCGAGAGCAGCGGCTACGA
15 GGTACTAACAAAGAATATCCAGTTCGCACATGGCCAATTA

SEQ ID NO: 131

- >gi|186385|gb|M63099.1|HUMILRA Human interleukin 1 receptor antagonist (IL1RN) gene, complete cds
- 20 ATGGAAATCTGCAGAGGCCTCCGCAGTCACCTAATCACTCTCCTCCTCTTCCTGTT
CCATTCAGAGACGATCTGCCGACCCTCTGGGAGAAAATCCAGCAAGATGCAAGC
CTTCAGAATCTGGGATGTTAACCAGAAGACCTTCTATCTGAGGAACAACCAACTA
GTTGCTGGATACTTGCAAGGACCAATGTCAATTTAGAAGAAAAGATAGATGTG
GTACCCATTGAGCCTCATGCTCTGTTCTTGGGAATCCATGGAGGGAAGATGTGCC
25 TGTCTGTGTCAAGTCTGGTGTATGAGACCAGACTCCAGCTGGAGGCAGTTAACAT
CACTGACCTGAGCGAGAACAGAAAGCAGGACAAGCGCTTCGCCTTCATCCGCTC
AGACAGCGGCCCCACCACCAGTTTTGAGTCTGCCGCCTGCCCCGGTTGGTTCCTC
TGCACAGCGATGGAAGCTGACCAGCCCGTCAGCCTCACCAATATGCCTGACGAA
GGCGTCATGGTCAACAAATTCTACTTCCAGGAGGACGAGTAG
30

SEQ ID NO: 132

- >gi|186738|gb|M60828.1|HUMKGF Human keratinocyte growth factor mRNA, complete cds
- ACGCGCTCACACACAGAGAGAAAATCCTTCTGCCTGTTGATTTATGGAAACAATT
ATGATTCTGCTGGAGAACTTTTCAGCTGAGAAATAGTTTGTAGCTACAGTAGAAA
35 GGCTCAAGTTGCACCAGGCAGACAACAGACATGGAATTCTTATATATCCAGCTGT
TAGCAACAAAACAAAAGTCAAATAGCAAACAGCGTCACAGCAACTGAACTTACT
ACGAACTGTTTTTATGAGGATTTATCAACAGAGTTATTTAAGGAGGAATCCTGTG
TTGTTATCAGGAATAAAAGGATAAGGCTAACAATTTGGAAAGAGCAAGTACTC
TTTCTTAAATCAATCTACAATTCACAGATAGGAAGAGGTCAATGACCTAGGAGTA
40 ACAATCAACTCAAGATTCATTTTCATTATGTTATTCATGAACACCCGGAGCACTA
CACTATAATGCACAAATGGATACTGACATGGATCCTGCCAACTTTGCTCTACAGA
TCATGCTTTCACATTATCTGTCTAGTGGGTACTATATCTTTAGCTTGCAATGACAT
GACTCCAGAGCAAATGGCTACAAATGTGAACTGTTCCAGCCCTGAGCGACACAC
AAGAAGTTATGATTACATGGAAGGAGGGGATATAAGAGTGAGAAGACTCTTCTG
45 TCGAACACAGTGGTACCTGAGGATCGATAAAAGAGGCAAAGTAAAGGGGACCC
AAGAGATGAAGAATAATTACAATATCATGGAAATCAGGACAGTGGCAGTTGGAA
TTGTGGCAATCAAAGGGGTGGAAAGTGAATTCATCTTGCAATGAACAAGGAAG
GAAAACCTCTATGCAAAGAAAGAATGCAATGAAGATTGTAACCTCAAAGAATAA
TTCTGGAAAACCAATTACAACACATATGCATCAGCTAAATGGACACACAACGGAG

GGGAAATGTTTGTTCCTTAAATCAAAAAGGGGATTCTGTAAAGAGGAAAAAAAAA
CGAAGAAAGAACAAAAAACAGCCCACTTTCTTCCTATGGCAATAACTTAATTGC
ATATGGTATATAAAGAACCCAGTTCAGCAGGGAGATTTCTTTAAGTGGACTGTT
TTCTTTCTTCTCAAAATTTCTTTCTTTTATTTTTTAGTAATCAAGAAAGGCTGGA
5 AAAACTACTGAAAACTGATCAAGCTGGACTTGTGCATTTATGTTTGTTTAAGA
CACTGCATTAAAGAAAGATTTGAAAAGTATACACAAAAATCAGATTTAGTAACT
AAAGGTTGTAAAAAATTGTAAACTGGTGTACAATCATGATGTTAGTAACAGTA
ATTTTTTTCTTAAATTAATTTACCCTTAAGAGTATGTTAGATTTGATTATCTGATA
ATGATTATTTAAATATTCCTATCTGCTTATAAAATGGCTGCTATAATAATAAAT
10 ACAGATGTTGTTATATAAGGTATATCAGACCTACAGGCTTCTGGCAGGATTTGTC
AGATAATCAAGCCACACTAACTATGGAAAATGAGCAGCATTTTAAATGCTTTCTA
GTGAAAAATTATAATCTACTTAAACTCTAATCAGAAAAAAATTCTCAAAAAAA
CTATTATGAAAGTCAATAAAATAGATAATTTAACAAAAGTACAGGATTAGAACA
TGCTTATACCTATAAATAAGAACAAAATTTCTAATGCTGCTCAAGTGGAAGGGT
15 ATTGCTAAAAGGATGTTTCCAAAAATCTTGTATATAAGATAGCAACAGTGATTGA
TGATAATACTGTACTTCATCTTACTTGCCACAAAATAACATTTTATAAATCCTCAA
AGTAAAATTGAGAAATCTTTAAGTTTTTTTCAAGTAACATAATCTATCTTTGTATA
ATTCATATTTGGGAATATGGCTTTTAATAATGTTCTTCCCACAAATAATCATGCTT
TTTTCTATGGTTACAGCATTAAACTCTATTTTAAGTTGTTTTTGAACTTTATTGTT
20 TTGTTATTTAAGTTTATGTTATTTATAAAAAAAAACCTTAATAAGCTGTATCTGT
TTCATATGCTTTTAATTTTAAAGGAATAACAAAACCTGTCTGGCTCAACGGCAAGT
TTCCCTCCCTTTTCTGACTGACACTAAGTCTAGCACACAGCACTTGGGCCAGCAA
ATCCTGGAAGCAGACAAAAATAAGAGCCTGAAGCAATGCTTACAATAGATGTCT
CACACAGAACAATACAAATATGTAAAACTCTTTCACCACATATTCTTGCCAATT
25 AATTGGATCATATAAGTAAAATCATTACAAATATAAGTATTTACAGGATTTTAAA
GTTAGAATATATTTGAATGCATGGGTAGAAAATATCATATTTTAAAACTATGTAT
ATTTAAATTTAGTAATTTTCTAATCTCTAGAAATCTCTGCTGTTCAAAAGGTGGCA
GCACTGAAAGTTGTTTTCTGTAGATGGCAAGAGCACAAATGCCCAAATAGAA
GATGCAGTTAAGAATAAGGGGCCCTGAATGTCATGAAGGCTTGAGGTCAGCCTA
30 CAGATAACAGGATTATTACAAGGATGAATTTCCACTTCAAAGTCTTTTATTGGC
AGATCTTGGTAGCACTTTATATGTTACCAATGGGAGGTCAATATTTATCTAATTT
AAAAGGTATGCTAACCACTGTGGTTTTAATTTCAAATATTTGTCATTCAAGTCC
CTTTACATAAATAGTATTTGGTAATACATTTATAGATGAGAGTTATATGAAAAGG
CTAGGTCAACAAAAACAATAGATTCATTTAATTTCTGTGGTTGACCTATACGA
35 CCAGGATGTAGAAAAC TAGAAAGAACTGCCCTTCCTCAGATATACTCTGGGAG
AGAGCATGAATGGTATTCTGAACATACCTGATTCAAGGACTTTGCTAGCTAGG
TTTTGAGGTCAGGCTTCAGTAACCTGTAGTCTTGTGAGCATATTGAGGGCAGAGGA
GGACTTAGTTTTTCATATGTGTTTTCTTAGTGCCTAGCAGACTATCTGTTTATAAT
CAGTTTTTCAGTGTGAATTCAGTGAATGTTTATAGACAAAAGAAAATACACACTAA
40 AACTAATCTTCATTTTAAAAGGGTAAAACATGACTATACAGAAATTTAAATAGAA
ATAGTGTATATACATATAAAATACAAGCTATGTTAGGACCAAATGCTCTTTGTCT
ATGGAGTTATACTTCCATCAAATTACATAGCAATGCTGAATTAGGCAAAACCAAC
ATTTAGTGGTAAATCCATTCCTGGTAGTATAAGTCACCTAAAAAAGACTTCTAGA
AATATGTACTTTAATTATTTGTTTTTCTCCTATTTTTAAATTTATTATGCAAATTTT
45 AGAAAATAAAATTTGCTCTAGTTACACACCTTTAGAATTCTAGAATATTAATACT
GTAAGGGGCCCTCCATCCCTCTTACTCATTTGTAGTCTAGGAAATTGAGATTTTGAT
ACACCTAAGGTCACGCAGCTGGGTAGATATACAGCTGTCACAAGAGTCTAGATC
AGTTAGCACATGCTTTCTACTCTTCGATTATTAGTATTATTAGCTAATGGTCTTTG
GCATGTTTTTGTTTTTTATTTCTGTTGAGATATAGCCTTTACATTTGTACACAAAT

GTGACTATGTCTTGGCAATGCACTTCATACACAATGACTAATCTATACTGTGATG
ATTTGACTCAAAAGGAGAAAAAGAAATTATGTAGTTTCAATTCTGATTCTTATTC
ACCTTTTGTATGAATGGAAAGCTTTGTGCAAAATATACATATAAGCAGAGTAA
GCCTTTTAAAAATGTTCTTTGAAAGATAAAATTAAATACATGAGTTTCTAACAAT
5 TAGA

SEQ ID NO: 133

>gi|1399238|gb|U59832.1|HSU59832 Human transcription factor, forkhead related activator
4 (FREAC-4) mRNA, complete cds

10 CGCCGCCACCCGGCAGCCCCGGCGCAGCTCCGGCAGCCGAGTCGCAGCGCCCC
CAGCGTGGCGCCCCCGGCCGGGCTGCCGCCGGGACCCGGGCTGGGGCGCAG
AGGGAGCCCGGAGCCCGGCCGCCCATGCGCCGCCCGCCGCCGCCGCCACA
GCTATGACCCTGAGCACTGAGATGTCCGATGCCTCTGGCCTCGCCGAGGAAACA
GACATCGACGTGGTGGGGGAGGGCGAGGACGAAGAAGACGAGGAAGAGGAGGA
15 CGACGACGAGGGCGGCGGTGGCGGGCCCCGGCTGGCTGTCCCCGCGCAGCGGCG
GCGGCGGCGGCGCTCGTACGCCGGGGAGGACGAGCTGGAGGATCTGGAGGAGG
AGGAGGACGACGATGACATCCTGCTGGCCCCGCCTGCTGGGGCTCCCCGGCGCC
CCCGGGCCCCGGCCCCGGCGGCGGGGGCAGGAGCCGGTGGGGGCGGCGGCGGCG
GCGGCGCGGGCGGCGGCGGGAGCGCGGGTAGCGGCGCCAAGAACCCGCTGGTG
20 AAGCCGCCCTACTCGTATATCGCGCTCATCACTATGGCCATCCTGCAGAGCCCCA
AGAAGCGGCTGACGCTGAGCGAGATCTGTGAGTTCATCAGCGGCCGCTTCCCCTA
CTACCGGGAGAAGTTCCCCGCCTGGCAGAACAGCATCCGCCACAACCTCTCGCTC
AACGACTGCTTCGTCAAGATCCCCCGCGAGCCCGGCAACCCGGGCAAGGGCAAC
TACTGGACGCTGGACCCGGAGTCCGCCGACATGTTTCGACAACGGCAGCTTCCTGC
25 GCCGGAGGAAGCGCTTCAAGCGGCAGCCGCTGCTCCACCCAACGCCGCGGCCG
CCGAGTCTCTGCTGCTGCGCGGCGCGGGAGCCGCAGGGGGGCGCGGGCGACCCGG
CAGCCGCCCGCCGCGCTCTTCCCGCCCCGCGCCCCCGCCGCCCGCCGCTACGG
CTACGGCCCCCTACGGCTGCGGCTACGGCCTGCAGCTGCCGCTTACGCGCCGCC
TCGGCCCTCTTCGCCGCCGCAGCGGCCGCCGCCGCCGCCGCCGCTTCCACCCGC
30 ACTCGCCCCCGCCGCCGCCGCCACCGCACGGCGCGGCCGCCGAGCTGGCCCCGA
CCGCTTCGGCTACCGGCCGCACCCGCTCGGCGCCGCCCTACCCGGCCCCCTGCC
GGCCTCCGCGGCCAAGGCGGGCGGCCCGGGCGCCTCAGCGCTGGCGCGCTCGCC
CTTCTCCATCGAGAGCATCATCGGGGGCAGCTTGGGCCCCGGCCGCCGCTGCCGCC
GCCGCCGCGCAGGCCGCCGCCGCCGCTCAGGCCTCGCCCTCGCCCTCGCCGGTGG
35 CGGCGCCGCCAGCTCCCGGATCCAGCGGAGGAGGCTGCGCGGCGCAGGCGGCCG
TGGGCCCCGGCGGCCGCGCTCACCCGATCCCTCGTGGCCGCCGCGGCCGCCGCCG
CTCCTCAGTCTCCTCGTCCGCCGCTTGGGGACTCTGCACCAAGGGACTGCCCTG
TCCAGTGTCGAGAACTTTACTGCTAGGATTTCCAATTGTTAATAACGCTATGTTA
GCGCGCTCGAGGAAGAAGGTAGGAATCCCGGCTCCTTTTCTCGTCTTGGTGGTTC
40 GGTGTTTTGTTTCGCTCCTCCAGGCGCGGCCCTCTCGACCTCGCGCGCCATTTC
GCCGCTGCGAATTCTCGGACAAAAGTGTCAACAGCCCCGGGCGCGCCTTTTGGCTC
TGCGGGTCCCTCTATTTATGCAAAGCCGACCTATGCTACAGCCCCCAACCCCG
ACCTGGGGTAGGGAGGAAGAGGGTGCCGGGGAAGGGAGTCCGCCCTGTCCAGG
CACTAGAGGCTCCCTTGACGTTTGGCAGATGAAAAACAATAAGCCTTTTTGAGG
45 TGTAGAGATTCTCAGGTCCAGGCGTTAAAAATAATGGTCAAAAGAATAATACA
AAAATAGTAAAGGTCTTGAAGAATGCCAGCGAAGCAATTCTTTTTTATTTGAGGA
CACTTGTCTGGTGTACTTTTTTCATGAAAAGGAAAAATGGTTAACATGTTTACACA
AGAAAAAAAGTCAAAATTATCATTTATTTCAACCTGTGTTTGTATCATAACAGA
CGTGTGGATTTTTTTGTACTTACTGCGTATTCTTTACAAGGAGTATTGTAAATTTT

ACTGGCAATTATTATTGTACTATTCTAAATGTAAGATTTTACACTTTTTCAGAAA
TAAAAATGCTTAATTTTCAAAGAAAATTACCAAAA

SEQ ID NO: 134

5 >gi|181977|gb|M38425.1|HUMEGFR Human EGF receptor (EGFR) gene, 5' end
AAGCTTCCGCGAGTTTCCCAGGCATTTCTCCTCGCGGGACTACCAGGGGTTAGTGG
GACACTTAGCCTCTCTAAAAGCACCTCCACGGCTGTTTGTGTCAAGCCTTTATTCC
AAGAGCTTCACTTTTGC GAAGTAATGTGCTTCACACATTGGCTTCAAAGTACCCA
TGGCTGGTTGCAATAAACATTAAGGAGGCCTGTCTCTGCACCCGGAGTTGGTGCC
10 CTCATTTTCAGATGATTTTCGAGGGTGTGACAAGATCTGAAGGACCCTCGGACTT
TAGAGCACCACTCGGAACGCCTGGCACCCCTGCCGCGCGGGCACGGCGACCTC
CTCAGCTGCCAGGCCAGCCTCTGATCCCCGCGAGGGGTCCCGTAGTGCTGCAGGG
GGAGGCTGGGGACCCGAATAAAGGAGCAGTTTCCCCGTCGGTGCCATTATCCGA
CGCTGGCTCTAAGGCTCGGCCAGTCTGTCTAAAGCTGGTACAAGTTTGCTTTGTA
15 AAACAAAAGAAGGGAAAGGGGAAGGGGACCCTGGCACAGATTTGGCTCGACC
TGGACATAGGCTGGGCTGCAAGTCCGCGGGGACCGGGTCCAGAGGGGCAGTGCT
GGGAACGCCCCCTCTCGGAAATTAACCTCCTCAGGGCACCGCTCCCCCTCCATGCGC
CGCCCCACTCCCGCCGGAGACTAGGTCCCGCGGGGGGCCACCGTGTCCACCGCCTC
GCGGCCGCTGGCCTTGGGTCCCCGCTGCTGGTTCTCCTCCCTCCTCCTCGCATTCT
20 CCTCCTCCTCTGCTCCTCCCGATCCCTCCTCCGCCGCTGGTCCCTCCTCCTCCCG
CCCTGCCTCCCGCGCCTCGGCCCGCGCGAGCTAGACGTCCGGGCAGCCCCCGGCG
CAGCGCGGCCGCAGCAGCCTCCTCCCCCGCACGGTGTGAGCGCCCGCCGCGCC
GAGGCGGCCGGAGTCCCGAGCTAGCCCCGCGGCCGCGCCGCCCAGACCGGACG
ACAGGCCACCTCGTCGCGTCCGCCCCGAGTCCCCGCCTCGCCGCCAACGCCACAAC
25 CACCGCGCACGGCCCCCTGACTCCGTCCAGTATTGATCGGGAGAGCCGGAGCGA
GCTCTTCGGGGAGCAGCGATGCGACCCTCCGGGACGGCCGGGGCAGCGCTCCTG
GCGCTGCTGGCTGCGCTCTGCCCCGGCGAGTCGGGCTCTGGAGGAAAAGAAAGGT
AAGGGCGTGTCTCGCGGCTCCCCGCCGCCCCCGGATCGCGCCCCGGACCCCGCA
GCCCCGCCAACCGCACCGCGCACCGGCTTCGCCCCGCGCCCCCGCCGCTCTTTCC
30 TGTTTCCTTGAGATCACGTGCGCCGCGACCGGGACCGCGGGAGGAACGGGACG
TTTCGTTCTTCGGCCGGGAGAGTCTGGGGCGGGCGGAGGAGGAGACGCGTGGA
CACCGGGCTGCAGGCCAGGCGGGGAACGGCCGCGGGGACCTCCGGCGCCCCGAA
CCGCTCCCAACTTTCTTCCCTCACTTTCCCCGCCAGCTGCGCAGGATCGGCGTCA
CTGGGGCGAAACCGGGTGTGGTGGGGCGCCTGGGGCCGGGGTCCCGCACGGGCT
35 CCCCCGCGCTGTCTTCCAGGGCGCGACGGGGTCTGGCGCGCACCCGAGGGCCG
CTGCCCACCCCGCGAGACTGCCTGTTTAGGGAAGCTGAGGAAGGAACCAAAAA
TACAGCCTCCGCTCGGACCCCGCGGGACAGGCGGCTTTCTGAGAGGACCTCCCCG
CCTCCGCGCTCCGCGCAGGTCTCAAACCTGAAGCCGGCGCCCGCCAGCCTGGCCCC
GGCCCCCTCTCCAGGTCCCCGCGATCCTCGTTCCCCAGTGTGGAGTCGCAGCCTCG
40 ACCTGGGAGCTGGGAGAACTCGTCTACCACCACTGCGGCTCCCGGGGAGGGGT
GGTGCTGGCGGCGGTTAGTTTCTCGTTGGCAAAAGGCAGGTGGGGTCCGACCC
GCCCTTGGGGCGCAGACCCCGGCCGCTCGCCTCGCCCGGTGCGCCCTCGTCTTGC
CTATCCAAGAGTGCCCCCACTCCCGGGACCCAGCTCCCTCCGCGCCCGCGCCG
AAAGCCCCAGGCTCTCCTTCGATGGCCGCCTCGCGGAGACGTCCGGGTCTGCTCC
45 ACCTGCAGCCCTTCGGTCGCGCCTGGGCTTCGCGGTGGAGCGGGACGCGGCTGTC
CGGCCACTGCAGGGGGGGATCGCGGGACTCTTGAGCGGAAGCCCCGGAAGCAGA
GCTCATCCTGGCCAACACCATGGTGTTTCAAATGGGGCTCACAGCAAATTTCTC
CTCAAAACCCGGAGACTTTCTTTCTTGATGTCTTTTTTGCTGTTTGAAGAATTT
GAGCCAACCAAAATATTAAACCTGTCTTACACACACACACACACACACACAC

ACACACACCGGATTGCTGTCCCTGGTTCAAGTGTGCCAAGTGTGCAGAAGAACAT
 GAGCGAGTCTGGCTTCGTGACTACCGACCATAAACCCACTTGACAGGGGAAACA
 TGCCTTGGAAGGTTTAATTGCACAATCCAACCTTGACTGCGCGGGTTCCAAGAG
 CCAGGCCCGTACTTGCTGTTGATGTCAATTGGCTTGGGGAGTTGGGGTTTGGTGCC
 5 CAGCGCGGTCGTTGGGGGAGGGGCGGAAGGCATAGAACAGTGGTTCCTGCGCC
 CTTCTGCACATTGGAATTACCTGGGATTAATAAAAAAAAAAATCAAAACAAAAACC
 AGTGTCTCGTCCCGCCCCAGACATTCTGATTTAATTGGCATGGGGCAAGACCTG
 GACTTGGGATTTTTTTAATGCTCTTCATGTGATCTGTTGGGCAGCCAGATTTGGG
 GATCACTAGACGGAAGAAGGATTGTTAAAGTCTCCGGAGATGTTACTTGCCAAT
 10 GCTAAGAGCTCTTTGAGACATCTGGAATTGTTACAATATTGCCAAATATAGGAAA
 GAGGGAAAAGGTAGAGTGTGATTCCAATAATAAAGGATTCCGCTTTTCATTGAA
 GGAAGTGGTGGAAGGTTTCTTCTCTGCTAGACCTGCAGGCCCGTCTGCCTGCC
 TGGGGCGCCCGGGAGACGCGGGCCTGCTCCGGAGACTGCTGACTGCCGGTCTCTG
 TTAGTCAGGTGTCAGCCCTGTCTCTGCCGAAGAGACTCTCTCTTTATTTTAAATTA
 15 AACCCTCAGAGCACCACCAAAGCATCACTTTTCTCCCTCCATTGGTGTTCTCATTC
 TTTGATGTTACTTGTITGAACACCACTATTAGTAGTTGGAGATTTGTTCTGAGAA
 AAATATAAATACCACTTAATTTGCCTGTTTGTCCCGCATTCACTCAAAACAGAAT
 GCTCCTGAAGACAAGAGAGAGAGTAGGAGAACAGACGCTATTCCATTACAGTAA
 CATAAAAGACTGGATTTTCAGGGGCAAATTATTAATAAGGAGATGAGCTCTTTT
 20 AACAGAAATTTGTTTAAGGCCTGTGTCTATCAAATTCAGTGGATTTTATTCAAGA
 TGCACTTTGTITAGTGGGAGTTTTGTTTGGTTCTGGGACATGCTAACTTCTAGACT
 TGCTGCTCTTAGAGGTAATGACTGCCAGACACCATTTCATGAGTCCTAATCCCCA
 CATTAAGCATAAGAGGTGCACACTCTCCTCCTATGGGGGAAACTGAGGTACGAA
 GAACTAAAGTGACTTTCCACAGCTGGTGGGAGGCAGACGGGAAATTCACACCA
 25 GGGGCTTCCAACCTCAGATCCCTCTCTCAACTTCCAACCTCACTGCCTTGTCCGA
 GTTCTGGTTTCAGGAGATCCAAATCAGGTGTGTGCAAATGTCTAATGTCAGAGCT
 GGCAAGGGGAAAGGGCCAGGGAGCCGGCTCATGACGATGAGCCTGTCTGAAGC
 TT

30 SEQ ID NO: 135

>gi|2162425|gb|AA448755.1|AA448755 zx10d10.r1 Soares_total_fetus_Nb2HF8_9w Homo sapiens cDNA clone IMAGE:786067 5' similar to gb:S78187 M-PHASE INDUCER PHOSPHATASE-2 (HUMAN);, mRNA sequence

35 CAGTCTGTTGAGTTAGTTAAGTTGGGTAAATACCAGCTTAAAGGCAGTATTTTGT
 GTCCTCCAGGAGCTTCTTGTTCCTTGTTAGGGTTAACCCTTCATCTTCCTGTGTC
 CTGAAACGCTCCTTTGTGTGTGTGTCAGCTGAGGCTGGGGGAGAGCCGTGGTCCC
 TGAGGATGGGTCAGAGCTAAACTCCTTCCTGGCCTGAGAGTCAGCTCTCTGCCCT
 GTGTACTTCCCGGGCCAGGGCTGCCCTAATCTCTGTAGGAACCGTGGTATGTCT
 GCCATGTTGCCCTTTCTCTTTTCCCTTTCTGTCCACCATACGAGCACCTCCA
 40 GCCTGAACAGAAGCTCTTACTCTTTCTATTTTCAAGTGTACCTGTGTGCTTGGTCT
 GTTTGACTTTACGC

SEQ ID NO: 136

>gi|189389|gb|M97016.1|HUMOP2A Homo sapiens osteogenic protein-2 (OP-2) mRNA, complete cds

45 CCACAGTGGCGCCGGCAGAGCAGGAGTGGCTGGAGGAGCTGTGGTTGGAGCAGG
 AGGTGGCACGGCAGGGCTGGAGGGCTCCCTATGAGTGGCGGAGACGGCCCAGGA
 GGCGCTGGAGCAACAGCTCCCACACCGCACCAAGCGGTGGCTGCAGGAGCTCGC
 CCATCGCCCCTGCGCTGCTCGGACCGCGGCCACAGCCGGAAGTGGCGGGTACGGC

GCGACAGACGGATTGGCCGAGAGTCCCAGTCCGCAGAGTAGCCCCGGCCTCGA
 GCGGTGGCGTCCCGGTCCTCTCCGTCCAGGAGCCAGGACAGGTGTCGCGCGGC
 GGGGCTCCAGGGACCGCGCCTGAGGCCGGCTGCCCCCGCGTCCCGCCCCGCCCC
 GCGCCCCGCGCCCCGCCGAGCCAGCCTCCTTGCCGTCGGGGCGTCCCCAGGCCC
 5 TGGGTGCGCCGCGGAGCCGATGCGCGCCCGCTGAGCGCCCCAGCTGAGCGCCCC
 CGGCCTGCCATGACCGCGCTCCCCGGCCCGCTCTGGCTCCTGGGCCTGGCGCTAT
 GCGCGCTGGGCGGGGGCGGCCCGGCCTGCGACCCCCGCCCCGGCTGTCCCCAGC
 GACGTCTGGGCGCGCGAGCGCCGGGACGTGCAGCGCGAGATCCTGGCGGTGC
 TCGGGCTGCCTGGGCGGCCCCGGCCCCGCGCGCCACCGCCGCCTCCCGGCTGCC
 10 CGCGTCCGCGCCGCTCTTCATGCTGGACCTGTACCACGCCATGGCCGGCGACGAC
 GACGAGGACGGCGCGCCCGCGGAGCGGCGCCTGGGCCGCGCCGACCTGGTCATG
 AGCTTCGTAAACATGGTGGAGCGAGACCGTGCCCTGGGCCACCAGGAGCCCCAT
 TGGAAGGAGTTCCGCTTTGACCTGACCCAGATCCCGGCTGGGGAGGCGGTCACA
 GCTGCGGAGTTCCGGATTTACAAGGTGCCAGCATCCACCTGCTCAACAGGACCC
 15 TCCACGTCAGCATGTTCCAGGTGGTCCAGGAGCAGTCCAACAGGGAGTCTGACTT
 GTTCTTTTTGGATCTTCAGACGCTCCGAGCTGGAGACGAGGGCTGGCTGGTGTCTG
 GATGTCACAGCAGCCAGTGACTGCTGGTTGCTGAAGCGTCACAAGGACCTGGGA
 CTCCGCCTCTATGTGGAGACTGAGGACGGGCACAGCGTGGATCCTGGCCTGGCC
 GGCCTGCTGGGTCAACGGGGCCCCACGCTCCCAACAGCCTTTCGTGGTCACTTTCT
 20 TCAGGGCCAGTCCGAGTCCCATCCGCACCCCTCGGGCAGTGAGGCCACTGAGGA
 GGAGGCAGCCGAAGAAAAGCAACGAGCTGCCGCAGGCCAACCAGACTCCAGGG
 ATCTTTGATGACGTCCACGGCTCCACGGCCGGCAGGTCTGCCGTCGGCACGAGC
 TCTACGTCAGCTTCCAGGACCTCGGCTGGCTGGACTGGGTGTCGCTCCCCAAGG
 CTACTCGGCCTATTACTGTGAGGGGGAGTGCTCCTTCCCACTGGACTCCTGCATG
 25 AATGCCACCAACCACGCCATCCTGCAGTCCCTGGTGCACCTGATGAAGCCAAAC
 GCAGTCCCCAAGGCGTGCTGTGCACCCACCAAGCTGAGCGCCACCTCTGTGCTCT
 ACTATGACAGCAGCAACAACGTCATCCTGCGCAAGCACCGCAACATGGTGGTCA
 AGGCCTGCGGCTGCCACTGAGTCAGCCCGCCAGCCCTACTGCAGCCACCCTTCT
 CATCTGGATCGGGCCCTGCAGAGGCAGAAAACCCTTAAATGCTGTACAGCTCA
 30 AGCAGGAGTGTACAGGGGCCCTCACTCTCTGTGCCTACTTCCTGTCAGG

SEQ ID NO: 137

>gi|181979|gb|M29366.1|HUMEGFRBB3 Human epidermal growth factor receptor
(ERBB3) mRNA, complete cds

35 ACCAATTTCGCCAGCGGTTCAAGTGGCTCTTGCCCTCGATGTCCTAGCCTAGGGGCC
 CCCGGGCCGGACTTGGCTGGGCTCCCTTACCCCTCTGCGGAGTCATGAGGGCGAA
 CGACGCTCTGCAGGTGCTGGGCTTGCTTTTTCAGCCTGGCCCCGGGGCTCCGAGGTG
 GGCAACTCTCAGGCAGTGTGTCCTGGGACTCTGAATGGCCTGAGTGTGACCGGCG
 ATGCTGAGAACCAATACCAGACACTGTACAAGCTCTACGAGAGGTGTGAGGTGG
 40 TGATGGGGAACCTTGAGATTGTGCTCACGGGACACAATGCCGACCTCTCCTTCT
 GCAGTGGATTTCGAGAAGTGACAGGCTATGTCCTCGTGGCCATGAATGAATTCTCT
 ACTCTACCATTGCCAACCTCCGCGTGGTGCAGGGGACCCAGGTCTACGATGGGA
 AGTTTGCCATCTTCGTCATGTTGAACTATAACACCAACTCCAGCCACGCTCTGCG
 CCAGCTCCGCTTGACTCAGCTCACCAGATTCTGTCAGGGGGTGTATATTGAG
 45 AAGAACGATAAGCTTTGTACATGGACACAATTGACTGGAGGGACATCGTGAGG
 GACCGAGATGCTGAGATAGTGGTGAAGGACAATGGCAGAAGCTGTCCCCCTGT
 CATGAGGTTTGCAAGGGGGCGATGCTGGGGTCTGGATCAGAAGACTGCCAGACA
 TTGACCAAGACCATCTGTGCTCCTCAGTGTAATGGTCACTGCTTTGGGCCCCAAC
 CCAACCAGTGCTGCCATGATGAGTGTGCCGGGGGCTGCTCAGGCCCTCAGGACA

CAGACTGCTTTGCCTGCCGGCACTTCAATGACAGTGGAGCCTGTGTACCTCGCTG
TCCACAGCCTCTTGTCTACAACAAGCTAACTTTCCAGCTGGAACCCAATCCCCAC
ACCAAGTATCAGTATGGAGGAGTTTGTGTAGCCAGCTGTCCCCATAACTTTGTGG
TGGATCAAACATCCTGTGTGAGGGCCTGTCCTCCTGACAAGATGGAAGTAGATAA
5 AAATGGGCTCAAGATGTGTGAGCCTTGTGGGGGACTATGTCCCAAAGCCTGTGA
GGGAACAGGCTCTGGGAGCCGCTTCCAGACTGTGGACTCGAGCAACATTGATGG
ATTTGTGAACTGCACCAAGATCCTGGGCAACCTGGACTTTCTGATCACCGGCCTC
AATGGAGACCCCTGGCACAAGATCCCTGCCCTGGACCCAGAGAAGCTCAATGTC
TTCCGGACAGTACGGGAGATCACAGGTTACCTGAACATCCAGTCCTGGCCGCCCC
10 ACATGCACAACCTTCAGTGTTTTTTCCAAATTTGACAACCATTTGGAGGCAGAAGCCT
CTACAACCGGGGCTTCTCATTGTTGATCATGAAGAACTTGAATGTCACATCTCTG
GGCTTCCGATCCCTGAAGGAAATTAGTGCTGGGCGTATCTATATAAGTGCCAATA
GGCAGCTCTGCTACCACCACTCTTTGAACTGGACCAAGGTGCTTCGGGGGCGCTAC
GGAAGAGCGACTAGACATCAAGCATAATCGGCCGCGCAGAGACTGCGTGCCAGA
15 GGGCAAAGTGTGTGACCCACTGTGCTCCTCTGGGGGATGCTGGGGCCCAGGCCCT
GGTCAGTGCTTGTCTGTGCGAAATTATAGCCGAGGAGGTGTCTGTGTGACCCACT
GCAACTTTCTGAATGGGGAGCCTCGAGAATTTGCCCATGAGGCCGAATGCTTCTC
CTGCCACCCGGAATGCCAACCCATGGAGGGGCACTGCCACATGCAATGGCTCGGG
CTCTGATACTTGTGCTCAATGTGCCCATTTTCGAGATGGGCCCCACTGTGTGAGC
20 AGCTGCCCCCATGGAGTCCTAGGTGCCAAGGGCCCAATCTACAAGTACCCAGAT
GTTCAGAATGAATGTCGGCCCTGCCATGAGAATGCACCCAGGGGTGTAAAGGA
CCAGAGCTTCAAGACTGTTTAGGACAAACACTGGTGCTGATCGGCAAAACCCAT
CTGACAATGGCTTTGACAGTGATAGCAGGATTGGTAGTGATTTTCATGATGCTGG
GCGGCACTTTTCTCTACTGGCGTGGGCGCCGGATTGAGAATAAAAGGGCTATGAG
25 GCGATACTTGGAACGGGGTGAGAGCATAGAGCCTCTGGACCCCAAGTGAGAAGGC
TAACAAAGTCTTGGCCAGAATCTTCAAAGAGACAGAGCTAAGGAAGCTTAAAGT
GCTTGGCTCGGGTGTCTTTGGAAGTGTGCACAAAGGAGTGTGGATCCCTGAGGGT
GAATCAATCAAGATTCCAGTCTGCATTAAAGTCATTGAGGACAAGAGTGGACGG
CAGAGTTTTCAAGCTGTGACAGATCATATGCTGGCCATTGGCAGCCTGGACCATG
30 CCCACATTGTAAGGCTGCTGGGACTATGCCCAGGGTCATCTCTGCAGCTTGTAC
TCAATATTTGCCTCTGGGTTCTCTGCTGGATCATGTGAGACAACACCGGGGGGCA
CTGGGGCCACAGCTGCTGCTCAACTGGGGAGTACAAATTGCCAAGGGAATGTAC
TACCTTGAGGAACATGGTATGGTGCATAGAAACCTGGCTGCCCGAAACGTGCTA
CTCAAGTCACCCAGTCAGGTTGAGGTCAGATTTTGGTGTGGCTGACCTGCTGC
35 CTCCTGATGATAAGCAGCTGCTATACAGTGAGGCCAAGACTCCAATTAAGTGGAT
GGCCCTTGAGAGTATCCACTTTGGGAAATACACACACCAGAGTGATGTCTGGAG
CTATGGTGTGACAGTTTGGGAGTTGATGACCTTCGGGGCAGAGCCCTATGCAGGG
CTACGATTGGCTGAAGTACCAGACCTGCTAGAGAAGGGGGAGCGGTTGGCACAG
CCCCAGATCTGCACAATTGATGTCTACATGGTGTGATGGTCAAGTGTGGATGATTG
40 ATGAGAACATTCGCCCAACCTTTAAAGAACTAGCCAATGAGTTCACCAGGATGG
CCCGAGACCCACCGGTATCTGGTCATAAAGAGAGAGAGTGGGCCTGGAATAG
CCCCTGGGCCAGAGCCCCATGGTCTGACAAACAAGAAGCTAGAGGAAGTAGAGC
TGGAGCCAGAAGTAGACCTAGACCTAGACTTGGAAAGCAGAGGAGGACAACCTGG
CAACCACCACACTGGGCTCCGCCCTCAGCCTACCAGTTGGAACACTTAATCGGCC
45 ACGTGGGAGCCAGAGCCTTTTAAAGTCCATCATCTGGATACATGCCCATGAACCAG
GGTAATCTTGGGGAGTCTTGCCAGGAGTCTGCAGTTTCTGGGAGCAGTGAACGGT
GCCCCCGTCCAGTCTCTCTACACCCAATGCCACGGGGATGCCTGGCATCAGAGTC
ATCAGAGGGGCATGTAACAGGCTCTGAGGCTGAGCTCCAGGAGAAAGTGTCAAT
GTGTAGAAGCCGGAGCAGGAGCCGGAGCCACGGCCACGCGGAGATAGCGCCT

ACCATTCCCAGCGCCACAGTCTGCTGACTCCTGTTACCCCACTCTCCCCACCCGG
 GTTAGAGGAAGAGGATGTCAACGGTTATGTCATGCCAGATACACACCTCAAAGG
 TACTCCCTCCTCCCGGGAAGGCACCCCTTCTTCAGTGGGTCTTAGTTCTGTCTGG
 GTACTGAAGAAGAAGATGAAGATGAGGAGTATGAATACATGAACCGGAGGAGA
 5 AGGCACAGTCCACCTCATCCCCCTAGGCCAAGTTCCTTGAGGAGCTGGGTATG
 AGTACATGGATGTGGGGTCAGACCTCAGTGCCTCTCTGGGCAGCACACAGAGTT
 GCCCACTCCACCCTGTACCCATCATGCCCACTGCAGGCACAACCTCCAGATGAAGA
 CTATGAATATATGAATCGGCAACGAGATGGAGGTGGTCCTGGGGGTGATTATGC
 AGCCATGGGGGCCTGCCCAGCATCTGAGCAAGGGTATGAAGAGATGAGAGCTTT
 10 TCAGGGGCCTGGACATCAGGCCCCCATGTCCATTATGCCCGCCTAAAACTCTA
 CGTAGCTTAGAGGCTACAGACTCTGCCTTTGATAACCCTGATTACTGGCATAGCA
 GGCTTTTCCCAAGGCTAATGCCCAGAGAACGTAACCTCCTGCTCCCTGTGGCACT
 CAGGGAGCATTTAATGGCAGCTAGTGCCTTTAGAGGGTACCGTCTTCTCCCTATT
 CCCTCTCTCTCCAGGTCCCAGCCCCTTTTCCCCAGTCCCAGACAATTCCATTCAA
 15 TCTTTGGAGGCTTTTAAACATTTTGACACAAAATTCTTATGGTATGTAGCCAGCTG
 TGCATTTCTTCTCTTTCCCAACCCAGGAAAGGTTTTCCTTATTTTGTGTGCTTTC
 CCAGTCCCATTCTCAGCTTCTTCACAGGCACTCCTGGAGATATGAAGGATTACT
 CTCCATATCCCTTCTCTCAGGCTCTTGACTACTTGGAAGTGGCTCTTATGTGTG
 CCTTTGTTTCCCATCAGACTGTCAAGAAGAGGAAAGGGAGGAAACCTAGCAGAG
 20 GAAAGTGTAATTTTGGTTTATGACTCTTAACCCCTAGAAAGACAGAAGCTTAAA
 ATCTGTGAAGAAAGAGGTTAGGAGTAGATATTGATTACTATCATAATTCAGCACT
 TAACTATGAGCCAGGCATCATACTAACTTCACCTACATTATCTCACTTAGTCCTT
 TATCATCCTTAAACAATTCTGTGACATACATATTATCTCATTTTACACAAAGGG
 AAGTCGGGCATGGTGGCTCATGCCTGTAATCTCAGCACTTTGGGAGGCTGAGGCA
 25 GAAGGATTACCTGAGGCAAGGAGTTTGAGACCAGCTTAGCCAACATAGTAAGAC
 CCCCATCTCTTT

SEQ ID NO: 138

>gi|1123184|gb|H98534.1|H98534 yv97d06.s1 Soares melanocyte 2NbHM Homo sapiens
 30 cDNA clone IMAGE:250667 3', mRNA sequence
 ATCTAACATTATTGCTTTAGGAAAGTATTTCCCTGAACCAAGAATACAATGCTAA
 TTGCATAAAAACATACACATATAAAAAGTAGTTCTCCATTTTCCCAGGAAAAAAT
 CCAAGTATAACTTCTAGAATAGTCAAGTTTCTTATTTTATTATAATTAAAGTCTT
 GGTCATTTTCATTTATTAGCTCTGCAACTTACATATTTAAATTAAAGAAACGTTATT
 35 AGACAACNGTTACAATTTATAAATGTAAGGTGCCATTATTGAGTAAATATATTCC
 TCCAAGAGTGGATGTGNCCCTTCTCCCANCAACTAATGAAGCAGCAACATTAGGT
 TAAATTTATTAGGAGATGATACACTGGCTGNAAACGCTAATTCNCCTTCTCCAAC
 CCAAG

40 SEQ ID NO: 139

>gi|1813881|dbj|D49728.1|HUMNAK1 Human NAK1 mRNA for DNA binding protein,
 complete cds
 CGAACTTGGGGGGAGTGCACAGAAGAACTTCGGGAGCGCACGCGGGACCAGGG
 ACCAGGCTGAGACTCGGGGCGCCAGTCCGGGCAGGGGCAGCGGGAGCCGGCCG
 45 GAGATGCCCTGTATCCAAGCCCAATATGGGACACCAGCACCGAGTCCGGGACCC
 CGTGACCACCTGGCAAGCGACCCCTGACCCCTGAGTTCATCAAGCCCACCATGG
 ACCTGGCCAGCCCCGAGGCAGCCCCGCTGCCCCCACTGCCCTGCCAGCTTCAG
 CACCTTCATGGACGGCTACACAGGAGAGTTTGACACCTTCCTCTACCAGCTGCCA
 GGAACAGTCCAGCCATGCTCCTCAGCCTCCTCCTCGGCCCTCTCCACATCCTCGTC

CTCAGCCACCTCCCCTGCCTCTGCTTCCTTCAAGTTCGAGGACTTCCAGGTGTACG
GCTGCTACCCCGGCCCTGAGCGGCCAGTGGATGAGGCCCTGTCTCCAGTGG
CTCTGACTACTATGGCAGCCCCTGCTCGGCCCGTCGCCCTCCACGCCAGCTTC
CAGCCGCCCCAGCTCTCTCCCTGGGATGGCTCCTTCGGCCACTTCTCGCCCAGCC
5 AGACTTACGAAGGCCTGCGGGCATGGACAGAGCAGCTGCCCAAAGCCTCTGGGC
CCCCACAGCCTCCAGCCTTCTTTTCTTCAAGTCTCCACCGGCCCCAGCCCCAGC
CTGGCCCAGAGCCCCCTGAAGTTGTTCCCTCACAGGCCACCCACCAGCTGGGGG
AGGGAGAGAGCTATTCCATGCCTACGGCCTTCCAGGTTTGGCACCCACTTCTCC
ACACCTTGAGGGCTCGGGGATACTGGATACACCCGTGACCTCAACCAAGGCCCG
10 GAGCGGGGCCCCAGGTGGAAGTGAAGGCCGCTGTGCTGTGTGTGGGGACAACGC
TTCATGCCAGCATTATGGTGTCCGCACATGTGAGGGCTGCAAGGGCTTCTTCAAG
CGCACAGTGCAGAAAAACGCCAAGTACATCTGCCTGGCTAACAAGGACTGCCCT
GTGGACAAGAGGCGGCGAAACCGCTGCCAGTTCTGCCGCTTCCAGAAGTGCCTG
GCGGTGGGCATGGTGAAGGAAGTTGTCCGAACAGACAGCCTGAAGGGGCGGCG
15 GGGCCGGCTACCTTCAAAACCCAAGCAGCCCCCAGATGCCTCCCCTGCCAATCTC
CTCACTTCCCTGGTCCGTGCACACCTGGACTCAGGGCCCAGCACTGCCAACTGG
ACTACTCCAAGTTCCAGGAGCTGGTGCTGCCCCACTTTGGGAAGGAAGATGCTGG
GGATGTACAGCAGTTCTACGACCTGCTCTCCGGTTCTCTGGAGGTCATCCGCAAG
TGGGCGGAGAAGATCCCTGGCTTTGCTGAGCTGTCACCGGCTGACCAGGACCTGT
20 TGCTGGAGTCGGCCTTCCCTGGAGCTCTTCATCCTCCGCCTGGCGTACAGGTCTAA
GCCAGGCGAGGGCAAGCTCATCTTCTGCTCAGGCCTGGTGCTACACCGGCTGCAG
TGTGCCCCTGGCTTCGGGGACTGGATTGACAGTATCCTGGCCTTCTCAAGGTCCC
TGCACAGCTTGCTTGTGATGTCCCTGCCTTCGCCTGCCTCTCTGCCCTTGTCTC
ATCACCGACCGGCATGGGCTGCAGGAGCCGCGGCGGGTGGAGGAGCTGCAGAAC
25 CGCATCGCCAGCTGCCTGAAGGAGCACGTGGCAGCTGTGGCGGGCGAGCCCCAG
CCAGCCAGCTGCCTGTACGTCTGTTGGGCAAACTGCCCGAGCTGCGGACCCTGT
GCACCCAGGGCCTGCAGCGCATCTTCTACCTCAAGCTGGAGGACTTGGTGCCCC
TCCACCCATCATTGACAAGATCTTCATGGACACGCTGCCCTTCTGACCCCTGCCT
GCCTGGGAACACGTGTGCACATGCGCACTCTCTCATATGCCACCCCATGTGCCTT
30 TAGTCCACGGACCCCAAGAGCACCCCAAGCCTGGGCTTAGCTGCAGAACAGAGG
GACCTGCTCACCTGCCCAAAGGGGATGAAGGGAGGGAGGCTCAAGGCCCTTGGG
GGAGGGGGATGCCTTCATGGGGGTGACCCACGATGTGTTCTTATCCCCCCCCGCT
GGCCACCGGCCTTTATGTTTTTTGTAAGATAAACCGTTTTTAACACATAGCGCCGT
GCTGTAAATAAGCCCCAGTACTGCTGTAAATACAGGAAGAAAGAGCTTGAGGTGG
35 GAGCGGGCTGGGAGGAAGGGATGGGCCCCGGCCTTCCCTGGGCAGCCTTCCAGC
CTCCTGCTGGGCTCTCTCTTCCCTACCTCCTTCCACATGTACATGTACATAAACTG
TCACTCTAGGAAGAAGACAAATGACAGATTCTGACCATTATATTGTGTATTTT
CCAGGATTTATAGTATGTGACTTTTCTGATTAATATATTTAATATATTGAATAAAA
AATAGACATGTAGTTGG

40

SEQ ID NO: 140

>gi|178049|gb|M93415.1|HUMACTIIA Human activin type II receptor mRNA, complete cds
GGGGCCGCCCCTTCCCCGCGCCGACGCCCTCGCCGCCACCGCCGCGAGCTCGG
CCGCCAGTGGTCCTCGGACTTTAGGTGTCTGGGTTGAAGGAGGTTTGTCTCCGAG
45 GAAGACCCAGGGAAGTGGATATCTAGCGAGAACTTCCCTCCGATTCCCCGGCGC
CTCGGGAAAAATGGGAGCTGCTGCAAAGTTGGCGTTTGCCGTCTTCTTATCTCCT
GTTCTTCAGGTGCTATACTTGGTAGATCAGAACTCAGGAGTGTCTTTTCTTTAAT
GCTAATTGGGAAAAAGACAGAACCAATCAAACCTGGTGTGAACCGTGTTATGGT
GACAAAGATAAACGGCGGCATTGTTTTGCTACCTGGAAGAATATTTCTGGTTCCA

40

TTGAAATAGTGAAACAAGGTTGTTGGCTGGATGATATCAACTGCTATGACAGGA
 CTGATTGTGTAGAAAAAAGACAGCCCTGAAGTATATTTTTGTTGCTGTGAGGG
 CAATATGTGTAATGAAAAGTTTTCTTATTTTCCGGAGATGGAAGTCACACAGCCC
 ACTTCAAATCCAGTTACACCTAAGCCACCCTATTACAACATCCTGCTCTATTCCTT
 5 GGTGCCACTTATGTTAATTGCGGGGATTGTCATTTGTGCATTTTGGGTGTACAGG
 CATCACAAGATGGCCTACCCTCCTGTACTTGTTCCTCAACTCAAGACCCAGGACCAC
 CCCCACCTTCTCCATTACTAGGTTTGAACCACTGCAGTTATTAGAAGTGAAAGC
 AAGGGGAAGATTTGGTTGTGTCTGGAAAGCCCAGTTGCTTAACGAATATGTGGCT
 GTCAAAATATTTCCAATACAGGACAAACAGTCATGGCAAAATGAATACGAAGTC
 10 TACAGTTTGCCTGGAATGAAGCATGAGAACATATTACAGTTCATTGGTGCAGAAA
 AACGAGGCACCAAGTGTGATGTGGATCTTTGGCTGATCACAGCATTTTCATGAAAA
 GGGTTCACTATCAGACTTTCTTAAGGCTAATGTGGTCTCTTGAATGAACTGTGT
 CATATTGCAGAAACCATGGCTAGAGGATTGGCATATTTACATGAGGATATACCTG
 GCCTAAAAGATGGCCACAAACCTGCCATATCTCACAGGGACATCAAAAAGTAAAA
 15 ATGTGCTGTTGAAAAACAACCTGACAGCTTGCATTGCTGACTTTGGGTGGCCTT
 AAAATTTGAGGCTGGCAAGTCTGCAGGCGATACCCATGGACAGGTTGGTACCCG
 GAGGTACATGGCTCCAGAGGTATTAGAGGGTGCTATAAACTTCCAAAGGGATGC
 ATTTTGTAGGATAGATATGTATGCCATGGGATTAGTCCTATGGGAAGTGGCTTCT
 CGCTGTACTGCTGCAGATGGACCTGTAGATGAATACATGTTGCCATTTGAGGAGG
 20 AAATTGGCCAGCATCCATCTCTTGAAGACATGCAGGAAGTTGTTGTGCATAAAAA
 AAAGAGGCCTGTTTTAAGAGATTATTGGCAGAAACATGCTGGAATGGCAATGCT
 CTGTGAAACCATTGAAGAATGTTGGGATCACGACGCAGAAGCCAGGTTATCAGC
 TGGATGTGTAGGTGAAAGAATTACCCAGATGCAGAGACTAACAAATATTATTAC
 CACAGAGGACATTGTAACAGTGGTCACAATGGTGACAAATGTTGACTTTTCTCCC
 25 AAAGAATCTAGTCTATGATGGTTGCGCCATCTGTGCACACTAAGAAATGGGACTC
 TGAAGTGGAGCTGCTAAGCTAAAGAAACTGCTTACAGTTTATTTTCTGTGTAAAA
 TGAGTAGGATGTCTCTTGGAAATGTTAAGAAAGAAGACCCTTTGTGAAAAATGT
 TGCTCTGGGAGACTTACTGCATTGCCGACAGCACAGATGTGAAGGACATGAGAC
 TAAGAGAAACCTTGCAAACTCTATAAAGAAACTTTTGAAAAAGTGTACATGAAG
 30 AATGTAGCCCTCTCCAAATCAAGGATCTTTTGGACCTGGCTAATGGAGTGTGTA
 AACTGACATCAGATTTCTTAATGTCTGTCAGAAGACACTAATTCCTTAAATGAA
 CTACTGCTATTTTTTTTAAATCAAAAACCTTTTCATTTTCAAGATTTTAAAAAGGGTAA
 CTTGTTTTTATTGCATTTGCTGTTGTTTCTATAAATGACTATTGTAATGCCAATAT
 GACACAGCTTCTGAAATGTTTAGTGTGCTGCTGTTCTGTGTACATAAAGTCATCAA
 35 AGTGGGGTACAGTAAAGAGGCTTCCAAGCATTACTTTAACCTCCCTCAACAAGGT
 ATACCTCAGTTCCACGGTTGCTAAATTATAAAATTGAAAACACTAACAAAATTTG
 AATAATAAATCGATCCATGTTTCCC

SEQ ID NO: 141

40 >gi|2162949|gb|AA448929.1|AA448929 zx05d04.r1 Soares_total_fetus_Nb2HF8_9w Homo
 sapiens cDNA clone IMAGE:785575 5' similar to gb:U05875 INTERFERON-GAMMA
 RECEPTOR BETA CHAIN PRECURSOR (HUMAN);, mRNA sequence
 AACATATCTTGCTACGAAACAATGGCAGATGCTCCACTGAGCTTCAGCAAGTCAT
 CCTGATCTCCGTGGGAACATTTTCGTTGCTGTGCGGTGCTGGCAGGAGCCTGTTTCT
 45 TCCTGGTCTGAAATATAGAGGCCTGATTAAATACTGGTTTCACACTCCACCAAG
 CATCCCATACAGATAGAAGAGTATTTAAAAGACCCAACCTCAGCCCATCTTAGAG
 GCCTTGGACAAGGACAGCTCACCAAAGGATGACGTCTGGGACTCTGTGTCCAT

SEQ ID NO: 142

>gi|2216790|gb|AA486626.1|AA486626 ab16a03.r1 Stratagene lung (#937210) Homo sapiens cDNA clone IMAGE:840940 5' similar to gb:Y00345_cds1 POLYADENYLATE-BINDING PROTEIN (HUMAN);, mRNA sequence

5 GCCGCTCCTTGGGCTACGCGTATGTGAACTTCCAGCAGCCGGCGGATCCGGACGT
GCATTTGGACACCATGAATTTTGATGTTATAAAGGGCAAGCCAGTACGCATCATG
TGGTCTCAGCGTGATCCATCACTTCGCAAAAGTGGAGTAGGCAACATATTCATTA
AAAATCTGGACAAATCCATTGATAATAAAGCACTGTATGATACATTTTCTGCTTT
10 TGGTAACATCCTTTTCATGTAAGGTGGTTTGTGATGAAAATGGTTCCAAGGGCTAT
GGATTTGTACACTTTGAGACGCAGGAAGCAGCTGAAAGAGCTATTGAAAAAATG
AATGGAATGCTCCTAAATGATCGCAAAGTATTTGTTGGACGATTAAAGTCTCGTA
AAGAACGAGAAGCTGAACTTGGAGCTAGGGCAAAGAATTCCACAATGTTTACA
TC

15 SEQ ID NO: 143

>gi|189713|gb|M21571.1|HUMPDGFA1 Human platelet-derived growth factor (PDGFA) A chain gene, exon 1

GAGGGAGGGGCGCGGAGCCCCGGCGCGGAGCCGGGCGCGGGGCTTTGATGGATT
TAGCTGCTTGC GCGAGCGCGTGTGTGCTCCCTGCCGAGCGGCGGCGCCCGGGCC
20 CTGCCGGGTCCGCACGAACCCCGAGCGCTTCCGAGGTGCGGGTCCCAGGCCCGG
AATCCGGGGGAGGCGGGGGGGGGGGGGCGGGGGCGGGGGCGGGGGAGGGGCG
CGGCGGCGGCGCTATAACCCTCTCCCCGCCGCCGGCCGGCTCCACACGCGCGCCC
TGCGGAGCCCCGCCAACTCCGGCGAGCCGGGCGCTGCGCCTACTCCTCCTCCTCCT
CTCCCCGGCGGCGGCTGCGGCGGAGGCGCCGACTCGGCCTTGCGCCCCGCCCTCAG
25 GCCCCGCGCGGGCGGCGCAGCGAGGCCCGGGCGGCGGGTGGTGGCTGCCAGGCG
GCTCGGCCGCGGGCGCTGCCCGGCCCGGCGAGCGGAGGGCGGAGCGCGGCGCC
GGAGCCGAGGGCGCGCCGCGGAGGGGGTGTGTTGGCCGCGCTGTGCCCGGCCGGG
CGGCGGCTGCAAGAGGAGGCGGAGGCGAGCGCGGGGCCGGCGGTGGGCGCGC
AGGGCGGCTCGCAGCTCGCAGCCGGGGCCGGGCCAGGCGTTCAGGCAGGTGATC
30 GGTGTGGCGGCGGCGGCGGCGGCCCCAGACTCCCTCCGGAGTTCTTCTTGGG
GCTGATGTCCGCAAATATGCAGAATTACCGGCCGGGTGCTCCTGAAGCCAGCG
CGGGGAGCGAGCGCGGCGGCGGCCAGCACCGGGAACGCACCGAGGAAGAAGCC
CAGCCCCCGCCCTCCGCCCTTCCGTCCCCACCCCTACCCGGCGGCCCCAGGAGG
CTCCCCGCGCTTCCGGGCGCGCACTCCCTGTTTCTCCTCCTCCTGGCTGGCGCTGCC
35 TGCCTCTCCGCACTCACTGCTCGCGCCGGGCGCGCTCCGCCAGCTCCGTGCTCCC
CGCGCCACCCTCCTCCGGGCCGCGCTCCCTAAGGGATGGTACTGAATTCGCCCGC
CACAGGAGACCGGCTGGAGCGCCCCGCCCGCGGCCTCGCCTCTCCTCCGAGCAG
CCAGCGCCTCGGGACGCGATGAGGACCTTGGCTTGCCTGCTGCTCCTCGGCTGCG
GATACCTCGCCCATGTTCTGGCCGAGGTTGGTGCCGCCCCCGCGCCCCGTCCCTG
40 CGCCGGCTCCTCCG

SEQ ID NO: 144

>gi|2217690|gb|AA487526.1|AA487526 ab20e09.s1 Stratagene lung (#937210) Homo sapiens cDNA clone IMAGE:841384 3', mRNA sequence

45 TTGTGGAAAACCTCAACCTTTATTATTACCTGCCTAGTGCAGGGGATTAAAATTGC
CTCAAGCTAGGTCCATATATTAGTG

SEQ ID NO: 145

>gi|219911|dbj|D12614.1|HUMLTNFB Human mRNA for lymphotoxin (TNF-beta),
complete cds

5 GCCCCATCTCCTTGGGCTGCCCGTGCTTCGTGCTTTGGACTACCGCCCAGCAGTGT
CCTGCCCTCTGCCTGGGCCTCGGTCCCTCCTGCACCTGCTGCCTGGATCCCCGGCC
TGCTTGGGCCTGGGCCTTGGTTCTCCCCATGACACCACCTGAACGTCTCTTCCTCC
CAAGGGTGTGTGGCACCACCCTACACCTCCTCCTTCTGGGGCTGCTGCTGGTTCT
GCTGCCTGGGGGCCAGGGGCTCCCTGGTGTGGCCTCACACCTTCAGCTGCCCAG
10 ACTGCCCGTCAGCACCCCAAGATGCATCTTGGCCACAGCACCTCAAACCTGCTG
CTCACCTCATTGGAGACCCCAGCAAGCAGAACTCACTGCTCTGGAGAGCAAACA
CGGACCGTGCCTTCTCCAGGATGGTTTCTCCTTGAGCAACAATTCTCTCCTGGTC
CCCACCAGTGGCATCTACTTCGTCTACTCCCAGGTGGTCTTCTCTGGGAAAGCCT
ACTCTCCCAAGGCCACCTCCTCCCCACTCTACCTGGGCCATGAGGTCCAGCTCTTC
TCCTCCCAGTACCCCTTCCATGTGCCTCTCCTCAGCTCCCAGAAGATGGTGTATCC
15 AGGGCTGCAGGAACCCTGGCTGCACTCGATGTACCACGGGGCTGCGTTCAGCTC
ACCCAGGGAGACCAGCTATCCACCCACACAGATGGCATCCCCACCTAGTCCTCA
GCCCTAGTACTGTCTTCTTTGGAGCCTTCGCTCTGTAGAACTTGGAATAATCCAG
AAAGAAAAAATAATTGATTCAAGACCTTCTCCCCATTCTGCCTCCATTCTGACC
ATTTACAGGGGTCGTACACCTCTCCTTTGGCCATTCCAACAGCTCAAGTCTTCCC
20 TGATCAAGTCACCGGAGCTTTCAAAGAAGGAATTCTAGGCATCCCAGGGGACCA
CACCTCCCTGAACCATCCCTGATGTCTGTCTGGCTGAGGATTTCAAGCCTGCCTA
GGAATTCCCAGCCCAAAGCTGTTGGTCTGTCCCACCAGCTAGGTGGGGCCTAGAT
CCACACACAGAGGAAGAGCAGGCACATGGAGGAGCTTGGGGGATGACTAGAGG
CAGGGAGGGGACTATTTATGAAGGCAAAAAAATTAAATTATTTATTTATGGAGG
25 ATGGAGAGAGGGGAATAATAGAAGAACATCCAAGGAGAAACAGAGACAGGCCC
AAGAGATGAAGAGTGAGAGGGCATGCGCACAAGGCTGACCAAGAGAGAAAGAA
GTAGGCATGAGGGATCACAGGGCCCCAGAAGGCAGGGAAAGGCTCTGAAAGCC
AGCTGCCGACCAGAGCCCCACACGGAGGCATCTGCACCCTCGATGAAGCCCAAT
AAACCTCTTTTCTCTG

30

SEQ ID NO: 146

>gi|1012035|gb|H59203.1|H59203 yr03c12.r1 Soares fetal liver spleen 1NFLS Homo sapiens
cDNA clone IMAGE:204214.5', mRNA sequence

35 AAAAGGAAGCTGTCTCGGGCATTGAACAAGCTAAAACTCCAGTGATGCCAAA
CTAGAACCAACAAATGTCCAAACCGTAACCTGTTCTCCTCGTGTAAGCCCTGC
CTCTCAGCCCCAGGANACGTCTGGGCGATGACAACCTATGCAAACTCCCCATTT
ACCTCCTTGTTCTCCACCAAAGCAAGGCAAGAAAGAGAATGGTCCCCCTCACTCA
CATACACTTAAGGGACGAAGATTGGTATTTGACAATCAGCTGACAATTAAGTCTC
CTAGCAAAAGAGAACTAGCCAAAGTTCACCAAAAACAAAATACTTTCTTTTCAAGTTA
40 GGAAAAAGTCAAGGGNTTCACAACAAATTTTTGAGGCAGGGGTGTCCACTGAAG
GANAGGANTCTGGCTGCGTGGGGANTATTTCAAGGCAAGAAGGGCATTGTGCTAC
CNGCAGGCAAAGTTGGTNC

SEQ ID NO: 147

45 >gi|1162368|gb|N39161.1|N39161 yv26a01.s1 Soares fetal liver spleen 1NFLS Homo
sapiens cDNA clone IMAGE:243816 3' similar to gb:M98399 PLATELET

GLYCOPROTEIN IV (HUMAN);, mRNA sequence

TTAAGGAAGAACATATTTTAATGGTTGAAACCTGTCTTTATGAGGCGATTATGAC
AGCAAAAAATATTATAATGAATAACAATGCATAGTCTACGCTTTGTAATATTTCA

TACAATAATTCCTTTATCATTTACATCTCTTAATGCTAGAAAAGCATTCTGAAGAT
GCCAAGCGTAAGTTGCAACTGAGTAAAAAAGCAAAATTTACTCAATTT
CCAGAAGAGGTGCAGAACAGAGAATGAAGGTCCTTAAATATAAACCGCTAGTG
TGCTAAAATGATGTCCATTTGCAGGATCAGTGGACAAAATATTTAAGCCCATAAA
5 GAAAAGAGTTATACCTGCTGTATGAAGGTATTCCATAGAGAAATATGAGTCATA
AGCCAATTATTTATAAATGGCCTTCCAAATATTTGGT

SEQ ID NO: 148

>gi|1548486|gb|AA056148.1|AA056148 zf55d10.r1 Soares retina N2b4HR Homo sapiens
10 cDNA clone IMAGE:380851 5' similar to TR:G1143719 G1143719 RS-REX-B. ;, mRNA
sequence
CTGTCTCGGAGCAGGCGGAGTAAAGGGACTTGAGCGAGCCAGTTGCCGGATTA
TTCTATTTCCCTCCCTCTCTCCCGCCCCGTATCTCTTTTACCCTTCTCCCACCCT
CGCTCGCGTANCATGGCGGACGTNNGGCGNCCACTCAGTCCCATTCCATCTCCTC
15 GTCGTCTTTCGGAGCCGAGCCGTCCGCGCCCCGGCGCGGCGNGNAGCCANGGAGC
CTGCCCCGCCCTGGGGACGAAGAGCTGCAGCTCCTCCTGTGCGGTGCAGATTCTG
ATTTTCTGGAGAGATGTGAAGAAGACTGGGTTTGTCTTTGGCACCACGCTGATCA
TGCTGCTTTCCCTGGCAGCTTTCAGTGTATCAGTGTGGATTTCTTACCTCATCCT
GGCTCTTCTCTGTGTCACCATCAGCTTCAGGATCTACAAGTCCGTCATCCAAGCTG
20 TACAGAAGTCAGAAGAAGGCCATCCATTCAAAGCCTACTGGACGTAGACATTAC
TCTGTCTAGAAGTTTCATAATTACATGAATGTGCATGTGACATAACAGGGCCTGA
AACNATATTCGTTNTTTGGTAGAAATTGGTTGATCTTGAAGT

SEQ ID NO: 149

>gi|545303|gb|S69200.1|S69200 EP3 prostanoid receptor isoform EP 3-II {alternatively
25 spliced} [human, mRNA, 1682 nt]
AGAGAGGAAGGCGTGGCTCCCTCCCGGGCCAGTGAGCCCTGGCGCCCGCCGCGGC
CGCGGTCCCAGCAGCGGAGTAGGGCGGCGGCTGCGCCCCGCACCATGGGGGGCA
GCCCAGCCCCAGCCGCGGTAAACGCCGACCTCCGCGCCGCGCCCGCGCCGCGTCT
30 GCCCCCTCCCGCTGCGGCTCTCTGGACGCCATCCCCCTCCTCACCTCGAAGCCAAC
ATGAAGGAGACCCGGGGCTACGGAGGGGATGCCCCCTTCTGCACCCGCTCAAC
CACTCCTACACAGGCATGTGGGCGCCCGAGCGTTCCGCGGAGGCGCGGGGCAAC
CTCACGCGCCCTCCAGGGTCTGGCGAGGATTGCGGATCGGTGTCCGTGGCCTTCC
CGATCACCATGCTGCTCACTGGTTCGTTGGGCAACGCACTGGCCATGCTGCTCGT
35 GTCGCGCAGCTACCGGCGCCGGGAGAGCAAGCGCAAGAAGTCCTTCTGCTGTG
CATCGGCTGGCTGGCGCTACCGACCTGGTCGGGCAGCTTCTACCAACCCCGGTC
GTCATCGTCTGTACCTGTCCAAGCAGCGTTGGGAGCACATCGACCCGTCGGGGC
GGCTCTGCACCTTTTTTCGGGCTGACCATGACTGTTTTTCGGGCTCTCCTCGTTGTTT
ATCGCCAGCGCCATGGCCGTCGAGCGGGCGCTGGCCATCAGGGCGCCGCACTGG
40 TATGCGAGCCACATGAAGACGCGTGCCACCCGCGCTGTGCTGCTCGGCGTGTGGC
TGGCCGTGCTCGCCTTCGCCCTGCTGCCGGTGCTGGGCGTGGGCCAGTACACCGT
CCAGTGGCCCGGGACGTGGTGCTTCATCAGCACCCGGGCGAGGGGGCAACGGGAC
TAGCTCTTCGCATAACTGGGGCAACCTTTTCTTCGCCTCTGCCTTTGCCTTCCTGG
GGCTCTTGGCGCTGACAGTCACCTTTTCTGCAACCTGGCCACCATTAAAGGCCCT
45 GGTGTCCCGCTGCCGGGCCAAGGCCACGGCATCTCAGTCCAGTGGCCAGTGGGG
CCGCATCACGACCGAGACGGCCATTCAGCTTATGGGGATCATGTGCGTGTGTCG
GTCTGCTGGTCTCCGCTCCTGATAATGATGTTGAAAATGATCTTCAATCAGACAT
CAGTTGAGCACTGCAAGACACACACGGAGAAGCAGAAAGAATGCAACTTCTTCT
TAATAGCTGTTTCGCTGGCTTCACTGAACCAGATCTTGGATCCTTGGGTTTACCTG

CTGTAAAGAAAGATCCTTCTTCGAAAGTTTTGCCAGGTAGCAAATGCTGTCTCCA
GCTGCTCTAATGATGGACAGAAAGGGCAGCCTATCTCATTATCTAATGAAATAAT
ACAGACAGAAGCATGAAAGAAAACACTTAACTTGCATGTGCACAGCTTCTGGTA
ACAAATATCGCTAAACCTTACTGTGAATTTAGGCATCTCTGGCATGCCACTGTTT
5 ATGCATTGAAGTGGAATTTTTGGTATAAAGCTAAATGGTCTTAGAAGCATAGAAA
ATCCCTATGTGCCAAAAGTAGTGAAACACAAACAAAGGAAAATATATTAATAAC
AGTCTAGTGTTTTTGTGAGTCTGCCATTCGTAGCTGAATATGTGATTAATTATGT
GATGAAAACCTTTTTTATAAATGATCTTGGTCTATTGGGG

10 SEQ ID NO: 150

>gi|4481752|gb|M86849.2|HUMGAPJUNC Homo sapiens connexin 26 (GJB2) mRNA,
complete cds

GATTAAATCCTATGACAACTAAGTTGGTTCTGTCTTCACCTGTTTTGGTGAGGTT
GTGTAAGAGTTGGTGTGTTGCTCAGGAAGAGATTTAAGCATGCTTGCTTACCCAGA
15 CTCAGAGAAGTCTCCCTGTTCTGTCCTAGCTATGTTCTGTGTTGTGTGCATTTCGT
CTTTTCCAGAGCAAACCGCCCAGAGTAGAAGATGGATTGGGGCACGCTGCAGAC
GATCCTGGGGGGTGTGAACAAACACTCCACCAGCATTGGAAAGATCTGGCTCAC
CGTCCTCTTCATTTTTTCGCATTATGATCCTCGTTGTGGCTGCAAAGGAGGTGTGGG
GAGATGAGCAGGCCGACTTTGTCTGCAACACCCTGCAGCCAGGCTGCAAGAACG
20 TGTGCTACGATCACTACTTCCCCATCTCCACATCCGGCTATGGGCCCTGCAGCT
GATCTTCGTGTCCAGCCCAGCGCTCCTAGTGGCCATGCACGTGGCCTACCGGAGA
CATGAGAAGAAGAGGAAGTTCATCAAGGGGGAGATAAAGAGTGAATTTAAGGA
CATCGAGGAGATCAAAACCCAGAAGGTCCGCATCGAAGGCTCCCTGTGGTGGAC
CTACACAAGCAGCATCTTCTTCCGGGTCATCTTCGAAGCCGCCTTCATGTACGTCT
25 TCTATGTCATGTACGACGGCTTCTCCATGCAGCGGCTGGTGAAGTGCAACGCCTG
GCCTTGTCCCAACACTGTGGACTGCTTTGTGTCCCGGCCACGGAGAAGACTGTC
TTCACAGTGTTTCATGATTGCAGTGTCTGGAATTTGCATCCTGCTGAATGTCACTGA
ATTGTGTTATTTGCTAATTAGATATTGTTCTGGGAAGTCAAAAAAGCCAGTTTAA
CGCATTGCCCAGTTGTTAGATTAAGAAATAGACAGCATGAGAGGGATGAGGCAA
30 CCCGTGCTCAGCTGTCAAGGCTCAGTCGCCAGCATTTCCCAACACAAAGATTCTG
ACCTTAAATGCAACCATTTGAAACCCCTGTAGGCCTCAGGTGAAACTCCAGATGC
CACAATGAGCTCTGCTCCCCTAAAGCCTCAAAACAAAGGCCTAATTCTATGCCTG
TCTTAATTTTCTTTTCACTTAAGTTAGTTCCTACTGAGACCCAGGCTGTTAGGGGTT
ATTGGTGTGAGGTACTTTTCATATTTTAAACAGAGGATATCGGCATTTGTTTCTTTG
35 TCTGAGGACAAGAGAAAAAAGCCAGGTTCCACAGAGGACACAGAGAAGGTTTG
GGTGTCTCCTGGGGTTCTTTTTGCCAACTTTCCCCACGTTAAAGGTGAACATTGG
TTCTTTTCATTTGCTTTGGAAGTTTTAATCTCTAACAGTGGACAAAGTTACCAGTGC
CTTAAACTCTGTTACACTTTTTGGAAGTGAAAACCTTTGTAGTATGATAGGTTATTT
TGATGTAAAGATGTTCTGGATAACATTATATGTTCCCCCTGTTTCAGAGGCTCAG
40 ATTGTAATATGTAAATGGTATGTCATTTCGCTACTATGATTTAATTTGAAATATGGT
CTTTTGGTTATGAATACTTTGCAGCACAGCTGAGAGAGGCTGTCTGTTGTATTTCAT
TGTGGTCATAGCACCTAACAACATTGTAGCCTCAATCGAGTGAGACAGACTAGA
AGTTCCTAGTTGGCTTATGATAGCAAATGGCCTCATGTCAAATATTAGATGTAAT
TTTGTGTAAGAAATACAGACTGGATGTACCACCACTACTACCTGTAATGACAGG
45 CCTGTCCAACACATCTCCCTTTTCCATGCTGTGGTAGCCAGCATCGGAAAGAACG
CTGATTTAAAGAGGTGAGCTTGGGAATTTTATTGACACAGTACCATTTAATGGGG
AGACAAAAATGGGGGCCAGGGGAGGGAGAAAGTTTCTGTCTGTTAAAAACGAGTTT
GGAAAGACTGGACTCTAAATTCTGTTGATTAAAGATGAGCTTTGTCTACCTTCAA
AAGTTTGTGTTGGCTTACCCCTTCAGCCTCCAATTTTTTAAGTGAAAATATACTA

ATAACATGTGAAAAGAATAGAAGCTAAGGTTTAGATAAATATTGAGCAGATCTA
TAGGAAGATTGAACCTGAATATTGCCATTATGCTTGACATGGTTTCCAAAAAATG
GTACTCCACATACTTCAGTGAGGGTAAGTATTTTCCTGTTGTCAAGAATAGCATT
GTAAAAGCATTTTGTAAATAATAAAGAATAGCTTTAATGATATGCTTGTAACATAA
5 ATAATTTTGTAAATGTATCAAATACATTTAAAACATTAAAATATAATCTCTATAAT

SEQ ID NO: 151

>205581R6

CAGAGGCTTGGAGGGGATGTGCAGAGCCCCAACTGCCCATCTGAGGATGTAGTC
10 ATCACTCCAGAAAGCTTTGGAAGAGATTTCATCCCTCACATGCCTGGCTGGGAATG
TCAGTGCATGTGACGCCCTATTCTCTCCTCTTCCAGGTCCCTAGACTGCAGGGA
GAGTGGCAAGAATGGGCCTCATGTGTACCAGGACCTCCTGCTTAGCCTTGGGACT
ACAAACAGCACGCTGCCCCCTCCATTTTCTCTCCAATCTGGAATCCTGACATTGA
ACCCAGTTGCTCAGGGTCAGCCCATCTTACTTCCCTGGGATCAAATCAAGAAGA
15 AGCATATGTCACCATGTCCAGCTTCTACCAAACACAGTGAAGTGTAAAGAAAACC
CCAGAACTGAACTTACCGTGAGCGACCAAAGATGATTTAAAAAGGGAAGTCTAG
AGTTCCTAGTCTCCCTAACAGCACCAGAGAAGACA

SEQ ID NO: 152

20 >3386845H1

TGCCTGTAAGAAACATGATATAACTGTCAAAAGGACAGAAAGTCAGCTACATCA
ATGGCAAGATGTGAGTAGTAGGTTCCGTTTGTACCAGGACAGTGCAGAAATGGC
AAATTTTCCCTCAATATGAAAAAAGAAACAAAGAAAATCTATGAGAAGTGCCA
CCACATGGACAGACCACCCTCCCGCGGGCATGTGGTCTGCAGCCCCTGCCCGTT
25 TCCAACAACCTTCCTACTAACAGGCTTTCTCCTTC

SEQ ID NO: 153

>gi|29707|emb|X07549.1|HSCATH Human mRNA for cathepsin H (E.C.3.4.22.16.)

TTGCTGAAATAAAACACAAGTATCTCTGGTCAGAGCCTCAGAATTGCTCAGCCAC
30 CAAAAGTAACTACCTTCGAGGTACTGGTCCCTACCCACCTTCCGTGGACTGGCGG
AAAAAAGGAAATTTTGTCTCACCTGTGAAAAATCAGGGTGCCTGCGGCAGTTGCT
GGACTTTCTCCACCACTGGGGCCCTGGAGTCTGCAATCGCCATCGCAACCGGAAA
GATGCTGTCTTGGCGGAACAGCAGCTGGTGGACTGCGCCCAGGACTTCAATAAT
TACGGCTGCCAAGGGGGTCTCCCCAGCCAGGCTTTTCGAGTATATCCTGTACAACA
35 AGGGGATCATGGGTGAAGACACCTACCCCTACCAGGGCAAGGATGGTTATTGCA
AGTTCCAACCTGGAAAGGCCATCGGCTTTGTCAAGGATGTAGCCAACATCACAAT
CTATGACGAGGAAGCGATGGTGGAGGCTGTGGCCCTCTACAACCCTGTGAGCTTT
GCCTTTGAGGTGACTCAGGACTTCATGATGTATAGAACGGGCATCTACTCCAGTA
CTTCCTGCCATAAACTCCAGATAAAGTAAACCATGCAGTACTGGCTGTTGGGTA
40 TGGAGAAAAAATGGGATCCCTTACTGGATCGTGAAAAACTCTTGGGGTCCCCA
GTGGGGAATGAACGGGTACTTCCTCATCGAGCGCGGAAAGAACATGTGTGGCCT
GGCTGCCTGCGCCTCCTACCCCATCCCTCTGGTGTGAGCCGTGGCAGCCGCAGCG
CAGACTGGCGGAGAAGGAGAGGAACGGGCAGCCTGGGCCTGGGTGGAAATCCT
GCCCTGGAGGAAGTTGTGGGGAGATCCACTGGGACCCCCAACATTCTGCCCTCAC
45 CTCTGTGCCAGCCTGGAAACCTACAGACAAGGAGGAGTTCCACCATGAGCTCA
CCCGTGTCTATGACGCAAAGATCACCAGCCATGTGCCTTAGTGTCTTCTTAACA
GACTCAAACCACATGGACCACGAATATTCTTTCTGTCCAGAAGGGCTACTTTCCA
CATATAGAGCTCCAGGGACTGTCTTTTCTGTATTTCGCTGTTCAATAAACATTGAGT
GAGCACCTCCA

SEQ ID NO: 154

>gi|1927579|gb|AA284668.1|AA284668 zt24g06.r1 Soares ovary tumor NbHOT Homo sapiens cDNA clone IMAGE:714106 5' similar to gb:M15476 UROKINASE-TYPE

5 PLASMINOGEN ACTIVATOR PRECURSOR (HUMAN);
TTTTTCTGGACTGAAGCCTGCAGGAGTTAAAAAGGGCAGGGCATCTCCTGTGCAT
GGGTGAAGGGAGGGCCAGCTCCCCCGACGGTGGGCATTTGTGAGGCCCATGGTT
GAGAAATGAATAATTTCCCAATTAGGAAGTGTAAACAGCTGAGGTCTCTTGAGGG
AGCTTAGCCAATGTGGGAGCAGCGGTTTGGGGAGCAGAGACACTAACGACTTCA
10 GGGCAGGGCTCTGATATTCCATGAATGTATCAGGAAATATATATGTGTGTGTATG
TTTGCACACTTGTGTGTGGGCTGTGAGTGTAAAGTGTGAGTAAGAGCTGGTGTCTG
ATTGTTAAGTCTAAATATTTCTTAAACTGGCGTGGACTGTGATGCCACACAGAG
TTGTCTTTCTGGGAGAGGTTATAGGTCACCCCTGGGGCCTTCTTGGTCCCCCAGCT
GACAGTGGCTGGGAATGTATTAGTCCTCAGCATGACCTGTGACAACACTGTCTCA
15 AGTTCCTTTCACATAGATGTCCGTTCTT

SEQ ID NO: 155

>gi|186496|gb|M59911.1|HUMINTA3A Human integrin alpha-3 chain mRNA, complete cds

20 AGGTGAACAGGTCCTCACGCCAGCTCCGCCCCCTCACGCGCTCTCGCCGGGACC
CCGCTTCCGCTGGCAGCCATGGGCCCCGGCCCCAGCCGCGCGCCCCGCGCCCCAC
GCCTGATGCTCTGTGCGCTCGCCTTGATGGTGGCGGCGCGGCTGCGTCTCTC
CGCCTTCAACCTGGATACCCGATTCTGGTAGTGAAGGAGGCCGGGAACCCGGG
CAGCCTCTTCGGCTACTCGGTGCCCCCTCCATCGGCAGACAGAGCGGCAGCAGCGC
TACCTGCTCCTGGCTGGTGGCCCCCGGGAGCTCGCTGTGCCCGATGGCTACACCA
25 ACCGGACTGGTGTGTGTACCTGTGCCCACTCACTGCCCAACAAGGATGACTGTGA
GCGGATGAACATCACAGTGAAAAATGACCCTGGCCATCACATTATTGAGGACAT
GTGGCTTGGAGTGACTGTGGCCAGCCAGGGCCCTGCAGGCAGAGTTCTGGTCTGT
GCCACCGCTACACCCAGGTGCTGTGGTTCAGGGTCAGAAGACCAGCGGCGCATG
GTGGGCAAGTGCTACGTGCGAGGCAATGACCTAGAGCTGGACTCCAGTGATGAC
30 TGGCAGACCTACCACAACGAGATGTGCAATAGCAACACAGACTACCTGGAGACG
GGCATGTGCCAGCTGGGCACCAGCGGTGGCTTCACCCAGAACAACCTGTGTACTTCG
GCGCCCCCGGTGCCTACAACCTGGAAAGGAAACAGCTACATGATTCAGCGCAAGG
AGTGGGACTTATCTGAGTATAGTTACAAGGACCCAGAGGACCAAGGAAACCTCT
ATATTGGGTACACGATGCAGGTAGGCAGCTTCATCCTGCACCCCCAAAAACATCAC
35 CATTGTGACAGGTGCCCCACGGCACCGACATATGGGCGCGGTGTTCTTGCTGAGC
CAGGAGGCAGGCGGAGACCTGCGGAGGAGGCAGGTGCTGGAGGGCTCGCAGGT
GGGCGCCTATTTTGGCAGCGCAATTGCCCTGGCAGACCTGAACAATGATGGGTG
GCAGGACCTCCTGGTGGGCGCCCCCTACTACTTCGAGAGGAAAGAGGAAGTAGG
GGGTGCCATCTATGTCTTCATGAACCAGGCGGGAACCTCCTTCCCTGCTCACCCC
40 TCACTCCTTCTTCATGGCCCCAGTGGCTCTGCCTTTGGTTTATCTGTGGCCAGCAT
TGGTGACATCAACCAGGATGGATTTTCAGGATATTGCTGTGGGAGCTCCGTTTGAA
GGCTTGGGCAAAGTGTACATCTATCACAGTAGCTCTAAGGGGCTCCTTAGACAGC
CCCAGCAGGTAATCCATGGAGAGAAGCTGGGACTGCCTGGGTTGGCCACCTTCG
GCTATTCCCTCAGTGGGCAGATGGATGTGGATGAGAACTTCTACCCAGACCTTCT
45 AGTGGGAAGCCTGTGAGACCACATTGTGCTGCTGCGGGCCCCGGCCAGTCATCAA
CATCGTCCACAAGACCTTGGTGGCCAGGCCAGCTGTGCTGGACCCTGCACTTTGC
ACGGCCACCTCTTGTGTGCAAGTGGAGCTGTGCTTTGCTTACAACCAGAGTGCCG
GGAACCCCAACTACAGGCGAAACATCACCTGGCCTACACTCTGGAGGCTGACA
GGGACCGCCGGCCGCCCCGGCTCCGCTTTGCCGGCAGTGAGTCCGCTGTCTTCCA

CGGCTTCTTCTCCATGCCCCGAGATGCGCTGCCAGAAGCTGGAGCTGCTCCTGATG
GACAACCTCCGTGACAACTCCGCCCCATCATCTCCATGAACTACTCTTTAC
CTTTGCGGATGCCCGATCGCCCCCGGCTGGGGCTGCGGTCCCTGGACGCCTACCC
GATCCTCAACCAGGCACAGGCTCTGGAGAACCACACTGAGGTCCAGTTCCAGAA
5 GGAGTGCGGGCCTGACAACAAGTGTGAGAGCAACTTGCAGATGCGGGCAGCCTT
CGTGTGAGAGCAGCAGCAGAAGCTGAGCAGGCTCCAGTACAGCAGAGACGTCCG
GAAATTGCTCCTGAGCATCAACGTGACGAACACCCGGACCTCGGAGCGCTCCGG
GGAGGACGCCCACGAGGCGCTGCTCACCTGGTGGTGCCTCCCGCCCTGCTGCTG
TCCTCAGTGCGCCCCCCCCGGGGCCTGCCAAGCTAATGAGACCATCTTTTGCGAGC
10 TGGGGAACCCCTTCAAACGGAACCAGAGGATGGAGCTGCTCATCGCCTTTGAGG
TCATCGGGGTGACCCTGCACACAAGGGACCTTCAGGTGCAGCTGCAGCTCTCCAC
GTCGAGTCACCAGGACAACCTGTGGCCCATGATCCTCACTCTGCTGGTGGACTAT
ACACTCCAGACCTCGCTTAGCATGGTAAATCACCGGCTACAAAGCTTCTTTGGGG
GGACAGTGATGGGTGAGTCTGGCATGAAAAGTGTGGAGGATGTAGGAAGCCCCC
15 TCAAGTATGAATTCCAGGTGGGCCCAATGGGGGAGGGGCTGGTGGGCCTGGGGA
CCCTGGTCTTAGGTCTGGAGTGGCCCTACGAAGTCAGCAATGGCAAGTGGCTGCT
GTATCCCACGGAGATCACCGTCCATGGCAATGGGTCTGGCCCTGCCGACCACCT
GGAGACCTTATCAACCCTCTCAACCTCACTCTTTCTGACCCTGGGGACAGGCCAT
CATCCCCACAGCGCAGGCGCCGACAGCTGGATCCAGGGGGAGGCCAGGGCCCCC
20 CACCTGTCACTCTGGCTGCTGCCAAAAAGCCAAGTCTGAGACTGTGCTGACCTG
TGCCACAGGGCGTGCCCACTGTGTGTGGCTAGAGTGCCCCATCCCTGATGCCCCC
GTTGTACCAACGTGACTGTGAAGGCACGAGTGTGGAACAGCACCTTCATCGAG
GATTACAGAGACTTTGACCGAGTCCGGGTAAATGGCTGGGCTACCCTATTCTCTCC
GAACCAGCATCCCCACCATCAACATGGAGAACAAGACCACGTGGTTCTCTGTGG
25 ACATTGACTCGGAGCTGGTGGAGGAGCTGCCGGCCGAAATCGAGCTGTGGCTGG
TGCTGGTGGCCGTGGGTGCAGGGCTGCTGCTGCTGGGGCTGATCATCCTCCTGCT
GTGGAAGTGCGGCTTCTTCAAGCGAGCCCGCACTCGCGCCCTGTATGAAGCTAAG
AGGCAGAAGGCGGAGATGAAGAGCCAGCCGTCAGAGACAGAGAGGCTGACCGA
CGACTACTGAGGGGGCAGCCCCCGCCCCGGGCCACCTGGTGTGACTTCTTTAA
30 GCGGACCCGCTATTATCAGATCATGCCAAGTACCACGCAGTGCGGATCCGGGA
GGAGGAGCGCTACCCACCTCCAGGGAGCACCTGCCACCAAGAAGCACTGGGT
GACCAGCTGGCAGACTCGGGACCAATACTACTGACGTCTCCTGATCCCCACCC
CTCCTCCCCCAGTGTCCCCTTTCTTCTTATTTATCATAAGTTATGCCTCTGACAGT
CCACAGGGGGCCACCACCTTTGGCTGGTAGCAGCAGGCTCAGGCACATACACCTC
35 GTCAAGAGCATGCACATGCTGTCTGGCCCTGGGGATCTTCCCACAGGAGGGCCA
GCGCTGTGGACCTTACAACGCCGAGTGCATGCAATCCTGTGCCCTAGATGCACG
TGGGGCCCACTGCTCGTGGACTGTGCTGGTGCATACGGATGGTGCATGGGCTCG
CCGTGTCTCAGCCTCTGCCAGCGCCAGCGCCAAAACAAGCCAAAGAGCCTCCCA
CCAGAGCCGGGAGGAAAAGGCCCTGCAATGTGGTGACACCTCCCCTTTACAC
40 CTGGATCCATCTTGAGAGCCACAGTCACTGGATTGACTTTGCTGTCAAACTACT
GACAGGGAGCAGCCCCCGGGCCGCTGGCTGGTGGGCCCCCAATTGACACCCATG
CCAGAGAGGTGGGGATCCTGCCTAAGGTTGTCTACGGGGGCACTTGGAGGACCT
GGCGTGCTCAGACCCAACAGCAAAGGAAGTAGAAAGAAGGACCCAGAAGGCTT
GCTTTCCTGCATCTCTGTGAAGCCTCTCTCCTTGGCCACAGACTGAACTCGCAGG
45 GAGTGCAGCAGGAAGGAACAAAGACAGGCAAACGGCAACGTAGCCTGGGCTCA
CTGTGCTGGGGCATGGCGGGATCCTCCACAGAGAGGAGGGGACCAATTCTGGAC
AGACAGATGTTGGGAGGATACAGAGGAGATGCCACTTCTCACTACCACTACCA
GCCAGCCTCCAGAAGGCCCCAGAGAGACCCTGCAAGACCACGGAGGGAGCCGA
CACTTGAATGTAGTAATAGGCAGGGGGCCCTGCCACCCCATCCAGCCAGACCCC

AGCTGAACCATGCGTCAGGGGCTAGAGGTGGAGTTCTTAGCTATCCTTGGCTTT
CTGTGCCAGCCTGGCTCTGCCCCCTCCCCCATGGGCTGTGTCTAAGGCCCATTTG
AGAAGCTGAGGCTAGTTCCAAAAACCTCTCCTGACCCCTGCCTGTTGGCAGCCCA
CTCCCCAGCCCCAGCCCCCTTCCATGGTACTGTAGCAGGGGAATTCCTCCCCCTC
5 CTTGTGCCTTCTTTGTATATAGGCTTCTACCGCGACCAATAAACAGCTCCCAGTT
TGT

SEQ ID NO: 156

>gi|189204|gb|M14764.1|HUMNGFR Human nerve growth factor receptor mRNA, complete
10 cds

GCCGCGGCCAGCTCCGGCGGGCAGGGGGGGCGCTGGAGCGCAGCGCAGCGCAG
CCCCATCAGTCCGCAAAGCGGACCGAGCTGGAAGTCGAGCGCTGCCGCGGGAGG
CGGGCGATGGGGGCAGGTGCCACCGGCCGCGCCATGGACGGGCGCGCCTGCTG
CTGTTGCTGCTTCTGGGGGTGTCCCTTGGAGGTGCCAAGGAGGCATGCCCCACAG
15 GCCTGTACACACACAGCGGTGAGTGCTGCAAAGCCTGCAACCTGGGCGAGGGTG
TGGCCCAGCCTTGTGGAGCCAACCAGACCGTGTGTGAGCCCTGCCTGGACAGCGT
GACGTTCTCCGACGTGGTGAGCGCGACCGAGCCGTGCAAGCCGTGCACCGAGTG
CGTGGGGCTCCAGAGCATGTGCGGCGCCGTGCGTGGAGGCCGACGACGCCGTGTG
CCGCTGCGCCTACGGCTACTACCAGGATGAGACGACTGGGCGCTGCGAGGCGTG
20 CCGCGTGTGCGAGGCGGGCTCGGGCCTCGTGTTCTCCTGCCAGGACAAGCAGAA
CACCGTGTGCGAGGAGTGCCCCGACGGCACGTATTCCGACGAGGCCAACCACGT
GGACCCGTGCCTGCCCTGCACCGTGTGCGAGGACACCGAGCGCCAGCTCCGCGA
GTGCACACGCTGGGCGGACGCCGAGTGCGAGGAGATCCCTGGCCGTTGGATTAC
ACGGTCCACACCCCCAGAGGGCTCGGACAGCACAGCCCCCAGCACCCAGGAGCC
25 TGAGGCACCTCCAGAACAAAGACCTCATAGCCAGCACGGTGGCAGGTGTGGTGAC
CACAGTGATGGGCAGCTCCCAGCCCGTGGTGACCCGAGGCACCACCGACAACCT
CATCCCTGTCTATTGCTCCATCCTGGCTGCTGTGGTTGTGGGCCTTGTGGCCTACA
TAGCCTTCAAGAGGTGGAACAGCTGCAAGCAGAACAAAGCAAGGAGCCAACAGC
CGGCCAGTGAACCAGACGCCCCCACCAGAGGGAGAAAACTCCACAGCGACAGT
30 GGCATCTCCGTGGACAGCCAGAGCCTGCATGACCAGCAGCCCCACACGCAGACA
GCCTCGGGCCAGGCCCTCAAGGGTGACGGAGGCCTCTACAGCAGCCTGCCCCCA
GCCAAGCGGGAGGAGGTGGAGAAGCTTCTCAACGGCTCTGCGGGGGACACCTGG
CGGCACCTGGCGGGCGAGCTGGGCTACCAGCCCGAGCACATAGACTCCTTTACC
CATGAGGCCTGCCCCGTTGCGGCCCTGCTTGCAAGCTGGGCGACCCAGGACAGCG
35 CCACACTGGACGCCCTCCTGGCCGCCCTGCGCCGCATCCAGCGAGCCGACCTCGT
GGAGAGTCTGTGCAGTGAGTCCACTGCCACATCCCCGGTGTGAGCCCAACCGGG
GAGCCCCCGCCCCGCCCCACATTCCGACAACCGATGCTCCAGCCAACCCCTGTGG
AGCCCGCACCCCCACCCTTTGGGGGGGGCCCGCCTGGCAGAACTGAGCTCCTCTG
GGCAGGACCTCAGAGTCCAGGCCCCAAAACCACAGCCCTGTCAGTGCAGCCCGT
40 GTGGCCCCCTTCACTTCTGACCACACTTCCTGTCCAGAGAGAGAAGTGCCCTGCT
GCCTCCCCAACCCCTGCCCTGCCCCGTACCATCTCAGGCCACCTGCCCCCTTCTC
CCACACTGCTAGGTGGGCCAGCCCTCCACCACAGCAGGTGTCATATATGGGG
GGCCAACACCAGGGATGGTACTAGGGGGGAAGTGACAAGGCCCCAGAGACTCAG
AGGGAGGAATCGAGGAACCAGAGCCATGGACTCTACACTGTGAACTTGGGGAAAC
45 AAGGGTGGCATCCCAGTGGCCTCAACCCTCCCTCAGCCCTCTTGCCCCCACCC
CAGCCTAAGATGAAGAGGATCGGAGGCTTGTGAGAGCTGGGAGGGGTTTTCGAA
GCTCAGCCCACCCCCCTCATTTTGGATATAGGTCAGTGAGGCCAGGGAGAGGCC
ATGATTGCCCCAAAGCCAGACAGCAACGGGGAGGCCAAGTGCAGGCTGGCACCG
CCTTCTCTAAATGAGGGGCCTCAGGTTTGCCTGAGGGCGAGGGGAGGGTGGCAG

GTGACCTTCTGGGAAATGGCTTGAAGCCAAGTCAGCTTTGCCTTCCACGCTGTCT
CCAGACCCCCACCCCTTCCCCACTGCCTGCCACCCGTGGAGATGGGATGCTTGC
CTAGGGCCTGGTCCATGATGGAGTCAGGTTTGGGGTTCGTGGAAAGGGTGCTGCT
TCCCTCTGCCTGTCCCTCTCAGGCATGCCTGTGTGACATCAGTGGCATGGCTCCA
5 GTCTGCTGCCCTCCATCCCGACATGGACCCGGAGCTAACACTGGCCCCCTAGAATC
AGCCTAGGGGTTCAGGGACCAAGGACCCCTCACCTTGCAACACACAGACACACGC
ACACACACACACAGGAGGAGAAATCTCACTTTTCTCCATGAGTTTTTCTCTTGG
GCTGAGACTGGATACTGCCCCGGGCAGCTGCCAGAGAAGCATCGGAGGGAATTG
AGGTCTGCTCGGCCGTCTTCACTCGCCCCCGGGTTTGGCGGGCCAAGGACTGCCG
10 ACCGAGGCTGGAGCTGGCGTCTGTCTTCAAGGGCTTACACGTGGAGGAATGCTCC
CCCATCTCCCTTCCCTGCAAACATGGGGTTGGCTGGGCCCAGAAGGTTGCGAT
GAAGAAAAGCGGGCCAGTGTGGGAATGCGGCAAGAAGGAATTGACTTCGACTGT
GACCTGTGGGGATTTCTCCCAGCTCTAGACAACCCTGCAAAGGACTGTTTTTCC
TGAGCTTGGCCAGAAGGGGGGCCATGAGGCCTCAGTGGACTTTCCACCCCTCCCT
15 GGCCTGTTCTGTTTTGCCTGAAGTTGGAGTGAGTGTGGCTCCCTCTATTTAGCAT
GACAAGCCCCAGGCAGGCTGTGCGCTGACAACCACCGCTCCCCAGCCAGGGTT
CCCCCAGCCCTGTGGAAGGGACTAGGAGCACTGTAGTAAATGGCAATTCTTTGAC
CTCAACCTGTGATGAGGGGAGGAACTCACCTGCTGGCCCCTCACCTGGGCACCT
GGGGAGTGGGACAGAGTCTGGGTGTATTTATTTTCTCCCCAGCAGGTGGGGAG
20 GGGGTTTGGTGGCTTGCAAGTATGTTTTAGCATGTGTTTGGTTCTGGGGCCCCTTT
TTACTCCCCTTGAGCTGAGATGGAACCCTTTTGGCCCCCAGCTGGGGGCCATGAG
CTCCAGACCCCCAGCAACCCTCCTATCACCTCCCCTCCTTGCCTCCTGTGTAATCA
TTTCTTGGGGCCCTCCTGAACTTACACACAAAACGTTAAGTGATGAACATTAAAT
AGCAAAG

25

SEQ ID NO: 157

>873 BLOOD 234929.1 U34038 g1041728 Human protease-activated receptor-2 mRNA,
complete cds. 0

CACGAGCCCTGGGGAGGCGCGCAGCAGAGGCTCCGATTCGGGGCAGGTGAGAG
30 GCTGACTTTCTCTCGGTGCGTCCAGTGGAGCTCTGAGTTTCGAATCGGTGGCGGC
GGATTCCCCGCGCGCCCGGCGTCCAGGAGGATGCGGAGCCCCAGCG
CGGCGTGGCTGCTGGGGGCCGCCATCCTGCTAGCAGCCTCTCTCTCCTGCAGTGG
CACCATCCAAGGAACCAATAGATCCTCTAAAGGAAGAAGCCTTATTGGTAAGGT
TGATGGCAGATCCCACGTCACCTGGGAAAAGGAGTTACAGTTGAAACAGTCTTTTC
35 TGTGGATGAGTTTTCTGCATCTGTCCTCACTGGAAAAGTACCCTGTCTTCCTTC
CAATTGTCTACACAATTGTGTTTGTGGTGGGGTTTGAAGTAACGGCATGGCCCT
GTGGGTCTTTCTTTTCCGAACCTAAGAAGAAGCACCCTGCTGTGATTACATGGCC
AATCTGGCCTTGGCTGACCTCCTCTCTGTCATCTGGTTCCCCTTGAAGATTGCCTA
TCACATACATGGCAACAACCTGGATTTATGGGGAAGCTCTTTGTAATGTGCTTATT
40 GGCTTTTTCTATGGCAACATGTACTGTTCCATTCTCTTCATGACCTGCCTCAGTGT
GCAGAGGTATTGGGTGATCGTGAACCCCATGGGGCACTCCAGGAAGAAGGCAAA
CATTGCCATTGGCATCTCCCTGGCAATATGGCTGCTGATTCTGCTGGTCACCATCC
CTTTGTATGTCGTGAAGCAGACCATCTTCATTCCCTGCCCTGAACATCACGACCTGT
CATGATGTTTTGCCTGAGCAGCTCTTGGTGGGAGACATGTTCAATTACTTCCTCTC
45 TCTGGCCATTGGGGTCTTTCTGTTCCAGCCTTCCTCACAGCCTCTGCCTATGTGC
TGATGATCAGAATGCTGCGATCTTCTGCCATGGATGAAAAGTACAGAGAAGAAAA
GGAAGAGGGCCATCAAACCTATTGTCACTGTCTGGCCATGTACCTGATCTGCTT
CACTCCTAGTAACCTTCTGCTTGTGGTGCATTATTTCTGATTAAAGAGCCAGGGCC
AGAGCCATGTCTATGCCCTGTACATTGTAGCCCTCTGCCTCTCTACCTTAACAGC

TGCATCGACCCCTTTGTCTATTACTTTGTTTCACATGATTTTCAGGGATCATGCAAA
 GAACGCTCTCCTTTGCCGAAGTGTCCGCACTGTAAAGCAGATGCAAGTATCCCTC
 ACCTCAAAGAAACACTCCAGGAAATCCAGCTCTTACTCTTCAAGTTCAACCACTG
 TTAAGACCTCCTATTGAGTTTTCCAGGTCCTCAGATGGGAATTGCACAGTAGGAT
 5 GTGGAACCTGTTTAATGTTATGAGGACGTGTCTGTTATTTCTAATCAAAAAGGT
 CTCACCACATAACCATGTGGATGCAGCACCTCTCAGGATTGCTAGGAGCTCCCCTG
 TTTGCATGAGAAAAGTAGTCCCCCAAATTAACATCAGTGTCTGTTTCAGAATCTC
 TCTACTCAGATGACCCCAAGAACTGAACCAACAGAAGCAGACTTTTTCAGAAGAT
 GGTGAAGACAGAAACCCAGTAACTTGCAAAAAGTAGACTTGGTGTGAAGACTCA
 10 CTTCTCAGCTGAAATTATATATATACACATATATATATTTTACATCTGGGATCATG
 ATAGACTTGTTAGGGCTTCAAGGCCCTCAGAGATGATCAGTCCAACCTGAACGACC
 TTACAAATGAGGAAACCAAGATAAATGAGCTGCCAGAATCAGGTTTCCAATCAA
 CAGCAGTGAGTTGGGATTGGACAGTAGAATTTCAATGTCCAGTGAGTGAGGTTCT
 TGTACCACTTCATCNN
 15 NNN
 NNN
 NNN
 NNT
 20 AGTCGTGAATCTTGTTCAAAATGCAGATTCCTCAGATTCAATAATGAGAGCTCAG
 ACTGGGAACAGGGCCAGGAATCTGTGTGGTACAAACCTGCATGGTGTATTATGC
 ACACAGAGATTTGAGAACCATTGTTCTGAATGCTGCTTCCATTTGACAAAGTGCC
 GTGATAATTTTTGAAAAGAGAAGCAAACAATGGTGTCTCTTTTATGTTTCAGCTTA
 TAATGAAATCTGTTTGTGACTTATTAGGACTTTGAATTATTTCTTTATTAACCTT
 25 CTGAGTTTTTGTATGTATTATTATTAAGAAAAATGCAATCAGGATTTTAAACAT
 GTAAATACAAATTTTGTATACTTTTGATGACTTCAGTGAAATTTTCAGGTAGTCT
 GAGTAATAGATTGTTTTGCCACTTAGAATAGCATTGCGCACTTAGTATTTTAAAA
 AATAATTGTTGGAGTATTTATTGTCAGTTTTGTTCACTTGTTATCTAATAAAAAT
 TATAAAGCCTTCAGAGGGTTTGGACCACATCTCTTTGGAAAATAGTTTGCAACAT
 30 ATTTAAGAGATACTTGATGCCAAAATGACTTTATACAACGATTGTATTTGTGACT
 TTTAAAAATAATTATTTTATTGTGTAATTGATTATATAAATAACAAAATTTTTTTAC

SEQ ID NO: 158

279279H1

35 AGCACACCAAGGAGTGATTTTNAAACTTACTCTGTTTTCTNNTTCCCAACAAGA
 TTATCATTTTCCTTTAAAAAAAATAGTTATCCTGGGGCATAACAGCCATACCATTNT
 GAAGGTGTCTTATCTCCTCTGATCTAGAGAGCACCATGAAGCTTCTCACGGGCCT
 GGTNTTNTGCTCCTTGGTCCTGGGTGTCAGCAGCCGAAGCTTCTTTTCGTTCTTGG
 40 G

SEQ ID NO: 159

>gi|340155|gb|K03226.1|HUMUKM1 Human preprourokinase mRNA, complete cds

TCCACCTGTCCCCGCAGCGCCGGCTCGCGCCCTCCTGCCGCAGCCACCGAGCCGC
 CGTCTAGCGCCCCGACCTCGCCACCATGAGAGCCCTGCTGGCGCGCCTGCTTCTC
 45 TGCGTCTTGGTCTGTGAGCGACTCCAAAGGCAGCAATGAACTTCATCAAGTTCCAT
 CGAACTGTGACTGTCTAAATGGAGGAACATGTGTGTCCAACAAGTACTTCTCCAA
 CATTCACTGGTGCAACTGCCCAAAGAAATTCGGAGGGCAGCACTGTGAAATAGA
 TAAGTCAAAAACCTGCTATGAGGGGAATGGTCACTTTTACCGAGGAAAGGCCAG
 CACTGACACCATGGGCCCGGCCCTGCCTGCCCTGGAACCTCTGCCACTGTCTTCAG

CAAACGTACCATGCCCACAGATCTGATGCTCTTCAGCTGGGCCTGGGGAAACATA
ATTACTGCAGGAACCCAGACAACCGGAGGCGACCCTGGTGCTATGTGCAGGTGG
GCCTAAAGCCGCTTGTCCAAGAGTGCATGGTGCATGACTGCGCAGATGGAAAAA
AGCCCTCCTCTCCTCCAGAAGAATTAATAATTTAGTGTGGCCAAAAGACTCTGAG
5 GCCCCGCTTTAAGATTATTGGGGGAGAATTCACCACCATCGAGAACCAGCCCTGG
TTTGCGGGCCATCTACAGGAGGCACCGGGGGGGCTCTGTCACCTACGTGTGTGGAG
GCAGCCTCATCAGCCCTTGCTGGGTGATCAGCGCCACACACTGCTTCATTGATTA
CCCAAAGAAGGAGGACTACATCGTCTACCTGGGTGCTCAAGGCTTAACTCCAA
CACGCAAGGGGAGATGAAGTTTGAGGTGGAAAACCTCATCTACACAAGGACTA
10 CAGCGCTGACACGCTTGCTCACCACAACGACATTGCCTTGCTGAAGATCCGTTCC
AAGGAGGGCAGGTGTGCGCAGCCATCCCGGACTATACAGACCATCTGCCTGCCC
TCGATGTATAACGATCCCCAGTTTGGCACAAGCTGTGAGATCACTGGCTTTGGAA
AAGAGAATTCTACCGACTATCTCTATCCGGAGCAGCTGAAGATGACTGTTGTGAA
GCTGATTTCCACCGGGAGTGTGAGCAGCCCCACTACTACGGCTCTGAAGTCACC
15 ACCAAAATGCTGTGTGCTGCTGACCCACAGTGGAAAACAGATTCCTGCCAGGGA
GACTCAGGGGGGACCCCTCGTCTGTTCCCTCCAAGGCCGCATGACTTTGACTGGAA
TTGTGAGCTGGGGCCGTGGATGTGCCCTGAAGGACAAGCCAGGCGTCTACACGA
GAGTCTCACACTTCTTACCCTGGATCCGCAGTCACACCAAGGAAGAGAATGGCCT
GGCCCTCTGAGGGTCCCCAGGGAGGAAACGGGCACCACCCGCTTTCTTGCTGGTT
20 GTCATTTTTGCAGTAGAGTCATCTCCATCAGCTGTAAGAAGAGACTGGGAAGAT

SEQ ID NO: 160

>4727571H1

GGCTCAGCCTGGAGGGACCCAACCAGAGCCTGGCCTGGGAGCCAGGATGGCCAT
25 CCACAAAGCCTTGGTGATGTGCCTGGGACTGCCTCTCTTCCTGTTCCAGGGGCC
TGGGCCAGGGCCATGTCCACCCGGCTGCAGCCAAGGCCTCAAGCCCCTGTACT
ACAACCTGTGTGACCGCTCTGGGGCGTGGGGCATCGTCCTGGACGCCGTTGCTGG
GGCGGGCATTGTCACCACGTTTGTGCTCACCATCATCCT

30 SEQ ID NO: 161

>2135769H1

GCTCGCGTCGCATTTGGCCGCCTCCCTACCGCTCCAAGCCCAGCCCTCAGCCATG
GCATGCCCCCTGGATCAGGCCATTGGCCTCCTCGTGGCCATCTTCCACAAGTACT
CCGGCAGGGAGGGTGAACAAGCACACCCTGAGCAAGAAGGAGCTGAAGGAGCTG
35 ATCCAGAAGGAGCTCACCATTGGCTCGAAGCTGCAGGATGCTGAAATTGCAAGG
CTGATGGAAGACTTGGACCGGAACAAGGACCAGGAGGTGAACTTCCAGGAGTAT
GTCACCTTCCTGGGGGC

SEQ ID NO: 162

40 >gi|2179161|gb|AA456585.1|AA456585 zx73c10.s1 Soares ovary tumor NbHOT Homo
sapiens cDNA clone IMAGE:809394 3' similar to SW:RECQ_HUMAN P46063 ATP-
DEPENDENT DNA HELICASE Q1. ; mRNA sequence

TCTTTAAAGGCTTTATTTGCATTCTTGTAATTTTATTATTTCAAGTCAATGTGTTA
AGAATTACTGCGCATATAGTTATTTCTTTTATAAATTTGTTTTCCGTGATTCCTTC
45 AAAAGCTTTCTTATTGTTGGCCTTTATTTTCTGCAGAGAAGACTACAGTTTTACAG
CTTATGCTACCATTTCTGATTTGAAAATAGGACCTAAAGCTAATCTTCTGAACAA
TGAGGCACATGCTATTACTATGCAAGTGACAAAGTCCACGCAGAACTCTTTCAGG
GTAAATGGCTATTAATTTTCAGTTTTATATATT

SEQ ID NO: 163

>1452259F6

CTGGTTCAATTTTACAGGAATTCAGTAAGATAAATACTATTCTCTGAATTCAAA
AAACAACCTTCTTCAGGGCCACAAAACACTGGGGATAAAGACAAGAAGAACTACA
5 GCAGGGGTCCCCACCTACTCGNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNAGGTGATTCTGATCGGATGTTACATAG
CCATATCCAGGTACATCCACAAATCCAGCAGGCAATTCATAAGTCAGTCAAGCC
GANAGCGAAAACATAACCAGAGCATCAGGGTGTGTGGCTGTGTTTTTACCTG
CTTTCTATCATATCACTGTGCGAGAATTCCTTTTACTTTTAGTCACTTAGACTAGG
10 CTTTATAGATGAATCTGCACAA

SEQ ID NO: 164

>1650566F6

CAATTCAGGCAACAGGAGCNANGGGCCAGGAAAGAACACCACCTTTCACAATG
15 AATTTGACACAATTGTCTTGCCGGTGCTTTATCTCATTATATTTGTGGCAAGCATC
TTGCTGAATGGTTTAGCAGTGTGGATCTCTCCACATTAGGAATAAAACCAGCTT
CATATTCTATCTCAAAAACATAGTGGTTGCAGACCTCATAATGACGCTGACATT
CCATTTCGAATAGTCCATGATGCAGGATTTGGACCTTGGTACTTCAAGTTTATTCC
CTGCAGATACACCTCAGTTTTGTTTTATGCAAACATGTATACTTCCATCGTG
20

SEQ ID NO: 165

>gi|2177519|gb|AA454743.1|AA454743 zx77e01.s1 Soares ovary tumor NbHOT Homo
sapiens cDNA clone IMAGE:809784 3', mRNA sequence

AGCTTTTTTTTTCATAATAAAATGCATTCTTTATTGAGTGCATGGTGGCCCAGGT
25 GCTATTCCATGTATGTATAGGTGTGAACTTTAAATCTTCCAACAGCCACTGC
CTTATGGAGACTGTATCATCCTTATCTTCATCTTACAGGTGAGAAATCTGCAGTG
AAGAAAGGTACATCCCAAG

SEQ ID NO: 166

30 >gi|2072424|gb|U83115.1|HSU83115 Human non-lens beta gamma-crystallin like protein
(AIM1) mRNA, partial cds

CAGCTCCGAGGGGAGTCGGACCGGAGCAAACAGCCACCCCCGGCTTCGTCCCCC
ACGAAGAGGGAAGGGCAGGAGCGCTGCCCTCGAGGCCGTGCCCGCCCCGCCGCC
AGCGGCCCCCGGGCTCCCGCCAAGGAGTCCCCACCCAAGAGGGTGCCCGATCCC
35 AGCCAGTCACCAAGGGCACTGCGGCCGAGAGCGGGGAGGAGGCGGCGCGGGC
CATCCCCCGCGAGCTCCCGGTCAAGAGCAGCTCGCTGCTGCCGGAGATCAAGCC
CGAGCACAAGAGGGGGCCCGCTCCCCAACCATTCAACGGCCGGGCAGAGGGAGG
TCGAAGCAGAGAGCTGGGCAGAGCGGCCGGAGCGCCTGGAGCTTCTGACGCCGA
CGGCTTGAAGCCCAGGAACCATTTTCGGCGTGGGCAGGTCGACAGTGACCACTAA
40 AGTGACCCTCCCTGCCAAGCCCAAACATGTGGAATAAATCTTAAACCCCTAAG
AATCTTGACAGTTTGGGAAATGAGCACAATCCATTTAGCCAGCCAGTTCACAAAG
GCAACACTGCCACCAAAATCTCCTTATTTGAAAACAAACGGACAAACAGTAGCC
CAAGACACACTGACATTTCGAGGCCCAAGGAATACTCCTGCCTCTAGTAAACGTT
TGTTGGGAGGGCAAAGCTGAATTTAGCCAAAAAGCCAAAGAAATGGAGCAACC
45 TGAAAAGAAAGTAATGCCAAACAGTCCCCAGAATGGTGTGCTGGTTAAGGAAAC
TGCTATAGAAACCAAGTTACCGTCTCGGAAGAAGAGATTCTGCCAGCAACCAG
AGGAATGAATGGAGACTCTTCTGAGAATCAAGCTCTTGGTCCTCAGCCTAACCAG
GATGATAAAGCAGATGTACAAACAGATGCTGGCTGCCTTTCAGAACCAGTGGCT
TCTGCTCTGATTCTGTCAAGGATCATAAGCTCTTAGAGAAGGAGGACTCAGAGG

CTGCAGACAGCAAAAAGCCTTGTACTTGAAAATGTAACCGATACAGCACAAGACA
TCCCCACCACTGTGGATACCAAAGATTTACCTCCAACGGCCATGCCAAAGCCACA
GCATACATTTTCTGACTCACAGTCCCCTGCTGAGTCATCTCCTGGGCCTTCTCTTT
CACTGTCTGCACCCGCTCCTGGGGATGTTCCCAAAGACACATGTGTTCAATCACC
5 CATAAGCAGTTTCCCATGCACTGATCTAAAAGTGTGAGAAAACCATAAAGGATG
TGTTTTGCCTGTGTCTCGTCAGAACAAATGAGAAAATGCCACTTTTAGAACTTGGA
GGAGAAACAACCCCTCCTTTGTCCACAGAGCGTAGTCCAGAAGCTGTGGGAAGT
GAGTGTCCATCCAGAGTCCTCGTCCAGGTCAGGTCCTTCGTGCTCCCCGTGGAGA
GCACCCAGGATGTGAGCTCCCAGGTCATCCAGAGAGCTCTGAAGTTAGAGAAG
10 TGCAGTTGCCAACTTGTCACAGTAATGAACCTGAAGTGGTTTCCGTTGCAAGTTG
TGCTCCCCCAAGAGGAAGTACTGGGCAATGAACACTCTCATTGCACAGCAGA
GCTCGCGGCAAAATCTGGCCCAAGTCATACCGCCAGCATCAGAGAAAACCTCT
GCCTATTCAAGGCTCAAAGTCAGGGCAGCAGAACACCCCTGATGGCTGAATCCAG
TCCCACCAACTCTCCCAGCAGCGGAAATCACTTAGCCACTCCTCAAAGGCCAGAT
15 CAGACTGTTACAAATGGCCAGGATAGCCCTGCCAGCCTTTTGAACATTTCTGCTG
GTAGTGATGATAGTGTATTTGATTCTTCTCTGATATGGAAAAATTCAGTGAATT
ATAAAACAGATGGATAGCGCAGTTTGTATGCCCATGAAAAGAAAAGAGGCCAGG
ATGCCAAACTCTCCTGCTCCTCACTTTGCCATGCCTCCTATTCACGAAGACCATT
AGAAAAGGTGTTTGATCCCAAAGTGTTACCTTTGGTTTGGGGAAGAAGAAGGA
20 AAGTCAGCCAGAAATGTCAACCGCTTTACATTTGATGCAGAACCTTGACACAAA
ATCCAAACTGAGACCCAAACGTGCATCTGCTGAACAGAGCGTCCTCTTCAAGTCC
CTGCACACCAACACTAATGGGAACAGTGAGCCTCTGGTGATGCCGGAAATCAAT
GACAAAGAGAACAGGGACGTCACAAATGGTGGCATTAAAGAGATCGAGACTAGA
AAAAAGTGCATTTTCTCAAGCTTGTTATCTTCTTTACCACAAGACAAAATCTTTT
25 CTCCTTCTGTGACATCAGTCAACACTATGACCACGGCTTTCAGTACTTCTCAGAA
CGGTTCCCTATCTCAGTCTTCAGTGTCACAGCCCACGACTGAGGGTGCCCCGCCC
TGTGGTTTGAACAAAGAACAGTCAAATCTTCTGCCCAGCAACTCCTTAAAGGTCT
TCAATTTCAACTCGTCAAGTACATCACACTCCAGTTTGAAAAGTCCAAGCCACAT
GGAAAAATACCCGCAAAAAGAGAAAACCAAAGAAGATCTGGATTACGAAGCA
30 ACCTACACTTGCCAGAACTAAATTTTCTGAATTGTCAAACTGAAGAATGATGA
TATGGAAAAGGCTAATCATATTGAAAGTGTTATTAATCAAACTTGCCAACTGT
GCAAACAGTGACACCGACTTCATGGGTCTTTTCAAATCAAGCCGGTATGACCCAA
GCATTTCTTTTCTGGAATGTCATTATCAGACACAATGACACTTAGAGGAAGTGT
CCAAAAATAAATCAATCCCCGACCTGGAAAGGTAGTGATATATAGTGAACCCGA
35 CGTCTCTGAGAAGTGCATTGAAGTTTTTCAGTGACATTCAGGATTGCAGTTCTTGG
AGCCTCTCTCCAGTGATACTCATAAAAGTTGTTAGAGGATGTTGGATTTTGTATG
AGCAACCAAATTTTGAAGGGCACTCCATCCCCTTAGAAGAAGGAGAATTGGAAC
TCTCTGGTCTCTGGGGTATAGAAGACATTTTGAAAGGCACGAAGAAGCAGAGT
CTGATAAGCCAGTGGTGATTGGTTCCATCAGACATGTGGTTCAGGATTACAGAGT
40 TAGTCACATTGACTTATTTACTGAACCAGAAGGGTTAGGAATCCTAAGTTCCTAC
TTTGATGATACTGAAGAAATGCAGGGATTGGTGTAATGCAGAAGACTTGTTCCA
TGAAAGTACATTGGGGCACGTGGCTGATTTATGAAGAACCTGGATTTACAGGGTGT
TCCTTTCATCCTGGAACCTGGTGAATACCCTGACTTGTCTTCTGGGATACAGAA
GCAGCGTACATTGGATCCATGCGGCCTCTGAAAATGGGTGGCCGTAAAGTTGAA
45 TTCCCTACAGATCCAAAGGTAGTTGTTTATGAAAAGCCTTTCTTTGAAGGAAAAT
GTGTGGAAGTAGAAACAGGAATGTGTAGTTTGTGCATGGAGGGAGGTGAAACAG
AAGAGGCGACTGGAGACGATCATTGCGGTTTACGTCAAGTGGGGTCTATGAAAG
TTCTAAGAGGCATTTGGGTGTCATATGAGAAGCCTGGATTTACCGGTCATCAGTA
TTTGCTAGAAGAAGGAGAATACAGGGACTGGAAAGCCTGGGGAGGTTACAATGG

AGAGCTTCAGTCTTTACGACCTATATTAGGTGATTTTTCAAATGCTCACATGATA
ATGTACAGTGAAAAAACTTTGGATCCAAAGGTTCCAGTATTGATGTATTGGGAA
TTGTTGCTAATTTAAAGGAGACTGGATATGGAGTGAAGACACAGTCTATTAATGT
ACTGAGTGGAGTATGGGTAGCCTATGAAAATCCTGACTTCACAGGAGAACAGTA
5 TATACTGGATAAAGGATTTTATACCAGTTTGTAGGACTGGGGAGGCAAAAATTAT
AAGATCTCTTCTGTTCAACCTATATGTTTGGATTCTTTCACTGGCCCAAGGAGACG
AAATCAGATTCACTTGTTTTTCAGAACCACAGTTTCAAGGTCACAGTCAAAGTTT
GAAGAAACAACAAGTCAAATTGATGATTCATTTTCTACCAAGTCTTGCAGAGTTT
CAGGAGGCAGCTGGGTTGTATATGATGGAGAAAATTTCACTGGTAATCAATACG
10 TGTGGAAGAAGGCCATTATCCTTGTCTGTCTGCAATGGGATGCCCCCTGGAGC
AACTTTCAAGTCTCTTCGTTTTATAGATGTTGAATTTTCTGAACCAACAATTATTC
TCTTTGAAAGAGAAGACTTCAAAGGAAAAAAGATTGAACTTAATGCAGAACTG
TCAATCTCCGATCCCTGGGATTCAACACACAAATACGCTCTGTTCAAGTTATTGG
TGGCATATGGGTTACTTATGAATATGGCAGTTACAGAGGGCGACAGTTCCTATTG
15 TCACCTGCAGAAGTACCTAATTGGTATGAATTCAGTGGCTGTCGCCAAATAGGTT
CTCTACGACCTTTTGTTCAGAAGCGAATTTATTTTCAGACTTCGAAACAAAGCAAC
AGGGTTATTTCATGTCAACCAATGGAACTTAGAGGATCTGAAGCTTCTGAGGATA
CAGGTCATGGAGGATGTCGGGGCCGATGATCAGATTTGGATCTATCAAGAAGGA
TGTATCAAATGCAGGATAGCAGAAGACTGCTGCCTGACGATTGTGGGCAGCCTG
20 GTAACATCTGGCTCCAAGCTAGGCCTGGCCCTGGACCAGAATGCTGACAGCCAG
TTCTGGAGCTTGAAGTCCGATGGCAGGATTTACAGCAAGTTGAAGCCAAATTTAG
TTTTAGACATTAAAGGGGGCACACAGTATGATCAAAATCACATTATCCTCAACAC
TGTCAGCAAAGAGAAGTTTACACAAGTGTGGGAAGCCATGGTCCTATATACCTG
AACAAAGAAGGAAGAAGAATCTTCTGGAGGTCCTTCCAGCCACCTTATTTCTTAA
25 AAAGGACAATGCTGATGGAAGACCAGACTGGAAAGTGGATCGACTCCTCCTTCA
TTGATTCTAAATTC AACCTTAAATCATGCTGCCATGACTCAGAGAACTTACTCAT
CGTTTCAAAGACTATCATAGCTTTAAACCAATAATTTGTCCTCCTTTTCAATTTCTT
GCCTTTCAATTTTGGTAGCTGCTTAAACAGGTTGCCTAATTAGCAGCTTTTGGGTG
ATTTTGTAATAATGTTATATCAAGATTTCAAGACTGTGTACATTTTAAATTATTTCC
30 AAAGATAGTGACAGGAGAGAACTGGAACAAATTTACCAACTTTGTGGACCTACA
AAGCCCTTACACTTTTAAAGGGTAAGACAAAGGCTTAAGTTTGAAAGGTAGAGAA
CTGTTTAGCATCTGAGAAGAAATACTTTATTAGGCCTGTAATTTTGGTTCTTGGCC
TTAAACACTTTTCTGGAACCTTTAAATATGCTGCATAGCACAATGGGAAAGCCTTA
GGTATTCACACATTTAAGGAACTCTAAACAAAATACTATTTTCTTTAGTTTCATAT
35 TAAAAATTAATACATTTTAAAAATTTAATGTCAAAGTCTGGTAACATTTGTTAGT
AGGATTTGAGTTATTATTTTGTAGACAGGATCTCAGGCTGGAGTGCAGTGGCAC
AATCACGGCTCACTGCAGCCTCTACCTCCCCAGGCTCAGGTGATCCTCCCACCTC
AGCCTCCCAAGTAGCTGGGACTATAGGCACACATCACCAAGCCCAGCCAAATTTT
GTTTTTTTTTTGTAGAGATGGGGTTTCATCACGTTGCCCAGGCTGATCTCGAACCT
40 CTGGGCTCAAGCAATTCACCTCGCCTCGGCCTCCCAAATGCTGGGATTACAGGCC
TGAGCCACTGCGCCCAGCCAGGATTTGAATTATTTTAACTCATCCATGGGCTGCC
CTAGAATGTCACAAATGAGGGTTGTTTAAATGCCTTTCTTATAGCTGCTACTGGAA
CACTATTATGACCTAATTTATGAGCCATCCTTACTCATCTACAAGTGCTGAAGCA
ATGTTACATACTTTTTTGCTAAACTCAGATTTTTTAGCCTAATTTCTTGTCTCCTA
45 TCCACCTGCATCCACACATGGCCTGCATGGGGCTGCCTTCCCTGCAGTGTTCTGC
AGCCATGCTTCAGGGTATAGCTGTTGGTGGACAGCCTCAGGTCTTGGGGGCACTA
TAGCCACTAAACGAGGTGTGAAAGGCTCAAGAGGATGACCAGCAATTAATTATC
CCCAGAAAGTGAAGGAAAAGAGACCTTTAGGGATGTTGCTGGTCAAGTCTTGAT
TTGACCGGAGTCAAATCAATCTTCAAGCAATCTTGAATCCTCAACTGCAGTAAG

CATTTCAAAATGCAAACAACTGCTTAACAACTGACAAGACACCAGCCCATATG
CTGCTCTTCCAACAGTGGGTTCTAGCTTTGAACAAAAGTGCTAAACATTTCTTG
AATATATTCTTCTCTTTTTGTCTCATCACTCAATACTGGTGCTCTTGTCACAGG
TAGAACAGCTTGTTTCTTTTCCATCTATTCAAGTGTGTTTCTAATTCTAAAATGCT
5 GATCTTCTCTGGAGTCTATGGTAGGCAATTATGGTCACTGGAATAGTTTGTCTTGT
TTTAAATATTATTGGTGCATGTACAACAGCATCCAACATATCTGTCTTGTTCTTA
GATATATAGCTCTGATTTTAGGCCTTTTGTGCATACCATTACAATATGGTGGGGT
AAGACATTCTACAGTAGCCTGTGCTGAAGTATCTCTTAAATAAACTTGCTTCTG
GTTAACTAAAAAAAAAAAAAAAAAAAAA

10 SEQ ID NO: 167

>gi|1518787|gb|U62801.1|HSU62801 Human protease M mRNA, complete cds

AGGCGGACAAAGCCCGATTGTTCTGGGCCCTTTCCCCATCGCGCCTGGGCCTGC
TCCCCAGCCCGGGGCGAGGGGCGGGGGCCAGTGTGGTGACACACGCTGTAGCTGT
15 CTCCCCGGCTGGCTGGCTCGCTCTCTCTGGGGACACAGAGGTCTGGCAGGCAGCA
CACAGAGGGACCTACGGGCAGCTGTTCTTCCCCCGACTCAAGAATCCCCGGAG
GCCCCGAGGCCTGCAGCAGGAGCGGCCATGAAGAAGCTGATGGTGGTGCTGAGT
CTGATTGCTGCAGCCTGGGCAGAGGAGCAGAATAAGTTGGTGCATGGCGGACCC
TGCGACAAGACATCTCACCCCTACCAAGCTGCCCTCTACACCTCGGGCCACTTGC
20 TCTGTGGTGGGGTCTTATCCATCCACTGTGGGTCTCACAGCTGCCCACTGCAA
AAAACCGAATCTTCAGGTCTTCTGGGGAAGCATAACCTTCGGCAAAGGGAGAG
TTCCCAGGAGCAGAGTTCTGTTGTCCGGGCTGTGATCCACCCTGACTATGATGCC
GCCAGCCATGACCAGGACATCATGCTGTTGCGCCTGGCACGCCAGCCAAACTCT
CTGAACTCATCCAGCCCCCTTCCCCTGGAGAGGGACTGCTCAGCCAACACCACCAG
25 CTGCCACATCCTGGGCTGGGGCAAGACAGCAGATGGTGATTTCCTGACACCATC
CAGTGTGCATACATCCACCTGGTGTCCCGTGAGGAGTGTGAGCATGCCTACCCTG
GCCAGATCACCCAGAACATGTTGTGTGCTGGGGATGAGAAGTACGGGAAGGATT
CCTGCCAGGGTGATTCTGGGGGTCCGCTGGTATGTGGAGACCACCTCCGAGGCCT
TGTGTCTATGGGGTAACATCCCCTGTGGATCAAAGGAGAAGCCAGGAGTCTACAC
30 CAACGCTGCAGATACACGAACTGGATCCAAAAAACCATTACAGGCCAAGTGACC
CTGACATGTGACATCTACCTCCCGACCTACCACCCCACTGGCTGGTTCCAGAACG
TCTCTCACCTAGACCTTGCCCTCCCTCCTCTCCTGCCAGCTCTGACCCTGATGCT
TAATAAACGCAGCGACGTGAGGGTCTGATTCTCCCTGGTTTTACCCAGCTCCA
TCCTTGATCACTGGGGAGGACGTGATGAGTGAGGACTTGGGTCTCTCGGTCTTAC
35 CCCCACCACTAAGAGAATACAGGAAAATCCCTTCTAGGCATCTCCTCTCCCCAAC
CCTTCCACACGTTTGATTTCTTCTGTCAGAGGCCAGCCACGTGTCTGGAATCCC
AGCTCCGCTGCTTACTGTGCGGTGTCCCTTGGGATGTACCTTTCTTCACTGCAGAT
TTCTCACCTGTAAGATGAAGATAAGGATGATACAGTCTCCATCAGGCAGTGGCTG
TTGGAAAGATTTAAGATTTACACCTATGACATACATGGGATAGCACCTGGGCCG
40 CCATGCACTCAATAAAGAATGTATTTT

SEQ ID NO: 168

>gi|2570124|dbj|AB000712.1|AB000712 Homo sapiens hCPE-R mRNA for CPE-receptor,
complete cds

45 GAAGGAACTGGTTCTGCTCACACTTGCTGGCTTGCGCATCAGGACTGGCTTTATC
TCCTGACTCACGGTGCAAAGGTGCACTCTGCGAACGTTAAGTCCGTCGCCAGCGC
TTGGAATCCTACGGCCCCCACAGCCGGATCCCCTCAGCCTTCCAGGTCCTCAACT
CCCGTGGACGCTGAACAATGGCCTCCATGGGGCTACAGGTAATGGGCATCGCGC
TGGCCGTCCTGGGCTGGCTGGCCGTCATGCTGTGCTGCGCGCTGCCCATGTGGCG

CGTGACGGCCTTCATCGGCAGCAACATTGTCACCTCGCAGACCATCTGGGAGGGC
CTATGGATGAACTGCGTGGTGCAGAGCACCGGCCAGATGCAGTGCAAGGTGTAC
GACTCGCTGCTGGCACTGCCGCAGGACCTGCAGGCGGCCCGCGCCCTCGTCATCA
TCAGCATCATCGTGGCTGCTCTGGGCGTGCTGCTGTCCGTGGTGGGGGGCAAGTG
5 TACCAACTGCCTGGAGGATGAAAGCGCCAAGGCCAAGACCATGATCGTGGCGGG
CGTGGTGTTCCTGTTGGCCGGCCTTATGGTGATAGTGCCGGTGTCTGGACGGCC
CACAACATCATCCAAGACTTCTACAATCCGCTGGTGGCCTCCGGGCAGAAAGCGG
GAGATGGGTGCCTCGCTCTACGTCGGCTGGGCGCCTCCGGCCTGCTGCTCCTTG
GCGGGGGGCTGCTTTGCTGCAACTGTCCACCCCGCACAGACAAGCCTTACTCCGC
10 CAAGTATTCTGCTGCCCCGCTCTGCTGCTGCCAGCAACTACGTGTAAGGTGCCACG
GCTCCACTCTGTTCTCTCTGCTTTGTTCTTCCCTGGACTGAGCTCAGCGCAGGCT
GTGACCCAGGAGGGCCCTGCCACGGGCCACTGGCTGCTGGGGACTGGGGACTG
GGCAGAGACTGAGCCAGGCAGGAAGGCAGCAGCCTTCAGCCTCTCTGGCCCACT
CGGACAAC TTCCCAAGGCCGCTCCTGCTAGCAAGAACAGAGTCCACCCTCCTCT
15 GGATATTGGGGAGGGACGGAAGTGACAGGGTGTGGTGGTGGAGTGGGGAGCTG
GCTTCTGCTGGCCAGGATAGCTTAACCCTGACTTTGGGATCTGCCTGCATCGGCG
TTGGCCACTGTCCCATTTACATTTTCCCACTCTGTCTGCCTGCATCTCCTCTGTT
CCGGGTAGGCCTTGATATCACCTCTGGGACTGTGCCTTGCTCACCGAAACCCGCG
CCCAGGAGTATGGCTGAGGCCTTGCCACCCACCTGCCTGGGAAGTGCAGAGTG
20 GATGGACGGGTTTAGAGGGGAGGGGCGAAGGTGCTGTAAACAGGTTTGGGCAGT
GGTGGGGGAGGGGGCCAGAGAGGGCGGCTCAGGTTGCCAGCTCTGTGGCCTCAG
GACTCTCTGCCTCACCCGCTTCAGCCAGGGCCCCTGGAGACTGATCCCCTCTGA
GTCCTCTGCCCTTCCAAGGACACTAATGAGCCTGGGAGGGTGGCAGGGAGGAG
GGGACAGCTTCACCCTTGGAAGTCCTGGGGTTTTTCTCTTCTTTGTGGTTT
25 CTGTTTTGTAAATTTAAGAAGAGCTATTCATCACTGTAATTATTATTATTTCTACA
ATAAATGGGACCTGTGCACAGG

SEQ ID NO: 169

>2027449H1

30 CTCTGCCACCTGGTCTGCCACAGATCCATGATGTGCAGTTCTCTGGAGCAGGCGC
TGGCTGTGCTGGTCACTACCTTCCACAAGTACTCCTGCCAAGAGGGCGACAAGTT
CAAGCTGAGTAAGGGGGAAATGAAGGAACTTCTGCACAAGGAGCTGCCCAGCTT
TGTGGGGGAGAAAGTGGATGAGGAGGGGTGAAGAAGCTGATGGGCAGCCTGGA
TGAGAACACGACAAGCAGGTGGACTTCCAGGAGTATGCTGTTTTCTGGGAAC
35 TCATCA

SEQ ID NO: 170

>gi|338633|gb|J05392.1|HUMSYN Human syndecan mRNA, complete cds

40 GGAGAGGTGCGGGCCGAATCCGAGCCGAGCGAGAGGAATCCGGCAGTAGAGAG
CGGACTCCAGCCGGCGGACCCTGCAGCCCTCGCCTGGGACAGCGGCGCGCTGGG
CAGGCGCCCAAGAGAGCATCGAGCAGCGGAACCCGCGAAGCCGGCCCCGAGCC
GCGACCCGCGCAGCCTGCCGCTCTCCCGCCGCGGTTCCGGGCAGCATGAGGCGC
GCGGCGCTCTGGCTCTGGCTGTGCGCGCTGGCGCTGAGCCTGCAGCTGGCCCTGC
CGCAAATTGTGGCTACTAATTTGCCCCCTGAAGATCAAGATGGCTCTGGGGATGA
45 CTCTGACAACTTCTCCGGCTCAGGTGCAGGTGCTTTGCAAGATATCACCTTGTC
CAGCAGACCCCTCCACTTGGAAGGACACGCAGCTCCTGACGGCTATTCCACAGT
CTCCAGAACCCACCGGCCTGGAGGCTACAGCTGCCTCCACCTCCACCCTGCCGGC
TGGAGAGGGGGCCCAAGGAGGGAGAGGCTGTAGTCCTGCCAGAAGTGGAGCCTG
GCCTCACCGCCCCGGGAGCAGGAGGCCACCCCCGACCCAGGGAGACCACACAGC

TCCCGACCACTCATCAGGCCTCAACGACCACAGCCACCACGGCCCCAGGAGCCCG
CCACCTCCCACCCCCACAGGGACATGCAGCCTGGCCACCATGAGACCTCAACCCC
TGCAGGACCCAGCCAAGCTGACCTTCACACTCCCCACACAGAGGATGGAGGTCC
TTCTGCCACCGAGAGGGCTGCTGAGGATGGAGCCTCCAGTCAGCTCCCAGCAGC
5 AGAGGGCTCTGGGGAGCAGGACTTCACCTTTGAAACCTCGGGGGAGAATACGGC
TGTAAGTGGCCGTGGAGCCTGACCGCCGGAACCAAGTCCCCAGTGGATCAGGGGGC
CACGGGGGCCTCACAGGGCCTCCTGGACAGGAAAGAGGTGCTGGGAGGGGTCAT
TGCCGGAGGCCTCGTGGGGCTCATCTTTGCTGTGTGCCTGGTGGGTTTCATGCTGT
ACCGCATGAAGAAGAAGGACGAAGGCAGCTACTCCTTGGAGGAGCCGAAACAA
10 GCCAACGGCGGGGGCCTACCAGAAGCCCACCAAACAGGAGGAATTCTATGCCTGA
CGCGGGAGCCATGCGCCCCCTCCGCCCTGCCACTACTAGGCCCCCACTTGCCCTC
TTCCTTGAAGAACTGCAGGCCCTGGCCTCCCCTGCCACCAGGCCACCTCCCCAGC
ATTCCAGCCCCTCTGGTCGCTCCTGCCCACGGAGTCGTGGGTGTGCTGGGAGCTC
CACTCTGCTTCTCTGACTTCTGCCTGGAGACTTAGGGCACCAGGGGTTTCTCGCAT
15 AGGACCTTTCCACCACAGCCAGCACCTGGCATCGCACCATTCTGACTCGGTTTCT
CCAAACTGAAGCAGCCTCTCCCCAGGTCCAGCTCTGGAGGGGAGGGGGATCCGA
CTGCTTTTGACCTAAATGGCCTCATGTGGCTGGAAGATCTGCGGGTGGGGCTTGG
GGCTCACACACCTGTAGCACTTACTGGTAGGACCAAGCATCTTGGGGGGGTGGC
CGCTGAGTGGCAGGGACAGGAGTCACTTTGTTTCGTGGGGAGGTCTAATCTAGAT
20 ATCGACTTGTTTTTGACATGTTTCCTCTAGTTCTTTGTTTCATAGCCCAGTAGACC
TTGTTACTTCTGAGGTAAAGTTAAAGTAAGTTGATTCCGTATCCCCCATCTTGCTTC
CCTAATCTATGGTCGGGAGACAGCATCAGGGTTAAGAAGACTTTTTTTTTTTTTTT
TTAAACTAGGAGAACCAAATCTGGAAGCCAAAATGTAGGCTTAGTTTGTGTGTTG
TCTCTTGAGTTTGTGCTCATGTGTGCAACAGGGTATGGACTATCTGTCTGGTGGC
25 CCCGTTTCTGGTGGTCTGTTGGCAGGCTGGCCAGTCCAGGCTGCCGTGGGGCCGC
CGCCTCTTTCAAGCAGTCGTGCCTGTGTCCATGCGCTCAGGGCCATGCTGAGGCC
TGGGCCGCTGCCACGTTGGAGAAGCCCGTGTGAGAAGTGAATGCTGGGACTCAG
CCTTCAGACAGAGAGGACTGTAGGGAGGGCGGCAGGGGCCTGGAGATCCTCCTG
CAGACCACNCCGTCCTGCCTGTGCGCCGTCTCCAGGGGCTGCTTCCTCCTGGAA
30 ATTGACGAGGGGTGTCTTGGGCAGAGCTGGCTCTGAGCGCCTCCATCCAAGGCC
AGGTTCTCCGTTAGCTCCTGTGGCCCCACCCTGGGCCCTGGGCTGGAATCAGGAA
TATTTTCCAAAGAGTGATAGTCTTTTGCTTTTGGCAAACTCTACTTAATCCAATG
GGTTTTTCCCTGTACAGTAGATTTTCCAAATGTAATAAACTTTAATATAAAGT

35 SEQ ID NO: 171

>gi|602452|gb|M25315.1|HUMCYTNEWA Homo sapiens (clone pAT 464) potential
lymphokine/cytokine mRNA, complete cds

GAATTCCCGGGCAGCAGACAGTGGTCAGTCCCTTTCTTGGCTCTGCTGACACTCGA
GCCACATTCCGTCACCTGCTCAGAATCATGCAGGTCTCCACTGCTGCCCTTGCT
40 GTCCTCCTCTGCACCATGGCTCTCTGCAACCAGTTCTCTGCATCACTTGCTGCTGA
CACGCCGACCGCCTGCTGCTTCAGCTACACCTCCCGGCAGATTCCACAGAATTTT
ATAGCTGACTACTTTGAGACGAGCAGCCAGTGCTCCAAGCCCGGTGTCATCTTCC
TAACCAAGCGAAGCCGGCAGGTCTGTGCTGACCCAGTGAGGAGTGGGTCCAGA
AATATGTCAGCGACCTGGAGCTGAGTGCCTGAGGGGTCCAGAAGCTTCGAGGCC
45 CAGCGACCTCGGTGGGCCAGTGGGGAGGAGCAGGAGCCTGAGCCTTGGAACA
TGCGTGTGACCTCCACAGCTACCTCTTCTATGGAAGTGGTTGTTGCCAAACAGCCA
CACTGTGGGACTCTTCTTAACTTAAATTTTAAATTTAATTTATACTATTTAGTTTTGT
AATTTATTTTCGATTTACAGTGTGTTTGTGATTGTTTGTCTGAGAGTTCCCCTG
TCCCCTCCCCCTTCCCTCACACCGCGTCTGGTGACAACCGAGTGGCTGTCATCAG

CCTGTGTAGGCAGTCATGGCACCAAAGCCACCAGACTGACAAATGTGTATCGGA
TGCTTTTGTTCAGGGCTGTGATCGGCCTGGGGAAATAATAAAGATGCTCTTTTAA
AAGGT

5 SEQ ID NO: 172

>gi|179039|gb|M30704.1|HUMARXC Human amphiregulin (AR) mRNA, complete cds,
clones lambda-AR1 and lambda-AR2

AGACGTTTCGCACACCTGGGTGCCAGCGCCCCAGAGGTCCCGGGACAGCCCGAGG
CGCCGCGCCCGCCGCCCCGAGCTCCCCAAGCCTTCGAGAGCGGCGCACACTCCC
10 GGCTCTCCACTCGCTCTTCCAACACCCGCTCGTTTTGCGGCAGCTCGTGTCCCAGA
GACCGAGTTGCCCCAGAGACCGAGACGCGCCGCTGCGAAGGACCAATGAGAGC
CCCGCTGCTACCGCCGGCGCCGGTGGTGTGCTGCTCGCTCTTGATACTCGGCTCAGGC
CATTATGCTGCTGGATTGGACCTCAATGACACCTACTCTGGGAAGCGTGAACCAT
TTTCTGGGGACCACAGTGCTGATGGATTGAGGTTACCTCAAGAAGTGAGATGTC
15 TTCAGGGAGTGAGATTTCCCTGTGAGTGAAATGCCTTCTAGTAGTAACCGTCC
TCGGGAGCCGACTATGACTACTCAGAAGAGTATGATAACGAACCACAAATACCT
GGCTATATTGTCGATGATTCAGTCAGAGTTGAACAGGTAGTTAAGCCCCCCCCAAA
ACAAGACGGAAAGTGAAAATACTTCAGATAAACCCAAAAGAAAGAAAAAGGGA
GGCAAAAATGGAAAAAATAGAAGAAACAGAAAGAAGAAAAATCCATGTAATGC
20 AGAATTTCAAATTTCTGCATTACCGGAGAATGCAAATATATAGAGCACCTGGA
AGCAGTAACATGCAAATGTCAGCAAGAATATTTCTGGTGAACGGTGTGGGGAAAA
GTCCATGAAAACCTCACAGCATGATTGACAGTAGTTTATCAAAAATTGCATTAGCA
GCCATAGCTGCCTTTATGTCTGCTGTGATCCTCACAGCTGTTGCTGTTATTACAGT
CCAGCTTAGAAGACAATAACGTCAGGAAATATGAAGGAGAAGCTGAGGAACGAA
25 AGAAACTTCGACAAGAGAATGGAAATGTACATGCTATAGCATAACTGAAGATAA
AATTACAGGATATCACATTGGAGTCACTGCCAAGTCATAGCCATAAATGATGAGT
CGGTCTCTTTCCAGTGGATCATAAGACAATGGACCCTTTTGTATGATGGTTTT
AACTTTCAATTGTCACTTTTTATGCTATTTCTGTATATAAAGGTGCACGAAGGTA
AAAAGTATTTTCAAGTTGTAAATAATTTATTTAATATTTAATGGAAGTGTATTT
30 ATTTTACAGCTCATTAACCTTTTTTAACC

SEQ ID NO: 173

>1227785H1

AAGATTTGCATTACCTGGCCCAAACCTTTTTGTCTCTTTGGGTGACCGGAAAA
35 CTCCACCTCAAGTTTTCTTTTGTGGGGCTGCCCCCAAGTGTCGTTTGTTTTACTG
TAGGGTCTCCCCGCCC GGCGCCCCCAGTGTCTTCTGAGGGCGGAAATGGCCAATT
CGGGCCTGCAGTTGCTGGGCTTCTCCATGGCCCTGCTGGGCTGGGTGGGTCTGGT
GGCCTGCACCGCCATCCCGNAGTGGCAGATGAGCTCCTATGCGGGTGACA

40 SEQ ID NO: 174

>4872203H1

CTGCTGGCTCACCTCCGAGCCACCTCTGCTGCGCACCGCACCTCGGACCTACAGC
CCAGGATACTTTGGGACTTGCCGGCGCTCAGAAACGCGCCCAGACGGCCCCCTCC
ACCTTTTGTITGCCTAGGGCGCCGAGAGCGCCCGGAGGGAACCGCCTGGCCTTCG
45 GGGACCACCAATTTTGTCTGGAACCACCTCCCGGCGTATCCTACTCCCTGTGCC
GCGAGCCATCGCTTCACTGGAGGG

SEQ ID NO: 175

>gi|1011705|gb|H58873.1|H58873 yr36a12.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:207358 3' similar to gb:K03195 GLUCOSE TRANSPORTER TYPE 1, ERYTHROCYTE/BRAIN (HUMAN);, mRNA sequence

5 ACTATAACTTAGTGTCTGTATTTAATATTGACAACCAAAAATATATATANTTTTNT
TGCATCTATACACAACAGGGCAGGAGTCTCCATGTNTTCTTGAGCAGTGAGTTTG
CAGGCTCCACAGGCCCTCTTCTCATGGTAATAGTGTGGCCCTAGTGCAAAGGAG
ACTAGAACCCGGCAGCCCAGACTGGCCCTTCCCCTCTCCTCCCTGCACTCCAGTG
CTTCCCAACTGGTCTCAGGTAAAGAAAGNTTANTTTGAGTGGTTGGGTAGGAAG
10 AGATGGGAAGGGGCAAATCCTAATGGGAGCCTGACCCCTAGAGTGGGGAGTTCC
AGGGCCAGCAGAACGGGTGGGCCATAGCCCTNCCTGGGGNTAGAAGCTTTGTAG
TTCATAGTTCGATTAGTNTGTCCNTAGGGCATNAGGTNCCAGCCCTACAGATTAG
CT

15 SEQ ID NO: 176

>1858095F6

CATCCATTCATCGATTCGCGCATTCTCCAGACCTTTACAGCCTGTGCTGGGTACTG
GAGACTCCCTGGGTGGGGGCCCTGAGGGCCCGTGCTTCTGCCCCACCCCTGCAA
CCTGACACGCTATGGGAAAGAGATCTCCATGGTCAGGATCCCCAACAGGGGCTC
20 AGCCCGGTACCTGGCGAGGAAGTACAACGCAACGAGACCTACATACGGGAGAA
CTTCCTGGTCTTAGATGTCTTCTTTGAGGCCCTGACCTCTGAAGCCATGGAGCAG
CGAGCAGCCTATGGCCTGTCAGCCCTGCTGGGAGACCTCGGGGGACAGATGGGC
CTGTTCAATTGGGGCCAGCATCCTCACGTTGCTGGAGATCCTCGACTACATCTATG
AGGTGTCCTGGGATCGACTGAAGCGGGTATGGAGGCGTCCCAAGACCCCCCTG
25 GGGACCTCCACTGGGGGCATCTCCA

SEQ ID NO: 177

>gi|2046919|gb|AA393950.1|AA393950 zt78a10.r1 Soares_testis_NHT Homo sapiens cDNA clone IMAGE:728442 5' similar to gb:L29007_cds1 AMILORIDE-SENSITIVE SODIUM CHANNEL ALPHA-SUBUNIT (HUMAN);, mRNA sequence

30 AGGAGAGCATGATCAAGGAGTGTGGCTGTCTACATCTTCTATCCGCGGCCCCAGA
ACGTGGAGTACTGTGACTACAGAAAGCACAGTTCCTGGGGGTACTGCTACTATA
AGCTCCAGGTTGACTTCTCCTCAGACCACCTGGGCTGTTTCACCAAGTGCCGGAA
GCCATGCAGCGTGACCAGCTACCAGCTCTCTGCTGGTTACTCACGATGGCCCTCG
35 GTGACATCCCAGGAATGGGTCTTCCAGATGCTATCGCGACAGAAACAATTACACC
GTCAACAACAAGAGAAATGGAGTGGCCAAAGTCAACATCTTCTTCAAGGAGCTG
AACTACAAAACCAATTCTGAGTCTCCCTCTGTACGATGGTCACCCTCCTGTCCA
ACCTGGGCAGCCAGTGGAGCCTGTGGTTTCGGCTCCTCGGTGTTGTCTGTGGTGGA
GATGGCTGAGCTCGTCTTTGACCTGCTGGTCATCATGTTCTCATGCTGCTCGAAG
40 TTCTNN

SEQ ID NO: 178

>gi|2184104|gb|AA459197.1|AA459197 zx88h05.r1 Soares ovary tumor NbHOT Homo sapiens cDNA clone IMAGE:810873 5', mRNA sequence

45 GTGCCAGCCCCCGACTGGCCTGGCCACACTGCTCTCCAGTAGCACAGATGTCTGC
TCCTCCTCTTGAACCTGGGTGGGAAACCCACCCAAAAGCCCCCTTTGTTACTTA
GGCAATTCCCCTTCCCTGACTCCCGAGGGGCTAGGGCTAGAGCAGACCCGGGTAA
GTAAAGGCAGACCCAGGGCTCCTCTAGCCTCATACCCGTGCCCTCACAGAGCCAT
GCCCCGTACCTCTGCCCTGTGTCTTTCATACCTCTACATGTCTGCTTGAGATATT

TCCTCAGCCTGAAAGTTTCCCCAACCATCTGCCAGAGAACTCCTATGCATCCCTT
AGAACCCTGCTCAGACACCATTACTTTTGTGAACGCTTCTGCCACATCTTGTCTTC
CCCAAATTGATCACT

5 SEQ ID NO: 179

>2701503T6

ACACTGAAGTCCACCCTGGGAGCTGGTAAAACAATTTTCAGTCTCAGACCCGTCTG
TTTTCCAGGGTCTCTCCGAGCCTGGGCTTCCTCAAGAGCGTGGCCCAAGGGCCCCA
CAGCCCAGATCCGGCAGCCCCACCACCTTCACTGAGGAGGCCCCGAAGCTCCGTT
10 CCGCTGCTCCTTAGAGACAGGGGAGGCAGATATGCACAAACGCGCCTCGGCCC
AGCTTGGGGCTGGCGGGGGAGGCTGTGTCTTCAAACCTTTGCCCCCAGTTGGGTC
AGTAGAACCACCAAGTGTCTCCCCTTCTACCTCCCAGCTCCACTTTGGAGGCTGA
GGAAGCGAGAGGTTTCTAGGCAGATTTGGAGCCCTGGAGATTGAGTTCACAGT
GTATGTTCTGGGGGCGCTGGTGCAGTCAGCGGTCCAGTCTCCAGCCTGCAGGCGT
15 GCACACTGGGGTGGACGATGGGTGGCCCCGAGTGTACACATTTGGGTGGGCCC
CGGCCCCCTATACCCCAGTGTTCTCTTTGATCCAGTCCCGAAACAGAAGGGAGCTT
GTGTACAC

SEQ ID NO: 180

20 >2798465H1

CAGATCTGGATGGAGTTGTGACCTTTGACTTGTTTAAGTGGTTGCAGCTGACCAT
GTTTGCATGAGGCAGGGACTCGGTCCCCCTTGCCGTGCTCCCCTCCCTCCTCGTCT
GCCAAGCCTCGCCTCCTACCACACCACACCAGGCCACCCCAGCTGCAAGTGCCTT
CCTTGGAGCAGAGAGGCAGCCTCGTCTCCTGTCCCCCTCTCCTCCCA

25

SEQ ID NO: 181

>gi|29370|emb|Y00106.1|HSBAR Human gene for beta-adrenergic receptor (beta-2 subtype)

GAATTCATGCCGCGTTTCTGTGTTGGACAGGGGTGACTTTGTGCCGGATGGCTTC
TGTGTGAGAGCGCGCGCGAGTGTGCATGTGCGGTGAGCTGGGAGGGTGTGTCTCA
30 GTGTCTATGGCTGTGGTTCGGTATAAGTCTAAGCATGTCTGCCAGGGTGTATTTG
TGCTGTATGTGCGTGCCTCGGTGGGCACTCTCGTTTCCTTCCGAATGTGGGGCA
GTGCCGGTGTGCTGCCCTCTGCCTTGAGACCTCAAGCCGCGCAGGCGCCCAGGGC
AGGCAGGTAGCGGCCACAGAAGAGCCAAAAGCTCCCGGGTTGGCTGGTAAGCAC
ACCACCTCCAGCTTTAGCCCTCTGTTGGGCGCCAGCCAGGGTAGCCGGGAAGCAGTGG
35 TGGCCCGCCCTCCAGGGAGCAGTTGGGCCCCGCCCCGGGCCAGCCTCAGGAGAAG
GAGGGCGAGGGGAGGGGAGGGAAAGGGGAGGAGTGCCTCGCCCCCTTCGCGGCT
GCCGGCGTGCCATTGGCCGAAAGTTCCTGTACGTACGGCGAGGGCAGTTCCCCT
AAAGTCCTGTGCACATAACGGGCAGAACGCACTGCGAAGCGGCTTCTTCAGAGC
ACGGGCTGGAAGTGGCAGGCACCGCGAGCCCCTAGCACCCGACAAGCTGAGTGT
40 GCAGGACGAGTCCCCACCACACCCACACCACAGCCGCTGAATGAGGCTTCCAGG
CGTCCGCTCGCGGGCCCGCAGAGCCCCGCCGTGGGTCCGCTGCTGAGGCGCCCCC
AGCCAGTGCCTTACCTGCCAGACTGCGCGCCATGGGGCAACCCGGGAACGGCA
GCGCCTTCTTGCTGGCACCCAATAGAAGCCATGCGCCGGACCACGACGTCACGC
AGCAAAGGGACGAGGTGTGGGTGGTGGGCATGGGCATCGTCATGTCTCTCATCG
45 TCCTGGCCATCGTGTTTGGCAATGTGCTGGTCATCACAGCCATTGCCAAGTTCGA
GCGTCTGCAGACGGTCACCAACTACTTCATCACTTCACTGGCCTGTGCTGATCTG
GTCATGGGCTGGCAGTGGTGCCCTTTGGGGCCGCCCATATTCTTATGAAAATGT
GGACTTTTGGCAACTTCTGGTGCGAGTTTTGGACTTCCATTGATGTGCTGTGCGTC
ACGGCCAGCATTGAGACCCTGTGCGTGATCGCAGTGGATCGCTACTTTGCCATTA

CTTCACCTTTCAAGTACCAGAGCCTGCTGACCAAGAATAAGGCCCGGGTGATCAT
TCTGATGGTGTGGATTGTGTCAGGCCTTACCTCCTTCTTGCCCATTCAGATGCACT
GGTACCGGGGCCACCCACCAGGAAGCCATCAACTGCTATGCCAATGAGACCTGCT
GTGACTTCTTCACGAACCAAGCCTATGCCATTGCCTCTTCCATCGTGTCTTCTAC
5 GTTCCCCTGGTGATCATGGTCTTCGTCTACTCCAGGGTCTTTCAGGAGGCCAAAA
GGCAGCTCCAGAAGATTGACAAATCTGAGGGCCGCTTCCATGTCCAGAACCTTA
GCCAGGTGGAGCAGGATGGGCGGACGGGGCATGGACTCCGCAGATCTTCCAAGT
TCTGCTTGAAGGAGCACAAAGCCCTCAAGACGTTAGGCATCATCATGGGCACTTT
CACCCCTCTGCTGGCTGCCCTTCTTCATCGTTAACATTGTGCATGTGATCCAGGATA
10 ACCTCATCCGTAAGGAAGTTTACATCCTCCTAAATTGGATAGGCTATGTCAATTC
TGGTTTCAATCCCCTTATCTACTGCCGGAGCCCAGATTTTCAGGATTGCCTTCCAGG
AGCTTCTGTGCCTGCGCAGGTCTTCTTTGAAGGCCTATGGGAATGGCTACTCCAG
CAACGGCAACACAGGGGAGCAGAGTGGATATCACGTGGAACAGGAGAAAGAAA
ATAAACTGCTGTGTGAAGACCTCCAGGCACGGAAGACTTTGTGGGCCATCAAG
15 GTACTGTGCCTAGCGATAACATTGATTACAAAGGGAGGAATTGTAGTACAAATG
ACTCACTGCTGTAAAGCAGTTTTTCTACTTTTAAAGACCCCCCCCCCAACAGAA
CACTAAACAGACTATTTAACTTGAGGGTAATAAACTTAGAATAAAAATTGTAAAAT
TGTATAGAGATATGCAGAAGGAAGGGCATCCTTCTGCCTTTTTTTATTTTTTTAAGC
TGTA AAAAGAGAGAAA ACTTATTTGAGTGATTATTTGTTATTTGTACAGTTCAGT
20 TCCTCTTTGCATGGAATTTGTAAGTTTATGTCTAAAGAGCTTTAGTCCTAGAGGAC
CTGAGTC

SEQ ID NO: 182

>gi|2110744|gb|AA429219.1|AA429219 zv78h08.r1 Soares_total_fetus_Nb2HF8_9w Homo
25 sapiens cDNA clone IMAGE:759807 5' similar to TR:G1136412 G1136412 KIAA0176
PROTEIN ;; mRNA sequence
GTGATCTGCATGTGGCAGGGCTGCGCAGTGGAGCGGCCAGTGGGCAGGATGACG
AGCCAGACCCCTCTGCCCCAGTCCCCCGGCCAGGCGGCCAACGATGTCTACTG
TTGTGGAGCTGAACGTCGGGGGTGAGTTCCACACCACCACCTGGGTACCCTGAG
30 GAAGTTTCCGGGCTCAAAGCTGGCAGAGATGTTCTCTAGCTTAGCCAAGGCCTCC
ACGGACGCGGAGGGGCCGCTTCTTCATCGACCGCCCCAGCACCTATTTACAGACCA
TCCTGGACTACCTGCGCACTGGGCAAGTGCCACACAGCACATCCCTGAAGTGTAC
CGTGAGGCTCAGTTCTACGAAATCAAGCCTTTGGTCAAGCTGCTGGAGGACATGC
CACAGATCTTTGGTGAGCAGGTGTCCTCGGAAGCAGT

35

SEQ ID NO: 183

>903559H1

CAACTTCACAGAAGCTCTCGCTGAGACAGCCTGTAGGCAGATGGGCTACAGCAG
CAAACCCACTTTCAGAGCTGTGGAGATTGGCCCAGACCAGGATCTGGATGTTGTT
40 GAAATCACAGAAAACAGCCAGGAGCTTCGCATGCGGAACTCAAGTGGGCCCTGT
CTCTCAGGCTCCCTGGTCTCCCTGCACTGTCTTGCTGTGGGAAGAGCCTGAAGA
CCCGGGGTGTGGTGGGTGGGGAGGAG

SEQ ID NO: 184

>gi|189952|gb|M86400.1|HUMPHPLA2 Human phospholipase A2 mRNA, complete cds
45 GCCCACTCCCACCGCCAGCTGGAACCCTGGGGACTACGACGTCCCTCAAACCTTG
CTTCTAGGAGATAAAAAGAACATCCAGTCATGGATAAAAATGAGCTGGTTCAGA
AGGCCAAACTGGCCGAGCAGGCTGAGCGATATGATGACATGGCAGCCTGCATGA
AGTCTGTA ACTGAGCAAGGAGCTGAATTATCCAATGAGGAGAGGAATCTTCTCTC

AGTTGCTTATAAAAAATGTTGTAGGAGCCCGTAGGTCATCTTGGAGGGTCGTCTCA
AGTATTGAACAAAAGACGGAAGGTGCTGAGAAAAAACAGCAGATGGCTCGAGA
ATACAGAGAGAAAATTGAGACGGAGCTAAGAGATATCTGCAATGATGTAAGTCTC
TCTTTTGGAAAAGTTCTTGATCCCCAATGCTTCACAAGCAGAGAGCAAAGTCTTC
5 TATTTGAAAATGAAAGGAGATTACTACCGTTACTTGGCTGAGGTTGCCGCTGGTG
ATGACAAGAAAGGGATTGTGATCAGTCACAACAAGCATAACCAAGAAGCTTTTG
AAATCAGCAAAAAGGAAATGCAACCAACACATCCTATCAGACTGGGTCTGGCCC
TTAACTTCTCTGTGTTCTATTATGAGATTCTGAACTCCCCAGAGAAAGCCTGCTCT
10 CTTGCAAAGACAGCTTTTGATGAAGCCATTGCTGAACTTGATACATTAAGTGAAG
AGTCATACAAAGACAGCACGCTAATAATGCAATTACTGAGAGACAACCTTGACAT
TGTGGACATCGGATACCCAAGGAGACGAAGCTGAAGCAGGAGAAGGAGGGGAA
AATTAACCGGCCTTCCAACCTTTTGTCTGCCTCATTCTAAAATTTACACAGTAGACC
ATTTGTCATCCATGCTGTCCACAAATAGTTTTTTGTGTTACGATTTATGACAGGTT
TATGTTACTTCTATTTGAATTTCTATATTTCCCATGTGGTTTTTATGTTTAATATTA
15 GGGGAGTAGAGCCAGTTAACATTTAGGGAGTTATCTGTTTTTCATCTTGAGGTGGC
CAATATGGGGATGTGGAATTTTTATACAAGTTATAAGTGTTTGGCATAGTACTTT
TGGTACATTGTGGCTTCAAAGGGGCCAGTGTAAGTCTTCCATGTCTAAGCAA
AGAAAAGTGCCTACATACTGGTTTGTCTGGCGGGGAATAAAAGGGATCATTGG
TTCCAGTCACAGGTGTAGTAATTGTGGGTACTTTAAGGTTTGGAGCACTTACAAG
20 GCTGTGGTAGAATCATACCCCATGGATACCACATATTAACCATGTATATCTGTG
GAATACTCAATGTGTACACCTTTGACTACAGCTGCAGAAGTGTTCCCTTTAGACAA
AGTTGTGACCCATTTTACTCTGGATAAGGGCAGAAACGGTTCACATTCCATTATT
TGTAAGTTACCTGCTGTTAGCTTTTATTATTTTGTCTACACTCATTATTTATTTGTAT
TTAAATGTTTTAGGCAACCTAAGAACAAATGTAAAAGTAAAGATGCAGGAAAAA
25 TGAATTGCTTGGTATTCTTACTTCATGTATATCAAGCACAGCAGTAAAACAAAA
ACCCATGTATTTAACTTTTTTTTAGGATTTTGTCTTTTGTGATTTTTTTTTTTTTT
TTGATACTTGCTTAACATGCATGTGCTGTAAAAATAGTTAACAGGGAAATAACTT
GAGATGATGGCTAGCTTTGTTAATGTCTTATGAAATTTTCATGAACAATCCAAG
CATAATTGTTAAGAACACGTGTATTAAATTCATGTAAGTGGAATAAAAGTTTAT
30 GAATGGACTTTTCACTACTTTCTCTACAGCTTTTCATGTAAATTAGTCTTGGTTC
TGAACTTCTCTAAAGGAAATTGTACATTCTTTGAAATTTATTCCTTATTCCCTCT
TGGCAGCTAATGGGCTCTTACCAAGTTTAAACACAAAATTTATCATAACAAAAAT
ACTACTAATATACTACTGTTTCCATGTCCCATGATCCCCTCTCTTCTCTCCACC
CTGAAAAAATGAGTTCTATTTTTCTGGGAGAGGGGGGATTGATTAGAAAA
35 AAATGTAGTGTGTTCCATTTAAAATTTTGGCATATGGCATTTTCTAACTTAGGAA
GCCACAATGTTCTTGGCCCATCATGACATTGGGTAGCATTAACTGTAAGTTTGT
GCTTCCAAATCACTTTTTTGGTTTTTAAGAATTTCTTGATACTCTTATAGCCTGCCTT
CAATTTTGATCCTTTATTCTTTCTATTTGTGAGGTGCACAAGATTACCTTCCTGTTT
TAGCCTTCTGTCTTGTACCAACCATTCTTACTTGGTGGCCATGTACTTGAAAAA
40 GGCCGCATGATCTTTCTGGCTCCACTCAGTGTCTAAGGCACCCTGCTTCCTTTGCT
TGCATCCACAGACTATTTCCCTCATCCTATTTACTGCAGCAAATCTCTCCTTAGT
TGATGAGACTGTGTTTATCTCCCTTTAAACCCCTACCTATCCTGAATGGTCTGTCA
TTGTCTGCCTTTAAATCCTTCCTCTTTCTCTCCTCTATTCTCTAAATAATGATG
GGGCTAAGTTATACCCAAAGCTCACTTTACAAAATATTTCTCAGTACTTTGCAG
45 AAAACACCAAACAAAAATGCCATTTTAAAAAAGGTGTATTTTTCTTTTAGAATG
TAAGCTCCTCAAGAGCAGGGACAATGTTTTCTGTATGTTCTATTGTGCCTAGTAC
ACTGTAAATGCTCAATAAATATTGATGATGGGAGGCAGTGAGTCTTGATGATAA
GGGTGAGAACTGAAATCCC

SEQ ID NO: 185

>2301338H1

GTGACCTTTGACTTGTTTAAAGTGGTTGCAGCTGACCATGTTTGCATGAGGCAGGG
ACTCGGTCCCCCTTGCCGTGCTCCCCTCCCTCCTCGTCTG

5

SEQ ID NO: 186

>gi|1209100|gb|U41163.1|HSU41163 Human creatine transporter (SLC6A10) gene, partial
cds

10 CATGCGTGACTGCCCCCACACTCACACAGCTCTCACTCCCCACATGCTCCATGCC
TCCTGTCCCCACTGAGGAGAGCTCCTAGAGGCTCGCCCGCTCCCCACTGACATGC
ATCCCTGCAGACAAACGAGGCGCCAGAGAGCTTCCCCACTGCACTTGCCAGGG
CTGCGGGGCCAGCCTTGCCCTAGCTTCTCTGGCGGGAGCTATGGCTCGGAGGA
GAATGGGGACTTCTGAACATACCTGCCCCGAAGGGGGACCGGAGGTGCTCGGAG
TGGGCTTGTGAGGGAGGTGGTGGCGCAGTCCCCGCTGAGCAGCCTGGCCCCCA
15 GATCGTGTACTTCACTGCTACATTCCTTACGTGGTCGTGGTCGTGCTTGTGC
TTGGAGTGCTGCTGCCTGGCGCCCTGGACAGCATATTTACTATCTCAAGCCTGA
CTGGTCAAAGCTGGGGTCCCCTCAGGTGAGGTGGAGGTGGGGAGGCTGCAGCAG
GGTGTGTGGGGGAGCCCTGCAGGCCCTCATGCCTGCACTCTCCAGCCCTTTCT
CTGTAGGTATGGATAGATGTGGGGACCCAGATTTTCTTTTCTTATGCCATTGGCCT
20 GGGGGCCCTCACAGCCCTGGGCAGCTACAACCGCTTCAACAACAAGTCTACAA
GTAAGCACTGCTGCCCTGCCACCCGTGCCCTGTCCCGCCCTGCCCTGCCCAGCAG
CCTAACCCATCCACTCTGGCCCCCTCACCCCTCCAGGACGCCATCATCCTGGCTG
TCATCAACAGTGGGACCAGCTTCTTTGCTGGCTTCGTGGTCTTCTCCATCCTGGGC
TTCATGGCTGCAGAGCAGGGCATGCACATCTCCAAGGTGGCAGAGTCAGGTAGG
25 GCCCTACCCCCAGCCCCGCTCCAGAGCAGCAACTGCCACCCAGATGCATGATGT
ACAAGAACACGCAATAGAAATGCTGAAAAGTGATGAGGATTCAAACAGAAGTTC
TCAGATTGTGGGCCTGTGGGGGAGGTCTCTGGGATTTTCAATGTTGACAGAGAC
AGGACCTCCCAGCCCCTGCTGCATGACCCAGGGTTGACAGCACCTCAGAGGCAG
GCGTGGGCATGGGCGTGAGTGTTGCAGGCAGGGCTCAGGGTGCGCGCAGGGCAC
30 GACATCGGCTGCAAGGTCTAGAGCCTGCACCTTCCACAGGGCCGGGCCTGGCC
TTCATCGCCTACCCACAGGCTGTCACACTGATGCCAGTGGCCCCACTCTGGGCTG
CCCTGTTCTTCTTCATGCTGTTGCTGCTTGGTCTCGACAACCAGTTTGCATGGGCT
CTGGGACAGGGAGCCAGGAGAGGGGCGGAGTGAGGGCTGCGGGCAAGGAAAGG
GGTGGAGGCTGCTGCGGGGCTCGGCCTGAGCTAGCCTGGCCACAGTTTGTAGGT
35 GTGGAGGGCTTCATCACCGGCCTCCTCAACCTCCTCCCGGCCTCCTACTACTTCTG
TTTCCAAAGGGAGATCTCTGTGGCCCTCTGTTGTGCCCTCCGCTTTGTCAATTGATC
TCTCCATGGTGACTGATGTGAGTGGGGTGGGGGGTCTGCCTGTGACCTCTGGTGG
CCGTCTGCCATCCTCCCTGACTGGGCTCTGTCCCCCAGGGTGGGATGTATGTCTTC
CAGCTGTTTGACTACTACTCGGCCAGCGGCACCACCCTGCTCTGGCAGGCCTTTT
40 GGGAGTGCGTGGTGGTGGTCTGGGTGTATGGTAGGTCATGGCTGAGGGCTGGGC
TGGGGCATGGTGACGGGAAGGCAGGTCTCCAGCTTGGCCCTCCCGCCTCGCCTT
GCCACAGGAGCTGACCGCTTACGGACGACATTGCCTGTATGATCGGGTACCGA
CCTTGCCCCCTGGATGAAATGGTGCTGGTCCTTCTTACCCCGCTGGTTTGCATGGT
AAGGGCTGGGGGAGGTGGGGCGGGGTGGGGGGGGCGGGGCGGGGTGGGGGGCC
45 CATTAAGGACGGGCATTCTGGTCTGTAGGGCATCTTCATCTTCAACGTTGTGTAC
TACAAGCCGCTGGTCTACAACAACACCTACGTGTACCCGTGGTGGGGTGAGGCC
ATGGGCTGGGCCTTCGTGCTGTCTCCATGCTGTGCATGCCACTGCACCTCCTGG
GCTGCCTCCTCAGGGCCAAGGGCACCATGGCTGAGGTAAGGCTCCCTCCCGGCCT
GCCCTCCCCTCCCCTGCTATGAACATTCAACCCAGCCTGCTTCTAGCCAAGGAG

TGGCCCTGACTAGGGTGGCAGGCAGCAGGAGCTGGAGAGAGAGGCAGAGGAAG
TCACCGTGGGGATGAGCAGGTGACTCTGGGGGCTTCAACATGTCCTCTCCTGCAG
TGCTGGAAGCACCTGACCCAGCCCATCTGGGGCCTCCACCACTTGGAGTACCGAG
CTCAGGATGCAGATGTCAGGGGCTGACCACCCTGACCCCACTGTCCGAGAGCA
5 GCAAGGTCGTCGTGGTGGAGAGTGTTCATGGGACAGCTCAGCTCACATCACCAGC
TCACCTCTGGTAGCCATAGCAGCCCCTGCTTCATCCCCACCCACCCCTCCAGGG
GGCCTGCCTTTCCCTGACACTTTTGGGGTCTGCCTGGGAGAGGAGGGGAGAAAG
CACCATGAGTGCTCACTAAAACAACCTTTTCCATTTTAATAAAACGCCAAAAAT
ATCACAACCCACCAAAAATAGATGCCTCTCCCCCTCCAGTCCTAGCCCAGCTGGT
10 CCTAGGCCCCGCCTAGTGCCCCACCCCAACACAGTGCTGCACTCCTCCTGCCC
CTGCCACGCCCACCCCTGCCACCTCTCCAGGTTCTGCTCTGTAGCACACCCTTG
GGTGACCCCTCACCCAGAAAGCAGCAGTGGCAGCTTGGGAAATGTGAGGAAGGG
AAGGAGGGAGAGACGGGAGGGAGGAGAGAGAGGAGAAGGGAGGCAGGGGAGG
GGCAGCAGAACCAAGACAAATATTTAGCTGGGCTATACCCCTCTCCCCATCCCT
15 GTTATAGAAGCTTAGAGAGCCAGCCAGCAGTGGAACTTCTGGTTCCTGCGCCAA
TCACCACCAATATCAATTGTGTGAGCTTGGGTGCGAGTGACGCGTGCGTGAGCA
CGTAGAGTATATATAGATCTCTATCTCTTAGCAAAGGTGAATACCAGATGTAAAT
GGTGCCTCTGGGCAAAGGAGGCTTGTATTTTGCACATTTTATAACAACCTTGAGAG
AATGAGATTTCTGCTTGTATATTTCTAAAAAGAGGAAGGAGCCCCAAACCCATCC
20 TCTCCTTTACCACTCCCCATTTCTGTGAGCCCTACCTTACCCCTCTGCCCTAGC
CTAGGAGTGTGAATTTATAGATCTAACTTTAGAGGGCAAAACAAAAGCTTCGAG
CTGTTGATGTGCAGTCTGTTGTGTGGATGTGTGTGTGTGGTCCCCCAGACCCAGA
ATGGATTGAAAAGTGCATGGTGGGGCCTCGGGGCTGTCCCCACGCTGTCCCTTT
GCCACAGGTCTGTGGGGCAACAGGCTGCAATATTCCATCCTGGGTGTCTGGGCT
25 GCTAACCTGGCCTGCTCAGGCTTCCCACCCTGTGCCCTGGGCTGGGCACACCCCC
GGGAAGGGACCCCGGACACGGCTCCACATCCAGGCTCAAGGCGGATGCACTTC
CTGCACCTCCAGTCTTCTGTGTAGCGGCTTTAACCACGTATGTCTGTACGTCCA
GTCCCGAGACGGCTGAGTGACCCCAAGAAAGGCTTCCCTGACACCCGGACAGAG
GCTGGAGGGCTGGGGCTGGGTGAGGGTGGTGGGCTGCGGGGACATTCTACTGT
30 GCTA

SEQ ID NO: 187

>gi|681577|gb|T70429.1|T70429 yd13g08.r1 Soares fetal liver spleen 1NFLS Homo sapiens

cDNA clone IMAGE:67070 5', mRNA sequence

35 CCAAACCATGTCAGACATGATATGATCAGATTTGTGTTTTGAAAAATTAACACTG
CAATGTGGAGAATTGATTGGAGGGAATCAGAAGAGTCCAGTAAGTAGGAAAAA
GTAATAACTTACACTAGGGTGGTAGCAGTAAGAATGGAAAGAAGTAGATGCATT
TGAATGATACTCAAAAGGTGAAAATAACTGTTCTTAGTGATGAGATAGATGTAG
GGATAAGCTGAAGCACTTAATGTAAAGGGACGGATGGTGTGTTCTTTCATTAAGA
40 TAGGGAAGAGTAGGAGATTAGATTTCCAGAGGGAAGATCATGAGGTTGNATTTA
AGGACGTCTTTGAGTTTTAAATGCCTCTGCCCTTCTTAAGTGGGAGATGTCCAAG
TTAAGNCATTTGGGAT

SEQ ID NO: 188

45 >gi|1177439|emb|Z67743.1|HSCLC7MR H.sapiens mRNA for CLC-7 chloride channel
protein

GACGAGGAGGCGGCGCCGCTGCTGCGGAGGACGGCGCGGCCCGGCGGGGGGAC
GCCGCTGCTGAACGGGGCTGGGCCCCGGGCTGCGCGCCAGTCACCACGTTCTGC
GCTTTTCCGAGTCGGACATATGAGCAGCGTGGAGCTGGATGATGAACTTTTGAC

CCGGATATGGACCCTCCACATCCCTTCCCCAAGGAGATCCCACACAACGAGAAG
CTCCTGTCCCTCAAGTATGAGAGCTTGGACTATGACAACAGTGAGAACCAGCTGT
TCCTGGAGGAGGAGCGGCGGATCAATCACACGGCCTTCCGGACGGTGGAGATCA
AGCGCTGGGTTCATCTGCGCCCTCATTGGGATCCTCACGGGCCTCGTGGCCTGCTT
5 CATTGACATCGTGGTGGAAAACCTGGCTGGCCTCAAGTACAGGGTCATCAAGGG
CAATATCGACAAGTTCACAGAGAAGGGCGGACTGTCCTTCTCCCTGTTGCTGTGG
GCCACGCTGAACGCCGCCCTTCGTGCTCGTGGGCTCTGTGATTGTGGCTTTCATAG
AGCCGGTGGCTGCTGGCAGCGGAATCCCCCAGATCAAGTGCTTCTCAACGGGG
TGAAGATCCCCCACGTGGTGGCGCTCAAGACGTTGGTGATCAAAGTGTCGGGTGT
10 GATCCTGTCCGTGGTCGGGGGCTGGCCGTGGGAAAGGAAGGGCCGATGATCCA
CTCAGGTTCAAGTATTGCCGCCGGGATCTCTCAGGGAAGGTCAAGCTCACTGAAA
CGAGATTTCAAGATCTTCGAGTACCTCCGCAGAGACACAGAGAAGCGGGACTTC
GTCTCCGCAGGGGCTGCGGCCGGAGTGTACGCGCGCTTGGAGCCCCCGTGGGT
GGGGTCTGTTTCAAGCTTGGAGGAGGGTGCGTCTTCTGGAACCAAGTTCCTGACCT
15 GGAGGATCTTCTTTGCTTCCATGATCTCCACGTTTACCCTGAATTTTGTCTGAGC
ATTTACCACGGGAACATGTGGGACCTGTCCAGCCCAGGCCTCATCAACTTCGGAA
GGTTTGACTCGGAGAAAATGGCCTACACGATCCACGAGATCCCGGTCTTCATCGC
CATGGGCGTGGTGGGCGGTGTGCTTGGAGCAGTGTTCAATGCCTTGAACACTGG
CTGACCATGTTTTGAATCAGGTACATCCACCGGCCCTGCCTGCAGGTGATTGAGG
20 CCGTGCTGGTGGCCGCCGTACGGCCACAGTTGCCTTCGTGCTGATCTACTCGTC
GCGGGATTGCCAGCCCCTGCAGGGGGGCTCCATGTCCTACCCGCTGCAGCTCTTT
TGTGCAGATGGCGAGTACAACCTCCATGGCTGCGGCCCTTCTTCAACACCCCGGAGA
AGAGCGTGGTGAGCCTCTTCCACGACCCGCCAGGCTCCTACAACCCCTGACCCT
CGGCCTGTTACGCTGGTCTACTTCTTCTTGGCCTGCTGGACCTACGGGCTCACG
25 GTGTCTGCCGGGGTCTTCATCCCGTCCCTGCTCATCGGGGCTGCCTGGGGCCGGC
TCTTTGGGATCTCCCTGTCTACCTCACGGGGGCGGCGATCTGGGCGGACCCCGG
CAAATACGCCCTGATGGGAGCTGCTGCCAGCTGGGCGGGATTGTGCGGATGAC
ACTGAGCCTGACCGTCATCATGATGGAGGCCACCAGCAACGTGACCTACGGCTTC
CCCATCATGCTGGTGCTCATGACCGCCAAGATCGTGGGCGACGTCTTCATTGAGG
30 GCCTGTACGACATGCACATTCAGCTGCAGAGTGTGCCCTTCTTGCAGTGGGAGGC
CCCGGTACCTCACACTCACTCACTGCCAGGGAGGTGATGAGCACACCAAGTGAC
CTGCCTGAGGCGGCGTGAGAAGGTGCGGCGTCATTGTGGACGTGCTGAGCGACAC
GGCGTCCAATCACAACGGCTTCCCCGTGGTGGAGCATGCCGATGACACCCAGCCT
GCCCGGCTCCAGGGCCTGATCCTGCGCTCCAGCTCATCGTTCTCTCTAAAGGACA
35 AGGTGTTTGTGGAGCGGTCCAACCTGGGCCTGGTACAGCGGCGCCTGAGGCTGA
AGGACTTCCGAGACGCCTACCCGCGCTTCCCACCCATCCAGTCCATCCACGTGTC
CCAGGACGAGCGGGAGTGACCATGGACCTCTCCGAGTTCATGAACCCCTCCCC
TACACGGTGCCCCAGGAGGCGTCGCTCCACGGGTGTTCAAGCTGTTCCGGGCCC
TGGGCCTGCGGCACCTGGTGGTGGTGGACAACCGCAATCAGGTGTGCGGGTGGT
40 GACCAGGAAGGACCTCGCCAGGTACCGCCTGGGAAAGAGAGGCTTGGAGGAGCT
CTCGCTGGCCCAGACGTGAGGCCAGCCCTGCCATAATGGG

SEQ ID NO: 189

>gi|190135|gb|M33882.1|HUMPMX1A Human p78 protein mRNA, complete cds

45 AGAGCGGAGGCCGCACTCCAGCACTGCGCAGGGACCGCCTTGGACCGCAGTTGC
CGGCCAGGAATCCCAGTGTACGGTGGACACGCCTCCCTCGCGCCCTTGCCGCCC
ACCTGCTCACCCAGCTCAGGGGCTTTGGAATTCTGTGGCCACACTGCGAGGAGAT
CGGTTCTGGGTGCGAGGCTACAGGAAGACTCCCACTCCCTGAAATCTGGAGTGA
AGAACGCCGCCATCCAGCCACCATCCAAGGAGGTGCAGGAGAACAGCTCTGTG

ATACCATTAACTTGTTGACATTACTTTTATTTGAAGGAACGTATATTAGAGCTTA
CTTTGCAAAGAAGGAAGATGGTTGTTTCCGAAGTGGACATCGCAAAAGCTGATC
CAGCTGCTGCATCCCACCCTCTATTACTGAATGGAGATGCTACTGTGGCCCAGAA
AAATCCAGGCTCGGTGGCTGAGAACAACCTGTGCAGCCAGTATGAGGAGAAGGT
5 GCGCCCCCTGCATCGACCTCATTGACTCCCTGCGGGCTCTAGGTGTGGAGCAGGAC
CTGGCCCCCTGCCAGCCATCGCCGTCATCGGGGACCAGAGCTCGGGCAAGAGCTCC
GTGTTGGAGGCACTGTCAGGAGTTGCCCTTCCCAGAGGCAGCGGGATCGTGACC
AGATGCCCCGCTGGTGCTGAAACTGAAGAACTTGTGAACGAAGATAAGTGGAGA
GGCAAGGTCAGTTACCAGGACTACGAGATTGAGATTTCCGATGCTTCAGAGGTA
10 GAAAAGGAAATTAATAAAGCCCAGAATGCCATCGCCGGGGAAGGAATGGGAAT
CAGTCATGAGCTAATCACCTGGAGATCAGCTCCCGAGATGTCCCGGATCTGACT
CTAATAGACCTTCCTGGCATAACCAGAGTGGCTGTGGGCAATCAGCCTGCTGACA
TTGGGTATAAGATCAAGACACTCATCAAGAAGTACATCCAGAGGCAGGAGACAA
TCAGCCTGGTGGTGGTCCCCAGTAATGTGGACATCGCCACCACAGAGGCTCTCAG
15 CATGGCCCAGGAGGTGGACCCCGAGGGAGACAGGACCATCGGAATCTTGACGAA
GCCTGATCTGGTGGACAAAGGAACTGAAGACAAGGTTGTGGACGTGGTGCGGAA
CCTCGTGTTCCACCTGAAGAAGGGTTACATGATTGTCAAGTGCCGGGGCCAGCAG
GAGATCCAGGACCAGCTGAGCCTGTCCGAAGCCCTGCAGAGAGAGAAGATCTTC
TTTGAGAACCACCCATATTTAGGGATCTGCTGGAGGAAGGAAAGGCCACGGTT
20 CCCTGCCTGGCAGAAAACTTACCAGCGAGCTCATCACACATATCTGTAAATCTC
TGCCCCTGTTAGAAAATCAAATCAAGGAGACTCACCAGAGAATAACAGAGGAGC
TACAAAAGTATGGTGTGACATAACCGGAAGACGAAAATGAAAAAATGTTCTTCC
TGATAGATAAAATTAATGCCTTTAATCAGGACATCACTGCTCTCATGCAAGGAGA
GGAAACTGTAGGGGAGGAAGACATTCGGCTGTTTACCAGACTCCGACACGAGTT
25 CCACAAATGGAGTACAATAATTGAAAACAATTTTCAAGAAGGCCATAAAATTTT
GAGTAGAAAAATCCAGAAATTTGAAAATCAGTATCGTGGTGAAGAGCTGCCAGG
CTTTGTGAATTACAGGACATTTGAGACAATCGTGAAACAGCAAATCAAGGCACT
GGAAGAGCCGGCTGTGGATATGCTACACACCGTGACGGATATGGTCCGGCTTGC
TTTCACAGATGTTTCGATAAAAAATTTTGAAGAGTTTTTTAACCTCCACAGAACC
30 GCCAAGTCCAAAATTGAAGACATTAGAGCAGAACAAGAGAGAGAAGGTGAGAA
GCTGATCCGCCTCCACTTCCAGATGGAACAGATTGTCTACTGCCAGGACCAGGTA
TACAGGGGTGCATTGCAGAAGGTCAGAGAGAAGGAGCTGGAAGAAGAAAAGAA
GAAGAAATCCTGGGATTTTGGGGCTTTCCAGTCCAGCTCGGCAACAGACTCTTCC
ATGGAGGAGATCTTTCAGCACCTGATGGCCTATCACCAGGAGGCCAGCAAGCGC
35 ATCTCCAGCCACATCCCTTTGATCATCCAGTTCTTCATGCTCCAGACGTACGGCCA
GCAGCTTCAGAAGGCCATGCTGCAGCTCCTGCAGGACAAGGACACCTACAGCTG
GCTCCTGAAGGAGCGGAGCGACACCAGCGACAAGCGGAAGTTCCTGAAGGAGC
GGCTTGACGCTGACGCAGGCTCGGCGCCGGCTTGCCCAGTTCCCCGGTTAACC
ACACTCTGTCCAGCCCCGTAGACGTGCACGCACACTGTCTGCCCCCGTTCCCGGG
40 TAGCCACTGGACTGACGACTTGAGTGCTCAGTAGTCAGACTGGATAGTCCGTCTC
TGCTTATCCGTTAGCCGTGGTGATTTAGCAGGAAGCTGTGAGAGCAGTTTGGTTT
CTAGCATGAAGACAGAGCCCCACCCTCAGATGCACATGAGCTGGCGGGATTGAA
GGATGCTGTCTTCGTACTGGGAAAGGGATTTTCAGCCCTCAGAATCGCTCCACCT
TGCAGCTCTCCCTTCTCTGTATTCCTAGAACTGACACATGCTGAACATCACAG
45 CTTATTTCTCATTTTTATAATGTCCCTTCACAAACCCAGTGTTTTAGGAGCATGA
GTGCCGTGTGTGTGCGTCCTGCGGAGCCCTGTCTCCTCTCTCTGTAATAAACTCAT
TTCTAGCCCC

SEQ ID NO: 190

>gi|184570|gb|M13755.1|HUMIFN15K Human interferon-induced 17-kDa/15-kDa protein mRNA, complete cds

5 CGGCTGAGAGGCAGCGAACTCATCTTTGCCAGTACAGGAGCTTGTGCCGTGGCCC
ACAGCCCACAGCCCACAGCCATGGGCTGGGACCTGACGGTGAAGATGCTGGCGG
GCAACGAATTCCAGGTGTCCCTGAGCAGCTCCATGTCGGTGTGAGAGCTGAAGG
CGCAGATCACCCAGAAGATTGGCGTGCACGCCTTCCAGCAGCGTCTGGCTGTCCA
CCCGAGCGGTGTGGCGCTGCAGGACAGGGTCCCCCTTGCCAGCCAGGGCCTGGG
CCCTGGCAGCACGGTCCTGCTGGTGGTGGACAAATGCGACGAACCTCTGAGCAT
10 CCTGGTGAGGAATAACAAGGGCCGACGACACCTACGAGGTCCGGCTGACGCA
GACCGTGGCCACCTGAAGCAGCAAGTGAGCGGGCTGGAGGGTGTGCAGGACGA
CCTGTTCTGGCTGACCTTCGAGGGGAAGCCCCTGGAGGACCAGCTCCCGCTGGGG
GAGTACGGCCTCAAGCCCCTGAGCACCGTGTTTCATGAATCTGCGCCTGCGGGGA
GGCGGCACAGAGCCTGGCGGGCGGAGCTAAGGGCCTCCACCAGCATCCGAGCAG
15 GATCAAGGGCCGGAAATAAAGGCTGTTGTAAGAGAAT

SEQ ID NO: 191

>gi|183032|gb|M10901.1|HUMGCRA Human glucocorticoid receptor alpha mRNA, complete cds

20 TTTTGTAGAAAAAATAATATATTTCCCTCCTGCTCCTTCTGCGTTCACAAGCTAAG
TTGTTTATCTCGGCTGCGGCGGGAAGTGGGACGGTGGCGGGCGAGCGGCTCCTC
TGCCAGAGTTGATATTCAGTATGACTGACTCCAAAGAATCATTAAGTCTGGTAGAG
AAGAAAACCCAGCAGTGTGCTTGTCTCAGGAGAGGGGAGATGTGATGGACTTCT
ATAAAACCCCTAAGAGGAGGAGTACTGTGAAGGTTTCTGCGTCTTCACCTCACT
25 GGCTGTCGCTTCTCAATCAGACTCCAAGCAGCGAAGACTTTTGGTTGATTTTCCA
AAAGGCTCAGTAAGCAATGCGCAGCAGCCAGATCTGTCCAAAGCAGTTTCACTC
TCAATGGGACTGTATATGGGAGAGACAGAAACAAAAGTGATGGGAAATGACCTG
GGATTCCACAGCAGGGCCAAATCAGCCTTTCCTCGGGGGAAACAGACTTAAAG
CTTTTGAAGAAAGCATTGCAAACCTCAATAGGTGACACAGTGTTCAGAGAAC
30 CCAAAGAGTTTCAAGCATCCACTGCTGTGTCTGCTGCCCCACAGAGAAGGAGTTT
CAAAAACCTCACTCTGATGTATCTTCAGAACAGCAACATTTGAAGGGCCAGACTG
GCACCAACGGTGGCAATGTGAAATTGTATACCACAGACCAAAGCACCTTTGACA
TTTTGCAGGATTTGGAGTTTCTTCTGGGTCCCCAGGTAAAGAGACGAATGAGAG
TCCTTGGAGATCAGACCTGTTGATAGATGAAAGTCTTTTCTCTCTCTGGCG
35 GGAGAAGACGATTTCATTCCTTTTGAAGGAAACTCGAATGAGGACTGCAAGCCT
CTCATTTTACCGGACACTAAACCCAAAATTAAGGATAATGGAGATCTGGTTTTGT
CAAGCCCCAGTAATGTAACTGCCCCAAGTGAAAACAGAAAAAGAAGATTTC
TCGAACTCTGCACCCCTGGGGTAATTAAGCAAGAGAACTGGGCACAGTTTACT
GTCAGGCAAGCTTTCCTGGAGCAAATATAATTGGTAATAAAATGTCTGCCATTTT
40 TGTTTCATGGTGTGAGTACCTCTGGAGGACAGATGTACCACTATGACATGAATACA
GCATCCCTTTCTCAACAGCAGGATCAGAAGCCTATTTTTTAATGTCATTCCACCAA
TTCCCGTTGGTTCCGAAAATTGGAATAGGTGCCAAGGATCTGGAGATGACAACTT
GACTTCTCTGGGACTCTGAACTTCCCTGGTTCGAACAGTTTTTTCTAATGGCTATT
CAAGCCCCAGCATGAGACCAGATGTAAGCTCTCCTCCATCCAGCTCCTCAACAGC
45 AACAACAGGACCACCTCCCAAACCTCTGCCTGGTGTGCTCTGATGAAGCTTCAGGA
TGTCATTATGGAGTCTTAACCTTGTGGAAGCTGTAAAGTTTTCTTCAAAAGAGCAG
TGGAAGGACAGCACAAATTACCTATGTGCTGGAAGGAATGATTGCATCATCGATA
AAATTCGAAGAAAAAACTGCCAGCATGCCGCTATCGAAAATGTCTTCAGGCTG
GAATGAACCTGGAAGCTCGAAAAACAAAGAAAAAATAAAAGGAATTCAGCAG

GCCACTACAGGAGTCTCACAAAGAAACCTCTGAAAATCCTGGTAACAAAACAATA
GTTCTGCAACGTTACCACAACCTACCCCTACCCTGGTGTCACTGTTGGAGGTTA
TTGAACCTGAAGTGTTATATGCAGGATATGATAGCTCTGTTCCAGACTCAACTTG
GAGGATCATGACTACGCTCAACATGTTAGGAGGGCGGCAAGTGATTGCAGCAGT
5 GAAATGGGCAAAGGCAATACCAGGTTTCAGGAACTTACACCTGGATGACCAAAT
GACCCTACTGCAGTACTCCTGGATGTTTCTTATGGCATTGCTCTGGGGTGGAGA
TCATATAGACAATCAAGTGCAAACCTGCTGTGTTTTGCTCCTGATCTGATTATTAA
TGAGCAGAGAATGACTCTACCCTGCATGTACGACCAATGTAAACACATGCTGTAT
GTTTCCTCTGAGTTACACAGGCTTCAGGTATCTTATGAAGAGTATCTCTGTATGA
10 AAACCTTACTGCTTCTCTCTTCAGTTCCCTAAGGACGGTCTGAAGAGCCAAGAGCT
ATTTGATGAAATTAGAATGACCTACATCAAAGAGCTAGGAAAAGCCATTGTCAA
GAGGGAAGGAACTCCAGCCAGAACTGGCAGCGGTTTTATCAACTGACAAAACCT
CTTGGATTCTATGCATGAAGTGGTTGAAAATCTCCTTAACCTATTGCTTCCAAACAT
TTTTGGATAAGACCATGAGTATTGAATCCCCGAGATGTTAGCTGAAATCATCAC
15 CAATCAGATACCAAAATATTCAAATGGAAATATCAAAAAACTTCTGTTTCATCAA
AAGTGACTGCCTTAATAAGAATGGTTGCCTTAAAGAAAGTCGAATTAATAGCTTT
TATTGTATAAACTATCAGTTTGTCTGTAGAGGTTTTGTTGTTTTATTTTTTATTGT
TTTCATCTGTTGTTTTGTTTTAAATACGCACTACATGTGGTTTATAGAGGGCCAAG
ACTTGGCAACAGAAGCAGTTGAGTCGTCATCACTTTTCAGTGATGGGAGAGTAG
20 ATGGTGAAATTTATTAGTTAATATATCCAGAAATTAGAAACCTTAATATGTGGA
CGTAATCTCCACAGTCAAAGAAGGATGGCACCTAAACCACCAAGTGCCCAAAGTC
TGTGTGATGAACTTTCTCTTCATACTTTTTTTCACAGTTGGCTGGATGAAATTTTC
TAGACTTTCTGTTGGTGTATCCCCCCCCTGTATAGTTAGGATAGCATTTTTGATTT
ATGCATGGAAACCTGAAAAAAAGTTTACAAGTGTATATCAGAAAAGGGAAGTTG
25 TGCCTTTTATAGCTATTACTGTCTGGTTTTAAACAATTTCTTTTATATTTAGTGAAC
ACGCTTGCTCATTTTTTCTTACATAATTTTTTATTCAAGTTATTGTACAGCTGTTTA
AGATGGGCAGCTAGTTCTGAGCTTTCCCAAATAAACTCTAAACATTAATCAATCA
TCTGTGTGAAAATGGGTTGGTGTCTTAACCTGATGGCACTTAGCTATCAGAAGA
CCACAAAAATTGACTCAAATCTCCAGTATTCTTGTCAAAAAAAAAAAAAAAAAAAAA
30 GCTCATATTTTGTATATATCTGCTTCAGTGGAGAATTATATAGGTTGTGCAAATTA
ACAGTCCTAACTGGTATAGAGCACCTAGTCCAGTGACCTGCTGGGTAAACTGTGG
ATGATGGTTGCAAAAGACTAATTTAAAAAATAACTACCAAGAGGCCCTGTCTGT
ACCTAACGCCCTATTTTTGCAATGGCTATATGGCAAGAAAGCTGGTAAACTATTT
GTCTTTCAGGACCTTTTGAAGTAGTTTGTATAACTTCTTAAAGTTGTGATTCCAG
35 ATAACCAGCTGTAAACACAGCTGAGAGACTTTTAATCAGACAAAGTAATTCCTCTC
ACTAACTTTACCCAAAAACTAAATCTCTAATATGGCAAAAATGGCTAGACACCC
ATTTTCACATTCCCATCTGTCACCAATTGGTTAATCTTTCCTGATGGTACAGGAAA
GCTCAGCTACTGATTTTTGTGATTTAGAACTGTATGTCAGACATCCATGTTTGTA
AACTACACATCCCTAATGTGTGCCATAGAGTTTAACACAAGTCCTGTGAATTTCT
40 TCACTGTTGAAAATTATTTTAAACAAAAATAGAAGCTGTAGTAGCCCTTTCTGTGT
GCACCTTACCAACTTTCTGTAAACTCAAACTTAACATATTTACTAAGCCACAAG
AAATTTGATTTCTATTCAAGGTGGCCAAATTATTTGTGTAATAGAAAACCTGAAAA
TCTAATATTAATAAATATGGAACCTCTAATATATTTTTATATTTAGTTATAGTTTCA
GATATATATCATATTGGTATTCATAATCTGGGAAGGGAAGGGCTACTGCAGCTT
45 TACATGCAATTTATTAAATGATTGTAAAATAGCTTGTATAGTGTAATAAAGAA
TGATTTTTAGATGAGATTGTTTTATCATGACATGTTATATATTTTTTGTAGGGGTC
AAAGAAATGCTGATGGATAACCTATATGATTTATAGTTTGTACATGCATTCATAC
AGGCAGCGATGGTCTCAGAAACCAACAGTTTGCTCTAGGGGAAGAGGGGAGATG
GAGACTGGTCCTGTGTGCAGTGAAGGTTGCTGAGGCTCTGACCCAGTGAGATTAC

AGAGGAAGTTATCCTCTGCCTCCCATTTCTGACCACCCTTCTCATTCCAACAGTGA
GTCTGTCAGCGCAGGTTTAGTTTACTCAATCTCCCCTTGCACTAAAGTATGTAAA
GTATGTAAACAGGAGACAGGAAGGTGGTGCTTACATCCTTAAAGGCACCATCTA
ATAGCGGGTTACTTTACATACAGCCCTCCCCCAGCAGTTGAATGACAACAGAAG
5 CTTCAGAAAGTTTGGCAATAGTTTGCATAGAGGTACCAGCAATATGTAAATAGTGC
AGAATCTCATAGGTTGCCAATAATACACTAATTCCTTTCTATCCTACAACAAGAG
TTTATTTCCAAATAAAATGAGGACATGTTTTTGTTCCTTGAATGCTTTTTGAAT
GTTATTTGTTATTTTCAGTATTTTGGAGAAATTATTTAATAAAAAACAATCATTT
GCTTTTTG

10

SEQ ID NO: 192

>gi|340868|gb|M23317.1|HUMCD3E01 Human membrane protein (CD3-epsilon) gene,
exons 1 and 2

TGTTAATAAGAGGCTGCTCCCTGTGCTCCATGCCTGATCCACCACACAGAAAGCA
15 AATTTTCAGTGCATCTCCCTCTTCCTGTGAGAGCTTATAGAGGAAGGAAGACCCC
GCAATGTGGAGGCATATTGTATTACAATTACTTTTAATGGCAAAAAGTGCAGTTA
CTTGTCACCAACCTACTACATGGTCTGGACAGCTAAATGTCATGTATTTTCATGGC
CCCTCCAGGTATTGTCAGAGTCCCTCTTGTTCCTTCTAGGAAGGCTGTGGGAC
CCAGCTTTCTTCAACCAGTCCAGGTGGAGGCCTCTGCCTTGAACGTTTCCAAGTG
20 AGGTAAAACCCGCAGGCCAGAGGCCTCTCTACTTCCTGTGTGAGGTTCAGAAAC
CCTCCTCCCCCTCCCAGCCTCAGGTGCCTGCTTCAGAAAATGGTGAGTCTCTCTCTT
ATAAAGCCCTCCTTTTTCATCCTAGCATTGGGAGCAATGGCCCCAGGGTCCTTAT
CTCTAGCAGATGTTTTGAAAAAGTCATCTGTTTTGCTTTTTTCCAGAAGTAGTAA
GTCTGCTGGCCTCCGCCATCTTAGTAAAGTAACAGTCCCATGAAACAAAGATGCA
25 GTCGGGCACTCACTGGAGAGTTCTGGGCCTCTGCCTCTTATCAGGTGAGTAGGAT
GGA

SEQ ID NO: 193

>gi|307505|gb|L12350.1|HUMTHRSPO Human thrombospondin 2 (THBS2) mRNA,
complete cds

ACGGCATCCAGTACAGAGGGGCTGGACTTGGACCCCTGCAGCAGCCCTGCACAG
GAGAAGCGGCATATAAAGCCGCGCTGCCCCGGAGCCGCTCGGCCACGTCCACCG
GAGCATCCTGCACTGCAGGGCCGCTCTCTCGCTCCAGCAGAGCCTGCGCCTTTCT
GACTCGGICCGGAACACTGAAACCAGTCATCACTGCATCTTTTTGGCAAACCAGG
35 AGCTCAGCTGCAGGAGGCAGGATGGTCTGGAGGCTGGTCCTGCTGGCTCTGTGG
GTGTGGCCCAGCACGCAAGCTGGTCACCAGGACAAAGACACGACCTTCGACCTT
TTCAGTATCAGCAACATCAACCGCAAGACCATTGGCGCCAAGCAGTTCGCGGG
CCCGACCCCGGCGTGCCGGCTTACCGCTTCGTGCGCTTTGACTACATCCCACCGG
TGAACGCAGATGACCTCAGCAAGATCACCAAGATCATGCGGCAGAAGGAGGGCT
40 TCTTCCTCACGGCCCAGCTCAAGCAGGACGGCAAGTCCAGGGGCACGCTGTTGG
CTCTGGAGGGCCCCGGTCTCTCCAGAGGCAGTTCGAGATCGTCTCCAACGGCCC
CGCGGACACGCTGGATCTCACCTACTGGATTGACGGCACCCGGCATGTGGTCTCC
CTGGAGGACGTCGGCCTGGCTGACTCGCAGTGGAAGAACGTCACCGTGCAGGTG
GCTGGCGAGACCTACAGCTTGCACGTGGGCTGCGACCTCATAGGACCAGTTGCTC
45 TGGACGAGCCCTTCTACGAGCACCTGCAGGCGGAAAAGAGCCGGATGTACGTGG
CCAAAGGCTCTGCCAGAGAGAGTCACTTCAGGGGTTTGCTTCAGAACGTCCACCT
AGTGTTTGAAAAGTCTGTGGAAGATATTCTAAGCAAGAAGGGTTGCCAGCAAGG
CCAGGGAGCTGAGATCAACGCCATCAGTGAGAACACAGAGACGCTGCGCCTGGG
TCCGCATGTCACCACCGAGTACGTGGGCCCCAGCTCGGAGAGGAGGCCCGAGGT

GTGCGAACGCTCGTGCGAGGAGCTGGGAAACATGGTCCAGGAGCTCTCGGGGCT
CCACGTCCTCGTGAACCAGCTCAGCGAGAACCTCAAGAGAGTGTCGAATGATAA
CCAGTTTCTCTGGGAGCTCATTGGTGGCCCTCCTAAGACAAGGAACATGTCAGCT
TGCTGGCAGGATGGCCGGTTCTTTGCGGAAAATGAAACGTGGGTGGTGGACAGC
5 TGCACCACGTGTACCTGCAAGAAATTTAAAACCATTTGCCACCAAATCACCTGCC
CGCTGCAACCTGCGCCAGTCCATCCTTTGTGGAAGGCGAATGCTGCCCTTCCTG
CCTCCACTCGGTGGACGGTGAGGAGGGCTGGTCTCCGTGGGCAGAGTGGACCCA
GTGCTCCGTGACGTGTGGCTCTGGGACCCAGCAGAGAGGCCGGTCTGTGACGTC
ACCAGCAACACCTGCTTGGGGCCCTCGATCCAGACACGGGCTTGCAGTCTGAGC
10 AAGTGTGACACCCGCATCCGGCAGGACGGCGGCTGGAGCCACTGGTCACCTTGG
TCTTCATGCTCTGTGACCTGTGGAGTTGGCAATATCACACGCATCCGTCTCTGCA
ACTCCCCAGTGGCCCGAGATGGGGGGCAAGAATTGCAAAGGGAGTGGCCGGGAGA
CCAAAGCCTGCCAGGGCGCCCCATGCCCAATCGATGGCCGCTGGAGCCCCTGGT
CCCCGTGGTTCGGCCTGCACTGTACCTGTGCCGGTGGGATCCGGGAGCGCACCCG
15 GGTCTGCAACAGCCCTGAGCCTCAGTACGGAGGGAAGGCCTGCGTGGGGGATGT
GCAGGAGCGTCAGATGTGCAACAAGAGGAGCTGCCCCGTGGATGGCTGTTTATC
CAACCCCTGCTTCCCGGGAGCCCAGTGCAGCAGCTTCCCCGATGGGTCTGTGTC
TGCGGCTTCTGCCCTGTGGGCTTCTTGGGCAATGGCACCCACTGTGAGGACCTGG
ACGAGTGTGCCCTGGTCCCCGACATCTGCTTCTCCACCAGCAAGGTGCCTCGCTG
20 TGTCAACACTCAGCCTGGCTTCCACTGCCTGCCCTGCCCGCCCCGATACAGAGGG
AACCAGCCCCGTCGGGGTTCGGCCTGGAAGCAGCCAAGACGGAAAAGCAAGTGTGT
GAGCCCCGAAAACCCATGCAAGGACAAGACACAACTGCCACAAGCACGCGGA
GTGCATCTACCTGGGTCACTTCAGCGACCCCATGTACAAGTGCAGAGTGCAGACA
GGCTACGCGGGCGACGGGCTCATCTGCGGGGAGGACTCCGACCTGGACGGCTGG
25 CCAAACCTCAATCTGGTCTGCGCCACCAACGCCACCTACCACTGCATCAAGGATA
ACTGCCCCCATCTGCCAAATTCTGGGCAGGAAGACTTTGACAAGGACGGGATTG
GCGATGCCTGTGATGATGACGATGACAATGACGGTGTGACCGATGAGAAGGACA
ACTGCCAGCTCCTCTTCAATCCCCGCCAGGCTGACTATGACAAGGATGAGGTTGG
GGACCGCTGTGACAACCTGCCCTTACGTGCACAACCCTGCCAGATCGACACAGA
30 CAACAATGGAGAGGGTGACGCCTGCTCCGTGGACATTGATGGGGACGATGTCTT
CAATGAACGAGACAATTGTCCCTACGTCTACAACACTGACCAGAGGGACACGGA
TGGTGACGGTGTGGGGGATCACTGTGACAACCTGCCCCCTGGTGCACAACCCTGAC
CAGACCGACGTGGACAATGACCTTGTGGGGACCAGTGTGACAACAACGAGGAC
ATAGATGACGACGGCCACCAGAACAAACCAGGACAACCTGCCCTACATCTCCAAC
35 GCCAACCAGGCTGACCATGACAGAGACGGCCAGGGCGACGCCTGTGACCCTGAT
GATGACAACGATGGCGTCCCCGATGACAGGGACAACCTGCCGGCTTGTGTTCAAC
CCAGACCAGGAGGACTTGGACGGTGTGACGGGGTGTATTTGTAAAGATGAT
TTTGACAATGACAACATCCCAGATATTGATGATGTGTGTCCTGAAAACAATGCCA
TCAGTGAGACAGACTTCAGGAACCTCCAGATGGTCCCCCTGGATCCCAAAGGGA
40 CCACCCAAATTGATCCCAACTGGGTCAATTCGCCATCAAGGCAAGGAGCTGGTTCA
GACAGCCAACTCGGACCCCGGCATCGCTGTAGGTTTTGACGAGTTTGGGTCTGTG
GACTTCAGTGGCACATTCTACGTAAACACTGACCGGGACGACGACTATGCTGGCT
TCGTCTTTGGTTACCAGTCAAGCAGCCGCTTCTATGTGGTGTGTTGGAAGCAGGT
GACGCAGACCTACTGGGAGGACCAGCCACGCGGGCCTATGGCTACTCCGGCGT
45 GTCCCTCAAGGTGGTGAACCTCCACCACGGGGACGGGCGAGCACCTGAGGAACGC
GCTGTGGCACACGGGGAAACACGCCGGGGCAGGTGCGAACCTTATGGCACGACCC
CAGGAACATTGGCTGGAAGGACTACACGGCCTATAGGTGGCACCTGACTCACAG
GCCCAAGACCGGCTACATCAGAGTCTTAGTGCATGAAGGAAAACAGGTCATGGC
AGACTCAGGACCTATCTATGACCAAACCTACGCTGGCGGGCGGCTGGGTCTATTT

GTCTTCTCTCAAGAAATGGTCTATTTCTCAGACCTCAAGTACGAATGCAGAGATA
TTTAAACAAGATTTGCTGCATTTCCGGCAATGCCCTGTGCATGCCATGGTCCCTA
GACACCTCAGTTCATTGTGGTCCCTGCGGCTTCTCTCTCTAGCAGCACCTCCTGTC
CCTTGACCTTAACTCTGATGGTTCTTCACCTCCTGCCAGCAACCCCAAACCCAAG
5 TGCCTTCAGAGGATAAATATCAATGGAACCTCAGAGATGAACATCTAACCCACTA
GAGGAAACCAGTTTGGTGATATATGAGACTTTATGTGGAGTGAAAATTGGGCAT
GCCATTACATTGCTTTTTCTTGTTTGTAAAGAAATGACGTTTACATATAAAAT
GTAATTACTTATTGTATTTATGTGTATATGGAGTTGAAGGGAATACTGTGCATAA
GCCATTATGATAAATTAAGCATGAAAAATATTGCTGAACTACTTTTGGTGCTTAA
10 AGTTGTCACTATTCTTGAATTAGAGTTGCTCTACAATGACACACAAATCCCGCTA
AATAAATTATAACAAGGGTCAATTCAAATTTGAAGTAATGTTTTAGTAAGGAG
AGATTAGAAGACAACAGGCATAGCAAATGACATAAGCTACCGATTAATAATCG
GAACATGTAAACAGTTACAAAAATAAACGAACTCTCCTCTTGTCCTACAATGAA
AGCCCTCATGTGCAGTAGAGATGCAGTTTCATCAAAGAACAACATCCTTGCAA
15 ATGGGTGTGACGCGGTTCCAGATGTGGATTTGGCAAACCTCATTTAAGTAAAAG
GTTAGCAGAGCAAAGTGCGGTGCTTTAGCTGCTGCTTGTGCCGTTGTGGCGTCGG
GGAGGCTCCTGCCTGAGCTTCCTTCCCCAGCTTTGCTGCCTGAGAGGAACCAGAG
CAGACGCACAGGCCGGAAGAGCGCATCTAACGCGTATCTAGGCTTTGGTAAT
GCGGACAAGTTGCTTTTACCTGATTTGATGATACATTTTATTAAGGTTCCAGTTAT
20 AAATATTTTGTAAATATTTATTAAGTGACTATAGAATGCAACTCCATTACCAGTA
ACTTATTTTAAATATGCCTAGTAACACATATGTAGTATAATTTCTAGAAACAAAC
ATGTAATAAGTATATAATCCTGTGAAAATATGAGGCTTGATAATATTAGGTTGTC
ACGATGAAGCATGCTAGAAGCTGTAACAGAATACATAGAGAATAATGAGGAGTT
ATGATGGAACCTTAATATATAATGTTGCCAGCGATTTTAGTTCAATATTTGTTAC
25 TGTTATCTATCTGCTGTATATGGAATTCTTTAATTCAAACGCTGAAAACGAATCA
GCATTTAGTCTTGCCAGGCACACCCAATAATCAGTCATGTGTAATATGCACAAGT
TTGTTTTTGTGTTTTGTTTTTTTGTGTTGGTTGGTTTTTTGCTTTAAGTTGCATGATCT
TTCTGCAGGAAATAGTCACTCATCCCACTCCACATAAGGGGTTTAGTAAGAGAAG
TCTGTCTGTCTGATGATGGATAGGGGGCAAATCTTTTTCCCCTTTCTGTTAATAGT
30 CATCACATTTCTATGCCAAACAGGAACGATCCATAACTTTAGTCTTAATGTACAC
ATTGCATTTTGATAAAATTAATTTTGTGTTTCTTTGAGGTTGATCGTTGTGTTGT
TTTGCTGCACTTTTTACTTTTTTGCCTGTGGAGCTGTATTCCCGAGACAACGAAGC
GTTGGGATACTTCATTAAATGTAGCGACTGTCAACAGCGTGCAGGTTTTCTGTTT
CTGIGTTGTGGGGTCAACCGTACAATGGTGTGGGAATGACGATGATGTGAATATT
35 TAGAATGTACCATATTTTTTGTAAATTATTTATGTTTTTCTAAACAAATTTATCGT
ATAGGTTGATGAAACGTCATGTGTTTTGCCAAAGACTGTAAATATTTATTTATGT
GTTACATGGTCAAAATTTCAACACTGAAACCCTGCACTTAGCTAGAACCTCATT
TTTAAAGATTAAACAACAGGAAATAAATTGTAAAAAAGGTTTTCT

40 SEQ ID NO: 194

>2499967T6

AGAAAAGAGGGGAAGGTGGGGACCTAGTAACAATAACCATTTATTCCAAGGAGGC
CCTGGCCCTGAACCCGGGGTTCCACAGGAATCAGGGAGGCACCTGAGTCCCCC
AGGACCAGGGCATCCCAAGGCATCATGGCAGCNGCGTTGTTCAAAGGAAGTTT
45 CATTGAGCTTCATCTTGGGAGNGTGANGCGNGTCCCGANACCGCTGGACGCCC
ACGNNNCTGGNGTGGGTNGCCGTCGGANGTCTGGCCCCACTCCGCACCAGTTCCT
GGCAGCGTTCCACAAAGCTGCNCCCACCACGGCGCCGGGCCTCAGCCTGCGGGG
GGCTTGGGCTCCACGGTGGCCAGACAAGGAGGTGTTGCTGGAGGCTGAGTGGA
GGCTGGTGAGGGAGATGCGGGGTGANGGGCTGGGGAGACAGCNCCATGAGGGA

GCTGAAGGAGCNGGCGGGGGCAGCTCACAGTGTTCAGCTGTTCCATCAGCTCTT
GCTNCGTTANGCCACCTGCAAGGGGCTGGCCGAGGNCGTNCATGGNGGTGGT

SEQ ID NO: 195

5 >093603H1
TGGAAATAAAGCTTCCTNAATGTNGTATATGTNTTTAAAGTNCATCCGTGCATTT
TTTTTNAGCATCCAACCATTCCTCCCTTGTAAGTTCTCGCCCCCTCAAATNACCCCTC
TCCCGTAGCCACCCGACTAACATCTCANTNTCTGAAAATGCACAGAGATGCCTG
10 GCTACCTCGCCCTGCCTTCAGCCTCACGGGGCTCAGGTNCTTTTTTTNTTTGGTGC
CACCAGGNCGGAGCATGGAGGTCACAGTACCTGCCACC

SEQ ID NO: 196

>gi|30081|emb|X57527.1|HSCOL8A1 Human COL8A1 mRNA for alpha 1(VIII) collagen
15 ATGGCTGTGCTGCCTGGCCCTCTGCAGCTGCTGGGAGTGCTGCTTACCATTTCCCT
GAGTTCATCAGGCTCATTAGGCTGGTGCCTACTATGGGATCAAGCCGCTGCCA
CCTCAAATTCCTCCTCAGATGCCACCACAAATTCCACAATACCAGCCCCTGGGTC
AGCAAGTACCTCACATGCCCTTTGGCCAAAGATGGCCTCGCCATGGGCAAGGAGA
TGCCCCACTTGCAATATGGCAAAGAGTATCCACACCTACCCCAATATATGAAGGA
AATTCAACCGGCGCCAAGAATGGGCAAGGAAGCCGTTCCCAAGAAAGGCAAAG
20 AAATACCATTAGCCAGTTTACGAGGGGAACAAGGTCCCCGTGGAGAGCCTGGCC
CAAGAGGACCACCTGGGCCCCCTGGTTTACCAGGTCATGGGATACCTGGAATTA
AAGGAAAACCAGGGCCACAGGGATATCCAGGAGTTGGAAAGCCAGGTATGCCTG
GAATGCCAGGGAAGCCAGGAGCCATGGGCATGCCTGGGGCAAAAGGAGAAATT
GGACAGAAAGGGGAAATTGGGCCTATGGGGATCCCAGGACCACAAGGACCTCCA
25 GGGCCTCATGGACTTCCTGGCATTGGGAAGCCAGGTGGGGCCAGGGTTACCAGGG
CAACCAGGACCAAAGGGTGATCGAGGACCCAAAGGACTACCAGGACCTCAAGG
CCTTCGGGGTCCTAAAGGAGACAAGGGCTTCGGGATGCCAGGTGCGCCAGGTGT
AAAGGGGCCTCCAGGGATGCACGGCCTCCCCGGCCCTGTTGGACTGCCAGGAGT
GGGCAAACCAGGAGTGACAGGCTTCCCTGGGCCCCAGGGCCCCCTGGGAAAGCC
30 AGGGGCTCCAGGAGAACCCGGTCGACAAGGCCCTATTGGGGTACCGGGGGTTCA
AGGACCTCCTGGGATACCCGGAATTGGAAAGCCAGGCCAGGATGGGATCCCAGG
CCAGCCAGGATTTCCAGGTGGCAAAGGGGAGCAAGGACTGCCAGGGCTACCAGG
GCCCCCAGGCCTTCCAGGGATTGGGAAACCAGGCTTCCCAGGACCCAAAGGTGA
CCGGGGCATGGGAGGTGTTCTTGGGGCTCTTGACCAAGAGGGGAGAAAGGACC
35 AATAGGTTCCCCAGGAATAGGGGGTTCTCCAGGAGAGCCAGGCCTGCCTGGAAT
CCCAGGTCCTATGGGCCCCCTCAGGTGCTATTGGTTTTCTGGACCCAAAGGAGAA
GGTGGGATTGTAGGGCCACAGGGGCCACCAGGTCCCAAGGGTGAGCCAGGGCTT
CAAGGCTTCCCAGGAAAGCCAGGTTTCTTGGTGAAGTAGGGCCTCCTGGCATGA
GGGGTTTCCCAGGTCCCATAGGCCCAAGGGGGAACATGGGCAAAAAGGTGTAC
40 CAGGACTCCCTGGTGTTCCAGGGCTTCTCGGACCTAAGGGAGAACCAGGAATCC
CAGGGGATCAGGGTTTACAGGGCCCCCAGGTATCCCAGGGATTGGGGGCCCTA
GTGGCCCCATTGGACCACCTGGGATTCCAGGCCCCCAAAGGGGAGCCTGGCCTCC
CAGGGCCCCCTGGGTTCCTGGTATAGGGAAACCCGGAGTGGCAGGACTTCATG
GCCCCCAGGGAAGCCTGGTGCCCTTGGTCCTCAAGGCCAGCCTGGCCTTCCAGG
45 ACCCCCAGGCCCTCCAGGACCTCCAGGACCCCCAGCTGTGATGCCCCCTACACCA
CCACCCCAGGGAGAGTATCTGCCAGATATGGGGCTGGGAATTGATGGCGTGA
CCCCCCCATGCTACGGGGGCTAAGAAAGGCAAGAATGGAGGGCCAGCCTATGAG
ATGCCTGCATTTACCGCCGAGCTAACCGCACCCCTTTCCACCGGTGGGGGGCCAG
TGAAGTTTAACAAACTGCTGTATAACGGCAGACAGAACTACAACCCGCAGACAG

GCATCTTCACCTGTGAGGTCCCTGGTGTCTACTACTTTGCATACCACGTTCACTGC
AAGGGGGGGAACGTGTGGGTTGCTCTATTCAAGAACAACGAGCCCGTGATGTAC
ACGTACGACGAGTACAAAAAGGGCTTCCTGGACCAGGCATCTGGGAGTGCAGTG
CTGCTGCTCAGGCCCCGGAGACCGGGTGTTCCTCCAGATGCCCTCAGAACAGGCTG
5 CAGGACTGTATGCCGGGACAGTATGTCCACTCCTCCTTTTCAGGATATTTATTGTAT
CCCATGTAA

SEQ ID NO: 197

>g1949404

10 ACCCACAGGGCCCCTACCCACAAGAGGGCTACCCACAGGGCCCCTACCCCCAAG
GGGGCTACCCCCAGGGGCCATATCCCCAGAGCCCCTTCCCCCTATCCCCTATGG
ACAGCCACAGGTCTTCCCAGGACAAGACCCTGACTCACCCCAGCATGGAACTA
CCAGGNGGAGGGTCCCCCATCCTACTATGACAACCAGGACTTTCCTGCCAACAAAC
TGGGATGACAAGAGCATCCGACAAGNCTTCATCCGCAAGTGTTCTAGTGCTTGA
15 CCT

SEQ ID NO: 198

>gi|1057867|gb|H79778.1|H79778 yu77h11.r1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:239877 5' similar to SP:S43160 S43160 YEAST RPD3

20 HOMOLOG - AFRICAN CLAWED FROG ;, mRNA sequence

NGTTATCAACCAGGTAGTGGACTTCTACCAACCCACGTGCATTGTGCTCCAGTGT
GGANTGGACTCTCTGGGCTGTGATCGATTGGGCTGCTTTAACCTCAGCATCCGAG
GGCATGGGGAATGCGTTGAATATGTCAAGAGCTTCAATATCCCTCTACTCGTGCT
GGGTGGTGGTGGTTATACTGTCCGAAATGTTGCCCGCTGCTGGACATATGAGACA
25 TCGCTGCTGGTAGAAGAGGCCATTAGTGAGGAGCTTCCCTATAGTGAATACTTCG
AGTACTTTGCCCCAGACTTCACACTTCATCCAGATGTCAGCACCCCTCATCGAGAA
TCAGAACTTCACGNCATATCTNNGGAACCAGATCCGCCAGACAATCTTTGAAAACC
CTGGAAGATGCTGGAACCTGGCACNTAGTGTTCCAGATTTCATGGACGTGCCTGCA
GAC

30

SEQ ID NO: 199

>gi|3928429|emb|X72781.1|HSTRPIV Homo sapiens mRNA for trypsinogen IV a-form

GGGCTTGAGCTGCACCCGCTTCTGGGTGGACGCACTTGGCGAGCGGCGCGGGA
TGCAGACGGCTGCGAGGCGCTGGGCACAGTTGCTGTCCCTTTGACGATGATGAC
35 AAGATTGTTGGGGGCTACACCTGTGAGGAGAATTCTCTCCCTACCAGGTGTCCC
TGAATTCTGGCTCCCACTTCTGCGGTGGCTCCCTCATCAGCGAACAGTGGGTGGT
ATCAGCAGCTCACTGCTACAAGACCCGCATCCAGGTGAGACTGGGAGAGCACAA
CATCAAAGTCCTGGAGGGGAATGAGCAGTTCATCAATGCGGCCAAGATCATCCG
CCACCCTAAATACAACAGGGACACTCTGGACAATGACATCATGCTGATCAAAC
40 CTCCTCACCTGCCGTCATCAATGCCCGCGTGTCCACCATCTCTCTGCCACCGCCC
CTCCAGCTGCTGGCACTGAGTGCCTCATCTCCGGCTGGGGCAACACTCTGAGCTT
TGGTGCTGACTACCCAGACGAGCTGAAGTGCCTGGATGCTCCGGTGCTGACCCAG
GCTGAGTGTAAGCCTCCTACCCTGGAAAGATTACCAACAGCATGTTCTGTGTGG
GCTTCCTTGAGGGAGGCAAGGATTCTGCCAGCGTGAATCTGGTGGCCCTGTGGT
45 CTGCAACGGACAGCTCCAAGGAGTTGTCTCCTGGGGCCATGGCTGTGCCTGGAA
GAACAGGCCTGGAGTCTACACCAAGGTCTACAACATATGTGGACTGGATTAAGGA
CACCATCGCTGCCAACAGCTAAAGCCCCCGGTCCCTCTGCAGTCTCTATACCAAT
AAAGTGGCCCTGCTCTCAAAAAAAAAAAAAAAAAA

SEQ ID NO: 200

>5171695H1

GGATGCTGTAAAAGTAGAAGAGGAATTGACCCTATCTTGGACAGCACCTGGAGA
AGACTTTGATCAGGGCCAGGCTACAAGCTATGAAATAAGAATGAGTAAAAGTCT
5 ACAGAATATCCAAGATGACTTTAACAATGCTATTTTAGTAAATACATCAAAGCGA
AATCCTCAGCAAGCTGGCATCAGGGAGATATTTACGTTCTCACCCCAAATTTCCA
CGAATGGACCTGAACATCAGCCAAATGGAGAAACACAT

SEQ ID NO: 201

10 >gi|182734|gb|K00650.1|HUMFOS Human fos proto-oncogene (c-fos), complete cds
GCAGGAACAGTGCTAGTATTGCTCGAGCCCGAGGGCTGGAGGTTAGGGGATGAA
GGTCTGCTTCCACGCTTTGCACTGAATTAGGGCTAGAATTGGGGATGGGGGTAGG
GGCGCATTCCTTCGGGAGCCGAGGCTTAAGTCCTCGGGGTCTGTACTCGATGCC
GTTTCTCCTATCTCTGAGCCTCAGAACTGTCTTCAGTTTCCGTACAAGGGTAAAA
15 AGGCGCTCTCTGCCCCATCCCCCGACCTCGGGAACAAGGGTCCGCATTGAACC
AGGTGCGAATGTTCTCTCTCATTCTGCGCCGTTCCCGCCTCCCCTCCCCAGCCGC
GGCCCCCGCCTCCCCCGCACTGCACCCTCGGTGTTGGCTGCAGCCCGCGAGCAG
TTCCCGTCAATCCCTCCCCCTTACACAGGATGTCCATATTAGGACATCTGCGTCA
GCAGGTTTCCACGGCCTTTCCCTGTAGCCCTGGGGGGAGCCATCCCCGAAACCCC
20 TCATCTTGGGGGGCCACGAGACCTCTGAGACAGGAAGTGCAGAAATGCTCACGA
GATTAGGACACGCGCCAAGGCGGGGGCAGGGAGCTGCGAGCGCTGGGGACGCA
GCCGGGCGGCCGAGAAAGCGCCAGGCCCGCGCGCCACCCCTCTGGCGGCCACCG
TGGTTGAGCCCGTGACGTTTACACTCATTCAATAAAACGCTTGTTATAAAAGCAGT
GGCTGCGGCGCCTCGTACTCCAACCGCATCTGCAGCGAGCAACTGAGAAGCCAA
25 GACTGAGCCGGCGGGCCGCGGCGCAGCGAACGAGCAGTGACCGTGCTCCTACCCA
GCTCTGCTTCACAGCGCCACCTGTCTCCGCCCCTCGGCCCTCGCCCGGCTTTGC
CTAACCGCCACGATGATGTTCTCGGGCTTCAACGCAGACTACGAGGCGTCATCCT
CCCGCTGCAGCAGCGCGTCCCCGGCCGGGGATAGCCTCTCTTACTACCACTCACC
CGCAGACTCCTTCTCCAGCATGGGCTCGCCTGTCAACGCGCAGGTAAGGCTGGCT
30 TCCCGTCCGCGCGGGGCGGGGGCTTGGGGTTCGCGGAGGAGGAGACACCGGGCG
GGACGCTCCAGTAGATGAGTAGGGGGCTCCCTTGTGCCTGGAGGGAGGCTGCCG
TGGCCGGAGCGGTGCCGGCTCGGGGGCTCGGGACTTGCTCTGAGCGCACGCACG
CTTGCCATAGTAAGAATTGGTTCCCCCTTCGGGAGGCAGGTTCTGTTCTGAGCAAC
CTCTGGTCTGCACTCCAGGACGGATCTCTGACATTAGCTGGAGCAGACGTGTCCC
35 AAGCACAAACTCGCTAACTAGAGCCTGGCTTCTTCGGGGAGGTGGCAGAAAGCG
GCAATCCCCCTCCCCCGCAGCCTGGAGCACGGAGGAGGGATGAGGGAGGAGG
GTGCAGCGGGCGGGTGTGTAAGGCAGTTTCATTGATAAAAAGCGAGTTCATTCTG
GAGACTCCGGAGCGGCGCCTGCGTCAGCGCAGACGTCAGGGATATTTATAACAA
ACCCCTTTCAAGCAAGTGATGCTGAAGGGATAACGGGAACGCAGCGGCAGGAT
40 GGAAGAGACAGGCACTGCGCTGCGGAATGCCTGGGAGGAAAAGGGGGAGACCT
TTCATCCAGGATGAGGGACATTTAAGATGAAATGTCCGTGGCAGGATCGTTTCTC
TTCACTGCTGCATGCGGCACTGGGAACTCGCCCCACCTGTGTCCGGAACCTGCTC
GCTCACGTCGGCTTTTCCCCTTCTGTTTTGTTCTAGGACTTCTGCACGGACCTGGCC
GTCTCCAGTGCCAACTTCATTCACGGTCACTGCCATCTCGACCAGTCCGGACC
45 TGCAGTGGCTGGTGCAGCCCGCCCTCGTCTCCTCTGTGGCCCCATCGCAGACCAG
AGCCCCTCACCTTTTCGGAGTCCCCGCCCCCTCCGCTGGGGCTTACTCCAGGGCT
GGCGTTGTGAAGACCATGACAGGAGGCCGAGCGCAGAGCATTGGCAGGAGGGG
CAAGGTGGAACAGGTGAGGAACTCTAGCGTACTCTTCCTGGGAATGTGGGGGCT
GGGTGGGAAGCAGCCCCGAGATGCAGGAGCCCAGTACAGAGGATGAAGCCAC

TGATGGGGCTGGCTGCACATCCGTAACCTGGGAGCCCTGGCTCCAAGCCCATTCCA
TCCCAACTCAGACTCTGAGTCTCACCCTAAGAAGTACTCTCATAGTTTCTTCCCTA
AGTTTCTTACCGCATGCTTTCAGACTGGGCTCTTCTTTGTTCTCTTGCTGAGGATC
TTATTTTAAATGCAAGTCACACCTATTCTGCAACTGCAGGTCAGAAATGGTTTCA
5 CAGTGGGGTGCCAGGAAGCAGGGAAGCTGCAGGAGCCAGTTCTACTGGGGTGGG
TGAATGGAGGTGATGGCAGACACTTTTACTGAATGTCGGTCTTTTTTTGTGATTAT
TCTAGTTATCTCCAGAAGAAGAAGAGAAAAGGAGAATCCGAAGGGAAAGGAAT
AAGATGGCTGCAGCCAAATGCCGCAACCGGAGGAGGGAGCTGACTGATACTC
CAAGCGGTAGGTACTCTGTGGGTGCTCCTTTTTTAAACTTAAGGGAAAGTTGGA
10 GATTGAGCATAAGGGCCCTTGAGTAAGACTGTGTCTTATGCTTTTCTTTATCCCTC
TGTATACAGGAGACAGACCAACTAGAAGATGAGAAGTCTGCTTTGCAGACCGAG
ATTGCCAACCTGCTGAAGGAGAAGGAAAACTAGAGTTCATCCTGGCAGCTCAC
CGACCTGCCTGCAAGATCCCTGATGACCTGGGCTTCCCAGAAGAGATGTCTGTGG
CTTCCCTTGATCTGACTGGGGGCCTGCCAGAGGTTGCCACCCCGGAGTCTGAGGA
15 GGCCTTCACCCTGCCTCTCCTCAATGACCCTGAGCCCAAGCCCTCAGTGGAACCT
GTCAAGAGCATCAGCAGCATGGAGCTGAAGACCGAGCCCTTTGATGACTTCCTGT
TCCCAGCATCATCCAGGCCCAGTGGCTCTGAGACAGCCCGCTCCGTGCCAGACAT
GGACCTATCTGGGTCTTCTATGCAGCAGACTGGGAGCCTCTGCACAGTGGCTCC
CTGGGGATGGGGCCCATGGCCACAGAGCTGGAGCCCTGTGCACTCCGGTGGTC
20 ACCTGTACTCCCAGCTGCACTGCTTACACGTCTTCTTTCGTCTTACCTACCCCGA
GGCTGACTCCTTCCCCAGCTGTGCAGCTGCCACCGCAAGGGCAGCAGCAGCAA
TGAGCCTTCTCTGACTCGCTCAGCTCACCCACGCTGCTGGCCCTGTGAGGGGGC
AGGGAAGGGGAGGCAGCCGGCACCCACAAGTGCCACTGCCCAGCTGGTGCATT
ACAGAGAGGAGAAACACATCTTCCCTAGAGGGTTCCTGTAGACCTAGGGAGGAC
25 CTTATCTGTGCGTGAAACACACCAGGCTGTGGGCCTCAAGGACTTGAAAGCATCC
ATGTGTGGACTCAAGTCTTACCTCTTCCGGAGATGTAGCAAAACGCATGGAGTG
TGTATTGTTCCCAGTGACACTTCAGAGAGCTGGTAGTTAGTAGCATGTTGAGCCA
GGCCTGGGTCTGTGTCTCTTTTCTCTTTCTCCTTAGTCTTCTCATAGCATTAACATA
TCTATTGGGTTCAATTATTGGAATTAACCTGGTGCTGGATATTTTCAAATTGTATCT
30 AGTGCAGCTGATTTTAAACAATAACTACTGTGTTCCCTGGCAATAGTGTGTTCTGATT
AGAAATGACCAATATTATACTAAGAAAAGATACGACTTTATTTTCTGGTAGATAG
AAATAAATAGCTATATCCATGTACTGTAGTTTTTCTTCAACATCAATGTTCAATTGT
AATGTTACTGATCATGCATTGTTGAGGTGGTCTGAATGTTCTGACATTAAAGGTTT
TCCATGAAAACGTTTTATTGTGTTTTTAATTTATTTATTAAGATGGATCTCAGAT
35 ATTTATATTTTTATTTTATTTTTTCTACCTTGAGGTCTTTTGACATGTGGAAAGTG
AATTTGAATGAAAAATTTAAGCATTGTTTGCTTATTGTTCCAAGACATTGTCAAT
AAAAGCATTTAAGTTGAATGCGACCAACCTTGTGCTCTTTTCATTCTGGAAGTCTT
GTAAGTTTCTGAAAGGTATTATTGGAGACCAGTTTGTCAAGAAGGGTAGCTGCTG
GAGGGGGACACACCCTCTGTCTGATCCCTTATCAAAGAGGACAAGGAAACTATA
40 GAGCTGATTTTAGAATATTTTACAAATACATGCCTTCCATTGGAATGCTAAGATT
TTCTACTGCTTCTGGGGACGGGAAACCGCTGTGTAACAGCTTTTGTGGGAATACA
TTTTTCTGTTTCTGACTCGCAGGGGGAAATATTTAAATTTTGTGTGCTAATAT
TAAATTGAGATGTTTTGATCTTAAAGGAACCTTTAAGCAAACAGAACCTAGCTT
TGTACAGACTATTTTAACTTTTTATTCTCAGAAAATCACGTGGAGGGTTATTCTAC
45 TTCAAAGATGAGCAAATTGAAGAATGGTTAGAATAAACAACCTTTCTTGATATTCC
GTTATCGGCATTAGAATCTTCTGCTCGTTATCGTATCCAGCAGGCTGAACTGCCT
CTTGATACTTGGTTAAAAAAAATTTTCAGGCCGGGCGCGGTGGCCCATGCCTGTA
ATCCTAGCACTTTGGGAGGCCGAGGCAGGCGGATCACCTGAGGTCGGGAGTTCTG
AGACCAGCCTGACCAACATGGAGAAACCCCGTCTTTACTAAAAATACAAAATTA

GCCTGGTGTGGTGGTGCATGCCTGTAATCCTAGCTACTTGAGAGGCTGAGACAGG
AAAATCACTTGAACCTCGGGAGGCGGATGTTGCAGCGAACTGAGATTGCGCCATT
GCACTCCAGCCTGGGCAACAAGATTGAACTCTGTTTAAAAAAAAAAGTTTTCAC
TAATGTGTACATTTTTTTGTACTCTTTTATTCTCGAAAGGGAAGGAGGGCTATTGC
5 CCTATCCCTTATTAATAAATGCATTGTGGTTTCTGGTTTCTCTAATACCATATGCC
CTTCATTCAGTTTATAGTGGGCGGAAGTGGGGGAGAAAAAGTTGCTCAGAAATC
AAAAGATATCTCAAACAGCACAAATAATGGCTGATCGTTCTGCAAACAAAAAGT
TACATAATAGCTCAAGAAGGAGAAGTCAACATGACTCTGAACAAGCTTTAACTT
AGAAACTTTATCATCTTAAGGAAGAACGTGACCTTTGTCCAGGACGTCTCTGGTA
10 ATGGGGCACTTACACACACATGCACACGTACAAACCACAGGGAAAGGAGACCGC
CCTTCTGCCTCTGCTCGCGAGTATCACGCAGGCACCATGCACTATGTTTTACAC
ACACTGGGTGGAAGAAGAGCTTCAGCGCCAGTCTTCTAATGCTTTGGTGATAATG
AAAATCACTGGGTGCTTATGGGGTGTCATATTCAATCGAGTTAAAAGTTTAAATT
CAAAATGACAGTTTTACTGAGGTTGATGTTCTCGTCTATGATATCTCTGCCCCTCC
15 CATAAAAATGGACATTTAAAGCAACTTACCGCTCTTTAGATCACTCCTATATCA
CACACCACTTGGGGTGCTGTTTCTGCTAGACTTGTGATGACAGTGGCCTTAGGAT
CCCTGTTTGCTGTTCAAAGGGCAAATATTTTATAGCCTTTAAATATACCTAAACTA
AATACAGAATTAATATACTAACAACACCTGGTCTGAAATAACAAGGTGATCT
ACCCTGGAAGGAACCCAGCTGGTGGGCCAGGAGCGGTGGCTCACACCTGTAATT
20 CCAGCACTTTGGGAGGCTGAGACAGGAGGATCACTGGAGTCCAGGAGTTTGAGA
CCAGCCTGGGCAACATGGCAAACCCAGTGTGCTTCTGTTGTCCCAGCTACACTA
CTCAGGAGGCTGAGGCAGGAGTATGACTTGAGCCTGGGAGGGGGAGGTTGCAGA
GAACTGATATTGCACCACCACTGCACTCCAGCCTGGGTGACACAGCAAAACCT
ATCTCAAAAAAAAAAAAAAAAAAAAAAGGAACCCAGCTGGTTCCTGTAGGTGTGCA
25 ATAATAACAACCAGAGGAAGAAAAGGAAGACGATTTCACAGATGAAGAAGGGC
AGCTGGACCTTCGGAC

SEQ ID NO: 202

>gi|1049052|gb|U26644.1|HSU26644 Human fatty acid synthase (fas) mRNA, complete cds

30 ATGGAGGAGGTGGTGATTGCCGGCATGTTTCGGGAAGCTGCCAGAGTCGGAGAAC
TTGCAGGAGTTCTGGGACAACCTCATCGGCGGTGTGGACATGGTCACGGACGAT
GACCGTCGCTGGAAGGCTGGGCTCTACGGCCTGCCCCGGCGGTCCGGCAAGCTG
AAGGACCTGTCTAGGTTTGATGCCTCCTTCTTCGGAGTCCACCCCAAGGAGGCAC
ACACGATGGACCCTCAGCTGCGGCTGCTGCTGGAAGCTACCTATGAAGCCATCGT
35 GGACGGAGGCATCAACCCAGATTCACTCCGAGGAACACACACTGGCGTCTGGGT
GGGCGTGAGCGGCTCTGAGACCTCGGAGGCCCTGAGCCGAGACCCCGAGACACT
CGTGGGCTACAGCATGGTGGGCTGCCAGCGAGCGATGATGGCCAACCGGCTCTC
CTTCTTCTTCGACTTCAGAGGGCCCAGCATCGCACTGGACACAGCCTGCTCCTCC
AGCCTGATGGCCCTGCAGAACGCCTACCAGGCCATCCACAGCGGGCAGTGCCCT
40 GCCGCCATCGTGGGGGGCATCAACGTCCTGCTGAAGCCCAACACCTCCGTGCAGT
TCTTGAGGCTGGGGATGCTCAGCCCCGAGGGCACCTGCAAGGCCTTCGACACAG
CGGGGAATGGGTACTGCCGCTCGGAGGGTGTGGTGGCTGTCTGCTGACCAAGA
AGTCCCTGGCCCGGAAGGTCTACACCACCATCCTGAACAAAGGCACCAATACAG
ATGGCTTCAAGGAGCAAGGCGTGACCTTCCTCAGGATATCCAGGAGCAGCCTA
45 TCCGCTCGTTGTACCAAGTCGGCCGGAGTGGCCCCCTGAGTCATTTGAATACATCGA
AGCCACGGACCAGGCACCAAGGTGGGCGACCCCCAGGAGCGTAATGGCATCAC
CCGAGCCCTGTGCGCCACCCGCCAGGAGCCGCTGCTCATCGGCTCCACCAAGTCC
AACATGGGGCACCCGGAGCCAGCCTCGGGGCTCGACGCCCTGGCCAAGGTGCTG
CTGTCCCTGGAGCACGGGCTCTGGGCCCCCAACCTGCACTTCCATAGCCCCAACC

CTGAGATCCCAGCGCTGTTGGATGGGCGGCTGCAGGTGGTGGACCAGCCCCTGC
CCGTCCGTGGCGGCAACGTGGGCATCAACTCCTTTGGCTTCGGGGGCTCCAACAT
GCACATCATCCTGAGGCCCAACACGCAGTCCGCCCCCGCACCCGCCCCACATGCC
ACCCTGCCCCGTCTGCTGCGGGCCAGCGGACGCACCCCTGAGGCCGTGCAGAAG
5 CTGCTGGAGCAGGGCCTCCGGCACAGCCAGGGCCTGGCTTTCCTGAGCATGCTGA
ACGACATCGCGGCTGTCCCCGCCACCGCCATGCCCTTCCGTGGCTACGCTGTGCT
GGGTGGTGAAGACGCGGTGGCCCAGAGTGCAGCAGGTGCCCCTGGCGAGCGCCC
GCTCTGGTTCATCTGCTCTGGGATGGGCACACAGTGGCGTGGAATGGGGCTGAGC
CTTATGCGCCTGGACCGCTTCCGAGATTCCATCCTACGCTCCGATGAGGCTGTGA
10 ACCGATTCCGGCCTGAAGGTGTACAGCTGCTGCTGAGCACAGACGAGAGCACCT
TTGATGACATCGTCCATTCGTTTGTGAGCCTGACTGCCATCCAGATAGGCCTCAT
AGACCTGCTGAGCTGCATGGGACCTGAGGCAGATGGCATCGTCGGCCACTCCCT
GGGGGAGTGGCTGTCCGTACGCGACGGCTGCCTGTCCCAGGAGGAGGCCGTCTCT
CGCTGCCTACTGGAGGGGACAGTGCATCAAAGAAGCCCCACTTCCCGCCGGCGC
15 CATGGCAGCCGTGGGCTTGTCTGGGAGGAGTGTAAACAGCGCTGCCCCCTGC
GGTGGTGCCCCGCTGCCACAACCTCCAAGGACACAGTCACCATCTCGGGACCTCA
GGCCCCGGTGTGTTGAGTTCGTGGAGCAGCTGAGGAAGGAGGGTGTGTTTGCCAA
GGAGGTGCGGACCGGCGGTATGGCCTTCCACTCCTACTTCATGGAGGCCATCGCA
CCCCACTGCTGCAGGAGCTCAAGAAGGTGATCCGGGAGCCGAAGCCACGTTCA
20 GCCCGCTGGCTCAGCACCTCTATCCCCGAGGCCAGTGGCACAGCAGCCTGGCAC
GCACGTCTTCCGCCGAGTACAATGTCAACAACCTGGTGAAGCCCTGTGCTGTTCCA
GGAGGCCCTGTGGCACGTGCCTGAGCACGCGGTGGTGTGAGATCGCCCCGAC
CCCGTGCCCTCAGGCTGTCTGAAGCGGGTCCGTAAGCCGAGCTGCACCATCATC
CCCCGTATGAAGAAGGATCACAGGGACAACCTGGAGTTCTTCTGGCCGGCATC
25 GGCAGGCTGCACCTCTCAGGCATCGACGCCAACCCCAATGCCTTGTTCCACCTG
TGGAGTCCCCAGCTCCCCGAGGAACCTCCCCTCATCTCCCCACTCATCAAGTGGGA
CCACAGCCTGGCCTGGGACGCGCCGGCCGCGGAGGACTTCCCCAACGGTTCAGG
TTCCCCCTCAGCCACCATCTACACATGCACACCAAGCTCCGAGTCTCCTGACCGC
TACCTGGTGGACCACACCATCGACGGTCGCGTCTCTTCCCCGCCACTGGCTACC
30 TGAGCATAGTGTGGAAGACGCTGGCCCCGCGCCTGGGCTGGGCTCGAGCAGCTGC
CTGTGGTGTGTTGAGGATGTGGTGCAGCACCAGGCCACCATCCTGCCCAAGACTGG
GACAGTGTCTTGGAGGTACGGCTCCTGGAGGCCACCGGTGCCTTCGAGGTGTCA
GAGAACGGCAACCTGGTAGTGAGTGGGAAGGTGTACCAGTGGGATGACCCTGAC
CCCAGGCTCTTCGACCACCCGGAAGTCCCCACCCCAATTCCCCACGGAGTCCCC
35 TCTTCTGGCCCAGGCAGAAAGTTTACAAGGAGCTGCGTCTGCGTGGCTACGACTA
CGGCCCTCATTTCAGGGCATCCTGGAGGCCAGCCTGGAAGGTGACTCGGGGAG
GCTGCTGTGGAAGGATAACTGGGTGAGCTTCATGGACACCATGCTGCAGATGTCC
ATCCTGGGCTCGGCCAAGCACGGCCTGTACCTACCCACCCGTGTCACCGCCATCC
ACATCGACCCTGCCACCCACAGGCAGAAAGCTGTACACACTGCAGGACAAGGCC
40 AAGTGGCTGACGTGGTGGTGAAGCAGGTGGCCGAGGGTCACAGTGGCGGGAGGCG
TCCACATCTCCGGGCTCCACACTGAGTCGGCCCCCGCGGCGGCACGAGGAGCAGC
AGGTGCCCATCCTGGAGAAGTTTTGCTTCACTCCCCACACGGAGGAGGGGTGCCT
GTCTGAGCACGCTGCCCTCGAGGAGGAGCTGCAACTGTGCAAGGGGCTGGTGA
GGCACTCGAGACCAAGGTGACCCAGCAGGGGCTGAAGATGGTGGTGCCGGAAGT
45 GACGGGGCCCAGATCCCCCGGGACCCCTCACAGCAGGAACTGCCCCGGCTGTT
GTCGGCTGCCTGCAGGCTTCAGCTCAACGGGAACCTGCAGCTGGAGCTGGCGCA
GGTGTGGCCAGGAGAGGGCCCAAGCTGCCAGAGGACCCTCTGCTCAGCGGCCT
CCTGGACTCCCCGGCACTCAAGGCCTGCCTGGACACTGCCGTGGAGAACATGCCC
AGCCTGAAGATGAAGGTGGTGGAGGTGCTGGCCGGCCACGGTCACCTGTATTCC

CGCATCCCAGGCCTGCTCAGCCCCCATCCCCTGCTGCAGCTGAGCTACACGGCCA
CCGACCGCCACCCCCAGGCCCTGGAGGCTGCCCAGGCCGAGCTGCAGCAGCACG
ACGTTGCCCAGGGCCAGTGGGATCCCGCAGACCCTGCCCCAGCGCCCTGGGCA
GCGCGGACCTCCTGGTGTGCAACTGTGCTGTGGCTGCCCTCGGGGACCCGGCCTC
5 AGCTCTCAGCAACATGGTGGCTGCCCTGAGAGAAGGGGGCTTTCTGCTCCTGCAC
AACTGCTCCGGGGGCACCCTCGGGACATCGTGGCCTTCCTCACCTCCACTGAGC
CGCAGTATGGCCAGGGCATCCTGAGCCAGGACGCGTGGGAGAGCCTCTTCTCCA
GGGTGTCGCTGCGCCTGGTGGGCCTGAAGAAGTCCTTCTACGGCGCCACGCTCTT
CCTGTGCCGCGGCCACCCCGCAGGACAGCCCCATCTTCCTGCCGGTGGACGAT
10 ACCAGCTTCCGCTGGGTGGAGTCTCTGAAGGGCATCCTGGCTGACGAAGACTCTT
CCCGGCCTGTGTGGCTGAAGGCCATCAACTGTGCCACCTCGGGCGTGGTGGGCTT
GGTGAAGTGTCTCCGCCGAGAGCCCGGCGGAACCGTCCGGTGTGTGCTGCTCTCC
AACCTCAGCAGCACCTCCACGTCCCGGAGGTGGACCCGGGCTCCGCAGAAGTGT
CAGAAGGTGTTGCAGGGAGACCTGGTGTATGAACGTCTACCGCGACGGGGCCTGG
15 GGGGTTTTCCGCCACTTCCTGCTGGAGGACAAGCCTGAGGAGCCGACGGCACAT
GCCTTTGTGAGCACCTCACCCGGGGGGACCTGTCTCCATCCGCTGGGTCTGCT
CCTCGCTGCGCCATGCCCAGCCACCTGCCCTGGCGCCCAGCTCTGCACGGTCTA
CTACGCCTCCCTCAACTTCCGCGACATCATGCTGGCCACTGGCAAGCTGTCCCCT
GATGCCATCCCAGGGAAGTGGACCTCCCAGGACAGCCTGCTAGGTATGGAGTTC
20 TCGGGCCGAGACGCCAGCGGCAAGCGTGTGATGGGACTGGTGCCTGCCAAGGGC
CTGGCCACCTCTGTCTGCTGTACCGGACTTCCTCTGGGATGTGCCTTCCAAGTGT
GACGCTGGAGGAGGCGGCCTCGGTGCTGTCTACAGCACGGGCTACTACGC
GCTGGTGGTGCCTGGGGGGGTGCGCCCGGGGAGACGCTGCTCATCCACTCGGG
CTCGGGCGGCGTGGGCCAGGCCGCCATCGCCATCGCCCTCAGTCTGGGCTGCCGC
25 GTCTTACCACCGTGGGGTGGCTGAGAAGCGGGCGTACCTCCAGGCCAGGTTC
CCCAGCTCGACAGCACCGCTTCGCCAACTCCCGGGACACATCCTTCGAGCAGCA
TGTGCTGTGGCACACGGGCGGGAAGGGCGTTGACCTGGTCTTGAAGTCTTGGCG
GAAGAGAAGCTGCAGGCCAGCGTGAGGTGCTTCGGTACGCACGGTGCCTTCCTG
GAAATTGGCAAATTCGACCTTTCTCAGAACCACCCGCTCGGCATGGCTATCTTCC
30 TGAAGAACGTGACATTCCACGGGGTCTACTGGATGCGTTCTTCAACGAGAGCA
GTGCTGACTGGCGGGAGGTGTGGGCGCTTGTGAGGCGGCCATCCGGGATGGGG
TGGTACGGCCCCCTCAAGTGCACGGTGTTCATGGGGCCCAGGTGGAGGACGCCTT
CCGCTACATGGCCCAAGGGAAGCACATTGGCAAAGTCTGCTGTCAGGTGCTTGC
GGAGGAGCCGGCAGTGTGTAAGGGGGCCAAACCCAAGCTGATGTCGGCCATCTC
35 CAAGACCTTCTGCCCCGGCCACAAGAGCTACATCATCGCTGGTGGTCTGGGTGGC
TTCGGCCTGGAGTTGGCGCAGTGGCTGATACAGCGTGGGGTGCAGAAGCTCGTG
TTGACTTCTCGCTCCGGGATCCGGACAGGCTACCAGGCCAAGCAGGTCCGCCGGT
GGAGGCGCCAGGGGCTACAGGTGCAGGTGTCCACCAGCAACATCAGCTCACTGG
AGGGGGCCCGGGGCCTCATTGCCGAGGCGGCGCAGCTTGGGCCCCTGGGGGGCG
40 TCTTCAACCTGGCCGTGGTCTTGAGAGATGGCTTGTGAGAGAACCAGACCCAGA
GTTCTTCCAGGACGTCTGCAAGCCCAAGTACAGCGGCACCCTGAACCTGGACAG
GGTGACCCGAGAGGCGTGCCCTGAGCTGGACTACTTTGTGGTCTTCTCCTCTGTG
AGCTGCGGGCGTGGCAATGCGGGACAGAGCAACTACGGCTTTGCCAATTCGCC
ATGGAGCGTATCTGTGAGAAACGCCGGCACGAAGGCCTCCCAGGCCTGGCCGTG
45 CAGTGGGGCGCCATCGGCACCGTGGGCATTTTGGTGGAGACGATGAGCACCAAC
GACACGATCGTCAGTGGCACGCTGCCACGCGCATTGGCGTCCTTGGCCTGGAGG
TGCTGGACCTCTTCTGAACCAGCCCCACATGGTCCTGAGCAGCTTTGTGCTGGC
TGAGAAGGCTGCGGCCTATAGGGACAGGGACAGCCAGCGGGACCTGGTGGAGG
CCGTGGCACACATCCTGGGCATCCGCGACTTGGCTGCTGTCAACCTGGGCGGCTC

ACTGGCGGACCTGGGCCTGGACTCGCTCATGAGCGCGCCGGTGCGCCAGACGCT
GGAGCGTGAGCTCAACCTGGTGTCTGTCGTGCGCGAGGTGCGGCAACTCACGCT
CCGGAAGCTGCAGGAGCTGTCCTCAAAGGCGGATGAAGCCAGCGAGCTGGCATG
CCCCACGCCCAAGGAGGATGGTCTGGCCCAGCAGCAGACTCAGCTGAACCTGCG
5 CTCCCTGCTGGTCAAACCGGAGGGGCCCCACCCTGATGCGGCTCAACTCCGTGCAG
AGCTCGGAGCGGCCCCCTGTTCTTGGTGCACCCAATCGAGGCTACCACCGTGTTC
ACAGCCTCGGTCCCGGTCTCAGCATCCCCACCTATGGCCTGCAGTGCACCCCGGC
TGCGCCCCTTGACAGCATCCACAGCCTGGCTGCCTACTACATCGACTGCATCAGG
CAGGTGCAGCCCCGAGGGCCCCCTACCGCGTGGCCGGCTACTCCTACGGGGCCTGC
10 GTGGCCTTTGAAATGTGCTCCAGCTGCAGGCCAGCAGAGCCAGCCCCACCC
ACAACAGCCTCTTCTGTTGACGGCTCGCCACCTACGTACTGGCCTACACCCA
GAGTACCGGGCAAAGCTGACCCAGGCTGTAAGGCTGAGGCTGAGACGGAGGC
CATATGCTTCTTCGTGCAGCAGTTCACGGACATGGAGCACAACAGGGTGCTGGA
GGCGCTGCTGCCGCTGAAGGGCCTAGAGGAGCGTGTGGCAGCCGCCGTGGACCT
15 GATCATCAAGAGCCACCAGGGCCTGGACCGCCAGGAGCTGAGCTTTGCGGCCCG
GTCCTTCTACTACAGGCTGCGTGCCGCTGACCAGTATACACCCAAGGCCAAGTAC
AGTGGCAACGTGATGCTACTGCGGGCCAAGACGGGTGGCCGCTACGGCGAGGAC
CTGGGCGCGGACTACAACCTCTCCAGGTATGCGACGGGAAAGTATCCGTCCAT
ATCATCGAGGGTGACCACCGCACGCTGCTGGAGGGCAGCGGCCTGGAGTCCATC
20 ATCAGCATCATCCACAGCTCCCTGGCTGAGCCACGTGTGAGTCGGGAGGGCTAG

SEQ ID NO: 203

>gi|748131|gb|T98394.1|T98394 ye59f12.s1: Soares fetal liver spleen 1NFLS Homo sapiens
cDNA: clone IMAGE:122063-3', mRNA sequence

25 ACTTTTATTGTCATCCAGCACCTGTGATAGTTTCATGTCTCTCTAAAGGAGACAG
GAAATTGGAGCATTGTGGGCCCTTTTAAAAGAAAAGAGGAGTAGGTAGGCACAC
CCAGGTGCTTCTAAAACAACCAAGCCCAAACCTGACATGCTCCTCCCCACAGTCA
CCTTCATTGTCCCCTTTAAAAGTCTGGAACAGTATGTAGCAAAACAAATAAATTA
CTTTTCATTTCAAAAGTAAGTCCAAAGGTTGAAGCTGCCTAGGCCAGGGGTTCTG
30 GGACAGGGTGCTTCCAAAGGAAGTGAGGCTTTCTTTTCAACTTCCTTAGGCTCT
AGCCAGTAGGACCAGGAAACCCCTGCTTTTCCACATCAGGGNTTCCAGGATGGG
NGTTTTAGGTTAGGACTTNGGGGGATCCCGTTNGCTT

SEQ ID NO: 204

35 >gi|476704|gb|L26336.1|HUMHSPA2A Homo sapiens heat shock protein (HSPA2) gene,
complete cds

CCTCCACCTCCCGGGTTCAAGCGATTCTCCTGCCTCAGCCTCCCGAGTAGCTGAG
ACTACAGGCACGCGCCACCACGCCAGCTAATTTTTGTATCTTTAGTAGAGACGG
GCTTTCACCATGTTGGCCAGGATGGTCTCGATGTCTTAACGTCGTGATCCGGCCG
40 CCTCGGCCTCCCAAGTGCTGGGATTACAGGCGTTAGCCACTGCGCCCCGGCCCCAG
CCAGGCAGTTTAAATCGAGCGCTCACAACCACTGAGACGCAGCGAAGCACCCAC
CATAATATCCAGGAGGCCGACCGCCGGTTCAGACTTTTTCTTTTCTTAATCCCC
GTCCAAGGGATCCGCCCTACCCCCCAGCCACCCCAATTCCCTATTCCT
CCCCTTGGACGGCGCCGGGAAAACAAGCTGCTCGAGCTTTATTTCTTCGGTGCA
45 ACCAACTCAGAATGAATTCCTCCGCCCTGCGTGCTCAGTGAGTCGGCACCCCTAG
CAGTGAAGTGCATTTAAAACCTCAGGAATTGAGCGAACTCTCCAGTGGCTCTCC
TCACCGGGATCCCCTTCCACGCCTCCTCCCCGTGCCGCGCCTCAGTCCGCACTGCT
CATTGGCCGCGTGCTGCCAATCCGATGCACGTCGGCTAGGGCAAAGACCGCGA
AAAAGCGCGTACACCTGGCTCTGGGAGCGCGCGCCTAACGCCAGCCAGCAGCAG

GAGGCGCGGAGGCACCGGCCTGGCGGCCGAGAGTCAGGGAGGAACCTCATT
TACATAACGGCCGCCCTCTGTCTCCTGGCGGGGGCCGGAGTCCCGCCCCTCGTC
CAACTTGAAATCTGTTGGGTACGGGCCAGTCACTCCGACCTAGGCAAGCCTGTG
GTGGAGCTGGAAGAGTTTGTGAGGGCGGTCCCGGGAGCGGATTGGGTCTGGGAG
5 TTCCCAGAGGCGGCTATAAGAACCGGGAACCTGGGCGCGGGGAGCTGAGTTGCTG
GTAGTGCCCGTGGTGCTTGGTTCGAGGTGGCCGTTAGTTGACTCCGCGGAGTTCA
TCTCCCTGGTTTTCCCGTCCTAACGTCGCTCGCCTTTTCAGTCAGGATGTCTGCCCG
TGGCCCGGCTATCGGCATCGACCTGGGCACCACTATTCGTGCGTCGGGGTCTTC
CAACATGGCAAGGTGGAGATCATCGCCAACGACCAGGGCAATCGCACCAACCCCC
10 AGCTACGTGGCCTTCACGGACACCGAGCGCCTCATCGGCGACGCCGCCAAGAAC
CAGGTGGCCATGAACCCCAACAACACCATCTTCGACGCCAAGAGGCTGATTGGA
CGGAAATTCGAGGATGCCACAGTGCAGTCGGATATGAAACACTGGCCGTTCCGG
GTGGTGAGCGAGGGAGGCAAGCCCAAAGTGCAAGTAGAGTACAAGGGGGAGAC
CAAGACCTTCTTCCCAGAGGAGATATCCTCCATGGTCCTCACGAAGATGAAGGA
15 GATCGCGGAAGCCTACCTGGGGGGCAAGGTGCACAGCGCGGTCTATAACGGTCCC
GGCCTATTTCAACGACTCGCAGCGCCAGGCCACCAAGGACGCAGGCACCATCAC
GGGGCTCAATGTGCTGCGCATCATCAACGAGCCACGGCGGGCGGCCATCGCCTA
CGGCCTGGACAAGAAGGGCTGCGCGGGCGGCGGAGAAGAACGTGCTCATCTTTGA
CCTGGGCGGTGGCACTTTCGACGTGTCCATCCTGACCATCGAGGATGGCATCTTC
20 GAGGTGAAGTCCACGGCCGGCGATAACCACTGGGCGGTGAGGACTTCGACAAC
CGCATGGTGAGCCACCTGGCGGAGGAGTTCAAGCGCAAGCACAAGAAGGACATT
GGGCCCAACAAGCGCGCCGTGAGGCGGCTGCGCACCGCTTGCGAGCGCGCCAAG
GGCACCTGAGCTCGTCCACGCAGGCGAGCATCGAGATCGACTCGCTCTACGAG
GGCGTGGACTTCTATACGTCCATCACGCGCGCCCGCTTCGAGGAGCTCAATGCCG
25 ACCTCTTTCGCGGGACCCTGGAGCCGGTGGAGAAGGCGCTGCGCGACGCCAAGC
TGGACAAGGGCCAGATCCAGGAGATCGTGCTGGTGGGCGGCTCCACTCGTATCC
CCAAGATCCAGAAGCTGCTGCAGGATTTCTTCAACGGCAAGGAGCTGAACAAGA
GCATCAACCCCGACGAGGCGGTGGCCTATGGCGCCGCGGTGCAGGCGGCCATCC
TCATCGGCGACAAATCAGAGAATGTGCAGGACCTGCTGCTACTCGACGTGACCC
30 CGTTGTGCTGCGTCGGCATCGAGACAGCTGGCGGTGTCATGACCCCACTCATCAAGAG
GAACACCACGATCCCCACCAAGCAGACGCAGACCTTCACCACCTACTCGGACAA
CCAGAGCAGCGTACTGGTGCAGGTATACGAGGGCGAACGGGCCATGACCAAGGA
CAATAACCTGCTGGGCAAGTTCGACCTGACCGGGATTCCCCCTGCGCCTCGCGGG
GTCCCCCAAATCGAGGTTACCTTCGACATTGACGCCAATGGCATCCTTAACGTTA
35 CCGCCGCCGACAAGAGCACCGGTAAGGAAAACAAAATCACCATCACCATGACA
AAGGTCGTCTGAGCAAGGACGACATTGACCGGATGGTGCAGGAGGCGGAGCGGT
ACAAATCGGAAGATGAGGCGAATCGCGACCGAGTCGCGGCCAAAAACGCCCTGG
AGTCCTATACCTACAACATCAAGCAGACGGTGGAAGACGAGAACTGAGGGGCA
AGATTAGCGAGCAGGACAAAAACAAGATCCTCGACAAGTGTGAGGAGGTGATCA
40 ACTGGCTCGACCGAAACCAGATGGCAGAGAAAGATGAGTATGAACACAAGCAG
AAAGAGCTCGAAAGAGTTTGCAACCCCATCATCAGCAAACCTTTACCAAGGTGGT
CCTGGCGGGCGGACGGCGGGCGGCGGTCAGGAGCCTCCGGGGGACCCACCATC
GAAGAAGTGGACTAAGCTTGCACTCAAGTCAGCGTAAACCTCTTTGCCCTTTCTCT
CTCTCTCTTTTTTTTTTTGTTTTGTTTCTTTGAAATGTCCTTGTGCCAAGTACGAGATC
45 TATTGTTGGAAGTCTTTGGTATATGCAAATGAAAGGAGAGGTGCAACAACCTTAGT
TTAATTATAAAAGTTCCAAAGTTTGTTTTTTAAAAACATTATTCGAGGTTTCTCTT
TAATGCATTTTTCGCTGTTTGTGCTGACTTGAGCATTTTTGATTAGTTTCGTGCATGGAG
ATTTGTTTGAGATGAGAAACCTTAAGTTTGCACACCTGTTCTGTAGAAGCTTGGA
AACAGTAAAATATATAGGAGCTTAAATTGTTTATTTTTATGTACTACTTTAAAACCT

AAACTGAACATTGCAGTAATGTTAAGGACAGGTATACTTTTTGCAAACAAATGCA
TAAATGCAAATGTAAAGTAAA

SEQ ID NO: 205

5 >gi|483537|emb|Z29330.1|HSUCEH2 H.sapiens (23k/2) mRNA for ubiquitin-conjugating
enzyme UbcH2
CCGGGCCGTGACAGACGGCCGGCAGAGGAAGGGAGAGAGGCGGCGGCGACACC
ATGTCATCTCCCAGTCCGGGCAAGAGGCGGATGGACACGGACGTGGTCAAGCTC
ATCGAGAGTAAACATGAGGTTACGATCCTGGGAGGACTTAATGAATTTGTAGTG
10 AAGTTTTATGGACCACAAGGAACACCATATGAAGGCGGAGTATGGAAAGTTAGA
GTGGACCTACCTGATAAATACCTTTCAAATCTCCATCTATAGGATTCATGAATA
AAATTTTCCATCCCAACATTGATGAAGCGTCAGGAACTGTGTGTCTAGATGTAAT
TAATCAAACCTGGACAGCTCTCTATGATCTTACCAATATATTTGAGTCCTTCCTGC
CTCAGTTATTGGCCTATCCTAACCCCATAGATCCTCTCAATGGTGACGCTGCAGC
15 CATGTACCTCCACCGACCAGAAGAATACAAGCAGAAAATTAAAGAGTACATCCA
GAAATACGCCACGGAGGAGGCGCTGAAAGAACAGGAAGAGGGTACCGGGGACA
GCTCATCGGAGAGCTCTATGTCTGACTTTTCCGAAGATGAGGCCCAGGATATGGA
GTTGTAGTAGAAAAAGCACCTGCTTTTCAGAAAGACTATTATTTCTAACCATGA
GAAGCAGACTATAATATTCATATTTAAACAAAGCAATTTTTTTTATTACTAAACA
20 AGGTTTTTATGAATAATAGCATTGATATATATATATATATACACCCTTTAGATC
TTGATTTCTTGGTCATTTCTCAACCTGAGGTGCATAGCATATTCCCACATTCCATT
TGGTAGCAATATGCGGTCTGAATGCATGCATTCATGAGTCCATGTGGCCAAGTCA
GCGCTGTGTGCTACTGAACTGTGCAAGGAAATAGCCGCTCTGATAGGTAGATGTGA
GTAAAAAAGAACAGGAAAAAATTGCTTCTTTTATTGGTTTCCAAAGAAACAAACC
25 AAACCAACCAGCTCTTGGATGTGAAGATAAAATAGTGCTTTTTTGAATGGAGA
GGAAAAACTTGGGGAGGAAGAGGCCTGCTGTGGGGGCATCGGAGCCAGCCATGT
AAGAATCAGAGCTGCTCCTTCCTGTGAATCCTAGGTGGCCCTATGTCTTCTGTGG
AGTTACAGTATAAAGCAGGGAGCTAATTAAGAGTATTA AAACTTAAACCATTTT
TTGACTCTGATTTTAAGTACATTTTATATGTCAGTTGCTGCCCTTCACACTACCA
30 GGCCCTGCAGCCACAGTGTTCTGTTGGAGAACTTGGGGAAGTGTTTTCTGAACC
AGTTCTTTTTCTTGGGGTAGAGCGTGAAATCCAGACCTGTTTTTGAAAGGACAGC
ACAGGAGGAGAAAAGTGACTGGGACGATGCTTCCTCTCATCCAAAACACATGCA
GAGTCACATCCTCATCCTAGTGTTTGGGAGTTTGAGACCGCTACCCTGAACTTAA
GAGCTTTAAATATGAGGGTTGTGTTTCTGGGGGGGTTATTTTTTTGGTGTGTGTGT
35 GTGTGTATTGTGCTTAGAAAGGTTGCAGATTCATCTTCACCTACC

SEQ ID NO: 206

>4694921H1

GAGCCTAAGTGGGAGCCAGACCACGCAGGAGCTGGAGAACGTGGGGCGCATTGT
40 CCAGGTGTTGAGGCTGCTCAGGGCTCTGCGCATGCTAAAGCTGGGCAGACATTCC
ACAGGATTACGCTCCGTTGGGATGACAATCACCCAGTGTTAC

SEQ ID NO: 207

45 >gi|1162368|gb|N39161.1|N39161 yv26a01.s1 Soares fetal liver spleen 1NFLS Homo
sapiens cDNA clone IMAGE:243816 3' similar to gb:M98399 PLATELET
GLYCOPROTEIN IV (HUMAN);, mRNA sequence
TTAAGGAAGAACATATTTTAATGGTTGAAACCTGTCTTTATGAGGGCGATTATGAC
AGCAAAAAATATTATAATGAATAACAATGCATAGTCTACGCTTTGTAATATTTCA
TACAATAATTCCTTTATCATTTACATCTCTTAATGCTAGAAAAGCATTCTGAAGAT

GCCAAGCGTAAGTTGCAACTGAGTAAAAAAAAAAAAAGCAAAATTTACTCAATTT
 CCAGAAGAGGTGCAGAACAGAGAATGAAGGTCCTTAAAATATAAACCGCTAGTG
 TGCTAAAATGATGTCCATTTGCAGGATCAGTGGACAAAATATTTAAGCCCATAAA
 GAAAAGAGTTATACCTGCTGTATGAAGGTATTCCATAGAGAAATATGAGTCATA
 5 AGCCAATTATTTATAAATGGCCTTCCAAATATTTGGT

SEQ ID NO: 208

>gi|1469913|gb|U41070.1|HSU41070 Human P2 purinergic receptor mRNA, complete cds

GGCGGTGCTCTACGTCTTCACCGCTGGAGATCTGCTGCCCCGGGCAGGTCCCCGT
 10 TTCTCACGCGGCTCTTCGAAGGCTCTGGGGAGGCCCCAGGGGGCGGCCGCTCTA
 GGGAAGGGACCATGGAGCTCCGAACCTACCCCTCAGCTGAAAGTGGTGGGGCAGG
 GCCGCGGCAATGGAGACCCGGGGGGTGGGATGGAGAAGGACGGTCCGGAATGG
 GACCTTTGACAGCAGACCCTACAACCTGCTGCCCTTCCCTGTCCCTTTCCACCCCC
 CACCCACCCTCCAGAGGTCTCCCGACGGCCATGAACACTACATCTTCTGCAGCA
 15 CCCCCCTCACTAGGTGTAGAGTTCATCTCTCTGCTGGCTATCATCCTGCTGTCAGT
 GGCGCTGGCTGTGGGGCTTCCCGGCAACAGCTTTGTGGTGTGGAGTATCCTGAAA
 AGGATGCAGAAGCGCTCTGTCACTGCCCTGATGGTGTGTAACCTGGCCCTGGCCG
 ACCTGGCCGTATTGCTCACTGCTCCCTTTTTCCTTCACTTCCTGGCCCAAGGCACC
 TGGAGTTTGGACTGGCTGGTTGCCGCCTGTGTCACTATGTCTGCGGAGTCAGCA
 20 TGTACGCCAGCGTCTGCTTATCACGGCCATGAGTCTAGACCGCTCACTGGCGGT
 GGCCCGCCCCCTTTGTGTCCCAGAAGCTACGCACCAAGGCGATGGCCCGGCGGGT
 GCTGGCAGGCATCTGGGTGTTGTCCTTTCTGCTGGCCACACCCGTCTCGCGTAC
 CGCACAGTAGTGCCCTGGAAAACGAACATGAGCGTGTGCTTCCCGCGGTACCCC
 AGCGAAGGGCACCGGGCCTTCCATCTAATCTTCGAGGCTGTCACGGGCTTCCTGC
 25 TGCCCTTCTGGCTGTGGTGGCCAGCTACTCGGACATAGGGCGTTCGGCTACAGGC
 CCGGCGCTTCCGGCCGACGCCGCCGACCGGCCGCTGGTGGTGTCTATCATCCTG
 ACCTTCGCCGCTTCTGGCTGCCCTACCACGTGGTGAACCTGGCTGAGGCGGGCC
 GCGCGCTGGCCGGCCAGGCCGCCGGGTAGGGCTCGTGGGGAAGCGGCTGAGCC
 TGGCCCGCAACGTGCTCATCGTACTCGCCTTCTGAGCAGCAGCGTGAACCCCGT
 30 GCTGTACGCGTGCGCCGGCGGGCCTCGTGCGCTCGGCGGGCGTGGGCTTCGTC
 GCCAAGCTGCTGGAGGGCACGGGCTCCGAGGCGTCCAGCACGCGCCGCGGGGGC
 AGCCTGGGCCAGACCGCTAGGAGCGGCCCGCCGCTCTGGAGCCCGGCCCTTCC
 GAGAGCCTCACTGCCTCCAGCCCTCTCAAGTTAAACGAACTGAACCTAGGCCTGGT
 GGAAGGAGGCGCACTTTCCTCCTGGCAGAATGCTAGCTCTGAGCCAGTTCAGTAC
 35 CTGGAGGAGGAGCAGGGGCGTGGAGGGCGTGGAGGGCGTGGGAGCGTGGGAGG
 CGGGAGTGGAGTGGAAGAAGAGGGAGAGATGGAGCAAAGTGAGGGCCGAGTGA
 GAGCGTGCTCCAGCCTGGCTCCCACAGGCAGCTTTAACCATTAAACTGAAGTCT
 GAAATTTGGTCAAAAAAAAAAAAAA

40 SEQ ID NO: 209

>gi|2196448|dbj|D89078.1|D89078 Homo sapiens mRNA for leukotriene b4 receptor,
 complete cds

GCCATTCTCTCACATCCCGTGCGGTCAGGAAGCCCTTCTGAACTCTGACTTCAG
 TTCTTGCTGCGGTTTCTGCCCATTCTTTTTCATATCCTCTGACAGCTGCGAGGTCAT
 45 CTCTGCTCTGGCTTTTCTCCAAGCAGAACAAGTGGGGGCTCTGGAAAGGTAAAG
 GACCTCAGTGGCCACCATTAATACTTTGCATCTTTCCTGAGAAGTGAGAGTTGAAA
 GGGAAGCAGGAAGGCCCATGGTCAGATTGAAGGAAGGACTTTTTAGTTTCTTTTT
 TTTTTTTTTGAAATGGAGTCTCGCTCTGTCAATTCAGGCTGGAGTGCAGTGGTGC
 TCTCAGCTCACTGCAGCCTCCACTTCCTGGGTTACATGATTCTCCTGCCTCAGCC

TCCCAAGTAGCTGAGACTACAGGCACATGCCACTACACCCAGCTAACTTTTGTAT
TTTTAGTAGAGACGGGGTTTCACCATGTTGGCCAGGCTGGTCTCAAACCTGCTAAC
ATCAAGTGATCTGCTCCCCTCAGCCTCCCAAAGTGCTGGGATTACCGGTATGAAC
CACCACAACCTGCCAGGAATTTTTAGTTTTTAGCTTTTGCAGGAGACTTCAAGGA
5 AAGGAGACATTCTCTGTCCAGGAAACGGGTAAGGGGACCATTCTGCAATTGCTG
GTTTCCCCTCTTGGCAGGGTGGGCATGAGGCATCACTGTTCTGCTCCCTCACTCC
TGCTCCTCATGCTCAGCCTGCCAGCTCGGCCTCAACTTTGTGTGTCTAAAGTGGA
ACTGAATAGTAGCTGTGAGAAGATAGGAAAGAGGTAGTGCCAATCTCCTTGCCC
AGATCATAAATCCAGACTCAGCAGGGTAACCACATGGGCAAGCACAAGGTAGGT
10 GCTTGGGGAAAGGGGAAGTAATTGGCATTCTGTGTGATACCAAGGAGACCATT
GGATTTTGGCTTCTACCAAAGAGAATGGAGAATTGGTTGACCTAAATGGAACCA
GTCCCTTTAAGTAAGGGGAGGAAAGGGGGTGCTGGAAGATGGCCCTCTTCCCAC
CACCTAGATCATAGCTTGAAGTGAAGCCAAGGACAGAGTGCTGCCCCCTTCGGC
ATTTACTGATGTGCCCTCTTTAAATCATGATGTTATCTAACCCTAAACCCAGACCC
15 AGGACCTAGTCACAGCTCCAACCTACACTTCCTATTAATCTTAAACAAAGCGAA
ACAAACACAAAAAGATATCAGCATTGTAGCCTCCAATCTGAGCCCATTTCCCTTC
TCTGGCTACCATACTCCTTCTCCTATATGATACCATTCACACTTTTGTCAATTA
TCCAGTCTAGACCTGCATCTTGAGGCCACACCCAGCCTTCTCACTCCCCACACCC
CTCTTTCCTCTCTCACTGCTCCTTCCTGGTCTCTTCTCATCTGGCCCCACCTCTAAG
20 GAGTCCTCCTGCCTTCTGGGTTGCCCTGGAAAACAGACTATCCCCCTCCTAGTG
AAGGGAGTGGGTAGGGGTTTCAGCCCCACCCTCAGGAAGATGCGTCTTCCCTGTC
CTCTGCTCTGTGGTACTTCCTCTCTGGCTGATTTAGCAAACAGCACCTAGACCTGG
GGCCAGGCCTTTGGCAGTGGGACAGATCCAGGGATAGGCTACACACCCCTGCCC
TGACCCTGGGATTGGCATCAGCTTCCAACCAAGTTCCTGCCAAAGCTTGTAAGTCC
25 TCCCGACGGCCATGAACACTACATCTTCTGCAGCACCCCCCTCACTAGGTGTAGA
GTTTCATCTCTCTGCTGGCTATCATCCTGCTGTGAGTGGCGCTGGCTGTGGGGCTTC
CCGGCAACAGCTTTGTGGTGTGGAGTATCCTGAAAAGGATGCAGAAGCGCTCTG
TCACTGCCCTGATGGTGTGAACCTGGCCCTGGCCGACCTGGCCGTATTGCTCAC
TGCTCCCTTTTTCCTTCACTTCCTGGCCCAAGGCACCTGGAGTTTTGGACTGGCTG
30 GTTGCCGCCTGTGTCACTATGTCTGCGGAGTCAGCATGTACGCCAGCGTCCTGCT
TATCACGGCCATGAGTCTAGACCGCTCACTGGCGGTGGCCCGCCCCTTTGTGTCC
CAGAAGCTACGCACCAAGGCGATGGCCCGGCGGGTGCTGGCAGGCATCTGGGTG
TTGTCTTTCTGCTGGGACACCCGTCCTCGCGTACCGCACAGTAGTGCCCTGGA
AAACGAACATGAGCCTGTGCTTCCCGCGGTACCCAGCGAAGGGCACCGGGCCT
35 TCCATCTAATCTTCGAGGCTGTACGGGCTTCCTGCTGCCCTTCCTGGCTGTGGTG
GCCAGCTACTCGGACATAGGGCGTCGGCTACAGGCCCGGCGCTTCCGCCGACG
CGCCGCACCGGCCCGCTGGTGGTGTCTATCATCCTGACCTTCGCCGCCTTCTGGC
TGCCCTACCACGTGGTGAACCTGGCTGAGGCGGGCCGCGCGCTGGCCGGCCAGG
CCGCCGGGTAGGGCTCGTGGGGAAGCGGCTGAGCCTGGCCCGCAACGTGCTCA
40 TCGCACTCGCCTTCCTGAGCAGCAGCGTGAACCCCGTGCTGTACGCGTGCGCCG
CGGCGGCCTGCTGCGCTCGGCGGGCGTGGGCTTCGTGCGCAAGCTGCTGGAGGG
CACGGGTTCGAGGCGTCCAGCACGCGCCGCGGGGGCAGCCTGGGCCAGACCGC
TAGGAGCGGCCCCGCGCTCTGGAGCCCGGCCCTTCGAGAGCCTCACTGCCTCC
AGCCCTCTCAAGTTAAACGAAGTGAAGTGAAGGAGGAGGAGGAGGAGGAGGAGG
45 CCTCCTGGCAGAATGCTAGCTCTGAGCCAGTTCAGTACCTGGAGGAGGAGCAGG
GGCGTGGAGGGCGTGGAGGGCGTGGGAGCGTGGGAGGCGGGAGTGGAGTGGAA
GAAGAGGGAGAGATGGAGCAAAGTGAGGGCCGAGTGAGAGCGTGCTCCAGCCT
GGCTCCCACAGGCAGCTTTAACCATTAAACTGAAGTCTGAA

SEQ ID NO: 210

>gi|521217|gb|M27602.1|HUMTRPSGNB Human pancreatic trypsinogen (TRY2) mRNA,
complete cds

5 AACACCATGAATCTACTCCTGATCCTTACCTTTGTTGCAGCTGCTGTTGCTGCCCC
CTTTGATGATGATGACAAGATCGTTGGGGGCTACATCTGTGAGGAGAATTCTGTC
CCCTACCAGGTGTCCTTGAATTCTGGCTACCACTTCTGCGGTGGCTCCCTCATCAG
CGAACAGTGGGTGGTGTGTCAGCAGGTCACTGCTACAAGTCCCGCATCCAGGTGAG
ACTGGGAGAGCACAAACATCGAAGTCCTGGAGGGGAATGAACAGTTTCATCAATGC
GGCCAAGATCATCCGCCACCCCAAATACAACAGCCGGACTCTGGACAATGACAT
10 CCTGCTGATCAAGCTCTCCTCACCTGCCGTCATCAATTCCCGCGTGTCCGCCATCT
CTCTGCCCCTGCCCCCTCCAGCTGCTGGCACCGAGTCCCTCATCTCCGGCTGGGG
CAACACTCTGAGTTCTGGTGCCGACTACCCAGACGAGCTGCAGTGCCTGGATGCT
CCTGTGCTGAGCCAGGCTGAGTGTGAAGCCTCCTACCCTGGAAAGATTACCAACA
ACATGTTCTGTGTGGGCTTCCTCGAGGGAGGCAAGGATTCTGCCAGGGTGATTCT
15 TGGTGGCCCTGTGGTCTCCAATGGAGAGCTCCAAGGAATTGTCTCCTGGGGCTAT
GGCTGTGCCCAGAAGAACAGGCCTGGAGTCTACACCAAGGTCTACAACATATGTG
GACTGGATTAAGGACACCATAGCTGCCAACAGCTAAAGCCCCCAGTCCCTCTGC
AGTCTCTATACCAATAAAGTGACCCTGCTCTCAC

20 SEQ ID NO: 211

>gi|186262|gb|M24594.1|HUMII56KD Human interferon-inducible 56 Kd protein mRNA,
complete cds

25 CCAGATCTCAGAGGAGCCTGGCTAAGCAAAACCCCTGCAGAACGGCTGCCTAATT
TACAGCAACCATGAGTACAAATGGTGATGATCATCAGGTCAAGGATAGTCTGGA
GCAATTGAGATGTCACTTTACATGGGAGTTATCCATTGATGACGATGAAATGCCT
GATTTAGAAAACAGAGTCTTGGATCAGATTGAATTCCTAGACACCAAATACAGT
GTGGGAATACACAACCTACTAGCCTATGTGAAACACCTGAAAGGCCAGAATGAG
GAAGCCCTGAAGAGCTTAAAAGAAGCTGAAAACCTTAATGCAGGAAGAACATGAC
AACCAAGCAAATGTGAGGAGTCTGGTGACCTGGGGCAACTTTGCCTGGATGTATT
30 ACCACATGGGCAGACTGGCAGAAGCCCAGACTTACCTGGACAAGGTGGAGAACA
TTTGCAAGAAGCTTTCAAATCCCTTCCGCTATAGAATGGAGTGTCCAGAAATAGA
CTGTGAGGAAGGATGGGCCTTGCTGAAGTGTGGAGGAAAGAATTATGAACGGGC
CAAGGCCTGCTTTGAAAAGGTGCTTGAAGTGGACCCTGAAAACCCCTGAATCCAG
CGCTGGGTATGCGATCTCTGCCATCGCCTGGATGGCTTTAAATTAGCCACAAAA
35 AATCACAAGCCATTTTCTTTGCTTCCCCTAAGGCAGGCTGTCCGCTTAAATCCAG
ACAATGGATATATTAAGGTTCTCCTTGCCCTGAAGCTTCAGGATGAAGGACAGGA
AGCTGAAGGAGAAAAGTACATTGAAGAAGCTCTAGCCAACATGTCCTCACAGAC
CTATGTCTTTCGATATGCAGCCAAGTTTTACCGAAGAAAAGGCTCTGTGGATAAA
GCTCTTGAGTTATTAAGGCTTGCAGGAAACACCCACTTCTGTCTTACTGC
40 ATCACCAGATAGGGCTTTGCTACAAGGCACAAATGATCCAAATCAAGGAGGCTA
CAAAAGGGCAGCCTAGAGGGCAGAACAGAGAAAAGCTAGACAAAATGATAAGA
TCAGCCATATTTCAATTTTGAATCTGCAGTGGAAGAAAAGCCCACATTTGAGGTGG
CTCATCTAGACCTGGCAAGAATGTATATAGAAGCAGGCAATCACAGAAAAGCTG
AAGAGAATTTTCAAAAATTGTTATGCATGAAACCAAGTGGTAGAAGAAACAATGC
45 AAGACATACATTTCTACTATGGTCGGTTTCAGGAATTTCAAAAAGAAATCTGACGT
CAATGCAATTATCCATTATTTAAAAGCTATAAAAATAGAACAGGCATCATTAACA
AGGGATAAAAAGTATCAATTCTTTGAAGAAATTGGTTTTAAGGAAACTTCGGAGA
AAGGCATTAGATCTGGAAAGCTTGAGCCTCCTTGGGTTTCGTCTATAAATTGGAAG
GAAATATGAATGAAGCCCTGGAGTACTATGAGCGGGCCCTGAGACTGGCTGCTG

ACTTTGAGAACTCTGTGAGACAAGGTCCTTAGGCACCCAGATATCAGCCACTTTC
ACATTTTCATTTTCATTTTATGCTAACATTTACTAATCATCTTTTCTGCTTACTGTTTT
CAGAAACATTATAATTCAGTGTAAATGATGTAATTCTTGAATAATAAATCTGACAA
AATATT

5

SEQ ID NO: 212

>1442951T6

AAGAGACATGAGACAACCACTGAGAACCAGCCACCCGGAGCTCAGTTTCTGCTA
CAGAGCACCTCCTCTTCAACGAATCACTGGATAACCATTGGAGAGCAAGTCACTGT
10 TGTGTAAGCAGCAGAGCTGGAGGTGCTGTCAAGAGTCTCAGCAGACTCATTGGC
CAGATGCACCGAACTCAATGAGGCACCTTAGAGATGAGAAACGATCTGTACTGGG
ATTTCCCAGCAGAAGAGACTTTGGTTTTTGTTCATCCTGAAGTTGCCACTCCACCA
CCAGTTTTATAGAGGGATATTCGCTTTTCACTGGTAGTTTATTTCAGGTAGCTATAG
GTCTTGTCTTTTTGGATAGGGCAGTTAATTCCACTCTTACAACCATCAGGCTCAGG
15 AATGGGAAAGGGAACTGGGACGCCCATCAGGATGCCATGCACCACGGCCTTGCT
GCTTTTAGACTGAATATTGCTGGTGAAGGTGACATTGACGCTGTAAGACTGTCCT
TTGCTCAGCTGGCAGGGTTTGGTGGGGCATGGGGCTCACATTCAGTTCCTTTATA
A

20 SEQ ID NO: 213

>gi|2216521|gb|AA486305.1|AA486305 ab35c01.r1 Stratagene HeLa cell s3 937216 Homo sapiens cDNA clone IMAGE:842784 5' similar to gb:X60036 MITOCHONDRIAL

PHOSPHATE CARRIER PROTEIN PRECURSOR (HUMAN);, mRNA sequence

GTCTTAAGTTGTGGTCTGAGACACACTGCTGTGGTTCCCCTGGATTTAGTGAAAT
25 GCCGTATGCAGGTGGACCCCCAAAAGTACAAGGGCATATTAAACGGATTCTCAG
TTACACTTAAAGAGGATGGTGTTCGTGGTTTGGCTAAAGGATGGGCTCCGACTTT
CCTTGGCTACTCCATGCAGGGACTCTGCAAGTTTGGCTTTTATGAAGTCTTTAAA
GTCTTGTATAGCAATATGCTTGGAGAGGAGAATACTTATCTCTGGCGCACATCAC
TATATTTGGCTGCCTCTGCCAGTGCTGAATTCCTTGCTGACATTGCCCTGGCTCCT
30 ATGGAAGCTGCTAAGGTTTCAATTCAAACCCAGCCAGGTTATGCCAACACTTTGA
GGGATGCAGCTCCCAAATGTATAAGGAAGAAGGCCTAAAAGCATTCTACAAGG
GGGTTGCTCCTCTCTGGATGAGACAGATAACATACACCATGATGAAGTTCGCTG
CTTTG

35 SEQ ID NO: 214

>gi|186620|gb|M59373.1|HUMJTK2 Human tyrosine kinase (JTK2) mRNA, partial cds

ACCGGGACCTGGCTGCCCCGAATGTGCTGGTGAAGTGAAGACAATGTGATGAAGA
TTGCTGACTTTGGGCTGGCCCGCGGCCTCCACCACATTGACTACTATAAGAAAAC
CAGCAACGGCCGCTGCCTGTGAAGTGGATGGCGCCCGAGGCCTTGTTTGACCG
40 GGTGTACACACACCAGAGTGACGTGTGGTCCTT

SEQ ID NO: 215

>gi|1527336|gb|AA047666.1|AA047666 zf14b02.s1 Soares_fetal_heart_NbHH19W Homo sapiens cDNA clone IMAGE:376875 3' similar to gb:M64082 DIMETHYLANILINE

45 MONOOXYGENASE (HUMAN);, mRNA sequence

ATAAGTAAAAGATCTCCTAAATGGAAGATGCACAGAGTAGATTTACAATGCTCC
AATTCCTCTCTTACAGCAATATTGCCTTCACAGTTATAAACTGTATTCAAATAGTA
AAGGTCACCCTCTCGCTTCCCTGGCTGGCCCCAGGGCTACCACTGGTATTCTCTGA
GCCTCTCCCAGCTCCACTTCTAATGCTAGAGAATGATAACTAAGATTTCTGTGCA

TTTGAAGGTTGTTGGAAAGTTACAGGTTTATTTTAGAAAGAAANGCTGTTCTTGA
CAGCACTCCTGAGCCATCATACCTCTTTCCCATATAAACTATTTTCACAGATCTCA
ACTAAAACCCCTTNACTTTCACAAAATGGATTGTGGTTGGTGCTGGAAATGGTGC

5 SEQ ID NO: 216

>gi|2218571|gb|AA488969.1|AA488969 aa55h08.r1 NCI_CGAP_GCB1 Homo sapiens
cDNA clone IMAGE:824895 5', mRNA sequence

GACTACAACGTGGCCCTTCAGAGATCGCGGATGGTCGCACGATCCTCCGACACA
GCTGGGCCTTCATCCGTACAGCAGCCACATGGGCATCCCACCAGCAGCAGGCCT
10 GTGAACAAACCTCAGTGGCATAAACCGAACGAGTCTGACCCGCGCCTCGCCCCCTT
ATCAGTCCCAAGGGTTTTCCACCGAGGAGGATGAAGATGAACAAGTTTCTGCTGT
TTGAGGCACAGACTTTTCTGGAAGCAGAGCGNGCCACCTGAAAGGAGAGCACAA
GAAGACGTCTTGAGCATTGGAGCCTTGGAATCACATTCTGAGGACGGTGGACC
AGTTTGCCTCCTTCCCTGCCTTAAAAGCAGCATGGGGCTTCTTCTCCCTTCTTCC
15 TTTCCCTTTGTCATGTGAAATACTGTGAAGAAATTGCCCTGGCACTTTTCAGACTT
TGTTGCTTGAAATGCACAGTGCAGCAATCTTCGAGCT

SEQ ID NO: 217

>gi|588224|gb|I09069.1| Sequence 5 from Patent WO 8809376

20 GTCCCGAGCGCGAGCGGAGACGATGCAGCGGAGACTGGTTCAGCAGTGGAGCGT
CGCGGTGTTCTGTGAGCTACGCGGTGCCCTCCTGCGGGCGCTCGGTGGAGGGT
CTCAGCCGCGCCTCAAAAGAGCTGTGTCTGAACATCAGCTCCTCCATGACAAGG
GGAAGTCCATECAAGATTTACGGCGACGATTTCTCCTTCACCATCTGATCGCAGA
AATCCACACAGCTGAAATCAGAGCTACCTCGGAGGTGTCCCCTAACTCCAAGCCC
25 TCTCCCAACACAAAGAACCACCCCGTCCGATTTGGGTCTGATGATGAGGGCAGAT
ACCTAACTCAGGAACTAACAAGGTGGAGACGTACAAAGAGCAGCCGCTCAAGA
CACCTGGGAAGAAAAAGAAAGGCAAGCCCGGGAACGCAAGGAGCAGGAAAAG
AAAAAACGGCGAACTCGCTCTGCCTGGTTAGACTCTGGAGTGAAGTGGGAGTGGG
CTAGAAGGGGACCACCTGTCTGACACCTCCACAACGTCGCTGGAGCTCGATTAC
30 GGAGGCATTGAAATTTTCAGCAGAGACCTTCCAAGGACATATTGCAGGATTCTGT
AATAGTGAACATATGGAAAGTATTAGAAATATTTATTGTCTGTAAATACTGTAAA
TGCATTGGAATAAACTGTCTCCCCCATTGCTCTATGAAACTGCACATTGGTCAT
TGTGAATATTTTTTTTTTTTGCCAAAGGCTAATCCAATTATTATTATCACATTTACCA
TAATTTATTTTGTCCATTGATGTATTTATTTTGTAAATGTATCTTGGTGCTGCTGA
35 ATTTCTATATTTTTTGTAAACATAATGCACTTTAGATATACATATCAAGTATGTTGA
TAAATGACACAATGAAGTGTCTCTATTTTGTGGTTGATTTTAATGAATGCCTAAA
TATAATTATCCAAATTGATTTTCTTCGTGCATGTAAAAATAACAGTATTTTAAAT
TTGTAAAGAATGTCTAATAAAATATAATCTAATTAC

40 SEQ ID NO: 218

>gi|182891|gb|M63904.1|HUMGA16 Human G-alpha 16 protein mRNA, complete cds

TGTTCCCAGCACTCAAGCCTTGCCACCGCCGAGCCGGGCTTCCTGGGTGTTTCAG
GCAAGGAAGTCTAGGTCCCTGGGGGGTGACCCCAAGGAAAAGGCAGCCTCCCT
GCGCACCCGGTTGCCCGGAGCCCTCTCCAGGGCCGGCTGGGCTGGGGGTTGCCCT
45 GGCCAGCAGGGGCCCCGGGGGCGATGCCACCCGGTGCCGACTGAGGCCACCGCAC
CATGGCCCGCTCGCTGACCTGGCGCTGCTGCCCTGGTGCTGACGGAGGATGAG
AAGGCCGCCGCCGGGTGGACCAGGAGATCAACAGGATCCTCTTGAGCAGAAG
AAGCAGGACCGCGGGGAGCTGAAGCTGCTGCTTTTGGGCCCAGGCGAGAGCGGG
AAGAGCACCTTCATCAAGCAGATGCGGATCATCCACGGCGCCGGCTACTCGGAG

GAGGAGCGCAAGGGCTTCCGGCCCCCTGGTCTACCAGAACATCTTCGTGTCCATGC
GGGCCATGATCGAGGCCATGGAGCGGCTGCAGATTCCATTTCAGCAGGCCCGAGA
GCAAGCACACGCTAGCCTGGTCATGAGCCAGGACCCCTATAAAGTGACCACGT
TTGAGAAGCGCTACGCTGCGGCCATGCAGTGGCTGTGGAGGGATGCCGGCATCC
5 GGGCCTGCTATGAGCGTCGGCGGGAATTCACCTGCTCGATTTCAGCCGTGTACTA
CCTGTCCCACCTGGAGCGCATCACCGAGGAGGGCTACGTCCCCACAGCTCAGGA
CGTGCTCCGCAGCCGCATGCCACCACTGGCATCAACGAGTACTGCTTCTCCGTG
CAGAAAACCAACCTGCGGATCGTGGACGTCGGGGGCCAGAAAGTCAGAGCGTAAG
AAATGGATCCATTGTTTCGAGAACGTGATCGCCCTCATCTACCTGGCCTCACTGA
10 GTGAATACGACCAGTGCCTGGAGGAGAACAACCAGGAGAACC GCATGAAGGAG
AGCCTCGCATTGTTTGGGACTATCCTGGAACCTACCCTGGTTCAAAAGCACATCCG
TCATCCTCTTTCTCAACAAAACCGACATCCTGGAGGAGAAAATCCCCACCTCCCA
CCTGGCTACCTATTTCCCCAGTTTCCAGGGCCCTAAGCAGGATGCTGAGGCAGCC
AAGAGGTTTCATCCTGGACATGTACACGAGGATGTACACCGGGTGCGTGGACGGC
15 CCCGAGGGCAGCAAGAAGGGCGCACGATCCCGACGCCTTTTCAGCCACTACACA
TGTGCCACAGACACACAGAACATCCGCAAGGTCTTCAAGGACGTGCGGGACTCG
GTGCTCGCCCGCTACCTGGACGAGATCAACCTGCTGTGACCCAGGCCCCACCTGG
GGCAGGCGGCACCGGCGGGCGGGTGGGAGGTGGGAGTGGCTGCAGGGACCCTA
GTGTCCTGGTCTATCTCTCCAGCCTCGGCCACACGCAAGGGAGTCGGGGGACGG
20 CCCGCTGCTGGCCGCTCTCTTCTCTGCCTCTCACCAGGACAGCCGCCCCCAGGG
TACTCCTGCCCTTGCTTGACTCAGTTTCCCTCCTTTGAAAGGGAAGGAGCAAAAC
GGCCATTTGGGATGCCAGGGTGGATGAAAAGGTGAAGAAATCAGGGGATTGAGA
CTTGGGTGGGTGGGCATCTCTCAGGAGCCCCATCTCCGGGCGTGTCAECTCCTGG
GCAGGGTTCTGGGACCCTCTGTGGGTGACGCACACCCTGGGATGGGGCTAGTAG
25 AGCCTTCAGGCGCCTTCGGGCGTGGACTCTGGCGCACTCTAGTGGACAGGAGAA
GGAACGCCTTCCAGGAACCTGTGGACTAGGGGTGCAGGGACTTCCCTTTGCAAG
GGGTAACAGACCGCTGGAACAACTGTCACTTTTCAGAGCTCGGTGGCTCACAGC
GTGTCCTGCCCCGTTTTCGGACGAGAGAAATCGCGGCCACAAGCATCCCCAT
CCCTTGACAGGCTGGGGGCTGGGCATGCTGCATCTTAACCTTTTGTATTTATTCCT
30 CACCTTCTGCAGGGCTCCGTGCGGGCTGAAATTAAAGATTCTTAG

SEQ ID NO: 219

>gi|1056573|gb|H78484.1|H78484.yu12d08.r1 Soares fetal liver spleen 1NFLS Homo
sapiens cDNA clone IMAGE:233583 5' similar to gb:X59770 INTERLEUKIN-1

35 RECEPTOR, TYPE II PRECURSOR (HUMAN);, mRNA sequence
GGATGGGAGATACTGTTGTGGTCACCTCTGGAAAATACATTCTGCTACTCTTAAA
AACTAGTGACGCTCATACAAATCAACAGAAAGAGCTTCTGAAGGAAGACTTTAA
AGCTGCTTCTGCCACGTGCTGCTGGGTCTCAGTCCTCCACTTCCCGTGTCTCTGG
AAGTTGTCAGGAGCAATGTTGCGCTTGACGTGTTGGTAATGGGAGTTTCTGCCT
40 TCACCCTTCAGCCTGCGGCACACACAGGGGCTGCCAGAAGCTGCCGGTTTTCGTGG
GAGGCATTACAAGCGGGAGTTCAGGCTGGAAGGGGAGCCTGTAGCCCTGAGGTG
CCCCAGGTGCCCTACTGGTTGTGGGGCCTCTGTTTCAGCCCCCGCATCAACCTNA
ACATGGGCATTAAAAATTGACTCTTNTTAGGGACGGTCCCAGGGAGTAAGAAGN
AGACACGGATGTGGGTCCCAGGGACGGTTNCG

45

SEQ ID NO: 220

>3386358H1

GCCGCGCTACCAGATTGCACCGGGGCTGATTTGGGGGCTGGGAATTTGCCATTCT
GCTGTACAGACACTGATTTTTTTTTCTTCTTTTTAAAAAGCAAGATTTTAGGTGAT

GGGCAAGTCAGAAAGTCAGATGGATATAACTGATATCAACACTCCAAAGCCAAA
GAAGAAACAGCGATGGACTCCACTGGAGATCAGCCTCTCGGTCCTTGTCTGCTC
CTCACCATCATAGCTGTGACAATGATC

5 SEQ ID NO: 221

>gi|759483|gb|R07560.1|R07560 ye97g06.r1 Soares fetal liver spleen 1NFLS Homo sapiens
cDNA clone IMAGE:125722 5' similar to SP:DEOK_HUMAN P27707 DEOXYCYTIDINE
KINASE ;, mRNA sequence

10 ATGGCCGCGGCACNCTNCTTTCTAAGTCGGCTTCGAGCACCCCTTCAGTTCATGG
CCAAGAGCCCCTCGAGGGCGTTTCTCTCCAGAGGCCTGCACGCGGGGCGNGG
CCCANANGGCTTCTCCATCGAAGGCAACATTGGCCTGCACTGCCCAAAGTCTTG
AACTTGCTGGATATGATGTACCGGGAGCCAGCACGATGGTCCTACACATTCCAG
ACATTTTCTTTTGTAGCCGCCTGAAAGTACAGCTGGGAGCCCTTCCCTGAGGAA
ACTCTTTACAGGGCCAGGGAAGCCAGTTACAGATCTTTTGAGGAGGTCTGTGTAA
15 CAGTGGACAGGGTTCCATTTTGTAGGGTTTGGATGGAACATTTCC

SEQ ID NO: 222

>4730434H1

20 GCTGGGAGAAGCAGGAATCTGCGCTCGGGTTCCGCAGATGCAGAGGTTGAGGTG
GCTGCGGGACTGGAATCATCGGGCAGAGGTCTCACAGCAGCCAAGGAACCTGG
GGCCCGCTCCTCCCCCTCCAGGCCATGAGGATTCTGCAGTTAATACTGCTTGCT
CTGGCAACAGGGCTTGTAGGGGGAGAGACCAGGATCATCAAGGGGTTGAGTGC
AAGCCTCACTCCCAGCCCTGGCAGGCAGCCCTGTTGAGAAAGACGC

25 SEQ ID NO: 223

>gi|815554|gb|R53652.1|R53652 yg84c05.r1 Soares infant brain 1NIB Homo sapiens cDNA
clone IMAGE:40056 5' similar to SP:PGG2_RAT Q00657 CHONDROITIN SULFATE
PROTEOGLYCAN NG2 ;, mRNA sequence

30 AGGGCGAGGTGGTCTTTGCCTTACCAACTTCTCCTCCTCTCATGACCACTTCAGA
GTCCTGGCACTGGCTAGGGGTGTCAATGCATCAGCCGTAGTGAACGTCACTGTGA
GGGCTCTGCTGCATGTGTGGGCAGGTGGGCCATGGCCAGNGGTGCCACCCTGCG
CCTGGACCCACCGTCCTAGATGCTGGCGAGCTGGCCAACCGCACAGGCAGTGT
GCCGCGCTTCCGCCTCCTGGAGGGACCCGGGATGGCCCGNTGGTCCGCGTGCCC
CGAGCCAGGACGGAGCCCGGGGGAAGCCAGCTGGTGGAGCAGTTCACTNAGCA
35 GGACCTTGAGGACGGGAGGCTNNGGCTGGAGGTGGGCAGGCCAGAGGGGAGGG
CCCCCGGCCGNCAGGTGNACAATTCTCAATTTTNGAGCTTTTNGGGCAC

SEQ ID NO: 224

40 >gi|2051920|gb|AA398883.1|AA398883 zt64f10.s1 Soares testis_NHT Homo sapiens cDNA
clone IMAGE:727147 3' similar to gb:S66896 SQUAMOUS CELL CARCINOMA
ANTIGEN (HUMAN);, mRNA sequence

TATGTCACTATTTTATTGATGATGTGTTTTATAGAATCACAAAATTTAGAAACATA
AGAAGGATTTAGGTATCACCTAAATTCAAAGAAATGTGTGTTTCTAGGTTGCTAA
ATTCAAAGAAAAAGTATGATTTGGTTTGGTTCATTTAAAACAGGTCACAAACAGA
45 ATTATATTTCAAATTTAGAAGATACGGTATTAAGTGATTCATCTTATTTTGGACAT
TTTTCTCAAGGAGAATTTTCTGGAAGAAAAAGTACATTTATATGTGGGCTTAT
TAAGAGAAAGAGAGAAAGGCATGCTATTTTAATCATTAATTTCTTGATGATGAC
GATCATCATCAAGATGAGAAAGAAAGAAATATGAGCCAAGAGAATCTGTTGTT
GCCAGCAATCAGTTTACCAGAACATCTGCAGGTGAACATTTTCCAAATGGAGTGA

CAGACTAATTGCATCTACGGGGATGAGAATCTGCCATAGAGAGGATGCTGTGGG
CTTATTTTGCTTATGTAGATAGGAAGGGTGATACATGGA

SEQ ID NO: 225

5 >gi|2432448|gb|AA598776.1|AA598776 ae38a04.s1 Gessler Wilms tumor Homo sapiens
cDNA clone IMAGE:898062 3' similar to TR:G468032 G468032 P55CDC.; mRNA
sequence
AAAAAAAAAACATGAAGGGAGACATGACTTTATTAGAAAAATAAAAAACAAC
GAGGTGATGGGTTGGTCTTCAGCGGATCCTTGGTGGATGAGGCTGCTTTTGGCTG
10 CACTGGCCTTCTCCCGCTCCCGCCGCCGCGCAGGGTCCAACCTCAAACAGCGCCA
TAGCCTCAGGGTCTCATCTGCTGCTGCGGATGCCACTGTGGCCCCATCTGGGCTC
ATGGTCAGACTCAGGACCCGGGATGTGTGACCTTTGAGTTCAGCCACCTTGGCCA
TGGTTGGGTACTTCCAAATAACTAGCTGATTCTGTGCAAAGCCATGGCCTGAGAT
GAGCTCCTTGTAAGGGGGAGACCAGAGGATGGAGCACACCTGGGAATGGGCATC
15 CACGGCACTCAGACAGGCCCCAGAGCAAAAATTCCAGATGCGAATGTGTGATC
ACTGGTGCACCCTCCTGTGGCAAGGACATTTGA

SEQ ID NO: 226

20 >gi|2102846|gb|AA423867.1|AA423867 zv79f01.s1 Soares_total_fetus_Nb2HF8_9w Homo
sapiens cDNA clone IMAGE:759865 3', mRNA sequence
TTTTCATTTTTGAGTAATTTATTTAAATTTGTGAATCTAGAAAATGTGTGTTATA
TATTTATATACAGGGAATAACAAAAGTTAAGTGTTTAATTGGAAAGAAAACCTGT
GACTGATAATATGTTGTAATTACCATTTTATAATATTACTTTCCATTGCAATGACT
TAAAATGAAGAAATAAGAATAGGAATAATTATGCTAACAAATTCACTTTGTTTTT
25 TGTGCCACTAAATTTCTTTAGGATCAAGAACTCTTTCATATTTCAGACATTAAACA
ATATTCAAATAATTTTATAAAATAGACATACAAGTTTACTCATATTAATAAAAAACA
AGTTGATTTTCATTTCTCTGTA

SEQ ID NO: 227

30 >gi|3087789|emb|Y14734.1|HSY14734 Homo sapiens mRNA for cathepsin L2
CGGCTGTAATCTCAGAGGCTTGTTTGCTGAGGGTGCCTGCGCACGTGCGACGGCT
GCTGGTTTTGAAACATGAATCTTTCGCTCGTCTGGCTGCCTTTTGCTTGGGAATA
GCCTCCGCTGTTCCAAAATTTGACCAAATTTGGATACAAAGTGGTACCAGTGGA
AGGCAACACACAGAAGATTATATGGCGCGAATGAAGAAGGATGGAGGAGAGCA
35 GTGTGGGAAAAGAATATGAAAATGATTGAACTGCACAATGGGGAATACAGCCAA
GGGAAACATGGCTTCACAATGGCCATGAATGCTTTTCCTGACATGACCAATGAAG
AATTCAGGCAGATGATGGGTTGCTTTTCGAAACCAGAAATTCAGGAAGGGGAAAG
TGTTCCGTGAGCCTCTGTTTCTTGATCTTCCCAAATCTGTGGATTGGAGAAAGAA
AGGCTACGTGACGCCAGTGAAGAATCAGAAACAGTGTGGTTCCTTGTGGGCTTTT
40 AGTGCGACTGGTGCTCTTGAAGGACAGATGTTCCGGAAAACCTGGGAAACTTGTCT
CACTGAGCGAGCAGAATCTGGTGGACTGTTTCGCGTCCTCAAGGCAATCAGGGCT
GCAATGGTGGCTTCATGGCTAGGGCCTTCCAGTATGTCAAGGAGAACGGAGGCC
TGGACTCTGAGGAATCCTATCCATATGTAGCAGTGGATGAAATCTGTAAGTACAG
ACCTGAGAATTCTGTTGCTAATGACACTGGCTTCACAGTGGTCGCACCTGGAAAG
45 GAGAAGGCCCTGATGAAAGCAGTCGCAACTGTGGGGCCCATCTCCGTTGCTATG
GATGCAGGCCATTCTGCTCTTCCAGTTCTACAAATCAGGCATTTATTTTGAACCAG
ACTGCAGCAGCAAAAACCTGGATCATGGTGTTCCTGGTGGTTGGCTACGGCTTTGA
AGGAGCAAATTCGAATAACAGCAAGTATTGGCTCGTCAAAAACAGCTGGGGTCC
AGAATGGGGCTCGAATGGCTATGTAAAAATAGCCAAAGACAAGAACAACCACTG

TGGAATCGCCACAGCAGCCAGCTACCCCAATGTGTGAGCTGATGGATGGTGAGG
 AGGAAGGACTTAAGGACAGCATGTCTGGGGAAATTTTATCTTGAAACTGACCAA
 ACGCTTATTGTGTAAGATAAACCAAGTTGAATCATTGAGGATCCAAGTTGAGATTT
 TAATTCTGTGACATTTTACAAGGGTAAAATGTTACCACTACTTTAATTATTGTTA
 5 TACACAGCTTTATGATATCAAAGACTCATTGCTTAATTCTAAGACTTTTGAATTTT
 CATTTTTTAAAAAGATGTACAAAACAGTTT

SEQ ID NO: 228

>gi|967948|gb|R93782.1|R93782 yq35f04.r1 Soares fetal liver spleen 1NFLS Homo sapiens
 cDNA clone IMAGE:197791 5', mRNA sequence

10 TGGATTTGGATGCTGCAAAAACGAGACTAAAAAAGGCAAAAGCTGCAGAAACTA
 GAAATTCATCTGAACAGGAATTAAGAATAACTCAAAGTGAATTTGATCGTCAAG
 CAGAGATTACCAGACTTCTGCTAGAGGGAATCAGCAGTACACATGCCCATCACCT
 TCGCTGTCTGAATGACTTTGTAGAAGCCCAGATGACTTACTATGCACAGTGTTAC
 15 CAGTATATGTTGGACCTCCAGAAACAACCTGGGAAGTTTTCCATCCAATTATCTTA
 GTAACAACAATCAGACTTCTGTGACACCTGTACCATCAGTTTTACCAAATGCGAT
 TGGTTCTTCTGCCATGGCTTTCAACAAGTGGCCTAGTAATCACCTCTCCTTCCAAC
 CTCAGTGACCTTAAGGGAGTGTAGTGGGCAGCAGGAAAGGGCCGGGGTTCTCTT
 ATGGATTTATGGATGGCAGCAACAGTACTGGAATTATTCATTCTGGGCAGTTG
 20 AGGGTGATCANTGTGTTTCAAGTGTGTTGGGATGGGATTGAGNTTGGCTAATTGGG
 GGNAAGGGGAACCCNGGAGGGCAAGGTGCCATTA

SEQ ID NO: 229

>2723646H1

25 GTTCCGCAGATGCAGAGGTTGAGGTGGCTGCGGGACTGGAAGTCATCGGGCAGA
 GGTCTCACAGCAGCCAAGGAACCTGGGGCCCGCTCCTCCCCCTCCAGGCCATGA
 GGATTCTGCAGTTAATCCTGCTTGCTCTGGCAACAGGGCTTGTAGGGGGAGAGAC
 CAGGATCATCAAGGGGTTTCGAGTGCAAGCCTCACTCCCAGCCCTGGCAGGCAGC
 CCTGTTTCGAGAAGACGCGGCTACTCTGT

SEQ ID NO: 230

>gi|1335871|gb|U46005.1|HSU46005 Human MDC15 mRNA, complete cds

ATGCGGCTGGCGCTGCTCTGGGCCCTGGGGCTCCTGGGCGCGGGCAGCCCTCTGC
 CTTCTGGCCGCTCCCAAATATAGGTGGCACTGAGGAGCAGCAGGCAGAGTCAG
 35 AGAAGGCCCGAGGGAGCCCTTGGAGCCCCAGGTCCTTCAGGACGATCTCCCAA
 TTAGCCTCAAAAAGGTGCTTCAGACCAGTCTGCCTGAGCCCCTGAGGATCAAGTT
 GGAGCTGGACGGTGACAGTCATATCCTGGAGCTGCTACAGAATAGGGAGTTGGT
 CCCAGGCCGCCCAACCCTGGTGTGGTACCAGCCCGATGGCACTCGGGTGGTCAGT
 GAGGGACACACTTTGGAGAACTGCTGCTACCAGGGAAGAGTGCAGGGGATATGCA
 40 GGCTCCTGGGTGTCCATCTGCACCTGCTCTGGGCTCAGAGGCTTGGTGGTCCTGA
 CCCCAGAGAGAAGCTATACCCTGGAGCAGGGGCCTGGGGACCTTCAGGGTCCTC
 CCATTATTTTCGGAATCCAAGATCTCCACCTGCCAGGCCACACCTGTGCCCTGAG
 CTGGCGGGAATCTGTACACACTCAGACGCCACCAGAGCACCCCTGGGACAGCG
 CCACATTCGCCGGAGGCGGGATGTGGTAACAGAGACCAAGACTGTGGAGTTGGT
 45 GATTGTGGCTGATCACTCGGAGGCCCAGAAATACCGGGACTTCCAGCACCTGCTA
 AACC GCACACTGGAAGTGGCCCTCTTGCTGGACACATTCTTCCGGCCCTGAATG
 TACGAGTGGCACTAGTGGGCCTGGAGGCCTGGACCCAGCGTGACCTGGTGGAGA
 TCAGCCCCAAACCAGCTGTCAACCTCGAAAACCTCCTCCACTGGCGCAGGGCACA
 TTTGCTGCCTCGATTGCCCCATGACAGTGCCAGCTGGTGACTGGTACTTCATTCT

CTGGGCCTACGGTGGGCATGGCCATTGAGAACTCCATCTGTTCTCCTGACTTCTC
AGGAGGTGTGAACATGGACCACTCCACCAGCATCCTGGGAGTCGCCTCCTCCATA
GCCCATGAGTTGGGCCACAGCCTGGGCCTGGACCATGATTTGCCTGGGAATAGCT
GCCCCTGTCCAGGTCCAGCCCCAGCCAAGACCTGCATCATGGAGGCCTCCACAG
5 ACTTCCTACCAGGCCTGAACTTCAGCAACTGCAGCCGACGGGCCCTGGAGAAAG
CCCTCCTGGATGGAATGGGCAGCTGCCTCTTCGAACGGCTGCCTAGCCTACCCCC
TATGGCTGCTTTCTGCGGAAATATGTTTGTGGAGCCGGGCGAGCAGTGTGACTGT
GGCTTCCTGGATGACTGCGTCGATCCCTGCTGTGATTCTTTGACCTGCCAGCTGA
GGCCAGGTGCACAGTGTGCATCTGACGGACCCTGTTGTCAAAATTGCCAGCTGCG
10 CCCGTCTGGCTGGCAGTGTGTCCTACCAGAGGGGATTGTGACTTGCCCTGAATTC
TGCCCAGGAGACAGCTCCCAGTGTCCCCCTGATGTCAGCCTAGGGGATGGCGAG
CCCTGCGCTGGCGGGCAAGCTGTGTGCATGCACGGGCGTTGTGCCTCCTATGCCC
AGCAGTGCCAGTCACCTTTGGGGACCTGGAGCCCAGCCCGCTGCGCCACTTTGCCT
CCAGACCGCTAATACTCGGGGAAATGCTTTTGGGAGCTGTGGGCGCAACCCCAAG
15 TGGCAGTTATGTGTCCTGCACCCCTAGAGATGCCATTTGTGGGCAGCTCCAGTGC
CAGACAGGTAGGACCCAGCCTCTGCTGGGCTCCATCCGGGATCTACTCTGGGAG
ACAATAGATGTGAATGGGACTGAGCTGAACTGCAGCTGGGTGCACCTGGACCTG
GGCAGTGATGTGGCCCAGCCCCTCCTGACTCTGCCTGGCACAGCCTGTGGCCCTG
GCCTGGTGTGTATAGACCATCGATGCCAGCGTGTGGATCTCCTGGGGGACAGG
20 AATGTCGAAGCAAATGCCATGGACATGGGGTCTGTGACAGCAACAGGCACTGCT
ACTGTGAGGAGGGCTGGGCACCCCCTGACTGCACCACTCAGCTCAAAGCAACCA
GCTCCCTGACCACAGGGCTGCTCCTCAGCCTCCTGGTCTTATTGGTCTTGGTGTATG
CTTGGTGCCAGCTACTGGTACCGTGCCCGCCTGVACCAGCGACTCTGCCAGCTCA
AGGGACCCACCTGCCAGTACAGGGCAGCCCAATCTGGTCCCTCTGAACGGCCAG
25 GACCTCCGCAGAGGGCCCTGCTGGCACGAGGCACTAAGTCTCAGGGGCCAGCCA
AGCCCCACCCCCAAGGAAGCCACTGCCTGCCGACCCCCAGGGCCGGTGCCCAT
CGGGTGACCTGCCCGGCCAGGGCCTGGAATCCCGCCCCTAGTGGTACCCTCCAG
ACCAGCGCCACCGCCTCCGACAGTGTCTCGCTCTACCTCTGACCTCTCCGGAGG
TTCCGCTGCCTCCAAGCCGGAAGTATAGGGCTTCAAGAGGCGGGCGTGCCCTCTGGA
30 GTCCCCTACCATGACTGAAGGCGCCAGAGACTGGCGGTGTCTTAAGACTCCGGG
CACCGCCACGCGCTGTCAAGCAACACTCTGCGGACCTGCCGGCGTAGTTGCAGC
GGGGGCTTGGGGAGGGGCTGGGGGTTGGACGGGATTGAGGAAGGTCCGCACAG
CCTGTCTCTGCTCAGTTGCAATAAACGTGACATCTTGGGAGCGTTAA

35 SEQ ID NO: 231

>gi|2207808|gb|AA479252.1|AA479252 zv17f03.r1 Soares_NhHMPu_S1 Homo sapiens
cDNA clone IMAGE:753917 5', mRNA sequence

AAGAAGTCCAGTGTGTCCAGTTAAACAGAAATAAATTAAACTCTTCATCAACA
AAGACCTGTTTTTGTGACTGCCTTGAGTTTTATCAGAATTATTGGCCTAGTAATCC
40 TTCAGAAACACCGTAATTCTAAATAAACCTCTTCCCATACACCTTTCCCCCATAA
GATGTGTCTTCAACACTATAAAGCATTTGTATTGTGATTTGATTAAGTATATATTT
GGTTGTTCTCAATGAAGAGCAAATTTAAATATTATGTGCATTTGTAAATACAGTA
GCTATAAAATTTTCCATACTTCTAATGGCAGAATACAGGAGGCCATATTAAATAA
TACTGATGAAAGGCAGGACACTGCATTGTAAATAGGATTTTCTAGGCTCGGTAGG
45 CAGAAAGAATTATTTTTCTTTGAA

SEQ ID NO: 232

>gi|681270|gb|T70122.1|T70122 yc17c10.r1 Stratagene lung (#937210) Homo sapiens cDNA
clone IMAGE:80946 5' similar to SP:MALK_ECOLI P02914

MALTOSE/MALTODEXTRIN TRANSPORT ATP-BINDING PROTEIN ;, mRNA
sequence

NTTATACTCACCCACAANTTTGTGACCCGANTGTAATGAAAGCCTCTGCAAATTG
AAAACATCATTGATCAAGAGGTGCAGACATTATCTGGTGGTGAACCTACAGCGAG
5 TAGCTTTAGCCCTTTGCTTGGGCAAACCTGCTGATGTCTATTTAATTGATGAACCA
TCTGCATATTTGGATTCTGAGCAAAGACTGATGGCAGCTCGAGTTGTCAAACGTT
TCATACTCCATGCAAAAAAGACAGCCTTTGTTGTGGAACATGACTTCATCATGGC
CACCTATCTAGCGGATCGGTNCATCGTTTTTGTGATGGTGTTCATCTAAGGAACAC
AGTTGCAAACAGTCCTCAAACCCTTTGGGCTGGGCTTGAATAAATTTTTGTGCTT
10 CAGCTTGAAATTTACATTTAGGAGGNGTTCCAAACCAACTATTGGGCCACGGA
TTAAACAAACTTATTTCAATTTAGGGTGTAGGNC

SEQ ID NO: 233

>3447387H2

15 TAATGTTTATGCAAAGTATTGATTCTGTTGTTGAATTTTGTAAACGAAAAAACCCA
TAAATCAAGAAGCTCCAAGCCTACAAAACATAAAGTGCAATTTTAGAAGTACAT
GGGAGGTGATTAGCAATTCTGAGGATTTTAAAAACACCATACCCATGGTGACAC
CACCTCCTCCACCTGTCTTCTCATTGCTGAAGATCAGTCAAAGAATTGTGTGCTTA
GTTCTTGATAAGTCTGGAAGCATGGGGGGTAAGGACCGCCTAAATCGAATGAAT
20 CAAGCA

SEQ ID NO: 234

>2863932H1

GGGGGCTGGGAATTTGCCATTCTGCTGTACAGACACTGATTTTCTTCTTTT
25 TAAAAAGCAAGATTTTAGGTGATGGGCAAGTCAGAAAGTCAGATGGATATAACT
GATATCAACACTCCAAAGCCAAAGAAGAAACAGCGATGGACTCCACTGGAGATC
AGCCTCTCGGTCCTTGTCTGCTCCTCACCATCATAGCTGTGACAATGATCGCACT
CTATGCAACCTACGATGATGGTAATTGCAAGTCATCAGACTGCATAA

30 SEQ ID NO: 235

>5208013H1

GAAACGGATGACCAGGGCAAATACATGACCCTAGTTTTGTCCCGGATCGACCTA
GTGTTCAATTGTTCTGTTCACTGGAGAATTTGTGCTGAAGCTCGTCTCCCTCAGACA
CTACTACTTCACTATAGGCTGGAACATCTTTGACTTTGTGGTGGGGATTCTCTCCA
35 TTGTAGGTATGTTTCTGGCTGAGATGATAGAAAAGTATTTTGTGTCCCTACCTTG
GTCCGAGTGATCCGTCTTGCCA

SEQ ID NO: 236

>873192H1

40 CAGCGATGTCTNACCACCGGTGCTGCAACCCCTGCTGNTGNTGNTGNCTCTGCT
GAATGTGGAGCCTTNCGGGGCCAAAATGATCCGCATCCCTNTTCATCGAGTCCAA
NCTGGANGCAGGATCCTGAANCTACTGAGGGGATGGAGAGAACCAGCAGAGCTC
CCCAAGTTGGGGGCCC

45 SEQ ID NO: 237

>gi|928147|gb|R83270.1|R83270 yp85c04.s1 Soares fetal liver spleen 1NFLS Homo sapiens
cDNA clone IMAGE:194214 3', mRNA sequence

NNNNNAGGGAAAAAAATGGAAAATTTATTAATTAGACAGTATGTGGGCATCCT
GTNCCACATGGGAATGAGAAGATGCTATAGGTNCTCTAAGTATTGCACAGTCTG

AAAAAATAACAAAAAAGGGAAGGGGAGGAAAAAATCACATGATATTGGG
ANCCATCTCACATTATGANTANTCTACCAAGAAACATTTAAAAAAGAAANCCCTT
TGTTTCTACAGTAGGCTTTAAGTTTATAGTTCTTGGGANTGACTGTATTCCATTGA
AGGACATCTCAGGTAACAGGGAAGGCTGTTTAGGCAATCCCCATGTGGCAAAT
5 ATTAATAAANATATATANTTTTTTGCCAATTCATCTCTNGCCTTACCCCCGGGCA
ATCATGACATTTNCGAG

SEQ ID NO: 238

>gi|307424|gb|L12060.1|HUMRARG7A Homo sapiens retinoic acid receptor (gamma-7)

10 mRNA

CGGCAGAGTCAGTGTGCGGTTTGGGAGAAAATGTGTCGGATATTTTGGGGCGGT
CACGTGGGCGGGCGGGCTCCGAGAGGCCCGGGACAGTCCCAGCCTAGAGCCGT
GCCCCCCCAGGAGCCCCCAGTACGGCGAGCCCCGGACATTGCGACGCTCCATC
CAAGAGACTGCCCGACGCCGGGACCTCGGGGCTCCGCCGCCTCCCTTCCCCCTCC
15 CACTCCAGCAGCTACGGCCAGTTCCCTCAACCTGACCCAGTATGTAGAAGCCAG
TCTCTGCAGGCGGCCAGCGGCGGTGGAGACACAGAGCACCAGCTCAGAGGAGAT
GGTGCCAAGCTCGCCCTCGCCCCCTCCGCCTCCTCGGGTCTACAAGCCATGCTTC
GTGTGCAATGACAAGTCCTCTGGCTACCACTATGGGGTCAGCTCTTGTGAAGGCT
GCAAGGGCTTCTTTCGCCGAAGCATCCAGAAGAACATGGTGTACACGTGTCACC
20 GCGACAAAACTGTATCATCAACAAGGTGACCAGGAATCGCTGCCAGTACTGCC
GGCTACAGAAGTGCTTCGAAGTGGGCATGTCCAAGGAAGCTGTGCGAAATGACC
GGAACAAGAAGAAGAAAGAGGTGAAGGAAGAAGGGTCACCTGACAGCTATGAG
CTGAGCCCTCAGTTAGAAGAGCTCATCACCAAGGTCAGCAAAGCCCATCAGGAG
ACTTTCCTCGCTCTGCCAGGTGGGCAAGTATACCAAGAACTCCAGTGCAGACC
25 ACCGCGTGACAGCTGGATCTGGGGCTGTGGGACAAAGTTCAGTGAGCTGGCTACCA
AGTGCATCATCAAGATCGTGGAGTTTGCCAAGCGGTTGCCTGGCTTTACAGGGCT
CAGCATTGCTGACCAGATCACTCTGCTCAAAGCTGCCTGCCTAGATATCCTGATG
CTGCGTATCTGCACAAGGTACACCCCAGAGCAGGACACCATGACCTTCTCCGACG
GGCTGACCCTGAACCGGACCCAGATGCACAATGCCGGCTTCGGGGCCCTCACAG
30 ACCTTGCTTTTGCTTTGCTGGGCAGCTCCTGCCCCTGGAGATGGATGACACCGA
GACAGGGCTGCTCAGCGCCATCTGCCTCATCTGCGGAGACCGCATGGACCTGGA
GGAGCCCGAAAAAGTGGACAAGCTGCAGGAGCCACTGCTGGAAGCCCTGAGGCT
GTACGCCCGGCGCCGGCGGCCAGCCAGCCAGCTACATGTTTCGCAAGGATGCTAAT
GAAAATCACCGACCTCCGGGGCATCAGCACTAAGGGAGCTGAAAGGGCCATTAC
35 TCTGAAGATGGAGATTCCAGGCCCGATGCCTCCCTTAATCCGAGAGATGCTGGAG
AACCCTGAAATGTTTGAGGATGACTCCTCGCAGCCTGGTCCCCACCCCAATGCCT
CTAGCGAGGATGAGGTTTCTGGGGGCCAGGGCAAAGGGGGCCTGAAGTCCCCAG
CCTGACCAGGGCCCCCTGACCTCCCCGCTGTGGGGGTTGGGGCTTCAGGCAGCAG
ACTGACCATCTCCAGACCGCCAGTGACTGGGGGAGGACCTGCTCTGCCCTCTCC
40 CCAACCCCTTCCAATGAGCG

SEQ ID NO: 239

>1909132F6

CGCCATCCCATCTCCAAAATCCTCAGTCCTGTGATGACCTTTCCTACTTTATAGG
45 CCTAAGCATGCTGAGCGCCATCAGCACCGAGCGCTGCCTGTCCATCCTGTGGCCC
ATCTGGTACCACTGCCGCCGCCCCAGATACCTGTCATCGGTCATGTGTGCTCTGC
TCTGGGGCCCTGTCCCTGCTGCGGAGTATCCTGGAGTGGATGTTCTGTGACTTCCTG
TTTAGTGGTGCTGATTCTGTTTGGTGTGAAACGTCAGATTTTATTACAATCGCGTG
GCTGGTTTTTTTATGTGTGGTTCTCTGTGGGTCCAGCCTGGTCCTACTGGTCAGGA

TTCTCTGTGGATCCCCGGAAGATGCCGCTGACCAGGCTGTACGTGACCATCCTCCT
CACAGTGCTGGTCTTCCTCCTCTGTGGCCTGCCCTTTGGCATTCAAGTGGGCCCTGT
TTTCCAGGATCCACCTGGATTGGAAAGTCTTATTTTGTTCATGTGCATCTAGTTTCC
ATTTTCCTGTCCGCTCTTAACAGCAGTGCCAACCCCATCATTTACTTCTTCGTGGG
5 CTCCTTTAGGCAGCGTCAAAATAGGCAGAACCTGAAGCTGGTTCTCCAGAGGGCT
CTGCAGGACACGCCTGAGGTGGATGAAGGTGGAGGGTGGCTTCCTCAGGAAACC
CTGGAGCTGTCGGGAAGCAGATTGGAGCAGTGAGGAAGAACCTCTGCCCTGTCA
GACAGGACTTTGAGAGCAATGCTGCCCTGNCACCTTGACAATTATATGC

10 SEQ ID NO: 240

>gi|1940577|gb|AA292583.1|AA292583 zt31e07.r1 Soares ovary tumor NbHOT Homo
sapiens cDNA clone IMAGE:723972 5' similar to TR:G562077 G562077 TATA-BINDING
PROTEIN ASSOCIATED FACTOR 30 KDA SUBUNIT. [1] ;, mRNA sequence
GCTGGAGCAGCTGCTGGGGGCACGGGACCGTTGGCGGCGCGGGCCAGGGGAGCC
15 AGCTGAGCGGCGTGGGGCGGCTCCGGTGTTCGGCGGGTGGCGCGGCGCCCCCGGA
GGCANTGATCATAACGGGGTTTACGTACTGCCGAGCGCGGCCAACGGAGACGTG
AAGCCCGTGGTGTCCAGCACGCCTTTGGTGGACTTCTTGATGCAGCTGGAAGATT
ACACGCCTACGATCCCAGATGCAGTGACTGGTTACTACCTGAACCGTGTCTGGCTT
TGAGGCCTCAGACCCACGCATAATTTCGGCTCATCTCCTTAGCTGCCCAGAAATTC
20 ATCTCAGATATTGCCAATGATGCCCTACAGCACTGCAAAATGGAAGGGCA

SEQ ID NO: 241

>2581223T6
CCCACCAGGACCAAGGCTTGAGAGCAGATTGGACCTATTGATTATGTGTATATA
25 AAAAACAAGACATCTTTTAAAGCAAAGCTGGGCAAATTCTCTATGGAAAGGGCG
CCACTGGCACTTGATTTTGACTTTCCAAAGTGCAGCAATGTGTTCCAGAACAGCT
CAAATCCTAAAAGGTGAAGTTCAAGTTCTTTGGTGGCCCAGTTGTCAAGCCACTT
AAATAGCAAATCCTGATGGCTTGAGGATTTCAATTTCTCCAGCCCAGAGCATATTA
GCATAAGAAGAGTACAAGTAATCAAGCATTCTACACGGTGTCCAGGTGAAAACC
30 ATACAATCAGCAATAGTGTGGTCAAGTTTCAGCCATGAATATGAACTATACAAG
ACATATTTAAAAGATAACTCAAAGTTGAATTGCATTACAGTAACTCAATGGGGTC
TTAAATTTTCTTAATCTTTAAGAAAATTTATAAAGGGCNAACNATAATAAAAATA
GTAATAATATTTGTTTTTAAAAGTAGGNGTGAATGTTAAGAGNCATAAAGACTGC
TTATAG

35

SEQ ID NO: 242

>gi|728269|gb|T94781.1|T94781 ye33c06.s1 Stratagene lung (#937210) Homo sapiens cDNA
clone IMAGE:119530 3', mRNA sequence
ACAATTTGAATTATGAGAGTTCACTTTCAGACGAAGCACCTAACAGGAAATCTCT
40 CAAACACAGAAATGCTGGTTTAGCCACAAGATCAAAGGAAAAGATTGATTTTGT
ATGTCCGTGCAGTTTTTGAGAGTGCCTTACACATTTTCGTTTTACAGCAATCTT
TGTGTTTGAAGGGAGTTCTGATGTGGAAACAGCTTGCAGGGTTAAACCTGGATGG
CGCCCCTGTGATCAGACATTGCTCTGTTGTAATAAAAGTGTCTCAGTNCTCTTTC
CCNCTGATCCTCCTGCCTGTACTTCTCCTCGAGTTGCTGTTTCTCAGAATCTGCAC
45 AGTAAATGTGCCAATCTGGGGCTTTNCCGAANCCGGTTCAAACCTGACTGAAATC

SEQ ID NO: 243

>gi|1220042|gb|N67917.1|N67917 yz52h03.s1 Morton Fetal Cochlea Homo sapiens cDNA
clone IMAGE:286709 3' similar to gb:V01512_ma5 P55-C-FOS PROTO-ONCOGENE
PROTEIN (HUMAN);, mRNA sequence

5 TTTTTTTCGCATTCAACTTAAATGCTTTTATTGACAATGTCTTGGAACAATAAGCA
AACAAATGCTTAAATTTTTCATTCAAATTCACCTTCCACATGTCAAAAGACCTCAA
GGTAGAAAAAATAAAATAAAATATAAATATCTGAGAATCCATCTTAATAAAT
AAATTA AAAACACAATAAAACGTTTTCATGGAAAAC TGTTAATGTCAGAACATTC
AGACCACCTCAACAATGCATGATCAGTAACATTACAATGAACATTGATGTTGAA
10 GAAAAACTACAGTACATGGATATAGCTATTTATTTCTATCTACCAGAAAATAAAG
TCGTATCTTTTCTTAGTATAATATTGGGTCATTTCTAATCAGAACACACTATTGCC
AGGAACACAGTAGTTATTGTTAAATCAGCCGCACTAGATACCATTGGAATAT
CCAGCACCAGGTTAATTCCCATAATGNACCCCATAGG

15 SEQ ID NO: 244

>gi|187354|gb|M69226.1|HUMMAOAAA Human monoamine oxidase (MAOA) mRNA,
complete cds

GAATTCCTGACACGCTCCTGGGTCGTAGGCACAGGAGTGGGGGCCAAAGCATGG
AGAATCAAGAGAAGGCGAGTATCGCGGGCCACATGTTTCGACGTAGTCGTGATCG
20 GAGGTGGCATTTCAGGACTATCTGCTGCCAAACTCTTGACTGAATATGGCGTTAG
TGTTTTGGTTTTAGAAAGCTCGGGACAGGGTTGGAGGAAGAACATATACTATAAG
GAATGAGCATGTTGATTACGTAGATGTTGGTGGAGCTTATGTGGGACCAACCCAA
AACAGAATCTTACGCTTGTCTAAGGAGCTGGGCATAGAGACTTACAAAGTGAAT
GTCAGTGAGCGTCTCGTTCAATATGTCAAGGGGAAAACATATCCATTTCTGGGGCG
25 CCTTCCACCAGTATGGAATCCCATTCATATTTGGATTACAATAATCTGTGGAG
GACAATAGATAACATGGGGAAGGAGATTCCAACCTGATGCACCCTGGGAGGCTCA
ACATGCTGACAAATGGGACAAAATGACCATGAAAGAGCTCATTGACAAAATCTG
CTGGACAAAGACTGCTAGGCGGTTTGCTTATCTTTTGTGAATATCAATGTGACC
TCTGAGCCTCACGAAGTGTCTGCCCTGTGGTTCTTGTGGTATGTGAAGCAGTGCG
30 GGGGCACCACTCGGATATTCTCTGTCAACCAATGGTGGCCAGGAACGGAAGTTTGT
AGGTGGATCTGGTCAAGTGAGCGAACGGATAATGGACCTCCTCGGAGACCAAGT
GAAGCTGAACCATCCTGTCACTCACGTTGACCAGTCAAGTGACAACATCATCATA
GAGACGCTGAACCATGAACATTATGAGTGCAAATACGTAATTAATGCGATCCCTC
CGACCTTGACTGCCAAGATTCACCTTCAGACCAGAGCTTCCAGCAGAGAGAAACC
35 AGTTAATTCAGCGTCTTCCAATGGGAGCTGTCATTAAGTGCATGATGTATTACAA
GGAGGCCTTCTGGAAGAAGAAGGATTACTGTGGCTGCATGATCATTGAAGATGA
AGATGCTCCAATTTCAATAACCTTGGATGACACCAAGCCAGATGGGTCACTGCCT
GCCATCATGGGCTTCATTCTTGCCCGGAAAGCTGATCGACTTGCTAAGCTACATA
AGGAAATAAGGAAGAAGAAAATCTGTGAGCTCTATGCCAAAGTGCTGGGATCCC
40 AAGAAGCTTTACATCCAGTGCATTATGAAGAGAAGAACTGGTGTGAGGAGCAGT
ACTCTGGGGGCTGCTACACGGCCTACTTCCCTCCTGGGATCATGACTCAATATGG
AAGGGTGATTCTGCAACCCGTGGGCAGGATTTTCTTTGCGGGCACAGAGACTGCC
ACAAAGTGAGCGGCTACATGGAAGGGGCAGTTGAGGCTGGAGAACGAGCAGC
TAGGGAGGTCTTAAATGGTCTCGGGAAGGTGACCGAGAAAGACATCTGGGTACA
45 AGAACCTGAATCAAAGGACGTTCCAGCGGTAGAAATCACCCACACCTTCTGGGA
AAGGAACCTGCCCTCTGTTTCTGGCCTGCTGAAGATCATTGGATTTTCCACATCA
GTAAGTGCCTGGGGTTTGTGCTGTACAAATACAAGCTCCTGCCACGGTCTTGAA
GTTCTGTTCTTATGCTCTCTGCTCACTGGTTTTCAATACCACCAAGAGGAAAATAT
TGACAAGTTTAAAGGCTGTGTCATTGGGCCATGTTTAAGTGTACTGGATTAACT

ACCTTTGGCTTAATTCCAATCATTGTTAAAGTAAAAACAATTCAAAGAATCACCT
AATTAATTTTCAGTAAGATCAAGCTCCATCTTATTTGTCAGTGTAGATCAACTCAT
GTTAATTGATAGAATAAAGCCTTGTGATCACTTTCTGAAATTCACAAAGTTAAAC
GTGATGTGCTCATCAGAAAC

5

SEQ ID NO: 245

>gi|1472327|gb|AA011215.1|AA011215 ze23f02.s1 Soares_fetal_heart_NbHH19W Homo
sapiens cDNA clone IMAGE:359835 3' similar to gb:M77693 DIAMINE

ACETYLTRANSFERASE (HUMAN);, mRNA sequence

10 TCCTCAGTAGTTTGAACACTTGCTGGCTATTTTTCTGTCCAAGTTCTCAGTAACT
TCGGCCTGTGTAGTCAGTGGTTCTACACAGCCGACACTACTTCTTACATAACACT
TGGTCTCTCTGGCTTCTGGAAAGGGCGAGGGGTACCTTCCGGAGTCCAGTGCTC
TTTCGGCACTTCTGCAACCAGGCAGTGGTAAAAGGGGTGCTCTCCAAAACCATCT
TCTAGCAGATCTTTTTTCAGTTAAGATTACTTGTCTTCCATGTATTCATATTTAAG
15 CCAGCTCCTTGATCAGCCGAGTATGTCAGTGCAGTCGGCGGCAGTGGCTGGGCG
GATCACCGAATTTAGCCATTTTCGGTCTTTTTGCTTTTTCTTCCCTTTGCGGGACC
AGGGCCCCCTGGTACTTGAACAGTAGGAGGAAGGTGGGTTCNCAATCGGTCTC
CCGGGGANGCGGTN

20 SEQ ID NO: 246

>1693028H1

CACAGATGAAGGACGTGTTCTTCTTCTTCTTCTCCTCGGCGTGTGGCTGGTAGCC
TATGGCGTGGCCACGGAGGGGCTCCTGAGGCCACGGGACAGTGACTTCCCAAGT
ATCCTGCGCCGCGTCTTCTACCGTCCCTACCTGCAGATCTTCGGGCAGATTCCCA
25 GGAGGACATGGACGTGGCCCTCATGGAGCACAGCAACTGCTCGT

SEQ ID NO: 247

>2519384H1

GGCAGCCTCGCCAGCGGGGGCCCCGGGCCTGGCCATGCCTCACTGAGCCAGCGC
30 CTGCGCCTCTACCTCGCCGACAGCTGGAACCAAGTGCAGACCTAGTGGCTCTCACCT
GCTTCCTCCTGGGCGTGGGCTGCCGGCTGACCCCGGGTTTGTACCACCTGGGCGG
CACTGTCCTCTGCATCGACTTCATGGTTTTCACGGTGCAGGCTGCTTCACATCTTCA
CGGTCAA

35 SEQ ID NO: 248

>gi|787364|gb|R31521.1|R31521 yh72b04.s1 Soares placenta Nb2HP Homo sapiens cDNA
clone IMAGE:135247 3', mRNA sequence

TTGGAGAATCAAATGGAAACACAGGGGGAAAGATATAGAGCTTCCGTCCACCAT
CTATGAAGCCCTCCACCTGCCTGACATCAAGTTTTTCTAATGTGTATGCATTGC
40 TGAAGGTCCTGTGTATTCTTCTGTGATGAAGGTTGAGAATGAGCGGTATGAAAA
TGGGACGAAAGCGTCTTTAAAGCATATTTGAGGGAACACTTTGACAGACCCAAA
GGTCAAGTACTTTGGCTTTTNCCTTAAACATAAATTTNGATATTAAA

SEQ ID NO: 249

45 >gi|1110336|gb|H96850.1|H96850 yw03b12.s1 Soares melanocyte 2NbHM Homo sapiens
cDNA clone IMAGE:251135 3' similar to contains Alu repetitive element; mRNA sequence
TTTTTGAGGGCAACATCTCGCTTTATTTTTATTTATTTATTTATTTATTTATTTG
AGACAGAGTCTTAACACTGTTGCCAGGCTGGAGTGCAATGGCGTGATCTCAGCT
CACTGCAAGCTCTGCCTCCTGGATTTCATGCCTTTCTCCTGCCTCAGCCTCCCGAGT

AGCTGGGACCACAGGTGCCCACCACCACGCCAGCTAATTTTTTGTACTTTTAGT
 AGAGACAGGGTTTTACCGTGTTAGCCAGGATAGTCTCGATCTCCTGACCTCGTGA
 GCCGCCCCGCTCGGNCTCCCAAAGTGCTGGGATTACAGGCATGAGCACCGTGCCT
 GGCCACGTCCCTATTTTAGAAATGAGAGGAGTGACTGCACATAGGAAAAATGCC
 5 ACTTTTA

SEQ ID NO: 250

>gi|1177578|emb|X95383.1|OCCRYAB O.cuniculus mRNA for alpha-B-crystallin

CCGACACTCACCTAGCCACCATGGACATCGCTATCCACCACCCCTGGATCCGCCG
 10 CCCCTTCTTTCTTTTCACTCGCCCAGCCGCCTCTTTGACCAGTTCTTCGGAGAGC
 ACCTGTTGGAGTCTGATCTCTTCCCAACTTCTACTTCCCTGAGCCCCTTCTATCTT
 CGGCCACCCCTCATTCTGCGGGCACCAGCTGGATTGACACTGGACTCTCAGAGA
 TCGCCTGGAGAAGGACAGGTTCTCTGTCAACCTGGATGTGAAGCACTTCTCCCC
 AGAGGAGCTCAAGGTCAAAGTGTTGGGTGATGTGATTGAGGTGCACGGCAAACA
 15 TGAAGAGCGCCAGGATGAACATGGTTTCATCTCCAGGGAGTTCCACAGGAAATA
 CCGGATCCCAGCTGATGTGGACCCTCTCACCATTACTTCATCCCTGTCATCTGATG
 GGGTCCTCACTGTGAATGGACCAAGGAAGCAAGCCCCTGGCCCAGAGCGCACCA
 TTCCATAACCCGTGAAGAGAAGCCTGCTGTCACTGCAGCCCCCAAGAAGTAG

20 SEQ ID NO: 251

>gi|2167332|gb|AA453663.1|AA453663 aa18e04.r1 Soares_NhHMPu_S1 Homo sapiens

cDNA clone IMAGE:813630.5' similar to gb:M54915 PIM-1 PROTO-ONCOGENE.

SERINE/THREONINE-PROTEIN KINASE (HUMAN);, mRNA sequence.

AAATCGGCCCGAGGGTCAGAACCTGCCATGGAAGTGTTTCTTCATCATGAGTT
 25 CTGCTGAATGCCGCGATGGGTCAAGTAGGGGGGAAACAGGTTGGGATGGGATAG
 GACTAGCACCATTTTAAGTCCCTGTACCTCTTCCGACTCTTTCTGAGTGCCTTCT
 GTGGGGACTCCGGCTGTGCTGGGAGAAATACTTGAACCTGCCTCTTTTACCTGCT
 GCTTCTCCAAAAATCTGCCTTGGGTTTTGTTCCCTATTGTTGCTCTCGTGTCTTCT
 TAACCCCTCCTTCATAATGAAGGGTGCATGGGAGA

30

SEQ ID NO: 252

>gi|2240364|gb|AA504204.1|AA504204 aa59h01.s1 NCI_CGAP_GCB1 Homo sapiens

cDNA clone IMAGE:825265 3', mRNA sequence

TTTTTAACTCATGTGGTTAACATGGTATTGTATAAAAAGAAAAAAAACACCA
 35 CTCAATACTTACTAAGCCTTGCAGACAGCTCAGAGTTGAGGCAGCATATTGGGCA
 TAGAGATCATAGGATTTGTATTATCCCTTGCAAGATGGAACCTCCAACCAACACCA
 GAATTTTCCAATTCAAATTCAGTTTTAGTCGAGACCCAGCATAATTTTTAGAAA
 AAAGATTGGATTGTTGCTTTTCTTTTAATTTTCCATTCCTATTAGACAAATGACC
 AGAGGCAATGACAAAAGTAACTGTTTAAAAGGGATTCTCTCCAGAAGTTTTTC
 40 TAAAGGTTTAAAGTCCAGGCTTTCCATCCTTCTCTCCATCCTTTTCAATTTAAAAA
 GAAGGGTTTTGGAATATGTCAACCTTACTCAGCTTGCTATACAAA

SEQ ID NO: 253

>gi|1203432|gb|N59542.1|N59542 yv76d05.s1 Soares fetal liver spleen 1NFLS Homo

sapiens cDNA clone IMAGE:248649 3', mRNA sequence

GTGATTGAACAGAGGCAGTGTACTGGAGTTTGGAACCAGAAAGATGAATTACCT
 ATTGAAGTGGACCTTGGTAAAAAGTGCTGGTATCACTCTATATTGCTGCCCA
 TTCTTCGTGAGCAAACAACAGATAACAATCCACCCATGAAATTGGTCTGTGGTCA
 TATTATATCAAGAGATGCCCTGAATAAAATGTTTAATGGTAGCAAATTAAATGT

CCCTACTGTCCAATGGAACAAAGTCCAGGAGATGCCAAACAGATATTTTTCTGAA
 GAGATAACTTTAGTTTGCAATTTGTAAGTGAACTGAATCGTGGGTGCATTTTCAG
 AAGAGAACGTTCCATATAATGCAGCTAACCAAGGACTCCTGTGTTTCTATAAGCT
 AATGCTCCAGAACTTTTGCCAACCTGTTAGTGTACACACACTGAGGGGAGTGCT
 5 CCCGGTGAATATTATCATAGGGCCTTATT

SEQ ID NO: 254

>gi|2432801|gb|AA599176.1|AA599176 ae46c08.s1 Stratagene lung carcinoma 937218

Homo sapiens cDNA clone IMAGE:949934 3', mRNA sequence

10 TTGTAAAGAATTGAATTCTTTATTTGTGATATCCATAAACGTTGCTATTCTCTATT
 TCTATCCAGAAAGGCAATTTTCACCTATTATCACTTTTGTTCCTTCTTATAAACA
 ACAACTTGAATGCTATTGCAGGAAAGGGCTACAAATATACATTTGTTAACCAAGC
 AGAATACACAGATATTTTGCTTTACAACCTGCACCTAAAATACCAGTATACGTAG
 CTGGTTCATTAGTTGTCATAGCAATTTAGGGGCTATTGCCAAGCTATGCATAGCAG
 15 TTTACATTTTCAAACCTCATATAGAAAGGGCTATTGTGATATGAACTGGCAACTA
 CATTCTGTGAAGCCCATCTCAGTTACAAGCAAATGTGTTAACTTCCAATTCTGC
 AAAGAATTTTGATGGCAAACTTCCAATCTGATGCAATTGTCTTAAGCAAGTTT
 TTAAACAAATTGTTTCGCAGCTACTCTGCCATTCTGCCAGTAGATGGTGCT

20 SEQ ID NO: 255

>gi|659863|gb|T58002.1|T58002 yb19g05.r1 Stratagene fetal spleen (#937205) Homo sapiens

cDNA clone IMAGE:71672 5' similar to similar to gb:J04058 ELECTRON TRANSFER

FLAVOPROTEIN ALPHA-SUBUNIT (HUMAN), mRNA sequence

25 TGGTATCTGGTGGTTCGAGGCTTGAAGAGTGGAGAGAACTTTAAGTTGTTATATGA
 CTTGGCAGATCAACTACATGCTGCAGTTGGTGCTTCCCGTGCTGCTGTTGATGCT
 GGCTTTGTTCCCAATGACATGCAAGTTGGACAGACGGGAAAAATAGTAGCACCA
 GAACTTTATATTGCTGTTGGAATATCTGGGAGCCATCCAACATTTAGCTGGGGAT
 GAAAGACAGCAAGACAATTGTGGCCAATTAATAAAGACCCAGAAGCTCCCAATT
 TTCCCAAGTNGCCAGATTATGGGATTAGTTGCAGGTTTATTTTAAGGTAGTTCCT
 30 GGAANTGACTTGAGGTATT

SEQ ID NO: 256

>gi|182666|gb|M76672.1|HUMFMLPX Human FMLP-related receptor II (FMLP R II)

mRNA, complete cds

35 ATGGAAACCAACTTCTCCACTCCTCTGAATGAATATGAAGAAGTGCCTATGAGT
 CTGCTGGCTACACTGTTCTGCGGATCCTCCCATTGGTGGTGCTTGGGGTCACCTTT
 GTCCTCGGGGTCCTGGGCAATGGGCTTGTGATCTGGGTGGCTGGATTCCGGATGA
 CACGCACAGTCACCACCATCTGTTACCTGAACCTGGCCCTGGCTGACTTTTCTTTC
 ACGGCCACATTACCATTCCTCATTGTCTCCATGGCCATGGGAGAAAAATGGCCTT
 40 TTGGCTGGTTCCTGTGTAAGTTAATTCACATCGTGGTGGACATCAACCTCTTTGGA
 AGTGTCTTCTTGATTGGTTTCATTGCACTGGACCGCTGCATTTGTGTCCTGCATCC
 AGTCTGGGCCCAGAACCCGCACTGTGAGTCTGGCCATGAAGGTGATCGTCGG
 ACCTTGGATTCTTGCTCTAGTCCTTACCTTGCCAGTTTTCTCTTTTTGACTACAGT
 AACTATTCCAAATGGGGACACATACTGTACTTTCAACTTTGCATCCTGGGGTGGC
 45 ACCCTGAGGAGAGGCTGAAGGTGGCCATTACCATGCTGACAGCCAGAGGGATT
 ATCCGGTTTGTCAATTGGCTTTAGCTTGCCGATGTCCATTGTTGCCATCTGCTATGG
 GCTCATTGCAGCCAAGATCCACAAAAAGGGCATGATTAAATCCAGCCGTCCTTA
 CGGGTCTCACTGCTGTGGTGGCTTCTTTCTTCATCTGTTGGTTTCCCTTTCAACTG
 GTTGCCCTTCTGGGCACCGTCTGGCTCAAAGAGATGTTGTTCTATGGCAAGTACA

AAATCATTGACATCCTGGTTAACCCAACGAGCTCCCTGGCCTTCTTCAACAGCTG
CCTCAACCCCATGCTTTACGTCTTTGTGGGCCAAGACTTCCGAGAGAGACTGATC
CACTCCCTGCCACCAGTCTGGAGAGGGCCCTGTCTGAGGACTCAGCCCCAACTA
ATGACACGGCTGCCAATTGTGCTTCACCTCCTGCAGAGACTGAGTTACAGGCAAT
5 GTGAGG

SEQ ID NO: 257

>gi|1047029|gb|H73961.1|H73961 yu04e02.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:232826 3', mRNA sequence

10 TATGTTAGAAATTNCTTTATTATTACTTATCCTTATTAAGCGCCANNTTNAATGCT
GCAGAAAATTTCAAATCACCTTGATAACCCACTTNCTTTCCTCCCACCCAAATN
CTTGANCAAGAGTTTTTCAAGTAAAGACATGCTCTTCTCTCTCCTGTATAAACTT
TACGAAATAAAGGCCAAAAGATTGTGTACATCTTGCTGGGAAAATGCTGCCCGGG
GCTCTGGGAGACGGTGGGCTGCCCGGGCTCCCTTCACTGTCCGGGTCCTGAAAGG
15 ACTCTTGTTTCATGGAAGTGTCTCTTCACAAAGGCAAGGTCCACCACTTGCTGGGG
GTTTATCATTCTGAGGGGTGCGAAAACCTTTTCTCACAAGGTCTCAGGTCCAGTCT
CTTGGCCTTAGGCTGTTGTAAAAGGGGTTTTTCATCANTTCANCTTCCCTTTGTTTG
GAGGGTTGGGGATAANTGGGGTTAGGGGGGGNAACGGGGGTTTNGGGGGTTGG
GGAATTAG

20

SEQ ID NO: 258

>gi|1477389|gb|L76631.1|HUMMGLUB Homo sapiens metabotropic glutamate receptor 1 beta (mGluR1beta) mRNA, complete cds

25 GCGCAGGTACTCAGGTATGTCTCAAGTCCATGTCTCCAAACAGACTCAGCATCT
AGCTCACCGCTGCCAACACGACTTCCACTGTACTCTTGATCAATTTACCTTGATGC
ACTACCGGTGAAGAACGGGGACTCGAATTCCTTACAAACGCCTCCAGCTTGATG
AGGCGGTCTGGAGGACCCAGAGGAGGAGACGAAGGGGAAGGAGGCGGTGGTG
GAGGAGGCAAAGGCCTTGGACGACCATTGTTGGCGAGGGGCACCACTCCGGGAG
AGGCGGCGCTGGGCGTCTTGGGGGTGCGCGCCGGGAGCCTGCAGCGGGACCAGC
30 GTGGGAACGCGGCTGGCAGGCTGTGGACCTCGTCCTCACCACCATGGTCGGGCTC
CTTTTGTTTTTTTTCCAGCGATCTTTTGGAGGTGTCCCTTCTCCCCAGAAGCCCC
GGCAGGAAAGTGTGCTGGCAGGAGCGTCGTCTCAGCGCTCGGTGGCCAGAATG
GACGGAGATGTCATCATTGGAGCCCTCTTCTCAGTCCATCACCAGCCTCCGGCCG
AGAAAGTGCCCGAGAGGAAGTGTGGGGAGATCAGGGAGCAGTATGGCATCCAG
35 AGGGTGGAGGCCATGTTCCACACGTTGGATAAGATCAACGCGGACCCGGTCCTC
CTGCCCAACATCACCTGGGCAGTGAGATCCGGGACTCCTGCTGGCACTCTTCCG
TGGCTCTGGAACAGAGCATTGAGTTCATTAGGGACTCTCTGATTTCATTCGAGA
TGAGAAGGATGGGATCAACCGGTGTCTGCCTGACGGCCAGTCCCTCCCCCAGG
CAGGACTAAGAAGCCCATTGCGGGAGTGATCGGTCCCGGCTCCAGCTCTGTAGC
40 CATTCAAGTGCAGAACCTGCTCCAGCTCTTCGACATCCCCCAGATCGCTTATTCA
GCCACAAGCATCGACCTGAGTGACAAAACCTTTGTACAAATACTTCCTGAGGGTTG
TCCCTTCTGACACTTTGCAGGCAAGGGCCATGCTTGACATAGTCAAACGTTACAA
TTGGACCTATGTCTCTGCAGTCCACACGGAAGGGAATTATGGGGAGAGCGGAAT
GGACGCTTTCAAAGAGCTGGCTGCCCAGGAAGGCCTCTGTATCGCCCATCTGAC
45 AAAATCTACAGCAACGCTGGGGAGAAGAGCTTTGACCGACTCTTGCGCAAACCTC
CGAGAGAGGGCTTCCCAAGGCTAGAGTGGTGGTCTGCTTCTGTGAAGGCATGACA
GTGCGAGGACTCCTGAGCGCCATGCGGCGCCTTGGCGTCGTGGGCGAGTTCTCAC
TCATTGGAAGTGATGGATGGGCAGACAGAGATGAAGTCATTGAAGGTTATGAGG
TGGAAGCCAACGGGGGAATCACGATAAAGCTGCAGTCTCCAGAGGTCAGGTCAT

TTGATGATTATTTCTGAAACTGAGGCTGGACACTAACACGAGGAATCCCTGGTT
CCCTGAGTTCTGGCAACATCGGTTCCAGTGCCGCCTTCCAGGACACCTTCTGGAA
AATCCCAACTTTAAACGAATCTGCACAGGCAATGAAAGCTTAGAAGAAAACTAT
GTCCAGGACAGTAAGATGGGGTTTGTTCATCAATGCCATCTATGCCATGGCACATG
5 GGCTGCAGAACATGCACCATGCCCTCTGCCCTGGCCACGTGGGCCTCTGCGATGC
CATGAAGCCCATCGACGGCAGCAAGCTGCTGGACTTCCTCATCAAGTCCTCATT
ATTGGAGTATCTGGAGAGGAGGTGTGGTTTGTATGAGAAAGGAGACGCTCCTGGA
AGGTATGATATCATGAATCTGCAGTACACTGAAGCTAATCGCTATGACTATGTGC
ACGTTGGAACCTGGCATGAAGGAGTGCTGAACATTGATGATTACAAAATCCAGA
10 TGAACAAGAGTGAGGTGGTGGCTGTGTGCAGTGAGCCTTGCTTAAAGGGCC
AGATTAAGGTTATACGGAAAGGAGAAGTGAGCTGCTGCTGGATTTGCACGGCCT
GCAAAGAGAATGAATATGTGCAAGATGAGTTCACCTGCAAAGCTTGTGACTTGG
GATGGTGGCCCAATGCAGATCTAACAGGCTGTGAGCCCATTCTGTGCGCTATCT
TGAGTGGAGCAACATCGAATCCATTATAGCCATCGCCTTTTCATGCCTGGGAATC
15 CTTGTTACCTTGTGTTGTACCCCTAATCTTTGTACTGTACCGGGACACACCAGTGGT
CAAATCCTCCAGTCGGGAGCTCTGCTACATCATCCTAGCTGGCATCTTCCTTGGTT
ATGTGTGCCCATTCCTCTCATTGCCAAACCTACTACCACCTCCTGCTACCTCCAG
CGCCTCTTGGTTGGCCTCTCCTCTGCGATGTGCTACTCTGCTTTAGTGACTAAAAC
CAATCGTATTGCACGCATCCTGGCTGGCAGCAAGAAGAAGATCTGCACCCGGAA
20 GCCCAGGTTTCATGAGTGCCTGGGCTCAGGTGATCATTGCCTCAATTCTGATTAGT
GTGCAACTAACCCCTGGTGGTAACCCTGATCATCATGGAACCCCTATGCCCATTC
TGTCTACCCAAGTATCAAGGAAGTCTACCTTATCTGCAATACCAGCAACCTGGG
TGTGGTGGCCCTTTGGGCTACAATGGAATCCTCATCATGAGCTGTACCTACTAT
GECTTCAAGACCCGCAACGTGCGCGCCAACTTCAACGAGGCCAAATATATCGCGT
25 TCACCATGTACACCACCTGTATCATCTGGCTAGCTTTTGTGCCCATTTACTTTGGG
AGCAACTACAAGATCATCACAACCTTGCTTTGCAGTGAGTCTCAGTGTAACAGTGG
CTCTGGGGTGCATGTTCACTCCCAAGATGTACATCATTATTGCCAAGCCTGAGAG
GAATGTCCGCAGTGCCCTTACCACCTCTGATGTTGTCCGCATGCATGTTGGCGAT
GGCAAGCTGCCCTGCCGCTCCAACACTTTCCTCAACATCTTCCGAAGAAAGAAGG
30 CAGGGGCAGGGAATGCCAAGAAGAGGCAGCCAGAATTCTCGCCCACCAGCCAAT
GTCCGTCGGCACATGTGCAGCTTTGAAAACCCCACTGCAGTGAATGTTTCTA
ATGGCAAGTCTGTGTATGTTCTGAACCAGGTGGAGGACAGGTGCCCAAGGGAC
AGCATATGTGGCACCGCCTCTCTGTGCACGTGAAGACCAATGAGACGGCCTGCA
ACCAAACAGCCGTCATCAAACCCCTCACTAAAAGTTACCAAGGCTCTGGCAAGA
35 GCCTGACCTTTTC

SEQ ID NO: 259

>gi|1374674|gb|L78207.1|HUMSUR1RNA Homo sapiens sulfonylurea receptor (SUR1)

mRNA, complete cds

40 GCCAGCTGAGCCCGAGCCCAGACCGCGCCCGCGCCGCGCCATGCCCTGGCCTTCTG
CGGCAGCGAGAACCACTCGGCCGCCTACCGGGTGGACCAGGGGGTCTCAACAA
CGGCTGCTTTGTGGACGTCCTCAACGTGGTGCCGCACGTCTTCTACTCTTCATCA
CCTTCCCCATCCTCTTCATTGGATGGGGAAGTCAGAGCTCCAAGGTGCACATCCA
CCACAGCACATGGCTTCATTTCCCTGGGCACAACCTGCGGTGGATCCTGACCTTC
45 ATGCTGCTCTTCGTCCTGGTGTGTGAGATTGCAGAGGGCATCCTGTCTGATGGGG
TGACCGAATCCCACCATCTGCACCTGTACATGCCAGCCGGGATGGCGTTCATGGC
TGCTGTACCTCCGTGGTCTACTATCACAACATCGAGACTTCCAACCTCCCCAAG
CTGCTAATTGCCCTGCTGGTGTATTGGACCCTGGCCTTCATACCAAGACCATCA
AGTTTGTCAAGTTCTTGGACCACGCCATCGCGTTCTCGCAGGTACGCTTCTGCCTC

ACAGGGCTGCTGGTGATCCTCTATGGGATGCTGCTCCTCGTGGAGGTCAATGTCA
TCAGGGTGAGGAGATACATCTTCTTCAAGACACCGAGGGAGGTGAAGCCTCCCG
AGGACCTGCAAGACCTGGGGGTACGCTTCTGACGCCCTTCGTGAATCTGCTGTC
CAAAGGCACCTACTGGTGGATGAACGCCTTCATCAAGACTGCCACAAGAAGCC
5 CATCGACTTGCGAGCCATCGGGAAGCTGCCCATCGCCATGAGGGCCCTCACCAA
CTACCAACGGCTCTGCGAGGCCTTTGACGCCCAGGTGCGGAAGGACATTCAGGG
CACTCAAGGTGCCCGGGCCATCTGGCAGGCACTCAGCCATGCCTTCGGGAGGCG
CCTGGTCCTCAGCAGCACTTTCCGCATCTTGGCCGACCTGCTGGGCTTCGCCGGG
CCACTGTGCATCTTTGGGATCGTGGACCACCTTGGGAAGGAGAACGACGTCTTCC
10 AGCCCAAGACACAATTTCTCGGGGTTTACTTTGTCTCATCCCAAGAGTTTCTTGCC
AATGCCTACGTCTTAGCTGTGCTTCTGTTCCCTTGCCCTCCTACTGCAAAGGACATT
TCTGCAAGCATCCTACTATGTGGCCATTGAACTGGAATTAATTGAGAGGAGCA
ATACAGACCAAGATTTACAATAAAATTATGCACCTGTCCACCTCCAACCTGTCCA
TGGGAGAAATGACTGCTGGACAGATCTGTAATCTGGTTGCCATCGACACCAATCA
15 GCTCATGTGGTTTTTCTTCTTGTGCCCAAACCTCTGGGCTATGCCAGTACAGATCA
TTGTGGGTGTGATTCTCCTCTACTACATACTCGGAGTCAGTGCCTTAATTGGAGC
AGCTGTCATCATTCTACTGGCTCCTGTCCAGTACTTCGTGGCCACCAAGCTGTCTC
AGGCCCAGCGGACGACACTGGAGTATTCCAATGAGCGGCTGAAGCAGACCAACG
AGATGCTCCGCGGCATCAAGCTGCTGAAGCTGTACGCCTGGGAGAACATCTTCCG
20 CACGCGGGTGGAGACGACCCGCAGGAAGGAGATGACCAGCCTCAGGGCCTTTCG
CATCTATACCTCCATCTCCATTTTCATGAACACGGCCATCCCCATTGCAGCTGTCC
TCATAACTTTTCGTGGGCCATGTCAGCTTCTTCAAAGAGGGCCGACTTCTCGCCCTCC
GTGGCCTTTGCCTCCCTCTCCCTCTTCCATATCTTGGTCACACCGGTGTTCTCTGCT
GTCCAGTGTGGTCCGATCTACCGTCAAAGCTCTAGTGAGCGTGCAAAAGCTAAGC
25 GAGTTCCTGTCCAGTGCAGAGATCCGTGAGGAGCAGTGTGCCCCCATGAGCCC
ACACCTCAGGGCCCAGCCAGCAAGTACCAGGCGGTGCCCTCAGGGTTGTGAAC
CGCAAGCGTCCAGCCCGGGAGGATTGTGCGGGGCCTCACCGGCCCACTGCAGAGC
CTGGTCCCCAGTGCAGATGGCGATGCTGACAACCTGCTGTGTCCAGATCATGGGAG
GCTACTTCACGTGGACCCAGATGGAATCCCCACACTGTCCAACATCACCATTCG
30 TATCCCCCGAGGCCAGCTGACTATGATCGTGGGGCAGGTGGGCTGCGGCAAGTC
CTCGCTCCTTCTAGCCGCACTGGGGGAGATGCAGAAGGTCTCAGGGGCTGTCTTC
TGGAGCAGCCTTCCTGACAGCGAGATAGGAGAGGACCCAGCCAGAGCGGGAG
ACAGCGACCGACTTGGATATCAGGAAGAGAGGCCCGTGGCCTATGCTTCGCAG
AAACCATGGCTGCTAAATGCCACTGTGGAGGAGAACATCATCTTGAGAGTCCCT
35 TCAACAAACAACGGTACAAGATGGTCAATTGAAGCCTGCTCTCTGCAGCCAGACA
TCGACATCCTGCCCCATGGAGACCAGACCCAGATTGGGGAACGGGGCATCAACC
TGCTGTGGTGGTCAACGCCAGCGAATCAGTGTGGCCCGAGCCCTCTACCAGCACGC
CAACGTTGTCTTCTTGGATGACCCCTTCTCAGCTCTGGATATCCATCTGAGTGACC
ACTTAATGCAGGCCGGCATCCTTGAGCTGCTCCGGGACGACAAGAGGACAGTGG
40 TCTTAGTGACCCACAAGCTACAGTACCTGCCCCATGCAGACTGGATCATTGCCAT
GAAGGATGGCACCATCCAGAGGGAGGGTACCCTCAAGGACTTCCAGAGGTCTGA
ATGCCAGCTCTTTGAGCACTGGAAGACCCTCATGAACCGACAGGACCAAGAGCT
GGAGAAGGAGACTGTCACAGAGAGAAAAGCCACAGAGCCACCCAGGGCCTAT
CTCGTGCCATGTCTCGAGGGATGGCCTTCTGCAGGATGAGGAAGAGGAGGAAG
45 AGGAGGCAGCTGAGAGCGAGGAGGATGACAACCTGTCGTCCATGCTGCACCAGC
GTGCTGAGATCCCATGGCGAGCCTGCGCCAAGTACCTGTCTCCGCCGGCATCCT
GCTCCTGTCGTTGCTGGTCTTCTCACAGCTGCTCAAGCACATGGTCCTGGTGGCC
ATCGACTACTGGCTGGCCAAGTGGACCGACAGCGCCCTGACCCTGACCCCTGCA
GCCAGGAAGTGTCCCTCAGCCAGGAGTGACCCCTCGACCAGACTGTCTATGCCA

TGGTGTTCACGGCTGTCTGCAGCCTGGGCATTGTGCTGTGCCTCGTCACGTCTGTC
ACTGTGGAGTGGACAGGGCTGAAGGTGGCCAAGAGACTGCACCGCAGCCTGCTA
AACCGGATCATCCTAGCCCCCATGAGGTTTTTTGAGACCACGCCCTTGGGAGCA
TCCTGAACAGATTTTCATCTGACTGTAACACCATCGACCAGCACATCCCATCCAC
5 GCTGGAGTGCCTGAGCCGCTCCACCCTGCTCTGTGTCTCAGCCCTGGCCGTCATC
TCCTATGTCACACCTGTGTTCCCTCGTGGCCCTCTTGCCCCTGGCCATCGTGTGCTA
CTTCATCCAGAAGTACTTCCGGGTGGCGTCCAGGGACCTGCAGCAGCTGGATGAC
ACCACCCAGCTTCCACTTCTCTCACACTTTGCCGAAACCGTAGAAGGACTCACCA
CCATCCGGGCCTTCAGGTATGAGGCCCGGTTCCAGCAGAAGCTTCTCGAATACAC
10 AGACTCCAACAACATTGCTTCCCTCTTCCTCACAGCTGCCAACAGATGGCTGGAA
GTCCGAATGGAGTACATCGGTGCATGTGTGGTGTCTATCGCAGCGGTGACCTCCA
TCTCCAACTCCCTGCACAGGGAGCTCTCTGCTGGCCTGGTGGGCCTGGGCCTTAC
CTACGCCCTAATGGTCTCCAACCTCAACTGGATGGTGAGGAACCTGGCAGAC
ATGGAGCTCCAGCTGGGGGCTGTGAAGCGCATCCATGGGCTCCTGAAAACCGAG
15 GCAGAGAGCTACGAGGGGACTCCTGGCACCATCGCTGATCCCAAAGAACTGGCCA
GACCAAGGGAAGATCCAGATCCAGAACCTGAGCGTGCCTACGACAGCTCCCTG
AAGCCGGTGCTGAAGCACGTCAATGCCCTCATCTCCCCTGGACAGAAGATCGGG
ATCTGCGGCCGACCCGGCAGTGGGAAGTCCTCCTTCTCTTGCCTTCTTCCGCAT
GGTGGACACGTTCTGAAGGGCACATCATCATTGATGGCATTGACATCGCCAACT
20 GCCGCTGCACACCCTGCGCTCACGCTCTCCATCATCCTGCAGGACCCCGTCCTC
TTCAGCGGCACCATCCGATTAACTGACCCTGAGAGGAAGTGCTCAGATAGC
ACACTGTGGGAGGCCCTGGAAATCGCCAGCTGAAGCTGGTGGTGAAGGCACTG
CCAGGAGGCCTCGATGCCATCATCACAGAAGGCGGGGAGAATTCAGCCAGGGA
CAGAGGCAGCTGTTCTGCCTGGCCCGGGCCTTCGTGAGGAAGACCAGCATCTTCA
25 TCATGGACGAGGCCACGGCTTCCATTGACATGGCCACGGAAAACATCTCCAAA
AGGTGGTGATGACAGCCTTCGCAGACCGCACTGTGGTCACCATCGCGCATCGAGT
GCACACCATCCTGAGTGCAGACCTGGTGATCGTCCTGAAGCGGGGTGCCATCCTT
GAGTTCGATAAGCCAGAGAAGCTGCTCAGCCGGAAGGACAGCGTCTTCGCCTCC
TTCGTCCGTGCAGACAAGTGACCTGCCAGAGCCCAAGTGCCATCCCACATTCTGGA
30 CCCTGCCCATACCCCTGCCTGGGTTTTCTAACTGTAAATCACTTGTAATAAATA
GATTTGATTATTTCTTAAA

SEQ ID NO: 260

>2211267F6

35 GAAAGAAACAGATAACACCAAACCAAACCCCGTAGCTCCATATTGGACATCCCC
AGAAAAGATGGAAAAGAAATTGCATGCAGTGCCGGCTGCCAAGACAGTGAAGTT
CAAATGCCCTTCCAGTGGGACCCCAAACCCACACTGCGCTGGTTGAAAAATGG
CAAAGAATTCAAACCTGACCACAGAATTGGAGGCTACAAGGTCCGTTATGCCAC
CTGGAGCATCATAATGGACTCTGTGGTGGCCTCTGACAAGGGCAACTACACCTGC
40 ATTGTTGGAGAATGAGTACGGCAGCATCAACCACACATACCAGCTGGATGTCGTG
GAGCGGTCCCCTCACCGGCCCATCCTGCAAGCAGGGTTGCCCGCCAAACAAAACA
GTGGCCTGGGTAGCAACGTGGAGTTCATGTGTAAGGTGTACAGTGACCCGCAGC
CGCACATCCAGTGGCTAAAGCACATCGAGGTGAATGGGAGCAAGATTGGCCCAG
ACAACCTGCTTATGTC
45

SEQ ID NO: 261

>gi|186287|gb|M54933.1|HUMIL1C Human monocyte interleukin mRNA, complete cds

GACAAACCTTTTCGAGGCAAAAGGCAAAAAAGGCTGCTCTGGGATTCTCTTCAG
CCAATCTTCAATGCTCAAGTGTCTGAAGCAGCCATGGCAGAAGTACCTAAGCTCG

CCAGTGAAATGATGGCTTATTACAGTGGCAATGAGCATGACTTGTTCTTTGAAGC
 TGATGGCCCTAAACAGATGAAGTGCTCCTTCCAGGACCTGGACCTCTGCCCTCTG
 GATGGCGGCATCCAGCTACGAATCTCCGACCACCACTACAGCAAGGGCTTCAGG
 CAGGCCGCGTCAGTTGTTGTGGCCATGGACAAGCTGAGGAAGATGCTGGTTCCT
 5 GCCCACAGACCTTCCAGGAGAATGACCTGAGCACCTTCTTCCCTTCATCTTTGA
 AGAAGAACCTATCTTCTTCGACACATGGGATAACCAGGCTTATGTGCACGATGCA
 CCTGTACGATCACTGAACTGCACGCTCCGGGACTCACAGCAAAAAAGCTTGGTG
 ATGTCTGGTCCATATGAACTGAAAGCTCTCCACCTCCAGGGACAGGATATGGAGC
 AACAAGTGGTGTCTCCATGTCTTTGTACAAGGAGAAGAAAGTAATGACAAAA
 10 TACCTGTGGCCTTGGCCCTCAAGGAAAAGAATCTGTACCTGTCTGCGTGTGAA
 AGATGATAAGCCCACTCTACAGCTGGAGAGTGTAGATCCCAAAAATTACCCAAA
 GAAGAAGATGGAAAAGCCATTTGTGTTCAACAAGATAGAAATCAATAACAAGCT
 GGAATTTGAGTCTGCCAGTTCCCAACTGGTACATCAGCACCTCTCAAGCAGAA
 AACATGCCCGTCTTCTGGGAGGGACCAAAGGCGGCCAGGATATAACTGACTTC
 15 ACCATGCAATTTGTGTCTTCTTAAAGAGAGCTGTACCCAGAGAGTCTGTGCTGA
 ATGTGGACTCAATCCCTAGGGCTGGCAGAAAGGGAACAGAAAGGTTTTTCAGTA
 CGGCTATAGCCTGGACTTTCTGTGTCTACACCAATGCCCAACTGCCTGCCTTAG
 GGTAAGTGTAAAGAGGATCTCCTGTCCATCAGCCAGGACAGTCAGTCTCTCCTTT
 CAGGCCAATCCCAGCCCTTTTGTGTAGCCAGGCCTCTCTCACCTCTCCTACTCACT
 20 TAAAGCCCGCCTCACAGAAACCAGGCCACATTTTGGTTCTAAGAAACCCTCCTCT
 CTCATTGCTCCCACATTCTGATGAGCAACCGCTTCCCTATTTATTTATTTATTTGT
 TTGTTTGTTTTGATTCAATTTATTCAAAGGGGGCAAGAAGTAGCAGT
 GTCTGTAAAAGAGCCTAGTTTTAATAGCTATGGAATCAATTCAATTTGGACTGG
 TGTGCTCTCTTAAATCAAGTCCTTTAATTAAGACTGAAAATATATAAGCTCAGA
 25 TTATTTAAATGGGAATATTTATAAATGAGCAAATATCATACTGTTCAATGGTTCT
 CAAATAAACTTCACT

SEQ ID NO: 262

>gi|2056756|gb|AA402960.1|AA402960 zu54d12.s1 Soares ovary tumor NbHOT Homo
 sapiens cDNA clone IMAGE:741815 3', mRNA sequence
 30 TTTTTTTTTTTATATTTACCTTTTTTATTGAATTTGTATTAAAGGAGGTAGTGAG
 GGGGCGGAACGACTTAAGAGTCAGAATCCATATTAGACTCTGGGGAGTGAAAAA
 TTAAATTAAATCAGTAAGATGGGGAGTGGGGGAAGAGTCAGAGGGAACCTTTGCC
 CACCTTTGAAGATCAAATCAAGAAATCAGGGAAAGCAAAGACTTAGGAGAGGA
 35 GAAAGACATTCTCTCAATCCATCCTCCTTCCCCAGGGCAGAGAATTAAACAACGT
 TACTGAGTGAGCCTCTG

SEQ ID NO: 263

>gi|285960|dbj|D14695.1|HUMORF12 Human mRNA for KIAA0025 gene, complete cds
 40 CGTGAACGGTCGTTGCAGAGATTGCGGGCGGCTGAGACGCCGCCTGCCTGGCAC
 CTAGGAGCGCAGCGGAGCCCCGACACCGCCGCCGCCATGGAGTCCGAGACC
 GAACCCGAGCCCGTCACGCTCCTGGTGAAGAGCCCCAACCAGCGCCACCGCGAC
 TTGGAGCTGAGTGGCGACCGCGGCTGGAGTGTGGGCCACCTCAAGGCCACCTG
 AGCCGCGTCTACCCCGAGCGTCCGCGTCCAGAGGACCAGAGGTTAATTTATTCTG
 45 GGAAGCTGTTGTTGGATCACCAATGTCTCAGGGACTTGCTTCCAAAGCAGGAAA
 AACGGCATGTTTTGCATCTGGTGTGCAATGTGAAGAGTCCTTCAAAAATGCCAGA
 AATCAACGCCAAGGTGGCTGAATCCACAGAGGAGCCTGCTGGTTCTAATCGGGG
 ACAGTATCCTGAGGATTCTCAAGTGATGGTTTAAGGCAAAGGGAAGTTCTTCGG
 AACCTTTCTTCCCTGGATGGGAAAACATCTCAAGGCCTGAAGCTGCCCAGCAGG

CAITCCAAGGCCTGGGTCCTGGTTTCTCCGGTTACACACCCTATGGGTGGCTTCA
GCTTTCCTGGTTCCAGCAGATATATGCACGACAGTACTACATGCAATATTTAGCA
GCCACTGCTGCATCAGGGGCTTTTGTTCACCAACCAAGTGCACAAGAGATACCTG
TGGTCTCTGCACCTGCTCCAGCCCCTATTCACAACCAGTTTCCAGCTGAAAACCA
5 GCCTGCCAATCAGAATGCTGCTCCTCAAGTGGTTGTTAATCCTGGAGCCAATCAA
AATTTGCGGATGAATGCACAAGGTGGCCCTATTGTGGAAGAAGATGATGAAATA
AATCGAGATTGGTTGGATTGGACCTATTGAGCAGCTACATTTTCTGTTTTTCTCAG
TATCCTCTACTTCTACTCCTCCCTGAGCAGATTCCCTCATGGTCATGGGGGCCACCG
TTGTTATGTACCTGCATCACGTTGGGTGGTTTCCATTTAGACCGAGGCCGGTTCA
10 GAACTTCCCAAATGATGGTCCTCCTCCTGACGTTGTAAATCAGGACCCCAACAAT
AACTTACAGGAAGGCACTGATCCTGAAACTGAAGACCCCAACCACCTCCCTCCA
GACAGGGATGTACTAGATGGCGAGCAGACCAGCCCCTCCTTTATGAGCACAGCA
TGGCTTGTCTTCAAGACTTTCTTTGCCTCTCTTCTTCCAGAAGGCCCCCAGCCAT
CGCAAACCTGATGGTGTGTTGTGCTGTAGCTGTTGGAGGCTTTGACAGGAATGGACT
15 GGATCACCTGACTCCAGCTAGATTGCCTCTCCTGGACATGGCAATGATGAGTTTT
TAAAAAACAGTGTGGATGATGATATGCTTTTGTGAGCAAGCAAAAGCAGAAACG
TGAAGCCGTGATACAAATTGGTGAACAAAAAATGCCCAAGGCTTCTCATGTGTTT
ATTCTGAAGAGCTTTAATATATACTCTATGTAGTTTAATAAGCACTGTACGTAGA
AGGCCTTAGGTGTTGCATGTCTATGCTTGAGGAACTTTCCAAATGTGTGTGTCTG
20 CATGTGTGTTTGTACATAGAAGTCATAGATGCAGAAAGTGGTTCTGCTGGTAAGAT
TTGATTCCCTGTTGGAATGTTTAAATTACACTAAGTGTACTACTTTATATAATCAAT
GAAATTGCTAGACATGTTTTAGCAGGACTTTTCTAGGAAAGACTTATGTATAATT
GCTTTTTAAATGCAGTGCTTTACTTTAAACTAAGGGGAACTTTGCGGAGGTGAA
AACCTTTGCTGGGTTTCTGTTCAATAAAGTTTACTATGAATGACCCCTG
25

SEQ ID NO: 264

>gi|1004270|emb|X87159.1|HSSCNN1B H.sapiens mRNA for beta subunit of epithelial
amiloride-sensitive sodium channel

TCGCCGGGTGTCCCAAGTGTACCAACACTCGGCCGCCGCCGCCAGCTTGGCGCGC
30 ACCGCCGCCTCCGCCACCGCCGACAGCGCGCATCCTCCGTGTCCCCGCTCCGCCG
CCCGAGCAGGTGCCACTATGCACGTGAAGAAGTACCTGCTGAAGGGCCTGCATC
GGCTGCAGAAGGGCCCCGGCTACACGTACAAGGAGCTGCTGGTGTGGTACTGCG
ACAACACCAACACCCACGGCCCCAAGCGCATCATCTGTGAGGGGCCCAAGAAGA
AAGCCATGTGGTTCCTGCTCACCCTGCTCTTCGCCGCCCTCGTCTGCTGGCAGTGG
35 GGCATCTTCATCAGGACCTACTTGAGCTGGGAGGTCAGCGTCTCCCTCTCCGTAG
GCTTCAAGACCATGGACTTCCCCGCCGTCACCATCTGCAATGCTAGCCCCTTCAA
GTATTCCAAAATCAAGCATTGCTGAAGGACCTGGATGAGCTGATGGAAGCTGTC
CTGGAGAGAATCCTGGCTCCTGAGCTAAGCCATGCCAATGCCACCAGGAACCTG
AACTTCTCCATCTGGAACCACACACCCCTGGTCCTTATTGATGAACGGAACCCCC
40 ACCACCCCATGGTCCTTGATCTCTTTGGAGACAACCACAATGGCTTAACAAGCAG
CTCAGCATCAGAAAAGATCTGTAATGCCACGGGTGCAAAATGGCCATGAGACT
ATGTAGCCTCAACAGGACCCAGTGTACCTTCCGGAACCTCACCAGTGCTACCCAG
GCATTGACAGAGTGGTACATCCTGCAGGCCACCAACATCTTTGCACAGGTGCCAC
AGCAGGAGCTAGTAGAGATGAGCTACCCCGGCGAGCAGATGATCCTGGCCTGCC
45 TATTCGGAGCTGAGCCCTGCAACTACCGGAACCTCACGTCCATCTTCTACCCCTCA
CTATGGCAACTGTTACATCTTCAACTGGGGCATGACAGAGAAGGCACTTCCTTCG
GCCAACCCCTGGAAGTGAATTGCGCCTGAAGTTGATCCTGGACATAGGCCAGGAA
GACTACGTCCCCTTCTTGCCTCCACGGGCGGGGTCAGGCTGATGCTTCACGAGC
AGAGGTCATACCCCTTCATCAGAGATGAGGGCATCTACGCCATGTCGGGGACAG

AGACGTCCATCGGGGTACTCGTGGATAAGCTTCAGCGCATGGGGGAGCCCTACA
 GCCCGTGACCGTGAATGGTTCTGAGGTCCCCGTCCAAAACCTTCTACAGTGACTA
 CAACACGACCTACTCCATCCAGGCCTGTCTTCGCTCCTGCTTCCAAGACCACATG
 5 ATCCGTAACCTGCAACTGTGGCCACTACCTGTACCCACTGCCCCGTGGGGAGAAAT
 ACTGCAACAACCGGGACTTCCCAGACTGGGCCCATTTGCTACTCAGATCTACAGAT
 GAGCGTGGCGCAGAGAGAGACCTGCATTGGCATGTGCAAGGAGTCCTGCAATGA
 CACCCAGTACAAGATGACCATCTCCATGGCTGACTGGCCTTCTGAGGCCTCCGAG
 GACTGGATTTTCCACGTCTTGTCTCAGGAGCGGGACCAAAGCACCAATATCACCC
 TGAGCAGGAAGGGAATTGTCAAGCTCAACATCTACTTCCAAGAATTTAACTATCG
 10 CACCATTGAAGAATCAGCAGCCAATAACATCGTCTGGCTGCTCTCGAATCTGGGT
 GGCCAGTTTGGCTTCTGGATGGGGGGCTCTGTGCTGTGCCTCATCGAGTTTGGGG
 AGATCATCATCGACTTTGTGTGGATCACCATCATCAAGCTGGTGGCCTTGGCCAA
 GAGCCTACGGCAGCGGCGAGCCCAAGCCAGCTACGCTGGCCACCGCCACCGT
 GGCCGAGCTGGTGGAGGCCACACCAACTTTGGCTTCCAGCCTGACACGGCCCCC
 15 CGCAGCCCCAACACTGGGCCCTACCCAGTGAGCAGGCCCTGCCATCCCAGGC
 ACCCCGCCCCCAACTATGACTCCCTGCGTCTGCAGCCGCTGGACGTCATCGAGT
 CTGACAGTGAGGGTGATGCCATCTAACCTGCCCTGTCCACCCCGGGTGGGTGA
 AACTCACTGAGCAGCCAAGACTGTTGCCCGAGGACTCACTGTATGGTGGCCTCTC
 CAAAGGGTCGGGAGGGTAGCTCTCAGGCCAGAGCTTGTGTCCTTCAACAGAGA
 20 GGCCAGCGGCAACTGGTCCGTTACTGGCCAAGGGCTCTGAAGAATCAACGGTGC
 TGGTACAGGATACAGGAATAAATTGTATCTTCACCTGGTTCCTACCTCGTCCCT
 25 ACCTGTCTGATCCTGGTCCTGAAGACCCCTCGGAACACCCTCTCCTGGTGGCAG
 GCCACTTCCCTCCCAGTGCCAGTCTCCATCCACCCAGAGAGGAACAGGGGGGTG
 GGCCATGTGGTTTCTCCTTCTGGCCTTGGCTGGCCTCTGGGGCAGGGGTGGTG
 GAGAGATGGAAGGGCATCAGGTGTAGGGACCCTGCCAAGTGGCACCTGATTTAC
 TCTAGAAAATAAAAGTAGAAAATACTGAGAAAAA

SEQ ID NO: 265

>gi|1408187|gb|U59167.1|HSU59167 Human desmin mRNA, complete cds

30 CCTCGCCGCATCCACTCTCCGGCCGGCCGCTGCCCGCCGCTCCTCCGTGCGCC
 CGCCAGCCTCGCCCGCGCCGTCACCATGAGCCAGGCCTACTCGTCCAGCCAGCGC
 GTGTCCTCCTACCGCCGCACCTTCGGCGGCGCCCCGGGCTTCCCGCTCGGCTCCC
 CGCTGAGCTCGCCCGTGTTCGGCGGGCGGGTTTCGGCTCTAAGGGCTCCTCCAG
 CTCGGTGACGTCCCGCGTGTACAGGTGTGCGGCACGTGCGGCGGGGCGGGGG
 35 CCTGGGGTCGCTGCGGGCCAGCCGGCTGGGGACCACCCGCACGCCCTCCTCCTAC
 GGCGCAGGCGAGCTGCTGGACTTCTCACTGGCCGACGCGGTGAACCAGGAGTTT
 CTGACCACGCGCACCAACGAGAAGGTGGAGCTGCAGGAGCTCAATGACCGCTTC
 GCCAACTACATCGAGAAGGTGCGCTTCTTGAGCAGCAGAACGCGCTCGCCGCC
 GAAGTGAACCGGCTCAAGGGCCGCGAGCCGACGCGAGTGGCCGAGCTCTACGAG
 40 GAGGAGCTGCGGGAGCTGCGGCGCCAGGTGGAGGTGCTACTAACCAGCGCGCG
 CGGTCGACGTCGAGCGCGACAACCTGCTCGACGACCTGCAGCGGCTCAAGGCC
 AAGCTGCAGGAGGAGATTCAAGTTGAAGGAAGAAGCAGAGACAATTTGGCTGCC
 TTCCGAGCGGACGTGGATGCAGCTACTCTAGCTCGCATTGACCTGGAGCGCAGA
 ATTGAATCTCTCAACGAGGAGATCGCGTTCTTAAGAAAGTGCATGAAGAGGAG
 45 ATCCGTGAGTTGCAGGCTCAGCTTCAGGAACAGCAGGTCCAGGTGGAGATGGAC
 ATGTCTAAGCCAGACCTCACTGCCGCCCTCAGGGATATCCGGGCTCAGTATGAGA
 CCATCGCGGCTAAGAACATTTCTGAAGCTGAGGAGTGGTACAAGTCGAAGGTGT
 CAGACCTGACCCAGGCAGCCAACAAGAACAACGACGCCCTGCGCCAGGCCAAGC
 AGGAGATGATGGAATACCGACACCAGATCCAGTCCTACACCTGCGAGATTGACG

CCCTCAAGGGCACTAACGATTCCCTGATGAGGCAGATGCGGGAATTGGAGGACC
GATTTGCCAGTGAGGCCAGTGGCTACCAGGACAACATTGCGCGCCTGGAGGAAG
AAATCCGGCACCTCAAGGATGAGATGGCCCGCCATCTGCGCGAGTACCAGGACC
TGCTCAACGTGAAGATGGCCCTGGATGTGGAGATTGCCACCTACCGGAAGCTGCT
5 GGAGGGAGAGGAGAGCCGGATCAATCTCCCCATCCAGACCTACTCTGCCCTCAA
CTTCCGAGAAACCAGCCCTGAGCAAAGGGGTCTGAGGTCCATACCAAGAAGAC
GGTGATGATCAAGACCATCGAGACACGGGATGGGGAGGTTCGTCAGTGAGGCGAC
ACAGCAGCAGCATGAAGTGCTCTAAAGACGAGAGACCCTCTGCCACCAGAGACC
GTCCTCACCCCTGTCTCACTGCTCCCTGAAGCCCAGCCTTCTTCCATCCCAGGAC
10 ACCACACCCAGCCTCAGTCCTCCCGTCACAGCCTCTGACCCCTCCTCACTGGCCA
TCCCTCGTGGTCCCCAACAGCGACATAGCCCATCCCTGCCTGGTCACAGGCATGC
CCCGGCCACCTCTGCGGACCCCAAGCTGTGAGCCTTGGCTGTTGGCAGTGAGTGAG
CCTGGCTCTTGTGCTGGATGGAGCCCAGGCGGGAGCGGTGGCCCTGTCCCTCCCA
CCTCTGTGACCTGAGGCCTACGCTTTGGCTCTGGAGATAGCCCCAGAGCAGGGTG
15 TTGGGATACTGCAGGGCCAGGACTGAGCCCCGCAGACCTCCCCAGCCCCTAGCC
CAGGAGAGAGAAAGCCAGGCAGGTAGCCTGGGGGACTAGCCCTGTGGAGACTG
GGGGGCTTGAAATTGTCCCCGTGGTCTCTTACTTTCTTTCCCCAGCCCAGGGTGG
ACTTAGAAAGCAGGGGGCTACAAGAGGGGAATCCCCGAAGGTGCTGGAGGTGGGA
GCAGGAGATTGAGAAGGAGAGAAAGTGGGTGAGATGCTGGAGAAGAGAGAGGA
20 GGAGAGAGGCAGAGAGCGGTCTGAGGCTGGTGGGAGGGGCGCCCACCTCCCCAC
GCCCTCCCCCCCCCTGCTGCAGGGGCTCTGGAGAGAAACAATAAA

SEQ ID NO: 266

>1649377H1

25 GCCCAGTTAAATAACATTGACAGACTTGCCAACACGATCACAATGATCGAAGAG
GAGATGGTGCAGCTTCGCAAAGATACGAAAAAGCTGTTTCAGCATCGAAATGAA
AGGTAAAAACCAGCCTCTGCCTCTGAATTTGACCATAGTGGCGTTCAGCTGATAG
AGCGGGAAGAAGAAATATGCATTTTTTATGAAAAAATAAATATCCAAGAGAAGA
TGAAACTAAAT

30

SEQ ID NO: 267

>gi|347522|gb|L22206.1|HUMV2R Human vasopressin receptor V2 gene, complete cds

35 AGAAGATCCTGGGTCTGTGCATCCGTCTGTCTGACCATCCCTCTCAATCTTCCCT
GCCCAGGACTGGCCATACTGCCAUCGCAACACGIGCACACACGCCAACAGGCATC
TGCCATGCTGGCATCTCTATAAGGGCTCCAGTCCAGAGACCCTGGGCCATTGAAC
TTGCTCCTCAGGCAGAGGCTGAGTCCGCACATCACCTCCAGGCCCTCAGAACACC
TGCCCCAGCCCCACCATGCTCATGGCGTCCACCACTTCCGGTAAGGCTTGCCCT
CCATGAGTCCGGTGGGCAGAGTGGGTTTGACGATTGAGGGAAGCCCCTCTTTCTA
AAGACCTCCTTCACCTCACCTCTGGGTGTGTCTCTCCAGGCTGCCAATGAGTGG
40 GGAGGGGAGCACAGCCCCACTTCCCCGCCAGGGCTGGGGCTGGGGCTGGGGCTG
GGCTTTCTTGAGTCCCCTCTGCTAGGAGCCAGGAAGTGGGTGTCCGGATGGGG
GCACGGGAGGCAGGCCTGAGTCCCCCTGCACAGCACCTCTCTAACCAGGCCCTC
TTCCCGACTCCTGCCCAGCTGTGCCTGGGCATCCCTCTCTGCCAGCCTGCCAGC
45 AACAGCAGCCAGGAGAGGCCACTGGACACCCGGGACCCGCTGCTAGCCCGGGCG
GAGCTGGCGCTGCTCTCCATAGTCTTTGTGGCTGTGGCCCTGAGCAATGGCCTGG
TGCTGGCGGCCCTAGCTCGGCGGGGCGGGCGGGGCCACTGGGCACCCATACACG
TCTTCATTGGCCACTTGTGCCTGGCCGACCTGGCCGTGGCTCTGTTCCAAGTGCTG
CCCCAGCTGGCCTGGAAGGCCACCGACCGCTTCCGTGGGCCAGATGCCCTGTGTC

GGGCCGTGAAGTATCTGCAGATGGTGGGCATGTATGCCTCCTCCTACATGATCCT
GGCCATGACGCTGGACCGCCACCGTGCCATCTGCCGTCCCATGCTGGCGTACCGC
CATGGAAGTGGGGCTCACTGGAACCGGCCGGTGCTAGTGGCTTGGGCCTTCTCGC
5 TCCTTCTCAGCCTGCCCCAGCTCTTCATCTTCGCCCAGCGCAACGTGGAAGGTGG
CAGCGGGGTCACTGACTGCTGGGCCTGCTTTGCGGAGCCCTGGGGCCGTGCGACC
TATGTCACCTGGATTGCCCTGATGGTGTTCGTGGCACCTACCCTGGGTATCGCCG
CCTGCCAGGTGCTCATCTTCCGGGAGATTCATGCCAGTCTGGTGCCAGGGCCATC
AGAGAGGCCTGGGGGGCGCCGACGGGGACGCCGGACAGGCAGCCCCGGTGAGG
GAGCCACGTGTCAGCAGCTGTGGCCAAGACTGTGAGGATGACGCTAGTGATTG
10 TGGTCGTCTATGTGCTGTGCTGGGCACCCTTCTTCCTGGTGCAGCTGTGGGCCGC
GTGGGACCCGGAGGCACCTCTGGAAGGTGGGTGTAGCCGTGGCTAGGGCTGACG
GGGCCACTTGGGCTTGGCCGCATGCCCTGTGCCCCACCAGCCATCCTGAACCCA
ACCTAGATCCTCCACCTCCACAGGGGGCGCCCTTTGTGCTACTCATGTTGCTGGCC
AGCCTCAACAGCTGCACCAACCCCTGGATCTATGCATCTTTCAGCAGCAGCGTGT
15 CCTCAGAGCTGCGAAGCTTGCTCTGCTGTGCCCGGGGACGCACCCACCCAGCCT
GGGTCCCCAAGATGAGTCTGCACCACCGCCAGCTCCTCCCTGGCCAAGGACACT
TCATCGTGAGGAGCTGTGGGTGTCTTGCTCTAGAGGCTTTGAGAAGCTCAGCT
GCCTTCCTGGGGCTGGTCCTGGGAGCCACTGGGAGGGGGACCCGTGGAGAATTG
GCCAGAGCCTGTGGCCCCGAGGCTGGGACACTGTGTGGCCCTGGACAAGCCACA
20 GCCCCTGCCTGGGTCTCCACATCCCCAGCTGTATGAGGAGAGCTTCAGGCCCCAG
GACTGTGGGGGGCCCTCAGGTCAGCTCACTGAGCTGGGTGTAGGAGGGGCTGCA
GCAGAGGCCTGAGGAGTGGCAGGAAAGAGGGAGCAGGTGCCCCCAGGTGAGAC
AGCGGTCCCAGGGGCTGAAAAGGAAGGACCAGGCTGGGGCCAGGGGACCTTCC
TGCTCTCCGCCTTCTAATCCCTCCCTCCTCATTCTCTCCCTAATAAAAATTGGAGC
25 TCATTTTCCACATGGCAAGGGGTCTCCTTGATCCTCT

SEQ ID NO: 268

>gi|28720|emb|X06989.1|HSAPA4R Human mRNA for amyloid A4(751) protein

GAATTCCCGCGGAGCAGCGTGCGCGGGGCCCCGGGAGACGGCGGGCGGTAGCGGC
30 GCGGGCAGAGCAAGGACGCGCGGATCCCACTCGCACAGCAGCGCACTCGGTGC
CCCGCGCAGGGTCGCGATGCTGCCCGGTTTGGCACTGCTCCTGCTGGCCGCCTGG
ACGGCTCGGGCGCTGGAGGTACCCACTGATGGTAATGCTGGCCTGCTGGCTGAA
CCCCAGATTGCCATGTTCTGTGGCAGACTGAACATGCACATGAATGTCCAGAATG
GGAAGTGGGATTGAGATCCATCAGGGACCAAAACCTGCATTGATACCAAGGAAG
35 GCATCCTGCAGTATTGCCAAGAAGTCTACCCTGAACTGCAGATCACCAATGTGGT
AGAAGCCAACCAACCAGTGACCATCCAGAACTGGTGCAAGCGGGGCCGCAAGCA
GTGCAAGACCCATCCCCACTTTGTGATTCCCTACCGCTGCTTAGTTGGTGAGTTTG
TAAGTGATGCCCTTCTCGTTCCTGACAAGTGCAAATTCTTACACCAGGAGAGGAT
GGATGTTTGCGAAACTCATCTTCACTGGCACACCGTCGCCAAAGAGACATGCAGT
40 GAGAAGAGTACCAACTTGCATGACTACGGCATGTTGCTGCCCTGCGGAATTGAC
AAGTTCCGAGGGGTAGAGTTTGTGTGTTGCCCACTGGCTGAAGAAAGTGACAAT
GTGGATTCTGCTGATGCGGAGGAGGATGACTCGGATGTCTGGTGGGGCGGAGCA
GACACAGACTATGCAGATGGGAGTGAAGACAAAGTAGTAGAAGTAGCAGAGGA
GGAAGAAGTGGCTGAGGTGGAAGAAGAAGCCGATGATGACGAGGACGATG
45 AGGATGGTGATGAGGTAGAGGAAGAGGCTGAGGAACCCTACGAAGAAGCCACA
GAGAGAACCACCAGCATTGCCACCACCACCACCACCACAGAGTCTGTGGAA
GAGGTGGTTCGAGAGGTGTGCTCTGAACAAGCCGAGACGGGGCCGTGCCGAGCA
ATGATCTCCCGCTGGTACTTTGATGTGACTGAAGGGAAGTGTGCCCCATTCTTTT
ACGGCGGATGTGGCGGCAACCGGAACAACCTTTGACACAGAAGAGTACTGCATGG

CCGTGTGTGGCAGCGCCATTCTACAACAGCAGCCAGTACCCCTGATGCCGTTGA
CAAGTATCTCGAGACACCTGGGGATGAGAATGAACATGCCCATTTCAGAAAGC
CAAAGAGAGGCTTGAGGCCAAGCACCGAGAGAGAATGTCCCAGGTCATGAGAG
AATGGGAAGAGGCAGAACGTCAAGCAAAGAAGCTTGCCTAAAGCTGATAAGAAG
5 GCAGTTATCCAGCATTTCCAGGAGAAAGTGGAATCTTTGGAACAGGAAGCAGCC
AACGAGAGACAGCAGCTGGTGGAGACACACATGGCCAGAGTGGAAGCCATGCTC
AATGACCGCCGCCGCTGGCCCTGGAGAACTACATCACCGCTCTGCAGGCTGTTC
CTCCTCGGCCTCGTCACGTGTTCAATATGCTAAAGAAGTATGTCCGCGCAGAACA
GAAGGACAGACAGCACACCCCTAAAGCATTTCGAGCATGTGCGCATGGTGGATCC
10 CAAGAAAGCCGCTCAGATCCGGTCCCAGGTTATGACACACCTCCGTGTGATTTAT
GAGCGCATGAATCAGTCTCTCTCCCTGCTCTACAACGTGCCTGCAGTGGCCGAGG
AGATTCAGGATGAAGTTGATGAGCTGCTTCAGAAAGAGCAAACTATTTCAGATG
ACGTCTTGCCCAACATGATTAGTGAACCAAGGATCAGTTACGGAAACGATGCTCT
CATGCCATCTTTGACCGAAACGAAAACCAACCGTGGAGCTCCTTCCCGTGAATGGA
15 GAGTTCAGCCTGGACGATCTCCAGCCGTGGCATTCTTTTGGGGCTGACTCTGTGC
CAGCCAACACAGAAAACGAAGTTGAGCCTGTTGATGCCCCGCCCTGCTGCCGACC
GAGGACTGACCACTCGACCAGGTTCTGGGTTGACAAATATCAAGACGGAGGAGA
TCTCTGAAGTGAAGATGGATGCAGAATTCGACATGACTCAGGATATGAAGTTC
ATCATCAAAAATTGGTGTCTTTTGAGAAGATGTGGGTTCAAACAAAGGTGCAAT
20 CATTGGACTCATGGTGGGCGGTGTTGTCATAGCGACAGTGATCGTCATCACCTTG
GTGATGCTGAAGAAGAAACAGTACACATCCATTTCATCATGGTGTGGTGGAGGTT
GACGCGCTGTCACCCCAGAGGAGCGCCACCTGTCCAAGATGCAGCAGAACGGC
TACGAAAATCCAACCTACAAGTTCTTTGAGCAGATGCAGAACTAGACCCCGCC
ACAGCAGCCTCTGAAGTTGGACAGCAAAACCAATTGCTTCACTACCEATCGGTGTC
25 CATTTATAGAATAATGTGGGAAGAAACAAACCCGTTTTATGATTTACTCATTATC
GCCTTTTGACAGCTGTGCTGTAACACAAGTAGATGCCTGAACTTGAATTAATCCA
CACATCAGTAATGTATTCTATCTCTCTTTACATTTTGGTCTCTATACTACATTATTA
ATGGGTTTTGTGTACTGTAAAGAATTTAGCTGTATCAAACCTAGTGCATGAATAGA
TTCTCTCCTGATTATTTATCACATAGCCCCCTTAGCCAGTTGTATATTATTCTTG
30 GTTTGTGACCCAATTAAGTCCTACTTTACATATGCTTTAAGAATCGATGGGGGAT
GCTTCATGTGAACGTGGGAGTTCAGCTGCTTCTCTTGCCTAAGTATTCCTTTCCTG
ATCACTATGCATTTTAAAGTTAAACATTTTAAAGTATTCAGATGCTTTAGAGAG
ATTTTTTTTCCATGACTGCATTTTACTGTACAGATTGCTGCTTCTGCTATATTTGTG
ATATAGGAATTAAGAGGATACACACGTTTGTCTTCTGTCCTGTTTTATGTGCAC
35 ACATTAGGCATTGAGACTTCAAGCTTTTCTTTTTTTGTCCACGTATCTTTGGGTCT
TTGATAAAGAAAAGAATCCCTGTTTATTGTAAGCACTTTTACGGGGCGGGTGGGG
AGGGGTGCTCTGCTGGTCTTCAATTACCAAGAATTC

SEQ ID NO: 269

40 >3107995H1
TAAACATCCCAAAACTGGAGTTTTTCGAAGAGAAACATGCCAAACCTCCAGATGT
AGACCT
TAAAAAGTTCTTTACAGACAGGAAGACTCATCTTTATACCCTTGTGATGAATCCA
GATGA
45 CACATTTGAGGTGTTAGTTGATCAAACAGTTGTAAACAAAGGAAGCCTCCTAGA
GGATGT
GGTTCCTCCTATCAAACCTCC

SEQ ID NO: 270

>gi|179579|gb|M17017.1|HUMBTLP Human beta-thromboglobulin-like protein mRNA,
complete cds

5 ACAAACCTTTCAGAGACAGCAGAGCACACAAGCTTCTAGGACAAGAGCCAGGAAG
AAACCACCGGAAGGAACCATCTCACTGTGTGTAAACATGACTTCCAAGCTGGCC
GTGGCTCTCTTGGCAGCCTTCCTGATTTCTGCAGCTCTGTGTGAAGGTGCAGTTTT
GCCAAGGAGTGCTAAAGAACTTAGATGTCAGTGCATAAAGACATACTCCAAACC
TTTCCACCCCAAATTTATCAAAGAACTGAGAGTGATTGAGAGTGGACCACACTGC
10 GCCAACACAGAAATTATTGTAAAGCTTTCTGATGGAAGAGAGCTCTGTCTGGACC
CCAAGGAAAACCTGGGTGCAGAGGGTTGTGGAGAAGTTTTTGAAGAGGGCTGAGA
ATTCATAAAAAAATTCATTCTCTGTGGTATCCAAGAATCAGTGAAGATGCCAGTG
AACTTCAAGCAAATCTACTTCAACACTTCATGTATTGTGTGGGTCTGTTGTAGG
GTTGCCAGATGCAATACAAGATTCTGTTAAATTTGAATTTTCAGTAAACAATGA
ATAGTTTTTTCATTGTACCATGAAATATCCAGAACATACTTATATGTAAAGTATTAT
15 TTATTTGAATCTACAAAAACAACAATAATTTTTGAATATAAGGATTTTCCTAG
ATATTGCACGGGAGAATATACAAATAGCAAAATTGGGCCAAGGGCCAAGAGAAT
ATCCGAACCTTAAATTTACAGGAATTGAATGGGTTTGCTAGAATGTGATATTTGAAG
CATCACATAAAAAATGATGGGACAATAAATTTTGCCATAAAGTCAAATTTAGCTGG
AAATCCTGGATTTTTTTCTGTAAATCTGGCAACCCTAGTCTGCTAGCCAGGATCC
20 ACAAGTCCTTGTTCCACTGTGCCTTGGTTTCTCCTTTATTTCTAAGTGGAAAAAGT
ATTAGCCACCATCTTACCTCACAGTGATGTTGTGAGGACATGTGGAAGCACTTTA
AGTTTTTTCATCATAACATAAATTATTTTCAAGTGTAACCTATTAACCTATTTATT
ATTTATGTATTTATTTAAGCATCAAATATTTGTGCAAGAATTTGGAAAAATAGAA
GATGAATCATTGATTGAATAGTTATAAAGATGTTATAGTAAATTTATTTATTTTA
25 GATATTAAATGATGTTTTATTAGATAAATTTCAATCAGGGTTTTTAGATTAAACA
AACAAACAATTGGGTACCCAGTTAAATTTTCATTTTCAGATAAACAACAATAATT
TTTTAGTATAAGTACATTATTGTTTATCTGAAATTTTAATTGAACTAACAAATCCTA
GTTTGATACTCCCAGTCTTGTCATTGCCAGCTGTGTTGGTAGTGCTGTGTTGAATT
ACGGAATAATGAGTTAGAACTATTAACAGCCAAAACCTCCACAGTCAATATTA
30 GTAATTTCTTGCTGGTTGAACTTGTTTATTATGTACAAATAGATTCTTATAATAT
TATTTAAATGACTGCATTTTTAAATACAAGGCTTTATATTTTAACTTTAAGATGT
TTTTATGTGCTCTCCAAATTTTTTTTACTGTTTCTGATTGTATGGAAATATAAAG
TAAATATGAAACATTTAAATATAATTTGTGTGTCAAAGT

35 SEQ ID NO: 271

>gi|521214|gb|L33404.1|HUMSERPROT Human stratum corneum chymotryptic enzyme
mRNA, complete cds

GGATTTCCGGGCTCCATGGCAAGATCCCTTCTCCTGCCCTGCAGATCCTACTGCT
ATCCTTAGCCTTGGAACCTGCAGGAGAAGAAGCCAGGGTGACAAGATTATTGA
40 TGGCGCCCCATGTGCAAGAGGCTCCCACCCATGGCAGGTGGCCCTGCTCAGTGGC
AATCAGCTCCACTGCGGAGGCGTCCTGGTCAATGAGCGCTGGGTGCTCACTGCCG
CCCCTGCAAGATGAATGAGTACACCGTGCACCTGGGCAGTGATACGCTGGGCG
ACAGGAGAGCTCAGAGGATCAAGGCCTCGAAGTCATTCCGCCACCCCGGCTACT
CCACACAGACCCATGTTAATGACCTCATGCTCGTGAAGCTCAATAGCCAGGCCAG
45 GCTGTCATCCATGGTGAAGAAAGTCAGGCTGCCCTCCCGCTGCGAACCCCTGGA
ACCACCTGTACTGTCTCCGGCTGGGGCACTACCACGAGCCAGATGTGACCTTTC
CCTCTGACCTCATGTGCGTGGATGTCAAGCTCATCTCCCCCAGGACTGCACGAA
GGTTTACAAGGACTTACTGGAAAATTCATGCTGTGCGCTGGCATCCCCGACTCC
AAGAAAAACGCCTGCAATGGTGACTCAGGGGGACCGTTGGTGTGCAGAGGTACC

CTGCAAGGTCTGGTGTCTCTGGGGAACCTTCCCTTGCGGCCAACCCAATGACCCAG
GAGTCTACACTCAAGTGTGCAAGTTCACCAAGTGGATAAATGACACCATGAAAA
AGCATCGCTAACGCCCACTGAGTTAATTAAGTGTGTGCTTCCAACAGAAAATGC
ACAGGAGTGAGGACGCCGATGACCTATGAAGTCAAATTTGACTTTACCTTTCCTC
5 AAAGATATATTTAAACCTCATGCCCTGTTGATAAACCAATCAAATTGGTAAAGAC
CTAAAACCAAAACAAATAAAGAAACACAAAACCCTCAA

SEQ ID NO: 272

>2726949H1

10 GTAAAACGGTGGTCTCAATGCCCCACTTAGCCTCTGCCTCTGAATTTGACCATAGT
GGCGTTCAGCTGATAGAGCGGGAAGAAGAAATATGCATTTTTTATGAAAAAATA
AATATCCAAGAGAAGATGAAACTAAATGGAGAAATTGAAATACATCTACTGGAA
GAAAAGATCCAATTCCTGAAAATGAAGATTGCTGAGAAGCAAAGACAAATTTGT
GTGACCCAGAAATTACTGCCAGCCAAGAGG

15

SEQ ID NO: 273

>2726952H1

TGGTCTCAATGCCCCACTTAGCCTCTGCCTCTGAATTTGACCATAGTGGCGTTCAGC
TGATAGAGCGGGAAGAAGAAATATGCATTTTTTATGAAAAAATAAATATCCAAG
20 AGAAGATGAAACTAAATGGAGAAATTGAAATACATCTACTGGAAGAAAAGATCC
AATTCCTGAAAATGAAGATTGCTGAGAAGCAAAGACAAATTTGTGTGACCCAGA
CAATTAATGCTGCCAGCCAAGAGGTC

SEQ ID NO: 274

25 >gi|990907|gb|H51066.1|H51066 yp84g12.s1 Soares fetal liver spleen 1NFLS Homo sapiens
cDNA clone IMAGE:194182 3', mRNA sequence
TGAGCAGGTAACACCCAGGNCATTTTGATGAGATCCAAAGGAGTTGTATGCACA
TGAAAGTTTGAGAAGCATCATCATAGAGAAGTAAACATCACACCCAACTTCCTTA
TCTTTCAGTGGCTAAACCACTTAACCTCTCTGGGTGTTACCTGCTCATTGTGTTA
30 AAAAAAAAAAAAAAAAAAGTCTCACCTGCTTTCATGCTGAGGNCAAGTTCAGATGTT
CAAGCCTATAATATTTNNGCAGTTCNCNAAATTTATGAAAAGNGTTCAGAAATT
GGGGAGACAGTCAAAGGGTNCAAAGCCTCAGTTAGGGGGGNTAAGTGTGATTTT
TTTTTAAAGNTCACTTGCACAGCCTGGCTAAATTTAGGGGTAATTGGAATGTATA
TTTNCAA

35

SEQ ID NO: 275

>gi|2159230|gb|AA446565.1|AA446565 zw84b11.s1 Soares_total_fetus_Nb2HF8_9w Homo
sapiens cDNA clone IMAGE:783645 3', mRNA sequence

TTTTTCAAATATATACATTTTAAATATTTGAAATATTTACATAATGGAACCACAT
40 CAGGGTTCGAGGGTAAGAACAGTGTTCATCAAATGTCCTCTCCAGGTGTGTTAAA
AAAAAAAAAAATCCAGTAATCCAAAGCTCACATTATGCTTTTCTAACAGGCCAA
TCTTTACCTTTCTTTTAAATAAGTACTCAGACATGGGAACAGTTGCATCTAATTTG
TGTGAAAAGCTGTTTAAACCTTCTTACGTTTTCAGGTAATTTTACTCCCTGGTGAA
ATTCTGATCTACAACGAAGAAAGCCCCAGGAATTTCTCTAAGCACATCATCAGTA
45 CATTTTAAACACTAATGAGCCAAGGTAAACAAGATATAAACCTTCTACAAGA
CAAAAATGAAAACAAATGGTTAGTGGTTGGTAACTGCCTTGAA

SEQ ID NO: 276

>gi|749387|gb|T99650.1|T99650 ye73h09.s1 Soares fetal liver spleen 1NFLS Homo sapiens
cDNA clone IMAGE:123425 3', mRNA sequence

5 CAATAAAATGATTTATTTTATATATGCAAAATCAAAATCTCTTTGTACACTTTAAT
TTTTGCAAATTCATACAAACATAACAATACTGCTCCATATAAACTTTTGTATAAA
CATTAAAGGAAATATACACATATTTNGTTCTTCTTGTGCTTCCAAAGCACAGAAT
GTATAAGTCCATCTGAAGACTTTCTATCATCACATGCAAGAACAAATGTCAGAGG
TTGGGGGCGAGCCTCAAGTGCACCTTTGTAATGTCTCTAGACAAAAGAGAAGAGAG
10 TTGGAGGTAGGATTGTTTGGGTGACTCTCCCTGCCCCTTCCCACAGAGGAAATAA
GGTTACCCCAAATAGGCAGCTTCTTACTTCTTTGGATTCAAACATATCCTGGANTAT
TGCATGGGTTTTAAAAGGGCNCACAAC

SEQ ID NO: 277

>463614H1

15 GCTTTGGTCTATGACCTCTGATATCTACTTTGATAATTTTATTATCTGTTTCGAAAA
AGGAAGTAGCAGATCACTGGGCTGCAGATGGTTGGAGATGGAAAATAATGATAG
CAAATGCTAATAAGCCTGGTGTATTAAAACAGTTAATGGCAGCTGCTGAAGGGC
ACCCATGGCTTTGGTTGATTATCTTGTGACAGCAGGAGTGCCAATAGCATTAAT
TACTTCATTTTGT

20

SEQ ID NO: 278

>gi|31298|emb|Y00318.1|HSFAC1 Human mRNA for complement control protein factor I

GAGAGACAAAGACCCCGAACACCTCCAACATGAAGCTTCTTCATGTTTTCTGT
ATTTCTGTGCTTCCACTTAAGGTTTTGCAAGGTCACCTATACATCTCAAGAGGATC
25 TGGTGGAGAAAAAGTGCTTAGCAAAAAAATATACTCACCTCTCCTGCGATAAAG
TCTTCTGCCAGCCATGGCAGAGATGCATTGAGGGCACCTGTGTTTGTAAGTACC
GTATCAGTGCCCAAGAATGGCACTGCAGTGTGTGCAACTAACAGGAGAAGCTT
CCCAACATACTGTCAACAAAAGAGTTTGGAAATGTCTTCATCCAGGGACAAAGTTT
TTAAATAACGGAACATGCACAGCCGAAGGAAAGTTTAGTGTTTCCTTGAAGCAT
30 GGAAATACAGATTCAGAGGGAATAGTTGAAGTAAAACCTTGTGGACCAAGATAAG
ACAATGTTTCATATGCAAAAGCAGCTGGAGCATGAGGGAAGCCAACGTGGCCTGC
CTTGACCTTGGGTTTTCAACAAGGTGCTGATACTCAAAGAAGGTTTAAGTTGTCTG
ATCTCTCTATAAATTCCACTGAATGTCTACATGTGCATTGCCGAGGATTAGAGAC
CAGTTTGGCTGAATGTACTTTTACTAAGAGAAGAACTATGGGTTACCAGGATTTCT
35 GCTGATGTGGTTTGTATACACAGAAAGCAGATTCTCCAATGGATGACTTCTTTC
AGTGTGTGAATGGGAAATACATTTCTCAGATGAAAGCCTGTGATGGTATCAATGA
TTGTGGAGACCAAGTGATGAACTGTGTTGTAAAGCATGCCAAGGCAAAGGCTT
CCATTGCAAATCGGGTGTGTTGCATTCCAAGCCAGTATCAATGCAATGGTGAGGTG
GACTGCATTACAGGGGAAGATGAAGTTGGCTGTGCAGGCTTTCATCTGTGGCTC
40 AAGAAGAAACAGAAATTTTGAAGTGTGACATGGATGCAGAAAGAAGACGGATA
AAATCATTATTACCTAACTATCTTGTGGAGTTAAAAACAGAATGCACATTCGAA
GGAAACGAATTGTGGGAGGAAAGCGAGCACAACCTGGGAGACCTCCCATGGCAG
GTGGCAATTAAGGATGCCAGTGAATCACCTGTGGGGGAATTTATATTGGTGGCT
GTTGGATTCTGACTGCTGCACATTGTCTCAGAGCCAGTAAAACCTATCGTTACCA
45 AATATGGACAACAGTAGTAGACTGGATACACCCCGACCTTAAACGTATAGTAAT
TGAATACGTGGATAGAATTATTTCCATGAAAACCTACAATGCAGGCACTTACCAA
AATGACATCGCTTTGATTGAAATGAAAAAAGACGGAAACAAAAAAGATTGTGAG
CTGCCTCGTTCATCCCTGCCTGTGTCCCCTGGTCTCCTTACCTATTCCAACCTAA
TGATACATGCATCGTTTCTGGCTGGGGACGAGAAAAAGATAACGAAAGAGTCTT

TTCAC TTCAGTGGGGTGAAGTTAACTAATAAGCAACTGCTCTAAGTTTTACGGA
AATCGTTTCTATGAAAAAGAAATGGAATGTGCAGGTACATATGATGGTTCCATCG
ATGCCTGTAAAGGGGACTCTGGAGGCCCTTAGTCTGTATGGATGCCAACAAATGT
GACTTATGTCTGGGGTGTGTGAGTTGGGGGGAAAACTGTGGAAAACCAAGAGTT
5 CCCAGGTGTTTACACCAAAGTGGCCAATTATTTTGACTGGATTAGCTACCATGTA
GGAAGGCCTTTTATTTCTCAGTACAATGTATAAAATTGTGATCTCTCTCTTCATTC
TATTCTTTTCTCTCAAGAGTTCCATTTAATGGAAATAAAACGGTATAATTAATAA
TTCTCTAGGGGGGAAAAATGAAGCAAATCTCATTGGATATTTTAAAGGTCTCCA
CAGAGTTTATGCCATATTGGAATTTTGTGTATAATTCTCNNGCGAATTC

10

SEQ ID NO: 279

>gi|181244|gb|M64349.1|HUMCYCD1 Human cyclin D (cyclin D1) mRNA, complete cds
GCAGTAGCAGCGAGCAGCAGAGTCCGCACGCTCCGGCGAGGGGCAGAAAGAGCG
CGAGGGAGCGCGGGGCGAGCAGAAGCGAGAGCCGAGCGCGGACCCAGCCAGGAC
15 CCACAGCCCTCCCCAGCTGCCAGGAAGAGCCCCAGCCATGGAACACCAGCTCC
TGTGCTGCGAAGTGGAAACCATCCGCCGCGCGTACCCCGATGCCAACCTCCTCAA
CGACCGGGTGCTGCGGGCCATGCTGAAGGCGGAGGAGACCTGCGCGCCCTCGGT
GTCCTACTTCAAATGTGTGCGAGAAGGAGGTCCTGCCGTCCATGCGGAAGATCGTC
GCCACCTGGATGCTGGAGGTCTGCGAGGAACAGAAAGTGCAGAGGAGGAGGTCTTC
20 CCGCTGGCCATGAACTACCTGGACCGCTTCTGTGCTGGAGCCCGTGAAAAAGA
GCCGCCTGCAGCTGCTGGGGGCCACTTGCATGTTCTGCTGGCCTCTAAGATGAAGGA
GACCATCCCCCTGACGGCCGAGAAGCTGTGCATCTACACCGACGGCTCCATCCGG
CCCAGAGAGCTGCTGCAAATGGAGCTGCTCCTGGTGAACAAGCTCAAGTGGAAC
CTGGCCGCAATGACCCCGCACGATTTCAATTGAACACTTCCTCTCCAAAATGCCAG
25 AGGEGGAGGAGAAACAAACAGATCATCCGCAAACACGCGCAGACCTTCGTTGCCT
CTTGTGCCACAGATGTGAAGTTCATTTCCAATCCGCCCTCCATGGTGGCAGCGGG
GAGCGTGGTGGCCGCAAGTGAAGGCTGAACCTGAGGAGCCCCAACAACCTTCCT
GTCCTACTACCGCCTCACACGCTTCTCTCCAGAGTGATCAAGTGTGACCCAGAC
TGCCTCCGGGCCTGCCAGGAGCAGATCGAAGCCCTGCTGGAGTCAAGCCTGCGC
30 CAGGCCCAGCAGAACATGGACCCCAAGGCCCGCCAGGAGGAGGAAGAGGAGGA
GGAGGAGGTGGACCTGGCTTGCACACCCACCGACGTGCGGGACGTGGACATCTG
AGGGGCCCAGGCAGGCGGGCGCCACCGCCACCGCAGCGAGGGCGGAGCCGGC
CCCAGGTGCTCCACATGACAGTCCCTCCTCTCCGGAGCATTTTGATAACCAGAAGG
GAAAGCTTCATTCTCCTTGTGTTGGTTGTTTTCCTTTGCTCTTTCCCCCTTCCA
35 TCTCTGACTTAAGCAAAAGAAAAAGATTACCAAAAACCTGTCTTTAAAGAGAG
AGAGAGAAAAAAGAAAAAAGAAAAAAGAAAAAAGAAAAAAGAAAAAAGAAAAA
AAAAAAGAAAAAAGAAAAAAGAAAAAAGAAAAAAGAAAAAAGAAAAAAGAAAAA

40 SEQ ID NO: 280

>gi|3004498|gb|U04357.1|HSU04357 Homo sapiens arginine vasopressin receptor type II,
V2 antidiuretic hormone receptor (AVPR2) gene, complete cds
CTTGCTCCTCAGGCAGAGGCTGAGTCCGCACATCACCTCCAGGCCCTCAGAACAC
CTGCCCCAGCCCCACCATGCTCATGGCGTCCACCACTTCCGGTAAGGCTTGCCCC
TCCATGAGTCCGGTGGGCAGAGTGGGTTTGACGATTCAGGGAAGCCCCTCTTTCT
45 AAAGACCTCCTTACCCCTCACCTCTGGGTGTGTCTCTCAGGCTGCCAATGAGTG
GGGAGGGGAGCACAGCCCCACTTCCCAGCCAGGGCTGGGGCTGGGGCTGGGGCT
GGGGCTGCCCTTCTTCTGGACTGCATGAGCCTGGGGTGTGTATCCCTCATAACA
TGGCTTTCTTGGAGTCCCCTCTGCTAGGAGCCAGGAAGTGGGTGTCCGGATGGGG
GCACGGGAGGCAGGCCTGAGTCCCCCTGCACAGCACCCCTCTCTAACCAGGCCCTC

TTCCCGACTCCTGCCCAGCTGTGCCTGGGCATCCCTCTCTGCCCAGCCTGCCCAGC
AACAGCAGCCAGGAGAGGCCACTGGACACCCGGGACCCGCTGCTAGCCCGGGCG
GAGCTGGCGCTGCTCTCCATAGTCTTTGTGGCTGTGGCCCTGAGCAATGGCCTGG
TGCTGGCGGCCCTAGCTCGGCGGGGCGGCGGGGCCACTGGGCACCCATACACG
5 TCTTCATTGGCCACTTGTGCCTGGCCGACCTGGCCGTGGCTCTGTTCCAAGTGCTG
CCCCAGCTGGCCTGGAAGGCCACCGACCGCTTCCGTGGGCCAGATGCCCTGTGTC
GGGCCGTGAAGTATCTGCAGATGGTGGGCATGTATGCCTCCTCCTACATGATCCT
GGCCATGACGCTGGACCGCCACCGTGCCATCTGCCGTCCCATGCTGGCGTACCGC
CATGGAAGTGGGGCTCACTGGAACCGGCCGGTGCTAGTGGCTTGGGCCCTTCTCGC
10 TCCTTCTCAGCCTGCCCCAGCTCTTCATCTTCGCCAGCGCAACGTGGAAGGTGG
CAGCGGGGTCAGTACTGCTGGGCCTGCTTTGCGGAGCCCTGGGGCCGTCGCACC
TATGTCACCTGGATTGCCCTGATGGTGTTCGTGGCACCTACCCTGGGTATCGCCG
CCTGCCAGGTGCTCATCTTCCGGGAGATTCATGCCAGTCTGGTGCCAGGGCCATC
AGAGAGGCCTGGGGGGCGCCGCAGGGGACGCCGGACAGGCAGCCCCGGTGAGG
15 GAGCCACGTGTCAGCAGCTGTGGCCAAGACTGTGAGGATGACGCTAGTGATTG
TGGTCGTCTATGTGCTGTGCTGGGCACCCTTCTTCCTGGTGCAGCTGTGGGGCCGC
GTGGGACCCGGAGGCACCTCTGGAAGGTGGGTGTAGCCGTGGCTAGGGCTGACG
GGGCCACTTGGGCTTGGCCGCATGCCCCTGTGCCCCACCAGCCATCCTGAACCCA
ACCTAGATCCTCCACCTCCACAGGGGCGCCCTTTGTGCTACTCATGTTGCTGGCC
20 AGCCTCAACAGCTGCACCAACCCCTGGATCTATGCATCTTTCAGCAGCAGCGTGT
CCTCAGAGCTGCGAAGCTTGCTCTGCTGTGCCCGGGGACGCACCCACCCAGCCT
GGGTCCCCAAGATGAGTCCTGCACCACCGCCAGCTCCTCCCTGGCCAAAGGACACT
TCATCGTGAGGAGCTGTTGGGTGTCTTGCTCTAGAGGCTTTGAGAAGCTCAGCT
GCCTTCCTGGGGCTGGTCTGGGAGCCACTGGGAGGGGGACCCGTGGAGAATTG
25 GCCAGAGCCTGTGGCCCCGAGGCTGGGACACTGTGTGGCCCTGGACAAGCCACA
GCCCCTGCCTGGGTCTCCACATCCCCAGCTGTATGAGGAGAGCTTCAGGCCCCAG
GACTGTGGGGGGCCCTCAGGTCAGCTCACTGAGCTGGGTGTAGGAGGGGGCTGCA
GCAGAGGCCTGAGGAGTGGCAGGAAAGAGGGGAGCAGGTGCCCCCAGGTGAGAC
AGCGGTCCAGGGGCCTGAAAAGGAAGGACCAGGCTGGGGCCAGGGGACCTTCC
30 TGTCTCCGCCTTTCTAATCCCTCCCTCCTCATTCTCTCCCTAATAAAAATTGGAGC
TCA

SEQ ID NO: 281

>4161733H1

35 CAGCACCATCGCAACCAGTGCCAGTACTGCCGCTCAAAAAGTGCCTCAAAGTG
GGCATGAGACGGGAAGGTATCGGCCTCTCATTTCTCCTTCCCTCGTCCTGGGTCC
CGGGGTCTGGGTACGTTTGGCTAGCCTGCTCTGGGTAAGGACAAGAAGCCCCA
AGCTCTTCTCTTCGTATTGCAGCGGAAAAGGGTTTTATACTAGAAGCGAGTTCTG
CATTGGAACCCAGACCCCAAATCCGCATGCTTT

40

SEQ ID NO: 282

>gi|183866|gb|M60278.1|HUMHBEGF Human heparin-binding EGF-like growth factor
mRNA, complete cds

45 GCTACGCGGGCCACGCTGCTGGCTGGCCTGACCTAGGCGCGCGGGGTGCGGGCGG
CCGCGCGGGGCGGGCTGAGTGAGCAAGACAAGACACTCAAGAAGAGCGAGCTGC
GCCTGGGTCCCGGCCAGGCTTGACGCGAGAGGCGGGCGGCAGACGGTGCCCCGGC
GGAATCTCCTGAGCTCCGCCGCCAGCTCTGGTGCCAGCGCCAGTGGCCGCCGC
TTCGAAAGTGACTGGTGCCTCGCCGCCTCCTCTCGGTGCGGGACCATGAAGCTGC
TGCCGTGGGTGGTGCTGAAGCTCTTTCTGGCTGCAGTTCTCTCGGCACTGGTGACT

GGCGAGAGCCTGGAGCGGCTTCGGAGAGGGCTAGCTGCTGGAACCAGCAACCCG
GACCCCTCCCACTGTATCCACGGACCAGCTGCTACCCCTAGGAGGCGGCCGGGAC
CGGAAAGTCCGTGACTTGCAAGAGGCAGATCTGGACCTTTTGAGAGTCACTTTAT
CCTCCAAGCCACAAGCACTGGCCACACCAACAAGGAGGAGCACGGGAAAAGA
5 AAGAAGAAAGGCAAGGGGCTAGGGAAGAAGAGGGACCCATGTCTTCGGAAATA
CAAGGACTTCTGCATCCATGGAGAATGCAAATATGTGAAGGAGCTCCGGGCTCC
CTCCTGCATCTGCCACCCGGGTACCATGGAGAGAGGTGTCATGGGCTGAGCCTC
CCAGTGGAATAATCGCTTATATACCTATGACCACACAACCATCCTGGCCGTGGTGG
CTGTGGTGTCTGTATCTGTCTGTCTGCTGGTCATCGTGGGGCTTCTCATGTTTAGG
10 TACCATAGGAGAGGAGGTTATGATGTGGAATAATGAAGAGAAAGTGAAGTTGGGC
ATGACTAATTCCCACTGAGAGAGACTTGTGCTCAAGGAATCGGCTGGGGACTGCT
ACCTCTGAGAAGACACAAGGTGATTTCACTGTCAGAGGGGAAAGACTTCCATC
TAGTCACAAAGACTCCTTCGTCCCCAGTTGCCGTCTAGGATTGGGCCTCCATAA
TTGCTTTGCCAAAATACCAGAGCCTTCAAGTGCCAAACAGAGTATGTCCGATGGT
15 ATCTGGGTAAAGAAGAAAGCAAAAGCAAGGGACCTTCATGCCCTTCTGATTCCCT
CCACCAAACCCCACTTCCCCTCATAAGTTTGTTTAAACACTTATCTTCTGGATTAG
AATGCCGGTTAAATTCCATATGCTCCAGGATCTTTGACTGAAAAAAAAAAGAA
GAAGAAGAAGGAGAGCAAGAAGGAAAGATTTGTGAAGTGAAGAAAGCAACAA
AGATTGAGAAGCCATGTACTCAAGTACCACCAAGGGATCTGCCATTGGGACCCT
20 CCAGTGCTGGATTTGATGAGTTAACTGTGAAATACCACAAGCCTGAGAAGTGAAT
TTTGGGACTTCTACCCAGATGGAAAAATAACAACCTATTTTGTGTTGTTGTTTGT
TAAATGCCTCTTAAATTATATATTTATTTTATTTCTATGTATGTAAATTTATTTAGTTT
TTAACAATCTAACAATAATAATTCAAGTGCCCTAGACTGTTACTTTGGCAATTECCT
GGCCCTCCACTCCTCATCCCCACAATCTGGCTTAGTGCCACCCACCTTTGCCACA
25 AAGETAGGATGGTTCTGTGACCCATCTGTAGTAATTTATTGTCTGTCTACATTTCT
GCAGATCTTCCGTGGTCAGAGTGCCACTGCGGGAGCTCTGTATGGTCAGGATGTA
GGGGTTAACTTGGTCAGAGCCACTCTATGAGTTGGACTTCAGTCTTGCCCTAGGCG
ATTTTGTCTACCATTTGTGTTTTGAAAGCCCAAGGTGCTGATGTCAAAGTGTAAC
AGATATCAGTGTCTCCCCGTGTCTCTCCCTGCCAAGTCTCAGAAGAGGTTGGGC
30 TTCCATGCCTGTAGCTTTCCTGGTCCCTCACCCCATGGCCCCAGGCCACAGCGT
GGGAACCTCACTTTCCCTTGTGTCAAGACATTTCTCTAACTCCTGCCATTCTTCTGG
TGCTACTCCATGCAGGGGTCAGTGCAGCAGAGGACAGTCTGGAGAAGGTATTAG
CAAAGCAAAAGGCTGAGAAGGAACAGGGAACATTGGAGCTGACTGTTCTTGGTA
ACTGATTACCTGCCAATTGCTAECGAGAAGGTTGGAGGTGGGGAAGGCTTTGTAT
35 AATCCCAACCCACCTCACCAAAACGATGAAGGTATGCTGTATGGTCTTTCTGGA
AGTTTCTGGTGCCATTTCTGAACTGTTACAACCTTGATTTCCAAACCTGGTTCATA
TTTATACTTTGCAATCCAAATAAAGATAACCCTTATTCCATAAAAAAAAAAAAAA
AAAA

40 SEQ ID NO: 283

>gi|35039|emb|X61498.1|HSNFKBS H.sapiens mRNA for NF-kB subunit

ACTTTCCTGCCCTTCCCCGGCCAAGCCCACTCCGGATCTCGCTCTCCACCGGAT
CTCACCCGCCACACCCGGACAGGCGGCTGGAGGAGGCGGGCGTCTAAAATTTCTG
GGAAGCAGAACCTGGCCGGAGCCACTAGACAGAGCCGGGCCTAGCCCAGAGAC
45 ATGGAGAGTTGCTACAACCCAGGTCTGGATGGTATTATTGAATATGATGATTTCA
AATTGAACTCCTCCATTGTGGAACCCAAGGAGCCAGCCCCAGAAACAGCTGATG
GCCCCACCTGGTGATCGTGGAACAGCCTAAGCAGAGAGGCTTCCGATTTTCGATA
TGGCTGTGAAGGCCCTCCCATGGAGGACTGCCCGGTGCCTCCAGTGAGAAGGG
CCGAAAGACCTATCCCACTGTCAAGATCTGTAACCTACGAGGGACCAGCCAAGAT

CGAGGTGGACCTGGTAACACACAGTGACCCACCTCGTGCTCATGCCCACAGTCTG
GTGGGCAAGCAATGCTCGGAGCTGGGGATCTGCGCCGTTTCTGTGGGGCCCAAG
GACATGACTGCCCAATTTAACAACCTGGGTGTCTGCATGTGACTAAGAAGAAG
ATGATGGGGACTATGATACAAAACTTCAGAGGCAGCGGCTCCGCTCTAGGCCC
5 CAGGGCCTTACGGAGGCCGAGCAGCGGGAGCTGGAGCAAGAGGCCAAAGAACT
GAAGAAGGTGATGGATCTGAGTATAGTGCGGCTGCGCTTCTCTGCCTTCCTTAGA
GCCAGTGATGGCTCCTTCTCCCTGCCCCTGAAGCCAGTCACCTCCCAGCCCATCC
ATGATAGCAAATCTCCGGGGGCATCAAACCTGAAGATTTCTCGAATGGACAAGA
CAGCAGGCTCTGTGCGGGGTGGAGATGAAGTTTATCTGCTTTGTGACAAGGTGCA
10 GAAAGATGACATTGAGGTTCTGTTCTATGAGGATGATGAGAATGGATGGCAGGC
CTTTGGGGACTTCTCTCCACAGATGTGCATAAACAGTATGCCATTGTGTTCCGG
ACACCCCCCTATCACAAGATGAAGATTGAGCGGCCTGTAACAGTGTTTCTGCAAC
TGAAACGCAAGCGAGGAGGGGACGTGTCTGATTCCAAACAGTTCACCTATTACC
CTCTGGTGGAAAGACAAGGAAGAGGTGCAGCGGAAGCGGAGGAAGGCCTTGCCC
15 ACCTTCTCCCAGCCCTTCGGGGGTGGCTCCCACATGGGTGGAGGCTCTGGGGGTG
CAGCCGGGGGCTACGGAGGAGCTGGAGGAGGTGGCAGCCTCGGTTTCTTCCCT
CCTCCCTGGCCTACAGCCCTACAGTCCGGCGCGGGCCCCATGCGGTGCTACCC
GGGAGGCGGGGGCGGGGCGCAGATGGCCGCCACGGTGCCAGCAGGGACTCCG
GGGAGGAAGCCGCGGAGCCGAGCGCCCCCTCCAGGACCCCCCAGTGCGAGCCGC
20 AGGCCCCGGAGATGCTGCAGCGAGCTCGAGAGTACAACGCGCGCCTGTTCCGGC
TGCGGCACGCAGCCCCGAGCCCTACTCGACTACTGCGTCACCGCGGACGCCGCG
CGCTGCTGGCGGGACAGEGCCACCTGCTGACGGCGCAGGACGAGAACGGAGACA
GACCACTGCACTAGCCATCATCCACGGGCAGACCAAGTGTCATTGAGCAGATAGT
GCTATGTCATCCACCACGCCAGGACCTCGGCGTTGTCAACCTCACCAACCACCTG
25 TCACCAGACGCCCTGCACCTGGCGGTGATCACGGGGCAGACGAGTGTGGTGAGC
TTTCTGCTGCGGGTAGGTGCAGACCCAGCTCTGCTGGATCGGCATGGAGACTCAG
CCATGCATCTGGCGCTGCGGGCAGGCGCTGGTGCTCCTGAGCTGCTGCGTGCACT
GCTTCAGAGTGGAGCTCCTGCTGTGCCCCAGCTGTTGCATATGCCTGACTTTGAG
GGACTGTATCCAGTACACCTGGCGGTCCGAGCCCCGAAGCCCTGAGTGCCTGGATC
30 TGCTGGTGGACAGTGGGGCTGAAGTGGAGGCCACAGAGCGGCAGGGGGGACGA
ACAGCCTTGCATCTAGCCACAGAGATGGAGGAGCTGGGGTTGGTCACCCATCTG
GTCACCAAGCTCCGGGGCAACGTGAACGCTCGCACCTTTGCGGGAAACACACCC
CTGCACCTGGCAGCTGGACTGGGGTACCCGACCTCACCCGCCTCCTTCTGAAGG
CTGGTCTGAGATCCATGCTGAAAACGAGGAGCCCCTGTGCCCACTGCCTTCACC
35 CCCTACCTCTGATAGCGACTCGGACTCTGAAGGGCCTGAGAAGGACACCCGAAG
CAGCTTCCGGGGCCACACGCCTCTTGACCTCACTTGCAGCACCTTGGTGAAGACC
TTGCTGCTAAATGCTGCTCAGAACACCATGGAGCCACCCCTGACCCCGCCAGCC
CAGCAGGGCCGGGACTGTCACTTGGTGATACAGCTCTGCAGAACCTGGAGCAGC
TGCTAGACGGGCCAGAAGCCCAGGGCAGCTGGGCAGAGCTGGCAGAGCGTCTGG
40 GGCTGCGCAGCCTGGTAGACACGTACCGACAGACAACCTCACCCAGTGGCAGCC
TCCTGCGCAGCTACGAGCTGGCTGGCGGGGACCTGGCAGGTCTACTGGAGGCC
TGTCTGACATGGGCCTAGAGGAGGGAGTGAGGCTGCTGAGGGGTCCAGAAACCC
GAGACAAGCTGCCAGCACAGAGGTGAAGGAAGACAGTGCGTACGGGAGCCAG
TCAGTGGAGCAGGAGGCAGAGAAGCTGGGCCCCACCCCTGAGCCACCAGGAGG
45 GCTCTCGCACGGGCACCCCTGTACAGCGTCCCCACCTATTTCAAATCTTATTTAACAC
CCCACACCCACCCCTCAGTTGGGACAAATAAAGGATTCTCATGGGAAGGGGAGG
ACCCGAATTCCT

SEQ ID NO: 284

>gi|183537|gb|M37724.1|HUMGPLEU02 Human MDR1/P-glycoprotein gene, exon 7

GCCATAAACTACCCTACACTCAAAACAGGCTTCACGAGAAAAGTTGATGTTTAAAC
ATTCTGACAATTATTTCTAACACTATCTGTTCTTTCAGTGATGTCTCCAAGATTAA
5 TGAAGGAATTGGTGACAAAATTGGAATGTTCTTTCAGTCAATGGCAACATTTTTC
ACTGGGTTTATAGTAGGATTTACACGTGGTTGGAAGCTAACCC

SEQ ID NO: 285

>1322305T6

10 GTGAGTTACACTTCTTCCTCCCCACCAGGTGCTCTCTGCAGCTCTGGAAAAATGG
TGTCCTCTTTGTTGTCCCACCAGGGGGCGCCACCTCCAGCCCCGCCAGCCTCA
TACCCAGTTCTTCAGCTCGGCCAGCGGTAAGTGAAGCCTCCAGAATCCTGGATC
CGGGCCCCTAGTACCCTCTTTCCCAGGGACCCAGGAGTCCTGCCTCCAGTCGCCT
GCACTTGTAAGTGAAGAGCTGGAGGTGCTCCATAGCAGCATAGTGAGAGTGTTTTT
15 GATGAGGGTATGCAGAGTGGGGGTGACCATGTTCCACCTGGGGCCTCAGGTGG
GCCAAGGCCTACCCACTTTAGCCAGCGTCCCCTCCAGCAGCCATCAGCAAGCCAA
CCCCTCCAAGCCAGGGCCCCCTTTGGTCTTGCACCTTGAGGTGCTTTGTTGAGG
GCTGGGTGAGGAGTGGCAGAGACGATGTCCAACAACCTCAGTACTGGGGGAAAA
GTAGCCTGG

20

SEQ ID NO: 286

>1284795H1

GTGTGAGAAGACTGGCTAGTGTGGAAGCATAGTGAACACACTGATTAGGTTATG
GTTTAATGTTACAACAACCTATTTTTTAAGAAAAACAAGTTTGTAGAAATTTGGTTTC
25 AAGTGTACATGTGTGAAAACAATATTGTATACTACCATAGTGAGCCATGA

SEQ ID NO: 287

>349590H1

30 GTTGGCTGGATGGGTCTTATCAAAAGCAAAGAAAGATGACATGGATGAGGAAAT
TTCAATATACGATGGAAGATGGGAAATTGAAGAGTTGAAAGAAAACCAGGTACC
TGGTGACAGAGGACTGGTATTAAATCTAGAGCAAAGCATCATGCAATATCTGC
TGTATTAGCAAACCATTCATTTTTTGCTGATAAACCTTGNTAGTTCAATATGAA
GTAAATTTTCAAGATGGTATTGATGTTGGAGGTGCATACATTAAACTCCTAG

35 SEQ ID NO: 288

>gi|181075|gb|M28638.1|HUMCRYABA Human alpha-B-crystallin gene, 5' end

GTCGACACCACCCAAAATAGTGCCGAGCCTCTTGGGGGGGGAGGGGCTGGGAGT
GGGGGCCCTGAGTGAGAGCAACGAGGGTGTGACCAGCGCCGCCCGGACCCCTAG
TCCCCTCCCCCGCACACTCTTCAGCTGTCGAGGGGGCCTGAGAGGACAGCTGAG
40 GGTCTGGCTGGGAACGAGCTGGGGAGGGGGAGCTGGTGGTGCCTGGGGCATGA
AGAGGCCTCGCTGAGACCCTCACAAACGGTTTGCACGTTTCCACACCTCATTTTC
TCCTCTTCGGTGGCAGGCACTGTGCACCCAATTCTTAAAGCACTCCTGGATTAA
TGTTCTGAGAGCCACATAGAACGAAAGATGCAAGAAATCTGTTTGCTCTTTTTTC
AGGGGGTGGGGTCTTTCTGCCCAGATGTGGGATCCTCTCCTAAACCCAGGTCAAC
45 CCAGGGCACGAGGCAGATGGCTGGTGTGACATGTTGACCATCACTGCTCTCTTC
CAAGGACTCACAAAGAGTTAATGTCCCTGGGGCTCAGCCTAGGAAGATTCCAGT
CCCTGCCCAGGCCCAAGATAGTTGCTGGCCTGATTCCCCTGGCATTGAGGACTGG
AAAGGAGGAGGAGGGGCACACTACGCCGGCTCCCATCCTCCCCCACCCTCGCT
GCCTGCTTGGGATTCTGACTCTGTACCAGCTTCAGAGAACAGGGGGTGGGGGTGG

GTGCCATTGGGTGTGGACAGAAAGCTAGTGAAACAAGACCATGACAAGTCACTG
GCCGGCTCAGACGTGTTTGTGTCTCTCTTTTCTTAGCTCAGTGAGTACTGGGTATG
TGTCACATTGCCAAATCCCGGATCACAAGTCTCCATGAACTGCTGGTGAGCTAGG
ATAATAAAACCCCTGACATCACCATTCCAGAAGCTTCACAAGACTGCATATATAA
5 GGGGCTGGCTGTAGCTGCAGCTGAAGGAGCTGACCAGCCAGCTGACCCCTCACA
CTCACCTAGCCACCATGGACATCGCCATCCACCACCCCTGGATCCGCCGCCCTT
CTTTCCTTTCCACTCCCCCAGCCGCCTCTTTGACCAGTTCTTCGGAGAGCACCTGT
TGGAGTCTGATCTTTTCCCGACGTCTACTTCCCTGAGTCCCTTCTACCTTCGGCCA
CCCTCCTTCCCTGCGGGCACCCAGCTGGTTTGACACTGGACTCTCAGAGGTGAGTC
10 TCCCCACAGCTAGGACGGGAGAGTCCTTACTGGAACCTCCTGGAACTTCTCCAT
CCATTTTCTTTTCTACCTGCCTAAACCATTTTAGGCACATGTGTGTCCAAATGT
GAAGAAAAATGAGGAGGTTGCTAGTGCCTTCTCCCCCATCACCTGTTTCTATTT
GATAGTCCTCTGTATCCCATTTATTACATTTTTTTCATGCACTGTCAAGTTTATCCTC
CGTCCCCTAACTTCTCTACAGGATAACCCCTTTCTGGTTTGGTTCATGACAATCTGC
15 AGGGAAAGAGCTGCCTTCAAACCTTTGCTTATCTCTTCCAACACCTTGGACTCT
TGACCGATTTTACCATCTCAGGTTTCAGAGCCAGGAGAGAGCCCTGCCTCATCCT
GAGCTGTTTCATCCCCATGGGTATTTTCTGCCTTTCTATTCCCTCTTCTATGATTTTC
TGGGTTTCTCAGGGCTACGACAGGGCGCTGGCCTGGGTCCAATCAAGCCCTACGA
GGAAACAATATAGGGACGCCATTTGTCTTAAGAGGGTGGAAGAACAGGGTGAA
20 CAAATAAGGTTGACAGAGCTGTCACAGATAACACTCTGGTTTAAAAATATTCAA
GTGTGAGTAAACAGGAGCTGAGTGGGCAAGGGCTTTGGAAGGACAAGCAGGAC
CAGCAGAACATTCCAGATTGGGTGGGTGGAAAACCTGGCAAAGAGACCTGAGCCA
GAAGAAGAGGCCCTTTGTCTCACAGACAAACCACAAAGCCAGGCATTGGAGTCAG
AGAGGCAGCAGATGCCAGGCTTGCACCCATCCTTGCCTGAGTGGTCCCCTGGGTGAT
25 CTGTCTTCTTCTCTGTCCCTGTAAATAAAGTTTGGGTCTGATCACCATGAGCCTTA
GGTATCACTGTGGTGGCTCCCTGAAGCAGACAGCTATGTTTATTTAAAAAGGAGA
TTTTTTAAGCAGAGAAGAGAAGGATGAATTACCCGGACAGAAAGCAGCTCTGCA
GAATAAGACAGCACCTGTGTAATCAGTATTTTTGCCCTCTTCTCCCATCCCATT
CCTTACCTTGCTATTTCTAGATGCGCCTGGAGAAGGACAGGTTCTCTGTCAACCT
30 GGATGTGAAGCACTTCTCCCCAGAGGAACTCAAAGTTAAGGTGTTGGGAGATGT
GATTGAGGTGCATGGAAAACATGAAGAGCGCCAGGTATGTAGCTTGTTTTTTTGT
TTTCTGCTCATTCAATCAGTGATACTGTAATAGTCCAGGTAGTGCTATCAGCTTTG
GAGGCTGGCTACATTCCAGTCCCAAGCCATAACAGTCGGGATCAGGGGTACAA
ATCAATGTCTAGAAGACTAAGTTAGGATAGACATATTGCTGTTGTTACTATTATG
35 GCCAGAGATGTGGCCTTTGATTTGATCGCCTTAGATGGGATGATGGGATGCTGAT
GCCCCATTTAAGCCAGTGGTTCTGAATCTGGGCCACATTAGAATCACCAGGGGAA
CTTTCAAAAACCTAATGCTCGGGCATCCTCCAGACCAATTAGCATATGTGCTGCC
GAAGCGAGCACTACTCCAGACCAATTAAATCAGCATTTTAAAGGTGGGACCCA
GGCATCAGCAATTTTTAAGGTAATTCTAATCTACAGTCAAGGTTGAGAACCACTG
40 ATTAGGTATAGGGCTGTGAGACACCTAGTTGCTTTGCATAATTACATTAACCTACA
GGTACCCTAAAAGCACTTGAGTTGTGACTTCTCTTTTAGCTGTGCAAGAATCCGT
GTCTCTTCTTTAGCCCATCTTAATGCTGAACTACTTGGTTTGTCTAAATTTAGAG
CTGTGCTCAGTCTTTAATCCCCTACAGCCCATGTGGTAATCAGTTAACGAGAGCC
TGTTTGGCTACATGCTTGAGAGTCAGCAGGCATACGGGTAAAGGTCATCTACTCT
45 TTGGGGGAGTTCTGACAAATGGAACAGCTTGTTATGACTTTATAAGAGGGCTTTA
AAATTGCTTCTCACCATTTAACGATAGCTCAGAACCTGTGCGTCAACCAGTACAG
TTTGTCTCAGTAATGTCCTCAGGCTGTTTCAATTTTGTCTTATATGATTTAGGTTT
GGGTCATAGTCTCCTTGGATGGAGTCATTTTTTTTTTTTTTAATTTAGCAGCAG
TCCTATTGTTCTGGAACCTTCTGGGACATTCCTGAAGAGTCAGGACAATTTAGG

GCTTCCTCAGGGACTCAGATTCTAAATGAGATTCCAAATTCTGTAGGCCCAGCCA
ACATTGATCTAAACCTTTGGGAAATACCCCTAAACATATCTATGCCTCAGGGTTT
GAAAAACAATGAAGTGTTGGACTGTTTCAGACTTCTCAGATTCTCACTGGTAGGA
GTGACTACCTAGGCAATTTTCATCTTAGCTGCAACCCTGAAACGAAGCTCTATTTA
5 TTTTTCCTATGTTGTCATGGCATTGTTGGTCTCACCTAAGGGGAAATCAGGATGCCTG
AGTTCTGGGCAGGTGATAATAGTTTCTGTTCTTATCTCTCTGCCTCTTTCTCATT
CTTTTGGGTAGGATGAACATGGTTTCATCTCCAGGGAGTTCCACAGGAAATACC
GGATCCCAGCTGATGTAGACCCTCTCACCATTACTTCATCCCTGTCATCTGATGG
GGTCTCACTGTGAATGGACCAAGGAAACAGGTCTCTGGCCCTGAGCGCACCATT
10 CCCATCACCCGTGAAGAGAAGCCTGCTGTCACCGCAGCCCCCAAGAAATAGATG
CCCTTTCTTGAATTGCATTTTTTAAACAAGAAAGTTTCCCCACCAGTGAATGAA
AGTCTTGTGACTAGTGCTGAAGCTTATTAATGCTAAGGGCAGGCCCAAATTATCA
AGCTAATAAAATATCATTGAGCAACAGATAACTGTCTTGTGTTTGAATATTCCAC
ACACTTTTAAATAAATATACAGATACCACAGATCTATTTATGATTGCATTATGAT
15 TTAGAGGGCTCCAAGGATTTTAGAGT

SEQ ID NO: 289

>gi|1398343|gb|W85914.1|W85914 zh52c10.s1 Soares_fetal_liver_spleen_1NFLS_S1 Homo sapiens cDNA clone IMAGE:415698 3', mRNA sequence

20 TTGTAAATGTAGACAGTTTAAATTGTAGTATCAGAAACTGGTGGGGAGGAAACA
AATTGTGGTATATTCATACAATGGAAAACCTTTCAGAAATAAGAAGGAACAAAC
CACTGAATCACACAACATGGACAAATCTCAAATCATTATGCTGATGGAAAGAAA
CCATTCCATAAGAATACACAGTACATGACGCCGCTTTCATGATGTTCTGGAAACAAA
GAAAACCTAACCTATAGTGATAGAATTCCTATCAATGGCTGCCAACAATCGGGAG
25 TGAAAGGAACTGACTGAGCAGGTATACAAGAGAACCTTCTGGGGTGATGGAAAT
ATTCTGAAGCTTGACTGGAGTGTTGGTTACATGGGTATATCNATTTATCAAACT
CACTGAATTGTATATTTAAAGTAGGAACATTTTATTGTAAATAAATTACCCNCTA
TAATGTTCTGTTTTAAAAATATTAGATACANCGCTGGAAANCCCTGGGTTTACAAA
AAAT

30

SEQ ID NO: 290

>3526532H1

GGTACTCAACACTGAGCAGATCTGTTCTTTGAGCTAANAACCATGTGCTGTACCA
AGAGTTTGCTCCTGGCTGCTTTGATGTGCTGCTGCTACTCCACCTCTGCGGCGA
35 ATCAGAAGCAAGCAACTTTGACTGCTGTCTTGGATACACAGACCGTATTCTTCAT
CCTAAATTTATTGTGGGCTTCACACGGCAGCTGGCCAATGAAGGCTGTGACATCA
ATGCTATGATCTTTCACACAAAGAACAAGTTGTCTGTGTGCGCA

SEQ ID NO: 291

40 >gi|186351|gb|M54894.1|HUMIL6CSF Human interleukin 6 mRNA, complete cds

GAATTCGGGAACGAAAGAGAAGCTCTATCTCCCCTCCAGGAGCCCAGCTATGA
ACTCCTTCTCCACAAGCGCCTTCGGTCCAGTTGCCTTCTCCCTGGGGCTGCTCCTG
GTGTTGCCTGCTGCCTTCCCTGCCCCAGTACCCCCAGGAGAAGATTCCAAAGATG
TAGCCGCCCCACACAGACAGCCACTCACCTCTTCAGAACGAATTGACAAACAAA
45 TTCGGTACATCCTCGACGGCATCTCAGCCCTGAGAAAGGAGACATGTAACAAGA
GTAACATGTGTGAAAGCAGCAAAGAGGCACTGGCAGAAAACAACCTGAACCTTC
CAAAGATGGCTGAAAAAGATGGATGCTTCCAATCTGGATTCAATGAGGAGACTT
GCCTGGTGAAAATCATCACTGGTCTTTTGGAGTTTGAGGTATACCTAGAGTACCT
CCAGAACAGATTTGAGAGTAGTGAGGAACAAGCCAGAGCTGTGCAGATGAGTAC

AAAAGTCCTGATCCAGTTCCTGCAGAAAAAGGCAAAGAATCTAGATGCAATAAC
 CACCCCTGACCCAACCACAAATGCCAGCCTGCTGACGAAGCTGCAGGCACAGAA
 CCAGTGGCTGCAGGACATGACAACTCATCTCATTCTGCGCAGCTTTAAGGAGTTC
 CTGCAGTCCAGCCTGAGGGGCTCTTCGGGCAAATGTAGCATGGGCACCTCAGATTGT
 5 TGTGTGTAATGGGCATTCTTCTTCTGGTCAGAAACCTGTCCACTGGGCACAGAA
 CTTATGTTGTTCTCTATGGAGAACTAAAAGTATGAGCGTTAGGACACTATTTTAA
 TTATTTTAAATTTATTAATATTTAAATATGTGAAGCTGAGTTAATTTATGTAAGTC
 ATATTTATATTTTAAAGAAGTACCACTTGAAACATTTTATGTATTAGTTTTGAAAT
 AATAATGGAAAGTGGCTATGCAGTTTGAATATCCTTTGTTTCAGAGCCAGATCAT
 10 TTCTTGGAAAGTGTAGGCTTACCTCAAATAAATGGCTAACTTATACATATTTTAA
 AAGAAATATTTATATTGTATTTATATAATGTATAAATGGTTTTTATACCAATAAAT
 GGCATTTTAAAAAATTC

SEQ ID NO: 292

15 >14611 BLOOD Hs.82109 gnl|UG|Hs#S269762 H.sapiens syndecan-1 gene (exons 2-5)
 /cds=(0,866) /gb=Z48199 /gi=666051 /ug=Hs.82109 /len=2802
 CAAATTGTGGCTACTAATTTGCCCCCTGAAGATCAAGATGGCTCTGGGGATGACT
 CTGACAACTTCTCCGGCTCAGGTGCAGGTGCTTTGCAAGATATCACCTTGTGACA
 GCAGACCCCTCCACTTGGAAGGACACGCAGCTCCTGACGGCTATTCCCACGTCT
 20 CCAGAACCCACCGGCTGGAGGCTACAGCTGCCTCCACCTCCACCCTGCCGGCTG
 GAGAGGGGGCCCAAGGAGGGAGAGGCTGTAGTCCTGCCAGAAGTGGAGCCTGGC
 CTCACCGCCCGGGAGCAGGAGGCCACCCCECGACCCAGGGAGACACACAGCTC
 CCGACCACTCATCAGGCCTCAACGACCACAGCCACCACGGCCAGGAGCCCGCC
 ACCTECCACCCCCACAGGGACATGCAGCCTGGCCACCATGAGACCTCAACCCCTG
 25 CAGGACCCAGCCAAGCTGACCTTCACTCCCCACACAGAGGATGGAGGTCCTT
 CTGCCACCGAGAGGGCTGCTGAGGATGGAGCCTCCAGTCAGCTCCCAGCAGCAG
 AGGGCTCTGGGGAGCAGGACTTCACCTTTGAAACCTCGGGGGAGAATACGGCTG
 TAGTGGCCGTGGAGCCTGACCGCCGGAACCAGTCCCCAGTGGATCAGGGGGCCA
 CGGGGGCCTCACAGGGCCTCCTGGACAGGAAAGAGGTGCTGGGAGGGGTGATTG
 30 CCGGAGGCCTCGTGGGGCTCATCTTTGCTGTGTGCCTGGTGGGTTTCATGCTGTA
 CCGCATGAAGAAGAAGGACGAAGGCAGCTACTCCTTGGAGGAGCCGAAACAAG
 CCAACGGCGGGGCTACCAGAAGCCCAACAAACAGGAGGAATTCTATGCCTGAC
 GCGGGAGCCATGCGCCCCCTCCGCCCTGCCACTCACTAGGCCCCCACTTGCCTCT
 TCCTTGAAGAACTGCAGGCCCTGGCCTCCCTGCCACCAGGCCACCTCCCCAGCA
 35 TTCCAGCCCCTCTGGTCGCTCCTGCCCACGGAGTCGTGGGTGTGCTGGGAGCTCC
 ACTCTGCTTCTCTGACTTCTGCCTGGAGACTTAGGGCACCAGGGGTTTCTCGCAT
 AGGACCTTTCCACCACAGCCAGCACCTGGCATCGCACCATTCTGACTCGGTTTCT
 CCAAACCTGAAGCAGCCTCTCCCCAGGTCCAGCTCTGGAGGGGAGGGGGATCCGA
 CTGCTTTGGACCTAAATGGCCTCATGTGGCTGGAAGATCCTGCGGGTGGGGCTTG
 40 GGGCTCACACACCTGTAGCACTTACTGGTAGGACCAAGCATCTTGGGGGGGTGG
 CCGCTGAGTGGCAGGGGACAGGAGTCACTTTGTTTCGTGGGGAGGTCTAATCTAG
 ATATCGACTTGTTTTTGCACATGTTTCTCTAGTTCTTTGTTTCATAGCCCAGTAGA
 CCTTGTTACTTCTGAGGTAAGTTAAGTAAGTTGATTTCGGTATCCCCCATCTTGCT
 TCCCTAATCTATGGTCGGGAGACAGCATCAGGGTTAAGAAGACTTTTTTTTTTTT
 45 TTTAAACTAGGAGAACCAAATCTGGAAGCCAAAATGTAGGCTTAGTTTGTGTGTT
 GTCTCTTGAGTTTGTGCTCATGTGTGCAACAGGGTATGGACTATCTGTCTGGTG
 GCCCCGTTCTGGTGGTCTGTTGGCAGGCTGGCCAGTCCAGGCTGCCGTGGGGCCG
 CCGCCTCTTCAAGCAGTCGTGCCTGTGTCCATGCGCTCAGGGCCATGCTGAGGC
 CTGGGCCGCTGCCACGTTGGAGAAGCCCGTGTGAGAAGTGAATGCTGGGACTCA

GCCTTCAGACAGAGAGGACTGTAGGGAGGGCGGCAGGGGCCTGGAGATCCTCCT
GCAGGCTCACGCCCCTCCTCCTGTGGCGCCGTCTCCAGGGGCTGCTTCCTCCTGG
AAATTGACGAGGGGTGTCTTGGGCAGAGCTGGCTCTGAGCGCCTCCATCCAAGG
CCAGGTTCTCCGTTAGCTCCTGTGGCCCCACCCTGGGCCCTGGGCTGGAATCAGG
5 AATATTTTCCAAAGAGTGATAGTCTTTTGCTTTTGGCAAACTCTACTTAATCCAA
TGGGTTTTTCCCTGTACAGTAGATTTTCCAAATGTAATAAACTTTAATATAAAGTA
GTCTGTGAATGCCACTGCCTTCGCTTCTTGCTCTGTGCTGTGTGTGACGTGACCG
GACTTTTCTGCAACACCAACATGTTGGGAACTTGGCTCGAATCTCTGTGCCTT
CGTCTTTCCCATGGGGAGGGATTCTGGTTCAGGGTCCCTCTGTGTATTGCTTTT
10 TTGTTTTGGCTGAAATTCTCCTGGAGGTCGGTAGGTTCAAGCAAGGTTTTATAAG
GCTGATGTCAATTTCTGTGTTGCCAAGCTCCAAGCCCATCTTCTAAATGGCAAAG
GAAGGTGGATGGCCCCAGCACAGCTTGACCTGAGGCTGTGGTCACAGCGGAGGT
GTGGAGCCGAGGCCTACCCNCAGACACCTTGGACATCCTCCTCCACCCGGCTG
CAGAGGCCAGANNCCAGCCCAGGGTCCTGCACTTACTTGCTTATTTGACAACGTT
15 TCAGCGACTCCGTTGGCCACTCCGAGAGTGGGCCAGTCTGTGGATCAGAGATGC
ACCACCAAGCCAAGGGAACCTGTGTCCGGTATTCGATACTGCGACTTTCTGCCTG
GAGTGTATGACTGCACATGACTCGGGGGTGGGGAAAGGGGTCGGCTGACCATGC
TCATCTGCTGGTCCGTGGGACGGTNCCCAAGCCAGAGGTGGGTTCAATTTGTGTAA
CGACAATAAA

20

SEQ ID NO: 293

gi|36628|emb|X07820.1|HSSTROM2 Human mRNA for metalloproteinase: stromelysin-2

AAAGAAGGTAAGGGCAGTGAGAAATGATGCATCTTGCATTCCTTGTGCTGTTGTGT
CTGCCAGTCTGCTCTGCCTATCCTCTGAGTGGGGCAGCAAAAGAGGAGGACTCCA
25 ACAAGGATCTTGCCCAGCAATACCTAGAAAAGTACTACAACCTCGAAAAGGATG
TGAAACAGTTTAGAAGAAAGGACAGTAATCTCATTGTTAAAAAATCCAAGGAA
TGCAGAAAGTTCCTTGGGTTGGAGGTGACAGGGAAGCTAGACACTGACACTCTGG
AGGTGATGCGCAAGCCCAGGTGTGGAGTTCCTGACGTTGGTCACTTCAGCTCCTT
TCCTGGCATGCCGAAGTGGAGGAAAACCCACCTTACATACAGGATTGTGAATTAT
30 ACACCAGATTTGCCAAGAGATGCTGTTGATTCTGCCATTGAGAAAGCTCTGAAAG
TCTGGGAAGAGGTGACTCCACTCACATTCTCCAGGCTGTATGAAGGAGAGGCTG
ATATAATGATCTCTTTCGCAGTTAAAGAACATGGAGACTTTTACTCTTTTGATGGC
CCAGGACACAGTTTGGCTCATGCCTACCCACCTGGACCTGGGCTTTATGGAGATA
TTCACTTTGATGATGATGAAAAATGGACAGAAGATGCATCAGGCACCAATTTATT
35 CCTCGTTGCTGCTCATGAACTTGGCCACTCCCTGGGGCTCTTCACTCAGCCAACA
CTGAAGCTTTGATGTACCCACTCTACAACCTCATTACAGAGCTCGCCCAGTTCCG
CCTTTCGCAAGATGATGTGAATGGCATTCACTCTCTCTACGGACCTCCCCCTGCCT
CTACTGAGGAACCCCTGGTGCCCAAAAATCTGTTCCCTTCGGGATCTGAGATGCC
AGCCAAGTGTGATCCTGCTTTGTCCTTCGATGCCATCAGCACTCTGAGGGGAGAA
40 TATCTGTTCTTTAAAGACAGATATTTTTGGCGAAGATCCCACTGGAACCCTGAAC
CTGAATTTCAATTTGATTTCTGCATTTTGGCCCTCTCTTCCATCATATTTGGATGCTG
CATATGAAGTTAACAGCAGGGACACCGTTTTTATTTTTAAAGGAAATGAGTTCTG
GGCCATCAGAGGAAATGAGGTACAAGCAGGTTATCCAAGAGGCATCCATACCTT
GGGTTTTCTCCAACCATAAGGAAAATTGATGCAGCTGTTTCTGACAAGGAAAAG
45 AAGAAAACATACTTCTTTGCAGCGGACAAATACTGGAGATTTGATGAAAATAGC
CAGTCCATGGAGCAAGGCTTCCCTAGACTAATAGCTGATGACTTTCAGGAGTTG
AGCCTAAGGTTGATGCTGTATTACAGGCATTTGGATTTTTCTACTTCTTCAGTGGA
TCATCACAGTTTGAGTTTGACCCCAATGCCAGGATGGTGACACACATATTAAAGA
GTAACAGCTGGTTACATTGCTAGGCGAGATAGGGGGAAGACAGATATGGGTGTT

TTTAATAAATCTAATAATTATTCATCTAATGTATTATGAGCCAAAATGGTTAATTT
TTCCTGCATGTTCTGTGACTGAAGAAGATGAGCCTTGCAGATATCTGCATGTGTC
ATGAAGAATGTTTCTGGAATTCTTCACTTGCTTTTGAATTGCACTGAACAGAATT
AAGAAATACTCATGTGCAATAGGTGAGAGAATGTATTTTCATAGATGTGTTATTA
5 CTTCCTCAATAAAAAGTTTATTTTGGGCCTGTTTCCTT

SEQ ID NO: 294

>gi|750011|gb|R00275.1|R00275 ye72b08.s1 Soares fetal liver spleen 1NFLS Homo sapiens
cDNA clone IMAGE:123255 3', mRNA sequence

10 TTANTCAATTTGCTATGTATATACGNGTTTATTATATGCTTATTACAAAAGAAAA
AGTCTTTTGCCTTATTTTAGGGCTTCCATGTAAAACCTAGTTAAAATACAAAAG
TAAATTAGNGAAAAATTCTGCTTAGGNAGTGAAANTTGATAGCAACTTATAAGC
TGTATCCTTAAAANCCTAGTCACAGATNTAGNNTTACGTAAAGNTAAANTGATA
AGCCTACTTNTTGGCAAGAANCAGGTTAGGCCACTTANGCAGCATGTTTCTNCCA
15 CTNTACANTTACATCGGCAGGTCCAAACNTTAANCCACCNTTCGNTTGACAACCT
TCTATTTTCAACTT

SEQ ID NO: 295

>gi|1496145|gb|AA029889.1|AA029889 zk08e05.s1 Soares_pregnant_uterus_NbHPU Homo
sapiens cDNA clone IMAGE:469952 3', mRNA sequence

20 TTTTTTTTCTGTTTGTCTGATTTTATTATTTAAAAAAATGGAAAAACAAAAGT
GCATTTTTCATTCAAATAAATGTTCCATCCTTATTTAGTTTGTGCGGAAAGTGAA
GTCCATGACTTTAGAATGATAGCAATTTATCAACCAAAGAATCCGTCTTCACACC
GTTTCAATAAAGTGCAGCAATTTTCTTGAAGTGTGTGTAGAAATTCTGAAACTGTG
25 GAATCGTCATTTCAAAGCACTTGGTCTTACTTGGCCTGAATGATCTGCCACTTTT
AGCATCACTGCAACGTAAGGATACTTAAGAGATCTGCAAGTGTCTGAGCTCACA
GCCATACCCAGTTTCCACTGAAAATCTACAAGCTGGGTGGTGACATCGGACTTAG
CATCCAGCGGCGGCCTCGGTGCC

30 SEQ ID NO: 296

>gi|307127|gb|L08096.1|HUMLIGAND Human CD27 ligand mRNA, complete cds

CCAGAGAGGGGCAGGCTTGTCCTTGACAGGTTGAAGCAAGTAGACGCCAGGA
GCCCCGGGAGGGGGCTGCAGTTTCCTTCCTTCCTTCTCGGCAGCGCTCCGCGCCC
CCATCGCCCCCTCCTGCGCTAGCGGAGGTGATCGCCGCGGCGATGCCGGAGGAGG
35 GTTCGGGCTGCTCGGTGCGGCGCAGGCCCTATGGGTGCGTCCTGCGGGCTGCTTT
GGTCCCATTTGGTTCGCGGGCTTGGTGATCTGCCTCGTGGTGTGCATCCAGCGCTTC
GCACAGGCTCAGCAGCAGCTGCCGCTCGAGTCACTTGGGTGGGACGTAGCTGAG
CTGCAGCTGAATCACACAGGACCTCAGCAGGACCCAGGCTATACTGGCAGGGG
GGCCCAGCACTGGGCCGCTCCTTCCTGCATGGACCAGAGCTGGACAAGGGGCAG
40 CTACGTATCCATCGTGATGGCATCTACATGGTACACATCCAGGTGACGCTGGCCA
TCTGCTCCTCCACGACGGCCTCCAGGCACCAACCCACCCCTGGCCGTGGGAAT
CTGCTCTCCCGCCTCCCGTAGCATCAGCCTGCTGCGTCTCAGCTTCCACCAAGGTT
GTACCATTGTCTCCAGCGCCTGACGCCCCTGGCCCGAGGGGACACACTCTGCAC
CAACCTCACTGGGACACTTTTGCCTTCCCGAAACACTGATGAGACCTTCTTTGGA
45 GTGCAGTGGGTGCGCCCCCTGACCACTGCTGCTGATTAGGGTTTTTTAAATTTTATT
TTATTTTATTTAAGTTCAAGAGAAAAAGTGTACACACAGGGGCCACCCGGGGTTG
GGGTGGGAGTGTGGTGGGGGGTAGTTTGTGGCAGGACAAGAGAAGGCATTGAGC
TTTTTCTTTCATTTTCCTATTAAAAAATACAAAATCAAAAACAAAAA

SEQ ID NO: 297

>gi|788599|gb|R32756.1|R32756.yh74b09.s1 Soares placenta Nb2HP Homo sapiens cDNA clone IMAGE:135449 3' similar to gb:X66899 RNA-BINDING PROTEIN EWS (HUMAN);, mRNA sequence

5 GAGGAAGACGAGGTGGCCCTGGGGCCCNCTGGACCTTTGATGGAACAGATGGGA
GGAAGAAGAGGAGGACGTGGAGGACCTGGAAAAATGGATAAAGGCGAGCACCG
TCAGAGCGCAGAGATCGGCCCTACTAGATGCAGAGACCCCGCAGAGCTGCATTG
ACTACCAGATTTATTTTTTAAACCAGAAAAATGTTTTAAATTTATTAATTCCATATT
TATAATGTTGGCCACAACATTATTGATTATTCCTTGTCTGTACTTTAGTATTTTTTC
10 ACCATTTGTGAAGGAAACATTAAAACAAGTTTAAATGGGTNAAAAAAAAAACCT
CGTGCCCGATTCTTNGGCCTTCGAGGGCCAATTTCCCTNTTGGTGAGTCCTATTN
AAT

SEQ ID NO: 298

15 >556963H1
CTTTCACACAAAGAAAAAGTTGTCTGTGTGCGCAAATCCAAAACAGACTTGGGT
GAAATATATTGTGCGTCTCCTCAGTAAAAAAGTCAAGAACATGTAAAACTGTG
GCTTTTCTGGAATGGAATTGGACATAGCCCAAGAACAGAAAGAACCTTGCTGGG
GTTGGAGGTTTCACTTGCACATCATGGAGGGTTTAGTGCTTATCTAATTTGTG

20

SEQ ID NO: 299

>gi|179413|gb|M37722.1|HUMBFGFS Human shorter form basic fibroblast growth factor (bFGF) receptor mRNA, complete cds

CCGGCCGCGGAGCTCTTGCGACCCCGCCAGGACCCGAACAGAGCCCGGGGGCGG.
25 CGGGCCGGAGCCGGGGACGCGGGCACACGCCCGCTCGCACAAAGCCACGGCGGA
CTCTCCCGAGGCGGAACCTCCACGCCGAGCGAGGGTCAGTTTGAAAAGGAGGAT
CGAGCTCACTGTGGAGTATCCATGGAGATGTGGAGCCTTGTACCAACCTCTAAC
TGCAGAACTGGGATGTGGAGCTGGAAGTGCCTCCTCTTCTGGGCTGTGCTGGTCA
CAGCAACACTCTGCACCGCTAGGCCGTCCCCGACCTTGCCTGAACAAGATGCTCT
30 CCCCTCCTCGGAGGATGATGATGATGATGATGACTCCTCTTCAGAGGAGAAAGA
AACAGATAACACCAAACCAAACCCCGTAGCTCCATATTGGACATCCCCAGAAAA
GATGGAAAAGAAATTGCATGCAGTGCCGGCTGCCAAGACAGTGAAGTTCAAATG
CCCTTCCAGTGGGACCCCAAACCCCACTGCGCTGGTTGAAAAATGGCAAAGA
ATTCAAACCTGACCACAGAATTGGAGGCTACAAGGTCCGTTATGCCACCTGGAG
35 CATCATAATGGACTCTGTGGTGCCCTCTGACAAGGGCAACTACACCTGCATTGTG
GAGAATGAGTACGGCAGCATCAACCACACATACCAGCTGGATGTCGTGGAGCGG
TCCCCTCACCGGCCCATCCTGCAAGCAGGGTTGCCCGCCAACAAACAGTGGCCC
TGGGTAGCAACGTGGAGTTCATGTGTAAGGTGTACAGTGACCCGCAGCCGCACA
TCCAGTGGCTAAAGCACATCGAGGTGAATGGGAGCAAGATTGGCCCAGACAACC
40 TGCCTTATGTCCAGATCTTGAAGACTGCTGGAGTTAATACCACCGACAAAGAGAT
GGAGGTGCTTCACTTAAGAAATGTCTCCTTTGAGGACGCAGGGGAGTATACGTGC
TTGGCGGGTAACTCTATCGGACTCTCCCATCACTCTGCATGGTTGACCGTTCTGG
AAGCCCTGGAAGAGAGGCCCGGCAGTGATGACCTCGCCCCTGTACCTGGAGATCA
TCATCTATTGCACAGGGGCCCTTCCTCATCTCCTGCATGGTGGGGTCGGTCATCGTC
45 TACAAGATGAAGAGTGGTACCAAGAAGAGTGAAGTCCACAGCCAGATGGCTGTG
CACAAGCTGGCCAAGAGCATCCCTCTGCGCAGACAGGTAACAGTGTCTGCTGAC
TCCAGTGCATCCATGAACTCTGGGGTTCTTCTGGTTTCGGCCATCACGGCTCTCCTC
CAGTGGGACTCCCATGCTAGCAGGGGTCTCTGAGTATGAGCTTCCCGAAGACCTT
CGCTGGGAGCTGCCTCGGGACAGACTGGTCTTAGGCAAACCCCTGGGAGAGGGC

TGCTTTGGGCAGGTGGTGTGGCAGAGGCTATCGGGCTGGACAAGGACAAACCC
 AACCGTGTGACCAAAGTGGCTGTGAAGATGTTGAAGTCGGACGCAACAGAGAAA
 GACTTGTGACACCTGATCTCAGAAATGGAGATGATGAAGATGATCGGGAAGCAT
 AAGAATATCATCAACCTGCTGGGGGCTGCACGCAGGATGGTCCCTTGTATGTCA
 5 TCGTGGAGTATGCCTCCAAGGGCAACCTGCGGGAGTACCTGCAGGCCCGGAGGC
 CCCCAGGGCTGGAATACTGCTACAACCCAGCCACAACCCAGAGGAGCAGCTCT
 CCTCCAAGGACCTGGTGTCTGCGCCTACCAGGTGGCCCGAGGCATGGAGTATCT
 GGCCTCCAAGAAGTGCATACACCGAGACCTGGCAGCCAGGAATGTCCTGGTGAC
 AGAGGACAATGTGATGAAGATAGCAGACTTTGGCCTCGCACGGGACATTACCA
 10 CATCGACTACTATAAAAAGACAACCAACGGCCGACTGCCTGTGAAGTGGATGGC
 ACCCGAGGCATTATTTGACCGGATCTACACCCACCAGAGTGATGTGTGGTCTTTC
 GGGGTGCTCCTGTGGGAGATCTTCACTCTGGGCGGCTCCCCATACCCGGTGTGC
 CTGTGGAGGAACTTTTCAAGCTGCTGAAGGAGGGTCACCGCATGGACAAGCCCA
 GTAACCTGCACCAACGAGCTGTACATGATGATGCGGGACTGCTGGCATGCAGTGC
 15 CCTCACAGAGACCCACCTTCAAGCAGCTGGTGGAAAGACCTGGACCGCATCGTGG
 CCTTGACCTCCAACCAGGAGTACCTGGACCTGTCCATGCCCCTGGACCAGTACTC
 CCCCAGCTTTCCCGACACCCGAGCTCTACGTGCTCCTCAGGGGAGGATTCCGTC
 TTCTCTCATGAGCCGCTGCCCAGGAGCCCTGCCTGCCCCGACACCCAGCCCAGC
 TTGCCAATGGCGGACTCAAACGCCGCTGACTGCCACCCACACGCCCTCCCCAGAC
 20 TCCACCGTCAGCTGTAACCCTCACCCACAGCCCCTGCTGGGCCACCACTGTCC
 GTCCTGTCCCCTTTCTGCTGGCAGGAGCCGGCTGCCTACCAGGGGCCTTCTCTG
 TGTGGCCTGCCTTCACCCCACTCAGCTCACCTCTCCCTCCACCTCCTCTCCACCTG
 CTGGTGAGAGGTGCAAAGAGGCAGATCTTTGCTGCCAGCCACTTCATCCCCTCCAA
 GATGTTGGACCAACACCCCTCCCTGCGACCAGGCATCTGCCGGATGGGCAGAGT
 25 GGAGCAATGAACAGGCATGCAAGTGAGAGCTTCCTGAGCTTTCTCCTGTCCGTTT
 GGTCTGTTTTGCCTTCACCCATAAGCCCCTCGCACTCTGGTGGCAGGTGCTTGTCC
 TCAGGGCTACAGCAGTAGGGAGGTGAGTGCTTCGTGCCTCGATTGAAGGTGACCT
 CTGCCCCAGATAGGTGGTGGCAGTGGCTTATTAATTCCGATACTAGTTTGTCTTGC
 TGACCAAATGCCTGGTACCAGAGGATGGTGAAGCGAAGGCCAGGTTGGGGGCAG
 30 TGTGTGCCCCTGGCCCAGCCAACTGGGGGCTCTGTGGGGGCTCTGTATATAGCT
 ATGAAGAAAACACAAAGTGTATAAATCTGAGTATATATTTACATGTCTTTTTAAA
 AGGGTCGTTACCAGAGATTTACCCATCGGGTAAGATGCTCCTGGTGGCTGGGAG
 GCATCAGTTGCTATATATTAATAAACAACAAAAAGAAAAAAGGAAAATGTTTTTA
 AAAAGGTCATATAATTTTTTGCTACTTTTGCTGTTTTATTTTTTTAAATTATGTTCTA
 35 AACCTATTTTCAGTTTAGGTCCCTCAATAAAAATTGCTGCTGCTTAAAAACC

SEQ ID NO: 300

>gi|2161764|gb|AA448094.1|AA448094 zw82c03.r1 Soares_testis_NHT Homo sapiens

cDNA clone IMAGE:782692 5', mRNA sequence

40 CCGTTCTGGGGCCCAGGAAGTGGGGAAGAGTAGGTTCTCGGTACTTAGGACTTG
 ATCCTGTGGTTGGCCACTGGCATGCTGCTGCCAGCTCTACCCCTCCCAGGGACC
 TACCCCTCCCAGGGACCGACCCCTGGCCCAAGCTCCCCTTGCTGGCGGGCGCTGC
 GTGGGCCCTGCACTTGCTGAGGTTCCCATCATGGGCAAGGAAGGGAATTCCCAC
 AGCCCTCCAGTGTACTGAGGGTACTGGCCTAGCCATGTGGAATTCCCTACCCTGA
 45 CTCCTTCCCCAAACCCAGGGAAAAGAGCTCTCAATTTTTTATTTTAAATTTTGT
 TGAAATA

SEQ ID NO: 301

>gi|2219002|gb|AA489400.1|AA489400 ab41a09.r1 Stratagene HeLa cell s3 937216 Homo sapiens cDNA clone IMAGE:843352 5' similar to SW:PRCF_HUMAN P40306

PROTEASOME COMPONENT MECL-1 PRECURSOR ;, mRNA sequence

5 CAAAGGTCCGGAAACTGGCACGACCATCGCTGGGGTGGTCTATAAGGATGGCA
TAGTTCTTGGAGCAGATACAAGAGCAACTGAAGGGATGGTTGTTGCTGACAAGA
ACTGTTCAAAAATACACTTCATATCTCCTAATATTTATTGTTGTGGTGCTGGGACA
GCTGCAGACACAGACATGACAACCCAGCTCATTTCTTCCAACCTGGAGCTCCACT
CCCTCTCCACTGGCCGTCTTCCCAGAGTTGTGACAGCCAATCGGATGCTGAAGCA
10 GATGCTTTTCAGGTATCAAGGTTACATTGGTGCAGCCCTAGTTTTAGGGGGAGTA
GATGTTACTGGACCTCACCTCTACAGCATCTATCCTCATGGATCAACTGATAAGT
TGCCTTATGTCACCATGGGTTCTGGCTCCTTGGCAGCAATGGCTGTATTTGAAGA
TAAG

15 SEQ ID NO: 302

>g1751443

TGAGGGCACATGTTTATTTAGCAGACAAGGTGGGGCTCCATCAGCGGGGTGGCC
TGGGGAGCAGCTGCATGGGTGGCACTGTGGGGAGGGTCTCCCAGCTCCCTCAAT
GGTGTTTCGGGCTGGTGCGGCANTGGCGGCACCTGTNACTCAGCCGTCGATACACT
20 GGTCGATTGGGACAGGGAAGACGATGTGGTTTTTC

SEQ ID NO: 303

>2731293H1

GAGAGGCAGCAGCTTGCTCAGCGGACAAGGATGCTGGGCGTGAGGGACCAAGG
25 CCTGCCCTGCACTCGGGCCTCCTCCAGCCAGTGCTGACCAGGGACTTCTGACCTG
CTGGCCAGCCAGGACCTGTGTGGGGAGGCCCTCCTGCTGCCTTGGGGTGACAATC
TCAGCTCCAGGCTACAGGGAGACCGGGAGGATCACAGTGCCAGCATGGATCCTG
ACAGTGATCAACCTCTGAACAG

30 SEQ ID NO: 304

>gi|2261974|gb|AA521431.1|AA521431 aa69b11.s1 NCI_CGAP_GCB1 Homo sapiens
cDNA clone IMAGE:826173 3' similar to gb:J03191 PROFILIN I (HUMAN);, mRNA
sequence

TTGTTAGTAG
35 AATCTTTTTTATTTCAGAAAAAAAACCCCAAAAAACAAAAGTTTCCAACCACA
CACGGGAGGGATATGGGTAGGGGGAGGTGTCTGTCCATCCAGCCCTGGCCCCCA
GCCCATGTGGTTTTGGCAGCAATAAGGGGTATGGGGTAATGGCCCCAAAAAATAA
AATGGTTTGTGTGTGTATGGGGAGGAAAGGGGTGCAAAGCTGTGGGGAGGGGTG
AAGGGGAAGGGACAGACGAGGTCAGTACTGGGAACGCCGAAGTGTGGAGGCCA
40 TTTCATAACATTTCTTGTGATCAAACCACCGTGGAAACCTTCTTTGCCCATCAGC
AGGACTAGCGTCTTGTCAGTCTTGGTGACAGTGACATTTAAGGTTGGGGCCCCAC
CGGTGCTCTTGGTACGAAGATCCATGCAAATTTCCCTCGTTAGGAAGTGAGTCCG
GGTCACTGTTTATTTTTTGGCTCTATTTTTTTTTTGGGCGGTTTTTTTTTGTGTTGGGT
TTTTTTTTCGGGGGGGGGTTCTTTTTTGTAT
45

SEQ ID NO: 305

>gi|1856267|gb|AA233079.1|AA233079 zr69f11.r1 Soares_NhHMPu_S1 Homo sapiens
cDNA clone IMAGE:668685 5' similar to gb:M59316_ma1 INSULIN-LIKE GROWTH
FACTOR BINDING PROTEIN 1 PRECURSOR (HUMAN);, mRNA sequence

TGTTCTGTCACGTGAAATATTTAAGTATATAGTATATTTATACTCTAGAACATGCA
CATTTATATATATATGTATATGTATATATATATAGTAACTACTTTTTATACTCCAT
ACATAACTTGATATAGAAAGCTGTTTATTTATTAAGTGTAAAGTTTATTTTTCTAC
ACAGTAAAAACTTGTACTATGTTAATAACTTGTCTATGTCAATTTGTATATCATG
5 AAACACTTCTCATCATAATGGAAGGAAGGTAATTGCATTCTGCTCTTCCAAAGC
TCCTGCGTCTGTTTTTAAAGAGCATGGAAAAATACTGCCTAGAAAATGCAAAATG
AAATAAGAGAGAGTAGTTTTTCAGCTAGTTTGAAGGAGGACGGTTAACTTGTATA
TTCCACCATTACATTTGATGTACATGTGTAGGGAAAGTAAAAGTGTTGATACAT
AATCAAGCTACCGTGGTGATGTTGCCACTGTTAAATGTACCTGGATATGTTGTTA
10 ACACGTGTCTATAATGGAA

SEQ ID NO: 306

>gi|188627|gb|M26383.1|HUMMONAP Human monocyte-derived neutrophil-activating
protein (MONAP) mRNA, complete cds

15 AGCAGAGCACACAAGCTTCTAGGACAAGAGCCAGGAAGAAACCACCGGAAGGA
ACCATCTCACTGTGTGTAAACATGACTTCCAAGCTGGCCGTGGCTCTCTTGGCAG
CCTTCCTGATTTCTGCAGCTCTGTGTGAAGGTGCAGTTTTGCCAAGGAGTGCTAA
AGAACTTAGATGTCAGTGCATAAAGACATACTCCAAACCTTCCACCCCAAATTT
ATCAAAGAACTGAGAGTGATTGAGAGTGGACCACACTGCGCCAACACAGAAATT
20 ATTGTAAGCTTTCTGATGGAAGAGAGCTCTGTCTGGACCCCAAGGAAAAGTGG
GTGCAGAGGGTTGTGGAGAAGTTTTTGAAGAGGGCTGAGAATTCATAAAAAAAT
TCATTCTCTGTGGTATCCAAGAATCAGTGAAGATGCCAGTGAAACTTCAAGCAAA
TCTACTTCAACACTTCATGTATTGTGTGGGTCTGTTGTAGGGTTGCEAGATGCAAT
ACAAGATTCTGGTTAAATTTGAATTTTCAAGTAAACAATGAATAGTTTTTCATTGT
25 ACCATGAAATATCCAGAACATACTTATATGTAAAGTATTATTTATTTGAATCTAC
AAAAACAACAAATAATTTTTAAATATAAGGATTTTCCTAGATATTGCACGGGAG
AATATACAAATAGCAAAATTGAGCCAAGGGCCAAGAGAATATCCGAACCTTTAAT
TTCAGGAATTGAATGGGTTTGCTAGAATGTGATATTTGAAGCATCACATAAAAAAT
GATGGGACAATAAATTTTGCCATAAAGTCAAATTTAGCTGGAAATCCTGGATTTT
30 TTTCTGTAAATCTGGCAACCCTAGTCTGCTAGCCAGGATCCACAAGTCCTTGTTT
CACTGTGCCTTGGTTTTCTCCTTTATTTCTAAGTGGAAAAAGTATTAGCCACCATCT
TACCTCACAGTGATGTTGTGAGGACATGTGGAAGCACITTAAGTTTTTTCATCAT
AACATAAATTATTTTCAAGTGTAACTTATTAACCTATTTATTATTTATGTATTTAT
TTAAGCATCAAATATTTGTGCAAGAATTTGGAAAAATAGAAGATGAATCATTGAT
35 TGAATAGTTATAAAGATGTTATAGTAAATTTATTTTATTTTAGATATTAAATGATG
TTTTATTAGATAAATTTCAATCAGGGTTTTTAGATTAAACAAAGAAACAATTGGG
TACCCAGTTAAATTTTCATTTTCAAGATAAACAACAATAATTTTTTTAGTATAAGTA
CATTATTGTTTATCTGAAAGTTTTAATTGAACATAACAATCCTAGTTTGATACTCCC
AGTCTTGTCATTGCCAGCTGTGTTGGTAGTGTGTGTTGAATTACGGAATAATGA
40 GTTAGAACTATTAAACAGCCAAAACCTCCACAGTCAATATTAGTAATTTCTTGCT
GGTTGAACTTGTTTATTATGTACAAATAGATTCTTATAATATTATTTAAATGACT
GCATTTTTAAATACAAGGCTTTATATTTTAACTTTAAGATGTTTTTATGTGCTCT
CCAAATTTTTTTTACTGTTTCTGATTGTATGGAAATATAAAAGTAAATATGAAAC
ATTTAAATATAATTTGTTGTCAAAGTAAAAAAAAAAAAAAAAA
45

SEQ ID NO: 307

>3530687H1

AGATCATTTACACAATGCTGGCCTCCTTGATGAATAAAGATGGGGTTCTCATATC
CGAGGGCCAAGGCTTCATGACAAGGGAGTTTCTAAAGAGCCTGCGAAAGCCTTT

TGGTGACTTTATGGAGCCCAAGTTTGAGTTTGCTGTGAAGTTCAATGCACTGGAA
TTAGATGACAGCGACTTGGCAATATTTATTGCTGTCAATTATTCTCAGTGGAGACC
GCCCAGGTTTGCTGAATGTGAAGCCCATGAAGACATTCAAGACAACCTGCTACA
AGCCCTGGAGCTCCAGCTGAAG

5

SEQ ID NO: 308

>gi|1164660|gb|N41062.1|N41062 yy53h05.s1 Soares_multiple_sclerosis_2NbHMSP Homo sapiens cDNA clone IMAGE:277305 3' similar to gb:X06820 TRANSFORMING PROTEIN RHOB (HUMAN);, mRNA sequence

10 GCGACCGCTCTCTACCCGGACACCGACGTCATTCTCATGTGCTTCTCGGTGGAC
AGCCCGGACTCGCTGGAGAACATCCCCGAGAAAGTGGGTCCCCGAGGTGAAGCAC
TTCTGTCCCAATGTGCCCATCATCCTGGTGGCCAACAANAAAGACCTGCGCAGGA
CGAGCATGTCCGCACAGAGCTGGCCCGCATGAAGCAGGAACCCGTGCGCACGGA
TGACGGCCGCGCATGGCCGTGCGCATCCAAGCCTACGACTACCTCGAGTGCTCTG
15 CCAAGACCAAGGAAGGCGTGCGCGAGGTCTTCGAGACGGCCACGCGCGCCGNNT
GCAAGAAAGCGTTACGGCTCCCAGAACGGCTGCATCAACTGCTGCAAGGTGCTA
TGAGGGCCGCGC

SEQ ID NO: 309

20 >gi|2078854|gb|AA419108.1|AA419108 zv34a06.r1 Soares ovary tumor NbHOT Homo sapiens cDNA clone IMAGE:755506 5' similar to gb:M82809 ANNEXIN IV (HUMAN);, mRNA sequence

CGGTCTCGTGGGCAGAGGAACAACCAGGAACCTGGGGCTCAGTCTCCACCCCAACA
GTGGGGGCGGATCCGTCGCCGATAAGAGCCGCTGTCTGGCCCTGAGTAGGGTGTG
25 ACCTCCGCAGCCGCAGAGGAGGAGCGCAGCCGGCCTCGAAGAACTTCTGCTTGG
GTGGCTGAACTCTGATCTTGACCTAGAGCATGGCATGCAACCAAAGGAGGTACT
GTCAAAGCTGCTTCAGGATTCAATGCCATGGAAGATGCCCAGACCCTGAGGAAG
GCCATGAAAGGGCTCGGCACCGATGAAGACGCCATTATTAGCGTCCTTGCCCTACC
GCAACACCGCCAGCGCCAGGAGATCAGGACAGCCTACAAGAGCACCATCGGCA
30 GGGACTTGATAGACGACCTGAAGTCAGAACTGAGTGGCACTTCGAGCAGGTGAT
TGTGGGGATGATGACGCCACGTGCTGTATGACGTGCAAGAGCTGCGAAGGGCC
ATGAAGGGAGCCGACTGATGAGGGCTGCTAATTGAGATCTTGGCTTCCGGACC
CTTAGGAGATCGGCGCATA

35 SEQ ID NO: 310

>gi|183622|gb|J03561.1|HUMGRO Human gro (growth regulated) gene

CTCGCCAGCTCTTCCGCTCCTCTCACAGCCGCCAGACCCGCCTGCTGAGCCCCAT
GGCCCGCGCTGCTCTCTCCGCGCCCCCAGCAATCCCCGGCTCCTGCGAGTGGCA
CTGCTGCTCCTGCTCCTGGTAGCCGCTGGCCGGCGCGCAGCAGGAGCGTCCGTGG
40 CCACTGAACTGCGCTGCCAGTGCTTGCAGACCCTGCAGGGAATTCACCCCAAGA
ACATCCAAAGTGTGAACGTGAAGTCCCCCGGACCCCACTGCGCCCCAAACCGAAG
TCATAGCCACACTCAAGAATGGGCGGAAAGCTTGCCTCAATCCTGCATCCCCCAT
AGTTAAGAAAATCATCGAAAAGATGCTGAACAGTGACAAATCCAATGACCAGA
AGGGAGGAGGAAGCTCACTGGTGGCTGTTCCCTGAAGGAGGCCCTGCCCTTATAG
45 GAACAGAAGAGGAAAGAGAGACACAGCTGCAGAGGCCACCTGGATTGTGCCTA
ATGTGTTTGAGCATCGCTTAGGAGAAGTCTTCTATTTATTTATTTATTCATTAGTT
TTGAAGATTCTATGTAAATATTTTAGGTGTAAAATAATTAAGGGTATGATTA
CTACCTGCACACTGTCCTATTATATTCATTCTTTTTGAAATGTCAACCCCAAGTTA
GTTCAATCTGGATTCATATTTAATTTGAAGGTAGAATGTTTTCAAATGTTCTCCAG

TCATTATGTTAATATTTCTGAGGAGCCTGCAACATGCCAGCCACTGTGATAGAGG
CTGGCGGATCCAAGCAAATGGCCAATGAGATCATTGTGAAGGCAGGGGAATGTA
TGTGCACATCTGTTTTGTAAGTGTCTTAGATGAATGTCAGTTGTTATTTATTGAAAT
GATTTACAGTGTGTGGTCAACATTTCTCATGTTGAAACTTTAAGAACTAAAATG
5 TTCTAAATATCCCTTGGACATTTTATGTCTTTCTTGTAAAGGCATACTGCCTTGT
AATGGTAGTTTTACAGTGTCTTGGCTTAGAACAAAGGGGCTTAATTATTGATGT
TTTCGGA

SEQ ID NO: 311

10 >gi|416292|gb|M34064.1|HUMNCADH Human N-cadherin mRNA, complete cds
GACTGGGTCATCCCTCCAATCAACTTGCCAGAAAACCTCCAGGGGACCTTTTCCTC
AAGAGCTTGTGAGGATCAGGTCTGATAGAGATAAAAAACCTTTCACTGCGGTACA
GTGTAAGTGGGCCAGGAGCTGACCAGCCTCCAAGTGGTATCTTCATTCTCAACCC
CATCTCGGGTCAGCTGTGCGGTGACAAAGCCCCTGGATCGCGAGCAGATAGCCCCG
15 GTTTCATTTGAGGGCACATGCAGTAGATATTAATGGAAATCAAGTGGAGAACCC
CATTGACATTGTCAATGTTATTGACATGAATGACAACAGACCTGAGTTCTTA
CACCAGGTTTGGAAATGGGACAGTTCTCTGAGGGATCAAAGCCTGGAACATATGTG
ATGACCGTAACAGCAATTGATGCTGACGATCCCAATGCCCTCAATGGGATGTTGA
GGTACAGAATCGTGTCTCAGGCTCCAAGCACCCCTTCACCCAACATGTTTACAAT
20 CAACAATGAGACTGGTGACATCATCACAGTGGCAGCTGGACTTGATCGAGAAAA
AGTGCAACAGTATACGTTAATAATTCAAGCTACAGACATGGAAGGCAATCCAC
ATATGGCCTTTCAAACACAGCCACGGCCGTCATCACAGTGACAGATGTCATGA
AATCCTCCAGAGTTTACTGCCATGACGTTTTATGGTGAAGTTCTTGAGAACAGGC
TAGACATCATAGTAGCTAATCTAACTGTGACCGATAAGGATCAACCCCATACAC
25 AGCCTGGAACGCAGTGTACAGAATCAGTGGCGGAGATCCTACTGGACGGTTCGC
CATCCAGACCGACCCAAACAGCAACGACGGGTTAGTCACCGTGGTCAAACCAAT
CGACTTTGAAACAAATAGGATGTTTGTCTTACTGTTGCTGCAGAAAATCAAGTC
CCATTAGCCAAGGGAATTCAGCACCCGCCTCAGTCAACTGCAACCGTGTCTGTTA
CAGTTATTGACGTAAATGAAAACCTTATTTTGCCCCCAATCCTAAGATCATTTCG
30 CCAAGAAGAAGGGCTTCATGCCGGTACCATGTTGACAACATTCACTGCTCAGGA
CCCAGATCGATATATGCAGCAAAATATTAGATACTAAATTATCTGATCCTGCC
AATTGGCTAAAAATAGATCCTGTGAATGGACAAATAACTACAATTGCTGTTTTGG
ACCGAGAATCACCAAATGTGAAAAACAATATATATAATGCTACTTTTCCTTGCTTC
TGACAATGGAATTCCTCCTATGAGTGGAAACAGGAACGCTGCAGATCTATTTACTT
35 GATATTAATGACAATGCCCTCAAGTGTTACCTCAAGAGGCAGAGACTTGCGAA
ACTCCAGACCCCAATTCAATTAATATTACAGCACTTGATTATGACATTGATCCAA
ATGCTGGACCAATTTGCTTTTGATCTTCCTTTATCTCCAGTGACTATTAAGAGAAAT
TGGACCATCACTCGGCTTAATGGTGATTTTGCTCAGCTTAATTTAAAGATAAAAT
TTCTTGAAGCTGGTATCTATGAAGTTCCCATCATAATCACAGATTCCGGTAATCC
40 TCCCAAATCAAATATTTCCATCCTGCGCGTGAAGGTTTGCCAGTGTGACTCCAAC
GGGGACTGCACAGATGTGGACAGGATTGTGGGTGCGGGGCTTGGCACCGGTGCC
ATCATTGCCATCCTGCTCTGCATCATCCTGCTTATCCTTGTGCTGATGTTTGT
GGTATGGATGAAACGCCGGGATAAAGAACGCCAGGCCAAACAACCTTTTAATTGA
TCCAGAAGATGATGTAAGAGATAATATTTTAAAATATGATGAAGAAGGTGGAGG
45 AGAAGAAGACCAGGACTATGACTTGAGCCAGCTGCAGCAGCCTGACACTGTGGA
GCCTGATGCCATCAAGCCTGTGGGAATCCGACGAATGGATGAAAGACCCATCCA
CGCCGAGCCCCAGTATCCGGTCCGATCTGCAGCCCCACACCCTGGAGACATTGGG
GACTTCATTAATGAGGGCCTTAAAGCGGCTGACAATGACCCACAGCTCCACCAT
ATGACTCCCTGTTAGTGTTGACTATGAAGGCAGTGGCTCCACTGCTGGGTCCTT

GAGCTCCCTTAATTCCTCAAGTAGTGGTGGTGAGCAGGACTATGATTACCTGAAC
GACTGGGGGCCACGGTTCAAGAACTTGCTGACATGTATGGTGGAGGTGATGAC
TGAACCTCAGGGTGAACCTTGGTTTTTGGACAAGTACAAACAATTTCAACTGATAT
TCCCAAAAAGCATTTCAGAAGCTAGGCTTTAACTTTGTAGTCTACTAGCACAGTGC
5 CTGCTGGAGGCTTTGGCATAGGCTGCAAACCAATTTGGGCTCAGAGGGAATATC
AGTGATCCATACTGTTTGGAAAAACACTGAGCTCAGTTACACTTGAATTTTACAG
TACAGAAGCACTGGGATTTTATGTGCCTTTTGTACCTTTTTCAGATTGGAATTAG
TTTTCTGTTTAAGGCTTTAATGGTACTGATTTCTGAAACGATAAGTAAAAGACAA
AATATTTTGTGGTGGGAGCAGTAAGTTAAACCATGATATGCTTCAACACGCTTTT
10 GTTACATTGCATTTGCTTTTATTAAAATACAAAATTAACAAACAAAAAACTCA
TGGAGCGATTTTATTATCTTGGGGGATGAGACCATGAGATTGGAAAATGTACATT
ACTTCTAGTTTTAGACTTTAGTTTTGTTTTTTTTTTTTTCACTAAAATCTTAAACT
TACTCAGCTGGTTGCAAATAAAGGGAGTTTTCATATCACCAATTTGTAGCAAAAT
TGAATTTTTTTCATAAACTAGAATGTTAGACACATTTTGGTCTTAATCCATGTACAC
15 CTTTTTATTTCTGTATTTTCCACTTCACTGTAAAAATAGTATGTGTACATAATGTT
TTATTGGCATACGTCTATGGAGAAGTGCAGAACTTCAGAACATGTGTATGTATT
ATTTGGACTATGGATTGAGGTTTTTGCATGTTTATATCTTTCGTTATGGATAAAG
TATTTACAAAACAGTGACATTTGATTCAATTGTTGAGCTGTAGTTAGAATACTCA
ATTTTAAATTTTTTAAATTTTTTATTTTTTCTTTTTGGTTTGGGGAGGGAG
20 AAAAGTTCTTAGCACAAATGTTTTACATAATTTGTACCAAAAAAAAAAAAAAAG
GAAAGGAAAGAAAGGGGTGGCCTGACACTGGTGGCACTACTAAGTGTGTGTTTT
TTTAAAAAAAAAATGGAAAAAAAAAAGCCTTTAAACTGGAGAGACTTCTGACAA
CAGCTTTGCCTCTGTATTGTGTACCAGAATATAAATGATACACCTCTGACCCAG
CGTCTGAATAAAATGCTAATTTTGGATAACAAAAAAGGGGAATTC

SEQ ID NO: 312

>1334463H1

CACACAGTCAAGCTTTAAAGAAAGTGTTTGGCTGAAAATAAAGAAATCCAGAAAT
TGGCAGAGCAGTTTGTCTCCTCAATCTGGTTTATGAAACAACTGACAAACACCT
30 TTCTCCTGATGGCCAGTATGTCCCAGGATTATGTTTGTGACCCATCTCTGACAG
TTAGAGCCGATATCACTGGAAGATATTCAAACCGTCTCTATGCTTACGAACCTGC
AGATACAGCTC

SEQ ID NO: 313

>gi|2216301|gb|AA486085.1|AA486085 ab14c11.s1 Stratagene lung (#937210) Homo
sapiens cDNA clone IMAGE:840788 3' similar to gb:S54005 THYMOSIN BETA-10
(HUMAN);, mRNA sequence

GGTGTGTTTTATTTTCATTATTCATACAAATAATTTTCTATAATATCCCGGGGCAA
ACCGGAGAATTTGGCAGTCCGATTGGGGGG

SEQ ID NO: 314

>gi|292418|gb|M64749.1|HUMRDC1A Human homologue of the canine orphan receptor
(RDC1) mRNA, 5' end

ATGGATCTGCACCTCTTCGACTACGCCGAGCCAGGCAACTTCTCGGACATCAGCT
45 GGCCATGCAACAGCAGCGACTGCATCGTGGTGGACACGGTGATGTGTCCCAACA
TGCCCAACAAAAGCGTCCTGCTCTACACGCTCTCCTTCATTTACATTTTCATCTTC
GTCATCGGCATGATTGCCAACTCCGTGGTGGTCTGGGTGAATATCCAGGCCAAGA
CCACAGGCTATGACACGCACTGCTACATCTTGAACCTGGCCATTGCCGACCTGTG
GGTTGTCCTCACCATCCAGTCTGGGTGGTCACTCTCGTGCAGCACAACCAGTGG

CCCATGGGCGAGCTCACGTGCAAAGTCACACACCTCATCTTCTCCATCAACCTCT
TCAGCGGCATTTTCTTCTCACGTGCATGAGCGTGGACCGCTACCTCTCCATCACC
TACTTCACCAACACCCCCAGCAGCAGGAAGAAGATGGTACGCCGTGTCGTCTGC
ATCCTGGTGTGGCTGCTGGCCTTCTGCGTGTCTCTGCCTGACACCTACTACCTGAA
5 GACCGTCACGTCTGCGTCCAACAATGAGACCTACTGCCGGTCCTTCTACCCCGAG
CACAGCATCAAGGAGTGGCTGATCGGCATGGAGCTGGTCTCCGTTGTCTTGGGCT
TTGCCGTTCCCTTCTCCATTATCGCTGTCTTCTACTTCCTGCTGGCCAGAGCCATC
TCGGCGTCCAGTGACCAGGAGAAGCACAGCAGCCGGAAGATCATCTTCTCCTAC
GTGGTGGTCTTCCCTTGTCTGCTGGCTGCCCTACCACGTGGCGGTGCTGCTGGACA
10 TCTTCTCCATCCTGCACTACATCCCTTTCACCTGCCGGCTGGAGCACGCCCTCTTC
ACGGCCCTGCATGTCACACAGTGCCTGTGCTGGTGCCTGCTGCGTCAACCCTG
TCCTCTACAGCTTCATCAATCGCAACTACAGGTACGAGCTGATGAAGGCCTTCAT
CTTCAAGTACTCGGCCAAAACAGGGCTCACCAAGCTCATCGATGCCTCCAGAGTG
TCGGAGACGGAGTACTCCGCCTTGGAGCAAAACGCCAAG

15

SEQ ID NO: 315

>gi|183866|gb|M60278.1|HUMHBEGF Human heparin-binding EGF-like growth factor
mRNA, complete cds

20

GCTACGCGGGCCACGCTGCTGGCTGGCCTGACCTAGGCGCGCGGGGTCGGGCGG
CCGCGCGGGCGGGCTGAGTGAGCAAGACAAGACACTCAAGAAGAGCGAGCTGC
GCCTGGGTCCCGGCCAGGCTTGACGCGAGAGGCGGGCGGCAGACGGTGCCCGGC
GGAATCTCCTGAGCTCCGCCGCCAGCTCTGGTGCCAGCGCCAGTGGCCGCCGC
TTGAAAGTGACTGGTGCCTCGCCGCCTCCTCTCGGTGCGGGACCATGAAGCTGC
TGCCGTGCGTGGTGTGAAGCTCTTCTGGCTGCAGTTCTCTCGGCACTGGTGACT
25 GCGGAGAGCCTGGAGCGGCTTCGGAGAGGGCTAGCTGCTGGAACCAGCAACCCG
GACCCTCCCCTGTATCCACGGACCAGCTGCTACCCCTAGGAGGCGGCCGGGAC
CGGAAAGTCCGTGACTTGCAAGAGGCAGATCTGGACCTTTTGAGAGTCACTTTAT
CCTCCAAGCCACAAGCACTGGCCACACCAAAACAAGGAGGAGCACGGGAAAAGA
AAGAAGAAAGGCAAGGGGCTAGGGAAGAAGAGGGACCCATGTCTTCGGAAATA
30 CAAGGACTTCTGCATCCATGGAGAATGCAAATATGTGAAGGAGCTCCGGGCTCC
CTCCTGCATCTGCCACCCGGGTTACCATGGAGAGAGGTGTATGGGCTGAGCCTC
CCAGTGGAATAATCGTTATATACCTATGACCACACAACCATCCTGGCCGTGGTGG
CTGTGGTGTCTCATCTGTCTGTCTGCTGGTCATCGTGGGGCTTCTCATGTTTAGG
TACCATAGGAGAGGAGGTTATGATGTGGAATAATGAAGAGAAAGTGAAGTTGGGC
35 ATGACTAATTCCCACTGAGAGAGACTTGTGCTCAAGGAATCGGCTGGGGACTGCT
ACCTCTGAGAAGACACAAGGTGATTTCACTGTCAGAGGGGAAAGACTTCCATC
TAGTCACAAAGACTCCTTCGTCCCCAGTTGCCGTCTAGGATTGGGCCTCCATAA
TTGCTTTGCCAAAATACCAGAGCCTTCAAGTGCCAAACAGAGTATGTCCGATGGT
ATCTGGGTAAAGAAGAAAGCAAAAGCAAGGGACCTTCATGCCCTTCTGATTCCCCT
40 CCACCAAACCCCACTTCCCCTCATAAGTTTGTTTAAACACTTATCTTCTGGATTAG
AATGCCGGTTAAATTCCATATGCTCCAGGATCTTTGACTGAAAAAAAAAAGAA
GAAGAAGAAGGAGAGCAAGAAGGAAAGATTTGTGAACTGGAAGAAAGCAACAA
AGATTGAGAAGCCATGTACTCAAGTACCACCAAGGGATCTGCCATTGGGACCCT
CCAGTGCTGGATTTGATGAGTTAACTGTGAAATACCACAAGCCTGAGAACTGAAT
45 TTTGGGACTTCTACCCAGATGGAAAAATAACAACATATTTTGTGTTGTTGTTTGT
AAATGCCTCTTAAATTATATATTTATTTTATTTCTATGTATGTTAATTTATTTAGTTT
TTAACAATCTAACAATAATATTTCAAGTGCCTAGACTGTTACTTTGGCAATTTCT
GGCCCTCCACTCCTCATCCCCACAATCTGGCTTAGTGCCACCCACCTTTGCCACA
AAGCTAGGATGGTTCTGTGACCCATCTGTAGTAATTTATTGTCTGTCTACATTTCT

GCAGATCTTCCGTGGTCAGAGTGCCACTGCGGGAGCTCTGTATGGTCAGGATGTA
GGGGTTAACTTGGTCAGAGCCACTCTATGAGTTGGACTTCAGTCTTGCCTAGGCG
ATTTTGTCTACCATTTGTGTTTTGAAAGCCCAAGGTGCTGATGTCAAAGTGTAAC
AGATATCAGTGTCTCCCCGTGTCTCTCCCTGCCAAGTCTCAGAAGAGGTTGGGC
5 TTCCATGCCTGTAGCTTTCCTGGTCCCTCACCCCCATGGCCCCAGGCCACAGCGT
GGGAACTCACTTTCCTTGTGTCAAGACATTTCTCTAACTCCTGCCATTCTTCTGG
TGCTACTCCATGCAGGGGTCAGTGCAGCAGAGGACAGTCTGGAGAAGGTATTAG
CAAAGCAAAAGGCTGAGAAGGAACAGGGAACATTGGAGCTGACTGTTCTTGGTA
ACTGATTACCTGCCAATTGCTACCGAGAAGGTTGGAGGTGGGGAAGGCTTTGTAT
10 AATCCACCCACCTCACCAAAACGATGAAGGTATGCTGTCATGGTCCCTTCTGGA
AGTTTCTGGTGCCATTTCTGAACTGTTACAACCTTGTATTTCCAAACCTGGTTCATA
TTTATACTTTGCAATCCAAATAAAGATAACCCTTATTCATAAAAAAAAAAAAAA
AAAA

15 SEQ ID NO: 316

>gi|179664|gb|K02765.1|HUMC3 Human complement component C3 mRNA, alpha and beta
subunits, complete cds

CTCCTCCCCATCCTCTCCCTCTGTCCCTCTGTCCCTCTGACCCTGCACTGTCCCAG
CACCATGGGACCCACCTCAGGTCCCAGCCTGCTGCTCCTGCTACTAACCACCTC
20 CCCCTGGCTCTGGGGAGTCCCATGTACTCTATCATCACCCCAACATCTTGCGGC
TGGAGAGCGAGGAGACCATGGTGTCTGGAGGCCACGACGCGCAAGGGGATGTTT
CAGTCACTGTTACTGTCCACGACTTCCCAGGCCAAAAAACTAGTGCTGTCCAGTGA
GAAGACTGTGCTGACCCCTGCCACCAACACCATGGGCAACGTCACCTTCACGATC
CCAGCCAACAGGGAGTTCAAGTCAAGAAAGGGGGGCAACAAGTTCGTGACCGTG
25 CAGGCCACCTTCGGGAACCAAGTGGTGGAGAAGGTGGTGTCTGGTCAGCCTGCAG
AGCGGGTACCTCTTCATCCAGACAGACAAGACCATCTACACCCCTGGCTCCACAG
TTCTCTATCGGATCTTCACCGTCAACCACAAGCTGCTACCCGTGGGCCGGACGGT
CATGGTCAACATTGAGAACCCGGAAGGCATCCCGGTCAAGCAGGACTCCTTGTCT
TCTCAGAACCAGCTTGCGCTCTTGCCCTTGTCTTGGGACATTCCGGAACCTCGTCA
30 ACATGGGCCAGTGGAAGATCCGAGCCTACTATGAAAACCTACCACAGCAGGTCT
TCTCCACTGAGTTTGAGGTGAAGGAGTACGTGCTGCCAGTTTCGAGGTATAGT
GGAGCCTACAGAGAAATTCTACTACATCTATAACGAGAAGGGCCTGGAGGTCAC
CATCACCGCEAGGFTCCTCTACGGGAAGAAAGTGGAGGGAACTGCCTTTGTATC
TTCGGGATCCAGGATGGCGAACAGAGGATTTCCCTGCCTGAATCCCTCAAGCGCA
35 TTCCGATTGAGGATGGCTCGGGGGAGGTTGTGCTGAGCCGGAAGGTACTGCTGG
ACGGGGTGCAGAACCTCCGAGCAGAAGACCTGGTGGGGAAGTCTTTGTACGTGT
CTGCCACCGTCATCTTGCACTCAGGCAGTGACATGGTGCAGGCAGAGCGCAGCG
GGATCCCCATCGTGACCTCTCCCTACCAGATCCACTTCACCAAGACACCCAAGTA
CTTCAAACCAGGAATGCCCTTTGACCTCATGGTGTTCGTGACGAACCCTGATGGC
40 TCTCCAGCCTACCGAGTCCCCGTGGCAGTCCAGGGCGAGGACACTGTGCAGTCTC
TAACCCAGGGAGATGGCGTGGCCAAACTCAGCATCAACACACACCCAGCCAGA
AGCCCTTGAGCATCACGGTGCGCACGAAGAAGCAGGAGCTCTCGGAGGCAGAGC
AGGCTACCAGGACCATGCAGGCTCTGCCCTACAGCACCGTGGGCAACTCCAACA
ATTACCTGCATCTCTCAGTGCTACGTACAGAGCTCAGACCCGGGGAGACCCTCAA
45 CGTCAACTTCCTCCTGCGAATGGACCGCGCCACGAGGCCAAGATCCGCTACTAC
ACCTACCTGATCATGAACAAGGGCAGGCTGTTGAAGGCGGGACGCCAGGTGCGA
GAGCCCGGCCAGGACCTGGTGGTGTCTGCCCTGTCCATCACCACCGACTTCATCC
CTTCCTTCCGCCTGGTGGCGTACTACACGCTGATCGGTGCCAGCGGCCAGAGGGA
GGTGGTGGCCGACTCCGTGTGGGTGGACGTCAAGGACTCCTGCGTGGGCTCGCTG

GTGGTAAAAAGCGGCCAGTCAGAAGACCGGCAGCCTGTACCTGGGCAGCAGATG
ACCCTGAAGATAGAGGGTGACCACGGGGCCCGGGTGGTACTGGTGGCCGTGGAC
AAGGGCGTGTTCTGTCTGAATAAGAAGAACAACTGACGCAGAGTAAGATCTGG
GACGTGGTGGAGAAGGCAGACATCGGCTGCACCCCGGGCAGTGGGAAGGATTAC
5 GCCGGTGTCTTCTCCGACGCAGGGCTGACCTTCACGAGCAGCAGTGGCCAGCAG
ACCGCCCAGAGGGCAGAACTTCAGTGCCCCGCAGCCAGCCGCCCCGCCGACGCCGT
TCCGTGCAGCTCACGGAGAAGCGAATGGACAAAGTCGGCAAGTACCCCAAGGAG
CTGCGCAAGTGCTGCGAGGACGGCATGCGGGAGAACCCCATGAGGTTCTCGTGC
CAGCGCCGGACCCGTTTCATCTCCCTGGGCGAGGCGTGCAAGAAGGTCTTCCTGG
10 ACTGCTGCAACTACATCACAGAGCTGCGGCGGCAGCACGCGCGGGCCAGCCACC
TGGGCCTGGCCAGGAGTAACCTGGATGAGGACATCATTGCAGAAGAGAACATCG
TTTCCCGAAGTGAGTTCCAGAGAGCTGGCTGTGGAACGTTGAGGACTTGAAAG
AGCCACCGAAAAATGGAATCTCTACGAAGCTCATGAATATATTTTGAAGACTC
CATCACACGTGGGAGATTCTGGCTGTCAGCATGTCGGACAAGAAAGGGATCTG
15 TGTGGCAGACCCCTTCGAGGTCACAGTAATGCAGGACTTCTTCATCGACCTGCGG
CTACCCTACTCTGTTGTTTCGAAACGAGCAGGTGGAAATCCGAGCCGTTCTCTACA
ATTACCGGCAGAACCAAGAGCTCAAGGTGAGGGTGGAAGTACTCCACAATCCAG
CCTTCTGCAGCCTGGCCACCACCAAGAGGCGTCACCAGCAGACCGTAACCATCCC
CCCCAAGTCCTCGTTGTCCGTTCCATATGTCATCGTGCCGCTAAAGACCGGCCTG
20 CAGGAAGTGGAAGTCAAGGCTGCCGTCTACCATCATTTTCATCAGTGACGGTGTCA
GGAAGTCCCTGAAGGTCGTGCCGGAAGGAATCAGAATGAACAAAACCTGTGGCTG
TTCGCACCCTGGATCCAGAACGCCTGGGCCGTGAAGGAGTGCAGAAAGAGGACA
TCCCACCTGCAGAGCTEAGTGACCAAGTCCCGGACACCGAGTCTGAGACCAGAA
TTCCTCTGCAAGGGACCCAGTGGCCCAGATGACAGAGGATGCCGTGACGCGG
25 AACGGCTGAAGCACCTCATTGTGACCCCTCGGGCTGCGGGGAACAGAACATGA
TCGGCATGACGCCACGGTCATCGCTGTGCATTACCTGGATGAAACGGAGCAGT
GGGAGAAGTTCGGCCTAGAGAAGCGGCAGGGGGCCTTGGAGCTCATCAAGAAG
GGGTACACCCAGCAGCTGGCCTTCAGACAACCCAGCTCTGCCTTTGCGGCCTTCG
TGAAACGGGCACCCAGCACCTGGCTGACCGCCTACGTGGTCAAGGTCTTCTCTCT
30 GGCTGTCAACCTCATCGCCATCGACTCCCAAGTCCTCTGCGGGGCTGTAAATGG
CTGATCCTGGAGAAGCAGAAGCCCGACGGGGTCTTCCAGGAGGATGCGCCCGTG
ATACACCAAGAAATGATTGGTGGATTACGGAACAACAACGAGAAAGACATGGCC
CTCACGGCCTTTGTTCTCATCTCGCTGCAGGAGGCTAAAGATATTTGCGAGGAGC
AGGTCAACAGCCTGCCAGGCAGCATCACTAAAGCAGGAGACTTCCTTGAAGCCA
35 ACTACATGAACCTACAGAGATCCTACACTGTGGCCATTGCTGGCTATGCTCTGGC
CCAGATGGGCAGGCTGAAGGGGCCTCTTCTTAACAAATTTCTGACCACAGCCAA
AGATAAGAACCGCTGGGAGGACCCTGGTAAGCAGCTCTACAACGTGGAGGCCAC
ATCCTATGCCCTCTTGGCCCTACTGCAGCTAAAAGACTTTGACTTTGTGCCTCCCG
TCGTGCGTTGGCTCAATGAACAGAGATACTACGGTGGTGGCTATGGCTCTACCCA
40 GGCCACCTTCATGGTGTTCGAAGCCTTGGCTCAATACCAAAAGGACGCCCTGAC
CACCAGGAACCTGAACCTTGATGTGTCCCTCCAACTGCCAGCCGCAGCTCCAAGA
TCACCCACCGTATCCACTGGGAATCTGCCAGCCTCCTGCGATCAGAAGAGACCAA
GGAAAATGAGGGTTTCACAGTCACAGCTGAAGGAAAAGGCCAAGGCACCTTGTC
GGTGGTGACAATGTACCATGCTAAGGCCAAAGATCAACTCACCTGTAATAAATTC
45 GACCTCAAGGTCACCATAAAACCAGCACCGGAAACAGAAAAGAGGCCTCAGGAT
GCCAAGAACACTATGATCCTTGAGATCTGTACCAGGTACCGGGGAGACCAGGAT
GCCACTATGTCTATATTGGACATATCCATGATGACTGGCTTTGCTCCAGACACAG
ATGACCTGAAGCAGCTGGCCAATGGTGTGACAGATACATCTCCAAGTATGAGCT
GGACAAAGCCTTCTCCGATAGGAACACCCTCATCATCTACCTGGACAAGGTCTCA

CACTCTGAGGATGACTGTCTAGCTTTCAAAGTTCACCAATACTTTAATGTAGAGC
 TTATCCAGCCTGGAGCAGTCAAGGTCTACGCCTATTACAACCTGGAGGAAAGCTG
 TACCCGGTTCTACCATCCGGAAGAGGAGTGGAAAGCTGAACAAGCTCTGCCG
 TGATGAACTGTGCCGCTGTGCTGAGGAGAATTGCTTCATACAAAAGTCGGATGAC
 5 AAGGTCACCCTGGAAGAACGGCTGGACAAGGCCTGTGAGCCAGGAGTGGACTAT
 GTGTACAAGACCCGACTGGTCAAGGTTCAAGTGTCCAATGACTTTGACGAGTACA
 TCATGGCCATTGAGCAGACCATCAAGTCAGGCTCGGATGAGGTGCAGGTTGGAC
 AGCAGCGCACGTTTCATCAGCCCCATCAAGTCAGAGAAGCCCTGAAGCTGGAGG
 AGAAGAAACACTACCTCATGTGGGGTCTCTCTCCGATTTCTGGGGAGAGAAGCC
 10 CAACCTCAGCTACATCATCGGGAAGGACACTTGGGTGGAGCACTGGCCTGAGGA
 GGACGAATGCCAAGACGAAGAGAACCAGAAACAATGCCAGGACCTCGGCGCCTT
 CACCGAGAGCATGGTTGTCTTTGGGTGCCCCAACTGACCACACCCCCATTCC

SEQ ID NO: 317

15 >gi|2185691|gb|AA460571.1|AA460571 zx60a08.r1 Soares_testis_NHT Homo sapiens
 cDNA clone IMAGE:795830 5' similar to gb:M95724 CENTROMERE PROTEIN C
 (HUMAN);, mRNA sequence
 AAAGTTTTGCCAGTAGATCTTGGATTACAATACCAAGAAAGGCAGGGTCTCTGA
 AACAACGCACAATATCCCCGGCTGAGAGCACTGCACTCCTTCAAGGTAGAAAGT
 20 CAAGAGAAAAGCATCATAATATATTACCTAAGACTTTGGCAAATGACAAACATT
 CCCATAAACCTCACCCAGTAGAGACATCTCAGCCCTCTGATAAAACAGTACTGGA
 TACAAGTTATGCTTTGATAGGTGAAACAGTAAATAATTATAGATCTACAAAATAT
 GAAATGTATTCGAAGAATGCAGAAAACCATCTAGAAGCAAAAGGACTATAAAA
 CAAAAACAGGAGAAGAAATTCATGGCTAAACCAGCTGAAGAACAGCTTGATGTG
 25 GGACAGTCTAAAGATGAAAACATACATACATACATATTACCCANGACGAATTT
 CAAAGAAATTCAGACAGAAAATATGGAAGAGCCTGAAGAGATTGGGAAATGATT
 GTGGTTCCAAAAACAGATGCCACCTGTGGGAAGCCAGAAAGGTAGCACTGAAA
 AGATTGGGGGATTCTTAAAGGAGCGCTTTTCAGT

30 SEQ ID NO: 318

>1226731H1

CTCCTCTGGCAGAACCTCGGCTCTCAGGAGGTCTTGTTCAGGGAACAGCTGCT
 TCTCT

GGGGCTGGGCTCTACTCCCTGCAGCCCCTCGCACTACCCAGCTGGAACCAGGGAC
 35 AACGC
 CTGAGTCCAACCCTCGTGTCTATTTCCAGAAAACGGGCAATGCTGTGAGAGCCA
 TTGGA
 AGACTGTCCTCTATGGCAATGATCTCAGGGCTCAGTGGCAGGAAATCCTCAACAG
 G

40

SEQ ID NO: 319

>874 BLOOD 239973.4 D13645 g286008 Human mRNA for KIAA0020 gene, complete cds.
 0

CGGAGAGGCGGTCGGGATCCGCTGCGCGAGCTGTCTCGGTCCCACGTGTGCGAG
 45 TTGCTACGATGGAAGTTAAAGGGAAAAAGCAATTCACAGGAAAGAGTACAAAG
 ACAGCACAAGAAAAAACAGATTTTATAAAAATAGTGATTCTGGTTCTTCAAAG
 ACATTTCCAACAAGGAAAGTTGCTAAAGAAGGTGGACCTAAAGTCACATCTAGG
 AACTTTGAGAAAAGTATCAGAAAACCTTGGGAAAAAGGGTGTAAAGCAGTTCAAG
 AATAAGCAGCAAGGGGACAAATCACCAAAGAACAAATTCCAGCCGGCAAATAA

ATTCAACAAGAAGAGAGAAAATTCCAGCCAGATGGTAGAAGCGATGAATCAGCAGC
CAAGAAGCCCCAAATGGGATGACTTCAAAAAGAAGAAGAAAGAACTGAAGCAAA
GCAGACAACCTCAGTGATAAAACCAACTATGACATTGTTGTTTCGGGCAAAGCAGA
TGTGGGAGATTTTAAAGAAGAAAAGACTGTGACAAAGAAAAAAGAGTAAAGTTA
5 ATGAGTGATTTGCAGAAGTTGATTCAAGGGAAAATTA AAACTATTGCATTTGCAC
ACGATTCAACTCGTGTGATCCAGTGTTACATTCAAGTATGGTAATGAAGAACAGAG
AAACAGGCTTTTGAAGAATTGCGAGATGATTTGGTTGAGTTAAGTAAAGCCAA
ATATTCGAGAAATATTGTTAAGAAATTTCTCATGTATGGAAGTAAACCACAGATT
GCAGAGATAATCAGAAGTTTAAAGGCCACGTGAGGAAGATGCTGCGGCATGCG
10 GAAGCATGCAGCCATCGTGGAGTACGCATACAATGACAAAGCCATTTTGGAGCA
GAGGAACATGCTGACGGAAGAGCTCTATGGGAACACATTTTCAAGCTTTACAAGTC
AGCAGATCACCCAACCTCTGGACAAAGTGTTAGAGGTACAGCCAGAAAAATTAGA
ACTTATTATGGATGAAATGAAACAGATTCTAACTCCAATGGCCCCAAAGGAAGC
TGTGATTAAGCACTCATTGGTGCATAAAGTATTCTTGGACTTTTTTACCTATGCAC
15 CCCCCAACTCAGATCAGAAATGATTGAAGCCATCCGCGAAGCGGTGGTCTACC
TGGCACACACACACGATGGCGCCAGAGTGGCCATGCACTGCCTGTGGCATGGCA
CGCCCCAAGGACAGGAAAGTGATTGTGAAAACAATGAAGACTTATGTTGAAAAGG
TGGCTAATGGCCAATACTCCCATTGTTTACTGGCGGCATTTGATTGTATTGAT
GATACTAAGCTTGTGAAGCAGATAATCATATCAGAAATTATCAGTTCATTGCCTA
20 GCATAGTAAATGACAAATATGGAAGGAAGGTCTATTGTACTTACTAAGCCCCA
GAGATCCTGCACATACAGTACGAGAAATCATTGAAGTTCTGCAAAAAGGAGATG
GAAATGCACACAGTAAGAAAGATACAGAGGTCCGCAGACGGGAGCTCCTAGAAT
CCATTTCTCCAGCTTTGTTAAGCTACCTGCAAGAACATGCCCAAGAAAGTGGTGCT
GAGATAAGTCTGCGTGTGTGTTGGTGTCTGACATTCTGGGATCTGCCACTGGAGAC
25 GTTCAGCCTACCATGAATGCCATCGCCAGCTTGGCAGCAACAGGACTGCATCCTG
GTGGCAAGGACGGAGAGCTTCACATTGCAGAACATCCTGCAGGACATCTAGTTC
TGAAGTGGTTAATAGAGCAAGATAAAAAGATGAAAGAAAATGGGAGAGAAGGT
TGTTTTGCAAAAACACTTGTAGAGCATGTTGGTATGAAGAACCTGAAGTCCTGGG
CTAGTGTAATCGAGGTGCCATTATTCTTTCTAGCCTCCTCCAGAGTTGTGACCTG
30 GAAGTTGCAAAACAAAGTCAAAGCTGCACTGAAAAGCTTGATTCCTACATTGGAA
AAAACCAAAAAGCACCAGCAAAGGAATAGAAATTCTACTTGAAAACTGAGCACA
TAGGTGGAAGAGTTAAGAGCAAGATGGAATGATTTTTTCTGTTCTCTGTTCTGT
TTCCCAATGCAGAAAAGAAGGGGTAGGGTCCACCATACTGGTAATTGGGGTACT
CTGTATATGTGTTTCTTCTTTGTATACGAATCTATTTATATAAATTGTTTTTTAAA
35 TGGTCTTTTTT

SEQ ID NO: 320

>gi|30125|emb|X54925.1|HSCOLL1 H.sapiens mRNA for type I interstitial collagenase

40 ATATTGGAGTAGCAAGAGGCTGGGAAGCCATCACTTACCTTGAAGAGAAAGA
AGACAAAGGCCAGTATGCACAGCTTTCTCCACTGCTGCTGCTGCTGTTCTGGGG
TGTGGTGTCTCACAGCTTCCCAGCGACTCTAGAAACACAAGAGCAAGATGTGGA
CTTAGTCCAGAAATACCTGGA AAAATACTACAACCTGAAGAATGATGGGAGGCA
AGTTGAAAAGCGGAGAAATAGTGGCCCAGTGGTTGAAAAATTGAAGCAAATGCA
45 GGAATTCTTTGGGCTGAAAGTGACTGGGAAACCAGATGCTGAAACCCTGAAGGT
GATGAAGCAGCCCAGATGTGGAGTGCCTGATGTGGCTCAGTTTGTCTCACTGAG
GGGAACCCTCGCTGGGAGCAAACACATCTGACCTACAGGATTGAAAATTACACG
CCAGATTTGCCAAGAGCAGATGTGGACCATGCCATTGAGAAAGCCTTCCAACCTCT
GGAGTAATGTCACACCTCTGACATTCACCAAGGTCTCTGAGGGTCAAGCAGACAT

CATGATATCTTTTGTTCAGGGGAGATCATCGGGACAACCTCTCCTTTTGATGGACCT
GGAGGAAATCTTGCTCATGCTTTTCAACCAGGCCAGGTATTGGAGGGGATGCTC
ATTTTGATGAAGATGAAAGGTGGACCAACAATTTTCAGAGAGTACAACCTTACATC
GTGTTGCGGCTCATGAACTCGGCCATTCTCTTGGACTCTCCCATTCTACTGATATC
5 GGGGCTTTGATGTACCCTAGCTACACCTTCAGTGGTGATGTTTCAGCTAGCTCAGG
ATGACATTGATGGCATCCAAGCCATATATGGACGTTCCCAAAATCCTGTCCAGCC
CATCGGCCACAAACCCCAAAAGCATGTGACAGTAAGCTAACCTTTGATGCTATA
ACTACGATTCGGGGAGAAGTGATGTTCTTTAAAGACAGATTCTACATGCGCACAA
ATCCCTTCTACCCGGAAGTTGAGCTCAATTTTCTGTTTTCTGGCCACAACCTG
10 CCAATGGGCTTGAAGCTGCTTACGAATTTGCCGACAGAGATGAAGTCCGGTTTT
TCAAAGGAATAAGTACTGGGCTGTTTCAGGGACAGAATGTGCTACACGGATACC
CCAAGGACATCTACAGCTCCTTTGGCTTCCCTAGAACTGTGAAGCATATCGATGC
TGCTCTTTCTGAGGAAAACACTGGAAAAACCTACTTCTTTGTTGCTAACAAATAC
TGGAGGTATGATGAATATAAACGATCTATGGATCCAGGTTATCCCAAAATGATA
15 GCACATGACTTTTCTGGAATTGGCCACAAAGTTGATGCAGTTTTTCATGAAAGATG
GATTTTTCTATTTCTTTTCATGGAACAAGACAATACAAATTTGATCCTAAAACGAA
GAGAATTTTGACTCTCCAGAAAGCTAATAGCTGGTTCAACTGCAGGAAAAATTG
AACATTACTAATTTGAATGGAAAAACACATGGTGTGAGTCCAAAGAAGGTGTTTTCT
CTGAAGAAGTGTCTATTTTCTCAGTCATTTTAACTCTAGAGTCACTGATACACA
20 GAATATAATCTTATTTATACCTCAGTTTGCATATTTTTTTACTATTTAGAATGTAG
CCCTTTTGTACTGATATAATTTAGTTCCACAAATGGTGGGTACAAAAAGTCAAG
TTTGTGGCTTATGGATTCATATAGGCCAGAGTTGCAAAGATCTTTTCCAGAGTAT
GCAACTCTGACGTTGATCCCAGAGAGCAGCTTCAGTGACAAACATATCCTTTCAA
GACAGAAAGAGACAGGAGACATGAGTCTTTGCCGGAGGAAAAGCAGCTCAAGA
25 ACACATGTGCAGTCACTGGTGTACCCTGGATAGGCAAGGGATAACTCTTCTAAC
ACAAAATAAGTGTTTTATGTTTGAATAAAGTCAACCTTGTTTCTACTGTTTT

SEQ ID NO: 321

>gi|882877|gb|H16637.1|H16637 ym26e06.r1 Soares infant brain 1NIB Homo sapiens cDNA
30 clone IMAGE:49164 5' similar to gb:M73255_rna1 VASCULAR CELL ADHESION
PROTEIN 1 PRECURSOR (HUMAN);, mRNA sequence
GCCTATACCATCCGAAAGCCCAGTTGAAGGATGCGGGAGTATATGAATGTGAAT
CTAAAAACAAAGTTGGCTCACAATTAAGAAGTTTAACTTGTATGTTCAAGGAA
GAGAAAAACAACAAAGACTATTTTCTCCTGAGCTTCTCGTGCTCTATTTTGCATCC
35 TCCTTAATAATACCTGCCATTGGAATGATAATTTACTTTGCAAGAAAAGCCAACA
TGAAGGGGTCATATAGTCTTGTAGAACACAGAAATCAAAAGTGTAGCTAATGC
TTGATATGTTCAACTGGGAGACACTATTTATCTGTGCAAATCCTTGGATACTGCTC
ATCATTCTTGGGGAAAAACAATGGGGCTGAGAGGGCAGACTTTCCCTGGATGT
ATTTGGAAGTTGGGGAAAGGAAATGCCCTCTATGGTCCCTTGGCTGTGGAGCCA
40 GGAAGTCCAAAGTTAAACCTTGGNTGCCNGGAAGGGACNGTTAACCGGCCNTCA
GGTGNGGGGGACTGGG

SEQ ID NO: 322

>2496910H1

45 CTTAGACTGGGGCTCGGCCTCGCTCTGAAAAGTGCTTAAGAAAATCTTCTCAGTT
CTCCTTGCAGAGGACTGGCGCCGGGACGCGAAGAGCAACGGGCGCTGCACAAAG
CGGGCGCTGTGCGTGGTGGAGTGCGCATGTACGCGCAGGCGCTTCTCGTGGTTGG
CGTGCTGCAGCGACAGGCGGCAGCACAGCACCTGCACGAACACCCGCCGAACT

GCTGCGAGGACACCGTGTACAGGAGCGGGTTGATGACCGAGCTGAGGTAGAAAA
ACGTCTCCGAGAAGGGGAGGAGGATCATGTACGCCCCG

SEQ ID NO: 323

5 >3558269H1
CAGATCCAAGGAGAAAGTCAGGGGGCCAGTGCGCGCTACAGCCAGCGCCCAGTAC
CGCGGTGTGATGGGCACCATCTGACCATGGTGCCTACTGAGGGCCCCCGAAGC
CTCTACAATGGGCTGGTTGCCGGCCTGCAGCGCCAAATGAGCTTTGCCTCTGTCC
GCATCGGCCTGTATGATTCTGTCAAACAGTTCTACACCAAGGGCTCTGAGCATGC
10 CAGCATTGGGAGCCGCCTCCTAGCAGGCAGCACACAGGTGCCCTGGCTGTGGC
TGTGAGCCAGCCCACGGA

SEQ ID NO: 324

>gi|718888|gb|T90375.1|T90375 yd43e04.s1 Soares fetal liver spleen 1NFLS Homo sapiens
15 cDNA clone IMAGE:111006 3', mRNA sequence
ATNATTTTTGTAGGTACAATAAATCTGATTGATTTTTATTACACATCTTAGTTTAC
AATCACTTTTACATTCTAGACAAAGAGATGATACAAATAAATATCAATTGTAAA
ACTTAGAGCCCCAAGTATTGATTGGCGTATTCTTTGTCTAAAGGTAGCCAAAGAG
AAGGTCAAGATCAGTAATAACTTCAAGGAGCCATGAAGCCCACTGCCTCCTGCCT
20 GCCCCAGGGATCACTCCTTTCATAAATAACCCAGAAAGCATTTCATTCAGGGAAA
CAAGGGGGCAGGCAGGAAAGGGTGACAGNTTCTGGAACAGGTACCAAAAACAAG
GGCCTTGCGTGGATAGGACAATCACCGGGGNCCEACTTTTTCTTTGGGGCCAGGTTC
CCTCAGGGGGCCTTTTT

25 SEQ ID NO: 325

>gi|2197196|gb|U81233.1|HSU81233 Human cystatin E mRNA, complete cds
CCGACGGCACTGACGGCCATGGCGCGTTTCGAACCTCCCGCTGGCGCTGGGCCTG
GCCCTGGTCGCATTCTGCCTCCTGGCGCTGCCACGCGATGCCCCGGGCCCCGGCCGC
AGGAGCGCATGGTCGGAGAACTCCGGGACCTGTCGCCCCGACGACCCGCAGGTGC
30 AGAAGGCGGCGCAGGCGGCCGTGGCCAGCTACAACATGGGCAGCAACAGCATCT
ACTACTTCCGAGACACGCACATCATCAAGGCGCAGAGCCAGCTGGTGGCCGGCA
TCAAGTACTTCTTGACGATGGAGATGGGGAGCACAGACTGCCGCAAGACCAGGG
TCACTGGAGACCACGTCGACCTCACCACTTGCCCCCTGGCAGCAGGGGCGCAGC
AGGAGAAGCTGCGCTGTGACTTTGAGGTCTTGTGGTTCCCTGGCAGAACTCCTC
35 TCAGCTCCTAAAGCACAACTGTGTGCAGATGTGATAAGTCCCCGAGGGCGAAGG
CCATTGGGTTTGGGGCCATGGTGGAGGGCACTTACGTCCTGGGCGGTATCTGT
CACAATAAATGGCCAGTGCTGCTTCTTGCAAAAAAAAAAAAAAAAAAAAA

SEQ ID NO: 326

40 >gi|199842|gb|M84683.1|MUSMUC1A Mus musculus episialin (Muc1) mRNA, complete
cds
TGTTCAACCACCACCATGACCCCCGGGCATTTCGGGCTCCTTTCTTCCTGCTGCTACTT
CTAGCAAGTCTAAAAGGTTTTCTTGCCCTTCCAAGTGAGGAAAACAGTGTCACCT
CATCTCAGGACACCAGCAGTTCCTTAGCATCGACTACCACTCCAGTCCACAGCAG
45 CAACTCAGACCCAGCCACCAGACCTCCAGGGGACTCCACCAGCTCTCCAGTCCA
GAGTAGCACCTCTTCTCCAGCCACCAGAGCTCCTGAAGACTCTACCAGTACTGCA
GTCCTCAGTGGCACCTCCTCCCCAGCCACCACAGCTCCAGTGAAGTCCGCCAGCT
CTCCAGTAGCCCATGGTGACACCTCTTCCCCAGCCACTAGCCTTTCAAAGACTC
CAACAGCTCTCCAGTAGTCCACAGTGGCACCTCTTCAGCTCCGGCCACCACAGCT

CCAGTGGATTCCACCAGCTCTCCAGTAGTCCACGGTGGTACCTCGTCCCCAGCCA
CCAGCCCTCCAGGGGACTCCACCAGCTCTCCAGACCATAGTAGCACCTCTTCTCC
AGCCACCAGAGCTCCCGAAGACTCTACCAGTACTGCAGTCCTCAGTGGCACCTCC
TCCCCAGCCACCACAGCTCCAGTGGACTCCACCAGCTCTCCAGTAGCCCATGATG
5 ACACCTCTTCCCCAGCCACTAGCCTTTCAGAAGACTCCGCCAGCTCTCCAGTAGC
CCACGGTGGCACCTCTTCTCCAGCCACCAGCCCTCTAAGGGACTCCACCAGTTCT
CCAGTCCACAGTAGTGCCTCCATCCAAAACATCAAGACTACATCAGACTTAGCTA
GCACTCCAGACCACAATGGCACCTCAGTCACAACTACCAGCTCTGCACTGGGCTC
AGCCACCAGTCCAGACCACAGTGGTACCTCAACTACAATAACAGCTCTGAATC
10 AGTCTTGGCCACCCTCCAGTTTACAGTAGCATGCCATTCTCTACTACCAAAGTG
ACGTCAGGCTCAGCTATCATTCCAGACCACAATGGCTCCTCGGTGCTACCTACCA
GTTCTGTGTTGGGCTCAGCTACCAGTCTAGTCTATAATACCTCTGCAATAGCTAC
AACTCCAGTCAAGCAATGGCACTCAGCCTTCAGTGCCAAGTCAATACCCTGTTTCT
CCTACCATGGCCACCACCTCCAGCCACAGCACTATTGCCAGCAGCTCTTACTATA
15 GCACAGTACCATTTTCTACCTTCTCCAGTAACAGTTTACCCCCAGTTGTCTGTTGGG
GTCTCCTTCTTCTTCTTGTCTTTTTACATTCAAACACCCATTTAATTCTTCTCTG
GAAGACCCAGCTCCAATACTACCAAGAACTGAAGAGGAACATTTCTGGATTG
TTTCTGCAGATTTTAAACGGAGATTTTCTGGGGATCTCTAGCATCAAGTTCAGGTC
AGGCTCCGTGGTGGTAGAATCGACTGTGGTTTTCCGGGAGGGTACTTTTAGTGCC
20 TCTGACGTGAAGTCACAGCTTATACAGCATAAGAAGGAGGCAGATGACTATAAT
CTGACTATTTCAAGAAGTCAAAGTGAATGAGATGCAGTTCCCTCCCTCTGCCCAGT
CCCCGGCCGGGGGTACCAGGCTGGGGCATTCGCCCTGCTGGTGGTCTGTATTTT
GGTGTCTTTGGCTATCGTCTATTTCCCTTGGCCCTGGCAGTGTGCCAGTGGCGCCGAA
AGAGCTATGGGCAGCTGGACATCTTTCCAACCCAGGACACCTACCATCTATGAG
25 TGAATACCCTACCTACCACACTCACGGACGCTACGTGCCCCCTGGCAGTACCAAG
CGTAGCCCCTATGAGGAGGTTTCGGCAGGTAATGGCAGTAGCAGTCTCTCTTATA
CCAACCCAGCTGTGGTGACCACTTCTGCCAACTTGTAAGGAGCAAGTCAACCCACC
CACTTGGGGCAGCTTTGGCGGTCTGCTCCCTCAGTGGTCACTGCCAGACCCCTGC
ACTCTGATCTGGGCTGGTGAGCCAGGACTTCTGGTAGGCTGTTTCATGCCCTTTGT
30 CAAGCGCCTCAACTACGTAAGCCTGGTGAAGCCCAGCCCTGCCCTGGGGGACAC
TGGGGCAGTTAGTGGTGGCTCTCAGAAGGACTGGCCTGGAAAACCTGGAGACAGG
GATGGGAACCCAAACATAGCT

SEQ ID NO: 327

35 >1484836T6

TGCTATTCCATGTATGTCATAGGTGTGAAACCTTAAATCTTTCCAACAGCCACTG
CCTTATGGAGACTGTATCATCCTTATCTTCATCTTACAGGTGAGAAATCTGCAGT
GAAGAAAGGTACATCCCAAGGGGACACCGACAGTAAGCAGCGGACTGGGGATT
CCAGACACGTGGCTGGNCCTCTGCAGGAAGAAATCAAACGTGTGGAAGGGTTGG
40 GGAGAGGAGATGCCTAGAAGGGATTTTCCTGTATTCTCTTAGTGGTGGGGGTAAG
ACCGAGGACCCAAGTCCTCACTCATCACGTCTCTCCCAAGTGATGCAAGGATGGA
GCTGGGGTAAAACCAGGGAGAATCAGGACCCTCACGTGCTGCGTTTATTAAGC
ATCAGGGTCAGAGCTGGGCAGGNNANGNGGGGAGGCAAGGTCTAGGTGAGAGA
CGTTCTGGAACCCAGCCAGTGGGGTGGTAA

45

SEQ ID NO: 328

>gi|654754|gb|T52894.1|T52894 ya81f08.s1 Stratagene ovary (#937217) Homo sapiens
cDNA clone IMAGE:68103 3' similar to similar to gb:M31211 MYOSIN LIGHT CHAIN 1,
SLOW-TWITCH MUSCLE A ISOFORM (HUMAN), mRNA sequence

AAGAGAGGAACCCAGTCTTTATTTTGAACAATAGGTGGCCTCCTGGTGGCTGGA
 ACGTGCTTTTCGCTGCGGGGCCAGTGTCCGGACCCCACTGGATCTGCAGCACTC
 AGACGCTTAGGATGTGTTTCAAGAAGGCCTCGTAGTTGATGCAGCCGTTGCTGTC
 CTCGTGTCCTGCCAGAACGGTCTCCACCTCCTCCTCAGTCATCTTCTCTCCAAGGG
 5 TGGTGAGAACATGTCTGAGCTCTGCTCCCATGACTTTGCCGTTCCCTCCTTGTC
 AACACACGAAACCCCTCCAAGTAGTCCTCATATGTGCCTTGGCCTCGGTTCTTG
 CCACTGCTGGGAGCATGGGCAGGAAAGTCTCAAAGTCCACACGCCGCGANTTCA
 GCTCATCACTCTTGGGGTTCACAGGGACCTTGAGCACCTNGGCGTT

10 SEQ ID NO: 329

>gi|758680|gb|M23699.1|HUMAMYSA2A Homo sapiens serum amyloid A2-alpha (SAA2)
 mRNA, complete cds

ATGAAGCTTCTCACGGGCCTGGTTTTCTGCTCCTTGGTCCTGAGTGTGAGCAGCC
 GAAGCTTCTTTTCGTTCCCTTGGCGAGGCTTTTGATGGGGCTCGGGACATGTGGAG
 15 AGCCTACTCTGACATGAGAGAAGCCAATTACATCGGCTCAGACAAATACTTCCAT
 GCTCGGGGGAAGTATGATGCTGCCAAAAGGGGACCTGGGGGTGCCTGGGCGCA
 GAAGTGATCAGCAATGCCAGAGAGAATATCCAGAGACTCACAGGCCATGGTGCG
 GAGGACTCGCTGGCCGATCAGGCTGCCAATAAATGGGGCAGGAGTGGCAGAGAC
 CCAATCACTTCCGACCTGCTGGCCTGCCTGAGAAATACTGA

20

SEQ ID NO: 330

>2656 BLOOD 230638.6 U32986:gi1136227 Human xeroderma pigmentosum group E UV-
 damaged DNA binding factor mRNA, complete cds. 0

GGCGGTCGTAGTCTCCTGGCCCCGGGGGTGTCCACAGCGCCAGCTCCACCTGC
 25 TTGCCGTCACCTCAATGTCTCTGGGGCGGAGGCAGCGGCAGTGGAGTTCGCTGC
 GCGGCTGTTGGGGGCCACCTGTCTTTTCGCTTGTGTCCCTCTTTCTAGTGTGCGCG
 TCGAGTCCCGACGGGGCCGCTCCAAGCCTCGACATGTCGTACAACACTACGTGGTAAC
 GGCCCAGAAGCCCACCGCCGTGAACGGCTGCGTGACCGGACACTTTACTTCGGC
 CGAAGACTTAAACCTGTTGATTGCCAAAAACACGAGATTAGAGATCTATGTGGTC
 30 ACCGCCGAGGGGCTTCGGCCCGTCAAAGAGGTGGGCATGTATGGGAAGATTGCG
 GTCATGGAGCTTTTCAGGCCCAAGGGGGAGAGCAAGGACCTGCTGTTTATCTTGA
 CAGCGAAGTACAATGCCTGCATCCTGGAGTATAAACAGAGTGGCGAGAGCATTG
 ACATCATTACGCGAGCCCATGGCAATGTCCAGGACCGCATTGGCCGCCCTCAGA
 GACCGGCATTATTGGCATCATTGACCCTGAGTGCCGGATGATTGGCCTGCGTCTC
 35 TATGATGGCCTTTTCAAGGTTATTCCACTAGATCGCGATAATAAAGAACTCAAGG
 CCTTCAACATCCGCCTGGAGGAGCTGCATGTCATTGATGTCAAGTTCCTATATGG
 TTGCCAAGCACCTACTATTGCTTTGTCTACCAGGACCCTCAGGGGGCGGCACGTA
 AAAACCTATGAGGTGTCTCTCCGAGAAAAGGAATTCAATAAGGGCCCTTGAAA
 CAGGAAAATGTCGAAGCTGAAGCTTCCATGGTGATCGCAGTCCCAGAGCCCTTTG
 40 GGGGGGCCATCATCATTGGACAGGAGTCAATCACCTATCACAATGGTGACAAAT
 ACCTGGCTATTGCCCCCTCCTATCATCAAGCAAAGCACGATTGTGTGCCACAATCG
 AGTGGACCCTAATGGCTCAAGATACCTGCTGGGAGACATGGAAGGCCGGCTCTT
 CATGCTGCTTTTGGAGAAGGAGGAACAGATGGATGGCACCGTCACTCTCAAGGA
 TCTCCGTGTAGAACTCCTTGGAGAGACCTCTATTGCTGAGTGCTTGACATACCTT
 45 GATAATGGTGTGTGTTTGTGCGGTCTCGCCTGGGTGACTCCCAGCTTGTGAAGC
 TCAACGTTGACAGTAATGAACAAGGCTCCTATGTAGTGGCCATGGAAACCTTTAC
 CAACTTAGGACCCATTGTGATATGTGCGTGGTGGACCTGGAGAGGCAGGGGCA
 GGGGCAGCTGGTCACTTGCTCTGGGGCTTTCAAGGAAGGTTCTTTGCGGATCATC
 CGGAATGGAATTGGAATCCACGAGCATGCCAGCATTGACTTACCAGGCATCAAA

GGATTATGGCCACTGCGGTCTGACCCTAATCGTGAGACTGATGACACTTTGGTGC
TCTCTTTTGTGGGCCAGACAAGAGTTCTCATGTTAAATGGAGAGGAGGTAGAAG
AAACCGAACTGATGGGTTTCGTGGATGATCAGCAGACTTTCTTCTGTGGCAACGT
GGCTCATCAGCAGCTTATCCAGATCACTTCAGCATCGGTGAGGTTGGTCTCTCAA
5 GAACCCAAAGCTCTGGTCACTGAATGGAAGGAGCCTCAGGCCAAGAACATCAGT
GTGGCCTCCTGCAATAGCAGCCAGGTGGTGGTGGCTGTAGGCAGGGCCCTCTACT
ATCTGCAGATCCATCCTCAGGAGCTCCGGCAGATCAGCCACACAGAGATGGAAC
ATGAAGTGGCTTGCTTGACATCACCCATTAGGAGACAGCAATGGACTGTCCCC
TCTTTGTGCCATTGGCCTCTGGACGGACATCTCGGCTCGTATCTTGAAGTTGCCCT
10 CTTTTGAACTACTGCACAAGGAGATGCTGGGTGGAGAGATCATTCTCGCTCCAT
CCTGATGACCACCTTTGAGAGTAGCCATTACCTCCTTTGTGCCTTGGGAGATGGA
GCGCTTTTCTACTTTGGGCTCAACATTGAGACAGGTCTGTTGAGCGACCGTAAGA
AGGTGACTTTGGGCACCCAGCCCACCGTATTGAGGACTTTTCGTTCTCTTTCTACC
ACCAACGTCTTTGCTTGTTCTGACCGCCCCACTGTCATCTATAGCAGCAACCACA
15 AATTGGTCTTCTCAAATGTCAACCTCAAGGAAGTGAACATACATGTGTCCCCTCAA
TTCAGATGGCTATCCTGACAGCCTGGCGCTGGCCAACAATAGCACCTCACCATT
GGCACCATCGATGAGATCCAGAAGCTGCACATTCGCACAGTTCCCCTCTATGAGT
CTCCAAGGAAGATCTGCTACCAGGAAGTGTCCAGTGTTTCGGGGTCTCTCCAG
CCGCATTGAAGTCCAAGACACGAGTGGGGGGCAGACAGCCTTGAGGCCCAGCG
20 CTAGCACCCAGGCTCTGTCCAGCAGTGTAAGCTCCAGCAAGCTGTTCTCCAGCAG
CACTGCTCCTCATGAGACCTCCTTTGGAGAAGAGGTGGAGGTGCACAACCTACTT
ATCATTGACCAACACACCTTTGAAGTGCTTCATGCCACCAGTTTCTGCAGAATG
AATATGCCCTCAGTCTGGTTTCTGCAAGCTGGGCAAGACCCCAACACTTACTT
CATTGTGGGCAGAGCAATGGTGTATCCTGAAGAGGCAGAGCCCAAGCAGGGTCG
25 CATTGTGGTCTTTCAGTATTCGGATGGAAAACACAGACTGTGGCTGAAAAGGAA
GTGAAAGGGGGCCGTGTACTCTATGGTGGAAATTTAACGGGAAGCTGTTAGCCAGC
ATCAATAGCACGGTGCGGCTCTATGAGTGGACAACAGAGAAGGAGCTGCGCACT
GAGTGCAACCACTACAACAACATCATGGCCCTCTACCTGAAGACCAAGGGCGAC
TTCATCCTGGTGGGCGACCTTATGCGCTCAGTGCTGCTGCTTGCTTGCCTACAAGCCA
30 TGGAAGGAACTTTGAAGAGATTGCTCGAGACTTTAATCCCAACTGGATGAGTG
CTGTGGAAATCTTGGATGATGACAATTTTCTGGGGGCTGAAAATGCCTTTAACTT
GTTTGTGTGTCAAAAGGATAGCGCTGCCACCACTGACGAGGAGCGGCAGCACCT
CCAGGAGGTTGGTCTTTTCCACCTGGGCGAGTTTGTCAATGTCTTTTGCCACGGCT
CTCTGGTAATGCAGAATCTGGGTGAGACTTCCACCCCCACACAAGGCTCGGTGCT
35 CTTCCGCACGGTCAACGGCATGATAGGGCTGGTGACCTCACTGTCAGAGAGCTG
GTACAACCTCCTGCTGGACATGCAGAATCGACTCAATAAAGTCATCAAAAGTGT
GGGGAAGATCGAGCACTCCTTCTGGAGATCCTTTCACACCGAGCGGAAGACAGA
ACCAGCCACAGGTTTCATCGACGGTGACTTGATTGAGAGTTTCCTGGATATTAGC
CGCCCCAAGATGCAGGAGGTGGTGGCAAACCTACAGTATGACGATGGCAGCGGT
40 ATGAAGCGAGAGGCCACTGCAGACGACCTCATCAAGGTTGTGGAGGAGCTAACT
CGGATCCATTAGCCAAGGGCAGGGGGCCCCCTTTGCTGACCCTCCCCAAAGGCTTT
GCCCTGCTGCCCTCCCCCTCCTCTCCACCATCGTCTTCTTGGCCATGGGAGGCCTT
TCCCTAAGCCAGCTGCCCCCAGAGCCACAGTTCCCCTATGTGGAAGTGGGGCGG
GCTTCATAGAGACTTGGAATGAGCTGAAGGTGAAACATTTTCTCCCTGGATTTT
45 TACCAGTCTCACATGATTCCAGCCATCACCTTAGACCACCAAGCCTTGATTGGTG
TTGCCAGTTGTCCTCCTTCCGGGGAAGGATTTTGCAGTTCTTTGGCTGAAAGGAA
GCTGTGCGTGGTNTNTGTGTGTATGTNTGTGTGTGTATGTGTATCTCACACTCATG
CATTGTCCTCTTTTTATTAGATTGGCAGTGTAAGGAGTTGTGGGTAGTGGGGAA
GAGGGTTAGGAGGGTTTCATTGTCTGTGAAGTGAGACCTTCCTTTTACTTTTCTTC

TATTGCCTCTGAGAGCATCAGGCCTAGAGGCCTGACTGCCAAGCCATGGGTAGCC
TGGGTGTAAACCTGGAGATGGTGGATGATCCCCACGCCACAGCCCTTTTGTCTC
TGCAAACCTGCCTTCTTCGAAAGAAGAAGGTGGGAGGATGTGAATTGTTAGTTTC
TGAGTTTACCAAATAAAGTAGAATATAAGAAGAAAGGTAAAAAA

5

SEQ ID NO: 331

>2742 BLOOD 334388.1 D14660 g285944 Human mRNA for KIAA0104 gene, complete
cds. 0

ACGTGAGCTAGCTGGCATGGCGGCCTGCATTGCAGCGGGGCACTGGGCTGCAAT
10 GGGCCTAGGCCGGAGTTTCCAAGCCGCCAGGACTCTGCTCCCCCGCCGGCCTCT
ATCGCCTGCAGGGTCCACGCGGGGCCTGTCCGGCAGCAGAGCACTGGGCCTTCC
GAGCCCGGTGCGTTCCAACCGCCGCCGAAACCGGTCATCGTGGACAAGCACCGC
CCCGTGGAACCGGAACGCAGGTTCTTGAGTCCTGAATTCATTCCTCGAAGGGGAA
GAACAGATCCTCTGAAATTTCAAATAGAAAGAAAAGATATGTTAGAAAGGAGAA
15 AAGTACTCCACATTCCAGAGTTCTATGTTGGAAGTATTCTTCGTGTTACTACAGCT
GACCCATATGCCAGTGGAAAAATCAGCCAGTTTCTGGGGATTTGCATTCAGAGAT
CAGGAAGAGGACTTGGAGCTACTTTCATCCTTAGGAATGTTATCGAAGGACAAG
GTGTCGAGATTTGCTTTGAACTTTATAATCCTCGGGTCCAGGAGATTCAGGTGGT
CAAATTAGAGAAACGGCTGGATGATAGCTTGCTATACTTACGAGATGCCCTTCCT
20 GAATATAGCACTTTTGATGTGAATATGAAGCCAGTAGTACAAGAGCCTAACCAA
AAAGTTCCTGTTAATGAGCTGAAAGTAAAAATGAAGCCTAAGCCCTGGTCTAAA
CGCTGGGAACGTCCAAATTTTAATATTAAAGGAATCAGATTTGATCTTTGTTTAA
CTGAACAGCAAAATGAAA'GAAGCTCAGAAAGTGGAATCAGCCATGGCTTGAATTTG
ATATGATGAGGGAATATGATACTTCAAAAAATTGAAGCTGCAATATGGAAGGAAA
25 TTGAAGCGTCGAAAAGGTCTTGATTCTGAGAATGAATTTGGTTAGTTGCAGAGA
TACATTGGCTCTAAGAGGATATATTTTGAGACCAATTTAATTTCAATTTATAAGAA
CATAGTAATTAAGTGAACATAAGCATTCAATTGTTTTATTAATACTTTTTTTCTAAAA
TAAACCTTGACACCAGTTTATTACTCTAAAAAGAGAATTACACATGCCAAATGG
ACCAATGTCCATTTGCTTATTGGAGGCAAAGCTACAATAGAAGTCAGAGCATCAC
30 CAGAATGGTCTTTAATGAGCATGGAACCTGAGCAAAGGGAATAGGTGGGATGAA
TTTTTTTTTTAATTGTGAAACAATTCATAAGCACAAATATGATTTACAGAATAATAA
ACATTCATGTACCCACTATCAGGTAAAGAAATAGAACATTTATTAATATGTAGGA
ATGTTAAGAAAATAAAACATTTAATAAGATCTCAGAAGACTCCAGTAAATCTGCA
ATTGTATCTCTCTCCITTTTAAATGTAAATATCATCTTGACTTGTTAATTATTCCT
35 TGCATTTCTTTTAGTTTACTGCCAACACATATATTCTTCAACAATATATTTAATTTT
GAAAAACCTGAAAAAATAAACCTGTTAGCAAGTATAAAGGGGCAGTATTACTAT
TATTGCATGAAGGCTTCAAGGGAAACGTTACAGTCTTTGGGCCCTAGAGGGGCTT
CAGCTTCCTCTGAGAGTTTACAGGGGGCCAATTTTTGAGGCAAATTCATGGGCTA
AGGTTTATGGAGTGGAGTTCTTGCCAAAACAGGAAAGGGCTCACCAACAAGGGT
40 GATCTGGNGCAGGGGTTTATTACTGGGGGATACCTGGGATTGTTTCGAAGAAATT
GGTGGGTTAGGAGGGGAAAGTAAAC

SEQ ID NO: 332

>2772 BLOOD 344645.4 AF026086 g2655140 Human peroxisome biogenesis disorder
protein 1 (PEX1) mRNA, complete cds. 0

45 CCGGGTCCCGGGTCCCTTTCGCGCGCTAGGGTGGGCGAACCCAGAGCGACGCTCC
GGGACGATGTGGGGCAGCGATCGCCTGGCGGGTGCTGGGGGAGGCGGGGCGGC
AGTGACTGTGGCCTTCACCAACGCTCGCGACTGCTTCCTCCACCTGCCGCGGCGT
CTCGTGGCCCAGCTGCATCTGCTGCAGAATCAAGCTATAGAAGTGGTCTGGAGTC

ACCAGCCTGCATTCTTGAGCTGGGTGGAAGGCAGGCATTTTAGTGATCAAGGTGA
AAATGTGGCTGAAATTAACAGACAAGTTGGTCAAAAACCTGGACTCTCAAATGG
GGGACAGGTATTTCTCAAGCCATGTTCCCATGTGGTATCTTGTCAACAAGTTGAG
GTGGAACCCCTCTCAGCAGATGATTGGGAGATACTGGAGCTGCATGCTGTTCCC
5 TTGAACAACATCTTCTAGATCAAATTCGAATAGTTTTTCCAAAAGCCATTTTCT
GTTTGGGTGATCAACAAACGTACATATTTATCCAAATTGTTGCACTAATACCAG
CTGCCTCTTATGGAAGGCTGGAACTGACACCAAACCTCCTTATTCAGCCAAAGAC
ACGCCGAGCCAAAGAGAATACATTTTCAAAAAGCTGATGCTGAATATAAAAACT
TCATAGTTATGGAAGAGACCAGAAAGGAATGATGAAAGAACTTCAAACCAAGCA
10 ACTTCAGTCAAATACTGTGGGAATCACTGAATCTAATGAAAACGAGTCAGAGAT
TCCAGTTGACTCATCATCAGTAGCAAGTTTATGGACTATGATAGGAAGCATTTTT
TCCTTTCAATCTGAGAAGAAACAAGAGACATCTTGGGGTTTAACTGAAATCAATG
CATTCAAAAATATGCAGTCAAAGGTTGTTCTCTAGACAATATTTTCAGAGTATG
CAAATCTCAACCTCCTAGTATATATAACGCGTCAGCAACCTCTGTTTTTCATAAA
15 CACTGTGCCATTTCATGTATTTCCATGGGACCAGGAATATTTTGATGTAGAGCCCA
GCTTTACTGTGACATATGGAAAGCTAGTTAAGCTACTTTCTCCAAAGCAACAGCA
AAGTAAAACAAAACAAAATGTGTTATCACCTGAAAAAGAGAAGCAGATGTCAGA
GCCACTAGATCAAAAAAAAATTAGGTCAGATCATAATGAAGAAGATGAGAAGGC
CTGTGTGCTACAAGTAGTCTGGAATGGACTTGAAGAATTGAACAATGCCATCAA
20 ATATACCAAAAATGTAGAAGTTCTCCATCTTGGGAAAGTCTGGATTCCAGATGAC
CTGAGGAAGAGACTAAATATAGAAATGCATGCCGTAGTCAGGATAACTCCAGTG
GAAGTTACCCCTAAAATTCCAAGATCTCTAAAGTTACAACCTAGAGAGAATTTAG
CTAAAGACATAAGTGAAGAAGACATAAAAACCTGTATTTTATTCATGGGTACAGC
AGTCTACTACCACCATGCTTCCTTGGTAATATCAGAGGAAGAATTTATTAAGCT
25 GGAAACTAAAGATGGACTGAAGGAATTTTCTCTGAGTATAGTTCAATCTTGGGAA
AAAGAAAAAGATAAAAATATTTTTCTGTTGAGTCCCAATTTGCTGCAGAAGACTA
CAATACAAGTCCTTCTAGATCCTATGGTAAAAGAAGAAAAACAGTGAGGAAATTG
ACTTTATTCCTTCTTTTTTAAAGCTGAGCTCTTTGGGAGGAGTGAATTCCTTAGGC
GTATCCTCCTTGGAGCACATCACTCACAGCCTCCTGGGACGCCCTTTGTCTCGGC
30 AGCTGATGTCTTGTGTCAGGACTTAGGAATGGAGCTCTTTTACTCACAGGAGG
AAAGGGAAGTGGAAAATCAACTTTAGCCAAAGCAATCTGTAAAGAAGCATTGTA
CAAACCTGGATGCCCATGTGGAGAGAGTTGACTGTAAAGCTTTACGAGGAAAAAG
GCTTGAAAACATACAAAAAACCTAGAGGTGGCTTTCTCAGAGGCAGTGTGGAT
GCAGCCATCTGTTGCTGCTGGATGACCTTGACCTCATTGCTGGACTGCCTGCTG
35 TCCCGGAACATGAGCACAGTCCTGATGCGGTGCAGAGCCAGCGGCTTGCTCATG
CTTTGAATGATATGATAAAAGAGTTTATCTCCATGGGAAGTTTGGTTGCACTGAT
TGCCACAAGTCAGTCTCAGCAATCTCTACATCCTTTACTTGTCTGCTCAAGGAG
TTCACATATTTCAAGTGCCTCCAACACATTCAGCCTCCTAATCAGGAACAAAGATG
TGAAATTCTGTGTAATGTAATAAAAAATAAATTGGACTGTGATATAACAAGTTC
40 ACCGATCTTGACCTGCAGCATGTAGCTAAAGAACTGGAGGGTTTGTGGCTAGA
GATTTTACAGTACTTGTGGATCGAGCCATACATTCTCGACTCTCTCGTCAGAGTAT
ATCCACCAGAGAAAAATTAGTTTTAAACAACATTGGACTTCCAAAAGGCTCTCCGC
GGATTTCTTCTGCGTCTTTGCGAAGTGTCAACCTGCATAAACCTAGAGACCTGG
GTTGGGACAAGATTGGTGGGTACATGAAGTTAGGCAGATACTCATGGATACTAT
45 CCAGTTACCTGCCAAGTATCCAGAATTATTTGCAAACCTTGCCCATACGACAAAGA
ACAGGAATACTGTTGTATGGTCCGCTGGAACAGGAAAAACCTTACTAGCTGGG
GTAATTGCACGAGAGAGTAGAATGAATTTTATAAGTGTCAAGGGGCCAGAGTTA
CTCAGCAAATACATTGGAGCAAGTGAACAAGCTGTTTCGGGATATTTTTATTAGAG
CACAGGCTGCAAAGCCCTGCATTCTTTCTTTGATGAATTTGAATCCATTGCTCCT

CGGCGGGGTCATGATAATACAGGAGTTACAGACCGAGTAGTTAACCAGTTGCTG
ACTCAGTTGGATGGAGTAGAAGGCTTACAGGGTGTTTATGTATTGGCTGCTACTA
GTCGCCCTGACTTGATTGACCCTGCCCTGCTTAGGCCTGGTCGACTAGATAAATG
TGTATACTGTCCTCCTCCTGATCAGGTGTCACGTCTTGAAATTTTAAATGTCCTCA
5 GTGACTCTCTACCTCTGGCAGATGATGTTGACCTTCAGCATGTAGCATCAGTAAC
TGACTCCTTTACTGGAGCTGATCTGAAAGCTTTACTTTACAATGCCCAATTGGAG
GCCTTACATGGAATGCTGCTCTCGAGTGGACTCCAGGATGGAAGTTCCAGCTCTG
ATAGTGACCTAAGTCTGTCTTCAATGGTCTTTCTTAACCATAGCAGTGGCTCTGAC
GATTCAGCTGGAGATGGAGAATGTGGCTTAGATCAGTCCCTTGTTTCTTTAGAGA
10 TGTCCGAGATCCTTCCAGATGAATCAAAATTCAATATGTACCGGCTCTACTTTGG
AAGCTCTTATGAATCAGAACTTGAAATGGAACCTCTTCTGATTTGAAGCTCACA
TTGTCTCTCTGCACCAAGCTCCATGACTCAGGATTTGCCTGGAGTTCCTGGGAAA
GACCAGTTGTTTTACAGCCTCCAGTGTTAAGGACAGCTTCACAAGAGGGTTGCC
AAGA ACTTACACAAGAACAAGAGATCAACTGAGGGCAGATATCAGTATTATCA
15 AAGGCAGATACCGGAGCCAAAGTGGAGAGGACGAATCCATGAACCAACCAGGA
CCAATCAAAACCAGACTGGCTATTAGTCAGTCACATTTAATGACTGCACTTGGTC
ACACAAGACCATCCATTAGTGAAGATGACTGGAAGAATTTTGCTGAGCTATATG
AAAGCTTTCAAAATCCAAAGAGGAGAAAAAATCAAAGTGGAACAATGTTTCGAC
CTGGACAGAAAGTAACTTTAGCATAAAATATACTTCTTTTTGATTTGGTTCTGTTA
20 AGTTTTTTGATGGCTTTTCCATATGTTGTAACAGGAAAAAATGGTGTCTATGAA
TTTCTTCTTAATTTAACAAATTTGGTTAATTTATAAAATCACAGATTGGTAAATGC
TATAATTATGTAATGATCAGGATTGAGATTAATACTGTAGTATAAATTGGGACAT
TATAACAGATTCCATATTTTATTTCTTAAATCTAAATTCAGTCTTTAATGAAATA
ATATTAGCCAAATGGTGGAAGTAATTTATTTCTTTTGAGGAAAAGATAATAAGA
25 ATGTAATTAATTTAAATTTCTTGGAATTTCCAGTTGTATATTCATCACCTTTGTA
GCATTTGACAAATTTTATGCTTAGCAGCTTCTTCACTGTTTTGAAATAAAATATCC
TATTACCTACTG

SEQ ID NO: 333

30 >2812 BLOOD 1091854.1 X53416 g28242 Human mRNA for actin-binding protein
(filamin) (ABP-280). 0

GCGCCTGGCGCGGGCGCGGGCGCGGAAGGCGATCCGGGCGCCACCCCGCGGTCAT
CGGTACCGGTCGCTCTCAGGAACAGCAGCGCAACCTCTGCTCCCTGCCTCGCCT
CCCGCGCGCCTAGGTGCCTGCGACTTTAATTAAAGGGCCGTCCTCGCCGAGGC
35 TGCAGCACCGCCCCCGGCTTCTCGCGCCTCAAAATGAGTAGCTCCCACTCTCG
GGCGGGCCAGAGCGCAGCAGGGCGCGGCTCCGGGCGGCGGCGTCGACACGCGG
GACGCCGAGATGCCGGCCACCGAGAAGGACCTGGCGGAGGACGCGCCGTGGAA
GAAGATCCAGCAGAACACTTTCACGCGCTGGTGCAACGAGCACCTGAAGTGCGT
GAGCAAGCGCATCGCCAACCTGCAGACGGACCTGAGCGACGGGCTGCGGCTTAT
40 CGCGCTGTTGGAGGTGCTCAGCCAGAAGAAGATGCACCGCAAGCACAACCAGCG
GCCACTTTCCGCCAAATGCAGCTTGAGAACGTGTCGGTGGCGCTCGAGTTCCTG
GACCGCGAGAGCATCAAACTGGTGTCCATCGACAGCAAGGCCATCGTGGACGGG
AACCTGAAGCTGATCCTGGGCCTCATCTGGACCCTGATCCTGCACTACTCCATCT
CCATGCCCATGTGNNNNNNNNNNNNNNNNNNNNNNNCCAAGAAGCAGACCCCC
45 AAGCAGAGGCTCCTGGGCTGGATCCAGAACAAGCTGCCGAGCTGCCCATCACC
AACTTCAGCCGGGACTGGCAGAGCGGCCGGGCCCTGGGCGCCCTGGTGGACAGC
TGTGCCCCGGGCCTGTGTCTGACTGGGACTCTTGGGACGCCAGCAAGCCCGTTA
CCAATGCGCGAGAGGCCATGCAGCAGGCGGATGACTGGCTGGGCATCCCCAGG
TGATCACCCCGAGGAGATTGTGGACCCCAACGTGGACGAGCACTCTGTCATGA

CCTACCTGTCCCAGTTCCCCAAGGCCAAGCTGAAGCCAGGGGCTCCCTTGCGCCC
CAAACCTGAACCCGAAGAAAGCCCGTGCCTACGGGCCAGGCATCGAGCCCACAGG
CAACATGGTGAAGAAGCGGGCAGAGTTCAGTGTGGAGACCAGAAGTGCTGGCCA
GGGAGAGGTGCTGGTGTACGTGGAGGACCCGGCCGGACACCAGGAGGAGGCAA
5 AAGTGACCGCCAATAACGACAAGAACCGCACCTTCTCCGTCTGGTACGTCCCCGA
GGTGACGGGGACTCATAAGGTTACTGTGCTCTTTGCTGGCCAGCACATCGCCAAG
AGCCCCCTTCGAGGTGTACGTGGATAAGTACAGGGTGACGCCAGCAAAGTGACA
GCCCAAGGTCCCGGCCTGGAGCCCAGTGGCAACATCGCCAACAAGACCACCTAC
TTTGAGATCTTTACGGCAGGAGCTGGCACGGGCGAGGTGAGGTTGTGATCCAG
10 GACCCCATGGGACAGAAGGGCACGGTAGAGCCTCAGCTGGAGGGCCCGGGGCGA
CAGCACATAACCGCTGCAGCTACCAGCCCACCATGGAGGGCGTCCACACCGTGCA
CGTCACGTTTGC CGGCGTGCCCATCCCTCGCAGCCCCTACACTGTCACTGTTGGC
CAAGCCTGTAACCCGAGTGCCTGCCGGGCGGTTGGCCGGGGCCTCCAGCCCAAG
GGTGTGCGGGTGAAGGAGACAGCTGACTTCAAGGTGTACACAAAGGGCGCTGGC
15 AGTGGGGAGCTGAAGGTCAACGTGAAGGGCCCCAAGGGAGAGGAGCGCGTGAA
GCAGAAGGACCTGGGGGATGGCGTGTATGGCTTCGAGTATTACCCCATGGTCCCT
GGAACCTATATCGTCACCATCACGTGGGGTGGTCAGAACATCGGGGCGAGTCCCT
TCGAAGTGAAGGTGGGCACCGAGTGTGGCAATCAGAAGGTACGGGCCTGGGGCC
CTGGGCTGGAGGGCGGCGTCGTTGGCAAGTCAGCAGACTTTGTGGTGGAGGCTA
20 TCGGGGACGACGTGGGCACGCTGGGCTTCTCGGTGGAAGGGCCATCGCAGGCTA
AGATCGAATGTGACGACAAGGGCGACGGCTCCTGTGATGTGCGCTACTGGCCGC
AGGAGGCTGGCGAGTATGCCGTTTCAGTGCTGTGCAACAGCGAAGACATCCGCC
TCAGCCCCCTTCATGGCTGACATCGGTGACGCGCCCCAGGACTTCCAGGCGAGACAG
GGTGAAGGCACGTGGGCGCTGGATTGGAGAAGACAGGTGTGGCCGTCAACAAGCC
25 AGCAGAGTTCACAGTGGATGCCAAGCACGGTGGCAAGGGCCCCACTTCGGGTCCA
AGTCCAGGACAATGAAGGCTGCCCTGTGGAGGCGTTGGTCAAGGACAACGGCAA
TGGCACTTACAGCTGCTCCTACGTGCCCAGGAAGCCGGTGAAGCACACAGCCAT
GGTGTCTTGGGGAGGCGTCAGCATCCCCAACAGCCCCCTTCAGGGTGAATGTGGG
AGCTGGCAGCCACCCCAACAAGGTCAAAGTATACGGCCCCGGAGTAGCCAAGAC
30 AGGGCTCAAGGGCCACGAGCCCACCTACTTCACTGTGGACTGCGCCGAGGCTGG
CCAGGGGGACGTGAGCATCGGCATCAAGTGTGCCCCCTGGAGTGGTAGGCCCCGC
CGAAGCTGACATCGACTTCGACATCATCCGCAATGACAATGACACCTTCACGGTC
AAGTACACGCCCCGGGGGGCTGGCAGCTACACCATTATGGTCTCTTTGCTGACC
AGGCCACGCCCACCAGCCCCATCCGAGTCAAGGTGGAGCCCTCTCATGACGCCA
35 TAAGGTGAAGGCCGAGGGCCCTGGCCTCAGTCGCACTGGTGTGAGCTTGGCAA
GCCCACCCACTTCACAGTAAATGCCAAAGCTGCTGGCAAAGGCAAGCTGGACGT
CCAGTTCTCAGGACTACCAAGGGGGATGCAGTGCAGAGATGTGGACATCATCGA
CCACCATGACAACACCTACACAGTCAAGTACACGCCTGTCCAGCAGGGTCCAGT
AGGCGTCAATGTCACTTATGGAGGGGATCCCATCCCTAAGAGCCCTTTCTCAGTG
40 GCAGTATCTCCAAGCCTGGACCTCAGCAAGATCAAGGTGTCTGGCCTGGGAGAG
AAGGTGGACGTTGGCAAAGACCAGGAGTTCACAGTCAAATCAAAGGGTGCTGGT
GGTCAAGGCAAAGTGGCATCCAAGATTGTGGGGCCCTCGGGTGCAGCGGTGCC
TGCAAGGTGGAGCCAGGCCTGGGGGCTGACAACAGTGTGGTGCCTTCCTGCCC
CGTGAGGAAGGGCCCTATGAGGTGGAGGTGACCTATGACGGCGTGCCGTGCCTG
45 GCAGCCCTTTCTCTGGAAGCTGTGGCCCCACCAAGCCTAGCAAGGTGAAGGCGT
TTGGGCCGGGGCTGCAGGGAGGCAGTGCGGGCTCCCCCGCCGCTTCACCATCG
ACACCAAGGGCGCCGGCACAGGTGGCCTGGGCCTGACGGTGGAGGGCCCCTGTG
AGGCGCAGCTCGAGTGCTTGGACAATGGGGATGGCACATGTTCCGTGTCCTACGT
GCCACCGAGCCCGGGGACTACAACATCAACATCCTCTTCGCTGACACCCACATC

CCTGGCTCCCCATTCAAGGCCACGTGGTTCCTTGCTTTGACGCATCCAAAGTCA
AGTGCTCAGGCCCCGGGCTGGAGCGGGCCACCGCTGGGGAGGTGGGCCAATTCC
AAGTGGACTGCTCGAGCGCGGGCAGCGCGGAGCTGACCATTGAGATCTGCTCGG
AGGCGGGGCTTCCGGCCGAGGTGTACATCCAGGACCACGGTGATGGCACGCACA
5 CCATTACCTACATTCCCCTCTGCCCCGGGGCCTACACCGTCACCATCAAGTACGG
CGGCCAGCCCGTGCCCAACTTCCCCAGCAAGCTGCAGGTGGAACCTGCGGTGGA
CACTTCCGGTGTCCAGTGCTATGGGCCTGGTATTGAGGGCCAGGGTGTCTTCCGT
GAGGCCACCACTGAGTTCAGTGTTGACGCCCCGGGCTCTGACACAGACCGGAGGG
CCGCACGTCAAGGCCCGTGTGGCCAACCCCTCAGGCAACCTGACGGAGACCTAC
10 GTTCAGGACCGTGGCGATGGCATGTACAAAGTGGAGTACACGCCTTACGAGGAG
GGACTGCACTCCGTGGACGTGACCTATGACGGCAGTCCCGTGCCCAGCAGCCCCT
TCCAGGTGCCCGTGACCGAGGGCTGCGACCCCTCCCGGGTGCGTGTCCACGGGGC
AGGCATCCAAAGTGGCACCACCAACAAGCCCAACAAGTTCAGTGTGGAGACCAG
GGGAGCTGGCACGGGGCGGCCTGGGCCTGGCTGTAGAGGGCCCCCTCCGAGGCCA
15 AGATGTCCTGCATGGATAACAAGGACGGCAGCTGCTCGGTTCGAGTACATCCCTTA
TGAGGCTGGCACCTACAGCCTCAACGTCACCTATGGTGGCCATCAAGTGCCAGGC
AGTCCTTTCAAGGTCCCTGTGCATGATGTGACAGATGCGTCCAAGGTCAAGTGCT
CTGGGGCCCCGGCCTGAGCCCAGGCATGGTTCGTGCCAACCTCCCTCAGTCCTTCC
AGGTGGACACAAGCAAGGCTGGTGTGGCCCCATTGCAGGTCAAAGTGCAAGGGC
20 CCAAAGGCCTGGTGGAGCCAGTGGACGTGGTAGACAACGCTGATGGCACCCAGA
CCGTCAATTATGTGCCCAGCCGAGAAGGGCCCTACAGCATCTCAGTACTGTATGG
AGATGAAGAGGTACGCCGGAGCCCCTTCAAGGTCAAGGTGCTGCCTACTCATGA
TGCCAGCAAGGTGAAGGCCAGTGGCCCCGGGCTCAACACCACTGGCGTGCCTGC
GAGCCTGCCCCGTGGAGTTCACCATCGATGCAAAGGACGCCGGGGAGGGCCTGCT
25 GGCTGTCCAGATCACGGATCCCGAAGGCAAGCCGAAGAAGACACACATCCAAGA
CAACCATGACGGCACGTATACAGTGGCCTACGTGCCAGACGTGACAGGTGCGTA
CACCATCCTCATCAAGTACGGTGGTGACGAGATCCCCCTTCTCCCCGTACCGCGTG
CGTGCCGTGCCACCGGGGACGCCAGCAAGTGCAGTGTACAGTGTCAATCGGA
GGTCACGGGCTAGGTGCTGGCATCGGCCCCACCATTGAGATTGGGGAGGAGACG
30 GTGATCACTGTGGACACTAAGGCGGCAGGCAAAGGCAAAGTGACGTGCACCGTG
TGCACGCCTGATGGCTCAGAGGTGGATGTGGACGTGGTGGAGAATGAGGACGGC
ACTTTCGACATCTTCTACACGGCCCCCAGCCGGGCAAATACGTATCTGTGTGC
GCTTTGGTGGCGAGCACGTGCCCAACAGCCCCCTTCCAAGTGACGGCTCTGGCTGG
GGACCAGCCCTCGGTGCAGCCCCCTTACGGTCTCAGCAGCTGGCCCCACAGTAC
35 ACCTACGCCCAGGGCGGCCAGCAGACTTGGGCCCCGGAGAGGCCCTGGTGGGT
GTCAATGGGCTGGATGTGACCAGCCTGAGGCCCTTTGACCTTGTATCCCCTTCA
CCATCAAGAAGGGCGAGATCACAGGGGAGGTTTCGGATGCCCTCAGGCAAGGTGG
CGCAGCCCACCATCACTGACAACAAAGACGGCACCGTGACCGTGCGGTATGCAC
CCAGCGAGGCTGGCCTGCACGAGATGGACATCCGCTATGACAACATGCACATCC
40 CAGGAAGCCCCTTGCAATTCTATGTGGATTACGTCAACTGTGGCCATGTCACTGC
CTATGGGCCTGGCCTACCCATGGAGTAGTGAACAAGCCTGCCACCTTCACCGTC
AACACCAAGGATGCAGGAGAGGGGGGCTGTCTCTGGCCATTGAGGGCCCGTCC
AAAGCAGAAATCAGCTGCACTGACAACCAGGATGGGACATGCAGCGTGTCTTAC
CTGCCTGTGCTGCCGGGGGACTACAGCATTCTAGTCAAGTACAATGAACAGCAC
45 GTCCCAGGCAGCCCCTTCACTGCTCGGGTCACAGGTGACGACTCCATGCGTATGT
CCCACCTAAAGGTCGGCTCTGCTGCCGACATCCCCATCAACATCTCAGAGACGGA
TCTCAGCCTGCTGACGGCCACTGTGGTCCCGCCCTCGGGCCGGGAGGAGCCCTGT
TTGCTGAAGCGGCTGCGTAATGGCCACGTGGGGATTTCATTTCGTGCCCAAGGAGA
CGGGGGAGCACCTGGTGCATGTGAAGAAAAATGGCCAGCACGTGGCCAGCAGCC

CCATCCCGGTGGTGATCAGCCAGTCGGAAATTGGGGATGCCAGTCGTGTTTCGGGT
CTCTGGTCAGGGCCTTCACGAAGGCCACACCTTTGAGCCTGCAGAGTTTATCATT
GATACCCGCGATGCAGGCTATGGTGGGCTCAGCCTGTCCATTGAGGGCCCCAGC
AAGGTGGACATCAACACAGAGGACCTGGAGGACGGGACGTGCAGGGTCACCTAC
5 TGCCCCACAGAGCCAGGCAACTACATCATCAACATCAAGTTTGCCGACCAGCAC
GTGCCTGGCAGCCCCTTCTCTGTGAAGGTGACAGGCGAGGGCCGGGTGAAAGAG
AGCATCACCCGCAGGCGTTCGGGCTCCTTCAGTGGCCAACGTTGGTAGTCATTGTG
ACCTCAGCCTGAAAATCCCTGAAATTAGCATCCAGGATATGACAGCCCAGGTGA
CCAGCCCATCGGGCAAGACCCATGAGGCGGAGATCGTGGAAGGGGAGAACCAC
10 ACCTACTGCATCCGCTTTGTTCCCGCTGAGATGGGCACACACACAGTCAGCGTGA
AGTACAAGGGCCAGCACGTGCCTGGGAGCCCCTTCCAGTTCACCGTGGGGCCCCCT
AGGGGAAGGGGGAGCCCACAAGGTCCGAGCTGGGGGGCCCTGGCCTGGAGAGAG
CTGAAGCTGGAGTGCCAGCCGAATTCAGTATCTGGACCCGGGAAGCTGGTGCTG
GAGGCCTGGCCATTGCTGTGAGGGGCCCCAGCAAGGCTGAGATCTCTTTTGAGGA
15 CCGCAAGGACGGCTCCTGTGGTGTGGCTTATGTGGTCCAGGAGCCAGGTGACTAC
GAAGTCTCAGTCAAGTTCAACGAGGAACACATTCCCGACAGCCCCTTCGTGGTGC
CTGTGGCTTCTCCGTCTGGCGACGCCCGCCGCCTCACTGTTTCTAGCCTTCAGGAG
TCAGGGCTAAAGGTCAACCAGCCAGCCTCTTTTGAGTCAGCCTGAACGGGGCC
AAGGGGGCGATCGATGCCAAGGTGCACAGCCCCTCAGGAGCCCTGGAGGAGTGC
20 TATGTCACAGAAATTGACCAAGATAAGTATGCTGTGCGCTTCATCCCTCGGGAGA
ATGGCGTTTACCTGATTGACGTCAAGTTCAACGGCACCCACATCCCTGGAAGCCC
CTTCAAGATCCGAGTTGGGGAGCCTGGGCATGGAGGGGACCCAGGCTTGGTGTG
TGCTTACGGAGCAGGTCTGGAAGGCGGTGTACAGGGGAACCCAGCTGAGTTCTG
CGTGAACACGAGCAATGCGGGAGCTGGTGCCCTGTGGGTGACCATTGAGGGCGC
25 CTCCAAGGTGAAGATGGATTGCCAGGAGTGCCCTGAGGGCTACCGCGTCACCTA
TACCCCATGGCACCTGGCAGCTACCTCATCTCCATCAAGTACGGCGGGCCCCCTAC
CACATTGGGGGCAGCCCCTTCAAGGCCAAAGTCACAGGCCCCCGTCTCGTCAGC
AACCACAGCCTCCACGAGACATCATCAGTGTTTGTAGACTCTCTGACCAAGGCCA
CCTGTGCCCCCAGCATGGGGCCCCGGGTCTGGGCCTGCTGACGCCAGCAAGGT
30 GGTGGCCAAGGGCCTGGGGCTGAGCAAGGCCTACGTAGGCCAGAAGAGCAGCTT
CACAGTAGACTGCAGCAAAGCAGGCAACAACATGCTGCTGGTGGGGGTTTCATGG
CCCAAGGACCCCCTGCGAGGAGATCCTGGTGAAGCACGTGGGCAGCCGGCTCTA
CAGCGTGTCTACCTGCTCAAGGACAAGGGGGAGTACACACTGGTGGTCAAATG
GGGGGACGAGCACATCCCAGGCAGCCCCTACCGCGTTTGTGGTGCCCTGAGTCTG
35 GGGCCCGTGCCAGCCGGCAGCCCCCAAGCCTGCCCGCTACCCAAGCAGCCCCG
CCCTCTTCCCCTCAACCCCGGCCAGGCCGCCCTGGCCGCCCGCCTGTCACTGCA
GCCGCCCTGCCCTGTGCCGTGCTGCGCTCACCTGCCTCCCCAGCCAGCCGCTGA
CCTCTCGGCTTTCACTTGGGCAGAGGGAGCCATTTGGTGGCGCTGCTTGTCTTCT
TGGTTCTGGGAGGGGTGAGGGATGGGGGTCTGTACACAACCACCCACTAGTTCT
40 CTTCTCCAGCCAAGAGGAATAAAGTTTTGCTTCCATTCTCAAAA

SEQ ID NO: 334

>2827 BLOOD 006880.13 U87278 g4099426 Human splicing factor SRp30c gene, exon 2. 0

GGGCGACGGGCGCATCTACGTGGGGAACCTTCCGACCGACGTGCGCGAGAAGGA
45 CTTGGAGGACCTGTTCTACAAGTACGGCCGCATCCGCGAGATCGAGCTCAAGAA
CAGGCACGGCCTCGTGCCCTTCGCCTTCGTGCGCTTCGAGGACCCCCGAGATGCA
GAGGATGCTATTTATGGAAGAAATGGTTATGATTATGGCCAGTGTGGGCTTCGTG
TGGAGTTCCCCAGGACTTATGGAGGTGGGGGTGGGTGGCCCCGTGGTGGGAGGA
ATGGGCCTCCTACAAGAAGATCTGATTTCCGAGTTCTTGTTCAGGTATGTTCTT

TCAAACAGAATGAGATGATACATGTAAAATACTTAACACAGACTCTGTGTTCCAA
 GAAATGATAGCTGTTATTCTTCAGTGCATGGGACACGGGGGCTTTCTTTTCAATA
 GCCTGTGTGAAGCCTTGCCCTGGATTGCCAATGAGGAAAGTATCCTGCAAATGAA
 ATTGCGCTGGGAGTGCAGCCTTGAAGAACATAACCATATTTCTTGTAAGGAGT
 5 TTTCTAGTGGTGAGAAGGAAAGATGATGGGAAAACCTTGAGCTACAATTCTAAAG
 ATGCTTCTTTTGGGAATATACTTGGCATCAGACATGGTAGAAAGGCATTCAAGGAG
 CCAGATTTGAACAACCTTACCCAGCCTTGGATCCTGAAGAAGATCAGATTTTGTGG
 TGGTTTTAGAATTAAATATTTTTTAAAACCCCGTAACTTAAGAGTCTTAGAGATTT
 TATTGGAAAGTATAGACTATTTCTGTCTAGTGTATAAGTGATGAAATGCTAAA
 10 CTGGGAGGTTTATCTATCTTCAAAATATTAACACACTGGAAAGACCTGGGGCCTT
 CTGCATATTGCATGGGAGTTTTAGGGCCCTGGTGGAATGAAATAAATCGAGGAG
 CCTGGCACCTTTTTAAGATGTGAATGTCACACAATCACAGCATACTCCCATGTGC
 TTAAGAGTGATACTCTCAGTATCTGCCTATCTTGTGTCCCTTTGTAATTTTTTAAC
 CCCAGAACTCTATTCCCTCCTTCAGGATGTCATACATTATCTTTTTTCTCTCCATG
 15 CTGCTCTGAAATCCTGCTTAGAAAACCTATTAGGAAATGGCTGCAGTCTGAGCTG
 TGAGCGGTAAACACAGCCTTTGAGAGCAGGAGCACATTTCCCTTTCATGACATCA
 GGTAGGGTTGTATGACTCCCGACTAGTTTTAGCATCTGAGTCTTACCTTCCCCCCC
 ACTGTATTGAAGAATGTTGGTGATCTTTTAAGAGGTACTCTGTATAGTTTGTCTATT
 CATACCTACAAGAAAACAACTTTAGATTTTTTGTGTGTGTGTGTGTACCTTCAGC
 20 TACTCTTTGGTTATTTTCATGTCTGGTTTCAAAATTCCCATGTCCTGTGAAACCCTG
 TCAAGCAATAAATAATTGGTACTGTTAAATTTTATAATGGAAAAAATTGGAATC
 AAAGTATTAGGAGTTTGGCATTGATTTTAAAGGACAAAGAAAGAGGCTATGAAT
 TCTCAAAGATACTAAACCTGTAATGGGATGGACTTCTTGCTCTGTTGAAAAGGCC
 TGGTCTCTGGAAGATGAACTTAAAACCAGCTTCTCAAAGTGGTTCATTTACCACA
 25 CATACTTCAGTGCTCTTTTCTGATTTTCATGTCCCTTATCAAGGTTTATGATTTGGG
 GACCCTCAGGATTTAAGTGATCATGGAGAAAGGACCATAGGTATTGCTGGCTCTT
 AACAGGGCAGTTAACATAGCTGAAGGATGTGGGCTTTCTTATGTTCTCCATGCCT
 AGGACTTCCTCCGTCAGGCAGCTGGCAGGACCTGAAGGATCACATGCGAGAAGC
 TGGGGATGTCTGTTATGCTGATGTGCAGAAGGATGGAGTGGGGATGGTTCGAGTA
 30 TCTCAGAAAAGAAGACATGGAATATGCCCTGCGTAAACTGGATGACACCAAATT
 CCGCTCTCATGAGGGTGAACTTCCTACATCCGAGTTTATCCTGAGAGAAGCACC
 AGCTATGGCTACTCACGGTCTCGGTCTGGGTCAAGGGGCCGTGACTCTCCATACC
 AAAGCAGGGGTTCCCCACACTACTTCTCTCTTTCAGGCCCTACTGAGACAGGTG
 ATGGGAATTTTTTCTTTAATTTTTTAGGTTAACTGAGCTGCTTTGTGCTCAGAATCT
 35 ACATTCCAGATTGAGGATTTAGTGTCTTAGGAAATTTTTTTAATTTTTTTTTTTTA
 AAGNAGAAAAAACTACATAATTTCTACCAGGGCCATATTAGCAGTGAAACATT
 TTAAACTGCAGAAATTGTGGTTTGGGTTTCAAGAAACAAGTTGTATATTTTACCCC
 CTGATTATGGGAAAAAAATCAGTTCTGTCTTGGTGGGTTGCTCTACTATGGAGAT
 CAACAGTTACTGTGACTGAGTCGGCCCATCTGTTTAGAAATATATTTTAAATGTT
 40 TAGTGTTCCTCGCTTTCCAAGTTACATTTTATCTTGAGCAGATTTAAAACGAGAT
 TAGCTGTAATAGGACTCCAGGATGTGGGCAGATGTCTACTTGTCAAAGGGAGAA
 TCCAAATACAAC

SEQ ID NO: 335

45 >2846 BLOOD 407165.16 AF048693 g3170416 Human transcription factor forkhead-like 7
 (FKHL7) gene, complete cds. 0
 GGCTACCCGGGCCAGCAGCAGAACTTCCACTCGGTGCGGGAGATGTTTCGAGTCA
 CAGAGGATCGGCTTGAACAACCTCTCCAGTGAACGGGAATAGTAGCTGTCAAATG
 GCCTTCCCTTCCAGCCAGTCTCTGTACCGCACGTCCGGAGCTTTCGTCTACGACTG

TAGCAAGTTTTTGACACACCCTCAAAGCCGAACTAAATCGAACCCCAAAGCAGGA
AAAGCTAAAGGAACCCATCAAGGCAAAATCGAACTAAAAAAAAAAAAATCCAA
TTAAAAAAAAACCCCTGAGAATATTCACCACACCAGCGAACAGAATATCCCTCCA
AAAATTCAGCTCACCAGCACCAGCACGAAGAAACTCTATTTTCTTAACCGATTA
5 ATTCAGAGCCACCTCCACTTTGCCTTGTCTAAATAAACAAACCCGTAAACTGTTT
TATACAGAGACAGCAAAATCTTGGTTTATTAAGGACAGTGTTACTCCAGATAAC
ACGTAAGTTTCTTCTTGCTTTTCAGAGACCTGCTTTCCCTCCTCCCGTCTCCCTC
TCTTGCTTCTTCTTGCTCTCACCTGTAAGATATTATTTATCCTATGTTGAAGG
GAGGGGGAAAGTCCCGTTTATGAAAGTCGCTTTCTTTTATTTCATGGACTTGTTT
10 TAAAATGTAAATTGCAACATAGTAATTTATTTTAATTTGTAGTTGGATGTCGTGG
ACCAAACGCCAGAAAGTGTTCCCAAAACCTGACGTTAAATTGCCTGAAACTTTAA
ATTGTGCTTTTTTTCTCATTATAAAAAGGGAACTGTATTAATCTTATTCTATCCT
CTTTTCTTTCTTTTGTGTAACATATTCATTGTTGTTTATTAATAAATTACCATTC
AGTTTGAATGAGACCTATATGTCTGGATACTTTAATAGAGCTTTAATTATTACGA
15 AAAAGATTTTCAGAGATAAAACACTAGAAGTTACCTATTCTCCACCTAAATCTCT
GAAAAATGGAGAAACCCCTCTGACTAGTCCATGTCAAATTTTACTAAAAGTCTTTT
TGTTTAGATTTATTTTCTGAGCATCTTCTGCAAAATGTACTATATAGTCAGCTT
GCTTTGAGGCTAGTAAAAAGATATTTTCTAAACAGATTGGAGTTGGCATATAAA
CAAATACGTTTCTCACTAATGACAGTCCATGATTTCGAAATTTTAAGCCCATGA
20 ATCAGCCGCGGTCTTACCACGGTGATGCCTGTGTGCCGAGAGATGGGACTGTGCG
GCCAGATATGCACAGATAAATATTTGGCTTGTGTATTCCATATAAAATTGCAGTG
CATATTATACATCCCTGTGAGCCAGATGCTGAATAGATATTTTCTATTATTTTCTC
TGCTTTATAAAAGGAAAAATAAACGAGTTTTTAAATGTATGTATAFAATTCTCCC
CCATTACAATCCTTCATGTATTACATAGAAGGATTGCTTTTTTAAAAATATACTG
25 CGGGTTGGAAAGGGATATTTAATCTTTGAGAACTATTTTAGAAAAATATGTTTGT
AGAACAATTATTTTGA AAAAGATTTAAAGCAATAACAAGAAGGAAGGCGAGAG
GAGCAGAACATTTTGGTCTAGGGTGGTTTCTTTTTAAACCATTTTTTCTTGTTAAT
TTACAGTTAAACCTAGGGGACAATCCGGATTGGCCCTCCCCCTTTTGTAATAAC
CCAGGAAATGTAATAAATTCATTATCTTAGGGTGATCTGCCCTGCCAATCAGACT
30 TTGGGGAGATGGCGATTTGATTACAGACGTTTCGGGGGGGTGGGGGGCTTGCACT
TTGTTTTGGAGATAATACAGTTTCTGCTATCTGCCGCTCCTATCTAGAGGCAACA
CTTAAGCAGTAATTGCTGTTGCTTGTGTCAAAATTTGATCATTGTTAAAGGATTG
CTGCAATAAATACACTTTAATTTCACTCCAAAAAANAAAAAAGGGC

35 SEQ ID NO: 336

>2898 BLOOD 257782.19 D49738 g736703 Human cytoskeleton associated protein (CG22)
mRNA, complete cds. 0

TTTTTCTGGGTTTCTAGTGAATTTAATGCATGAGTCTCAAAAATCAATGGCAAA
GGAAAAATGAATAAAATTAATGAGGTCAGGAGAAAAGGGCCATGGGCACA
40 CACAGGAGGGGCAGTCAGTGGCTGAGCTAGGAGCTGAAGCAGGGGAATTCCTTA
GGTGTATATCTCGTCCAACCCGTAGTCCTCCTCCGGGAAGTCCCCACCGTCAC
GACTGCTGGCTTGACAAAGGCGCCATACTTGGCCTGGCATTTCGAAGTAGCGTTTC
CCATTCACTGCCATCATTTTTCCCCAGTGGCTCATCATAGCGGACACCAATCC
AGTAGCCAGGCTTGAAATCTGTGAGACCTACATACATGACGGTGCCCCGGCGAG
45 GGGATTGTCCCGCCGCCGACCTCACAGCGGCTGCCACGGGGATGGAGCTGG
CCTGGGCCTTCTCCTCGGCCAGGCGCTGGGCGGCCTCGGCCTCCTGCTGAGCCCG
CTCCTCCTCGTTGTACCGGCCGAGCTTGTGCGCTTCAGGAAAGAGCGGACCGTG
TCTTGCTCTGGTCGTAGGCTTCTTGTGAGATCGTGTACTTCTCCACCCGGGACAC
GTCCTCATACTACCAAGGCGGGCGCCACTGTGGTCAATGACGTGGATGCGGCA

GCCGTCATCTACAGGGTAGGAGCCCAGGAGCGCATCCTCTTGATCCAGCTTGCTG
 TAGAACTTGTCGTCAACTCCATACAGCTCCAGTTCCATGCAGGAAGCAGGGCTGC
 CCACCAGCAACTCCAGTTTACACTTGAAGTACAGCGATGGTGAGGCTGCGGCTGTA
 TCGCTTCTCGGAGCGGAAGGTGTTGAGGGAGCTGCTGATGAAAACGGTCACCGT
 5 GGGTGCCGACACCCCGTCACCTCCATCTTGCCGCGCCCTGCGGATGCCTGCAGC
 GCAGGTCCAGCCGCCTCACACCCGCTCCGCAGCCGCCGCC

SEQ ID NO: 337

>2901 BLOOD GB_AA504617 gi|2240777|gb|AA504617|AA504617 aa63b04.s1

10 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:825583 3' similar to TR:G642094
 G642094 AUTOANTIGEN P542 ;, mRNA sequence [Homo sapiens]

GCTGGGATGCGTTGGGGGAGGAGGCGCCTGCTGCCAGCTTTCCTCTGGTACCCGC
 TGTGGGGGTGGCATCCAGGGTTGGGTGCCCGGCTTGACAGGTACGTTAGTTTGA
 CACGCCGGACCAAAGGGACTGTGACCCGGGGTTCGCTTACAGGGACCGCCCTGG
 15 GCACTGGCACGGGCGACAGACGGCCCCGGTAGTCGAAGAGCCTGTCGTAGA

>2912 BLOOD 1162375.1 U09202 g852427 Human ornithine decarboxylase antizyme (Oaz)
 mRNA, complete cds. 0

GTGCTGAGTGGCGGCACTCTACATCGAGATCCCGGGCGGCGGCTGCCCCAGGGG
 AGCAAGGACAGCTTTGCAGTTCTCCTGGAGTTCGCTGAGGAGCAGCTGCGAGCC
 20 GACCATGTCTTCATTTGCTTCCACAAGAACCGCGATGACAGAGCCGCCCTTGCTCC
 GAACCTTCAGCTTTTTGGGCTTTGAGATTGTGAGACCGGGGCATCCCCTTGTCCT
 CAAGAGACCCGACGCTTGCTTCATGGGCTACACGTTTCGAGAG

SEQ ID NO: 338

25 >2917 BLOOD 358853.44 Z19554 g37851 Human vimentin gene. 0

GAGGGCGCCCCACCCACCCGCCACCTCCCCGCTTCTCGCTAGGTCCCGATT
 GGCTGGCGCGCTCCGCGGCTGGGATGGCAGTGGGAGGGGACCCTCTTTCCTAAC
 GGGGTTATAAAACAGCGCCCTCGGCGGGGTCCAGTCCTCTGCCACTCTCGCTCC
 GAGGTCCCCGCGCCAGAGACGCAGCCGCGCTCCACCAACCCACACCCACCGCGC
 30 CCTGCGTTTCGCTCTTCTCCGGGAGCCAGTCCCGCGCCACCGCCGCCGCCAGGC
 CATCGCCACCCTCCGCAGCCATGTTCCACCAGGTCCGTGTCCTCGTCTCTACCG
 CAGGATGTTTCGGCGGCCCCGGGCACCGCGAGCCGCGGAGCTCCAGCCGGAGCTA
 CGTGACTACGTCCACCCGCACCTACAGCCTGGGGAGCGCGCTGCGCCCCAGCACC
 AGCCGCAGCCTCTACGCCTCGTCCCCGGGCGGCGTGTATGCCACGCGCTCCTCTG
 35 CCGTGCGCCTGCGGAGCAGCGTGCCCGGGGTGCGGCTCCTGCAGGACTCGGTGG
 ACTTCTCGCTGGCCGACGCCATCAACACCGAGTTCAAGAACACCCGCACCAACG
 AGAAGGTGGAGCTGCAGGAGCTGAATGACCGCTTCGCCAACTACATCGACAAGG
 TCGCTTCCTGGAGCAGCAGAATAAGATCCTGCTGGCCGAGCTCGAGCAGCTCA
 AGGGCCAAGGCAAGTCGCGCCTGGGGGACCTCTACGAGGAGGAGATGCGGGAG
 40 CTGCGCCGGCAGGTGGACCAGCTAACCAACGACAAAGCCCGCGTCGAGGTGGAG
 CGCGACAACCTGGCCGAGGACATCATGCGCCTCCGGGAGAAATTGCAGGAGGAG
 ATGCTTCAGAGAGAGGAAGCCGAAACACCCTGCAATCTTTCAGACAGGATGTT
 GACAATGCGTCTCTGGCACGTCTTGACCTTGAACGCAAAGTGGAATCTTTGCAAG
 AAGAGATTGCCTTTTTGAAGAACTCCACGAAGAGGAAATCCAGGAGCTGCAGG
 45 CTCAGATTCAAGAACAGCATGTCCAAATCGATGTGGATGTTTCCAAGCCTGACCT
 CACGGCTGCCCTGCGTGACGTACGTACGCAATATGAAAGTGTGGCTGCCAAGAA
 CCTGCAGGAGGCAGAAGAATGGTACAAATCCAAGTTTGCTGACCTCTCTGAGGC
 TGCCAACCGGAACAATGACGCCCTGCGCCAGGCAAAGCAGGAGTCCACTGAGTA
 CCGGAGACAGGTGCAGTCCCTCACCTGTGAAGTGGATGCCCTTAAAGGAACCAA

TGAGTCCCTGGAACGCCAGATGCGTGAAATGGAAGAGAAGCTTTGCCGTTGAAGC
TGCTAACTACCAAGACACTATTGGCCGCCTGCAGGATGAGATTCAGAATATGAA
GGAGGAAATGGCTCGTCACCTTCGTGAATACCAAGACCTGCTCAATGTTAAGATG
GCCCTTGACATTGAGATTGCCACCTACAGGAAGCTGCTGGAAGGCGAGGAGAGC
5 AGGATTTCTCTGCCTCTTCCAAACTTTTCCCTCCCTGAACCTGAGGGGAACTAATCT
GGATTCACCTCCCTCTGGTTGATACCCACTCAAAAAGGACACTTCTGATTAAGACG
GTTGAAACTAGAGATGGACAGGTTATCAACGAACTTCTCAGCATCACGATGAC
CTTGAATAAAAATTGCACACACTCAGTGCAGCAATATATTACCAGCAAGAATAA
AAAAGAAATCCATATCTTAAAGAAACAGCTTTCAAGTGCCTTTCTGCAGTTTTTC
10 AGGAGCGCAAGATAGATTTTGAATAGGAATAAGCTCTAGTTCTTAACAACCGAC
ACTCCTACAAGATTTAGAAAAAAGTTTACAACATAATCTAGTTTACAGAAAAATC
TTGTGCTAGAATACTTTTTAAAAGGTATTTTGAATACTATTAAACTGCTTTTTTT
TTTCCAGCAAGTATCCAACCAACTTGGTTCTGCTTCAATAAATCTTTGGAAAAAC
AAAGCAGTTTTAATAGTATTCAAAAATACCTTTTAAAAAGTATTCTAGCACAAGAT
15 TTTTCTGTAACTAGATTATGTTGTAAACTTTTTTCTAAATCTTGTAGGAGTGTCG
GTTGTTAAGAACTAGAGCTTATTCCTATTCCAAATCTATCTTGCGCTCCTGAAAA
ACTGCAGAAAGGCACCTTGAAAGCTGTTTCTTTAAGATATGGATTTCTTTTTTACCT
TGCTGGTAATATATTGCTGCACTGAGTGTGTGCAATTTTTATTCAAGGTCATCGTG
ATGCTGAGAAGTTTCGTTGATAACCTGTCCATCTCTAGTTTCAACCGTCTTAATCA
20 GAAGTGTCTTTTTTGAGTGGGTATCAACCAGAGGGAGTGAATCCAGATTAGTTTC
CCTCAGGTTTCAAGGAGGAAAAGTTTGAAGAGGCAGAGAAATCCTGCTCTCCTC
GCCTTCCAGCTGCTAACTACCAAGACACTATTGGCCGCCTGCAGGATGAGATTCA
GAATATGAAGGAGGAAATGGGCTCGTCACCTTCGTGAATACCAAGACCTGCTCAA
TGTTAAGATGGCCCTTGACATTGAGATTGCCACCTACAGGAAGCTGCTGGAAGGC
25 GAGGAGAGCAGGATTTCTCTGCCTCTTCCAAACTTTTCCCTCCCTGAACCTGAGGG
AACTAATCTGGGATTCACCTCCCCTCTGGTTGATACCCACTCAAAAAGGACACTT
CTGATTAAGACGGTTGAACTAGAGATGGACAGGTTATCAACGAACTTCTCAG
CATCACGATGACCTTGAATAAAAATTGCACACACTCAGTGCAGCAATATATTACC
AGCAAGAATAAAAAAGAAATTTCATATCTTAAAGAAACAGCTTTCAAGTGCCTTT
30 CTGCAGTTTTTTCAGGAGCGCAAGATAGATTTGGAATAGGAATAAGCTCTAGTTCT
TAACAACCGACACTCCTACAAGATTTAGAAAAAAGTTTACAACATAATCTAGTTT
ACAGAAAAATCTTGTGCTAGAATACTTTTTAAAAGGTATTTTGAATACCATTAAA
ACTGCTTTTTTTTTTCCAGCAAGTATCCAACCAACTTGTCTGCTTCAATAAATC
TTTTGAAAAACTCAAAA

35

SEQ ID NO: 339

>2925 BLOOD 235943.40 J05581 g188869 Human polymorphic epithelial mucin (PEM)

mRNA, complete cds. 0

CGCTCCACCTCTCAAGCAGCCAGCGCCTGCCTGAATCTGTTCTGCCCCCTCCCCA
40 CCCATTTACCAACCACCATGACACCGGGCACCCAGTCTCCTTTCTTCCTGCTGCTG
CTCCTCACAGTGCTTACAGTTGTTACAGGTTCTGGTCATGCAAGCTCTACCCAG
GTGGAGAAAAGGAGACTTCGGCTACCCAGAGAAGTTCAGTGCCAGCTCTACTG
AGAAGAATGCTGTGAGTATGACCAGCAGCGTACTCTCCAGCCACAGCCCCGGTT
CAGGCTCCTCCACCACTCAGGGACAGGATGTCACTCTGGCCCCGGCCACGGAAC
45 CAGCTTCAGGTTCACTGCCACCTGGGGACAGGATGTACCTCGGTCCAGTCAC
CAGGCCAGCCCTGGGCTCCACCACCCCGCCAGCCACGATGTACCTCAGCCCCG
GACAACAAGCCAGCCCCGGGCTCCACCGCCCCCCCCAGCCACGGTGTACCTCG
GCCCCGGACACCAGGCCGGCCCCGGGCTCCACCGCCCCCCCCAGCCCATGGTGT
ACCTCGGCCCCGGACAACAGGCCCGCCTTGGGCTCCACCGCCCCCTCAGTCCACA

ATGTCACCTCGGCCTCAGGCTCTGCATCAGGCTCAGCTTCTACTCTGGTGCACAA
CGGCACCTCTGCCAGGGCTACCACAACCCAGCCAGCAAGAGCACTCCATTCTCA
ATTCCCAGCCACCACTCTGATACTCCTACCACCCTTGCCAGCCATAGCACCAAGA
CTGATGCCAGTAGCACTCACCATAGCACGGTACCTCCTCTCACCTCCTCCAATCA
5 CAGCACTTCTCCCCAGTTGTCTACTGGGGTCTCTTTCTTTTCTCTGTCTTTTACAT
TTCAAACCTCCAGTTTAATTCCTCTCTGGAAGATCCCAGCACCGACTACTACCAA
GAGCTGCAGAGAGACATTTCTGAAATGTTTTTGACAGATTTATAAACAAGGGGGT
TTCTGGGCCTCTCCAATATTAAGTTCAGGCCAGGATCTGTGGTGGTACAATTGAC
TCTGGCCTTCCGAGAAGGTACCATCAATGTCCACGACGTGGAGACACAGTTCAAT
10 CAGTATAAAACGGAAGCAGCCTCTCGATATAACCTGACGATCTCAGACGTCAGC
GTGAGTGATGTGCCATTTCTTTCTCTGCCAGTCTGGGGCTGGGGTGCCAGGCT
GGGGCATCGCGCTGCTGGTGTCTGTGTTCTGGTTGCGCTGGCCATTGTCTAT
CTCATTGCCCTTGGCTGTCTGTGAGTGCCTGCGGAAAGAACTACGGGCAGCTGGACA
TCTTTCCAGCCCGGGATACCTACCATCCTATGAGCGAGTACCCACCTACCACAC
15 CCATGGGCGCTATGTGCCCCCTAGCAGTACCGATCGTAGCCCCTATGAGAAGGTT
TCTGCAGGTAATGGTGGCAGCAGCCTCTCTTACACAAACCCAGCAGTGGCAGCC
ACTTCTGCCAACTTGTAGGGGCACGTCGCCCCGCTGAGCTGAGTGGCCAGCCAGTG
CCATTCCACTCCACTCAGGTTCTTCAGGGCCAGAGCCCCTGCACCCTGTTTGGGC
TGGTGAGCTGGGAGTTCAGGTGGGCTGCTCACAGCCTCCTTCAGAGGCCCCACCA
20 ATTTCTCGGACACTTCTCAGTGTGTGGAAGCTCATGTGGGCCCCCTGAGGGCTCAT
GCCTGGGAAGTGTTGTGGTGGGGGCTCCCAGGAGGACTGGCCCAGAGAGCCCTG
AGATAGCGGGGATCCTGAACTGGACTGAATAAAACGTGGTCTCCCACTGCGCCA
AAAAAATTAATAAA
25 SEQ ID NO: 340
>2948 BLOOD 331753.1 AB002311 g2224566 Human mRNA for KIAA0313 gene,
complete cds. 0
GTCCTACGTAGATAACAGCTTCCGCCAGGCGGTGATGAAGAATCCCCCGAAAG
GACCCCCCAGGATCTGGAAATAGTATATTCCTATTTACATGGTATGGAAGCCTTA
30 TCAAACCTTGAGGGAGCATCAACTTAGGTTAATGTGTGAAACTGTGAGATATGAG
AGACACGAAGCAAATGAAGTTTTATACTACCCTGATGATATTGGGACCTGCTGGT
ATATCCTTCTTTCTGGTTCCGTGTTCAATCAAGGAATCCATGTTTCTTCCAAGAAGC
AGTTTTGGCAAGCGTCTGCAAGGAAGTTTTAGGCGTGGCTGTGAATGCATTGTTT
TAGAGCCTTCTGAAATGATGTGTGGTGGACTATATGGATGAAAATGAAGAATATTT
35 TCAGCGGCAAGCTTCCCATAGACAGTCTCGAAGGAGATTTAGAAAAATCAACCA
GAAAGGTGAAAGACAAACAATTATTGACACTGTGGATCCTTATCCCATGGGCAA
ACCTCCTTTGCCTAGAGGCTATCACACGGAATGCACTAAATCTCAGCTTCCTGCA
GATTTCAAAAACACTGCATCTTACTGACAGTCTCCACCCACAGGTGACCCACGTTT
CTTCTAGCCATTCAGGATGTAGTATCACTAGTGATTCTGGGAGCAGCAGTCTTTC
40 TGATATCTACCAGGCCACAGAAAGCGAGGCTGGTGATATGGACCTGAGTGGGT
GCCAGAAACAGCAGTGGATTCCGAAGACGACGACGATGAAGAAGACATTGAGA
GAGCATCAGATCCTCTGATGAGCAGGGACATTGTGAGAGACTGCCTAGAGAAGG
ACCCAATTGACCGGACAGATGATGACATTGAACAACCTTGGAAATTTATGCACCA
GTTGCCTGCTTTTGCCAATATGACAATGTCAGTGAGGCGAGAACTCTGTGCTGTG
45 ATGGTGTTTCGCACTGGTGGAAAGAGCAGGGACCATAGTGTTAAATGATGGTGAA
GAGCTGGACTCCTGGTCACTGATTCTCAATGGATCTGTGGAAGTGACTTATCCAG
ATGGAAAAGCAGAAATACTGTGCATGGGAAATAGTTTTGGTGTCTCTCCTACCAT
GGACAAAGAATACATGAAAGGAGTGATGAGAACAAAGGTGGATGACTGCCAGT
TTGTCTGCATAGCCCAGCAAGATTACTGCCGTATTCTCAATCAAGTAGAAAAGAA

CATGCAAAAAGTTGAAGAGGAAGGAGAGATTGTTATGGTGAAAGAACACCGAG
AACTTGATCGAACTGGAACAAGAAAGGGACACATTGTCATCAAGGGTACCTCAG
AAAGGTTAACAATGCATTTGGTGGAAGAGCATTAGTAGTAGATCCAACATTCAT
AGAAGACTTTCTGTTGACCTATAGGACTTTTCTTTCTAGCCCAATGGAAGTGGGC
5 AAAAAAGTTATTGGAGTGGTTTAATGACCCGAGCCTCAGGGATAAGGTTACACGG
GTAGTATTATTGTGGGTAAATAATCACTTCAATGACTTTGAAGGAGATCCTGCAA
TGACTCGATTTTGTAGAAGAAATTTGAAAACAATCTGGAAAGAGAGAAAATGGGTG
GACACCTAAGGCTGTTGAATATCGCGTGTGCTGCTAAAGCAAAAAGAAGATTGA
TGACGTTAACAAAACCATCCCGAGAAGCTCCTTTGCCTTTTATCTTACTTGGAGG
10 CTCTGAGAAGGGATTTGGAATCTTTGTTGACAGTGTAGATTTCAGGTAGCAAAGCA
ACTGAAGCAGGCTTGAAACGGGGGGGATCAGATATTAGAAGTAAATGGCCAAAAC
TTTGAAAACATTTCAGCTGTCAAAGCTATGGAAATTCTTAGAAATAACACACATT
TATCTATCACTGTGAAAACCAATTTATTTGTATTTAAAGAACTTCTAACAAGATT
GTCAGAAGAGAAAAGAAATGGTGCCCCCACCTTCCTAAAATTGGTGACATTAA
15 AAAGGCCAGTCGCTACTCCATTCCAGATCTTGCTGTAGATGTAGAACAGGTGATA
GGACTTGAAAAAGTGAACAAAAAAAGTAAAGCCAACACTGTGGGAGGAAGGAA
CAAGCTGAAAAAGATACTCGACAAGACTCGGATCAGTATCTTGCCACAGAAACC
ATACAATGATATTGGGATTGGTCAGTCTCAAGATGACAGCATAGTAGGATTAAG
GCAGACAAAGCACATCCCAACTGCATTGCCTGTCAGTGGAACCTTATCATCCAGT
20 AATCCTGATTTATTGCAGTCACATCATCGCATTTTAGACTTCAGTGCTACTCCTGA
CTTGCCAGATCAAGTGCTAAGGGTTTTTAAGGCTGATCAGCAAAGCCGCTACATC
ATGATCAGTAAGGACACTACAGCAAAGGAAGTGGTCATTTCAGGCTATCAGGGAG
TTTGCTGTTACTGCCACCCCGGATCAATATTCATCTATGTGAGGTCTCTGTACACCC
TGAGGGAGTAATCAAACAAAGAAGACTTCCAGATCAGCTTTCCAAACCTTGCGAG
25 CAGAATACAACTGAGTGGAAGGTATTATCTGAAAAACAACATGGAAACAGAAAC
TCTTTGTTTCAGATGAAGATGCTCAGGAGTTGTTGAGAGAGAGTCAAATTTCCCTC
CTTCAGCTCAGCACTGTGGAAGTTGCAACACAGCTCTCTATGCGAAATTTTGAAC
TCTTTCGCAACATTGAACCTACTGAATATATAGATGATTTATTTAACTCAGATC
AAAAACCAGCTGTGCCAACCTGAAGAGATTTGAAGAAGTCATTAACCAGGAAAC
30 ATTTTGGGTAGCATCTGAAATTCTCAGAGAAACAACCAGCTGAAGAGGATGAA
GATCATTAAGCATTTTCATCAAGATAGCACTGCACTGTAGGGAATGCAAGAATTTT
AACTCAATGTTTGCAATCATCAGTGGCCTAAACCTGGCACCAGTGGCAAGACTGC
GAACGACCTGGGAGAAACCTCCCAATAAATACGAAAAACTATTTCAAGATCTCC
AAGACCTGTTTGATCCTTCCAGAAACATGGCAAAATATCGTAATGTTCTCAATAG
35 TCAAAATCTACAACCTCCCATAATCCCTCTATTCCCAGTTATCAAAAAGGATCTC
ACCTTCCTTCACGAAGGAAATGACTCAAAAGTAGACGGGCTGGTCAATTTTGAG
AAGCTAAGGATGATTGCAAAAGAAATTCGTACGTTGGCCGAATGGCTTCAGTG
AACATGGACCCTGCCCTCATGTTTCAGGACTCGGAAGAAGAAATGGCGGAGTTTG
GGGTCTCTCAGCCAGGGTAGTACAAATGCAACAGTGCTAGATGTTGCTCAGACA
40 GGTGGTCATAAAAAGCGGGTACGTCTGATGTTCTTTCTCAATGCCAAAAAGCTTT
ATGAAGATGCCCAAATGGCTCGAAAAGTGAAGCAGTACCTTTCCAATTTGGAGC
TAGAAATGGACGAGGAGAGTCTTCAGACATTATCTCTGCAGTGTGAGCCAGCAA
CCAACACATTGCCTAAGAATCCTGGTGACAAAAAGCCTGTCAAATCCGAGACCT
CTCCAGTAGCTCCAAGGGCAGGGTCACAACAGAAAGCTCAGTCCCTGCCACAGC
45 CCCAGCAGCAGCCACCACCAGCACATAAAATCAACCAGGGACTACAGGTTCCCG
CCGTGTCCCTTTATCCTTCACGGAAGAAAGTGCCCGTAAAGGATCTCCACCTTT
TGGCATAAACTCTCCACAAGCTTTAAAAAAAATTCTTTCTTTGTCTGAAGAAGGA
AGTTTGAACGTCACAAGAAACAGGCTGAAGATACAATATCAAATGCATCTTCG
CAGCTTTCTCTCCTCCTACTTCTCCACAGAGTTCTCCAAGGAAAGGCTATACTTT

GGCTCCCAGTGGTACTGTGGATAATTTTTTCAGATTCTGGTCACAGTGAAATTTCTT
CACGATCCAGTATTGTTAGCAATTCGTCTTTTGAAGTCAAGTCCAGTCTCACTGCAC
GATGAGAGGCGCCAGAGGCATTCTGTCAGCATCGTGGAAACAAACCTAGGGATG
GGCAGGATGGAGAGGCGGACCATGATTGAACCTGATCAGTATAGCTTGGGGTCC
5 TATGCACCAATGTCCGAGGGCCGAGGCTTATATGCTACAGCTACAGTAATTTCTT
CTCCAAGCACAGAGGAACTTTCCAGGATCAGGGGGATCGCGCGTCACTTGATG
CTGCTGACAGTGGCCGTGGGAGCTGGACGTCATGCTCAAGTGGCTCCCATGATAA
TATACAGACGATCCAGCACCAGAGAAGCTGGGAGACTCTTCCATTTCGGGCATAC
TCACTTTGATTATTCAGGGGATCCTGCAGGTTTATGGGCATCAAGCAGCCATATG
10 GACCAAATTATGTTTTCTGATCATAGCACAAAGTATAACAGGCAAAATCAAAGT
AGAGAGAGCCTTGAACAAGCCCAGTCCCAGCAAGCTGGGCGTCTTCCACAGGT
TACTGGGGAGAAGACTCAGAAGGTGACACAGGCACAATAAAGCGGAGGGGTGG
AAAGGATGTTTCCATTGAAGCCGAAAGCAGTAGCCTAACGTCTGTGACTACGGA
AGAAACCAAGCCTGTCCCCATGCCTGCCCACATAGCTGTGGCATCAAGTACTACA
15 AAGGGGCTCATTGCACGAAAGGAGGGCAGGTATCGAGAGCCCCCGCCACCCCT
CCCGGCTACATTGGAATTCCTTACTGACTTTCCAGAAGGGCACTCCCATCCAG
CCAGGAAACCGCCGGACTACAACGTGGCCCTTCAGAGATCGCGGATGGTCGCAC
GATCCTCCGACACAGCTGGGCCTTCATCCGTACAGCAGCCACATGGGCATCCCAC
CAGCAGCAGGCCTGTGAACAAACCTGCAGTGGCATAAACCGAACGAGTCTGACC
20 CGCGCCTCGCCCCCTATCAGTCCCAAGGGTTTTCCACCGAGGAGGATGAAGATGA
ACAAGTTTCTGCTGTTTGAGGCACAGACTTTTCTGGAAGCAGAGCGAGCCACCTG
AAAGGAGAGCACAAGAAAGAGGTCCTGAGCATTGGAGCCTTGGAACTGACATTCT
GAGGACGGTGGACCAGTTTGCCTCCTTCCCTGCTTAAAAGCAGCATGGGGCTTC
TTCTCCCCTTCTTCCCTTTCCCTTTTGCATGTGAAATACTGTGAAGAAATTGCCCTG
25 GCACTTTTCAGACTTTGTTGCTTGAATGCACAGTGCAGCAATCTTCGAGCTCCC
ACTGTTGCTGCCTGCCACATCACACAGTATCATTCCAAATTCCAAGATCATCACA
ACAAGATGATTCACTCTGGCTGCACTTCTCAATGCCTGGAAGGATTTTTTTTAATC
TTCCTTTTAGATTTCAATCCAGTCCTAGCACTTGATCTCATTGGGATAATGAGAAA
AGCTAGCCATTGAACTACTTGGGGCCTTTAACCCACCAAGGAAGACAAAGAAAA
30 ACAATGAAATCCTTTGAGTACAGTGCTTGTCCACTTGTTTACAATGTCTCCTTTT
AAAAAAAAAAATGAGTTTAAAGATTTTGTTCAGAGAGTAAATATATATCCATTTA
ATGATTACAGTATTATTTTAAACCTTAAGTAGGGTTGCCAGCCTGGTTTCTGAAA
AACCAAATATGCCGGACAGGGTGTGGCCACACCAAGAAGACGGGAAGACCTGG
CTTGTGACCCTGGCTTCCCATGTCTTCTGCTCACCCTGCGAAGTGGCCTATCCT
35 GGAAGTATGAAATGTTAGCCAATTAATACCAAGACACCTCATCTGCTCCTTCCCC
AGTGGATGGGGTTCTTCTGTAAACTGTTTGCACATGGCCAGGGGAGGGAATA
GGACCCTTGTGTCTGTCTGAGCCTTATGGAGGCAGGACGGTGTGATTGGCGGAT
GTGTCTGCTCCATTGAGATGGATGGCAAACCCCATTTTTTAAGTTATATTTCTTTG
ATTTTTGTAAATTTAGAGGTGTAGGTTTTGTTTTTTGTTTTTTTGTAAAAAG
40 AGAAACATTTATAACTGGATAGCATTGCAGTGAAAGCAGCTTGGGATGTTGGAG
CTAATGCCAGCTGTTTATACTGCTCTTCAAGACAGCCTCCCTTTATTGAATTGGC
ATTAGGGAATAAACAAGCCTTTAAACGTGATAAAAGATCAAAAACCTGGTTAGA
CATGCCAGCCTTTGCAAGGCAGGTAGTCACCAAAGACTAACCTCCAAGTGGCTT
TATGGACGCTGCATATAGAGAAGGCCTAAGTGTAGCAACCATCTGCTCACAGCT
45 GCTATTAACCTATAATGACTGAAATGACCCCTCCACTCTATTTTTGTGTTGTTTT
GCACAGACTCCGGAAGAGTGAAGGCTGCCAATCTGAGTAGTACTCAAATGTGAG
GAACTGCTGGTCTTGGATTTTTTTTCCATTAAATTCAGCTGATCATATTGATCAGT
AGATAAACGTAAATAGCTTCAAATTTTAAAGTGAATTGCAGTGTTTTTTCCT
GTATCAAACAATGTCAGTGCTTTATTTAATAATTCTCTTCTGTATCATGGCATTG

TCTACTTGCTTATTACATTGTCAATTATGCATTTGTAATTTTACATGTAATATGCA
 TTATTTGCCAGTTTTATTATATAGGCTATGGACCTCATGTGCATATAGAAAGACA
 GAAATCTAGCTCTACCACAAGTTGCACAAATGTTATCTAAGCATTAAAGTAATTGT
 AGAACATAGGACTGCTAATCTCAGTTCGCTCTGTGATGTCAAGTGCAGAATGTAC
 5 AATTAAGTGGTGATTTTCTCATACTTTTGATACTACTTGTACCTGTATGTCTTTTA
 GAAAGACATTGGTGGAGTCTGTATCCCTTTTGTATTTTAAATAACAATAATTGTACA
 TATTGGTTATATTTTGTGGAAGATGGTAGAAATGTACTATGTTTATGCTTCTACA
 TCCAGTTTGTACAAGCTGGAAAATAAATAAATAACATAAAGCCTTGCCAT

10 SEQ ID NO: 341

>2957 BLOOD 425165.31 AF005898 g2209237 Human Na,K-ATPase beta-3 subunit
 pseudogene, complete sequence. 0

CTCGAGTACTCCCCGTAACGAGGAGGTGTTCTCGGCCGTCCCACCCTTCACTGCC
 GTCTCCGGGCTGCGCCGCCGGAGCCGGGACGCGCCTCCGCAGCCCTCGCCGGCTC
 15 CATCCCCGCGGCCGCAGCTCCTCTCGCCGTCCGCGCGCACACCATGACGAAGAAC
 GAGAAGAAGTCCCTCAACCAGAGCCTGGCCGAGTGGAAGCTCTTCATCTACAAC
 CCGACCACCGGAGAATTCTGGGGCGCACCGCCAAGAGCTGGGGTTTGATCTTG
 CTCTTCTACCTAGTTTTTTATGGGTTCTGGCTGCACTCTTCTCATTACGATGTG
 GGTATGCTTCAGACTCTCAACGATGAGGTTCCAAAATACCGTGACCAGATTCCT
 20 AGCCCAGGACTCATGGTTTTTCCAAAACCAGTGACCGCATTGGAATATACATTCA
 GTAGGTCTGATCCAACCTTCGTATGCAGGGTACATTGAAGACCTTAAGAAGTTTCT
 AAAAACCATATACTTTAGAAGAAGACAAGAAGCTCACAGTCTGTCTGATGGAGC
 AACTTTTTGAACAGAAGGGTCCAGTTTATGTTGCATGTCAGTTTCCTATTTCAATAC
 TTCAAGCATGCAGTGGTATGAATGATCCTGATTTTGGCTATTCTCAAGGAAACCC
 25 TTGTATTCTTGTGAAAATGAACAGAATAATTGGATTAAAGCCTGAAGGAGTGCCA
 AGGATAGATTGTGTTTCAAAGAATGAAGATATACCAAATGTAGCAGTTTATCCTC
 ATAATGGAATGATAGACTTAAAATATTTCCCATATTATGGGAAAAAACTGCATGT
 TGGGTATCTACAGCCATTGGTTGCTGTTCAAGTCAGCTTTGCTCCTAACAACT
 GGGAAAGAAGTAACAGTTGAGTGCAAGATTGATGGATCAGCCAACCTAAAAAGT
 30 CAGGATGATCGTGACAAGTTTTTGGGACGAGTTATGTTCAAATCACAGCACGTG
 CATAGTATGAGTAGGATATCTCCACAGAGTAAATGTTGTGTTGTCTGTCTTCATTT
 TGTAACAGCTGGACCTTCCATTCTAGAATTATGAGACCACCTTGGAGAAAGGTGT
 GTGGTACATGACATTGGGTTACATCATAACGTGCTTCCAGATCATAGTGTTCAGT
 GTCCTCTGAAGTAACTGCCTGTTGCCTCTGCTGCCCTTGAACCAGTGTACAGTCG
 35 CCAGATAGGGACCGGTGAACACCTGATTCCAAACATGTAGGATGGGGGTCTTGT
 CCTCTTTTTATGTGGTTTAATTGCCAAGTGTCTAAAGCTTAATATGCCGTGCTATG
 TAAATATTTTATGGATATAACAACGTGCATATTTGATGTCAACAGAGTTTATAGG
 GATAAAATGGTACCCGGCCAACATCAAGTGACTTTATAGCTGCAAGAAATGTGG
 TATGTGGAGAAGTTCTGTATGTGAGCTTCCGTTATCTACCTGGCCCCCTGTAGGAA
 40 TTCCAGTTTGAGACCCCCTACTGCATACGAACCTCTGGAATCCTACAAATTCTAC
 AGGCAGCTGTGGACTGGGAATCTCAGAACCAAA

SEQ ID NO: 342

>2959 BLOOD 977665.8 U76421 g2039299 Human dsRNA adenosine deaminase

45 DRADA2b (DRADA2b) mRNA, complete cds. 0

GAGCCCTGGGCGGGGCGGCTGTTGGGGGGAATGGGTTTCGGGGTGCCTTGGGCAG
 GGGGCTACTGGGGGCGGCTGTGAGGAGGAGTTGGGTTTCAGGGAGCCCTGGGCG
 GGGTGGCTGTCAGGGGGAACCTGGGTTCCGGGAGCCCTGGGCGGGGCGGGGGG
 GGCTGTAGGAAGGAACTGGTTTCGGGGAGCCCTGGGCGGGGCGGCTGTGGGGAG

GAAGGTGACGTGCAGGGGACCAGAGGCTCTGCACTGCTCCTAGGACAGCTCATC
TGTAATCAGAAAAAATAAACAAAATACAGAACGCTGACTCCTCCGTGAGACA
GATCGGGGACCTTAGCACTTTAATCCCTCCCTTCTGAGCGCTCGGTGTGCACTTTT
AGACTATAGCTGTTTCATTGACGTGTCACTCTCCATCCAGTGTCTTGATGTGGCT
5 TTTAGAGACTTAGCAGAAAATTCGACACAAGCAGGAACCTTGATTTTTTAAGAAA
AAATATTACATTTTGAGGACATTTTGACAAAGTAGGGGAAGAGAGGGGCTTCTGTTG
TTTTGTTTTGTTTTGTTTTGTTAACTAAACCTGAAGTATTAATTCCACAAAGACAC
TGTCCTCAGGACCACTCAGGTACAGCTCTGCCAGGGACAGAGTCCTGCTAGTGG
GAGGTCTCAGGTGGGGCGGTGTGTTCTGTGCCATGAGGCAGCGACAGGTCCAGA
10 TGGATGTCGTCACCACCTTCCTCAGCTCTCATCACCTGGTTCGTACGCCAGGCCCA
CCTCTTCCCAGCAAGGGACGCCAAAGAACTGCAGTTTTTATTCTGAGTCTTAATT
TAACTTTTTCATCATCTTTTCCTATTTTGGAGAATTTTTTGTAAATAAAAGCAATTA
TTTTAAATGTGCAAGCCAGTATCTCACAAGGCATGGATTTCTGTGGAATTTATT
TTTATTCAAATAACCATATTTATCTCCAGGCTGTGGAATCGCCACTTTCTTTGTGA
15 AGACAGTGTCTCTCCTTGTAATCTCACACAGGTACACTGAGGAGGGGACGGCTCC
GTCTTCACATTGTGCACAGATCTGAGGATGGGATTAGCGAAGCTGTGGAGACTGC
ACATCCGGACCTGCCCATGTCTCAAAACAAACACATGTACAGTGGCTCTTTTTCC
TTCTCAAACACTTTACCCCAAGAAGCAGGTGGTCTGCCCCAGGCATAAAGAAGGA
AAATTGGCCATCTTTCCACCTCTAAATTCTGTAAAATTATAGACTTGCTCAAAA
20 GATTCCTTTTGATCATCCCCACGCTGTGTAAAGTGGAAGGGCATTGTGTTCCGTG
TGTGTCCAGTTTACAGCGTCTCTGCCCCCTAGCGTGTTTTGTGACAATCTCCCTGG
GTGAGGAGTGGGTGCACCCAGCCCCGAGGGCCAGTGGTTGCTCGGGGCCCTCCGT
GTGAGTTCTAGTGTTCACTTGATGCCGGGGGAATAGAATTAGAGAAAACCTGTGACC
TGCCGGGTTCAGGGACTGGTGGAGGTGGATGGCAGGTCCGACTCGACCATGAC
25 TTAGTTGTAAGGGTGTGTCGGCTTTTTCAGTCTCATGTGAAAATCCTCCTGTCTCT
GGCAGCACTGTCTGCACTTTCTTGTTTACTGTTTGAAGGGACGAGTACCAAGCCA
CAAGAACACTTCTTTTGGCCACAGCATAAGCTGATGGTATGTAAGGAACCGATG
GGCCATTAAACATGAACCTGAACGGTTAAAAGCACAGTCTATGGAACGCTAATGG
AGTCAGCCCCTAAAGCTGTTTGCTTTTTTCAGGCTTTGGATTACATGCTTTTAATTT
30 GATTTTAGAATCTGGACACTTTCTATGAATGTAATTCGGCTGAGAAACATGTTGC
TGAGATGCAATCCTCAGTGTCTCTGTATGTAAATCTGTGTATACACCACACGTT
ACAACCTGCATGAGCTTCCTCTCGCACAAGACCAGCTGGAACCTGAGCATGAGACG
CTGTCAAATACAGACAAAGGATTTGAGATGTTCTCAATAAAAAGAAAATGTTTC
ACT

35

SEQ ID NO: 343

>2971 BLOOD 198145.6 U51205 g1730283 Human COP9 homolog (HCOP9) mRNA,
complete cds. 0

CGGGCGCGACGCCTGTAGGGACAGTCTGGGGTTTGGCTGTCCGGACGGTGCAGC
40 GGCGAGGCCCGCCGCGAAGATGCCAGTGGCGGTGATGGCGGAAAGCGCCTTTAG
TTTCAAAAAGTTGCTGGATCAGTGCAGAAACCAGGAGCTCGAGGCCCTGGAGG
AATTGCTACACCCCCAGTGTATGGTCAGCTTCTAGCTTTATATTTGCTCCATAATG
ACATGAATAATGCAAGATATCTTTGGAAAAGAATACCACCTGCTATAAAATCTGC
AAATTCTGAACCTTGGGGGAATTTGGTCAGTAGGACAAAGAATCTGGCAGAGAGA
45 TTTCCCTGGGATCTATAACAACCATCAACGCTCACCAGTGGTCTGAGACGGTCCAG
CCAATTATGGAAGCACTTAGAGATGCAACAAGGAGACGCGCCTTTGCCCTGGTCT
CTCAAGCGTATACTTCAATCATCGCCGATGATTTTGCAGCCTTTGTTGGACTTCCT
GTAGAAGAGGCTGTGAAAGGCATATTAGAACAAGGATGGCAAGCTGATTCCACC
ACAAGAATGGTTCTGCCAGAAAGCCAGTTGCAGGGGGCCCTGGATGTTTCCTTTA

ACAAGTTTATTCCCTTATCAGAGCCTGCTCCAGTTCCCCCAATACCCAATGAACA
 GCAGTTAGCCAGACTGACGGATTATGTGGCTTTCCTTGAAAAGTGAATTTATCACT
 CTGAGTTCAAGATTTCATCTTCAGAATCCTGTATACTGACAAACGTAGAAATGTAA
 AGTTTGTATTTTCAATTTATTGGATGGCTTAAGCACCTCAGCATTCTTACTATGT
 5 GATAAAATACATATAGAATATAAGATATACTATATACATTTTGTCCATAAACGTT
 ATGCTGAATAGTTGTTGAAACAGTTCTCATTTTGTAGTATTTAATAATCTGGATGG
 AGCCTGTCAGTATTACAGTTAGTTTTCTAGTGACTCATAAAATAAGATTTCTGTT
 TCATGTAGAATAGTGTGTTGTCAACTGTCTTTCTCTGTCCCAGCACATGCCGTA
 CTTATATGTACCATTTGGTTGATAATTATAATGATTCATTTGGACTTGAAGAAAGA
 10 TTGTCCCCAGGCACAGTATCTGAATCACTGGGGATTATGATTCACCTCTTTGGA
 GAACATGCTCTCTTTTACCCCCCACCTCCTGAGAGCCACTAATGTAAGATACAG
 AAACATAGCTGAGGAACAAATAGACCATTTCCTATACTAAACCAGTTTGTAACTT
 TAGATTTTTTCCAATAGTGTGAGTATATCCATTGCTGGCAGTGGAGGGCTTGCCA
 TGAAAATGCAACTTATTTAAGACATTTATGAGACATATTAAGTTGTGCTGTCGCC
 15 TTTTAGAAGGAGAACTTAAGTGTGGAATGCATTATATGGGCAAAGAAGCTATG
 AAGATACATGATACACTTTGTACAACATCTCTGCAGCCCATTGGTTGCTTATATTT
 ATCGCTTGGCTCAAGTTCTGCCCTTTGGAGAAATACTGAGCAAGTCTTTCATTCTC
 TGTGTGACAGCCCTCTGAATATTTGAAGTTGTTTGTGTAAGTTAAGTTATAACA
 GCCCTTAGTTTCACTTCTGCATTTGTTCAATAAATATTTAACTGAATTCTTCAA
 20 TTATTTTCATCTAAGATAGTTTCTGGAAATTTCACTCTCGATCTTTCTGTGGACACA
 ATCTATTTTGTCTATTGTGTCTATATGAATCTCTTAAGTAGAAATGAGTTGTATGGT
 GAATCTGTGTAGTGATAATTATATAATTTATTTTGAATGCA

SEQ ID NO: 344

25 >2986 BLOOD Hs.75260 grn|UG|Hs#S269695 H.sapiens mitogen inducible gene mig-2,
 complete CDS /cds=(0,2164) /gb=Z24725 /gi=505032 /ug=Hs.75260 /len=3270
 CAAAAAGTGTGTGGAAGGTGGATTGAGGGAGCGGGACCCCGCGGGACCCGA
 GGGGGCGGCAGGCGGGGAACGGGGAGTCAGCCCGCGCTGTGTCTCGGGGCGGCG
 CGGCAGGAAGGAGCCATGGCTCTGGACGGGATAAGGATGCCAGATGGCTGCTAC
 30 GCGGACGGGACGTGGGAACTGAGTGTCCATGTGACGGACCTGAACCGCGATATC
 ACCCTGAGAGTGACCGGCGAGGTGCACATTGGAGGCGTGATGCTTAAGCTGGTG
 GAGAACTCGATGTAAAAAAGATTGGTCTGACCATGCTCTCTGGTGGGAAAAG
 AAGAGAACTTGGCTTCTGAAGACACATTGGACCTTAGATAAGTATGGTATTCAGG
 CAGATGCTAAGCTTCAGTTCACCCCTCAGCACAACTGCTCCGCCTGCAGCTTCC
 35 CAACATGAAGTATGTGAAGGTGAAAGTGAATTTCTCTGATAGAGTCTTCAAAGCT
 GTTTCTGACATCTGTAAGACTTTTAATATCAGACACCCCGAAGAAGCTTCTCTCTT
 AAAGAAACCCAGAGATCCAACAAAGAAAAAAGAAGAAGCTAGATGACCAAGT
 CTGAAGATGAGGCACCTGAATTAGAGGGGCTCTTATCACTCCTGGATCAGGAA
 GTATATATTCAAGCCCAGGACTGTATAGTAAACAATGACCCCACTTATGATGC
 40 TCATGATGGAAGCCCCTTGTACCAACTTCTGCTTGGTTTGGTGACAGTGCTTTGT
 CAGAAGGCAATCCTGGTATACTTGCTGTCAACCAATCACGTCAACAGAAAT
 CTTGGCAAAAATGTTCAAGCCTCAAGCTCTTCTTGATAAAGCAAAAATCAACCAA
 GGATGGCTTGATTCTCAAGATCTCTCATGGAACAAGA\TGTGAAGGAAAATGAG
 GCCTTGCTGCTCCGATTCAAGTATTACAGCTTTTTTGATTTGAATCCAAAGTATGA
 45 TGCAATCAGAATCAATCAGCTTTATGAGCAGGCCAAATGGGCCATTCTCCTGGAA
 GAGATTGAATGCACAGAAGAAGAAATGATGATGTTTGCAGCCCTGCAGTATCAT
 ATCAATAAGCTGTCAATCATGACATCAGAGAATCATTTGAACAACAGTGACAAA
 GAAGTTGATGAAGTTGATGCTGCCCTTTCAGACCTGGAGATTACTCTGGAAGGGG
 GTAAAACGTCAACAATTTTGGGTGACATTACTTCCATTCTGAACTTGCTGACTA

CATTAAAGTTTTC AAGCCAAAAAAGCTGACTCTGAAAGGTTACAAACAATATTG
 GTGCACCTTCAAAGACACATCCATTTCTTGTTATAAGAGCAAAGAAGAATCCAGT
 GGCACACCAGCTCATCAGATGAACCTCAGGGGATGTGAAGTTACCCAGATGTA
 AACATTTCAAGGCCAAAAATTTAACATTAAACTCCTGATTCCAGTTGCAGAAGGCA
 5 TGAATGAAATCTGGCTTCGTTGTGACAATGAAAAACAGTATGCACACTGGATGG
 CAGCCTGCAGATTAGCCTCCAAAGGCAAGACCATGGCGGACAGTTCTTACAACCT
 AGAAGTTCAGAAATATTCTTTCTTTCTGAAGATGCAGCATTAAACCCAGATCCT
 CAGTTAATAACCAGAGCAGATCACGACTGATATAACTCCTGAATGTTTGGTGTCTC
 CCCGCTATCTAAAAAAGTATAAGAACAAGCAGATAACAGCGAGAATCTTGAGG
 10 CCCATCAGAATGTAGCTCAGATGAGTCTAATTGAAGCCAAGATGAGATTTATTCA
 AGCTTGGCAGTCACTACCTGAATTTGGCATCACTCACTTCATTGCAAGGTTCCAA
 GGGGGCAAAAAAGAAGAACTTATTGGAATTGCATACAACAGACTGATTTCGGATG
 GATGCCAGCACTGGAGATGCAATTAACATGGCGTTTCAGCAACATGAAACAG
 TGGAATGTCAACTGGGAAATCAAAATGGTCACCGTAGAGTTTGCAGATGAAGTA
 15 CGATTGTCTTTCATTTGTACTGAAGTAGATTGCAAAGTGGTTCATGAATTCATTG
 GTGGCTACATATTTCTCTCAACACGTGCAAAAGACCAAAACGAGAGTTTAGATG
 AAGAGATGTTCTACAAACTTACCAGTGGTTGGGTGTGAATAGAAATACTGTTTAA
 TGAAACTCCACGGCCATAACAATATTTAACTTTAAAAGCTGTTTGTATATGCTG
 CTTAATAAAGTAAGCTTGAAATTTATCATTTTATCATGAAAACCTCTTTGCCTTAC
 20 CAGACCAGTTAATATGTGCACTAAACAAGCAGACTATTAATCTATCATGTTATG
 ATATAATAAAGTTGAATTTGGCACACATTCTTAGGGCCATGAATTGAAAACCTGA
 AATAGTGGGCAAATCAGGAACAAACCATCACTGATTACTGATTTAAGCTAGCC
 AAAGTAAAGAAACAAGCCATCTATTTTAAAGCTATCCAGGGCTTAACCTATATG
 AACTCTATTTATCATGTCTAATGCATGTGATTTAATGTATGTTTAAATTTGATATCA
 25 TGTTTTAAAAATATCCTACTTCTGGTAGCCATTTAATTCTCCCTACCCCCAAAT
 AAATCAGGCATGCAGGAGGCCTGATATTTAGTAATGTCATTGTGTTTGACCTTGA
 AGGAAAATGCTATTAGTCCGTCGTGCTTNATTTGTTTTGTCTTGAATAAGCATG
 TTATGTATATNGTCTCGTGTTTTTATTTTTACACCATATTGTATTACACTTTTAGTA
 TTCACCAGCATAANCACTGTCTGCCTAAAATATGCAACTCTTGCATTACAATAT
 30 GAAGTAAAGTTCTATGAAGTATGCATTTTGTGTAACTAATGTAAAAACACAAATT
 TTATAAAATTGTACAGTTTTTTTAAAACTACTCACAACCTAGCAGATGGCTTAAAT
 GTAGCAATCTCTGCGTTAATTAATGCCTTTAAGAGATATAATTAACGTGCAGTT
 TTAATATCTACTAAATTAAGAATGACTTCATGATGATCATGATTTGCCACAATGTC
 CTTAACTCTAATGCCTGGACTGGCCATGTTCTAGTCTGTTGCGCTGTTACAATCTG
 35 TATTGGTGCTAGTCAGAAAAATTCCTAGCTCACATAGCCCCAAAAGGGTGCGAGGG
 AGAGGTGGATTACCAGTATTGTTCAATAATCCATGGTTCAAAGACTGTATAAATG
 CATTTTATTTTAAATAAAAGCAAACTTTTATTAAA

SEQ ID NO: 345

40 >2992 BLOOD 1329299.6 AF053944 g3288915 Human aortic carboxypeptidase-like protein
 ACLP mRNA, complete cds. 0
 GAGGACTATGAGGACTGTGAGTAGGGTCTGCCAGCCCCACCTGGGTTCGGACCC
 CTGGCCTGGGGGATGTGCCAATGGGCCCATCCAGCCTTGGGCCCCACTCTGAGC
 CAGCCTCCCCCTCAGTTGAGTACATTCGGCGCCAGAAGCAACCCAGGCCACCCCC
 45 AAGCAGAAGGAGGAGGCCCCGAGCGGGTCTGGCCAGACCCCCCTGAGGAGAAGG
 CCCCCGCCCCAGCCCCGAGGAGAGGATTGAGCCTCCTGTGAAGCCTCTGCTGCC
 CCGCTGCCCCCTGACTATGGTGATGGTTACGTGATCCCCAACTACGATGACATG
 GACTATTACTTTGGGCCTCCTCCGCCCCAGAAGCCCGATGCTGAGCGCCAGACGG
 ACGAAGAGAAGGAGGAGCTGAAGAAACCCAAAAAGGAGGACAGCAGCCCCAAG

GAGGAGACCGACAAGTGGGCAGTGGAGAAGGGCAAGGACCACAAAGAGCCCCG
AAAGGGCGAGGAGTTGGAGGAGGAGTGGACGCCTACGGAGAAAGTCAAGTGTC
CCCCATTGGGATGGAGTCACACCGTATTGAGGACAACCAGATCCGAGCCTCCTC
CATGCTGCGCCACGGCCTGGGGGCACAGCGCGGCCGGCTCAACATGCAGACCGG
5 TGCCACTGAGGACGACTACTATGATGGTGCGTGGTGTGCCGAGGACGATGCCAG
GACCCAGTGGATAGAGGTGGACACCAGGAGGACTACCCGGTTCACAGGCGTCAT
CACCCAGGGCAGAGACTCCAGCATCCATGACGATTTTGTGACCACCTTCTTCGTG
GGCTTCAGCAATGACAGCCAGACATGGGTGATGTACACCAACGGCTATGAGGAA
ATGACCTTTCATGGGAACGTGGACAAGGACACACCCGTGCTGAGTGAGCTCCCA
10 GAGCCGGTGGTGGCTCGTTTCATCCGCATCTACCCACTCACCTGGAATGGCAGCC
TGTGCATGCGCCTGGAGGTGCTGGGGTGTCTGTGGCCCCCTGTCTACAGCTACTA
CGCACAGAATGAGGTGGTGGCCACCGATGACCTGGATTTCCGGCACCACAGCTA
CAAGGACATGCGCCAGCTCATGAAGGTGGTGAACGAGGAGTGCCCCACCATCAC
CCGCACTTACAGCCTGGGCAAGAGCTCACGAGGCCTCAAGATCTATGCCATGGA
15 GATCTCAGACAACCCTGGGGAGCATGAACTGGGGGAGCCCGAGTTCCGCTACAC
TGCTGGGATCCATGGCAACGAGGTGCTGGGCCGAGAGCTGTTGCTGCTGCTCATG
CAGTACCTGTGCCGAGAGTACCGCGATGGGAACCCACGTGTGCGCACGCTGGTG
CAGGACACACGCATCCACCTGGTGGCCTCACTGAACCCTGATGGCTACGAGGTG
GCAGCGCAGATGGGCTCAGAGTTTGGGAACTGGGCGCTGGGACTGTGGACTGAG
20 GAGGGCTTTGACATCTTTGAAGATTTCCCGGATCTCAACTCTGTGCTCTGGGGAG
CTGAGGAGAGGAAATGGGTCCCCTACCGGGTCCCCAACAATAACTTGCCCATCC
CTGAACGCTACCTTTCGCCAGATGCCACGGTATCCACGGAGGTCCGGGCCATCAT
TGCCTGGATGGAGAAGAACCCTTCGTGCTGGGAGCAAATCTGAACGGGGCGA
GCGGCTAGTATCCTACCCCTACGATATGGGCCGCACGCCTACCCAGGAGCAGCTG
25 CTGGCCGCAGCCATGGCAGCAGCCCGGGGGGAGGATGAGGACGAGGTCTCCGAG
GCCCAGGAGACTCCAGACCACGCCATCTTCCGGTGGCTTGCCATCTCCTTCGCCT
CCGCACACCTCACCTTGACCGAGCCCTACCGCGGAGGCTGCCAAGCCCAGGACT
ACACCGGCGGCATGGGCATCGTCAACGGGGCCAAGTGGAACCCCCGGACCGGGA
CTATCAATGACTTCAGTTACCTGCATACCAACTGCCTGGAGCTCTCCTTCTACCTG
30 GGCTGTGACAAGTTCCTCATGAGAGTGAGCTGCCCCGCGAGTGGGAGAACAAC
AAGGAGGCGCTGCTCACCTTCATGGAGCAGGTGCACCGTGGCATTAAAGGGGGTG
GTGACGGACGAGCAAGGCATCCCCATTGCCAACGCCACCATCTCTGTGAGTGGC
ATTAATCACGGCGTGAAGACAGCCAGTGGTGGTGATTACTGGCGAATCTTGAAC
CCGGGTGAGTACCGCGTGACAGCCACGCGGAGGGCTACACCCCGAGCGCCAAG
35 ACCTGCAATGTTGACTATGACATCGGGGCCACTCAGTGCAACTTCATCCTGGCTC
GCTCCAATGGAAGCGCATCCGGGAGATCATGGCCATGAACGGGAACCGGCCTA
TCCCACACATAGACCCATCGCGCCCTATGACCCCCAACAGCGACGCCTGCAGCA
GCGACGCCTACAACACCGCCTGCGGCTTCGGGCACAGATGCGGCTGCGGCGCCT
CAACGCCACCACCACCTAGGCCCCACACTGTGCCTCCCACGCTGCCCCCTGCC
40 CCTGCCACCACCCTGAGCACTACCATAGAGCCCTGGGGCCTCATACCGCCAACCA
CCGCTGGCTGGGAGGAGTCGGAGACTGAGACCTACACAGAGGTGGTGACAGAGT
TTGGGACCGAGGTGGAGCCCGAGTTTGGGACCAAGGTGGAGCCCGAGTTTGAGA
CCCAGTTGGAGCCTGAGTTTGGAGCCAGCTGGAACCCGAGTTTGAGGAAGAGG
AGGAGGAGGAGAAAGAGGAGGAGATAGCCACTGGCCAGGCATTCCCCTTCACA
45 ACAGTAGAGACCTACACAGTGAACCTTGGGGACTTCTGAGATCAGCGTCTTACCA
AGACCCAGCCCAACTCAAGCTACAGCAGCAGCACTTCCCAAGCCTGCTGACCA
CAGTCACATCACCCATCAGCACATGGAAGGCCCTGGTATGGACACTGAAAGGA
AGGGCTGGTCTGCCCCCTTGAGGGGGTGCAAACATGACTGGGACCTAAGAGCC
AGAGGCTGTGTAGAGGCTCCTGCTCCACCTGCCAGTCTCGTAAGAGATGGGGTTG

CTGCAGTGTGGAGTAGGGGCAGAGGGAGGGAGCCAAGGTCACTCCAATAAAAC
AAGCTCATGGCAAAAAAAAAA

SEQ ID NO: 346

- 5 >3030 BLOOD GB_AA486221 gi|2216437|gb|AA486221|AA486221 ab35e07.s1 Stratagene
HeLa cell s3 937216 Homo sapiens cDNA clone IMAGE:842820 3', mRNA sequence
[Homo sapiens]
CTTTATTGGGAAACGTAAGACTTGGGTACATCAAATAAAACCAATTTCTGGGGGA
AAAAATCAAAACCCA
10 CAATAAAAAAAAAAAGTTAACTGTCTGGGCCACAGCAGAACCCAAAGAACATAT
TCGTATAAT

SEQ ID NO: 347

- >3033 BLOOD 371542.10 M93056 g188621 Human monocyte/neutrophil elastase inhibitor
mRNA sequence. 0
15 CTCACTTCTGCTTGCACCTTAGGCGACCTCGGGAGCTCGGACTCCTACGCAGTCAC
CGGGAAGGGCCGCCGCCCGCCGCGGCTGCTGGCCCGGGTGACACTTCCGCCT
GCTATAAGAGCAGCGGCCCTCGGTGCCTCCTTCCTGACCTCGCACCCAGCTCGGA
GCCCCGAGCGTGCCTCGGGCGGCCTGTCGGTTTTCACCATGGAGCAGCTGAGCTC
20 AGCAAACACCCGCTTCGCCTTGGACCTGTTGCCTGGCGTTGAGTGAGAACATCC
GGCTGGAAACATCTTCATCTCTCCCTTCAGCATTTTCATCTGCTATGGCCATGGTTT
TCTGGGGGACCAGAGGTAACACGGCAGCAACAGCTGTCCAAGACTTTCCATTTCAA
CACGGTTGAAGAGGTTTCATTCAAGATTCAGAGTCTGAATGCTGATATCAACAAA
CGTGGAGCGTCTTATATTCTGAAACTTGCTAATAGATTATATGGAGAGAAAACTT
25 ACAATTTCTTCCTGAGTTCTTGGTTTCGACTCAGAAAACATATGGTGCTGACETG
GCCAGTGTGGATTTTCAGCATGCCTCTGAAGATGCAAGGAAGACCATAAACCAG
TGGGTCAAAGGACAGACAGAAGGAAAAATTCGGAAGTGTGGCTTCGGGCATG
GTTGATAACATGACCAAACCTGTGCTAGTAAATGCCATCTATTTCAAGGGAACT
GGAAGGATAAATTCATGAAAGAAGCCACGACGAATGCACCATTGAGATTGAATA
30 AGAAAGACAGAAAACTGTGAAAATGATGTATCAGAAAGAAAAAATTTGCATATG
GCTACATCGAGGACCTTAAGTGCCGTGTGCTGGAAGTGCCTTACCAAGGCGAGG
AGCTCAGCATGGTCATCCTGCTGCCGGATGACATTGAGGACGAGTCCACGGGCCT
GAAGAAGATTGAGGAACAGTTGACTTTGAAAAGTTGCATGAGTGGACTAAACC
TGAGAATCTCGATTTTCATTGAAGTTAATGTCAGCTTGCCCAGGTTCAAACCTGGAA
35 GAGAGTTACACTCTCAACTCCGACCTCGCCCGCCTAGGTGTGCAGGATCTCTTTA
ACAGTAGCAAGGCTGATCTGTCTGGCATGTCAGGAGCCAGAGATATTTTATATC
AAAAATTGTCCACAAGTCATTTGTGGAAGTGAATGAAGAGGGAACAGAGGCGGC
AGCTGCCACAGCAGGCATCGCAACTTTCTGCATGTTGATGCCCGAAGAAAATTC
ACTGCCGACCATCCATTCCTTTTCTTTATTCGGCATAATTCCTCAGGTAGCATCCT
40 ATTCTTGGGGAGATTTTCTTCCCCTTAGAAGAAAGAGACTGTAGCAATACAAAAA
TCAAGCTTAGTGCTTTATTACCTGAGTTTTTAATAGAGCCAATATGTCTTATATCT
TTACCAATAAAACCACTGTTTCAGAAAAA

SEQ ID NO: 348

- 45 >3050 BLOOD 243794.24 Y00345 g35569 Human mRNA for polyA binding protein. 0
CCTTCTCCCCGGCGGTTAGTGCTGAGAGTGCGGAGTGTGTGCTCCGGGCTCGGAA
CACACATTTATTATTAATAAAATCCAAAAAAATCTAAAAAAATCTTTTAAAAAAC
CCCAAAAAAATTTACAAAAATCCGCGTCTCCCCCGCCGGAGACTTTTATTTTTT
TTCTTCCTCTTTTATAAAATAACCCGGTGAAGCAGCCGAGACCGACCCGCCCGCC

CGCGGCCCCGACGACGCTCCAAGAAGGAACCAAGAGACCGAGGCCTTCCCGCTG
CCCGGACCCGACACCGCCACCCTCGCTCCCCGCCGGCAGCCGGCAGCCAGCGGC
AGTGGATCGACCCCGTTCTGCGGCCGTTGAGTAGTTTTCAATTCCGGTTGATTTTT
GTCCCTCTGCGCTTGCTCCCCGCTCCCTCCCCCGGCTCCGGCCCCCAGCCCCGG
5 CACTCGCTCTCCTCCTCTCACGGAAGGTGCGGCGCTGTAGAAGTCCGACGCCGT
GCCGAGATGAACCCAGTGCCCCAGCTACCCCATGGCCTCGCTCTACGTGGGGG
ACCTCCACCCCGACGTGACCGAGGCGATGCTCTACGAGAAGTTCAGCCCCGGCCG
GGCCCATCCTCTCCATCCGGGTCTGCAGGGACATGATCACCCGCCGCTCCTTGGG
CTACGCGTATGTGAACTTCCAGCAGCCGGCGGACGCGGAGCGTGCTTTGGACAC
10 CATGAATTTTGATGTTATAAAGGGCAAGCCAGTACGCATCATGTGGTCTCAGCGT
GATCCATCACTTCGCAAAAGTGGAGTAGGCAACATATTCATTAATAATCTGGAC
AAATCCATTGATAATAAAGCACTGTATGATACATTTTCTGCTTTTGGTAACATCCT
TTCATGTAAGGTGGTTTGTGATGAAAATGGTTCCAAGGGCTATGGATTTGTACAC
TTTGAGACGCGAGGAAGCAGCTGAAAGAGCTATTGAAAAAATGAATGGAATGCTC
15 CTAAATGATCGCAAGTATTTGTTGGACGATTTAAGTCTCGTAAAGAACGAGAA
GCTGAACTTGGAGCTAGGGCAAAAGAATTCACCAATGTTTACATCAAGAATTTTG
GAGAAGACATGGATGATGAGCGCCTTAAGGATCTCTTTGGCAAGTTTGGGCCTGC
CTTAAGTGTGAAAGTAATGACTGATGAAAGTGGAAAATCCAAAGGATTTGGATT
TGTAAGCTTTGAAAGGCATGAAGATGCACAGAAAGCTGTGGATGAGATGAACGG
20 AAAGGAGCTCAATGGAAAACAAATTTATGTTGGTCGAGCTCAGAAAAAGGTGGA
ACGGCAGACGGAACCTTAAGCGCAAATTTGAACAGATGAAACAAGATAGGATCAC
CAGATAACAGGGTGTTAATCTTTATGTGAAAAATCTTGATGATGGTATGATGAT
GAACGTCTCCGAAAGAGTTTCTCCATTTGGTACAATCACTAGTGCAAAGGTTA
TGATGGAGGGTGGTCGCAGCAAAGGGTTTGGTTTTGTATGTTTCTCTCCCCAGA
25 AGAAGCCACTAAAGCAGTTACAGAAATGAACGGTAGAATTGTGGCCACAAAGCC
ATTGTATGTAGCTTTAGCTCAGCGCAAAGAAGAGCGCCAGGCTCACCTCACTAAC
CAGTATATGCAGAGAATGGCAAGTGTACGAGCTGTTCCCAACCCTGTAATCAACC
CCTACCAGCCAGCACCTCCTTCAGGTTACTTCATGGCAGCTATCCCACAGACTCA
GAACCGTGCTGCATACTATCCTCCTAGCCAAATTGCTCAACTAAGACCAAGTCCT
30 CGCTGGACTGCTCAGGGTGCCAGACCTCATCCATTCCAAAATATGCCCGGTGCTA
TCCGCCAGCTGCTCCTAGACCACCATTTAGTACTATGAGACCAGCTTCTTCACA
GGTTCCACGAGTCATGTCAACACAGCGTGTGCTAACACATCAACACAGACAAT
GGGTCCACGTCTGCTGAGCTGCAGCCGCTGCAGCTACTCCTGCTGTCCGCACCGTT
CCACAGTATAAATATGCTGCAGGAGTTCGCAATCCTCAGCAACATCTTAATGCAC
35 AGCCACAAGTTACAATGCAACAGCCTGCTGTTTCATGTACAAGGTCAGGAACCTTT
GACTGCTTCCATGTTGGCATCTGCCCCCTCTCAAGAGCAAAGCAAATGTTGGGT
GAACGGCTGTTTCCTCTTATTCAAGCCATGCACCCTACTCTTGCTGGTAAAATCAC
TGGCATGTTGTTGGAGATTGATAATTCAGAACTTCTTCATATGCTCGAGTCTCCA
GAGTCACTCCGTTCTAAGGTTGATGAAGCTGTAGCTGTACTACAAGCCCACCAAG
40 CTAAAGAGGCTGCCCAGAAAGCAGTTAACAGTGCCACCGGTGTTCCAACGTGTTA
AAATTGATCAGGGACCATGAAAAAGAACTTGTGCTTCACCGAAGAAAAATATCT
AAACATCGAAAAACTTAAATATTATGAAAAAAAACATTGCAAAATATAAAATA
AATAAAAAAAGGAAAGGAAACTTTGAACCTTATGTACCGAGCAAATGCCAGGTC
TAGCAAACATAATGCTAGTCCTAGATTACTTATTGATTTAAAAACAAAAAACAC
45 AAAAAAATAGTAAATATAAAAAACAAATTAATGTTTTATAGACCCTGGGAAAAA
GAATTTTCAGCAAAGTACAAAAATTTAAAGCATTCTTTCTTTAATTTTGTAATTC
TTTACTGTGGAATAGCTCAGAATGTCAGTTCTGTTTTAAGTAACAGAATTGATAA
CTGAGCAAGGAAACGTAATTTGGATTATAAAATTCTTGCTTTAATAAAAAATTCCT
TAAACAGTGCACGGATTTGCTTTTTTTCAAAGTCTTTATAATTGCCATGCATAAAT

5

>3052 BLOOD 988653.1 X52541 g31129 Human mRNA for early growth response protein 1 (hEGR1). 0

10

GATTTTGGATAAATCATTTTCAGTATCATCTCCATCATATGCCTGACCCCTTGCTCC
CTTCAATGCTAGAAAATCGAGTTGGCAAATGGGGTTTGGGCCCCCTCAGAGCCCT
GCCCTGCACCCTTGTACAGTGTCTGTGCCATGGATTTCGTTTTCTTGGGGTACTC
TTGATGTGAAGATAATTTGCATATTCTATTGTATTATTTGGAGTTAGGTCCTCACT
5 TGGGGGAAAACCAAAAAGGAAAAGCCAAGCAAACCAATGGTGATCCTCTATTT
TGTGATGATGCTGTGACAATAAGTTTGAACCTTTTTTTTTTGAACAGCAGTCCCA
GTATTCTCAGAGCATGTGTCAGAGTGTGTTCCGTTAACCTTTTTTGTAATACTGC
TTGACCGTACTCTCACATGTGGCAAATATGGTTTGGTTTCTTTTNTTTTTTTTT
TGAAAGTGTTTTTCTTCGTCTTTTGGTTTAAAAAGTTTCACGTCTTGGTGCCTTT
10 TGTGTGATGCGCCTTGCTGATGGCTTGACATGTGCAATTGTGAGGGACATGCTCA
CCTCTAGCCTTAAGGGGGGCGAGGGAGTGATGATTTGGGGGAGGCTTTGGGAGCA
AAATAAGGAAGAGGGCTGAGCTGAGCTTCGGTCTCCAGAATGTAAGAAAACAA
AATCTAAAACAAAATCTGAACCTCTCAAAGTCTATTTTTTTAACTGAAAATGTAA
ATTTATAAATATATTCAGGAGTTGGAATGTTGTAGTTACCTACTGAGTAGGCGGC
15 GATTTTTGTATGTTATGAACATGCAGTTCATTATTTTGTGGTTCTATTTTACTTTGT
ACTTGTGTTTGCTTAAACAAAGTGACTGTTTGGCTTATAAACACATTGAATGCGC
TTTATTGCCCATGGGATATGTGGTGTATATCCTTCCAAAAAATTAAACGAAAAT
AAAGTAGCTGCGATTGGGTATGTGTTTCTGGGTAGGGGAAGGACTCTGCCCTA
TTGAGGGCTGTGAGGTTTTCTGAAGACTTGGCCTTAGAGATACAAGGATCCTCC
20 AGCCAGAGTCAGGCCCACTGTGTGAAACTGGAGTTCGTTATTTATGAGGACTGAG
TATGGGNNN
NN
NN
NNNTTC
25 TTGATAATGGGCCTGTTCTCTTCAGTCTGTTGGGCTGAAGCTTACCTTGGTTAG
CTAAAGCCAAGAAAGGCAAGAGTTAGGGCTGGGACATGTGTGGCCAAAGGCAGT
GTTACTCTCCTGGCATCAAATGTTGGGCCAGTCCCGTCCCCACCTCTACTCAGG
GTTGGAAGAACCCATGATCTTGGGAATCCCTGCCATGTGCAGTTAGAGGAGGTAA
GAAGTAGGCACAAGGCCTTTAGGGGAACAGTAACAATGCTGGGGCCGACTCAGC
30 CTCTCCCTCCCATTTCCCCAGGTCCCCAGCAACTTGAGGGCATCAAAGAAGCCTAG
ACGAGGTAAAGGCCAGTTCTCAAGCCAAGAATCCTTCCAGGAAGAAATTCTTATT
ACTTGCCAGCTGGAAGTCCCATCCTTGGCAGCTTCGTGGGACAAAGGATAGAGT
GGGCAGAAGCCTGGCCTGGTGTCTAAAGTTCCCATCCGGGCCAAATCTGTTCCCA
TTGTGTAGGAGGCCTCAGGTTCTAGGTTCTTTTGGGCC

35

SEQ ID NO: 350

>3057 BLOOD 346395.5 AF187016 g6601393 Human myosin regulatory light chain
interacting protein MIR mRNA, complete cds. 0

40 CGCCACCGCGGAGGACAGGTGCAGCTGGCGGGCAGCGGGTGAGGGGGTGGCGG
GGACGCGAGTGGCGGGCCGCGGGGCCCGGACAAGGGTCCGCAGAGCTGCAGCCT
TCGAGGGCCAGCCCTCTCCGAGTCCGGGGCTGGGTCCCACCAAGTGACAAGGCGG
CAGCCCCGCGCACACCAAAGAGAAGGCGGCTGTGGCGGCAGCGGCAGCCCCAGC
CATGCTGTGTTATGTGACGAGGCCGACGCGGTGCTGATGGAGGTGGAGGTGGA
GGCGAAAGCCAACGGCGAGGACTGCCTCAACCAGGTGTGCAGGCGACTGGGAAT
45 CATAGAAGTTGACTATTTTGGACTGCAGTTTACGGGTAGCAAAGGTGAAAGTTTA
TGGCTAAACCTGAGAAACCGGATCTCCAGCAGATGGATGGGCTAGCCCCTTAC
AGGCTTAAACTTAGAGTCAAGTTCTTCGTGGAGCCTCATCTCATCTTACAGGAGC
AGACTAGGCATATCTTTTTCTTGACATCAAGGAGGCCCTCTTGGCAGGCCACCT
CTTGTGTTCCCCAGAGCAGGCAGTGGAAGTCAAGTGCCTCCTGGCCCAGACCAAG

TTTGGAGACTACAACCAGAACACTGCCAAGTATAACTATGAGGAGCTCTGTGCC
AAGGAGCTCTCCTCTGCCACCTTGAACAGCATTGTTGCAAAACATAAGGAGTTGG
AGGGGACCAGCCAGGCTTCAGCTGAATACCAAGTTTTGCAGATTGTGTGGCAAT
GGAAACTATGGCATAGAATGGCATTCTGTGCGGGATAGCGAAGGGCAGAACT
5 GCTCATTGGGGTTGGACCTGAAGGAATCTCAATTTGTAAAGATGACTTTAGCCCA
ATTAATAGGATAGCTTATCCTGTGGTGCAGATGGCCACCCAGTCAGGAAAGAAT
GTATATTTGACGGTCACCAAGGAATCTGGGAACAGCATCGTGCTCTTGTTTAAAA
TGATCAGCACCAGGGCGGCCAGCGGGCTCTACCGAGCGATAACAGAGACGCACG
CATTCTACAGGTGTGACACAGTGACCAGCGCCGTGATGATGCAGTATAGCCGTG
10 ACTTGAAGGGCCACTTGGCATCTCTGTTTCTGAATGAAAACATTAACCTTGGCAA
GAAATATGTCTTTGATATTAAAAGAACATCAAAGGAGGTGTATGACCATGCCAG
GAGGGCTCTGTACAATGCTGGCGTTGTGGACCTCGTTTCAAGAAGCAACCAGAG
CCCTTCACACTCGCCTCTGAAGTCCTCAGAAAGCAGCATGAACTGCAGCAGCTGC
GAGGGCCTCAGCTGCCAGCAGACCCGGGTGCTGCAGGAGAAGCTACGCAAGCTG
15 AAGGAAGCCATGCTGTGCATGGTGTGCTGCGAGGAGGAGATCAACTCCACCTTC
TGTCCTGTGGCCACACTGTGTGCTGTGAGAGCTGCGCCGCCAGCTACAGTCAT
GTCCCGTCTGCAGGTGCGGTGTGGAGCATGTCCAGCACGTCTATCTGCCAACGCA
CACCAGTCTTCTCAATCTGACTGTAATCTAATCTGTTGTGCTTTTGTGGACTTGG
CATGTTTCCATGAACTGCACTATTATAAACTATTAATAATGATAGATTGTGGAGAA
20 AGTAATTATTCCAACACCCATCTGCCATGCGATGTTAAAAAAAAAAAAAAGGAA
GAAAAATAACACAGCTACTCCTCACTGCAAAAACATATCCATGCGTAGAATCAA
CAACTCCAGTCATGGGACCAGGAGGAGCTCTGGGACGCAGACACATTCCTTGGAA
TGTGTGATTTTTTTTATGATCTAGTAAAGGAATAGGTAAAGTCTTTGATGTCAGTGA
AGTGGCAACATAGCCAAAAAGTTGGGTAGCTTTTAGGAAATGATGTTGTAAGTCT
25 CCTTAATGTATCCTGAGGTAAGTTTCTACTGGCAGCAGATTTTGTAAGAATTAC
TTTTAAGAATTTTCAATCTTTTTGTATGGTCATGGAGCTCCAACCATTTTAAATAGG
AAAGTCTTTTGTAATTTGTTGTCGTTTTAATGTCATTTCTGTCTTTATAACTTGATC
AAGAATGATTGGAAGGCAAACAGGTTTACAAATCAATTCTGTGACTTTTAAAAA
GTTGACAATGTTGTCAGATTTAAACCAGTGTGGCTAGTAAAAAGCAGCTCACTCA
30 ATGTGGGTGGCTCCCTATTCCTTTACGCTCCCCCTATCCCTACCCCAAGCCTTT
CGATTATAAAATACTACCAATCTTGTTATAAGATTACTGTGGAGTAGTCAAGTAC
TCCCCGGGCCTTCTGAGCTGGTGGAAATATTTTATTTTCACTGAAAACAGAGAGC
ACTCTCCTTGGGAAGGGAAAGCGGAGCTTGCTGAGTGAGAGATGGAGCCTCATG
GTGTACAACCTGAGGGTAGTTAACTCATCACTTCTCCCAAGCACTCGATCCAGCT
35 TCACCCACTGGTGTGCTTTGCTTGAACCTGTTCAAGCCTTTTATAGCCTTACCATA
AGTATTTAGATATGGTGTCCTTTTCTGTTTTTGGGGGGGGAGTTTTGTTGTGTTTT
TTTAAAGTAAGTGCTTAAGTATTAACCTTTGGGTGTCCCCTCTGTATGTTTCGAAG
GGGTTTTGGTTCTTTTTGCTTCTGTTTTCTTAAACATGTTTTCCACTCCACTTGGG
CATTTTGGAAGCTGGTCAGCTAGCAGGTTTTCTGGGATGTCGGGAGACCTAGATG
40 ACCTTATCGGGTGCAATACTAGCTAAGGTAAAGCTAGAAACCTACACTGTCATT
TACTGAGATTTCTGAGTATACTTTTCATATTGCCTTAATGTAGCAGTAATGTGTTT
ATGCATTTGTTTTCTTGCACAGACATTTTGTCAAATATTAAAACTCTACTTTTTTA
TGGCACATATTAGCATATAAGCCTTTATTCCAAGAGGTATTTATTTTTTCACTTGT
AAAAAAATAATGTTTCCACGTAAAGAACTCTGTTATATCCTAGAGGACTCTGTCT
45 TTTATATTGCGGATAATAAAGACTTTAAAGC

SEQ ID NO: 351

>3072 BLOOD 1327030.1 U26162 g829622 Human myosin regulatory light chain mRNA,
complete cds. 0

CGGAGCTACCAAAGGAGTGGGGGACGAGGGCCGGGCTGCGGGCGACCGCCGCA
GCGCAGGCCGCGATATCGCAGCGGATCGGAGCAGGCCGGAGGGGCAATTAAGA
CCCCGGCCGTGTGCGTCCGGCCTCAGCAGCCCCGCGCTCGGCGGACACGCAGA
CCCCGCCGGCCCGGGCGCGAACACTCAGCGCACCCCCGTTCCACTTGGTCCCGCC
5 GCGCCTTCCGGTGC GCCTTCCGGTGC GCCTTCCGCTCCGCCCTTCAGGCAGGAA
GTGTCGGCGCCGCCACTGTCCGGCCACAGCCTAACGCTCTTCGCTGTGCTTGTG
GTCTCGCGCAGGGCGGCCCGGTTCTGGTGTGTTGGCGTCGGAATTAAACAACCAC
CATGTCGAGCAAAAAGGCAAAAGACCAAGACCACCAAGAAGCGCCCTCAGCGTGC
AACATCCAATGTGTTTGCCATGTTTGACCAGTCACAGATTCAGGAGTTCAAAGAG
10 GCCTTCAACATGATTGATCAGAACAGAGATGGCTTCATCGACAAGGAAGATTG
CATGATATGCTTGCTTCTCTAGGGAAGAATCCCCTGATGCATACCTTGATGCCA
TGATGAATGAGGCCCCAGGGCCCATCAATTTACCATGTTCTTGACCATGTTTGG
TGAGAAGTTAAATGGCACAGATCCTGAAGATGTCATCAGAAACGCCTTTGCTTGC
TTTGATGAAGAAGCAACAGGCACCATTACAGGAAGATTACCTAAGAGAGCTGCTG
15 ACAACCATGGGGGATCGGTTTACAGATGAGGAAGTGGATGAGCTGTACAGAGAA
GCACCTATTGACAAAAAGGGGAATTTCAATTACATCGAGTTCACACGCATCCTGA
AACATGGAGCCAAAGACAAAGATGACTGAAAGAACTTTAGCTAAAATCTTCCAG
TTACATTGTCTTACTCTCTTTTACTTCTCAGACACTTCCCCCACCCTCATAGAACC
TGTTGCATGCAACTTAGTTTCACAGCTTTGCCTCTTCTTTTGTATGTATTTATTCCA
20 GACCTTTCTGCCACTTAGCACTTGTATAATCAGACTGGAAATGGGGATGAGGGTG
TAAATTGTATTGAAAAAGATCGCGAATAAAAAATCAACAAATGTGAAAGCCCAGA
AAAAATATATTCGTATTTCTGGTFTTGCTGGATTTTACATTTTATATAATAAAAA
TGTTATTTTGAATAAAGATTATGCTGAGTCAAATGC

25 SEQ ID NO: 352

>3210 BLOOD 1095563.3 D00762 g220027 Human mRNA for proteasome subunit HC8. 0

TTTGCGGCATCCTGTGGTATAGGGGAAGCGTCCGGGCCTGGAATCCCTACGCGT
CCCTTTGGGTTTAGCACGATGAGCTCAATCGGCACTGGGTATGACCTGTCAGCCT
CTACATTCTCTCCTGACGGAAGAGTTTTTCAAGTTGAATATGCTATGAAGGCTGT
30 GGAAAATAGTAGTACAGCTATTGGAATCAGATGCAAAGATGGTGTGCTTTGG
GGTAGAAAAATTAGTCCTTTCTAACTTTATGAAGAAGGTTCCAACAAAAGACTT
TTAATGTTGATCGGCATGTTGGAATGGCAGTAGCAGGTTTGTGTCAGATGCTC
GTTCTTTAGCAGACATAGCAAGAGAAGAAGCTTCCAACCTTCAGATCTAACTTTGG
CTACAACATTCCACTAAAACATCTTGCAGACAGAGTGGCCATGTATGTGCATGCA
35 TATACACTCTACAGTGCTGTAGACCTTTTGGCTGCAGTTTCATGTTAGGGTCTTA
CAGTGTGAATGACGGTGCGCAACTCTACATGATTGACCCATCAGGTGTTTCATAC
GGTTATTGGGGCTGTGCCATCGGCAAAGCCAGGCAAGCTGCAAAGACGGAAATA
GAGAAGCTTCAGATGAAAGAAATGACCTGCCGTGATATCGTTAAAGAAGTTGCA
AAAATAATTTACATAGTACATGACGAAGTTAAGGATAAAGCTTTTGAAGTAGAA
40 CTCAGCTGGGTGGTGAATTAATAATGGAAGACATGAAATTGTTCCAAAAGAT
ATAAGAGAAGAAGCAGAGAAATATGCTAAGGAATCTCTGAAGGAAGAAGATGA
ATCAGATGATGATAATATGTAACATTTACTCCAGCATCTATTGTATTTTAAATTC
TACTCCAGTCCAATGTAACATTTAGCCCTGGATTATACATACTGTCCAATTTTCA
45 TTAAATTTTGTCTTAC

SEQ ID NO: 353

>3230 BLOOD 480496.45 L38616 g603444 Human brain and reproductive organ-expressed protein (BRE) gene, complete cds. 0

GCGCGCTCGGGTACCTGTACCCACGTAAGTCGCCGGTTACCGATCGGACTAAGTT
 CCAGAAGCAAGAGATAAAGTAATAATGGGTACTGTGGGGAAAAACACAGAAGA
 ACAATTCGGTAATATAGTGGTGATTACAAAGTCAAGTTAAAATGTCCCCAGAAGT
 5 GGCCTTGAACCGAATATCTCCAATGCTCTCCCCTTTCATATCTAGCGTGGTCCGG
 AATGGAAAAGTGGGACTGGATGCTACAACTGTTTGAGGATAACTGACTTAAAA
 TCTGGCTGCACATCATTGACTCCTGGGCCCACTGTGACCGATTAACTGCACA
 TACCATATGCTGGAGAGACATTAAAGTGGGATATCATTTTCAATGCCCAATACCC
 AGAACTGCCTCCCGATTATCTTTGGAGAAGATGCTGAATTCCTGCCAGACCCC
 TCAGCTTTGCAGAATCTTGCCTCCTGGAATCCTTCAAATCCTGAATGTCTCTTACT
 10 TGTGGTGAAGGAACTTGTGCAACAATATCACCAATTCCAATGTAGCCGCCTCCGG
 GAGAGCTCCCGCCTCATGTTTGAATACCAGACATTACTGGAGGAGCCACAGTATG
 GAGAGAACATGGAAATTTATGCTGGGAAAAAACAACCTGGACTGGTGAATTTT
 CAGCTCGTTTCTTTTGAAGCTGCCCGTAGATTTTCAGCAATATCCCCACATACCTT
 CTCAAGGATGTAAATGAAGACCCTGGAGAAGATGTGGCCCTCCTCTCTGTAGTT
 15 TTGAGGACACTGAAGCCACCCAGGTGTACCCCAAGCTGTACTTGTACCTCGAAT
 TGAGCATGCACTTGGAGGCTCCTCAGCTCTTCATATCCCAGCTTTTCCAGGAGGA
 GGATGTCTCATTGATTACGTTCTCAAGTATGCCACCTGCTCACCAACAAGGTGC
 AGTACGTGATTCAAGGGTATCACAAAAGAAGAGAGTATATTGCTGCTTTTCTCAG
 TCACTTTGGCACAGGTGTCTGGAATATGATGCAGAAGGCTTTACAAAACCTCACT
 20 CTGCTGCTGATGTGGAAAGATTTTGTCTTGTACACATTGACCTGCCTCTGTT
 TTTCCCTCGAGACCAGCCAACCTCTCACATTTCACTCCGTTTATCACTTTACCAACA
 GTGGACAGCTTTACTCCAGGCCCAAAAAAATTATCCGTACAGCCCCAGATGGG
 ATGGAAATGAAATGGCCAAAAGAGCAAAAGGCTTATTTCAAAACCTTTGTCCCTC
 AGTTCAGGAGGCAGCATTTGCCAATGGAAAGCTCTAGGAAACACCAGTCTTGA
 25 GAGGTGGCCAGCCAGACTGCCTGTCCACATGCGTGTGTCAGCACATACAGCCGCTTC
 CTGGAAGCCGCTGGAATGTCTTCACGGCAGCGTTTTGTCTCACACAGCAGCTTTT
 GCACGCCCCAGGCAGCCCCGACTGCTGAAATCCAACCTTGAGCTGGCTGGTGGTCC
 CTGGATCCTAGAGCCCTTCACTTCGGGTACTCCCTCTTTCTTGCCTCTATTTCTTA
 GTTGAAGAAATAAACTCACAAATTATGGTGCAGTAATTTCCGGGGAAAGTAA
 30 AGCCTCAGGAATGCCACGCCTTTCTTCAAAGCCTTTGTCTCTGAGACCTCTTAA
 GTTCTAAGATTAAATGCCCCCTCGCTGTTCTTCTCTG

SEQ ID NO: 354

>3242 BLOOD 201279.14 U37408 g3702074 Human phosphoprotein CtBP mRNA,

35 complete cds. 0

TGCACCCTGAGCTCAATGGGGCTGCCTATAGGTACCCGCNCCACGCCCTTCTCC
 TGGCCAAACCGTCAAGCCCGAGGCGGATAGAGACCACGCCAGTGACCAGTTGTA
 GCCCGGGAGGAGCTCTCCAGCCTCGGCGCCTGGGCAGAGGGCCCGGAAACCCTC
 GGACCAGAGTGTGTGGAGGAGGCATCTGTGTGGTGGCCCTGGCACTGCAGAGAC
 40 TGGTCCGGGCTGTGAGGAGGCGGGAGGGGGCAGCGCTGGGCCTCGTGTGCTTG
 TCGTCTCGTCCGTCTGTGGGCGCTCTGCCCTGTGTCTTCGCGTTCCTCGTTAAGCA
 GAAGAAGTCAGTAGTTATTTCTCCCATGAACGTTCTTGTCTGTGTACAGTTTTAGA
 ACATTACAAAGGATCTGTTTGTCTAGCTGTCAACAAAAAGAAAACCTGAAGGAG
 CATTTGGAAGTCAATTTGAGGNNNNNNNNNNNNNNNNNNNNNNNNNNNTTGTATGT
 45 GGAACGTGCCCCAGAATGAGGCAGTTGGCAAACCTTCTCAGGACAATGAATCCTC
 CCGTTTTTCTTTTATGCCACACAGTGCATTGTTTTTCTACCTGCTTGTCTTATTTT
 TAGAATAATTTAGAAAAACAAAACAAAGGCTGTTTTTCCTAATTTTGGCAGAACC
 CCCC

SEQ ID NO: 355

>3284 BLOOD Hs.6453 gnl|UG|Hs#S377401 Human inositol 1,3,4-trisphosphate 5/6-kinase mRNA, complete cds /cds=(118,1362) /gb=U51336 /gi=1322037 /ug=Hs.6453 /len=3049

5 CGCGAGGACCAGGCCGAGGAGGAAGTGGCGGCGGCGGCGGCGGGCTCCCCGCC
CGAGGAGGAAGATGCAGACCTTTCTGAAAGGGAAGAGAGTTGGCTACTGGCTGA
GCGAGAAGAAAATCAAGAAGCTGAATTTCCAGGCTTTCGCCGAGCTGTGCAGGA
AGCGAGGGGATGGAGGTTGTGCAGCTGAACCTTAGCCGGCCGATCGAGGAGCAGG
10 GCGGCTGGACGTCATCATCCACAAGCTGACTGACGTCATCCTTGAAGCCGACCA
GAATGATAGCCAGTCCCTGGAGCTGGTGCACAGGTTCCAGGAGTACATCGATGC
CCACCCTGAGACCATCGTCCTGGACCCGCTCCCTGCCATCAGAACCCTGCTTGAC
CGCTCCAAGTCCTATGAGCTCATCCGGAAGATTGAGGCCTACATGGAAGACGAC
AGGATCTGCTCGCCACCCTTCATGGAGCTCACGAGCCTGTGCGGGGATGACACCA
15 TGCGGCTGCTGGAGAAGAACGGCTTGACTTTCCATTTCATTGCAAAACCAGAGT
GGCTCATGGCACCAACTCTCACGAGATGGCTATCGTGTTCAACCAGGAGGGCCTG
AACGCCATCCAGCCACCCTGCGTGGTCCAGAATTTTCATCAACCACAACGCCGTCC
TGTACAAGGTGTTCTGTGGTTGGCGAGTCTACACCGTGGTCCAGAGGCCCTCACT
CAAGAACTTCTCCGCAGGCACATCAGACCGTGAGTCCATCTTCTTCAACAGCCAC
AACGTGTCAAAGCCGGAGTCGTCATCGGTCTGACGGAGCTGGACAAGATCGAG
20 GCGTGTTCGAGCGGCCGAGCGACGAGGTCATCCGGGAGCTCTCCCGGGCCCTG
CGGCAGGCACTGGGCGTGTCACTCTTCGGCATCGACATCATCAACAACCAGA
CAGGGCAGCACGCCGTGATTGACATCAATGCCCTCCAGGCTACGAGGGCGTGA
GCGAGTTCCTTCACAGACCTCTGAACCAACATCGCCACTGTCTGCAGGGCCAGAG
CACAGCCATGGCAGGCACAGGGGACGTGGCCCTGTGTGAGGCACAGCAAGCTTCT
25 GGCCGAGCCGGCGGGCGGCCTGGTGGGCGAGCGGACATGCAACGCCAGCCCGG
CTGCTGCGGCAGCATGATGGGCCAGGACGCGCCCTGGAAAGCTGAGGCCGACGC
GGGCGGCACCGCCAAGCTGCCGCACCAGAGACTCGGCTGCAACGCCGGCGTGTC
TCCCAGCTTCCAGCAGCATTGTGTGGCCTCCCTGGCCACCAAGGCCTCCTCCCAG
TAGCCACGGAGCCGGGACCCAGAGGGCAGCGCAGGCGCAGGAGCACACCCGCT
30 GGGCCAGCAGCTCCCAACGGCGATGCTACTACTAAGAATCCCCAGTGATCTGATT
CTTCTGTTTTTTAATTTTTAACCTGATTTTCTGATGTCATGATCTAAATGAGGGGT
AGAAGAGAGTACCAGGTGGTCCACCGTTGGGGAGCGGGGCCGTCCGCCTGCTCT
CTACTGTGCAGACCTCCTAACTGAGTTTACACACGCTTGTGTTGCAACACTAGGT
CTGGATGGGAGGTGAGGGGGGTGCGTATACTGCCATGCCAGTGTCTGTGCACAT
35 CCTGTCTGTTGTCTCCATGGCCACTGTGGACTGGGACCCTTGAAGCCTGCCCAT
GTGGGTGTGGGAGGCTGATCAGTGCCTGTGAGAGTGGCTTCCCTTCTGCCTGACT
CCCCACTCCCTGACCTGCCCCCTCCTTGTTTTCTCCTACTGGTCTCCACCAAGG
CTTTGTTAGCCCCCACCCTGCCTGGTGTGCAGCTAACCCCTCCCTCCCCACAGCCA
GAGGAGGCCACAGACCCCTCAGGGAGTCCGCGCTGGGGTCTGGGCTGTGCTCC
40 CTCATAAAGGGAAGGAAAGGAAGCTGGGCGTCTCCGGGCCCCCAACACAG
TCCCATTAGCCCTGCACAGCGGTCTCCTTCCCCTAAGCCAGCACTGCTGCTCCCT
GGAGCCGGGAAGGAGGCTGCCTGGCTGGAGGCCGAGCCGATGGGCCTGTGCTGA
GGATTTGTGCTGTGATTTGGGCAAATCATTCCAGGTCTTTGGGCCTCCACCCCCTC
GTCTCTAGTGGACATTTGAGATCAGAGAGCACCACAGGGCTGGCTTTGTGCCCTA
45 ACCCCTGGGATGCAGCCTGCCTTTCCATAAAGTCACCTAGGTGAGGATAGGCGCG
GGAGCCTCGGCATGACACCATGGAGATCGGGGCCCTCTTCCCAGTGGGTTCACTC
CTTTTCACACCTGCTGGGTCCCTCCTCGCCCAGCAGGCCTGGTCCACCTCTCATTG
CAAGCCCGCAAGCACTGAGCCGAGTAAGGTGCTTAGTGTGAGCCACCCGCCCCC
CATAGCTTCTGCACACCTCAGACTCACCCCATCACCTTGGCAGCAAAGCACTGCT

CTGCCGTCTGACCCCTGATCCAGGCAGCAGCCCCCTCCGCAGAGAAAAAGGGTTG
GGGAGAAGCCTCTGCAGTCCTGGAAGATGTGGGGTGCTGGGTGAGAGGCATCAG
CCCCACAAGTATGTTTTTGTGTCTTAAGATAGCAGTTTACTTTGAAAAAGTGAA
AAAGGCTTCCGGGCTGTCTCTGCCCAGTGAGATGGAGGACGCTAGAGAAAGTG
5 CTGAGTGTCCCGAGAGAGGCCCCCGAGCCAGTGCATGGAGGTCTTCGGCCTGGC
TCAGCTGGGCTGCAGGATGCCCACTTTGAGGAGGGAGGCACAGGGCTTGGGCGA
GGGGCAGAGGCCATCAGAACTGCCCGGCTTTTTTGGAACTGAGGACCCAACAA
CTAACACGTTTACACGACTTGAGTTTTGAACCCCGATTAATGTCTGTACGTAC
CTTTCTAGTTCTGACCCTGAGCCCTGGGGAACAGGAAAGCGTGGCTGGCCTCTT
10 GCACTGCTTTGTCTCCAAAATAAACTACTGAAATCAAACCGCATTTC

SEQ ID NO: 356

>3325 BLOOD 434815.28 X13916 g34338 Human mRNA for LDL-receptor related protein.

0

15 CAGCGGTGCGAGCTCCAGGCCCATGCACTGAGGAGGCGGAAACAAGGGGAGCC
CCCAGAGCTCCATCAAGCCCCCTCAAAGGCTCCCCCTACCCGGTCCACGCCCCC
ACCCCCCTCCCCGCCTCCTCCCAATTGTGCATTTTTGCAGCCGGAGGCGGCTCC
GAGATGGGGCTGTGAGCTTCGCCCGGGGAGGGGGAAAGAGCAGCGAGAGTGAA
GCGGGGGGTGGGTGAAGGGTTTGGATTTGCGGGCAGGGGGCGCACCCCCGTCAG
20 CAGGCCCTCCCCAAGGGGCTCGGAACTCTACCTCTTACCCACGCCCCCTGGTGCG
CTTTGCCGAAGGAAAGAATAAGAACAGAGAAGGAGGAGGGGGAAAGGAGGAAA
AGGGGGACCCCCCAACTGGGGGGGGTGAAGGAGAGAAAGTAGCAGGACCAGAGG
GGAAGGGGCTGCTGCTTGCATCAGCCCCACCATGCTGACCCCGCCGTTGCTCCT
GCTGGTGCCCTGCTCTCAGCTCTGGTTCGGGGCGGCTATCGACGCCCTAAGACT
25 TGCAGCCCCAAGCAGTTTGCCTGCAGAGATCAAATAACCTGTATCTCAAAGGGCT
GGCGGTGCGACGGTGAGAGGGACTGCCCAGACGGATCTGACGAGGCCCCCTGAGA
TTTGTCCACAGAGTAAGGCCCAGCGATGCCAGCCAAACGAGCATAACTGCCTGG
GTACTGAGCTGTGTGTTCCCATGTCCCGCCTCTGCAATGGGGTCCAGGACTGCAT
GGACGGCTCAGATGAGGGGCCCCACTGCCGAGAGCTCCAAGGCAACTGCTCTCG
30 CCTGGGCTGCCAGCACCATTTGTGTCCCCACACTCGATGGGCCCCACCTGCTACTGC
AACAGCAGCTTTTCACTTCAGGCAGATGGCAAGACCTGCAAAGATTTTGATGAG
TGCTCAGTGTACGGCACCTGCAGCCAGCTATGCACCAACACAGACGGCTCCTTCA
TATGTGGCTGTGTTGAAGGATACCTCCTGCAGCCGGATAACCGCTCCTGCAAGGC
CAAGAACGAGCCAGTAGACCGGCCCCCTGTGCTGTTGATAGCCAACCTCCCAGAA
35 CATCTTGCCACGTACCTGAGTGGGGGCCAGGTGTCTACCATCACACCTACGAGC
ACGCGGCAGACCACAGCCATGGACTTCAGCTATGCCAACGAGACCGTATGCTGG
GTGCATGTTGGGGACAGTGCTGCTCAGACGCAGCTCAAGTGTGCCCGCATGCCTG
GCCTAAAGGGCTTCGTGGATGAGCACACCATCAACATCTCCCTCAGTCTGCACCA
CGTGGAACAGATGGCCATCGACTGGCTGACAGGCAACTTCTACTTTGTGGATGAC
40 ATCGATGATAGGATCTTTGTCTGCAACAGAAATGGGGACACATGTGTACATTGC
TAGACCTGGAACCTTACAACCCCAAGGGCATTGCCCTGGACCCTGCCATGGGGA
AGGTGTTTTTCACTGACTATGGGCAGATCCCAAAGGTGGAACGCTGTGACATGGA
TGGGCAGAACCGCACCAAGCTCGTCGACAGCAAGATTGTGTTTCCTCATGGCATC
ACGCTGGACCTGGTCAGCCGCCTTGTCTACTGGGCAGATGCCTATCTGGACTATA
45 TTGAAGTGGTGGACTATGAGGGCAAGGGCCGCCAGACCATCATCCAGGGCATCC
TGATTGAGCACCTGTACGGCCTGACTGTGTTTGAGAATTATCTCTATGCCACCAA
CTCGGACAATGCCAATGCCCAGCAGAAGACGAGTGTGATCCGTGTGAACCGCTT
TAACAGCACCGAGTACCAGGTTGTACCCCGGTGGACAAGGGTGGTGCCCTCCA
CATCTACCACCAGAGGCGTCAGCCCCGAGTGAGGAGCCATGCCTGTGAAAACGA

CCAGTATGGGAAGCCGGGTGGCTGCTCTGACATCTGCCTGCTGGCCAAACAGCCAC
AAGGCGCGGACCTGCCGCTGCCGTTCCGGCTTCAGCCTGGGCAGTGACGGGAAG
TCATGCAAGAAGCCGGAGCATGAGCTGTTCTCTCGTGTATGGCAAGGGCCGGCCA
GGCATCATCCGGGGCATGGATATGGGGGCCAAGGTCCCGGATGAGCACATGATC
5 CCCATTGAAAACCTCATGAACCCCCGAGCCCTGGACTTCCACGCTGAGACCGGCT
TCATCTACTTTGCCGACACCACCAGCTACCTCATTGGCCGCCAGAAGATTGATGG
CACTGAGCGGGAGACCATCCTGAAGGACGGCATCCACAATGTGGAGGGTGTGGC
CGTGGACTGGATGGGAGACAATCTGTACTGGACGGACGATGGGCCCCAAAAGAC
AATCAGCGTGGCCAGGCTGGAGAAAAGCTGCTCAGACCCGCAAGACTTTAATCGA
10 GGGCAAAATGACACACCCCAGGGCTATTGTGGTGGATCCACTCAATGGGTGGAT
GTACTGGACAGACTGGGAGGAGGACCCCAAGGACAGTCGGCGTGGGCGGCTGG
AGAGGGCGTGGATGGATGGCTCACACCGAGACATCTTTGTACCTCCAAGACAG
TGCTTTGGCCCAATGGGCTAAGCCTGGACATCCCGGCTGGGCGCCTCTACTGGGT
GGATGCCTTCTACGACCGCATCGAGACGATACTGCTCAATGGCACAGACCGGAA
15 GATTGTGTATGAAGGTCTGAGCTGAACCACGCCTTTGGCCTGTGTCACCATGGC
AACTACCTCTTCTGGACTGAGTATCGGAGTGGCAGTGTCTACCGCTTGGAACGGG
GTGTAGGAGGCGCACCCCCCACTGTGACCCTTCTGCGCAGTGAGCGGCCCCCAT
CTTTGAGATCCGAATGTATGATGCCCAGCAGCAGCAAGTTGGCACCAACAAATG
CCGGGTGAACAATGGCGGCTGCAGCAGCCTGTGCTTGGCCACCCCTGGGAGCCG
20 CCAGTGCGCCTGTGCTGAGGACCAGGTGTTGGACGCAGACGGCGTCACTTGCTTG
GCGAACCCATCCTACGTGCCTCCACCCCAGTGCCAGCCAGGCGAGTTTGCCTGTG
GCAACAGCCGCTGCATCCAGGAGCGCTGGAAGTGTGACGGAGACAAGGATTGCC
TGGACAACAGTGATGAGGCCCCAGCCCTGTGCCATCAGCACACCTGCCCCTCGGA
CCGATTCAAGTGCGAGAACAACCGGTGCATCCCCAACCCTGGCTCTGCGACGG
25 GGACAATGACTGTGGGAACAGTGAAGATGAGTCCAATGCCACTTGTGAGCCCG
CACCTGCCCCCCCCAACCAAGTTCTCCTGTGCCAGTGGCCGCTGCATCCCCATCTCCT
GGACGTGTGATCTGGATGACGACTGTGGGGACCGCTCTGATGAGTCTGCTTCGTG
TGCTATCCCACCTGCTTCCCCCTGACTCAGTTTACCTGCAACAATGGCAGATGT
ATCAACATCAACTGGAGATGCGACAATGACAATGACTGTGGGGACAACAGTGAC
30 GAAGCCGGCTGCAGCCACTCCTGTTCTAGCACCCAGTTCAAGTGCAACAGCGGG
CGTTGCATCCCCGAGCACTGGACCTGCGATGGGGACAATGACTGCGGAGACTAC
AGTGATGAGACACACGCCAACTGCACCAACCAGGCCACGAGGCCCCCTGGTGGC
TGCCACACTGATGAGTCCAGTGCCGGCTGGATGGACTATGCATCCCCCTGCGGT
GGCGCTGCGATGGGGACACTGACTGCATGGACTCCAGCGATGAGAAGAGCTGTG
35 AGGGAGTGACCCACGTCTGCGATCCCAGTGTCAAGTTTGGCTGCAAGGACTCAG
CTCGGTGCATCAGCAAAGCGTGGGTGTGTGATGGCGACAATGACTGTGAGGATA
ACTCGGACGAGGAGAACTGCGAGTCCCTGGCCTGCAGGCCACCCTCGCACCCCTT
GTGCCAACAAACCTCAGTCTGCCTGCCCCCTGACAAGCTGTGTGATGGCAACGA
CGACTGTGGCGACGGCTCAGATGAGGGCGAGCTCTGCGACCAGTGCTCTCTGAA
40 TAACGGTGGCTGCAGCCAACTGCTCAGTGGCACCTGGCGAAGGCATTGTGTGT
TCCTGCCCTCTGGGCATGGAGCTGGGGCCCCGACAACCACACCTGCCAGATCCAG
AGCTACTGTGCCAAGCATCTCAAATGCAGCCAAAAGTGCGACCAGAACAAGTTC
AGCGTGAAGTGCTCCTGCTACGAGGGCTGGGTCTTGGAACTGACGGCGAGAGC
TGCCGCGACCTGGACCCCTTCAAGCCGTTTCATCATTTTCTCCAACCGCCATGAAA
45 TCCGGCGCATCGATCTTCACAAAGGAGACTACAGCGTCCTGGTGCCCGGCTGCG
CAACACCATCGCCCTGGACTTCCACCTCAGCCAGAGCGCCCTCTACTGGACCGAC
GTGGTGGAGGACAAGATCTACCGCGGGAAGCTGCTGGACAACGGAGCCCTGACT
AGTTTCGAGGTGGTGATTGAGTATGGCCTGGCCACACCCGAGGGCCTGGCTGTAG
ACTGGATTGCAGGCAACATCTACTGGGTGGAGAGTAACCTGGATCAGATCGAGG

TGGCCAAGCTGGATGGGACCCTCCGGACCACCCTGCTGGCCGGTGACATTGAGC
ACCCAAGGGCAATCGCACTGGATCCCCGGGATGGGATCCTGTTTTGGACAGACT
GGGATGCCAGCCTGCCCCGCATTGAGGCAGCCTCCATGAGTGGGGCTGGGCGCC
GCACCGTGACCCGGGAGACCGGCTCTGGGGGCTGGCCCAACGGGCTCACCGTGG
5 ACTACCTGGAGAAGCGCATCCTTTGGATTGACGCCAGGTGAGATGCCATTTACTC
AGCCCGTTACGACGGCTCTGGCCACATGGAGGTGCTTCGGGGACACGAGTTCCTG
TCGCACCCGTTTGCAGTGACGCTGTACGGGGGGGAGGTCTACTGGACTGACTGGC
GAACAAACACACTGGCTAAGGCCAACAAGTGGACCGGCCACAATGTCACCGTGG
TACAGAGGACCAACACCCAGCCCTTTGACCTGCAGGTGTACCACCCCTCCCGCCA
10 GCCCATGGCTCCCAATCCCTGTGAGGCCAATGGGGGCCAGGGCCCCCTGCTCCAC
CTGTGTCTCATCAACTACAACCGGACCGTGTCTGCGCCTGCCCCACCTCATGA
AGCTCCACAAGGACAACACCACCTGCTATGAGTTTAAGAAGTTCCTGCTGTACGC
ACGTCAGATGGAGATCCGAGGTGTGGACCTGGATGCTCCCTACTACAACCTACATC
ATCTCCTTCACGGTGCCCGACATCGACAACGTCACAGTGCTAGACTACGATGCCC
15 GCGAGCAGCGTGTGTACTGGTCTGACGTGCGGACACAGGCCATCAAGCGGGCCT
TCATCAACGGCACAGGCGTGGAGACAGTCGTCTCTGCAGACTTGCCAAATGCCC
ACGGGCTGGCTGTGGACTGGGTCTCCCGAAACCTGTTCTGGACAAGCTATGACAC
CAATAAGAAGCAGATCAATGTGGCCCGGCTGGATGGCTCCTTCAAGAACGCAGT
GGTGCAGGGCCTGGAGCAGCCCCATGGCCTTGTCTGCCACCCTCTGCGTGGGAAG
20 CTCTACTGGACCGATGGTGACAACATCAGCATGGCCAACATGGCATGGCAGCAA
TCGCACCCTGCTCTTCAGTGGCCAGAAGGGCCCCGTGGGCCTGGCTATTGACTTC
CCTGAAAGCAAACCTCTACTGGATCAGCTCCGGGAACCATAACCATCAACCGCTGC
AAGCTGGATGGGAGTGGGCTGGAGGTGATCGATGCCATGCCGAGGCCAGCTGGGC
AAGGCCACCGCCTGGCCATCATGGGGGAACAAGCTGTGGTGGGCTGATCAGGTG
25 TCGGAAAAGATGGGCACATGCAGCAAGGCTGACGGCTCGGGCTCCGTGGTCCTT
CGGAACAGCACCACCCTGGTGATGCACATGAAGGTCTATGACGAGAGCATCCAG
CTGGACCATAAGGGGCACCAACCCCTGCAGTGTCAACAACGGTGACTGCTCCCAG
CTCTGCCTGCCACGTCAGAGACGACCCGCTCCTGCATGTGCACAGCCGGCTATA
GCCTCCGGAGTGGCCAGCAGGCCTGCGAGGGCGTAGGTTCTTTCTCTGTACTC
30 TGTGCATGAGGGAATCAGGGGAATTCCTTGGATCCCAATGACAAGTCAGATGC
CCTGGTCCCAGTGTCCGGGACCTCGCTGGCTGTGCGCATCGACTTCCACGCTGAA
AATGACACCATCTACTGGGTGGACATGGGCCTGAGCACGATCAGCCGGGCCAAG
CGGGACCAGACGTGGCGTGAAGACGTGGTGACCAATGGCATTGGCCGTGTGGAG
GGCATTGCACTGGACTGGATCGCAGGCAACATCTACTGGACAGACCAGGGCTTT
35 GATGTCATCGAGGTGCCCCGGCTCAATGGCTCCTTCCGCTACGTGGTGATCTCCC
AGGGTCTAGACAAGCCCCGGGCCATCACCGTCCACCCGGAGAAAGGGTACTTGT
TCTGGACTGAGTGGGGTCAGTATCCGCGTATTGAGCGGTCTCGGCTAGATGGCAC
GGAGCGTGTGGTGCTGGTCAACGTGACATCAGCTGGCCCAACGGCATCTCAGT
GGACTACCAGGATGGGAAGCTGTACTGGTGCATGCACGGACAGACAAGATTGA
40 ACGGATCGACCTGGAGACAGGTGAGAACCGCGAGGTGGTTCTGTCCAGCAACAA
CATGGACATGTTTTAGTGTCTGTGTTTGAGGATTTTCTACTGGAGTGACAGG
ACTCATGCCAACGGCTCTATCAAGCGCGGGAGCAAAGACAATGCCACAGACTCC
GTGCCCCCTGCGAACCGGCATCGGCGTCCAGCTTAAAGACATCAAAGTCTTCAACC
GGGACCGGCAGAAAGGCACCAACGTGTGCGCGGTGGCCAATGGCGGGTGCCAGC
45 AGCTGTGCCTGTACCGGGGCCGTGGGCAGCGGGCCTGCGCCTGTGCCACGGGA
TGCTGGCTGAAGACGGAGCATCGTGCCGCGAGTATGCCGGCTACCTGCTCTACTC
AGAGCGCACCATTTCTCAAGAGTATCCACCTGTGCGATGAGCGCAACCTCAATGC
GCCCCGTGCAGCCCTTCGAGGACCCTGAGCACATGAAGAACGTCATCGCCCTGGC
CTTTGACTACCGGGCAGGCACCTCTCCGGGCACCCCCAATCGCATCTTCTTCAGC

GACATCCACTTTGGGAACATCCAACAGATCAACGACGATGGCTCCAGGAGGATC
 ACCATTGTGGAACACGTGGGCTCCGTGGAAGGCCTGGCCTATCACCGTGGCTGG
 GACACTCTCTATTGGACAAGCTACACGACATCCACCATCACGCGCCACACAGTGG
 ACCAGACCCGCCCAGGGGCCTTCGAGCGTGAGACCGTCATCACTATGTCTGGAG
 5 ATGACCACCCACGGGCCTTCGTTTTGGACGAGTGCCAGAACCTCATGTTCTGGAC
 CAACTGGAATGAGCAGCATCCCAGCATCATGCGGGCGGCGCTCTCGGGAGCCAA
 TGTCTGACCCTTATCGAGAAGGACATCCGTACCCCCAATGGCCTGGCCATCGAC
 CACCGTGCCGAGAAGCTCTACTTCTCTGACGCCACCCTGGACAAGATCGAGCGGT
 GCGAGTATGACGGCTCCCACCGCTATGTGATCCTAAAGTCAGAGCCTGTCCACCC
 10 CTTCGGGCTGGCCGTGTATGGGGAGCACATTTTCTGGACTGACTGGGTGCGGCGG
 GCAGTGACGCGGGCCAACAAGCACGTGGGCAGCAACATGAAGCTGCTGCGCGTG
 GACATCCCCCAGCAGCCCATGGGCATCATCGCCGTGGCCAACGACACCAACAGC
 TGTGAACCTCTCTCCATGCCGAATCAACAACGGTGGCTGCCAGGACCTGTGTCTGC
 TCACTCACCAGGGCCATGTCAACTGCTCATGCCGAGGGGGGCCGAATCCTCCAGG
 15 ATGACCTCACCTGCCGAGCGGTGAATTCCTCTTGCCGAGCACAAGATGAGTTTGA
 GTGTGCCAATGGCGAGTGCATCAACTTCAGCCTGACCTGCGACGGCGTCCCCCAC
 TGCAAGGACAAGTCCGATGAGAAGCCATCCTACTGCAACTCCCGCCGCTGCAAG
 AAGACTTTCCGGCAGTGCAGCAATGGGCGCTGTGTGTCCAACATGCTGTGGTGCA
 ACGGGGCCGACGACTGTGGGGATGGCTCTGACGAGATCCCTTGCAACAAGACAG
 20 CCTGTGGTGTGGGCGAGTTCGCTGCCGGGACGGGACCTGCATCGGGAACCTCCA
 GCCGCTGCAACCAGTTTGTGGATTGTGAGGACGCCTCAGATGAGATGAACTGCA
 GTGCCACCGACTGCAGCAGCTACTTCCGCCTGGGCGTGAAGGGCGTGCTCTTCCAA
 GCGCTGCGAGCGGACCTCACTCTGCTACGCAAGCAGCTGGGTGTGTGATGGCGCC
 AATGACTGTGGGGACTACAGTGATGAGCGCGACTGCCAGGTGTGAAACGCCCG
 25 AGATGCCCTCTGAATTACTTCGCCTGCCCTAGTGGGCGCTGCATCCCCATGAGCT
 GGACGTGTGACAAAGAGGATGACTGTGAACATGGCGAGGACGAGACCCACTGCA
 ACAAGTTCTGCTCAGAGGCCAGTTTGAGTGCCAGAACCATCGCTGCATCTCCAA
 GCAGTGGCTGTGTGACGGCAGCGATGACTGTGGGGATGGCTCAGACGAGGCTGC
 TCACTGTGAAGGCAAGACGTGCGGCCCTCCTCCTTCTCCTGCCCTGGCACCCAC
 30 GTGTGCGTCCCCGAGCGCTGGCTCTGTGACGGTGACAAAGACTGTGCTGATGGTG
 CAGACGAGAGCATCGCAGCTGGTTGCTTGTACAACAGCACTTGTGACGACCGTG
 AGTTCATGTGCCAGAACC GCCAGTGCATCCCCAAGCACTTCGTGTGTGACCACGA
 CCGTGACTGTGCAGATGGCTCTGATGAGTCCCCCGAGTGTGAGTACCCGACCTGC
 GGCCCCAGTGAGTTCGCTGTGCCAATGGGCGCTGTCTGAGCTCCCGCCAGTGGG
 35 AGTGTGATGGCGAGAATGACTGCCACGACCAGAGTGACGAGGCTCCCAAGAACC
 CAACTGCACAGCCCAGAGCACAAGTGCAATGCCTCGTCACAGTTCCTGTGCAG
 CAGTGGGCGCTGTGTGGCTGAGGCACTGCTCTGCAACGGCCAGGATGACTGTGG
 CGACAGCTCGGACGAGCGTGGCTGCCACATCAATGAGTGTCTCAGCCGCAAGCT
 CAGTGGCTGCAGCCAGGACTGTGAGGACCTCAAGATCGGCTTCAAGTGCCGCTG
 40 TCGCCCTGGCTTCCGGCTGAAGGACGACGGCCGGACGTGTGCTGATGTGGACGA
 GTGCAGCACCACTTCCCCTGCAGCCAGCGCTGCATCAACACCCATGGCAGCTAT
 AAGTGTCTGTGTGTGGAGGGCTATGCACCCCGCGGCGGCGACCCCCACAGCTGC
 AAGGCTGTGACTGACGAGGAACCGTTTCTGATCTTCGCCAACC GGTA CTACCTGC
 GCAAGCTCAACCTGGACGGGTCCA ACTACACGTTACTTAAGCAGGGCCTGAACA
 45 ACGCCGTTGCCTTGGATTTTGACTACCGAGAGCAGATGATCTACTGGACAGATGT
 GACCACCCAGGGCAGCATGATCCGAAGGATGCACCTTAACGGGAGCAATGTGCA
 GGTCTACACCGTACAGGCCTCAGCAACCCCGATGGGCTGGCTGTGGACTGGGT
 GGGTGGCAACCTGTACTGGTGCACAAAGGCCGGGACACCATCGAGGTGTCCAA
 GCTCAATGGGGCCTATCGGACGGTGCTGGTCAGCTCTGGCCTCCGTGAGCCCAGG

GCTCTGGTGGTGGATGTGCAGAATGGGTACCTGTACTGGACAGACTGGGGTGAC
CATTCACTGATCGGCCGCATCGGCATGGATGGGTCCAGCCGCAGCGTCATCGTGG
ACACCAAGATCACATGGCCCAATGGCCTGACGCTGGACTATGTCACTGAGCGCA
TCTACTGGGCCGACGCCCCGAGGACTACATTGAATTTGCCAGCCTGGATGGCTC
5 CAATCGCCACGTTGTGCTGAGCCAGGACATCCCGCACATCTTTGCACTGACCCTG
TTTGAGGACTACGTCTACTGGACCGACTGGGAAACAAAGTCCATTAACCGAGCC
CACAAGACCACGGGCACCAACAAAACGCTCCTCATCAGCACGCTGCACCGGCC
ATGGACCTGCATGTCTTCCATGCCCTGCGCCAGCCAGACGTGCCCAATCACCCCT
GCAAGGTCAACAATGGTGGCTGCAGCAACCTGTGCCTGCTGTCCCCCGGGGAG
10 GGCACAAATGTGCCTGCCCCACCAACTTCTACCTGGGCAGCGATGGGCGCACCTG
TGTGTCCAATGCACGGCTAGCCAGTTTGTATGCAAGAACGACAAGTGCATCCCC
TTCTGGTGGAAAGTGTGACACCGAGGACGACTGCGGGGACCACTCAGACGAGCCC
CCGACTGCCCTGAGTTCAAGTGCCGGCCCGGACAGTTCCAGTGCTCCACAGGTA
TCTGCACAAACCCTGCCTTCATCTGCGATGGCGACAATGACTGCCAGGACAACAG
15 TGACGAGGCCAACTGTGACATCCACGTCTGCTTGCCCAGTCAGTTCAAATGCACC
AACACCAACCGCTGTATTCCCGGCATCTTCCGCTGCAATGGGCAGGACAACCTGCG
GAGATGGGGAGGATGAGAGGGACTGCCCCGAGGTGACCTGCGCCCCCAACCAGT
TCCAGTGCTCCATTACCAAACGGTGCATCCCCCGGGTCTGGGTCTGCGACCGGGA
CAATGACTGTGTGGATGGCAGTGATGAGCCCGCCAACTGCACCCAGATGACCTG
20 TGGTGTGGACGAGTTCCGCTGCAAGGATTCGGGCCGCTGCATCCCAGCGCGTTGG
AAGTGTGACGGAGAGGATGACTGTGGGGATGGCTCGGATGAGCCCAAGGAAGA
GTGTGATGAACGCACCTGTGAGCCATAACAGTCCGCTGCAAGAAACAACCGCTG
CGTGCCCGGCCGCTGGCAGTGCGACTACGACAACGATTGCGGTGAGAAATCCGA
TGAAAGAGAGCTGCACCCCTCGGCCCTGCTCCGAGAGTGAGTTCTCCTGTGCCAAC
25 GGCCGCTGCATCGCGGGGGCGCTGGAAATGCGATGGAGACCACGACTGCGCGGAC
GGCTCGGACGAGAAAGACTGCACCCCCCGCTGTGACATGGACCAGTTCAGTGC
AAGAGCGGCCACTGCATCCCCCTGCGCTGGCGCTGTGACGCAGACGCCGACTGC
ATGGACGGCAGCGACGAGGAGGCCTGCGGCACTGGCGTGCGGACCTGCCCCCTG
GACGAGTTCAGTGCAACAACACCTTGTGCAAGCCGCTGGCCTGGAAGTGCAT
30 GCGGAGGATGACTGTGGGGACAACCTCAGATGAGAACCCCGAGGAGTGTGCCCG
TTCGTGTGCCCTCCCAACCGGCCCTTCCGTTGCAAGAATGACCGCGTCTGTCTGT
GGATCGGGCGCCAATGCGATGGCACGGACAACCTGTGGGGATGGGACTGATGAAG
AGGACTGTGAGCCCCCACAGCCACACCACCACTGCAAAGACAAGAAGGAGT
TTCTGTGCCGGAACCAGCGCTGCCTCTCTCTCTCTGCGCTGCAACATGTTTCAT
35 GACTGCGGGGACGGCTCTGACGAGGAGGACTGCAGCATCGACCCCAAGCTGACC
AGCTGCGCCACCAATGCCAGCATCTGTGGGGACGAGGCACGCTGCGTGCGCACC
GAGAAAGCGGCCTACTGTGCCTGCCGCTCGGGCTTCCACACCGTGCCCGGCCAGC
CCGGATGCCAAGACATCAACGAGTGCTGCGCTTCGGCACCTGCTCCCAGCTCTG
CAACAACACCAAGGGCGGCCACCTCTGCAGCTGCGCTCGGAACTTCATGAAGAC
40 GCACAACACCTGCAAGGCCGAAGGCTCTGAGTACCAGGTCCTGTACATCGCTGA
TGACAATGAGATCCGCAGCCTGTTCCCCGGCCACCCCATTCGGCTTACGAGCAG
GCATTCCAGGGTGACGAGAGTGTCCGCATTGATGCTATGGATGTCCATGTCAAGG
CTGGCCGTGTCTATTGGACCAACTGGCACACGGGCACCATCTCCTACCGCAGCCT
GCCACCTGCTGCGCCTCCTACCACTTCCAACCGCCACCGGCGACAGATTGACCGG
45 GGTGTACCCACCTCAACATTTTCAGGGCTGAAGATGCCAGAGGCATCGCCATCG
ACTGGGTGGCCGGAACGTGTACTGGACCGACTCGGGCCGAGATGTGATTGAGG
TGGCGCAGATGAAGGGCGAGAACCGCAAGACGCTCATCTCGGGCATGATTGACG
AGCCCCACGCCATTGTGGTGGACCCACTGAGGGGGACCATGTACTGGTCAGACT
GGGGCAACCACCCCAAGATTGAGACGGCAGCGATGGATGGGACGCTTCGGGAGA

CACTGGTGCAGGACAACATTTCAGTGGCCACAGGCCTGGCCGTGGATTATCACA
 ATGAGCGGCTGTACTGGGCAGACGCCAAGCTTTTCAGTCATCGGCAGCATCCGGCT
 CAATGGCACGGACCCCATTTGTGGCTGCTGACAGCAAACGAGGCCTAAGTCACCC
 CTTTCAGCATCGACGTCTTTGAGGATTACATCTATGGTGTACCTACATCAATAAT
 5 CGTGTCTTCAAGATCCATAAGTTTGGCCACAGCCCCTTGGTCAACCTGACAGGGG
 GCCTGAGCCACGCCTCTGACGTGGTCTTTACCATCAGCACAAGCAGCCCGAAGT
 GACCAACCCATGTGACCGCAAGAAATGCGAGTGGCTCTGCCTGCTGAGCCCCAG
 TGGGCCTGTCTGCACCTGTCCCAATGGGAAGCGGCTGGACAACGGGCACATGCGT
 GCCTGTGCCCTCTCCAACGCCCCCCCCAGATGCTCCCCGGCCTGGAACCTGTAAC
 10 CTGCAGTGCTTCAACGGTGGCAGCTGTTTCTCAATGCACGGAGGCAGCCCAAGT
 GCCGCTGCCAACCCCGCTACACGGGTGACAAGTGTGAACTGGACCAGTGCTGGG
 AGCACTGTGCAATGGGGGCACCTGTGCTGCCTCCCCCTCTGGCATGCCACGTG
 CCGGTGCCACGGGCTTCACGGGCCCAAATGCACCCAGCAGGTGTGTGCGGG
 CTACTGTGCCAACAACAGCACCTGCACTGTCAACCAGGGCAACCAGCCCCAGTG
 15 CCGATGCCTACCCGGCTTCTGGGCGACCGCTGCCAGTACCGGCAGTGCTCTGGC
 TACTGTGAGAACTTTGGCACATGCCAGATGGCTGCTGATGGCTCCCGACAATGCC
 GCTGCACTGCCTACTTTGAGGGATCGAGGTGTGAGGTGAACAAGTGCAGCCGCT
 GTCTCGAAGGGGCTGTGTGGTCAACAAGCAGAGTGGGGATGTCACCTGCAACT
 GCACGGATGGCCGGGTGGCCCCAGCTGTCTGACCTGCGTCGGGCACTGCAGCA
 20 ATGGCGGCTCCTGTACCATGAACAGCAAAATGATGCCTGAGTGCCAGTGCCAC
 CCCACATGACAGGGCCCCGGTGTGAGGAGCACGTCTTCAGCCAGCAGCAGCCAG
 GACATATAGCCTCCATCCTAATCCCTCTGCTGTTGTGCTGCTGCTGGTCTGGTGG
 CCGGAGTGGTATTCTGGTATAAGCGGCGAGTCCAAGGGGCTAAGGGCTTCCAGC
 ACCAACGGATGACCAACGGGGCCATGAACGTGGAGATTGGAACCCACCTACA
 25 AGATGTACGAAGGCGGAGAGCCTGATGATGTGGGAGGCCTACTGGACGCTGACT
 TTGCCCTGGACCCTGACAAGCCCACCAACTTCACCAACCCCGTGTATGCCACACT
 CTACATGGGGGGCCATGGCAGTCGCCACTCCCTGGCCAGCACGGACGAGAAGCG
 AGAACTCCTGGGCGGGGGCCCTGAGGACGAGATAGGGGACCCCTTGGCATAGGG
 CCCTGCCCCGTCGGAAGTCCCCAGCCAGCCCTTCCCTGGCCCCGCGGATGTATAAATG
 30 TTCAGTGAGCCCCTCCCCAGCCAGCCCTTCCCTGGCCCCGCGGATGTATAAATG
 TAAAAATGAAGGAATTACATTTTATATGTGAGCGAGCAAGCCGGCAAGCGAGCA
 CAGTATTATTTCTCCATCCCCTCCCTGCCTGCTCCTTGGCACCCCCATGCTGCCTT
 CAGGGAGACAGGCAGGGAGGGCTTGGGGCTGCACTCCTACCCTCCCACCAGAA
 CGCACCCCACTGGGAGAGCTGGTGGTGCAGCCTTCCCTCCCTGTATAAGACACT
 35 TTGCCAAGGCTCTCCCTCTCGCCCCATCCCTGCTTGCCCGCTCCCACAGCTTCCT
 GAGGGCTAATTCTGGGAAGGGAGAGTTCTTTGCTGCCCCGTCTGGAAGACGTGG
 CTCTGGGTGAGGTAGGCGGGAAAGGATGGAGTGTTTTAGTTCTTGGGGGAGGCC
 ACCCCAAACCCAGCCCCAACTCCAGGGGCACCTATGAGATGGCCATGCTCAAC
 CCCCCTCCCAGACAGGCCCTCCCTGTCTCCAGGGCCCCCACCAGGTTCCCAGGG
 40 CTGGAGACTTCTCTGGTAAACATTCTCCAGCCTCCCCTCCCCTGGGGACGCCA
 AGGAGGTGGGCCACACCCAGGAAGGGAAAGCGGGCAGCCCCGTTTGGGGACGT
 GAACGTTTTAATAATTTTGTGTAATTCCTTACAATAAATAACACAGATATTGT
 TATAAATAAATTGTAAAAAA

45 SEQ ID NO: 357

>3404 BLOOD 235992.7 D87969 g1694636 Human mRNA for CMP-sialic acid transporter, complete cds. 0

CTTTCTTACAAATAAAGTTTATTGCTGAATTTCCCCATTAACATTATAGAAAACAC
 TGAAATTTACAAATTATTGAGAGCCCAACAGTTAAACATACTTTATTTAAAAAA

GTACAAAAGTGACATTAGAAATTTTTTTGAAGAAATGTGTATCATCTAACAGCAA
 AGAAATATGAACCAGATAATGAATGGCACAAATATAGCACTAAAGGGGTA
 CTAAAGGGGTA
 5 CTTGTAAGAAAAGAGCTAGGTCTTTATGCTGCTAGGACAAAATACTGTACATGAA
 TTGGAGAATAAGGAGGGGGTCATCCTTCTCCCCGGTACCGGAACAAGAGAACAGT
 TAGTACAGAAATGGCTTTGGCACTTTAACCCTTAGACATTGTCCCAAACCTTGTT
 ACTTGAGTATTGTAGCCTCACCATGATTTTTTTTAACACCGTATCATCTCCATACT
 TTTTATTTACAAATTATATATACACACAATAACAATTCCTTCATTCTAAAACAA
 10 TAGTAGACCCCAAACAGGTCTACATTAAGTTTCTGTATTAGCAGTTCACCTCAGAT
 AGCTTCGTTTGTGTTGTTGTTGTTTCCACATAACCGCACTGATCATGCCATACAGTT
 AATTTTTATTTGTTTATGCTACCTTCTGAGATTGACTTAAGGCTCTAGTTTAATGC
 AAAT

15 SEQ ID NO: 358

>3406 BLOOD 198773.4 U91932 g1923269 Human AP-3 complex sigma3A subunit
 mRNA, complete cds. 0

GGGGCGGGTGGGGAAGGATCGCAGGCGAGATTACGAGGCGAGGCTCGCGCGCC
 CGCCCCCGCCCTGGCCCCCAGTGGCCACCCGGTCCGGCCCGGCACAGCCATGAT
 20 CAAGGCGATCCTAATCTTCAACAACACGGGAAGCCGCGGCTCTCCAAGTTCTAC
 CAGCCCTACAGTGAAGATACACAACAGCAAATCATCAGGGAGACTTTCCATTTG
 GTATCTAAGAGAGATGAAAATGTTTGTAAATTCCTAGAAAGGAGGATTATTAATTG
 GAGGATCTGACAACAACTGATTTATAGACATTATGCAACGTTATATTTTGTCTT
 CTGTGTGGATTCTTCAGAAAGTGAACCTGGCATTTTAGATCTAATTCAAGTATTG
 25 TGGAAACATTAGACAAATGTTTTGAAAATGTCTGTGAGCTGGATTTGATTTTCCA
 TGTAGACAAGGTTACAAATATTCTTGCAGAAATGGTGATGGGGGAATGGTATT
 GGAGACAAATATGAATGAGATTGTTACACAAATTGATGCACAAAATAAGCTGGA
 AAAATCTGAGGCTGGCTTAGCAGGAGCTCCAGCCCGTGCTGTATCAGCTGTAAA
 GAATATGAATCTTCTGAGATCCCAAGAAATATTAACATTGGTGACATCAGTATA
 30 AAAGTGCCAAACCTGCCCTCTTTTAAATAAAAATGTAAAAAGGCCACTCCCAGGT
 AAAATCCAGGGGGAAGAGTCATCTAAGTTTACCATGCAGTTGTTTACCAAAAAT
 AGAGGAGGAGAGTCTTAACCTTTTGCTCTTGGATTTAAGTCAAGGTACTGTATAGA
 AGTTGTGTAAAATCAGTATGAAAGTTCAATGTTGCTGTTCTTGCTCAGTGATTTTA
 AAGAAATTGAGTAGTTCCATGTGATTTTTTTTTTCTTTTCTAAACTGCATTCCTG
 35 TGCCACCTACGGCATGCCTCTATGTATTGGCTACTACAGTGTTTTAAAAAGTGTT
 TCAGATATTTCTCTAATTATGTACAACCTAAAATGTTGGTGTTTTGTATGGATCAC
 AAGTGCAGCATTCTTAATTCCTTCTGCTATATGTCACACAGTTGTTATTTGGAGA
 ACCAAGTATGTATTGCATGAAAACATTATGACTTTTTTCTCTTAGTTTAAATAAAC
 TCCAAGGTAACCTGGACTTCTAAAGCACCTTCTGTTTGCCTGATATCTACTTTAGC
 40 AATAATTTTTTTTACAACCCTCTGACTCAACAAAGTAAATAAAAAGTATATTTTATC
 ACTAAAAAAGGG

SEQ ID NO: 359

>3533 BLOOD 287871.2 U89505 g2078528 Human Hlark mRNA, complete cds. 0

45 GCCGCCGCCATTTTAGCGTTTTGTCAGAAGCGTCCGCGCCGCGAGGAGGAGGCCC
 TGCTGGTTTTCTGTGCGGGCTCTTGTGAGGATGGTGAAGCTGTTTCATCGGAAACCT
 GCCCCGGGAGGCTACAGAGCAGGAGATTCGCTCACTCTTCGAGCAGTATGGGAA
 GGTGCTGGAATGTGACATCATTAAGAATTACGGGCTTTGTGCACATAGAAGACA
 AGACGGCAGCTGAGGATGCCATACGCAACCTGCACCATTACAAGCTTCATGGGG

AGCCTTAATCTGGACTGCAGAGAGTATAACGCAGACAAGGCCATCGTGGACAAC
CTGCAAGGGGACTCTGGCCGCGGCTACTACCTGGAGATGCTGATCGGGACCCCC
CCGCAGAAGCTACAGATTCTCGTTGACACTGGAAGCAGTAACTTTGCCGTGGCAG
GAACCCCGCACTCCTACATAGACACGTACTTTGACACAGAGAGGTCTAGCACAT
35 ACCGCTCCAAGGGCTTTGACGTCACAGTGAAGTACACACAAGGAAGCTGGACGG
GCTTCGTTGGGGAAGACCTCGTCACCATCCCCAAAGGCTTCAATACTTCTTTTCTT
GTCAACATTGCCACTATTTTTGAATCAGAGAATTTCTTTTTTGCCTGGGATTAAATG
GAATGGAATACTTGGCCTAGCTTATGCCCACTTGCCAAGCCATCAAGTTCTCTG
GAGACCTTCTTCGACTCCCTGGTGACACAAGCAAACATCCCCAACGTTTTCTCCA
40 TGCAGATGTGTGGAGCCGGCTTGCCCGTTGCTGGATCTGGGACCAACGGAGGTA
GTCTTGTCTTGGGTGGAATTGAACCAAGTTTGTATAAAGGAGACATCTGGTATAC
CCCTATTAAGGAAGAGTGGTACTACCAGATAGAAATTCTGAAATTGGAAATTGG
AGGCCAAAGCCTTAATCTGGACTGCAGAGAGTATAACGCAGACAAGGCCATCGT
GGACAGTGGCACCACGCTGCTGCGCCTGCCCCAGAAGGTGTTTGATGCGGTGGT
45 GGAAGCTGTGGCCCGCGCATCTCTGATTCCAGAATTCTCTGATGGTTTCTGGACT
GGGTCCCAGCTGGCGTGCTGGACGAATTTCGGAACACCTTGGTCTTACTTCCCTA
AAATCTCCATCTACCTGAGAGACGAGAACTCCAGCAGGTCATTCCGTATCACAAT
CCTGCCTCAGCTTTACATTACGCCCATGATGGGGGCCGGCCTGAATTATGAATGT
TACCGATTTCGGCATTTCCTCCCATCCACAAATGCGCTGGTGATCGGTGCCACGGTGA

TGGAGGGCTTCTACGTCATCTTCGACAGAGCCCAGAAGAGGGTGGGCTTCGCAG
 CGAGCCCCTGTGCAGAAATTGCAGGTGCTGCAGTGTCTGAAATTTCCGGGCCTTT
 CTCAACAGAGGATGTAGCCAGCAACTGTGTCCCCGCTCAGTCTTTGAGCGAGCCC
 ATTTTGTGGATTGTGTCCTATGCGCTCATGAGCGTCTGTGGAGCCATCCTCCTTGT
 5 CTTAATCGTCCTGCTGCTGCTGCCGTTCCGGTGTGAGCGTCGCCCCCGTGACCCTG
 AGGTCGTCAATGATGAGTCCTCTCTGGTCAGACATCGCTGGAAATGAATAGCCAG
 GCCTGACCTCAAGCAACCATGAACTCAGCTATTAAGAAAATCACATTTCCAGGGC
 AGCAGCCGGGATCGATGGTGGCGCTTTCTCCTGTGCCACCCGCTTCAATCTCT
 GTTCTGCTCCCAGATGCCTTCTAGATTCACTGTCTTTTGATTCTTGATTTTCAAGCT
 10 TTCAAATCCTCCCTACTTCCAAGAAAAATAATTAATAAAAAAAAAACTTCATTCTAAA
 CAAAACAGAGTGGATTGGGCTGCAGGCTCTATGGGGTTTGTATGCCAAAGTGT
 CTACATGTGCCACCAACATAAAACAAAACCAAGCCTTGGCTCGTTCTCTTCTCTC
 TTCAATCTCTGAAAAATAAGTACATATAGTTGATAACCCCTCTTAGCTTACAGG
 AAGCTTTTTGTATTAATTGCCTTTGAGGTTATTTTCCGCCAGACCTCAACCTGGGT
 15 CAAAGTGGTACAGGAAGGCTTGCAGTATGATGGCAGGAGAATCAGCCTGGGGCC
 TGGGGATGTAACCAAGCTGTACCCTTGAGACCTGGAACCAGAGCCACAGGCCCC
 TTTTGTGGGTTTCTCTGTGCTCTGAATGGGAGCCAGAATCACTAGGAGGTCATC
 AACCGATGGTCCTCACAAGCCTCTTCTGAAGATGGAAGGCCTTTTGCCCGTTGAG
 GTAGAGGGGAAGGAAATCTCCTCTTTTGTACCCAATACTTATGTTGTATTGTTGG
 20 TGCGAAAGTAAAAACACTACCTCTTTTGTAGACTTTGCCAGGGTCCTGTGCCTGG
 ATGGGGGTGCAGGCAGCCTTGACCACGGCTGTTCCCTCACCCAAAAGAATTATC
 ATCCCAACAGCCAAAGACCCAAACAGGTGCTGAACTGTGCATCAACCAGGAAGAGT
 TCTATCCCCAAGCTGGCCACTATCAGATATGCTTACTCTTGCTTAAATTAATAAA
 TCAATGTTTGTATGAGAAAAACTATTGTATTTCACTAGCTTAGTTGTCTCTTTTC
 25 CAAATCTTCTCTGGAAGTAGGTTGGCTATTACCCTGTTGGGAAACAGGGAAATGG
 CCTGATGCCCTATTTCTGACCAGCTGTCAGGGAAGGAAGATGCCAGATGTGCAG
 AAGACACAAGGTAACGTCTACTTATTCCCGTGCTTCGA

SEQ ID NO: 361

30 >3598 BLOOD 440860.23 AF044321 g3170263 Human cytochrome c oxidase assembly
 protein COX11 (COX11) mRNA, complete cds. 0
 ACTGCAACTTAATATTTCTATTTAGAACACAGAAAAATGAAAATATTTAGAATAAG
 TTGTACATTTGATGACAAATAAATCACTATTAAAACAATTTAATACNNNNNNNNNN
 NNNNNNNNGGTTTGTTCAGAAAGAACTTTTGATGTCAGTAAATCTTCACAATCC
 35 CACCTGTACATTTTAACATTCATGGACTTGTAATGGTGTGCTTTGGCTAACAGC
 CTAGTAGATGTATTTTATTTCAATTTTATGATACTACAGTTTCAAAGTAATTATTC
 AGAACTCTGAATATAAAATAGCCCTAAACCTTAAAGGACAAATCAAATTTGAAA
 TAAGAATTTAAATCTTTGGACAAGCTGTTAGGGCTTAGTGACTCCTCTTCTACTTT
 GAGCTTTTAAAATACTGACTATTCATAATGAAGGAAAATAGCAACCAACTCTTTT
 40 AGACACAATAAACATGGTTAGAAGTTCTGGCCTATGACTTGAAACAAATAACCC
 TGAGCATACATTTTGTAAAAACATTGTCAGATTCAATTGCTGTAAGTNTGAAGAGT
 TAATAATCTGGAAGGGAATTATGGAATTAAGCTGAACCCATGCCTGCATATTTAA
 AAAACAAAGCGGCTTATTTAATAGTATCAAACCTCTTCAGTATGGTATTGAATAG
 TCAGTCATATATTCTAGCTAGGCATATGAGTTTCTTATGATAAAAGCTGAACTTG
 45 TTCTCTCAAGTTTAAAGTAAAAAAATAGTTGAGAAAAAATAATTATTTAAAATA
 TAAGCCTTCATATTATTGTACAATATTTCTCCTTTGAGAAGATAGGATATATGATT
 TTCCCAAAAATCACAACCTTGAAGGAAGACTTAGTTGCTGACTTCAATTATATCC
 TGGAACCTGGCAACTTGTGCCCTTCCTTTGCTTCAAAAAAAGTGTAAGAAAGAGTG
 ATAAGATCAACTTTAATCATTCTTGGATCTTCAGCAAATTCAGGATCAATGTAGA

AAAACACTGGCATACTACTTCCTCTTGGGGATTAAGCCTTTGTTCTTCAAAACA
GAAGCACTGGAAATTATAGAAAGATTTTAATAACATTTCTATTCTCGTATTACAT
AACAGAACTATACAGTTCTTTTATCTTAGCATTCCAGTACACTTCGTGATTTTAA
TAAGCATACTATTAAATACACAGTTCTGTGATAAAATTAAGAGCATCTTTTCATCT
5 CAATGAGTTCTGCTTTAAGGATGAAGAACAAATTCTAATCTTAAAAGCAGATATC
CATTTGGTTTGGTTCTCAATCTCTGCATAGCAGGTATAGATAGTGAAGAAAAATA
GCTTGATGTTTAGAAGAAATTCGTTTTTCAGAAATCACAAGATCTACTAAAACACT
AAGTTTCATACTAAACCGTTTCATGTATCTTTATCATATTCTGTAAAGTTTACACT
TTGATGTACCTGTATTTTATTGAAATACTGTCCAGCTTCAAATGGAACAATATTGT
10 ATGTAGAAATTCCAATTACTGGTTTGTGAGTAGGATTCTTAGCTCTGTAAACGC
CAGTGCAGTCTCTCCTGGCACCACATATATTTCTGTTTGCTGAGGTCTAAAGTTCC
ACTGGAGACTTGCATGCACATCTGCATTAAAGCTAATTTTAATGATTTCGATCTTT
AACAGGCACCATGTTTTCAATCTTGTCTGAGGCATGACCTGC

15 SEQ ID NO: 362

>3627 BLOOD 198840.10 L08850 g437364 Human AD amyloid mRNA, complete cds. 0
GAGGAGGACTAGGAGGAGGAGGACGGCGACGACCAGAAGGGGGCCCAAGAGAG
GGGGCGAGCGACCGAGCGCCGCGACGCGGAAGTGAGGTGCGTGCGGGCTGCAG
CGCAGACCCCGGCCCGGCCCTCCGAGAGCGTCTGGGCGCTCCCTCACGCCTTG
20 GCCTTCAAGCCTTCTGCCTTTCACCCTCGTGAGCGGAGAACTGGGAGTGGCCAT
TCGACGACAGTGTGGTGTAAGGAATTCATTAGCCATGGATGTATTTCATGAAAG
GACTTTCAAAGGCCAAGGAGGGAGTTGTGGCTGCTGCTGAGAAAACCAACAGG
GTGTGGCAGAAGCAGCAGGAAAGACAAAAGAGGGTGTTCTCTATGTAGGGCTCCA
AAACCAAGGAGGGAGTGGTGCATGGTGTGGCAACAGTGGCTGAGAAGACCAAA
25 GAGCAAGTGACAAATGTTGGAGGAGCAGTGGTGACGGGTGTGACAGCAGTAGCC
CAGAAGACAGTGGAGGGAGCAGGGAGCATTGCAGCAGCCACTGGCTTTGTCAAA
AAGGACCAGTTGGGCAAGAATGAAGAAGGAGCCCCACAGGAAGGAATTCTGGA
AGATATGCCTGTGGATCCTGACAATGAGGCTTATGAAATGCCTTCTGAGGAAGG
GTATCAAGACTACGAACCTGAAGCCTAAGAAATATCTTTGCTCCCAGTTTCTTGA
30 GATCTGCTGACAGATGTTCCATCCTGTACAAGTGCTCAGTTCCAATGTGCCAGT
CATGACATTTCTCAAAGTTTTTACAGTGTATCTCGAAGTCTTCCATCAGCAGTGAT
TGAAGTATCTGTACCTGCCCCCACTCAGCATTTTCGGTGCTTCCCTTTCACTGAAGT
GAATACATGGTAGCAGGGTCTTTGTGTGCTGTGGATTTTGTGGCTTCAATCTACG
ATGTTAAACAAATTAAACACCTAAGTGACTACCACTTATTTCTAAATCCTCA
35 CTATTTTTTTGTTGCTGTTGTTTCAGAAGTTGTTAGTGATTGCTATCATATATTATA
AGATTTTTAGGTGTCTTTAATGATACTGTCTAAGAATAATGACGTATTGTGAAA
TTTGTTAATATATATAATACTTAAAAATATGTGAGCATGAAACTATGCACCTATA
AATACTAAATATGAAATTTTACCATTTTGCATGTGTTTTATTCACTTGTGTTTGT
ATATAAATGGTGAGAATTAAATAAAAACGTTATCTCATTGCAAAAATATTTTATT
40 TTTATCCCATCTCACTTTAATAATAAAAATCATGCTTATAAGCAACATGAATTAA
GAACTGACACAAAGGACAAAAATATAAAGTTATTAATAGCCATTTGAAGAAGGA
GGAATTTTAGAAGAGGTAGAGAAAATGGAACATTAACCCTACACTCGGAATTCC
CTGAAGCAACACTGCCAGAAGTGTGTTTTGGTATGCACTGGTTCCTTA

45 SEQ ID NO: 363

>3650 BLOOD 1102321.2 D15057 g493244 Human mRNA for DAD-1, complete cds. 0
CGCAAACAGCACATCCGGTGTGGTGCACGGGTCCTCCAAGAGTTTGGGGCGCGG
ACCGGAGTACCTTGCGTGCAGTTATGTCGGCGTCGGTAGTGTCTGTCAATTCGCG
GTTCTTAGAAGAGTACTTGAGCTCCACTCCGACGCTCTGAAGTTGCTGGACGCG

TACCTGCTGTATATACTGCTGACCGGGGCGCTGCAGTTCGGTTACTGTCTCCTCGT
GGGGACCTTCCCCTTCAACTCTTTTCTCTCGGGCTTCATCTCTTGTGTGGGGAGTT
TCATCCTAGCGGTTTGCCTGAGAATACAGATCAACCCACAGAACAAAGCGGATTT
CCAAGGCATCTCCCCAGAGCGAGCCTTTGCTGATTTTCTCTTTGCCAGCACCATCC
5 TGCACCTTGTGTGCATGAACCTTTGTTGGCTGAATCATTCTCATTACTTAATTGAG
GAGTAGGAGACTAAAAGAATGTTCACTCTTTGAATTTCTTGATAAGAGTTCTGG
AGATGGCAGCTTATTGGACACATGGATTTTCTTCAGATTTGCACTTACTGCTAGCT
CTGCTTTTATGCAGGAGAAAAGCCCAGAGTTCACTGTGTGTCAGAACAACTTTC
TAACAAACATTTATTAATCCAGCCTCTGCCTTTCATTAAATGTAACTTTTGCCTT
10 CCAAATTAAGAAGCTCCATGCCACTCCTCAAAAA

SEQ ID NO: 364

>3715 BLOOD 1100675.3 U21128 g699576 Human lumican mRNA, complete cds. 0

CATATCTCTCTCCCATTCATAGGGAATGAGCTGGGCTGTCCTTTCTCCCCACGTT
15 CACCTGCACCTTCGTTAGAGAGCAGTGTTACATGCCACACCACAAGATCCCCACA
ATGACATAACTCCATTCAGAGACTGGCGTGACTGGGCTGGGTCTCCCCACCCCC
CCTTCAGCTCTTGTATCACTCAGAATCTGGCAGCCAGTTCCGTCCTGACAGAGTT
CACAGCATATATTGGTGGATTCTTGTCCATAGTGCATCTGCTTTAAGAATTAACG
AAAGCAGTGTCAAGACAGTAAGGATTCAAACCATTTGCCAAAAATGAGTCTAAG
20 TGCATTTACTCTCTTCTGGCATTGATTGGTGGTACCAGTGGCCAGTACTATGATT
ATGATTTTCCCCTATCAATTTATGGGCAATCATCACCAAAGTGTGCACCAGAATG
TAACTGCCCTGAAAGCTACCCAAAGTGCCATGTAAGTGTGATGAGCTGAAATTGAAA
TAACTGAGTGTAACCAATGGTGCCTCCTGGAATCAAGTATCTTTACCTTAGGAATAACAGAG
TGGACCATATTGATGAAAAGGCCTTTGAGAATGTAAGTATCTGAGTGGCTCAT
25 TCTAGATCACAACTTCTAGAAAAGTCCAAGATAAAAGGGAGAGTTTTCTCTAAA
TTGAAACAACTGAAGAAGCTGCATATAAACCACAACAACCTGACAGAGTCTGTG
GGCCCACTTCCCAAATCTCTGGAGGATCTGCAGCTTACTCATAACAAGATCACAA
AGCTGGGCTCTTTTGAAGGATTGGTAAACCTGACCTTCATCCATCTCCAGCACAA
TCGGCTGAAAGAGGATGCTGTTTCAGCTGCTTTTAAAGGTCTTAAATCACTCGAA
30 TACCTTGACTTGAGCTTCAATCAGATAGCCAGACTGCCTTCTGGTCTCCCTGTCTC
TCTTCTAACTCTCTACTTAGACAACAATAAGATCAGCAACATCCCTGATGAGTAT
TTCAAGCGTTTAAATGCATTGCAGTATCTGCGTTTATCTCACAACGAACTGGCTG
ATAGTGGAAATACCTGGAAATTCTTTCAATGTGTGCATCCCTGGTTGAGCTGGATCT
GTCCTATAACCAAGCTTAAAAACATACCAACTGTCAATGAAAACCTTGAAAACATAT
35 TACCTGGAGGTCAATCAACTTGAGAAGTTTGACATAAAGAGCTTCTGCAAGATCC
TGGGGCCATTATCCTACTCCAAGATCAAGCATTGCGTTTGGATGGCAATCGCAT
CTCAGAAACCAGTCTTCCACCGGATATGTATGAATGTCTACGTGTTGCTAACGAA
GTCACCTCTTAATTAATATCTGTATCCTGGAACAATATTTTATGGTTATGTTTTCT
GTGTGTCAGTTTTCATAGTATCCATATTTTATTACTGTTTATTACTTCCATGAATTT
40 TAAAATCTGAGGGAAATGTTTTGTAAACATTTATTTTTTTTAAAGAAAAAGATGAA
AGGCAGGCCTATTTTCATCACAAGAACACACACATATACACGAATAGACATCAAA
CTCAATGCTTTATTTGTAAATTTAGTGTTTTTTTATTTCTACTGTCAAATGATGTGC
AAAACCTTTTACTGGTTGCATGGAAATCAGCCAAGTTTATAATCCTTAAATCTT
AATGTTTCTCAAAGCTTGGATTAAATACATATGGATGTTACTCTCTTGCACCAAA
45 TTATCTTGATACATTCAAATTTGTCTGGTTAAAAAATAGGTGGTAGATATTGAGG
CCAAGAATATTGCAAAATACATGAAGCTTCATGCACTTAAAGAAGTATTTTTAGA
ATAAGAATTTGCATACTTACCTAGTGAAACTTTTCTAGAATTATTTTTCACTCTAA
GTCATGTATGTTTCTCTTTGATTATTTGCATGTTATGTTTAAATAAGCTACTAGCAA
AATAAAACATAGCAAATGGCATCACTGTGTTTGACTTCTTGTGAAATTTCTGTAC

TTTGTATATAAAATACATAAAACAATAGATTAGAAATCAAAAGATATCTCTGGCC
 TGCAATATTTTACTGATGTGAACATAGGATTTTCCACTAAATAATTTGTCTACTTC
 TAGCATTCACTTACAAAGAGTTCTTAAAAACACCTATAATAGGTACTTAGATTTC
 ACAACTTACTTAGATATTTGTCAATTATCCCATTCCTGGTGTTTTTACTGGTTCAT
 5 ATACAATGGTATTCTATTAGATAAGAAGCTGCTATGTGATCTCAGCACTCACTCC
 TTGGTTGTCAAGAAATGGTGGATAACTCACAGGATTAATAATGAATGAATATAA
 AATTTTCTGAAATAGATATTTAAAAAATCATTTTAGCTTGAAGCCAATATGTCTG
 GATCATAGGTTTTGAGTTCATAATCCAGTAATAACAGCTTTCAGCTTTCATGAGT
 ATATACAATTCTATACAATGATAAATACTCTGCATATAATTTATAAAAAATAACTT
 10 CTGTTTTACCTAGTTAACAATAAAACCTATGTGTGGAGCCAAATGTTATGCAGAC
 AAAGGTCTGCTCATCCCATACAGTGTATATATAGTCAAATATGTGTCTAGTACA
 AATAAAATGTATCTCTAAGGCATAAAATGTTTTAACACACCACTTTTAGTGAAC
 CTATCTTATGGTACAGCGGCCTTTCATCAAAGGATCATCATTGAGACTGAGTTGA
 CTGGCAGATATGTGCGATGGATATTACATTAGGTACAATGTGTATTTTTGATTTTC
 15 ATGAGTTTTCTACATTAAAGGTAAATTCCTTAGAGTGTGATAGCAGCCTCAGTTTA
 TTTGTTGGTTTAAACTTGAAATCTACTTTTCTCGATAAAACTATAATGTAGATGA
 ATTG

SEQ ID NO: 365

20 >3743 BLOOD 1328438.3 U35451 g1177844 Human heterochromatin protein p25 mRNA,
complete cds. 0

TGGGAGCGGCGGGGAGCGCAGACTGCGAGGCTCTTTTGTTCGGCTGAGGGGAGGGG
 CCGTTGGCCGGGGGAGTGCAGTACGCCGCTTCAGTGAGGGAGCGCACTGCGGGC
 ACCCGGCTTGCTGCTTCCCTGGGCGCCACTCCCCAGGCGACCCGACGCGACGCG
 25 CCAGTAGCGCAGCACCGATTCCCTCTCGGGGCTCTTGGGCGCTGCTCTGAGCAGCG
 TCACCCTTTACACCAGAAAGCTGGCGGGCACTATGGGGAAAAACAACAAGA
 AGAAAGTGGAGGAGGTGCTAGAAGAGGAGGAAGAGGAATATGTGGTGGAAAAA
 GTTCTCGACCGTCGAGTGGTAAAGGGCAAAGTGGAGTACCTCCTAAAGTGGAAAG
 GGATTCTCAGATGAGGACAACACATGGGAGCCAGAAGAGAACCTGGATTGCCCC
 30 GACCTCATTGCTGAGTTTCTGCAGTCACAGAAACAGCACATGAGACAGATAAA
 TCAGAGGGGAGGCAAGCGCAAAGCTGATTCTGATTCTGAAGATAAGGGAGAGGAG
 AGCAAACCAAAGAAGAAGAAGAAGAGTCAAGAAAGGCCACGAGGCTTTGCTCG
 AGGTTTGGAGCCGGAGCGGATTATTGGAGCTACAGACTCCAGTGGAGAGCTCAT
 GTTCCTGATGAAATGGAAAACTCTGATGAGGCTGACCTGGTCCCTGCCAAGGA
 35 AGCCAATGTCAAGTGCCACAGGTTGTCATATCCTTCTATGAGGAAAGGCTGACG
 TGGCATTCTACCCCTCGGAGGATGATGACAAAAAAGATGACAAGAACTAACGC
 TCCTGAGTACCAGCCCCTGTCACATCTGACTGTGGGTTTCAAGTGGGAAGGGAAG
 GAGTTCTACTTGTCTTGACACCATAGAGGTGGCTTGAGAAGATGTCCTTTGAAGA
 GCCAGTATAGTTTCTGTGCCCTGCAGCAGCCCAAGTGCTTTAAAGCCGTTTCAAG
 40 CTGTATAGTTTGCACACCCATCCCAGTGGAGGGGAAAGGGGATAAGTGTTTCAA
 GGCAACCTTTTCTGCACTTTGCTGCGAAAAGCAAAGGGCCTTCTATGAAGGACAA
 AACTTGCAGAATTGGGTGTGTGGGAGAGCAAAAAAATACTGTAGATCTTCAAAG
 AGCATCTCCACAACCCACAGCCTTCTTCCAATAGTGTTAACTCTGCATTTTTACA
 GCGTAGCATGTGTGTAGTTTTTGGCTATTACTGGTGTATTATTTGGGGGAGGGAG
 45 GGATGGGGAGGGGAGAAAGGGAGATGGGTAGCATCATTTTGATTAACATTTGGG
 GCCTGATAGGGGAAATGGTGAAGCAATGGAAAAGAACAGACAATAATGATTTG
 CTTCTATGTCCAGAATATTTTACCTTTAAAAAATGTCATTGGCACCATAAATAA
 GGACTGTGAGAGACTGTTTAAAGCTGTGAAAGTCTGAAACCTATAAGCCAAGG
 TGTCCCTGCCTAACTTATTGCTGTTCCACAAAGGACTAAGCCTGTTCAATAGT

TACCAAAGTTGCCATTTTGGAGATGGAAATTGACGAGGAGGGAAGGTCTTTTATT
GGAGAGTATACAGTACAAGCAGATCATTCTGCCTTAGAGGTGCTAATTCCCGAA
ATTAGAAGACCCTTTCTTTTCCAGTAACGAAGTTATAAATATCAGCTTGTTTCATCC
AAGCCACTGGCTGAGGTGTTAGGAAGAGGAAGAGGGTGGTAGAGGAGGTAAGA
5 CAGTAGGGGAAAGACAAGGGCCCATGCTCTTAGTGGGGAAAACCTCTTGAGCCGT
TTACTTTGAGCTTTGAACACTGAAACCATTGTTGGCAGGGTTCAGTCACTGACAG
CACAAGTTTCACTGAATTGATCCAAGAGTTTAGTGATTTCAAAAGCCTTGGTCTC
AGGAGAAGATTAAACTTTTCATATTGGGCAGTGGTTCACTTTAAAACACACACATA
CACACACAAAACAATTTTTTAAGAAATCCTAATAAGTAACATACCCAAAATGCTC
10 TGTCTTGAGTCATGAGAACCATCAGTTCTTGATATTGTCTAGACTTGTCATCTAGA
GCTACGTTGTAAAATTCTTTTAGGCATGTGTTAGATTCTGTGTAAACTTTGTTTA
AATGTAAACTTCATACTACATTGTCAGTTTTTGTCTTAATAAAACTATAGATTTAT
AATCCCTGATTTCTGTCTTAAGTCTTACCAGGAACCCTTCTTGCCTTATAGGTTCA
GCCTGTTGGAAATGGCTTCCTCACTTGAATGGTTTTATTTCTTGAACACTGTAGGC
15 TTGAAAATCTAGTGCCTGGCCTGAATCTTTAAGTGGTCAC

SEQ ID NO: 366

>3747 BLOOD 233301.19 M81934 g180172 Human cdc25B mRNA, complete cds. 0

GCCAGCTGTGCCGGCGTTTGTGGCTGCCCTGCGCCCGGCCCTCCAGCCAGCCTT
20 CTGCCGGCCCCGCCGCGATGGAGGTGCCCCAGCCGGAGCCCGCGCCAGGCTCGG
CTCTCAGTCCAGCAGGCGTGTGCGGTGGCGCCAGCGTCCGGGGCCACCTCCCGGG
CCTCCTGCTGGGATCTCATGGCCTCCTGGGGTCCCGGTGCGGGGGGGCGGCTTCC
TGGGCGGTCAACCACCCTCACCCAGACCATGCACGACCTCGCCGGGGCTCGGCAGCC
GCAGCCGCGCTGACGCACCTATCCCTGTCTCGACGGGGATCCGAATCCTCCGTGTC
25 GTCTGAATCCTCCGAATCTTCTGATGCAGGTCTCTGCATGGATTCCCCCAGCCCTA
TGGACCCCCACATGGCGGAGCAGACGTTTGAACAGGCCATCCAGGCAGCCAGCC
GGATCATTCGAAACGAGCAGTTTGCCATCAGACGCTTCCAGTCTATGCCGGTGAG
GCTGCTGGGCCACAGCCCCGTGCTTCGGAACATCACCAACTCCCAGGCGCCCGAC
GGCCGGAGGAAGAGCGAGGCGGGCAGTGGAGCTGCCAGCAGCTCTGGGGAAGA
30 CAAGGAGAATGATGGATTTGTCTTCAAGATGCCATGGAAGCCACACATCCAG
CTCCACCCATGCTCTGGCAGAGTGGGCCAGCCGCAGGGAAGCCTTTGCCAGAG
ACCCAGCTCGGCCCCCGACCTGATGTGTCTCAGTCCTGACCGGAAGATGGAAGTG
GAGGAGCTCAGCCCCCTGGCCCTAGGTGCGCTTCTCTCTGACCCCTGCAGAGGGGG
ATACTGAGGAAGATGATGGATTTGTGGACATCCTAGAGAGTGACTTAAAGGATG
35 ATGATGCAGTTCCCCCAGGCATGGAGAGTCTCATTAGTGCCCCACTGGTCAAGAC
CTTGGAAGGAAGAGGAAAGGACCTCGTCATGTACAGCAAGTGCCAGCGGCT
CTTCCGCTCTCCGTCCATGCCCTGCAGCGTGATCCGGCCCCATCCTCAAGAGGCTG
GAGCGGCCCCAGGACAGGGACACGCCCCGTGCAGAATAAGCGGAGGCGGAGCGT
GACCCCTCCTGAGGAGCAGCAGGAGGCTGAGGAACCTAAAGCCCGCGTCTCTCCG
40 CTCAAAATCACTGTGTACGATGAGATCGAGAACCTCCTGGACAGTGACCACCG
AGAGCTGATTGGAGATTACTCTAAGGCCTTCCTCCTACAGACAGTAGACGGAAA
GCACCAAGACCTCAAGTACATCTCACCAGAAACGATGGTGGCCCTATTGACGGG
CAAGTTCAGCAACATCGTGGATAAGTTTGTGATTGTAGACTGCAGATACCCCTAT
GAATATGAAGGCGGGCACATCAAGACTGCGGTGAACTTGCCCCTGGAACGCGAC
45 GCCGAGAGCTTCTACTGAAGAGCCCCATCGCGCCCTGTAGCCTGGACAAGAGA
GTCATCCTCATTTTCCACTGTGAATTCTCATCTGAGCGTGGGCCCCGCATGTGCCG
TTTCATCAGGGAACGAGACCGTGCTGTCAACGACTACCCAGCCTCTACTACCCT
GAGATGTATATCCTGAAAGGCGGCTACAAGGAGTTCTTCCCTCAGCACCCGAAC
TCTGTGAACCCAGGACTACCGGCCCATGAACCACGAGGCCTTCAAGGATGAGC

25 SEO ID NO: 367

GC GG G C C C T G C G C G C C C T G C G C T C G C C A T G G C G G T T T G G G C G G C G A C G T G A G C G
G C T C C G C G G A C C C C G A G C G G G G C C C C G G C C G C G A C C T G A G C C G C C G C C G A G C G C
30 C C G G G G C C A T G C G A C C G A C G C T G C T G T G G T C G C T G C T G C T G C T G C T C G G A G T C T T
C G C C G C C G C C G C C G C G G C C C C G C C A G A C C C T C T T T C C C A G C T G C C C G C T C C T C A G
C A C C C G A A G A T T C G C C T G T A C A A C G C A G A G C A G G T C C T G A G T T G G G A G C C A G T G
G C C C T G A G C A A T A G C A C G A G G C C T G T T G T C T A C C A A G T G C A G T T T A A A T A C A C C G
A C A G T A A A T G G T T C A C G G C C G A C A T C A T G T C C A T A G G G G T G A A T T G T A C A C A G A
35 T C A C A G C A A C A G A G T G T G A C T T C A C T G C C G C C A G T C C C T C A G C A G G C T T C C C A A T
G G A T T T C A A T G T C A C T C T A C G C C T T C G A G C T G A G C T G G G A G C A C T C C A T T C T G C C
T G G G T G A C A A T G C C T T G G T T T C A A C A C T A T C G G A A T G T G A C T G T C G G G C C T C C A G
A A A A C A T T G A G G T G A C C C C A G G A G A A G G C T C C C T C A T C A T C A G G T T C T C C T C T C C
C T T T G A C A T C G C T G A T A C C T C C A C G G C C T T T T T T T G T T A T T A T G T C C A T T A C T G G G
40 A A A A G G A G G A A T C C A A C A G G T C A A A G G C C T T T C A G A A G C A A C T C C A T T T C A T
T G G A T A A C T T A A A A C C C T C C A G A G T G T A C T G T T T A C A A G T C C A G G C A C A A C T G C T
T T G G A C A A A A G T A A C A T C T T T A G A G T C G G G C A T T T A A G C A A C A T A T C T T G C T A C
G A A C A A T G G C A G A T G C C T C C A C T G A G C T T C A G C A A G T C A T C C T G A T C T C C G T G G
G A A C A T T T T C G T T G C T G T C G G T G C T G G C A G G A G C C T G T T T C T T C C T G G T C C T G A A A
45 T A T A G A G G C C T G A T T A A A T A C T G G T T T C A C A C T C C A C C A A G C A T C C C A T T A C A G A
T A G A A G A G T A T T T A A A A G A C C C A A C T C A G C C C A T C T T A G A G G C C T T G G A C A A G G
A C A G C T C A C C A A A G G A T G A C G T C T G G G A C T C T G T G T C C A T T A T C T C G T T T C C G G A
A A A G G A G C A A G A A G A T G T T C T C C A A A C G C T T T G A A C C A A A G C A T G G G C C T A G C C
C A C T G G C T C C C T G G A A G A G A T C A A G C C A T C G G A G C T G C T A G A G T T C T G T C T G G A C

TTTCCAGAGACCAGTATTCCCTTTTGCTGCCTCTAAAAGGCCTGTCCCTGCAGAC
 ATGAGAGACAGCAGGTCTCATGGGGGTGACAAGCTTTTTTTTTTTCTTAAAGA
 ATTTTCAAATCAAATTCAGAATGATTTTACGGAGATATCCCAGGAAAATTAAG
 GCTTCTCTTAAACACTAAAAAGGCATGTAATTGCTTGTTAGCAAAATGGATATGA
 5 CACATCTCTGATACITTTTTTCATTATTGGTTGGGCTGAGCAGTCAGAAGACCTGGT
 CGTCGTCTTGACTTTGGCAAATGAGCCGGAGCCCCTTGGGCAGGTCACACAACCT
 GTCCCAGCGAGGGACACTGAGTGGCCCTTCATGTACATCCATGGTGTGCTGGCTT
 AAAATGTAATTAATCTTGTAATATACTCCTAGTAATTTAAGATTTTGTTTTTAAA
 CTGGAAATAAAAGATTGTATAGTGCATGTTTTTTAAAGTCTATGTGAAGTGT
 10 CTTTATTGTAGCCTATTTTCTGCAGAGTTTCAGCTTTCTAAAATTACTCAATCTAA
 ACTTGTTTTTTCTTAAATAACACCTGCTAGAGCTACTGAGGCCTCATGGGAACCTC
 AGCAAACACTTCCTATGGATGTCACCTGATCCTCCCAAAGTGCTGGGATTAC

SEQ ID NO: 368

15 >3770 BLOOD 475174.21 S67970 g460902 ZNF75=KRAB zinc finger [Human, lung
 fibroblast, mRNA, 1563 nt]. 0
 TAGGAAACAGAAATTTCCCTGGCTATTTTCTACCCACAGCTGTCATGATCAACA
 GATGTTAGCCCTTTCTGAGCAGAAAAGAATCAAACACTGGAAGATGGCATCTAA
 ACTCATCCTGCCTGAGTCCCTGGTGAGCTGTTATTTCTGGCTTTTACAGGTGACT
 20 TGACTGTGGCCTTGCCCTCTGCTTGTCCTATTGCCTAGGACTCATAGTGTCCAGCA
 GGTGCTTTGAGGCATTTTAGCCCCAGTTATTCTCTAGGCAACTAGGCTTGGCACA
 CTGGGAACTGGGCACCTCCCAGGTGATTTACTGATCCTCTTTGCTCCTTCTTCT
 CTGCCTTCTCACTTTTTTCCCCTAAATCTTGTACTGTTTCACATCTTCAGCACCTGGC
 CTACCATGTAATTCAGAAATGGGTGGTAGGACAGCTTCTGAAGTGGCAAGTACT
 25 AAATATAGCCCATTTCTCTTTAGAGTTTGTGACATTTGAAGATGTGGCTGTG
 TATTTTCTGAGGAAGAGTGGCAATTATTGAATCCTCTTGAGAAGACTCTCTACA
 ATGATGTAATGCAGGATATCTATGAGACTGTCATCTCTCTAGGGTTAAAGCTAAA
 AAATGACACTGGAAATGATCATCCTATATCTGTTTCTACATCAGAAATACAAACA
 TCAGGATGCGAAGTATCAAAAAAGACCAGAATGAAAATTGCCAGAAAACAATG
 30 GGCAGGGAAAATCCTGGTGATACACACAGTGTACAGAAATGGCATCGAGCTTTT
 CCAAGGAAGAAAAGAAAGAAACCTGCAACTTGTAACAAGAGCTTCCAAAACCTT
 ATGGATCTTCATGGGAAAGGCCCCACAGGGGAGAAACCTTTTAAGTGTGAGGAA
 TGTGGGAAAAGCTTCAGAGTTAGCTCTGATCTTATTAACACCAACAGAAATTCACA
 CTGGAGAGAAACCCTATAAATGTCAACAATGTGACAGGAGGTTTAGATGGAGTT
 35 CAGATCTTAATAAGCACTTCATGACCCATCAAGGAATAAAACCATATAGATGCTC
 ATGGTGTGGGAAAAGCTTTAGTCATAACACAAATCTACACACACACCAAAGAAT
 TCACACAGGAGAGAAGCCCTTTAAATGTGATGAATGTGGAAAAAGATTTCATTCA
 GAACTCCCACCTTATTAACACCAAGAGAACTCACACAGGTGAGCAGCCTTATAC
 ATGTAGCTTATGCAAGAGAACTTTAGTAGGCGATCGAGCCTTCTTAGACACCAG
 40 AAATCCACAGAGAAGGAAGCATGTCTAGTGTCTCCAACTGAGGAAAGTTA
 CCATGTAGAGCTTGACTTTAGAAGTGGTGAAAGAATACAAAATTATGAGGCACC
 CAATGATAGGAATCTGTGATTAATAAAACATTTGGGAAGGGTACATGTTACACTT
 CACAAAAGGAATCTAAGCTGTCTGTTTTATTTCAGCATTGCATCTTCTGTGCCTA
 GCACAAGAGTTGATACATAAGGAGTACTTTATAAATAAAAAAATGAAAGTGTAG
 45 TGATGAGATTCCTTTAGCTATCTATCTATATGTATATATCTGGTTATTCAAAGCTT
 CCCCACCCCCAGTCATCTAAATTTTTTCAGGTATCAAGTGCTCAACAGACATATGA
 TAGTCAAGGCTCTTAGTCTCATTTTTTACTCTTTGTCAAGAGAAATGGAAAATAA
 GAGTACTTGGGCCCTCTTAAGGGAGCTCAGAGAGAATTACTAAATTAGGGACAG
 TTCAATAGTTATCATTCTATCTACATGAACAATCAAGACCAGGACTCAGGGAAC

TTTACTCTGTAACAGAAAGAGAGGATTTCAGTGTGTTGCCCTGGGAGAATTGTCCCA
 TTCTTGTTGCTTCTCTCCTGAGTACCCACTACCACAATGTCTTCTGTCAAGGAATT
 ACAAGTAGCAAGGGAAGGTCTGAATGTAAGGACAGGCCTAGGGACCTTGCAAGC
 ACTTGATATCTCTCCTCTTGCTGACTTTGTCAACATAGACATATAGTGAAATGATG
 5 AGGGAGGCAGTCTTGGCCCTCATCCAGGTATCTGGTTTTTTTTTGTAGAAAGCAC
 AGATAAGTGGTAAATGGTCTTTTTCTGACTTTCATTATGTGGACTGGATGGAGGC
 TTTCAAACTGGTGGCCATACTGCTGCAGGACCTAAAGGGAGCCCCATCTTTATGGC
 TGATCAACTACAACCCTATATGCCTGAATACTCTGCAAGAAGGCCTGGAGATTTT
 GCAAACTGATTTATTGAGAATGGCAAGGAGAGCCTTGTGAACTTTTAGCTTTGG
 10 TGCACAGCTGATACCAGGAGGGAACATCCTGAAGTGTGAGAGAAAAGTAAGGCA
 TATGGCTCACAGTGATGATGCCAGTCAGAGCCAGGCCAGATGGAAATTGTTTTCT
 GATGTTACTGGTTTTCTTTTCCCTATTAGCCAAAGTGAATCTCTTAAGAGAAGA
 TAATGTGACGTCAAGGGAAGTTGGAAGGCATGGATTTATATCTATGTCAGATCCT
 GGTTTATAATGTTGGCCAAGGCTTATTTATATATGTTTATTTAGTATTCCATAAAA
 15 TTGTACTTCGTAATGAAAATGACACATTTTATCTTAAATTTAGACAATAAACAAA
 ACTTTGTTACCAAATC

SEQ ID NO: 369

>3787 BLOOD 256010.6 X63679 g37264 Human mRNA for TRAMP protein. 0

20 GGCGGCTGCGTACTGGCTGTGGGATGGGAAGTGAAGCCCCAGCGAGCGGCTGCA
 GCGGGGCCGTGAGGAGCAGCCAGCGGGAGGCGGCGGCGAGTCGGTGAGCAGCT
 GGGGAAGAGCAGAACCGGGGGGGAGGACCTGCAGGCCCGGGCGGCGGCCCCACC
 ATGGGCGATTTCGAAGAAAAGCAGCAAGAGCCCCCAGTGTGTGAGGCGACGAATTC
 GTCCTGCAGAATCACGCGGAGATGCTCTCCTGTGTGGCGATGGTCTTCCTGCTGG
 25 GGCTCATGTTTGAGATAACGGCAAAAGCTTCTATCATTTTTTGTACTCTTCAGTAC
 AATGTCACCCCTCCAGCAACAGAAGAACAAGCTACTGAATCAGTGTCCCTTTATT
 ACTATGGCATCAAAGATTTGGCTACTGTTTTCTTCTACATGCTAGTGGCGATAATT
 ATTCATGCCGTAATTCAAGAGTATATGTTGGATAAAATTAACAGGCGAATGCACT
 TCTCCAAAACAAAACACAGCAAGTTAATGAATCTGGTCAGCTTAGTGCGTTCTA
 30 CCTTTTTGCCTGTGTTTGGGGCACATTCATTCTCATCTCTGAAAACATCATCTCAG
 ACCCAACTATCTTATGGAGGGCTTATCCCCATAACCTGATGACATTTCAAATGAA
 GTTTTTCTACATATCACAGCTGGCTTACTGGCTTCATGCTTTTCCGAACTCTACT
 TCCAGAAAACCAAAAAAGAAGATATTCCTCGTCAGCTTGTCTACATTGGTCTTTA
 CCTCTTCCACATTGCTGGAGCTTACCTTTTGAACCTTGAATCATCTAGGACTTGTTC
 35 TTCTGGTGCTACATTATTTTGTGAAATTTCTTTTCCACATTTCCCGCCTGTTTTATT
 TTAGCAATGAAAAGTATCAGAAAGGATTTTCTCTGTGGGCAGTTCCTTTTGTGTTG
 GGAAGACTTCTGACTTTAATTCCTTCAGTAACTAAAGGCAGATCTTCTAAAAAAG
 GAACAGAAAATGGTGTGAATGGAACATTAACCTCAAATGTAGCAGACTCTCCCC
 GGAATAAAAAAGAGAAATCTTCATAATGAATTATAAACTAATTGATTAATGTCCC
 40 CAAAGAAATCTGCTTTCTACTATATCTTTCAGCATTAGAGATTTTTCTGTTCTTGA
 AAATACAGTCTGTGCTCTTTGATTTTTGCTATTGTACGGTTTCATGCATTTTTTTAA
 AGGGCATTTGAGGGGAGGATTATTGCTATGAATGAAAAAATATTTTAGCTTAG
 ACTAAGCTACCTGCCTTCAAATAGTTTAGGGACCACCACCATATTTTATTTTGT
 TTTATTTTGAACATTTTCTAATGATTTGGAGAGAAAACATTTTACAAAAATTCC
 45 ACATATCAGTGATACAATTTCTTGCTGTCACCAATTTTTTATAATAGCAGAGTGG
 CCTGTTCTAAGAAGGCCATATTTTTTAAGTTATCTTTCAGGGTAACATGGAAATA
 CTATAAAGTTGGATGTCAAACCTTAATATGTTTTTCAGTGTTCTCTAATTTTTTGA
 ATTTTTGTAGACTTTACACCTGGAAAAAAGATTTGTAAATCACCGGAACAATT
 GTGTGCTTTATTTTATAGGTAGTGGTTATTAGTATTACATCCCCATTTTAAAAACA

AAAACATAATAATGGTTACAACACGTGGAGTTTTACTAACATACATATTAAATCA
AAGTATATTCTTAAAAGTACTTGTGAAGTAAAATCTTTCTTGTGCATTTTCAATAC
TTGTAAACTGGAAATCAGAAAATATTTACTATGAACAGGAAAATCTGACATATA
GCCCTTTTGTATATGTTTATTAATAATGATTCTTAATGGGGCTCATAATAAGTTTA
5 ATATGCACAGCATCTTAGAAAAAGTTTAACTGCAAAACACTTTTAAAAACATAATGC
CTACTTGATTTATATCTATAAAAAAGACTGACAGGTAATTATATTTGGAAAACATT
TAATGCACTAACTTTAAAGAAATTGAAAATTCAGGTGGATAAAATAGTCTTACAAA
AGACAATGTGCTTTTATGTTATACCTATAGCTTTGGTCCCATCTTTAATTGAGAAAC
ATTTATCTGTATAAAACATATTTTTGGATAAATATATATATATATATATTTGTATTGC
10 TACAGAAAGGCTCTAAAAAGCATTTGAGGAAAATATTTGGTTCCCTTTTCTATAA
TCATCCTTTAAGATTCTTATAGCTACATTTGGTTTATTCATCATATTTACAGTATA
TATATTGTTCTTTTCAGTGTTACATCTTGTTCCTTCTCACTTGTGTCACCAG
CTGTTTGTGCCATTTTGTAGTGTAAGTTGCAGACCTATTAGATCTGCAGTTTAAAG
TTGCCATGCTGCTAGGAAATTGTCCTTTTCTTTCTAGCTGTTAACCTACTTCTCTG
15 GAAAAAGTAGTAGCTCTCTGTAGCATTATGGAGTTTCAGTGGAACCAAATTTTTG
CCATTAAAAACTGGCATTATACTGAACCTATACATTGAGAAATCAATCAAATAA
AAATTTTACTTTCACAAGTTGTATCCTGGATGTTTCTGTCATTGTTGGTGATTAG
GCTATTTTGGTATATAACCTCATTAAAATGTACCATATTTAAACACTTCATAGA
CATTGAGAATAACCTTTTCAAATTTGTGTTCTGCAAATAAACAGATTGTGCCA
20 CAGAAAA

SEQ ID NO: 370

>3790 BLOOD Hs.76252.gn|UG|Hs#S4668:H.sapiens mRNA for endothelin-1 receptor

/cds=(484,1767)/gb=X61950/gi=288312/ug=Hs:76252/len=4105

25 GAATTCGCGGCCCGCCTCTTGCGGTCCCAGAGTGGAGTGAAGGTCTGGAGCTTTG
GGAGGAGACGGGGAGGACAGACTGGAGGCGTGTTCCCTCCGGAGTTTCTTTTTCG
TGCGAGCCCTCGCGCGCGGTACAGTCATCCCGCTGGTCTGACGATTGTGGAGAG
GCGGTGGAGAGGCTTCATCCATCCCACCCGGTCGTCGCCGGGGATTGGGGTCCCA
GCGACACCTCCCCGGGAGAAGCAGTGCCCAGGAAGTTTTCTGAAGCCGGGGAAG
30 CTGTGCAGCCGAAGCCGCCGCCGCCGGAGCCCGGGACACCGGCCACCCTCCG
CGCCACCCACCCTCGCTTTCTCCGGCTTCCTCTGGCCCAGGCGCCGCGCGGACCC
GGCAGCTGTCTGCGCACGCCGAGCTCCACGGTGAAAAAAAAGTGAAGGTGTAA
AAGCAGCACAAAGTGCAATAAGAGATATTTCTCAAATTTGCCTCAAGATGGAAA
CCCTTTGCCTCAGGGCATCTTTTGGCTGGCACTGGGTGGATGTGTAATCAGTGAT
35 AATCCTGAGAGATACAGCACAAATCTAAGCAATCATGTGGATGATTTCAACCACT
TTCGTGGCACAGAGCTCAGCTTCCTGGTTACCACTCATCAACCCACTAATTTGGT
CCTACCCAGCAATGGCTCAATGCACAACTATTGCCACAGCAGACTAAAATTACT
TCAGCTTTCAAATACATTAACACTGTGATATCTTGTACTATTTTCATCGTGGGAAT
GGTGGGGAATGCAACTCTGCTCAGGATCATTTACCAGAACAAATGTATGAGGAA
40 TGGCCCCAACGCGCTGATAGCCAGTCTTGCCCTTGGAGACCTTATCTATGTGGTC
ATTGATCTCCCTATCAATGTATTTAAGCTGCTGGCTGGGCGCTGGCCTTTTGATCA
CAATGACTTTGGCGTATTTCTTTGCAAGCTGTTCCCCTTTTGCAGAAGTCCTCGG
TGGGGATCACCGTCTCAACCTCTGCGCTCTTAGTGTTGACAGGTACAGAGCAGT
TGCCTCCTGGAGTCGTGTTTCAAGGAATTGGGATTCTTTGGTAACTGCCATTGAA
45 ATTGTCTCCATCTGGATCCTGTCTTTATCCTGGCCATTCTGAAGCGATTGGCTT
CGTCATGGTACCCTTTGAATATAGGGGTGAACAGCATAAAACCTGTATGCTCAAT
GCCACATCAAATTCATGGAGTTCTACCAAGATGTAAAGGACTGGTGGCTCTTCG
GGTTCTATTTCTGTATGCCCTTGGTGTGCACTGCGATCTTCTACACCCTCATGACT
TGTGAGATGTTGAACAGAAGGAATGGCAGCTTGAGAATTGCCCTCAGTGAACAT

CTTAAGCAGCGTCGAGAAGTGGCAAAAACAGTTTTCTGCTTGGTTGTAATTTTTG
CTCTTTGCTGGTTCCCTCTTCACTTAAGCCGTATATTGAAGAAAACCTGTGTATAAC
GAAATGGACAAGAACCGATGTGAATTACTTAGTTTTCTTACTGCTCATGGATTACA
TCGGTATTAACCTTGGCAACCATGAATTCATGTATAAACCCCATAGCTCTGTATTTT
5 GTGAGCAAGAAATTTAAAAATTGTTTCCAGTCATGCCTCTGCTGCTGCTGTTACC
AGTCCAAAAGTCTGATGACCTCGGTCCCCATGAACGGAACAAGCATCCAGTGGA
AGAACCACGATCAAAACAACCACAACACAGACCGGAGCAGCCATAAGGACAGC
ATGAACTGACCACCCTTAGAAGCACTCCTCGGTACTCCCATAATCCTCTCGGAGA
AAAAAATCACAAGGCAACTGTGACTCCGGGAATCTCTTCTCTGATCCTTCTTCCT
10 TAATTCACTCCCACACCCAAGAAGAAATGCTTTCCAAAACCGCAAGGTAGACTG
GTTTATCCACCCACAACATCTACGAATCGTACTTCTTTAATTGATCTAATTTACAT
ATTCTGCGTGTTGTATTTCAGCACTAAAAAATGGTGGGAGCTGGGGGAGAATGAA
GACTGTAAATGAAACCAGAAGGATATTTACTACTTTTGCATGAAAATAGAGCTT
TCAAGTACATGGCTAGCTTTTATGGCAGTTCTGGTGAATGTTCAATGGGAACTGG
15 TCACCATGAACTTTAGAGATTAACGACAAGATTTTCTACTTTTTTTAAGTGATTT
TTTGTCCTTCAGCCAAACACAATATGGGCTCAGGTCACTTTTATTTGAAATGTCAT
TTGGTGCCAGTATTTTTTAACTGCATAATAGCCTAACATGATTATTTGAACCTTATT
TACACATAGTTTGAAAAAAAAGACAAAAATAGTATTCAGGTGAGCAATTAGA
TTAGTATTTTCCACGTCCTATTTATTTTTTTAAACACAAATTCTAAAGCTACAA
20 CAAATACTACAGGCCCTTAAAGCACAGTCTGATGACACATTTGGCAGTTTAATAG
ATGTTACTCAAAGAATTTTTTAAAGAACTGTATTTTATTTTTTAAATGGTGTTTTAT
TACAAGGGACCTTGAACATGTTTTGTATGTTAAATTCAAAAGTAATGCTTCAATC
AGATAGTTCTTTTTCACAAGTTCAATAGTGTTTTCATGTAAATTTTGTATGAAAA
ATCAATGTCAAGTACCAAAATGTTAATGTATGTGTCAATTAACCTCTGCCTGAGAG
25 TTTTCAGTGCCTGTATATAGAAGTCTAAAACACACCTAAGAGAAAAAGATCGAA
TTTTTCAGATGATTTCGGAATTTTCATTTCAGGTATTTGTAATAGTGACATATATAT
GTATATACATATCACCTCCTATTCTCTTAATTTTTTGTAAAAATGTTAACTGGCAGT
AAGTCTTTTTTGTATTCCTTTTCCATATAGGAAACATAATTTTGAAGTGGCCA
GATGAGTTTATCATGTCAAGTAAAAATAATTACCCACAAATGCCACCAGTAACTT
30 AACGATTCTTCACTTCTTGGGGTTTTTCAGTATGAACCTAACTCCCCACCCCAACAT
CTCCCTCCACATTGTCACCATTTCAAAGGGCCACAGTGACTTTTGCTGGGCATT
TTCCCAGATGTTTACAGACTGTGAGTACAGCAGAAAAATCTTTTACTAGTGTGTGT
GTGTATATATATAAACAATTGTAAATTTCTTTTLAGCCCATTTTCTAGACTGTCTC
TGTGGAATATATTTGTGTGTGTGATATATGCAATGTGTGTGATGGTATGTATGGATT
35 TAATCTAATCTAATAATTGTGCCCCGCAGTTGTGCCAAAGTGCATAGTCTGAGCT
AAAATCTAGGTGATTGTTTCATCATGACAACCTGCCTCAGTCCATTTTAACCTGTA
GCAACCTTCTGCATTCAATAATCTTGTAAATCATGTTACCATTACAAATGGGATAT
AAGAGGCAGCGTGAAAGCAGATGAGCTGTGGACTAGCAATATAGGGTTTTGTTT
GGTTGGTTGGTTTGATAAAGCAGTATTTGGGGTCATATTGTTTCCTGTGCTGGAG
40 CAAAAGTCATTACACTTTGAAGTATTATATTGTTCTTATCCTCAATTCAATGTGGT
GATGAAATTGCCAGGTTGTCTGATATTTCTTTCAGACTTCGCCAGACAGATTGCT
GATAATAAATTAGGTAAGATAATTTGTTGGGCCATATTTTAGGACAGGTAATAA
ACATCAGGTTCCAGTTGCTTGAATTGCAAGGCTAAGAAGTACTGCCCTTTTGTGT
GTTAGCAGTCAAATCTATTATCCACTGGCGCATCATATGCAGTGATATATGCCT
45 ATAATATAAGCCATAGGTTACACCATTTTGTTTAGACAATTGTCTTTTTTTCAAG
ATGCTTTGTTTCTTTCATATGAAAAAATGCATTTTATAAATTCAGAAAGTCATA
GATTTCTGAAGGCGTCAACGTGCATTTTATTTATGGACTGGTAAGTAACTGTGGT
TTACTAGCAGGAATATTTCCAATTTCTACCTTTACTACATCTTTTCAACAAGTAAC

TTTGTAGAAATGAGCCAGAAGCCAAGGCCCTGAGTTGGCAGTGGCCCATAAGTG
TAAATAAAAGTTTACAGAAACCTT

SEQ ID NO: 371

5 >3890 BLOOD 474320.4 U18423 g624185 Human spinal muscular atrophy gene product
mRNA, complete cds. 0
CGGGGCCCCACGCTGCGCACCCGCGGGTTTGCTATGGCGATGAGCAGCGGCGGC
AGTGGTGGCGGCGTCCCGGAGCAGGAGGATTCCGTGCTGTTCCGGCGCGGCACA
GGCCAGAGTGATGATTCTGACATTTGGGATGATACAGCACTGATAAAAGCATAT
10 GATAAAGCTGTGGCTTCATTTAAGCATGCTCTAAAGAATGGTGACATTTGTGAAA
CTTCGGGTAAACCAAAAACACACCTAAAAGAAAACCTGCTAAGAAGAATAAAA
GCCAAAAGAAGAATACTGCAGCTTCCTTACAACAGTGGAAAGTTGGGGACAAAT
GTTCTGCCATTTGGTCAGAAGACGGTTGCATTTACCCAGCTACCATTGCTTCAATT
GATTTTAAAGAGAGAAACCTGTGTTGTGGTTTACACTGGATATGGAAATAGAGAG
15 GAGCAAAATCTGTCCGATCTACTTCCCCAATCTGTGAAGTAGCTAATAATATAG
AACAGAATGCTCAAGAGAATGAAAATGAAAGCCAAGTTTCAACAGATGAAAGTG
AGAACTCCAGGTCTCCTGGAAATAAATCAGATAACATCAAGCCCAAATCTGCTCC
ATGGAACCTTTTCTCCCTCCACCACCCCCCATGCCAGGGCCAAGACTGGGACCA
GGAAAGCCAGGTCTAAAATTCAATGGCCCACCACCGCCACCAGCCACCACCA
20 CCCCACTTACTATCATGCTGGCTGCCTCCATTTCTTCTGGACCACCAATAATTCC
CCCACCACCTCCCATATGTCCAGATTCTCTTGATGATGCTGATGCTTTGGGAAGT
ATGTTAATTTTCATGGTACATGAGTGGCTATCATACTGGCTATTATATGGGTTTAC
ACAAAATCAAAAAGAAGGAAGGTGCTCACATTCCTTAAATTAAGGAGAAATGCT
GGCATAGAGCAGCACTAAATGACACCACTAAAGAAACGATCAGACAGATCTGGA
25 ATGTGAAGCGTTATAGAAGATAACTGGCCTCATTTCTTCAAAATATCAAGTGTTG
GGAAAGAAAAAAGGAAGTGGAATGGGTAACCTCTTCTTGATTAAAAGTTATGTAA
TAACCAAATGCAATGTGAAATATTTTACTGGACTCTATTTTGAAAAACCATCTGT
AAAAGACTGAGGTGGGGGTGGGAGGCCAGCACGGTGGTGAGGCAGTTGAGAAA
ATTTGAATGTGGATTAGATTTTGAATGATATTGGATAATTATTGGTAATTTTATGA
30 GCTGTGAGAAGGGTGTTGTAGTTTATAAAAGACTGTCTTAATTTGCATACTTAAG
CATTTAGGAATGAAGTGTTAGAGTGTCTTAAATGTTTCAAATGGTTTAAACAAAA
TGTATGTGAGGCGTATGTGGCAAAATGTTACAGAATCTAACTGGTGGACATGGCT
GTTCAATTGTACTGTTTTTTTCTATCTTCTATATGTTTAAAGTATATAATAAAAAAT
ATTTAATTTTTTTTTTAAAAA

SEQ ID NO: 372

35 >3951 BLOOD 344496.2 AF069765 g3243032 Human signal recognition particle 72
(SRP72) mRNA, complete cds. 0
TCAGACATCTAGTGAGTCGCAGAGCCAGGGAAGTACCACGGGCATTTTCACCC
40 CATTACCCCTCCAGCTTATTGCCGACTGCTCCCGAAGGGAGCGAAAAGGACAGG
CAAAGGGTTTCACCAAACCCCTTTGTAATGGGAGATTCTTGCCCTTCTTACCTTTCT
CACGTTTGCTTCTCTGCCAGAATGTCTTCCCGCACTTTCCCCAGAACCCAAGTTCT
CCTAATCATCTTTCAAGATCCCTTTCCCTCAACCACAGATGAGCCGTGCCTATTTCT
TCCTTCAAATGACTCCCTATGGCTTCTAGTTGGTAGTCTTTTATTTACCACCTCAT
45 AGTCCTTTTATTTATATCCATAAATGATCGTCCGGCCCCGCACCGTGGGACCAG
GACGCTGCCTCGACCATGGCGGTCTCCTGGAAACAGGCTGCTTTGAGCCGAAACT
GGTGACCGTTTCCCAACCCCGTCCAGGAGTCCGACGCCTCTTTTCTCCAGGCCAA
CTTCAAGTGAGGTGTATCAACTCTATCCGCACAAATTTCTTGCCACGAGAGCAGA
AGATTATGATCTCTGATGCTGCCTTAGGGCTGAAGACACTCCCAACTCGGCGACG

CTTAGCAATCATCGACTTCCTCCTCCTCTTGGCTGCCTCGGAGATCCTGTTCCGGG
GCAGAGGTCTCNCCGCCCCGCCCCCTCGTCTCCTCCAAGATGGCGAGCGGCGGCA
GCGGGGGGGTGTCTAGTACCTGCGCTGTGGAGTGAAGTGAACCGGTATGGCCAGA
ACGGCGACTTCACGCGCGCTCTCAAGACCGTCAATAAGATACTACAGATCAACA
5 AAGATGACGTAAGTGCCTGCATTGTAAAGTGGTATGCCTTATCCAGAATGGAAG
TTTCAAGGAAGCTTTGAATGTCATCAATACTCACACCAAAGTGTTAGCCAATAAC
TCTCTCTCCTTTGAAAAGGCATATTGCGAGTACAGGCTGAACAGAATTGAGAATG
CCTTGAAGACAATAGAAAGTGCCAACCAGCAGACAGACAAACTGAAGGAGCTTT
ATGGACAAGTGTTATACCGTTTGGAACGCTATGATGAATGCTTAGCAGTGTATAG
10 AGATCTCGTCCGAAACTCCCAAGATGATTATGATGAGGAGAGGAAAACAAACCT
TTCAGCAGTTGTTGCAGCTCAAAGCAATTGGGAAAAAGTGGTTCCAGAGAACCT
GGGGCCTCCAAGAAGGCACACATGAGCTGTGCTACAACACTGGCATGTGCACTG
ATAGGCCAAGGCCAGCTGAACCAGGCCATGAAAATCCTACAAAAAGCTGAAGAT
CTTTGCCGCCGTTTATTATCAGAAGACACTGATGGGACTGAGGAAGACCCACAG
15 GCAGAACTGGCCATCATTATGTCAGATGGCTTATATTCTGCAGCTTCAGGGTC
GAACAGAGGAGGCTTTGCAACTTTACAATCAAATAATAAACTAAAACCAACAG
ATGTGGGATTACTAGCTGTAATTGCAAATAACATCATTACCATTAAACAAGGACCA
AAATGTCTTTGACTCCAAGAAGAAAGTGAAATTAACCAATGCGGAAGGAGTAGA
GTTTAAGCTTTCCAAGAAACAACCTACAAGCTATAGAATTTAACAAGCTTTACTT
20 GCTATGTACACAAACCAGGCTGAACAATGCCGCAAAATATCTGCCAGTTTACAGT
CCCAAAGTCCCGAGCATCTCTTACCTGTGTAAATCCAAGCTGCCAGCTCTGCCG
TGAATAAGCAGCACACAAAAGCAATAGAGCTGCTTCAGGAATTTTCAGATCAGCA
TTCAGAAAATGCAGCTGAAATTAAGCTGACCATGGGCACAGTTGAAAATTTCTCA
AGGFAATATTTCTAAAGCATGTCTAATATTGAGAAGCATAGAGGAGTTAAAGCA
25 TAAACCAGGCATGGTATCTGCATTAGTTACCATGTATAGCCATGAAGAAGATATT
GATAGTGCCATTGAGGTCTTCACACAAGCTATCCAGTGGTATCAAAACCATCAGC
CAAAATCTCCTGCTCATTTGTCTTGATAAGAGAAGCTGCAAACTTCAAACCTCAA
ATATGGGCGGAAGAAGGAGGCAATTAGTGACCTACAACAGCTGTGGAAACAAA
ATCCAAAAGATATTACACCCTGGCACAGCTTATTTCTGCTTACTCACTTGTAGAT
30 CCAGAGAAAGCCAAAGCTCTTAGTAAACACTTGCCATCGTCAGATAGTATGTCTC
TAAAAGTAGATGTTGAGGCTCTTGAAAATTCTGCTGGTGCTACATACATTCCGAA
GAAGGGTGGAAGGTTACTGGAGATAGTCAACCAAAGGAACAAGGACAGGGAG
ATTTGAAAAAGAAGAAAAAGAAAAAGAGGGAAAAATTGCCTAAGAATTATGAC
CCAAAAGTTACCCAGATCCAGAAAGATGGCTGCCAATGCGAGAACGTTCTTAC
35 TACCGGGGAAGAAAGAAGGGTAAAAAGAAGGATCAGATTGGAAAAGGGACCCA
GGGAGCAACTGCAGGAGCTTCATCTGAACTGGATGCCAGTAAACTGTGAGCAG
CCCACCCACCTCCCCAAGACCTGGCAGTGCTGCAACAGTATCTGCCTCTACAAGT
AACATCATACCCCCAAGACACCAGAAACCTGCAGGGGCTCCAGCAACAAAAAAG
AAACAGCAACAGAAAAAGAAGAAAGGTGGAAAAGGTGGCTGGTGATGAGAATA
40 TTCTTGTTGCAGGCTGTTTTTAAACTAGTGTGAGTACACTAGGAATATAATAAA
GGTAACACAGCAAGAAGCACAGAACTACTCCCTCTTCATCTCCATATTTTCATAA
TTTCTTGTTTCAAATAGGGAAACATCTTCCTCAAAGTCTGCCTAGTGAGATAC
GGCCTACTGGTTGCCTCATAGCTTTGTACAGATTATGAGGACTGAAAATAATTGG
GCATTTACCCATCTTGGTATCTGTTGTATCCTTTATCTGTGTGTGCTGATTTGATCT
45 TTTTTCAGTTTCACATACCTTATCTAAGGTTTCCCAGGATTTAAACAGAACTACT
TCTATGATTTTCAGCTGGAGTCTGAAGATACTTGTCTGTTCAAGTCCCACTTTAA
ATTATGTCTTAGGAGACTGAAAGTGGAATCTTCTGAGCATTCTAAATATCTGCT
TAGAAATATCATGTGATAAAGAGGGACCTTCTTAATACTGATGTTCTTCACTA
AATGGATGGCCACAAGAAAAATAAAGTAAATGTCTTAAATAATTTAACCATAAA

TTTTCTGTCATGTGATACTGGAATATGGGATACTTTTCATGTTTATATATATNTAT
ATATGTATATATATATACGATATATATATATATAAACNTGAAATATATATATA
TGGCTCCTTTGTGCCCCATGTCATTTTCAGATTATGGTAGCATGCTGATACAGCAC
CATGAAAGAACTCAAGGAAAATATATCAATGTAAGAAGTTCACCTCTAGACCCA
5 GTGTTCTGAGGTCACATGGGTTTGGACTGTCTCAATCAGAAAGATTAATGACTGT
TATCAAGAACATGAACATTGGCTTCCTCCATAGAGAAGAAATCAGTATCTGAGTT
GCATACCAGGCAGTATTAATACTAACAGGTCTGTTTGGCCCATGATAGATACT
CAAAATGGTGTCTCCTTCTGGTTATGGATTTTGACCATTGATTACCTTTCTCAATGT
AATGAAGTATTTTACAGTCAATTTGTGGTGTAATGTTGCTCTTGTCTTTCCTTGC
10 TTACAAACTACTTTTACATTGAACAGCTGTGAGACAGACATATTGAGATGCCTGC
CCTTGTTAGTATTCAATTTTATGCTGCCCAAGATATCATTTAATTTAGACTTAACAA
GTATTTCTTGTGATTATATTACTCTGTCTTGTAAATAAAGTGCTGCTGTGTTTG
ACTCTGAACATACTACCAAACCTTCTTCAAAGAGTTTTTTATGAAAGACTTTCCTC
CTTTACAAGAAAGAAATGGGGTGCTGCCTTTCTGTTTAGTAAAAGCAGAATTTGC
15 AGTGGCATCTAAAGAGATCTTTTTTAAATAAAAATTATGTATTGTGGCATAATCC
TTTTTTGAGCTCTACAGAGAACAGTCTTTTGGTAATAGTGGCAGGTATTTATTCC
TTCTGAATATATACCCCATATAGGAATAACTGTTACTTATTTAGGATTCCATCAT
TGAAAATTTTGACCCAAGGCACAGCAGTGAAATTTATAGTTCTCAATTTAGTTGT
CATTATTGACAGGCATTGGTATTATTAGTCATTGCTAAGCAACTAAAACCTTCATC
20 AGTTCAAATAAGTTTTAATTGTCAAATGAAGTATAAACACATGAACTTTCTAGAA
ATATTTCTCTTTTGGATAGGTCTTTAACCAGTTCATATATATACTTTGTCAAATA
TATGGATGTGTATGTGTACATTTATAAGAACCAGTATGGATACATCCATTCAGTG
TGGTACATTTTAAAATAAAAATATTTTAGCAGTG
25 SEQ ID NO: 373
>3957 BLOOD 469133.9 U79258 g1710211 Human clone 23732 mRNA, partial cds. 0
AACCCTTCCGGTGGGCTAGGTACTGAGCGCGCGAGGTGAGGAGTTGTGCAGGGT
TTGGGGAAGGAAGGCTGGCTTGGCGAGAGGGCAGGTTTGCGGGCTTTCGCCCC
CTTTTCCAAAGACCAACAAAGAGTCCTTCCCAACTCCCAACTCAACCCCTTTTG
30 GAACTATGTGTGGTGGTGGGACCCTGTGGCGCATCCTTGTGCTCGTGTCTCTCT
CATGCCCGGCGACGCGTCTTTGTGGTAACGCCCTGCTGCCATCTCTTTTCTCTCT
ATGCGAGGATTTGGACTGGCAGTGAGAATAAGAGACAACGATTCACGTCTACTT
TCTAGGATGACTTCCATGTGCTCCATCTCGCGCGTCCCTGAGCATGTTGAATTTCC
AAATCCTAAATAAGCCGCGCGGTGTAGTTTGTATTATGTTGCGTTTCTCTTTCTGC
35 TTTCTCGCCCTTTCTCCATCATCCTTTAGGCTCTACAGAGTGAAGGTTTAAATCC
AAGGTCATGGCAAACATCTGAAGTTCATCGCCAGGACTGTGATGGTACAGGAA
GGGAACGTGGAAAGCGCATAACAGGACCCTAAACAGAATCCTCACTATGGATGGG
CTCATTGAGGACATTAAGCATCGGCGGTATTATGAGAAGCCATGCCGCCGGCGA
CAGAGGGAAAGCTATGAAAGGTGCCGGCGGATCTACAACATGGAAATGGCTCGC
40 AAGATCAACTTCTTGATGCGAAAGAATCGGGCAGATCCGTGGCAGGGCTGCTGA
GGCCTGTGGGTGGGACACCCAGTGCAGAAACCCTCATCCAGTTTCTCTCCATCTC
TTTTCTTTGTACAATCCCATTTCTATTACCATCTCTGCAATAAACTCAAATCAC
ATGTCTGCAAGAAGGCCTCCAAATATAGAAACAATCCCATTAGTCAGCAGTGGA
CCCTGTCTTTTATTAAGTGAAAGAAGAACTGAGTCTGAAAGTACTCTAGGAGTA
45 GAATGGTATTTGCCAGGGACTGGAGGAGGGGGCAGTGATNNNNNNNNNNNNNNNN
NN
NN
NNNGGA
AAATTTTTTTAATGTAGTGAAATATGTCTACCATTTCCTACCCAATTTTTTTGAAT

CCCCAAGCAAAATCTTACTGAGAAAGCATCTATTACTTTTTATTAAACTGTTCCAT
GTTAGGTAGAGAGGAGAAGATGCATGTATGTATTTGGAATAAAATTCTGCTTCTGA
AAACACCTATCAACCT

5 SEQ ID NO: 374

>3976 BLOOD 228434.6 U66097 g5058996 Human cell-line THP-1 GTP cyclohydrolase I
mRNA, complete cds. 0

TGTGCTCTAAAGGTGATCTAAGCAGGTCGCGTACCTTCCTCAGGTGACTCCGGCC
ACAGCCCATTGTCCGCGGCCACCGGCGGAGTTTAGCCGCAGACCTCGAAGCGCC
10 CCGGGGTCTTCCCGAACGGCAGCGGCTGCGGCGGGTCCATGGAGAAGGGGCCCT
GTGCGGGCACCGGCGGAGAAGCCGCGGGGCGCCAGGTGCAGCAATGGGTTCCTCC
GAGCGGGATCCGCCGCGGCCCGGGGCCAGCAGGCCGCGGAGAAGCCCCCGCG
GCCCCGAGGCCAAGAGCGCGCAGCCCCGCGACGGCTGGAAGGGCGAGCGGCCCC
GCAGCGAGGAGGATAACGAGCTGAACCTCCCTAACCTGGCAGCCGCCTACTCGT
15 CCATCCTGAGCTCGCTGGGCGAGAACCCCCAGCGGCAAGGGCTGCTCAAGACGC
CCTGGAGGGCGGCCTCGGCCATGCAGTTCTTCACCAAGGGCTACCAGGAGACCA
TCTCAGATGTCTAAACGATGCTATATTTGATGAAGATCATGATGAGATGGTGAT
TGTGAAGGACATAGACATGTTTTCCATGTGTGAGCATCACTTGGTTCCATTTGTTG
GAAAGGTCCATATTGGTTATCTTCCTAACCAAGCAAGTCCTTGGCCTCAGCAAAC
20 TGCAGAGGATTGTAGAAATCTATAGTAGAAGACTACAAGTTCAGGAGCGCCTTAC
AAAACAAATTGCTGTAGCAATCACGGAAGCCTTGCGGCCTGCTGGAGTCGGGGT
AGTGGTTGAAGCAACACACATGTGTATGGTAATGCGAGGTGTACAGAAAATGAA
CAGCAAAACTGTGACCAGCACAAATGTTGGGTGTTCCGGGAGGATCCAAAGAC
TCGGGAAGAGTTCTGACTCTCATTAGGAGCTGAGCTTCATTCACTGTGTGTGCG
25 TTGGTTGCCGATCGTACTGCCAGTAGCATTGTCTGTCTGTCCGGTCTTGTTTGAC
ATTCCATTTTCAATTGTTACAGATGTGAACCTTATTCCTTGTCACTAATTATATTT
AAAATTATTTCTAGGAAGTCAAATAAATATAATAAAGGGTTGAGCCCTCTACTTT
CTTCTTGCCACCTTTTTGTGGCAATATTAAGTGAAGTGAAGTGAAGTAC
GTGCACAAAACCACTGCCAGATAACCAGAGGGGCCTGGGAAGGGAGAAGAATT
30 AGTGTATTTTTTCAAATAGTACAGTAATTTGCCTCATAAGCATAGGAGCATTGG
GAATGAGAGGGAACTGTGCCAGTATACTGTTTTTTTTCTTCCTCCAATAAAAGT
GGTGTAGTGCCGAAAGTGCTAAAATATTTAGTGCGGTATTGCTCTGTGAATTCAA
GTTCAACAGACTTCACTTTGGTCATGTTTATTAAACCACCAGTGACATTTAAAAA
TATATTTTAGCAGTCGTAAATGTTAGTACCAAGGGAAGGTGGTGGAATGTCTAT
35 GTTTTTGATTTTACTGTGAGTTAAAAAGGCACATTTCTACCTTCTATTGTTTTAA
ATTCAAGAATAGGGAATTAGTTCCTGGTGTGTTACGAGTGTATTCTCGTGTC
ACATACAGGGATTTAGACATTTAACTCTCTGTGCCTTGATAAGAATATCATTAG
AGTGTAGATACTTTTGCCTTTTTAAAAAAGCCATTATTTTATGAGACTTAGTACTC
ACACTGCAAATAACTAGTCAGCTCAGTTTTAACTTTATAGGTTTATTGAGTTTCCT
40 TTGTGTGATCCATGTAGATGCCTCAAAATGTNNNNNNNNNNNNNNNNNNNNNAATC
TTATAAGATATTTTTCTAAGTATTTCCAGAAACATTTGAGAGTGCCCATCATTTTC
AGGTCTGCAGAACCATAGCTTCCACGCACCTGAACGAGCACAGAATGAACTGAC
GGTGGAAGACATTATGAGCTGTGTCCAACGTTTTAAACCAAGCGTATCGTACCAA
CGATCTGTGAAAATGCACTGGAAGCTTCTGGTCCCGGTTTCTTTGTGGTCTATGT
45 GGGTCTTGCTCCTCATTGTAACCTCCGTATAGATGGTATAGGTATTTTAATCCTGGAA
GCTGTTGCCTTATTAATGATTATCTTAAATTTCTCCTCCATGGGGCAGCGTGGGCC
AAATTAAACAAACAAAACCGCAACTCCTCCACAGAAACACAAACACAGTTATT
CCATGAAGTTTAGTATTTGGTTGACATAGTGCTCTTCAAATTCATCCCATTACCCT
AAAAGTAATAACTTTGATGCTTGCTTTAACTTTAGTCCCATCTCTGCCACTTTGAT

GCTATTTGGGTTATGATGGGGCAAGATGGCAGAGGTATTGGGTTTTTTTGT
TCCATTCTCTCTACTTCTGTTTCCTAGCTTTTCTTTCTGGAGTTTAAGTACAGTG
ATGGTTGGCTTGAGTACCTTTTTAAATCTAGCCCAGTATAAACATTAGCCTGCTTA
ATATTTAGACATTTATAGGTAGAATTCTGAGCACTCAACTCATGTTTGGCATTTTA
5 AAGTAAAAACAAGTGTGACTTCGAGGACCAAAGAAATTGTCAGCTATACATTTA
TCTTTATGAACTCATTTATATTCCTTTTTAATGACTCGTTGTTCTAACATTTCTAG
AAGTGTTCCTATAAAGGTCTAATGTATCCACAGGCTGTTGTCTTATTAGTAAATG
CAAAGTAATGACTTTGTCTGTTTTACTCTAGTCTTTAGTACTTCAAAATTACCTTT
TCATATCCATGATCTTGAGTCCATTTGGGGGATTTTTAAGAATTTGATGTATTCA
10 ATACACTGTTCAAAATTAAATTGTTTAATTTTATGTATGAGTATGTATGTTCTGA
AGTTGGTCCTATTTAAATTATTAAGTATTGTAACCTTG

SEQ ID NO: 375

>4133 BLOOD 331022.43 U20938 g1926407 Human lymphocyte dihydropyrimidine
dehydrogenase mRNA, complete cds. 0

15 GAAAATGTATCCAAGGAAACATTTTATCATTA AAAAATTACCTTTAATTTTAATGC
TGTTTCTAAGAAAATGTAGTTAGCTCCATAAAGTACAAATGAAGAAAGTCAAAA
AATTATTTGCTATGGCAGGATAAGAAAGCCTAAAATTGAGTTTGTAGAAGCTTTAT
TAAGTAAAATCCCCTTCGCTGAAATTGCTTATTTTTGGTGTGGATAGAGGATAG
20 GGAGAATATTTACTAACTAAATACCATTCCTACTCATGCGTGAGATGGGTGTAC
AACTCATCCTCTTTAATGGCATTCTCTTTAACTATGTTTCTAACAAAATGAG
ATGATAGGATAGATCCTGGTTACCACTCTTTTGCTGTGCACATACGGGCTCTGAC
TGGTTTAAATAGTCACCTTCATGATTATAGGAACTAATGTTTGAACAAAGCTCAA
AGTATGCAATGCTTCATTATTCAAGAATGAAAAATATAATGTTGATAATATATAT
25 TAAGTGTGCCAAATCAGTTTGACTACTCTCTGTTTTAGTGTATGTTTAAAGAA
ATATATTTTTTGTATTATTAGATAATATTTTTGTATTTCTCTATTTTCATAATCAG
TAAATAGTGTATATAAACTCATTTATCTCCTCTTCATGGCATCTTCAATATGAAT
CTATAAGTAGTAAATCAGAAAGTAACAATCTATGGCTTATTTCTATGACAAATTC
AAGAGCTAGAAAAATAAAATGTTTCATTATGCACCTTTAGAAATGCATATTTGCC
30 ACAAACCTGTATTACTGAATAATATCAAATAAAATATCATAAAGCATTTT

SEQ ID NO: 376

>4152 BLOOD 399962.1 AL137305.g6807770 Human mRNA; cDNA DKFZp434J197
(from clone DKFZp434J197). 3e-09

35 GCCTCGGTGTTCCACCTAGGGGCGGGCAGCCAGGGGCACTTCCGCTGGCCCAA
GTGATCTGCATGTGGCAGGGCTGCGCAGTGTGAGCGGCCAGTGGGCAGGATGAC
GAGCCAGACCCCTCTGCCCCAGTCCCCCGGGCCAGGCGGCCGACGATGTCTACT
GTTGTGGAGCTGAACGTCGGGGGTGAGTTCCACACCACCACCTGGGTACCCTGA
GGAAGTTTCCGGGCTCAAAGCTGGCAGAGATGTTCTCTAGCTTAGCCAAGGCCTC
40 CACGGACGCGGAGGGCCGCTTCTTCATCGACCGCCCCAGCACCTATTTAGACCC
ATCCTGGACTACCTGCGCACTGGGCAAGTGCCACACAGCACATCCCTGAAGTGT
ACCGTGAGGCTCAGTTCTACGAAATCAAGCCTTTGGTCAAGCTGCTGGAGGACAT
GCCACAGATCTTTGGTGAGCATGGTGTCTCGGAAGCAGTTTTTGCTGCAAGTGCC
GGGCTACAGCGAGAACCTGGAGCTCATGGTGCCTGGCACGTGCAGAAGCCAT
45 AACAGCACGGAAGTCCAGCGTGCTTGTGTCTGTTGGTGGAACTGAGGAGCAGGAT
GCATATTATTCAGAGGTCCTGTGTTTTCTGCAGGATAAGAAGATGTTCAAGTCTG
TTGTCAAGTTTGGGCCCTGGAAGGCGGTCTAGACAACAGCGACCTCATGCACTG
CCTGGAGATGGACATTAAGGCCAGGGGTACAAGGTATTCTCCAAGTTCTACCTG
ACGTACCCCAACAAAAGAAACGAATTCCATTTTAACATTTATTCATTCACCTTCA

CCTGGTGGTGATCCTCAGGAGCAGAGACTGTTATGAATTCTGGCGTGGCTTATGA
 AATTAAAAGTTGCCATCAAAGCCATTTTCTTTTAATTTACAAACATCAGGCAAT
 TTCCAGGGTTGGTCTAGAGTCTTGCCACTAAATATTGATCACTCGTTTAAGGACTT
 TCCACTCCATTGCAACTGATGCCACTATATTTGCCTAGCAACTTGCAGCTACTTCC
 5 TTTTCAAAGCCTCATGTATCTCCCAGACCCTTCTCTTGAAGTCCAATAACAAGAC
 CAAGTAAGAATGTTTCAACAATGCGTTGGCAAGAGATGTGAGATGACAACAGGA
 ACATACAAGATACTGTGAATCTAGATGTTCTGACCTAAAGATGTAGTCTACATAG
 CCCCAGCTTGGGGTCCAATCCATCTGTCCCTGGCATGTGCCTTCATGTAGTAGGT
 GCTTTCCTGATCCCCCTTTGCGAGATGCTGTGGGTGCTAACACCTCAGAGCTGTCCT
 10 CTTCTCTAGAGTGGAGGTTTTCAAAGTGCATCATCAGCATTACCTGTGAACTTGC
 TGGAAATACAAATCCTCAGGCCCCACCTCAGACCTACTGAATCAGAATCTCTGGG
 GGTGGGACACAGCATTCTGATTTACCAAACCCTCCAAGTGATTTTGATGTATTCT
 AATTTTGAGACCATCTCTAGAAAAGAATTGCTACCTCTTGTATGGAGGTACAAAA
 GACTGACCTCTTACATCAAGGAACCTTCCCTTCCCAGAGCTCCTCATGGAATCAAG
 15 CTGAAGTCAGTCTTCTTCTGAGAGCACATTCTTACTCAGTTTTTTTCTCTGTCT
 ACGCTGCTTCCCTCACTCCCCCTTCTCCTAAGAGCACTCCATCAATAAACCACTTGC
 ACGAG

SEQ ID NO: 377

20 >4181 BLOOD 350387.28 Z27113 g415387 Human gene for RNA polymerase II subunit
 14.4 kD. 0

GGGTTACGGCGCAGGCGCAAGATAAGCTAGGAGCCGCGCGAGTCGTAGTGTTCG
 TGTGTTGCGGGTCTCCGCGCGGGACCGGGGCGCAGCGGGGTGCTGAGGCGAGGG
 TGTCATGTCAGACAACGAGGACAATTTTGATGGCGACGACTTTGATGATGTGGAG
 25 GAGGATGAAGGGCTAGATGACTTGGAGAATGCCGAAGAGGAAGGCCAGGAGAA
 TGTCGAGATCCTCCCCTCTGGGGAGCGACCGCAGGCCAACCAGAAGCGAATCAC
 CACACCATAACATGACCAAGTACGAGCGAGCCCGCGTGTGGGCACCCGAGCGCT
 CCAGATTGCGATGTGTGCCCTGTGATGGTGGAGCTGGAGGGGGAGACAGATCC
 TCTGCTCATTGCCATGAAGGAACTCAAGGCCCGAAAGATCCCCATCATCATTTCG
 30 CGTTACCTGCCAGATGGGAGCTATGAAGACTGGGGGGTGGACGAGCTCATCATC
 ACCGACTGAGCTGGAGTCATCTTCTGCCCCTTGCCCCATGCCCAATTTTCATTCTC
 ACTTTATATGTGTAATAATAAAATATTCAACTTTCCAAAAAAAAAAAAAAAAAGGG

SEQ ID NO: 378

35 >4191 BLOOD Hs.171495 gn|UG|Hs#S4798 Human hap mRNA encoding a DNA-binding
 hormone receptor /cds=(321,1667) /gb=Y00291 /gi=32025 /ug=Hs.171495 /len=2972
 CGGGGTAGGATCCGGAACCCATTGGAAGGCTTTTGGCAAGCATTACTTGGAAG
 GAGAACTTGGGATCTTTCTGGGAACCCCCCGCCCCGGCTGGATTGGCCGAGCAA
 GCCTGGAAAATGGTAAATGATCATTGGATCAATTACAGGCTTTTAGCTGGCTTG
 40 TCTGTCATAATTCATGATTGCGGGCTGGGAAAAAGACCAACAGCCTACGTGCCA
 AAAAAGGGGCAGAGTTTGATGGAGTTGGGTGGACTTTTCTATGCCATTTGCCTCC
 ACACCTAGAGGATAAGCACTTTTGCAGACATTCAGTGCAAGGGAGATCATGTTTG
 ACTGTATGGATGTTCTGTCACTGAGTCCTGGGCAAATCCTGGATTTCTACACTGC
 GAGTCCGTCTTCTGTCATGCTCCAGGAGAAAGCTCTCAAAGCATGCTTCAGTGGA
 45 TTGACCCAAACCGAATGGCAGCATCGGCACACTGCTCAATCAATTGAAACACAG
 AGCACCAGCTCTGAGGAACTCGTCCCAAGCCCCCATCTCCACTTCTCCCCCTC
 GAGTGTACAAACCCTGCTTCGTCTGCCAGGACAAATCATCAGGGTACCACTATGG
 GGTGAGCGCCTGTGAGGGATGTAAGGGCTTTTTCCGCAGAAGTATTCAGAAGAA
 TATGATTTACACTTGTACCCGAGATAAGAACTGTGTTATTAATAAAGTCACCAGG

AATCGATGCCAATACTGTCGACTCCAGAAGTGCTTTGAAGTGGGAATGTCCAAA
 GAATCTGTCAGGAATGACAGGAACAAGAAAAAGAAGGAGACTTCGAAGCAAGA
 ATGCACAGAGAGCTATGAAATGACAGCTGAGTTGGACGATCTCACAGAGAAGAT
 CCGAAAAGCTCACCAGGAACTTTCCCTTCACTCTGCCAGCTGGCTAAATACACC
 5 ACGAATTCCAGTGCTGACCATCGAGTCCGACTGGACCTGGGCCTCTGGGACAAAT
 TCAGTGAAGTGGCCACCAAGTGCATTATTAAGATCGTGGAGTTTGCTAAACGTCT
 GCCTGGTTTCACTGGCTTGACCATCGCAGACCAAATTACCCTGCTGAAGGCCGCC
 TGCCTGGACATCCTGATTCTTAGAATTTGCACCAGGTATACCCCAGAACAAGACA
 CCATGACTTTCTCAGACGGCCTTACCCTAAATCGAACTCAGATGCACAATGCTGG
 10 ATTTGGTCTCTGACTGACCTTGTGTTACCTTTGCCAACCAGCTCCTGCCTTTGG
 AAATGGATGACACAGAAACAGGCCTTCTCAGTGCCATCTGCTTAATCTGTGGAGA
 CCGCCAGGACCTTGAGGAACCGACAAAAGTAGATAAGCTACAAGAACCATTGCT
 GGAAGCACTAAAAATTTATATCAGAAAAAGACGACCCAGCAAGCCTCACATGTT
 TCCAAAGATCTTAATGAAAATCACAGATCTCCGTAGCATCAGTGCTAAAGGTGCA
 15 GAGCGTGTAATTACCTTGAAAATGGAAATTCCTGGATCAATGCCACCTCTCATTC
 AAGAAATGATGGAGAATTCTGAAGGACATGAACCTTGACCCCAAGTTCAAGTG
 GGAACACAGCAGAGCACAGTCCTAGCATCTCACCAGCTCAGTGGAACACAGTG
 GGGTCAGTCAGTCACCACTCGTGCAATAAGACATTTTCTAGCTACTTCAAACATT
 CCCAGTACCTTCAGTTCAGGATTTAAAATGCAAGAAAAAACATTTTACTGCT
 20 GCTTAGTTTTTGGACTGAAAAGATATTAATACTCAAGAAGGACCAAGAAGTTTTT
 ATATGTATCAATATATACTCCTCACTGTGTAACCTACCTAGAAATACAACTTT
 TCCAATTTTAAAAAATCAGCCATTTTCATGCAACCAAGAACTAGTTAAAAGCTTGT
 ATTTTCCTCTTTGAACAGTCAAGATGCATGGCAAGACCCAGTCAAAATGATTTA
 CCCCTGGTTAAGTTTCTGAAGACTTTGTACATACAGAAGTATGGCTCTGTTCTTTC
 25 TATACTGTATGTTTGGTGCTTTTCCTTTTGTCTTGCACTCAAAATAACCATGACA
 CCAAGGTTATGAAATAGACTACTGTACACGTCTACCTAGGTTCAAAAAGATAACT
 GTCTTGCTTTTCATGGAATAGTCAAGACATCAAGGTAAGGAAACAGGACTATTGA
 CAGGACTATTGTACAGTATGACAAGATAAGGCTGAAGATATTCTACTTTAGTTAG
 TATGGAAGCTTGCTTTTGCTCTTTCTGATGCTCTCAAAGTGCATCTTTTATTTTCATG
 30 TTGCCCAGTAAAAGTATACAAATTCCTTGCACTAGCAGAAGAGAATTCTGTATCA
 GTGTAAGTGCAGTTCAGTTAATCAAATGTCATTTGTTCAATTGTTAATGTCACCT
 TAAATTAAGTGGTTTATTACTTGTTTAATGACATAACTACACAGTTAGTTAAA
 AAAAATTTTTTTTACAGTAATGATAGCCTCCAAGGCAGAAACACTTTTCAGTGTTA
 AGTTTGTGTTTACTTGTTCACAAGCCATTAGGGAAATTTTCATGGGATAATTAGCA
 35 GGCTGGTCTACCACTGGACCATGTAAGTCTAGTGTCTTCTGATTTCATGCCTGAT
 ATTGGGATTTTTTTCCAGCCCTTCTTGATGCCAAGGGCTAATTATATTACATCCCA
 AAGAAACAGGCATAGAATCTGCCTCCTTTGACCTTGTTCAATCACTATGAAGCAG
 AGTGAAAGCTGTGGTAGAGTGGTTAACAGATACAAGTGTGAGTTTCTTAGTTCTC
 ATTTAAGCACTACTGGAATTTTTTTTTTTGATATATTAGCAAGTCTGTGATGTACT
 40 TTCACTGGCTCTGTTTGTACATTGAGATTGTTTGTGTTAACAATGCTTTCTATGTTT
 ATATACTGTTTACCTTTTCCATGGACTCTCCTGGCAAAGAATAAAATATATTTAT
 TTT

SEQ ID NO: 379

45 >4215 BLOOD 237648.6 AF006305 g2213931 Human 26S proteasome regulatory subunit
 (SUG2) mRNA, complete cds. 0
 CATGGACAGGTCCAGGTACTCCTGGTTGGAGTCACAGGCCACGATGCGGTCCAG
 GTCTTCCACCAGCTGCTTGAAGGTGGGTCTCTGTGAGGGCACTGCATGCCAGCAG
 TCCCGCATCATCATGTACAGCTCGTTGGTGCAGTTACTGGGCTTCTCATCATGGC

GGACCCTAGAGATAAGGCGCTTCAGGACTACCGCAAGAAGTTGCTTGAACACAA
GGAGATCGACGGCCGCTCTTAAGGAGTTAAGGGAACAATTAAGAAGCTTACCAA
GCAGTATGAAAAGTCTGAAAATGATCTGAAGGCCCTACAGAGTGTTGGGCAGAT
CGTGGGTGAAGTGCTTAAACAGTTAACTGAAGAAAAATTCATTGTTAAAGCTACC
5 AATGGACCAAGATATGTTGTGGGTTGTCGTCGACAGCTTGACAAAAGTAAGCTG
AAGCCAGGAACAAGAGTTGCTTTGGATATGACTACACTAACTATCATGAGATATT
TGCCGAGAGAGGTGGATCCACTGGTTTATAACATGTCTCATGAGGACCCTGGGA
ATGTTTCTTATTCTGAGATTGGAGGGCTATCAGAACAGATCCGGGAATTAAGAGA
GGTGATAGAATTACCTCTTACAAACCCAGAGTTATTTACGCGTGTAGGAATAATA
10 CCTCCAAAAGGCTGTTTGTATATGGACCACCAGGTACGGGAAAAACACTCTTG
CACGAGCCGTTGCTAGCCAGCTGGACTGCAATTTCTTAAAGGTTGTATCTAGTTC
TATTGTAGACAAGTACATTGGTGAAAGTGCTCGTTTGATCAGAGAAATGTTTAAT
TATGCTAGAGATCATCAACCATGCATCATTTTTATGGATGAAATAGATGCTATTG
GTGGTCGTCGGTTTTCTGAGGGTACTTCAGCTGACAGAGAGATTTCAGAGAACGTT
15 AATGGAGTTACTGAATCAAATGGATGGATTGATACTCTGCATAGAGTTAAAATG
ATCATGGCTACAAACAGACCAGATACACTGGATCCTGCTTTGCTGCGTCCAGGAA
GATTAGATAGAAAAATACATATTGATTTGCCAAATGAACAAGCAAGATTAGACA
TACTGAAAATCCATGCAGGTCCCATACAAAGCATGGTGAAATAGATTATGAAG
CAATTGTGAAGCTTTCGGATGGCTTTAATGGAGCAGATCTGAGAAATGTTGTAC
20 TGAAGCAGGTATGTTTCGAATTCGTGCTGATCATGATTTTGTAGTACAGGAAGAC
TTCATGAAAGCAGTCAGAAAAGTGGCTGATTCTAAGAAGCTGGAGTCTAAATTG
GACTACAAACCTGTGTAATTTACTGTAAGATTTTGTATGGCTGCATGACAGATGT
TGGCTTATTGTAAAAATAAAGTTAAAGAAAATAATGTATGTATTGGTAATGATGT
CATTAAGTATATGAATAAAATATGAGTAACATCATAAAAATTAGTAATTCA
25 ACTTTTAAGATACAGAAGAAATTTGTATGTTTGTTAAAGTTGCATTTATTGCAGC
AAGTTACAAAGGGAAAGTGTGTAAGCTTTTCATATTTGCTGCGTGAGCATTTTGT
AAAATATTGAAAGTGGTTTGAGATAGTGGTATAAGAAAGCATTTCTTATGACTTA
TTTTGTATCATTTGTTTTCTCATCTAAAAAGTTGAATAAAATCTGTTTGATTGAG
TTCTCCTACAAAAAAGTCATAAGAAATGCTTTCTTATACCACTATCTCAAACCA
30 CTTTCAATATTTTACAAAATGCTCACGCAGCAAATATGAAAAGCTTCAACACTTT
CCCTTTGTAACCTTGCTGCAATAAATGCAACTTTAACAAACATACAAATTTCTTCTG
TATCTTAAAGTTGAATTACTAATTTT

SEQ ID NO: 380

35 >4222 BLOOD 1099671.1 X71901 g483524 Human ERF-1 mRNA 3' end. 0
CGCGATCTAGAACCCAAACCTAACAGTATATATTTTATCATTTTCAAGGGAGTCA
TGCTCCATTGCGGGCCCTTCGGTTTCGTGGCTCCCATGTCCCCCTCTCCACCTCCC
GCCAAAACGGCGCAGCGTGACAAGCCATATGTTCCACTCCGGTGGGGGCGAGAG
AGAAGCAACAATAAGTTAAAGTGCCGCCCTCCCTCCACCTCTTTACCTTCATTCT
40 TACCAAAGTAACCTTTTTTTCATTGTTCTAGAGTCTTGAGGTGTGTGTGGGGAGGA
TGGAGGAGGAGGGAGGGTTGTGGCGCCGCCAGAAATTCGGAGCGCGCGTGGA
AGTAGTGAGTTGCTCGGTGGGCTTTTTCTGGGAGGAAGGGGCATTTCAGGAAGGA
TTAGGGTTTTCTTGACTAAAAAGTTTAAAGATTGGATGCGTGAAAAGAAACGGC
ACGCCTAGGCCTGGTAAACAAACAATCGTCCCGGGTTGTGGTCTTTTTTTTGGC
45 GCGCCCCCACC CGCCACACCCGGAGAGCGCCGGCTGCAAAGCGAGCGCGAGT
GTCGACGCGTGCGACGCACTAAATTGTGCCGCGCTCGCGCCCCGCCAGACCATGT
CCTCCTGGGGAAAAAGTTCCCTAGTCCCCCAGCACCGCGCCCCACCCTACGCC
CCGCTGGAAAAAAACAGCAACATAAAATCCTAGGCTTGAACATTCTGTGCGTC
CCAAATTTCTAATGTCTCGGCCTGCCCGGTTTGCCGAAGGGAGCCGAGTGTCGA

AGAGAAGTCGGGTAAAGGTAAGTTGTGCAGACACTTGGGGAAGTTTCAAGGAGA
CCGCCAGCTCAAGATGGAACCGCGGCCCGGGCGCTAAGGACGGGCTTCAGCTC
CCGCTGGCAAAAAGAGAAAGTCGAGCCCGCCTTCCTGCCAACAAAAACAACA
ACATGACAACAAGAACCCCGGAGGGGAGTGGAATGAGTGACGTACAGCCGCGCT
5 CTGAGGCTGACAAAGGAGGGGGCGCGCCCTCCCGCTCTGCGCCCGCGCGGCC
CGGAGAGGGGGCGCCTGAAGCGCCGGGTAGGGAAGTCAGCCGACTTGAACTTT
TCCTCTTNNNNNNNNNNNNNNNNNNNNNGTTGTGCGCGGCTCACAGTGGGGTTTT
TTTTTTTTCCGCCTTCTTTTCTCGTCTCCCTCCCCCTTCTTCCTTTTGAAAGTTTCTT
CTCCTCCCCCTGCCCCCCTCCCCGCCTGACCGCATGGCTGATTCAACTCCAGTGT
10 CAATCAACTTCTTTTTCTCCTCTTCTCATTTAAATAAGTTTAAAGCTCCTCCTCC
CCCCGGCCACCAAATCTGAACCTTATAAATTGGGCTTTGCGCGCCCCAGCCCGG
AGTCAGAAAGGCGAGGGGGCGCCGGGAAGTGGCGTGTGGGACTCCAGACAGGAG
AGGCTGCGCCTTCCCCGCACCGGGACCTTCGCGACACACCAGATCCTCGCCCTG
GCTCGCGCGAACGCACAGGATGACCACCACCCTCGTGTCTGCCACCATCTTCGAC
15 TTGAGCGAAGTTTTATGCAAGGTAAGGGGGGGCGGAGCATTTGCTTTTCAAAAA
GTCTTTTTCTTTTGCCTTAAGAAAGAACCCCAAAAGTTTGGGTCTTGGAAGGCA
ATGGGGAAAGTGGTGCAGCGAGATGATTCTTTTCTCCTCCGGCATTCTCCCAAG
TTTGAAGGAATTTGGCCCCGTCTTCCCACCCTTTGAGTTTCAACAGTTGCTGGCG
GGGATTACATGTGAATCTGGAGGCCAGGGTTTTGAGGGGCGAAGTTTGCCTGGC
20 AGGGCAGCCCGGGGGCTTCGGGGGGAGGGCTGGGATTGGGACAAGTTTGGGCG
ATCCTGTTTTACGTAACGTGCTGCTGGATCCCAGGTTTGCTGGTCTGATCGGGTTC
GCAGTCTGCGCCCTAGGTCTGCGGAGCGGCATTACCCACCCGTGGGGTTGGGAGT
GGGAGGTCCCTEGGGGAAGTGAAGTCTCGGGACAATGTTTTCTTCCACTCTTTGGG
GGGAGCTGGGGATATGCGAGGAAGAAAGGCCAAGTTGTGATTCAAAAAGATGTT
25 GCAGAACAAGTTTGCAGTGGGGCTTGAGTCCGCCCTAGCTCCGTTGGGCTTCTTC
CCGCGATAGCCGATCGTGCAGCAAACCTTTGGGGTGAAAGAGGCATTCAGGTTGA
CCCGCTTACCTGTGTTGCCGAGGCATTGCGGCTCATCGATTGCGGGCGGGGTTGG
GGGGGGAGGTGGCGACAAAATGCTGGCTTGAAGTTCGAGAGTCCGCGAGTAAGG
ATTTAATGGGGGCCTCCTTAAACATGTTGCTTGTGAGCCAGTGTGAAAAAGCA
30 AGTTTTAAACTCGGAATGTTCCAGGACTGCGGTTTAAATGTACATAGCAAAAGTC
TATGGATGTTGTTAAATTTCTTTCCAACCTCCCCCTCCCAATTTGAAAGGGTGAAG
CTGCTGGGCTACTTTTAAATTGCTGAAGTGTGTTGCTTCTCCAGCCAGGAGCTGG
CAAGCCTCTTTGCCCTAGCATGGGGCTGCCCGGGGGTGGCTCCCCGACCACCTT
CCTCTTCCGGCCCATGTCCGAGTCCCCTCACATGTTTGACTCTCCCCCAGCCCTC
35 AGGATTCTCTCTCGGACCAGGAGGGCTACCTGAGCAGCTCCAGCAGCAGCCACA
GTGGCTCAGACTCCCCGACCTTGGAACACTCAAGACGCCTGCCCATCTTCAGCAG
ACTTTCATCTCAGATGACTAAGCCAGGGTAGGGAGGGACCTCCTGCCTACTCCA
GCCCCTACCCTGCACCCACATCCCATACCCTCTTCTCCCTACCCATCCCATTCCCC
ACAGGCCCTACATTAACAAGGTTAAGCTCAACCCCTTTCCCCCAGCACCTCAGAA
40 TGTGCCCTCCCTCTCCCCCTCATAACCCACCTAACATAAGGACAAGTCAATTTG
TCAGTAGCTTCTTCTGGCTTGAAACCCCTCCCTGGGATTTTATAGCCCACTTACC
ATGCATAACAGACAAGTCCCATATTTTGTGAGTAGATGCCTTTTTTTTTCCGGCTT
AAGCCTTAAGTGCCAAATCACAAGAGAAAAAGCAGTAACAGTTTACAGAAGCAA
CTTAGTGCCTTGTAATCTAACTTTGTCACTGTGACTACATTACCTCTTCAGCGCCA
45 GAGGGCACCCGTGGGCCTCCCGGAGCCTCTGCCCATGGCGGGGTGGAGACCCGG
AACCAGCAGCCCCCTCCACTGGCGACACAAGTGCACCTTCCCTCATTTCAGTCTC
CCGCACACTTATTCCTCCTCCCCTCTTCCCGGTGGCACCTCTCCACCTGTACCCGC
CCCCGCCCCACCACCCCGGCCCTTGGAAGAGTTGTTGCCAGACCAGGGTTTTGG
GGGAAACCTGTCTTGACATTCAAAACCTTTTTCTTCCCGATCTGAACCCCTGTTGA

CTAATCTTGCCTGGGTTTGTGTAGGTCTGCAGGAAGGAAGGCTGAAAAAGCGGA
CGAAGATTTTGA CTTAAGTGGGACTTTGTGATTTAATTTTTTCTTTTTTTAAGTG
GGGAGGAAGGGGAAGCTAGATGGACTAGGAGAGACTTGATTTTGGTGCTAAAGT
TCCCCAGTTCATATGTGACATCTTTTTAAAAAAAATAACAACAAAAAAAATG
5 AGAGAAAAGCTAAAAAAAAGTAAGGGGTGAGCAGTTAATGGTATTCATTC
CACATACAATATCTGTGTAAAACGATTTCTGTAGAAAGTAGCTTTAATGGTTTTT
GCTCTAGAATACCGTAGGTCTATCCTTAGAGCACTCACGCCATGCTTTCTTCCCTG
GGTTTTAACTTCATATACTTTTCAGAAATTGGAGAGCAAAAATTTTGCTTGTC
CTGCACATCAATATAAAAAAGCTTATTTAACTTATCAAAACGTATTTATTGCCAA
10 ACTATGCTTTTTTTTTGTTAATTTTGTTCATATTTATCGGGATGACAAATCCATAGA
ATATATTCTTTTATGTTAAATTATGATCTTCATATTAATCTTAAAATTTTGTGACG
TGTCTTTTTCTTTTTTTCCACAGTTTAAATATATTATTCTTCAACGACATTTTTTG
TAACTTTACACTTTTTTGGTTATTTTATTTTAAAAAAAATGAAAAATTAATTTAAA
AAAATGCAAAAAACTGTTGGATTATTTATTTTAGAAAATCCCCCCTTTGTGTTGG
15 ACTGCAAATTGAGTTTCTTTCTCTTTAGGCCTTTCACAACTAGGACTGAGAATGTA
TGTAAGAGTTCTGTGACAGTACAGAAGGAAAACAACCTTTTTATGTATAGCTTCTA
AAAGGGGAAAAAAAAGAGAAACCCTTTGACTTCCACGTGCCCATCTCA
AGACATTCCACTCACAGATTTGAGGTTCTGGATTCCAGGTCTGGAGTTTCCAAT
GTTAATGTAAACAGAACTGGCACACACATTAAAGATGAATGTAATTATTATTCC
20 TCTTGCTGGTCACTACCGTCGCTTTCTATTTCTCTTTCTTTGTGTGAATTTATTAA
AAGAAAAAAAACCTTTTGTAAACGACTATTTGCAGTTTAAAAATCAATAAACCCC
GTTTTTCAAGAAAGAAAA

SEQ ID NO: 381

25: >4336 BLOOD 992306.1 X51521 g31282 Human mRNA:for ezrin. 0:

CCATCTTTGTATATTTACATGCTTAGAGGGGTGAAAATTATTTTGGAAATTGAGT
CTGAAGCACTCTCGCACACACAGTGATTCCCTCCTCCCGTCACTCCACGCAGCTG
GCAGAGAGCACAGTGATCACCAGCGTGAGTGGTGGAGGAGGACACTTGGATATT
TTTTTAGTTTTTTTTTTTTTGGCTTAACAGTTTTAGAATACATTGTACTTATACACC
30 TTATTAATGATCAGCTATATACTATTTATATACAAGTGATAATACAGATTTGTAA
CATTAGTTTTTAAAAAGGGAAAGTTTTGTCTGTATATTTTGTACCTTTTACAGAA
TAAAAGAATTACATATGAAAAACCCTCTAAACCATGGCACTTGATGTGATGTGGC
AGGAGGGCAGTGGTGGAGCTGGACCTGCCTGCTGCAGTCACGTGTAAACAGGAT
TATTATTAGTGTTTTATGCATGTAATGGACTATGCACACTTTTAATTTTGTTCAGAT
35 TCACACATGCCACTATGAGCTTTCAGACTCCAGCTGTGAAGAGACTCTGTTTGCT
TGTGTTTGTGTCAGTCTCTCTGCCATGGCCTTGGCAGGCTGCTGGAAGGCAG
CTTGTTGGAGGCCGTTGGTTCCGCCACTCATTCTCTCGTGCAGTCTTTCTCCT
TCACAGCTAAGATGCCATGTGCAGGTGGATTCCATGCCGCAGACATGAAATAAA
AGCTTTG

40

SEQ ID NO: 382

>4365 BLOOD 198264.2 D42039 g577290 Human mRNA for KIAA0081 gene, partial cds.
0

GGAGGCGGGGCCTCGGAAAGGCGGACAGGAAGGCGTGTGCAAGGCGGGGTCCG
45 GCCCGCGCAGGTCGGGTAAGCGCGTCTAGGGCGCTGCGCGGCGCAGCGAAAATG
GCGGCTTCCAGGTGGGCGCGCAAGGCCGTGGTCCTGCTTTGTGCCTCTGACCTGC
TGCTGCTGCTGCTACTGCTACCACCGCCTGGGTCCTGCGCGGCCGAAGGCTCGCC
CGGGGACGCCCGACGAGTCTACCCACCTCCCCGGAAGAAGAAGAAGGATATTC
GCGATTACAATGATGCAGACATGGCGCGTCTTCTGGAGCAATGGGAGAAAGATG

ATGACATTGAAGAAGGAGATCTTCCAGAGCACAAAGAGACCTTCAGCACCTGTGCG
ACTTCTCAAAGATAGACCCAAGCAAGCCTGAAAGCATATTGAAAATGACGAAAA
AAGGGAAGACTCTCATGATGTTTGTCACTGTATCAGGAAGCCCTACTGAGAAGG
AGACAGAGGAAATTACGAGCCTCTGGCAGGGCAGCCTTTTCAATGCCAACTATG
5 ACGTCCAGAGGTTCAATTGTGGGATCAGACCGTGCTATCTTCATGCTTCGCGATGG
GAGCTACGCTGGGAGATCAAGGACTTTTTGGTTCGGTCAAGACAGGTGTGCTGAT
GTAACCTCTGGAGGGCCAGGTGTACCCCGGCAAAGGAGGAGGAAGCAAAGAGAA
AAATAAAACAAAGCAAGACAAGGGCAAAAAAAGAAGGAAGGAGATCTGAAAT
CTCGGTCTTCCAAGGAAGAAAATCGAGCTGGGAATAAAAGAGAAGACCTGTGAT
10 GGGGCAGCAGTGACGCGCTGTGGGGGGACAGGTGGACGTGGAGAGCTCTTTGCC
CAGCTCCTGGGGTGGGAGTGGTCTCAGGCAACTGCACACCGGATGACATTCTAGT
GTCTTCTAGAAAGGGTCTGCCACATGACCAGTTTGTGGTCAAAGAATTACTGCTT
AATAGGCTTCAAGTAAGAAGACAGATGTTTTCTAATTAATACTGGACACTGACAA
ATTCATGTTTACTATAAAATCTCCTTACATGGAAATGTGACTGTGTTGCTTTTTCC
15 CATTTACACTTGGTGAGTCATCAACTCTACTGAGATTCCACTCCCCTCCAAGCAC
CTGCTGTGATTGGGTGGCCTGCTCTGATCAGATAGCAAATTCTGATCAGAGAAGA
CTTTAAACTCTTGACTTAATTGAGTAAACTCTTCATGCCATATACATCATTTTCA
TTATGTTAAAGGTAAAATATGCTTTGTGAACTCAGATGTCTGTAGCCAGGAAGCC
AGGGTGTGTAAATCCAAAATCTATGCAGGAAATGCGGAGAATAGAAAATATGTC
20 ACTTGAAATCCTAAGTAGTTTTGAATTTCTTTGACTTGAATCTTACTCATCAGTAA
GAGAACTCTTGGTGTCTGTCAGGTTTTATGTGGTCTGTAAAGTTAGGGGTTCTGTT
TTGTTTCTTATTTAGGAAAGAGTACTGCTGGTGTGCGAGGGGTTATATGTTCCATT
TAATGTGACAGTTTTTAAAGGATTTAAGTAGGGAATCAGAGTCCTTTGAGAGTGT
GACAGACGACTCAATAACCTCATTTGTTTTCTAAACATTTTCTTTGATAAAGTGCC
25 TAAATCTGTGCTTTCGTATAGAGTAACATGATGTGCTACTGTTGATGTCTGATTTT
GCCGTTTCATGTTAGAGCCTACTGTGAATAAGAGTTAGAACATTTATATACAGATG
TCATTTCTAAGAACTAAAATTCTTTGGGAAAAACCCTCAATTGTGATTTTAATAA
ATTAAGTAGCACATTACATGGTTAGAAAATGTCAGTGTTAAAGAATGGTACA
AAGTGAAAAGTGTATCCCTCTCTTGCCGCCGGTGGTAGCTTGTCACAGTGGAAGC
30 TGCTGTAAACAATTTGTGCCCCACATCCCCCTCCCTGCCATCCACCAAAAAA
AGTACATTTACTTATGTAAATGTACTTATGGTGATGTATGTTTGTGTTTGGCCTCAC
AGCATCTGTTTCCCTTAAATTTGGTAGCTGCTCACATTTCCCTCGAAAGAACCACA
CCCTCTGCATTCTCAGTTCTTTGCTTTGGATGGGACATTTGCCCTGCAGTCCCCC
ACCCTCCAGGCCATGCCCTCTCCAGGGTGAGGCCTGTGTGATTTACCGTACTAGG
35 GTACTAGGCCCTGAAAGAGGCTTTTCTTGTTCCTCCTGCATCTTGAACCTGGAGC
GGGAGCTGTTGTAGGCCCCGCCCTTGGAGAAGAGAACTGTCTGACAGTGGGGAG
AGAGCGCCACACCCTGGTGGCATAAACGAGTCCCTGAATCATGCCGTGGCTGAA
CCAAGCCCTGTCTGTGGGCTTTTTCTGTTGTACTCAGGGCAGTTTGATGGGGTTAC
TGTCCTGCATAGCCATAATGGCCCAGTATAAAGCAGCTGTTTGTGATGAGATAATT
40 GCTTTAATTAAGCAAAAGGTAGCAAAGCTTTCACTCCGCCCTGTACCTTCTGTTTC
CACTTAGGAGCCTTCCCATGTGAGAATGTGCAGATCTGTCTCATTGTTTCTGTGC
AGTGTGCCCCCACTTCACCCAGTAGTTTCTGTGTGTCTGTTATGTACTAGGTACTA
CAAGGTGCCAGGACGGTGTAGATACAGCCTCTGCTATCGTAAACTCAATGATTC
GGTGGGGGAAGACAAATGTGAGTAATGTACAAAGTAAAATGGCAGCTGTTAGAA
45 GTATGAAAGGGGCAGGGTAGGGGGAGGTAGAATCTTCCCTGACCAGGTAAAGAA
AACCAGAGGCCTTCTCTGAGGGCAAGAGGAGGAGAGGAGAAATAGAGTAAGGC
AGGCAGAGGAAACAGTCTGAGCTAAGACCCTGTGGCTAGAAGTGGCAGAGGGA
GAGGCAGCAGGAAGGCCAGCGGGGAGGCTGGGGCCCAGTGCAGGCCCAGGTTG
GAGGAGCGTAGCACATGGAGTTTGGTAGGAGTTTGGGACGCCCTGGTGGATCTT

AATTGTGATGGGGTGGGTGTGAAAGGCAGTCCAGGTTGCACTGGTTGCACAGGA
 GAAGTGATCAGAAGAGGACCCCAGCAGGTGTGAGCCGTGAGCAGAGGTGCTTCA
 GTAGTGCAGGCCATAGCTGAAGGTGTCTACATCAGCAGGGTGATGGTGAGGTT
 TGAACCACTGTTTCACTGCATAGTCCCTGCTGATGGACACTTGAGTGTTTCAATTT
 5 TTTGCTGGTATATTCACTGCTGCAGTGGACATTTTCATACAAAATATTTCCGTACA
 CTTTTGTTTATATCTGAAAGGTAAATTTCCTAGCAGTAGAATTATTAGAGCAAACG
 GAATTTAACATTTTGGTGTGTATTGCCAAATTGCCCTCCCAAGTGGTTTAGTCAGC
 TTACCCTTGCCAACAATAGATCTATCCTTGCCAGCCTTGGGCATCACATTTACCA
 GTTTAATAGATTGTAAAACCATATCTTAATTGGCTACCCTGAAGCCACCATACTG
 10 GAGAGGCTGCGTACAGTGTTTCACGTAGAGAGAGGGATACCCAGGAGGGCCACC
 TGCTCCAACCCAGCTGCATGAGTCTTCCCAGCCCAGGCACAGACATGTGGATAA
 GATTTAAACATTTCCAGCCCCAGCCTTCAAGCAATCCTAGTTGACACTGAGGGGA
 GCCAACATAAGCTGAGCTGAGAAACAGTCTGCCAGTCTGCAGATTCATGAGCA
 AAAGAAATGTTG

SEQ ID NO: 383

>4369 BLOOD Hs.77274 gnl|UG|Hs#S572505 H.sapiens uPA gene /cds=(119,1414)
 /gb=X02419 /gi=37601 /ug=Hs.77274 /len=2344

AGCACAGTCGGAGACCGCAGCCCGGAGCCCGGGCCAGGGTCCACCTGTCCCCGC
 20 AGCGCCGGCTCGCGCCCTCCTGCCGCAGCCACCGAGCCGCCGTCTAGCGCCCCGA
 CCTCGCCACCATGAGAGCCCTGCTGGCGCGCCTGCTTCTCTGCGTCTGGTTCGTG
 AGCGAGTCCAAAGGCAGCAATGAACTTCATCAAGTTCCATCGAACTGTGACTGTC
 TAAATGGAGGAACATGTGTGTCCAACAAGTACTTCTCCAACATTCACTGGTGCAA
 CTGCECAAGAAATTCCGAGGGGCAGCACTGTGAAATAGATAAGTCAAAAACCTG
 25 CTATGAGGGGAATGGTCACTTTTACCGAGGAAAGGCCAGCACTGACACCATGGG
 CCGGCCCTGCCTGCCCTGGAACCTCTGCCACTGTCTTCAGCAAACGTACCATGCC
 CACAGATCTGATGCTCTTCAGCTGGGCCTGGGGAAACATAATTACTGCAGGAACC
 CAGACAACCGGAGGCGACCCTGGTGTCTATGTGCAGGTGGGCCTAAAGCCGCTTG
 TCCAAGAGTGCATGGTGCATGACTGCGCAGATGGAAAAAGCCCTCCTCTCCTCC
 30 AGAAGAATTAATAATTTCACTGTGGCCAAAAGACTCTGAGGCCCCGCTTTAAGATT
 ATTGGGGGAGAATTCACCACCATCGAGAACCAGCCCTGGTTTGCGGCCATCTACA
 GGAGGCACCGGGGGGGCTCTGTACCTACGTGTGTGGAGGCAGCCTCATGAGCC
 CTTGCTGGGTGATCAGCGCCACACACTGCTTCATTGATTACCCAAAGAAGGAGGA
 CTACATCGTCTACCTGGGTGCTCAAGGCTTAACTCCAACACGCAAGGGGAGATG
 35 AAGTTTGAGGTGGAAAACCTCATCCTACACAAGGACTACAGCGCTGACACGCTT
 GCTCACCACAACGACATTGCCCTTGCTGAAGATCCGTTCCAAGGAGGGCAGGTGT
 GCGCAGCCATCCCGGACTATACAGACCATCTGCCTGCCCTCGATGTATAACGATC
 CCCAGTTTGGCACAAGCTGTGAGATCACTGGCTTTGGAAAAGAGAATTCTACCGA
 CTATCTCTATCCGGAGCAGCTGAAAATGACTGTTGTGAAGCTGATTTCCACCGG
 40 GAGTGTGAGCAGCCCCACTACTACGGCTCTGAAGTCACCACCAAATGCTGTGTG
 CTGCTGACCCACAGTGGAAAACAGATTCTTGCCAGGGGAGACTCAGGGGGACCCC
 TCGTCTGTTCCCTCCAAGCCGCATGACTTTGACTGGAATTGTGAGCTGGGGCCG
 TGGATGTGCCCTGAAGGACAAGCCAGGCGTCTACACGAGAGTCTCACACTTCTTA
 CCCTGGATCCGCAGTCACACCAAGGAAGAGAATGGCCTGGCCCTCTGAGGGTCC
 45 CCAGGGAGGAAACGGGCACCACCCGCTTTCTTGCTGGTTGTCAATTTTGCAGTAG
 AGTCATCTCCATCAGCTGTAAGAAGAGACTGGGAAGATAGGCTCTGCACAGATG
 GATTTGCCTGTGCCACCCACCAGGGTGAACGACAATAGCTTTACCCTCAGGCATA
 GGCCTGGGTGCTGGCTGCCAGACCCCTCTGGCCAGGATGGAGGGGTGGTCTCTG
 ACTCAACATGTTACTGACCAGCAACTTGTCTTTTCTGGACTGAAGCCTGCAGGA

GTTAAAAAGGGCAGGGCATCTCCTGTGCATGGGTGAAGGGAGAGCCAGCTCCCC
 CGACGGTGGGCATTTGTGAGGCCCATGGTTGAGAAATGAATAATTTCCCAATTAG
 GAAGTGTAACAGCTGAGGTCTCTTGAGGGAGCTTAGCCAATGTGGGAGCAGCGG
 TTTGGGGAGCAGAGACACTAACGACTTCAGGGCAGGGCTCTGATATTCCATGAA
 5 TGTATCAGGAAATATATATGTGTGTGTATGTTTGCACACTTGTGTGTGGGCTGTG
 AGTGTAAGTGTGAGTAAGAGCTGGTGTCTGATTGTTAAGTCTAAATATTTCCCTTA
 AACTGTGTGGACTGTGATGCCACACAGAGTGGTCTTTCTGGAGAGGTTATAGGTC
 ACTCCTGGGGCCTCTTGGGTCCCCCACGTGACAGTGCCTGGGAATGTACTTATTC
 TGCAGCATGACCTGTGACCAGCACTGTCTCAGTTTCACCTTCACATAGATGTCCCT
 10 TTCTTGGCCAGTTATCCCTTCCTTTTAGCCTAGTTCATCCAATCCTCACTGGGTGG
 GGTGAGGACCACTCCTTACACTGAATATTTATATTTCACTATTTTTATTTATATTT
 TTGTAATTTTAAATAAAAGTGATCAATAAAATGTGATTTTTCTGA

SEQ ID NO: 384

15 >4373 BLOOD 347357.1 M30818 g188902 Human interferon-induced cellular resistance
 mediator protein (MxB) mRNA, complete cds. 0
 GGGACAGGAGAGGAGCTGAATCCTGAGATTGTATCGCTAGGAGCCCCCAAAGTA
 CGATGACGGTCTCGGGCCAGCATGGGGGTGCATTGGCACCATGTAAGGAAAGG
 GGCCCTCCCGTGGCACCGTTGGAGTGGGGCGGTGTGGGGTTGTTTCGGAGAGAAA
 20 AGTTTCCCATGAGCTCTGTTTCAGCAAACGGCGATGACCACTTTCGTGGCAACTA
 AACAGTCTTGCTTCCCTGCACGTGGACATTTTTCTTCATGCATATTTCTCTTGCAA
 ATGGTTCTATTGTTTGTATAACAGTATTTTCATGAGCGGAGAAAGAGTTGGAAGCAA
 AAATCTGTTCATGAGAAATAGCTTGTCAAGGAAGATCGGAGGTGCCAAGTAGCAG
 AGAAAGCATCCCCCAGCTCTGACAGGGAGACAGCAGATGTCTAAGGCCCAACAAG
 25 CCTTGGCCCTACCGGAGGAGAAGTCAATTTTCTTCTCGAAAATACCTGAAAAAAG
 AAATGAATTCTTCCAGCAACAGCCACCGCCATTTCGGCACAGTGCCACCACAAAT
 GATGTTTCTCTCCAACTGGCAGGGGGCAGAGAAGGACGCTGCTTCTCGCCAA
 GGACTTCAACTTTCTCACTTTGAACAATCAGCCACCACCAGGAAACAGGAGCCA
 ACCAAGGGCAATGGGGCCCGAGAACAACCTGTACAGCCAGTACGAGCAGAAGG
 30 TGCGCCCTGCATTGACCTCATCGACTCCCTGCGGGCTCTGGGTGTGGAGCAGGA
 CCTGGCCCTGCCAGCCATCGCCGTCTCGGGGACCAGAGCTCGGGCAAGAGCTC
 TGTGCTGGAGGCACTGTCAGGAGTCGCGCTTCCCAGAGGCAGCGGAATCGTAAC
 CAGGTGTCCGCTGGTGTGAACTGAAAAGCAGCCCTGTGAGGCATGGGCCGG
 AAGGATCAGCTACCGGAACACCGAGCTAGAGCTTCAGAGACCCTGGCCAGGTGG
 35 AGAAAGAGATACACAAAGCCGAGAACGTCATGGCCGGGAATGGCCGGGGCATC
 AGCCATGAGCTCATCAGCCTGGAGATCACCTCCCCTGAGGTTCCAGACCTGACCA
 TCATTGACCTTCCCGGCATCACCAGGGTGGCTGTGGACAACCAGCCCCGAGACAT
 CGGACTGCAGATCAAGGCTCTCATCAAGAAGTACATCCAGAGGCAGCAGACGAT
 CAACTTGGTGGTGGTTCCCTGTAACTGGACATTGCCACCACGGAGGCGCTGAGC
 40 ATGGCCCATGAGGTGGACCCGGAAGGGGACAGGACCATCGGTATCCTGACCAAA
 CCAGATCTAATGGACAGGGGCACTGAGAAAAGCGTCATGAATGTGGTGCGGAAC
 CTCACGTACCCCCTCAAGAAGGGCTACATGATTGTGAAGTGCCGGGGCCAGCAG
 GAGATCACAAACAGGGCTGAGCTTGGCAGAGGCAACCAAGAAAGAAATTACATT
 CTTTCAAACACATCCATATTTTCAGAGTTCTCCTGGAGGAGGGGTCAGCCACGGTT
 45 CCCCAGCTGGCAGAAAGACTTACCACTGAACTCATGCATATCCAAAAATCGC
 TCCCGTTGTTAGAAGGACAAATAAGGGAGAGCCACCAGAAGGCGACCGAGGAG
 CTGCGGCGTTGCGGGGCTGACATCCCCAGCCAGGAGGCGGACAAGATGTTCTTTC
 TAATTGAGAAAATCAAGATGTTTAAATCAGGACATCGAAAAGTTAGTAGAAGGAG
 AAGAAGTTGTAAGGGAGAATGAGACCCGTTTATACAACAAAATCAGAGAGGATT

GCGGAACCTATGCATAGTTGACAACCTCAAGCCTGAGCTTTTTGGTCTTGTTCTGA
TTTGGAAAGGTGAATTGAGCAGGTCTGCTGCTGTTGGCCTCTGGAGTTCATTTAGT
TAAAGCACATGTACACTGGTGTGGACAGAGCAGCTTGGCTTTTCATGTGCCAC
CTACTTACCTACTACCTGCGACTTTCTTTTTCCTTGTTCTAGCTGACTCTTCATGCC
5 CCTAAGATTTTAAGTACGATGGTGAACGTTCTAATTTTCAGAACCAATTGCGAGTC
ATGTAGTGTGGTAGAATTAAAGGAGGACACGAGCCTGCTTCTGTTACCTCCAAGT
GGTAACAGGACTGATGCCGAAATGTCACCAGGTCCTTTCAGTCTTCACAGTGGAG
AACTCTTGCCCAAAGGTTTTTGGGGGGAGGAGGAGGAAACCAGCTTTCTGGTTA
AGGTAAACACCAGATGGTGGCCCTCATTGGTGTCTTTTAAAAAATATTTACTGT
10 AGTCCAATAAGATAGCAGCTGTACAAAATGACTAAAATAGATTGTAGGATCATA
TGGCGTATATCTTGTTTCATCTTCAAAATCAGAGACTGAGCTTTGAAACTAGTGG
TTTTTAATCAAAGTTGGCTTTATAGGAGGAGTATAATGTATGCACTACTGTTTTAA
AAGAATTAGTGTGAGTGTGTTTTTGTATGAATGAGCCCATTTCATGGTAAGTCTTA
AGCTTGTTGGAAATAATGTACCCATGTAGACTAGCAAAAATAGTATGTAGATGTGA
15 TCTCAGTTGTAAATAGAAAAATCTAATTCAATAAACTCTGTATCAGCCCCCAACA
TATTATTTTTTCATTATTTGGGGGATATTTTCAGTTCAGAGCAGCAGTATCATGTTT
TCTTTGTTGGTGCTGTCTATAGTTCATCATGGTTTACGTGTGTTTTTCGTTATAGCTG
TTGCCAGATTCTAAAGGGCTTGATATTCAAAAAACACAGATGCTTTCAGTCCAG
TATATCCTAGAAATATAGAGCTCTACTTTGTGCAATGCACTGGGGATACAGTGGC
20 GATACTGTCTTGTTCTTCAAGGAGTTCGGAGTCCTAGTATAGG

SEQ ID NO: 386

>4379 BLOOD 234480.12.X76648 g531404.Human mRNA for glutaredoxin. 0
GCACCTTATGCTTCCCCAGAGGTGACTAAACTCTGATCATTGCCAATGGGCAGGC
25 ACTCCCCAAATGTCCAAGGACAACAAAGATACCCAGAGTGTCTTTCATAGCTACC
AATGATTAAATAGCAAGTATTGCATTCTGGGCATTGCTAACTAGTGAAGTATAC
CAGATGGAAATGTCTTCGAAGCTGTCCCTTTAAAACTCGAGCAAGCTACCAGGCA
AACTCCGCCTCCAGGGAGGTTCTTATTAAATAGGAGCCAACCTGGCTGGGTGCGG
GCTCAATACCCCAAGCAATACCTGCAACTGAGGATTCTTCCCGGGGAGACCGCA
30 GCCCATCGGCATGGCTCAAGAGTTTGTGAAGTGCAAAATCCAGCCTGGGAAGGT
GGTTGTGTTTCATCAAGCCCACCTGCCCCGTAAGTGCAGGAGGGCCCAAGAGATCCT
CAGTCAATTGCCCATCAAACAAGGGCTTCTGGAATTTGTGATATCACAGCCACC
AACCACACTAAGGAGATTCAAGATTATTGCAACAGCTCACGGGAGCAAGAACG
GTGCCTCGAGTCTTTATCGGTAAAGATTGTATAGGCGGATGCAGTGATCTAGTCT
35 CTTTGCAACAGAGTGGGGAAGTGTGACGCGGCTAAAGCAGATTGGAGCTCTGC
AGTAACCACAGATCTCATAGGAAATGTTCAACAATTCTGTGAAAGGTCACAGGA
CCCAATTGGAGAAATCATATGAAAAGCATAGTTGGTCTTGGTGTATATGGATCA
GAGGCACAAGTGCAGAGGCTGTGGTCATGCGGAACACTCTGTTATTTAAGATGG
CTATCCAGATAATCCTGAACACTGTGTATTTATTTTATTTAGACTACCAGCAAAG
40 ATTAAGCATGAAATGTAAAACATCTGATAAACTTACAGCCCCCTACACCAAG
AGTGTATCTGTGAAAGAGCTCCTACACTTTGAAAACCTTAAGAATCCCTTATCATG
AAGTTTGCTGTTCTAGAATTGTAAGATTGTAAATTTCTTCAATCTCTAGTGACA
ACACTTAATTTCTTTTCTAATAAAAAAACCTATAGATGATTCAGTGATTTTGTG
CAATTCATTTGCATGTTCTCAAGACATTAAGGAATGTTATGCGAAATACACTAAC
45 TTAAAACTGTGTTTATATTTGGCCCTGCCATTATAAATAAAGACACGTGCTGCTG
TCACTCACTGAGTACAAATGGCTGATATAATTTTGAAGTTTCATATAAACATGA

SEQ ID NO: 387

>4400 BLOOD 331689.11 L36870 g685175 Human MAP kinase kinase 4 (MKK4) mRNA,
complete cds. 0

CTCCCAACAATGGCGGCTCCGAGCCCCGAGCGGCGGGCGGGCTCCGGGGGGCGGC
5 AGCGGCAGCGGCACCCCCGGCCCCGTAGGGTCCCCGGCGCCAGGCCACCCGGCC
GTCAGCAGCATGCAGGGTAAACGCAAAGCACTGAAGTTGAATTTTGCAAATCCA
CCTTTCAAATCTACAGCAAGGTTTACTCTGAATCCCAATCCTACAGGAGTTCAAA
ACCCACACATAGAGAGACTGAGAACACACAGCATTGAGTCATCAGGAAAACCTGA
AGATCTCCCCTGAACAACACTGGGATTTCACTGCAGAGGACTTGAAAGACCTTGG
10 AGAAATTGGACGAGGAGCTTATGGTTCTGTCAACAAAATGGTCCACAAACCAAG
TGGGCAAATAATGGCAGTTAAAAGAATTTCGGTCAACAGTGGATGAAAAAGAACA
AAAACAACCTTCTTATGGATTTGGATGTAGTAATGCGGAGTAGTGATTGCCCATAC
ATTGTTTCAGTTTTATGGTGCACCTCTTCAGAGAGGGTGACTGTTGGATCTGTATGG
AACTCATGTCTACCTCGTTTGATAAGTTTTACAAATATGTATATAGTGTATTAGAT
15 GATGTTATTCCAGAAGAAATTTTAGGCCAAAATCACTTTAGCAACTGTGAAAGCAC
TAAACCACTTAAAAGAAAACCTTGAAAATTATTCACAGAGATATCAAACCTTCCA
ATATTCTTCTGGACAGAAAGTGGAAATATTAAGCTCTGTGACTTCGGCATCAGTGG
ACAGCTTGTGGACTCTATTGCCAAGACAAGAGATGCTGGCTGTAGGCCATACATG
GCACCTGAAAGAATAGACCCAAGCGCATCACGACAAGGATATGATGTCCGCTCT
20 GATGTCTGGAGTTTGGGGATCACATTGTATGAGTTGGCCACAGGCCGATTTCCCTT
ATCCAAAGTGGAATAGTGTATTTGATCAACTAACACAAGTCGTGAAAGGAGATC
CTCCGCAGCTGAGTAATCTGAGGAAAGGGAAATCTCCCCGAGTTTCATCAACTT
TGTCAACTTGTGCTTACGAAGGATGAATCCAAGGGCCAAAGTATAAAGAGCT
TCTGAAACATCCCTTTATTTGATGTATGAAGAACGTGCCGTTGAGGTCGCATGC
25 TATGTTTGTAAAATCCTGGATCAAATGCCAGCTACTCCCAGCTCTCCCATGTATGT
CGATTGATATCGCTGCTACATCAGACTCTAGAAAAAAGGGCTGAGAGGAAGCAA
GACGTAAAGAATTTTCATCCCGTATCACAGTGTTTTTATTGCTCGCCCAGACACC
ATGTGCAATAAGATTGGTGTTCGTTTCCATCATGTCTGTATACTCCTGTCACCTAG
AACGTGCATCCTTGTAATACCTGATTGATCACACAGTGTAGTGCTGGTCAGAGA
30 GACCTCATCCTGCTCTTTTGTGATGAACATATTCATGAAATGTGGAAGTCAGTAC
GATCAAGTTGTTGACTGTGATTAGATCACATCTTAAATTCATTTCTAGACTCAAA
ACCTGGAGATGCAGCTACTGGAATGGTGTTTTGTGCACTTCCAAATCCTGGAAG
GACACAGTGATGAATGTACTATGTCTGAACATAGAACTCGGGCTTGAGTGAGA
AGAGCTTGCACAGCCAACGAGACACATTGCCCTTCTGGAGCTGGGAGACAAAGGA
35 GGAATTTACTTTCTTCACCAAGTGCAATAGATTACTGATGTGATATTCTGTTGCTT
TACAGTTACAGTTGATGTTTGGGGATCGATGTGCTCAGCCAAATTTCCCTGTTTGA
AATATCATGTTTAAATTAGAATGAATTTATCTTTACCAAAAACCATGTTGCGTTCA
AAGAGGTGAACATTAAAATATAGAGACAGGACAGAATGTGTTCTTTTCTCCTTTA
CCAGTCCTATTTTTCAATGGGAAGACTCAGGAGTCTGCCACTTGTCAAAGAAGGT
40 GCTGATCCTAAGAATTTTTCAATCTCAGAAATTCGGTGTGCTGCCAACTTGATGTTT
CACCTGCCACAAACCACCAGGACTGAAAGAAGAAAACAGTACAGAAGGCAAAG
TTTACAGATGTTTTTAATTCTAGTATTTTATCTGGAACAACCTTGTAGCAGCTATAT
ATTTCCCCTTGGTCCCAAGCCTGATACTTTAGCCATCATAACTACTAACAGGGA
GAAGTAGCTAGTAGCAATGTGCCTTGATTGATTAGATAAAGATTTCTAGTAGGCA
45 GCAAAAGACCAAATCTCAGTTGTTTGGCTTCTTGCCATCACTGGTCCAGGTCTTCA
GTTTCCGAATCTCTTTCCCTTCCCCTGTGGTCTATTGTCGCTATGTGACTTGCGCTT
AATCCAATATTTTGCCCTTTTTTCTATATCAAAAAACCTTTACAGTTAGCAGGGATG
TTCCCTTACCAAGGATTTTTAGCCCCAAATCTCTCATATTCGCTAGTGTTTAAAAGG
CTAAGAATAGTGGGGCCCAGCCGATGTGGTAGGTGATAAAGAGGCATCTTTTCT

AGAGACACATTGGACCAGATGAGGATCCGAAACGGCAGCCTTTACGTTTCATCAC
CTGCTAGAACCTCTCGTAGTCCATCACCATTCTTGGCATTGGAATTCTACTGGAA
AAAAATACAAAAAGCAAAACAAAACCTCAGCACTGTTACAAGAGGCCATTTAA
GTATCTTGTGCTTCTTCACTTACCCATTAGCCAGGTTCTCATTAGGTTTTGCTTGG
5 GCCTCCCTGGCACTGAACCTTAGGCTTTGTATGACAGTGAAGCAGCACTGTGAGT
GGTTCAAGCACACTGGAATATAAAACAGTCATGGCCTGAGATGCAGGTGATGCC
ATTACAGAACCAAATCGTGGCACGTATTGCTGTGTCTCCTCTCAGAGTGACAGTC
ATAAATACTGTCAAACAATAAAGGGAGAATGGTGCTGTTTAAAGTCACATCCCT
GTAAATTGCAGAATTCAAAAGTGATTATCTCTTTGATCTACTTGCCTCATTTCCCT
10 ATCTTCTCCCCACGGTATCCTAAACTTTAGACTTCCCACTGTTCTGAAAGGAGA
CATTGCTCTATGTCTGCCTTCGACCACAGCAAGCCATCATCCTCCATTGCTCCCGG
GGACTCAAGAGGAATCTGTTTCTCTGCTGTCAACTTCCCATCTGGCTCAGCATAG
GGTCACTTTGCCATTATGCAATGGAGATAAAAGCAATTCTGACTGTCCAGGAGC
TAATCTGACCGTTCTATTGTGTGGATGACCACATAAGAAGGCAATTTTATGTGTAT
15 TAATCATAGATTATTATAAACTATAAACTTAAGGGCAAGGAGTTTATTACAATGT
ATCTTTATTAAAACAAAAGGGTGTATAGTGTTTCAAACTGTGAAAATAGTGTA
GAACTGTACATTGTGAGCTCTGGTTATTTTTCTTGTACCATAGAAAAATGTATA
AAAATTATCAAAAAGCTAATGTGCAGGGATATTGCCTTATTTGTCTGTAAAAAAT
GGAGCTCAGTAACATAACTGCTTCTTGGAGCTTTGGAATATTTTATCCTGTATTCT
20 TGTTTGAATTCCTCCTCTATTTAAGATATATACATGGAATCGAAGTGTTTATGTAA
TAGTTCTATCCTTTTGCCTGCAGGTCAGTTGTAATAAATCTAGGATGTGATGATG
ACTTGTGAATTTGATTTTCTGAAATCAGACCCTGAGAGGGGAAAATCTTAAAGTA
AATTACATTAAATATCTGTGCAATTCACACCAGG
25 SEQ ID NO: 388
>4408 BLOOD gi|2046421|gb|AA393452.1|AA393452 zt71c01.r1 Soares_testis_NHT Homo
sapiens cDNA clone IMAGE:727776 5' similar to WP:D2045.8 CE00608 TNF-ALPHA
INDUCED PROTEIN B12 ;, mRNA sequence
CTCATTGTTTTGGACAGTCTCAAACAGCACTATTTTCATTGACAGAGATGGACAGA
30 TGTTTCAAGACTACACTTTGTTATATGAAGAGGCAAAATATTTTCAGCTTCAGCCCA
TGTTGTTGGAGATGGAAAGATGGAAGCAGGACAGAGAACTGGTCGATTTTCAA
GGCCCTGTGAGTGCCTCGTCGTGCGTGTGGCCCCAGACCTCGGAGAAAGGATCA
CGCTAAGCGCTGACAAATCCTTGATAGAAGAAGTATTTCCAGAGATCGGCGACG
35 TGATGTGTAACCTCTGTCAATGCAGGCTGGAATCACGACTCGACGCACGTCATCAG
GTTTCCACTAAATGGCTACTGTCACCTCAACTCAGTCCAGGTCCTCTAGAGGTTG
CAGCANAGAGGATTTGAAATCGTGGGCT

SEQ ID NO: 389
40 >4409 BLOOD Hs.197877 gnl|UG|Hs#S1969960 Homo sapiens cDNA FLJ20693 fis, clone
KAIA2667 /cds=(83,1195) /gb=AK000700 /gi=7020950 /ug=Hs.197877 /len=3148
AACTTCTCGGGAAGATGAGGCAGTTTGGCATCTGTGGCCGAGTTGCTGTTGCCGG
GTGATAGTTGGAGCGGAGACTTAGCATAATGGCAGAACCTGTTTCTCCACTGAAG
CACTTTGTGCTGGCTAAGAAGGCGATTACTGCAGTCTTTGACCAGTTACTGGAGT
45 TTGTTACTGAAGGATCACATTTTGTGGAAGCAACATATAAGAATCCGGAAGTTGA
TCGAATAGCCACTGAAGATGATCTGGTAGAAATGCAAGGATATAAAGACAAGCT
TTCCATCATTGGTGAGGTGCTATCTCGGAGACACATGAAGGTGGCATTTTTTTGGC
AGGACAAGCAGTGGGAAGAGCTCTGTTATCAATGCAATGTTGTGGGATAAAGTT
CTCCCTAGTGGGATTGGCCATATAACCAATTGCTTCCTAAGTGTTGAAGGAACTG

ATGGAGATAAAGCCTATCTTATGACAGAAGGATCAGATGAAAAAAGAGTGTGA
AGACAGTTAATCAACTGGCCCATGCCCTTCACATGGACAAAGATTTGAAAGCTG
GCTGTCTTGTACGTGTGTTTTGGCCAAAAGCAAAATGTGCCCTCTTGAGAGATGA
CCTGGTGTTAGTAGACAGTCCAGGCACAGATGTCACTACAGAGCTGGATAGCTG
5 GATTGATAAGTTTTGCCTAGATGCTGATGTCTTTGTTTTGGTCGCAAACTCTGAAT
CAACACTAATGAATACGGAAAAACACTTTTTTCACAAGGTGAATGAGCGGCTTTC
CAAGCCTAATATTTTCATTCTCAATAATCGTTGGGATGCCTCTGCATCAGAGCCA
GAATATATGGAAGACGTACGCAGACAGCACATGGAAAGATGCCTGCATTTCTTG
GTGGAGGAGCTCAAAGTTGTAAATGCTTTAGAAGCACAGAATCGTATCTTCTTTG
10 TTTTCAGCAAAGGAAGTTCTTAGTGCTAGAAAGCAAAAAGCACAGGGGATGCCAG
AAAGTGGTGTGGCACTTGCTGAAGGATTTTCATGCAAGATTACAGGAATTTTCAGA
ATTTTGAACAAATCTTTGAGGAGTGTATCTCGCAGTCAGCAGTGAAAACAAAGTT
CGAACAGCACACTATCAGAGCTAAACAGATACTAGCTACTGTGAAAAACATAAT
GGATTCAGTAAACCTGGCAGCTGAAGATAAAAGGTTTCATGTGCAATGACAGAT
15 GAAATTTGTGCACTGTCTGTTTTGGTTGATGAATTTTGTTCAGAGTTTCATCCTAA
TCCAGATGTATTAATAAATATATAAAAGTGAATTAAATAAGCACATAGAGGATGG
TATGGGAAGAAATTTGGCTGATCGATGCACCGATGAAGTAAACGCCTTAGTGCTT
CAGACCCAGCAAGAAATTATTGAAAATTTGAAGCCATTACTTCCAGCTGGTATAC
AGGATAAACTACATACACTGATCCCTTGCAAGAAATTTGATCTCAGTTATAATCT
20 AAATTACCACAAGTTATGTTTCAGATTTTCAAGAGGATATTGTATTTCTGTTTTCCC
TGGGCTGGTCTTCCCTTGACATCGATTTTTGGGCCCTAGAAATGCTCAAAGGGT
AGCTCCTAGGATTATCAGAGCCTATCTTTGAGCTCCCTAGATCTTTAGCTTCTACTC
CCACTGCTCCTACCACTCCAGCAACGCEAGATAATGCATCACAGGAAGAAGTCAAT
GATTACATTAGTAACAGGATTGGCGTCCGTTACATCTAGAACTTCTATGGGCATC
25 ATTATTGTTGGAGGAGTGATTTGGAAAACCTATAGGCTGGAAACTCCTATCTGTTT
CATTAACTATGTATGGAGCTTTGTATCTTTATGAAAGACTGAGCTGGACCACCCA
TGCCAAGGAGCGAGCCTTTAAACAGCAGTTTGTAACCTATGCAACTGAAAAACT
GAGGATGATTGTTAGCTCCACGAGTGCAAACTGCAGTCACCAAGTAAAACAACA
AATAGCTACCACTTTTGCTCGCCTGTGCCAACAAGTTGATATTACTCAAAAACAG
30 CTGGAAGAAGAAATTGCTAGATTACCCAAAGAAATAGATCAGTTGGAGAAAATA
CAAAACAATTCAAAGCTCTTAAGAAATAAAGCTGTTCAACTTGAAAATGAGCTG
GAGAATTTTACTAAGCAGTTTCTACCTTCAAGCAATGAAGAATCCTAACAATAGA
GATTGCTTTGGTGACCATGATAGGAGGAAACGAAACTTGTAAGATTGGAACAGT
TGTTATTTTTATGAAATTACTTTAAATATGAATTGTAATACTGTACCTAAATAGC
35 AAAGCCCTGTGTAGATTCTGGTAATGATCTGTCTCAGGGTATGTGTATTTTTGAA
GAGTGTATGTCCTTAGTTTTAATTTTGAGTAAAGAAAAGGCTAAAATCATGAAT
TAGTTACAAGCAACAGTACCAACTTATGTGACCCCTGAGGGGTGGGGCTGTGAG
CTCTTAATTTGTTTTTGATTCTGAAAAACTCTGCTTCCTGGCATCCAGGAGTTAGA
GATTGAGCCTTTTCATCTTCTTTCTCAAAACTAGTTTTTGATGCTTTCTTTTCATGGG
40 AATAGTCACTTTTTTATTTAGTAAATCGCATTGCTGGAACCACCAAGGAGTGTGG
AATGTCCTTGAGTGTATTATTTATGCAAGTCACAGTCACGTTGCCATCATGGCAG
CTATGTGAAACACTAATAAATGTGTTTTTACTTTTTATTCCCGTTAAACTGATGT
AAAACAGGATAAAGGCTTGTTATAGTCACTTATAAGTATCTGGGTCTAAGTAATT
TCCTTAGATGTTTCTAAAGAAACATTTTCAGCTTTGCTCCCATTATGATTCCAATA
45 AGGAACGCTTTCCTAGTGCAATTTTAGGAGTAAAGTTTGAAGAGATAAAAAATAG
CCAAAGATAGGAGACGTCTGAATTTTGAATGATAAACAGTGATGTTTTAAAAAA
GCTGTTGTTCTTCAGGAGGCATTTGCCTAGGATAATTGCTGGATTATACCCCATTTG
AGGCTTTTAATTTTATTTGTATGAATTTTCCAGGATTTCAATAAAAATTATTATTG

TATTTTTTACCTTAATGAAAGATTTTGGGTCAAATATCTTTCTATATTAAGCT
GATTGAGTCTGTACATATGT

SEQ ID NO: 390

- 5 >4415 BLOOD 347990.5 D87465 g1665814 Human mRNA for KIAA0275 gene, complete
cds. 0

CGGACGCGTGGGAACGAAGCCACCCATTACGGTATGATGATGTCAAACGTGATG
CTGATGCTACAGTTACAGCCCCTGCTGGCGCAGCCTCTCTGATTCTCTCTCCCTCT
CCGCGTCCAGTGCTGGGCTTTTTCAGACAAGTGCATCTCCTAACCAGGTCACATT
10 TCAGCCGCGACCCACTCTCCGCCAGTCACCGGAGGCAGACCGCGGGAGGAGAGC
TGAGGACAGCCGCGTGCGCTTCGCCAGCAGCGGGGTGGGAGGAAGGACATTAAA
ATACTGCAGAAGTCAAGACCCCCCAGGTCGAACCCAGACCACGATGCGCGCCC
CGGGCTGCGGGCGGCTGGTGCTGCCGCTGCTGCTCCTGGCCGCGGCAGCCCTGGC
CGAAGGCGACGCCAAGGGGCTCAAGGAGGGCGAGACCCCCGGCAATTTTCATGGA
15 GGACGAGCAATGGCTGTCGTCCATCTCGCAGTACAGCGGCAAGATCAAGCACTG
GAACCGCTTCCGAGACGAAGTGGAGGATGACTATATCAAGAGCTGGGAGGACAA
TCAGCAAGGAGATGAAGCCCTGGATACCACCAAGGACCCCTGCCAGAAGGTGAA
GTGCAGCCGCCACAAGGTGTGCATTGCCAGGGCTACCAGCGGGCCATGTGCAT
CAGTCGCAAGAAGCTGGAGCACAGGATCAAGCAGCCGACCGTGAAACTCCATGG
20 AAACAAAGACTCCATCTGCAAGCCCTGCCACATGGCCCAGCTTGCCCTGTGTCTGC
GGCTCAGATGGCCACACTTACAGCTCTGTGTGTAAGCTGGAGCAACAGGCGTGC
CTGAGCAGCAAGCAGCTGGCGGTGCGATGCGAGGGGCCCTGCCCTGCCCCAG
GAGCAGGCTGCCACCTCCACCGCCGATGGCAAACCCAGAGACTTGCACGGTTCAG
GAGCTGGCTGACCTGGGAGATCGGCTGCGGGACTGGTTCCAGCTCCTTCATGAGA
25 ACTCCAAGCAGAATGGCTCAGCCAGCAGTGTAGCCGGCCCGGCCAGCGGGCTGG
ACAAGAGCCTGGGGGCCAGCTGCAAGGACTCCATTGGCTGGATGTTCTCCAAGC
TGGACACCAGTGCTGACCTCTTCCCTGGACCAGACGGAGCTGGCCGCCATCAACCT
GGACAAGTACGAGGTCTGCATCCGTCCCTTCTTCAACTCCTGTGACACCTACAAG
GATGGCCGGGTCTCTACTGCTGAGTGGTGCTTCTGCTTCTGGAGGGAGAAGCCCC
30 CCTGCCTGGCAGAGCTGGAGCGCATCCAGATCCAGGAGGCCGCAAGAAGAAGC
CAGGCATCTTCATCCCGAGCTGCGACGAGGATGGCTACTACCGGAAGATGCAGT
GTGACCAGAGCAGCGGTGACTGCTGGTGTGTGGACCAGCTGGGCCTGGAGCTGA
CTGGCAGCGGCACGCATGGGAGCCCCGACTGCGATGACATCGTGGGCTTCTCGG
GGGACTTTGGAAAGCGGTGTGCGCTGGGAGGATGAGGAGGAGAAGGAGACGGAG
35 GAAGCAGGCGAGGAGGCCGAGGAGGAGGAGGGCGAGGCAGGCGAGGCTGACG
ACGGGGGCTACATCTGGTAGACGCCCTCAGAAGCCGGCTGCCGGGGGGGGACTC
AACAGCAGAGCTCTGAGCAGCAGCAGGCAACTTCGAGAACGGATCCAGAAATGC
AGTCAGAAGGACCCTGCTCCACCTGGGGGGACTGGGAGTGTGAGTGTGCATGGC
ATGTGTGTGGCACAGATGGCTGGGACGGGTGACAGTGTGAGTGCATGTGTGCAT
40 GCATGTGTGTATGTGTAGTGTGTGTGTGGCATGCGCTGACAAATGTGTCTTGAT
CCACACTGCTCCTGGCAGAGTGAGTAACCCAAAGGCCCTTCGGCCTCCTTGAT
CTGTTTTCTTTCTTTTGTGTTGGTTTTAAATACATTACACACAAATACAAAT
TGACAGGTCAAAATCCATGAAATGAGATCCCCCAGCCGTGTCTCCAGCCCAGCC
CTGACCCCTTGTTTTCTACCCTGGCTCCCCCTGGTTTTCTACCCTGGCTCAACCGAC
45 CCCTGTCTGCCCTTCTCCCTCCTGCTTCTGAGGTCAAGCTCTGGCCTGCGAGCCTG
TCCCCATTGCAAAGGGGAGGGAGGGGAGGGAGCTGTCTACCAGCTGAGGTCCT
CCCAAAACTGGGCCGATGTGGTGTGACATCCCCACCAGCCTCAGATGAGACGGG
CCAGGACGCCCAGCCACAGCAAGCCCTGTCCCTTTGCCGGATCCCCAAACACTAG
AGAAGCTCTCCTAACCCAAGGCGGAGAATGAAGGTGGTGGCGGCAGAGGAGGA

GGGCAGCAGCTGAGAGGCCAGGGACAGGGTGCCTCGCCAAGCTGTCTGAGGTCT
GTCCCAGGTGGCCCAGGTGGTGCAGGTAGAACAGGGTGAGGAGAGGGGGTTCGG
CTCAGCAGGAGGAGGCTGTGGCTGCAGAGCCTGGGGGAGCTTTTAGGTGTTGAG
ATGGGGCAGCTCTGAATCCTAGACCCTGGAATAGCCTGTCCCTTTTCTCTGGGTC
5 TCGTGGTGGAGCCATGATCTGGGCTGCTCTCTTGGGGACACTGGGTGGTGGTTAC
ACAGTTGACCTCTGCCTGGCTCCCCCTTGGTGCAACTCCTGCCTCCATCCCCCTTG
CTGGGGTCCCCCTCATCCACTTGAGGGGCGCCTGAGGGCCAGGAGCAGCAGGCAAG
GAGCCTGGGTCTAGGCTAAGGGGGTGTGTGCCACCTCCTCCCTGACCCTTAACA
CTCCTGTCTGCCCAGACCAACAGAGAGAGCTGTCCCTGAGACCCCGAGAGAA
10 GCAGCTGCCGAAAGCTGCAGCCTTTCGCACTCTGAGACCATGATCTTCCTCCTG
CCAGGGGAGAGCCACCCACAGGCCATGTCCAGCCCCACTTCCCTCAGCCCCCAG
GGCTTCCTTCTGGCCCCCTCTGAGGATTCCCTAGGGCTGCCCCGCAGAGGGGCTTC
CCCAAGCTCTGTTTTGAAGCCTGCAATGTGGAAAAGTGAGAAGTCAGAGGGAAC
AGGACAGGTGCAGCCGGGCTCTGAGGCCACACCTCACACCTCGCTGTTCCCCAAC
15 ATCCCCTGAGCAGTGTGAGCTCATCTCACCAGATGAGAAGAGGGCCCTGTGCATTT
CTTTTGTGTTGTTGTTGCTGTTTTCCCCCACCCATCCAGTTCTCCTCAGCAAAGCA
AATTCCTTAACACCTTTGGTGGAGAATTTCTTACCCAGACTTGGGGCTGTGATGC
CCTTCAGTGCCTGGTGGTGCAGCGTGTGTGCGTGTGCCTGTGTGTGAACCTGGG
GGCCATCCTGGTGGCCTGGGAGCGTGAGGAGAGGCCCCCTGTGTGCTGGGTGAG
20 TGGTGGGTGTGGGGTCAATGCAGTGAGGCTCTCTGGGTGAGGCTCCCAACCTGGC
AGTCCCCAGCCTCCCAGCATCTGTGAGCGTCTGTTGGACTTTACAGAAGAGCCTC
ATCCCGTCTGCCCCCTCACTCTGCCCTGGAATCAACATCTTCCGAGTCCTTCTTGGG
GGAAATAGCAGAGCECCACTAAGTCCATAAAGTGGCTTCCCATTCGCGAGCCGAG
TTCTGATTGTTGAGGTGTGCGGTGTTCCAGGTCCCCAGTCCCCCTCTTCTCCTG
25 TCCTCTCTCTGTCTTACCTCCCCACTCCAGCCCCGGCTCAGTTCAGGGAAATGC
TGTTCCATATCAGCCCTCTGCTCTCTGAGGCAGCCGCGCCTCTGACTCGGAGCTA
CTTGAAACTTCTGCTCTTGCTAGGATTGGAGTCTACCTATCTTCCATTTGTCCC
AGCTGGAGTTCTGGAACCTTCTCCTCGGGGTGGGGGTGGGGGTGTTAAGGATG
CTGGGGGGCCTGGGGAAGGAAGGAGTTCAGAGGAAGGGTGTCCCCTGTCCTCTT
30 GATGTACCCCTCCGCTCCTGGGACACGTGCTCTCTGTCTCTGGGTCTTCTGGCT
GTGCACGTTTGTGTGTCCTTGTAATAATGTTTTAGGAAGAAAGCAAAAGGGACTG
AACTAGCCTCTGGTAGGATTGCAGGGGTCCAGCCTTGCTGTTTCCGAAGCCCCC
ACACTGECTTTEGCCCCACTGAGACTGGTCCCCTCAAAGGTAGACAAAACAGC
AGCTCCCTGTGAGCTGAAGGGCGGCCTCAAAGTGGCTTTTGTAGACAAGGTT
35 AAGGTTTCCTCATGAGCAAGGTTGCAGATCGGTCCCTCCTCAGCTCCTTGATTTGT
GACCTTGACCAAGGGGCTGCCACCCAGCCCCCTCAGTGCCCTCTCCTCGATGCC
TCGCTCCTTCTGCCCCACTCCCCTGGCTTAGGCAGGTAGGGGAATTAGGGCCA
TGCTGGAAGAAGCTTAACCATGTGTTCAAAGAACGGTTTCTTGCTTGCTTGGTCC
TGGAACCTCCCCTTGGCTGCCCCAGGCCTCCTTGGCCCATGGGTGCTGGGGGAGGT
40 GGATGTCAGATCTGGTAGGTTGCAGCAGAGAAAATAAATGTGCCTTGAGAGACC
ACTCAGAGAGGGTCCAAGGGTGATGGAGAAGGAAGCATGGCCTGGGAGCTTGG
AAGGGAGGGGTGGTGGGTGGCGGCATCTTGACTGCCCCCTGTTGTCCCCACACGT
GGGGGGTGGTCACCCCCCTTCACTCCAGCCCGCCTGCCTTCAGCCTTCCATGAGC
TTCACCTGCTTCCAACCTTCACTTTGGAGGGGGTGGGGTCCGTTGGCATCAACACG
45 GGGACCCTCTGCTTACCAAAGCCCGAGCCCTCAGCCCCTGGGGAGAACAAATG
GCTGAGCTTTGATACCTGGGGTTCGTCGAGAGGCTGCGGGCTGGCGGCAGTCCCA
GGGGAGAGACACCACAGAAGGAGACCCAGACATCCCGAGGAAGTTCCCAGCAG
AGCAAACCTGCTTCCAGCCTGAAGCCTGCTTAAACTGTGTGATGTGCAATAACTG
AGCTTAGAGTTAGGAATTGTGTTCAAGTGCTTGGATTTCCGTCTGTAGATTTAACT

GCTGAAATTGTATCTCTCAGTAATTTTAGATGTCTTTTAAAAAATTGAAAAACAA
AGTGTTAGACTGTGTGCGTGTGCGTTGATGGGCACTCAAGAGTCCCGTGAGTCAT
CCAGCCCTGCCTTTCCCCTGCGCCCCCATCTCTCACGTCCCGCCCCGCCTCCACT
TGGGGACCCTGCCTCGTGTGCTCTTTATCTGCCTATTACTCAGCCTAAGGAAACA
5 AGTACACTCCACACATGCATAAAGGAAATCAAATGTTATTTTAAAGAAAATGGA
AAATAAAAACCTTTATAAACACCAAAAAAAAAAATAAAGGGG

SEQ ID NO: 391

>4435 BLOOD Hs.278634 gnl|UG|Hs#S417730 Human mRNA for KIAA0146 gene, partial
10 cds /cds=(0,2756) /gb=D63480 /gi=1469873 /ug=Hs.278634 /len=3218

CTCCCGGAGATGCCCCGCGGCAGCCGCGCTCGGGGCTCTAAGAGAAAAAGGAGT
TGGAATACAGAATGCCCATCCTTTCCAGGAGAAAGACCACTGCAGGTCAGAAGA
GCAGGTCTCAGGACAGCAGGGGCAGCTGCCTCTCTCTCTGAAGCATGGCTCAGGT
GTGGAGAAGGGTTTCAGAACACTTCTGGGAATCCGTCATTAACAGCTGAAGAGA
15 AGACGATTACAGAAAAGCACCTTGAATTATGCCCTAGACCCAAGCAAGAAACCA
CCACATCTAAAAGCACCAAGTGGGCTTACAGACATAACATGGAGCTCCAGTGGAA
GTGATTTGTCGGATGAAGATAAGACACTTTCTCAGTTACAGAGAGATGAATTACA
GTTTATCGACTGGGAGATTGACAGTGACAGGGCAGAGGCTAGTGACTGTGATGA
ATTTGAAGATGACGAGGGTGTGTGGAAATCTCAGACTGTGCTTCTTGTGCAAGT
20 AATCAGTCTTTGACAAGTGATGAGAAGCTGTGCGAGCTTCCCAAGCCAAGTTCTA
TAGAAATTTTAGAGTATTCATCAGATAGTGAAAAAGAAGATGATTTGGAAAATG
TCCTACTCATTGATTCAGAATCCCTCACAATAACCAAGTGCAGTTTGCATCGGA
TGCAAGACAGATTATGGAGAGAGTGATAGATCCAAGGACAAAATCAACAGAGAC
CATTTCATACACCTCAGAAAACCCACAGCTAAGTTTCCCAGGACTCCAGAAAAT
25 TCAGCAAAGAAGAAGCTTTTAAAGAGGTGGACTAGCAGAAAGACTAAATGGACTG
CAGAATCGAGAGAGATCTGCTATTTCTTTGTGGAGACATCAATGTATTTCTTACC
AAAAGACACTTTCAGGTAGAAAATCTGGTGTATTAAGTGTGAAAATTTTAGAGCT
GCATGAGGAATGTGCCATGCAAGTTGCCATGTGTGAGCAGTTATTGGGGTCACCA
GCCACCAGCTCCTCCCAAAGTGTGGCTCCAGGCCTGGAGCTGGCCTGAAAGTTC
30 TCTTCACCAAGGAGACTGCAGGCTACCTCAGGGGCCGTCCCCAGGACACTGTCCG
GATCTTCCCTCCCTGGCAAAAACCTGATTATTCCAAGTGGAAAGTTGCCCTGTTATTC
TGAATACTTACTTTTGTGAGAAAGTTGTTGCCAAAGAAGATTACAGAAAAACTTG
TGAAGTGTACTGTCCGGACATACCCCTTCCAAGAAGAAGCATCTCTTTGGCCAG
ATGTTTGTAAATTAAGGGTCTAACAATAATTACCTGAAATCCAGGTTGTGTGTA
35 GTGGTGTAGCCACTACAGGGACAGCCTGGACCCATGGGCACAAAGAAGCAAAAC
AGCGCATCCCAACCAGCACTCCCCTGAGGGATTCTCTCCTGGATGTGGTGGAAAG
CCAGGGAGCTGCCTCGTGGCCAGGAGCTGGAGTCCGAGTGGTGGTGGCAAGAGT
GTATTCTCTTCCCAGCAGAGACAGCACCAGGGGTCAGCAGGGGGCCAGCTCAGG
ACACACAGACCCAGCTGGAAGTCGAGCCTGCCTTCTGGTACAAGATGCCTGTGG
40 AATGTTCCGGTGAAGTGCAGTTGGAGTTCACCATGTGCAAGGCAAGACAGTTGGA
AGGGAAGTCTTGCAGCCTGGTGGGAATGAAGGTTCTACAGAAAGTCACCAGAGG
AAGGACAGCGGGGATTTTCAGTTTGATTGACACCCTGTGGCCCCCAGCGATACCT
CTGAAAACACCTGGCCGCGACCAGCCCTGTGAAGAGATAAAAACTCATCTGCCT
CCTCCAGCCTTGTGTTACATCCTCACAGCTCATCCAAATCTGGGACAAATTGATA
45 TAATTGACGAAGACCCCATTTATAAGCTTTACCAGCCTCCAGTTACCCGCTGCTT
AAGAGACATTCTCCAGATGAATGATCTTGGTACCCGTTGCAGTTTCTATGCCACG
GTGATTTACCAAAAACACAGCTGAAGAGTCTGCTGCTTCTGGAGCAAAGGGAG
ATCTGGCTGCTAGTGACCGATGTCACTCTGCAAACGAAGGAGGAGAGACCCC
AGGCTCCCCAAAACCCTGCTGGTCTATGTGGCCCCCTTGTGTGTGCTGGGCTCTG

AAGTCCTGGAGGCACTCGCTGGGGCTGCCCCTCACAGCCTCTTCTTCAAGGACGC
TCTCCGTGACCAGGGTCGGATTGTTTGTGCTGAACGAACTGTCCTCTTGCTTCAG
AAGCCCCCTTTGAGTGTGGTCTCTGGTGCAAGTTCTGTGAGCTGCCTGGCCCCG
TGATGCTCGACAGCCTGGACTCTGCAACACCTGTCAACTCCATCTGCAGTGTTC
5 AGGCACTGTGGTTGGCGTGGACGAGAGCACTGCTTTCTCATGGCCTGTGTGTGAC
ATGTGTGGCAACGGGAGATTGGAACAGAGGCCGGAAGACAGAGGCGCCTTTTCC
TGTGGGGACTGCTCCCGGGTGGTCAACATCTCCTGTTCTCAAGAGGCACCTGCAGG
TCTTCCTGGACTGCCGCTCAAGACCGCAGTGCAGAGTGAAGGTCAAGCTGTTGCA
GCGCAGCATTTCTCCTCCCTGCTGAGGTTTGCCGCCGGTGAAGATGGGAGCTACGAA
10 GTGAAGAGTGTCTCGGAAAGGAAGTGGGGTTGTTAAATTGTTTTGTCCAGTCCG
TAACCGCCACCCGACCAGCTGCATTGGATTGGAGGAAATCGAGCTTCTGAGTGC
AGGAGGGGCCTCTGCAGAACACTAGCGGTTGCCGCAGGATCTGTGAACCTTGCA
ATGTGGCTGCAAGGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGT
TATGGACACAGTGAACGTAGTTTACGATCTTGAAATGAAACTTAGATTTTCTGG
15 GGAAATGTTTCAAGATACAGTTTTGTGAACGTAAATCAAAATACCTTTTTCTACAG
TTTATCTTTTATTTTCTGCAAATTTAGGAACATATTTACTCGTTTTTACATTGAATC
TTAAGTTTAAGCTCTTCATTTGGTATTTAGGCAATATATGAGAAAAAAATTTTTT
TGTTCAATTTGTAATTTTAAACAAGTTGAACATTTTACCATGATTGAACATGTTTTTA
TTACAGTATTTAACATTCCCCCAAAGAATACCCTGCAAAGTGTAACCTTTGTCC
20 CATACTGTGATATTACTGTTCTGCTACAATAAATGTCAAACCT

SEQ ID NO: 392

>4460 BLOOD 021654.1.U32849 g1322219: Human Nimi mRNA, complete cds. 0
GTGTTAGTGACTAATCATTGGAGACAACCATGTTTAGTATTTGAGCATTCGGTTAA
25 ATGCTAAAGAAAAATCGCCGTTAAAGCAGTTTTCTTTTTCACTGTCTTTTTCTTTT
CGCGGGGAACCCAGCTGTTCTGCGAGGGCCACCTCCTCAGGAAGACCCCGCAG
CTCTCCCGCGGCGCTTCTGCAGGAGGCAGCGACAGTTTCGAGAACCCGGGCCTTC
CCCTCCCAGTGCCTCCCGGGGTTCCGGCGTTTCAGGCGCTGCTGTTTTCCGGGAA
GGGCAGGCGCGCTGGGCCTTGGGGAGCTGCGCTCGGCGGGCGGACGCGGGGGAT
30 CATGGAAGCTGATAAAGATGACACACAACAAATTCTTAAGGAGCATTCCGCCAGA
TGAATTTATAAAAGATGAACAAAATAAGGGACTAATTGATGAAATTACAAAGAA
AAATATTCAACTAAAGAAGGAGATCCAAAAGCTTGAAACGGAGTTACAAGAGGC
TACCAAAGAATTCCAGATTAAAGAGGATATTCCTGAAACAAAGATGAAATTCCT
ATCAGTTGAAACTCCTGAGAATGACAGCCAGTTGTCAAATATCTCCTGTTCTGTTT
35 CAAGTGAGCTCGAAAGTTCCTTATGAGATACAAAAAGGACAAGCACTTATCACC
TTTGAAAAAGAAGAAGTTGCTCAAAATGTGGTAAGCATGAGTAAACATCATGTA
CAGATAAAAGATGTAAATCTGGAGGTTACGGCCAAGCCAGTTCCATTAAATTCA
GGAGTCAGATTCCAGGTTTATGTAGAAGTTTCTAAAATGAAAATCAATGTTACTG
AAATTCCTGACACATTGCGTGAAGATCAAATGAGAGACAACTAGAGCTGAGCT
40 TTTCAAAGTCCCGAAATGGAGGCGGAGAGGTGGACCGCGTGGACTATGACAGAC
AGTCCGGGAGTGCAGTCATCACGTTTGTGGAGATTGGAGTGGCTGACAAGATTTT
GAAAAAGAAAGAATACCCTCTTATATAAATCAAACCTGCCATAGAGTTACTGTT
TCTCCATACACAGAAATACACTTGAAAAAGTATCAGATATTTTCAGGAACATCTA
AGAGGACAGTGCTTCTGACAGGAATGGAAGGCATTCAAATGGATGAAGAAATTG
45 TGGAGGATTTAATTAACATTCACTTTCAACGGGCAAAGAATGGAGGTGGAGAAG
TAGATGTGGTCAAGTGTCTCTAGGTCAACCTCACATAGCATACTTTGAAGAATA
GACTTAACAGAATCATGAAACTATAGCTTTTTTAACCCGGATTACTGTAAATGTT
TGACAAAAATGAATATGCTTTTCTTAAAAAATGAAAACCTTAATTTTTTACCATC
CATTTATGTTTAGATACAAAACCTTATTTCCATGTTTCTGAATCTTCTTTGTTTCAA

ATGGTGTGTCATGTTTTCAACTACAATAAGTGCACGTGTAATAAAGAAGATTCAGA
AACATGGAAATAAGTTTTGTATCTAAACATAAATGGATGGTAAAAATTAAAGTTT
TCATTTTTTAAGGAAAAGCATATTCATTTTTGTCAAACATTTACAGTAATCCGGGT
TAAAAAGCTATAGTTTTTCATGATTCTGTAAAGTCTATTCTTCAAAGTATGCTATGT
5 GAGGTTGACCTAGAGAACAACCTTGACCACATCTACTTCTCCACCTCCATTCTTTGCC
CGTTGAAAGTGAATGTTAATTAATCCTCCACAATTTCTTCATCCATTGGAATGCC
TTCCATTCTGTGTCAGAAGCACTGTCCTCTTAGATGTTTCTGAAAATATCTAAGAA
GGAAAAAATGATAAATAGAAAGATTTCTAAGAGCTTTGAATTACAAAACCTTAC
ATTCATAATCTCTGCTTAATATTTTTTATTTTATCTTAGAAGAGACAAGAAATCTT
10 AGGAAGATTTTCCAAGCAAGAGAATATCCAAGTCAGATCTGAGTTTTAGAAAGA
GAACTCTGGTGGCATTATGGAACACAGAGGAAAGGAGGGATGCTCTGGGAACAG
AAAGACCAGGTAAAGAGGTAGTCAGAAGTGGAGCTGGCAAGATTTAGTGACCAA
ATGAATGTTGGAGGTGAAGCAAACCTGAAGATTTAAGTATGAGTTCTAGCTTTTAA
GTTGGTGGAGTAGGTAGATGGTGGTACCATTGGATACCTGAGAAGGAAGAGGAA
15 AAGGGAGCAGGTCTCGGGTAAAGATAATGAGTTCAGAGAAAGTAGGCAGGAATT
CTTTCTCATGCTCACTGACAGTAGACATATGAGAGAAATGCAACTATGTCTCCAT
GTACAAAAATAAAAATTGTGCCATTATCTGAGTAATTTTCAAGTTTTAAAAATTGTA
TAATAAAGTACAGTTTTGCATTAAAATGCTCCTTCAAAGACAAACTCATTTTGC
ACCAAGCAAAAATGAAGTAAAGAAACCATTTTGCTATCCCTCATTGATAAGATG
20 CATAAGTAACAGACTCACAACTTTATTTTTTGTGGGGTGGGTTTGGG

SEQ ID NO: 393

4472: BLOOD: 993722: 2: X51818: g181036: Human: carbonyl reductase mRNA, complete cds.

25 GCGCCTGCGCGCTCAGCGGCCGGGCGTGTAACCCACGGGTGCGCGCCCACGACC
GCCAGACTCGAGCAGTCTCTGGAACACGCTGCGGGGCTCCCGGGCCTGAGCCAG
GTCTGTTCTCCACGCAGGTGTTCCGCGCGCCCCGTTTCAAGCCATGTCGTCCGGCAT
CCATGTAGCGCTGGTGAAGTGGAGGCAACAAGGGCATCGGCTTGGCCATCGTGCG
CGACCTGTGCCGGCTGTTCTCGGGGGACGTGGTGCTCACGGCGCGGGACGTGAC
30 GCGGGGCCAGGCGGCCGTACAGCAGCTGCAGGCGGAGGGCCTGAGCCCGCGCTT
CCACCAGCTGGACATCGACGATCTGCAGAGCATCCGCGCCCTGCGCGACTTCCTG
CGCAAGGAGTACGGGGGCTGGACGTGCTGGTCAACAACGCGGGGCATCGCCTTC
AAGGTTGCTGATCCCACACCCTTTTCATATTCAAGCTGAAGTGACGATGAAAACAA
ATTTCTTTGGTACCCGAGATGTGTGCACAGAATTAATCTCTCTAATAAAACCCCA
35 AGGGAGAGTGGTGAACGTATCTAGCATCATGAGCGTCAGAGCCCTTAAAAGCTG
CAGCCCAGAGCTGCAGCAGAAGTTCCGCAGTGAGACCATCACTGAGGAGGAGCT
GGTGGGGCTCATGAACAAGTTTGTGGAGGATACAAAGAAGGGAGTGACACAGAA
GGAGGGCTGGCCCAGCAGCGCATACGGGGTGACGAAGATTGGCGTCACCGTTCT
GTCCAGGATCCACGCCAGGAACTGAGTGAGCAGAGGAAAGGGGACAAGATCC
40 TCCTGAATGCCTGCTGCCCAGGGTGGGTGAGAACTGACATGGCGGGACCCAAGG
CCACCAAGAGCCCAGAAGAAGGTGCAGAGACCCCTGTGTAATTTGGCCCTTTTGCC
CCCAGATGCTGAGGGTCCCCATGGACAATTTGTTTCAGAGAAGAGAGTTGAACA
GTGGTGAGCTGGGCTCACAGCTCCATCCATGGGCCCCATTTTGTACCTTGTCTTG
AGTTGGTCCAAAGGGCATTTACAATGTCATAAATATCCTTATATAAGAAAAAAA
45 ATGATCTCTTATCAATTAGCACTCACTAATGTACTACTAATTGAGCAACCTACGC
ACTCAGTTGACTACGTAAATCTGTCAGGTCTTTTGTGATTTCTCTGATGCAGGAG
AGGAAAAATTGTAATTGATGAAAATAATGAATGAAAATCAACAGATGAATAAAT
GGTTCTTTATAAGTAAAAAAGGG

SEQ ID NO: 394

>4545 BLOOD 234816.2 M31158 g189980 Human cAMP-dependent protein kinase subunit RII-beta mRNA, complete cds. 0

5 GGGGCCCAGTGCGCCGCGCTCGCAGCCGGTAGCGCGCCAGCCGTAGGCGTCGCT
CGGCAGCCGCGGGGCCCTAGGCGTGCCGGGGAGGGGGCGAGGGCGGCCAGGCG
CCTGCCGCCCCGGAGGCAGGATGAGCATCGAGATCCCGGCGGGACTGACGGAGC
TGCTGCAGGGCTTCACGGTGGAGGTGCTGAGGCACCAAGCCGCGGACCTGCTGG
AGTTCGCGCTGCAGCACTTCACCCGCGCTGCAGCAGGAGAACGAGCGCAAAGGCA
CCGCGCGCTTCGGCCATGAGGGCAGGACCTGGGGGGACCTGGGCGCCGCTGCCG
10 GGGGCGGCACCCCCAGCAAGGGGGTCAACTTCGCCGAGGAGCCCATGCAGTCCG
ACTCCGAGGACGGGGAGGAGGAGGAGGCGGCGCCCGCGGACGCGAGGGGCGTTC
AATGCTCCAGTAATAAACCGATTACAAAGGCGTGCCTCAGTATGTGCAGAAGCTT
ATAATCCTGATGAAGAAGAAGATGATGCAGAGTCCAGGATTATACATCCAAAAA
CTGATGATCAAAGAAATAGGTTGCAAGAGGCTTGCAAGACATCCTGCTGTTTA
15 AGAATCTGGATCCGGAGCAGATGTCTCAAGTATTAGATGCCATGTTTGAAAAATT
GGTCAAAGATGGGGAGCATGTAATTGATCAAGGTGACGATGGTGACAACTTTTA
TGTAATTGATAGAGGCACATTTGATATTTATGTGAAATGTGATGGTGTTGGAAGA
TGTGTTGGTAACTATGATAATCGTGGGAGTTTCGGCGAACTGGCCTTAATGTACA
ATACACCCAGAGCAGCTACAATCACTGCTACCTCTCCTGGTGCTCTGTGGGGTTT
20 GGACAGGGTAACCTTCAGGAGAATAATTGTGAAAAACAATGCCAAAAAGAGAA
AAATGTATGAAAGCTTTATTGAGTCACTGCCATTCCTTAAATCTTTGGAGTTTCT
GAACGCCTGAAAGTAGTAGATGTGATAGGCACCAAAGTATACAACGATGGAGAA
CAAATCATTGCTCAGGGAGATCGGGCTGATTCTTTTTTCATTGTAGAATCTGGAG
AAGTGAAAATTACTATGAAAAGAAAGGGTAAATCAGAAGTGGAAGAGAATGGT
25 GCAGTAGAAATCGCTCGATGCTCGCGGGGACAGTACTTTGGAGAGCTTGCCCTG
GTAACATAACAAACCTCGAGCAGCTTCTGCCCACGCCATTGGGACTGTCAAATGTT
TAGCAATGGATGTGCAAGCATTTGAAAGGCTTCTGGGACCTTGCATGGAAATTAT
GAAAAGGAACATCGCTACCTATGAAGAACAGTTAGTTGCCCTGTTTGGAACAAA
CATGGATATTGTTGAACCCACTGCATGAAGCAAAAGTATGGAGCAAGACCTGTA
30 GTGACAAAATTACACAGTAGTGGTTAGTCCACTGAGGAATGTGTTTGTGTAGATG
CCAAGCATTTTCTGTGATTTTCAGGTTTTTTCCTTTTTTTACATTTACAACGTATCAA
TAAACAGTAGTGATTTAATAGTCAATAGGCTTTAACATCACTTTCTAAAGAGTAG
TTCATAAAAAAATCAACATACTGATAAAATGACTTTGTACTCCACAAAATTATGA
CTGAAAGGTTTATTAATAATGATTGTAATATATAGAAAGTATCTGTGTTTAAGAAG
35 ATAATTAAAGGATGTTATCATAGGCTATATGTGTTTTACTTATTCAGACTGATAAT
CATATTAGTGACTATCCCCATGTAAGAGGGCACTTGGCAATTAAACATGCTACAC
AGCATGGCATCACTTTTTTTTATAACTATTAAACACAGTAAAATTTTAATCATTT
TTGTTTTAAAGTTTTCTAGCTTGATAAGTTATGTGCTGGCCTTGGCCTATTGGTGA
AATGGTATAAAATATCATATGCAGTTTTAAACTTTTTATATTTTTTGCAATAAAGT
40 ACATTTTGACTTTGTTGGCATAATGTCAGTAACATACATATTCAGTGGTTTTATG
GACAGGCAATTTAGTCATTATGATAATAAGGAAAACAGTGTTTTAGATGAGAGA
TCATTAATGCATTTTTCCCTCATCAAGCATATATCTGCTTTTTTTTATTTTGCAATT
CTCTGTATTCTATGTCTTTAAAAATTTGATCTTGACATTTAATGTCACAAAGTTTT
GTTTTTTTTTAAAAAGTGATTTAAACTTAAGATCCGACATTTTTTGATTCTTTAAG
45 ATTTTACACCTAAAAAATCTCTCCTATCCCAAAAATAATGTGGGATCCTTATCAG
CATGCCACAGTTTATTTCTTTGTTCTTCACTAGGCCTGCATAATACAGTCCTATG
TAGACATCTGTTCCCTTGCCTTTCCGTTCTTTCTTAGGATGGTTGCCAACCCACAA
TCTCATTGATCAGCAGCCAATATGGGTTTTGTTTGGTTTTTTTTAATTCTTAAAAACA
TCCTCTAGAGGAATAGAAACAAATTTTTATGAGCATAACCCTATATAAAGACAA

AATGAATTTCTGACCTTACCATATATACCATTAGGCCTTGCCATTGCTTTAATGTA
 GACTCATAGTTGAAATTAGTGCAGAAAGAACTCAGATGTACTAGATTTTCATTGT
 TCATTGATATGCTCAGTATGCTGCCACATAAGATGAATTTAATTATATTCAACCA
 AAGCAATATACTCTTACATGATTTCTAGGCCCATGACCCAGTGTCTAGAGACAT
 5 TAATTCTAACCAGTTGTTTGCTTTTAAATGAGTGATTTTCATTTTGGGAAACAGGTT
 TCAAATGAATATATATACATGGGTAAAATTACTCTGTGCTAGTGTAGTCTTACTA
 GAGAATGTTTATGGTCCCACCTTGATATATGAAAATGTGGTTAGAATGTTAATTGGA
 TAATGTATATATAAGAAGTTAAAGTATGTAAAGTATAACTTCAGCCACATTTTAA
 GAACACTGTTTAACATTTTGCAAAACCTTCTTGTAGGAAAAGAGAGCTCTCTAC
 10 ATGAAGATGACTTGTTTATATTTTCAGATTTTATTTTAAAAGCCATGTCTGTAAA
 CAAGAAAAAACACAAAAGAAGTCCAGATTCCTGGTTCATCATTCTGTATTCTTAC
 TCACTTTTTCAGTTATCTATTTTGTTCATAAACTAATTGTAACTATTTCATGGA
 ACAGCAAACGCCTGTTTAAATAAAGAAGTTCACCAAGGCTATAAATGCCACGTA
 CATTATTTTCAGTATTGTTGGTTATATTTAAATTTTCCTTACAATAAAGCACACTT
 15 TTATAATAAAATACATGAATTATTGTTTTTCATACTTTTTTGCTTGTTTCTTTAAAG
 TTTTCTGACGTGCATAATGCATAATTCATTGAAAAGCATGATAGCAATGTGGCAT
 GTGGAAGCGAACCCCCAGGGCATAACATAGTAAGAAAGTATGGTTCTGTATGGC
 AATAGGTTTTTAAATTTATTAGCTATTCATCATGTGTGGGAGAAATAATTGTGGT
 GTGTTGCAGATTTATTTGGCCATTTAGAATAACCAAATCAATCTGGCTAACTAGG
 20 AATTTATGTGTAATAATTATCTGATTAAAACAGCTC

SEQ.ID:NO: 395
 >4588 BLOOD 349746:5:E08895 g292289 Human MADS/MEF2-family transcription factor
 (MEF2C) mRNA, complete cds. 0
 25 GAATTCCCAGCTCTCTGCTCGCTCTGCTCGCAGTCACAGACACTTGAGCACACGC
 GTACACCCAGACATCTTCGGGCTGCTATTGGATTGACTTTGAAGGTTCTGTGTGG
 GTCGCCGTGGCTGCATGTTTGAATCAGGTGGAGAAGCACTTCAACGCTGGACGA
 AGTAAAGATTATTGTTGTTATTTTCTNNNNNNNNNNNNNNNNNNNTAAGAAAG
 GAAAATATCCCAAGGACTAATCTGATCGGGTCTTCCTTCATCAGGAACGAATGCA
 30 GGAATTTGGGAAGTGAAGTGTGCAAGTGTGAAGAAGGAGATTGTTTGGAGGA
 AACAGGAAAGAGAAAGAAAAGGAAGGAAAAAATACATAATTCAGGGACGAGA
 GAGAGAAGAAAAACGGGGACTATGGGGAGAAAAAAGATTTCAGATTACGAGGAT
 TATGGATGAACGTAACAGACAGGTGACATTTACAAGAGGAAATTTGGGTGAT
 GAAGAAGGCTTATGAGCTGAGCGTGCTGTGTGACTGTGAGATTGCGCTGATCATC
 35 TTCAACAGCACCAACAAGCTGTTCCAGTATGCCAGCACCGACATGGACAAAGTG
 CTTCTCAAGTACACGGAGTACAACGAGCCGCATGAGAGCCGGACAACTCAGAC
 ATCGTGGAGACGTTGAGAAAGAAGGGCCTTAATGGCTGTGACAGCCCAGACCCC
 GATGCGGACGATTCCGTAGGTCACAGCCCTGAGTCTGAGGACAAGTACAGGAAA
 ATTAACGAAGATATTGATCTAATGATCAGCAGGCAAAGATTGTGTGCTGTTCCAC
 40 CTCCCAACTTCGAGATGCCAGTCTCCATCCCAGTGTCCAGCCACAACAGTTTGGT
 GTACAGCAACCCTGTCAGCTCACTGGGAAACCCCAACCTATTGCCACTGGCTCAC
 CCTTCTCTGCAGAGGAATAGTATGTCTCCTGGTGTAACACATCGACCTCCAAGTG
 CAGGTAACACAGGTGGTCTGATGGGTGGAGACCTCACGTCTGGTGCAGGCACCA
 GTGCAGGGAACGGGTATGGCAATCCCCGAACTCACCAGGTCTGCTGGTCTCAC
 45 CTGGTAACTTGAACAAGAATATGCAAGCAAAATCTCCTCCCCCAATGAATTTAGG
 AATGAATAACCGTAAACCAGATCTCCGAGTTCTTATTCCACCAGGCAGCAAGAAT
 ACGATGCCATCAGTGTCTGAGGATGTGACCTGCTTTTGAATCAAAGGATAAATA
 ACTCCAGTCGGCTCAGTCATTGGCTACCCAGTGTTTCCGTAGCAACTCCTAC
 TTTACCAGGACAAGGAATGGGAGGATATCCATCAGCCATTCAACAACATATGG

TACCGAGTACTCTCTGAGTAGTGCAGACCTGTCATCTCTGTCTGGGTTTAAACACC
GCCAGCGCTCTTCACCTTGGTTTCACTAACTGGCTGGCAACAGCAACACCTACATA
ACATGCCACCATCTGCCCTCAGTCAGTTGGGAGCTTGCACTAGCACTCATTTATC
TCAGAGTTCAAATCTCTCCCTGCCTTCTACTCAAAGCCTCAACATCAAGTCAGAA
5 CCTGTTTCTCCTCCTAGAGACCGTACCACCACCCCTTCGAGATACCCACAACACA
CGCGCCACGAGGCGGGGAGATCTCCTGTTGACAGCTTGAGCAGCTGTAGCAGTT
CGTACGACGGGAGCGACCGAGAGGATCACCGGAACGAATTCCACTCCCCCATTG
GACTCACCAGACCTTCGCCGGACGAAAGGGAAAGTCCCTCAGTCAAGCGCATGC
GACTTTCTGAAGGATGGGCAACATGATCAGATTATTACTTACTAGTTTTTTTTTTT
10 TTCTTGACAGTGTGTGTGTGTGTCTATACCTTAATGGGGAAGGGGGGTCGATATGCA
TTATATGTGCCGTGTGTGGAAAAAAAAAAGTCAGGTACTCTGTTTTGTAAAAGT
ACTTTTAAATTGCCTCAGTGATACAGTATAAAGATAAACAGAAATGCTGAGATA
AGCTTAGCACTTGAGTTGTACAACAGAACACTTGTACAAAATAGATTTTAAAGGCT
AACTTCTTTTCACTGTTGTGCTCCTTTGCAAAATGTATGTTACAATAGATAGTGTC
15 ATGTTGCAGGTTCAACGTTATTTACATGTAAATAGACAAAAGGAAACATTTGCCA
AAAGCGGCAGATCTTTACTGAAAGAGAGAGCAGCTGTTATGCAACATATAGAAA
AATGTATAGATGCTTGGACAGACCCGGTAATGGGTGGCCATTGGTAAATGTTAG
GAACACACCAGGTCACCTGACATCCCAAGAATGCTCACAAACCTGCAGGCATAT
CATTTGGCGTATGGCACTCATTA AAAAGGATCAGAGACCATTAAAAGAGGACCAT
20 ACCTATTA AAAAAAAAAAATGTGGAGTTGGAGGGCTANNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNCTGGGTCTGCATCTCTTATTA AATA AAAAAATATA AAAAAATATGTACAT
TACATTTTGCTTATTTTCATATA AAGGTAAGACAGAGTTTGCAAAGCATTTGTG
GCTTTTGTAGTTTACTTAAGCCAAAATGTGTTTTCCTTCCCTTGATAGCTTCGCT
AATATTTTAAACAGTCCTGTAAAAAACCAAAAAGGACTTTTTGTATAGAAAGCAC
25 TACCCTAAGCCATGAAGAACTCCATGCTTTGCTAACCAAGATAACTGTTTTCTCTT
TGTAAGAGTTTTGTTTTTGAATGTGTATTTCTAATTATATA AATATTAAGAATC
TTTTAAAAAATCTGTGAATTAACATGCTTGTGTATAGCTTTCTAATATATATAA
TATTATGGTAATAGCAGAAGTTTTGTTATCTTAATAGCGGGAGGGGGGTATATTT
GTGCAGTTGCACATTTGAGTAACTATTTTCTTTCTGTTTTCTTTACTCTGCTTACA
30 TTTTATAAGTTTAAGGTCAGCTGTCAAAGGATAACCTGTGGGGTTAGAACATAT
CACATTGCAACACCCTAAATTGTTTTTAATACATTAGCAATCTATTGGGTCAACT
GACATCCATTGTATATACTAGTTTTCTTTCATGCTATTTTTATTTTGTTTTTTGCATT
TTTATCAAATGCAGGGCCCCCTTTCTGATCTCACCATTTCACCATGCATCTTGGAAT
TCAGTAAGTGCATATCCTA ACTTGCCCATATTCTAAATCATCTGGTTGGTTTTCAG
35 CCTAGAATTTGATACGCTTTTTAGAAATATGCCCAGAATAGAAAAGCTATGTTGG
GGCACATGTCCTGCAAATATGGCCCTAGAAACAAGTGATATGGAATTTACTTGGT
GAATAAGTTATAAATTTCCACAGAAGAAAAATGTGAAAGACTGGGTGCTAGACA
AGAAGGAAGCAGGTAAAGGGATAGTTGCTTTGTCATCCGTTTTTAATTATTTTAA
CTGACCCTTGACAATCTTGTGCAATATAGGACTGTTGAACAATCCCGGTGTGT
40 CAGGACCCCCAAATGTCACTTCTGCATAAAGCATGTATGTCATCTATTTTTCTTC
AATAAAGAGATTTAATAGCCATTTCAAGAAATCCCATAAAGAACCTCTCTATGTC
CCTTTTTTTAATTTAAAAAATGACTCTTGTCTAATATTTCGTCTATAAGGGATTAA
TTTTCAGACCCTTTAATAAGTGAGTGCCATAAGAAAGTCAATATATATTGTTTAA
AAGATATTTCACTCTAGGAAAGATTTTCTTCTCTTGGAAATGTGAAGATCTGTG
45 ATTCATCTCCAATCATATGCATTGACATACACAGCAAAGAAGATATAGGCAGTA
ATATCAACACTGCTATATCATGTGTAGGACATTTCTTATCCATTTTTTCTCTTTTAC
TTGCATAGTTGCTATGTGTTTCTCATTGTAAAAGGCTGCCGCTGGGTGGCAGAAG
CCAAGAGACCTTATTA ACTAGGCTATATTTTTCTTAACTTGATCTGAAATCCACA
ATTAGACCACAATGCACCTTTGGTTGTATCCATAAAGGATGCTAGCCTGCCTTGT

ACTAATGTTTTATATATTAATAAAAAAAAAATCTATCAACCATTTCATATATATCCC
ACTACTCAAGGTATCCATGGAACATGAAAGAATAACATTTATGCAGAGGAAAAA
CAAAAACATCCCTGAAAATATACACACTCATACACACACACGCACAGGGGAATA
AAATAAGAAAACCATTTTCCTCACCATAGACTTGATCCCATCCTTACAACCCATC
5 CTTCTAACTTGATGTGTATAAAATATGCAAACATTTACAAATGTTCTTTGTCAAT
TCAAATACTTTAGTATATCAATATCAGTAGATACCAGTGGGTGGGAAAGGGTC
ATTACATGAAAATATGAAGAAATAGCCATATTAGTTTTTTAACCTGCAATTTGCC
TCAGCAACAAAGAAAAAGTGAATTTTTAATGCTGAAGATAAAGTAAGCTAAAGT
ACCAGCAGAAGCCTTGGCTATTTATAGCAGTTCTGACAATAGTTTTATAAGAACA
10 TGAAGAGAACAGAATCACTTGAAAATGGATGCCAGTCATCTCTTGTTCCTACTAC
TGAATTCTTATAAAGTGGTGGCAAGATAGGGAAGGGATAATCTGAGAATTTTTA
AAAGATGATTTAATGAGAAGAAGCACAATTTTGATTGTGATGAGTCACTTTCTGT
AAACAATCTTGGTCTATCTTTACCTTATACCTTATCTGTAATTTACCATTTATTGT
ATTTGCAAAGCTAGTATGGTTTTTAATCACAGTAAATCCTTTGTATTCCAGACTTT
15 AGGGCAGAGCCCTGAGGGAGTATTATTTTACATAACCCGTCCTAGAGTAACATTT
TAGGCAACATTCTTCATTGCAAGTAAAAGATCCATAAGTGGCATTTTACACGGCT
GCGAGTATTGTTATATCTAATCCTATTTTAAAAGATTTTGGTAATATGAAGCTTG
AATACTGGTAACAGTGATGCAATATACGCAAGCTGCACAACCTGTATATTGTATG
CATTGCTGCCGTGGAGGCTGTTTATTTCAACCTTTTTAAAAATTGTGTTTTTAGT
20 AAAATGGCTTATTTTTTCCCAAAGGTGGAATTTAGCATTTTGTAAATGATGAATAT
AAAAATACCTGTCAATCCCCAGATCATTTTAAAAGTTAACTAAAGTGAGAATGAAA
AAACAAAATTTCCAAGACACTTTTTTAAAAGATGCTCTGCCCTCACACACTTTATG
GATTGGTTTTTTCTTACATACCCATCTTTTAACTTAGAGATAGCATTTTTTGCCCTCT
TTATTTGTTGTTTGTCTTCCAGAGAGTAAACGCTTTGTAGTTCTTTCTTTAAAA
25 AACATTTTTTTTTAAAGAAGAAGAAGCCACTTGAACCCTCAATAAAGGCTGTTGCC
TAAGCATGGCATACTTCATCTGTTCTCATTTGTGCCATCTGCCGTGATGTCGTCAC
TTTTATGGCGTTAATTTCTGCCACTACAGATCTTTTGAAGATTGCTGGAATACTG
GTGTCTGTTAGAATGCTTCAGACTACAGATGTAATTAAGGCTTTTCTTAATATGT
TTTAACCAAAGATGTGGAGCAATCCAAGCCACATATCTTCTACATCAAATTTTTTC
30 CATTTTGGTTATTTTCATAATCTGGTATTGCATTTTGCCCTCCCTGTTCCATACCTCA
AATTGATTTCATACCTCAGTTTAATTCAGAGAGGTCAGTTAAGTGACGGATTCTGT
TGTGGTTTGAATGCAGTACCAGTGTTCTCTTCGAGCAAAGTAGACCTGGGTCACT
GTAGGCATAGGACTTGGATTGCTTCAGATGGTTTGCTGTATCATTTTTCTTCTTTT
TCTTTTCTGCGGACTTGTTCCTTTTAAATGAGAGTAATTAATAATCGCTTGTAAT
35 GAGGGCATACAAGCATTGCAACAAATATTCAAATAGAGGCTCACAGCGGCATA
AGCTGGACTTTGTCGCCACTAGATGACAAGATGTTATAACTAAGTTAAACCACAT
CTGTGTATCTCAAGGGACTTAATTCAGCTGTCTGTAGTGAATAAAAGTGGGAAAT
TTTCAAAGTTTCTCCTGCTGGAAATAAGGTATAATTTGTATTTTGCAGACAATTC
AGTAAAGTTACTGGCTTTCTTAGTGAAAAAAA

40

SEQ ID NO: 396

>4599 BLOOD Hs.71891 gn|UG|Hs#S5389 H.sapiens mRNA for receptor protein tyrosine
kinase /cds=(353,2920) /gb=X74764 /gi=433337 /ug=Hs.71891 /len=3096

45 CATCTTGCATCAGCCTGTGGATGTATGCCTACCACCGGGCTCCTTCACCAGCAAA
GTGGAAAAAGAAGCGTTTCAACAATAATCTTCTTTTTGGGTTGGGGAAACGCAG
TGGATTATAGCTCTGTTTTCTTCTTTCCAAAACCTGTGCACCCCTGGATGAAACCTC
CATCAAGGGAGACCTACAAGTTGCCTGGGGTTTCAAGTGCTCTAGAAAGTTCCAAG
GTTTGTGGCTTGAATTATTCTAAAGAAGCTGAAATAATTGAAGAGAAGCAGAGG
CCAGCTGTTTTTGAGGATCCTGCTCCACAGAGAATGCTCTGCACCCGTTGATACT

CCAGTTCCAACACCATCTTCTGAGATGATCCTGATTCCCAGAATGCTCTTGGTGCT
GTTCTGCTGCTGCCTATCTTGAGTTCTGCAAAGCTCAGGTTAATCCAGCTATAT
GCCGCTATCCTCTGGGCATGTCAGGAGGCCAGATTCCAGATGAGGACATCACAG
CTTCCAGTCAGTGGTCAGAGTCCACAGCTGCCAAATATGGAAGGCTGGACTCAG
5 AAGAAGGGGATGGAGCCTGGTGCCCTGAGATTCCAGTGGAACCTGATGACCTGA
AGGAGTTTCTGCAGATTGACTTGCACACCCTCCATTTTATCACTCTGGTGGGGAC
CCAGGGGCGCCATGCAGGAGGTCATGGCATCGAGTTTGCCCCCATGTACAAGAT
CAATTACAGTCGGGATGGCACTCGCTGGATCTCTTGGCGGAACCGTCATGGGAA
ACAGGTGCTGGATGGAAATAGTAACCCCTATGACATTTTCCTAAAGGACTTGGAG
10 CCGCCCATTTGTAGCCAGATTTGTCCGGTTCATTCCAGTCACCGACCACTCCATGA
ATGTGTGTATGAGAGTGGAGCTTTACGGCTGTGTCTGGCTAGATGGCTTGGTGTC
TTACAATGCTCCAGCTGGGCAGCAGTTTGTACTCCCTGGAGGTTCCATCATTTATC
TGAATGATTCTGTCTATGATGGAGCTGTTGGATACAGCATGACAGAAGGGCTAG
GCCAATTGACCGATGGTGTGTCTGGCCTGGACGATTTACCCAGACCCATGAATA
15 CCACGTGTGGCCCGGCTATGACTATGTGGGCTGGCGGAACGAGAGTGCCACCAA
TGGCTACATTGAGATCATGTTTGAATTTGACCGCATCAGGAATTTCACTACCATG
AAGGTCCACTGCAACAACATGTTTGCTAAAGGTGTGAAGATCTTTAAGGAGGTA
CAGTGCTACTTCCGCTCTGAAGCCAGTGAGTGGGAACCTAATGCCATTTCCCTCC
CCCTTGTCTGGATGACGTCAACCCAGTGCTCGGTTTGTACGGTGCCTCTCCAC
20 CACCGAATGGCCAGTGCCATCAAGTGTCAATACCATTTTGCAGATACCTGGATGA
TGTTCACTGAGATCACCTTCCAATCAGATGCTGCAATGTACAACAACCTCTGAAGC
CCTGCCCACCTCTCCTATGGCACCCACAAGCTATGATCCAATGCTTAAAGTTGAT
GACAGCAACACTCGGATCCTGATTGGCTGGTGGTGGCCATCATCTTATCTCCT
GGCCATCATTGTCATCATCCTCTGGAGGGAAGTTCTGGCAGAAAATGCTGGAGAAG
25 GCTTCTCGGAGGATGCTGGATGATGAAATGACAGTCAGCCTTTCCCTGCCAAGTG
ATTCTAGCATGTTCAACAATAACCGCTCCTCATCACCTAGTGAACAAGGGTCCAA
CTCGACTTACGATCGCATCTTTCCCTTCGCCCTGACTACCAGGAGCCATCCAGG
CTGATACGAAAACCTCCAGAAATTTGCTCCAGGGGAGGAGGAGTCAGGCTGCAGC
GGTGTGTGAAGCCAGTCCAGCCAGTGGCCCTGAGGGGGTGCCCCACTATGCA
30 GAGGCTGACATAGTGAACCTCCAAGGAGTGACAGGAGGCAACACATACTCAGTG
CCTGCCGTCACCATGGACCTGCTCTCAGGAAAAGATGTGGCTGTGGAGGAGTTCC
CCAGGAAACTCCTAACTTTCAAAGAGAAGCTGGGAGAAGGACAGTTTGGGGAGG
TTCATCTCTGTGAAGTGGAGGGAATGGAAAAATTCAAAGACAAAGATTTTGCCCT
AGATGTCAGTGCCAACAGCCTGTCTGGTGGCTGTGAAAATGCTCCGAGCAGAT
35 GCCAACAAGAATGCCAGGAATGATTTTCTTAAGGAGATAAAGATCATGTCTCGG
CTCAAGGACCCAAACATCATCCATCTATTATCTGTGTGTATCACTGATGACCCTCT
CTGTATGATCACTGAATACATGGAGAATGGAGATCTCAATCAGTTTCTTTCCCGC
CACGAGCCCCCTAATTCTTCCCTCCAGCGATGTACGCACTGTCAGTTACACCAATC
TGAAGTTTATGGCTACCCAAATTGCCTCTGGCATGAAGTACCTTTCTCTTAAT
40 TTTGTTACCGAGATCTGGCCACACGAACTGTTTAGTGGGTAAGAACTACACAA
TCAAGATAGCTGACTTTGGAATGAGCAGGAACCTGTACAGTGGTGACTATTACCG
GATCCAGGGCCGGGCAGTGCTCCCTATCCGCTGGATGTCTTGGGAGAGTATCTTG
CTGGGCAAGTTCACCTACAGCAAGTGATGTGTGGGCCTTTGGGGTTACTTTGTGGG
AGACTTTACCTTTTGTCAAGAACAGCCCTATTCCCAGCTGTCAGATGAACAGGT
45 TATTGAGAATACTGGAGAGTTCTTCCGAGACCAAGGGAGGCAGACTTACCTCCCT
CAACCAGCCATTTGTCCTGACTCTGTGTATAAGCTGATGCTCAGCTGCTGGAGAA
GAGATACGAAGAACCGTCCCTCATTCCAAGAAATCCACCTTCTGCTCCTTCAACA
AGGCGACGAGTGATGCTGTCAAGTGCCTGGCCATGTTTCTACGGCTCAGGTCCTCC
CTACAAGACCTACCACTACCCATGCCTATGCCACTCCATCTGGACATTTAATGA

AACTGAGAGACAGAGGCTTGTTTGCTTTGCCCTCTTTTCCTGGTCACCCCCACTCC
CTACCCCTGACTCATATATACT

SEQ ID NO: 397

5 >4730 BLOOD 345818.4 Y11651 g2125811 Human mRNA for phosphate cyclase. 0
CGGCTCGAGGGCGAACCCGGGGGTTTCGTTTCTGCTGACTCCAGTGTCCCGAGAGG
CGCCGCTTCTTCCGCTTTCTCGTCAGGCTCCTGCGCCCCAGGCATGAACCAAGGT
TTCTGAACTACTGGGCGGGAGCCAACGTCTCTTCTTTCTCCCGCTCTGGCGGAGG
CTTTGTGCTGCGGGCTGGGCCCCAGGGTGTCCCCCATGGCGGGGGCCGCGGGTGG
10 AGGTTCGATGGCAGCATCATGGAAGGGGGCGGCCAGATCCTGAGAGTCTCTACGG
CCTTGAGCTGTCTCCTAGGCCTCCCCTTGCGGGTGCAGAAGATCCGAGCCGGCCG
GAGCACGCCAGGCCTGAGGCCTCAACATTTATCTGGACTGGAAATGATTCGAGA
TTTGTGTGATGGGCAACTGGAGGGGGCAGAAATTGGCTCAACAGAAATAACCTT
TACACCAGAGAAGATCAAAGGTGGAATCCACACAGCAGATACCAAGACAGCAG
15 GGAGTGTGTGCCTCTTGATGCAGGTCTCAATGCCGTGTGTTCTCTTTGCTGCTTCT
CCATCAGAACTTCATTTGAAAGGTGGAATAATGCTGAAATGGCACACAGATC
GATTATACAGTGATGGTCTTCAAGCCAATTGTTGAAAAATTTGGTTTCATATTTA
ATTGTGACATTAAAAACAAGGGGGATATTACCCAAAAGGGGGTGGTGAAGTGATT
GTTTCAATGTCACCAGTTAAACAATTGAACCCTATAAATTTAACTGAGCGTGGCT
20 GTGTGACTAAGATATATGGAAGAGCTTTCGTTGCTGGTGTGTTTGCCATTTAAAGT
AGCAAAAGATATGGCAGCGGCAGCAGTTAGATGCATCAGAAAGGAGATCCGGG
TTTAAATTTGTATGTTAACATCCAGCCTGTTCAAGAACCTAAAGAGCAAGCATTGCGCA
TGGAAATGGAATAATAATTATTGCTGAGACCTCCACTGGCTGTTTGTGTTGCTGGA
TCATCGCTTGGTAAACGAGGTGTAATGTCAGACAAAGTTGGAATTGAAGCTGCC
25 GAAATGCTATTAGCAAATCTTAGACATGGTGGTACTGTGGATGAGTATCTGCAAG
ACCAGCTGATTGTTTTTCATGGCATTAGCCAATGGAGTTTCCAGAATAAAAAACAGG
ACCAGTTACACTCCATACGCAAAACCGCGATACATTTTGCTGAACAAATAGCAAA
GGCTAAATTTATTGTGAAGAAATCAGAAGATGAAGAAGACGCCGCTAAAGATAC
TTATATTATTGAATGCCAAGGAATTGGGATGACAAATCCAAATCTATAGAGTATT
30 TGCCTCTTAAATGATACCTCATTGATATATTGCACTATTTCATAAATACTATAAAA
TAATGACTAGGAAGTAACTTATTAAGGCTATGACTTAAATTTGAAGATGAAGTA
CAGTGTCTAGGTTTGCTGAGAAGGCTTCATTAAATTAATCTCACTTTGAATATCT
CCTGAGAGATGGACAATGAAATATCAGTTGGTGGATATGTGTGATAGCTGATTTT
AATATTGAAGTATTGAAATATAAATATTCTTTACACCTGAAGTAAATACATTTTTC
35 TTTTTTATGTAATTAATTAAATCAGGGATATAGATTTGATCTGTAATTTGGGTATA
ATTCTAATCTTTGCTGAAATCACATCTCAAGTATAATGAGGCAACTTTATGCAAA
TGTAATTGTTGTGACAACAATAACA

SEQ ID NO: 398

40 >4830 BLOOD 233438.4 L47345 g992562 Human elongin A mRNA, complete cds. 0
CCAGTTCGGCGGAGGAGGCCGCGCCAGTGACAGCGATGGCGGCGGAGTCCGGCGC
TCCAAGTTGTGGAGAAGCTGCAGGCGCGCCTGGCCGCGAACCCGACCCCTAAGA
AGCTATTGAAATATTTGAAGAACTCTCCACCCTGCCTATTACAGTAGACATTCT
TGCGGAGACTGGGGTTGGGAAAACAGTAAATAGCTTGCGAAAACACGAGCATGT
45 TGGAAGCTTTGCCAGGGACCTAGTGGCCCAGTGAAGAAGCTGGTTCCTGTGGA
ACGAAATGCTGAGCCTGATGAACAGGACTTTGAGAAGAGCAATCCCCGAAAGCG
CCCTCGGGATGCCCTGCAGAAGGAGGAGGAGATGGAGGGGGACTACCAAGAAA
CCTGGAAAGCCACGGGGAGCCGATCCTATAGCCCTGACCACAGGCAGAAGAAAC
ATAGGAAACTCTCGGAGCTCGAGAGACCTCACAAAGTGTCTCACGGTCATGAGA

GGAGAGATGAGAGAAAGAGGTGTCACAGAATGTCACCAACTTACTCTTCAGACC
CTGAGTCTTCTGATTATGGCCATGTTCAATCCCCTCCATCTTGTACCAGTCCTCAT
CAGATGTACGTCGACCACTACAGATCCCTGGAGGAGGACCAGGAGCCCATTTGTT
TCACACCAGAAGCCTGGGAAAGGCCACAGCAATGCCTTTCAGGACAGACTCGGG
5 GCCAGCCAAGAACGACACCTGGGTGAACCCCATGGGAAAGGGGTTGTGAGTCAA
AACAAGGAGCACAAATCTTCCCACAAGGACAAACGCCCCGTGGATGCCAAGAGT
GATGAGAAGGCCTCTGTGGTGAGCAGAGAGAAATCACACAAGGCCCTCTCCAAA
GAGGAGAACCGAAGGCCACCCTCAGGGGACAATGCAAGGGAGAAACCGCCCTC
TAGTGGCGTAAAGAAAGAGAAGGACAGAGAGGGCAGCAGCCTGAAGAAGAAGT
10 GTTTGCCTCCCTCAGAGGCCGCTTCAGACAACCACCTGAAAAAGCCAAAGCACA
GAGACCCAGAGAAAGCCAAATTGGACAAAAGCAAGCAAGGTCTGGACAGCTTTG
ACACAGGAAAAGGAGCAGGAGACCTGTTGCCCAAGGTAAAAGAGAAGGGTTCT
AACAACCTAAAGACTCCAGAAGGGAAAAGTCAAACTAATTTGGATAGAAAGTCA
CTGGGGCTCCCTCCCTAAAGTTGAGGAGACAGATATGGAGGATGAATTCGAGCAG
15 CCAACCATGTCTTTTGAATCCTACCTCAGCTATGACCAGCCCCGGAAGAAAAAGA
AAAAGATTGTGAAAACCTCAGCCACGGCACTTGGAGATAAAGGACTTAAAAAAA
ATGACTCTAAAAGCACTGGTAAAAACCTTGGACTCAGTTCAGAAATTACCCAAGG
TGAACAAAACCAAGTCAGAGAAGCCGGCTGGAGCTGATTTAGCCAAGCTGAGAA
AGGTGCCTGATGTGTTGCCAGTGTTGCCAGACCTCCCGTTACCCGCGATACAGGC
20 CAATTACCGTCCACTGCCTTCCCTCGAGCTGATATCCTCCTTCCAGCCAAAGCGA
AAAGCGTTCTCTTACCCCCAGGAAGAAGAAGAAGCTGGATTTACTGGGCGCAGA
ATGAATTCGAAGATGCAGGTGTATTCTGGTTCCAAGTGTGCCTATCTCCCTAAAA
TGATGACCTTGCACCAGCAATGCATCCGAGTACCTTAAAAACAACATCGATTCAAT
CTTTGAAGTGGGAGGAGTCCCATACTCTGTCTTGAACCCGTTTTTGGAGAGGTGT
25 ACACCTGATCAGCTGTATCGCATAGAGGAATACAATCATGTATTAATTGAAGAA
ACAGATCAATTATGGAAAGTTCATTGTACCCGAGACTTTAAGGAAGAAAGACCC
GAAGAGTATGAGTCGTGGCGAGAGATGTACCTGCGGCTTCAGGACGCCCCGAGAG
CAGCGGCTACGAGTACTAACAAGAATATCCAGTTCGCACATGCCAATAAGCCC
AAAGGCCGACAAGCAAAGATGGCCTTTGTCAACTCTGTGGCCAAGCCACCTCGT
30 GACGTCCGGAGGAGGCAGGAAAAGTTTGGAACGGGAGGAGCAGCTGTCCCTGA
GAAAATCAAGATCAAGCCAGCCCCGTACCCCATGGGAAGCAGCCATGCTTCCGC
CAGTAGCATCAGCTTTAACCCAGCCCTGAGGAGCCGGCCTATGATGGCCCAAG
CACCAGCAGTGCCCACTTGGCACCAGTGGTCAGCAGCACTGTTTCCCTATGATCCT
AGGAAACCCACTGTGAAGAAAATTGCCCAATGATGGCCAAGACAATTAAAGCT
35 TTCAAGAACAGATTCTCCCGACGATAAACTGAGGACTTGCCTTGGAAATGGAATC
TGGGGAGGCAGGAATACAAGGACAGTGGGGGTTGGGGAATGGAATTCTACAGG
AGACTGGAGTCTTGCTTTGTGGATCCTTTTGGTCTCCGAGTCCTGCAGTCTGCAGG
TGCTGCCCCTGGGAACCTGCGTGCCACAGCCCCGCCTCCCTGCCTGGAGCACACT
TTAGAATTCTGAAGATGTGAAGCCTCTGTCTCACTGAGGATTTTAAAGGTCAATT
40 ATACTTTTGTGTTTATTAGCATCTTTGTAAACTATAAGACGTAGTTTAAATTAAT
AAATATTGCCCCCAGATTGTATTTATATTATCCCCCAGGTTTGTGTTTTTGT
CCTCTACCACACATTTAGCCTTTTATCTTCCAGGTCCTTATTAATAATCAGATGAAA
GCCTAGTGAAAGCCAGTCTCCTGCCCCAGCTCAGCTCTGTGTGGACTCTGGTCCA
GACAGAGGACTGGGCATCTCCAGAGCCTGCACAGTACCTGCTGCACGTAGGGCA
45 AGGAATGAGCACTAGACCGCCTGTCCCAAGGGAGCCTCAGTGGGGCGACAGGG
TGCTCGGCGGACTCCACCTCAGGCCCTCCCCACTGTTGCTGTGCATTCTGTGCA
GGTGATCTCTTTCTTACTAACTGGTATTTATTAAGGCAGGTGCTCTGTAGGTCTG
GAGCCTTTCCCTCATCCTTTTTCGAGTCCCCACNNNNNNNNNNNNNNNNNNNN
NNNNGAGGCTCACTAGAGGACGCAGAACCTTGGGAGATTGATTTGCACAGAACT

CCCCACCTCCCACCTTTTACAATTTCCAGTTTCTGATTGAAAATTTTAGGGTTTCTC
 CCCACTGCCCTTCCCTATCTTTCCCTCCCCTCAACACCATGAAGGAAAAACACAC
 ACGGCAGGGCTTTTGTAGCCCTGAAGGCAACTTTAGACATTTAAAATCCAGCAC
 TTTAATCTCTTGTTCTCTGTGAATCACTATGAGAAGTGAATGGTTTTAAAGGCTGT
 5 AATGCTATGTTGGAAATTGGTTTTGTTTTGCCTTTTATTGAAAAGGTAAGATCATGT
 GATTGGAAGAACACAACCTGTTGGCTTGGGAAGAGGACTTTGCTGCTGAAGTGT
 TCTACCTTCTGAGTGTGTTTAAGGCAGGATTTGGAGGGAAGGACCAGCTTAGGGA
 GAGTGTCTGAGCCACAGCGTCAGGATGGGGGAAACCACATGGGATCCATCAAGT
 TCCAGTTGAACAGGAGCAAGATCAGAACTTAGGAGGGCAGTGTGAGCTCCCTTG
 10 TTGGCTGTCAAGGAACACCGATCTAGTAGAAACCCACTTGGTTGTGACCCAGGTA
 GAGGTAGATGCCATACATTTGAGATATGCGTCCTTAAGGAACCTGACAAGCAGA
 CTGAAGGGATGGTAAGTGTGACAGCCTGATAAGTTTTCTCAAAGCCCAGGATAC
 AGAGCCAGTGTTTTCTGTAAGTGGAGACCTCAGTTAGGCCAACTTCGAATTCAG
 AGCAACGTAGGAAGTCTATTGAGCAGAACTCGACATTGTTCAAGTGTGTATTGCT
 15 GTGCAGGGTGCCTATTGTGACAGGACACAAATGTTACTATGTTTTAATTTGCTAT
 ATTTTGAATGGGTAAAGCATTACTTTACTTCTCTTGGTTACTTGTACCACCATTC
 CACCCCTATCCCTAGCCTGCCCCACAAATCTAATATTAGGAAGCCTCTTAAGTGA
 AACCAATGAACATTTGGGTCAGGTGCCAGATGTCTGCTGCCTAGAATAGCTTTT
 TCTAGGTGTCTACCACCTTGAATTTATCTCTTAAGTGTGTGTTCAAGTCTTTGTCA
 20 TTGAAACTAGTTTTTCATATCTTAGATTGAGTTGTGTATGATTTAATGTCCCTTAT
 TAGGAGTCTTTAGGCAGGGAGGGGAAGAAAAACAGATTTGTTTCATAGCAATGTC
 AGTATCCATTTTGGGCACATAAAGATTTTGTATGAGCCCTGTTTGCATAGAGCCAG
 ATGTTTTCCCTTCCCTCAAGAGTATCTACATCAGGGATGTGACTTGGTGCGAAGA
 ATCAGGGGAAAGAGGAAAAACCCAAATTTCTAAATGACCTCCTTGCCAGCTTACT
 25 AAAATGGCTGCAGAGCAGACACAGGATGAATTTGAACCTGACACAGGATGAATT
 TGAACCTTTGGTCTCATTTATGGAAAACTTGTGCAATTTTTTTTCTGTGCTACAC
 TACATACAAATCACCAAAATTACAAATTACCTTTTGTGATCCTTGGTGTACTGAG
 CAGTTTCTTTGGGGCTTTTCTTTCTGGGAAGCGGGAGGGAAAGGAGCAAGGTGT
 CATCCTGCTCTTCATTTGTATTTTGGTCCCAAAATGTAAATACAATTTTCTATGTT
 30 ACTTTTTTGTGGTAACTACCGAGATGAATATTTTAATTAGATAAGTTATATGAAA
 AGGAAAATTCCATGTCTAAATAANAAACAACTCC

SEQ ID NO: 399

5061 BL00D 211277.19 AF020351 g2655052 Human NADH:ubiquinone oxidoreductase

35 18 kDa IP subunit mRNA, nuclear gene encoding mitochondrial protein, complete cds. 0
 CGTCCTTTCATCCTGGCGTTTGCCTGCAGCAAGATGGCGGCGGTCTCAATGTCAG
 TGGTACTGAGGCAGACGTTGTGGCGGAGAAGGGCAGTGGCTGTAGCTGCCCTTT
 CCGTTTCCAGGGTTCCGACCAGGTCGTTGAGGACTTCCACATGGAGATTGGCACA
 GGACCAGACTCAAGACACACAACCTCATAACAGTTGATGAAAAATTGGATATCAC
 40 TACTTTAACTGGCGTTCCAGAAGAGCATATAAAAAGTAGAAAAGTCAGGATCTTT
 GTTCCTGCTCGCAATAACATGCAGTCTGGAGTAAACAACACAAAGAAATGGAAG
 ATGGAGTTTGATACCAGGGAGCGATGGGAAAATCCTTTGATGGGTTGGGCATCA
 ACGGCTGATCCCTTATCCAACATGGTTCTAACCTTCAGTACTAAAGAAGATGCAG
 TTTCTTTGCAGAAAAAAATGGATGGAGCTATGACATTGAAGAGAGGAAGGTTTC
 45 CAAAACCCAAGTCCAAGTCTTATGGTGCAAACTTTTCTTGAACAAAAGAACA
 GAGTATCCACAAAATAGGTTGGCACTGACTATATCTCTGCTTGACTGTGAATAAA
 GTCAGCTATGCAGTATTTATAGTCCATGTATAATAAATACATCTCTTAATCTCCTA
 ATAAATTGGACCTTTAACTAC

SEQ ID NO: 400

>5065 BLOOD 140122.18 AF125099 g5106993 Human HSPC038 protein mRNA, complete cds. 0

5 GGGGCGCCGAGGAGAGCGGCGCGGCGTGC GCGGGCACGAGGCGTAGTGGTCTCC
CCTAAGGCTGAGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGTGC GAGGCTGTT
GTGCTCCCGGCTCTCGTGTTCCTTCCTCCTGAGCGGGTGGAGGAGGCCCAAGCGGT
GCTGGGCGCGCTCCCCCTTCCTTTCCCTCCGGCGTCTCTCCCGGCCCTCTCGCGC
TGC ACTGTCTCTCCGACGCAAGACTGTCCCGGCCCGGATATGGCTCGTGGACAGC
AGAAAATTCAGTCTCAGCAGAAAATGCCAAAAGCAAGCTGGACAAAAGAAG
10 AAACAAGGACATGACCAAAAGGCTGCTGCCAAAGCTGCCTTAATATATACCTGC
ACTGTCTGTAGGACACAAATGCCAGACCCTAAGACCTTCAAGCAGCACTTTGAG
AGCAAGCATCCTAAGACTCCACTTCCTCCAGAATTAGCTGATGTT CAGGCATAAG
GTTGTTTACAGGTGAATTCATGACACCTTTGACTCTTCTACTGTCTCAGACCTTAG
GTAACATACCTGCAGCTGCTTTTCTAACAACTGTTGATCAGCAAAAATAAAGGG
15 GCTACAGAAACACTCATTTTTATGCTGTTCCCTCTTGGGCTTCATGCAAAGACAA
TTCTGTGTAAATGTACAGTTGACTCTGATTTGGAAATATGAAATCAGTCCATCC
TTGTTATAAAAAATTTTTTTACAATTGTAATTATATTGATGTT CATATTGTGTA
ATAACTCATTTAATAAAATAGTACTTTGATTTACGACATCACAGGATAAATGGTT
TTAGAAATTCGTCTAACTTTCCACATTATTTGCCTTATAAAAAATCTAATGAATT
20 CATCAGCTAGAATTGCAAGTGCAATTCCTATATCCCTTTCTCTGCTCAGTGGCAG
GTTCTCAGTTAACTAGAGCAGACTGATTCATTAAATTTGTGCATACGATTTTA
TGGGTCAGTGTGATGATCTAGGTGAAAAATGACTTATCTGCTGCCTTAGTATATTGC
GGTATGTGTCAATTGTACCCCTCTGATCATTTCTCTGTGTTGAGTTGGAAATATTTA
AAAATTCAGTATGACCTGGNTCTAACTNCCAGTCAGGTGTACCCTGTAGATAACT
25 GATAGCTTCCTAAAAGCGGTTGGATTGT CAGTGAGCCCTTGTGAAAGGTTAGGTT
CTAATGTATATGCCGTAATGAAATAATCATT AAGCCTATTGTTTAATGCAAAATA
TGGAACAAATGTGAACTGGTAAAGGTCGATCTTGATACTATATTCTTTGAAAATT
CTTGAAGTTCTTTAATTTGAAATTGAAACATTAATTTTGTAGGTTTTTGGAAAGTTA
CTATTTGGCCATTTTACAAATGGATTTTGCATTAACAGGAAGATTGGAATGACT
30 TGTGGCTGGATTAATCCCAGAACCTCTCCCTCCTTTCTTTTCTAAGTGAGTTGT
TGATTTTAGGAGTTTGCTTTGTGCTGTTACCTAAAATCAGAGACTGGTGTACAGT
ATGACTTCCATCTGAACTTGAAAAGTATTA AAAATGGGTCAATATTCACATTCTTTT
AGATCTCAGGATGGGAAAATGGGTTTGTTCAGATGGATATGGTAAATCTTACCCA
ATTAAGGAAGGCTAATTTTAGAGTTCTTCTAATTTGCTTGTGTCAACTCTTAACCT
35 GTAAAACCTGCTGTTAACTCGGTTTAAATTTTAAATTAATATAATAGAAAGAACA
CTAAAATACTTACTGGTAACTGCTTAGAGCCATTTATCTGATCCTGTGGATTACA
GAATGCATTCCCTCTTCTGCTGTAGCTTATCATTGCTTTGTTTTGTAGCTCTGCAT
ATTTTGCCACCTTGTCTTCCCTGTAAGTTTAAGACGTTTCCAAGGAAAAGCTTCA
GGGCTGATAGTTTCTTAGCAATTCCTATTCTTATGCCCTTACTTTAAAATAGTCCT
40 TTTATTTTGTGATTTTATTTCTTAAGTTTCAGATGTAATATCTGTTGTTTCCTAAC
ATGTCGATTACCAGAACGTTAGAATTTTACCTAATTTCTTGTGGATATTGCAGAA
GTTCTGGTTAAATCACAACCTTAAAAGTTTTTAAAAGTGCTTTGAGCATATGTATA
TGTTTAGTGACAAATCATATAAAACCATT CACAAGTTTTTGGTTTTTTTTTTTCGT
TTGTTTTAGTGACTAATTCAGGATGAAAGTTTTTTTGTCTTGTATTTAACCTTTT
45 TTATAAGCAGCTGAAGACACCATATTTAACACTATATCTCAGTGATAGGGAAATA
GCTGCATTGATCTTACATGAGCATAATCATCCTTATACTTCATGAGGGGATTATT
AGTACAATCCCATTTTACTGTGTTTGAGTTAAAAACCAAACATCCCTGTAATTT
AATTTGAAGATTCTTTAACAGATTGCAGCAAAGTTCATTATAAAACTGTTATGGT
GTCTTCAAAGACTTGATAAAATAACACTGAGAGAGAATTGGTCCATTTGTATGCT

GTATTTCTATTACTTGCCAAAAGGAATGGGGTTAAGATTAAACTTGTTTCCATTCT
CTTCACATGGATATACATCCCCATGTTTAACTGACACACTGGGGGCTCAGTTGTG
TGCTGTAATGTCTTATTAAAGAAGATATTAAAGAAAAAAA

5 SEQ ID NO: 401

>5083 BLOOD 1144730.1 AF059524 g4091867 Human reticulon gene family protein
(RTN3) mRNA, complete cds. 0

CTGTCTCGGAGCAGGCGGAGTAAAGGGACTTGAGCGAGCCAGTTGCCGGATTA
TTCTATTTCCCCTCCCTCTCTCCCGCCCCGTATCTCTTTTCACCCTTCTCCCACCCT
10 CGCTCGCGTAGCCATGGCGGAGCCGTCGGCGGCCACTCAGTCCCATTCCATCTCC
TCGTCTGCTTTCGGAGCCGAGCCGTCCGCGCCCGGCGGCGGGAGCCCAGGA
GCCTGCCCCGCCCTGGGGACGAAGAGCTGCAGCTCCTCCTGTGCGGTGCACGATC
TGATTTTCTGGAGAGATGTGAAGAAGACTGGGTTTGTCTTTGGCACCACGCTGAT
CATGCTGCTTTCCCTGGCAGCTTTCAGTGTATCAGTGGGGTTTCTTACCTCATCC
15 TGGCTCTTCTCTCTGTACCATCAGCTTCAGGATCTACAAGTCCGTCATCCAAGCT
GTACAGAAGTCAGAAGAAGGCCATCCATTCAAAGCCTACCTGGACGTAGACATT
ACTCTGCTCTCAGAAGCTTTCCATAATTACATGAATGCTGCCATGGGGCCCATCA
ACAGGGCCCTGAAACTCATTAT

20 SEQ ID NO: 402

>5105 BLOOD 322303.2 X51602 g31431 Human flt mRNA for receptor-related tyrosine
kinase.0

GACCCAATGCATCACGTACCCCACTGGGCCAGCCCTGCAGCCCAAAACCCAGGG
CAACAAGCCCGTTAGCCCCAGGGATCACTGGCTGGCCTGAGCAACATCTCGGGA
25 GTCCTCTAGCAGGCCTAAGACATGTGAGGAGGAAAAGGAAAAAAGCAAAAAG
CAAGGGAGAAAAGAGAAAACCGGGAGAAAGGCATGAGAAAGAATTTGAGACGCAC
CATGTGGGCACGGAGGGGGACGGGGCTCAGCAATGCCATTTCAGTGGCTTCCCA
GCTCTGACCCTTCTACATTTGAGGGCCCAGCCAGGAGCAGATGGACAGCGATGA
GGGGACATTTTCTGGATTCTGGGAGGCAAGAAAAGGACAAATATCTTTTTTGGAA
30 CTAAAGCAAATTTTAGAACTTTACCTATGGAAGTGGTTCTATGTCCATTCTCATTC
GTGGCATGTTTTGATTTGTAGCACTGAGGGTGGCACTCAACTCTGAGCCATACT
TTTGGCTCCTCTAGTAAGATGCACTGAAAACCTTAGCCAGAGTTAGGTTGTCTCCA
GGCCATGATGGCCTTACACTGAAAATGTCACATTCTATTTTGGGTATTAATATAT
AGTCCAGACACTTAACTCAATTTCTTGGTATTATTCTGTTTTGCACAGTAGTGT
35 GAAAGAAAGCTGAGAAGAATGAAAATGCAGTCCTGAGGAGAGGAGTTTCTCCA
TATCAAAACGAGGGCTGATGGAGGAAAAAGGTCAATAAGGTCAAGGGAAAAACC
CCGTCTCTATACCAACCAACCAATTCACCAACACAGTTGGGACCCAAAACACA
GGAAGTCAGTCACGTTTCCTTTTCATTTAATGGGGATTCCACTATCTCACACTAAT
CTGAAAGGATGTGGAAGAGCATTAGCTGGCGCATATTAAGCACTTTAAGCTCCTT
40 GAGTAAAAAGGTGGTATGTAATTTATGCAAGGTATTTCTCCAGTTGGGACTCAGG
ATATTAGTTAATGAGCCATCACTAGAAGAAAAGCCCATTTTCAACTGCTTTGAAA
CTTGCTGGGGTCTGAGCATGATGGGAATAGGGAGACAGGGTAGGAAAGGGCGC
CTACTCTTCAGGGTCTAAAGATCAAGTGGGCCCTTGGATCGCTAAGCTGGCTCTGT
TTGATGCTATTTATGCAAGTTAGGGTCTATGTATTTATGATGTCTGCACCTTCTGC
45 AGCCAGTCAGAAGCTGGAGAGGCAACAGTGGATTGCTGCTTCTTGGGGAGAAGA
GTATGCTTCCTTTTATCCATGTAATTTAACTGTAGAACCTGAGCTCTAAGTAACCG
AAGAATGTATGCCTCTGTTCTTATGTGCCACATCCTTGTTTAAAGGCTCTCTGTAT
GAAGAGATGGGACCGTCATCAGCACATTCCCTAGTGAGCCTACTGGCTCCCTGGC
AGCGGCTTTTGTGGAAGACTCACTAGCCAGAAGAGAGGAGTGGGACAGTCTCT

CCACCAAGATCTAAATCCAAACAAAAGCAGGCTAGAGCCAGAAGAGAGGACAA
ATCTTTGTTCTTCTCTTTACATACGCAAACCACCTGTGACAGCTGGCAATTT
TATAAATCAGGTAACCTGGAAGGAGGTTAAACACAGAAAAAAGAAGACCTCAGTC
AATTCTCTACTTTTTTTTTTTTTTCCAAATCAGATAATAGCCCAGCAAATAGTGAT
5 AACAAATAAAACCTTAGCTATTCATGTCTTGATTTCAATAATTAATTCTTAATCAT
TAAGAGACCATAATAAATACTCCTTTTCAAGAGAAAAAGCAAAACCATTAGAATT
GTTACTCAGCTCCTTCAAACCTCAGGTTTGTAGCATACATGAGTCCATCCATCAGT
CAAAGAATGGTTCCATCTGGAGTCTTAATGTAGAAAGAAAAATGGGAGACTTGTA
ATAATGAGCTAGTTACAAAGTGCTTGTTTCATTAATAATAGCACTGAAAATTGAAAC
10 ATGAATTAACCTGATAATATTCCAATCATTTGCCATTTATGACAAAAATGGTTGGC
ACTAACAAAGAACGAGCACTTCCTTTCAGAGTTTCTGAGATAATGTACGTGGAAC
AGTCTGGGTGGAATGGGGCTGAAACCATGTGCAAGTCTGTGTCTTGTGAGTCCAA
GAAGTGACACCGAGATGTTAATTTTAGGGACCCGTGCCTTGTTTCCTAGCCCACA
AGAATGCAAACATCAAACAGATACTCGCTAGCCTCATTTAAATTGATTAAAGGA
15 GGAGTGCATCTTTGGCCGACAGTNGTGTAAACNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNCGTGTTTTGTGCATAACTATTTAAGGAACTGG
AATTTTAAAGTTACTTTTATACAAACCAAGAATATATGCTACAGATATAAGACAG
ACATGGTTTGGTCCTATATTTCTAGTCATGATGAATGTATTTGTATACCATCTTC
ATATAATAAAATTAACCTTCCAAAAATGTAAAAAAGAAAAAAAAGGGA

20

SEQ ID NO: 403

>5125.BLOOD GB_AA069517 gi|1576885|gb|AA069517|AA069517 zf74a12.s1
Soares, pineal_gland_N3HPG
Homo sapiens cDNA clone IMAGE:382654 3' similar to gb:J05252 NEUROENDOCRINE
25 CONVERTASE 2 PRECURSOR (HUMAN); mRNA sequence [Homo sapiens]
CATCTGCTGAGCGACCGGTCTTCACGAATCATTTTCTTGTGGAGTTGCATAAAGG
GGGAGAGGACAAAGCTCGCCAAGTTGCAGCAGAACACGGCTTTGGAGTCCGAAA
GCTTCCCTTTGCTGAAGGTCTGTACCACTTTTATCACAATGGCCTTGCAAAGGCA
AGTAGAAGACGCAGCCTACACCACAAGCAGCAGCTGGAGAGAGACCCAGGGT
30 AAAGATGGCTTTGCAGCAGGAAGGATTTGACCCGAAAAAANGCGAGGTTACAGA
GNNCATCAATGNGATCGGACATCAACCATGAAACGANCNCTCTTTTT

SEQ ID NO: 404

>5612 BLOOD 997231.12 D86198 g3062805 Human hDPM1 mRNA for dolichol-
35 phosphate-mannose synthase, complete cds. 0
ATCTGGCTCAGTTCCGCCATGGCCTCCTTGGAAGTCAGTCGTAGTCCTCGCAGGT
CTCGGCGGGAGCTGGAAGTGCGCAGTCCACGACAGAACAAATATTCCGGTGCTTT
TACCTACCTACAACGAGCGCGAGAACCTGCCGCTCATCGTGTGGCTGCTGGTGAA
AAGCTTCTCCGAGAGTGGAATCAACTATGAAATTATAATCATAGATGATGGAAG
40 CCCAGATGGAACAAGGGATGTTGCTGAACAGTTGGAGAAGATCTATGGGTCAGA
CAGAATTCTTCTAAGACCACGAGAGAAAAAGTTGGGACTAGGAACTGCATATAT
TCATGGAATGAAACATGCCACAGGAACTACATCATTATTATGGATGCTGATCTC
TCACACCATCCAAAATTTATTCCTGAATTTATTAGCTAATTTATTCTACAGGAAGC
AAAAGGAGGGTAATTTTGATATTGTCTCTGGAACCTCGCTACAAAGGAAATGGAG
45 GTGTATATGGCTGGGATTTGAAAAGAAAAATAATCAGAAGATCTGATTGTTTTAT
TTGGCAGCCGTGGGGCCAATTTTTTAACTCAGATCTTGCTGAGACCAGGAGCATC
TGATTTAACAGGAAGTTTCAGATTATACCGAAAAAGAGTTCTAGAGAAATTAAT
AGAAAAATGTGTTTCTAAAGGCTACGTCTTCAGATGGAGATGATTGTTCCGGGCA
AGACAGTTGAATTATACTATTGGCGAGGTTCCAATATCATTTGTGGATCGTGTTT

ATGGTGAATCCAAGTTGGGAGGAAATGAAATAGTATCTTTCTTGAAAGGATTATT
GACTCTTTTTGCTACTACATAAAAGAAAGATACTCATTTATAGTTACGTTCAATTC
AGGTTAAACATGAAAGAAGCCTGGTTACTGATTTGTATAAAATGTACTCTTAAAG
TATAAAATATAAGGTAAGGTAAATTTTCATGCATCTTTTTATGAAGACCACCTATT
5 TTATATTTCAAATTAAATAATTTTAAAGTTGCTGGCCTAATGAGCAATGTTCTCAA
TTTTCGTTTTTCATTTTGCTGTATTGAGACCTATAAATAAATGTATATTTTTTTTGC
ATAAAGTATTGCTGCCTTAAAAAAA

SEQ ID NO: 405

10 >5707 BLOOD 018945.3 AAC53540.1 g2739105 G protein-coupled receptor 2.6e-86
GGCAAAAAGCATGCAGAAAAAGAAGCAGACGTTTTACATTGGGAATTAATGAAA
GCGTGTCTGCTAGTTTTGGGTAGGAGAACTGGGAAGTTGTTGCTTAAAATTTTAT
ATCACCTCCACAAACAAAACCTCTTCGGAAATGGTAAAATAAGAAAATGCATGAT
TCTAGAGGCATTCTTAAGCACCCACGTGTGGGCTTTGTGGTGTCTGTGGTATCA
15 TCCGACCGTTTGGACTGGTTAGGGCTTACTGAGAGCTCCATTTCTGGAAAGCCTT
ACAAGACTGAGGAATATCAGACTGCGAATCACCGGGAACGGTTCCTTTCAGCA
CAGAAGCAATCTCTCTCCCCATCTTCGCATATTCTGATGGCAAAAACAAGTGAAG
AAAAGAGGAAGCATGACTGCAGATCAGATCAGTTCTCTTTGTGGATTATATTTTC
AGTAAAATGTATGGATCTATCTTTTCCTTGTCTTATATCTAGATCATGAGACTTG
20 ACTGAGGCTGTATCCTTATCCTCCATCCATCTATGGCGAACTATAGCCATGCAGC
TGACAACATTTTGCAAAATCTCTCGCCTCTAACAGCCTTTCTGAAACTGACTTCCT
TGGGTTTCATAATAGGAGTCAGCGTGGTGGGCAACCTCCTGATCTCCATTTTGCT
AGTGAAAGATAAGACCTTGCATAGAGCACCTTACTACTTCCTGTTGGATCTTTGC
TGTTCAGATATCCTCAGATCTGCAATTTTTTCCCATTGTGTTCACCTCTGTCAA
25 AAATGGTTCTACCTGGACTTATGGGACTCTGACTTGCAAAGTGATTGCCTTTCTG
GGGGTTTTGTCTGTTTCCACACTGCTTTCATGCTCTTCTGCATCAGTGTCAACAG
ATATTTAGCTATCGCCCATCACCGCTTCTATACAAAGAGGCTGACCTTTTGGACG
TGTCTGGCTGTGATCTGTATGGTGTGGACTCTGTCTGTGGCCATGGCATTTCCTCC
GGTTTTAGACGTGGGCACTTACTCATTATTAGGGAGGAAGATCAATGCACCTTC
30 CAACACCGCTCCTTCAGGGCTAATGATTCCTTAGGATTTATGCTGCTTCTTGCTCT
CATCCTCCTAGCCACACAGCTTGTCTACCTCAAGCTGATATTTTTCGTCCACGATC
GAAGAAAAATGAAGCCAGTCCAGTTTGTAGCAGCAGTCAGCCAGAACTGGACTT
TTCATGGTCCTGGAGCCAGTGGCCAGGCAGCTGCCAATTGGCTAGCAGGATTTGG
AAGGGGTCCCACACCACCCACCTTGCTGGGCATCAGGCAAAATGCAACACCAC
35 AGGCAGAAGAAGGCTATTGGTCTTAGACGAGTTCAAAATGGAGAAAAGAATCAG
CAGAATGTTCTATATAATGACTTTTCTGTTTCTAACCTTGTGGGGCCCCTACCTGG
TGGCCTGTTATTGGAGAGTTTTTGCAAGAGGGCCTGTAGTACCAGGGGGATTCT
AACAGCTGCTGTCTGGATGAGTTTTGCCCAAGCAGGAATCAATCCTTTTGTCTGC
ATTTTCTCAAACAGGGAGCTGAGGCGCTGTTTCAGCACAAACCCTTCTTTACTGCA
40 GAAAATCCAGGTTACCAAGGGAACCTTACTGTGTTATATGAGGGAGCATCTGTA
AATCTTTAGCCTTGTGAAAATAACCTTCTCTGCTGAGCAATTGTGGCCCATAGC
CATATTTTGAGAAGAAATTCAAGAATGGAATCAGCAGTTTTAAGGATTTGGGCA
ACATTCTGCAGTCTTTGCAATAGTTCACCTATAATCCTATTTTAAATCTCAGAGTG
ATCCTGCTGACTGCCAGCAAAGGTTTGTAAATTAAGAAGGGACTGAACCACTGCCC
45 TAAGTTTCTTTATGTGGTCAAAAATAAGATAATGAAAGTAGCAGGTGCTAAGTAT
CAGTGCTAAATGCTCTGTATGTCACTACATATGAAAAACATCAAAAAACAATTA
GCATTGGACATCTTAATAAATTAAGTTGACATGAGGTAAATGTGTTGATAAAAAC
TAATTTTAGAAGTTTGAAGACTTTAAACAG

SEQ ID NO: 406

>5710 BLOOD 024322.1 Incyte Unique

GGTGTCCACCCAGGGCTCCAGAGCCTGCTTCCTGGTTCCTCAAGGGCAGATATTG
GACACTCCTTATTTGTCACCAAAGGATGACTGTAGGCCGTGTGCTGGCCTTTCTTT
5 CTAAGAAGCTGCTTTGAGCTCCTGGACTCACCTGAGGCTCCCTGGGGGATGACAC
TCAGTTCTGTCACTGTCAAGGATGCAGAGAGCTGGTGGTAGGTGGGAAGCATGG
TGTCACCTGCCTGCTGACCACTGGACGCTGCTCCATGCTGAAGAAAAGTGACAG
TCTCCAGGGGACATTTTCAGCCATGCTGAAAGGGAGGCTGGCAGTGGTCATTTGGC
CCGGATCTAACATGGCACCTCGTCTCCACAGGGTAGTGGTGGCTGCTTCAACCCA
10 AATATTATTCAGCTGGTACTAACGACATTGTGCCAGCTGGGACTCTTGGGCTCT
GTGCCTGAGGGAAAATGTTTCACAACTAGTGGCTGCCCAATTGCTGCTGACCAGT
TGTCTTAGAAATGGTCAATTGGATTCAACTTTAGTCCTCTCCTTCCCCCTAAAAGC
GAA

15 SEQ ID NO: 407

>5773 BLOOD 000873.5 AF224741 g6980069 Human chloride channel protein 7 (CLCN7)
mRNA, complete cds. 0

AAACACGGGGGCAGCCGGCGCTTCCCGGCCGGTGTGCTCCGCGGCGGGCCATG
GCCAACGTCTCTAAGAAGGTGTCCTGGTCCGGCCGGGACCGGGACGACGAGGAG
20 GCGGCGCCGCTGCTGCGGAGGACGGCGCGGCCCGGCGGGGGGACGCCGCTGCTG
AACGGGGCTGGGCCTGGGGCTGCGCGCCAGTCACCACGTTCTGCGCTTTTCCGAG
TCGGACATATGAGCAGCGTGGAGCTGGATGATGAACTTTTGGACCCGGATATGG
AAGCTCCACATCCCTTCCCCAAGGAGATCCCAACAAACGAGAAGCTCCTGTCCCT
CAAGTATGAGAGCTTGGACTATGACAAGAGTGAGAACCAGCTGTTCTGGAGGA
25 GGAGCGGCGGATCAATCACACGGCCTTCCGGACGGTGGAGATCAAGCGCTGGGT
CATCTGCGCCCTCATTGGGATCCTCACGGGCCTCGTGGCCTGCTTCATTGACATC
GTGGTGGAAAACCTGGCTGGCCTCAAGTACAGGGTCATCAAGGGCAATATCGAC
AAGTTCACAGAGAAGGGCGGACTGTCCTTCTCCCTGTTGCTGTGGGCCACGCTGA
ACGCCGCCTTCGTGCTCGTGGGCTCTGTGATTGTGGCTTTCATAGAGCCGGTGGC
30 TGCTGGCAGCGGAATCCCCCAGATCAAGTGCTTCTCAACGGGGTGAAGATCCCC
CACGTGGTGCGGCTCAAGACGTTGGTGATCAAAGTGTCCGGTGTGATCCTGTCCG
TGGTCCGGGGCCTGGCCGTGGGAAAGGAAGGGCCGATGATCCACTCAGGTTTCA
TGATTGCCGCCGGGATCTCTCAGGGAAGGTCAACGTCACFGAAACGAGATTTC
AGATCTTCGAGTACTTCCGCAGAGACACAGAGGAAGCGGGACTTCGTCTCCGCAG
35 GGGCTGCGGCCGGAGTGTACGCGCGCTTTGGAGCCCCCGTGGGTGGGGTCTGTT
CAGCTTGGAGGAGGGTGCCTCCTTCTGGAACCAAGTTCCTGACCTGGAGGATCTTC
TTTGCTTCCATGATCTCCACGTTACCCCTGAATTTTGTTCAGCATTTACCACGG
GAACATGTGGGACCTGTCCAGCCCAGGCCTCATCAACTTCGGAAGGTTTGACTCG
GAGAAAATGGCCTACACGATCCACGAGATCCCGGTCTTCATCGCCATGGGCGTG
40 GTGGGCGGTGTGCTTGGAGCAGTGTTCAATGCCTTGAACACTGGCTGACCATGT
TTCGAATCAGGTACATCCACCGGCCCTGCCTGCAGGTGATTGAGGCCGTGCTGGT
GGCCGCCGTACGGGCCACAGTTGCCTTTCGTGCTGATCTACTCGTCGCGGGATTGC
CAGCCCCTGCAGGGGGGCTCCATGTCTACCCGCTGCAGCTCTTTTGTGCAGATG
GCGAGTACAACCTCCATGGCTGCGGCCTTCTTCAACACCCCGGAGAAGAGCGTGG
45 TGAGCCTCTTCCACGACCCGCCAGGCTCCTACAACCCCTGACCCTCGGCCTGTT
CACGCTGGTCTACTTCTTCTTGGCCTGCTGGACCTACGGGCTCACGGTGTCTGCC
GGGGTCTTCATCCCGTCCCTGCTCATCGGGGCTGCCTGGGGCCGGCTCTTTGGGA
TCTCCCTGTCTACCTACGGGGGGCGGCGATCTGGGCGGACCCCGGCAAATACGC
CCTGATGGGAGCTGCTGCCCAGCTGGGCGGGATTGTGCGGATGACACTGAGCCT

GACCGTCATCATGATGGAGGCCACCAGCAACGTGACCTACGGCTTCCCCATCATG
CTGGTGCTCATGACCGCCAAGATCGTGGGCGACGTCTTCATTGAGGGCCTGTACG
ACATGCACATTCAGCTGCAGAGTGTGCCCTTCCTGCACTGGGAGGCCCCGGTCAC
CTCACACTCACTCACTGCCAGGGAGGTGATGAGCACACCAGTGACCTGCCTGAG
5 GCGGCGTGAGAAGGTCGGCGTCATTGTGGACGTGCTGAGCGACACGGCGTCCAA
TCACAACGGCTTCCCCGTGGTGGAGCATGCCGATGACACCCAGCCTGCCCCGGCTC
CAGGGCCTGATCCTGCGCTCCCAGCTCATCGTTCTCCTAAAGCACAAAGGTGTTTG
TGGAGCGGTCCAACCTGGGCTGGTACAGCGGCGCCTGAGGCTGAAGGACTTCC
GAGACGCCTACCCGCGCTTCCACCCCATCCAGTCCATCCACGTGTCCCAGGACGA
10 GCGGGAGTGCACCATGGACCTCTCCGAGTTCATGAACCCCTCCCCCTACACGGTG
CCCCAGGAGGCGTCGCTCCACGGGTGTTCAAGCTGTTCCGGGGCCCTGGGCCTGC
GGCACCTGGTGGTGGTGGACAACCGCAATCAGGTTGTCGGGTGGTGACCAGGA
AGGACCTCGCCAGGTACCGCCTGGGAAAGAGAGGCTTGGAGGAGCTCTCGCTGG
CCCAGACGTGAGGCCCAGCCCTGCCATAATGGGCACTGGCGCTGGCACCCCGG
15 CCCTTCTGCATTTCTCCTCCCGGAGTCACTGGTTTCTCGGCCCAAACCATGCTCCCCA
GCAGTGGCAATGGCGAGCACCTGACAGCTGGGCGGGCAGGCGGCAGGCGCGGA
ACTGACCCTCTCGCGGGACTGACCCTGTTGTGGGCAGTGGTCTCCCCCTTGGCG
CCTCCTTGCGCAGGCCCAGCCTCCACTCTCCTCGTCTAGGTTTCTTTACCTCCAGG
GATCAGCTGTGTGTGTGTGACCTCCCTACCGGGCTATCGGCCTCTTGGGAGCCAG
20 CGGCAGGGCCGGCACCTGCGTGCTGTGCCCGTGTGCGTGAGACAGAGCCCTTG
CCCCTGCTGCTGCCCCGAGGGCTGCCCTGCCCTGGAAGGGCCCCCTCTGCCTCCAC
AGCAGTGGAGTCTTGGAGACTTGGGAGCTGCTTGGCCTCATTTTCAGCCATGAGC
AGACGGCCTGTGGTCCCTGGGCTGAGGCAAGGACTCGTAGCACCAGGGTTTGG
AGGCTGCGACCGCCCCGGAGAGGAGCTTCACTAGGCGCCACAGAGGAGCCCCA
25 CGTGCACTCCCCGGCCTGCATCCGGCTTGGGTACACAGGCCCAGAGGACTGGGG
TGA CTACAGGGCCCTGTGCTGTGATGTTGAGAGCTGAGAAAAACCTCCAAGGCC
CTGAGCCCCATGCCAGCCCTGCCTTGGTCCCCCAATCCCCAGAGCTTGGAGTCT
GGGCCCCACACCCAGCCCTGCCTTGGTCCCTGAGCCTCAGAGCGTGGAATTGCTG
CCCTGTGGACACTGGCTGGGAAGGCAGGTCTTCCCCTAGCACATGGGGACCCCG
30 GCCTCGAGGGTGACCTCCCTACCTTGCCCCTGCCAGCCACCAAGCGCAGGTGCAG
CGGGGGCCAGACTCCTGCCGGCCTCAGAGGACACCTGGCCCAGCACAGGCAGCT
AGAAGGGCCGGTGGGCACCGGGGCCGGGAAGCCCCACCTCACCACCTGAGGGC
CCCTGGGAGGCTCCTCTGGCCTGGCTGGGCTGGGTCTGGGGCCGCCACAGGCCCC
TCACGGGGCGGCAGAGGCAACTTCAGTGTCCCTGTTAGAGCAACACGGGTCCCT
35 CCGTGGGGGGCTGGGTGCGGCCCCCTGCCGTGTATTTCTCCCCAGGGAGTGGGG
CCTCCCCGGGAGCTGACGCCACCACCCTGCTTAGCCCTCACAGGGCCCCAAGGTG
TCCGAGTGTGTTGGGTCTGAACGCGAAATAAAGAAATCCTCTCAGCCCGCCTTTG
CCAGCGTCGTCCCTCCCACCCACCCAGACCACGTCCAACAGCCTGGGACTTTCG
GGACCCTGGGGTGGGGCACCGTGTGGAGTGAGACAGGCGTGAAAGACAGCGG
40 CTGCGGCCACCCAGGGCACCAAGCCACATCCTCTTCCTCGTCCCCGCCCTCAGCC
TCCCTCCTCTGGCTCCTGGCTGGTGGGTCTGGGGGCAAGGCAGAGGCGCTCCAGG
TGGAGGGGGGCGGGCCGGGTGCCACGCTGGGGTGACGCAAGAAGAAACTC
CCGGGCCTCAGAGTCGGCGCCGAAACCTAGGTCTGGGTTTCCCTCGTGGTGGTT
GTGTACTGAGGACCTGGAAGTGATCATATTCTGGATCTCTTCGGTTAAATAAAAT
45 CAGCGGTTAGGATTCACAAAAA

SEQ ID NO: 408

>5777 BLOOD 335198.1 X89066.1 g1370118 Human mRNA for TRPC1 protein. 0

GAGGCAGCAGTGGGAACGACTCATCCTTTTTCCAGCCCTGGGGCGTGGCTGGGGT
CGGGGTCGGGGTCGGGGCCGGTGGGGGCCCGCCCCCGTCTCCTGGCCTGCCCC
TTCATGGGCCGCGATGATGGCGGCCCTGTACCCGAGCACGGACCTCTCGGGCGCC
TCCTCCTCCTCCCTGCCTTCCTCTCCATCCTCTTCCTCGCCGAACGAGGTGATGGC
5 GCTGAAGGATGTGCGGGAGGTGAAGGAGGAGAATACGCTGAATGAGAAGCTTTT
CTTGCTGGCGTGCGACAAGGGTGACTATTATATGGTTAAAAAGATTTTGGAGGAA
AACAGTTCAGGTGACTTGAACATAAATTGCGTAGATGTGCTTGGGAGAAATGCT
GTTACCATAACTATTGAAAACGAAAACCTTGGATATACTGCAGCTTCTTTTGGACT
ACGGTTGTGAGTCTGCAGATGCACCTTTTGGTGGCAATCGACTCTGAAGTAGTGGG
10 AGCTGTTGATATACTACTTAATCATCGACCAAAACGATCATCAAGACCAACTATA
GTAAACTAATGGAACGAATTCAGAATCCTGAGTATTCAACAACATATGGATGTTG
CACCTGTCATTTTAGCTGCTCATCGTAACAACATATGAAATTCCTACAATGCTCTTA
AAACAGGATGTATCTCTACCCAAGCCCCATGCAGTTGGCTGTGAATGCACATTGT
GTTCTGCAAAAAACAAAAAGGATAGCCTCCGGCATTCCAGGTTTCGTCTTGATAT
15 ATATCGATGTTTGGCCAGTCCAGCTCTAATAATGTTAACAGAGGAGGATCCAATT
CTGAGAGCATTGAACTTAGTGCTGATTAAAAAGAACTAAGTCTTGTGGAGGTGG
AATTCAGGAATGATTATGAGGAACTAGCCCGGCAATGTAAAATGTTTGCTAAGG
ATTTACTTGACAAAGCCCGGAATTCTCGTGAATTGGAAGTTATTCTAAACCATAC
GTCTAGTGACGAGCCTCTTGACAAACGGGGATTATTAGAAGAAAGAATGAATTT
20 AAGTCGTCTAAAACCTTGCTATCAAAATATAACCAGAAAGAGTTTGTCTCCAGTCT
AACTGCCAGCAGTTCCTGAACACTGTTTGGTTTGGACAGATGTCAGGTTACCGAC
GCAAGCCACCTGTAAAGAGATAATGACTGTTTGGACAGTAGGCATCTTTTGGCC
AGTTTGTGCACTTTGTTATTTGATAGCTCCCAAATCTCAGTTTGGCAGAATCATTCT
ACACAECTTTTATGAAATTTATCATTTCATGGAGCATCATATTTACATTTCTGCTG
25 TTGCTTAATCTATACTCTCTTGTCTACAATGAGGATAAGAAAAACACAATGGGGC
CAGCCCTTGAAAGAATAGACTATCTTCTTATTCTGTGGATTATTGGGATGATTTG
GTCAGACATTAAAAGACTCTGGTATGAAGGGTTGGAAGACTTTTTAGAAGAATCT
CGTAATCAACTCAGTTTTGTGATGAATTCTCTTTATTTGGCAACCTTTGCCCTCAA
AGTGGTTGCTCACAACAAGTTTCATGATTTTGTGCTGATCGGAAGGATTGGGATGCA
30 TTCCATCCTACACTGGTGGCAGAAGGGCTTTTTGCATTTGCAAATGTTCTAAGTTA
TCTTCGTCTCTTTTTTATGTATACAACCAGCTCTATCTTGGGTCCATTACAGATTTCT
AATGGGACAGATGTTACAAGATTTTGGAAAATTTCTTGGGATGTTTCTTCTTGTTT
TGTTTTCTTTCACAATTGGACTGACACAACCTGTATGATAAAGGATATACTTCAAA
GGAGCAGAAGGACTGTGTAGGCATCTTCTGTGAACAGCAAAGCAATGATACCTT
35 CCATTCGTTTATTGGGCACCTGCTTTGCTTTGTTCTGGTATATTTTCTCCTTAGCGC
ATGTGGGCAATCTTTGTGACAAAGATTTAGCTATGGAGAAGAACTGCAGTCCTTTG
TGGGAGCTGTCATTGTTGGTACATACAATGTCGTGGTTGTGATTGTGCTTACCAA
ACTGCTGGTGGCAATGCTTCATAAAAGCTTTCAGTTGATAGCAAATCATGAAGAC
AAAGAATGGAAGTTTGTGCTCGAGCAAAATTATGGCTTAGCTACTTTGATGACAAAT
40 GTACGTTACCTCCACCTTTCAACATCATTCCCTCACCAAAGACTATCTGCTATATG
ATTAGTAGCCTCAGTAAGTGGATTTGCTCTCATACATCAAAAGGCAAGGTCAAAC
GGCAAAACAGTTTAAAGGAATGGAGGAATTTGAAACAGAAGAGAGATGAAAAC
TATCAAAAAGTGATGTGCTGCCTAGTGCATCGTTACTTGACTTCCATGAGACAGA
AGATGCAAAGTACAGATCAGGCAACTGTGGAAAATCTAAACGAAGTGCGCCAAG
45 ATCTGTCAAATTTCCGAAATGAAATAAGGGATTTACTTGGCTTTTCGGACTTCTAA
ATATGCTATGTTTTATCCAAGAAATTAACCATTTTCTAAATCATGGAGCGAATAA
TTTTCAATAACAGATCCAAAAGACTATATTGCATAACTTGCAATGAAATTAATGA
GATATATATTGAAATAAAGAATTATGTAAAAGCCATTCTTTAAAATATTTATAGC
ATAAATATATGTTATGTAAAGTGTGTATATAGAATTAGTTTTTTAAACCTTCTGTT

AGTGGCTTTTTGCAGAAGCAAAACAGATTAAGTAGATAGATTTTGTAGCATGCT
 GCTTGGTTTTCTTACTTAGTGCTTTAAATGTTTTTTTTATGTTTAAGAGGGGCA
 GTTATAAATGGACACATTGCCCAGAATGTTTGTAAATGAAGACCAGCAAATGT
 AGGCTGATCTCCTTCACAGGATACACTTGAAATATAGAAGTTATGTTTTAAATAT
 5 CTCTGTTTTAGGAGTTCACATATAGTTCAGCATTTATTGTTTAGGAGTATAATTTT
 ATTTTATCTAAAATAATAGTCTATTTTTCTTTTGTATTTTGTATAATCTTAAGCA
 ACAAAGAAAAAACCTAATATTTGAATCTATTTATGTCTTTCAATTTAAATTCACT
 TCAGTTTTTGTATTGTAAATATATTTACTTTTACATGGTTATAATCACTTTATATTT
 TTAATGTTTTTTTCACTTAATATTTTATATATACATTTCCATGTATTGATGTAGTTA
 10 GTCCACATTTAAATTTTTATAGAATTATATAGTTTTTGAAAAATACAGTCAGTAG
 ATGTTTTATTTTTAGCTATTCAGTTATGTTTATAAGTTTGCATAGCTACTTCTCGA
 CATTTGGTTTGTTTAATTTTTTTGTATCATAATAGTCCTATTTTTTTTTCAAGTTG
 GAGTGAATGTTTTAGTTTTAAGATAGATAGGAGACACTTTTTTATCACATGTAG
 TCACAACCTGTTTTGTTTTGTAAACATAGGAAGTCTCTTAATGCAATGATTTG
 15 TTTTATATTTGGACTAAGGTTCTTGAGCTTATCTCCCAAGGTACTTTCCATAATTT
 AACACAGCTTCTATAAAAGTGACTTCATGCTTACTTGTGGATCATTCTTGCTGCTT
 AAGATGAAAAGCATTGGTTTTTTAAATTAGAGAATAAAATATGTATTTAAATTT
 TTGGTGTGTTACATAAAGGGATGTAGCTAAATGTTTTCATAGGCTATTATATA
 TTCTCGCAGCATTTCAGTTAAGAGGATATTAGGTATATAATTCTCTTCTTAACCG
 20 AATGTCAGATGGTCTTACGCCACAGGGTGCAGGTAACCTTGGTCTGTAAGCACC
 ACCGATCCAGGGATCATTGTCTAAATAGGTACTATTGTTTGTTCATCTTGCTTT
 TGCATTTTTATTTTTAATTTCCAAATTTAAAGTGTTCCCTCTTTGGGGCAAATCT
 TATAAAAATGTTTATTGTAAAGTTATATATTTTGTCTACGATGGGATTATGCACTT
 CCCAATTGGGATTTTACATCTGGATTTTATAGTCAFTCTAAAAACACCTAATTATT
 25 AAAACATTATAGAGTGCCTACTGTATGCATGAGTTGAGTTGCTTCTGAGGTACA
 TTTTGAATGACAGCATATTGTAGAAAAAAAAGGTGAATAAAATTTGACATTAG
 ATTATAAAAAAAAAGGAATTC

SEQ ID NO: 409

30 >5806 BLOOD 978358.7 U73304 g1657840 Human CB1 cannabinoid receptor (CNR1)
 gene, complete cds. 0
 CTTCTGTTTCTCACCATTTCGGCTTATTTGTTTTCCCTCCTCTTAGGATTGCCCCCT
 GTGGGTCACCTTCTCAGTCATTTGAGCTCAGCCTAATCAAAGACTGAGGTTATG
 AAGTCGATCCTAGATGGCCTTGCAGATAACACCTTCGGCACCATCACCCTGACC
 35 TCCTGTACGTGGGCTCAAATGACATTTCAGTACGAAGACATCAAAGGTGACATGG
 CATCCAAATTAGGGTACTTCCCACAGAAATCCCTTTAACTTCTTTAGGGGAAG
 TCCCTTCCAAGAGAAGATGACTGCGGGAGACAACCCCAAGCTAGTCCCAGCAGA
 CCAGGTGAACATTACAGAATTTTACAACAAGTCTCTCTCGTCCTTCAAGGAGAAT
 GAGGAGAACATCCAGTGTGGGGAGAACTTCATGGACATAGAGTGTTCATGGTC
 40 CTGAACCCCAAGCAGCAGCTGGCCATTGCAGTCCTGTCCCTCACGCTGGGCACCT
 TCACGGTCTTGAGAACCTCCTGGTGTCTGTGCGTCATCCTCCACTCCCGCAGCCT
 CCGCTGCAGGCCTTCTTACCCTTCATCGGCAGCCTGGCGGTGGCAGACCTCCTG
 GGGAGTGTCATTTTGTCTACAGCTTCATTGACTTCCACGTGTTCACCGCAAAG
 ATAGCCGCAACGTGTTTCTGTTCAAACCTGGGTGGGGTCACGGCCTCCTTCACTGC
 45 CTCCGTGGGCAGCCTGTTCTCACAGCCATCGACAGGTACATATCCATTACAGG
 CCCCTGGCCTATAAGAGGATTGTCACCAGGCCCAAGGCCGTGGTGGCGTTTTGCC
 TGATGTGGACCATAGCCATTGTGATCGCCGTGCTGCCTCTCCTGGGCTGGAAGT
 CGAGAACTGCAATCTGTTTGCTCAGACATTTTCCCACACATTGATGAAACCTAC
 CTGATGTTCTGGATCGGGGTACCAGCGTACTGCTTCTGTTTCATCGTGTATGCGTA

CATGTATATTCTCTGGAAGGCTCACAGCCACGCCGTCCGCATGATTCAGCGTGGC
ACCCAGAAGAGCATCATCATCCACACGTCTGAGGATGGGAAGGTACAGGTGACC
CGGCCAGACCAAGCCCGCATGGACATTAGGTTAGCCAAGACCCTGGTCCTGATC
CTGGTGGTGTGATCATCTGCTGGGGCCCTCTGCTTGCAATCATGGTGTATGATGT
5 CTTTGGGAAGATGAACAAGCTCATTAAGACGGTGTTCGATTCTGCAGTATGCTC
TGCCTGCTGAACCTCCACCGTGAACCCCATCATCTATGCTCTGAGGAGTAAGGACC
TGCGACACGCTTTCCGGAGCATGTTTCCCTCTTGTGAAGGCACTGCGCAGCCTCT
GGATAACAGCATGGGGGACTCGGACTGCCTGCACAAACACGCAAACAATGCAGC
CAGTGTTCACAGGGCCGCGAGAAAGCTGCATCAAGAGCACAGTCAAGATTGCCAA
10 GGTAACCATGTCTGTGTCCACAGACACGTCTGCCGAGGCTCTGTGAGCCTGATGC
CTCCCTGGCAGCACAGGAAAAGAATTTTTTTTTTAAAGCTCAAAATCTAGAAGAG
TCTATTGTCTCCTTGGTTATATTTTTTTAACTTTACCATGCTCAATGAAAAGGTGA
TTGTCACCATGATCACTTATCAGTTTGCTAATGTTTCCATAGTTTAGGTACTCAAA
CTCCATTCTCCAGGGGTTTACAGTGAAGAAAGCCTGTTGTTTAAAGTACTGAACG
15 ATCCTTCAAAGTCTCAATGAAATAGGAGGGAAACCTTTGGCTACACAATTGGAA
GTCTAAGAACCCATGGAAAAATGCCATCAAATGAATAATGCCTTGTAACCACAA
CTTTCATATAATGTGAAATGTAAGTGTCCGTAGTATCAGAGATGTCCATTTTTAC
AAGTTATAGTACTAGAGATATTTTGTAAGTGTATTATGTCCTGTGAGATGTGTA
TCAGTGTATGTGCTATTAATATTTGTTTAGTTTACGCAAACTGAAAGGTAGAC
20 TTTTATGAGAACAAATGGACAAGCAGTGGATACGTGTCAATGTGTGCACTTTTTTT
CTATATTATTGCCCATGATATAACTTTAGAAATAAACCTTAATATTTCTTCAAATA
TCTCTATTTAATTTTGACACTGAAATAACCGTAAAGGTTATTTTTCTGTACCTC
AACAAGAAGAATTTGAAGAGTTCAAAATATTGAGCAGAATTCATTCATACTTAA
AAAATTTATTAGCCCTGCATTTTCATAGGAAGACACATTATCTTCTGGAATATAGCT
25 GTTCTAATGGATTATAATCAGAATGGAAGAGAGAAAGCATATTGACTTTTTTTGA
GCGACATCTCTGACTTTCTTTAGTCTTTAGCTATTACTGGATCTCTTAAGACAGCA
TGTGTTAATCTTAATGTATATCGTTATCACTGTGCAGTTGCTGTTTACTTGAATAG
TATTGTGTTCTATATTCCAGGTTTAAAGTAGATTTTCATGCCTGGGTGGCCAAACA
ACAGTCTTCATTTTTTTTTAATTGAAAAGAAGTAGTGTCTGGATCAGTAAAATTAT
30 ACTGTGTGTGAGTGTGAATATAAATGTGTGTATGTGTGTTTCTGTCCGTAAGTGT
ACAGTAATGTCATAAAGTGAGAAAAGTGTGACCAAGTATAAACTTTTACCACCTG
CTGCACTCTTGCACATGGATTTCAGTTTCTAAAATTGAGTTCTTCTGTAACTTGT
TGATAAAAATACTGACTCCAACCATTCAAAAATTTACCCCATCCCTCCTTAAGA
GATTGGATCAAGTATTTACTAAATTGACCTTTAGGTATTACACAAGACCAGTGCTT
35 AGCAAAAAATAATGACAGGCATCCAAGGAAGGGATGTATTTGTAGTGTTATTGC
CAGGAAAGGAGAGTACTTTGGTTTCTGAGCACCGAATATTGAGCAATATGTCAGT
CACTAAAAGGAAGACAGTTCTACAGAAAAACAATGGTAACATTTTTCAATAGCG
TGTGTAGATAGTATGCACTATATACATCACGTTAAAGTAGGACTATCACACCCAG
CCCATGTGGCTAAAAAAGCTGAATCAGACAGTGGATGAGACACACAACGGCAGT
40 GAAGAACCGATACACTTGGCATTGACGTCTAGCTATGCTGTATCTGTGCTTTGCC
CACATGCCCTTGGTGACAGCTGAGCACCCAGCTCTGTCTTGGTAGGTTTGGGCTA
AGGAACAAATCTCTCCTTTGCTCGTGGTTAGCAAGATACACTCAAGCATGAAGAT
AAACACAGCTGCTTTCTTCTACACCCGGTCTCATGCTCCTTAATGGCGCCATGGG
TGCTTGTGGGCTTTTTCCAGTAAGGAATGATATTGCTGAAGAATCTACTTAAC
45 CCTGACAAATTTTAATTATAATCTCTTCTTATACAGATAAAACATGACTCCTACA
AGGCCCAAGGTTTACATAGTCTGAAGTGAAGTACAGAGCTGGCATCTATCTGGT
GATTTCTAGCTCTCGAGATACCAAGCAGCCTGATGGGGCAGTTCCCCTTCTTAC
GGTTCACGCTCTAAGGCAGGATGTGGCTTATGAGATACTTTGCATTGTCTGTCTG
CACACCTTGAATCTGCCTGCTGGCTCCCTTACTTTACCTCTCTGTATGTGCAGAT

GAAGGCTCAGGGTGCTAGAGGATTAGTAAGATCTCTTTCTAAAGACAGGAGAGA
 TTATTTACAAGAAGAAGCTCACCAGGGTTTAGTTTGCATTTAAGAATTGCCAGTCT
 TTTGTCCTGCATCATCTTGAACATTAATCCACATGTTTCAGAGCTCACCAGGCAGT
 ACCAATGCTCTTTTCACAGCTATGAAGAGCTAGAGAAATTCTTGTTATGGTAGAA
 5 AAATTTACGATTCATTTTTGAACTGCATTTGTGCGTATGCAGTGTAGATTTTAT
 AGTGTGTTGTGCTTTCAAGATCTAAATCATATATAATAAATTAAGGGACAATGGG
 GCTGACAGCACTAACTTGGTGCTTATTGATATTCTAAGAAATATCTGTGAAATA
 TCATCACGTATGTTATACAACCTTCATTTAAAAAGGTTTAAAACTAGTTAGATTC
 ACTTTGACACTTTTCATATCATTTCTTAACCCAAGTGACGAAAACATTGTCCCCAA
 10 TGAATATACTCATTAGAATTACCATTTGTTAATATCACTCATTAAATTAACCCATA
 ATTAGATCCATTAATTTAAATGATTTAAATTTAAGTAAGTTTTATAAGGTCTGAC
 ATCAGAGGTATCTTACTTTCTCTGAGGATGATGTACTTGCCCTGACCATGCATTT
 TACCATCACACATGTTTCAAGAAAGGGCCAAATTCCCAACCTGCTCATTTTTTTTTT
 ATCAGAGTCATGATGAATCAGTCCTAGAATGTTTCATTTGCACAAGTAGGGCTGC
 15 CTCCAAGAGGAACCTCTGATTTATTTTGTATGAAATATATGTGAAAGGATATGAA
 TCTGAGAGATGCTGTAGACATCTGTCCTACACTTGAGATGATTTCCAAGCCTCTC
 TGGCACTTTGAGTTAAGTCTATCTGGTATTAAATGCCAAGGACCTTTTGCTGCCTA
 AATCCACTCTGCAGGAAATAGGCCCAACCACCAGATGAGAATTAGGCCCTGGAT
 GAGTAGCGCTATAGTTACTGTCTGTTGATTAATTTCTGCCATTTTCATGTCCATAA
 20 AAGAGACCACCCATATCATGCACACAATTAGATTTCTCACACTCTAACTGTATAT
 TTGTATGATATTTTAAAAATCTCCTAAATGCTGGGCAATGGCTATTAACAATTAATT
 GTCTTGCACTGGGCCTTCTGATGAAATGTTAAACAATGCCTATTGTAATATAGAAA
 AAAACATTCTATCTACTGATTTGGGCTGAATGTATGTAAATAGGTTTCTAAAAAG
 TCAGATGTTTGAGCAGTGGCCTACAAATCAGTAATTTTCGGATGGGAGAGTTTCT
 25 TTACATTGCCGTGGCATCTTAAAAGCTATCTTCATGTAAATTGACTGTACTAGGC
 CTACTGGGGATCAGAGTTCCCAAGAAAGGAAACCTTTTCTTGATCTGGATTCAA
 ATTTATTTCCAATGTTTCAAGCGGGAAACATGACTCTTTATTGTCTGTAAATCTAA
 CATTATTACTTTTCTCTTAGAAGAATATTGTATTGTTAGATGTTTGTGAGCTGG
 TAACATCGTTGCAACCACTGCAATATCTTCGTTAGTAATCTGTATAATACTTTGTA
 30 TACAAGTACTGGTAAGATTGTTATTAAATGTAGCTTCAGTCATTAAATTACTATA
 GCAAAGTAGTACTTCTTCTGTAATATTTACAATGTATTAAGCCCACAGTATATTTT
 ATTTCAATGTAATTAAGCTGTTAACTTATTCAAAGAGAAAAACATCTCATCATGTC
 TATTGTCCAAAGTTACCTGGAATCAAATAAAAAATTCTAGATTACCATGAAGAAC
 ATAAAAATGCCTTTGAACCTCTGCCATTATTCACAGTCTGATGGCAAAATACTAAGG
 35 ATTTAATTTCTAAAAGATTGCTGAACATAATTTATTCCTCAAAAAGCACTAATGAC
 TACTTGAAAAGTGGGGACATATTGGATT

SEQ ID NO: 410

>5824 BLOOD 228699.5 X92106 g1321857 Human mRNA for bleomycin hydrolase. 0

40 CCGAGCCGGTTTCCTTTTCCGGCGCTCCGGGTGCGAGAGACAGGTCGGGCCCCC
 TAGGCAGCGAGCCGCAGCGCAATCCCGGCGCTCGCCCAAGGACCCTGGAAGCTA
 CCGTTACCCCGCCGGGCAGCGTGGGCGCCATGAGCAGCTCGGGACTGAATTCGG
 AGAAGGTAGCTGCTCTGATACAGAACTGAATTCGACCCCAAGTTCGTACTTGC
 CCAGAATGTCGGGACCACCCACGACCTGCTGGACATCTGTCTGAAGCGGGCCAC
 45 GGTGCAGCGCGCGCAGCATGTGTTCCAGCACGCCGTGCCCCAGGAGGGCAAGCC
 AATACCAACCAGAAGAGCTCAGGGCGATGCTGGATCTTTTCTTGCTGAATGTT
 ATGAGGCTTCCATTTCATGAAAAAGTTAAATATTGAAGAATTTGAGTTTAGCCAAT
 CTTACCTGTTTTTTTTGGGACAAGGTTGAACGCTGTTATTTCTTCTTGAGTGCTTTT
 GTGGACACAGCCCAGAGAAAGGAGCCTGAGGATGGGAGGCTGGTGCAGTTTTTG

CTTATGAACCCTGCAAATGATGGTGGCCAATGGGATATGCTTGTTAATATTGTTG
AAAAATATGGTGTATCCCTAAGAAATGCTTCCCTGAATCTTATACAACAGAGGC
AACCAGAAGGATGAATGATATTCTGAATCACAAGATGAGAGAATTCTGTATACG
ACTGCGGAACCTGGTACACAGTGGAGCAACGAAAGGAGAAATCTCGGCCACACA
5 GGACGTCATGATGGAGGAGATATTCCGAGTGGTGTGCATCTGTTTGGGTAATCCA
CCAGAGACATTCACCTGGGAATATCGAGACAAAGATAAAAAATTATCAGAAAATT
GGCCCCATAACACCCTTGGAGTTTTACAGGGAACATGTCAAGCCACTCTTCAATA
TGGAAGATAAGATTTGTTTAGTGAATGACCCTAGGCCCCAGCACAAGTACAACA
AACTTTACACAGTGAATACTTAAGCAATATGGTTGGAGGGAGAAAACTCTAT
10 ACAACAACCAGCCCATTGACTTCCTGAAAAAGATGGTTGCTGCCTCCATCAAAGA
TGGAGAGGCTGTGTGGTTTGGCTGTGATGTTGGAAAACACTTCAATAGCAAGCTG
GGCCTCAGTGACATGAATCTCTATGACCATGAGTTAGTGTTTGGTGTCTCCTTGA
AGAACATGAATAAAGCGGAGAGGCTGACTTTTGGTGAGTCACTTATGACCCACG
CCATGACCTTCACTGCTGTCTCAGAGAAGGATGATCAGGATGGTGCTTTCACAAA
15 ATGGAGAGTGGAGAATTCATGGGGTGAAGACCATGGCCACAAAGGTTACCTGTG
CATGACAGATGAGTGGTTCTCTGAGTATGTCTACGAAGTGGTGGTGGACAGGAA
GCATGTCCCTGAAGAGGTGCTAGCTGTGTTAGAGCAGGAACCCATTATCCTGCCA
GCATGGGACCCCATGGGAGCTTTGGCTGAGTGATACTGCCCTCCAGCTCTTTCCT
CCTTCCATGGAACCTGACGTAGCTGCAAAGGACAGATCCAGGGACTGAAGCCAA
20 AGTTATGCAAGGGACTGTGTGTTGCCACAGGACACAGTCAGATTTCCAGTCTCCA
CCAGGAACCTCTTCAGAAAGTGTGCTTTATGCTGAAACAGAATACTGTAAAGGA
AAAAAAAGAGGGGGGAAGATCAGGTCATACTATCTACTCTCCTCATCTCTAACA
GCTCAGGATCTCTTAGCATTTTAATTAAGATGTAATTTGTTTGTCTTTAACTGTCAAA
AAGTTTGGTTCTGTGTCTGTGTTTAATAAGACGAGAGGACGAGCGATTGAGGTG
25 TATGGAGAGAAAACAGACCTAATGCTCCTTGTTTCTAGAGTAGAGTGGAGGGAG
GGTGGCCTAAGAGTTGAGCTCTCGGAACCTGCATGCTGCTGGACAGTATCACTGTC
TTTCTAGATGGCAGTCACTGAATTCCATTTTTTCAAGGTAATTTCTTGTGCCTCT
AATAGCCCAAGAATGGGAGGTTGATCAGATCTGACATGATTCTTCTCTGTTCTGA
ACTGTGGGGTGTGCACATCTCTGCTTGAGTCAGGTTTGAAGTAGAGGCTTAGAGAC
30 AGTTGGGTGAGAACAACCAAAATCTTATCATGGTCTCAGTCATAATCATTAGGGG
GAACTCTAGCCAAATGGTTTAACTTCTGCCTGTGGAACCTGGGGATTGGGTGGGCA
GGAAAAGGTGATATCCATTCTTCTGATAACTAGATGGTGCTGAGAAGCTTTTGA
ATAAAAACCTTGCTAAATGAGAATAAGCTG

35 SEQ ID NO: 411

>5836 BLOOD 343991.1 J02960 g178203 Human beta-2-adrenergic receptor gene, complete cds. 0

CTTTTGCTTTCTATAGCTTCAAAATGTTCTTAATGTTAAGACATTCTTAATACTCT
GAACCATATGAATTTGCCATTTTGGTAAGTCACAGACGCCAGATGGTGGCAATTT
40 CACATGGCACAACCCGAAAGATTAAACAACTATCCAGCAGATGAAAGGATTTTT
TTTAGTTTCATTGGGTTTACTGAAGAAATTTGTTTGAATTCTCATTGCATCTCCAGT
TCAACAGATAATGAGTGAGTGATGCCACACTCTCAAGAGTTAAAAACAAAACAA
CAAAAAAATTAACAAAGCACACAACTTTCTCTCTCTGTCCCAAAATACATAC
TTGCATACCCCCGCTCCAGATAAAATCCAAAGGGTAAAACTGTCTTCATGCCTGC
45 AAATTCCTAAGGAGGGGCACCTAAAGTACTTGACAGCGAGTGTGCTGAGGAAATC
GGCAGCTGTTGAAGTCACCTCCTGTGCTCTTGCCAAATGTTTGAAAGGGGAATACA
CTGGGTTACCGGTGTATGTTGGGAGGGGAGCATTATCAGTGCTCGGGTGAGGC
AAGTTCGGAGTACCCAGATGGAGACATCCGTGTCTGTGTGCTCTGGATGCCTCC
AAGCCAGCGTGTGTTTACTTTCTGTGTGTGTACCATGTCTTTGTGCTTCTGGGTG

CTTCTGTGTTTGTCTTCTGGCCGCGTTTCTGTGTTGGACAGGGGTGACTTTGTGCCG
GATGGCTTCTGTGTGAGAGCGCGCGAGTGTGCATGTCGGTGAGCTGGGAGGG
TGTGTCTCAGTGTCTATGGCTGTGGTTTCGGTATAAGTCTGAGCATGTCTGCCAGG
GTGTATTTGTGCCTGTATGTGCGTGCCTCGGTGGGCACTCTCGTTTCCTTCCGAAT
5 GTGGGGCAGTGCCGGTGTGCTGCCCTCTGCCTTGAGACCTCAAGCCGCGCAGGGCG
CCCAGGGCAGGCAGGTAGCGGCCACAGAAGAGCCAAAAGCTCCCGGGTTGGCTG
GTAAGGACACCACCTCCAGCTTTAGCCCTCTGGGGCCAGCCAGGGTAGCCGGGA
AGCAGTGGTGGCCCGCCCTCCAGGGAGCAGTTGGGGCCCCGCCCCGGGCCAGCCCC
AGGAGAAGGAGGGCGAGGGGAGGGGAGGGGAAAGGGGAGGAGTGCCTCGCCCCCT
10 TCGCGGCTGCCGGCGTGCCATTGGCCGAAAGTTCCCGTACGTCACGGCGAGGGC
AGTTCCCCTAAAGTCCTGTGCACATAACGGGCAGAACGCACTGCGAAGCGGCTT
CTTCAGAGCACGGGGCTGGAAGTGGCAGGCACCGCGAGCCCCCTAGCACCCGACA
AGCTGAGTGTGCAGGACGAGTCCCCACCACACCCACACCACAGCCGCTGAATGA
GGCTTCCAGGGCGTCCGCTCGCGGGCCCGCAGAGCCCCGCGGTGGGGTCCGCTGCT
15 GAGGCGCCCCCAGCCAGTGCCTTACCTGCCAGACTGCGCGCCATGGGGCAACC
CGGGAACGGCAGCGCCTTCTTGCTGGCACCCAATAGAAGCCATGCGCCGGACCA
CGACGTCACGCAGCAAAGGGACGAGGTGTGGGTGGTGGGCATGGGCATCGTCAT
GTCTCTCATCGTCCTGGCCATCGTGTTTGGCAATGTGCTGGTCATCACAGCCATTG
CCAAGTTCGAGCGTCTGCAGACGGTCACCAACTACTTCATCACTTCACTGGCCTG
20 TGCTGATCTGGTCATGGGCCTGGCAGTGGTGCCCTTTGGGGCCGCCATATTCTT
ATGAAAATGTGGACTTTTGGCAACTTCTGGTGCGAGTTTGGACTTCCATTGATG
TGCTGTGCGTCACGGCCAGCATTGAGACCTGTGCGTGATCGCAGTGGATCGCTA
CTTGGCATTACTTCACCTTCAAGTACCAGAGCCTGCTGACCAAGAATAAGGCC
CGGGTGATCATTCTGATGGTGTGGATTGTGTCAGGCCTTACCTCCTTCTTGCCCAT
25 TCAGATGCACTGGTACCGGGCCACCCACCAGGAAGCCATCAACTGCTATGCCAA
TGAGACCTGCTGTGACTTCTTCACGAACCAAGCCTATGCCATTGCCTCTTCCATCG
TGTCCTTCTACGTTCCCCTGGTGATCATGGTCTTCGTCTACTCCAGGGTCTTTTCA
GAGGCCAAAAGGCAGCTCCAGAAGATTGACAAATCTGAGGGCCGCTTCCATGTC
CAGAACCTTAGCCAGGTGGAGCAGGATGGGCGGACGGGGCATGGACTCCGCAGA
30 TCTTCCAAGTTCTGCTTGAAGGAGCACAAAGCCCTCAAGACGTTAGGCATCATCA
TGGGCACTTTTACCCTCTGCTGGCTGCCCTTCTTCATCGTTAACATTGTGCATGTG
ATCCAGGATAACCTCATCCGTAAGGAAGTTTACATCCTCCTAAATTGGATAGGCT
ATGTCAATTCTGGTTTCAATCCCCTTATCTACTGCCGGAGCCCAGATTTCAAGGATT
GCCTTCCAGGAGCTTCTGTGCCTGCGCAGGTCTTCTTTGAAGGCCTATGGGAATG
35 GCTACTCCAGCAACGGCAACACAGGGGAGCAGAGTGGATATCACGTGGAACAGG
AGAAAGAAAATAAACTGCTGTGTGAAGACCTCCAGGCACGGAAGACTTTGTGG
GCCATCAAGGTACTGTGCCTAGCGATAACATTGATTCAAGGGAGGAATTGTA
GTACAAATGACTCACTGCTGTAAAGCAGTTTTTCTACTTTTAAAGACCCCCCCCC
GCCCAACAGAACACTAAACAGACTATTTAACTTGAGGGTAATAAACTTAGAATA
40 AAATTGTAAAATTGTATAGAGATATGCAGAAGGAAGGGCATCCTTCTGCCTTTTT
TATTTTTTTAAGCTGTAAAAAGAGAGAAAACCTTATTTGAGTGATTATTTGTTATTT
GTACAGTTCAGTTCCTCTTTGCATGGAATTTGTAAGTTTATGTCTAAAGAGCTTTA
GTCCTAGAGGACCTGAGTCTGCTATATTTTTCATGACTTTTCCATGTATCTACCTCA
CTATTCAAGTATTAGGGGTAATATATTGCTGCTGGTAATTTGTATCTGAAGGAGA
45 TTTTCCTTCCCTACACCCTTGGACTTGAGGATTTTGGAGTATCTCGGACCTTTCAGCT
GTGAACATGGACTCTTCCCCCACTCCTCTTATTTGCTCACACGGGGTATTTTAGGC
AGGGATTTGAGGAGCAGCTTCAGTTGTTTTCCCGAGCAAAGTCTAAAGTTTACAG
TAAATAAATTGTTTGACCATGCCTTCATTGCACCTGTTTCTCCAAAACCCCTTGAC
TGGAGTGCTGTTGCCTCCCCCACTGGAAACCGCAGGTAACCTACTTGAATTACTG

CCCATGACTTAATGTAGAATGATACAAGAATGACATGCACAGATTGCTTAACCCCT
TTCATTTGCCTTTGAGTCTGCTGCTGCAAAGCTGCATCTCTCCTGACACTTGTGCC
CCAAATCAGTTCTGCCTGCTCTTAGTATAGCTCAACTCTCCCTATGGTTATTGTTT
TGTGTTGTTACCTCAGAAACACTGACTCACAGAAGCGGAGTTAAGGGGATATGTT
5 TTTTCTCTCCACGTGCACCCACCACCCACCTTCCAGTTCTACTTGTTCAAAAC
GTTTATATTTCTGTCTTGGCCATGTGTTTACAG

SEQ ID NO: 412

>5885 BLOOD 345860.21 X16832 g29709 Human mRNA for cathepsin H (EC 3.4.22.16). 0

10 CGCTCCCGCCGCTCCTCCACGCTCGTGCCGCCCCCCCCCGCGCTCCCAGTTGACGC
TCTGGGCCGCCACCTCCGCGGACCCTGCAGCGCAAGAGCCAAGCCGCCAGCGCT
GGCTATGTGGGCCACGCTGCCGCTGCTCTGCGCCGGGGCCTGGCTCCTGGGAGTC
CCCGTCTGCGGTGCCGCCGAACGTCCGTGAACTCCTTAGAGAAGTTTCACTTCA
AGTCATGGATGTCTAAGCACCGTAAGACCTACAGTACGGAGGAGTACCACCACA
15 GGCTGCAGACGTTTGCCAGCAACTGGAGGAAGATAAACGCCCAACAATGGGA
ACCACACATTTAAAAATGGCACTGAACCAATTTTCAGACATGAGCTTTGCTGAAAT
AAAACACAAGTATCTCTGGTCAGAGCCTCAGAATTGCTCAGCCACCAAAAAGTAA
CTACCTTCGAGGTACTGGTCCCTACCCACCTTCCGTGGACTGGCGGAAAAAAGGA
AATTTTGTCTCACCTGTGAAAAATCAGGGTGCTGCGGCAGTTGCTGGACTTTCT
20 CCACCACTGGGGCCCTGGAGTCTGCGATCGCCATCGCAACCGGAAAGATGCTGT
CCTTGGCGGAACAGCAGCTGGTGGACTGCGCCAGGACTTCAATAATCACGGCT
GCGAAGGGGGTCTCCCCAGCCAGGCTTTCGAGTATATCCTGTACAACAAGGGGA
TCATGGGTGAAGACACCTACCCCTACCAGGGCAAGGATGGTTATTGCAAGTTCCA
ACCTGGAAAGGCCATCGGCTTTGTCAAGGATGTAGCCAACATCACAATCTATGAC
25 GAGGAAGCGATGGTGGAGGCTGTGGCCCTCTACAACCCTGTGAGCTTTGCCTTTG
AGGTGACTCAGGACTTCATGATGTATAGAACGGGCATCTACTCCAGTACTTCCTG
CCATAAAACTCCAGATAAAGTAAACCATGCAGTACTGGCTGTTGGGTATGGAGA
AAAAAATGGGATCCCTTACTGGATCGTGAAAACTCTTGGGGTCCCCAGTGGGG
AATGAACGGGTACTTCCTCATCGAGCGCGGAAAGAACATGTGTGGCCTGGCTGC
30 CTGCGCCTCCTACCCCATCCCTCTGGTGTGAGCCGTGGCAGCCGCAGCGCAGACT
GGCGGAGAAGGAGAGGAACGGGCAGCCTGGGCCTGGGTGGAAATCCTGCCCTG
GAGGAAGTTGTGGGGAGATCCACTGGGACCCCCAACATTCTGCCCTCACCTCTGT
GCCCAGCCTGGAAACCTACAGACAAGGAGGAGTTCCACCATGAGCTCACCCGTG
TCTATGACGCAAAGATCACCAGCCATGTGCCTTAGTGTCTTCTTAACAGACTCA
35 AACCACATGGACCACGAATATTCTTTCTGTCCAGAAGGGCTACTTTCCACATATA
GAGCTCCAGGGACTGTCTTTTCTGTATTCTGTGTTCAATAAACATTGAGTGAGCA
CCTCCCCAGATGGAGCATGCTGGTCCTGGAA

SEQ ID NO: 413

40 >5900 BLOOD 982889.1 Y00290 g36610 Human mRNA for steroid hormone receptor
hERR2. 0

CTCCTCCAAGTGGGAATGCTAAAACGGGACTGATGGACGTGTCCGAAGTCTGCAT
CCCGGACCCCTCGGCTACCACAACCAGTAGGTTGCTGAACCGAATGTCGTCCGA
AGACAGGCACCTGGGCTCTAGCTGCGGCTCCTTCATCAAGACGGAGCCATCTAGC
45 CCATCCTCGGGCATTGATGCCCTCAGCCACCACAGCCCCAGCGGCTCGTCGGACG
CCAGCGGTGGCTTTGGCATGGCCCTGGGCACCCACGCCAACGGTCTGGACTCTCC
GCCTATGTTTCGAGGTGCGGGGCTGGGAGGCAACCCGTGTCGCAAGAGCTACGA
GGACTGTACTAGCGGTATCATGGAGGACTCGGCCATCAAGTGCGAGTACATGCTT
AACGCCATCCCCAAGCGCCTGTGCCTCGTGTGCGGGGACATTGCTTCTGGCTACC

ACTATGGAGTGGCCTCCTGCGAGGCTTGCAAGGCGTTCTTCAAGAGAACCATTCA
AGGAAACATCGAATACAGCTGCCCTGCCACCAACGAGTGTGAGATCACCAAACG
GAGGCGCAAGTCCTGTGAGGCTGCCGGTTCATGAAATGCCTCAAAGTGGGGAT
GCTGAAGGAAGGCGTGCGCCTTGACCGGGTGCGAGGAGGCCGCCAGAAGTACAA
5 GAGACGGCTGGATTTCGGAGAACAGCCCCTACCTGAGCTTACAGATTTCCCCGCCT
GCTAAAAAGCCATTGACTAAGATTGTCTCGTATCTACTGGTGGCCGAGCCGGACA
AGCTGTACGCTATGCCTCCCGACGATGTGCCTGAAGGGGATATCAAGGCCCTGAC
CACTCTCTGTGACTTGGCAGATCGGGAGCTTGTGTTCCCTCATTAGCTGGGCCAAG
CACATCCCAGGTTTCTCCAACCTGACACTCGGGGACCAGATGAGCCTGCTGCAGA
10 GTGCCTGGATGGAGATCCTCATCCTGGGCATCGTGTACCGCTCGCTTCCCTATGA
TGACAAGCTGGCATAACGCGGAGGACTATATCATGGATGAGGAACACTCTCGCCT
GGTGGGGCTGCTGGAGCTTTACCGAGCCATCTTGACGCTCGTACGCAGGTACAAG
AAGCTCAAGGTGGAGAAGGAAGAGTTTGTGATGCTCAAAGCCCTGGCCCTTGCC
AACTCAGATTCAATGTACATCGAGAACCTGGAGGCTGTGCAGAAGCTTCAGGAC
15 CTGCTGCATGAGGCGCTGCAGGACTATGAGCTGAGCCAGCGCCATGAGGAGCCA
CGGAGGGCGGGCAAGCTGCTGTTGACACTGCCCTGCTGCGGCAGACGGCAGCC
AAAGCCGTCCAGCACTTCTACAGTGTGAAACTGCAGGGCAAGGTGCCCATGCAC
AACTCTTCTGAGATGCTGGAGGCCAAGGTGTGATGGCCCCGCATGCAGACG
GATGGACACGATCCACATGGAGACTTCCACGGCCACCAGCCTCGACTTTCTCACA
20 CCTGCATCGGGGCTCTGAGCTGTCCCAGAAGAAGGGGTTTCTTGCTTCCTGGCCA
TGTGCAGACTCCTGGGGGGCAGCAGATGGGGAGATGGGGATGGGAGGGTGGGG
GGGGGGGGCTCATCTGTACCCGAATTTTCTTTGGTATTTTTTTTTTCTTCTCCA
TGGGCAGTGCTAAGGCTTGGGGCCGGGGCTGACTTCCCTTAGGGCTGGAGACCAC
GGGAGGAAGCATCCCTTCTGCAAGGGATCCATTTCTGGACCACTCCATATTTAG
25 GACCTGGAGGTACCTGGATGGGCAGGGCTTAGTGCCAGGGCCCAAGAGACTTA
GATTGGGTGCTCCTGAAGGTGTTGGTATCACAGAGGGCAGGCCCTTGGAACAGG
AGGTCTCTGTGGCCTCTCCTGGGGCTCTGTGCCTCCTCAGTCTAGCTGTCTCCCTC
CCCTTCCCCCTTTCTTGTCTAGTACATCCAGCTCTCAGTGGATGCTCCTGCTAGA
GTAGCCACATCCCCACCACTAAGAGGGCCCTCCCCTGCTTCTGCCCCCTACCTCA
30 GCCAGCTGAGGTAACCTCCAGGACATGCACCTGGGAACTCGCTGGCTCAGAAAAG
AGTTGGGTCTATACCCACCCTTGCCCTGTTGTTTCTCCTAATCCTCTTGGGCATGG
CGAGTCTAGAAACCTATGGA

SEQ ID NO: 414

35 >5918 BLOOD 403530.1 M67439 g181830 Human D5 dopamine receptor (DRD5) gene,
complete cds. 0
CCCGGCGCAGCTCATGGTGAGCGCCTCTGGGGCTCGAGGGTCCCTTGGCTGAGG
GGGCGCATCCTCGGGGTGCCGATGGGGCTGCCTGGGGGTGCGAGGGCTGAAGT
TGGGATCGCGCAAAACCGACCCTGCAGTCCAGCCCGAAATGCTGCCGCCAGGC
40 AGCAACGGCACC GCGTACCCGGGGCAGTTCGCTCTATACCAGCAGCTGGCGCAG
GGGAACGCCGTGGGGGGCTCGGCGGGGGCACCGCCACTGGGGCCCTCACAGGTG
GTCACCGCCTGCCTGCTGACCCTACTCATCATCTGGACCCTGCTGGGCAACGTGC
TGGTGTGCGCAGCCATCGTGCGGAGCCGCCACCTGCGCGCCAACATGACCAACG
TCTTCATCGTGTCTCTGGCCGTGTCTGACCTTTTCGTGGCGCTGCTGGTCATGCCC
45 TGGAAGGCAGTCGCCGAGGTGGCCGTTACTGGCCCTTTGGAGCGTTCTGCGACG
TCTGGGTGGCCTTCGACATCATGTGCTCCACTGCCTCCATCCTGAACCTGTGCGTC
ATCAGCGTGGACCGCTACTGGGCCATCTCCAGGCCCTTCCGCTACAAGCGCAAGA
TGACTCAGCGCATGGCCTTGGTCATGGTCGGCCTGGCATGGACCTTGTCCATCCT
CATCTCCTTCATTCCGGTCCAGCTCAACTGGCACAGGGACCAGGCGGCCTTTGG

GCGGGGCTGGACCTGCCAAACAACCTGGCCAACTGGACGCCCTGGGAGGAGGAC
 TTTTGGGAGCCCGACGTGAATGCAGAGAACTGTGACTCCAGCCTGAATCGAACCT
 ACGCCATCTCTTCCTCGCTCATCAGCTTCTACATCCCCGTTGCCATCATGATCGTG
 ACCTACACGCGCATCTACCGCATCGCCAGGTGCAGATCCGCAGGATTTCCTCCC
 5 TGGAGAGGGCCGCAGAGCACGCGCAGAGCTGCCGGAGCAGCGCAGCCTGCGCG
 CCCGACACCAGCCTGCGCGCTTCCATCAAGAAGGAGACCAAGGTTCTCAAGACC
 CTGTCCGTGATCATGGGGGTCTTCGTGTGTTGCTGGCTGCCCTTCTTCATCCTTAA
 CTGCATGGTCCCTTTCTGCAGTGGACACCCCGAAGGCCCTCCGGCCGGCTTCCCC
 TCGTCAGTGAGACCACCTTCGACGTCTTCGTCTGGTTCGGCTGGGCTAACTCCT
 10 CACTCAACCCCGTCATCTATGCCTTCAACGCCGACTTTCAGAAGGTGTTTGCCCA
 GCTGCTGGGGTGCAGCCACTTCTGCTCCCGCACGCCGGTGGAGACGGTGAACATC
 AGCAATGAGCTCATCTCCTACAACCAAGACATCGTCTTCCACAAGGAAATCGCA
 GCTGCCTACATCCACATGATGCCCAACGCCGTTACCCCGGCAACCGGGAGGTG
 GACAACGACGAGGAGGAGGGTCTTTCGATCGCATGTTCCAGATCTATCAGACG
 15 TCCCCAGATGGTGACCCTGTTGCTGAGTCTGTCTGGGAGCTGGACTGCGAGGGGG
 AGATTTCTTTAGACAAAATAACACCTTTCACCCCGAATGGATTCCATTAACTGC
 ATTAAGAAACCCCTCATGGATCTGCATAACCGCACAGACACTGACAAGCACGC
 ACACACACGCAAATACATGGCTTTCAGTGCTGCTCCCTTTATCATGTGTTTCTGT
 GTAGTAGCTCGTGTGCTTAGAAACCTCACCCATTGATTGATAGTTTGAAGAATT
 20 GGCAGAAAGCAGTTGCAATAAACTCAGTCAAATGTACCCAGCCTACCAGAGATGG
 ACCAACGATCCTATGAGAGAAGAGAGTATGGTGCTGGGTCTTAAAAAAAAAAAA
 TGATACTTGGTCCTTAAAAAATATGCTCTCCCTCCCTTTTTTAAACAAATGGCTTG
 TTCAGTCACTTGTTTGTGTTTGAATTGATTTTAAACAGCAGGTTGTGTGTGTGTG
 CAGTGATGTGGTGGGAGCAGAGCTTTCCTGGGTCTGGATTCCCGTGGCTTTGTGCT
 25 TTATGTCAATTCTTCTCTGTGCTGGTGGGGGCCTCTTACCATAGCTTAAGAAG
 TATCCCTG

SEQ ID NO: 415

>5932 BLOOD gi|3928192|emb|X62421.1|HSDNAJ Homo sapiens mRNA for DnaJ protein
homologue

30 GGGGCCGGGGGACGGCGACACGGGGTCCGGCGGGCCGCAGGAGGGGGTTCATGGG
 TAAAGATTACTACCAGACGTTGGGCCAGGCCGCGCGCTCGGACGAGGAGATCA
 AGCGGGCCTACCGCCGCCAGGCCTGCGCTACCACCCGGACAAGAACAAGGAGCC
 CGGCGCCGAGGAGAAGTTCAAGGAGATCGCTGAGGCCTACGACGTGCTCAGCGA
 35 CCCGCGCAAGCGCGAGATCTTCGACCGCTACTTGGAGGAAGGCCTAAAGGGGAG
 TGGCCCCAGTGGCGGTACGGCGGAGGAGCCAATGGTACCTCTTTCAGCTACACAT
 TCCATGGAGACCCTCATGCCATGTTTGTGCTGAGTTCTTCGGTGGCAGAAATCCCTTT
 GACACCTTTTTTGGGCAGCGGAACGGGGAGGAAGGCATGGACATTGATGACCCA
 TTCTCTGGCTTCCCTATGGGGCATGGGTGGCTTACCAACGTGAACTTTGGCCGC
 40 TCTTGCTCTGCCCAAGAGCCCGCCCGAAAGAAGCAAGATCCCCCAGTCACGCAC
 GACCTTCGAGTCTCCCTTGAAGAGATCTACAGCGGCTGTACCAAGAAGACGAAA
 ATCTCCCACAAGCGGCTAAACCCCGACGGAAAGAGCATTTCGAAACGAAGACAAA
 ATATTGACCATCGAAGTGAAGAAGGGGTGGAAAGAAGGAACCAAAATCACTTTC
 CCAAGGAAGGAGACCAGACCTCCAACAACATTCCAGCTGATATCGTCTTTGTTT
 45 TAAAGGACAAGCCCCACAATATCTTTAAGAGAGATGGCTCTGATGTCATTTATCC
 TGCCAGGATCAGCCTCCGGGAGGCTCTGTGTGGCTGCACAGTGAACGTCCCCACT
 CTGGACGGCAGGACGATACCCGTCGTATTCAAAGATGTTATCAGGCCTGGCATGC
 GGCAGAAAGTTCTTGAGAAAGGCCTCCCCCTCCCCAAAACACCCGAGAAACGTG
 GGGACCTCATTATTGAGTTTGAAGCGATCTTCCCCGAAAGGATTCCCCAGACATC

AAGAACCGTACTTGAGCAGGTTCTTCCAATATAGCTATCTGAGCTCCCCAAGGAC
TGACCAGGGACCTTTCCAGAGCTCAAGGATTTCTGGACCTTTCTACCAGTTGTGG
ACCATGAGAGGGTGGGAGGGCCCCAGGGAGGGCTTTTCGTAAGTGAATGTTTTTC
CAGAGCATATATTACAATCTTTCAAAGTCGCACACTAGACTTCAGTGGTTTTTCG
5 AGCTATAGGGCATCAGGTGGTGGGAACAGCAGGAAAAGGCATTCCAGTCTGCCC
CACTGGGTCTGGCAGCCCTCCCGGGATGGGCCCACATCCACCTCCAGTCCCTGGC
CAGGGGTGAGAGGCAGACCAGCAGATGGACTTGATCCCTCTGTGTCTTTTTTGCTT
CTGGCTGGTAGATAATGTCAACCTGCAGTCTTGATTCCCAGACCCTGTACACTCC
TCCTTTTCTGCCGCGCGATCAGTTTGTGCTTTATTCTGTATTTGTCTCCCATGTCTT
10 GCTCTTCTCCTGGA

SEQ ID NO: 416

>5934 BLOOD 197542.1 S37375 g32468 Human HSJ1 mRNA. 0

CCCGCCTGACGACTGACCAGTTGCCATGGCATCCTACTACGAGATCCTAGACGTG
15 CCGCGAAGTGCGTCCGCTGATGACATCAAGAAGGCGTATCGGCGCAAGGCTCTC
CAGTGGCACCCAGACAAAAACCCAGATAATAAAGAGTTTGCTGAGAAGAAATTT
AAGGAGGTGGCCGAGGCATATGAAGTGCTGTCTGACAAGCACAAGCGGGAGATT
TACGACCGCTATGGCCGGGAAGGGCTGACAGGGACAGGAACTGGCCCATCTCGG
GCAGAAGCTGGCAGTGGTGGGCCTGGCTTCACCTTCACCTTCGCGAGCCCCGAGG
20 AGGTCTTCCGGGAATTCTTTGGGAGTGGAGACCCTTTTGCAGAGCTCTTTGATGA
CCTGGGCCCCCTTCTCAGAGCTTCAGAACCGGGGTTCCCGACACTCAGGCCCTTC
TTTACCTTCTCTTCCCTCCTTCCCTGGGGAGTCCGATTTCTCCTCCTCATCTTTCTCC
TTCACTCCTGGGGCTGGTGCTTTTCGCTCTGTTTCEACATCTACCACCTTTGTCCA
AGGAGCGCCGATCACCACACGCGAATCATGGAGAACGGGCAGGAGCGGGTGG
25 AAGTGGAGGAGGATGGGCAGCTGAAGTCAGTCACAATCAATGGTGTCCCAGATG
ACCTGGCACGTGGCTTGGAGCTGAGCCGTCGCGAGCAGCAGCCGTCAGTCACTTC
CAGGTCTGGGGGCACTCAGGTCCAGCAGACCCCTGCCTCATGCCCCTTGGACAGC
GACCTCTCTGAGGATGAGGACCTGCAGCTGGCCATGGCCTACAGCCTGTCAGAG
ATGGAGGCAGCTGGGAAGAAACCCGCAGGTGGGCGGGAGGCACAGCACCGACG
30 GCAGGGGCGCCCAAGGCCCAGCACCAAGATCCAGGCTTGGGGGGGAGCCAGGA
GGGTGCGAGGGGTGAAGCAACCAAACGCAGTCCATCCCCAGAGGAGAAGGCCTC
TCGCTGCCTCATCCTCTGAACACCGGGGCCAACCTGATCTGATCCAGATCTTGAC
TGGGGGGTCTGACTCACTGTGGGAAGAGAAGAGGGGAGTATCCTGAGTTGTAGG
AACTGCTTTCCAACCTCCAAGCTCCCTCCACAAGTTTCCCTCCCCAGGCCCCCAC
35 ACCCCAGTGTGGACTTGGGATTTGCTGTGCTCAGCCCAGGGCTGATAGGTCCCTG
GTGAAGCCCAGGGTGGGGGGTGTGAGGGCAGTGGAGGGGGCCCGAGGAGCCAGG
TTGCATTTATTGGATGGGGAGCTCCAAGGGGCATTAGTGGTTTGGGCTGGGCTTT
TGTGCCCTGGTACTCTGCCACCTGTGTTGCTGATGGTGTCAAGGAAGGAGGACTT
GGCCTAGGGTTGTCTGAGCCGGAGCCGGCAGCTCCACTGGAGAGCAGTGCAGGC
40 AGAGTGGAGCCTCCTGCTCTCCTGGACCAGCTGCAGACCCCCAACCTGGTTTCT
GTGCCATGTTGCGCTCTGACCGTCTCTGTTGCTTCTCTTCTGGTGTGCTTCTCCTC
CCTCCCATTCTCTCTGCAACTCCTGCGGGCGCATCGCTTGCTTTCACTGCCGTCTG
GCTAGGACTCCCTTCTTCCCTTCCCTTCCCCGAGAAGGCCTCAATGTGGCGAGGAAG
ATGCTGGGGCCGGTAGGGCTGTGAGATCTTCTGGGGAGGCTAGCCGGGTGGGGC
45 GGGAGCCTCTCAGCTGTCCAGATTGAGAAGTGGAGCCCACTCCTCCTCCCTCTCG
TTGCCTCAGCCCTGCCCTCACCTCAGACTAGGCAGAGGTGAGGCTGGCTCACCC
TGAAGAGGTGGGATAGGAGGGGACTGCACCCATACTGCTTCCCTACCACAAATC
AGGGCTCAGGGAGAGGCCATGCGGCAGCCAGGTCTGCATGCTGAGCCCCATCC
TCCACAGCTTGGCGCTGACGCTCTCTCTGTCAACCCGCCCTGCTCTCTCCCCAG

ATGTGTTCTGAGCTGGATGCCGGGTTCAGAATCGCTGCACAGTTCCAACAGGAC
 AGCGCCTTCCCCCATGCGCTGGGAGGGGACCCTCCATTTCTCCCCCTCACCCATG
 CTGAGTGTAGAGCCGGGGCCTGGGTGGCGGGTGGGGGCCGGGTGGGAGGTGGCA
 GTAGTCTTAGCCTGTGCACTCTCTTCCTTGGGTGTTTGGTGCTGGCTCCTGGGGAC
 5 TACAAATCCCAGAGTGCGGTGTGCCCGGCCTCATTTCTGATAGATCCCGCTTGGG
 GGAGGTGGTGTATGGTTACGGAGCTGTGCATCTTGGGACATGTAGTAGCCCAGGT
 CTTGTCACTCGCTGTGAGATGGGGAGATTTTGTCTTTTGATTTATCCCTGTAGGGC
 TGGCAGGGTTGTAGATGAAGGGGAATGATCTGAGCCTTGGTTCCTTGACACGT
 CTTGCTAGCCCCAGGGTTAGAGTGGGCAGGGCAGAGCCGCGCAGCACCTGGGAG
 10 CGGTACCTTTCCCTTGGGCAGCCTGGGGTCCCAGGAACAAGCCAGGGCGAGTGG
 CATGTCTGCCTGAGCAGGGTGTGGCCCCAGAAAGCTGAGGAGTGTGGGCTGGCA
 GAGAGCTTCGAGGGCAAGGCCACCCGCGGGGGCGTGTGTGTGGTGGGGCTTGGC
 ATGTGATGGCAGCTCCAGCTCCAGGCATGCCGCTGCTTGTATGGCTTTCTTTGGC
 CTCTGACCCTGCTGCCCATTTCTTTCCAACATCACAGATGAACTGCCTCTCCTCCTC
 15 CCTGCCTGGGGAGCCCAGTGGCCAGGGAGGGAGTGGTGGAGCCAGTCGCTGTAA
 CACTGAGCCTCAGAGACGAACCAAAACCAGCTGGGCTGAGCTCAGATCCAGGGG
 GAAGAAATGCTGGAAGTCAATAAAACTGAGTTTGAG

SEQ ID NO: 417

20 >5950 BLOOD 337103.1 S54181 g35020 Human mRNA for neurotensin receptor. 0
 TCAAGCTCGCCCCGCGCAGCCCGAGCCGGGCTGGGCGCTGTCTCGGGGGCCTG
 GGGAAACGCGCGGTTTGGAGATCGGAGGCACCTGGAACCCGTGGCAAGCGCCGA
 GCGGGGAGACAGCCCGAGGAACCAAGGGTTCTGGAGCTAGGAGGCGGAAGCTG
 GGAGTCCGGAGGAGAGGCGGAGCCCGGAGCCCGGAGCCCGGGGCGGCGCTCTG
 25 GGTCTGGCGCTTCCCGACTGGACGGCGCGCCCGCTGGTCTTCGCCACGCGCCCTC
 CCCTGGGCTCGCGTTCATCGGTCCCCGCTGAGACGCGCCCACTCCTGCCCGGAC
 TTCCAGCCCCGGAGGGCGCCGGACAGAGCCGCGGACTCCAGCGCCCAACATGCGC
 CTCAACAGCTCCGCGCCGGGAACCCCGGGCACGCGGCGCCGACCCCTTCCAG
 CGGGCGCAGGCCGGACTGGAGGAGGCGCTGCTGGCCCCGGGCTTCGGCAACGCT
 30 TCGGGCAACGCGTTCGAGCGCGTCTGGCGGCACCCAGCAGCGAGCTGGACGTG
 AACACCGACATCTACTCCAAAGTGCTGGTGACCGCCGTGTACCTGGCGCTCTTCG
 TGGTGGGCACGGTGGGCAACACGGTGACGGCGTTCACGCTGGCGCGGAAGAAGT
 CGCTGCAGAGCCTGCAGAGCACGGTGCATTACCACCTGGGCAGCCTGGCGCTGT
 CCGACCTGCTCACCTGCTGCTGGCCATGCCCGTGGAGCTGTACAACTTCATCTG
 35 GGTGCACCAACCCTGGGCCTTCGGCGACGCCGGCTGCCGCGGCTACTACTTCCTG
 CGCGACGCTGCACCTACGCCACGGCCCTCAACGTGGCCAGCCTGAGTGTGGAG
 CGCTACCTGGCCATCTGCCACCCCTTCAAGGCCAAGACCCTCATGTCCCGAAGCC
 GCACCAAGAAGTTCATCAGCGCCATCTGGCTCGCCTCGGCCCTGCTGACGGTGCC
 TATGCTGTTACCATGGGCGAGCAGAACCAGCAGCGCCGACGGCCAGCACGCCGG
 40 CGGCCTGGTGTGCACCCCCACCATCCACACTGCCACCGTCAAGGTCGTACATACAG
 GTCAACACCTTCATGTCCTTCATATCCCCATGGTGGTTCATCTCGGTCTGAACAC
 CATCATCGCCAACAAGCTGACCGTCATGGTACGCCAGGCGGCCGAGCAGGGCCA
 AGTGTGCACGGTTCGGGGGCGAGCACAGCACATTACAGCATGGCCATCGAGCCTGG
 CAGGGTCCAGGCCCTGCGGCACGGCGTGCAGCTCCTACGTGCAGTGGTTCATCGCC
 45 TTTGTGGTCTGCTGGCTGCCCTACCACGTGCGGCGCCTCATGTTCTGCTACATCTC
 GGATGAGCAGTGGACTCCGTTCTCTATGACTTCTACCACTACTTCTACATGGTG
 ACCAACGCACTCTTCTACGTACGTCCACCATCAACCCCATCCTGTACAACCTCG
 TCTCTGCCAACTTCCGCCACATCTTCCTGGCCACACTGGCCTGCCTCTGCCCGGTG
 TGGCGGCGCAGGAGGAAGAGGCCAGCCTTCTCGAGGAAGGCCGACAGCGTGTCC

AGCAACCACACCTCTCCAGCAATGCCACCCGCGAGACGCTGTACTAGGCTGTGC
GCCCCGGAACGTGTCCAGGAGGAGCCTGGCCATGGGTCTTGCCCCGACAGAC
AGAGCAGCCCCACCCGGGAGCCTTGATGGGGGTCAGGCAGAGGCCAGCCTGCA
CTGGAGTCTGAGGCCTGGGACCCCCCTCCACCCCTAACCCATGTTTCTCATT
5 AGTGTCTCCCGGGCCTGTCCCAACTCCTCCCCACCCCTCCCCATCTCCTCTTTG
AAAGCCAGAACAAGAGAGCGCTCCTCTCCAGATAGGAAAAGGGCCTCTAACAA
GGAGAAATTAGTGTGCGGCAAAAGGCAGTTTTCTTTGTTCTCAGACTAATGGATG
GTTCCAGAGAAGGAAATGAAATGTGCTGGGTGGGGCCGGGCCTCCGGCGGCCCG
GCTGCTGTTCCCATGTCCACATCTCTGAGGCCTGCACCCCTCTGTCTAGCTCGGG
10 GAGTCCAGCCCCAGTCCCGCAGGCTCCGTGGCTTTGGGCCTCACGTGCAGACCCT
GCCATGCAGACCCATGCCCCCTCCCCAGGCAGCTCCAAGAAAGCTCCCTGACT
CGCCCCTTCAGGCCTGGCAAGCTGGGGGCCCATCGCCGTGGGGAGTCCCTCCCAC
CACCTCGCCGCAGGCAGCTGCAGCCCCAGAGGGGACCACAAGCCCAAAAAGG
ACAAAAATGGGCTGGCCTGGAATGGCCAGACCCAGCCTCCCCTCCTCCCTCCC
15 ATCTCACCCAGGCCAAGGCCAGGGGCTCTGCCAGGACACCACATGGGAGGGG
GCTCAGGCCTCAGCCTCAAGATCTTCAGCTGTGGCCTCTCGGGCTCGGCAGAAGG
GACGCCGGATCAGGGGCCTGGTCTCCAGCACCTGCCCCAGTGGCCGTGGCCAGG
ATGGGGTGCGCATTCCGTGTGCTTTGCTTGTAGCTGTGCAGGCTGAGGTCTGGAG
CCAGGCCCAGAGCTGGCTTCAGGGTGGGGCCTTGAGAAGGGGAATGTGGGACAG
20 GGGCGATGGTGCCTGGTCTCTGAGTAAGATGCCAGGTCCCAGGAAGTCCAGGCTTC
AGGTGAGAAGGAGCGGTGTGTCCAGGCACCGCTGGCCGGCAGCCCTGGGCTGAG
GCACAGACTCATTTGTCACTTCTGGCGGCGGCAGCCTGGCCCCGGCCTCCAAG
GAGTTGAAAAAGCTGGCGCCTCCTTGGTCTGTAGGATCCAGGCTCCACAGAGGAC
ATGAETAGCCAGGCCCTTGGCTTAAGAAGGTGCGCTAAGCCTAAGAGAAGACAG
25 TCCCAGGAGAAGCTGGCCGGGACCAGCCAGGAGCTGGGAGCCACAGGAAGCAA
AAGTCAGCCTTTTCTTCAAGGGATTTCCCTGTCTCAGAGCAGCCTTTGCCCCAGG
GAAATGGGCTCTGGGCTGGCTGCCTGCACCGGCCATGTCGACCCAGGACCCGGA
CACCTGGTCTTGGGCTGTGTTACGCCACTTTGCCTTCTCTGGACTCAGTTTCCCCG
TCTGAGAAATGAGAGTCGAATGCTACAGTATCTGCAGTCGCTTGGATCTGGCTGT
30 TGAGTTGACGGGTTCTTGAACCCACAAAAATCCCTCTCCAACCACAGGACCCTT
CGGCTCACCAAGAACGGGGCCCAGGGGAGTCAGGCCTATTCGCTGCACTTCCTG
CCAAACTTTGCCCCCACAAGCCTGGTCATCAGCCAGGCAGCCCTTCCAGTGCCCA
AGGGCCACCAACCCAGGGGAAACAGGGCCAGCACAGAGGGGCCTTCCCTCCCCCA
CAGAGCTCCCATGACATAGTCTGCTCTGGGCGGAAGAGCTTTGCTGCCAGCCAGG
35 GATGTCCAGAGGTCGGTGCAGCCCCTATCCCTGCTCAGGAGTGGGCTCAGAGTCT
AGCAAATGCTAAGGCCCTCAGGCTGGGCTCTGAACGAGGACCTGGACTCAGAG
CCAGACAGGGCAGCCTCAGACCCTTCTCTGGGGCTCCTGGACCTTGGGCCATAAT
TTCTGAGCCTCGGTTTCCCCATCTAAGGAACAGATGTGGTCGTTCCGCCCTCTCA
GCTGGATGAGACTGTCCTGGAGGATCCACCCCGGAACAGACAGAATGGTGTCTC
40 TCAGGATGGTGTCTGAGAGAGGGCAGAGTGGATGCCCCACTGCCCTAGACCCT
CGGTAGACGTGGGGTCTCTGGGGCGGGGTCTGTGGCTGTGACTGAAGTCGGCTTT
CCCGTTGATGTCTTGATGCTCCTATCTGTGCACTTACCGTAGGTAGGGACACGTG
TCCATGCACCACAGACACACCCACGACACCTGATCTCGTATCACTAGCTTGCGGC
CAGGTCATGATGTGGCCCCGGAAGCTGGCCCTGCGTGCCATGAGTGCGTCGGTCA
45 TGGAGTCCGGAGCCCCTGAGCCGGCCCCCTGGTGACGGCACAGCCCTCACAGCTC
AAACGCCACCCCCACTCCCACCATCTGCAGGTGGTGAAAACAAACCCCGTGTAT
CTCTCAATAAAGGTGGCCGAAGGGCCTCGATGTGG

SEQ ID NO: 418

>5956 BLOOD Hs.92208 gnl|UG|Hs#S376155 Human metargidin precursor mRNA,
complete cds /cds=(7,2451) /gb=U41767 /gi=1235673 /ug=Hs.92208 /len=2740

CGCTGCCATGCGGCTGGCGCTGCTCTGGGCCCTGGGGCTCCTGGGCGCGGGCAGC
5 CCTCTGCCTTCCTGGCCGCTCCCAAATATAGGTGGCACTGAGGAGCAGCAGGCAG
AGTCAGAGAAGGCCCCGAGGGAGCCCTTGGAGCCCCAGGTCCTTCAGGACGATC
TCCCAATTAGCCTCAAAAAGGTGCTTCAGACCAGTCTGCCTGAGCCCCCTGAGGAT
CAAGTTGGAGCTGGACGGTGACAGTCATATCCTGGAGCTGCTACAGAATAGGGA
GTTGGTCCCAGGCCGCCCAACCCTGGTGTGGTACCAGCCCGATGGCACTCGGGTG
10 GTCAGTGAGGGACACACTTTGGAGAACTGCTGCTACCAGGGAAGAGTGCGGGGA
TATGCAGGCTCCTGGGTGTCCATCTGCACCTGCTCTGGGCTCAGAGGCTTGGTGG
TCCTGACCCCAGAGAGAAGCTATACCCTGGAGCAGGGGCCTGGGGACCTTCAGG
GTCCTCCCATTAATTCGCGAATCCAAGATCTCCACCTGCCAGGCCACACCTGTGC
CCTGAGCTGGCGGGAATCTGTACACACTCAGACGCCACCAGAGCACCCCTGGG
15 ACAGCGCCACATTCGCCGGAGGCGGGATGTGGTAACAGAGACCAAGACTGTGGA
GTTGGTGATTGTGGCTGATCACTCGGAGGCCCAGAAATACCGGGACTTCCAGCAC
CTGCTAAACCGCACACTGGAAGTGGCCCTCTTGCTGGACACATTCTTCCGGCCCC
TGAATGTACGAGTGGCACTAGTGGGCCTGGAGGCCTGGACCCAGCGTGACCTGG
TGGAGATCAGCCCAAACCCAGCTGTCACCCTCGAAAACCTCCTCCACTGGCGCAG
20 GGCACATTTGCTGCCTCGATTGCCCCATGACAGTGCCAGCTGGTGACTGGTACT
TCATTCTCTGGGCCTACGGTGGGCATGGCCATTGAGAACTCCATCTGTTCTCCTGA
CTTCTCAGGAGGTTGTGAACATGGACCACTCCACCAGCATECTGGGAGTCGCCTCC
TCCATAGCCCATGAGTTGGGCCACAGCCTGGGCCTGGACCATGATTTGCCTGGGA
ATAGCTGCCCTGTCCAGGTCCAGCCCGAGCCAAGACCTGCATCATGGAGGCCTC
25 CACAGACTTCTACCAGGCCTGAACTTCAGCAACTGCAGCCGACGGGCCCTGGA
GAAAGCCCTCCTGGATGGAATGGGCAGCTGCCTCTTCGAACGGCTGCCTAGCCTA
CCCCCTATGGCTGCTTTCTGCGGAAATATGTTTGTGGAGCCGGGCGAGCAGTGTG
ACTGTGGCTTCTGGATGACTGCGTCGATCCCTGCTGTGATTCTTTGACCTGCCAG
CTGAGGCCAGGTGCACAGTGTGCATCTGACGGACCCTGTTGTCAAATTGCCAGC
30 TGCGCCCGTCTGGCTGGCAGTGTGCTCCTACCAGAGGGGATTGTGACTTGCCTGA
ATTCTGCCCAGGAGACAGCTCCAGTGTCCCCCTGATGTCAGCCTAGGGGATGGC
GAGCCCTGCGCTGGCGGGCAAGCTGTGTGCATGCACGGGCGTTGTGCCTCCTATG
CCCAGCAGTGCCAGTCACTTTGGGGACCTGGAGCCAGCCCGCTGCGCCACTTTG
CCTCCAGACAGCTAATACTCGGGGAAATGCTTTTGGGAGCTGTGGGCGCAACCCC
35 AGTGGCAGTTATGTGTCCTGCACCCCTAGAGATGCCATTTGTGGGCAGCTCCAGT
GCCAGACAGGTAGGACCCAGCCTCTGCTGGGCTCCATCCGGGATCTACTCTGGGA
GACAATAGATGTGAATGGGACTGAGCTGAACTGCAGCTGGGTGCACCTGGACCT
GGGCAGTGATGTGGCCAGCCCCCTCCTGACTCTGCCTGGCACAGCCTGTGGCCCT
GGCCTGGTGTGTATAGACCATCGATGCCAGCGTGTGGATCTCCTGGGGGCACAG
40 GAATGTGGAAGCAAATGCCATGGACATGGGGTCTGTGACAGCAACAGGCACTGC
TACTGTGAGGAGGGCTGGGCACCCCTGACTGCACCACTCAGCTCAAAGCAACC
AGCTCCCTGACCACAGGGCTGCTCCTCAGCCTCCTGGTCTTATTGGTCTGGTGAT
GCTTGGTGCCGGCTACTGGTACCGTGCCCGCCTGCACCAGCGACTCTGCCAGCTC
AAGGGACCCACCTGCCAGTACAGGGCAGCCCAATCTGGTCCCTCTGAACGGCCA
45 GGACCTCCGCAGAGGGGCCCTGCTGGCACGAGGCACTAAGTCTCAGGGGCCAGCC
AAGCCCCCACCCTCAAGGAAGCCACTGCCTGCCGACCCCAAGGGCCGGTGCCCA
TCGGGTGACCTGCCCGGCCAGGGGCTGGAATCCCGCCCTAGTGGTACCCTCCA
GACCAGCGCCACCGCCTCCGACAGTGTCTCGTCTACCTCTGACCTCTCCGGAG
GTTCCGCTGCCTCCAAGCCGACTTAGGGCTTCAAGAGGCGGGCGTGCCCTCTGG

AGTCCCCTACCATGACTGAAGGCGCCAGAGACTGGCGGTGTCTTAAGACTCCGG
GCACCGCCACGCGCTGTCAAGCAAACTCTGCGGACCTGCCGGCGTAGTTGCAG
CGGGGGCTTGGGGAGGGGCTGGGGGTTGGACGGGATTGAGGAAGGTCCGCACA
GCCTGTCTCTGCTCAGTTGCAATAAACGTGACATCTTGGGAGCGTTAAAAA
5 AAAAAA

SEQ ID NO: 419

>5982 BLOOD 410650.1 U59831 g1399236 Human transcription factor, forkhead related
activator 4 (FREAC-4) gene, complete cds. 0

10 AGCAAGCCCAAGAACAGCCTAGTGAAGCCGCCTTACTCGTACATCGCGCTCATC
ACCATGGCCATCCTGCAGAGCCCGCAGAAGAAGCTGACCCTGAGCGGCATCTGC
GAGTTCATCAGCAACCGCTTCCCCTACTACAGGGAGAAGTTCCCCGCTGGCAGA
ACAGCATCCGCCACAACCTCTCGCTCAACGACTGCTTCGTCAAGATCCCCCGCGA
GCCCCGCAACCCGGGCAAGGGCAACTACTGGACGCTGGACCCGGAGTCCGCCGC
15 CTTGGGGACTCTGCACCAAGGGACTGCCCTGTCCAGTGTGAGAACTTTACTGCT
AGGATTTCCAATTGTTAATAACGCTATGTTAGCGCGCTCGAGGAAGAAGGTAGG
AATCCCGGCTCCTTTTCTCGTCTTGGTGGTTCGGTGTGTTTGTTCGCTCCTCCAGGC
GCGGCCCTCTCGACCTCGCGCGCCATTTTCGCCGCTGCGAATTCTCGGACAAA
ACTGTCAACAGCCCGGGCGCGCCTTTTGGCTCTGCGGGTCCCTCTATTTATGCAA
20 AGCCGACCTATGCTACAGCCCCCAACCCCGACCTGGGGTAGGGAGGAAGAGG
GTGCCGGGGAAGGGAGTCCGCCCTGTCCAGGCACTAGAGGCTCCCTTGACGTTTG
GCAGATGAAAAACAACCTAAGCCTTTTGTAGGTGTAGAGATTCTCAGGTCCAGGC
AGTTAAAAAATAATGGTCAAAAGAATAATACAAAAATAGTAAAGGTCTTGAAGAA
ATGCCAGCGAAGCAATTCTTTTATTTGAGGACAGTTGTCTGGTGTACTTTTTCAT
25 GAAAAGGAAAAATGGTTAACATGTTTACACAAGAAAAAAGTCAAAATTATCAT
TTATTTCAACCTGTGTTTTGTATCATAACAGACGTGTGGATTTTTTTGTACTTACT
GCGTATTCTTTACAAGGAGTATTGTAAATTTTACTGGCAATTATTATTGTACTATT
CTAAATGTAAGATTTTACACTTTTTCAGAAATAAAAATGCTTAATTTTCAAAGA
AAATTCACCAAAATG
30

SEQ ID NO: 420

>5987 BLOOD 220325.2 AF013988 g2318114 Human serine protease mRNA, complete cds.

ATCTCAGTGTAGCAGTTTTCTATTGCTATATAACATATTCCTTAAAAATATAGCGG
35 TTAAAGCTACACAGATGTCTTATCTCACTGTTCCAGAAGACAGGCATGGCTCAG
CTGGGATCTCTGCTTCAGTCTCAAAACGATGCAATCAAGGTGTCAGCAGGGCTGC
ATTTCTCCCTGGATGCTCAGAGGAAGAATCTACTTCCAAGCCTCTATGGTTTGAA
TGTGTCCTCTCCAAAATCCAGCTGTTGCCAATGGGATAGTATTAAGAGGTGGGGA
CACAGAGGTTCGGCAGGCAGCACACAGAGGGACCTACGGGCAGCTGTTCTTCCC
40 CCGACTCAAGAATCCCCGGAGGCCCGGAGGCCTGCAGCAGGAGCGGCCATGAAG
AAGCTGATGGTGGTGTGCTGAGTCTGATTGCTGCAGCCTGGGCAGAGGAGCAGAAT
AAGTTGGTGCATGGCGGACCCTGCGACAAGACATCTCACCCCTACCAAGCTGCCC
TCTACACCTCGGGCCACTTGCTCTGTGGTGGGGTCCCTATCCATCCACTGTGGGTC
CTCACAGCTGCCCACTGCAAAAAACCGAATCTTCAGGTCTTCCCTGGGGAAGCATA
45 ACCTTCGGCAAAGGGAGAGTTCCCAGGAGCAGAGTTCTGTTGTCCGGGCTGTGAT
CCACCCTGACTATGATGCCGCCAGCCATGACCAGGACATCATGCTGTTGCGCCTG
GCACGCCAGCCAACTCTCTGAACTCATCCAGCCCCTTCCCCTGGAGAGGGACT
GCTCAGCCAACACCACAGCTGCCACATCCTGGGCTGGGGCAAGACAGCAGATG
GTGATTTCCCTGACACCATCCAGTGTGCATACATCCACCTGGTGTCCCGTGAGGA

GTGTGAGCATGCCTACCTGGCCAGATCACCCAGAACATGTTGTGTGCTGGGGAT
GAGAAGTACGGGAAGGATTCTGCCAGGGTGATTCTGGGGGTCCGCTGGTATGT
GGAGACCACCTCCGAGGCCTTGTGTCATGGGGTAACATCCCCTGTGGATCAAAG
GAGAAGCCAGGAGTCTACACCAACGTCTGCAGATACACGAACTGGATCCAAAAA
5 ACCATTACAGGCCAAGTGACCCTGACATGTGACATCTACCTCCCGACCTACCACCC
CACTGGCTGGTTCCAGAACGTCTCTCACCTAGACCTTGCCTCCCCTCCTCTCCTGC
CCAGCTCTGACCCTGATGCTTAATAAACGCAGCGACGTGAGGGTCTGATTCTCC
CTGGTTTTACCCAGCTCCATCCTTGCATCACTGGGGAGGACGTGATGAGTGAGG
ACTTGGGTCTCTCGGTCTTACCCCCACCACTAAGAGAATACAGGAAAATCCCTTCT
10 AGGCATCTCCTCTCCCCAACCCTTCCACACGTTTGATTTCTTCTGTCAGAGGCCCA
GCCACGTGTCTGGAATCCCAGCTCCGCTGCTTACTGTGCGGTGTCCCCTTGGGATG
TACCTTTCTTCACTGCAGATTTCTCACCTGTAAGATGAAGATAAGGATGATACAG
TCTCCATAAGGCAGTGGCTGTTGGAAAGATTTAAGGTTTCACACCTATGACATAC
ATGGAATAGCACCTGGGCCACCATGCACTCAATAAAGAATGAATTTTATTATG

15 SEQ ID NO: 421

>6005 BLOOD 350249.10 U78180 g1871167 Human sodium channel 2 (hBNaC2) mRNA,
alternatively spliced, complete cds. 0

TTTTTTTGGTTGAAACCCAGTTTATTAGACCAGAGGCATGCGTCACCCAGAGCC
20 CTGCCTGCTGTTCCCTATCCAATGCACACTTTTGGCCTCATTCTGCTTCCCTCT
GGGGAGGTATGATCTCTGAGGAACTCTTAGGAACCAAGAGATTCCAAAGATCC
TACAGCCTTACTCTCCAGCTCCAGGCCAATGCAGCTGCTCACAGGTCTGTCTG
GGATTGAAGACCAAGACACAGCTAGGGAAGGAAGGCCTGAAGAGGGGTGGGG
CTCAGGCCTGGAAGGAGTGTCTGCTGGAGGGAGGGGGGGCAGGECCTCCACCTC
25 ACTTGTCTCTCATTAAAGATAGGGTGAGACAACAGCAGAGCTTCAACTCCTCCTC
TAGGCCTCTCTTTCCTCCCAAACCCACCTCACCAGAAAATAAAAGTGGTGGGCTT
GGGTATCAGGTGAGGAAAGGGGGCTGGGCACCCAGAAGGAGGAAAGGCCACTG
ACTGAGGACCTCAGCTTCTGCCTGTCAGCATCCCACTGCCCCAACTTCAGGAGTC
GCCAATCCCCAGCTCCCTTCTGTCTCTGACACACTTGGCTTAGTGTCCAGGGTAG
30 ACCTCCATCCCCTGGGTGGGGGCTATCTCTACAGCAACCCCTTCCCTGGGGATGC
CACTGTCAGCTGGGCAGAGGGCAATGGGATAGGAGGAGCAGGGGAAGAGAATG
TTAAGGCTGCAGGGAGGGCCGAGGGTGCCCGGGTTGGGGGAGAGGGTGAGGCC
AGAAAGAGGCAGAGCTTGTGATTACAGCTTCCCTTGTGCGCACTGAGACAGTGC
AAAGGTTACAATGCGCGTGTGCTCTCCTTGTGCTTCTCAGAGGGATGTGTGTACA
35 CAGTACAGACACCAGGGGAGAGAGTCCAACCTCTTATACAGGCAAGGCATTGAG
AGACCAGGGAGGGAGTAGAAACATAGAAGGTGGAACCTGGGGTGGGAGAATGG
TTCTCAGAGACAAGAGGGGATGGGGTGGAGACAGAGGGCTGGGAAAGTATA
TACAGAGATATAGCAATATAGAGTCTGTATCATATAGAAATAGAAAATGCAGAT
GAGGTTGTTGAGAGAAGCAAATGAAGTTGGGGAAGAGGATGTGGGAGAGTTCCA
40 TAAGAAAATTTATGGACGTGGCCCTCTACAAGGGCCTCCGGGAGAGGGACCAGT
GAGGTTAGGCACTAGCGCCCTTCTCCCTGAGCTGGACGCTAACCAGCCGGTCTTT
AATGGGATGGTGAGGAAGGGCTGCCTCTTGGGATTTCTCTCCAGCAGCTGTGGGG
TGGGGGTGAACTTATAGGTATCAGGATGTAGCCTACAGCACCAGGGCCGCATCTT
GTCCCCATTACCACTTCTTAAGGGGATCCCCGACCCACAGAGATTCCACATGGT
45 GTGAGAGAGTGGGGCTGAGGTTTTAGTTTCTGCCAGGAGACTTGGGTTTGGGGA
CAGTCACTGGGCTGAGAGGGTCTCTTAAGGCTGGGGAAGCCTCCCTCCCCACAC
TAGCCCTCCCCCTTAAGGTACATTCTCTGGTTTGGGGCCAAATTCCAGACCCAG
AGATCCCTTCCACCCCTCACTGGGAAGGGCCTTTGGTGAAGTGGCAGCAGAAT
GTAGATGGACACTCAGATGGCAGACAGCTAGATAGACAGAATTCAGGCTGGGAG

CTAGGGGAGGCAGCATGGAGGAGAGAGGGGCAGCCTGAGGTCCCTTGCCCCGTT
 CTCCCTTTTATGTTCTTTTTTAGATTAGTTTTGTAAATGTAAAAGAATGGGATAG
 AGGCAGAGAGAGGACTCTATGGTCAAGACTCCTTCCTTACCACAGACAAGAGGA
 AAGATCTGCCCCGGAGTGTGGGGAGTCCCAGGGCAGATGTGAGGAGGCAGCTGG
 5 GGGCCCCCGCTCTCCTAGTCCTCCCCATCTAGGCCTTTGGTTCAGCGGCCTGCG
 GGGCTCAGCAGGTAAAGTCCTCGAACGTGCCTCGGGCCGGATGGTGAGGTAGGA
 TGTGTCAGCGTATGTCATCCCGGCAGGGTGGCCCCGAAGGCTCTCGCACGGGTT
 GTGTCTTTTGACGTGTCAGGCTGAGGGCCACGCCCTTGTCGCGACTGCTCCTTT
 TGGCCTCCTTCTGGCATTTCCTCGTCGGCACAGCTTGTGCTTAATGACCTCGTAG
 10 GCGTAGTCAAAGAGCTCCAGCACCGTGAGGATGCTGGCCCCGATGAACAGCCCC
 ATCTGGCCCCCGATGTCACCAAGACAACAGGGTTTGGGGAAGGGCCTCTGGGGT
 GGAGGACCCTCATGGGACAGAAGTGAGCACCTGCTTTTGGATGATAGGGAGCC
 ACGCCATGCCCATGGCATGAGAAGGGGACAGGTGTCATCAGCAGCTCACCCAGG
 AGCCCTGCAATCTCATAGGCCTTCTTCTGTTCAATGGTCTCATAGTTGAGGACTTC
 15 AAAGAAAATGTCCAGCACCCAGGATGTTCTCCCTATGTATTGCTCAGATTTGTTG
 AACTTCTTGGCCAGGTACTTGGCTGAGGCTTTGCTGGGGATCTTGACCATGGACA
 GCTCTTTGCCATAGCGGGTCAGGTTGCAAGGCATTTACACACGCGAGTACTCCTG
 GTCCTTCTCCACCAGGAAGTCCAGAGCAGGATCTGCACACTCCTTGACTGCTCT
 GGAGTACAGTATGGGGCATCCCCTGGCATGTGCACCATGCGGCAGTTGCAGTTCT
 20 CCACCAGGTAGCGCGTCTCACAGTCGATGCGGCAGGCAGTGATGCTGTAGGAGT
 CGAAGAAATCCAAATCCGAGTCCATGGTAACAGCTTTGCAGGTGCCCCAGGGTG
 GGGGCAGGTAGATGAGCCGCTGCTCCTGGCAGGCCACAAAGGTCTGGAAGCCTG
 GGGCCACGCCAAAGCCAGCTGGTGGATGAAGGAGGTTTCATCCTGACTATGGA
 TCTGCACTTTGATGCCTGCTCGAAGGACGTCTCGTCAGTCTCCCCCACACAGG
 25 CAGGTACTCGTCCTGCTGGATGTCCAGCATGATTTCCAGCCCATTGCCCCGTCCCA
 TCCTTCATGGTCTTCAGCCGCGGCCGCCATCTCGGCCCGAGTTGAACGTGTAGC
 ACTTTCCATAGCGTGTGAAGACCACCTTGAAGTCTTCAGCGCTGCAGACCTCCCC
 CCGGAAGTGGCAGGAGAGCAGCATGTCTCGAATGTCGTGCCAGCTCGGTGCTA
 GAACTCACGCATGTTGAAGGGTTTGGGTTTGAAGCTGCGGAAGTTGGCTTTGTCC
 30 TGCAGTATCTCCAGCTGCTTTTCATCTGCCATCTGTGTGTCTGGTATCTCATACCT
 GTTGTGAGCAGGGCCAGCAGCTCCCCAGCATGATACAGGTCATTCTTGGAGACT
 TGGCTAAAGCGGAACCTCGTTGAGGTTGCACAGCGTGACAGCAGGGAAGGTAAGC
 TGAGAGGCAGCCACCTCGTCGAGCTTGGTGACATGGTGGTAGTGGAAGTAGTAC
 TGCACACGCTCCGTGCACACACACAGCAGCACAGCCAGCGAGCCCAGGAAGCAC
 35 AGGGCCACAGTGCCCGCTTCAGAGACAGCCGCTCGTAGGAGAAGATGTGGGCC
 AGGCCGTGCAGTGTGGAGCTGCTGGCGAAGGCCTGGATGCTCACCGGCTGGACG
 CCACCCACCTCCTCCTCCTCGGCCTTCAGTTCCATCCTTGTGAGGGGATCCTGAG
 GGGGCTTCGGCAAGCCGGCAGCCGGCGGGCTCCTGGGGCGCTGGACCGGTGG
 CGGGCTCAGCGCCGAGTCGCGGAGGGGCTCATGGCCCGGGCGGCGGGCGGGCGG
 40 CCGCCGCGGCACGCCGCGCAGAGCCCTGCAGGGAGCGCCCCGCCCGGCCCGCT
 CGGCTCCGATCTGTCCGCCCGCCGCGCGCTGGCTCGCTGGCTC

SEQ ID NO: 422

>6009 BLOOD gi|2281751|gb|U79666.1|HSU79666 Homo sapiens alpha1A-voltage-
 45 dependent calcium channel mRNA, splice form BI-1-Vi-GGCAAG, complete cds
 GGCTCGGCCCCGGGCAGCCGCCTTCTGAGCCCCCGACCCGAGGCGCCGAGCCGCC
 GCCGCCCGATGGGCTGGGCGGTGGAGCGTCTCCGCAGTCGTAGCTCCAGCCGCC
 GCGCTCCAGCCCCGGCAGCCTCAGCATCAGCGGCGGGCGGGCGGGCGGGCGGCG
 GCGTCTTCGCATCGTTCCGCCAGCGTAACCCGGAGCCCTTTGCTCTTTGCAGA

ATGGCCCGCTTCGGAGACGAGATGCCGGCCCGCTACGGGGGAGGAGGCTCCGGG
GCAGCCGCCGGGGTGGTCGTGGGCAGCGGAGGCGGGCGAGGAGCCGGGGGCAG
CCGGCAGGGCGGGCAGCCCGGGGCGCAAAGGATGTACAAGCAGTCAATGGCGC
AGAGAGCGCGGACCATGGCACTCTACAACCCCATCCCCGTCCGACAGAACTGCC
5 TCACGGTTAACCGGTCTCTCTTCTCTTCAGCGAAGACAACGTGGTGAGAAAATA
CGCCAAAAAGATCACCGAATGGCCTCCCTTTGAATATATGATTTTAGCCACCATC
ATAGCGAATTGCATCGTCCTCGCACTGGAGCAGCATCTGCCTGATGATGACAAGA
CCCCGATGTCTGAACGGCTGGATGACACAGAACCATACTTCATTGGAATTTTTTG
TTTCGAGGCTGGAATTAATAATCATTGCCCTTGGGTTTGCCTTCCACAAAGGCTCC
10 TACTTGAGGAATGGCTGGAATGTCATGGACTTTGTGGTGGTGCTAACGGGCATCT
TGGCGACAGTTGGGACGGAGTTTGACCTACGGACGCTGAGGGCAGTTCGAGTGC
TGCGGCCGCTCAAGCTGGTGTCTGGAATCCCAAGTTTACAAGTCGTCCTGAAGTC
GATCATGAAGGCGATGATCCCTTTGCTGCAGATCGGCCTCCTCCTATTTTTTGCAA
TCCTTATTTTTGCAATCATAGGGTTAGAATTTTATATGGGAAAATTCATACCACC
15 TGCTTTGAAGAGGGGACAGATGACATTCAGGGTGAGTCTCCGGCTCCATGTGGG
ACAGAAGAGCCCGCCCGCACCTGCCCAATGGGACCAAATGTCAGCCCTACTGG
GAAGGGCCCAACAACGGGATCACTCAGTTCGACAACATCCTGTTTGCAGTGCTG
ACTGTTTTCCAGTGCATAACCATGGAAGGGTGGACTGATCTCCTCTACAATAGCA
ACGATGCCTCAGGGAACACTTGGAAGTGGTTGTACTTCATCCCCCTCATCATCAT
20 CGGCTCCTTTTTTATGCTGAACCTTGTGCTGGGTGTGCTGTCAGGGGAGTTTGCCA
AAGAAAGGGAACGGGTGGAGAACCGGCGGGCTTTTCTGAAGCTGAGGCGGCAA
CAACAGATTGAACGTGAGCTCAATGGGTACATGGAATGGATCTCAAAGCAGAA
GAGGTGATCCTCGCCGAGGATGAAAGTGAACGGGGAGCAGAGGCATCCCTTTGAT
GGAGCTCTGCGGAGAACCACCATAAAGAAAAGCAAGACAGATTGTCTGAACCC
25 GAAGAGGCTGAGGATCAGCTGGCTGATATAGCCTCTGTGGGTCTCCCTTCGCCC
GAGCCAGCATTAAGAGTGCCAAGCTGGAGAACTCGACCTTTTTTCAAAAAAGG
AGAGGAGGATGCGTTTTCTACATCCGCCGCATGGTCAAACTCAGGCCTTCTACTG
GACTGTACTCAGTTTGGTAGCTCTCAACACGCTGTGTGTTGCTATTGTTCACTACA
ACCAGCCCGAGTGGCTCTCCGACTTCCTTTACTATGCAGAATTCATTTTCTTAGGA
30 CTCTTTATGTCCGAAATGTTTATAAAAATGTACGGGCTTGGGACGCGGCCTTACT
TCCACTCTTCCTTCAACTGCTTTGACTGTGGGGTTATCATTGGGAGCATCTTCGAG
GTCATCTGGGCTGTCTATAAAACCTGGCACATCCTTTGGAATCAGCGTGTTACGAG
CCCTCAGGTTATTGCGTATTTTCAAAGTCACAAAGTAAGTGGGCATCTCTCAGAAA
CCTGGTCGTCTCTCTCCTCAACTCCATGAAGTCCATCATCAGCCTGTTGTTTCTCC
35 TTTTCCTGTTCAATTGTCGTCTTCGCCCTTTGGGAATGCAACTCTTCGGCGGCCAG
TTTAATTTTCGATGAAGGGACTCCTCCCACTTTCGATACTTTTCAGCAGCAA
TAATGACGGTGTTCAGATCCTGACGGGCGAAGACTGGAACGAGGTCATGTACG
ACGGGATCAAGTCTCAGGGGGGCGTGCAGGGCGGCATGGTGTCTCCATCTATTT
CATTTGACTGACGCTCTTTGGGAACTACACCCTCCTGAATGTGTTCTTGGCCATCG
40 CTGTGGACAATCTGGCCAACGCCAGGAGCTCACCAAGGACGAGCAAGAGGAAG
AAGAAGCAGCGAACCAGAACTTGCCCTACAGAAAGCCAAGGAGGTGGCAGAA
GTGAGTCCTCTGTCCGCGGCCAACATGTCTATAGCTGTGAAAGAGCAACAGAAG
AATCAAAAGCCAGCCAAGTCCGTGTGGGAGCAGCGGACCAGTGAGATGCGAAA
GCAGAACTTGCTGGCCAGCCGGGAGGCCCTGTATAACGAAATGGACCCGGACGA
45 GCGCTGGAAGGCTGCCTACACGCGGCACCTGCGGCCAGACATGAAGACGCACTT
GGACCGGCCGCTGGTGGTGGACCCGAGGAGAACCGCAACAACAACCAACA
AGAGCCGGGCGGCCGAGCCACCTGTGGACCAGCGCCTCGGCCAGCAGCGCGCCG
AGGACTTCCTCAGGAAACAGGCCCGCTACCACGATCGGGCCCGGGACCCAGCG
GCTCGGCGGGCCTGGACGCACGGAGGCCCTGGGCGGGAAGCCAGGAGGCCGAG

CTGAGCCGGGAGGGACCCTACGGCCGCGAGTCGGACCACCACGCCCCGGGAGGGC
AGCCTGGAGCAACCCGGGTCTGGGAGGGCGAGGCCGAGCGAGGCAAGGCCGG
GGACCCCCACCGGAGGCACGTGCACCGGCAGGGGGGCAGCAGGGAGAGCCGCA
GCGGGTCCCCGCGCACGGGCGCGGACGGGGAGCATCGACGTCATCGCGCGCACC
5 GCAGGCCCGGGGAGGAGGGTCCGGAGGACAAGGCGGAGCGGAGGGCGCGGCAC
CGCGAGGGCAGCCGGCCGGCCCGGGGCGGCGAGGGCGAGGGCGAGGGCCCCGA
CGGGGGCGAGCGCAGGAGAAGGCACCGGCATGGCGCTCCAGCCACGTACGAGG
GGGACGCGCGGAGGGAGGACAAGGAGCGGAGGCATCGGAGGAGGAAAGAGAA
CCAGGGCTCCGGGGTCCCTGTGTGCGGGCCCCAACCTGTCAACCACCCGGCCAATC
10 CAGCAGGACCTGGGCCGCCAAGACCCACCCCTGGCAGAGGATATTGACAACATG
AAGAACAACAAGCTGGCCACCGCGGAGTCGGCCGCTCCCCACGGCAGCCTTGGC
CACGCCGGCCTGCCCCAGAGCCCAGCCAAGATGGGAAACAGCACCGACCCCGGC
CCCATGCTGGCCATCCCTGCCATGGCCACCAACCCCCAGAACGCCGCCAGCCGCC
GGACGCCCAACAACCCGGGGAACCCATCCAATCCCGGCCCCCCCAAGACCCCGG
15 AGAATAGCCTTATCGTACCAACCCCCAGCGGCACCCAGACCAATTGAGCTAAGA
CTGCCAGGAAACCCGACCACACCACAGTGGACATCCCCCAGCCTGCCACCCC
CCCTCAACCACACCGTCGTACAAGTGAACAAAAACGCCAACCAGACCCACTGC
CAAAAAAAGAGGAAGAGAAGAAGGAGGAGGAGGAAGACGACCGTGGGGAAGA
CGGCCCTAAGCCAATGCCTCCCTATAGCTCCATGTTTCATCCTGTCCACGACCAAC
20 CCCCTTCGCCGCCTGTGCCATTACATCCTGAACCTGCGCTACTTTGAGATGTGCAT
CCTCATGGTCATTGCCATGAGCAGCATCGCCCTGGCCGCCGAGGACCCTGTGCAG
CCCCAACGCACCTCGGAACAAGGTGCTGCGATACTTTGACTACGTTTTCAGGGC
TCTTTACCTTTGAGATGGTGATCAAGATGATTGAGCTGGGGCTCGTCTGTCATCA
GGGTGCCTACTTCCGTGACCTCTGGAATATTCTCGACTTCATAGTGGTCACTGGG
25 GCCCTGGTAGCCTTTGCCTTCACTGGCAATAGCAAAGGAAAAGACATCAACAAG
ATTAAATCCCTCCGAGTCCTCCGGGTGCTACGACCTCTTAAAACCATCAAGCGGC
TGCCAAAGCTCAAGGCTGTGTTTGACTGTGTGGTGAACCTACTTAAAAACGTCTT
CAACATCCTCATCGTCTACATGCTATTTCATGTTTCATCTTCGCCGTGGTGGCTGTGC
AGCTCTTCAAGGGGAAATTCTTCCACTGCACTGACGAGTCCAAAGAGTTTGAGAA
30 AGATTGTCGAGGCAAATACCTCCTCTACGAGAAGAATGAGGTGAAGGCGCGAGA
CCGGGAGTGGAAGAAGTATGAATTCCATTACGACAATGTGCTGTGGGCTCTGCTG
ACCCTCTTACCGTGTCCACGGGAGAAGGCTGGCCACAGGTCCTCAAGCATTTCGG
TGGACGCCACCTTTGAGAACCAGGGCCCCAGCCCCGGGTACCGCATGGAGATGT
CCATTTTCTACGTGCTACTTTGTGGTGTCCCCTTCTTCTTTGTCAATATCTTTG
35 TGGCCTTGATCATCATCACCTTCCAGGAGCAAGGGGACAAGATGATGGAGGAAT
ACAGCCTGGAGAAAAATGAGAGGGCCTGCATTGATTTCCGCATCAGCGCCAAGC
CGCTGACCCGACACATGCCGCAGAACAAGCAGAGCTTCCAGTACCGCATGTGGC
AGTTCGTGGTGTCTCCGCCTTTCGAGTACACGATCATGGCCATGATCGCCCTCAA
CACCATCGTGCTTATGATGAAGTTCTATGGGGCTTCTGTTGCTTATGAAAATGCC
40 CTGCGGGTGTTCAACATCGTCTTACCTCCCTCTTCTCTGGAATGTGTGCTGAA
AGTCATGGCTTTTGGGATTCTGAATTATTTCCGCGATGCCTGGAACATCTTCGACT
TTGTGACTGTTCTGGGCAGCATCACCGATATCCTCGTGAAGTGTGGGAATAA
CTTCATCAACCTGAGCTTTCTCCGCCTTCTCCGAGCTGCCCGGCTCATCAAACTTC
TCCGTGAGGGTTACACCATCCGCATTCTTCTCTGGACCTTTGTGCAGTCCTTCAAG
45 GCCCTGCCTTATGTCTGTCTGCTGATCGCCATGCTCTTCTTCATCTATGCCATCAT
TGGGATGCAGGTGTTTGGTAACATTGGCATCGACGTGGAGGACGAGGACAGTGA
TGAAGATGAGTTCCAAATCACTGAGCACAATAACTTCCGGACCTTCTTCCAGGCC
CTCATGCTTCTCTCCGGAGTGCCACCGGGGAAGCTTGGCACAACATCATGCTTT
CCTGCCTCAGCGGGAAACCGTGTGATAAGAACTCTGGCATCCTGACTCGAGAGT

GTGGCAATGAATTTGCTTATTTTTACTTTGTTTCCTTCATCTTCCTCTGCTCGTTTC
 TGATGCTGAATCTCTTTGTGCGCGTCATCATGGACAACCTTTGAGTACCTCACCCG
 AGACTCCTCCATCCTGGGCCCCCACCACCTGGATGAGTACGTGCGTGTCTGGGCC
 GAGTATGACCCCGCAGCTTGC GGTCGGATTCAATTATAAGGATATGTACAGTTTAT
 5 TACGAGTAATATCTCCCCCTCTCGGCTTAGGCAAGAAATGTCCTCATAGGGTTGC
 TTGCAAGCGGCTTCTGCGGATGGACCTGCCCCGTGCGAGATGACAACACCGTCCAC
 TTCAATTCCACCCTCATGGCTCTGATCCGCACAGCCCTGGACATCAAGATTGCCA
 AGGGAGGAGCCGACAAACAGCAGATGGACGCTGAGCTGCGGAAGGAGATGATG
 GCGATTTGGCCCAATCTGTCCCAGAAGACGCTAGACCTGCTGGTCACACCTCACA
 10 AGTCCACGACCTCACCGTGGGGAAGATCTACGCAGCCATGATGATCATGGAGT
 ACTACCGGCAGAGCAAGGCCAAGAAGCTGCAGGCCATGCGCGAGGAGCAGGAC
 CGGACACCCCTCATGTTCCAGCGCATGGAGCCCCCGTCCCCAACGCAGGAAGGG
 GGACCTGGCCAGAACGCCCTCCCCTCCACCCAGCTGGACCCAGGAGGAGCCCTG
 ATGGCTCACGAAAGCGGCCTCAAGGAGAGCCCCGTCTGGGTGACCCAGCGTGCC
 15 CAGGAGATGTTCCAGAAGACGGGCACATGGAGTCCGGAACAAGGCCCCCCCTACC
 GACATGCCCAACAGCCAGCCTAACTCTCAGTCCGTGGAGATGCGAGAGATGGGC
 AGAGATGGCTACTCCGACAGCGAGCACTACCTCCCCATGGAAGGCCAGGGCCGG
 GCTGCCTCCATGCCCCGCTCCCTGCAGAGAACCAGAGGAGAAGGGGCCGCGCA
 CGTGGGAATAACCTCAGTACCATCTCAGACACCAGCCCCATGAAGCGTTCAGCCT
 20 CCGTGCTGGGCCCCAAGGCCCGACGCCTGGACGATTACTCGCTGGAGCGGGTCC
 CGCCCGAGGAGAACCAGCGGCACCACCAGCGGCGCCGCGACCGCAGCCACCGCG
 CCTETGAGCGCTCCCTGGGCGGCTACACCGATGTGGACACAGGCTTGGGGACAG
 CCGTGAAGGAGCGGGACAGG
 AGCGGGGCCGGGCCAAGGATCGGAAGCATCGACAGCACCAACCACCAAGCAGCACC
 25 ACCACCACCATCCCCCGCCCCCGACAAGGACCGCTATGCCCAGGAACGGCCGG
 ACCACGGCCGGGCACGGGCTCGGGACCAGCGCTGGTCCCGCTCGCCACGAGG
 GCCGAGAGCACATGGCGCACCGGCAGGGCAGTAGTTCGGTAAGTGGAAGCCCAG
 CCCCCTCAACATCTGGTACCAGCACTCCGCGGCGGGGCCGCGCCAGCTCCCCCA
 GACCCCTCCACCCCCCGGCCACACGTGTCTATTCCCCTGTGATCCGTAAGGCC
 30 GCGGGCTCGGGGCCCGGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGGCG
 GGTGGCCAGGCGGGGCCGGGCCACCAGCGGCCCTCGGAGGTACCCAGGCCC
 CACGGCCGAGCCTCTGGCCGGAGATCGGCCGCCACGGGGGGCCACAGCAGCGG
 CCGCTCGCCAGGATGGAGAGGCGGGTCCCAGGCCCGGCCCGGAGCGAGTCCCC
 CAGGGCCTGTGACACGGCGGGGCCCGGTGGCCGGCATCTGGCCCGCACGTGTC
 35 CGAGGGGCCCGGGTCCCCGGCACCATGGCTACTACCGGGGCTCCGACTACGA
 CGAGGCCGATGGCCCGGGCAGCGGGGGCGGCGAGGAGGCCATGGCCGGGGCCT
 ACGACGCGCCACCCCCGTACGACACGCGTCTCGGGCGCCACCGGGCGCTCGC
 CCAGGACTCCCCGGGCCTCGGGCCCCGGCCTGCGCCTCGCCTTCTCGGCACGGCCG
 GCGACTCCCCAACGGCTACTACCGGGCGCACGGACTGGCCAGGCCCCGCGGGCC
 40 GGGCTCCAGGAAGGGCCTGCACGAACCCTACAGCGAGAGTGACGATGATTGGTG
 CTAAGCCCGGGCGAGGGAATTCGATATCAAGCTTATCGATACCGTCGACCTCGA
 GGGGGGGCCCGGTACCAATTGCGCCTATAGTGAGTCGTATTA

SEQ ID NO: 423

45 >6010 BLOOD Hs.75794 gnl|UG|Hs#S2650864 Homo sapiens cDNA FLJ12746 fis, clone
 NT2RP2000842, highly similar to Human lysophosphatidic acid receptor homolog mRNA
 /cds=UNKNOWN /gb=AK022808 /gi=10434421 /ug=Hs.75794 /len=2687
 ACGGCGCGCTGGGCTCACACTGTCCCGCCGCGGACGGGCTTTGTGGTTGGGGGC
 GCGCGTGCGAGTGCCAGTGAGAGTGTGGGTGCGCGCTGTGGGCCGCGGCGCGGG

TGGGTGGCCGTGCGTTCTTGCGAGCCGGCCTGCAGGAGGCGAGGCTCCCCTGGCC
TCCCGCACCCAGCGGCGGACCGAGCCCCTGGAGGGAAGTTGCCGCAGCCGCCCG
GGCCGCCGGCCCTCCTGTCCCGCGCCAGGTACACAGCTTCTCCTAGCATGACTTC
GATCTGATCAGCAAACAAGAAAATTTGTCTCCCGTAGTTCTGGGGCGTGTTACCC
5 ACCTACAACCACAGAGCTGTCATGGCTGCCATCTCTACTTCCATCCCTGTAATTT
ACAGCCCCAGTTCACAGCCATGAATGAACCACAGTGCTTCTACAACGAGTCCATT
GCCTTCTTTTATAACCGAAGTGGAAAGCATCTTGCCACAGAATGGAACACAGTCA
GCAAGCTGGTGATGGGACTTGGAATCACTGTTTGTATCTTCATCATGTTGGCCAA
CCTATTGGTCATGGTGGCAATCTATGTCAACCGCCGCTTCCATTTTCCTATTTATT
10 ACCTAATGGCTAATCTGGCTGCTGCAGACTTCTTTGCTGGGTTGGCCTACTTCTAT
CTCATGTTCAACACAGGACCCAATACTCGGAGACTGACTGTTAGCACATGGCTCC
TTCGTCAAGGCCCTCATTGACACCAGCCTGACGGCATCTGTGGCCAACTTACTGGC
TATTGCAATCGAGAGGCACATTACGGTTTTCCGCATGCAGCTCCACACACGGATG
AGCAACCGGCGGGTAGTGGTGGTCATTGTGGTCATCTGGACTATGGCCATCGTTA
15 TGGGTGCTATACCCAGTGTGGGCTGGAAGTGTATCTGTGATATTGAAAATTGTTT
CAACATGGCACCCCTCTACAGTGACTCTTACTTAGTCTTCTGGGCCATTTTCAACT
TGGTGACCTTTGTGGTAATGGTGGTCTCTATGCTCACATCTTTGGCTATGTTTCG
CAGAGGACTATGAGAATGTCTCGGCATAGTTCTGGACCCCGGCGGAATCGGGAT
ACCATGATGAGTCTTCTGAAGACTGTGGTCATTGTGCTTGGGGCCTTTATCATCTG
20 CTGGACTCCTGGATTGGTTTTGTTACTTCTAGACGTGTGCTGTCCACAGTGCGACG
TGCTGGCCTATGAGAAATTCCTTCTCCTTGCTGAATTCAACTCTGCCATGAAC
TGGCATCATTTACTCCTACCGCGACAAAGAAATGAGCGCCACCTTTAGGCGAGTCC
TCTGCTGCCAGCGCAGTGAGAACCCACCGGCCCGACAGAAGGCTCAGACCGCT
CGGCTTCTCCTCAACCAACCATCTTGGCTGGAGTTCACAGCAATGACCACTC
25 TGTGGTTTTAGAACGGAAACTGAGATGAGGAACCAAGCCGCTCTCTTGGAGGAT
AAACAGCCTCCCCCTACCCAATTGCCAGGGCAAGGTGGGGTGTGAGAGAGGAGA
AAAGTCAACTCATGTACTTAAACACTAACCAATGACAGTATTTGTTCTTGGACCC
CACAAGACTTGATATATATTGAAAATTAGCTTATGTGACAACCCTCATCTTGATC
CCCATCCCTTCTGAAAGTAGGAAGTTGGAGCTCTTGCAATGGAATTCAAGAACAG
30 ACTCTGGAGTGTCCATTTAGACTACACTAACTAGACTTTTAAAAAGATTTTGTGTG
GTTTGGTGCAAGTCAGAATAAATCTGGCTAGTTGAATCCACAACCTTCATTTATA
TACAGGCTTCCCTTTTTTATTTTTAAAGGATACGTTTCACTTAATAAACACGTTTA
TGCCTATCAGCATGTTTGTGATGGATGAGACTATGGACTGCTTTTAAACTACCAT
AATTCATTTTTCCTTACATAGGAAAACCTGTAAGTTGGAATTATCTTTGTTTA
35 GAAAGCATGCATGTAATGTATGTATGCAGTATGCCTTACTTAAAAAGATTAAAAG
GATACTAATGTAAATCTTCTAGGAAATAGAACCTAGACTTCAAAGCCAGTATTT
GTTTAGGTCATGAAGCAAACAATGCTCTAATCACAATATTAAGTGTTAATTTAA
ATGTTGTAACAAGTATAAAACAGGGAATGTAAGTTTATTACCAAAGTGATATGTA
TTCCAAAAAAGTCATAGAAGATGAAGCACTATAATATTGTTCCCATATATTTAAA
40 ATACCCAAGTACATTCTAATTACCAAGTATATCAGAGGAAAATTTTCGTAGTCTTT
GTAAAATAATATACTCATCATAGAAAACCTTGA AAAATGCAGAAATGTATAAAAA
AGCAAAAATGATTACTGATAATATCACAACCCAGAAGTAACCACCTTTAAAAAG
CAACCCCATGTATGCCTATATGTGTATTGTATACTTTTTTTACATAATTGGAGTC
ATACTGTAAACAGTTTTTATAAGTAGATCTTTTTTCATTGCAAAAATTGCCACATTTTC
45 TTATGGCATTAAAAATTTTACAAAAACATAATTTTAATGGCTATATTATATCCAT
TTAATGGATGCAACTCAGTTTATTTAACCATTCCCATGTTGTAACTATTTAGGTT
GTTTCTAATTTTCATTATTATAAAGTTGCAGAAATTTGGTGT

SEQ ID NO: 424

>6044 BLOOD 1089570.2 L35539 g577412 Human G-protein-coupled receptor (GPR1)

gene, complete cds. 0

5 GATAAAAGTGGAATGAGGAATGCAGCCGTTCTGAACACCACCCTCCATTTTCATTC
TGGAACCGGGAAGGTACACCCAGGCATGACAATAGCTTCTCTCCTCACAGAAAT
TTAACTGATTTCTTCATTCTCCATTTAGCAAGGTCATGGAAGATTTGGAGGAAAC
ATTATTTGAAGAATTTGAAAACCTATTCCTATGACCTAGACTATTACTCTCTGGAGT
CTGATTTGGAGGAGAAAGTCCAGCTGGGAGTTGTTCACTGGGTCTCCCTGGTGTT
ATATTGTTTGGCTTTTGTCTGGGAATTCCAGGAAATGCCATCGTCATTTGGTTCA
10 CGGGGTTCAAGTGGAAGAAGACAGTCACCACTCTGTGGTTCCTCAATCTAGCCAT
TGCGGATTTTCATTTTTCTCTCTTTCTGCCCCTGTACATCTCCTATGTGGCCATGAA
TTTCCACTGGCCCTTTGGCATCTGGCTGTGCAAAGCCAATTCCTTCACTGCCCAGT
TGAACATGTTTGCCAGTGTTTTTTCTGACAGTGATCAGCCTGGAGCACTATATT
CACTTGATCCATCCTGTCTTATCTCATCGGCATCGAAACCTCAAGAACTCTCTGAT
15 TGTCATTATAT

SEQ ID NO: 425

>6051 BLOOD gi|762887|gb|U16953.1|HSU16953 Human potassium channel beta3 subunit

mRNA, complete cds

20 GCAAGATACAGTGAGTCTTAAAGTTAAGCACCGTGCAATTAGCTTTGCTTCCTTG
GGTTTTTGAACATGCATCTGTATAAACCTGCCTGTGCAGACATCCCGAGCCCCA
AGCTGGGTCTGCCAAATECAGTGAATCGGCTCTAAAATGTAGATGGCACCTAG
CAGTGACCAAGACTCAGCCTCAGGEGGCCTGCAAACCTGTGAGGCCCAGTGGAG
CAGCCGAACAGAAATATGTGGAAAAGTTTCTACGTGTTTCATGGAATTCGTTGCA
25 GGAAACCACCAGAGCAGAGACGGGCATGGCATAACAGGAATCTTGGAAAATCAG
GACTCAGAGTTTCTTGCTTGGGTCTTGGAACATGGGTGACATTTGGAGGTCAAAT
TTCAGATGAGGTTGCTGAACGGCTGATGACCATCGCCTATGAAAGTGGTGTTAAC
CTCTTTGATACTGCCGAAGTCTATGCTGCTGGAAAGGCTGAAGTGATTCTGGGGA
GCATCATCAAGAAGAAAGGCTGGAGGAGGTCCAGTCTGGTCATAACAACCAAAC
30 TCTACTGGGGTGGAAGGCTGAAACAGAAAGAGGGCTGTCAAGAAAGCATATTA
TTGAAGGATTGAAGGGCTCCCTCCAGAGGCTGCAGCTCGAGTATGTGGATGTGGT
CTTTGCAAATCGACCGGACAGTAACACTCCCATGGAAGAAATTGTCCGAGCCAT
GACACATGTGATAAACCAAGGCATGGCGATGTACTGGGGCACCTCGAGATGGAG
TGCTATGGAGATCATGGAAGCCTATTCTGTAGCAAGACAGTTCAATATGATCCCA
35 CCGGTCTGTGAACAAGCTGAGTACCATCTTTTCCAGAGAGAGAAAGTGGAGGTC
CAGCTGCCAGAGCTCTACCACAAAATAGGTGTTGGCGCAATGACATGGTCTCCAC
TTGCCTGTGGAATCATCTCAGGAAAATACGGAAACGGGGTGCCTGAAAGTTCCA
GGGCTTCACTGAAGTGCTACCAGTGGTTGAAAGAAAGAATTGTAAGTGAAGAAG
GGAGAAAACAGCAAAACAAGCTAAAAGACCTTTCCCAATTGCGGAGCGTCTGG
40 GATGCACACTACCTCAGCTAGCTGTTGCGTGGTGCCTGAGAAATGAAGGTGTGA
GTTCTGTGCTCCTGGGATCATCCACTCCTGAACAACTCATTGAAAACCTTGGTGC
CATTGAGTTCTCCCAAAGATGACATCACATGTGGTAAATGAGATTGATAACATA
CTGCGCAACAAGCCCTACAGCAAGAAGGACTATAGATCATAAGGCAATGCATGA
ACCACAGAAGCTGCATGGTTAAAATAGCGGCCTGTGCCCAGTACAGAAAGGTGT
45 TACTAACCAGTCTTTTGAATCACTTAGCAGCTTGCTGCAACCTCTAGTGTCCCTCC
CTGGATTCTTTGAGGTGTCTGACTGTCGCTACCACTGTGCACATCTGAAAACCTCA
CAACCAAGAAAATCCATTCTATTTTCTTATCTTGGACTGGAGTCACCTATTATTGC
ATTGCTGTATACACCTCATGCTTATGCAATGGG

SEQ ID NO: 426

>6117 BLOOD 197754.2 U67319 g1894912 Human Lice2 beta cysteine protease mRNA,
complete cds. 0

5 GACTTCAATCATCACCCAAATGTTGCTAACTCCCAAAGGCCTGCCTCCATCCAGA
CCTATCTTCCAGAGCTCCCCACTCACAGGCACAGGAGTCACTACGTCAGCATTTA
CTGTGTACCGTTTTAGGGGCTGGTCTGCAGTGAACCAGACTGCCTGTGTCCATGG
AGCTTAGAAGAAGTGGGAAGAGCATTATCAGGCTACGAAGACAGAGTGGGGTA
AAACAGCAGAGATCAATGAGATCAGAGCACACCCTCGGAGGAAGGGATACATG
ACAAATGCCTGAACGGAGAGAGGGAGTGAAGTGTGCAAACACACAGCCAGGAG
10 TTTTCCAAGGACAGGGAGGAGAAAGTATAAGGCCTGCTGTACCCTCGATGCAAA
ACATGAGAAAGCCGACTGTGCCAGTCCCAGCCGCCCTACCGCCGTGGGAACGAT
GCTGTAATGGACTGTGTTGGTTGGCCTCCAGGCAGGAAGTGGCACTTGGAAG
AACACCAGCTGCGGTGGTAGCAGTGGGATTTGTGCTTCTTATGTTACCCAGATGG
CAGATGATCAGGGCTGTATTGAAGAGCAGGGGGTTGAGGATTCAGCAAATGAAG
15 ATTCAGTGGATGCTAAGCCAGACCGGTCCTCGTTTGTACCGTCCCTCTTCAGTAA
GAAGAAGAAAAATGTCACCATGCGATCCATCAAGACCACCCGGGACCGAGTGCC
TACATATCAGTACAACATGAATTTTGAAGCTGGGCAAATGCATCATAATAAA
CAACAAGAACTTTGATAAAGTGACAGGTATGGGCGTTTCGAAACGGAACAGACAA
AGATGCCGAGGCGCTCTTCAAGTGCTTCCGAAGCCTGGGTTTTGACGTGATTGTC
20 TATAATGACTGCTCTTGTGCCAAGATGCAAGATCTGCTTAAAAAAGCTTCTGAAG
AGGACCATACAAATGCCGCCTGCTTCGCCTGCATCCTCTTAAGCCATGGAGAAGA
AAATGTAATTTATGGGAAGATGGTGTACACCAATAAAGGATTTGACAGECCA
CTTTAGGGGGGATAGATGCAAAACCTTTTAGAGAAACCCAAACTCTTCTTCATT
CAGGCTTGCCGAGGGACCGAGCTTGATGATGGCATCCAGGCCGAETCGGGGGCCC
25 ATCAATGACACAGATGCTAATCCTCGATACAAGATCCCAGTGGAAGCTGACTTCC
TCTTCGCCTATTCCACGGTTCAGGCTATTACTCGTGGAGGAGCCCAGGAAGAGG
CTCCTGGTTTGTGCAAGCCCTCTGCTCCATCCTGGAGGAGCACGGAAAAGACCTG
GAAATCATGCAGATCCTCACCAGGGTGAATGACAGAGTTGCCAGGCACCTTGAG
TCTCAGTCTGATGACCCACACTTCCATGAGAAGAAGCAGATCCCCTGTGTGGTCT
30 CCATGCTCACCAAGGAACTCTACTTCAGTCAATAGCCATATCAGGGGTACATTCT
AGCTGAGAAGCAATGGGTCACTCATTAAATGAATCACATTTTTTTATGCTCTTGAA
ATATTCAGAAATTCTCCAGGATTTTAATTTAGGAAAATGTATTGATTCAACAGG
GAAGAACTTTCTGGTGTCTTTTTGTTCTCTGAATTTTCAGAGACTTTTTTTAT
AATGTTATTCAATTTGGTGACTGTGTAACCTTCTCTTAAGATTAATTTTCTCTTTGTA
35 TGTCTGTTACCTTGTTAATAGACTTAATACATGCAACAGAAGTGACTTCTGGAGA
AAGCTCATGGCTGTGTCCACTGCAATTGGTGGTAACAGTGGTAGAGTCATGTGTG
CACTTGGCAAAAAGAATCCCAATGTTTGACAAAACACAGCCAAGGGGATATTTA
CTGCTCTTTATTGCAGAATGTGGGTATTGAGTGTGATTGAATGATTTTTTCATTGG
CTTAGGGCAGATTTTCATGCAAAAGTTCTCATATGAGTTAGAGGAGAAAAAGCTT
40 AATGATTCTGATATGTATCCATCAGGATCCAGTCTGGAAAACAGAAACCATTCTA
GGTGTTC AACAGAGGGAGTTTAATACAGGAAATTGACTTACATAGATGATAAA
AGAGAAGCCAAACAGCAAGAAGCTGTTACCACACCCAGGGCTATGAGGATAATG
GGAAGAGGTTTGGTTTCCTGTGTCCAGTAGTGGGATCATCCAGAGGAGCTGGAA
CCATGGTGGGGGCTGCCTAGTGGGAGTTAGGACCACCAATGGATTGTGGAAAAT
45 GGAGCCATGACAAGAACAAAACCACTGACTGAGATGGAGTGAGCTGAGACAGA
TAAGAGAATACCTTGGTCTCACCTATCCTGCCCTCACATCTTCCACCAGCACCTTA
CTGCCCAGGCCTATCTGGAAGCCACCTCACCAAGGACCTTGAAGAGCAAGGGA
CAGTGAGGCAGGAGAAGAACAAGAAATGGATGTAAGCCTGGCCCATAATGTGA
ACATAAGTAATCACTAATGCTCAACAATTTATCCATTCAATCATTTATTATTGGG

TTGTCAGATAGTCTATGTATGTGTAAACAATCTGTTTTGGCTTTATGTGCAAAAT
CTGTTATAGCTTTAAAATATATCTGGAACCTTTTAGATTATTCCAAGCCTTATTTT
GAGTAAATATTTGTTACTTTTAGTTCTATAAGTGAGGAAGAGTTTATGGCAAAGA
TTTTTGGCACTTTGTTTTCAAGATGGTGTATCTTTTGAATTCTTGATAAATGACT
5 GTTTTTTCTGCCTAATAGTAACTGGTTAAAAAACAAATGTTTCATATTTATTGATT
AAAAATGTGGTTGCTTAATTCCT

SEQ ID NO: 427

>6121 BLOOD 138709.5 U40992 g6031211 Human heat shock protein hsp40 homolog

10 mRNA, complete cds. 0

GGAGGCTGTCTCCTGTGTAGTGTATATTTATCTGTAAGTGAGCCGTTGGGGAAGG
ATTGAATACAGAGACGCTGTCTGCTTGCTGCCTTAAGACAGCTAGCTGAATTGCT
GATTAACTTTTAAAATACCCAGCTTGGTTTATTTTTCTTAGAATCTGTTGCTAAGA
CTGGGGACGCTGTTTTCTTTACAAAGGGAAATCTAAGTTAATTTCAAGGCATTC
15 GAAATGGGGAAAGACTATTATTGCATTTTGGGAATTGAGAAAGGAGCTTCAGAT
GAAGATATTAAAAAGGCTTACCGAAAACAAGCCCTCAAATTTTCATCCGGACAAG
AACAAATCTCCTCAGGCAGAGGAAAAATTTAAAGAGGTTCGAGAAAGCTTATGAA
GTATTGAGTGATCCTAAAAAGAGAGAAATATATGATCAGTTTGGGGAGGAAGGG
TTGAAAGGAGGAGCAGGAGGTACTGATGGACAAGGAGGTACCTTCCGGTACACC
20 TTTTCATGGCGATCCTCATGCTACATTTGCTGCATTTTTTCGGAGGGTCCAACCCCTT
TGAAATTTTCTTTGGAAGACGAATGGGTGGTGGTAGAGATTCTGAAGAAATGGA
AATAGATGGTGATCCTTTTAGTGCTTTGGTTTCAGCATGAATGGATATCCAAGA
GACAGGAATTCTGTGGGGCCATCCCGCCTGAAACAAGATCCTCCAGTTATTCATG
AATCTAGAGTATCACTTGAAGAGATATATAGTGGTTGTACCAAACGGATGAAGA
25 TTTCTCGAAAAAGGCTAAACGCTGATGGAAGGAGTTACAGATCTGAGGACAAAA
TTCTTACCATTGAGATTAAAAAAGGGTGGAAAGAAGGCACCAAAATTACTTTTCC
AAGAGAAGGAGATGAAACACCAAAATAGTATTCCAGCAGACATTGTTTTTATCATT
AAAGACAAAGATCATCCAAAATTTAAAAGGGATGGATCAAATATAATTTATACT
GCTAAAATTAGTTTACGAGAGGCATTGTGTGGCTGCTCAATTAATGTACCAACAC
30 TGGATGGAAGAAACATACCTATGTCAGTAAATGATATTGTGAAACCCGGAATGA
GGAGAAGAATTATTGGATATGGGCTGCCATTTCCAAAAAATCCTGACCAACGTG
GTGACCTTCTAATAGAATTTGAGGTGTCCTTCCCAGATACTATATCTTCTTCATCC
AAAGAAGTACTTAGGAAACATCTTCCTGCCTCATAGAATGAAGAAGCTTTGTTAGA
CATATTTTGATAAGGCACTGAAAATATAAAAGGACTGGTAGTTTACTGATGTAGA
35 TGTGAATTCTGTATAAAGATGTGTAAATTCCTTTGAGGGTTCATTAAATTGCATG
AATAGAGACGGGTCAAATAAATAGGCAAAAGGGATTTTACAGTTAGAGATAAA
AGAGAAAACCATTCATCTGATTTTATTTTCAATTTCTCCTGATTCAGATATTTTAGT
AATTTGCTTATATGTAAAAGTTGTTTTGTGGAGTCAGTGGATATATTTCTAATGA
AGTGCTAGACTATCCAATTACTTAATTTCTTATACCTTTAGATAATCAGTATGAAA
40 AGTTCCCATTTATAATGGAAATGAAAATTCCTTAACATAACTATACATGTAATATG
TATTTCTAGAAGAGAATAAAAACCCAAGTCAGTTATTAGATTTAAATCACCTTCT
GAAATGCTGCTATAGGGCTGGTATCTGTAAAAGAATATCCTGATGCATCTGTTTC
ACCATTTTGATTTTTAAAGTATGCTGTAGCATTTCTTAATAACATCGTTGTGATGT
TCTTAAGGCAGATCTTTCTTCATAAAAAGGAAAGTAATGGCAATTTCTCTCCTGT
45 GGAAATCCCAATTGCTTGAATTACTGATATTTTAGAATAGACTTTTTAAATGCC
ATATGTAATTTTATGCAAGTTGACTATATATCTTGTACTTAATAAATTATAGGCTC
ATTTTGTTCTCTGCTAGTTTAAAGTAATTCGTTAATAATAGATGTGTTTTAGAG
GAAATGCTGTTACTTGGAATTAATTTCCAGTTATACAGTCTTCTATAACTTACTA
ATAATATTCTATATGTACTTTATGTAATTTCCCTAAAAAGAATGAACTACCACTA

CACTATGGTGTAAACCAAAATATAGGGAAAATAAACACTAACTGCTGCTTATG
GATAATGTTGCAACTACTTGTTATGCATATAAATATTTTACTTTTTACATGTATA
GATTGCATTTCTTAGGTGTTTTAATTTTTTAAATATATTTATGTTTTAAAAATTTAG
TTTTGTTTTCTGTTTTATAACTATAGTGAGAATGATGTTTTGAAGCAAAATTTTTG
5 GTTATAAAATAGTTTTTCAGGATTATATATATATACTGGATCCTATCGCCTTTTA
GTAGAATATGAAATATTCTTTTAGAAATCCAATATAAATAGGTTATAATAGCCAT
ATTCTTTATTACTTTATTGAGATATAATTTACATGCCATAAAGTTTACCCTTAAAA
TAGATAATTCAGTGGTTTTTAGTGATATTACAAAGTGGTACAATCATCATCACTT
TCTAATTCAGAATATT

10

SEQ ID NO: 428

>6133 BLOOD 474194.5 M88279 g186389 Human immunophilin (FKBP52) mRNA,
complete cds. 0

15

GCCGCGTGCGAGAGGTGCTCAAGCCTCCTGCGCGGTCCGCAGTCAGTGCCGCCGC
GCCCCGCCCTCCCGCACGCCCCGCAGGTAGCGCCCCCGCCGCGGCCAGAGTGC
GCTCGCGCCGGCACCAGCTCCCGGATAAACGCGCGCGCGCGGAGATGACAGC
CGAGGAGATGAAGGCGACCGAGAGCGGGGCGCAGTCGGCGCCGCTGCCCATGG
AGGGAGTGGACATCAGCCCCAACAGGACGAAGGCGTGCTGAAGGTCATCAAG
AGAGAGGGCACAGGTACAGAGATGCCCATGATTGGGGACCGAGTCTTTATCCAC
20 TACACTGGCTGGGCTATTAGATGGCACAAAGTTTGACTCCAGTCTGGATCGCAAG
GACAAATTCTCCTTTGACCTGGGAAAAGGGGAGGTCATCAAGGCTTGGGACATT

20

GCCATAGCCACCATGAAGGTGGGGGAGGTGTGCGACATCACCTGCAAACCAGAA
TATGCTACGGTTCAAGCAGGCAAGTCCCTCAAAGATTCCCCCAATGCGACGCTTG
TATTTGAGGTGGAGTTGTTTGAGTTTAAGGGAGAAGATCTGACGGAAGAGGAAG

25

ATGGCGGAATCATTTCGAGAATACAGACTCGCGGTGAAGGCTATGCTAAGCCCA
ATGAGGGTGCTATCGTGGAGGTTGCACTGGAAGGGTACTACAAGGACAAGCTCT
TTGACCAGCGGGAGCTCCGCTTTGAGATTGGCGAGGGGGAGAACCTGGATCTGC
CTTATGGTCTGGAGAGGGCCATTCAGCGCATGGAGAAAGGAGAACATTCCATCG
TGTACCTCAAGCCCAGCTATGCTTTTGGCAGTGTTGGGAAGGAAAAGTTCCAAAT

30

CCCACCAAATGCTGAGCTGAAATATGAATTACACCTCAAGAGTTTTGAAAAGGC
CAAGGAGTCTTGGGAGATGAATTCAGAAGAGAAGCTGGAACAGAGCACCATAGT
GAAAGAGCGGGGCACTGTGTACTTCAAGGAAGGTAAATACAAGCAAGCTTTACT
AGAGTATAAGAAGATCGTGTCTTGGCTGGAATATGAGTCTAGTTTTTCCAATGAG
GAAGCACAGAAAGCACAGGCCCTTCGACTGGCCTCTCACCTCAACCTGGCCATGT

35

GTCATCTGAAACTACAGGCCTTCTCTGCTGCCATTGAAAGCTGTAACAAGGCCCT
AGAACTGGACAGCAACAACGAGAAGGGCCTCTCCGCCGGGGAGAGGGCCACCT
GGCCGTGAATGACTTTGAACTGGCACGGGCTGATTTCCAGAAGGTCCTGCAGCTC
TACCCCAACAACAAGCCGCCAAGACCCAGCTGGCTGTGTGCCAGCAGCGGATC
CGAAGGCAGCTTGCCCCGGGAGAAGAAGCTCTATGCCAATATGTTTGAGAGGCTG

40

GCTGAGGAGGAGAACAAGGCCAAGGCAGAGGCTTCTCAGGAGACCATCCCACT
GACACAGAGATGAAGGAGGAGCAGAAGAGCAACACGGCAGGGAGCCAGTCTCA
GGTGGAGACAGAAGCATAGCCCCTCTCCACCAGCCCTACTCCTGCGGCTGCCTGC
CCCCCAGTCTCCCCACTCCACCCTGTTAGTTTTGTAAAACTGAAGAATTTTGAGT
GAATTAGACCTTTATTTTTCTATCTGGTTGGATGGTGGCTTTAGGGGAAGGGGGA

45

AAGGTGTAGGCTGGGGGATTGAGGTGGGGAATCATTTTAGCTGGTGTGAGCCCT
CTTCCCTTCCCTCCATTGCACATGAACATATGTCCATCCATATATATTCATCAGAAT
GTTAATTTATTTTGCTCCCTCTGTTAGGTCCATTTTCTAAGGGTAGAAGAGGCAAG
TGGTAGGGATGAGGTCTGATAAGAACCCAGGGTGGAGAGGGAGACTCCTGGGCA
GCCGTTTTCTCATCCTTTCCCTCTCCAGTCCATTTCCAAATGTGGCCTCCATGT

GGGTGCTAGGGACATGGGAAAAACCACTGCTATGCCATTTCTTCTCTCTGTTCCC
 TTCTCACCCCCGACGGTGTGGCTGATGATGTCTTCTGGTGTGATGGTGACCACC
 CCCTGTTCCCTGTTCTGGTATTTCCCCTGTCAGTTTCCCCTCTCGGCCAGGTTGTGT
 CAAAAATCCCCTCAGCCTCTTCTCTGCACGTTGCTGAAGGTCCAGGCTTGCCTC
 5 AAGTTCCATGCTTGAGCAATAAAGTGGAAACAATAAAACCTGGGTGTGAGACAA
 CCGTTTCTGTT

SEQ ID NO: 429

>6157 BLOOD Hs.1613 gn||UG|Hs#S4015 H.sapiens mRNA for A2a adenosine receptor

10 /cds=(893,2131) /gb=X68486 /gi=400451 /ug=Hs.1613 /len=2988
 CATCACCTTTTTTTAAGTAGTAAGAATAAAGCCACTGTATGATTCTCTTAATAGCT
 ATACATTAATCCTGTTTTTAGTGCTGACTGGGCCAGCCTTCCGGAACTGGAGTC
 TGTCCTTTTTCAGTGCTTTTTTGTGTTTTTGTGTTTTTTCGAGACGGGGTCGATCAC
 GGCTCACACAGCCTTAACCTCCAGGGCTCCAGCAATCCTCCCACCTCAGCCTCC
 15 TGAGTAGCTGGGACCACAGGTGTGTGCCACCATCTCCAGCAGTTTGTGTTATTTAT
 TTTTCTTTTTTTTTTTTTTGGTAGAAATGGGCTTTTCGCCCATGTTGCCCAAGCTGG
 TCTTGCACTTCTGGGCTGAAGCAATCCTCTCGCCTTGGCCTCCCAGAGCCTTGGG
 ATTACAGAATCATGGGTGAGAGCTGGCATGGCCCCCTAGAGGTCATTTGGGGTCC
 AGCTGCCTCACCGTATCAATGAGGAACTGAGGCCCAGAAAAGAAAAGCATTTT
 20 TGCCCAGAGTCCCTCAGAAAAAAACAGACCACATCTGATCCTTGGCCCTGAGTCC
 AGAGTGGGAGGCACCGTGACAACAATGCGCAGAGCAGGGAATGCAGGGAGCCA
 TGGATAGTGCTGGGGTGCCTCAGGAAACCTGAAGCTGGGCTGAGCCATGATGCT
 GCTGCCAGAACCCCTGCAGAGGGCCTGGTTTCAGGAGACTCAGAGTGCTCTGTGA
 AAAAGCCCTTGGAGAGCGGCCCCAGCAGGGCTGCACTTGGCTCCTGTGAGGAAGG
 25 GGCTCAGGGGTCTGGGCCCTCCGCCTGGGCCGGGCTGGGAGCCAGGCGGGCGG
 CTGGGCTGCAGCAATGGACCGTGAGCTGGCCCAGCCCGCGTCCGTGCTGAGCCT
 GCCTGTGCTGTGTGGCATGCCCATCATGGGCTCCTCGGTGTACATCACGGTGGAG
 CTGGCCATTGCTGTGCTGGCCATCCTGGGCAATGTGCTGGTGTGCTGGGCCGTGT
 GGCTCAACAGCAACCTGCAGAACGTCAACCACTACTTTGTGGTGTCACTGGCGGC
 30 GGCCGACATCGCAGTGGGTGTGCTCGCCATCCCCCTTGCCATCACCATCAGCACC
 GGGTTCTGCGCTGCCTGCCACGGCTGCCTCTTCATTGCCTGCTTCGTCTGGTCTT
 CACGCAGAGCTCCATCTTCAGTCTCCTGGCCATCGCCATTGACCGCTACATTGCC
 ATCCGCATCCCGCTCCGGTACAATGGCTTGGTGACCGGCACGAGGGCTAAGGGC
 ATCATTGCCATCTGCTGGGTGCTGTGCTTGGCATCGGCCTGACTCCCATGCTAGG
 35 TTGGAACAACCTGCGGTGAGCCAAAGGAGGGCAAGAACCACTCCCAGGGCTGCGG
 GGAGGGCCAAGTGGCCTGTCTCTTTGAGGATGTGGTCCCCATGAACTACATGGTG
 TACTTCAACTTCTTTGCCTGTGTGCTGGTGCCCTGCTGCTCATGCTGGGTGTCTA
 TTTGCGGATCTTCTGGCGGCGCGACGACAGCTGAAGCAGATGGAGAGCCAGCC
 TCTGCCGGGGGAGCGGGCACGGTCCACACTGCAGAAGGAGGTCCATGCTGCCAA
 40 GTCACTGGCCATCATTGTGGGGCTCTTTGCCCTCTGCTGGCTGCCCCTACACATCA
 TCAACTGCTTCACTTTCTTCTGCCCCGACTGCAGCCACGCCCCTCTCTGGCTCATG
 TACCTGGCCATCGTCCTCTCCACACCAATTGGTGTGAATCCCTTCATCTACGC
 CTACCGTATCCGCGAGTTCCGCCAGACCTTCCGCAAGATCATTCGCAGCCACGTC
 CTGAGGCAGCAAGAACCTTTCAAGGCAGCTGGCACCAGTGCCCGGGTCTTGGCA
 45 GCTCATGGCAGTGACGGAGAGCAGGTGAGCCTCCGTCTCAACGGGCCACCCGCCA
 GGAGTGTGGGCCAACGGCAGTGCTCCCCACCTGAGCGGAGGCCCAATGGCTAT
 GCCCTGGGGCTGGTGAGTGGAGGGAGTGCCCAAGAGTCCAGGGGAACACGGGC
 CTCCCAGACGTGGAGCTCCTTAGCCATGAGCTCAAGGGAGTGTGCCAGAGCCC
 CCTGGCCTAGATGACCCCTGGCCCAGGATGGAGCAGGAGTGTCTGATGATTCA

TGGAGTTTGCCCCCTTCCTAAGGGAAGGAGATCTTTATCTTTCTGGTTGGCTTGACC
AGTCACGTTGGGAGAAGAGAGAGAGTGCCAGGAGACCCTGAGGGCAGCCGGTTC
CTACTTTGGACTGAGAGAAGGGAGCCCCAGGCTGGAGCAGCATGAGGCCAGCA
AGAAGGGCTTGGGTTCTGAGGAAGCAGATGTTTCATGCTGTGAGGCCTTGCACCA
5 GGTGGGGGCCACAGCACCAGCAGCAGCATCTTTCTGGGCAGGCCAGCCCTCCA
CTGCAGAAGCATCTGGAAGCACCACCTTGTCTCCACAGAGCAGCTTGGGCACAG
CAGACTGGCCTGGCCCTGAGACTGGGGAGTGGCTCCAACAGCCTCCTGCCACCC
ACACACCACTCTCCCTAGACTCTCCTAGGGTTCAGGAGCTGCTGGGCCAGAGGT
GACATTTGACTTTTTTCCAGGAAAAATGTAAGTGTGAGGAAACCCCTTTTATTTT
10 ATTACCTTTACTCTCTGGCTGCTGGGTCTGCCGTCGGTCCTGCTGCTAACCTGGC
AGCAGAGCCTCTGCCCCGGGGAGCCTCAGGCAGTCCTCTCCTGCTGTCACAGCTGC
CATCCACTTCTCAGTCCCAGGGCCATCTCTTGAGTGACAAAGCTGGGATCAAGG
ACAGGGAGTTGTAACAGAGCAGTGCCAGAGCATGGGCCAGGTCCCAGGGGAG
AGGTTGGGGCTGGCAGGCCACTGGCATGTGCTGAGTAGCGCAGAGCTACCCAGT
15 GAGAGGCCTTGTCTAACTGCCTTTCCTTCTAAAGGGAATGTTTTTTCTGAGATAA
AATAAAAACGAGCCACATCGTGTTTAAAG

SEQ ID NO: 430

>6176 BLOOD 480902.3 X83860 g633213 Human mRNA for prostaglandin E receptor

20 (EP3c). 0

ACCAGAGGTTTCCCAGAGAGGAAGGCGTGGCTCCCTCCCGGGCCAGTGAGCCCT
GGCGCCGCGCGCGCCGCGGTCCAGCAGCGGAGTAGGGCGGCGGCTGGGCGGCGG
CACCATGGGGGGGAGGCCAGCCCCAGCGCGGTAAACGCCGACCTCCGCGGCGG
CCGCGCGCCGCTCTGCGCCCTCCCGGTGGGGCTCTCTGGACGCCATCCCTCCTCAG
25 CTGGAAGCCAACATGAAGGAGACCCGGGGCTACGGAGGGGATGCCCCCTTCTGC
ACCCGCCTCAACCACTCCTACACAGGCATGTGGGCGCCCCGAGCGTTCGCGCGAG
GCGCGGGGCAACCTCACGCGCCCTCCAGGGTCTGGCGAGGATTGCGGATCGGTG
TCCGTGGCCTTCCCGATCACCATGCTGCTCACTGGTTTCGTGGGCAACGCACTGG
CCATGCTGCTCGTGTGCGCAGCTACCGGCGCCGGGAGAGCAAGCGCAAGAAGT
30 CCTTCCTGCTGTGCATCGGCTGGCTGGCGCTACCGACCTGGTCGGGCAGCTTCT
CACCACCCCGGTCGTCATCGTCGTGTACCTGTCCAAGCAGCGTTGGGAGCACATC
GACCCGTCGGGGCGGCTCTGCACCTTTTTTCGGGCTGACCATGACTGTTTTCGGGC
TCTCCTCGTTGTTTCATCGCCAGCGCCATGGCCGTCGAGCGGGCGCTGGCCATCAG
GGCGCCGCACTGGTATGCGAGCCACATGAAGACGCGTGCCACCCGCGCTGTGCT
35 GCTCGGCGTGTGGCTGGCCGTGCTCGCCTTCGCCCTGCTGCCGGTGTGGGCGTG
GGCCAGTACACCGTCCAGTGGCCCCGGGACGTGGTGCTTCATCAGCACCGGGCGA
GGGGGCAACGGGACTAGCTCTTCGCATAACTGGGGCAACCTTTTCTTCGCCTCTG
CCTTTGCCTTCTGGGGCTCTTGGCGCTGACAGTCACCTTTTCTGCAACCTGGCC
ACCATTAAGGCCCTGGTGTCCCGCTGCCGGGCCAAGGCCACGGCATCTCAGTCCA
40 GTGCCAGTGGGGCCGCATCACGACCGAGACGGCCATTACGCTTATGGGGATCA
TGTGCGTGTGTCGGTCTGCTGGTCTCCGCTCCTGATAATGATGTTGAAAATGAT
CTTCAATCAGACATCAGTTGAGCACTGCAAGACACACACGGAGAAGCAGAAAGA
ATGCAACTTCTTCTTAATAGCTGTTGCGCTGGCTTCACTGAACCAGATCTTGATC
CTTGGGTTTACCTGCTGTTAAGAAAGATCCTTCTTCGAAAGTTTTGCCAGGTAGC
45 AAATGCTGTCTCCAGCTGCTCTAATGATGGACAGAAAGGGCAGCCTATCTCATTA
TCTAATGAAATAATACAGACAGAAGCATGAAAGAAAACACTTAACCTGCATGTG
CACAGCTTTTGGTAACAAATATCGCTAAACCTTACTGTGAATTTAGGCATCTCTG
GCATGCCACTGTTTATGCATTGAAGTGAATTTTTGGTATAAAGCTAAATGGTCT
TAGAAGCATAGAAAATCCCTATGTGCCAAAAGTAGTGAAACACAAACAAAGGAA

AATATATTAATAACAGTCTAGTGTTTTTGTGAGTCTGCCATTTCGTAGCTGAATAT
GTGATTAATTATGTGATGAAAACATTTTTTATAAATGATCTTGGTCTATTGGGGA
GCGGGGATAGTTAATATTCCAGTACACTGAATACATGAGGAATTTAACCACATAC
ATCATTGAAGACAAGGGATAGCAGTTTGTGTTTTATTCAAAGACATTGCTGTGTTT
5 TCTTTCATTGCCTCTCTCGCTTTCTGTCACTTTTTTCCCTCCTTACATTAAAGAAAAG
TTTAATTACAGTTAAAAATGTATAATGTATTTATAAATATTCATCGATACCATTATT
CAAATATTGCTCAATACAGCAAATTAGCTCCTAACCTAACAAAGTTTAAAGTTTAC
TTGGATTGATAATTAGGTTTACTCTTTATCTGAATAAGAACCAATTCCATTTGTTT
GAAATATGGAGTTTGTGACTACCCAAATTGCTAATTATTCTTTCTTTTGAATATAT
10 TTTACATTTCTATGAGCCTAAGGAAGATTCATGAAACTGACCTATGAGAGTCGTG
AAGTGGTTTTTTCAGAATGCTATGTAAGGACCGATTTGAGCACTAACTATAGGTAC
TCTGAATATATATTTCCCTTGATTATTCACCAAAAAGTGTTCCCCAGTCTTTGACTC
TTTAAATTCCAATACTGATTCCAAAACAAATAAATATTTTGAAGACTCAATGAAT
ACTTTCATATTTTGGCCTATTTATATAAGAAAGTTAATAACATTGACCCTTCACA
15 GCTCTTCTGCCTGCTCCTCAAAGTGGCTCTATCTAAATATTTATTACTAAAATGTT
TTTCCTACAGTCTACATGAATACAAACCTCAATAGCTAAGCTTGACGTATTTGTG
CACAAGTAGATCACTACATTAAGTTTTGGGAATTGCACTTCTTAAAAATGTCTCC
CCACCAAACATAGTAATCCTGTAGTTATGCCTACACAAAGCTTGCCATATTCTTT
GGTCGATTCATTTTGTAACCCATTAACTTTTTATTGTGAAGATTTTCATTTGCAG
20 TTTCTTGCACTGCTTTTCTAGTTTTTAAAGCTTGAGATTTATTTATACTTCTTGT
AGTAACTGCATATTTCTGTGTGTGTTTAGTGGTAAAGAATTAATTTTGATAGGTA
GGAATATGTCTATCAGATTGATATATAGACCAGCCTATGTCAATTGGGGCTAATTA
TTTAAATGACCATGTCAAATTGAATTTGGAGACAAAATCTGTTGAGAGTGGCTTA
TTGTAATTAATGATGGTTCTACTAACTAAATTTTGGAAAAGGTGATAAATAGACTA
25 TACTAAAATCTCTCTATGCCATAGAATTGGATTATCCTGTAGGTCATCTCATTGGG
TCTAAGACAAAACCTACTTTTTTCAAAGGTGCACTGAAATCACATAATAAAA
GAGGCTTTACCTCTTGGTTGGTCCTGTGACCCTAAGTTCTAGTCAGATAGACACA
GAGGCAATGTGAATTTGAGTGGCATGAGCATGATTAGGTTATTCCTTCCAGCATC
TAGTATAGCACCTGGAATATAGAACTGTCTAATACATATTTATTCAGTGAATCA
30 ATGAGCAGAAGTTTGCCAGGACAGTACACATTGGCAAGGCACATACCATATGAT
TGAAGTGCTTCATGCCATTACAGTCCATCAGGCTGATAAAGTGAATTATTTCTGA
TTATTTAATTACAGAAATATGAATTTATCTTCAAGGGGTTAGTGTCACTGCTGT
ACAACACAGTGCTTTATTTATACTAATAATTTAGGAGACTGATACTTCCAAATGA
TAGTGGACATTACTATCANAGAATATCACTTTTCATCAAACCTGCAAAAATACAG
35 AAAGGCCAAAAACCTGACACTTATCTTAACTGCAAAATTAAATTCCTGCCCAGGG
GATATATTTTAGGTGGGGATGAATGGCAGCTTTTGTGTTTTTTTAAACAAGCTTGA
AAGGGAGGTGGAAAACAAAGAAATTATGTAAATGGCATATGAGTTTTATTATCT
AGGCATTCGTTAGTATGGGGAAACCTGCATAAGCAACTGAAAATCCCAAATGAT
TTCAGCCTTTTCATGATGGTTGAGGTTAGATTTTCAAGAGATGTACAGAGACTAGAG
40 CGGTGGTTAGAAAGAGGATATATGTAGTCACAGCAGAAAGACGTGTCTAAGTTT
AATTTTATTGGCTTTCAAGTTCACCTCATGTATACTTAGTTTGTCCATACATATGTC
TAATCAGGAAAAATGCATGTATAGATTATGACAATTCCTGAATTTTGAAGTATTG
GTTAAAAGACAATTAAAGGCCAAGAAAACCATGGTGGAAGAAGTAAGCGAATG
AAATGTAGAAATATATGTAAAATTAGCAAGTGTCAATTTTACCAAGTAGTGTGTA
45 TTTTCCAAACAATGAATTTATATACTATGCTGAGTCACAGAGAAGAATGATCACA
TGTTACTTAATGAGAGCAGTTTACTTTTTCAAATAAAAATAGGTATGATGAATGTCT
TAAAAATATCTTGAAGTTGAAGAAACAAAAATGAGTTATCTCAATATTTACCAAG
TTAACCTAGTGCTGTATATATCCCAAGATATTTTAGGTAAATGTAAGTGTTAATC
ATGCCAGATTTAAACTAGTCTGAAATATAGGGTATACATATATTTCTACTTACAT

TTCTTTATTTTATGAAATATCCGACCATGTTGCAGAAAATAATGCAAAACCTCAT
GTAAGTTAACTATGAAAGATCCTGTGAGCACATTGGCATTGAGTGACAGACAAA
CTAAAACTGGCAAACAGTATTTTAATAAGGGGGTCACTCTGTGGCAGTATTCTA
ATATTGGATTTTCAAGTAGATTAGGCTTTTTATTTATTCAACGCTTTTTATAATTTT
5 GTTCTTTTTGACTCCAAATTATTGGTCAGCTTTCAACCTTCTCCACATCAGCAATC
ACTAATAGTTCTTTTGGTTGAGATCAACTCAGAA

SEQ ID NO: 431

>6204 BLOOD 350550.3 S74902 g984506 Human P2U nucleotide receptor mRNA,

complete cds. 0

10 GGGGAACAGCGCAGGGAGGTGGGTAGCCGGGCTCCCAGGCACGTGGGTCTCTGC
GGCTGCGGCGGGACCCGGGCACTGGCACCCGGGAGCGGCGGCGACGGCACCCCG
AGAGGAGAAGCGCAGCGCAGTGGCGAGAGGAGCCCCCTGTGGCAGCAGCACTA
CCTGCCCAGAAAAATGCTGGAGGCTGGGCGTGGCCCCAGGCCTGGGGACCTGTT
15 TTTCTGTTCCTCGCAGAGTTCCTGTCAGCCCGGTCCAGGTCCAGGCGTGTGCATT
CATGAGTGAGGAACCCGTGCAGGCGCTGAGCATCCTGACCTGGAGAGCAGGGGC
TGGTCAGGGCGATGGCAGCAGACCTGGGCCCCCTGGAATGACACCATCAATGGCA
CCTGGGATGGGGATGAGCTGGGCTACAGGTGCCGCTTCAACGAGGACTTCAAGT
ACGTGCTGCTGCCTGTGTCTACGGCGTGGTGTGCGTGTCTGGGCTGTGTCTGAA
20 CGCCGTGGCGCTCTACATCTTCTGTGCCGCCTCAAGACCTGGAATGCGTCCACC
ACATATATGTTCCACCTGGCTGTGTCTGATGCACTGTATGCGGCCTCCCTGCCGCT
GCTGGTCTATTACTACGCCCGGGGGGACCACTGGCCCTTCAGCAGCGTGTCTGC
TAGGTGGTGGCGCTTCCTCTTCTACACCAACCTTACTGTCAGCATGCTCTTCTCAG
CTGGCATCAGCGTGCACCGGTGTCTGGGCGTCTTACGACCTCTGCGCTCCCTGCGC
25 TGGGGGCCGGGCCCCGCTACGCTCGCCGGGTGGCCGGGGCCGTGTGGGTGTTGGTG
CTGGCCTGCCAGGCCCCCGTGTCTACTTTGTCAACCACCAGCGCGCGGGGGGCC
GCGTAACCTGCCACGACACCTCGGCACCCGAGCTCTTCAGCCGCTTCGTGGCCTA
CAGCTCAGTCATGCTGGGCCTGCTCTTCGCGGTGCCCTTTGCCGTCATCCTTGCT
GTTACGTGCTCATGGCTCGGCGACTGCTAAAGCCAGCCTACGGGACCTCGGGCG
30 GCCTGCCTAGGGCCAAGCGCAAGTCCGTGCGCACCATCGCCGTGGTGTCTGGCTGT
CTTCGCCCTCTGCTTCCTGCCATTCCACGTCACCCGCACCCTCTACTACTCCTTCC
GCTCGCTGGACCTCAGCTGCCACACCCTCAACGCCATCAACATGGCCTACAAGGT
TAECGGGCCGCTGGCCAGTGCTAACAGTTGCCTTGAGCCCGTGCTCTACTTCCTG
GCTGGGCAGAGGCTCGTACGCTTTGCCCGAGATGCCAAGCCACCCACTGGGCCC
35 CAGCCCTGCCACCCCGGCTCGCCGCAGGCTGGGCCTGCGCAGATCCGACAGAAC
TGACATGCAGAGGATAGAAGATGTGTTGGGCAGCAGTGAGGACTCTAGGCGGAC
AGAGTCCACGCCGGCTGGTAGCGAGAACACTAAGGACATTCCGGCTGTAGGAGCA
GAACACTTCAGCCTGTGCAGGTTTATATTGGGAAGCTGTAGAGGACCAGGACTTG
TGCAGACGCCACAGTCTCCCCAGATATGGACCATCAGTGAATCATGCTGGATGAC
40 CCCATGCTCCGTCATTTGACAGGGGCTCAGGATATTCACTCTGTGGTCCAGAGTC
AACTGTTCCCATAAACCCCTAGTCATCGTTTGTGTGTATAAGTTGGGGGAATTAAG
TTTCAAGAAAGGCAAGAGCTCAAGGTCAATGACACCCCTGGCCTGACTCCCATG
CAAGTAGCTGGCTGTACTGCCAAGGTACCTAGGTTGGAGTCCAGCCTAATCAAGT
CAAATGGAGAAACAGGCCCAGAGAGGAAGGTGGCTTACCAAGATCACATACCA
45 GAGTCTGGAGCTGAGCTACCTGGGGTGGGGGCCAAGTCACAGGTTGGCCAGAAA
ACCCTGGTAAGTAATGAGGGCTGAGTTTGCACAGTGGTCTGGAATGGACTGGGT
GCCACGGTGGACTTAGCTCTGAGGAGTACCCCCAGCCCAAGAGATGAACATCTG
GGGACTAATATCATAGACCCATCTGGAGGCTCCCATGGGCTAGGAGCCAGTGTG
AGGCTGTAACCTATACTAAAGGTTGTGTTGCCTGCTGAAAAAAA

>6217 BLOOD gi|535478|gb|U12512.1|HSU12512 Human bradykinin receptor B1 subtype mRNA, complete cds

SEQ ID NO: 433

>6227 BLOOD gi|182389|gb|M57285.1|HUMFACX Human coagulation factor X (F10)
mRNA, complete cds

362

CTGGAGGTGCCCTACGTGGACCGCAACAGCTGCAAGCTGTCCAGCAGCTTCATCA
TCACCCAGAACATGTTCTGTGCCGGCTACGACACCAAGCAGGAGGATGCCTGCC
AGGGGGACAGCGGGGGCCCGCACGTCACCCGCTTCAAGGACACCTACTTCGTGA
CAGGCATCGTCAGCTGGGGAGAGGGCTGTGCCCGTAAGGGGAAGTACGGGATCT
5 ACACCAAGGTCACCGCCTTCCTCAAGTGGATCGACAGGTCCATGAAAACCAGGG
GCTTGCCCAAGGCCAAGAGCCATGCCCGGAGGTCATAACGTCCTCTCCATTA
GTGAGATCCCACTCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

SEQ ID NO: 434

10 >6233 BLOOD 988660.1 L33930 g500848 Human CD24 signal transducer mRNA, complete
cds and 3' region. 0

CCTTTCCTCTGCGGCGGGCCGAGAGATAACCCTGCCCGAGGGGTCCCGGCGCCCG
CCCCCACGCGGTGCGACTGGAATTCGACGCCCTCTCGGGTCCCGGGGCGCAT
TTTGACGTCTGAGTGGCAATGCACTTGCTCCAGGACAGGCGGCTACCCCGCCGCA
15 GCGAGGCGCGGACTTTTCTTTTGGGGGGTTTCGCCGGCTCGCCGCGCTCCCCACCT
TGCTTGCGCCCGCCCGGAGCCAGCGGTTCTCCAAGCACCCAGCATCCTGCTAGAC
GCGCCGCGCACCGACGGAGGGGACATGGGCAGAGCAATGGTGGCCAGGCTCGG
GCTGGGGCTGGCTGCTGCTGGCACTGCTCCTACCCACGCAGATTTATTCCAGTGA
AACAACAACCTGGAACCTCAAGTAACTCCTCCAGAGTACTTCCAACCTCTGGGTTG
20 GCCCCAAATCCAATAATGCCACCACCAAGGCGGCTGGTGGTGGCCTGCAGTCA
ACAGCCAGTCTCTTCGTGGTCTCACTCTCTCTTCTGCATCTCTACTCTTAAGAGAC
TCAGGCCAAGAAACGTCTTCTAAATTTCCCATCTTCTAAACCCAAATCOAAATGG
CGEETGGAAGTCCAATGTGGCAAGGAAACAGGGTCTTCATCGAATCTAGTAATT
CCACACCTTTTATTGACACAGAAAATGTTGAGAAATCCCAAATTTGATTGATTGA
25 AGAACATGTGAGAGGTTTGACTAGATGATGGATGCCAATATTAAATCTGCTGGA
GTTTCATGTACAAGATGAAGGAGAGGCAACATCCAAAATAGTTAAGACATGATT
TCCTTGAATGTGGCTTGAGAAATATGGACACTTAATACTACCTTGAAAATAAGAA
TAGAAATAAAGGATGGGATTGTGGAATGGAGATTCAGTTTTCATTTGGTTCATTA
ATTCTATAAAGGCCATAAAACAGGTAATATAAAAAGCTTCCATGATTCTATTTATA
30 TGTACATGAGAAGGAACTTCCAGGTGTTACTGTAATTCCTCAACGTATTGTTTCG
ACAGCACTAATTTAATGCCGATATACTCTAGATGAAGTTTACATTGTTGAGCTA
TTGCTGTTCTCTTGGGAACTGAACTCACTTTCCTCCTGAGGCTTTGGATTTGACAT
TGCATTTGACCTTTTATGTAGTAATTGACATGTGCCAGGGCAATGATGAATGAGA
ATCTACCCCCAGATCCAAGCATCCTGAGCAACTCTTGATTATCCATATTGAGTCA
35 AATGGTAGGCATTTCCCTATCACCTGTTTCCATTCAACAAGAGCACTACATTCATTT
AGCTAAACGGATTCCAAAGAGTAGAATTGCATTGACCACGACTAATTTCAAANN
NN
NN
NN
40 NNN
NN
NN
NNNTATTTCTGCATATGTTTGAATACTTTTACAATTTAAAAAAATGATCTGTTT
TGAAGGCAAAATTGCAAATCTTGAAATTAAGAAGGCAAAATGTAAAGGAGTCAA
45 ACTATAAATCAAGTATTTGGGAAGTGAAGACTGGAAGCTAATTTGCATAAATTC
CAAACCTTTTATACTCTTTCTGTATATACATTTTCTTTTAAAAACAACATATGG
ATCAGAATAGCAACATTTAGAACACTTTTTGTTATCAGTCAATATTTTATAGATAGT
TAGAACCTGGTCCTAAGCCTAAAAGTGGGCTTGATTCTGCAGTAAATCTTTTACA
ACTGCCTCGACACACATAAACCTTTTTTAAAAATAGACACTCCCCGAAGTCTTTTG

TTCGCATGGTCACACACTGATGCTTAGATGTTCCAGTAATCTAATATGGCCACAG
 TAGTCTTGATTACCAAAGTCCTTTTTTCCATCTTTAGAAAACACTACATGGGAACAA
 ACAGATCGAACAGTTTTGAAGCTACTGTGTGTGTGAATGAACACTCTTGCTTTAT
 TCCAGAATGCTGTACATCTATTTTGGATTGTATATTGTGTTTGTGTATTTACGCTT
 5 TGATTCATAGTAACTTCTTATGGAATTGATTTGCATTGAACACAAACTGTAAATA
 AAAAGAAATGGCTGAAAGAGCAA

SEQ ID NO: 435

>6245 BLOOD 222810.1 M33537 g182662 Human N-formylpeptide receptor (fMLP-R98)

10 mRNA, complete cds. 0

GTCACTCTCCCCAGGAGACCCAGACCTAGAACTACCCAGAGCAAGACCACAGCT
 GGTGAACAGTCCAGGAGCAGACAAGATGGAGACAAATTCCTCTCTCCCCACGAA
 CACCTCTGGAGGGACACCTGCTGTATCTGCTGGCTATCTCTTCCTGGATATCATCA
 CTTATCTGGTATTTGCAGTCACCTTTGTCTCGGGGTCTGGGCAACGGGCTTGTG
 15 ATCTGGGTGGCTGGATTCCGGATGACACACACAGTCACCACCATCAGTTACCTGA
 ACCTGGCCGTGGCTGACTTCTGTTTCACCTCCACTTTGCCATTCTTCATGGTCAGG
 AAGGCCATGGGAGGACATTGGCCTTTCGGCTGGTTCCTGTGCAAATTCCTCTTTA
 CCATAGTGGACATCAACTTGTTTCGGGAAGTGTCTTCCTGATCGCCCTCATTGCTCT
 GGACCGCTGTGTTTGCCTCCTGCATCCAGTCTGGACCCAGAACCACCGCACCGTG
 20 AGCCTGGCCAAGAAGGTGATCATTGGGCCCTGGGTGATGGCTCTGCTCCTCACAT
 TGCCAGTTATCATTCGTGTGACTACAGTACCTGGTAAAACGGGGACAGTAGCCTG
 CACTTTTAACTTTTCGCCCTGGACCAAGGACCCTAAAGAGAGGATAAAACGTGGCC
 GTTGGCATGTTGACGGTGAGAGGGCATTCTCGGTTTCATCATTTGGCTTGAGCGCAC
 CCATGTCCATCGTTGCTGTGAGTTATGGGCTTATTGCCACCAAGATCCACAAGGA
 25 AGGCTTGATTAAAGTCCAGTCGTCCCTTACGGGTCTCTCCTTTGTGCGCAGCAGCCT
 TTTTCTCTGCTGGTCCCCATATCAGGTGGTGGCCCTTATAGCCACAGTCAGAATC
 CGTGAGTTATTGCAAGGCATGTACAAAGAAATTGGTATTGCAGTGGATGTGACA
 AGTGCCCTGGCCTTCTTCAACAGCTGCCTCAACCCCATGCTCTATGTCTTCATGGG
 CCAGGACTTCCGGGAGAGGCTGATCCACGCCCTTCCCGCCAGTCTGGAGAGGGC
 30 CCTGACCGAGGACTCAACCCAAACCAGTGACACAGCTACCAATTCTACTTTACCT
 TCTGCAGAGGTGGCGTTACAGGCAAAGTGAGGAGGGAGCTGGGGGACACTTTCG
 AGCTCCCAGCTCCAGCTTCGTCTCACCTTGAGTTAGGCTGAGCCACAGGCATTTT
 CTGCTTATTTTAGGATTACCCACTCATCAGAAAAAAGCCTTTGTGTCC
 CCTGATTTGGGGAGAAATAAACAGATATGAGTTTATTATTGACTTCTTTTTTGATTT
 35 TGGACCTCAGCCTCGGGTGGTCAGGGTGGGAAATGATAGGAAGAAGCTGTCATC
 TGCATCCTAGTTTGCCTGAAATGAACCCAAATAATACCCATTATTATTAGTCCTG
 AATTATGAGTAGTGAATGATACCCATCATTCTGGCATCATGATGAGTAGTGTCCA
 CTTCCATTCTGAAAAGTGCCCTGCTGTGAAAAATAAATTATATAGTCATCCTAGG
 TAAATGAAGGAGGAGGGAGAAGTGTGAAAGAGTATGGCTTAAATCAGACAAGA
 40 TATACAAGAAGATACTTT

SEQ ID NO: 436

>6269 BLOOD 234630.33 M59040 g180129 Human cell adhesion molecule (CD44) mRNA, complete cds. 0

45 CTTTCGCTCGCTCCCTCCCTCCGTCTTAGGTCACTGTTTTCAACCTCGAATAAAAAC
 TGCAGCCAACTTCCGAGGCAGCCTCATTGCCCAGCGGACCCCAGCCTCTGCCAGG
 TTCGGTCCGCCATCCTCGTCCCGTCTCCGCCGGCCCTGCCCGCGCCAGGGA
 TCCTCCAGCTCCTTTCGCCCGCGCCCTCCGTTTCGCTCCGGACACCATGGACAAGTT
 TTGGTGGCACGCAGCCTGGGGACTCTGCCTCGTGCCGCTGAGCCTGGCGCAGATC

GATTTGAATATAACCTGCCGCTTTTGCAGGTGTATTCCACGTGGAGAAAAATGGTC
 GCTACAGCATCTCTCGGACGGAGGCCGCTGACCTCTGCAAGGCTTTCAATAGCAC
 CTTGCCCAACAATGGCCAGATGGAGAAAGCTCTGAGCATCGGATTTGAGACCTG
 CAGGTATGGGTTCATAGAAGGGCACGTGGTGATTCCCCGGATCCACCCCAACTCC
 5 ATCTGTGCAGCAAACAACACAGGGGTGTACATCCTCACATCCAACACCTCCCAGT
 ATGACACATATTGCTTCAATGCTTCAGCTCCACCTGAAGAAGATTGTACATCAGT
 CACAGACCTGCCCAATGCCTTTGATGGACCAATTACCATAACTATTGTTAACCGT
 GATGGCACCCGCTATGTCCAGAAAGGAGAATACAGAACGAATCCTGAAGACATC
 TACCCCAAGCAACCCTACTGATGATGACGTGAGCAGCGGCTCCTCCAGTGAAAGG
 10 AGCAGCACTTCAGGAGGTTACATCTTTTACACCTTTTCTACTGTACACCCCATCCC
 AGACGAAGACAGTCCCTGGATCACCGACAGCACAGACAGAATCCCTGCTACCAG
 AGACCAAGACACATTCCACCCCAAGTGGGGGGTCCCATAACCACTCATGGATCTGA
 ATCAGATGGACACTCACATGGGAGTCAAGAAGGTGGAGCAAACACAACCTCTGG
 TCCTATAAGGACACCCCAAATTCCAGAATGGCTGATCATCTTGGGCATCCCTCTT
 15 GGCCTTGGCTTTGATTCTTGCAGTTTGCATTGCAGTCAACAGTCAAGAAGGTGT
 GGGCAGAAGAAAAAGCTAGTGATCAACAGTGGCAATGGAGCTGTGGAGGACAG
 AAAGCCAAGTGGACTCAACGGAGAGGCCAGCAAGTCTCAGGAAATGGTGCATT
 GGTGAACAAGGAGTCGTCAGAACTCCAGACCAGTTTATGACAGCTGATGAGAC
 AAGGAACCTGCAGAATGTGGACATGAAGATTGGGGTGTAAACACCTACACCATTA
 20 TCTTGAAAGAAACAACCGTTGGAAACATAACCATTACAGGGAGCTGGGACACT
 TAACAGATGCAATGTGCTACTGATTGTTTCATTGCGAATCTTTTTTAGCATAAAAT
 TTCTACTCTTTTGTGTTTGTGTTTGTGTTTAAAGTCAGGTCCAATTTGTAAA
 AACAGCATTGCTTTCTGAAATTAGGGGCCAATTAATAATCAGCAAGAATTGATC
 GTTCCAGTCCCACTTGGAGGCCCTTCATCCCTCGGGTGTGCTATGGATGGCTCT
 25 AACAAAACTACACATATGTATTCCCTGATCGCCAACCTTTCCCCCACCAGCTAAG
 GACATTTCCCAGGGTTAATAGGGCCTGGTCCCTGGGAGGAAATTTGAATGGGTCC
 ATTTTGGCCTTCCATAGCCTAATCCCTGGGCATTGCTTTCCACTGAGGTTGGGGT
 TGGGGTGTACTAGTTACACATCTTCAACAGACCCCTCTAGAAATTTTTCAGATG
 CTTCTGGGAGACACCCAAAGGGTGAAGCTATTTATCTGTAGTAACTATTTATCT
 30 GTGTTTTTGAATATTAAACCCTGGATCAGTCCTTTGATCAGTATAATTTTTTAAA
 GTTACTTTGTGAGGACACAAAAGGGTTTAACTGATTCATAATAAATATCTGTA
 CTTCTTCGATCTTCA

SEQ ID NO: 437

35 >6289 BLOOD GB_M80800 gi(164698) PIGTRKC Pig gp145-trkC (trkC) mRNA, complete
 cds
 CGGGCTCCGATAACCGAAGCAGCGATCGGAGATGGATGTCTCTCTTTGCCAGCC
 AAGTGTAGTTTCTGGCGGATTTTCTTGCTGGGAAGCGTCTGGCTGGACTATGTGG
 GCTCCGTGCTGGCTTGGCCTGCAAATTGTGTCTGCAGCAAGACTGAGATCAATTG
 40 CCGGCGGCCGGACGATGGGAACCTCTTCCCCCTCCTGGAAGGGCAGGATTCAGG
 GAACAGCAATGGGAATGCCAGCATCAACATCACGGACATCTCAAGGAATATCAC
 TTCCATACACATAGAGAACTGGCGCGGTCTGCACACGCTCAACGCTGTGGACATG
 GAGCTCTACACCGGCCTCCAGAAGCTGACCATCAAGAACTCAGGACTTCGGAGC
 ATCCAGCCCAGAGCCTTTGCCAAGAACCCCACTGCGCTACATAAACCTGTGCA
 45 GTAACCGGCTCACCACACTCTCATGGCAGCTCTTCCAGACGCTGAGTCTTCGGGA
 ATTGAGATTGGAGCAGAACTTCTTCAACTGCAGCTGTGACATCCGCTGGATGCAG
 CTGTGGCAGGAGCAGGGGGAGGCCAAGCTGAACAGCCAGAGCCTCTATTGCATC
 AGTGCCGATGGCTCCCAGCTCCCCCTCTTCCGCATGAACATTAGCCAGTGTGACC
 TTCCTGAGATCAGTGTGAGCCACGTCAATCTGACCGTTTCGGGAGGGTGACAATGC

TGTTGTCACCTGCAATGGCTCTGGATCACCCCTGCCCGACGTGGACTGGATCGTC
ACTGGACTGCAGTCCATCAACACCCACCAGACAAATCTGAATTGGACCAACGTA
CACGCCATCAACCTGACACTGGTCAATGTGACGAGTGAGGACAACGGCTTCACC
CTGACGTGCATTGCAGAGAACGTGGTGGGCATGAGCAATGCCAGCGTCGCCCTC
5 ACTGTTCACTACCCCCACGAGTGGTGAGCCTGGAGGAGCCAGAGCTGCGCCTG
GAACACTGCATCGAGTTTGTGGTGGTGGCAACCCGCCGCCACGCTGCACTGGC
TGCACAACGGGCAGCCGCTGCGTGAGTCCAAGATCACCCACGTGGAGTACTACC
AGGAGGGCGAGGTCTCCGAGGGGCTGCCTGCTCTTCAACAAGCCCACCCACTACA
ACAATGGCAACTACACACTCAATCGCCAAGAACCCCTTGGCACAGCCAACCAGA
10 CCATCAATGGCCACTTCTCAAGGAGCCTTTTCCAGAGAGCACGGATAACTTTGT
CTCTTTCTATGAAGTGAGCCCCACCCCTCCCATCACTGTGACGCACAAGCCAGAG
GAAGATACATTTGGGGTATCCATAGCTGTTGGACTTGCCGCTTTTGCCTGTGTCCT
TCTGGTGGTTCTCTTTATCATGATCAACAAGTATGGTCGACGGTCTAAATTTGGA
ATGAAGGGTCTGTGGCTGTCATCAGTGGTGAAGAGGACTCAGCCAGCCCACTG
15 CATCACGATCAACCATGGCATCACACACCCTCATCACTGGACGCCGGGCCGGA
CACAGTGTCATTGGCATGACCCGCATCCCAGTCATTGAGAACCCCCAGTACTTCC
GCCAGGGACACAACCTGCCACAAGCCAGACACGTATGTGCAGCACATTAAGGA
GGGACATCGTGCTGAAGCGAGAACTGGGTGAGGGAGCCTTTGGGAAGGTCTTCC
TGGCCGAGTGCTACAACCTCAGCCCCACCAAGGTCAAGATGCTCGTGGCTGTGA
20 AGGCCCTGAAGGATCCCACCCTGGCCGCCCGGAAGGATTTCAGAGGGAGGCTG
AGCTGCTACCAACCTGCAGCATGAGCACATTGTCAAGTTCTATGGGGTGTGCGG
GGACGGGGACCCACTCATGATGGTTTTTGTAGTACATGAACACGGGGATCTGAA
CAAGTTCTCAGGGCCCATGGGGCAGATGCCATGATGCTGGTGGACGGGCCAGCC
ACGCCAGGCAAAAGGCGAGGTGGGGCTCTCCAGATGCTGCACATTGCCAGTCA
25 GATCTGCTCTGGCATGGTGTACCTGGCCTCCAGCATTTCGTGCACCGGGACCTG
GCCACCAGGAACCTGCCTGGTTGGAGCCAACCTGCTGGTGAAGATTGGCGATTTCG
GCATGTCCAGAGATGTCTACAGCACGGATTACTACAGGGTAGGAGGACACACCA
TGCTCCCAATTTCGCTGGATGCCTCCTGAAAGCATCATGTACCGGAAGTTCCTAC
TGAGAGTGACGTGTGGAGCTTCGGGGTGATCCTCTGGGAGATCTTCACCTACGGA
30 AAGCAGCCATGGTTCCAACCTCTCAAACACAGAGGTCATTGAGTGCATCACCCAA
GGTCGCGTTTTTGAACGGCCCCGGGTCTGCCCCAAAGAGGTGTATGATGTCATGC
TGGGGTGCTGGCAGAGGGAACCGCAGCAGCGGCTGAACATCAAGGAAATCTACA
AAATCCTCCATGCTTTGGGGAAAGCCACCCCCATCTACCTGGACATCCTTGGCTA
GEGGTGGCCGGTGGTAC

35

SEQ ID NO: 438

>6304 BLOOD 447973.12 D50683 g1827474 Human mRNA for TGF-beta1R alpha,
complete cds. 0

GTTGGCGAGGAGTTTCCTGTTTCCCCCGCAGCGCTGAGTTGAAGTTGAGTGAGTC
40 ACTCGCGCGCACGGAGCGACGACACCCCCGCGCGTGCACCCGCTCGGGACAGGA
GCCGGACTCCTGTGCAGCTTCCCTCGGCCGCCGGGGGCTCCCCGCGCCTCGCCG
GCCTCCAGGCCCCCTCCTGGCTGGCGAGCGGGCGCCACATCTGGCCCGCACATCT
GCGCTGCCGGCCCGGCGCGGGGTCCGGAGAGGGCGCGGCGCGGAGGGCGCAGCC
AGGGGTCCGGGAAGGCGCCGTCCGCTGCGCTGGGGGCTCGGTCTATGACGAGCA
45 GCGGGGTCTGCCATGGGTGCGGGGCTGCTCAGGGGCCTGTGGCCGCTGCACATC
GTCCTGTGGACGCGTATCGCCAGCACGATCCCACCGCACGTTCAAGTTCACAACTGT
ATAACGACATGATAGTCACTGACAACAACGGTGCAGTCAAGTTTCACAACTGT
GTAAATTTTGTGATGTGAGATTTTCCACCTGTGACAACCAGAAATCCTGCATGAG
CAACTGCAGCATCACCTCCATCTGTGAGAAGCCACAGGAAGTCTGTGTGGCTGTA

TGGAGAAAGAATGACGAGAACATAAACTAGAGACAGTTTGCCATGACCCCAAG
CTCCCCTACCATGACTTTATTCTGGAAGATGCTGCTTCTCCAAAGTGCATTATGAA
GGAAAAAAAAAAGCCTGGTGAGACTTTCTTCATGTGTTCTGTAGCTCTGATGAG
TGCAATGACAACATCATCTTCTCAGAAGAATATAACACCAGCAATCCTGACTTGT
5 TGCTAGTCATATTTCAAGTGACAGGCATCAGCCTCCTGCCACCACTGGGAGTTGC
CATATCTGTCATCATCATCTTCTACTGCTACCGCGTTAACCGGCAGCAGAAGCTG
AGTTCAACCTGGGAAACCGGCAAGACGCGGAAGCTCATGGAGTTCAGCGAGCAC
TGTGCCATCATCCTGGAAGATGACCGCTCTGACATCAGCTCCACGTGTGCCAACA
ACATCAACCACAACACAGAGCTGCTGCCCATTGAGCTGGACACCCTGGTGGGGA
10 AAGGTCGCTTTGCTGAGGTCTATAAGGCCAAGCTGAAGCAGAACACTTCAGAGC
AGTTTGAGACAGTGGCAGTCAAGATCTTTCCTATGAGGAGTATGCCTCTTGGA
GACAGAGAAGGACATCTTCTCAGACATCAATCTGAAGCATGAGAACATACTCCA
GTTCTTGACGGCTGAGGAGCGGAAGACGGAGTTGGGGAAACAATACTGGCTGAT
CACCGCCTTCCACGCCAAGGGCAACCTACAGGAGTACCTGACGCGGCATGTCAT
15 CAGCTGGGAGGACCTGCGCAAGCTGGGCAGCTCCCTCGCCCGGGGGATTGCTCA
CCTCCACAGTGATCACACTCCATGTGGGAGGCCCAAGATGCCCATCGTGCACAG
GGACCTCAAGAGCTCCAATATCCTCGTGAAGAACGACCTAACCTGCTGCCTGTGT
GACTTTGGGCTTTCCCTGCGTCTGGACCCTACTCTGTCTGTGGATGACCTGGCTAA
CAGTGGGCAGGTGGGAAGTCAAGATACATGGCTCCAGAAGTCCTAGAATCCAG
20 GATGAATTTGGAGAATGTTGAGTCCTTCAAGCAGACCGATGTCTACTCCATGGCT
CTGGTGCTCTGGGAAATGACATCTCGCTGTAATGCAGTGGGAGAAGTAAAGAT
TATGAGCCTECATTTGGTTCCAAGGTGGGGGAGCACCCCTGTGTGCGAAAGCATGA
AGGAAEACGTTGAGAGATCGAGGGCGAECAGAAATTCAGCTTCTGGCTCA
ACCAGCAGGGCATCCAGATGGTGTGTGAGACGTTGACTGAGTGCTGGGAGGACG
25 ACCCAGAGGGCCCGTCTCACAGCCCAGTGTGTGGCAGAACGCTTCAGTGAGCTGG
AGCATCTGGACAGGCTCTCGGGGAGGAGCTGCTCGGAGGAGAAGATTCTGAAG
ACGGCTCCCTAAACACTACCAAATAGCTCTTCTGGGGCAGGCTGGGCCATGTCCA
AAGAGGCTGCCCCCTCTACCAAAGAACAGAGGCAGCAGGAAGCTGCCCCCTGAAC
TGATGCTTCTTGAAAAACCAAGGGGGTCACTCCCCTCCCTGTAAGCTGTGGGGAT
30 AAGCAGAAACAACAGCAGCAGGGAGTGGGTGACATAGAGCATTCTATGCCTTTG
ACATTGTCATAGGATAAGCTGTGTTAGCACTTCCTCAGGAAATGAGATTGATTTT
TACAATAGCCAATAACATTTGCACTTTATTAATGCCTGTATATAAATATGAATAG
CTATGTNTTATATATATNTATATNTCTATATATGTCTATAGCTCTATATATATAGC
CATACTTGAAAAGAGACAAGGAAAAACATCAAATATTCCCAGGAAATTGGTTT
35 TATTGGAGAACTCCAGAACCAAGCAGAGAAGGAAGGGACCCATGACAGCATTAG
CATTTGACAATCACACATGCAGTGGTTCTCTGACTGTAAAACAGTGAACCTTGCA
TGAGGAAAGAGGCTCCATGTCTCACAGCCAGCTATGACCACATTGCACTTGCTTT
TGCAAAATAATCATTCCCTGCCTAGCACTTCTCTTCTGGCCATGGAACCTAAGTAC
AGTGGCACTGTTTGAGGACCAGTGTTCCTGGGGTTCCTGTGTGCCCTTATTTCTCC
40 TGGACTTTTCATTTAAGCTCCAAGCCCCAAATCTGGGGGGCTAGTTTAGAACTC
TCCCTCAACCTAGTTTAGAACTCTACCCCATCTTTAATACCTTGAATGTTTTGAA
CCCCACTTTTACCTTCATGGGTTGCAGAAAAATCAGAACAGATGTCCCCATCCA
TGCGATTGCCCCACCATCTACTAATGAAAAATTGTTCTTTTTTTCATCTTTCCCT
GCACTTATGTTACTATTCTCTGCTCCCAGCCTTCATCCTTTTCTAAAAAGGAGCAA
45 ATTCTCACTCTAGGCTTTATCGTGTTTACTTTTTTATTACACTTGACTTGATTTTCT
AGTTTTCTATACAAACACCAATGGGTTCCATCTTTCTGGGCTCCTGATTGCTCAAG
CACAGTTTGGCCTGATGAAGAGGATTTCAACTACACAATACTATCATTGTCAGGA
CTATGCACCTCAGGCACTCTAAAACACATGT

SEQ ID NO: 439

>6308 BLOOD Hs.22675 gnl|UG|Hs#S1969031 Homo sapiens mRNA for KIAA1144

protein, partial cds /cds=(119,1588) /gb=AB032970 /gi=6329972 /ug=Hs.22675 /len=5027

5 CACACTCGCACCCGCGCACGCACCGCCAGCAGGCAGCGGCCACCGCCGCGATGC
TCGCCCCGCGGGTTGGGGAAGTTTCCCGCCGGCCTCGGCCGCGGGCACCCGTGCTC
CCAGGTGTAGCGCCCCCGCGCGGGCGCGGGCGGCCCTCCAGCATGACCGG
CCAGAGCCTGTGGGACGTGTGCGGAGGCTAACGTCGAGGACGGGGAGATCCGCAT
CAATGTGGGCGGCTTCAAGAGGAGGCTGCGCTCGCACACGCTGCTGCGCTTCCCC
10 GAGACGCGCCTGGGCGGCTTGCTGCTCTGCCACTCGCGCGAGGCCATTCTGGAGC
TCTGCGATGACTACGACGACGTCCAGCGGGAGTTCTACTTCGACCGCAACCCTGA
GCTCTTCCCCTACGTGCTGCATTTCTATCACACCGGCAAGCTTCACGTCATGGCTG
AGCTATGTGTCTTCTCCTTCAGCCAGGAGATCGAGTACTGGGGCATCAACGAGTT
CTTCATTGACTCCTGCTGCAGCTACAGCTACCATGGCCGCAAAGTAGAGCCCGAG
15 CAGGAGAAGTGGGACGAGCAGAGTGACCAGGAGAGCACCACGTCTTCTTCGAT
GAGATCCTTGCTTCTACAACGACGCCTCCAAGTTCGATGGGCAGCCCCCTCGGCA
ACTTCCGCAGGCAGCTGTGGCTGGCGCTGGACAACCCCGGCTACTCAGTGCTGAG
CAGGGTCTTCAGCATCCTGTCCATCCTGGTGGTGATGGGGTCCATCATCACCATG
TGCCTCAATAGCCTGCCCGATTTCCAAATCCCTGACAGCCAGGGCAACCCTGGCG
AGGACCCTAGGTTGAAATCGTGGAGCACTTTGGCATTGCCTGGTTCACATTTGA
20 GCTGGTGGCCAGGTTTGCTGTGGCCCCCTGACTTCCTCAAGTTCTTCAAGAATGCC
CTAAACCTTATTGACCTCATGTCCATCGTCCCCCTTTTACATCACTCTGGTGGTGAA
CCTGGTGGTGGAGAGCACACCTACTTTAGCCAACTTGGGCAGGGTGGCCCCAGGT
CCTGAGGCTGATGCGGATCTTCGCGCATCTTAAAGCTGGCCAGGCACTCCACTGGC
CTCCGCTCCCTGGGGGGCCACTTTGAAATACAGCTACAAAGAAGTAGGGCTGCTCT
25 TGCTCTACCTCTCCGTGGGGATTTCCATCTTCTCCGTGGTGGCCTACACCATTGAA
AAGGAGGAGAACGAGGGGCTGGCCACCATCCCTGCCTGCTGGTGGTGGGCTACC
GTCAGTATGACCACAGTGGGGTACGGGGATGTGGTCCCAGGGACCACGGCAGGA
AAGCTGACTGCCTCTGCCTGCATCTTGGCAGGCATCCTCGTGGTGGTCTGCCCCA
TCACCTTGATCTTCAATAAGTTCTCCCACTTTTACCGGCGCCAAAAGCAACTTGA
30 GAGTGCCATGCGCAGCTGTGACTTTGGAGATGGAATGAAGGAGGTCCCTTCGGT
CAATTTAAGGGACTATTATGCCCATAAAGTTAAATCCCTTATGGCAAGCCTGACG
AACATGAGCAGGAGCTACCAAGTGAAGTCAAGTTTAAATGATTCCCTACGTTAGC
GGGGAGGACTTGTACCCCTCCACCCACATTGCTGAGCTGCCTCTTGTGCCTCTG
GCACAGCCCAGGCACCTTATGGTTATGGTGTAAGGAGTATGCCAGGCCCTGAG
35 GGGAGAGATGCATGGGATATGCACCCAGGTTTCTTTTACAGTTTTTAGAATCGTT
TTTAGAGGGTGGTGTGTCTGACACCATGCCTTTGCACCTTTCCATGAAATGACAC
TCACTGGTCTTTGCATCGTGGGCATAAAATGTTACCTTTTGGCAGATGAGTAC
ACCCAGAATGCTAATTTTTCTGTCCATCGTGTACGCTATTCTAGTGCTTGTGGCCC
AGTACTGTCTATGAGTTGTCGTGCTCCTGTTTCTGAGGTTGTCGTGTGAGTTCTGT
40 ACAAAAAGCCCCACAAGTCGTCCAGTAGAAATGCATCTATGAGGTCAGCAAGG
ATATGATGAGATTTTGCTCACAGTCATGTGAAAACAAAATCTCAGCTCTTTATCC
ATTGCTTTCACCTAGTTTGTAGTACCAAACAAAGAGAATGCAAAGTTAAGCAGAC
TTGACCAATGCAAGTCTCTAAGTTGTTTTTATAAATGATCTGTAGTTCGGTGGCTT
GCATGGGTGCACCAATCATCTTTAGAACGATGTACACTGATGTTTCATCTCATAAA
45 TGTCACTCTTTAGAGAATGTTACTTAGTTAAACATGCAGTGAAGATCGAATTTTTT
TCCCAAGAACAGATGTGTTAGGGAGAGGGGCTTCAGCTAAATAGTCCAAACCCT
AGGGTGCTTAAAGCCAAGTTAGTGCAGGCTGAGCCCCTTGGTTCACAGTCAAGCC
TCCTTGTTTCCTAGGGTGACTGTAGAGAAATGTATTTCCGGATGAGGTTTCTGATC
TAGGCCATTTGACCAAACTTTGCTGTGTCTAAGATATTAGCATGTTTTTGAAATAT

TTATTTTTTAAGATGTTTAGGAGTAAGGTCGTGTTGTCTTCCTCAACTAAAAAGA
AGTTTACTGTTGTATCGTCTCCCTGAGGTGAACGTTGTTGGGTTGCTAGCAAGGG
CAGTAGCTTAAATACTTTTGTTCCTACTCTGAAAGCTCATCAAATGAGAGCCCT
TTTATTTCCAAGCAGAATTTAGTCAGATAATTTTGCTTCTAGGATATAGTATGTTG
5 TATATGATGCTGTGATTGCCCTGGAGTTCCTGCCATGACATGGAAACCTGGTGGT
ATGGAAGCATGTACTCAAAATATAGACGTGCACGATGGTGGTGTGGCTTACCCA
GGATGGAAACACTGCAGTTCCTACTTGCATTCCCACTGCCTTTCATGGGGGGTGA
CTGGGTAGAGGCCAGGAGAAAGGAAAGAGTTGTAAAATAAAAAACTGCTAGTTC
ATAAAATGTCATAAAAAAATTGTAACTTGAAAAGCTTAATGCTATTCAAAAGAC
10 CTTCAAGCTTCCAACTTGTATTGAAGGGAGACGACTGTTTCCTCCTCCAAAATG
CTCCTGCTCCTCTTGTTGCGTTAACCAGCACATAACATTGTGATGGGGAACCTGG
GTTCTCTATAAGATAATTCTTCTCCATCATCTTTAAGGTAATCTGATGGTTTTCC
AGGTGGCTTTTCAATTATTGTTCCATCTTTGAAAAGGCAATAGAACCCAGGGGTCTG
AGCATGGAGCTATCCAGGGTTTTTCATCCAAAGGTTGGGCCTCTTCTTAAGAGGTC
15 CTTTTGTGTTTCAGTTGATTGAAGATGATACTTACCTCATTGGAGGTGTGGCAAG
GATCTTATCAGAAGGCTTTGTGTTCTTGTAGTTGTCATGGCTACTACAGTGTGGT
GATTTATTGAATGAATTCCTAGCCACTTGTGTCCTGGAGCCCCAGTTCAAATC
TTTCCATTGGACTGGAGGCTTGTGGGAGGCTGGGAGGTGGCTGTCTCCTAGTGTC
TACATCCGTGTCTCTGAAGCATCAGGAAAAGTGAGATGACTTAGAGGCAACTGG
20 GCACTGAATCAGAGGAGCAGAGTTATTTTTTCAGAATTTGCACATGGAACACTTAG
ATTTGGCTGGTGTCTCCAGCCCTGGAAGGCATAACATTTACGGACTCATCCCCAG
CTGCACTGAAGGCAGGTGGTGGTACAGACTTATGAGGACGGATCAGTTTGGCAA
GGCTGATGGTATTTGGGTCACTGAGGCTGGTATCCATGGCCGCTGACCAAGGAAGCT
TATGGAAGTGGAAAGCAAGGAACAAGGCAGAAATAACTCAGTCAGTTTCATGAAG
25 ATTTTTCTAAACAAGAAGGCTTACCACCAAAAAAGAGGTACCCCTAGTGGTTACCC
TTTGCAGATGTGAAAGCTGGAAAACCTGACTTTTCTTTTTGGTAATGACTTGCATT
TATCTGGTGCCTTTCGTTGGAGGAATCCCAACGTGCTTTAGAGACTATCTTTTTAA
CATCTCTTGACATACATATATACTTATATAAAATATTATCTTGCCCAACTGGACC
TTTACTCACTTCTGAGCATGAGAATGTCCCAATAGCATTGAGTTTTTCAAGTGGT
30 GGTTCAGATAAGTGGGAGAAAGAACAACCCGGCTGGCTTAAACCCTGGAGCTA
ATTCCCACAAGGAATGTAGACTGAATGGTGACCCAGGGAGAAATAATCTTCCTCT
CCCCTAAAGTCTCACTAAGGTTTGAAGTTTACAGGTGCTCTCCACTGGGTCTTTG
ATCGACCTTGCTAGATAACATCTAACTAAAAGCAGTTTCTTTTAGTCCCTGAAGC
TAACCAGGGAGAGTCAGGTAAATTTTCTGTAAAAATATGAGGTGACATCTTTGGC
35 AACCAGGCTGTCAGACTGACCTGTAAACCTCCTTTAGGGGGACAGAGTAGAAAC
TGGAGATGACTTGTTCAGCTGTGAGCTTGAGAGAAGTGTCACTCCAGCATT
GAAGGTTATTGTTTTCAATGCCAGTGGGCCAAATATATGGGCCAGGCTTTGATAT
CTGTGATGTGCATTTTGGAAAGTGCTGGGTTGGGAAGTGACACGTCTGTTGCACAA
ATGCATATTGGTTATAGGTTTGTGTTTTCTGCCAAACCCCCACATTTCTCGGGTTT
40 GTGAGTGAGGAAGGGCATGTTGTAATGCCAAGCTGATTTGTAGCTCGTAAGGTA
GTAATTGGTATTTAACATTTGCATTTGTTATTTCTACTTATCTTAGCACTCAAATA
ATTGAACTACCTGCTAATTCTTGCCGCATTTCAAAGAAAATAAGTTGTTATGCAC
TTTGGGATAGTGGTGATCTGTACAGGCTGTGTGTTAGCTACTTGAAGGCGTAAC
GGTATTTCTTGTTGTTTAAACAGCATGACTTCTTACAGAGCTGTAATTTTTTAAAA
45 TTGAGGATGCCATTTTGAGATGTCAGTTTAAACACTCATTAACACACTACTGTG
CAAGCATTGACACAGGCTGCACTG

SEQ ID NO: 440

>6321 BLOOD gi|177991|gb|M16405.1|HUMACHRM4 Human m4 muscarinic
acetylcholine receptor gene

5 TCTAGACCACCAGCCTGGACAACATACCAAGACCCTGTCTCTACAAATAAATAG
ATAAATAAATAGACACTTTTTTTAAGTGTCAAAAGTGCTTGGCACTTAGTAGACC
ATCAGTGTTAGGTGCTCATACATACCCCGATTATTGCCTTGTCCAGTGCTTTGTA
CAGGGGTTGGAGAGNAGGTGTTAAGAAATGACCGAATGGGTAAATGGATGAAC
AGAACACCTCCCTCCAGAGCCACATGCTCGTGGGCCTCTGGGACCACTCTCCTC
CTCCTCTTGCTTCCCTGAGCTCCCCCAGCATGGCCTCTGTCCAGGCCTTGCGCTGC
10 CTCCAGGCCTTTGCTGTGGCTACTGCCCCTGGAGCGCCATNTCCACAGCTCCTCCT
GTGGCTGGCTCCTCATCACCCAGATGACCTGGTGGGTGAGGCCACCTAGCAAGG
AGTCATGCCTGTCCTGCCTTCTGACTCACTCTCTCATCACCTGCCTTTTTTTTCTT
TTGTGGCTCACGTGTTTGCATGTCTCCCCCATGAGGCAGGGGGCCATGTGTGTC
TTATTCACCTTCTGTAGCCACAGCACCCCTGAGCAATGCTTGGCACATAGTAGGTGC
15 TCAATTAATGTTGAATGAATGGGCAAAATGCGGGATGGCGGGACAGAGTTCTCT
CAAGGCATTCTGCCAGAGAATGTCCCTCTGTACCTTGAATCCAGTGTACCTCCA
GATGACTCCCCATTCCCTCCTGTAGTTCATGCTTTTCTCTCCCTTCTCCTCCAG
ACACGGCCTACCCACCCCTGGCAACCAACATGGCCAACCTTCACACCTGTCAATGG
CAGCTCGGGCAATCAGTCCGTGCGCCTGGTCACGTCAATCATCCCACAATCGCTAT
20 GAGACGGTGGAAATGGTCTTCATTGCCACAGTGACAGGCTCCCTGAGCCTGGTG
ACTGTCGTGGGCAACATCCTGGTGATGCTGTCCATCAAGGTCAACAGGCAGCTGC
GAGACAGTCAACAACCTACTTCTCTTTCAGGCTGGCGTGTGCTGATCTCATCATAGG
CGCGCTCTCCATGAACCTCTACACCGTGACATCATCAAGGGCTACTGSGCCCTG
GGCGCGGTGGTCTGCGACCTGTGGCTGGCCCTGGACTACGTGGTGAGCAACGGCT
25 CCGTCATGAACCTTCTCATCATCAGCTTTGACCGCTACTTCTGCGTCACCAAGCCT
CTCACCTACCCTGCCCCGCGCACCAACCAAGATGGCAGGCCTCATGATTGCTGCTG
CCTGGGTACTGTCCTTCGTGCTCTGGGCGCCTGCCATCTTGTCTGGCAGTTTGTG
GTGGGTAAAGCGGACGGTGCCCGACAACCACTGCTTCATCCAGTTTCTGTCCAACC
CAGCAGTGACCTTTGGCACAGCCATTGCTGCCTTCTACCTGCCTGTGGTCATCAT
30 GACGGTGTGTACATCCACATCTCCCTGGCCAGTCGCAGCCGAGTCCACAAGCAC
CGGCCCCGAGGGCCCCGAAGGAGAAGAAAGCCAAGACGCTGGCCTTCCTCAAGAGC
CCACTAATGAAGCAGAGCGTCAAGAAGCCCCGCGGGAGGCCGCCCCGGGAGG
ACTGCGCAATGGCAAGCTGGAGGAGGCCCCCGGCCAGCGCTGCCAAGCGCCACC
GCGCCCCGTGGCTGATAAGGACACTTCCAATGAGTCCAGCTCAGGCAGTGCCAC
35 CCAGAACACCAAGGAACGCCAGCCACAGAGCTGTCCACCACAGAGGCCACCAC
TCCCGCCATGCCCGCCCCTCCCCTGCAGCCGCGGGCCCTCAACCCAGCCTCCAGA
TGGTCCAAGATCCAGATTGTGACGAAGCAGACAGGCAATGAGTGTGTGACAGCC
ATTGAGATTGTGCCTGCCACGCCGGCTGGCATGCGCCCTGCGGCCAACGTGGCCC
GCAAGTTCGCCAGCATCGCTCGCAACCAGGTGCGCAAGAAGCGGCAGATGGCGG
40 CCCGGGAGCGCAAAGTGACACGAACGATCTTTGCCATTCTGCTAGCCTTCATCCT
CACCTGGACGCCCTACAACGTCATGGTCCTGGTGAACACCTTCTGCCAGAGCTGC
ATCCCTGACACGGTGTGGTCCATTGGCTACTGGCTCTGCTACGTCAACAGCACCA
TCAACCCTGCCTGCTATGCTCTGTGCAACGCCACCTTTAAAAAGACCTTCCGGCA
CCTGCTGCTGTGCCAGTATCGGAACATCGGCACTGCCAGGTAGGCAGGCAGGAG
45 TGCCCTAGGAGGTGCGGTGTGCGTGTGCTGGGGGACCACACGGCTCACTTG
CTGTGGGGGAAGAGTGCAGGCACCATTCTGCGTTTACGTTTGCTGAGGAGGAAGTT
CAGAAGAGGCTCTGTGGCTGCATTACAGAGACCAGATCTCTGCTCACCCGTGAGG
AGGCTCACCCAGGGAGTGTCTGAACTGGGGCTGCCTGGCCACCTCTGTGGCCC
TGCTTCAGCGAGCTGCGGGGCACTGGCCTGGGTGGGCACCTGCCCACTGTGACCA

SEO ID NO: 441

TTAGAGCCCCAGGTTCTGTGCCCTTTTCTATCATCGAAAACATCATGATGCTCCG
GCTGCTCAGTTCCTCTCCTTGTGGCCGTTGCCCTCAGGCTATGGCCACCTTCCT
CTCGCCCTTCCAGCCGCGTTGTCAATGGTGAGGATGCGGTCCCCTACAGCTGGCC
CTGGCAGGTTTCCCTGCAGTATGAGAAAAGTGGAAGCTTCTACCACACGTGTGGC
GGTAGCCTCATCGCCCCCGACTGGGTGTGACTGCCGGCCACTGCATCTCGAGCT
CCTGGACCTACCAGGTGGTGTGGGCGAGTACGACCGTGCTGTGAAGGAGGGCC
CCGAGCAGGTGATCCCCATCAACTCTGGGGACCTCTTTGTGCATCCACTCTGGAA
CCGCTCGTGTGTGGCCTGTGGCAATGACATCGCCCTCATCAAGCTCTCACGCAGC
GCCCAGCTGGGGAGACGCCGTCCAGCTCGCCTCACTCCCTCCCGCTGGTGACATC
CTTCCCAACGAGACACCCTGCTACATCACCGGCTGGGGCCGTCTCTATACCAACG
GGCCACTCCCAGACAAGCTGCAGGAGGCCCTGCTGCCCGTGGTGGACTATGAAC
ACTGCTCCAGGTGGAAGTGGTGGGGTTCTCCGTGAAGAAGACCATGGTGTGTGC
TGGAGGGGACATCCGCTCCGGCTGCAACGGTGACTCTGGAGGACCCCTCAACTG
CCCCACAGAGGATGGTGGCTGGCAGGTCCATGGCGTGACCAGCTTTGTTTCTGCC
TTTGGCTGCAACACCCGCAGGAAGCCCACGGTGTTCCTCGAGTCTCCGCCTTCA

SEO ID NO: 442

>6332 BLOOD 1095450.1 X87949 g1143491 Human mRNA for BiP protein. 0

371

ACATGGATCTGTTCCGGTCTACTATGAAGCCCGTCCAGAAAGTGTTGGAAGATTC
 TGATTTGAAGAAGTCTGATATTGATGAAATTGTTCTTGGTGGCTCGACTCGA
 ATTCCAAAGATTGAGCAACTGGTTAAAGAGTTCTTCAATGGCAAGGAACCATCCC
 GTGGCATAAACCAGATGAAGCTGTAGCGTATGGTGCTGCTGTCCAGGCTGGTGT
 5 GCTCTCTGGTGATCAAGATACAGGTGACCTGGTACTGCTTGATGTATGTCCCCTT
 ACACTTGGTATTGAAACTGTGGGAGGTGTCATGACCAAAGTATTCCAAGGAAC
 ACAGTGGTGCCTACCAAGAAGTCTCAGATCTTTTCTACAGCTTCTGATAATCAAC
 CAACTGTTACAATCAAGGTCTATGAAGGTGAAAGACCCCTGACAAAAGACAATC
 ATCTTCTGGGTACATTTGATCTGACTGGAATTCCTCCTGCTCCTCGTGGGGTCCCA
 10 CAGATTGAAGTCACCTTTGAGATAGATGTGAATGGTATTCTTCGAGTGACAGCTG
 AAGACAAGGGTACAGGGAACAAAAATAAGATCACAATCACCAATGACCAGAAT
 CGCCTGACACCTGAAGAAATCGAAAGGATGGTTAATGATGCTGAGAAGTTTGCT
 GAGGAAGACAAAAAGCTCAAGGAGCGCATTGATACTAGAAATGAGTTGGAAAG
 CTATGCCTATTCTCTAAAGAATCAGATTGGAGATAAAGAAAAAGCTGGGAGGTAA
 15 ACTTTCCTCTGAAGATAAGGAGACCATGGAAAAAGCTGTAGAAGAAAAGATTGA
 ATGGCTGGAAAGCCACCAAGATGCTGACATTGAAGACTTCAAAGCTAAGAAGAA
 GGAAGTGGAAAGAAATTGTTCAACCAATTATCAGCAAAGTCTATGGAAGTGCAGG
 CCTCCCCCAACTGGTGAAGAGGATACAGCAGAAAAAGATGAGTTGTAGACACT
 GATCTGCTAGTGCTGTAATATTGTAATACTGGACTCAGGAAGTTTGTAGGAA
 20 AAAATTGAAAGAACTTAAGTCTCGAATGTAATTGGAATCTTCACCTCAGAGTGGA
 GTTGAAGTCTATAGCCTAAGCGGCTGTTTACTGCTTTTCATTAGCAGTTGCTCA
 CATGTCTTTGGGTGGGGGGGAGAAGAAGAAATGGCCATCTTAAAAAGGGGGTAA
 AAAACCTGGGTAGGGTGTGTGTTACCTTCAAAATGTTCTATTTAACAAGTGGG
 TCATGTGCATCTGGTGTAGGAAGTTTTTCTACCATAAGTGACACCAATAAATGT
 25 TTGTTATTTACACTGGAAAAAATAAANGNGGCCNCCGA

SEQ ID NO: 443

>6336 BLOOD 988256.7 M21121 g339420 Human T-cell-specific protein (RANTES)

mRNA, complete cds. 0

30 GACGTAGGATCAAGACAGCACGTGGACCTCGCACAGCCTCTCCCACAGGTACCA
 TGAAGGTCTCCGCGGCAGCCCTCGCTGTGCATCCTCATTGCTACTGCCCTCTGCG
 CTCCTGCATCTGCCTCCCCATATTCTCGGACACCAACCCCTGCTGCTTTGCCTAC
 ATTGCCCCGCCCCTGCCCCGTGCCACATCAAGGAGTATCTTACACCAAGTGGCA
 AGTGCTCCAACCCAGCAGTCGTCTTTGTACCCGAAAGAACCGCCAAGTGTGTGC
 35 CAACCCAGAGAAGAAATGGGTTCGGGAGTACATCAACTCTTTGGAGATGAGCTA
 GGATGGAGAGTCCTTGAACCTGAACTTACACAAATTTGCCTGTTTCTGCTTGCTCT
 TGTCTAGCTTGGGAGGCTTCCCCTCACTATCTACCCACCCGCTCCTTGAAGG
 GCCCAGATTCTACCACACAGCAGCAGTTACAAAAACCTTCCCCAGGCTGGACGT
 GGTGGCTCACGCCTGTAATCCCAGCACTTTTGGGAGGCTGAGGCGGGTGGACCC
 40 CGGGGTAAAGAGATCCGAGCCATTCTTGGTTACCCCGGTGAAACCCAGTCTCC
 ACTAAGAATTTAAAAAATTAGCCGGGCGTGGTAGCGGGCGCCTGTAGTCCCAGC
 TACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCA
 GTGAGCCGAGATCGCGCCACTGCACTCCAGCCTGGGAGACAGTGTAAGACTGTC
 TCAAAAAAATAAAAATAAAAAGTCAAGATCAGTAAACTGATAAACCCCT
 45 ACCCAACCTGATTAGGAAAGTGAGAACAGAAATTACCAGTATCATAATGAAAAG
 GAAATTATCAACACAGCTCCTAAAGACATTAAGGGTAAGAAGGGACCATTAT
 AAATAACCTTATGTCTACAAATTTGATAACCTGGGTCAAAGGATAGATTTCTTG
 GATAGATTCAATACCTAAATGACACCAAGATCAAACCAAAAAATGTGAATAGCC
 CTATATTTATTAATACACTATAGAAAACCAGACAAAGAAAAATTAAGGCCAG

ATGGTTTCAGACATTAATTCTACAGCCCTGACAAGGAAAAAGGGGATAGTTAGA
ATTGGGTTACTAAAAAGTTAGCTTTTAATATCAACAGGAATACTGGTCAAGAGTC
CACATTATGCAGGTTGTAAATGGTAGACACTATAAACAAATAGGAATCAGCTCT
GATGATACTCATTTTTTCTTCCCTTTCAAAGGCTTGGCAAATAAAGCCGGGTCAA
5 TTTGCTCCTTTGCCAGTCCTCTGACAGAGAAGAGTCTTGCTGCCCCTCCTGCAG
AGTGCCCCCACATTTTCAAGTCCAAGGGCCATCAGTTCACATTTGAGCTTCTCCAAA
CCCAGCAACTCCAGTTCTGCAACAGAGGTGAACGCCAATAAATCTATAGTTTCCT
TATCAATAACTGCGTTTCCTGGCTGGCTTTTCTGCAAGTTTGGCAACGGCAACGTTT
TCCCTTTCTTCAGGTGCTACCTCAGCAACTCTTTCCCATCAGTCCTTTCTTCTGTC
10 TCTTTATCCTTATTTCAGTCCAGCCCCAGTGGGCTCCTCTTCTATGGGTTCTTTACTC
TCTGCCTTCTTCTCCTGGGTCTCTTCTGTTTCTGTAACCATCCTGCTTCCATGTGC
TCTTTGGACTCCCCCAGCTCAGCACATGAGTCTTCTAAAATATGCCTCCAGAGT
CAGTCACCGGGATCTGCAGTTGTTCTGGTGATCCATGGTCTGTATTCACTACTCTC
GCCCTCTGAGAACCACTGGGAAATTTGGCTGCCATCTCGACACCATTGCTACCAA
15 TTTTGGAGCATGGAAACCCATTCTGAAGTGCTTGGTGCTTCTTCACTGTCACTCA
TCTGAACTCTCAGAGTTGGACCCTTCTGCAGTCTCTAGTCCCTCCATGCCCAACCA
GAAGCATCTCCTCTTTCCCGCACTGGCTCCTCTGTCTGTTTGAGATTTAGTAGGCC
ATTGCCGTTTCCGATTCTCACTGATTTCTGCTGAAACCATCTTGCTGGAGGCAGCC
TGCATACCTTTGAGGACGGAATCCTCCAGACGCTCAGCCATCTCATGGCACTGCT
20 GCTGGTAGTCGGGGCTGGTGAAGCAGTGCTTGGGTTCTACAAGCTTCCGCTGCAG
TCGCTCCAGCCGCTTCTGCTCCTTTTTCAGCCTCTCGCTCGGCTTGTGTTTACCCA
TTTCAGCCATTGCTTTTTTCATGATTGACATCGCGTAGTCTCCTTCCACTGAGATCCC
GACAAGGTTCTCGATTGGTTGTCTTCTCAATCTGAGCACCAAGTGGTGGGAGCAT
AGATCCAAAGCTCCTTTTCCAACGCAAGTCTGGGTTCCAAACCTATAAACAGCT
25 CCATGCTGCACTGTGTCACTGGTGTAAATGAGTGCTCCATTGCATTTACAAAGA
AGTTTTCCACTGGAACATTCTGATCTTGGCAGTGCCGGTGGATAAAATCCCGGAC
GGTGACCGACCCGAGGCACACCGCACCGCCTTGACCCGAAGCCAGGGCCGCG
AATCCACACCAGCGCCGCGGCCTCCGGCCATGTCACCGACTACCCGAACCTCAA
GCCTCTCTGTAGAC

30

SEQ ID NO: 444

>6352 BLOOD 346440.22 M24899 g537521 Human triiodothyronine (ear7) mRNA,
complete cds. 0

CCCCGGGCGCAGGAGGCGGGCGGCCCGGCCCCACCGGCCCCCATGGACGCCCC
35 CAGCACGGGGCGCTGAGACCCCGCGTCGCTGCCAGCCCGGTCCGGCGCGCCA
CGCCGAGGGATCTCTGGACAGGACAAGACTCCGAAGCTACTCCCCAGCACACA
GCCCGGGACCCACAAACCCAGCTTGCCCCCAGCCCTCCACCTGCCACTCCCTGG
CCCCCTCCACCGCCCCGCCCCCTTGGGGCGCAGGGCATGGTGTGAAAGGCCAAG
TGCTGAGGCGGGTATCATGGGTGCTGTGCCCTAGGGCCTGGGTGGCAGGGGGTG
40 GGTGGCCTGTGGGTGTGCCGGGGGGGCCAGTGTGCCACCCAGTCTCTTGGCGT
GCTGGAGGGCATCCTGGATGGAATTGAAGTGAATGGAACAGAAGCCAAGCAAG
GTGGAGTGTGGGTGACACCCAGAGGAGAACAGTGCCAGGTCAACAGATGGAAA
GCGAAAAAGAAAGAACGGCCAATGTTCCCTGAAAACAGCATGTCAGGGTATAT
CCCTAGTTACCTGGACAAAGACGAGCAGTGTGTCGTGTGGGGACAAGGCAAC
45 TGGTTATCACTACCGCTGTATCACTTGTGAGGGCTGCAAGGGCTTCTTTCGCCGC
ACAATCCAGAAGAACCTCCATCCACCTATTCTGCAAATATGACAGCTGCTGTG
TCATTGACAAGATCACCCGCAATCAGTGCCAGCTGTGCCGCTTCAAGAAGTGCAT
CGCCGTGGGCATGGCCATGGACTTGGTTCTAGATGACTCGAAGCGGGTGGCCAA
GCGTAAGCTGATTGAGCAGAACCGGGAGCGGCGGCGGAAGGAGGAGATGATCC

GATCACTGCAGCAGCGACCAGAGCCCACTCCTGAAGAGTGGGATCTGATCCACA
 TTGCCACAGAGGCCCATCGCAGCACCAATGCCAGGGCAGCCATTGGAAACAGA
 GGCGGAAATTCCTGCCCGATGACATTGGCCAGTCACCCATTGTCTCCATGCCGGA
 CGGAGACAAGGTGGACCTGGAAGCCTTCAGCGAGTTTACCAAGATCATCACCCC
 5 GGCCATCACCCGTGTGGTGGACTTTGCCAAAAAACTGCCCATGTTCTCCGAGCTG
 CCTTGCGAAGACCAGATCATCCTCCTGAAGGGGTGCTGCATGGAGATCATGTCCC
 TGGCGGCGGTGTCCGCTACGACCCTGAGAGCGACACCCTGACGCTGAGTGGGG
 AGATGGCTGTCAAGCGGGAGCAGCTCAAGAATGGCGGCCTGGGCGTAGTCTCCG
 ACGCCATCTTTGAACTGGGCAAGTCACTCTCTGCCTTTAACCTGGATGACACGGA
 10 AGTGGCTCTGCTGCAGGCTGTGCTGCTAATGTCAACAGACCGCTCGGGCCTGCTG
 TGTGTGGACAAGATCGAGAAGAGTCAGGAGGCGTACCTGCTGGCGTTCGAGCAC
 TACGTCAACCACCGCAAACACAACATTCCGCACTTCTGGCCCAAGCTGCTGATGA
 AGGAGAGAGAAGTGCAGAGTTCGATTCTGTACAAGGGGGCAGCGGCAGAAGGC
 CGGCCGGGCGGGTCACTGGGCGTCCACCCGGAAGGACAGCAGCTTCTCGGAATG
 15 CATGTTGTTCAAGGTCCGCGAGGTCCGGCAGCTTGAGCAGCAGCTTGGTGAAGCG
 GGAAGTCTCCAAGGGCCGGTTCTTCAGCACCAGAGCCCGAAGAGCCCGCAGCAG
 CGTCTCCTGGAGCTGCTCCACCGAAGCGGAATTCTCCATGCCCGAGCGGTCTGTG
 GGGAAGACGACAGCAGTGAAGGCGGACTCCCCGAGCTCCTCTGAGGAGGAACCGG
 AGGTCTGCGAGGACCTGGCAGGCAATGCAGCCTCTCCCTGAAGCCCCCAGAAG
 20 GCCGATGGGGAAGGAGAAGGAGTGCCATACCTTCTCCAGGCCTCTGCCCAAG
 AGCAGGAGGTGCCTGAAAGCTGGGAGCGTGGGCTCAGCAGGGCTGGTCACTCC
 CATCCCGTAAGACCACCTTCCCTTCCTCAGCAGGCCAAACATGGCCAGACTCCCT
 TGCTTTTGTGCTGTGTAGTTCCCTCTGCCTGGGATGCGCTTCCCGCTTCTGTGCTG
 GCAACATCTTACTTGTCTTTGAGGGCCCAACTCAAGTGTCACTCCTTCCCGCAGC
 25 TCCCCAGGCAGAAATAGTTGTCTGTGCTTCCCTTGGTTCATGCTTCTACTGTGACA
 CTTATCTCACTGTTTTATAATTAGTCGGGCATGAGTCTGTTTCCCAAGCTAGACTG
 TGTCTGAATCATGTCTGTATCCCCAGTGCCCGGTGCAGGGCCTGGCATAGAGTAG
 GTACTCCATAAAAGGTGTGTTGAATTGAAGTGCCTCTGCCTCCTCCCCGGGTCA
 GGCGAGAGCCTGACCTACCTGCAGAGACAAGCACCACCGCGGTGAAGAGGCCCA
 30 GCTCCTCCTCGGTAAAGCGCCAGGGAGTTGAGCTTCTCGCTGAAGTCGAACATGGC
 ACTGAGCAGGTCTCCCATGCCCATGGCACCAAGCTCCTGCAGGCTGTAGGTG

SEQ ID NO: 445

>6353 BLOOD Hs.73817 gnl|UG|Hs#S268571 Homo sapiens gene for LD78 alpha

precursor, complete cds /cds=(86,364) /gb=D90144 /gi=219905 /ug=Hs.73817 /len=781
 35 CAGAAGGACACGGGCAGCAGACAGTGGTCAGTCCTTTCTTGGCTCTGCTGACACT
 CGAGCCCACATTCCGTACCTGCTCAGAATCATGCAGGTCTCCACTGCTGCCCTT
 GCTGTCCTCCTCTGCACCATGGCTCTCTGCAACCAGTTCTCTGCATCACTTGCTGC
 TGACACGCCGACCGCCTGCTGCTTCAGCTACACCTCCCGGCAGATTCCACAGAAT
 40 TTCATAGCTGACTACTTTGAGACGAGCAGCCAGTGCTCCAAGCCCGGTGTCATCT
 TCCTAACCAAGCGAAGCCGGCAGGTCTGTGCTGACCCAGTGAGGAGTGGGTCC
 AGAAATATGTCAGCGACCTGGAGCTGAGTGCCTGAGGGGTCCAGAAGCTTCGAG
 GCCCAGCGACCTCGGTGGGCCCAGTGGGGAGGAGCAGGAGCCTGAGCCTTGGGA
 ACATGCGTGTGACCTCCACAGCTACCTCTTCTATGGACTGGTTGTTGCCAAACAG
 45 CCACACTGTGGGACTCTTCTTAACTTAAATTTTAAATTTATTTATACTATTTAGTTTT
 TGTAATTTATTTTCGATTTACAGTGTGTTTGTGATTGTTTGCTCTGAGAGTTCCC
 CTGTCCCCTCCCCCTTCCCTCACACCGCGTCTGGTGACAACCGAGTGGCTGTCATC
 AGCCTGTGTAGGCAGTCATGGCACCAAGCCACCAGACTGACAAATGTGTATCG

GATGCTTTTGTTCAGGGCTGTGATCGGCCTGGGGAAATAATAAAGATGCTCTTTT
AAAAGGTAAA

SEQ ID NO: 446

- 5 >6372 BLOOD 902559.1 M34309 g183990 Human epidermal growth factor receptor
(HER3) mRNA, complete cds. 0

CTCTCACACACACACACCCCTCCCCTGCCATCCCTCCCCGGACTCCGGCTCCGGC
TCCGATTGCAATTTGCAACCTCCGCTGCCGTGCGCCGACGAGCCACCAATTCGCC
AGCGGTTCAAGGTGGCTCTTGCCCTCGATGTCCTAGCCTAGGGGCCCCCGGGCCGGA
10 CTTGGCTGGGCTCCCTTCACCCCTCTGCGGAGTCATGAGGGCGAACGACGCTCTGC
AGGTGCTGGGCTTGCTTTTCAGCCTGGCCCCGGGGCTCCGAGGTGGGCAACTCTCA
GGCAGTGTGTCTGGGACTCTGAATGGCCTGAGTGTGACCGGCGATGCTGAGAA
CCAATACCAGACACTGTACAAGCTCTACGAGAGGTGTGAGGTGGTGTATGGGGAA
CCTTGAGATTGTGCTCACGGGACACAATGCCGACCTCTCCTTCCTGCAGTGGATT
15 CGAGAAGTGACAGGCTATGTCCTCGTGGCCATGAATGAATTCTCTACTCTACCAT
TGCCCAACCTCCGCGTGGTGGCAGGGACCCAGGTCTACGATGGGAAGTTTGCCAT
CTTCGTATGTTGAACTATAACACCAACTCCAGCCACGCTCTGCGCCAGCTCCGC
TTGACTCAGCTCACCGAGATTCTGTGAGGGGGTGTATATATTGAGAAGAACGATA
AGCTTTGTACATGGACACAATTGACTGGAGGGACATCGTGAGGGACCGAGATG
20 CTGAGATAGTGGTGAAGGACAATGGCAGAAGCTGTCCCCCTGTCATGAGGTTT
GCAAGGGGCGATGCTGGGGTCTGGATCAGAAGACTGCCAGACATTGACCAAGA
GCTATCTGTGCTCCTCAGTGAATGGTCACTGCTTTGGGGCCCAACCCCAACCAAGT
GCTGCCATGATGAGTGTGCGGGGGGCTGCTGAGGGCCCTCAGGACACAGACTGCTTT
GGCTGCGGGCACTTCAATGACAGTGGAGCCCTGTGTACCTCGCTGTCCACAGCCTC
25 TTGTCTACAACAAGCTAACTTTCCAGCTGGAACCCAATCCCCACACCAAGTATCA
GTATGGAGGAGTTTGTGTAGCCAGCTGTCCCCATAACTTTGTGGTGGATCAAACA
TCCTGTGTGAGGGCCTGTCTCCTGACAAGATGGAAGTAGATAAAAATGGGCTCA
AGATGTGTGAGCCTTGTGGGGGACTATGTCCCAAAGCCTGTGAGGGGAACAGGCT
CTGGGAGCCGCTTCCAGACTGTGGACTCGAGCAACATTGATGGATTTGTGAACTG
30 CACCAAGATCCTGGGCAACCTGGACTTTCTGATCACCGGCCTCAATGGAGACCCC
TGGCACAAGATCCCTGCCCTGGACCCAGAGAAGCTCAATGTCTTCCGGACAGTAC
GGGAGATCACAGGTTACCTGAACATCCAGTCCTGGCCGCCCCACATGCACAACCT
CAGTGTTTTTTCCAATTGACAACCATTGGAGGCAGAAGCCTCTACAACCGGGGC
TTCTCAITGTTGATCATGAAGAAGTTGAATGTACATCTCTGGGCTTCCGATCCCT
35 GAAGGAAATTAGTGCTGGGCGTATCTATATAAGTGCCAATAGGCAGCTCTGCTAC
CACCCTCTTTGAACTGGACCAAGGTGCTTCGGGGGCCTACGGAAGAGCGACTA
GACATCAAGCATAATCGGCCGCGCAGAGACTGCGTGGCAGAGGGCAAAGTGTGT
GACCCACTGTGCTCCTCTGGGGGATGCTGGGGGCCAGGCCCTGGTCAGTGCTTGT
CCTGTGCAAATTATAGCCGAGGAGGTGTCTGTGTGACCCACTGCAACTTTCTGAA
40 TGGGGAGCCTCGAGAATTTGCCCATGAGGCCGAATGCTTCTCCTGCCACCCGGAA
TGCCAACCCATGGAGGGCACTGCCACATGCAATGGGCTCGGGCTCTGATACTTGT
GCTCAATGTGCCCATTTTCGAGATGGGCCCCACTGTGTGAGCAGCTGCCCCCATG
GAGTCCTAGGTGCCAAGGGCCCAATCTACAAGTACCCAGATGTTTCAAGATGAAT
GTCGGCCCCCTGCCATGAGAACTGCACCCAGGGGTGTAAAGGACCAGAGCTTCAA
45 GACTGTTTAGGACAAACACTGGTGTGATCGGCAAAACCCATCTGACAATGGCTT
TGACAGTGATAGCAGGATTGGTAGTGATTTTCATGATGCTGGGCGGCACTTTTCT
CTACTGGCGTGGGCGCCGGATTGAGAATAAAAGGGCTATGAGGCGATACTTGGA
ACGGGGTGAGAGCATAGAGCCTCTGGACCCCAAGTGAGAAGGCTAACAAAGTCTT
GGCCAGAATCTTCAAAGAGACAGAGCTAAGGAAGCTTAAAGTGCTTGGCTCGGG

TGTCTTTGGAAGTGTGCACAAAGGAGTGTGGATCCCTGAGGGTGAATCAATCAA
GATTCCAGTCTGCATTAAAGTCATTGAGGACAAGAGTGGACGGCAGAGTTTTC
AGCTGTGACAGATCATATGCTGGCCATTGGCAGCCTGGACCATGCCACATTGTA
AGGCTCCTGGGACTATGCCAGGGTCATCTCTGCAGCTTGCTACTCAATATTTGC
5 CTCTGGGTTCTCTGCTGGATCATGTGAGACAACACCGGGGGGCACTGGGGCCAC
AGCTGCTGCTCAACTGGGGAGTACAAATTGCCAAGGGAATGTACTACCTTGAGG
AACATGGTATGGTGCATAGAAACCTGGCTGCCCGAAACGTGCTACTCAAGTCAC
CCAGTCAGGTTTCAGGTGGCAGATTTTGGTGTGGCTGACCTGCTGCCTCCTGATGA
TAAGCAGCTGCTATACAGTGAGGCCAAGACTCCAATTAAGTGGATGGCCCTTGA
10 GAGTATCCACTTTGGGAAATACACACACCAGAGTGATGTCTGGAGCTATGGTGTG
ACAGTTTGGGAGTTGATGACCTTCGGGGCAGAGCCCTATGCAGGGCTACGATTG
GCTGAAGTACCAGACCTGCTAGAGAAGGGGGAGCGGTTGGCACAGCCCCAGATC
TGCACAATTGATGTCTACATGGTGTGTTCAAGTGTGGATGATTGATGAGAACA
TTCGCCCAACCTTTAAAGAACTAGCCAATGAGTTCACCAGGATGGCCCCGAGACCC
15 ACCACGGTATCTGGTCATAAAGAGAGAGAGTGGGCCTGGAATAGCCCCCTGGGCC
AGAGCCCCATGGTCTGACAAACAAGAAGCTAGAGGAAGTAGAGCTGGAGCCAG
AACTAGACCTAGACCTAGACTTGGAAAGCAGAGGAGGACAACCTGGCAACCACCA
CACTGGGCTCCGCCCTCAGCCTACCAGTTGGAACACTTAATCGGCCACGTGGGAG
CCAGAGCCTTTTAAGTCCATCATCTGGATACATGCCCATGAACCAGGGTAATCTT
20 GGGGAGTCTTGCCAGGAGTCTGCAGTTTCTGGGAGCAGTGAACGGTGGCCCCGTG
CAGTCTCTACACCCAATGCCACGGGGATGCCTGGCATCAGAGTCATCAGAGG
GGCATGTAACAGGCTCTGAGGCTGAGCTCCAGGAGAAAGTGTCAATGTGTAGAA
GGCCGGAGCAGGAGCCGGAGGCCAGGGCCACGCGGAGATAGCGCCTACCATTCCC
AGCGCCACAGTCTGCTGACTCCTGTTACCCCACTCTCCCCACCCGGGTTAGAGGA
25 AGAGGATGTCAACGGTTATGTCATGCCAGATACACACCTCAAAGGTACTCCCTCC
TCCCCGGAAGGCACCCTTTCTTCAGTGGGTCTCAGTTCTGTCTTGGGTACTGAAG
AAGAAGATGAAGATGAGGAGTATGAATACATGAACCGGAGGAGAAGGCACAGT
CCACCTCATCCCCCTAGGCCAAGTTCCCTTGAGGAGCTGGGTTATGAGTACATGG
ATGTGGGGTCAGACCTCAGTGCCTCTCTGGGCAGCACACAGAGTTGCCCACTCCA
30 CCCTGTACCCATCATGCCCACTGCAGGCACAACCTCCAGATGAAGACTATGAATAT
ATGAATCGGCAACGAGATGGAGGTGGTCTTGGGGGTGATTATGCAGCCATGGGG
GCCTGCCCAGCATCTGAGCAAGGGTATGAAGAGATGAGAGCTTTTCAGGGGCCT
GGACATCAGGGCCCCCATGTCCATTATGCCCCGCTAAAACTCTACGTAGCTTAG
AGGCTACAGACTCTGCCTTTGATAACCCTGATTACTGGCATAGCAGGCTTTTCCC
35 CAAGGCTAATGCCCAGAGAACGTAACCTCTGCTCCCTGTGGCACTCAGGGAGCA
TTTAATGGCAGCTAGTGCTTTAGAGGGTACCGTCTTCTCCCTATTCCCTCTCTCT
CCCAGGTCCCAGCCCCCTTTTCCCCAGTCCCAGACAATTCCATTCAATCTTTGGAG
GCTTTTAAACATTTTGACACAAAATTCTTATGGTATGTAGCCAGCTGTGCACTTTC
TTCTCTTTCCCAACCCCAGGAAAGGTTTTCTTATTTTGTGTGCTTTCCCAGTCCC
40 ATTCCTCAGCTTCTTCACAGGCACTCCTGGAGATATGAAGGATTACTCTCCATAT
CCCTTCCTCTCAGGCTCTTGACTACTTGGAACTAGGCTCTTATGTGTGCCTTTGTT
TCCCATCAGACTGTCAAGAAGAGGAAAGGGAGGAAACCTAGCAGAGGAAAGTG
TAATTTTGGTTTATGACTCTTAACCCCCTAGAAAGACAGAAGCTTAAATCTGTG
AAGAAAGAGGTTAGGAGTAGATATTGATTACTATCATAATTCAGCACTTAACTAT
45 GAGCCAGGCATCATACTAACTTCACCTACATTATCTCACTTAGTCCTTTATCATC
CTTAAACAATTCTGTGACATACATATTATCTCATTTTNNNNNNNNNNNNNNNNNN
NN
NN
NN

10

20

25

30

35

40

45

377

GCAGAAATGATTAAAAATGTTTGAGCACAACTTGCCGTGCATGTGTGAAGTGAAA
TGAAGAACATCCGCTCTTGGCCTCCCCTTCCCCTCCAAAGTCCAGGGCCACCAGA
ACTGACTTTATTAAAAAAATGACAAAACAGGTCTATACATATTTACAGGCTGGGA
GCCAGGAGGCTCAGGTCCGACAGCAGGGGGCCAGGCTGCTCACTTCTTGGAGAGC
5 TTGACTTGCTTGTGCTTGGGGGGTGCCCACTTGAGGCAGACGGAGTCCACTGTGA
TGGGTGGTTTCTTATACTGGGCACCTTTTGAGGTGCTCCTCCACCAGCTTGGGTGTG
ACACAGATCACGTGCTGGCCCTTCCAGTACTTGACCATATTGAGGGATTGCAGGG
TACTGATGATGTCATTTTGGGTGATACTGGTCATCTGGCTGAGGTCCTTGATGGA
CAGTGTGCCCCGGAAGTCCCGCAGGATCTCCAGCAGCACCCAGGACCAGTAGCT
10 GCGGTAGCTGAGCTTGCCCAAGTTCAGACAGCGGCTTCTCCGGGGAGCCGACTGT
GCTCTCCAGCTTGAGAGCTCATAACTGAAAGCGATGAGGAACTTCCCGTAGCC
GCGGCGTTGGTAGGGGGGCAAGGTCAGGATGCAGGCCACATTGTTTCCATCCGG
GGA CTCTTCTCCTTGAGAGAAGTAGCCAACAATGTGGGCCCCCTGCCGGTCCACC
TCAGTCAGGATGTAAAAGACGAACGGCTCCACGTCAAAGTACAGTGTCTTATGG
15 TCCAGGAAAAGCTTGCCAGCAGACACAGGTTCTGACAGTAAATCTTATGGTCTT
TGCCATCAACTTCGTACACGGAGATGTTGCTCTTGCGGTAGATCTCTTCCCGGG
GGGCTGCCGCCACTGGCACTGACCCAAGTGGAAGCGGTAGCTCTTCTCATATTTCT
ATGTACTTGAGGCAGTACTCGCAGAGCCAGAGCTTGGGCTGTTTCCCATAGTCTT
CGGGGAATGGTGAGAAATACCAGGCATCAATTCGTAGTTCCCGATGTGGATCTT
20 GTCCACATACTTCACCTTGGTGATCGCCTCATGCTCCTTCTCCAAGGCTGCTGTGG
TGGGGTCCATCTCTGCATAAGTCTTCTGCACATGGTTGATCTCATCATGCTTGCGC
TTTGGTTGCGAGTGATCTTGGGCTCAGGCTGCTCTGCGAGCTCGCTGAGGTACTT
CTCTGAGTTCTTCTGTAGAGCATCTTCACTGTCTTGGTCAGCGCCAGCCGGTTCT
TGTCTACCCACTCGTCCAGCCCGCGGTTAAAGCCACAGTAGTGACATAGAATTC
25 CTCTCGGCCCTCCTGGTCGTTCACTCGAGACTGGATCACTTCAGCAGAATGCCAG
GTGCTATCCGGTCGCCGGCACAGGTACGTTTCTCCGATCTCCACCGTGACTTCCG
GCTCGCCGCGCGCCGGGGTCGGCGGAGAGACGCGGCCCGGGGATGGGGCGGTCC
CCTCAGCGGCCGCATTCTCCCCGGGGCCCGGGCTCGCCCTCCCCCGCGACCCCTGA
AGTCCCCGCCGCAACCGCCGCAGCAGCTCCCTGTGCC

30

SEQ ID NO: 448

>6407 BLOOD 199338.3 M31315 g182291 Human coagulation factor XII (Hageman)

mRNA, 3' end. 0

GCTGGACCAACGGACGGATGCCATGAGGGCTCTGCTGCTCCTGGGGTTCCTGCTG
35 GTGAGCTTGGAGTCAACACTTTCGATTCCACCTTGGGAAGCCCCCAAGGAGCATA
AGTACAAAGCTGAAGAGCACACAGTCGTTCTCACTGTCACCGGGGAGCCCTGCC
ACTTCCCCTTCCAGTACCACCGGCAGCTGTACCACAAATGTACCACAAAGGGCCG
GCCAGGCCCTCAGCCCTGGTGTGCTACCACCCCCAACTTTGATCAGGACCAGCGA
TGGGGATACTGTTTGGAGCCCAAGAAAGTGAAAGACCACTGCAGCAAACACAGC
40 CCCTGCCAGAAAGGAGGGACCTGTGTGAACATGCCAAGCGGCCCCCACTGTCTC
TGTCCACAACACCTCACTGGAAACCACTGCCAGAAAGAGAAGTGCTTTGAGCCT
CAGCTTCTCCGGTTTTTCCACAAGAATGAGATATGGTATAGAACTGAGCAAGCAG
CTGTGGCCAGATGCCAGTGCAAGGGTCTGATGCCCACTGCCAGCGGCTGGCCA
GCCAGGCCTGCCGCACCAACCCGTGCCTCCATGGGGGTGCTGCTAGAGGTGG
45 AGGGCCACCGCCTGTGCCACTGCCCGGTGGGCTACACCGGACCCTTCTGCGACGT
GGACACCAAGGCAAGCTGCTATGATGGCCGCGGGCTCAGCTACCGCGGCCTGGC
CAGGACCACGCTCTCGGGTGCGCCCTGTCAGCCGTGGGCCTCGGAGGCCACCTAC
CGGAACGTGACTGCCGAGCAAGCGCGGAAGTGGGGACTGGGCGGCCACGCCTTC
TGCCGGAACCCGGACAACGACATCCGCCCGTGGTGCTTCGTGCTGAACCGCGAC

CGGCTGAGCTGGGAGTACTGCGACCTGGCACAGTGCCAGACCCCAACCCAGGCG
GCGCCTCCGACCCCGGTGTCCCCTAGGCTTCATGTCCCCTCATGCCCCGCGCAGC
CGGCACCGCCGAAGCCTCAGCCCACGACCCGGACCCCGCCTCAGTCCCAGACCC
CGGGAGCCTTGCCGGCGAAGCGGGAGCAGCCGCCTTCCCTGACCAGGAACGGCC
5 CACTGAGCTGCGGGCAGCGGCTCCGCAAGAGTCTGTCTTCGATGACCCGCGTCGT
TGGCGGGCTGGTGGCGCTACGCGGGGCGCACCCCTACATCGCCGCGCTGTACTG
GGGCCACAGTTTCTGCGCCGGCAGCCTCATCGCCCCCTGCTGGGTGCTGACGGCC
GCTCACTGCCTGCAGGACCGGCCCGCACCCGAGGATCTGACGGTGGTGCTCGGC
CAGGAACGCCGTAACCACAGCTGTGAGCCGTGCCAGACGTTGGCCGTGCGCTCC
10 TACCGCTTGACAGAGGCCTTCTCGCCCGTCAGCTACCAGCACGACCTGGCTCTGT
TGCGCCTTCAGGAGGATGCGGACGGCAGCTGCGCGCTCCTGTGCGCTTACGTTCA
GCCGGTGTGCTGCCAAGCGGCGCCGCGCGACCCCTCCGAGACCACGCTCTGCCA
GGTGGCCGGCTGGGGCCACCAGTTCGAGGGGGCGGAGGAATATGCCAGCTTCCT
GCAGGAGGCGCAGGTACCGTTCCTCTCCCTGGAGCGCTGCTCAGCCCCGGACGTG
15 CACGGATCCTCCATCCTCCCCGGCATGCTCTGCGCAGGGTTCCTCGAGGGCGGCA
CCGATGCGTGCCAGGGTGATTCCGGAGGCCCGCTGGTGTGTGAGGACCAAGCTG
CAGAGCGCCGGCTCACCTGCAAGGCATCATCAGCTGGGGATCGGGCTGTGGTG
ACCGCAACAAGCCAGGCGTCTACACCGATGTGGCCTACTACCTGGCCTGGATCCG
GGAGCACACCGTTTCCTGATTGCTCAGGGACTCATCTTCCCTCCTTGGTGATTCC
20 GCAGTGAGAGAGTGGCTGGGGCATGGAAGGCAAGATTGTGTCCCATTCCCCCAG
TGCGGCCAGCTCCGCGCCAGGATGGCGCAGGAAGTCAATAAAGTGCTTTGAAAA
TGCTGAGAAAAAAGAAAAA
SEQ.ID NO: 449
25 >6436 BLOOD gi|219919|dbj|D13515.1|HUMMARR Homo sapiens mRNA for key subunit
of N-methyl-D-aspartate receptor, complete cds
GCTTCAGCGCCCCCTTCCCTCGGCGGACGTCCCGGGACCGCCGCTCCGGGGGAGAC
GTGGCGTCCGCAGCCCGCGGGGCGGGCGAGCGCAGGACGGCCCGGAAGCCCCG
CGGGGGATGCGCCGAGGGCCCCGCGTTCGCGCCGCGCAGAGCCAGGCCCCGCGGC
30 CCGAGCCCATGAGCACCATGCGCCTGCTGACGCTCGCCCTGCTGTTCTCCTGCTC
CGTCGCCCCGTGCCGCGTGCGACCCCAAGATCGTCAACATTGGCGCGGTGCTGAGC
ACGCGGAAGCACGAGCAGATGTTCCGCGAGGCCGTGAACCAGGCCAACAAGCG
GCACGGCTCCTGGAAGATTCAGCTCAATGCCACCTCCGTACGCACAAGCCCAAC
GCCATCCAGATGGCTCTGTGCGGTGTGCGAGGACCTCATCTCAGCCAGGTCTACG
35 CCATCCTAGTTAGCCATCCACCTACCCCCAACGACCACTTCACTCCCACCCCTGTC
TCCTACACAGCCGGCTTCTACCGCATACCCGTGCTGGGGCTGACCACCCGCATGT
CCATCTACTCGGACAAGAGCATCCACCTGAGCTTCCTGCGCACCGTGCCGCCCTA
CTCCCACCAGTCCAGCGTGTGGTTTGAGATGATGCGTGTCTACAGCTGGAACCAC
ATCATCCTGCTGGTCAGCGACGACCACGAGGGCCGGGCGGCTCAGAAACGCCTG
40 GAGACGCTGCTGGAGGAGCGTGAGTCCAAGGCAGAGAAGGTGCTGCAGTTTGAC
CCAGGGACCAAGAACGTGACGGCCCTGCTGATGGAGGCGAAAGAGCTGGAGGC
CCGGGTATCATCCTTTCTGCCAGCGAGGACGATGCTGCCACTGTATACCGCGCA
GCCGCGATGCTGAACATGACGGGCTCCGGGTACGTGTGGCTGGTCGGCGAGCGC
GAGATCTCGGGGAACGCCCTGCGCTACGCCCCAGACGGCATCCTCGGGCTGCAG
45 CTCATCAACGGCAAGAACGAGTCGGCCACATCAGCGACGCCGTGGGCGTGGTG
GCCCAGGCCGTGCACGAGCTCCTCGAGAAGGAGAACATCACCGACCCGCCGCGG
GGCTGCGTGGGCAACACCAACATCTGGAAGACCGGGCCGCTCTTCAAGAGAGTG
CTGATGTCTTCCAAGTATGCGGATGGGGTGACTGGTCGCGTGGAGTTCAATGAGG
ATGGGGACCGGAAGTTCGCCAACTACAGCATCATGAACCTGCAGAACCGCAAGC

TGGTGCAAGTGGGCATCTACAATGGCACCCACGTCATCCCTAATGACAGGAAGA
TCATCTGGCCAGGCGGAGAGACAGAGAAGCCTCGAGGGTACCAGATGTCCACCA
GACTGAAGATTGTGACGATCCACCAGGAGCCCTTCGTGTACGTCAAGCCACGCT
GAGTGATGGGACATGCAAGGAGGAGTTCACAGTCAACGGCGACCCAGTCAAGAA
5 GGTGATCTGCACCGGGGCCAACGACACGTCGCCGGGCAGCCCCGCCACACGGT
GCCTCAGTGTTGCTACGGCTTTTGCATCGACCTGCTCATCAAGCTGGCACGGACC
ATGAACCTTACCTACGAGGTGCACCTGGTGGCAGATGGCAAGTTCGGCACACAG
GAGCGGGTGAACAACAGCAACAAGAAGGAGTGGAATGGGATGATGGGCGAGCT
GCTCAGCGGGCAGGCAGACATGATCGTGGCGCCGCTAACCATAAACAACGAGCG
10 CGCGCAGTACATCGAGTTTCCAAGCCCTTCAAGTACCAGGGCCTGACTATTCTG
GTCAAGAAGGAGATTCCCCGGAGCACGCTGGACTCGTTCATGCAGCCGTTCCAG
AGCACACTGTGGCTGCTGGTGGGGCTGTCGGTGCACGTTGGTGGCCGTGATGCTGT
ACCTGCTGGACCGCTTCAGCCCCCTTCGGCCGGTTCAAGGTGAACAGCGAGGAGG
AGGAGGAGGACGCACTGACCCTGTCCTCGGCCATGTGGTTCTCCTGGGGCGTCCT
15 GCTCAACTCCGGCATCGGGGAAGGCGCCCCCAGAAGCTTCTCAGCGCGCATCCT
GGGCATGGTGTGGGCCGGCTTTGCCATGATCATCGTGGCCTCCTACACCGCCAAC
CTGGCGGCCTTCTTGGTGTGACCGGCCGGAGGAGCGCATCACGGGCATCAAC
GACCCTCGGCTGAGGAACCCCTCGGACAAGTTTATCTACGCCACGGTGAAGCAG
AGCTCCGTGGATATCTACTTCCGGCGCCAGGTGGAGCTGAGCACCATGTACCGGC
20 ATATGGAGAAGCACAACCTACGAGAGTGCGGCGGAGGCCATCCAGGCCGTGAGA
GACAACAAGCTGCATGCCTTCATCTGGGACTCGGCGGTGCTGGAGTTCGAGGCCT
CGCAGAAGTGCGACCTGGTGACGACTGGAGAGCTGTTTTTCCGCTCGGGCTTCGG
CATAGGCATGCGCAAAGACAGCCCTGGAAGCAGAACGTCTCCCTGTCCATCCTC
AAGTCCACGAGAATGGCTTCATGGAAGACCTGGACAAGACGTGGGTTCGGTAT
25 CAGGAATGTGACTCGCGCAGCAACGCCCTGCGACCCTTACTTTTGAGAACATGG
CCGGGGTCTTCATGCTGGTAGCTGGGGGCATCGTGGCCGGGATCTTCCTGATTTT
CATCGAGATTGCCTACAAGCGGCACAAGGATGCTCGCCGGAAGCAGATGCAGCT
GGCCTTTGCCGCCGTTAACGTGTGGCGGAAGAACCTGCAGGATAGAAAGAGTGG
TAGAGCAGAGCCTGACCCTAAAAAGAAAGCCACATTTAGGGCTATCACCTCCAC
30 CCTGGCTTCCAGCTTCAAGAGGCGTAGGTCTCCAAAGACACGAGCACCAGGGGG
TGGACGCGGCGCTTTGCAAAACCAAAAAGACACAGTGCTGCCGCGACGCGCTAT
TGAGAGGGAGGAGGGCCAGCTGCAGCTGTGTTCCCGTCATAGGGAGAGCTGAGA
CTCCCCGCCCGCCCTCCTCTGCCCCCTCCCCCGCAGACAGACAGACAGACGGACG
GGACAGCGGCCCCGGCCACGCAGAGCCCCGGAGCACCACGGGGTCGGGGGAGG
35 AGCACCCCCAG

SEQ ID NO: 450

>6437 BLOOD 242455.2 U72648.1 g3914602 Human alpha2-C4-adrenergic receptor gene,
complete cds. 0

GGCGCTCGATGTGCTGTTTTGCACCTCGTCGATCGTGCATCTGTGTGCCATCAGCC
TGGATCGCTACTGGTCGGTGACGCANGCCGTCGAGTACAACCTGAAGCGCACAC
CACGCNCGTCAAGGCCACCATCGTCGCCGTGTGGCTCATCTCGGCCGTCTCTC
CTTCCCGCCGCTGGTCTCGCTCTACCGCCAGCCCGACGGCGCCGCTACCCGCAG
TGCGGCCTCAACGACGAGACCTGGTACATCCTGTCCTCCTGCATCGGCTCCTTCTT
40 CGCGCCCTGCCTCATCATGGGCCTGGTCTACGCGCGCATCTACCGAGTGGCCAAG
CGTCGCACGCGCACGCTCAGCGAGAAGCGCGCCCCCGTGGGCCCCGACGGTGGC
TCCCCGACTACCGAAAACGGGCTGGGCGCGGCGGCAGGCGAGGCGAGAACGGG
CACTGCGCGCCCCCGCCCGCCGACGTGGAGCCGGACGAGAGCAGCGCAGCGGCC
GAGAGGCGGCGCGCCGGGGCCGTTGCGGCGGGGCGGGCGGCGGCGAGCGGGCG

CGGAGGGGGGCGCGGGCGGTGCGGACGGGCAGGGGGCGGGGCCGGGGGCGGGT
CAGTCGGGGGCGCTGACCGCCTCCAGGTCCCCGGGGCCCGGTGGCCGCTCTCGC
GCGCCAGCTCGCGCTCCGTCGAGTTCTTCTGTGCGCGCCGGCGCCGGGCGCGCAG
CAGCGTGTGCCGCCGCAAGGTGGCCCAGGCGCGCGAGAAGCGCTTCACCTTTGT
5 GCTGGCTGTGGTCATGGGCGTGTTCGTGCTCTGCTGGTTCCTTCTTCTCAGCT
ACAGCCTGTACGGCATCTGCCGCGAGGCCTGCCAGGTGCCCGGCCCGCTCTTCAA
GTTCTTCTTCTGGATCGGCTACTGCAACAGCTCGCTCAACCCGGTCATCTACACG
GTCTTCAACCAGGATTTCCGGCGATCCTTTAAGCACATCCTCTTCCGACGGAGGA
GAAGGGGCTTCAGGCAGTGACTCGCACCCGTCTGGGAATCCTGGACAGCTCCGC
10 GCTCGGGGCTGGGCAGAAGGGGCGGCCCGGACGGGGGAGCTTTCCAGAGACCC
GGGGAGCTCTCCCAGAGACCCGGGGATGGATTGGCCTCCAGGGCGCAGGGGAGG
GTGCGGCAGGGCAGGAGCTTGGCAGAGAGATAGCCGGGCTCCAGGGAGTGGGG
AGGAGAGAGGGGGAGACCCCTTTGCCTTCCCCCTCAGCAAGGGGCTGCTTCTG
GGGCTCCCTGCCTGGATCCAGCTCTGGGAGCCCTGCCGAGGTGTGGCTGTGAGGT
15 CAGGGTTTTAGAGAGCAGTGGCAGAGGTAGCCCCCTAAATGGGCAAGCAAGGAG
CCCCCAAAGACACTACCACTCCCCATCCCCGTCTGACCAAGGGCTGACTTCTCC
AGGACCTAGTCGGGGGGTGGCTGCCAGGGGGCAAGGAGAAAGCACCGACAATC
TTTGATTACTGAAAGTATTTAAATGTTTGCCAAAAACAACAGCCAAAACAACCAA
ACTATTTTCTAAATAAACCTTTGTAATCTAAGATTGTCGGTGCTTTCTCCTTGCCC
20 CCTGGCAGCCACCCCCGACTAGGTCCTGGAGAAGTCAGCCCTTGGTCAGACGG
GGATGGGGAGTGGTAGTGTGTTTCGGGGGGCTCCTTGCTCGCCATTAGGAAGC
TACCTCTGACACTGCTCTCTAAAACCCTGACCTCACAGCCACACCTCGGAGGGC
CGCCACAGCTGGAT

SEQ ID NO: 451
>6460 BLOOD gi|603954|dbj|D43950.1|HUMKG1DD Homo sapiens mRNA for KIAA0098
protein, partial cds
ATTCCGGTTGTTGCACCATGGCGTCCATGGGGACCCTCGCCTTCGATGAATATGG
GCGCCCTTTCCTCATCATCAAGGATCAGGACCGCAAGTCCCGTCTTATGGGACTT
30 GAGGCCCTCAAGTCTCATATAATGGCAGCAAAGGCTGTAGCAAATACAATGAGA
ACATCACTTGGACCAAATGGGCTTGATAAGATGATGGTGGATAAGGATGGAGAT
GTGACTGTAACATAATGATGGGGCCACCATCTTAAGCATGATGGATGTTGATCATC
AGATTGCCAAGCTGATGGTGGAACTGTCCAAGTCTCAGGATGATGAAATTGGAG
ATGGAACCACAGGAGTGGTTGTCTGGCTGGTGCCITGTTAGAAGAAGCGGAGC
35 AATTGCTAGACCGAGGCATTACCCAATCAGAATAGCCGATGGCTATGAGCAGG
CTGCTCGTGTTGCTATTGAACACCTGGACAAGATCAGCGATAGCGTCCTTGTTGA
CATAAAGGACACCGAACCCCTGATTACAGACAGCAAAAACACGCTGGGCTCCAA
AGTGGTCAACAGTTGTACCGACAGATGGCTGAGATTGCTGTGAATGCCGTCTC
ACTGTAGCAGATATGGAGCGGAGAGACGTTGACTTTGAGCTTATCAAAGTAGAA
40 GGCAAAGTGGGCGGCAGGCTGGAGGACACTAAACTGATTAAGGGCGTGATTGTG
GACAAGGATTTCAGTACCCACAGATGCCAAAAAAGTGGAAGATGCGAAGATT
GCAATTCTCACATGTCCATTTGAACCACCCAAACCAAAAACAAGCATAAGCTG
GATGTGACCTCTGTGCAAGATTATAAAGCCCTTCAGAAATACGAAAAGGAGAAA
TTTGAAGAGATGATTCAACAAATTAAGAGAGACTGGTGCTAACCTAGCAATTTGTC
45 AGTGGGGCTTTGATGATGAAGCAAATCACTTACTTCTTCAGAACAACCTGCCTGC
GGTTCGCTGGGTAGGAGGACCTGAAATTGAGCTGATTGCCATCGCAACAGGAGG
GCGGATCGTCCCCAGGTTCTCAGAGCTCACAGCCGAGAAGCTGGGCTTTGCTGGT
CTTGACAGGAGATCTCATTTGGGACAACCTAAGGATAAAATGCTGGTCATCGAGC
AGTGTAAGAACTCCAGAGCTGTAACCATTTTTATTAGAGGAGGAAATAAGATGA

TCATTGAGGAGGCGAAACGATCCCTTCACGATGCTTTGTGTGTCATCCGGAACCT
CATCCGCGATAATCGTGTGGTGTATGGAGGAGGGGCTGCTGAGATATCCTGTGCC
CTGGCAGTTAGCCAAGAGGCGGATAAGTGCCCCACCTTAGAACAGTATGCCATG
AGAGCGTTTGCCGACGCACTGGAGGTCATCCCCATGGCCCTCTCTGAAAACAGTG
5 GCATGAATCCCATCCAGACTATGACCGAAGTCCGAGCCAGACAGGTGAAGGAGA
TGAACCCTGCTCTTGGCATCGACTGTTTGCACAAGGGGACAAATGATATGAAGCA
ACAGCATGTATAGAAACCTTGATTGGCAAAAAGCAACAGATATCTCTTGCAAC
ACAAATGGTTAGAATGATTTTGAAGATTGATGACATTCGTAAGCCTGGAGAATCT
GAAGAATGAAGACATTGAGAAAACCTATGTAGCAAGATCCACTTCTGTGATTAAG
10 TAAATGGATGTCTCGTGATGCATCTACAGTTATTTATTGTTACATCCTTTTCCAGA
CACTGTAGATGCTATAATAAAAATAGCTGTTTGGTAACCATAGTTTCACCTTGTTT
AAAGCTGTGTAATCGTGGGGGTACCATCTCAACTGCTTTTGTATTCAATTGTATTAA
AAGAATCTGTTTAAACAACCTTTATCTTCTCTTCGGGTTTAAGAAACGTTTATTGT
AACAGTAATTAAATGCTGCCTTAATTG

SEQ ID NO: 452

>6469 BLOOD 478620.78 D55696 g1890049 Human mRNA for cysteine protease, complete
cds. 0

GCGGCGGCGCCCGCAGCAATCACAGCAGTGCCGACGTCGTGGGTGTTTGGTGTG
20 AGGCTGCGAGCCGCGCGAGTTCTACGGTCCCGCGCGCCACCACCGCGGTC
ACTCACCGCGCGCGCGCCACCCTGCCACCACGGTCGCCTGCCACAGGTGTCTG
CAATTGAACCTCAAAGGTGCAGAAATGGTTTGGAAAGTAGCTGTATTCTCAGTGTG
GECCTGGGCATTGGTGCGCTTCTATAGATGATCCTGAAGATGGAGGGCAAGCACT
GGGTGGTGTATCGTGGCAGGTTCAAATGGCTGGTATAATTATAGGCACCAGGCAG
25 ACGCGTGCCATGCCTACCAGATCATTACCGCAATGGGATTCTGACGAACAGAT
CGTTGTGATGATGTACGATGACATTGCTTACTCTGAAGACAATCCCACTCCAGGA
ATTGTGATCAACAGGCCCAATGGCACAGATGTCTATCAGGGAGTCCCGAAGGAC
TACACTGGAGAGGATGTTACCCCAAAAATTTCTTGCTGTGTTGAGAGGCGATG
CAGAAGCAGTGAAGGGCATAGGATCCGGCAAAGTCCTGAAGAGTGGCCCCCAGG
30 ATCACGTGTTCAATTACTTCACTGACCATGGATCTACTGGAATACTGGTTTTTCCC
AATGAAGATCTTCATGTAAAGGACCTGAATGAGACCATCCATTACATGTACAAA
CACAAAATGTACCGAAAGATGGTGTCTACATTGAAGCCTGTGAGTCTGGGTCCA
TGATGAACCACCTGCCGGATAACATCAATGTTTATGCAACTACTGCTGCCAACCC
CAGAGAGTCGTCCTACGCTTGTACTATGATGAGAAGAGGTCCACGTACCTGGG
35 GGACTGGTACAGCGTCAACTGGATGGAAGACTCGGACGTGGAAGATCTGACTAA
AGAGACCCTGCACAAGCAGTACCACCTGGTAAAATCGCACACCAACACCAGCCA
CGTCATGCAGTATGGAAACAAAACAATCTCCACCATGAAAGTGATGCAGTTTCA
GGGTATGAAACGCAAAGCCAGTTCTCCCGTCCCCCTACCTCCAGTCACACACCTT
GACCTCACCCCCAGCCCTGATGTGCCTCTCACCATCATGAAAAGGAAACTGATGA
40 ACACCAATGATCTGGAGGAGTCCAGGCAGCTCACGGAGGAGATCCAGCGGCATC
TGGATGCCAGGCACCTCATTGAGAAGTCAGTGCGTAAGATCGTCTCCTTGCTGGC
AGCGTCCGAGGCTGAGGTGGAGCAGCTCCTGTCCGAGAGAGCCCCGCTCACGGG
GCACAGCTGCTACCCAGAGGCCCTGCTGCACTTCCGGACCCACTGCTTCAACTGG
CACTCCCCCACGTACGAGTATGCGTTGAGACATTTGTACGTGCTGGTCAACCTTT
45 GTGAGAAGCCGTATCCGCTTCACAGGATAAAATTGTCCATGGACCACGTGTGCCT
TGGTCACTACTGAAGAGCTGCCTCCTGGAAGCTTTTCCAAGTGTGAGCGCCCCAC
CGACTGTGTGCTGATCAGAGACTGGAGAGGTGGAGTGAGAAGTCTCCGCTGCTC
GGGCCCTCCTGGGGAGCCCCCGCTCCAGGGCTCGCTCCAGGACCTTCTTCAACAAG
ATGACTTGCTCGCTGTTACCTGCTTCCCCAGTCTTTTCTGAAAAACTACAAATTAG

GGTGGGAAAAGCTCTGTATTGAGAAGGGTCATATTTGCTTTCTAGGAGGTTTGTT
GTTTTGCCTGTTAGTTTTGAGGAGCAGGAAGCTCATGGGGGCTTCTGTAGCCCCT
CTCAAAGGAGTCTTTATTCTGAGAATTTGAAGCTGAAACCTCTTTAAATCTTCA
GAATGATTTTATTGAAGAGGGCCGCAAGCCCCAAATGGAAAACCTGTTTTTAGAA
5 AATATGATGATTTTTGATTGCTTTTGTATTTAATTCTGCAGGTGTTCAAGTCTTAA
AAAATAAAGATTTATAACAGAACCCAAATATTCACGT

SEQ ID NO: 453

>6521 BLOOD 244633.12 L11066 g307322 Human mRNA sequence. 0

10 CGAGGACCGGGGCTGTCCGAGATACGGCCTTCATATCCCTCTTCTCCCTGGAC
TCTTTCTGAGCTCAGAGCCGCCGACGCCGGGACAGGAGGGCAGGCTTTCTCCAAC
CATCATGCTGCGGAGCATATTACCTGTACGCCCTGGCTCCGGGAGCGGCAGTCGA
GTATCCTCTGGTCAGGCGGCGCGGGCGGCCCTCAGCGGAAGAGCGGGCCTCTG
NNGGCCGCATGTGACCAACCCCCGGCCCCCTCACCCNNCACGTGGTTGGAGGTTT
15 CCAGAAGCGCTGCCGCCACCGCATCGCGCAGCTCTTTGCCGTCGGAGCGCTTGTT
TGCTGCCTCGTACTCCTCCATTTATCCGCCATGATAAGTGCCAGCCGAGCTGCAG
CAGCCCGTCTCGTGGGCGCCGACGCTCCCGGGGGCCCTACGGCCGCCGCCACCA
GGATAGCTGGAATGGCCTTAGTCATGAGGCTTTTAGACTTGTTTCAAGGCGGGAT
TATGCATCAGAAGCAATCAAGGGAGCAGTTGTTGGTATTGATTTGGGTACTACCA
20 ACTCCTGCGTGGCAGTTATGGAAGGTAAACAAGCAAAGGTGCTGGAGAATGCCG
AAGGTGCCAGAACCACCCCTTCAGTTGTGGCCTTTACAGCAGATGGTGAGCGACT
TCTTTGGAATGCCGGCCAAAGCGACAGGCTGTACCAACCCAAACAATAGATTTTAT
TCTGAGGCTAGCAAGCGTCTCATTTGGCCGGCGATATGATGATCCTGAAGTACAGAAAGAC
TCTGAGGCTAGCAAGCGTCTCATTTGGCCGGCGATATGATGATCCTGAAGTACAGAAAGAC
TCTGAGGCTAGCAAGCGTCTCATTTGGCCGGCGATATGATGATCCTGAAGTACAGAAAGAC
TCTGAGGCTAGCAAGCGTCTCATTTGGCCGGCGATATGATGATCCTGAAGTACAGAAAGAC
25 AGGCTCATGGGAAATTGTATTCTCCGAGTCAGATTGGAGCATTGTGTTGATGAA
GATGAAAGAGACTGCAGAAAATTACTTGGGGCACACAGCAAAAAATGCTGTGAT
CACAGTCCCAGCTTATTTCAATGACTCGCAGAGACAGGCCACTAAAGATGCTGGC
CAGATATCTGGACTGAATGTGCTTCGGGTGATTAATGAGCCCACAGCTGCTGCTC
TTGCCTATGGTCTAGACAAATCAGAAGACAAAGTCATTGCTGTATATGATTTAGG
30 TGGTGGAACTTTTGATATTTCTATCCTGGAAATTCAGAAAGGAGTATTTGAGGTG
AAATCCACAAATGGGGATACCTTCTTAGGTGGGGAAGACTTTGACCAGGCCTTGC
TACGGCACATTGTGAAGGAGTTCAAGAGAGAGACAGGGGTTGATTTGACTAAAG
ACAACATGGCACTTCAGAGGGTACGGGAAGCTGCTGAAAAGGCTAAATGTGAAC
TCTCCTCATCTGTGCAGACTGACATCAATTTGCCCTATCTTACAATGGATTCTTCT
35 GGACCCAAGCATTTGAATATGAAGTTGACCCGTGCTCAATTTGAAGGGATTGTCA
CTGATCTAATCAGAAGGACTATCGCTCCATGCCAAAAAGCTATGCAAGATGCAG
AAGTCAGCAAGAGTGACATAGGAGAAGTGATTCTTGTGGGTGGCATGACTAGGA
TGCCCAAGGTTTCAGCAGACTGTACAGGATCTTTTTTGGCAGAGCCCCAAGTAAAGC
TGTCATCCTGATGAGGCTGTGGCCATTGGAGCTGCCATTCAGGGAGGTGTGTTG
40 GCCGGCGATGTCACGGATGTGCTGCTCCTTGATGTCACTCCCCTGTCTCTGGGTAT
TGAAACTCTAGGAGGTGTCTTTACCAAACTTATTAATAGGAATACCACTATTCCA
ACCAAGAAGAGCCAGGTATTCTCTACTGCCGCTGATGGTCAAACGCAAGTGGAA
ATTAAAGTGTGTCAGGGTGAAAGAGAGATGGCTGGAGACAACAACTCCTTGGA
CAGTTTACTTTGATTGGAATTCACACAGCCCCCTCGTGGAGTTCCTCAGATTGAAG
45 TTACATTTGACATTGATGCCAATGGGATAGTACATGTTTCTGCTAAAGATAAAGG
CACAGGACGTGAGCAGCAGATTGTAATCCAGTCTTCTGGTGGATTAAGCAAAGA
TGATATTGAAAATATGGTTAAAAATGCAGAGAAATATGCTGAAGAAGACCGGCG
AAAGAAGGAACGAGTTGAAGCAGTTAATATGGCTGAAGGAATCATTACGACAC
AGAAACCAAGATGGAAGAATTCAAGGACCAATTACCTGCTGATGAGTGCAACAA

GCTGAAAGAAGAGATTTCCAAAATGAGGGAGCTCCTGGCTAGAAAAGACAGCGA
AACAGGAGAAAATATTAGACAGGCAGCATCCTCTCTTCAGCAGGCATCACTGAA
GCTGTTTCGAAATGGCATACAAAAAGATGGCATCTGAGCGAGAAGGCTCTGGAAG
TTCTGCACTGGGGAACAAAGGAAGATCAAAAGGAGGAAAACAGTATAATA

5

SEQ ID NO: 454

>6538 BLOOD 332156.1 AF004021 g2257849 Human prostaglandin F2 alpha receptor
mRNA, complete cds. 0

10 GCCGCGCGCGCCCCGCAGTTTCCGCGCTAAGGGAACGAGTGCGCGGAGGGGACG
AGCGGCTGGACCACAGCCGGCGCCCGATCAGGATCTCCGCGCTGGGATCGGTGG
AACTTGAGGCAGCGGCGGCGCGGGGCGCCATGGCACACCGAGCGGCTCCGTCTT
CTGCTCCTCAGAGAGCCCGGCTGGCGGCCTGGGATGACAAGATGTCTGGACTGC
AATCCTGCACAGTTTTGAGAGGGAGATGACTTGAGTGGTTGGCTTTTATCTCCAC
AACAATGTCCATGAACAATTCCAAACAGCTAGTGTCTCCTGCAGCTGCGCTTCTT
15 TCAAACACAACCTGCCAGACGGAACCGGCTTTCCGTATTTTTTTCAGTAATCT
TCATGACAGTGGGAATCTTGTCAAACAGCCTTGCCATCGCCATTCTCATGAAGGC
ATATCAGAGATTTAGACAGAAGTCCAAGGCATCGTTTCTGCTTTTGGCCAGCGGC
CTGGTAATCACTGATTTCTTTGGCCATCTCATCAATGGAGCCATAGCAGTATTTGT
ATATGCTTCTGATAAAGAATGGATCCGCTTGACCAATCAAATGTCCTTTGCAGT
20 ATTTTGGTATCTGCATGGTGTCTTCTGGTCTGTGCCCACTTCTTCTAGGCAGTGT
GATGGCCATTGAGCGGTGTATTGGAGTCACAAAACCAATATTTTCATTCTACGAAA
ATTACATCCAAACATGTGAAAATGATGTTAAGTGGTGTGTGCTTGTTTGGTGTGTTT
CATAGCTTTGCTGCCCCATCCTTGGACATCGAGACTATAAAATTCAGGGCTCGAGG
ACCTGGTGTCTTACAACACAGAAGACATCAAAGACTGGGAAGATAGATTTTATC
25 TTCTACTTTTTTCTTTTCTGGGGCTCTTAGCCCTTGGTGTTCATTGTTGTGCAATG
CAATCACAGGAATTACACTTTTAAGAGTTAAATTTAAAAGTCAGCAGCACAGAC
AAGGCAGATCTCATCATTTGGAAATGGTAATCCAGCTCCTGGCGATAATGTGTGT
CTCCTGTATTTGTTGGAGCCCATTTCTGGTTACAATGGCCAACATTGGAATAAAT
GGAAATCATTCTCTGGAACCTGTGAAACAACACTTTTTGCTCTCCGAATGGCAA
30 CATGGAATCAAATCTTAGATCCTTGGGTATATATTCTTCTACGAAAGGCTGTCCTT
AAGAATCTCTATAAGCTTGCCAGTCAATGCTGTGGAGTGCATGTCATCAGCTTAC
ATATTTGGGAGCTTAGTTCATTAAAAATTCCTTAAAGGTTGCTGCTATTTCTGAG
TCACCAGTTGGAGAGAAAACAGCAAGCACCTAGCTTAATAGGACAGTAAATCTG
TGTGGGGCTAGAACAAAATTAAGACATGTTTGGCAATATTTTCAGTTAGTTAAATA
35 CCTGTAGCCTAACTGGAATAATTCAGGCTTCATCATGTAGTTTGAAGATACTATTG
TCAGATTCAGGTTTTGAAATTTGTCAAATAAACAGGATAACTGTACATTTTTCAC
TTGTTTTTGCCAATGGGAGGTAGACACAATAAAATAATGCCATGGGAGTCACACT
GAAAGCAATTTTGAGCTTATCTGTCTTATTTATGCTTTGAGTGAATCATCTGTTGA
GGTCTAATGCCTTTACTTGGCCTATTTGCCAGAGAACATCTTAATGCAGCCTGCA
40 TAGTGAAATGGTTATTTTGGAGATCACCGCTCTGTAGCTAACCCTTATAAACTAGG
CTCAGTAAAATAAAGCACTCTTATTTTTTGTATCTGGCCTATTTTGGCCCTCATTGT
GTAGCCTCAATTAACACATGCATGGTCATGACACCCAGAATTCATGATGGTTTGT
TATAACAACCTCTGCATATTCCAGGTCTGGCAGACAGGTTGCCTGACCCTGCAAT
CCTATCTAGAATGGGCTCATTCTTGTCAATTTGACAAATAGGACTGCCTACATTT
45 ATTATTATGAAGGTCGATTGTTGTTGGAAGTGTTTTTTCATGTCATAGATTAGCAA
TTTTCAAATAATTATTTTTTCTCTGAAAATTTTGTGTGTGATTGCACAATAAATAA
TTTTTAGAGAAACAAAGGCTCTTCTCAGCACATTGATGGGCAACTAGAATTACA
GCAGTTTCAAACTCTACCATGGATAATGCAAACAAACCGAAGCTACATGCCAA
TGATAGGTGCAAAGAATATTGGCAAAAGGTGCTTTACCTTGAGCCATTATTTGTG

20 SEQ ID NO: 455

dependent calcium channel alpha-1E-1 subunit mRNA, complete cds. 001308080.1

385

CTGTCCGGATCAGAGCCATAAGTGTGGAGGTGAAGTGGACCGTCATGTCCTCAG
CTACTGGCATGTTTCATCAGGACCAACCTCTTATATGCCACTTTGGAGGGACATCT
CTTGCCGAGGCCTAGCGGAGGTGACATGAGAGTCAGCATTTCATACATCTCAGTG
TAATGGATGCGGCCACATGCTGCTCGGTCAATTCTGCCCAGACGCGGACAACT
5 CGTCCAAGTGGTGAGGCCCCAGGATGGAGGAGTCCCGAGTCAGGTAACAAGT
TGTCCATGATGACGGCCACAAACAGGTTGAGCATCAAGAAGGAGCAGAAGAAG
ATGAAGGAGACAAAGTACACGTAGGCCAGATCGGTGCCGCAGCGTTTATTCTCG
TTCTGCCCTGATGGTGCAGGTGGTGTGAGGCTCACAGCCCTTCTCCCCAAGGCATG
ACAGCATAATCTCCTGCCAGGCCTCACCTGTGGCACTCCTGAAGAGTAGCATTAG
10 GGACCCAAAGAACTCCGGAAGTTGTTGTGCCGTTGATGTGACTCTCCTCGTCT
AATTTTATGTTTCCAAATACCTGCATCCCAATGATGGCATAAATGAAGAAAAGCA
TGGCAATTAAGAGGCAGACATAAGGGAGGGCCTTAAAGGACTGCACAAAGGTCC
ACAGCAAAATGCGTATGGTATAGCCCTGACGCAGGAGCTTTATGAGGCGGGCAG
CTCGGAAGAGCTTCAGAAAGCTCATATTGAAGCCACTGGTGTTCACCAGCTTGCT
15 GTCTGTCAGGATAATTTCTGTGATACTGCCAATCACGGTGATGAAGTCAAAGATA
TTCCAGGTGTCTCGGAAATAGTTCAAAAAGCCAAAAGCGATGACCTTCAGGACA
CATTCAGGGAAAACACCATGGTGAAGGCGATATTCAGGTAATTCAGGGCCAGC
TCATAGGTACAGGGAGCAGAATAATACTTCATCATCAGCACAACAGTATTCAAG
GCGATCATGGCCATAATGGTGTACTCAAAGGACGGAGACACCACAAAGTGCCAC
20 ACGCGGTACTGGAAGGTGTGTCTGTTCTGCGGCATGTAGCGGGTGAGAGGTTTGG
CGCTGATGGCGAAGTCGATGCACGCCCTCTCATTCTTCTCCAGGCTGCACTCCTC
CATCATCTTATCCCTTGCTCCTGGAAGGTGATGATGATGAGAGCCACAAAGATA
TTGACAAAGAAGAAGGGGAAGACCAACAAGTAGACTACATAAAAGATAGACAT
CTCCATGCGGTTGCTGCGGCTTGGGCTCGGTCTTCTCTGTTCACATCTACAGAGT
25 GCTGCAGAACTTGAGGCCATCCTTCCCCTGTGGAGACGGTGAAGAGGGTCAGCA
GGGCCCAGATAATGTTGTCGTAGTGAATTCATGGCGCTTCCATTCCCGGCCCTT
CACCTCCATCTTGTCTTCTCGTGATCTACATAGTTGCCTATGCACTCCTTCTCTGT
GTCCTTGGAAGTGTCCGTGCAATAAAAGAACTTCCCTTGAAGAGCTGAACTGCG
ATGACAGCAAAGATGAACATGAAGAGCTTGTACACAATGAGTATGTTGAAGACA
30 TTCTTCAAGGAGGTCACTACGCAGTCGAAGACGGCCTTGAGCTTGGGCAAGCGCT
TGATGGTTTTTCACTGGCCTTAGAACTCGGAGCACCCGCAGAGACTTGATGGTCTT
GATGTCCCGTCTTTGTTGGTTCCCAAAGCGTTCGCCAGAGCAAAGGCCACCAAT
GCGCCAAAGACCACCACAAAGTCCAGGATGTTCCACAAGTCTCGGAAGTAGGAC
CCATCCTGCAGGATCAAGCCTTGGTCTATCATCTTTATAACCATCTCAAAGGTGA
35 ACACGCCCCGTGAACACATAGTCAAAATACCTCAGGACTTTGTTGCGCTCCGAGTT
GGTCAGGACGGGGTCTCTGCCGCCAGGGCGATGCTGCTGGCTGCAATCACCAG
GAGGATGCACATCTCAAAGTAGCGCAGGTTACAGATGTAGTGGCAGGCCCTCCG
GATCGGGTTGGTGGTGTGAAGATGAACATTGAGCTGTGGGGCACCATGGCTTTG
CCTGTCTCACGCTTNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNACCTCCTCATCC
40 TCTCTGATCTCTGCCTCCTTCAAGGGACTGGCTTCCCCATCCGTCTTGTGCTAAT
GTGCACCACGGTTGAGTCCACCAAGGGGTCCACGTCGGGGATGGCGACGGTGAC
GCTGGTGCTCTCGGTGGTGGCCTTGTCCGTGTTGGCCGTGATGCAGGAGAGGTCA
GGCTCGCTCTGGCTGATGACCCGGCCCATGTCTAGCTGCACATTCCCCAGCAGGG
CCTGCTCACTGCTGCCTTCTGGCTCCTGCTCCGTGAGCACCACGTGCTTCCCCACT
45 TCCAGCTCAGGATGGGGCAGGACTAGGGGGGTGTCAGCCTCATCAAGGCCTCCT
GCCAGCCCGGAGCCTCTGGACACCATCAGACTGTTGGTCTCCTTAAATCCTGGG
CTCTCTCTTCTTGGATCGTTGGCTCCTTGGCACCATGGTTGCCCTGAGCTCATGG
TCCTTCTCCCCTTCACTGGGCATGGCTTCATCCAGACTGCGTTCTGGCTGGCAGA
CCTGCTCCGGGAGGCTGAAGAGGACTCCTTGCTTCTGTCTGACGCGGCGATGC

CGGCTGCGCCGTTGGCTCTGCCTGTGCCTGGCCCGGTCCTCAAAGGTCACCACAG
CCTCTCCTCCCCCTGCCTCCTGCTGAGTCGGGTACAGTTTCCATGACAGGGCCTG
GCCAGCCATGGTGGCTCCCGCTGGCCAGGGACAAAGGGGTCTCTGGTTGTCCA
GGGCACTGGATCGGTCCCCTCCATCCCCCTTGAGGGACCCCCACGGCTGATGCG
5 CTCCTCCTCGAACTTCTCCAGGGGCCAGGCCAGGGCCAGGCCCTCAATGGCCCTG
GGTCGCCGATAAAGGCTGGGGTGGGCATTGAGCGGGTTGAGGGAGCTGAGCGGG
TTGAGGGGGTTGAGCGGGTTCATGGTCGGCGCCTCCTCTCTGTTGAGGGCCTCCT
GGCTGGACATCTGCATGTGCTTCCTCAGCTGGCTGGTACGCTGCTCCACACGGA
CATGTGGTGCCGGCGCCTCCGCTCCCTCAGGTGGCTGCTGCGTGGCTCCACATC
10 GACATGTGGTGTCTTCTCCTTCTGTCTCTTTGATCGAAGGCATGTTGGGTGCAGA
CATCGGGCTGACCTCCTTGGCCTTCTGCAGTGCATGTTTCTGGTTGAAGGCCTCTT
CTTCTCCTGTTTCATCCTTGGTCAGTTCCTGGGCGTTGGCGAGATTATCCACAGCG
ATAGCCAAGAACACATTTCAGTAGCGTGTAGTTGCCAAACAAGGTGAGCACAATG
AAGTAGATGGCAGACCACATGCCTGAGCTGACCCACCCCTGGGAGCGGATCCCA
15 TTGTACATCACCTCATTCCAGTCCTCACCCGTCAGGATCTGGAACACAGTCATGA
TGGCTGCAGGGAAGGTATCAAAATTTGCCGAAGGAGTCCCATCATTAAAGTTAA
ACCTGCCTCCAAATAACTGCATTCCCTAGGAGAGCAAAGACAACGATGAAGAGGA
AGAGGAGGAAAAGCAAACCTGATGATAGACTTCATTGAGCTCATCAAGGAGACCA
CCAAATTCGCTAGGGAAGCCCAATACTTGGTTATTTTAAATATTCTTAGAAGCCG
20 GAGGGCTCGCAAGACACTGATTCCAAAAGACGTACCAGGTCTGAAGATTGCCCA
GACCACTTCAAAGATACTGCCCACTGTGACCCCAAAATCAAAGCAGTTGAATGA
AGAGTGAAAATAAAGGCGAGGCCCCATGCCATACATCTTCAGGGACATCTCCAA
AGAGGAGAGTCCCAGAAACAGAAATTTCTGCATAGTAGAGGAGGTGGGTGAGCG
ACTGGGGCTGGTTGTGATGGACAATGGCCACACAGGCAGTGTGAGTGCCACAA
25 GGCTCAGCACAATCCAGTAAACACCTGGGATTTAACCATGTGGCGAATGGAGA
TGCGCAGAAGCCTTTCTTGTGCCGGAATAAGAGACCCCGTCTACCTTTGCACT
TTTGATACTGGCTCGGGCCAGAGGTGTGCCACAGAGGAGATATCAACACAGTG
TCATCACTGGAGTCTCGAGTCATGGCCTCTGTCCGGCTCCTCTTGATGGTTGCCCT
TCGAAGCACTTCTAAGGCGGATGTTCCAGCATTTTTATTTTCTTCAGCGAGCATG
30 ACTTCCTCTGCTTTGTCTATCCAGGCACGGTAGCCATTCAGCTCACGCTCAATCTG
CTGCTGGCGCCGACGCTTCATGAAAGCCCTTCGGTTCTCCACTCTCTCTCTCTT
TGGCAAATTCGCCGGAAGCACTCCCAGGACTAGGTTGAGAACAAGAAGGATC
CAATGATGATGAGGGGGATGAAGTACAGCCAATTCCAGGTGGCTCCTAAGGCAT
CATTGGTATTGTACAGCACAGTGGTCCACCCTTCCATGGTGATGCACTGGAAGAC
35 AGTCAGCACAGCAAAAAGGATGTTATCAAACCTGGGTGATCCCATCATTGGGGCC
GATCCAGTCCTTGCAATCATAACCAGCTGGGCAGCCCTGCACACCACATGGGTGA
GGGGGGTCAAATCCTTCTAGAATACTGAATTGTTTCATGAAGCACGCTCGATGTA
ACTTGCCACTGTAGAACTCCAAACCAATGATAGCAAACATCAGGATGGCAAAGA
AGAGCAGAAGGCCAATCTGCAGAAGAGGTACCATGGCCTTCATGATGGACTTCA
40 ACACAATCTGCAGGCTAGGTATCCCTGACACGAGCTTCAAAGGCCGACAGGACAC
GCACAGCCCGGAGGGTCTCAGGTCCACGTGAGTATTGAAGTGGGTTCCTGCAGT
GGCCAGGATGCCACTGAGGACCACGATGAAGTCCATGACATTCCAGCCATTGCG
GAGGTAAGAGCCCTTATGGAAGATGAACCCAGGGCCACAATTTTGATCCCAGC
TTCAAAGCAAAAAGATCCCAATGAAATAAGGTTCTGTCTTCTCCAGTCTTCGGGAC
45 ATGGGGGTCTTGTTCATCCTCAGGAAGATGCTGCTCCAGGGCCAGGACGATGCAG
TTGGCAATGATGGTGGCCAGGATCATGTACTCAAATGGCGGCCAATCGATGAGC
TTCTTGGCATATTTCTGACAATGTTATCTTCTCCGAAGATGAACAGGGATCTGTT
GACGGTGAAACAGTTCTGCCGGACGGGAATGGGGTTGTACAAAGCCATAGTCCG
CGCCCTCTGTGCTTTCGTCTGCTTGTAGGCGGCCGCTGCCCCGAGGCCGGCACG

GGGGTTCCTTGCCGGTTCCTGCTCTGGTCCGAGTCTCCATCGCCGGACCCTGGCCT
GGCGACCACCGCCTCCCCGAAGCGAGCCATCCTGAGGTTTAAACAGACAGAAGA
CACACAAAGGTGATCGCGGCCGAACACCCGCACACAGCAACAAGCAGAAAGAC
ACACGGAGACTCAGAGCCGCATCCAGACAAGCACGGGGACCACCGCCTCTGGGG
5 AGCTCCGCGAGCTCTTCGGAGAGGCAGCAGCAGC

SEQ ID NO: 456

>6559 BLOOD 404061.1 U21051 g687793 Human G-protein-coupled receptor (GPR4) gene,
complete cds. 0

10 GCGGAGAGAGGTGCCGCCGCCCGCCCCGTCAGTCGCCGCGCGCAGGCACTGCA
GTCAGCGGTGAACTGACTTCATCCCAATCCCTCAGCCCCACCAGGACCAGTCTG
GAGTCCCTCCCCTGCCCCATTGAAATTTCCCTTCGTCGCCCAAACCTTACCTCTGA
TCTAGACCTTACTCACCTCCTTCCTGTTTCCTAAGACTCCTTCCTGCCGTCCACAG
ACCGAGCCTTTTATCTTTGTCCACCCTGTGCCAGACACCTCCTTTTCCAGAACCTT
15 CTCCTTACTGGTGACCTTACTTATCTCTGTTGCTTTCTGGGGTCTAGGAAATGCC
AGCACTCCCAACCCACATTGCCTGAACCTTCCAACACTCCCTAACTGCGCTGTGTC
CTATCTCAACACTTTCTCATGTATTTCTTGTGCTTCTAGAACATTCCCCCGCCATT
ATTACTTCAATATGGCTACACATACTTCCTAATTGCCCTGCAAACCATCTCCTTCT
CACCATTGCCCAGCGATGCTTTCGTCTCCTCCATAAACACTCCCGGAGACCAATT
20 TTTGTGTCAACCCCATACTCCCTCGTTGACACACTGACTCCATACATAACCTCCTT
GAAAAACCTCTTTATTAATCTCACCATCCTCCAGACTTCCCTCCTGTCTATAATTCC
ATCCCTCCTCCAACTTTTCCCTCTCAAGCTCTGCCCTTCCAGCCCAGCCCAGCCT
ACCCAACTCATCTCTTCCGTGTAGAGCACATCCGAGCATGTTCCCCTGAGCCTCC
AAGGAAGGGGCTGAGGGGGGCCCATGGCTCCCGCTCCCTGTGGCCCCAAGAGCC
25 CCCGTGGGCCAGGGGAAGCGCCCCAGAAGCCGAAGTGCCACCATGGGCAACCA
CACGTGGGAGGGCTGCCACGTGGACTCGCGCGTGGACCACCTCTTCCGCCATCC
CTCTACATCTTTGTCTATCGGCGTGGGGCTGCCACCAACTGCCTGGCTCTGTGGG
CGGCCTACCGCCAGGTGCAACAGCGCAACGAGCTGGGCGTCTACCTGATGAACC
TCAGCATCGCCGACCTGCTGTACATCTGCACGCTGCCGCTGTGGGTGGACTACTT
30 CCTGCACCACGACAACCTGGATCCACGGCCCCGGGTCTGCAAGCTCTTTGGGTTC
ATCTTCTACACCAATATCTACATCAGCATCGCCTTCCTGTGCTGCATCTCGGTGGA
CCGCTACCTGGCTGTGGCCCACCACTCCGCTTCGCCCCGCTGCGCCGCGTCAAG
ACCGCCGTGGCCGTGAGCTCCGTGGTCTGGGCCACGGAGCTGGGGGCCAACTCG
GCGCCCCTGTTCCATGACGAGCTCTTCCGAGACCGCTACAACCAACACCTTCTGCT
35 TTGAGAAGTTCCTCATGGAAGGCTGGGTGGCCTGGATGAACCTCTATCGGGTGT
CGTGGGCTTCCTCTTCCCGTGGGCGCTCATGCTGCTGTCTGCTACCGGGGCATCCTG
CGGGCCGTGCGGGGCAGCGTGTCCACCGAGCGCCAGGAGAAGGCCAAGATCAA
GCGGCTGGCCCTCAGCCTCATCGCCATCGTGCTGGTCTGCTTTGCGCCCTATCAC
GTGCTCTTGCTGTCCCGCAGCGCCATCTACCTGGGCGCCCTGGGACTGCGGCT
40 TCGAGGAGCGCGTCTTTTCTGCATACCACAGCTCACTGGCTTTCACCAGCCTCAA
CTGTGTGGCGGACCCCATCCTCTACTGCCTGGTCAACGAGGGCGCCCGCAGCGAT
GTGGCCAAGGCCCTGCACAACCTGCTCCGCTTTCTGGCCAGCGACAAGCCCCAGG
AGATGGCCAATGCCTCGCTCACCTGGAGACCCCACTCACCTCCAAGAGGAACA
GCACAGCCAAAGCCATGACTGGCAGCTGGGCGGCCACTCCGCCCTCCAGGGGG
45 ACCAGGTGCAGCTGAAGATGCTGCCGCCAGCACAATGAACCCCGAGTGGCACAG
AATCCCCAGTTTTCCCTCTCATCCACAGTCCCTTCTCTCCTGGTCTGGTGTATG
CAAATTGTATGGAAAAAGGGCTGTGTTAATATTCATAAGAATACAAGAAGTCTAG
GAAGAGTGAGGTTGGTGTGTCAGTGGTCAACCTTTGTGCTCCAGATCCCATCAC
AGTTTGGCGATTGTGGAGGGCCTCCTGAAGGAGGAGATGAGTAAANNNNNNNNNN

10

>6649 BLOOD 222735.9 J05036 g181193 Human cathepsin E mRNA, complete cds. 0

30

CTCCTCTCTCCAGCTCCACATGCTGTACCTGGATCATTCTGAAGCAAATTCGGAG
 CATTACATCATTTTGTCCATAAATATTTCTAACATCCTTAAATATACAATCGGAAT
 TCAAGCATCTCCCATTTGTCCACAAATGTTTGGCTGTTTTGTAGTTGGATTGTTT
 GTATTAGGATTCAAGCAAGGCCCATATATTGCATTTATTTGAAATGTCTGTAAGT
 5 CTCTTTCCATCTACAGAGTTTAGCACATTTGAACGTTGCTGGTTGAAATCCCGAG
 GTGTCATTTGACATGGTTCTCTGAACTTATCTTTCCTATAAAATGGTAGTTAGATC
 TGGAGGTCTGATTTTGTGGCAAAAATACTTCCTAGGTGGTGGTGGGTACTTCTTG
 TTGCATCCTGTCAGGAGGCAGATAATGCTGGTGCCTCTCTATTGGTAATGTAAAG
 ACTGCTGGGTGGGTTTGGAGTTCTTGGCTTTAATCATTATTACAAAGTTCAGCAT
 10 TTT

SEQ ID NO: 458

>6653 BLOOD 416874.3 M15476 g340159 Human pro-urokinase mRNA, complete cds. 0

15 GACCGCAGCCCCGGAGCCCCGGCCAGGGTCCACCTGTCCCCGCAGCGCCGGCTC
 GCGCCCTCCTGCCGCAGCCACCGAGCCGCGTCTAGCGCCCCGACCTCGCCACCA
 TGAGAGCCCTGCTGGCGCGCCTGCTTCTCTGCGTCCTGGTTCGTGAGCGACTCCAA
 AGGCAGCAATGAACTTCATCAAGTTCATCGAACTGTGACTGTCTAAATGGAGG
 AACATGTGTGTCCAACAAGTACTTCTCCAACATTCACTGGTGCAACTGCCCAAAG
 AAATTCGGAGGGCAGCACTGTGAAATAGATAAGTCAAAAACCTGCTATGAGGGG
 20 AATGGTCACTTTTACCGAGGAAAGGCCAGCACTGACACCATGGGCCGGCCCTGC
 CTGCCCTGGAACCTCTGCCACTGTCCTTCAGCAAACGTACCATGCCACAGATCTG
 ATGCTCTTCAGCTGGGGCTGGGGAAACATAATTACTGCAGGAACCCAGACAACG
 GGAGGGCGAECCTGGTGGTATGTGGAGGTGGGCCTAAAGCCGCTTGTCCAAGAGT
 GCATGGTGCATGACTGCGGAGATGGAAAAAAGCCCTCCTCTCCTCCAGAAAGAA
 25 TAAAATTTCACTGTGGCCAAAAGACTCTGAGGCCCGCTTTAAGATTATTGGGGG
 AGAATTCACCACCATCGAGAACCAGCCCTGGTTTGCGGCCATCTACAGGAGGCA
 CCGGGGGGGCTCTGTACCTACGTGTGTGGAGGCAGCCTCATCAGCCCTTGCTGG
 GTGATCAGCGCCACACACTGCTTCATTGATTACCCAAAGAAGGAGGACTACATC
 GTCTACCTGGGTGCTCAAGGCTTAACCTCCAACACGCAAGGGGAGATGAAGTTT
 30 GAGGTGGAAAACCTCATCCTACACAAGGACTACAGCGCTGACACGCTTGCTCAC
 CACAATGACATTGCCTTGCTGAAGATCCGTTCCAAGGAGGGCAGGTGTGCGCAG
 CCATCCCGGACTATACAGACCATCTGCCTGCCCTCGATGTATAACGATCCCCAGT
 TTGGCACAAGCTGTGAGATCACTGGCTTTGGAAAAGAGAATTCTACCGACTATCT
 CTATCCGGAGCAGCTGAAAATGACTGTTGTGAAGCTGATTTCCACCGGGAGTGT
 35 CAGCAGCCCCACTACTACGGCTCTGAAGTCACCACCAAATGCTGTGTGCTGCTG
 ACCCACAGTGGAACAGATTCTGCCAGGGAGACTCAGGGGGACCCCTCGTCT
 GTTCCCTCCAAGGCCGCATGACTTTGACTGGAATTGTGAGCTGGGGCCGTGGATG
 TGCCCTGAAGGACAAGCCAGGCGTCTACACGAGAGTCTCACACTTCTTACCCTGG
 ATCCGCAGTCACACCAAGGAAGAGAATGGCCTGGCCCTCTGAGGGTCCCCAGGG
 40 AGGAAACGGGCACCAACCCGCTTTCTTGCTGGTTGTCATTTTTGCAGTAGAGTCAT
 CTCCATCAGCTGTAAGAAGAGACTGGGAAGATAGGCTCTGCACAGATGGATTTG
 CCTGTGCCACCCACCAGGGCGAACGACAATAGCTTTACCCTCAGGCATAGGCCTG
 GGTGCTGGCTGCCCAGACCCCTCTGGCCAGGATGGAGGGGTGGTCCTGACTCAA
 CATGTTACTGACCAGCAACTTGTCTTTTTCTGGACTGAAGCCTGCAGGAGTTAAA
 45 AAGGGCAGGGCATCTCCTGTGCATGGGTGAAGGGAGAGCCAGCTCCCCCGACGG
 TGGGCATTTGTGAGGCCCATGGTTGAGAAATGAATAATTCCCAATTAGGAAGTG
 TAACAGCTGAGGTCTCTTGAGGGAGCTTAGCCAATGTGGGAGCAGCGTTTGGG
 GAGCAGAGACACTAACGACTTCAGGGCAGGGCTCTGATATCCATGAATGTATC
 AGGAAATATATATGTGTGTATGTTTGCACACTTGTGTGTGGGCTGTGAGTGTA

AGTGTGAGTAAGAGCTGGTGTCTGATTGTTAAGTCTAAATATTTTCCTTAAACTGT
 GTGGACTGTGATGCCACACAGAGTGGTCTTTCTGGAGAGGTTATAGGTCACCTCCT
 GGGGCCTCTTGGGTCCCCACGTGACAGTGCCTGGGAATGTATTATTCTGCAGCA
 TGACCTGTGACCAGCACTGTCTCAGTTTCACTTTCACATAGATGTCCCTTTCTTGG
 5 CCAGTTATCCCTTCCTTTTAGCCTAGTTCATCCAATCCTCACTGGGTGGGGTGAGG
 ACCACTCCTTACACTGAATATTTATATTTCACTATTTTTATTTATATTTTTGTAAAT
 TTAAATAAAAGTGATCAATAAAATGTGATTTTTCTGATGAC

SEQ ID NO: 459

10 >6657 BLOOD 284616.2 D10924 g219868 Human mRNA for HM89. 0
 TGTTTTTATAAAAGTCCGGCCGCGGCAGAACTTCAGTTGTTGGCTGCGGCAGCA
 GGTAGCAAAGTGACGCCGAGGGCCTGAGTGCTCCAGTAGCCACCGCATCTGGAG
 AACCAGCGGTTACCATGGAGGGGATCAGTATATACACTTCAGATAACTACACCG
 AGGAAATGGGCTCAGGGGACTATGACTCCATGAAGGAACCCTGTTTCCGTGAAG
 15 AAAATGCTAATTTCAATAAAATCTTCCTGCCACCACCTACTCCATCATCTTCTTA
 ACTGGCATTGTGGGCAATGGATTGGTCATCCTGGTCATGGGTTACCAGAAGAAAC
 TGAGAAGCATGACGGACAAGTACAGGCTGCACCTGTCAGTGGCCGACCTCCTCTT
 TGTCATCACGCTTCCCTTCTGGGCAGTTGATGCCGTGGCAAACCTGGTACTTTGGG
 AACTTCCTATGCAAGGCAGTCCATGTCATCTACACAGTCAACCTCTACAGCAGTG
 20 TCCTCATCCTGGCCTTCATCAGTCTGGACCGCTACCTGGCCATCGTCCACGCCACC
 AACAGTCAGAGGCCAAGGAAGCTGTTGGCTGAAAAGGTGGTCTATGTTGGCGTC
 TGGATCCCTGCCCTCCTGCTGACTATTCCCGACTTCATCTTTGCCAACGTCAGTGA
 GGCAGATGACAGATATATCTGTGACCGCTTCTACCCCAATGACTTGTGGGTGGTT
 TGGTTCAGTTTCAGCACATCATGGTTGGCCTTATCCTGCCTGGTATTGTCACTCT
 25 GTCCTGCTATTGCATTATCATCTCCAAGCTGTCACACTCCAAGGGCCACCAGAAG
 CGCAAGGCCCTCAAGACCACAGTCATCCTCATCCTGGCTTTCTTCGCCTGTTGGCT
 GCCTTACTACATTGGGATCAGCATCGACTCCTTCATCCTCCTGGAAATCATCAAG
 CAAGGGTGTGAGTTTGAGAACACTGTGCACAAGTGGATTTCATCACCGAGGCC
 CTAGCTTTCTTCCACTGTTGTCTGAACCCCATCCTCTATGCTTTCCTTGGAGCCAA
 30 ATTTAAAACCTCTGCCCAGCACGCACTCACCTCTGTGAGCAGAGGGTCCAGCCTC
 AAGATCCTCTCCAAAGGAAAGCGAGGTGGACATTATCTGTTTCCACTGAGTCTG
 AGTCTTCAAGTTTTCACTCCAGCTAACACAGATGTAAAAGACTTTTTTTTATACGA
 TAAATAACTTTTTTTTAAAGTTACACATTTTTCAGATATAAAAGACTGACCAATATT
 GTACAGTTTTTTATTGCTTGTGGATTGTTGTCTTGTGTTTCTTTAGTTTTTGTGAAG
 35 TTAAATTGACTTATTTATATAAATTTTTTTTGTTCATATTGATGTGTGTCTAGGCA
 GGACCTGTGGCCAAGTTCTTAGTTGCTGTATGTCTCGTGGTAGGACTGTAGAAAA
 GGGAACTGAACATTCCAGAGCGTGTAGTGAATCACGTAAAGCTAGAAATGATCC
 CCAGCTGTTTATGCATAGATAATCTCTCCATTCCCGTGGAACGTTTTTCTGTTCT
 TAAGACGTGATTTTGCTGTAGAAGATGGCACTTATAACCAAAGCCCAAAGTGGT
 40 ATAGAAATGCTGGTTTTTCAGTTTTTCAGGAGTGGGTTGATTTTCAGCACCTACAGT
 GTACAGTCTTGTATTAAGTTGTTAATAAAAGTACATGTAAACTTAAANAAAAA

SEQ ID NO: 460

45 >12205 BLOOD gi|2257932|gb|AF004327.1|AF004327 Homo sapiens angiopoietin-2
 mRNA, complete cds
 TGGGTTGGTGTTTATCTCCTCCCAGCCTTGAGGGAGGGAACAACACTGTAGGATC
 TGGGGAGAGAGGAACAAAGGACCGTGAAAGCTGCTCTGTAAAAGCTGACACAG
 CCCTCCCAAGTGAGCAGGACTGTTCTTCCCACTGCAATCTGACAGTTTACTGCAT
 GCCTGGAGAGAACACAGCAGTAAAAACCAGGTTTGCTACTGGAAAAAGAGGAA

AGAGAAGACTTTTCATTGACGGACCCAGCCATGGCAGCGTAGCAGCCCTGCGTTTC
AGACGGCAGCAGCTCGGGACTCTGGACGTGTGTTTGCCCTCAAGTTTGCTAAGCT
GCTGGTTTATTACTGAAGAAAGAATGTGGCAGATTGTTTTCTTACTCTGAGCTGT
GATCTTGTCTTGGCCGCAGCCTATAACAACCTTTCGGAAGAGCATGGACAGCATAG
5 GAAAGAAGCAATATCAGGTCCAGCATGGGTCTGCAGCTACACTTTCCTCCTGCC
AGAGATGGACAACTGCCGCTCTTCCTCCAGCCCCCTACGTGTCCAATGCTGTGCAG
AGGGACGCGCCGCTCGAATACGATGACTCGGTGCAGAGGCTGCAAGTGCTGGAG
AACATCATGGAAAACAACACTCAGTGGCTAATGAAGCTTGAGAATTATATCCAG
GACAACATGAAGAAAGAAATGGTAGAGATACAGCAGAATGCAGTACAGAACCA
10 GACGGCTGTGATGATAGAAATAGGGACAAACCTGTTGAACCAAACAGCTGAGCA
AACGCGGAAGTTAACTGATGTGGAAGCCCAAGTATTAAATCAGACCACGAGACT
TGAACCTTCAGCTCTTGGAACACTCCCTCTCGACAAACAAATTGGAAAAACAGATT
TTGGACCAGACCAGTGAAATAAACAAATTGCAAGATAAGAACAGTTTCCTAGAA
AAGAAGGTGCTAGCTATGGAAGACAAGCACATCATCCAACCTACAGTCAATAAAA
15 GAAGAGAAAGATCAGCTACAGGTGTTAGTATCCAAGCAAAATTCATCATTGAA
GAACTAGAAAAAAAATAGTGACTGCCACGGTGAATAATTCAGTTCTTCAAAAG
CAGCAACATGATCTCATGGAGACAGTTAATAACTTACTGACTATGATGTCCACAT
CAAACCTCAGCTAAGGACCCCACTGTTGCTAAAGAAGAACAATCAGCTTCAGAG
ACTGTGCTGAAGTATTCAAATCAGGACACACCACAAATGGCATCTACACGTTAAC
20 ATTCCCTAATTCTACAGAAGAGATCAAGGCCTACTGTGACATGGAAGCTGGAGG
AGGCGGGTGGACAATTATTCAGCGACGTGAGGATGGCAGCGTTGATTTTCAGAG
GACTTGGAAAGAATATAAAGTGGGATTTGGTAACCTTCAGGAGAATAATGGCTA
GGGAAATGAGTTTGTTCGCAACTGACTAATCAGCAACGCTATGTGCTTAAATAA
CACCTTAAAGACTGGGAAGGGAATGAGGCTTACTCATTGTATGAACATTTCTATC
25 TCTCAAGTGAAGAACTCAATTATAGGATTCACCTTAAAGGACTTACAGGGACAG
CCGGCAAAATAAGCAGCATCAGCCAACCAGGAAATGATTTTAGCACAAAGGATG
GAGACAACGACAAATGTATTTGCAAATGTTACAAATGCTAACAGGAGGCTGGT
GGTTTGATGCATGTGGTCCTTCCAACCTTGAACGGAATGTACTATCCACAGAGGCA
GAACACAAATAAGTTCAACGGCATTAAATGGTACTACTGGAAAGGCTCAGGCTA
30 TTCGCTCAAGGCCACAACCATGATGATCCGACCAGCAGATTTCTAAACATCCCAG
TCCACCTGAGGAACTGTCTCGAACTATTTTCAAAGACTTAAGCCCAGTGCACTGA
AAGTCACGGCTGCGCACTGTGTCCTCTTCCACCACAGAGGGCGTGTGCTCGGTGC
TGACGGGACCCACATGCTCCAGATTAAGAGCCTGTAAACTTTATCACTTAACTTG
CATCACTTAAACGGACCAAAGCAAGACCCTAAACATCCATAATTGTGATTAGACA
35 GAACACCTATGCAAAGATGAACCCGAGGCTGAGAATCAGACTGACAGTTTACAG
ACGCTGCTGTCAACAACCAAGAATGTTATGTGCAAGTTTATCAGTAAATAACTGGA
AAACAGAACACTTATGTTATACAATACAGATCATCTTGGAAGTGCATTCTTCTGA
GCACTGTTTATACACTGTGTAAATACCCATATGTCCT

40 SEQ ID NO: 461
>12266 BLOOD Hs.90786 gnl|UG|Hs#S1368546 Homo sapiens multidrug resistance-
associated protein 3B (MRP3) mRNA, complete cds /cds=(36,1568) /gb=AF085692
/gi=4106443 /ug=Hs.90786 /len=5346
CCGCGCTCGCCTTCCTTGCAGCCGCGCCTCGGCCCATGGACGCCCTGTGCGGTT
45 CCGGGGAGCTCGGCTCCAAGTTCTGGGACTCCAACCTGTCTGTGCACACAGAAA
ACCCGGACCTCACTCCCTGCTTCCAGAACTCCCTGCTGGCCTGGGTGCCCTGCAT
CTACCTGTGGGTGCGCCTGCCCTGCTACTTGCTCTACCTGCGGCACCATTTGTCGTG
GCTACATCATCTCTCCACCTGTCCAAGCTCAAGATGGTCCTGGGTGTCCTGCT
GTGGTGCGTCTCCTGGGCGGACCTTTTTTACTCCTTCCATGGCCTGGTCCATGGCC

GGGCCCCTGCCCTGTTTTCTTTGTACCCCCTTGGTGGTGGGGGTACCATGCTG
CTGGCCACCCTGCTGATACAGTATGAGCGGCTGCAGGGCGTACAGTCTTCGGGG
GTCCTCATTATCTTCTGGTTCCTGTGTGTGGTCTGCGCCATCGTCCCATTCGCTC
CAAGATCCTTTTAGCCAAGGCAGAGGGTGAGATCTCAGACCCCTTCCGCTTCACC
5 ACCTTCTACATCCACTTTGCCCTGGTACTCTCTGCCCTCATCTTGGCCTGCTTCAG
GGAGAAACCTCCATTTTTCTCCGCAAAGAATGTGACCCCTAACCCCTACCCTGAG
ACCAGCGCTGGCTTTCTCTCCCGCCTGTTTTCTGGTGGTTCACAAAGCTGCTAAA
CCCTGACCCTCTGCGGGGCTGCCTGCCGGGCTTCACCTCCCCCAGGATGGCCAT
CTATGGCTACCGGCATCCCCCTGGAGGAGAAGGACCTCTGGTCCCTAAAGGAAGA
10 GGACAGATCCCAGATGGTGGTGCAGCAGCTGCTGGAGGCATGGAGGAAGCAGG
AAAAGCAGACGGCACGACACAAGGCTTCAGCAGCACCTGGGAAAAATGCCTCCG
GCGAGGACGAGGTGCTGCTGGGTGCCCGGCCAGGCCCGGAAGCCCTCCTTCC
TGAAGGCCCTGCTGGCCACCTTCGGCTCCAGCTTCCTCATCAGTGCCTGCTTCAA
GCTTATCCAGGACCTGCTCTCCTTCATCAATCCACAGCTGCTCAGCATCCTGATCA
15 GGTTTATCTCCAACCCCATGGCCCCCTCCTGGTGGGGCTTCCTGGTGGCTGGGCT
GATGTTCTGTGCTCCATGATGCAGTCGCTGATCTTACAACACTATTACCACTAC
ATCTTTGTGACTGGGGTGAAGTTTCGTAAGGATCATGGGTGTCATCTACAGGA
AGGCTCTGGTTATCACCAACTCAGTCAAACGTGCGTCCACTGTGGGGGAAATTGT
CAACCTCATGTGAGTGGATGCCAGCGCTTCATGGACCTTGCCCCCTTCCTCAAT
20 CTGCTGTGGTCAGCACCCCTGCAGATCATCCTGGCGATCTACTTCCTCTGGCAGA
ACCTAGGTCCTCTGTCTGGCTGGAGTCGCTTTCATGGTCTTGCTGATTCCACTC
AAGCGAGCTGTGGCCGTGAAGATGCGCGCCTTCAGGTAAGCAAATGAAATTG
AAGGAETCGCGCATCAAGCTGATGAGTGAGATCCTGGACGGGCATCAAGGTGGTG
AAGCTGTACGCTGGGAGCCAGCTTCCTGAAGCAGGTGGAGGGCATCAGGCAG
25 GGTGAGCCCCAGCTGCTGCGCACGGCGGCTACCTCCACACCACAACCACCTTCA
CCTGGATGTGCAGCCCCCTTCCTGGTGACCCTGATCACCTCTGGGTGTACGTGTA
CGTGGACCCAAACAATGTGCTGGACGCCGAGAAGGCCTTTGTGTCTGTGTCCTTG
TTAATATCTTAAGACTTCCCTCAACATGCTGCCCCAGTTAATCAGCAACCTGA
CTCAGGCCAGTGTGTCTCTGAAACGGATCCAGCAATTCTGAGCCAAGAGGAAC
30 TTGACCCCCAGAGTGTGGAAAGAAAGACCATCTCCCCAGGCTATGCCATCACCAT
ACACAGTGGCACCTTCACCTGGGCCCAGGACCTGCCCCCACTCTGCACAGCCTA
GACATCCAGGTCCCGAAAGGGGCACTGGTGGCCGTGGTGGGGCCTGTGGGCTGT
GGGAAGTCTCTGGTGTCTGCCCTGCTGGGAGAGATGGAGAAGCTAGAAGGC
AAAGTGCACATGAAGGGCTCCGTGGCCTATGTGCCCCAGCAGGCATGGATCCAG
35 AACTGCACTCTTCAGGAAAACGTGCTTTTCGGCAAAGCCCTGAACCCCAAGCGCT
ACCAGCAGACTCTGGAGGCCTGTGCCTTGCTAGCTGACCTGGAGATGCTGCCTGG
TGGGGATCAGACAGAGATTGGAGAGAAGGGCATTAACTGTCTGGGGGCCAGCG
GCAGCGGGTCAGTCTGGCTCGAGCTGTTTACAGTGATGCCGATATTTCTTGCTG
GATGACCCACTGTCCGCGGTGGACTCTCATGTGGCCAAGCACATCTTTGACCACG
40 TCATCGGGCCAGAAGGCGTGCTGGCAGGCAAGACGCGAGTGCTGGTGACGCACG
GCATTAGCTTCCTGCCCCAGACAGACTTCATCATTGTGCTAGCTGATGGACAGGT
GTCTGAGATGGGCCCCGTACCCAGCCCTGCTGCAGCGCAACGGCTCCTTTGCCAAC
TTTCTCTGCAACTATGCCCCGATGAGGACCAAGGGCACCTGGAGGACAGCTGG
ACCGCGTTGGAAGGTGCAGAGGATAAGGAGGCACTGCTGATTGAAGACACACTC
45 AGCAACCACACGGATCTGACAGACAATGATCCAGTCACCTATGTGGTCCAGAAG
CAGTTTATGAGACAGCTGAGTGCCCTGTCTCAGATGGGGAGGGACAGGGTCGG
CCTGTACCCCGGAGGCACCTGGGTCCATCAGAGAAGGTGCAGGTGACAGAGGCG
AAGGCAGATGGGGCACTGACCCAGGAGGAGAAAGCAGCCATTGGCACTGTGGA
GCTCAGTGTGTTCTGGGATTATGCCAAGGCCGTGGGGCTCTGTACCACGCTGGCC

ATCTGTCTCCTGTATGTGGGTCAAAGTGCGGCTGCCATTGGAGCCAATGTGTGGC
TCAGTGCCTGGACAAATGATGCCATGGCAGACAGTAGACAGAACAACACTTCCC
TGAGGCTGGGCGTCTATGCTGCTTTAGGAATTCTGCAAGGGTTCTTGGTGATGCT
GGCAGCCATGGCCATGGCAGCGGGTGGCATCCAGGCTGCCCCGTGTGTTGCACCA
5 GGCCTGCTGCACAACAAGATACGCTCGCCACAGTCCTTCTTTGACACCACACCA
TCAGGCCGCATCCTGAACTGCTTCTCCAAGGACATCTATGTCGTTGATGAGGTTT
TGGCCCCGTGCATCCTCATGCTGCTCAATTCCTTCTTCAACGCCATCTCCACTCTT
GTGGTCATCATGGCCAGCACGCCGCTCTTCACTGTGGTCATCCTGCCCCCTGGCTG
TGCTCTACACCTTAGTGACGCGCTTCTATGCAGCCACATCACGGCAACTGAAGCG
10 GCTGGAATCAGTCAGCCGCTCACCTATCTACTCCCACTTTTCGGAGACAGTGACT
GGTGCCAGTGTGATCCGGGCTACAACCGCAGCCGGGATTTTGAGATCATCAGTG
ATACTAAGGTGGATGCCAACCAGAGAAGCTGCTACCCCTACATCATCTCCAACCG
GTCAGAAGCCGCTCCCTCGCTCCCTGCTCCTCCAGGAATTCCCAGCAGGCTCTC
TGGTGTTGAGGGTCTTGTCCCTCCTTTCCCTAAGCAGAAAAGTGGCCCTGCCCT
15 GCCCCTGCCCCATTTCTCCTCATCTGATCCCCCATAGGTGGCTGAGCATCGGAG
TGGAGTTCGTGGGGAAGTGCCTGGTGGTCTTTGCTGCACTATTTGCCGTCATCGG
GAGGAGCAGCCTGAACCCGGGGCTGGTGGGCCTTTCTGTGTCCTACTCCTTGACG
GTGACATTTGCTCTGAACTGGATGATACGAATGATGTGAGATTGGAATCTAACA
TCGTGGCTGTGGAGAGGGTCAAGGAGTACTCCAAGACAGAGACAGAGGCGCCCT
20 GGGTGGTGGAAAGGCAGCCGCCCTCCCGAAGGTGGCCCCCAGTGGGGAGGTGG
AGTTCCGGAATTATTCTGTGCGCTACCGGCCGGGCTAGACCTGGTGCTGAGAGA
CCTGAGTCTGCATGTGCACGGTGGCGAGAAAGGTGGGGATCGTGGGGCCGCACTGG
GGCTGGCAAGTCTTCCATGACCCCTTGGCTGTTCCGCACTCCTGGAGGCGGCAAG
GGTGAAATCCGCATTGATGGCCTCAATGTGGCAGACATCGCCCTCCATGACCTGC
25 GCTCTCAGCTGACCATCATCCCGCAGGACCCCATCCTGTTCTCGGGGACCCTGCG
CATGAACCTGGACCCCTTCGGCAGCTACTCAGAGGAGGACATTTGGTGGGCTTTG
GAGCTGTCCACCTGCACACGTTTGTGAGCTCCCAGCCGGCAGGCCTGGACTTCC
AGTGCTCAGAGGGCGGGGAGAATCTCAGCGTGGGCCAGAGGCAGCTCGTGTGCC
TGGCCCGAGCCCTGCTCCGCAAGAGCCGCATCCTGGTTTTAGACGAGGCCACAGC
30 TGCCATCGACCTGGAGACTGACAACCTCATCCAGGCTACCATCCGCACCCAGTTT
GATACCTGCACTGTCCTGACCATCGCACACCGGCTTAACACTATCATGGACTACA
CCAGGGTCTTGGTCTGGACAAAGGAGTAGTAGCTGAATTTGATTCTCCAGCCAA
CCTCATTTGCAGCTAGAGGCATCTTCTACGGGATGGCCAGAGATGCTGGACTTGCC
IAAAATATATTCCTGAGATTTCTCCTGGCCTTTCTTGGTTTTTCATCAGGAAGGAA
35 ATGACACCAAATATGTCCGCAGAATGGACTTGATAGCAAACACTGGGGGCACCT
TAAGATTTTGCACCTGTAAAGTGCCTTACAGGGTAACTGTGCTGAATGCTTTAGA
TGAGGAAATGATCCCCAAGTGGTGAATGACACGCCTAAGGTCACAGCTAGTTTG
AGCCAGTTAGACTAGTCCCCCGGTCTCCCGATTCCCAACTGAGTGTTATTTGCAC
ACTGCACTGTTTTCAAATAACGATTTTATGAAATGACCTCTGTCTCCTCCTGATT
40 TTTTCATATTTTCCTAAAGTTTCGTTTCTGTTTTTAATAAAAAGCTTTTTCTCCTG
GAACAGAAGACAGCTGCTGGGTCAGGCCACCCCTAGGAACTCAGTCCTGTACTC
TGGGGTGCTGCCTGAATCCATTAATAAATGGGAGTACTGATGAAATAAAACTACA
TGGTCAACAGTAAAAA

45 SEQ ID NO: 462

>13258 BLOOD 411233.5 D10995 g219678 Human gene for serotonin 1B receptor,
complete cds. 0

GAGCTCCGGCGCGAGGGCGCGGCGCAGCGCTGCTCCTAGACTTCACCCACCCAG
CTCTGGCGGCGCTGCAGCCCCCAAAAGTGCCCCAGCTTGGGGCGAGGGGTGG

GAATGCAAGATCTCGGGACCTCTCGCTGGCCTGCAAGCTTTGGTCTCTACACCTA
GGAAACTCCTGTGGGCAAAGTCTGCAGATCCAAAAGCGTCCAGGTTAGGAGACG
CTCAGCCTCAAGCAACTGGGGTAAGAGATCCCATTGGTCAAAGCCTTCTCCTCA
AGCAGTACTTCACCCTCCTGCACTAGACGCCTCCAGGGAGCTGGAGCGGAGCAG
5 GGCTCGGTGGGCCAGCTCTTAGCAACCCAGGTCTAAGACCCGGTGTGGAGAGGA
ACAACCACAGACGCGGCGGCTTAGCTAGGCGCTCTGGAAGTGCAGGGGAGGCGC
CCGCCTGCCTTGCGTGCCGCACCCATGACCTCTAGTTTCAGCTGTGAACCTGGGC
GGAGGAATAATTGAGGAACTCACGGAATATCAACTGGGGACAAACCTGCGATC
GCCACGGTCCTTCCGCCCTCTCCTTCGTCCGCTCCATGCCCAAGAGCTGCGCTCCG
10 GAGCTGGGGCGAGGAGAGCCATGGAGGAACCGGGTGCTCAGTGCGCTCCACCGC
CGCCCGCGGGCTCCGAGACCTGGGTTCCTCAAGCCAACTTATCCTCTGCTCCCTC
CCAAAAGTGCAGCGCCAAGGACTACATTTACCAGGACTCCATCTCCCTACCCTGG
AAAGTACTGCTGGTTATGCTATTGGCGCTCATCACCTTGGCCACCACGCTCTCCA
ATGCCTTTGTGATTGCCACAGTGTACCGGACCCGGAACCTGCACACCCCGGCTAA
15 CTACCTGATCGCCTCTCTGGCGGTCACCGACCTGCTTGTGTCCATCCTGGTGATGC
CCATCAGCACCATGTACACTGTCACCGGCCGCTGGACACTGGGGCCAGGTGGTCTG
TGACTTCTGGCTGTCGTCGGACATCACTTGTGCACTGCCTCCATCCTGCACCTCT
GTGTCATCGCCCTGGACCGCTACTGGGCCATCACGGACGCCGTGGAGTACTCAGC
TAAAAGGACTCCCAAGAGGGCGGCGGTGATGATCGCGCTGGTGTGGGTCTTCTCC
20 ATCTCTATCTCGCTGCCGCCCTTCTTCTGGCGTCAGGCTAAGGCCGAAGAGGAGG
TGTCGGAATGCGTGGTGAACACCGACCACATCCTCTACACGGTCTACTCCACGGT
GGGTGCTTTCTACTTCCCCACCCTGCTGCTCATGGGCCTCTATGGCCGGATCTACG
TAGAAGCCCGCTCCCGGATTCTGAAACAGACGCCCAACAGGACCCGGCAAGCGCT
TGACCCGAGCCAGCTGATAACCGACTCCCGGGGTCCACGTCTCTCGGTACCTC
25 TATTAAGTCAAGTGCGAGTCTCCGACGTGCCAGCGAATCCGGATCTCCTGTGTATGTG
AACCAAGTCAAAGTGCGAGTCTCCGACGCCCTGCTGGAAAAGAAGAACTCATG
GCCGCTAGGGAGCGCAAAGCCACCAAGACCCTAGGGATCATTTTGGGAGCCTTT
ATTGTGTGTTGGCTACCCTTCTTCATCATCTCCCTAGTGATGCCTATCTGCAAAGA
TGCTGCTGGTTCCACCTAGCCATCTTTGACTTCTTCACATGGCTGGGCTATCTCA
30 ACTCCCTCATCAACCCCATATCTATAACCATGTCCAATGAGGACTTTAAACAAGC
ATTCCATAAACTGATACGTTTTAAGTGCACAAGTTGACTTGCCGTTTGCAGTGGG
GTCGCCTAAGCGACCTTTGGGGACCAAGTTGTGTCTGGTTCCACAGGTAGGTGGA
ATCTTCTTTTCGCGGTTTCTGGGTCCCAGCGAGGCTCTCTCTCCTGGGCAAGGGCA
ATGGATCCTGAGAAGCCAGAATAGTCCTGAGAGAGAGCTCTGAAAGGAGAAGTG
35 TTGAAACTAAATGTAGAGCTTCCCTGCCAGGAGGAGGCTCACTTCTCCCTCA
AGCCCCGGGCTCAGCACTGACCCTGCGGTAGCCAATCCCAAAGGGGGTTGCAAC
TTTTAAAAATTGATAATGGAAGGGAATCCCTGCCCTGCTTTGGTATCGTGGATAA
TGCCCACTAGAAGCAGTGTACTTGAATTGTTGTCTGAAGCCTGTCTGAGACAGA
TCTACATACAGCCTGGCAGTACTTGAAGTACGCTTAATGCCCTGTGTTTTTGG
40 GGGGAGAACTTTGTGTTACAGCTTAATTTAAGAACAGTTACTTTGGCATCATTCA
GTCTTCACTTTTTGTCTATTTAACTTGGTTGGAGAACTTGTGGATTGGTGCTT
CAAACCTATGTGTGGCTTGGATGGCGCAGAGAAACCTTGAAGAGTTAACAGCA
AAATTCTGATGCTGAGATCTCTATTTTTATTATACTTGAAACTATATGGGGGTGG
GTGGGTGGGAATGGGAGATGAGGAGTGTTAACTGAGAATCAACACCTATGATT
45 GTTTGTTTTCTGCAGATTTACAATTTTGTAAATTCCTGTTTAGCGATTGTCAAGCCA
CAACTCTAACAACAAACCATTATGTGTGCTAGTGCCAAAGTCTGCAGACTGCTT
TATTTTTTCTCTTAATTTTATGTACCTGTCACCTTACACATTTAAATCCCCATAAAT
GAAGGGTATGATGGGTGACTCAGCCACACTGCTGCTATATTTCTTACTAATGCA
ATTGGTAAAACCGATTAGTATTGGAAATATACTGTTTCTTAACAAGAAAAGTGTG

TTTATTTCTTATCCAATTTAGTGAGATGTGAAGGAGACTGATGACATGGGGATAG
TTCTTACACAATTGAGGAATGGGGTGGGGGCAATAGGAGGATGTATATTTTGACT
TGTAATAAAATCTTAAAGTGCATGAACTTTTATCTGATAGTCATTTGCACTCTC
CTTCCCATCTGTGATTCCTTGTGTGCTAACATATAAAGAAACCAAGAGAACTATC
5 TTCCTTCTCCAGAAACCTTAAAAATACAGTTAAGGGCCCTAAAAACGATATTGAA
AAGAAAATAAACTTGTCTNNNNNNNNNNNNNNNNNNNNNNNNNTGGGCAG
GAGAAAAGATTGCTAGAAAATGACATATAAGAACTTTAGAAAAGCTT

SEQ ID NO: 463

10 >13306 BLOOD 1096917.19 K01500 g177808 Human alpha-1-antichymotrypsin (AACT)
mRNA, complete cds. 0
GCTAGATGTGGTGGCACACGTCTGTAATACCAGCTGCTGGTATTACAGACGTGTG
CTACATCCAGCTCCCTGAGGACTGAGTGGGCGGAGGCTGAAGAGTTGAGAATGG
AGAGAATGTTACCTCTCCTGGCTCTGGGGCTCTTGGCGGCTGGGTTCTGCCCTGC
15 TGTCCTCTGCCACCCTAACAGCCCACTTGACGAGGAGAATCTGACCCAGGAGAA
CCAAGACCGAGGGACACACGTGGACCTCGGATTAGCCTCCGCCAACGTGGACTT
CGCTTTCAGCCTGTACAAGCAGTTAGTCCTGAAGGCCCTGATAAGAATGTCATC
TTCTCCCCACTGAGCATCTCCACCGCCTTGGCCTTCTGTCTCTGGGGGCCATAA
TACCACCCTGACAGAGATTCTCAAAGGCCTCAAGTTCAACCTCACGGAGACTTCT
20 GAGGCAGAAATTCACCAGAGCTTCCAGCACCTCCTGCGCACCTCAATCAGTCCA
GCGATGAGCTGCAGCTGAGTATGGGAAATGCCATGTTTGTCAAAGAGCAACTCA
GTCTGCTGGACAGGTTACGGAGGATGCCAAGAGGCTGTATGGCTCCGAGGCCT
TTGCCACTGACTTTCAGGACTCAGCTGCAGCTAAGAAGCTCATCAACGACTACGT
GAAGAATGGAAGTGGGGGAAAATCACAGATCTGATCAAGGACCTTGACTCGCA
25 GACAATGATGGTCCTGGTGAATTACATCTTCTTTAAAGCCAAATGGGAGATGCCC
TTTGACCCCCAAGATACTCATCAGTCAAGGTTCTACTTGAGCAAGAAAAAGTGGG
TAATGGTGCCCATGATGAGTTTGCATCACCTGACTATACCTTACTTCCGGGACGA
GGAGCTGTCTGACCGTGGTGGAGCTGAAGTACACAGGCAATGCCAGCGCACT
CTTCATCCTCCCTGATCAAGACAAGATGGAGGAAGTGGAAGCCATGCTGCTCCCA
30 GAGACCCTGAAGCGGTGGAGAGACTCTCTGGAGTTCAGAGAGATAGGTGAGCTC
TACCTGCCAAAGTTTTCCATCTCGAGGGACTATAACCTGAACGACATACTTCTCC
AGCTGGGCATTGAGGAAGCCTTCACCAGCAAGGCTGACCTGTCAGGGATCACAG
GGGCCAGGAACCTAGCAGTCTCCCAGGTGGTCCATAAGGCTGTGCTTGATGTATT
TGAGGAGGGCACAGAAGCATCTGCTGCCACAGCAGTCAAAATCACCCCTCTTCT
35 GCATTAGTGGAGACAAGGACCATTGTGCGTTTCAACAGGCCCTTCTGATGATCA
TTGTCCCTACAGACACCCAGAACATCTTCTTCATGAGCAAAGTCACCAATCCCAA
GCAAGCCTAGAGCTTGCCATCAAGCAGTGGGGCTCTCAGTAAGGAACTTGGAAT
GCAAGCTGGATGCCTGGGTCTCTGGGCACAGCCTGGCCCCCTGTGCACCGAGTGGC
CATGGCATGTGTGGCCCTGTCTGCTTATCCTTGGAAGGTGACAGCGATTCCCTGT
40 GTAGCTCTCACATGCACAGGGGCCCATGGACTCTTCAGTCTGGAGGGTCCTGGGC
CTCCTGACAGCAATAAATAATTCG

SEQ ID NO: 464

45 >13478 BLOOD 233142.9 D79986 g1136389 Human mRNA for KIAA0164 gene, complete
cds. 0
GTGACTCTGCTGACCTTCGGCATGACATTGATCGCCGTAGAAAAGAAAGAAGTA
AAGAACGGGGAGATTCCAAGGGCTCCAGGGAATCCAGTGGATCAAGAAAGCAG
GAAAAAACTCCAAAAGATTACAAGGAATACAAATCTTACAAAGATGACAGTAAA
CATAAAAGAGAGCAAGATCATTCTCGATCTTCATCCTCTTCAGCATCACCTTCTTC

1 TCCCAGTTCTCGAGAAGAAAAGGAGAGTAAGAAGGAAAAGAGAAGAAGAATTTA
AAACTCACCATGAAATGAAAGAATACTCAGGCTTTGCAGGAGTTAGCCGACCAC
5 GAGGAACCTTTCATGACGACAGAGATGATGGTGTGGATTATTGGGCCAAAAGAG
GAAGAGGTCGTGGTACTTTTCAACGTGGCAGAGGGCGCTTTAACTTCAAAAAATC
AGGTAGCAGTCCTAAATGGACTCATGACAAATACCAAGGGGATGGGATTGTTGA
AGATGAAGAAGAGACCATGGAAAATAATGAAGAAAAGAAGGACAGACGCAAGG
AAGAAAAGGAATAATAAATATGAAGTAAGATTACAACAGAGCAGAACTTGCACC
CACCATTTTTTTTACCTGATTTTGGTTTTTCAAATAAGAATGTAAGCATTTTACTTA
AATTTTACTGTTTGCAAGTAGTCTATAGAAATTTGGTTTTAAGTCTTCAAATATCT
10 TGAGAAATAGTAGACTGTATGTTGAAAATTGTACTGAAATAAAGTAGAAAATTG
TTACGTACCATATTTGTAACATCAACTTTTAAAACCTTTTAACGTTTTTGTTACAT
GCATTGTAATTCTGCTTTGTCTATAAGATATGGTCAAGTACAGCTCTGTGAAAGT
TCTGATTCTCTTCCCTGTTTGTCAATGTTTTATTCTGAAGTAAACGTTAGCTC
TACATATAAATCCTGGAACAGAAATTGTTTATAGAGACTACACTAATTATTTTAA
15 CTGTATACATCTGTTTAATTTGAACACACTACATCGTAGGGTGACTGATTTTTGAA
GTATACCACAGACAAAAAGTTGTTACTATGGTAAACTAAGCTAGTTTAACTTG
AGCAAATGCTTAAGAAGGAATTAAAAAAAAAAAGCTTTGCCAATAGCTAAAAAG
TACAAGCTATTA AAAATCAGATTGAAAAGTTTTGAGAAAATGTTATTTTTACTGA
AAGCAAGCAGTGGCCTATAAAGAACATTCTTAGGAGCCTTTTCTATTTGCGTTCA
20 AAACGTGTGTCTCTTTCTATTCTATTGATAGTTGAGTCATGGTCTTAGATA
TTAGCTATTTGTGAGAGGAACTGGTTTGTAAACAATACTGCAAAATAGAAACCCCA
TTTCTACTGAACATCCTAGTTTTTAAACAGAAGAAAACTGTAATCCTGGGGTTGG
TATGTAGGAGGTCTATCCTGCAGAAATAAGTTGATACATTAGTACCTGATTTCATA
TCTTACATATTTATTTGAGCTGAACATTAGTTTGAGTGTAACATTAGTAAAAAT
25 AGAGAAACACAGCATACTGTTCAATTAATAGTATTTTAAAAAAATTGTTTTTCAA
TGTCACCAATAAAAAGTTTTGGCAGGAAGCTTGTTGCGGCATTGATCTAACCTTTT
TCCCCCCCATTTCAGTTGCAGTTTTTTGTAGAATGGCTTTTTCTTTTCCTCTTAAGA
GTTCTATTCTTCAGGTAGATAATTTTTCAAATGTGAATTATCTTTTGTGTCTATATT
GATAGCTCTTAAAGGAGTGAAAATCTAAAATAGTAAATTTCAATGTAAAGTGTCT
30 GCTTTATGGGCATATATAAAAGTAGACACATTTCAATTTGTTAATTTAGTTGTGTGT
GTGTGTTAAAGGAGCTAATGCTTATTCTGTTAATGTAAACTTTTGAAGATCTTA
AGTGTATTGCTCTTTCATCTTAAACACTTTTCGAGGATTTGCAGTGCGTCTAGCACC
TAGATTACAGCCAGGAACATTGGTTAAGAACTGTTGGAAACAAAACCTAAAAGCA
AACTCAACATATGTGATGTTTATGGCCCTCAGATCCCTAGTATGTGTGATTTTCC
35 CCCGTTAACATGTCTTTCTAAAATTGTCTATTAAAGCAGAGGAAATACCTGCCAA
AGGAAGTATGTATTGCATTAATCAGGGCATAACTAATATTCTCCTGTTCAGAATA
ATACTTATTTACGTGTGAAAGCAACATGGATGTGATTCCCAACACAGAAATTTTCA
TGACCCTTTTATTGTATACAAATAAATACCATAACAGTTACTTGGTTAGACATCA
AATCTGTGTGCATGACTATGTGCTTATCCACTTAAGACAATAGGTAAAAGGGGAT
40 CTGAGAAATTATGTAATAGGGAGTGGGAATAAACTACTTAATTCCTGTGGGCA
GGTTATATTTTAAAGTTCAAATGCATTGCTTTAACCTTTGGTTACTTTTATTCTGTTA
AACAGAATTGAAGAAAGAGTATTATACCAGAGTGTAGTAGGCTAGGGTGATTGT
AAGAACTCTGTAATAGAATGTCATTGTGGATGTTACCTTTTTCAGATCCAAGCAT
ATAAAAAGCCTGTATATTTTTTAAAAACACATCTTAACTCCACGCTTTACGATATT
45 ATAAAAGTTGAATGGTTCCTCTTGTTAAGGATATTTGCTTACAAGTGCTAGGAAA
TAACTCACTGATACCTGCGTTAACATACTTTGTTTTGCCTAGAGAGGGGCAATAA
AAATGAACCAAAGGATATTTCCAGAAAGGATTAAGAAAGCTGTTTAAAGAGGCC
ATGACTCTTTAGGTGTGTATGTGTACCTTTTCAGCATCCTAGGAATTTTTATACTAA
AAGCAAAATGTTTTTTCCAGTTAGTCTTCTTCAAGGAATTACTATTGTTCCTTTTG

TCACAGGTA AAAATCAGTGT TGGGAATTATAATTTGAGAAAAATATTACCCAGTAA
CATTGAATGTAGATGGCTAAACGATTCTTACTCAGTGTGATGTATAATGATGCAA
CAGGGACCCTTGTA AATTGTCATACGCCAATAAAAATGTCACAAGTAATAACTGCT
GTTGTTTGT TTTACCTGTGTCTATTTTACACATCTTATTTCTGTGGCCTATTTTAGAA
5 TATCAGCGCATCTGTTAGGAAGATTACTGGTGTGGTAAGGCTTGATAAATGCTTT
ATAAACTCCCTCAAACCTTTCTTTACTGTTTTTTTTGT TTTTGTCTTGT TTTTGT TTTT
TTTTTGT TTTTGT TTTTGT TTTTCCCTTGTCTCCCCTGGGAAAATGGGAAATTTTAC
AGTTGGTA AATCTAAGCCAAAATTATTTTGAAATAAAGGAATTCTGGATGTCCAG
TTTAGTCCTCGTTTTCTTACGTTAATCTGGGACCTTATCACCCATAATATGGTGAT
10 TACTTCTCTTTCTAAAAACATAGTAGCTAGTAAATAAGTAAAAAGAATTGTCTTT
TCATTCAC TTTAAGTAAGATGTGGTATAATTCTTACCATGTGCCATCCTGTCAGTT
TTAACAAAGCATTTTTCACAGAAATTTGTGTACTAAGACAAACTGACACATTTTGA
CTCATACAAATGGCAAATTAGTCCTTAAAAATTCTGTGAGAGAAATAACTCTGTG
TGTACATACATATGCATGTAAAGTGTTGTGTAAAGATCATTGGTAGCTTAATTATA
15 CTGGATAATTGTAATGTTATATACAAATTTCTTATATAAAAGTATGCTGCATT

SEQ ID NO: 465

>13519 BLOOD gi|894352|gb|H25229.1|H25229 y145d06.s1 Soares breast 3NbHBst Homo sapiens cDNA clone IMAGE:161195 3' similar to contains LTR3 repetitive element ;, mRNA sequence

20 ATTCTTTAAAAAATTAGTTGCTTTTTATACAGCTATACAAAGTTCTTAATGTTTCT
TTGGCAATGGAATATAATGGAATTTTACAACCTATATAAAAAAGTTACCTTTGCCT
AAGAAACAGTATTTACTGTGTGTACATAGTTGACTGACAAAATTCTCTACCATCC
AGCACCTTAATTAATTGACGAAATAAGCTACCTCATATTACAGGATTCCCCAAAA
25 GAAAGGNGGAAAAAGNACACACATACACACACACACACACACACACACACACAC
ACACACACACACACACACAACCTTCTGNGGGCTCAAAACACAGTNTCACGGG
CCCTTTCTGCAGGGCAACTTGGAATTGCCAAATACAATTTAGNGGAT

SEQ ID NO: 466

30 >13524 BLOOD Hs.229619 gnl|UG|Hs#S219269 y149d08.s1 Homo sapiens cDNA, 3' end
/clone=IMAGE:161583 /clone_end=3' /gb=H25761 /gi=894884 /ug=Hs.229619 /len=495
CCTCATGANCNGNNTTTAATGTNCCANAAAAACACTNAAAGATATTCNTGTAA
ATACANATAAGCTNTGTGTCAACATTCAGTACTANGCAAATCATTTTGTACTANG
ACAAAATGACCAACTTACACACTTCNNGGTAGCGCTTAATACITATCTTTGAACT
35 CTATTGCTGATGCTAGGCCCTAAAGAGCAATGACTCAACCAGAAAAAATAGTAA
AGGCTGCCTCTTTCTTTTAAAGCGCTTATTAGCTTTANATCCACAAACAATGGG
TTTTTACANCTACATACTACTGAAAGGGTGCTCAAANCGTCACCNCTTACAGGCC
TTCGAACATGTCAATTTTCTAACCCTGGCACATGTAAACTTGT TTTTATCCGGCATTC
AATGGAGGTCCGCTTNCAATGGGCTCCCAATCATCNGGTTTCAAATCAGGNCA
40 GGGGCCAAGGGTCCCCGCCCGGATTAAACNGGCGGCAGGNGGGGCCAAACCCCC
GG

SEQ ID NO: 467

45 >13526 BLOOD Hs.260516 gnl|UG|Hs#S219414 y155d09.s1 Homo sapiens cDNA, 3' end
/clone=IMAGE:162161 /clone_end=3' /gb=H25907 /gi=895030 /ug=Hs.260516 /len=352
GGTGAACCAGNNTNTTTATCAGTTTATTAATCTATTTTAAATATATAGACTTTTCA
GTAGACAACAGCATAAAAACATATTCTTTTCAAGTTCAAATTGAACTTTACCAAC
ATAGACCATATTCTGGGCCATAAAATAAACATTGGCAAATTTAAATAATTGAA
ATCATATTAAAGTTTGTCTCTGACCCTGATAGAGGTAAGCCAGAAATCAAGANCA

GAAAGATATCTAGAAAAATCCCAAATAATTTGGAAGTAAAAGANCACAATTTTA
AATAAACCATGGGGCCAAAGGNAAAGGTACAGGGGGAANCTCTTAGGNACTG
GANCTAAAATAGGGGGGNATTTTAC

5 SEQ ID NO: 468

>13580 BLOOD 978116.6 Incyte Unique

GGCATGCAGTTTTTGTCTAGGCTGCACAGAAAAGCCAGTCATTGAGCTCTGGAAG
AAGCACACGCTAGCCCGAGAGGATGTCTTCCGGCCAATGCCCTCCTGGAATCC
GGCCATTCCAAGTTTGGCTCCATCACCTCGACCACAACGTGAGCCCCAACATCTT
10 CGCCTGGGTCTACAGGGAGATCAATGATGACCTGTCTTACCAGATGGACTGCCAC
GCCGTGGAGTGCAGAGCAAGCTCGAGGCCAAGAACTGGCCACGCCATGATG
GAGGCCTTCAGGAAGACTTTCCACAGTATGAAGAGCGACGGGCGGATCCACAGC
AACAGCTCCTCCGAAGAGGTTTCCAGGAATTGGAATCCGATGATGGCTGAATG
AACTTGAGACGCTTCAGCAAAGGCAGCATTGGTACGGAGTTCAAGGGAATAGA
15 TGAGTAAGCAACGTTTCAAATTTGGGATGAAAAGACTGCCAACTATTGGCTGA
CCAAGGTTTTTAAATTCAGAAGAGCAATTCTAAATCTAAAGAAATGTATCATTA
AGTAATTACGTTACATTGAAACCTGCTGCTGCTGTGACTGTGAGGAGGGTGGGAG
TGTTGATGGGGAGGAAGGTTCTAGGCTCTCTTCTTATTTTCTCATTTCCCAATGC
CTCTCTGTGGGAGAGCTCCATGCCAGTTTTACACGCTCAGGCAAATACTCTGC
20 AGCTGTTATTGGATGGGCCATTCCGATCTGCCTTATGAAATTCCACAAGAATGTT
AGGGGCACCTATGGGATCTCTAGTGGGGTGGGCAGGGTGCTGATGGGGACGCTG
GCGCGAGGGAGGAAGGAACATCTCGGGAGGGGCTCTGTTCCTCTCCACGGCA
GATGCCCTCCTCTGTATGCAAATCAGCAGAGCCTTTATTGAGCTTTACAATAAC
AAGCTGATAGTTGGCAGTTAATTCAAGATTACAGATAATGCTTTTATTACATAA
25 ATATACCAAGTAGTACCCTCTTATTGTATTCATCTCATCTATTTTCTTAGAATACT
TGCAATTACTAATGACCCCTTCCCTTTCCCTCCTGCTGCCCTGTCCACCCTCTTTCC
CCTTCTAACATCCTTAGAGGGATGAAATCTCAGCATATGTTGCAGGACACCAAAA
GGAAGAAAACAATCAAGCAAATAAAATAAACAGTCAAACAAACCAGGAGTTTA
AAACAACAACCCCAACAACAGAAGCCTTGGCAAAGAGGAATGAGTGATCAGCA
30 AGTGAACACACTCTATGTCAACTCTCCTTTTATCCAGCTGAGATTTATGGTAACTT
ATTTAATTAATGGTCCTGTCTGATGCATCCTTGATGGCAAGCTTCAAATCTGATTT
GGTGTACCGAGGAAACCTTGCCCCATCACTCAGCATTGCACTTAGATACAGAA
TGAGTTAGATAAACTTGGCTTGTCTAGAGACCCATGTCATCTTAACTAAAGGGA
AATCTTATTGCGTTATCATAAAATTGATGATATCTTAGGGTCAGAAATGCCCTTTT
35 TTTTATTTTGAATGGGAAGTTCTCACTAAAACAATCCTGAGATTTCTTAATTTCA
TGGTTCTTTAAATATTATAAACACAGAGTCAACATAGAATGAAATTGTATTTGTT
AAAATACACACATTGGAGGACAAGAGCAGATGACTACTTTTCGAAGTAATGCTG
CTCCTTCCT

40 SEQ ID NO: 469

>13715 BLOOD 021290.12 L08488 g186425 Human inositol polyphosphate 1-phosphatase mRNA, complete cds. 0

GGCTCGGGCAAGCGTGGGGGGCCCGCGCGTCCCGGGAGCCCCGAGGCGGCAGCG
CGCGTTTCCACGCCGCGGTCCCGCGGGAAAGCCGGGGGCGGCGGCCTGGCTGAG
45 GCCAAGCTCGGATCCGGTGCCGAGCCAAGCGGGGCGGTGCGTCGCCGGGGCTTC
GCCTTCGCTCGCGTGACCTCCGCCGTCTCCCCAACCTCGTCCTCTGGCCGCGCC
TGCGGCCGCACGCCAGCGCCCTCGCCTAACCTCGCGCCCGGGCGCGCCTCCT
CCTCCTCCTGCTCCCCGCGCTTCCGTTTCTCGAGGGAAAGGCTGCTGCCTCCTGC
TCTGTCTCATCCCCGGCTTAGCTGACGGCCAGAGGGTGGGTGCCAATTCCACC

AGCAGCTGCAACTGAAAAGCAAGGTTTCAGAAATGTCAGATATCCTCCGGGAGCT
GCTCTGTGTCTCTGAGAAGGCTGCTAACATTGCCCGGGCGTGACAGACAGCAGGA
AGCCCTCTTCCAGCTGCTGATCGAAGAAAAGAAAGAGGGAGAAAAGAACAAGA
AGTTTGCAGTTGACTTCAAGACTCTGGCTGATGTACTGGTACAGGAAGTTATAAA
5 ACAGAATATGGAGAACAAGTTTCCAGGCTTGGAATAATATTTTGGAGAAGA
ATCCAATGAGTTTACTAATGACTGGGGGGAAAAGATTACCTTGAGGTTGTGTTCA
ACAGAGGAAGAAACAGCAGAGCTTCTTAGCAAAGTCCTCAATGGTAACAAGGTA
GCATCTGAAGCATTAGCCAGGGTTGTTTCATCAGGATGTTGCCTTTACTGACCCAA
CTCTGGATTCCACAGAGATCAATGTTCCACAGGACATTTTGGGAATTTGGGTGGA
10 CCCCATAGATTCAACTTATCAGTATATAAAAGGTTCTGCTGACATTAAATCCAAC
CAGGGAATCTTCCCCTGTGGACTTCAGTGTGTCACCATTTTAATTGGTGTCTATGA
CATACAGACAGGGGTTCCCCTGATGGGAGTCATCAATCAACCTTTTGTGTCACGA
GATCCAAACACCCTCAGGTGGAAAGGACAGTGCTATTGGGGCCTTTCTTACATGG
GGACCAACATGCATTCACTACAGCTCACCATCTCTAGAAGAAACGGCAGTGAAA
15 CACACACTGGAAACACCGGCTCTGAGGCAGCATTCTCCCCAGTTTTTCAGCCGT
AATTAGTACAAGTGAAAAGGAGACTATCAAAGCTGCATTGTCACGTGTGTGTGG
AGATCGCATATTTGGGGCAGCTGGGGCTGGTTATAAGAGCCTATGTGTTGTCCAA
GGCCTCGTTGACATTTACATCTTTTCAGAAAGATACCACATTCAAATGGGACTCTT
GTGCTGCTCATGCCATACTGCGGGCCATGGGTGGGGGAATAGTAGACTTGAAAG
20 AATGCTTAGAAAGAAATCCAGAAACAGGGCTTGATTTGCCACAGTTGGTGTACC
ACGTGGAAAATGAGGGTGCTGCTGGGGTGGATCGGTGGGCCAACAAGGGAGGA
CTCATTCGCATACAGATCCAGGAAGCGGCTGGAGACATTCTTGAGCCTCTTGCTCC
AAAACCTGGCAGCTGCAGAGACGCATACCTAGAGGAACTCTAACCCCGGTGTAC
CTGTATAAACTGAACTGTGAACTGTTTCGGTTATCTCTGTCTTTTGAGGATGGCT
25 TTGTCCTGTTGCTGGTTAACATTCACCTTCCTCTTTTGAGGAGTATTTTCCATTAT
GTATTCATAATAATGTTAATTTCAATAAATGACATTCATGCAGCAATTATATTGG
TGTATGAAATTCTTACAGTGAATATTGTGCTGTTAGTGCTGCTTGAAACATTTCAA
TAAAATATTGACCAGGAAAAAAAAAAAAA

30 SEQ ID NO: 470

>13823 BLOOD 335527.4 M37238 g190035 Human phospholipase C mRNA, complete cds.
0

GAATTCGGCGCTGAGTGACCCGAGTCGGGACGCGGGCTGCGCGCGCGGGACCCC
GGAGCCCAAACCCGGGGCAGGCGGGCAGCTGTGCCCGGGCGGCACGGCCAGCTT
35 CCTGATTTCTCCGATTCTTCTCTCCCTGGAGCGGCCGACAATGTCCACCACG
GTCAATGTAGATTCCCTTGCGGAATATGAGAAGAGCCAGATCAAGAGAGCCCTG
GAGCTGGGGACGGTGATGACTGTGTTTCAGCTTCCGCAAGTCCACCCCCGAGCGG
AGAACCGTCCAGGTGATCATGGAGACGCGGCAGGTGGCCTGGAGCAAGACCGCC
GACAAGATCGAGGGCTTCTTGGATATCATGGAAATAAAAGAAATCCGCCAGGG
40 AAGAACTCCAAAGATTTTCGAGCGAGCAAAAGCAGTTCGCCAGAAAGAAGACTGC
TGCTTCACCATCCTATATGGCACTCAGTTCGTCTCAGCACGCTCAGCTTGGCAG
CTGACTCTAAAGAGGATGCAGTTAACTGGCTCTCTGGCTTGAAAATCTTACACCA
GGAAGCGATGAATGCGTCCACGCCACCATTATCGAGAGTTGGCTGAGAAAGCA
GATATATTCTGTGGATCAAACCAGAAGAAACAGCATCAGTCTCCGAGAGTTGAA
45 GACCATCTTGCCCCTGATCAACTTTAAAGTGAGCAGTGCCAAGTTCCTTAAAGAT
AAGTTTGTGGAAATAGGAGCACACAAAGATGAGCTCAGCTTTGAACAGTTCCAT
CTCTTCTATAAAAACTTATGTTTGAACAGCAAAAATCGATTCTCGATGAATTCA
AAAAGGATTTCGTCCGTGTTTCATCCTGGGGAACACTGACAGGCCGGATGCCTCTGC
TGTTTACCTGCATGACTTCCAGAGGTTTCTCATACATGAACAGCAGGAGCATTGG

GCTCAGGATCTGAACAAAGTCCGTGAGCGGATGACAAAGTTCATTGATGACACC
ATGCGTGAAACTGCTGAGCCTTTCTTGTTTGTGGATGAGTTCCTCACGTACCTGTT
TTCACGAGAAAACAGCATCTGGGATGAGAAGTATGACGCGGTGGACATGCAGGA
CATGAACAACCCCTGTCTCATTACTGGATCTCCTCGTCACATAACACGTACCTT
5 ACAGGTGACCAGCTGCGGAGCGAGTCGTCCCCAGAAGCTTACATCCGCTGCCTG
CGCATGGGCTGTGCTGCATTGAACTGGACTGCTGGGACGGGCCCCGATGGGAAG
CCGGTCATCTACCATGGCTGGACGCGGACTACCAAGATCAAGTTTGATGACGTGC
TGCAGGCCATCAAAGACCACGCCTTTGTTACCTCGAGCTTCCCAGTGATCCTGTC
CATCGAGGAGCACTGCAGCGTGGAGCAACAGCGTCACATGGCCAAGGCCTTCAA
10 GGAAGTATTTGGCGACCTGCTGTTGACGAAGCCACGGAGGCCAGTGCTGACCA
GCTGCCCTCGCCCAGCCAGCTGCGGGAGAAGATCATCATCAAGCATAAGAAGCT
GGGCCCCCGAGGCGATGTGGATGTCAACATGGAGGACAAGAAGGACGAACACA
AGCAACAGGGGGAGCTGTACATGTGGGATTCCATTGACCAGAAATGGACTCGGC
ACTACTGCGCCATTGCTGATGCCAAGCTGTCCTTCAGTGATGACATTGAACAGAC
15 TATGGAGGAGGAAGTGCCCCAGGATATACCCCTACAGAACTACATTTTGGGGA
GAAATGGTTCCACAAGAAGGTGGAGAAGAGGACGAGTGCCGAGAAGTTGCTGC
AGGAATACTGCATGGAGACGGGGGGCAAGGATGGCACCTTCCTGGTTCGGGAGA
GCGAGACCTTCCCAATGACTACACCCTGTCCTTCTGGCGGTGAGGCCGGGTCCA
GCACTGCCGGATCCGCTCCACCATGGAGGGCGGGACCCTGAAATACTACTTGACT
20 GACAACCTCACCTTCAGCAGCATCTATGCCCTCATCCAGCACTACCGCGAGACGC
ACCTGCCGTGCGCCGAGTTCGAGCTGCGGCTCACGGACCCTGTGCCCAACCCCAA
GCGCCACGAGTCCAAGCCGTGGTACTATGACAGCCTGAGCCGCGGAGAGGCAGA
GGACATGCTGATGAGGATCCCGGGACGGGGCCTTCCTGATCCGGAGCGGAGA
GGGGAGCGACTCCTATGCCATCACCTTCAGGGCTAGGGGCAAGGTAAAGCATTG
25 TCGCATCAACCGGGACGGCCGGCACTTTGTGCTGGGGACCTCCGCCTATTTT
AGTCTGGTGGAGCTCGTCAGTTACTACGAGAAGCATTCACTCTACCGAAAGATGA
GACTGCGCTACCCCGTGACCCCGAGCTCCTGGAGCGCTACAATATGGAAAGAG
ATATAAACTCCCTCTACGACGTCAGCAGAATGTATGTGGATCCCAGTGAAATCAA
TCCGTCCATGCCTCAGAGAACCGTGAAAGCTCTGTATGACTACAAAGCCAAGCG
30 AAGCGATGAGCTGAGCTTCTGCCGTGGTGCCCTCATCCACAATGTCTCCAAGGAG
CCCGGGGGCTGGTGGAAAGGAGACTATGGAACCAGGATCCAGCAGTACTTCCCA
TCCAATACTACGTCGAGGACATCTCAACTGCAGACTTCGAGGAGCTAGAAAAGCAG
ATTATTGAAGACAATCCCTTAGGGTCTCTTGCAGAGGAATATTGGACCTCAATA
CCTATAACGTGCTGAAAGCCCTCAGGGAAAAAACCAGAAGTCCTTTGTCTTCAT
35 CCTGGAGCCCAAGCAGCAGGGCGATCCTCCGGTGGAGTTTGCCACAGACAGGGT
GGAGGAGCTCTTTGAGTGGTTTCAGAGCATCCGAGAGATCACCTGGAAGATTGA
CACCAAGGAGAACAAACATGAAGTACTGGGAGAAGAACCAGTCCATCGCCATCGA
GCTCTCTGACCTGGTTGTCTACTGCAAACCAACCAGCAAAACCAAGGACAACCTA
GAAAATCCTGACTTCCGAGAAATCCGCTCCTTTGTGGAGACGAAGGCTGACAGC
40 ATCATCAGACAGAAGCCCGTCGACCTCCTGAAGTACAATCAAAAGGGCCTGACC
CGCGTCTACCCAAAGGGACAAAGAGTTGACTCTTCAAACCTACGACCCCTTCCGCC
TCTGGCTGTGCGGTTCTCAGATGGTGGCACTCAATTTCCAGACGGCAGATAAGTA
CATGCAGATGAATCACGCATTGTTTTCTCTCAATGGGCGCACGGGCTACGTTCTG
CAGCCTGAGAGCATGAGGACAGAGAAATATGACCCGATGCCACCCGAGTCCCAG
45 AGGAAGATCCTGATGACGCTGACAGTCAAGGTTCTCGGTGCTCGCCATCTCCCCA
AACTTGAGCGAAGTATTGCCTGTCCCTTTGTAGAAGTGAGATCTGTGGAGCCGA
GTATGACAACAACAAGTTCAAGACGACGGTTGTGAATGATAATGGCCTCAGCCC
TATCTGGGCTCCAACACAGGAGAAGGTGACATTTGAAATTTATGACCCAAACCTG
GCATTTCTGCGCTTTGTGGTTTATGAAGAAGATATGTTTCAGCGATCCCAACTTTCT

TGCTCATGCCACTTACCCCATTAAGCAGTCAAATCAGGATTCAGGTCCGTTCTCT
CTGAAGAATGGGTACAGCGAGGACATAGAGCTGGCTTCCCTCCTGGTTTTCTGTG
AGATGCGGCCAGTCCTGGAGAGCGAAGAGGAACTTTACTCCTCCTGTCGCCAGCT
GAGGAGGCGGCAAGAAGAACTGAACAACCAGCTCTTTCTGTATGACACACACCA
5 GAACCTTGCGBAATGCCAACCGGGATGCCCTGGTTAAAGAGTTCAGTGTTAATGA
GAACCAGCTCCAGCTGTACCAGGAGAAATGCAACAAGAGGTAAAGAGAGAAGA
GAGTCAGCAACAGCAAGTTTTACTCATAGAAGCTGGGGTATGTGTGTAAGGGTA
TTGTGTGTGTGCGCATGTGTGTTTGCATGTAGGAGAACGTGCCCTATTCACACTCT
GGGAAGACGCTAATCTGTGACATCTTTTCTTCAAGCCTGCCATCAAGGACATTTC
10 TTAAGACCCAACTGGCATGAGTTGGGGTAATTTCTTAATTATTTTCATCTTGGACA
ACTTTCTTAACCTATATTCTTTATAGAGGATTCCCCAAAATGTGCTCCTCATTTTT
GGCCTCTCATGTTCCAAACCTCATTGAATAAAAGCAATGAAAACCTTGATCAATT
AAGCCTTCTGTTGCACGACCTGTGCAGTGAACAGGATTTCTTTTCTGGCCAAGAA
GATTCTACCTCTAATGATCCAGGTAACCTGATGTCCATGGAGGATGAGCTGGAAAT
15 GTAAGAAACTATTCATGAGACTCTGAAAAAAAAA

SEQ ID NO: 471

>13831 BLOOD 232067.6 AL137411 g6807963 Human mRNA; cDNA DKFZp434M082
(from clone DKFZp434M082). 1e-86

20 GCAGCTGCAGCGGGCGTGAGTTGGGGGAGGACGGGTTGCCGACTCGCCTACCTA
GCGGTCTCTTGATTGTCGATATTTTGTGGCATAGGTTTATGTAGAGACGTATACA
TATATATAGACACACTGTCTTTAAATCTAGGCCTGTATCCGGTGTCCGAGGCGAA
CTCAGTAAGATGATGTTAAAGAGGAAACCTGAAGCAAGTGCGCATTGAGAAAAAC
CGGGCCCGCCCTTCGCGCCCTGGAGTCCGCGGTGGGCGAGAGCGAGCGCGCGGCC
25 GNGGCAGCCATGGCGCTCGCTCTTGCCGGGGAGCCGGCACCCGCCCGCGCCCGCG
CCTCCAGAGGACCACCCGGACGAGGAGATGGGGTTCACTATCGACATCAAGAGT
TTCCTCAAGCCGGGCGAGAAGACGTACACGCAGCGCTGCCGCCTCTTCGTGGGA
AATCTGCCCACCGACATCACGGAGGAGGACTTCAAGAGGCTCTTCGAACGCTAT
GGCGAGCCCAGCGAAGTCTTCATCAACCGGGACCGTGGCTTCGGCTTCATCCGCT
30 TGGAATCCAGAACCCTGGCTGAAATTGCAAAAGCAGAGCTGGACGGCACCATTTC
TCAAGAGCAGACCTCTACGGATTTCGCTTCGCTACACATGGAGCAGCCTTGACTGT
CAAGAACCTTTCTCCAGTTGTTTCCAATGAGCTGCTAGAGCAAGCATTTTCTCAG
TTTGGTCCAGTAGAGAAAAGCTGTTGTGGTTGTGGATGATCGCGGTAGAGCTACAG
GAAAAGGTTTTGTAGAGTTTGCAGCAAAACCTCCTGCACGAAAGGCTCTGGAAA
35 GATGTGGTGATGGGGCATTCTTGCTAACAACGACCCCTCGTCCAGTCATTGTGGA
ACCCATGGAGCAGTTTGATGATGAAGATGGCTTGCCAGAGAAGCTGATGCAGAA
AACTCAACAATATCATAAGGAAAGAGAACAACCACCACGTTTTGCTCAACCTGG
GACATTTGAATTTGAGTATGCATCTCGATGGAAGGCTCTTGATGAAATGGAAAAG
CAGCAGCGTGAGCAGGTTGATAGAAACATCAGAGAAGCCAAAGAGAAACTGGA
40 GGCAGAAATGGAAGCAGCTAGGCATGAACACCAATTAATGCTAATGAGGCAAGA
TCTAATGAGGCGTCAAGAAGAACTCAGACGCTTGGAAGAACTCAGAAACCAAGA
GTTGCAAAAACGGAAGCAAATACAATAAGACATGAAGAGGAGCATCGGCGGC
GTGAGGAAGAAATGATCCGACACAGAGAACAGGAGGAACTGAGGCGACAGCAA
GAGGGCTTTAAGCCAAACTACATGGAAAATAGAGAACAGGAAATGAGAATGGG
45 TGATATGGGTCCCCGTGGAGCAATAAACATGGGAGATGCGTTTAGCCAGCCCT
GCTGGTAACCAAGGTCCTCCTCCAATGATGGGTATGAATATGAACAACAGAGCA
ACTATACCTGGCCCACCAATGGGTCCTGGTCCTGCCATGGGACCAGAAGGAGCC
GCAAAATATGGGAACCTCAATGATGCCAGATAATGGAGCAGTGCACAATGACAGA
TTTCCTCAAGGACCACCATCTCAGATGGGTTACCTATGGGGAGTAGAACAGGTT

5

10

mRNA s

20

[illegible]

25

GGCAAGAGGTAGCA

30

35

40

45

GCAGGCCGGCGGACCCTGCACCTCATAGGCCTCGCTGGCATGGCGGGTGTGCC
ATACTCATGACCATCGCGCTAGCACTGCTGGAGCAGCTACCCTGGATGTCCTATC
TGAGCATCGTGGCCATCTTTGGCTTTGTGGCCTTCTTTGAAGTGGGTCTGGCCCC
ATCCCATGGTTCATCGTGGCTGAACTCTTCAGCCAGGGTCCACGTCCAGCTGCCA
5 TTGCCGTTGCAGGCTTCTCCAACCTGGACCTCAAATTTTCATTGTGGGCATGTGCTTC
CAGTATGTGGAGCAACTGTGTGGTCCCTACGTCTTCATCATCTTCACTGTGCTCCT
GGTTCTGTTCTTCATCTTCACCTACTTCAAAGTTCCTGAGACTAAAGGCCGGACCT
TCGATGAGATCGCTTCCGGCTTCCGGCAGGGGGGAGCCAGCCAAAGTGACAAGA
CACCCGAGGAGCTGTTCCATCCCCTGGGGGCTGATTCCCAAGTGTGAGTCGCCCC
10 AGATCACCAGCCCGGCCTGCTCCCAGCAGCCCTAAGGATCTCTCAGGAGCACAG
GCAGCTGGATGAGACTTCCAAACCTGACAGATGTCAGCCGAGCCGGGCCTGGGG
CTCCTTTCTCCAGCCAGCAATGATGTCCAGAAGAATATTCAGGACTTAACGGCTC
CAGGATTTTAACAAAAGCAAGACTGTTGCTCAAATCTATTCAGACAAGCAACAG
GTTTTATAATTTTTTTTATTACTGATTTTTGTTATTTTTATATCAGCCTGAGTCTCCTG
15 TGCCACATCCCAGGCTTCACCCTGAATGGTTCATGCCTGAGGGTGGAGACTAA
GCCCTGTCGAGACACTTGCCCTTCTTCACCCAGCTAATCTGTAGGGCTGGACCTAT
GTCCTAAGGACACACTAATCGAACTATGAACTACAAAGCTTCTATCCCAGGAGGT
GGCTATGGCCACCCGTTCTGCTGGCCTGGATCTCCCCACTCTAGGGGTCAGGCTC
CATTAGGATTTGCCCTTCCCATCTCTTCTACCCAACCACTCAAATTAATCTTTC
20 TTTACCTGAGACCAGTTGGGAGCACTGGAGTGCAGGGAGGAGAGGGGAAGGGCC
AGTCTGGGCTGCCGGGTTCTAGTCTCCTTTGCACTGAGGGCCACACTATTACCAT
GAGAAGAGGGCCTGTGGGAGCCTGCAAACCTCACTGCTCAAGAAGACATGGAGAC
TCCTGCCCTGTTGTGTATAGATGCAAGATATTTATATATATTTTTGGTTGTCAATA
TTAAATACAGACACTAAGTTATAGTATATCTGGACAAGCCAACTTGTAATACAC
25 CACCTCACTCCTGTTACTTACCTAAACAGATATAAATGGCTGGTTTTTAGAAACA
TGGTTTTGAAATGCTTGTGGATTGAGGGTAGGAGGTTTGGATGGGAGTGAGACA
GAAGTAAGTGGGGTTGCAACCACTGCAACGGCTTAGACTTCGACTCAGGATCCA
GTCCCTTACACGTACCTCTCATCAGTGTCTCTTGCTCAAAAATCTGTTTGATCCC
TGTTACCCAGAGAATATATACATTCTTTATCTTGACATTCAAGGCATTTCTATCAC
30 ATATTTGATAGTTGGTGTTCAAAAAACACTAGTTTTGTGCCAGCCGTGATGCTC
AGGCTTGAAATCGCATTATTTTGAATGTGAAGTAAATACTGTACCTTTATTTGAC
AGGCTCAAAGAGGTTATGTGCCTGAAGTCGCACAGTGAATAAGCTAAAACACCT
GCTTTTAAACAATGGGTACGATACAACCACTACTCCATTAAGTCCACCCACCTCCT
GCACCCCCTCCACACACACAAAATGAACCACGTTCTTTGTATGGGCCCAATGAG
35 CTGTCAAAGCTGCCCTGTGTTCAATTCATTTGGAATTGCCCCCTCTGGTTCCTCTG
TATACTACTGCTTCATCTCTAAAGACAGCTCATCCTCCTCCTTCACCCCTGAATTT
CCAGAGCACTTCATCTGCTCCTTCATCACAAGTCCAGTTTTCTGCCACTAGTCTGA
ATTTCATGAGAAGATGCCGATTTGGTTCCTGTGGGTCCTCAGCACTATTCAGTAC
AGTGCTTGATGCACAGCAGGCACTCAGAAAATACTGGAAAAAATACCCCCACCA
40 AAGATATTTGTCAAAA

SEQ ID NO: 474

>13879 BLOOD 480881.12 X04790 g28820 Human mRNA for A-raf-1 oncogene. 0

45 CAGGAGGCCCTGACCAGAGAAGGACCTGGAAGGACTTCAGATGTGAGCAGGATC
TCTTGGACTGTCGTGTGAAAATTAGGCTGCAGGGGTCGACAGGAGCCTGGACTTT
GAATTTAATTTTGTCCCCTGCCACTTTGCTTCTAGACTATCATTATTGGACCTCTG
AATTCCTGTCTGCCCTTCTTGTAGGAGCCCCATGGCACCTGCCAGCCCCACCTCA
GCCCATCTTGACAAAATCTAAGGCTCCATGGAGCCACCACGGGGCCCCCCTGCCA
ATGGGGCCGAGCCATCCCGGGCAGTGGGCACCGTCAAAGTATACCTGCCCAACA

45 ATCCTGACTTTAGTTGCTGGCCGCCTTTGCTTTCCATCCGCTATAGTGGCCTCCTT
TGTCCTTGCAGGGGAAACCGAGGCCACAGCCTTGCAGCGCAGGCCTGAATCGCC
CGGATTTCCCGCCCCCTGCTCGTGCAGGGCCTCACTGTCTCCTTCTGGGCTGGGGG
CTTGCGACACCGCCCTCCGGCCGACTCGCTCGTGGGGTGCTGGTGGCAGTGGCTG
GGTCACTCGTGCTCTGGTCAGGAGAGCGGGTCTCCGGCAGCCTCCGGGCCTCGTA

GACCGGGTACCCGGGAGGGTGAGGGTTAGTGCTGTCGCCTCCGCCGTGCTGACTC
 AGTCATAGGGCCCAGCAACGCAGCGGACCTTGGGTTGGGAGGACAAAGTGTCT
 TCCCGGGCGCACTGACCGGGCGGGGGTCTCAGCTTTCAGTCATGGCCTCCGGTAA
 CGCGCGCATCGGAAAGCCAGCCCCTGACTTCAAGGCCACAGCGGTGGTTGATGG
 5 CGCCTTCAAAGAGGTGAAGCTGTGCGACTACAAAGGGAAGTACGTGGTCTCTTT
 TTCTACCCTCTGGACTTCACTTTTGTGTGCCCCACCGAGATCATCGCGTTCAGCAA
 CCGTGCAAGGACTTCCGCAAGCTGGGCTGTGAAGTGCTGGGCGTCTCGGTGGA
 CTCTCAGTTCACCCACCTGGCTTGGATCAACACCCCCCGGAAAGAGGGAGGCTTG
 GGCCCCCTGAACATCCCCCTGCTTGTGACGTGACCAGACGCTTGTCTGAGGATT
 10 ACGGCGTGCTGAAAACAGATGAGGGCATTGCCTACAGGGGCCTCTTTATCATCG
 ATGGCAAGGGTGTCTTTCGCCAGATCACTGTTAATGATTTGCCTGTGGGACGCTC
 CGTGGATGAGGCTCTGCGGCTGGTCCAGGCCTTCCAGTACACAGACGAGCATGG
 GGAAGTTTGTCCCGCTGGCTGGAAGCCTGGCAGTGACACGATTAAGCCCAACGT
 GGATGACAGCAAGGAATATTTCTCCAAACACAATTAGGCTGGCTAACGGATAGT
 15 GAGCTTGTGCCCCCTGCCTAGGTGCCTGTGCTGGGTGTCCACCTGTGCCCCACCT
 GGGTGGCCTATGCTGACCCAGGAAAGGCCAGACCTGCCCCCTCCAAACTCCACAG
 TATGGGACCCTGGAGGGCTAGGCCAAGGCCTTCTCATGCCTCCACCTAGAAGCTG
 AATAGTGACGCCCTCCCCCAAGCCACCCAGCCGCACACAGGCCTAGAGGTAAC
 CAATAAAGTATTAGGGAAAGGTGAGAGTCTGTGTTGGTGTGCTCTGTACTTTTCGT
 20 GCTCCCCTGCAACCCCCTTCTTCTTCAGGCTC

SEQ ID NO: 476
 >14107 BLOOD GB_H72027 gi|1043843|gb|H72027|H72027: ysl6e12.r1 Soares breast
 2NbHBst Homo sapiens cDNA:clone IMAGE:214990 5' similar to gb:X04412 GELSOEIN
 25 PRECURSOR, PLASMA (HUMAN);, mRNA sequence [Homo sapiens]
 GGATTNAATTTCCCAAACACTGACATTTTAGACAATTTTGCAAGGACTCTGAATT
 TTTGCAGGGCTATTTTGGATA

SEQ ID NO: 477
 30 >14178 BLOOD GB_H75632 gi|1049954|gb|H75632|H75632 yu07b04.s1 Soares fetal liver
 spleen 1NFLS Homo sapiens cDNA clone IMAGE:233071 3', mRNA sequence [Homo
 sapiens]
 TTATCCAATAATATATTTAATAGGTAAGANCTCATTTCATCAATATACAAAAAAA
 AAAAAACAAACCAGAAAAACAAAAAACTAACTTTGATTAGGACATGTGCCCTTNG
 35 TAGGGGCCTTNACANTTGAANGGTTTNTCGGTGGCACTTTGNGGTNGCATNTTT
 TGTAANGTCACAGGGCTGCTCTGCGTTTTCTCCNGGGTTACAAGGGTNGAGGCCN
 TCAGCCTTTGCCCCGGGAAGAGGGAAAGTGAANTTNTCTGTACTCNTTGCCAGTG
 TCAGCCTGGANCACTTTCTACCACCCACCCTTGGGCCATCCCTCCTCTACACTT
 TATGCGTCGGGGGGTTTA

SEQ ID NO: 478
 >14251 BLOOD 977429.8 AF113534 g6523822 Human HP1-BP74 protein mRNA,
 complete cds. 0
 CAGGCATGAGCCACTGCACCCAGCCTATCGTCTGTTGTTAAATGTTCTAATGCAC
 45 CTATTAGGTGCACAGAGTACTGTTATATACTCAGAATAAAATTTACATAATGCTT
 TAAATCTCACAAAATTGTTTTGATAAACATACTCTTATAATTCTTGCAACACCTTG
 GGAAATAGTTGGTTCTATATTACTGTTTTATAGCTGAGGAGAAAGACTCACATCA
 TTTACTAAGATCATATAGCTAGCTAGTAAATGTTTGAGTGAAAATACAAACAAAG
 GTTTTCTGACTTTAAGAGCTTGAGTTTTTCCACTATACCATATTGCATCTGTTGT

AATTGTTAACTAATGTGCATTTTAAAATTCTCATTTGTCTTATGTACTGAGCCCTT
ATACCAGTGCTAATTTATGTGACTCCTTTCTCCTGCAGCTAAGAGAAAAATACCT
TTTTAATTCATTTATAGTACCCAGTTTTTAAAGAAGATTTATTTTGTAATAATTTTG
CTTATGGTACATGTCATCTTAGCCTGTAAATAAATTAAAGCATTAATTTTTATCCC
5 TCCCTGGTCTTTTCTCCTTCTGACTTTATACGTCTTTCTAGAGAGCTTATCTTCTA
TAATAACAATTCTTTGTTTTAAAGTGAGAAAGATCAGTCTAAAGAAAAGGAGAA
GAAAGTGAAAAAACAATTCCTTCCCTGGGCTACCCTTTCTGCCAGCCAGCTAGCC
AGGGCCCAGAAACAAACACCGATGGCTTCTTCCCACGTCCCAAGATGGATGCA
ATCTTAACTGAGGCCATTAAGGCATGCTTCCAGAAGAGTGGTGCATCAGTGGTTG
10 CTATTCGAAAATACATCATCCATAAGTATCCTTCTCTGGAGCTGGAGAGAAGGGG
TTATCTCCTTAAACAAGCACTGAAAAGAGAATTAAATAGAGGAGTCATCAAACA
GGTTAAAGGAAAAGGTGCTTCTGGAAGTTTTGTTGTGGTTCAGAAATCAAGAAA
AACACCTCAGAAATCCAGAAACAGAAAGAATAGGAGCTCTGCAGTGGATCCAGA
ACCACAAGTAAAATTGGAGGATGTCCTCCCACTGGCCTTTACTCGCCTTTGTGAA
15 CCTAAAGAAGCTTCCCTACAGTCTCATCAGGAAATATGTGTCTCAGTATTATCCTA
AGCTTAGAGTGGACATCAGGCCTCAGCTGTTGAAGAACGCTCTGCAGAGAGCAG
TAGAGAGGGGCCAGTTAGAACAGATAACTGGCAAAGGTGCTTCGGGGACATTCC
AGCTGAAGAAATCAGGGGAGAAACCCCTGCTTGGTGGGAAGCCTGATGGAATATG
CAATCTTGTCTGCCATTGCTGCCATGAATGAGCCGAAGACCTGCTCTACCACTGC
20 TCTGAAGAAGTATGTCCTAGAGAATCACCCAGGAACCAATTCTAACTATCAAATG
CATTTGCTGAAAAAAACCCTGCAGAAATGCGAAAAGAATGGGTGGATGGAACAG
ATCTCTGGGAAAGGGTTCAGTGGCACCTTCCAGCTCTGTTTTCCCTATTATCCCAG
CCCAGGAGTTCTGTTTCCGAAGAAAGAGCCAGATGATTCTAGAGATGAGGATGA
AGATGAAGATGAGTCATCAGAAGAAGACTCTGAGGATGAAGAGCCGCCACCTAA
25 GAGAAGGTTGCAGAAGAAAACCCAGCCAAGTCCCAGGGAAGGCCGCATCTGT
GAAGCAGAGAGGGTCCAAACCTGCACCTAAAGTCTCAGCTGCCAGCGGGGGAA
AGCTAGGCCCTTGCCCTAAGAAAGCACCTCCTAAGGCCAAAACGCCTGCCAAGAA
GACCAGACCCTCATCCACAGTCATCAAGAAACCTAGTGGTGGCTCCTCAAAGAA
GCCTGCAACCAGTGCAAGAAAGGAAGTAAAATTGCCGGGCAAGGGCAAATCCAC
30 CATGAAGAAGTCTTTCAGAGTGAAAAAGTAAATTTTATAGGAAAAAAGGGTATC
ATGATGAAATTCAAATCTTATTTTCTAAGGTCAGTGTGCATTTGTTTAGTTTGA
TGCTTTTCAAATTACATTATTTTCTCCTCCCCTATGAACATTGTGGGGAGGGACTCTA
AATAAACGAGTTTAGGCATTTGCTAGCTTTAGGTGCTTTTATTGGTGCCTGCCCTT
TTCTTGTTCATTTTAATTTCTGCAATAATCCTGGACTTTCCTAAACTATGTAATG
35 TATACTTGTCTTTTCTCTGCCTCCCCCAACCCCTGTTGTTTTTATGGTCAGCTT
TGCTTTTTTTTTTCTTCCAATTTTATCTAAACAGTTGCAGAGATTTTATATTTGT
AGAAAGCATCAAGAACGGTATGCCAGTCAGGTCTGGAAGTAAAATGGAGGCAC
AATATAGCACTGACTGAGTTGTAAAGCCTCCTGCCTGGAGACTTCAGTTATAGCT
GTAATAATTAATCTTATTTATAAAAGCCACTCCACTAACCTTTTCTCTCCAATGT
40 AAACACAGAGACAGCTTTGGGAATAAGCCAAAAACAGGGTGATCTCATTAGATT
TTGAAGATATATGACTCCTTTGGGCTACATTTTCATATTGATCAATTTCTAGGTATT
TTTCACTGGCCCAAAGTATTGCATTCCCTTAACAGCAAGCACAAGTTCTCTATAT
CACTTGTNN
NN
45 NNN
NN
NN
NN
NNNNNNNNNNNNCCCACTTGGTTTTTGAAGGGGAAGTGTAGAAATATATTG

ATTTGTGATTTCTGGTGTACCTGTGTTACCAAAAATCAAAACAAATCTTTTTTAT
TTTTATTATTATNATTATTTTGAGACA

SEQ ID NO: 479

5 >14308 BLOOD 407458.2 L07894 g292432 Human rod outer segment membrane protein 1 (ROM1) mRNA, complete cds. 0

TGACAGGGGGGCGCGTTATTAGGGCTGAGGATGGGAGGATGCTCAGGGTATTGG
GGTCAGGGTGGCATTAGCCCAGCTCAAGCCGGGCGGGCTGACTCAGCATCCTG
CCCCAGCCAGCTTCCATCCCTGACACCTCTGCACTCCCTTGGGCAGAGATGGGAG
10 ATGGCGCCGGTGTGCCCCCTGGTGTGCCCCCTGCAGCCCCGCATCCGCCTGGCAC
AAGGGCTCTGGCTCCTCTCCTGGCTGCTGGCGCTGGCTGGTGGCGTCATCCTCCT
CTGTAGTGGGCACCTCCTGGTCCAGCTAAGGCACCTTGGCACCTTCCTGGCTCCC
TCCTGTACAGTTCCCTGTCCTGCCCCAGGCTGCCCTGGCAGCGGGCGCGGTGGCTC
TGGGCACAGGACTAGTGGGTGTAGGAGCCAGCCGGGCAAGTCTGAATGCAGCTC
15 TATACCCTCCCTGGCGAGGGGTCCTGGGCCCCGCTGCTGGTGGCTGGCACGGCTGG
TGGGGGGGGGCTCCTGGTCGTCGCCCTCGGGCTAGCCCTGGCTTTGCCTGGGAGT
CTGGATGAGGCGCTGGAGGAGGGCCTGGTGAAGTGCCTTGGCTCACTACAAGGAC
ACAGAGGTGCCTGGGCACTGTCAGGCCAAAAGGCTGGTGGATGAGCTGCAACTG
AGGTACCACTGCTGCGGGCGCCACGGGTACAAGGATTGGTTTGGGGTCCAGTGG
20 GTCAGCAGCCGTTACCTGGATCCCGGTGACCGGGATGTGGCTGACCGGATCCAG
AGCAATGTAGAAGGCCTATACCTGACTGATGGGGTCCCTTTCTCCTGTTGCAACC
CCCACTCACCCCGGCCTTGCCTGCAAAAACCGTCTTTCAGACTCCTACGCCCAACC
GCTGTTTCGATCCCCGACAACCCAAACCAAAACCGTCTGGGGCCCAAGGGTGCCATGA
GGTGCTGCTGGAGCACTTGCAGGACTTGGCAGGCACACTGGGTAGCATGCTGGC
25 TGTCACCTTCCTACTGCAGGCTCTGGTGTCTCCTTGGCCTGCGGTACCTGCAAACA
GCACTGGAGGGGCTTGGAGGGGTCATTGATGCGGGAGGAGAGACCCAGGGCTAT
CTCTTCCCAGTGGGCTGAAAGATATGCTGAAAACAGCATGGCTACAGGGAGGG
GTTGCCTGCAGGCCAGCACCTGAGGAGGCCCCACCAGGAGAAGCACCTCCCAAG
GAGGATCTATCTGAGGCCTAGAGGCCTGGAGCTTGGGGTGAGGAAGAGGGAGGG
30 ATGGACAAGTCTGAAAACCTCACAACCTCCTTACCAAGGCTCCAGGTTGGGGGGA
TCGTAGGATTAGAGGGGCTAAGGATAGTCAGCGAGCTGGACTGGGGTAAGAAAG
AAAACCAGATGTCCTAGGGCCTAGCCCTTGTAGTCAGAACCACCAGGGAACAGC
AAAGAACAGAGTGATGGGAAAGTGACATGAGAAGGCCTGGAGGCTGATTCTGAT
ATAGACTCAATAAAGTTTTTGGATGGAAAAAAGAGCGGCCGCC

35 SEQ ID NO: 480

>14315 BLOOD GB_H84982 gi|1064703|gb|H84982|H84982 ys88a08.s1 Soares retina
N2b5HR Homo sapiens cDNA clone IMAGE:221846 3' similar to SP:HTLF_HUMAN
P32314 HUMAN T-CELL LEUKEMIA VIRUS ENHANCER FACTOR ;contains MER22

40 repetitive element ;, mRNA sequence [Homo sapiens]
GCTCCCCAGTGGTCAGCGGAGACCCCAAGGAGGATCACAACCTACAGCAGTGCCA
AGTCCTCCAACGCCCCGGAGCACCTCGCCCACCAGCGACTCCATCTCCTCCTCCTC
CTCCTCAGCCGACGACCACTATGAGTTTGGCCACCAAGGGGAGCCAGGAGGGCAG
CGAGGGCAGCGAGGGGAGCTTCCGGAGCCACGAGAGCCCCAGCGACACGGAAG
45 AGGACGACAGGAAGNACAGCCAGAAGGAGCCCAAGGATTTTTTNGGGGACAGC
GGGTACGATTNCC

SEQ ID NO: 481

>14385 BLOOD 474480.3 Incyte Unique

ATCCTGCCCCGGCCTGTACATCGGCAACTTCAAAGATGCCAGAGACGCGGAACAA
TTGAGCAAGAACAAGGTGACACATATTCTGTCTGTCCACGATAGTGCCAGGCCTA
TGTTGGAGGACAAGACATTTCAAAGAAAGTATTAAATTCATTCACGAGTGCCGG
CTCCGCGGTGAGAGCTGCCTTGTACACTGCCTGGCCGGGGTCTCCAGGAGCGTGA
5 CACTGGTGATCGCATACATCATGACCGTCACTGACTTTGGCTGGGAGGATGCCCT
GCACACCGTGCGTGCTGGGAGATCCTGTACCAACCCCAACGTGGGCTTCCAGAG
ACAGCTCCAGGAGTTTGAGAAGCATGAGGTCCATCAGTATCGGCAGTGGCTGAA
GGAAGAATATGGAGAGAGCCCTTTGCAGGATGCAGAAGAAGCCAAAAACATTCT
GGGTAAATATAAGGAGCAAGGGCGCACAGAGCCCCAGCCCGGCGCCAGGCGGT
10 GGAGCAGTTTTCCGGCACTGGCTCCGCTGACCTACGATAATTATACGACGGAGAC
CTAACGCAAGCGACCTGCTGCCTTCCTTCCCACTGCTTGTCTTCAGTGTGCCCGGC
TGGGCAGGGGTGCGGTGGTGGTGGCCGATGAGGACAGGAAAGGGAGATAGCCA
GGGCGAGGTGGGGCGAGGGCTCCTTTCCCCCAAGCAACACCGCCCAGCCCTGCT
CCAGGCCCTGCACTCAGCCCACCCCTACCCTGGCTGCACCTGAGCTTGCTGCCC
15 CCGGGGATGTTGCCAGTGGCTGTGCACTGCTCTGTGCACGTGCGTGTGTGTGAG
TGCACTTGTGTGTGGGTGACTAAGTGGATGCATGTGTGTGCCTGTGTGAGTGAGG
GTATGTGCACCTAAGTGTGTACATGTGTGTATGTNNNNNNNNNNNNNNNNNNNN
NN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNCCACCTTTCCCTTTGTCCAAGACTCCACA
20 TGGAAGGCATTTGAGCTCGACCTCCGAAAAGCTACCCAGCAAAGAGCAGTCTGT
GCCTCTGAGCAGACCGTGAGAACTCAGGGGACGAGTGGCTAAGAGCATGGCCTC
TCCGAGAACCCACCCAGGGTGGTGTGGTGGGGGCAACAGGGGGCCAGACTCCTCT
AGAGGGAGGGTGGCTCTGGGGCCCTGGAAAACGTGAGAGACTGCCCTGAGCTGG
TCCAGTGGGGCAGCACTTTATACCAACTCAGCATTTAAGGGAAGTATCTTAGATT
25 GCCTCCATCTCAATGTGAATGCACCAGGCTGAGGGTTCCTAGCGCCTTGAGTCA
AGGCCACTTTTCAGCCCATCGAGCCCTGAGTTCTACTTGGTGTGTTGTTCTCTGGAG
CTGATTGCACTTGAGCTCTGTGGTGGGCAGGCGCACTTTAGCCTAAGTTGGGTGC
CCCAGGGCACCCCTCCTCTCTGCTCCTTGCCAGCTTCATTCACTCCCAGCCTCTC
GCTGTCCTCACTTTGCAGGGGCTCCTCCTCAACATTTGCATGCACCTGCAAGAAT
30 TGGAAGAAAGAGCATTATATTAGGCACTGTAGCAATTTGCATTTTAAAATGCCTG
AGCATTATTAAGCTTCTTGGTATTCACTTGGGTTTGATAATTGATCTGAGCTACC
TCATTGAATGTTTTTGGAAAGGTGTTTTTGGTATGCAAGTCAGCTTTGCCTCACA
GTTGAAAATGTTTCGGTCATGATTGCTTTTGAAACCAAAGGGGAAGGTACCGATAT
CATTGAGCTATTTAAAGTTGCCAGTTTGGGCTCCAGTAATGCTTTCTGGTGGGTA
35 AAATTCACATTCAGGCCACGAGAGCATCTACAGTTTGTACTCTGGGGCTGCAGG
CATCCTGGGACGCTGTACGCAATTCAGTGGTCTAGTCCTTTATACCGACTCAGAT
TCCTTAAGCATGCAGAGTCACTCGAATGAAAAACATACTCGACCTCTCCCTAAA
AAGATGTTGCAACCCAGTTTCTCTGAATTCACCACAAAAAGAGACCCTGAATAA
GAAGAGCAGTTTTCTATGCATATAGAGGGTGTGTCAAAGGTGAGCTTTTTGGGG
40 ACCGGGAAAAACAAAGTTGCCTGATTCCGCGCAGGTGCACAGGCCCCGGATGTA
CACCCGGAAAGGGGAGTGTGGCTGTAGAATCATCCATCCGTCTACAGCTAAAC
AATTTGCCAATAAAGTACATGTTTTCTTAAGCCAAAAATAAATATAAATACGTT
AACAGAAAAATGATTTAGGATATAGCTTGAATGCTTAAATATGTGCACCTTTACA
AACCTCTCAGTGTATTCTTGGAGTTCTTGAAATGTTGTTTTAATATTTGTTGCCAG
45 TAATGTTCTTTCTTC

SEQ ID NO: 482

>14445 BLOOD GB_H94163 gi|1101459|gb|H94163|H94163 yv14c07.r1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:242700 5' similar to contains Alu repetitive element;, mRNA sequence [Homo sapiens]

5 CCTGCTTCAGCCTCCCAAGTAGCTGGGATTACAGGCGCCACCACCGCACCCGGC
TAATTTTTGTATTTTATAGTAGGGACGGGATTTCTCCGTGTTGGCCAGGCTTTTTGA
ACTCCTGACCTTAGGTGATCTGCCTGCCTTGGCCTCCCAAAGTGCTGGGATTACA
GGTATGAGCCACTGTGCCCATCCTCATGTCAATTTTAAAGTGATAAATCCTGAT
ATTANACATTGCAATTAGTGTAGAATAAACGCTTGGCTTATAGA ACTCTCTGTTT
10 TTNAGTCTAAAG

SEQ ID NO: 483

>14450 BLOOD 347864.28 Incyte Unique

15 GCAGCCAGCTCTGAGCGGGAGGCCTGAGCGGGAAGCATTGGGCGTCCGAGCGAC
TTCTAGGAGCCTGGGGTTCGGCGCTATGGAGGAGCTCGATGGCGAGCCAACAGT
CACTTTGATTCCAGGCGTGAATTCCAAGAAGAACC AAAATGTATTTGACTGGGGT
CCAGGGGAGATGCTGGTATGTGAAACCTCCTTCAACAAAAAAGAAAAATCAGAG
ATGGTGCCAAGTTGCCCCTTATCTATATCATCCGTAAGGATGTAGATGTTTACTC
TCAAATCTTGAGAAA ACTCTTCAATGAATCCCATGGAATCTTCTGGGCCTCCAG
20 AGAATTGACGAAGAGTTGACTGGAAAATCCAGAAAATCTCAATTGGTTCGAGTG
AGTAAAAACTACCGATCAGTCATCAGAGCATGTATGGAGGAAATGCACCAGGTT
GCAATTGCTGCTAAAGATCCAGCCAATGGCCGCGCAGTTCAGCAGCCAGGTCTCCA
TTTTGTGAGCAATGGAGCTCATCTGGAAGCTGTGTGAGATTCTTTTATTGAAGTG
GCCCCAGCTGGCCCTCTCCTCCTCCATCTCGTTGACTGGGTCCGGCTCCATGTG
25 CGAGGTGGACAGTTTGTGCGGCAGATGTTCTGGGCAGTGAGAATCCAAGCAAACA
TGACAGCTTCTGGA ACTTGGTGACCATCTTGGTGCTGCAGGGCCGGCTGGATGAG
GCCCCAGAGATGCTCTCCAAGGAAGCCGATGCCAGCCCCGCCTCTGCAGGCATA
TGCCGAATCATGGGGGACCTGATGAGGACAATGCCCATCTTAGTCCTGGGAAC
ACCCAGACACTGACAGAGCTGGAGCTGAAGTGGCAGCACTGGCACGAGGAATGT
30 GAGCGGTACCTCCAGGACAGCACATTCGCCACCAGCCCTCACCTGGAGTCTCTCT
TGAAGATTATGCTGGGAGACGAAGCTGCCTTGTTAGAGCAGAAGGA ACTTCTGA
GTAATTGGTATCATTTCTAGTGACTCGGCTCTTGTACTCCAATCCCACAGTAAA
ACCCATTGATCTGCACTACTATGCCCAGTCCAGCCTGGACCTGTTTCTGGGAGGT
GAGAGCAGCCCAGAACCCCTGGACAACATCTTGTTGGCAGCCTTTGAGTTTGACA
35 TCCATCAAGTAATCAAAGAGTGCAGCATCGCCCTGAGCAACTGGTGGTTTGTGGC
CCACCTGACAGACCTGCTGGACCACTGCAAGCTCCTCCAGTCACACAACCTCTAT
TTCGGTTCCAACATGAGAGAGTTCCTCCTGCTGGAGTACGCCTCGGGACTGTTTG
CTCATCCCAGCCTGTGGCAGCTGGGGGTGATTACTTTGATTACTGCCCCGAGCT
GGGCCGAGTCTCCCTGGAGCTGCACATTGAGCGGATACCTCTGAACACCGAGCA
40 GAAAGCCCTGAAGGTGCTGCGGATCTGTGAGCAGCGGCAGATGACTGAACAAGT
TCGCAGCATTTGTAAGATCTTAGCCATGAAAGCCGTCCGCAACAATCGCCTGGGT
TCTGCCCTCTCTTGGAGCATCCGTGCTAAGGATGCCGCCTTTGCCACGCTCGTGTC
AGACAGGTTCTCAGGGATTACTGTGAGCGAGGCTGCTTTTCTGATTGGATCTC
ATTGACAACCTGGGGCCAGCCATGATGCTCAGTGACCGACTGACATTCCTGGGA
45 AAGTATCGCGAGTTCCACCGTATGTACGGGGAGAAGCGTTTTGCCGACGCAGCTT
CTCTCCTTCTGTCTTGATGACGTCTCGGATTGCCCTCGGTCTTTCTGGATGACT
CTGCTGACAGATGCCTTGCCCTTTTGGAAACAGAAACAGGTGATTTTCTCAGCAG
AACAGACTTATGAGTTGATGCGGTGTCTGGAGGACTTGACGTCAAGAAGACCTG
TGCATGGAGAATCTGATACCGAGCAGCTCCAGGATGATGACATAGAGACCACCA

AGGTGGAAATGCTGAGACTTTCTCTGGCACGAAATCTTGCTCGGGCAATTATAAG
AGAAGGCTCACTGGAAGGTTCTTGAGAACTGCTTCAATGTGGTATCTTTGTATGG
CAATGTATATAGATTTTTTTTAAAAGAATAAATGTTGTTTGCAAATGTAGGTTCTTA
GAAGTCCACCCAGGGAATTTTTTATCTGTCTAGTCTGAACCTGAAGGTGGTAAGA
5 GATTAAAAAATGC

SEQ ID NO: 484

>14476 BLOOD GB_H94944 gi|1102577|gb|H94944|H94944 yu57h03.r1 Soares fetal liver
spleen 1NFLS Homo sapiens cDNA clone IMAGE:230261 5' similar to gb:M29893 RAS-

10 RELATED PROTEIN RAL-A (HUMAN);, mRNA sequence [Homo sapiens]
NTCCTCATNCTCCTNACCCTCCTCCTTCNCNTTCTTNTCCTCCTCCTCCTCCAGCN
GCCCAGNTCNCCCCGCNACCCGTCAGACTCCTCCTTCGACCGCTCCCGGCGCGGG
GCCTTCCAGGCGACAAGGACCGAGTACCCTCCGGCCGGAGCCACGCAGCCGNGC
TTCCGGAGCCCTCGGGGNGCTGGACTGGCTCGCGGTGCAGATTCTTCTTAATCCT
15 TTGGTGAAAACCTGAGACACAAAATGGCTGCAAATAAGCCCAAGGGTCAGAATTC
TTTGGCTTTTACACAAAGTNCATCATGGTGGGCAGTGGTGGCGTGGGCAAGTCAG
CTCTGAATTCTAACAGTTTCATGTTACGGATGAAGTTTGTGTAGGACTATGTA

SEQ ID NO: 485

20 >14509 BLOOD Hs.75929 gnl|UG|Hs#S417461 Human mRNA for OB-cadherin-2, complete
cds/cds=(476,2557) /gb=D21255 /gi=575578 /ug=Hs.75929 /len=3867

ACAGGCGCGCGACGCTCCCGCTCAGCTGGGGGGGGGCGCGGAGAGATGCCGCGGG
GGCGGCTCGCAGCCGCGGCTGACTTGTGAATGGGACCGGGACTGGGGCGCGGAG
TGACACCGCAGCGCTTGGCCTGGGCGAGGGACTGGCGGCTCGGAGGTTGCGTCC
25 AGCCTCAAGGGCCCCAGAAATCACTGTGTTTTTCAGCTCAGCGGCCCTGTGACATT
CCTTCGTGTTGTCAATTTGTTGAGTGACCAATCAGATGGGTGGAGTGTGTTACAGA
AATTGGCAGCAAGTATCCAATGGGTGAAGAAGAAGCTAACTGGGGACGTGGGCA
GCCCTGACGTGATGAGCTCAACCAGCAGAGACATTCCATCCCAAGAGAGGTCTG
CGTGACGCGTCCGGGAGGCCACCCTCAGCAAGACCACCGTACAGTTGGTGGAAAG
30 GGGTGACAGCTGCATTCTCCTGTGCCTACCACGTAACCAAAAATGAAGGAGAAC
TACTGTTTACAAGCCGCCCTGGTGTGCCTGGGCATGCTGTGCCACAGCCATGCCT
TTGCCCCAGAGCGGCGGGGGCACCTGCGGCCCTCCTTCCATGGGCACCATGAGA
AGGGCAAGGAGGGGCAGGTGCTACAGCGCTCCAAGCGTGGCTGGGTCTGGAACC
AGTTCTTCGTGATAGAGGAGTACACCGGGCCTGACCCCGTGCTTGTGGGCAGGCT
35 TCATTCAAGATATTGACTCTGGTGATGGGAACATTAAATACATTCTCTCAGGGGAA
GGAGCTGGAACCATTTTTGTGATTGATGACAAATCAGGGAACATTCATGCCACCA
AGACGTTGGATCGAGAAGAGAGAGCCCAGTACACGTTGATGGCTCAGGCGGTGG
ACAGGGACACCAATCGGCCACTGGAGCCACCGTCGGAATTCATTGTCAAGGTCC
AGGACATTAATGACAACCCTCCGGAGTTCCTGCACGAGACCTATCATGCCAACGT
40 GCCTGAGAGGTCCAATGTGGGAACGTCAGTAATCCAGGTGACAGCTTCAGATGC
AGATGACCCCACTTATGGAAATAGCGCCAAGTTAGTGTACAGTATCCTCGAAGG
ACAACCCTATTTTTTCGGTGGAAAGCACAGACAGGTATCATCAGAACAGCCCTACCC
AACATGGACAGGGAGGCCAAGGAGGAGTACCACGTGGTGATCCAGGCCAAGGA
CATGGGTGGACATATGGGCGGACTCTCAGGGACAACCAAAGTGACGATCACACT
45 GACCGATGTCAATGACAACCCACCAAAGTTTCCGCAGAGCGTATACCAGATATCT
GTGTCAGAAGCAGCCGTCCCTGGGGAGGAAGTAGGAAGAGTGAAAGCTAAAGA
TCCAGACATTGGAGAAAATGGCTTAGTCACATACAATATTGTTGATGGAGATGGT
ATGGAATCGTTTGAAATCACAACGGACTATGAAACACAGGAGGGGGTGATAAAG
CTGAAAAAGCCTGTAGATTTTGAAACCAAAGAGCCTATAGCTTGAAGGTAGAG

GCAGCCAACGTGCACATCGACCCGAAGTTTATCAGCAATGGCCCTTTCAAGGAC
 ACTGTGACCGTCAAGATCGCAGTAGAAGATGCTGATGAGCCCCCTATGTTCTTGG
 CCCCAGTTACATCCACGAAGTCCAAGAAAATGCAGCTGCTGGCACCGTGGTTG
 GGAGAGTGCATGCCAAAGACCCTGATGCTGCCAACAGCCCGATAAGGTATTCCA
 5 TCGATCGTCACACTGACCTCGACAGATTTTTCACTATTAATCCAGAGGATGGTTTT
 ATTA AAACTACAAAACCTCTGGATAGAGAGGAAACAGCCTGGCTCAACATCACT
 GTCTTTGCAGCAGAAATCCACAATCGGCATCAGGAAGCCAAAGTCCCAAGTGGCC
 ATTAGGGTCCTTGATGTCAACGATAATGCTCCCAAGTTTGCTGCCCTTATGAAG
 GTTTCATCTGTGAGAGTGATCAGACCAAGCCACTTTCCAACCAGCCAATTGTTAC
 10 AATTAGTGCAGATGACAAGGATGACACGGCCAATGGACCAAGATTTATCTTCAG
 CCTACCCCTGAAATCATTCAACAATCCAAATTTACAGTCAGAGACAACCGAGAT
 AACACAGCAGGCGTGTACGCCCGGCGTGGAGGGTTCAGTCGGCAGAAGCAGGAC
 TTGTACCTTCTGCCCATAGTGATCAGCGATGGCGGCATCCCGCCCATGAGTAGCA
 CCAACACCCTCACCATCAAAGTCTGCGGGTGCGACGTGAACGGGGGCACTGCTCTC
 15 CTGCAACGCAGAGGCCTACATTCTGAACGCCGGCCTGAGCACAGGCGCCCTGAT
 CGCCATCCTCGCCTGCATCGTCATTCTCCTGGGTGCCCAAGCTTAATGGAACCC
 CCCTCTCCCAGGGAAGACATGAGATTGCTTTATCTGGGCTTCCAGCTGATGCTAT
 TTTCTATGTTAAAGTAAACAGAAGATTTTGTCTTCTGGGGGTCTTTATAAACTT
 CCTTTCCTCTATGTGGTGGCTACAGAGAGTCCAACCACACTTACGTCATTGTAGT
 20 ATTGTTTGTGACCCTGAGAAGGCCAAAAGAAAGAACCACTCATTGTCTTTGAGGA
 AGAAGATGTCCGTGAGAACATCATTACTTATGATGATGAAGGGGGTGGGGAAGA
 AGACAGAGAAGCCTTTGATATTGCCACCCCTCCAGAATCCTGATGGTATCAATGGA
 TTTATCCCGCGCAAAGACATCAAACCTGAGTATCAGTACATGCCCTAGACCTGGGC
 TCCGGGCGAGCGCCCAACAGCGGTGGATGTGATGACTTCATCAACACGAGAATAC
 25 AGGAGGCAGACAATGACCCACGGCTCCTCCTTATGACTCCATTCAAATCTACGG
 TTATGAAGGCAGGGGCTCAGTGGCCGGGTCCCTGAGCTCCCTAGAGTCGGCCAC
 CACAGATTCAGACTTGGACTATGATTATCTACAGAACTGGGGACCTCGTTTAAAG
 AAAGTAGCAGATTTGTATGGTTCCAAAGACACTTTTGATGACGATTCTTAACAAT
 AACGATACAAATTTGGCCTTAAGAACTGTGTCTGGCGTTCTCAAGAATCTAGAAG
 30 ATGTGTAAACAGGTATTTTTTTTAAATCAAGGAAAGGCTCATTTAAACAGGCAAA
 GTTTTACAGAGAGGATACATTTAATAAACTGCGAGGACATCAAAGTGGTAAAT
 ACTGTGAAATACCTTTTCTCACAAAAAGGCAAATATTGAAGTTGTTTATCAACTT
 CGCTAGAAAAAAAACACTTGGCATACAAAATATTTAAGTGAAGGAGAAGTCT
 AACGCTGAACTGACAATGAAGGGAAATTGTTTATGTGTTATGAACATCCAAGTCT
 35 TTCTTCTTTTTTAAAGTTGTCAAAGAAGCTTCCACAAAATTAGAAAGGACAACAGT
 TCTGAGCTGTAATTTGCGCTTAAACTCTGGACACTCTATATGTAGTGCATTTTAA
 ACTTGAATATATAATATTCAGCCAGCTTAAACCCATACAATGTATGTACAATAC
 AATGTACAATTATGTCTCTTGAGCATCAATCTTGTTACTGCTGATTCTTGTAATC
 TTTTGTCTTCTACTTTTCATCTTAAACTAATACGTGCCAGATATAACTGTCTTGTTT
 40 AGTGAGAGACGCCCTATTTCTATGTCATTTTTAATGTATCTATTTGTACAATTTA
 AAGTTCTTATTTTAGTATACATATAAATATCAGTATTCTGACATGTAAGAAAATG
 TTACGGCATCACACTTATATTTTATGAACATTGTAAGTTGCTTTAATATGAGCTT
 CAATATAAGAAGCAATCTTTGAAATAAAAAAAGATTTTTTTTT

45 SEQ ID NO: 486

>14510 BLOOD Hs.260473 gnl|UG|Hs#S133063 yf99h12.s1 Homo sapiens cDNA, 3' end
 /clone=IMAGE:30797 /clone_end=3' /gb=R42293 /gi=817160 /ug=Hs.260473 /len=471
 TTTTTTTTTTTNTTTCGCTTTATTTTNATTTATTTATTTATTTATTTATTTATNT
 ATATNTGAGACAGAGTCTTAACACTGTNGCCAGGNTGGTAGTGCAATGGCGTG

ATCTCAGCTCACTGCAAGCTCTGCCNCTTGGATTTCATGCCTTTCTCCNGCCTCAGC
 CTCCCGAGTAGCTGGGACTACAGGGGGCCACCACCACGCCAGCTAATTTTTTGT
 ACTTTTAGTAGAGACAGGGTTTTACCNTGTTAGCCAGGGTAGTCTCGATCTCCTG
 ACCTCGTGAGCCGCTGCCTNGGCCTCCCAAAGTGCTGGGATTACAGGCATGAGC
 5 CACCGTGCCTGGGCCACGTCCCTATTTTAGNAAATGAGAGGAGTGACTGCACATA
 GGGAAAAATGCCACTTTTAGGCAATTTCAAAGTGGGAAAAAATTTTTTTATATNA
 AAATTTATNCCAATTNCCACCTTTGG

SEQ ID NO: 487

10 >14521 BLOOD 441403.1 L34789 g514934 Human (clone L6) E-cadherin (CDH1) gene,
 exon 16. 0
 AGCTGCTGTGCCCAGCCTCCATGTTTTAATATCAACTCTCACTCCTGAATTCAGTT
 GCTTTGCCCAAGATAGGAGTTCTCTGATGCAGAAATTATTGGGCTCTTTTAGGGT
 AAGAAGTTTGTGTCTTTGTCTGGCCACATCTTGACTAGGTATTGTCTACTCTGAAG
 15 ACCTTTAATGGCTTCCCTCTTTCATCTCCTGAGTATGTAACCTTGCAATGGGCAGCT
 ATCCAGTGACTTGTTCTGAGTAAGTGTGTTTATTAATGTTTATTTAGCTCTGAAGC
 AAGAGTGATATACTCCAGGACTTAGAATAGTGCCTAAAGTGCTGCAGCCAAAGA
 CAGAGCGGAATATGAAAAGTGGGCTTGGAGATGGCAGGAGAGCTTGTCAATTGA
 GCCTGGCAATTTAGCAAATGATGCTGAGGATGATTGAGGTGGGTCTACCTCATC
 20 TCTGAAAATTCTGGAAGGAATGGAGGAGTCTCAACATGTGTTTCTGACACAAGAT
 CCGTGGTTTGTACTCAAAGCCCCAGAATCCCCAAGTGCCTGCTTTTGATGATGTCT
 ACAGAAATGCTGGCTGAGCTGAACACATTTGCCCAATTCCAGGTGTGCACAGA
 AAACCCGAGAATATTCAAAATTCCAAATTTTTTTCTTAGGAGCAAGAAGAAATGT
 GGGCCCTAAAGGGGGTTAGTTGAGGGGTAGGGGGTAGTGAGGATCTTGATTTGGA
 25 TCTCTTTTTATTTAAATGTGAATTTCAACTTTTGACAATCAAAGAAAAGACTTTTG
 TTGAAATAGCTTTACTGTTTCTCAAGTGTTTTGGAGAAAAAATCAACCCTGCAA
 TCACTTTTTGGAATTGTCTTGATTTTTTCGGCAGTTCAAGCTATATCGAATATAGTT
 CTGTGTAGAGAATGTCACTGTAGTTTTGAGTGTATACATGTGTGGGTGCTGATAA
 TTGTGTATTTCTTTGGGGGTGGAAAAGGAAAACAATTCAAGCTGAGAAAAGTAT
 30 TCTCAAAGATGCATTTTTATAAATTTTATTAAACAATTTTGTT

SEQ ID NO: 488

>14531 BLOOD 903254.4 U44103 g1174146 Human small GTP binding protein Rab9
 mRNA, complete cds. 0
 35 GTTGTTCCTCCGACGCTGGACGGGAGCAGCTGGAGCGGGAGCCTGGCTGCGCT
 ACCGCGGCTGCCTCCTGCTGTGCAGGTCCCCGACCCTCTCTGTCTCATTGCGC
 CCAGACGGGCGGCCAGAGCTCCCGGGTCGTCTTTCGTGTGGCCGCGAGACACT
 CTTGCACTCCTGTAATGAGCCTGGCACTGTGATGAAACACTTTTCCCGTGTCTGTT
 GAGTGCATCTTCTCAACAACCCTAGGAGGGTTCTTGAAGCTTTTGAGATTAAACA
 40 TGGCAGGAAAATCATCACTTTTTAAAGTAATTCTCCTTGGAGATGGTGGAGTTGG
 GAAGAGTTCACTTATGAACAGATATGTAACATAAAGTTTGATAACCAGCTCTTC
 CATAAATAGGTGTGGAATTTTTAAATAAAGATTTGGAAGTGGATGGACATTTTG
 TTACCATGCAGATTTGGGACACGGCAGGTCAGGAGCGATTCCGAAGCCTGAGGA
 CACCATTTTACAGAGGTTCTGACTGCTGCCTGCTTACTTTTAGTGTGATGATTCA
 45 CAAAGCTTCCAGAACTTAAGTAAGTGAAGAAAGAATTCATATATTATGCAGAT
 GTGAAAGAGCCTGAGAGCTTTCTTTTGTGATTCTGGGTAACAAGATTGACATAA
 GCGAACGGCAGGTGTCTACAGAAGAAGCCCAAGCTTGGTGCAGGGACAACGGCG
 ACTATCCTTATTTTGAAACAAGTGCAAAAGATGCCACAAATGTGGCAGCAGCCTT
 TGAGGAAGCGGTTTGAAGAGTTCTTGCTACCGAGGATAGGTCAGATCATTTGATT

CAGACAGACACAGTCAATCTTCACCGAAAGCCCAAGCCTAGCTCATCTTGCTGTT
GATTGTTAGATTGTTGATGCATTCTAACCAACTCACACATATACACAAAATCAAC
ATGGGGATGGAGAAGAGAATTAGCGTTTGCAGCAGTGTATCATCTACTAATAAA
ATTAACTAATGTTGCTGCTTCATTAGTTGGTGGGAGAAGGGACACATCCACTCT
5 TGGAGGAATATATTTACTCAATAATGGCACCTTACATTTATAAAATTGTAACAGTT
GTCTAATAACGTTTCTTTAATTTAAATATGTAAGTTGCAGAGCTAATAAATGAAA
TGACCAAGACTTTAATTATAATAAAAAATAAGAACTTGACTATTCTAGAAGTTAT
ACTTGGATTTTTTCTGCGGAAAATGGAGAACTACTTTTTATATGTGTATGTTTTTA
TGCAATTAGCATTGTATTCTTGGTTCAGGGAAATACTTTCCTAAAGCAATAATGT
10 TAGATATTAAAGATTAAAATCTAATGTATTTGCAATGCAAAANANANANAAAA

SEQ ID NO: 489

>14654 BLOOD 237623.3 L15203 g402482 Human secretory protein (P1.B) mRNA,
complete cds. 0

15 CCGGAACCAGAACTGGAATCCGCCCTTACCGCTTGCTGCCAAAACAGTGGGGGC
TGAAGTACCTCTCCCCTTTGGGAGAGAAAACTGTCTGGGAGCTTGACAAAGG
CATGCAGGAGAGAACAGGAGCAGCCACAGCCAGGAGGGAGAGCCTTCCCCAAG
CAAACAATCCAGAGCAGCTGTGCAAACAACGGTGCATAAATGAGGCCTCCTGGA
CCATGAAGCGAGTCCTGAGCTGCGTCCCGGAGCCACGGTGGTCATGGCTGCCA
20 GAGCGCTCTGCATGCTGGGGCTGGTCTGCGCTTGCTGTCCTCCAGCTCTGCTGA
GGAGTACGTGGGCCTGTCTGCAAACCAAGTGTGCCGTGCCAGCCAAGGACAGGGT
GGACTGCGGCTACCCCATGTACCCCCAAGGAGTGCAACAACCGGGGCTGCTG
GCTTGACTCCAGGATCCCTGGAGTGCCTTGGTGTTCGAAGCCCTGCAGGAAGCA
GAATGCACCTTCTGAGGCACCTCCAGCTGCCCGCGCGGGGGATGCGAGGCTC
25 GGAGCACCTTGCCCGGCTGTGATTGCTGCCAGGCACTGTTTCATCTCAGCTTTTCT
GTCCCTTTGCTCCCGGCAAGCGCTTCTGCTGAAAGTTCATATCTGGAGCCTGATG
TCTTAACGAATAAAGGTCCCATGCTCCACCCGAGGACAGTTCTTCGTGCCTGAGA
AAAAACAAAGGGGCGGCCG

30 SEQ ID NO: 490

>14709 BLOOD 422524.4 L31409 g493131 Human creatine transporter mRNA, complete
cds. 0

GGCCGTGCGGCCCCGCGGGGCCATGGCGAAGAAGAGCGCCGAGAACGGCATCTA
TAGCGTGTCCGGCGACGAGAAGAAGGGTCTCTCATCTGTCCGGGCGCGATGG
35 TGCCCCGTCCAAGGGCGATGGCCCTGCGGGCCTGGGGGCGCCAGCAGCCGCCT
GGCCGTGCCGCGCGAGACCTGGACGCGCCAGATGGACTTCATCATGTCTGTG
CGTGGGCTTCGCCGTGGGCTTGGGCAACGTGTGGCGCTTCCCCTACCTGTGCTAC
AAGAACGGCGGAGGTGTGTTCTTATTCCCTACGTCCTGATCGCCCTGGTTGGAG
GAATCCCCATTTTCTTCTTAGAGATCTCGCTGGGCCAGTTCATGAAGGCCGGCAG
40 CATCAATGTCTGGAACATCTGTCCCCTGTTCAAAGGCCTGGGCTACGCCTCCATG
GTGATCGTCTTCTACTGCAACACCTACTACATCATGGTGTGCTGGCCTGGGGCTTCT
ATTACCTGGTCAAGTCCTTTACCACCACGCTGCCCTGGGCCACATGTGGCCACAC
CTGGAACACTCCCGACTGCGTGGAGATCTTCCGCCATGAAGACTGTGCCAATGCC
AGCCTGGCCAACCTCACCTGTGACCAGCTTGCTGACCGCCGGTCCCCTGTCATCG
45 AGTTCTGGGAGAACAAAGTCTTGAGGCTGTCTGGGGGACTGGAGGTGCCAGGGG
CCCTCAACTGGGAGGTGACCCCTTGTCTGCTGGCCTGCTGGGTGCTGGTCTACTTC
TGTGTCTGGAAGGGGGTCAAATCCACGGGAAAGATCGTGTACTTCACTGCTACAT
TCCCCTACGTGGTCTGCTGCTGCTGGTGCCTGGAGTGCTGCTGCCTGGCGC
CCTGGATGGCATCATTTACTATCTCAAGCCTGACTGGTCAAAGCTGGGGTCCCCT

CAGGTGTGGATAGATGCGGGGACCCAGATTTTCTTTTCTTACGCCATTGGCCTGG
GGGCCCTCACAGCCCTGGGCAGCTACAACCGCTTCAACAACAACCTGCTACAAGG
ACGCCATCATCCTGGCTCTCATCAACAGTGGGACCAGCTTCTTTGCTGGCTTCGT
GGTCTTCTCCATCCTGGGCTTCATGGCTGCAGAGCAGGGCGTGCACATCTCCAAG
5 GTGGCAGAGTCAGGGCCGGGCCTGGCCTTCATCGCCTACCCGCGGGGCTGTCACGC
TGATGCCAGTGGCCCCACTCTGGGCTGCCCTGTTCTTCTTCATGCTGTTGCTGCTT
GGTCTCGACAGCCAGTTTGTAGGTGTGGAGGGCTTCATCACCGGCCTCCTCGACC
TCCTCCCGGCCTCCTACTACTTCCGTTTCCAAAGGGAGATCTCTGTGGCCCTCTGT
TGTGCCCTCTGCTTTGTCATCGATCTCTCCATGGTGAAGTGTGGCGGGATGTACGT
10 CTTCCAGCTGTTTGACTACTACTCGGCCAGCGGCACCACCCTGCTCTGGCAGGCC
TTTTGGGAGTGCCTGGTGGTGGCCTGGGTGTACGGAGCTGACCGCTTCATGGACG
ACATTGCCTGTATGATCGGGTACCGACCTTGCCCCTGGATGAAATGGTGTGGTC
CTTCTTCAACCCCGCTGGTCTGCATGGGCATCTTCATCTTCAACGTTGTGTACTACG
AGCCGCTGGTCTACAACAACACCTACGTGTACCCGTGGTGGGGTGAGGCCATGG
15 GCTGGGCCTTCGCCCTGTCTCCATGCTGTGCGTGCCGCTGCACCTCCTGGGCTGC
CTCCTCAGGGCCAAGGGCACCATGGCTGAGCGCTGGCAGCACCTGACCCAGCCC
ATCTGGGGCCTCCACCACTTGGAGTACCGAGCTCAGGACGCAGATGTCAGGGGC
CTGACCACCCTGACCCCACTGTCCGAGAGCAGCAAGGTCGTGCTGGTGGAGAGT
GTCATGTGACAACTCAGCTCACATCACCAGCTCACCTCTGGTAGCCATAGCAGCC
20 CCTGCTTCAGCCCCACCGCACCCCTCCAGGGGGCCTGCCTTTCCCTGACACTTTTG
GGGTCTGCCTGGGGGAGGAGGGGAGAAAGCACCATGAGTGCTCACTAAAACAAC
TTTTCCTATTTTAAATAAAACGCCAAAAATATCACAACCCACGAAAAATAGATGC
CTCTCCCCCTCCAGCCCTAGCCGAGCTGGTCTAGGGCCCGCCTAGTGCCCGACC
CCAGCCACAGTGCTGCACTCCTGCTGCGCCTGCCACGCCCACCCCTGCCCGACC
25 TCTCCAGGCTCTGCTCTGCAGCACACCCGTGGGTGACCCCTCACCCAGAAAGCAG
CAGTGGCAGCTTGGGAAATGTGAGGAAGGGAAGGAGGGAGAGACGGGAGGGAG
GAGAGAGAGGAGAAGGGAGGCAGGGGAGGGGCAGCAGAACCAAGGCAAATATT
TCAGCTGGGCTATACCCCTCTCCCCATCCCTGTTATAGAAGCTTAGAGAGCCAGC
CAGCAATGGAACCTTCTGGTTCCTGCGCCAATCGCCACCAGTATCAATTGTGTGA
30 GCTTGGGTGCGAGTGACGCGTGCGTGAGTACGGAGAGTATATATAGATCTCTAT
CTCTTAGCAAAGGTGAATGCCAGATGTAAATGGCGCCTCTGGGCAAAGGAGGCT
TGTATTTTGCACATTTTATAAAAACCTTGAGAGAATGAGATTTCTGCTTGTATATTT
CTAAAAAGAGGAAGGAGCCCAAACCATCCTCTCCTTACCACTCCCATCCCTGTGA
GCCCTACCTTACCCCTCTGCCCCTAGCCAAGGAGTGTGAATTTATAGATCTAACT
35 TTCATAGGCAAAACAAAAGCTTCGAGCTGTTGCGTGTGTGAGTCTGTTGTGTGGA
TGTGCGTGTGTGGTCCCCAGCCCCAGACTGGATTGGAAAAGTGCATGGTGGGGG
CCTCGGGGCTGTCCCCACGCTGTCCCTTTGCCACAAGTCTGTGGGGCAAGAGGCT
GCAATATTCGCTCCTGGGTGTCTGGGCTGCTAACCTGGCCTGCTCAGGCTTCCCA
CCCTGTGCGGGGCACACCCCAAGGAAGGGACCCTGGACACGGCTCCACGTCCA
40 GGCTTAAGGTGGATGCACTTCCCGCACCTCCAGTCTTCTGTGTAGCAGCTTTAAC
CCACGTTTGTCTGTACGTCCAGTCCCGAGACGGCTGAGTGACCCCAAGAAAGGC
TTCCCGACACCCAGACAGAGGCTGCAGGGCTGGGGCTGGGTGAGGGTGGCGGG
CCTGCGGGGACATTCTACTGTGCTAAAAAGCCACTGCAGACATAGCAATAAAAA
CATGTCATTTTCCAAAGCAAAAAA
45

SEQ ID NO: 491

>14753 BLOOD Hs.125359 gnl|UG|Hs#S1973371 Homo sapiens mRNA; cDNA
DKFZp761B15121 (from clone DKFZp761B15121); complete cds /cds=(56,541)
/gb=AL161958 /gi=7328010 /ug=Hs.125359 /len=1791

GGAGGCTGCAGCAGCGGAAGACCCAGTCCAGATCCAGGACTGAGATCCCAGAA
CCATGAACCTGGCCATCAGCATCGCTCTCCTGCTAACAGTCTTGCAGGTCTCCCG
AGGGCAGAAGGTGACCAGCCTAACGGCCTGCCTAGTGGACCAGAGCCTTCGTCT
GGACTGCCGCCATGAGAATACCAGCAGTTCACCCATCCAGTACGAGTTCAGCCTG
5 ACCCGTGAGACAAAGAAGCACGTGCTCTTTGGCACTGTGGGGGTGCCTGAGCAC
ACATACCGCTCCCGAACCAACTTCACCAGCAAATACAACATGAAGGTCCTCTACT
TATCCGCCTTCACTAGCAAGGACGAGGGCACCTACACGTGTGCACTCCACCACTC
TGGCCATTCCCCACCCATCTCCTCCAGAACGTCACAGTGCTCAGAGACAACTG
GTCAAGTGTGAGGGCATCAGCCTGCTGGCTCAGAACACCTCGTGGCTGCTGCTGC
10 TCCTGCTCTCCCTCTCCCTCCTCCAGGCCACGGATTTTCATGTCCCTGTGACTGGTG
GGGCCCATGGAGGAGACAGGAAGCCTCAAGTTCAGTGCAGAGATCCTACTTCT
CTGAGTCAGCTGACCCCCCTCCCCGCAATCCCTCAAACCTTGAGGAGAAGTGGGG
ACCCACCCCTCATCAGGAGTTCAGTGCTGCATGCGATTATCTACCCACGTCCA
CGCGGCCACCTCACCTCTCCGCACACCTCTGGCTGTCTTTTTGTACTTTTTGTTC
15 CAGAGCTGCTTCTGTCTGGTTTATTTAGGTTTTATCCTTCCTTTTCTTTGAGAGTTC
GTGAAGAGGGGAAGCCAGGATTGGGGACCTGATGGAGAGTGAGAGCATGTGAGG
GGTAGTGGGATGGTGGGGTACCAGCCACTGGAGGGGTTCATCCTTGCCCATCGGG
ACCAGAAACCTGGGAGAGACTTGATGAGGAGTGGTTGGGCTGTGCCTGGGCCT
AGCACGGACATGGTCTGTCCTGACAGCACTCCTCGGCAGGCATGGCTGGTGCCTG
20 AAGACCCAGATGTGAGGGCACCACCAAGAATTTGTGGCCTACCTTGTGAGGGA
GAGAACTGAGCATCTCCAGCATTCTCAGCCACAACCAAAAAAAAAAATAAAAAGGG
GAGCCCTCCTTACCACTGTGGAAGTCCCTCAGAGGCCTTGGGGCATGACCCAGTG
AAGATGCAGGTTTGACCAGGAAAGCAGCGCTAGTGGAGGGTTGGAGAAGGAGG
TAAGGATGAGGGTTCATCATCCCTCCCTGCGTAAGGAAGCTAAAGCATGGCCCT
25 GCTGCCCCCTCCCTGCCTCCACCCACAGTGGAGAGGGCTACAAAGGAGGACAAGA
CCCTCTCAGGCTGTCCCAAGCTCCCAAGAGCTTCCAGAGCTCTGACCCACAGCCT
CCAAGTCAGGTGGGGTGGAGTCCCAGAGCTGCACAGGGTTTGGCCCAAGTTTCT
AAGGGAGGCACTTCCTCCCTCGCCCATCAGTGCCAGCCCCTGCTGGCTGGTGCC
TGAGCCCCTCAGACAGCCCCCTGCCCCGAGGCCTGCCTTCTCAGGGACTTCTGC
30 GGGGCCTGAGGCAAGCCATGGAGTGAGACCCAGGAGCCGGACACTTCTCAGGAA
ATGGCTTTTCCCAACCCCCAGCCCCACCCGGTGGTTCTTCCTGTTCTGTGACTGT
GTATAGTGCCACCACAGCTTATGGCATCTCATTGAGGACAAAGAAAACCTGCACA
ATAAAACCAAGCCTCTGGAATCTAAAAAAAAAAAAAAAAAAAAA

35 SEQ ID NO: 492

>14789 BLOOD 221059.6 M16768 g339399 Human T-cell receptor gamma chain VJCI-CII-
CIII region mRNA, complete cds. 0

CCCAGTGCTGCAGGCTGTGTGGGTAGCTGAGCAGAGCTAAGCGGCTTGACGGAC
CAACATCTCTCCAGCTGGTTGAAGACAAGCTCTCAGAAGACAATGCTGCATGTCA
40 CAGCCCCAGCAACCAACAACACCAGCCTGACAACCTTGTGGGGTGGCCGCCTTG
TGGTCTGAGGTGGCCGTCTAAACTATGTGGTCTGATCTCAGGCTGCAGACCTTGC
AGGACTGTCTTCACACAGACTGGAAGTGCTAACAGGTGGTGAGGACACCGCTTT
ACAACGATGCAGGGGGGCCCATGTACCCCTCACCCATGGGAAGTTTGACTTGGTG
GACTCAGCCAAGCCACAGAGGTCTAACGCTTCTCTGCGGTGATTCAGGCTGCCC
45 TGGCAGAAAGCACAGTGCCTGCAGACATGCTGTCACTGCTCCACACATCAACGCT
GGCAGTCCTTGGGGCTCTGTGTGTATATGGTGCAGGTACCTAGAGCAACCTCAA
ATTTCCAGTACTAAAACGCTGTCAAAAACAGCCCGCCTGGAATGTGTGGTATCTG
GAATAACAATTTCTGCAACATCTGTATATTGGTATCGAGAGAGACCTGGTGAAGT
CATACAGTTCCTGGTGTCCATTTTCATATGACGGCACTGTCAGAAAGGAATCCGGC

ATTCGTCAGGCAAATTTGAGGTGGATAGGATACCTGAAACGTCTACTACCACTC
TCACCATTACAATGTAGAGAAACAGGACATAGCTACCTACTACTGTGCCTTGTG
GGAGGTGTAACCTTTCGAATTATTATAAGAACTCTTTGGCAGTGGAACAACACTT
GTTGTCACAGATAAAACAACCTTGATGCAGATGTTTCCCCCAAGCCCACTATTTTCT
5 TCCTTCAATTGCTGAAACAAAGCTCCAGAAGGCTGGAACATACCTTTGTCTTCTT
GAGAAATTTTTCCTGATGTTATTAAGATACATTGGCAAGAAAAGAAGAGCAAC
ACGATTCTGGGGATCCCAGGAGGGGAACACCATGAAGACTAACGACACATACAT
GAAATTTAGCTGGTTAACGGTGCCAGAAAAGTCACTGGACAAAGAACACAGATG
TATCGTCAGACATGAGAATAATAAAAACGGAGTTGATCAAGAAATTATCTTTCT
10 CCAATAAAGACAGATGTCATCACAATGGATCCCAAAGACAATTGTTCAAAAGAT
GCAAATGATACACTACTGCTGCAGCTCACAAACACCTCTGCATATTACACGTACC
TCCTCCTGCTCCTCAAGAGTGTGGTCTATTTTGCCATCATCACCTGCTGTCTGCTT
AGAAGAACGGCTTTCTGCTGCAATGGAGAGAAATCATAACAGACGGTGGCACA
GGAGGCCATCTTTTCTCATCGGTTATTGTCCCTAGAAGCGTCTTCTGAGGATCTA
15 GTTGGGCTTTCTTTCTGGGTTTGGGCCATTTTCAGTTCTCATGTGTGTACTATTCTAT
CATTATTGTATAACGGTTTTCAAACCAGTGGGCACACAGAGAACCTCACTCTGTA
ATAACAATGAGGAATAGCCACGGCGATCTCCAGCACCAATCTCTCCATGTTTTCC
ACAGCTCCTCCAGCCAACCCAAATAGCGCCTGCTATAGTGTAGACATCCTGCGGC
TTCTAGCCTTGTCCCTCTCTTAGTGTTCTTTAATCAGATAACTGCCTGGAAGCCTT
20 TCATTTTACACGCCCTGAAGCAGTCTTCTTTGCTAGTTGAATTATGTGGTGTGTTT
TTCCGTAATAAGCAAAATAAATTTAAAAAATGAAAAGTT

SEQ ID NO: 493
14796 BLOOD 1008401.6 M17783.g183063 Human glia-derived nexin (GDN) mRNA, 5'

25 end. 0
GGACGGCAGGACCAAGAAGCAGCTCGCCATGGTGGAAAGGAACCATGAACTGGC
ATCTCCCCCTCTTCCTCTTGGCCTCTGTGACGCTGCCTTCCATCTGCTCCCACTTCA
ATCCTCTGTCTCTCGAGGAAGTGGCTCCAACACGGGGATCCAGGTTTCAATCA
GATTGTGAAGTCGAGGCCTCATGACAACATCGTGATCTCTCCCATGGGATTGCG
30 TCGGTCTGGGGACGCTTCAGCTGGGGGCGGACGGCAGGACCAAGAAGCAGCTC
GCCATGGTGTGATGAGATACGGCGTAAATGGAGTTGGTAAATATTAAAGAAGATC
AACAAGGCCATCGTCTCCAAGAAGAATAAAGACATTGTGACAGTGGCTAACGCC
GTGTTTGTAAAGAATGCCTCTGAAATTGAAGTGCCTTTTGTACAAGGAACAAAG
ATGTGTTCCAGTGTGAGGTCCGGAATGTGAACTTTGAGGATCCAGCCTCTGCCTG
35 TGATTCCATCAATGCATGGGTAAAAACGAAACCAGGGATATGATTGACAATCT
GCTGTCCCAGATCTTATTGATGGTGTGCTCACCAGACTGGTCCTCGTCAACGCA
GTGTATTTCAGGGTCTGTGGAAATCACGGTTCCAACCCGAGAACACAAAGAAA
CGCACTTTCGTGGCAGCCGACGGGAAATCCTATCAAGTGCCAATGCTGGCCCAGC
TCTCCGTGTTCCGGTGTGGGTCGACAAGTGCCCCCAATGATTTATGGTACAACCTT
40 CATTGAACTGCCCTACCACGGGGAAAGCATCAGCATGCTGATTGCACTGCCGACT
GAGAGCTCCACTCCGCTGTCTGCCATCATCCACACATCAGCACCAAGACCATAG
ACAGCTGGATGAGCATCATGGTGCCCAAGAGGGTGCAGGTGATCCTGCCCAAGT
TCACAGCTGTAGCACAAACAGATTTGAAGGAGCCGCTGAAAGTTCTTGGCATTAC
TGACATGTTTGATTTCATCAAAGGCAAATTTTGCAAAAATAACAAGGTCAGAAAA
45 CCTCCATGTTTCTCATATCTTGCAAAAAGCAAAAATTGAAGTCAGTGAAGATGGA
ACCAAAGCTTCAGCAGCAACAACCTGCAATTCTCATTGCAAGATCATCGCTCCCT
GGTTTATAGTAGACAGACCTTTTCTGTTTTTCATCCGACATAATCCTACAGGTGCT
GTGTTATTCATGGGGCAGATAAACAACCCCTGAAGAGTATACAAAAGAAACCAT

SEQ ID NO: 494

>14808 BLOOD 336093.2 X12830.1 g33845 Human mRNA for interleukin-6 (IL-6)

receptor. 0

5 GGCGGTCCCCTGTTCTCCCCGCTCAGGTGCGGCGCTGTGGCAGGAAGCCACCCCC
TCGGTCGGCCGGTGCGCGGGGCTGTTGCGCCATCCGCTCCGGCTTTTCGTAACCGC
ACCCTGGGACGGCCCAGAGACGCTCCAGCGCGAGTTCCTCAAATGTTTTCTGCG
TTGCCAGGACCGTCCGCCGCTCTGAGTCATGTGCGAGTGGGAAGTCGCACTGACA
CTGAGCCGGGCCAGAGGGAGAGGAGCCGAGCGCGGCGCGGGGCCGAGGGACTC
GCAGTGTGTGTAGAGAGCCGGGCTCCTGCGGATGGGGGCTGCCCCCGGGGCCTG
10 AGCCCGCCTGCCCGCCACCGCCCCGCCCCGCCCCCTGCCACCCCTGCCGCCCGGT
TCCCATTAGCCTGTCCGCCTCTGCGGGACCATGGAGTGGTAGCCGAGGAGGAAG
CATGCTGGCCGTCGGCTGCGCGCTGCTGGCTGCCCTGCTGGCCGCGCCGGGAGCG
GCGCTGGCCCCAAGGCGCTGCCCTGCGCAGGAGGTGGCGAGAGGCGTGCTGACC
AGTCTGCCAGGAGACAGCGTGACTCTGACCTGCCCGGGGGTAGAGCCGGAAGAC
15 AATGCCACTGTTCACTGGGTGCTCAGGAAGCCGGCTGCAGGCTCCCACCCAGCA
GATGGGCTGGCATGGGAAGGAGGCTGCTGCTGAGGTCGGTGCAGCTCCACGACT
CTGGAAACTATTTCATGCTACCGGGCCGGCCGCCAGCTGGGACTGTGCACTTGCT
GGTGGATGTTCCCCCGAGGAGCCCCAGCTCTCCTGCTTCCGGAAGAGCCCCCTC
AGCAATGTTGTTTGTGAGTGGGGTCCTCGGAGCACCCCATCCCTGACGACAAAGG
20 CTGTGCTCTTGGTGAGGAAGTTTCAGAACAGTCCGGCCGAAGACTTCCAGGAGCC
GTGCCAGTATTCCCAGGAGTCCCAGAAGTTCTCCTGCCAGTTAGCAGTCCCGGAG
GGAGACAGCTCTTTCTACATAGTGTCCATGTGCGTCCGCACTAGTGTCCGGAGCA
AGTTTCAGCAAACTCAAACCTTTCAGGGTTGTGGAATCTTGCAGCCTGATCCGCC
TGCCAACATCACAGTCACTGCCGTGGGAGAGAAACCCCGCTGGCTCAGTGTCAAC
25 TGGCAAGACCCCCACTCCTGGAACATCATCTTTCTACAGACTACGGTTTGAGCTCA
GATATCGGGCTGAACGGTCAAAGACATTACAAACATGGATGGTCAAGGACCTCC
AGCATCACTGTGTATCCACGACGCCTGGAGCGGCCTGAGGCACGTGGTGCAGC
TTCGTGCCCAGGAGGAGTTCGGGCAAGGCGAGTGGAGCGAGTGGAGCCCCGAGG
CCATGGGCACGCCTTGGACAGAATCCAGGAGTCCTCCAGCTGAGAACGAGGTGT
30 CCACCCCCATGCAGGCACTTACTACTAATAAAGACGATGATAATATTCTCTTCAG
AGATTCTGCAAATGCGACAAGCCTCCAGTGCAAGATTCTTCTTCAGTACCACTG
CCCACATTCTGGTTGCTGGAGGGAGCCTGGCCTTCGGAACGCTCCTCTGCATTG
CCATTGTTCTGAGGTTCAAGAAGACGTGGAAGCTGCGGGCTCTGAAGGAAGGCA
AGACAAGGATGCATCCGCGTACTCTTTGGGGCAGCTGGTCCCGGAGAGGCCTC
35 GACCCACCCCACTGCTTGTTCCTCTCATCTCCCCACCGGTGTCCCCCAGCAGCCTG
GGGTCTGACAATACCTCGAGCCACAACCGACCAGATGCCAGGGACCCACGGAGC
CCTTATGACATCAGCAATACAGACTACTTCTTCCCCAGATAGCTGGCTGGGTGGC
ACCAGCAGCCTGGACCCTGTGGATGACAAAACACAAACGGGCTCAGCAAAAGAT
GCTTCTCACTGCCATGCCAGCTTATCTCAGGGGTGTGCGGCCTTTGGCTTCACGG
40 AAGAGCCTTGCGGAAGGTTCTACGCCAGGGGAAAATCAGCCTGCTCCAGCTGTT
CAGCTGGTTGAGGTTTCAAACCTCCCTTTCCAAATGCCAGCTTAAAGGGGTTAG
AGTGAACCTGGGCCACTGTGAAGAGAACCATATCAAGACTCTTTGGACACTCAC
ACGGACACTCAAAGCTGGGCAGGTTGGTGGGGGCTCGGTGTGGAGAAGCGGC
TGGCAGCCCACCCCTCAACACCTCTGCACAAGCTGCACCCTCAGGCAGGTGGGAT
45 GGATTTCCAGCCAAAGCCTCCTCCAGCCGCCATGCTCCTGGCCCACTGCATCGTT
TCATCTTCCAACCTCAAACCTCTTAAAACCCAAGTGCCCTAGCAAATTCTGTTTTCT
AGGCCTGGGGACGGCTTTTACTTAAACCGCCAAGGCTGGGGGAAGAAGCTCTCT
CCTCCCTTTCTTCCCTACAGTTGAAAAACAGCTGAGGGTGAGTGGGTGAATAATA
CAGTATCTCAGGGCCTGGTCGTTTTCAACAGAATTATAATTAGTTCCTCATTAGC

ATTTTGCTAAATGTGAATGATGATCCTAGGCATTTGCTGAATACAGAGGCAACTG
 CATTGGCTTTGGGTTGCAGGACCTCAGGTGAGAAGCAGAGGAAGGAGAGGAGAG
 GGGCACAGGGTCTCTACCATCCCCTGTAGAGTGGGAGCTGAGTGGGGGATCACA
 GCCTCTGAAAACCAATGTTCTCTCTTCTCCACCTCCCACAAAGGAGAGCTAGCAG
 5 CAGGGAGGGCTTCTGCCATTTCTGAGATCAAAACGGTTTTACTGCAGCTTTGTTT
 GTTGTGAGCTGAACCTGGGTAAGTAAAGGATAATATTAAGGAAGACAATGTG
 AAAAGAAAAATGAGCCTGGCAAGAATGCGTTTAAACTTGGTTTTTAAAAAACTG
 CTGACTGTTTTCTCTTGAGAGGGTGGAATATCCAATATTCGCTGTGTGTCAGCATAG
 AAGTAACTTACTTAGGTGTGGGGGAAGCACCATAACTTTGTTTAGCCCAAAACCA
 10 AGTCAAGTGAAAAAGGAGGAAGAGAAAAAATATTTTCCTGCCAGGCATGGTGGC
 CCACGCACTTCGGGAGGTCGAGGCAGGA

SEQ ID NO: 495

ye38d08.r1 Stratagene lung (#937210) Homo sapiens cDNA clone IMAGE:120015 5' similar
 15 to SP:NINS_DROME P10677 NINAC SHORT PROTEIN; mRNA sequence

gi|728449|gb|T94961.1|T94961|728449]
 TGATTGAGGAAATTGGATACAACTGTGTAGCAGACATCTGGTCCCTGGGAATAAC
 TGCCATAGAAATGGCTGAAGGAAAGCCCCCTTATGCTGATATCCATCCAATGAG
 GGCAATCTTCATGATTCTACAAATCCTCCTCCACATTCCGAAAACCAGAGCTA
 20 TGGTCAGATAACTTTACAGATTTTGTGAAACAGTGTCTTGTAAGAGCCCTGAGC
 AGAGGGCCACAGCCACTTCAGGTTCTGCAGGCACCCATTTGTTTACAGGGAGTTGC
 CAAAGGGAGTGTTCATTATTGGGAGGATTTAATTTAATGGAAGGGCATGGGAT
 GTGGAAATTGNAAACGCCAGGGGNTTCCAGCAGCGGGGAAGTNGGACCGGGG
 NCGTTGAAGGAAAATTTGAGGAAGNCGGTTGAATTTGGGT TTNTTGGT

SEQ ID NO: 496

>14817 BLOOD 348110.1 X03795 g35365 Human mRNA for platelet derived growth factor
 A-chain (PDGF-A). 0

CCCAGACTCCCTCCGGAGTTCTTCTTGGGGCTGATGTCCGCAAATATGCAGAATT
 30 ACCGGCCGGGTGCTCCTGAAGCCAGCGCGGGGAGCGAGCGCGGCGGGCGGCCAG
 CACCGGGAACGCACCGAGGAAGAAGCCCAGCCCCCGCCCTCCGCCCCCTTCCGTC
 CCCACCCCCATCCCGGCGGCCAGGAGGCTCCCCGCGCTGGCGCGCACTCCCTGT
 TTCTCCTCCTCCTGGCTGGCGCTGCCTGCCTCTCCGCACTACTGCTCGCAGCCGG
 GCGCGCTCCGCCAGCTCCGTGCTCCECCGCGCCACCCTCCTCCGGGCGCGCTCCC
 35 TAAGGGATGGTACTGAATTCGCCGCCACAGGAGACCGGCTGGAGCGCCCGCCC
 CGCGGCCTCGCCTCTCCTCCGAGCAGCCAGCGCCTCGGGACGCGATGAGGACCTT
 GGCTTGCTGCTGCTCCTCGGCTGCGGATACCTCGCCCATGTTCTGGCCGAGGAA
 GCCGAGATCCCCCGCGAGGTGATCGAGAGGCTGGCCCGCAGTCAGATCCACAGC
 ATCCGGGACCTCCAGCGACTCCTGGAGATAGACTCCGTAGGGAGTGAGGATTCTT
 40 TGGACACCAGCCTGAGAGCTCACGGGGTCCATGCCACTAAGCATGTGCCCCGAGA
 AGCGGCCCTGCCATTTCGGAGGAAGAGAAGCATCGAGGAAGCTGTCCCCGCTG
 TCTGCAAGACCAGGACGGTCATTTACGAGATTCTCCTCGGAGTCAGGTCGACCCAC
 GTCCGCCAACTTCCTGATCTGGCCCCCGTGCGTGGAGGTGAAACGCTGCACCGGC
 TGCTGCAACACGAGCAGTGTCAAGTGCCAGCCCTCCCGCGTCCACCACCGCAGC
 45 GTCAAGGTGGCCAAGGTGGAATACGTCAGGAAGAAGCCAAAATTAAAAGAAGT
 CCAGGTGAGGTTAGAGGAGCATTTGGAGTGCGCCTGCGCGACCACAAGCCTGAA
 TCCGGATTATCGGGAAGAGGACACGGGAAGGCCTAGGGAGTCAGGTAAAAAAC
 GGAAAAGAAAAAGGTTAAAACCCACCTAAAGCAGCCAACCAGATGTGAGGTGA
 GGATGAGCCGCAGCCCTTTCCTGGGACATGGATGTACATGCCGTGTTACATTCTT

5

10

CCGGCCGGGCGCGCCGAGCCCGAGCCCCAGCCGGAGCGGGGCGGGGGAGGGAG
GAGCCAGAGCGGCCCGCCGCTCTGCCGGAGGAGCCGCGGGGCCGCCACACTCG

15

25

35

TGGGAGGCTGGGGGAGCTGTGTCCTGCAGTTCCCAGGACCCCATCCTCTCAGAAG
GTAGGGGAAGGGCGGGAGGATTGAGAAGGGACAAGCCACCTTGACCGTAGGGG
AAGGAGGAATGTGGGCTGGGGGAAGATGCCCTCAACTACCCCCCTACACACACA
TGAGAGAGAGCCCCCAGGTTCTTGGCCTAGGTCTCCCCTCCAGGCTGAGGG
5 CCTCTCTACTTCCCCAGATGCCTGGGTGCAAAGAACGGCTTGGCTTGGCTCCTCC
TCTGGAGGTTAAAATTTATAGTCATTCTAACTGCACTTTGGAAACCAAGCAAGGG
GAGAAGACAAATGAAGAAAACTAGACAGAGAGAAAAATACAAAAAAGAGAG
AGCGAGCGATAGAGAGAGATGATATTAAGTTATTAAGTGAAGGCTGACCAGAGGG
GAGGACCCCCCTTTACCACCCCATGCACTTTGCGAGCTGCCCCCTTCTTCCCCCAC
10 ATCAGAGAGAAATGCCCCCACACCAGAGCCCCCTTCTCCTGGTGGCGGGTCTGCA
GGGCTGGGAGAGGGCAGGGCGTTGTGAGAGAGAGACCGTCCATAAGGAGGACA
GTAATCCTGTCCTGGGAACCTCTGGGCGGGGGGGAGGGGGACACTGCCCAGA
GGCGC

15 SEQ ID NO: 498

>14849 BLOOD 403113.1 M26685 g186569 Human IsK protein (exhibiting a slowly
activating channel activity) gene, complete cds, clone pHKI2. 0

GGGAACAACGCATTTGACACTTGAAGGATACACTACCGGATCCTCCGAGGGT
GATGGTTCTCAAGAAGGCAGAAGCAATGGTGACCAATAGACCTCCTTAAAGGCT
20 GAGCCGCTGGGCACCTTCTACTCCTCTCGACCGTGCTAGGATGACTGCAGCAGA
GTCCCCGAGTCCTTTGATGCAAGGGTCTAGCAACCACCAACAGACAAGCCCTTC
GGCCTGTCTTGGAGGGCGTTGAATGGCATGGCCTGGAGCTCAACCAGGAGAAAGG
GTGCTCAGGAGGAAGAGACCAGAAGGATAAAGTCAAAAAAGTTCTGAGAAAGTTCT
AAGACCACCTGAAGAGAAGGAGGCTGCTGCCAATGGTGTGGACACCGCAGTGTG
25 CTTGAGGAGACTTCAGAAACGAGAACTGTTTCACACAATCATCAGGTGAGCCGA
GGATCCATTGGAGGAAGGCATTATCTGTATCCAGAGGAAATAGCCAAGGATATT
CAGAGGTGTGCCTGGGAAGTTTGAAGTGCAGCAGTGGAAACCTTAATGCCCAGGA
TGATCCTGTCTAACACCACAGCGGTGACGCCCTTTCTGACCAAGCTGTGGCAGGA
GACAGTTCAGCAGGGTGGCAACATGTCCGGGCTGGCCCCGAGGTCCCCCGCAG
30 CGGTGACGGCAAGCTGGAGGCCCTCTACGTCTCATGGTACTGGGATTCTTCGGC
TTCTTCAACCCTGGGCATCATGCTGAGCTACATCCGCTCCAAGAAGCTGGAGCACT
CGAACGACCCATTCAACGTCTACATCGAGTCCGATGCCTGGCAAGAGAAGGACA
AGGCCTATGTCCAGGCCCCGGTCTGGAGAGCTACAGGTCTGTGCTATGTCGTTGA
AAACCATCTGGCCATAGAACAACCCAACACACACCTTCTGAGACGAAGCCTTC
35 CCCATGAACCCCACTGGCTAAA

SEQ ID NO: 499

>14852 BLOOD 474647.3 M27492 g186289 Human interleukin 1 receptor mRNA, complete
cds. 0

GTACCAGCTGGGGCCGTCCGGCAAGATGTGAGTTGTCACCTCTGCTGCGGCACAG
ACCTGAATTAACAACTCTAGCTAGGGCTGACTTCAAAAAGCACTTTCGTTTTTA
ATAACCAACATCAGCTCAGCAGGCTTCATTTGGGAAAAGAAACCTTGTCTGGATTA
CCCCGACATTCTCCACCTCCTGGGAGGCCAGCCATTCCCAAATGCCCAAGGATG
AAGAACGGAGACGGTAGACGCACCTCTGAAGATGGTGAAGTCCCTCCTGAGAAG
45 CTGGACCCCTTGGTAAAAGACAAGGCCTTCTCCAAGAAGAATATGAAAGTGTTA
CTCAGACTTATTTGTTTCATAGCTCTACTGATTTCTTCTCTGGAGGCTGATAAATG
CAAGGAACGTGAAGAAAAAATAATTTTAGTGTCATCTGCAAATGAAATTGATGT
TCGTCCCTGTCTCTTAACCCAAATGAACACAAAGGCACTATAACTTGGTATAAA
GATGACAGCAAGACACCTGTATCTACAGAACAAGCCTCCAGGATTCATCAACAC

AAAGAGAAGCTTTGGTTTGTTCCTGCTAAGGTGGAGGATTCAGGACATTACTATT
GCGTGGTAAGAAATTCATCTTACTGCCTCAGAATTAATAAGTGCAAAATTTGT
GGAGAATGAGCCTAACTTATGTTATAATGCACAAGCCATATTTAAGCAGAAACT
ACCCGTTGCAGGAGACGGAGGACTTGTGTGCCCTTATATGGAGTTTTTTAAAAAT
5 GAAAATAATGAGTTACCTAAATTACAGTGGTATAAGGATTGCAAACCTCTACTTC
TTGACAATATACACTTTAGTGGAGTCAAAGATAGGCTCATCGTGATGAATGTGGC
TGAAAAGCATAGAGGGAACTATACTTGTGCATGCATCCTACACATACTTGGGCAA
GCAATATCCTATTACCCGGGTAATAGAATTTATTACTCTAGAGGAAAACAAACCC
ACAAGGCCTGTGATTGTGAGCCCAGCTAATGAGACAATGGAAGTAGACTTGGGA
10 TCCCAGATACAATTGATCTGTAATGTCAACCGGCCAGTTGAGTGACATTGCTTACT
GGAAGTGGAATGGGTGAGTAATTGATGAAGATGACCCAGTGCTAGGGGAAGACT
ATTACAGTGTGGAAAATCCTGCAAAACAAAAGAAGGAGTACCCTCATCACAGTGC
TTAATATATCGGAAATTGAAAGTAGATTTTATAAACATCCATTTACCTGTTTTGCC
AAGAATACACATGGTATAGATGCAGCATATATCCAGTTAATATATCCAGTCACTA
15 ATTTCCAGAAGCACATGATTGGTATATGTGTACGTTGACAGTCATAATTGTGTG
TTCTGTTTTTCATCTATAAAATCTTCAAGATTGACATTGTGCTTTGGTACAGGGATT
CCTGCTATGATTTTCTCCCAATAAAAAGCTTCAGATGGAAAGACCTATGACGCATA
TATACTGTATCCAAAGACTGTTGGGGAAGGGTCTACCTCTGACTGTGATATTTTT
GTGTTTAAAGTCTTGCCCTGAGGTCTTGGA AAAACAGTGTGGATATAAGCTGTTCA
20 TTTATGGAAGGGATGACTACGTTGGGGAAGACATTGTTGAGGTCATTAATGAAA
ACGTAAAGAAAAGCAGAAGACTGATTATCATTTTAGTCAGAGAAACATCAGGCT
TCAGCTGGCTGGGTGGTTCATCTGAAGAGCAATAGCCATGTATAATGCTGTTGT
TCAGGATGGAATTAAGTTGTCTGCTGAGCTGGAGAAAATCCAAGACTATGA
GAAAATGCCAGAATCGATTAAATTCATTAAGCAGAAACATGGGGCTATCCGCTG
25 GTCAGGGGACTTTACACAGGGACCACAGTCTGCAAAGACAAGGTTCTGGAAGAA
TGTCAGGTACCACATGCCAGTCCAGCGACGGTCACCTTCATCTAAACACCAGTTA
CTGTCACCAGCCACTAAGGAGAAACTGCAAAGAGAGGCTCACGTGCCTCTCGGG
TAGCATGGAGAAGTTGCCAAGAGTTCTTTAGGTGCCTCCTGTCTTATGGCGTTGC
AGGCCAGGTATGCCTCATGCTGACITGCAGAGTTCATGGAATGTA ACTATATCA
30 TCCTTTATCCCTGAGGTCACCTGGAATCAGATTATTAAGGGAATAAGCCATGACG
TCAATAGCAGCCCAGGGCACTTCAGAGTAGAGGGCTTGGAAGATCTTTTAAAA
AGGCAGTANNN
NN
NN
35 NNN
NN
NN
NN
CTCTGAATGTTTGAAGTGCCTAAGAAAAGGCATGGAGACAGCGAACTAGAAGAAA
GGGCAAGAAGGAAATAGCCACCGTCTACAGATGGCTTAGTTAAGTCATCCACAG
40 CCCAAGGGCGGGGCTATGCCTTGTCTGGGGACCCTGTAGAGTCACTGACCCTGGA
GCGGCTCTCCTGAGAGGTGCTGCAGGCAAAGTGAGACTGACACCTCACTGAGGA
AGGGAGACATATTCTTGGAGAACTTTCCATCTGCTTGTATTTTCCATACACATCCC
CAGCCAGAAGTTAGTGTCCGAAGACCGAATTTTATTTTACAGAGCTTGAAAACCTC
ACTTCAATGAACAAAGGGATTCTCCAGGATTCCAAAGTTTGAAGTCATCTTAGC
45 TTTCCACAGGAGGGAGAGAACTTAAAAAAGCAACAGTAGCAGGGAATTGATCCA
CTTCTTAATGCTTTCCTCCCTGGCATGACCATCCTGTCCTTTGTTATTATCCTGCAT
TTTACGTCTTTGGAGGAACAGCTCCCTAGTGGCTTCCTCCATCTGCAATGTCCCTT
GCACAGCCCACACATGAACCATCCTTCCCATGATGCCGCTCTTCTGTCATCCCGC
TCCTGCTGAAACACCTCCCAGGGGCTCCACCTGTTCAAGGAGCTGAAGCCCATGCT

TTCCCACCAGCATGTCACTCCCAGACCACCTCCCTGCCCTGTCCTCCAGCTTCCCC
TCGCTGTCCTGCTGTGTGAATTCCCAGGTTGGCCTGGTGGCCATGTCGCCTGCCCC
CAGCACTCCTCTGTCTCTGCTCTTGCCTGCACCCCTCCTCCTCCTTTGCCTAGGAG
GCCTTCTCGCATTTTCTCTAGCTGATCAGAATTTTACCAAATTCAGAACATCCTC
5 CAATTCCACAGTCTCTGGGAGACTTTCCTAAGAGGCGACTTCCTCTCCAGCCTT
CTCTCTCTGGTCAGGCCCCTGCAGAGATGGTGGTGAGCACATCTGGGAGGCTGG
TCTCCCTCCAGCTGGAATTGCTGCTCTCTGAGGGAGAGGCTGTGGTGGCTGTCTC
TGTCCTCACTGCCTTCCAGGAGCAATTTGCACATGTAAACATAGATTTATGTAAT
GCTTTATGTTTAAAAACATTCCCCAATTATCTTATTTAATTTTGAATTATTCTA
10 ATTTTATATATAGAGAAAGTGACCTATTTTTTAAAAAATCACACTCTAAGTTCT
ATTGAACCTAGGACTTGAGCCTCCATTTCTGGCTTCTAGTCTGGTGTCTGAGTAC
TTGATTTTCAGGTCAATAACGGTCCCCCTCACTCCACACTGGCACGTTTGTGAGA
AGAAATGACATTTTGCTAGGAAGTGACCGAGTCTAGGAATGCTTTTATTCAAGAC
ACCAAATTCCAACTTCTAAATGTTGGAATTTTCAAAAATTGTGTTTAGATTTTAT
15 GAAAAACTCTTCTACTTTTCATCTATTCTTTCCCTAGAGGCAAACATTTCTTAAAT
GTTTCATTTTCATTAAAAATGAAAGCCAAATTTATATGCCACCGATTGCAGGACA
CAAGCACAGTTTTAAGAGTTGTATGAACATGGAGAGGACTTTTGGTTTTTATATT
TCTCGTATTTAATATGGGTGAACACCAACTTTTATTTGGAATAATAATTTTCTCC
TAAACAAAAACACATTGAGTTTAAAGTCTCTGACTCTTGCCTTTCCACCTGCTTTCT
20 CCTGGGCCCCGCTTTGCCTGCTTGAAGGAACAGTGCTGTTCTGGAGCTGCTGTTCC
AACAGACAGGGCCTAGCTTTTCAATTTGACACACAGACTACAGCCAGAAGCCCATG
GGAGCAGGGATGTCACGTCTTGAAAAGCCTATFAGATGTTTTACAAATTTAATTT
TGCAGATTTATTTAGTCTGTCAATCCAGAAAATGTGTACGATGCATAGTGGTAAG
AAAGCAAGCCAATTTGGAACTTAGGTTAGTGACAAAATTGGCCAGAGAGTGGG
25 GGTGATGATGACCAAGAATTACAAGTAGAATGGCAGCTGGAATTTAAGGAGGGA
CAAGAATCAATGGATAAGCGTGGGTGGAGGAAGATCCAAACAGAAAAGTGCAA
AGTTATTCCTCATCTTCCAAGGGTTGAATTCTGGAGGAAGAAGACACATTCCTAG
TTCCCGTGAACCTTCCTTTGACTTATTGTCCCCACTAAAACAAAAACAAAACTT
TTAATGCCTTCCACATTAATTAGATTTTCTTGCAGTTTTTTTATGGCATTTTTTTAA
30 AGATGCCCTAAGTGTTGAAGAAGAGTTTGCAAATGCAACAAAATATTTAATTACC
GGTTGTTAAACTGGTTTAGCACAATTTATATTTTCCCTCTCTTGCCTTTCTTATTT
GCAATAAAAGGTATTGAGCCATTTTTTAAATGACATTTTGTATAAATTATGTTTGT
ACTAGTTGATGAAGGAGTTTTTTTTTAACCTGTTTATATAATTTTGCAGCAGAAGCC
AAATTTTTTGTATATTAAAGCACCAAAATTCATGTACAGCATGCATCACGGATCAA
35 TAGACTGTACTTATTTTCCAATAAAAATTTTCAAACCTTTGTACTGTAAAAA

SEQ ID NO: 500

>14870 BLOOD 470771.8 J05038 g190823 Human ras-related C3 botulinum toxin substrate
(rac) mRNA, complete cds. 0

40 CTAGATCGCGAGCGGCCATTTCCCTGTTTCTCTGCAGTTTTTCCTCAGCTTTGGGTGG
TGGCCGCTGCCGGGCATCGGCTTCCAGTCCGCGGAGGGCGAGGCGGCGTGGACA
GCGGCCCCGGCACCCAGCGCCCCGCGCCCGCAAGCCGCGCGCCCGTCCGCCGC
GCCCCGAGCCCGCCGCTTCTATCTCAGCGCCCTGCCGCGCCCGCCGCGGCCAG
CGAGCGGCCCTGATGCAGGCCATCAAGTGTGTGGTGGTGGGAGACGGAGCTGTA
45 GGTAAACTTGCCTACTGATCAGTTACACAACCAATGCATTTCCCTGGAGAATATA
TCCCTACTGTCTTTGACAATTATTCTGCCAATGTTATGGTAGATGGAAAACCGGT
GAATCTGGGCTTATGGGATACAGCTGGACAAGAAGATTATGACAGATTACGCCC
CCTATCCTATCCGCAAACAGATGTGTTCTTAATTTGCTTTTCCCTTGTGAGTCCTG
CATCATTTGAAAATGTCCGTGCAAAGTGGTATCCTGAGGTGCGGCACCACTGTCC

CAACACTCCCATCATCCTAGTGGGAACTAAACTTGATCTTAGGGATGATAAAGAC
ACGATCGAGAACTGAAGGAGAAGAAGCTGACTCCCATCACCTATCCGCAGGGT
CTAGCCATGGCTAAGGAGATTGGTGCTGTAAAATACCTGGAGTGCTCGGCGCTCA
CACAGCGAGGCCTCAAGACAGTGTTTGACGAAGCGATCCGAGCAGTCCTCTGCC
5 CGCCTCCCGTGAAGAAGAGGAAGAGAAAATGCCTGCTGTTGTAAATGTCTCAGC
CCCTCGTTCTTGGTCTGTCCCTTGAACCTTTGTACGCTTTGCTCAAAAAAANC
AAAACAAAANAACAAAAANTAACAACGGTGGAGCCTTCGCACTCAATGCCAACT
TTTTGTTACAGATTAATTTTTCCATAAAACCATTTTTTTGAACCAATCAGTAATTTT
AAGGTTTTGTTTGTCTAAATGTAAGAGTTCAGACTCACATTCTATTAATAATTTAG
10 CCCTAAAATGACAAGCCTTCTTAAAGCCTTATTTTTCAAAGCGCCCCCCCCATT
CTTGTTACAGATTAAGAGTTGCCAAAATACCTTCTGAACTACACTGCATTGTTGTG
CCGAGAACACCGAGCACTGAACTTTGCAAAGACCTTCGTCTTTGAGAAGACGGT
AGCTTCTGCAGTTAGGAGGTGCAGACACTTGCTCTCCTATGTAGTTCTCAGATGC
GTAAAGCAGAACAGCCTCCCGAATGAAGCGTTGCCATTGGAACCTACCAGTGGA
15 GTTAGCAGCACGTGTTCCCGACATAACATTGTACTGTAATGGAGTGAGCGTAGCA
GCTCAGCTCTTTGGATCAGTCTTGTGATTTTCATAGCGAGTTTTCTGACCAGCCCTC
TTTGCCGGCAGCACTTTCTGAACCAGCACANCTGCTTACTTTCCCTCCTAACTGAA
CGAACTTCCTGCTATTACGCCTTGCTGCGCGCTGCTAGCCCGAGCGCCTGCGCGC
GTCTGTCTAGCTTGCTGCACCTCCACACACGCGCATCCACACACGCATCTACGTC
20 TACTTTCTCTGCAGCCACACAACTATCCGCACACGCTGCGACGCACTCTTACC
ACTTACCCTTGGTACCAACGGCAACTGCAAAGCTGTCACGGCGTAACAAACCTC
TTACAAACGGTTAACTCTTCTGCTCAAACCTGCAGCTACGATGACTGCAAAGAAAG
CGTTGGCTATTATCACGGAAAGCTGTTTTCTCTAAGCCTTTTCCCTTCTCTTACAC
CTGCCATGCCTCCCCAAATTGGGCATTTAATTCATCTTTAAACCTGGTTGTTCTGTT
25 AGTCGCTAACTTAGTAAGTGCTTTTCTTATAGA'ACCCCTTCTGACTGAGCAATAT
GCCTCCTTGTATTATAAAATCTTTCTGATAATGCATTAGAAGGTTTTTTTGTGAT
TAGTAAAAGTGCTTTCCATGTTACTTTATTCAGAGCTAATAAGTGCTTTCCTTAGT
TTTCTAGTAACTAGGTGTAAAATCATGTGTTGCAGCTATAGTTTTTAAATATTT
TAGATATTCTTAACTATGAACCTTCTTAACATCACTGTCTTGCCAGATTACCGAC
30 ACTGTCACCTTGACCAATAC

SEQ ID NO: 501

>14871 BLOOD 232589.59 AF077208 g4679029 Human HSPC022 mRNA, complete cds. 0

CTCCTGCCCCACCACCGCTGCTCCTCAGCAGGCGCCTCACCAGCCTCCACACCCC
35 TTGCGCCCCGAGAAACGCGCCTGGGCCCTGAGCTGTGCACCACCGACACTCTCCA
GGCTCCGGACACGATGCAGGCCATCAAGTGTGTGGTGGTGGGAGATGGGGCCGT
GGGCAAGACCTGCCTTCTCATCAGCTACACCACCAACGCCTTTCCCGGAGAGTAC
ATCCCCACCGTGTTTGACAACTATTACGCCAATGTGATGGTGGACAGCAAGCCAG
TGAACCTGGGGCTGTGGGACACTGCTGGGCAGGAGGACTACGACCGTCTCCGGC
40 CGCTCTCCTATCCACAGACGGACGTCTTCTCATCTGCTTCTCCCTCGTCAGCCCA
GCCTCTTATGAGAACGTCCGCGCCAAGTGGTTCCCAGAAGTGCGGCACCACTGCC
CCAGCACACCCATCATCCTGGTGGGCACCAAGCTGGACCTGCGGGACGACAAGG
ACACCATCGAGAACTGAAGGAGAAGAAGCTGGCTCCCATCACCTACCCGCAGG
GCCTGGCACTGGCCAAGGAGATTGACTCGGTGAAATACCTGGAGTGCTCAGCTCT
45 CACCCAGAGAGGCCTGAAAACCGTGTTTCGACGAGGCCATCCGGGCCGTGCTGTG
CCCTCAGCCCACGCGGCAGCAGAAGCGCGCCTGCAGCCTCCTCTAGGGGTTGCA
CCCCAGCGCTCCACCTAGATGGGTCTGATCCTCCAGGATCCCCACCCAAAGCCT
GATGGCACCCCGGCTGGCCATGCTGTCCCCTCCCTGTGGCGTTTCTTAGCAGATG
GCTGCAGAGCTTCGTTGATGGTCTTTTCTGTACTGGAGGCCTCCTGAGGCCAGGA

ACGTGCAAATTTGCAGGTGCTGCATCCCAAGCCCCTCATGCTCCTGCCTTCCTGA
 GGGCCAGAGGGGAGCCCCAGGACCCATTAAGCCACCCCCGTGTTCTGCCGTCA
 GTGCCAACTGCCGCATGTGGAAGCATCTACCCGTTCACTCCAGTCCCACCCACG
 CCTGACTCCCCTCTGGAACTGCAGGCCAGATGGTTGCTGCCACAACCTTGTGTAC
 5 CTTACAGGGATGGGGCTCTTACTCCCTCCTGAGGCCAGCTGCTCTAATATCGATGG
 TCCTGCTTGCCAGAGAGTTCTCTACCCAGCAAAAATGAGTGTCTCAGAAAGTGTG
 CTCCTCTGGCCTCAGTTCTCCTCTTTTGAACAACATAAAAACAAATTTAATTTCT
 ACGCCTCTGGGGATATCTGCTCAGCCAATGGAAAATCTGGGTTCAACCAGCCCCT
 GCCATTTCTTAAGACTTTCTGCTGCACTCACAGGATCCTGAGCTGCACTTACCTGT
 10 GAGAGTCTTCAAACCTTTTAAACCTTGCCAGTCAGGACTTTTGCTATTGCAAATAG
 AAAACCCAACTCAACCTGCTTAAGCAGAAAATAAATTTATTGATTCAAAAAAAA
 AAA

SEQ ID NO: 502

15 >14873 BLOOD 462958.2 M30471 g178133 Human class III alcohol dehydrogenase
 (ADH5) chi subunit mRNA, complete cds. 0
 CGTCAGTGCGCGGCCACCCCGATGTACGCCCCCGCGCCGACCAGAATCCGT
 GAAACATGGCGAACGAGGTTATCAAGTGGCAAGGCTGCAGTTGCTTGGGAGGCT
 GGAAAGCCTCTGCTCCATAGAGGAGATAGAGGTGGCACCCCCAAAGGCTCATGA
 20 AGTTCGAATCAAGATCATTGCCACTGCGGTTTGCCACACCCGATGCCTATAACCT
 GAGTGGAGCTGATCCTGAGGGTTGTTTCCAGTGATCTTGGGACATGAAGGTGCT
 GGAATTGTGGAAAGTGTGTTGGTGAGGGAGTTACTAAGCTGAAGGCGGGTGACACT
 GTCATCCCACTTTACATGCCACAGTGTGGAGAATGCAAATTTGTCTAAATCCTA
 AAACCTAACCTTTGCCAGAAGATAAGAGTCACTCAAGGGAAAGGATTAATGCCAG
 25 ATGGTACCAGCAGATTTACTTGCAAAGGAAAGACAATTTTGCATTACATGGGAA
 CCAGCACATTTTCTGAATACACAGTTGTGGCTGATATCTCTGTTGCTAAAATAGA
 TCCTTTAGCACCTTTGGATAAAGTCTGCCTTCTAGGTTGTGGCATTTCACCCGTT
 ATGGTGTCTGCTGTGAACACTGCCAAGTTGGAGCCTGGCTCTGTTTGTCCGCTCTTT
 GGTCTGGGAGGAGTCGGATTGGCAGTTATCATGGGCTGTAAAGTGGCTGGTGCTT
 30 CCCGGATCATTGGTGTGGACATCAATAAAGATAAATTTGCAAGGGCCAAAGAGT
 TTGGAGCCACTGAATGTATTAACCCTCAGGATTTTAGTAAACCCATCCAGGAAGT
 GCTCATTGAGATGACCGATGGAAGAGTGGACTATTCCTTTGAATGTATGGTAATG
 TGAAGGTCATGAGAGCAGCACTTGAGGCATGTCACAAGGGCTGGGGCGTCAGCG
 TCGTGGTTGGAGTAGCTGCTTCAGGTGAAGAAATTGCEACTGTTCCATTCCAGCT
 35 GGTAACAGGTCGCACATGGAAAGGCACTGCCTTTGGAGGATGGAAGAGTGTAGA
 AAGTGTCCCAAAGTTGGTGTCTGAATATATGTCCAAAAAGATAAAAGTTGATGA
 ATTTGTGACTCACAATCTGTCTTTTGATGAAATCAACAAAGCCTTTGAACTGATG
 CATTCTGGAAAGAGCATTTCGAACTGTTGTAAAGATTTAATTCAAAAGAGAAAAA
 TAATGTCCATCCTGTCGTGATGTGATAGGAGCAGCTTAACAGGCAGGGAGAAGC
 40 GCCTCCAACCTCACAGCCTCGTAGAGCTTCACAGCTACTCCAGAAAATAGGGTTA
 TGTGTGTCATTTCATGAATCTCTATAATCAAGGACAAGGATAATTCAGTCATGAAC
 CTGTTTTCTGGATGCTCCTCCACATAAATAATTGCTAGTTTATTAAGGAATATTTT
 AACATAATAAAAGTAATTTCTACATTTGTGTGGAAATTGTCTTGTTTTATGCTGTC
 ATCATTGTACGGTTTGTCTGCCCATTATCTTCATTCTGCAAGGGAAAGGGAAAG
 45 GAAGCAGGGCAGTGGTGGGTGTCTGAAACCTCAGAAACATAACGTTGAACTTTT
 AAGGGTCTCAGTCCCCGTTGATTAAAGAACAGATCCTAGCCATCAGTGACAAAG
 TTAATCAGGACCCAAGTCTGCTTCTGTGATATTATCTTTAAGGGAGGTACTGTGC
 CTTGTTTCATACCTGTACCCCAAATTCCTAGGATGGCATCTGCCCTTCAGGGGGCA
 CTAAAATGTATTATTGAAACAGCATTCTGGGCTTAAATAGGTGTATGTATGTGT

GGTGTGACTGTACTATTTCTAGTATAGTGAACACTACATACTGAATATCCAAGTTCT
 CAGCACCTACTTTTGTCAAATCTTAACATTTTGCCACTTCGAGATCACATTGCCAT
 TCCCTCCCCTCCAGAGGTAACAATTATCCACAATTTGATGTTTATCATTCTGTGTT
 GTTGTACTTTCACTGTGTATAACCTAAACCATCTACTCTTTAGTACTGTTTTATAT
 5 ATTTTAAAGCCTCATACTTGCTCATTCTACAGCTTTTTTCACTCATTATTGTATAAT
 TATATCTGAAGCTCTCGTTCATTAATTTTAGTCCTGTGTAGCAGAATTCAATTACG
 GGAACCTACCATAATTTATCTGTTCTCCAGTTGAAGGCATGAAGTTGTTGCCAGTT
 TCTGTATTATAAACTGTAGTGGAACATTCTTCTGCATTGGGCTCACTGCGTGTTA
 CCTAAGACGTATCACAGAATAAACACATTTAGCCTTATAGACATTGCCAAATTGC
 10 TCTTCAAAGTAAATGTGAGTTTTTGTGAATTACATGAGTATGGAATGGTGTTTTAT
 TATGACTTTAGTTTGCATTTTCTCAATTCTCGTTAAATCCTTCATTCTAATGGAC
 ATTTTATTGTGAAGAACCTGTTTCATATCCTGTGCTCAACTTTGTATTGAATTATTT
 TTCTCTGAATAATTTTAGGAGTTCTTTTATTCTAGACATCAATCATTGTGAGTTT
 TATATGTTGCAAATATCTTCTAGTCTATCTTGTGACTTTTCTTTTTACTTTATGGTA
 15 TTTTGTGTAATAAAGTTTTAATGTAGTCACATAAAAAAGATGACTAAGAGGGAG
 GACGTTTGGGAGGGGAAAGAGTGTGGGGTGTGGAGATGTGAGCACGCGGCGGG
 GCGCTGAGGGGGGAGCGCGGGAAGTGCGGACGAGGGAGAAAAGAGGGGGGG
 CGGCGCGCGGGTTCGGGGTGGGAGGCGTTTGAGGGCACCCGGGGCATGGAGAGCC
 CGCTGGTGCAGGGGCAGCGCGGGAGGGTGGAGCGAGGGTGATGCCCCGAGTAT
 20 GGGCGAGTCCGGTGTAGAGTCTCTTGTGGGAGGATGTGCGTGGGAGGAGAGGGC
 GGTTGTGCCGCGCGGGTACCGCGCGTGTGATGAAGGTTTGTAGAACGCGCCCCC
 GAGAATGGCATGCCGGTGTGCATGTGAGAGTGGTTCGGGGGG
 SEQ ID NO: 503
 25 >14882 BLOOD 113621.5 AL110197.g5817115 Human mRNA; cDNA DKFZp586J021
 (from clone DKFZp586J021). 0
 AGCCCCCGGGCCCGCCATGGGCGCCGCGGGCCCGCACCCCTGCGGCTGGCGCTCGG
 CCTCCTGCTGCTGGCGACGCTGCTTCGCCCCGGCCGACGCCTGCAGCTGCTCCCCG
 GTGCACCCGCAACAGGCGTTTTGCAATGCAGATGTAGTGATCAGGGCCAAAGCG
 30 GTCAGTGAGAAGGAAGTGGACTCTGGAAACGACATTTATGGCAACCCTATCAAG
 AGGATCCAGTATGAGATCAAGCAGATAAAGATGTTCAAAGGGCCTGAGAAGGAT
 ATAGAGTTTATCTACACGGCCCCCTCCTCGGCAGTGTGTGGGGTCTCGCTGGACG
 TTGGAGGAAAGAAGGAATATCTCATTGCAGGAAAGGCCGAGGGGGACGGCAAG
 ATGCACATCACCTCTGTGACTTCTGCTGCGCTGGGACACCCTGAGCACCACCC
 35 AGAAGAAGAGCCTGAACCACAGGTACCAGATGGGCTGCGAGTGCAAGATCACGC
 GCTGCCCCATGATCCCGTGCTACATCTCCTCCCCGGACGAGTGCCTCTGGATGGA
 CTGGGTACACAGAGAAGAACATCAACGGGCACCAGGCCAAGTTCTTCGCCTGCAT
 CAAGAGAAGTGACGGCTCCTGTGCGTGGTACCGCGGCGCGGGCGCCCCCAAGCA
 GGAGTTTCTCGACATCGAGGACCCATAAGCAGGCCTCCAACGCCCCTGTGGCCA
 40 ACTGCAAAAAAAGCCTCCAAGGGTTTCGACTGGTCCAGCTCTGACATCCCTTCCT
 GGAAACAGCATGAATAAAACACTCATCCCATGGGTCCAAATTAATATGATTCTGC
 TCCCCCTTCTCCTTTTAGACATGGTTGTGGGTCTGGAGGGAGACGTGGGTCCAA
 GGTCCTCATCCCATCCTCCTCTGCCAGGCACTATGTGTCTGGGGCTTCGATCCTT
 GGGTGCAGGCAGGGCTGGGACACGCGGCTTCCCTCCCAGTCCCTGCCTTGGCACC
 45 GTCACAGATGCCAAGCAGGCAGCACTTAGGGATCTCCCAGCTGGGTTAGGGCAG
 GGCCTGGAAATGTGCATTTTGCAAGAACTTTGAGGGTTCGTTGCAAGACTGTGTA
 GCAGGCCTACCAGGTCCCTTTCATCTTGAGAGGGACATGGCCCTTGTTTTCTGCA
 GCTTCCACGCCTCTGCACTCCCTGCCCTGGCAAGTGCTCCCATCGCCCCGGTGC
 CCACCATGAGCTCCAGCACCTGACTCCCCCACATCCAAGGGCAGCCTGGAACC

AGTGGCTAGTTCTTGAAGGAGCCCCATCAATCCTATTAATCCTCAGAATTCCAGT
GGGAGCCTCCCTCTGAGCCTTGTAGAAATGGGAGCGAGAAACCCAGCTGAGCT
GCGTTCCAGCCTCAGCTGAGTCTTTTTGGTCTGCACCCACCCCCCNANCCTGCTCC
CCGCCCACATGCTCCCCAGCTTGCAGGAGGAATCGGTGAGGTCCTGTCTGAGGC
5 TGCTGTCCGGGGCCGGTGGCTGCCCTCAAGGTCCCTTCCCTAGCTGCTGCGGTTG
CCATTGCTTCTTGCCTGTTCTGGCATCAGGCACCTGGATTGAGTTGCACAGCTTTG
CTTTATCCGGGCTTGTGTGCAGGGCCCCGGCTGGGCTCCCCATCTGCACATCCTGA
GGACAGAAAAAGCTGGGTCTTGCTGTGCCCTCCCAGGCTTAGTGTTCCCTCCCTC
AAAGACTGACAGCCATCGTTCTGCACGGGGCTTTCTGCATGTGACGCCAGCTAAG
10 CATAGTAAGAAGTCCAGCCTAGGAAGGGAAGGATTTTGGAGGTAGGTGGCTTTG
GTGACACACTCACTTCTTTCTCAGCCTCCAGGACACTATGGCCTGTTTTAAGAGA
CATCTTATTTTTCTAAAGGTGAATTCTCAGATGATAGGTGAACCTGAGTTGCAGA
TATACCAACTTCTGCTTGTATTTCTTAAATGACAAAGATTACCTAGCTAAGAAAC
TTCCTAGGGAAGTGGGAACCTATGTGTTCCCTCAGTGTGGTTTCCTGAAGCCAG
15 TGATATGGGGGTTAGGATAGGAAGAACTTTCTCGGTAATGATAAGGAGAATCTC
TTGTTTCCTCCCACCTGTGTTGTAAAGATAAACTGACGATATACAGGCACATTAT
GTAAACATACACACGCAATGAAACCGAAGCTTGGCGGCCTGGGCGTGGTCTTGC
AAAATGCTTCCAAAGCCACCTTAGCCTGTTCTATTAGCGGCAACCCCAAAGCAC
CTGTTAAGACTCCTGACCCCCAAGTGGCATGCAGCCCCCATGCCACCGGGACCT
20 GGTCAGCACAGATCTTGATGACTTCCCTTTCTAGGGCAGACTGGGAGGGTATCCA
GGAATCGGCCCCCTGCCCCACGGGCGTTTTTCATGCTGTACAGTGACCTAAAGTTGG
TAAGATGTCATAATGGACCAGTCCATGTGATTTTCAAGTATATACAACCTCCACCAGA
TCCCTCCAAACCCATATAACACCCCAACCCCTGTTTCGCTTCTGTATGGTGATATCAT
ATGTAACATTTACTCCTGTTTCTGCTGATGTTTTTTTTTAATGTTTTGGTTGTTTTT
25 GACATCAGCTGTAATCATTCCCTGTGCTGTGTTTTTTATTACCCTTGGTAGGTATTA
GACTTGCACTTTTTTTTAAAAAAGGTTTCTGCATCGTGGAAGCATTGACCCAGA
GTGGAACGCGTGGCCTATGCAGGTGGATTCCCTCAGGTCTTTCCTTTGGTTCTTTG
AGCATCTTTGCTTTCATTCTGCTCTCCCGTCTTTGGTTCTCCAGTTCAAATTATTGCA
AAGTAAAGGATCTTTGAGTAGGTTCCGTCTGAAAGGTGTGGCCTTTATATTTGAT
30 CCACACACGTTGGTCTTTTAACCGTGCTGAGCAGAAAACAAAACAGGTAAAGAA
GAGCCGGGTGGCAGCTGACAGAGGAAGCCGCTCAAATACCTTACAATAAATAG
TGGCAATATATATATAGTTTAAGAAGGCTCTCCATTTGGCATCGTTTAATTTATAT
GTTATGTTCTAAGCACAGCTCTCTTCTCCTATTTTCATCCTGCAAGCAACTCAAAA
TATTTAAAAATAAAGTTTACATTGTAGTTATTTTCAAATCTTTGCTTGATAAGTATT
35 AAGAAATATTGGACTTGCTGCCGTAATTTAAAGCTCTGTTGATTTTGTTCGGTTT
GGATTTTGGGGGAGGGGAGCACTGTGTTTATGCTGGAATATGAAGTCTGAGACC
TTCCGGTGCTGGGAACACACAAGAGTTGTTGAAAGTTGACAAGCAGACTGCGCA
TGTCTCTGATGCTTTGTATCATTCTTGAGCAATCGCTCGGTCCGTGGACAATAAAC
AGTATTATCAAAGAATGATACAAAGCATCAGAGACATGCGCAGTCTGCTTGTCA
40 ACTTTCAACAACTCTTGTGTG

SEQ ID NO: 504

>14911 BLOOD 337076.6 M36089 g340396 Human DNA-repair protein (XRCC1) mRNA,
complete cds. 0

45 TAATACAGCAAAAAGATTTGCTTTCTCGGCTTCAGTGTGGGCGGTAACCTCCATCG
TGCAATGAGAAAGGCGAATTTCTTCCAGACACCAATCCCGGAGGTGCTTCTGTT
GCTAGGCTCCAGAAAGCAGGGTTCGGACGTCATTGGGAGGCGAGGCTAGAGCG
GGGTTGTGTGTGGCGGAGGGAGGCGGGGCTGGAGGAAACGCTCGTTGCTAAGGA
ACGCAGCGCTCTTCCCGCTCTGGAGAGGCGCGACTGGGCTTGCGCAGTGTGACG

CCGGCGCCGGCGCGCCGGGGTTTGAAAGGCCCGAGCCTCGCGCGCTTGCGCACT
TTAGCCAGCGCAGGGCGCACCCCGCTCCCTCCCACTCTCCCTGCCCCCTCGGACCC
CATACTCTACCTCATCCTTCTGGCCAGGCGAAGCCCACGACGTTGACATGCCGGA
GATCCGCCTCCGCCATGTCGTGTCCTGCAGCAGCCAGGACTCGACTCACTGTGCA
5 GAAAATCTTCTCAAGGCAGACACTTACCGAAAATGGCGGGCAGCCAAGGCAGGC
GAGAAGACCATCTCTGTGGTCTACAGTTGGAGAAGGAGGAGCAGATACACAGT
GTGGACATTGGGAATGATGGCTCAGCTTTCGTGGAGGTGCTGGTGGGCAGTTCAG
CTGGAGGCGCTGGGGAGCAAGACTATGAGGTCTTCTGGTCACCTCATCTTTCAT
GTCCCCTTCCGAGAGCCGCACTGGCTCAAACCCCAACCGCGTTCGCATGTTTGGG
10 CCTGACAAGCTGGTCCGGGCAGCCGCCGAGAAGCGCTGGGACCGGGTCAAATT
GTTTGCAGCCAGCCCTACAGCAAGGACTCCCCCTTGGCTTGAGTTTTGTACGGT
TTCATAGCCCCCAGACAAAGATGAGGCAGAGGCCCGTCCCAGAAGGTGACAG
TGACCAAGCTTGGCCAGTTCGTGTGAAGGAGGAGGATGAGAGCGCCAACCTCTC
TGAGGCCGGGGGCTCTCTTCTTCAGCCGGATCAACAAGACATCCCCAGTCACAGC
15 CAGCGACCCGGCAGGACCTAGCTATGCAGCTGCTACCCTCCAGGCTTCTAGTGCT
GCCTCCTCAGCCTCTCCAGTCTCCAGGGCCATAGGCAGCACCTCCAAGCCCCAGG
AGTCTCCCAAGGGAAGAGGAAGTTGGATTTGAACCAAGAAGAAAAGAAGACC
CCCAGCAAACCACAGCCAGCTGTCGCCATCTGTTCCCAAGAGACCTAAATTGC
CAGTCCAACCTCGTACCCAGCCACAGCCCCAGTCCCTGCCCCAGCACAGGGGG
20 CAGTGACAGGCAAACCCCGAGGAGAAGGCACCGAGCCCAGACGACCCCGAGCT
GGCCCAGAGGAGCTGGGGAAGATCCTTCAGGGTGTGGTAGTGGTGCTGAGTGGC
TTCCAGAACCCCTTCCGCTCCGAGCTGGGAGATAAGGCCCTAGAGCTTGGGGCCA
AGTATEGGGCCAGACTGGACECCGGGACAGCACGCACCTCATCTGTGECTTTGCCAA
CACCECCAAAGTACAGCCAGGTCCTAGGCTGGGAGGCCGCATCGTGCGTAAGGA
25 GTGGGTGCTGGACTGTCACCGCATGCGTCCGGCGGCTGCCCTCCCAGAGGTACCTC
ATGGCAGGGCCAGGTTCCAGCAGTGAGGAGGATGAGGCCTCTCACAGCGGTGGC
AGCGGAGATGAAGCCCCCAAGCTTCCTCAGAAGCAACCCAGACCAAAACCAAG
CCCACTCAGGCAGCTGGACCCAGCTCACCCAGAAGCCCCCAACCCCTGAAGAG
ACCAAAGCAGCCTCACCAGTGCTCCAGGAAGATATAGACATTGAGGGGGTACAG
30 TCAGAAGGACAGGACAATGGGGCGGAAGATTCTGGGGACACAGAGGATGAGCT
GAGGAGGGTGGCAGAGCAGAAGGAACACAGACTGCCCCCTGGCCAGGAGGAGA
ATGGGGAAGACCCGTATGCAGGCTCCACGGATGAGAACACGGACAGTGAGGAA
CACCAGGAGCCTCCTGATCTGCCAGTCCCTGAGCTCCCAGATTTCTTCCAGGGCA
AGCACTTCTTTCTTACGGGGAGTTCCCTGGGGACGAGCGGCGGAAACTCATCCG
35 ATACGTCACAGCCTTCAATGGGGAGCTCGAGGACTATATGAGTGACCGGGTTCA
GTTTGTGATCACAGCACAGGAATGGGATCCAGCTTTGAGGAGGCCCTGATGGA
CAACCCCTCCCTGGCATTTCGTTTCGTCGCCGATGGATCTACAGTTGCAATGAGAAG
CAGAAGTTACTTCCTCACCAGCTCTATGGGGTGGTGCCGCAAGCCTGAAGTATGT
GCTATAC

40

SEQ ID NO: 505

>14916 BLOOD 337528.6 M37763 g189300 Human neurotrophin-3 (NT-3) gene, complete
cds. 0

GCTGGGTGGAGGGAACGACTCGGCAGCCTCTTCTGGCCCTGAGGAAGACGTCGA
45 TATTTTGGCACGAGGGGAGCCACTGAAGGACTACCCTACCCTTGCGAGGGACCG
CAGGAGGTGACGCCCCCTGGGCCTCGGTGGGCGCTTCTGGCGGTTTTTCGATGTGGC
AACCCCATCAGCCAGGATAATGATGAGATCTTACAGGTGAACAAGGTGATGTC
CATCTTGTTTTATGTGATATTTCTCGCTTATCTCCGTGGCATCCAAGGTAAACA
TGGATCAAAGGAGTTTGCCAGAAGACTCGCTCAATTCCCTCATTATTAAGCTGAT

CCAGGCAGATATTTTGA AAAACAAGCTCTCCAAGCAGATGGTGGACGTTAAGGA
 AAATTACCAGAGCACCCTGCCCAAAGCTGAGGCTCCCCGAGAGCCGGAGCGGGG
 AGGGCCCGCCAAGTCAGCATTCCAGCCGGTGATTGCAATGGACACCGAACTGCT
 GCGACAACAGAGACGCTACAACCTACCGCGGGTCCTGCTGAGCGACAGCACCCC
 5 CTTGGAGCCCCCGCCCTTGTATCTCATGGAGGATTACGTGGGCAGCCCCGTGGTG
 GCGAACAGAACATCACGGCGGAAACGGTACGCGGAGCATAAGAGTCACCGAGG
 GGAGTACTCGGTATGTGACAGTGAGAGTCTGTGGGTGACCGACAAGTCATCGGC
 CATCGACATTCGGGGACACCAGGTCACGGTGCTGGGGGAGATCAAAACGGGGCAA
 CTCTCCCGTCAAACAATATTTTTATGAAACGCGATGTAAGGAAGCCAGGCCGGTC
 10 AAAAAACGGTTGCAGGGGTATTGATGATAAACTGGAACCTCTCAGTGCAAAACA
 TCCCAAACCTACGTCCGAGCACTGACTTCAGAGAACAATAAACTCGTGGGCTGG
 CGGTGGATACGGATAGACACGTCTCTGTGTGTGCTTGTGAGAAAAATCGGA
 AGAACATGAATTGGCATCTCTCCCATATATAAATTATTACTTTAAATTATATGAT
 ATGCATGTAGCATATAAATGTTTATATTGTTTTATATATTATAAGTTGACCTTTA
 15 TTTATTAACTTCAGCAACCCTACAGTATATAAGCTTTTTTCTCAATAAAATCAGT
 GTGCTTGCCTTCCCTCAGGCCTCTCCCATCTGTAAAACCTTGTTTTGTGATCCGGC
 TCTCAGGAGTCACTCTGTAAAATCTGTGTACACCAGTATTTTGCATTAGTATTGT
 CAAGGCCATGACTGTTGTTTTAGTAAACTTGTTAAAATCAGATGATGTCAGAGTT
 GTGTATAAACACAGTGTATATC

20

SEQ ID NO: 506

14923 BLOOD 332483.1:M36634.g340264 Human vasoactive intestinal peptide (VIP)
 mRNA, complete cds. 0

25 CATAAAATGATGGGCTTTGAAATGCTGGTCAGGGTAGAGTGAGAAGCACEAGCAG
 GCAGTAACAGCCAACCCTTAGCCATTGCTAAGGGCAGAGAACTGGTGGAGCCTT
 TCTCTTACTCCCAGGACTTCAGCACCTAAGACAGCTCCAAAACAAACCAGAAC
 GTCAGCTCCGGGGGAGCACCAGTGGGCGAGAGGCACAGAAATGGACACCAGA
 AATAAGGCCCAGCTCCTTGTGCTCCTGACTCTTCTCAGTGTGCTCTTCTCACAGAC
 TTCGGCATGGCCTCTTTACAGGGCACCTTCTGCTCTCAGGTTGGGTGACAGAATA
 30 CCCTTTGAGGGAGCAAATGAACCTGATCAAGTTTCATTAAGAAGACATTGAC
 ATGTTGCAAAATGCATTAGCTGAAAATGACACACCCTATTATGATGTATCCAGAA
 ATGCCAGGCATGCTGATGGAGTTTTACCAGTGACTTCAGTAACTCTTGGGTCA
 ACTTTCTGCCAAAAAGTACCTTGAGTCTCTTATGGGAAAACGTGTTAGCAGTAAC
 ATCTCAGAGACCCCTGTACCACTCAAACGTCCTCAGATGCAGTCTTCACTGACA
 35 ACTATACCCGCCTTAGAAAACAAATGGCTGTAAAGAAATATTTGAACTCAATTCT
 GAATGGAAAGAGGAGCAGTGAGGGAGAATCTCCCGACTTCCAGAAGAGTTAGA
 AAAATGATGAAAAAGACCTTTGGAGCAAAGCTGATGACAACTTCCCAGTGAATT
 CTTGAAGGAAAATGATACGCAACATAATTAAATTTTGAGTTCTACATAAGTAATT
 CAAGAAAACAACTTCAATATCCAAACCAAATAAAAAATATTGTGTTGTGAATGTTG
 40 TGATGTATTCTAGCTAATGTAATAACTGTGAAGTTTACATTGTAAATAGTATTTG
 AGAGTTCTAAATTTTGTCTTTAACTCATAAAAAGCCTGCAATTTCATATGCTGTAT
 ATCCTTTCTAACAAAAAATATATTTAATGATAAGTAAATGCTAGGTTAATTCCA
 ATTATATGAGACGTTTTTGGAAAGAGTAGTAATAGAGCAAAATTGATGTGTTTATT
 TATAGAGTGTACTTAATATTCAGGAGAGTAGAACAGATAATCAGTGTGTCTAAA
 45 TTTGAATGTAAAGCAGATGGAATGCTGTGTAAATAAACCTCAAAATGTCTAAGA
 TAGTAACAATGAAGATAAAAAGACATTCTTCCAAAAAGATTTTCAGAAAATATT
 ATGTGTTTCCATATTTTATAGGCAACCTTTATTTTAAATGGTGTTTAAAAAATCT
 CAAATTTGGATTGCTAATCACCAAAGGCTCTCTCCTGATAGTCTTTCAGTTAAGG
 AGAACGACCCCTGCTTCTGACACTGAAACTTCCCTTCTGCTTGTGTTAAGTATGT

GTAAATGTGAAGTGAATGAAACACTCAGTTGTTCAATAATAAATATTTTTGCCA
TAATGACTCAGAATATTGCTTTGGTCATATGAGCTTCCTTCTGTGAAAGTACATTT
GGAGACACAACACTATTTTTCCAAAATAATTTTAAGAAATCAAAGAGAGAAAATAA
AGACCTTGCTTATGATTGCAGAT

5

SEQ ID NO: 507

>14933 BLOOD 332882.1 X58377 g22952 Human mRNA for adipogenesis inhibitory
factor. 0

5 GCTCAGGGGCACATGCCTCCCCTCCCCAGGCCGCGGCCAGCTGACCCTCGGGGCT
10 CCCCCGGCAGCGGACAGGGAAGGGTTAAAGGCCCGGCTCCCTGCCCCCTGCC
CTGGGGAACCCCTGGCCCTGTGGGGACATGAACTGTGTTTGCCGCCTGGTCCTGG
TCGTGCTGAGCCTGTGGCCAGATACAGCTGTCGCCCCTGGGCCACCACCTGGCCC
CCCTCGAGTTTCCCCAGACCCTCGGGCCGAGCTGGACAGCACCGTGCTCCTGACC
CGCTCTCTCCTGGCGGACACGCGGCAGCTGGCTGCACAGCTGAGGGACAAATTC
15 CCAGCTGACGGGGACCACAACCTGGATTCCCTGCCACCCTGGCCATGAGTGCA
GGGGCACTGGGAGCTCTACAGCTCCCAGGTGTGCTGACAAGGCTGCGAGCGGAC
CTACTGTCCTACCTGCGGCACGTGCAGTGGCTGCGCCGGGCAGGTGGCTCTTCCC
TGAAGACCCTGGAGCCCGAGCTGGGCACCCTGCAGGCCCGACTGGACCGGCTGC
TGCGCCGGCTGCAGCTCCTGATGTCCCGCCTGGCCCTGCCCCAGCCACCCCCGGA
20 CCGGCCGGCGCCCCCGCTGGCGCCCCCCTCCTCAGCCTGGGGGGGCATCAGGGCC
GCCACGCCATCCTGGGGGGGCTGCACCTGACACTTGACTGGGCCGTGAGGGGA
CTGCTGCTGCTGAAGACTCGGCTGTGACCCGGGGGCCAAAGCCACCACCGTCTT
CCAAAGCCAGATCTTATTTATTTATTTATTTATTCAGTACTGGGGGCGAAACAGCCAG
GTGATCCCCCGCCATTATCTCCCCCTAGTTAGAGACAGTCCTTCCGTGAGGCCCT
25 GGGGGGCATCTGTGCCTTATTTATACTTATTTATTTTTCAGGAGCAGGGGGTGGGAGG
CAGGTGGACTCCTGGGTCCCCGAGGAGGAGGGGACTGGGGTCCCGGATTCTTGG
GTCTCCAAGAAGTCTGTCCACAGACTTCTGCCCTGGCTCTTCCCCATCTAGGCCTG
GGCAGGAACATATATTATTTATTTAAGCAATTACTTTTCATGTTGGGGTGGGGAC
GGAGGGGAAAGGGAAGCCTGGGTTTTTGTACAAAATGTGAGAAACCTTTGTGA
30 GACAGAGAACAGGGAATTAATGTGTCATACATATCCACTTGAGGGGCGATTTGT
CTGAGAGCTGGGGCTGGATGCTTGGGTAAGTGGGGCAGGGCAGGTGGAGGGGAG
ACCTCCATTGAGGTGGAGGTCCCGAGTGGGCGGGGCAGCGACTGGGAGATGGGT
CGGTACCCAGACAGCTCTGTGGAGGCAGGGTCTGAGCCTTGCTTGGGGCCCCG
CACTGCATAGGGCCGNN
35 NNN
NN
NN
NN
NN
40 NNNNNNNNNNNNNNAGGTCTTCAATAAATATTTAATGGAAGGTCCACAAGTCACC
CTGTGATCAACAGTACCCGTATGGGACAAAGCTGCAAGGTCAAGATGGTTCATT
ATGGCTGTGTTTACCATAGCAAACCTGGAAACAATCTAGATATCCAACAGTGAGG
GTTAAGCAACATGGTGCATCTGTGGATAGAACACCACCCAGCCGCCCGGAGCAG
GGACTGTCATTGAGGAGGCTAAGGAGAGAGGCTTGCTTGGGATATAGAAAGAT
45 ATCCTGNN
NN
NN
AACAGCAGGCTACAAAACCACTGCATGCTGTGATCCCAATTTTGTGTTTTTCTTTC
TATATATGGATTAAAACAAAAATCCTAAAGGGAAATACGCCAAAATGTTGACAA

TGACTGTCTCCAGGTCAAAGGAGAGAGGTGGGATTGTGGGTGACTTTTAATGTGT
ATGATTGTCTGTATTTTACAGAATTTCTGCCATGACTGTGTATTTTGCATGACACA
TTTTAAAAATAATAAACACTATTTTATAG

5 SEQ ID NO: 508

>14948 BLOOD 351209.16 X59960 g402620 Human mRNA for sphingomyelinase. 0

TCAGAGGAAGAGGAAGGGGCGGACTGCTTTGCGGCCGCGCCGCGGAGCAGTCAGC
CGACTACAGAGAAGGGTAATCGGGTGTCCCCGGCGCCGCCCCGGGGCCCTGAGGG
CTGGCTAGGGTCCAGGCCGGGGGGGACGGGACAGACGAACCAGCCCCGTGTAGG
10 AAGCGCGACAATGCCCCGCTACGGAGCGTCACTCCGCCAGAGCTGCCCCAGGTC
CGGCCGGGAGCAGGGACAAGACGGGACCGCCGAGCCCCCGGACTCCTTTGGAT
GGGCCTGGCGCTGGCGCTGGCGCTGGCGCTGGCGCTGGCGCTGGCGCTGGCGCT
GGCTCTGTCTGACTCTCGGGTTCTCTGGGCTCCGGCAGAGGCTCACCTCTTTCTC
CCCAAGGCCATCTGCCAGGTTACATCGCATAGTGCCCCGGCTCCGAGATGTCTT
15 TGGGTGGGGGAACCTCACCTGCCCAATCTGCAAAGGTCTATTACCGCCATCAAC
CTCGGGCTGAAGAAGGAACCCAATGTGGCTCGCGTGGGCTCCGTGGCCATCAAG
CTGTGCAATCTGCTGAAGATAGCACCACTGCCGTGTGCCAATCCATTGTCCACC
TCTTTGAGGATGACATGGTGGAGGTGTGGAGACGCTCAGTGCTGAGCCCATCTGA
GGCCTGTGGCCTGCTCCTGGGCTCCACCTGTGGGCACTGGGACATTTTCTCATCTT
20 GGAACATCTCTTTGCCTACTGTGCCGAAGCCGCCCCCAAACCCCTAGCCCCC
AGCCCCAGGTGCCCTGTGAGCCGCATCCTCTTCTCACTGACCTGCACTGGGAT
CATGACTACCTGGAGGGGGACGGACCCCTGACTGTGCAGACCCACTGTGCTGCCG
CCGGGGTCTGCGCTGCCGCCCGCATCCCGGCCAGGTGCCGGATACTGGGGCGA
ATACAGCAAGTGTGACCTGCCCTGAGGACCTGGAGAGCCTGTTGAGTGGGCT
25 GGGCCAGCCGGCCCTTTTGATATGGTGTACTGGACAGGAGACATCCCCGCACAT
GATGTCTGGCACCAGACTCGTCAGGACCAACTGCGGGCCCTGACCACCGTCACA
GCACTTGTGAGGAAGTTCCTGGGGCCAGTGCCAGTGTACCCTGCTGTGGGTAACC
ATGAAAGCACACCTGTCAATAGCTTCCCTCCCCCTTCATTGAGGGCAACCACTC
CTCCCGCTGGCTCTATGAAGCGATGGCCAAGGCTTGGGAGCCCTGGCTGCCTGCC
30 GAAGCCCTGCGCACCTCAGAATTGGGGGGTCTATGCTCTTTCCCATACCCCG
GTCTCCGCCTCATCTCTCTCAATATGAATTTTGTTCCTGAGAACTTCTGGCTC
TTGATCAACTCCACGGATCCCGCAGGACAGCTCCAGTGGCTGGTGGGGGAGCTTC
AGGCTGCTGAGGATCGAGGAGACAAAGTGCATATAATTGGCCACATTTCCCCAG
GGCACTGTCTGAAGAGCTGGAGCTGGAATTATTACCGAATTGTAGCCAGGTATG
35 AGAACACCCTGGCTGCTCAGTTCTTTGGCCACACTCATGTGGATGAATTTGAGGT
CTTCTATGATGAAGAGACTCTGAGCCGGCCGCTGGCTGTAGCCTTCCTGGCACCC
AGTGCAACTACCTACATCGGCCTTAATCCTGGTTACCGTGTGTACCAAATAGATG
GAACTACTCCAGGAGCTCTCACGTGGTCTGGACCATGAGACCTACATCCTGAA
TCTGACCCAGGCAAACATACCGGGAGCCATACCGCACTGGCAGCTTCTCTACAG
40 GGCTCGAGAAACCTATGGGCTGCCCAACACACTGCCTACCGCCTGGCACAACT
GGTATATCGCATGCGGGGCGACATGCAACTTTTCCAGACCTTCTGGTTTCTCTAC
CATAAGGGCCACCCACCCTCGGAGCCCTGTGGCACGCCCTGCCGTCTGGCTACTC
TTTGTGCCAGCTCTCTGCCCGTGTGACAGCCCTGCTCTGTGCCGCCACCTGATG
CCAGATGGGAGCCTCCAGAGGCCAGAGCCTGTGGCCAAGGCCACTGTTTTGCT
45 AGGGCCCCAGGGCCACATTTGGGAAAGTTCTTGATGTAGGAAAGGGTGAAAAA
GCCCAAATGCTGCTGTGGTTCAACCAGGCAAGATCATCCGGTGAAAGAACCAGT
CCCTGGGCCCCAAGGATGCCGGGGAAACAGGACCTTCTCCTTTCTGGAGCTGGT
TTAGCTGGATATGGGAGGGGGTTTGGCTGCCTGTGCCAGGAGCTAGACTGCCTT
GAGGCTGCTGTCTTTACAGCCATGGAGTAGAGGCCTAAGTTGACACTGCCCTG

GGCAGACAAGACAGGAGCTGTCGCCCCAGGCCTGTGCTGCCCAGCCAGGAACCC
TGTA CTGCTGCTGCGACCTGATGCTGCCAGTCTGTTAAAATAAAGATAAGAGACT
TGGACTCCAAAAAAGG

5 SEQ ID NO: 509

>14954 BLOOD 289783.4 M38694 g339561 Human transforming growth factor-beta (tgf-beta) mRNA, complete cds. 0

GGAGTCCGTGGCGAGAGCGCGCTCAGCCCCGCCGCGATGCCCGCGCGCCCAGGA
CGCCTCCTCCCGCTGCTGGCCCCGGCCGGCGTGCCTGACTGCGCTGCTCTTGCAGC
10 TGCTGGGTCAATGGCGGCGGCGGGCGCTGGGGCGCCCGGGCCCAGGAGGCGGCGG
CGTGCGGCGGCGGACGGGGCCCCCGCGGCAGACGGCGAGGACGGACAGGACCC
GCACAGCAAGCACCTGTACACGGCCGACATGTTACGCACGGGATCCAGAGCGC
CGCGCACTTCGTCATGTTCTTCGCGCCCTGGTGTGGACACTGCCAGCGGCTGCAG
CCGACTTGGAATGACCTGGGAGACAAATACAACAGCATGGAAGATGCCAAAGTC
15 TATGTGGCTAAAGTGGACTGCACGGCCCACTCCGACGTGTGCTCCGCCCAGGGG
GTGCGAGGATACCCACCTTAAAGCTTTTCAAGCCAGGCCAAGAAGCTGTGAAG
TACCAGGGTCTTCGGGACTTCCAGACACTGGAAAAGTGGATGCTGCAGACACTG
AACGAGGAGCCAGTGACACCAGGGCCGGAAGTGGAACCGCCCAAGTGCCCCCGA
GCTCAAGCAAGGGCTGTATGAGCTCTCAGCAAGCAACTTTGAGCTGCACGTTGCA
20 CAAGGCGACCACTTTATCAAGTTCTTCGCTCCGTGGTGTGGTCACTGCAAAGCCC
TGGCTCCAACCTGGGAGCAGCTGGCTCTGGGCCTTGAACATTCCGAAACTGTCAA
GATFGGCAAGGTTGATTGTACACAGCACTATGAACTCTGCTCCGGAACACAGGTT
CGTGGCTATCCCACTCTTCTCTGGTTCCGAGATGGGAAAAAGGTGGATCAGTACA
AGGGAAAGCGGGATTTGGAGTCACTGAGGGAGTACGTGGAGTCGCAGCTGCAGC
25 GCACAGAGACTGGAGCGACGGAGACCGTCAAGCCCTCAGAGGCCCGGCTGCTGG
CAGCTGAGCCCGAGGCTGACAAGGGCACTGTGTTGGCACTCACTGAAAATAACT
TCGATGACACCATTGCAGAAGGAATAACCTTCATCAAGTTTTATGCTCCATGGTG
TGGTCATTGTAAGACTCTGGCTCCTACTTGGGAGGAACTCTCTAAAAAGGAATTC
CCTGGTCTGGCGGGGGTCAAGATCGCCGAAGTAGACTGCACTGCTGAACGGAAT
30 ATCTGCAGCAAGTATTCGGTACGAGGCTACCCACGTTATTGCTTTTCCGAGGAG
GGAAGAAAGTCAGTGAGCACAGTGGAGGCAGAGACCTTGACTCGTTACACCGCT
TTGTCCTGAGCCAAGCGAAAGACGAACCTTAGGAACACAGTTGGAGGTCACCTC
TCCTGCCCAGCTCCCGCACCCCTGCGTTTAGGAGTTCAGTCCCACAGAGGCCACTG
GGTCCCAGTGGTGGCTGTTTCAAGCAACACACTCTACAGATTCTTTATTAAGTTAAGT
35 TTTGTGTGTGTGTTTTCCAAGCCAACACACTCTACAGATTCTTTATTAAGTTAAGT
TTCTCTAAGTAAATGTGTAACATCATGGTCACTGTGTAAACATTTTCAGTGGCGAT
ATATCCCCTTTGACCTTCTCTTGATGAAATTTACATGGTTTCCTTTGAGACTAAAA
TAGCGTTGAGGGAAATGAAATTGCTGGACTATTTGTGGCTCCTGAGTTGAGTGAT
TTTGGTGAAAGAAAGCACATCCAAAGCATAGTTTACCTGCCCACGAGTTCTGGAA
40 AGGTGGCCTTGTGGCAGTATTGACGTTCTCTGATCTTAAGGTCACAGTTGACTC
AATACTGTGTTGGTCCGTAGCATGGAGCAGATTGAAATGCAAAAACCCACACCT
CTGGAAGATACTTCACGGCCGCTGCTGGAGCTTCTGTTGCTGTGAATACTTCTCT
CAGTGTGAGAGGTTAGCCGTGATGAAAGCAGCGTTACTTCTGACCGTGCCTGAGT
AAGAGAATGCTGATGCCATAACTTTATGTGTCGATACTTGTCAAATCAGTTACTG
45 TTCAGGGGATCCTTCTGTTTCTCACGGGGTGAAACATGTCTTTAGTTCCCTCATGTT
AACACGAAGCCAGAGCCCATGAACCTGTTGGATGTCTTCTTAGAAAGGGTAG
GCATGGAAAATTCCACGAGGCTCATTCTCAGTATCTCATTAACCTCATTGAAAGAT
TCCAGTTGTATTTGTACCTGGGGTGACAAGACCAGACAGGCTTTCCAGGCCTG
GGTATCCAGGAGGCTCTGCAGCCCTGCTGAAGGGCCCTAACTAGAGTTCTAGA

GTCTTCTGATTCTGTTTCTCAGTAGTCCTTTTAGAGGCTTGCTATACTTGGTCTGCTT
CAAGGAGGTCGACCTTCTAATGTATGAAGAATGGGATGCATTTGATCTCAAGACC
AAAGACAGATGTCAGTGGGCTGCTCTGGCCCTGGTGTGCACGGCTGTGGCAGCT
GTTGATGCCAGTGTCTCTAACTCATGCTGTCCTTGTGATTAAACACCTCTATCTC
5 CCTTGGGAATAAGCACATACAGGCTTAAGCTCTAAGATAGATAGGTGTTTGTCT
TTTACCATCGAGCTACTTCCCATAATAACCACTTTGCATCCAACACTCTTCACCCA
CCTCCCATACGCAAGGGGATGTGGATACTTGGCCCAAAGTAACTGGTGGTAGGA
ATCTTAGAAACAAGACCACTTATACTGTCTGTCTGAGGCAGAAGATAACAGCAG
CATCTCGACCAGCCTCTGCCTTAAAGGAAATCTTTATTAATCACGTATGGTTCAC
10 AGATAATTCTTTTTTAAAAAAACCCAACCTCCTAGAGAAGCACAACCTGTCAAGA
GTCTTGTACACACAACCTTCAGCTTTCATCAGAGTCTTGTATTCCAAGAAAATC
AAAGTGGTACAATTTGTTTGTACACTATGATACTTTCTAAATAAACTCTTTTTT
TTTAAAGTCTGGTCTTTCCTTCAATGTTACAGCAAAAACAGATATAAAATAGACA
ATAAATTATAGTTTATATTTACAAAAAAAGCTGTAAGTGCAAACAGTTGTAGATT
15 ATAAATGTATTATTTAATCAGTTTAGTATGAAATTGCCTTCCCAGTACATGATTGT
GAAAAAGACATTTAGAAAATATTCTAAATTTAATCTGAGCCTCACTTTCTACAA
GGGAAATCATGATTTCCGTTTATAAACAGCATGCTCATCCCCCTAACACCATTCT
TATAAGCTGGGCACCCTCATTTTATTTTCTTCGTTGGTTCTAACCCCTGTGGCGTGG
TATGCTGTATAGTAAAAAGGCAGAGAACCCTTTACTGAAAAGGTACTAGAGCC
20 GGCAGTCCAGAAGTTAATGTGCTGGTCAAAGAACCGTTCTGGTAAAGAAGAGGT
GAGCATTGCCTTCACGTGTTACACGGTTACACACCCCTTGTAGCCTCACCTCAGT
GTAATCAGTCTACTTTTGGTACTAGCAAAGAGTACAGCAAATGGAGGATTGAGG
TGTAAGAAATGGTATGTTTTGGCTGAAATAAGTGTATTTTCACACCAACAAAACCTC
CAGCAACGAACATACAAACAGCAATGACTGAGACAAGGGCGCCCGTGGAGCCCTG
25 GCTGTGGCCTGGGCTGTGCGTCTGTGGACTTCTGGGAATGAACTGAACAGAGGC
GTTCCCCCACTTCCCCGATTTCTGTTCTCTGTAAAATCTACCTTTGATAGACAGT
ACTGAACCAGCTGATCCTTTAGCCAAGAATACATTTAACTCCTTTGAGATTATTTT
CCCTATTTACTAACAAACACCCCAAATAGCTTGATCTACAGCTAAAACCTAATTTT
GGTGGGTTTTTTGGGGGAGGAGGGTAGGAAGAGCTTCACGGTTATGTTTCTGCAGT
30 TACCAGACCTTATGCTACAGACATCCAACTCAGCTTGCTACAGACCAACAACCTA
CTCACGTCAATTTACCAAGTGAGCAAATTATTAATGAGGTCCTTTAAAATCTTCCT
GGGTAATAAGGCACTGGCATGAGATAGTTTCAAAGTCTCATCGTCCACCTCCAA
CTGTGCTTCCGTGTTTTTTTAAAGGCAGATGTAATCTAGGAATCCAAGGCAGAATG
TGTGTCCCCAGCATCTGGTTTCGAGTTAGTGGCATCCACAAGCTCTTACAACCAT
35 ATTCCTGTATTTTTTTCAGAATGACATTGGAGTTGTCATCAAAGTAAAGAACCGAG
ATGGCATTAGCTTAGTTGGCGCACAGCACGGTTTGGGGACATACTCGGGGTTCA
TAAGGTGAACCAAGGTCTGCACAATCGCGTGGTTGGTTGCATTTCATGTGTGCGTT
GAGTGGGAAGGAGCATTCTCCATCACAGTAATTGGCAGCATAGCCCTTGGGTGC
AATGATCCAGTCCTGCCATCCCAGGTCTTGGAACCTCACATACAGCTCATGCTTC
40 CTGCAGGCTGTTTTCAATTCAGTCTGTTGTAATCTGAAGCACTGGAGACCCGCG
CCACGTCTGGGACTGGGTAGAGCGATTACGACTCTGTTGTGCGGCGCCGGCTGGA
GGCTGACCTGGTGGTGCACGCTGGACCTCACTCACTTTGAAGAAAGCCACCATG
AAGGGCTGCTTGTGCGTAAGGGCCGTCTCTGCCCACCAGGCCTGCGGCTCGGGGGT
GGACGTGGACTCCATCCCTTGTCAACACGCTCAGCTGAAGCCCATGTTATGCTG
45 TGGAGTCACAACCCACAGATTGCTAGTGGCCGTGATGTCAAATTCCAGCCAGCCT
TCTTCTGAGGCCATACTACACGGGTGTCCAACAAAAACAGGTCAGAGTCTCTGT
GCTGATGCTCCTGTAAGACTTGATAAATGCTGATAAGAAAAGTTTGGTTTTTAAA
ACTCCCCATAACACAGTCCTTGTAGATGCGGAATTCTGCAGCCGTCACCACCTCA
CCCTCAGGAATCTGGGATAAGTTGAACTTGAACCTTTTGTGGTGTGCTGACGAG

GGGAGAACTCCTTGTCTGTA CTCCACCAGGTTACAAAGCTCATGACCATGTCCGC
GTCGTTGAGGAAGGCGCTGTCCTGCGCGCTGGTCAGTGGGGACGCGCCGCCGCT
GCCAGATCCGGGGGGCCAGAAGGCTCTTGCGGTTGAGCGGGTGC GCGGCCGCCCG
GGGCGGCTGCCGACGCTGGGACGAGCTGGCTGCTTCGTGGGGCCAGGACTGCTG
5 CCTCTCCCCCTCCGACGCCCCGTCTCGTCTGTCGGCGGACAGGGCGTTGTAC
AGATCCAGCATGAAGAGGGGGCGCGGACTTCAGTCGCCCCGGGAGGGGGCTCTCCG
CGAGGCAGCTGCTGCTGCTGCTGCTGCTCCTCCTGCTGCCGGAGCGCCGGGGGCT
GCGGCTGTTGGAGGCCGTGCAGGGGGCCGGGGCCGGTGC GGGAGCCCCAGCACCG
ACAAGATCTCCTTCTGCATCTCCCGCTTCTCCTGCGTCTTGAGCCGCCGGTACAGG
10 AAGCCCGAGGAGGACTGCGGCGACGGCGGCGGCTGCTCCGTGCGGCCGGGGCTC
CCGCCGTCCCCCAGCAGCTGCCCCCGGCGGCGGCGGCGCGGAGCGGGCAAG
GGCGGCCGCGAGCGGCGGGGGCCCCGAGCAGCTGCACAGCAGCCCCACCACCAG
CACAGCCACTGCGCCCTCCGCCCCAGCCCCGGCATCCCCGCCGGCGGGGCTGCC
CCCGCGGATCCCGCGAGGCGTGGAGCGGCGGAGCGAGGCCGGAGCGCGGCCGCT
15 GTGGCCCTTGGCGTGAGCAGTCCCCGCCACCTCTCGGCGGGCTCGCTTCCCC

SEQ ID NO: 510

>14959 BLOOD 995976.15 M25295 g186738 Human keratinocyte growth factor mRNA,
complete cds. 0

20 AGCACACACGCGCTCACACACAGAGAGAAAATCCTTCTGCCTGTTGATTTATGGA
AACAATTATGATTCTGCTGGAGAACTTTTCAGCTGAGAAATAGTTTGTAGCTACA
GTAGAAAGGCTCAAGTTGCACCAGGCAGACAACAGACATGGAATTCTTATATAT
CGAGCTGTTAGCAACAAACAAAGTCAAATAGCAAACAGCGTCACAGCAACTG
AACTTACTACGAACCTGTTTTTATGAGGATTTATCAACAGAGTTATTTAAGGAGGA
25 ATCCTGTGTTGTTATCAGGAATAAAAGGATAAGGCTAACAAATTGGAAGAGC
AACTACTCTTTCTTAAATCAATCTACAATTCACAGATAGGAAGAGGTCAATGACC
TAGGAGTAACAATCAACTCAAGATTCATTTTCATTATGTTATTCATGAACACCCG
GAGCACTACACTATAATGCACAAATGGATACTGACATGGATCCTGCCAACTTTGC
TCTACAGATCATGCTTTCACATTATCTGTCTAGTGGTACTATATCTTTAGCTTGC
30 AATGACATGACTCCAGAGCAAATGGCTACAAATGTGAACTGTTCCAGCCCTGAG
CGACACACAAGAAGTTATGATTACATGGAAGGAGGGGATATAAGAGTGAGAAG
ACTCTTCTGTCTGAACACAGTGGTACCTGAGGATCGATAAAAGAGGCAAAGTAAA
AGGGACCCAAGAGATGAAGAATAATTACAATATCATGGAAATCAGGACAGTGGC
AGTTGGAATTGTGGCAATCAAAGGGGGTGGAAAAGTGAATTCTATCTTGAATGAA
35 CAAGGAAGGAAAACCTCTATGCAAAGAAAGAATGCAATGAAGATTGTAACCTCAA
AGAACTAATTCTGGAAAACCATTAACAACATATGCATCAGCTAAATGGACACA
CAACGGAGGGGAAATGTTTGTTCCTTAAATCAAAGGGGATTCCTGTAAGAGG
AAAAAAAACGAAGAAAGAACAAAAACAGCCCACTTTCTTCCTATGGCAATAAC
TTAATTGCATATGGTATATAAAGAACCAGTTCCAGCAGGGAGATTCTTTAAGTG
40 GACTGTTTTCTTTCTTCTCAAAATTTTCTTTCTTTTATTTTTTAGTAATCAAGAAA
GGCTGGAAAACACTGAAAAACTGATCAAGCTGGACTTGTGCATTTATGTTTGT
TTAAGACACTGCATTAAAGAAAGATTTGAAAAGTATACACAAAAATCAGATTTA
GTAATAAAGGTTGTAAAAAATTGTAAACTGGTTGTACAATCATGATGTTAGTA
ACAGTAATTTTTTCTTAAATTAATTTACCCTTAAGAGTATGTTAGATTTGATTAT
45 CTGATAATGATTATTTAAATATTCCTATCTGCTTATAAAATGGCTGCTATAATAAT
AATAATACAGATGTTGTTATATAAGGTATATCAGACCTACAGGCTTCTGGCAGGA
TTTGTCTAGATAATCAAGCCACACTAACTATGGAAAATGAGCAGCATTTTAAATGC
TTTCTAGTGAAAAATTATAATCTACTTAACTCTAATCAGAAAAAAATTCTCAA
AAAAACTATTATGAAAGTCAATAAAATAGATAATTTAACAAAAGTACAGGATTA

GAACATGCTTATACCTATAAATAAGAACAAAATTTCTAATGCTGCTCAAGTGGAA
AGGGTATTGCTAAAAGGATGTTTCCAAAAATCTTGTATATAAGATAGCAACAGTG
ATTGATGATAATACTGTACTTCATCTTACTTGCCACAAAATAACATTTTATAAATC
CTCAAAGTAAAATTGAGAAATCTTTAAGTTTTTTTCAAGTAACATAATCTATCTTT
5 GTATAATTCATATTTGGGAATATGGCTTTTAATAATGTTCTTCCCACAAAATAATCA
TGCTTTTTTCCTATGGTTACAGCATTAACTCTATTTTAAGTTGTTTTGAACTTTA
TTGTTTTGTTATTTAAGTTTATGTTATTTATAAAAAAAAAAACCTTAATAAGCTGTA
TCTGTTTCATATGCTTTTAATTTTAAGGAATAACAAAACCTGTCTGGCTCAACTGC
AAGTTTCCCTCCCCTTTGTGACTGACACTAAGCTAGCACACAGCACTTGGGCCAG
10 CAAATCCTGGAAGGCAGACAAAAATAAGAGCCTGAAGCAATGCTTACAATAGAT
GTCTCACACAGAACAATACAAACATGTAAAAAATCTTTCACCACATATTCTTGCC
AATTAATTGGATCATATAAGTAAAATCATTACAAATATAAGTATTTACAGGATTT
TAAAGTTAGAATATATTTGAATGCATGGGTAGAAAATATCATATTTTAAACTAT
GTATATTTAAATTTAGTAATTTTCTAATCTCTAGAAATCTCTGCTGTTCAAAAGGT
15 GGCAGCACTGAAAGTTGTTTTCTGTTAGATGGCAAGAGCACAATGCCCAAAAT
AGAAGATGCAGTTAAGAATAAGGGGCCCTGAATGTCATGAAGGCTTGAGGTCAG
CCTACAGATAACAGGATTATTACAAGGATGAATTTCCACTTCAAAAGTCTTTCAT
TGGCAGATCTTGGTAGCACTTTATATGTTTACCAATGGGAGGTCAATATTTATCT
AATTTAAAAGGTATGCTAACCACTGTGGTTTTAATTTCAAAATATTTGTCATAAA
20 AGTCCCTTTACATAAAATAGTATTTGGTAATACATTTATAGATGAGAGTTATATGA
AAAGGCTAGGTCAACAAAAACAATAGATTCAATTTAATTTTCTGTGGTTGACCTA
TAGGACCAGGATGTAGAAAACCTAGAAAGAACTGCCCTTCTCTCAGATATACTCTTG
GGAGAGAGCAGGAATGGTATTCTGAAGTATCAGCTGATTCAAGGACTTGGCTAGC
TAGGTTTTGAGGTGAGGCTTCAGTAACTGTAGTCTTGTGAGCATAATGAGGGCAG
25 AGGAGGACTTAGTTTTTTCATATGTGTTTCTTAGTGCCTAGCAGACTATCTGTTCA
TAATCAGTTTTTCAGTGTGAATTCAGTGAATGTTTATAGACAAAAGAAAATACACA
CTAAAACCTAATCTTCATTTTAAAAGGGTAAAACATGACTATACAGAAATTTAAAT
AGAAATAGTGTATATACATATAAAATACAAGCTATGTTAGGACCAAATGCTCTTT
GTCTATGGAGTTATACTTCCATCAAATTACATAGCAATGCTGAATTAGGCAAAAC
30 CAACATTTAGTGGTAAATCCATTCCTGGTAGTATAAGTCACCTAAAAAAGACTTC
TAGAAATATGTACTTTAATTATTTGTTTTTCTCCTATTTTTTAAATTTATTATGCAAA
TTTTAGAAAATAAAATTTGCTCTAGTTACACACCTTTAGAATTCTAGAATATTAA
AACTGTAAGGGGCCCTCCATCCCTCTTACTCATTGTTAGTCTAGGAAATTGAGATT
TTGATACACCTAAGGTCACGCAGCTGGGTAGATATACAGCTGTCAAGAGTCTA
35 GATCAGTTAGCACATGCTTTCTACTCTTCGATTATTAGTATTATTAGCTAATGGTC
TTTGGCATGTTTTTGTTTTTTATTTCTGTTGAGATATAGCCTTTACATTTGTACACA
AATGTGACTATGTCTTGGCAATGCACTTCATACACAATGACTAATCTATACTGTG
ATGATTTGACTCAAAAGGAGAAAAGAAATTATGTAGTTTTCAATTCTGATTCTTA
TTCACCTTTTGTATGAATGGAAAGCTTTGTGCAAAATATACATATAAGCAGAG
40 TAAGCCTTTTAAAAATGTTCTTTGAAAGATAAAATTAATAACATGAGTTTCTAAC
AATTAGAAAAGAAAAAATTAAAACATGANATGATAACAAAAGTAAACAAAAGA
TACTTTCAAAGCAGTGAACAAAACATTTTGACATAAGCCATAATATAAATTATAA
TATAAAAAATAAAAACCATAGTATAAATTGTCAGCCTTTGAGTTGGCTACAAATT
CAATTTAATGACAGAAGAGAAGGGATGCTGGAGGTAAATTCTTAGGGTTTCTATC
45 TCATAGAGTTTGCTCTTCTGGTTCTCTAGACTGCCAAAGAACATAAAGATGTGTG
AGGGGACCTAGCTGTAGTAAAAGCAATCCTATAACAAGAAAACTCTAAAACAG
TGCCCTTACGATTTTCTACTGAAATTTCTCTAATAGTAGAGGTGTAAAATAAGA
AGTTAGAGAATAATGCAAAGGGGGGCCACCACAGACGGAACATTTCTTTTCTCTT
AAGACTCATGTGATTTTTGTCATCTTACTCCATAATATATTTGTGGTTGCGTTAATA

10

>14966 BLOOD 153659.5 X52015 g32576 Human mRNA for interleukin-1 receptor

AGCTCCACCTGGGAGGGACTGTGGCCACGGTACTGCCCGGGTGCTACTTTATGG

25

30

35

40

CCCTCTTTCTCTCTTTTGGGATGTCCTCAACCTGTAAAAAATAAAAGTTATGGT
ACTATCTTACGGGGGATAAGCTTTTAAATTTTATGAACTTCTGCGGAGATGAG

SEQ ID NO: 512

>15111 BLOOD 350447.18 M14333 g181171 Human c-syn protooncogene mRNA,
complete cds. 0

CTAACATGCTTCTTCATCACAGGCACTCAGCAGCACAAAGACTCTCGTCCTGAAT
5 CATTTCCCTTCCCCTAAATGAAACCTTGCTTCTTACCTCGTGACTGTAAGAGGGCGG
GGTTTCCGAGACGAATGTTTGAAGTGGGACTGGGTGGCCTCGTGATGAAGGTCA
AAGCTCGAGGACTCCTGAACTGGATCCAGAGGCACCATCCCCCTTGCAGCATCT
CAGGTCCATGAACTTGACCTGGGACCTGTTGTCTGATAAATCAAGCTCCAAGTC
TTCTAGAAGGGTCACGGCCTCCTCTCCACTATCGGGGCGGTATTCTGCAGCCAG
10 ACCTGGAGCTCCTTGGGCAGGATGGAAAGAACTGCTCTAGCACCAGAAGCTCC
AGGATCTGTTCTTGGTGTATTATTTCTGGCCGCAGCCACTGATGACAAAGTTCCTT
CAGCCGACTGAGAGCCTCTCGGGGCCCAAAAGTGTCTGGTAACAGAAGCGCCT
GAAGCGTTGGCGGAATATCTCTGGGTCTGGAGGAGGCGTGTCTGTAGGGTGA
ATCCTGCCCCCACATGTGGTCTTCTCATCTTCTCTTCCACCTTCACTATTACGA
15 TACCATCCTTCTCCTGTGCAGCCTGTGGGGACAGACCCGTGGCTTCCCGTGATTC
AGCAGTCATCATTAGGCTCCAGGAAGTACTTGATCCAAACAGGGTCTGTGCTC
ACCTTTATGTCTGGGAGGTTTTATGATGTGTTTCTTTACTATTCCGTGAGCCCCG
GGAGCGGCCTGGGGGCGCTGGGCGAGAAAGGGGAGCTGACTCTGGGGCTCAGG
CCGGCCGAAGGGCACCGGCGAGGAGGGGGCTGCCGCGGGCGAGGAGGAGGGGT
20 CGCCGCGAGCCGAAGGCCTTCGAGACCCGCCCGCCCGCGGCGGCGAGAGTAGA
GGCGAGGTTGTTGTGCGAGCGGCGCGTCTCTCCCGCCCGGGCGCGCCGCGCTTC
TCCCAGCGCACCGAGGACCGCCCGGGGCGCACAAAGCCGCCGCCGCGCGCGGCA
CCGCGCGGCGGCGCCGCCCGCGGCCAGGGAGGGATTCCGGCCGCCGGGCGGGGA
CAGCGCGGCGCGCCGCCCTCGGTGCTCTCGGAAGGCCACCGGCTCCCGGGCCCG
25 CCGGGGACCCCCCGGAGCCGCTCGGCCGCGCCGGAGGAGGGCGGGGAGAGGA
CCATGTGAGTGGGCTCCGGAGCCTCAGCGCCGCGCAGTTTTTTTGAAGAAGCAGG
ATGCTGATCTAAACGTGGAAAAAGACCAGTCCTGCCTCTGTTGTAGAAGACATGT
GGTGTATATAAAGTTTGTGATCGTTGGCGGAAATTTTGAATTTAGATAATGGGC
TGTGTGCAATGTAAGGATAAAGAAGCAACAAACTGACGGAGGAGAGGGACGG
30 CAGCCTGAACCAGAGCTCTGGGTACCGCTATGGCACAGACCCACCCCTCAGCA
CTACCCAGCTTCGGTGTGACCTCCATCCCCAACTACAACAATTCCACGCAGCC
GGGGGCCAAGGACTCACCGTCTTTGGAGGTGTGAACTCTTCGTCTCATACGGGGA
CCTTGCGTACGAGAGGAGGAACAGGAGTGACACTCTTTGTGGCCCTTATGACTA
TGAAGCACGGACAGAAGATGACCTGAGTTTTCAAAAGGAGAAAAATTTCAAAT
35 ATTGAACAGCTCGGAAGGAGATTGGTGGGAAGCCCGCTCCTTGACAACTGGAGA
GACAGGTTACATTCCAGCAATTATGTGGCTCCAGTTGACTCTATCCAGGCAGAA
GAGTGGTACTTTGGAAAACCTTGCCGAAAAGATGCTGAGCGACAGCTATTGTCCT
TTGGAAACCCAAGAGGTACCTTTCTTATCCGCGAGAGTGAAACCACCAAAGGTG
CCTATTCACTTTCTATCCGTGATTGGGATGATATGAAAGGAGACCATGTCAAACA
40 TTATAAAATTCGCAAACTTGACAATGGTGGATACTACATTACCACCCGGGCCAG
TTTGAAACACTTCAGCAGCTTGTACAACATTACTCAGAGAGAGCTGCAGGTCTCT
GCTGCCGCTAGTAGTTCCCTGTCAAAAGGGATGCCAAGGCTTACCGATCTGTC
TGTCAAAACCAAAGATGTCTGGGAAATCCCTCGAGAATCCCTGCAGTTGATCAA
GAGACTGGGAAATGGGCAGTTTGGGGAAGTATGGATGGGTACCTGGAATGGAAA
45 CACAAAAGTAGCCATAAAGACTCTTAAACCAGGCACAATGTCCCCGAATCATT
CCTTGAGGAAGCGCAGATCATGAAGAAGCTGAAGCACGACAAGCTGGTCCAGCT
CTATGCAGTGGTGTCTGAGGAGCCCATCTACATCGTCACCGAGTATATGAACAAA
GGAAGTTTACTGGATTTCTTAAAAGATGGAGAAGGAAGAGCTCTGAAATTACCA
AATCTTGTGGACATGGCAGCACAGGTGGCTGCAGGAATGGCTTACATCGAGCGC

ATGAATTATATCCATAGAGATCTGCGATCAGCAAACATTCTAGTGGGGAATGGA
 CTCATATGCAAGATTGCTGACTTCGGATTGGCCCGATTGATAGAAGACAATGAGT
 ACACAGCAAGACAAGGTGCAAAGTTCCCCATCAAGTGGACGGCCCCCGAGGCAG
 CCCTGTACGGGAGGTTTACAATCAAGTCTGACGTGTGGTCTTTTGGAAATCTTACT
 5 CACAGAGCTGGTCACCAAAGGAAGAGTGCCATACCCAGGCATGAACAACCGGGA
 GGTGCTGGAGCAGGTGGAGCGAGGCTACAGGATGCCCTGCCCGCAGGACTGCCC
 CATCTCTCTGCATGAGCTCATGATCCACTGCTGGAAAAAGGACCCTGAAGAACGC
 CCCACTTTTGGAGTACTTGCAGAGCTTCTGGAAGACTACTTTACCGCGACAGAGC
 CCCAGTACCAACCTGGTGAAAACCTGTAAGGCCCGGGTCTGCGGAGAGAGGCCT
 10 TGTCACAGAGGCTGCCCCACCCCTCCCCATTAGCTTTCAATTCCGTAGCCAGCTG
 CTCCCCAGCAGCGGAACCGCCCAGGATCAGATTGCATGTGACTCTGAAGCTGAC
 GAACTTCCATGGCCCTCATTAATGACACTTGTCCCCAAATCCGAACCTCCTCTGT
 GAAGCATTTCGAGACAGAACCTTGTTATTTCTCAGACTTTGGAAAATGCATTGTAT
 CGATGTTATGTAAAAGGCCAAACCTCTGTTCAAGTGTAATAGTTACTCCAGTGCC
 15 AACAATCCTAGTGCTTTTCTTTTTTAAAAATGCAAATCCTATGTGATTTTAACTCT
 GTCTTCACCTGATTCAACTAAAAAAGTATTATTTTCCAAAAGTGGCCTC
 TTTGTCTAAAACAATAAAATTTTTTTTTCATGTTTAAACAAAAACCAATCAGGACA
 GGTGTTTGTGTTTTGTTTTCTTTTTTATAAATATGAATATATATAATATATATGTCCC
 TGACATATACAATGTGGGTGCTAATGTGGAGACTGTGGCCGGCCTGAGCCACCA
 20 AGCTGCGGGACCCAGAGGGAGGATTTTACTGCAAGTCAGCATCAAAGCACCGGT
 GTTATTCTGAAAACACCAGTGGCCTCATTTTTGGCTTTTGCAAAGCATGAATTTTT
 TTTTCTCATTTGGATTGCACTTTCCTGGTTCATGACTGTACCTGTAGGTGGTGTGTTACTT
 TTTTCTGACTTTTTTTCAGGAACCAACCCGCAAGCTGAATTTACAAGTTCTGTAGCACTAT
 TTTTCTGCTTCACTTACTGCGATTGTTCTTCAAAACCTTAAAAATAAGCAAGCAAATGG
 25 CTGATACTACCAAGAGAACTGGAAGATGGATACCACACAACTTCTTGTATAAA
 AATATGAATGCTGAAATGTTTCAGACATTTTAAATTTAATAAACCTGTAACCACA
 TTTAAGTGATCTAAAACCCATAGCATTGTAGTCATGGCAACCCGCTAAACTTTCT
 CATGCAACTAAAATTTCTGGGGGAAATGAGGGTGGGGGTGTACATTTCCCATTG
 TAAAATAAGTGTTTTAAATGTCTGTACTGCTAACGAATGACTTTCTATATGTCCA
 30 GGAGTTCTCCAGTGAATAACTATGCACTACTTTACATTTTCATGGGGATGCACAA
 AAACAAAAAAGTATTACATTTTTAGTTGCTGTTTGTACCAACCTTAAATTACATA
 TGTTTAACAACAACAAATCAAAAATCCTATTTCTATTGAGTTTTTAATACTGACTA
 GCAACTCTGAAGTCTTAATTCCTTTTTTGTATGATTTATTTGTGAGTTTACATTTT
 TAAATTGTTTAACTTTCTTAAATTTAGTAATTAATAAGAGAGCATTTTACATTTGAN
 35 AAAAAANAAAAANGGGCGGCCGCGACTAGTGA

SEQ ID NO: 513

>15354 BLOOD 337518.7 Z32765 g525231 Human CD36 gene exon 15. 0

AGAAGGGAGACCTGTGTACATTTGCTGATGTCTAGCACNCCATATGGTGTGCTAG
 40 ACATCAGCAAATGCAAAGAAGGGAGACCTGTGTACATTTCACTTCCTCATTTTCT
 GTATGCAAGTCCTGATGTTTCAGAACCTATTGATGGATTAAACCCAAATGAAGAA
 GAACATAGGACATACTTGGATATTGAACCTATAACTGGATTCACTTTACAATTTG
 CAAAACGGCTGCAGGTCAACCTATTGGTCAAGCCATCAGAAAAAATTCAGTAT
 TAAAGAATCTGAAGAGGAACTATATTGTGCCTATTCTTTGGCTTAATGAGACTGG
 45 GACCATTTGGTGATGAGAAGGCAAACATGTTTCAAGAGTCAAGTAAGTGGAAAAAT
 AAACCTCCTTGGCCTGATAGAAATGATCTTACTCAGTGTGGTGTGGTGATGTTT
 GTTGCTTTTATGATTTTCATATTGTGCATGCAGATCGAAAACAATAAAATAAACCT
 GGCTCAAGCACAAACCAATTTGTGTTGTTCTGATTCAATAATTGGTTTCTGGGTG
 GCCAATTCAGAAGAAGAGTGTACATGCTCAACAAATCCTAGGCCCTGCATTCCTG

TCATCCTCATCCGGGGGAAACACCATCATCCCAGTAGCTGCCCTATTCAACTGCA
ACAGTCTCCAGGACCATCAGTATACTGCATTTTCATGTGCACCAAATATTTTGAAA
GACATTTATAAATAAATTGGCTTATGACTCATATTTCTCTATGAATACCTTCATACA
GCAGGTATAAATCTTTTCTTTATGGGCTTAAATATTTTGTCACTGATCCTGCAAAT
5 GGACATCATTTTAGCACACTAGCGGTTTATATTTTAAGGACCTTCATTCTCTGTTT
TGCACCTCTTCTGGAAATTGAGTAAATTTTGCTTTTTTTTTTTTACTCAGTTGCAAC
TTACGCTTGGCATCTTCAGAATGCTTTTCTAGCATTAAAGAGATGTAAATGATAAA
GGAATTATTGTATGAAATATTACAAAGCGTAGACTATGCATTGTTATTATTATA
ATATTTTTTGCTGTCATAATCGCCTCATAAAGACAGGTTTCAACCATTAATAATAT
10 GTTCTTCCCTAAATTCCTGTGCTTTTTCTAGTTCCCTCTTGTGTCATAAAATGTTTAT
CCTAATTTTCTCTCTGAAGTATATTTTATCTGAATCCACATTTCTTTATAAATCCAT
AGTCCTTGCTGAAATATGCTTTCTAAATTTCTACCACTTTGTTCTAGGCTAATTTT
TTAAGCTAATTGGATGAAGAACAAAAAGACATTTGGTTTCATCCTTTACAGCAGT
AGGACAATTGCAAAGGTTTTTCTTTTTTCATAAGGAGACACATTAATAGGTAAT
15 CTGTTTCTTGAGCAGGGGTTCACTTATTCTGAGAGCATTAGTTCTCCTAAAAAGCT
CCAGCATAGAAAGGGAAGATAAACCAAATTCTAGCTTGTGTTTTACCCACAGAA
GGATACAGGACAAAGGAATAGTAAGTGGCCTGTTTGGATACTAAAATTGAAAAT
AACTTTTAGCCTCCTCCTTATGATAGCCGCCAGAGTAAATGTTGAGCATTACTAC
AGAAAAGCCACAAACCAAGAATCTACCTGTTTGGAAAGATCTTTTGCATCTCTGA
20 AGGTGCTTAAAGCATACTTTAGTGCCTTTCTTTTAACTGGGAAGATAAAAGAAG
TATCTGTCCAAGATATTAATATGTAAGATAACATTGTAGACATGTTCTTCTGATA
ATAACAAGGTTTATTCTATTTGCATTAGGATATTTGTGGACATGTCCATCTAATATA
AAGGAAAGTTTTTAAATCATTGAGGGCATGAGGGCTGAGTTATATAATGTAGAAA
CTTCTAAAGATAATTGGATGAGAATATAACATATTGACCTGTATATTATGACTAAT
25 CATGACTCAGATCTTAATACAGGGATGATCTCATAGCATTTAGATATCAGAAAAG
GTTTTGACCTATATGTCTTTAATATTTTTTGAATACATGTATAATCTTTATCATTCC
TCAGTGTTCATTTCTCAAATTTCTGTAAAAGGAATATAAGAGGAAAGACAATTCA
TATACAAAGACAACGAGATTAATAATATGTCAGTAGGAAAAATAATTACTTAAGG
GGAGATTTTTTTTACATGAAATCTGGGCTTTGGATGTGTGTGTGTGTGGTGTGTGT
30 GTGTGCACATATGCACTGTGGTGGGAGTGGGGCAACTTGGGGAATATGTTACAT
GTGTGACTTTGTTTTGCCCTGGCGAAGTTAATGTTGTTTCAAGAAAGGGTAAATGTT
TGGACACTTGCAATTGCTCATGGATGAATTTATATGTTTTAGTCATAGAAAAATT
GTACCTTTGATAGAAGCACATTTTCTTTCCAAAGTTGGTTATTAACACAGAATT
ATAGCAGGTATTCATAACTTAAGTTTGAATAATCAATAGCGTCTGCAAATGGATTA
35 ACAGATTAGAGAATCAACAGCATCGGAAAATAGGTTAATGCATATTGCTTCTAA
CAAGTGCATGAAGAAATAGAAGAAGCTATGTAGCTTTCAGTTCTGACAGAAAAG
GGTGAAGGAGGGTATCATTTCAAGAAAAAAAATAGCTATCACGCAATGGTTATC
TCTGAAAATATTTGTATTAAAGATGTGTATACATGGCCAGGCATGGTGGCTCATGC
C

40

SEQ ID NO: 514

>15389 BLOOD gi|1186305|gb|N45139.1|N45139 yz13g11.s1

Soares_multiple_sclerosis_2NbHMSP Homo sapiens cDNA clone IMAGE:282980 3',

mRNA sequence

45

CTGTTCAAAACAGTTTATTTTATTTTATTTTTTTTTTTTGTGAGACAAACACATTGAT
TTCTGGACCACAGTAGAGGATGGAAACCTTTCACAACTTATTTATTGAAAATA
CAAATATAAAATTATACTTTCCACATCTGTGATGTGAGAGACTGCCATCCACATA
GTAATTTTTTACAACAGGGCTTTAAGAAAGCCACACACAAAGACCTGAAAGATG
CTTAGATATATATATAGATAGATACATATATATGTATATATAT

SEQ ID NO: 515

>15418 BLOOD GB_N46975 gi|1188141|gb|N46975|N46975 yv28f12.r1 Soares fetal liver
spleen 1NFLS Homo sapiens cDNA clone IMAGE:244079 5', mRNA sequence [Homo
sapiens]

TTGGTCAACCACGCCAAGGGANNTNTCAGACTCCTTTCACAAGCCAGCTTCTGAC
CCAGGCAGCTGACCCTCACCATGGACACTACAGGCCCTGGAATGGCCAGGGTGG
ACCAAAAGCCATGCCAGCTGGGCATGACCCAGGCAGCCAGCCACAGGTGANAG
GGGGCTTGTGGCTGAGTGATCTGCAGAGGAGANAGCAGCCCCAGC

SEQ ID NO: 516

>15620 BLOOD 238262.4 Incyte Unique

TGTGCTCCCATCTTTACCCAGCCACTGTGTCCAGTCCATGGTGCCCCCATCTTTGC
CCAGCCACCACCTCTTGTCTGACTCCCCGTCCTCCCCTTGGTGCTGGGGCTCCTGCC
TGTCCCTCCTCTGTCAAGTGCACCTGGACCTGGGAGTGACCTTGGAGTGACCTTG
ACCCTGGCAGCTCCAACCTCTCAACCCGTCAGCCAGGCTCCTTGAAACCTGGCTGG
AGGGAAACGGCAAACCCTGCCACCTGGAGTCGCCTAAAATTTCGACGCCACGGTC
CTCCAACAGGCCCCACGCTTCCCGCCAGTCCAGCACATTTCTGGTTAATTTATA
ATTCTGTTTTCCAGGCAGCTATTTTGCAATTTCCAGGCTCAACAAAGCCTCCAAC
AGTTCTTCACCTTCCTAATTCCGAGCTGTTGCCACATTTGTTTATTTTATCAAAA
GAACTTCCGGGCCGGGTGCAGTGGCTCANNNNNNNNNNNNNNNNNNNNNNNNNNNNNN

NNCC

AAATGGGAAGTGAATTTAACTAGATGTAGTAACCTTTTCTTTCTTTACTTCTAAAAA

AGTTACAGTTTACTAATAAAGTAAAGTCTGGTTCTGTCCTAGAGGAATAAATTC

ACTATTAATTCATGTCTTAAGTTACTTGGGTAAAACACTTTCAGCCACCCAGATT

AATTAAAGTGGAGCAGTGGAGCCCCTGGCTGGGAGATGGCCTCCAGAGGAGCAG

CTGCAGGGCATGTTCTGGGCTTAGCGACAGAGGCAAGCAAGGGACTGGTGTCTC

TGGTGAGAGGTGGGTTTGATGTATCTCTGTCTATGCTGGTCTCTCTTCTCCTTTA

TAAAATCCTCTGTGGTCAACTGACTACTGCGTATCGCAGTGGAATAAGACTGCAC

AGTTGCTGGTAGGTGAGTTTAAAGTCTTAATCTATGCATTTCAGAGAAATATTTTT

ATATGCTTTGTGTAATTTATAACAAGGATTTTTTTTTTTAGCTTTGTTAACTGTGAA

TTCACCCCTCCTCCTCCACTGCATATTTAAAGCATGTGTTTCACTGTGTGTAAAC

ATTCAGTGAAGATTTTTTCTTTGTGCAATTGCTGACTGTTCAAACATAACAAGTATT

ATTAAATTAATATTAAGTACTCAAAAAACAAAAAGAAAAGAAAAAAATT

GGAA

SEQ ID NO: 517

>15743 BLOOD Hs.75277 gnl|UG|Hs#S1569956 Homo sapiens mRNA; cDNA
DKFZp586M141 (from clone DKFZp586M141) /cds=UNKNOWN /gb=AL050139
/gi=4884349 /ug=Hs.75277 /len=3312

TATTATTCTGATGGATACAGATAATGATCTTTTCTCTTGTGAGGTATCTTCATTTA
TGCACTGTCCAAAAATAGCCATGTGTAAGAGTCTTTCTGTATGACGAACTACATG
GAAAAGACTTCTGTGGACATAATTCTGACCGAAACCCATGAAGTTACTTCAGTAT
AAGAAGAACGTTACACGGAAATCACCAATATTTTGCAACTTTATTTCTTCTGAC
ATGGAGTGAACATCAATAGGAATACTTTCAAAGAAAATGAAAACACAGAAGCAA
AGAGAAATGTGGCACTTCACATTTTAACTACAGATGGACTTGGTTTGAGGGAG
GGGGAATCACAGATTTGGTGCTAAGTTAATTAGAACTGGCAGCGTTTTACAGTA
GTACACCAGCCTGGATGTTTTTCTAAAATGTTTACCTGGGAGAGCTGGGGTTTG
TTTGTGAGGAGAAAGAGTACTGTGGAAAACCTCTGCTTGAGTACCATGTGGCCA

GGCCTATGTGGATGGCTACTCCGTGCTGTGCGGCTTCACCAGCGGTTGGGATTGG
CCCAGCTTGGAGTGCTTGTGTGGTCCAACCTCAGTCTGGCCCCATAGTGACTTTT
GCCCCATGATTCTGCTTCACTGTTGGAATCCTCTTTGAAGTTCCCCCTCTCTTTGC
TAAAGCAGTGAAGGAAGAGAACAGAGACAAACTCTTTGGACTGTGAAAGAGAA
5 GGTAGAGAATTCCAGGCAACAGTCTGACCAAGGGTGTAAACCAGTTTATTATAT
ATATATTTTTTCCCTTTGAATTAACCTAGAGTGTGTATTTTTCTTTCTTTTTTTT
TTTTTTTTTTTTTACCCTTTTTCTCCTTAGGCCAAGTTTAGCTTATTCTTATCTTTCC
ACCCAAACACCTACACAACGTTTAGGCTTCCTGTAAAGGTTTGAATGAGACAGATG
TACTCTGAAGGCTGGTGGTAAATGTGTTTGATGACCAGACTCTTCATACAGTCGG
10 CTGGGAGCCAAATAAGGACAAAAGCCAGAGCTCAGCTTTATCCCTCTCCCAGTG
CTGGGAGCCAAAAAACTGTTGACAGTTTTTTGTGCAGCTCAAGAAAACCTTGAAA
AGAACATGCTTTAACTGAAGCATTGGACTCTGCAGCTTCTGTGTAAAGGCCGTG
TACTCCCACTGGGCAGGGTGAGGACCAAAAATCTGAAACTCTTATGAATCTGAC
ATATTATATGGAAATTATATCTTGTGACCGTCTTCAAGTGCATGGACTTAAAATT
15 CATGAGAGACTAAATGTGAGGGAGAGGTGGATTTAAAGAGGCCAGACCTTAACC
AAAGATGCTGAGATACAGCATTCTGTCCCCCTGCCCTAGAACTCCATAAATGC
TGTCACAACCCTATCATTGCTGATGCTTCTGCATGTCAGCAGTCCAGGAGGATG
CTTTTTGTCTCTCTTTCCTCCACTTTACAAAAGATAATATGATAGAGGCAACGTT
TATAACAGTCACATTTAATTATAATGTACATCAAAGGCAGAATTCAGAATGGTT
20 TCTTAAATTTCCCTTGGGAACGTTTTCCACATATCAGTTATAGACAAAGGCCATGG
GACTATGCTAAACCAATAAAACCTTATTAGCAAATCTTAGATTCTGACTTAGCC
AGAGCATCTGAGTGTTCAGTACAGTTTTACAGTGGGTAAGGTTGTCTCTTGATG
TTTTCTCCGTTGTGTGATGACAGATGCTATTTCTGTTTTATTTGGTGATTATACGA
GACTTCTAATACATAAATGAACGGGTATTGGTGCCTCTTTATTTTAAAAAATTTG
25 AAGAAAAGAGCCACCTCATATTCATAGGGTGTGTATTTTTTGAGTGTGAGCATT
AATTGAAAATAAGAAAGCTATGAAGTAAATGTAACTTCTCTGTAGCAGCTAATG
CATAGAGACACTAAAACCCACACCACATTTTGTGGGAAATGAGGATCCTGATCCT
CTTTTGTCTCTCCAGGTAGTCTCGCAGGTTATGCAGCTTAAGTTCAGTCTTCTTT
ATGCTGCGATTGATTTCCACCTCAGTGGCTTAGCCTTTGGGACAGTGGATACTGC
30 AACAGCCAAGAACTCTTGGTTATCCGCACAAGCTGCTGGTAGACTACATTAGCCC
TCTGGTTTTCCAGCTCAACCTCTGATAAAGTGGACTGAGAGCCACGCTGCTCAGT
CTGTTTCGTCAGCCGACTCAGGTTATTTTCAGGGAAGGCATGGAGGCATAGTTTG
GTTAGTTTCATCACTAGGATGTATAAGGTGACGACACAAACCAAATACCTTTCTT
TCATCACTTAACTATACGTACTTTATCTCTGTTAACTAGAAATGCTGTGGTCTTG
35 AGGGAATGTTAGCAAGGAACACATAGAAGATTTGGTGTTCATAAGCCTGTCTA
GGTGTGGCAGGTTTTGTGTGGTACACTGATGTTTACCATAAGCAGGTACAAGCTT
CATGAACCGTTCTTAATGAAGTATAATTGAATAGATACCAAAAATAGAATGACA
AATGTATTTTAATAGCAGATGAGGCAGTTTTAGGATGAATTTTCCACTGTTGATTT
TACTTCAAGACATAGCAAGAGAAACAAAATTTTGTTCATAGACATTTCCACTGC
40 AGTTTCAAGCTGTAGTGGGCATATGCTTCATTTACTTCCAAAGAGGCCAAAAGCAG
CTGGAATTGGCTTACAGCACATGCTTTGTTTCATGTTATGGGTGAGGACCTACAT
ACACTCTTACTTTAGCAGTCACTTAACCTTCTCCAGCAAGGCAGTTGTGGGGTTC
ACTAGGATTTAGTGCCTGATCTTTTTTTTTGGGAAGGGGCGGGAATGAATGTGTTG
GGGCTGGGAGGGAAGCAGAAGAAAATGGGAGTGTGAGTGTGATGTGTCT
45 GAAGTTCACCATTGCCCCACCTGCACCTAGCAAGGAACAGGTGTTTGATGTATT
TTGCTCATGACTGCAGTATGCATGTATTTTTTCTTCTCTGTGTTTTCTAAACTTA
CACTAAAGGATTCATCAAATCATCTTGTTTCAGATGGCTCAGGATTGTATTTATTT
GCTTACCCCGTGCTCTTGGGTCTATAGTATTTCTATAATTATGTAACGAGAATAG
TGTTGCACTGTAATCTATCATATAGAGCTATATGTATGGAAAATTTTGATCAATTT

TTTAAGAAATGTATCCTGTTTGCAAAGGCACAGTAAAGTTGCATCTTATAGACTA
TAGGCAATAAAGCTAACAATAAACCTTATTTAACACAAACCAAAAAAAAAAAAAA
AAAAGG

5 SEQ ID NO: 518

>15833 BLOOD GB_N63635 gi|1211464|gb|N63635|N63635 za16c12.s1 Soares fetal liver
spleen 1NFLS Homo sapiens cDNA clone IMAGE:292726 3' similar to gb:M54915 PIM-1
PROTO-ONCOGENE SERINE/THREONINE-PROTEIN KINASE (HUMAN);, mRNA
sequence [Homo sapiens]

10 TTTTTTCCAGGTTAGAATGCGCATCTTTCAAAAAAAAAAAAAAAAAACAGGTAAA
ATAACTTAAAGGCCAAAATTTCTTAAAAATTAGATCCACTACAATCTTTTTGTATA
CTACCATGCCAACTGTACACACATTTACAGCTTTTCTGTTGATTGCATTGTTTGTG
CATTTTTTGTGTGTGTGAGGTCTTGGCTTTGAAACAGTTAAGTAAAAACCAAAAA
GGAAGACCAGTTCNCNCGGAGTTTACNAAAGGAGGCAGAAAAAAGGGCAGGT
15 GGCCAGCGTTTGGCCAGTAGCCNCTTCCATGGCNCCTTTC

SEQ ID NO: 519

>15915 BLOOD 233764.7 Y12711 g6759555 Human mRNA for putative progesterone
binding protein. 0

20 GCCTAGCGCGGCCCAACCTTTACTCCAGAGATCATGGCTGCCGAGGATGTGGTGG
CGACTGGCGCCGACCCAAGCGATCTGGAGAGCGGCGGGCTGCTGCATGAGATTT
TCACGTCGCGCTCAAGGTGCTGCTGCTGGGCTCTGCATCTTCTGCTCTAAG
ATCGTGGCGGACTTCACCCCGCGCGAGCTGGGCGCTTCGACGGCGTCCAGGACC
ACGCGCATACTCATGGGCATCAACGGCAAGGTGTTTCGATGTGACCAAAGGCCGCA
25 AATTCTACGGGCCCCGAGGGGGCCGTATGGGGTCTTTGCTGGAAGAGATGCATCCA
GGGGCCTTGCCACATTTTGCCTGGATAAGGAAGCACTGAAGGATGAGTACGATG
ACCTTTCTGACCTCACTGCTGCCAGCAGGAGACTCTGAGTGAAGTGGGAGTCTCA
GTTCACTTTCAAGTATCATCACGTGGGCAAACTGCTGAAGGAGGGGGAGGAGCC
CACTGTGTACTCAGATGAGGAAGAACCAAAAGATGAGAGTGCCCGGAAAAATGA
30 TTAAAGCATTTCAGTGGAAGTATATCTATTTTTGTATTTTGCAAACCATTTGTAAC
AGTCCACTCTGTCTTTAAACATAGTGATTACAATATTTAGAAAGTTTTGAGCAC
TTGCTATAAGTTTTTTAATTAACATCACTAGTGACACTAATAAAATTAAGTTCTTA
GAATGCATGATGTGTTTGTGTGTCACAAATCCAGAAAGTGAAGTGCAGTGCTGTA
ATACACATGTTAATACTGTTTTTCTTCTATCTGTAGT

35

SEQ ID NO: 520

>15974 BLOOD 981864.1 Incyte Unique

AACTAATATTAAATAGTAAATTTAATGTGTATTAATATTGTCATATAATATTGTA
ATTACTCATGTAAATGTAAATATTACATTGAGGATATAGTAAATATTAAATTTAC
40 TATGTCATTGAGGACAGTATTTCAAAGTACTTTTTTAAAAAGAAAAACAGAAGA
TGGCAGTGAATAGAACAGTGATTGTTCACTACTTGGATCTACTGCCTTAATTT
ATACTAGGATGTCAATCCACCATTGATTTTGTACCATCAGTGCAAATGTCAACGT
AGCAAAAAAGGCAAATAATGTCTGAGTACTATTACTAAAATAATTTTGACTTTGT
CAAGCCCTGAAAGGGTCTCCAGGACCCTCATGGGGTTTGTGGATCAACTTAAAG
45 AACCATTGATAAAATCAAATGAGCAAAGTGGGCTTATGTTTCTTGAAAATATTCT
GGG

SEQ ID NO: 521

>16020 BLOOD Hs.30211 gnl|UG|Hs#S2005168 EST382554 Homo sapiens cDNA

/gb=AW970473 /gi=8160318 /ug=Hs.30211 /len=707

5 ATTTGGCCCTCGAGGCCAAGAATTCGGCACGAGGTTTTCTTTAGGCTTCTCATG
CATATGAATATTTTAAGCACGAATGGACTACTAAATATCTGAGTTTTTTTTTTTTT
AAAGATCCTAACAGAACATAGCGTAACAATATTGGTCTTCCAGGTGTTACTCATT
TCAATTATGTGTAGTATACCAGGACAGACCTATTTTCATGTCTTATTTCTTTAAAG
AGCTGCTTCATTGGCCGGGCGCCATGGCTCACGTCTGTAATCCCAGCACTTTGGG
AGGCCGAGGCGGGTGGGTACTTGAGGTCAGGAGTTCGAGACCAGCCTGGCAAA
10 CATGGCGAAACCCCATCTTAATAAAAAATACAAAAAATTAGCCGGGTGTGGTG
TCACGCGCCTGTAATCCCAGCTACTTGGGGGGCTCAGGCAGGAGAATTGCCTGA
ACCCAGGAGGCGGAGGTTGCAGTGAGCTGAGATTGGGCCACTGCACTCCACCCT
GGGCGACAGAGTGAGACTCGGTCTCAGAAAAAAGAGCTGCTTCAC
ATATAAATGTCTATAGCTAGTAGCCTGGCCCTTTAATGTTTAATTTGAATAGATAT
15 ATCTGTTTTCCGTGAATTATCTTGAAAAGTTTTAAACAAAATGACCTCATAGTTTTT
AAATAAAAATATTATTTACCTAAAATGTGCTAGTAGCATCTTTGCCCAA

SEQ ID NO: 522

>16166 BLOOD 346280.34 AB020692 g4240258 Human mRNA for KIAA0885 protein,

20 complete cds. 0

TTTTTTTTTAGTTTCTCAAAAATCAGTAAACTTTATGGGGTTCCATTCTTTCGCC
ATTAAAGAGAAACTGGAGAAAGCAAAAATGTTTCGGTGTTTACAAAGATAAACT
GGGCTCTTTACCCAGAGATCAAAACCTGAAACTGACAAAGGGGAAGATAAAACC
GGGCTCCCCACATCCCCTGAGCTGAACCTTGTCATCTTAGGACAAAGGCTTCGA
25 GTCCACTGGCCAGGGGACCCTGTATATGGCCAATTCAGAAGAGGGGCAAGAAA
TCAGACCCATCCATTCCCCTGATATAAAGTTGAACAGAAGCTACACCAAGGGTC
AAGTGTCTCGTATTTTACAGGACACAGTAACCAGGCGGCTACTTATAAAAAAA
ACAAGATTCATTTTCAGGCACAACCTTTTTTATTTTTTTTTTGTGTTTTTAAATCA
GTAAAAGAAACCGGGTCCTAGAAGCTGCAGTGATCTAAGCAGCAGCAAGTTTGT
30 GCATTCATTTTTTTTTGTTTTTGTGTTAAATATGTTTAAATTATCACACTGCTGGCACT
CCTCATTTGCATGAAATTCTGCACCATACTTACTAATTCGTAGTAAAGTTACCCCC
CAACCCACGAAAAAAAACCTACTCTGGAAGAAAATTTTCACTGAAATATAACC
AACTTCTTTAAGTGGGATTGTGACAAGATTATAAATGATATGAAAAATAACATT
TTTAAAATTTGGCCATCCAACCTTTANAGAAATGGTTTGCCCTATACAAATTTTGT
35 AATTTTTTAAAGATAATATATTCTACCCTCATATGGTCCTCAGAATTAAGCATAA
TGAACAGGAAGAAAAGGAAAAGAATGCAACTGAGTGCTAAGGCAGAACATCTT
GCCAGAAGTAATTAATGAAGGTAGAGTATATAATGAAAAGTGCAGAATTTTATA
GGGCCAACAAAGATAACAGTCTATATTTTCACTTACACAGGCAAAGTGGATTCTG
CAATTACCAGTTGCGTTAAATGCACCAAATAAAGCTCCTAAAATTGATACTATAA
40 GCGGCCACCTTAAGTTTTTCCAGGCTGCAACTGTGCATTATTTAAAATGGTTTTCT
TAAATTTATTTATTTTTTAAACATAACACGAGGAAGGTGTTAAAATGGTGTAA
TAGCTCAATAGAATAAGTATTCCAGATTTCTGGGAGGGATGAAGAGGGAGATATT
CAGAACCCTTCACCAGATTCCCCCAACTTGATCATAGTGGATTAATGGTGTGCT
TTGTGGATGTGGTTAGTCAATGACACCAGCTTGACGGATCTTTCTTCTGCACCA
45 AACCCCATTTGAGTTATCTGGTCCCCTTGGCTGACGAAGAACCATTAGGCGAGGAG
CACTGGCATCATCCAGAGTGATATTCTTCAAGCGATTGACCAACCGATCAGGTCTG
AGGAGCTGCAACAGCCTTGGGGCCCTCACAGACTCGCCAAACATTACAGGCGCT
GCACTTGCCAGTGCCTGATTAAGAATCACTGAGAAGTCCACCTCATCTCCTGCC
TGTAAGCTCAATGCCATCCTGAACCTCTTTCACATGGAAAAAGAGCTTCTTGCTAT

CTCCTACTTCATAGTTAATGAAGCCAAACTGATCTTTACACATTCCACTGTGGCC
CTGCGCAGGGGTGTGATGTTGTAAGCCATAGTTTGTGCATTTTGGCCCAGGACAC
ACAATTGGAACCTTGACGCTCTCCCCTTTCTGCAGGCAATCCCCTTTGTTGGCCATC
CCAACGATGCCAAATGGATAGACCTCACCTTTCATATCGCCCTCCTCCACAATCT
5 CAATCATTCCCTTGGTACTCAGTCTGTGTTGGATCAAACTCCTCAGGGGGCGAAT
TACTTTGCCAGAGTAAATGGTGGGATCAGCTTCCTCAGTAATGCCATTCACTGAG
TGTGTTTTGTTCACTTTTTCTGCACTGACTTTGTTGCCTTTGCCTTTGGACAAGCTA
TACTCGACCATGTCCCCCAGTTCCAGGCTATCAACATCACCAGAGAACTCACTGT
AATGGAAAAAGATTTCCCTTATCATGATTGGCTGTTTCAATAAATCCAAAATTATC
10 CTTCAGAGTTGCCACATAACCCAAGAGCCTCTTGGAGTTAGAATTACGACCTAAA
AGTCGCACACAAGTTGCAACCTGCTGTCCAGGCCTCTGTTTGTCACTAATACTAA
ATTCAACCTTATCTCCTATTTGAGGAGAAGTAGATCCTTCCACATCCTTGGCTTGA
AAAGCAATAGTCAGTTTACCCCCACAGTCATCATAAGCAATAATGCCATCCTCAG
CCTCCTTCTCTTTGCCTTTATTTGGGCTAGTGGTTTTAGGATTGGAAAAAGTGGCT
15 TCTTTTTCTACCGTGCCAGAAAACGGTGATCTGAATGGGAATGAAATGAAACCG
TGCCCTTGGGAAGTTTTTAAATCCTAATAGCATGATTTCTTTGAGCAGAGAGCAT
ATCAGGAACACAGTAACTCTACTTCATCTGCAATATGGAGCTGGTTCCCATCC
AGAATTTCACTGAAGTGAAGAACATACGAACATCACGATCCACACACTTGATG
AAACCAAACCATCTCTCATGGCAGCAATCACACCCATTTCTCGGGCTTCATTAG
20 TGAAGTGAATGTATTTGACAGAACTTCTATATTGGTTGCTCGCTCTAATTTGTCA
CGTCGGTCTGTTGAAATATTAAACCTAACATGGTCACCTTCCAGCAGGGTCACCT
TGGATTTCGGTATCTTTGTCTCCAAAGGGGAAGTTCTTTAGGGATCAGAAAGTCAA
CTTGGATGGCTCCTGGCAATGGGTGATTCTGGTTTTACTGGGTACTTTTGGGATA
TAAAGTCTTGGTTACAGTTCCTTCAAAATGTTCAATGCTGATATCTTCAAAAANGGAGT
25 GTTCCTTGAGGCAAATAGNCTGACATCTGTTGCAACTTNTTNAACCATNTCTGTCC
GTGATTGTNGAATTCACATCATCGCCAGGCTGTAAGGTTTCTAAGTCACCCTTA
AATCACTATAGTGAAAGAATATCTCTTTTACAACATCACCTCTTTCAATAAAGC
CAATGCCTCCTTCATGGCACAACTACTCCCTGACAGCGGGCTTGTTTCTTTTCA
ACAGTATAATGTTGCGAGCACTTACAGCACCAGTATGTTTATTGTTATCAATTAC
30 AAAGTTTATTTTATCTCCAGTTTCCAGCTGAACGTTCCCTTCGACATCTTCAGGGG
TGTAAGTCAGATAAAACAAGAAATCCTCCCTGAAGAACGAATGAATGGACAAGA
AGTGTTTTATCTGACTTACACCCCTGAAGATGTGCAAGGGAACGTTTCAGCTGGAA
ACTGGAGATAAAATAAACTTTGTAATTGATAACAATAAACATACTGGTGCTGTAA
GTGCTCGCAACATTATGCTGTTGAAAAAGAAACAAGCCCGCTGTCAGGGGAGTAG
35 TTTGTGCCATGAAGGAGGCATTTGGCTTTATTGAAAGAGGTGATGTTGTAAAAGA
GATATTCTTTCACTATAGTGAATTTAAGGGTGACTTAGAAACCTTACAGCCTGGC
GATGATGTGGAATTCACAATCAAGGACAGAAATGGTAAAGAAGTTGCAACAGAT
GTCAGACTATTGCCTCAAGGAACAGTCATTTTGAAGATATCAGCATTGAACATT
TTGAAGGAACTGTAACCAAAGTTATCCCAAAGTACCCAGTAAAAACCAGAATG
40 ACCCATTGCCAGGACGCATCAAAGTTGACTTTGTGATCCCTAAAGAAGTTCCTT
TGGAGACAAAGATACGAAATCCAAGGTGACCCTGCTGGAAGGTGACCATGTTAG
GTTTAATATTTCAACAGACCGACGTGACAAATTAGAGCGAGCAACCAATATAGA
AGTTCTGTCAAATACATTTCACTTCACTAATGAAGCCCGAGAAATGGGTGTGATT
GCTGCCATGAGAGATGGTTTTGGTTTCATCAAGTGTGTGGATCGTGATGTTTCGTA
45 TGTTCTTCCACTTCAGTGAATTTCTGGATGGGAACCAGCTCCATATTGCAGATGA
AGTAGAGTTTACTGTGGTTTCTGATATGCTCTCTGCTCAAAGAAATCATGCTATT
AGGATTAAAAAAAGTTCCTCAAGGGCACGGTTTCATTTCAATCCCATTCAGATCACC
GTTTTCTGGGCACGGTAGAAAAAGAGCCACTTTTTCCAATCCTAAAACCACTAG
CCCAAATAAAGGCAAAGAGAAGGAGGCTGAGGATGGCATTATTGCTTATGATGA

CTGTGGGGTGAAACTGACTATTGCTTTTCAAGCCAAGGATGTGGAAGGATCTACT
TCTCCTCAAATAGGAGATAAGGTTGAATTTAGTATTAGTGACAAACAGAGGCCTG
GACAGCAGGTTGCAACTTGTGTGCGACTTTTAGGTCGTAATTCTAACTCCAAGAG
GCTCTTGGGTTATGTGGCAACTCTGAAGGATAATTTTGGATTTATTGAAACAGCC
5 AATCATGATAAGGAAATCTTTTCCATTACAGTGAGTTCTCTGGTGATGTTGATA
GCCTGGAAGTGGGGGACATGGTCGAGTATAGCTTGTCCAAAGGCAAAGGCAACA
AAGTCAGTGCAGAAAAAGTGAACAAAACACACTCAGTGAATGGCATTACTGAGG
AAGCTGATCCCACCATTACTCTGGCAAAGTAATTCGCCCCCTGAGGAGTGTTGA
TCCAACACAGACTGAGTACCAAGGAATGATTGAGATTGTGGAGGAGGGCGATAT
10 GAAAGGTGAGGTCTATCCATTTGGCATCGTTGGGATGGCCAACAAAGGGGATTG
CCTGCAGAAAGGGGAGAGCGTCAAGTTCCAATTGTGTGTCCTGGGCCAAAATGC
ACAACTATGGCTTACAACATCACACCCCTGCGCAGGGGCCACAGTGGAATGTGT
GAAAGATCAGTTTGGCTTCATTAAGTATGAAGTAGGAGATAGCAAGAAGCTCTTT
TTCCATGTGAAAGAAGTTCAGGATGGCATTGAGCTACAGGCAGGAGATGAGGTG
15 GAGTTCTCAGTGATTCTTAATCAGCGCAACTGGCAAAGTGCAGCGCCTGTAATGT
TTGGCGAAGTCTGTGAAGGGCCCCCAAGGCTGTTGCAAGCTCCCTCGACCTGAAT
CGGTTGGGTCAATCGCTTGAAGAATATCACCTCTGGATGATGCCAGTGCTCCTCG
GCCTAATGGTTCCTTCGTGAGCCCAAGGGGGACCAGATAACTCAATGGGGTTTGG
TGCAGAAAGAAAGATCCGTCAAGCTGGTGTCAATTGACTAACCACATCCACAAAG
20 CACACCATTAAATCCACTATGATCAAGTTGGGGGGAATCTGGTGAAGGGTTCTGAA
TATCTCCCTCTTCATCCCTCCCGAAATCTGGAATACTTATTCTATTGAGCTATTAC
ACGAGTTTAAACACCTTCTCATGTTATGTTTAAAAAATAAATAATTTAAAGAA
AAGCATTTTAAATAATGCACAGTTGCAGCCTGGAAAAACTTAAGGTGGCGCCTTA
TAGTATCAATTTTAGGAGCTTTATTTGGTGCAATTAACGCAACTGGTAATTGCAG
25 AATCCACTTTGCCTGTGTAAGTGA AAAAATATAGACTGTTATCTTGTTGGCCCTAT
GAAATTCTGCACTTTTCATTATATACTCTACCTTCATTAATTACTTCTGGCAAGAT
GTTCTGCCTTAGCACTCAGTTGTATTCTTTTCTTTTCTTCTTCTGTTTATTATGCTT
TAATTCTGAGGACCATATGAGGGTAGAATATATTATCTTTTAAAAATTACAAAAA
TTTGTATAGGCAAACCATTCTTAAAGTTGATGGGCCAAATTTTAAATGTTATTT
30 TTCATATCATTTATAATCTTGTGACAATCCACTTAAAGAAGTTTGGTTATATTTCA
GTGAAAATTTTCTTCCAGAGTAGGTTTTTTTTTCGTGGGTTGGGGGGGTAACTTTAC
TACAATTAGGTAAGTATGGTGCAGAAATTCATGCAAATGAGGAGTGCCAGCAGT
GTGATAATTTAAACATATTTAAACAAAAACAAAAAATGAATGCACAACTTGC
TGCTGCTTAGATCACTGCAGCTTCTAGGACCCGGTTTCTTTTACTGATTT

35

SEQ ID NO: 523

>16184 BLOOD 237729.6 AL117521 g5912037 Human mRNA; cDNA DKFZp434P0735
(from clone DKFZp434P0735). 0

CTCATTGTACTTAGACAAAGAGGCAGCTGAACGTCTTTCAAAAACAGTAGATGA
40 AGCATGTCTGTTACTAGCAGAAATATAACGGGGCGCCTGGCAGCAGAACTGGAGGA
CCGTCGCCAGCTGGCTCGGATGTTGGTGGAGTATACCCAGAATCAGAAAGATGTT
TTGTCGGAGAAGGAGAAAAAAGTAAAGGAATACAAACAGAAAGCTTGCACGAGT
AACCCAGGTCCGCAAGGAACTGAAATCCCATATTTCAGAGCTTGCCAGACCTCTCA
CTGCTGCCCAACGTACAGGGGGCTTAGCCCCCTGCCCTCTGCTGGGGACCTGT
45 TTTCAACTGACTAGGATGGGTGTCATGTCCCAGATTTCTGTTTGTACCAGCAGAA
AGAAGAGGGCAAGTCATGGTTGGAAATAACCTTCTAGCCCCTGGTTCTATCCCTT
CTTCCGCCCAGCCCCCAGCCTCAAGAAAGAACCTCAGACTCTGATTCTCCTCTT
CAGCCTCTCATCTTGAGCACAGTTCAGAACAGTGGCGACTGGAATCTGGTTTATA
TTCATATTTGCAAAGACTACAGACTTTTTCTCCCACTTCATATTTTCATGCCCCC

TGTGTTGTTTTCCATTCTTAACTGTCTCCTTATACCTAAGAAGTTATGAAAATCATG
 TGTACTTCTGGAAGCTTTCGAAAGAATCTTGTCCCTCATGACAGCATTATCATG
 AAAGCAGCTTCTCCTTTCTGGGCTGGGCTTGTTCAGTTTCGGTGTGGGCTTCCACT
 AAGGCACTTGTCTGAGACGTTGGCTTTCCAGCTGCATCTGCCCCAAAAGGTT
 5 GTAGGCACAGCTGTCGTAGCGTTGCCATAAAGAGTTTGCCAAATCTCTGATCCTC
 CCTTTCCATTGCTTCTCCTAGTGATGCACGAAGATTAGGTGCATTTATTTTGTA
 CAGATTGGAGAATCTAGCAATAAGATTCAAAGCTAATCTGGAGCATAAAGGCAC
 AGTTCAGAGACAGAATAACAGGGATCACAAGCATGAATTAAGGAATTTATTT
 GCTTCAAGTTCTAGATAACAACCTTCCCATGCTGCACTTCTCCACTGTGCGAGCA
 10 CGTTCCGAAAAACAGAATGCCTTGATCCCTGGTGGGTGCGAAGGCAGTTGTTAG
 GGATGGCAGGCATTGGTGGGCTCCAAAAGATGAAGGCCCCACACACAGGTGTGC
 TGCATTTGGGATCTGTGTGGGTGTTTCTTGGACCCTTTCTTCTGGGAGTAGGGTAC
 AACTAACGTTTAAATCCGCTGTCTGGGTGCATGTCCACAGTACGGTGGCTAAACT
 CGAACATCACTGCAAATAGGACGCTGAGCAGGTCCGTCTGTCTCATGTACGCCACT
 15 GCACAGGTCTTGTCCCCACACGACGGGGAGTACTTGCCTCAGATGTTATTGAAT
 AGCTCGTCTCGGGCAGGGGAAGCGGGGAGTTGGGGATATTAATTGGGGGTTTAA
 ATTCTATTATCATGTGACGCTGACATTATGACTATATAATGTAGTTAGAGACAATTT
 TTATCTTGCTTATAGTAAAGGTTGAGCCTGCCAATTGTAAATCATTCTAATTTGGC
 AGGCTTATTTTGGACATTGGAAAGGGCAGAAAGCGATTTGCCCCAGTAGTGTAAT
 20 AGGAGTTATAGACCAGAGGCTGAAACCCAACTATATAAAAAGGAATTCAGTGG
 AGGGGGCTTTGTAATCTCCATTAATTTGTGTTGCTACTTCCAGGATCACCAAAAA
 TTACATGTAATTTTACATGTTAAACACATTGAAACATAACCTATGTTTATAAAGC
 ATAACGGGCTTCCCTTCCAGAAGCTCTCCTGCTTGTGATGAAGTGAGAAGAATGA
 AAAGTCATAGCAGATACTCAGTTTAACTCTGTGAGAACCTAGTAGTGTGTTGAGC
 25 TGTATTTCAGATTTGAATTGAGCTGTGTGTTGTTTGTCTTATGGACACTGCCTGTC
 GTTCTGTCACTGTAAATTAATGAGTCTATAAGGTTTTTCTTCCAGAGGCCATAGG
 TGACATCACTAAAATTGCAAGATAAATTGTAATCTTTGCTGCTGCTGCACTCCCC
 AACCTCTCCCCCACCCCCCGTGGTGTGCTGCTTTCTAGATGAGCGTGTGTTTGGAGC
 AGGCCCATCTGGGACACTCTATGCTTTCACCAAGGAAGTGCGATCTGAGCAGCCA
 30 CAATCCAGCCAAAAGAGGATCGTAGATATTTGCTCTGATCAACTAGATGAAAAT
 ATAGCAGAATGGATTTAGCCCACTGCTCTGTTTTATCCAAGTGTCTCTGACCA
 GCAATTGGTGCATAATTATTACAGCAAAAGTTAAGAAATGAACTGTAGCAATT
 ATGTAAATGAATGTGTTGGCCTCTTAATACCTGTTACTAGTGGACTTCCTGTGAG
 GAAGTTAGTTTTTTGTTTGTGATGAAATGCTTTCGTTTTTAAATCTTAATTCTGCTG
 35 TCCACATCTCCCAAAGTGTGCTTACTTCATTTGTTTAAATTTAAATGAACTTTCCT
 CCTTGTATGTATGAGGTGACTTGGTGGGTGGGGTGGGTGGTTTTTGTTTTGTGTT
 TTTTCTTCTTAGGGCATCTGTAGGCCTCAAAGGACCTTTCCTTAGGTCATATTC
 CTCAGAAAGTCTTCAATCTTCCCTTGTTTTGTTTGTGTTTTCTTAAAGAATAT
 TTTCAAAGCTTAAATTTGTATATTAATTTAGGACTATTTAGAAGTATAGGCTGTG
 40 TTGGCGGCAGCAGTATATTCTGAAATGTCTCATAGATATATATTTTGAATAAAG
 ATGGTGTGTTGAAC

SEQ ID NO: 524

>16303 BLOOD gi|1443464|gb|N90137.1|N90137 zb17h09.s1 Soares_fetal_lung_NbHL19W

45 Homo sapiens cDNA clone IMAGE:302369 3' similar to gb:X17576 CYTOPLASMIC

PROTEIN NCK (HUMAN);, mRNA sequence

GCGNCCGAGTGGCGTCTGAGGCCCTCCTCAGTGCTGAAGCTGCTGAAAGATGG
 CAGAAGAAGTGGTGGTAGTAGCCAAATTTGATTATGTGGCCCAACAAGAACAAG
 AGTTGGACATCAAGAAGAATGAGAGATTATGGCTTCTGGATGATTCTAAGTCCTG

GTGGCGAGTTCGAAATTCCATGAATAAAACAGGTTTTGTGCCTTCTAACTATGTG
GAAAGGAAAAACAGTGCTCGGAAAGCATCTATTGTGAAAAACCTAAAGGATACC
TTAGGCATTGGAAAAGTGAAAAGAAAACCTAGTGTGCCAGATTCTGCATCTCCTG
CTGATGATAGTTTTGTTTGACCCAGGGGAACGTCTCTATGGACCTCAACATGCCC
5 GCTTTATGTGAAATTTAACTTACATGGCTGAGAGAGAGGATGAATTATCATTGA
TAAAGGGGGACAAAGGTT

SEQ ID NO: 525

>16305 BLOOD 474565.9 M18391 g339716 Human tyrosine kinase receptor (eph) mRNA,
complete cds. 0

10 GCCCCCGCCCGGCCCGCCCGCTCTCCTAGTCCCTTGCAACCTGGCGCTGCATCC
GGGCCACTGTCCCAGGTCCCAGGTCCCGGCCCGGAGCTATGGAGCGGCGCTGGC
CCCTGGGGCTAGGGCTGGTGCTGCTGCTGCGCCCCGCTGCCCCGGGGGCGCG
CGCCAAGGAAGTTACTCTGATGGACACAAGCAAGGCACAGGGAGAGCTGGGCTG
15 GCTGCTGGATCCCCCAAAGATGGGTGGAGTGAACAGCAACAGATACTGAATGG
GACACCCCTGTACATGTACCAGGACTGCCAATGCAAGGACGCAGAGACACTGA
CCACTGGCTTCGCTCCAATTGGATCTACCGCGGGGAGGAGGCTTCCCGCGTCCAC
GTGGAGCTGCAGTTCACCGTGCGGGACTGCAAGAGTTTCCCTGGGGGAGCCGGG
CCTCTGGGCTGCAAGGAGACCTTCAACCTTCTGTACATGGAGAGTGACCAGGATG
20 TGGGCATTACAGCTCCGACGGCCCTTGTTCAGAAAGGTAACCACGGTGGCTGCAGA
CCAGAGCTTCACCATTGAGACCTTGCCTGCTGGCTCCGTGAAGCTGAATGTGGAG
CGCTGCTCTCTGGGGCCGCTGACCCGCGCTGGGCTCTACCTCGCTTTCACAAACCG
GGGTGGCTGTGTGGCCCTGGTGTCTGTCCGGGTCTTCTACCAAGCGCTGTCTCTGAG
ACCTTGAATGGCTTGGCCCAATTCAGAGACACTCTGCCCTGGCCCCGCTGGGTTGG
25 TGGAAGTGGCGGGGACCTGCTTGCCCCAAGCGCGGGGCCAGCCCCAGGCCCTCAG
GTGCACCCCGCATGCACTGCAGCCCTGATGGCGAGTGGCTGGTGCCTGTAGGAC
GGTGCCACTGTGAGCCTGGCTATGAGGAAGGTGGCAGTGGCGAAGCATGTGTTG
CCTGCCCTAGCGGCTCCTACCGGATGGACATGGACACACCCCATTTGTCTCACGTG
CCCCAGCAGAGCACTGCTGAGTCTGAGGGGGCCACCATCTGTACCTGTGAGAG
30 CGGCCATTACAGAGCTCCCGGGGAGGGCCCCCAGGTGGCATGCACAGGTCCCCC
CTCGGCCCCCGAAACCTGAGCTTCTCTGCCTCAGGGACTCAGCTCTCCCTGCGT
TGGGAACCCCCAGCAGATACGGGGGGGACGCCAGGATGTCAGATACAGTGTGAGG
TGTTCCCAAGTGTGAGGGCACAGCACAGGACGGGGGGCCCTGCCAGCCCTGTGGG
GTGGGCGTGCACTTCTCGCCGGGGGCCCCGGGCGCTCACCACACCTGCAGTGCATG
35 TCAATGGCCTTGAACCTTATGCCAACTACACCTTTAATGTGGAAGCCCAAAATGG
AGTGTGAGGGCTGGGCAGCTCTGGCCATGCCAGCACCTCAGTCAGCATCAGCAT
GGGGCATGCAGAGTCACTGTGAGGCCTGTCTCTGAGACTGGTGAAGAAAGAACC
GAGGCAACTAGAGCTGACCTGGGCGGGGTCCCGGCCCGAAGCCCTGGGGCGAA
CCTGACCTATGAGCTGCACGTGCTGAACCAGGATGAAGAACGGTACCAGATGGT
40 TCTAGAACCCAGGGTCTTGCTGACAGAGCTGCAGCCTGACACCACATACATCGTC
AGAGTCCGAATGCTGACCCCACTGGGTCCCTGGCCCTTTCTCCCCTGATCATGAGT
TTCGGACCAAGCCACCAAGTGTCCAGGGGCCTGACTGGAGGAGAGATTGTAGCCG
TCATCTTTGGGCTGCTGCTTGGTGCAGCCTTGTGCTTGGGATTCTCGTTTTCCGG
TCCAGGAGAGCCCAGCGGCAGAGGCAGCAGAGGCAGCGTGACCGCGCCACCGA
45 TGTGGATCGAGAGGACAAGCTGTGGCTGAAGCCTTATGTGGTACCTCCAGGCAT
ACGAGGACCCTGCACAGGGAGCCTTGGACTTTACCCGGAGGCTGGTCTAATTTTC
CTTCCCGGGAGCTTGATCCAGCGTGGCTGATGGTGGACACTGTCATAGGAGAAG
GAGAGTTTGGGGAAGTGTATCGAGGGACCCTGAGGCTCCCCAGCCAGGACTGCA
AGACTGTGGCCATTAAGACCTTAAAAGACACATCCCCAGGTGGCCAGTGGTGA

ACTTCCTTCGAGAGGGCAACTATCATGGGCCAGTTTAGCCACCCGCATATTCTGCA
TCTGGAAGGCGTCGTCACAAAGCGAAAGCCGATCATGATCATCACAGAATTTAT
GGAGAATGGAGCCCTGGATGCCTTCCTGAGGGAGCGGGAGGACCAGCTGGTCCC
TGGGCAGCTAGTGGCCATGCTGCAGGGCATAGCATCTGGCATGAACTACCTCAGT
5 AATCACAATTATGTCCACCGGGACCTGGCTGCCAGAAACATCTTGGTGAATCAAA
ACCTGTGCTGCAAGGTGTCTGACTTTGGCCTGACTCGCCTCCTGGATGACTTTGAT
GGCACATACGAAACCCAGGGAGGAAAGATCCCTATCCGTTGGACAGCCCCTGAA
GCCATTGCCCATCGGATCTTCACCACAGCCAGCGATGTGTGGAGCTTTGGGATTG
TGATGTGGGAGGTGCTGAGCTTTGGGGACAAGCCTTATGGGGAGATGAGCAATC
10 AGGAGGTTATGAAGAGCATTGAGGATGGGTACCGGTTGCCCCCTCCTGTGGACT
GCCCTGCCCCCTCTGTATGAGCTCATGAAGAACTGCTGGGCATATGACCGTGCCCG
CCGGCCACACTTCCAGAAGCTTCAGGCACATCTGGAGCAACTGCTTGCCAACCCC
CACTCCCTGCGGACCATTGCCAACTTTGACCCCAGGGTGACTCTTCGCCTGCCCA
GCCTGAGTGGCTCAGATGGGATCCCGTATCGAACCCTCTCTGAGTGGCTCGAGTC
15 CATA CGCATGAAACGCTACATCCTGCACTTCCACTCGGCTGGGCTGGACACCATG
GAGTGTGTGCTGGAGCTGACCGCTGAGGACCTGACGCAGATGGGAATCACACTG
CCCGGGCACCAGAAGCGCATTCTTTGCAGTATTCAGGGATTCAAGGACTGATCCC
TCCTCTACCCCCATGCCAGTCAGGGTGCAAGGAGCAAGGACGGGGCCAAGGTC
GCTCATGGTCACTCCCTGCGCCCCCTTCCACAACCTGCCAGACTAGGCTATCGGT
20 GCTGCTTCTGCCCACTTTCAGGAGAACCCTGCTCTGCACCCCAGAAAACCTCTTT
GTTTTAAAAGGGAGGTGGGGGTAGAAAGTAAAAGGATGATCATGGGAGGGAGCT
GAGAGGGGTTAATATATATACATACATTACACATATATATATTTTGTAAATAAACA
GAGAACTGATTTTCTGCCTCCATCCCACCCATGAGGGCTGCAGGCACTACAAAGA
GCTGACTACTGAGAATTCTGGAAAGCAAGGTCTGGGCTCTAGCAGTGTGGGACTT
25 CCGACAGAGCACGTGACCGTCCAGGGGGAAGCAGCCATTGTCATCTGCCTCAAT
CGACAGGGGCTTCCCGCAGTCCTGGGAAGAAGGAAGGGTGAGGGGCACTGGACC
GGAAGGCCCCCTGCTCTGCTCCACCCTACCCACCCCCATCCAGCTCCATCTTGAA
TTAGAAAGATGCTTCATGGCTCAGAGCTGGTGTATCGCTTTTTCCAGCCACACC
CAACTCCCCATCCCTATCCTACTTCCAGTCACCCACTAGGACCTTCCTGCAAGAG
30 GGCAAGCAGTGGGTAGAGCTGCTCCCAAGGTGCTTGCTCCCCTGCCACCACCAC
CCTAATAAAATAGAGGTTGGCTCACCTCCATTCTGAAGACCTCTTCTCTCAGCTCC
TGTTTCCCCATCCCCTACCACGGTAAAACACCATGCCCTTCTTCTCTCCTATTGGC

SEQ ID NO: 526

35 >16466 BLOOD Hs.6820 gnl|UG|Hs#S2451360 601487048F1 Homo sapiens cDNA, 5' end
/clone=IMAGE:3889762 /clone_end=5' /gb=BE875609 /gi=10324385 /ug=Hs.6820 /len=915
CTTCTGAGCTTTCTTCCTCACCAGTGGGCTGTGCTTGTTCATTTCTGTACACCCTT
ATTTTATAACCGTTTTTCTTCAACAATGGCGAAATTGACTGTAGTGCTGAACCAAA
AGTATCCCTTTCCCTCCTTATTCTCACCCTCAAGAACATTCTAGATCACATGGGTG
40 CTTGTGCCTTCCGATTTTCTTGCAATTTGTTTTTTTCTGACCTGAAGTTGTTGTAC
AAAATCAGTCAGACTTTGTGGGCTGAAGGACACGGTGCAGCAGAGGGTGTCCCT
GTGAGAGTTCTGCAGAGTGCTGGGCATGTGCCTGGAACCTACCGAGTAGGAGCCA
TTTCTTTGTACCCCTGCCTAATCCATTCTCTCCTTCCAAGTCCATTGTTGCAAGC
AATATTCTTCTCAATTTTTATATGTTTACTTTAAATCAAAGTTAGTCTATTTGTATA
45 AAATTTTTTAAAAAATCTAAAAGAAAAAGAAAAAAACAAGGGTGGGTTGGGTAT
TCCAGTGGGAAGATCATTGAAGGGAAAAAATGTTACTATTTACTGAGGTATTTTT
CACCAGAATGATTGAATTAATAAATCAATTGCATTTTCATTGTGGGTGCTTAGA
GAAGTTCTACAAAATTCACACCTGGCAAGGTTATGCTTCATTTAATTATGGACCC
ATACTTTTCAATTTCTGAAGATACCGGAATTCCTTATGAATCAAAGAAATTTTTC

ATTCCAGTCAACGCACGCGGCGGACTCGCGAATTCCAAACGGGATCTGCTGAGA
CCTCACAGAGGTGGGCCGCGATTATAAGGACGGGATGACATATCTTGAGCCACG
ACAGGTCTCGAGGCCCCAGTACGAGACACGGAGCAGGGCTGTGACACCCACG
CAGGCAAGAGCGCTAGGATGCACAGCACACCC

5

SEQ ID NO: 527

>16524 BLOOD 474681.7 D50525 gl167502 Human mRNA for TI-227H. 0

GGATTTGGAGCGGCCGGGGAGGCGGGGGTGGCCGGGGCCGGCTTGAGAGCCTGG
CGCCACCCTTCGGGGCCTGCAAGGACCCAGTTGGGGGGGCAGGAGGGGGCCGGA
10 GGATGGTTGGTTGTGGGATTTCTACTTTGCCTTTTCCTCCTTATGCCGCCTTAGTG
AGGGGCGGGAGCTCTGGCGGCAGCCCCGGGGTGGGGAGACGAGCTCCGGAGTC
GGAAGAGCTGGGTTTTCTTCCGGGCCTAGCCACCAGTTGGCGGAGTGACCTTAGG
CGAGTCACTCTGTAATTTGTCTGCGCCTCAGTTTCCTCCTCTGCCTATCAATGTGT
GTGGGGTTGAAATCGCTTTGTAAACTATAAAGCGTGGGTGTACGTAAAGGATGG
15 TTATTGTTTATAATTTTTTTTGTAGTTGTAAGAAACTTAGCAGTTCCCCAATCCTT
GGGTTTTGAACCTGGGAACCTTGGATTGGAGTTGGGGATCCCCAACTTCCTGAA
ATTGTGGGAATGTGCGGTTTGGGGGAATGATGGGAATTTGTGGGAATGTGCGTTT
TAGGGGAATGATGATCCATCGCTAGCAAGTTTTCCAAGGGGGCTGTGACCCAGA
AGAGTTAAGAATCACAATTTCTTCATGCTACAGAGAGGAACTGAGGCCTAGAT
20 GTCATTTGGGACCCTTCACAACCATTTTGAAGCCCTGTTTGAGTCCCTGGGATAT
GTGAGCTGTTTCTATGCATAATGGATATTCGGGGTTAACAACAGTCCCCTGCTTG
GCTTCTATTCTGAATCCTTTTCTTTCACCATGGGGTGCCTGAAGGGTGGCTGATGC
AATATGGTACAATGGCACCCAGTGTAAGGAGCTACAATTAGGAGTGGATGTGTT
CTGTAGCATCCTATTTAAATAAGCCTATTTTATCCTTTGGCCCGTCAACTCTGTIA
25 TCTGCTGCTTGTACTGGTGCTGTACTTTTCTGACTCTCATTGACCATATTCACG
ACCATGGTTGTCATCCATTACTTGATCCTACTTTACATGTCTAGTCTGTGTGGTTG
GTGGTGAATAGGCTTCTTTTACATGGTGCTGCCAGCCCAGCTAATTAATGGTGC
ACGTGGACTTTTAGCAAGCGGGCTCACTGGAAGAGACTGAACCTGGCATGGAAT
TCCTGAAGATGTTTGGGGTTTTTTTCTTTCTTAATCGAAAGTTAACATTGTCTGAA
30 AAGTTTTGTTAGAACTACTGCGGAACCTCAAAATCAGTAGATTGGAAGTGATTC
AAAGCTAACTTTTTCCTTGGCCCTCCTTGTGTTCTAATTGCTTGCAAGTGTAATA
CTAGGATGTCCAAGATGCCAGTTTTTGCTTCTTTGTTAGTTGTCAGCTGCTTTTAT
CAAATTCAGGCCATTATCCAACAAACACTATAAAAATGTTTGAACAATTGGATT
TCAAACATTTTCGTTTTGTGGAGTGGTGCTACCAAGTGGTACAGCCCTAAGCAA
35 GTGAACACAAACACATTTAAGTGTATTTGTCTGATTAGATGTTAGCCAGTTATG
CTATTTCAATCAAATGTCTGAAAAAATCAATTGACTATTCCTTTTCTAAAGGGC
AGAGACAGATAATCTCACTTCCAGAGAAATGACTTGGAGAAAAAAAAGTGTTGG
TCTTTTGTCTTTTGTAAATTAATCCGGATGTACCTCAAAGACTTAAGACTGTG
GTGATAAGATGCTTTCCTCAGCAGAAAGGAGGGAAAAAAAACAACCTGGAACCTCA
40 AAGCTTGAAATTCTGTGGCAAAACATGAGATGTCCAGGATTGGAGGTTGAAAAG
ATTTCACTACAGTGTTCTGCAATAGTTGGAGCAGATAACTTTCAGTGTAGCCACA
GCCATGGACTCCAGATTTCCAGATTTTCAAGACCTGGACCTGGAACCCGAAAGA
GCTTGTACGATGCGGCAGGAACACTGGAGGTAGATTTTTTTTTTATTTTGAATTT
TGGGACTGTTGACCTTGTGTGAGAAAAGAGACAACGACTGAGCAAGCACTACC
45 ACCAGCACTGTTACTGGGAATTAGAAGACCTGAGTTTCTGTCCAGACCCTCAGTG
CAAACCTGAGGATGCTCCATCCAAAGTGAATTATGTCCTGTGCCTCCTGATTGCTG
AGTGTTACCTGGACCTTCTGACTACCTTCCCTGTGCTATTCATCAGCCTACAGA
CCTGGTACCTGGATTTTGGCCGAGATGATTCCTACCACCTTACTACTGACGAAG
ACACCCATTCCAGTGGACCACTGTGACCCAGGAGGCATTACGCCATCATGATGTG

GCCTTTACCTCCACTCCTGTCTTGTCTACCCAGATTTCAGCACAGCCCTTTATAGT
GAAGTCAGAGTCCTCAAGCCAAATAGCTAAAGCTGTTTTATCACAACAAAGGCC
TAGTTTGTTCATGAGTGTGCATTTTCTTCAGTTAAAGCCTTCAGAGACACA
CAATAAATTTGGACCAGGGGATTTTTTAGTTATTAATGCTCTCTGAAGAAAGGCA
5 ACATCTTTTTGAGAGCAGCATTGGACCACACCCCAATCTCAAATGATTGAAAT
TCATGAACATCTAGGATCCCGTGAAGGTCCTGGACCCTGTTTTTCTACTTCAA
ATCCTGTAGTAGCCTACTGAATGAGAAAACATATTCTGACCCATTGGGATCAAAT
CAAAGGCACAGTGAACCTCATAGCATCTTCTTTGGAATTACTCAGGAACCAGA
ACTTTTTACACAAATGTAAGAAATTCTACCAAGGAGTCCCCTTACCTAACAGCAT
10 CTCACAAGGCTGCACCAGATTCCAGAAAAGGCTTCTCTTGATACATCAAGGTAGA
ACCTCTATGCATTTTGTGACCGACTTATTCTTAGATCATTGGTTTTCCAAAGGCTT
TGTGGCCATGAAGCCCTTTGAGTGAAAACCTGTGCAGAAGCCAGAGTAAAAGTG
AAGCTGCTCTGGATGAAGTAGTGAAGCAAGAGTAGGGGCCTGAATCCTGCTACA
ACTATCTTCCTTTACCACCGTGGTGACACCTAAGGGGACTTCCTTACAACACCTT
15 GAACTCTTCCGAACACAGTTTGAAAACCACTGCCCCAGACAGCAATATGTTTGAC
CTGAATGGCATTCCAATCTTTTCTGTACCTCCACTCAGCACAGTTCATGTTTCAGTA
GATGCTGAACATTCTTAGAAATACTGTGTGTGAACTTAGAAAAGTGCAAGAAGA
CAGGCATGTCTTTGACCCAGGAATGATCATTGCTGAAGATGGTGTCAAGTGAA
CCTAGATTAACAGCCCTCCACTCCAGATGGATATCCAGTGATTCCCTAGAATGGGA
20 TATAGCCAGAGAACAATTCTATGCACCCTACACTGACAGACTCCCTTAAGCAACA
CCAGATGCTCTACTGGTACTTGAAGTACATGACTTTGAAGTCTTGACCCCTCCATG
AATAACCTGAATTATCAGCAAGCGGGTTTGAAGCTGGTGCCTCATTGAGGCCATA
TAGAGCAACTTGTACATTTGACCTCTTGTATCAGGCATGGTACTTACTTCCGTG
TGCAAGAGATAACTATGAAGCCAAATTCAAATACTGGCAACATTTCTAAAGG
25 GGCTCAATATCTTATCATTTCGTCTTCTTTTCCAACTACACATCACTGTATGACTC
AACCAGTAGCAGTTATATTGCCCCTTGTTTTTATTCAGTTTAACTACTGTTTCCA
AGATAAATGAGCTAATAAGCTTTAAAAAAAAAAAAAAAAAGGCTGAATTCTTTT
TTCTTCATCACTGGCATATCTGCCTATTCTCCAGAATTATTATGACTATTCAGCTC
ACTTTAACAGTTGAACTTCAAGCGACAATCTTTGAACACCCCTTCTCATGTGATTT
30 AAAATGAAACCATTTGGAAGGTTTCTTCTAGCCAGTAATAGATTTTTTTTTTAAT
TGCTCTGCCTTGTGCCGAGAGATGTTCTTTTAAGATGAATCTTTTGATGTCTGATA
CCACCAAATATAGGTGGTAGGGAGAGTTGGAGGCTGGCCCTTTGAGCAGGCCAT
TAGCTTACTTGCTGGGCATTTCCGATAGCTTATTGCCTACCTTTTTTGCTGGAAACA
AACTGATTTGAAAAACAAAATCTATGAAGACTGCAGCTAAGGATTTTATCGGTA
35 GACTTAAGAGCTTTTGTCTTGTGGATATTTTAGTGGAACCACATCAGTCTCAAT
ACTGTCATTTTACACTGACTCAGAGCAGCTGACTTCATTCCCTGCCATGATATATA
TTTAAGGCAGGCATTGTAACAGACATAAAGACAACCTATCTGTTTCAGCAGGAA
GGATTCAGTTTATGAACTCTCAGACCAGATCATGTTGAACAAGGAGACTTTGATG
TGTGTCATGAGAAAACCTATTCTTTACTTCCCAGTCAATTTAAAGGCCAGCTATC
40 CTGAGCTACTCGAATGAATGCACTGGTTAAACATTGGAAATAGTTTGTATATC
CTTGTCTCTCTTAGGCCAATTGTGATTACATGACTCGACTCTACATCTCGTCAAA
CAAGGCCTAGGTCTGGTTGCTGTAGACTGCTCGCCCTCAACAAATAAAATCTGGT
TGACTAGCCTCCTTGATATATACTAATTATTTGTGAAGAAGAAATTATCGTCAAT
TTTCTACTACCTTCCAATTGTCAGCTCTTTTTTCTCTCTGGTTTTTCTTACTTT
45 ACAGAAAAAGACATTGATCTATACTGCCATTCCCTCTAATCCTGCCATACTCAGT
CAAAAGGAATGACTTAAGATGAAGATGATCATCTGCTCGAGTCTAAAATATACA
TTGTATATAAGAATTGGTGATTAGAAAAGCAAAAAACCTAAACTTAAATCTAG
GAGTCTGTATACTGTCTCCATGTCTCCATGCCTCAGATCTCATCTAAATCTTTGAA
CAGCACCATTCAACCAATCTGAGGCCTTGACTTGCTTGTAAGATGATTCTCAGAG

ATCGGCTGAGTTAAAAAAGATGACGACTTGATTACCAAAGAAAGTAGGGCCAAC
 TTTGACAAATCTGGCTCTGCTGACCCTGTCACTCCCAGATGTAGCATAGACTCCT
 AAACAGAACCTCAAGTCTGATTGAGGATAAGGCCTTCTCCTGAGCTGAAAGTTCT
 TTGGCAGATGAGCAAGAACTGAAAGCTGATGTACCTGACTGGCTCTGTAAGAT
 5 CAGAAAAGTGTATCCAGAATAAGCCCTATGGATTAACCCCTGAGTACCCAGAGT
 AAAAATAATTTACAGAACTTCCTTATTGATCTGCTGGTTCTTCCAGATCATATTC
 TGGCTATTGGTATGGCTGGCCTTTCTGAAGGTACCCTGCTTGTCTATTTTCCTGAC
 TCAGCTCTTGCCCTGCCTTTTTTACATGTTGCTGCAATTAGACTCACCGTGAGGACT
 ACAGTCAATTTTCAGTCTATCTTGTGCCCAATACAACAAGGATTTTAAATAGTAAC
 10 AACCCACACCTCACCCACTAGGACTCAATGTTTACAACAGGAAGGACCATTGCT
 GCATACTCCTTGACCAGCAACTTTTTTTGAAGATATTTTAAAGTGCAGAGTAGGCC
 TCTATTCTGTATGTAATTGTTTCAATTTTTCAGCACCTGGAACCTCATCTATCGGGTC
 TGGAAGGAATACAGCAGTTCGAAAGCCGCGTCCATTTCTCTCCTTCAGTAGTGCA
 GAAATGAGTCCGATTACCCAGTACACACAGAACTGTACCAGTTCAACCTAGCAA
 15 AAGAAGAAAAGTTTCCACTGTACTTAAAATTTACAGCTGACTCAAATTGCCTCAC
 AGAATTATTTGATGTAGAAGGCTAGTTGTCTTACTTCAGATCAGCAGGACAGTTG
 GGCTCTCAGACTCATGACCCTGAGTTTGTCTTGTGTTGAAACTGTGGTTTCATCCA
 ACATATGCTATTGGACATGATTATTATTCCATTCAAATGGATTACAGACTTCTTGA
 GGACAGGACAACTTATCTCTCATGGTGTTTTTTTAGAATACTTTTATAACCAAG
 20 GAAGAAACCATGCCAGCTGTTACCATTCAACTTCTTAAGCAGAGATTAAGCTTTT
 TCATATCTGTTCTTATCCTGGACATCAGTAGTTTTTAATTGCCCAGCATCCGTTCC
 ATCTTGTAACTCCCTGATGTTTCTTAAAACCACTCTTCTATTTTCAGTCTG
 TGGTTTGGACAGTCTGACCAAGCTTGAGCTTTGTGGGTGAACATGTAATTCAGAT
 CCTCATCAATCAGCAAAATCCATCTGAAGTGTGGAGGAGAAGCTCTCTTTAAGTGA
 25 GGTGCTTTAGCTTTGTAGGATGAAAACCTCAAACCTAACAGGGCCTACCATGTAGA
 GAATGAAGCCAGTGCAGGGGAAAGCAGAGCCAAAATATGGAGAGACTTGAATC
 CTGATGACAGCGTTTGTGCCCTGGATCCAACCGTGCCTGAAGCTAGAATATCCC
 CTGGACTTTTCAGTTATGTGAACCAATAAATACCCTTTTTTGTCTTAAGTTACTTTG
 AGTTGGGTTTCTGTTACTTGAAATTGAATCCACACTAATATATCTACCAACATTG
 30 AGACTTGACAGATCCAAGTATTTATTAAGCTAGAGGTCATGGTCACTGAAATTAC
 TTTCCAAAGTGGAAGACAAAATGAAACAGGAACTGAGGGAATATTTAAGATCCC
 ACAGAAGCGTAAAAATGACATGGTAGAAAGTAATAGAAAACCTAAATGTCTGTC
 ATTAAGGATAGGTTAAGGTGTGGTTCAGCCATATAGGAATATCTCGTATCTGTT
 AAAATGAATAAAGTACATTCATTGTGTATGGAAAAATGGCCATGATACATTAGG
 35 TGAAACAAGTTATTAATAGAAAAGTGTACAGTGTGAACTCATTTTAAAATGTGTG
 TGCTTATGTTTATAAATGCATAGAAAGGTCTATTTCACAGCTTTCTTTGAACAGTGT
 AGATCACATGAACTTTCAACTTTATACATTTCTGTATTAATATTTTACACTACCC
 ACATTATTTTTAACTTTATTTTAAATAAAGAATTTTTTAAAT

40 SEQ ID NO: 528

>16759 BLOOD GB_R09836 gi|761792|gb|R09836|R09836 yf30b12.r1 Soares fetal liver
spleen 1NFLS Homo sapiens cDNA clone IMAGE:128351 5', mRNA sequence [Homo
sapiens]

AAGATCACAAGGTTTACATCTGGCACAAACGTAGTANACCTGCCAATTGCGGAC
 45 TCAGGGGACACACAGTACAGTAACTGTGTGAGCTGGAACCCACAGATTCCATC
 CATGATGGCCAGCGCCTCAGATGATGGCACTGTTAGAATATGGGGACCAGCACC
 TTTTATAGGACCACCAGAATATTGGAAGAGGGAATGCAGTAGCATGGGATAGTT
 TGATGGGTGATTTGGGAGCAGACGANTTCTTGTTTTAACTTTAAATTTAGTTCGTA

TTTTTAATTGGCTTNGGGGTTTTTGGGTGCCAAACCAAACNTGATTTGATAGCTTG
GGACAGGACATGCTTCCGT

SEQ ID NO: 529

5 >16991 BLOOD 978861.1 Incyte Unique
CGGCCCCCACCTCTGCCTCCTTCTACTCGGGCGCCCCGGCCGCCGCCACCTCTCCC
CAGCCCAGGAGAGGCTGCGGAGCCGCAGCCGCCCAGACCGCGCAGCGCGGGGA
GGCAGGTTCCGCACGAAATAAATCAGAATGAGTTATGCAGAAAAACCCGATGAA
ATCACGAAAGATGAGTGGATGGAAAAGCTCAATAACTTGCATGTCCAGAGAGCA
10 GACATGAACCGCCTCATCATGAACTACCTGGTCACAGAGGGCTTTAAGGAAGCA
GCGGAGAAGTTTTCGAATGGAATCTGGAATCGAACCTAGTGTGGATCTGGAAACA
CTTGATGAACGAATCAAGATCCGGGAGATGATACTGAAAGGTCAGATTGAGGAG
GCCATCGCCTTGATCAACAGCCTCCACCCAGAGCTCTTGGACACAAACCGGTATC
TTTACTTCCATTTGCAGCAACAGCATTTGATCGAGCTGATCCGCCAGCGGGAGAC
15 AGAGGCGGCGCTGGAGTTTGCACAGACTCAGCTGGCGGAGCAGGGCGAGGAGA
GCCGAGAGTGCCTCACAGAGATGGAGCGTACCCTGGCACTGCTGGCCTTTGACA
GTCCCAGAGGAGTCGCCCTTCGGAGACCTCCTCCACACCATGCAGAGGCAGAAGG
TGTGGAGTGAAGTTAACCAAGCTGTGCTAGATTATGAAAATCGCGAGTCAACAC
CCAAACTGGCAAAATTACTGAACTACTACTTTGGGCTCAGAACGAGCTGGACC
20 AGAAGAAAGTAAAATATCCCAAAATGACAGACCTCAGCAAGGGTGTGATTGAGG
AGCCCAAGTAGCGCCTGCGCTTGGTGGTGGATCCAACACCAGCCCTGCGTCGTG
GGACTTGCCTCAGATCAGCCTGCGACTGCAAGATTCTTACTGCAGTAGAGAACTG
TTTTTCTCCCTTGTACTTTTTTTTGACCTGGCATCTTTTATAGGGAAAAATGGGC
TTTGTAGGCAGTGGAAAACTTGCAGGAAAGCTGCGCTCTCTTTGGCAGTCTGAT
25 GCAGAGCCTGCACTCTGGCACTCGCTGAAGAATCTGGAAGGTTGCGGTTTGCTCT
TCCAGTGTTCGGGGGCCTCTGGCTGCTGAAGGATTCGGTCTACCACGGAGGGCTG
TGCTGTTAGGCTGCATCCCACTCAAAATACAGGAAAAGCACGAATCATGATTCTG
CTTTCTGTTAGCTTAGGCAGACATTGGGCCTTCACCTACAAGTTTTTCCTTACCCC
TGTGGTTTTTGTGTTTTTTTTTTTCTTTTTCCATAGGAAAGAATATATAAATTTGT
30 AAATCCTAATTCAAAGATGGCTCGTGTGTGAGGGCATTGAGTTTGATTTGTTTTT
CCTTTGGTCTGGGTTGTGTGGCTTTTGGGGGATGCGTGTGAGGGGGCTATGTGTT
TTTTAATTTTTTAAATATATATTTTGGTGCTGTGTGTGGTAAGAGACTTGTTCCTA
GTGGATCAATGAACCATCTCTTCTGGGCAGTTTTTGTGAAAATAAAGGTTTCTCTT
TGATTTCAAGAATGACCAAAATGGCCTCTAAAAGATGTTAATCATCTCAAATGAC
35 CTTTTGTCTTTGGGGCGTTCTTCCCCCTGTGATAGCGGCAGTGGCTTTTTCTGGTA
CCTGCAGCTGGAAAGGCCACTTGGCCCTGTGCTGAGTGAGCGGCCTTCATTAGAG
CGAGGCAGCCCTTGGCCGGTGGGGACGCAGAGCCCCAGCAGGTGGTGCACGACT
GTTGGCGGAAGGAACGCGTGTTTCATCCTCAGTGATCTGCCCTCCAGCATCTCGGC
AGCATCTCATCCTCCATCGTCAGCTGGCTCTGCCGATGTCCTGCTTCTGTTCACTC
40 ACAGAACTGTCCCCTGCTCCGTGGTGGGCAGGAGGGAAGTGGTGCAGGGCTGCG
TGCATTGCCTGCGAGTCGGGACAGTTGATGGGCACATGGCCTTGTAGCTCTGGGC
ACAGATGTGTTTGGATTCAATTGCAGCGGACCACCGGGCACTGTTGACCCCACTGA
GCAGTGCTAAGTGTGTTTGTAGTGGATGTTTCGTGGAATTGCTGACCCATCCAAGG
GCGTCCTTTGGAGCCAGTGGAGCCTGCCGGCGCATCTGAGGGGCAGAATGCTGC
45 TAGCACTTGAATCTGGGATCTCGCCTTATTCTCAAGTAGCAAGGCATCTCGACAA
GCATGGTCTAGGTCTGGTGGCCAGCTTGCCAGTACCTGAGCCGGTCGGGTCATCT
GCCTCTGAGGGACCGTCCTCACCGAGCTCCTGCATCCCTTGAGTGTGATCAGGA
GGCGTCCACAGCATTGTTCTCGCCTCTGAATGATGCTTCTTTCTGTGTTGGAGCCT
GGCGAAGTTGTGTTTTCAAGCCCTCTACTTCTCTTTCCAGTGGGTAGGAGCTTTTG

SEQ ID NO: 530

>17028 BLOOD GB R25895 gi|782030|gb|R25895|R25895 yh43f12.r1 Soares placenta

453

SEQ ID NO: 531

>17066 BLOOD GB_R27082 gi|783217|gb|R27082|R27082 yh52b06.r1 Soares placenta
Nb2HP Homo sapiens cDNA clone IMAGE:133331 5', mRNA sequence [Homo sapiens]
GCACCGCACTGCCGCCTCCTGACTGCCCCCTATCCCCGCAGCCCCTGTGCCGGATT
5 TCATTTCCCTCCTCTCTCCCAGGGTACCTGGCNCCCAGCACTCTCCCATCTGTTCT
TCAGGAACCGACTCCTCTCCAGTTGCAACACCAGGGGAGAAAGGGGGCCTCCACA
TGCCCAAGTACCCCTGCAGGATGAAGGGCAGGCCGGCCCTTGATGTGCCATTTCT
GAATAATAGTCACTGCCGCCGAGTCTAGGGATGTCCTGTTTTAACTTAGCCCTG
CCTTGGGATGC

SEQ ID NO: 532

>17168 BLOOD GB_R33030 gi|788873|gb|R33030|R33030 yh70d06.s1 Soares placenta
Nb2HP Homo sapiens cDNA clone IMAGE:135083 3' similar to gb:D16234 PROBABLE
PROTEIN DISULFIDE ISOMERASE ER-60 PRECURSOR (HUMAN);, mRNA sequence
[Homo sapiens]

TTTTTTTTTAAAGGGGTCTCATTTATTGTCACTGTTCCAAATGTACAAAAAAATT
AGAAAATACCCCCAACTCAACCCACCCCCACAACATTTCCCCCAACACAAATA
ATTTTCCCAAACCACAAACATAAACTGGTCCNGGGGATTTCATAAACAGTGC
AGCTAAGAAACAGTTTAGNGAAANTTTAACAGGGNTTCAGATTATATCCATTCTG
20 TCCTCTCGGGCCCTGAGNGGGTAATAATTCCCATATGGGGNCCTAGGTCCTCCCC
AATGGGTTTTCCCATCTCTGATGGGGAGGAGGTCCTTTTTACAAGTGGGGTGTTT
GGGGCTACTGCTTAAAGGGGATCCTCCTGGNGGGCCTTCTTCTNCTTCTGGGGGTTT
TCTTCTTGNATTTACNNGGGGGGGGTTTAAAGGCTTC

SEQ ID NO: 533

>17191 BLOOD 445041.11 X15480 g31947 Human mRNA for anionic glutathione S-
transferase (GST-pi-1). 0

GCCGCAGTCTTCGCCACCAGTGATGCCGCCCTACACCGTGGTCTATTTCCAGTT
CGAGGCCGCTGCGCGGCCCTGGCGCATGCTGCTGGCAGATCAGGGCCAGAGCTG
30 GAAGGAGGAGGTGGTGACCGTGGAGACGTGGCAGGAGGGCTCACTCAAAGCCTC
CTGCCTATACGGGCAGCTCCCCAAGTTCAGGACGGAGACCTCACCTGTACCAG
TCCAATACCATCCTGCGTCACCTGGGCCGCACCTTGGGCTCTATGGGAAGGACC
AGCAGGAGGCAGCCCTGGTGGACATGGTGAATGACGGCGTGGAGGACCTCCGCT
GCAAATACATCTCCCTCATCTACACCAACTATGAGGCGGGCAAGGATGACTATGT
35 GAAGGCACTGCCCCGGGCAACTGAAGCCTTTTGAGACCCTGCTGTCCCAGAACCA
GGGAGGCAAGACCTTCATTGTGGGAGACCAGATCTCCTTCGCTGACTACAACCTG
CTGGACTTGCTGCTGATCCATGAGGTCTAGCCCCCTGGCTGCCTGGATGCGTTCC
CCCTGCCCGCCTCATAGTTGGTGTAGATGAGGGAGATGTATTTGCAGCGGAGGTC
CTCCACGCCGTCA

SEQ ID NO: 534

>17309 BLOOD 994439.4 S78569 g1042081 laminin alpha 4 chain [Human, fetal lung,
mRNA, 6204 nt]. 0

CAAAGTGAATCCTGCTTTAATTCAAGCTTGTGGAGAACAAAGTCCTACAGAAACA
45 TTCCACAGAATTTTCTGGAAAAGAGGGATCACAAACACCTGTAAAAAGGTGAG
AAGGAAGCCAGGACAGCGCAGTCCCCAGTCCCGAACGGCCAGGGAGAGGAGGT
GGCCTAGCGCTGGCGGGGCTCACCCCAATCCGTCTGCCTTTTGATGCCGTACTCT
GCTGGTTGGCGCAGCCACCTCGGGATACTGCACACGGAGAGGAGGGAAAATAAG
CGAGGCACCGCCGCACCACGCGGGAGACCTACGGAGACCCACAGCGCCCGAGCC

CTGGAAGAGCACTACTGGATGTCAGCGGAGAAATGGCTTTGAGCTCAGCCTGGC
GCTCGGTTCTGCCTCTGTGGCTCCTCTGGAGCGCTGCCTGCTCCCGCGCCGCGTCC
GGGGACGACAACGCTTTTCTTTTACATTGAAGGGAGCTCAGCGGTTGGCAGGC
AAGACCCGCTGAGACGAGCGAACCCCGCGTGGCTCTGGGACGCTGCCGCTG
5 CGGCCGAGAAATGCAATGCTGGATTCTTTCACACCCTGTCTGGGAGAATGTGTGCC
CTGCGACTGTAATGGCAATTCCAACGAGTGTGGGACGGCTCAGGATACTGTGNN
AGANGGGCTTCATCCGTCCAGCAAGAACTCAGACAAATTTAACCCAGCCTACA
AGCAGCCCTGCCAGATTGTTTATGGNNTAGTTTCATGGTAGTTGGCACTGCCAGC
GGAACACAACAGGAGAGCACTGTGAAAAGTGTCTGGATGGTTATATCGGAGATT
10 CCATCAGGGGAGCACCCCAATTCTGCCAGCCGTGCCCCTGTCCCCTGCCCCACTT
GGCCAATTTTGCAGAATCCTGCTATAGGAAAAATGGAGCTGTTCCGTGCATTTGT
AACGAAAATTATGCTGGACCTAACTGTGAAAGATGTGCTCCCGGTTACTATGGAA
ACCCCTTACTCATTGGAAGCACCTGTAAGAAATGTGACTGCAGTGGAATTCAGA
TCCCAACCTGATCTTTGAAGATTGTGATGAAGTCACTGGCCAGTGTAGGAATTGC
15 TTACGCAACACCACCGGATTCAAGTGTGAACGTTGCGCTCCTGGCTACTATGGGG
ACGCCAGGATAGCCAAGAACTGTGCAGTGTGCAACTGCGGGGGAGGCCCATGTG
ACAGTGTAAACCGGAGAATGCTTGAAGAAGGTTTGAACCCCTACAGGCTGTG
ATAAGTGCCTCTGGGACCTGACTGATGACCTGCGGTTAGCAGCGCTCTCCATCGA
GGAAGGCAAATCCGGGGTGCTGAGCGTATCCTCTGGGGCCGCGCTCATAGGCA
20 CGTGAATGAAATCAACGCCACCATCTACCTCCTCAAAACAAAATTGTCAGAAAG
AGAAAACCAATACGCCCTAAGAAAGATACAAATCAACAATGCTGAGAACACGAT
GAAAAGCCTTCTGTCTGACGTAGAGGAATTAGTTGAAAAGGAAAATCAAGCCTC
CAGAAAAGGACAACCTGTTCAGAAAGGAAGCATGGACACCATTAACCAAGCAAG
TEAGCTGGTAGAGCAAGCCCATGATATGAGGGATAAAATCCAAGAGATCAACAA
25 CAAGATGCTCTATTATGGGGAAGAGCATGAACTTAGCCCCAAGGAAATCTCTGA
GAAGCTGGTGTTGGCCCAGAAGATGCTTGAAGAGATTAGAAGCCGTCAACCAT
TTTACCCAACGGGAGCTCGTGGATGAGGAGGCAGATGAGGCTTACGAACTACT
GAGCCAGGCTGAGAGCTGGCAGCGGCTGCACAATGAGACCCGCACTCTGTTTCC
TGTCGTCTCTGGAGCAGCTGGATGACTACAATGCTAAGTTGTCAGATCTCCAGGAA
30 GCACTTGACCAGGCCCTTAACCTATGTCAGGGATGCCGAAGACATGAACAGGGCC
ACAGCAGCCAGGCAGCGGGACCATGAGAAACAACAGGAAAGAGTGAGGGAACA
AATGGAAGTGGTGAACATGTCTCTGAGCACATCTGCGGACTCTCTGACAACACCT
CGTCTAACTCTTTCAGAACTTGATGATATAATAAAGAATGCGTCAGGGATTTATG
CAGAAATAGATGGAGCCAAAAGTGAACCTACAAGTAAACTATCTAACCTAAGTA
35 ACCTCAGCCATGATTTAGTCCAAGAAGCTATTGACCATGCACAGGACCTTCAACA
AGAAGCTAATGAATTGAGCAGGAAGTTGCACAGTTCAGATATGAACGGGCTGGT
ACAGAAGGCTTTGGATGCATCAAATGTCTATGAAAATATTGTTAATTATGTTAGT
GAAGCCAATGAAACAGCAGAATTTGCTTTGAACACCACTGACCGAATTTATGAT
GCGGTGAGTGGGATTGATACTCAAATCATTTACCATAAAGATGAAAGTGAGAAC
40 CTCCTCAATCAAGCCAGAGAACTGCAAGCAAAGGCAGAGTCTAGCAGTGATGAA
GCAGTGGCTGACACTAGCAGGCGTGTGGGTGGAGCCCTAGCAAGGAAAAGTGCC
CTTAAAACCAAGACTCAGTGATGCCGTTAAGCAACTACAAGCAGCAGAGAGAGGG
GATGCCCAGCAGCGCTGGGGCAGTCTAGACTGATCACCGAGGAAGCCAACAGG
ACGACGATGGAGGTGCAGCAGGCCACTGCCCCCATGGCCAACAATCTAACCAAC
45 TGGTCACAGAATCTTCAACATTTTGAATCTTCTGCTTACAACACTGCAGTGAACCT
TGCTAGGGATGCAGTAAGAAATCTGACCGAGGTTGTCCCTCAGCTCCTGGATCAG
CTTCGTACGGTTGAGCAGAAGCGACCTGCAAGCAACGTTTCTGCCAGCATCCAGA
GGATCCGAGAGCTCATTGCTCAGACCAGAAGTGTGCGCAGCAAGATCCAAGTCT
CCATGATGTTTGATGGCCAGTCAGCTGTGGAAGTGCCTCGAGAACCAGTATGG

ATGACTTAAAGGCCTTCACGTCTCTGAGCCTGTACATGAAACCCCCTGTGAAGCG
GCCGGAAGTGAACGAGACTGCAGATCAGTTTATCCTGTACCTCGGAAGCAAAAA
CGCCAAAAAAGAGTATATGGGTCTTGCAATCAAAAATGATAATCTGGTATACGT
CTATAATTTGGGAAGTAAAGATGTGGAGATTCCCCTGGACTCCAAGCCCGTCAGT
5 TCCTGGCCTGCTTACTTCAGCATTGTCAAGATTGAAAGGGTGGGAAAACATGGAA
AGGTGTTTTTAACAGTCCCGAGTCTAAGTAGCACAGCAGAGGAAAAGTTCATTA
AAAAGGGGGAATTTTCGGGAGATGACTCTCTGCTGGACCTGGACCCTGAGGACA
CAGTGTTTTATGTTGGTGGAGTGCCTTCCAACCTTCAAGCTCCCTACCAGCTTAAAC
CTGCCTGGCTTTGTTGGCTGCCTGGAAGTGGCCACTTTGAATAATGATGTGATCA
10 GCTTGTACAACCTTTAAGCACATCTATAATATGGACCCCTCCACATCAGTGCCATG
TGCCCGAGATAAGCTGGCCTTCACTCAGAGTCGGGCTGCCAGTTACTTCTTCGAT
GGCTCCGGTTATGCCGTGGTGAGAGACATCACAAGGAGAGGGAAATTTGGTCAG
GTGACTCGCTTTGACATAGAAGTTCGAACACCAGCTGACAACGGCCTTATTCTCC
TGATGGTCAATGGAAGTATGTTTTTCAGACTGGAAATGCGCAATGGTTACCTACA
15 TGTGTTCTATGATTTTGGATTTCAGCAGTGGCCCTGTGCATCTTGAAGATACGTTAA
AGAAAGCTCAAATTAATGATGCAAAAATACCATGAGATCTCAATCATTTACCACA
ATGATAAGAAAATGATCTTGGTAGTTGACAGAAGGCATGTCAAGAGCATGGATA
ATGAAAAGATGAAAATACCTTTTACAGATATATACATTGGAGGAGCTCCTCCAG
AAATCTTACAATCCAGGGCCCTCAGAGCACACCTTCCCCTAGATATCAACTTCAG
20 AGGATGCATGAAGGGCTTCCAGTTCCAAAAGAAGGACTTCAATTTACTGGAGCA
GACAGAAACCCTGGGAGTTGGTTATGGATGCCCAGAAGACTCACTTATATCTCGC
AGAGCATATTTCAATGGACAGAGCTTCATIGCTTCAATTCAGAAAATATCTTTCT
TTGATGGCTTTGAAGGAGGTTTAAATTTCCGAACATTACAACCAAAATGGGTACT
ATTCTATTAATGCTTCAGGGTCAGACGTGTTCTCCATCTCACTGGATAATGGTACTG
25 TCATCATGGATGTAAAGGGAATCAAAGTTCAGTCAGTAGATAAGCAGTACAATG
ATGGGCTGTCCCACTTCGTCATTAGCTCTGTCTCACCCACAAGATATGAACTGAT
AGTAGATAAAAGCAGAGTTGGGAGTAAGAATCCTACCAAAGGGAAAAATAGAAC
AGACACAAGCAAGTGAAGAAGTTTTACTTCGGTGGCTACCAATCAGTGCTC
AGTATGCTAATTTCACTGGCTGCATAAGTAATGCCTACTTTACCAGGGTGGATAG
30 AGATGTGGAGGTTGAAGATTTCCAACGGTATACTGAAAAGGTCCACACTTCTCTT
TATGAGTGTCCCATGAGTCTTCACCATTGTTTCTCCTCCATAAAAAAGGAAAAA
ATTTATCCAAGCCTAAAGCAAGTCAGAATAAAAAAGGGAGGGAAAAGTAAAGAT
GCACCTTCATGGGATCCTGTTGCTCTGAACTCCAGAGCGGAATACTCCAAGAA
ACTCTCATTGCCACCTTTCCACAGCCCTAGAGCAATAGAGCACGCCTATCAATA
35 TGGAGGAACAGCCAACAGCCGCCAAGAGTTTGAACACTTAAAAGGAGATTTTGG
TGCCAAATCTCAGTTTTCCATTTCGTCTGAGAACTCGTTCCTCCCATGGCATGATCT
TCTATGTCTCAGATCAAGAAGAGAATGACTTCATGACTCTATTTTTGGCCCATGG
CCGCTTGGTTTACATGTTAATGTTGGTCACAAAAAACTGAAGATTAGAAGCCAG
GAGAAATACAATGATGGCCTGTGGCATGATGTGATATTTATTCGAGAAAGGAGC
40 AGTGGCCGACTGGTAATTGATGGTCTCCGAGTCTAGAAAGAAAGTCTTCTCCTA
CTGAAGCTACCTGGAATAATCAAGGGTCCCATTATTTGGGAGGTGTGGCTCCTGG
AAAGGCTGTGAAAAATGTTCAAGTTAACTCCATCTACAGTTTTAGTGGCTGTCTC
AGCAATCTCCAGCTCAATGGGGCCTCCATCACCTCTGCTTCTCAGACATTCAGTG
TGACCCCTTGCTTTGAAGGCCCCATGGAAACAGGAACTTACTTTTCAACAGAAGG
45 AGGATACGTGGTTCTAGATGAATCTTTCAATATTGGATTGAAGTTTGAAATTGCA
TTTGAAGTCCGTCCCAGAAGCAGTTCCGGAACCCTGGTCCACGGCCACAGTGTCA
ATGGGGAGTACCTAAATGTTACATGAAAAATGGACAGGTCATAGTGAAAGTCA
ATAATGGCATCAGAGATTTTTCCACCTCAGTAACACCCAAGCAGAGTCTCTGTGA
TGGCAGATGGCACAGAATTACAGTTATTAGAGATTCTAATGTGGTTCAGTTGGAT

GTGGACTCTGAAGTGAACCATGTGGTTGGACCCCTGAATCCAAAACCAATTGATC
ACAGGGAGCCTGTGTTTGTGGAGGTGTTCCAGAATCTCTACTGACACCACGCTT
GGCCCCCAGCAAACCCCTTCACAGGCTGCATACGCCACTTTGTGATTGATGGACAC
CCAGTGAGCTTCAGTAAAGCAGCCCTGGTCAGCGGCGCCGTAAGCATCAACTCCT
5 GTCCAGCAGCCTGACATGACAGAGCACAGCTGCCCAAATACAAAGTTCTTTAGA
GCACTGAAAGAAACACAAAGCCAGCCAGGAGGAACAGTAACTCTTCCTTCGGGT
GGAAGCTTTCATCGAGTTGAACAGGACTTAAACGAATCATCAGGGACCGGATAT
TTCTTATTTCTCATTGATTCTTAACCTTGAATCCAAAGTGTCTGCAATGGACAA
CAATTGAAGGAGTGGCAAACCTTACTTGTATTGAGAGCACACGCAATTCCTACTGG
10 TGAAATTACTGTTTCTGTTTCTAATAAAATAGAAGGGATTCCAAATAAACACTTG
CACACATTTTGAAGTGCGGCTAGATTCTCAGATTACCTTCTTCCAGGGAAGA
TAACTTTCAATCTATATAAAAATCTCTGTCCTAAAACCTACCTTCTTTATTTTGA
GAGACTTACTAACTTACATATAATCTAAATTAGATGATAGATTTGTTTTAGCCCT
TTTGTTTGGTCTATCAGTATAAGAAGAATATTTTAGGTTTATAGCTGAAGTTATCA
15 AGGTTTAATAAAGTAAATTTCTAACAGAATACTAGAAAAATGCAGTATAATTTAA
TTTTTTCTAAATAAGAAACACAGGAAATCAACTACTTTTTCCCCTTCCTTATCTCC
TTAAAAGAAAAATAAAATTGTACATGAGAGGAGGCTTCTGTAGGTTATTATTACC
ATTATTGTGTGTTCTATGGGAATCATTGAGGATATCACAGCAAAAACAGTAGGAC
AAAATCATAAAATTCAATTTAAGAGTACACAAGTCCTTTATAANAGTTTGCTCCT
20 AGCCTGGGGCAACATAATGAGATCCCATCTCTGC

SEQ ID: NO: 535
17456: BLOOD 245885.4: AJ000517 g2370154 Human mRNA for spinocerebellar ataxia 7

25 AGTCAGCCACCGAATTGCTTTTATCAGTGTTAAAGTGGTCTGAACTGCTTGCTAC
CAATCTGTGAGAAGTTTTTGTGTTTTGTTTTGTTTTTAACTTGCAGTATATCACAG
AGCCACTCTTCAAGTAGATTGGCTGGGCAAAAGAATGTTTTGGCAAGAGCGTTAC
TG TAGACCTTTCTCCCTCCTTCCTTTTACTACCATTTTTTTTTTAACACTGTCATCTG
TAGGTCACTCTCCAGCAGTTAGGCACCTTAACTGGAGACCAGAAACCTTCCAGAG
30 AACACAGGGCTGCATCCCGAGCAACCCTCTGAAGAAGGGAATTAGGCTTTAGAT
TTTGATAGCAATGTTCCAGGAATGAAATATAGATGTTAGCCCAAGACACCATGAC
AAAATAGCCCAGCCTTTTGAGAGTAATTTGGGAAAAGAAGCTGTCAGAAGTTTCT
AACTTACAACTGGTTTGAAATTTTGTATGCCAGACAGCAAGTATAAATCATTT
TGGAGGCTTACTTTTCATGATACAAAAGCAATTCTGTGTGANNNNNNNNNNNNNN
35 NNNNNNNNNNNNATGCAAGCTAGTTTTGAGAAAGGAAGGCCAAATTGGGTGCGG
GGAGGGTGGGAGTGAGGAAGTTAAAATCACTATAGGGAGAAAAAACTTTTTTCA
AGATTTCCAAAGAGATGAAATTTTCTTAATCCTTTTAAAGTTTTCATAGTAAACAGT
ATGGCAGATTGGGTTGGTTGTCTACCTGGTCTATTTTTTAAAAGTCACCTTTTAAA
GTGACATTATTAGATACACTTAAATGTTTCCAAGGCACTCTCTACATTACCCTTGT
40 TTTTCTCTTTGGATACTGTCCTGGGACTAAGTGTAGATTTCTGCTTCAAGCACTTC
TGGCATTGTGTGTTTTTGTATGCACTCCCCTTCATGCCACTTCAGATGTTTATTTG
GATGTGGTTGGGGACGAGAGCAGACACCAAGGAAAGGGAGTTGGAGAGAATGT
AAGTCCTGACCTGAAGGTCTTTTGTGATGCATGTATAGGATTGCCCTGACACACA
CCCTCCTTTCTTGGGATTATACCAGCCATCTTCCTGAGAGTTTTGGAGCCCTCTAG
45 GATATTTTTTCTAGTACCCACCCCCCACCCTAAAGAAAGACCTTAATATGTTA
AAACAGCATTGCTTGGAGAAGGTGTCATTGAATTCGGGACGAGCCGGAGCCTT
TAAATGGGTGCTTCCACCACTACAGGCTCCTGACACGAGTAACAGGCACTGTTGC
TTAGAAGAACACACGAAGTTGCCGAACACAGGGTAAAATTTCCAAGGCGCTGAT
CGTTGCCCTGGCCAGGGCCTGATGAGAGCCAGTCAGTACATTCTTTTTTCTCTAC

AGTTCCTGGGTTTCAAACCTTCAGTTTCAGGGAATTTCAAGTCAACAACAGGTAGA
ATGAATAAACTTGGTTACCAGCCTAATAATGTGAATTGCTACAGAATTATTCTTA
TTATGTAAGAAAACAAAACTTTATGCAGATACTTTAGCTATAAATTGATGTAAA
ATACTGATTTTTTTAAAGGAAGGAGAGAACAGTATCTTGTTCAATTATTATGCAA
5 TCAATCAGTAAATGTTTTTAAAATGATACTACAGGAGAGCTTAGTAAGGAGAGG
GCATGGATGGGCCAGTTTGGCATAGTTGGGAGAAATCAGTCTGGTTTCCATCCCA
GTCGGGGAAGAGAGAGGTGAGAGGGAATCAGAACGTACCTAGTTGATTCCTTGG
TGACAAGTGCAATGGGGTATGGGTAGAATTTATTTTCAGAGCCAAGAGGACTTG
ATGGTTATAAATAAAGTTGCCTTTAGCAATGGAATTTACAGATCGATCATGTTGT
10 TCCGAAAGATGTGAATAGGATCCACAATAACAAGTTGATTCAGACTAATGTAGA
TATTTAGATTAGCAAGTATTGAACATTTGATTTCTTAGACTGAGGTTTTAAATGA
ATTTCAATTATTTCTCCCGTAATACACAGAGCATCGGGATTAGGAAATTAGCCAT
TTTGGATTCTGTCTGCCACAAACAGACCTATTCTAAACAGTGCTATTAAATTTTAG
ACTGTTGTTCAAATATTTTTATTTTCTCCTAACTACTTTTTATGGTGATGAATAAT
15 TAAGACCATTAAAAACACGGGAGTACAAGTATTTTTTTGAATTAAATTAAGTGC
AAAAACCAAATTTGCAGTGGTTGGGTTGTTTCTAGACAGACTTTGGTATCAATTT
AAAACCAAGATAATTTTTATATTCTTTCCAATAGAATTTTCATGACAACCTCCTGCA
GTTTTCTTAACCTAC

20 SEQ ID NO: 536

>17486 BLOOD gi|836069|gb|R64190.1|R64190 yi18b07.r1 Soares placenta Nb2HP Homo sapiens cDNA: clone IMAGE:139573 5', mRNA sequence

GGTCAAATGCCCGGAATGCAGAGCTCCGGCTGGGATGGGGCCAAATCGTCCTTA
AGAACGACCACCAGGAAGATTTCTGGAAAGTGAAGGAGTTCCTGCATAAECAGG
25 GGAAGCAGAAGTATACACTTCCGCTCTACCACGCAATGATGGGTGGCAGTGAGG
TGGCCAGACCCTCGCCAAGGAGACTTTTGCATCCACCGCCTCCCAGCTCCACAG
CAATGTTGTCAACTATGTCCAGCAGATCGTGGCACCCAAGGGCAGTTAGAGGCTC
GTGTGCATGGCCCCTGNCTCTTTCAGGCTCTCCAGGGTTTCAGAATAATTGTTTGT
TCCCAAATTCCTGTTTCCCTGATCAATTTCTGGGAGTTTATATTCCCTTCAGG

30

SEQ ID NO: 537

>17501 BLOOD Hs.12342 gnl|UG|Hs#S998603 Homo sapiens clone 24538 mRNA sequence
/cds=UNKNOWN /gb=Af055030 /gi=3005760 /ug=Hs.12342 /len=1725

GTTTGCTGTGAACCTTGCTACTTGTACTTGGTTGAAGTTCTAGGTACCTTTAGTCA
35 AGGGATGGAAAAATAAAGCCATACGCAGTTTTGTTACCTCAGTTACCCCAAAAA
TAGGAAAAGCAGCAAGCACAGTATTTTAAAGATCATAATTCCTATAAAAGGACT
GTGCACAAAGTGTTTAGACTCCATTTTCATTAGGCAGGTTGACTAAAAATGATTG
CAGTAACAGGTTTATATAAAATAGAGCAACCTTTCATGCTGTGACACAAATCAAA
AGGTTGATAACTTTGTAATTTTACTCTGGAGATTCTAACCGAAGTTGGTGTAAAGT
40 TTTCAAGAGTTACTAAAATCAAGTTGGAAATGATTTACGTACACTTCCCTGAGCC
TGGACTAAAGCCTCATGCCTGTACCCCAAGTAGGTGATGGTACTTTTCTATACAA
AAAGGATTTTCTGGCAGGCAGGTATTTACAAAGTTTGTTCCTGTACCAGTCCAAT
AATGACAACCTCTAAATCCAGCTGCACCAAATCTTAGTGGGCCATTTGTCATACCT
ATGAAAATTCTTCAGTTATTAAATAACTTTGTCAGTGCTACCTATGGTAGGCCGG
45 AAACAATGTAGATTAGGAAGTTTCATGAAAATTAACCTTTTGGGGCTATGGAGAA
ACAGTTAAGTATCTTAAGTTACTAAACATTTCCACTGAATTTTTGGAGTGAGCCA
AGGTTACTATAAAATACTTTGGAAGATGAATTCTCTACCTGGAGTTAGTTTCGAG
AGTAAGCGTAGCTTTTAAACAGAAATAACTGCAGATTTTAAAGCTCATAATTTGCAA
AAAAAATCTTTTATTGGCATGAAAATAATGTTGTAAATGGCACCAAATATTCCAC

TTAAATGCATATACAGTATTAGAGTCAAAAACCTATTTTATCCCTCTTTGCTGTTTT
TCCCCCTTCTGCCCACCTTTCCTGGGTGTTGGGGGGGCCCCGCTGACAACAGTCACA
AATCCAGCGACCTAGGAAAAAAATTGTTAATATAGAATGAAAAATTATCTTTAC
AGGACTGAATTTTAAGCCCATCTAAACTCTTCTGCCTTAGCTATCACTAATGATAT
5 TCCTCTCTGGATTTTGTGGTGAGAAGGGCACTATGAGTTCCTTAATTTAAGGAAA
AAATGTAAACTTAATCAATGTAATCAATGCCATGCAAAATTCATTGCAAGTCAAG
GGGGATGGGAGAGATGCAATGCCATACGGTGATACGGACCTTTAAGAAAGTACA
ATCTTTCCTGAAATTCAAACACTATCATACTTCAAAGGTCAAAACCCATTCCGG
AATTTGGCTTTTTTAAGACTTTTTCTCTCCTGCTCACTGGCAGCTGTGTGTCTTAA
10 CAGCATTCTTTCAAGTCCTGGTGTACTCTGCTGACAGCACTTTAAAACCTTTAACA
GCACAATGATAACTTGTACTACATACTTGATCTGAATTACTACAGAAAAATAATT
ATGTTGCTTGCTTAATGATTCCCAGGAACTTCGTTGTAGGCATATATTTTATAAG
AGTATTATACAGTGTTAACTATGCAAGTAAGTTCTAAAATTACACAATTATCTGT
GTAATGTTTTAGTCCAATTACTGTGATTTATTCAACTCTGTTCTAAAGTTATCTGG
15 AATTGTCATGCTGCCTCAATTTACAGAAATCTATAATAGATTTCTATAGAAATGT
AAAAAAAAAAAAAAAAAAAA

SEQ ID NO: 538

>17504 BLOOD 238178.2 Incyte Unique

20 CTGACAAAATGATCTCAATATTGGTGTAATAACACCTCCCCTTTCAAGGGTCTTC
CAAAGCACTTCCTGTCTGCGGCATACAAAATGTATGGCACGGAATTTTAAGCTTA
CTGAGCTTTATAAACACGTCACATTCACACATTCAAGACACACACTGGATATTCTG
GATAAAAACAAACAAACAAAACAGGGCTAAATACCCATTCCCCTCAATAACTT
GGATAAGATACCTAAAAAAGGTGAGCTTCGGTACCTTTCTGTCTTCTCCCTCTC
25 GCTATTTGCCTACACTGGCTTCCTCACCTCCACTTTTTCTCACGTTTATCTGAGCG
AAAACAAGCACGGTTCGGCAGCCTCCTTTCCCAGCCCTACCTTTGTGCTGCAAAA
GCGAAAATTCAAAGCCAAGTACAATAGGAGACCGCCCACCCTGGCTCCCTCGT
GACACGAGGGAGCGCGAAGCGGAGGGCGCCTCGCGGCAGGAGCGGGATTTCG
GGGTACGCGGAACCGGCAGGGGAACGGGATAAAGTTCCCGGAGAAAGGAAAGG
30 AGAGCGTGGGATAGTAAAAGAGAAGACGCGGAGAAGAGGAGAGGACCTACAAG
AACGGAGGACAGGGGCGCACGATGGTCCCGGGGGGAGCGGAAACAAAGGCACG
CAAAACGGAAAAGCGTGTGTAGGGGAGCGGAAAAGGAAGTCACCACCGTGGCC
TGCGACGAAATGGCGAAAAGTCTTTTGAAGACAGCCTCTCTGTCTGGAAGGACA
AAATTGCTACATCAAAACAGGATTGTCACTTTATAGTACATCCCATGGATTTTATG
35 AGGAAGAAGTGAAAAAACACTTCAGCAGTTTCCTGGTGGATCCATTGACCTTC
AGAAGGAAGACAATGGCATTGGCATTCTTACTCTGAACAATCCAAGTAGAATGA
ATGCCTTTTCAGGTGTTATGATGCTACAACTTCTGGAAAAAGTAATTGAATTGGA
AAATTGGACAGAGGGGAAAGGCCTCATTGTCCGTGGGGCAAAAAATACTTTCTC
TTCAGGATCTGATCTGAATGCTGTGAAATCACTAGGAACTCCAGAGGATGGAAT
40 GGCCGTATGCATGTTTCATGCAAAACACCTTAACAAGATTTATGAGACTTCCTTTA
ATAAGTGTTGCGCTGGTTCAAGGTTGGGCATTGGGTGGAGGAGCAGAATTTACTA
CAGCATGTGATTTCAAGTTAATGACTCCAGAGAGTAAGATCAGATTCGTCCACAA
AGAGATGGGCATAATACCAAGCTGGGGTGGCACCACCCGGCTAGTTGAAATAAT
CGGAAGTAGACAAGCTCTCAAAGTGTTGAGTGGGGCCCTTAAACTGGATTCAAA
45 AAATGCTCTAAACATAGGAATGGTTGAAGAGGTCTTGCACTTTCAGATGAAACT
AAATCTCTAGAAGAGGCACAAGAATGGCTAAAGCAATTCATCCAAGGGCCACCG
GAAGTAATTAGAGCTTTGAAAAAATCTGTTTGTTCAGGCAGAGAGCTATATTTGG
AGGAAGCATTACAGAACGAAAGAGATCTTTTAGGAACAGTTTGGGGTGGGCCTG
CAAATTTAGAGGCTATTGCTAAGAAAGGAAAATTTAATAAATAATTGGTTTTTCG

TGTGGATGTACTCCAAGTAAAGCTCCAGTGACTAATATGTATAAATGTTAAATGA
 TATTAAATATGAACATCAGAATTACTTTGAAGGCTACTATTAATATGCAGACTTA
 CTTTAAATCATTTGAATATCTGAACTCATTTACCTCATTTCTTGCCAATTACTCACT
 TGGGTATTTACTGCGTAATCTGGAACATTTAGCTAAAATATACACTTTTGGCTTA
 5 AAAATTATTGCTGTCAATTCCAATAATAATTCTTAGCTTATAACCAAAGAGCAGT
 GTTTAAAAGGAGAGCTTCTATACAAAACCTATTCTGCGTACTTTTCATACAA
 TTTTGTCTGTTTTACCTGGAAATAATTTACCAAATAAAGTGAAGTGTGCTGCTA
 AAGAACAAAAGTGGGGAGGTATCAGGGAACAAGAAAACAAGAAAGGGTATGAT
 CAATCATTTTCTTCTGCTCCAAACAGCTGGAGTAAAATTCATGGGAAATGGCCCT
 10 TCATTTAAAAAAGATGTACCTCACTACCCACTACAAATTTGGAACCTTTGTTCTTT
 TCAATAATTAGTTTTCTATTGTAAATTACCTACTAAACAGTGGTAGCCATGACAT
 GGAAAGTCAACTGATTCTACAATTGGACATTCATTTGTGTGCCCTGGAATTTCCA
 ACTAGTAATAAACAACACTACTGTTGATGTAGTTTTAAACCACTGAAGGGACTCAT
 GAAGCATCCTGCAACATAAATTTGCATTTTACATCAGATTTCTTTTTTTCTCTGA
 15 AAAACAACCTAACCCTTCTAACAACCTATCTTTCAAAGTAAATGTAATAAAAATGCA
 CAACATAAAATGTTTATGATCCCAGCAATACACTTTTTAAAAAATGTGAAAGTCA
 AAGAATTAAGTTCTAGTTCTGACTCATCACAAGAGGTCAAAGTATTTGCTACTG
 TAACATTCAATTCACATTTGAGAATCATGGTAAAAATAACTTGCATTTGCCTTAC
 CATCATGATCCTACTGTTGAGTTAGGAAAATATGGTTAGACAGACTCACATTACT
 20 TTTTTTCAGAGGTAAACTCTAGATTACTGTGTCAACCCAATACTATTTGGCCATAG
 ATGTAAAAACTACCAAATAAAAGTGGATTTTGTGGTCTACAACATTTTGTGTAAA
 GTGAATTCATGCTGCTAAGACCGTTAAGTCTGCC
 SEQ ID NO: 539
 25 >17616 BLOOD GB_R70598 gi|844115|gb|R70598|R70598 yi41g08.r1 Soares placenta
 Nb2HP Homo sapiens cDNA clone IMAGE:141854 5' similar to contains Alu repetitive
 element; mRNA sequence [Homo sapiens]
 GATCCACCCACCTCAGCCTCCACAGTGCTGGGACTACAGGCATGAGGATCATCT
 GAGGCCAAGAGTTCAAGATCAGCCTGGGCAACATAGTGATACCCTATCTCTTAA
 30 AAAAGAAGAAGTTTTTAAATTTGAAATAATAATAGGTACTGGATTTATGCAAATG
 TCTTTTCTGCGTCTTTTGAGATGAGTATCAGGTTTTTTTTTCTNTTATCATCTG
 ATGATGANCTTAATGTTTCCATTTGTATTAATGGGAATACTAAGTCCCTCTGTGAT
 TTTCTGAACCCAAGCTATTTCCCTANGGCCTGAGTTTNATTTTNGTTTGACACAGTA
 ATTAAAAATTAGGANGGCCCAAGCCGTGGGTGGCCATGTTGNCCTGTAAGTCCCN
 35 AAGTTGNCTGANGGTAAGGAAGGATTTGCTTTGNAGCCCCA

SEQ ID NO: 540

>17691 BLOOD 327226.7 Incyte Unique

GCTTAAGAGACCCCGCAGTGGGGCGCTCGTCCGAAGCCAGGCCGCGTCCGCCAT
 40 AGTACCTGGCTTGGAGGTGTCGCCGCCGCTCGGTGAGAGCCCCGAGCGGCAGG
 GGGCCAACACAAAAAGGGAGCCGGAGAAGCCCTAGCCGCTGCCAGCAGCTTGC
 GGGCGTGTTCTCGCGGTTCCGGGCCTCAAGGCGACGGAAACGAAAGGCGAGCGA
 AGCGCGGAGGATCCGGCGAGAAGAAGCGTCAGGGAGCCTCGGCGGTGTCCCCGG
 GGTCCGCCGAAGCCACCCGGCCGCCGGCTGGGGCCCGGGGTGGTGAGGAAGTGC
 45 TCCGAGGCCTCGCCGAGGCCTAGCGCCGGCTTTGTGTCCGAGGCGGCGGCTGGC
 GGCGGGGGGAGGCTGGAGCCGGGGGCGTGCTGCGGGAAGGCCTCTCCTCCGCCG
 ACCGCGCGTTTTTCGGCCTAGGCCGTGGGGCCGCTCGTGGCCTCCGGGGAGCAGG
 CGCCAGGGGTTTGTAGTGCGGAGGGGGCCTGGGCCTGGGCCTGGGGAAGCTGAC
 GCCGGTCGTCCGAAGCCAGGAGGAGGCGTGAGGCCGCTCGTGGACTCCGGGCC

TAGGCCCTCTCCCTCAACCTTCTCCCGGGCCTGGGTACCCCAATCCACGGAG
AGAGAGACCCGCCGGGAGGTGCGGGCCGCGCTATGGACCCCTGACCCCGTGGGGT
CGCTCGGACTCTTAACGTGTGGACTGACCGCTACTGACTGCACCGCCAATCCCC
CGTCTCTGCCGGCCCCCTTAGCATGAGCGAGGGGGACCCAGCCGGGTGACATTGT
5 GCCCGTTGGCGGATTCTCGATTTCCTCTCTCCCGTCCTCGTCCTCCTCNTCCNN
CATGAAGTGATTCTGAGTATCGGGGGGTCTCTGGATTATTGTTCTGACGAACCCC
TGCTTGTGGTTGGGGGGTATTTAATCTGAGGCCTTAGGGTCCTTCGGTGTCTTTGA
GTGTTTTGTGTGTACATATTTTGCTCTTAAAGTTTATAAATATACGTATATTGAGA
GTGTCCACGTCTCCTCGCTGAACCTTAGGAATCCCTTGGCACCATGTCCTGTGTGC
10 ATTATAAATTTTCTCTAAACTCAACTATGATACCGTCACCTTTGATGGGCTCCAC
ATCTCCCTCTGCGACTTAAAGAAGCAGATTATGGGGAGAGAGAAGCTGAAAGCT
GCCGACTGCGACCTGCAGATCACCAATGCGCAGACGAAAGAAGAATATACTGAT
GATAATGCTCTGATTCTTAAGAATTCTTCTGTAATTGTTAGAAGAATTCCTATTGG
AGGTGTTAAATCTACAAGCAAGACATATGTTATAAGTCGAACTGAACCAGCGAT
15 GGCAACTACAAAAGCAGTATGTAAAAACACAATCTCACACTTTTTCTACACATTG
CTTTTACCTTTATAATGTAGCAGTGAAGTAAATCATTTTAGAACTTAATATCCAAC
TGATCATAGTACATATTGTAAATAAAATGTATTTTGATGACAGCTCAGTTGAATA
TGGATAATATGTGGCATCACTTGCACACTTATTTTGTAGAAATGGGTAATTTGTG
CCCGTAACACTGTTTCATATTAAATATGATAGCATTATCCCTGTATGACACTGTGT
20 TGTACAGTTAATGTATGATCCTTTTTAGATCGTTTAGGTTTTACACTAAGGAACAT
GATGACATGTTCTACATTTGTCTGTCTATAGTTAGTATTTTGTATGTATGTACAGG
CTGTTGTGTGCTTTTGTGTTCTTGCAATAAAAAATGTTTGGAGTGTATATTTGCC
ATTTACAGTTGTATCACTTAGTATTGTTAG

25 SEQ ID NO: 541
>17713 BLOOD GB_R78516 gi|854797|gb|R78516|R78516 yi73h02.r1 Soares placenta
Nb2HP Homo sapiens cDNA clone IMAGE:144915 3', mRNA sequence [Homo sapiens]
GTGCGTGTGATTACCAGAGAACTACTAAAAAAACCAACTGCTTTTTAAATCCTAT
TGTGTAGTTAAAGTGTTCATGCCTTGACCAATCTAATGAATTGATTAATTAAGTGG
30 GCCTTTTATACTTAACTAAATAAAAAACTAAGCAGATATGAGTTAAATTTAAAAAA
AAAAAAAANAAG

SEQ ID NO: 542
 >17805 BLOOD 099572.2 AF001862 g2232149 Human FYN binding protein mRNA,
 complete cds. 0
 TAAGGTATAGTATTTTAAACTGTGCAAGTAAGACTTTTGTCTCTCAGCTATTTTTT
 GTTCCCTATGTTTGTAGGATGGAAAGGCAGATGTAAAGTCCCTCATGGCGAAATA
 TAACACGGGGGGCAACCCGACAGAGGATGTCTCAGTCAATAGCCGACCC TTCAG
 AGTCACAGGGCCAAACTCATCTTCAGGAATACAAGCAAGAAAGAACTTATTCAA
 CAACCAAGGAAATGCCAGCCCTCCTGCAGGACCCAGCAATGTACCTAAGTTTGG
 GTCCCCAAAGCCACCTGTGGCAGTCAAACCTTCTTCTGAGGAAAAGCCTGACAA
 GGAACCCAAGCCCCCGTTTCTAAAGCCCACTGGAGCAGGCCAAAGATTTCGGAAC
 ACCAGCCAGCTTGACCACCAGAGACCCCGAGGCGAAAGTGGGATTTCTGAAACC
 TGTAGGCCCCAAGCCCATCAACTTGCCCAAAGAAGATTCCAAACCTACATTTCCC
 TGGCCTCCTGGAAACAAGCCATCTCTTCACAGTGTAACCAAGACCATGACTTAA
 AGCCACTAGGCCCGAAATCTGGGGCTACTCCTCCAACCTCAGAAAATGAACAGA
 AGCAAGCGTTTCCCAAATTGACTGGGGTTAAAGGGGAAATTTATGTCAGCATCACA
 AGATCTTGAACCCAAGCCCCCTTCCCCCAAACCCGCCTTTGGCCAGAAGCCGCCC
 CTAAGTACCGAGGAACTCCCATGAAGACGAAAGCCCCATGAAGAATGTGTCTTC

ATCAAAAGGGTCCCCAGCTCCCCTGGGAGTCAGGTCCAAAAGCGGCCCTTTAAA
ACCAGCAAGGGAAGACTCAGAAAATAAAGACCATGCAGGGGAGATTTCAAGTTT
GCCCTTTCCTGGAGTGGTTTTGAAACCTGCTGCGAGCAGGGGAGGCCTAGGTCTC
TCCAAAATGGTGAAGAAAAAAGGAAGATAGGAAGATAGATGCTGCTAAGAA
5 CACCTTCCAGAGCAAAATAAATCAGGAAGAGTTGGCCTCAGGGACTCCTCCTGC
CAGGTTCCCTAAGGCCCCCTTCTAAGCTGACAGTGGGGGGGCCATGGGGCCAAAG
TCAGGAAAAGGAAAAGGGAGACAAGAATTCAGCCACCCCGAAACAGAAGCCAT
TGCCTCCCTTGTTTACCTTGGGTCCACCTCCACCAAAACCCAACAGACCACCAAA
TGTTGACCTGACGAAATTCACAAAACCTCTTCTGGAAACAGTACTAGCAAAGG
10 GCCAGACGTCTTACTCAACAACCTTCCCTGCCACCACCTCCACCATCCCATCCGGC
CAGCCAACCACCATTGCCAGCATCTCACCCATCACAACCACCAGTCCCAAGCCTA
CCTCCCAGAAACATTAAACCTCCGTTTGACCTAAAAAGCCCTGTCAATGAAGACA
ATCAAGATGGTGTACGCACTCTGATGGTGCTGGAAATCTAGATGAGGAACAAG
ACAGTGAAGGAGAAACATATGAAGACATAGNNNNNNNNNNNNNNNNNNNNNNNN
15 NNN
NNAG
GCCCTATTCAAGTCATCCATCTTGCAAAAGCTTGTTGTGATGTCAAAGGAGGAAA
GAATGAACTGAGCTTCAAGCAAGGAGAGCAAATTGAAATCATCCGCATCACAGA
CAACCCAGAAGGAAAATGGTTGGGCAGAACAGCAAGGGGTTTCATATGGCTATAT
20 TAAACAACCTGCTGTAGAGATTGACTATGATTCTTTGAAACTGAAAAAGACTCT
CTTGGTGCCCCCTTCAAGACCTATTGAAGATGACCAAGAAGTATATGATGATGTTG
CAGAGCAGGATGATATTAGCAGCCACAGTCAGAGTGGAAAGTGGAGGGGATATTC
CTCCACCACCAGATGATGACATTTATGATGGGATTGAAGAGGAAGATGCTGATG
ATGGTTTCCCTGCTCCTCCTAAACAATTGGACATGGGAGATGAAGTTTACGATGA
25 TGTGGATACCTCTGATTTCCCTGTTTCATCAGCAGAGATGAGTCAAGGAACFAAT
TTTGAAAAGCTAAGACAGAAGAAAAGGACCTTAAGAAGCTAAAAAAGCAGGA
AAAAGAAGAAAAGACTTCAGGAAAAAATTTAAATATGATGGTGAAATTAGAGT
CCTATATTCAACTAAAGTTACAACCTTCCATAACTTCTAAAAAGTGGGGAACCAGA
GATCTACAGGTAAAACCTGGTGAATCTCTAGAAGTTATACAAACCACAGATGAC
30 ACAAAGTTCTCTGCAGAAATGAAGAAGGGAAATATGGTTATGTCCTTCGGAGT
TACCTAGCGGACAATGATGGAGAGATCTATGATGATATTGCTGATGGCTGCATCT
ATGACAATGACTAGCACTCAACTTTGGTCATTCTGCTGTGTTTATTAGGTGCCAA
TGTGAAGTCTGGATTTTAATTGGCATGTTATTGGGTATCAAGAAAATTAATGCAC
AAAACCACTTATTATCATTTGTTATGAAATCCCAATTATCTTTACAAAGTGTTTAA
35 AGTTTGAACATAGAAAATAATCTCTCTGCTTAATTGTTATCTCAGAAGACTACAT
TAGTGAGATGTAAGAATTATTAAATATTCCATTTCCGCTTTGGCTACAATTATGA
AGAAGTTGAAGGTACTTCTTTTAGACCACCAGTAAATAATCCTCCTTCAAAAAAT
AAAAATAAAAGAAAAAGGAAAATCATTGAGGAAGAAATGACCTGTCTAAAAAA
ACCTAAGGAAGAATAATAATAAGAAAGGAAATTTAAAAACATTCCACAAGAA
40 GAAAAATTATTGTTTATACTCCTACTTATGGTTATATCTTATATTCTATTCAAG
TGACCTGTCTTTTAAAAAGGCAGTGTCTTACCTCTTGCTAGTGGGTAAATGT
TTTCAAAAATTATAGCAGTAGTAGAAGTTTTGTATAAAATTTGTCCTTATTTGTTA
ATTGTATATAAATGTTAATTATTTGATACGAATGTTATGCATTTAGTATGCACATT
GAAGTCTAACTGTAGAAGAGTCTAAAACAAGTTCTCTTTTGCAGATTCACATA
45 CTAATGGTTTAATTCTGTGCTCTGTTTAAAGTACTATTATACTAGAGTAGATCTG
AATGAGGATAACCCTAAAATCATGAGGAATGGAAGAATGGACCTTGAACTACC
TAGGCTTTTATGCATGGCACCTCTTTATAATGAAGACACTTTTTAAAGTTTTTGT
TTTGTTCATTACCGCTAGATTTTTTTTTCTCTTTTTTAAATCCATTTTACTGG
AAAGTTGGCCAGCAGAGGGAGTAGAAATTATTAATTTCTAGTGTTTGGATTGG

GCCCTTCTCTAACAGTACATACTCATTCCCAAAGCAATCCAAAAACAAAATGTGA
ACCATTTGGGTTTCAAATGTTAAGAACACTAAATAGCATGATTTAAAAAATGAAA
AATGCTAACACCCAAGAAAAGAAGATATTAAGTGCTTTTAACTCCTAGAGT
ACAAAATGAGTACATCATAATGCTGGGCTCTTCTACTAATGAACCATCGAGTGAT
5 ATTGAATAAAATTATTTATCTTCTCAGTTTTCTTATCTGTAAATTACAATATTAGAC
TAAGTAAGTTTTTCCAACCTCTTCACTACCAATTACCTTAGGCTTTTATAATGCTCC
GCCTACTTCAGTCCCATGTTTCAGAAAGCTTTTGTCTATTTTTTAACTCATTGATT
AAATAATGATTAATGCATTCTCCACATTTTAATATTGCAAAGGCCCATTTGGAGTT
TCTGAAGTGGCTCCACAGAATTGAAATAATTTCAAATAACTGTAAAGGAACTGA
10 AAATCTTCACAGAGATGAAGTGGGGTTTCCATTAGGTGCTTTGAAATTTGATAAC
AAATCATCAACTTCCACTGGTCAATATATAGATTTTGGGTGTCTGAGGCCCAAG
ATTAGATGCCACTAATCTCCAAAGATTCCCTCCAATTATGAAATATTTTAATGTCT
ACTTTTAGAGAGCACTAGCCAGTATATGACCATGTGATTAATTTCTTTTCACACTA
GATAAAATTACCTGGTTCAAAGTGGTTTTTGTATTATAAATTTGGTAATAAATAT
15 ATATAATACACAGACAGGATAGTTTTTATGCTGAAGTTTTTGGCCAGCTTTAGTTT
GAGGACTCCTTGATAAGCTTGCTAAACTTTCAGAGTGCCCTGAGACACTTCCAGC
CATCCCTCCTCCTGCCTTCATTGGGGCAGACTTGCATTGCAGTCTGACAGTAATTT
TTTTTCTGATTGAGAATTATGTAAATTCAATACAATGTCAGTTTTTAAAAGTCAAA
GTTAGATCAAGAGAATATTTACAGAGTTTTGGTTTACACATCAAGAAACAGACACA
20 CATACCTAGGAAAGATTTACACAATAGATAATCATCTTAATGTGAAAGATATTTG
AAGTATTAATTTAATATATTAATATGATTTCTGTTATAGTCTTCTGTATGGAAT
TTTGTCACTTAAGATGAGCTGCAAAATAATAATACCTTCAATGGAAAAAATAA
NNNGNAAAAAAAAAANAAC
25 SEQ ID NO: 543
>17862 BLOOD 207683.2 M83751 g178990 Human arginine-rich protein (ARP) gene,
complete cds. 0
TCCTGCTGTAGTGCCCTTCTGCGCCAGGCCCCGGTTCAATCAGCGGCCACAACCTGTC
TAGGGCTCAGACACCACCAGCCAATGAGGGAGGGCACGTGGAGCCGCGTCTGGG
30 CTCGCGGCTCCTGACCAATGGGGAAGTGGCATGTGGGAGGGCGCCGGGGTTCCC
CCCGCCAATGGGGAGCTACGGCGCGCGGCCGGGACTTGGAGGCGGTGCGGCGCG
GCGGGTGCGGTTTCAGTCGGTTCGGCGGCGGCAGCGGAGGAGGAGGAGGAGG
AGGATGAGGAGGATGAGGAGGATGTGGGCCACGCAGGGGCTGGGCGGTGGCGC
TGGCTCTGAGCGTGCTGCCGGGCAGCCGGGCGCTGCGGCCGGGCGACTGCGAAG
35 TTTGTATTTCTTATCTGGGAAGATTTTACCAGGACCTCAAAGACAGAGATGTCAC
ATTCTCACCAGCCACTATTGAAAACGAACTTATAAAGTTCTGCCGGGAAGCAAG
AGGCAAAGAGAATCGGTTGTGCTACTATATCGGGGCCACAGATGATGCAGCCAC
CAAAATCATCAATGAGGTATCAAAGCCTCTGGCCACCACATCCCTGTGGAGAA
GATCTGTGAGAAGCTTAAGAAGAAGGACAGCCAGATATGTGAGCTTAAGTATGA
40 CAAGCAGATCGACCTGAGCACAGTGGACCTGAAGAAGCTCCGAGTTAAAGAGCT
GAAGAAGATTCTGGATGACTGGGGGGAGACATGCAAAGGCTGTGCAGAAAAGTC
TGACTACATCCGGAAGATAAATGAACTGATGCCTAAATATGCCCCAAGGCAGC
CAGTGACGACGACCGATTTGTAGTCTGCTCAATCTCTGTTGCACCTGAGGGGGAAA
AAACAGTTCAACTGCTTACTCCCAAACAGCCTTTTTGTAAATTTATTTTTTAAGTG
45 GGCTCCTGACAATACTGTATCAGATGTGAAGCCTGGAGCTTTCCTGATGATGCTG
GCCCTACAGTACCCCATGAGGGGATTCCTTCTTCTGTTGCTGGTGTACTCTAG
GACTTCAAAGTGTGTCTGGGATTTTTTTTATTAAAGAAAAAAATTTCTAGCTGTC
CTTGCAGAATTATAGTGAATACCAAATGGGGTTTTGCCCCAGGAGGCTCCTACC
AGTTTCTGCTTTCAGTTGCAGAGTTTGGGGGGTTATTCATTCCCATTATCTCTC

AACCCACCAGTGCTGAAAATACCAGAGCAGGACATAGGGGCTGGGGCCAGCTGA
TGTGTGTGGGTGTGTACCACTAGAGGGCAGCAGGCACTCAGCAGAAAGGAGGTG
GCGGGGGCGGGGGGTGCTGCGCTTGATACCCTGCCCTTGATACAGTATCTGTCT
TACCCGCCCAAGAGAGCTGGAGGCCACAGCTCTAGGAGGAT

5

SEQ ID NO: 544

>17898 BLOOD 064333.4 X03663 g29899 Human mRNA for c-fms proto-oncogene. 0

GGCTTCAGGAAGGGCAGACAGAGTGTCCAAAAGCGTGAGAGCACGAAGTGAGG
AGAAGGTGGAGAAGAGAGAAGAGGAAGAGGAAGAGAGGAAGCGGAG
10 GGAAGTGCAGGCCAGGCTAAAAGGGGAAGAAGAGGATCAGCCCAAGGAGGAGGA
AGAGGAAAACAAGACAAACAGCCAGTGCAGAGGAGAGGAACGTGTGTCCAGTG
TCCCGATCCCTGCGGAGCTAGTAGCTGAGAGCTCTGTGCCCTGGGCACCTTGACG
CCCTGCACCTGCCTGCCACTTCCCCACCGAGGCCATGGGCCCAGGAGTTCTGCTG
CTCCTGCTGGTGGCCACAGCTTGGCATGGTCAGGGAATCCCAAGTGATAGAGCCCA
15 GTGTCCCCGAGCTGGTCGTGAAGCCAGGAGCAACGGTGACCTTGCATGTGTGG
GCAATGGCAGCGTGGAATGGGATGGCCCCCATCACCTCACTGGACCTGTACTC
TGATGGCTCCAGCAGCATCCTCAGCACCAACAACGCTACCTTCCAAAACACGGG
GACCTATCGCTGCACTGAGCCTGGAGACCCCTGGGAGGCAGCGCCGCCATCCA
CCTCTATGTCAAAGACCCTGCCCGGCCCTGGAACGTGCTAGCACAGGAGGTGGTC
20 GTGTTGAGGACCAGGACGCACTACTGCCCTGTCTGCTCACAGACCCGGTGCTGG
AAGCAGGCGTCTCGCTGGTGGTGGTGGCGTGGCCGGCCCCCTCATGCGCCACACCAA
CTAGTGGTTCTCGCCCTGGCATGGCTTACCATCCACAGGGCCAAGTTCATTTCAG
AGCCAGGACTATCAATGCAGTGCCTGATGGGTGGCAGGAAGGTGATGTCCATG
AGCATCCGGCTGAAAGTGCAGAAAGTCATCCCAGGGGCCCCCAGCCTTGACACTG
25 GTGCCTGCAGAGCTGGTGGGATTGAGGGGAGGCTGCCCAGATCGTGTGCTCA
GCCAGCAGCGTTGATGTAACTTTGATGTCTTCCCTCCAACACAACAACACTAAGC
TCGCAATCCCTCAACAATCTGACTTTCATAATAACCGTTACCAAAAAGTCCTGAC
CCTCAACCTCGATCAAGTAGATTTCCAACATGCCGGCAACTACTCCTGCGTGGCC
AGCAACGTGCAGGGCAAGCACTCCACCTCCATGTTCTTCCGGGTGGTAGAGAGT
30 GCCTACTTGAACCTGAGCTCTGAGCAGAACCTCATCCAGGAGGTGACCGTGGGG
GAGGGGCTCAACCTCAAAGTCATGGTGGAGGCCTACCCAGGCCTGCAAGGTTTT
AACTGGACCTACCTGGGACCCTTTTCTGACCACCAGCCTGAGCCCAAGCTTGCTA
ATGCTACCACCAAGGACACATACAGGCACACCTTCACCCTCTCTTGCCCCGCCT
GAAGCCCTCTGAGGCTGGCCGCTACTCCTTCCCTGGCCAGAAACCCAGGAGGCTG
35 GAGAGCTCTGACGTTTGAGCTCACCTTCGATACCCCCCAGAGGTAAGCGTCATA
TGGACATTCATCAACGGCTCTGGCACCCTTTTGTGTGCTGCCTCTGGGTACCCCCA
GCCCAACGTGACATGGCTGCAGTGCAGTGGCCACACTGATAGGTGTGATGAGGC
CCAAGTGCTGCAGGTCTGGGATGACCCATACCCTGAGGTCTGAGCCAGGAGCC
CTTCCACAAGGTGACGGTGCAGAGCCTGCTGACTGTTGAGACCTTAGAGCACAA
40 CCAAACCTACGAGTGCAGGGCCCAACAGCGTGGGGAGTGGCTCCTGGGCCTT
CATACCCATCTCTGCAGGAGCCACACGCATCCCCCGGATGAGTTCCTCTTACA
CCAGTGGTGGTCGCTGCATGTCCATCATGGCCTTGCTGCTGCTGCTGCTCCTGCT
GCTATTGTACAAGTATAAGCAGAAAGCCCAAGTACCAGGTCCGCTGGAAGATCAT
CGAGAGCTATGAGGGCAACAGTTATACTTTCATCGACCCACGCAGCTGCCTTAC
45 AACGAGAAGTGGGAGTTCCCCCGGAACAACCTGCAGTTTGGTAAGACCCTCGGA
GCTGGAGCCTTTGGGAAGGTGGTGGAGGCCACGGCCTTTGGTCTGGGCAAGGAG
GATGCTGTCCTGAAGGTGGCTGTGAAGATGCTGAAGTCCACGGCCCATGCTGATG
AGAAGGAGGCCCTCATGTCCGAGCTGAAGATCATGAGCCACCTGGGCCAGCACG
AGAACATCGTCAACCTTCTGGGAGCCTGTACCCATGGAGGCCCTGTACTGGTCAT

CACGGAGTACTGTTGCTATGGCGACCTGCTCAACTTTCTGCGAAGGAAGGCTGAG
 GCCATGCTGGGACCCAGCCTGAGCCCCGGCCAGGACCCCGAGGGAGGCGTCGAC
 TATAAGAACATCCACCTCGAGAAGAAATATGTCCGACGGACAGTGGCTTCTCC
 AGCCAGGGTGTGGACACCTATGTGGAGATGAGGCCTGTCTCCACTTCTTCAAATG
 5 ACTCCTTCTCTGAGCAAGACCTGGACAAGGAGGATGGACGGCCCCCTGGAGCTCC
 GGGACCTGCTTCACTTCTCCAGCCAAGTAGCCAGGGCATGGCCTTCTCGCTTC
 CAAGAATTGCATCCACCGGGACGTGGCAGCGCGTAACGTGCTGTTGACCAATGG
 TCATGTGGCCAAGATTGGGGACTTCGGGCTGGCTAGGGACATCATGAATGACTCC
 AACTACATTGTCAAGGGCAATGCCCGCCTGCCTGTGAAGTGGATGGCCCCAGAG
 10 AGCATCTTTGACTGTGTCTACACGGTTCAGAGCGACGTCTGGTCCTATGGCATCC
 TCCTCTGGGAGATCTTCTCACTTGGGCTGAATCCCTACCCTGGCATCCTGGTGAA
 CAGCAAGTTCTATAAACTGGTGAAGGATGGATACCAAATGGCCCAGCCTGCATTT
 GCCCCAAAGAATATATACAGCATCATGCAGGCCTGCTGGGCCTTGGAGCCCACC
 CACAGACCCACCTTCCAGCAGATCTGCTCCTTCTTCAGGAGCAGGCCCAAGAGG
 15 ACAGGAGAGAGCGGGACTATACCAATCTGCCGAGCAGCAGCAGAAGCGGTGGC
 AGCGGCAGCAGCAGCAGTGAGCTGGAGGAGGAGAGCTCTAGTGAGCACCTGACC
 TGCTGCGAGCAAGGGGATATCGCCCAGCCCTTGCTGCAGCCCAACAACTATCAGT
 TCTGCTGAGGAGTTGACGACAGGGAGTACCACTCTCCCCTCCTCCAACTTCAAC
 TCCTCCATGGATGGGGCGACACGGGGAGAACATACAAACCTCTGCCTTCGGTCATT
 20 TCACTCAACAGCTCGGCCAGCTCTGAACTTGGGAAGGTGAGGGATTCAGGGG
 AGGTCAGAGGATCCCCTTCTGAGCATGGGCCATCACTGCCAGTCAGGGGCTG
 GGGGCTGAGCCCTCACCCCCCGCCTCCCTACTGTTCTCATGGTGTTCGCTCGTG
 TTTGCTATGCCAACTAGTAGAACCTTCTTTCCTAATGCCCTTATCTTCATGGAAAT
 GGACTGACTTTATGCCTATGAAGTCCCCAGGAGCTACACTGATACTGAGAAAACC
 25 AGGCTCTTTGGGGCTAGACAGACTGGCAGAGAGTGAGATCTCCCTCTCTGAGAG
 GAGCAGCAGATGCTCACAGACCACACTCAGCTCAGGCCCTTGGAGCAGGATGG
 CTCCTCTAAGAATCTCACAGGACCTCTTAGTCTCTGCCCTATACGCCGCCTTCACT
 CCACAGCCTCACCCCTCCCACCCCATACTGGTACTGCTGTAATGAGCCAAGTGG
 CAGCTAAAAGTTGGGGGTGTTCTGCCAGTCCCGTCATTCTGGGCTAGAAGGCAG
 30 GGGACCTTGGCATGTGGCTGGCCACACCAAGCAGGAAGCACAACTCCCCAAG
 CTGACTCATCCTAACTAACAGTCACGCCGTGGGATGTCTCTGTCCACATTAACT
 AACAGCATTAATGCAAAAAAAAAAAAAAAAAA

SEQ ID NO: 545

35 >17915 BLOOD GB_R93149 gi|967315|gb|R93149|R93149 yq15g08.s1 Soares fetal liver
 spleen 1NFLS Homo sapiens cDNA clone IMAGE:197054 3', mRNA sequence [Homo
 sapiens]
 CTATTTTCCACAAATCATTGGTTTATTAGAAAGTTCCTTTCCCTCATTTTACAGCA
 TATATATCTCTATCATATGTGATAAAGTTAAATACAATCTGTTATGCTTGTAAGTA
 40 AGGTTTATTTTATTTTACTTTTAAAATCACTATTCTGGAAGTTAAAGAAAATGC
 CCCTAGGGAAGGCAAAGAGGCAGCCAGAGTATGGCTCAATCTACAAGCTAATGG
 GGAAGCAGGCACGGAAAATGTTAATACTGTATTATTTATTACATGGGGCTGAAA
 GCAAAGGAAAAATGAGTCCCTTCACTTACACAGGNTGGATTTTCATTTTTCCCGGG
 C

45

SEQ ID NO: 546

>17952 BLOOD 337221.6 Incyte Unique
 AAAAAAAAAAGAAAAAAGAAAAAAGAGAAAAAAGCGAAATAGGTTATATTTTAA
 AAACAATAGAAAGGCAATAAGTTGCGATAAGCTCTTACTATTGACCAAGGTTAT

ACAGGAAAGAGACTGAAGTGTACCCTTGAATAGGTTTTCTGTAGTCAGAGTTCTA
AACTCTAATTTGTAACCTTGGACTTTCTAATTGCAAATGGCAATAACTATTAAGTT
ATCAGCAATAATAAATTTAGCATTAAATTTGAGTACAATGTTTTGTTTTGCACTC
CCCATAGTGCGTATGTATTAAGACAGTGGATAGTGTTTAGGTCCTGTTAATTTTCT
5 TTGGAATTC AATGTGGTTGTGAATCAAACCTTAAGGAAGGAACGTTAAATAGCA
ATGAGATACAGAATTATGGGCCTTTGGAACAAGCCCGACTTCCCCTAAATCTCC
TTAGTTTGTTAATAACAGTATTCAGATTCTGATTCAATTTATACATCTGTTTCCAT
ATGGCAGGGACATTATGATACTTAATGAATAATGCTTTGAGGAGTTCTGCAGTTA
ACTTTCAAGTCTTCCAGATGATTGTCAACAACAAAAAGGCTTATTGAATCCCAT
10 CTTGCTATGCAAGTTTATCAGATGATCAAATAGTAGATCTGATACATCCCCATT
GTATGTACGACATTTTCAAACCAAGTCTTAACCTTTTCAAGGACATTTTAGTAGCT
AATTCAGGGGAGGGGGAAGAATGATGCAGGTTTTTAGATTGACTGACTATTTTTG
AGTTATGGGGCTCATTTTGAAAGACTGCTGTCCAGATCAGCTTGTTGCTGCAGAT
AATAGAAGGTTCTTATGAATCCAAGTTGTATATTCACCTTGTAGGATAATTTAAAA
15 ATTAGATTTTTTTTGCATATGAGCAAAAACCTTTTGCTGGATACAGGAGAAGGTT
GGACTTTATCTACAGTTATCTTTTGATTACAGCAACAGCTCTGGGTGAGAGTAGA
ATTTATAGAGGGATAATTTGTCAAGCCATAGAAAGAAAATCTAAATTAATCTAGT
AAGTGTATGACCTCTCACCATTTTAAGAGGTATCAGATTCATTTGCACTATTAGG
AATGCTAGTTTTGTGCAAAAATAATGCCTTACCTGTTTTTCCCCACATTTAGGTT
20 GAAAAGCTTCAAATGTTCCAAGTTATGCTGAANNNNNNNNNNNNNNNNNNNNNN
NNNCAAAACACACAAAA
TAAAAAGCCACACTTTTATTCTGCTTCGAAATGCAAATGGATAGAGCACGGT
TTCTCTGACAGTATAATGATAGCTTTGTGAGTTAGTTTCATGTCATGCTGGGA
CTCTATGAGGTGGCCATAAGCAGCAACCAGCCCAAACACCCACTTGGGTTCTATT
25 AGTATGGAACCATTTGCATTTGTTTTTTTAAAGCTTTATCTTTCCTTGTGCATCCTG
ACCAAGAAATATCTTTGATTATGATTAATGTATTATGTCAAAATGTAGGCTAGTT
AACTTTTGTAAAGTTGCCTGGAATGTCATTTGTTAGGTTATAAACACAAGATCT
AAATGAAGGGTTTTATGTGTTGTGTACAAATCTTATTTTGAATGGACAAACTGT
TCATTACATTTGTAACCTTGTACAGAGGATTTTCACTATGTGCCTAGCTTGGTGT
30 CCATTCAGCTAAAATTGAAAAAAGGTTGCATGAAGAGTTAAAAATCAA
ATTAAAGTATATGTAGAGATGACTATTTTATATTACATGACCCAATCCTGTATTTA
TTTCTACCCCTTTTGAAGTATTTATAAACTAGTTGAGGACAGCTGTATTTTT
TTGTTGAACATTTAGTAGAATTGTGCCTTTTGTCTGTATGTGAATAAATGCTGT
ACATTTTGCAATAC

35

SEQ ID NO: 547

>18005 BLOOD 442042.5 Z70293.1 g1296611 Human mRNA for chemokine CC-2 and CC-3.0

CCTGCTCTATCTTGTCTCGGTCTCTCACTCTGCCTTATACCCCTCAGTTGAATTATT
40 TCTTCTGAGGAGGCAAGAACTGAGGCTGCTGCAGACTGATATGGATTCACTCTG
CTAACACCTCCTGGTTGGAACCTACAGGAATAGAACTGGAAAGGGAAAAAAGGCA
GCATTCACCACATCCCAATCCTGAATCCAAGAGTCTAAGATAGTCCCCCACTCCT
ATCTCAGGCTTAGAGGATTAGATTAATCTCCTGGAGGGGAAGACTCTTCCTTGAA
ACATTTTTTTTTATCTGCCTGTAGCTATTGGGATAATTCGGGAAATCCACAGGGA
45 CAGTTCAAGTCATCTTTGTCTCTACTTTCTGTTGCACTCTCAGCCTTGTTCTCTTT
TTAGAACTGCATGGTAACTATTATATAGCTAAAGAAGAGCATTCTGACCTCTGC
CCTGGGACTTCCTGGATCCTCCTCTTCTTATAAATAACAAGGGCAGAGCTGGTATC
CCGGGGAGCCAGGAAGCAGTGAGCCAGGAGTCCTCGGCCAGCCCTGCCTGCCC
ACCAGGAGGATGAAGGTCTCCGTGGCTGCCCTCTCCTGCCTCATGCTTGTGCTG

TCCTTGGATCCCAGGCCAGTTCACAAATGATGCAGAGACAGAGTTAATGATGTC
AAAGCTTCCACTGGAAAATCCAGTAGTTCTGAACAGCTTTCACTTTGCTGCTGAC
TGCTGCACCTCCTACATCTCACAAAGCATCCCGTGTTCACTCATGAAAAGTTATTT
5 GCGGCAAGTCTGTGCCAAACCCAGTGGTCCGGGAGTTCAGGATTGCATGAAAAA
GCTGAAGCCCTACTCAATATAATAATAAGAGACAAAAGAGGCCAGCCACCCAC
CTCCAACACCTCCTGAGCCTCTGAAGCTCCCACCAGGCCAGCTCTCTCCCAACAA
CAGCTTCCCACAGCATGAAGATCTCCGTGGCTGCCATTCCCTTCTTCTCTCATC
10 ACCATCGCCCTAGGGACCAAGACTGAATCCTCCTCACAACTGGGGGGAAACCG
AAGTTGTATAAAATACAGCTAAAGTTGGTGGGGGGACCTTACCACCCCTCAGAGT
GCTGCTTACCTACACTACCTACAAGATCCCGCGTCAGCGGATTATGGATTACTA
TGAGACCAACAGCCAGTGTCTCAAGCCCGGAATTGTCTTCATCACCAAAAGGGG
CCATTCCGTCTGTACCAACCCCAAGTGACAAGTGGGTCCAGGACTATATCAAGGAC
ATGAAGGAGAACTGAGTGACCCAGAAGGGGTGGCGAAGGCACAGCTCAGAGAC
15 ATAAAGAGAAGATGCCAAGGCCCTCCTCCACCCACCGCTAACTCTCAGCCCCA
GTCACCCCTCTTGGAGCTTCCCTGCTTTGAATTAAAGACCACTCATGCTC

SEQ ID NO: 548

>18046 BLOOD 1326922.7 M12125 g339951 Human fibroblast muscle-type tropomyosin

20 mRNA, complete cds. 0

GCGGCCGCACCCCCCGGCCGGCCGTGCTTCTGCCCTGCAAGGTTTGGGCCGAG
GTTGGGGGAGGGTCCCTGGTTGCCGGCCCCGCCCGTCCGTCCCCGCCCTTTAGGCG
GCGGGGTGGCCGGGACGTCCAGTCCCGCTCCGTCTCTCGCTGCCACCGGTG
GACCCAGTCCGCTCACCCAGCCAGTCCGTCCGGTCCCTCACCGCTGCCGGCCGG
25 CCCACCCCCCACCAGCCATGGACGCCATCAAGAAGAAGATGCAGATGCTGAA
GCTGGACAAGGAGAACGCCATCGACCGCGCCGAGCAGGCCGAAGCCGACAAGA
AGCAAGCTGAGGACCGCTGCAAGCAGCTGGAGGAGGAGCAGCAGGCCCTCCAG
AAGAAGCTGAAGGGGACAGAGGATGAGGTGGAAAAGTATTCTGAATCCGTGAA
GGAGGCCCAGGAGAACTGGAGCAGGCCGAGAAGAAGGCCACTGATGCTGAGG
30 CAGATGTGGCCTCCCTGAACCGCCGCATTGAGCTGGTTGAGGAGGAGCTGGACC
GGGCCCAGGAGCGCCTGGCTACAGCCCTGCAGAAGCTGGAGGAGGCCGAGAAG
GCGGCTGATGAGAGCGAGAGAGGAATGAAGGTCATCGAAAACCGGGCCATGAA
GGATGAGGAGAAGATGGAAGTGCAGGAGATGCAGCTGAAGGAGGCCAAGCACA
TCGCTGAGGATTGAGACCGCAAATATGAAGAGGTGGCCAGGAAGCTGGTGATCC
35 TGGAAGGAGAGCTGGAGCGCTCGGAGGAGAGGGCTGAGGTGGCCGAGAGCCGA
GCCAGACAGCTGGAGGAGGAACTTCGAACCATGGACCAGGCCCTCAAGTCCCTG
ATGGCCTCAGAGGAGGAGTATTCACCAAAGAAGATAAATATGAAGAGGAGATC
AAACTGTTGGAGGAGAAGCTGAAGGAGGCTGAGACCCGAGCAGAGTTTGCCGAG
AGGTCTGTGGCAAAGTTGGAGAAAACCATCGATGACCTAGAAGAGACCTTGGCC
40 AGTGCCAAGGAGGAGAACGTCGAGATTCACCAGACCTTGGACCAGACCCTGCTG
GAACTCAACAACCTGTGAGGGCCAGCCCCACCCCAAGGCTATGGTTGCCA
CCCCAACCAATAAAACTGATGTTACTAGCCTCTCAAAAAAAAAAGAAAAGGGC
GGC

45 SEQ ID NO: 549

>18061 BLOOD 227748.5 M74826 g182931 Human glutamate decarboxylase (GAD-2)

mRNA, complete cds. 0

ACCCGCCCTCGCCGCTCGGCCCGCGCGTCCCCGCGCGTGCCCTCCTCCCGCCAC
ACGGCACGCACGCGCGCGCAGGGCCAAGCCGAGGCAGCCGCCCGCAGCTCGCAC

TCGCTGGCGACCTGCTCCAGTCTCCAAAGCCGATGGCATCTCCGGGCTCTGGCTT
 TTGGTCTTTCGGGTCGGAAGATGGCTCTGGGGATTCCGAGAATCCCGGCACAGCG
 CGAGCCTGGTGCCAAGTGGCTCAGAAAGTTCACGGGCGGCATCGGAAACAAACTG
 TCGCCCTGCTCTACGGAGACGCCGAGAAGCCGGCGGAGAGCGGCGGGAGCCAA
 5 CCCCCGCGGGCCGCCGCCGGAAGGCCGCTGCGCCTGCGACCAGAAGCCCTGC
 AGCTGCTCCAAAGTGGATGTCAACTACGCGTTTCTCCATGCAACAGACCTGCTGC
 CGGCGTGTGATGGAGAAAGGCCCACTTTGGCGTTTCTGCAAGATGTTATGAACAT
 TTTACTTCAGTATGTGGTGAAAAGTTTCGATAGATCAACCAAAGTGATTGATTTT
 CATTATCCTAATGAGCTTCTCCAAGAATATAATTGGGAATTGGCAGACCAACCAC
 10 AAAATTTGGAGGAAATTTTGATGCATTGCCAAACAACTCTAAAATATGCAATTAA
 AACAGGGCATCCTAGATACTTCAATCAACTTTCTACTGGTTTGGATATGGTTGGA
 TTAGCAGCAGACTGGCTGACATCAACAGCAAATACTAACATGTTACCTATGAA
 ATTGCTCCAGTATTTGTGCTTTTGGAATATGTCACACTAAAGAAAATGAGAGAAA
 TCATTGGCTGGCCAGGGGGCTCTGGCGATGGGATATTTTCTCCCGGTGGCGCCAT
 15 ATCTAACATGTATGCCATGATGATCGCACGCTTTAAGATGTTCCCAGAAGTCAAG
 GAGAAAGGAATGGCTGCTCTTCCCAGGCTCATTGCCTTCACGTCTGAACATAGTC
 ATTTTTCTCTCAAGAAGGGAGCTGCAGCCTTAGGGATTGGAACAGACAGCGTGAT
 TCTGATTAAATGTGATGAGAGAGGGAAAATGATTCCATCTGATCTTGAAAGAAG
 GATTCTTGAAGCCAAACAGAAAGGGTTTGTTCCTTTCTCGTGAGTGCCACAGCT
 20 GGAACCACCGTGTACGGAGCATTTGACCCCTCTTAGCTGTCGCTGACATTTGCA
 AAAAGTATAAGATCTGGATGCATGTGGATGCAGCTTGGGGTGGGGGATTACTGA
 TGTCCCGAAAACACAAGTGGAACTGAGTGGCGTGGAGAGGGGCCAACTCTGTGA
 CGTGGAAATCCAGACAAGATGATGGGAGTCCCTTTGCAGTGCTCTGCTCTCCTGGT
 TAGAGAAGAGGGATTGATGCAGAATTGCAACCAAATGCATGCCTCCTACCTCTTT
 25 CAGCAAGATAAACATTATGACCTGTCCTATGACACTGGAGACAAGGCCTTACAG
 TGCGGACGCCACGTTGATGTTTTTAAACTATGGCTGATGTGGAGGGCAAAGGGG
 ACTACCGGGTTTGAAGCGCATGTTGATAAATGTTTGGAGTTGGCAGAGTATTTAT
 ACAACATCATAAAAAACCGAGAAGGATATGAGATGGTGTGTTGATGGGAAGCCTC
 AGCACACAAATGTCTGCTTCTGGTACATTCTCCTCAAGCTTGCGTACTCTGGAAGA
 30 CAATGAAGAGAGAATGAGTCGCCTCTCGAAGGTGGCTCCAGTGATTAAAGCCAG
 AATGATGGAGTATGGAACCACAATGGTCAGCTACCAACCCTTGGGAGACAAGGT
 CAATTTCTTCCGCATGGTCATCTCAAACCCAGCGGCAACTCACCAAGACATTGAC
 TTCCTGATTGAAGAAATAGAACGCCTTGGACAAGATTATAATAACCTTGCTCAC
 CAAGCTGTTCCACTTCTCTAGAGAACATGCCCTCAGCTAAGCCCCCTACTGAGAA
 35 ACTTCCTTTGAGAATTGTGCGACTTCACAAAATGCAAGGTGAACACCACTTTGTC
 TCTGAGAACAGACGTTACCAATTATGGAGTGTACACAGCTGCCAAAATCGTAGGT
 GTTGGCTCTGCTGGTCACTGGAGTAGTTGCTACTCTTCAGAATATGGACAAAGAA
 GGCACAGGTGTAAATATAGTAGCAGGATGAGGAACCTCAAACCTGGGTATCATTT
 GCACGTGCTCTTCTGTTCTCAAATGCTAAATGCAAACACTGTGTATTTATTAGTTA
 40 GGTGTGCCAAACTACCGTTCCCAAATTGGTGTTTCTGAATGACATCAACATTCCC
 CCAACATTACTCCATTACTAAAGACAGAAAAAATAAAAAACATAAAATATACAA
 ACATGTGGCAACCTGTTCTTCTACCAAATATAAACTTGTGTATGATCCAAGTAT
 TTTATCTGTGTTGTCTCTCTAAACCCAAATAAATGTGTAAATGTGGACACA

45 SEQ ID NO: 550

>18101 BLOOD 351841.7 U22384 g733134 Human lysyl oxidase gene, partial cds. 0
 TTAATACGACCACTATAGGGAATTTGGCCCTCGAGGCAAGAATTCGGCACGATG
 CGTGAACAAATAGCTGAGGGGGCGGCCGGGCCAGAACGGCTTGTGTAACCTTTGCA
 AACGTGCCAGAAAGTTTAAATCTCTCCTCCTTCACTCCAGACACTGCCCCG

CTCTCCGGGACTGCCGCGCCGCTCCCCGTTGCCTTCCAGGACTGAGAAAGGGGAA
AGGGAAGGGTGCCACGTCCGAGCAGCCGCTTGACTGGGGAAGGGTCTGAATCC
CACCCTTGGCATTGCTTGGTGGAGACTGAGATACCCGTGCTCCGCTCGCCTCCTT
GGTTGAAGATTTCTCCTTCCCTCACGTGATTTGAGCCCCGTTTTTATTTTCTGTGA
5 GCCACGTCCTCCTCGAGCGGGGTCAATCTGGCAAAAGGAGTGATGCGCTTCGCCT
GGACCGTGCTCCTGCTCGGGCCTTTGCAGCTCTGCGCGCTAGTGCCTGCGCCCC
TCCCGCCGCGGCCAACAGCAGCCCCCGCGCGAGCCGCGCGGCTCCGGGCGC
CTGGCGCCAGCAGATCCAATGGGAGAACAACGGGCAGGTGTTTCAGCTTGCTGAG
CCTGGGCTCACAGTACCAGCCTCAGCGCCGCGGGACCCGGGCGCCCGCTCCCT
10 GGTGCAGCCAACGCCTCCGCCAGCAGCCCCGCACTCCGATCCTGCTGATCCGCG
ACAACCGCACCCGCGCGCGCGAACGCGGACGGCCGGCTCATCTGGAGTCACCG
CTGGCCGCCCCAGGCCACCGCCCGTCACTGGTTCCAAGCTGGCTACTCGACATC
TAGAGCCCGCGAAGCTGCGGCCTCGCGCGCGGAGAACCAGACAGCGCCGGGAG
AAGTTCTGCGCTCAGTAACCTGCGGCCGCCCAGCCGCGTGACGGCATGGTGG
15 GCGACGACCCTTACAACCCCTACAAGTACTCTGACGACAACCCTTATTACAATA
CTACGATACTTATGAAAGGCCAGACCTGGGGGCAGGTACCGGCCCGGATACGG
CACTGGCTACTTCCAGTACGGTCTCCAGACCTGGTGGCCGACCCCTACTACATC
CAGGCGTCCACGTACGTGCAGAAGATGTCCATGTACAACCTGAGATGCGCGGCG
GAGGAAAACCTGTCTGGCCAGTACAGCATACAGGGCAGATGTCAGAGATTATGAT
20 CACAGGGTGCTGCTCAGATTTCCCCAAAGAGTGAAAAACCAAGGGACATCAGAT
TTCTTACCCAGCCGACCAAGATATTCTGGGAATGGCACAGTTGTCATCAACATT
ACCACAGTATGGATGAGETTAGCCACTATGACCTGCTTGATGCCAACACCCAGAG
GAGAGTGGCTGAAGGCCACAAAGCAAGTTTGTGTCTTGAAGACACATCCTGTGA
CTATGGCTACCACAGGCGATTTGCATGTAAGTGCACACACAGGGATTGAGTCCT
25 GGCTGTTATGATACCTATGGTGCAGACATAGACTGCCAGTGGATTGATATTACAG
ATGTAAAACCTGGAAACTATATCCTAAAGGTCAGTGTAACCCCAAGCTACCTGGT
TCCTGAATCTGACTATACCAACAATGTTGTGCGCTGTGACATTGCTACACAGGA
CATCATGCGTATGCCTCAGGCTGCACAATTTACCGTATTAGAAGGCAAAGCAAA
ACTCCCAATGGATAAATCAGTGCCTGGTGTCTGAAGTGGGAAAAAATAGACTA
30 ACTTCAGTAGGATTTATGTATTTTGAAAAAGAGAACAGAAAACAACAAAAGAAT
TTTTGTTTGGACTGTTTTCAATAACAAAGCACATAACTGGATTTTGAACGCTTAA
GTCATCATTACTTGGGAAATTTTTAATGTTTATTATTTACATCACTTTGTGAATTA
ACACAGTGTTCATTCTGTAATTACATATTTGACTCTTCAAAGAAATCCAAATT
TCTCATGTTCCTTTTGAAATTTGTAAGTGCAAAATGGTCAAGTATTATCTAAATGAATG
35 AGCCAAAATGACTTTGAACTGAAACTTTTCTAAAGTGCTGGAACCTTAGTGAAAC
ATAATAATAATGGGTTTATATATGTCATAGCATAGATGAATTTAGAAACAATGCT
CCTACTGTTTAAATACATATGGACACATCTGGTGCTGAGAAAGAAACAAACACA
TTACCATTGGTGTCAAGAAATATTACTATATAGCAGAGAAATGGCAATACATGTA
CTCAGATAGTTACATCCCTATATAAAAAGTATGTTTACATTTAAAAAATTAGTAG
40 ATAACCTTCCTTTCTTTCAAGTGCACAATTTCATTTTGACTTGAGTCAACTTTTGTTT
TGGAACAAATTAAGTAAGGGAGCTGCCCAATCCTGTCTGATATTTCTTGAGGCTG
CCCTCTATCATTTTATCTTTCCCATGGGCAGAGATGTTGTAAGTGGGATTCTTAAT
ATCACCATTCTTGGGACTGGTATACATAAGGCAGCCGTGAAACTGGAAAGTCATT
TTGATGACTGATGTGATACATCCAGAGGTAAAATGCATTTAAACATATTAAAGTA
45 TTTGCCAAAGATACAATTTTCTTGCTGACATAAAAAATCACACAAACAAGTCCCCC
CCAAACCACAACCTGTCTCTCAATAGCTTAAAAAAATTGAAAAACATTTTAGGAT
TTTTCAAGTTTTCTAGATTTTAAAAAGATGTTTCAGCTATTAGAGGAATGTTAAAA
ATTTTATATTATCTAGAACACAGGAACATCATCCTGGGTTATTCAGGAATCAGTC
ACACATGTGTGTGTGTCTGAGATATAGTCTAAATTAGCAAAGCACATAGTATTAC

ATACTTGAGGGGTTGGTGAACAAAGGAAAAATATACTTTCTGCAAAACCAAGGA
 CTGTGCTGCGTAATGAGACAGCTGTGATTTCAATTTGAAACTGTGAAACCATGTGC
 CATAATAGAATTTTGAGAATTTTGCTTTTACCTAAATTCAAGAAAATGAAATTAC
 ACTTTTAAGTTAGTGGTGGCTTAAGCATAATTTTTCCTATATTAACCAGTATTA
 5 TCTCAAGTAAGATTTTCCAGTGCCAGAACATGTTAGGTGGAATTTTAAAAGTGCC
 TCGGCATCCTGTATTACATGTCATAGAATTGTAAAGTCAACATCAATTACTAGTA
 ATCATTCTGCACTCACTGGGTGCATAGCATGGTTAGAGGGGCTAGAGATGGACC
 AGTCATCAACTGGCGGATATAGCGGTACATATGATCCTTAGCCACCAGGGCACA
 AGCTTACCAGTAGACAATACAGACAGAGCTTTTGTGAGCTGTAAGTGAAGCTATG
 10 GAATAGCTTCTTTGATGTACCTCTTTGCCTTAAATTGCTTTTTAGTTCTAAGATTG
 TAGAATGATCCTTTCAAATTGTAATCTTTTCTAACAGAGATATTTTAATATACTTG
 CTTTCTTAAAAAACAAAAAACTACTGTCAGTATTAATACTGAGCCAGACTGGCA
 TCTACAGATTTTCAAGATCTATCATTTTATTGATTCTTAAGCTTGATTAAAAAACTAG
 GCAATATCATCATGGATACATAGGAGAAGACACATTTACAATCATTTCATTGGGCC
 15 TTTTATCTGTCTATCCATCCATCATCATTTGAAGGCCTAATATATGCCAAGTACTC
 ACATGGTATGCATTGAGACATAAAAAAGACTGTCTATAACCTCAATAAGTATTAA
 AAATCCCATTATTACCCATAAGGTTTCATCTTATTTTCAATTTTAGGGAATAAAATTA
 CATGTCTATGAAATTTCAATTTTAAAGCACTATTGTTTTTCATGACCATAATTTATT
 TTTAAAAATAAATTAAAGGTTAATTATATGCATGTATGTATTTCTAATAATTAAA
 20 AATGTGTTCAATCCCTGAAATGTCTGCCTTTTAAATATAACACCTACTATTTGGTT
 AATTTTGACGATTTTTTTTTTTTCAATTAGGAAGCTAAAAATACTACTTTATTCCTT
 ATATGAAEATTCATCCCCC

SEQ ID NO: 551

25 >18105 BLOOD 350513.1 M95167 g703094 Human dopamine transporter (SLC6A3)
 mRNA, complete cds. 0
 ACCGCTCCGGAGCGGGAGGGGAGGCTTCGCGGAACGCTCTCGGCGCCAGGACTC
 GCGTGCAAAGCCCAGGCCCGGGCGGCCAGACCAAGAGGGAAGAAGCACAGAAT
 TCCTCAACTCCCAGTGTGCCCATGAGTAAGAGCAAATGCTCCGTGGGACTCATGT
 30 CTTCCTGTTGGCCCCGGCTAAGGAGCCCAATGCCGTGGGCCCCGAAGGAGGTGG
 AGCTCATCCTTGTCAAGGAGCAGAACGGAGTGCAGCTCACCAGCTCCACCCTCAC
 CAACCCGCGGCAGAGCCCCGTGGAGGCCAGGATCGGGAGACCTGGGGCAAGA
 AGATCGACTTTCTCCTGTCCGTCAATGGCTTTGCTGTGGACCTGGCCAACGTCTGG
 CGGTTCCCCTACCTGTGCTACAAAAATGGTGGCGGTGCCTTCCTGGTCCCCTACC
 35 TGCTCTTCATGGTCATTGCTGGGATGCCACTTTTCTACATGGAGCTGGCCCTCGGC
 CAGTTCAACAGGGAAGGGGCCGCTGGTGTCTGGAAGATCTGCCCCATACTGAAA
 GGTGTGGGCTTCACGGTCATCCTCATCTCACTGTATGTGGCTTCTTCTACAACGT
 CATCATCGCCTGGGCGCTGCACTATCTTCTCCTCCTTACCACGGAGCTCCCCT
 GGATCCACTGCAACAACCTCTGGAACAGCCCCAACTGCTCGGATGCCCATCCTGG
 40 TGACTCCAGTGGAGACAGCTCGGGCCTCAACGACACTTTTGGGACCACACCTGCT
 GCCGAGTACTTTGAACGTGGCGTGTGTCACCTCCACCAGAGCCATGGCATCGACG
 ACCTGGGGCCTCCGCGGTGGCAGCTCACAGCCTGCCTGGTGTGCTGGTCATCGTGCT
 GCTCTACTTCAGCCTCTGGAAGGGCGTGAAGACCTCAGGGAAGGTGGTATGGAT
 CACAGCCACCATGCCATACGTGGTCTCACTGCCCTGCTCCTGCGTGGGGTCACC
 45 CTCCCTGGAGCCATAGACGGCATCAGAGCATACCTGAGCGTTGACTTCTACCGGC
 TCTGCGAGGCGTCTGTTTGGATTGACGCGGCCACCCAGGTGTGCTTCTCCCTGGG
 CGTGGGGTTTCGGGGTGTGATCGCCTTCTCCAGCTACAACAAGTTCACCAACAAC
 TGCTACAGGGACGCGATTGTCACCACCTCCATCAACTCCCTGACGAGCTTCTCCT
 CCGGCTTCGTCGTCTTCTCCTTCTCCTGGGGTACATGGCACAGAAGCACAGTGTGCC

CATCGGGGACGTGGCCAAGGACGGGGCCAGGGCTGATCTTCATCATCTACCCGGA
AGCCATCGCCACGCTCCCTCTGTCCTCAGCCTGGGCCGTGGTCTTCTTCATCATGC
TGCTCACCCCTGGGTATCGACAGCGCCATGGGTGGTATGGAGTCAGTGATCACCGG
GCTCATCGATGAGTTCAGCTGCTGCACAGACACCGTGAGCTCTTCACGCTCTTC
5 ATCGTCTGGCGACCTTCCTCCTGTCCCTGTTCTGCGTCACCAACGGTGGCATCTA
CGTCTTCACGCTCCTGGACCATTTTGCAGCCGGCACGTCCATCCTCTTTGGAGTGC
TCATCGAAGCCATCGGAGTGGCCTGGTTCTATGGTGTGGGCAGTTCAGCGACGA
CATCCAGCAGATGACCGGGCAGCGGCCAGCCTGTACTGGCGGCTGTGCTGGAA
GCTGGTCAGCCCCCTGCTTTCTCCTGTTTCGTGGTCGTGGTCAGCATTGTGACCTTCA
10 GACCCCCCCTACTACGGAGCCTACATCTTCCCCGACTGGGCCAACGCGCTGGGCTG
GGTCATCGCCACATCCTCCATGGCCATGGTGCCCATCTATGCGGCCTACAAGTTC
TGCAGCCTGCCTGGGTCTTTCGAGAGAACTGGCCTACGCCATTGCACCCGAGA
AGGACCGTGAGCTGGTGGACAGAGGGGAGGTGCGCCAGTTCACGCTCCGCCACT
GGCTCAAGGTGTAGAGGGAGCAGAGACGAAGACCCCAGGAAGTCATCCTGCAAT
15 GGGAGAGACACGAACAAACCAAGGAAATCTAAGTTTCGAGAGAAAGGAGGGCA
ACTTCTACTCTTCAACCTCTACTGAAAACACAAACAAAGCAGAAGACTCCTC
TCTTCTGACTGTTTACACCTTTCCGTGCCGGGAGCGCACCTCGCCGTGTCTTGTGT
TGCTGTAATAACGACGTAGATCTGTGCAGCGAGGTCCACCCCGTTGTTGTCCCTG
CAGGGCAGAAAAACGTCTAACTTCATGCTGTCTGTGTGAGGCTCCCTCCCTCCCT
20 GCTCCCTGCTCCCGGCTCTGAGGCTGCCCCAGGGGCACTGTGTTCTCAGGCGGGG
ATCACGATCCTTGTAGACGCACCTGCTGAGAATCCCCGTGCTCACAGTAGCTTCC
TAGACCATTTACTTTGCCCATATTAAGGCAAGTGTCTGCTTGGTTAGCTGT
GCAGAAGGTGAAATGGAGGAAACCAAAATTCATGCAAAGTCCTTTCCCGATGC
GTGGCTCCCAGCAGAGGCCGTAAATTGAGCGTTCAGTTGACACATTCACACAC
25 AGTCTGTTTCAGAGGCATTGGAGGATGGGGGTCTGGTATGTCTCACCAGGAAATT
CTGTTTATGTTCTTGCAGCAGAGAGAAATAAACTCCTTGAAACCAGCTCAGGCT
ACTGCCACTCAGGCAGCCTGTGGGTCTTGTGGTGTAGGGAACGGCCTGAGAGG
AGCGTGTCTATCCCCGGACGCATGCAGGGCCCCCACAGGAGCGTGTCTATCCC
CGGACGCATGCAGGGCCCCCACAGGAGCATGTCTATCCCTGGACGCATGCAGG
30 GCCCCCACAGGAGCGTGTACTACCCACAGACGCATGCAGGGCCCCCACAGGAGC
GTGTACTACCCACAGGACGCATGCAGGGCCCCCACTGGAGCGTGTACTACCCAG
GACGCATGCAGGGCCCCCACAGGAGCGTGTCTATCCCCGGACCGGACGCATGC
AGGGCCCCCACAGGAGCGTGTACTACCCACAGGACGCATGCAGGGCCCCCACAGG
AGCGTGTACTACCCACAGGATGCATGCAGGGGCCCCCACAGGAGCGTGTACTACCC
35 CAGGACGCATGCAGGGCCCCCATGCAGGCAGCCTGCAGACCACACTCTGCCTGG
CCTTGAGCCGTGACCTCCAGGAAGGGACCCCACTGGAATTTTATTTCTCTCAGGT
GCGTGCCACATCAATAACAACAGTTTTTATGTTTGCGAATGGCTTTTTAAATCA
TATTTACCTGTGAATCAAAACAAATTCAAGAATGCAGTATCCGCGAGCCTGCTTG
40 CTGATATTGCAGTTTTTGTTTACAAGAATAATTAGCAATACTGAGTGAAGGATGT
TGGCCAAAAGCTGCTTTCCATGGCACACTGCCCTCTGCCACTGACAGGAAAGTGG
ATGCCATAGTTTGAATTCATGCCTCAAGTCGGTGGGCCTGCCTACGTGCTGCCCCG
AGGGCAGGGGCGGTGCAGGGCCAGTCATGGCTGTCCCCTGCAAGTGGACGTGGG
CTCCAGGGACTGGAGTGTAATGCTCGGTGGGAGCCGTCAGCCTGTGAACTGCCA
GGCAGCTGCAGTTAGCACAGAGGATGGCTTCCCCATTGCCTTCTGGGGAGGGAC
45 ACAGAGGACGGCTTCCCCATCGCCTTCTGGCCGCTGCAGTCAGCACAGAGAGCG
GCTTCCCCATTGCCTTCTGGGGAGGGACACAGAGGACAGCTTCCCCATCGCCTTC
TGGCTGCTGCAGTCAGCACAGAGAGCGGCTTCCCCATCGCCTTCTGGGGAGGGG
CTCCGTGTAGCAACCCAGGTGTTGTCCGTGTCTGTTGACCAATCTCTATTACGCAT

CGTGTGGGTCCCTAAGCACAATAAAAGACATCCACAATGGAAAAAAAAAAGG
AATTC

SEQ ID NO: 552

- 5 >18166 BLOOD 350204.2 U07695 g495472 Human tyrosine kinase (HTK) mRNA,
complete cds. 0

GCGCCCTGGGGCCGAGGCCACCGGGAAGGTGAATGTCAAGACGCTGCGTCTGGG
ACCGCTCAGCAAGGCTGGCTTCTACCTGGCCTTCCAGGACCAGGGTGCCTGCATG
GCCCTGCTATCCCTGCACCTCTTCTACAAAAAGTGCGCCCAGCTGACTGTGAACC
10 TGACTCGATTCCCGGAGACTGTGCCTCGGGAGCTGGTTGTGCCCCTGGCCGGTAG
CTGCGTGGTGGATGCCGTCCCCGCCCTGGCCCCAGCCCCAGCCTCTACTGCCAG
CACGCTCCGGGCCCGCCGCCCGCGCGCGGAACAGACGCGGGGCCACACTTGG
CGCCGACGACCGGTGCCCGCACGCTCGCATGGGCCCCGCGCTGAGGGCCCCGAC
GAGGAGTCCCGCGCGGAGTATCGGAGTCCACCCGCCAGGGAGAGTCAGACCTG
15 GGGGGGCGAGGGCCCCCAAACCTCAGTTCGGATCCTACCCGAGTGAGGCGGCGC
CATGGAGCTCCGGGTGCTGCTCTGCTGGGCTTCGTTGGCCGCAGCTTTGGAAGAG
ACCCTGCTGAACACAAAATTGGAACTGCTGATCTGAAGTGGGTGACATTCCCTC
AGGTGGACGGGCAGTGGGAGGAACTGAGCGGCCTGGATGAGGAACAGCACAGC
GTGCGCACCTACGAAGTGTGTGACGTGCAGCGTGCCCCGGGCCAGGCCCACTGG
20 CTTTCGCACAGGTTGGGTCCCACGGCGGGGCGCCGTCCACGTGTACGCCACGCTGC
GCTTACCATGCTCGAGTGCCTGTCCCTGCCTCGGGCTGGGCGCTCCTGCAAGGA
GACCTTACCGTCTTCTACTATGAGAGCGATGCGGACACGGCCACGGCCCTCAG
CCAGCCTGGATGGAGAACCCTACATCAAGGTGGAACGGTGGCCGCGGAGCAT
CTCACCCGGAAGCGCCCTGGGGCCGAGGCCACCGGGAAGGTGAATGTCAAGACG
25 CTGCGTCTGGGACCGCTCAGCAAGGCTGGCTTCTACCTGGCCTTCCAGGACCAGG
GTGCCTGCATGGCCCTGCTATCCCTGCACCTCTTCTACAAAAAGTGCGCCCAGCT
GACTGTGAACCTGACTCGATTCCCGGAGACTGTGCCTCGGGAGCTGGTTGTGCCC
GTGGCCGGTAGCTGCGTGGTGGATGCCGTCCCCGCCCTGGCCCCAGCCCCAGCC
TCTACTGCCGTGAGGATGGCCAGTGGGCCGAACAGCCGGTCACGGGCTGCAGCT
30 GTGCTCCGGGGTTCGAGGCAGCTGAGGGGAACACCAAGTGCCGAGCCTGTGCCC
AGGGCACCTTCAAGCCCCTGTCAGGAGAAGGGTCCTGCCAGCCATGCCAGCCA
ATAGCCACTCTAACACCATTTGGATCAGCCGTCTGCCAGTGCCGCGTCGGGTACTT
CCGGGCACGCACAGACCCCGGGGTGCACCCTGCACCACCCCTCCTTCGGCTCCG
CGGAGCGTGGTTTCCCGCCTGAACGGCTCCTCCCTGCACCTGGAATGGAGTGCCC
35 CCCTGGAGTCTGGTGGCCGAGAGGACCTCACCTACGCCCTCCGCTGCCGGGAGTG
CCGACCCGGAGGCTCCTGTGCGCCCTGCGGGGGAGACCTGACTTTTGACCCCGGC
CCCCGGGACCTGGTGGAGCCCTGGGTGGTGGTTTCGAGGGCTACGTCCTGACTTCA
CCTATACCTTTGAGGTCACTGCATTGAACGGGGTATCCTCCTTAGCCACGGGGCC
CGTCCCATTTGAGCCTGTCAATGTCACCACTGACCGAGAGGTACCTCCTGCAGTG
40 TCTGACATCCGGGTGACGCGGTCTCACCCAGCAGCTTGAGCCTGGCCTGGGCTG
TTCCCCGGGCACCCAGTGGGGCTGTGCTGGACTACGAGGTCAAATACCATGAGA
AGGGCGCCGAGGGTCCCAGCAGCGTGCGGTTTCTGAAGACGTCAGAAAACCGGG
CAGAGCTGCGGGGGCTGAAGCGGGGAGCCAGCTACCTGGTGCAGGTACGGGCGC
GCTCTGAGGCCGGCTACGGGCCCTTCGGCCAGGAACATCACAGCCAGACCCAAC
45 TGGATGAGAGCGAGGGCTGGCGGGAGCAGCTGGCCCTGATTGCGGGCACGGCAG
TCGTGGGTGTGGTCTTGGTGGTTCATTGTGGTTCGAGTTCTCTGCCTCAGG
AAGCAGAGCAATGGGAGAGAAGCAGAATATTCGGACAAACACGGACAGTATCT
CATCGGACATGGTACTAAGGTCTACATCGACCCCTTCACTTATGAAGACCCTAAT
GAGGCTGTGAGGGAATTTGCAAAAGAGATCGATGTCTCCTACGTCAAGATTGAA

GAGGTGATTGGTGCAGGTGAGTTTGGCGAGGTGTGTCTGGGGGGCGGCTCAAGGCC
CCAGGGAAGAAGGAGAGCTGTGTGGCAATCAAGACCCTGAAGGGTGGCTACACG
GAGCGGCAGCGGCGTGAGTTTCTGAGCGAGGCCTCCATCATGGGCCAGTTCGAG
CACCCCAATATCATCCGCCTGGAGGGCGTGGTCACCAACAGCATGCCCCTCATGA
5 TTCTCACAGAGTTCATGGAGAACGGCGCCCTGGACTCCTTCCTGCGGCTAAACGA
CGGACAGTTCACAGTCATCCAGCTGCGTGGGCATGCTGCGGGGCATCGCCTCGG
GCATGCGGTACCTTGCCGAGATGAGCTACGTCCACCGAGACCTGGCTGCTCGCAA
CATCCTAGTCAACAGCAACCTCGTCTGCAAAGTGTCTGACTTTGGCCTTTCCCGA
TTCTTGAGGAGAACTCTTCCGATCCACCTACACGAGCTCCCTGGGAGGAAAG
10 ATTCCCATCCGATGGACTGCCCCGAGGGCCATTGCCTTCCGGAAGTTCATTCCG
CCAGTGATGCCTGGAGTTACGGGATTGTGATGTGGGAGGTGATGTCATTTGGGGA
GAGGCCGTACTGGGACATGAGCAATCAGGACGTGATCAATGCCATTGAACAGGA
CTACCGGCTGCCCCCGCCCCAGACTGTCCACCTCCCTCCACCAGCTCATGCTG
GACTGTTGGCAGAAAGACCGGAATGCCCGGCCCGCTTCCCCCAGGTGGTCAGC
15 GCCCTGGACAAGATGATCCGGAACCCCGCCAGCCTCAAAATCGTGGCCCCGGGAG
AATGGCGGGGCCTCACACCCTCTCCTGGACCAGCGGCAGCCTCACTACTCAGCTT
TTGGCTCTGTGGGCGAGTGGCTTCGGGCCATCAAAATGGGAAGATACGAAGAAA
GTTTCGCAGCCGCTGGCTTTGGCTCCTTCGAGCTGGTCAGCCAGATCTCTGCTGA
GGACCTGCTCCGAATCGGAGTCACTCTGGCGGGACACCAGAAGAAAATCTTGGC
20 CAGTGTCCAGCACATGAAGTCCCAGGCCAAGCCGGGAACCCCGGGTGGGACAGG
AGGACCGGCCCCGAGTACTGACCTGCAGGAACCTCCCCACCCAGGGACACCGC
CTCCGCATTTTCCGGGGCAGAGTGGGGACTCACAGAGGCCCCCAAGCCCTGTGCCC
CGCTGGATTGCACTTTGAGCCCGTGGGGTGAGGAGTTGGCAATTTGGAGAGACA
GGATTTGGGGGTCTGCCATAATAGGAGGGGAAAATCACCCCCAGCCACCTCG
25 GGGAACCTCCAGACCAAGGGTGAGGGCGCCTTTCCCTCAGGACTGGGTGTGACCA
GAGGAAAAGGAAGTGCCCAACATCTCCAGCCTCCCCAGGTGCCCCCTCACCTT
GATGGGTGCGTTCCCGCAGACCAAGAGAGTGTGACTCCCTTGCCAGCTCCAGA
GTGGGGGGGCTGTCCCAGGGGGCAAGAAGGGGTGTCAGGGCCCAGTGACAAAA
TCATTGGGGTTTGTAGTCCCAACTTGCTGCTGTCAACCACCAAACTCAATCATTTT
30 TTCCCTTGTAATGCCCTCCCCAGCTGCTGCCTTCATATTGAAGGTTTTTGAGT
TTTGTTTTTGGTCTTAATTTTTCTCCCCGTTCCCTTTTTGTTTTCTTCGTTTTGTTTT
CTACCGTCTTGTGATAACTTTGTGTTGGAGGGAACCTGTTTCACTATGGCCTCCT
TTGCCCAAGTGTAAACAGGGGCCCATCATCATGTCTGTTTCCAGAACAGTGCCTT
GGTCATCCACATCCCGGACCCCGCCTGGGACCCCCAAGCTGTGTCTATGAAG
35 GGGTGTGGGGTGAGGTAGTGAAGAGGGCGGTAGTTGGTGGTGAACCCAGAAAC
GGACGCCGGTGCTTGGAGGGGTCTTAAATTATTTAAAAAAGTAACCTTTTGT
ATAAATAAAAGAAAATGGGACGTGTCCAGCTCCAGGGGTG

SEQ ID NO: 553

40 >18214 BLOOD 407199.2 AF154830 g5020419 Human carbamyl phosphate synthetase I
mRNA, complete cds. 0
GAGCTGTAGATTTCGGCACGAGACACTGACTGCACCCCTCCCAGATTTCTTTTACA
TTAACTAAAAAGTCTTATCACACAATCTCATAAAATTTATGTAATTTCAATTAAAT
TTAGCCACAAATCATCTTCAAAATGACGAGGATTTTGACAGCTTTCAAAGTGGTG
45 AGGACACTGAAGACTGGTTTTTGGCTTTACCAATGTGACTGCACACCAGAAATGG
AAATTTTCAAGACCTGGCATCAGGCTCCTTTCTGTCAAGGCACAGACAGCACACA
TTGTCCTGGAAGATGGAACCTAAGATGAAAGGTTACTCCTTTGGCCATCCATCCTC
TGTTGCTGGTGAAGTGGTTTTTAATACTGGCCTGGGAGGGTACCCAGAAGCTATT
ACTGACCCTGCCTACAAAGGACAGATTCTCACAATGGCCAACCCTATTATTGGGA

ATGGTGGAGCTCCTGATACTACTGCTCTGGATGAACTGGGACTTAGCAAATATTT
GGAGTCTAATGGAATCAAGGTTTCAGGTTTGCTGGTGGATTATAGTAAAGAC
TACAACCACTGGCTGGCTACCAAGAGTTTAGGGCAATGGCTACAGGAAGAAAAG
GTTCTGCAATTTATGGAGTGGACACAAGAATGCTGACTAAAATAATTCGGGATA
5 AGGGTACCATGCTTGGGAAGATTGAATTTGAAGGTCAGCCTGTGGATTTTGTGGA
TCCAAATAAACAGAATTTGATTGCTGAGGTTTCAACCAAGGATGTCAAAGTGTAC
GGCAAAGGAAACCCCACAAAAAGTGGTAGCTGTAGACTGTGGGATTA AAAACAAT
GTAATCCGCCTGCTAGTAAAGCGAGGAGCTGAAGTGCACCTTAGTTCCTGGAACC
ATGATTTTACCAAGATGGAGTATGATGGGATTTTGATCGCGGGAGGACCGGGGA
10 ACCCAGCTCTTGCAGAACCACTAATTCAGAATGTCAGAAAGATTTTGGAGAGTG
ATCGCAAGGAGCCATTGTTTGGGAATCAGTACAGGAACTTAATAACAGGATTGG
CTGCTGGTGCCAAAACCTACAAGATGTCCATGGCCAACAGAGGGCAGAATCAGC
CTGTTTTGAATATCACAAACAAACAGGCTTTCATTACTGCTCAGAATCATGGCTA
TGCCTTGGACAACCTCTCTCCCTGCTGGCTGGAAACCACTTTTTGTGAATGTCAAC
15 GATCAAAACAAATGAGGGGATTATGCATGAGAGCAAACCCTTCTTCGCTGTGCAG
TTCCACCCAGAGGTCACCCCGGGGCCAATAGACACTGAGTACCTGTTTGATTCT
TTTTCTCACTGATAAAGAAAGGAAAAGCTACCACCATTACATCAGTCTTACCGAA
GCCAGCACTAGTTGCATCTCGGGTTGAGGTTTCCAAAGTCCTTATTCTAGGATCA
GGAGGTCTGTCCATTGGTCAGGCTGGAGAATTTGATTACTCAGGATCTCAAGCTG
20 TAAAAGCCATGAAGGAAGAAAATGTCAAAACTGTTCTGATGAACCCAAACATTG
CATCAGTCCAGACCAATGAGGTGGGCTTAAAGCAAGCGGATACTGTCTACTTTCT
TCCCATCACCCCTCAGTTTGTACAGAGGTCATCAAGGCAGAACAGCCAGATGG
GTTAATTTCTGGGCATGGGTGGCCAGAGAGCTCTGAACTGTGGAGTGGAACTATTC
AAGAGAGGTGTGCTCAAGGAATATGGTGTGAAAGTCCTGGGAACTTCAGTTGAG
25 TCCATTATGGCTACGGAAGACAGGCAGCTGTTTTCAGATAAACTAAATGAGATCA
ATGAAAAGATTGCTCCAAGTTTTCAGTGGAAATCGATTGAGGATGCACTGAAGG
CAGCAGACACCATTGGCTACCCAGTGATGATCCGTTCCGCCTATGCACTGGGTGG
GTTAGGCTCAGGCATCTGTCCCAACAGAGAGACTTTGATGGACCTCAGCACAAA
GGCCTTTGCTATGACCAACCAAAATTCTGGTGGAGAAGTCAGTGACAGGTTGGAA
30 AGAAATAGAATATGAAGTGGTTCGAGATGCTGATGACAATTGTGTCACTGTCTGT
AACATGGAAAATGTTGATGCCATGGGTGTTACACAGGTGACTCAGTTGTTGTGG
CTCCTGCCAGACACTCTCCAATGCCGAGTTTCAGATGTTGAGACGTACTTCAAT
CAATGTTGTTGCGCCACTTGGGCATTGTGGGTGAATGCAACATTCAGTTTGGCCTTC
ATCCTACCTCAATGGAATACTGCATCATTGAAGTGAATGCCAGACTGTCCCGAAG
35 CTCTGCTCTGGCCTCAAAAGCCACTGGCTACCCATTGGCATTCAATTGCTGCAAAG
ATTGCCCTAGGAATCCCACTTCCAGGAATTAAGAACGTCGTATCCGGGAAGACAT
CAGCCTGTTTTGAACCTAGCCTGGATTACATGGTCACCAAGATTCCCCGCTGGGA
TCTTGACCGTTTTCATGGAACATCTAGCCGAATTGGTAGCTCTATGAAAAGTGTA
GGAGAGGTCATGGCTATTGGTCGTACCTTTGAGGAGAGTTTCCAGAAAGCTTTAC
40 GGATGTGCCACCCATCTATAGAAGGTTTCACTCCCCGTCTCCAATGAACAAAGA
ATGGCCATCTAATTTAGATCTTAGAAAAGAGTTGTCTGAACCAAGCAGCACGCGT
ATCTATGCCATTGCCAAGGCCATTGATGACAACATGTCCCTTGATGAGATTGAGA
AGCTCACATAACATTGACAAGTGGTTTTTGTATAAGATGCGTGATATTTTAAACAT
GGAAAAGACACTGAAAGGGCTCAACAGTGAGTCCATGACAGAAGAAACCCTGA
45 AAAGGGCAAAGGAGATTGGGTTCTCAGATAAGCAGATTTCAAAATGCCTTGGGC
TCACTGAGGCCCAGACAAGGGAGCTGAGGTTAAAGAAAAACATCCACCCTTGGG
TTAAACAGATTGATACTGGCTGCAGAATAACCATCAGTAACAAACTATCTCTA
TGTTACCTACAATGGTCAGGAGCATGATGTCAATTTTGATGACCATGGAATGATG
GTGCTAGGCTGTGGTCCATATCACATTGGCAGCAGTGTGGAATTTGATTGGTGTG

CTGTCTCTAGTATCCGCACACTGCGTCAACTTGGCAAGAAGACGGTGGTGGTGAA
TTGCAATCCTGAGACTGTGAGCACAGACTTTGATGAGTGTGACAAACTGTACTTT
GAAGAGTTGTCCTTGGAGAGAATCCTAGACATCTACCATCAGGAGGCATGTGGT
GGCTGCATCATATCAGTTGGAGGCCAGATTCCAAACAACCTGGCAGTTCCTCTAT
5 ACAAGAATGGTGTCAAGATCATGGGCACAAGCCCCCTGCAGATCGACAGGGCTG
AGGATCGCTCCATCTTCTCAGCTGTCTTGGATGAGCTGAAGGTGGCTCAGGCACC
TTGGAAAGCTGTTAATACTTTGAATGAAGCACTGGAATTTGCAAAGTCTGTGGAC
TACCCCTGCTTGTGAGGCCCTTCTATGTTTTGAGTGGGTCTGCTATGAATGTGGT
ATTCTCTGAGGATGAGATGAAAAAATTCCTAGAAAGAGGGCGACTAGAGTTTCTCA
10 GGAGCACCAGTGGTGTGACAAAATTTGTTGAAGGGGCCCCGAGAAGTAGAAAT
GGACGCTGTTGGCAAAGATGGAAGGGTTATCTCTCATGCCATCTCTGAACATGTT
GAAGATGCAGGTGTCCACTCGGGAGATGCCACTCTGATGCTGCCACACAAAACC
ATCAGCCAAGGGGCCATTGAAAAGGTGAAGGATGCTACCCGGAAGATTGCAAAG
GCTTTTGCCATCTCTGGTCCATTCAACGTCCAATTTCTTGTCAAAGGAAATGATGT
15 CTTGGTGATTGAGTGTAACCTTGAGAGCTTCTCGATCCTTCCCCTTTGTTTCCAAGA
CTCTTGGGGTTGACTTCATTGATGTGGCCACCAAGGTGATGATTGGAGAGAATGT
TGATGAGAAACATCTTCCAACATTGGACCATCCCATAATTCCTGCTGACTATGTT
GCAATTAAGGCTCCCATGTTTTCTGGCCCCGGTTGAGGGATGCTGACCCCATTC
TGAGATGTGAGATGGCTTCCACTGGAGAGGTGGCTTGCTTTGGTGAAGGTATTCA
20 TACAGCCTTCCCTAAAGGCAATGCTTTCCACAGGATTAAAGATACCCAGAAAGGC
ATCCTGATAGGCATCCAGCAATCATTCCGGCCAAGATTCCTTGGTGTGGCTGAAC
AATTACACAATGAAGGTTTCAAGCTGTTTGGCACGGAAGCCACATCAGACTGGCT
GAACGCCAACAATGTGCTGCCCAGTGGCATGGCCGTCTCAAGAAGGACA
GAATECCAGCCTCTGTTCCATCAGAAATTTGATTAGAGATGGCAGCATTGACCTA
25 GTGATTAACCTTCCCAACAACAACACTAAATTTGTCCATGATAATTATGTGATTC
GGAGGACAGCTGTTGATAGTGGAATCCCTCTCCTCACTAATTTTCAGGTGACCAA
ACTTTTTGCTGAAGCTGTGCAGAAATCTCGCAAGGTGGACTCCAAGAGTCTTTTC
CACTACAGGCAGTACAGTGTGAAAAGCAGCATAGAGATGCAGACACCCAGC
CCCATTATTAATCAACCTGAGCCACATGTTATCTAAAGGAACTGATTCACAAC
30 TTCTCAGAGATGAATATTGATAACTAACTTCATTTAGTTTACTTTGTTATGCCT
TAATATTCTGTGCTTTTGAATTAATTTGTCAGTCACTTCTTCAAAACCTTACAG
TCCTTCTAAGTTACTCTTCATGAGATTTTCATCCATTTACTAATACTGTATTTTGG
TGGACTAGGCTTGCCATGTGCTTATGTGTAGCTTTTACTTTTATGGTGTGCTGAT
TATGGTGATCAAGGTAGGAAAAGTTGCTGTTCTATTTTCTGAACTCCTTCTATAC
35 TTTAAGATACTCTATTTTAAAACACTATCTGCAAACCTCAGGACACTTTAACAGG
GCAGAATACTCTAAAAACTTGATAAAATTAATATAGATTTAATTTATGAACCTT
CCATCATGATGTTTGTGTATTGCTTCTTTTGGATCCTCATTCTACCCATTGCGT
AATCCAGGAATATTGTTATCCCTTCCCATTATATTGAAGTTGAGAAATGTGACAG
AGGCATTTAGAGTATGGACTTTTCTAANCTNNNNNNNNNNNNNNNNNNNNNNNN
40 NNN
NN
TTTCTTTAAGGAATACTGGTTTGCAGTTTTGTTTTCTGGACTATATCAGCAGATGG
TAGACAGTGTATGTAGATGTGTTGTTGTTTTATCATTGGATTTAACTTGGCC
CGAGTGAAATAATCAGATTTTGTCACTCACACTCTCCCCAGTTTTGGAATAACT
45 TGGAAGTAAGGTTCAATCCCTTAAGACGATGGATTCTGTTGAACTATGGGGTCCC
AACTGCATTAATTCACCCACTGTAAGGGCAAGGACACCATTCTTCTACA
TATAAGAAAAAAGTCTCTCCCAAGGGCAGCCTTTGTTACTTTTAAATATTTCTG
TTATTACAAGTGCTCTAATTGTGAACTTTTAAATAAAATACTATTAAGAGGTAAA
AAAAAACAAAAGG

SEQ ID NO: 554

>18219 BLOOD 1143363.1 AF031425 g2623890 Human galectin 3 (LGALS3) gene, exon 6, and complete cds. 1e-54

5 GATTATATCATGGTATATGAAGCACTGGTGAGGTCTATGTCACCAGAAATTCCCA
GTTTGCTGATTTCAATTGAGTTTTTTAAACCCGATGATNGTACTGCAACAAGTNAGC
ATNNGTCACTGCAACCNAACNNGNNGGGGGGNAGGTNCACCCNNNNNTNTTTTT
TGAAAGGGTTCCCATTTTCNAANGGGGAAACCGNTNTTTTTCTTCCCTNCCCNGT
TATTATCCAGCTTTGTATTGCAAACAATGACTCTCCTGTTGTTCTCATTGAAGCGT
10 GGGGTTAAAGTGGGAGGGCAACATCATTCCCTCTTTGGGAAATCTAAGGCAATTC
TGTTTGCATTGGGGC

SEQ ID NO: 555

>18229 BLOOD 400534.5 L22342 g402204 Human nuclear phosphoprotein mRNA, complete cds. 0

15 GCCCAGCCTCCTCACTAGCACTGTGCAAGTGGCCAGTGACAACCTGATCCCCCAA
ATAAGAGATAAAGAAGACCCTCAAGAGATGCCCCACTCTCCCTTGGGCTCTATGC
CAGAGATAAGAGATAATTCTCCAGAACCAAATGACCCAGAAGAGCCCCAGGAGG
TGTCAGCACACCTTCAGACAAGAAAGGAAAGAAAAGAAAAGATGTATCTGGT
20 CAACTCCAAAAAGGAGACATAAGAAAAAAGCCTCCCAAGAGAGATCATTGATG
GCACTTCAGAAATGAATGAAGGAAAGAGGTCCCAGAAGACGCCTAGTACACCAC
GAAGGGTCACACAAGGGGGCAGCCTCAGCTGGGCATGGCATCCAAGAGAAGCTCC
AAGTGGTGGATAAGGTGACTCAAAGGAAAGACGACTCAACCTGGAAGTCAAGAGG
TCATGATGAGGGTCCAAAAGGCAAGAACTAAATGTGCCCGAAAGTCCAGATTGA
25 AAGAAAAGAAAAGGAGAAAGATATCTGTTCAAGCTCAAAAAGGAGATTTCAG
AAAAATATTCACCGAAGAGGAAAACCCAAAAGTGACACTGTGGATTTTCACTGT
TCTAAGCTCCCCGTGACCTGTGGTGAGGCGAAAGGGATTTTATATAAGAAGAAA
ATGAAACACGGATCCTCAGTGAAGTGCATTCGGAATGAGGATGGAAGTGGTTA
ACACCAAATGAATTTGAAGTGAAGGAAAGGAAGGAACGCAAAGAACTGGAA
30 ACGGAATATACGTTGTGAAGGAACGACCCTAGGAGAGCTGCTGAAGAGTGGACT
TTTGCTCTGTCCTCCAAGAATAAATCTCAAGAGAGAGTTAAATAGCAAGTGAATT
TCTACTACCCTCTCAGTCACCATGTTGCAGACTTTCCCTGTCTGGAGGCTCACCTT
AGAGCTTCTGAGTTTCCAAGCTCTGAGTCACCTCCACATTTGGGCATGGCATCTT
CAAAAACAATTAATTTGCATAGTTAATTTGGGATGGGGAAGCAAATGACTCTAAA
35 ATAAATCTCAAGAGAGAGTTCAATAGCAAGTGAATTTCTACTACCCTCTCAGTCA
CCATGTTGCAGACTTTCCCTGTCTGGAGGCTCACCTTAGAGCTTCTGAGTTTCCAA
GCTCTGAGTCACCTCCACATTTGGGCATGGCATCTTCAAAAACAATTAATTTGCAT
AGTTAATTTGGGATGGGGAAGCCAATGACTCTTAAAT

40 SEQ ID NO: 556

>18298 BLOOD 406471.1 X52638 g35502 Human mRNA for 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (EC 2.7.1.105, EC 3.1.3.46).

0TATTTTCATACGACTCACTATAGGGAATTTGCCCCGAAACGGAATTCGGGCACGA
GCCCATTTACACTGAAGATCGATCTGAAACTCAGCACCAGCGAAATCCAGAACTT
45 GCCTGTCTCCATGGCTGGTTTTAATTTCCCCATTCTGCAGTGGCTTGTTAATATTA
GTTCTGACCTTTGGGGCAAGGTGAACACATGGTTGGACTGAAGAGAAAAGGCTT
CTGGTGGCTCAGGAACGTCTTTGGCAACTACAACAGCTGATATTTCAACAGAGCA
CATAACATCCCCCACTTAACAAGGGTACGTCTCAGCCTTCTCAGGGAACCAACGA
ACACCTCCAGGCTTCCTCTTTGATGCCACCCACTGGACCTGCCTTGGGGGTCTGT

AAATGCAAGAGAACCGAGTGTTGGATAATTAGCGATGGAAGAAAAAACCTCTAG
AATAAAAGCATCCATACCCAGTTTACCAATTCCCCACAATGGTGATCATGGTG
GGTTTACCAGCTCGAGGCAAGACCTATATCTCCACAAAGCTCACACGATATCTCA
ACTGGATAGGAACACCAACTAAAGTGTTTAATTTAGGCCAGTATCGACGAGAGG
5 CAGTGAGCTACAAGAACTATGAATTCCTTCTTCCAGACAACATGGAAGCCCTGCA
AATCAGGGAAGCAGTGCGCCCTGGCAGCCCTGAAGGATGTTCACAACTATCTCA
GCCATGAGGAAGGTCATGTTGCGGTTTTTGATGCCACCAACACTACCAGAGAAC
GACGGTCACTGATCCTGCAGTTTGCAAAAGAACATGGTTACAAGGTGTTTTTCAT
TGAGTCCATTTGTAATGACCCTGGCATAATTGCAGAAAACATCAGGCAAGTGAA
10 ACTTGGCAGCCCTGATTATATAGACTGTGACCGGGAAGGTTCTGGAAGACTTT
CTAAAGAGAATTGAGTGCTATGAGGTCAACTACCAACCCTTGGATGAGGAACTG
GACAGCCACCTGTCCTACATCAAGATCTTCGACGTGGGCACACGCTACATGGTGA
ACCGAGTGCAGGATCACATCCAGAGCCGCACAGTCTACTACCTCATGAATATCCA
TGTCACACCTCGCTCCATCTACCTTTGCCGACATGGCGAGAGTGAACCAACATC
15 AGAGGCCGCATCGGAGGTGACTCTGGCCTCTCAGTTCGCGGCAAGCAGTATGCCT
ATGCCCTGGCCAACCTTCATTCAGTCCCAGGGCATCAGCTCCCTGAAGGTGTGGAC
CAGTCACATGAAGAGGACCATCCAGACAGCTGAGGCCCTGGGTGTCCCCTATGA
GCAGTGGAAGGCCCTGAATGAGATTGATGCGGGTGTCTGTGAGGAGATGACCTA
TGAAGAAATCCAGGAACATTACCCTGAAGAATTTGCACTGCGAGACCAAGATAA
20 ATATCGCTACCGCTATCCCAAGGGAGAGTCCTATGAGGATCTGGTTCAGCGTCTG
GAGCCAGTGATAATGGAGCTAGAACGACAGGAGAATGTACTGGTGATCTGCCAC
CAGGCTGTCATGCGGTGCGCTCCTGGCCTATTTCCCTGGATAAAAGTTTCAGATGAGC
TTCGGTATCTCAAGTGCCCTCTGGACACAGTGCTCAAACCTCACTCCTGTGGCTTAT
GGCTGCAAAAGTGGAATCCATCTACCTGAATGTGGAGGCCGTGAACACACACCGG
25 GAGAAGCCTGAGAATGTGGACATCACCCGGGAACCTGAGGAAGCCCTGGATACT
GTCCCAGCCCACTACTGAGCCCTTTCCAAGAAGTCAAACCTGCCTGTGTCCTCATC
GCCTTCCACCTTTAGGAAATGCTATCTTTGCTCTTCTCCTACTCTGCCTTGGCCTC
ACTGAGGCACCCCACTTCCAGTGAAGAAGTCCTCCGCAACTCCCAAACAAGCCTC
GCTTGCTGGCCGCAACCAAGGAGCTATCTAGCTCTGGAGGAACTTTCTTTCTTA
30 ATTCCTATTCTCTGACGAATAAAGACTTACTGCCTACAAGAGG

SEQ ID NO: 557

>18501 BLOOD 201402.1 AL080184 g5262661 Human mRNA; cDNA DKFZp4340071
(from clone DKFZp4340071). 0

35 GTGGGAGTGGAGGAGGAAGAGGCGGTAGGGGGTACGGGGGCTGGTCCCAGAAG
ATGGCGGAGGCGGGGGATTCTGGTAGGTCCTACTTTAGGACAAGATGTGGTAC
CGTTGAAGCGTCAGTCTTTGATTACAGACAGTTGAGCTTTTCAGCTGGGAAGCC
TTTCCATTTTTTTTTTTTAAAGGGCTTTCTGAACCTATGAAACCAGGGCAGAAGGA
40 GAGACAGAGTCACCGGGGCCCCAAAAGGGGGGCCCATATATTTTCATCTGTCCT
AGCCAGAGGGGTGAACTGGAGTGATCGAGGAGTAGGGCTATTTTAAATGGGAGT
ATTTCTGGCATTAGGGTTAAATTTACTTCAGATTCAGAGAAAGGTGACGCTCTTT
CCACCGTGAGTGGTGATGGCAAGCATCTTTTCTTCGGCGTGGGGGGTACCCCTT
GCTGGGGCACGGCTTCTGCTGTGATTGGGTATTATACCCCTGCATTGACAGACA
TCTAGGAGAACCACATAAAATTTAAAAGAGAGTGGTCCAGTGTAATGCGGTGTGT
45 AGCAGTCTTTGTTGGTATAAATCATGCCAGTGCTAAAGTGGAATTCGATAACAAC
ATACAGTTGTCTCTCACACTGGCTGCACTATCCATTGGACTGTGGTGGACTTTTGA
TAGATCTAGAAGTGGTTTTGGCCTTGGAGTAGGAATTGCCTTCTTGGCAACTGTG
GTCACTCAACTGCTAGTATATAATGGTGTTTACCAATATACATCTCCAGATTTCT
CTATGTTTCGTTCTTGGTTACCATGTATATTTTTTGCTGGAGGCATAACAATGGGAA

ACATTGGTCGACAACTGGCAATGTACGAATGTAAAGTTATCGCAGAAAAATCTC
ATCAGGAATGAAGAAGGCAAAAAATATCTTTGTACAGAAAAGCAAGATGAAAA
GGATGTGAAATGGTAGATATACCAACAAAACCTTCAGACTGTAAAATTGCCAGGA
TGCAGTTTTCCCCTTGATTGGCGTGTGTGTATATATGGAATAAATATATATATACA
5 CACACACATATTACTGCAATCTGTGATTGCTTCATCTGTAAATCAGTTGTAAACCT
TTACATATTTGACTTAAATAACTGTAAGATATATATGTACTACATTA AAAAGTGT
TGATTAATAGATGAAATTTTTAAATTAATTTTTTAAAACATGCCATACATTGTATC
ACAATGTTAATGTGCCAAGATATTGTTCCCTGTCATGCAGAGTATAAGAATGCTTT
GAACAATTTGTAGACTTAGTGAAATAAAAATAAGAGGAAAGCCAAAAACAAACNT
10 ACAAAAAGCATATGGGGAGCTGGTATTTTCTCTTTAGCTTACTGTTGTGCCTTTTT
ATTTTTCTAATCACAGCAGTATGAGTTATGAGTGCCCTAATTTGTGGTTAGTTTCT
AATTTAATGTTGTTTCATAGAGTTTGGAGTGTTTTGATACAGGGTGAAAATGAAC
TTCTGGTTTTCAAACCTGCGTACTGGAGACAGCCCAAAGAGTAATTTTCTGTTTTG
ACAGGTTTTACTGGAAGTATATGTGATGAGCAGAAGAGGTTATCAGCATTAAATT
15 GTTTTGGTTCTAAATTTGGAACAGTATATATAATTA AAAAGTAAGGAACATTAGAG
GATTTAATTAGAATAAATACATGTTTTGGAAATACAGTGACCTCTTGCAAGTGTC
CAAAAGTGCAAAGTGATATTAGCTGTCATCTGCAATACAGAATCTCATTGCTTTT
GCACATGGAGCATATAGGAACTCCAAACAGATCACAATGAGGTTTCTAAATCT
GTTGGGTTCTGTCTTCTATTGGGTTCTGTGAAGCAAACCACTGTAGCTTTAGCTGG
20 GTTCAGTCATATGACTCGTTGGTGGAATGCCTAGGTTTTTCATCTTACATGCAGTC
TTGGGGGTGGATGAATACATAATTTCTTATGTATTTCGTGTATCCATTAGTGAATA
GTTCAGTCTGTTTAAAGAGTGTATTGAGATGGCATTCTCTGCATGTTAAAGATCTT
AATGGCAACCAGCACCTCTTAAGTATGGTTTAAACATATTCTTAGCTAATTTTTC
CATFAGTTTTTGAAATTGGTGGCAGTTGTCTGATCCACAAGGGCAAGATCTCTG
25 AGTACTCTGGGGTGTGAGTATGTGTGCACACGTGTGTGTTGGAGTGAGTGAGAG
AATGTGTCTGTGCATGTGGCCATGCTTTCCTAGAAATGTCAAGTAGATATTTTTACA
CTTTGAGTTTTAAAGCAATTACTATCAGACTGAGATCTTGTATGCCAAACTTTAAT
CTGCTTTTATGTTTTTCAGGCTGAAGGTGTGAAAATCCTAAGAGGATTTTCATATTG
AATATGTGTACACAATCTTAACTATCGTGGTGGA AAAACATACTACTATAATTTAT
30 TATTATATCTTCCAGATAATGTTATTCATTTAGAACAAAATAAGGTATATTTTTTAG
AATCAACTTTGTAAGCACTATAAAAATCTTTAATAAGTTATAAGGTCTATGATGTG
TTTACTTTAAAAATTGCTGTTAAAGCAACACGTATTAAATATGTAATTATCATCT
GGGTAAAGAGTCTGTTTTTCTTCTTTGTGGTAAGTCTTAGAATATGGTACTGTGGA
TTAATCTAATGAAATTAACATATGTGGTTGAAGTTACCAAGAAACGATGAAAAG
35 AAATAAATATAGTNGACCCTTGAACAACAGGAGTTAGGGGCACCACTCCCCAA
CATAGTTGAAAATCCATGTATAACTTTTGACTCCTCCAAAACCTTAACTACTAATA
GCCTACTCTTGATGGGAAGCCTTACCAATAAGAAACAGTTGATGAACACATATTG
TGTATGGTATATGTATTATATACTGTTTTCTTACAATAGTGTAAGTCTAAGGAAA
AAAAAAA

40

SEQ ID NO: 558

>18526 BLOOD 238447.3 Incyte Unique

TCCTACAGGTGTATCGTCAGCGAGTGGATCGCCGAGCAGGGCAACTGGCAGGAA
ATCCAAGAAAAGGCCGTGGAAGTTGCCACCGTGGTGATCCAGCCGACAGATGTA
45 TTTGTTTTTAATTTTCAAGTTCTGCGAGCAGCTGTGCCCAAGAATGTGTCTGTGGC
TGAAGGAAAGGAACTGGACCTGACCTGTAACATCACAACAGACCGAGCCGATGA
CGTCCGGCCCGAGGTGACGTGGTCCTTCAGCAGGATGCCTGACAGCACCTACCT
GGCTCCCGCGTGTGGCGCGGCTTGACCGTGATTCCCTGGTGCACAGCTCGCCTC
ATGTTGCTTTGAGTCATGTGGATGCACGCTCCTACCATTACTGGTTCGGGATGTT

AGCAAAGAAAACCTCTGGCTACTATTACTGCCACGTGTCCCTGTGGGCACCCGGAC
ACAACAGGAGCTGGCACAAAGTGGCAGAGGCCGTGTCTTCCCCAGCTGGTGTGG
GTGTGACCTGGCTAGAACCAGACTACCAGGTGTACCTGAATGCTTCCAAGGTCCC
CGGGTTTTCGGATGACCCACAGAGCTGGCATGCCGGGTGGTGGACACGAAGAG
5 TGGGGAGGGCAATGTCCGATTCACGGTTTCGTGGTACTACAGGATGAACCGGCG
CAGCGACAATGTGGTGACCAGCGAGCTGCTTGCAGTCATGGACGGGGACTGGAC
GCTAAAATATGGAGAGAGGAGCAAGCAGCGGGCCCAGGATGGAGACTTTATTTT
TTCTAAGGAACATACAGACACGTTCAATTTCCGGATCCAAAGGACTACAGAGGA
AGACAGAGGCAATTATTACTGTGTTGTGTCTGCCTGGACCAAACAGCGGAACAA
10 CAGCTGGGTGAAAAGCAAGGATGTCTTCTCCAAGCCTGTTAACATATTTTGGGCA
TTAGAAGATTCCGTGCTTGTGGTGAAGGCGAGGCAGCCAAAGCCTTTCTTTGCTG
CCGGAATACATTTGAGATGACTTGCAAAGTATCTTCCAAGAATATTAAGTCGCC
ACGCTACTCTGTTCTCATCATGGCTGAGAAGCCTGTGCGCGACCTCTCCAGTCCC
AATGAAACGAAGTACATCATCTCTCTGGACCAGGATTCTGTGGTGAAGCTGGAG
15 AATTGGACAGATGCATCACGGGTGGATGGCGTTGTTTTAGAAAAAGTGCAGGAG
GATGAGTTCGCTATCGAATGTACCAGACTCAGGTCTCAGACGCAGGGCTGTACC
GCTGCATGGTGACAGCCTGGTCTCCTGTCAGGGGCAGCCTTTGGCGAGAAGCAG
CAACCAGTCTCTCCAATCCTATTGAGATAGACTTCCAAACCTCAGGTCCTATATTT
AATGCTTCTGTGCATTACAGACACACCATCAGTAATTCGGGGAGATCTGATCAAAT
20 TGTCTGTATCATCACTGTGAGGGAGCAGCACTGGATCCAGATGACATGGCCTT
TGATGTGTCCTGGTTTTCGGGTGCACTCTTTTGGCCTGGACAAGGCTCCTGTGCTCC
TGTCTTCCCTGGATCGGAAGGGCATCGTGACCACCTCCCGGAGGGGACTGGAAGA
GCGACCTCAGCCTGGAGCGCGTGAGTGTGCTGGAATTCTTGTGCAAGTGCATGG
CTCCGAGGACCAGGACTTTGGCAACACTACTGTTCGGTGAATCCATGGGTGAAG
25 TCACCAACAGGTTCTGGCAGAAGGAGGCAGAGATCCACTCCAAGCCCGTTTTA
TAACTGTGAAGATGGATGTGCTGAACGCCTTCAAGTATCCCTTGCTGATCGGCGT
CGGTCTGTCCACGGTCATCGGGCTCCTGTCTCATCGGGTACTGCAGCTCCC
ACTGGTGTGTGAAGAAGGAGGTTTCAAGGAGACACGGCGCGAGCGCCGACGGCTCA
TGTCGATGGAGATGGACTAGGCTGGCCCCGGGAGGGGAGTGACAGAGGGACGTTT
30 TAGGAGCAATTGGGNCAAGAAGAAGCCAGTGATATTTTTTAAACAAAGTGTGT
TACACTAAAACAGTCTCTCTAATCTNAGGTGGGACTTGGCGCTCTCTCTTTTC
TGCATGTCAAGTTCTGAGCGCGGACATGTTTACCAGCACACGGCTCTTCTTCCA
CGGCACTTTCTGATGTAACAATCGAGTGTGTGTTTTTCCCAACTGCAGCTTTTAAAT
GGTTAACCTTCATCTAATTTTTTTTCTCCCACTGGTTTATAGATCCTTGTGCTG
35 TGTGTTTATAGCTTTTGTTCGCGGGGTGTGGTGAAGGGGTGATGGCATGC
GGAGTTCTTTATCTTCAGTGAGAATGTGCCTGCCCGCCTGAGAGCCAGCTTCCGC
GTTGGAGGCACGTGTTCAAGAGAGCTGCTGAGCGCCACCCTCTACCCGGCTGACA
GACAACACAGACCTGTGCCGAAGGCTAATTTGTGGCTTTTACGACCCTACCCAC
CCCCTGTTTTCAGGGGTTTAGACTACATTTGAAATCCAAACTTGGAGTATATAAC
40 TTCTTATTGAGCCCAACTGCTTTTTTATTTTTATGGGATTTTGGGCCCTTTCCAT
TTCTTTTGTATTTGTTTCTGTGAGAGCACTGAAATGGCGGCCCTGGAATCTACAA
TTTGGCTCTCCACTGAGCACCTTATCTTGCCACCTTAGCCTTAAGAATGAATATGA
AGAAAAATACACAGCCACCTCTGTCCAGGGCAGTAAGAAGGGCTGCAAGGAAG
GGGAGGATGGGGACAAGGAAAGGATCAGATACCTGCTCCAGTAGTTGTGAGGCC
45 ACTGTGTCTCAGGGGACTCCAGGAAGAGCAGAAGAGGGATCCCACGAAGTTATT
TTTATGCAGCTGGGGCCAGGAGGGTCAGAGTGGTGCCAGGTGCAAGTTAGGCTA
AAGAAGCCACCACTATTCTCTGCTCTTGCCCATTTGTGGGGGGCAAAGGCATTGG
TCACCAAGAGTCTTGCAAGGGGGACCCACAGATATGCCATGTCCTTCACACGTGCT
TGGGCTCCTTAACCTGAAGGCAAATTGCTACTTGCAAGACTGACTGACTTCAAGG

AATCAGAAATTACCTAGAAGCACCATGTTTTTTCTATGACCTTTTCAGTCCTTCAG
GTCATTTTAAGGTCCACTGCAGGGGGTTAGTGAGAAAGGGTATACTTTGTGGTAT
GTTTTGCTTTCCTAATAGGGACATGAAGGAAACCCAGCAATTTGCTGTTATGTGA
ATGGCCTGTAGAGCAGAGTCAAGAGCGGTGTGCTTTGCCCCGACTGCTCCCATCAG
5 GAATAGGAGAGTAGACAGAGATCTTCCACATCCCAGGCTTCTGCTGCTGCTTTAA
AAGCTCTGTCTTGGAGCCTCCCGCTCCCTGAAGTGTCTCGCCCCCTGCACAGCA
CTGGCCTTTCGGAAGCATCCCAGTAGGGTTTTCTGAGGCTCGCTGGTGA CT CATG
CCCTAATTGCAATCCTCTGCTTTTATCTTGACTTTGAAGGATCTAACACTGCTCTC
TCTTCCAAAGGGGAAAAAAGATTCAATTTGTTTTGAGCAATAAACTAATAACAAA
10 ATGATGGCCATTTCATGTGCAGCTCTTTGTCAACCATGGGCCGGATGAGTTGTGCTC
CTCCTGGCTCACCATTTCCCCCTGCTCCCCACAGCCGGTTCTGCACTTATCACCG
AGTCGCCCTGGAAGCAGATTCCCATTGAGTTTTCCCCACCAAGGGGACCATGCA
CATGGTAGAAACATTAGATTCTGCATTGACAGTAGCCTTTCTTGGGCCCCGGGCC
TGTGGTGGGAAGACGGGCAACAAGTATACCCACCAGGGCCTGAGTGA CT AGAG
15 GAAGAGGACGAGGCCTTGTGGCACTAGATTTGGGTATTTTCTGCATGTCATAAC
ATATCCTAACTGCTATTTCAGAAGAGGCAGCTTGTAGGTGATTGTACAAGTGAGA
ATTAAAGAGAGAACAGATATTTAAACAGGTGCTGTATTAGTAACAGCCAGTGCC
CTTTCAGCCCTTGCATCTATTTAAAGGAGATTGAGGATTTTATTGGCACAGGCCC
TTCTTAGTAGGAAGAAAGGGTGCTTAGCTTTGGACCTGACCGGGTGTGTGTA AAA
20 CCATGGACTGAGTCACAGCAGACACTCGATGGTGGTAAATGTGACGGGTGCTTA
CACACTGTACCTTTTCTTTTCATACTGATGCTGCAGTTCAGGGCTGGAGTTGTAA
GGGATTGACCTCCACCCACCTGCCCCATGTCCGCTGGGCTGCCCAAGCTGCATGT
GACCTGAGGGCTGGCAGGAAGGGGCGAGAAATCCGAGGGCATTTGTACCAAGGAC
CTAGTTTCTTCTAGGGATATAAAATTTCCAGGAATGTGTATTTTAAATGTGGTGAG
25 ATGCACTCTTTTGTGTACCAAATAGGGCTCCCCACCCACCCCTGCGACAAGTG
CTCTTCTAGAACAGGTTCTTACCAGCAGCACTGGTGTGAATGAAAGAGAGACCC
AGCCGCGTCTCACACAGGTGGAATTGCACTTCTTAACAAAAAGGAACCTTTATAAA
AGTTTGGGATTTTTTTTCTTAATCATAAAAATAGCCCCAGAAAGAGCCTAAGCTA
TGTTTCAGATAGAAGCCTCGAAATTCCTGTGAATTGTTTACTTTATGATGTTTACAT
30 ACACGTTTCACTTTGAAAAAAAATGCAATCGACTTTTAAACAACTGTTGAGATG
TTTCATGGGACAGTAGAACTCTGACTCACCAACTGGGCTAAATTTTAAATTTAAAA
ATGTATTTATTTGAGTGTCTTTCCCCCCTCACCTCACCATCTGAGGGGCTCCCT
GAGATCTTGGTAGAGGAGGCCCTCCTGCCAGACCTTCGTTTGTTCCTCCGGTG
GCCCTTGCTTCTTGCTTTGCAGACTGCCTGCAGCCATGATTTTGTCACTGACATCT
35 GTGAGCCAAAGACTGAGCCTTTTTGGCAGGAATAATAAGCAATACTACACA ACT
TGCTACTTTCAGAAAACCTTTTTTTAGCTTCACCGATGACAACAGAGGAAGAAGG
GAACTGGGATTTGGGTAAGTTCTCCTCCACTGTTTGACCAAATTCTCAGTGATAA
ATATGTGTGCAGATCCCTAGAAGAGAAAAACGTTGACTTTGTTTTTAAGTGTGGCA
CATAAGGATCTGCAGAATTTTCCGTAGACAAAGAAAGGATCTTGTGTATTTTGT
40 CCATATCCAATGTTATATGAACTAATTGTATTGTTTTATACTGTGACCACAAATAT
TATGCAATGCACCATTTGGGTAAGTTCTCCTCCACTGTTTGACCAAATTCTCAGTG
ATAAATATGTGTGCAGATCCCTAGAAGAGAAAAACGTTGACTTTCTTTTTAAGTGT
GGCACATAAGGATCTGCAGAATTTTCCGTAGACAAAGAAAGGATCTTGTGTATTT
TTGTCCATATCCAATGTTATATGAACTAATTGTATTGTTTTATANTGTGACCACAA
45 ATATTATGCAATGCACCATTTGTTTTTTATTTTCAATTAAGGAAGTTTAATTTAA

SEQ ID NO: 559

>18550 BLOOD 234287.1 Incyte Unique

AAAGAAAGAAAAAGAAAACTGCAGATAAACCTATACATTAATACTGGTATCTCG
 AGGTGACTCTTCTGACCAAGGGTGGTTAAGTGACACATAGAAGCTTTTCTAAGAGA
 AGACAGACAAGTTGACAGGCATGCCTTGTAAGCTGTGTTTCATGTGGTGGTCT
 GTGGAAAGAAAAGAAGACTCATTTGGAAATGAAGCTGTCCCTTTCCAAGCAGTC
 5 TCTGGTGCTTTTCTTCTCTCAAAATGGATCCGATAAATATTTGAATAGAGCAGATT
 GTAGAATGTCGTGCTGTCACCAGAAAGCTGCTGTTTTGGGTTCTGCATTGAGCCA
 AATATGTAGAGGACCTACCAAGCCCACTGAGGGACTAGGTTTTTCATGTCTCTAGT
 CATACCTAGAATGTTCTGAGCCGTCTGAGGGCCTTCATGCCGGCAGCAGCTAGCA
 AAGCCAGAAAGCAAGTCTAACAGGATCTAAGATGACCATCAGGAGAAGGAGTTT
 10 GAGACTGTGTATGCAACCCCCAATAGACCCCTTTTACTCTGATCTGGAGAATGT
 ATCTGGCTTCATATTTTCAAGTCACATGTCTCTCAGACCCCTGGGATTGAGAACCC
 AAGGCCACAAATCATAGGCATGAAGCACTTTCTTAAGACTGACCTAACGCTGGA
 TTATTTCCCGTCCAATGCCTGCATGCTGCTTGAATTGCTCCACCCACACCTCCATG
 ACCAAGGGCGCCAGAGTGCTGCAACTGGGGCGTGGGCCGCTCTCTGCTTTTCTG
 15 TCTGACTCTGACAAGTCTCCCTCACTGAATGTAGAATCGTTGCCAAGTTTCTGA
 GAAGTGTCGATTCCCTGTAAACATGGATATCAGTTCTGCCTCACATTTCCCACTTG
 AGGTTGAGGCGTACTGGAGACAACACCTCAGACCATCTGAACCCCATCAGTGGA
 CGAAAATGGGGCTGTAAATATACTCTAAAAGCCATACTAAAAATGCTCTGAGGG
 AACTGGCTAAGAATAGTGGGCCTGGTGATTGTCTATCACGCAAGGCTTTGTTTTG
 20 TACTGTTGAGAAATCTGTCACCTTTCTGCCTGCCCTTGTTTCTGAATGAAATGCT
 TCTGGGGTTATTTATGAAAGGAGTGATCCTGGGGCAGGCAGGAGGCAGTGGGCT
 TCATGGCTCCTTGAAGTTATTACTGATCTTGAGCTTCTCTTTGGCTACCTTTAGAC
 AAAGAATACGCCAATCAATACTTGGGGCTCTAAGTTTACAAATTGATATTTATTT
 GTATCATCTCTTTGTCTAGGAATGTAAAAGTGATTTCTAAACTAAGATGTGTAATA
 25 AAAATCAATCAGATTTATTTGACCTACAAAAA

SEQ ID NO: 560

>18555 BLOOD 200000.3 AF054175 g3341993 Human mitochondrial proteolipid 68MP

homolog mRNA, nuclear gene encoding mitochondrial protein, complete cds. 0

30 GCTCAATAAACGTTTATTAAGCAGTAGAATACAAGTTAGTGCCTGGATCCTGATC
 ACCGAGTTGGCTGCAGATTTGTGGTGCCTTCTGAGCCGTCTGTCCTGCGCCAAGA
 TGCTTCAAAGTATTATTAACAAACATATGGATCCCCATGAAGCCCTACTACACCAA
 AGTTTACCAGGAGATTTGGATAGGAATGGGGCTGATGGGCTTCATCGTTTATAAA
 ATCCGGGCTGCTGATAAAAGAAGTAAGGCTTTGAAAGCTTCAGCGCCTGCTCCTG
 35 GTCATCACTAACCAGATTTACTTGGAGTACATGTGAAAGAAAACGTCAGTCTGCC
 TGTAATTTTCAGCAAGCCGTGTTAGATGGGGAGCGTGGAACGTCAGTGTACACTT
 GTATAAGTACCGTTTACTTCATGGCATGAATAAATGGATCTGTGAGATGCACTGC
 TACCTGGTACTGCTTTCAGTGTGTTCCCCCTCAGCCCCCTCCGGCGTGTGAGGCATA
 CTCTGAGTAGATAATTTGTCATGCAGCGCATGCAATCAGAATCTCACTGAGCCAC
 40 CCATCATTGTGAAATAATTACCTCAGTTGTACAGGACTTGGTGATCAGGATCCAG
 GCACTCACTTGTATTCTACTGCTCAATAAACGTTTATTAACTTGATCCTGCTACT
 TAAA

SEQ ID NO: 561

45 >18576 BLOOD 481208.4 U60207 g1477790 Human stress responsive serine/threonine

protein kinase Krs-2 mRNA, complete cds. 0

GCGGGGCGGGCTCAGGAGGTCCGCGGGAGGATGGAGCAGTGAGCGGGTCTGGG
 CGGCTGCTGGCAGCGCCATGGGAGACGGTACAGCTGAGGAACCCGCCGCGCCGG
 CAGCTGAAAAAGTTGGATGAAGATAGTTTAACCAAACAACCAGAAGAAGTATTT

GATGTCTTAGAGAACTTGGAGAAGGGTCCTATGGCAGCGTATACAAAGCTATT
CATAAAGAGACCGGCCAGATTGTTGCTATTAAGCAAGTTCCTGTGGAATCAGACC
TCCAGGAGATAATCAAAGAAATCTCTATAATGCAGCAATGTGACAGCCCTCATGT
AGTCAAATATTATGGCAGTTATTTTAAGAACACAGACTTATGGATCGTTATGGAG
5 TACTGTGGGGCTGGTTCTGTATCTGATATCATTTCGATTACGAAATAAAACGTTAA
CAGAAGATGAAATAGCTACAATATTACAATCAACTCTTAAGGGACTTGAATACCT
TCATTTTATGAGAAAAATACACCGAGATATCAAGGCAGGAAATATTTTGCTAAAT
ACAGAAGGACATGCAAAACTTGCAGATTTTGGGGTAGCAGGTCAACTTACAGAT
ACCATGGCCAAGCGGAATACAGTGATAGGAACACCATTTTGGATGGCTCCAGAA
10 GTGATTACAGGAAATTGGATACAACCTGTGTAGCAGACATCTGGTCCCTGGGAATA
ACTGCCATAGAAATGGCTGAAGGAAAGCCCCCTTATGCTGATATCCATCCAATGA
GGGCAATCTTCATGATTCCTACAAATCCTCCTCCACATTCCGAAAACCAGAGCT
ATGGTCAGATAACTTTACAGATTTTGTGAAACAGTGTCTTGTAAGAGCCCTGAG
CAGAGGGCCACAGCCACTCAGCTCCTGCAGCACCCATTTGTCAGGAGTGCCAAA
15 GGAGTGTCAATACTGCGAGACTTAATTAATGAAGCCATGGATGTGAAACTGAAA
CGCCAGGAATCCCAGCAGCGGGAAGTGGACCAGGACGATGAAGAAAACCTCAGA
AGAGGATGAAATGGATTCTGGCACGATGGTTTCGAGCAGTGGGTGATGAGATGGG
CACTGTCCGAGTAGCCAGCACCATGACTGATGGAGCCAATACTATGATTGAGCA
CGATGACACGTTGCCATCACAACCTGGGCACCATGGTGATCAATGCAGAGGATGA
20 GGAAGAGGAAGGAACTATGAAAAGAAGGGATGAGACCATGCAGCCTGCGAAAC
CATCCTTTCTTGAATATTTGAACAAAAAGAAAAGGAAAACCAGATCAACAGCTT
TGGCAAGAGTGTACCTGGTCCACTGAAATTTCTTCAGATTGGAAAATACCACA
GGATGGAGACTACGAGTTTCTTAAGAGTTGGACAGTGGAGGACCTTCAGAAGAG
GCTCTTGGCCCTGGAGCCCATGATGGAGGAGGAGATTGAAGAGATCCGGCAGAA
25 GTACCAGTCCAAGCGGGAGCCCATCTGGATGCCATAGAGGCTAAGAAGAGACG
GCAACAAAACCTTCTGAGCAAGGCCAGGCTGTGAGGGCCCCAGCTCCACCCAGGC
TTTGGGTGAATTCTGGATGGCTTGCCTCATGTTTGTAGCCAGCACTTCTGCTCTG
TCGTCTCTCCACAGCACCTTTGTGAACTCAGGAATGTGCGCCAGTGGGAAGGGCT
CTCTTGACAGTCAGCGTGCCATCTTGATGTGTGTATGTACATTGGTCAGGTATATT
30 ATCTCAAAGGATTTATATTGGCGCTTTTAACTCAGAGTTTTAAACCCAGGAACA
GAGACTCCTAGTTGAGTGATAGCTGGGAAAGTTTTACATTGTCTGTTTTCTTCTC
CCAATAGCTTTCAATTGTTCTTTCTGGAAGACTTTTAAAAAATATAAATATGCA
TATATATATATAAATTATAAAAAACTTATTAATACAAAAAAGATCTTTAATTA
AGGAGTGCAAGCTTATTCCATTTAGTGAGTGT

35

SEQ ID NO: 562

>18601 BLOOD 217961.1 Incyte Unique

AGATGTTCCAGGAGTAGAATTCCTGACTGCTGTGTGAAAGTGAAGTCTACTCCA
TCTCTGAAACATATCTGAGAAACGGGGCAGAAAACCAGTGTAAGTCTCGTGG
40 TGAAATTATTGAACATTGAAGTGTGAGGCTTGTCTTAAGAGCACGTCACCTCCCT
TGACACAGATTCTGCATGTCCTTCCCTCTGGTAGGGATCCTCCAGTTCGGTTTCTC
AGGCGAAGTAACCAGAGGTTCCAGTCTGCTCTTCTGGGAGGAAGACAGA
GCACCTAGTAATAGATTCCCAGGGTACTGATTGGCACCACACATGACTCAGAGG
GGACCTAAGCCCATCAGCAGGCTGCTCTAAGGACCTACCTCAGGGCACTCAGAC
45 AGCCTCACCAATCAGAGGCTCAGGAGAGGGTTTTCTCACTGCCCTCCTTGTGTG
CACTGGTTTCTGTTTAGAGCAGCATTTAGCAGCACACACCTCAGATGTAGA
GGATGAACCTCTCTTATATGAAATAAAATGATGTCCAGCAAAANANAAA

SEQ ID NO: 563

>18628 BLOOD GB_T96731 gi|735355|gb|T96731|T96731 ye51f02.r1 Soares fetal liver
spleen 1NFLS Homo sapiens cDNA clone IMAGE:121275 5' similar to gb:M24922_cds1
HLA CLASS II HISTOCOMPATIBILITY ANTIGEN, DX BETA CHAIN (HUMAN);,

5 mRNA sequence [Homo sapiens]

NTTCGGCACGGNGGCTCTGCAGATCCCTGGAGGCTTTTGGGCAGCAGCTGTGACC
GTGATGCTGGTGATGCTGAGCACCCAGTGGCTGAGGCAGANGACTTTCCCAAG
GATTTNTTGGTCCAGTTTAAGGGCATGTGCTACTTCACCAACGGGACAGAGCGCG
TGGNGGTGTGGCCAGATACATCTATAACCGCGAGAGTACGGGCGCTTCGACAGC
10 GACGTTGGGGAGTTCCAGGCGGTGACCGAGCTGGGGCGNACATNCGAGGACTGG
AACAATAAAGGACTTCTTTGAGCAGGAGCGNGCCGGNTNGGACAAGGTGTGC
AGACACAACCT

SEQ ID NO: 564

15 >18649 BLOOD 205772.16 Incyte Unique

ACGATTCTTAGATGACATTTTCTCTTTCCCCTTTTTTCCCCCTAACCTCAATCTAGG
CTCACTTATCTAAAGAATATGAGGAGGCTAATTTTCAGAGCTATATGTGCGAGATA
ACTGCCACCCCTTCAAAGCCACTGTGTTGGTTTGGATTTCAGCTTCCAATGTGGATC
TTCATGTCTTTTGCTCTCCGGAATTTAAGCACGGGGGCAGCACATTCAGAAGCAG
20 GTTTTTCTGTTTCAGGAACAGTTAGCTACTGGTGGAATTCTGTGGTTTCTGACCTC
ACTGCACCCGACTCCACTTGGATTCTGCCTATCTCTGTTGGCGTCATCAATTTGTT
AATAGTGGAGATTTGTGCTCTACAAAAAATTGGAATGTCTCGTTTTTCAGACGTAT
AATACGTACTTTGTCCGTGCAATGTGGGTGTTGATGATACCAATTGCTGCAACGG
TACCCTCATCAATTGTTCTCTACTGGTTATGCTCCAGCTTCGTGGGCCTTTCAAG
25 AATTTGCTGCTGCGTTCTCCTGGATTTCCGCAACTTTGCCGAATACCATCGACCAA
GTCAGATTCAGAAACTCCTTATAAAGACATATTTGCTGCCTTTAATACCAAGTTC
ATTTCAAGAAAATGACATATTTTCCAATAATTTTGAAACAGTTGCAGGAGTCACT
ATCATCTAAATGTATTTAGACTTAGAAATTCAGATGTTACTTGATTTCCTTTTATT
TATAGTCAATTGTTCTCTACTGGTTATGCTCCAGCTTCGTGAGCCACTGTGCCCAG
30 CTGAGATGGTTCTTATTATTTTGGAGGTGGAGAGGATTTTAGACCTCTTTGAGCA
TCTGAAAAAAGGCTATATATGTATGGTTTTCTCTTCAGAAAAATCTTAAGACTCA
CAATACGGGGACTTCCTTGTTACCAGGAAGATTTTCTGGCAATTCCTAGTTAATA
AATCTTATTCTAATGGAACATACATTGATCTTGAGTTAATGCGTGTTGAAAAAA
AAAGCGGGGGCAACTTGAAATATATGCAGTAAAGTAGTCCATGCATACAAGTCC
35 CTAACATGGTAGATGATGTTGCCTCCCGGCCCTGCTCAGAAAGAATACAAAAAG
TGTACATTCCTTTTTCTATAATTTAAGAAGTCTGGAATACAGAGTGTAACACTGT
GTACTGCTAGCACCCAAAGTGGAATACTTAAGCATTTCAGATTGTTTAGTCAAAG
AAGAAAACCAGAAAGGGCAGTTGCCTATTGAGGTGATTTTAAACCTGTTTATTTGT
AAGGATTAAGTACCCTAATAGGCTTAAACTATGATAGAGGTTTAATACAGAAAA
40 AATTGACAGGTATTATAAATTGTGGATCCAGTTACTTGCTTATTTAATTTGTAAAG
AGGTAAAATTAGCTCTGGTTGAGATATCAAGTATGGCAGGTATTTGAGAAGGCT
ATAAATCATAATTTTCATTTAGTTAAAATATGGACCTGATTCTGGGAAACCTAT
CATTCATCTCAATGTTTTACAATAAAATAAAACTAAAGT

45 SEQ ID NO: 565

>18713 BLOOD GB_T98559 gi|748296|gb|T98559|T98559 ye70f11.s1 Soares fetal liver
spleen 1NFLS Homo sapiens cDNA clone IMAGE:123117 3', mRNA sequence [Homo
sapiens]

AACACTTTAATATTNATGGTGTATCACATAAAAAACAAAGTCATATACTTTTGCATTAATCAAAAAATAGCAAATCCATATAATGGCAAAATCAGGAAAAAATTCTAGTATTTCCACAAAATACATAATGTCTTACAGATGATTATGTGAACTTTAAATGTCTGCAGCCCTACAGAGCTTTTGTGTCANTTGAAAAACAAAAAATCCCAACACAGGATGTTCAAAAAGCCTAATTCATAAAAANGACANTTTATTCCNATGTTTAAATATAGTGTTTTTTAGGATGGTANCCATAAGTCATGCAACNAGCTCTGTAAANCCAAAACCAAACCAAGNAACCTACGGATGTGCGGCTGCGGGTTTA

SEQ ID NO: 566

10 >18817 BLOOD Hs.93213 gnl[UG][Hs#S1972075 Human DNA sequence from clone RP1-291J10 on chromosome 6p21.2-21.33 Contains BAK1 (BCL2-antagonist/killer 1) gene, ESTs, STSs, GSSs and a CpG Island /cds=(249,884) /gb=Z93017 /gi=5921377 /ug=Hs.93213 /len=2136

15 GCCGGGTGCCGCTGGCACCTCTATGATCACTGGAGTCTCGCGGGTCCCTCGGGCTGCACAGGGACAAGTAAAGGCTACATCCAGATGCCGGAATGCACTGACGCCCATTCTTGAAACTGGGCTCCCACTCAGCCCCCTGGGAGCAGCAGCCGCCAGCCCCCTCGGGACCTCCATCTCCACCCTGCTGAGCCACCCGGGTTGGGCCAGGATCCCGGCAGGCTGATCCCGTCTCTCACTGAGACCTGAAAAATGGCTTCGGGGCAAGGCCCAGGTCCTCCAGGCAGGAGTGCGGAGAGCCTGCCCTGCCCTCTGCTTCTGAGGAGCAGGT

20 AGCCCAGGACACAGAGGAGGTTTTCCGCAGCTACGTTTTTTACCGCCATCAGCAGGAACAGGAGGCTGAAGGGGTGGCTGCCCTGCCGACCCAGAGATGGTCACCTTACCTCTGCAACCTAGCAGCAACATGGGGCAGGTGGGACGGCAGCTCGCCATCATC

25 GGGGACGACATCAACCGAGGCTATGACTCAGAGTCCAGACCATGTTGACAGCAGCTGCAGCCACGGCAGAGAAATGGCTATGAGTACTTCAECAAAGATTGCCAECAGCCTGTTTGAGAGTGGCATCAATTGGGGCCGTGTGGTGGCTCTTCTGGGCTTCGGCTACCGTCTGGCCCTACACGTCTACCAGCATGGCCTGACTGGCTTCCTAGGCCAGGTGACCCGCTTCGTGGTTCGACTTCATGCTGCATCACTGCATTGCCCGGTGGATTGCA

30 CAGAGGGGTGGCTGGGTGGCAGCCCTGAACCTGGGCAATGGTCCCATCCTGAACGTGCTGGTGGTTCTGGGTGTGGTTCTGTTGGGCCAGTTTGTGGTACGAAGATTCTTCAAATCATGACTCCCAAGGGTGCCCTTTGGGGTCCCGGTTCCAGACCCCTGCCTGGACTTAAGCGAAGTCTTTGCCTTCTCTGTTCCCTTGACAGGGGTCCCCCTCAAGAGTACAGAAGCTTTAGCAAGTGTGCACTCCAGCTTCGGAGGGCCCCCTGCGTGGGGGC

35 CAGTCAGGCTGCAGAGGCACCTCAACATTGCATGGTGCTAGTGGGCCCTCTCTCTGGGECCAGGGGCTGTGGCCGTCTCTCTCTCTCTCTGGGACCTCCTTAGCCC

40 TGTCTGCTAGGCGCTGGGGAGACTGATAACTTGGGGAGGCAAGAGACTGGGAGCCACTTCTCCCCAGAAAGTGTTTAAACGGTTTTAGCTTTTTATAATACCCTTGTGAGAGCCCATTCCCACCATCTACCTGAGGCCAGGACGTCTGGGGTGTGGGGATTGGTGGTCTATGTTCCCCAGGATTCAGCTATTCTGGAAGATCAGCACCCCTAAGAGATGG

45 GACTAGGACCTGAGCCTGGTCCTGGCCGTCCCTAAGCATGTGTCCAGGAGCAGGACCTACTAGGAGAGGGGGGCCAAGGTCCTGCTCAACTCTACCCCTGCTCCCATTCCTCCCTCCGGCCATACTGCCTTTGCAGTTGGACTCTCAGGGATTCTGGGCTTGGGGTGTGGGGTGGGGTGGAGTCGCAGACCAGAGCTGTCTGAACTCACGTGTCAGAGCCTCCAAGCCTGCCTCCCAAGGTCCTCTCAGTTCTCTCCCTTCTCTCTCTTAGACACTTGCTCCCAACCCATTCACTACAGGTGAAGGCTCTCACCCCATCCCT

50 GGGGGCCTTGGGTGAGTGGCCTGCTAAGGCTCCTCCTTGCCCAGACTACAGGGCTTAGGACTTGTTTGTATATCAGGGAAAAGGAGTAGGGAGTTCATCTGGAGGGTTCTAAGTGGGAGAAGGACTATCAACACCACTAGGAATCCCAGAGGTGGGATCCTCCCTCATGGCTCTGGCACAGTGTAATCCAGGGGTGTAGATGGGGGAAGTGTGAAT

55 ACTTGAAGTCTGTTCCCCCACCTCCATGCTCCTCACCTGTCTAGGTCTCCTCAGG

GTGGGGGGTGACAGTGCCTTCTCTATTGGGCACAGCCTAGGGTCTTGGGGGTCAG
GGGGGAGAAGTTCTTGATTCAGCCAAATGCAGGGAGGGGAGGCAGATGGAGCCC
ATAGGCCACCCCCTATCCTCTGAGTGTITGGAAATAAACTGTGCAATCCCCTCA

5 SEQ ID NO: 567

>18899 BLOOD 285978.2 U43431 g1292911 Human DNA topoisomerase III mRNA,
complete cds. 0

GGCGGCTGCGGCACGGGAAAGGCTCAGTGAAGCTCCAAAGGCCAGCAGGC
TGGTGGGGACGTGACCGAAGCGAGGCTCTGGTTCCCTTTCGGTGGGCGCCATTG
10 AGCCTCATCTCTGGCTTCCCCAGGATGCGCCGGCAGCCGGGGAGCGGCTCCGGG
CGCGAGGTCTGAGGATGATCTTTCCTGTCGCCCCTACGCGCTCCGGTGGCTGCG
ACGGCCCCGAAGACCGTGCCTTTTCCCGCGCCGCCATGGAGATGGCCCTCCGAGGC
GTGCGGAAAGTCTCTGTGTGGCCGAAAAAACGACGCGGCCAAGGGGATCGCC
GACCTGCTGTCAAACGGTCGCATGAGGCGGAGAGAAGGACTTTCAAAATTCAAC
15 AAGATCTATGAATTTGATTATCATCTGTATGGCCAGAATGTTACCATGGTAATGA
CTTCAGTTTCTGGACATTTACTGGCTCATGATTTCCAGATGCAGTTTCGAAAATGG
CAGAGCTGCAACCCTCTTGTCTCTTTGAAGCAGAAATTGAAAAGTACTGCCCAG
AGAATTTTGTAGACATCAAGAAAACCTTTGGAACGAGAGACTCGCCAGTGCCAGG
CTCTGGTGATCTGGACTGACTGTGATAGAGAAGGCGAAAACATCGGGTTTGAGA
20 TTATCCACGTGTGTAAGGCTGTAAAGCCCAATCTGCAGGTGTTGCGAGCCCGATT
CTCTGAGATCACACCCCATGCCGTCAGGACAGCTTGTGAAAACCTGACCGAGCCT
GATCAGAGGGGTGAGCGATGCTGTGGATGTGAGGOAGGAGCTGGACCTGAGGATT
GGAGCTGCCTTTACTAGGTTCCAGAACCTGCGGCTTCAGAGGATTTTTCCTGAGG
TGCTGGCAGAGCAGCTCATCAGTTACGGCAGGTGCCAGTTCCCCAAGCTGGGCTT
25 TGTGGTGGAGCGGTTCAAAGCCATTACAGGCTTTTGTACCAGAAATCTTCCACAGA
ATTAAAGTAACTCATGACCACAAAGATGGTATCGTAGAATTCAACTGGAAAAGG
CATCGACTCTTTAACCACACGGCTTGCTAGTTCTCTATCAGTTGTGTGTGGAGG
ATCCCATGGCAACTGTGGTAGAGGTCAGATCTAAGCCCAAGAGCAAGTGGCGGC
CTCAAGCCTTGGACACTGTGGAGCTTGAGAAGCTGGCTTCTCGAAAGTTGAGAAT
30 AAATGCTAAAGAAACCATGAGGATTGCTGAGAAGCTCTACACTCAAGGGTACAT
CAGCTATCCCCGAACAGAAACAAACATTTTCCCAGAGACTTAAACCTGACGGTG
TTGGTGGAAACAGCAGACCCCCGATCCACGCTGGGGGGCCTTTGCCCAGAGCATT
TAGAGCGGGGTGGTCCCACCCACGCAATGGGAACAAGTCTGACCAAGCTCACC
CTCCCATTACCCCCACCAAATACAGCAACAACCTTACAGGGAGATGAACAGCGAC
35 TGTACGAGTTTATTGTTCCGCAATTTCTGGCTTGTGCTCCCAGGATGCTCAGGGG
CAGGAGACCACAGTGGAGATCGACATCGCTCAGGAACGCTTTGTGGCCCATGGC
CTCATGATTCTGGCCCGAAACTATCTGGATGTGTATCCATATGATCACTGGAGTG
ACAAGATCCTCCCTGTCTATGAGCAAGGATCCCACTTTCAGCCCAGCACCGTGGA
GATGGTGGACGGGGAGACCAGCCCACCCAAGCTGCTCACCAGGCGCGACCTCAT
40 TGCCCTCATGGAGAAGCATGGCATTGGTACGGATGCCACTCATGCGGAGCACAT
CGAGACCATCAAAGCCCGGATGTACGTGGGCTCACCCCAGACAAGCGGTTCT
CCCTGGGCACCTGGGCATGGGACTTGTGGAAGGTTATGATTCCATGGGCTATGAA
ATGTCTAAGCCTGACCTCCGGGCTGAACTGGAAGCTGATCTGAAGCTGATCTGTG
ATGGCAAAAAGGACAAATTTGTGGTTCTAAGGCAGCAAGTGCAGAAATACAAGC
45 AGGTTTTTCATTGAAGCGGTGGCTAAAGCAAAGAAATTGGACGAGGCCTTGGCCC
AGTACTTTGGGAATGGGACAGAGTTGGCCCAGCAAGAAGATATCTACCCAGCCA
TGCCAGAGCCCATCAGGAAGTGCCACAGTGCAACAAGGACATGGTCCTTAAGA
CCAAGAAGAATGGCGGGTTCTACCTCAGCTGCATGGGTTTCCCAGAGTGTGCTC
AGCTGTGTGGCTTCCTGACTCGGTGCTGGAGGCCAGCAGGGACAGCAGTGTGTGT

CCAGTTTGTGTCAGCCACACCCTGTGTACAGGGTTAAAGTTAAAGTTTAAGCGCGGT
 AGCCTTCCCCCGACCATGCCTCTGGAGTTTGTGCTGCATCGGCGGATGCGACG
 ACACCCTGAGGGAGATCCTGGACCTGAGATTTTCAGGGGGCCCCCAGGGCTA
 GCCAGCCCTCTGGCCGCCTGCAGGCTAACCAGTCCCTGAACAGGATGGACAACA
 5 GCCAGCACCCCCAGCCTGCTGACAGCAGACAGACTGGGTCCTCAAAGGCTCTGG
 CCCAGACCCTCCCACCACCCACGGCTGCTGGTGAAGCAATTCTGTGACCTGCAA
 CTGTGGCCAGGAGGCTGTGCTGCTCACTGTCCGTAAGGAGGGCCCCAACCGGGG
 CCGGCAGTTCTTTAAGTGCAACGGAGGTAGCTGCAACTTCTTCCTGTGGGCAGAC
 AGCCCCAATCCGGGAGCAGGAGGGCCTCCTGCCTTGGCATATAGACCCTGGGC
 10 GCCTCCCTGGGATGCCACCAGGCCAGGGATCCACCTAGGTGGGTTTGGCAACC
 CTGGTGTATGGCAGTGGTAGTGGCACATCCTGCCTTTGCAGCCAGCCCTCCGTCAC
 ACGGACTGTGCAGAAGGATGGACCCAACAAGGGGCGCCAGTTCCACACATGTGC
 CAAGCCGAGAGAGCAGCAGTGTGGCTTTTTCCAGTGGGTCGATGAGAACACCGC
 TCCAGGGACTTCTGGAGCCCCGTCCTGGGACAGGAGACAGAGGAAGAACCCTGG
 15 AGTCGGAAGCCAGAAGCAAAAGGCCCGGGCCAGTTCCTCAGACATGGGGTCCA
 CAGCAAAGAAACCCCGGAAATGCAGCCTTTGCCACCAGCCTGGACACACCCGTC
 CCTTTTGTCTCAGAACAGATGAGCTCAGGGTAGGGTAGAGAACGCCACTTTCTC
 AGACCTGTCCCCTTTGTGTTTAGAAATGAGTTAACCAGGACCAAGTGGCCATTTA
 GTGTCTGGAACTTAGAGGACAGTGTGGCCTTTGGAGTCGGGCCTTCTTGTGT
 20 TAAGGGGCACAAGGTCCAGATCACTCTGGAGCAGGCCAGCTCTGCTGGACAGTG
 ACCCTCTTCCCAGGCCTCAGGAGTGACCATAGCCACTGCTGAAAAGTCACGCAGC
 TGCTCCCTCGGACCCCCCAAGGATGGTTGCTGTTAGCAGAGGATGGGTGCAGTCC
 CAGCTGAAGGCCACTGTGTGCGAAAGGAAGAAGCTCCCAGGGCTGCTTGCCTCAG
 CTGEGAGAAAGGCCCAAGTGAGGCCACAGCACTCATGGGGTAGTCCCTGTGAGG
 25 CTGCCCAGGGCTTCTCATAGACGTCTGAGAAGGACGGTGTAATGCAAGGAAAT
 GGCTGTGGTAACACTGATCCTTCAGAAGAAGCTTCATTCCCTCTTAATCTAGTTA
 AGCCAGGACATCCAGAATTCATTGCTTTAATAAAGAACCCAGGCCGGG

SEQ ID NO: 568

30 >18910 BLOOD Hs.244613 gnl|UG|Hs#S377417 Human signal transducer and activator of
 transcription Stat5B mRNA, complete cds /cds=(146,2509) /gb=U47686 /gi=1330323
 /ug=Hs.244613 /len=2782

GGAGCCGTCACCCCGGGCGGGGACCCAGCGCAGGCAACTCCGCGCGGGCGCCCCGG
 CCGAGGGAGGGAGCGAGCGGGCGGGCGGGCAAGCCAGACAGCTGGGCGGGAGC
 35 AGCCGCCGGCGCCCCAGGGGCCGAGCGAGATTGTAAACCATGGCTGTGTGGATA
 CAAGCTCAGCAGCTCCAAGGAGAAGCCCTTCATCAGATGCAAGCGTTATATGGC
 CAGCATTTTCCCATTGAGGTGCGGCATTATTTATCCCAGTGGATTGAAAGCCAAG
 CATGGGACTCAGTAGATCTTGATAATCCACAGGAGAACATTAAGGCCACCCAGC
 TCCTGGAGGGCCTGGTGCAGGAGCTGCAGAAGAAGGCAGAGCACCAGGTGGGG
 40 GAAGATGGGTTTTTACTGAAGATCAAGCTGGGGCACTATGCCACACAGCTCCAG
 AACACGTATGACCGCTGCCCCATGGAGCTGGTCCGCTGCATCCGCCATATATTGT
 ACAATGAACAGAGGTTGGTCCGAGAAGCCAACAATGGTAGCTCTCCAGCTGGAA
 GCCTTGCTGATGCCATGTCCCAGAAACACCTCCAGATCAACCAGACGTTTGAGGA
 GCTGCGACTGGTCACGCAGGACACAGAGAATGAGTTAAAAAAGCTGCAGCAGAC
 45 TCAGGAGTACTTCATCATCCAGTACCAGGAGAGCCTGAGGATCCAAGCTCAGTTT
 GGCCCGCTGGCCCAGCTGAGCCCCCAGGAGCGTCTGAGCCGGGAGACGGCCCTC
 CAGCAGAAGCAGGTGTCTCTGGAGGCCTGGTTGCAGCGTGAGGCACAGACTG
 CAGCAGTACCGCGTGGAGCTGCCCCGAGAAGCACCAGAAGACCCTGCAGCTGCTG
 CGGAAGCAGCAGACCATCATCCTGGATGACGAGCTGATCCAGTGGAAGCGGCGG

CAGCAGCTGGCCGGGAACGGCGGGCCCCCGAGGGCAGCCTGGACGTGCTACAG
 TCCTGGTGTGAGAAGTTGGCGGAGATCATCTGGCAGAACCAGGCAGCAGATCCGC
 AGGGCTGAGCACCTCTGCCAGCAGCTGCCCATCCCCGGCCAGTGGAGGAGATG
 CTGGCCGAGGTCAACGCCACCATCACGGACATTATCTCAGCCCTGGTGACCAGCA
 5 CGTTCATCATTGAGAAGCAGCCTCCTCAGGTCTCTGAAGACCCAGACCAAGTTTGC
 AGCCACTGTGCGCCTGCTGGTGGGCGGGAAGCTGAACGTGCACATGAACCCCCC
 CCAGGTGAAGGCCACCATCATCAGTGAGCAGCAGGCCAAGTCTCTGCTCAAGAA
 CGAGAACACCCGCAATGATTACAGTGGCGAGATCTTGAACAACTGCTGCGTCAT
 GGAGTACCACCAAGCCACAGGCACCCTTAGTGCCCACTTCAGGAATATGTCCCTG
 10 AAACGAATTAAGAGGTCAGACCGTCGTGGGGCAGAGTCGGTGACAGAAGAAAA
 ATTTACAATCCTGTTTGAATCCCAGTTCAGTGTGGTGGAATGAGCTGGTTTTTC
 AAGTCAAGACCCTGTCCCTGCCAGTGGTGGTGATCGTTCATGGCAGCCAGGACA
 ACAATGCGACGGCCACTGTTCTCTGGGACAATGCTTTTGCAGAGCCTGGCAGGGT
 GCCATTTGCCGTGCCTGACAAAGTGCTGTGGCCACAGCTGTGTGAGGCGCTCAAC
 15 ATGAAATTCAAGGCCGAAGTGCAGAGCAACCGGGGCCTGACCAAGGAGAACCCTC
 GTGTTCCCTGGCGCAGAACTGTTCAACAACAGCAGCAGCCACCTGGAGGACTAC
 AGTGGCCTGTCTGTGTCCTGGTCCCAGTTCAACAGGGAGAATTTACCAGGACGGA
 ATTACACTTTCTGGCAATGGTTTGACGGTGTGATGGAAGTGTTAAAAAACATCT
 CAAGCCTCATTGGAATGATGGGGCCATTTTGGGGTTTGTAACAAGCAACAGGC
 20 CCATGACCTACTGATTAACAAGCCAGATGGGACCTTCCTCCTGAGATTCAGTGAC
 TCAGAAATTGGCGGCATCACCATTGCTTGGAAGTTTGATTCTCAGGAAAGAATGT
 TTTGGAATCTGATGCCTTTTACCAACAGAGACTTCTCCATCAGGTCCCTAGCCGA
 CCGCTTGGGAGACTTGAATTAGCTTATCTAGGTGTTTCCCTGATCGGGCCAAAGAT
 GAAGTATACTCCAAATACTACACACCAGTTCCTGCGAGTCTGCTACTGCTAAAG
 25 CTGTTGATGGATACGTGAAGCCACAGATCAAGCAAGTGGTECCTGAGTTTGTGAA
 CGCATCTGCAGATGCCGGGGGCGGCAGCGCCACGTACATGGACCAGGCCCCCTC
 CCCAGCTGTGTGTCCCCAGGCTCACTATAACATGTACCCACAGAACCCTGACTCA
 GTCCTTGACACCGATGGGGACTTCGATCTGGAGGACACAATGGACGTAGCGCGG
 CGTGTGGAGGAGCTCCTGGGCGGCCAATGGACAGTCAGTGGATCCCGCACGCA
 30 CAATCGTGACCCCGCGACCTCTCCATCTTCAGCTTCTTCATCTTCACCAGAGGAAT
 CACTCTTGTGGATGTTTTAATTCCATGAATCGCTTCTCTTTTGAACAATACTCAT
 AATGTGAAGTGTTAATACTAGTTGTGACCTTAGTGTTTCTGTGCATGGTGGCACC
 AGCGAAGGGAGTGCGAGTATGTGTTTGTGTGTGTGTGTGTGTGTGTGTGTGTG
 CGTTGGTGCACGTTATGGTGTTCCTCTCACTGTCTGAGAGTTTAGTTGTAGC
 35 AGA

SEQ ID NO: 569

>18954 BLOOD 475048.3 AF100143 g4323512 Human fibroblast growth factor 13 isoform 1A (FGF13) mRNA, complete cds. 0

40 GAAGCGGTGGTGGTGGGCGTCGTGGCATGGCGGCGGCTATCGCCAGCTCGCTCA
 TCCGTCAGAAGAGGCAAGCCCGCGAGCGCGAGAAATCCAACGCCTGCAAGTGTG
 TCAGCAGCCCCAGCAAAGGCAAGACCAGCTGCGACAAAAACAAGTTAAATGTCT
 TTTCCCGGGTCAAACCTCTTCGGCTCCAAGAAGAGGCGCAGAAGAAGACCAGAGC
 CTCAGCTTAAGGGTATAGTTACCAAGCTATACAGCCGACAAGGCTACCACTTGCA
 45 GCTGCAGGCGGATGGAACCATTGATGGCACCAAGATGAGGACAGCACTTACAC
 TCTGTTTAACCTCATCCCTGTGGGTCTGCGAGTGGTGGCTATCCAAGGAGTTCAA
 ACCAAGCTGTACTTGGCAATGAACAGTGAGGGATACTTGTACACCTCGGAACCTT
 TCACACCTGAGTGCAAATTCAAAGAATCAGTGTTTGAAAATTATTATGTGACATA
 TTCATCAATGATATACCGTCAGCAGCAGTCAGGCCGAGGGTGGTATCTGGGTCTG

AACAAAGAAGGAGAGATCATGAAAGGCAACCATGTGAAGAAGAACAAGCCTGC
AGCTCATTTTCTGCCTAAACCACTGAAAGTGGCCATGTACAAGGAGCCATCACTG
CACGATCTCACGGAGTTCTCCCGATCTGGAAGCGGGACCCCAACCAAGAGCAGA
AGTGTCTCTGGCGTGCTGAACGGAGGCAAATCCATGAGCCACAATGAATCAACG
5 TAGCCAGTGAGGGCAAAAGAAGGGCTCTGTAAACAGAACCTTACCTCCAGGTGCT
GTTGAATTCTTCTAGCAGTCCTTCACCCAAAAGTTCAAATTTGTCAGTGACATTTA
CCAAACAAACAGGCAGAGTTCCTATTCTATCTGCCATTAGACCTTCTTATCATC
CATACTAAAGCCCCATTATTTAGATTGAGCTTGTGCATAAGAATGCCAAGCATT
TAGTGAACATAAATCTGAGAGAAGGACTGCCAAATTTTCTCATGATCTCACCTATA
10 CTTTGGGGATGATAATCCAAAAGTATTTACAGCACTAATGCTGATCAAAATTTG
CTCTCCCAACCAAGAAAATGTAAAAGACCACAATTGTTCTTCAAAAACAAAACAA
ACAAAACAAAACAAAATTAAGTCTTAAATGTTTTGTGGGGCAAACAAAATTA
TGTGAATTGTGTTGTTTTCTTGGCTTGATGTTTTCTATCTACGCTTGATTCACATGT
ACTCTTTTCTTTGGCATAGTGCAACTTTATGATTTCTGAAATTCAATGGTTCTATT
15 GACTTTTTGCGTCACTTAATCCAAATCAACCAAATTCAGGGTTGAATCTGAATTG
GCTTCTCAGGCTCAAGGTAACAGTGTTCTTGTGGTTTGACCAATTGTTTTTCTTTC
TGTTNTNTTTTTTTTAGATTTGTGGTATTCTGGTCAAGTTATTGTGCTGTACTTTGT
GCGTAGAAATTGAGTTGTATTGTCAACCCCAAGTCAGTAAAGAGAAGTTCAAAAA
ATTATCCTCAAGTGTAGATTTCTCTTAATTCCATTTGTGTATCATGTTAACTATT
20 GTTGTGGCTTCTTGTGTAAAGACAGGAAGTGTGGAAGTGTGATGTTGTCTTTGT
GTTGTAAATAAGAAATGTCTTATCTGTATATGTATGAGTCTTCTGTCAATTGTA
TTTGGGCACATGAATATTGTGTACAAGGAATTGTTAAGACTGGTTTTCCGTCACAA
ACATATATATATACTTGCTACTGGAAAAGTGTTTAAAGACTTAGCTAGGTTTCATT
TAGATCTTCATATCTGTTGCATGGAAGAAAGTTGGGTTCTTGGCATAGAGTTGCAT
25 GATATGTAAGATTTTGTGCATTCATAATTGTTAAAAATCTGTGTTCCAAAAGTGG
ACATAGCATGTACAGGCAGTTTCTGTCTGTGCACAAAAAGTTTAAAAAAGTTG
TTAATATTTGTTGTTGTATACCCAAATACGCACCGAATAAACTCTTTGAATGAAT
ATAAAGAGTTTATTTCGGTGCATTTTGTGTTGTATACCCAAATACGCACCGAAT
AAACTCTTTATATTGATTCAAAG

30

SEQ ID NO: 570

>18972 BLOOD 263164.34 X74929 g400415 Human KRT8 mRNA for keratin 8. 0

GGTGGCAGGTGACGGGTAGGCCAGCCCCCTCTGGGCCTAGCCACTCAGGTAC
GAGGCCTTCECECECCATECCCCGGGGCTGGGATCTCTTTTATAAAAGGCCATT
35 CTGAGAGCTCTCCTACCAAGCAGCAGCTTCTCCGCTCCTTCTAGGATCTCCGCCT
GGTTCGGCCCGCCTGCCTCCACTCCTGCCTCCACCATGTCCATCAGGGTGACCCA
GAAGTCCTACAAGGTGTCCACCTCTGGCCCCCGGGCCTTCAGCAGCCGCTCCTAC
ACGAGTGGGCCCCGGTTCCTCGCATCAGCTCCTCGAGCTTCTCCCGAGTGGGCAGCA
GCAACTTTCGCGGTGGCCTGGGCGGCGGCTATGGTGGGGCCAGCGGCATGGGAG
40 GCATCACCGCAGTTACGGTCAACCAGAGCCTGCTGAGCCCCCTTGTCTGGAGGT
GGACCCCAACATCCAGGCCGTGCGCACCCAGGAGAAGGAGCAGATCAAGACCCT
CAACAACAAGTTTGCCTCCTTCATAGACAAGGTACGGTTCCTGGAGCAGCAGAA
CAAGATGCTGGAGACCAAGTGGAGCCTCCTGCAGCAGCAGAAGACGGCTCGAAG
CAACATGGACAACATGTTTCGAGAGCTACATCAACAACCTTAGGCGGCAGCTGGA
45 GACTCTGGGCCAGGAGAAGCTGAAGCTGGAGGCGGAGCTTGGCAACATGCAGGG
GCTGGTGGAGGACTTCAAGAACAAGTATGAGGATGAGATCAATAAGCGTACAGA
GATGGAGAACGAATTTGTCCTCATCAAGAAGGATGTGGATGAAGCTTACATGAA
CAAGGTAGAGCTGGAGTCTCGCCTGGAAGGGCTGACCGACGAGATCAACTTCCT
CAGGCAGCTGTATGAAGAGGAGATCCGGGAGCTGCAGTCCCAGATCTCGGACAC

ATCTGTGGTGCTGTCCATGGACAACAGCCGCTCCCTGGACATGGACAGCATCATT
 GCTGAGGTCAAGGCACAGTACGAGGATATTGCCAACCGCAGCCGGGCTGAGGCT
 GAGAGCATGTACCAGATCAAGTATGAGGAGCTGCAGAGCCTGGCTGGGAAGCAC
 GGGGATGACCTGCGGCGCACAAAGACTGAGATCTCTGAGATGAACCGGAACATC
 5 AGCCGGCTCCAGGCTGAGATTGAGGGCCTCAAAGGCCAGAGGGCTTCCCTGGAG
 GCCGCCATTGCAGATGCCGAGCAGCGTGGAGAGCTGGCCATTAAGGATGCCAAC
 GCCAAGTTGTCCGAGCTGGAGGCCGCCCTGCAGCGGGCCAAGCAGGACATGGCG
 CGGCAGCTGCGTGAGTACCAGGAGCTGATGAACGTCAAGCTGGCCCTGGACATC
 GAGATCGCCACCTACAGGAAGCTGCTGGAGGGCGAGGAGAGCCGGCTGGAGTCT
 10 GGGATGCAGAACATGAGTATTCATACGAAGACCACCAGCGGCTATGCAGGTGGT
 CTGAGCTCGGCCTATGGGGGCCTCACAAGCCCCGGCCTCAGCTACAGCCTGGGCT
 CCAGCTTTGGCTCTGGCGCGGGCTCCAGCTCCTTCAGCCGCACCAGCTCCTCCAG
 GGCCGTGGTTGTGAAGAAGATCGAGACACGTGATGGGAAGCTGGTGTCTGAGTC
 CTCTGACGTCCTGCCCAAGTGAACAGCTGCGGCAGCCCCTCCCAGCCTACCCCTC
 15 CTGCGCTGCCCCAGAGCCTGGGAAGGAGGCGCTATGCAGGGTAGCACTGGGAA
 CAGGAGACCCACCTGAGGCTCAGCCCTAGCCCTCAGCCACCTGGGGAGTTTACT
 ACCTGGGGACCCCCCTTGCCCATGCCTCCAGCTACAAAACAATTCAATTGCTTTT
 TTTTTTGGTCCAAAATAAACCTCAGCTAGCTCTGCCAATGTCAA

20 SEQ ID NO: 571

>19004 BLOOD 083318.1 K00488 g182106 Human enkephalin gene, 5' flank and intron c

(5' end): 0

GTTGGGGAGCTGTGCCCGCCCTCTTTCCTTCACATTTCAATGCATGGGTTCGCC
 AACAGCGTTCCCTGGTTCTTCTTTGTGACCCGAGTCAATGTCCTGCCTCCCCCGGC
 25 TCCCGCTCTCTCGCCCCCTGGTCTGCGGCGTTCTCTCCGGAATCTTGGCCTGGGGCCG
 CGGACGCCCAGGAAAAGAGCCGGGTGCCCCAGGCAGCCTCGCGTTGGGGGCGAC
 CGCGCCATCCCGGGAA

SEQ ID NO: 572

30 >19039 BLOOD 135014.5 M64925 g189785 Human palmitoylated erythrocyte membrane protein (MPP1) mRNA, complete cds. 0

GGGCGGTGACTGGCCCAGCCGCACCGCGTCTCCCGCCTTCTCCGCAGCCCCGCAG
 GCCCCGGGCCCTGTCAATCCAGCGCTGCCCTGTCTTGCCTTCCAGTGTTCCAGCT
 TCTGCGAGATGACCCCTCAAGGCGAGCGAGGGCGAGAGTGGGGGCAGCATGCACA
 35 CGGCGCTCTCCGACCTCTACCTGGAGCATTGCTGCAGAAGCGTAGTCGGCCAGA
 GGCTGTATCGCATCCATTGAATACTGTGACCGAGGACATGTACACCAACGGGTCT
 CCTGCCCCAGGTAGCCCTGCCCAGGTCAAGGGACAGGAGGTGCGGAAAGTGCGA
 CTCATACAGTTTGAGAAGGTCACAGAAGAGCCCATGGGAATCACGCTGAAGCTG
 AATGAAAAACAGTCCTGTACGGTGGCCAGAATTCTTCATGGTGGCATGATCCATA
 40 GACAAGGCTCCCTTACGTTGGGGGATGAGATCCTAGAAATCAATGGCACAAATG
 TGACAAATCATTCAGTGGATCAGCTGCAGAAGGCGATGAAAGAAACCAAAGGAA
 TGATCTCATTAAGTAATTCCCAACCAGCAAAGCCGTCCTTCTGCACTACAGAT
 GTTCATGAGAGCGCAGTTTGACTATGATCCCAAAAAGGACAAATCTGATCCCTTGC
 AAGGAGGCGGGACTGAAGTTTGCTACTGGGGACATTATCCAGATTATCAACAAG
 45 GATGACAGCAATTGGTGGCAGGGACGGGTGGAAGGCTCCTCCAAGGAGTCAGCA
 GGATTGATCCCTTCCCCTGAGCTGCAGGAATGGCGAGTGGCAAGTATGGCTCAGT
 CAGCTCCTAGCGAAGCCCCGAGCTGCAGTCCCTTTGGGAAGAAGAAGAAGTACA
 AAGACAAATATCTGGCCAAGCACAGCTCGATTTTTGATCAGTTGGATGTTGTTTC
 CTACGAGGAAGTCGTTCCGCTCCCTGCATTCAAGAGGAAGACCCTGGTGCTGATC

GGAGCCAGTGGGGTGGGTGCGAGCCACATTAAGAATGCCCTGCTCAGCCAGAAT
 CCGGAGAAGTTTGTGTACCCTGTCCCATATACAACACGGCCGCCAAGGAAGAGT
 GAGGAAGATGGGAAGGAGTACCACTTTATCTCAACGGAGGAGATGACGAGGAA
 CATCTCTGCCAATGAGTTCTTGGAGTTTGGCAGCTACCAAGGCAACATGTTTGGC
 5 ACCAAATTTGAAACAGTGCACCAGATCCATAAGCAGAACAAGATTGCCATCCTT
 GACATTGAGCCCCAGACCCTGAAAATTGTTTCGGACAGCAGAACTTTTCGCCTTTCA
 TTGTGTTTATTGCACCTACTGACCAGGGCACTCAGACAGAAGCCCTGCAGCAGCT
 GCAGAAGGACTCTGAGGCCATCCGCAGCCAGTACGCTCACTACTTTGACCTCTCA
 CTGGTCAATAATGGTGTGATGAAACCCTTAAGAAATTACAAGAAGCCTTCGACC
 10 AAGCGTGCAGTTCTCCACAGTGGGTGCCTGTCTCCTGGGTTTACTAAGCTTGTAG
 AATGGGGGAACCCACTGTATGCCCTCTCCAGCATTTGGAATTCACCCGCCTTG
 CTTTAAGACAAACAGGGCTGCTCCAAGTAGTTTGTGTGTCAGCTTCCAGCTCTCTG
 CAGCTATCCTAATTCAGCCAGTAAGGTTTCAGTCTTCTTGCTCAGGCTCCTGAAGG
 GTTGATTCTCCTGATAGATGGGGCCCCACTGATCTGGATTTGAAAAGGATTTCTA
 15 GAAATTGGGGGTAAAGAAGTACTACCAAAATGTAAGTCTAATCAAGGGTGATGC
 ACAGCAAAAGCAATGGACCCCATCCCTCTAAAGCCTGCCCTCCTTTGCCTTCAAC
 TGTATATGCTGGGTATTTTATTTGTCTTTTTATTTTGGAGAAAGCGTTTTAACTG
 CAACTTTCTATAATGCCAAAATGACACATCTGTGCAATAGAATGATGTCTGCTCT
 AGGGAAACCTTCAAAGCAATAAAAATGCTGTGTTGAAATGCCAGAAAAAAA

SEQ ID NO: 573

>19055 BLOOD_GB_W02116 gi|1274164|gb|W02116|W02116-zc66e09.s1

Soares fetal heart NbHH19.W Homo sapiens cDNA clone IMAGE:327304.3 mRNA
 sequence [Homo sapiens]

TTTTTTCGGGAGAAAGAAAAGCTTTACTGGGAGAAAATACAACAAATTCCAGAGT
 GCATGGTTTTTAGCCACCCCTATCACCCACCAGCAATAGGAACACAGACCACTC
 GATCACCACACATTCCCTACCTCAGGGAGTAAGTACATCAGCCAACATCTNGGTC
 TCNGAGCTGCTGGGAAAAGGGGCAGGAGNAAGAAGTATCTGGNAATACCATTCT
 CTCACTCTNTTCCCCTCCTT

SEQ ID NO: 574

>19319 BLOOD_331040.8 M92449 g190094 Human LTR mRNA, 3' end of coding region
 and 3' flank_0

STCTTGAGCTGGAGCGCTTCCTGCCCCAGCCCTTACCCGGCGAGATCCGCGGCA
 35 TGTGTGACTTCATGAACCTCAGCCTGGCGGACTGCCTTCTGGTCAACCTGGCCTA
 CGAGTCCTCCGTGTTCTGCACCAGTATTGTGGCTCAAGACTCCAGAGGCCACATT
 TACCATGGTCGGAATTTGGATTATCCTTTTGGGAATGTCTTACGCAAGCTGACAG
 TGGATGTGCAATTCTTAAAGAATGGGCAGATTGCATTACAGGAAGTACTTTTAT
 TGGCTATGTAGGATTATGGACTGGCCAGAGCCCACACAAGTTTACAGTTTCTGGT
 40 GATGAACGAGATAAAGGCTGGTGGTGGGAGAATGCTATCGCTGCCCTGTTTCGG
 AGACACATTCCCGTCAGCTGGCTGATCCGCGCTGTGGTTCCGAGTTGAGACAAAT
 TACGACCACTGGAAGCCAGCACCAAGGAAGATGACCGGAGAACATCTGCCATC
 AAGGCCCTTAATGCTACAGGACAAGCAAACCTCAGCCTGGAGGCACTTTTCCAG
 ATTTTGTCTGGTGGTTCCAGTTTATAACAAATGATTTTTTAAAAAATGAAATCTTG
 45 AAGAGCTGCACCTTAAAAAATAAGACAAAGTGAAAGTATTGTATTATGTTACAA
 ACAATGCAGGCTCCTTCTCATTTAACTTTACAACCTTGCGAAGTGGGTCCAGGA
 GATTTGGAGTTTGTGGTAAAGCCAGTAATGGGCATTGTCCTGCATTCCCTTCCCTT
 CATGGTTTGCCTCGATCCTCTCTAAGCTTCTATCCTGGCCTGAATAACTCAAAGAT
 AATTGGTCTCAGAGATCAAGCCATATCCTCAGGCCTTATTTCCATCTTCTCATGAT

TCTGCCATCATACCTTTGCTTCTCCGCTAATGAAATGAGCTGGCAAGACCTCTGTT
CATTGTGAAGTGCTTCTGAAAGAGCCTAAGAAAAAAGGCTCATCTGAAAGAAAT
GGAGAACTCTATTTCTGAACCAAGCCTGTTTGAATGTGTGTTAGTCTGATCTTTGAT
CATGTGTTTCCATGTAATGGGAGTCTCGTTTTTTATAATGTTTCTAACGTTTTATT
5 GAAAAACCTATGGCCCTCCTTCTTTCTCAATAGCTACTTTCTTACTGCTTTTTGAA
AATAATATGCAACCAAATTATTTCTTAATGTCACATAATTAAGTAATAAAATGTC
AAAAGAAATGTTGGCAAGGAGAATAAAAAAATTTCCAAGAAAAA

SEQ ID NO: 575

10 >19391 BLOOD 197556.13 Z50853 g963047 Human mRNA for CLPP. 0
GACCGGGGCGTGCGGAGGGATGTGGCCCGGAATATTGGTAGGGGGGGCCCGGGT
GGCGTCATGCAGGTACCCCGCGCTGGGGCCTCGCCTCGCCGCTCACTTTCCAGCG
CAGCGGCCGCCGAGCGTACACTCCAGAACGGCCTGGCCCTGCAGCGGTGCCTG
CACGCGACGGCGACCCGGGCTCTCCCGCTCATTCCCATCGTGGTGGAGCAGACG
15 GGTCGCGGCGAGCGCGCCTATGACATCTACTCGCGGCTGCTGCGGGAGCGCATC
GTGTGCGTCATGGGCCCCGATCGATGACAGCGTTGCCAGCCTTGTTATCGCACAGC
TCCTCTTCTGCAATCCGAGAGCAACAAGAAGCCCATCCACATGTACATCAACAG
CCCTGGTGGTGTGGTGACCGCGGGCCTGGCCATCTACGACACGATGCAGTACATC
CTCAACCCGATCTGCACCTGGTGCCTGGGCCAGGCCGCCAGCATGGGCTCCCTGC
20 TTCTCGCCGCCGGCACCCAGGCATGCGCCACTCGCTCCCCAACTCCCGTATCAT
GATCCACCAGCCCTCAGGAGGCGCCCGGGGCCAAGCCACAGACATTGCCATCCA
GGCAGAGGAGATCATGAAGCTGAAGAAGCAGCTCTATAACATCTACGCCAAGCA
CACCAAACAGAGCCTGCAGGTGATCGAGTCCGGCATGGAGAGGGACCGCTAGAT
GAGCCCCATGGAGGCCCAGGAGTTTGGCATCTTAGACAAGGTTCTGGTCCACCCT
25 CCCCAGGACGGTGAGGATGAGCCACGCTGGTGCAGAAGGAGCCTGTAGAAGCA
GCGCCGGCAGCAGAACCTGTCCCAGCTAGCACCTGAGAGCTGGGCCTCCTCTCCA
GAATCATGTGGAGGGGCCAGAGGCCTGCCAGACCCCCAGCTGGGCCCTGCTCAC
CCCTTGTTGCTGGGCTTGGAGGGGCCCTCTTGAGGAACTTTTAATTTGCAGGGGTG
CCCGCTATGGACGGGGCATTCCAGCTGAGACACTGTGATTTTAAATTAATCTTT
30 GTGGTCTTTG

SEQ ID NO: 576

>19403 BLOOD 1144353.1.X12953 g35836.Human rab2 mRNA, YPT1-related and member
of ras family. 0

35 TTCAAGTACATCATAATCGGCGACACAGGTGTTGGTAAATCATGCTTATTGCTAC
AGTTTACAGACAAGAGGTTTTCAGCCAGTGCATGACCTTACTATTGGTGTAGAGTT
CGGTGCTCGAATGATAACTATTGATGGGAAACAGATAAAACTTCAGATATGGGA
TACGGCAGGGCAAGAATCCTTTCGTTCCATCACAAGGTCGTATTACAGAGGTGCA
GCAGGAGCTTTACTAGTTTACGATATTACACGGAGAGATACATTCAACCACTTGA
40 CAACCTGGTTAGAAGATGCCCCGCCAGCATTCCAATTCCAACATGGTCATTATGCT
TATTGGAAATAAAAGTGATTTAGAATCTAGAAGAGAAGTAAAAAAGAAGAAG
GTGAAGCTTTTGCACGAGAACATGGACTCATCTTCATGGAAACGTCTGCTAAGAC
TGCTTCCAATGTAGAAGAGGCATTTATTAATACAGCAAAAGAAATTTATGAAAA
AATTCAAGAAGGAGCTTTGACATTAATAATGAGGCCAATGGCATTAAAATTGGC
45 CCTCAGCATNTGTTACCATGCCACACATGCAGGCNATCAGGGAGGCANCAGCTG
GGGCNGCTCTGTTGANTCTGTTTATGCTANTGCCACGGGCTTCTCCCTTATCTTAN
CCTTCCTCTGGNACTGGNTGACCTTTGAAAGGTTTGCCAGAGATTANCCGCAATC
T

SEQ ID NO: 577

>19425 BLOOD gi|1376913|gb|W68044.1|W68044 zd39f04.r1

Soares_fetal_heart_NbHH19W Homo sapiens cDNA clone IMAGE:343039 5', mRNA
sequence

5 AATATTTTCAGCTTCANCCATGTTGTTGGAGATGGAAAGATGGAAGCAGGACAG
AGAAACTGGTCGATTTTCAAGGCCCTGTGAGTGCCTCGTCGTGCGTGTGGCCCCA
GACCTCGGAGAAAGGATCACGCTAAGCGGTGACAAATCCTTGATAGAAGAAGTA
TTTCCAGAGATCCGGCGACGTGATGTGTAACCTCTGTCAATGCAGGCTGGAATCAC
GACTCGACGCACGTCATCAGGTTTCCACTAAATGGCTACTGTCACCTCAACTCAG
10 TCCAAGGTCCTCGAGAGGTTGCAAGCAAAGAAGGATTTGAAATCCGTGGGCTCC
TGTGGGGGAGGAGTAGACTCCGTCCCAAGTTCAGCCGAATACGTCCTTCGGCGG
GAACTTGAGGCGGACCCCCCGTGTACCCTCCGTGATCCCGGATAAAGCAAAGAG
CCTCTGGACTAAAATGGACATANTTCTTTAATGCAAAAAAGGAAAACACACACA
AACCNATT

15

SEQ ID NO: 578

>19535 BLOOD 157116.31 Incyte Unique

AAGACCACTAGATTTTCTGGATTTAGAAAGACCTCCTACAACCCCTCAAAATGAA
GAAATCCGAGCAGTTGGCAGACTAAAAAGAGAGCGGTCTATGAGTGAAAATGCT
20 GTTCGCCAAAATGGACAGCTGGTCAGAAATGATTCTCTGTGGCACAGATCAGATT
CTGCCCCAAGAAATAAAATTTCAAGGTTCCAGGCACCGATTCTGCACCGGAGTA
GACTGTGACACCATGCGCCACAACAGGCTGGGGTCTGTCTCCCATATGTTACCT
GAGATGGAGCTAATCTTCTCTGTCTGGTGGCATTTTGTCTGCTTATCCAGTCTTC
TACTCGTAGGGCATACCAGCAGATCTTGGATGTGCTGGATGAAAATCGCAGACCT
25 GTGTTGCGTGGTGGGTCTGCTGCCGCCACTTCTAATCCTCATCATGACAACGTCA
GGTATGGCATTTCAAATATAGATAACAACATTGAAGGAACGTCAGATGACCTGA
CTGTTGTAGATGCAGCTTCACTAAGACGACAGATAATCAAACATAAATAGACGTCT
ACAACCTTCTGGAAGAGGAGAACAAAGAACGTGCTAAAAGAGAAATGGTCATGTA
TTCAATTACTGTAGCTTTCTGGCTGCTTAATAGCTGGCTCTGGTTTCGCCGCTAGA
30 GGTAACATCAGCCCTCAAAAATACTGTCTCAACAGCTGGAAATATAAAAGATTT
GCAAACCTTCTTTGTTTCTGTCTCTGCATTGTATGCCATTTTATAGTCCACACCCTG
AAAATGTATTTCTTCCAGAAAGTCTGGAGGAAGGACCTATATTTGTAGAAGTAAA
GGTATATTCTGTCACTCAGCTGTATTCAGTCTGAGCAGTTCTGCAGTAACACCT
GCTTAAAATTCTCCCTTTGCAATGTTTGTAAATAGGCTCCAGTTTGTTTTTTAAA
35 AGGAATTTATTTTTGCCTCATCAGTCCACCCAAGTCTGATTCTGAATGGGAGAGAG
TCTGTAGAGAATTGATTTCAGAAAAGTGTCTGTGAAAGAAAAACAATTATTTGTC
CTGTTTCTCAAACAGTGTTAAGCAGTTTGTGTAATAGACATTTTGCATCGACACT
TCAACATTAACACTTTGAAAGTCATGGTCTGGTGCCAGATTTAAGAAACTCGAAC
CACCTAATATTTTATAACCTTCTTCATTAGGTACTTGTACAGATTAATTTCTAACA
40 TTGCAGCAGTTTCATATGTGTGCAATATGTGCATTCTTTCATTTTAGTTTTGCACT
TGGTTTTCTATAAAGTACGTTTTTACTCAGTTCATGCGTGAACAATTTAAAAAAC
GACAGAATAAGGTACAAATGTAGTGTATTTAATAAACTGTCAACCAAAGA

SEQ ID NO: 579

45 >19539 BLOOD 238238.1 Incyte Unique

CTTTTTTTATTTTTTATCTCTATGCTTAATAGAAAACATATTTTTATTCCGTACTTT
AAAAATATAGACTTTCTAGCAACTTATAAATTTCTATTATAATAATAAATTGATA
CTTTGAGCCAAGAAAACAATATAACCAAAAATTCATTTGTTCCCTTTGTTTAGGG
GTGTTTTACATTTATGCATAATTTTGCTTTTATAAAAGATGATTGTTACAATCAGG

700: NNNCTATFGGCTTCAAGTTGTTTACGCTT
 710: AATTGGTAGGTTTGTGGCTTGTTCCCTCAAAGGATCCCTTETTCATGTCCTCCCATGATG
 720: TTGCAGGCAAGGGTCTCTTGTATATGTGGTACTAACTCGGGGCCACCTGGTCAT

>19696 BLOOD gil1401816jgb|W87741.1|W87741_zh68c06.s1

35 Soares_fetal_liver_spleen_1NFLS_S1 Homo sapiens cDNA clone IMAGE:417226 3' similar
to gb:K02276 MYC PROTO-ONCOGENE PROTEIN (HUMAN);, mRNA sequence
CAATGATATATTTATTGTGTAAATCTTAAAATTTTTTAAAAACAATTCTTAAATAC
AAATCTGTAAAGAAAAAAAAAAGATGGTAAGCATAAAAAAGTTCTTTTATGCC
CAAAGTCCAATTTGAGGCAGTTTACATTATGGCTAAATCTTTCAGTCTCAAGACT
40 CAGCCAAGGTTGTGAGGTTGCATTTGATCATGCATTTGAAACAAGTTCATACGGT
GATTGCTCAGGACATTTCTGTTAGAAGGAATCGTTTTCTTACTTTTCCTTACGCA
CAAGAGTTCCGTAGCTGTTCAAGTTTCGTGTTTCAACTGTTCTCGTCGTTTCCGCA
ACAAGTCCTCTTCAGAAATGAGCTTTTGCTCCTCTGCTTGGACGGACAGGATGTA
TGCTGTGGCTTTTTTAAAGATAACTACCTTGGGGGCCTTTTCATTGTTTCCAAC
45 CCGGGATCTGGGTCACGCAGGGCAAAAAGCTCCGTTTTAAGCTCGTTTCTCCTC
TGGGCGCTCCTCGTGCC

>19853 BLOOD 1096264.4 L22009 g347313 Human hnRNP H mRNA, complete cds. 0

TTCACATGGCCGTTATAACGACGCGCGTCGTGGCCGTTTCGTATTTACAACGTCGT
GACTGGAAAACAGTGTAATTCTAAGCACCTCTTTCAGTATTCAAGTCAAACAACG
TGAAATAGGATGGGTGTAAAGCATACTGGTCCAAATAGTCCTGACACGGCCAAT
GATGGCTTAGTACGGCTTAAGAGGACTACCCTATAGGATGTAGCAAGGAAGAAA
5 TTGTACAGTTCTATCTACAGGTATGTAGTCATAGTTAGTTGCTAGAGCAGTGAGT
ATAAAGGCTAGCTTATGGCAAGGTGATTTAATAGACGTTAAAGTTGAGTAGCTTA
GGTATTTTCAGTAGGTTGTAAATATGCCAATGAATTAATGTTTACTTCCTAGAGAC
CTTCAAATAATTTAAGCCCATCTTAAAGGTGGAAATGAAGTACTATCCAAAATGT
TAACCTTTCCTATATTTAGTATTATAGTTTCAGAGTAGATCTTTCATTGAGGATTGC
10 CCTCAACAGCTTAACTACTTTCCTCACATTGGTGTCCAGCTAAGTACCTCAAGTTA
AAGGTAAGATCCCTTTACCAGCAGATCATCAGTGCGATGAATTAGGTTGTTGTAA
ATTATGGCAAGTGTCTGTGTTGCAAGACACACGTATTTGGGTCATGTGACCAGAA
GCATCTAATGGTCTAATTCTCTTTAATGCAAAAGTCGGTTTATGAAAGACTTGGT
TTAACCTGTGTGGTATAACTTACTGAAAATCAGATGTAGTGAGAGTAGTTTGAAT
15 GCTTGTAGTCTCAGTATCTGAAATAAGTGTTTTGAAATTGTTTCCTGGGCCTAAAG
TATTTGAATGTTTTTATGCTGAAGAGCTGATAAGATTGCATGTTTAACAATGTTA
GATAAGATATCGTATATTTGAAGTATTAATATTGATGAGGTGATACACTGGAAGC
AAGAAATCCTTTCATGGTTTAGTGTAGTATGTTAAAAATTGATATATGTATCGAG
TCCTAATGTCAGAAATTTTTAAATCAAGTCTGTTTTGTTTTGACACTAAATTGGTG
20 AGAATTGAATGCTGTCAACGTTAAATATGAACATAATTCATATCTTCTAGGAAA
GTGCTTTAAGTCCTTTTTGTAAGCTTGGGAATGTATCCACGGAAAGGATTTTTTCAT
TAGACGGAATTTCCAGAAGTGAATCATAACTACTGTTAGAGCATAAGCATGCATG
ATTGTGCTGTGTAGATCAGTTTGGTTGAAAGTTTAGATTGTTGTTGTTGTCAAATTA
TAATTTAATGTTTCAGTTTTTATATGAAATGTTGTAAATGTATACCTTTTAAAAA
25 CTTGAAGTTCCAATAACTTAAAGCATTGAAATATAAAATGAGGTAAAAGGTGTT
TGAATTTAGTAAAACTGTTATTTAATGCTTAAAACTTAATTGAATTGTATAATTCT
CAACATTAAGTTGCATAGATATGTGTTCTTAAGTTGTTGAATTCTTAATGCATCCT
GTGTTTCAGCAAGTTTTTTTTTAATATATACTGTACCATGGGTGTGTTAAGAATAGTT
ATACTTTATAATAATGGAACCTCATATTATTGCAATGCATATTTAAAGAGTACTT
30 GTTGAAAGCATACCATTACCTAAAGTTAAAAATTCTGGTTTATTTAAAGCTATA
AGAAGAATCATTTCTGGGCTTGTGATGTTAATATTGCCCCCTACTGGGGTTATTT
GTCCTTGGGTTGAAGGGTTGGAAATCGTGCCAAATGGGATAACATTGCCGGTGG
ACTTCCAGGGGAGGAGTACGGGGGAGGCCTTCGTGCAGTTTGCTTCACAGGAAA
TAGCTGAAAGGCTCTAAAGAAACACAAGGAAAGAATAGGGCACAGGTGGGGA
35 TGGATGGTTGGTTGGATATGTCACCTTTCTTATGGTAAACAATTAAATCCATATTC
TCTCTGCTTAAAAGAAGAAATTAATGTTTTGTAGTCCTAGGTAATTGATGTTTTGC
CATGATTTCCAAACTTGTGTCAGTCCCACGTTACACGCAAACTAAATTTTAGGTTT
GAAATTTGTCCCTAGTTAATTGGTCTGCTTGACAATTTTGTGAGTCTTATTAACCC
CAATCAATAGAGTTGAGAGACTATGGCTTTAAAAAATTAATGCAAACCTGGCTTT
40 AGCTGTAATAACACCCACCTAGAATAAATTAATATTACCATAAGAAAATGTGAT
ACTTTCTGATCTTGTTTTTAAAGTTGAAATGCAACAACTTTTTCTTGCTGTATAT
AAATATTCTGCATAGTATTAATAAGCATAGCTTTCAAGAAATTGTCACAAAAGGT
TTTATTCTCTTGCTTGACTATTTTTTATTGGAAGCATGCGCTTACCTATGCTGAT
TCTTACTAAAAGCATAGGCTGGGGTATTTATTGGCGAAAGGAAATGTGTAGTGTG
45 GGCTGGACTGTTGGTGGAGGCTGGCTTTTTAGCCCACTTGCTATACATGCTGCCA
ATGGATTTAAGACTTGAAATGTTGAAAGTTGAGTGGAATTATTTCCCTCCTAAAA
CATTTATTTACAGTACTCCTCTCTACCCCTAAGGTTGGGCTCTGCCTCAGAGGAGT
GAGTTTTTTTTTTTTTCTATAAAGTTTACATTGTCTTACTATTTATTGAGTGAATT
TCTGGTCATTGCCTATGCAAATATAAGAAATCTGGCTTTAAATATTAGTCAGTTTC

ATGGCTATGACTAGATTGTTTTCTTGTATAACTAAATACCTGTATAAAATGAACT
AATGTTTTCTCTCCCCTCCCTACCCCTTCCTTATGAACAATGCTTTAGGTATATTG
AAATCTTTAAGAGCAGTAGAGCTGAAGTTAGAAGCTCATTATGATCCACCACGAA
AGCTTATGGCCATGCAGCGGCCAGGTCCTTATGACAGACCTGGGGCTGGTAGAG
5 GGTATAACAGCATTGGCAGAGGAGCTGGCTTTGAGAGGATGAGGCGTGGTGCTT
ATGGTGGAGGCTATGGAGGCTATGATGATTACAATGGCTATAATGATGGCTATG
GATTTGGGTCAGATAGATTTGGAAGAGACCTCAATTACTGTTTTTCAGGAATGTC
TGATCACAGATACGGGGATGGTGGCTCTACTTTCCAGAGCACAAACAGGACACTG
TGTACACATGCGGGGATTACCTTACAGAGCTACTGAGAATGACATTTATAATTTT
10 TTTTCACCGCTCAACCCTGTGAGAGTACACATTGAAATTGGTCTGATGGCAGAG
TAACTGGTGAAGCAGATGTCGAGTTCGCAACTCATGAAGATGCTGTGGCAGCTAT
GTCAAAGACAAAGCAAATATGCAACACAGATATGTAGAAGCTCTTCTTGAATTCT
ACAGCAGGAGCAAGCGGTGGTGCTTACGAACACAGATATGTAGAAGCTCTTCTTG
AATTCTACAGCAGGAGCAAGCGGTGGTGCTTATGGTAGCCAAATGATGGGAGGC
15 ATGGGCTTGTCAAACCAGTCCAGCTACGGGGGCCAGCCAGCCAGCAGCTGAGT
GGGGGTTACGGAGGCGGCTACGGTGGCCAGAGCAGCATGAGTGGATACGACCAA
GTTTTACAGGAAACTCCAGTGATTTTCAATCAAACATTGCATAGGTAACCAAGG
AGCAGTGAACAGCAGCTACTACAGTAGTGGAAGCCGTGCATCTATGGGCGTGAA
CGGAATGGGAGGGTTGTCTAGCATGTCCAGTATGAGTGGTGGATGGGGAATGTA
20 ATTGATCGATCCTGATCACTGACTCTTGGTCAACCTTTTTTTTTTTTTTTTTTTC
TTTAAAGAAACTTCAGTTTAAACAGTTTCTGCAATACAAGCTTGTGATTTATGCTTA
CTCTAAGTGGAAATCAGGATTGTTATGAAGACTTAAGGCCAGTATTCTTGAATA
CAATACTCATCEAGGATGTAAACAGTGAAGCTGAGTAACTATAACTGTAAACTT
AAGTTCAGCTTTTCTCAAGTTAGTTATAGGATGTACTTAAGCAGTAAGCGTATT
25 TAGGTAAAAGCAGTTGAATTATGTTAAATGTTGCCCTTTGCCACGGTAAANTGGA
CCACTGTTTTGGGATGCATGTTGAAAGACATGCTTTTATTTTTTTGTAAAACAATA
TAGGAGCTGTGTCTACTATTAAAAGTGAAACATTTTGGGCATGTTTGTTTAAATT
CTTAGTTTTCATTTTAAATAAACCCCTGTTAAGGGCAACGGTAAAGTTTTAAAGCC
TTTTNTNTNTNTNTNTTTTAAAGTTTAAATGGGGGGAAAAAAAATTTT

30

SEQ ID NO: 582

>19871 BLOOD GB_X00187 X00187 Preproenkephalin (leu-enkephalin, met-enkephalin)

CAGCCGTTAAGCCCCGGGACGGCGAGGCAGGCGCTCAGAGCCCCGCAGCCTGGC
CCGTGACCCCGCAGAGACGCTGAGGACC

35

SEQ ID NO: 583

>19872 BLOOD 1102297.22 X63432 g28335 Human ACTB mRNA for mutant beta-actin (beta'-actin). 0

TTTGGCTTTATTCATTTTTTGTGAGAGTTGACCATCAGGTATATTGGGGAAGGGA
40 GAGATGGAGGCACCTTCATGAGTGCCTCCCAAGGGCAGTAGCCTCTGCAACTTGC
TGGGGGTTTCAGGGGAAGCAGGGAGTTTCATGGGGCTCCTCCAGCAAAGATGAGCT
CCAGGGCTGCTTGGATGTCCCCACCGGTGGCCTGCAGGGCCCGCAGGCTCAGCTC
ATCGTCCTGGATGCCCATGTACGTAGCTGCTGCAGCTGGGGCTGCCACTGGCTC
TGAAGGCTGGGCTGCCAGAGGCCTGAAGGGCATGCTGTAGGGCTTGGCTGAAG
45 AGATCATTGGTGATGGGCGTCCCTGACTGGACACCAGAGGACATTGGTGAGGTC
CCTGAGGAATGACCCTGGGTGCCAGGAGTCGGTGTGTGAGAGCTGCTCTCCGGA
GTGCTGGCCAGGGCCAAGGCGGTGGCCAGCTCACTCTGGGTGATGGGCCGGGGC
CCAGCAGCTCCACTGTACCCAGGGAGGCTGGGCGGGAGCTGGGAGTACTGCTA
GAGGGTGTGGACCTGGTGTTTGGGTGAAAGTCATCCTCATCATCTGAGAGCCCTT

CAAACAGGAAGCCACCTGGCATATCCCGGTATGAGCTGGAGGGCATGCTCCGGG
AAGAGGAGTCAGTCCCAGGCATTGGGGCACTGCCTGCTACGGAGTGCAGAACCA
GGACAATGGCATTGACGAGGGCTGGGTGAGCAGGCACCAACGTATCAAGCATAT
TGGGATCAGCGAAGACAGAGAAGAGGTCTTGTCTGGAGAACCCCAAGAGCAA
5 TAGGGTCACTGCTGAGGCCTGGGGTGGCCACAATGATCTGATCCAGAGACTCCTT
ATTGCTGAGCATCTTAAAGACCGCCTCCCTGTAAGAGGAGCTGCTGTGCAGGGCA
GTGTGCAACACCCGGAACCTCTCATGGCAGCCACTTTGTCCACAGGTTCCGGTT
TCTGATCAGGTTCAAGGCCAGGACTTTTCGAGAACATGGACAGTGGACCCAGGTT
GAATGCCATAGAAGTCAAGTGTCTGGTCATCTTTTAGCTTCCGACCACAGTAGAT
10 CAGATCAATCAGCTCAGGGTCTGGAACAGACTCCTGGAGTTTGCCAGCAATAAG
CTGCTTCAGAAATGAAATACTATAGCCCCCTAGCGAGTATTCTCCAGTTCTGTC
TCTGGCAACCGAAGAATAGACTTTGGAGTAAGTGGCTGGTCAGCCAGCTTCACC
GCCAGGTGCCAGTCTGAGAGAGACATCCTCTCTTTTCGCGCTCTCTCTTTCTCCC
CGTCCCGCCGAGACCGCGTCCGCCCGCGAGCACAGAGCCTCGCCTTTGCCGATC
15 CGCCGCCCGTCCACACCCGCCGCGCAGCTCACCATGGATGATGATATCGCCGCGCT
CGTCGTCGACAACGGCTCCGGCATGTGCAAGGCCGGCTTCGCGGGCGACGATGC
CCCCCGGGCGTCTTCCCCTCCATCGTGGGGCGCCCCAGGCACCAGGGCGTGATG
GTGGGCATGGGTGAGAAGGATTCTATGTGGGCGACGAGGCCAGAGCAAGAGA
GGCATCCTCACCTGAAGTACCCCATCGAGCACGGCATCGTCACCAACTGGGAC
20 GACATGGAGAAAATCTGGCACCACACCTTCTACAATGAGCTGCGTGTGGCTCCCG
AGGAGCACCCCGTGTCTGCTGACCGAGGCCCCCTGAACCCCAAGGCCAACCGCG
AGAAGATGACCCAGATCATGTTTGAGAGCTTGAACAGCCCAGCCATGTACGTGTC
TATCCAGGCTGTGCTATCCCTGTACGGCTCTGGCCGTACCACTGGCATCGTGATG
GACTCCGGTGACGGGGTCAACCAAGCTGTGCCCATCTACGAGGGGTATGCCCTCC
25 CCCATGCCATCCTGCGTCTGGACCTGGCTGGCCGGGACCTGACTGACTAECTCAT
GAAGATCCTCACCGAGCGCGGCTACAGCTTCAACCACCACGGCCGAGCGGGAAAT
CGTGCGTGACATTAAGGAGAAGCTGTGCTACGTGCGCCCTGGACTTCGAGCAAGA
GATGGCCACGGCTGCTTCCAGCTCCTCCCTGGAGAAGAGCTACGAGCTGCCTGAC
GGCCAGGTCATCACCATTGGCAATGAGCGGTTCCGCTGCCCTGAGGCACTCTTCC
30 AGCCTTCTTCTGGGCATGGAGTCTGTGGCATCCACGAACTACCTTCAACTC
CATCATGAAGTGTGACGTGGACATCCGCAAGACCTGTACGCCAACACAGTGCT
GTCTGGCGGCACCACCATGTACCCTGGCATTGCCGACAGGATGCAGAAGGAGAT
CACTGCCGTGGCACCCAGCACAAATGAAGATCAAGATCATTGCTCCTCCTGAGCGC
AAGTACTCCGTGTGGATCGGCGGGCTCCATCCTGGCCTCGCTGTCCACCTTCCAGC
35 AGATGTGGATCAGCAAGCAGGAGTATGACGAGTCCGGCCCCCTCCATCGTCCACC
GCAATGCTTCTAGGCGGACTATGACTTAGTTGCGTTACACCCTTTCTTGACAAA
ACCTAACTTGCGCAGAAAACAAGATGAGATTGGCATGGCTTTATTTGTTTTTTT
GTTTTGTTTTGGTTTTCTTTTTTTTTTGGCTTGACTCAGGATTTAAAACTGGAAC
GGTGAAGGTGACAGCAGTCGGTTGGAGCGAGCATCCCCAAAGTTCACAATGTG
40 GCCGAGGACTTTGATTGCACATTGTTGTTTTTTAATAGTCATTCCAAATATGAGA
TGCATTGTTACAGGAAGTCCCTTGCCATCCTAAAAGCCACCCCACTTCTCTCTAA
GGAGAATGGCCAGTCCTCTCCCAAGTCCACACAGGGGAGGTGATAGCATTGCT
TTCGTGTAAATTATGTAATGCAAAATTTTTTTAATCTTCGCCTTAATACTTTTTTAT
TTTGTTTTATTTGAATGATGAGCCTTCGTGCCCCCCTTCCCCCTTTTTTGTCCCC
45 CAACTTGAGATGTATGAAGGCTTTTGGTCTCCCTGGGAGTGGGTGGAGGCAGCCA
GGGCTTACCTGTACACTGACTTGAGACCAGTTGAATAAAAGTGCACACCTTAAAA
ATGAAAAAA

SEQ ID NO: 584

>19885 BLOOD 236030.3 M17752 g33917 Human mRNA for gamma-interferon inducible early response gene (with homology to platelet proteins). 0

5 GGAACAGCCAGCAGGTTTTGCTAAGTCAACTGTAATGCCCTTATCCAATCAGAAT
TAGGGAGGGAAAATGGCTTTGCAGATAAATATGGNACACTAGCCCCACGNTTTC
TGAGACATTCTCAATTGCTTAGACATATTCTGAGCCTACAGCAGAGGAACCTCC
AGTCTCAGCACCATGAATCAAACCTGCCATTCTGATTTGCTGCCTTATCTTTCTGAC
TCTAAGTGGCATTCAAGGAGTACCTCTCTCTAGAACTGTACGCTGTACCTGCATC
AGCATTAGTAATCAACCTGTTAATCCAAGGTCTTTAGAAAACTTGAAATTATTC
10 CTGCAAGCCAATTTTGTCCACGTGTTGAGATCATTGCTACAATGAAAAAGAAGGG
TGAGAAGAGATGTCTGAATCCAGAATCGAAGGCCATCAAGAATTTACTGAAAGC
AGTTAGCAAGGAAAGGTCTAAAAGATCTCCTTAAAACCAGAGGGGAGCAAAATC
GATGCAGTGCTTCCAAGGATGGACCACACAGAGGCTGCCTCTCCCATCACTTCCC
TACATGGAGTATATGTCAAGCCATAATTGTTCTTAGTTTGCAGTTACACTAAAAG
15 GTGACCAATGATGGTCACCAAATCAGCTGCTACTACTCCTGTAGGAAGGTAAATG
TTCATCATCCTAAGCTATTCAGTAATAACTCTACCCTGGCACTATAATGTAAGCTC
TACTGAGGTGCTATGTTCTTAGTGGATGTTCTGACCCTGCTTCAAATATTTCCCTC
ACCTTTCCCATCTTCCAAGGGTACTAAGGAATCTTTCTGCTTTGGGGTTTATCAGA
ATTCTCAGAATCTCAAATAACTAAAAGGTATGCAATCAAATCTGCTTTTAAAGA
20 ATGCTCTTTACTTCATGGACTTCCACTGCCATCCTCCCAAGGGGCCCAAATCTTT
CAGTGGCTACCTACATACAATTCCAAACACATACAGGAAGGTAGAAATATCTGA
AAATGTATGTGTAAGTATCTTATTTAATGAAAGACTGTACAAAGTAGAAGTCTT
AGATGTATATATTTCCCTATATTGTTTCAGTGTACATGGAATAACATGTAATTAAG
TACTATGTATCAATGAGTAACAGGAAAAATTTTAAAAATACAGATAGATATATGCT
25 CTGCATGTTACATAAGATAAATGTGCTGAATGGTTTTCAAATAAAAAATGAGGTA
CTCTCCTGGAAATATTAAGAAAGACTATCTAAATGTTGAAAGACCAAAAAGGTTA
ATAAAGTAATTATAACT

SEQ ID NO: 585

30 >19887 BLOOD 272980.8 X02544 g24444 Human mRNA for alpha1-acid glycoprotein (orosomucoid). 0

GCAGGATTGTGTACAGACACAGAGTAAACTTTTGCTGGGCTCCAAGTGACCGCC
CATAGTTTATTATAAAGGTGACTGCACCCTGCAGCCACCAGCACTGCCTGGCTCC
ACGTGCCTCCTGGTCTCAGTATGGCGCTGTCTGCGGTTCTTACAGTCCTGAGCCTC
35 CTACCTCTGGCTGGAAGCCCAGATCCCATTTGTGTGCCAACCTAGTACCGGTGCCC
ATCACCAACGCCACCCTGGACCGGATCACTGGCAAGTGGTTTTATATCGCATCGG
CCTTTCGAAACGAGGAGTACAATAAGTCGGTTCAGGAGATCCAAGCAACCTTCTT
TTACTTCACCCCCAACAAGACAGAGGACACGATCTTTCTCAGAGAGTACCAGACC
CGACAGGACCAGTGCATCTATAACACCACCTACCTGAATGTCCAGCGGGAAAAT
40 GGGACCATCTCCAGATACGTGGGAGGCGGAGAGCATTTGCTCACTTGCTGATCC
TCAGGGACACCAAGACCTACATGCTTGCTTTTGACGTGAACGATGAGAAGAACT
GGGGGCTGTCTGTCTATGCTGACAAGCCAGAGACGACCAAGGAGCAACTGGGAG
AGTTCTACGAAGCTCTCGACTGCTTGCGCATTCCCAAGTCAGATGTCGTGTACAC
CGATTGGAAAAAGGATAAGTGTGAGCCACTGGAGAAGCAGCACGAGAAGGAGA
45 GGAAACAGGAGGAGGGGGAATCCTAGCAGGACACAGCCTTGGATCAGGACAGA
GACTTGGGGGCCATCCTGCCCTCCAACCCGACATGTGTACCTCAGCTTTTCCCT
CACTTGCATCAATAAAGCTTCTGTGTTTGAACAGCTAAAAAAA

SEQ ID NO: 586

>19916 BLOOD 234842.5 M16447 g181552 Human dihydropteridine reductase (hDHPR)
mRNA, complete cds. 0

5 CTGGCAGGAGCAGGATGGCGGCGGCGGCGGCTGCAGGCGAGGCGCGCCGGGTG
CTGGTGTACGGCGGCAGGGGCGCTCTGGGTTCTCGATGCGTGCAGGCTTTTCGGG
CCCGCAACTGGTGGGTTGCCAGCGTTGATGTGGTGGAGAATGAAGAGGCCAGCG
CTAGCATCATTGTTAAAATGACAGACTCGTTCACTGAGCAGGCTGACCAGGTGAC
TGCTGAGGTTGAAAAGCTCTTGGGTGAAGAGAAGGTGGATGCAATTCTTTGCGTT
GCTGGAGGATGGGCGGGGGCAATGCCAAATCCAAGTCTCTCTTTAAGAACTGT
10 GACCTGATGTGGAAGCAGAGCATATGGACATCGACCATCTCCAGCCATCTGGCT
ACCAAGCATCTCAAGGAAGGAGGCCTCCTAACCTTGGCTGGCGCAAAGGCTGCC
CTGGATGGGACTCCTGGTATGATCGGGTACGGCATGGCCAAGGGTGCTGTTACCC
AGCTCTGCCAGAGCCTGGCTGGGAAGAACAGCGGCATGCCGCCCCGGGGCAGCCG
CCATCGCTGTGCTCCCGGTTACCCTGGATACCCCGATGAACAGGAAATCAATGCC
15 TGAGGCTGACTTCAGCTCCTGGACACCCTTAGAATTCCTAGTTGAAACTTTCCAT
GACTGGATCACAGGGAAAAACCGACCGAGCTCAGGAAGCCTAATCCAGGTGGTA
ACCACAGAAGGAAGGACGGAACCTACCCCGAGCATATTTTATAGGCCTCATCTCAGT
GCCTATGAGGGGCGCTGCCAGAAAAGTCACTAACCTGTCTCAGTGTGGCCTTGTC
AGCCTTGTGTTTTCTGTAACCCCTGTTTGTGGTACGAGATAATGAGTCCTATTTTT
20 CTCTCACATAATATGCATTTGCTCTCCTAGGACAGTGTAATACATTTATGTGAAGT
AAAGACATGCGAGACTGGTGGCCTGCAAAATAGCATCCGTCAATCTGTGTTAACTG
GATAGGGAGGGCTCTGCATAGCACCTGCTATAGCGGTGTCATGTTGGATCGCTTT
TGAGACTGTTTCATCTGTCCTTGACAGTGGCTGTCATCTTGACTACTTGGTTGATTT
GTGGGTATTGGGGACATTTTAAAGGCTGAGTTATTTTTGAATGTCATGTTTATGTC
25 ATAGACGTAGTTTTTCGCATCCTTGAATTAAACTGCCTTAACTCCTTTTGTGGTATA
AGCAAAACTACATGGACTCTGTCCTGGTATCCTTTTCCTGTGTGGTTGCCCTGTGT
CCTCTGGCCTAGGGTTAAGTGTGCAAGATAACTACTCGTGAGTATTCAGAATGTT
GTTCTTAATAAATGCACCTGTTGTCTGTCTTCTTTAATCAAATCACATCTTATATA
CAGCAGTCAGAGATGAGTATACTAGAATCATGGATTGCTGGAGGTCTTTTAATCT
30 GGTGTTCTCGGAAGGGGGTGCATTTAAATCCTGAAATAAATATTTCAACACAAGA
ACACAGGCCTGATTCTGCCTTGGACATGTCCAAATCTGGGGGTGATGGGATGGCC
CTGTGCATTTAGAAGCAGCTCTCCACATATGGCCAATGTAGGCTGTCCTGGTTCGA
AACTAGTAGTGGTTTAATTCAAGGATGCGGAAAACCTACGTCTTATGACATAAAC
ATGACATTCAAAAATAACTCAGCCTTTAACTGGCAGAGCTAAGCCCAGATCTCTA
35 GTCACCAGACTCTTGCTGTTTTTAAAGGCCTTTACCACGTATTTTCTTTCTTTTTT
AGTGAGGTGAAATTCACATAA

SEQ ID NO: 587

>19943 BLOOD 425535.24 D14533 g286028 Human mRNA for XPAC protein. 0

40 TTTCCATTTTAATCCAGCATTTAAAAAGCTATCTAGACTAATGTAAAGTCCCACA
ATAGAGGCCCCAAGAGTACAGAAAACATGATCAGACTCGTACAACTCAATGTTT
ATTTCTGCTATTAGGGCTTTTTCCAGCAGTAGTTCCCCACTGTTTCCACCATCGTG
GAGACAGAAATCGTCCTAAAAAACACATGACTAGAACCTGGGGTACAGTGGTGC
ACCACCATTGCTATTATTTGTTTCTTGGTTAAGAATCCAGTTCAGCCTTTGTTGAA
45 CCCTTTTCCCTCTACCCCAATCTAGGGTTTGCCTTGGTATCTTGTCTCAAATTTGT
AGCTGACCTACCACTTCTGCACCTACTCTAGCACTCAGCTCCCATCTCTGTTGTAA
GAAGGCAATCACAGACATGACATTGTGCACACAACCAGGCCAGGTGACCTTCAC
TGAAACTTGCTTTTTAAGCCATAACATAACATAATTATTACTGAAGTATTACTTATAC
AAGGGTTTCATTCATCTATGAAGATGTTGCTTTTTTTTTTTGAATTTTGAAAAGGAC

499

GCGGCATGGGGTCCGGGGGCCTGGCCACCGGGATAGCCGGGGGTCTGGCAGGAA
TGGGAGGCATCCAGAACGAGAAGGAGACCATGCAAAGCCTGAACGACCGCCTG
GCCTCTTACCTGGACAGAGTGAGGAGCCTGGAGACCGAGAACCGGAGGCTGGAG
AGCAAAATCCGGGAGCACTTGGAGAAGAAGGGACCCAGGTCAGAGACTGGAG
5 CCATTACTTCAAGATCATCGAGGACCTGAGGGCTCAGATCTTCGCAAATACTGTG
GACAATGCCCCGCATCGTTCTGCAGATTGACAATGCCCCGTCTTGCTGCTGATGACT
TTAGAGTCAAGTATGAGACAGAGCTGGCCATGCGCCAGTCTGTGGAGAACGACA
TCCATGGGCTCCGCAAGGTCATTGATGACACCAATATCACACGACTGCAGCTGGA
GACAGAGATCGAGGCTCTCAAGGAGGAGCTGCTCTTCATGAAGAAGAACCACGA
10 AGAGGAAGTAAAAGGCCTACAAGCCCAGATTGCCAGCTCTGGGTTGACCGTGGA
GGTAGATGCCCCCAAATCTCAGGACCTCGCCAAGATCATGGCAGACATCCGGGC
CCAATATGACGAGCTGGCTCGGAAGAACCGAGAGGAGCTAGACAAGTACTGGTC
TCAGCAGATTGAGGAGAGCACCACAGTGGTCACCACACAGTCTGCTGAGGTTGG
AGCTGCTGAGACGACGCTCACAGAGCTGAGACGTACAGTCCAGTCCCTTGGAGAT
15 CGACCTGGACTCCATGAGAAATCTGAAGGCCAGCTTGGAGAACAGCCTGAGGGA
GGTGGAGGCCCCGCTACGCCCTACAGATGGAGCAGCTCAACGGGATCCTGCTGCA
CCTTGAGTCAGAGCTGGCACAGACCCGGGCAGAGGGACAGCGCCAGGCCAGGA
GTATGAGGCCCTGCTGAACATCAAGGTCAAGCTGGAGGCTGAGATCGCCACCTA
CCGCCGCCTGCTGGAAGATGGCGAGGACTTTAATCTTGGTGATGCCTTGGACAGC
20 AGCAACTCCATGCAAACCATCCAAAAGACCACCACCCGCGGATAGTGGATGGC
AAAGTGGTGTCTGAGACCAATGACACCAAAGTTCTGAGGCATTAAGCCAGCAGA
AAGCAGGGTACCATGATAFTTTTGTFTTCCCTGGACTGAAACATAGTCTGGGTCTC
AACGTEGCGGTGATGATGGTTGAACATCATGTTTATATAAACCTTAATTTCTCA
TTTAATAGGAAGAAAATCTCAGGAGAGCCAAAAGGGAGGACCTGAAGGTGAGC
25 ATCCACCAAATGGAGATGGAGAGGATCCGCTACGTCCTCAGCAGCTACTTGCGG
TGTCGCCTCATGAAGGTTTGACGTGGAGATACCTCAAAGTCTCCGACCTCCGGGG
AGCCGAGAGCGGGACGTGGGAGCCGGGCTTG

SEQ ID NO: 588

30 >19975 BLOOD gi|28229|emb|X15357.1|HSAANP Human mRNA for natriuretic peptide
receptor (ANP-A receptor)

CCATGGTAGGAGCGCTCGCCTCGCTGCGGTGCCCGCTGAGGCCATGCCGGGGGCC
CCGGCGCCCCGCTGGCTCCCGCCTGCGCCTGCTCCTGCTCCTGCTGCTGCCGGCCG
CTGCTGCTGCTGCTCCGGGGCAGCCACGCGGGCAACCTGACGGTAGCCGTGGTA
35 CTGCCGCTGGCCAATACCTCGTACCCCTGGTCGTGGGCGCGCGTGGGACCCGCGG
TGGAGCTGGCCCTGGCCCAGGTGAAGGCGCGCCCCGACTTGCTGCCGGGCTGGA
CGGTCCGCACGGTGCTGGGCAGCAGCGAAACGCGCTGGGCGTCTGCTCCGACA
CCGCAGCGCCCCTGGCCGCGGTGGACCTCAAGTGGGAGCACAACCCCGCTGTGT
TCCTGGGCCCCGGCTGCGTGTACGCCGCCGCCCCAGTGGGGCGCTTCACCGCGCA
40 CTGGCGGGTCCCGCTGCTGACCGCCGGCGCCCCGGCGCTGGGCTTCGGTGTCAAG
GACGAGTATGCGCTGACCAACCCGCGCGGGGGCCAGCTACGCCAAGCTGGGGGAC
TTCGTGGCGGCGCTGCACCGACGGCTGGGCTGGGAGCGCCAAGCGCTCATGCTCT
ACGCCTACCGGCCGGGTGACGAAGAGCACTGCTTCTTCCTCGTGGAGGGGCTGTT
CATGCGGGTCCGCGACCGCCTCAATATTACGGTGGACCACCTGGAGTTCGCCGAG
45 GACGACCTCAGCCACTACACCAGGCTGCTGCGGACCATGCCGCGCAAAGGCCGA
GTTATCTACATCTGCAGCTCCCCTGATGCCTTCAGAACCCCTCATGCTCCTGGCCCT
GGAAGCTGGCTTGTGTGGGGAGGACTACGTTTTCTTCCACCTGGATATCTTTGGG
CAAAGCCTGCAAGGTGGACAGGGCCCTGCTCCCCGAGGCCCTGGGAGAGAGGG
GATGGGCAGGATGTCAAGTGGCCGCCAGGCCTTTCAGGCTGCCAAAATCATTACAT

ATAAAGACCCAGATAATCCCGAGTACTTGGAAATTCCTGAAGCAGTTAAAACACC
TGGCCTATGAGCAGTTCAACTTCACCATGGAGGATGGCCTGGTGAACACCATCCC
AGCATCCTTCCACGACGGGCTCCTGCTCTATATCCAGGCAGTGACGGAGACTCTG
GCACATGGGGGAACTGTTACTGATGGGGAGAACATCACTCAGCGGATGTGGAAC
5 CGAAGCTTTCAAGGTGTGACAGGATACTGAAAATTGATAGCAGTGGCGATCGG
GAAACAGACTTCTCCCTCTGGGATATGGATCCCGAGAATGGTGCCTTCAGGGTTG
TACTGAACTACAATGGGACTTCCCAAGAGCTGGTGGCTGTGTGCGGGGCGCAAAC
TGAAGTGGCCCCTGGGGTACCCTCCTCCTGACATCCCCAAATGTGGCTTTGACAA
CGAAGACCCAGCATGCAACCAAGATCACCTTTCCACCCTGGAGGTGCTGGCTTTG
10 GTGGGCAGCCTCTCCTTGCTCGGCATTCTGATTGTCTCCTTCTTCATATACAGGAA
GATGCAGCTGGAGAAGGAACTGGCCTCGGAGCTGTGGCGGGTGCCTGCGGAGGA
CGTTGAGCCCAGTAGCCTTGAGAGGCACCTGCGGAGTGCAGGCAGCCGGCTGAC
CCTGAGCGGGAGAGGCTCCAATTACGGCTCCCTGCTAACCACAGAGGGCCAGTT
CCAAGTCTTTGCCAAGACAGCATATTATAAGGGCAACCTCGTGGCTGTGAAACGT
15 GTGAACCGTAAACGCATTGAGCTGACACGAAAAGTCCTGTTTGAAGTGAAGCAT
ATGCGGGATGTGCAGAATGAACACCTGACCAGGTTTGTGGGAGCCTGCACCGAC
CCCCCAATATCTGCATCCTCACAGAGTACTGTCCCCGTGGGAGCCTGCAGGACA
TTCTGGAGAATGAGAGCATCACCTGGACTGGATGTTCCGGTACTCACTCACCAA
TGACATCGTCAAGGGCATGCTGTTTCTACACAATGGGGCTATCTGTTCCCATGGG
20 AACCTCAAGTCATCCAACTGCGTGGTAGATGGGCGCTTTGTGCTCAAGATCACCG
ACTATGGGCTGGAGAGCTTCAGGGACCTGGACCCAGAGCAAGGACACACCGTTT
ATGCCAAAAGCTGTGGACGGGCCCTGAGCTCCTGCGAATGGCTTCACCCCTGT
TGGGGGGCTCCCAGGCTGGTCAAGTATACAGCTTTGGGATCATCCTTCAGGAGATT
GGCCCTGAGGAGTGGGGTCTTCCAGGTGGAAGGTTTGGACCTGAGCCCCAAAGAG
25 ATCATCGAGCGGGTGAATCGGGGTGAGCAGCCCCCTTCCGGCCCTCCCTGGCCC
TGCAGAGTCACCTGGAGGAGTTGGGGCTGCTCATGCAGCGGTGCTGGGCTGAGG
ACCCACAGGAGAGGCCACCATTCCAGCAGATCCGCCTGACGTTGCGCAAATTTA
ACAGGGAGAACAGCAGCAACATCCTGGACAACCTGCTGTCCCGCATGGAGCAGT
ACGCGAACAACTCTGGAGGAACTGGTGGAGGAGCGGACCCAGGCATACCTGGAG
30 GAGAAGCGCAAGGCTGAGGCCCTGCTCTACCAGATCCTGCCTCACTCAGTGGCTG
AGCAGCTGAAGCGTGGGGAGACGGTGCAGGCCGAAGCCTTTGACAGTGTTACCA
TCTACTTCAGTGACATTGTGGGTTTACAGCGCTGTCGGCGGAGAGCACACCCAT
GCAGGTGGTGACCCTGCTCAATGACCTGTACACTTGCTTTGATGCTGTCTAGAC
AACTTTGATGTGTACAAGGTGGAGACAATTGGCGATGCCTACATGGTGGTGTGAG
35 GGCTCCCTGTGCGGAACGGGGCGGCTACACGCCTGCGAGGTAGCCCCGATGGCCC
TGGCACTGCTGGATGCTGTGCGCTCCTTCCGAATCCGCCACCGGCCCCAGGAGCA
GCTGCGCTTGCAGATTGGCATCCACACAGGACCTGTGTGTGCTGGAGTGGTGGGA
CTGAAGATGCCCCGTTACTGTCTCTTTGGGGATACAGTCAACACAGCCTCAAGAA
TGGAGTCTAATGGGGAAGCCCTGAAGATCCACTTGTCTTCTGAGACCAAGGCTGT
40 CCTGGAGGAGTTTGGTGGTTTCGAGCTGGAGCTTCGAGGGGATGTAGAAATGAA
GGGCAAAGGCAAGGTTCCGACCTACTGGCTCCTTGGGGAGAGGGGGAGTAGCAC
CCGAGGCTGACCTGCCTCCTCTCCTATCCCTCCACACCTCCCTACCCTGTGCCAG
AAGCAACAGAGGTGCCAGGCCTCAGCCTCACCCACAGCAGCCCCATCGCCAAAG
GATGGAAGTAATTTGAATAGCTCAGGTGTGCTGACCCAGTGAAGACACCAGAT
45 AGGACCTCTGAGAGGGGACTGGCATGGGGGGATCTCAGAGCTTACAGGCTGAGC
CAAGCCCACGGCCATGCACAGGGACACTCACACAGGCACACGCACCTGCTCTCC
ACCTGGACTCAGGCCGGGCTGGGCTGTGGATCCTTGATCCCTCCCTCCCATG
CTCTCCTCCCTCAGCCTTGCTACCCTGTGACTTACTGGGAGGAGAGTCACCTGAA
GGGGAACATGAAAAGAGACTAGGTGAAGAGAGGGCAGGGGAGCCCACATCTGG

GGCTGGCCCCACAATACCTGCTCCCCCGACCCCCTCCACCCAGCAGTAGACACAGT
GCACAGGGGGAGAAGAGGGGTGGCGCAGAAGGGTTGGGGGCCTGTATGCCTTGCT
TCTACCATGAGCAGAGACAATTAATAATCTTTATTCCAGTG

5 SEQ ID NO: 589

>20014 BLOOD Hs.347 gnl|UG|Hs#S3990 Human mRNA for lactoferrin /cds=(294,2429)

/gb=X53961 /gi=34415 /ug=Hs.347 /len=2619

GACTCCTAGGGGCTTGCAGACCTAGTGGGAGAGAAAGAACATCGCAGCAGCCAG
GCAGAACCAGGACAGGTGAGGTGCAGGCTGGCTTTCCTCTCGCAGCGCGGTGTG

10 GAGTCCTGTCCTGCCTCAGGGCTTTTCGGAGCCTGGATCCTCAAGGAACAAGTAG
ACCTGGCCGCGGGGAGTGGGGAGGGAAGGGGTGTCTATTGGGCAACAGGGGCGG

CAAAGCCCTGAATAAAGGGGCGCAGGGCAGGCGCAAGTGCAGAGCCTTCGTTTG
CCAAGTCGCCTCCAGACCGCAGACATGAAACTTGTCTTCCTCGTCCTGCTGTTCT

15 CGGGGCCCTCGGACTGTGTCTGGCTGGCCGTAGGAGAAGGAGTGTTCAAGTGGTG
CGCCGTATCCCAACCCGAGGCCACAAAATGCTTCCAATGGCAAAGGAATATGAG

AAAAGTGCGTGGCCCTCCTGTCAGCTGCATAAAGAGAGACTCCCCCATCCAGTGT
ATCCAGGCCATTGCGGAAAACAGGGCCGATGCTGTGACCCTTGATGGTGGTTTCA

TATACGAGGCAGGCTGGCCCCCTACAACTGCGACCTGTAGCGGCGGAAGTCT
ACGGGACCGAAAGACAGCCACGAACTCACTATTATGCCGTGGCTGTGGTGAAGA

20 AGGGCGGCAGCTTTCAGCTGAACGAACTGCAAGGTCTGAAGTCCTGCCACACAG
GCCTTCGCAGGACCGCTGGATGGAATGTCCCTACAGGGACACTTCGTCCATTCTT

GAATGGACGGGTCCAGCTGAGGCAATTGAGGACAGCTGTGGECAGGTTCTTCTCA
GCGAGCTGTGTTCCGGTGCAGATAAAGGACAGTTCCCAACCTGTGTGCGCTGT

GTGCGGGGACAGGGGAAAACAAATGTGCCTTCTCTCCAGGAACCGTACTTCA
GCTACTCTGGTGCCTTCAAGTGTCTGAGAGACGGGGCTGGAGACGTGGCTTTTAT

25 CAGAGAGAGCACAGTGTGTTGAGGACCTGTCAGACGAGGCTGAAAGGGACGAGTA
TGAGTTACTCTGCCAGACAACACTCGGAAGCCAGTGGACAAGTTCAAAGACTG

CCATCTGGCCCGGGTCCCTTCTCATGCCGTTGTGGCACGAAGTGTGAATGGCAAG
GAGGATGCCATCTGGAATCTTCTCCGCCAGGCACAGGAAAAGTTTGGAAAGGAC

30 AAGTCACCGAAATTCCAGCTCTTTGGCTCCCTAGTGGGCAGAAAGATCTGCTGT
TCAAGGACTCTGCCATTGGGTTTTTCGAGGGTGCCCCCGAGGATAGATTCTGGGCT

GTACCTTGGCTCCGGCTACTTCACTGCCATCCAGAACTTGAGGAAAAGTGAGGAG
GAAGTGGCTGCCCGGCGTGCAGCGGGTCTGTGTTGTTGCGGTGGGCGAGCAGGAG

CTGCGCAAGTGTAACCAAGTGGAGTGGCTTGAGCGAAGGCAGCGTGACCTGCTCC
35 TCGGCCTCCACCACAGAGGACTGCATCGCCCTGGTGCTGAAAGGAGAAGCTGAT

GCCATGAGTTTGGATGGAGGATATGTGTACACTGCATGCAATGTGGTTTGGTGC
CTGTCTGGCAGAGAACTACAAATCCCAACAAAGCAGTGACCCTGATCCTAACT

GTGTGGATAGACCTGTGGAAGGATATCTTGCTGTGGCGGTGGTTAGGAGATCAG
ACACTAGCCTTACCTGGAACCTGTGAAAAGGCAAGAAGTCCTGCCACACCGCCGT

40 GGACAGGACTGCAGGCTGGAATATCCCCATGGGCCTGCTCTTCAACCAGACGGG
CTCCTGCAAATTTGATGAATATTTCAAGTCAAAGCTGTGCCCTGGGTCTGACCCG

AGATCTAATCTCTGTGCTCTGTGTATTGGCGACGAGCAGGGTGAGAATAAGTGCG
TGCCCAACAGCAACGAGAGATACTACGGCTACACTGGGGCTTTCCGGTGCCTGG

CTGAGAATGCTGGAGACGTTGCATTTGTGAAAGATGTCACTGTCTTGCAGAACAC
45 TGATGGAAATAACAATGAGGCATGGGCTAAGGATTTGAAGCTGGCAGACTTTGC

GCTGCTGTGCCTCGATGGCAAACGGAAGCCTGTGACTGAGGCTAGAAGCTGCCA
TCTTGCCATGGCCCCGAATCATGCCGTGGTGTCTCGGATGGATAAGGTGGAACGC

CTGAAACAGGTGCTGCTCCACCAACAGGCTAAATTTGGGAGAAATGGATCTGAC
TGCCCGGACAAGTTTTGCTTATTCCAGTCTGAAACCAAAAACCTTCTGTTCAATG

ACAACACTGAGTGTCTGGCCAGACTCCATGGCAAAACAACATATGAAAAATATT
 TGGGACCACAGTATGTCGCAGGCATTACTAATCTGAAAAAGTGCTCAACCTCCCC
 CCTCCTGGAAGCCTGTGAATTCCTCAGGAAGTAAAACCGAAGAAGATGGCCCAG
 CTCCCCAAGAAAGCCTCAGCCATTCACTGCCCCCAGCTCTTCTCCCCAGGTGTGT
 5 TGGGGCCTTGGCTCCCCTGCTGAAGGTGGGGATTGCCCATCCATCTGCTTACAAT
 TCCCTGCTGTCGTCTTAGCAAGAAGTAAAATGAGAAATTTTGTGATATTCAAAA
 AAAA

SEQ ID NO: 590

10 >20031 BLOOD gi|35521|emb|X54936.1|HSPLGF H.sapiens mRNA for placenta growth
 factor (PIGF)
 GGGATTTCGGGCGCCGAGCTACGGGAGGACCTGGAGTGGCACTGGGCGCCCGAC
 GGACCATCCCCGGGACCCGCTGCCCCCTCGGCGCCCCGCCCGGGGCCGCTCC
 CCGTCGGGTTCCCCAGCCACAGCCTTACCTACGGGCTCCTGACTCCGCAAGGCTT
 15 CCAGAAGATGCTCGAACCACCGGCCGGGGCCTCGGGGCAGCAGTGAGGGAGGC
 GTCCAGCCCCCACTCAGCTCTTCTCCTCCTGTGCCAGGGGCTCCCCGGGGGATG
 AGCATGGTGGTTCCTCGGAGCCCCCTGGCTCGGGACGTCTGAGAAGATGCCG
 GTCATGAGGCTGTTCCCTTGCTTCTGCAGCTCCTGGCCGGGCTGGCGCTGCCTG
 CTGTGCCCCCCCAGCAGTGGGCCTTGTCTGCTGGGAACGGCTCGTCAGAGGTGGA
 20 AGTGGTACCCTTCCAGGAAGTGTGGGGCCGCAGCTACTGCCGGGCGCTGGAGAG
 GCTGGTGGACGTTCGTGTCCGAGTACCCAGCGAGGTGGAGCACATGTTACGCC
 ATCCTGTGTCTCCCTGCTGGGCTGCACCGGCTGCTGCGGCGATGAGAATCTGCAC
 TGTGTGCCGGTGGAGACGGGCAATGTCAACATGAGCTCCTAAAGATCCGTTCTG
 GGGACCGGCCCTGCTACGTGGAGCTGACGTTCTCTCAGCACGTTTCGCTGCGAATG
 25 CCGGCCTCTGCGGGAGAAGATGAAGCCGGAAGGTGCGGCGATGCTGTTCCCCG
 GAGGTAACCCACCCCTTGGAGGAGAGAGACCCCGCACCCGGCTCGTGTATTTATT
 ACCGTCACACTCTTCAGTGACTCCTGCTGGTACCTGCCCTCTATTTATTAGCCAAC
 TGTTTCCCTGCTGAATGCCTCGCTCCCTTCAAGACGAGGGGCAGGGAAGGACAG
 GACCCTCAGGAATTCAGTGCCTTCAACAACGTGAGAGAAAGAGAGAAGCCAGCC
 30 ACAGACCCCTGGGAGCTTCCGCTTTGAAAGAAGCAAGACACGTGGCCTCGTGAG
 GGGCAAGCTAGGCCCCAGAGGCCCTGGAGGTCTCCAGGGGCCTGCAGAAGGAAA
 GAAGGGGGCCCTGCTACCTGTTCTTGGGCCTCAGGCTCTGCACAGACAAGCAGCC
 CTTGCTTTCGGAGCTCCTGTCCAAAGTAGGGATGCGGAJTTCTGCTGGGGCCGCCA
 CGGCCTGGTGGTGGGAAGGCCGGCAGCGGGCGGAGGGGAFTCAGCCACTTCCCC
 35 CTCTTCTTCTGAAGATCAGAACATTACAGCTCTGGAGAACAGTGGTTGCCTGGGGG
 CTTTGGCACTCCTTGTCCTCCCGTGATCTCCCCTCACACTTTGCCATTTGCTTGTAC
 TGGGACATTGTTCTTCCGGCCGAGGTGCCACCACCCTGCCCCCACTAAGAGACA
 CATAAGAGTGGGCCCCGGGCTGGAGAAAGAGCTGCCTGGATGAGAAACAGCTC
 AGCCAGTGGGGATGAGGTCACCAGGGGAGGAGCCTGTGCGTCCCAGCTGAAGGC
 40 AGTGGCAGGGGAGCAGGTTCCCCAAGGGCCCTGGCACCCCCACAAGCTGTCCCT
 GCAGGGCCATCTGACTGCCAAGCCAGATTCTCTTGAATAAAGTATTCTAGTGTGG
 AAACGC

SEQ ID NO: 591

45 >20039 BLOOD Hs.2064 gnl|UG|Hs#S1973578 Human DNA sequence from clone RP11-
 124N14 on chromosome 10. Contains the VIM gene for vimentin, the DNMT2 gene for DNA
 methyl transferase 2, the 5' end of the gene for intrinsic factor-B12 receptor precursor, ESTs,
 STSs, GSSs and two putative CpG islands /cds=(492,1892) /gb=AL133415 /gi=7160477
 /ug=Hs.2064 /len=2215

CCACGCCCCCTTTGGCGTGGTGGCCACCGGACCCCTCTGGTTTCAGTCCCAGGCGGAC
CCCCCCTCACCGCGCGACCCCGCCTTTTTCAGCACCCAGGGTGAGCCCAGCTC
AGACTATCATCCGGAAAGCCCCCAAAGTCCCAGCCCAGCGCTGAAGTAACGGG
ACCATGCCCAGTCCCAGGCCCCGGAGCAGGAAGGCTCGAGGGCGCCCCACCCC
5 ACCCGCCACCCCTCCCCGCTTCTCGCTAGGTCCCTATTGGCTGGCGCGCTCCGCG
GCTGGGATGGCAGTGGGAGGGGACCCCTCTTTCCTAACGGGGTTATAAAAACAGC
GCCCTCGGCGGGGTCCAGTCTCTGCCACTCTCGCTCCGAGGTCCCCGCGCCAGA
GACGCAGCCGCGCTCCCACCACCCACACCCACCGCGCCCTCGTTTCGCTCTTCTC
CGGGAGCCAGTCCGCGCCACCGCCGCGCCAGGCCATCGCCACCCTCCGCAGC
10 CATGTCCACCAGGTCCGTGTCTCTGCTCCTACCGCAGGATGTTTCGGCGGCCCCG
GGCACCGCGAGCCGGCCGAGCTCCAGCCGGAGCTACGTGACTACGTCCACCCGC
ACCTACAGCCTGGGCAGCGCGCTGCGCCCCAGCACCGCCGAGCCTCTACGCCT
CGTCCCCGGGCGGCGTGTATGCCACGCGCTCCTCTGCCGTGCGCCTGCGGAGCAG
CGTGCCCGGGGTGCGGCTCCTGCAGGACTCGGTGGACTTCTCGCTGGCCGACGCC
15 ATCAACACCGAGTTCAAGAACACCCGCACCAACGAGAAGGTGGAGCTGCAGGAG
CTGAATGACCGCTTCGCCAACTACATCGACAAGGTGCGCTTCTTGAGCAGCAG
AATAAGATCCTGCTGGCCGAGCTCGAGCAGCTCAAGGGCCAAGGCAAGTCGCGC
CTGGGGGACCTCTACGAGGAGGAGATGCGGGAGCTGCGCCGGCAGGTGGACCAG
CTAACCAACGACAAAGCCCGCGTCGAGGTGGAGCGCGACAACCTGGCCGAGGAC
20 ATCATGCGCCTCCGGGAGAAATTGCAGGAGGAGATGCTTCAGAGAGAGGAAGCC
GAAAACACCCCTGCAATCTTTCAGACAGGATGTTGACAATGCGTCTCTGGCACGTC
TTGACCTTGAACGCAAAGTGGAATCTTTGCAAGAAGAGATTGCCTTTTGAAGAA
AGTCCACGAAGAGGAAATCCAGGAGCTGAGGCTCAGATTACAGGAACAGCATGT
CCAAATCGATGTGGATGTTTCAAGCCTGACCTCACGGCTGCCCTGCGTGACGTA
25 CGTCAGCAATATGAAAGTGTGGCTGCCAAGAACCTGCAGGAGGCAGAAAGAAATGG
TACAAATCCAAGTTTGCTGACCTCTCTGAGGCTGCCAACCAGGAAACAATGACGCCC
TGCGCCAGGCAAAGCAGGAGTCCACTGAGTACCGGAGACAGGTGCAGTCCCTCA
CCTGTGAAGTGGATGCCCTTAAAGGAACCAATGAGTCCCTGGAACGCCAGATGC
GTGAAATGGAAGAGAACTTTGCCGTTGAAGCTGCTAACTACCAAGACACTATTG
30 GCCGCTGCAGGATGAGATTGAGAATATGAAGGAGGAAATGGCTCGTCACCTTC
GTGAATACCAAGACCTGCTCAATGTAAAGATGGCCCTTGACATTGAGATTGCCAC
CTACAGGAAGCTGCTGGAAGGCGAGGAGAGCAGGATTTCTCTGCCTCTTCCAAA
CTTTTCCTCCCTGAACCTGAGGGGAACTAATCTGGATTCACTCCCTCTGGTTGATA
CCCCTCAAAAAGGACACTTCTGATTAAGACGGTTGAACTAGAGATGGACAGG
35 TTATCAACGAACTTCTCAGCATCACGATGACCTTGAATAAAAATGCACACACT
CAGTGCAGCAATATATTACCAGCAAGAATAAAAAAGAAATCCATATCTTAAAGA
AACAGCTTTCAAGTGCCTTTCTGCAGTTTTTCAGGAGCGCAAGATAGATTTGGAA
TAGGAATAAGCTCTAGTTCTTAAACACCGACACTCCTACAAGATTTAGAAAAAA
GTTTACAACATAATCTAGTTTACAGAAAAATCTTGTGCTAGAATACTTTTAAAA
40 GGTATTTTGAATACCATTAAAACTGCTTTTTTTTTTCCAGCAAGTATCCAACCAAC
TTGGTTCTGCTTCAATAAATCTTTGGAAAACTC

SEQ ID NO: 592

>20082 BLOOD 025811_Mm.1 X61800 g50378 Mouse mRNA for C/EBP delta. 0

45 AGCGATTTAAATGCTTCTTTATTCTTACAAATACTGTAAACATGAATATAAAAAG
CATGCGCAGTCTCTTCTCTTATCTACAAAAGTCTGTCGGAAATGTCTTTTCTACA
AATGTACCTTAGCTGCAATGGTAATAAGACGTAGAAAATGCTACCATTATAAAA
AATAATTTAAGGGGAAAGATTAATATAGCTTCTCTCGCAGTCCAGTGCCCAAGCT
GCAGCTTCCTGTGCTCGCTCGCAGGTCCCAAAGGAACCTTGCCGATCCGGCCGGCGTCT

GCTCCCCGCCTGTCGGGGTCTGAGGTATAGGTTCGTTTCAGAGTCTCAAAGGCCAC
 GCCGCGCGTTACCGGCAGTCGGCGCCGGTGGCGCGGCAGGAAAGGCGGGCTGGG
 CAGTTTTTTGAAAAAACTGCCGGAGGCCAGCCAGGTCCCGGGTGAGCTGCTCCAC
 GCGCTGATGCAGCTTCTCGTTCTCGCCCGACAACCTCCACCAGCTTCTGCTGCATCT
 5 CCTGGTTGCGGCGCTTGGCCTTGTGCGGGCTCTTGCGCACAGCGATGTTGTTGCG
 CTCGCGCCGCTGCCGGTACTCCGGGGCTGCCGCGGTCCGGACCCCTCTTGCCCGCG
 CCCTTTTCTCGGACTGTGCCGGGCGCGAGGCTCGGCCCGGGCTGCCTCGAGGAG
 GCTCCGGCGAAGTGGGTGGAGT

10 SEQ ID NO: 593

>20091 BLOOD 235852.13 M15395 g186933 Human leukocyte adhesion protein (LFA-
 1/Mac-1/p150,95 family) beta subunit mRNA. 0

GTCAGGACTTTACGACCCGCGCCTCCAGCTGAGGTTTCTAGACGTGACCCAGGGC
 AGACTGGTAGCAAAGCCCCACGCCAGCCAGGAGCACCGCCGAGGACTCCAGC
 15 ACACCGAGGGACATGCTGGGCCTGCGCCCCCACTGCTCGCCCTGGTGGGGCTGC
 TCTCCCTCGGGTGCGTCCTCTCTCAGGAGTGCACGAAGTTCAAGGTCAGCAGCTG
 CCGGGAATGCATCGAGTCGGGGCCCGGCTGCACCTGGTGCCAGAAGCTGAACCT
 CACAGGGCCGGGGGATCCTGACTCCATTGCTGCGACACCCGGCCACAGCTGCTC
 ATGAGGGGCTGTGCGGCTGACGACATCATGGACCCACAAGCCTCGCTGAAACC
 20 CAGGAAGACCACAATGGGGGCCAGAAGCAGCTGTCCCCACAAAAAGTGACGCTT
 TACCTGCGACCAGGCCAGGCAGCAGCGTTCAACGTGACCTTCCGGCGGGCCAAAG
 GGCTACCCCATCGACCTGFACTATCTGATGGACCTCTCCTACTCCATGCTTGATGA
 CCTCAGGAATGTCAAGAAGCTAGGTGGCGACCTGCTCCGGGGCCCTCAACGAGAT
 CACCGAGTCCGGCCGCATTGGCTTCGGGTCCCTCGTGGACAAGACCGTGCTGCGG
 25 TFCGTGAACACGCACCCTGATAAGCTGCGAAACCCATGCCCAACAAGGAGAAA
 GAGTGCCAGCCCCCGTTTGCCTTCAGGCACGTGCTGAAGCTGACCAACAACCTCCA
 ACCAGTTTCAGACCGAGGTCCGGGAAGCAGCTGATTTCCGGAAACCTGGATGCAC
 CCGAGGGTGGGCTGGACGCCATGATGCAGGTGCGCGCCTGCCCGGAGGAAATCG
 GCTGGCGCAACGTCACGCGGCTGCTGGTGTGTTGCCACTGATGACGGCTTCCATTT
 30 CGCGGGCGACGGGAAGCTGGGCGCCATCCTGACCCCCAACGACGGCCGCTGTCA
 CCTGGAGGACAACCTGTACAAGAGGAGCAACGAATTCGACTACCCATCGGTGGG
 CCAGCTGGCGCACAAAGCTGGCTGAAAACAACATCCAGCCCATCTTCGCGGTGAC
 CAGTAGGATGGTGAAGACCTACGAGAACTCACCGAGATCATCCCCAAGTCAGC
 CGTGGGGGAGCTGTCTGAGGACTCCAGCAATGTGGTCCATCTCATTAAGAATGCT
 35 TACAATAAACTCTCCTCCAGGGTCTTCTGGATCACAACGCCCTCCCCGACACCC
 TGAAAGTCACCTACGACTCCTTCTGCAGCAATGGAGTGACGCACAGGAACCAGC
 CCAGAGGTGACTGTGATGGCGTGACAGATCAATGTCCCGATCACCTTCCAGGTGAA
 GGTCACGGCCACAGAGTGCATCCAGGAGCAGTCGTTTGTATCCGGGCGCTGGG
 CTTACGGACATAGTGACCGTGACGGTCCTTCCCCAGTGTGAGTGCCGGTGCCGG
 40 GACCAGAGCAGAGACCGCAGCCTCTGCCATGGCAAGGGCTTCTTGGAGTGCCGGC
 ATCTGCAGGTGTGACACTGGCTACATTGGGAAAAAACTGTGAGTGCCAGACACAG
 GGCCGGAGCAGCCAGGAGCTGGAAGGAAGCTGCCGGAAGGACAACAACCTCCAT
 CATCTGCTCAGGGCTGGGGGACTGTGTCTGCGGGCAGTGCTGTGCCACACCAGC
 GACGTCCCCGGCAAGCTGATATACGGGCAGTACTGCGAGTGTGACACCATCAAC
 45 TGTGAGCGCTACAACGGCCAGGTCTGCGGCGGGCCCGGGAGGGGGCTCTGCTTC
 TGCGGGAAGTGCCGCTGCCACCCGGGCTTTGAGGGCTCAGCGTGCCAGTGCGAG
 AGGACCACTGAGGGCTGCCTGAACCCGCGGCGTGTGAGTGTAGTGGTCGTGGC
 CGGTGCCGCTGCAACGTATGCGAGTGCCATTACGGCTACCAGCTGCCTCTGTGCC
 AGGAGTGCCCCGGCTGCCCTCACCTGTGGCAAGTACATCTCCTGCGCCGAGTG

CCTGAAGTTCGAAAAGGGCCCCCTTTGGGAAGAACTGCAGCGCGGCGTGTCCGGG
CCTGCAGCTGTGCAACAACCCCGTGAAGGGCAGGACCTGCAAGGAGAGGGACTC
AGAGGGCTGCTGGGTGGCCTACACGCTGGAGCAGCAGGACGGGATGGACCGCTA
CCTCATCTATGTGGATGAGAGCCGAGAGTGTGTGGCAGGCCCAACATCGCCGC
5 CATCGTCGGGGGCACCGTGGCAGGCATCGTGCTGATCGGCATTCTCCTGCTGGTC
ATCTGGAAGGCTCTGATCCACCTGAGCGACCTCCGGGAGTACAGGCGCTTTGAG
AAGGAGAAGCTCAAGTCCCAGTGGAAACAATGATAATCCCCTTTTCAAGAGCGCC
ACCACGACGGTCATGAACCCCAAGTTTGCTGAGAGTTAGGAGCACTTGGTGAAG
ACAAGGCCGTCAGGACCCACCATGTCTGCCCCATCACGCGGCCGAGACATGGCT
10 TGCCACAGCTCTTGAGGATGTCACCAATTAACCAGAAATCCAGTTATTTTCCGCC
CTCAAATGACAGCCATGGCCGGCCGGGTGCTTCTGGGGGCTCGTCGGGGGGAC
AGCTCCACTCTGACTGGCACAGTCTTTGCATGGAGACTTGAGGAGGGAGGGCTTG
AGGTTGGTGAGGTTAGGTGCGTGTTTCTGTGCAAGTCAGGACATCAGTCTGATT
AAAGGTGGTGCCAATTTATTTACATTTAACTTGTGAGGGTATAAAATGACATCC
15 CATTAATTATATTGTTAATCAATCACGTGTATAGAAAAAAATAAACTTCAATA
CAGGCTGTCCATGGAAAAAAAAGGG

SEQ ID NO: 594

>20222 BLOOD gi|32025|emb|Y00291.1|HSHAPRA Human hap mRNA encoding a DNA-
binding hormone receptor
20 CGGGGTAGGATCCGGAACCCATTTCGGAAGGCTTTTTGCAAGCATTTACTTGGAAG
GAGAACTTGGGATCTTTCTGGGAAGCCCCCGCCCGGCTGGATTGGCCGAGCAA
GGCTGGAAAAATGGTAAATGATCATTGGGATCAATTAGAGGCTTTTAGCTGGGTTG
TCTGTCAFAATTCATGATTCGGGGGCTGGGAAAAAGACCAAGAGCCTACGTGCCA
25 AAAAAAGGGGCAGAGTTTGATGGAGTTGGGTGGACTTTTCTATGCCATTTGCCTCC
ACACCTAGAGGATAAGCACTTTTGCAGACATTCAAGTGCAAGGGAGATCATGTTTG
ACTGTATGGATGTTCTGTCAAGTGAAGTCTGGGCAAATCCTGGATTTCTACACTGC
GAGTCCGTCTTCTGTGATGCTCCAGGAGAAAGCTCTCAAAGCATGCTTCAGTGGA
TTGACCCAAACCGAATGGCAGCATCGGCACACTGCTCAATCAATTGAAACACAG
30 AGCACCAGCTCTGAGGAACTCGTCCCAAGCCCCCATCTCCACTTCCTCCCCCTC
GAGTGTACAAACCCTGCTTCGTCTGCCAGGACAAATCATCAGGGTACCACTATGG
GGTCAGCGCCTGTGAGGGATGTAAGGGCTTTTTCCGCAGAAGTATTCAGAAGAA
TATGATTTACACTTGTACCCGAGATAAGAACTGTGTTATTAATAAAGTCACCAGG
AATCGATGCCAATACAGTCTGACTCCAGAAGTGCTTTGAAGTGGGAATGTCCAAA
35 GAATCTGTGAGGAATGACAGGAACAAGAAAAAGAAGGAGACTTCGAAGCAAGA
ATGCACAGAGAGCTATGAAATGACAGCTGAGTTGGACGATCTCACAGAGAAGAT
CCGAAAAGCTCACCAGGAACTTTCCCTTCACTCTGCCAGCTGGCTAAATACACC
ACGAATTCCAGTGCTGACCATCGAGTCCGACTGGACCTGGGCCTCTGGGACAAAT
TCAGTGAAGTGGCCACCAAGTGCAATTATTAAGATCGTGGAGTTTGCTAAACGTCT
40 GCCTGGTTTCACTGGCTTGACCATCGCAGACCAAATTACCCTGCTGAAGGCCGCC
TGCCTGGACATCCTGATTCTTAGAATTTGCACCAGGTATACCCCAAGACA
CCATGACTTTCTCAGACGGCCTTACCCTAAATCGAACTCAGATGCACAATGCTGG
ATTTGGTCCTCTGACTGACCTTGTGTTTACCTTTGCCAACCAGCTCCTGCCTTTGG
AAATGGATGACACAGAAACAGGCCTTCTCAGTGCCATCTGCTTAATCTGTGGAGA
45 CCGCCAGGACCTTGAGGAACCGACAAAAGTAGATAAGCTACAAGAACCATTGCT
GGAAGCACTAAAAATTTATATCAGAAAAAGACGACCCAGCAAGCCTCACATGTT
TCCAAAGATCTTAATGAAAATCACAGATCTCCGTAGCATCAGTGCTAAAGGTGCA
GAGCGTGTAATTACCTTGAAAATGGAAATTCCTGGATCAATGCCACCTCTCATTC
AAGAAATGATGGAGAATTCTGAAGGACATGAACCCTTGACCCCAAGTTCAAGTG

GGAACACAGCAGAGCACAGTCCTAGCATCTCACCCAGCTCAGTGGAACACAGTG
 GGGTCAGTCAGTCACCACTCGTGCAATAAGACATTTTCTAGCTACTTCAAACATT
 CCCAGTACCTTCAGTTCAGGATTTAAAATGCAAGAAAAACATTTTACTGCT
 GCTTAGTTTTTGGACTGAAAAGATATTAAACTCAAGAAGGACCAAGAAGTTTT
 5 ATATGTATCAATATATATACTCCTCACTGTGTAACCTACCTAGAAATACAACTTT
 TCCAATTTTAAAAAATCAGCCATTTTCATGCAACCAGAACTAGTTAAAAGCTTCT
 ATTTTCTCTTTGAACACTCAAGATGCATGGCAAAGACCCAGTCAAAATGATTTA
 CCCCTGGTTAAGTTTCTGAAGACTTTGTACATACAGAAGTATGGCTCTGTTCTTTC
 TATACTGTATGTTTGGTGCTTTCTTTTGTCTTGCATACTCAAATAACCATGACA
 10 CCAAGGTTATGAAATAGACTACTGTACACGTCTACCTAGGTTCAAAAAGATAACT
 GTCTTGCTTTCATGGAATAGTCAAGACATCAAGGTAAGGAAACAGGACTATTGA
 CAGGACTATTGTACAGTATGACAAGATAAAGGCTGAAGATATTCTACTTTAGTTAG
 TATGGAAGCTTGTCTTTGCTCTTTCTGATGCTCTCAAACCTGCATCTTTTATTTTCATG
 TTGCCAGTAAAAGTATACAAATTCCTGCACTAGCAGAAGAGAATTCTGTATCA
 15 GTGTAACCTGCCAGTTCAGTTAATCAAATGTCATTTGTTCAATTGTTAATGTCACCTT
 TAAATTAAAAGTGGTTTATTACTTGTTTAATGACATAACTACACAGTTAGTTAAA
 AAAAATTTTTTACAGTAATGATAGCCTCCAAGGCAGAAACACTTTTCAGTGTTA
 AGTTTTGTACTTGTTCACAAGCCATTAGGGAAATTTTCATGGGATAATTAGCA
 GGCTGGTCTACCACTGGACCATGTAACCTCTAGTGTCTTCTGATTCATGCCTGAT
 20 ATTGGGATTTTTTCCAGCCCTTCTTGATGCCAAGGGCTAATTATATTACATCCCA
 AAGAAACAGGCATAGAATCTGCCTCCTTTGACCTTGTTCAATCACTATGAAGCAG
 AGTGAAAGCTGTGGTAGAGTGGTTAACAGATACAAGTGTGAGTTTCTTAGTTCTC
 ATTAAAGCACTACTGGAATTTTTTTTTTGATATATTAGCAAGTCTGCGATGTACT
 TTCAGTGGCTCTGTTTGTACATTTGAGATTGTTTGTATAACAATGCTTTCTATGTTTC
 25 ATATACTGTTTACCTTTTCCATGGACTCTCCTGGCAAAGAATAAAATATATTTAT
 TTT

SEQ ID NO: 595

yr12e06.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:205090 3'
 30 similar to gb|M87905|HUMALND184 Human carcinoma cell-derived Alu RNA transcript,
 (rRNA); gb:J03934 NAD(P)H DEHYDROGENASE (HUMAN);contains Alu repetitive
 element;; mRNA sequence

gi|1010773|gb|H57941.1|H57941[1010773]: 1-1000

CATAAGCGAAACATGATTTTGGAAATTTTCAGGATGGGGAAAAGAAACAAATAA
 35 ATTATGGGAGTTTTTTGTGTTTTTTTTTGAGACTGGCTCTCATTCTCTGTACAT
 GGGCTGGAGTGCAGTAGTGAATCTCAGCTTACTGCAACCTCTGCCTCAAGTGAT
 CCTCCACCTCAGACTCCAGAGTAGCTGGGGAGCACATAAAATTAAAACATCTA
 AACTCTCATAATGGGTCATTTTGCCAGGGTTCTGCAGGCAAACCTTTTATTTGAAG
 TATTCTTTTTTGTGCTTTGTATTGAAAGTAAAGTTAGGGTAGCNAAGGGGGACTA
 40 CTTCAACCTGAGGAACACGGCCGNGGAAA
 ACTGCAGGCATATGGATGTTTGTCC

SEQ ID NO: 596

>20244 BLOOD 113392.11 AJ225028 g3892593 Human mRNA for GABA-B R1a receptor.
 45 0

GGCGCCCTCTCCCCGGTCTTCCCCTCTCTTCCCCCGCCCTGCCTTCCCTTGCACC
 CTCCTTCTTCCCTCCGCCCAGGAGCTCTCCCTGGTCCCCGGCGCCGCTCTTCCC
 TCCCGGCTCCCCGCTCCCCGCTCCCGTGGCTGCCGCCGCCCGGGGAAGAAGAGA
 CAGGGGTGGGGTTTGGGGGAAGCGAGAGAGGAGGGGAGAGACCCTGGCCAGGC

TGGAGCCTGGATTTCGAGGGGAGGAGGGACGGGAGGAGGAGAGAAAGGTGGAGGAG
AAGGGAGGGGGGAGCGGGGAGGAGCGGCCGGGCTGGGGCCTTGAGGCCCGGG
GAGAGCCGGGGAGCCGGGGCCCGCGCGCCGAGATGTTGCTGCTGCTGTTACTGGC
GCCACTCTTCCTCCGCCCCCGGGCGCGGGCGGGGCGCAGACCCCCAACGCCAC
5 CTCAGAAGGTTGCCAGATCATACACCCGCCCTGGGAAGGGGGCATCAGGTACCG
GGGCTGACTCGGGACCAGGTGAAGGCTATCAACTTCCTGCCAGTGGACTATGA
GATTGAGTATGTGTGCCGGGGGGAGCGCGAGGTGGTGGGGCCCAAGGTCCGCAA
GTGCCTGGCCAACGGCTCCTGGACAGATATGGACACACCCAGCCGCTGTGTCCG
AATCTGCTCCAAGTCTTATTTGACCCTGGAAAATGGGAAGGTTTTCTGACGGGT
10 GGGGACCTCCCAGCTCTGGACGGAGCCCGGGTGGATTTCGGGTGTGACCCCGACT
TCCATCTGGTGGGCAGCTCCCGGAGCATCTGTAGTCAGGGCCAGTGGAGCACCCC
CAAGCCCCACTGCCAGGTGAATCGAACGCCACACTCAGAACGGCGCGCAGTGTA
CATCGGGGCACTGTTTCCCATGAGCGGGGGCTGGCCAGGGGGCCAGGCCTGCCA
GCCCCGCGGTGGAGATGGCGCTGGAGGACGTGAATAGCCGCAGGGACATCCTGCC
15 GGACTATGAGCTCAAGCTCATCCACCACGACAGCAAGTGTGATCCAGGCCAAGC
CACCAAGTACCTATATGAGCTGCTCTACAACGACCCTATCAAGATCATCCTTATG
CCTGGCTGCAGCTCTGTCTCCACGCTGGTGGCTGAGGCTGCTAGGATGTGGAACC
TCATTGTGCTTTCTATGGCTCCAGCTCACCAGCCCTGTCAAACCGGCAGCGTTTC
CCCACCTTTCTTCCGAACGCACCCATCAGCCCACTCCACAACCCTACCCGCGTGA
20 AACTCTTTGAAAAGTGGGGCTGGAAGAAGATTGCTACCATCCAGCAGACCACTG
AGGTCTTCACTTCGACTCTGGACGACCTGGAGGAACGAGTGAAGGAGGCTGGAA
CTGAGATTACTTTCCGCCAGAGTTTCTTCTCAGATCCAGCTGTGCCCGTCAAAAA
CCTGAAGCGCCAGGATGCGCGAATCATCGTGGGACTTTTCTATGAGACTGAAGCG
GGGAAAGTTTTTTGTGAGGTGTACAAGGAGCGTCTTTGGGAAGAAGTACGTCT
25 GGTTCTCATTGGGTGGTATGCTGACAATTGGTTCAAGATCTACGACCCTTCTATC
AACTGCACAGTGGATGAGATGACTGAGGCGGTGGAGGGCCACATCACAACCTGAG
ATTGTCATGCTGAATCCTGCCAATAACCCGCAGCATTTCACACATGACATCCCAGG
AATTTGTGGAGAACTAACCAAGCGACTGAAAAGACACCCTGAGGAGACAGGA
GGCTTCCAGGAGGCACCGCTGGCCTATGATGCCATCTGGGCCTTGGCACTGGCCC
30 TGAACAAGACATCTGGAGGAGGCGGCCGTTCTGGTGTGCGCCTGGAGGACTTCA
ACTACAACAACCAGACCATTACCGACCAAATCTACCGGGCAATGAACTCTTCGTC
CTTTGAGGGTGTCTCTGGCCATGTGGTGTGTTGATGCCAGCGGCTCTCGGATGGCA
TGGACGCTTATCGAGCAGCTTCAGGGTGGCAGCTACAAGAAGATTGGCTACTAT
GACAGCACCAAGGATGATCTTTCCTGGTCCAAAACAGATAAATGGATTGGAGGG
35 TCCCCCCCAGCTGACCAGACCCTGGTCATCAAGACATTCCGCTTCCTGTACAGA
AACTCTTTATCTCCGTCTCAGTTCTCTCCAGCCTGGGCATTGTCCTAGCTGTTGTC
TGTCTGTCTTTAACATCTACAACCTCACATGTCCGTTATATCCAGAACTCACAGCC
CAACCTGAACAACCTGACTGCTGTGGGCTGCTCACTGGCTTTAGCTGCTGTCTTC
CCCCTGGGGCTCGATGGTTACCACATTGGGAGGAACCAGTTTCCTTTCTGCTGCC
40 AGGCCCGCCTCTGGCTCCTGGGCCTGGGCTTTAGTCTGGGCTACGGTTCATGTT
CACCAAGATTTGGTGGGTCCACACGGTCTTCACAAAGAAGGAAGAAAAGAAGGA
GTGGAGGAAGACTCTGGAACCCTGGAAGCTGTATGCCACAGTGGGCCTGCTGGT
GGGCATGGATGTCCTCACTCTCGCCATCTGGCAGATCGTGGACCCTCTGCACCGG
ACCATTGAGACATTTGCCAAGGAGGAACCTAAGGAAGATATTGACGTCTCTATTC
45 TGCCCCAGCTGGAGCATTGCAGCTCCAGGAAGATGAATACATGGCTTGGCATTTC
CTATGGTTACAAGGGGCTGCTGCTGCTGCTGGGAATCTTCCTTGCTTATGAGACC
AAGAGTGTGTCCACTGAGAAGATCAATGATCACCGGGCTGTGGGCATGGCTATC
TACAATGTGGCAGTCCTGTGCCTCATCACTGCTCCTGTACCATGATTCTGTCCAG
CCAGCAGGATGCAGCCTTTGCCTTTGCCTCTCTTGCCATAGTTTTCTCCTCCTATA

TCACTCTTGTTGTGCTCTTTGTGCCCAAGATGCGCAGGCTGATCACCCGAGGGGA
 ATGGCAGTCGGAGGCGCAGGACACCATGAAGACAGGGTCATCGACCAACAACA
 ACGAGGAGGAGAAGTCCCGGCTGTTGGAGAAGGAGAACCGTGAACTGGAAAAG
 ATCATTGCTGAGAAAAGAGGAGCGTGTCTCTGAACTGCGCCATCAACTCCAGTCTC
 5 GGCAGCAGCTCCGCTCCCGGCGCCACCCACCGACACCCCCAGAACCCTCTGGGG
 GCCTGCCCAGGGGACCCCCCTGAGCCCCCGACCGGCTTAGCTGTGATGGGAGTC
 GAGTGCATTTGCTTTATAAGTGAGGGTAGGGTGAGGGAGGACAGGCCAGTAGGG
 GGAGGGAAAGGGAGAGGGGAAGGGCAGGGGACTCAGGAAGCAGGGGGTCCCCA
 TCCCCAGCTGGGAAGAACATGCTATCCAATCTCATCTCTTGTAATACATGTCCC
 10 CCTGTGAGTTCTGGGCTGATTTGGGTCTCTCATACCTCTGGGAAACAGACCTTTTT
 CTCTCTTACTGCTTCATGTAATTTTGATCACCTCTTCACAATTTAGTTTCGTACCTG
 GCTTGAAGCTGCTCACTGCTCACACGCTGCCTCCTCAGCAGCCTCACTGCATCTTT
 CTCTTCCCATGCAACACCCTCTTCTAGTTACACGCGCAACCCCTGCAGCTCCTCTG
 CCTTTGTGCTCTGTTCTGTCCAGCAGGGGTCTCCCAACAAGTGCTCTTTCCACCC
 15 CCAAAGGGGCCTCTCCTTTTCTCCACTGTCATAATCTCTTTCCATCTTACTTGCCC
 TTCTATACTTTCTCACATGTGGCTCCCCCTGAATTTTGCTTCCTTTGGGAGCTCATT
 CTTTTGCCAAAGGCTCACATGCTCCTTGCTCTGCTCTGTGCACTCACGCTCAGCA
 CACATGCATCCTCCCCCTCTCCTGCGTGTGCCCACTGAACATGCTCATGTGTACAC
 ACGCTTTTCCCGTATGCTTTCTTCATGTTCAAGTCACATGTGCTCTCGGGTGCCCTG
 20 CATTACAGCTACGTGTGCCCTCTCATGGTCATGGGTCTGCCCTTGAGCGTGTTT
 GGGTAGGCATGTGCAATTTGTCTAGCATGCTGAGTCATGTCTTTCCTATTTGCACA
 CGTGCAATGTTTATCATGTACTTTCCCTGTGTACCCCTCCATGTACCTTGTGTACTTT
 CTTCCTTAAATCATGGTATTTCTTCTGACAGAGCCATATGTACCCCTACCCTGGAGA
 TTGTTATGCACTTTTCCCCAATTCATGTTTGGTGGGGCCATCCACACCCTCTCTCT
 25 GTCACAGAATCTCCATTTCTGCTCAGATTCCCCCATCTCCATTGCATTTCATGTAC
 TACCCTCAGTCTACACTCACAATCATCTTCTCCCAAGACTGCTCCCTTTTGTTTTG
 TGTTTTTTTGAGGGGAATTAAGGAAAAATAAGTGGGGGCAGGTTTGGAGAGCTG
 CTTCCAGTGGATAGTTGATGAGAATCCTGACCAAAGGAAGGCACCCTTGACTGTT
 GGGATAGACAGATGGACCTATGGGGTGGGAGGTGGTGTCCCTTTCACACTGTGG
 30 TGTCTCTTGGGGAAGGATCTCCCCGAATCTCAATAAACCAGTGAACAGTGTGAAA
 AAACAAAACAAGGGGCGGCCGCCGATTATTG

SEQ ID NO: 597

>20284 BLOOD 1039926.6 X02488 g179595 Human collagen alpha-2 type I mRNA,

35 complete cds, clone pHCOL2A1.0
 GTGTCCCATAGTGTTCCAAACCTTGGAAAGGGCGGGGGAGGGCGGGAGGATGCG
 GAGGGCGGAGGTATGCAGACAACGAGTCAGAGTTTCCCCTTGAAAGCTCAAAAG
 TGTCCACGTCCTCAAAAAGAATGGAACCAATTTAAGAAGCCAGCCCCGTGGCCA
 CGTCCCTTCCCCCATTTCGCTCCCTCCTCTGCGCCCCCGCAGGCTCCTCCCAGCTGT
 40 GGCTGCCCCGGGCCCCAGCCCCAGCCCTCCCATTTGGTGGAGGCCCTTTTGGAGGC
 ACCCTAGGGCCAGGGAAACTTTTGCCGTATAAATAGGGCAGATCCGGGCTTTATT
 ATTTTAGCACACGGCAGCAGGAGGTTTCGGCTAAGTTGGAGGTAAGTGGCCACG
 ACTGCATGCCCGCGCCCGCCAGGTGATACCTCCGCGGCTGACCCAGGGGGCTCTG
 CGACACAAGGAGTCTGCATGTCTAAGTGCTAGACATGCTCAGCTTTGTGGATACG
 45 CGGACTTTGTTGCTGCTTGCAGTAACCTTATGCCTAGCAACATGCCAATCTTTACA
 AGAGGAAACTGTAAGAAAGGGCCCAGCCGGAGATAGAGGACCACGTGGAGAAA
 GGGGTCCACCAGGCCCCCCAGGCAGAGATGGTGAAGATGGTCCCACAGGCCCTC
 CTGGTCCACCTGGTCTCCTGGCCCCCTGGTCTCGGTGGGAACTTTGCTGCTCAG
 TATGATGGAAAAGGAGTTGGACTTGGCCCTGGACCAATGGGCTTAATGGGACCT

AGAGGCCACCTGGTGCAGCTGGAGCCCCAGGCCCTCAAGGTTTCCAAGGACCT
GCTGGTGAGCCTGGTGAACCTGGTCAAACCTGGTCCTGCAGGTGCTCGTGGTCCAG
CTGGCCCTCCTGGCAAGGCTGGTGAAGATGGTCACCCTGGGAAAACCCGGACGA
CCTGGTGAGAGAGGAGTTGTTGGACCACAGGGTGCTCGTGGTTTCCCTGGAACCTC
5 CTGGACTTCCTGGCTTCAAAGGCATTAGGGGACACAATGGTCTGGATGGATTGAA
GGGACAGCCCGGTGCTCCTGGTGTGAAGGGTGAACCTGGTGCCCTGGTGAAAA
TGGAACCTCCAGGTCAAACAGGAGCCCGTGGGCTTCCTGGTGAGAGAGGACGTGT
TGGTGCCCTGGGCCAGCTGGTGCCCGTGGCAGTGATGGAAGTGTGGGTCCCGTG
GGTCTGCTGGTCCCATTGGGTCTGCTGGCCCTCCAGGCTTCCCAGGTGCCCTG
10 GCCCCAAGGGTGAAATTGGAGCTGTTGGTAACGCTGGTCCTGCTGGTCCCGCCGG
TCCCGTGGTGAAGTGGGTCTTCCAGGCCTCTCCGGCCCCGTTGGACCTCCTGGT
AATCCTGGAGCAAACGGCCTTACTGGTGCCAAGGGTGCTGCTGGCCTTCCCGGCG
TTGCTGGGGCTCCCGGCCTCCCTGGACCCCGCGGTATTCCTGGCCCTGTTGGTGCT
GCCGGTGCTACTGGTGCCAGAGGACTTGTGGTGAGCCTGGTCCAGCTGGCTCCA
15 AAGGAGAGAGCGGTAACAAGGGTGAGCCCGGCTCTGCTTGGGCCCCAAGGTCCT
CCTGGTCCCAGTGGTGAAGAAGGAAAGAGAGGCCCTAATGGGGAAGCTGGATCT
GCCGGCCCTCCAGGACCTCCTGGGCTGAGAGGTAGTCCTGGTTCTCGTGGTCTTC
CTGGAGCTGATGGCAGAGCTGGCGTCATGGGCCCTCCTGGTAGTCGTGGTGCAA
GTGGCCCTGCTGGAGTCCGAGGACCTAATGGAGATGCTGGTCGCCCTGGGGAGC
20 CTGGTCTCATGGGACCCAGAGGTCTTCTGGTTCCCCTGGAAATATCGGCCCCGC
TGGAAGAAGGTCTGTGCGCCTCCCTGGCATCGACGGCAGGCCTGGCCCAAT
TGGCCAGCTGGAGCAAGAGGAGAGCCTGGCAACATGGATTCCCTGGAGCCAA
AGGCCCACTGGTGATCCTGGCAAAAAGGGTGATAAAGGTGATGCTGGTCTTGCT
GGTGCTGGGGTGCTCCAGGTGCTGATGGAAACAATGGTGCTCAGGGACCTCCTG
25 GACCACAGGGTGTTCAAGGTGGAAAAGGTGAACAGGGTCCCGCTGGTCTCCAG
GCTTCCAGGGTCTGCCTGGCCCTCAGGTCCCGCTGGTGAAGTTGGCAAACAGG
AGAAAGGGTCTCCATGGTGAGTTTGGTCTCCCTGGTCCTGCTGGTCCAAGAGGG
GAACGCGGTCCCCCAGGTGAGAGTGGTGCTGCCGGTCTACTGGTCCTATTGGAA
GCCGAGGTCTTCTGGACCCCCAGGGCCTGATGGAAACAAGGGTGAACCTGGTG
30 TGGTTGGTGCTGTGGGCACTGCTGGTCCATCTGGTCCTAGTGGACTCCCAGGAGA
GAGGGGTGCTGCTGGCATACTGGAGGCAAGGGAGAAAAGGGTGAACCTGGTCT
CAGAGGTGAAATTGGTAACCCTGGCAGAGATGGTGCTCGTGGTGCTCCTGGTGCT
GTAGGTGCCCTGGTCTGCTGGAGCCACAGGTGACCGGGGCGAAGCTGGGGCT
GCTGGTCTGCTGGTCTGCTGGTCTCGGGGAAGCCCTGGTGAACGTGGTGAGG
35 TCGGTCTGCTGGCCCCAATGGATTTGCTGGTCTGCTGGTGCTGCTGGTCAACCT
GGTGCTAAAGGAGAAAAGAGGAGCCAAAGGGCCTAAGGGTGAAAACGGTGTTGT
TGGTCCCACAGGCCCGTGGAGCTGCTGGCCAGCTGGTCAAATGGTCCCCC
GGTCTGCTGGAAGTCGTGGTGATGGAGGCCCCCTGGTATGACTGGTTTCCCTG
GTGCTGCTGGACGGAAGTGGTCCCCAGGACCTCTGGTATTTCTGGCCCTCCTGG
40 TCCCCCTGGTCTGCTGGGAAAGAAGGGCTTCGTGGTCCTCGTGGTGACCAAGGT
CCAGTTGGCCGAACCTGGAGAAGTAGGTGCAGTTGGTCCCCCTGGCTTCGCTGGTG
AGAAGGGTCCCTCTGGAGAGGCTGGTACTGCTGGACCTCCTGGCACTCCAGGTCC
TCAGGGTCTTCTTGGTGCTCCTGGTATTCTGGGTCTCCCTGGCTCGAGAGGTGAA
CGTGGTCTACCAGGTGTTGCTGGTGCTGTGGGTGAACCTGGTCTCTTGGCATTG
45 CCGGCCCTCCTGGGGCCCGTGGTCTCCTGGTGCTGTGGGTAGTCCTGGAGTCAA
CGGTGCTCCTGGTGAAGCTGGTCGTGATGGCAACCCTGGGAACGATGGTCCCCCA
GGTCGCGATGGTCAACCCGGACACAAGGGAGAGCGCGGTTACCCTGGCAATATT
GGTCCCGTTGGTGCTGCAGGTGCACCTGGTCTCATGGCCCCGTGGGTCTGCTG
GCAAACATGGAAACCGTGGTGAAACTGGTCCTTCTGGTCTGTTGGTCTGCTGG

TGCTGTTGGCCCAAGAGGTCCTAGTGGCCCAACAAGGCATTTCGTGGCGATAAAGG
AGAGCCCGGTGAAAAGGGGCCAGAGGTCTTCCTGGCTTAAAGGGACACAATGG
ATTGCAAGGTCTGCCTGGTATCGCTGGTCACCATGGTGATCAAGGTGCTCCTGGC
TCCGTGGGTCTGCTGGTCCTAGGGGCCCTGCTGGTCCTTCTGGCCCTGCTGGAA
5 AAGATGGTCGCACTGGACATCCTGGTACAGTTGGACCTGCTGGCATTTCGAGGCCC
TCAGGGTCACCAAGGCCCTGCTGGCCCCCTGGTCCCCCTGGCCCTCCTGGACCT
CCAGGTGTAAGCGGTGGTGGTTATGACTTTGGTTACGATGGAGACTTCTACAGGG
CTGACCAGCCTCGCTCAGCACCTTCTCTCAGACCCAAGGACTATGAAGTTGATGC
TACTCTGAAGTCTCTCAACAACCAGATTGAGACCCTTCTTACTCCTGAAGGCTCT
10 AGAAAGAACCCAGCTCGCACATGCCGTGACTTGAGACTCAGCCACCCAGAGTGG
AGCAGTGGTTACTACTGGATTGACCCTAACCAAGGGATGCACTATGGATGCTATC
AAAGTATACTGTGATTTCTCTACTGGCGAAACCTGTATCCGGGCCCAACCTGAAA
ACATCCCAGCCAAGAAGTGGTATAGGAGCTCCAAGGACAAGAAACACGTCTGGC
TAGGAGAACTATCAATGCTGGCAGCCAGTTTGAATATAATGTAGAAGGAGTGA
15 CTTCCAAGGAAATGGCTACCCAACCTTGCCCTCATGCGCCTGCTGGCCAACCTATGC
CTCTCAGAACATCACCTACCACTGCAAGAACAGCATTGCATACATGGATGAGGA
GACTGGCAACCTGAAAAAGGCTGTCATTCTACAGGGCTCTAATGATGTTGAACCT
GTTGCTGAGGGCAACAGCAGGTTCACTTACACTGTTCTTGTAGATGGCTGCTCTA
AAAAGACAAATGAATGGGGAAAGACAATCATTGAATACAAAACAAATAAGCCA
20 TCACGCCTGCCCTTCCTTGATATTGCACCTTTGGACATCGGTGGTGCTGACCAGG
AATTCTTTGTGGACATTGGCCCCAGTCTGTTTCAAATAAATGAACTCAATCTAAAT
TAAAAAAGAAAGAAATTTGAAAAAACTTTCTCTTTGCCATTTCCTTCTTCTTT
TTAACTGAAAGCTGAATCCTTCGATTTCTTCTGACATCTACTTGCTTAAATTGTF
GGCAAAAGAGAAAAAGAAGGATTGATCAGAGCATTGTGCAATACAGTTTCAATTA
25 ACTCCTTCCCCCGCTCCCCCAAAAATTTGAATTTTTTTTTTCAACACTCTTACACCT
GTTATGGAAAATGTCAACCTTTGTAAGAAAACCAAAATAAAAAATTGAAAAATAA
AAACCATAAACATTTGCACCACTTGTGGCTTTTGAATATCTTCCACAGAGGGAAG
TTTAAACCCAAACTTCCAAAGGTTTAACTACCTCAAACACTTTCCCATGAGT
GTGATCCACATTGTTAGGTGCTGACCTAGACAGAGATGAACTGAGGTCCTTGTTT
30 TGTTTTGTTTATAATAACAAAGGTGCTAATTAATAGTATTTTCAAGATACTTGAAGAA
TGTTGATGGTGCTAGAAGAATTTGAGAAGAAATACTCCTGTATTGAGTTGTATCG
TGTGGTGTATTTTTTAAAAAATTTGATTTAGCATTTCATATTTTCCATCTTATTCCCA
ATTAAGATATGCAGATTATTTGCCCAAAGTTGTCCTCTTCTTCAAGATTTCAGCATT
TGTTCTTTGCCAGTCTCATTTTTCATCTTCTTCCATGGTTCCACAGAAGCTTTGTTTC
35 TTGGGCAAGCAGAAAAATTAAATTGTACCTATTTAAACATCTCACATATACAAAA
TAGGTACAATGTTTAAATAAATTGTGAAAAAAATGAAATAAAGCATGTTTGGTTT
TCCAAAAGAAAAAAGGGCG

SEQ ID NO: 598

40 >20804 BLOOD 1095729.1 D29990 g484049 Human mRNA for cationic amino acid
transporter 2, complete cds. 0

GAATTCGGCTCTCAAATTTTCTATAGAATCAAGATAGAACCTTTAGATGTCTCA
CCACGAAACTAGCAACTGGAATGAAGATAGAAACAAGTGGTTATAACTCAGACA
AACTAATTTGTCGAGGGTTTATTGGAACACCTGCCCCACCGGTTTGCGACANAAG
45 TTTCTCCTGTCGCCTTCGTCAGACGTCAGAATGATTCCTTGCAGAGCCGCGCTGA
CCTTTGCCCGATGTCTGATCCGGAGAAAAATCGTGACCCTGGACAGTCTAGAAGA
CACCAAATTATGCCGCTGCTTATCCACCATGGACCTCATTGCCCTGGGCGTTGGA
AGCACCTTGGGGCCGGGGTTTATGTCCTCGCTGGGGAGGTGGCCAAGGCAGAC
TCGGGCCCCAGCATCGTGGTGTCTTCCTCATTGCTGCCCTGGCTTCAGTGATGGC

TGGCCTCTGCTATGCCGAATTTGGGGCCCGTGTTCCCAAGACGGGGTCTGCATAT
TTGTACACCTACGTGACTGTCGGAGAGCTGTGGGCCTTCATCACTGGCTGGAATC
TCATTTTATCGTATGTGATAGGTACATCAAGTGTGCAAGAGCCTGGAGTGGCAC
CTTTGATGAACTTCTTAGCAAACAGATTGGTCAGTTTTTGGAGACATACTTCAGA
5 ATGAATTACACTGGTCTTGCAGAATATCCCGATTTTTTTGCTGTGTGCCTTATATT
ACTTCTAGCAGGTCTTTTGTCTTTTGGAGTAAAAGAGTCTGCTTGGGTGAATAAA
GTCTTCACAGCTGTTAATATTCTCGTCCTTCTGTTTGTGATGGTTGCTGGGTTTGT
GAAAGGAAATGTGGCAAACCTGGAAGATTAGTGAAGAGTTTCTCAAAAATATATC
AGCAAGTGCCAGAGAGCCACCTTCTGAAAACGGAACAAGTATCTATGGGGCTGG
10 TGGCTTTATGCCTTATGGCTTTACGGGAACGTTGGCTGGTGCTGCAACTTGCTTTT
ATGCCTTTGTGGGATTTGACTGCATTGCAACAACCTGGTGAAGAAGTTCGGAATCC
CCAGAAAGCTATTCCCATTGGAATTGTGACGTCTTTGCTTGTTTGTCTTTATGGCCT
ATTTTGGGGTCTCTGCAGCTTTAACACTTATGATGCCGTACTACCTCCTCGATGAA
AAAAGCCCCCTTCCTGTAGCGTTTGAATATGTGGGATGGGGTCCTGCCAAATATG
15 TCGTCGCAGCTGGTTCTCTCTGCGCCTTGTCAACAAGTCTTCTTGGATCCATTTTC
CCAATGCCTCGTGTAATCTATGCTATGGCGGAGGATGGGTTGCTTTTCAAATGTC
TAGCTCAAATCAATTCCAAAACGAAGACACCAATAATTGCTACTTTATCATCGGG
TGCAGTGGCAGCTTTGATGGCCTTTCTGTTTGACCTGAAGGCGCTTGTGGACATG
ATGTCCATTGGCACACTCATGGCCTACTCTCTGGTGGCAGCCTGTGTTCTCATCCT
20 CAGGTACCAGCCTGGCTTATCTTACGACCAGCCCAAATGTTCTCCTGAGAAAGAT
GGTCTGGGATCGTCTCCAGGGTAACCTCGAAGAGTGAGTCCCAGGTCACCATGC
CTGAGAGACAGGGCTTCAGCATGCGGAACCTCTTCTGCCCCFCCCTCTGCCAAC
CTGAGCAGTCAGCTTCTCTCGTGAGCTTTCTGGTAGGATTCTTAGCTTCTCGTGT
CTGGGCTGAGTGTCTTGACCACTTACGGAGTTTCATGCCATCACCAGGCTGGAGGC
25 CTGGAGCCTCGCTCTCCTCGCGCTGTTTCTTGTTCTCTTCGTTGCCATCGTTCTCAC
CATCTGGAGGCAGCCCCAGAATCAGCAAAAAGTAGCCTTCATGGTTCCATTCTTA
CCATTTTTGCCAGCGTTCAGCATCTTGGTGAACATTTACTTGATGGTCCAGTTAAG
TGCAGACACTTGGGTCAGATTCAGCATTTGGATGGCAATTGGCTTCCTGATTTAC
TTTTCTTATGGCATTAGACACAGCCTGGAGGGTCATCTGAGAGATGAAAACAATG
30 AAGAAGATGCTTATCCAGACAACGTTTCATGCAGCAGCAGAAGAAAAATCTGCCA
TTCAAGCAAATGACCATCACCCAAGAAATCTCAGTTCACCTTTCATATTCCATGA
AAAGACAAGTGAATTCTAACACTTGCAGGAGCAGAGCTGGTCATCGTCTTAGCA
TACATATCCTACACTGAGTAAACCGTAACGGGATGTATCAGCATGCTGGGTTGT
CATGGGTTTGCTGCATACATAGTTACCCCTAATTTATACTTACTCATCTGGACAGC
35 ATCTCCTCAGATGGTGAATTATGTGCACGGGGAAACCTCCTGAGTGGAAGTTTCA
TTCATCAGTGATGAATAGCCCCCAAACAGTGGGANNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNGCTTGGGAACATGAGTGTTACAAGTTAGCTGGTGT
TTTACTATTATTGTGTTACATTTTCCAGTGTCTCATTAATCGGTGGCATATACT
GCACATACTGAAATAGAGCGAAATCACTGAATGTAAAGAGGTTTCATCTAT
40

SEQ ID NO: 599

>20816 BLOOD 1102307.12 M14058 g179643 Human complement C1r mRNA, complete
cds. 0

CTTTTGTATGCAAATAGTTCATTCCCTCCAACATTCTCCGGGAATGGTCCCCC
45 CTCCACTCCACAGAAAACCTCCCTCCCTGCTGTGCATGACGCGGGCTCCCTCT
GCACACAGTGCACGAAGACGCTGTGGGAGAGCCCAGGATTCAACACGGGCCTT
GAGAAATGTGGCTCTTGTACCTCCTGGTGGCGGCCCTGTTCTGCAGGGCAGGAGG
CTCCATTCCCATCCCTCAGAAGTTATTTGGGGAGGTGACTTCCCTCTGTTCCCCA
AGCCTTACCCCAACAACCTTTGAAACAACCACTGTGATCACAGTCCCCACGGGATA

CAGGGTGAAGCTCGTCTTCCAGCAGTTTGACCTGGAGCCTTCTGAAGGCTGCTTC
TATGATTATGTCAAGATCTCTGCTGATAAGAAAAGCCTGGGGAGGTTCTGTGGGC
AACTGGGTTCTCCACTGGGCAACCCCCCGGAAAGAAGGAATTTATGTCCCAAG
GGAACAAGATGCTGCTGACCTTCCACACAGACTTCTCCAACGAGGAGAATGGGA
5 CCATCATGTTCTACAAGGGCTTCCTGGCCTACTACCAAGCTGTGGACCTTGATGA
ATGTGCTTCCCGGAGCAAATCAGGGGAGGAGGATCCCCAGCCCCAGTGCCAGCA
CCTGTGTCACAACCTACGTTGGAGGCTACTTCTGTTTCTGCCGTCCAGGCTATGAG
CTTCAGAAAGACAGGCATTCTTGCCAGGCTGAGTGCAGCAGCGAGCTGTACACG
GAGGCATCAGGCTACATCTCCAGCCTGGAGTACCCTCGGTCTACCCCCCTGACC
10 TGCCTGCAACTACAGCATCCGGGTGGAGCGGGGCCTCACCCTGCACCTCAAGTT
CCTGGAGCCTTTTGATATTGATGACCACCAGCAAGTACACTGCCCTATGACCAG
CTACAGATCTATGCCAACGGGAAGAACATTGGCGAGTTCTGTGGGAAGCAAAGG
CCCCCGACCTCGACACCAGCAGCAATGCTGTGGATCTGCTGTTCTTCACAGATG
AGTCGGGGGACAGCCGGGGGCTGGAAGCTGCGCTACACCACCGAGATCATCAAGT
15 GCCCCAGCCCAAGACCTAGACGAGTTCACCATCATCCAGAACCTGCAGCCTCA
GTACCAGTTCCGTGACTACTTCATTGCTACCTGCAAGCAAGGCTACCAGCTCATA
GAGGGGAACCAAGGTGCTGCATTCTTCACAGCTGTCTGCCAGGATGATGGCACGT
GGCATCGTGCCATGCCCAGATGCAAGATCAAGGACTGTGGGCAGCCCCGAAACC
TGCCTAATGGTGACTTCCGTTACACCACCACAATGGGAGTGAACACCTACAAGGC
20 CCGTATCCAGTACTACTGCCATGAGCCATATTACAAGATGCAGACCAGAGCTGGC
AGCAGGGAGTCTGAGCAAGGGGTGTACACCTGCACAGCACAGGGGCATTTGGAAG
AATGAACAGAAGGGGAGAGAAGATTCCTCGGTGCTTGCCAGTGTGTGGGAAGCCC
GTGAACCCCGTGGAACAGAGGGCAGCGCATCATCGGAGGGGCAAAAAGCCAAGAT
GGGCAACTTCCCCTGGGAGGTGTGTAACCAATCCACGGGCACGGGGGCGGGGC
25 CCTGCTGGGGGACCGCTGGATCCTCACAGCTGCCACACCCTGTATCCCAAGGAA
CACGAAGCGCAAAGCAACGCCTCTTTGGATGTGTTCTGGGCCACACAAATGTG
GAAGAGCTCATGAAGCTAGGAAATCACCCCATCCGCAGGGTCAGCGTCCACCCG
GACTACCGTCAGGATGAGTCCTACAATTTTGAGGGGGACATCGCCCTGCTGGAGC
TGGAAAATAGTGTACCCCTGGGTCCCAACCTCCTCCCCATCTGCCTCCCTGACAA
30 CGATACCTTCTACGACCTGGGCTTGATGGGCTATGTCAGTGGCTTCGGGGTTCATG
GAGGAGAAGATTGCTCATGACCTCAGGTTTGTCCGTCTGCCCGTAGCTAATCCAC
AGGCCTGTGAGAACTGGCTCCGGGGAAAGAATAGGATGGATGTGTTCTCTCAAA
ACATGTTCTGTGCTGGACACCCATCTCTAAAGCAGGACGCCTGCCAGGGGGATA
GTGGGGGCGTTTTTGAAGTAAGGGACCCGAACACTGATCGCTGGGTGGCCACGG
35 GCATCGTGTCTGGGGCATCGGGTGCAGCAGGGGCTATGGCTTCTACACCAAAGT
GCTCAACTACGTGGACTGGATCAAGAAAGAGATGGAGGAGGAGGACTGAGCCC
AGAATTCAGTGGTTCGAATCCAGAGAGCAGTGTGGAAAAAAAAACAAAAA
CAACTGACCAGTTGTTGATAACCACTAAGAGTCTCTATTAAATTAAGTATGATGCAG
AAAGACCGTGTGTGAAATTCTCTTCTCTGTAGTCCCATGATGTACTTTACCTGAA
40 ACAACCCAAAGGGCCCCCTTTCTTTCTTCTGAGGATTGCAGAGGATATAGTTATCA
ATCTCTAGTTGTCACTTTCTCTTCCACTTTGATACCATTGGGTGATTGAATATAA
CTTTTCCAAATAAAGTTTTATGAGAAATGCCTTATATTTTGTATTTCTGTTTCTA
TTGCATGTAATAGACAACCTTTCTCCACATCAAACATCACCATGTNTTTTTATAAA
GTCACAGAATAAAATTTCTTGATATTGATGAAATTGTTCTTAAGCAAGGAATAC
45 CAATTTCCGCAACGTTGGATTGAGTCCCTTATGTCTTCTAAAAGCTATAGTTTAT
ACACTATTTTCAAGCTTAAATTGATTCTACAGGTTTAAAGTGTTGGAAAAAATTT
GTCTGAAACATTTTCATAATTTGTTTCCAGCATGAGGTATCTAAAGGATTTAGACC
AGAGGTCTAGATTAAATAACTCTATTTTAAACATTTTAAACCTTTTATTATTAAG

TTCTTTACATTAAAACCATTTNCTTTGTNTAACTTCTTCTTNCCATCATTGTTTAA
CTTGGGATTAANATTTNGTNTTTAGGTNGGGAAAANATNAGGGGCTTTTGT

SEQ ID NO: 600

- 5 >20825 BLOOD 1000084.27 AF022375 g3719220 Human vascular endothelial growth factor mRNA, complete cds. 0

AAGGCCCTTCGGGGCCGGCCACCCTTTCCTACTTCTCCCCGGACTCCTTGGTA
GTCTGTAGTGGGAGATCCTTGTGCCGTCCCTTCGCCTCCTTCACCGCCGCAGAC
CCCTTCAAGTTCTAGTCATGCGTGAGTGCATCTCCATCCACGTTGGCCAGGGCTG
10 GTGTCCAGATTGGGCAATGCCTGCTGGGAGCTCTACTGCCTGGAACACGGCATCC
AGCCCGATGGCCAGATGCCAAGTGACAAGACCATTGGGGGAGGAGATGATTCTT
TCAACACCTTCTTCAGTGAAACGGGTGCTGGCAAGCATGTGCCCCGGGCAGTGTT
TGTAAGCTTGGAAACCCACAGTCATTGATGAAGTTCGCACTGGCACTTACCGCCAG
CTCTTCCACCCTGAGCAACTCATCACAGGCAAGGAAGATGCTGCCAATAACTATG
15 CCGAGGGGCACTACACCATTGGCAAGGAGATCATTGACCTCGTGTGGACCGAA
TTCGCAAGCTGGCTGACCAGTGCACCGGTCTTCAGGGCTTCTTGGTTTTCCACAG
CTTTGGTGGGGGAACTGGTTCTGGGTTACCTCGCTGCTCATGGAACGTCTCTCA
GTTGATTATGGCAAGAAGTCCAAGCTGGAGTTCTCCATTTACCGGGCGCCCCAGG
TTTCCACAGCTGTAGTTGAGCCCTACAACCTCCATCCTCACCACCCACACCACCT
20 GGAGCACTCTGATTGTGCCTTCATGGTAGACAATGAGGCCATCTATGACATCTGT
CGTAGAAACCTCGATATCGAGCGCCCAACCTACACTAACCTTAACCGCCTTATTA
GGCAGATTGTGCTCTCCATCACTGCTTCCCTGAGATTGATGGAGCCCTGAATGTT
GACCTGACAGAATTCCAGACCAAGCTGGTGGCCCTAGCCCGGCATCCACTTCCCTCA
TGGCCACATATGCCCTGTCTCTGTCTGAGAAAGCCTACCATGAAGAGCTTCTG
25 TGTAGCAGAGATCACCAATGCTTGCTTTGAGCCAGCCAACCAGATGGTGAAATGT
GACCCTCGCCATGGTAAATACATGGCTTGCTGCCTGTTGTACCGTGGTGACGTGG
TTCCCAAAGATGTCAATGCTGCCATTGCCACCATCAAAACCAAGCGCAGCATCCA
GTTTGTGGATTGGTGGCCCACTGGCTTCAAGGTTGGCATCAACTACCAGCCTCCC
ACTGTGGTGCCTGGTGGAGACCTGGCCAAGGTACAGAGAGCTGTGTGCATGCTG
30 AGCAACACCACAGCCATTGCTGAGGCCTGGGCTCGCCTGGACCACAAGTTTGAC
CTGATGTATGCCAAGCGTGCCTTTGTTCACTGGTACGTGGGTGAGGGGATGGAGG
AAGGCGAGTTTTTCAGAGGCCCCTGAAGATATGGCTGCCCTTGAGAAGGATTATG
AGGAGGTTGGTGTGGATTCTGTTGAAGGAGAGGGTGAGGAAGAAGGAGAGGAA
TACTAATTATCCATTCTTTTGGCCCTGCAGCATGTCATGCTCCCAGAATTTTCAGC
35 TTCAGCTTAAGTACAGACGTTAAAGCTTTCTGGTTAGATTGTTTTCACTTGGTGA
TCATGTCTTTTCCATGTGTACCTGTAATATTTTCCATCATATCTCAAAGTAAACT
TTGTCGTTGTTTAAAAATAAATATGTACTACGGAATATCTCGAAAACTGCACTA
GAGACAAAGACGTGATGTTAATATCTTTTCCCCACAATTATTACGGATAAACAGT
AGCACCAATAAATAAATGATAACAAATATTTAAATTAATAAAGGAGAGAGATTT
40 AGTATGTAGAATTCTCTATTTTCTTGTGTTTTGTTTTACATATAAAAAACAGAAT
AGCAATGTCTATTTTATCAGAATCACATATATACATAAACATATGTATATATATA
TACACACAAATACAAGTTGCCAAATATATATATAGTATGTAGATGTATATTGAAA
CCTTATTTCAAAGGAATGTGTGCTGGGGAGCCAGGGGATCGGGGAGGGCAGAGC
TGAGTGTTAGCAAAATTAATATCTGTTCAAGATAAGCTAGTGAAGTGTACCGAT
45 CAGGGAGAGAGAGATTGGAAACATGAATTTTATATACAAAAACCGGTACAAATA
AGAGAGCAAGAGAGAGCAAAAGATACATCTCATAAATAGTTGAAATTAATATT
AACCAAGAATACTGAAAAAAAACCCCTACTCTTTAATTAATTAAGTGTTTTAAAT
TTCTAATTAATAAAGGGATATTAATAAGTACCGTATATAAAACACTTTCTCTTTT
CTCTGCCTCCACAATGGGCACGTGGATCCTGCCCTGTCTCTCTGGTCCTTCCCTTC

CCTTCCCGAGGCACAGAGAGACAGGGCAGGATCCACGTGCCCATTTGTGGAGGGA
AGGGAAGGACCAGGGGATGGAGGAAGGTCAACCACTCACACACACAACCAG
GTCTCCTGGGGGGACAGAACTAGTGGTTTCAATGGTGTGAGGACATAGGTCCTTT
TAGGCTGCATCCCAGGAAGGGGAGCAGGAAGAGGATGAGGGCGAGTCCCAGGA
5 AGGGGAGCTGTCATGGGCTGCTTCTTCCAACAATGTGTCTCTTCTCTCGCCGGG
ACATCTGCCAGTGGTCTCCTGGGCAACTCAGAAGCAGGTGAGAGTAAGCGAAGG
CCGCCCAGGCTCCTGAATCTTCCAGGCAGTGCCCCTGGGGGCGAGATGCGCGTGC
AGCATGTGGAGGGAATCCCCAAAGCACAGCAATGTCTGAAGCTCCCCAACTC
CTGGTCAGAGCCGGTGTCTCATCCCTGTACCTGTGATCTGTCTTTCTGTCCGTCT
10 GACCTGGGGTAGAGAGGCTCAGCGCCAGGGCTGGGTTTGTGCGGTGTTCCCAAAA
CTGGGTCATATTTGCCCCCATGCCCTGGCCTTGACATTCTGGGCAGGGGAGAG
GACCCTGGCCCCACCAAGTGGGACAAAAAAGATCATGCCAGAGTCTCTCATC
TCCTCCTCTTCCCTGTGAGGATCTGAGTGGGAACATTCCCCTCCCAACTCAAGTCC
ACAGCAGTCAAATACATCCAGTGAAGACACCAATAACATTAGCACTGTTAATTTA
15 AAAAAAGAATATATATATTTTATATATATAAAATAGAGATATTTATTTTATATA
TATATAATATATATATATATAAATGTATGTATGTGGGTGGGTGTGTCTACAGGAA
TCCCAGAAATAAACTCTCTAATCTTCCGGGCTCGGTGATTTAGCAGCAAGAAAA
ATAAAATGGCGAATCCAATTCCAAGAGGGACCGTGCTGGGTCACCCGCCCGGGA
ATGCTTCCGCCGGAGTCTCGCCCTCCGGACCCAAAGTGCTCTGCGCAGAGTCTCC
20 TCTTCCTTCATTTAGGTTTCTGGATTAAGGACTGTTCTGTGATGGTGATGGTGT
GGTGGCGGCAGCGTGGTTTCTGTATCGATCGTTCTGTATCAGTCTTTCCTGGTGAG
AGATGTGGTTCGGAAACCCTGAGGGAGGCTCCTTCCCTCCTGCCCGGCTCACCGC
CTCGGCTTGTCATCTGCAAGTACGTTEGTTTAACTCAAGCTGCCTCGCCTTGCA
ACGCGAGTCTGTGTTTGCAGGAACAATTAACACGTCTGCGGATCTTGTACAAAC
25 AAATGCTTTCTCCGCTCTGAGCAAGGCCACAGGGATTTTCTTGTCTTGCTCTATC
TTTCTTTGGTCTGCATTCACATTTGTTGTGCTGTAGGAAGCTCATCTCTCCTATGT
GCTGGCCTTGGTGAGGTTTGATCCGCATAATCTGCATGGTGATGTTGGACTCCTC
AGTGGGCACACACTCCAGGCCCTCGTCATTGCAGCAGCCCCCGCATCGCATCAGG
GGCACACAGGATGGCTTGAAGATGTACTCGATCTCATCAGGGTACTCCTGGAAG
30 ATGTCCACCAGGGTCTCGATTGGATGGCAGTAGCTGCGCTGATAGACATCCATGA
ACTTCACTTCTCGTATGATTCTGCCCTCCTCCTTCTGCCATGGGTGCAGCCTGG
GACCACTTGGCATGGTGGAGGTAGAGCAGCAAGGCAAGGCTCCAATGCACCCAA
GACAGCAGAAAGTTCATGGTTTCGGAGGCCCGACCGGGGCGGCGCGGCTCGCG
CTCCCTCTCGGCTCGGGCTGTGGGGCGGCCCGCTCTCCTCGGCGCCTCGGCGAG
35 CTACTCTTCTCCCCGGCCCGAGGCCCGGGCCAGGGCCTGGGGAGCGCGCGCGG
CTGGAGCACTGTCTGCGCACACCGCCGCTCACCCGTCCATGAGCCCGGCTTCCG
AGCGCCGAGTCGCCACTGCGGCCCCCTCTCCTCTTCTTCTTCTTCTCCTCCC
CCTCCTCCGGCTGCGGCTCCTCCCGGCCCGAGCTAGCACTTCTCGCGGCTCCGCT
CGGCTCGGCTTCCCCCGCGCGGACCACGGCTCCTCCGAAGCGAGAACAGCCAG
40 AAGTTGGACGAAAAGTTTCAGTGCGACGCCGCGAGCCCCGACCCCTCCACCC
GCCTCCGGGCGCGGGCTCCGGCCCCTGCCGCGGCTCGCCGCCGCGTCCACTGTC
CGCCGCCGGCCGGGGAGGAGGTGGTAGCTGGGGCTGGGGGCGGNNNNNNNNNN
NNNNNNNNNNNNCGCGACTGGTCACTGCGGGATCCCAAGGGGGAGGGCTCAC
GCCGCGCTCCGGCGGTACCCCCAAAAGCAGGTCACTCACTTTGCCCTGTGCT
45 TTCGCTGCTCGCACGCCCGCGCGCTCTCTTGACCCCGTCTCTCTTCTCCTCGACT
TCTCTCTGGAGCTCTTGCTACCTCTTCTCTTCTGCTGGTTTCCAAAATCCACA
GTGATTTGGGGAAGTAGAGCAATCTCCCCAAGCCGTCGGCCCGATTCAAGTGGG
GAATGGCAAGCAAAAATAAATTAACGAGAAACAATACAGTTTTAAAAAAA
ATGTTTAAGAAAAAAGAAGAGGGATAAAACCCGGATCAATGAATATCAAATTCC

AGCACCGAGCGCCCTGGCCGGTGAGTCCGCTGACCGGTCCACCTAACCGCTGCG
CCTCCCGACAGAGCGCTGGTGCTAGCCCCAGCGCCACGACCTCCGAGCTACCCG
GCTGCCCCAAG

5 SEQ ID NO: 601

>20881 BLOOD GB_R98877 gi|985478|gb|R98877|R98877 yq67f04.r1 Soares fetal liver
spleen 1NFLS Homo sapiens cDNA clone IMAGE:200863 5' similar to contains Alu
repetitive element;; mRNA sequence [Homo sapiens]

10 GCTTTTATACACAACGTTTTTGTAGGCATCACAGTTTTGCAACCTCTGCTCCAAA
GAGAAACATAGAATGAGTTTTCTTTCTTTTTTTTTTTTGGAGTCAGAGTCTCGC
TCTCTTGTCCAGGNTGGAGTGCAATAGCGGATCTGGGCTCACTGCAACCTCCGC
CTCCCTGGTTCAAGCAATTCTCCTGCCTGCCTCCTGAGTAGCTGGGATTACAGG
CGTGTGTACACACGCTTCGGCTAATTTTTGTATTTTATAGTAGAGGCAGGGTTTCAC
CATGTCAAGCTGGTTCTTNGGACTCCCTGACGTCGTGATCCACCCGCCTTNGCCTT
15 CCCAAAGTACTGGGGATTACAGGTNTGACATCTTTTNGCCCGNTCCGTTTTTCTTN
AAAGTNGAGGCTTTAAATTTCTNGAACTCTTAGGTGNATTTTCAT

SEQ ID NO: 602

>20921 BLOOD 478620.65 S62138 g386158 TLS/CHOP=hybrid gene {translocation
breakpoint} [Human, myxoid liposarcomas cells, mRNA Mutant, 1682 nt]. 0

20 GAATTCCAGGCGTCGGTGCTCAGCGGTGTTGGAACCTTCGTTGGCTTGCTTGCCTG
TGGGGCGGTGCGCGGACATGGGCTCAAAGCGGTAGATTATACCCAACAAGCAACC
CAAAGCTATGGGGCCTACCCACCCAGCCCGGGCAGGGGCTATTCCGAGCAGAGG
MAGTCAGCCCTACGGACAGCAGAGTTACAGTGGTTATAGCCAGTCCACGGACACT
25 TCCAGGCTATGGCCAGAGCAGCTATTCTTCTTATGGCCAGAGCCAGAACACAGGCT
ATGGAACCTCAGTCAACTCCCCAGGGATATGGCTCGACTGGCGGCTATGGCAGTA
GCCAGAGCTCCCAATCGTCTTACGGGCAGCAGTCCTCCTATCCTGGCTATGGCCA
GCAGCCAGCTCCCAGCAGCACCTCGGGAAGTTACGGTAGCAGTTCTCAGAGCAG
CAGCTATGGGCAGCCCCAGAGTGGGAGCTACAGCCAGCAGCCTAGCTATGGTGG
30 ACAGCAGCAAAGCTATGGACAGCAGCAAAGCTATAATCCCCCTCAGGGCTATGG
ACAGCAGAACCAGTACAACAGCAGCAGTGGTGGTGGAGGTGGAGGTGGAGGTG
GAGGTAACCTATGGCCAAGATCAATCCTCCATGAGTAGTGGTGGTGGCAGTGGTG
GCGGTTATGGCAATCAAGACCAGAGTGGTGGAGGTGGCAGCGGTGGCTATGGAC
AGCAGGACCGTGGAGGGCGCGGCAGGGGTGGCAGTGGTGGCGGCGGGGCGGCG
35 GCGGTGGTGGTTACAACCGCAGCAGTGGTGGCTATGAACCCAGAGGTCGTGGAG
GTGGCCGTGGAGGCAGAGGTGGCATGGGCGGAAGTGACCGTGGTGGCTTCAATA
AATTTGGTGTGTTCAAGAAGGAAGTGTATCTTCATACATCACACACCTGAAAGC
AGATGTGCTTTTCCAGACTGATCCAATGCAGAGATGGCAGCTGAGTCATTGCCT
TTCTCCTTCGGGACACTGTCCAGCTGGGAGCTGGAAGCCTGGTATGAGGACCTGC
40 AAGAGGTCCTGTCTTCAGATGAAAATGGGGGTACCTATGTTTCACCTCCTGGAAA
TGAAGAGGAAGAATCAAAAATCTTCACCACTCTTGACCCTGCTTCTCTGGCTTGG
CTGACTGAGGAGGAGCCAGAACCAGCAGAGGTCACAAGCACCTCCCAGAGCCCT
CACTCTCCAGATTCCAGTCAGAGCTCCCTGGCTCAGGAGGAAGAGGAGGAAGAC
CAAGGGAGAACCAGGAAACGGAAACAGAGTGGTCATTCCCCAGCCCGGGCTGG
45 AAAGCAGCGCATGAAGGAGAAAGAACAGGAGAATGAAAGGAAAGTGGCACAGC
TAGCTGAAGAGAATGAACGGCTCAAGCAGGAAATCGAGCGCCTGACCAGGGAA
GTAGAGGCGACTCGCCGAGCTCTGATTGACCGAATGGTGAATCTGCACCAAGCA
TGAACAATTGGGAGCATCAGTCCCCCACTTGGGCCACACTACCCACCTTTCCAG
AAGTGGCTACTGACTACCCTCTCACTAGTGCCAATGATGTGACCCTCAATCCCAC

ATACGCAGGGGGAAGGCTTGGAGTAGACAAAAGGAAAGGTCTCAGCTTGTATAT
AGAGATTGTACATTTATTTATTACTGTCCCTATCTATTAAAGTGACTTTCTATGAG
CCAAGGTCTTTTACTTTTCTTCTTGCCTTTAGGGGCTTCAGGGGGTTTCCCCTCA
GCTACAGCCAACTGTTTCTTTAGATCCAAGAGTTTCGCCACCTCCGCAGCAACCT
5 CGTTCCTGTCTGCCTTTTGTGCTTTCAGTTCTCGGACAATGTTTCCCTAAGATAAA
GGGGGGTGGGGAGGTAACAGTGAGGCAAGAAAAAGATCTATTTAGGATTTCAGCT
TGTCCAGTCTCCACAGGGCTTAAGCTTCATACTTGTTTTGTCACTTCATCCATCA
GCGCTTGTATCTGCTGTGGCTTGGCTGTTGTAACAGTCTCTACAACCTGCTGGCTTC
GGGGACGTTTTGCCTGGAGAACAACAAAGTTATCACCAGCAACCATAAATATCC
10 CCTAACCTCCAGTTTTATACAGCATCTCAGAGGGAAAGTGGTTACCTTTAAGTCG
AAGGTCTCTTCTAGTTAAGACAGGAAAGAAAACTGTAAGTGAGGAAGCGGCAG
GGCCAAAAGATGGAAAGAGTGATGGGTGAGGACTACTTAGGGAAATTAGGGAA
GTGATGCTGTGGCTGTTGTGGAGCGAGGGCACAGCCTTTAGCTTTCTCACCTGGC
CCCCCCAAAGCGCTGCCTTAAACTTTCAATCTGGTCATTTTCCAATTTTTGGAAC
15 AAGGGACTGACCTGTAAAAAAGAGTTCAGAATCATCTACTGATTGGATACAG
ACTCTACCATAGACTATACAGATGACCTCTCCAACCCCAATCTCTGATGTGTTTTA
GAAAGAACGAGCTTAACACTGAGCTAATATCTGCTGATTTTAGGAAATTAGCTGT
AGCTTTCCCTGTGAAACCCCAAATAATTTGTAGGGTCAAAGATTCTTTAAGCTCT
CTAAGGATGCTAGGCTGATCCAGAAGTTTAGCAATGTACTTACTTTTTCATTTTGT
20 GTCAAAGAGGAAATGGCTTTTCTGTATTTTCCCTGCCCACTATCTGCTAGCATTAT
GGAGACTAGGTGATCACAGTGTTTCTTCAAATATCTGTTTACCAGTTAGTTTTGTG
TGCCAGGTTCTGGTTTTCTGGCATGAAGAACAATGAAGATGTACAGATAATTCGGG
ACTTGTGAACGACTACCAAGGAGTTTATATCAGAACTTAGGAGTCCCATGACCA
AAGTAACACTGGAGAGATGTTAGGTCTTCTCTCACCCACTCCAAAAGCTGCATGG
25 CAAGAGTATCAATTTTAAGAGAGGCTGGCTCTTCCACCTACTGTGCCAATCTGGT
GTCCTGCTGGTAAGGTACACAGGAAGTTTGTGTCAGCAGGATACTGCAGGCTGGAG
GTGGGAGCTGCAGCTGGGCCTGGATTGTGGCACTAACCCTGGGCATGTAAGGCT
GAAG

30 SEQ ID NO: 603

>20929 BLOOD 896499.1 X60111 g34768 Human mRNA for MRP-1. 0

AAGTGCAGGAAGCGCTTGGGGACTGCCAGCCCTCAGCTGTGTTATTATTCGGTG
ATAGGTATTTGCTAATTACTTCCAAAAGCCTCCCATCTGTTCATCCCACCCAGACT
GCGCGCTTCTAATTCCTCCTACCCACATGCTGTGCCCAATGAAAAGTATGGTCA
35 GCGAGCGAAGGTTTGCAAGGAGACAGACGAGGGGCGAAATTAAGCCAGGCGGCT
TCCCTTTAAATCCTCGCAAAGCAGAAGGGCCCTCACTCTGGCAGCAGGCCTTGG
CCAAGGGGCTTTAGCCCTGACGACCCGGGGAAGAGTCTCCCAAAGCAGAACGC
CCGGTCCGGCGCCCAGACCAAACGCGGGGGAACCGGAAGGGCGAGGCCTCCACC
TTGCCGGGATTGCTGTCCTTGCCATTGGACTATGGCTCCGATTCTCAGACTCTCAGACC
40 AAGAGCATCTTCGAGCAAGAACTAATAATAATAATTCCAGCTTCTACACAGGA
GTCTATATTCTGATCGGAGCCGGCGCCCTCATGATGCTGGTGGGCTTCCTGGGCT
GCTGCGGGGCTGTGCAGGAGTCCCAGTGCATGCTGGGACTGTTCTTCGGCTTCCT
CTTGGTGATATTCGCCATTGAAATAGCTGCGGCCATCTGGGGATATTCCCACAAG
GATGAGGTGATTAAGGAAGCCAGGAGTTTACAAGGACACCTACAACAAGCTGA
45 AAACCAAGGATGAGCCCCAGCGGGAAACGCTGAAAGCCATCCACTATGCGTTGA
ACTGCTGTGGTTTGGCTGGGGGCGTGGAACAGTTTATCTCAGACATCTGCCCCAA
GAAGGACGTA CTGAAACCTTCACCGTGAAGGTAAACTCAGACCAGGATCCTGG
TGTCCCTGCCCCCATTGCTCTGGACAAACCCTGCAAGCATGAAAGTGACAGCAGC
CAAGTGCTGCTTCAGCAAGACCCGTTCTGCCTGTGAAAGGGCCCCAGGGCACCC

ATCTCTTTCTCTCCCACTTTGGGCCCTCTGTTTACTCAAGGGCAATAAAACAAAG
GCCGGACCAGGGGAATGACAAGTGTTCTGGCACCGCCCACTGCTGCCAGCCCGG
AAGCTCTCAAGGGCAGGCGTGCTTCTGAGTCTTGGACTCCCACTCTGACTTTGTC
AGTGGCTCCTGTCTGTAAGCCAGAGTTAATGTCCAACCTCCAGAATAGTAAAAGGT
5 GACCTTACAACCATGTCAGAAATAGACCCCCAAGCAGGGCTGTCCCTCCTCCTTC
CCTGACGTCCTGCCCAGATTTTAGGGATCCACTAGCATAGCCATCCCTTTGTTTCG
CTTTTCATCCACCAGCCAGAACTTCTCTTATCCCCGAACACTCCTGTCCCCAGCCC
ACCTCTGTCCCACCAGTTCTCCCGGGTGAGACGGGGGCCATGGGAGGGAGGAGG
TGCCCTGGGAGGAAGGATTGTGTGTGACCCAGGTCTTGGTTTGTCTCCCCAAGTC
10 CTGTCCTGATGCCATCAAAGAGGTCTTCGACAATAAATTCCACATCATCGGCGCA
GTGGGCATCGGCATTGCCGTGGTCATGATATTTGGCATGATCTTCAGTATGATCT
TGTGCTGTGCTATCCGCAGGAACCGCGAGATGGTCTAGAGTCAGCTTACTTTCT
GGTCAGGGATGTAAGCTGACTCTAGACCAGGAAAGTTTACCCATGAAGATTGNN
NN
15 NNAAAGCTGAAGTTA
CTTTATGTTTGTCTTTTAATGCTTCATTCAATATTGACATTTGTAGTTGAGCGGGG
GGTTTGGTTTGTCTTGGTTTATATTTTTTCAGTTGTTTGTCTTGTATATTA
AGCAGAAATCCTGCAATGAAAGGTACTATATTTGCTAGACTCTAGACAAGATATT
GTACATAAAAGAATTTTTTGTCTTTAAATAGATACAAATGTCTATCAACTTTAAT
20 CAAGTTGTAACCTTATATTGAAGACAATTTGATACATAATAAAAAATTATGACAAT
GTCCTGG

SEQ ID NO: 604

20937 BLOOD 476760.8 AF030455 g3169829 Human epithelial V-like antigen precursor

25 (EVA) mRNA, complete cds. 0

GGCAGAGCGGGCTGAGTCACAGGCACAGGTGAGGAATCAACTCAAACCTCCTCTC
TCTGGGAAAACGCGGTGCTTGGCTCCTCCCGGAGTGGCCTTGGCAGGGTGTGGAG
CCCTCGGTCTGCCCCGTCCGGTCTCTGGGGCCAAGGCTGGGTTTCCCTCATGTAT
GGCAAGAGCTCTACTCGTGCGGTGCTTCTTCTCCTTGGCATAACAGCTCACAGCTC
30 TTTGGCCTATAGCAGCTGTGGAAATTTATACCTCCCGGGTGCTGGAGGCTGTAA
TGGGACAGATGCTCGGTTAAAATGCACCTTCTCCAGCTTTGCCCTGTGGGTGAT
GCTCTAACAGTGACCTGGAATTTTCGTCTCTAGACGGGGGACCTGAGCAGTTTG
TATTCTACTACCACATAGATCCCTTCCAACCCATGAGTGGGCGGTTTAAAGGACCG
GGTGTCTTGGGATGGGAATCCTGAGCGGTACGATGCCTCCATCCTTCTCTGGAAA
35 CTGCAGTTCGACGACAATGGGACATACACCTGCCAGGTGAAGAACCCACCTGAT
GTTGATGGGGTGATAGGGGAGATCCGGCTCAGCGTCGTGCACACTGTACGCTTCT
CTGAGATCCACTTCTGGCTCTGGCCATTGGCTCTGCCTGTGCACTGATGATCATA
ATAGTAATTGTAGTGGTCCTCTTCCAGCATTACCGGAAAAAGCGATGGGCCGAA
AGAGCTCATAAAAGTGGTGGAGATAAAATCAAAAGAAGAGGAAAGGCTCAACCA
40 AGAGAAAAAGGTCTCTGTTTATTAGAAAGACACAGACTAACAATTTTAGATGGA
AGCTGAGATGATTTCCAAGAACAAGAACCCTAGTATTTCTTGAAGTTAATGGAAA
CTTTTCTTTGGCTTTTCCAGTTGTGACCCGTTTCCAACCAGTTCTGCAGCATATT
AGATTCTAGACAAGCAACACCCCTCTGGAGCCAGCACAGTGCTCCTCCATATCAC
CAGTCATACACAGCCTCATTATTAAGGTCTTATTTAATTTTCAAGTGTAAATTTTT
45 TCAAGTGCTCATTAGGTTTATAAACAAGAAGCTACATTTTGGCCTTAAGATAC
TACTTACAGTGTTATGACTTGTATACACATATATTGGTATCAAAAGGGATAAAAG
CCAATTTGTCTGTTACATTTCTTTTACAGTATTTCTTTTAGCAGCACTTCTGCTACT
AAAGTTAATGTGTTTACTCTCTTTCTTCCACATTCTCAATTAAAAGGTGAGCTA
AGCCTCCTCGGTGTTTCTGATTAACAGTAAATCCTAAATTCAAACCTGTAAATGA

CATTTTTATTTTTATGTCTCTCCTTAACTATGAGACACATCTTGTTTTACTGAATTT
CTTTCAATATTCCAGGTGATAGATTTTTGTTGTTTTGTTAATTAATCCAAGATTTA
CAATAGCACAAACGCTAAATCACACAGTAACTACAAAAGGTTACATAGATATGAA
AAGATTGGCAGAGGCCATTGCAGGATGAATCACTTGTCACTTTTCTTCTGTGCTG
5 GGAAAAATAATCAACAATGTGGGTCTTTCATGAGCAGTGACGGATAGTTTAGCTT
ACTATGTTTCCCCCCTCAATGATCTATAACAACAGAGCAAAGTCTATGCTC
ATTTGCAGACTGGAATCATTAAAGTAATTTAATAAAAAGATTGTGAAACAGCATAT
TACAAGTTTGAAAATTCAGGGCTGGTGAAAAAAATCAACTCTAAATGATGATA
ATTTTGTACAGTTTTATATAAACTCTGAGAACTAGAAGAAATTATTAACCTTTTTT
10 TCTTTTTTAATTCTAATTCACCTTGTTTTATTTTGGGGGAGGAAGACTTTGGTATGGA
GCAAAGAAATACCAAACTACTTTAAATGGAATAAAACCAACTTTATTCTTTTTT
TCCCCCATACTGGTAGATAAAGCAAACCTTTATAAGTGGGCTATTGAAAGAAAAG
TTACAAGCTTAAGATACAGAAGCATTGTTCAAAGGATAGAAAGCATCTAAAAG
TTTAGGCTCAAGATCAATCTTTACAGATTGATATTTTCAGTTTTTAATCGACTGGA
15 CTGCAGATGTTTTTTCTTTTAAACAACTGGAATTTTCAAACAGATTATCTGTATTT
AAATGTATAGACCTTGATATTTTTTCCAATACTATTTTTTAAAAAATTGTATGATTT
ACATATGAACCTCAGTTCTGAAATTCATTACATATCTGTCTCATTCTGCCTTTTAT
ACTGTCTAAAAAAGCAAAGTTTTAAAGTGCAATTTTAAAACGTAAATTACATCT
GAAGGCTATATATCCTTTAATCACATTTTATATTTTTTCTTCACAATTCTAACCTTT
20 GAAAATATTATAACTGGATATTTCTTCAAACAGATGTCCTGGATGATGGTCCATA
AGAATAATGAAGAAGTAGTTAAAAATGTATGGACAGTTTTTCCGGCAAAATTTGT
AGCTTATGTCTTGGCTAAATAGTCAAGGGGTAATATGGGCCTGTTGTTTAGTGTCT
TCCTTCCTAAAGAGCACTTTTGATTGTAAATTTATTTTATATGCTTTAAACACT
ATGTAAATAAACCTTTAGTAATAAAGCAATTATCAGTTATAT

SEQ ID NO: 605

>20969 BLOOD INCYTE_3358822T6

TTATACTCTGATTGCTCACTTACAGTATAAAATATTCACCCCGCTAAATAAATAA
GACGACATTATTGCAAACGGCACTTAAACCCCCCTGAGAGATAAGACCTCCCTT
30 AGCTCAGGCAGGGGGTGCTCCTGAGTTTCTGTGTGAGATTCCCCAAGCACAGATA
TACTCTGGGGGCTGAGATGGACAAAGGCTTGGGAAACCGCACTTTGTGCTTCTGG
TCCTGCAGTAGCTCCAAACAGGGTTGTGGAGCTGGTGGGGAAAGTTGGGGGTAG
GGGAAAGTTGGGGGTAGGGGAAATTTTGGGCAGTGCCTTCATCAGCCNGTCTCT
AGAGAGAGTAGAGGGGAATGGAAGTGGGGGGAACNNNCTGGGGNCAAGAGAA
35 GAGGGGNNGTT

SEQ ID NO: 606

>20988 BLOOD 233843.3 AK001972 g7023569 Human cDNA FLJ11110 fis, clone
PLACE1005921, weakly similar to AIG1 PROTEIN. 0

ATCAGGTGGGCAGGTCCCTTGACAAAGTAAATCTGGACAGCTCCTCCCCTCACTT
CCTCTCTTCTCCTGTTTCTCAACATCCTGGCTTAGTATTGTGTGCAAAATCAGAGA
GGGGTGCAAGATCCTGATTTTTCAGGAGTTCAAGCGACAATGGCAGCCCAATAC
GGCAGTATGAGCTTCAACCCCAGCACACCAGGGGCCAGTTATGGGCCTGGAAGG
CAAGAGCCCAGAAATTCCCAATTGAGAATTGTGTAGTGGGTAAAACCGGAGCA
45 GGAAAAAGTGCAACAGGAAACAGCATCCTTGCCCGGAAAGTGTTCATTCTGGC
ACTGCAGCAAAATCCATTACCAAGAAGTGTGAGAAACGCAGCAGCTCATGGAAG
GAAACAGAACTTGTCGTAGTTGACACACCAGGCATTTTCGACACAGAGGTGCC
AATGCTGAAACGTCCAAGGAGATTATTCGCTGCATTCTTCTGACCTCCCCAGGGC
CTCATGCTCTGCTTCTGGTGGTTCCACTGGGCCGTTACACTGAGGAAGAGCACAA

25 GTTCATTGAAGAACAGAGACCTGTCTGGAAAATCGATCTCTACAAATTCAATTAA
ATAATGATCCCCAAATGCTGAAAAAGTGAAATACAGCAATTCACAGATAATAG
AGCAATGTTTAGTATATTCACTGTATCTGTAGAACTCTTTGACGAACCTCAAT
TTAACCAATTTGATGAATACCCAGTTCTCTTCTTTTCTAGAGAAAGATAGTTGCA
ACCTCACCTCCCTCACTCAACACTTTGAATACTTATTGTTTGGCAGGTCATCCACA
CACTTCTGCCCCACTGCATTGAATTTTTTGCTTATGTTGTTTATAATAAACTTTT
CAATTATCTCATAAAA

30 SEO ID NO: 607

>21053 BLOOD INCYTE g1967662

GCATTTCCCTGAAACCTGGGCTCTTGAAGACGCATCACTGGAGCAGATGGATAAT
GGAGACTGGGGCNN
NN
NNNNNNNNNNNNCTGACCCAGTCACATTAAATGTAGGTGGACACTTGTATAACA
GTCTCTCACACATTGACGCGTTACCCGGATTCCATGCTTGGAGCTATGTTTGGG
GGGACTTCCCCACAGCTCGAGACCCTCAAGGCAATTACTTTATTGATCGAGATG
GACCTCTTTTCCGATATGTCCTCAACTTCTTAAGAACTTCAGAATTGACCTTACCG
TTGGATTTT

40

SEQ ID NO: 608

>21057 BLOOD INCYTE g819904

TTTTTTTTGAAGGTAGCAGTGTCTTTTATTTACTTTTTATTGTCATCAAGCAGTTTTTC
TAGGAATTTTCAGCAAAATACCAATTCAGCTATAAGTCTAATATGAAACACAGG
45 AACTGTGAATATAAGCTTTTGGTGCTTGCTATGAAAAATCAAATCAATAGCTTT
AATGTCTTCTTACAATCTCATTTTGTTTCACTATAGCTCTGTTTTAGTTAGNATCTG
CACATCTGTTTTGCTCCAGGGTAGTTAATTTNGCCAGTTCAGTTTCTCTGTAGGAT
TTTTGCCATAGGTAGGAAAAGGGATTTTAAATATTAATAGGCC

SEQ ID NO: 609

>21063 BLOOD 474850.14 AF118224 g6647301 Human matriptase mRNA, complete cds. 0

GCCTGCCGGACGCCTCCCATGTCTTCCCTGCCGGCAAGGCCATCTGGGTACAGGG
CTGGGGACACACCCAGTATGGAGGCACTGGCGCGCTGATCCTGCAAAAGGGTGA
5 GATCCGCGTCATCAACCAGACCACCTGCGAGAACCTCCTGCCGCAGCAGATCAC
GCCGCGCATGATGGTGATTCCGGGGGACCCCTGTCCAGCGTGGAGGCGGATGGG
CGGATCTTCCAGGCCCGGTGTGGTGAGCTGGGAGACGGCTGCGCTCAGAGGAACA
AGCCAGGCGTGTACACAAGGCTCCCTCTGTTTCGGGACTGGATCAAAGAGAACA
CTGGGGTATAGGGGCCGGGGCCACCCAAATGTGTAACTGCGGGGCCACCCATC
10 GTCCACCCCAAGTGTGCACGCCTGCAGGCTGGAGACTGGACCGCTGACTGCACCA
GCGCCCCCAGAACATACTGTGAACCTCAATCTCCAGGGCTCCAAATCTGCCTAG
AAAACCTCTCGCTTCCCTCAGCCTCCAAAGTGGAGCTGGGAGGTAGAAGGGGAGG
AACTGGTGGTTCTACTGACCCAACTGGGGGCAAAGGTTTGAAGACACAGCCTC
CCCCGCCAGCCCCAAGCTGGGCCGAGGCGCGTTTGTGTATATCTGCCTCCCCTGT
15 CTGTAAGGAGCAGCGGGAACGGAGCTTCGGAGCCTCCTCAGTGAAGGTGGTGGG
GCTGCCGGATCTGGGCTGTGGGGCCCTTGGGGCCACGCTCTTGAGGAAGCCCAGG
CTCGGAGGACCCTGGAAAACAGACGGGTCTGAGACTGAAATTGTTTTACCAGCT
CCCAGGGTGGACTTCAGTGTGTGTATTTGTGTAAATGAGTAAAACATTTATTTCTT
TTT

20

SEQ ID NO: 610

>21080 BLOOD 1218745.1 X04366 g29663 Human mRNA for calcium activated neutral

protease large subunit (muCANP; calpain; EC:3.4.22.17). 0

CAGATCTGGATGGAGTTGTGACCTTTGACTTGTTTAAGTGGTTGCAGCTGACCAT
25 GTTTGCATGAGGCAGGGACTCGGTCCCCCTTGCCGTGCTCCCCCTCCCTCCTCGTCT
GCCAAGCCTCGCCTCCTACCACACCACACCAGGCCACCCCAGCTGCAAGTGCCTT
CCTTGAGCAGAGAGGCAGCCTCGTCCTCCTGTCCCCTCTCCTCCCAGCCACCAT
CGTTCATCTGCTCCGGGC

30 SEQ ID NO: 611

>21089 BLOOD 478379.2 U58913 g4204907 Human chemokine (hmrp-2a) mRNA,
complete cds. 0

GGAAAGCAGTGAGCCCAGGAGTCCTCGGCCAGCCCTGCCTGCCACCAGGAGGAT
GAAGGTCTCCGTGGCTGCCCTCTCCTGCCTCATGCTTGTTACTGCCCTTGGATCCC
35 AGGCCCCGGGTCACAAAAGATGCAGAGACAGAGTTCATGATGTCAAAGCTTCCAT
TGGAATAATCCAGTACTTCTGGACATGCTCTGGAGGAGAAAGATTGGTCCTCAGAT
GACCTTTTCTCATGCTGCAGGATTCCATGCTACTAGTGCTGACTGCTGCATCTCCT
ACACCCCACGAAGCATCCCGTGTTCACTCCTGGAGAGTTACTTTGAAACGAACAG
CGAGTGCTCCAAGCCGGGTGTCATCTTCCTACCAAGAAGGGGCGACGTTTCTGT
40 GCCAACCCCAAGTGAAGCAAGTTCAGGTTTGCATGAGAATGCTGAAGCTGGAC
ACACGGATCAAGACCAGGAAGAATTGAACCTTGCAAGGTGAAGGGACACAAGTT
GCCAGCCACCAACTTTCTTGCTCAACTACCTTCCTGAATTATTTTTTAAAGAAGC
ATTTATTCTTGTGTTCTGGATTTAGAGCAATTCATCTAATAAACAGTTTCTCACTT
AAAAAAA

45

SEQ ID NO: 612

>21097 BLOOD 197014.6 AF095742 g4588081 Human serine protease ovasin mRNA,
complete cds. 0

GTGCAGGAGGAGAAGGAGGAGGAGCAGGAGGTGGAGATTCCCAGTTAAAAGGC
TCCAGAATCGTGTACCAGGCAGAGAACTGAAGTACTGGGGCCTCCTCCACTGGG
TCCGAATCAGTAGGTGACCCCGCCCCTGGATTCTGGAAGACCTCACCATGGGACG
CCCCCGACCTCGTGCGGCCAAGACGTGGATGTTCCCTGCTCTTGCTGGGGGGAGCC
5 TGGGCAGGACACTCCAGGGGCACAGGAGGACAAGGTGCTGGGGGGTCA TGAGTGC
CAACCCCATTCGCAGCCTTGGCAGGCGGCCCTTGTTCCAGGGCCAGCAACTACTCT
GTGGCGGTGTCCTTG TAGGTGGCAACTGGGTCTTACAGCTGCCCACTGTAAAAA
ACCGAAATACACAGTACGCCTGGGAGACCACAGCCTACAGAATAAAGATGGCCC
AGAGCAAGAAATACCTGTGGTTCAGTCCATCCACACCCCTGCTACAACAGCAG
10 CGATGTGGAGGACCACAACCATGATCTGATGCTTCTTCAACTGCGTGACCAGGCA
TCCCTGGGGTCCAAAGTGAAGCCCATCAGCCTGGCAGATCATTGCACCCAGCCTG
GCCAGAAGTGCACCGTCTCAGGCTGGGGCACTGTCACCAGTCCCCGAGAGAATT
TTCCTGACACTCTCAACTGTGCAGAAGTAAAAATCTTTCCCCAGAAGAAGTGTGA
GGATGCTTACCCGGGGCAGATCACAGATGGCATGGTCTGTGCAGGCAGCAGCAA
15 AGGGGCTGACACGTGCCAGGGCGATTCTGGAGGCCCCCTGGTGTGTGATGGTGC
ACTCCAGGGCATCACATCCTGGGGCTCAGACCCCTGTGGGAGGTCCGACAAACC
TGGCGTCTATACCAACATCTGCCGCTACCTGGACTGGATCAAGAAGATCATAGGC
AGCAAGGGCTGATTCTAGGATAAGCACTAGATCTCCCTTAATAAACTCACAAC TC
TCTGAAAAAAAAAAAA

20

SEQ ID NO: 613

>21102 BLOOD INCYTE_3090747H1
CTTCTTTGTTAGGCTGTGTCTCCCTAANCCGTTGNCCCCACCCAGAGTTTCCCGTC
CCCTTCACTGATTTCTGTTGTCTCTGCTGACTGTGTGGGTGGAATGTCCCAAGAAA
25 AGTGCATCTGGGAATTGCCAGTCCAGCTGGGTAGTCCCAGGCTCCTGTCTTGGGG
ATGTTTCCCCTGTCAGCAAGTAACCTGGTGAAGTCTATTGAAGGCCAGACTNCCC
CCCTAGGGTCACTGCTTCACTAGCCGCNNCCCACCCAG

SEQ ID NO: 614

30 >21104 BLOOD 987163.5 AF082182 g3435251 Human inwardly rectifying potassium
channel Kir7.1 gene, complete intron, and partial cds. 0

GTTTGCCATTTTCTCTTTCCTGATAGAGTACAGCTGAGACCCGGACACTGGTTAG
AGGGCTAGGTCGGGTGTTGGCCACTTGAAGATAAGATTAGGTTTGCCATCCATG
TGAGCTACTACTGCTATGTCAGTAAAGCGAATTGAAAAAGCTCGATTTTTTTGGCC
35 GGGCAATCTTCGCCACAAAAGCACCTAAATAAGAAATTATTGATTTTTTTTAGA
ATGAAGACTTTAAATATCAATACTTTTTCTGAATGACAAGTGTATATCAAATATT
TACACATTTCTTGGTGCCATGCCTTTCAGTGAGTCAGGAATTGAACTCATTGTAA
TTTGGTCAGTCTTATTTGCCTGAAGCATTTTCAAAGTACATTTCTGTTTAAAAAC
CATGATTTCAGAATAGATAAGCAAAATGATTTTGTTACAGAGAAATGTAAACTT
40 CATCCTCTAGTTTCTTACAAAGTCAAAGAATTGGTCATTTTCCTATATTCCTGCCTG
TGCTTAAAAAAAAGTAATAGAAAATAAATGCAACTTGGCTACAGCCAGATTACG
TTGAAGTAGAGACTAGGTTCAAGTAGAATGATTTGGGATGGGGAGGGGACCAA
TAGAATGAGTGATATT

45 SEQ ID NO: 615

>21140 BLOOD 104171.1 AF037447 g6466790 Human ribosomal S6 protein kinase mRNA,
complete cds. 0

AATTCACCAGGTAAGTTACAAGAAGATCAGGTCTTCCTTCATCAGTACCACTGAC
ATCATCAAAAGCAGCATCTTTAAATGAAATAACTGGCACTGAGTCATCTGAGCCC

CTGCTAATGGTGTCTGAGCTTTAAACTCTACCTTGCTTTCACTAGTATTAAAAC
CCTAGAAGCACTGTCTCCATCTGGAAGAGTAAAGAATGGTTTCAGTGCTTCTAGG
AGTTTTAATACTAGTGAAAGCAAGGTAGAGTTTAAAGCTCAGGACACCATTAGC
AGGGGCTCAGATGACTCAGTGCCAGTTATTTCAATTTAAAGATGCTGCTTTTGATG
5 ATGTCAGTGGTACTGATGAAGGAAGACCTGATCTTCTTGTAATTTACCTGGTGA
ATTGGAGTCAACAAGAGAAGCTGCAGCAATGGGACCTACTAAGTTTACACAAAC
TAATATAGGGATAATAGAAAATAAACTCTTGGAAGCCCCTGATGTTTTATGCCTC
AGGCTTAGTACTGAACAATGCCAAGCACATGAGGAGAAAGGCATAGAGGAACTG
AGTGATCCCTCTGGGCCCAAATCCTATAGTATAACAGAGAAACACTATGCACAG
10 GAGGATCCCAGGATGTTATTTGTAGCAGCTGTTGATCATAGTAGTTCAGGAGATA
TGTCTTTGTTACCCAGCTCAGATCCTAAGTTTCAAGGACTTGAGAGTGGTTGAGTC
AGCAGTAACTGCAAACAACACAGAAGAAAGCTTATTCGTATTTGTAGTCCACTC
TCAGGTGCTAATGAATATATTGCAAGCACAGACACTTTAAAAACAGAAGAAGTA
TTGCTGTTTACAGATCAGACTGATGATTTGGCTAAAGAGGAACCAACTTCTTTAT
15 TCCAGAGAGACTCTGAGACTAAGGGTGAAAGTGGTTTAGTGCTAGAAGGAGACA
AGGAAATACATCAGATTTTTTGAGGACCTTGATAAAAAATTAGCACTAGCCTCCAG
GTTTTACATCCCAGAGGGCTGCATTCAAAGATGGGCAGCTGAAATGGTGGTAGC
CCTTGATGCTTTACATAGAGAGGGAATTGTGTGCCGCGATTTGAACCCAAACAAC
ATCTTATTGAATGATAGAGGACACATTCAGCTAACGTATTTAGCAGGTGGAGTG
20 AGGTTGAAGATTCCTGTGACAGCGATGCCATAGAGAGAATGTACTGTGCCCCAG
AGGTTGGAGCAATCACTGAAGAACTGAAGCCTGTGATTGGTGGAGTTGGGTG
CTGTECTCTTTGAACTTCTCACTGGCAAGACTCTGGTTGAATGCCATCCAGCAGG
AATAAATACTCACACTACTTTGAACATGCCAGAATGTGTCTCTGAAAGAGGCTCGC
TCACTCATTCACAGGCTCTTGCAAGTTCAATCCTCTGGAACGACTTGGTGCTGGAG
25 TTGCTGGTGTGTAAGATATCAAATCTCATCCATTTTTTACCCCTGTGGATTGGGCA
GAACTGATGAGATGAACGTAATGCAGGGTTATCTTCACACATTCTGATCTTCTCT
GTGACAGGCATCTCCAGCACTGAGGCACCTCTGACTCACAGTTACTTATGGAGCA
CCAAAGCATTGGAATAAGACCGTTATAGGAAATGGGGGGGAAATGGCTAAAAG
AGAACAATTTCGTTTACAATTACAAGATATTAGCTAATTGTGCCAGGGGCTGTTAT
30 ATACATATATACACAACCAAGGTGTGATCTGAATTTAATCCACATTTGGTGTGTC
AGATGAGTTGTAAAGCCAACTGAAAGAGTTCCTTCAAGAAGTTCCTCTGATAGG
AAGCTAGAAGTGTAGAATGAAGTTTACTTGACAGAAGGACCTTTACATGGCAG
CTAACAGTGCTTTTGTGCTGACCAGGATTGGTTTATATGATTAAATTAATATTTGCT
FAATAATACACTAAAAGTATATGAACAATGTCATCAATGAACTTAAAAGCGAG
35 AAAAAAGAATATACACATAATTTCTGACGGAAAACCTGTACCCTGATGCTGTATA
ATGTATGTTGAATGTGGTCCCAGATTATTTCTGTAAGAAGACACTCCATGTTGTC
AGCTTTGTACTCTTTGTTGATACTGCTTATTTAGAGAAGGGTTCATATAAACTC
ACTCTGTGTCTTCAACAGCATCTTTCTTTCCCATCTTTCTATTTCTGCACCCTCT
GCTTGTTCCCTCATATTCTGTTCTTCCGACTCCTGCTAACACACATGCAACAAAA
40 AGGGAAGGGAGTGCTTATTTCCCTTTGTGTAAGGACTAAGAAATCATGATATCAA
ATAAACATGGTGAAACATTAGATCTTCTTTCATTTAATAANNNNNNNNNNNNN
NNNNNNNNGAAGAAATGCGTCTGTTCCCTTTCCTTGTGAAATATTATCAGTTTCTA
CCATTGCTTCTCATGCTTGACTTTGTTTTACTTTTTGGCTTGGTATACTAAGAAGC
AAAGGATCTCATCTAAATGGAATTGAATGGCAGTCCTAGTTTGTACTTATGGTG
45 ATGAGATTTTCAGA

SEQ ID NO: 616

>21152 BLOOD 221063.3 U78181 g1871169 Human sodium channel 2 (hBNC2) mRNA,
complete cds. 4e-12

CATCCATTCATCGATTTCGCGCATTCTCCAGACCTTTACAGCCTGTGCTGGGTACTG
GAGACTCCCTGGGTGGGGGCCCTGAGGGCCCGTGCTTCTGCCCCACCCCTGCAA
CCTGACACGCTATGGGAAAGAGATCTCCATGGTCAGGATCCCCAACAGGGGCTC
AGCCCCGGTACCTGGCGAGGAAGTACAACCGCAACGAGACCTACATACGGGAGAA
5 CTTCTTGGTCTAGATGTCTTCTTTGAGGCCCTGACCTCTGAAGCCATGGAGCAG
CGAGCAGCCTATGGCCTGTCAGCCCTGCTGGGAGACCTCGGGGGACAGATGGGC
CTGTTCAATTGGGGCCAGCATCCTCACGTTGCTGGAGATCCTCGACTACATCTATG
AGGTGTCCTGGGATCGACTGAAGCGGGTATGGAGGCGTCCCAAGACCCCCCTG
GGGACCTCCACTGGGGGCATCTCCA

10

SEQ ID NO: 617

>21181 BLOOD 410188.1 M77235 g184038 Human cardiac tetrodotoxin-insensitive
voltage-dependent sodium channel alpha subunit (HH1) mRNA, complete cds. 0

15 GCCGCTGAGCCTGCGCCAGTGCCCCGAGCCCCGCGCCGAGCCGAGTCCGCGCC
AAGCAGCAGCCGCCACCCCGGGGCCCGGCCGGGGGACCAGCAGCTTCCCCACA
GGCAACGTGAGGAGAGCCTGTGCCCAGAAGCAGGATGAGAAGATGGCAAACCTTC
CTATTACCTCGGGGCACCAGCAGCTTCCGCAGGTTACACGGGAGTCCCTGGCAG
CCATCGAGAAGCGCATGGCGGAGAAGCAAGCCCGCGGCTCAACCACCTTGCAGG
AGAGCCGAGAGGGGCTGCCCGAGGAGGAGGCTCCCCGGCCCCAGCTGGACCTGC
20 AGGCCTCCAAAAGCTGCCAGATCTCTATGGCAATCCACCCCAAGAGCTCATCG
GAGAGCCCCTGGAGGACCTGGACCCCTTCTATAGCACCCAAAAGACTTTCATCGT
ACTGAATAAAGGCAAGACCATCTTCCGGTTEAGTGCCACCAACGCCTTGATGTG
CTCAGTCCCTTCCACCCCATCCGGAGAGCGGGCTGTGAAGATTCTGGTTEACTCGC
TCTTGAACATGCTCATCATGTGACCATCCTCACCAACTGCGTGTTCATGGCCCA
25 GCACGACCCTCCACCCTGGACCAAGTATGTGAGTACACCTTCACCGCCATTTAC
ACCTTTGAGTCTCTGGTCAAGATTCTGGCTCGAGGCTTCTGCCTGCACGCGTTTAC
TTTCCTTCGGGACCCATGGAACCTGGCTGGACTTTAGTGTGATTATCATGGCATA
ACAACCTGAATTTGTGGACCTGGGCAATGTCTCAGCCTTACGCACCTTCCGAGTCC
TCCGGGCCCTGAAAACCTATATCAGTCATTTACAGGGCTGAAGACCATCGTGGGGG
30 CCTGATCCAGTCTGTGAAGAAGCTGGCTGATGTGATGGTCCTCACAGTCTTCTGC
CTCAGCGTCTTTGCCCTCATCGGCCTGCAGCTCTTCATGGGCAACCTAAGGCACA
AGTGTGTGCGCAACTTCACAGCGCTCAACGGCACCAACGGCTCCGTGGAGGCCG
ACGGCTTGGTCTGGGAATCCCTGGACCTTTACCTCAGTGATCCAGAAAATTACCT
GCTCAAGAACGGCACCTCTGATGTGTTACTGTGTGGGAACAGCTCTGACGCTGGG
35 ACATGTCCGGAGGGCTACCGGTGCCTAAAGGCAGGCGAGAACCCCGACCACGGC
TACACCAGCTTCGATTCCTTTGCCTGGGCCTTTCTTGCACTCTTCCGCCTGATGAC
GCAGGACTGCTGGGAGCGCCTCTATCAGCAGACCCTCAGGTCCGCAGGGAAGAT
CTACATGATCTTCTTCATGCTTGTATCTTCTGGGGTCTTCTACCTGGTGAACC
TGATCCTGGCCGTGGTCGCAATGGCCTATGAGGAGCAAAACCAAGCCACCATCG
40 CTGAGACCGAGGAGAAGGAAAAGCGCTTCCAGGAGGCCATGGAAATGCTCAAG
AAAGAACACGAGGGCCCTCACCATCAGGGGTGTGGATAACCGTGTCCCGTAGCTCC
TTGGAGATGTCCCCTTTGGCCCCAGTAAACAGCCATGAGAGAAGAAGCAAGAGG
AGAAAACGGATGTCTTCAGGAACCTGAGGAGTGTGGGGAGGACAGGCTCCCCAAG
TCTGACTCAGAAGATGGTCCCAGAGCAATGAATCATCTCAGCCTCACCCGTGGCC
45 TCAGCAGGACTTCTATGAAGCCACGTTCCAGCCGCGGGAGCATTTTCACCTTTCG
CAGGCGAGACCTGGGTTCTGAAGCAGATTTTGCAGATGATGAAAACAGCACAGC
GGGGGAGAGCGAGAGCCACCACACATCACTGCTGGTGCCCTGGCCCCCTGCGCCG
GACCAGTGCCCAGGGACAGCCAGTCCCGGAACCTCGGCTCCTGGCCACGCCCT
CCATGGCAAAAAGAACAGCACTGTGGACTGCAATGGGGTGGTCTCATTACTGGG

GGCAGGCGACCCAGAGGCCACATCCCCAGGAAGCCACCTCCTCCGCCCTGTGAT
GCTAGAGCACCCGCCAGACACGACCACGCCATCGGAGGAGCCAGGCGGCCCCCA
GATGCTGACCTCCCAGGCTCCGTGTGTAGATGGCTTCGAGGAGCCAGGAGCACG
GCAGCGGGCCCTCAGCGCAGTCAGCGTCTCACCAGCGCACTGGAAGAGTTAGA
5 GGAGTCTCGCCACAAGTGTCCACCATGCTGGAACCGTCTCGCCCAGCGCTACCTG
ATCTGGGAGTGCTGCCCCTGTGGATGTCCATCAAGCAGGGAGTGAAGTTGGTG
GTCATGGACCCGTTTACTGACCTCACCATCACTATGTGCATCGTACTCAACACAC
TCTTCATGGCGCTGGAGCACTACAACATGACAAGTGAATTCGAGGAGATGCTGC
AGGTGCGAAACCTGGTCTTCACAGGGATTTTCACAGCAGAGATGACCTTCAAGAT
10 CATTGCCCTCGACCCCTACTACTTCCAACAGGGCTGGAACATCTTCGACAGC
ATCATCGTCATCCTTAGCCTCATGGAGCTGGGCCTGTCCCGCATGAGCAACTTGT
CGGTGCTGCGCTCCTTCCGCCTGCTGCGGGTCTTCAAGCTGGCCAAATCATGGCC
CACCCTGAACACACTCATCAAGATCATCGGGAACCTCAGTGGGGGCACTGGGGAA
CCTGACACTGGTGCTAGCCATCATCGTGTTCATCTTTGCTGTGGTGGGCATGCAG
15 CTCTTTGGCAAGAACTACTCGGAGCTGAGGGACAGCGACTCAGGCCTGCTGCCTC
GCTGGCACATGATGGACTTCTTTTCATGCCTTCCTAATCATCTTCCGCATCCTCTGT
GGAGAGTGGATCGAGACCATGTGGGACTGCATGGAGGTGTGCGGGCAGTCATTA
TGCCTGCTGGTCTTCTTGCTTGTATGGTCATTGGCAACCTTGTGGTCTGAATCT
CTTCTGGCCTTGCTGCTCAGCTCCTTCAGTGCAGACAACCTCACAGCCCCTGAT
20 GAGGACAGAGAGATGAACAACCTCCAGCTGGCCCTGGCCCGCATCCAGAGGGGC
CTGCGCTTTGTCAAGCGGACCACCTGGGATTTCTGCTGTGGTCTCCTGCGGCACC
GGCCTCAGAAGCCCGCAGCCCTTGCCGGCCAGGGCCAGCTGCCCAGCTGCATTGCG
CACCCCTACTCCCGGCCACCCCGCAGAGACGGAGAAGGTGCCTCCACCCCGCAA
GGAAACACAGTTTGAGGAAGGCGAGCAACCAGGCCAGGGCACCCCGGGGATC
25 CAGAGCCCGTGTGTGTGCCCATCGCTGTGGCCGAGTCAGACACAGATGAECAAG
AAGAGGATGAGGAGAACAGCCTGGGCACGGAGGAGGAGTCCAGCAAGCAGCAG
GAATCCCAGCCTGTGTCCGGCTGGCCAGAGGCCCTCCGGATTCCAGGACCTGGA
GCCAGGTGTCAGCGACTGCCTCCTCTGAGGCCGAGGCCAGTGCATCTCAGGCCG
ACTGGCGGCAGCAGTGGAAAGCGGAACCCAGGCCCCAGGGTGCGGTGAGACCC
30 CAGAGGACAGTTGCTCCGAGGGCAGCACAGCAGACATGACCAACACCGCTGAGC
TCCTGGAGCAGATCCCTGACCTCGGCCAGGATGTCAAGGACCCAGAGGACTGCT
TCACTGAAGGCTGTGTCCGGCGCTGTCCCTGCTGTGCGGTGGACACCACACAGGC
CCCAGGGAAGGTCTGGTGGCGGTTGCGCAAGACCTGCTACCACATCGTGGAGCA
CAGCTGGTTCGAGACATTCATCATCTTCATGATCCTACTCAGCAGTGGAGCGCTG
35 GCCTTCGAGGACATCTACCTAGAGGAGCGGAAGACCATCAAGGTTCTGCTTGAG
TATGCCGACAAGATGTTACATATGTCTTCGTGCTGGAGATGCTGCTCAAGTGGG
TGGCCTACGGCTTCAAGAAGTACTTCACCAATGCCTGGTGTGGCTCGACTTCCT
CATCGTAGACGTCTCTGCTGCTCAGCCTGGTGGCCAACACCCTGGGCTTTGCCGAG
ATGGGCCCCATCAAGTCACTGCGGACGCTGCGTGCATCCGTCCTCTGAGAGCTC
40 TGTCACGATTTGAGGGCATGAGGGTGGTGGTCAATGCCCTGGTGGGCGCCATCCC
GTCCATCATGAACGTCTCCTCGTCTGCCTCATCTTCTGGCTCATCTTCAGCATCA
TGGGCGTGAACCTCTTTGCGGGGAAGTTTGGGAGGTGCATCAACCAGACAGAGG
GAGACTTGCCCTTTGAACTACACCATCGTGAACAACAAGAGCCAGTGTGAGTCCTT
GAACTTGACCGGAGAATTGTACTGGACCAAGGTGAAAGTCAACTTTGACAACGT
45 GGGGGCCGGGTACCTGGCCCTTCTGCAGGTGGCAACATTTAAAGGCTGGATGGA
CATTATGTATGCAGCTGTGGACTCCAGGGGGTATGAAGAGCAGCCTCAGTGGGA
ATACAACCTCTACATGTACATCTATTTTGTCAATTTTCATCATCTTTGGGTCTTTCTT
CACCCTGAACCTCTTTATTGGTGTCACTATTGACAACCTTCAACCAACAGAAGAAA
AAGTTAGGGGGCCAGGACATCTTCATGACAGAGGAGCAGAAGAAGTACTACAAT

GCCATGAAGAAGCTGGGCTCCAAGAAGCCCCAGAAGCCCATCCCACGGCCCCCTG
AACAAGTACCAGGGCTTCATATTCGACATTGTGACCAAGCAGGCCTTTGACGTCA
CCATCATGTTTCTGATCTGCTTGAATATGGTGACCATGATGGTGGAGACAGATGA
CCAAAGTCCTGAGAAAATCAACATCTTGGCCAAGATCAACCTGCTCTTTGTGGCC
5 ATCTTCACAGGCGAGTGTATTGTCAAGCTGGCTGCCCTGCGCCACTACTACTTCA
CCAACAGCTGGAATATCTTCGACTTCGTGGTTGTCATCCTCTCCATCGTGGGCACT
GTGCTCTCGGACATCATCCAGAAGTACTTCTTCTCCCCGACGCTCTTCCGAGTCAT
CCGCCTGGCCCGAATAGGCCGCATCCTCAGACTGATCCGAGGGGGCCAAGGGGAT
CCGCACGCTGCTCTTTGCCCTCATGATGTCCCTGCCTGCCCTCTTCAACATCGGGC
10 TGCTGCTCTTCTCGTCATGTTTCTACTCCATCTTTGGCATGGCCAACCTTCGCT
TATGTCAAGTGGGAGGCTGGCATCGACGACATGTTCAACTTCCAGACCTTCGCCA
ACAGCATGCTGTGCCTCTTCCAGATCACCACGTGCGCCGGCTGGGATGGCCTCCT
CAGCCCCATCCTCAACACTGGGCCGCCCTACTGCGACCCCACTCTGCCCAACAGC
AATGGCTCTCGGGGGGACTGCGGGAGCCCAGCCGTGGGCATCCTCTTCTTACCA
15 CCTACATCATCATCTCCTTCTCATCGTGGTCAACATGTACATTGCCATCATCCTG
GAGAACTTCAGCGTGGCCACGGAGGAGAGCACCGAGCCCCTGAGTGAGGACGAC
TTCGATATGTTCTATGAGATCTGGGAGAAATTTGACCCAGAGGCCACTCAGTTTA
TTGAGTATTCGGTCTGTCTGACTTTGCCGACGCCCTGTCTGAGCCACTCCGTATC
GCCAAGCCCAACCAGATAAGCCTCATCAACATGGACCTGCCCATGGTGAGTGGG
20 GACCGCATCCATTGCATGGACATTCTCTTTGCCCTTACCAAAAGGGTCTGGGGG
AGTCTGGGGAGATGGACGCCCTGAAGATCCAGATGGAGGAGAAGTTCATGGCAG
CCAAACCCATCCAAGATCTCCTACGAGCCCATCACCAACCACTCCGGGGCAAGCA
CGAAGAGGTGTGGGCCATGGTTATCCAGAGAGCGTTCCGCAGGGCAAGGTGCTGCA
AAGCTCTTTGAAGCATGCGCTCCTTCTTCCGTGAGCAGGCGGGGAGCGGCCCTC
25 TCCGAAGAGGATGCCCTGAGCGAGAGGGCCTCATCGCTACGTGATGAGTGAG
AACTTCTCCCGACCCCTTGGCCCACCCTCCAGCTCCTCCATCTCCTCCACTTCTT
CCCACCTCCTATGACAGTGTCACTAGAGCCACCAGCGATAACCTCCAGGTGCGG
GGGTCTGACTACAGCCACAGTGAAGATCTCGCCGACTTCCCCCTTCTCCGGACA
GGGACCGTGAGTCCATCGTGTGAGCCTCGGCCTGGCTGGCCAGGACACACTGAA
30 AAGCAGCCTTTTTTACCATGGCAAACCTAAATGCAGTCAGTCACAAACCAGCCTG
GGGCCTTCTTGGCTTTGGGAGTAAGAAATGGGCCTCGGCCCGCGGATCAACCA
GGCAGAGTTCTGTGGCGCCGCGTGGACAGCCGAGCAGTTGGCCTGTGCTTGGGA
GGCCTCAGATAGACCTGTGACCTGGTCTGGTCAGGCAATGCCCTGCGGCTCTGG
AAAGCAACTTCATCCCAGCTGCTGAGGGCGAAATATAA¹AACTGAGACTGTATATG
35 TTGTGAATGGGCTTTCATAAATTTATTATATTTGATATTTTTTTACTTGAGCAAAG
AACTAAGGATTTTTCCATGGACATGGGCAGCAATTCACGCTGTCTCTTCTTAACC
CTGAACAAGAGTGTCTATGGAGCAGCCGGAAGTCTGTTCTCAAAGCAGAAGTGG
AATCCAGTGTGGCTCCACAGGTCTTCACTGCCCAGGGGTGCAATGGGGTCCCCC
TCCCCTTGATGAGATGCTGGGAGGGCTGAACCCCACTCACACAAGCANACAC
40 ACACAGTCCTCACACACGGAGGCCAGACACAGGCCGTGGGACCCAGGCTCCCAG
CCTAAGGGAGACAGGCCTTTCCTTCCCGGCCCCCCCAAGGATGGGGTTCTTGTCCA
CGGGGCTCACTCTGGCCCCCTATTGTCTCCAAGGTCCCATTTTCCCCCTGTGTTTT
CACGCAGGTCATATTGTGAGTCTTACAAAAATAAAAGGCTTCCAGAGGAGAGTG
GCCTGGGGTCCCAGGGCTGGGCCNTAGGCACTGATAGTTGCCTTTTCTTCCCCTC
45 CTGTAAGAGTATTAACAAAACCAAAGGACACAAGGGTGCAAGCCCCATTACGG
CCTGGCATGCAGCTTGTCTTGTCTCTGGAACCTGGCAGGCCCTGCCAGCCAGCC
AATGGAAGAGAGGGGCTGAGCCATGGGGGTTTGGGGCTAAGAAGTTCACCAGCC
CTGAGCCATGGNCCCTCAGCCTGCCTGAAGAGAGGAAACTGGCGATCTCCCAGG
GCTCTCTGGACCATAACNCGGAGGAGTTTTCNNGTGTGGTCTCCAGCTCCTCTCCA

GACACAGAGACATGGGAGTGGGGAGCGGACGTTGGCCCTGGCCCTGTGCAGGGA
 AAGGGATGGTCAGGCCCAGTTCTCGTGCCCTTAGAGGGGAATGAACCATGGCA
 CCTTTGAGAGAGGGGGGCACTGTGGTCAGGCCCAGCCTCTCTGGCANNAGTCCCGG
 GATCCTGATGGCACCCACACAGAGGACCTCTTTGGGGCAAGATCCAGGTGGNTC
 5 CCATAGGTCTTGTGAAAAGGCTTTTTTCAGGGAAAAATATTTTACTAGTCCAATCA
 CCCCCAGGACCTCTTCAGCTGCGACAATCCTATTTAGCATATGCAAATCTTTTAA
 CATAGAGAACTGTCACCTGAGGTAACAGGGTCAACTGGCGAAGCTGAAGCAGG
 CAGGGGCTTGGCTGCCCCATTCCAGCTCTCCACGGAGCCCCTCCAACCGGGGCGC
 ATGCTCCCAGGCCACCTCAGTCTCACCTGCCGGCTCTGGGCTGGCTGCTCCTAAC
 10 CTACCTCGCCGAGCTGTGCGAGGGCTGGACATTTGTGGCAGTGCTGAAGGGGGC
 ATTGCCGGCGAGTAAAGTATTATGTTTCTTCTTGTACCCCAAGTTCCCTTGGTGGC
 AACCCAGACCCAACCCATGCCCCTGACAGATCTAGTTCTCTTCTCTGTGTTCCC
 TTTGAGTCCAGTGTTGGGACACGGTTTAACTGTCCAGCGACATTTCTCCAAGTGG
 AAATCCTATTTTTGTAGATCTCCATGCTTTGCTCTCAAGGCTTGGAGAGGTATGTG
 15 CCCCTCCTGGGTGCTCACCGCCTGCTACACAGGCAGGAATGCGGTTGGGAGGCA
 GGTCGGGCTGCCAGCCCAGCTNGCCGGAAGGAGACTGTGGTTTTTGTGTGTGTGG
 ACAGCCCGGGAGCTTTGAGACAGGTGCCTGGGGCTGGCTGCAGACGGTGTGGTT
 GGGGGTGGGAGGTGAGCTAGACCCAACCCTTAGCTTTTAGCCTGGCTGTCACCTT
 TTTAATTTCCAGAACTGCACAATGACCAGCAGGAGGGGAGAAGAGAGTAGGAAA
 20 AAGGAGGGAAGGACAGACATCAAGTGCCAGATGTTGTCTGAACTAATCGAGCAC
 TTCTACCAAACCTTCATGTATAAATAAAATACATATTTTTTAAACAAACCAATAA
 ATGGCTTACATGACCTGG

SEQ ID NO: 618

25 >21187 BLOOD 319829.1 AJ009936 g5852062 Human mRNA for nuclear hormone
 receptor PRR1. 0
 TGAAATATAGGTGAGAGACAAGATTGTCTCATATCCGGGGAAATCATAACCTAT
 GACTAGGACGGGAAGAGGAAGCACTGCCTTTACTTCAGTGGGAATCTCGGCCTC
 AGCCTGCAAGCCAAGTGTTACAGTGAGAAAAGCAAGAGAATAAGCTAATACTC
 30 CTGTCCTGAACAAGGCAGCGGCTCCTTGGTAAAGCTACTCCTTGATCGATCCTTT
 GCACCGGATTGTTCAAAGTGGACCCCAGGGGAGAAGTCGGAGCAAAGAAGTAC
 CACCAAGCAGTCCAAGAGGCCAGAAAGCAAACCTGGAGGTGAGACCCAAAGAA
 AGCTGGAACCATGCTGACTTTGTACACTGTGAGGACACAGAGTCTGTTCTCGGAA
 AGCCCAAGTGTCACGCAGATGAGGAAAGTCGGAGGTCCCAAAATCTGCCGTGTAT
 35 GTGGGGACAAGGCCACTGGCTATCACTTCAATGTCATGACATGTGAAGGATGCA
 AGGGCTTTTTTCAGGAGGGCCATGAAACGCAACGCCCGGCTGAGGTGCCCTTCC
 GGAAGGGCGCCTGCGAGATCACCCGGAAGACCCGGCGACAGTGCCAGGCCTGCC
 GCCTGCGCAAGTGCCTGGAGAGCGGCATGAAGAAGGAGATGATCATGTCCGACG
 AGGCCGTGGAGGAGAGGCGGGCCTTGATCAAGCGGAAGAAAAGTGAACGGACA
 40 GGGACTCAGCCACTGGGAGTGCAGGGGCTGACAGAGGAGCAGCGGATGATGATC
 AGGGAGCTGATGGACGCTCAGATGAAAACCTTTGACACTACCTTCTCCCATTTCA
 AGAATTTCCGGCTGCCAGGGGTGCTTAGCAGTGGCTGCGAGTTGCCAGAGTCTCT
 GCAGGCCCCATCGAGGGAAGAAGCTGCCAAGTGGAGCCAGGTCCGAAAGATCT
 GTGCTCTTTGAAGGTCTCTCTGCAGCTGCGGGGGGAGGATGGCAGTGTCTGGAAC
 45 TACAAACCCCCAGCCGACAGTGGCGGGAAAGAGATCTTCTCCCTGCTGCCCCAC
 ATGGCTGACATGTCAACCTACATGTTCAAAGGCATCATCAGCTTTGCCAAAGTCA
 TCTCCTACTTCAGGGACTTGCCCATCGAGGACCAGATCTCCCTGCTGAAGGGGGC
 CGCTTTCGAGCTGTGTCAACTGAGATTCAACACAGTGTTCACGCGGAGACTGGA
 ACCTGGGAGTGTGGCCGGCTGTCCTACTGCTTGAAGACACTGCAGGTGGCTTCC

AGCAACTTCTACTGGAGCCCATGCTGAAATTCCACTACATGCTGAAGAAGCTGCA
GCTGCATGAGGAGGAGTATGTGCTGATGCAGGCCATCTCCCTCTTCTCCCCAGAC
CGCCCAGGTGTGCTGCAGCACCGCGTGGTGGACCAGCTGCAGGAGCAATTCGCC
ATTACTCTGAAGTCCTACATTGAATGCAATCGGCCCCAGCCTGCTCATAGGTTCT
5 TGTTCCTGAAGATCATGGCTATGCTCACCGAGCTCCGCAGCATCAATGCTCAGCA
CACCCAGCGGCTGCTGCGCATCCAGGACATACACCCCTTTGCTACGCCCCCTCATG
CAGGAGTTGTTTCGGCATCACAGGTAGCTGAGCGGCTGCCCTTGGGTGACACCTCC
GAGAGGCAGCCAGACCCAGAGCCCTCTGAGCCGCCACTCCCGGGCCAAGACAGA
TGGAACTGCCAAGAGCCGACAATGCCCTGCTGGCCTGTCTCCCTAGGGAATTCC
10 TGCTATGACAGCTGGCTAGCATTCCTCAGGAAGGACATGGGTGCCCCCACCCTCC
AGTTCAGTCTGTAGGGAGTGAAGCCACAGACTCTTACGTGGAGAGTGCCTGAC
CTGTAGGTCAGGACCATCAGAGAGGCAAGGTTGCCCTTTCTTTTAAAAGGCCCT
GTGGTCTGGGGAGAAATCCCTCAGATCCCACTAAAGTGTCAAGGTGTGGAAGGG
ACCAAGCGACCAAGGATGGGCCATCTGGGGTCTATGCCACATACCCACGTTTGT
15 TCGCTTCTGAGTCTTTTCATTGCTACCTCTAATAGTCTGTCTCCCACTTCCCACT
CGTTCCTCTCTTCCGAGCTGCTTTGTGGGCTCCAGGCCTGTACTCATCGGCAG
GTGCATGAGTATCTGTGGGAGTCTCTAGAGAGATGAGAAGCCAGGAGGCCTGC
ACCAAATGTCAGAAGCTTGGCATGACCTCATTCCGGCCACATCATTCTGTGTCTC
TGCATCCATTTGAACACATTATTAAGCACCGATAATAGGTAGCCTGCTGTGGGGT
20 ATACAGCATTGACTCAGATATAGATCCTGAGCTCACAGAGTTTATAGTTAAAAAA
ACAAACAGAAACACAAACAATTTGGATCAAAAGGAGAAATGATAAGTGACAAA
AGCAGCACAAAGGAATTTCCCTGTGTGGATGCTGAGCTGTGATGGCGGGCACTGG
GTACCCAAGTGAAGGTTCCCGAGGACATGAGTCTGTAGGAGCAAGGGCACAAAC
TGCAGCTGTGAGTGCCTGTGTGTGATTTGGTGTAGGTAGGTCTGTTTGCCACTTG
25 ATGGGGCCTGGGTTTGTTCCTGGGGCTGGAATGCTGGGTATGCTCTGTGACAAGG
CTACGCTGACAATCAGTTAAACACACCGGAGAAGAACCATTTACATGCACCTTAT
ATTTCTGTGTACACATCTATTCTCAAAGCTAAAGGGTATGAAAGTGCCTGCCTTG
TTTATAGCCACTTGTGAGTAAAAATTTTTTTGCATTTTCACAAATTATACTTTATA
TAAGGCATTCCACACCTACGAAGTATGTTTGGGAAATGTAGCCCTGGGTTTAATG
30 TCAAATCAAGGCAAAAGGAATTAAATAATGTACTTTTGGCTAGAGGGGTAAACT
TTTTTGGCCTTTTTCTGGGGAAAATAATGTGGGGGTGTGGAAATAGAAACATACG
CAAGCATACATATTTTACTACTTATTTTATTATTATCCTGTATAAAT

SEQ ID NO: 619

35 >21189 BLOOD 232328.1 AF169677 g6808606 Human leucine-rich repeat transmembrane
protein FLRT3 (FLRT3) mRNA, complete cds. 0
GTCCAATAATAACCTAAGTAATTTACCTCAGGGTATCTTTGATGATTTGGACAAT
ATAACACAACCTGATTCTTCGCAACAATCCCTGGTATTGCGGGTGCAAGATGAAAT
GGGTACGTGACTGGTTACAATCACTACCTGTGAAGGTCAACGTGCGTGGGCTCAT
40 GTGCCAAGCCCCAGAAAAGGTTCTGTGGGATGGCTATTAAGGATCTCAATGCAGA
ACTGTTTGATTGTAAGGACAGTGGGATTGTAAGCACCATTCAGATAACCACTGCA
ATACCCAACACAGTGTATCCTGCCCAAGGACAGTGGCCAGCTCCAGTGACCAAA
CAGCCAGATATTAAGAACCCCAAGCTCACTAAGGATCAACAAACCACAGGGAGT
CCCTCAAGAAAAACAATTACAATTACTGTGAAGTCTGTCACCTCTGATACCATTC
45 ATATCTCTTGAAACTTGCTCTACCTATGACTGCTTTGAGACTCAGCTGGCTTAAA
CTGGGCCATAGCCCGGCATTTGGATCTATAACAGAAACAATTGTAACAGGGGAA
CGCAGTGTGTACTTGGTCACAGCCCTGGAGCCTGATTCACCTATAAAGTATGCA
TGGTTCCTATGGAAACCAGCAACCTCTACCTATTTGATGAAACTCCTGTTTGTATT
GAGACTGAAACTGCACCCCTTCGAATGTACAACCCTACAACCACCCTCAATCGAG

AGCAAGAGAAAGAACCTTACAAAAACCCCAATTTACCTTTGGCTGCCATCATTGG
TGGGGCTGTGGCCCTGGTTACCATTGCCCTTCTTGCTTTAGTGTGTTGGTATGTTT
ATAGGAATGGATCGCTCTTCTCAAGGAAGTGTGCATATAGCAAAGGGAGGAGAA
GAAAGGATGACTATGCAGAAGCTGGCACTAAGAAGGACAAGTCTATCCTGGAAA
5 TCAGGGAACTTCTTTTCAGATGTTACCAATAAGCAATGAACCCATCTCGAAGGA
GGAGTTTGTAAATACACACCATATTTCCCTCCTAATGGAATGAATCTGTACAAAAAC
AATCACAGTGAAAGCAGTAGTAACCGAAGCTACAGAGACAGTGGTATTCCAGAC
TCAGATCACTCACACTCATGATGCTGAAGGACTCACAGCAGACTTGTGTTTTGGG
TTTTTTAAACCTAAGGGAGGTGATGGTAGGAACCCCTGTTCTACTGCAAAACACTG
10 GAAAAAGAGACTGAAAAAAGCAATGTACTGTACATTTGCCATATAATTTATATT
TAAGAACTTTTTATTAAAAGTTTCAAATTTCAAGGTTACTGCTGCGATTGATGTAGT
GGAGATGCCTGAACACAATTCTATATTTTAGTATTTTTTAGTAATTTGTACTGTAT
TTTCCTTGCAAATATTGGAGTTATAAACCATTTACTTTGTGTTCTACTGAGTAAGA
TGACTTGTGACTGTGAAAGTGAATTTTCTTGCTGTGTGCGAACAATCAGGACTGC
15 ATTCATATGAGATCCTTGTAAGTATAAGCACAGGCCATTTTTCACTTTGGTATTAAT
AAAATGTAAAAAAGCAATGTACTGTACATTTGCCATATAATTTATATT
TAAAAAATGGTTATGAAATAATGTTCCAATTATTAAATTTGTATTATCCCAGTGG
TATTCAATAAATCAAAATGTGTGAAGTAATGGGCAATATCAAAGTCTCCTGCATAT
CTCCATTTTTGCTCTAGGCAAATTAATTATCCTTAAAAAAGTTAAGCATATCTTCT
20 GAACTGAATACATCAGCTGGCATAAAAGGAGCATGAAGTCTGTTAAAGCCATTG
TCAGCAAAGCTTTGAAAATAAAGGACTTCACAAAAACGGTAATGTAAATGTGCT
TCCAAGTTGGGGGGAAAATGFGTACTTAGGAAAACATGGAAACTTAGACTTGTA
TAGTGTAAATGAACACAAATACCAAACTGCATTTTGGTTTTGCCTATACCATCCT
GATTTTTGAAAAGTGAATTATAAACACAAAATTGTTAGTGTATTATGATGTTTTAT
25 CATAAAGGATGTCAGAGAACTTTATGCATATTAATAAATGTAATGTAATTATAAG
CGATCCCCCTCAACAATCCAGAGAAAGTAGTTCTTTAAATAAGAGATAATTTAAA
GAAAAATAAATACTAGACATCAAATTTAGATCTGGTTTATGTCAAAGGTTTTAAC
ACTGTACATAAATGTTCAATTTACTTTTACAAAGATCAAGAATACTGCCCATAC
TGTCACAATTTTCCAGATATTATATAATGAACTCGTAATGTAACATTTCTTCTAG
30 CTTCTACTGAATTGTGAGCTGTTACTTGTGAAAAACCATATCACTTTTCTGTTG
CCATGATTTTTTTTTTCAACAAAAAACCAAAGTGCATTGTACGCCCTTTGGCCAGT
CTTGATGTGCCTTGATCCAACGCTACATGTATTCAGCTTTTAAACTCCACAAAT
TTTTCATACTCCTTAAATATGAAAAATFATGGTCTTATTGCTGAATAAACTTTTA
AAAAGTACAGAATAATTGTGCTTGTCTTTTTCAGGATTGTGTTACTATCACTAAGT
35 AGCAAATTGCCAGACATTAAGTCTTAAACGTCCCATGTATTTTTCTAGGCATAA
AAATAAAAGTTGGCTAAAAATTTTAAAAAATC

SEQ ID NO: 620

>21213 BLOOD 474592.17 AF061749 g3372676 Human tumorous imaginal discs protein

40 Tid56 homolog (TID1) mRNA, complete cds. 0
GATGGCTGCGCGGTGCTCCACACGCTGGTTGCTGGTGGTTGTGGGGACCCCGCGG
CTGCCGGCTATATCGGGTAGAGGGGGCCCGGCCAGGGAGGGCGTGGTGGGG
GCATGGCTGAGCCGCAAGCTGAGCGTCCCCGCCTTTGCGTCTTCCCTGACCTCTT
GCGGCCCCCGAGCGCTGCTGACATTGAGACCTGGTGTGAGCCTCACAGGAACAA
45 AACATTACCCTTTCATTTGTACTGCCTCCTTCCACACGAGTGGCCCTTTGGCCAAA
GAAGATTATTATCAGATATTAGGAGTGCCTCGAAATGCCAGCCAGAAAGAGATC
AAGAAAGCCTATTATCAGCTTGCCAAGAAGTATCACCTGACACAAATAAGGAT
GATCCCAAAGCCAAGGAGAAGTTCTCCAGCTGGCAGAAGCCTATGAGGTTTTG
AGTGATGAGGTGAAGAGGAAGCAGTACGATGCCTACGGCTCTGCAGGCTTCGAT

CCTGGGGCCAGCGGCTCCCAGCATAGCTACTGGAAGGGAGGCCCCACTGTGGAC
 CCGGAGGAGCTGTTTCAGGAAGATCTTTGGCGAGTTCTCATCCTCTTCATTTGGAG
 ATTTCCAGACCGTGTTTGATCAGCCTCAGGAATACTTCATGGAGTTGACATTCAA
 TCAAGCTGCAAAGGGGGTCAACAAGGAGTTCACCGTGAACATCATGGACACGTG
 5 TGAGCGCTGCAACGGCAAGGGGAACGAGCCCGGCACCAAGGTGCAGCATTGCCA
 CTACTGTGGCGGCTCCGGCATGGAAACCATCAACACAGGCCCTTTTGTGATGCGT
 TCCACGTGTAGGAGATGTGGTGGCCGCGGCTCCATCATCATATCGCCCTGTGTGG
 TCTGCAGGGGAGCAGGACAAGCCAAGCAGAAAAAGCGAGTGATGATCCCTGTGC
 CTGCAGGAGTCGAGGATGGCCAGACCGTGAGGATGCCTGTGGGAAAAAGGGAA
 10 ATTTTCATTACGTTTCAGGGTGCAGAAAAGCCCTGTGTTCCGGAGGGACGGCGCAG
 ACATCCACTCCGACCTCTTTATTTCTATAGCTCAGGCTCTTCTTGGGGGAACAGCC
 AGAGCCCAGGGCCTGTACGAGACGATCAACGTGACGATCCCCCTGGGACTCAG
 ACAGACCAGAAGATTTCGGATGGGTGGGAAAGGCATCCCCCGGATTAACAGCTAC
 GGCTACGGAGACCACTACATCCACATCAAGATACGAGTTCCAAAGAGGCTAACG
 15 AGCCGGCAGCAGAGCCTGATCCTGAGCTACGCCGAGGACGAGACAGATGTGGAG
 GGGACGGTGAACGGCGTCAACCCTCACCAGCTCTGGAAAAAGATCCACTGGAAAC
 TAGGCCGGGAAGCAGCAGCCCCCTCCAAGGGCCAGGGCACCTGGGAGACGGGAG
 GATTCCAGAACAGCAGCACTGAGCTCCACCCGCAGAGCCTCTGGACGGCCTTG
 GCAACAGCAAAATCATGGGACAACACCTCTCTCCACGGAAAGGTCACAGTGGAC
 20 AGCCCGGGCAGTAGGATGCAGCCCCAGAGGCTGGTGGCAGTTTCCTGTCCATTG
 GTAGGTGACGGCCCCCTGGCTCAGGCAGAGGGAGATGGTTAGACTCTTGCAGGGC
 TAAAACTCTAATTTGGAATTGAATATTGTGGATATCTTAGTTAAAGGCCATGCTT
 ACAGCTTAGAAATGAAGCCTTAAGCTGCATCAAGTTACGAAGTGATTAATTTCTC
 TCTCAGCAAACCTCCGGGAGGTTTGGAGATGAGTTCCTCCTGACAGGTTGTCTTC
 25 ACTGGGAGCGTGGGGCCCCCAGGCCCCACCAGCACCGTCCTCCCCTAATGAGGG
 GCCCTGCCGAGGCATCAGCTGCTCTGCTCAGTTAGTTTTTATTCCCGGGGTACCA
 AGCAGCTGCACAGTCGGTGCCTGGGAGGCACGTAGAGGCCCAGAGAGTCCCTGG
 GGGTTCTGCTCTGACCGTGTGGGTGGTGATCCTTGTGAGGATGTACAGTCCCTGC
 TCCCACCCCATCCAGGATGGCCGCCTGTCCCTGACTATTGAGTCCTGTTGTTGTAA
 30 GCCAGGCATGGAGGGCTCCTGCCCTTCTGCTGAGCCACAGCCCATTGCAGCACTG
 TGCTGGCCAGACTTCAGCTGCCTTGGGAACTGAAGCCCTGCCACTGTTGCTAGTC
 AGGGGCTTGGTTCTCCCACTTACACTGTTGACATCTATTTTCTGAAGTGTGTTTAA
 ATTATTCAAGTGCTAATCATTGTTTTTCTTTGTAAATGTTGATTCAGAAAAGGAA
 AGCACAGGCTAAGCAGTTGAAGGTTCCCCACCATTCAAGTGAAGAGCAGAACCCCC
 35 ATTCCCCAGCCTCTGCTGGTAGCATGTCGAGTTTCCATGTGTTTCAGGATCTTCG
 GGCTGTCGTTAGACAGGTTAATGAAGAACACTTCTCAACAGTTTCTTTTGT
 CCTTTATAATTCACTAAAATAAAGCATCTATTAGTGTCTGATTTAGGAATGTAAA
 ATGATTCTGTATTAATGTAAATAAGATTATCTATTGCAAAAAGATATTTCAAACC
 TAAAA

40

SEQ ID NO: 621

>21224 BLOOD 197014.6 AF095742 g4588081 Human serine protease ovasin mRNA,
complete cds. 0

GTGCAGGAGGAGAAGGAGGAGGAGCAGGAGGTGGAGATTCCCAGTTAAAAGGC
 45 TCCAGAATCGTGTAACAGGCAGAGAACTGAAGTACTGGGGCCTCCTCCACTGGG
 TCCGAATCAGTAGGTGACCCCGCCCTGGATTCTGGAAGACCTCACCATGGGACG
 CCCCCGACCTCGTGCGGCCAAGACGTGGATGTTCTGCTCTTGCTGGGGGGAGCC
 TGGGCAGGACACTCCAGGGCACAGGAGGACAAGGTGCTGGGGGGTTCATGAGTGC
 CAACCCCATTCGCAGCCTTGGCAGGCGGCCTTGTTCCAGGGCCAGCAACTACTCT

GTGGCGGTGTCCTTGTAGGTGGCAACTGGGTCCTTACAGCTGCCCCACTGTAAAAA
ACCGAAATACACAGTACGCCTGGGAGACCACAGCCTACAGAATAAAGATGGCCC
AGAGCAAGAAATACCTGTGGTTCAGTCCATCCCACACCCCTGCTACAACAGCAG
CGATGTGGAGGACCACAACCATGATCTGATGCTTCTTCAACTGCGTGACCAGGCA
5 TCCCTGGGGTCCAAAGTGAAGCCCATCAGCCTGGCAGATCATTGCACCCAGCCTG
GCCAGAAGTGCACCGTCTCAGGCTGGGGCACTGTCACCAGTCCCCGAGAGAATT
TTCCTGACACTCTCAACTGTGCAGAAGTAAAAATCTTTCCCCAGAAGAAGTGTGA
GGATGCTTACCCGGGGCAGATCACAGATGGCATGGTCTGTGCAGGCAGCAGCAA
AGGGGCTGACACGTGCCAGGGCGATTCTGGAGGCCCCCTGGTGTGTGATGGTGC
10 ACTCCAGGGCATCACATCCTGGGGCTCAGACCCCTGTGGGAGGTCCGACAAACC
TGGCGTCTATACCAACATCTGCCGCTACCTGGACTGGATCAAGAAGATCATAGGC
AGCAAGGGCTGATTCTAGGATAAGCACTAGATCTCCCTTAATAAACTCACAATC
TCTGGTTC

15 SEQ ID NO: 622

>21240 BLOOD 255990.12 AJ011497 g4128014 Human mRNA for Claudin-7. 0

CCCACGCGTCCGCTCACCTCCGAGCCACCTCTGCTGCGCACCGCAGCCTCGGACC
TACAGCCCAGGATACTTTGGGACTTGCCGGCGCTCAGAAACGCGCCCAGACGGC
CCCTCCACCTTTTGTGTGCTAGGGTCGCCGAGAGCGCCCGAGGGGAACCGCCTG
20 GCCTTCGGGGACCACCAATTTTGTCTGGAACCACCCTCCCGCGTATCCTACTCC
CTGTGCCGCGAGGCCATCGCTTCACTGGAGGGGTGATTTGTGTGTAGTTGGTG
ACAAAGATTTGCATTACCTGGGCCAAACCCCTTTTGTCTCTTTGGGTGACCGGAA
AACTCCACCTCAAGTTTCTTTGTGGGGCTGCCCCCAAGTGTCTGTTTGTTTTA
CTGTAGGGTCTCCCCGCCCGGGCGCCCGAGTGTCTTCTGAGGGCGGAAATGGCCA
25 ATTCGGGCCTGCAGTTGCTGGGCTTCTCCATGGGCCCTGCTGGGCTGGGTGGGTC
TGGTGGCCTGCACCGCCATCCCGCAGTGGCAGATGAGCTCCTATGCGGGTGACA
ACATCATCACGGCCCAGGCCATGTACAAGGGGCTGTGGATGGACTGCGTCACGC
AGAGCACGGGGATGATGAGCTGCAAAATGTACGACTCGGTGCTCGCCCTGTCCG
CGGCCTTGCAAGGCCACTCGAGCCCTAATGGTGGTCTCCCTGGTGTGGGCTTCCT
30 GGCCATGTTTGTGGCCACGATGGGCATGAAGTGCACGCGCTGTGGGGGAGACGA
CAAAGTGAAGAAGGCCCGTATAGCCATGGGTGGAGGCATAATTTTCATCGTGGC
AGGTCTTGCCGCTTGGTAGCTTGCTCCTGGTATGGCCATCAGATTGTCACAGAC
TTTTATAACCCTTTGATCCCTACCAACATTAAGTATGAGTTTGGCCCTGCCATCTT
TATTGGCTGGGCAGGGTCTGCCCTAGTCATCCTGGGAGGTGCACTGCTCTCCTGT
35 TCCTGTCCTGGGAATGAGAGCAAGGCTGGGTACCGTGTACCCCGCTCTTACCCTA
AGTCCAACCTCTTCCAAGGAGTATGTGTGACCTGGGATCTCCTTGCCCCAGCCTGA
CAGGCTATGGGAGTGTCTAGATGCCTGAAAGGGCCTGGGGCTGAGCTCAGCCTG
TGGGCAGGGTGCCGGACAAAGGCCTCCTGGTCACTCTGTCCCTGCACTCCATGTA
TAGTCCTCTTGGGTTGGGGGTGGGGGGGTGCCGTTGGTGGGAGAGACAAAAAGA
40 GGGAGAGTGTGCTTTTTGTACAGTAATAAAAAATAAGTATTGGGAAGCAGGCTTT
TTTCCCTTCAGGGCCTCTGCTTTCCTCCCGTCCAGATCCTTGCAGGGAGCTTGGAA
CCTTAGTGCACCTACTTCAGTTCAGAACACTTAGCACCCCACTGACTCCACTGAC
AATTGACTAAAAGATGCAGGTGCTCGTATCTCGACATTCATTCCCACCCCCCTCT
TATTTAAATAGCTACCAAAGTACTTCTTTTTTAATAAAAAAATAAAGATTTTTATT
45 AGGTAAANAAAAA

SEQ ID NO: 623

>21270 BLOOD INCYTE_1381683H1

GCTTATTCACCTTTGTGTTTTCTTTGTTTTATTTTGTCCAATTTTGTCTTTAGCTGTG
TTTATTAACCTCTCCGGTCTTGTTTTGTTTTAATGCTCTTGGCCCAGTGGGTGTCA
AGAACACTGGCTTAATTCAAGTCAGTTGATTTTTTTCTATTAAAACTGTTGTAA
AATATTTTTTAAAACAAAACATTATTTGTGCCCTCTTTTATATATGTCAAAGGGA
5 CACTGTCAAGTATTTCAATT

SEQ ID NO: 624

>21285 BLOOD 1008401.7 M17783 g183063 Human glia-derived nexin (GDN) mRNA, 5'
end. 0

10 GTGTGCTGGCAAAGTGCTTGGCTGCGCGGCGTCTGCAGGCGCCACCGCTGCCTCT
TTCCGGCTGTGACCCTCCTCGCCGCCGCCGCTTCGCTGCGTCCTCCGACTCCCCGC
GCCGCCGAGACCAGGCTCCCGCTCCGGTTGCGGCCGCACCGCCCTCCGCGGCCGC
CCCCTGGGGATCCAGCGAGCGCGGTCGTCCTTGGTGGAAGGAACCATGAACTGG
CATCTCCCCCTCTTCCTCTTGGCCTCTGTGACGCTGCCTTCCATCTGCTCCCACTTC
15 AATCCTCTGTCTCTCGAGGAAGTAGGCTCCAACACGGGGATCCAGGTTTTCAATC
AGATTGTGAAGTCGAGGCCTCATGACAACATCGTGATCTCTCCCCATGGGATTGC
GTCGGTCCTGGGGATGCTTCAGCTGGGGGCGGACGGCAGGACCAAGAAGCAGCT
CGCCATGGTGATGAGATACGGCGTAAATGGAGTTGGTAAAATATTAAAGAAGAT
CAACAAGGCCATCGTCTCCAAGAAGAATAAAGACATTGTGACAGTGGCTAACGC
20 CGTGTTTGTAAAGAATGCCTCTGAAATTGAAGTGCCTTTTGTACAAAGGAACAAA
GATGTGTTCCAGTGTGAGGTCCGGAATGTGAACTTTGAGGATCCAGCCTCTGCCT
GTGATTCATCAATGCATGGGTTAAAAATGAAACCAGGGATATGATGACAATCT
GCTGTCCCGAGATCTTATGATGGTGTGCTCACCAGACTGGTCCTCGTCAACGCA
GTGTATTTCAAGGGTCTGTGGAAATCACGGTTCCAAACCGAGAACACAAAGAAA
25 CGCACTTTCGTGGCAGCCGACGGGAAATCCTATCAAGTGCCAATGCTGGCCCCAGC
TCTCCGTGTTCCGGTGTGGGTCGACAAGTGCCCCCAATGATTTATGGTACAACCTT
CATTGAACTGCCCTACCACGGGGAAAGCATCAGCATGCTGATTGCACTGCCGACT
GAGAGCTCCACTCCGCTGTCTGCCATCATCCACACATCAGCACCAAGACCATAG
ACAGCTGGATGAGCATCATGGTGCCCAAGAGGGTGCAGGTGATCCTGCCCAAGT
30 TCACAGCTGTAGCACAAACAGATTTGAAGGAGCCGCTGAAAGTTCTTGGCATTAC
TGACATGTTTGATTATCAAAAGGCAAATTTTGCAAAAATAACAAGGTCAGAAAA
CCTCCATGTTTCTCATATCTTGCAAAAAGCAAAAATTGAAGTCAGTGAAGATGGA
ACCAAAGCTTCAGCAGCAAGAACTGCAATCTCATTGCAAGATCATCGCCTCCCT
GGTTTATAGTAGACAGACCTTTTCTGTTTTTCATCCGACATAATCCTACAGGTGCT
35 GTGTTATTCATGGGGCAGATAAAACAAACCCTGAAGAGTATACAAAAGAAACCAT
GCAAAGCAACGACTACTTTGCTACGAAGAAAGACTCCTTTCTGCATCTTTCATA
GTTCTGTTAAATATTTTTGTACATCGCTTCTTTTCAAACTAGTTCTTAGGAACA
GACTCGATGCAAGTGTTTCTGTTCTGGGAGGTATTGGAGGGAAAAACAAGCAG
GATGGCTGGAACACTGTACTGAGGAATGAATAGAAAGGCTTCCAGATGTCTAAA
40 AGATTCTTTAACTACTGAACTGTTACCTAGGTAAACAACCCTGTTGAGTATTTGC
TGTTTGTCCAGTTCAGGAATTTTTGTTTTGTTTTGTCTATATGTGCGGCTTTTCAGA
AGAAATTTAATCAGTGTGACAGAAAAAAAATGTTTTATGGTAGCTTTTACTTTT
TATGAAAAAAAATTTATTTGCCTTTTAAATCTTTTCCCCCATCCCCCTCCAAAGT
CTTGATAGCAAGCGTTATTTTGGGGGTAGAAACGGTGAAATCTCTAGCCTCTTTG
45 TGTTTTTGN TGATGCTGTTGTTGTTGTTTTATATAATGCATGTATTCACTAAAATA
AAATTTAAAAAACTCCTGTCTTGCTAGACAAGGTTGCTGTTGTGCAGTGTGACAG
AAAAAAAATGTTTTATGGTAGCTTTTACTTTTTATGAAAAAAAATTTATTTGGC
TTTTAAATCTTTTCCCCCANCCCCCTCCAAAGTCTTGATAGCAAGCGTTATTTNG
GGGGTAGAAACGGNGAAATCTCTAGCCTCNNNNNNNNNNNNNNNNNNNNNNNNNNNN

NNNNNNNNNNNNNTAATGCATGTATTCACTAAAATAAAATTTAAAAAACTCGA
AGGCTGCTCAGGGCCTTATAAACTGTTGTAGACAGCCCTGAATGTCCCCTGCTT
CCCACCACCCAGAGCCTGGGATCATGCAAGCTGGGAGAGAAGCTACAGAGGTAG
TGCCGTGTTTGGTGGAGTGACCTCTGCAGCCTCCCTCCCTCAGAGTGAGAATTTT
5 ATGTAATTCTTATCTGCAGTTGGGAATAAAAGAAGTTTGATTCTAGACACTGAA
ATACACGAAAGTTTATCATGCCACCCTTTTCCATCTCTTAGGAGAAATGGAAAAA
GAACACTCCAAACCTGGCCACTACCTGAGGATGTGTAAAGAGGTTTTCTGCAGGC
AATTAGACCCCACTACAGTGGAAGCTTGTAGAACATCACACATCGACAGTCTGA
AATGCACCACAAGAACTGCTCGAAGAGTGTGTCACTTTCACACTTACCTGACCGT
10 GGGATGGAAGTGCAGCGTAAGCCATGGGCTGATTCATCACTCCTTTCTGCTTCAT
GAGAAGCAGGCGTTTCTGGTCTTCGCTCAGGTGTGCCCTGGGGGCCTGGAGCTGT
GGAGGTGNN
NNNNNNNNNNNNNGATATACGGCATCAAGGGGTTTTTGTGGGGTTGGCCACTG
GTGGTGTCTCCTCTGACTCAGGTCTGCATTGAAGTGGGTCAGGGGTTTAGTGTT
15 GCCATAAGTCAGAATATTGTGCTGTTTGTAAAGGAGTTTGTACCCAAGTTATTTG
GCTGCTGATTGATCATATTTCATGTGATTCTGAGGGAGGTAGTTATTTCATTGTTGTC
TTCTGCAGGTTGTTTGCCATTGGAGGCACTATAGGGTTTTGGTTGTAAAGGCTTG
GGGGTACATCATTGGGCTATTTGGTTTTTCTGCAGTAAAAGCTGCTCCATATGGA
CTAGAGGGAGGTCCTAAGGGAGACCAATTTGAAGTCTGATTTGAGNNNNNNNN
20 NNGTTTCTGCTGCATGAGTTT
GGCCCTTTGTTGCTGCTGTGCAGCCATCTGTTTGAGCTGTTCTGCTGGAGACATGT
CAGAGCTGGGCACAGCCACAGGCCCTGACGCTGAACCGGCCACTGTCACTGCTG
CCGGATTTCAGGAGATAACCATTTCCAGGCCGAGGTGGAGCTTGGCCTGGAGTGT
GGGCTTGGTTTGGAGTTTGAAGGGGACTGGACAGCAAGTTTGCTGGTGAAGCTTGC
25 AGGGTTTGGAGCTGCGGGAGTGTGCGAACAGAAAGGTAAACTAGTGGCCGTGGA
GACAGTAGAAAAGGGGAAGGAACCCAAGGAAGGAAGAAGGCCCTTCGCCCTGG
GGGAGATCCCATGGAGACATGTGCGAAGGGAGAGTGAGAGGGGTCGCTCTTCAC
GCTCGCACTCTCCTGGGAGAGAGGGGTCTCAGTTGCTGGCTGCGAGAATTCTGGC
TCCTTCTTCTCTTCAAAGTCTTCGTTGAACAGGTCCTGTATGTCATCCTCAGGAAC
30 CGTGTGTCCAATTCATCTATTAATTCTTGCCACTCCTGATCATTAGATTAAATGT
CTGAGAACAGCTTGTCTGATTTGAAAGAGATGTTTCTGATGTGTCTATGCAAGT
AGGGTCATCGAGAGGTTCTTGTTGAGGTCTTTGCTCTGCAAGATGGTGAAGCTA
TCCTCCAGGTCAGTGCAACCGTTGACAGGAAGTTTAATCTCAGGGAGCCTACCAT
TCTTACTTAGATCTTCTAGAAGCCAGGAGTGTGAGTTCCACTGTTCTGCAAGGG
35 CAAAGAAGGTTTCAGGTCAAGTTGGTGAAGAGGAGAAGCTGAAGGCAGTGGCAT
GTTACTGGGCAAATTGTTGATGGCTTCCATCCCCGCAGAAATGTCCTTTTCAATT
CGTTTGCTAGTCGGAGAAAAATTCCCATCACAAGCACCATTCTGCTGGTCTCCAT
TAAGTGGTGATCGAGCTCCTTCCAACCTCCTTTTACAGTCTCTTGTAGCATGATC
AGCGTGTGGTTCTCTGCTCCGCCGAGGCAGCCTCCGCATCTTGCTGGGGTTTGC
40 TCGGGTGCTGCTGTTTGCCGGTGCCGGCGCCGATTTCTTGGCCCTCTGCTCCAGG
TCCGC

SEQ ID NO: 625

>21292 BLOOD INCYTE_157873H1

45 AGTAGCGTGACTACGTTTAAAACGGAGCAGCCAGGTGCTCCAAGCCCAGGTTTC
ATCTTCCTAACCAAGAAAGGCCGNCAAGTCTGTNCTGACCCCAGTAAGGAGTGG
TTCCAGGAAATACGGTCAGTAACCTGGGANCTGAGTGNCTTANGGGTCCAGAA
CTTNGANGNCCAGGCAACCTGAGTTGGCCAGNNNGGGAGGAGNAGGGGCCTG
NACCTTGGGGNACATG

SEQ ID NO: 626

>21294 BLOOD INCYTE_1594625F6

5 GGANATGGAAGGCAATGACNGCNACGAGGGCTCTGTGTGGANATGTTCAAGGNG
CTGGCAANAGATCCTNCGATTCAACTACAAGATCCGACTGGTTGGGGATGGNGT
GTACGGCGTTCCNGAGGNACAACGGCACCTGGAAGGGAATGGTNGGNGAGCTG
ATCNCTAGGAAAGCAGTCTGGCNGTGGCAGGCCTCACCATTACAGNTGAACGGG
AGAAGGTGNTTGATTTCTCTAAGC

10 SEQ ID NO: 627

>21298 BLOOD 441249.1 AF086432 g3483777 Human full length insert cDNA clone
ZD79H11.0

15 GGCAGGAGAATTTGAAAGGGTGCCCCAAAGGACAATCTCTAAAGGGGTAAGGG
AGATACCTACCTTGTCTGGTAGGGGAGATGTTTCGTTTTTCATGCTTTACCAGAAA
ATCCACTTCCCTGCCGACCTTAGTTTCAAAGCTTATTCTTAATTAGAGACAAGAA
ACCTGTTTCAACTTGAAGACACCGTATGAGGTGAATGGACAGCCAGCCACCACA
ATGAAAGAAATCAAACCAAGGAATAACCTATGCTGAACCCACGCCTCAATCGTCC
CCAAGTGTTTCTGACACGCATCTTTGCTTACAGTGCATCACAACCTGAAGAATGG
GGTTCAACTTGACGCTTGCAAAATTACCAAATAACGAGCTGCACGGCCAAGAGA
20 GTCACAATTCAGGCAACAGGAGCGACGGGCCAGGAAAGAACACCACCCTTCACA
ATGAATTTGACACAATTGTCTTGCCGGTGCTTTATCTCATTATATTTGTGGCAAGC
ATCTTGCTGAATGGTTTAGCAGTGTGGATCTTCTCCACATTAGGAATAAAACCA
GCTTCATAFTCTATCTCAAAAACATAGTGGTGGCAGACCTCATAATGACGCTGAG
ATTFCCATTTCTGAATAGTCCATGATGCAGGATTTGGACCTTGGTACTTCAAGTTTA
25 TTCTCTGCAGATACACTTCAGTTTTGTTTTATGCAAACATGTATACTTCCATCGTG
TTCTTGGGCTGATAAGCATTGATCGCTATCTGAAGGTGGTCAAGCCATTTGGGG
ACTCTCGGATGTACAGCATAACCTTCACGAAGGTTTTATCTGTTTGTGTTTGGGTG
ATCATGGCTGTTTTGTCTTTGCCAAACATCATCCTGACAAATGGTCAGCCAACAG
AGGACAATATCCATGACTGCTCAAACTTAAAAGTCCTTTGGGGGTCAAATGGC
30 ATACGGCAGTCACCTATGTGAACAGCTGCTTGTGTTGTGGCCGTGCTGGTGATTCT
GATCGGATGTTACATAGCCATATCCAGGTACATCCACAAATCCAGCAGGCAATTC
ATAAGTCAGTCAAGCCGAAAGCGAAAACATAACCAGAGCATCAGGGTTGTTGTG
GCTGTGTTTTTTACCTGCTTTCTACCATATCACTTGTGCAGAATTCCTTTTACTTTT
AGTCACTTAGACAGGCTTTTAGATGAATCTGCACAAAAAATCCTATATTACTGCA
35 AAGAAATTACACTTTTCTTGTCTGCGTGTAATGTTTGCCTGGATCCAATAATTTAC
TTTTTCATGTGTAGGTCATTTTCAAGAAGGCTGTTCAAAAAATCAAATATCAGAA
CCAGGAGTGAAAGCATCAGATCACTGCAAAGTGTGAGAAGATCGGAAGTTCGCA
TATATTATGATTACACTGATGTGTAGGCCTTTTATTGTTTGTGGAATCGATATGT
ACAAAGTGTAATAAAATGTTTCTTTTCATTAATAAAAAAAAAAAAAAAAAAAG

40

SEQ ID NO: 628

>21307 BLOOD 336954.1 AF033383 g2739502 Human potassium channel mRNA,
complete cds. 0

45 GCTGCTGCGCCGCGCTCCCGGCGCACTCGGAGCCCGGCGGGGACCGGGAGGCAG
AGACGGGGGCGGCCGTGGCTCCGAGGGCGGGAGCTGAGCCGGGCCCCGGGACCG
AAGTTTGGCGGCGGCTCCGGGAGGCAGAGCGGGCTCCCCGGGCGACTTCCAGGC
CCCTCTCGCGTCCTCGCCCCGACCCGTGGGCAGCCGGGGGGGACGGAAGCCGC
GGCCGGGCCAACTCCGAGGCGGGGACGCCGCGACGGGAACCTTGAGGTGGGAAC
TTGCGCGCTGCAGCCTCGCCGGGCGCCACCGAAGCGCGAACCGGACCCCGAGCC

TGCAAACCTCGGGCTCGGGGGCGGGCTGCACGTGGCCGTGGCCCTGAACTCCCTGC
 GGGGGCCTCGAAACCCGCCTGCGGGGAGGCCAGGGCGACAGAGGACTCGGGAG
 TCACCGCTGGTGCGTGGCGGCGTGGAGCGCGCTTGTTACGGCCAAGGGAGCAGG
 CTGCGCTAATGAAGGAGCCAGGCTTGACACAGACAATTCTAGAACTGGTGGCCC
 5 GAGAGGGATGTGAAGGCCCAAATGACCCTCTTACCGGGAGACAATTCTGACTA
 CGACTACAGCGCGCTGAGCTGCACCTCGGACGCCTCCTTCCACCCGGCCTTCCTC
 CCGCAGCGCCAGGCCATCAAGGGCGCGTTCTACCGCCGGGCGCAGCGGCTGCGG
 CCGCAGGATGAGCCCCGCCAGGGCTGTCTGCCCGTAGGACCGCCGCGCTCGGAT
 CATCATCAACGTAGGCGGCATCAAGTACTCGCTGCCCTGGACCACGCTGGACGA
 10 GTTCCCGCTGACGCGCCTGGGCCAGCTCAAGGCCTGCACCAACTTCGACGACATC
 CTCAACGTGTGCGATGACTACGACGTCACCTGCAACGAGTTCTTCTTCGACCGCA
 ACCCGGGGGCCTTCGGCACTATCCTGACCTTCCTGCGCGCGGGCAAGCTGCGGCT
 GCTGCGCGAGATGTGCGCGCTGTCTTCCAGGAGGAGCTGCTGTACTGGGGCATC
 GCGGAGGACCACCTGGACGGCTGCTGCAAGCGCCGCTACCTGCAGAAGATTGAG
 15 GAGTTCGCGGAGATGGTGGAGCGGGAGGAAGAGGACGACGCGCTGGACAGCGA
 GGGCCCGCGACAGCGAGGGCCCGGCCGAGGGCGAGGGCCGCGCTGGGGCGCTGC
 ATGCGGCGACTGCGCGAACATGGTGGAGAGGCCGCACTCGGGGCTGCCTGGCAA
 AGGTGTTGCGCTGCTGTGCGGTGCTCTTCGTGACCGTCACCGCCAGTCAACCTCTC
 CGTCAGCACCTTGCCCAGCCTGAGGGAGGAGGAGGAGCAGGGCCACTGTTCCCA
 20 GATGTGCCACAACGTCTTCATCGTGGAGTCGGTGTGCGTGGGCTGGTTCTCCCTG
 GAGTTCCTCCTGCGGCTCATTAGGCGCCCAGCAAGTTCGCTTCCTGCGGAGCC
 GCGCTGACGCTGATCGACCTGGTGGGCGCATCCTGCCCTACTACATCACGCTGCTGGT
 GCGGACGGCGCGCGCGCGGGCCGCTCGCAAGCGCGGCGGGCAAGAGCTACCTGGA
 CAAGGTGGGGCTGGTGTGCGCGTGTGCGGGCGCTGCGCATCCTGTAGGTGATG
 25 CGCCTGGCGCGCCACTCCCTGGGGCTGCAGACGCTGGGGCTACGGCCCCGCGCT
 GCACCCGCGAGTTCGGGGCTCCTGCTGCTCTTCTCTGCGTGGCCATCGCCCTCTTC
 GCGCCCCCTGCTCTACGTCATCGAGAACGAGATGGCCGACAGCCCCGAGTTCACC
 AGCATCCCTGCCTGCTACTGGTGGGCTGTCATCACCATGACGACGGTGGGCTATG
 GCGACATGGTCCCCAGGAGCACCCCGGGCCAGGTAGTGGCCCTGAGCAGCATCC
 30 TGAGCGGCATCCTGCTCATGGCCTTCCCAGTCACCTCCATCTTCCACACCTTCTCC
 CGCTCCTACCTGGAGCTCAAGCAGGAGCAAGAGAGGGTTGATGTTCCGGAGGGC
 GCAGTTCCTCATCAAAACCAAGTCGCAGCTGAGCGTGTCCAGGACAGTGACAT
 CTGTTTCGGAAGTGCCTTCCTCGGACACCAAGAGACAATAACTGAGCGCGGAGG
 ACACGCCTGCCCTGCCTGCCATCTGTGGCCCGAAGCCATTTGCCATCCACTGCAA
 35 ACGCCTGGAGAGGGACAGGCCGCTTCCGAGTGCAGTCCTGGCGCAGCACCGACT
 GCCACGCACCCGGGGAAGGACACCCTCACTCCCACACCTCCGGGAAGAACACT
 AGAACATCAGCAGAGGGGGCCCTGCCCCTCCGCCTGCAGCCGTGAAAGGAAGCTG
 GGTCATCAGCCCAGCCCCGCCACCCAGCCCCCTATGTGTGTTTCCCTCAATAAG
 GAGATGCCTTGTTCTTTTACCATGCGAATAACATGCCAGCAAAAACCGTGCTT
 40 TATGGGTCTGCCTGGAGAAAAAATAACCACCAGCAGAAACAGCAC

SEO ID NO: 629

>21310 BLOOD 246163.2 AK002158 g7023867 Human cDNA FLJ11296 fis, clone

PLACE1009731, weakly similar to AIG1 PROTEIN. 0

45 CAGCACATCGCTGCATTTCGGCTGGTTTTTCAGGGTCTTGTTCCCAATCAGTTTCCAG
CCAACACCAGGGTGTCCCTAGTCCGCAGAGGTGTGGGGGACACACTCCATAATC
TCTACTTTTCTTTTTGTGCAGCTGAGTCATGGAGCTTTCAGCCCCAGCATATGGCT
CCTCCTTAAGTGCCTCTGCTCAACCTCCCTCAGCCCTGTGAACAGCATCCCCGCA
CACAGACGCAGAGCAGGACTCTCTCTGCTGCCACTTCACCTTCCTGAGAGAGGAC

CAGCGGCCAGAGCCTCAGTGA CTGCTGCCACCCTGGAGGACAGGGCACAACAACCGT
TTCTGGAGAGAATGGGAGGATTCCAGAGGGGCAAATATGGA ACTATGGCTGAAG
GTAGATCAGAAGATAACTTGTCTGCAACACCACCGGCATTGAGGATTATCCTAGT
GGGCAAAACAGGCTGCGGGAAAAGTGCCACAGGGAACAGCATCCTTGGCCAGCC
5 CGTGTTTGAGTCCAAGCTGAGGGCCCAGTCAGTGACCAGGACGTGCCAGGTGAA
AACAGGAACATGGAACGGGAGGAAAGTCCTGGTGGTTGACACGCCCTCCATCTT
TGAGTCACAGGCCGATACCCAAGAGCTGTACAAGAACATCGGGGACTGCTACCT
GCTCTCTGCCCCGGGGCCCCACGTCTCTGCTTCTGGTGATCCAGCTGGGGCGTTTC
ACTGCTCAGGACACAGTGGCCATCAGGAAGGTGAAAGAGGTCTTTGGGACAGGG
10 GCCATGAGACATGTGGTCATCCTCTTCACCCACAAAGAGGACTTAGGGGGCCAG
GCCCTGGATGACTATGTAGCAAACACGGACA ACTGCAGCCTGAAAGACCTGGTG
CGGGAGTGTGAGAGAAGGTACTGTGCCTTCAACA ACTGGGGCTCTGTGGAGGAG
CAGAGGCAGCAGCAGGCAGAGCTCCTGGCTGTGATTGAGAGGCTGGGGAGGGA
GCGAGAGGGCTCCTTCCACAGCAATGACCTCTTCTTGGATGCCAGCTGCTCCAA
15 AGAACTGGAGCTGGGGCCTGCCAGGAAGACTACAGGCAGTACCAGGCCAAAGTG
GAATGGCAGGTGGAGAAGCACAAGCAAGAGCTGAGGGAGAACGAGAGTAACTG
GGCATAACAAGGCGCTCCTCAGAGTCAAACACTTGATGCTTTTGCATTATGAGATT
TTTGTTTTTCTATTGTTGTGCAGCATACTTTTTTTCATTATTTTTCTGTTTCATCTTTC
ATTACATTTAAATCTCTGGACCCTGGAGCACTTCTAATGTATCACCCCATGGAGT
20 CATTGTTCTAATAATCACCAATTGAGACTCAGATCCTCGTGGTCTATGGAGCATG
CTGCTTGCTGTCTGTGCAGCTCCCATTTCCCTTCTTCTGATAGACTTGGAGCTG
TGTGCTCCACTCCAAGGCTGCTGCTGCTGTAAACACTATTCCACTCTGTCTGC
CAACA ACTGCTTCAGGAATGGGCCTGAGATCCCATGCAGGTCCCTGAGAGTGA
GTAAAAGTCCGCAGAGGTGGGGATGGAAGATCTCTCCTTAGATAGAACCTGTCTT
25 CCTCCCTGGCATTGTGGGGTCTGGGCGTGACA CTGGGACTCTCAGCAGCTTTGTG
CTGCCAACCTGAGATTGAAGGCAGTGCCTCAGAGCAGCACAGAGAGTTGGGGCC
CCCTGAGCCCTGAGCCACCAGCCCTGCAGCCTGCCCTATCTCCGCATTTCAGTT
GTATTAGCCAATAGATTTCTACTTATTTAAGCTATTTGAGCTCCGGGTCTCTTCT
ACCTGCATTCTAAAACATTCAAAGTAATAAAAATTTCTCCAC
30

SEQ ID NO: 630

>21313 BLOOD 271789.7 M94055 g456678 Human voltage-gated sodium channel mRNA,
complete cds. 0

GGAATTTTAGCIGCAGTCTTCTTGGTGCCAGCTTATCAATCCCAA ACTCTGGGTGT
35 AAAAGATTCTACAGGGCACTTTCTTATGCAAGGAGCTAAACAGTGATTAAAGGA
GCAGGATGAAAAGATGGCACAGTCAGTGCTGGTACCGCCAGGACCTGACAGCTT
CCGCTTCTTTACCAGGGAATCCCTTGCTGCTATTGAACAACGCATTGCAGAAGAG
AAAGCTAAGAGACCCAAACAGGAACGCAAGGATGAGGATGATGAAAATGGCCC
AAAGCCAAACAGTGA CTTGAAGCAGGAAAATCTCTTCCATTTATTTATGGAGAC
40 ATTCCTCCAGAGATGGTGTGCTGCCCCCTGGAGGATCTGGACCCCTACTATATCA
ATAAGAAAACGTTTATAGTATTGAATAAAGGGAAAGCAATCTCTCGATTGAGTG
CCACCCCTGCCCTTTACATTTTAACTCCCTTCAACCCTATTAGAAAATTAGCTATT
AAGATTTTGGTACATTCTTTATTCAATATGCTCATTATGTGCACGATTCTTACCAA
CTGTGTATTTATGACCATGAGTAACCCTCCAGACTGGACAAAGAATGTGGAGTAT
45 ACCTTTACAGGAATTTATACTTTTGAATCACTTATTTAAATACTTGCAAGGGGCTT
TTGTTTAGAAGATTTACATTTTACGGGATCCATGGAATTGGTTGGATTTACAG
TCATTACTTTTGCATATGTGACAGAGTTTGTGGACCTGGGCAATGTCTCAGCGTT
GAGAACATTGAGAGTTCTCCGAGCATTGAAAACAATTTGAGTCATTCCAGGCCTG
AAGACCATTGTGGGGGCCCTGATCCAGTCAGTGAAGAAGCTTTCTGATGTCATGA

TCTTGACTGTGTTCTGTCTAAGCGTGTTTGGCGCTAATAGGATTGCAGTTGTTTCATG
GGCAACCTACGAAATAAATGTTTGCAATGGCCTCCAGATAATTCTTCCTTTGAAA
TAAATATCACTTCCTTCTTTAACAATTCATTGGATGGGAATGGTACTACTTTCAAT
AGGACAGTGAGCATATTTAACTGGGATGAATATATTGAGGATAAAAGTCACTTTT
5 ATTTTTTAGAGGGGGCAAAATGATGCTCTGCTTTGTGGCAACAGCTCAGATGCAGG
CCAGTGTCTGAAGGATACATCTGTGTGAAGGCTGGTAGAAACCCCAACTATGG
CTACACGAGCTTTGACACCTTTAGTTGGGCCTTTTTGTCTTATTTCTGCTCATGA
CTCAAGACTTCTGGGAAAACCTTTATCAACTGACACTACGTGCTGCTGGGAAAAC
GTACATGATATTTTTTGTGCTGGTCATTTTCTTGGGCTCATTCTATCTAATAAATTT
10 GATCTTGGCTGTGGTGGCCATGGCCTATGAGGAACAGAATCAGGCCACATTGGA
AGAGGCTGAACAGAAGGAAGCTGAATTTACAGCAGATGCTCGAACAGTTGAAAAA
GCAACAAGAAGAAGCTCAGGCGGCAGCTGCAGCCGCATCTGCTGAATCAAGAGA
CTTCAGTGGTGTGGTGGGATAGGAGTTTTTTCAGAGAGTTCTTCAGTAGCATCT
AAGTTGAGCTCCAAAAGTGAAAAAGAGCTGAAAAACAGAAAGAAAGAAAAAGAA
15 ACAGAAAGAACAGTCTGGAGAAGAAGAGAAAAATGACAGAGTCCGAAAATCGG
AATCTGAAGACAGCATAAGAAGAAAAGGTTTCCGTTTTTCTTGGAAAGGAAGTA
GGCTGACATATGAAAAGAGATTTTCTTCTCCACACCAGTCCTTACTGAGCATCCG
TGGCTCCCTTTTTCTCTCCAAGACGCAACAGTAGGGCGAGCCTTTTCAGCTTCAGA
GGTCGAGCAAAGGACATTGGCTCTGAGAATGACTTTGCTGATGATGAGCACAGC
20 ACCTTTGAGGACAATGACAGCCGAAGAGACTCTCTGTTTCGTGCCGCACAGACAT
GGAGAACGGCGCCACAGCAATGTCAGCCAGGCCAGCCGTGCCTCCAGGGTGCTC
CCCATGCTGCCCATGAATGGGAAGATGCATAGCGCTGTGGACTGCAATGGTGTG
GTCTCCCTGGTTCGGGGGCCCTTCTACCTCAGATCTGCTGGGCAGCTCCTACCAG
AGGGCACAACACTGAAACAGAAATAAGAAAGAGACGGTCCAGTTCTTATCATG
25 TTTCCATGGATTTATTGGAAGATCCTACATCAAGGCAAAGAGCAATGAGTATAGC
CAGTATTTTGACCAACACCATGGAAGAACTTGAAGAATCCAGACAGAAATGCCC
ACCATGCTGGTATAAATTTGCTAATATGTGTTTGATTTGGGACTGTTGTAAACCAT
GGTTAAAGGTGAAACACCTTGTCAACCTGGTTGTAATGGACCCATTTGTTGACCT
GGCCATCACCATCTGCATTGTCTTAAATACACTCTTCATGGCTATGGAGCACTAT
30 CCCATGACGGAGCAGTTCAGCAGTGTACTGTCTGTTGGAAACCTGGTCTTCACAG
GGATCTTCACAGCAGAAATGTTTCTCAAGATAATTGCCATGGATCCATATTATTA
CTTTCAAGAAGGCTGGAATATTTTTGATGGTTTTATTGTGAGCCTTAGTTTAATGG
AACTTGGTTTGGCAAATGTGGAAGGATTGTCAGTTCTCCGATCATTCCGGCTGET
CCGAGTTTTCAAGTTGGCAAATCTTGGCCAACCTCTAAATATGCTAATTAAGATC
35 ATTGGCAATTCTGTGGGGGCTCTAGGAAACCTCACCTTGGTATTGGCCATCATCG
TCTTCATTTTTGCTGTGGTTCGCATGCAGCTCTTTGGTAAGAGCTACAAAGAATG
TGTCTGCAAGATTTCCAATGATTGTGAACTCCCACGCTGGCACATGCATGACTTT
TTCCACTCCTTCCTGATCGTGTTCGCGTGCTGTGTGGAGAGTGGATAGAGACCA
TGTGGGACTGTATGGAGGTCGCTGGCCAAACCATGTGCCTTACTGTCTTCATGAT
40 GGTCATGGTGATTGGAAATCTAGTGGTTCTGAACCTCTTCTTGGCCTTGCTTTTGA
GTTCTTCAGTTCTGACAATCTTGCTGCCACTGATGATGATAACGAAATGAATAA
TCTCCAGATTGCTGTGGGAAGGATGCAGAAAGGAATCGATTTTGTTAAAGAAA
AATACGTGAATTTATTCAGAAAGCCTTTGTTAGGAAGCAGAAAGCTTTAGATGAA
ATTAACCGCTTGAAGATCTAAATAATAAAAAAGACAGCTGTATTTCCAACCATA
45 CCACCATAGAAATAGGCAAAGACCTCAATTATCTCAAAGACGGAAATGGAACCTA
CTAGTGGCATAGGCAGCAGTGTAGAAAAATATGTCGTGGATGAAAGTGATTACA
TGTCATTTATAAACAACCCTAGCCTCACTGTGACAGTACCAATTGCTGTTGGAGA
ATCTGACTTTGAAAATTTAAATACTGAAGAATTCAGCAGCGAGTCAGATATGGA
GGAAAGCAAAGAGAAGCTAAATGCAACTAGTTCATCTGAAGGCAGCACGGTTGA

TATTGGAGCTCCCGCCGAGGGAGAACAGCCTGAGGTTGAACCTGAGGAATCCCT
 TGAACCTGAAGCCTGTTTTACAGAAGACTGTGTACGGAAGTTCAAGTGTGTGTCAG
 ATAAGCATAGAAGAAGGCAAAGGGAAACTCTGGTGGAATTTGAGGAAAACATG
 CTATAAGATAGTGGAGCACAAATTGGTTCGAAACCTTCATTGTCTTCATGATTCTG
 5 CTGAGCAGTGGGGCTCTGGCCTTTGAAGATATATACATTGAGCAGCGAAAAACC
 ATTAAGACCATGTTAGAATATGCTGACAAGGTTTTCACTTACATATTCATTCTGG
 AAATGCTGCTAAAGTGGGTTGCATATGGTTTTCAAGTGTATTTTACCAATGCCTG
 GTGCTGGCTAGACTTCCTGATTGTTGATGTCTCACTGGTTAGCTTAACTGCAATG
 CCTTGGGTACTCAGAACTTGGTGCCATCAAATCCCTCAGAACACTAAGAGCTCT
 10 GAGGCCACTGAGAGCTTTGTCCCGTTTGAAGGAATGAGGGCTGTTGTAAATGCT
 CTTTTAGGAGCCATTCCATCTATCATGAATGTACTTCTGGTTTGTCTGATCTTTTG
 GCTAATATTCAGTATCATGGGAGTGAATCTCTTTGCTGGCAAGTTTTACCATTGTA
 TTAATTACACCACTGGAGAGATGTTTGATGTAAGCGTGGTCAACAACACTACAGTGA
 GTGCAAAGCTCTCATTGAGAGCAATCAAACCTGCCAGGTGGAAAAATGTGAAAGT
 15 AAACCTTTGATAACGTAGGACTTGGATATCTGTCTCTACTTCAAGTAGCCACGTTT
 AAGGGATGGATGGATATTATGTATGCAGCTGTTGATTACGAAATGTAGAATTAC
 AACCCAAGTATGAAGACAACCTGTACATGTATCTTTATTTTGTCTCTTTATTATT
 TTTGGTTCATTCTTTACCTTGAATCTTTTCATTGGTGTCTCATAGATAACTTCAA
 CCAACAGAAAAAGAAGTTTGGAGGTCAAGACATTTTTATGACAGAAGAACAGAA
 20 GAAATACTACAATGCAATGAAAAAACTGGGTTCAAAGAAACCACAAAAACCCAT
 ACCTCGACCTGCTAACAAATTCCAAGGAATGGTCTTTGATTTTGTAACCAAAACAA
 GTCTTTGATATCAGCATCATGATCCTCATCTGCCTTAACATGGTCAACCATGATGGT
 GGAAACCGATGACCAGAGTCAAGAAATGACAAACATTCGTACTGGATTAATCT
 GGTGTTTATTGTTCTGTTCACTGGAGAATGTGTGCTGAAACTGATCTCTCTCGTT
 25 ACTACTATTTCACTATTGGATGGAATATTTTGTGATTTTGTGGTGGTCATTCTCTCC
 ATTGTAGGAATGTTTCTGGCTGAACTGATAGAAAAGTATTTTGTGTCCCCTACCC
 TGTTCCGAGTGATCCGCTTGCCAGGATTGGCCGAATCCTACGTCTGATCAAAGG
 AGCAAAGGGGATCCGCACGCTGCTCTTTGCTTTGATGATGTCCCTTCCTGCGTTGT
 TTAACATCGGCCTCCTTCTTTTCTGGTCATGTTTCATCTACGCCATCTTTGGGATG
 30 TCCAATTTTGCCTATGTTAAGAGGGAAAGTTGGGATCGATGACATGTTCAACTTTG
 AGACCTTTGGCAACAGCATGATCTGCCTGTTCCAAATTACAACCTCTGCTGGCTG
 GGATGGATTGCTAGCACCTATTCTTAATAGTGGACCTCCAGACTGTGACCCTGAC
 AAAGATCACCCCTGGAAGCTCAGTTAAAGGAGACTGTGGGAACCCATCTGTTGGG
 ATTTTCTTTTTTGTGAGTTACATCATCATATCCTTCCTGGTTGTGGTGAACAATGTA
 35 CATCGCGGTATCCTGGAGAACTTCAGTGTGCTACTGAAGAAAGTGCAGAGCCT
 CTGAGTGAGGATGACTTTGAGATGTTCTATGAGGTTTGGGAGAAGTTTGATCCCG
 ATGCGACCCAGTTTATAGAGTTTGCCAAACTTTCTGATTTTGCAGATGCCCTGGA
 TCCTCCTCTTCTCATAGCAAAACCCAAACAAAGTCCAGCTCATTGCCATGGATCTG
 CCCATGGTGAGTGGTGACCGGATCCACTGTCTTGACATCTTATTTGCTTTTACAAA
 40 GCGTGTTTTGGGTGAGAGTGGAGAGATGGATGCCCTTCGAATACAGATGGAAGA
 GCGATTATGTCATCAAACCCCTCCAAAGTCTCTTATGAGCCCATTACGACCACG
 TTGAAACGCAAACAAGAGGAGGTGTCTGCTATTATTATCCAGAGGGGCTTACAGA
 CGCTACCTCTTGAAGCAAAAAGTTAAAAAGGTATCAAGTATATACAAGAAAGAC
 AAAGGCAAAGAATGTGATGGAACACCCATCAAAGAAGATACTCTCATTGATAAA
 45 CTGAATGAGAATTCAACTCCAGAGAAAACCGATATGACGCCTTCCACCACGTCTC
 CACCCTCGTATGATAGTGTGACCAAACCAGAAAAAGAAAAATTTGAAAAAGACA
 AATCAGAAAAGGAAGACAAAGGGAAAGATATCAGGGAAAGTAAAAAGTAAAAA
 GAAACCAAGAATTTTCCATTTTGTGATCAATTGTTTACAGCCCGTGATGGTGATG
 TGTTTGTGTCAACAGGACTCCACAGGAGGTCTATGCCAAACTGACTGTTTTTAC

AAATGTATACTTAAGGTCAGTGCCTATAACAAGACAGAGACCTCTGGTCAGCAA
 ACTGGAACCTCAGTAACTGGAGAAATAGTATCGATGGGAGGTTTCTATTTTCACA
 ACCAGCTGACACTGCTGAAGAGCAGAGGCGTAATGGCTACTCAGACGATAGGAA
 CCAATTTAAAGGGGGGAGGGAAGTTAAATTTTATGTAAATTCAACATGTGACAC
 5 TTGATAATAGTAATTGTCACCAGTGTATGTGTTTAACTGCCACACCTGCCATATT
 TTTACAAAACGTGTGCTGTGAATTTATCACTTTTCTTTTAAATTCACAGGTTGTTT
 ACTATTATATGTGACTATTTTGTAAATGGGTTTGTGTTTGGGGAGAGGGATTAA
 AGGGAGGGAATTCTACATTTCTCTATTGTATTGTATAACTGGATATATTTTAAATG
 GAGGCATGCTGCAATTCTCATTACACATAAAAAAATCACATCACAAAAGGGAA
 10 GAGTTTACTTCTTGTTCAGGATGTTTTAGATTTTGTAGGTGCTTAAATAGCTAT
 TCGTATTTTAAAGGTGTCTCATCCAGAAAAAATTTAATGTGCCTGTAAATGTTCCA
 TAGAATCACAAGCATTAAAGAGTTGTTTTATTTTACATAACCCATTAAATGTAC
 ATGTATATATGTATATATGTAAAAGGGGCGGGAAAAATACATATATATGTATACAC
 ACATGCACACACAGAGATATACACATAACCATTACATTGTCATTACATCCCAGGC
 15 GC

SEQ ID NO: 631

>21321 BLOOD INCYTE_078114H1

ATGTTGGCCAACCTATTGGTCATGGTGGCAATCTATGTCAACCGCCGCTTCCATTT
 20 NCCTATTTATNACCTAATGGCTAATCTGGCTGCTGCAGACTTCTTTNCTGGGTG
 CCTACTTCTATCTCATGTTCAACACAGGACCCAATACTCGGNGACTGACTGTNAG
 CACATGGCTCCTTCGTNAGGGGCTCATTGACACCAGCCTGAGGGCATCTNTGGCC
 AACTTACTGGNTATTGCAATNGAGAGGCAGATTACGGTTT

25 SEQ ID NO: 632

>21334 BLOOD 345288.5 AF080157 g4185272 Human Ikb kinase-a (IKK-alpha) mRNA, complete cds. 0

CCGGCCTTGAACAACCTGTGGAACCTGAGGCCGCTTGCCCTCCCGCCCCATGGAG
 CGGCCCCCGGGGCTGCGGCCGGGCGCGGGCGGGCCCTGGGAGATGCGGGAGCG
 30 GCTGGGCACCGGCGGCTTCGGGAACGTCTGTCTGTACCAGCATCGGGAACCTTGAT
 CTCAAAATAGCAATTAAGTCTTGTGCGCTAGAGCTAAGTACCAAAAACAGAGAA
 CGATGGTGCCATGAAATCCAGATTATGAAGAAGTTGAACCATGCCAATGTTGTA
 AAGGCCTGTGATGTTCTGAAGAATTGAATATTTGATTCATGATGTGCCTCTTCT
 AGCAATGGAATACTGTTCTGGAGGAGATCTCCGAAAGCTGCTCAACAAACCAGA
 35 AAATTGTTGTGGACTTAAAGAAAGCCAGATACTTTCTTTACTAAGTGATATAGGG
 TCTGGGATTTCGATATTTGCATGAAAACAAAATTATACATCGAGATCTAAAACCTG
 AAAACATAGTTCTTCAGGATGTTGGTGGAAAGATAATACATAAAATAATTGATCT
 GGGATATGCCAAAGATGTTGATCAAGGAAGTCTGTGTACATCTTTTGTGGGAACA
 CTGCAGTATCTGGCCCCAGAGCTCTTTGAGAATAAGCCTTACACAGCCACTGTTG
 40 ATTATTGGAGCTTTGGGACCATGGTATTTGAATGTATTGCTGGATATAGGCCTTTT
 TTGCATCATCTGCAGCCATTTACCTGGCATGAGAAGATTAAGAAGAAGGATCCA
 AAGTGTATATTTGCATGTGAAGAGATGTCAGGAGAAGTTTCGGTTTAGTAGCCATT
 TACCTCAACCAAATAGCCTTTGTAGTTTAATAGTAGAACCCATGGAAAACCTGGCT
 ACAGTTGATGTTGAATTGGGACCCTCAGCAGAGAGGAGGACCTGTTGACCTTACT
 45 TTGAAGCAGCCAAGATGTTTTGTATTAATGGATCACATTTTGAATTTGAAGATAG
 TACACATCCTAAATATGACTTCTGCAAAGATAATTTCTTTTCTGTTACCACCTGAT
 GAAAGTCTTCATTCACTACAGTCTCGTATTGAGCGTGAAACTGGAATAAATACTG
 GTTCTCAAGAACTTCTTTTCAGAGACAGGAATTTCTCTGGATCCTCGGAAACCAGC
 CTCTCAATGTGTTCTAGATGGAGTTAGAGGCTGTGATAGCTATATGGTTTATTTGT

TTGATAAAAGTAAAACTGTATATGAAGGGCCATTTGCTTCCAGAAGTTTATCTGA
TTGTGTAAATTATATTGTACAGGACAGCAAAATACAGCTTCCAATTATACAGCTG
CGTAAAGTGTGGGCTGAAGCAGTGCACTATGTGTCTGGACTAAAAGAAGACTAT
AGCAGGCTCTTTCAGGGACAAAGGGCAGCAATGTAAAGTCTTCTTAGATATAATG
5 CTAACCTTAACAAAAATGAAGAACACTTTGATCTCAGCATCACAACTGAAAG
CTAAATTGGAGTTTTTTCACAAAAGCATTTCAGCTTGACTTGGAGAGATACAGCGA
GCAGATGACGTATGGGATATCTTCAGAAAAAATGCTAAAAGCATGGAAAGAAAT
GGAAGAAAAGGCCATCCACTATGCTGAGGTTGGTGTCATTGGATACCTGGAGGA
TCAGATTATGCTTTTGCATGCTGAAATCATGGAGCTACAGAAGAGCCCCTATGGA
10 AGACGTCAGGGAGACTTGATGGAATCTCTGGAACAGCGTGCCATTGATCTATATA
AGCAGTTAAAACACAGACCTTCAGATCACTCCTACAGTGACAGCACAGAGATGG
TGAAAATCATTGTGCACACTGTGCAGAGTCAGGACCGTGTGCTCAAGGAGCTGTT
TGGTCATTTGAGCAAGTTGTTGGGCTGTAAGCAGAAGATTATTGATCTACTCCCT
AAGGTGGAAGTGGCCCTCAGTAATATCAAAGAAGCTGACAATACTGTCATGTTT
15 ATGCAGGGGAAAAAGGCAGAAAAGAAATATGGCATCTCCTTAAAATTGCCTGTACA
CAGAGTTCTGCCCGGTCCCTTGTAGGATCCAGTCTAGAAGGTGCAGTAACCCCTC
AGACATCAGCATGGCTGCCCCGACTTCAGCAGAACATGATCATTCTCTGTCATG
TGTGGTAACTCCTCAAGATGGGGAGACTTCAGCACAAATGATAGAAGAAAATTT
GAACTGCCTTGGCCATTTAAGCACTATTATTCATGAGGCAAATGAGGAACAGGG
20 CAATAGTATGATGAATCTTGATTGGAGTTGGTTAACAGAATGAGTTGTCACTTGT
TCACTGTCCCCAAACCTATGGAAGTTGTTGCTATACATGTTGGAAATGTGTTTTT
CCCCATGAAACCATTCTTCAGACATCAGTCAATGGAAGAAATGGCTATGAACAG
TAACTACATTCTACTATGATCAGAAGAACATGATTTTACAAGTATAACAGTTTT
GAGTAATTCAAGCCTCTAAACAGACAGGAATTTAGAAAAAGTCAATGTACTTGTT
25 TGAATATTTGTTTTAATACCACAGCTATTTAGAAGCATCATCACGACACATTTGC
CTTCAGTCTTGGTAAAACATTACTTATTTAACTGATTAATAATACCTTCTATGTAT
TAGTGTCAACTTTTAACTTTTGGGCGTAAGACCAAATGTAGTTTTGTATACAGAG
AAGAAAACCTCAAGTAATAGGCATTTTAAAGTAAAAGTCTACCTGTGTTTTTTCT
AAAAAGGCTGCTCACAAGTTCTATTTCTTGAAGAATAAATTCTACCTCCTTGTGTT
30 GCACTGAACAGGTTCTCTTCCCTGGCATCATAAGGAGTTGGTGTAATCATTTTAAA
TTCCACTGAAAATTTAACAGTATCCCCTTCTCATCGAAGGGATTGTGTATCTGTGC
TTCTAATATTAGTTGGCTTTTATAAATCATGTTGTTGTGTGTATATGTATTTAAGA
TGTACATTTAATAATATCAAAGAGAAGATGCCTGTTAATTTATAATGTATTTGAA
AATTACATGTTTTTTTCATTTGTAAAAATGAGTCATTTGTTTAAACAATCTTTCATG
35 TCTTGTACATACAAATTTATAAAGGTCTGCACTCCTTTATCTGTAATTGTAATTCCA
AAATCCAAAAAGCTCTGAAAACAAGGTTTCCATAAGCTTGGTGACAAAATTCATT
TGCTTGCAATCTAATCTGAACTGACCTTGAATCTTTTTATCCCATTTAGTGTGAAT
ATTCCTTTATTTTGCTGCTTGATGATGAGAGGGAGGGCTGCTGCCACAGACTGTG
GTGAGGGCTGGTTAATGTAGTATGGTATATGCACAAAACACTTTTCTAAAATCT
40 AAAATTTTATAATTCTGAAACAACCTTGCCCCAAGGGTTTCAGAGAAAGGACTGTG
GACCTCTATCATCTGCTAAGTAATTTAGAAGATATTATTTGTCTTAAAAAATGTG
AAATGCTTTTATATTCTAATAGTTTTTCACTTTGTGTATTAAATGGTTTTTAAATTA
ANAAAAA

45 SEQ ID NO: 633

>21349 BLOOD 441249.1 AF086432 g3483777 Human full length insert cDNA clone
ZD79H11.0

GGCAGGAGAATTTGAAAGGGTGCCCCAAAGGACAATCTCTAAAGGGGTAAAGGG
AGATACCTACCTTGTCTGGTAGGGGAGATGTTTCGTTTTTCATGCTTTACCAGAAA

ATCCACTTCCCTGCCGACCTTAGTTCCTTCAAAGCTTATTCTTAATTAGAGACAAGAA
 ACCTGTTTCAACTTGAAGACACCGTATGAGGTGAATGGACAGCCAGCCACCACA
 ATGAAAGAAATCAAACCAGGAATAACCTATGCTGAACCCACGCCTCAATCGTCC
 CCAAGTGTTTCCTGACACGCATCTTTGCTTACAGTGCATCACAACCTGAAGAATGG
 5 GGTTCAACTTGACGCTTGCAAAATTACCAAATAACGAGCTGCACGGCCAAGAGA
 GTCACAATTGAGGCAACAGGAGCGACGGGCCAGGAAAGAACACCACCCTTCACA
 ATGAATTTGACACAATTGCTTTGCCGGTGCTTTATCTCATTATATTTGTGGCAAGC
 ATCTTGCTGAATGGTTTAGCAGTGTGGATCTTCTCCACATTAGGAATAAAACCA
 GCTTCATATTCTATCTCAAAAACATAGTGGTTGCAGACCTCATAATGACGCTGAC
 10 ATTTCCATTTTGAATAGTCCATGATGCAGGATTTGGACCTTGGTACTTCAAGTTTA
 TTCTCTGCAGATACACTTCAGTTTTGTTTTATGCAAACATGTATACTTCCATCGTG
 TTCCTTGGGCTGATAAGCATTGATCGCTATCTGAAGGTGGTCAAGCCATTTGGGG
 ACTCTCGGATGTACAGCATAACCTTCACGAAGGTTTTATCTGTTTGTGTTTGGGTG
 ATCATGGCTGTTTTGTCTTTGCCAAACATCATCCTGACAAATGGTCAGCCAACAG
 15 AGGACAATATCCATGACTGCTCAAAACTTAAAAGTCCTTTGGGGGTCAAATGGC
 ATACGGCAGTCACCTATGTGAACAGCTGCTTGTGTTGTGGCCGTGCTGGTGATTCT
 GATCGGATGTTACATAGCCATATCCAGGTACATCCACAAATCCAGCAGGCAATTC
 ATAAGTCAGTCAAGCCGAAAGCGAAAACATAACCAGAGCATCAGGGTTGTTGTG
 GCTGTGTTTTTTACCTGCTTTCTACCATATCACTTGTGCAGAATTCCTTTACTTTT
 20 AGTCACTTAGACAGGCTTTTAGATGAATCTGCACAAAAAATCCTATATTACTGCA
 AAGAAATTACACTTTTCTTGTCTGCGTGTAATGTTTGCCTGGATCCAATAATTTAC
 TTTTTCATGTGTAGGTCATTTTCAAGAAGGCTGTTTCAAAAAATCAAATATCAGAA
 CCAGGAGTGAAAGCATCAGATCACTGCAAGTGTGAGAAGATCGGAAGTTCGCA
 TATATTATGATTACACTGATGTGTAGGCCTTTTATTTGTTTGTGGAATCGATATGT
 25 ACAAAGTGTAATAAATGTTTCTTTTCATTAAAAAATAAAAAAAAAAAAAAAG

SEQ ID NO: 634

>21357 BLOOD 332459.2 AF216312 g911218 Human type II membrane serine protease mRNA, complete cds. 0

30 CAGGTTACAAGACACATAATCATTCCAGTTTGGCGAGGTCACCTTGTAGGGCTGTT
 TTAATCAAGCTGCCCAAAGTCCCCCAATCACTCCTGGAATACACAGAGAGAGGC
 AGCAGCTTGCTCAGCGGACAAGGATGCTGGGCGTGAGGGACCAAGGCCTGCCCT
 GCACTCGGGCCTCCTCCAGCCAGTGCTGACCAGGGACTTCTGACCTGCTGGCCAG
 CCAGGACCTGTGTGGGGAGGCCCTCCTGCTGCTTGGGGTGACAATCTCAGCTCC
 35 AGGCTACAGGGAGACCGGGAGGATCACAGAGCCAGCATGGATCCTGACAGTGAT
 CAACCTCTGAACAGCCTCGATGTCAAACCCCTGCGCAAACCCCGTATCCCCATGG
 AGACCTTCAGAAAGGTGGGGATCCCCATCATCATAGCACTACTGAGCCTGGCGA
 GTATCATCATTGTGGTTGTCCTCATCAAGGTGATTCTGGATAAATACTACTTCCTC
 TGCGGGCAGCCTCTCCACTTCATCCCGAGGAAGCAGCTGTGTGACGGAGAGCTG
 40 GACTGTCCCTTGGGGGAGGACGAGGAGCACTGTGTCAAGAGCTTCCCCGAAGGG
 CCTGCAGTGGCAGTCCGCCTCTCCAAGGACCGATCCCACTGCAGGTGCTGGACT
 CGGCCACAGGGAAGTGGTTCTCTGCCTGTTTCGACAACTTCACAGAAGCTCTCGC
 TGAGACAGCCTGTAGGCAGATGGGCTACAGCAGCAAACCCACTTTCAGAGCTGT
 GGAGATTGGCCCAGACCAGGATCTGGATGTTGTTGAAATCACAGAAAACAGCCA
 45 GGAGGCTTCGCATGCGGAAGTCAAGTGGGCCCTGTCTCTCAGGCTCCCTGGTCTC
 CCTGCACTGTCTTGCTGTGGGAAGAGCCTGAAGACCCCCCGTGTGGTGGGTGGG
 GAGGAGGCCTCTGTGGATTCTTGGCCTTGGCAGGTCAGCATCCAGTACGACAAAC
 AGCACGTCTGTGGAGGGAGCATCCTGGACCCCCACTGGGTCCTCACGGCAGCCC
 ACTGCTTCAGGAAACATACCGATGTGTTCAACTGGAAGGTGCGGGCAGGCTCAG

ACAAACCTGGGCAGCTTCCCATCCCTGGCTGTGGCCAAGATCATCATCATTGAATT
 CAACCCCATGTACCCCAAAGACAATGACATCGCCCTCATGAAGCTGCAGTTCCCA
 CTCACCTTCTCAGGCACAGTCAGGCCCATCTGTCTGCCCTTCTTTGATGAGGAGCT
 CACTCCAGCCACCCCACTCTGGATCATTGGATGGGGCTTTACGAAGCAGAATGGA
 5 GGGAAGATGTCTGACATACTGCTGCAGGCGTCAGTCCAGGTCATTGACAGCACA
 CGGTGCAATGCAGACGATGCGTACCAGGGGGAAGTCACCGAGAAGATGATGTGT
 GCAGGCATCCCGGAAGGGGGTGTGGACACCTGCCAGGGTGACAGTGGTGGGCCC
 CTGATGTACCAATCTGACCAGTGGCATGTGGTGGGCATCGTTAGCTGGGGCTATG
 GCTGCGGGGGGCCCCGAGCACCCAGGAGTATACACCAAGGTCTCAGCCTATCTCA
 10 ACTGGATCTACAATGTCTGGAAGGCTGAGCTGTAATGCTGCTGCCCCCTTGCAGT
 GCTGGGAGCCGCTTCCTTCCTGCCCTGCCACCTGGGGATCCCCCAAAGTCAGAC
 ACAGAGCAAGAGTCCCCCTTGGGTACACCCCTCTGCCACAGCCTCAGCATTTCTT
 GGAGCAGCAAAGGGCCTCAATTCTATAAGAGACCCTCGCAGCCCAGAGGCGCC
 CAGAGGAAGTCAGCAGCCCTAGCTCGGCCACACTTGGTGCTCCCAGCATCCCAG
 15 GGAGAGACACAGCCCACTGAACAAGGTCTCAGGGGTATTGCTAAGCCAAGAAGG
 AACTTTCCCACTACTGAATGGAAGCAGGCTGTCTTGTAAGGCCAGATCACT
 GTGGGCTGGAGAGGAGAAGGAAAGGGTCTGCGCCAGCCCTGTCCGTCTTACCC
 ATCCCCAAGCCTACTAGAGCAAGAAACCAGTTGTAATATAAAATGCACTGCCCT
 ACTGTTGGTATGACTACCGTTACCTACTGTTGTCATTGTTATTACAGCTATGGCCA
 20 CTATTATTAAAGAGCTGTGTAACATCTCTGGCAAAA

SEQ ID NO: 635
 >21372.BLOOD 413969.2 U38431.g4096733.Human clone rasi-6 matrix metalloproteinase 1

RASI-6 mRNA, splice variant, complete cds. 0

25 GGCACGAGCCAAGGCTCCCAGAAATCTCAGGTCAGAGGCACGGACAGCCTCTGG
 AGCTCTCGTCTGGTGGGACCATGAACTGCCAGCAGCTGTGGCTGGGCTTCCTACT
 CCCCATGACAGTCTCAGGCCGGGTCTGGGGCTTGACAGAGGTGGCGCCCGTGGA
 CTACCTGTCACAATATGGGTACCTACAGAAGCCTCTAGAAGGATCTAATAACTTC
 AAGCCAGAAGATATCACCGAGGCTCTGAGTCTCAGGTCAGCTGGATGATGCCAC
 30 AAGGGCCCGCATGAGGCAGCCTCGTTGTGGCCTAGAGGATCCCTTCAACCAGAA
 GACCCTTAAATACCTGTTGCTGGGCCGCTGGAGAAAGAAGCACCTGACTTTCCGC
 ATCTTGAACCTGCCCTCCACCCTTCCACCCACACAGCCCGGGCAGCCCTGCGTC
 AAGCCTTCCAGGACTGGAGCAATGTGGCTCCCTTGACCTTCCAAGAGGTGCAGGC
 TGGTGCGGCTGACATCCGCCTCTCCTTCCATGGCCGCCAAAGCTCGTACTGTTCC
 35 AATACTTTTGATGGGCCTGGGAGAGTCTGGCCCATGCCGACATCCCAGAGCTGG
 GCAGTGTGCACTTCGACGAAGACGAGTTCTGGACTGAGGGGACCTACCGTGGGG
 TGAACCTGCGCATCATTGCAGCCCATGAAGTGGGCCATGCTCTGGGGCTTGGGCA
 CTCCCGATATTCCCAGGCCCTCATGGCCCCAGTCTACGAGGGCTACCGGCCCCAC
 TTTAAGCTGCACCCAGATGATGTGGCAGGGATCCAGGCTCTCTATGGCAAGAAG
 40 AGTCCAGTGATAAGGGATGAGGAAGAAGAAGAGACAGAGCTGCCCACTGTGCCC
 CCAGTGCCCAACAGAACCCAGTCCCATGCCAGACCCTTGCAGTAGTGAAGTGGAT
 GCCATGATGCTGGGTGAGGCCCTCCCTCCAGGCTGTTGGCAGGCGGTGGGGG
 CAGCCTGCTGATCCTGAGGCCTGGACAAATGGGAGTGACATGGGACTTCAGCAT
 GAGCAATGGAGGGCCCCGTGGGAAGACCTATGCTTTCAAGGGGGACTATGTGTG
 45 GACTGTATCAGATTGAGGACCGGGCCCTTGTTCGAGTGTCTGCCCTTTGGGAG
 GGGCTCCCCGGAACCTGGATGCTGCTGTCTACTCGCCTCGAACACAATGGATTC
 ACTTCTTTAAGGGAGACAAGGTGTGGCGCTACATTAATTTCAAGATGTCTCCTGG
 CTTCCCCAAGAAGCTGAATAGGGTAGAACCTAACCTGGATGCAGCTCTCTATTGG
 CCTCTCAACCAAAAGGTGTTCTCTTTAAGGGCTCCGGGTACTGGCAGTGGGACG

AGCTAGCCCCGAACTGACTTCAGCAGCTACCCCCAAACCAATCAAGGGTTTGTTTAC
GGGAGTGCCAAACCAGCCCTCGGCTGCTATGAGTTGGCAAGATGGCCGAGTCTA
CTTCTTCAAGGGCAAAGTCTACTGGCGCCTCAACCAGCAGCTTCGAGTAGAGAA
AGGCTATCCCAGAAATATTTCCCACTGGATGCACTGTCGTCCCCGGACTATA
5 GACACTACCCCATCAGGTGGGAATACCACTCCCTCAGGTACGGGCATAACCTTGG
ATACCACTCTCTCAGCCACAGAAACCACGTTTGAATACTGACTGCTCACCCACAG
ACACAATCTTGACATTAACCCCTGAGGCTCCACCACCCACCCCTTTCATTTCCCCC
CCAGAAGCCTAAGGCCTAATAGCTGAATGAAATACCTGTCTGCTCAGTAGAACCT
TGCAGGTGCTGTAGCAGGCGCAAGACCGTAGATCTCAGGCCTCTAACACTTCCAA
10 CTCCAGCCACCCTTTCCTGTGCATTTTCACTCCTGAGAAGTGCTCCCCTAACTCA
GATCCCCTAACTTAGATTTGGCCCCCACTCCATTTCTGTCTGTCTTAGACAGCC
CTTCCAACCTGTGTCATCTCTTCTCTGGAGGTCAATGGTGGAGGGAGATGCCTGGG
TCCTGTTCTTCTACATAAAATGCAAGAAAACAGCATGGCCAGTAACTGAGCA
AGGGCCTTGGAATCCTTGAGAATCACATTTATGTGCTTATGATTACGGGCAAGCT
15 AATTAACCTTGTGTAATCTCAGATTCCCCATTTGCAACATTAGGTAAAGACCAGT
ACTGCAGGATTGTTGCACTAAATGAAATACTGTATGTGAAGTGCCTGGCACAGTG
TCTGGTACATTTGTGTTTAATAAAAGCTAACTCCATGTTTCAT

SEQ ID NO: 636

>21384 BLOOD 403324.1 AF027957 g2739108 Human G-protein-coupled receptor
(GPR35) gene, complete cds. 0

TGGGAAGAGGATCTGTCCAGGGGTTAGACCTTCAAGGGTGACTTGGAGTTCTTTA
CGGCAACCATGCTTCTTGGAGAGTTTGTGTTTGTGGGTGTGGGGTCTGGGGCTC
ACCTCCTCCACATCCTGCCCAGAGGTGGGCAGAGTGGGGGCAGTGCCTTGCTCC
25 CCCTGCTCGCTCTCTGCTGACTCCGGCTCCCTGTGCTGCCCCAGGACCATGAATG
GCACCTACAACACCTGTGGCTCCAGCGACCTCACCTGGCCCCCAGCGATCAAGCT
GGGCTTCTACGCCTACTTGGGCGTCCCTGCTGGTGCTAGGCCTGCTGCTCAACAGC
CTGGCGCTCTGGGTGTTCTGCTGCCGCATGCAGCAGTGGACGGAGACCCGCATCT
ACATGACCAACCTGGCGGTGGCCGACCTCTGCCTGCTGTGCACCTTGCCCTTCGT
30 GCTGCACTCCCTGCGAGACAGCCTCAGACACGCCGCTGTGCCAGCTCTCCAGGG
CATCTACCTGACCAACAGGTACATGAGCATCAGCCTGGTCACGGCCATCGCCGTG
GACCGCTATGTGGCCGTGCGGCACCCGCTGCGTGCCCGCGGGCTGGCGGTCCCCC
AGGCAGGCTGCGGGCCGTGTGCGCGGTCTCTGGGTGCTGGTTCATCGGCTCCCTGG
TGGCTCGCTGGCTCCTGGGGATTGAGGAGGGCGGCTTCTGCTTCAGGAGCACCCG
35 GCACAATTTCAACTCCATGGCGTTCCCGCTGCTGGGATTCTACCTGCCCCCTGGCC
GTGGTGGTCTTCTGCTCCCTGAAGGTGGTGAAGTGGCCCTGGCCCAGAGGCCACCCA
CCGACGTGGGGCAGGCAGAGGCCACCCGCAAGGCTGCCCCGCATGGTCTGGGCCA
ACCTCCTGGTGTTCGTGGTCTGCTTCTGCCCCTGCACGTGGGGCTGACAGTGCG
CCTCGCAGTGGGCTGGAACGCCTGTGCCCTCCTGGAGACGATCCGTCGCGCCCTG
40 TACATAACCAGCAAGCTCTCAGATGCCAACTGCTGCCTGGACGCCATCTGCTACT
ACTACATGGCCAAGGAGTTCCAGGAGGCGTCTGCACTGGCCGTGGCTCCCCGTGC
TAAGGCCCAAAAAGCCAGGACTCTCTGTGCGTGACCCCTCGCCTAAGAGGCGTG
CTGTGGGCGCTGTGGGCCAGGTCTCGGGGGCTCCGGGAGGTGCTGCCTGCCAGG
GGAAGCTGGAACCAAGTAGCAAGGAGCCCGGATCAGCCCTGAACTCACTGTGTA
45 TTCTCTTGGAGCCTTGGGTGGGCAGGGACGGCCAGGTACCTGCTCTCTTGGGAA
GAGAGAGGGACAGGGACAAGGGCAAGAGGACTGAGGCCAGAGCAAGGCCAATG
TCAGAGACCCCCGGGATGGGGCCTCACACTTGCCACCCCCAGAACCAGCTCACCT
GGCCAGAGTGGGTTCCTGCTGGCCAGGGTGCAGCCTTGATGACACCTGCCGCTGC
CCCTCGGGGCTGGAATAAACTCCCCACCCAGAGTCAGTCCTAGTGGGGCCCTCT

GTGTTTCGCACTCGTGTGGTGGGAGGCAGGGAGGGAGCGCGTGGCTCGGAGGGC
 TGGCGGACATCTTCCAGGGACCCTTCGGGGCTCTTCACTTTGAGGTCCCCCTTGG
 ACCCTTTCACCCCTTCCCACCCCCACCCACCTGGAGCGTGAGCAGGGGCTGTTGG
 AAGCTCCTGGCAGGACCACAGTAGAGGGCCCCAGCCCAGGTTTCCTTGCTCAAG
 5 ACAGGGCTGGGAGCAGCTGATCTCCATGTAGGGGCTGCAACAGCGGTGCAAGGG
 GGGGTGAACCAAGGTCAAGCAGGTGAGGGTGGGGTGGGGTGGGTCAGTGAA
 GGGGTGGCCAGGGTCTGTCAAGGAACCCAGCCCTCTTCTCCTTCCTTCAGGNAC
 AGGCTGGAACCATNTCTAGGCAGGGGCAGGGGTTGGGTGCCCACTCAGGTAAAG
 GCACGATGTCCTGCTGGTTTC

10

SEQ ID NO: 637

>21387 BLOOD 014253.1 CAA04483.1 g2326776 sodium/glucose symporter-like protein
 8e-42

CTGGCAGCAATGGGGCCTGGAGCTTCAGGGGACGGGGTCAGGACTGAGACAGCT
 15 CCACACATAGCACTGGACTCCAGAGTTGGTCTGCACGCCTACGACATCAGCGTGG
 TGGTCATCTACTTTGTCTTCGTCATTGCTGTGGGGATCTGGTTCGTCCATCCGTGCA
 AGTCGAGGGACCATTGGCGGCTATTTCTTGCCGGGAGGTCCATGAGCTGGTGG
 CCAATTGGAGCATCTCTGATGTCCAGCAATGTGGGCAGTGGCTTGTTTCATCGGCC
 TGGCTGGGACAGGGGCTGCCGGAGGCCTTGCCGTAGGTGGCTTCGAGTGGAACG
 20 CAACCTGGCTGCTCCTGGCCCTTGCTGGGTCTTCGTCCCTGTGTACATCGCAGC
 AGGTGTGGTCACAATGCCGCAGTATCTGAAGAAGCGATTTGGGGGCCAGAGGAT
 CCAGGTGTACATGTCTGTCTCTCATCCTCTACATCTTCACCAAGATCTCGG
 TAGGTGTCACTGCAATGTGGTCACTGTGTCTGGAAATGCTAATTAGGGAACTGCT
 GAGTGCATCACCATGTGCGTGTGTCTGAGGGGAAGCTGACAATCACTGTTGAAA
 25 AAAAGGAAAGCAGGACCTATAAACATTTAATGCATGTTCTGCCTCAGCACTGGG
 GTAC

SEQ ID NO: 638

>21390 BLOOD 300437.18 M94046 g187393 Human zinc finger protein (MAZ) mRNA. 0

GAATTCCGGGGGTTCCGGCGCTCCGCGGCCCAAGCGCCCTCCTTTCTCCCTCC
 30 GCCGGCCGGGGTTGCGGGCGCGGGGCGCCGCGGGGCCATGCGATCTCGGCGCGGC
 CCAGCCCCGGCCGGCGGCGCCCCGCCCCCGCTGGAGCCCTGGGGGCCCGCTGCG
 GCCGAGGCATGTTCCCGGTGTCTCTTGACAGCTGCTGGCCCCCCCCCTTCCCCGT
 GCTGGGCCTGGAATCCCGGGGGGTGGGCGGCCTCATGAACTCCTTCCCGCCACCT
 35 CAGGGTCACGCCCAGAACCCCCCTGCAGGTCGGGGCTGAGCTCCAGTCCCGCTTCT
 TTGCCTCCAGGGCTGCGCCCAGAGTCCATTCCAGGCCGCGCCGGCGCCCCCGCC
 CACGCCCCAGGCCCCGGCGGCCGAGCCCCCTCCAGGTGGACTTGCTCCCGGTGCTC
 GCCGCCGCCAGGAGTCCGCCGCGGCTGCTGCGGCCTGCTGCCGCCGCTGCTGCC
 GCCGTGCTGCCGCGCCCCCGGCCCTGCCGCCGCTCTACGGTGGACACAGCGG
 40 CCCTGAAGCAGCCTCCGGCGCCCCCTCCGCCACCCCCGCCAGTGTGGCGCCCCGC
 GGCCGAGGCCGCGCCCCCGCCTCCGCCGCCACTATCGCCGCGGCGGGCGGCCAC
 CGCCGTGCTAGCCCCAACCTCGACGGTCGCCGTGGCCCCGGTCGCGTCTGCCTTG
 GAGAAGAAGACAAAGAGCAAGGGGCCCTACATCTGCGCTCTGTGCGCCAAGGAG
 TTCAAGAACGGCTACAATCTCCGGAGGCACGAAGCCATCCACACGGGAGCCAAG
 45 GCCGGCCGGGTCCCCTCGGGTGCTATGAAGATGCCGACCATGGTGCCCCCTGAGCC
 TCCTGAGCGTGCCCCAGCTGAGCGGAGCCGGCGGGGGAGGGGGAGAGGCGGGT
 GCCGGCGGCGGCGCTGCCGCAGTGGCCGCCGGTGGCGTGGTGACCACGACCGCC
 TCGGGGGAAGCGCATCCGGAAGAACCATGCCTGCGAGATGTGTGGCAAGGCCTT
 CCGCGACGTCTACCACCTGAACCGACACAAGCTGTCGCACTCGGACGAGAAGCC

CTACCAGTGCCCGGTGTGCCAGCAGCGCTTCAAGCGCAAGGACCGCATGAGCTA
CCACGTGCGCTCACATGACGGCGCTGTGCACAAGCCCTACAACTGCTCCCACTGT
GGCAAGAGCTTCTCCCGGCCGGATCACCTCAACAGTCACGTCAGACAAGTGCAC
TCAACAGAACGGCCCTTCAAATGTGAGAAATGTGAGGCAGCTTTCGCCACGAAG
5 GATCGGCTGCGGGCGCACACAGTACGACACGAGGAGAAAGTGCCATGTCACGTG
TGTGGCAAGATGCTGAGCTCGGCTTATATTTTCGGACCACATGAAGGTGCACAGCC
AGGGTCTCACCATGTCTGTGAGCTCTGCAACAAAGGTAAGTGGTGAGGTTTGTCC
AATGGCGGCGGCAGCGGCGGCGGCAGCGGCAGCGGCGGCAGCGGCAGCAGCGG
CAGCAGTAGCAGCCCCCTCCACAGCTGTGGGCTCCCTCTCGGGGGCGGAGGGGG
10 TGCCTGTGAGCTCTCAGCCACTTCCCTCCCAACCCTGGTGAGCTCCAAGTTGGTT
GCGGGGGAGAGGGGAGAATGGAGTAGAGTCCCTTGGTACAAGCTCCTCTCCCCC
CTCTTTTCCCACTCCTATTTCCCTACCAACCAAGGAGCCTCCAGAAGGAAA
GGAGGAAGAAATGTTTTCTTAGGGGAATTCGCTAGGTTTTAACGATTTGTTTCTC
CTGCTCCTCTTCTATCAGACCTGACCCACACAAACCTGTCCCCTCGGTTGTGTG
15 AAGTCCCCTGGACAGTGGGCAGGGGTGGCAGAGGACACGAGCAGCCACTGCCCG
TACCCCTCTCCTCTCTGTAAGCCCATGCCCTGTCTTCCCAGGGACTTGTGAGCCT
CTTCCCTCGACGGTCTCTTCTCTCCTTCCAGTCTCTCCCCCTGCTGTCTGCAGCC
CCTCCCCGGGGAGTTGGTGCTTTCTTTTCTTTTTTTTTTCCCAGGGGGAGGGAG
GAGAGGAAGGAGGGGGGATCAGAGCTGTCCCAAGAGGGAAAGCGGTGAGGTTT
20 GAGGAGGGGCAGAAGCAGGGCCGGCAAAGGTTGTACCTTCATAAGGTGGTATGG
GGGGTTGGGGTCAGGCCCTGAACATCGTCCTACTTGAGAATCTGTCAGGGGAAA
AAGTCAAGGGGAGCAGGAGGAAGAGCCAGGAGGGCCAGAGGCAGAGAAAGAGA
TGGAGTCTTAGGGGGCCAGGGTGAAGCAGGGGTCCAGGGCCTAGAGGTGCTTCT
GGGGGGGGGGGAATGCAGCCAGTGTCCCCTCCCCTCTTCCACCCCAAGCTCGAGC
25 CCTGGTCTTGTCTTTTCATCCCTCTTCCCCACGACAGAAGAAGTTGTGGCCCTGGC
CATGTCATCGTGTTCCTGTGTCCCCTGCATGTACCCCAACCCTCCACCCCTTCCTTT
TGCGCGGAACCCATTACAATAAATTTTAAATAAAATCCTGTTTCTGGCTCTGGAA
AA

30 SEQ ID NO: 639

>21406 BLOOD 040519.2 AF103796 g4185795 Human placenta-specific ATP-binding
cassette transporter (ABCP) mRNA, complete cds. 0

GCGCCTCCACGCGCGCGCGCGCGACGTGATCGCTCGGGCGCGCCGGGCGTGG
TTGGGGGAAGGGGTTGTGCCGCGCGACGGTCTGCGTGCTGTGCCCACTCAAAG
35 GTTCCGGGCGCGCAGGAGGGAAGAGGCAGTGCTCGCCACTCCCCTGAGATTGA
GAGACGCGCAAGGAGGCAGCCTGTGGAGGAACTGGGTAGGATTTAGGAACGC
ACCGTGCACATGCTTGGTGCTTGTGTTAAGTGAAACTGCTGCTTTAGAGTTTGT
TGGAAGGTCCGGGTGACTCATCCCAACATTTACATCCTTAATTGTTAAAGCGCTG
CCTCCGAGCGCACGCATCCTGAGATCCTGAGCCTTGGTTAAGACCGAGCTCTAT
40 TAAGCTGAAAAGATAAAAACTCTCCAGATGTCTTCCAGTAATGTCGAAGTTTTTA
TCCCAGTGTCAAGGAAACACCAATGGCTTCCCCGCGACAGCTTCCAATGACCT
GAAGGCATTTACTGAAGGAGCTGTGTTAAGTTTTTATAACATCTGCTATCGAGTA
AACTGAAGAGTGGCTTTCTACCTTGTGCAAAACCAGTTGAGAAAGAAATATTAT
CGAATATCAATGGGATCATGAAACCTGGTCTCAACGCCATCCTGGGACCCACAG
45 GTGGAGGCAAATCTTCGTTATTAGATGTCTTAGCTGCAAGGAAAGATCCAAGTGG
ATTATCTGGAGATGTTCTGATAAATGGAGCACCGCGACCTGCCAATTTCAAATGT
AATTCAGGTTACGTGGTACAAGATGATGTTGTGATGGGCACTCTGACGGTGAGA
GAAAACCTACAGTTCTCAGCAGCTCTTCGGCTTGCAACAACTATGACGAATCATG
AAAAAAACGAACGGATTAACAGGGTCATTCAAGAGTTAGGTCTGGATAAAGTGG

CAGACTCCAAGGTTGGAACCTCAGTTTATCCGTGGTGTGTCTGGAGGAGAAAGAA
AAAGGACTAGTATAGGAATGGAGCTTATCACTGATCCTTCCATCTTGTTCTTGGA
TGAGCCTACAACCTGGCTTAGACTCAAGCACAGCAAATGCTGTCCTTTTGCTCCTG
AAAAGGATGTCTAAGCAGGGACGAACAATCATCTTCTCCATTTCATCAGCCTCGAT
5 ATTCCATCTTCAAGTTGTTTGATAGCCTCACCTTATTGGCCTCAGGAAGACTTATG
TTCCACGGGCTGCTCAGGAGGCTTGGGATACTTTGAATCAGCTGGTTATCACT
GTGAGGCTATAATAACCCTGCAGACTTCTTCTTGACATCATTAAATGGAGATTC
CACTGCTGTGGCATTAAACAGAGAAGAAGACTTTAAAGCCACAGAGATCATAGA
GCCTTCCAAGCAGGATAAGCCACTCATAGAAAAATTAGCGGAGATTTATGTCAA
10 CTCCTCCTTCTACAAAGAGACAAAAGCTGAATTACATCAACTTTCCGGGGGTGAG
AAGAAGAAGAAGATCACAGTCTTCAAGGAGATCAGCTACACCACCTCCTTCTGT
CATCAACTCAGATGGGTTTCCAAGCGTTCATTCAAAAACCTTGCTGGGTAATCCCC
AGGCTCTATAGCTCAGATCATTGTACAGTCGTACTGGGACTGGTTATAGGTGC
CATTTACTTTGGGCTAAAAAATGATTCTACTGGAATCCAGAACAGAGCTGGGGTT
15 CTCTTCTTCTGACGACCAACCAGTGTTCAGCAGTGTTCAGCCGTGGAACCTTT
TGTGGTAGAGAAGAAGCTCTTCATACATGAATACATCAGCGGATACTACAGAGT
GTCATCTTATTTCTTGGAAAACCTGTTATCTGATTTATTACCCATGAGGATGTTAC
CAAGTATTATATTACCTGTATAGTGTACTTCATGTTAGGATTGAAGCCAAAGGC
AGATGCCTTCTTCGTTATGATGTTTACCCTTATGATGGTGGCTTATTCAGCCAGTT
20 CCATGGCACTGGCCATAGCAGCAGGTCAGAGTGTGGTTTCTGTAGCAAACTTCT
CATGACCATCTGTTTTGTGTTTATGATGATTTTTTCAGGTCTGTTGGTCAATCTCA
GAACEATTGCATCTTGGCTGTGATGGCTTCAGTACTTCAGCATTCCACGATATGG
ATTACGGCTTTGCAGCATAATGAATTTTTGGGACAAAATTTCTGCCCAGGACTC
AATGCAACAGGAAACAATCCTTGTAACATATGGAACATGTACTGGGGAAGAATAT
25 TTGGTAAAGCAGGGCATCGATCTCTCACCTGGGGCTTGTGGAAGAATCACGTGG
CCTTGGCTTGTATGATTGTTATTTTCTCACAAATTGCCTACCTGAAATTGTTATTTT
TTAAAAAATATTCTTAAATTTCCCCTTAATTCAGTATGATTTATCCTCACATAAAA
AAGAAGCACTTTGATTGAAGTATTCAATCAAGTTTTTTTGTGTTTCTGTTCCCT
TGCCATCACACTGTTGCACAGCAGCAATTGTTTTAAAGAGATACATTTTTAGAAA
30 TCACAACAACTGAATTAAACATGAAAGAACCCAAGACATCATGTATCGCATAT
TAGTTAATCTCCTCAGACAGTAACCATGGGGAAGAAATCTGGTCTAATTTATTAA
TCTAAAAAAGGAGAATTGAATTCTGGAACTCCTGACAAGTTATTACTGTCTCTG
GCATTTGTTTCTCCTCATCTTTAAATGAATAGGTAGGTTAGTAGCCCTTCAGTCTTA
ATACTTTATGATGCTATGGTTTGCCATTATTTAATAAATGACAAATGTATTAATGC
35 TATACTGGAAATGTAAAATTGAAAATATGTTGGAAAAAAGATTCTGTCTTATAGG
GTAAAAAAAGCCACCGTGATAGAAAA

SEQ ID NO: 640

>21416 BLOOD 094071.9 M87068 g179896 Human CaN19 mRNA sequence. 0

40 CTCCCACTTCCCCTGTGGCCTGGGTGGGCTCAGGGGCTGCCCTTGACCTGGCCT
AGAGCCCTCCCCCAGCTGGTGGTGGAGCTGGCACTCTCTGGGAGGGAGGGGGCT
GGGAGGGAATGAGTGGGAATGGCAAGAGGCCAGGGTTTGGTGGGATCAGGTTG
AGGCAGGTTTGGTTTCTTAAATGCCAAGTTGGGGGCCAGTGGGGCCACATAT
AAATCCTCACCTGGGAGCCTGGCTGCCTTGCTCTCCTTCTGGGTCTGTCTCTGC
45 CACCTGGTCTGCCACAGATCCATGATGTGCAGTTCTCTGGAGCAGGCGCTGGGCT
GTGCTGGTCACTACCTTCCACAAGTACTCCTGCCAAGAGGGCGACAAGTTCAAGC
TGAGTAAGGGGGAAATGAAGGAACCTTCTGCACAAGGAGCTGCCCAGCTTTGTGG
GGGAGAAAGTGGATGAGGAGGGGCTGAAGAAGCTGATGGGCAGCCTGGATGAG
AACAGTGACCAGCAGGTGGACTTCCAGGAGTATGCTGTTTTCTGGCACTCATCA

CTGTCATGTGCAATGACTTCTTCCAGGGCTGCCAGACCGACCTGAAGCAGAAC
TCTTGACTTCCTGCCATGGATCTCTTGGGCCAGGACTGTTGATGCCTTTGAGTTT
TGTATTCAATAAACTTTTTTGTCTGTTGATAATATTTTAATTGCTCAGTGATGTTT
CATAACCCGGCTGGCTCAGCTGGAGTGCTGGGAGATGAGGGCCTCCTGGATCCT
5 GCTCCCTTCTGGGCTCTGACTCTCCTGGAAATCTCTCCAAGGCCAGAGCTATGCTT
TAGGTCTCAATTTTGGAAATTTCAAACACCAGCAAAAATTTGGAAATCGAGATAG
GTTGCTGACTTTTATTTTGTCAAATAAAGATATT

SEQ ID NO: 641

10 >21419 BLOOD 406378.10 M29696 gl186365 Human interleukin-7 receptor (IL-7) mRNA,
complete cds. 0
CAGGGCTGGCTTTTTTTTTTTTAATAAGATAGCTGGTGCCCAAGATTGTTTTCCAC
CTTAAGGATAAAACCTGTTAAGAAAGCCTGAACAATTACAAAAAAGGAAGAAAA
GGAGACTTGGCCAACTGGTGTGAGGAGTCTTAACAAGGTCATAGTTTGCCAGCCC
15 CTGCCCTAAACAAATAATTCTTGAATGCCTACTGTGGTGTGTAAGATATGAGTAA
ATACCAGGGATACACAGAGAACAAAAGAGAAAAACTGCTATTCTTGTGAAACTT
GGAAGTTGGAGGAGACTTGGAAGATGCAGAACTGGATGACTACTCATTCTCATG
CTATAGCCAGTTGGAAGTGAATGGATCGCAGCACTCACTGACCTGTGCTTTTGAG
GACCCAGATGTCAACACCACCAATCTGGAATTTGAAATATGTGGGGCCCTCGTGG
20 AGGTAAAGTGCCTGAATTTCAAGAACTACAAGAGATATATTTTCATCGAGACAA
AGAAATTTCTACTGATTGGAAAGAGCAATATATGTGTGAAGGTTGGAGAAAAGA
GTCTAACCTGCAAAAATAAGACCTAACCACTATAGTTAAACETGAGGCTCCTTT
TGACCTGAGTGTGATCTATCGGGAAGGAGGCAATGACTTTGTGGTGACATTTAAT
GACATCACACTTGCAAAAGAAGTATGTAAAAGTTTAAATGCATGATGTAGCTTACC
25 GCCAGGAAAAGGATGAAAACAAATGGAAGCATGTGAATTTATCCAGCACAAAGC
TGACACTCCTGCAGAGAAAAGCTCCAACCGGCAGCAATGTATGAGATTAAAGTTC
GATCCATCCCTGATCACTATTTTAAAGGCTTCTGGAGTGAATGGAGTCCAAGTTA
TTACTTCAGAACTCCAGAGATCAATAATAGCTCAGGGGAGATGGATCCTATCTTA
CTAACCATCAGCATTTTGTAGTTTTTCTCTGTGCTCTGTTGGTTCATCTTGGCCTGT
30 GTGTTATGAAAAAAAGGATTAAGCCTATCGTATGGCCCAGTCTCCCCGATCATA
AGAAGACTCTGGAACATCTTTGTAAGAAACCAAGAAAAAATTTAAATGTGAGTT
TCAATCCTGAAAGTTTCTGGACTGCCAGATTTCATAGGGTGGATGACATTCAAGC
TAGAGATGAAAGTGGAAAGTTTTCTGCAAGATACGTTTCTCAGCAACTAGAAGA
ATCTGAGAAAGCAGAGGCTTGGAGGGGATGTGCAGAGCCCCAACTGCCCATCTGA
35 GGATGTAGTCATCACTCCAGAAAGCTTTGGAAGAGATTCATCCCTCACATGCCTG
GCTGGGAATGTCAGTGCATGTGACGCCCCATTCTCTCCTCTTCCAGGTCCCTAG
ACTGCAGGGAGAGTGGCAAGAATGGGCCTCATGTGTACCAGGACCTCCTGCTTA
GCCTTGGGACTACAAACAGCACGCTGCCCCCTCCATTTTCTCTCCAATCTGGAAT
CCTGACATTGAACCCAGTTGCTCAGGGTCAGCCCATTCTTACTTCCCTGGGATCA
40 AATCAAGAAGAAGCATATGTCACCATGTCCAGCTTCTACCAAAACCAAGTGAAGT
GTAAGAAACCCAGACTGAACTTACCGTGAGCGACAAAGATGATTTAAAAGGGAA
GTCTAGAGTTCTAGTCTCCCTCACAGCACAGAGAAGACAAAATTAGCAAAACC
CCACTACACAGTCTGCAAGATTCTGAAACATTGCTTTGACCACTCTTCTGAGTTC
AGTGGCACTCAACATGAGTCAAGAGCATCCTGCTTCTACCATGTGGATTTGGTCA
45 CAAGGTTTAAAGGTGACCCAATGATTGAGCTATTTAAAAAAGAGGAAAGAA
TGAAAGAGTAAAGGAAATGATTGAGGAGTGAGGAAGGCAGGAAGAGAGCATGA
GAGGAAAGACAGACAGGAAAATAAAAAATGATAGTTGCCATTATTAGGATTTAA
TATATATCCAGTGCTTTGCAAGTGCTCTGCGCACCTTGTCTCACTCCATCCTGACA
ATAATCCTGGGAGGTGTGTGCAATTACTACGACTACTCTTTTTTTATAGATCATT

AAATTCAGAACTAAGGAGTTAAGTAACTTGTCCAAGTTGTTACACACAGTGAAGG
GAGGGGCCAAGATATGATGGCTGGGAGTCTAATTGCAGTTCCTGAGCCATGTG
CCTTTCTCTTCACTGAGGACTGCCCCATTCTTGAGTGCCAAACGTCAGTAGTAAC
AGGGTGTGCCTAGATAATTTATGATCCAACTGAGTCAGTTTGGAAGTGAAAG
5 GGAAACTTACATATAATCCCTCCGGGACAATGAGCAAAAACTAGGACTGTCCCC
AGACAAATGTGAACATACATATCATCACTTAAATTTAAATGGCTATGAGAAAGA
AAGAGGGGGAGAAACAGTCTTGCGGGTGTGAAGTCCCATGACCAGCCATGTCAA
AAGAAGGTAAAGAAGTCAAGAAAAAGCCATGAAGCCCATTTGATTTTCAATTTTCT
GAAAATAGGCTCAAGAGGGAATAAATTAGAACTCACAATTTCTCTTGTTTGTTA
10 CCAAGACAGTGATTCTCTTGCTGCTACCACCCAAGTGCATCCGTCCATGATCTCA
GAGGAACTGTCGCTGACCCTGGACATGGGTACGTTTGACGAGTGAGAGGAGGC
ATGACCCCTCCCATGTGTATAGACACTACCCCAACCTAAATTCATCCCTAAATTG
TCCCAAGTTCTCCAGCAATAGAGGCTGCCACAACTTCAGGGAGAAAGAGTTAC
AAGTACATGCAATGAGTGAAGTGAAGTGTGGCTACATTCTTGAAGATATACGGAA
15 GAGACGTATTATTAATGCTTGACATATATCATCTTGCTTTCTTGGTCTAGACTGA
CTTCTAATGACTAACTCAAAGTCAAGGCAACTGAGTAATGTCAGCTCAGCAAAGT
GCAGCAAACCCATCTCCACAGGCCTCCAAACCTGGCTGTTACAGAACCACA
AAGGGCAGATGCTGCACAGAACTAGAGAAGGGGTCATAGGTTTCAATGGTTTTG
TTTGAGATTTGTTGCTACTGTTTTCTGTTTTGAATTTTCTTCTTTGTTCTGTTTTA
20 CTTTATTTAGGGGGACTAGGTGTTTTCTGATATTTTAGTTTTCTTGTTTGTTTTGTT
TGTGTTGTCTGTGAATGGGGTTTTAACTGTGGATGAATGGACCTTATCTGTTGGCT
TAAAGGACTGGTAAAATCAGACCATCTTATTCTTCAGGTGAATGTTTTACTTTCC
TAAAGTGCTCTCCTCTGCAACAGCAGTAATAAATACAATGCCATAATCCCTTAGGT
TTGCCTAGTGCTTTTGCAATTTTCAAAGCACTTCCATAAGCATTCCTTCCACCTEC
25 TTGATAGGCATTTATGGAAAGCCTGCTACATGTCAATCATACTGTTAGGCACAGG
GGACCTAAAGACACATAAAAGGATGGCATTCTGCCTCATAAATTGCAAAACCTA
ATGAAAGTGACTGCTTGGTAAACAAATTATTATTATATTATAAAATGCTATAAAA
GAGCCATATTGAAAGTGCCCTGTTGGAGACAGGGCAAATGCCACAAAAATGATG
TAAATTTACATGGAGGAAAAGTAGAATCTGCCTGGTTTGTAGGCAGCAGAAGAC
30 ATTTTTCATCAGTGGGCAGGTGTTCTTTACCTTTTGTAGAAATGGGAGTCAAGTCT
CAAATAGGAGGCTCCACAAAAATCTCATGCCAGGTCTCTGATACCTTATTCACAGA
AGTTCTTTGAAGTATTTATTGTTATTTTCTTTGACTTATGGGAAAACCTGGGACACA
GGAAGACAGGTAAATTACCCAACCTCACACGTAAAGTCAGAACTGGGAGCCATA
ATTTTGTATCCCTGGIATAAATAGACAATCTCTCGAAGAAATGAAGAGATGACCA
35 TAGAAAAACATCGAGATATCTCCAGCTCTAAAATCCTTTGTTTCAATGTTGTTTG
GCATATGTTATCTTTGGAATTTAGTGTCTGAGCCTCTGTCTGTTACTGTAGTATTT
AAAATGCATGTATTATAATCATATAATCATAACTGCTGTTAATTCTTGATTATATA
CCTAGGGACAATGTGTAATGTAAGATTACTAATTGGTTCTGCCCAATCTCCTTTC
AGATTTTATTAGGAAAAAAAATAAACCTCCTGATCGGAGACAATGTATTAATC
40 AGAAGTGTAACCTGCCAGTTCTATATAGCATGAAATGAAAAGACAGCTAATTTG
GTCCAACAAACATGACTGGGTCTAGGGCACCCAGGCTGATTCAGCTGATTTCTTA
CCAGCCTTTGCCTCTTCCTTCAATGTGGTTTTCCATGGGAATTTGCTTCAGAAAAGC
CAAGTATGGGCTGTTTACAGAGGTGCACACCTGCATTTTCTTAGCTCTTCTAGAGGG
GCTAAGAGACTTGGTACGGGCCAGGAAGAATATGTGGCAGAGCTCCTGGAAATG
45 ATGCAGATTAGGTGGCATTTTTGTGAGCTCTGTGGTTTATTGTTGGGACTATTCTT
TAAAATATCCATTGTTCACTACAGTGAAGATCTCTGATTTAACCGTGTACTATCC
ACATGCATTACAAACATTTTCGAGAGCTGCTTAGTATATAAGCGTACAATGTATG
TAATAACCATCTCATATTTAATTAAATGGTATAGAAGAACA

SEQ ID NO: 642

>21422 BLOOD 354768.27 M18981 g179767 Human prolactin receptor-associated protein (PRA) gene, complete cds. 0

5 CCGAGCTGGCCTCCGGGGCACCGACCGCTATAAAGGCCAGTCGGACTGCGACAC
AGCCCATCCCCTCGACCGCTCGCGTCGCATTTGGCCGCCTCCCTACCGCTCCAAG
CCCAGCCCTCAGCCATGGCATGCCCCCTGGATCAGGCCATTGGCCTCCTCGTGGC
CATCTTCCACAAGTACTCCGGCAGGGAGGGTGACAAGCACACCCTGAGCAAGAA
GGAGCTGAAGGAGCTGATCCAGAAGGAGCTCACCATTGGCTCGAAGCTGCAGGA
TGCTGAAATTGCAAGGCTGATGGAAGACTTGGACCGGAACAAGGACCAGGAGGT
10 GAACTTCCAGGAGTATGTCACCTTCCTGGGGGCCTTGGCTTTGATCTACAATGAA
GCCCTCAAGGGCTGAAAATAAATAGGGAAGATGGAGACACCCTCTGGGGGTCTCT
CTCTGAGTCAAATCCAGTGGTGGGTTATTGTACAATAACCCACCACTGGATTTGA
CTCAGAGAGGACCCCCAGAGGGTGTCTCCATCTTCCCTATTTATTTTCAGCCCTTG
AGGGCTTCATTGTAGATCAAAGCCAAGGCCCCAGGAAGGTGACATACTCCTGG
15 AAGTTCACCTCCTGGTCCTTGTTCCGGTCCAAGTCTTCCATCAGCCTTGCAATTTTC
AGCATCCTGCAGCTTCGAGCCAATGGTGAGCTCCTTCTGGATCAGCTCCTTCAGC
TCCTTCTTGCTCAGGGTGTGCTTGTACCCTCCCTGCCGGAGTACTTGTGGAAGAT
GGCCACGAGGAGGCCAATGGCCTGATCCAGGGGGCATGCCATGGCTGAGGGCTG
GGCTTGGAGCTGGCACAGCACTGCTGCTCCTGACTATCCCTCCAGCGGGGGAGCG
20 CCACAGATGGCCCCAGTCTGGATCCAGCGGCTGAACTGGGCAGGGGATGGCTGG
ACCCCCAGCGTGAGGGCAGCTGGCCCTGGAAAGTACCCAGGGCTCCTGGAGAGA
ACTCACCGGTAGGGAGGCGGCCAAATGCGACGCGAGC

SEQ ID NO: 643

25 >21425 BLOOD 286742.1 AF105201 g4336773 Human G-protein alpha subunit 14 (Galpha14) mRNA, complete cds. 0

GGACGCGCGCCGTGAGCTTAAGCTGCTGCTGCTGGGAACTGGTGAAAGTGGGAA
AAGCACCTTTATCAAGCAGATGNGAATTATCCATGGGTCTGGTTACAGCGACGA
AGACAGAAAGGGGTTACGAAGCTGGTTTACCAAACATATTCACCGCCATGCA
30 AGCCATGATCAGAGCGATGGACACGCTAAGGATACAGTATGTGTGTGAACAGAA
TAAGGAAAATGCCCAGATAATCAGAGAAGTGGAAGTGGACAAGGTCTCCATGCT
CTCCAGGGAGCAGGTGGAGGCCATCAAGCAGCTCTGGCAAGATCCAGGCATCCA
GGAGTGTACGACAGGAGGAGGGAGTACCAGCTGTCGGACTCTGCCAAATATTA
CCTGACTGACATTGACCGCATCGCCACACCATCATTCGTGCCTACCCAACAAGAT
35 GTGCTTCGCGTCCGAGTGCCACACCGGCATCATTGAGTATCCATTTGACTTGG
AAAACATCATCTTTCGGATGGTGGATGTTGGTGGCCAACGATCGGAAAGACGGA
AGTGGATTCACTGCTTTGAGAGTGTACCTCCATTATTTCTTGGTTGCTCTGAGT
GAATATGACCAGGTCCTGGCTGAGTGTGACAACGAGAATCGCATGGAAGAGAGC
AAAGCCTTATTTAAACCATCATCACCTACCCCTGGTTTCTGAATTCATCTGTGAT
40 TTTATTCTTGAACAAGAAGGATCTTTTGGAAAGAGAAAATCATGTACTCTCATCTA
ATTAGCTATTTCCAGAATACACAGGACCGAAACAGGATGTCAGAGCTGCCAGA
GACTTTATCCTGAAGCTTTACCAAGATCAGAATCCTGACAAAGAGAAAGTCATCT
ACTCTCACTTCACATGTGCTACAGATACAGACAATATTCGCTTTGTGTTTGCTGCT
GTCAAAGACACAATTCTACAGCTAAACCTAAGGGAATTCAACCTTGTCTAAAAG
45 CTGCTGCCCACTCCTCCCCTATAACAGAAGATGTGATTTGCAAACCTCCTTGTTTTA
TTTGCAAGTGCTTCTGACATCACCAAGAGCCAGCCCCATGCCAGGAACTAAGGATG
TCATGTAGATCGTGGGGACAGAGATGGGTGATGGAACCTTGGAAAGATATTTGAGT
TTACCAACATACTTTAAAAGTCCTTACATCCCAAATTGTGTTTATAATTATTTTCT
TGACTTTTGGCTATAAGATTTTGTGTAATTTTGAATTTGGTGTTTTCTAGAATTTT

TAAAAGCCACTTTGATTTAGTTTTAAATATGTTTAAAAATAGCGATTAAAATTAT
GTAAGCAAGGAGCCTGTTAGTTTATAGATCATGCCTTCAAACCTCTAGAGTTAAT
TTGGGTGACTTTTTTAAAAATAAGAATGTTAATGGGTTTGAAGCTTTTTATTAAAC
CTTGTAATTTAGAGACATTTTAAATTGTGTTTCTCACCTCATGCTGAAGGGTGACT
5 CCTTTAACATGCCACCAAAGATTTTTTTTAAACACTTGGTTCTTTTTGTGTGTAA
CTTTCTAAGCCAAATTAATGGATATATAAGTATATCTAATTTAGCTTTGCCACAGT
TTGATCACCAAGAAGCCAAAGCTGACATAGAGTAAATGGGCTCTAGATAGCATA
TATGTTTTATTGGTGAAAAANNNGTGTGGTGTGCNCCGTGTGTTGTGTGTGTACA
TTTTTACCCCAATGTATATGACCAGATCTTAAAAATGTATGAAATGGCTAGAAG
10 TCCACATTGTTTGACAAATGTTACGTAAACCCTGCCAAAGTTCTGATGGCCACCAC
AGATTTGCTGTTTGAATTATGTATGCTGTGCCTTTCTGAGGAGGCTAAGAATATA
CCATTCTGCTATTAAAAAAGG

SEQ ID NO: 644

15 >21427 BLOOD 337355.1 AL050214 g4884452 Human mRNA; cDNA DKFZp586H2123
(from clone DKFZp586H2123); partial cds. 0
GGGAGAGCCTGGCGAGCTGAAACCCGAGCTCCCGCTCAGCTGGGGCTCGGGGAG
GTCCCTGTAAAACCCGCCTGCCCCCGGCCTCCCTGGGTCCCTCCTCCTCCCTCCCA
GTAGACGCTCGGGCACCAGCCGCGGCAAGGATGGAGCTGGGTTGCTGGACGCAG
20 TTGGGGCTCACTTTTCTTCAGCTCCTTCTCATCTCGTCCTTGCCAAGAGAGTACAC
AGTCATTAATGAAGCCTGCCCTGGAGCAGAGTGGAATATCATGTGTCGGGAGTG
CTGTGAATATGATCAGATTGAGTGCCTCTGCCCCGAAAGAGGGAAAGTCTGGG
TTATAACCATCCCTTGCTGCAGGAATGAGGAGAATGAGTGTGACTCCTGCCTGATC
EACCCAGGTTGTACCATCTTTGAAAAGTGCAGAGCTGCCGAAATGGCTCATGGG
25 GGGGTACCTTGGATGACTTCTATGTGAAGGGGTTCTACTGTGCAGAGTGCCGAGC
AGGCTGGTACGGAGGAGACTGCATGCGATGTGGCCAGGTTCTGCGAGCCCCAAA
GGGTCAGATTTTGTGGAAGCTATCCCCTAAATGCTCACTGTGAATGGACCATT
CATGCTAAACCTGGGTTTGTATCCAACTAAGATTTGTATGTTGAGCCTGGAGT
TTGACTACATGTGCCAGTATGACTATGTTGAGGTTTCGTGATGGAGACAACCGCGA
30 TGGCCAGATCATCAAGCGTGTCTGTGGCAACGAGCGGCCAGCTCCTATCCAGAG
CATAGGATCCTCACTCCACGTCCTCTTCCACTCCGATGGCTCCAAGAATTTTGAC
GGTTTCCATGCCATTTATGAGGAGATCACAGCATGCTCCTCATCCCCTTGTTTCCA
TGACGGCACGTGCGTCCTTGACAAGGCTGGATCTTACAAGTGTGCCTGCTTGGCA
GGCTATACTGGGCAGCGCTGTGAAAATCTCCTTGAAGAAAGAACTGCTCAGAC
35 CCTGGGGGGCCAGTCAATGGGTACCAGAAAATAACAGGGGGCCCTGGGCTTATC
AACGGACGCCATGCTAAAATTGGCACCGTGGTGTCTTTCTTTTGTAACTCCT
ATGTTCTTAGTGGCAATGAGAAAAGAACTTGCCAGCAGAATGGAGAGTGGTCAG
GGAAACAGCCCATCTGCATAAAAGCCTGCCGAGAACCAAAGATTTAGACCTGG
TGAGAAGGAGAGTTCTTCCGATGCAGGTTCAGTCAAGGGAGACACCATTACACC
40 AGCTATACTCAGCGGCCTTACAGCAAGCAGAACTGCAGAGTGCCCTACCAAGA
AGCCAGCCCTTCCCTTTGGAGATCTGCCCATGGGATACCAACATCTGCATACCA
GCTCCAGTATGAGTGCATCTCACCTTCTACCGCCGGCCTGGGCAGCAGCAGGAG
GACATGTCTGAGGACTGGGAAGTGGAGTGGGCGGGCACCATCCTGCATCCCTAT
CTGCGGGAAAATTGAGAACATCACTGCTCCAAAGACCCAAGGGTTGCGCTGGCC
45 GTGGCAGGCAGCCATCTACAGGAGGACCAGCGGGGTGCATGACGGCAGCCTACA
CAAGGGAGCGTGGTTCCTAGTCTGCAGCGGTGCCCTGGTGAATGAGCGCACTGT
GGTGGTGGCTGCCACTGTGTTACTGACCTGGGGAAGGTCACCATGATCAAGAC
AGCAGACCTGAAAGTTGTTTGGGGAAATTCTACCGGGATGATGACCGGGATGA
GAAGACCATCCAGAGCCTACAGATTTCTGCTATCATTCTGCATCCCAACTATGAC

CCCATCCTGCTTGATGCTGACATCGCCATCCTGAAGCTCCTAGACAAGGCCCGTA
TCAGCACCCGAGTCCAGCCCATCTGCCTCGCTGCCAGTCGGGATCTCAGCACTTC
CTTCCAGGAGTCCCACATCACTGTGGCTGGCTGGAATGTCCTGGCAGACGTGAGG
AGCCCTGGCTTCAAGAACGACACACTGCGCTCTGGGGTGGTCAGTGTGGTGGACT
5 CGCTGCTGTGTGAGGAGCAGCATGAGGACCATGGCATCCCAGTGAGTGTCACTG
ATAACATGTTCTGTGCCAGCTGGGAACCCACTGCCCCTTCTGATATCTGCACTGC
AGAGACAGGAGGCATCGCGGCTGTGTCTTCCCGGGACGAGCATCTCCTGAGCC
ACGCTGGCATCTGATGGGACTGGTCAGCTGGAGCTATGATAAAACATGCAGCCA
CAGGCTCTCCACTGCCTTCACCAAGGTGCTGCCTTTTAAAGACTGGATTGAAAGA
10 AATATGAAATGAACCATGCTCATGCACTCCTTGAGAAGTGTTTCTGTATATCCGT
CTGTACGTGTGTCAATTGCGTGAAGCAGTGTGGGCCTGAAGTGTGATTTGGCCTGT
GAACTTGGCTGTGCCAGGGCTTCTGACTTCAGGGACAAAACCTCAGTGAAGGGTG
AGTAGACCTCCATTGCTGGTAGGCTGATGCCGCGTCCACTACTAGGACAGCCAAT
TGGAAGATGCCAGGGCTTGCAAGAAGTAAGTTTCTTCAAAGAAGACCATATACA
15 AAACCTCTCCACTCCACTGACCTGGTGGTCTTCCCCAACTTTCAGTTATACGAATG
CCATCAGCTTGACCAGGGAAGATCTGGGCTTCATGAGGCCCTTTTGAGGCTCTC
AAGTTCTAGAGAGCTGCCTGTGGGACAGCCAGGGCAGCAGAGCTGGGATGTGG
TGCATGCCTTTGTGTACATGGCCACAGTACAGTCTGGTCCTTTTCTTCCCCATCT
CTTGACACATTTTAATAAAATAAGGGTTGGCTTCTGAACTACAAAAAAAAAAAA
20 AAAGG

SEQ ID NO: 645

21436 BLOOD 348119.3:U40215 g1594276 Human synapsin IIb mRNA, complete cds.

CACTGCCGCTGCTGTCTGCGGGGTCTGGCGCCGGGGTCTGAGTCTCTGCTGGCTA
25 AGCCGCCGCTCAGCGCCTCAGTCGCCTCAATCTCGCTTCCGCCCTCGCTCTCC
CTCCGCGCCACCAGACCCCGTAGCCCCGCGCGCCCCCAGCCCTTTAAGCCAGATG
ATGAACTTCTGCGGCGCCGGCTGTGCGACAGCAGCTTCATCGCCAACTGCCCA
ACGGCTACATGACCGACCTGCAGCGGCCCGAGCCCCAGCAGCCGCCGCCGCCGC
CGCCCCCGGTCCGGGCGCCGCCTCGGCCTCGGCGGCCCGCCGCGCAGCCCGCGCC
30 GGGCCCGGAGCGGAGGCCGCCGCCCGCCTCGGCGGCCCGCCGCGCAGCCCGCGCC
GACGCCGTGCGTGGGACAGCAGCTTCTTCAGCTCGCTGTCCCAAGCCGTGAAGCAG
ACGGCCGCCTCGGCTGGCCTGGTGGACGCGCCCGCTCCCGCGCCCGCAGCCGCC
AGGAAGGCCAAGGTGCTGCTGGTGGTGCAGCAGCCGCACGCCGACTGGGCCAAG
TGCTTTCGGGGCAAAAAAAGTCCTTGGAGATTATGATATCAAGGTGGAACAGGC
35 AGAATTTTCAGAGCTCAACCTGGTGGCCCATGCAGATGGCACCTATGCTGTGGAT
ATGCAGGTTCTCCGGAATGGCACAAAGGTTGTCCGGTCCTTCCGGCCAGACTTCG
TGCTCATCCGGCAGCATGCATTTGGCATGGCGGAGAATGAGGACTTCCGCCACCT
GATCATTGGTATGCAGTATGCAGGCCTCCCCAGCATCAACTCACTGGAATCCATA
TACAACTTCTGTGACAAGCCATGGGTGTTTGCCCAGCTGGTTCGCTATCTATAAGA
40 CACTGGGAGGAGAAAAGTTCCCTCTCATTGAACAGACATACTACCCCAACCACA
AAGAGATGCTGACACTGCCACGTTCCCTGTGGTGGTGAAGATTGGCCACGCTCA
CTCAGGCATGGGCAAGGTCAAAGTGGAACCACTACGACTTCCAGGACATTGC
CAGCGTGGTGGCTCTACCCAGACCTATGCCACTGCAGAGCCTTTCATTGACTCC
AAGTATGACATCCGGGTCCAGAAGATTGGCAACAACCTACAAGGCTTACATGAGG
45 ACATCGATCTCAGGGAAGTGAAGACGAACACTGGCTCTGCGATGCTGGAGCAG
ATTGCCATGTCAGACAGGTACAACTGTGGGTGGACACCTGCTCTGAGATGTTTG
GCGGCCTGGACATCTGTGCTGTCAAAGCTGTACATGGCAAAGATGGGAAAGACT
ACATTTTGGAGGTCATGGACTGTAGCATGCCACTGATTGGGGAACATCAGGTGGA
GGACAGGCAACTCATCACCGAACTAGTCATCAGCAAGATGAACCAGCTGCTGTC

CAGGACTCCTGCCCTGTCTCCTCAGAGACCCCTAACAACCCAGCAGCCACAGAGC
GGAACACTTAAGGATCCGGACTCAAGCAAGACCCACCTCAGCGGCCACCCCT
CAAGGTTGTTTACAGTATATTCTCGACTGTAATGGCATTGCAGTAGGGCCAAAAC
AAGTCCAAGCTTCTTAAAATGATTGGTGGTTAATTTTCAAAGCAGAAATTTTAA
5 GCCAAAAACAAACGAAAGGAAAGCGGGGAGGGGAAAACAGACCCTCCCCTGG
TGCCGTTGCTGCGTTCTTTCAATGCTGACTGGACTGTGTTTTCTCTATGCAGTGTG
AGCTCCTCTGTCTGGTTGTTACCTGTTCTGTTCTGCTGCTTGTAAATGCTCACTTATG
TTTTCTCTGTATAACTTGTGATTCCAGGGCTGTTTGTCAACAGTATACAAAAGAAT
TGTGCCTCTCCCAAGTCCAGTGTGACTTTATCTTCTGGGTGGTTTGATAGTGT
10 TAAAAGTAATATATAATGTGGGGTGAAATGGGAGTAGGGGGGTGGACAGGGGA
GAAACGAAAACCACAAAAAGAAAACCCAACTCCTCTCCTCCCCCAAGCTCAGT
TAAATCCCCCACCTCCAACCTTCCCTCCACCAGTGTGCTTGGGATCTTCAATGAAC
TGTGCTTTTCGCTTTCTTTCTGCAATGACTATTGTAAGTAGATAGAACATTAAGAGA
TTTTCAAGATCAAACCTCCATAGCTTCATCCACTGAATTTGAAGGCATCCACCTTT
15 TTCTCCATTTGCTAAAATTTGGTGCAGTTTGAGTTTATGTGAATAGGCTGGCTGTG
CCTGTAGAGCTCTTGTGTTTTTAGTGATGACATGAAATACAAAGAACAAGCTATT
TCCAGGAATGTGTTCTGTATTTTACATCCCAGTGTACCCTTTATTTTATTATTAAC
TAATTAAGTATGAGATTTTAAAAAATGGGGCCGCTGATGTGCAATATCAAAGTG
AACTTGTGAGTATTTTGTGTGTGTTGATCTCAGTTGTTTCTTCATTGTTGCTGTTTC
20 TGGATCCAGCCATGTGTGCGCTTGTGTGGACCTGAGGCTGCTTTCTGTTCCCAA
GCTTGACCTGTGTACAGAGATAATTCCTTGGCAATGTTGGACATAGAATGCAGGG
AGCTACTGAAGGTCTGTGAGGGATTTGTCCATTCTGCTCTTGGCCTCTCCTGAGGC
CTCATAATGGGAGACCAAATCAAAAATGTCCCATGTCACTTGAAGTGGGTACACTG
CCTACAGAACCTTGAGGTGAGTCTGCTTCAGTTCTCAGCTGTTTACCACAGCCC
25 TCCAGGGTCCAAAGATTGAGGAGCTTCTCTTTCCTGGGAGGAACTGTCTCAGAT
TTAGCTTGTGTGTGTTTTGGACAGAGGCTCCACAGCGGTGGCTCTTGAGGAATCC
TCACCAGTTTGTCTCTTCCCTCTGACAAGCAGCACCTGAGCAGATGCTGAGGCA
GTTTATTAAACCAGGCCTCAGCTTCAGTGCCTCATCTTGCCATCTCCCGGCCAGG
CTGGGAACGGGCACCAAGCAGCCGCCTCTAACAAACACCATGGTCCGTGGAAGT
30 TCATGCCAGCAGCTTGCCTTTGAGAAGAAATGCTGCTGGCTCTATTTTACATTCC
CTTCCACCTCTATACTGTGATGTACCGTTCTGAACTCCCAGATCTGAGAAGGAA
CTAGTGTTGGTGGTATGTAACAAGAGTTACGTATCCAGGGGCTTGTGCCTTGGTT
TCTCCTTTGATTGCTGGTAAATTTCTGAGGCCACAGAGAAATGCATTGAGTGTGAA
TGTTGTGATCTGTAATCCCTCCCTCAGCTGATAATGGTAGTTGATCTGTTGTAAAT
35 ATATACATATATGCATATTTGCACTTCCAGATGGGTTGCATAAGAATCAGGTCCT
TAAATACCTCCCAATCTGATGAAACGATAGAATAAAGTAACATTTCCCAGAATG
GAGGAATACATTATTTTATCGTATATTTTGTCCAAGCGATGAGCTGACGGTGGT
ATTGCTTCTCTGCATGTTATCAGTGTGTACATCTGGTGCTTTTCATGTGTCAATTTGT
GAGCCACAAATGCAAAGTTGCCATTTGAATTCAGTCAGGCTACAGGGTGGTGTG
40 AGTCAAGGTCTTTCAGGTGGGGGAGAAATTTGGTTAGGGCTCCCCTGCCAAATG
CAAGCAGATAGCATAACCTGACTGTTATGTGCCCTCAGGCAGCATGCTTAGGGAC
AACTCTGTGGCCTGGGGGACATCTGTGTACAGTATAGGATTGCCATTCAGGTGT
TTTGTACCTATTTCTTTCCTGACGTTGTCCCTTTTTTTGTACTGATCCAACTGGGA
GAACCTCAGCCAATGCTGGAAGTATGATTGAAGTACCTCTCTTTTGTGACTCTTG
45 TACAGCTTAATGTGCAATAAAGGAAAAGTTATATCTGTCAAAAA

SEQ ID NO: 646

>21463 BLOOD 251776.14 X53002 g33952 Human mRNA for integrin beta-5 subunit. 0

CGGGGGAGTCTCGGCGCTGGGCGCGTTCGGAGCCCAAGTCGCGGGCCGCGGAGCG
GAGCCAGCCCCTCCCCTACCCGGAGCAGCCCGCTGGGTGCCTGTCCCGAGCGGC
GACACACTAGGAGTCCCGGCCGCGCCAGCCAGGCAGCCGCGGTCCCGGGACTCGG
CCGTGAGTGCTGCGGGACGGATGGTGGCGGCGGGGCGCGGGCCACGGCGGGCGC
5 CGTGGAGCCGGGCGCCGTGAGCCGGAGCTGCGCGCGGGGCATGCGGGCTGCGCCC
CGGCCCCCTCGGCCCCCGGCCTCGGCCCCCGCGCTCCGGCCCCAGCCCCGGCCGCC
GGCCCCCGCGGAGTGCAGCGACCGCGCCGCGCTGAGGGAGGCGCCCCACCATG
CCGCGGGCCCCGGCGCCGCTGTACGCCTGCCTCCTGGGGCTCTGCGCGCTCCTGC
CCCGGCTCGCAGGTCTCAACATATGCACTAGTGGAAGTGCCACCTCATGTGAAGA
10 ATGTCTGCTAATCCACCCAAAATGTGCCTGGTGTCTCAAAGAGGACTTCGGAAGC
CCACGGTCCATCACCTCTCGGTGTGATCTGAGGGCAAACCTTGTCAAAAATGGCT
GTGGAGGTGAGATAGAGAGCCCAGCCAGCAGCTTCCATGTCCTGAGGAGCCTGC
CCCTCAGCAGCAAGGGTTCGGGCTCTGCAGGCTGGGACGTCATTGAGATGACAC
CACAGGAGATTGCCGTGAACCTCCGGCCCCGGTGACAAGACCACCTTCCAGCTAC
15 AGGTTCCGCCAGGTGGAGGACTATCCTGTGGACCTGTACTACCTGATGGACCTCTC
CCTGTCCATGAAGGATGACTTGGACAATATCCGGAGCCTGGGCACCAAACCTCGC
GGAGGAGATGAGGAAGCTCACCAGCAACTTCCGGTTGGGATTTGGGTCTTTTGT
GATAAGGACATCTCTCCTTTCTCCTACACGGCACCGAGGTACCAGACCAATCCGT
GCATTGGTTACAAGTTGTTTCCAAATTGCGTCCCCTCCTTTGGGTTCCGCCATCTG
20 CTGCCTCTCACAGACAGAGTGGACAGCTTCAATGAGGAAGTTCGGAAACAGAGG
GTGTCCCGGAACCGAGATGCCCTGAGGGGGGCTTTGATGCAGTACTCCAGGCA
GCCGTCTGCAAGGAGAAGATTGGCTGGCGAAAGGATGCACTGCAATTGCTGGTG
TTTCAACAACAGATGATGTGCCCCACATCGCATGGGATGGAAAATTGGGAGGCCTG
GTGCAGCCACACGATGGGCGAGTGCCACCTGAACGAGGCCAACGAGTACACTGCA
25 TCCAACCAGATGGACTATCCATCCCTTGCTTGGAGAGAAATTGGCAGAGA
ACAACATCAACCTCATCTTTGCAGTGACAAAAAACCATTATATGCTGTACAAGAA
TTTTACAGCCCTGATACCTGGAACAACGGTGGAGATTTTAGATGGAGACTCCAAA
AATATTATTCAACTGATTATTAATGCATACAATAGTATCCGGTCTAAAGTGGAGT
TGTCAGTCTGGGATCAGCCTGAGGATCTTAATCTCTTCTTTACTGCTACCTGCCAA
30 GATGGGGTATCCTATCCTGGTCAGAGGAAGTGTGAGGGTCTGAAGATTGGGGAC
ACGGCATCTTTTGAAGTATCATTGGAGGGCCGAAGCTGTCCCAGCAGACACACG
GAGCATGTGTTTGCCCTGCGGCCGGTGGGATTCGGGGACAGCCTGGAGGTGGGG
GTCACCTACAACCTGCACGTGCGGCTGCAGCGTGGGGCTGGAAACCAACAGCGCC
AGGTGCAACGGGAGCGGGACCTATGTCTGCGGCCTGTGTGAGTGCAGCCCCGGC
35 TACCTGGGCACCAGGTGCGAGTGCCAGGATGGGGAGAACCAGAGCGTGTACCAG
AACCTGTGCCGGGAGGCAGAGGGCAAGCCACTGTGCAGCGGGCGTGGGGACTGC
AGCTGCAACCAGTGCTCCTGCTTCGAGAGCGAGTTTGGCAAGATCTATGGGCCTT
TCTGTGAGTGCAGAACTTCTCCTGTGCCAGGAACAAGGGAGTCTCTGCTCAGG
CCATGGCGAGTGTCACTGCGGGGAATGCAAGTGCCATGCAGGTTACATCGGGGA
40 CAACTGTAACCTGCTCGACAGACATCAGCACATGCCGGGGCAGAGATGGCCAGAT
CTGCAGCGAGCGTGGGCACTGTCTGTGGGCAGTGCCAATGCACGGAGCCGGG
GGCCTTTGGGGAGATGTGTGAGAAAGTGGCCACCTGCCCGGATGCATGCAGCAC
CAAGAGAGATTGCGTCGAGTGCCTGCTGCTCCACTCTGGGAAACCTGACAACCA
GACCTGCCACAGCCTATGCAGGGATGAGGTGATCACATGGGTGGACACCATCGT
45 GAAAGATGACCAGGAGGCTGTGCTATGTTTCTACAAAACCGCCAAGGACTGCGT
CATGATGTTACCTATGTGGAGCTCCCCAGTGGGAAGTCCAACCTGACCGTCCTC
AGGGAGCCAGAGTGTGGAAACACCCCCAACGCCATGACCATCCTCCTGGCTGTG
GTCGGTAGCATCCTCCTTGTGGGCTTGCACTCCTGGCTATCTGGAAGCTGCTTGT
CACCATCCACGACCGGAGGGAGTTTGCAAAGTTTCAGAGCGAGCGATCCAGGGC

CCGCTATGAAATGGCTTCAAATCCATTATACAGAAAGCCTATCTCCACGCACACT
GTGGACTTCACCTTCAACAAGTTCAACAAATCCTACAATGGCACTGTGGACTGAT
GTTTCCTTCTCCGAGGGGCTGGAGCGGGGATCTGATGAAAAGGTCAGACTGAAA
CGCCTTGCACGGCTGCTCGGCTTGATCACAGCTCCCTAGGTAGGCACACAGAGA
5 AGACCTTCTAGTGAGCCTGGGCCAGGAGCCACAGTGCCTGTACAGGAAGGTGC
CTGGCCATGTACCTGGCTGCTAGGCCAGAGCCATGCCAGGCTGCGTCCCTCCGA
GCTTGGGATAAAGCAAGGGGACCTTGGGCGCTCTCAGCTTTCCTGCCACATCCA
GCTTGTGTGCCAATGAAATACTGAGATGCTGGGCTGTCTCTCCCTTCCAGGAAT
GCTGGGCCCCCAGCCTGGCCAGACAAGAAGACTGTCAGGAAGGGTCGGAGTCTG
10 TAAAACCAGCATAACAGTTTGGCTTTTTTTCACATTGATCATTTTTATATGAAATAAA
AAGATCCTGCATTTATGGTGTAGTTCTGAGTCCTGAGACTTTTCTGCGTGATGGCT
ATGCCTTGCACACAGGTGTTGGTGATGGGGCTGTTGAGATGCCTGTTGAAGGTAC
ATCGTTTGCAAATGTCAGTTTCCTCTCCTGTCCGTGTTGTTTAGTACTTTTATAAT
GAAAAGAAACAAGATTGTTTGGGATTGGAAGTAAAGATTAAAACCAAAAGAATT
15 TGTGTTTGTCTGATACTCTCTGTGTGTTTCTTTCTTTCTGAGCGGACTTAAAATGG
TGCCCCCAGTGGGGATTGAAGCGGCCGTGTACTTCCTCAGGGATGGGACACAGG
CTGGTCTGATACTCCAGACTGCAGCTTGTCAAGTAAGCATGAGGTGCTCGGGGCA
GTGAGGGCTGTGCAAGGGGGAACACTGAGCAGATAGATACCTTTGGCCCCCTTCC
AGCTTTTACTGACAGAGAGTTCCAGGCTAGACACCATAAAAACCACCCCTTGGTC
20 TCCCTCCCTTGTTCTGAGGGGCTGAGGCTGGAAATAGATTGTACAGACAAGCAAG
GGTTGAGTGGTGGTTCCACACGAAGTCATCTCTTAAACATCATTAGCAATAGCA
GTTCCCTTCCAAGGCTCCCTEACFCCGAAACACTTACGTCCCATGCAAGGCC
AATGCAAAAAACACATTTGAGCTTTTCCCGCAGGGCCATGAAGTCCCTTAA
GTTCCCATATCTAAGATGGTTGACTGACCCTCTCCCCTTATGNANNNNNNNNNNN
25 NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNTGTTTGTTAGGAGGTTAC
TGAATGACAACTGTTCTAAGACCCCATCTCATGCTGGCCAGAGGGCCAGCCTC
CTCATTCTGCTTGCTCTTAGAAAATCTTTCACTGATCATTTTTTGTCACTGGAAT
AACTTCAAGGTTATTATGCTTTCATTCCAAATGGATCTGTCTCAGCTCTGGACCC
AATTCCCCTTACTTCATTTTGGCAAACACTAAGTCAAATAGTGAAATGCCTGTCA
30 CTACATAGAACCTATTACCTGGGGCAAATACGAACAGATTGAGTTTCCTTCATCT
TGTGTAATATGATGAAACAGAGACCTGGTAACTTGGTGACACTGTAAACCCCT
TTTGGGATAAAGCCAAATGTAAATGAAACATTAAACAGATAAATTGTGGCGTT
GAGACTTTTCTGAATTGAGAAAAATAAATGTAATTTTGAAGAAAAAAGGG
ANNANNAANNNGGANNACAGNNNANNNAAAAAAGGG

SEQ ID NO: 647

>21515 BLOOD 410296.1 AF085690 g4106439 Human multidrug resistance-associated
protein 3 (MRP3) mRNA, complete cds. 0

GGGTCCGACCGCGCTCGCCTTCCCTGCAGCCGCGCCTCGGCCCCATGGACGCCCT
40 GTGCGGTTCCGGGGAGCTCGGCTCCAAGTTCTGGGACTCCAACCTGTCTGTGCAC
ACAGAAAACCCGGACCTCACTCCCTGCTTCCAGAACTCCCTGCTGGCCTGGGTGC
CCTGCATCTACCTGTGGGTGCGCCTGCCCTGCTACTTGCTCTACCTGCGGCACCAT
TGTCGTGGCTACATCATCCTCTCCACCTGTCCAAGCTCAAGATGGTCCTGGGTG
TCCTGCTGTGGTGCGTCTCCTGGGCGGACCTTTTTTACTCCTTCCATGGCCTGGTC
45 CATGGCCGGGCCCTGCCCTGTTTTCTTTGTACCCCTTGGTGGTGGGGGTCAC
CATGCTGCTGGCCACCCTGCTGATACAGTATGAGCGGCTGCAGGGCGTACAGTCT
TCGGGGGTCCTCATTATCTTCTGGTTCCTGTGTGTGGTCTGCGCCATCGTCCCAT
CCGCTCCAAGATCCTTTAGCCAAGGCAGAGGGTGAGATCTCAGACCCCTTCCGC
TTCACCACCTTCTACATCCACTTTGCCCTGGTACTCTCTGCCCTCATCTTGGCCTG

CTTCAGGGAGAAACCTCCATTTTTCTCCGCAAAGAATGTCGACCCTAACCCCTAC
CCTGAGACCAGCGCTGGCTTTCTCTCCCGCTGTTTTCTGGTGGTTCACAAAGAT
GGCCATCTATGGCTACCGGCATCCCCTGGAGGAGAAGGACCTCTGGTCCCTAAA
GGAAGAGGACAGATCCCAGATGGTGGTGCAGCAGCTGCTGGAGGCATGGAGGA
5 AGCAGGAAAAGCAGACGGCACGACACAAGGCTTCAGCAGCACCTGGGAAAAAT
GCCTCCGGCGAGGACGAGGTGCTGCTGGGTGCCCCGGCCAGGCCCCGGAAGCCC
TCCTTCCTGAAGGCCCTGCTGGCCACCTTCGGCTCCAGCTTCCTCATCAGTGCCTG
CTTCAAGCTTATCCAGGACCTGCTCTCCTTCATCAATCCACAGCTGCTCAGCATCC
TGATCAGGTTTATCTCCAACCCCATGGCCCCCTCCTGGTGGGGCTTCCTGGTGGCT
10 GGGCTGATGTTCTGTGCTCCATGATGCAGTCGCTGATCTTACAACACTATTACC
ACTACATCTTTGTGACTGGGGTGAAGTTTCGTACTGGGATCATGGGTGTCATCTA
CAGGAAGGCTCTGGTTATACCAACTCAGTCAAACGTGCGTCCACTGTGGGGGA
AATTGTCAACCTCATGTGAGTGGATGCCAGCGCTTCATGGACCTTGCCCCCTTC
CTCAATCTGCTGTGGTCAGCACCCCTGCAGATCATCCTGGCGATCTACTTCCTCTG
15 GCAGAACCTAGGTCCCTCTGTCTGGCTGGAGTCGCTTTCATGGTCTTGCTGATTC
CACTCAACGGAGCTGTGGCCGTGAAGATGCGCGCCTTCAGGTAAAGCAAATGA
AATTGAAGGACTCGCGCATCAAGCTGATGAGTGAGATCCTGAACGGCATCAAGG
TGCTGAAGCTGTACGCCTGGGAGCCCAGCTTCCTGAAGCAGGTGGAGGGCATCA
GGCAGGGTGAGCTCCAGCTGCTGCGCACGGCGGCCTACCTCCACACCACAACCA
20 CCTTCACCTGGATGTGCAGCCCCCTTCCTGGTGACCCTGATCACCTCTGGGTGTAC
GTGTACGTGGACCCAAACAATGTGCTGGACGCCGAGAAGGCCTTTGTGTCTGTGT
GCTGTTTAATATCTTAAGACTTCCACACAACATGCTGCCCCAGTTAATCAGCAA
CCTGAGTCAGGCCAGTGTGTCTCTGAAACGGATCCAGCAATTTCCTGAGCCAAAGAG
GAACTTGACCCCCAGAGTGTGGAAAGAAAGACCATCTCCCCAGGCTATTCCATC
25 ACATACACAGTGGCACCTTCACCTGGGCCCAGGACCTGCCCCCACTCTGCACAG
CCTAGACATCCAGGTCCCGAAAGGGGCACTGGTGGCCGTGGTGGGGCCTGTGGG
CTGTGGGAAGTCTCCCTGGTGTCTGCCCTGCTGGGAGAGATGGAGAAGCTAGA
AGGCAAAGTGCACATGAAGGGCTCCGTGGCCTATGTGCCCCAGCAGGCATGGAT
CCAGAACTGCACTCTTCAGGAAAACGTGCTTTTCGGCAAAGCCCTGAACCCCAAG
30 CGCTACCAGCAGACTCTGGAGGCCTGTGCCTTGCTAGCTGACCTGGAGATGCTGC
CTGGTGGGGATCAGACAGAGATTGGAGAGAAGGGCATTAAACCTGTCTGGGGGCC
AGCGGCAGCGGGTCAGTCTGGCTCGAGCTGTTTACAGTGATGCCGATATTTTCTT
GCTGGATGACCCACTGTCCGCGGTGGACTCTCATGTGGCCAAGCACATCTTTGAC
CACGTCACTGGGCCAGAAAGGCGTGCTGGCAGGCAAGACGCGAGTGCTGGTGACG
35 CACGGCATTAGCTTCCTGCCCCAGACAGACTTCATCATTGTGCTAGCTGATGGAC
AGGTGTCTGAGATGGGCCCGTACCCAGCCCTGCTGCAGCGCAACGGCTCCTTTC
CAACTTTCTCTGCAACTATGCCCCCGATGAGGACCAAGGGCACCTGGAGGACAG
CTGGACCGCGTTGGAAGGTGCAGAGGATAAGGAGGCACTGCTGATTGAAGACAC
ACTCAGCAACCACACGGATCTGACAGACAATGATCCAGTCACCTATGTGGTCCA
40 GAAGCAGTTTATGAGACAGCTGAGTGCCCTGTCTCAGATGGGGAGGGACAGGG
TCGGCCTGTACCCCGGAGGCACCTGGGTCCATCAGAGAAGGTGCAGGTGACAGA
GGCGAAGGCAGATGGGGCACTGACCCAGGAGGAGAAAGCAGCCATTGGCACTG
TGGAGCTCAGTGTGTTCTGGGATTATGCCAAGGCCGTGGGGCTCTGTACCACGCT
GGCCATCTGTCTCCTGTATGTGGGTCAAAGTGCGGCTGCCATTGGAGCCAATGTG
45 TGGCTCAGTGCCTGGACAAATGATGCCATGGCAGACAGTAGACAGAACAACACT
TCCCTGAGGCTGGGCGTCTATGCTGCTTTAGGAATTCTGCAAGGGTTCTTGGTGA
TGCTGGCAGCCATGGCCATGGCAGCGGGTGGCATCCAGGCTGCCCCGTGTGTTGCA
CCAGGCACTGCTGCACAACAAGATACGCTCGCCACAGTCCTTCTTTGACACCACA
CCATCAGGCCGCATCCTGAACTGCTTCTCCAAGGACATCTATGTCGTTGATGAGG

TTCTGGCCCCCTGTCATCCTCATGCTGCTCAATTCCCTTCTTCAACGCCATCTCCACT
CTTGTGGTCATCATGGCCAGCACGCCGCTCTTCACTGTGGTCATCCTGCCCCCTGGC
TGTGCTCTACACCTTAGTGCAGCGCTTCTATGCAGCCACATCACGGCAACTGAAG
CGGCTGGAATCAGTCAGCCGCTCACCTATCTACTCCCACTTTTCGGAGACAGTGA
5 CTGGTGCCAGTGTTCATCCGGGCTACAACCGCAGCCGGGATTTTGAGATCATCAG
TGATACTAAGGTGGATGCCAACCAGAGAAGCTGCTACCCCTACATCATCTCCAAC
CGGTGGCTGAGCATCGGAGTGGAGTTCGTGGGGAAGTGCCTGGTGCTCTTTGCTG
CACTATTTGCCGTTCATCGGGAGGAGCAGCCTGAACCCGGGGCTGGTGGGCCCTTTC
TGTGTCTACTCCTTGCAGGTGACATTTGCTCTGAACTGGATGATACGAATGATG
10 TCAGATTTGGAATCTAACATCGTGGCTGTGGAGAGGGTCAAGGAGTACTCCAAG
ACAGAGACAGAGGGCGCCCTGGGTGGTGGAAAGGCAGCCGCCCTCCCGAAGGTTGG
CCCCACGTGGGGAGGTGGAGTTCGGAATTATTCTGTGCGCTACCGGCCGGGCC
TAGACCTGGTGCTGAGAGACCTGAGTCTGCATGTGCACGGTGGCGAGAAGGTGG
GGATCGTGGGGCCGCACTGGGGCTGGCAAGTCTTCCATGACCCCTTGCCTGTTCCG
15 CATCCTGGAGGCGGCAAAGGGTGAATCCGCATTGATGGCCTCAATGTGGCAGA
CATCGGCCTCCATGACCTGCGCTCTCAGCTGACCATCATCCCGCAGGACCCCATC
CTGTTCTCGGGGACCCTGCGCATGAACCTGGACCCCTTCGGCAGCTACTCAGAGG
AGGACATTTGGTGGGCTTTGGAGCTGTCCACCTGCACACGTTTGTGAGCTCCCA
GCCGGCAGGCCTGGACTTCCAGTGTCTCAGAGGGCGGGGAGAATCTCAGCGTGGG
20 CCAGAGGCAGCTCGTGTGCCTGGCCCCGAGCCCTGCTCCGCAAGAGCCGCATCCTG
GTTTTAGACGAGGCCACAGCTGCCATCGACCTGGAGACTGACAACCTCATCCAG
GCTGACCATCCGCACCCAGTTTGATACTGCACTGTCTTGACCATCGCACACCGGC
CTAACACTATCATGGACTACACCAGGGTCTGGTCTTGACAAAGGAGTAGTAG
CTGAATTTGATTCTCCAGCCAACCTCATTGCAGCTAGAGGCATCTTCTACGGGAT
25 GGCCAGAGATGCTGGACTTGCTAAAATATATTCTGAGATTTCTCTCTGGCCTT
TCCTGGTTTTTCATCAGGAAGGAAATGACACCAAATATGTCCGCAGAATGGACTTG
ATAGCAAACACTGGGGGCACCTTAAGATTTTGCACCTGTAAAGTGCCTTACAGGG
TAACTGTGCTGAATGCTTTAGATGAGGAAATGATCCCAAGTGGTGAATGACAC
GCCTAAGGTCACAGCTAGTTTGAAGCCAGTTAGACTAGTCCCCGGTCTCCCGATTC
30 CCAACTGAGTGTTATTTGCACACTGCACTGTTTTCAAATAACGATTTTATGAAAT
GACCTCTGTCTCCTCCTCTGATTTTTTCATATTTTCTAAAGTTTCGTTTTCTGTTTTTA
ATAAAAAGCTTTTTCTCCTGGAACAGAAGACAGCTGCTGGGTGAGGCCACCCCT
AGGAACTCAGTCTGTACTCTGGGGTGCTGCCTGAATCCATTAAAAATGGGAGTA
CTGATGAAATAAACTACATGGTCAACAGTATATACACAGTAGTCTTTTTGCACT
35 TGTTCAAGGTTTGGGGATTAGGATCTTTGGAGGAGGCCAAGAGGAAGACTTT
CTACACATGTACATGGTTGTAGTTACCTGAACTTCAGACCCAAGAGCTCTTGGCT
GCAAATATTGCCTTCAC

SEQ ID NO: 648

40 >21518 BLOOD 244943.4 AJ001309 g3171907 Human mRNA for DnaJ protein. 0
GTCTCCCTCGGCCTGTGCCGCCGCGACGCCGCTTGTGGGCCCCGACTCCGCTCTG
TCTGCTTCGCCACCTTCTCCCCGAGCACTGCCCGGCCGGCCGCCATGGCTAACGT
GGCTGACACGAAGCTGTACGACATCCTGGGCGTCCCGCCCGGCCAGCGAGAA
CGAGCTGAAGAAGGCATACAGAAAGTTAGCCAAGGAATATCATCCTGATAAGAA
45 TCCAAATGCAGGAGACAAATTTAAAGAAATAAGTTTTGCATATGAAGTACTATC
AAATCCTGAGAAGCGTGAGTTATATGACAGATACGGAGAGCAAGGTCTTCGGGA
AGGCAGCGCGGAGGTGGTGGCATGGATGATATTTCTCTCACATTTTGGTGGG
GGATTGTTTCGGCTTCATGGGCAATCAGAGTAGAAGTCGAAATGGCAGAAGAAGA
GGAGAGGACATGATGCATCCACTCAAAGTATCTTTAGAAGATCTGTATAATGGC

AAGACAACCAAACCTACAACCTTAGCAAGAATGTGCTCTGTAGTGCATGCAGTGGC
CAAGGCGGAAAGTCTGGAGCTGTCCAAAAGTGTAGTGCTTGTGCGAGGTCGAGGT
GTGCGCATCATGATCAGACAGCTGGCTCCAGGGATGGTACAACAGATGCAGTCT
GTGTGCTCTGATTGTAATGGAGAAGGAGAGGTAATTAATGAAAAAGACCGCTGT
5 AAAAAATGTGAAGGGAAGAAGGTGATTAAGAAGTCAAGATTCTTGAAGTCCAC
GTAGACAAAGGCATGAAACATGGACAGAGAATTACATTCACTGGGGAAGCAGAC
CAGGCCCCAGGAGTGGAACCCGGAGACATTGTTCTTTTGCTACAGGAGAAAGAA
CATGAGGTATTTTCAGAGAGATGGGAATGATTTGCACATGACATATAAAATAGGA
CTTGTTGAAGCTCTATGTGGATTTTCAGTTCACATTTAAGCACCTTGATGGACGTCA
10 GATTGTGGTGAAATACCCCCCTGGCAAAGTAATTGAACCAGGGTGTGTTTCGTGTA
GTTTCGAGGTGAAGGGATGCCGCAGTATCGTAATCCCTTTGAAAAAGGTGATCTTT
ACATAAAGTTTGATGTGCAGTTTCTGAAAACAACCTGGATCAACCCAGACAAGCT
TTCTGAACTAGAAGATCTTCTGCCATCTAGACCGGAAGTTCCTAACATAATTGGA
GAAACAGAGGAGGTAGAGCTTCAGGAATTTGATAGCACTCGAGGCTCAGGAGGT
15 GGTCAGAGGCGTGAAGCCTATAATGATAGCTCTGATGAAGAAAGCAGCAGCCAT
CATGGACCTGGAGTGCAGTGTGCCCATCAGTAAACTCTGCAAACAAATTGCACA
GGTGGATTTTCTTTCCACATTTGCCTGATTTGTTCTCAGCAATCCAGCTGGAGTGT
CTTATCAATCCAGATGAACTGAGGGACATCTGTTGGTCTATGTATAACTTTTAAA
ATTGGTATAGTATCTACAGAGTGTATAATTTAACTAACCACAAAGCTTTACATC
20 TTCATTTTGACTGTTCCATAGCAGAATAAAGCACTTGAAAGGAAACAAGACTCCC
TTTCACACATGGATTATTATAAGTTTCAATCCTGGTATCTGTGCTTGATTTTATC
AGTTTTGTGTAGATTTTATGTTTCAATTTTAAATTTAAATGCCACATTGTAAAG
TTTGTAGAATTTGTCTGAAGCTTTGTGTTTGGCTGCACCTGCATAAGCTGCTACA
AATAGAATAAAGAATTTTCATAGCCTGTATCTATCATTTAGATGCATGGAAAAAAA
25 TGGGCTTTGCACACAATGGGTTTGGAGCTGACTGGGAACAATGGAAAAAATTAC
ATTAGCTGTGGTTGTAAAGTTTTTTTTGTTTTTGGTTTTGTTTTTTTTTCTTTTNTCT
TTTTTTTTTNTATTACCATCTTGTGAAAGGTTTCTGAAACTCGATAATAAAAAGCG
GTTGGTGTAAATTATTCTTTGTGTACATTTTGTAGAAGGAAAAACATAAAAGAA
TGTATCCTTAGTACTGGTTCTTAAACAGCCCATAAAAACCCATTGGCCTGAAGCT
30 TATATCTCAGGCCTATGCCCATCTTATAGTCTTGGAAGACAAAAGGCTGGTAGAG
ACAGTCTTCAGTGGCTTCAGTGATGCTCTGTAGAGGCCAGGGTGTCTTGAGTGCT
GTAACCTCCCAAGCACTGGGCTAGCCTGACTTCTGTATCTCCCTACCACCACCCCC
TTAAAAAAATAAGGTAACAGCAAATCTATAGTAAAACCATGTCTGCATAGAACG
TGTTCAAATCCTCTGTTTTTCAATTAATGTAAAAGATGCTGTCTCCATTAAGTTGAA
35 TATTTGGAATTGGAGAAGCCATTGATTATTATTTGAGTTTCTGTAATGTTTTATA
GAAAAGTAAGATGCTTATTCAGAATTTAAGAATGAAGGCAACTGAAATATGCAT
TGTTGTAGTTATTTATATTTCAAACATAAAATAAGCAAAAAAAAAGGCTGGTTT
GAGAAAAATCAGGTAAAATTGATGAAACGGATGTTGTGTTTCTCTTTCCATCATC
TGGTTTTTACCATTTCACTCAGTAGGTATTTTTAGAACACACTTATTTGAGGAAAG
40 AGACATCAGATGCACAATTTTACATTTATAAAGGAACAAATGGGGAAAACTGAA
AACTAAAAATTTTAAATGTATTAATGCCATCCCTGAGCCTAAATCTAGTATTTG
TAGTTTATTTCTAGGTCTGCTAGAACCTGAAAACCTGAATGAAAAAAGGTGTGCT
GACACTAATCAAGTCCTGTGAGGTTTAAATTATTGACCTATCCACTCTACCTCCAT
TGTACAAAAAATATTTTACAACAAGCCTGGGTAAGATTCAACAGCATAGTAGTTT
45 TGTATCCAAGGTTACTTCCCCACAACCACTTTAAACATAAGAAATGTGGTGGCAA
TATAAAGTTTGTAGCCTTTCCAATAAAGGTTTATAAAAC

SEQ ID NO: 649

>21530 BLOOD 231654.4 AF056085 g3719225 Human GABA-B receptor mRNA,
complete cds. 0

5 CCGTTCTGAGCCGAGCCGGAACCCTAGCCCGAGACGGAGCCGGGGCCCGGGCCG
GCGCCATTGCGCGGGCGCCGCGGGAAGACCTTGGCGCGGGGCGGCGGGCCCGGGC
CAGGCCATGCGGGCCGAGTGAGCCGGCGCCCGCAGCCCGCGGCGCGGCATGGCT
TCCCCGCGGAGGTCCGGGCAGCCCGGGCCGCGCCCGCCGCCACCGCCGCCC
GCGCGCCTGCTACTGCTACTGCTGCTGCCGCTGCTGCTGCCTCTGGCGCCCGGGG
CCTGGGGCTGGGCGCGGGGCGCCCCCGGCCGCCGCCAGCAGCCCGCCGCTCT
10 CCATCATGGGCCTCATGCCGCTCACCAAGGAGGTGGCCAAGGGCAGCATCGGGC
GCGGTGTGCTCCCCGCCGTGGAAGTGGCCATCGAGCAGATCCGCAACGAGTCAC
TCCTGCGCCCCTACTTCCTCGACCTGCGGCTCTATGACACGGAGTGCGACAACGC
AAAAGGGTTGAAAGCCTTCTACGATGCAATAAAATACGGGGCCGAACCACTTGAT
GGTGTGTTGGAGGCGTCTGTCCATCCGTCACATCCATCATTGCAGAGTCCCTCCAA
15 GGCTGGAATCTGGTGCAGCTTTCTTTTGGCTGCAACCACGCCTGTTCTAGCCGATA
AGAAAAAATAACCCTTATTTCTTTTCGGACCGTCCCATCAGACAATGCGGTGAATCC
AGCCATTCTGAAGTTGCTCAAGCACTACCAGTGGAAGCGCGTGGGCACGCTGAC
GCAAGACGTTCAAGAGTTCTCTGAGGTGCGGAATGACCTGACTGGAGTTCTGTAT
GGCGAGGACATTGAGATTTAGACACCGAGAGCTTCTCCAACGATCCCTGTACCA
20 GTGTCAAAAAGCTGAAGGGGAATGATGTGCGGATCATCCTTGGCCAGTTTGACC
AGAATATGGCAGCAAAAAGTGTTCTGTTGTGCATACGAGGAGAACATGTATGGTA
GTAAATATCAGTGGATCATTECGGGCTGGTACGAGCCTTCTTGGTGGGAGCAGGT
GCACACGGAAGCCAACTCATCCCGCTGCCCTCCGGAAGAATCTGCTTGCTGCCATG
GAGGGCTACATTGGCGTGGATFTCGAGCCCTGAGCTCCAAGCAGATCAAGACC
25 ATCTCAGGAAAGACTCCACAGCAGTATGAGAGAGAGTACAACAACAAGCGGTCA
GGCGTGGGGCCAGCAAGTTCACGGGTACGCCTACGATGGCATCTGGGTCATC
GCCAAGACACTGCAGAGGGCCATGGAGACACTGCATGCCAGCAGCCGGCACCAG
CGGATCCAGGACTTCAACTACACGGACCACACGCTGGGCAGGATCATCCTCAAT
GCCATGAACGAGACCAACTTCTTCGGGGTACGCGGTCAAGTTGTATTCCGGAATG
30 GGGAGAGAATGGGGACCATTAAATTTACTCAATTTCAAGACAGCAGGGAGGTGA
AGGTGGGAGAGTACAACGCTGTGGCCGACACACTGGAGATCATCAATGACACCA
TCAGGTTCCAAGGATCCGAACCACCAAAAGACAAGACCATCATCCTGGAGCAGC
ETGCGGAAGATCTCCCTACCTCTCTACAGCATCCTCTCTGCCCTCACCATCCTCGGG
ATGATCATGGCCAGTGCTTTTCTCTTCTTCAACATCAAGAACCGGAATCAGAAGC
35 TCATAAAGATGTCGAGTCCATACATGAACAACCTTATCATCCTTGGAGGGATGCT
CTCCTATGCTTCCATATTTCTCTTTGGCCTTGATGGATCCTTTGTCTCTGAAAAGA
CCTTTGAAACACTTTGCACCGTCAGGACCTGGATTCTCACCGTGGGCTACACGAC
CGCTTTTGGGGCCATGTTTGCAAAGACCTGGAGAGTCCACGCCATCTTCAAAAAT
GTGAAAATGAAGAAGAAGATCATCAAGGACCAGAACTGCTTGTGATCGTGGGG
40 GGCATGCTGCTGATCGACCTGTGTATCCTGATCTGCTGGCAGGCTGTGGACCCCC
TGCGAAGGACAGTGGAGAAGTACAGCATGGAGCCGGACCCAGCAGGACGGGAT
ATCTCCATCCGCCCTCTCCTGGAGCACTGTGAGAACACCCATATGACCATCTGGC
TTGGCATCGTCTATGCCTACAAGGGACTTCTCATGTTGTTTCGGTTGTTTCTTAGCT
TGGGAGACCCGCAACGTGAGCATCCCCGCACTCAACGACAGCAAGTACATCGGG
45 ATGAGTGTCTACAACGTGGGGATCATGTGCATCATCGGGGCCGCTGTCTCCTTCC
TGACCCGGGACCAGCCCAATGTGCAGTTCTGCATCGTGGCTCTGGTCATCATCTT
CTGCAGCACCATCACCTCTGCCTGGTATTTCGTGCCGAAGCTCATCACCTGAGA
ACAAACCCAGATGCAGCAACGCAGAACAGGCGATTCCAGTTCACTCAGAATCAG
AAGAAAGAAGATTCTAAAACGTCCACCTCGGTACCAAGTGTGAACCAAGCCAGC

ACATCCCGCCTGGAGGGCCTACAGTCAGAAAACCATCGCCTGCGAATGAAGATC
ACAGAGCTGGATAAAGACTTGGAAGAGGTCACCATGCAGCTGCAGGACACACCA
GAAAAGACCACCTACATTAAACAGAACCACTACCAAGAGCTCAATGACATCCTC
AACCTGGGAACTTCACTGAGAGCACAGATGGAGGAAAGGCCATTTTAAAAAAT
5 CACCTCGATCAAAATCCCCAGCTACAGTGGAACACAACAGAGCCCTCTCGAACA
TGCAAAGATCCTATAGAAGATATAAACTCTCCAGAACACATCCAGCGTCGGCTGT
CCCTCCAGCTCCCCATCCTCCACCACGCCTACCTCCCATCCATCGGAGGGCGTGA
CGCCAGCTGTGTGTCAGCCCCTGCGTCAGCCCCACCGCCAGCCCCCGCCACAGACAT
GTGCCACCCTCCTTCCGAGTCATGGTCTCGGGCCTGTAAGGGTGGGAGGCCTGGG
10 CCGGGGGCCTCCCCCGTGACAGAACCACACTGGGCAGAGGGGTCTGCTGCAGAA
ACACTGTGCGGCTCTGGCTGCGGAGAAGCTGGGCACCATGGCTGGCCTCTCAGGA
CCACTCGGATGGCACTCAGGTGGACAGGACGGGGCAGGGGGGAGACTTGGCACCT
GACCTCGAGCCTTATTTGTGAAGTCCTTATTTCTTCACAAAGAAGAGGAACGGAA
ATGGGACGTCTTCCTTAACATCTGCAAACAAGGAGGCGCTGGGATATCAAACCTTG
15 CNNCTAGACAAGGAGAGAGGC
ACTAGAACTCCAGCTGGAAGTCACGGAGTGGCTCGAGCAGCCTTGGGAAGAGGC
AAGGAGCTTCTGAAGAACTGCCTCTGCACACACATCACTGGCTGTGACCCCTCA
GGCTAGCCCTTCTCCACTCTGGGGGAGGAGGTGGGAAGGGCCACCAGGCCCCCA
GCTGCCAGGCCAGCTGACCCCAGCCTTCTGGAACAGGGAGTCTGCAGGAGCGC
20 AGACAGGCACAGCCCTGGAGCAGGCAGGCCGAGGGCTGCGGCACTGGAGCAGG
CTGACTTACATGCTCCACATGGGACCTGTGTACCCAATGAGATGTTTGTACTCT
GGTAAATGCCACACGTTAACACAATAACACCCATTCTCTGGGACCGTGGGGATTTA
GGGCACGTCACTGCAGACACGCTCTGCAGCATTACCGACAGTCTGTATGCAAC
CACCACGTTGGCCATGTCTTGTGTTCTATCGGATGCTCCGAGTAACCAGGGGG
25 ACCACCCGAGCTAATCATGGAATGTCTGTTCCAGCAAACACGATAAAGAAAGA
TTGTGCACTTTAACCTCTCTCATCAGGGCCCAAGGGCTGGCTGGGANNNNNNNN
NNNNNNNNNNNCCCCTAACTTTGTTTCTGACCAAAGTGAATTGGAGGCACTCTGC
TAAAAGACATCCCCGTAGACATAGGGGAGAGAGTTGCTGGCTGAGGGCTTCCCT
TGGCTTCCAGAAGGCAGCCTTCCATCCAGACAAGCCAGTGAGCTCTCCCTTGGG
30 ATCACTGGGGTGATCAGTCAGCAGATTGATTCTCATTTCATAAGATCATTCCTCCC
TTTAAATTGAGCCCCTAAGAGCACTGGCCTGGGAGTCAGACAGACCTGGGTTCA
AGTCCTCAGTCCCCTGCCACTCCCTACGTGACTTTGATCAGGTCAGTGTCTC
TCTGAGCCTCAGTTTCCCCTCTGTAATTGGGGTTGAACTAAAACACCTGTCTGCC
TACCTCACAAGGTCACTCTGAGGATTGAACTTGATCTTGTCCAGGAAAGCTTTG
35 TACCAAACAGTGAAGCCGCCCTGATCCGTGAGGTATGAGTATGACTCTGACCTTC
AGCCCTCCCTACAGCCGGGGGTGTGGCCCAGAGAAGCTTCCAGCACAGCCCTCT
ACCCAGAACATCCGGGCTGGAGGGAGGCTCCAGTGACTTTTCTGACATTCCTAG
ACAGGTTTATTCTTTGCTCAAGAAAGGCCTGAATGACAATGTCCAGGATGTCTGC
ACAACTGAGCAGCTCGCTCACTCCCTAAAGAAACCTATTGGCAGCTTCAACAGGC
40 AGGCAATAATCTCTTCCAGAACCACTGCAGTCAGGAATAAACTGTTTTCTCCAC
CAGGCTTTGACAAAAGGGCCCACAGGAATCTTACCAATGCCAACATTTCAAAGC
ACCTATTTACGTAGCATAGCTTTCTGCTCCCCTTCCCCAAAGAGAGGTTATGG
AGGTACTGTAGCTTTTAGGGAAAAAAAATGTTAACACATCACAGGTCAAGTTG
AAGTCATTCTCTGTTTAGGCACTAAAAATCGGTGTTGTCACTCACTGTGTATTACC
45 AGTATTTACTTGCTTTCTTGATTTACCAAAACCAAATTTAATTTAAAGGACCACA
TTAATTTTTCAAAGGGAAAGAGACAATTAATTGTACATAATGTATACACACACAA
AAAAAAAATACCTGTAGAAATATTATTCCAGCATAGCAGGAAAACAAACAAAAG
TATTGGACTGTGCGAGGTGAGCCTGTGCGTCTGTAACCTTTGTGACTCCTGAGC
GTGCGCTGTCTTCTAGGTTAACTCACGAAGTACATTCTCTGTCTTACTGATACTGT

AGGTTACCCATTTTTTTTAAATTCCTCGCAAATAACAAGACCCACAGAAGTGA
CTCTAGCTACTTAATGGTTCTGTTCTTTATATGCAGCAAACACACCGTCCATTTTC
TGAAGAGGCTTCGGCCTGAAGGCATTTTCCAATGATGTTAGTGCACAAAACGCTT
TAAATTAGACTGGAAGTCCAGAAATCAAATGTAAATGAGGAATTTCTCGTACCCC
5 TACTGCATGGTATCGATTTTAAATAAAATTGTTGCAAATTTGTTTTTATGAATAAAA
GGAAAAAACCTGTCG

SEQ ID NO: 650

>21545 BLOOD INCYTE_3384890H1

10 GTGGGCGCGGCTTCCTGCAGCTTGGGCTGGGGATATAGGCGCCCCACACCCGG
GCCCCGCTCAGCGCCGCCGCGCTCCTCGCCTCCTGCTGCACGATGGCCTCGCT
CCGGGTGGAGCGCGCNGGCGGCCGNNCTCCTTAGGACCCGAGTCGGGCGGCC
GGCAGCGCTCCGCTCCTCCTTNTGCTGGGCGCTGTCNTGAATCCCCACGAGGCC
CTGGCTCAGNNTCTTCCCACCANAGGCA

15 SEQ ID NO: 651

>21551 BLOOD 235484.21 AF135960 g7416899 Human latent transforming growth factor
beta binding protein 3 mRNA, partial cds. 0

20 GCTGCTGCTGGGCCTGGGCGGCAGGGTCGAGGGGGGGCCGGCCGGCGAGCGGG
GCGCAGGCGGGGGCGGGGCGCTGGCCCGCGAGCGCTTCAAGGTGGTCTTTGCGC
CGGTGATCTGCAAGCGGACCTGTCTCAAGGGCCAGTGTCTGGGACAGTTGTCTCAGC
AGGCCGCGGAGCGCTTCAAGGTGGTCTTTGCGCCGGTGTCTGCAAGCGGACCTG
TCTCAAGGGCCAGTGTCTGGGACAGTTGTCTCAGCAGGGCTCCAAACATGACGCTCATC
GGAGAGAACGGCCACAGCAACAGCAAGGCTCACGGGCTCCGGCTTCCGCGTGGTG
25 GTGTGCCCTCTCCCCTGCATGAATGGCGGCCAGTGTCTCCTCGCGAAACCAGTGCC
TGTGTCCCCCGGACTTCACTGGGCGCTTCTGCCAGGTGCCCGCAGGAGGAGCCGG
TGGGGGTACCGGCGGCTCAGGCCCGGCGCTGAGCAGGACAGGGGGCCCTGTCCAC
AGGGGCGCTGCCGCCCTGGCTCCGGAGGGCGACTCTGTGGCCAGCAAGCACGC
CATCTACGCCGTCCAGGTGATCGCTGACCCTCCTGGGCCCGGGAGGGGCCTCCT
30 GCCCAGCACGCAGCCTTCTTGGTGGCCCTAGGCCCGGGACAGATCTCAGCAGAA
GGTACCAGGCAACTGGCAAACCCGGGAAGGTGCGCCAGTGGGTGGGCACTAGGGT
GGCCAGGGCAGGGCAGGTTTCAAGCCCTGGAGGAGCTCAGCGCGGTGACCCGCGGC
GCGGTGCGGGCAGCCCTGAGGCCACCGCGCCCGCCCCAGTGCAGGCCCGGCC
CCCGTGGTGAATGTGCGCGTCCATCACCCGCCCCGAGGGCTTCAAGTCCAGGTGCACC
35 GCATTGAGAGCTCGAACGCCGAGAGCGCAGCCCCCTCCAGCACCTGCTGCCGC
ACCCAAGCCCTCGCACCCCCGGCCGCCACCCAGAAGCCCTGGGCCGCTGCTT
TCAGGACACTCTGCCCAAGCAGCCGTGTGGCAGCAACCCCTCCCCGGCCTCACC
AAGCAGGAAGACTGCTGCGGTAGCATCGGCACTGCCTGGGGCCAGAGCAAGTGC
CACAAGTGTCCCCAGCTGCAGTACACAGGAGTGCAGAAGCCAGGGCCTGTACGT
40 GGGGAAGTGGGCGCTGACTGTCCCCAGGGCTACAAGAGGCTTAACAGCACCCAC
TGCCAGGACATCAACGAGTGCAGCAATGCCGGGCGTGTGTCTGCCATGGTGACTGC
CTCAACAACCCTGGCTCCTATCGCTGTGTCTGCCACCTGGCCATAGTTTAGGCC
CCTCCCGTACACAGTGCATTGCAGACAAACCGGAGGAGAAGAGCCTGTGTTTCC
GCCTGGTGAAGCCCTGAGCACCAGTGCCAGCACCCACTGACCACCCGCTGACCC
45 GCCAGCTCTGCTGCTGCAAGTGTGCGCAAGGCCTGGGGCGCGCGGTGTCTCAGCGCT
GCCCAACAGATGGCACCGCTGCGTTCAAGGAGATCTGCCCAGCTGGGAAGGGAT
ACCACATTCTCACCTCCCACCAGACGCTCACCATTGAGGGCGAGAGTGACTTTTC
CCTTTTCTGCAACCCTGACGGGCCACCCAAGCCCCAGCAGCTTCCGGAGAGCCCT
AGCCAGGCTCCACCACCTGAGGACACAGAGGAAGAGAGAGGGGTGACCACGGA

CTCACCGGTGAGTGAGGAGAGGTCAGTGCAGCAGAGCCACCCAAGTCCACCAC
GACTCCTGCCCCGGCCCTACCCCGAGCTGATCTCCCGTCCCTCGCCCCCGACCATG
CGCTGGTTCCTGCCGGACTTGCCCTCTTCCCGCAGCGCCGTAGAGATCGCTCCCA
CTCAGGTCACAGAGACTGATGAGTGCCGACTGAACCAGAACATCTGTGGCCACG
5 GAGAGTGCGTGCCGGGCCCCCTGACTACTCCTGCCACTGCAACCCCGGCTACCG
GTCACATCCCCAGCACCGCTACTGCGTGGATGTGAACGAGTGCGAGGCAGAGCC
CTGTGGCCCCGGGGAGGGGCATCTGCATGAACACCGGCGGCTCCTACAATTGCCA
CTGCAACCGCGGCTACCGCCTGCACGTGGGCGCCGGGGGGCGCTCGTGCGTGGA
CCTGAACGAATGCGCCAAGCCCCACCTGTGCGGCGACGGCGGCTTCTGCATCAA
10 CTTTCCCGGTCACTACAAGTGCAACTGCTACCCCGGCTACCGGCTCAAAGCCTCC
CGGCCTCCTGTGTGCGAAGACATCGACGAGTGCCGGGACCCAAGCTCTTGCCCG
GATGGCAAATGCGAGAACAAGCCCGGGAGCTTCAAGTGCATCGCCTGTCAGCCT
GGCTACCGCAGCCAGGGGGGCGGGGCTGTGCGGACGTGAACGAGTGCGCCGAG
GGCAGCCCCTGCTCGCCTGGCTGGTGCGAGAACCTCCCGGGCTCCTTCCGCTGCA
15 CCTGTGCCCAGGGCTACGCGCCCCGCGCCCGACGGCCGCGAGTTGCTTGATGTGGA
CGAGTGTGAGGCTGGGGACGTGTGTGACAATGGCATCTGCAGCAACACGCCAGG
ATCTTTCCAGTGTGAGTGCCCTCTCTGGCTACCATCTGTCCAGGGACCGGAGCCAC
TGCGAGGACATTGATGAGTGTGACTTCCCTGCAGCCTGCATTGGGGGTGACTGCA
TCAATACCAATGGCTCCTACAGATGTCTTTGCCCCCAGGGGCATCGGCTGGTGGG
20 TGGCAGGAAATGCCAAGACATAGATGAGTGCAGCCAGGACCCGAGCCTGTGCCT
TCCCCATGGGGCCTGCAAGAACCTTCAGGGCTCCTATGTGTGTGTCTGCGATGAG
GGCTTCACTCCCACCCAGGACCAGCAGGCTTGTGAGGAGGTGGAGCAGCCCCAC
CACAAGAAGGAGTGCTACCTGAACCTTCGATGACACAGTGTTCTGCGAGAGCGTA
TTGGGCACCAACGTGACCCAGCAGGAGTGCTGCTCTCTGGGGGCGCGCTGG
25 GCGGACCACTGCGAAATCTACCCCTGCCAGTCTACAGCTCAGCCGAGTCCACA
CAACATACGAGCATGCGAAAG

SEQ ID NO: 652

>21553 BLOOD INCYTE_3437994H1

30 GCGGGCAGGCGACTCCTGTCCCGGGTGGAGGCGGCGGANCGGANGCCGGGGG
AGGGGGCAGCGGCTGTCTACGGACCACGGCGGCGCCCGCAGCTCCTCACCGAA
ACAAGGAGACCAGTGCTGGTCCAANGGCTGTGATGGGAAAAGATTATTACAAGA
TTCTTGGGATCCCATCGGGGGCCAACGAGGATGAGATCAAGAAAGCCTACCGGA
AGATGGCCTTGAAGTACCACCCAGACAAGAATAAA

SEQ ID NO: 653

>21568 BLOOD 407563.4 Y17829 g4128042 Human mRNA for Homer-related protein
Syn47.0

40 CCCAGTCTCCTGGCCCCAACGCGGGCTTAGCCTCCCGCCTTGGCTCGGGCAGGA
NCCCGTCGACCTTCGGCCCCCTTTCGCCCCGCTGGAGCTGGGGGCAGGGTGCCA
GTGGAAGCGTGGGGCTTGGCTCTGTGATTCATTCTCCGCCGACGGGAGCCT
CAGACCCGCTGTGCTCTGAAGAGAGGAGGGAAGAGGGGGCAGCCGGAATGAA
GGGCCGGGCACCAGCCGGGCTCCATTGTGCTCGGCGGCGGGGGGCGGGAAGGGG
CTGAGGGAGGTGGGATCGGGTCCCCTCCTCCAGCTCTCCGGCGTGCGCTGCGCCC
45 CCAGCCTGCTGCCAGCCTGGAAATGGCTCCGTTTATTCTCTTCGGGAGAATGAAT
CGATCCTGCCTAGCCTTCTCTTCGTCCTCCCCACCTCTTCTGCTCCGAGTCTTA
GGAGGAGAAACATTTAAAAAGACAGATTCCAATGTGGAGTGCCGTGCAGGTTGC
GAGCTGCCGGGTTTGCACCTTCGAGGAGATTTTCTGTGTAGTTTTTTTCTAATGT
GAGCGCAGGGAAGCCGTGGCATTACTGCTTTTGGGATTTTTATTACGTGCACGT

CGCGTTTGGTTGCTCGCTCCACCCCCGGAGACCTGGTGTGGTGGAGAAATTTGAA
CCCGCAGCCTTAGCTCCGAAAAGGCCGAGTTACCTGGCTCTCCCTGAGTGTGAG
GAGGACATGAGTGAAATGACCAGCGAACTCATTTTTATAGGACTCGGTGAAGC
CGGATTCTGCATTTCCCTACTTGTAGACTCATTTTGTGGAATAGAGTTGATCGCTG
5 TCTCCTCCGCAAAGCATTTTAACTCGAATAAGCAAATGCCGCCTCTGTTTGAACG
TTTTGGTATTTACAAGAGAGAAATCATTTTACCTAAGAGAACTAATTGAATTGGC
AGCATCCTTGAAATACCTCCGGACAAGGATCTGGGGGTGGGGGTGGAAAAGCAA
CTGCGAAATAGCAGACGGAGAAATTCCTTTGGAAGTTATTCCGTAGCATAAGAG
CTGAAACTTCAGAGCAAGTTTTCATTGGGCAAAATGGGGGAACAACCTATCTTCA
10 GCACTCGAGCTCATGTCTTCCAAATTGACCCAAACACAAAGAAGAAGTGGGTAC
CCACCAGCAAGCATGCAGTTACTGTGTCTTATTTCTATGACAGCACAAGAAATGT
GTATAGGATAATCAGTTTAGATGGCTCAAAGGCAATAATAAATAGTACCATCAC
CCCAAACATGACATTTACTAAAACATCTCAGAAGTTTGGCCAGTGGGCTGATAGC
CGGGCAAACACCGTTTATGGATTGGGATTCTCCTCTGAGCATCATCTTTCGAAAT
15 TTGCAGAAAAGTTTCAGGAATTTAAAGAAGCTGCTCGACTAGCAAAGGAAAAAT
CACAAGAGAAGATGGAAGTTACCAGTACACCTTCACAGGAATCCGCAGGCGGGG
ATCTTCAGTCTCCTTTAACACCGGAAAGTATCAACGGGACAGATGATGAAAGAA
CACCTGATGTGACACAGAAGTCAAGAGCCAAGGGCTGAACCAACTCAGAATGCAT
TGCCATTTTCACATAGTTCAGCAATCAGCAAACATTGGGAGGCTGAACTGGCTAC
20 CCTCAAAGGAAATAATGCCAACTCACTGCAGCCCTGCTGGAGTCCACTGCCAAT
GTGAAACAATGGAAACAGCAACTTGCTGCCTATCAAGAGGAAGCAGAACGTCTG
GACAAGCGGGTGACTGAACTTGAATGTGTTAGTAGCCAAGCAAATGCAGTACAT
ACTCATAAGACAGAAATTAATCAGACAATACAAAGAAGTGGAAAGAGACAETGAAA
CTGAAGGAAGAGAGGAAATAGAAAGGTTAAACAAGAAATTGATAATGCCAGAGA
25 ACTACAAGAACAGAGGGGATTCTTTGACTCAGAAACTACAGGAAGTAGAAATTCG
GAACAAAGACCTGGAGGGACAAGTGTCTGACTTAGAGCAACGTCTGGAGAAAAG
TCAGAATGAACAAGAAGCTTTTCGCAATAACCTGAAGACACTCTTAGAAATTCGT
GATGGAAAGATATTTGAACTAACAGAATTACGAGATAACTTGGCCAAGCTACTA
GAATGCAGCTAAGGAAAGTGAAATTTCAAGTGCCAATTAATTAAGATACACTG
30 TCTCTCTTCATAGGACTGTTTAGGCTCTGCATCAAGATTGCNNNNNNNNNNNNNN
NNNNNNNTTGAATATCACTCCTCCAGGAGGAGGATCTTTTGAAATTGGAATTGTA
TATTTCACTGTAAATTTTAGAATCCAGCTTGTAGCTAGTTGGGGAAAAAAGATGA
AAAAGTGAAGTACAAATTACCTCCATGTATATTATTGGCCATAGTTAACTAGAA
AGTTATAAATAGACACTTAATGCAATCTTTTTCCTGATAATTAGCCAATGGGAGA
35 ATTAACAATGTCTAGGTCACATCCCTTTTTGTGTTCAACACAGTGAAGATTATCT
GCTTTTTAAATTAATTTATTTACGATATCTAGAGCTGTGTTTTGTGCAAAAAGT
GTGATGAAAGCCTGTCTTTTGTGTAATCTGAATAATTTCTCAGGATATTTTGA
CTGCTGAGAAGCAGTGCCATTACCAATTAATTTCTGCCAGGAGTGAGAGAGAGC
TGTATCTTTAATTGAAATATACTATAACTGGGTGTATAGAGTTCTTCCCTTTTTTG
40 TGCTGGAAGATATTTCACTCTGGTGAAGTACTCTGGTACACTCTGGTGTCTCTAAT
CTTGTCTGTTGTATAGTTTACTTTTCCATATTGATTCCATGTATTTATGAGAAGAT
ATTGTCTCCATTTTATTACACATTTTAAAGCCAATAACGAAGGCAGCTGAGTC
CCTCAGAAATTTTTCTTTTAAAGTTTCTAATAAATTTGACACACAGTACTGAAATA
CAGCAGCCCGTCATTGACAGGCTGGTCTAGCAATGTAAAGTATATTTACAGAATA
45 TGCAGTTACATTTATTTATATATTTTGAAGAAATCTTTTCTGAATGATCAATGCA
TTTCAATTTACGAATAATAATGGTTATTGGGGAACTGTTTATTATAGATAATTTTA
AGGTGTATAGCTATTTTAAAGGGGGTCCATTTACATCAAACAGCCGATCAGAGG
ACTCTATCTAAATTGTGATCGTGGCAGATAGAGATGGAGTCATGTACTCTATCTG
GCTCTACACATCAATCACATCTTGATTCAAACCTCACAAGGCAATATTCTGAATT

GTAACTAGGTATTTCAAAACAGGAATTAAATTCAATAGGCTCTTCTCAGTGAAC
AGGTTTAAATGTTGTTTGTATGTAATTTAAAAGACTTTTAGCAAACATGCATTTCT
TTTATATGATATATTTCTTTTACGAAGCTATTTTAAAAGTAAGCCAAGTGCTGTCT
AGTCTGCTTATAAAGTAGGAATTGCATCAGAGTACATATATTCTTGCTGTACAAT
5 GCCTGTGATGTTGAGGAGGGTCTTTTTTAAAGTGTATGCTTGAGTAACTGACTCT
ATGGAGTCTATAAATGCACTGACTTCTTGTTTGTACCCCAAATGATCGAATTGT
TAAGTACAAAATTAAGCTAATTAACCAATTTGTAACCATTTTTCTACTCATAAAC
AGCTACTCAATACTAGACAATTTTGTTTTTTATGTATGTGTATGTACGTAAATACA
TACATATTAATTTACATTAGAGTGAAAAATAAATGGTTTGTCTGAAGTTAGTTT
10 CTTAAGTGAGTTTTTCAGGTGTCTCTGAAAAATTTATAACAATCATGTATTATATGT
GCTGTAACATCATGTACGTTACCTCCATCTATTTTAGGATATTTTCTCACCTATA
TATTATAGGGAGAATAATTTAGATACACATGCTCAGAGCTGAGATATTTCTCTGA
TAAATCAGGTAACAAAATGTATTTGATTGATGGAATTTTGAAGTAAATGTGTTTT
TATCCATCAGTTTCTGAGTAACAAAGAGCACCAAGTTTAAATTTAAATAGGAGAT
15 TTAACACTAGGGATCAGGGAGTTTAGTATGAAGAGTTAAAAAAATTTAAAAAAC
AGTGTAAAGCTGTTGAAATGGCAAGTGAATTATTTAATGATGTAATAAAATATTT
TTAAATTTTGACATAGTGATCATTTAATGAAAAAACTCACCAAAATGTCTCCATT
TGAATTGTATTGATAATGTGGGACATATGTGTGATTCAATATATACATATACCCA
TATGTATATACAGAAAATTATTTTAATACTTTCTACTGATAATGAAATTTAAAA
20 TTGGAAATTTTGTGAGTGTTTTTCTTGCCAATAGAGCCTAATTGTTTCTTTTTTA
GTGATTTAACAATCTCTTGAGGGCTGCACCTTTAAATTCCCAGATTGTCAATAGA
CATGTACAGTATATGGGATAAGGTGGACACAAGTGCACATATAAATAAAATCTT
CTTAAGACTTTTAAGTATTCAATTTACAGTAGGAGAGTATGTAGAAATCATCATCC
ACAAGTCATAATTAGGTTGFGTGCCTACTGEAGTTTTTTCCATTTGTGTATTATAT
25 TAAACATTTGCATATTAATAATTTGATTTTTCCCAGAGACAAGTATTATATACTGTAT
CTATATTTAAATCAAACGTGTTGTAATATATTTCTCAGAAAATAATGTTGGGGACT
ATAGCCTGAACATGTGGACTTGAAGCGACATGGAGGAGGAGGTTGATCCCATTG
TGTATAAGTTAATATGTGATAACTATTGAATCTTGTAACAAAAACAAAAATTGANA
AANANAAAGAAAAGCAAAAATACAGTTTTTATTTTGAATAACATTTGTTCTCTGG
30 AGAATGTACTTTATCTTTTTTCTCCTCCAGTCTTTTACAGATATTTAAAAGCATTTA
AATGATGACAGCATTTACTTAAATCTTTCAGGTGCTACTGGATTTTGCATTAGTGT
GTTATGTTGTGAAATCCTAACTTTGACATAAAAAGGTTTTATAAGTATCCCCTGCC
TGGAATAATTAGTTTTTGTCTCCNCTCTCTCTCTTTCTGTNTCCACTTTCTTTCTG
CAGACTAAAACATGCTCACGAAGTTGCATCTCTCCTTGCTCTATAGAAGATCTC
35 CAGCACCATCATAGATTTGATGTTCTGCTGTCATTGNACTGTTGGGAAGCAGTTA
GAGGAAAAGCTCACTTTTTTTTTTTCAGGTGGAAATAAAAGGAACACTCAAAATTA
AGCCAACACCACCACTACCTTTAAAAACTAGTTTATTTGCCCTGTTAAAATTTAAA
TGATTCTTNAACATGTGGGCTACAGTCTCCCATGTTTTTATTTAACTGAAGCATAT
ACACTTCGGNCATTTATCTCCTGTGGNCCTGATTTTGTGAGTACTGGAATG
40

SEQ ID NO: 654

>21590 BLOOD INCYTE_3985758H1

GCNACGGTTGGCGCTCGNCCTGGAGCCTGCCCTGGCGTNCCCCCGCGGGCGCAG
CCAAGCTTCTTGGCNATGGTAGATAACTGCAGGGGACTCTGGCCGCGGCTAACTA
45 NCCTGGAGATGCTGATCGGGACCCCCCGCAGAAGCTACAGATTCTCGTTGACA
NTGGAAGCAGTAACTTTGA

SEQ ID NO: 655

>21591 BLOOD 404604.3 AF122922 g4585369 Human Wnt inhibitory factor-1 mRNA,
complete cds. 0

5 CCCAGCCGCTCTAAACGGGAACAGCCCTGGGCTGAGGGAGCTGCAGCGCAGCAGA
GTATCTGACGGCGCCAGGTTGCGTAGGTGCGGCACGAGGAGTTTTCCCGGCAGC
GAGGAGGTCTGAGCAGCATGGCCCGGAGGAGCGCCTTCCCTGCCGCCGCGCTC
TGGCTCTGGAGCATCCTCCTGTGCCTGCTGGCACTGCGGGCGGAGGCCGGGCCG
CGCAGGAGGAGAGCCTGTACCTATGGATCGATGCTCACCAGGCAAGAGTACTCA
TAGGATTTGAAGAAGATATCCTGATTGTTTCAGAGGGGAAAATGGCACCTTTTAC
10 ACATGATTTTCAGAAAAGCGCAACAGAGAATGCCAGCTATTCTGTCAATATCCAT
TCCATGAATTTTACCTGGCAAGCTGCAGGGCAGGCAGAATACTTCTATGAATTCC
TGTCCTTGCGCTCCCTGGATAAAGGCATCATGGCAGATCCAACCGTCAATGTCCC
TCTGCTGGGAACAGTGCCTCACAAGGCATCAGTTGTTCAAGTTGGTTTCCCATGT
CTTGAAAAACAGGATGGGGTGGCAGCATTGAAAGTGGATGTGATTGTTATGAATT
15 CTGAAGGCAACACCATTCTCCAAACACCTCAAAATGCTATCTTCTTTAAACATG
TCAACAAGCTGAGTGCCCGAGGCGGGTGCCGAAATGGAGGCTTTTGTAATGAAAG
ACGCATCTGCGAGTGTCTGATGGGTTCACGGACCTCACTGTGAGAAAGCCCTT
TGTACCCACGATGTATGAATGGTGGACTTTGTGTGACTCCTGGTTTCTGCATCTG
CCCACCTGGATTCTATGGAGTGAAGTGTGACAAAGCAAAGTCTCAACCACCTGC
20 TTTAATGGAGGGACCTGTTTCTACCCTGGAAAATGTATTTGCCCTCCAGGACTAG
AGGGAGAGCAGTGTGAAATCAGCAAATGCCCAACCCCTGTCGAAATGGAGGTA
AATGCATTGGTAAAAAGCAAATGTAAGTGTTCCAAAGGTTACCAGGGAGACCTCT
GTTCAAAGCCTGTCTGCGAGGCTGGCTGTGGTGCACATGGAAGCTGCCATGAACC
CAACAAATGCCAATGTCAAGAAGGTTGGCATGGAAGACACTGCAATAAAAAGGTA
25 CGAAGCCAGCCTCATAATGCCCTGAGGCCAGCAGGCGCCAGCTCAGGCAGCA
CACGCCTTCACTTAAAAAGGCCGAGGAGCGGCGGGATCCACCTGAATCCAATTA
CATCTGGTGAAGTCCGACATCTGAAACGTTTAAAGTTACACCAAGTTCATAGCCT
TTGTAAACCTTTTCATGTGTTGAATGTTCAAATAATGTTTATTACACTTAAGAATAC
TGGCCTGAATTTTATTAGCTTCATTATAAATCACTGAGCTGATATTTACTCTTCCT
30 TTTAAGTTTTCTAAGTACGTCTGTAGCATGATGGTATAGATTTTCTTGTTTCAGTG
CTTTGGGACAGATTTTATATTATGTCAATTGATCAGGTTAAAATTTTCAGTGTGTA
GTTGGCAGATATTTTCAAAATTACAATGCATTTATGGTGTCTGGGGGCAGGGGAA
CATCAGAAAGGTTAAATTGGGCAAAAATGCGTAAGTCACAAGAATTTGGATGGT
GCAGTTAATGTTGAAGTTACAGCATTTCAGATTTTATTGTCAGATATTTAGATGTT
35 TGTTACATTTTTAAAAATTGCTCTTAATTTTTTAAACTCTCAATACAATATATTTTG
ACCTTACCATTATTCCAGAGATTCAGTATTAAAAAATAAATTACACTGTGG
TAGTGGCATTTTAAACAATATAATATATTCTAAACACAATGAAATAGGGAATATA
ATGTATGAACTTTTTGCATTGGCTTGAAGCAATATAATATATTGTAAACAAAACA
CAGCTCTTACCTAATAAACATTTTATACTGTTTGTATGTATAAAATAAAGGTGCT
40 GCTTTAGTTTTCTGAGCATTGTGTGGAGGTNANCTTTGCACATGCTATCTTATGAA
AATAAAATTGGTTGCAATTTAGTGGT

SEQ ID NO: 656

>21600 BLOOD 480735.6 U60477 g1575342 Human apolipoprotein AI regulatory protein-
1/chicken ovalbumin upstream promoter transcription factor II (TFCOUP2) gene, complete
45 cds. 0

CATCGAGTGCGTGGTGTGCGGAGACAAGTCGAGCGGCAAGCACTACGGCCAGTT
CACGTGCGAGGGCTGCAAGAGCTTCTTCAAGCGCAGCGTGCGGAGGAACCTGAG
CTACACGTGCCGCGCCAACCGGAAGTGTCCCATCGACCAGCACCATCGCAACCA

GTGCCAGTACTGCCGCCTCAAAAAGTGCCTCAAAGTGGGCATGAGACGGGAAGG
TATCGGCCTCTCATTTCTCCTTCCCTCGTCCTGGGTCCCGGGGTCTGGGTACGTT
TGGCTAGCCTGCTCTGGGTAAGGACAAGAAGCCCCAAGCTCTTCTCTTCGTATTG
CAGCGGAAAAGGGTTTTATACTAGAAGCGAGTTCTGCATTGGAACCCAGACCCC
5 AAATCCGCATGCTTTGGCCGACTGATTTCTTCTTTACTCTCTCTTTGGGCTGTTTC
CATTTCTTTGCATTGATTGTGAGTTCAGTGGAGTCTGCCTTTCTGCAAGGGATGG
GGTGTGTTGTTGTGTCGTTTTAAAGCCTAGTTTACTTCTCTCTCTCTGCCCTTGTTT
TTCCTGCATGTTCAACATGTCCCACCCCC

10 SEQ ID NO: 657

>21611 BLOOD INCYTE_4504614H1

GGCAAGATCTGGAAGCTGGCCGACTGCGACTGCGACGGCATGCTTGATGAGGAG
GAGTTCGCGCTGGCCAAGCACCTCATCAAGATCAAGCTCGACGGCTACGAGCTG
CCCAGCAGCCTGCCCCCCCACCTCGTGCCCCCCTCGCACAGGAAGTCCCTGCCCA
15 AGGCCGACTGAGGGGTGGGCTGCAGAACGGGGTGGGAATGGGGGACCTGGGCC
TCAGGCCTGCTC

SEQ ID NO: 658

>21621 BLOOD 253228.8 Incyte Unique

20 GGAGCGCTTGGTGACGATCCCACGTACGCTTGGTGACTGGTGGAGGTCCCAGAG
AAGGACCGTGCGTGCAAAAGGCGAACCTCGGTGTGCGGTGTGTCCACGTGTGCA
AGCTGGGGAGGGGAGGGGGGCGAGAAGGCGTGAGTGTGCGCGCGCCCGCATGC
GGGGGCGTGGCAGTCAACAGCAACCAACCCACACGCGGCGAGGGGECAGAAACTCC
CATCTCCCTCACCAGCCGGAAGTACGAGTGGGTCAAGCCTGGAGGGACCCAAAC
25 CAGAGCCTGGCCTGGGAGCCAGGATGGCCATCCACAAAGCCTTGGTGATGTGCC
TGGGACTGCCTCTCTTCTGTTCCCAGGGGGCCTGGGCCCAGGGCCATGTCCCACC
CGGCTGCAGCCAAGGCCTCAACCCCTGTACTACAACCTGTGTGACCGCTCTGGG
GCGTGGGGCATCGTCCTGGAGGCCGTGGCTGGGGCGGGCATTGTACCCACGTTTG
TGCTACCATCATCCTGGTGGCCAGCCTCCCCTTTGTGCAGGACACCAAGAAACG
30 GAGCCTGCTGGGGACCCAGGTATTCTTCTTCTGGGGACCCTGGGCCTCTTCTGC
CTCGTGTGTTGCCTGTGTGGTGAAGCCCGACTTCTCCACCTGTGCCTCTCGGCGCTT
CCTCTTTGGGGTTCTGTTCCGCATCTGCTTCTTGTCTGGCGGCTCACGTCTTTGC
CCTCAACTTCCTGGCCCCGGAAGAACCACGGGCCCCGGGGCTGGGTGATCTTCACT
GTGGCTCTGCTGCTGACCCCTGGTAGAGGTCATCATCAATACAGAGTGGCTGATCA
35 TCACCCTGGTTCGGGGCAGTGGCGAGGGCGGCCCTCAGGGCAACAGCAGCGCAG
GCTGGGCGGTGGCCTCCCCCTGTGCCATCGCCAACATGGACTTTGTCATGGCACT
CATCTACGTCATGCTGCTGCTGCTGGGTGCCTTCCTGGGGGCCTGGCCCCGCCCTG
TGTGGCCGCTACAAGCGCTGGCGTAAGCATGGGGTCTTTGTGCTCCTCACCACAG
CCACCTCCGTTGCCATATGGGTGGTGTGGATCGTCATGTATACTTACGGCAACAA
40 GCAGCACAACAGTCCCACCTGGGATGACCCACGCTGGCCATCGCCCTCGCCGCC
AATGCCTGGGCCTTCGTCTCTTCTACGTTCATCCCCGAGGTCTCCCAGGTGACCA
AGTCCAGCCCAGAGCAAAGCTACCAGGGGGACATGTACCCACCCGGGGCGTGG
GCTATGAGACCATCCTGAAAGAGCAGAAGGGTCAAGAGCATGTTTCGTGGAGAACA
AGGCCTTTTCCATGGATGAGCCGGTTGCAGCTAAGAGGCCGGTGTACCATACAG
45 CGGGTACAATGGGCAGCTGCTGACCAAGTGTGTACCAGCCCACTGAGATGGCCCT
GATGCACAAAGTTCCGTCCGAAGGAGCTTACGACATCATCCTCCCACGGGCCACC
GCCAACAGCCAGGTGATGGGCAGTGCCAACTCGACCCTGCGGGCTGAAGACATG
TACTCGGCCCCAGAGCCACCAGGCGGCCACACCGCCGAAAGACGGCAAGAACTCT
CAGGTCTTTAGAAACCCCTACGTGTGGGACTGAGTCAGCGGTGGCGAGGAGAGG

CGGTCGGATTGTTGGGGAGGGCCCTGAGGACCTGGCCCCGGGCAAGGGACTCTCCA
GGCTCCTCCTCCCCCTGGCAGGCCAGCAACATGTGCCCCAGATGTGGAAGGGCC
TCCCTCTCTGCCAGTGTGTTGGGTGGGTGTCATGGGTGTCCCCACCCACTCCTCAGT
GTTTGTGGAGTCGAGGAGCCAACCCCAGCCTCCTGCCAGGATCACCTCGGCGGTG
5 AACTCCAGCCAAATAGTGTCTCGGGGTGGTGGCTGGGCAGCGCCTATGTTTCT
CTGGAGATTCTGCAACCTCAAGAGACTTCCCAGGCGCTCAGGCCTGGATCTTGC
TCCTCTGTGAGGAACAAGGGTGCCTAATAAATACATTTCTGCTTTATTAAAAGAA
AAACAAAAAAAAGGGG

10 SEQ ID NO: 659

>21628 BLOOD 255990.10 AJ011497 g4128014 Human mRNA for Claudin-7. 0

GCCGGAGGGGACAGTGGTAGGTGGGGAGGTTGAGTGCAAAGGGTTCAGGCTGTA
AGTCATGTTGGGTTGGAATGGGGGCACAGGAAGGTGGGGCTGTTGGGGAGCCAC
GCTAAGCCGGGTGTCTGTAGCAGAGCCAGAGAACCGGGACACTGAAGAGGGTGC
15 TGAAGGGGGCGACTCTCAGGGATCGAGCCAGGGCCCCCGAAGGTGGGATCGACC
AGGGTAGGAGACAGGAAAAAAGAGAGAGCAGCGGGTGGGGGCGAAAGCAGG
GCCGAGGAGAGAGCACTTTGGACAGAACCCGGCGGGGAAAGGGCGGGCGCCGAG
GCTTGTACAGGGGCGCCCCGACGCGTCCAGGCGCACCTGTTGGGAAGAAAGGAA
GGGGCTTCCCGGTGTTTCGAGGGAAATCCAGTCCGGAGGGGCTGACTCGGAGCTT
20 GGGACTCCTGGGGAGCCACCGCCTCCTCCCCAGCGGCGGTCAAACCGGGCAAG
CGAAGGGGCGTGACCCTGGTGCTCAGGTTTCTTCTCCTCACCTGGGCAAGGAGG
GGTGGGGGCGACGACTTCCGGTTCAGGTGAGTGTCCTTCCGGTGACGTCAGGTC
TCCTCGGCGCCCTCCGGTCCCGCTCCCCCTCCCGCGCTCCCGGGGCGCGCGG
GCCGCGCCCCCGACGCCCTACATATACTCAGGTGCGCCCCACCTGTCCGCCCCGA
25 CCTGCTGGCTCACCTCCGAGCCACCTCTGCTGCGCACCGCAGCCTCGGACCTACA
GCCCAGGATACTTTGGGACTTGCCGGCGCTCAGAAACGCGCCCAGACGGCCCCCT
CCACCTTTTGTGTTGCCTAGGGTCGCCGAGAGCGCCCCGAGGGAACCGCCTGGCCT
TCGGGGACCACCAATTTTGTCTGGAACCAACCTCCCGGCGTATCCTACTCCCTGT
GCCGCGAGGCCATCGCTTCACTGGAGGGGTCGATTTGTGTGTAGTTTGGTGACAA
30 GATTTGCATTACCTGGCCCAAACCTTTTTGTCTCTTTGGGTGACCGGAAACTC
CACCTCAAGTTTTCTTTTGTGGGGCTGCCCCCAAGTGTCGTTTGTGTTTACTGTAG
GGTCTCCCCGCCCGGCGCCCCCAGTGTTTTCTGAGGGCGGAAATGGCCAATTCGG
GCCTGCAGTTGCTGGGCTTCTCCATGGGECCTGCTGGGCTGGGTGGGTCTGGTGG
CCTGCACCGCCATCCCGCAGTGGCAGATGAGCTCCTATGCGGGTGACAACATCAT
35 CACGGCCCAGGCCATGTACAAGGGGCTGTGGATGGACTGCGTCACGCAGAGCAC
GGGGATGATGAGCTGCAAAATGTACGACTCGGTGCTCGCCCTGTCCGCGGCCTTG
CAGGCCACTCGAGCCCTAATGGTGGTCTCCCTGGTGCTGGGCTTCCTGGCCATGT
TTGTGGCCACGATGGGCATGAAGTGACGCGCTGTGGGGGAGACGACAAAGTGA
AGAAGGCCCCGTATAGCCATGGGTGGAGGCATAATTTTCATCGTGGCAGGTCTTGC
40 CGCCTTGGTAGCTTGCTCCTGGTATGGCCATCAGATTGTACAGACTTTTATAACC
CTTTGATCCCTACCAACATTAAGTATGAGTTTGGCCCTGCCATCTTTATTGGCTGG
GCAGGGTCTGCCCTAGTCATCCTGGGAGGTGCACTGCTCTCCTGTTCTCTGCTG
GGAATGAGAGCAAGGCTGGGTACCGTGTACCCCGCTCTTACCCTAAGTCCAACTC
TTCCAAGGAGTATGTGTGACCTGGGATCTCCTTGCCCCAGCCTGACAGGCTATGG
45 GAGTGTCTAGATGCCTGAAAGGGCCTGGGGCTGAGCTCAGCCTGTGGGCAGGGT
GCCGGACAAAGGCCTCCTGGTCACTCTGTCCCTGCACTCCATGTATAGTCCTCTT
GGGTTGGGGGTGGGGGGGTGCCGTTGGTGGGAGAGACAAAAAGAGGGGAGAGTG
TGCTTTTTGTACAGTAATAAAAAATAAGTATTGGGAAGCAGGCTTTTTTCCCTTC
AGGGCCTCTGCTTTCTCCCGTCCAGATCCTTGCAGGGAGCTTGGAACCTTAGTG

CACCTACTTCAGTTCAGAACAACCTTAGCACCCCACTGACTCCACTGACAATTGACT
AAAAGATGCAGGTGCTCGTATCTCGACATTCATTCCCACCCCCCTCTTATTTAAAT
AGCTACCAAAGTACTTCTTTTTTAATAAAAAAATAAAGATTTTTATTAGGTAAAN
AAAAAAAAAA

5

SEQ ID NO: 660

>21631 BLOOD 370788.1 AK000072 g7019922 Human cDNA FLJ20065 fis, clone
COL01613, highly similar to ECLC_BOVIN EPITHELIAL CHLORIDE CHANNEL
PROTEIN. 0

10 GACGCGTGGGGCCAGGAATAACTAGAGAGGAACAATGGGGTTATTCAGAGGTTT
TGTTTTCTCTTAGTTCTGTGCCTGCTGCACCAGTCAAATACTTCCTTCATTAAGC
TGAATAATAATGGCTTTGAAGATATTGTCATTGTTATAGATCCTAGTGTGCCAGA
AGATGAAAAAATAATTGAACAAATAGAGGATATGGTGACTACAGCTTCTACGTA
CCTGTTTGAAGCCACAGAAAAAAGATTTTTTTTCAAAAATGTATCTATATTAATT
15 CCTGAGAATTGGAAGGAAAATCCTCAGTACAAAAGGCCAAAACATGAAAACCAT
AAACATGCTGATGTTATAGTTGCACCACCTACACTCCCAGGTAGAGATGAACCAT
ACACCAAGCAGTTCACAGAATGTGGAGAGAAAGGCGAATACATTCACTTCACCC
CTGACCTTCTACTTGGAAAAAAAACAAAATGAATATGGACCACCAGGCAAACCTG
TTTGTCCATGAGTGGGCTCACCTCCGGTGGGGAGTGTTTGATGAGTACAATGAAG
20 ATCAGCCTTTCTACCGTGCTAAGTCAAAAAAATCGAAGCAACAAGGTGTTCCGC
AGGTATCTCTGGTAGAAATAGAGTTTATAAGTGTCAAGGAGGCAGCTGTCTTAGT
AGAGCATGCAGAATTGATTCTACAACAAAACCTGTATGGAAAAGATTGTCAATTCT
TTCCTGATAAAGTACAAACAGAAAAAGCATCCATAATGTTTATGCAAAGTATTGA
TTCTTGTGTTGTTGAATTTTGTAAACGAAAAAACCCATAATCAAGAAGCTCCAAGCCTA
25 CAAAACATAAAGTGCAATTTTAGAAGTACATGGGAGGTGATTAGCAATTCTGAG
GATTTTAAAAACACCATACCCATGGTGACACCACCTCCTCCACCTGTCTTCTCATT
GCTGAAGATCAGTCAAAGAATTGTGTGCTTAGTTCTTGATAAGTCTGGAAGCATG
GGGGGTAAAGACCGCCTAAATCGAATGAATCAAGCAGCAAAACATTTCTGCTG
CAGACTGTTGAAAATGGATCCTGGGTGGGGATGGTTCACTTTGATAGTACTGCCA
30 CTATTGTAAATAAGCTAATCCAAATAAAAAGCAGTGATGAAAGAAACACACTCA
TGGCAGGATTACCTACATATCCTCTGGGAGGAACTTCCATCTGCTCTGGAATTAA
ATATGCATTTACAGGTGATTGGAGAGCTACATTCCCAACTCGATGGATCCGAAGTA
CTGCTGCTGACTGATGGGGAGGATAAAGCTGCAAGTTCTTGTATTGATGAAGTGA
AACAAAGTGGGGCCATTGTTTATTTTATGCTTTGGGAAGAGCTGCTGATGAAGC
35 AGTAATAGAGATGAGCAAGATAACAGGAGGAAGTCATTTTTATGTTTCAGATGA
AGCTCAGAACAATGGCCTCATTGATGCTTTTGGGGCTTTACATCAGGAAATACT
GATCTCTCCAGAAAGTCCCTCAGCTCGAAAGTAAGGGATTAACACTGAATAGTA
ATGCCTGGATGAACGACACTGTCATAATTGATAGTACAGTGGGAAAGGACACGT
TCTTTCTCATCACATGGAACAGTCTGCCTCCAGTATTTCTCTCTGGGATCCCAGT
40 GGAACAATAATGGAAAATTTACAGTGGATGCAACTTCCAAAATGGCCTATCTC
AGTATTCCAGGAAGTGCAGGAGGTGGGCACTTGGGCATACAATCTTCAAGCCAAA
GCGAACCCAGAAACATTAAGTATTACAGTAAGTCTCGAGCAGCAAAATCTTCTG
TGCTCCAATCACAGTGAATGCTAAAATGAATAAGGACGTAAACAGTTTCCCA
GCCCAATGATTGTTTACGCAGAAATTCTACAAGGATATGTACCTGTTCTTGGAGC
45 CAATGTGACTGCTTTTATTGAATCACAGAATGGACATACAGAAGTTTTGGAAGTT
TTGGATAATGGTGCAGGCGCTGATTCTTTCAAGAATGATGGAGTCTACTCCAGGT
ATTTTACAGCATATACAGAAAATGGCAGATATAGCTTAAAAGTTCGGGCTCATGG
AGGAGCAAACACTGCCAGGCTAAAATTACGGCCTCCACTGAATAGAGCCGCGTA
CATACCAGGCTGGGTAGTGAACGGGGAAATTGAAGCAAACCCGCCAAGACCTGA

AATTGATGAGGATACTCAGACCACCTTGGAGGATTTTCAGCCGAACAGCATCCGG
 AGGTGCATTTGTGGTATCACAAGTCCCAAGCCTTCCCTTGCCTGACCAATACCCA
 CCAAGTCAAATCACAGACCTTGATGCCACAGTTCATGAGGATAAGATTATTCTTA
 CATGGACAGCACCAGGAGATAATTTTGATGTTGGAAAAGTTCAACGTTATATCAT
 5 AAGAATAAGTGCAAGTATTCTTGATCTAAGAGACAGTTTTGATGATGCTCTTCAA
 GTAAATACTACTGATCTGTCACCAAAGGAGGCCAACTCCAAGGAAAGCTTTGCA
 TTAAACCAGAAAATATCTCAGAAGAAAATGCAACCCACATATTTATTGCCATTA
 AAAGTATAGATAAAAGCAATTTGACATCAAAAGTATCCAACATTGCACAAGTAA
 CTTTGTATATCCCTCAAGCAAATCCTGATGACATTGATCCTACACCTACTTCCTAC
 10 TCCTACTCCTACTCCTGATAAAAGTCATAATTCTGGAGTTAATATTTCTACGCTGG
 TATTGTCTGTGATTGGGTCTGTTGTAATTGTAACTTTATTTTAAGTACCACCATT
 TGAACCTTAACGAAGAAAAAAATCTTCAAGTAGACCTAGAAGAGAGTTTTAAAA
 AACAAAACAATGTAAGTAAAGGATATTTCTGAATCTTAAAATTCATCCCATGTGT
 GATCATAAACTCATAAAAAATAATTTTAAGATGTCGGAAGGATACTTTGATTAA
 15 ATAAAAAACTCATGGATATGTAAAAACTGTCAAGATTAATAATTAATAGTTTCA
 TTTATTTGTTATTTTATTTGTAAGAAATAGTGATGAACAAAGATCCTTTTTTCATAC
 TGATACCTGGTTGTATATTATTTGATGCAACAGTTTTCTGAAATGATATTTCAAAT
 TGCATCAAGAAATTAAAATCATCTATCTGAGTAGTCAAAATACAAGTAAAGGAG
 AGCAAATAAACAACATTTGGAAAAAAATG

20

SEQ ID NO: 661

>21656 BLOOD INCYTE_547531H1
 CGAAAGTTGCTGGTTTCATATCTGCCACCACTGTATCAGCTAAAACAGGCANTE
 AGGANTTGTTCAGGGGTTAAGAAAGGTTTGGAGGTGGTTGAAAACTGAATGGA
 25 AAAGCTTATGGCTCTGTGATGATATTAGTGACCAGCGGAGATGATAAGCTTCTTG
 GCAATTGCTTACCCACTGTGCTCAGCAGTGGTTCAACAATTCACTCCATTGCCCT
 GGGTTCATCTGCAGCCCCAAATCTGGA

SEQ ID NO: 662

30 >21660 BLOOD 238908.1 AL137516 g6808175 Human mRNA; cDNA DKFZp564M2178
 (from clone DKFZp564M2178); partial cds. 0
 GAACCACCGGCAGACGCACCTCCGGGGCCACACCCACCAAGGCTCCTGCCCCTGTT
 GTCCTGGGGTCCCCAGTTGTTCTAGGGCCTCCTGTGGGGCCAGGCCCCGAGTGGCTG
 TGGAGCACTCATAACGAAAGGCAGAAAGAGGGTGGGGAAGGGGCGACTGTCCCAT
 35 CTGCCGCTGCCACCACCACTGAGGTAGTGACTGAGGTGGAGCTGCTCCTCTACAA
 GTGCTCTGAGTGCTCCAGCTCTTCCAGCTGCCGGCGGATTTCCTGGAGCACCAG
 GCCACTCACTTCCCTGCTCCTGTACCCGAGTCTCAGGAGCCTGCCTTACAGCAGG
 AGGTGCAGGCCTCGTCACCTGCAGAGGTGCCTGTGTCTCAGCCTGACCCCTTGCC
 AGCTTCTGACCACAGTTACGAGCTGCGCAATGGTGAAGCCATTGGGCGGGATCG
 40 CCGGGGGCGCAGGGCCCCGAGGAACAACAGTGGAGAAGCAGGCGGGGCAGCCA
 CACAGGAGCTCTTCTGCTCAGCCTGTGACCAGCTCTTTCTCTCACCCCAACCAGCTA
 CAGCAGCACCTGCGGAGTCACCGGGAGGGCGTCTTTAAGTGCCCCCTGTGCAGTC
 GTGTCTTCCCTAGCCCTTCCAGTCTGGACCAGCACCTTGGAGACCATAGCAGCGA
 GTCACACTTCCTGTGTGTAGACTGTGGCCTGGCCTTCGGCACAGAGGCCCTCCTC
 45 CTGGCCCACCGGCGAGCCCACACCCCGAATCCTCTGCATTCATGTCCATGTGGGA
 AGACCTTTGTCAACCTTACCAAGTTCCTTTATCACCGGCGTACTCATGGGGTAGG
 GGGTGTCCCTCTGCCCACAACACCAAGTCCCACCAAGAGGAACCTGTCATTGGTTTC
 CCTGAGCCAGCCCCAGCAGAGACTGGAGAGCCAGAGGCCCCCTGAGCCCCCTGTG
 TCTGAGGAGACCTCAGCAGGGCCCCGCTGCCCCAGGCACCTACCGCTGCCTCCTGT

GCAGCCGTGAATTTGGAAAGGCCTTGCAGCTGACCCGGCACCAACGTTTTGTGCA
TCGGCTGGAGCGGCGCCATAAATGCAGCATTTGTGGCAAGATGTTCAAGAAGAA
GTCTCACGTGCGTAACCACCTGCGCACACACACAGGGGAGCGGCCCTTCCCCTGC
CCTGACTGCTCCAAGCCCTTCAACTCACCTGCCAACCTGGCCCGCCACCGGCTCA
5 CACACACAGGAGAGCGGCCCTACCGGTGTGGGGACTGTGGCAAGGCTTTCACGC
AAAGCTCCACACTGAGGCAGCACCGCTTGGTGCATGCCCAGCACTTCCCCTACCG
CTGCCAGGAATGTGGGGTGCCTTTTACCGTCCTTACCGCCTGCTCATGCACCGC
TACCATCACACAGGTGAATACCCCTACAAGTGTGCGGAGTGCCCCCGCTCCTTCT
TGCTGCGTGGCTGCTGGAGGTGCACAGCTCGTGGTCCATGCCGGGCGCCAGCC
10 CCACCGCTGCCCATCCTGTGGGGCTGCCTTCCCCTCCTCACTGCGGCTCCGGGAG
CACCGCTGTGCAGCCGCTGCTGCCCAGGCCCCACGGCGCTTTGAGTGTGGCACCT
GTGGCAAGAAAGTGGGCTCAGCTGCTCGACTGCAGGCACACGAGGCGGCCCATG
CAGCTGCTGGGCCTGGAGAGGTCTGGCTAAGGAGCCCCCTGCCCTCGAGCCCC
ACGGGCCACTCGTGCACCAAGTTGCCTCTCCAGCAGCCCTTGGAAGCACTGCTACA
15 GCATCCCCTGCGGGCCCCTGCCCGCCGGGGTCTAGAGTGCAGCGAGTGCAAG
AAGCTGTTCAGCACAGAGACGTCACTGCAGGTGCACCGGCGCATCCACACAGGT
GAGCGGCCATACCCATGTCCAGACTGTGGCAAAGCGTTCCGTCAGAGTACCCAC
CTGAAAGACCACCGGCGCCTGCACACAGGTGAGCGGCCCTTTGCCTGTGAAGTG
TGTGGCAAGGCCTTTGCCATCTCCATGCGCCTGGCAGAACATCGCCGCATCCACA
20 CAGGCGAACGACCCTACTCCTGCCCTGACTGTGGCAAGAGCTACCGCTCCTTCTC
CAACCTCTGGAAGCACCAGCAAGACCCATCAGCAGCAGCATCAGGCAGCTGTGCG
GCAGCAGCTGGCAGAGGCGGAGGCTGCCGTTGGCCTGGCCGTCATGGAGACTGC
TGTGGAGGCGCTACCCCTGGTGGAAAGCATTGAGATCTACCCCTCTGGCCGAGGCT
GAGGGGGTCCAGATCAGTGGCTGACTCTGCCCGACTTCCTCTTTGGCACCTCCAT
25 TCCCTGTTGCTGAAGGCCCTCCAGCATCCCTTAAGCATCTGTACATACTGTGTCC
CTTCTCTTCCCATCCCCACCACCTTGTAAGTTCTAAATTGGATTTATTCTCTCGT
GAGGGGGGTGCTCTGGGGTCTTGACACACATAAAGGTGCCCCCCCACCTTCCAC
CTCTTAGCACTGGTGACCCCAAAAATGAAACCATCAATAAAGACTGAGTTGCC

30 SEQ ID NO: 663
>21669 BLOOD 132774.1 Incyte Unique
GCCGGACAGAGCAGAAGAACCCTCTTGGACTGGACGATTTGGGAATTCAAAACT
TGGGACAAAGTGTACGCTTGCCTCTGCTGTGGAGGCAGCCTCAATGCTGAAAAT
GGAGCCTCTGAAAGACAGCAGCCCCGGCACCAGCGCCTCCAGCAGCCCCCTGGA
35 GTCCCGTGCAGGCGGTGGCGGCAGCGGCAATGGCAACGAGTACTTCTACATTCTG
GTTGTCATGTCTTCTACGGCATTCTTCTTGATCGGAATCATGCTGGGCTACATGAA
ATCCAAGAGGCGGGGAGAAGAAGTCCAGCCTCCTGCTGCTGTACAAAGACGAGGA
GCGGCTCTGGGGGGAGGCCATGAAGCCGCTGCCCGTGGTGTGCGGCCCTGAGGTC
GGTGCAGGTGCCCTGATGCTGAACATGCTGCAGGAGAGCGTGGCGCCCGCGCT
40 GTCCTGCACCCTCTGTTCCATGGAAGGGGACAGCGTGAGCTCCGAGTCTCCTCC
CCGGACGTGCACCTCACCATTGAGGAGGAGGGGGCAGACGAGGAGCTGGAGGA
GACCTCGGAGACGCCCCCTCAACGAGAGCAGCGAAGGGTCTCGGAGAACATCCA
TCAGAATTCTTAGCACCCCCGGGACCCCTGCGGGTGGCTCCCATCAGCCAGCAAC
CTTAGAGAGAGGAAAGACAGTTTTTCAAGTGTCTGGTTTCACTTTCACAGTGCGGC
45 TGCCACTTTGAAGAGACCCTTGGTAAACCCCTGATTCCGGGGTGGGGTGGGGGACT
AGGCTCAGCCGGAACCAGCACCTCCAAGGAGTCCGGGAGGTGCCTGTGGTTTAC
ACCCACCACTGAAAAAGCCGCGGAGATGCGCAGCGCGTACACTGACTTTGGGGC
CTGGGTGTTGGGGTTCTGATCAGAAATTTGGCGGGATGATATGCTTGCCATTTTCTC
ACTGGATGCCCTGGGTAGCTCCTGCAGGGTCTGCCTGTTCCCAGGGCTGCCGAAT

GCTTAGGACACGCTGAGAGACTAGTTGTGATTTGCTATTTTGCCTAGAGCTTTGT
CCTTCTAGATCTGATTGGCTGTAAGTATCTCTACTGTGTACCTGTGGCATTCTTC
ACAGTGGGTACAAGCTTCTTTGGGATTAGAGGGGGATTTTGGATGGGAGAAAG
CGTGGGAGATCGTGGAACCCAGCCCATTTGCACACTATAAGAAAAAAGTAA
5 CTTTAAACCTGTAAACATTGGCCGGGGTTATAAGAGATGATCTTCTATTT

SEQ ID NO: 664

>21683 BLOOD 444662.14 Z58148 g1029379 Human CpG island DNA genomic MseI
fragment, clone 30a7, forward read cpg30a7.fl1d. 3e-15

10 CTCAGCGTCAGGCAAGTTGGCCTCTCTGTTGTAAATTAGTGGTTAAGGTTATCTA
TTATTGCCACTTTTCCAGCGCTAAAGGCTGTTTTGGAACCAAGTGTGCTTGTTCG
CGGGTGATTGGCTTTTTTTTTTTGGCAAACCAGTTATTCAAGTTTCTGGTCTTTAA
AAAACCTCTGTGGCGGTACGGTAACCGAGGAGGTTCCAGCGCGGCGGAAGTACCC
CGCGGGTGGGTGTGTGCGCAAGGCCAGGGCCAGAGGGGCACGTGGCGCCGGGA
15 GGAGAGAGAATGTCTTTTCGAGGCGGAGGTCGTGGAGGCTTTAATCGAGGTGGT
GGAGGTGGCCGGCTTCAACCGAGGCGGCAGCAGCAACCACTTCCGAGGTGGAGG
CGGCGGTGGAGGCGGCGGCAATTTAGAGGCGGCGGCAGGGGAGGATTTGGAC
GAGGGGGTGGCCGCGGAGGCTTTAACAAAGGCCAAGACCAAGGACCTCCAGAA
CGTGTAGTCTTATTAGGAGAGTTCCTGCATCCCTGTGAAGATGACATAGTTTGTA
20 AATGTACCACAGATGAAAATAAGGTGCCTTATTTCAATGCTCCTGTTACTTAGA
AAACAAAGAACAAATTGGAAAAAGTGGATGAAATATTTGGACAACTCAGAGATTT
TTATTTTTTCAGTTAAGTTGTCAGAAAACATGAAGGCTTCATCCTTTAAAAAACTA
CAGAAGTTTATATAGACCCATATAAGCTGCTGCCACTGCAGAGGTTTTACCTC
GACCTCCAGGTGAGAAAGGACCTCCAAGAGGTGGTGGCAGGGGAGGCCGAGGA
25 GGAGGAAGAGGAGGAGGTGGCAGAGGTGGTGGCAGAGGCGGTGGTTTTAGAGG
TGGAAGAGGAGGTGGAGGTGGGGGCTTCAGAGGAGGAAGAGGTGGTGGTTTCA
GAGGGAGAGGACATTAAGTGAAACAGTTGACAGACATCACCAGTTGACTTCTGC
ATTAACCTGCATGATCTGTTTCTACTATGGATTGGAACTTGTTTCTTGAACAAGT
CTTGAAGATCTTGGTCATTTTATGACAATGGATCTAAAATGTCAGCATCATGCAA
30 AGTGAACCGAATAGTGAATTTTGCTCTAAAAGAGCATGAACAAGTCTTTCTAAT
GTTTTGTACAGTGCCTGGNACTCTGTGGGTGCTCAATAAATGGATAGGAGTTTTC
ATTTGAAGGATATTTGAATTTTAAATAAAGTGTTTTATTCCTTAAAAAAA

SEQ ID NO: 665

35 yp61a02.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:191882 3',
mRNA sequence gi|908298|gb|H38799.1|H38799[908298]
TGATGCATCCTAAAATNNTAAGCTTCAAATCTGATTTGGTATCACCGAGGAAACC
TTGCCCCATCACTCAGCATTGCACTTAGATACAGAATGAGTTAGATAAACTTGG
CTTGTCTAGAGACCCATGTCATCTTAACCTAAAGGGAAATCTTATTGCGTTATCA
40 TAAATTTGATGATATCTTAGGGTCAGAATTGCCCTTTTTTTTATTTTGAATGGGA
AGTTCTCACTAAAACAATCCTGAGATTTCTTAATTTTCATGGGTTCTTTAAATATTA
TAAACACAGAGTCAACATAGGAATGAAATTGTATTTGTTAAAATACACACATTG
GGGGGNCAAGAGGCAGATGACTACTTTTC
GGAGGTAATGCTTGCTCCCTCCNAAAAGGCNGGTTTTCCATCCGGGGG
45

SEQ ID NO: 666

>21694 BLOOD 029567.1 Incyte Unique

GCCACCACACCCAGCTGCTTAAGCACAACTAATTTCAAAACCAGTCTTAGAAAT
TATATCCTACGCACTTGTCAAACGGGGTCAGTTTTTCTTGAAAGTAAACCTCTGCT

CTTCATCACACAATCTAAATCTGCCACCCTACCTAAGGCAGGGACTTAAAATGAG
GGGCAGGTTTTCTCAGATAAAATAAGCAAACAGACGAATTGGAATATTTCTGTCTC
AATTCCCATGTACAATTTTCAGCCTCATATGCAAATCAATATGGCAACCATCTCTT
TTTTCTATCAGCAAGAGCCATGTGTTGGTATTAAGAGGGCTAGGTTGTAGTTCCCC
5 TCTTGACACCAGAAACACCAGGCCTACTGTTTTGTTTGATAGCCTAGCACAGATG
TAACTCTTCTAAAGGGTAACATTTACTACTACACAGAAAGTCATTTTTAGAATGT
TCCTAGTCCATCCAAGAAAGGCTAAAAAATGTTCTGTGTGATTCTGGACTTAAGA
AGTCTTTTTTCACTGAATTCTGGCCCTAGATGCTCACTCAACTAGTAACCATAATGC
CCTGTTTTTCCCAAATGCTGAAATGGAACATTTACTGCATTGGCAATGTTTTCTAG
10 TGGGATTGGTTACAGAACTGTCATTCATTCTTACTGTGCAATATTACACAGCCA
TAATTAATGATGTAGTTAAAAACATTTGATGGCATATAATATATATATACATTGA
ATACATTGTAAGTAAGAAAAATATACAGGTTAGAAAACTGTAGGTATAGCATATT
GTAAAAAGAAAAATATATATACACGCATAGCGAAAAATGTCAGGAAGAATATACC
AAAATGTTAACGATTATCTTTAAGTAGTATCATCTTTTTTACTTCTTGTCTTTCTGT
15 TTCTCCTAAACTTCTAAAATAAAAAGGTATTATTTTTCAT

SEQ ID NO: 667

>21697 BLOOD 350207.6 X69086 g34811 Human mRNA for utrophin. 0

GCGGGCAGCAGCAGCCGGCCGGGCTTCTCCCGCCGAGGGGCGAGGAGGAGC
20 CTCTGGCTCCAGAAAGCCGATTGGGGAATCACGGGGAGCGGCGCCCCCTTCTTTT
GGGTCATTTCTGCAAACGGAAAACTCTGTAGCGTTTGGCAAAGTTGGTGCCTGCN
CGCCCCCTTCCAGGTTTGCGCTTTGACTGTTTTGTTTTGGCGGAACTACCAGGCAG
GAAGATTGCACAAGTAAGGGGCGTTTTTCAGTCGGGTGTCAANNNNNNNNNNNNNN
NNNNNNNNNNNNNAAAATTTTCGGTTCGTGTCTGCTTCTCCAAGCTTTATTTTTTTT
25 TAAAATACATCGCACCAACCAAACTAACACTCGCACACACCCCCGCGGTTACTCCG
TGTCAAACTCCTAGAGGAGCCCTTGGCCAGCTCGGGGTGCGGCGGTGGCGACCG
GCAGGCGAGGAGGCCCGCGGGCAGCAGGTATTGATGTCAAGCTGAACCATCGTA
GGAAGTTGAAAGCCTTAGAAAGAGGACTTGGTAAAGTTTTTGGATTATCTTGAAA
CTCTGGCAAATGGCCAAGTATGGAGAACATGAAGCCAGTCCTGACAATGGGCA
30 GAACGAATTCAGTGATATCATTAAGTCCAGATCTGATGAACACAATGACGTACA
GAAGAAAACCTTTACCAAATGGATAAATGCTCGATTTTCAAAGAGTGGGAAACC
ACCCATCAATGATATGTTACAGACCTCAAAGATGGAAGGAAGCTATTGGATCTT
CTAGAAGGCCTCACAGGAACATCACTGCCAAAGGAACGTGGTTCCACAAGGGTA
CATGCCTTAATAACGTCACACAGAGTGCTGCAGGTTTTACATCAGAACAATGTGG
35 AATTAGTGAATATAGGGGGAAGTACATTGTGGATGGAAATCACAACTGACTT
TGGGGTTACTTTGGAGCATCATTTTGCAGTGGCAGGTGAAAGATGTCATGAAGGA
TGTCATGTCGGACCTGCAGCAGACGAACAGTGAGAAGATCCTGCTCAGCTGGGT
GCGTCAGACCACCAGGCCCTACAGCCAAGTCAACGTCCTCAACTTCACCACCAGC
TGGACAGATGGACTCGCCTTAATGCTGTCCTCCACCGACATAAACCTGATCTCT
40 TCAGCTGGGATAAAGTTGTCAAAATGTCACCAATTGAGAGACTTGAACATGCCTT
CAGCAAGGCTCAAACCTTATTTGGGAATTGAAAAGCTGTTAGATCCTGAAGATGTT
GCCGTTCAAGCTTCTTGACAAGAAATCCATAATTATGTATTTAACATCTTTGTTTGA
GGTGCTACCTCAGCAAGTCACCATAGACGCCATCCGTGAGGTAGAGACACTCCC
AAGGAAATATAAAAAAGAATGTGAAGAAGAGGCAATTAATATACAGAGTACAG
45 CGCCTGAGGAGGAGCATGAGAGTCCCCGAGCTGAAACTCCCAGCACTGTCAGT
AGGTGCACATGGATCTGGACAGCTATCAGATTGCGTTGGAGGAAGTGCTGACCT
GGTTGCTTTCTGCTGAGGACACTTTCCAGGAGCAGGATGATATTTCTGATGATGT
TGAAGAAGTCAAAGACCAGTTTGCAACCCATGAAGCTTTTATGATGGAAGTACT
GCACACCAGAGCAGTGTGGGCAGCGTCCTGCAGGCAGGCAACCAACTGATAACA

CAAGGAACTCTGTCAGACGAAGAAGAATTTGAGATTCAGGAACAGATGACCCTG
CTGAATGCTAGATGGGAGGCTCTTAGGGTGGAGAGTATGGACAGACAGTCCCGG
CTGCACGATGTGCTGATGGAAGTGCAGAAGAAGCAACTGCAGCAGCTCTCCGCC
TGGTTAACTCACAGAGGAGCGCATTGAGAAGATGGAACTTGCCCCCTGGAT
5 GATGATGTAAATCTCTACAAAAGCTGCTAGAAGAACATAAAAGTTTGCAAAGT
GATCTTGAGGCTGAACAGGTGAAAGTAAATTCATACTCACATGGTGGTCATTG
TTGATGAAAACAGTGGTGAGAGCGCTACAGCTATCCTAGAAGACCAGTTACAGA
AACTTGGTGAGCGCTGGACAGCAGTATGCCGTTGGACTGAAGAACGCTGGAATA
GGTTACAAGAAATCAATATATTGTGGCAGGAATTATTGGAAGAAGAGTGGTTGTT
10 GAAAGCTTGGTTAACCAGAAAAGAGAGGCTTTAAATAAAGTCCAGACAAGCAA
CTTCAAAGACCAAAAAGGAACTAAGTGTGAGTGTTCGACGTCTGGCTATTTTGAAG
GAAGACATGGAAATGAAGCGTCAAACATTGGATCAGCTGAGTGAGATTGGCCAG
GATGTGGGACAATTACTTGATAATTCCAAGGCATCTAAGAAGATCAACAGTGAC
TCAGAGGAACTGACTCAAAGATGGGATTCTTTGGTTTCAGAGACTAGAAGATTCT
15 CCAACCAGGTGACTCAGGCTGTAGCAAAGCTGGGGATGTCTCAGATTCTCAGA
AGGACCTTTTGGAGACTGTTCTGTGTAAGAGAACAAAGCAATTACAAAAAATCTA
AGCAGGAACTGCCTCCTCCTCCTCCCCAAAGAAGAGACAGATCCATGTGGATAT
TGAAGCTAAGAAAAAGTTTGATGCTATAAGTGCAGAGCTGTTGAACTGGATTTG
AAATGGAAAACTGCCATTCAGACCACAGAGATAAAAGAGTATATGAAGATGCAA
20 GACACTTCCGAAATGAAAAAGAAGTTGAAGGCATTAGAAAAAGAACAGAGAGA
AAGAATCCCCAGAGCAGATGAATTAACCAAACCTGGACAAATCCTTGTGGAGCA
AATGGGAAAAGAAGGCCTTCTACTGAAGAAATAAAAAATGTTTGTGGAGAAGGT
TTCATCAGAATGGAAGAATGTATCTCAACATTTGGAAGATCTAGAAAGAAAGAT
TCAGCTACAGGAAGATATAAATGCTTATTTCAAGCAGCTTGATGAGCTTGAAAAG
25 GTCATCAAGACAAAGGAGGAGTGGGTAAAACACACTTCCATTTCTGAATCTTCCC
GGCAGTCCTTGCCAAGCTTGAAGGATTCCTGTCAGCGGGAATTGACAAATCTTCT
TGGCCTTCACCCCAAAATTGAAATGGCTCGTGCAAGCTGCTCGGCCCTGATGTCT
CAGCCTTCTGCCCCAGATTTTGTCCAGCGGGGCTTCGATAGCTTTCTGGGCCGCT
ACCAAGCTGTACAAGAGGCTGTAGAGGATCGTCAACAACATCTAGAGAATGAAC
30 TGAAGGGCCAACCTGGACATGCATATCTGGAAACATTGAAAACACTGAAAGATG
TGCTAAATGATTCAGAAAATAAGGCCAGGTGTCTCTGAATGTCCTTAATGATCT
TGCCAAGGTGGAGAAGGCCCTGCAAGAAAAAAGACCCTTGATGAAATCCTTGA
GAATCAGAAACCTGCATTACATAAACTTGCAGAAGAAACAAAGGCTCTGGAGAA
AAATGTTTATCTTGTATGAGAAAAATTATATAAGCAAGAATTTGATGATGTGCAA
35 GGAAAGTGGAAACAAGCTAAAGGTCTTGGTTTCCAAGATCTACATTTGCTTGAGG
AAATTGCTCTCACACTCAGAGCTTTTGAAGCCGATTCAACAGTCATTGAGAAGTG
GATGGATGGCGTGAAAGACTTCTTAATGAAACAGCAGGCTGCCCAAGGAGACGA
CGCAGGTCTACAGAGGCAGTTAGACCAGTGCTCTGCATTTGTTAATGAAATAGAA
ACAATTGAATCATCTCTGAAAAACATGAAGGAAATAGAGACTAATCTTCGAAGT
40 GGTCAGTTGCTGGAATAAAAACTTGGGTGCAGACAAGACTAGGTGACTACCAA
ACTCAACTGGAGAACTTAGCAAGGAGATCGCTACTCAAAAAAGTAGGTTGTCT
GAAAGTCAAGAAAAAGCTGCGAACCTGAAGAAAGACTTGGCAGAGATGCAGGA
ATGGATGACCCAGGCCGAGGAAGAATATTTGGAGCGGGATTTTGAGTACAAGTC
ACCAGAAGAGCTTGAGAGTGCTGTGGAAGAGATGAAGAGGGCAAAAGAGGATG
45 TGTTCGAGAAGGAGGTGAGAGTGAAGATTCTCAAGGACAACATCAAGTTATTAG
CTGCCAAGGTGCCCTCTGGTGGCCAGGAGTTGACGTCTGAGCTGAATGTTGTGCT
GGAGAATTACCAACTTCTTTGTAATAGAATTCGAGGAAAGTGCCACACGCTAGA
GGAGGTCTGGTCTTGTGGATTGAACTGCTTCACTATTTGGATCTTGAACTACCT
GGTTAAACACTTTGGAAGAGCGGATGAAGAGCACAGAGGTCCTGCCTGAGAAGA

CGGATGCTGTCAACGAAGCCCTGGAGTCTCTGGAATCTGTTCTGCGCCACCCGGC
AGATAATCGCACCCAGATTGAGAGCTTGGCCAGACTCTGATTGATGGGGGGAT
CCTGGATGATATAATCAGTGAGAACTGGAGGCTTCAACAGCCGATATGAAGA
TCTAAGTCACCTGGCAGAGAGCAAGCAGATTTCTTTGGAAAAGCAACTCCAGGT
5 GCTGCGGGAACTGACCAGATGCTTCAAGTCTTGCAAGAGAGCTTGGGGGAGCT
GGACAAACAGCTCACCACATACCTGACTGACAGGATAGATGCTTTCCAAGTTCCA
CAGGAAGCTCAGAAAATCCAAGCAGAGATCTCAGCCCATGAGCTAACCTAGAG
GAGTTGAGAAGAAATATGCGTTCTCAGCCCCTGACCTCCCCAGAGAGTAGGACT
GCCAGAGGAGGAAGTCAGATGGATGTGCTACAGAGGAACTCCGAGAGGTGTCC
10 ACAAAGTTCCAGCTTTTCCAGAAGCCAGCTAACTTCGAGCAGCGCATGCTGGACT
GCAAGCGTGTGCTGGATGGCGTGAAAGCAGAACTTCACGTTCTGGATGTGAAGG
ACGTAGACCCTGACGTATACAGACGCACCTGGACAAGTGTATGAACTGTATA
AACTTTGAGTGAAGTCAAACCTTGAAGTGGAACTGTGATTAACACAGGAAGAC
ATATTGTCCAGAAACAGCAAACGGACAACCCAAAAGGGATGGATGAGCAGCTGA
15 CTTCCCTGAAGGTTCTTTACAATGACCTGGGCGCACAGGTGACAGAAGGAAAAC
AGGATCTGGAAAGAGCATCACAGTTGGCCCCGAAAATGAAGAAAGAGGCTGCTT
CTCTCTCTGAATGGCTTTCTGCTACTGAACTGAATTGGTACAGAAGTCCACTTC
AGAAGGTCTGCTTGGTGACTTGGATACAGAAATTTCTGGGCTAAAAATGTTCTG
AAGGATCTGGAAAAGAGAAAAGCTGATTTAAATACCATCACAGAGAGTAGTGCT
20 GCCCTGCAAACTTGATTGAGGGCAGTGAGCCTATTTTAGAAGAGAGGCTCTGC
GTCCTTAACGCTGGGTGGAGCCGAGTTTCGTACCTGGACTGAAGATTGGTGCAATA
CCTTGATGAACCATCAGAAACAGCTAGAAAATATTTGATGGGAACGTGGCTCACAT
AAGTACCTGGCTTTATCAAGCTGAAGCTCTATTTGGATGAAATTGAAAAGAAACC
AACAAGTAAACAGGAAGAAATTGTGAAGCGTTTGTATCTGAGCTGGATGATGC
25 CAACCTCCAGGTTGAAAATGTCCGCGATCAAGCCCTTATTTTGATGAATGCCCGT
GGAAGCTCAAGCAGGGAGCTTGTAGAACCAGTTAGCTGAGCTGAATAGGAAC
TTTGAAAAGGTGTCTCAACATATCAAAAGTGCCAAATTGCTAATTGCTCAGGAAC
CATTATACCAATGTTTGGTCACCACTGAAACATTTGAACTGGTGTGCCTTTCTCT
GACTTGGAAAAATTAGAAAATGACATAGAAAATATGTTAAAATTTGTGGAAAAA
30 CACTTGAATCCAGTGATGAAGATGAAAAGATGGATGAGGAGAGTGCCAGATT
GAGGAAGTTCTACAAAGAGGAGAAGAAATGTTACATCAACCTATGGAAGATAAT
AAAAAAGAAAAGATCCGTTTGCAATTATTACTTTTGCATACTAGATACAACAAA
TTAAGGCAATCCCTATTCAACAGAGGAAAATGGGTCAACTTGCTTCTGGAATTAG
ATCATCACTTTCTTCTACAGATTATCTGGTTGAAATTAACAAAATTTTACTTTGCA
35 TGGATGATGTTGAATTATCGCTTAATGTTCCAGAGCTCAACACTGCTATTTACGA
AGACTTCTCTTTTCAGGAAGACTCTCTGAAGAATATCAAAGACCAACTGGACAAA
CTTGAGAGCAGATTGCAGTCATTCATGAAAAACAGCCAGATGTCATCCTTGAA
GCCTCTGGACCTGAAGCCATTCAGATCAGAGATACTTACTCAGCTGAATGCAA
AATGGGACAGAATTAATAGAATGTACAGTGATCGGAAAGGTTGTTTTGACAGGG
40 CAATGGAAGAATGGAGACAGTTCCATTGTGACCTTAATGACCTCACACAGTGGA
TAACAGAGGCTGAAGAATTACTGGTTGATACCTGTGCTCCAGGTGGCAGCCTGG
ACTTAGAGAAAGCCAGGATACATCAGCAGGAAGTTGAGGTGGGCATCAGCAGCC
ACCAGCCCAGTTTTGCAGCACTAAACCGAACTGGGGATGGGATTGTGCAGAAAC
TCTCCAGGCAGATGGAAGCTTCTTGAAAGAAAAACTGGCAGGTTTAAACCAAC
45 GCTGGGATGCAATTGTTGCAGAAGTGAAGGATAGGCAGCCAAGGCTAAAAGGAG
AAAGTAAGCAGGTGATGAAGTACAGGCATCAGCTAGATGAGATTATCTGTTGGT
TAACAAAGGCTGAGCATGCTATGCAAAAGAGATCAACCACCGAATTGGGAGAAA
ACCTGCAAGAATTAAGAGACTTAACTCAAGAAATGGAAGTACATGCTGAAAAAC
TCAAATGGCTGAATAGAACTGAATTGGAGATGCTTTCAGATAAAAGTCTGAGTTT

ACCTGAAAGGGATAAAATTTTCAGAAAGCTTAAGGACTGTAAATATGACATGGAA
 TAAGATTTGCAGAGAGGTGCCTACCACCCTGAAGGAATGCATCCAGGAGCCCAG
 TTCTGTTTCACAGACAAGGATTGCTGCTCATCCTAATGTCCAAAAGGTGGTGCTA
 GTATCATCTGCGTCAGATATTCCTGTTCACTCATCGTACTTCGGAAATTTCAAT
 5 TCCTGCTGATCTTGATAAAACTATAACAGAACTAGCCGACTGGCTGGTATTAATC
 GACCAGATGCTGAAGTCCAACATTGTCACTGTTGGGGATGTAGAAGAGATCAAT
 AAGACCGTTTCCCGAATGAAAATTACAAAGGCTGACTTAGAACAGCGCCATCCT
 CAGCTGGATTATGTTTTTACATTGGCACAGAATTTGAAAAATAAAGCTTCCAGTT
 CAGATATGAGAACAGCAATTACAGAAAAATTGGAAAGGGTCAAGAACCAGTGG
 10 GATGGCACCAGCATGGCGTTGAGCTAAGACAGCAGCAGCTTGAGGACATGATT
 ATTGACAGTCTTCAGTGGGATGACCATAGGGAGGAGACTGAAGAACTGATGAGA
 AAATATGAGGCTCGACTCTATATTCTTCAGCAAGCCCGACGGGATCCACTACCA
 AACAAATTTCTGATAACCAAATACTGCTTCAAGAACTGGGTCCTGGAGATGGTAT
 CGTCATGGCGTTTCGATAACGTCTGCAGAACTCCTGGAGGAATATGGGAGTGA
 15 TGACACAAGGAATGTGAAAGAAACACAGAGTACTTAAAAACATCATGGATCAA
 TCTCAAACAAAGTATTGCTGACAGACAGAACGCCTTGGAGGCTGAGTGGAGGAC
 GGTGCAGGCCCTCTCGCAGAGATCTGGAAAACCTTCTGAAGTGGATCCAAGAAGC
 AGAGACCACAGTGAATGTGCTTGTGGATGCCTCTCATCGGGAGAATGCTCTTCAG
 GATAGTATCTTGGCCAGGGAACCTCAAACAGCAGATGCAGGACATCCAGGCAGAA
 20 ATTGATGCCACAAATGACATATTTAAAAGCATTGACGGAAACAGGCAGAAAGATG
 GTAAAAGCTTTGGGAAATTTCTGAAGAGGCTACTATGCTTCAACATCGACTGGATG
 ATATGAACCAAAGATGGAATGACTTAAAAGCAAATCTGCTAGCATCAGGGCCC
 ATTTGGAGGCCAGCGCTGAGAAAGTGGAAACAGGTTGCTGATGTCTTAGAAGAAC
 TGATCAAATGGCTGAATATGAAAGATGAAGAGCTTAAGAAACAAATGCCATTTG
 25 GAGGAGATGTTCCAGCCTTACAGCTCCAGTATGACCATTGTAAGGCCCTGAGACG
 GGAGTTAAAGGAGAAAGAATATTCTGTCTGAATGCTGTGACAGGCCCCGAGT
 TTTCTTGGCTGATCAGCCAATTGAGGCCCTGAAGAGCCAAGAAGAAACCTACA
 ATCAAAAACAGAATTAACCTCTGAGGAGAGAGCCCCAAAAGATTGCCAAAGCCAT
 GCGCAAACAGTCTTCTGAAGTCAAAGAAAAATGGGAAAGTCTAAATGCTGTAAC
 30 TAGCAATTGGCAAAAGCAAGTGGACAAGGCATTGGAGAACTCAGAGACCTGCA
 GGGAGCTATGGATGACCTGGACGCTGACATGAAGGAGGCAGAGTCCGTGCGGAA
 TGGCTGGAAGCCCGTGGGAGACTTACTCATTGACTCGCTGCAGGATCACATTGAA
 AAAATCATGGCATTTAGAGAAGAAATGCACCAATCAACTTTAAAGTTAAAACGG
 TGAATGATTTATCCAGTCAGCTGTCTCCACTTGACCTGCATCCCTCTCTAAAGATG
 35 TCTCGCCAGCTAGATGACCTTAATATGCGATGGAAACTTTTACAGGTTTCTGTGG
 ATGATCGCCTTAAACAGCTTCAGGAAGCCACAGAGATTTTGGACCATCCTCTCA
 GCATTTTCTCTCTACGTCACTCAGCTGCCGTGGCAAAGATCCATTTACATAAT
 AAAGTGCCCTATTACATCAACCATCAAACACAGACCACCTGTTGGGACCATCCTA
 AAATGACCGAACTCTTTCAATCCCTTGCTGACCTGAATAATGTACGTTTTTCTGCC
 40 TACCGTACAGCAATCAAAATCCGAAGACTACAAAAGCACTATGTTTGGATCTCT
 TAGAGTTGAGTACAACAAATGAAATTTTCAAACAGCACAAGTTGAACCAAAATG
 ACCAGCTCCTCAGTGTTCAGATGTCATCAACTGTCTGACAACAACCTTATGATGG
 ACTTGAGCAAATGCATAAGGACCTGGTCAACGTTCCACTCTGTGTTGATATGTGT
 CTCAATTGGTTGCTCAATGTCTATGACACGGGTGCAACTGGAAAAATTAGAGTGC
 45 AGAGTCTGAAGATTGGATTAATGTCTCTCTCCAAAGGTCTCTTGGAAGAAAAATA
 CAGATATCTCTTTAAGGAAGTTGCAGGGCCAACAGAAATGTGTGACCAGAGGCA
 GCTGGGCCTGTTACTTCATGATGCCATCCAGATCCCCCGGCAGCTAGGTGAAGTA
 GCAGCTTTTGGAGGCAGTAATATTGAGCCTAGTGTTCGAGCTGCTTCCAACAGA
 ATAACAATAAACCAGAAATAAGTGTGAAAGAGTTTATAGATTGGATGCATTTGG

AACCACAGTCCATGGTTTGGCTCCCAGTTTTACATCGAGTGGCAGCAGCGGAGAC
TGCAAAACATCAGGCCAAATGCAACATCTGTAAAGAATGTCCAATTGTCGGGTTC
AGGTATAGAAGCCTTAAGCATTTTAACTATGATGTCTGCCAGAGTTGTTTCTTTTC
GGGTCTGAACAGCAAAAGGTCACAAATTACATTACCCAATGGTGGAATATTGTAT
5 ACCTACAACATCTGGGGAAGATGTACGAGACTTCACAAAGGTAAGTAAAGAACAA
GTTTCAGGTCTGAAGAAGTACTTTGCCAAACACCCTCGACTTGGTTACCTGCCTGTC
CAGACAGTTCTTGAAGGTGACAACTTAGAGACTCCTATCACACTCATCAGTATGT
GGCCAGAGCACTATGACCCCTCACAATCTCCTCAACTGTTTCATGATGACACCCA
TTCAAGAATAGAACAATATGCCACACGACTGGCCCAGATGGAAAGGACTAATGG
10 GTCTTTTCTCACTGATAGCAGCTCCACCACAGGAAGTGTGGAAGACGAGCACGCC
CTCATCCAGCAGTATTGCCAAACACTCGGAGGAGAGTCCCCAGTGAGCCAGCCG
CAGAGCCCAGCTCAGATCCTGAAGTCAGTAGAGAGGGAAGAACGTGGAGAAGT
GAGAGGATCATTGCTGACCTGGAGGAAGAACAAGAAATCTACAGGTGGAGTAT
GAGCAGCTGAAGGACCAGCACCTCCGAAGGGGGCTCCCTGTCGGTTCACCGCCA
15 GAGTCGATTATATCTCCCCATCACACGTCTGAGGATTCAGAAGTTATAGCAGAAG
CAAACTCCTCAGGCAGCACAAAGGTCTGGCTGGAGGCTAGGATGCAGATTTTAG
AAGATCACAATAAACAGCTGGAGTCTCAGCTCCACCGCCTCCGACAGCTGCTGG
AGCAGCCTGAATCTGATTCCCGAATCAATGGTGTTCCTCCATGGGCTTCTCCTCA
GCATTCTGCACTGAGCTACTCGCTTGATCCAGATGCCTCCGGCCACAGTTCAC
20 CAGGCAGCGGGAGAGGACCTGCTGGCCCCACCGCACGACACCAGCACGGATCTC
ACGGAGGTCATGGAGCAGATTCACAGCACGTTTCCATCTTGCTGCCCAAATGTTT
CCAGGAGGCCACAGGGAATGTGAAGTATTCATCCGGCCAACCAATGTTTCCTGAC
GTACAGTGTGTCCTTTTCAAGCAAAAGGCAATTCGAAGTTCATTAATCAGAAAG
CTCCATGGGTCTTGGGCCCACGATGTTGAGTGCTGACTGTGTCTTCTACTGAAAG
25 AGTAAACACTGACTATCCAAAGAGAAATGGATATTTTGTCTTTTATAATAACGAT
ATATTATTGTTTTCTTCTTCCCTTTCTATGCAAGTGTAATTAATGAACAGAGAGG
TATTTGGAAATGGTAATACATTTGTACGGATTTGTATAATGTATACAGCATTGG
GAAAGTGGGTGGGGGCTTTCTAATATGATACCGTCTTTTTTAATAACTATGACAAA
GCTTACATAAGAATTAGAAGACCACTTTACATTTTACATTCTTCTGCTGTTTAT
30 ATTAACCTTGCACAATTACTTCATTTTTTCTTTGACTCTTTTACCACAATGTTTTG
TTATTTATAATTTATCAGCCATATGTTTATCAGCCATATAACCAACTAGATCCCAA
ATAGATCCATGTATTTGTTTCCGTGATTTGGCCACATTAATAAATTCATAAATTTT
AATCAAATATCATATATATACACACATATGGTTTAAAGCTACAGCCCTGTGTATGC
CGTTTAACTTTATTTGACGTTGCCCACTTACTTCTTGTCTGACCACTTGGATAACC
35 GTAATAAAAATCCTATAAGCCTAAATGGCATTCTTTTGGGATATTTTCTGCTAT
TTTATTCCTTTTATATAAGTAGGAATTAATTTATTTTATGTCTTAATCTATT
TGATAAAGAAGACTACATTATAAATCTCAAAGATCATATTACCAAAGGTTGCC
CACTTGAGCATATTTTCATTTTGACACAGAAACAAAATTTAGTACAACCTTTCTT
AGTTCCCATGTCTTGATTTTCATCATTACATGCACAGCAGACCTTTACCTATTGTG
40 ATACCAGAACACATCATTGTCTTTGGTTCCCTTCAAAGAGAATTTTATTGTTGTTT
TGTATTTTCAAGTCCTTAATAGTTCTTGAAACTCCTAGTTGTTTTCTTGTTGAAAG
CAGACACACATTTAGTGCACGGCTTATTTTACCTTTCGGGTGAAAGATCAGATGT
TTTTATACCCTTCACTTGATCAATATATTTGGAAAGAATGTTTATCAAAGTCTAT
GTCCTGCTTCTACAGAAGAATGAAATTAATGCTTAGGTGATGGTACCTCCACCT
45 ACATCTTTTTGAGTGCATTCAATTATGTATTTTGGTTTAGCTTCTGATTTAACATTT
AATTGATTCAAGTTTAAACATGTTACTTAATTAGCAAATGTAGAGGAACCAAAAAA
AGGTGAAAATAATATGTTTTGATTCAAACCTAAAGACATAAAAAACATAAAGACA
TTTTAACTTTGGGTCTCTTTAGCTGGGATCTGGCCAGAAGGAGGCTTAAAGTTA
GAAATTGCTATTATTTTAGAATAGGTTGGGTGGGTGGGGGGCAAGGGTGTCTAT

TTGCAGCAGAGATATTTTGAAGAAAGAAATTGTTTTATATAAAAAGGAAAGC
 CATGACCACCTTTCTACCTCAGATCCATCTTCATCCATTGCATTGGAAACTGCTTT
 ATGCTGCTGCAGTCTGCAAAGTCTAGAGCTTTTATCAGGCCATGTCATACCCAAG
 AAAGCACCTATTTAAAGAAAAACAATTCCTGAGCTCTCAACTCCAAGTTGTAG
 5 ATTTGGTGTCTTCCTTGTCTTACTTTAAAAAGTCATGTGTTAATTTTTTTCTGCC
 TGTATTTGTATGCAAAATGTCCTCTATCTGCTATTAAAGAAAAGCTACGTAAAAC
 ACTACATTGTAACCTTCTAAGTAATAATAAATAAAAAGAAATATATTGCAGTAAC
 AATGGGAAGTAAGTATGTAGTTCTTTTGAATATGTGGTAAAGAACTAATCACAG
 ACTATCATCTAATCTGGTTACATATTGTATTTTTCATCCTGTGATTAAAGGCACA
 10 TGTGTAAAAGTCCAATTAGTATGCTTTTTCATTTCAAATAATCCATATAGCCTCCAG
 AAAAATATGCACATGTGTAAAAGTCCACGTTCAATTTCTTTCACTTCCAATATAAA
 GTATTCTGTATTTTGTATAAAGTACGTGCAAACACCTTTCTGCTAATCGGGTCCCC
 ACATTCTTTTCACTACAGGTACTTTACAAGTCTGCCCTCTGCTCAAACACTAACC
 TGCACTGACATCCTCCTTCTAGACAGCCATTCATCTCCCGGACTTCTTTCTCTCA
 15 GACATCCTCCTGACCTCCTGACCTCCCTGACCTGCTTCACCACTGTGTTACCTCA
 CTGGTTACTTGTACAGCAAAGTATGCAACTACTAGTCTACCTGGACAACATAT
 TAAACAGGTATCACCTAATAGGGTGGCAGCCTATCGGGGTGATTCTCTGGCGAAT
 ACACAGTAACCAACCACATACTGACACACTCAACCCATTGCTACAGATGGACCC
 AACTAATTGATATGACAATCCTTTATTCCTCGGCACATTTGGTTTCTTTGCATT
 20 TTCTTCCATTTTACATTGCAGGTGTGGCTACCAAGAGCTGGATAACGAGTCCCTC
 AAACAAAGTTTGAATGCGAGATATATTGGGGTACCTTGATTCTTGAGACAGTT
 GAATTCCTTCTAGTTGATCTTGTGTATTAATAAAGTCACTCTCAACTGAAGTGACC
 ACTGCATTTCTTTGTAAAAAGGTCAATTGACTGGCTTTTCTCTCACAAGTGGCACC
 CATGGAGTACAAAAGCAGGAATCCCTTTTCATGAAAGGTGTAAAGTACAAGATG
 25 ACATTTACATTTTTTTAAAAAAGAATCCTTCATGGGAATATATCCTAATAATC
 AATTATATGGAGACAGTTTTATGTACACCAAATTTCTGCAACTTTATAATAATGA
 AAATTAGAAACAACCTAAATAGTTAACAACATGGGAATGGTTAAATAAACTGAG
 TTGCATCCATTAAATGGAATATAATATAGCCATTAAATTTATGTTTTGTAAAATT
 TTTAATGCCATAAGAAAATGTGGCAATTTTGAATGAAAAAGATCTACTTATAAA
 30 ACTGTTTACAGTATGACTCCAATTATGTAAAAAAGTATACAATACACATATAGG
 CATAATGGGGGTTGCTTTTTTAAAGGTGGTTACTTCTGGGTTGTGATATTATCAGT
 AATCATTTTTGCTTTTTTATACATTTCTGTATTTTTCAAGTTTTCTATGATGAGTAT
 ATTATTTTACAAAGACTACGAAAATTTTCTCTGATATACTGGTAATTAGAATGT
 ACTTGGGTATTTTAAATATATGGGAACAATAATATAGTGCTTCATCTTCTATGACT
 35 TTTTGGGAATACATATCACTTTGGTAATAAACTTACATTCCCTGTTTTATACTTGT
 TACAACATTTTAAATTAACAGTTAATATTGTGATTAGAGCATTGTTTGCTTCATGA
 CCTAAACAAATACTGGCTTTGAAGTCTAGGTTCTATTTCTAGAAAGATTTAACAT
 TAGTATCCTTTTAAATCTTTTTAAGTAAGGCATACTGCATACATACATTACATGCAT
 GCTTTCTAAACAAAAGATAATCCAACTTACAGTTTTCTATGTAAGGGAAAAAA
 40 TGGAATTATGGTAGTTTAAAAGCAGTCCATAGTCTCATCCATCACAACATGCTG
 ATAGGCATAAACGTGTTTATTAAGTGAAACGTATCCTTTAAAAATAAAAAAGGG
 AAGCCTGTATATAAATGAAGTTGTGGATTCAACTAGCCAGAATTTATTCTGACTT
 GCACCAAACCACACAAAATCTTTTAAAAGTCTAGTTAGTGTAGTCTAAATGGACA
 CTCCAGAGTCTGTTCTTGAATTCCATTGCAAGAGCTCCAACCTCCTACTTTCAGAA
 45 GGGATGGGGATCAAGATGAGGGTTGTCACATAAGCTAATTTTCAATATATATCAA
 GTCTTGTGGGGTCCAGGAACAAATACTGTCATTGGTTAGTGTTAAGTACATGAG
 TTGACTTTTCTCCTCTCTCACACCCACCTTGCCCTGGCAATTGGGTAGGGGGAG
 GCTGTTTATCCTCCAAGAGAGGACGGCTGGTTCTCATCTCAGTTTCCGTTCTAAA
 CCACAGAGTGGTCATTGCTGTGAACTCCAGCCAAGATGGTGTGGGAGAGGCGAG

GAAGCCGAGCGGTCTGAGCCTTCTGTGGGGCCGGTGGGGTTCTCACTGCGCTGGC
 AGCAGAGGATCTGCCTAAAGGTGGCGCTCATTTCTTTGTCGCGGTAGGAGTAAAT
 GATGGGGTTCATGGCAGAGTTGAATTCAGCAAGGAGAAGGAAGAATTTCTCATA
 GGCCAGCACGTTCGCACTGTGGACAGCACACGTCTAGAAGTAACAAAACCAATCC
 5 AGGAGTCCAGCAGATGATAAAGGCCCAAGCACAAATGACCACAGTCTTCAGAAG
 ACTCATCATGGTATCCCGATTCCGCCGGGGTCCAGA ACTATGCCGAGACATTCTC
 ATAGTCCTCTGGCGAACATAGCCAAAGATGTGAGCATAGAGAACCACCATTACC
 ACAAAGGTCACCAAGTTGAAAATGGCCCAGAAGACTAAGTAAGAGTCACTGTAG
 AGGGGTGCCATGTTGGAACAATTTTCAATATCACAGATACAGTTCCAGCCCACAC
 10 TGGGTATAGCACCATAACGATGGCCATAGTCCAGATGACCACAATGACCACCA
 CTACCCGCCGGTTGCTCATCCGTGTGTGGAGCTGCATGCGGAAAACCGTAATGTG
 CCTCTCGATTGCAATAGCCAGTAAGTTGGCCACAGATGCCGTCAGGCTGGTGTCA
 ATGAGGCCCTGACGAAGGAGCCATGTGCTAACAGTCAGTCTCCGAGTATTGGGT
 CCTGTGTTGAACATGAGATAGAAGTAGGCCAACCCAGCAAAGAAGTCTGCAGCA
 15 GCCAGATTAGCCATTAGGTAATAAATAGGAAAATGGAAGCGGCGGTTGACATAG
 ATTGCCACCATGACCAATAGGTTGGCCAACATGATGAAGATACAAACAGTGATT
 CCAAGTCCCATCACCAGCTTGCTGACTGTGTTCCATTCTGTGGCAAGATGCTTTCC
 ACTTCGGTTATAAAAGAAGGCAATGGACTCGTTGTAGAAGCACTGTGGTTCATTC
 ATGGCTGTGAACTGGGGCTGTGAAATTACAGGGATGGAAGTAGAGATGGCAGCC
 20 ATGACAGCTCTGTGGTTGTAGGTGGTGAACACGCCCCAGAACTACGGGAGACAA
 ATTTTCTTGTTGCTGATCAGATCGAAGTCATGCTAGGAGAAGCTGTGTACCTGA
 TGGCTGTAGGTGTCAGTCTGAGAAAGTCAGGTA CTGATAGGTGGATGGGGAGC
 TTTTCATAAATCAGACGTCACCTCTGTTAGTTCTTTCCCATCACTCACAGGGAGACT
 TTTGAGAAATCCATGCTGAGTGGCCACAGACCTGGGCAGGAGCTGTTCGCCCCAGCGCCG
 25 GACAGCTGGCAGGACTCCGGTGGACGCCCGGACGCGGGGCATTTTCACGTTGTC
 GCTCTCTCTTCCCACCTTGAAGAGCTCTGGAAAACATCGCGGGGGCCCGCAAAACC
 CCGGAAATGTGGC

SEQ ID NO: 668

30 >21707 BLOOD 1147849.1 J03004 g183181 Human guanine nucleotide-binding regulatory
 protein (G) alpha-inhibitory-subunit mRNA, complete cds. 5e-78
 GCTGCACCGTGAGCGCCGAGGACAAGGCGGCGGCCGAGCGCTCTAAGATGATCG
 ACAAGAACCTGCGGGAGGACGGAGAGAAGGCGGCGCGGGAGGTGAAGTTGCTG
 CTGTTGGGTGCTGGGGAGTCAGGGAAGAGCAACCATCGTNAAGCAGGTTAGGTCA
 35 TTNCCGGGGTTGTTATTTCCGGGGGGGATTTCCNCAATACCCNGGGTTNTCTACAG
 CAACANCATCCAGTCCATCATGGCCATTGTCAAAGCCATGGGCAACCTGCAGATC
 GACTTTGCCGACCCCTCC

SEQ ID NO: 669

40 >25177 BLOOD Hs.227948 gnl|UG|Hs#S553844 squamous cell carcinoma antigen=serine
 protease inhibitor [human, mRNA, 1711 nt] /cds=(61,1233) /gb=S66896 /gi=239551
 /ug=Hs.227948 /len=1711
 CTCTCTGCCACCTCTGCTTCCTCTAGGAACACAGGAGTTCCAGATCACATCGAG
 TTCACCATGAATTCAGTGAAGCCAACACCAAGTTCATGTTGACCTGTTCC
 45 AACAGTTCAGAAAATCAAAAGAGAACAACATCTTCTATTCCCCTATCAGCATCAC
 ATCAGCATTAGGGATGGTCCTCTTAGGAGCCAAAGACAACACTGCACAACAGAT
 TAAGAAGGTTCTTCACTTTGATCAAGTCACAGAGAACACCACAGGAAAAGCTGC
 AACATATCATGTTGATAGGTGAGGAAATGTTTCATCACCAGTTTCAAAAGCTTCTG
 ACTGAATTCAACAAATCCACTGATGCATATGAGCTGAAGATCGCCAACAAGCTCT

TCGGAGAAAAAACGTATCTATTTTTACAGGAATATTTAGATGCCATCAAGAAATT
 TTACCAGACCAGTGTGGAATCTGTTGATTTTGCAAATGCTCCAGAAGAAAAGTCGA
 AAGAAGATTAACTCCTGGGTGGAAAGTCAAACGAATGAAAAAATTAAAAACCTA
 ATTCCTGAAGGTAATATTGGCAGCAATACCACATTGGTTCCTGTGAACGCAATCT
 5 ATTTCAAAGGGCAGTGGGAGAAGAAATTTAATAAAGAAGATACTAAAGAGGAA
 AAATTTTGGCCAAACAAGAATACATACAAGTCCATACAGATGATGAGGCAATAC
 ACATCTTTTCATTTTGCCTCGCTGGAGGATGTACAGGCCAAGGTCCTGGAAATAC
 CATACAAAGGCCAAAGATCTAAGCATGATTGTGTTGCTGCCAAATGAAATCGATG
 GTCTCCAGAAGCTTGAAGAGAACTCACTGCTGAGAAATTGATGGAATGGACAA
 10 GTTTGCAGAATATGAGAGAGACACGTGTCGATTTACACTTACCTCGGTTCAAAGT
 GGAAGAGAGCTATGACCTCAAGGACACGTTGAGAACCATGGGAATGGTGGATAT
 CTTCAATGGGGATGCAGACCTCTCAGGCATGACCGGGAGCCGCGGTCTCGTGCTA
 TCTGGAGTCCTACACAAGGCCTTTGTGGAGGTTACAGAGGAGGGAGCAGAAGCT
 GCAGCTGCCACCGCTGTAGTAGGATTCGGATCATCACCTGCTTCAACTAATGAAG
 15 AGTTCCATTGTAATCACCTTTTCTATTCTTCATAAGGCCAAAATAAGACCAACAG
 CATCCTCTTCTATGGCAGATTCTCATCCCCGTAGATGCAATTAGTCTGTCACTCCA
 TTTGGAAAATGTTACCTGCAGATGTTCTGGTAACTGATTGCTGGCAACAACAG
 ATTCTCTTGGCTCATATTTCTTTTCTTTCTCATCTTGATGATGATCGTCATCATCAA
 GAATTTAATGATTAATAATAGCATGCCTTTCTCTCTTTCTCTTAATAAGCCCACATA
 20 TAAATGTACTTTTCTTCCAGAAAAATTCTCCTTGAGGAAAAATGTCCAAAATAA
 GATGAATCACTTAATACCGTATCTTCTAAATTTGAAATATAATTCTGTTTGTGACC
 TGTGTTTAAATGAACCAAAACCAAATCATACTTTTCTTTGAATTTAGCAACCTAGA
 TAAACACACATTTCTTTGAATTTAGGTGATACCTAAATCCTTCTTATGTTTCTAAATTC
 TTTGTGATTCTATAAAACACATCATCAATAAAATAGTGACATAAAATCAAAAAAA
 25 AAAAAAAAAA

SEQ ID NO: 670

yc03e09.s1 Stratagene lung (#937210) Homo sapiens cDNA clone IMAGE:79624 3', mRNA
 sequence gi|666284|gb|T62627.1|T62627[666284]

30 TTTAGANACATTTGCTTNCCCATCCCAAATTAACATATGCAAATTAATTGTTTTGAA
 GATGCCATNCCAAATGTGGAGGTGCTCATGAGCTTGGAAACTCAGAAGCTCTAA
 GGTGAGCCTCCAGACAGGGAGAGTCTGCAACATGGTGACTGAGAGGGTAGTAGA
 AATTCACCTTGCTATNTAACTCTCTCTNGAGATTTATTCTTGGAGGACAGAGCAAA
 AGTCCACTCTTCAAGCAGCTCTCCGAGGGTCAITTCCTTCACAACGTATATTCCGTTT
 35 CCAGTTCTTTGCGTTCCTTCCCTTTTCCCTTCGACTTCAAATTCATTTGGTGTAAACCA
 AGTTCCATCCTCATTCCNGAATGCACTTCACTGAGGATCCCGTGTTTCATTTTCTT
 CTTATATAAAANCCCTTTTCGCCTCACCACAGGTCACGGGGGAGCTTNGGAACAGT
 GAAAATCCACAGTGTCACTTTTGGGGTTTTCTCTTCGGGTGAATATTTTCTGAA
 ATCTCCTTTTGTAGCTTGGACAGATATCTTGNTCCTTTGNCT
 40

SEQ ID NO: 671

ys88a08.s1 Soares retina N2b5HR Homo sapiens cDNA clone IMAGE:221846 3' similar to
 SP:HTLF_HUMAN P32314 HUMAN T-CELL LEUKEMIA VIRUS ENHANCER
 FACTOR ;contains MER22 repetitive element ;, mRNA sequence

45 gi|1064703|gb|H84982.1|H84982[1064703]
 GCTCCCCAGTGGTCAGCGGAGACCCCAAGGAGGATCACAACCTACAGCAGTGCCA
 AGTCCTCCAACGCCCGGAGCACCTCGCCACACGACTCCATCTCCTCCTCCTC
 CTCCTCAGCCGACGACCACTATGAGTTTGCCACCAAGGGGAGCCAGGAGGGCAG
 CGAGGGCAGCGAGGGGAGCTTCCGGAGCCACGAGAGCCCCAGCGACACGGAAG

AGGACGACAGGAAGNACAGCCAGAAGGAGCCCAAGGATTTTTTNGGGGACAGC
GGGTACGATTNCC

SEQ ID NO: 672

5 yq55b04.r1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:199663 5'
similar to SP:SISD_HUMAN P13501 T-CELL SPECIFIC RANTES PROTEIN
PRECURSOR ;, mRNA sequence gi|982328|gb|R96668.1|R96668[982328]
NCGCCCAGGAGTCTCTCGGCCAGCCCTGCCTGCCACCAGGAGGATGAAGGTCTC
CGTGGCTGCCCTCTCCTGCCTCATGCTTGTTGCTGTCCTTGGATCCCAGGCCAGT
10 TCACAAATGATGCAGAGACAGAGTTAATGATGTCAAAGCTTCCACTGGAAAATC
CAGTAGTTCTGAACAGCTTTCCTTTGCTGCTGACTGCTGCACCTCCTACATCTCA
CAAAGCATCCCGTGTTCATCATGAAAAGTTATTTTGAAACGAGCAGCGAGTGCT
CCAAGCCAGGGTGTTCATATTCCTCACCAAGAAGGGGCGGCAAGTCTGTGCCAAA
CCCAGTGGGTCCGGGAGTTCAGGATTGGCATGGAAAAAGCTTNAAGCCCTAATT
15 CAATATTANTAATTAAGGAGGACANAAGAGGGCCAGCNCACCCACCTCCAACA
CTTCNTGAGGCTTTGGAAGG

SEQ ID NO: 673

20 zt20b07.s1 Soares ovary tumor NbHOT Homo sapiens cDNA clone IMAGE:713653 3'
similar to TR:G577291 G577291 MRNA ;contains element MER28 repetitive element ;,
mRNA sequence
gi|1928812|gb|AA284495.1|AA284495[1928812]
CCGCCTCCTTTGCCGGGTACACCTGGCCCAAGAGACCTTCAGCACCGTGTGCA
CTTCTCAAAGATAGACCGGGGCATAGCCTGAAAGCATATTGAAAATGACGAAAA
25 AAGGGAAGACTCTCATGATGTGTGCTCACTGTATCAGGAAGCCCTACTGAGAAGG
AGACAGAGGAAATTACGAGCCTCTGGGAGGGCAGCCTTTTCAATGCCAACTATG
ACGTCCAGAGGTTTATTGTGGGATCAGACCGTGCTATCTTCATGCTTCGCGATGG
GAGCTACGCCTGGGAGATCAAGGACTTTTTGGTCCGGTCAAGACAGGTGTGCTGAT
GTAACCTCTGGAGGGCCAGGTGTACCCCGGCCAA GGAGGAGGAA

30

SEQ ID NO: 674

>L01639

CGCATCTGGAGAACCAGCGGTTACCATGGAGGGGATCAGTATATACACTTCAGA
TAACTACACCGAGGAAATGGGCTCAGGGGACTATGACTCCATGAAGGAACCTG
35 TTTCCGTGAAGAAAATGCTAATTTCAATAAAATCTTCCTGCCACCATCTACTCC
ATCATCTTCTTAACTGGCATTGTGGGCAATGGATTGGTCATCCTGGTCATGGGTT
ACCAGAAGAACTGAGAAGCATGACGGACAAGTACAGGCTGCACCTGTCACTGG
CCGACCTCCTCTTTGTACACGCTTCCCTTCTGGGCAGTTGATGCCGTGGCAAACCT
GGTACTTTGGGAACCTTCTATGCAAGGCAGTCCATGTCATCTACACAGTCAACCT
40 CTACAGCAGTGTCTCATCTGGCCTTCATCAGTCTGGACCGCTACCTGGCCATC
GTCCACGCCACCAACAGTCAGAGGCCAAGGAAGCTGTTGGCTGAAAAGGTGGTC
TATGTTGGCGTCTGGATCCCTGCCCTCCTGCTGACTATCCCGACTTCATCTTTGC
CAACGTCAGTGAGGCAGATGACAGATATATCTGTGACCGCTTCTACCCCAATGAC
TTGTGGGTGGTTGTGTTCCAGTTTCAGCACATCATGGTTGGCCTTATCCTGCCTGG
45 TATTGTCATCCTGTCTGCTATTGCATTATCATCTCCAAGCTGTCACACTCCAAGG
GCCACCAGAAGCGCAAGGCCCTCAAGACCACAGTCATCCTCATCCTGGCTTTCTT
CGCCTGTTGGCTGCCTTACTACATTGGGATCAGCATCGACTCCTTCATCCTCCTGG
AAATCATCAAGCAAGGGTGTGAGTTTGAGAACACTGTGCACAAGTGGATTTCCTCA
TCACCGAGGCCCTAGCTTTCTTCCACTGTTGTCTGAACCCCATCCTCTATGCTTTC

CTTGGAGCCAAATTTAAACCTCTGCCCAGCACGCACTCACCTCTGTGAGCAGAG
GGTCCAGCCTCAAGATCCTCTCCAAAGGAAAGCGAGGTGGACATTCTGTTC
CACTGAGTCTGAGTCTTCAAGTTTTCACTCCAGCTAACACAGATGTAAAAGACTT
TTTTTTTATACGATAAAATAACTTTTTTTTAAAGTTACACATTTTTCAGATATAAAAG
5 ACTGACCAATATTGTACAGTTTTTATTGCTTGTGGATTTTTGTCTTGTGTTTCTTT
AGTTTTTGTG

SEQ ID NO: 675

> Human tumor necrosis factor receptor 2 (TNFR2) gene, exon 10 and complete cds

10 gi|1469539|gb|U52165.1|HSTNFR2S10[1469539]
TCTTGGTCTCGGCTCCTGGCCCAGTGCTCTTTCCCATGTGTCTGAATCTGCATCTT
GGGCAGGGGTCCCTGGGCCCCACTCCTGGACCCCCGGACTGACCCCCACCCCATC
TTGTGCTTAGCAGATTCTTCCCCTGGTGGCCATGGGACCCAGGTCAATGTCACCT
GCATCGTGAACGTCTGTAGCAGCTCTGACCACAGCTCACAGTGCTCCTCCCAAGC
15 CAGCTCCACAATGGGAGACACAGATTCCAGCCCCTCGGAGTCCCCGAAGGACGA
GCAGGTCCCCTTCTCCAAGGAGGAATGTGCCTTTCGGTCACAGCTGGAGACGCCA
GAGACCCTGCTGGGGAGCACCGAAGAGAAGCCCCTGCCCCTTGGAGTGCCTGAT
GCTGGGATGAAGCCCAGTTAACCAGGCCGGTGTGGGCTGTGTCTAGCCAAGGT
GGGCTGAGCCCTGGCAGGATGACCCTGCGAAGGGGCCCTGGTCCTTCCAGGCC
20 CCACCACTAGGACTCTGAGGCTCTTCTGGGCCAAGTTCCTCTAGTGCCTCCAC
AGCCGCAGCCTCCCTCTGACCTGCAGGCCAAGAGCAGAGGCAGCGAGTTGGGGA
AAGCCTCTGCTGCCATGGTGTGTCCCTCTCGGAAGGCTGGCTGGGCATGGACGTT
CGGGGCATGCTGGGGCAAGTCCCTGACTCTCTGTGACCTGCCCCGCCAGCTGCA
TCTGCTGCCAGCCTGGCTTCTGGAGCCCTTGGGTTTTTTGTTTGTGTTGTTTGTG
25 TTTGTTTCTCCCCCTGGGCTCTGCCCAGCTCTGGCTTCCAGAAAACCCACGATCC
TTTTCTGCAGAGGGGCTTTCTGGAGAGGAGGGATGCTGCCTGAGTCACCCATGAA
GACAGGACAGTGCTTCAGCCTGAGGCTGAGACTGCGGGATGGTCCTGGGGCTCT
GTGTAGGGAGGAGGTGGCAGCCCTGTAGGGAACGGGGTCCTTCAAGTTAGCTCA
GGAGGCTTGGAAAGCATCACCTCAGGCCAGGTGCAGTGGCTCACGCCTATGATC
30 CCAGCACTTTGGGAGGCTGAGGCGGGTGGATCACCTGAGGTTAGGAGTTCGAGA
CCAGCCTGGCCAACATGGTAAAACCCCATCTCTACTAAAAATACAGAAATTAGC
CGGGCGTGGTGGCGGGCACCTATAGTCCCAGCTACTCAGAAGCCTGAGGCTGGG
AAATCGTTTGAACCCGGGAAGCGGAGGTTGCAGGGAGCCGAGATCACGCCACTG
CACTCCAGCCTGGGCGACAGAGCGAGAGTCTGTCTCAAAAGAAAAAAAAAAAAA
35 GCACCGCCTCCAAATGCTAACTTGTCTTTGTACCATGGTGTGAAAGTCAGATG
CCCAGAGGGCCCAGGCAGGCCACCATATTCAGTGCTGTGGCCTGGGCAAGATAA
CGCACTTCTAACTAGAAATCTGCCAATTTTTTAAAAAAGTAAGTACCACTCAGGC
CAACAAGCCAACGACAAAGCCAAACTCTGCCAGCCACATCCAACCCCCACCTG
CCATTTGCACCCTCCGCCTTCACTCCGGTGTGCCTGCAGCCCCGCGCCTCCTCCT
40 TGCTGTCTTAGGCCACACCATCTCCTTTCAGGGAATTCAGGAACTAGAGATGAC
TGAGTCCTCGTAGCCATCTCTCTACTCCTACCTCAGCCTAGACCCCTCCTCCTCCCC
CAGAGGGGTGGGTTCCTCTTCCCCACTCCCACCTTCAATTCCTGGGCCCCAAAC
GGGCTGCCCTGCCACTTTGGTACATGGCCAGTGTGATCCCAAGTGCCAGTCTTGT
GTCTGCGTCTGTGTTGCGTGTCTGGGTGTGTGTAGCCAAGGTCGGTAAGTTGAA
45 TGGCCTGCCTTGAAGCCACTGAAGCTGGGATTCTCCTCCCATTAGAGTCAGCCTTC
CCCCTCCAGGGCCAGGGCCCTGCAGAGGGGAAACCAGTGTAGCCTTGCCCGGA
TTCTGGGAGGAAGCAGGTTGAGGGGCTCCTGGAAAGGCTCAGTCTCAGGAGCAT
GGGGATAAAGGAGAAGGCATGAAATTGTCTAGCAGAGCAGGGGCAGGGTGATA
AATTGTTGATAAATTCCACTGGACTTGAGCTTGGCAGCTGAACTATTGGAGGGTG

GGAGAGCCCAGCCATTACCATGGAGACAAGAAGGGTTTTCCACCCTGGAATCAA
GATGTCAGACTGGCTGGCTGCAGTGACGTGCACCTGTACTCAGGAGGCTGAGGG
GAGGATCACTGGAGCCCAGGAGTTTGAGGCTGCAGCGAGCTATGATCGCGCCAC
TACACTCCAGCCTGAGCAACAGAGTGAGACCCTGTCTCTTAAAGAAAAAAAAAAG
5 TCAGACTGCTGGGACTGGCCAGGTTTCTGCCACATTGGACCCACATGAGGACAT
GATGGAGCGCACCTGCCCCCTGGTGGACAGTCCTGGGAGAACCTCAGGCTTCCTT
GGCATCACAGGGCAGAGCCGGGAAGCGATGAATTTGGAGACTCTGTGGGGCCTT
GGTTCCCTTGTGTGTGTGTGTGATCCCAAGACAATGAAAGTTTGCAGTGTATGC
TGGACGGCATTCTGCTTATCAATAAACCTGTTTGTTTTAAAAAAA

10

SEQ ID NO: 676

>R88734

ANNTNANATTCCATTGAAGGTATTATTTATTTGCAGCTCATCTTAAGTGACAAAA
TTCCATACAGAAGACTATAACAGAAATCATATTTAATATATTAAATTAATACTT
15 CAAATATCTTTCACATTANGATGATTATCTATTGTGTAAATCTTTCCTAGGTATGT
GTGTCTGTTTCTTGATGTGTAAACCAAACTCTGAAATATTCTCTTGATCTAACTT
TGACTTTTAAAACTGACATTGTATTGAATTTACATAATTCTCAATCAGAAAAAA
AATTACTGTCAGACTGCAATGCA AGTCTGCCCCAATGAAGGCCG

20 SEQ ID NO: 677

>AA418689

ATGAAAGTTGAATATTTTATTATTTACACATATAAAGTGAGAATGAAAATTGGGGCA
ATGGGGCAAGGGCAGGAAGATGACTCCAGCTCAGTCGGTGATGATGAGCTCGTCC
ACCCGCCAGTCTTCATAGCTCCCATCTGGCAGGTAACGGCGAATGATGATGGGGCA
25 TCTTTCGGGGCCTTGAGTTCCTTCATGGCAATGAGCAGAGGATCTGTCTCCGCCTCC
AGCTCCACCATCACAGGGGCACACATCGCAATCTGGAGCGCTCGGGTGCCCAGC
ACGCGGGCTCGCTCGTACTTGGTCATGTATGGTGTGGTGATTCTGCTTCTGGTTGG
CCTGCGGTCGCTCCCCAGAGGAGGNAGTCTCGACATTCTCCTGGCCTTCCTCTTC
GGCATTCTCCAAGTCATCTAGCCCTTCATCCTCCTC

30 CACATCATCAGAGTCGTCGCCATCAAA

SEQ ID NO: 678

>AA455281

TTTTTGGAGGAGTGGCATGGAGTTCCTTTAATTTGGAAGGCAAAAGGTTACATTTA
35 ATGAAAGGCAGAGGCTGGATTAATAAATGTTTGTAGAAAGTTGTTCTGACACAC
AGTGAACCTCTGGGCTTTTCTCCTGCATAAAAAGCAGAGCTAGCAGTAAGTGCAA
ATCTGAAGAAAATCCATGTGTCCAATAAGCTGCCATCTCCAGAACTCTTATCCAG
GAAATTCAAAGAGTGAACATTCTTTTAGTCTCCTACTCCTCAATTAAGTAAATGA
GAATGAGTCAGCCAACAAAGTTCATGACAACAAGGTGCAGGATGGTGCTGGCAA
40 AGAGAAAATCAGCAAAGGCTCGCTCTGGGGAGATGCCTTGGAATCCGCTTTGT
TCTGTGGGTTGATCTGTATTCTCAGGCAAACCGCTAGGATGAAACTCCCCACACA
AGAGATGAAGCCCGAGAGAAAAGAGTTGAAGGGGAAGGTCCC

SEQ ID NO: 679

45 >H94469

GCAAAACAACATTTATTCTTTTAAAAAATCTATATACATTGCCATACAAAGATAC
CACATTGAAGCAGTTCTCAGGAACCTTCCAGTGAGCCTTCTCTTATAATTGCCCCG
AGCAAGATTTCTGTGCCAGAGAAAGTCTCAGCATTTCACCTTGGTGTNCTCTATG
TCATCATCCTGGAGCTGCTCGGTATCAGATTCTCCATGCACAGGTCTTCTTGACGT

CAAGTCCTCCAGACACCGCATCAACTCATAAGTCTGTTCTGCTGAGAAAATCACC
TGTTCCTGTTCCAAAAGGGGCAAGGCATCTGTCAGCAGAGTTCATCCCAGAAAGA
CCGAAGGGGCAATCCGAGACGTCATCAAG GACAGAAGGA

5 SEQ ID NO: 680

aa79c05.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:827144 3' similar to
SW:RLX1_HUMAN P49406 PUTATIVE 60S RIBOSOMAL PROTEIN;; mRNA sequence
gi|2261786|gb|AA521243.1|AA521243[2261786]

TTTTTTTTTGGTGTACAAGTTTTATTTTAGAAAAAAAGTATTAATAAAACAATGA
10 ATGCTTAGTTCACCTTAATTACTATGTTCTTATAAATGAAATTAATTTGGTCTCAAA
ATATATCCTCTTAGAGCCAATGTATCTTCTGCAACTAACCAAATTCATTCTCAGA
ATCAAGACCTTTTCGACGCTTCAATTTCTTCCATATTGCAGCTTCAATTTTGA
GTATCATATTCCTCATCATATCAAATTCAAGCCATGGACTGATTCCACTTCTGAG
CTTCTTTCATTTGCTGTTTCAGTTAAACAAAGATCAAATCTGATTCTTTAATATTA
15 AAATTTGGACGTTCCCAGCGTTTAGACCAGGGCTTAGGCTTCATTTTACTTTTCAG
CTCATTAACAGGAACTTTTTGGTTAGGCTCTTGTACTACTGGCTTCATATTCACAT
CAAAAGTGCTATATTCAGGAAGGGCATCTCGTAAGTATAGCAAGCTATCATCCA
GCCGTTTCTCTAATTTGACCACCTGAATCTCCTGGACCCGAGGATTATAAAGTTC
AAAGCAAATCTCGACACCTTGTCTTCGATAACATTCCTAAGGAT GAAAGTAGC

20

SEQ ID NO: 681

Human Thy-1 glycoprotein gene, complete cds
gi|339682|gb|M11749.1|HUMTHY1A[339682]

GGATCCAGGACTGAGATCCCGAGAACCATGAACCTGGCCATCAGGATCGCTCTCCT
25 GCTAACAGGTACCCGGCATGGGGCAGGACTGGGGCTCCAGGCGCCCTGGCTTCC
TTCCCTCCAGAGAAGCAGCTTCTCCCTCACAGTCTCAGAAAAGCGCAGGTGACAA
AGAGAGGGGCTCTTTTTCATCCTGAAGTCAGCCGATCCACCGCGCTGATATTCTGA
CGGCCTGAGGTGGTTTTTGGAAACACAGTTTGCTGAGCCCTCCTTCACACTATTG
AACTAGAATCCCCAACTGAGAACCCAGGAACCCAGCATCAACTCCCTAAGATCTC
30 CTGTCCTTGAAACACATTGATAGGATCCAAGGCTCAAGCAGAGTGGGGAGGGAG
GCTGGGGTCTGCAAAGGAGAAGTGGGATCCCTGGGGTG421GGGAAAGGCACTC
AGAGAGCAGACCCCGGTCCCTCCCTAGCCAGGCCATCTCTCCACTTCAGGTGG
GTGGGAGGGCCCTGTGCCGAGGCCCTCCAGTTTGAAGGAGGCCTGCTGGTG
CCAGTCTTGCAAGTCTCCCGAGGGCAGAAAGGTGACCAGCCTAACGGCCTGCCTA
35 GTGGACCAGAGCCTTCGTCTGGACTGCCGCCATGAGAATACCAGCAGTTCACCCA
TCCAGTACGAGTTCAGCCTGACCCGTGAGACAAAGAAGCACGTGCTCTTTGGCAC
TGTGGGGGTGCCTGAGCACACATACCGCTCCCGAACCAACTTCACCAGCAAATA
CCACATGAAGGTCTCTACTTATCCGCTTCACTAGCAAGGACGAGGGGCACCTAC
ACGTGTGCACTCCACCACTCTGGCCATTCCCCACCCATCTCCTCCCAGAACGTCA
40 CAGTGCTCAGAGGTGAGACAAGCCCCTAACAAGGTCAAGTGAGCTGGGAGAGCC
AGGCTCGGGGACAGCAGGCAGTTCCTTGGCTGGACTAGAGAGGAGAATAGCCC
CATAACGCTCTCACCTCTCCCAACTGCTGCCTGGTCAACTGGGGAACCATTTGCC
TTCGGTGTGAATGGGGTGAAGAGCTCAGGGCCAGACAGGCAGAGCAGTGTGGTT
CCACCAGAACTGTGGGCAAGGCCTTTGGCCCCTAATCTTCCTTCTCCAGCGGGA
45 AACAGGGATGACACCACCTCCCTCAGCCAGTTTTCTTGTTCATGATGTTTAGTAAG
GTTTTTCATAAGATGATATGTGTGCAAGAGATCAGTAATCTGCAAATGGGAAAGA
TGGCTGGTTCTGTGAGACCAGGCTGTTCTTGGTCCCAGCTAAGACATTGCAGTAC
CCACCTCCCAAAGGGAGTACACCCTTGCTTTGGGCCTGTGCCTGCCTGAGTCCTG
ATCCGTCTTCCTTCTACCCTGCCCCCGCCCCCTTCTCTTCTGCAGACAAACTG

GTCAAGTGTGAGGGCATCAGCCTGCTGGCTCAGAACACCTCGTGGCTGCTGCTGC
 TCCTGCTGTCCCTCTCCCTCCTCCAGGCCACGGATTTCATGTCCCTGTGACTGGTG
 GGGCCCATGGAGGAGACAGGAAGCCTCAAGTTCCAGTGCAGAGATCCTACTTCT
 CTGAGTCAGCTGACCCCCTCCCCCAATCCCTCAAACCTTGAGGAGAAGTGGGGA
 5 CCCCACCCCTCATCAGGAGTTCCAGTGTGCATGCGATTATCTACCCACGTCCAC
 GCGGCCACCTCACCCCTCTCCGCACACCTCTGGCTGTCTTTTTGTACTTTTTGTTCC
 AGAGCTGCTTCTGTCTGGTTTATTTAGGTTTATCCTTCCTTTTCTTTGAGAGTTTCG
 TGAAGAGGGAAGCCAGGATTGGGGACCTGATGGAGAGTGAGAGCATGTGAGGG
 GTAGTGGGATGGTGGGGTACCAGCCACTGGAGGGGTCATCCTTGCCCATCGGGA
 10 CCAGAAACCTGGGAGAGACTTGGATGAGGAGTGGTTGGGCTGTGCTGGGCCTAG
 CACGGACATGGTCTGTCCTGACAGCACTCCTCGGCAGGCATGGCTGGTGCCTGAA
 GACCCAGATGTGAGGGCACCACCAAGAATTTGTGGCCTACCTTGTGAGGGAGA
 GAACTGAGGATCTCCAGCATTCTCAGCCACAACCAAAAAAAAAAATAAAAGGGCA
 GCCCTCCTTACCACTGTGGAAGTCCCTCAGAGGCCTTGGGGCATGACCCAGTGAA
 15 GATGCAGGTTTGACCAGGAAAGCAGCGCTAGTGGAGGGTTGGAGAAGGAGGTA
 AAGGATGAGGGTTCATCATCCCTCCCTGCCTAAGGAAGCTAAAAGCATGGCCCT
 GCTGCCCTCCCTGCCTCCACCCACAGTGGAGAGGGCTACAAAGGAGGACAAGA
 CCCTCTCAGGCTGTCCCAAGCTCCCAAGAGCTTCCAGAGCTCTGACCCACAGCCT
 CCAAGTCAGGTGGGGTGGAGTCCCAGAGCTGCACAGGGTTTGGCCCAAGTTTCT
 20 AAGGGAGGCACTTCCTCCCTCGCCCATCAGTGCCAGCCCTGCTGGCTGGTGCC
 TGAGCCCTCAGACAGCCCTCGCCCGCAGGCCTGCCTTCTCAGGGACTTCTGC
 GGGGCTGAGGCAAGCCATGGAGTGAGACCCAGGAGCCGGACACTTCTCAGGAA
 ATGGCTTTTCCCAACCCCCAGCCCCCAGCCGGTGGTTCTTCCTGTCTGTGACTGT
 GTATAGTGCCACCAACAGCTTATGGCATCTCATTGAGGACAAAGAAACTGCACA
 25 AATAAAACCAAGCCTCTGGAATCTGTCTCGTGTCCACCTGGCCTTCGCTCCTCCA
 GCAGTGCCTGCCTGCCCCCGCTT

SEQ ID NO: 682

yw08h11.s1 Soares melanocyte 2NbHM Homo sapiens cDNA clone IMAGE:251685 3',
 mRNA sequence gi|1110224|gb|H96738.1|H96738[1110224]

TAAAAANAAATCTTTTTTTTATTTCAAAGATTGCTTCTTATATTGAAGCTCATATTA
 AAGCAACAGTACAATGTTTATAAAATATAAGTGTGATGCCGTAACATTTTCTTAC
 ATGTCAGAATACTGATATTTATATGTATACTAAATAAGAACTTAAATTTGTAC
 AAATAGATACATTAATAATGACATAGAAATAGGGCGTCTCTCACTGAAACAAGA
 35 CAGTTATATCTGGCACGTATTAGTTTAAGATGAAAGTAGAAGCAAAAAGATTTAC
 AAGAATCAGCAGTAACAAGATTGATGCTCAAGAGACATAATTGTACATTGTATT
 GTACATACATTGTATGGGTTTAAGCTGGCTGGAATATTATATATTTCCAAGTTTAA
 AAAATGGCNCTACCANATAGAGTGGTCCNGAGTTTAAGGCGAAATTACAGCTCA
 GAACTGTTGTCCCTTCNAATTTTGGTGG

40

SEQ ID NO: 683

Human integral membrane serine protease Seprase mRNA, complete cds
 gi|1924981|gb|U76833.1|HSU76833[1924981]

CCACGCTCTGAAGACAGAATTAGCTAACTTTCAAAAACATCTGGAAAAATGAAG
 45 ACTTGGGTAAAAATCGTATTTGGAGTTGCCACCTCTGCTGTGCTTGCCTTATTGGT
 GATGTGCATTGTCTTACGCCCTTCAAGAGTTCATAACTCTGAAGAAAATACAATG
 AGAGCACTCACACTGAAGGATATTTTAAATGGAACATTTTCTTATAAAACATTTT
 TTCCAAACTGGATTTTCAGGACAAGAATATCTTCATCAATCTGCAGATAACAATAT
 AGTACTTTATAATATTGAAACAGGGCAATCATATACCATTTTGAGTAATAGAACC

ATGAAAAGTGTGAATGCTTCAAATTACGGCTTATCACCTGATCGGCAATTTGTAT
 ATCTAGAAAAGTGATTATTCAAAGCTTTGGAGATACTCTTACACAGCAACATATTA
 CATCTATGACCTTAGCAATGGAGAATTTGTAAGAGGAAATGAGCTTCCTCGTCCA
 ATTCAGTATTTATGCTGGTCGCCTGTTGGGAGTAAATTAGCATATGTCTATCAAA
 5 ACAATATCTATTTGAAACAAAGACCAGGAGATCCACCTTTTCAAATAACATTTAA
 TGGAAGAGAAAATAAAATATTTAATGGAATCCCAGACTGGGTTTATGAAGAGGA
 AATGCTTGCTACAAAATATGCTCTCTGGTGGTCTCCTAATGGAAAATTTTGGCA
 TATGCGGAATTTAATGATACGGATATACCAGTTATTGCCTATTCTATTATGGCG
 ATGAACAATATCCTAGAACAATAAATATTCCATACCCAAAGGCTGGAGCTAAGA
 10 ATCCCGTTGTTTCGGATATTTATTATCGATACCACTTACCCTGCGTATGTAGGTCCC
 CAGGAAGTGCCTGTTCCAGCAATGATAGCCTCAAGTGATTATTATTTAGTTGGC
 TCACGTGGGTTACTGATGAACGAGTATGTTTGCAGTGGCTAAAAAGAGTCCAGA
 ATGTTTCGGTCCTGTCTATATGTGACTTCAGGGAAGACTGGCAGACATGGGATTG
 TCCAAAGACCCAGGAGCATATAGAAGAAAGCAGAACTGGATGGGCTGGTGGATT
 15 CTTTGTTCACACCAGTTTTTCAGCTATGATGCCATTTCTGACTACAAAATATTTA
 GTGACAAGGATGGCTACAAACATATTTCACTATATCAAAGACACTGTGGAAAATG
 CTATTCAAATTACAAGTGGCAAGTGGGAGGCCATAAATATATTCAGAGTAACAC
 AGGATTCAGTGTTCATTCTAGCAATGAATTTGAAGAATACCTTGAAGAAGAAA
 CATCTACAGAATTAGCATTGGAAGCTATCCTCCAAGCAAGAAGTGTGTTACTTGC
 20 CATCTAAGGAAAGAAAGGTGCCAATATTACACAGCAAGTTTCAGCGACTACGCC
 AAGTACTATGCACTTGTCTGCTACGGCCCAGGCATCCCCATTTCCACCCTTCATG
 ATGGACGCACTGATCAAGAAATTAATAATCCTGGAAGAAAACAAGGAATTGGAAA
 ATGCTTTGAAAATATCCAGCTGCCTAAAGAGGAAATTAAGAACTTGAAAGTAG
 ATGAAATTACTTTATGGTACAAGATGATTCTTCCTCCTCAATTTGACAGATCAAA
 25 GAAGTATCCCTTGCTAATTCAAGTGTATGGTGGTCECTGCAGTCAGAGTGTAAGG
 TCTGTATTTGCTGTTAATTGGATATCTTATCTTGCAAGTAAGGAAGGGATGGTCA
 TTGCCTTGGTGGATGGTTCGAGGAACAGCTTTCCAAGGTGACAACTCCTCTATGC
 AGTGTATCGAAAGCTGGGTGTTTATGAAGTTGAAGACCAGATTACAGCTGTCAG
 AAAATTCATAGAAATGGGTTTCATTGATGAAAAAAGAATAGCCATATGGGGCTG
 30 GTCCTATGGAGGATACGTTTCATCACTGGCCCTTGCATCTGGAAGTGGTCTTTTCA
 AATGTGGTATAGCAGTGGCTCCAGTCTCCAGCTGGGAATATTACGCGTCTGTCTA
 CACAGAGAGATTTCATGGGTCTCCCAACAAAGGATGATAATCTTGAGCACTATAA
 GAATTCAACTGTGATGGCAAGAGCAGAATATTTGAGAAATGTAGACTATCTTCTC
 ATCCACGGAACAGCAGATGATAATGTGCACTTTTCAGAACTCAGCACAGATTGCT
 35 AAAGCTCTGGTTAATGCACAAGTGGATTTCCAGGCAATGTGGTACTCTGACCAGA
 ACCACGGCTTATCCGGCCTGTCCACGAACCACTTATACACCCACATGACCCACTT
 CCTAAAGCAGTGTTTCTCTTTGTGCACTAAAAACGATGCAGATGCAAGCCTGTA
 TCAGAATCTGA

40 SEQ ID NO: 684

zw83d07.s1 Soares_testis_NHT Homo sapiens cDNA clone IMAGE:782797 3', mRNA
 sequence gi|2161864|gb|AA448194.1|AA448194[2161864]

TTTTTTTTAAAAAAAATTAATATTTTTTATTATATACTTTTAAACATATAGAAGA
 TAGAAAAAACAGTACAATGAACAGCCATGTCCACCAGTTAGATTCTGTAACAT
 45 TTTGCCACATACGCCTCACATACATTTTGTAAACCATTTGAAACATTTTAAGACA
 CTCTAACACTTCATTCTAAATGCTTAAGTATGCAAATTAAGACAGTCTTTTATAA
 ACTACAACACCCTTCTCACAGCTCATAAAATTACCAATAATTATCCAATATCATT
 CAAAATCTAATCCACATTCAAATTTTCTCAACTGCCTCACCACCGTGCTGGCCTCC

CACCCCCACCTCAGTCTTTTACAGATGGTTTTTCAAATAGAGTCCAGTAAAATA
TTTCACATTGCATTGGTTATTACATAACTTT TAATCAAGAAGAGTTAC

SEQ ID NO: 685

5 Human gene for preproenkephalin gi|31150|emb|V00509.1|HSENK1[31150]
CCGACCCCTCCCGCGAAGGCGTCGGCGCGGGGCTGGCGTAGGGCCTGCGTCAGC
TGCAGCCCGCGGCGATTGGGGCGCGCGCGCCTCCTTCGGTTTGGGGCTAATTAT
AAAGTGGCTCCAGCAGCCGTTAAGCCCCGGGACGGCGAGGCAGGCGCTCAGAGC
CCCGCAGCCTGGCCCGTGACCCCGCAGAGACGCTGAGGACCGCGACGGTGAGGC
10 CCTACGTCCGCCAGCACACCCGGGCCCCGCTTCTCCCCGACGCCCGCCCTCCTCAC
ACTTGCTTCTTCTTCCCTCTAGAGTCGTGTCTGAACCCGGCTTTTCCAATTGG
CCTGCTCCATCCGAACAGCGTCAACGTGAGTGAATTTGCCCGAAGCTTGTCTTTG
CTGAGCGGGTTTGGGGACGTCTGCCCGCCCTCTTCCCTTCACATTTCAATTGCATG
GGTTCCCCAACAGCGTTCCCTGGTTCTTCTTTGTGACCCCAAGTCAATGTCTGCCT
15 CCCCCGGCTCCCGCTCTCTCGCCCCCTGGTCTGCGGCGTTCTCTCCGGAATCTTGCC
CTGGGCGCGGACGCCCAGGAAAAGAGCCGGGTGCCCCAGGCAGCCTCGCGTTG
GGGGCGACCGCGCCATCCCGGGAACCGCGAGGCGATCTGAGTCGCTCCACGTC
TACCTAAAAGCTGTGCGCCGGGAGGGCGGGGCCCCAGAAAGGAGCATTCTGCG
GGCTTTTGCTCGACGATCCCCTGCTGAGGCTGTGCGGCGAGGGTCTGCCGAGG
20 GACCCCGTTCTGCGCCCAGGCAGGCTCGAAGCACGCGTCCCTCTCTCTCGCAGT
CCATGGCGCGGTTCTTGACACTTTGCACTTGGCTGCTGTTGCTCGGCCCCGGGT
TCCCTGGCGACCGTGCGGGCGCAATGCAGCCAGGATTGCGCGACGTGCAGTACCG
TCTAGTGCGCCCGGCCGACATCAACTTCTGGTGAGTGTGCGCGCGGGGAGTGT
TGCACCTTGTGAGACAGAGTTTCGG

SEQ ID NO: 686

yi26g12.s1 Soares placenta Nb2HP Homo sapiens cDNA clone IMAGE:140422 3', mRNA
sequence gi|838397|gb|R65759.1|R65759[838397]

30 AAAATTTTTNTACCGTATTTATTGGTTCAAAAAGTCTAGTATTTATAGTTTCAGGCA
GATTTCAACCAAAGAGTCACCAAATTAATAACACAGGGTAGCTTGTGAGGCATA
GACACAGCCCATGTGTTTTCTCTACATTGTATATTCATTTCTCTTTGGCGATTTG
ACATTATAGCCATTCTCTGGAAGTCCTAAAGCAAAGTCTAGTATTTTATGTGCCATA
TTAAGTTAAAATTTCTTATGTGAGGATACCACTAATACTGGGTTTGGATTAGGG
CCATCCTTCTTGCCGGGGGGTATGGACAATGGGGGGCTTGTTTCTATGGATTAAG
35 GNCCCTACCCCTGGGGCCAGGTGNTATGGGGGNATTGTTAAAACCATGGCCATT
ATTATGGTGGGGGGCCAACCCCCACCCNTGGAAG GGA

SEQ ID NO: 687

>R91550

40 GGAGGATGTGGGCCACGCAGGGCTGGCGGTGGCGCTGGCTCTGAGCGTGCTGCC
GGGCACCGGGCGCTGCGGCCGGGCGACTGCGAAGTTTGTATTTCTTATCTGGGAA
GATTTTACCAGGACCTCAAAGACAGAGATGTACATTCTCACCAGCCACTATTGA
AAACGAACTTATAAAGTTCTGCCGGGAAGCAAGAGGCAAAGAGAATCGGTTGTG
CTACTATATCGGGGCCACAGATGATGCAGCCACCAAAATCATCAATGAGGTATC
45 AAAGCCTCTGGCCCCACCACATCCCTGTGGGAGAAGATCTGTGAGAAGCTTAAG
GAAGAAGGACAGCCAGATATGTGAGCTTAAGTAT GGACAAGCAGATCC

SEQ ID NO: 688

>M94054

GGGCGTGATTTGAGCCCCGTTTTTATTTTCTGTGAGCCACGTCCTCCTCGAGGGG
GTCAATCTGGCCAAAAGGAGTGATGCGCTTCGCCTGGACCGTGCTCCTGCTCGGG
CCTTTGCAGCTCTGCGCGCTAGTGCACTGCGCCCCTCCCGCCGCCGGCCAACAGC
AGCCCCCGCGGAGCCGCCGGCGGCTCCGGGCGCCTGGCGCCAGCAGATCCAAT
5 GGGAGAACAAACGGGCAGGTGTTACGCTTGCTGAGCCTGGGCTCACAGTACCAGC
CTCAGCGCCGCCGGGACCCGGGCGCCGCCGTCCCTGGTGCAGCCAACGCCTCCG
CCCAGCAGCCCCGCACTCCGATCCTGCTGATCCGCGACAACCGCACCGCCGCGGG
GCGAACGCGGACGGCCGGCTCATCTGGAGTCACCGCTGGCCGCCCCAGGCCAC
CGCCCGTCACTGGTTCCAAGCTGGCTACTCGACATCTAGAGCCCGCGAACGTGGC
10 GCCTCGCGCGCGGAGAACCAGACAGCGCCGGGAGAAGTTCCTGCGCTCAGTAAC
CTGCGGCCGCCAGCCGCGTGGACGGCATGGTGGGCGACGACCCTTACAACCCC
TACAAGTACTCTGACGACAACCTTATTACAATACTACTACGATACTTATGAAAGGC
CCAGACCTGGGGGCAGGTACCGGCCCGGATACGGCACTGGCTACTTCCAGTACG
GTCTCCCAGACCTGGTGGCCGACCCCTACTACATCCAGGCGTCCACGTACGTGCA
15 GAAGATGTCCATGTACAACCTGAGATGCGCGGCGGAGGAAAACCTGTCTGGCCAG
TACAGCATACAGGGCAGATGTCAGAGATTATGATCACAGGGTGCTGCTCAGATTT
CCCCAAAGAGTGAAAAACCAAGGGACATCAGATTTCTTACCCAGCCGACCAAGA
TATTCCTGGGAATGGCACAGTTGTCATCAACATTACCACAGTATGGATGAGTTTA
GCCACTATGACCTGCTTGATGCCAACACCCAGAGGAGAGTGGCTGAAGGCCACA
20 AAGCAAGTTTCTGTCTTGAAGACACATCCTGTGACTATGGCTACCACAGGCGATT
TGCATGTACTGCACACACAGGGATTGAGTCCTGGCTGTTATGATACCTATGGT
GCAGACATAGACTGCCAGTGGATTGATATTACAGATGTAAAACCTGGAAACTAT
ATCCTAAAGGTCAGTGTAACCCAGCTAGCTGGTTCCTGAATCTGACTATAGCA
ACAATGTTGTGCGCTGTGACATTCGCTACACAGGACATCATGCGTATGGCTCAGG
25 CTGCACAATTTACCGTATTAGAAGGCAAAGCAAAACCTCCAATGGATAAATCA
GTGCCTGGTGTCTGAAGTGGGAAAAAATAGACTAACTTCAGTAGGATTTATGTA
TTTTGAAAAAGAGAACAGAAAACAACAAAAGAATTTTTGTTTGGACTGTTTTCAA
TAACAAAGCACATAACTGGATTTTGAACGCTTAAGTCAATCATTACTTGGAAATT
TNTAATGTTTATTATTTACATCAACTTTGTGAATTAACACAGTGTTTCAATTCTGT
30 AATTCATATTTGACTCTTT

SEQ ID NO: 689

Human mRNA for beta-actin, gi|28251|emb|X00351.1|HSAC07[28251]

TTGCCGATCCGCCGCCCGTCCACACCCGCGCCAGCTCACCATGGATGATGATAT
35 CGCCGCGCTCGTCGTCGACAACGGCTCCGGCATGTGCAAGGCCGGCTTCGCGGG
CGACGATGCCCCCGGGCCGTCTTCCCTCCATCGTGGGGCGCCCCAGGCACCAG
GGCGTGATGGTGGGCATGGGTGAGAAGGATTCTATGTGGGCGACGAGGCCAG
AGCAAGAGAGGCATCCTCACCTGAAGTACCCATCGAGCACGGCATCGTCACC
AACTGGGACGACATGGAGAAAATCTGGCACACACCTTCTACAATGAGCTGCGT
40 GTGGCTCCCGAGGAGCACCCCGTGCTGCTGACCGAGGCCCCCTGAACCCCAAG
GCCAACCGCGAGAAGATGACCCAGATCATGTTTGAGACCTTCAACACCCAGCC
ATGTACGTTGCTATCCAGGCTGTGCTATCCCTGTACGCCTCTGGCCGTACCACTG
GCATCGTGATGGACTCCGGTGACGGGGTCACCCACACTGTGCCCATCTACGAGG
GGTATGCCCTCCCCCATGCCATCCTGCGTCTGGACCTGGCTGGCCGGGACCTGAC
45 TGACTACCTCATGAAGATCCTCACCGAGCGCGGCTACAGCTTCAACCACACGGCC
GAGCGGGAAATCGTGCGTGACATTAAGGAGAAGCTGTGCTACGTCGCCCTGGAC
TTCGAGCAAGAGATGGCCACGGCTGCTTCCAGCTCCTCCCTGGAGAAGAGCTAC
GAGCTGCCTGACGGCCAGGTCATACCATTGGCAATGAGCGGTTCCGCTGCCCTG
AGGCACTCTTCCAGCCTTCCTTCCTGGGCATGGAGTCCTGTGGCATCCACGAAAC

TACCTTCAACTCCATCATGAAGTGTGACGTGGACATCCGCAAAGACCTGTACGCC
AACACAGTGCTGTCTGGCGGCACCACCATGTACCCTGGCATTGCCGACAGGATGC
AGAAGGAGATCACTGCCCTGGCACCCAGCACAAATGAAGATCAAGATCATTGCTC
CTCCTGAGCGCAAGTACTCCGTGTGGATCGGCGGCTCCATCCTGGCCTCGCTGTC
5 CACCTTCCAGCAGATGTGGATCAGCAAGCAGGAGTATGACGAGTCCGGCCCCCTC
CATCGTCCACCGCAAATGCTTCTAGGCGGACTATGACTTAGTTGCGTTACACCCT
TTCTTGACAAAACCTAACTTGCGCAGAAAACAAGATGAGATTGGCATGGCTTTAT
TTGTTTTTTTTTGTGTTTTGTTTTGTTTTTTTTTTTTTTTTTTGGCTTGACTCAGGATTTAA
AAACTGGAACGGTGAAGGTGACAGCAGTCGGTTGGAGCGAGCATCCCCCAAAGT
10 TCACAATGTGGCCGAGGACTTTGATTGCACATTGTTGTTTTTTTAATAGTCATTCC
AAATATGAGATGCATTGTTACAGGAAGTCCCTTGCCATCCTAAAAGCCACCCAC
TTCTCTCTAAGGAGAATGGCCAGTCCTCTCCCAAGTCCACACAGGGGAGGTGAT
AGCATTGCTTTCGTGTAAATTATGTAATGCAAAATTTTTTTAATCTTCGCCTTAAT
ACTTTTTTATTTTTGTTTTATTTTTGAATGATGAGCCTTCGTGCCCCCCTTCCCCCTT
15 TTTGTCCCCCAACTTGAGATGTATGAAGGCTTTTGGTCTCCCTGGGAGTGGGTGG
AGGCAGCCAGGGCTTACCTGTACACTGACTTGAGACCAGTTGAATAAAAAGTGCA
CACCTTA

SEQ ID NO: 690

20 >AA435938

TTTCATGCTCATTGCTGTTTATTGAAACAAAAGAATCAGAAGAAGATCAGAATGA
AGACAATAATAAAAAGCAGAAAGCAGAAAGTACAAGAAGAATAAAGAAAAGAAAGG
GAAAGAATTGTAGGAAGGAAAAAACCTTGTAGAAGTAGAGGGTGGAGAGTGGGAA
GAGGTGGAGTATGATGGGAGTCCGATCTTTTCCATCTGGGCTTTCAGACAATGG
25 GATATGTCATGGAAGGCTTCTTTAAACACCAGAAGAAATTCAGGATAAAGCTCA
AAAAGAGCAGGCAATCGATAGGGGTTGAAAATCCACTCAGTAGGCCACGGAAG
GACTTCAAGAAGGTTGATCGTTCTGTCTGCTGGATGTTGTAGGTGTCCTACGTGAA
GGCAATCGACATCTGGATGGCTGTGTGTCTGCTCTTTGTGTT
CGCTGCCTTGCTGGAG

30

SEQ ID NO: 691

>AA443497

TCCAAGGTCATGGCAAAACATCTGAAGTTCATCGCGAGGACTGTGATGGTACAG
GAAGGGAACGTGGAAAGCGCATACAGGACCTTAAACAGAATCCTCACTATGGAT
35 GGGCTCATTGAGGACATTAAGCATCGGCGGTATTATGAGAAGCCATGCCGCCGC
GACAGAGGGAAAGCTATGAAAGGTGCCGGCGGATCTACAACATGGAAATGGCTC
GCAAGATCAACTTCTTGATGCGAAAGAATCGGGCAGATCCGTGGCAGGGCTGCT
GAGGCCTGTGGGTGGGACACCAGTGCAGAAACCCTCATCCAGTTTTCTCTCCATCT
CTTTTCTTTGTACAATCCCATTTCCTATTACCATTCTCTGCAATAAACTCAAATCA
40 CATGTCTGC

SEQ ID NO: 692

zfl7e01.s1 Soares_fetal_heart_NbHH19W Homo sapiens cDNA clone IMAGE:377208 3',
mRNA sequence gi|1547536|gb|AA055198.1|AA055198[1547536]

45 CACCTTAAAAACTAGGTTTCTATTTCTGGTTAGATTCTAGAGCAGTGGAAGTACAG
GAGTGATACTATAACCCTACCCAGTCCCACCACAGCCTGCCTCCTTCTCCACAG
AGATAACATTGTACAAAACCTGTATTTACAAGAAAACCAATTAATAAATTAAGGGT
GTGTGCAAAAGTAGACAGGAGAGTCAAGACATATCAATGCAGGGATGGCTTTGG
GGAATGGGGGACTCAAGGTTCTACACTGGAACCTGGGG

SEQ ID NO: 693

zt87h10.s1 Soares_testis_NHT Homo sapiens cDNA clone IMAGE:729379 3', mRNA sequence

5 gi|2140847|gb|AA435933.1|AA435933[2140847]
 TTTTGGTTCAAACAATGGAACATTTTATTATATCATATTACAAAGAGTCAGTGAT
 GGGCC
 ATTCAGGATTGGTTAATTCAGTAGTTCACCAAAGTCATCAAGGATCCGTCTTTC
 CATCTCCCTTCTCTGCCACCCTCAAGGTTTAAGACGGCTGTTGCAGTTCAGACAT
 10 TATATCAAGATGCAGTATTCACAGAAAGAGGACTGTTTCATTTCTTTACCAGAAGA
 TTCTCCCATATATCATGTGTCTACATCTAAACCAATCACTACTAAGGGGAAATTG
 ACCTACAACATTTGGATTAGACTAATCAAATTTACCTTCTGAGTTAGGCATAGAG
 TCAACTTCTATGAGCACATGGCTGAGCCAAGGATAAGCATTCTGCCAGCAAGAG
 AGGACATAATATGGGTGTGGGATTGGAGATGGGAGAG

15
 SEQ ID NO: 694

yo27c07.s1 Soares adult brain N2b5HB55Y Homo sapiens cDNA clone IMAGE:179148 3', mRNA sequence gi|989944|gb|H50103.1|H50103[989944]

20 AAATTTATCAATGACAAACAGACATAAACTCAAAGTTTGGCTCTTCTGAGGGGC
 AGGAGAAAACTGGTGATGTTCTTTTATACAGATGAAACATGGGTNCAGAAATT
 ACACGNCACCTCTAAAGCAACCAGAAGAGGGACACGAAAGCAAACCTGTACATT
 CACTAGGANTTTGCAGTCATTTTCAGATTTCCACTAGGTAAGAAAAATACANTTTTG
 CGTTCAGTTTTCNCCGTGCTCGGGTGFATGAAAAAAAANCCAGCCGACATGCAG
 CAACGTCTCCAGCGCTTAGGNCCGTAAAANTGTTTETAAGCACAGAAGTACATGT
 25 GGGAAGATTTCTCTCATCATTTTTTNGTAAANCAAAGCGTTCTAATATTTTACAGA
 CCAAGTTAGGGCCAGTTTTTTNTTTTCCCT

SEQ ID NO: 695

za29f01.r1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:293977 5', mRNA sequence gi|1267964|gb|N95657.1|N95657[1267964]

30 GCAGAAGCGAACAACCTGAGCTTTCCTTGGAGCCCCTGAGCAGGGAGAGGGCT
 CACAAGCTTGAGGCCATCTCTCGCCTCTGCGAGNACNAAGTACAAGGACCTAAG
 AAGATCCGCGAGAAGCGCTCAGCCAGTGCAGACAACCTGACTCTGCCCGGTGG
 TCCCCAGCCATCATCTCTTAACCTACGGAGGCCCGCCGGACCACACCATCCCTTAG
 35 TTTCTCCTTTAGTTTGAGAAAAGACAGACTTGGGGTNGGTTTGTGTTTTGTTTTTC
 TTTCTTTTCTTTTTTTACGCATAGCTCCCGTCAAAGCTGCCT

SEQ ID NO: 696

Human lysophosphatidic acid receptor homolog mRNA, complete cds

40 gi|1857424|gb|U80811.1|HSU80811[1857424]
 TCACCACCTACAACCACAGAGCTGTCATGGCTGCCATCTCTACTTCCATCCCTGT
 AATTTACAGCCCCAGTTCACAGCCATGAATGAACCACAGTGCTTCTACAACGAG
 TCCATTGCCTTCTTTTATAACCGAAGTGGAAGCATCTTGCCACAGAATGGAACA
 CAGTCAGCAAGCTGGTGATGGGACTTGGAATCACTGTTTGTATCTTCATCATGTT
 45 GGCCAACCTATTGGTCATGGTGGCAATCTATGTCAACCGCCGCTTCCATTTTCCTA
 TTTATTACCTAATGGCTAATCTGGCTGCTGCAGACTTCTTGCTGGGTTGGCCTAC
 TTCTATCTCATGTTCAACACAGGACCCAATACTCGGAGACTGACTGTTAGCACAT
 GGCTCCTGCGTCAGGGCCTCATTGACACCAGCCTGACGGCATCTGTGGCCAACCT
 ACTGGCTATTGCAATCGAGAGGCACATTACGGTTTTCCGCATGCAGCTCCACACA

CGGATGAGCAACCGGCGGGTAGTGGTGGTCATTGTGGTCATCTGGACTATGGCC
 ATCGTTATGGGTGCTATACCCAGTGTGGGCTGGAAGTGTATCTGTGATATTGAAA
 ATTGTTCCAACATGGCACCCCTCTACAGTGACTCTTACTTAGTCTTCTGGGCCATT
 TTCAACTTGGTGACCTTTGTGGTAATGGTGGTCTCTATGCTCACATCTTTGGCTA
 5 TGTCGCCAGAGGACTATGAGAATGTCTCGGCATAGTTCTGGACCCCGGCGGAAT
 CGGGATACCATGATGAGTCTTCTGAAGACTGTGGTCATTGTGCTTGGGGCCTTTA
 TCATCTGCTGGACTCCTGGATTGGTTTTGTACTTCTAGACGTGTGCTGTCCACAG
 TGCGACGTGCTGGCCTATGAGAAATTCTTCCTTCTCCTTGCTGAATTCAACTCTGC
 CATGAACCCCATCATTTACTCCTACCGCGACAAAGAAATGAGCGCCACCTTTAGG
 10 CAGATCCTCTGCTGCCAGCGCAGTGAGAACCCACCGGCCCCACAGAAAGCTCA
 GACCGCTCGGCTTCCCTCCCTCAACCACACCATCTTGGCTGGAGTTCACAGCAATG
 ACCACTCTGTGGTTTAGAACGGAACTGAGATGAGGAACCAGCCGCTCCTCTCTTG
 GAGGATAAACAGCCTCCCCCTACCCAATTGCCAGGGCAAGGTGGGGTGTGAGAG
 AGGAGAAAAGTCAACTCATGTACTTAAACACTAACCAATGACAGTATTTGTTTCCT
 15 GGACCCCAAGACTTGATATATATTGAAAATTAGCTTATGTGACAACCTCATC
 TTGATCCCCATCCCTTCTGAAAGTAGGAAGTTGGAGCTCTTGCAATGGAATTCAA
 GAACAGACTCTGGAGTGTCCATTTAGACTACACTAACTAGACTTTTAAAAGATTT
 TGTGTGGTTTGGTGCAAGTCAGAATAAATTCTGGCTAGTTGAATCCACAACITCA
 TTTATATACAGGCTTCCCTTTTTTATTTTTTAAAGGATACGTTTCACTTAATAAACA
 20 CGTTTATGCCTATCAGCAAAAAAAAAAAAAAAAAA

SEQ ID NO: 697
 zfl6g09.r1 Soares fetal heart NbHH19W Homo sapiens cDNA clone IMAGE:377152-5
 similar to SW:NUYM_BOVIN:Q02375 NADH-UBIQUINONE OXIDOREDUCTASE 18

25 KD SUBUNIT PRECURSOR ;, mRNA sequence
 gi|1547458|gb|AA055101.1|AA055101[1547458]
 GCAGCAAGATGGCGGCGGTCTCAATGTCAGTGGTACTGAGGCAGACGTTGTGGC
 GGAGAAGGGCAGTGGCTGTAGCTGCCCTTCCGTTTCCAGGGTCCGACCAGGTC
 GTTGAGGACTTCCACATGGAGATTGGCACAGGACCAGACTCAAGACACACAAC
 30 CATAACAGTTGATGAAAAATTGGATATCACTACTTTAACTGGCGTTCCAGAAGAG
 CATATAAAACTAGAAAAGTCAGGATCTTTGTTTCCTGCTCGCAATAACATGCAGT
 CTGGAGTAAACAACACAAAGAAATGGAAGATGGAGTTTGANTACCAGGGAGCG
 ATGGGAAAATCCTTTGATGGGTTNGGCATCAACCGGCTTGATCCCCTTTTCNA
 CATGGGTTCTAAAC

35
 SEQ ID NO: 698
 Human interleukin 11 mRNA, complete cds gi|186272|gb|M57765.1|HUMIL11[186272]
 GCTCAGGGCACATGCCTCCCCTCCCCAGGCCGCGGCCAGCTGACCTCGGGGCT
 CCCCCGCGAGCGGACAGGGAAGGGTTAAAGGCCCGGCTCCCTGCCCCCTGCC
 40 CTGGGGAACCCCTGGCCCTGTGGGGACATGAACTGTGTTTGCCGCCTGGTCTGG
 TCGTGCTGAGCCTGTGGCCAGATACAGCTGTCGCCCTGGGCCACCACTGGCCC
 CCCTCGAGTTTCCCCAGACCCTCGGGCCGAGCTGGACAGCACCGTGCTCCTGACC
 CGCTCTCTCCTGGCGGACACGCGGCAGCTGGCTGCACAGCTGAGGGACAAATTC
 CCAGCTGACGGGGACCACAACCTGGATTCCCTGCCACCCTGGCCATGAGTGCG
 45 GGGGCACTGGGAGCTCTACAGCTCCCAGGTGTGCTGACAAGGCTGCGAGCGGAC
 CTACTGTCTACCTGCGGCACGTGCAGTGGCTGCGCCGGGAGGTGGCTCTTCCC
 TGAAGACCCTGGAGCCCGAGCTGGGCACCCTGCAGGCCCGACTGGACCGGCTGC
 TGCGCCGGCTGCAGCTCCTGATGTCCCGCCTGGCCCTGCCCCAGCCACCCCGGA
 CCGCGCGGCGCCCCCGCTGGCGCCCCCTCCTCAGCCTGGGGGGGCATCAGGGCC

GCCCACGCCATCCTGGGGGGGCTGCACCTGACACTTGACTGGGCCGTGAGGGGA
CTGCTGCTGCTGAAGACTCGGCTGTGACCCGGGGCCCAAAGCCACCACCGTCCTT
CCAAAGCCAGATCTTATTTATTTATTTATTTTTCAGTACTGGGGGCGAAACAGCCAG
GTGATCCCCCGCCATTATCTCCCCCTAGTTAGAGACAGTCCTTCCGTGAGGCCT
5 GGGGGACATCTGTGCCTTATTTATACTTATTTATTTTTCAGGAGCAGGGGTGGGAGG
CAGGTGGACTCCTGGGTCCCCGAGGAGGAGGGGACTGGGGTCCCGGATTCTTGG
GTCTCCAAGAAGTCTGTCCACAGACTTCTGCCCTGGCTCTTCCCCATCTAGGCCTG
GGCAGGAACATATATTATTTATTTAAGCAATTACTTTTCATGTTGGGGTGGGGAC
GGAGGGGAAAGGGAAGCCTGGGTTTTTGTACAAAAATGTGAGAAACCTTTGTGA
10 GACAGAGAACAGGGAATTAAATGTGTCATACATATCC

SEQ ID NO: 699

Homo sapiens mRNA for GABA-BR1a (hGB1a) receptor

gi|2826760|emb|Y11044.1|HSGTHLA1[2826760]

15 ATGCTGCTGCTGCTGCTGGCGCCACTCTTCCTCCGCCCCCGGGCGCGGGCGGGG
CGCAGACCCCCAACGCCACCTCAGAAGGTTGCCAGATCATACACCCGCCCTGGG
AAGGGGGCATCAGGTACCGGGGCTGACTCGGGACCAGGTGAAGGCTATCAACT
TCCTGCCAGTGGACTATGAGATTGAGTATGTGTGCCGGGGGAGCGCGAGGTGG
TGGGGCCCAAGGTCCGCAAGTGCTGCCAACGGCTCCTGGACAGATATGGACA
20 CACCCAGCCGCTGTGTCCGAATCTGCTCCAAGTCTTATTTGACCCTGGAAAATGG
GAAGGTTTTCTTGACGGGTGGGGACCTCCAGCTCTGGACGGAGCCCGGGTGG
TTTTCGGGTGTGACCCCGACTTCCATCTGGTGGGCAGCTCCCGGAGCATCTGTAGT
CAGGGGCCAGTGGAGCAGCCCGAAGCCCGAGTGGCAGGTGAATCGAACGCCACAC
TCAGAACGGCGCGCAGTGTACATCGGGGGCACTGTTCCCATGAGCGGGGGCTGG
25 CCAGGGGGCCAGGCCTGCCAGCCCGCGGTGGAGATGGCGCTGGAGGACGTGAAT
AGCCGCAGGGACATCCTGCCGGACTATGAGCTCAAGCTCATCCACCACGACAGC
AAGTGTGATCCAGGCCAAGCCACCAAGTACCTATATGAGCTGCTCTACAACGAC
CCTATCAAGATCATCCTTATGCCTGGCTGCAGCTCTGTCTCCACGCTGGTGGCTG
AGGCTGCTAGGATGTGGAACCTCATTGTGCTTTCCTATGGCTCCAGCTCACCAGC
30 CCTGTCAAACCGGCAGCGTTTCCCCACTTTCTTCCGAACGCACCCATCAGCCACA
CTCCACAACCCTACCCGCGTGAAACTCTTTGAAAAGTGGGGCTGGAAGAAGATT
GCTACCATCCAGCAGACCACTGAGGTCTTCACTTCGACTCTGGACGACCTGGAGG
AACGAGTGAAGGAGGCTGGAATTGAGATTACTTTCGGCCAGAGTTTCTTCTCAGA
TCCAGCTGTGCCCGTCAAAAACCTGAAGCGCCAGGATGCCCGAATCATCGTGGG
35 ACTTTTCTATGAGACTGAAGCCCGGAAAGTTTTTTGTGAGGTGTACAAGGAGCGT
CTCTTTGGGAAGAAGTACGTCTGGTTCCTCATTGGGTGGTATGCTGACAATTGGT
TCAAGATCTACGACCCTTCTATCAACTGCACAGTGGATGAGATGACTGAGGCGGT
GGAGGGCCACATCACAACCTGAGATTGTCTGATGCTGAATCCTGCCAATAACCCGAG
CATTTCCAACATGACATCCCAGGAATTTGTGGAGAACTAACCAAGCGACTGAA
40 AAGACACCCTGAGGAGACAGGAGGCTTCCAGGAGGCACCGCTGGCCTATGATGC
CATCTGGGCCTTGGCACTGGCCCTGAACAAGACATCTGGAGGAGGCGGCCGTTCT
GGTGTGCGCCTGGAGGACTTCAACTACAACAACCAGACCATACCGACCAAATC
TACCGGGCAATGAACTCTTCGTCTTTGAGGGTGTCTCTGGCCATGTGGTGTG
ATGCCAGCGGCTCTCGGATGGCATGGACGCTTATCGAGCAGCCTCAGGGTGGCA
45 GCTACAAGAAGATTGGCTACTATGACAGCACCAAGGATGATCTTTCCTGGTCCAA
AACAGATAAATGGATTGGAGGGTCCCCCCCAGCTGACCAGACCCTGGTCATCAA
GACATTCCGCTTCTGTGTCACAGAACTCTTTATCTCCGTCTCAGTTCTCTCCAGCC
TGGGCATTGTCTAGCTGTTGTCTGTCTGTCTTTAACATCTACAACCTCACATGTC
CGTTATATCCAGAACTCACAGCCCAACCTGAACAACCTGACTGCTGTGGGCTGCT

CACTGGCTTTAGCTGCTGTCTTCCCCCTGGGGCTCGATGGTTACCACATTGGGAG
 GAACCAGTTTCCTTTCTGTCTGCCAGGCNCGCCTCTGGCTCCTGGGCCTGGGCTTTA
 GTCTGGGCTACGGTTCCATGTTACCAAGATTTGGTGGGTCCACACGGGCTTCAC
 AAAGAAGGAAGAAAAGAAGGAGTGGAGGAAGACTCTGGAACCCTGGAAGCTGT
 5 ATGCCACAGTGGGCCTGCTGGTGGGCATGGATGTCTCACTCTCGCCATCTGGCA
 GATCGTGGACCTCTGCACCGGACCATTGAGACATTTGCCAAGGAGGAACCTAA
 GGAAGATATTGACGTCTCTATTCTGCCCCAGCTGGAGCATTGCAGCTCCAGGAAG
 ATGAATACATGGCTTGGCATTCTTCTATGGTTACAAGGGGCTGCTGCTGCTGCTGG
 GAATCTTCCTTGCTTATGAGACCAAGAGTGTGTCCACTGAGAAAGATCAATGATCA
 10 CCGGGCTGTGGGCATGGCTATCTACAATGTGGCAGTCCTGTGCCTCATCACTGCT
 CCTGTCACCATGATTCTGTCCAGCCAGCAGGATGCAGCCTTTGCCTTTGCCTCTCT
 TGCCATAGTTTTCTCCTCTATATCACTCTTGTTGTGCTCTTTGTGCCAAGATGC
 GCAGGCTGATCACCCGAGGGGAATGGCAGTCGGAGGCGCAGGACACCATGAAG
 ACAGGGTCATCGACCAACAACAACGAGGAGGAGAAGTCCCGGCTGTTGGAGAA
 15 GGAGAACCGTGAAGTGGAAAAGATCATTGCTGAGAAAGAGGAGCGTGTCTCTGA
 ACTGCGCCATCAACTCCAGTCTCGGCAGCAGCTCCGCTCCCGGCGCCACCCACCG
 ACACCCCCAGAACCCTCTGGGGGCTGCCAGGGGACCCCTGAGCCCCCGAC
 CGGCTTAGCTGTGATGGGAGTCGAGTGCATTTGCTTTATAAGTGAGGGTAGGGTG
 AGGGAGGACAGGCCAGTAGGGGGAGGGAAAGGGAGAGGGGAAGGGCAGGGGA
 20 CTCAGGAAGCAGGGGGTCCCATCCCCAGCTGGGAAGAACATGCTATCCAATCT
 CATCTCTTGTAATACATGTCCCCCTGTGAGTTCTGGGCTGATTTGGGTCTCTCAT
 TACCTCTGGGAAACAGACCTTTCTCTCTTACTGCTTCATGTAATTTGTATCACC
 TCTTACAAATTAGTTCGTACCTGGCTTGAAGCTGCTCACTGCTCACACGCTGCCT
 TCTGAGCAGCCTCACTGCATGTTCTCTTCCCATGCAACACCCCTCTTCTAGTACCT
 25 ACGGCAACCCCTGCAGCTCCTCTGCCTTTGTGCTCTGTTCCTGTCCAGCAGGGGTC
 TCCCAACAAGTGCTCTTTCCACCCCAAGGGGCTCTCCTTTTCTCCACTGTCATA
 ATCTCTTTCCATCTTACTTGCCCTTCTATACTTTCTCACATGTGGCTCCCCCTGAAT
 TTTGCTTCCTTTGGGAGCTCATTCTTTTCGCCAAGGCTCACATGCTCCTTGCCCTCT
 GCTCTGTGCACTCACGCTCAGCACACATGCATCCTCCCCTCTCCTGCGTGTGCCCA
 30 CTGAACATGCTCATGTGTACACACGCTTTTCCCGTATGCTTTCTTCATGTTCACTC
 ACATGTGCTCTCGGGTGCCCTGCATTCACAGCTACGTGTGCCCTCTCATGGTCAT
 GGGTCTGCCCTTGAGCGTGTGTTGGGTAGGCATGTGCAATTTGTCTAGCATGCTGA
 GTCATGTCTTTCTATTTGCACACGTCCTATGTTTATCCATGTACTTTCCCTGTGTAC
 CCTCCATGTACCTTGTGTACTTTCTTCCCTTAAATCATGGTATTCTTCTGACAGAG
 35 CCATATGTACCCTACCCTGCACATTGTTATGCACTTTTCCCCAATTCATGTTTGGT
 GGGGCCATCCACACCCTCTCCTTGTACAGAAATCTCCATTTCTGCTCAGATTCCCC
 CCATCTCCATTGCATTATGTACTACCCTCAGTCTACACTCACAATCATCTTCTCC
 CAAGACTGCTCCCTTTTGTGTTTGTGTTTGTGAGGGGAATTAAGGAAAAATAAG
 TGGGGGCAGGTTTGGAGAGCTGCTTCCAGTGGATAGTTGATGAGAATCCTGACC
 40 AAAGGAAGGCACCCTTGACTGTTGGGATAGACAGATGGACCTATGGGGTGGGAG
 GTGGTGTCCCTTTCACACTGTGGTGTCTCTTGGGGAAGGATCTCCCCGAATCTCA
 ATAAACCAGTGAACAGTGTGACTCGGAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

SEQ ID NO: 700

45 zh96g08.s1 Soares_fetal_liver_spleen_1NFLS_S1 Homo sapiens cDNA clone
 IMAGE:429182 3', mRNA sequence gi|1448327|gb|AA004759.1|AA004759[1448327]
 ACTTTATGCAAAAAAAAAATATACATTTATTTATAGGTCTCAATACAGCAAAATGA
 AAACGAAAATTGAGAACATTGCTCATTAGGCCAGCAACTTTAAAATTATTTAATT
 TGAAATATAAAATAGGTGGTCTTCATAAAAAGATGCATGAAATTTACCTTACCTT

ATATTTTATACTTTAAGAGTACATTTTATACAAATCAGTAACCAGGCTTCTTTCAT
GTTTAACCTGAAATGAACGTAACATAAATGAGTATCTTTCTTTTATGTAGTAGC
AAAAAGAGTCAATAATCCTTTCAAGAAAGATACTATTTCAATTCCTCCCAACTTG
GGATTCNCCATAAACACGGA

5

SEQ ID NO: 701

Homo sapiens canalicular multispecific organic anion transporter 2 (CMOAT2) mRNA,
complete cds gi|3550323|gb|AF083552.1|AF083552[3550323]

AGCCGCGCCTCGGCCCATGGACGCCCTGTGCGGTTCCGGGGAGCTCGGCTCCAA
10 GTTCTGGGACTCCAACCTGTCTGTGCACACAGAAAACCCGGACCTCACTCCCTGC
TTCCAGAACTCCCTGCTGGCCTGGGTGCCCTGCATCTACCTGTGGGTGCGCCCTGC
CCTGCTACTTGCTCTACCTGCGGCACCATTTGTCGTGGCTACATCATCCTCTCCCAC
CTGTCCAAGCTCAAGATGGTCCTGGGTGTCCTGCTGTGGTGCGTCTCCTGGGCGG
ACCTTTTTTACTCCTTCCATGGCCTGGTCCATGGCCGGGCCCCCTGCCCCTGTTTTC
15 TTTGTACCCCCCTTGGTGGTGGGGGTACCATGCTGCTGGCCACCCTGCTGATAC
AGTATGAGCGGCTGCAGGGCGTACAGTCTTCGGGGGTCTCATTATCTTCTGGTT
CCTGTGTGTGGTCTGCGCCATCGTCCCATTCGCTCCAAGATCCTTTTAGCCAAGG
CAGAGGGTGAGATCTCAGACCCCTTCGCTTCACCACCTTCTACATCCACTTTGC
CCTGGTACTCTCTGCCCTCATCTTGGCCTGCTTCAGGGAGAAACCTCCATTTTTCT
20 CCGCAAAGAATGTCGACCCTAACCCTACCCTGAGACCAGCGCTGGCTTTCTCTC
CCGCCTGTTTTCTGGTGGTTCACAAAGATGGCCATCTATGGCTACCGGCATCCC
CTGGAGGAGAAGGACCTCTGGTCCCTAAAGGAAGAGGACAGATCCCAGATGGTG
CTGGCAGCAGCTGCTGGAGGCATGGAGGAAGCAGGAAAAGCAGACGGCACGACA
CAAGGCTTCAGCAGCACTGGGAAAATGCTCCGGCGAGGAAGAGGTGCTGGT
25 GGGTGCCCGGCCAGGCCCGGAAGCCCTCCTTCTGAAGGCCCTGCTGGCCACC
TTCGGCTCCAGCTTCCTCATCAGTGCCTGCTTCAAGCTTATCCAGGACCTGCTCTC
CTTCATCAATCCACAGCTGCTCAGCATCCTGATCAGGTTTATCTCCAACCCCATG
GGCCCTCCTGGTGGGGCTTCCTGGTGGCTGGGCTGATGTTCTGTGCTCCATGA
TGCAGTCGCTGATCTTACAACACTATTACCACTACATCTTTGTGACTGGGGTGAA
30 GTTTCGTACTGGGATCATGGGTGTCATCTACAGGAAGGCTCTGGTTATCACCAAC
TCAGTCAAACGTGCGTCCACTGTGGGGGAAATTGTCAACCTCATGTGAGTGGATG
CCCAGCGCTTCATGGACCTTGCCCCCTTCCTCAATCTGCTGTGGTTCAGCACCCCTG
CAGATCATCCTGGCGATCTACTTCTTGGCAGAACCTAGGTCCCTCTGTCTCTGG
CTGGAGTCGCTTTCATGGTCTTGTGATTCCTCAACGGAGCTGTGGCCGTGAA
35 GATGCGCGCCTTCCAGGTAAAGCAAATGAAATTGAAGGACTCGCGCATCAAGCT
GATGAGTGAGATCCTGAACGGCATCAAGGTGCTGAAGCTGTACGCCTGGGAGCC
CAGCTTCCTGAAGCAGGTGGAGGGCATCAGGCAGGGTGAGCTCCAGCTGCTGCG
CACGGCGGCCTACCTCCACACCACAACCACCTTCACCTGGATGTGCAGCCCCCTC
TTGGTGACCCTGATCACCTCTGGGTGTACGTGTACGTGGACCCAAACAATGTGC
40 TGGACGCCGAGAAGGCCTTTGTGTCTGTGTCTTGTGTTAATATCTTAAGACTTCCC
CTCAACATGCTGCCCCAGTTAATCAGCAACCTGACTCAGGCCAGTGTGTCTCTGA
AACGGATCCAGCAATTCTGAGCCAAGAGGAACTTGACCCCCAGAGTGTGGAAA
GAAAGACCATCTCCCCAGGCTATGCCATCACCATACACAGTGGCACCTTCACCTG
GGCCCAGGACCTGCCCCCACTCTGCACAGCCTAGACATCCAGGTCCCGAAAGG
45 GGCCTGCTGGGAGAGATGGAGAAGCTAGAAGGCAAAGTGCACATGAAGGGCTCC
GTGGCCTATGTGCCCCAGCAGGCATGGATCCAGAACTGCACTCTTCAGGAAAAC
GTGCTTTTCGGCAAAGCCCTGAACCCCAAGCGCTACCAGCAGACTCTGGAGGCCT
GTGCCTTGCTAGCTGACCTGGAGATGCTGCCTGGTGGGGATCAGACAGAGATTG

GAGAGAAGGGCATTAAACCTGTCTGGGGGCCAGCGGCAGCGGGTCAGTCTGGCTC
GAGCTGTTTACAGTGATGCCGATATTTTCTTGCTGGATGACCCACTGTCCGCGGT
GGACTCTCATGTGGCCAAGCACATCTTTGACCACGTCATCGGGCCAGAAGGCGTG
CTGGCAGGCAAGACGCGAGTGCTGGTGACGCACGGCATTAGCTTCCTGCCCCAG
5 ACAGACTTCATCATTGTGCTAGCTGATGGACAGGTGTCTGAGATGGGCCCCGTACC
CAGCCCTGCTGCAGCGCAACGGCTCCTTTGCCAACTTTCTCTGCAACTATGCCCC
CGATGAGGACCAAGGGCACCTGGAGGACAGCTGGACCGCGTTGGAAGGTGCAG
AGGATAAGGAGGCACTGCTGATTGAAGACACACTCAGCAACCACACGGATCTGA
CAGACAATGATCCAGTCACCTATGTGGTCCAGAAGCAGTTTATGAGACAGCTGA
10 GTGCCCTGTCTCAGATGGGGAGGGACAGGGTCGGCCTGTACCCCGGAGGCACC
TGGGTCCATCAGAGAAGGTGCAGGTGACAGAGGCGAAGGCAGATGGGGCACTG
ACCCAGGAGGAGAAAGCAGCCATTGGCACTGTGGAGCTCAGTGTGTTCTGGGAT
TATGCCAAGGCCGTGGGGCTCTGTACCACGCTGGCCATCTGTCTCCTGTATGTGG
GTCAAAGTGCGGCTGCCATTGGAGCCAATGTGTGGCTCAGTGCCTGGACAAATG
15 ATGCCATGGCAGACAGTAGACAGAACAACACTTCCCTGAGGCTGGGCGTCTATG
CTGCTTTAGGAATTCTGCAAGGGTTCTTGGTGATGCTGGCAGCCATGGCCATGGC
AGCGGGTGGCATCCAGGCTGCCCCGTGTGTTGCACCAGGCACTGCTGCACAACAA
GATACGCTCGCCACAGTCCTTCTTTGACACCACACCATCAGGCCGCATCCTGAAC
TGCTTCTCCAAGGACATCTATGTCGTTGATGAGGTTCTGGCCCCCTGTCATCCTCAT
20 GCTGCTCAATTCTTCTTCAACGCCATCTCCACTCTTGTGGTCATCATGGCCAGCA
CGCCGCTCTTCACTGTGGTCATCCTGCCCCCTGGCTGTGCTCTACACCTTAGTGCAG
CGCTTCTATGCAGCCACATCACGGCAACTGAAGCGGCTGSAATCAGTCAGCCGCT
CAGCTATCTACTCCCACTTTTCGGAGACAGTGACTGGTGGCAGTGTCTATCCGGC
CTACAACCGCAGCCGGGATTTTGAGATCATCAGTGATACTAAGGTGGATGCCAA
25 CCAGAGAAGCTGCTACCCCTACATCATCTCCAACCGGTGGCTGAGCATCGGAGTG
GAGTTCGTGGGGAACCTGCGTGGTGCTCTTTGCTGCACTATTTGCCGTCTATCGGA
GGAGCAGCCTGAACCCGGGGCTGGTGGGCCTTTCTGTGTCCTACTCCTTGCAAGT
GACATTTGCTCTGAACTGGATGATACGAATGATGTCAGATTTGGAATCTAACATC
GTGGCTGTGGAGAGGGTCAAGGAGTACTCCAAGACAGAGACAGAGGGCGCCCTGG
30 GTGGTGGAAGGCAGCCGCCCTCCCGAAGGTTGGCCCCACGTTGGGGAGGTGGAG
TTCCGGAATTATTCTGTGCGCTACCGGCCGGGCTAGACCTGGTGCTGAGAGACC
TGAGTCTGCATGTGCACGGTGGCGAGAAGGTGGGGATCGTGGGCCGCACTGGGG
CTGGCAAGTCTTCCATGACCCTTTGCCTGTTCCGCATCCTGGAGGCGGCAAAGGG
TGAAATCCGCATTGATGGCCTCAATGTGGCAGACATCGGCCTCCATGACGTGCGC
35 TCTCAGCTGACCATCATCCCGCAGGACCCCATCCTGTTCTCGGGGACCCTGCGCA
TGAACCTGGACCCCTTCGGCAGCTACTCAGAGGAGGACATTTGGTGGGCTTTGGA
GCTGTCCCACCTGCACACGTTTGTGAGCTCCAGCCGGCAGGCCTGGACTTCCAG
TGCTCAGAGGGCGGGGAGAATCTCAGCGTGGGCCAGAGGCAGCTCGTGTGCCTG
GCCCCAGCCCTGCTCCGCAAGAGCCGCATCCTGGTTTTAGACGAGGCCACAGCTG
40 CCATCGACCTGGAGACTGACAACCTCATCCAGGCTACCATCCGCACCCAGTTTGA
TACCTGCACTGTCTGACCATCGCACACCGGCTTAACACTATCATGGACTACACC
AGGGTCTTGGTCTGGACAAAGGAGTAGTAGCTGAATTTGATTCTCCAGCCAACC
TCATTGCAGCTAGAGGCATCTTCTACGGGATGGCCAGAGATGCTGGACTTGCCCTA
AAATATATTCTGAGATTTCTCTCTGGCCTTTCTTGGTTTTTCATCAGGAAGGAAAT
45 GACACCAAATATGTCCGCAGAATGGACTTGATAGCAAACACTGGGGGCACCTTA
AGATTTTGCACCTGTAAAGTGCTTACAGGGTAAGTGTGCTGAATGCTTTAGATG
AGGAAATGATCCCCAAGTGGTGAATGACACGCCTAAGGTCACAGCTAGTTTGAG
CCAGTTAGACTAGTCCCCGGTCTCCCGATTCCCAACTGAGTGTTATTTGCACACT
GCACTGTTTTCAAATAACGATTTTATGAAATGACCTCTGTCTCCTCCTCTGATTTTT

CATATTTTCTAAAGTTTCGTTTCTGTTTTTAATAAAAAAGCTTTTTCCTCCTGGAAC
 AGAAGACAGCTGCTGGGTCAGGCCACCCCTAGGAACTCAGTCCTGTACTCTGGG
 GTGCTGCCTGAATCCATTAAAAATGGGAGTACTGATGAAATAAACTACATGGT
 CAACAGTAAAAAAAAAAAAAAAAA

5

SEQ ID NO: 702

yq42d10.s1 Soares fetal liver spleen 1 NFLS Homo sapiens cDNA clone IMAGE:198451 3',
 mRNA sequence gi|970054|gb|R94659.1|R94659[970054]

TTGTTTTTTTGGTTCAGCATAACTTGGAACATTTGAAAGCTTTTCAACCTAAATG

10

TGGG

GAAAAAACAGGTAAGGCATTATTTTTGCACAAAAGTAGCATTCCTAATAGTGCA
 AATGAA

TCTGATACCTCTTAAAATGGTGAGAGGTCATACACTTACTAGATTAATTTAGATT
 TTCTT

15

TCTATGGCTTGACAAATTATCCCTCTATAAATTCTACTCTCAGGAGGCTGTTG
 CTGT

AATCAAAAGGATAACTGTAGGATAAAGGTCCAACCTTCTCCTGGTATCCGGCAA
 AAGGGT

TTTGTCTCATATGGCAAAAAAATCTAATTTTAAATTATCCTACAGNGGAATAT

20

ACAAC

TGGGNTTCCTNNGGACCCTCTATTTATCNGGCGGCAACAGGTGGTTCGGGGCGGC

GGNCTTCCAATGGGGGCCCCCTAACCCAAAATTGGGCGGNCAATCT

SEQ ID NO: 703

25

zd29f03.s1 Soares_fetal_heart_NbHH19W Homo sapiens cDNA clone IMAGE:342077 3',
 mRNA sequence gi|1367074|gb|W60315.1|W60315[1367074]

CATAACTTAAGTAAACTTTATTTTCAAAATGCTTCAGGTACAAAAGAAAACAATC

GGCAAAGTCTAACAATAATTAACAAACCAGCTCTTGAGCGGCAGAGTGCTCCAG

GGATGAGAGGGGCTGGGGATGGAAAGGTGGTGGGAGACACAACATTTTCTAG

30

CTTCAGAAAGTCAGGGAGCCCAGATCACAGCCTGAACCTCATGGTATTGGTTACA

GATTCTTTACAAAGGTGTTTACCTCTCTCATGAGGTCTTCTTGATTGGTTACTTCC

TCAGAAAAATCATCATTGACATCCAACACCAGCACTGGAATGTTTCATCAGAGCCT

CAAAGTGGAGCCTGTCACCTGTACACANGACCTCTCAAAGATCTGTACTGGCTTC

CTGGCCTGGTAAGAGTTCTCAGGGGAAG

35

SEQ ID NO: 704

yb54f05.r1 Stratagene ovary (#937217) Homo sapiens cDNA clone IMAGE:75009 5',
 mRNA sequence gi|653755|gb|T51895.1|T51895[653755]

TTTCTACCGTCCTTGTCATAACTTTGTGTTGGAGGGAACCTGTTTCACTATGGCCT

40

CCTTTGCCCAAGTTGAAACAGGGGCCCCATCATCATGTCTGTTTCCAGAACAGTGC

CTTGGTCATCCACATCCCCGGACCCCGCCTGGGGACCCCAAGCTGTGTCTTAT

GAAGGGGTGTGGGGGTGAGGTAGTGAAGGGCGGTAGTTGGTGGTGGGACCC

AGAAACGGACGCCGGTGCTTGGGAGGGGTTCTTAAATTAATATTTTAAAAAAG

TAACTTTTTTTGTATTAAATTAATAAAGAAAATNNGGGACG

45

SEQ ID NO: 705

zx69a01.s1 Soares_total_fetus_Nb2HF8_9w Homo sapiens cDNA clone IMAGE:796680 3',
 mRNA sequence gi|2185799|gb|AA460679.1|AA460679[2185799]

TACTCAGTCACCAACCCAGAAATTGTCCGAGTTATGAAATAGATTCATTTTGAGAA

GTTACACATTCAGTTTGTATTATGAACTAGCCTGTCTTGTTTCTGCCTCTTGTAAGA
AAAGAGCTAGGTCTTTATGCTGCTAGGACAAAATACTGTACATGAATTGGAGAA
TAAGGAGGGGTATCCTTCTCCCCGGTACCGGAACAAGAGAACAGTTAGTACAG
AAATGGCTTTGGCACTTTAACCCCTTAGACATTGTCCCAAACCTTGTTACTTGAGTA
5 TTGTAGCCTCACCATGATTTTATTTTAAACACCGTATCATCTCCATACTTTTATTTA
CAAATTATATATACACACAATAATACAATTCCTTCATTCTAAAACAATAGTAGAC
CCCAAACAGGTCTACATTAAGTTTC

SEQ ID NO: 706

10 zv64g11.s1 Soares_total_fetus_Nb2HF8_9w Homo sapiens cDNA clone IMAGE:758468 3',
mRNA sequence gi|2046825|gb|AA393856.1|AA393856[2046825]
TTTAACATCAGTTAAAGATTTTATTTGATTCATTAAAGAGGAACTGGTGAGGCA
TTTCCACCAGCTCAAGGAAGAATTTTGTAATGTTATATTTATGGATCAGAAATA
ACTGAAATGAATGTGCAAATGGAGGCAAACTGGCCTCTTCCACAGTGGGGAAG
15 AAAGTCAACAGAACCTCCACTAGGCATAATTTACATATGTACAGACTCAATCAGC
TTTTAATATAGAAAGATATTTGAACCCAAAATCTTTCATTAAAGGTAAAAAATACA
ATAATAATTTTAAATGAAATCCTGGAAAATTCATACAAATAAAATTTAAAGCCTC
CAATGGGGTATAATCCAGCAATATCCTAGGCAAATGCCTCCTGAAGAACAACAG
CCTTTTAAACATCACTGTTTATCATTCAAAATTCAGACGTCTCCTATCTTTGGC
20 TATTTTATCTCTTCAACT

SEQ ID NO: 707

faa47b01.f1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:824041 5' similar to
AF010001.1 (HSP70) mRNA sequence
25 gi|2219894|gb|AA490721.1|AA490721[2219894]
TATCTCAGAAAAGAAGACATGCGATATGCCCTGCGTAAACTGGATGACACCAAA
TTCCGCTCTCATGAGGGTGAACTTCCTACATCCGAGTTTATCCTGAGAGAAGCA
CCAGCTATGGCTACTCACGGTCTCGGTCTGGGTCAAGGGGCCGTGACTCTCCATA
CCAAAGCAGGGGTCTCCACACTACTTCTCTCCTTTTCAAGGCCCTACTGAGACAGGT
30 GATGGGAATTTTCTTTATTTTATAGGTAACTGAGCTGCTTTGTGCTCAGAATC
TACATTCCAGATTGAGGATTTAGTGTCTTAGGAAATTTTTTAAATTTTTTTTTTTA
AA

SEQ ID NO: 708

35 Human 78 kdalton glucose-regulated protein (GRP78) gene, complete cds
gi|183644|gb|M19645.1|HUMGRP78[183644]
CCCGGGGTCACCTCTGCTGGACCTACTCCGACCCCCTAGGCCGGGAGTGAAGGC
GGGACTTGTGCGGTTACCAGCGGAAATGCCTCGGGGTCAGAAAGTCGCAGGAGAG
ATAGACAGCTGCTGAACCAATGGGACCAGCGGATGGGGCGGATGTTATCTACCA
40 TTGGTGAACGTTAGAAACGAATAGCAGCCAATGAATCAGCTGGGGGGGCGGAGC
AGTGACGTTTATTGCGGAGGGGGCCGCTTCGAATCGGCGGGCGGCCAGCTTGGTG
GCCTGGGCCAATGAACGGCCTCCAACGAGCAGGGCCTTCACCAATCGGCGGCCT
CCACGACGGGGCTGGGGGAGGGTATATAAGCCGAGTAGGCGACGGTGAGGTCTG
ACGCCGGCCAAGACAGCACAGACAGATTGACCTATTGGGGTGTTTCGCGAGTGT
45 GAGAGGGAAGCGCCGCGCCTGTATTTCTAGACCTGCCCTTCGCCTGGTTCGTGG
CGCCTTGTGACCCCGGGCCCCTGCCGCTGCAAGTCGAAATTGCGCTGTGCTCCT
GTGCTACGGCCTGTGGCTGGACTGCCTGCTGCTGCCCAACTGGCTGGCAAGATGA
AGCTCTCCCTGGTGGCCGCGATGCTGCTGCTGCTCAGCGCGGCGGGGCCGAGG
AGGAGGACAAGAAGGAGGACGTGGGCACGGTGGTCGGCATCGACTTGGGGACC

ACCTACTCCTGGTAAGTGGGGTTGCGGATGAGGGGGACGGGGCGTGGCGCTGGC
TGGCGTGAGAAGTGCGGTGCTGATGTCCCTCTGTCGGGTTTTTGCAGCGTCGGCG
TGTTCAAGAACGGCCGCGTGGAGATCATCGCCAACGATCAGGGCAACCGCATCA
CGCCGTCCTATGTCGCCCTTCACTCCTGAAGGGGAACGTCTGATTGGCGATGCCGC
5 CAAGAACCAGCTCACCTCCAACCCCGAGAACACGGTCTTTGACGCCAAGCGGCT
CATCGGCCGCACGTGGAATGACCCGTCTGTGCAGCAGGACATCAAGTTCTTGCCG
TTCAAGGTTGACCCGGTTTTCTCATCCAGTTAGAGAACGGGTGGGTGGTGGGAG
TATTTAGAGTTATAAGTCTCTGGAAGTGTGAGACAACAGTTGAAGGTTATAG
ACATGATGTATGTAATAACTTTAATACTATTAGTATGTTACAAAACCTTAAGACAG
10 TTGCTGTCGTAAGTGTCTACGATAGTTTAGGAATAAAAGACCGATTAAACTGAAC
TTTGTAAGACACCTATACTCCCTGAAGTATTTCTAGTCAATTTGCAGCCCCAAGG
GACCAAAATAAACCAAAATTGTGGGGATGGTAGTGGGTCTTTTAACTTTGAGATG
TCATTGTATCTGTGTCTGAAAACAATAATTCTTTAAATAGGTGGTTGAAAAGAA
AACTAAACCATAACATTCAAGTTGATATTGGAGGTGGGCAAACAAAGACATTTGC
15 TCCTGAAGAAATTTCTGCCATGGTTCTCACTAAAATGAAAGAAACCGCTGAGGCT
TATTTGGGAAAGAAGGTAAATATTTCTAGAACAAATGTTAAGTATTTTTTGATCAT
TAGTATTCTCGGTTGGCTGTTATGTATAGAAGCCTTCGTGAAGGGTTTCAAAAAT
TTTAATCAGAAATGGTATTCATGCTTGTACGGTTTAATTATTGAGTCCCTTTACTA
TAAGCCAAACAAAAATAGACTTTTCATGTATTATTTAATGCTTACAATTCCAGGA
20 ACAATAAAATTTTATATGTTGTATTCATCAATAATTGGCTTAAAACTAAAGTGA
TGGTTTGACTGTAATTTTTTTTTTTTGGAGATGGAGTCTTGCTCTGTTGCCAGGCT
GGACTGCAGTGGCAGGATCTCAGCTCACTGCAACCTCTGCCTCCCGGGTTAAGCA
GCTCTCCTGCCTCAGCCTCCAAGTAATGGAAAGGACAGGCACACCCACACAGGTG
GCTAATTTTTTTTTTTTTTTTAAATTTTCAGTAGAGAGAGGGTTTCTCCACATTGCC
25 AGGCTGGTCTTGAAATCCTGCCCTCAGGTTGATCCTCCTGCCTAGCCTCCCAAAG
TGCTGGATTATAGGCAGAAGCCACCGCCTGGCCAGACTGTAATTTAAATAAGGG
TTAAACTATGTGACAATACACTTAATTATCTTTATCCTTTTAGGTTACCCATGCAG
TTGTTACTGTACCAGCCTATTTAATGATGCCCAACGCCAAGCAACCAAAGACGC
TGGAACATATTGCTGGCCTAAATGTTATGAGGATCATCAACGAGCCGTAAGTATGA
30 AATTCAGGGATACGGCATATTTGCCAAATAGTGGAAATGTGAAGTACTGACAAA
ACTTTTCCCTTTTTCAATCTAATAGTACGGCAGCTGCTATTGCTTATGGCCTGGAT
AAGAGGGAGGGGGAGAAGAACATCCTGGTGTGTTGACCTGGGTGGCGGAACCTTC
GATGTGTCTCTTCTCACCATTGACAATGGTGTCTTCGAAGTTGTGGCCACTAATG
GAGATACTCATCTGGGTGGAGAAGACTTTGACCAGCGTGTGATGGAACACTTCAT
35 CAAACTGTACAAAAAGAAGACGGGCAAAGATGTCAGGAAGGACAATAGAGCTG
TGCAGAACTCCGGCGCGAGGTAGAAAAGGCCAAGGCCCTGTCTTCTCAGCATC
AAGCAAGAATTGAAATTGAGTCCTTCTATGAAGGAGAAGACTTTTCTGAGACCCT
GACTCGGGCCAAATTTGAAGAGCTCAACATGGTATGTTTCCTTGTTTTCTGCTTTC
TAATGAGATCTCCTTAGACTCTGAATTCAGGACATTGCATCTAGATACTTAGATA
40 ACAGACATCACAGTAACCATGTCTTTTTTCTAGGATCTGTTCCGGTCTACTATGAA
GCCCCGTCCAGAAAGTGTGGAAGATTCTGATTTGAAGAAGTCTGATATTGATGAA
ATTGTTCTTGTTGGTGGCTCGACTCGAATTCCAAAGATTCAGCAACTGGTTAAAG
AGTTCTTCAATGGCAAGGAACCATCCCGTGGCATAAACCCAGATGAAGCTGTAG
CGTATGGTGCTGCTGTCCAGGCTGGTGTGCTCTCTGGTGATCAAGATACAGGTAG
45 GTCATCATCGCAGCATCTTTCTTAGTGATTGAGTAGCTTGATGGAAGAGCTCGGT
ACCCCTATTGCTTTAGAAAATACCAGAATATGAGCAACAAGGTCACACAGCTAG
TAAAGGGTATAAGTGAAGACAAGACTGGGGTAGTCTCCAAGATCATTAGCAACT
GTTTAATTCAGTGCCTTTAAATGTGTGTGTTAGAACCCTAACCAATGTTAGAGA
GATAAACTTTACATAGCTCATAGGGAGAACTTGAATTAAGTTAAATAACTTAT

CCTTACAGGTGACCTGGTACTGCTTCATGTATGTCCCCTTACACTTGGTATTGAAA
 CTGTAGGAGGTGTCATGACCAAAGTATTCCAAGTAATACAGTGGTGCCTACCAA
 GAACTCTCAGATCTTTTCTACAGCTTCTGATAATCAACCAACTGTTACAATCAAG
 GTCTATGAAGGTAATTACCTTAAGTTTGGTTAATATCATGGCTTTTTTTTTTGAGAT
 5 GAAGTCTTGCTCTGTTGCCAGGCTGGACTGCAGTGGCACGATCTCGGCTCACTG
 CAAATTCTGTCTCCCGGGTTCAAGTGATTCTCCTGCCTCAGCCTCCAGAGTAGCT
 GGATTACAGCCTGACCACCACACCTGGCTAATTTCTGTATTTTAGTAGAGGATG
 GGCTTTCACCATGTTTCCAGGCTGGTCTCCAACCTCCTGACCTCAGGTCATCTGCC
 TGCTCCACCGTCCCGAAAGTACTGGGATTATAGCGTGAGCCACCACGCCAGATC
 10 TATCTATCATGGCATATTTTAAAAGAACATGACTTAATATGTCCTATTGAAATGG
 CTAGGGAACATAAGTAAGTACTGCTGTTTTTCAGATGGAGGTCTTAATTTGAATAATGTT
 GATATTAGATATTTAGCATTCTTTTTTTTTTTTTTTTAAATGGAGTCTTGCTCTGTCG
 CCTAGGCTGGGGTGAGTGGCATGACTTGCAACCTCTGCCTCCCGAATAGCTGGG
 ATTACAGGTGCCACCATCACGCCCGGCTAAGTTTGTATTTTAGTAGAGGCGA
 15 GTTTCGCCATGTTGGCCAGGCTGGTCTTGAACCCCTAACCTCAGTGATCCACGG
 TCACCGACCTGGCCTCCCAAAAGTACTGTACCCAGCCAATGATTAGCATTCTCAC
 TAATAATAGCATCTGAGCTGGCTCCTAGAGTACAAGAAAAAGGAGTTCACAGTA
 CTTTAAAATAGATAAAATTCAGTTGAGTTAGTAACCTAACTCATTGTTAGTACTA
 GTTGCTGCTCCTTGTAGACCAATATGAAATTACTTTTAGCTCGATAAAACCAAAA
 20 GTGTCACCTTATGCTTCAGACTGAAATGCGGGGATCTAGATGTGCTAATGCTTGT
 CAGTAACAATAACAAGTTTTCTGTATGTAACCTCTAGGTGAAAGACCCCTGAC
 TAAAAGACAATCATCTTCTGGGTACATTTGATCTGACTGGAATTCCTCGTCTCCTC
 GTGGGGTCCACAGATGAAAGTCACTTTGAGATAGATGTGAATGGTATTCTTCG
 AGTGACAGCTGAAGACAAGGGTACAGGGGACAAAAATAAGATGACAATCACC
 25 ATGACCAGAATCGCTGACACCTGAAGAAATCGAAAGGATGGTTAATGATGCTG
 AGAAGTTTGCTGAGGAAGACAAAAAGCTGAAGGAGCGCATTGATACTAGAAATG
 AGTTGGAAGCTATGCCTATTCTCTAAAGAATCAGATTGGAGATAAAGAAAAGC
 TGGGAGGTAACTTTCCTCTGAAGATAAGGAGACCATGGAAAAAGCTGTAGAAG
 AAAAGATTGAATGGCTGGAAAGCCACCAAGATGCTGACATTGAAGACTTCAAAG
 30 CTAAGAAGAAGGAACTGGAAGAAATTGTTCAACCAATTATCAGCAAACCTCTATG
 GAAGTGCAGGCCCTCCCCCAACTGGTGAAGAGGATACAGCAGAAAAAGATGAGT
 TGTAGACACTGATCTGCTAGTGCTGTAATATTGTAATACTGGACTCAGGAACCTT
 TTGTTAGGAAAAAATTGAAAGAACTTAAGTCTCGAATGTAATTGGAATCTTCACC
 TCAGAGTGGAGTTGAAACIGCTATAGCCTAAGCGGCTGTTTACTGCTTTTCATTA
 35 GCAGTTGCTCACATGTCTTTGGGTGGGGGGGAGAAGAAGAATTGGCCATCTTAA
 AAAGCGGGTAAAAAACCTGGGTTAGGGTGTGTGTTACCTTCAAATGTTCTATT
 TAACAACCTGGGTCATGTGCATCTGGTGTAGGAGGTTTTTTCTACCATAAGTGACA
 CCAATAAATGTTTGTTATTTACACTGGTCTAATGTTTGTGAGAAGCTT

40 SEQ ID NO: 709

Human adenosine receptor (A2) gene, complete cds

gi|177891|gb|M97370.1|HUMA2XX[177891]

GGCACGAGGCTGGCTGAGCCATGATGCTGCTGCCAGAACCCCTGCAGAGGGCCT
 GGTTCAGGAGACTCAGAGTCCTCTGTGAAAAAGCCCTTGGAGAGGCGCCCCAG
 45 CAGGGCTGCACTTGGCTCCTGTGAGGAAGGGGCTCAGGGTCTGGGCCCCCTCCGCC
 TGGGCCGGGCTGGGAGCCAGGCGGGCGGCTGGGCTGCAGCAATGGACCGTGAGC
 TGGCCCAGCCCGCGTCCGTGCTGAGCCTGCCTGTCGTCTGTGGCCATGCCATCAT
 GGGCTCCTCGGTGTACATCACGGTGGAGCTGGCCATTGCTGTGCTGGCCATCCTG
 GGCAATGTGCTGGTGTGCTGGGCCGTGTGGCTCAACAGCAACCTGCAGAACGTC

ACCAACTACTTTGTGGTGTCACTGGCGGGCGGCCGACATCGCAGTGGGTGTGCTCG
 CCATCCCCTTTGCCATCACCATCAGCACCGGGTTCTGCGCTGCCTGCCACGGCTG
 CCTCTTCATTGCCTGCTTCGTCCTGGTCCTCACGCAGAGCTCCATCTTCAGTCTCC
 TGGCCATCGCCATTGACCGCTACATTGCCATCCGCATCCCGCTCCGGTACAATGG
 5 CTTGGTGACCGGCACGAGGGCTAAGGGCATCATTGCCATCTGCTGGGTGCTGTCTG
 TTTGCCATCGGCCTGACTCCCATGCTAGGTTGGAACAAGTGGGTGAGCCAAAGG
 AGGGCAAGAACCCTCCAGGGCTGCGGGGAGGGGCCAAGTGGCCTGTCTCTTTG
 AGGATGTGGTCCCCATGAACTACATGGTGTACTTCAACTTCTTTGCCTGTGTGCTG
 GTGCCCCCTGCTGCTCATGCTGGGTGTCTATTTGCGGATCTTCCTGGCGGGCGCGAC
 10 GACAGCTGAAGCAGATGGAGAGCCAGCCTCTGCCGGGGGAGCGGGGCACGGTCCA
 CACTGCAGAAGGAGGTCCATGCTGCCAAGTCACTGGCCATCATTGTGGGGCTCTT
 TGCCCTCTGCTGGCTGCCCCCTACACATCATCAACTGCTTCACTTTCTTCTGCCCCG
 ACTGCAGCCACGCCCCCTCTCTGGCTCATGTACCTGGCCATCGTCCTCTCCACACC
 AATTTCGGTTGTGAATCCCTTCATCTACGCCTACCGTATCCGCGAGTTCCGCCAGA
 15 CCTTCCGCAAGATCATTTCGCAGCCACGTCTGAGGCAGCAAGAACCTTTCAAGGC
 AGCTGGCACCAAGTGCCCGGGTCTTGGCAGCTCATGGCAGTGACGGAGAGCAGGT
 CAGCCTCCGTCTCAACGGCCACCCGCCAGGAGTGTGGGCCAACGGCAGTGCTCC
 CCACCCTGAGCGGAGGCCCAATGGCTATGCCCTGGGGCTGGTGAGTGAGAGGGAG
 TGCCCAAGAGTCCCAGGGGAACACGGGCCTCCAGACGTGGAGCTCCTTAGCCA
 20 TGAGCTCAAGGGAGTGTGCCAGAGCCCCCTGGCCTAGATGACCCCTGGCCCA
 GGATGGAGCAGGAGTGTCTGATGATTGAGGTTTGGCCCTTCTTAAGGGAAG
 GAGATCTTTATCTTTCTGGTTGGCTTGACCAAGTCAAGTTGGGAGAAGAGAGAGAG
 TGCCAGGAGACCCTGAGGGGACCGGGTCTTCACTTTGGACTGAGAGAAGGGAGC
 CCCAGGCTGGAGCAGCATGAGGGCCAGCAAGAAGGGCTTGGGTTCTGAGGAAGC
 25 AGATGTTTCATGCTGTGAGGCCTTGCACCAGGTGGGGGCCACAGCACCAGCAGC
 ATCTTTGCTGGGCAGGGCCCCAGCCCTCCACTGCAGAAGCATCTGGAAGCACCACC
 TTGTCTCCACAGAGCAGCTTGGGCACAGCAGACTGGCCTGGCCCTGAGACTGGG
 GAGTGGCTCCAACAGCCTCCTGCCACCCACACACCACTCTCCCTAGACTCTCCTA
 GGGTTCAGGAGCTGCTGGGCCCAGAGGTGACATTTGACTTTTTTCCAGGAAAAAT
 30 GTAAGTGTGAGGAAACCCCTTTTTATTTTATTACCTTTCACTCTCTGGCTGCTGGGT
 CTGCCGTCGGTCTGCTGCTAACCTGGCACCAGAGCCTCTGCCGGGGAGCCTCAG
 GCAGTCTCTCCTGCTGTACAGCTGCCATCCACTTCTCAGTCCCAGGGCCATCTC
 TTGGAGTGACAAAGCTGGGATCAAGGACAGGGAGTTGTAACAGAGCAGTGCCAG
 AGCATGGGGCCAGGTCCCAGGGGAGAGGTTGGGGCTGGCAGGCCACTGGCATGT
 35 GCTGAGTAGCGCAGAGCTACCCAGTGAGAGGCCTTGTCTAACTGCCTTTCCTTCT
 AAAGGGAATGTTTTTTTCTGAGATAAAATAAAAACGAGCCACATCGTGTTTAAAG
 CTTGTCCAAATGAAAAAAAAAAAAAAAAAA/

SEQ ID NO: 710

40 za59g01.r1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:296880 5'
 similar to gb:M64925 55 KD ERYTHROCYTE MEMBRANE PROTEIN (HUMAN);,
 mRNA sequence gi|1273219|gb|W01240.1|W01240[1273219]
 GAGGAACATCTCTGCCAATGAGTTCTTGGAGTTTGGCAGCTACCAAGGCAACATG
 TTTGGCACCAAATTTGAAACAGTGCACCAGATCCATAAGCAGAACAAGATTGCC
 45 ATCCTTGACATTGAGCCCCAGACCCTGAAAATTGTTTCGGACAGCAGAAGCTTTCGC
 CTTTCATTGTGTTTCATTGCACCTACTGACCAGGGCACTCAGACAGAAGCCCTGCA
 GCAGCTGCAGAAGGACTCTGAGGCCATCCGCAGCCAGTACGCTCACTACTTTGAC
 CTCTCACTGGTCAATAATGGTGTGATGAAACCCTTAANGAAATTACAAGAAGCC
 TTCGACCAAGCGTGCAGTTCTCCACAGTGGGGTGGCTGGTCTCCTGGGGTTTACT

NAAGCCTGGTAAGAATTGGGGGGAACCCACTTGGTATTGNCCCTCTTCCAGGATT
TTGGAAATTCCAACCGGCCTTGGNTTTAAGAGAAAANAAGGGNTGGTTCCCACT
AAT

5 SEQ ID NO: 711

ab36c08.r1 Stratagene HeLa cell s3 937216 Homo sapiens cDNA clone IMAGE:842894 5'
similar to TR:G1256802 G1256802 SODIUM/POTASSIUM-TRANSPORTING ATPASE
BETA-3 SUBUNIT.; mRNA sequence gi|2218877|gb|AA489275.1|AA489275[2218877]
CTGGCCGAGTGGGAAGCTCTTCATCTACAACCCGACCACCGGAGAATTCCTGGGGC
10 GCACCGCAAGAGCTGGGGTTTGTCTTGTCTTCTACCTAGTTTTTTATGGGTTCC
TGGCTGCACTCTTCTCATTACGATGTGGGTTATGCTTCAGACTCTCAACGATGA
GGTTCCAAAATACCGTGACCAGATTCTAGCCAGGACTCATGGTTTTTCCAAAA
CCAGTGACCGCATTGGAATATACATTCAAGTAGGTCTGATCCAACCTCGTATGCAG
GGTACATTGAAGACCTTAAGAAGTTTCTAAAACCATATACTTTAGAAGAACAGA
15 AGAACCTCACAGTCTGTCCTGATGGAGCACTTTTTGAACAGAAGGGTCCAGTTTA
TGTTGCATGTCAGTTTCCTATTTCACTTCAAGCATGCAGTGGTATGAATGATC
CTGATTTTGGCTATTCTCAAGGAAAC

SEQ ID NO: 712

20 za24e08.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:293510 3',
mRNA sequence gi|1225735|gb|N69574.1|N69574[1225735]

AACTAATATTAAATAGTAAATTTAATGEGTATFAATATTGTCATATAATATTGNN
AATTACTCATGTAAATGTAAATATTACATTGAGGATATAGTAAATATTAAATTEAC
TATGTCATTGAGGACAGTATTTCAAACCTAGCTTTTAAAAAGAAAAACAGAGA
25 TTGGCAGTGAATAGAACAGTGATTGTTCACTACTTGGATCTACTGCCTTAATTT
ATACTAGGATGTCAATCCACCATTGATTTTGGACCATCAGTGCCAATGTCNACGT
AGCCAAAAAGGCCAAT

SEQ ID NO: 713

30 Human mRNA for gamma-interferon inducible early response gene (with homology to
platelet proteins) gi|33917|emb|X02530.1|HSINFGER[33917]

GAGACATTCTCAATTGCTTAGACATATTCTGAGCCTACAGCAGAGGAACCTCCA
GTCTCAGCACCATGAATCAAACCTGCGATTCTGATTTGCTGCCTTATCTTTCTGACT
CTAAGTGGCATTCAGGAGTACCTCTCTCTAGAACCGTACGCTGTACCTGCATCA
35 GCATTAGTAATCAACCTGTTAATCCAAGGTCTTTAGAAAACTTGAAATTATTCC
TGCAAGCCAATTTTGTCCACGTGTTGAGATCATTGCTACAATGAAAAAGAAGGGT
GAGAAGAGATGTCTGAATCCAGAATCGAAGGCCATCAAGAATTTACTGAAAGCA
GTTAGCAAGGAAATGTCTAAAAGATCTCCTTAAAACCAGAGGGGAGCAAAATCG
ATGCAGTGCTTCCAAGGATGGACCACACAGAGGCTGCCTCTCCCATCACTCCCT
40 ACATGGAGTATATGTCAAGCCATAATTGTTCTTAGTTTGCAGTTACACTAAAAGG
TGACCAATGATGGTCACCAAATCAGCTGCTACTACTCCTGTAGGAAGGTAAATGT
TCATCATCCTAAGCTATTCAGTAATACTCTACCCTGGCACTATAATGTAAGCTCT
ACTGAGGTGCTATGTTCTTAGTGGATGTTCTGACCCTGCTTCAAATATTTCCCTCA
CCTTTCCCATCTTCCAAGGGTACTAAGGAATCTTTCTGCTTTGGGGTTTATCAGAA
45 TTCTCAGAAATCTCAAATAACTAAAAGGTATGCAATCAAATCTGCTTTTTAAAGAA
TGCTCTTTACTTCATGGACTTCCACTGCCATCCTCCCAAGGGGCCCAAATTCTTTC
AGTGGCTACCTACATACAATTCCAAACACATACAGGAAGGTAGAAATATCTGAA
AATGTATGTGTAAGTATTCTTATTTAATGAAAGACTGTACAAAGTATAAGTCTTA
GATGTATATATTTCTATATTGTTTTAGTGTACATGGAATAACATGTAATTAAGT

ACTATGTATCAATGAGTAACAGGAAAATTTTAAAAATACAGATAGATATATGCTC
TGCATGTTACATAAGATAAATGTGCTGAATGGTTTTCAAATAAAAATGAGGTACT
CTCCTGGAAATATTAAGAAAGACTATCTAAATGTTGAAAGATCAAAAGGTTAAT
AAAGTAATTATAACT

5

SEQ ID NO: 714

ab21g06.r1 Stratagene lung (#937210) Homo sapiens cDNA clone IMAGE:841498 5' similar
to gb:X54304 MYOSIN REGULATORY LIGHT CHAIN 2, NONSARCOMERIC
(HUMAN);, mRNA sequence gi|2217534|gb|AA487370.1|AA487370[2217534]

10 ACAAGGAAGATTTGTCATGATATGCTTGCTTCTCTAGGGAAGAATCCCACTGATGC
ATACCTTGATGCCATGATGAATGAGGCCCCAGGGCCATTCAATTTACCATGTTC
CTGACCATGTTTGGTGAGAAGTTAAATGGCACAGATCCTGAAGATGTCATCAGA
AACGCCTTTGCTTGCTTTGATGAAGAAGCAACAGGCACCATTGAGGAAGATTACC
TAAGAGAGCTGCTGACAACCATGGGGGATCGGTTTACAGATGAGGAAGTGGATG
15 AGCTGTACAGAGAAGCACCTATTGACAAAAAGGGGAATTTCAATTACATCGAGT
TCACACGCATCCTGAAACATGGAGCCAAAGACAAAGATGACTGAAAGAACTTTA
G

SEQ ID NO: 715

20 H.sapiens mRNA for central cannabinoid receptor
gi|736236|emb|X81120.1|HSCANN6[736236]

ATCGGCTTATTTGTTTTCCTCCTTAGGATTGCCCTGTGGGTCACTTTCTCAGT
TCATTTTGAGCTCAGCCTAATCAAAGACTGAGGTTATGAAGTCGATCCTAGATGGC
CTTGCAGATACCACTTCCGGACCATCACTGACCTCCTGTACGTGGGCTCAA
25 ATGACATTCAGTACGAAGACATCAAAGGTGACATGGCATCCAAATTAGGGTACT
TCCCACAGAAATTCCTTTAACTTCCTTTAGGGGAAGTCCCTTCCAAGAGAAGAT
GACTGCGGGAGACAACCCCCAGCTAGTCCCAGCAGACCAGGTGAACATTACAGA
ATTTTACAACAAGTCTCTCTCGTCTTCAAGGAGAATGAGGAGAACATCCAGTGT
GGGGAGAACTTCATGGACATAGAGTGTTTCATGGTCCTGAACCCCAGCCAGCAG
30 CTGGCCATTGCAGTCCTGTCCCTCACGCTGGGCACCTTCACGGTCCTGGAGAACC
TCCTGGTGCTGTGCGTCATCCTCCACTCCCGCAGCCTCCGCTGCAGGCCTTCCTAC
CACTTCATCGGCAGCCTGGCGGTGGCAGACCTCCTGGGGAGTGTCATTTTTGTCT
ACAGCTTCATTGACTTCCACGTGTTCCACCGCAAAGATAGCCGCAACGTGTTTCT
GTTCAAACCTGGGTGGGGTACGGCCTCCTTCACTGCCTCCGTGGGCAGCCTGTTC
35 CTCACAGCCATCGACAGGTACATATCCATTACAGGCCCTGGCCTATAAGAGGA
TTGTCACCAGGCCCAAGGCCGTGGTGGCGTTTTGCCTGATGTGGACCATAGCCAT
TGTGATCGCCGTGCTGCCTCTCCTGGGCTGGAAGTGCAGAACTGCAATCTGTT
TGCTCAGACATTTTCCCACACATTGATGAAACCTACCTGATGTTCTGGATCGGGG
TCACCAGCGTACTGCTTCTGTTTCATCGTGTATGCGTACATGTATATTCTCTGGAAG
40 GCTCACAGCCACGCCGTCCGCATGATTCAGCGTGGCACCCAGAAGAGCATCATC
ATCCACACGTCTGAGGATGGGAAGGTACAGGTGACCCGGCCAGACCAAGCCCGC
ATGGACATTAGGTTAGCCAAGACCCTGGTCCTGATCCTGGTGGTGTGATCATCT
GCTGGGGCCCTCTGCTTGCAATCATGGTGTATGATGTCTTTGGGAAGATGAACAA
GCTCATTAAAGACGGTGTGTTGATTCTGCAGTATGCTCTGCCTGCTGAACTCCACC
45 GTGAACCCCATCATCTATGCTCTGAGGAGTAAGGACCTGCGACACGCTTTCCGGA
GCATGTTTCCCTCTTGTGAAGGCACTGCGCAGCCTCTGGATAACAGCATGGGGGA
CTCGGACTGCCTGCACAAACACGCAAACAATGCAGCCAGTGTTACAGGGCCGC
AGAAAGCTGCATCAAGAGCACAGTCAAGATTGCCAAGGTAACCATGTCTGTGTC
CACAGACACGTCTGCCGAGGCTCTGTGAGCCTGATGCCTCCCTGGCAGCACAGG

AAAAGAATTTTTTTTTTTAAGCTCAAAATCTAGAAGAGTCTATTGTCTCCTTGGTT
ATATTTTTTTAACTTTACCATGCTCAATGAAAAGGTGATTGTCACCATGATCACTT
ATCAGTTTGCTAATGTTTCCATAGTTTAGGTACTCAAACCTCATTCTCCAGGGGTT
TACAGTGAAGAAAGCCTGTTGTTAAGTGACTGAACGATCCTTCAAAGTCTCAAT
5 GAAATAGGAGGGAAACCTTTGGCTACACAATTGGAAGTCTAAGAACCCATGGAA
AAATGCCATCAAATGAATAATGCCTTTGTAACCACTTTCACTATAATGTGAA
ATGTAAGTGTCCGTAGTATCAGAGATGTCCATTTTTACAAGTTATAGTACTAGAG
ATATTTTGTAATAATGTATTATGTCCTGTGAGATGTGTATCAGTGTTTATGTGCTAT
TAATATTTGTTTAGTTCAGCCAACTGAAAGGTAGACTTTTATGAGAACAATGGA
10 CAAGCAGTGGATACGTGTCAATGTGTGCACTTTTTTCTATATTATTGCCCATGAT
ATAACTTTAGAAATAAACCTTAATATTTCTTCCCAAAAAAAAAAAAA

SEQ ID NO: 716

Human mRNA for dihydropteridine reductase (hDHPR)

15 gi|30818|emb|X04882.1|HSDHPR[30818]
CGGAGCCGGGCTGGCAGGAGCAGGATGGCGGCGGCGGCGGCTGCAGGCGAGGC
GCGCCGGGTGCTGGTGTACGGCGGCAGGGGCGCTCTGGGTCTCGATGCGTGCA
GGCTTTTCGGGCCCCGCAACTGGTGGGTGCCAGCGTTGATGTGGTGGAGAATGAA
GAGGCCAGCGCTACGATCATTGTTAAAATGACAGACTCGTTCACTGAGCAGGCT
20 GACCAGGTGACTGCTGAGGTTGGAAAGCTCTTGGGTGAAGAGAAGGTGGATGCA
ATTCTTTGCGTTGCTGGAGGATGGGCCGGGGGCAATGCCAAATCCAAGTCTCTCT
TTAAGAAGTGTGACCTGATGTGGAAGCAGAGCATATGGACATCGACCATCTCCA
GCCATCTGGCTACCAAGCATCTCAAGGAAGGAGGGCTCCTGACCTTGGCTGGCGC
AAAGGCTGCCCTGGATGGGAGTCTTGGTATGATCGGGTACGGCATGGCCAAGGG
25 TGCTGTTCAACCAGCTCTGCCAGAGCCTGGCTGGGAAGAACAGCGGCATGCCGCC
CGGGGCAGCCGCCATCGCTGTGCTCCCGGTTACCCTGGATACCCCGATGAACAGG
AAATCAATGCCTGAGGCTGACTTCAGCTCCTGGACACCCTTAGAATTCCTAGTTG
AACTTTCCATGACTGGATCACAGGGAAAAACCGACCGAGCTCAGGAAGCCTAA
TCCAGGTGGTAACCAACAGAAGGAAGGACGGAACCTACCCAGCATATTTTTAGG
30 CCTCATCTCAGTGCCTATGAGGGGCTGCCAGAAAAGTCACTAACCTGTCTCAGT
GTGGCCTTGTCCAGCCTTGTGTTTTCTGTAAACCCCTGTTTGTGGTACGAGATAATG
AGTCCTATTTTTCTCTCACATAATATGCATTTGCTCTCCTAGGACAGTGTAAATACA
TTTATGTGAAGTAAAGACATGCGAGACTGGTGGCCTGCAAATAGCATCCGTCAAT
CTGTGTAACTGCATAGGGAGGGCTCTGCATAGCACCTGCTATAGCGGTGTCATG
35 TTGGATCGCTTTTGTGACTGTTTATCTGTCTTGACAGTGGCTGTCATCTTGACTA
CTTTGTTGATTTGTTGGTATTGGGGACATTTTAAAGGCTGAGTTATTTTTGAATGT
CATGTTTATGTCATAGACGTAGTTTTTCGCATCCTTGAATTAACTGCCTTAACCTC
TTTTGTGGTAT

40 SEQ ID NO: 717

aa24g12.r1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:814246 5' similar to
gb:D00762 PROTEASOME COMPONENT C8 (HUMAN);, mRNA sequence

gi|2191760|gb|AA465593.1|AA465593[2191760]

CGATGACTCAATCGGCACTGGGTATGACCTGTCAGCCTCTACATTCTCTCCTGAC
45 GGAAGAGTTTTTCAAGTTGAATATGCTATGAAGGCTGTGGAAAATAGTAGTACA
GCTATTGGAATCAGATGCAAAGATGGTGTGCTTTGGGGTAGAAAAATTAGTCC
TTTCTAACTTTATGAAGAAGGTTCCAACAAAAGACTTTTTAATGTTGATCGGCA
TGTTGGAATGGCAGTAGCAGGTTTGTGGCAGATGCTCGTTCTTTAGCAGACATA
GCAAGAGAAGAAGCTTCCAACCTCAGATCTAACTTTGGCTACAACATTCCACTAA

AACATCTTGCAGACAGAGTGGCCATGTATGTGCATGCATATACACTCTACAGTGC
TGTTAGACCTTTTGGGCTGCAGTTTCA

SEQ ID NO: 718

- 5 zx10e07.s1 Soares_total_fetus_Nb2HF8_9w Homo sapiens cDNA clone IMAGE:786084 3',
mRNA sequence gi|2162337|gb|AA448667.1|AA448667[2162337]
ATAAATCTATAGTTTTATTAAAGACAAAACTGACAATGTAGTATGAAGTTTACAT
TTAAA
CAAAGTTTACACAGGAATCTAACACATGCCTAAAAGAATTTTACAACGTAGCTCT
10 AGATGCAAGTCTAGACAATATCAAGAAGTATGATGGTTCTCATGACTCAAGACAGA
GCATTTTGGGTATGTTACTTATTAGGATTTCTTAAAAAATTGTTTTGTGTGTGTAT
GTGTGTGTTTTAAAGTGAACCACTGCCCAATATGAAAGTTTAATCTTCTCCTGAG
ACCAAGGCTTTTGAAATCACTAAACTCTTGATCAATTCAGTGAAACTTGTGCTG
TCAGTGAAGTGAACCTGCCAACAATGGTTTCAGTGTTCAAAGCTCAAAGAAAAC
15 GGCT

SEQ ID NO: 719

Human hyaluronate receptor (CD44) gene, exon 1

gi|180127|gb|M69215.1|HUMSCG01[180127]

- 20 TGGTTTGTGGTTTTTATGAAGAGATGTGAAAAAGGAAGTGTGGAATGATGGGAT
GAGAAGTTGTATGGGGAAGATGAATAGAAGAATTAGGTGGTTGAATAAAATTAA
TAAGGTGTGTGGTTGGATGAATGAATGAGTGGGATGATAGATGGACCTAAGTGGT
TAGTGGATGGACAGGAGGATGGATGGATGTGAGAGCCCCAGAAGGACATAAGG
TAAGATGGGTGGATAGATGGATGGGCGGATGGAAGGATATETAGGAGGATGAAT
25 GAGCATGTGTGTGGAGAGAGGTGCCCATTCACACTGGCTTGAACACATGGGTTA
GCTGAGCCAAATGCCAGCCCTATGACAGGCCATCAGTAGCTTTCCCTGAGCTGTT
CTGCCAAGAAGCTAAAATTCATTCAAGCCATGTGGACTTGTTATTGAGGGGAAA
AAGAATGAGCTCTCCCTCTTTCCACTTGGAAGATTCACCAACTCCCCACCCCTCA
CTCCCCACTGTGGGCACGGAGGCACTGCGCCACCCAGGGCAAGACCTCGCCCTCT
30 CTCCAGCTCCTCTCCAGGATATCCAACATCCCTGTGAAACCAGAGATCTTGCTC
CAGCCGGATTGAGAGAAATTTAGCGGGAAAGGAGAGGGCCAAAGGCTGAACCCA
ATGGTGCAAGGTTTTACGGTTCGGTTCATCCTCTGTCCTGACGCCGCGGGGCCAGC
GGGAGAAGAAAGCCAGTGCCTCTCTGGGCGCAGGGGCCAGTGGGGCTCGGAGG
CACAGGCACCCCGCGACACTCCAGGTTCCCCGACCCACGTCCCTGGCAGCCCCGA
35 TTATTTACAGCCTCAGCAGAGCACGGGGCGGGGGCAGAGGGGCCCCGCGGGGAG
GGCTGCTACTTCTTAAAACCTCTGCGGGCTGCTTAGTCACAGCCCCCTTGCTTGG
GTGTGTCCTTCGCTCGCTCCCTCCCTCCGTCTTAGGTCACTGTTTTCAACCTCGAA
TAAAAACTGCAGCCAACCTCCGAGGCAGCCTCATTGCCCAGCGGACCCAGCCTC
TGCCAGGTTCCGTCCGCCATCCTCGTCCCGTCCCTCCGCCGGCCCCCTGCCCCGCGC
40 CCAGGGATCCTCCAGCTCCTTTGCCCCGCGCCCTCCGTTCGCTCCGGACACCATG
GACAAGTTTTGGTGGCACGCAGCCTGGGGACTCTGCCTCGTGCCGCTGAGCCTGG
CGCAGATCGGTGAGTGCCCGCCGCAGGCTGGGCAGCAAGATGGGTGCGGGGTGC
TCAGCGCGGAC

45 SEQ ID NO: 720

yi63g06.r1 Soares_placenta_Nb2HP_Homo sapiens cDNA clone IMAGE:143962 5', mRNA
sequence gi|851402|gb|R76770.1|R76770[851402]

AATTCGGAACGAGGNCTGTACAACACAGTGTGCATACAGGGATAATGCTATCATA
TTAATATGAAACAGTGTACGGGCACAAATTACCCATTTCTACAAAATAAGTGT

GCAAGTGATGCCACATATTATCCATATTCAACTGAGCTGTCATCAAAATACATTT
 TATTTACAATATGTACTATGATCAGTTGGATATTAAGTTCTAAAATGATTTACTTC
 ACTGCTACATTATAAAGGTAAAAGCAATGTGTAGGAAAAAGTGTGAGATTGTGT
 TTTTACATACTGCTTTTGTAGTTGCCATCGCTGGTTCAGTTCGACTTATAACATAT
 5 GTCTTGCTTGTAGGATTTAACACCTCCAATAGGGGATTCTTCTAACATTACAGGA
 GGATTCTTAGGGGATCCGGGGGCTTTTTCANCAAGTATAT

SEQ ID NO: 721

yi07h02.r1 Soares placenta Nb2HP Homo sapiens cDNA clone IMAGE:138579 5', mRNA
 10 sequence gi|835174|gb|R63295.1|R63295[835174]

AATTCGGAACGAGGGAGAAATCAGTCTGGTTTCCATCCCAGTCGGGGAAGAGAG
 AGGTGAGAGGGAATCAGAACGTACCTAGTTGATTCTTGGTGACAAGTGCAATG
 GGGTATGGGTAGAATTTATTTTCAGAGCCAAGAGGACTTGATGGTTATAAATAAA
 GTTGCCTTTAGCAATGGAATTTACAGATCGATCATGTTGTTCCNAAAGATGTGAA
 15 TAGGATCCACAATAACAAGTTGATTTCAGACTAATGTAGATATTTAGATTAGCAAG
 TATTGAACATTTGATTTCTTAGGACTGAGCTTTTAAATGAATTTCCATTATTTCTT
 CC

SEQ ID NO: 722

20 Homo sapiens P2U nucleotide receptor mRNA, complete cds
 gi|984506|gb|U07225.1|HSU07225[984506]

CGGCACGAGGCACCCCGAGAGGAGAAGCGCAGCGEAGTGGCGAGAGGAGCCCC
 TTGTGGCAGCAGCACTAECTGCCGAGAAAAATGCTGGAGGCTGGGCGTGGCCCC
 AGGCCTGGGGACCTGTTTTTCTGTTTCCCGCAGAGTTCCCTGCAGCCCGGTCCA
 25 GGTCCAGGCGTGTGCATTCATGAGTGAGGAACCCGTGCAGGCGCTGAGCATCCT
 GACCTGGAGAGCAGGGGCTGGTCAGGGCGATGGCAGCAGACCTGGGCCCCCTGGA
 ATGACACCATCAATGGCACCTGGGATGGGGATGAGCTGGGCTACAGGTGCCGCT
 TCAACGAGGACTTCAAGTACGTGCTGCTGCCTGTGTCCTACGGCGTGGTGTGCGT
 GCTTGGGCTGTGTCTGAACGCCGTGGCGCTCTACATCTTCTTGTGCCGCCTCAAG
 30 ACCTGGAATGCGTCCACCACATATATGTTCCACCTGGCTGTGTCTGATGCACTGT
 ATGCGGCCTCCCTGCCGCTGCTGGTCTATTACTACGCCCGCGGCGACCACTGGCC
 CTTACGACGCGGTGCTCTGCAAGCTGGTGCCTTCTCTTCTACACCAACCTTTACT
 GCAGCATCCTCTTCTCACCTGCATCAGCGTGCACCGGTGTCTGGGCGTCTTACG
 ACCTCTGCGCTCCCTGCGCTGGGGCCGGGCCGCTACGCTCGCCGGGTGGCCGGG
 35 GCCGTGTGGGTGTTGGTGCTGGCCTGCCAGGCCCGCGTCTACTTTGTCACCA
 CCAGCGCGCGGGGGCCGCGTAACCTGCCACGACACCTCGGCACCCGAGCTCT
 TCAGCCGCTTCGTGGCCTACAGCTCAGTCATGCTGGGCGCTGCTCTTCGCGGTGCC
 CTTTGCCGTCATCCTTGTCTGTTACGTGCTCATGGCTCGGCGACTGCTAAAGCCAG
 CCTACGGGACCTCGGGCGGCCTCCCTAGGGCCAAGCGCAAGTCCGTGCGCACCA
 40 TCGCCGTGGTGCTGGCTGTCTTCGCCCTCTGCTTCCTGCCATTCCACGTCACCCGC
 ACCCTCTACTACTCCTTCCGCTCGCTGGACCTCAGCTGCCACACCCTCAACGCCAT
 CAACATGGCCTACAAGGTTACCCGGCCGCTGGCCAGTGCTAACAGTTGCCTTGAC
 CCCGTGCTCTACTTCTTGGCTGGGCAGAGGCTCGTACGCTTTGCCCGAGATGCCA
 AGCCACCCACTGGCCCCAGCCCTGCCACCCCGGCTCGCCGAGGCTGGGCCTGCG
 45 CAGATCCGACAGAACTGACATGCAGAGGATAGGAGATGTGTTGGGCAGCAGTGA
 GGACTTCAGGCGGACAGAGTCCACGCCGGCTGGTAGCGAGAACACTAAGGACAT
 TCGGCTGTAGGAGCAGAACACTTCAGCCTGTGCAGGTTTATATTGGGAAGCTGTA
 GAGGACCAGGACTTGTGCAGACGCCACAGTCTCCCCAGATATGGACCATCAGTG
 ACTCATGCTGGATGACCCCATGCTCCGTCATTTGACAGGGGCTCAGGATATTCAC

TCTGTGGTCCAGAGTCAACTGTTCCCATAACCCCTAGTCATCGTTTGTGTGTATAA
GTTGGGGGAATTAAGTTTCAAGAAAGGCAAGAGCTCAAGGTCAATGACACCCCT
GGCCTGACTCCCATGCAAGTAGCTGGCTGTACTGCCAAGGTACCTAGGTTGGAGT
CCAGCCTAATCAAGTCAAATGGAGAAACAGGCCCAGAGAGGAAGGTGGCTTACC
5 AAGATCACATAACCAGAGTCTGGAGCTGAGCTACCTGGGGTGGGGGCCAAGTCAC
AGGTTGGCCAGAAAACCCCTGGTAAGTAATGAGGGCTGAGTTTGCACAGTGGTCT
GGAATGGACTGGGTGCCACGGTGGACTTAGCTCTGAGGAGTACCCCCAGCCCAA
GAGATGAACATCTGGGGACTAATATCATAGACCCATCTGGAGGCTCCCATGGGC
TAGGAGCAGTGTGAGGCTGTAACCTTATACTAAAGGTTGTGTTGCCTGCTAAAAAA
10 AA

SEQ ID NO: 723

aa50e04.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:824382 3', mRNA
sequence

15 gi|2219301|gb|AA489699.1|AA489699[2219301]
TTTTTTTTTTGAAATAATTGAAGAATTCAGTTAAATATTTATTGAACAAATGCAG
AGTA
AATGAACATAAGGGCTGTTATAACCTTAAGTTACAACAAACAACCTTCAAATATTCA
GAGGGCTGTCACACAGAGAATGAAAGACTTGCTCAGTATTTCTCCAAAGGGCAG
20 AACTTGAGCCAAGGGATAAATATAAGCAACCAATGGGCTGCAGGATAGTTGTAC
AAAGTGTATCATGTATCTTCATAGCTTCTTTGCCCATATAATGCATTCCACACTTA
AGTTTCTCCTTCTAAAGGGGACACGACAAGTTAATATGTCTCATAAATGTCTTA
AATAAGTTGCATTTTCATGGCAAGCCCTCCACTGCCAGCAATGGATATACTCACA
CTATGGAAAAAATCTAAAGTTAACAACCTGGTTTAGTATGGAAATGGTCTATTT
25 GTTCCTCAGCTATGTTCTGTATCCTACATTAGTGGCTCTCAGGAGG

SEQ ID NO: 724

HUMHBC4799 Human pancreatic islet Homo sapiens cDNA similar to alpha-1
antichymotrypsin, mRNA sequence gi|1262485|dbj|D83812.1|D83812[1262485]

30 CGCAGACAATGATGGTCCTGGTGAATTACATCTTCTTTAAAGCCAAATGGGAGAT
GCCCTTTGACCCCAANATACTCATCAGTCAAGGTTCTACTTGAGCAAGAAAAAG
TGGGTAATGGTGCCCATGATGAGTTTGCATCACCTGACTATACCTTACTTCCGGG
ACGAGGAGCTGTCCTGCACCGTGGTGGAGCTGAAGTACACAGGCAATGCCAGCG
CACTCTTCATCCTCCCTGATCAAGACAAGATGGAGGAAGTGAAGCCATGCTGCT
35 CCCANAGACCCTGAAGCGGTGGAGAGACTCTCTGGAGTTCANAGAGATAGGTGA
GCTCTACCTGCCAAAGTTTCCANCTCGAGGGACTATAACCTGAACGACATNCTT
CTCCAGCTGGGCATTGAGGAAGCCTTC

SEQ ID NO: 725

zx84c12.s1 Soares ovary tumor NbHOT Homo sapiens cDNA clone IMAGE:810454 3',
mRNA sequence gi|2179839|gb|AA457119.1|AA457119[2179839]

CTCATCAAAACATGATTTATTAATTTTAAGCAAGAGTAAGCATATGTGATAGTGG
CCAGCTTGGGGATAGAACTCTTCCTGGTTGATGCACAGTTCAGCACCTGTTGGGT
CTTGGCTGTTGGGATGATAATTCTTTTGGGTGAGGGGAACAGCCGTGGTCAAGGC
45 TGCCTGCACCCCCATCCAGGCACAGGACCCTGGGCAAAGTCTCAAAAGAGGTA
TGTTTTTACTTTCGCACCAACAATACAACATAAGTATTGGGTACAAAAGAGGAGA
TTTCCTTCCCCTCTACCTCAACGGGCAAAGGCCTTCCATCTTCAGAAGAGGCTT
GTGAGGACCATCGGTTGGATGACCTCCTAGTGAGTTCTGGCTCCCATTCAGAGCA

CAGAGAAACCCACAAAAGGGGCCTGTGGATCTGGTTCAGGTCTCAAGGGTACA
GCTTGGTTACATCCCCAGGCCCC

SEQ ID NO: 726

5 yu10b07.r1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:233365 5',
mRNA sequence gi|1057977|gb|H79888.1|H79888[1057977]
GGCACGAGAAATNGAGGCACAATATAGCACTGACTGAGTTGTAAAGCCTCCTGCC
TGGAGACTTCAGTTATAGCTGTAATAATTAATCTTATTTATAAAAAGCCACTCCAC
TAACCTTTTCTCTCCAACCTGTAAACACAGAGACAGCTTTGGGAATAAGCCAAAAA
10 CAGGGTGATCTCATTAGATTTTGAAGATATATGACTCCTTTGGGCTACATTTTCATA
TTGATCAATTTCTAGGTATTTTCACTGGCCCAAAGTATTGCATTCCCTTAACAGC
AAGCACAAGTTCTCTATATCACTTGTTTTTGTGTTGTTGTTGTTGTTGTCGTCGTTGT
TTTGAGGACGGAGTTTTGNCTCAGGTGCCCCGGNAGTGGCAGTGGTGAATCTCA
GCTCACTGGCAACCTCCACCTCCGGGGGTCAAGGCAATTCTCCGGTT

SEQ ID NO: 727

yr38g10.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:207618 3'
similar to gb:L24038_ma1 A-RAF PROTO-ONCOGENE SERINE/THREONINE-
PROTEIN KINASE (HUMAN);, mRNA sequence
20 gi|1012590|gb|H59758.1|H59758[1012590]
AATNATTAACAAGCAAAGGCCAGCAGAATTCTGTGCTTCTTGGTGAAGAAAGA
GAGGAGTTCCTTGAATGGCGGGGGAGACAGAAAGGGACCCCCCAAATCCACAT
GGGGTGCTGGGAACCCCAAATCCAGTGGAAAGGCACATCAGGCACAAATTCAG
GAGAGGTTCTGAGTGGAAATCCCTGCCACAAATCCAGCCATTGGAGATGGAGGAG
25 CTCCCAAATTTAGAAGTATCCCCAAAGCCAAGAGGAAACCAAATGATGGGAGG
AGACAGGGGGCTCAGTCTTTGGGCGGGGGTCCCCCAATTTCCAGAAGAAGTGGG
AAAAGGCACATGGGGGNCCCCCTTCATCTTCCCGGGGTGGGGGAATGGGGGGAT
TCCTNAGGGCAGCNTCAGGGGCAGAGACGAACCTTGTGTTGGGTGGTNGGGCAA
GGTTCCTTGGGCTTNGGAG

SEQ ID NO: 728

Human thyroid hormone receptor alpha 1 (TR-alpha-1) gene, complete cds

gi|339662|gb|M24748.1|HUMTHRA1A[339662]
TGCCGGGGGGGCCAGTGTGCCACCCAGTCTCTTGGCGTGCTGGAGGGGCATCCT
35 GGATGGAATTGAAGTGAATGGAACAGAAGCCAAGCAAGGTGGAGTGTGGGTCA
GACCCAGAGGAGAACAGTGCCAGGTCACCAGATGGAAAGCGAAAAAGAAAGAA
CGGCCAATGTTCCCTGAAAACCAGCATGTCAGGGTATATCCCTAGTTACCTGGAC
AAAGACGAGCAGTGTGTCGTGTGTTGGGGACAAGGCAACTGGTTATCACTACCGC
TGTATCACTTGTGAGGGCTGCAAGGGCTTCTTTCGCCGCACAATCCAGAAGAACC
40 TCCATCCCACCTATTCTGCAAATATGACAGCTGCTGTGTCATTGACAAGATCAC
CCGCAATCAGTGCCAGCTGTGCCGCTTCAAGAAGTGCATCGCCGTGGGCATGGCC
ATGGACTTGGTTCTAGATGACTCGAAGCGGGTGGCCAAGCGTAAGCTGATTGAG
CAGAACCAGGGAGCGGCGGCGGAAGGAGGAGATGATCCGATCACTGCAGCAGCG
ACCAGAGCCCCTCCTGAAGAGTGGGATCTGATCCACATTGCCACAGAGGCCCA
45 TCGCAGCACCAATGCCAGGGCAGCCATTGGAAACAGAGGCGGAAATTCCTGCC
CGATGACATTGGCCAGTCACCCATTGTCTCCATGCCGGACGGAGACAAGGTGGA
CCTGGAAGCCTTCAGCGAGTTTACCAAGATCATCACCCCGGCCATCACCCGTGTG
GTGGACTTTGCCAAAAAACTGCCCATGTTCTCCGAGCTGCCTTGCGAAGACCAGA
TCATCCTCCTGAAGGGGTGCTGCATGGAGATCATGTCCCTGCGGGCGGCTGTCCG

CTACGACCCTGAGAGCGACACCCTGACGCTGAGTGGGGAGATGGCTGTCAAGCG
 GGAGCAGCTCAAGAATGGCGGCCTGGGCGTAGTCTCCGACGCCATCTTTGAACT
 GGGCAAGTCACTCTCTGCCTTTAACCTGGATGACACGGAAGTGGCTCTGCTGCAG
 GCTGTGCTGCTAATGTCAACAGACCGCTCGGGCCTGCTGTGTGTGGACAAGATCG
 5 AGAAGAGTCAGGAGGCGTACCTGCTGGCGTTCGAGCACTACGTCAACCACCGCA
 AACACAACATTCGCACTTCTGGCCCAAGCTGCTGATGAAGGTGACTGACCTCCG
 CATGATCGGGGCCTGCCACGCCAGCCGCTTCCTCCACATGAAAGTCGAGTGCCCC
 ACCGAACTCTTCCCCCACTCTTCCTCGAGGTCTTTGAGGATCAGGAAGTCTAAA
 GCCTCAGGCGGCCAGAGGGTGTGCGGAGCTGGTGGGGAGGAGCCTGGAGAGAA
 10 GGGGCAGAGCTGGGGGCTGAGGGAGACCCCCCACACCCCTTCTCTCCTTCCTCT
 CGTCCTTGATAGATTACAGTCCCACACACACACCCCGCACTGCCAGGTCCCTC
 CTCAGACCTCCAGCCCTGGGACAGGGCAAACAACCTGAACTTGCTATGGAAAGGA
 CAGTGTGGGAGGCTGGGGGAGCTGTGTCCTGCAGTCCCAGGACCCCATCCTCTC
 AGAAGGTAGGGGAAGGGCGGGAGGATTGAGAAGGGACAAGCCACCTTGACCGT
 15 AGGGGAAGGAGGAATGTGGGCTGGGGGAAGATGCCCTCAACTACCCCCCTCACA
 CACATGAGAGAGAGCCCCACCCAGTTCCTTGGCCTAGGTCTCCCCTCCAGGCTG
 AGGGCCTCTCTACTTCCCCAGATGCCTGGGTGCAAAGAACGGCTTGGGCTGGCTC
 CTCCTCTGGAGGTTAAAATTTATAGTCATTCTAACTGCACTTGGAACCAAGCAA
 GGGGAGAAGACAAATGAAGAAAACT

20

SEQ ID NO: 729

ae40d05.s1 Gessler Wilms tumor Homo sapiens cDNA clone IMAGE:398281.3' similar to
 gb:X53416 ENDOTHELIAL ACTIN-BINDING PROTEIN (HUMAN);, mRNA sequence: gi|
 gi|2432277|gb|AA598978.1|AA598978[2432277]

25 TTTTTTTTAAATGGAAGCAAACTTTATTCCTCTTGGCTGGAGAAGAGAACTAGT
 GGGTGGTTGTGTACAGGACCCCCATCCCTCACCCCTCCCAGAACCAGAAAGAC
 AAGCAGCGCCACCAAATGGCTCCCTCTGCCCAAGTGAAAGCCGAGAGGTCAGCG
 GCTGGCTGGGGAGGCAGGTGAGCGCACACGGCACAGGGCAGGGGCGGCTGCAG
 TGACAGGCGGGCGGCCAGGGCGGCCTGGGCCGGGGTTGAGGGGAAGAGGGCGG
 30 GGCTGCTTGGGTAGCGGGGCAGGCTTGGGGGCTGCCGGCTGGCACGGGCCCCAG
 ACTCAGGGCACCAACAACGCGGTAGGGGCTGCCTGGGATGTGCTCGTCCCCCATT
 TGACCACAGTGTGTAATCCCCCTTGTCTTGAGCAGGTAGGACACGCTGTAGAG
 CCGGATTGCCAAGTTCTTTACAGGAGTTTCCCGCAGGGGGCCTTTGGCCATTAA
 CCCCACC

35

SEQ ID NO: 730

yr86d03.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:212165 3'
 similar to gb:Z22548 THIOL-SPECIFIC ANTIOXIDANT PROTEIN (HUMAN);, mRNA
 sequence gi|1030355|gb|H68845.1|H68845[1030355]

40 TTCCCTAATACTTTATTGGNTACCTCTAGGCCTGTGTGCGGCTGGGTGGGCTTGG
 GGGAGGGCGTCACTATTACGCTTCTAGGTGGAGGCATGAGAAGGCCTTGGCTAG
 NCCCTCCAGGGTCCCATACTGTGGAGTTTGGAGGGGCAGGTCTGGCCTTTCCTGG
 GTCAGCATAGGGCACCCAGGTNGGGGCACAGGTGGACACCCAGCACAGGCACCT
 AGGCAGGGGCACAAGCTCACTATCCGTTAGCCAGCCTAATTGTGTTTGGAGAAAT
 45 ATTCCTTGCTGTCATCCACGTTGGGCTTAATCGTGTCACTACCAGGCTTCCAGCCA
 GCGGGANAACTTTCCCCATGCTCGTCTGTGTACTGGGAAGGNCTGGGACCAGC
 CGCAGAGCCTANATTCCACGGAGCGTCCCACAGGCAAAT

SEQ ID NO: 731

ab23b05.r1 Stratagene lung (#937210) Homo sapiens cDNA clone IMAGE:841617 5' similar to TR:E183625 E183625 ORNITHINE DECARBOXYLASE ANTIZYME ;, mRNA sequence

5 gi|2217845|gb|AA487681.1|AA487681[2217845]
 GTGCTGAGTGGCGGCACTCTACATCGAGATCCCGGGCGGCGGCTGCCCCGAGGGG
 AGCAAGGACAGCTTTGCAGTTCTCCTGGAGTTCGCTGAGGAGCAGCTGCGAGCC
 GACCATGTCTTCATTTGCTTCCACAAGAACCGCGATGACAGAGCCGCCTTGCTCC
 GAACCTTCAGCTTTTTGGGCTTTGAGATTGTGAGACCGGGGCATCCCCTTGTCCT
 10 CAAGAGACCCGACGCTTGCTTCATGGCCTACACGTTTCGAGAGAGAGTCTTCGGG
 A

SEQ ID NO: 732

Human elastase III B mRNA, complete cds, clone pCL1E3

15 gi|607029|gb|M18692.1|HUMELA3A[607029]
 CCTATCATCGCAAACTCATGATGCTCCGGCTGCTCAGTTCCTCCTCCTTGTTGGC
 CGTTGCCTCAGGCTATGGCCACCTTCCTCTCGCCCTTCCAGCCGCGTTGTCAATG
 GTGAGGATGCGGTCCCCTACAGCTGGCCCTGGCAGGTTTCCCTGCAGTATGAGAA
 AAGCGGAAGCTTCTACCACACCTGTGGCGGTAGCCTCATCGCCCCGACTGGGTT
 20 GTGACTGCCGGCCACTGCATCTCGAGCTCCCGGACCTACCAGGTGGTGTGGGCG
 AGTACGACCGTGCTGTGAAGGAGGGCCCCGAGCAGGTGATCCCCATCAACTCTG
 GGGACCTCTTTGTGCATCCACTCTGGAACCGCTCGTGTGTGGCCTGTGGCAATGA
 CATCGCCCTCATCAAGCTCTGAGGCAGCGCCAGCTGGGAGACGCGCTCCAGCTC
 GCCTCACTCCCTCCGGCTGGTGACATCCTTCCCAACGAGACACCCTGCTACATCA
 25 CCGGCTGGGGCCGTCTCTATACCAACGGGCCACTCCCAGACAAGCTGCAGGAGG
 CCCTGCTGCCGGTGGTGGACTATGAACACTGCTCCAGGTGGAAGTGGTGGGGTTC
 CTCCGTGAAGAAGACCATGGTGTGTGCTGGAGGGGACATCCGCTCCGGCTGCAA
 TGGTGAAGTCTGGAGGACCCCTCAACTGCCCCACAGAGGATGGTGGCTGGCAGGT
 CCATGGCGTGACCAGCTTTGTTTCTGCCTTTGGCTGCAACACCCGCAGGAAGCCC
 30 ACGGTGTTCACTCGAGTCTCCGCCTTCATTGACTGGATTGAGGAGACCATAGCAA
 GCCACTAGAACCAAGGCCAGCTGGCAGTGCTGATCGATCCCACATCCTGAATA
 AAGAADAAGATCTCTCAG

SEQ ID NO: 733

35 yq07g06.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:196282 3', mRNA sequence gi|960149|gb|R92609.1|R92609[960149]
 TGCTGTTAGTTTAATGTGGACAGAGACATCCACGGCGTGACTGTTAGTTAGGAT
 GAGTCAGCTTGGGGGAGTTTGTGCTTCCTGCTTGGNGTGGCCAGCCACATGCCAA
 GGTCCCCTGCCTTCTAGCCCAGAATGACGGGACTGGGCAGAACACCCCCAACTTT
 40 TAGCTGCCACTTGGCTCATTACAGCAGTACCAGTATGGGGGTGGGAGGGGTGAG
 GCTNTGGAGTGAAGGCGGCGTATAGGGCAGAGACTAAGAGGGTCCTGTGAGATT
 CTTAGAGGAGCCATCCTGNTCCAAGGGGCCTGAGCTGAGTNTGGGTCTGTGAGC
 ATCTGCTGCTCCTCTCAGAGAGGGGAGATCTCACTCTCTGCCAGTCTGTCTAGCC
 CCAAAG

45

SEQ ID NO: 734

yv19b06.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:243155 3', mRNA sequence gi|1102102|gb|H94469.1|H94469[1102102]
 GCAAAACAACATTTATTCTTTAAAAAATCTATATACATTGCCATACAAAGATAC

CACATTGAAGCAGTTCTCAGGAACCTTCCAGTGAGCCTTCTCTTATAATTGCCCCG
 AGCAAGATTTCTGTCGCCAGAGAAAGTCTCAGCATTTCCACCTTGGTGTNCTCTATG
 TCATCATCTTGGAGCTGCTCGGTATCAGATTCTCCATGCACAGGTCTTCTTGACGT
 CAAGTCTCCAGACACCGCATCAACTCATAAGTCTGTTCTGCTGAGAAAATCACC
 5 TGTCTTCTGTTCCAAAAGGGGCAAGGCATCTGTGTCAGCAGAGTTCATCCCAGAAAGA
 CCGAAGGGGCAATCCGAGACGTCATCAAGGACAGAAGGA

SEQ ID NO: 735

aa91g07.s1 Stratagene fetal retina 937202 Homo sapiens cDNA clone IMAGE:838716 3'

10 similar to TR:G173234 G173234 RIBOSOMAL 5S RNA-BINDING PROTEIN ;, mRNA
 sequence

gi|2180364|gb|AA457644.1|AA457644[2180364]

TAGTATGAACTTAGTGTTTTAGTAGATCTTGTGATTTCTGAAAACGAATTTCTTC
 TAAACATCAAGCTATTTTCTTCACTATCTATACCTGCTATGCAGAGATTGAGAA
 15 CCAAACCAAATGGATATCTGCTTTTAAGATTAGAATTTGTTCTTCATCCTTAAAGC
 AGAACTCATTGAGATGAAAAGATGCTCTTAATTTATCACAGAACTGTGTATTTAA
 TAGTATGCTTATTAATAATCACGAAGTGTACTGGAATGCTAAGATAAAAGAACTGT
 ATAGTTTCTGTTATGTAATACGAGAATAGAAATGTTATTAATAATCTTTCTATAATT
 TCCAGTGCTTCTGTTTTGAAGAACAAGGCTTAATCCCCAAGAGGAAGTAGATAT
 20 GCCAGTGTTTTTCTACATTGATCCTGAATTTGCTGAAGATCCA

SEQ ID NO: 736

H.sapiens CD18 exon 14 gi|29753|emb|X63924.1|HSCD18X14[29753]

CTCCCCGCAGCTCCTGCGCCGAGTGCCTGAAGTTCGAAAAGGGCCCCCTTTGGGAA
 25 GAACTGCAGCGCGGCGTGTCCGGGCCTGCAGCTGTGCAACAACCCCGTGAAGGG
 CAGGACCTGCAAGGAGAGGGACTCAGAGGGCTGCTGGGTGGCCTACACGCTGGA
 GCAGCAGGACGGGATGGACCGCTACCTCATCTATGTGGATGAGAGCCGAGGTGA
 GGCCGC

30 SEQ ID NO: 737

ye81h02.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:124179 3',

mRNA sequence gi|751008|gb|R01272.1|R01272[751008]

TCTTTATTTAAATAAAAGTTTAAATAATGTGGGTAGTGTAATAATATTAATACA
 GAAATGTATAAAAGTTGAAAGTTTCATGTGATCTACACTGTTCAAAGAAAGCTGTG
 35 AATAGACCTTTCTATGCATTTATAAACATAAGCACACACATTTTAAATGAGTTC
 AACTGTACACTTTTCTATTAATAACTTGTTCACCTAATGTATCATGGCCATTTT
 TCCATACACAATGAATGTACTTTATTCATTTTAACAGATACGAGGATATTCCTAT
 ATGGGCTGGAACACACCTTTAACCCTATCCCTTTAATGACAGGACATTTAGGGN
 TTTCTATTACTTTCTACCCATGGTCCATTTTACGGCTTCTGTGGGGGATCCTTAA
 40 ATATCCCCCTCAGGTTCCCGGTTTCCATTTTGTT

SEQ ID NO: 738

zx35f11.s1 Soares_total_fetus_Nb2HF8_9w Homo sapiens cDNA clone IMAGE:788493 3',

mRNA sequence gi|2166225|gb|AA452556.1|AA452556[2166225]

45 TTTTGAAAGTAAAAATTTTATTTTGATTGATTTCTCAATGTATAGTTCAGTATAA
 TGCCAGTTTTTAATGGCAAAAATTTGGTTCCACTGAAACTCCATAATGCTACAGA
 GAGCTACTACTTTTCCAGGAAGTAGGTAAACAGCTAGAAAAGAAAAAGGACAAT
 TTCTAGCAGCATGGCAACTTAACTGCAGATCTAATAGGTCTGCAACTTTTACA
 CTAATAATGGCACAAACAGCTGGTGACACAAGTGAGAAATGGGGAACAAGATG

SEO ID NO: 739

15

ye40b03.r1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:120173 5', mRNA sequence gi|734317|gb|T95693.1|T95693|734317|

25

Human (clone HSY3RR) neuropeptide Y receptor (NPYR) mRNA, complete cds
gi|189313|gb|L01639.1|HUMNYRECA[189313]

30

35

40

45

TTTTTTTATACGATAAATAAAGTTTAAAAAGTTTACACATTTTTCAGATATAAAAG
ACTGACCAATATTGTACAGTTTTTATTGCTTGTGGATTTTGTCTTGTGTTTCTTT
AGTTTTTGTG

5 SEQ ID NO: 742

>AA504554

CACCCACGGTGACCGTTTTTCATCAGCAGCTCCCTCAACACCTTCCGCTCCGAGAA
GCGATACAGCCGCAGCCTCACCATCGCTGAGTTCAAGTGTAAGTGGAGTTGCTG
GTGGGCAGCCCTGCTTCTGCATGGAAGTGGGAGCTGTATGGAGTTGACGACAA

10 GTTCTACAGCAAGCTG

GATCAAGAGGATGCGCTCCTGGGCTCCTACCCTGTAGATGACGGCTG

SEQ ID NO: 743

>M11723

15 TTGGAGTCAACACTTTCGATTCCACCTTGGGAAGCCCCCAAGGAGCATAAGTACA
AAGCTGAAGAGCACACAGTCGTTCTCACTGTCACCGGGGAGCCCTGCCACTTCCC
CTTCCAGTACCACCGGCAGCTGTACCACAAATGTACCCACAAGGGCCGGCCAGG
CCCTCAGCCCTGGTGTGCTACCACCCCAACTTTGATCAGGACCAGCGATGGGGA
TACTGTTTGGAGCCCAAGAAAGTGAAAGACCACTGCAGCAAACACAGCCCTGC

20 CAGAAAGGAGGGACCTGTGTGAACATGCCAAGCGGCCCCCACTGTCTCTGTCCA
CAACACCTCACTGGAAACCACTGCCAGAAAGAGAAGTGCTTTGAGCCTCAGCTT

CTCCGGTTTTTCCACAAGAATGAGATATGGTATAGAAGTGGAGCAAGCAGCTGTGG

ACCAGATGCCAGTGCAAGGGTCTGATGCCCACTGCCAGCGGCTGGCCAGCCAGG

CCTGCCGCACCAACCGGTGCTCCTCATGGGGGTGCTGCTGCTAGAGGTGGAGGGCC

25 ACCGCCTGTGCCACTGCCCGGTGGGCTACACCGGACCCTTCTGCGACGTGGACAC

CAAGGCAAGCTGCTATGATGGCCGCGGGCTCAGCTACCGCGGCCTGGCCAGGAC

CACGCTCTCGGGTGCGCCCTGTCAGCCGTGGGCTCGGAGGCCACCTACCGGAAC

GTGACTGCCGAGCAAGCGCGGAAGTGGGACTGGGCGGCCACGCCTTCTGCCGG

AACCCGGACAACGACATCCGCCCGTGGTGCTTCGTGCTGAACCGCGACCGGCTG

30 AGCTGGGAGTACTGCGACCTGGCACAGTGCCAGACCCCAACCCAGGCGGCGCCT

CCGACCCCGGTGTCCCCTAGGCTTCATGTCCCACTCATGCCCGCGCAGCCGGCAC

CGCCGAAGCCTCAGCCACGACCCGGACCCCGTCTCAGTCCCAGACCCCGGGAG

CCTTGCCGGCGAAGCGGGAGCAGCCGCCTTCCCTGACCAGGAACGGCCCACTGA

GCTGCGGGCAGCGGCTCCGCAAGAGTCTGTCTTCGATGACCCGCGTCTGTTGGCGG

35 GCTGGTGGCGCTACGCGGGGCGCACCCCTACATCGCCGCGCTGTACTGGGGCCA

CAGTTTCTGCGCCGGCAGCCTCATCGCCCCCTGCTGGGTGCTGACGGCCGCTCAC

TGCCTGCAGGACCGGCCCGCACCCGAGGATCTGACGGTGGTGTCTCGGCCAGGAA

CGCCGTAACCACAGCTGTGAGCCGTGCCAGACGTTGGCCGTGCGCTCCTACCGCT

TGCACGAGGCCTTCTCGCCCGTCAGCTACCAGCACGACCTGGCTCTGTTGCGCCT

40 TCAGGAGGATGCGGACGGCAGCTGCGCGCTCCTGTGCGCTTACGTTACGCCGGTG

TGCCTGCCAAGCGGCGCCGCGGACCCCTCCGAGACCACGCTCTGCCAGGTGGCC

GGCTGGGGCCACCAGTTCGAGGGGGCGGAGGAATATGCCAGCTTCTTGCAGGAG

GCGCAGGTACCGTTCCTCTCCCTGGAGCGCTGCTCAGCCCCGGACGTGCACGGAT

CCTCCATCCTCCCCGGCATGCTCTGCGCAGGGTTCTTCGAGGGCGGCACCGATGC

45 GTGCCAGGGTGATTCCGGAGGGCCCGCTGGTGTGTGAGGACCAAGCTGCAGAGCG

CCGGCTCACCTGCAAGGCATCATCAGCTGGGGATCGGGCTGTGGTGACCGCAA

CAAGCCAGGCGTCTACACCGATGTGGCCTACTACCTGGCCTGGATCCGGGAGCA

CACCGTTTCTGATTGCTCAGGGACTCATCTTCCCTCCTTGGTGATTCCGCAGTG

AGAGAGTGGCTGGGGCATGGAAGGCAAGATTGTGTCCCATCCCCAGTGCGGC
CAGCTCCGCGCCAGGATGGCGCAGGAACTCAATAAAGTGCTTTGAAAATGCTG

SEQ ID NO: 744

5 >S60489
CTACTCCTAGATATTTGGCATGATCTTCAGTATGATCTTGTGCTGTGCTATCCGCA
GGAACCGCGAGATGGTCTAGA

SEQ ID NO: 745

10 >M59916
GAATTCGGGCGGGGGCGCCGCCCGGGGCCCTGAGGGCTGGCTAGGGTCCAGGCC
GGGGGGGACGGGACAGACGAACCAGCCCCGTGTAGGAAGCGCGACAATGCCCC
GCTACGGAGCGTCACTCCGCCAGAGCTGCCCCAGGTCCGGCCGGGAGCAGGGAC
AAGACGGGACCGCCGGAGCCCCCGGACTCCTTTGGATGGGCCTGGTGCTGGCGC
15 TGGCGCTGGCGCTGGCGCTGGCTCTGTCTGACTCTCGGGTTCTCTGGGCTCCGGC
AGAGGGCTCACCTCTTTCTCCCCAAGGCCATCCTGCCAGGTTACATCGCATAGTG
CCCCGGCTCCGAGATGTCTTTGGGTGGGGGAACCTCACCTGCCCAATCTGCAAAG
GTCTATTCACCGCCATCAACCTCGGGCTGAAGAAGGAACCCAATGTGGCTCGCGT
GGGCTCCGTGGCCATCAAGCTGTGCAATCTGCTGAAGATAGCACCACCTGCCGTG
20 TGCCAATCCATTGTCCACCTCTTTGAGGATGACATGGTGGAGGTGTGGAGACGCT
CAGTGCTGAGCCCATCTGAGGCCTGTGGCCTGCTCCTGGGCTCCACCTGTGGGCA
CTGGGACATTTCTCATCTTGGAAACATCTCTTGGCTACTGTGCCGAAGCCGCCCC
CCAAACCCCCCTAGCCCCCGAGCECCAGGTGCCCCCTGTGAGCCGCATCCTGTTCTAG
CACTGAACCTGCACTGGGATCATGACTACCTGGAGGGCACGGACCCTGACTGTGC
25 AGACCCACTGTGCTGCGGCCGGGGTTCTGGCCTGCCGCCCGCATCCCGGCCAGGT
GCCGGATACTGGGGCGAATACAGCAAGTGTGACCTGCCCTGAGGACCCTGGAG
AGCCTGTTGAGTGGGCTGGGCCCAGCCGGCCCTTTTGATATGGTGTACTGGACAG
GAGACATCCCCGCACATGATGTCTGGCACCAGACTCGTCAGGACCAACTGCGGG
CCCTGACCACCGTCACAGCACTTGTGAGGAAGTTCCTGGGGCCAGTGCCAGTGTA
30 CCCTGCTGTGGGTAACCATGAAAGCATACCTGTCAATAGCTTCCCTCCCCCTTC
ATTGAGGGCAACCACTCCTCCCGCTGGCTCTATGAAGCGATGGCCAAGGCTTGGG
AGCCCTGGCTGCCTGCCGAAGCCCTGCGCACCCCTCAGAATTGGGGGGTTCTATGC
TCTTTCCCCATACCCCGGTCTCCGCCTCATCTCTCTCAATATGAATTTTTGTTCCTG
TGAGAACTTCTGGCTCTTGATCAACTCCACGGATCCCGCAGGACAGCTCCAGTGG
35 CTGGTGGGGGAGCTTCAGGCTGCTGAGGATCGAGGAGACAAAGTGCATATAATT
GGCCACATTCCCCAGGGCACTGTCTGAAGAGCTGGAGCTGGAATTATTACCGA
ATTGTAGCCAGGTATGAGAACACCCTGGCTGCTCAGTTCTTTGGCCAACTCATG
TGGATGAATTTGAGGTCTTCTATGATGAAGAGACTCTGAGCCGGCCGCTGGCTGT
AGCCTTCCTGGCACCCAGTGCAACTACCTACATCGGCCTTAATCCTGGTTACCGT
40 GTGTACCAAATAGATGGAACTACTCCAGGAGCTCTCACGTGGTCCTGGACCATG
AGACCTACATCCTGAATCTGACCCAGGCAAACATACCGGGAGCCATAACCGCACT
GGCAGCTTCTCTACAGGGCTCGAGAAACCTATGGGCTGCCCAACACACTGCCTAC
CGCCTGGCACAACCTGGTATATCGCATGCGGGGCGACATGCAACTTTTCCAGACC
TTCTGGTTTCTCTACCATAAGGGCCACCCACCCTCGGAGCCCTGTGGCACGCCCT
45 GCCGTCTGGCTACTCTTTGTGCCAGCTCTCTGCCCCGTGCTGACAGCCCTGCTCTG
TGCCGCCACCTGATGCCAGATGGGAGCCTCCCAGAGGCCAGAGCCTGTGGCCA
AGGCCACTGTTTTGCTAGGGCCCCAGGGCCCCACATTTGGGAAAGTTCTTGATGTA
GGAAAGGGTGAAAAAGCCCAAATGCTGCTGTGGTTCAACCAGGCAAGATCATCC
GGTGAAAGAACCAGTCCCTGGGCCCCAAGGATGCCGGGGAAACAGGACCTTCTC

CTTTCCTGGAGCTGGTTTAGCTGGATATGGGAGGGGGTTTGGCTGCCTGTGCCCA
GGAGCTAGACTGCCTTGAGGCTGCTGTCTTTCACAGCCATGGAGTAGAGGCCTA
AGTTGACACTGCCCTGGGCAGACAAGACAGGAGCTGTCGCCCCAGGCCTGTGCT
GCCCAGCCAGGAACCCTGTACTGCTGCTGCGACCTGATGCTGCCAGTCTGTAAAA
5 ATAAAGCCCGCCCGAATTC

SEQ ID NO: 746

>W74362

TGAAGATGGAGCTAATCTTTCCTCTGCTCGTGGCATTGTTGTCGCTTATCCAGTCTT
10 CTACTCGTAGGGCATAACCAGCAGATCTTGGATGTGCTGGATGAAAATCGCAGAC
CTGTGTTGCGTGGTGGGTCTGCTGCCGCCACTTCTAATCCTCATCATGACAACGT
NAGGTATGGCATTTCAAATATAGATACAACCATTGAAGGAAAGACCCCCNCNCC
NCGACTGTNNTAGATGCANCN
CCCCCCCAGAAGACAGATAATCAAATAAATAGACGTCTA

15

SEQ ID NO: 747

>N71365

AAAGATCCTAACAGAACATAGCGTAACAATATTGGTCTTCCAGGTGTTACTCATT
TCAATTATGTGTAGTATACCAGGACAGACCTATTTTCATGTCTTATTTCTTTAAAG
20 AGCTGCTTCATTGGCCGGGCGCCATGGCTCACGTCTGTAATCCCAGCACTTTGGG
AGGCCGAGGCGGGTCTGGGTACTTGAGGTCAGGAGTTCGAGACCAGCCTGGCAA
ACATGGCGAAACCCCATCTTAATAAAAAATACAAAAAAATTAGCCGGGTGTGGT
GTGTCACGCGCCTGTAAATCCCAGCTACTTGGGGGGGCTCAGGCAGGAGAATTGGCTG
AAGCCAGGAGGGCGGAGGTTGCAGTTGAAGCTNAGATTGGGCCATTGCACTCCAG
25 CCTGGGAAACAGAGTGAAGACGCTGTCTAAAAAAAAAAAAAAAAAAAAA

SEQ ID NO: 748

>AA454662

ACCATTTAAAAAACAATTTATATAAATAGATTTCGTATACAAAGAAGAAACACA
30 TATACAGAGTACCCCAATTACCAGTATGGTGGACCCTACCCCTTCTTTTCTGCATT
GGGAAACAGAACAGAGAACAGAAAAAATCATTCCATCTTGCTCTTAACTCTTTCC
ACCTATGTGCTCAGTTTTTCAAGTAGAATTTCTATTCCCTTGCTGGTGCTTTTGGTT
TTTTCCAATGTAGGAATCAAGCTTTTCAGTGCAGCTTTGACTTTGTTTGCAACTTC
CAGGTCACAACCTCTGGAGGAGGCTAGAAAGAATAATGGCACTCTCGATTACACT
35 AGCCCAGGACTTCAGGTTCTTCATACCAACATGCTC

SEQ ID NO: 749

>AA450180

TGATCTTCTGTGCCTAGCACAAGAGTTGATACATAAGGAGTACTTTATAAATAAA
40 AAAATGAAAGTGTAGTGATGAGATTCTTTAGCTATCTATCTATATGTATATATC
TGGTTATTCAAAGCTTCCCCACCCCAAGTCATCTAAATTTTTCAGGTATCAAGTGC
TCAACAGACATATGATAGTCAAGGCTCTTAGTCTCATTTTTTACTCTTTGTCAAGA
GAAATGGAAAATAAGAGTACTTGGGCCCTCTTAAGGGAGCTCAGAGAGAATTAC
TAAATTAGGGACAGTTTCAATAGTTATCATTCTGTCTACATGAACGATCAAGACC
45 AGGACTCAGGGAACCTTTACTCTGTAACAGAAAGAGAGGATTCAAGTGTGTTGCCCTG
GGAGAATTGTCCCATCTTGTGCTTCTCTCCTG AGTACCCACTAC

SEQ ID NO: 750

>N76338

5 GCGANTGGCATTGAGCTACAGGCAGGAGATGAGGTGGAGTTCTCAGTGATTCTT
AATCAGCGCACTGGCAAGTGAGCGCCCTGTAATGTTTGGCGAGTCTGTGAGGGC
CCCAAGGCTGTTGCAGCTCCTCGACCTGATCGGTTGGTCAATCGCTTGAAGAATA
TCACTCTGGATGATGCCAGTGCTCCTCGCNTAANANGNGNTTCTTCGTGAGCCAN
GGGGACCAGATAACTCAATGGGTTTTGGTGCAGAAAAGAAAGATCCGTCAAGCTG
GTGTCATTGACTAACCACNTCCACAANGCACACCATTTAATCCACTATGATCAAG
10 TTGGGGGGAATCTGGTNAAGGGTTCTGAATATCTCCCTCTTNATCCCTCCCGAAA
TCTGGGAATACTTATTCTATTGGNGCTATTACACCAGTTTTTAAANACCTTCCNCG
GGGTTATGGTTTTTAAAAAAATAAATAAATTTTAGAAAACCCTT
TTAAATAATGCACAGTTGCAGCCTGGNAAAA

SEQ ID NO: 751

15 >M60626

CCCAGAGCAAGACCACAGCTGGTGAACAGTCCAGGAGCAGACAAGATGGAGAC
AAATTCTCTCTCCCCACGAACATCTCTGGAGGGACACCTGCTGTATCTGCTGGC
TATCTCTTCCTGGATATCATCACTTATCTGGTATTTGCAGTCACCTTTGTCTCGG
GGTCTGGGCAACGGGCTTGTGATCTGGGTGGCTGGATTCCGGATGACACACAC
20 AGTCACCACCATCAGTTACCTGAACCTGGCCGTGGCTGACTTCTGTTTACCTCC
ACTTTGCCATTCTTCATGGTCAGGAAGGCCATGGGAGGACATTGGCCTTTCGGCT
GGTTCCTGTGCAAATTCCTCTTTACCEATAGTGGACATCAACTTGTTCGGGAAGTGTC
TTCCTGATCGCCCTCATTGCTCTGGACCGCTGTGTTTGGGTCTGTCATCGAGTCTG
GAGCCAGAACCAACCGCACCGTGAGGCTGGCCAAGAAGGTGATCATTGGGGCCCTG
25 GGTGATGGCTCTGCTCCTCACATTGCCAGTTATCATTCGTGTGACTACAGTACCTG
GTAAAACGGGGACAGTAGCCTGCACTTTTAACTTTTCGCCCTGGACCAACGACCC
TAAAGAGAGGATAAATGTGGCCGTGGCCATGTTGACGGTGAGAGGCATCATCCG
GTTTCATCATTGGCTTCAGCGCACCCATGTCCATCGTTGCTGTCAGTTATGGGCTTA
TTGCCACCAAGATCCACAAGCAAGGCTTGATTAAGTCCAGTCGTCCCTTACGGGT
30 CCTCTCCTTTGTGCGCAGCAGCCTTTTTTCTCTGCTGGTCCCATATCAGGTGGTGG
CCCTTATAGCCACAGTCAGAATCCGTGAGTTATTGCAAGGCATGTACAAAGAAAT
TGGTATTGCAGTGGATGTGACAAGTGCCCTGGCCTTCTTCAACAGCTGCCTCAAC
CCCATGCTCTATGTCTTCATGGGCCAGGACTTCCGGGAGAGGCTGATCCACGCCCT
TTCCCGCCAGTCTGGAGAGGGCCCTGACCGAGGAUTCAAGCCAAACCAGTGACA
35 CAGCTACCAATTCTACTTTACCTTCTGCAGAGGTGGCGTTACAGGCAAAGTGAGG
AGGGAGCTGGGGGACACTTTCGAGCTCCAGCTCCAGCTTCGTCTCACCTTGAGT
TAGGCTGAGCACAGGCATTTCTGCTTATTTTAGGATTACCCACTCATCAGAAAA
AAAAAAAAAAGCCTTTGTGTCCCCTGATTTGGGGAGAATAAACAGATATGAGTTT
ATTATTGACTTCTTTTTTGAATTTGGACCTCAGCCTCGGGTGGTCAGGGTGGGAAA
40 TGATAGGAAGAAGCTGTCATCTGCATCCTAGTTTGCCTGAAATGAACCCAAATAA
TACCCATTATTATTAGTCCTGAATTATGAGTAGTGAATGATACCCATCATTCTGGC
ATCATGATGAGTAGTGTCCACTTCCATTCTGAAAAGTGCCCTGCTGTGAAAAATA
AATTATATAGTCATCCTAGGTAAATGAAGGAGGAGGGAGAAGTGTGAAAGAGTA
TGGCTTAAATCAGACAAGATATACAAGAAGATACTTTATATAGGGCAGGAGCGG
45 TGGCTCATGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCAGGCGGATCACCA
GAGGTCAGGAATTCGAGAACAGCCTGGCCAACATGGTGAAACCCTGTCTCTACT
AAAAATACAAAAATTAGCTGGGCGTAGTGGCAGGCTCCCGTAATCCCAGCTACT
CAGGAGACCGAGGCAGGAGAATCGCTTGGACCTGGAAGGCGGAGGTTGTAGTGA

GCCAAGAAAACGCCACTACACTCCAGCCTGGGTGACAGAGAGAGACTCCGGCTC
AG

SEQ ID NO: 752

5 >X70070

TCAAGCTCGCCCCGCGCAGCCCGAGCCGGGCTGGGCGCTGTCCTCGGGGGCCTG
GGGAACCGCGCGGTTTGGAGATCGGAGGCACCTGGAACCCGTGGCAAGCGCCGA
GCCGGGAGACAGCCCGAGGAACACGGGTTCTGGAGCTAGGAGCCGGAAGCTG
GGAGTCCGGAGGAGAGCGGAGCCCGGAGCCCGGAGCCCGGGGCGGCGCGTCTG
10 GGTCTGGCGCTTCCCGACTGGACGGCGCGCCCGCTGGTCTTCGCCACGCGCCCTC
CCCTGGGCTCGCGTTCATCGGTCCCCGCCTGAGACGCGCCCACTCCTGCCCGGAC
TTCCAGCCCCGGAGGCGCCGGACAGAGCCGCGGACTCCAGCGCCCAACCATGCGC
CTCAACAGCTCCGCGCCGGGAACCCCGGGCACGCGCGCCGCGCCGACCCCTTCCAG
CGGGCGCAGGCCGGACTGGAGGAGGCGCTGCTGGCCCCGGGCTTCGGCAACGCT
15 TCGGGCAACCGCTCGGAGCGCGTCTTGGCGGCACCCAGCAGCGAGCTGGACGTG
AACACCGACATCTACTCCAAAGTGCTGGTGACCGCCGTGTACCTGGCGCTCTTCG
TGGTGGGCACGGTGGGCAACACGGTGACGGCGTTACGCTGGCGCGGAAGAAGT
CGCTGCAGAGCCTGCAGAGCACGGTGCAATTACCACCTGGGCAGCCTGGCGCTGT
CCGACCTGCTCACCTGCTGCTGGCCATGCCCGTGGAGCTGTAACTTCATCTG
20 GGTGCACCACCCCTGGGCCTTCGGCGACGCGCGCTGCCGCGGCTACTACTTCCTG
CGCGACGCCTGCACCTACGCCACGGCCCTCAACGTGGCCAGCCTGAGTGTGGAG
CGCTACCTGGCCATCTGCCACCCCTTCAAGGCCAAGACCCTCATGTCCCGAAGCC
GCAGCAAGAAGTTCATCAGGCGCATCTGGCTCGCCCTCGGCCCTGCTGACGGTGCG
TATGCTGTTACCATGGGGGAGCAGAACCGCAGCGCCGACGGCCAGCAGGCCCG
25 CGGCCTGGTGTGCACCCCCACCATCCACACTGCCACCGTCAAGGTCGTACATACAG
GTCAACACCTTCATGTCCTTCATATCCCCATGGTGGTCATCTCGGTCTGAACAC
CATCATCGCCAACAAGCTGACCGTCATGGTACGCCAGGCGGCCGAGCAGGGCCA
AGTGTGCACGGTCGGGGGCGAGCACAGCACATTACGATGGCCATCGAGCCTGG
CAGGGTCCAGGCCCTGCGGCACGGCGTGCGGCTCCTACGTGCAGTGGTCATCGCC
30 TTTGTGGTCTGCTGGCTGCCCTACCACGTGCGGCGCCTCATGTTCTGCTACATCTC
GGATGAGCAGTGGACTCCGTTCTCTATGACTTCTACCACTACTTCTACATGGTG
ACCAACGCACTCTTCTACGTACGCTCCACCATCAACCCCATCCTGTACAACCTCG
TCTCTGCCAACTTCCGCCACATCTTCTGGCCACACTGGCCTGCCTCTGCCCGGTG
TGGCGGCGCAGGAGGAAGAGGCCAGCCTTCTCGAGGAAGGCCGACAGCGTGTCC
35 AGCAACCACACCCTCTCCAGCAATGCCACCCGCGAGACGCTGTACTAGGCTGTGC
GCCCCGGAACGTGTCCAGGAGGAGCCTGGCCATGGGTCTTGGCCCCGACAGAC
AGAGCAGCCCCCACCCGGGAGCCTTGATGGGGGTGAGGCAGAGGCCAGCCTGCA
CTGGAGTCTGAGGCCTGGGACCCCCCTCCACCCCTAACCCATGTTTCTCATT
AGTGTCTCCCGGGCCTGTCCCAACTCCTCCCCACCCCTCCCCCATCTCCTCTTTG
40 AAAGCCAGAACAAGAGAGCGCTCCTCTCCAGATAGGAAAAGGGCCTCTAACAA
GGAGAAATTAGTGTGCGGCAAAAGGCAGTTTCTTTGTTCTCAGACTAATGGATG
GTTCCAGAGAAGGAAATGAAATGTGCTGGGTGGGGCCGGGCTCCGGCGGCCCG
GCTGCTGTTCCCATGTCCACATCTCTGAGGCCTGCACCCCTCTGTCTAGCTCGGG
GAGTCCAGCCCCAGTCCCGCAGGCTCCGTGGCTTTGGGCCTCACGTGCAGACCCT
45 GCCATGCAGACCCATGCCCCCTCCCCAGGCAGCTCCAAGAAAGCTCCCTGACT
CGCCCCCTCAGGCCTGGCAAGCTGGGGGGCCCATCGCCGTGGGGAGTCCCTCCCAC
CACCCTCGCCGCAGGCAGCTGCAGCCCCCAGAGGGGACCACAAGCCCAAAAAGG
ACAAAAATGGGCTGGCCTGGAATGGCCCAGACCCAGCCTCCCCTCCTCCCTCCC
ATCTCACCCAGGCCAAGGCCAGGGGCTCTGCCAGGACACCACATGGGAGGGG

GCTCAGGCCTCAGCCTCAAGATCTTCAGCTGTGGCCTCTCGGGCTCGGCAGAAGG
GACGCCGGATCAGGGGCCTGGTCTCCAGCACCTGCCCAGTGGCCGTGGCCAGG
ATGGGGTGCGCATTCCGTGTGCTTTGCTTGTAGCTGTGCAGGCTGAGGTCTGGAG
CCAGGCCCAGAGCTGGCTTCAGGGTGGGGCCTTGAGAAGGGGAATGTGGGACAG
5 GGGCGATGGTGCCTGGTCTCTGAGTAAGATGCCAGGTCCCAGGAACTCAGGCTTC
AGGTGAGAAGGAGCGGTGTGTCCAGGCACCGCTGGCCGGCAGCCCTGGGGCTGAG
GCACAGACTCATTTGTACCTTCTGGCGGCGGCAGCCCTGGCCCCGGCCTCCAAG
CAGTTGAAAAAGCTGGCGCCTCCTTGGTCTCTAGGATCCAGGCTCCACAGAGCAC
ATGACTAGCCAGGCCCTGGCTTAAGAAGGTGCGCTAAGCCTAAGAGAAGACAG
10 TCCCAGGAGAAGCTGGCCGGGACCAGCCAGGAGCTGGGAGCCACAGGAAGCAA
AAGTCAGCCTTTTCTTCAAGGGATTTCCCTGTCTCAGAGCAGCCTTTGCCCCAGG
GAAATGGGCTCTGGGCTGGCTGCCTGCACCGGCCATGTCGACCCAGGACCCGGA
CACCTGGTCTTGGGCTGTGTTACGCCACTTTGCCTTCTCTGGACTCAGTTTCCCCG
TCTGAGAAATGAGAGTCGAATGCTACAGTATCTGCAGTCGCTTGGATCTGGCTGT
15 TGAGTTGACGGGTTCCCTTGAACCCCAACAAAATCCCTCTCCAACCACAGGACCTT
CGGCTCACCAAGAACGGGGGCCAGGGGAGTCAGGCCTATTGCTGCCTTCCCTG
CCAACTTTGCCCCACAAGCCTGGTCATCAGCCAGGCAGCCCTCCCAGTGCCCA
AGGGCCACCAACCCAGGGAAACAGGGCCAGCACAGAGGGGCCTTCTCCCCCA
CAGAGCTCCCATGACATAGTCTGCTCTGGGCGGAAGAGCTTTGCTGCCAGCCAGG
20 GATGTCCAGAGGTGCGTGCAGCCCTATCCCTGCTCAGGAGTGGGCTCAGAGTCT
AGCAAATGCTAAGGCCCTCAGGCTGGGCTCTGAACGAGGACCTGGACTCAGAG
CCAGACAGGGCAGCCTCAGACCTTCTCTGGGGCTCCTGGACCTTGGGGCCATAAT
CTCTGAGCCTCGGTTTCCCCATCTAAGGAACAGATGTGGTTCGTTCCGCCCTCTCA
GGCTGGATGAGACTGTCTGAGAGGATCCACCCCGGAACAGACAGAACGGTGTCTC
25 TCAGGATGGTGTCTGAGAGAGGGCAGAGTGGATGCCCCACTGCCCTAGACCCT
CGGTAGACGTGGGGTCTCTGGGGCGGGTCTGTGGCTGTGACTGAAGTCGGCTTT
CCCGTTGATGTCTTGATGCTCCTATCTGTGCACTTACCGTAGGTAGGGACACGTG
TCCATGCACCACAGACACACCCACGACACCTGATCTCGTATCACTAGCTTGCGGC
CAGGTCATGATGTGGCCCCGGAAGCTGGCCCTGCGTGCCATGAGTGCGTCGGTCA
30 TGGAGTCCGGAGCCCCTGAGCCGGCCCCTGGTGACGGCACAGCCCTCACAGCTC
AAACGCCCAACCCCACTCCCAACCATCTGCAGGTGGTGAAAACAAACCCCGTGTAT
CTCTCAATAAAGGTGGCCGAAGGGCCTCGATGTGG

SEQ ID NO: 753

35 >X58454

ATGCTGCCGCCAGGCAGCAACGGCACCGCGTACCCGGGGCAGTTCGCTCTATAC
CAGCAGCTGGCGCAGGGGAACGCCGTGGGGGGCTCGGCCGGGGGCACCGCCACTG
GGGCCCTCACAGGTGGTCACCGCCTGCCTGCTGACCCTACTCATCATCTGGACCC
TGCTGGGCAACGTGCTGGTGTGCGCAGCCATCGTGCGGAGCCGCCACCTGCGCG
40 CCAACATGACCAACGTCTTCATCGTGTCTCTGGCCGTGTCAGACCTTTTCGTGGC
GCTGCTGGTCAATGCCCTGGAAGGCAGTCGCCGAGGTGGCCGGTTACTGGCCCTTT
GGAGCGTTCTGCGACGTCTGGGTGGCCTTCGACATCATGTGCTCCACTGCCTCCA
TCCTGAACCTGTGCGTCATCAGCGTGGACCGCTACTGGGCCATCTCCAGGCCCTT
CCGCTACAAGCGCAAGATGACTCAGCGCATGGCCTTGGTCATGGTCGGCCTGGC
45 ATGGACCTTGTCCATCCTCATCTCCTTCATTCCGGTCCAGCTCAACTGGCACAGG
GACCAGGCGGCCTCTTGGGGCGGGCTGGACCTGCCAAACAACCTGGCCAACCTGG
ACGCCCTGGGAGGAGGACTTTTGGGAGCCCGACGTGAATGCAGAGAAGTGTGAC
TCCAGCCTGAATCGAACCTACGCCATCTCTTCTCGCTCATCAGCTTCTACATCCC
CGTTGCCATCATGATCGTGACCTACACGCGCATCTACCGCATCGCCAGGTGCAG

ATCCGCAGGATTTCTCCTCCCTGGAGAGGGCCGCAGAGCACGCGCAGAGCTGCCGG
AGCAGCGCAGCCTGCGCGCCCGACACCAGCCTGCGCGCTTCCATCAAGAAGGAG
ACCAAGGTTCTCAAGACCCTGTCGGTGATCATGGGGGTCTTCGTGTGTTGCTGGC
TGCCCTTCTTCATCCTTAACTGCATGGTCCCTTTCTGCAGTGGACACCCCGAAGGC
5 CCTCCGGCCGGCTTCCCCTGCGTCAGTGAGACCACCTTCGACGTCTTCGTCTGGTT
CGGCTGGGCTAACTCCTCACTCAACCCCGTCATCTATGCCTTCAACGCCGACTTTC
AGAAGGTGTTTGCCAGCTGCTGGGGTGCAGCCACTTCTGCTCCCGCACGCCGGT
GGAGACGGTGAACATCAGCAATGAGCTCATCTCCTACAACCAAGACATCGTCTTC
CACAAGGAAATCGCAGCTGCCTACATCCACATGATGCCCAACGCCGTTACCCCGG
10 GCAACCGGGAGGTGGACAACGACGAGGAGGAGGGTCCTTTCGATCGCATGTTCC
AGATCTATCAGACGTCCCCAGATGGTGACCCTGTTGCTGAGTCTGTCTGGGAGCT
GGACTGCGAGGGGGAGATTTCTTTAGACAAAATAACACCTTTCACCCCGAATGG
ATTCCATTAA

15 SEQ ID NO: 754

>D13538

CCATGGCGTCCCCGGCGCTGGCGGCGGCGCTGGCGGTGGCGGCAGCGGCGGGCC
CCAATGCGAGCGGCGCGGGCGAGAGGGGCAGCGGCGGGGTGCCAATGCCTCGG
GGGCTTCTGGGGGCGCGCGCGGCCAGTACTCGGCGGGCGCGGTGGCAGGGC
20 TGGCTGCCGTGGTGGGCTTCCTCATCGTCTTACCGTGGTGGGCAACGTGCTGGT
GGTGATCGCCGTGCTGACCAGCCGGGCGCTGCGCGCGCCACAGAACCTCTTCTGT
GTGTCGCTGGCCTCGGCGGAGATCCTGCTGGCCACGGTGGTCATGCCCTTCTCGT
TGGCCAACGAGCTCATGGCCTACTGGTACTGGGGCAGGTGTGGTGGCGCGGTGA
CCTGGCGCTCGATGTGCTGTTCGACCTCGTTCGATCGTGCATCTGTGTGCCATCA
25 GCCTGGACCGCTACTGGTGGTGACGCGAGGCCGTGAGTACAACCTGAAGCGCA
CACCACGCCGCGTCAAGGCCACCATCGTGGCCGTGTGGCTCATCTCGGCCGTCAT
CTCCTTCCCGCCGCTGGTCTCGCTCTACCGCCAGCCCGACGGCGCCGCCTACCCG
CAGTGCGGCCCTAACGACGAGACCTGGTACATCCTGTCCTCCTGCATCGGCTCCT
TCTTCGCGCCCTGCCTCATCATGGGCCTGGTCTACGCGCGCATCTACCGAGTGGC
30 CAAGCTGCGCACGCGCACGCTCAGCGAGAAGCGCGCCCCCGTGGGCCCCGACGG
TGCGTCCCCGACTACCGAAAACGGGCTGGGCGCGGCGGCAGGCGCAGGCGAGAA
CGGGCACTGCGCGCCCCCGCCGCGGACGTGGAGCCGGACGAGAGCAGCGCAGC
GGCCGAGAGGCGGCGGCGCGGGGGCGGTTGCGGCGGGGCGGGCGGCGGCGAG
CGGGCGCCGAGGGGGGCGCGGGCGGTGCGGACGGGCAGGGGGCGGCTGAGTCG
35 GGGGCGCTGACCGCCTCCAGGTCCCCGGGGCCCGGTGGCCGCCTGTGCGCGCC
AGCTCGCGCTCCGTCGAGTTCTTCTGTGCGCGCGGCGCGCGGCGCGCAGCAGCG
TGTGCCCGCCGAAGGTGGCCCAGGCGCGCGAGAAGCGCTTCACCTTTGTGCTGGC
TGTGGTCATGGGTGTGTTCTGTGCTCTGCTGGTTCCCCTTCTTCTTACGCTACAGCC
TGTACGGCATCTGCCGCGAGGCCTGCCAGGTGCCCGGCGCCGCTCTTCAAGTTCTT
40 CTTCTGGATCGGCTACTGCAACAGCTCGCTCAACCCGGTCATCTACACGGTCTTC
AACCAGGATTTCCGGCGATCCTTTAAGCACATCCTCTTCCGACGGAGGAGAAGG
GGCTTCAGGCAGTGACTC

SEQ ID NO: 755

45 >N76944

TGTAACAGATTGGAGAATCTAGCAATAAGATTCAAAGCTAATCTGGAGCATAA
AGGCACAGTTCAGAGACAGAATAACAGGGATCACAAAGCATGAATTAAGGAA
TTTATTGCTTCAAGTTCCTAGATAACAACCTTCCCATGCTGCACTTCTCCACTGTC

GGAGCACGTTCCGAAAAACAGAATGCCTTGATCCCTGGTGGGTGCGAAGGAGTT
GTTAGGGATGGCAGGCATTGGTG GGC

SEQ ID NO: 756

>AA451716

TTTTGCAAAATCAGAGAAATAACCCACATTAGAAAAAGCAATATGCCTTTTTTTTTT
AAAATGGCACATCAAGTGACTCTCATTTTAAAATATCTCTTTTCTTAACCCCTTAAT
TTGAATGCAAAATGATGCTGTGGTCAGAAGGAATGCCAGGTGGCGACCGTGATA
CCTTTAATGACAATAGGAACGTAGCAGAGGGACAACAGCAATGACAACAGAAA
10 GCAGCTGTGATCCAGCAGCAGCTGGCAAAGCTTAGTAAGCAACCTCATCCCCAG
ATGCATCCGCTCAGCCAGTGTTGTGATTGCTAGATACTATCTGTAAGTGAACCAA
ACTAAAATTTCATTTATGAACCAAGAAAGGAAGCCAAGTTGAAAAGGTCTCGAGT
TAAATCGAGAATGATTCAGGCGGGCCGGCTCTCTGAGCA
CCTTTGGATGCACTTCAGCTTCTGTCTTG

SEQ ID NO: 757

>H19264

TCACATTTGAGCTGGTNGCCAGGTTTGCTGTGGCCCCTGACTTCCTCAAGTTCTTC
AAGAATGCCCTAAACCTTATTGACCTCATGTCCATCGTCCCCTTTTACATCACTCT
20 GGTGGTGAACCTGGTNGTGGAGAGCACACCTACTTTAGCCAACTTGGGCAGGGT
GGCCCAGGTCCTGAGGCTGATGCGGATCTTCCGATCTTAAAGCTGGCCAGGCACT
TNCAGTGGCCTCCGCTCGCT

SEQ ID NO: 758

>AA598527

GTATCAGTAGGTAATAGGATATTTTATTTCAAAACAGTGAAGAAGCTGCTAAGCA
TAAAATTTGTCAAATGCTACAAAGGTGATGAATATACAACCTGGGAATTCCAAGA
AATTTAAATTTAATTACATTCTTTATTATCTTTTCTCAAAGAAATAAATTAGTT
30 CCACCATTTGGCTAATATTATTTTCAATTAAGACTGAATTTAGATTTTAGGAAATA
AAATATGGAATCTGTTATAATGTCCCAATTTATACTACAGTATTAATCTCAATCCT
GATCATTACATAATTATAGCATTACCAATCTGTGATTTTATAAATTAACCAAATT
TGTTAAATTAAGAAGAAATTATAGACACCATTTTTTCTGTTACAACATATGG
AAAAGCCATCAAAAACTTAACAGAACCAATCAAAAAGAAGTATATTTTATGC
35 TAAAGTTACTTTCTGTCCAGGTGCAAAACATTGTTC

SEQ ID NO: 759

>AA286908

TCAGTGAGATGTCATTTATTAAGCAGTTACAATGCTGCAGGTGCTGTGCAGGAGA
40 CTGGACATACAAAAGAAGAATTTGACCCAGACCTTCCCCCTCGTGGGTGCTCATA
ATCTTGTAGGGGGAAGGGAATACAAATACAAATTAGCGAAGAATGATAGCAGTA
TCTTAGGACACTGTAACCTGTGTGCTACGGGACCCAAGGACTGGAGAGCCATCCCT
TCGTGAAGGTCAGGGAAGAGCTGGGTGGTGGAGAGAGCTGAGCCTGTGTGGACC
CCTGATGCATGCTCTGATGCTGAGGGAGTACAGTAGAGATGGACACTGATAGTG
45 ACAGAAGAGTTTGGCCCCAAAGCAGAAGCGGCATCCTGCACCGACTCCCCCTTAG
AATGAATGAGTACGCACAAGAAAACAACCACAGGCATCGCGCATCTTCAGTGGA
TCTCTTTGCTGGAGAATTGACAGAGTGCCTGTCGCGCCTGAGTGAGCCGGTAAAT
TCTCTCCTTAAGGATTCTTCTCTTGGTAGCGGTCTCACTCTGCTCTTTGAGCAGCC
AGGAATAGCGATTTTTTCTGTAGTATCTGCATCATGGCTTTC

SEQ ID NO: 760

>AA280924

5 GGAACACGCTGCGGGGCTCCCGGGCCTGAGCCAGTGTCTGTTCTCCACGCAGGTG
TTCCGCGCGCCCCGTTTCAGCCATGTCTGTCGGCATCCATGTAGAGCTGGTGACTG
GAGGCAACAAGGGCATCGGCTTGGCATCGTGC GCGACCTGTGCCGGCTGTTCTCG
GGGGACGTGGTGCTCACGGCGCGGGACGTGACGCGGGGGCCAGGCGGCGTACAGC
AGCTGCAGGCGGAGGGCCTGAGCCGCGCTTCCACCAGCTGGACATCGACGATCT
GCAGACATCCGCCCCTGCCNTTCTTGC GCAAGGAGTACGGGGGCCTGGACGTGC
10 TGGTCAACAACGCGGGGCATCGCTTCAAGGTTGCTGATCCCACACCCTTTCATATT
CAAGCTGAAGTGACGATGAAAACAAATTTCTTTGGTACCCGAGATGTGTGCACA
GAATTACTCCCTCTAATAAAACCCCAAGGGAGAGTGGTGAACGTATCTAG

SEQ ID NO: 761

15 >AA279601

AAAGATGTAAATCGTGGAGGTTACGGCCAAGCCAGTTCATTAAATTCAGGAGT
CAGATTCCAGGTTTATGTAGAAGTTTCTAAAATGAAAATCAATGTTACTGAAATT
CCTGACACATTGCGTGAAGATCAAATGAGAGACAACTAGAGCTGAGCTTTTCA
AAGTCGCGAAATGGAGGCGGAGAGGTGGACCGCGTGGACTATGACAGACAGTCC
20 GGGAGTGCAGTCATCACGGTTGT G

SEQ ID NO: 762

>N22980

GTAAAAACATGAAAAAAATTTTATTGTTTATAGACAAAGAGGGCCACTTTTGGAAA
25 ATAATACTTTTTTTTTTTTAGTTGAATCAGGTGAAGACAGAGTTAAAATCACATA
GGATTTGCATTTTTTAAAAAAGGAAAGCACTAGGATTGTTGGCACTGGAGTAACTA
TTTACACTGAACAGAGGTTTGGCCTTTTACATAACATCGATACAATGCATTTTCC
AAAGTCTGAGAAATAACAAGGTTCTGTCTCGAATGCTTCACAGAGGAGGTTCCG
ATTTGGGGACAAGTGTCATTAATGAGGGCCATGGAAGTTCGTCAGCTTCAGAGTC
30 ACATGCAATCTGATCCTGGGCGGTTCCCCNGCTGGGGAGCACTTGGCTACGGAAT
TGAAAGCTAATGGGGAGGGGTGGGGC

SEQ ID NO: 763

>T61575

35 GATTATATCATGGTATATGAAGCACTGGTGAGGTCTATGTCACCAGAAATTCCCA
GTTTGCTGATTTTCATTGAGTTTTTTAAACCCGATGATNGTACTGCAACAAGTNAGC
ATNNGTCACTGCAACCNAACNNGNGGGGGGNAGGTNCACCNNTNTNTTTTT
TGAAAGGGTTCCCATTTTCNAANGGGGAAACCGNTNTTTTTCTTCCCTNCCCNGT
TATTATCCAGCTTTGTATTGCAAACAATGACTCTCCTGTTGTTCTCATTGAAGCGT
40 GGGGTTAAAGTGGGAGGGCAACATCATTCCCTCTTTGGGAAATCTAAGGCAATTC
TGTTTGCATTGGGGCTTCACCGTGCCGAGAATTGTTATCAGCATGCGAGGGGACC
ACTCCCCCGGGGAAAGGGCAGGGTTATAGGGGACAATCAGTGGGCCCGNAGG
GGGNCCATGGGGNCCAGTGGCAGGGGNAGGGTNCCGTGGCNCTTGGCTTT

45 SEQ ID NO: 764

>R23586

AGAACGAGCTGGACCAGAAGAAAGTAAAATATCCCAAAATGACAGACCTCAGC
AAGGGTGTGATTGAGGAGCCCAAGTAGCGCCTGCTNCGTGGGTGGATCCAAC
ACCAGCCCTGCGTTCGTGGGACTTGCCTCAGATCAGCCTGCGACTGCAAGATTCT

TACTGCAGTAGAGAACTCTTTTTCTCCCTTGTACTTTTTTTTGGACCTGGGCATCTTT
TTATAGGGAAAAATGGCCTTTGTAGGCAGTGGAAAACTTGCAAGGAAAGCTGCC
GTCTCTTTGGGCAGTCTGATGCAGAGCCTGCACTCTGGGCACTTCGCTGGAAGAA
TCTGGGAAGGTTGCGGTTTGCTCTTCCAGTGTTCGGGGGCCTTGGCTGCTTNAAG
5 GGNITCGGTCTACACGGANGGCTTTGCTGTTTAGGG CTGCATCCC

SEQ ID NO: 765

>L08044

CAAGGTCTCGATGTCGTCGGGATCGACGACCTTGGGGTCGATCGTCACGCCGATC
10 ACCTCCCCGCTGCCTTTGACGACGACCTTGACCAGGCCCCACCGGCTTGACCGT
GCACCTCAGAGTTCGCCAGCTGTTGCTGGGCCTCCAGGAGCTTTTGCTGCATCTG
CTGCGCCTGAGCGAGCAGCGCCGACATGTCGCCTCCGGGTTCATGACAGTCCCC
TAGCATCTTGGTCTCGAGTTGGTTTCGCCTGTGGTTGTCGGGCGATTTCGGAACATT
CAGCCTAGACCGCGCCGCGTTACCTTTGCGCCGTGGACCTACGAGTTGGCCCGCG
15 TGTCGGGTTCGCCATGATAGTCGGGGTACTCGTCGCAGCAGCGACGCCGATCATC
TCGTCCGCGAGCGCAACCCCCGCCAACATCGCCGGCATGGTCGTCTTCATCGACC
CCGGACACAACGGAGCCAACGACGCATCGATCGGCCGCCAGGTACCCACCGGTC
GCGGCGGCACCAAGAACTGCCAGGCCAGCGGAACGTCAACCAACAGCGGCTACC
CGGAGCACACCTTCACCTGGGAAACCGGGCTGCGGCTGCGGGCCGCGTTGA
20

SEQ ID NO: 766

>H52141

GAGGGAAAGGCTGCTGGCTCTGCTCTGTCTCATCCCGGCTTAGCTGACGGCC
CAGAGGGTGGGTGCCAATTCACACAGCAGCTGCAACTGAAAAGCAAGGTTCA
25 AATGTCAGATATCCTCCGGGAGCTGCTCTGTGTCTCTGAGAAGGCTGCTAACATT
GCCCCGGGCGTGACAGACAGCAGGAAGCCCTCTTCCAGCTGCTGATCGAAGAAAAG
AAAGAGGGGAGAAAAGAACAAGAAGTTTGCAGTTGACTTCAAGACGCTGGGCTGA
TGTAAGGGTACAGGAAGTTATAAAACAGGAATATGGGAGAACAAGTTTTCAG
GGTTTGGAAAAAAATATTTTTTGGGAGAAGGAATCCAATGGAGNTTAANTATTG
30 ANTGGGGGGGGGAAAGGTTT

SEQ ID NO: 767

>U39613

ATGGCAGATGATCAGGGCTGTATTGAAGAGCAGGGGGTTGAGGATTCAGCAAAT
35 GAAGATTCAGTGGATGCTAAGCCAGACCGGTCCTCGTTTGTACCGTCCCTCTTCA
GTAAGAAGAAGAAAAATGTCACCATGCGATCCATCAAGACCACCCGGGACCGAG
TGCCTACATATCAGTACAACATGAATTTTGAAGAGCTGGGCAAATGCATCATAAT
AAACAACAAGAACTTTGATAAAGTGACAGGTATGGGCGTTTCGAAACGGAACAGA
CAAAGATGCCGAGGCGCTCTTCAAGTGCTTCCGAAGCCTGGGTTTTGACGTGATT
40 GTCTATAATGACTGCTCTTGTGCCAAGATGCAAGATCTGCTTAAAAAAGCTTCTG
AAGAGGACCATACAAATGCCGCTGCTTCGCCTGCATCCTCTTAAGCCATGGAGA
AGAAAATGTAATTTATGGGAAAGATGGTGTACACCAATAAAGGATTTGACAGC
CCACTTTAGGGGGGATAGATGCAAAACCCTTTTAGAGAAACCCAACTCTTCTTC
ATTGAGGCTTGCCGAGGGACCGAGCTTGATGATGCCATCCAGGCCGACTCGGGG
45 CCCATCAATGACACAGATGCTAATCCTCGATAACAAGATCCAGTGGAAGCTGACT
TCCTCTTCGCCTATTCCACGGTTCCAGGCTATTACTCGTGGAGGAGCCCAGGAAG
AGGCTCCTGGTTTGTGCAAGCCCTCTGCTCCATCCTGGAGGAGCACGGAAAAGAC
CTGGAAATCATGCAGATCCTCACCAGGGTGAATGACAGAGTTGCCAGGCACTTT

GAGTCTCAGTCTGATGACCCACACTTCCATGAGAAGAAGCAGATCCCCTGTGTGG
TCTCCATGCTCACCAAGGAAGTCTACTTCAGTCAATAG

SEQ ID NO: 768

>H91337

5 TGGTATGCAAGTCAGCTTTGNCTCACAGTTGAAAATGTTCCGGTCATGATTGCTTTT
GAAACCAAAGGGGAAGGTACCGATATCATTGAGCTATTTAAAGTTGCCAGTTTG
GGCTCCAGTAATGCTTTCTGGTGGGTAAAATTCCACATTCAGGCCACGAGAGCAT
CTACAGTTTGTACTCTGGGGCTGCAGGCATCCTGGGACGCTGTACGCAATTCAGT
10 GGTCTAGTCCTTTATACCGACTCAGATTCCTTAAGCATGCAGAGTCACTCGAATG
AAAAAA

SEQ ID NO: 769

>M29870

15 ATGCAGGCCATCAAGTGTGTGGTGGTGGGAGACGGAGCTGTAGGTAAACTTGC
CTACTGATCAGTTACACAACCAATGCATTTCTGGAGAATATATCCCTACTGTCTT
TGACAATTATTCTGCCAATGTTATGGTAGATGGAAAACCGGTGAATCTGGGCTTA
TGGGATACAGCTGGA1CAAGAAGATTATGACAGATTACGCCCCCTATCCTATCCG
CAAACAGATGTGTTCTTAATTTGCTTTTCCCTTGTGAGTCCTGCATCATTTGAAAA
20 TGTCCGTGCAAAGTGGTATCCTGAGGTGCGGCACCACTGTCCCAACACTCCCATC
ATCCTAGTGGGAACTAAACTTGATCTTAGGGATGATAAAGACACGATCGAGAAA
CTGAAGGAGAAGAAGCTGACTCCCATCACCTATCCGCAGGGTCTAGCCATGGCT
AAGGAGATTGGTGGCTGTAAAATACCTGGAGTGCTCGGCGCTCACACAGCGAGGC
CTCAAGACAGTGTGTTGACGAAGCGATCCGAGCAATCCTCTGCCCCGCTCCCGTGA
25 AGAAGAGGAAGAGAAAATGCCTGCTGTTGTAA

SEQ ID NO: 770

>AA454652

TAAGTTGTAAAAAAATTTTGTATTATTTATAAATGAATTACACAATAAAATAATTA
30 TTTTTAAAGTCACAAATACAATCGTTGTATAAAGTCATTTTGGCATCAAGTATC
TCTTAAATATGTTGCAAACCTATTTTCCAAAGAGATGTGGTCCAAACCCTCTGAAG
GCTTTATAATTTTGTATTAGATAACAAGTGAACAAAACCTGACAATAAATACTCCA
ACAATTATTTTTTAAAATAC
TAAGTGGCAAATGCTATTCTAAGTGGCAAAACAATC
35

SEQ ID NO: 771

>AA424315

AGGTCCCATTACAAAGCATGGTGAAATAGATTATGAAGCAATTGTGAAGCTTTTCG
GATGGCTTTAATGGAGCAGATCTGAGAAATGTTTGTACTGAAGCAGGTATGTTTCG
40 CAATTCGTGCTGATCATGATTTTGTAGTACAGGAAGACTTCATGAAAGCAGTCAG
AAAAGTGGCTGATTCTAAGAAGCTGGAGTCTAAATTGGACTACAAACCTGTGTA
ATTTACTGTAAGATTTTGTATGGCTGCATGACAGATGTTGGCTTATTGTAAAAAT
AAAGTTAAAGAAAATAATGTATGTATTGGCAATGATGTCATTAAAAGTATATGA
ATAAAAATATGAGTAACATCATAAAAATTAGTAATTCAACTTTTAAGATACAGA
45 AGAAATTTGTATGTTTGTAAAGTTGCATTTATTGCAGCAAG

SEQ ID NO: 772

>AA460727

TAATAGTGGTTAAAAAAAACCTTAATTTACTTTGTTGAGTCAGAGGGTTGTAAAA

AAAATTATTGCTAAAGTAGATATCAGGCAAACAGAAAGGTGCTTTAGAAGTCCA
GTTACCTTGGAGTTTATTTAAACTAAGAGAAAAAAGTCATAATGTTTTATGCAA
TACATACTTGGTTCTCCAAATAACAACTGTGTGACATATAGCAGAAGGAATTAAG
5 GAATGCTGCACTTGTGATCCATACAAAACACCAACATTTTAGGTTGTACATAATT
AGAGAAATATCTGAAACACTTTTTAAACACTGTAGTAGCCAATACATAGAGGC
ATGCCGTAGTGGGCACAGGAATGCAGTTTAGAAAAGAAGANAANAAAAAATCA
CATAGGAACACTCAATTTCTTTAAATCACTGAGCAAGAACAGCAACATTGAAC
TTTCATACTGATTTTACACAACCTTCTATACAGTACCTTGACTTAAATCCAAGAGCA
AAAGTTAAGACTCTCCTCCTCTATTTTTGGTAAACAACTGCATGGTAAACTTAGA
10 TGACTCTTCCCCCTGGATTTTACCT

SEQ ID NO: 773

>L15189

CCTGCCTCGTACTCCTCCATTTATCCGCCATGATAAGTGCCAGCCGAGCTGCAGC
15 AGCCCGTCTCGTGGGCGCCGCAGCCTCCCGGGGCCCTACGGCCGCCGCCACCA
GGATAGCTGGAATGGCCTTAGTCATGAGGCTTTTAGACTTGTTTCAAGGCGGGAT
TATGCATCAGAAGCAATCAAGGGAGCAGTTGTTGGTATTGATTTGGGTACTACCA
ACTCCTGCGTGGCAGTTATGGAAGGTAAACAAGCAAAGGTGCTGGAGAATGCCG
AAGGTGCCAGAACCACCCCTTCAGTTGTGGCCTTTACAGCAGATGGTGAGCGACT
20 TGTGGAATGCCGGCCAAGCGACAGGCTGTCACCAACCCAAACAATACATTTTAT
GCTACCAAGCGTCTCATTGGCCGGCGATATGATGATCCTGAAGTACAGAAAGAC
ATTAAAAATGTTCCCTTTAAATTTGTCCTGCTCCAATGGTGATGCCTGGGTTG
AGGCTCATGGGAAATTTGATTTCTCCGAGTCAGATTGGAGCATTTGTGTGATGAA
GATGAAAGAGACTGCAGAAAATTACTTGGGGCACACAGCAAAAAATGCTGTGAT
25 CACAGTCCCAGCTTATTTCAATGACTCGCAGAGACAGGCCACTAAAGATGCTGGC
CAGATATCTGGACTGAATGTGCTTCGGGTGATTAATGAGCCCACAGCTGCTGCTC
TTGCCTATGGTCTAGACAAATCAGAAGACAAAGTCATTGCTGTATATGATTTAGG
TGGTGGAACTTTGTATTTCTATCCTGGAAATTCAGAAAGGAGTATTTGAGGTG
AAATCCACAAATGGGGATACCTTCTTAGGTGGGGAAGACTTTGACCAGGCCTTGC
30 TACGGCACATTGTGAAGGAGTTCAAGAGAGAGACAGGGGTTGATTTGACTAAAG
ACAACATGGCACTTCAGAGGGTACGGGAAGCTGCTGAAAAGGCTAAATGTGAAC
TCTCCTCATCTGTGCAGACTGACATCAATTTGCCCTATCTTACAATGGATTCTTCT
GGACCCAAGCATTTGAATATGAAGTTGACCCGTGCTCAATTTGAAGGGATTGTCA
CTGATCTAATCAGAAGGACTATCGCTCCATGCCAAAAAGCTATGCAAGATGCAG
35 AAGTCAGCAAGAGTGACATAGGAGAAGTGATTCTTGTGGGTGGCATGACTAGGA
TGCCCAAGGTTTACGAGACTGTACAGGATCTTTTGGCAGAGCCCCAAGTAAAGC
TGTCATCCTGATGAGGCTGTGGCCATTGGAGCTGCCATTCAGGGAGGTGTGTTG
GCCGGCGATGTCACGGATGTGCTGCTCCTTGATGTCACCTCCCTGTCTCTGGGTAT
TGAAACTCTAGGAGGTGTCTTTACCAAATTTAATAGGAATACCACTATTCCA
40 ACCAAGAAGAGCCAGGTATTCTCTACTGCCGCTGATGGTCAAACGCAAGTGGA
ATTAAAGTGTGTCAGGGTGAAAGAGAGATGGCTGGAGACAACAACTCCTTGGA
CAGTTTACTTTGATTGGAATTCACAGCCCCTCGTGGAGTTCCTCAGATTGAAG
TTACATTTGACATTGATGCCAATGGGATAGTACATGTTTCTGCTAAAGATAAAGG
CACAAGACGTGAGCAGCAGATTGTAATCCAGTCTTCTGGTGGATTAAAGCAAAGA
45 TGATATTGAAAATATGGTTAAAAATGCAGAGAAATATGCTGAAGAAGACCGGCG
AAAGAAGGAACGAGTTGAAGCAGTTAATATGGCTGAAGGAATCATTACGACAC
AGAAACCAAGATGGAAGAATTCAAGGACCAATTACCTGCTGATGAGTGCAACAA
GCTGAAAGAAGAGATTTCCAAAATGAGGGAGCTCCTGGCTAGAAAAGACAGTGA
AACAGGAGAAAAATATTAGACAGGCAGCATCCTCTCTTCAGCAGGCATCATTGAA

GCTGTTTCGAAATGGCATACAAAAAGATGGCATCTGAGCGAGAAGGCTCTGGAAG
TTCTGGCACTGGGGAACAAAAGGAAGATCAAAAGGAGGAAAAACAGTAATAAT
AGCAGAAATTTTGAAGCCAGAAGGACAACATATGAAGCTTAGGAGTGAAGAGAC
TTCC

5

SEQ ID NO: 774

>W60890

TTCAAGTACATCATAATCGGCGACACAGGTGTTGGTAAATCATGCTTATTGCTAC
AGTTTACAGACAAGAGGTTTCAGCCAGTGCATGACCTTACTATTGGTGTAGAGTT
10 CGGTGCTCGAATGATAACTATTGATGGGAAACAGATAAACTTCAGATATGGGA
TACGGCAGGGCAAGAATCCTTTCGTTCCATCACAAGGTCGTATTACAGAGGTGCA
GCAGGAGCTTTACTAGTTTACGATATTACACGGAGAGATACATTCAACCACTTGA
CAACCTGGTTAGAAGATGCCCCGCCAGCATTCCAATTCCAACATGGTCATTATGCT
TATTGGAAATAAAAAGTGATTTAGAATCTAGAAGAGAAGTAAAAAAGAAGAAG
15 GTGAAGCTTTTGCACGAGAACATGGACTCATCTTCATGGAAACGTCTGCTAAGAC
TGCTTCCAATGTAGAAGAGGCATTTATTAATACAGCAAAAGAAATTTATGAAAA
AATTCAAGAAGGAGCTTTGACATTAATAATGAGGCCAATGGCATTAAAATTGGC
CCTCAGCATNTGTTACCATGCCACACATGCAGGCNATCAGGGAGGCANCAGCTG
GGGNGCTCTGTTGANTCTGTTTATGCTANTGCCACGGGCTTCTCCCTTATCTTAN
20 CCTTCCTCTGGNACTGGNTGACCTTTGAAAGGTTTGCCAGAGATTANCCGCAATC
T

SEQ ID NO: 775

>AA287196

GTACACTGGTGTGGACAGAGCAGCTTGGCTTTTCATGTGCCACCTACTTACCT
ACTACCTGCGACTTTCTTTTTCTTGTCTAGCTGACTCTTCATGCCCTAAGATTT
TAAGTACGATGGTGAACGTTCTAATTTCAAGACCAATTGCGAGTCATGTAGTGTG
GTAGAATTAAAGGAGGACACGAGCCTGCTTCTGTTACCTCCAAGTGGAACAGG
ACTGATGCCGAAATGTCACCAGGTCCTTTTCACTCTTCACAGTGGAGAACTCTTGG
30 CCAAAGGTTTTTGGGGGGAGGAGGAGGAAACCAGCTTTCTGGTTAAGGTTAACA
CCAGATGGTGCCCCCTCATTGGTGTCCTTTTAAAAAATATTTACTGTAGTCCAATA
AGATAGCAGCTGTACAAAATGACTAAAATAGATTGTAGGATCATATGGCGTATA
TCTTGGTTTCATCTTCAAAATCAGAGACTGAGCTTTGAAACTAGTGGTTTTTAATCA

35 SEQ ID NO: 776

>T97257

TTTCAAANTTAGTTTTTATTTTATTGTAAAACATTGAGATGGAATGATAGGGTTTC
CCAGAATCAGGTCCATATTTTAACTAAATGAAAATTATGATTTATAGCCTTCTCA
AATACCTGCCATACTTGATATCTCAACCAGAGCTAATTTTACCTCTTTACAAATTA
40 AATAAGGCAAGTAACTGGGATCCACAATTTATAATACCTGGTCAATTTTTTCTGT
ATTTAAACCTCTATCATAGGTTTAAAGGCCTATTGGGGGGGACTTTAATCCCTTACC
AAATAAACAGGGGTTTAAATCACCTCATGGGGGGGCACTGCCCTTCTGGGGG
TTTTCTTCCTTTGGACTTAAACCAATCTGGGAATGGCTTAGGGGATTTTCCC

45 SEQ ID NO: 777

>W96114

GTTACGGAGGCGGCTACGGTGGCCAGAGCAGCATGAGTGGATACGACCAAGTTT
TACAGGAAAACCTCAGTGATTTTCAATCAAAACATTGCATAGGTAAACCAAGGAGC
AGTGAACAGCAGCTACTACAGTAGTGGAAGCCCGTGCATCTATGGGCGTGAACG

GAATGGGAGGGTTGTCTAGCATGTCCAGTATGAGTGGTGGATGGGGAATGTAAT
TGATCGATCCTGATCACTGACTCTTGGTCAACCTTTTTTTTTTTTTTTTTTCTTTAA
GAAACTTCAGTTTAAACACGTTTCTGCAATACAAGCTTGTGATTTATGCTTACTCT
AAGTCGGAATCAGGATTGTTATGAAGACTTAAGGCCAGTATTTTGAATACAA
5 TACTCATCTAGGATGTAACAGTGAAGCTGAGTAAACTATAACTGTTAAACTTAAG
TTCCAGCTTTTCTCAAGTTAGTTATA

SEQ ID NO: 778

>AA486836

10 GAAAACTATGGCATAGAATGGCATTCTGTGCGGGATAGCGAAGGGCAGAACTG
CTCATTGGGGTTGGACCTGAAGGAATCTCAATTTGTAAAGATGACTTTAGCCCAA
TTAATAGGATAGCTTATCCTGTGGTGCAGATGGCCACCCAGTCAGGAAAGAATGT
ATATTTGACGGTCACCAAGGAATCTGGGAACAGCATCGTGCTCTTGTTTAAATG
ATCAGCACCAGGGCGGCCAGCGGGCTTACCGAGCGATAACAGAGACGCACGCA
15 TTCTACAGGTGTGACACAGTGACCAGCGCCGTGATGATGCAGTATAGCCGTGACT
TGAAGGGCACTTGGCATCTCTGTTTCTGAATGAAAACATTAACTTGGCAAGAAA
TATGTCTTTGATATT

SEQ ID NO: 779

20 >L24470

GTGCGCGGAGGGGACGAGCGGCTGGACCACAGCCGGCGCCCGATCAGGATCTCC
GCGCTGGGATCGGTGGAACCTTGAGGCAGCGGCGGCGGGGCGCCATGGCACAC
CGAGCGGCTCCGCTCTTCTGCTCCTCAGAGAGCCCGGCTGGCGGCTGGGATGACA
AGATGTCTGGACTGCAATCCTGCACAGTCTTGAGAGGGAGATGACTTGAGTGGTT
25 GGCTTTTATCTCCACAACAATGTCCATGAACAATTCCAAACAGCTAGTGTCTCCT
GCAGCTGCGCTTCTTTCAAACACAACCTGCCAGACGGAAAACCGGCTTTCCGTAT
TTTTTTCAGTAATCTTCATGACAGTGGGAATCTTGTCAAACAGCCTTGCCATCGCC
ATTCTCATGAAGGCATATCAGAGATTTAGACAGAAGTCCAAGGCATCGTTTCTGC
TTTTGGCCAGCGGCTGGTAATCACTGATTTCTTTGGCCATCTCATCAATGGAGCC
30 ATAGCAGTATTTGTATATGCTTCTGATAAAGAATGGATCCGCTTTGACCAATCAA
ATGTCCTTTGCAGTATTTTTGGTATCTGCATGGTGTCTTTCTGGTCTGTGCCCACTTC
TTCTAGGCAGTGTGATGGCCATTGAGCGGTGTATTGGAGTCACAAAACCAATATT
TCATTCTACGAAAATTAGATCCAAACATGTGAAAATGATGTAAAGTGGTGTGTGC
TTGTTTGTCTGTTTTCATAGCTTTGCTGCCCATCCTTGGACATCGAGACTATAAAAT
35 TCAGGCGTCGAGGACCTGGTGTCTTCTACAACACAGAAGACATCAAAGACTGGGA
AGATAGATTTTATCTTCTACTTTTTTCTTTTCTGGGGCTCTTAGCCCTTGGTGTTC
ATTGTTGTGCAATGCAATCACAGGAATTACACTTTTAAGAGTTAAATTTAAAAGT
CAGCAGCACAGACAAGGCAGATCTCATCATTTGGAAATGGTAATCCAGCTCCTG
GCGATAATGTGTGTCTCCTGTATTTGTTGGAGCCCATTTCTGGTTACAATGGCCAA
40 CATTGGAATAAATGGAAATCATTCTCTGGAAACCTGTGAAACAACACTTTTTGCT
CTCCGAATGGCAACATGGAATCAAATCTTAGATCCTTGGGTATATATTCTTCTAC
GAAAGGCTGTCCTTAAGAATCTCTATAAGCTTGCCAGTCAATGCTGTGGAGTGCA
TGTCATCAGCTTACATATTTGGGAGCTTAGTTCCATTAAAAATTCCTTAAAGGTTG
CTGCTATTTCTGAGTCACCAGTTGCAGAGAAATCAGCAAGCACCTAGCTTAATAG
45 GACAGTAAATCTGTGTGGGGCTAGAACAAAAATTAAGACATGTTTGGCAATATTT
CAGTTAGTTAAATACCTGTAGCCTAACTGGAAAAATTCAGGCTTCATCATGTAGTT
TGAAGATACTATTGTCAGATTCAGGTTTTGAAATTTGTCAAATAAACAGGATAAC
TGACATTTTCAACTTGTTTTTGCCAATGGGAGGTAGACACAATAAAATAATGCC
ATGGGAGTCACACTGAAAGCAATTTTGAGCTTATCTGTCTTATTTATGCTTTGAGT

GAATCATCTGTTGAGGTCTAATGCCTCTACTTGGCCTATTTGCCAGAGAACATCTT
AATGCAGCCTGCATAGTGAAATGGTTATTTTGAGATCACCGCTCTGTAGCTAACC
CTTATAAACTAGGCTCAGTAAAATAAAGCACTCTTATTTTTTGATCTGGCCTATTT
TGCCCCCTCATTGTGTAGCCTCAATTAACACATGCATGGTCATGACACCCAGAATT
5 CATGATGGTTTGTATAACAACCTCTGCATATTCCAGGTCTGGCAGACAGGTTGC
CTGACCTGCAATCCTATCTAGAATGGGCCCATTCTTGTACATTTGACAAATAG
GACTGCCTACATTTATTATTATGAAGGTCGATTGTTGTTGGAAGTGTTTTTCATG
TCATAGATTAGCAATTTTCAAATAATTATTTTTTCTCTGAAAATTTTGTGTGTGAT
TGCACAATAAATAATTTTGTAGAGAAACAAAGGCTCTTTCTCAGCACATTGATGGG
10 CAACTAGAATTACAGCAGTTTCAAACCTCTACCATGGATAATGCAAACAAACCGA
AGCTACATGCCAATGATAGGTGCAAAGAATATTGGCAAAAGGTGCTTTACCTTG
AGCCATTATTTGTGTGTCAGAGAAACAAAAGAAACAGAATCAATATATAAATTCAAA
GACTATCTGCAGCTAGTGTGTTTCTTCTTTACACACATATACACACAGACATCAG
AAAATTCTGTTGAGAGCAGGTTCAATTAATTTGTAAGATGGCATATTCTAAAGCC
15 TGTGCTACCAGTACTAAGAGGGGAAGACTGGCAATTTGCCAAGCACTTGGGGAT
TATTATAACAATTAAGTAGGAGATCAAGAGATAATAATCTCTCCCCAAATTTTCC
AATAATAATTGAG

SEQ ID NO: 780

20 >T61078

GACAATTTAATTGCAAAAGACACAGAATATTAAGGCATAACAAAGTAAACTGAA
ATGAAGTTTATGTTATCAATATTCATCTCTGAGAAAGTTGTGAATCAGTTCCCTTAG
ATAACATGTGGCTCAGGTTGATTFAATAATGGGGCTGGGGTGTCTGCATCTCTAT
GCTGCTTTTCCAGCACTGTACTGCCTGTAGTGGAAGAAAGACTCTTGGAGTCCACCT
25 TGCAGAGATTTCTGCACAGCTTCAGCCAAAAAGTTTGGGNCACCCCGAAAATTAG
GTGAGGGAGAGGG

SEQ ID NO: 781

>S40706

AGAGACTTAAGTCTAAGGCACTGAGCGTATCATGTAAAGATGAGCGGGTGGCA
GCGACAGAGCCAAAATCAGAGCTGGAACCTGAGGAGAGAGTGTTCAAGAAGGA
AGTGTATCTTCATACATCACACACCTGAAAGCAGATGTGCTTTTCCAGACTGAT
CCAAGTGCAGAGATGGCAGCTGAGTCATTGCCTTTCTCTTCGGACACTGTCAGCT
GGGAGCTGGAAGCCTGGTATGAGGACCTGCAAGAGGTCCTGTCTTCAGATGAAA
35 ATGGGGGTACCTATGTTTCACCTCCTGGAAATGAAGAGGAAGAATCAAAAATCT
TCACCACTCTTGACCCTGCTTCTCTGGCTTGGCTGACTGAGGAGGAGCCAGAACC
AGCAGAGGTCACAAGCACCTCCCAGAGCCCTCACTCTCCAGATTCCAGTCAGAG
CTCCCTGGCTCAGGAGGAAGAGGAGGAAGACCAAGGGAGAACCAGGAAACGGA
AACAGAGTGGTCATTCCCCAGCCCGGGCTGGAAAGCAGCGCATGAAGGAGAAAG
40 AACAGGAGAATGAAAGGAAAGTGGCACAGCTAGCTGAAGAGAATGAACGGCTC
AAGCAGGAAATCGAGCGCCTGACCAGGGAAGTAGAGGCGACTCGCCGAGCTCTG
ATTGACCGAATGGTGAATCTGCACCAAGCATGAACAATTGGGAGCATCAGTCCC
CCACTTGGGCCACACTACCCACCTTTCCCAGAAGTGGCTACTGACTACCTCTCA
CTAGTGCCAATGATGTGACCCTCAATCCCACATACGCAGGGGGGAAGGCTTGGAG
45 TAGACAAAAGGAAAGGTCTCAGCTTGTATATAGAGATTGTACATTTATTTATTAC
TGTCCTATCTATTAAAGTGACTTTCTAT

SEQ ID NO: 782

>H25907

GGTGAACCAGNNTNTTTATCAGTTTATTAATCTATTTTAAATATATAGACTTTTCA
GTAGACAACAGCATAAAAACATATTCTTTTCAAGTTCAAATTGAACTTTCACCAAC
5 ATAGACCATATTCTGGGGCCATAAAATAAACATTGGCAAATTTAAAATAATTGAA
ATCATATTAAGTTTGTCTCTGACCCTGATAGAGGTAAGCCAGAAATCAAGANCA
GAAAGATATCTAGAAAAATCCCAAATAATTTGGAAGTAAAAGANCACAATTTTA
AATAAACCATGGGGCCAAAGGNAAAGGTCACAGGGGGAANCTCTTAGGNACTG
GANCTAAAATAGGGGGGNATTTTAC

10

SEQ ID NO: 783

>N90246

TTTTTGTAGTGCCTGCAGCCCTCATGGGTGCGGATGGAGGCAGAAAATCAGTTC
CTGTTTATTTACAAAAATATATATATGTGTATGTATGTATATATATTAACCCCTCA
15 GCTCCCTCCCATGATCATCCTTTTACTTCTACCCCCACCTCCCTTTTAAAACAAAG
AGGTTTTCTGGGGTGCAGAGAGGGTCTCCTGAAAGTGGGCAGAAGCAGCACCG
ATAGCCTAGTCTGGCAGGTTGTGGGAAGGGGCGCAGGGAGTGACCATGAGCGAC
CTTGGCCCCGTCTTGCTCCTTGCAACCCTGATTGGGGCATGGGGTGAGAGGAGGG
ATCAGTCCTTGAATCCCTGAATACTGCAAA
20 GAATGCGCTTCTGGTGCCCGGGCAGTGT

20

SEQ ID NO: 784

>H84113

GATTCGGAACGAGGGATGGGAGANGGGGCGGCTGTTGCCCTGGTGCTGCCGCT
25 GCANCCCGNATCCGCCTGGCACAAGGGCTCTGGCTCCTCTCCTGGCTGCTGGCGC
TGGCTGGTGGCGTCATCCTCCTCTGTAGTGGGCACCTCCTGGTCCAGCTAAGGCA
CCTTGGCACCTTCCTGGCTCCCTCCTGTCTAGTTCCTGTCTGCCCCAGGCTGCCC
TGGCACGNGCGCGGTTGGCTCTGGGCACAGGACTAGTGGGTGTAGGAGCCAGC
CGGGCAAGTCTGAATGCAGCTCTATACCCTNCCTGGGCGAGGGGTCCTGGGGCC
30 CGCTTGCTGGTGGCTGGCACGGCTTNGTT

30

SEQ ID NO: 785

>AA477082

AGAGAGTATATTGCTGCTTTTCTCAGTCACTTTGGCACAGGTGTCGTGGAATATG
35 ATGCAGAAAGGCTTTACAAAACCTCACTCTGCTGCTGATGTGGAAAGATTTTGT
TCTTGTACACATTGACCTGCCTCTGTTTTTCCCTCGAGACCAGCCAACTCTCACAT
TTCAGTCCGTTTATCACTTTACCAACAGTGGACAGCTTTACTCCCAGGCCCAAAA
AAATTATCCGTACAGCCCCAGATGGGATGGAAATGAAATGGCCAAAAGAGCAAA
GGCTTATTTCAAAAACCTTTGTCCCTCAGTTCCAGGAGGCAGCATTGCGCAATGGA
40 AAGCTCTAGGAAACACCAAGTCTTGAGAGGTGGCCAGCCAGACTGCCTGTCCACA
TGCGTGTCAGCACATACAGCCGCTTCCTGGAAGC

40

SEQ ID NO: 786

>Z73903

GAATTCGGATCTCTCGTCCTCTTCCTGGGCTAGGCCGCCCCAGGCGCGGCCCTG
CGACTCCTGGCACGGCCCCGTGCTCGGCTGCCGCCCTGGCGCGCGCCACACTGTC
GTCCCCGGACGGGCGCGGACCGGCTCGGCCGGGGCGCCGGCGGCTGGGGAGGG
GTCGCTGGCCCCGGGGCCGCGCATGCGCCGCCACCAACTTGGGGCTGTCAGTGG
AGGGCGAGTGCTGGTTCTCAGGGGAGGCGACGCCTTCGGGCCAACGGGCCTCGA

45

GCCGAGGCAGCAGTGGGAACGACTCATCCTTTTTCCAGCCCTGGGGCGTGGCTGG
GGTCGGGGTTCGGGGTTCGGGGCCGGTGGGGGCCCCGCCCCCGTCTCCTGGCCTGC
CCCCTTTCATGGGCCGCGATGATGGCGGCCCTGTACCCGAGCACGGACCTCTCGGG
CGCCTCCTCCTCCTCCTGCCTTCCTCTCCATCCTCTTCCTCGCCGAACGAGGTGA
5 TGGCGCTGAAGGATGTGCGGGAGGTGAAGGAGGAGAATACGCTGAATGAGAAG
CTTTTCTTGCTGGCGTGCACAAAGGTGACTATTATATGGTTAAAAAGATTTTGG
AGGAAAACAGTTCAGGTGACTTGAACATAAATTGCGTAGATGTGCTTGGGAGAA
ATGCTGTTACCATAACTATTGAAAACGAAAACCTTGGATATACTGCAGCTTCTTTT
GGACTACGGTTGTCAGAACTAATGGAACGAATTCAGAATCCTGAGTATTCAAC
10 AACTATGGATGTTGCACCTGTCATTTTAGCTGCTCATCGTAACAACTATGAAATT
CTTACAATGCTCTTAAAACAGGATGTATCTCTACCCAAGCCCCATGCAGTTGGCT
GTGAATGCACATTGTGTTCTGCAAAAAACAAAAAGGATAGCCTCCGGCATTCCA
GGTTTCGTCTTGATATATATCGATGTTTGGCCAGTCCAGCTCTAATAATGTTAACA
GAGGAGGATCCAATTCTGAGAGCATTGAACTTAGTGCTGATTTAAAAGAACTA
15 AGTCTTGTGGAGGTGGAATTCAGGAATGATTATGAGGAACTAGCCCCGCAATGT
AAAATGTTTGCTAAGGATTTACTTGCACAAGCCCCGGAATTCTCGTGAATTGGAAG
TTATTCTAAACCATACGTCTAGTGACGAGCCTCTTGACAAACGGGGATTATTAGA
AGAAAGAATGAATTTAAGTCGTCTAAACTTGCTATCAAATATAACCAGAAAGA
GTTTGTCTCCAGTCTAACTGCCAGCAGTTCCTGAACACTGTTTGGTTTGGACAG
20 ATGTCGGGTACCGACGCAAGCCACCTGTAAGAAGATAATGACTGTTTGGACAG
TAGGCATCTTTTGGCCAGTTTGTCACTTTGTTATTTGATAGCTCCCAAATCTCAG
TTTGGCAGAATCATTACACACCTTTTATGAAATTTATCATTTCATGGAGCATCATA
TTTTCACATTTCTGCTGTTGCTTAATCTATACTCTCTTGTGTTACAATGAGGATAAGA
AAAACACAATGGGGCCAGCCCTTGAAAGAATAGACTATCTTCTTATTCTGTGGAT
25 TATTGGGATGATTTGGTCAGACATTAAGAACTCTGGTATGAAGGGTTGGAAGA
CTTTTTAGAAGAATCTCGTAATCAACTCAGTTTTGTGTCATGAATTCTCTTTATTTGG
CAACCTTTGCCCTCAAAGTGGTTGCTCACAACAAGTTTCATGATTTTGTGCTGATCG
GAAGGATTGGGATGCATTCCATCCTACACTGGTGGCAGAAGGGCTTTTTGCATTT
GCAAATGTTCTAAGTTATCTTCGTCTCTTTTTTATGTATACAACCAGCTCTATCTT
30 GGGTCCATTACAGATTTCAATGGGACAGATGTTACAAGATTTTGGAAAATTTCTT
GGGATGTTTCTTCTTGTGTTTCTTTTCTTTTCACAATTGGACTGACACAACCTGTATGA
TAAAGGATATACTTCAAAGGAGCAGAAGGACTGTGTAGGCATCTTCTGTGAACA
GCAAAGCAATGATACCTTCCATTCGTTTCATTGGCACCTGCTTTGCTTTGTTCTGGT
ATATTTTCTCCTTAGCGCATGTTGGCAATCTTTGTGTCACAAGATTTAGCTATGGAGA
35 AGAACTGCAGTCCTTTGTGGGAGCTGTCATTGTTGGTACATACAATGTCGTGGTT
GTGATTGTGCTTACCAAACCTGCTGGTGGCAATGCTTCATAAAAGCTTTCAGTTGA
TAGCAAATCATGAAGACAAAGAATGGAAGTTTGTCTCGAGCAAAATTATGGCTTA
GCTACTTTGATGACAAATGTACGTTACCTCCACCTTTCAACATCATTCCCTCACCA
AAGACTATCTGCTATATGATTAGTAGCCTCAGTAAGTGGATTTGCTCTCATACAT
40 CAAAAGGCAAGGTCAAACGGCAAAACAGTTTAAAGGAATGGAGGAATTTGAAA
CAGAAGAGAGATGAAAACCTATCAAAAAGTGATGTGCTGCCTAGTGCATCGTTAC
TTGACTTCCATGAGACAGAAGATGCAAAGTACAGATCAGGCAACTGTGGAAAAT
CTAAACGAACTGCGCCAAGATCTGTCAAAATTCCGAAATGAAATAAGGGATTTA
CTTGGCTTTTCGGACTTCTAAATATGCTATGTTTTATCCAAGAAATTAACCATTTTC
45 TAAATCATGGAGCGAATAATTTTCAATAACAGATCCAAAAGACTATATTGCATAA
CTTGCAATGAAATTAATGAGATATATATTGAAATAAAGAATTATGTAAANGCCAT
TCTTTAAATATTTATAGCATAAATATATGTTATGTAAAGTGTGTATATAGAATT
AGTTTTTTAANCCTTCTGTTAGTGGCTTTTTGCAGAAGCNAAACAGATTAAAGTAG
ATAGATTTTGTAGCATGCTGCTTGGTTTTCTTACTTAGTGCTTTAAATGTTTTT

TTTATGTTTAAAGAGGGGCAGTTATAAATGGACACATTGCCCAGAATNTTTTGTAA
NATGAAGACCAGCAAATGTAGGCTGATCTCCTTCACAGGATACACTTGAAATAT
AGAAGTTATGTTTAAATATCTCTGTTTTAGGAGTTCACATATAGTTCAGCATTTA
TTGTTTAGGAGTATAATTTTATTTTATCTAAAATAATAGTCTATTTTTTCTTTTGTA
5 TTTTGTATAATCTTAAGCAACAAAGAAAAACCCTAATATTTGAATCTATTTAT
GTCTTTCAATTTAAATTCACCTCAGTTTTTGTATTGTAATATATTTACTTTTACAT
GGTTATAATCACTTTATATTTTAAATGTTTTTTTCACTTAATATTTTATATACAT
TTCCATGTATTGATGTAGTTAGTCCACATTTAAATTTTTATAGAATTATATAGTTT
TTGAAAAATACAGTCAGTAGATGTTTTATTTTTTAGCTATTCAGTTATGTTTATAA
10 GTTTGCATAGCTACTTCTCGACATTTGGTTTGTTTTAATTTTTTTGTATCATAATAG
TCCTATTTTTTTTTCAAGTTGGAGTGAATGTTTTTAGTTTTAAGATAGATAGGAGA
CACTTTTTTATCACATGTAGTCACAACCTGTTTTGTTTTTGTAAAACATAGGAAGT
CTCTTTAATGCAATGATTTGTTTTATATTTGGACTAAGGTTCTTGAGCTTATCTCC
CAAGGTACTTTCCATAATTTAACACAGCTTCTATAAAAGTGACTTCATGCTTACTT
15 GTGGATCATTCTTGCTGCTTAAGATGAAAAGCATTGGTTTTTTAAAATTAGAGAA
TAAAATATGTATTTAAATTTTTGGTGTGTTTACATAAAGNGATGTAGCTAAAATG
TTTTCATAGGCTATTATATATNCTCGCAGCATTTCCAGTTAAGAGGATATTAGGT
ATATAATTCTCTTCTTAACCGAATGTCAGATGGTCTTACGCCACAGGGTGCAGGT
AACCCTTGGCCTGTAAGCACCACCGATCCAGGGATCATTGTCTAAATAGGTTACT
20 ATTGTTTGTTCATCTGGAATTCCGAGGGTGCACAAATTACCAGCAGCCTGAGGG
AGGTCTTATTGGAAGGCTTCCTGCAGGAGGTGGCATCTGATCCGGGCCTAGACAT
GGGAGTTGGAATTTTCCAGACAGGGAAGGGCACTGTGGGTGGAAAACAAAGCAC
GAACAAACGTATGGTGTGGGACCAAGCCTCACATGGTGCATAAATGATCAGAGG
TGAGGCTGAAGCCTAGGTGTGTGTGTCAGGGGAAGAGCTAGAAAGGAAGGTGGGG
25 CAGGGAAGCTCAGTGAGTGTCTGCTACATGTGAGGCTTCATTCTGAGCACCAACT
CTGCGCGCTAATGCCACGAAGTGGAGTCATGATTCTTCCATTTTCCAGGTGAAGA
AACCAAAGCACGGGGAGAATTAGCTTGTCCAAGGGCTCATGGCCAGTCGGTGGT
GCCACTGGGATTTAACCAGGGATTCCAGCTGTGGAAGCTGCATGCTGCCAGCTGA
GCACTCCGTCTGTCCACCCTGGCAAATGACATGCTGAGGGCTGGGGGCAGTCATC
30 TTTCCAGCAGTTGTGCGACCAGAAATAATGATAATGCATCAGCCAGGTGGGCAAG
AACTCAGACTTTGTGGTCAGACCTCGCTGTGGCAGGGAGCTTAGAAAAGTCACTT
TTCCTCCACAGCTGTGTAACATGGGGAAAGGGGGATGCTCAGCTCACCTCTCATG
GCCCTTGTGTGGGGATTTCAGGGTAAATGCTGGAAAAGCACTGAATATACAGC
ACTTAGTAGAGGCTTTGCAAGCGGCTGTCTCACCCAAACGGATCCTTCCCCAGG
35 AAAGCTCTGCAAATGGAGCCACTTGGCTTTTTGCCTGATGCCATATTCCGTTGTTT
AAAACGGCGATCCCAAACCTTAAGAGTATGAAAGGGGTGTTTTGCAGACAATGCA
TAATTAACCACTTCTAAACACAGGGTGTGCCAGGCTCCCTCAAAGCTGTTAATTA
TTCTTCATTAGTGATCTTAAGTTAATGTAAAATAATCCTGGAGCTCTGCCAGAGG
CTCGGGCAGGGGAAGGAGCAGAGCCGCTTATTTCAACTAGCAAACGGAAAGAAA
40 TCTTCACGGGGCGCCTCTGCGTTCTGCCTTGGTTGTGGGGAGATGCCTCTATAGA
CTCTTTAGCTCTGCCCCAAAGGCCATTGTGGGAGGCGGCAAGCCCTCTCCCAAGTT
CCCAGAGCCCAGCCGACCTCAGGGTACTTTGGTTAATGAAATAGTTCAGGTGGG
AAGAAAATATGGAGGAGAGTAGTATACCCATCGCCCAGCTTCCAAAATAAGCTG
TTAATGGTGTGGTGGACTGCCCCGTGTGGGCCACCCCAAAATCTTATCCCTTTCCT
45 GCTTCCCCAGAGCTAAGCCTAAACAGTCCCTCTTGTGTTGGTGTGTAGATTTCCCAT
GCACATTTTTTTAAATTGCTGTAGGTACATAGTAAGTGTATATATTTATGGGGTAC
GTGAGATGTTTTGACACAGGCACGCAATGTGAAATACACACTTCATGGAGAATTC

SEQ ID NO: 787

>M81882

AGCTCGCCCGCAGCTCGCACTCGCAGGCGACCTGCTCCAGTCTCCAAAGCCGATG
GCATCTCCGGGCTCTGGCTTTTGGTCTTTCGGGTCGGAAGATGGCTCTGGGGATT
5 CCGAGAATCCCGGCACAGCGCGAGCCTGGTGCCAAGTGGCTCAGAAGTTCACGG
GCGGCATCGGAAACAACTGTGCGCCCTGCTCTACGGAGACGCCGAGAAGCCGG
CGGAGAGCGGCGGGAGCCAACCCCCGCGGGCCGCCGCCGGAAGGCCGCTGCG
CCTGCGACCAGAAGCCCTGCAGCTGCTCCAAAGTGGATGTCAACTACGCGTTTCT
CCATGCAACAGACCTGCTGCCGGCGTGTGATGGAGAAAGGCCCACTTTGGCGTTT
10 CTGCAAGATGTTATGAACATTTTACTTCAGTATGTGGTGAAAAGTTTCGATAGAT
CAACCAAAGTGATTGATTTCCATTATCCTAATGAGCTTCTCCAAGAATATAATTG
GGAATTGGCAGACCAACCACAAAATTTGGAGGAAATTTTGATGCATTGCCAAAC
AACTCTAAAATATGCAATTAACAGGGCATCCTAGATACTTCAATCAACTTTCT
ACTGGTTTGGATATGGTTGGATTAGCAGCAGACTGGCTGACATCAACAGCAAAT
15 ACTAACATGTTACCTATGAAATTGCTCCAGTATTTGTGCTTTTGAATATGTCAC
ACTAAAGAAAATGAGAGAAATCATTGGCTGGCCAGGGGGCTCTGGCGATGGGAT
ATTTTCTCCCGGTGGCGCCATATCTAACATGTATGCCATGATGATCGCACGCTTA
AGATGTTCCAGAAAGTCAAGGAGAAAGGAATGGCTGCTCTTCCAGGCTCATTG
CCTTCACGTCTGAACATAGTCATTTTCTCTCAAGAAGGGAGCTGCAGCCTTAGG
20 GATTGGAACAGACAGCGTGATTCTGATTAAATGTGATGAGAGAGGGGAAAATGAT
TCCATCTGATCTTGAAAGAAGGATTCTTGAAGCCAAACAGAAAGGGTTTGTTCCT
TTCCCTCGTGAGTGCCACAGCTGGAACCAACCGTGACGGAGCATTGACCCCTCT
TAGCTGTGCTGACATTTGCAAAAAGTATAAGATCTGGATGCATGTGGATGCAGC
TTGGGGTGGGGGATTACTGATGTCCCGAAAACACAAGTGGAAGCTGAGTGGCGT
25 GGAGAGGGCCAACCTCTGTGACGTGGAATCCACACAAGATGATGGGAGTCCCTTT
GCAGTGCTCTGCTCTCCTGGTTAGAGAAGAGGGATTGATGCAGAATTGCAACCA
AATGCATGCCTCCTACCTCTTTCAGCAAGATAAACATTATGACCTGTCCTATGAC
ACTGGAGACAAGGCCTTACAGTGCGGACGCCACGTTGATGTTTTTAACTATGGC
TGATGTGGAGGGCAAAGGGGACTACCGGGTTTGAAGCGCATGTTGATAAATGTT
30 TGGAGTTGGCAGAGTATTTATACAACATCATAAAAAACCGAGAAGGATATGAGA
TGGTGTTTGATGGGAAGCCTCAGCACACAAATGTCTGCTTCTGGTACATTCTCTCC
AAGCTTGCGTACTCTGGAAGACAATGAAGAGAGAATGAGTCGCCTCTCGAAGGT
GGCTCCAGTGATTAAAGCCAGAATGATGGAGTATGGAACCACAATGGTCAGCTA
CCAACCCCTTGGGAGACAAGGTCAATTTCTTCCGCATGGTCATCTCAAACCCAGCG
35 GCAACTCACCAAGACATTGACTTCCTGATTGAAGAAATAGAACGCCTTGGACAA
GATTTATAATAACCTTGCTCACCAAGCTGTTCCACTTCTCTAGGTAGACAATTAA
GTTGTCACAACTGTGTGAATGTATTTGTAGTTTGTTCCAAAGTAAATCTATTTCT
ATATTGTGGTGTCAAAGTAGAGTTTAAAAATTAAACAAAAAAGACATTGCTCCTT
TTAAAAGTCCTTTCTTAAGTTTAGAATACCTCTCTAAGAATTCGTGACAAAAGGC
40 TATGTTCTAATCAATAAGGAAAAGCTTAAATTTGTTATAAATACTTCCCTTACTTT
TAATATAGTGTGCAAAGCAAACCTTTATTTTCACTTCAGACTAGTAGGACTGAATA
GTGCCAAATTGCCCCCTGAATCATAAAAGGTTCTTTGGGGTGCAGTAAAAAGGAC
AAAGTAAATATAAAATATATGTTGACAATAAAAACTCTTGCCTTTTTCATAGTAT
TAGAAAAAAATTTCTAATTTACCTATAGCAACATTTCAAATGTATTTAAATACAT
45 ATAATTTTACAAAAGGAAAATATATATATTAAAAAAGATATCCTATTTTGTAAACA
TATAGATTTTTATTTATATAGGTTATACAACTGCGGGGGCGGAATT

SEQ ID NO: 788

>AA401448

TTTTTTTTTACAGTTTATCTTTTATTTTCTGCAAATTTAGGAACATATTTACTCGTT
TTCACATTGAATCTTAAGTTTAAGCTCTTCATTTGGTATTTAGGCAATATATGAGA
5 AAAAAATTTTTTTTGTTCATTTGTAATTTTAACAAGTTGAACATTTTACCATGATT
GAACATGTTTTTATTACAGTATTTAACATTCCCCCAAAGAATACCCTGCAAAGTG
TAAACCTTTGTCCCATACTGTGATATTACTGTTCTGCTACAATAAATGTCAAACCT
AAGCACTTTGCAGTTCACTACTTTTGGGAAAATGTTCTAGGGAAGTGTATCACAG
GTGAAACTGTTACCCATAAAGTGTAGC

10

SEQ ID NO: 789

>T84762

ATTCGGCACAGGATGAGCAGAAGAGGTTATCAGCATTAAATTGTTTTGGTTCTAA
ATTTGGAACAGTATATATAATTAAGTAAGGAACATTAGAGGATTTAATTAGA
15 ATAAATACATGTTTTGGAAATACAGTGACCTCTTGCAAGTGTACAAAAGTGCAAA
GTGATATTAGCTGTCATCTGCAATACAGAATCTCATTGCTTTGCACATGGAGCA
TATAGGGAAACTCCANACAGATCACAATGAGGGTTTCTAAATCTGTTGGGGTTCT
GTCTTCTATTGGGGTTCTGTGAAGGCCAAACCACTGTAGGCTTTAGCTGGGGTTCTN
GTCCTATGGACTCGTTGGGGGGNATGCCNTG
20 GGTTTTTCCATNCTTACCTGGCAGTCTTGGGGGGGT

SEQ ID NO: 790

>E87069

TTTGTCTCTCTGCCCCCTTNCATTTCTTTTGTATTTGTTTCTGTGAGAGCACTGA
25 AATGGCAGCCCTGGAATCTACAATTTGGCTCTCCACTGAGCACCTTATCTTGCCA
CCTTAGCCTTAAGAATGAATATGAAGAAAAATACACAGCCACCTCTGTCCAGGG
CAGTAAGAAGGGCTGCAAGGAAGGGGAGGATGGGGACAAGGAAAGGATCAGAT
ACCTGCTCCAGTAGTTNTGAGGCCACTGTGTCTCAGGGGACTCCAGGGAGGAGC
AGAAGAGGGNTCCACGAAGTTATTCTTACGCAGCTGGGGCCAGGGAGGGTCAG
30 AGTNGGTGCCAGGGTGCAAGTTAGGCTAAAGAAGCCACCACTTATTCCTCTCTCT
TGCCCATTTNTGGGGGGGCAAAGGCCATTGGTCAACCAAGAGTCTTTCCAGGGG
GACCCACAGATATTGCCATGTCCCTNCACACGTCTTTGGNGTCCTTAACN

SEQ ID NO: 791

>AA424743

CATATTTATCGGGATGACAAATCCATAGAATATATTCTTTTATGTTAAATTATGAT
CTTCATATTAATCTTAAATTTTGTGACGTGTCTTTTTCCTTTTTTCCACAGTTT
AATATATTATTCTTCAACGACATTTTTTGTAACTTTACACTTTTTTGGTTATTTTAT
TTTAAAAAAATGAAAAATTAATTTAAAAAAATGCAAAAAACTGTTGGATTATTTA
40 TTTTAGAAATTCCCCCTGTTGTGTTGGACTGCAAATTGAGTTTCTTTCTCTTTAG
GCCTTTCACAACTAGGACTGAGAATGTATGTAAAAGTTCTGTGACAGTACAGAA
GGAAAACAACTTTTTATGTATAGCTTCTAAAAGGGGAAAAAAAAAAAAAAGAGAA
ACCCTTTGACTTCCACGTGCCCATCT

45 SEQ ID NO: 792

>AA489331

TTAGTGAAACATTTTCTTTTTATTGAGAACATCTCAAATCCTTTGTCTGTATTTGA
CAGCGTCTCATGCTCAGTTCAGCTGGTCTTGTGCGAGAGGAAGCTCATGCAGTT
GTAACGTGTGGTGTATACACAGATTTACATACAGAGAACACTGAGGATTGCATCT

CAGCAACATGTTTCTCAGCCGAATTACATTCATAGAAAGTGTCCAGATTCTAAAA
TCAAATTAAAAGCATGTAATCCAAAGCCTGAAAAAGCAAACAGCTTTAGGGGCT
GACTCCATTAGCGTTCCATAGACTGTGCTTTTAACCGTTCAGTTCATGTTTAATGG
CCCATCGGTTCCCTTACATACCATCAGCTTATGCTGTGGCCAAAAGAAGTGTTCTT
5 GTGGCTTGGTACTCGTCCCTTCAAACAGTAAACAAGAAAGTGCAGACAGTGCTG
CCAGAGACAG

SEQ ID NO: 793

>T67104

10 CCAGTTTACACTGAAGATCGATCTGAAACTCAGCACCAGCGANAATCCAGAACT
TTGCCTGTCTCCATGGCTGGTTTTAATTTCCCCATTCTGCAGTGGCTTGTTAATAT
TAGTTCTGACCTTTGGGGCAAGGTGAACACATGGTTGGACTGAAGAGAAAAGGC
TTCTGGTGGCTCAGGAACGTCTTTGGCAACTACAACAGCTGATATTTCAACAGAG
CACATACATCCCCCACTTAACAAGGGTACGTCCTCAGCCTTCTCAGGGAACCAAC
15 GAACACCTCCAGGCTTCCTCTTTGATGCCACCCACTGGACCTGCCTTGGGGGTCT
GTAAATGCAAGAGGAACCGAGTGTTGGATAATTAGCGATGGGAAGAAAAAACCT
CTTAGNATTAAAAGGTAGGTTT

SEQ ID NO: 794

20 >R65792

TCCAGAGAGTAAGATCAGATTCGTCCACAAAGAGATGGGCATAATACCAAGCTG
GGGTGGCACCACCGGCTAGTTGAAATAATCGGAAGTAGACAAGCTCTCAAAGTG
TTGAGTGGGGCCCTTAAACTGGATTCAAAAAATGCTCTAAACATAGGAATGGTTG
AAAGAGGTCTTGCAGTCTTCAGATGAAACTAAATCTCTAGAAGAGGCACAAGAAT
25 GGCTAAAGCAATTCATCCAAGGGCCACCGGAAGTAATTAGAGCTTTGAAAAAAT
CTGTTTGTTCAGGCAGAGAGCTATATTTGGGGGGAAGCATTACAGAACGAAAGA
GATCTTTTAGGGNACAGTTTTTGGGGTNGGCCNGCAAATTTTAGAGGCTATTTNCT
AAGGAAGGGNATTTTATTAATATTTGGGTTTTTCCCG

30 SEQ ID NO: 795

>T90621

AGCAGGANCAAGTTTAATAAACGTTTATTGAGCAGTAGAATACAAGTGAGTNCC
NGGANCCNGATCACCAAGTCCTGTACAACTGAGGTAATTTTACAATGATGG
GTGGCTCAGTGAGATTCTGATTGCATGCGCTGCATGACAAATTATCTACTCAGAG
35 TATGCCTGACACGCCGGAGGGCTNGAGGGGGAACACACTGAAAGCAGTACCAGG
GAGCAGTGCATCTCACAGANCCATTTNTTCATGCCATGAAGTAAACGGTACTTAT
ACAAGTGTACAGTGACGTTCCACGNTCCCCATCTAACACGGNTTGCTGGAANTTT
ACAGGCAGACTGACGTTTTCTTTACATGTACTCCAAGTAAATCTGGTTAGTGAT
GACCNGGGGGCAGGCGCTGAAGCTTTTCAAAGCCTTACTTCTTTTATCAGCAGCC
40 CGGNTTTTTAT

SEQ ID NO: 796

>AA464067

GAAAGGAAGCTGGGCGTCCCTCTGGGCCCCCAACACACGTCCTTATAGCCCTGC
45 ACAGCGGTCTCCTTCCCCTAAGCCAGCACCGCTGCTCCCTGGACCCGGGAAGGAG
GCTGCCTGGCTGGAGGCCGAGCGATGGGCCTGTGCTGAGGATTTGTGCTGTGATT
TGGGCAAATCATTCCAGGTCTTTGGGCCTCCACCCCCT

SEQ ID NO: 797

>AA291163

CATCTATAGGTTTTTTTTATTAGAAAAGAAATTAAGTGTGTCAGTAGAGATTGA
AGGAAATTAACAATCTTACAATTCTAGAACAGGCCAACTTCATGATAAGGGATT
5 CTTAAGTTTTCAAAGTGTAGGAGCTCTTTCACAGATACACTCTTGGTGTAGGGGG
CTGTAAGTTTTATCAGATGTTTTACATTTTCATGCTTTAATCTTTGCTGGTAGTCTA
AATAAAATAAATACACAGTGTTCAGGATTATCTGGATAGCCATCTTAAATAACAG
AGTGTTCACATGACCACAGCCTCTGCACTTGTGCCTCTGATCCATATGACACCA
AGACCAACTATGCTTTTCATATGATTTCTCCACATTGGGTCTTGTGACTTTTCACA
10 GAATTGTTGAACATTTCCCCAGAGATCCGTGGTTACAGAGAGCTCCAATCTGCTT

SEQ ID NO: 798

>N53024

TGGAGCCCCTGNTGCGGAGATGGCCTCCAGAGGNCAGCTGCAGGGGCACGTTCTG
15 GGCTTAGCGACAGAGGCAAGCAAGGGACTGGTGTCTCTGGTGAGAGGTGGGTTT
GATGTATCTCTGTCCTATGCTGGTCTCTCTTCTCCTTTATAAAATCCTCTGTGGTC
AACTGACTACTGCGTATCGCAGTGGGAATAAGACTGCACAGTTGCTGGTAGGTG
AGTTTAAAGTCTTAATCTATGCATTCAGAGAAATATTTTATATGCTTTGTGTAAT
TTATAACAAGGATTTTTTTTTTAGCTTTGTTAACTGTGAATTCACCCCTCCTCCTCC
20 ACTGCATATTTAAAGCATGTGTTACACTGTGTGTAAACATTCACTGGAAGATTT
TTTNTTGTGCATTGCTGACTGTTCCAACATNACAAGTATTATTAATAAATTAATAT
TAACTGGACCGGAAATAAAGAAAAAAGNFCCTTACCCG

SEQ ID NO: 799

25 >AA398230

GCGGAATGGGAAGCAGTTTATGGAGTTAAGTGGGGCTCTGCTATTTCCCCCAAGA
AGGACTCGGAAGATGTTGATTCCAGGGGCAGAGTGAGGGGCAGACGGGATGAGG
CTCTTCTGTAAAGTCCAACAGACGCTCACAGATGCTGGGAGGCTGGGGACTGCC
AGGTTGGGAGCCTCACCAGAGAGCCTCACTGCATTGACCCACACCCACCACTC
30 ACCCAGCACACAGGGGGCCTCTCCTCACGCTCCCAGGCCACCAGGATGGCCCCC
AGGTTACACACAGGCACACGACACACGCTGCACTCACCACGCACTGAAGGGC
ATCACAGCCCCAAGTCTGGGTAAGAAATTCTCCAC

SEQ ID NO: 800

35 >H21107

GTTGCATCATTATACATCACTGAGTAAGAATCGTTTAGCCATCTACATTCAAT
GTTACTGGGTAATATTTNNCTCAAATTATAATTCCCAACACTGATTTTACCTGTGA
CAAAAGGAACAATAGTAATTCCTTGAAGAAGACTAACTGGNAAAAACATTTNGC
TTTTAGTATAAAAGTTCCTAGGNTGCTGAAAGGNACACATACACACCTAAAGAG
40 TCATGGCCTTCTTAAACAGCTTTCTTAATCCTTTCTGGGAAATATCCTTTGGTTCA
TTTTTATTGCCCTCTCTNGGGCAAAACAAAGTATGTAAACGCAGGNATCAGTGA
GTTATNTCCTAGGCACTTGTAAGGCAATATCCTTACCAAGAGGGACCATTCAACT
TTTGTAATAATCCGTNAAGCG

45 SEQ ID NO: 801

zd20g08.s1 Soares_fetal_heart_NbHH19W Homo sapiens cDNA clone IMAGE:341246 3'

similar to WP:ZK970.2 CE02402 CLPP-LIKE PROTEASE ;, mRNA sequence

gi|1365390|gb|W58658.1|W58658[1365390]

GCGACCGCCGAGCGACAGATCCAGAACGGCCTGGCCTGCAGCGGTGCCTGACGC

GAACGGCANCCCCGGGCTCTCCCGCTCATTCCCATCGTGGTGGAGCAGACGGGTC
GCGGCGAGNCGCCTGATGACATCTACTCGCGGCTGCTGCGGGANGCACTCAGTG
TGCGTCATGGGCCCCGATCGATGACAGCGTTGCCAGCCTTGTTATCGCACAGCTCC
TCTTCCTGCAATCCNGAGAGCAACAAGAAGCCCATCCACATGTACATCAACAGC
5 CCTGGTGGTGTGGTGACCGCGGGCCTGGCATCTACGACACGATGCAGTACATCCT
CAACCCGATCTGCACCTGGTGGTGGGCCAGGCCGCCAGCATGGGCTCCCTTGC
TTCTCGCCGCCGGAACCCAGGCATGCGCCACTCGCTCCCCAACTCCCGTATCAT
GATCCACCAGCCCTCAGGAGGCGCCCCG

10 SEQ ID NO: 802

zw32b03.r1 Soares ovary tumor NbHOT Homo sapiens cDNA clone IMAGE:770957 5',
mRNA sequence gi|2112210|gb|AA428170.1|AA428170[2112210]

ATTCGGCAATGGAGAGGATAGGGAGAATATTTACTAACTAAATACCATTCACTA
CTCATGCGTGAGACTGGGTGTACAACTCATCCTCTTTTAATGGCATTCTCTTTA
15 AACTATGTTCTTAACAAAATGAGATGATAGGATAGATCCTGGTTACCACTCTTTT
GCTGTGCACATACGGGCTCTGACTGGTTTTAATAGTCACCTTCATGATTATAGCA
ACTAATGTTTGAACAAAGCTCAAAGTATGCAATGCTTCATTATTCAAGAATGAAA
AATATAATGTTGATAATATATATTAAGTGTGCCAAATCAGTTTGACTACTCTCTGT
TTTAGTGTTCATGTTTAAAAGAAATATATTTTTTGTATTATTAGATAATATTTTGT
20 TATTTCTCTATTTTCATAATCAGTAATAGTGTATATAAACTCATTTATCTCCTCTT
CATGGCATCTTCAATATGAATCTATAAGTAGTAAATCAGAAAGTAACAATCTATG
GCTTATTTCTATGACAAATTCAGAGCTAGAAAAATA

SEQ ID NO: 803

25 ab35g03.s1 Stratagene HeLa cell s3 937216 Homo sapiens cDNA clone IMAGE:842836 3'
similar to gb:M93056 LEUKOCYTE ELASTASE INHIBITOR (HUMAN);, mRNA
sequence

gi|2216491|gb|AA486275.1|AA486275[2216491]
TCTGGACAGTGGTTTTATTGGTAAAGATATAAGACATATTGGCTCTATTA AAAAC
30 TCAGGTAATAAAGCACTAAGCTTGATTTTTGTATTGCTACAGTCTCTTTCTTCTAA
GGGGAAGAAAATCTCCCCAAGAATAGGATGCTACCTGAGGAATTATGCCGAATA
AAGAAAAGGAATGGATGGTCGGCAGTGAAATTTCTTCGGGCATCAACATGCAG
AAAGTTGCGATGCCTGCTGTGGCAGCTGCCGCCTCTGTTCCCTCTTCATTCACCTC
CACAAATGACTTGTGGACAATTTTTGATATAAAAATATCTCTGGCTCCTGACATG
35 CCAGACAGATCAGCCTTGCTACTGTTAAAGAGATCCTGCACACCTAGGCGGGCG
AGGTCGGAGTTGAGAGTGTAACCTCTCTCCAGTTTGAACCTGGGCAAGCTGACAT
TAACTTCAATGAAATCGAGATTCTCAGGTTTAG